https://www.biopharmawatch.com/news/NVAX/nuvaxovid-vacina-contra-a-covid-19-da-novavax-recomendada-para-autorizac-a-o-de-comerciali-nvax-20220624monthly0.5https://www.biopharmawatch.com/news/NVAX/el-chmp-recomienda-la-ampliacio-n-de-la-autorizacio-n-de-comercializacio-n-condicional-de--nvax-20220624monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-covid-19-vaccine-nuvaxovid-recomendada-para-adolescentes-nvax-20220624monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nuvaxovid-covid-19-vaccine-receives-emergency-use-authorization-in-taiwan-for-use--nvax-20220623monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-covid-19-vaccine-nuvaxovid-recommended-for-expanded-conditional-marketing-authoriz-nvax-20220623monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-covid-19-vaccine-nuvaxovid-provisionally-registered-in-australia-as-a-booster-in-i-nvax-20220613monthly0.5https://www.biopharmawatch.com/news/NVAX/el-comite-asesor-de-la-fda-recomienda-la-autorizacio-n-de-uso-de-emergencia-de-la-vacuna-n-nvax-20220609monthly0.5https://www.biopharmawatch.com/news/NVAX/comite-consultivo-da-fda-recomenda-autorizac-a-o-de-uso-emergencial-da-vacina-contra-a-cov-nvax-20220609monthly0.5https://www.biopharmawatch.com/news/NVAX/beratender-ausschuss-der-fda-empfiehlt-notfallzulassung-des-novavax-covid-19-impfstoffs-fu-nvax-20220609monthly0.5https://www.biopharmawatch.com/news/NVAX/le-comite-consultatif-de-la-fda-recommande-l-nvax-20220609monthly0.5https://www.biopharmawatch.com/news/NVAX/fda-advisory-committee-recommends-emergency-use-authorization-of-novavax-covid-19-vaccine--nvax-20220607monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-bofa-securities-2022-healthcare-conference-nvax-20220504monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-first-quarter-2022-financial-results-and-operat-nvax-20220502monthly0.5https://www.biopharmawatch.com/news/NVAX/fda-announces-vaccines-and-related-biological-products-advisory-committee-review-of-novava-nvax-20220429monthly0.5https://www.biopharmawatch.com/news/NVAX/les-premiers-re-sultats-de-l-nvax-20220422monthly0.5https://www.biopharmawatch.com/news/NVAX/erste-ergebnisse-der-studie-mit-dem-covid-19-grippeimpfstoff-von-novavax-zeigen-erstmals-d-nvax-20220422monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-initiation-of-covid-19-vaccine-booster-study-in-adolescents-in-phase-3-p-nvax-20220422monthly0.5https://www.biopharmawatch.com/news/NVAX/resultados-iniciais-do-estudo-da-vacina-contra-a-covid-19-e-a-gripe-da-novavax-sa-o-os-pri-nvax-20220421monthly0.5https://www.biopharmawatch.com/news/NVAX/los-resultados-iniciales-del-ensayo-de-la-vacuna-contra-covid-19-influenza-de-novavax-son--nvax-20220421monthly0.5https://www.biopharmawatch.com/news/NVAX/resultados-positivos-de-la-vacuna-combinada-contra-la-covid-19-y-la-gripe-de-novavax-nvax-20220421monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-annonce-l-nvax-20220421monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-gibt-die-zulassung-des-impfstoffs-nuvaxovid-covid-19-fu-r-die-grund-und-auffrischu-nvax-20220421monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-la-aprobacio-n-de-la-vacuna-nuvaxovid-contra-la-covid-19-para-la-inmunizac-nvax-20220420monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-aprovac-a-o-da-vacina-nuvaxovid-contra-a-covid-19-para-imunizac-a-o-prima--nvax-20220420monthly0.5https://www.biopharmawatch.com/news/NVAX/initial-results-from-novavax-nvax-20220420monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-versta-rkt-seine-pra-senz-auf-dem-weltimpfstoffkongress-und-dem-32-europa-ischen-k-nvax-20220419monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-consolide-sa-pre-sence-au-congre-s-mondial-sur-les-vaccins-et-au-32e-congre-s-euro-nvax-20220419monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-approval-of-nuvaxovid-covid-19-vaccine-for-primary-and-booster-immunizat-nvax-20220419monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-aumenta-sua-presenc-a-no-congresso-mundial-de-vacinas-e-no-32o-congresso-europeu-d-nvax-20220418monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-aumenta-su-presencia-en-el-congreso-mundial-de-vacunas-y-el-32-congreso-europeo-de-nvax-20220418monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-aumenta-la-presencia-en-dos-congresos-nvax-20220418monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-grows-presence-at-world-vaccine-congress-and-32nd-european-congress-of-clinical-mi-nvax-20220418monthly0.5https://www.biopharmawatch.com/news/NVAX/swissmedic-erteilt-bedingte-marktzulassung-fu-r-novavax-covid-19-impfstoff-nvax-20220414monthly0.5https://www.biopharmawatch.com/news/NVAX/swissmedic-accorde-une-autorisation-de-mise-sur-le-marche-conditionnelle-pour-le-vaccin-co-nvax-20220414monthly0.5https://www.biopharmawatch.com/news/NVAX/swissmedic-grants-conditional-marketing-authorization-for-novavax-covid-19-vaccine-nvax-20220413monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-serum-institute-of-india-receive-emergency-use-authorization-for-novavax-nvax-20220408monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-pre-sente-une-demande-d-nvax-20220401monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-envia-solicitac-a-o-para-expandir-a-autorizac-a-o-de-comercializac-a-o-condicional-nvax-20220401monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-stellt-antrag-auf-erweiterung-der-bedingten-zulassung-des-covid-19-impfstoffs-in-d-nvax-20220401monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-presenta-una-solicitud-para-ampliar-la-autorizacio-n-condicional-de-comercializaci-nvax-20220401monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-solicita-autorizacio-n-para-vacunar-contra-la-covid-19-a-los-adolescentes-en-la-ue-nvax-20220331monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-submits-request-to-expand-conditional-marketing-authorization-of-covid-19-vaccine--nvax-20220331monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-participation-in-two-booster-studies-using-its-covid-19-vaccine-nvax-20220325monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-und-serum-institute-of-india-geben-die-erste-notfallzulassung-des-impfstoffs-covid-nvax-20220324monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-et-serum-institute-of-india-annoncent-la-premie-re-autorisation-d-nvax-20220323monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-e-serum-institute-of-india-anunciam-primeira-autorizac-a-o-de-uso-emergencial-da-v-nvax-20220323monthly0.5https://www.biopharmawatch.com/news/NVAX/autorizada-la-vacuna-de-la-covid-19-de-novavax-en-adolescentes-de-12-a-18-an-os-en-india-nvax-20220323monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-y-serum-institute-of-india-reciben-la-primera-autorizacio-n-de-uso-de-emergencia-d-nvax-20220323monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-serum-institute-of-india-announce-first-emergency-use-authorization-of-novavax-nvax-20220322monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-ku-ndigt-weltweite-informationsprogramme-u-ber-impfungen-an-nvax-20220310monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-annonce-le-lancement-de-programmes-d-nvax-20220310monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-o-lanc-amento-de-programas-globais-de-informac-o-es-sobre-vacinas-nvax-20220310monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-el-lanzamiento-a-nivel-mundial-de-programas-educativos-sobre-las-vacunas-nvax-20220310monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-el-lanzamiento-de-programas-globales-de-educacio-n-sobre-vacunas-nvax-20220310monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-launch-of-global-vaccine-education-programs-nvax-20220310monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-cowen-nvax-20220302monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-durabilidade-prolongada-da-protec-a-o-contra-a-infecc-a-o-e-doenc-a-em-est-nvax-20220302monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-una-mayor-durabilidad-de-la-proteccio-n-contra-infecciones-y-enfermedades--nvax-20220302monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-annonce-une-protection-durable-prolonge-e-contre-l-nvax-20220301monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anhaltender-schutz-vor-infektionen-und-krankheiten-in-klinischer-phase-iii-studie--nvax-20220301monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-la-eficacia-de-la-vacuna-de-covid-19-nvax-20220301monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-extended-durability-of-protection-against-infection-and-disease-in-unite-nvax-20220228monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-ku-ndigt-auslieferung-des-covid-19-impfstoffs-in-die-mitgliedstaaten-der-europa-is-nvax-20220225monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-annonce-l-nvax-20220225monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-el-envi-o-de-su-vacuna-de-covid-19-a-estados-miembros-de-la-unio-n-europea-nvax-20220223monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-2021-financial-res-nvax-20220221monthly0.5https://www.biopharmawatch.com/news/NVAX/health-canada-authorizes-novavax-covid-19-vaccine-nvax-20220217monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-de-pose-une-demande-d-nvax-20220215monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-beantragt-bedingte-marktzulassung-fu-r-covid-19-impfstoff-in-der-schweiz-nvax-20220215monthly0.5https://www.biopharmawatch.com/news/NVAX/singapore-health-sciences-authority-issues-interim-authorization-for-novavax-covid-19-vacc-nvax-20220214monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-files-for-conditional-marketing-authorization-of-covid-19-vaccine-in-switzerland-nvax-20220214monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-annonce-des-re-sultats-positifs-pour-le-vaccin-contre-la-covid-19-dans-la-populati-nvax-20220214monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-resultados-positivos-de-la-vacuna-contra-la-covid-19-en-la-poblacio-n-pedi-nvax-20220214monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-resultados-positivos-da-vacina-contra-a-covid-19-na-populac-a-o-pedia-tric-nvax-20220214monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-gibt-positive-ergebnisse-des-impfstoffs-covid-19-in-der-pa-diatrischen-population--nvax-20220211monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-fireside-chat-at-the-11th-annual-svb-leerink-global-healthcare-c-nvax-20220211monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-resultados-positivos-de-la-vacuna-de-la-covid-19-en-nin-os-en-el-ensayo-pr-nvax-20220211monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-positive-results-of-covid-19-vaccine-in-pediatric-population-of-prevent--nvax-20220210monthly0.5https://www.biopharmawatch.com/news/NVAX/la-medicines-and-healthcare-products-regulatory-agency-mhra-accorde-une-autorisation-de-mi-nvax-20220204monthly0.5https://www.biopharmawatch.com/news/NVAX/medicines-and-healthcare-products-regulatory-agency-erteilt-bedingte-marktzulassung-fu-r-n-nvax-20220204monthly0.5https://www.biopharmawatch.com/news/NVAX/age-ncia-reguladora-de-medicamentos-e-produtos-de-sau-de-concede-autorizac-a-o-de-comercia-nvax-20220204monthly0.5https://www.biopharmawatch.com/news/NVAX/la-agencia-reguladora-de-medicamentos-y-productos-para-el-cuidado-de-la-salud-concede-auto-nvax-20220204monthly0.5https://www.biopharmawatch.com/news/NVAX/new-zealand-nvax-20220203monthly0.5https://www.biopharmawatch.com/news/NVAX/mhra-concede-la-autorizacio-n-condicional-de-comercializacio-n-de-la-vacuna-novavax-covid--nvax-20220203monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-stellt-antrag-auf-notfallzulassung-fu-r-covid-19-impfstoff-bei-der-us-amerikanisch-nvax-20220202monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-pre-sente-une-demande-d-nvax-20220201monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-envia-solicitac-a-o-a-fda-dos-eua-para-autorizac-a-o-de-uso-emergencial-de-vacina--nvax-20220201monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-presenta-solicitud-ante-la-fda-de-los-estados-unidos-para-autorizacio-n-de-uso-de--nvax-20220201monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-solicita-a-la-fda-de-estados-unidos-la-autorizacio-n-de-uso-de-emergencia-de-la-va-nvax-20220201monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-submits-request-to-the-u-s-fda-for-emergency-use-authorization-of-covid-19-vaccine-nvax-20220131monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-israel-announce-advance-purchase-agreement-for-supply-of-covid-19-vaccine-nvax-20220128monthly0.5https://www.biopharmawatch.com/news/NVAX/australia-therapeutic-goods-administration-tga-grants-provisional-registration-for-novavax-nvax-20220119monthly0.5https://www.biopharmawatch.com/news/NVAX/south-korea-ministry-of-food-and-drug-safety-approves-novavax-covid-19-vaccine-nvax-20220112monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-serum-institute-of-india-file-for-emergency-use-authorization-of-novavax-nvax-20220110monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-the-40th-annual-j-p-morgan-healthcare-conference-nvax-20220104monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-submits-final-data-packages-to-u-s-fda-as-prerequisite-to-emergency-use-authorizat-nvax-20211231monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-e-serum-institute-of-india-recebem-autorizac-a-o-de-uso-emergencial-para-vacina-co-nvax-20211229monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-et-le-serum-institute-of-india-rec-oivent-une-autorisation-d-nvax-20211229monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-und-serum-institute-of-india-erhalten-notfallzulassung-fu-r-covid-19-impfstoff-in--nvax-20211229monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-y-serum-institute-of-india-reciben-la-autorizacio-n-de-uso-en-emergencia-de-la-vac-nvax-20211228monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-y-sii-reciben-autorizacio-n-de-uso-de-emergencia-para-la-vacuna-de-covid-19-en-ind-nvax-20211228monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-serum-institute-of-india-receive-emergency-use-authorization-for-covid-19-vacc-nvax-20211228monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-annonce-des-donne-es-initiales-sur-la-re-activite-croise-e-au-variant-omicron-prov-nvax-20211224monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-dados-iniciais-de-reatividade-cruzada-da-o-micron-no-reforc-o-da-vacina-co-nvax-20211224monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-los-datos-iniciales-de-reactividad-cruzada-contra-o-micron-de-la-vacuna-de-nvax-20211223monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-sk-bioscience-expand-manufacturing-agreement-nvax-20211223monthly0.5https://www.biopharmawatch.com/news/NVAX/sage-da-organizac-a-o-mundial-da-sau-de-emite-recomendac-o-es-proviso-rias-para-a-vacina-c-nvax-20211223monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-gibt-erste-daten-zur-kreuzreaktivita-t-von-omicron-aus-covid-19-impfstoff-booster--nvax-20211223monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-initial-omicron-cross-reactivity-data-from-covid-19-vaccine-booster-and--nvax-20211222monthly0.5https://www.biopharmawatch.com/news/NVAX/le-sage-de-l-nvax-20211222monthly0.5https://www.biopharmawatch.com/news/NVAX/el-sage-de-la-organizacio-n-mundial-de-la-salud-emite-recomendaciones-provisionales-para-l-nvax-20211222monthly0.5https://www.biopharmawatch.com/news/NVAX/weltgesundheitsorganisation-sage-gibt-vorla-ufige-empfehlungen-fu-r-novavax-covid-19-impfs-nvax-20211222monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-rec-oit-une-recommandation-positive-de-l-nvax-20211222monthly0.5https://www.biopharmawatch.com/news/NVAX/la-oms-emite-recomendaciones-provisionales-para-la-vacuna-novavax-covid-19-nvax-20211222monthly0.5https://www.biopharmawatch.com/news/NVAX/weltgesundheitsorganisation-erteilt-zweite-notfallzulassung-fu-r-novavax-covid-19-impfstof-nvax-20211222monthly0.5https://www.biopharmawatch.com/news/NVAX/l-organisation-mondiale-de-la-sante-accorde-une-deuxie-me-utilisation-d-urgence-pour-le-va-nvax-20211222monthly0.5https://www.biopharmawatch.com/news/NVAX/europa-ische-kommission-erteilt-bedingte-marktzulassung-fu-r-covid-19-impfstoff-von-novava-nvax-20211222monthly0.5https://www.biopharmawatch.com/news/NVAX/la-commission-europe-enne-accorde-une-autorisation-de-mise-sur-le-marche-conditionnelle-po-nvax-20211222monthly0.5https://www.biopharmawatch.com/news/NVAX/la-organizacio-n-mundial-de-la-salud-concede-la-segunda-autorizacio-n-de-uso-de-emergencia-nvax-20211221monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-initiation-of-prevent-19-covid-19-vaccine-phase-3-trial-booster-study-nvax-20211221monthly0.5https://www.biopharmawatch.com/news/NVAX/world-health-organization-sage-issues-interim-recommendations-for-novavax-covid-19-vaccine-nvax-20211221monthly0.5https://www.biopharmawatch.com/news/NVAX/comissa-o-europeia-concede-autorizac-a-o-de-comercializac-a-o-condicional-para-a-vacina-co-nvax-20211221monthly0.5https://www.biopharmawatch.com/news/NVAX/la-oms-concede-la-segunda-lista-de-uso-de-emergencia-a-la-vacuna-de-covid-19-de-novavax-nvax-20211221monthly0.5https://www.biopharmawatch.com/news/NVAX/organizac-a-o-mundial-da-sau-de-concede-segunda-permissa-o-de-uso-emergencial-para-vacina--nvax-20211221monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-recibe-recomendacio-n-positiva-de-la-agencia-europea-de-medicamentos-con-respecto--nvax-20211221monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-erha-lt-positive-empfehlung-der-europa-ischen-arzneimittelagentur-fu-r-die-bedingt-nvax-20211221monthly0.5https://www.biopharmawatch.com/news/NVAX/la-comisio-n-europea-otorga-autorizacio-n-condicional-de-comercializacio-n-para-la-vacuna--nvax-20211221monthly0.5https://www.biopharmawatch.com/news/NVAX/la-ce-concede-la-autorizacio-n-de-comercializacio-n-condicional-de-la-vacuna-de-covid-19-d-nvax-20211220monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-recibe-una-recomendacio-n-positiva-de-la-ema-para-la-comercializacio-n-de-su-vacun-nvax-20211220monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-recebe-recomendac-a-o-positiva-da-age-ncia-europeia-de-medicamentos-para-autorizac-nvax-20211220monthly0.5https://www.biopharmawatch.com/news/NVAX/world-health-organization-grants-second-emergency-use-listing-for-novavax-covid-19-vaccine-nvax-20211220monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-receives-positive-european-medicines-agency-recommendation-for-conditional-marketi-nvax-20211220monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-e-serum-institute-of-india-anunciam-o-subsi-dio-para-o-pedido-de-utilizac-a-o-emer-nvax-20211220monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-y-serum-institute-of-india-anuncian-que-la-organizacio-n-mundial-de-la-salud-conce-nvax-20211220monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-y-sii-anuncian-que-la-oms-concede-la-lista-de-uso-de-emergencia-para-la-vacuna-nvx-nvax-20211220monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-et-serum-institute-of-india-annoncent-l-nvax-20211220monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-und-serum-institute-of-india-geben-bekannt-dass-die-weltgesundheitsorganisation-de-nvax-20211220monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-serum-institute-of-india-announce-world-health-organization-grants-emergency-u-nvax-20211217monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-submission-of-new-drug-application-in-japan-for-approval-of-covid-19-vac-nvax-20211215monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-files-for-emergency-use-of-covid-19-vaccine-in-the-united-arab-emirates-nvax-20211213monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-files-for-interim-authorization-of-covid-19-vaccine-in-singapore-nvax-20211124monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-evercore-isi-nvax-20211123monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-und-serum-institute-of-india-erhalten-notfallzulassung-fu-r-covid-19-impfstoff-auf-nvax-20211119monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-et-le-serum-institute-of-india-rec-oivent-une-autorisation-d-nvax-20211119monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-besta-tigt-pru-fung-des-antrags-auf-bedingte-marktzulassung-des-covid-19-impfstoff-nvax-20211119monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-confirma-la-revisio-n-de-la-agencia-europea-de-medicamentos-de-la-solicitud-de-aut-nvax-20211118monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-confirma-ana-lise-da-age-ncia-europeia-de-medicamentos-do-registro-da-vacina-contr-nvax-20211118monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-confirme-l-nvax-20211118monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-confirma-que-la-ema-esta-revisando-su-solicitud-de-comercializacio-n-de-la-vacuna--nvax-20211118monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-y-serum-institute-of-india-reciben-autorizacio-n-para-la-vacuna-covid-19-en-filipi-nvax-20211118monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-e-serum-institute-of-india-recebem-autorizac-a-o-de-uso-emergencial-para-vacina-co-nvax-20211117monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-y-serum-institute-of-india-reciben-la-autorizacio-n-de-uso-en-emergencia-para-la-v-nvax-20211117monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-confirms-european-medicines-agency-review-of-covid-19-vaccine-filing-for-condition-nvax-20211117monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-serum-institute-of-india-receive-emergency-use-authorization-for-covid-19-vacc-nvax-20211117monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-annonce-le-de-po-t-d-nvax-20211116monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-envio-do-pedido-de-licenc-a-biolo-gica-na-coreia-do-sul-para-aprovac-a-o-d-nvax-20211116monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-la-presentacio-n-de-la-solicitud-de-licencia-para-nvx-cov2373-nvax-20211115monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-la-presentacio-n-de-una-solicitud-de-licencia-biolo-gica-en-corea-del-sur--nvax-20211115monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-ku-ndigt-einreichung-eines-antrags-auf-biologische-zulassung-in-su-dkorea-fu-r-nvx-nvax-20211115monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-submission-of-biologics-license-application-in-south-korea-for-approval--nvax-20211115monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-beantragt-bei-der-weltgesundheitsorganisation-die-zulassung-des-covid-19-impfstoff-nvax-20211106monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-presenta-la-vacuna-contra-la-covid-19-para-aprobacio-n-provisional-en-nueva-zeland-nvax-20211105monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-de-pose-aupre-s-de-l-nvax-20211105monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-registra-vacina-contra-a-covid-19-para-aprovac-a-o-proviso-ria-na-nova-zela-ndia-nvax-20211105monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-presenta-su-vacuna-contra-la-covid-19-para-su-inclusio-n-en-la-lista-de-fa-rmacos--nvax-20211105monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-registra-vacina-contra-a-covid-19-para-uso-emergencial-junto-a-organizac-a-o-mundi-nvax-20211105monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-presenta-la-vacuna-covid-19-para-su-uso-de-emergencia-en-la-lista-de-la-oms-nvax-20211105monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-de-pose-une-demande-d-nvax-20211104monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-beantragt-vorla-ufige-zulassung-des-covid-19-impfstoffs-in-neuseeland-nvax-20211104monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-files-covid-19-vaccine-for-emergency-use-listing-with-world-health-organization-nvax-20211104monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-presenta-la-vacuna-covid-19-para-aprobacio-n-provisional-en-nueva-zelanda-nvax-20211103monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-files-covid-19-vaccine-for-provisional-approval-in-new-zealand-nvax-20211103monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-y-serum-institute-of-india-reciben-la-autorizacio-n-de-uso-en-emergencia-de-la-vac-nvax-20211103monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-et-serum-institute-of-india-rec-oivent-une-autorisation-d-nvax-20211103monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-e-serum-institute-of-india-recebem-autorizac-a-o-de-uso-emergencial-para-vacina-co-nvax-20211102monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-und-serum-institute-of-india-erhalten-notfallzulassung-fu-r-covid-19-impfstoff-in--nvax-20211102monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-y-serum-institute-of-india-reciben-autorizacio-n-de-uso-para-la-vacuna-de-covid-19-nvax-20211101monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-serum-institute-of-india-receive-emergency-use-authorization-for-covid-19-vacc-nvax-20211101monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-files-for-covid-19-vaccine-authorization-with-health-canada-and-completes-submissi-nvax-20211101monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-de-pose-une-demande-d-nvax-20211029monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-beantragt-zulassung-seines-covid-19-impfstoffs-im-vereinigten-ko-nigreich-nvax-20211029monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-files-for-provisional-approval-of-its-covid-19-vaccine-in-australia-nvax-20211029monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-registra-autorizac-a-o-de-sua-vacina-contra-a-covid-19-no-reino-unido-nvax-20211028monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-solicita-autorizacio-n-para-su-vacuna-contra-la-covid-19-en-el-reino-unido-nvax-20211027monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-presenta-la-solicitud-de-autorizacio-n-de-su-vacuna-de-covid-19-en-reino-unido-nvax-20211027monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-third-quarter-financial-results-and-operational-nvax-20211018monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nimmt-am-weltimpfstoffkongress-europa-teil-nvax-20211018monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-participera-au-congre-s-mondial-des-vaccins-en-europe-nvax-20211018monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-participara-do-congresso-mundial-de-vacinas-europa-nvax-20211018monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-participara-en-el-world-vaccine-congress-europe-nvax-20211016monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-world-vaccine-congress-europe-nvax-20211015monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-leadership-appointment-and-updates-nvax-20211004monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-health-equity-and-vaccine-confidence-panel-at-maryland-life-scie-nvax-20210929monthly0.5https://www.biopharmawatch.com/news/NVAX/les-re-sultats-de-l-nvax-20210926monthly0.5https://www.biopharmawatch.com/news/NVAX/resultados-do-estudo-cli-nico-de-fase-3-da-vacina-contra-influenza-novavax-nanoflu-publica-nvax-20210924monthly0.5https://www.biopharmawatch.com/news/NVAX/ergebnisse-der-klinischen-phase-iii-studie-mit-dem-grippeimpfstoff-nanoflu-von-novavax-in--nvax-20210924monthly0.5https://www.biopharmawatch.com/news/NVAX/resultados-del-ensayo-cli-nico-de-fase-3-de-la-vacuna-contra-la-influenza-de-novavax-nanof-nvax-20210924monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-et-serum-institute-of-india-annoncent-le-de-po-t-d-nvax-20210924monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-und-serum-institute-of-india-geben-antrag-auf-notfallzulassung-des-novavax-impfsto-nvax-20210924monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-hosts-hm-king-carl-xvi-gustaf-and-hm-queen-silvia-of-sweden-during-royal-visit-to--nvax-20210924monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-e-serum-institute-of-india-anunciam-apresentac-a-o-de-pedido-para-uso-emergencial--nvax-20210923monthly0.5https://www.biopharmawatch.com/news/NVAX/results-from-novavax-nanoflu-influenza-vaccine-phase-3-clinical-trial-published-in-the-lan-nvax-20210923monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-y-serum-institute-of-india-anuncian-la-solicitud-a-la-organizacio-n-mundial-de-la--nvax-20210923monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-y-sii-presentan-a-la-oms-la-lista-de-uso-de-emergencia-de-la-vacuna-de-covid-19-de-nvax-20210923monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-serum-institute-of-india-announce-submission-to-world-health-organization-for--nvax-20210923monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-fireside-chat-at-the-2021-cantor-virtual-global-healthcare-confe-nvax-20210923monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-participara-de-conversa-informal-durante-devex-na-unga-76-nvax-20210921monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nimmt-am-fireside-chat-bei-devex-unga-76-teil-nvax-20210921monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-participara-de-una-charla-informal-en-devex-unga-76-nvax-20210921monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-participera-a-un-webinaire-a-devex-unga-76-nvax-20210921monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-participa-en-el-fireside-chat-en-devex-unga-76-nvax-20210921monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-fireside-chat-at-devex-unga-76-nvax-20210920monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-university-of-oxford-com-cov3-study-comparing-mixed-covid-19-vac-nvax-20210916monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-lance-l-nvax-20210910monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-startet-klinische-phase-i-ii-studie-mit-kombinationsimpfstoff-gegen-covid-19-und-s-nvax-20210910monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-inicia-estudo-cli-nico-de-fase-1-2-de-vacina-combinada-para-covid-19-e-influenza-s-nvax-20210909monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-inicia-ensayo-cli-nico-de-fase-1-2-para-la-vacuna-combinada-contra-la-covid-19-y-l-nvax-20210909monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-upcoming-september-conferences-nvax-20210909monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-inicia-un-ensayo-cli-nico-de-una-vacuna-combinada-para-covid-19-y-gripe-estacional-nvax-20210908monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiates-phase-1-2-clinical-trial-of-combination-vaccine-for-covid-19-and-seasona-nvax-20210908monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-citi-nvax-20210907monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-statement-on-cdc-guidance-update-for-covid-19-clinical-trial-participants-nvax-20210830monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-octave-duo-study-to-evaluate-third-dose-of-vaccine-in-participan-nvax-20210825monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-gibt-daten-zum-covid-19-auffrischimpfung-bekannt-die-einen-vierfachen-anstieg-der--nvax-20210807monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-publie-des-donne-es-sur-les-doses-de-rappel-du-vaccin-contre-la-covid-19-de-montra-nvax-20210807monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-und-serum-institute-of-india-ku-ndigen-antrag-auf-notfallzulassung-des-rekombinant-nvax-20210807monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-et-serum-institute-of-india-annoncent-le-de-po-t-d-nvax-20210807monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-y-serum-institute-of-india-anuncian-la-solicitud-de-la-autorizacio-n-de-uso-de-eme-nvax-20210806monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-e-serum-institute-of-india-anunciam-pedido-de-autorizac-a-o-de-uso-emergencial-da--nvax-20210806monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-dados-de-reforc-o-da-vacina-contra-a-covid-19-que-demonstram-aumento-de-qu-nvax-20210806monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-datos-de-las-vacunas-de-refuerzo-contra-la-covid-19-que-demuestran-un-aume-nvax-20210806monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-y-serum-institute-of-india-solicitan-la-autorizacio-n-de-la-vacuna-covid-19-de-nov-nvax-20210806monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-datos-de-refuerzo-de-la-vacuna-covid-19-nvax-20210806monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-covid-19-vaccine-booster-data-demonstrating-four-fold-increase-in-neutra-nvax-20210805monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-serum-institute-of-india-announce-submission-to-regulatory-agencies-in-india-i-nvax-20210805monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-und-die-europa-ische-kommission-schlie-en-einen-vorabkaufvertrag-u-ber-bis-zu-200--nvax-20210805monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-et-la-commission-europe-enne-concluent-un-accord-d-nvax-20210804monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-y-la-comisio-n-europea-finalizan-acuerdo-de-compra-anticipada-de-hasta-200-millone-nvax-20210804monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-e-comissa-o-europeia-finalizam-acordo-de-compra-antecipada-para-ate-200-milho-es-d-nvax-20210804monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-y-la-comisio-n-europea-concluyen-un-acuerdo-de-compra-de-200-millones-de-dosis-de--nvax-20210804monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-european-commission-finalize-advance-purchase-agreement-for-up-to-200-million--nvax-20210804monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-second-quarter-financial-results-and-operationa-nvax-20210706monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-publishes-results-of-united-kingdom-phase-3-clinical-trial-in-new-england-journal--nvax-20210630monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-fireside-chat-at-svb-leerink-cyberx-series-vaccine-forum-nvax-20210617monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-national-vaccine-advisory-committee-meeting-nvax-20210617monthly0.5https://www.biopharmawatch.com/news/NVAX/le-vaccin-novavax-contre-la-covid-19-de-montre-une-efficacite-globale-de-90-et-une-protect-nvax-20210615monthly0.5https://www.biopharmawatch.com/news/NVAX/prevent-19-phase-iii-studie-der-covid-19-impfstoff-von-novavax-zeigt-eine-gesamtwirksamkei-nvax-20210615monthly0.5https://www.biopharmawatch.com/news/NVAX/la-vacuna-de-novavax-contra-la-covid-19-demuestra-una-eficacia-general-del-90-y-una-protec-nvax-20210614monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-apresenta-90-de-efica-cia-geral-e-100-de-protec-a-o-contra-casos-moderados-e-grave-nvax-20210614monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-positive-results-from-first-study-of-influenza-vaccine-and-covid-19-vacc-nvax-20210614monthly0.5https://www.biopharmawatch.com/news/NVAX/la-vacuna-de-novavax-para-la-covid-19-demuestra-una-eficacia-global-del-90-nvax-20210614monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-positive-data-from-three-complementary-studies-of-covid-19-beta-b-1-351--nvax-20210611monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-maryland-governor-larry-hogan-at-site-of-future-novavax-vaccines-innovatio-nvax-20210609monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-panel-at-bio-digital-2021-nvax-20210607monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-jefferies-virtual-healthcare-conference-nvax-20210527monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-international-society-for-vaccines-virtual-congress-covid-19-vaccine-nvax-20210524monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-memorandum-of-understanding-to-explore-expansion-of-covid-19-vaccine-act-nvax-20210522monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-honored-by-maryland-tech-council-during-2021-industry-awards-celebration-nvax-20210521monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-annonce-des-donne-es-pre-cliniques-positives-pour-l-nvax-20210512monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-dados-pre-cli-nicos-positivos-em-relac-a-o-a-candidata-a-vacina-combinada--nvax-20210511monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-datos-precli-nicos-positivos-para-la-candidata-a-la-vacuna-combinada-contr-nvax-20210511monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-gibt-positive-pra-klinische-daten-fu-r-kombinations-impfstoffkandidaten-gegen-infl-nvax-20210511monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-positive-preclinical-data-for-combination-influenza-and-covid-19-vaccine-nvax-20210510monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-y-gavi-ejecutan-el-acuerdo-de-compra-anticipada-de-la-vacuna-contra-la-covid-19-pa-nvax-20210507monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-e-gavi-assinam-contrato-de-compra-antecipada-para-vacina-contra-covid-19-para-o-co-nvax-20210507monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-y-gavi-ejecutan-un-acuerdo-avanzado-de-compra-para-la-vacuna-de-la-covid-19-para-c-nvax-20210507monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-et-gavi-signent-un-accord-d-nvax-20210507monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-und-gavi-schlie-en-vorabkaufvertrag-u-ber-covid-19-impfstoff-fu-r-covax-facility-a-nvax-20210507monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-gavi-execute-advance-purchase-agreement-for-covid-19-vaccine-for-covax-facilit-nvax-20210506monthly0.5https://www.biopharmawatch.com/news/NVAX/new-england-journal-of-medicine-publishes-phase-2b-clinical-trial-results-demonstrating-ef-nvax-20210505monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiates-pediatric-expansion-for-phase-3-clinical-trial-of-covid-19-vaccine-nvax-20210503monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-first-quarter-financial-results-and-operational-nvax-20210423monthly0.5https://www.biopharmawatch.com/news/NVAX/malaria-vaccine-phase-2b-clinical-trial-results-published-in-preprints-with-the-lancet-nvax-20210423monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-university-of-oxford-com-cov2-study-comparing-mixed-covid-19-vac-nvax-20210414monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-leadership-updates-nvax-20210413monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-fireside-chat-at-goldman-sachs-virtual-conference-nvax-20210408monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-lance-un-essai-clinique-croise-pour-son-vaccin-contre-la-covid-19-nvax-20210407monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiiert-cross-over-der-klinischen-studie-mit-dem-impfstoff-covid-19-nvax-20210407monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-inicia-crossover-de-estudo-cli-nico-da-vacina-contra-a-covid-19-nvax-20210406monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-inicia-el-cruce-del-ensayo-cli-nico-de-la-vacuna-covid-19-nvax-20210406monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-inicia-el-ensayo-cli-nico-cruzado-de-la-vacuna-contra-la-covid-19-nvax-20210406monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiates-covid-19-vaccine-clinical-trial-crossover-nvax-20210405monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-ceo-stan-erck-to-participate-in-longwood-healthcare-leaders-meeting-nvax-20210405monthly0.5https://www.biopharmawatch.com/news/NVAX/gsk-to-support-manufacture-of-novavax-nvax-20210329monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-confirme-le-haut-niveau-d-nvax-20210314monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-confirma-altos-niveles-de-eficacia-contra-las-cepas-de-covid-19-originales-y-varia-nvax-20210314monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-besta-tigt-hohe-wirksamkeit-gegen-original-und-variant-covid-19-sta-mme-in-studien-nvax-20210312monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-confirma-altos-ni-veis-de-efica-cia-contra-cepas-de-covid-19-originais-e-variantes-nvax-20210312monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-confirma-alta-eficacia-contra-las-cepas-de-covid-19-originales-y-variantes-nvax-20210312monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-confirms-high-levels-of-efficacy-against-original-and-variant-covid-19-strains-in--nvax-20210311monthly0.5https://www.biopharmawatch.com/news/NVAX/reminder-novavax-to-host-an-rsv-f-vaccine-update-conference-call-and-webcast-on-july-24-20-nvax-20170721monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-an-rsv-f-vaccine-update-conference-call-and-webcast-on-july-24-2017-at-4-3-nvax-20170717monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-rsv-f-vaccine-phase-2-clinical-trial-data-in-women-of-child-bearing-age-published--nvax-20170607monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-positive-top-line-data-from-phase-2-clinical-trial-of-rsv-f-vaccine-to-p-nvax-20150929monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-noble-financial-7th-annual-equity-conference-nvax-20110513monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-named-biotechnology-firm-of-the-year-by-tech-council-of-maryland-nvax-20110511monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-first-quarter-2011-financial-results-nvax-20110509monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-report-first-quarter-2011-financial-results-on-may-9-2011-nvax-20110503monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-senior-management-appointments-nvax-20110426monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-change-in-leadership-nvax-20110419monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-s-vlp-influenza-vaccine-named-one-of-top-100-drugs-in-development-today-novavax-in-nvax-20110405monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-fourth-quarter-and-2010-year-end-financial-results-nvax-20110328monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-release-date-of-2010-year-end-financial-results-and-investor-conference--nvax-20110323monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-bit-life-science-nvax-20110322monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-roth-23rd-annual-oc-growth-stock-conference-nvax-20110311monthly0.5https://www.biopharmawatch.com/news/NVAX/maryland-governor-martin-o-nvax-20110303monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-awarded-hhs-barda-contract-valued-at-up-to-179-million-to-develop-pandemic-and-sea-nvax-20110301monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-licenses-recombinant-vlp-influenza-vaccine-to-lg-life-sciences-for-south-korea-and-nvax-20110301monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-citi-2011-global-health-care-conference-nvax-20110224monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-presents-final-results-from-h1n1-influenza-vaccine-trial-at-world-health-organizat-nvax-20110218monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-13th-annual-bio-ceo-investor-conference-nvax-20110210monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-h1n1-vlp-influenza-vaccine-clinical-data-at-7th-world-health-organizati-nvax-20110209monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-launches-phase-i-clinical-trial-to-evaluate-its-novel-vaccine-against-respiratory--nvax-20110104monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-university-of-massachusetts-medical-school-publish-preclinical-safety-and-effi-nvax-20101222monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-receives-fda-clearance-to-launch-phase-i-rsv-vaccine-clinical-trial-nvax-20101216monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-piper-jaffray-22nd-annual-healthcare-conference-nvax-20101129monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-lazard-7th-annual-healthcare-conference-nvax-20101111monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-third-quarter-2010-financial-results-nvax-20101105monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-awarded-nearly-1-million-in-grants-from-irs-under-qualifying-therapeutic-discovery-nvax-20101104monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-report-third-quarter-2010-financial-results-on-november-5-2010-nvax-20101015monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-bio-investor-forum-nvax-20100929monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-stifel-nicolaus-conference-nvax-20100908monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-interscience-conference-on-antimicrobial-agents-and-chemotherapy-nvax-20100908monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-endorses-new-u-s-initiatives-to-develop-medical-countermeasures-nvax-20100819monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-immunotherapeutics-and-vaccine-imvac-summit-nvax-20100817monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-positive-results-from-pre-clinical-safety-study-of-respiratory-syncytial-v-nvax-20100812monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-second-quarter-2010-financial-results-nvax-20100806monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-elects-richard-h-douglas-to-its-board-of-directors-nvax-20100806monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-report-first-quarter-2025-financial-results-on-tuesday-may-6-2025-hrtx-20250422monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-thursd-hrtx-20250213monthly0.5https://www.biopharmawatch.com/news/HRTX/u-s-district-court-upholds-validity-of-cinvanti-patents-hrtx-20241203monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-report-third-quarter-2024-financial-results-on-tuesday-november-12-2-hrtx-20241029monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-reaffirms-availability-and-ample-supply-of-cinvanti-sustol-and-aponvie--hrtx-20241010monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-fda-approval-of-the-prior-approval-supplement-application-for-hrtx-20240925monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-appointment-of-brett-fleshman-as-chief-business-officer-hrtx-20240903monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-report-second-quarter-2024-financial-results-on-tuesday-august-6-202-hrtx-20240730monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-the-inclusion-of-zynrelef-as-a-qualifying-product-under-the-p-hrtx-20240715monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-report-first-quarter-2024-financial-results-on-tuesday-may-7-2024-hrtx-20240424monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-host-investor-day-on-may-15-2024-in-new-york-city-hrtx-20240411monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-presentation-at-the-23rd-annual-needham-virtual-healthcare-co-hrtx-20240328monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-report-fourth-quarter-and-full-year-2023-financial-results-on-tuesda-hrtx-20240228monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-report-third-quarter-2023-financial-results-on-tuesday-november-14-2-hrtx-20231107monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-report-second-quarter-2023-financial-results-on-monday-august-14-202-hrtx-20230807monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-cost-reduction-plan-and-restructuring-hrtx-20230724monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-appointment-of-ira-duarte-as-chief-financial-officer-hrtx-20230623monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023-hrtx-20230504monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-centers-for-medicare-medicaid-services-cms-granted-pass-throu-hrtx-20230313monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-on-thursd-hrtx-20230310monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-presentation-at-43rd-annual-cowen-healthcare-conference-hrtx-20230227monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-virtual-presentation-at-evercore-isi-5th-annual-healthconx-co-hrtx-20221121monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-76-5-million-private-placement-financing-hrtx-20220809monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-report-second-quarter-2022-financial-results-on-tuesday-august-9-202-hrtx-20220802monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-restructuring-and-cost-reduction-plan-to-address-market-dynam-hrtx-20220630monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-the-2022-jefferies-global-healthcare-conference-hrtx-20220526monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-presents-zynrelef-data-at-the-society-for-obstetric-anesthesia-and-peri-hrtx-20220516monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-report-first-quarter-2022-financial-results-on-monday-may-9-2022-hrtx-20220503monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-the-21st-annual-virtual-needham-healthcare-conference-hrtx-20220405monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-42nd-annual-cowen-healthcare-conference-hrtx-20220302monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-report-fourth-quarter-and-full-year-2021-financial-results-on-monday-hrtx-20220222monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-upcoming-investor-conferences-hrtx-20211111monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-report-third-quarter-2021-financial-results-on-wednesday-november-3--hrtx-20211028monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-the-2021-cantor-virtual-global-healthcare-conference-hrtx-20210921monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-publication-of-results-from-hope-helping-opioid-prescription--hrtx-20210728monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-publication-showing-reduction-of-pain-and-opioid-use-compared-hrtx-20210721monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-340b-prime-vendor-contract-with-apexus-for-zynrelef-hrtx-20210706monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-u-s-commercial-launch-and-availability-of-zynrelef-for-the-ma-hrtx-20210701monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-the-2021-jefferies-virtual-investor-conference-hrtx-20210525monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-150-million-convertible-debt-financing-hrtx-20210525monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-u-s-fda-approval-of-zynrelef-htx-011-for-the-management-of-po-hrtx-20210513monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-several-upcoming-virtual-investor-conferences-hrtx-20210217monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-several-upcoming-virtual-investor-conferences-hrtx-20201111monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-cantor-virtual-global-healthcare-conference-hrtx-20200911monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-publication-of-results-from-study-209-a-phase-2b-study-of-htx-hrtx-20200604monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-the-19th-annual-needham-virtual-healthcare-conference-hrtx-20200409monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-the-40th-annual-cowen-healthcare-conference-hrtx-20200225monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-the-9th-annual-svb-leerink-global-healthcare-conference-hrtx-20200218monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-highlights-progress-in-pain-management-and-cinv-franchises-hrtx-20200113monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-the-evercore-isi-healthconx-conference-hrtx-20191126monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-the-jefferies-london-healthcare-conference-hrtx-20191114monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-the-stifel-2019-healthcare-conference-hrtx-20191113monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-announces-fda-approval-of-supplemental-new-drug-application-to-expand-cinvanti-label-hrtx-20191022monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-pricing-of-public-offering-of-common-stock-hrtx-20191003monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-proposed-public-offering-of-common-stock-hrtx-20191003monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-announces-positive-topline-results-from-phase-3b-clinical-study-of-htx-011-in-total--hrtx-20191002monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-appoints-kimberly-manhard-to-board-of-directors-hrtx-20191001monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-appoints-stephen-davis-to-board-of-directors-hrtx-20191001monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-resubmits-new-drug-application-to-fda-for-htx-011-for-the-management-of-hrtx-20191001monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-the-2019-cantor-global-healthcare-conference-hrtx-20190925monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-2019-jmp-securities-life-sciences-conference-hrtx-20190613monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-jefferies-2019-healthcare-conference-hrtx-20190529monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-the-bank-of-america-merrill-lynch-2019-healthcare-confere-hrtx-20190508monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-partners-with-the-national-academy-of-medicine-to-counter-the-opioid-ep-hrtx-20190507monthly0.5https://www.biopharmawatch.com/news/HRTX/77-of-patients-remain-opioid-free-when-htx-011-is-given-with-an-over-the-counter-analgesic-hrtx-20190311monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-the-39th-annual-cowen-healthcare-conference-hrtx-20190304monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-the-8th-annual-leerink-partners-global-healthcare-confere-hrtx-20190220monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-retirement-of-robert-rosen-as-president-hrtx-20190205monthly0.5https://www.biopharmawatch.com/news/HRTX/90-of-patients-remain-opioid-free-when-htx-011-is-given-with-an-over-the-counter-analgesic-hrtx-20190103monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-hrtx-20181231monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-the-evercore-isi-healthconx-conference-hrtx-20181120monthly0.5https://www.biopharmawatch.com/news/HRTX/u-s-surgeon-general-jerome-adams-discusses-opioid-alternatives-and-the-importance-of-partn-hrtx-20181112monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-announces-fda-submission-of-htx-011-nda-for-postoperative-pain-management-hrtx-20181031monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-to-present-at-the-2018-cantor-global-healthcare-conference-hrtx-20180924monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-to-announce-first-quarter-2026-financial-results-on-may-13-2026-xtnt-20260507monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-to-announce-third-quarter-2025-financial-results-on-november-11-2025-xtnt-20251104monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-the-launch-of-osteofactor-pro-xtnt-20250528monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-to-issue-first-quarter-2025-financial-results-on-may-12-2025-xtnt-20250506monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-launches-trivium-advanced-bone-graft-for-superior-performance-xtnt-20250423monthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-highlights-phase-1-data-in-an-investigator-initiated-study-of-lymphir-deni-ctor-20260601monthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-announces-presentation-of-lymphir-phase-1-combination-study-data-at-the-20-ctor-20260526monthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-deploys-ai-platform-to-amplify-the-performance-of-its-commercial-team-ahea-ctor-20250822monthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-announces-closing-of-9-0-million-public-offering-ctor-20250717monthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-expands-distribution-network-for-lymphir-with-execution-of-distribution-se-ctor-20250715monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-and-hope-therapeutics-inc-selected-to-present-at-the-w-nrxp-20250521monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-reports-first-quarter-2025-financial-results-and-provi-nrxp-20250515monthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-inc-a-subsidiary-of-nrx-pharmaceuticals-inc-nasdaq-nrxp-announces-signin-nrxp-20250515monthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-inc-and-nrx-pharmaceuticals-nasdaq-nrxp-announce-signing-of-definitive-a-nrxp-20250513monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-report-first-quarter-2025-financial-results-on-may--nrxp-20250512monthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaq-nrxp-to-host-investor-event-at-ma-nrxp-20250506monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-files-patent-application-for-nrx-100-its-proprietary-p-nrxp-20250505monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-announces-fda-award-of-filing-fee-waiver-for-upcoming--nrxp-20250430monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-and-hope-therapeutics-inc-to-participate-in-an-h-c-wai-nrxp-20250421monthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaq-nrxp-announce-signing-of-a-term-s-nrxp-20250403monthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaq-nrxp-announce-definitive-purchase-nrxp-20250331monthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaq-nrxp-announce-signing-of-binding--nrxp-20250324monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-reports-fourth-quarter-and-full-year-2024-financial-re-nrxp-20250317monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-report-fourth-quarter-and-full-year-2024-financial--nrxp-20250312monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheime-nrxp-20250206monthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaq-nrxp-engage-btig-as-financial-adv-nrxp-20250203monthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaq-nrxp-execute-agreement-for-27-mil-nrxp-20250128monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-advances-relationship-with-anson-funds-with-8-9-millio-nrxp-20250128monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-regains-compliance-with-nasdaq-minimum-market-value-of-nrxp-20250121monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-announces-the-appointment-of-michael-taylor-to-its-boa-nrxp-20250115monthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaq-nrxp-alert-investors-to-sanjay-gu-nrxp-20250114monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-announces-it-has-filed-an-application-with-nasdaq-to-u-nrxp-20250113monthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaq-nrxp-conduct-investor-workshop-at-nrxp-20250110monthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaq-nrxp-announce-dr-jonathan-javitt--nrxp-20250107monthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-inc-an-nrx-pharmaceuticals-inc-nasdaq-nrxp-subsidiary-will-host-an-inves-nrxp-20250103monthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaq-nrxp-announce-kadima-neuropsychia-nrxp-20250102monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-files-initial-section-of-u-s-new-drug-application-to-t-nrxp-20241230monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-announces-participation-in-the-noblecon20-noble-capital-ma-nrxp-20241126monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-announces-publication-of-paper-entitled-quality-assurance--nrxp-20241125monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-appoints-michael-abrams-as-chief-financial-officer-nrxp-20241118monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-reports-third-quarter-and-year-to-date-2024-financial-resu-nrxp-20241114monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-reschedules-conference-call-to-discuss-third-quarter-a-nrxp-20241113monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-report-third-quarter-and-year-to-date-2024-financia-nrxp-20241107monthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaq-nrxp-announce-signing-of-a-letter-nrxp-20241030monthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaq-nrxp-announce-signing-of-a-letter-nrxp-20241003monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-announces-completion-of-twelve-months-of-stability-on--nrxp-20240930monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-featured-on-psychiatrist-com-nrxp-20240911monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-and-hope-therapeutics-inc-announce-participation-at-th-nrxp-20240903monthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaq-nrxp-announce-potential-acquisiti-nrxp-20240826monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-reports-second-quarter-and-year-to-date-2024-financial-res-nrxp-20240814monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-report-second-quarter-and-year-to-date-2024-financi-nrxp-20240813monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-announces-up-to-16-million-senior-secured-debt-financi-nrxp-20240813monthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaq-nrxp-announce-alignment-with-fda--nrxp-20240729monthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-inc-and-nrx-pharmaceuticals-nasdaq-nrxp-announce-arbitration-order-enabl-nrxp-20240729monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-publishes-shareholder-update-letter-nrxp-20240701monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-to-proceed-with-two-new-drug-applications-in-2024-nrx-101--nrxp-20240628monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-participate-in-the-h-c-wainwright-5th-annual-neuro--nrxp-20240620monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-publishes-shareholder-update-letter-nrxp-20240610monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-presents-landmark-trial-of-nrx-101-in-suicidal-bipolar-dep-nrxp-20240528monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-participate-in-the-ef-hutton-annual-global-conferen-nrxp-20240508monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-report-first-quarter-2024-financial-results-on-may--nrxp-20240507monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-announces-final-clinical-trial-results-superior-safety-com-nrxp-20240506monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-receives-notice-from-nasdaq-that-the-company-has-demonstra-nrxp-20240418monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-announces-pricing-of-2-0-million-underwritten-public-offering-of-c-nrxp-20240418monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-announces-new-data-on-nrx-101-demonstrating-no-damage--nrxp-20240417monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-announces-development-of-new-proprietary-formulation-of-ht-nrxp-20240415monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-announces-data-lock-of-phase-2b-3-trial-of-nrx-101-in-suic-nrxp-20240408monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-reports-preliminary-fourth-quarter-and-full-year-2023-fina-nrxp-20240328monthly0.5https://www.biopharmawatch.com/news/NRXP/update-nrx-pharmaceuticals-nasdaq-nrxp-to-report-fourth-quarter-and-full-year-2023-financi-nrxp-20240326monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceutical-nrxp-20240325monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-to-report-fourth-quarter-and-full-year-2023-financial-results-and-prov-nrxp-20240321monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-announces-plan-to-distribute-shares-of-hope-therapeutics-a-nrxp-20240318monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-initiates-strategy-to-combat-short-sales-nrxp-20240312monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-completes-memorandum-of-understanding-and-collaborations-w-nrxp-20240311monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-announces-last-patient-last-visit-in-its-phase-2b-3-trial--nrxp-20240304monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-definitive-purchase-agreement-for-common-unregistered-shares-nrxp-20240301monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-announces-pricing-of-1-5-million-underwritten-public-offering-of-c-nrxp-20240227monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-launches-hope-therapeutics-inc-at-the-bio-ceo-investor-con-nrxp-20240226monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-reports-comments-by-strategic-partner-lotus-pharmaceut-nrxp-20240209monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-announces-the-incorporation-of-hope-therapeutics-inc-a-nrxp-20240205monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-to-present-keynote-address-on-ketamine-efficacy-and-risks--nrxp-20240102monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-demonstrates-compliance-with-nasdaq-mvls-standard-nrxp-20240102monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-the-election-of-janet-rehnquist-to-its-board-of-directors-nrxp-20231227monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-fda-clearance-of-its-investigational-new-drug-ind-applicatio-nrxp-20231218monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-provides-notice-of-annual-meeting-of-shareholders-nrxp-20231213monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-to-participate-in-lifesci-corporate-access-event-nrxp-20231211monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-to-present-at-noble-capital-markets-nrxp-20231127monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-to-report-third-quarter-2023-financial-results-on-november-14-2023-nrxp-20231107monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-and-nephron-pharmaceuticals-announce-joint-agreement-to-develop-intrav-nrxp-20231106monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-to-present-at-the-h-c-wainwright-25th-annual-global-investment-confere-nrxp-20230907monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-potent-antibacterial-activity-of-nrx-101-against-common-anti-nrxp-20230906monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-submission-of-an-investigational-new-drug-ind-application-fo-nrxp-20230830monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-reports-second-quarter-2023-financial-results-and-provides-business-up-nrxp-20230814monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-to-report-second-quarter-2023-financial-results-on-august-14-2023-nrxp-20230807monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-the-licensure-of-a-us-patent-to-support-use-of-nrx-101-for-c-nrxp-20230807monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-to-present-at-the-h-c-wainwright-4th-annual-neuropsychiatry-virtual-co-nrxp-20230620monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-closing-of-6-28-million-registered-direct-offering-nrxp-20230609monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-to-host-corporate-and-strategic-update-conference-call-on-monday-june--nrxp-20230602monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-reports-first-quarter-2023-financial-results-and-provides-business-upd-nrxp-20230516monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-reschedules-first-quarter-2023-financial-results-conference-call-nrxp-20230510monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-11-2023-nrxp-20230427monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-positive-recommendation-to-continue-enrollment-in-the-ongoin-nrxp-20230327monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-nrxp-20230317monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-builds-on-its-intellectual-property-foundation-for-neuropsychiatric-co-nrxp-20230222monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-reports-recommendations-of-data-safety-monitoring-board-for-trial-of-n-nrxp-20230202monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-provides-progress-update-on-interactions-with-the-fda-regarding-path-t-nrxp-20230119monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-to-present-scientific-update-at-the-6th-annual-sachs-associates-neuros-nrxp-20230105monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-initiates-phase-3-trial-treating-patients-with-bipolar-depression-with-nrxp-20230103monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-the-appointment-of-carrie-m-carretta-phd-apn-bc-ahn-bc-pmhnp-nrxp-20221205monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-receives-nasdaq-notice-of-listing-compliance-nrxp-20221202monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-reports-third-quarter-2022-financial-results-and-provides-business-upd-nrxp-20221114monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-to-report-third-quarter-2022-results-on-november-14-2022-nrxp-20221110monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-produces-first-phase-3-stage-nrx-101-drug-made-using-commercial-proces-nrxp-20221109monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-closes-11-million-unsecured-debt-financing-nrxp-20221107monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-leaders-to-present-at-the-h-c-wainwright-co-24th-annual-global-investm-nrxp-20220908monthly0.5https://www.biopharmawatch.com/news/NRXP/relief-therapeutics-holding-sa-and-nrx-pharmaceuticals-inc-announce-tentative-settlement-o-nrxp-20220822monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-provides-business-update-and-reports-second-quarter-2022-results-focus-nrxp-20220815monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-to-report-second-quarter-2022-results-on-august-15-2022-nrxp-20220810monthly0.5https://www.biopharmawatch.com/news/NRXP/fda-declines-emergency-use-authorization-for-zyesami-aviptadil-for-subgroup-of-patients-wi-nrxp-20220701monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-leaders-to-present-at-the-h-c-wainwright-co-1st-annual-mental-health-c-nrxp-20220623monthly0.5https://www.biopharmawatch.com/news/NRXP/class-action-suit-against-nrx-pharmaceuticals-dismissed-nrxp-20220622monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-provides-update-on-breakthrough-therapy-designation-btd-request-for-zy-nrxp-20220610monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-leaders-to-present-at-the-h-c-wainwright-co-global-investment-conferen-nrxp-20220519monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-provides-business-update-and-reports-first-quarter-2022-financial-resu-nrxp-20220516monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-enrollment-of-first-patient-in-phase-ii-study-of-bipolar-dep-nrxp-20220512monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-to-report-first-quarter-2022-results-on-may-16-2022-nrxp-20220510monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-files-new-breakthrough-therapy-designation-request-for-zyesami-aviptad-nrxp-20220421monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nrxp-20220408monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-provides-business-update-and-reports-full-year-2021-financial-results-nrxp-20220331monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-to-report-year-end-2021-results-on-march-31-2022-nrxp-20220328monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-appoints-ira-strassberg-as-chief-financial-officer-and-treasurer-nrxp-20220318monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-kpti-20260421monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20251103monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20251001monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20250902monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-second-quarter-2025-financial-results-on-august-11-2025-kpti-20250805monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20250801monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20250701monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-the-jefferies-global-healthcare-conference-kpti-20250603monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20250602monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-the-2025-rbc-capital-markets-global-healthcare-conference-kpti-20250519monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-poster-presentation-on-selinexor-in-myelofibrosis-at-the-2025-europea-kpti-20250514monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-first-quarter-2025-financial-results-on-may-12-2025-kpti-20250508monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20250501monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20250401monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20250303monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-1-for-15-reverse-stock-split-kpti-20250224monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-fourth-quarter-and-full-year-2024-financial-results-on-february-19-20-kpti-20250212monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20250203monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20250102monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-the-appointment-of-lori-macomber-as-chief-financial-officer-kpti-20250102monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-the-appointment-of-brendan-strong-as-senior-vice-president-of-investo-kpti-20241209monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-provides-endometrial-cancer-program-update-kpti-20241203monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20241202monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-the-piper-sandler-36th-annual-healthcare-conference-kpti-20241125monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-the-appointment-of-chief-accounting-officer-kpti-20241120monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-selinexor-data-at-the-66th-american-society-of-hematology-annual-mee-kpti-20241118monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-third-quarter-2024-financial-results-and-highlights-recent-company-prog-kpti-20241105monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20241101monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-third-quarter-2024-financial-results-on-november-5-2024-kpti-20241031monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-favorable-change-in-co-primary-endpoint-for-pivotal-phase-3-sentry-tr-kpti-20241031monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-host-investor-event-with-leading-myelofibrosis-kols-and-provide-a-favorable--kpti-20241030monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20241001monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20240903monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-upcoming-investor-conferences-kpti-20240903monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-second-quarter-2024-financial-results-and-highlights-recent-company-pro-kpti-20240806monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20240801monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-second-quarter-2024-financial-results-on-august-6-2024-kpti-20240731monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20240701monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20240603monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-presents-updated-exploratory-subgroup-analyses-from-siendo-study-in-patients-wi-kpti-20240601monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-the-jefferies-global-healthcare-conference-kpti-20240529monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-the-2024-rbc-capital-markets-global-healthcare-conference-kpti-20240508monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-first-quarter-2024-financial-results-and-highlights-recent-company-prog-kpti-20240508monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-significant-refinancing-transactions-and-amended-royalty-agreement-ex-kpti-20240508monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-first-quarter-2024-financial-results-on-may-8-2024-kpti-20240502monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20240501monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-presentations-in-endometrial-cancer-and-myelofibrosis-at-the-2024-ame-kpti-20240424monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20240401monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-barclays-26th-annual-global-healthcare-and-leerink-partners-g-kpti-20240306monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20240301monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-fourth-quarter-and-full-year-2023-financial-results-and-highlights-rece-kpti-20240229monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-fourth-quarter-and-full-year-2023-financial-results-on-february-29-20-kpti-20240222monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20240201monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-preliminary-unaudited-2023-revenue-and-2024-objectives-kpti-20240108monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-42nd-annual-j-p-morgan-healthcare-conference-kpti-20240103monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20240102monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-shares-data-at-ash-2023-showing-strong-svr-and-tss-durability-observed-from-pha-kpti-20231210monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20231201monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-upcoming-investor-conferences-kpti-20231108monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-new-preliminary-data-in-overall-survival-os-in-selinexor-treated-pati-kpti-20231106monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-presentations-at-the-65th-american-society-of-hematology-annual-meeti-kpti-20231102monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-third-quarter-2023-financial-results-and-highlights-recent-company-prog-kpti-20231102monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-clinical-trial-collaboration-with-bristol-myers-squibb-to-evaluate-no-kpti-20231030monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-third-quarter-2023-financial-results-on-november-2-2023-kpti-20231026monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20231002monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-selinexor-data-at-the-2023-international-myeloma-society-annual-meet-kpti-20230926monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-upcoming-investor-conferences-kpti-20230905monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20230901monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-appoints-zhen-su-md-mba-to-its-board-of-directors-kpti-20230901monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-second-quarter-2023-financial-results-and-highlights-recent-company-pro-kpti-20230802monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20230801monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-second-quarter-2023-financial-results-on-august-2-2023-kpti-20230726monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-presentation-of-updated-exploratory-subgroup-analyses-from-siendo-stu-kpti-20230725monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-updated-exploratory-subgroup-analysis-from-siendo-study-in-patients-w-kpti-20230719monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-receives-fda-fast-track-designation-for-selinexor-for-the-treatment-of-myelofib-kpti-20230717monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20230705monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-initiates-pivotal-phase-3-study-of-xpo1-inhibitor-selinexor-and-ruxolitinib-in--kpti-20230628monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20230601monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-the-jefferies-healthcare-conference-kpti-20230601monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-new-selinexor-data-at-the-2023-american-society-of-clinical-oncology-kpti-20230523monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-first-quarter-2023-financial-results-and-highlights-recent-company-prog-kpti-20230504monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-presentation-of-interim-data-from-phase-2-study-of-single-agent-eltan-kpti-20230503monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20230501monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-first-quarter-2023-financial-results-on-may-4-2023-kpti-20230501monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-presentation-of-updated-phase-1-selinexor-data-in-patients-with-treat-kpti-20230418monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-data-from-phase-1-study-of-selinexor-in-patients-with-treatment-nai--kpti-20230414monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20230403monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-updated-selinexor-data-in-patients-with-treatment-nai-ve-myelofibrosi-kpti-20230314monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-barclays-global-healthcare-conference-kpti-20230308monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20230301monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-and-menarini-group-receive-full-marketing-authorization-from-the-uk-medicines-h-kpti-20230221monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-fourth-quarter-and-full-year-2022-financial-results-and-highlights-rece-kpti-20230215monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-svb-securities-global-biopharma-conference-kpti-20230209monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-15-20-kpti-20230208monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20230201monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-preliminary-unaudited-fourth-quarter-and-full-year-2022-revenue-and-o-kpti-20230109monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-41st-annual-j-p-morgan-healthcare-conference-kpti-20230104monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20230103monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-presentation-of-updated-phase-1-selinexor-data-in-patients-with-treat-kpti-20221212monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-165-million-private-placement-kpti-20221205monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-investor-and-analyst-event-at-ash-2022-on-selinexor-data-in-patients--kpti-20221205monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20221201monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-upcoming-investor-conferences-kpti-20221108monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-third-quarter-2022-financial-results-and-highlights-recent-company-prog-kpti-20221103monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-new-selinexor-data-in-myelofibrosis-and-multiple-myeloma-to-be-presen-kpti-20221103monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20221101monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-and-menarini-group-announce-orphan-medicinal-product-designation-from-the-europ-kpti-20221031monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-third-quarter-2022-financial-results-on-november-3-2022-kpti-20221020monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20221003monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-upcoming-investor-conferences-kpti-20220907monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20220901monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-second-quarter-2022-financial-results-and-highlights-recent-company-pro-kpti-20220804monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-the-2022-wedbush-pacgrow-healthcare-conference-kpti-20220802monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20220801monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-second-quarter-2022-financial-results-on-august-4-2022-kpti-20220728monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-and-menarini-group-receive-full-marketing-authorisation-from-the-european-commi-kpti-20220721monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-granted-regulatory-designations-for-eltanexor-for-the-treatment-of-myelodysplas-kpti-20220720monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20220701monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20220601monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-the-jefferies-healthcare-conference-kpti-20220601monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-new-selinexor-data-at-the-2022-american-society-of-clinical-oncology-kpti-20220526monthly0.5https://www.biopharmawatch.com/news/KPTI/the-european-myeloma-network-and-karyopharm-announce-dosing-of-first-patient-in-collaborat-kpti-20220525monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-and-menarini-group-receive-positive-chmp-opinion-for-nexpovio-selinexor-for-the-kpti-20220520monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-xpovio-selinexor-data-to-be-presented-at-the-european-hematology-asso-kpti-20220512monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-the-2022-rbc-capital-markets-global-healthcare-conference-kpti-20220510monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-first-quarter-2022-financial-results-and-highlights-recent-company-prog-kpti-20220505monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20220502monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-first-quarter-2022-financial-results-on-may-5-2022-kpti-20220428monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-selinexor-data-to-be-presented-at-the-2022-american-society-of-clinic-kpti-20220427monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-the-canaccord-genuity-horizons-in-oncology-conference-kpti-20220407monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20220401monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-further-transition-of-co-founders-sharon-shacham-phd-mba-and-michael--kpti-20220329monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-upcoming-presentations-of-phase-3-siendo-study-of-selinexor-in-patien-kpti-20220316monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-names-new-head-of-investor-relations-kpti-20220314monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-the-barclays-global-healthcare-conference-kpti-20220309monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-provides-u-s-regulatory-update-on-selinexor-in-advanced-or-recurrent-endometria-kpti-20220301monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20220228monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-changes-to-its-clinical-leadership-team-kpti-20220222monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-11th-annual-svb-leerink-global-healthcare-conference-kpti-20220211monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-strong-fourth-quarter-and-full-year-2021-financial-results-and-highligh-kpti-20220208monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-phase-3-siendo-study-meets-primary-endpoint-with-statistically-signif-kpti-20220208monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-fourth-quarter-and-full-year-2021-financial-results-on-february-8-202-kpti-20220202monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20220201monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-receives-orphan-drug-designation-from-fda-for-eltanexor-for-the-treatment-of-my-kpti-20220124monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-b-riley-securities-oncology-investor-conference-kpti-20220121monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-promotes-sohanya-cheng-to-chief-commercial-officer-kpti-20220110monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-preliminary-unaudited-fourth-quarter-and-full-year-2021-net-product-r-kpti-20220110monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-40th-annual-j-p-morgan-healthcare-conference-kpti-20220104monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20220103monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-and-menarini-group-enter-into-exclusive-license-agreement-to-commercialize-nexp-kpti-20211221monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-kpti-20211217monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-presentation-of-updated-phase-2-selinexor-data-in-patients-with-myelo-kpti-20211211monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-the-appointment-of-peter-k-honig-md-mph-to-its-board-of-directors-kpti-20211206monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-dosing-of-first-patient-in-a-new-phase-2-study-evaluating-single-agen-kpti-20211206monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-completes-patient-recruitment-in-phase-3-siendo-study-of-selinexor-in-patients--kpti-20211202monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20211201monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-host-virtual-investor-day-on-december-8-2021-kpti-20211201monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-jefferies-london-healthcare-conference-kpti-20211111monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-new-interim-phase-2-selinexor-data-in-myelofibrosis-selected-for-oral-kpti-20211104monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-strong-third-quarter-2021-financial-results-and-provides-business-highl-kpti-20211103monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20211101monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-third-quarter-2021-financial-results-on-november-3-2021-kpti-20211027monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-dosing-of-first-patient-in-a-phase-2-study-investigating-oral-eltanex-kpti-20211021monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20211001monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-upcoming-virtual-investor-conference-participation-kpti-20210907monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20210901monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-business-highlights-and-second-quarter-2021-financial-results-kpti-20210805monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-upcoming-virtual-investor-conference-participation-kpti-20210803monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20210802monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-second-quarter-2021-financial-results-on-august-5-2021-kpti-20210729monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-dosing-of-first-patients-in-two-new-company-sponsored-clinical-studie-kpti-20210728monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20210701monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-expansion-of-royalty-agreement-with-healthcare-royalty-for-up-to-100--kpti-20210624monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-xpovio-selinexor-data-to-be-presented-at-the-european-hematology-asso-kpti-20210609monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-key-changes-to-its-commercial-leadership-team-kpti-20210608monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-xpovio-selinexor-is-now-available-in-additional-strength-tablets-kpti-20210603monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-receives-conditional-marketing-authorization-in-the-united-kingdom-uk-for-nexpo-kpti-20210602monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20210601monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-annonce-l-kpti-20210526monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-anuncia-la-apertura-de-inscripciones-para-un-estudio-de-fase-3-que-evalu-a-seli-kpti-20210526monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-ku-ndigt-offene-rekrutierung-an-teilnehmenden-kliniken-in-europa-fu-r-eine-phas-kpti-20210526monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-jefferies-2021-virtual-healthcare-conference-kpti-20210526monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-xpovio-selinexor-data-to-be-presented-at-the-2021-american-society-of-kpti-20210519monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20210504monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-first-quarter-2021-financial-results-and-highlights-recent-company-prog-kpti-20210503monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-the-appointment-of-richard-paulson-as-president-and-chief-executive-o-kpti-20210503monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-first-quarter-2021-financial-results-on-may-3-2021-kpti-20210428monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-european-medicines-agency-kpti-20210426monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-publication-of-health-related-quality-of-life-outcomes-from-phase-3-s-kpti-20210419monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20210401monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-receives-conditional-marketing-authorization-from-the-european-commission-for-n-kpti-20210329monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20210301monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-upcoming-virtual-investor-conference-participation-kpti-20210217monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-fourth-quarter-and-full-year-2020-financial-results-and-highlights-rece-kpti-20210211monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-fourth-quarter-and-full-year-2020-financial-results-on-february-11-20-kpti-20210204monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-xpovio-selinexor-receives-regulatory-approval-in-israel-for-the-treat-kpti-20210204monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20210201monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-receives-positive-chmp-opinion-for-nexpovio-selinexor-for-the-treatment-of-pati-kpti-20210129monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-preliminary-unaudited-fourth-quarter-and-full-year-2020-total-revenue-kpti-20210111monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20210104monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-39th-annual-j-p-morgan-healthcare-conference-kpti-20210104monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-fda-approval-of-xpovio-selinexor-as-a-treatment-for-patients-with-mul-kpti-20201218monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-appoints-michael-mano-as-senior-vice-president-general-counsel-and-reports-indu-kpti-20201215monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-national-comprehensive-cancer-network-adds-three-xpovio-selinexor-tre-kpti-20201211monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-presentation-of-new-xpovio-selinexor-data-in-patients-with-acute-myel-kpti-20201207monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-presents-xpovio-selinexor-data-in-multiple-myeloma-and-diffuse-large-b-cell-lym-kpti-20201207monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-investor-and-analyst-event-at-the-american-society-of-hematology-2020-kpti-20201201monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-expands-board-of-directors-and-executive-leadership-team-and-reports-inducement-kpti-20201201monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-ongoing-phase-3-siendo-study-of-xpovio-selinexor-in-patients-with-end-kpti-20201125monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-positive-phase-3-seal-data-in-oral-presentation-at-the-connective-tissu-kpti-20201120monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-publication-of-xpovio-selinexor-phase-3-boston-study-results-in-the-l-kpti-20201112monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-jefferies-2020-virtual-london-healthcare-conference-kpti-20201110monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-xpovio-selinexor-clinical-data-to-be-presented-at-the-american-societ-kpti-20201104monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20201103monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-third-quarter-2020-financial-results-and-highlights-recent-company-prog-kpti-20201102monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-phase-3-seal-study-meets-primary-endpoint-with-significant-increase-i-kpti-20201102monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-third-quarter-2020-financial-results-on-november-2-2020-kpti-20201026monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-selinexor-clinical-data-to-be-presented-at-the-international-society--kpti-20201006monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20201001monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-xpovio-selinexor-clinical-data-to-be-presented-at-european-society-fo-kpti-20200914monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-september-2020-virtual-investor-conference-participation-kpti-20200902monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20200901monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-appoints-christy-j-oliger-to-its-board-of-directors-kpti-20200831monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-kpti-20200821monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-second-quarter-2020-financial-results-and-highlights-recent-company-pro-kpti-20200804monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20200803monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-second-quarter-2020-financial-results-on-august-4-2020-kpti-20200728monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-oral-presentation-at-the-american-college-of-rheumatolog-kpti-20121112monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-multiple-publications-on-selective-inhibitors-of-nuclear-kpti-20121031monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-recognizes-the-contributions-of-co-founder-ronald-depinho-md-kpti-20121031monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-the-publication-of-two-preclinical-studies-on-the-activi-kpti-20120801monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-appointment-of-co-founder-dr-ronald-depinho-to-the-natio-kpti-20120508monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-multiple-presentations-on-selective-inhibitors-of-nuclea-kpti-20120307monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-presentations-by-seven-collaborators-showing-major-progr-kpti-20111108monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-closes-10-million-series-a2-financing-to-expand-planned-phase-1-pr-kpti-20111102monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-inc-and-katholieke-universiteit-leuven-sign-exclusive-collaboratio-kpti-20111011monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-inc-appoints-michael-kauffman-md-phd-as-chief-executive-officer-kpti-20110105monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-inc-closes-20-million-series-a-financing-to-advance-pipeline-of-no-kpti-20101103monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-u-s-commercial-availability-of-nereus-tradipitant-the-firs-vnda-20260504monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-third-quarter-2025-financial-results-on-october-29-2025-vnda-20251022monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-fda-granted-orphan-drug-designation-for-vgt-1849b-a-novel--vnda-20250828monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-seeks-fda-commissioner-review-of-outgoing-cder-director-vnda-20250821monthly0.5https://www.biopharmawatch.com/news/VNDA/in-a-major-win-for-vanda-a-federal-appeals-court-overturns-fda-vnda-20250818monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-second-quarter-2025-financial-results-on-july-31-2025-vnda-20250723monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-first-patient-dosed-in-a-trial-evaluating-vca-894a-in-char-vnda-20250610monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-presentation-at-2025-ascp-annual-meeting-vnda-20250527monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-in-the-mizuho-neuro-ophthalmology-summit-202-vnda-20250516monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-announces-bysanti-nda-filing-fda-decision-expected-in-early-2026-vnda-20250505monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-first-quarter-2025-financial-results-on-may-7-2025-vnda-20250502monthly0.5https://www.biopharmawatch.com/news/VNDA/fda-bureaucrats-unlawfully-delay-hearing-on-vanda-drug-and-falsely-blame-commissioner-maka-vnda-20250423monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-presentation-at-2025-aan-annual-meeting-vnda-20250407monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-the-submission-of-an-nda-to-the-fda-for-bysanti-for-the-tr-vnda-20250331monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-the-publication-of-an-article-titled-potential-aso-based-p-vnda-20250224monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2024-financial-results-on-f-vnda-20250205monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-and-anaptys-announce-exclusive-global-license-agreement-for-vanda-to-vnda-20250203monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-accepts-fda-opportunity-for-a-hearing-on-new-drug-application-for-tr-vnda-20250127monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-s-letter-to-fda-commissioner-highlights-faulty-gastroparesis-nda-review-vanda-pharma-vnda-20250108monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-orphan-drug-designation-granted-for-vgt-1849a-a-novel-and--vnda-20241220monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-at-november-2024-investor-conferences-vnda-20241112monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-third-quarter-2024-financial-results-on-november-6-2024-vnda-20241030monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-in-the-2024-cantor-global-healthcare-confere-vnda-20240911monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-in-the-h-c-wainwright-global-investment-conf-vnda-20240904monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-in-the-wells-fargo-2024-healthcare-conferenc-vnda-20240829monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-second-quarter-2024-financial-results-on-july-31-2024-vnda-20240726monthly0.5https://www.biopharmawatch.com/news/VNDA/federal-court-allows-vanda-vnda-20240701monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-in-the-jefferies-2024-global-healthcare-conf-vnda-20240530monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-completion-of-transfer-of-fda-marketing-authorization-for--vnda-20240530monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-presentations-at-sleep-2024-vnda-20240529monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-positive-results-from-a-second-phase-iii-study-of-tradipitan-vnda-20240515monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-first-quarter-2024-financial-results-on-may-8-2024-vnda-20240430monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reacts-to-u-s-supreme-court-vnda-20240422monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-confirms-rejection-of-unsolicited-takeover-proposals-from-future-pak-vnda-20240417monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2023-financial-results-on-f-vnda-20240131monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-receives-fda-approval-to-proceed-with-investigational-new-drug-vtr-2-vnda-20240131monthly0.5https://www.biopharmawatch.com/news/VNDA/court-orders-fda-to-resolve-vanda-pharmaceuticals-vnda-20240130monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-a-u-s-patent-allowance-for-ponvory-ponesimod-in-the-u-s-vnda-20240125monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-the-publication-of-an-article-on-the-efficacy-of-tradipita-vnda-20240125monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-receives-fda-approval-to-proceed-with-investigational-new-drug-vca-8-vnda-20240123monthly0.5https://www.biopharmawatch.com/news/VNDA/federal-court-allows-vanda-pharmaceuticals-vnda-20240119monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-the-publication-of-efficacy-and-safety-of-iloperidone-in-b-vnda-20240117monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-comments-on-fda-vnda-20240112monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-in-the-j-p-morgan-healthcare-conference-vnda-20240104monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-that-u-s-food-and-drug-administration-accepts-new-drug-app-vnda-20231204monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-at-november-2023-investor-conferences-vnda-20231109monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-third-quarter-2023-financial-results-on-november-8-2023-vnda-20231101monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-intends-to-petition-the-u-s-supreme-court-in-its-hetlioz-anda-litiga-vnda-20231020monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-in-the-jefferies-inaugural-biotech-cns-neuro-vnda-20231005monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-in-the-h-c-wainwright-global-investment-conf-vnda-20230906monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-second-quarter-2023-financial-results-on-july-27-2023-vnda-20230720monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-in-the-jefferies-2023-global-healthcare-conf-vnda-20230605monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-presentations-at-sleep-2023-vnda-20230601monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-orphan-drug-designation-granted-for-vca-894a-a-novel-antis-vnda-20230601monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-results-from-a-phase-iii-study-of-tradipitant-in-motion-sick-vnda-20230525monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-presentations-at-ddw-2023-vnda-20230504monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-sues-federal-government-for-misappropriation-of-trade-secrets-and-co-vnda-20230502monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-first-quarter-2023-financial-results-on-may-3-2023-vnda-20230427monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-prevails-in-jet-lag-litigation-against-the-fda-vnda-20230328monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2022-financial-results-on-f-vnda-20230201monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-in-the-j-p-morgan-healthcare-conference-vnda-20230106monthly0.5https://www.biopharmawatch.com/news/VNDA/fanapt-shown-to-be-effective-in-bipolar-i-disorder-in-phase-iii-clinical-study-vnda-20221219monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-results-in-a-phase-ii-clinical-study-of-vqw-765-in-the-treat-vnda-20221202monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-at-november-2022-investor-conferences-vnda-20221108monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-third-quarter-2022-financial-results-on-november-2-2022-vnda-20221026monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-orphan-drug-designation-granted-for-vpo-227-a-novel-candid-vnda-20221021monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-and-olipass-announce-strategic-partnership-to-develop-antisense-olig-vnda-20220929monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-in-the-h-c-wainwright-global-investment-conf-vnda-20220908monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-notice-of-opportunity-for-an-fda-hearing-on-the-snda-for-h-vnda-20220907monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-second-quarter-2022-financial-results-on-august-3-2022-vnda-20220727monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-in-the-jefferies-2022-global-healthcare-conf-vnda-20220602monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-presentations-at-sleep-2022-vnda-20220531monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-presentations-at-ddw-2022-vnda-20220519monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-in-the-bofa-securities-2022-healthcare-confe-vnda-20220504monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-first-quarter-2022-financial-results-on-may-5-2022-vnda-20220428monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2021-financial-results-on-f-vnda-20220217monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-at-november-2021-investor-conferences-vnda-20211110monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-third-quarter-2021-financial-results-on-november-3-2021-vnda-20211027monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-at-evercore-isi-vnda-20211014monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-at-the-citi-16th-annual-biopharma-virtual-co-vnda-20210907monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-closes-enrollment-in-the-odyssey-study-comparing-tradipitant-and-pla-vnda-20210803monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-second-quarter-2021-financial-results-on-july-28-2021-vnda-20210721monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-at-upcoming-2021-investor-conferences-vnda-20210512monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-first-quarter-2021-financial-results-on-may-5-2021-vnda-20210420monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2020-financial-results-on-f-vnda-20210202monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-receives-fda-approval-to-proceed-with-investigational-new-drug-vsj-1-vnda-20201026monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-third-quarter-2020-financial-results-on-october-28-2020-vnda-20201021monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-provides-update-on-tradipitant-development-program-vnda-20200831monthly0.5https://www.biopharmawatch.com/news/VNDA/fda-accepts-and-grants-priority-review-of-vanda-vnda-20200803monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-second-quarter-2020-financial-results-on-august-5-2020-vnda-20200729monthly0.5https://www.biopharmawatch.com/news/VNDA/fda-grants-authorization-for-individual-patient-expanded-access-protocol-for-the-use-of-tr-vnda-20200713monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-virtual-2020-stockholder-meeting-vnda-20200526monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-wins-motion-to-dismiss-false-claims-act-lawsuit-vnda-20200520monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-ceo-vnda-20200520monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-first-quarter-2020-financial-results-on-may-6-2020-vnda-20200429monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-initiation-of-calypso-to-study-the-role-of-genetic-variati-vnda-20200415monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-northwell-health-conduct-odyssey-trial-in-patients-with-severe-covid-vnda-20200415monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-inc-and-the-university-of-illinois-at-chicago-announce-partnership-t-vnda-20200408monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-the-initiation-of-odyssey-an-fda-approved-clinical-study-o-vnda-20200402monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-at-march-2020-investor-conferences-vnda-20200227monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2019-financial-results-on-f-vnda-20200218monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-comments-on-court-ruling-vnda-20200131monthly0.5https://www.biopharmawatch.com/news/VNDA/mihael-h-polymeropoulos-md-president-and-ceo-of-vanda-pharmaceuticals-inc-to-receive-the-p-vnda-20191212monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-at-november-2019-investor-conferences-vnda-20191118monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-third-quarter-2019-financial-results-on-november-6-2019-vnda-20191030monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-announces-new-study-results-showing-a-high-degree-of-inbreeding-in-beagle-dogs-vnda-20191023monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-applauds-white-house-issuance-of-executive-orders-requiring-federal-agencies-to-be-t-vnda-20191016monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-applauds-the-epa-vnda-20190911monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-the-appointments-of-a-chief-corporate-affairs-and-communic-vnda-20190821monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-second-quarter-2019-financial-results-on-july-31-2019-vnda-20190722monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-present-at-the-jmp-securities-life-sciences-conference-vnda-20190618monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-at-the-jefferies-2019-global-healthcare-conf-vnda-20190531monthly0.5https://www.biopharmawatch.com/news/VNDA/tradipitant-in-the-treatment-of-gastroparesis-vanda-presents-clinical-trial-results-at-ddw-vnda-20190522monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-first-quarter-2019-financial-results-on-may-1-2019-vnda-20190418monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-present-at-the-cowen-and-company-39th-annual-health-care-conferen-vnda-20190307monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2018-financial-results-on-f-vnda-20190125monthly0.5https://www.biopharmawatch.com/news/VNDA/fda-accepts-hetlioz-tasimelteon-supplemental-new-drug-application-for-review-in-the-treatm-vnda-20181220monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-at-november-2018-investor-conferences-vnda-20181108monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-receives-fda-letter-regarding-corporate-webpage-vnda-20181101monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-third-quarter-2018-financial-results-on-november-7-2018-vnda-20181022monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-at-oppenheimer-and-cantor-fitzgerald-fall-20-vnda-20180926monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-announces-listing-of-a-new-hetlioz-patent-in-the-fda-orange-book-vnda-20180920monthly0.5https://www.biopharmawatch.com/news/VNDA/hetlioz-tasimelteon-driving-study-demonstrates-no-impairment-in-next-morning-performance-vnda-20180912monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-at-september-2018-investor-conferences-vnda-20180904monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-the-appointment-of-general-counsel-vnda-20180813monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-second-quarter-2018-financial-results-on-august-1-2018-vnda-20180717monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-at-june-2018-investor-conferences-vnda-20180601monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-present-at-the-deutsche-bank-43rd-annual-health-care-conference-vnda-20180507monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-first-quarter-2018-financial-results-on-may-2-2018-vnda-20180418monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-wins-appeal-case-on-fanapt-vnda-20180413monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-to-present-tradipitant-scientific-posters-at-the-10th-georg-rajka-international-symp-vnda-20180409monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-at-march-2018-investor-conferences-vnda-20180306monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2017-financial-results-on-f-vnda-20180130monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-at-november-2017-investor-conferences-vnda-20171113monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-receives-negative-opinion-for-marketing-authorization-from-the-european-medicines-ag-vnda-20171110monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-third-quarter-2017-financial-results-on-november-7-2017-vnda-20171024monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-at-the-oppenheimer-specialty-pharma-summit-c-vnda-20171010monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-to-present-tradipitant-phase-ii-atopic-dermatitis-data-at-world-congress-of-itch-vnda-20171002monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-to-present-scientific-posters-at-world-sleep-2017-vnda-20170929monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-at-september-2017-investor-conferences-vnda-20170911monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-at-the-citi-12th-annual-biotech-conference-vnda-20170906monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-receives-negative-opinion-for-marketing-authorization-from-the-european-medicines-ag-vnda-20170721monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-second-quarter-2017-financial-results-on-august-2-2017-vnda-20170717monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-at-june-2017-investor-conferences-vnda-20170605monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-present-at-the-deutsche-bank-42nd-annual-health-care-conference-vnda-20170501monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-first-quarter-2017-financial-results-on-may-2-2017-vnda-20170413monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-and-ucsf-announce-license-agreement-for-cftr-activators-and-inhibitors-vnda-20170329monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-at-march-2017-investor-conferences-vnda-20170306monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2016-financial-results-on-f-vnda-20170119monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-at-november-2016-investor-conferences-vnda-20161114monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-third-quarter-2016-financial-results-on-november-2-2016-vnda-20161012monthly0.5https://www.biopharmawatch.com/news/VNDA/uspto-dismisses-petition-for-inter-partes-review-of-fanapt-patent-vnda-20160830monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-second-quarter-2016-financial-results-on-july-27-2016-vnda-20160712monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-present-at-the-jmp-securities-life-sciences-conference-vnda-20160620monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-present-at-the-jefferies-2016-healthcare-conference-vnda-20160603monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-first-quarter-2016-financial-results-on-may-4-2016-vnda-20160414monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-participate-in-the-canaccord-genuity-rare-disease-biopharma-one-o-vnda-20160201monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2015-financial-results-on-f-vnda-20160122monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-appoints-gian-piero-reverberi-as-acting-chief-commercial-officer-vnda-20151217monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-participation-at-upcoming-investor-conferences-vnda-20151112monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-participate-in-the-citi-2015-global-healthcare-1x1-conference-vnda-20151104monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-third-quarter-2015-financial-results-on-november-3-2015-vnda-20151015monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-announces-listing-of-a-new-fanapt-patent-in-the-fda-orange-book-vnda-20151014monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-announces-listing-of-a-new-fanapt-patent-in-the-fda-orange-book-vnda-20150923monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-the-appointment-of-general-counsel-vnda-20150914monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-announces-favorable-markman-ruling-in-fanapt-patent-infringement-litigation-vnda-20150910monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-the-appointment-of-european-general-manager-vnda-20150908monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-second-quarter-2015-financial-results-on-july-29-2015-vnda-20150709monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-announces-listing-of-a-new-hetlioz-patent-in-the-fda-orange-book-vnda-20150702monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-announces-positive-results-from-the-relapse-prevention-study-in-patients-with-schizo-vnda-20150623monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-present-at-the-jmp-securities-life-sciences-conference-vnda-20150619monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-present-at-the-jefferies-2015-global-healthcare-conference-vnda-20150602monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-receives-innovation-award-from-the-national-organization-for-rare-disorders-for-deve-vnda-20150526monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-present-at-the-bank-of-america-merrill-lynch-2015-health-care-con-vnda-20150511monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-recibe-opinio-n-para-hetlioz-tasimelteon-para-tratar-la-enfermedad-del-suen-o-retras-vnda-20150427monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-obtient-un-avis-favorable-du-chmp-pour-hetlioz-tasimelteon-en-vue-du-traitement-du-s-vnda-20150425monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-erha-lt-positive-stellungnahme-des-chmp-fu-r-hetlioz-tasimelteon-zur-behandlung-der--vnda-20150424monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-the-appointment-of-chief-commercial-officer-vnda-20150420monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-first-quarter-2015-financial-results-on-may-6-2015-vnda-20150416monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-announces-trial-date-for-fanapt-patent-cases-vnda-20150413monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-announces-listing-of-a-new-fanapt-patent-in-the-fda-orange-book-vnda-20150409monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-fourth-quarter-2014-financial-results-on-february-19-201-vnda-20150202monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-participate-in-the-canaccord-genuity-rare-disease-biopharma-one-o-vnda-20150129monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-announces-listing-of-a-new-fanapt-patent-in-the-fda-orange-book-vnda-20150116monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-present-at-the-26th-annual-piper-jaffray-healthcare-conference-vnda-20141201monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-present-at-the-stifel-nicolaus-2014-healthcare-conference-vnda-20141118monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-third-quarter-2014-financial-results-on-october-27-2014-vnda-20141014monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-second-quarter-2014-financial-results-on-august-7-2014-vnda-20140717monthly0.5https://www.biopharmawatch.com/news/VNDA/european-medicines-agency-accepts-hetlioz-tasimelteon-marketing-authorization-application--vnda-20140603monthly0.5https://www.biopharmawatch.com/news/VNDA/hetlioz-tasimelteon-data-in-patients-with-non-24-hour-sleep-wake-disorder-to-be-presented--vnda-20140602monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-present-at-the-jefferies-2014-global-healthcare-conference-vnda-20140529monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-first-quarter-2014-financial-results-on-may-8-2014-vnda-20140424monthly0.5https://www.biopharmawatch.com/news/VNDA/blind-adventurer-erik-weihenmayer-launches-national-campaign-to-raise-awareness-of-non-24--vnda-20140228monthly0.5https://www.biopharmawatch.com/news/VNDA/fda-approves-hetlioz-tasimelteon-for-the-treatment-of-non-24-hour-sleep-wake-disorder-vnda-20140131monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-fourth-quarter-2013-financial-results-on-february-13-201-vnda-20140123monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-present-at-the-25th-annual-piper-jaffray-healthcare-conference-vnda-20131203monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-stock-trading-halted-fda-advisory-committee-to-review-hetlioz-nda-vnda-20131114monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-third-quarter-2013-financial-results-on-november-7-2013-vnda-20131021monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-fda-advisory-committee-meeting-on-november-14-2013-vnda-20131016monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-present-at-the-stifel-nicolaus-2013-healthcare-conference-vnda-20130910monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-second-quarter-2013-financial-results-on-july-31-2013-vnda-20130729monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-participate-in-upcoming-investor-conferences-vnda-20130708monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-presents-data-from-phase-iii-studies-that-demonstrate-tasimelteon-restores-daily-cor-vnda-20130617monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-presents-data-from-tasimelteon-phase-iii-studies-in-non-24-hour-disorder-vnda-20130605monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-announces-submission-to-fda-of-a-new-drug-application-for-tasimelteon-for-the-treatm-vnda-20130531monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-present-at-the-jefferies-2013-global-healthcare-conference-vnda-20130531monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-to-present-tasimelteon-non-24-phase-iii-data-at-two-medical-meetings-vnda-20130530monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-named-the-2013-life-science-firm-of-the-year-by-the-tech-council-of--vnda-20130523monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-first-quarter-2013-financial-results-on-may-9-2013-vnda-20130418monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-appoints-dr-paolo-baroldi-as-chief-medical-officer-vnda-20130417monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-present-at-the-biocentury-future-leaders-in-the-biotech-industry--vnda-20130404monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-withdraws-its-marketing-authorization-application-for-fanaptum-in-the-european-union-vnda-20130314monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-present-at-the-cowen-and-company-33rd-annual-health-care-conferen-vnda-20130227monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-fourth-quarter-2012-and-full-year-2012-results-vnda-20130212monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-announces-phase-iib-iii-clinical-study-in-major-depressive-disorder-did-not-meet-the-vnda-20130131monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-fourth-quarter-2012-financial-results-on-february-12-201-vnda-20130122monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-receives-negative-opinion-from-chmp-on-fanaptum-for-the-treatment-of-schizophrenia-vnda-20121213monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-third-quarter-2012-results-vnda-20121107monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-present-at-the-lazard-healthcare-conference-vnda-20121105monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-third-quarter-2012-financial-results-on-november-7-2012-vnda-20121017monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-participate-in-two-september-healthcare-investor-conferences-vnda-20120823monthly0.5https://www.biopharmawatch.com/news/VNDA/fanapt-is-granted-market-approval-in-israel-for-the-treatment-of-schizophrenia-vnda-20120809monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-second-quarter-2012-results-vnda-20120802monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-second-quarter-2012-financial-results-on-august-2-2012-vnda-20120710monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-present-at-the-jmp-securities-healthcare-conference-vnda-20120705monthly0.5https://www.biopharmawatch.com/news/VNDA/seventy-percent-of-totally-blind-individuals-with-sleep-complaints-suffer-from-chronic-cir-vnda-20120611monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-present-at-sleep-2012-26th-annual-meeting-of-the-associated-profe-vnda-20120604monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-date-of-annual-meeting-of-stockholders-vnda-20120531monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-present-at-the-jefferies-2012-global-healthcare-conference-vnda-20120529monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-inc-presents-scientific-posters-at-society-for-research-on-biologica-vnda-20120522monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-first-quarter-2012-results-vnda-20120508monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-first-quarter-2012-financial-results-on-may-8-2012-vnda-20120418monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-participate-in-upcoming-investor-conferences-vnda-20120223monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-fourth-quarter-2011-and-full-year-2011-results-vnda-20120214monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-fourth-quarter-2011-financial-results-on-february-14-201-vnda-20120118monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-enters-into-an-exclusive-license-agreement-with-megapharm-ltd-for-co-vnda-20111213monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-third-quarter-2011-results-vnda-20111104monthly0.5https://www.biopharmawatch.com/news/VNDA/neue-website-zielt-auf-ha-ufig-vorkommende-schlafsto-rung-bei-blinden-menschen-ab-vnda-20111025monthly0.5https://www.biopharmawatch.com/news/VNDA/un-nouveau-site-web-consacre-a-un-trouble-du-sommeil-courant-chez-les-individus-aveugles-vnda-20111025monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-appoints-chief-commercial-officer-vnda-20111024monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-third-quarter-2011-financial-results-on-november-4-2011-vnda-20111018monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-participate-in-ubs-global-life-sciences-conference-vnda-20110914monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-participate-in-stifel-nicolaus-global-healthcare-conference-and-j-vnda-20110831monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-second-quarter-2011-results-vnda-20110804monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-enters-into-an-exclusive-license-agreement-with-biotoscana-farma-s-a-vnda-20110801monthly0.5https://www.biopharmawatch.com/news/VNDA/european-medicines-agency-accepts-vanda-pharmaceuticals-inc-vnda-20110726monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-second-quarter-2011-financial-results-on-august-4-2011-vnda-20110720monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-enters-into-an-exclusive-license-agreement-with-probiomed-s-a-de-c-v-vnda-20110711monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-present-at-the-jefferies-2011-global-healthcare-conference-vnda-20110602monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-date-of-annual-meeting-of-stockholders-vnda-20110524monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-first-quarter-2011-results-vnda-20110505monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-first-quarter-2011-financial-results-on-may-5-2011-vnda-20110422monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-announces-commencement-of-clinical-study-of-long-acting-injectable-f-vnda-20110411monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-evaluate-tasimelteon-in-major-depression-vnda-20110331monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-receives-orphan-drug-designation-in-europe-for-tasimelteon-vnda-20110308monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-fourth-quarter-and-full-year-2010-results-vnda-20110210monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-fourth-quarter-2010-financial-results-on-february-10-201-vnda-20110201monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-files-shelf-registration-statement-vnda-20110131monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-appoints-chief-financial-officer-vnda-20101112monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-third-quarter-2010-results-vnda-20101103monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-to-announce-third-quarter-2010-financial-results-on-november-3-2010-vnda-20101028monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-initiates-phase-iii-clinical-study-aimed-at-resetting-the-body-clock-vnda-20100826monthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-reports-second-quarter-2010-results-vnda-20100805monthly0.5https://www.biopharmawatch.com/news/BGM/in-depth-analysis-of-bgm-group-innovating-pharmaceuticals-and-insurance-through-ai-bgm-20241227monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-asco-2026-abstracts-highlighting-z-endoxifen-activity-across-atos-20260527monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-strengthens-clinical-leadership-team-with-the-addition-of-two-experien-atos-20260319monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-receives-fda-orphan-drug-designation-for-z-endoxifen-for-the-treatment-atos-20260116monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-receives-fda-study-may-proceed-letter-for-z-endoxifen-investigational--atos-20260106monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-advances-global-patent-strategy-for-z-endoxifen-with-new-protection-in-israel-and-o-atos-20251013monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-streamlines-evangeline-breast-cancer-clinical-trial-to-prioritize-for--atos-20251006monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-names-janet-r-rea-msph-as-senior-vice-president-r-d-to-accelerate-z-en-atos-20251001monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-ceo-to-discuss-clinical-progress-and-upcoming-milestones-at-27th-annua-atos-20250828monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-selects-psi-as-contract-research-organization-for-pivotal-dose-ranging-atos-20250820monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-positive-fda-feedback-advances-toward-ind-for-z-endoxifen-cl-atos-20250729monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-atos-20250602monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-full-results-from-i-spy-2-endocrine-optimization-sub-study-e-atos-20250514monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-to-host-first-quarter-financial-results-and-corporate-update-call-and-webcast-on--tlph-20260507monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-announces-second-quarter-2025-financial-results-and-provides-corporate-update-tlph-20250814monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-to-host-second-quarter-financial-results-and-corporate-update-call-and-webcast-on-tlph-20250807monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-announces-first-quarter-2025-financial-results-and-provides-corporate-update-tlph-20250514monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-to-host-first-quarter-financial-results-and-corporate-update-call-and-webcast-on--tlph-20250507monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-announces-fourth-quarter-and-full-year-2024-financial-results-and-provides-corpor-tlph-20250331monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-announces-agreement-with-the-fda-to-reduce-the-nephro-crrt-study-size-to-70-patie-tlph-20250331monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-to-host-fourth-quarter-and-full-year-2024-financial-results-and-corporate-update--tlph-20250326monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-announces-agreement-with-the-fda-for-prior-approval-supplement-review-to-reduce-t-tlph-20250114monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-announces-third-quarter-2024-financial-results-and-provides-corporate-update-tlph-20241113monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-to-host-third-quarter-2024-financial-results-and-corporate-update-call-and-webcas-tlph-20241106monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-to-participate-in-fireside-chat-at-the-2024-maxim-healthcare-virtual-summit-tlph-20241008monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-to-participate-in-the-h-c-wainwright-26th-annual-global-investment-conference-tlph-20240905monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-announces-first-patient-enrolled-in-the-registrational-trial-evaluating-nafamosta-tlph-20240819monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-announces-second-quarter-2024-financial-results-and-provides-corporate-update-tlph-20240814monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-to-host-second-quarter-2024-financial-results-and-corporate-update-call-and-webca-tlph-20240805monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tlph-20240520monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-to-participate-at-a-g-p-virtual-healthcare-conference-tlph-20240516monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-announces-first-quarter-2024-financial-results-and-provides-corporate-update-tlph-20240514monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-to-host-first-quarter-2024-financial-results-call-and-webcast-on-tuesday-may-14-2-tlph-20240502monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-announces-fourth-quarter-2023-financial-results-and-provides-corporate-update-tlph-20240306monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-announces-reduction-in-size-of-its-board-of-directors-from-ten-to-seven-members-tlph-20240301monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-to-host-fourth-quarter-and-full-year-2023-financial-results-call-and-webcast-on-m-tlph-20240226monthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-announces-26-million-capital-commitment-through-a-combination-of-a-non-dilutive-r-tlph-20240118monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-announces-rebranding-with-name-change-to-talphera-inc-tlph-20240109monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-upcoming-annual-general-meeting-and-second-quarter-financial--oncy-20250805monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-engage-fda-for-potential-registration-enabled-study-in-first-line-pa-oncy-20250729monthly0.5https://www.biopharmawatch.com/news/ONCY/key-opinion-leader-event-highlights-pelareorep-oncy-20250723monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-regains-compliance-with-nasdaq-trading-rules-oncy-20250722monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-presents-aggregated-translational-data-providing-evidence-of-pelareorep-oncy-20250716monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-host-key-opinion-leader-discussion-focusing-on-pancreatic-and-gastro-oncy-20250710monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-highlights-transformative-pelareorep-survival-data-in-multiple-tumors-a-oncy-20250708monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-appoints-former-ambrx-executive-as-chief-business-officer-to-drive-busi-oncy-20250630monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-names-new-ceo-to-accelerate-momentum-in-immunotherapy-programs-oncy-20250611monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-present-new-clinical-trial-data-at-asco-showing-pelareorep-oncy-20250523monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-first-quarter-financial-results-and-highlights-clinical-momentu-oncy-20250514monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-host-conference-call-to-discuss-first-quarter-financial-results-and--oncy-20250506monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-showcase-new-pancreatic-cancer-data-at-asco-highlighting-pelareorep-oncy-20250424monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-funds-pelareorep-oncy-20250410monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-and-pelareorep-discussed-during-recent-h-c-wainwright-key-opinion-leade-oncy-20250410monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-highlights-and-financial-results-for-q4-and-year-end-2024-oncy-20250307monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-advances-key-pancreatic-and-anal-cancer-trials-strengthening-pipeline-i-oncy-20250219monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-strengthens-its-pipeline-in-2025-with-key-pancreatic-and-anal-cancer-ad-oncy-20250218monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-receipt-of-nasdaq-notification-letter-regarding-minimum-bid-p-oncy-20250214monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-matt-coffey-ph-d-will-not-return-to-ceo-role-following-medica-oncy-20250207monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-present-compelling-new-efficacy-and-safety-data-in-anal-and-pancreat-oncy-20250122monthly0.5https://www.biopharmawatch.com/news/ONCY/regulatory-approval-clears-path-for-oncolytics-biotech-to-advance-promising-pancreatic-can-oncy-20250115monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-highlights-2024-achievements-and-prepares-for-an-influential-2025-with--oncy-20241223monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-present-promising-pelareorep-data-in-pancreatic-and-anal-cancers-at--oncy-20241218monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-completion-of-initial-safety-phase-enrollment-for-goblet-trial-oncy-20241203monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-third-quarter-2024-financial-results-and-operational-highlights-oncy-20241112monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-host-conference-call-to-discuss-third-quarter-financial-results-and--oncy-20241111monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-key-progress-and-upcoming-studies-for-breast-and-pancreatic-c-oncy-20241004monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-favorable-results-for-bracelet-1-breast-cancer-study-reinforcin-oncy-20240919monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-participate-in-fireside-chats-at-two-investment-conferences-in-septe-oncy-20240906monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-participate-in-a-fireside-chat-at-canaccord-genuity-oncy-20240802monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-second-quarter-2024-financial-results-and-operational-highlight-oncy-20240801monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-host-conference-call-to-discuss-second-quarter-financial-results-and-oncy-20240724monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-productive-fda-type-c-meeting-on-its-metastatic-breast-cancer-oncy-20240627monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-president-and-chief-executive-officer-dr-matt-coffey-to-take--oncy-20240624monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-doses-first-patient-in-study-of-pelareorep-folfirinox-combination-thera-oncy-20240620monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-asco-abstracts-highlight-pelareorep-oncy-20240524monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholder-oncy-20240516monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-preliminary-collaboration-with-gcar-for-inclusion-of-pelareor-oncy-20240515monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-first-quarter-2024-financial-results-and-operational-highlights-oncy-20240509monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-receives-regulatory-clearance-to-evaluate-pelareorep-in-combination-wit-oncy-20240509monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-participate-in-a-fireside-chat-at-the-2024-rbc-capital-markets-globa-oncy-20240508monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-host-conference-call-to-discuss-first-quarter-financial-results-and--oncy-20240430monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-upcoming-presentations-at-the-american-society-of-clinical-on-oncy-20240425monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-advances-toward-registration-enabling-trial-for-pelareorep-in-breast-ca-oncy-20240411monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-participate-in-a-panel-presentation-at-canaccord-genuity-oncy-20240402monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-fourth-quarter-and-full-year-2023-financial-results-and-operati-oncy-20240307monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-files-amendment-to-initiate-new-pancreatic-cancer-goblet-cohort-support-oncy-20240305monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financi-oncy-20240304monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-presentation-at-the-cancer-advocacy-group-of-louisiana-oncy-20240228monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-initiates-enrollment-expansion-of-goblet-anal-cancer-cohort-oncy-20240214monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-appoints-patricia-s-andrews-to-its-board-of-directors-oncy-20240109monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-recaps-2023-accomplishments-provides-outlook-for-2024-oncy-20240104monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-and-solti-present-positive-translational-data-at-sabcs-oncy-20231207monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-announces-the-anal-cancer-cohort-of-the-goblet-phase-1-2-study-of-pelareorep-an-oncy-20231109monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-provides-update-on-pancreatic-cancer-program-for-pelareorep-oncy-20231109monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-and-solti-present-further-positive-pelareorep-translational-data-at-sit-oncy-20231103monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-third-quarter-2023-financial-results-and-operational-highlights-oncy-20231103monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-presents-positive-updated-pancreatic-cancer-data-from-goblet-phase-1-2-study-at-oncy-20231023monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-achieves-success-criteria-for-efficacy-in-the-third-line-colorectal-cancer-coho-oncy-20231023monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-host-conference-call-to-discuss-third-quarter-financial-results-and--oncy-20231020monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-present-two-posters-on-the-pelareorep-based-goblet-study-at-esmo-202-oncy-20231016monthly0.5https://www.biopharmawatch.com/news/ONCY/the-pancreatic-cancer-action-network-selects-oncolytics-biotech-inc-to-receive-5-million-t-oncy-20230926monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-fireside-chat-at-the-cantor-global-healthcare-conference-oncy-20230919monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-full-exercise-of-over-allotment-option-from-public-offering-oncy-20230907monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-participate-in-a-fireside-chat-at-the-h-c-wainwright-25th-annual-glo-oncy-20230906monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-second-quarter-2023-financial-results-and-operational-highlight-oncy-20230814monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-successfully-raises-us-15-million-to-advance-breast-and-pancreatic-canc-oncy-20230808monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-participate-in-a-fireside-chat-at-canaccord-genuity-oncy-20230804monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-host-conference-call-to-discuss-second-quarter-financial-results-and-oncy-20230804monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-us-15-million-bought-deal-offering-of-units-oncy-20230731monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-oncy-20230622monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-updated-randomized-phase-2-data-from-bracelet-1-metastatic-br-oncy-20230605monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-host-key-opinion-leader-webinar-on-data-from-the-randomized-bracelet-oncy-20230526monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-positive-randomized-phase-2-data-from-bracelet-1-metastatic-b-oncy-20230525monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholder-oncy-20230510monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-first-quarter-2023-financial-results-and-operational-highlights-oncy-20230505monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-upcoming-oral-presentation-on-randomized-bracelet-1-trial-in--oncy-20230426monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-participate-in-a-panel-presentation-at-canaccord-genuity-oncy-20230412monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-host-conference-call-to-discuss-first-quarter-financial-results-and--oncy-20230412monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-filing-and-mailing-of-the-management-information-circular-in--oncy-20230412monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-participate-in-a-panel-presentation-at-cantor-fitzgerald-oncy-20230328monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-fourth-quarter-and-full-year-2022-financial-results-and-operati-oncy-20230303monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financi-oncy-20230221monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-oncy-20221208monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-receives-fda-fast-track-designation-for-the-treatment-of-advanced-metas-oncy-20221201monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-presentations-at-the-upcoming-san-antonio-breast-cancer-sympo-oncy-20221121monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-presents-updated-clinical-data-at-sitc-annual-meeting-showing-a-69-obje-oncy-20221110monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-third-quarter-2022-financial-results-and-recent-operational-hig-oncy-20221107monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-interim-results-from-phase-1-2-goblet-study-showing-a-70-object-oncy-20221107monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-host-conference-call-to-discuss-third-quarter-financial-results-and--oncy-20221027monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-ca-oncy-20221005monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-appoints-jonathan-rigby-to-its-board-of-directors-oncy-20220907monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-second-quarter-2022-financial-results-and-recent-operational-hi-oncy-20220811monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-host-conference-call-to-discuss-second-quarter-financial-results-and-oncy-20220727monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-achieves-success-criteria-for-efficacy-in-the-pancreatic-cancer-cohort--oncy-20220628monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholder-oncy-20220617monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-participate-in-a-fireside-chat-at-the-2022-rbc-capital-markets-globa-oncy-20220510monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-first-quarter-2022-financial-results-and-recent-operational-hig-oncy-20220505monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-and-solti-present-new-clinical-biomarker-data-demonstrating-pelareorep-oncy-20220504monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-and-solti-announce-upcoming-poster-presentation-at-the-european-society-oncy-20220502monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-host-conference-call-to-discuss-first-quarter-financial-results-and--oncy-20220428monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-present-at-the-bloom-burton-co-healthcare-investor-conference-oncy-20220421monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-publication-of-preclinical-data-demonstrating-the-synergistic-oncy-20220414monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-participate-in-a-fireside-chat-at-the-canaccord-genuity-horizons-in--oncy-20220412monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-positive-long-term-survival-data-from-phase-1b-glioblastoma-m-oncy-20220408monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-presents-new-data-demonstrating-durable-clinical-benefit-in-relapsed-re-oncy-20220408monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-letter-to-shareholders-update-on-recent-progress-oncy-20220406monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-provides-positive-safety-update-on-the-third-line-metastatic-colorectal-oncy-20220331monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-partner-adlai-nortye-advances-chinese-bridging-trial-of-pelareorep-pacl-oncy-20220324monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-publication-of-preclinical-and-patient-data-demonstrating-pel-oncy-20220317monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-phase-1b-data-demonstrating-clinical-proof-of-concept-for-pel-oncy-20220309monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-upcoming-poster-presentation-at-the-aacr-annual-meeting-oncy-20220309monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent--oncy-20220303monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financi-oncy-20220222monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-provides-positive-safety-update-on-the-pancreatic-cancer-cohort-of-its--oncy-20220202monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-partner-adlai-nortye-advances-to-the-second-dose-escalation-cohort-of-t-oncy-20220127monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-provides-enrollment-update-on-multi-indication-phase-1-2-gastrointestin-oncy-20220120monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-releases-a-letter-to-shareholders-2021-review-and-2022-outlook-oncy-20220111monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-promotes-thomas-c-heineman-m-d-ph-d-to-chief-medical-officer-oncy-20211221monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-the-presentation-of-preclinical-data-demonstrating-the-synerg-oncy-20211215monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-presents-positive-interim-safety-update-from-phase-2-triple-negative-br-oncy-20211210monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-present-phase-2-triple-negative-breast-cancer-trial-update-at-the-20-oncy-20211119monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-2021-third-quarter-development-highlights-and-financial-results-oncy-20211105monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-doses-first-patient-in-phase-1-2-goblet-study-evaluating-pelareorep-ant-oncy-20211103monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-partner-adlai-nortye-doses-first-patient-in-chinese-bridging-trial-eval-oncy-20211014monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-preclinical-data-demonstrating-the-synergistic-immunotherapeu-oncy-20210920monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-2021-second-quarter-development-highlights-and-financial-result-oncy-20210806monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-participate-in-virtual-fireside-chat-at-the-canaccord-genuity-41st-a-oncy-20210806monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-host-conference-call-to-discuss-second-quarter-financial-results-and-oncy-20210722monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-present-at-the-ladenburg-thalmann-healthcare-conference-oncy-20210630monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-clinical-and-biomarker-data-demonstrating-clinical-proof-of-c-oncy-20210520monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-participate-in-virtual-fireside-chat-at-the-2021-rbc-capital-markets-oncy-20210513monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholder-oncy-20210510monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-2021-first-quarter-development-highlights-and-financial-results-oncy-20210507monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-annual-general-meeting-oncy-20210430monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-onc-oncy-20210429monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-and-solti-achieve-primary-endpoint-in-aware-1-study-oncy-20210412monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-presents-preclinical-data-on-pelareorep-based-combination-therapies-at--oncy-20210412monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-participate-in-a-panel-discussion-at-the-canaccord-genuity-horizons--oncy-20210408monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-host-key-opinion-leader-webinar-to-discuss-aware-1-data-the-immunoth-oncy-20210405monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-upcoming-presentations-at-the-aacr-annual-meeting-oncy-20210310monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-establishes-new-at-the-market-facility-oncy-20210305monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-fourth-quarter-and-full-year-2020-financial-results-and-operati-oncy-20210305monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financi-oncy-20210226monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-preclinical-data-demonstrating-the-synergistic-anti-cancer-acti-oncy-20210223monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-and-solti-report-clinical-synergy-of-pelareorep-with-checkpoint-inhibitors-at-t-oncy-20201209monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-positive-clinical-results-against-glioblastoma-multiforme-at--oncy-20201119monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-present-aware-1-data-and-provide-updates-on-phase-2-bracelet-1-and-i-oncy-20201117monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-2020-third-quarter-development-highlights-and-financial-results-oncy-20201111monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-and-solti-present-clinical-breast-cancer-data-highlighting-pelareorep-i-oncy-20201109monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-abstract-publication-and-upcoming-oral-presentation-at-the-20-oncy-20201109monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-collaborates-with-roche-and-aio-to-initiate-a-phase-1-2-gastrointestina-oncy-20201027monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-participate-in-bio-investor-forum-digital-oncy-20201007monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-upcoming-presentations-at-investor-conferences-oncy-20200901monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-doses-first-patient-in-phase-2-irene-study-evaluating-pelareorep-anti-p-oncy-20200826monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-participate-in-virtual-fireside-chat-at-the-canaccord-genuity-40th-a-oncy-20200810monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-2020-second-quarter-financial-results-and-operational-highlight-oncy-20200804monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-investigator-sponsored-phase-2-trial-evaluating-pelareorep-an-oncy-20200625monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-doses-first-patient-in-phase-2-bracelet-1-study-evaluating-pelareorep-b-oncy-20200623monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-establishes-new-at-the-market-facility-oncy-20200615monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-provides-recap-of-key-opinion-leader-call-highlighting-the-induction-of-oncy-20200604monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-publication-of-abstracts-at-the-2020-american-society-of-clin-oncy-20200514monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-present-at-the-rbc-global-healthcare-conference-oncy-20200513monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-changes-to-annual-general-meeting-oncy-20200430monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-updates-clinical-development-and-operations-activities-during-the-covid-oncy-20200417monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-publication-of-pelareorep-oncy-20200402monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-favourable-aware-1-safety-update-oncy-20200324monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-fourth-quarter-and-full-year-2019-financial-results-and-operati-oncy-20200305monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-year-end-2019-fin-oncy-20200228monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-preliminary-unaudited-fourth-quarter-and-full-year-2025-results-and-b-ctso-20260112monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-to-participate-at-the-jefferies-global-healthcare-conference-in-london-ctso-20251111monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-to-report-third-quarter-2025-financial-results-and-recent-business-highlights-ctso-20251030monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-second-quarter-2025-financial-results-and-provides-business-update-ctso-20250807monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-to-report-second-quarter-2025-financial-results-and-recent-business-highlight-ctso-20250729monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-to-participate-at-the-jefferies-global-healthcare-conference-ctso-20250529monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-therapy-significantly-reduces-bleeding-in-urgent-cabg-patients-on-ticagrelor--ctso-20250522monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-to-report-first-quarter-2025-financial-results-and-recent-business-highlights-ctso-20250429monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-com-ctso-20250321monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-letter-to-shareholders-ormp-20240220monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-signs-term-sheet-with-htit-to-create-a-joint-venture-to-advance-oral-drug-delivery--ormp-20230802monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-the-83rd-american-diabetes-association-conference-ormp-20230620monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-novel-therapies-for-type-2-diabetes-obesity-summit-ormp-20230518monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-that-its-chinese-partner-htit-has-successfully-completed-a-phase-3-oral-i-ormp-20230515monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-appoints-ben-shapiro-to-its-board-of-directors-ormp-20230501monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-issues-shareholder-update-ormp-20230209monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-top-line-results-from-phase-3-trial-of-ormd-0801-for-the-treatment-of-typ-ormp-20230111monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-granted-u-s-combination-therapy-patent-for-oral-glp-1-insulin-for-the-treatment-of--ormp-20230104monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-letter-to-shareholders-ormp-20221221monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-publication-of-oral-insulin-study-in-peer-reviewed-journal-diabetes-obesi-ormp-20221129monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-additional-positive-safety-and-efficacy-data-from-its-phase-2-clinical-tr-ormp-20221117monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-signs-definitive-deal-with-medicox-to-commercialize-oral-insulin-in-south-korea-ormp-20221114monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-host-webinar-highlighting-detailed-safety-and-efficacy-data-from-its-positive-ph-ormp-20221109monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-subsidiary-oravax-reports-positive-preliminary-phase-1-data-for-its-oral-covid-19-v-ormp-20221007monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-reports-positive-top-line-results-from-phase-2-nash-trial-with-its-ormd-0801-oral-i-ormp-20220913monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-h-c-wainwright-24th-annual-global-investment-conference-ormp-20220906monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-reaches-50-enrollment-in-its-second-phase-3-oral-insulin-trial-ormp-20220726monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-the-upcoming-canaccord-genuity-annual-growth-conference-ormp-20220711monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-letter-to-shareholders-ormp-20220707monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-appoints-dr-anne-peters-to-its-scientific-advisory-board-ormp-20220601monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-granted-u-s-combination-therapy-patent-for-oral-glp-1-insulin-for-the-treatment-of--ormp-20220524monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-h-c-wainwright-global-investment-conference-ormp-20220518monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-termine-le-recrutement-des-patients-dans-l-ormp-20220503monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-finaliza-la-inscripcio-n-de-pacientes-en-el-estudio-ora-d-013-1-ormp-20220503monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-schlie-t-patientenrekrutierung-fu-r-die-pivotale-phase-3-studie-mit-oralem-insulin--ormp-20220503monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-completes-patient-enrollment-in-pivotal-phase-3-oral-insulin-study-ora-d-013-1-ormp-20220503monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-granted-nash-patent-in-europe-ormp-20220405monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-appoints-yadin-rozov-to-its-board-of-directors-ormp-20220404monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-s-diabetes-market-survey-shows-strong-interest-for-ormd-0801-oral-insulin-candidate-ormp-20220329monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-host-key-opinion-leader-webinar-on-need-for-oral-insulin-in-type-2-diabetes-ormp-20220322monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-completes-patient-enrollment-in-phase-2-oral-insulin-nash-trial-ormp-20220316monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-barclays-global-healthcare-conference-ormp-20220310monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-issues-annual-message-to-shareholders-ormp-20220112monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-granted-key-european-patent-for-platform-technology-in-oral-delivery-of-proteins-ormp-20220105monthly0.5https://www.biopharmawatch.com/news/ORMP/oravax-medical-filiale-d-ormp-20211229monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-subsidiary-oravax-medical-signs-cooperation-and-purchase-agreement-for-an-initial-p-ormp-20211229monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-tochtergesellschaft-oravax-medical-unterzeichnet-kooperations-und-kaufvertrag-fu-r--ormp-20211229monthly0.5https://www.biopharmawatch.com/news/ORMP/oravax-medical-acuerda-la-compra-anticipada-inicial-de-10-millones-de-vacunas-orales-contr-ormp-20211229monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-subsidiary-oravax-announces-first-participant-enrolled-in-phase-1-oral-covid-19-vac-ormp-20211214monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-appoints-chief-legal-officer-ormp-20211208monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-join-msci-usa-small-cap-index-ormp-20211124monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-reaches-75-enrollment-in-phase-3-oral-insulin-study-ormp-20211123monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-h-c-wainwright-7th-annual-israel-conference-ormp-20211111monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-closing-of-50-million-registered-direct-offering-of-common-stock-priced-a-ormp-20211108monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-50-million-registered-direct-offering-of-common-stock-priced-at-the-marke-ormp-20211103monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-oravax-ormp-20211029monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-cantor-fitzgerald-virtual-global-healthcare-conference-ormp-20210923monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-s-phase-2-oral-insulin-nash-trial-reaches-over-50-enrollment-oramed-pharmaceuticals-ormp-20210915monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference-ormp-20210909monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-reaches-25-enrollment-in-its-second-of-two-concurrent-phase-3-oral-insulin-trials-ormp-20210824monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-publication-of-oral-insulin-study-in-peer-reviewed-journal-diabetes-obesi-ormp-20210816monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-canaccord-genuity-ormp-20210809monthly0.5https://www.biopharmawatch.com/news/ORMP/oravax-to-present-keynote-talk-on-oral-covid-19-vaccine-at-the-arena-international-vaccine-ormp-20210805monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-appoints-chief-commercial-officer-ormp-20210729monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-provides-update-on-oravax-oral-vaccine-maker-gets-irb-approval-for-clinical-trial-ormp-20210721monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-to-join-russell-2000-and-russell-3000-indexes-ormp-20210622monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-reaches-50-enrollment-in-phase-3-oral-insulin-study-ormp-20210608monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-issues-letter-to-shareholders-with-updates-on-oral-insulin-and-covid-19-vaccine-ormp-20210525monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-and-oravax-medical-to-be-featured-in-alliance-global-partners-ormp-20210421monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-initiates-second-phase-3-oral-insulin-study-under-the-fda-ormp-20210323monthly0.5https://www.biopharmawatch.com/news/ORMP/fu-r-die-entwicklung-neuartiger-oraler-covid-19-impfstoffe-gru-ndet-oramed-das-joint-ventu-ormp-20210322monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-funda-la-sociedad-conjunta-oravax-medical-inc-para-desarrollar-nuevas-vacunas-orale-ormp-20210322monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-forms-a-joint-venture-oravax-medical-inc-for-the-development-of-novel-oral-covid-19-ormp-20210319monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-met-au-point-un-vaccin-covid-19-par-prise-oral-de-veloppe-par-sa-jo-ormp-20210319monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-reaches-25-randomization-in-world-ormp-20210316monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-h-c-wainwright-global-life-sciences-conference-2021-ormp-20210304monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-issues-letter-to-shareholders-ormp-20210127monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-doses-patients-across-multiple-sites-in-phase-3-oral-insulin-study-ormp-20210121monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-h-c-wainwright-bioconnect-2021-conference-ormp-20210107monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-reports-positive-first-in-human-data-from-oral-leptin-study-ormp-20201223monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-initiates-phase-2-nash-trial-of-oral-insulin-ormp-20201202monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-initiates-phase-3-trial-of-oral-insulin-ormp-20201124monthly0.5https://www.biopharmawatch.com/news/ORMP/nobel-laureate-oramed-sab-member-prof-avram-hershko-and-oramed-cso-dr-miriam-kidron-to-be--ormp-20201112monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-h-c-wainwright-6th-annual-israel-conference-ormp-20201110monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-phase-2b-oral-insulin-data-at-american-association-of-pharmaceutical-sci-ormp-20201028monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-ceo-nadav-kidron-premas-biotech-to-host-webinar-the-journey-of-oral-insulin-oramed--ormp-20201027monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-issues-shareholder-update-on-pivotal-phase-3-oral-insulin-studies-protocols-submitt-ormp-20201016monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-to-present-at-the-european-association-for-the-study-of-diabetes-ea-ormp-20200921monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-s-diabetes-market-survey-shows-strong-support-for-ormd-0801-oral-insulin-among-phys-ormp-20200915monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-h-c-wainwright-global-investment-conference-ormp-20200903monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-reports-positive-end-of-phase-2-meeting-with-the-fda-for-oral-insulin-ormp-20200715monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-positive-initial-clinical-trial-results-for-treatment-of-nash-with-oral-i-ormp-20200615monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-to-present-at-the-80th-american-diabetes-association-scientific-ses-ormp-20200505monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-patent-in-canada-allowed-for-oral-delivery-of-proteins-ormp-20200407monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-issues-ceo-shareholder-letter-providing-business-update-amid-covid--ormp-20200401monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-receives-positive-feedback-from-end-of-phase-2-oral-insulin-cmc-meeting-with-fda-ormp-20200319monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-inc-prices-public-offering-of-common-stock-for-aggregate-proceeds-o-ormp-20200227monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-inc-announces-proposed-public-offering-of-common-stock-ormp-20200226monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-reports-positive-results-in-the-final-cohort-of-its-phase-2b-oral-insulin-trial-ormp-20200226monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-bio-ceo-investor-conference-ormp-20200204monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-appoints-dr-julio-rosenstock-to-its-scientific-advisory-board-ormp-20200130monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-patent-in-europe-to-be-granted-for-oral-delivery-of-proteins-ormp-20200128monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-elects-dr-alexander-fleming-to-scientific-advisory-board-ormp-20200123monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-appoints-dr-jay-skyler-to-scientific-advisory-board-ormp-20200121monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-issues-letter-to-shareholders-ormp-20200109monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-appoints-dr-arie-mayer-to-board-of-directors-ormp-20191205monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-a-scientific-poster-at-international-diabetes-federation-congress-ormp-20191202monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-patent-granted-in-japan-for-protease-inhibitor-a-key-component-of-platform-technolo-ormp-20191121monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-provides-highlights-and-data-from-its-phase-iib-oral-insulin-study-investor-event-ormp-20191119monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-to-discuss-positive-phase-iib-data-at-investor-event-and-conference-ormp-20191114monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-successful-phase-iib-study-of-oral-insulin-in-type-2-diabetes-ormp-20191112monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-ladenburg-thalmann-2019-healthcare-conference-ormp-20190918monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-last-patient-treated-in-pivotal-phase-iib-trial-of-oral-insulin-ormd-0801-ormp-20190917monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-three-upcoming-conferences-ormp-20190903monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-world-diabetes-congress-ormp-20190710monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-xiaoming-gao-joins-board-of-directors-ormp-20190702monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-provides-clinical-update-with-meaningful-data-expected-by-year-end-ormp-20190618monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-bio-international-convention-ormp-20190603monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-completes-patient-recruitment-of-phase-iib-hba1c-trial-for-oral-insulin-capsule-orm-ormp-20190521monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-thinkequity-conference-ormp-20190429monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-3rd-annual-clinical-trials-summit-ormp-20190411monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-patent-allowed-in-the-u-s-for-oral-exenatide-ormp-20190404monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-h-c-wainwright-global-life-sciences-conference-ormp-20190403monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-patent-allowed-in-the-u-s-for-key-aspect-of-its-oral-delivery-technology-ormp-20190328monthly0.5https://www.biopharmawatch.com/news/ORMP/chinese-regulatory-authority-nmpa-approves-ind-application-of-oramed-ormp-20190326monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-bio-ceo-investor-conference-ormp-20190206monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-initiates-phase-i-oral-glp-1-study-under-ind-ormp-20190122monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-ormp-20190115monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-receives-additional-3-million-milestone-payment-from-htit-ormp-20190109monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-completes-over-50-randomization-in-its-pivotal-90-day-clinical-study-ormp-20181113monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-the-tides-europe-2018-conference-ormp-20181105monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-cardiometabolic-health-congress-ormp-20181023monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-enrolls-first-patient-in-its-clinical-study-for-oral-insulin-in-the-treatment-of-na-ormp-20181004monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-receives-fda-clearance-for-ind-application-for-its-oral-glp-1-analog-capsule-ormp-20180917monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-the-h-c-wainwright-global-investment-conference-ormp-20180828monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-granted-japanese-patent-for-glp-1-analog-capsule-ormp-20180724monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-closing-of-18-1-million-registered-direct-offering-ormp-20180706monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-18-1-million-registered-direct-offering-ormp-20180703monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-enrolls-first-patient-in-its-glucose-clamp-study-for-oral-insulin-ormp-20180625monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-initiates-food-effect-study-for-its-oral-insulin-capsule-ormd-0801-ormp-20180621monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-be-added-to-russell-microcap-index-ormp-20180619monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-the-american-diabetes-association-78th-scientific-sessions-ormp-20180612monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-patent-allowed-in-the-us-for-oral-administration-of-proteins-ormp-20180530monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-conferences-in-may-ormp-20180507monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-initiates-its-90-day-pivotal-dose-ranging-clinical-study-for-oral-insulin-ormp-20180423monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-h-c-wainwright-annual-global-life-sciences-conference-ormp-20180327monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-oppenheimer-ormp-20180315monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-adds-two-new-members-to-its-scientific-advisory-board-ormp-20180228monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-the-codhy-6th-world-congress-on-diabetes-obesity-and-hypertension-ormp-20180220monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-bio-ceo-investor-conference-ormp-20180206monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-ormp-20180119monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-receives-regulatory-approval-to-conduct-clinical-study-for-treatment-of-nash-with-i-ormp-20171114monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-granted-broad-composition-of-matter-patent-in-europe-for-oral-proteins-ormp-20171031monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-the-diabetes-technology-meeting-ormp-20171024monthly0.5https://www.biopharmawatch.com/news/ORMP/endocrinology-diabetes-and-metabolism-journal-publishes-scientific-paper-authored-by-orame-ormp-20171017monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-the-disruptive-growth-showcase-conference-ormp-20170925monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-successful-meeting-with-fda-for-oral-insulin-ormp-20170905monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-the-rodman-renshaw-global-investment-conference-ormp-20170829monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-appoints-dr-simon-bruce-as-vice-president-of-medical-affairs-ormp-20170718monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-bit-ormp-20170712monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-end-of-phase-2-meeting-with-fda-to-initiate-phase-3-program-ormp-20170711monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-dual-listing-on-tel-aviv-stock-exchange-ormp-20170705monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-granted-japanese-patent-for-combination-insulin-and-glp-1-analog-capsule-ormp-20170627monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-conferences-next-week-ormp-20170518monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-granted-canadian-patent-for-glp-1-analog-capsule-ormp-20170509monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-receives-israel-regulatory-approval-to-conduct-human-study-for-new-oral-leptin-caps-ormp-20170502monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-granted-european-patent-for-combination-oral-insulin-and-glp-1-analog-capsule-ormp-20170420monthly0.5https://www.biopharmawatch.com/news/ORMP/journal-of-diabetes-science-and-technology-publishes-scientific-paper-authored-by-oramed-s-ormp-20170404monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-oligonucleotide-and-peptide-therapeutics-opt-boston-conference-on-mar-ormp-20170322monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-appoints-dr-ronald-law-as-chief-strategy-officer-ormp-20170321monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-bio-ceo-and-investor-and-disruptive-growth-and-healthcare-conferences-ormp-20170207monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-s-ormd-0901-oral-glp-1-analog-found-safe-and-well-tolerated-in-phase-ib-study-orame-ormp-20161129monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-receives-additional-4-million-milestone-payment-from-htit-ormp-20161006monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-the-aegis-capital-growth-conference-ormp-20160919monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-the-rodman-renshaw-global-investment-conference-ormp-20160907monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-receives-additional-4-million-milestone-payment-from-htit-ormp-20160802monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-reports-additional-phase-iib-oral-insulin-study-data-demonstrating-significant-lowe-ormp-20160728monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-appoints-dr-roy-eldor-as-chief-medical-director-ormp-20160726monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-6-5-million-milestone-payment-from-htit-ormp-20160621monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-the-american-diabetes-association-76th-scientific-sessions-ormp-20160609monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-positive-top-line-results-from-phase-iib-oral-insulin-study-ormp-20160518monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-oppenheimer-annual-israeli-conference-ormp-20160516monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-patent-being-granted-in-china-for-oral-administration-of-proteins-ormp-20160511monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-pioneers-2016-presented-by-joseph-gunnar-ormp-20160428monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-receives-patent-term-adjustment-extending-the-term-of-its-u-s-patent-ormp-20160412monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-completes-phase-iib-oral-insulin-study-ormp-20160405monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-patent-granted-in-india-for-oral-administration-of-proteins-ormp-20160329monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-the-bio-ceo-investor-conference-ormp-20160204monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-ormp-20160106monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-closing-of-licensing-and-investment-deal-with-htit-for-oral-insulin-capsu-ormp-20151229monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-signs-up-to-50-million-licensing-and-investment-agreements-for-oral-insulin-capsule-ormp-20151130monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-the-aegis-capital-growth-conference-ormp-20151001monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-patent-allowed-in-the-us-for-oral-administration-of-proteins-ormp-20150924monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-completes-randomization-of-over-50-of-patients-in-phase-iib-oral-insulin-study-ormp-20150909monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-the-rodman-renshaw-global-investment-conference-ormp-20150904monthly0.5https://www.biopharmawatch.com/news/ORMP/sinopharm-capital-hefei-signs-letter-of-intent-with-oramed-for-50-000-000-investment-and-l-ormp-20150707monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-enrolls-first-patient-in-its-phase-iib-oral-insulin-study-ormp-20150630monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-granted-patent-in-russia-for-oral-administration-of-glp-1-ormp-20150616monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-closing-of-5-36-million-registered-direct-offering-ormp-20150611monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-raise-5-36-million-in-registered-direct-offering-ormp-20150605monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-the-american-diabetes-association-75th-scientific-sessions-ormp-20150602monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-submits-protocol-to-u-s-fda-for-its-phase-iib-oral-insulin-study-ormp-20150526monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-upcoming-conferences-ormp-20150505monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-inc-issues-phase-iib-study-update-letter-ormp-20150428monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-the-gtc-diabetes-summit-ormp-20150420monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-enrolls-first-patient-in-its-glucose-clamp-study-for-oral-insulin-ormp-20150401monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-the-roth-conference-ormp-20150304monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-poster-at-the-gtc-protease-inhibitors-in-drug-discovery-conference-ormp-20150219monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-the-bio-ceo-investor-conference-ormp-20150205monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-inc-issues-letter-to-shareholders-ormp-20150128monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-granted-patent-in-israel-for-oral-administration-of-glp-1-ormp-20150116monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-closes-5-million-investment-from-guangxi-wuzhou-pharmaceutical-company-ormp-20141203monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-at-ld-micro-main-event-micro-cap-growth-conference-on-december-2-20-ormp-20141201monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-report-key-top-line-results-from-u-s-phase-iia-trial-with-oral-insulin-in-type-1-ormp-20141031monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-the-firerock-annual-micro-cap-conference-ormp-20141024monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-reports-positive-top-line-data-from-u-s-phase-iia-trial-with-oral-i-ormp-20141022monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-family-office-wealth-management-conference-ormp-20140915monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-upcoming-conferences-ormp-20140903monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-granted-patent-in-spain-for-oral-administration-of-insulin-ormp-20140819monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-reports-last-patient-out-in-phase-iia-trial-for-ormd-0801-in-type-1-ormp-20140807monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-to-present-at-the-bio-international-convention-in-san-diego-ormp-20140623monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-added-to-the-morgan-stanley-capital-international-msci-microcap-ind-ormp-20140529monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-jefferies-global-healthcare-conference-on-june-2-in-new-york-city-ormp-20140527monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-to-present-at-the-iati-israel-innovation-conference-in-tel-aviv-ormp-20140519monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-poster-on-its-oral-insulin-capsule-at-the-yale-diabetes-symposium-ormp-20140513monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-granted-patent-in-hong-kong-for-oral-administration-of-insulin-ormp-20140410monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-announces-first-patient-enrolled-in-a-us-phase-2a-trial-for-ormd-08-ormp-20140327monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-granted-its-3rd-patent-in-australia-for-oral-administration-of-exenatide-ormp-20140311monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-upcoming-conferences-ormp-20140306monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-results-from-its-phase-2a-fda-trial-with-ormd-0801-at-the-2014-diabetes--ormp-20140303monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-successful-fda-phase-2a-clinical-trial-results-ormp-20140130monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-announce-results-of-its-phase-2a-clinical-trial-for-oral-insulin-on-january-30th-ormp-20140127monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-receives-patent-allowance-in-israel-and-australia-for-platform-technology-in-oral-d-ormp-20140102monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-raise-15-800-000-in-registered-direct-offering-ormp-20131224monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-successful-results-from-ex-us-pharmacokinetic-study-of-its-oral-insulin-f-ormp-20131220monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-receives-allowance-on-its-core-oral-glp-1-technology-patent-in-israel-ormp-20131210monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-receives-patent-in-the-european-union-for-the-oral-delivery-of-insulin-ormp-20131119monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-last-patient-out-in-phase-2a-fda-trial-of-its-ormd-0801-oral-insulin-caps-ormp-20131112monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-granted-patents-in-japan-and-canada-for-its-pod-technology-for-the-oral-delivery-of-ormp-20131003monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-participate-in-barclays-ormp-20130925monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-s-platform-technology-in-oral-delivery-of-proteins-receives-patent-in-russia-oramed-ormp-20130917monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-granted-patent-in-china-for-its-platform-technology-in-oral-delivery-of-proteins-ormp-20130910monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-submits-pre-ind-package-to-fda-for-ormd-0901-oral-exenatide-an-oral-glp-1-analog-fo-ormp-20130903monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-initiates-patient-recruitment-for-a-new-clinical-trial-in-israel-of-its-oral-insuli-ormp-20130821monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-submits-pre-ind-meeting-request-to-fda-for-its-oral-exenatide-capsule-ormd-0901-ormp-20130730monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-raise-4-600-000-in-registered-direct-offering-ormp-20130710monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-enrolls-first-patient-in-its-phase-2a-u-s-oral-insulin-clinical-trial-ormp-20130708monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-to-present-at-the-8th-annual-jmp-securities-healthcare-conference-in-new-york-city-ormp-20130702monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-to-present-findings-on-oral-insulin-to-the-american-diabetes-associ-ormp-20130621monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-announces-withdrawal-of-proposed-underwritten-public-offering-ormp-20130621monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-to-present-at-iati-biomed-conference-in-israel-ormp-20130610monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-selected-to-present-at-the-81st-european-atherosclerosis-society-congress-in-lyon-f-ormp-20130603monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-awarded-grant-by-the-office-of-the-chief-scientist-of-israel-ormp-20130530monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-ceo-to-present-at-new-york-biotechnology-association-and-the-israel-conference-ormp-20130528monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-receives-fda-clearance-to-initiate-oral-insulin-trials-in-the-u-s-ormp-20130517monthly0.5https://www.biopharmawatch.com/news/ORMP/clinical-results-for-oramed-ormp-20130501monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-to-present-results-of-its-key-clinical-studies-of-oral-insulin-in-t-ormp-20130429monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-ceo-to-be-panelist-at-bio-international-convention-breakout-session-on-israel-becom-ormp-20130422monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-chosen-to-present-at-the-5th-international-congress-on-prediabetes--ormp-20130418monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-appoints-new-chief-operating-officer-and-vp-of-business-development-ormp-20130416monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-submits-new-ind-application-for-oral-insulin-trial-in-the-us-ormp-20130411monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-granted-japanese-patent-for-its-core-technology-in-oral-delivery-of-ormp-20130403monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-selected-to-present-at-the-73rd-scientific-sessions-of-the-american-ormp-20130321monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-to-present-at-the-4th-annual-drug-delivery-formulation-summit-in-be-ormp-20130218monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-moves-forward-with-investigational-new-drug-application-for-oral-in-ormp-20130214monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-inc-investor-presentation-now-available-for-on-demand-viewing-at-re-ormp-20130211monthly0.5https://www.biopharmawatch.com/news/ORMP/shares-of-oramed-pharmaceuticals-are-approved-for-listing-on-the-nasdaq-capital-market-ormp-20130207monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-inc-to-webcast-live-at-retailinvestorconferences-com-on-february-7t-ormp-20130205monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-announces-reverse-stock-split-ormp-20130122monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-files-investigational-new-drug-application-with-the-fda-for-oral-in-ormp-20130107monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-completes-5-6-million-funding-to-advance-clinical-trials-ormp-20121211monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-to-present-at-the-12th-annual-diabetes-technology-society-meeting-i-ormp-20121107monthly0.5https://www.biopharmawatch.com/news/ORMP/former-johnson-johnson-and-bausch-lomb-executive-gerald-ostrov-joins-oramed-pharmaceutical-ormp-20121018monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-to-collaborate-with-leading-contract-research-organization-medpace--ormp-20121003monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-granted-2nd-patent-in-new-zealand-3rd-patent-for-core-technology-on-ormp-20120711monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-granted-core-technology-patent-in-new-zealand-ormp-20120529monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-to-present-at-the-11th-national-life-science-technology-week-ilsi-b-ormp-20120521monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-announces-educational-lecture-at-the-national-university-hospital-i-ormp-20120207monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-granted-australian-patent-for-important-part-of-the-company-ormp-20120124monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-files-us-patent-application-for-combination-oral-treatment-of-diabe-ormp-20120110monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-chosen-to-present-at-the-diabetes-technology-meeting-october-27-29--ormp-20111025monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-announces-successful-phase-1-clinical-trial-results-for-enterabio-ormp-20110927monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-chosen-to-present-at-the-8th-annual-israel-strategic-partner-and-ve-ormp-20110915monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-to-present-at-rodman-renshaw-13th-annual-global-investment-conferen-ormp-20110908monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-appoints-dr-michael-berelowitz-as-chairman-of-scientific-advisory-b-ormp-20110622monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-to-present-at-the-1st-asia-pacific-congress-on-controversies-to-con-ormp-20110518monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-to-present-at-the-10th-national-life-science-technology-week-ilsi-b-ormp-20110511monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-successfully-completes-toxicity-study-for-ormd-0801-ormp-20110323monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-announces-completion-of-3-4-million-private-placement-round-ormp-20110309monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-sells-its-stake-in-entera-bio-for-1-15-million-buyer-also-to-invest-ormp-20110228monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-presents-results-of-its-phase-iib-clinical-trial-at-the-diabetes-te-ormp-20101115monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-to-present-results-of-an-oral-insulin-administration-study-at-the-t-ormp-20101026monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-to-highlight-novel-obesity-and-metabolic-therapies-at-upcoming-life-sciences-virtu-mtva-20260617monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-to-highlight-novel-obesity-and-metabolic-therapies-at-upcoming-emerging-growth-con-mtva-20260604monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-to-highlight-novel-obesity-and-metabolic-therapies-at-upcoming-emerging-growth-con-mtva-20260217monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-announces-the-closing-of-9-3-million-underwritten-public-offering-including-full-e-mtva-20260116monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-presents-pre-clinical-data-on-da-1241-demonstrating-additive-hepatoprotective-effe-mtva-20250621monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-announces-poster-presentation-on-da-1241-at-the-ada-mtva-20250604monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-announces-late-breaking-poster-presentation-on-da-1241-at-the-easl-congress-2025-mtva-20250423monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-reports-year-end-2024-financial-results-and-provides-corporate-update-mtva-20250320monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-to-hold-advisory-committee-meeting-at-the-9th-annual-mash-tag-2025-conference-mtva-20250110monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-to-participate-in-the-9th-annual-mash-tag-2025-conference-after-releasing-positive-mtva-20241219monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-to-present-at-the-emerging-growth-conference-in-december-mtva-20241202monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-issuance-of-mexican-patent-covering-breast-cancer-vaccine-tech-anix-20260429monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-participate-in-water-tower-research-insights-conference-on-april-14-2-anix-20260407monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-participate-in-water-tower-research-fireside-chat-on-tuesday-november-anix-20251110monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-and-moffitt-cancer-center-complete-dosing-of-fourth-cohort-in-ovarian-ca-anix-20250908monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-time-change-for-presentation-at-the-h-c-wainwright-27th-annual-anix-20250902monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conferenc-anix-20250825monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-receives-notice-of-allowance-from-chinese-national-intellectual-property-anix-20250820monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-treatment-of-second-patient-in-fourth-cohort-of-ovarian-cancer-anix-20250818monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-issuance-of-additional-u-s-patent-for-car-t-technology-anix-20250812monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-dr-robert-wenham-will-speak-about-immunotherapy-in-surviving-o-anix-20250808monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-commencement-of-us-fda-approved-ind-transfer-to-support-upcomi-anix-20250804monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-receives-notice-of-allowance-from-canadian-intellectual-property-office--anix-20250730monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-awarded-new-u-s-patent-extending-breast-cancer-vaccine-ip-protection-int-anix-20250724monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-issuance-of-additional-u-s-patent-for-ovarian-cancer-vaccine-t-anix-20250709monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-initiates-dosing-in-fourth-cohort-in-its-ovarian-cancer-car-t-clinical-t-anix-20250623monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-host-an-investor-webcast-on-june-26-2025-anix-20250620monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-anix-20250610monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-poster-presentation-on-ovarian-cancer-car-t-clinical-trial-at--anix-20250609monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-anix-20250603monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-completion-of-enrollment-in-phase-1-trial-of-breast-cancer-vac-anix-20250602monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-ceo-provides-letter-to-shareholders-outlining-significant-progress-and-a-anix-20250519monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-poster-presentation-on-ovarian-cancer-car-t-clinical-trial-at--anix-20250512monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conferen-anix-20250430monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-receives-notice-of-allowance-from-u-s-patent-and-trademark-office-for-ca-anix-20250414monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-receives-notice-of-allowance-from-u-s-patent-and-trademark-office-for-pa-anix-20250409monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-the-jones-las-vegas-healthcare-and-technology-innovation-c-anix-20250401monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-enters-letter-of-intent-with-verdi-solutions-to-develop-artificial-intel-anix-20250325monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-receives-notice-of-allowance-from-uspto-for-ovarian-cancer-vaccine-anix-20250324monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-ceo-to-present-at-the-2025-cagla-neauxcancer-conference-on-march-28th-anix-20250317monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-2025-annual-meeting-of-stockholders-to-include-investor-presentation-ope-anix-20250310monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-chief-development-officer-dr-pam-garzone-to-speak-at-the-allia-anix-20250303monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-and-moffitt-cancer-center-complete-dosing-in-third-cohort-in-ovarian-can-anix-20250226monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-anix-20250225monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-featured-in-breaking-cancer-news-article-on-novel-car-t-therapy-for-ovar-anix-20250224monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-approval-of-protocol-amendment-for-ovarian-cancer-car-t-clinic-anix-20250218monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-chairman-and-ceo-discusses-pioneering-car-t-cell-therapy-and-breast-canc-anix-20250214monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-the-18th-annual-european-life-sciences-ceo-forum-anix-20250211monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-anix-20250204monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-ceo-provides-letter-to-shareholders-anix-20250121monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-the-iaccess-alpha-virtual-best-ideas-winter-conference-202-anix-20241204monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-board-of-directors-approves-purchase-of-bitcoin-as-treasury-reserve-asse-anix-20241122monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-initiates-dosing-in-third-cohort-in-its-ovarian-cancer-car-t-clinical-tr-anix-20241118monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-timing-of-public-release-of-data-from-the-phase-1-study-of-its-anix-20241106monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-the-sidoti-micro-cap-virtual-conference-on-november-13-14--anix-20241031monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-and-cleveland-clinic-to-present-additional-data-from-phase-1-study-of-br-anix-20241028monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-second-dose-administered-to-patient-in-ovarian-cancer-car-t-cl-anix-20241015monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-appoints-suyasha-gupta-as-senior-director-of-clinical-development-anix-20241007monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-submission-of-protocol-amendment-for-car-t-trial-anix-20240930monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-unveils-phase-2-study-plan-for-breast-cancer-vaccine-anix-20240924monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-presentation-on-its-ovarian-cancer-car-t-therapy-at-the-ovaria-anix-20240918monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-presentation-on-its-ovarian-cancer-car-t-therapy-at-the-rivkin-anix-20240903monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conferenc-anix-20240826monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-presentation-on-its-ovarian-cancer-car-t-clinical-trial-at-the-anix-20240729monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-fda-approval-of-individual-patient-ind-for-its-ovarian-cancer--anix-20240723monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-japanese-patent-on-breast-cancer-vaccine-technology-anix-20240717monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-5-million-share-repurchase-program-anix-20240715monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-treats-sixth-patient-in-its-ovarian-cancer-car-t-clinical-trial-anix-20240624monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-commences-treatment-of-fifth-patient-in-ovarian-cancer-car-t-clinical-tr-anix-20240521monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-expands-partnership-with-cleveland-clinic-to-develop-additional-cancer-v-anix-20240508monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-ceo-featured-on-target-cancer-podcast-by-oncologist-dr-sanjay-juneja-anix-20240506monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-participate-in-the-sidoti-micro-cap-virtual-conference-on-may-8-9-202-anix-20240430monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-welcomes-celebrity-oncologist-dr-sanjay-juneja-to-its-cancer-business-ad-anix-20240418monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-2024-annual-meeting-of-stockholders-to-include-investor-presentation-ope-anix-20240314monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-presentation-at-24th-annual-world-vaccine-congress-anix-20240311monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-initiates-dosing-in-second-cohort-of-ovarian-cancer-car-t-clinical-trial-anix-20240212monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-participation-in-2024-neauxcancer-oncology-conference-anix-20240129monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-japanese-patent-on-ovarian-cancer-vaccine-technology-anix-20240123monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-sidoti-micro-cap-virtual-conference-on-january-17-2024-anix-20240110monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-biotech-showcase-2024-anix-20231214monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-and-cleveland-clinic-present-positive-new-data-from-phase-1-study-of-bre-anix-20231206monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-host-conference-call-this-evening-to-discuss-positive-new-data-from-o-anix-20231206monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-european-patent-on-ovarian-cancer-vaccine-technology-anix-20231127monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-the-ovarian-cancer-research-alliance-ocra-ovarian-cancer-n-anix-20231031monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-appoints-accomplished-medical-oncologist-and-biotechnology-executive-dr--anix-20231023monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-completes-treatment-of-first-patient-cohort-in-ovarian-cancer-car-t-clin-anix-20231013monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-issuance-of-additional-u-s-patent-for-ovarian-cancer-vaccine-t-anix-20231003monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-establishes-cancer-business-advisory-board-anix-20230919monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-participate-in-september-investor-conferences-anix-20230831monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-treatment-of-third-patient-in-ovarian-cancer-car-t-clinical-tr-anix-20230828monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-invited-presentation-on-ovarian-cancer-car-t-therapy-at-the-8t-anix-20230814monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-opening-of-enrollment-for-keytruda-arm-in-ongoing-breast-cance-anix-20230807monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-notice-of-allowance-of-additional-patent-on-ovarian-cancer-vac-anix-20230727monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-issuance-of-canadian-patent-for-its-car-t-cancer-therapy-techn-anix-20230711monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-treatment-of-second-patient-in-its-ovarian-cancer-car-t-clinic-anix-20230522monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-clarifies-poster-presentation-on-company-website-anix-20230417monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-and-cleveland-clinic-present-positive-data-for-phase-1-study-of-breast-c-anix-20230417monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-presentation-on-breast-cancer-vaccine-trial-at-the-2023-aacr-a-anix-20230327monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-reassures-shareholders-it-has-no-accounts-at-silicon-valley-bank-anix-20230313monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-provide-corporate-update-at-its-2023-annual-meeting-of-stockholders-anix-20230302monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-notice-of-allowance-of-additional-key-patent-on-breast-cancer--anix-20230227monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-formation-of-breast-cancer-clinical-advisory-board-anix-20230221monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-biotech-showcase-2023-anix-20221219monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-maximum-tolerated-dose-reached-in-trial-of-preventative-breast-anix-20221208monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-presentation-on-breast-cancer-vaccine-trial-at-the-2022-san-an-anix-20221108monthly0.5https://www.biopharmawatch.com/news/ANIX/dr-jose-conejo-garcia-invited-to-present-keynote-address-at-duke-cancer-institute-will-dis-anix-20221031monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-commencement-of-phase-1b-trial-of-its-breast-cancer-vaccine-at-anix-20221026monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-presentation-on-ovarian-cancer-car-t-therapy-trial-at-the-soci-anix-20221010monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-anix-20220912monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conferenc-anix-20220831monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-treatment-of-first-patient-in-its-ovarian-cancer-car-t-clinica-anix-20220815monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-notice-of-allowance-of-additional-patent-on-breast-cancer-vacc-anix-20220721monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-publication-of-peer-reviewed-journal-article-in-clinical-and-e-anix-20220621monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-the-2022-h-c-wainwright-global-investment-conference-anix-20220505monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-presentation-on-breast-cancer-vaccine-trial-at-the-american-so-anix-20220428monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-anix-20220406monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-the-initiation-of-its-ovarian-cancer-car-t-phase-1-trial-at-mo-anix-20220330monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-participate-in-the-2022-virtual-growth-conference-hosted-by-m-vest-a--anix-20220317monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-japanese-patent-on-ovarian-cancer-vaccine-anix-20220125monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-and-molgenie-announce-early-potency-analysis-of-sars-cov-2-protease-inhi-anix-20220124monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-participate-in-upcoming-january-investor-conferences-lifesci-partners-anix-20211216monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-and-molgenie-announce-that-their-covid-19-compounds-are-expected-to-be-e-anix-20211207monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-patient-dosing-of-its-investigational-vaccine-candidate-in-a-f-anix-20211026monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-first-chinese-patent-on-its-car-t-cancer-therapy-technology-anix-20211006monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-notice-of-allowance-for-additional-patent-on-its-car-t-cancer--anix-20211001monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-anix-20210914monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conferenc-anix-20210908monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-appoints-dr-pamela-garzone-as-chief-development-officer-anix-20210907monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-and-moffitt-cancer-center-announce-fda-clearance-to-initiate-clinical-tr-anix-20210830monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-anix-20210825monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-congratulates-director-dr-arnold-baskies-for-his-appointment-to-the-who-anix-20210823monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-issuance-of-u-s-patent-for-ovarian-cancer-vaccine-technology-anix-20210818monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-support-from-the-national-cancer-institute-for-ovarian-cancer--anix-20210526monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-and-moffitt-cancer-center-receive-additional-information-request-from-us-anix-20210520monthly0.5https://www.biopharmawatch.com/news/ANIX/ontochem-assigns-anixa-covid-19-drug-discovery-project-to-molgenie-anix-20210507monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-and-moffitt-cancer-center-report-us-fda-request-of-additional-informatio-anix-20210419monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-and-ontochem-enter-next-stage-of-development-for-covid-19-therapeutic-anix-20210405monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-increases-previously-announced-bought-deal-offering-of-common-stock-to-2-anix-20210322monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-10-million-bought-deal-offering-of-common-stock-anix-20210322monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-and-moffitt-cancer-center-file-ind-application-for-ovarian-cancer-car-t--anix-20210322monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-anix-20210312monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-participate-in-m-vest-llc-and-maxim-group-llc-inaugural-emerging-grow-anix-20210308monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-european-patent-issued-for-its-car-t-cancer-therapy-anix-20210304monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-the-h-c-wainwright-global-life-sciences-conference-anix-20210225monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-begins-animal-testing-of-covid-19-therapeutic-candidates-anix-20210216monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-the-b-riley-oncology-investor-conference-anix-20210113monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-the-h-c-wainwright-bioconnect-2021-conference-anix-20210105monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-and-cleveland-clinic-announce-fda-clearance-to-initiate-clinical-trial-o-anix-20201221monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-covid-19-therapy-demonstrates-comparable-potency-to-remdesivir-in-pre-cl-anix-20201214monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-licensing-agreement-with-cleveland-clinic-for-ovarian-cancer-v-anix-20201201monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-and-cleveland-clinic-file-ind-application-for-breast-cancer-vaccine-anix-20201123monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-host-conference-call-to-provide-update-on-programs-anix-20201027monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-the-2020-h-c-wainwright-22nd-annual-global-investment-conf-anix-20200908monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-and-ontochem-announce-identification-of-additional-covid-19-compounds-anix-20200813monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-breast-cancer-vaccine-technology-nearing-fda-submission-anix-20200728monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-change-to-virtual-format-for-2020-annual-meeting-of-stockholde-anix-20200720monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-anix-20200710monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-and-ontochem-announce-completion-of-initial-screening-program-and-identification-of--anix-20200706monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-and-ontochem-have-synthesized-four-potential-covid-19-drugs-for-testing--anix-20200601monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-and-ontochem-announce-discovery-of-first-covid-19-therapeutic-candidate-anix-20200504monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-publication-of-peer-reviewed-journal-article-in-biomarker-insi-anix-20200423monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-and-ontochem-announce-collaboration-to-develop-novel-covid-19-therapeuti-anix-20200420monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-presentation-at-ai-and-big-data-in-cancer-conference-anix-20200302monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-and-moffitt-cancer-center-announce-completion-of-viral-vector-reformulat-anix-20200212monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-presentation-at-aacr-liquid-biopsies-conference-anix-20200106monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-biotech-showcase-2020-anix-20191223monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-commercial-launch-of-cchek-prostate-cancer-confirmatory-test-anix-20191216monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-host-conference-call-to-discuss-plans-for-2020-anix-20191213monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-provides-update-on-car-t-program-anix-20191213monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-presentation-at-the-2019-san-antonio-breast-cancer-symposium-anix-20191202monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-genesis-research-to-join-cchek-prostate-cancer-study-anix-20191126monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-collaboration-with-urology-centers-of-alabama-on-cchek-prostat-anix-20191122monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-collaboration-with-idaho-urologic-institute-on-cchek-prostate--anix-20191120monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-presentation-at-cell-symposia-hallmarks-of-cancer-anix-20191107monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-patent-issued-for-its-breast-cancer-vaccine-anix-20191105monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-names-novartis-executive-dr-emanuele-ostuni-to-scientific-advisory-board-anix-20191028monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-collaboration-with-urology-san-antonio-on-cchek-prostate-cance-anix-20191025monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-abstract-accepted-for-presentation-at-the-34th-annual-meeting--anix-20191022monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-appoints-dr-thomas-schlumpberger-as-executive-vice-president-of-diagnost-anix-20191015monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-names-cancer-vaccine-pioneer-dr-ian-h-frazer-to-scientific-advisory-boar-anix-20191010monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-university-of-maryland-school-of-medicine-to-join-cchek-prosta-anix-20190923monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-commences-collaboration-with-potomac-urology-center-on-cchek-prostate-ca-anix-20190919monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-congratulates-scientific-advisory-board-member-dr-h-michael-shepard-as-a-anix-20190916monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-two-upcoming-investor-conferences-anix-20190826monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-va-north-texas-health-care-system-to-join-cchek-prostate-cance-anix-20190729monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-additional-patent-issued-on-cancer-detection-technology-anix-20190724monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-u-s-department-of-veterans-affairs-va-maryland-health-care-sys-anix-20190722monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-a-strategic-alliance-and-licensing-agreement-with-cleveland-cl-anix-20190717monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-highlights-recent-publication-in-the-journal-of-experimental-medicine-on-anix-20190716monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-the-cyto-2019-34th-congress-of-the-international-society-f-anix-20190529monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-the-sachs-associates-5th-annual-immuno-oncology-bd-l-and-i-anix-20190521monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-completion-of-cchek-analytical-verification-at-clia-laboratory-anix-20190513monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-b-riley-fbr-institutional-investor-conference-anix-20190502monthly0.5https://www.biopharmawatch.com/news/ANIX/us-patent-trademark-office-issues-patent-on-anixa-biosciences-car-t-cancer-treatment-techn-anix-20190417monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-extends-and-expands-its-collaboration-with-new-jersey-urology-anix-20190411monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-presents-cchek-prostate-cancer-detection-data-at-aacr-annual-meeting-anix-20190403monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-ceo-to-present-at-the-new-york-academy-of-sciences-symposium-on-cancer-i-anix-20190327monthly0.5https://www.biopharmawatch.com/news/ANIX/u-s-department-of-veterans-affairs-and-mcguire-research-institute-join-anixa-biosciences-c-anix-20190325monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-notice-of-allowance-for-additional-cancer-detection-technology-anix-20190314monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-cchek-technology-and-data-at-the-molecular-medicine-tri-confe-anix-20190304monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-latest-prostate-cancer-data-at-the-2019-american-association--anix-20190228monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-partnership-with-researchdx-for-launch-of-cchek-prostate-cance-anix-20190225monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-extends-collaborative-research-agreement-with-the-wistar-institute-and-l-anix-20190221monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-moffitt-cancer-center-anix-20190213monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-car-t-cancer-therapy-patent-receives-notice-of-allowance-anix-20190124monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-hold-conference-call-to-discuss-outlook-for-2019-anix-20190116monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-completion-of-pre-sub-meeting-with-fda-for-its-cchek-cancer-di-anix-20181219monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-presents-positive-data-on-its-liquid-biopsy-for-early-detection-of-breas-anix-20181203monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-cchek-breast-cancer-data-at-aacr-special-conference-on-tumor--anix-20181115monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-presents-positive-data-from-its-artificial-intelligence-powered-liquid-b-anix-20181112monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-sitc-annual-meeting-anix-20181029monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-scheduling-of-pre-sub-meeting-with-fda-for-its-cchek-cancer-di-anix-20181024monthly0.5https://www.biopharmawatch.com/news/ANIX/moffitt-cancer-center-and-anixa-biosciences-announce-completion-of-pre-ind-meeting-with-fd-anix-20181022monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-releases-data-presented-at-aacr-artificial-intelligence-conference-anix-20181017monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-files-pre-submission-and-requests-meeting-with-fda-regarding-cchek-artif-anix-20181015monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-appoints-leading-researchers-in-immuno-oncology-to-its-scientific-adviso-anix-20181011monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-to-present-at-artificial-intelligence-conference-anix-20181005monthly0.5https://www.biopharmawatch.com/news/OSRH/woori-io-shareholders-approve-share-exchange-to-become-wholly-owned-subsidiary-of-osr-hold-osrh-20251219monthly0.5https://www.biopharmawatch.com/news/OSRH/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoart-osrh-20250409monthly0.5https://www.biopharmawatch.com/news/OSRH/osr-holdings-inc-nasdaq-osrh-enters-into-80-million-common-stock-purchase-agreement-with-w-osrh-20250403monthly0.5https://www.biopharmawatch.com/news/OSRH/vaximm-ag-an-osr-company-announces-results-from-phase-2a-trial-of-vxm01-and-avelumab-combi-osrh-20250326monthly0.5https://www.biopharmawatch.com/news/OSRH/osr-holdings-inc-and-osr-holdings-co-ltd-announce-completion-of-business-combination-osrh-20250214monthly0.5https://www.biopharmawatch.com/news/NRSN/c-o-r-r-e-c-t-i-o-n-neurosense-nrsn-20260318monthly0.5https://www.biopharmawatch.com/news/NRSN/primec-long-term-survival-data-to-be-presented-at-a-leading-als-scientific-conference-nrsn-20260309monthly0.5https://www.biopharmawatch.com/news/NRSN/world-renowned-alzheimer-nrsn-20260108monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-announces-transformative-phase-2b-microrna-data-highlighting-prime-nrsn-20250409monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-to-present-new-data-from-primec-nrsn-20250404monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-to-participate-in-the-2024-international-symposium-on-als-mnd-nrsn-20241121monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-announces-acceptance-of-two-primec-abstracts-at-the-2024-neals-ann-nrsn-20241007monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-granted-key-u-s-patent-for-novel-primec-formulation-its-lead-asset-nrsn-20240924monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-announces-private-placement-with-senior-management-participation-a-nrsn-20240807monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-announces-first-quarter-2024-business-update-nrsn-20240502monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-and-genetika-initiate-precision-medicine-collaboration-beginning-with-ongoing-p-nrsn-20240422monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-presents-positive-data-validating-phase-2b-topline-readout-during-emerging-scie-nrsn-20240418monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-to-present-paradigm-data-at-the-american-academy-of-neurology-annual-meeting-ap-nrsn-20240412monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-reports-additional-positive-results-from-its-als-phase-2b-paradigm-trial-nrsn-20240221monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-nrsn-20231205monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-to-present-at-upcoming-u-s-and-european-als-conferences-nrsn-20231109monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-to-participate-in-bio-europe-fall-nrsn-20231101monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-ceo-provides-q3-2023-update-nrsn-20231017monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-to-participate-in-upcoming-als-conferences-pactals-in-malaysia-and-neals-in-the-nrsn-20230914monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-to-host-investor-webinar-on-september-12-2023-nrsn-20230906monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-to-host-investor-event-in-cambridge-massachusetts-on-july-24-2023-nrsn-20230717monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-to-participate-in-upcoming-als-conferences-european-network-to-cure-als-everyth-nrsn-20230711monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-ceo-provides-q2-2023-update-nrsn-20230706monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-massachusetts-general-hospital-nrsn-20230327monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-to-present-at-the-als-and-alzheimer-nrsn-20230323monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-announces-year-end-2022-financial-results-and-provides-business-update-nrsn-20230322monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-to-participate-in-bio-europe-spring-nrsn-20230316monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-to-present-at-upcoming-leading-neuroscience-conferences-nrsn-20221027monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-to-participate-in-bio-europe-partnering-conference-on-october-24-2-nrsn-20221021monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-provides-ceo-nrsn-20221018monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-ceo-to-be-panelist-at-cantor-neurology-and-psychiatry-conference-nrsn-20220929monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-to-present-at-upcoming-u-s-and-european-als-conferences-nrsn-20220921monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-reports-positive-results-from-stage-iii-als-biomarker-study-nrsn-20220627monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-ceo-to-be-panelist-at-maxim-group-nrsn-20220622monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-to-present-at-the-als-drug-development-summit-in-boston-on-may-26--nrsn-20220523monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-granted-patent-in-canada-for-its-als-drug-primec-nrsn-20220406monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-to-participate-in-the-2022-virtual-growth-conference-presented-by--nrsn-20220315monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-granted-key-patent-for-its-als-drug-primec-in-australia-nrsn-20220301monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-to-present-at-american-society-for-experimental-neurotherapeutics--nrsn-20220224monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-to-present-at-aegis-virtual-conference-nrsn-20220222monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-to-present-at-bio-ceo-investor-conference-nrsn-20220131monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-ltd-announces-the-presentation-of-phase-iia-study-results-at-four--nrsn-20220104monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-ltd-expands-board-of-directors-and-adds-chief-medical-officer-to-l-nrsn-20211221monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-announces-closing-of-initial-public-offering-on-nasdaq-capital-mar-nrsn-20211213monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-publicly-files-registration-statement-with-sec-for-proposed-u-s-in-nrsn-20211019monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-announces-the-appointment-of-mark-leuchtenberger-as-chairman-of-th-nrsn-20210929monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-q3-2025-financial-results-company-update-cpix-20251028monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-phamaceuticals-announces-the-addition-of-an-established-fda-approved-product-to-cpix-20251020monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-cpix-20251013monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-23-revenue-growth-year-to-date-cpix-20250805monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-shares-phase-2-fight-dmd-trial-results-at-the-parent-project-mu-cpix-20250623monthly0.5https://www.biopharmawatch.com/news/CPIX/new-study-finds-caldolor-safe-and-effective-for-opioid-sparing-pain-management-in-older-ad-cpix-20250527monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-partners-with-qureight-to-advance-innovative-idiopathic-pulmona-cpix-20250513monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-38-revenue-growth-in-q1-2025-cpix-20250506monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-q1-2025-financial-results-company-update-cpix-20250429monthly0.5https://www.biopharmawatch.com/news/CPIX/fight-dmd-trial-results-selected-for-late-breaking-presentation-at-mda-clinical-scientific-cpix-20250319monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-11-6-fourth-quarter-2024-revenue-growth-cpix-20250304monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-annual-2024-financial-results-cpix-20250225monthly0.5https://www.biopharmawatch.com/news/CPIX/vibativ-receives-marketing-approval-in-china-cpix-20250218monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-announces-breakthrough-results-from-the-phase-2-fight-dmd-trial-cpix-20250204monthly0.5https://www.biopharmawatch.com/news/CPIX/fda-approves-acetadote-snda-cpix-20241209monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-third-quarter-2024-financial-results-and-company-update-cpix-20241107monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-receives-fda-orphan-drug-and-rare-pediatric-disease-designation-cpix-20241106monthly0.5https://www.biopharmawatch.com/news/CPIX/new-study-compares-caldolor-ibuprofen-injection-to-ketorolac-cpix-20241105monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-third-quarter-2024-financial-results-cpix-20241031monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-16-sequential-revenue-growth-in-second-quarter-2024-cpix-20240806monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-first-quarter-2024-financial-results-company-update-cpix-20240507monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-first-quarter-2024-financial-results-cpix-20240430monthly0.5https://www.biopharmawatch.com/news/CPIX/new-report-supports-use-of-caldolor-as-a-standard-of-care-across-patient-populations-cpix-20240402monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-annual-2023-financial-results-cpix-20240305monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-annual-2023-financial-results-cpix-20240227monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-third-quarter-2023-financial-results-cpix-20231107monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-revenue-and-earnings-growth-second-quarter-2023-cpix-20230808monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-second-quarter-2023-financial-results-cpix-20230801monthly0.5https://www.biopharmawatch.com/news/CPIX/new-publication-supports-the-use-of-caldolor-in-newborn-pediatric-patients-cpix-20230626monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-announces-fda-clearance-of-ind-for-new-treatment-of-idiopathic--cpix-20230523monthly0.5https://www.biopharmawatch.com/news/CPIX/caldolor-now-fda-approved-for-treatment-of-fever-pain-in-infants-cpix-20230515monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-first-quarter-2023-financial-results-company-update-cpix-20230509monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-first-quarter-2023-financial-results-cpix-20230502monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-17-revenue-growth-for-full-year-2022-cpix-20230307monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-annual-2022-financial-results-cpix-20230228monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-41-revenue-growth-cpix-20221108monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-third-quarter-2022-financial-results-cpix-20221101monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-moves-into-new-headquarters-at-broadwest-cpix-20221101monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-14-revenue-growth-cpix-20220809monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-2-4m-patient-doses-delivered-no-product-recalls-no-fda--cpix-20220808monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-second-quarter-2022-financial-results-cpix-20220802monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-appoints-martin-brown-jr-to-its-board-of-directors-cpix-20220719monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-6-revenue-growth-cpix-20220510monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-announces-key-co-promotion-agreement-with-verity-pharmaceutical-cpix-20220509monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-first-quarter-2022-financial-results-cpix-20220503monthly0.5https://www.biopharmawatch.com/news/CPIX/tabuk-and-cumberland-partner-to-bring-innovative-antibiotic-with-life-saving-potential-to--cpix-20220331monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-2021-financial-results-company-update-cpix-20220308monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-annual-2021-financial-results-cpix-20220301monthly0.5https://www.biopharmawatch.com/news/CPIX/caldolor-now-fda-approved-for-pre-operative-administration-cpix-20211129monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-third-quarter-2021-financial-results-company-update-cpix-20211109monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-third-quarter-2021-financial-results-cpix-20211102monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-launches-reditrex-product-line-for-active-rheumatoid-juvenile-i-cpix-20210929monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-second-quarter-2021-financial-results-company-update-cpix-20210810monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-second-quarter-2021-financial-results-cpix-20210803monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-2-5m-patient-doses-delivered-no-product-recalls-no-fda--cpix-20210726monthly0.5https://www.biopharmawatch.com/news/CPIX/vibativ-effectively-helps-treat-secondary-bacterial-infections-in-covid-19-patients-cpix-20210621monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-names-john-hamm-new-chief-financial-officer-cpix-20210519monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-first-quarter-2021-financial-results-company-update-cpix-20210511monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-first-quarter-2021-financial-results-cpix-20210504monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-9-revenue-growth-in-2020-cpix-20210309monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-fourth-quarter-and-annual-2020-financial-results-cpix-20210302monthly0.5https://www.biopharmawatch.com/news/CPIX/introducing-reditrex-a-new-methotrexate-delivery-system-cpix-20201117monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-third-quarter-2020-financial-results-company-update-cpix-20201110monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-third-quarter-2020-financial-results-cpix-20201103monthly0.5https://www.biopharmawatch.com/news/CPIX/newly-published-literature-supports-use-of-caldolor-for-postoperative-pain-and-reduction-o-cpix-20200818monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-second-quarter-2020-financial-results-company-update-cpix-20200811monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-second-quarter-2020-financial-results-cpix-20200804monthly0.5https://www.biopharmawatch.com/news/CPIX/caldolor-demonstrates-significant-reduction-of-opioid-use-in-orthopedic-trauma-patients-cpix-20200720monthly0.5https://www.biopharmawatch.com/news/CPIX/new-publication-reveals-real-world-usage-of-vibativ-in-patients-with-bacteremia-or-endocar-cpix-20200526monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-first-quarter-2020-financial-results-company-update-cpix-20200520monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-first-quarter-2020-financial-results-cpix-20200515monthly0.5https://www.biopharmawatch.com/news/CPIX/vibativ-sustained-potency-confirmed-in-two-surveillance-studies-cpix-20200511monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-releases-inaugural-report-on-its-environmental-social-and-gover-cpix-20200428monthly0.5https://www.biopharmawatch.com/news/CPIX/to-help-prepare-for-the-covid-19-patient-surge-cumberland-pharmaceuticals-expands-availabi-cpix-20200407monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-announces-initiative-to-expand-availability-of-caldolor-to-help-cpix-20200331monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-announces-initiative-to-expand-availability-of-vibativ-to-treat-cpix-20200323monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-17-revenue-growth-for-the-full-year-2019-cpix-20200318monthly0.5https://www.biopharmawatch.com/news/CPIX/caldolor-demonstrates-favorable-safety-profile-in-newborns-cpix-20200317monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reschedules-fourth-quarter-and-annual-2019-financial-results-cpix-20200306monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-fourth-quarter-and-annual-2019-financial-results-cpix-20200304monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-announces-the-national-launch-of-a-new-caldolor-ready-to-use-pr-cpix-20200107monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-hold-update-call-to-discuss-recent-major-developments-cpix-20200102monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-receives-fda-approval-for-reditrex-product-line-cpix-20191202monthly0.5https://www.biopharmawatch.com/news/CPIX/new-study-reveals-real-world-usage-of-vibativ-in-a-variety-of-infections-cpix-20191125monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-22-revenue-growth-in-the-third-quarter-cpix-20191112monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-third-quarter-2019-financial-results-cpix-20191105monthly0.5https://www.biopharmawatch.com/news/CPIX/new-study-reveals-superiority-of-vibativ-over-vancomycin-in-select-patients-with-bacterial-cpix-20191015monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-announces-fda-orphan-drug-grant-award-for-new-phase-ii-clinical-cpix-20190924monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-14-revenue-growth-in-the-second-quarter-cpix-20190814monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-second-quarter-2019-financial-results-cpix-20190807monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-signs-exclusive-licensing-agreement-for-distribution-in-china-cpix-20190515monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-38-revenue-growth-in-the-first-quarter-cpix-20190514monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-first-quarter-2019-financial-results-cpix-20190507monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-announces-strategic-review-cpix-20190329monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-fourth-quarter-revenue-growth-of-16-cpix-20190226monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-fourth-quarter-and-annual-2018-financial-results-cpix-20190219monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-third-quarter-2018-financial-results-cpix-20181113monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-third-quarter-2018-financial-results-cpix-20181107monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-acquire-vibativ-cpix-20181106monthly0.5https://www.biopharmawatch.com/news/CPIX/newly-published-data-demonstrates-amifostine-delayed-the-onset-of-acute-esophagitis-for-sm-cpix-20180927monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-announces-senior-music-industry-executive-joins-its-board-of-di-cpix-20180924monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-second-quarter-2018-financial-results-cpix-20180814monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-appoints-new-senior-executive-cpix-20180813monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-second-quarter-2018-financial-results-cpix-20180807monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-first-quarter-2018-financial-results-cpix-20180508monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-first-quarter-2018-financial-results-cpix-20180501monthly0.5https://www.biopharmawatch.com/news/CPIX/newly-published-data-demonstrates-85-eradication-of-ulcer-causing-bacteria-cpix-20180326monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-25-revenue-growth-for-the-full-year-2017-cpix-20180306monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-fourth-quarter-and-annual-2017-financial-results-cpix-20180227monthly0.5https://www.biopharmawatch.com/news/CPIX/newly-published-data-demonstrates-amifostine-reduces-gastro-intestinal-toxicity-for-multip-cpix-20180130monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceutical-reports-27-revenue-growth-in-the-third-quarter-cpix-20171107monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-third-quarter-2017-financial-results-cpix-20171031monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-launches-promotion-of-totect-in-the-u-s-for-emergency-oncology--cpix-20170925monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-second-quarter-2017-financial-results-cpix-20170801monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-begin-u-s-shipments-of-dexrazoxane-for-oncology-patient-support-cpix-20170731monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-revenue-growth-of-25-in-first-quarter-2017-cpix-20170515monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-first-quarter-2017-financial-results-cpix-20170508monthly0.5https://www.biopharmawatch.com/news/CPIX/new-kristalose-growth-driver-established-through-co-promotion-agreement-cpix-20170426monthly0.5https://www.biopharmawatch.com/news/CPIX/caldolor-demonstrates-significant-post-surgical-pain-reduction-and-decrease-in-opioid-use-cpix-20170327monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-fourth-quarter-and-full-year-2016-financial-results-cpix-20170307monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-fourth-quarter-and-annual-2016-financial-results-cpix-20170228monthly0.5https://www.biopharmawatch.com/news/CPIX/caldolor-pediatric-fever-study-published-supporting-its-efficacy-safety-and-pharmacokineti-cpix-20170207monthly0.5https://www.biopharmawatch.com/news/CPIX/u-s-court-of-appeals-affirms-cumberland-pharmaceuticals-cpix-20170130monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-announces-kenneth-j-krogulski-to-join-its-board-of-directors-cpix-20170116monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-and-clinigen-enter-exclusive-u-s-commercialization-agreement-fo-cpix-20170109monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-acquires-u-s-rights-to-nordic-group-cpix-20161116monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-third-quarter-2016-financial-results-cpix-20161025monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-launches-promotion-of-ethyol-in-the-united-states-for-oncology--cpix-20160926monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-announces-new-program-to-develop-portaban-for-portal-hypertensi-cpix-20160914monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-begins-u-s-shipments-of-ethyol-amifostine-for-oncology-patient--cpix-20160823monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-second-quarter-2016-financial-results-cpix-20160802monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-second-quarter-2016-financial-results-cpix-20160726monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-participate-in-avondale-partners-cpix-20160718monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-announces-caroline-young-to-join-its-board-of-directors-cpix-20160610monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-and-clinigen-group-enter-into-exclusive-u-s-commercialization-a-cpix-20160510monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-first-quarter-2016-financial-results-cpix-20160510monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-first-quarter-2016-financial-results-cpix-20160503monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-announces-new-program-to-develop-vasculan-for-systemic-sclerosi-cpix-20160427monthly0.5https://www.biopharmawatch.com/news/CPIX/caldolor-launched-for-the-treatment-of-pain-and-fever-in-children-cpix-20160324monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-fourth-quarter-and-full-year-2015-financial-results-cpix-20160303monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-fourth-quarter-and-annual-2015-financial-results-cpix-20160225monthly0.5https://www.biopharmawatch.com/news/CPIX/vaprisol-dose-comparison-published-supporting-its-efficacy-safety-and-pharmacokinetics-cpix-20160210monthly0.5https://www.biopharmawatch.com/news/CPIX/piramal-critical-care-and-cumberland-pharmaceuticals-announce-launch-of-caldolor-and-vapri-cpix-20160125monthly0.5https://www.biopharmawatch.com/news/CPIX/caldolor-approved-for-use-in-pediatric-patients-cpix-20151123monthly0.5https://www.biopharmawatch.com/news/CPIX/caldolor-launched-in-australia-for-treatment-of-pain-and-fever-cpix-20151123monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-announces-favorable-acetadote-patent-ruling-cpix-20151120monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-and-piramal-enterprises-announce-co-promotion-agreement-cpix-20151106monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-third-quarter-year-to-date-2015-financial-results-cpix-20151103monthly0.5https://www.biopharmawatch.com/news/CPIX/new-caldolor-integrated-safety-analysis-published-supporting-the-safety-of-caldolor-ibupro-cpix-20151027monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-third-quarter-2015-financial-results-cpix-20151027monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-and-clinigen-group-announce-strategic-alliance-cpix-20150917monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-second-quarter-2015-financial-results-cpix-20150728monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-first-quarter-2015-financial-results-cpix-20150507monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-first-quarter-2015-financial-results-cpix-20150430monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-clinical-and-regulatory-milestones-cpix-20150303monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-announces-return-to-growth-and-profitability-in-2014-cpix-20150303monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-fourth-quarter-and-annual-2014-financial-results-cpix-20150224monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-announces-pipeline-expansion-with-boxaban-ifetroban-oral-capsul-cpix-20150211monthly0.5https://www.biopharmawatch.com/news/CPIX/phase-iv-studies-published-supporting-the-safety-of-a-shortened-infusion-time-of-caldolor--cpix-20150202monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-third-quarter-2014-financial-results-cpix-20141104monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-third-quarter-2014-financial-results-on-november-4--cpix-20141021monthly0.5https://www.biopharmawatch.com/news/CPIX/caldolor-safely-treats-fever-in-hospitalized-children-cpix-20141014monthly0.5https://www.biopharmawatch.com/news/CPIX/caldolor-provides-favorable-inflammatory-response-results-in-laparoscopic-cholecystectomy--cpix-20141010monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-second-quarter-2014-financial-results-cpix-20140805monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-second-quarter-2014-financial-results-on-august-5-2-cpix-20140722monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-first-quarter-2014-financial-results-cpix-20140513monthly0.5https://www.biopharmawatch.com/news/CPIX/caldolor-pediatric-pain-study-results-to-be-presented-at-the-pediatric-anesthesiology-2014-cpix-20140307monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-2013-fourth-quarter-and-annual-financial-results-cpix-20140304monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-acquires-vaprisol-from-astellas-pharma-us-inc-cpix-20140303monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-2013-year-end-financial-results-on-march-4-2014-cpix-20140227monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-third-quarter-financial-results-cpix-20131105monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-third-quarter-2013-financial-results-on-november-5--cpix-20131029monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-and-pernix-therapeutics-enter-into-exclusive-agreement-to-promo-cpix-20131028monthly0.5https://www.biopharmawatch.com/news/CPIX/caldolor-studies-to-be-presented-at-the-annual-meeting-of-the-american-society-of-anesthes-cpix-20131010monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-second-quarter-financial-results-cpix-20130806monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-second-quarter-2013-financial-results-on-august-6-2-cpix-20130729monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-fda-approval-for-updated-acetadote-labeling-cpix-20130610monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-present-at-the-ubs-global-healthcare-conference-in-new-york-cpix-20130515monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-first-quarter-financial-results-cpix-20130502monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-first-quarter-2013-financial-results-on-may-2-2013-cpix-20130425monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-2012-annual-financial-results-cpix-20130228monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-licenses-caldolor-ibuprofen-injection-to-sandor-medicaids-pvt-l-cpix-20130221monthly0.5https://www.biopharmawatch.com/news/CPIX/caldolor-reduces-pain-and-fever-in-adult-patients-cpix-20130219monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-2012-year-end-financial-results-on-february-28-2013-cpix-20130214monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-and-pt-soho-industri-pharmasi-enter-into-exclusive-licensing-ag-cpix-20130129monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-receives-second-acetadote-patent-notice-of-allowance-cpix-20121107monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-third-quarter-2012-financial-results-cpix-20121101monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-third-quarter-2012-financial-results-on-november-1--cpix-20121018monthly0.5https://www.biopharmawatch.com/news/CPIX/caldolor-reduces-narcotic-doses-in-pediatric-pain-patients-cpix-20120919monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-present-at-the-ubs-global-life-sciences-conference-in-new-yo-cpix-20120906monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-second-quarter-2012-financial-results-cpix-20120802monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-second-quarter-2012-financial-results-on-august-2-2-cpix-20120712monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-present-at-the-2012-wells-fargo-securities-healthcare-confer-cpix-20120613monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-first-quarter-2012-financial-results-cpix-20120503monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-first-quarter-2012-financial-results-on-may-3-2012-cpix-20120412monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-present-at-needham-life-sciences-conference-in-new-york-on-a-cpix-20120327monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-signs-exclusive-licensing-agreement-for-china-cpix-20120228monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-2011-year-end-financial-results-on-february-29-2012-cpix-20120208monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-receives-acetadote-patent-notice-of-allowance-cpix-20120208monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-third-quarter-2011-financial-results-cpix-20111103monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-ranks-as-one-of-the-fastest-growing-companies-in-north-america--cpix-20111020monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-third-quarter-2011-financial-results-on-november-3--cpix-20111013monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-appoints-rick-s-greene-chief-financial-officer-cpix-20111012monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-present-at-the-ubs-global-life-sciences-conference-in-new-yo-cpix-20110831monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-present-at-the-stifel-nicolaus-2011-healthcare-conference-in-cpix-20110825monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-second-quarter-2011-financial-results-cpix-20110804monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-inks-new-bank-financing-deal-with-bank-of-america-cpix-20110804monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-present-at-the-2011-wells-fargo-securities-healthcare-confer-cpix-20110607monthly0.5https://www.biopharmawatch.com/news/CPIX/caldolor-clinical-study-in-hospitalized-burn-patients-published-in-journal-of-burn-care-re-cpix-20110516monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-present-at-the-2011-ubs-global-specialty-pharmaceuticals-con-cpix-20110511monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-first-quarter-2011-financial-results-cpix-20110504monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-first-quarter-2011-financial-results-on-may-4-2011-cpix-20110422monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-announces-new-product-addition-with-hepatoren-ifetroban-injecti-cpix-20110419monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-appoints-rick-s-greene-as-vice-president-finance-accounting-cpix-20110404monthly0.5https://www.biopharmawatch.com/news/CPIX/new-acetadote-formulation-now-available-in-the-u-s-cpix-20110322monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-fourth-quarter-and-full-year-2010-financial-results-cpix-20110308monthly0.5https://www.biopharmawatch.com/news/CPIX/anesthesiologists-use-caldolor-to-provide-preemptive-pain-control-for-surgical-patients-at-cpix-20110302monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-appoints-tan-cheow-choon-as-director-of-international-business-cpix-20110224monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-2010-financial-results-on-march-8-2011-cpix-20110217monthly0.5https://www.biopharmawatch.com/news/CPIX/caldolor-rapid-infusion-shown-to-be-safe-and-well-tolerated-in-newly-published-clinical-st-cpix-20110215monthly0.5https://www.biopharmawatch.com/news/CPIX/newly-published-data-demonstrates-caldolor-significantly-reduces-pain-and-morphine-use-in--cpix-20110127monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-receives-fda-approval-for-new-formulation-of-acetadote-cpix-20110113monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-announces-joey-jacobs-has-joined-its-board-of-directors-cpix-20110106monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-announces-voluntary-recall-of-acetadote-vials-cpix-20101230monthly0.5https://www.biopharmawatch.com/news/CPIX/fda-issues-complete-response-letter-regarding-acetadote-supplemental-new-drug-application--cpix-20101222monthly0.5https://www.biopharmawatch.com/news/CPIX/newly-published-data-shows-kristalose-preferred-by-77-more-patients-compared-to-liquid-lac-cpix-20101201monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-third-quarter-2010-financial-results-cpix-20101111monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-announce-third-quarter-2010-financial-results-on-november-11-cpix-20101028monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-and-phebra-pty-ltd-announce-the-launch-of-acetadote-in-australi-cpix-20101014monthly0.5https://www.biopharmawatch.com/news/CPIX/newly-published-caldolor-clinical-data-demonstrates-77-reduction-in-fever-in-hospitalized--cpix-20101007monthly0.5https://www.biopharmawatch.com/news/CPIX/caldolor-ibuprofen-injection-gaining-approval-on-formulary-at-u-s-medical-centers-cpix-20100923monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-present-at-the-ubs-global-life-sciences-conference-in-new-yo-cpix-20100913monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-to-present-at-the-stifel-nicolaus-2010-healthcare-conference-in-cpix-20100908monthly0.5https://www.biopharmawatch.com/news/CPIX/pre-and-post-operative-use-of-caldolor-ibuprofen-injection-significantly-reduces-pain-and--cpix-20100830monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-announces-extension-of-fda-review-of-acetadote-supplemental-new-cpix-20100820monthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-second-quarter-2010-financial-results-cpix-20100816monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-participate-in-upcoming-scientific-and-investor-conferences-ino-20260528monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-participate-in-upcoming-scientific-conferences-ino-20260508monthly0.5https://www.biopharmawatch.com/news/INO/inovio-and-akeso-announce-clinical-collaboration-to-advance-novel-combination-therapy-for--ino-20260304monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-inducement-grant-under-inducement-plan-ino-20251219monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-report-third-quarter-2025-financial-results-on-november-10-2025-ino-20251027monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-inducement-grant-under-inducement-plan-ino-20251002monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-participate-in-upcoming-scientific-conferences-ino-20250925monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-begin-rolling-submission-of-bla-for-ino-3107-for-the-treatment-of-rrp-in-adults-ino-20250826monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference-ino-20250825monthly0.5https://www.biopharmawatch.com/news/INO/data-published-in-the-laryngoscope-shows-ino-3107-resulted-in-long-term-surgery-reduction--ino-20250811monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-report-second-quarter-2025-financial-results-on-august-12-2025-ino-20250804monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-upcoming-scientific-conference-ino-20250707monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-pricing-of-25-million-public-offering-ino-20250703monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-upcoming-scientific-and-investor-conferences-ino-20250430monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-report-first-quarter-2025-financial-results-on-may-13-2025-ino-20250429monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-upcoming-scientific-conferences-ino-20250409monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-promising-interim-results-from-ongoing-proof-of-concept-clinical-trial-of-ino-20250313monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-18-2025-ino-20250312monthly0.5https://www.biopharmawatch.com/news/INO/clinical-and-immunological-results-from-phase-1-2-study-of-ino-3107-as-a-treatment-for-rec-ino-20250212monthly0.5https://www.biopharmawatch.com/news/INO/immune-response-data-for-ino-3107-to-be-presented-as-a-poster-at-american-association-for--ino-20250210monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference-ino-20250129monthly0.5https://www.biopharmawatch.com/news/INO/inovio-highlights-anticipated-2025-milestones-and-2024-key-accomplishments-ino-20250109monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-proposed-public-offering-ino-20241212monthly0.5https://www.biopharmawatch.com/news/INO/new-retrospective-data-shows-half-of-rrp-patients-treated-with-ino-3107-achieved-a-complet-ino-20241203monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-inducement-grant-under-inducement-plan-ino-20241129monthly0.5https://www.biopharmawatch.com/news/INO/immunology-data-shows-inovio-ino-20241113monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-upcoming-scientific-conferences-ino-20241106monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-report-third-quarter-2024-financial-results-on-november-14-2024-ino-20241106monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-new-data-at-scientific-conferences-for-lead-candidate-ino-3107-as-a-poten-ino-20241021monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-inducement-grants-under-inducement-plan-ino-20241002monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-upcoming-scientific-conferences-ino-20241001monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-upcoming-scientific-conference-ino-20240917monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-inducement-grant-under-inducement-plan-ino-20240801monthly0.5https://www.biopharmawatch.com/news/INO/inovio-receives-advanced-therapy-medicinal-product-certificate-from-european-medicines-age-ino-20240725monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-report-second-quarter-2024-financial-results-on-august-8-2024-ino-20240725monthly0.5https://www.biopharmawatch.com/news/INO/ino-3107-awarded-the-innovation-passport-designation-under-u-k-government-ino-20240711monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-appointment-of-steven-egge-as-chief-commercial-officer-ino-20240702monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-inducement-grant-under-inducement-plan-ino-20240701monthly0.5https://www.biopharmawatch.com/news/INO/inovio-added-to-russell-2000-index-effective-july-1-2024-ino-20240701monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-participate-in-virtual-fireside-chat-hosted-by-stephens-inc-ino-20240604monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-inducement-grants-under-inducement-plan-ino-20240531monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-inducement-grants-under-inducement-plan-ino-20240501monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-report-first-quarter-2024-financial-results-on-may-13-2024-ino-20240429monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-participate-in-upcoming-investor-conferences-in-may-ino-20240429monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-participate-in-the-citizens-jmp-novel-therapeutics-forum-at-penn-medicine-ino-20240326monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-fourth-quarter-and-full-year-2023-financial-results-and-operational-highlig-ino-20240306monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-report-fourth-quarter-and-year-end-2023-financial-results-on-march-6-2024-ino-20240221monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-the-oppenheimer-34th-annual-healthcare-life-sciences-conference-ino-20240207monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-inducement-grant-under-inducement-plan-ino-20240202monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-effective-date-of-1-for-12-reverse-stock-split-ino-20240123monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-participate-in-virtual-fireside-chat-on-the-potential-treatment-of-recurrent-res-ino-20240122monthly0.5https://www.biopharmawatch.com/news/INO/inovio-plans-to-submit-a-bla-for-ino-3107-as-a-potential-treatment-for-rrp-in-second-half--ino-20240103monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-inducement-grants-under-inducement-plan-ino-20231101monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-report-third-quarter-2023-financial-results-on-november-9-2023-ino-20231026monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-u-s-fda-breakthrough-therapy-designation-granted-for-ino-3107-for-the-tre-ino-20230907monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-ino-20230829monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-inducement-grants-under-inducement-plan-ino-20230804monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-report-second-quarter-2023-financial-results-on-august-9-2023-ino-20230726monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-inducement-grants-under-inducement-plan-ino-20230601monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-the-2023-jefferies-healthcare-conference-ino-20230525monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-orphan-drug-designation-for-ino-3107-for-the-treatment-of-recurrent-respi-ino-20230523monthly0.5https://www.biopharmawatch.com/news/INO/new-data-from-phase-1-2-trial-of-ino-3107-for-the-treatment-of-recurrent-respiratory-papil-ino-20230508monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-the-2023-rbc-capital-markets-global-healthcare-conference-ino-20230505monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-report-first-quarter-2023-financial-results-on-may-10-2023-ino-20230428monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-acceptance-of-abstract-for-oral-presentation-on-ino-3107-for-the-treatmen-ino-20230427monthly0.5https://www.biopharmawatch.com/news/INO/european-committee-for-orphan-medicinal-products-provides-positive-opinion-on-inovio-ino-20230426monthly0.5https://www.biopharmawatch.com/news/INO/data-from-phase-1b-trial-with-ino-4201-as-an-ebola-booster-for-rvsv-zebov-ervebo-presented-ino-20230417monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-acceptance-of-abstract-for-oral-presentation-on-ino-4201-as-an-ebola-boos-ino-20230412monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-inducement-grant-under-inducement-plan-ino-20230403monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-the-oppenheimer-33rd-annual-healthcare-conference-ino-20230303monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-positive-preliminary-results-from-second-cohort-of-phase-1-2-trial-with-i-ino-20230216monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-report-fourth-quarter-and-year-end-2022-financial-results-on-march-1-2023-ino-20230215monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-inducement-grants-under-inducement-plan-ino-20230203monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-positive-phase-1b-results-for-ino-4201-as-an-ebola-booster-for-rvsv-zebov-e-ino-20230202monthly0.5https://www.biopharmawatch.com/news/INO/inovio-provides-an-update-on-lassa-fever-and-mers-programs-ino-20221117monthly0.5https://www.biopharmawatch.com/news/INO/inovio-provides-update-on-covid-19-heterologous-booster-vaccine-candidate-ino-4800-ino-20221027monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-report-third-quarter-2022-financial-results-on-november-8-2022-ino-20221025monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-positive-interim-phase-1-2-results-for-ino-3107-for-the-treatment-of-recurr-ino-20221013monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-inducement-grants-under-inducement-plan-ino-20220901monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference-ino-20220830monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-report-second-quarter-2022-financial-results-on-august-9-2022-ino-20220726monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ino-20220701monthly0.5https://www.biopharmawatch.com/news/INO/inovio-appoints-dr-michael-sumner-mb-bs-mba-as-chief-medical-officer-ino-20220627monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-survival-results-for-ino-5401-ino-9012-in-combination-with-libtayo-cemipl-ino-20220527monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-jefferies-2022-healthcare-conference-ino-20220523monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-the-appointment-of-jacqueline-shea-ph-d-as-chief-executive-officer-ino-20220510monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-report-first-quarter-2022-financial-results-on-may-10-2022-ino-20220426monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-oppenheimer-ino-20220308monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-fourth-quarter-2021-and-year-end-financial-results-ino-20220301monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-report-fourth-quarter-and-year-end-2021-financial-results-on-march-1-2022-ino-20220215monthly0.5https://www.biopharmawatch.com/news/INO/inovio-highlights-key-updates-on-phase-3-program-for-vgx-3100-its-dna-based-immunotherapy--ino-20211214monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-strategy-to-address-omicron-b-1-1-529-and-future-sars-cov-2-variants-ino-20211130monthly0.5https://www.biopharmawatch.com/news/INO/inovio-collaborates-with-guardrx-and-geneva-university-hospitals-for-heterologous-booster--ino-20211116monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-give-eight-presentations-at-the-34th-international-papillomavirus-conference-ino-20211115monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-third-quarter-2021-financial-results-ino-20211109monthly0.5https://www.biopharmawatch.com/news/INO/inovio-receives-u-s-fda-authorization-to-proceed-with-innovate-phase-3-segment-for-its-cov-ino-20211109monthly0.5https://www.biopharmawatch.com/news/INO/inovio-expands-executive-leadership-to-prepare-for-commercial-operations-ino-20211105monthly0.5https://www.biopharmawatch.com/news/INO/inovio-further-expands-innovate-phase-3-trial-for-covid-19-dna-vaccine-candidate-ino-4800--ino-20211103monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-report-third-quarter-2021-financial-results-on-november-9-2021-ino-20211027monthly0.5https://www.biopharmawatch.com/news/INO/inovio-completes-enrollment-of-phase-1b-clinical-trial-for-its-dna-vaccine-candidate-again-ino-20211026monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-collaboration-with-colombia-memorandum-of-understanding-focuses-on-protec-ino-20211021monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-online-preprint-publication-of-homologous-boosting-data-for-its-covid-19--ino-20211012monthly0.5https://www.biopharmawatch.com/news/INO/inovio-expands-innovate-phase-3-for-ino-4800-its-dna-vaccine-candidate-for-covid-19-to-inc-ino-20211011monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-three-posters-at-idweek-2021-ino-20210929monthly0.5https://www.biopharmawatch.com/news/INO/inovio-receives-regulatory-authorization-to-conduct-phase-3-efficacy-trial-of-its-covid-19-ino-20210922monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-upcoming-investor-conferences-in-september-ino-20210901monthly0.5https://www.biopharmawatch.com/news/INO/inovio-receives-authorization-to-conduct-phase-3-efficacy-trial-of-its-covid-19-dna-vaccin-ino-20210826monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-second-quarter-2021-financial-results-ino-20210809monthly0.5https://www.biopharmawatch.com/news/INO/inovio-and-advaccine-receive-regulatory-allowance-for-two-heterologous-prime-boost-clinica-ino-20210809monthly0.5https://www.biopharmawatch.com/news/INO/inovio-doses-first-participant-in-phase-2-trial-for-its-dna-vaccine-against-middle-east-re-ino-20210804monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-report-second-quarter-2021-financial-results-on-august-9-2021-ino-20210726monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-the-jefferies-2021-virtual-healthcare-conference-ino-20210525monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-pan-covid-19-vaccine-candidate-ino-4802-induces-broad-immunity-against-major-vira-ino-20210512monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-first-quarter-2021-financial-results-ino-20210510monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-positive-data-from-phase-2-segment-of-clinical-trial-evaluating-ino-4800--ino-20210510monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-upcoming-investor-conferences-in-may-ino-20210504monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-report-first-quarter-2021-financial-results-on-may-10-2021-ino-20210427monthly0.5https://www.biopharmawatch.com/news/INO/inovio-planning-for-ex-us-global-phase-3-trial-for-ino-4800-ino-20210423monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-covid-19-vaccine-candidate-ino-4800-provides-broad-cross-reactive-immune-response-ino-20210415monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-the-appointment-of-michael-cordera-as-executive-vice-president-general-co-ino-20210315monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-upcoming-investor-conferences-in-march-ino-20210304monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-positive-results-from-reveal-1-a-phase-3-pivotal-trial-evaluating-vgx-310-ino-20210301monthly0.5https://www.biopharmawatch.com/news/INO/inovio-and-qiagen-expand-collaboration-to-develop-next-generation-sequencing-ngs-companion-ino-20210224monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-first-subject-dosed-in-phase-1b-clinical-trial-for-its-dna-vaccine-agains-ino-20210223monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-report-fourth-quarter-and-full-year-2020-financial-results-on-march-1-2021-ino-20210216monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwrit-ino-20210125monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-pricing-of-public-offering-of-common-stock-ino-20210120monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-vgx-3100-demonstrates-positive-phase-2-efficacy-in-treatment-of-precancerous-vulv-ino-20210106monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-publication-of-phase-1-data-from-its-covid-19-dna-vaccine-candidate-ino-4-ino-20201224monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-develop-dna-encoded-monoclonal-antibody-dmab-candidates-to-treat-covid-19-with-f-ino-20201215monthly0.5https://www.biopharmawatch.com/news/INO/inovio-and-advaccine-announce-first-dosing-of-subject-in-phase-2-clinical-trial-for-covid--ino-20201210monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-vgx-3100-demonstrates-positive-phase-2-efficacy-in-treatment-of-precancerous-anal-ino-20201209monthly0.5https://www.biopharmawatch.com/news/INO/inovio-doses-first-subject-in-phase-2-segment-of-its-innovate-phase-2-3-clinical-trial-for-ino-20201207monthly0.5https://www.biopharmawatch.com/news/INO/inovio-expands-global-manufacturing-consortium-for-its-covid-19-vaccine-candidate-ino-4800-ino-20201203monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-dosing-of-first-subject-in-phase-1-2-clinical-trial-for-ino-3107-its-dna--ino-20201123monthly0.5https://www.biopharmawatch.com/news/INO/inovio-presents-clinical-results-of-its-dna-medicines-ino-5401-ino-9012-in-novel-combinati-ino-20201120monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-third-quarter-2020-financial-results-ino-20201109monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-report-third-quarter-2020-financial-results-on-november-9-2020-ino-20201026monthly0.5https://www.biopharmawatch.com/news/INO/inovio-adds-thermo-fisher-scientific-to-global-manufacturing-consortium-ino-20200908monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-upcoming-investor-conferences-in-september-ino-20200901monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-second-quarter-2020-financial-results-provides-dna-medicines-clinical-progr-ino-20200810monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-covid-19-dna-vaccine-ino-4800-provides-protection-with-memory-immune-responses-in-ino-20200730monthly0.5https://www.biopharmawatch.com/news/INO/inovio-receives-orphan-drug-designation-from-u-s-fda-for-dna-medicine-ino-3107-to-treat-ra-ino-20200729monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-report-second-quarter-2020-financial-results-on-august-10-2020-ino-20200727monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-positive-interim-phase-1-data-for-ino-4800-vaccine-for-covid-19-ino-20200630monthly0.5https://www.biopharmawatch.com/news/INO/inovio-expands-senior-management-team-ino-20200625monthly0.5https://www.biopharmawatch.com/news/INO/inovio-and-ivi-partner-with-seoul-national-university-hospital-to-start-phase-1-2-clinical-ino-20200604monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-host-webinar-dna-medicines-from-covid-19-to-cancer-ino-20200526monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-covid-19-dna-vaccine-ino-4800-demonstrates-robust-neutralizing-antibody-and-t-cel-ino-20200520monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-ino-5401-in-combination-with-pd-1-inhibitor-libtayo-cemiplimab-demonstrates-85-of-ino-20200514monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-rbc-capital-markets-virtual-global-healthcare-conference-ino-20200512monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-first-quarter-2020-financial-results-provides-business-update-ino-20200511monthly0.5https://www.biopharmawatch.com/news/INO/inovio-expands-manufacturing-of-covid-19-dna-vaccine-ino-4800-with-new-funding-from-cepi-ino-20200430monthly0.5https://www.biopharmawatch.com/news/INO/inovio-and-geneone-life-science-report-positive-phase-1-2a-clinical-data-with-dna-vaccine--ino-20200428monthly0.5https://www.biopharmawatch.com/news/INO/inovio-completes-enrollment-in-the-phase-1-u-s-trial-of-ino-4800-for-covid-19-dna-vaccine--ino-20200428monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-report-first-quarter-2020-financial-results-on-may-11-2020-ino-20200427monthly0.5https://www.biopharmawatch.com/news/INO/ivi-inovio-and-knih-to-partner-with-cepi-in-phase-1-2-clinical-trial-of-inovio-ino-20200416monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-host-its-annual-meeting-of-stockholders-in-virtual-format-and-at-a-new-time-ino-20200415monthly0.5https://www.biopharmawatch.com/news/INO/inovio-initiates-phase-1-clinical-trial-of-its-covid-19-vaccine-and-plans-first-dose-today-ino-20200406monthly0.5https://www.biopharmawatch.com/news/INO/inovio-interim-results-of-an-open-label-phase-2-trial-of-vgx-3100-show-efficacy-against-hp-ino-20200330monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-positive-interim-phase-2-vgx-3100-results-in-patients-with-hpv-associated-a-ino-20200326monthly0.5https://www.biopharmawatch.com/news/INO/ology-bioservices-inovio-partner-to-manufacture-covid-19-dna-vaccine-with-11-9-million-dep-ino-20200324monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2019-fourth-quarter-and-year-end-financial-results-ino-20200312monthly0.5https://www.biopharmawatch.com/news/INO/inovio-receives-new-5-million-grant-to-accelerate-scale-up-of-smart-delivery-device-for-it-ino-20200312monthly0.5https://www.biopharmawatch.com/news/INO/inovio-accelerates-timeline-for-covid-19-dna-vaccine-ino-4800-ino-20200303monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-report-fourth-quarter-and-full-year-2019-financial-results-on-ma-ino-20200302monthly0.5https://www.biopharmawatch.com/news/INO/inovio-receives-authorization-from-the-u-s-fda-to-begin-phase-1-2-clinical-trial-for-ino-3-ino-20200210monthly0.5https://www.biopharmawatch.com/news/INO/inovio-publishes-patient-benefit-results-from-a-pilot-clinical-study-in-recurrent-respirat-ino-20200203monthly0.5https://www.biopharmawatch.com/news/INO/inovio-collaborating-with-beijing-advaccine-to-advance-ino-4800-vaccine-against-new-corona-ino-20200130monthly0.5https://www.biopharmawatch.com/news/INO/inovio-selected-by-cepi-to-develop-vaccine-against-new-coronavirus-ino-20200123monthly0.5https://www.biopharmawatch.com/news/INO/inovio-welcomes-biotech-leader-to-its-board-of-directors-ino-20200115monthly0.5https://www.biopharmawatch.com/news/INO/inovio-provides-update-on-clinical-program-plans-for-2020-ino-20200106monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-the-2019-piper-jaffray-31st-annual-healthcare-confere-ino-20191125monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-the-stifel-2019-healthcare-conference-ino-20191115monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2019-third-quarter-financial-results-ino-20191112monthly0.5https://www.biopharmawatch.com/news/INO/inovio-demonstrates-80-6-month-progression-free-survival-in-phase-2-glioblastoma-multiform-ino-20191105monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-report-third-quarter-2019-financial-results-on-november-12-2019-ino-20191029monthly0.5https://www.biopharmawatch.com/news/INO/inovio-receives-nih-funding-to-target-its-dmab-technology-against-antimicrobial-resistant--ino-20190917monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-upcoming-investor-conferences-ino-20190903monthly0.5https://www.biopharmawatch.com/news/INO/inovio-completes-enrollment-of-its-vgx-3100-open-label-phase-2-trial-for-treatment-of-hpv--ino-20190819monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2019-second-quarter-financial-results-ino-20190808monthly0.5https://www.biopharmawatch.com/news/INO/inovio-closes-15-million-private-placement-of-convertible-bonds-to-institutional-investors-ino-20190806monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-report-second-quarter-2019-financial-results-on-august-8-2019-ino-20190730monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-positive-first-in-human-mers-vaccine-results-published-in-the-lancet-infectious-d-ino-20190725monthly0.5https://www.biopharmawatch.com/news/INO/inovio-sharpens-focus-on-hpv-related-diseases-and-fast-to-market-product-candidates-ino-20190716monthly0.5https://www.biopharmawatch.com/news/INO/inovio-completes-enrollment-of-vgx-3100-phase-2-trial-for-the-treatment-of-hpv-related-vul-ino-20190708monthly0.5https://www.biopharmawatch.com/news/INO/inovio-completes-enrollment-of-vgx-3100-phase-3-trial-reveal-1-for-the-treatment-of-hpv-re-ino-20190626monthly0.5https://www.biopharmawatch.com/news/INO/inovio-receives-8-14-million-award-to-support-further-development-of-its-commercial-skin-d-ino-20190610monthly0.5https://www.biopharmawatch.com/news/INO/inovio-first-to-advance-lassa-fever-candidate-vaccine-into-a-clinical-trial-ino-20190521monthly0.5https://www.biopharmawatch.com/news/INO/inovio-and-qiagen-establish-collaboration-to-develop-diagnostic-test-for-vgx-3100-inovio-ino-20190516monthly0.5https://www.biopharmawatch.com/news/INO/inovio-and-plumbline-life-sciences-establish-animal-health-collaboration-to-develop-a-nove-ino-20190515monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2019-first-quarter-financial-results-ino-20190509monthly0.5https://www.biopharmawatch.com/news/INO/inovio-receives-european-medicines-agency-certification-for-quality-and-non-clinical-data--ino-20190506monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-report-first-quarter-2019-financial-results-on-may-9-2019-ino-20190501monthly0.5https://www.biopharmawatch.com/news/INO/inovio-publishes-cancer-killing-data-of-its-transformative-dna-encoded-bi-specific-t-cell--ino-20190418monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-phase-3-hpv-immunotherapy-selected-as-best-therapeutic-vaccine-at-world-vaccine-c-ino-20190417monthly0.5https://www.biopharmawatch.com/news/INO/inovio-achieves-third-cancer-indication-milestone-for-medi0457-phase-2-development-ino-20190408monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-novel-hpv-therapy-ino-3106-demonstrates-clinical-efficacy-against-rare-respirator-ino-20190403monthly0.5https://www.biopharmawatch.com/news/INO/inovio-presents-cancer-killing-data-of-its-transformative-dna-encoded-bi-specific-t-cell-e-ino-20190402monthly0.5https://www.biopharmawatch.com/news/INO/inovio-completes-enrollment-ahead-of-schedule-in-immuno-oncology-study-for-glioblastoma-gb-ino-20190401monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-h-c-wainwright-global-life-sciences-conference-in-lon-ino-20190327monthly0.5https://www.biopharmawatch.com/news/INO/inovio-appoints-global-commercial-leader-to-its-board-of-directors-ino-20190325monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-ebola-vaccine-delivered-intradermally-demonstrates-100-immunogenicity-in-a-clinic-ino-20190321monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2018-fourth-quarter-and-year-end-financial-results-ino-20190312monthly0.5https://www.biopharmawatch.com/news/INO/inovio-appoints-chief-operating-officer-announces-strategic-management-changes-ino-20190312monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2018-financial-results-and-ino-20190305monthly0.5https://www.biopharmawatch.com/news/INO/inovio-initiates-reveal-2-global-phase-3-clinical-study-for-the-treatment-of-hpv-related-c-ino-20190304monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-completes-sale-of-additional-convertible-senior-notes-ino-20190301monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-first-subject-dosed-with-its-dna-encoded-monoclonal-antibody-dmab-in-firs-ino-20190220monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-2nd-patient-achieving-full-remission-from-hpv-related-head-neck-cancer-afte-ino-20190124monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-dmab-pd-1-checkpoint-inhibitors-demonstrate-higher-and-more-prolonged-expression--ino-20190115monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-dna-encoded-monoclonal-antibody-dmab-platform-leaps-forward-with-first-in-human-t-ino-20190107monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-appointments-to-its-board-of-directors-ino-20190103monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-appoints-dr-mark-gelder-to-lead-clinical-development-of-cervical-dy-ino-20150129monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-ino-20150107monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-hiv-immunotherapy-shows-characteristics-considered-vital-to-treatin-ino-20150106monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-initiates-dna-immunotherapy-trial-for-breast-lung-and-pancreatic-ca-ino-20141218monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-appoints-zane-yang-m-d-vice-president-clinical-development-oncology-ino-20141217monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-ring-opening-bell-nov-25th-on-the-nasdaq-stock-market-ino-20141124monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-melanoma-dna-immunotherapy-inhibits-tumor-growth-and-increases-surv-ino-20141120monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-independently-develop-prostate-cancer-immunotherapy-will-maintai-ino-20141117monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-upcoming-investor-conferences-ino-20141111monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2014-third-quarter-financial-results-ino-20141110monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-report-third-quarter-2014-financial-results-on-november-10-2014-ino-20141104monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-medimmune-and-the-university-of-pennsylvania-partner-to-combat-infl-ino-20141021monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-appoints-vice-president-of-commercial-development-ino-20140930monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-ebola-vaccine-moving-into-human-trial-with-geneone-life-science-ino-20140924monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-expands-hpv-immunotherapy-development-to-aerodigestive-cancers-ino-20140922monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-upcoming-investor-conferences-ino-20140918monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-ino-begins-trading-on-nasdaq-global-select-market-exchange-ino-20140915monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-list-on-nasdaq-ino-20140904monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-upcoming-investor-conferences-ino-20140903monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2014-second-quarter-financial-results-ino-20140811monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-host-second-quarter-2014-financial-results-call-on-august-11-201-ino-20140801monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-hpv-immunotherapy-achieves-primary-efficacy-endpoint-in-randomized--ino-20140723monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-added-to-russell-global-russell-2000-and-russell-microcap-indexes-ino-20140701monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-initiates-cervical-cancer-clinical-trial-ino-20140623monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-broadens-its-intellectual-property-portfolio-from-the-university-of-ino-20140617monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-upcoming-healthcare-conferences-ino-20140616monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-clarifies-facts-of-its-vgx-3100-phase-ii-trial-and-immunotherapy-te-ino-20140611monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-initiates-immune-therapy-trial-for-head-neck-cancer-caused-by-hpv-ino-20140610monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-announces-reverse-stock-split-date-ino-20140530monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-subsidiary-sells-animal-health-assets-ino-20140527monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-breakthrough-dna-based-monoclonal-antibody-therapy-completely-prote-ino-20140527monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-announces-1-for-4-reverse-split-ino-20140523monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-jefferies-2014-global-healthcare-conference-ino-20140521monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-acquires-early-stage-dna-therapies-to-treat-alzheimer-ino-20140513monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2014-first-quarter-financial-results-ino-20140512monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-continues-building-its-senior-team-with-the-appointment-of-vp-of-qu-ino-20140401monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-recognized-with-best-therapeutic-vaccine-award-at-world-vaccine-con-ino-20140326monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2013-fourth-quarter-and-year-end-financial-results-ino-20140317monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-report-fourth-quarter-and-year-end-2013-financial-results-on-mar-ino-20140312monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-announces-public-offering-of-common-stock-ino-20140226monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-cowen-and-company-34th-annual-health-care-conference-ino-20140219monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-bolsters-research-and-clinical-development-leadership-as-it-advance-ino-20140218monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-invited-to-ring-the-opening-bell-at-the-new-york-stock-exchange-on--ino-20140211monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-bio-ceo-investor-conference-ino-20140130monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-unveils-potent-new-immune-activator-ino-20140123monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-biotech-showcase-2014-investor-conference-ino-20140106monthly0.5https://www.biopharmawatch.com/news/INO/ceo-dr-joseph-kim-to-discuss-inovio-ino-20131211monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceutical-ino-20131120monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-ceo-appointed-to-international-vaccine-institute-board-of-trustees-ino-20131119monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-upcoming-investor-conferences-ino-20131118monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-ceo-receives-2013-drug-discovery-achievement-award-ino-20131114monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2013-third-quarter-financial-results-ino-20131112monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-report-third-quarter-2013-financial-results-on-november-12-2013-ino-20131104monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-therapeutic-vaccine-for-hepatitis-c-enters-phase-i-clinical-trial-ino-20131021monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-participate-in-immunotherapy-panel-and-present-at-the-12th-annua-ino-20131001monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-targets-transformation-of-monoclonal-antibody-therapies-ino-20130924monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-investor-conferences-and-town-hall-los-angeles-ino-20130918monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-hold-investor-conference-call-to-discuss-partnership-with-roche-ino-20130910monthly0.5https://www.biopharmawatch.com/news/INO/roche-and-inovio-pharmaceuticals-partner-on-inovio-ino-20130910monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-upcoming-investor-conferences-ino-20130903monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-ino-20130815monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2013-second-quarter-financial-results-ino-20130809monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-responds-to-market-activity-ino-20130806monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-ino-20130724monthly0.5https://www.biopharmawatch.com/news/INO/synthetically-optimized-hif-1-alpha-dna-delivered-with-inovio-ino-20130718monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-ino-20130708monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-dna-vaccine-against-ebola-and-marburg-filoviruses-provides-complete-ino-20130514monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2013-first-quarter-financial-results-ino-20130510monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-universal-h1n1-influenza-vaccine-achieves-protective-immune-respons-ino-20130418monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2012-fourth-quarter-and-year-end-financial-results-ino-20130318monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-closes-15-1-million-offering-of-common-stock-and-warrants-ino-20130312monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-prices-15-1-million-offering-of-common-stock-and-warrants-ino-20130307monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-inc-investor-presentation-now-available-for-on-demand-viewing-at-re-ino-20130211monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-inc-to-webcast-live-at-retailinvestorconferences-com-on-february-7t-ino-20130205monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-initiate-clinical-trial-for-its-hepatitis-c-therapeutic-vaccine--ino-20130109monthly0.5https://www.biopharmawatch.com/news/INO/path-malaria-vaccine-initiative-and-inovio-pharmaceuticals-partner-to-accelerate-developme-ino-20130107monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-biotech-showcase-2013-investor-conference-ino-20121220monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-synthetic-flu-vaccine-doubles-rate-of-elderly-subjects-displaying-protective-immu-ino-20121210monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-announces-positive-interim-results-in-phase-ii-leukemia-trial-ino-20121206monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-cytomegalovirus-cmv-synthetic-vaccine-constructs-generate-strong-an-ino-20121126monthly0.5https://www.biopharmawatch.com/news/INO/inovio-expands-synthetic-vaccine-intellectual-property-license-with-university-of-pennsylv-ino-20121114monthly0.5https://www.biopharmawatch.com/news/INO/inovio-therapeutic-hepatitis-b-vaccine-killer-t-cells-demonstrate-potential-to-clear-hbv-i-ino-20121112monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2012-third-quarter-financial-results-ino-20121107monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-animal-health-subsidiary-ino-20121015monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-ino-20121010monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-named-best-mid-stage-product-development-company-by-the-philadelphi-ino-20121005monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-ino-20121004monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-noble-financial-life-sciences-conference-ino-20120918monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-takes-major-stride-toward-universal-influenza-vaccine-ino-20120906monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-liolios-stifel-and-rodman-renshaw-investor-conference-ino-20120827monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2012-second-quarter-financial-results-ino-20120809monthly0.5https://www.biopharmawatch.com/news/INO/inovio-initiates-h1n1-universal-influenza-vaccine-clinical-trial-targeting-over-65-populat-ino-20120710monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-jmp-investor-conference-ino-20120709monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-appoints-international-management-expert-dr-angel-cabrera-to-its-bo-ino-20120618monthly0.5https://www.biopharmawatch.com/news/INO/inovio-implements-new-atm-agreement-ino-20120601monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-ino-20120516monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-spi-2012-ino-20120515monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2012-first-quarter-financial-results-ino-20120509monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-granted-u-s-patent-protection-for-synthetic-vaccine-for-cervical-dy-ino-20120501monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-receives-defense-department-funding-for-bioterrorism-related-synthe-ino-20120402monthly0.5https://www.biopharmawatch.com/news/INO/inovio-appoints-retired-merck-vaccines-president-dr-adel-mahmoud-to-its-board-of-directors-ino-20120327monthly0.5https://www.biopharmawatch.com/news/INO/inovio-receives-u-s-patent-for-syncon-h1n1-influenza-universal-vaccine-ino-20120326monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-ino-20120313monthly0.5https://www.biopharmawatch.com/news/INO/inovio-appoints-vaccine-industry-leader-to-its-scientific-advisory-board-ino-20120307monthly0.5https://www.biopharmawatch.com/news/INO/inovio-therapeutic-vaccine-for-head-neck-and-other-hpv-related-cancers-induces-robust-t-ce-ino-20120305monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-cowen-and-roth-investor-conferences-ino-20120228monthly0.5https://www.biopharmawatch.com/news/INO/inovio-researchers-successfully-demonstrate-rna-drug-delivery-via-electroporation-ino-20120222monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-scientific-advisory-board-chairman-elected-as-a-fellow-by-the-american-associatio-ino-20120221monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-bio-ceo-investor-conference-ino-20120206monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-moves-closer-to-universal-influenza-vaccine-by-demonstrating-protec-ino-20120131monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-noble-financial-8th-annual-equity-conference-ino-20120111monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-biotech-showcase-investor-conference-ino-20120105monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-promotes-niranjan-sardesai-to-chief-operating-officer-ino-20120104monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-oppenheimer-investor-conference-ino-20111212monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-closes-4-0-million-underwritten-financing-ino-20111207monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-ino-20111117monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2011-third-quarter-financial-results-ino-20111107monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-cervical-dysplasia-and-cancer-treatment-highlighted-as-one-of-10-pr-ino-20111031monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-and-vgx-international-to-advance-therapeutic-hepatitis-c-and-hepati-ino-20111010monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-ino-20111006monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-ino-20111005monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-scientific-conferences-ino-20110930monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-enters-collaboration-with-u-s-dept-of-homeland-security-to-assess-f-ino-20110927monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-completes-pennvax-b-hiv-vaccine-phase-i-study-demonstrates-best-in--ino-20110914monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-ino-20110913monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-scientific-conferences-ino-20110907monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-adds-two-medical-innovators-to-its-scientific-advisory-board-ino-20110906monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-investor-conferences-ino-20110831monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2011-second-quarter-financial-results-ino-20110808monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-demonstrates-t-cell-immune-response-durability-with-fourth-dose-of--ino-20110715monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-demonstrates-positive-immune-responses-in-phase-i-clinical-trial-of-ino-20110714monthly0.5https://www.biopharmawatch.com/news/INO/inovio-expands-dna-vaccine-intellectual-property-license-with-the-university-of-pennsylvan-ino-20110707monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-synthetic-dna-vaccine-protects-against-hiv-in-non-human-primates-ino-20110705monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-announces-transition-of-avtar-dhillon-to-non-executive-chairman-of--ino-20110701monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-ino-20110630monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-ino-20110629monthly0.5https://www.biopharmawatch.com/news/INO/vgx-animal-health-dna-vaccine-for-dogs-could-reduce-tumor-growth-and-increase-survival-ino-20110617monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-subsidiary-vgx-animal-health-to-present-at-vethealth-global-2011-ju-ino-20110609monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-american-society-of-gene-cell-therapy-annual-meeting--ino-20110517monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-ino-20110512monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2011-first-quarter-financial-results-ino-20110511monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-long-term-immune-responses-from-therapeutic-cervical-dyspla-ino-20110509monthly0.5https://www.biopharmawatch.com/news/INO/article-in-current-opinion-in-immunology-journal-declares-coming-decade-of-dna-vaccines-ino-20110505monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-scientific-conferences-ino-20110504monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-investor-conferences-ino-20110429monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-transgene-and-chrontech-pharma-to-collaborate-on-heterologous-prime-ino-20110418monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-scientific-conferences-ino-20110329monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-receives-u-s-dod-small-business-innovation-research-grant-for-multi-ino-20110321monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2010-fourth-quarter-and-year-end-financial-results-ino-20110317monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-ino-20110314monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-enters-phase-ii-clinical-trial-with-syncon-dna-vaccine-for-cervical-ino-20110307monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-roth-23rd-annual-growth-stock-conference-ino-20110303monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-cowen-co-health-care-conference-ino-20110224monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-partnering-and-scientific-conferences-ino-20110222monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-13th-annual-bio-ceo-investor-conference-ino-20110208monthly0.5https://www.biopharmawatch.com/news/INO/university-of-southampton-and-inovio-pharmaceuticals-initiate-phase-2-clinical-study-to-ev-ino-20110131monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-closes-24-3-million-registered-offering-ino-20110127monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-announces-new-pilot-phase-data-from-phase-2-combination-trial-of-motixafortide-i-blrx-20250530monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-announces-uspto-allowance-of-new-composition-of-matter-patent-on-motixafortide-blrx-20241016monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-accesses-second-tranche-of-20-million-under-previously-announced-40-million-non--blrx-20240410monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-reports-first-quarter-2023-financial-results-and-recent-corporate-and-portfolio--blrx-20230524monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-to-report-2022-annual-financial-results-on-march-22-2023-blrx-20230315monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-announces-receipt-of-nasdaq-minimum-bid-price-notification-blrx-20221104monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-announces-closing-of-34-5-million-bought-deal-offering-and-full-exercise-of-the--blrx-20210122monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-receives-orphan-drug-designation-for-motixafortide-bl-8040-for-the-treatment-of--blrx-20200114monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-receives-orphan-drug-designation-from-the-fda-for-its-lead-therapeutic-candidate-blrx-20190204monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-announces-initiation-of-triple-combination-arm-of-phase-2a-combat-keynote-202-st-blrx-20181211monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-to-report-third-quarter-2018-results-on-november-8-2018-blrx-20181101monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-reports-first-quarter-2018-financial-results-blrx-20180522monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-announces-partial-monotherapy-results-from-phase-2a-combat-study-in-pancreatic-c-blrx-20180117monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-ltd-hosts-investor-breakfast-meeting-in-ny-blrx-20171205monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-reports-third-quarter-2017-financial-results-blrx-20171121monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-to-present-at-the-19th-annual-rodman-renshaw-global-investment-conference-in-new-blrx-20170907monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-reports-second-quarter-2017-financial-results-blrx-20170808monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-to-report-second-quarter-2017-results-on-august-8-2017-blrx-20170802monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-reports-second-quarter-2016-financial-results-blrx-20160811monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-s-bl-8040-to-be-presented-at-upcoming-scientific-conferences-biolinerx-ltd-nasda-blrx-20160519monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-reports-first-quarter-2016-financial-results-blrx-20160517monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-announces-initiation-of-phase-2-trial-for-bl-8040-as-novel-stem-cell-mobilizatio-blrx-20160323monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-to-report-annual-2015-results-on-march-10-2016-blrx-20160303monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-to-present-at-2016-bio-ceo-investor-conference-in-new-york-on-february-8-blrx-20160201monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-receives-confirmation-of-medical-device-classification-in-europe-for-celiac-trea-blrx-20160125monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-announces-collaboration-with-msd-to-investigate-the-combination-of-keytruda-pemb-blrx-20160112monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-to-present-at-biotech-showcase-2016-conference-in-san-francisco-blrx-20160104monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-inc-announces-that-int230-6-achieved-100-complete-response-rate-in--ints-20250630monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-inc-announces-pricing-of-public-offering-ints-20250611monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-inc-announces-patients-receiving-int230-6-prior-to-the-start-of-sta-ints-20250611monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-inc-ints-20250529monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-inc-to-collaborate-with-author-model-executive-producer-speaker-and-ints-20250528monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-inc-and-the-swiss-group-for-clinical-cancer-research-sakk-receive-e-ints-20250506monthly0.5https://www.biopharmawatch.com/news/INTS/drug-monitoring-committee-authorizes-continuation-of-intensity-therapeutics-ints-20250128monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-provides-business-update-highlighting-key-achievements-with-lead-dr-ints-20250110monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-inc-and-the-swiss-group-for-clinical-cancer-research-sakk-present-p-ints-20241212monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-presents-int230-6-phase-1-2-data-in-sarcoma-and-an-overview-of-its--ints-20241118monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-selected-for-oral-podium-presentation-in-a-late-breaking-session-at-ints-20241108monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-inc-and-the-swiss-group-for-clinical-cancer-research-sakk-announce--ints-20241031monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conf-ints-20240904monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-inc-announces-first-patient-dosed-in-its-global-randomized-phase-3--ints-20240709monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-inc-and-the-swiss-group-for-clinical-cancer-research-sakk-sign-a-co-ints-20240510monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-to-participate-in-the-ld-micro-invitational-xiv-conference-april-8--ints-20240402monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-to-participate-in-the-36th-annual-roth-conference-march-17-to-19-20-ints-20240314monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-to-present-at-the-2024-bio-ceo-investor-conference-ints-20240221monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-provides-business-update-reflecting-progress-in-phase-3-sarcoma-pro-ints-20240103monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-presents-positive-int230-6-data-in-patients-with-early-stage-breast-ints-20231208monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-selected-for-spotlight-oral-presentation-at-the-2023-san-antonio-br-ints-20231201monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-presents-positive-int230-6-data-in-patients-with-refractory-soft-ti-ints-20231102monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-announces-collaboration-with-sysmex-vnrx-20260617monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-files-new-patent-protecting-its-nu-q-nets-test-for-ebola-triage-and-treatment-m-vnrx-20260603monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-highlights-commercial-momentum-and-multi-pillar-execution-across-27-billion-tot-vnrx-20260527monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-announces-breakthrough-finger-prick-detection-of-nucleosomes-expanding-global-mar-vnrx-20260429monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-announces-mayo-clinic-study-demonstrates-nu-q-concentrations-are-elevated-in-trau-vnrx-20260330monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-reports-breakthrough-in-liquid-biopsy-achievement-of-over-99-purity-in-isolating--vnrx-20260318monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-announces-first-ever-automated-nu-q-vet-cancer-test-with-fujifilm-vet-systems-vnrx-20260306monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-secures-2-0-million-in-funding-vnrx-20260108monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-announces-breakthrough-clinical-data-for-nu-q-vet-cancer-test-in-cats-vnrx-20260108monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-solves-liquid-biopsy-vnrx-20251211monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-sponsors-upcoming-genomeweb-webinar-vnrx-20251002monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-signs-co-marketing-and-services-agreement-with-hologic-vnrx-20250929monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-signs-first-human-out-licensing-deal-vnrx-20250909monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-schedules-second-quarter-2025-earnings-conference-call-and-business-upd-vnrx-20250808monthly0.5https://www.biopharmawatch.com/news/VNRX/nu-q-discover-expands-global-adoption-and-epigenetic-innovation-vnrx-20250716monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-announces-groundbreaking-lateral-flow-test-for-point-of-care-quantification-of-nu-vnrx-20250708monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-announces-mars-consortium-clinical-study-suggests-nu-q-h3-1-concentrations-are-cl-vnrx-20250612monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-announces-two-oral-presentations-at-asian-meeting-of-animal-medicine-specialties-vnrx-20250604monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-successful-detection-of-nucleosomes-in-cats-vnrx-20250519monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-schedules-first-quarter-2025-earnings-conference-call-and-business-upda-vnrx-20250512monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-outlines-broad-strategy-to-become-the-vnrx-20250507monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-revolutionizing-the-diagnosis-and-monitoring-of-life-altering-diseases--vnrx-20250429monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-announces-two-poster-presentations-at-esmo-vnrx-20250328monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-to-host-virtual-investor-event-on-nu-q-cancer-a-look-to-the-future-of-cancer-diag-vnrx-20250327monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-schedules-full-fiscal-year-2024-earnings-conference-call-and-business-u-vnrx-20250325monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-s-nu-q-cancer-diagnostics-test-aims-to-disrupt-the-multi-billion-dollar-liquid-bi-vnrx-20250321monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-introduces-nu-q-cancer-blood-test-in-new-industry-primer-for-lung-cancer-vnrx-20250320monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-proudly-sponsors-the-44th-isicem-congress-vnrx-20250317monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-signs-first-ever-nu-q-vet-cancer-test-automation-agreement-with-fujifilm-vet-syst-vnrx-20250313monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-announces-first-patient-enrolled-in-ntu-hospital-vnrx-20250311monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-s-nu-q-discover-biomarkers-to-be-utilized-in-human-clinical-study-sponsored-by-le-vnrx-20250304monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-showcases-nu-q-vet-cancer-test-at-the-97th-wvc-annual-conference-vnrx-20250228monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-signs-first-commercial-project-utilizing-rapid-high-throughput-model-in-the-study-vnrx-20250206monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-managem-vnrx-20250205monthly0.5https://www.biopharmawatch.com/news/VNRX/large-clinical-study-establishes-nu-q-nets-h3-1-as-an-independent-predictor-of-28-day-mort-vnrx-20250130monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-issues-business-review-2024-vnrx-20250108monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-appoints-lifesci-advisors-as-investor-relations-consultants-vnrx-20241212monthly0.5https://www.biopharmawatch.com/news/VNRX/study-shows-nu-q-lung-cancer-test-differentiated-malignant-and-benign-nodules-found-by-low-vnrx-20241210monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-schedules-third-quarter-2024-earnings-conference-call-and-business-upda-vnrx-20241108monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-appoints-timothy-i-still-as-chairman-vnrx-20241106monthly0.5https://www.biopharmawatch.com/news/VNRX/multiple-studies-show-nu-q-nets-test-could-predict-sepsis-patients-at-risk-of-deterioratin-vnrx-20241031monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-to-share-new-vnrx-20241009monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-hosts-nets-in-sepsis-management-symposium-at-esicm-lives-2024-vnrx-20241003monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-hosts-kol-roundtable-on-sepsis-vnrx-20240911monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-schedules-second-quarter-2024-earnings-conference-call-and-business-upd-vnrx-20240806monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-appoints-pharmaventures-for-capture-pcr-and-oncology-portfolio-licensing-vnrx-20240709monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-to-present-at-jefferies-global-healthcare-conference-vnrx-20240529monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-schedules-first-quarter-2024-earnings-conference-call-and-business-upda-vnrx-20240508monthly0.5https://www.biopharmawatch.com/news/VNRX/nu-q-vet-cancer-test-launched-in-clinic-in-u-s-and-europe-through-antech-vnrx-20240423monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-schedules-fourth-quarter-and-full-year-2023-earnings-conference-call-an-vnrx-20240321monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-and-fujifilm-vet-systems-launch-nu-q-vet-cancer-test-in-japan-vnrx-20240320monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-to-share-nu-q-nets-strategy-update-at-upcoming-webinar-vnrx-20240202monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-issues-business-review-2023-vnrx-20240104monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-presents-at-the-5th-annual-congress-of-the-international-liquid-biopsy-society-vnrx-20231117monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-schedules-third-quarter-2023-earnings-conference-call-and-business-upda-vnrx-20231108monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-and-vpg-launch-nu-q-vet-cancer-test-in-uk-ireland-vnrx-20231106monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-presents-breakthrough-liquid-biopsy-blood-test-method-for-early-stage-cancer-vnrx-20231023monthly0.5https://www.biopharmawatch.com/news/VNRX/measuring-nucleosomes-using-nu-q-nets-is-a-promising-biomarker-for-septic-shock-vnrx-20231019monthly0.5https://www.biopharmawatch.com/news/VNRX/us-ambassador-adler-visits-belgian-volition-vnrx-20231018monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-presents-three-cancer-detection-abstracts-at-esmo-2023-vnrx-20231016monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-publishes-key-opinion-leader-roundtable-report-on-nets-in-sepsis-vnrx-20231013monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-to-reveal-new-cancer-detection-method-insights-at-upcoming-webinar-vnrx-20231002monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-hosts-key-opinion-leader-roundtable-on-sepsis-management-vnrx-20230913monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-schedules-second-quarter-2023-earnings-conference-call-and-business-upd-vnrx-20230809monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-exercise-of-over-allotment-option-by-underwriters-vnrx-20230623monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-closing-of-16-5-million-underwritten-public-offering-of-commo-vnrx-20230605monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-pricing-of-16-5-million-underwritten-public-offering-of-commo-vnrx-20230601monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-study-shows-nucleosome-concentrations-are-a-useful-tool-for-canine-cancer-treatme-vnrx-20230511monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-schedules-first-quarter-2023-earnings-conference-call-and-business-upda-vnrx-20230505monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-to-host-capital-markets-day-at-the-nyse-on-thursday-may-11-vnrx-20230426monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-schedules-full-year-2022-earnings-conference-call-and-business-update-vnrx-20230310monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-closing-of-8-7-million-underwritten-public-offering-of-common-vnrx-20230222monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-pricing-of-7-525-million-underwritten-public-offering-of-comm-vnrx-20230217monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-s-nu-q-vet-cancer-test-now-available-for-pre-order-at-the-point-of-care-through-h-vnrx-20230216monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-to-take-part-in-nu-q-vet-commercial-strategy-webinar-vnrx-20230120monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-announces-expansion-of-availability-of-the-nu-q-vet-cancer-test-through-idexx-vnrx-20230112monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-issues-business-review-2022-vnrx-20230108monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-announces-clinical-research-study-with-oncovet-vnrx-20221114monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-to-participate-in-a-lung-cancer-screening-study-in-france-vnrx-20221110monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-schedules-third-quarter-2022-earnings-conference-call-and-business-upda-vnrx-20221109monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-announces-the-launch-of-the-nu-q-vet-cancer-screening-test-in-the-u-s-and-europe--vnrx-20221103monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-signs-global-supply-agreement-for-nu-q-vet-cancer-test-vnrx-20221020monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-announces-u-s-clinical-study-for-nets-vnrx-20220810monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-schedules-second-quarter-2022-earnings-conference-call-and-business-upd-vnrx-20220808monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-appoints-dxocro-to-spearhead-u-s-fda-strategy-vnrx-20220808monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-awarded-1-5-million-in-non-dilutive-funding-vnrx-20220803monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-closing-of-6-9-million-underwritten-public-offering-of-common-vnrx-20220802monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-pricing-of-6-million-underwritten-public-offering-of-common-s-vnrx-20220729monthly0.5https://www.biopharmawatch.com/news/VNRX/new-nets-data-presented-at-international-society-on-thrombosis-and-haemostasis-isth-congre-vnrx-20220713monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-achieves-ce-mark-for-nu-q-nets-test-vnrx-20220531monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-schedules-first-quarter-2022-earnings-conference-call-and-business-upda-vnrx-20220506monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-to-host-capital-markets-day-on-friday-may-13-vnrx-20220505monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-launches-its-nu-q-vet-cancer-test-in-asia-through-its-appointed-distributor-sage--vnrx-20220425monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-presents-study-data-at-asco-gi-2022-on-circulating-nucleosomes-for-the-detection--vnrx-20220120monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-executes-its-first-supply-and-licensing-contract-for-its-nu-q-vet-cancer-screenin-vnrx-20211216monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-schedules-third-quarter-2021-earnings-conference-call-and-business-upda-vnrx-20211108monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-veterinary-presents-two-posters-at-the-2021-veterinary-cancer-society-conference-vnrx-20211104monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-s-nu-q-nets-assay-demonstrates-promising-results-in-covid-19-risk-stratification--vnrx-20210722monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-first-quarter-2021-financial-results-and-business-update-vnrx-20210511monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-schedules-first-quarter-2021-earnings-conference-call-and-business-upda-vnrx-20210506monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-publication-of-significant-nu-q-capture-mass-spectrometry-pap-vnrx-20210331monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-appoints-two-new-directors-vnrx-20210329monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-schedules-full-fiscal-year-2020-earnings-conference-call-and-business-u-vnrx-20210316monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-proposed-underwritten-public-offering-of-common-stock-vnrx-20210209monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-opens-its-new-manufacturing-facility-in-belgium-vnrx-20210125monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-awarded-an-additional-4-million-in-non-dilutive-funding-vnrx-20210106monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-announces-filing-of-registration-statements-vnrx-20200207monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-schedules-third-quarter-2018-earnings-conference-call-and-business-upda-vnrx-20181031monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-to-expand-its-nu-q-tm-trials-to-veterinary-diagnostics-vnrx-20181004monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-secures-additional-700-000-non-dilutive-funding-from-the-walloon-region-vnrx-20180702monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-interim-results-from-680-subject-clinical-trial-in-colorectal-vnrx-20180226monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-schedules-third-quarter-2017-earnings-conference-call-and-business-upda-vnrx-20171102monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-awarded-1-5-million-in-non-dilutive-funding-vnrx-20170921monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-schedules-second-quarter-2017-earnings-conference-call-and-business-upd-vnrx-20170803monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-to-host-a-conference-call-regarding-a-13-500-subject-colorectal-cancer--vnrx-20170719monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-to-present-at-multiple-investor-conferences-in-june-vnrx-20170526monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-opens-a-new-research-and-development-facility-in-belgium-with-a-state-of-the-art--vnrx-20170421monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-america-inc-retains-strategic-expert-in-securing-non-dilutive-funding-opportuniti-vnrx-20170328monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-the-formation-of-volition-america-inc-vnrx-20170320monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-celebrates-ce-mark-announcement-by-ringing-closing-bell-at-the-new-york-vnrx-20170314monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-to-ring-the-new-york-stock-exchange-closing-bell-on-monday-march-13th-a-vnrx-20170313monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-acquires-direct-ownership-of-nucleosomics-technology-patent-vnrx-20150224monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-to-present-positive-data-from-pilot-lung-cancer-study-at-biowin-day-2014-vnrx-20141124monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-to-present-at-the-seethruequity-conference-vnrx-20141105monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-initiates-sponsorship-of-two-time-cancer-survivor-to-drive-awareness-for-the-im-vnrx-20141031monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-announces-prostate-cancer-collaboration-with-the-university-of-texas-md-anderso-vnrx-20141002monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-to-present-at-the-aegis-capital-corp-2014-healthcare-technology-conference-vnrx-20140905monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-finds-simple-blood-test-detects-85-of-colorectal-cancers-and-over-50-of-polyps-vnrx-20131202monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-to-present-at-the-6th-annual-ld-micro-conference-vnrx-20131129monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-expands-sample-size-to-11-000-in-pivotal-colorectal-cancer-trial-with-hvidovre--vnrx-20131114monthly0.5https://www.biopharmawatch.com/news/VNRX/first-volitionrx-study-data-presented-at-cnaps-baltimore-vnrx-20131107monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-and-active-motif-enter-into-distribution-agreement-for-volition-vnrx-20130926monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-led-consortium-awarded-euro-780-000-1m-approx-eurostars-grant-vnrx-20130903monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-to-use-innova-biosciences-vnrx-20130722monthly0.5https://www.biopharmawatch.com/news/VNRX/racepoint-group-appointed-by-volitionrx-to-raise-awareness-of-its-new-early-stage-cancer-d-vnrx-20130501monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-files-two-patent-applications-vnrx-20130404monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-hires-head-of-us-operations-jason-terrell-md-vnrx-20130326monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-announces-collaboration-with-wales-cancer-bank-vnrx-20130109monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-launches-nuq-epigenetic-immunoassays-for-research-use-vnrx-20121217monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-vnrx-20121105monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-to-begin-prospective-clinical-trial-in-colon-cancer-vnrx-20120821monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-issues-ceo-letter-to-shareholders-vnrx-20120716monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-signs-collaboration-agreement-with-stefan-holdenrieder-of-rheinische-friedrich--vnrx-20120709monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-raises-over-1-million-to-begin-clinical-trials-of-blood-based-diagnostic-tests-vnrx-20120514monthly0.5https://www.biopharmawatch.com/news/VNRX/pioneering-new-science-nucleosomics-advances-blood-based-diagnostics-for-cancer-vnrx-20120327monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-signs-collaboration-agreement-with-abcodia-vnrx-20120217monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-intellectual-property-update-new-patent-filed-vnrx-20111222monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-issues-525-000-shares-to-valirx-final-requirement-of-share-purchase-agr-vnrx-20111209monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-subsidiary-enters-into-its-first-revenue-generating-agreement-to-profile-blood--vnrx-20111115monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-names-clinical-evaluation-committee-vnrx-20111109monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-issues-update-letter-to-shareholders-vnrx-20111031monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-ticker-symbol-changed-to-vnrx-ob-name-change-to-volitionrx-limited-completed-vnrx-20111011monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-announces-closure-of-share-exchange-agreement-vnrx-20111007monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-inc-to-host-virtual-kol-event-highlighting-unmet-needs-in-postpartum-depression-a-lpcn-20260604monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-h-c-wainwright-8th-annual-mash-investor-conference-lpcn-20240930monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-lpcn-1154-meets-bioequivalence-with-iv-brexanolone-in-pivotal-study-lpcn-20240625monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-presents-52-week-results-from-lpcn-1148-phase-2-study-in-late-breaking-session-at-lpcn-20240610monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-36th-annual-roth-conference-lpcn-20240306monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-continued-commercialization-of-tlando-through-verity-pharmaceuticals-lpcn-20240202monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-biotech-showcase-2024-lpcn-20231219monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-h-c-wainwright-annual-nash-investor-conference-lpcn-20231023monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-biotech-showcase-lpcn-20230105monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-h-c-wainwright-6th-annual-nash-investor-conference-lpcn-20221011monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-participate-in-the-cantor-neurology-psychiatric-conference-lpcn-20220927monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-ladenburg-thalmann-2022-healthcare-conference-lpcn-20220922monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-granted-us-patents-directed-to-cns-and-liver-programs-lpcn-20220614monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-presentation-at-2022-epilepsy-foundation-pipeline-conference-lpcn-20220606monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-clinical-data-on-lpcn-1144-at-2022-nash-tag-conference-lpcn-20220105monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-h-c-wainwright-5th-annual-nash-investor-conference-lpcn-20211005monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-fda-affirmation-of-class-1-nda-resubmission-for-tlando-lpcn-20210928monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-cantor-fitzgerald-virtual-global-healthcare-conference-lpcn-20210920monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference-lpcn-20210901monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-results-for-the-second-quarter-ended-june-30-2021-lpcn-20210805monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference-lpcn-20210706monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-raymond-james-human-health-innovation-conference-lpcn-20210616monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-lytham-partners-summer-2021-investor-conference-lpcn-20210607monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-m-vest-maxim-conference-and-at-the-lytham-partners-conference-lpcn-20210311monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-two-upcoming-investor-conferences-lpcn-20210226monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-closes-underwritten-public-offering-of-common-stock-lpcn-20210128monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-prices-25-million-underwritten-public-offering-of-common-stock-lpcn-20210126monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-launch-of-public-offering-of-common-stock-lpcn-20210125monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-uspto-declaration-of-interference-between-lipocine-and-clarus-patent-ap-lpcn-20210114monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-h-c-wainwright-bioconnect-2021-conference-lpcn-20210104monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-tentative-approval-of-tlando-lpcn-20201208monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-provides-new-regulatory-update-on-tlando-lpcn-20201204monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-provides-regulatory-update-on-tlando-lpcn-20201106monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-presentations-at-the-21st-annual-fall-meeting-of-the-sexual-medicine-so-lpcn-20201014monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-h-c-wainwright-4th-annual-nash-investor-conference-lpcn-20200929monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-participate-in-hc-wainwright-annual-global-investment-conference-lpcn-20200908monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-provides-regulatory-update-for-tlando-lpcn-20200828monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-regains-compliance-with-nasdaq-minimum-bid-price-requirement-lpcn-20200713monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-first-quarter-2020-financial-and-operational-results-lpcn-20200507monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-tlando-pdufa-date-of-august-28-2020-lpcn-20200304monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-closing-of-registered-direct-offering-of-common-stock-and-warrants-lpcn-20200227monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-6-million-registered-direct-offering-priced-at-the-market-lpcn-20200225monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-closing-of-public-offering-of-common-stock-and-warrants-lpcn-20191118monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-pricing-of-public-offering-of-common-stock-and-warrants-lpcn-20191114monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-launch-of-public-offering-of-common-stock-and-warrants-lpcn-20191113monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-b-riley-nash-symposium-lpcn-20191014monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-h-c-wainwright-3rd-annual-nash-investor-conference-lpcn-20191010monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-lpcn-1144-poster-of-distinction-at-the-liver-meeting-2019-lpcn-20191001monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-presentations-at-the-20th-annual-fall-meeting-of-the-sexual-medicine-so-lpcn-20190923monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-ladenburg-thalmann-2019-healthcare-conference-lpcn-20190917monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-participate-in-the-oppenheimer-co-fall-summit-focused-on-specialty-pharma-rare-lpcn-20190916monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-canaccord-genuity-39th-annual-growth-conference-lpcn-20190730monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-participate-at-the-roth-battle-of-the-nash-thrones-spring-investor-conference-lpcn-20190321monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-presentation-highlighting-therapeutic-potential-of-lpcn-1144-in-nafld-a-lpcn-20190314monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-participate-at-the-31st-annual-roth-conference-lpcn-20190311monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-ladenburg-thalmann-2018-healthcare-conference-lpcn-20180925monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-second-quarter-and-six-months-lpcn-20180807monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-canaccord-genuity-38th-annual-growth-conference-lpcn-20180802monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-17th-annual-needham-healthcare-conference-lpcn-20180321monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-leerink-partners-7th-annual-global-healthcare-conference-lpcn-20180207monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-presents-new-atnm-400-data-in-kras-and-egfr-mutant-models-at-snmmi-2026-supportin-atnm-20260603monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-appoints-accomplished-oncology-expert-steffen-heeger-md-msc-as-chief-medical-offi-atnm-20260601monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-presents-new-radiochemistry-data-at-snmmi-2026-demonstrating-that-atnm-20260601monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-announces-compelling-pan-tumor-data-for-atnm-400-demonstratin-atnm-20260422monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-highlights-transcriptional-reprogramming-as-a-key-mechanism-underpinning-mutation-atnm-20260422monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-new-pan-tumor-preclinical-data-for-atnm-400-in-solid-tu-atnm-20260406monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-to-present-two-abstracts-at-the-2026-aacr-annual-meeting-atnm-20260217monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-presents-data-showing-atnm-400-is-more-efficacious-than-pluvicto-and-is-highly-ef-atnm-20250428monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-highlights-mutation-agnostic-antileukemic-activity-of-actimab-a-against-flt3-npm1-atnm-20250428monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-atnm-400-a-novel-non-psma-targeting-first-in-class-pros-atnm-20250327monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-provides-business-update-after-presentation-at-trump-mar-a-lago-c-atnm-20250327monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-present-business-update-at-trump-mar-a-lago-club-today-atnm-20250326monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-host-kol-investor-call-at-8am-et-today-to-highlight-revamped-c-atnm-20250325monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-supply-agreement-with-eckert-ziegler-for-ac-225-radiois-atnm-20250324monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-research-collaboration-with-memorial-sloan-kettering-to-atnm-20250320monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-host-investor-kol-call-with-dr-ehab-atallah-of-the-medical-col-atnm-20250319monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-clinical-trial-program-in-solid-tumors-combining-actima-atnm-20250318monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-publication-of-actimab-a-clag-m-trial-results-in-patien-atnm-20250317monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-participate-at-the-37th-annual-roth-conference-atnm-20250312monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-initiation-of-actimab-a-triplet-combination-frontline-t-atnm-20250311monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-highlights-antibody-radiation-conjugate-program-developments-and--atnm-20241118monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-publication-of-results-from-the-phase-3-sierra-trial-of-atnm-20240920monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-expands-patent-coverage-over-iomab-act-its-next-generation-targeted-radiotherapy--atnm-20240801monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-fda-clearance-of-iomab-act-targeted-conditioning-ind-application-for-si-atnm-20240725monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-present-at-the-3rd-annual-targeted-radiopharmaceuticals-summit-atnm-20240725monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-presents-first-ever-data-demonstrating-actimab-a-in-combination-with-leading-meni-atnm-20240617monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-highlights-oral-presentation-at-eha-2024-annual-congress-featuring-improved-outco-atnm-20240614monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-results-of-actimab-a-clag-m-combination-trial-highlighted-in-oral-prese-atnm-20240611monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-highlights-mutation-data-from-the-phase-3-sierra-trial-of-iomab-b-and-novel-linke-atnm-20240610monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-to-host-kol-webinar-to-discuss-iomab-act-commercial-car-t-cell-therapy-trial-desi-atnm-20240515monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-oral-presentation-detailing-improved-survival-outcomes-in-tp53-positive-atnm-20240514monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-multiple-abstracts-highlighting-its-antibody-radiation-conjugates-iomab-atnm-20240513monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-kol-webinar-to-highlight-recently-announced-iomab-act-trial-with-leadin-atnm-20240507monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-highlights-ability-of-iomab-b-to-overcome-high-risk-tp53-mutation-resulting-in-si-atnm-20240418monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-iomab-b-phase-3-sierra-trial-results-demonstrating-survival-benefit-in--atnm-20240401monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-clinical-trial-to-study-iomab-act-targeted-radiotherapy-conditioning-wi-atnm-20240326monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-launches-actinium-225-focused-strategic-initiative-to-leverage-pr-atnm-20240311monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-iomab-b-markedly-increases-long-term-survival-in-patients-65-years-or-o-atnm-20240226monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-highlights-improved-survival-with-iomab-b-in-tp53-positive-relapsed-refractory-ac-atnm-20240223monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-acceptance-of-five-abstracts-for-presentation-at-the-2024-tandem-meetin-atnm-20240102monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-iomab-b-produces-high-response-rates-and-significant-improvement-in-ove-atnm-20231211monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-s-four-presentations-at-ash-highlight-the-positive-outcomes-for-iomab-b-and-actim-atnm-20231211monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-to-highlight-broad-potential-of-targeted-radiotherapies-iomab-b-and-actimab-a-for-atnm-20231208monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-presents-preclinical-data-at-sitc-demonstrating-actimab-a-atnm-20231106monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-appoints-lynn-bodarky-as-chief-business-officer-atnm-20231103monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-attend-bio-europe-munich-2023-atnm-20231102monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-oral-presentation-at-ash-annual-meeting-highlighting-iomab-b-treatment--atnm-20231102monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-nih-grant-extension-to-advance-clinical-development-of-next-generation--atnm-20231004monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharma-highlights-abstract-accepted-for-poster-presentation-at-the-sitc-38th-annu-atnm-20230927monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharma-presents-survival-data-from-extended-follow-up-from-actimab-a-clag-m-trial-atnm-20230907monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharma-highlights-three-abstracts-accepted-for-poster-presentation-at-the-soho-20-atnm-20230831monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharma-highlights-abstracts-accepted-for-oral-and-poster-presentation-at-the-eanm-atnm-20230821monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharma-to-present-at-the-2nd-annual-targeted-radiopharmaceuticals-summit-atnm-20230724monthly0.5https://www.biopharmawatch.com/news/ATNM/snmmi-2023-annual-meeting-abstract-of-the-year-awarded-to-actinium-atnm-20230626monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharma-highlights-six-abstracts-accepted-for-oral-and-poster-presentation-at-the--atnm-20230623monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharma-to-present-at-the-maxim-healthcare-virtual-conference-atnm-20230616monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharma-to-present-at-the-td-cowen-radiopharmaceutical-innovation-summit-atnm-20230614monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-positive-pivotal-phase-3-sierra-trial-results-in-an-oral-presentation-a-atnm-20230612monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharma-set-to-join-russell-2000-and-russell-3000-indexes-atnm-20230607monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharma-announces-six-abstracts-accepted-for-oral-and-poster-presentation-at-the-s-atnm-20230522monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharma-announces-iomab-b-sierra-trial-results-accepted-for-oral-presentation-at-t-atnm-20230511monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharma-to-present-at-guggenheim-healthcare-talks-radiopharmaceuticals-day-atnm-20230510monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-highlights-successful-administration-of-targeted-radiotherapy-iomab-b-across-vari-atnm-20230428monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-positive-pivotal-phase-3-sierra-trial-results-of-iomab-b-showcased-to-t-atnm-20230427monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-highlights-first-in-class-her3-targeted-radiotherapy-data-demonstrating-potent-an-atnm-20230419monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-presents-data-demonstrating-actimab-a-atnm-20230419monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-reports-2022-financial-results-and-highlights-recent-and-upcoming-atnm-20230403monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-to-showcase-first-in-class-targeted-radiotherapies-in-two-presentations-at-the-20-atnm-20230316monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-to-present-at-oppenheimer-atnm-20230315monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-dr-sergio-giralt-to-discuss-positive-results-from-the-p-atnm-20230227monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-to-present-full-results-from-pivotal-phase-3-iomab-b-sierra-trial-on-investor-cal-atnm-20230214monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-signs-cooperative-research-and-development-agreement-with-national-cancer-institu-atnm-20230206monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-to-present-at-the-3rd-annual-b-riley-securities-oncology-conf-atnm-20230117monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-phase-3-iomab-b-sierra-data-accepted-for-late-breaker-presentation-at-t-atnm-20230112monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-highlights-survival-data-in-relapsed-refractory-aml-patients-with-prior-venetocla-atnm-20221212monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-announces-research-collaboration-with-columbia-university-to--atnm-20221208monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-positive-1-year-and-2-year-overall-survival-data-for-patients-with-rela-atnm-20221103monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-appoints-seasoned-leader-caroline-yarbrough-as-chief-commercial-officer-to-spearh-atnm-20221102monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-expands-clinical-leadership-team-to-support-key-development-programs-for-iomab-b--atnm-20221027monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-participate-in-the-2022-bio-europe-conference-atnm-20221026monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-bolsters-its-senior-leadership-team-ahead-of-upcoming-clinical-data-for-iomab-b-atnm-20221025monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-to-present-at-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference-atnm-20220926monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-iomab-b-sierra-trial-database-lock-provides-corporate-u-atnm-20220921monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-participate-in-the-h-c-wainwright-24th-annual-global-investmen-atnm-20220908monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-announces-82-of-control-arm-patients-did-not-receive-a-bone-m-atnm-20220425monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-to-highlight-iomab-b-pivotal-phase-3-sierra-trial-data-at-the-atnm-20220419monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-and-immedica-announce-commercialization-agreement-for-iomab-b-atnm-20220412monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-highlights-potent-anti-tumor-activity-of-a-her3-targeted-radiothe-atnm-20220411monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-presents-preclinical-data-at-aacr-showing-her3-targeted-radiother-atnm-20220411monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-and-aveo-oncology-enter-research-collaboration-agreement-to-d-atnm-20220222monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-and-epicentrx-announce-strategic-research-collaboration-to-co-atnm-20220105monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-announces-72-mrd-negativity-rate-in-the-recently-completed-ph-atnm-20211214monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-reports-2-remissions-and-67-orr-in-patients-with-a-tp53-mutat-atnm-20211214monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-announces-greater-difference-of-approximately-5x-for-iomab-b--atnm-20211213monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-announces-participation-in-two-panel-discussions-at-the-3rd-t-atnm-20211208monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-presents-first-ever-data-with-a-cd47-immunotherapy-in-combination-with-a-her2-dir-atnm-20211112monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-highlights-actimab-a-combined-with-cd47-immunotherapy-results-in-upregulation-of--atnm-20211112monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-completion-of-enrollment-of-actimab-a-clag-m-combination-trial-in-patie-atnm-20211104monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-multiple-abstracts-highlighting-iomab-b-and-actimab-a-accepted-for-pres-atnm-20211104monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-two-abstracts-highlighting-combinations-of-cd47-targeting-immunotherapy-atnm-20211001monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-to-present-at-the-cantor-fitzgerald-virtual-global-healthcare-conference-on-septe-atnm-20210928monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-expansion-of-r-d-team-and-facilities-to-accelerate-research-programs-fo-atnm-20210927monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-to-present-at-four-upcoming-investor-conferences-atnm-20210920monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-completes-enrollment-in-the-pivotal-phase-3-sierra-trial-of-iomab-b-atnm-20210915monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-inclusion-in-russell-microcap-index-atnm-20210628monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-further-strengthens-patent-portfolio-with-international-ip-covering-the-compositi-atnm-20210617monthly0.5https://www.biopharmawatch.com/news/ATNM/pivotal-phase-3-sierra-trial-data-showing-100-bone-marrow-transplant-engraftment-in-patien-atnm-20210615monthly0.5https://www.biopharmawatch.com/news/ATNM/safety-data-highlighting-low-rates-of-adverse-events-and-non-relapse-transplant-related-mo-atnm-20210615monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-several-presentations-from-the-phase-3-sierra-study-of-iomab-b-at-the-s-atnm-20210603monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-to-participate-in-the-cell-gene-meeting-on-the-mediterranean-atnm-20210331monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-completion-of-enrollment-of-second-dose-cohort-in-actimab-a-venetoclax--atnm-20210325monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-initiation-of-patient-enrollment-in-iomab-act-trial-for-targeted-condit-atnm-20210324monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-to-highlight-expansion-of-targeted-conditioning-portfolio-at-aacr-with-next-gener-atnm-20210311monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-appointment-of-mark-kubik-mba-as-chief-business-officer-atnm-20210303monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-participation-in-h-c-wainwright-global-life-sciences-conference-atnm-20210302monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-showcases-targeted-conditioning-program-with-2-oral-presentations-highlighting-io-atnm-20210211monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-participation-in-bio-ceo-investor-digital-conference-atnm-20210210monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference-atnm-20210120monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-and-astellas-announce-research-collaboration-focused-on-novel-actinium-225-based--atnm-20210113monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-successful-pre-planned-ad-hoc-interim-analysis-of-phase-3-sierra-trial-atnm-20201229monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-highlights-presence-at-targeted-radiopharmaceuticals-summit-atnm-20201209monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-reports-67-percent-overall-response-rate-in-first-cohort-in-actimab-a-venetoclax--atnm-20201208monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-positive-interim-results-from-iomab-b-pivotal-phase-3-sierra-trial-at-7-atnm-20201207monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-highlights-iomab-b-safety-data-presented-at-the-62nd-american-society-of-hematolo-atnm-20201207monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-presents-interim-data-from-actimab-a-clag-m-phase-1-combination-trial-at-the-62nd-atnm-20201207monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-highlights-clinical-data-to-be-presented-at-the-upcoming-62nd-american-society-of-atnm-20201203monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-appoints-mary-mei-chen-m-d-ph-d-as-vice-president-of-clinical-development-atnm-20201201monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-highlights-foundational-patents-covering-the-composition-of-apamistamab-antibody--atnm-20201123monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-strengthens-leadership-team-with-appointment-of-dr-avinash-desai-as-executive-vic-atnm-20201119monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-to-participate-in-the-alliance-global-partners-atnm-20201116monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-to-host-kol-call-on-november-11th-featuring-actimab-a-aml-combination-trials-atnm-20201111monthly0.5https://www.biopharmawatch.com/news/ATNM/100-remission-rate-reported-in-third-dose-cohort-of-actimab-a-clag-m-phase-1-combination-t-atnm-20201104monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-two-oral-presentations-featuring-data-and-findings-from-the-phase-3-sie-atnm-20201104monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-actimab-a-venetoclax-first-in-human-data-accepted-for-poster-presentati-atnm-20201104monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-provides-corporate-update-and-year-end-2020-outlook-atnm-20201028monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-awarded-grant-by-national-institutes-of-health-to-study-novel-atnm-20201021monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-expands-r-d-capabilities-with-new-research-facility-to-enhanc-atnm-20201014monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-announces-clinical-trial-site-expansion-in-its-multi-center-p-atnm-20201006monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-successfully-completes-first-dosing-cohort-in-the-phase-1-study-o-atnm-20200923monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-successful-completion-of-planned-phase-1-actimab-a-clag-atnm-20200914monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-to-present-at-the-22nd-annual-h-c-wainwright-global-investor--atnm-20200910monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-announces-pricing-of-25-0-million-public-offering-atnm-20200616monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-announces-closing-of-31-6-million-public-offering-including-f-atnm-20200424monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-announces-pricing-of-27-5-million-public-offering-atnm-20200421monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-announces-proposed-public-offering-atnm-20200421monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-provides-update-on-iomab-b-sierra-trial-and-expected-topline-results-from-ad-hoc--atnm-20200416monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-first-patient-treated-in-third-and-final-dose-cohort-of-atnm-20200305monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-actimab-a-plus-7-3-combination-trial-for-newly-diagnosed-acute-myeloid--atnm-20200226monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-presents-positive-findings-from-mid-point-analysis-of-pivotal-sierra-trial-of-iom-atnm-20200221monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-to-highlight-targeted-conditioning-portfolio-at-2020-transplantation-cellular-the-atnm-20200213monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-to-present-at-the-22nd-annual-bio-ceo-investor-conference-atnm-20200205monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-iomab-act-program-gene-therapy-collaboration-with-uc-da-atnm-20200113monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-to-present-at-2020-biotech-showcase-atnm-20200107monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-highlights-86-response-rate-and-71-mrd-negative-rate-in-actimab-a-atnm-20191209monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-phase-3-sierra-trial-dosimetry-results-support-low-dose-atnm-20191209monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-present-at-the-25th-annual-bio-europe-2019-international-partn-atnm-20191107monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-interim-results-from-phase-1-actimab-a-clag-m-combination-trial-in-pati-atnm-20191106monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-present-new-clinical-findings-from-sierra-trial-supporting-the-atnm-20191106monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-positive-interim-results-from-iomab-b-pivotal-phase-3-sierra-trial-at-5-atnm-20191028monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-to-announce-interim-results-from-pivotal-phase-3-sierra-trial-on-conference-call--atnm-20191024monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-participation-at-the-2019-cell-gene-meeting-on-the-mesa-atnm-20190930monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-iomab-b-poster-selected-for-honorable-distinction-award-at-the-2019-soc-atnm-20190923monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-present-at-the-sachs-19th-annual-biotech-in-europe-forum-for-g-atnm-20190916monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-present-at-the-rodman-renshaw-21st-annual-global-investment-co-atnm-20190905monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-achieves-fifty-percent-enrollment-in-the-pivotal-phase-3-sierra-trial-for-iomab-b-atnm-20190723monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-highlights-two-presentations-at-the-health-physics-society-annual-meeting-support-atnm-20190711monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-poster-detailing-actinium-225-labeled-daratumumab-selected-in-top-poster-award-co-atnm-20190626monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-presents-new-data-demonstrating-effective-lymphodepletion-with-lutetium-177-for-c-atnm-20190625monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-s-portfolio-of-antibody-radiation-conjugates-to-be-highlighted-in-two-oral-and-tw-atnm-20190620monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-presents-new-pivotal-phase-3-sierra-trial-data-showing-rapid-peripheral-blast-red-atnm-20190604monthly0.5https://www.biopharmawatch.com/news/ATNM/abstract-highlighting-new-data-from-the-iomab-b-pivotal-phase-3-sierra-trial-to-be-present-atnm-20190516monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-appointment-of-niva-almaula-ph-d-as-chief-business-officer-atnm-20190507monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-announces-pricing-of-16-5-million-public-offering-of-common-s-atnm-20190418monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-announces-proposed-public-offering-of-common-stock-and-warran-atnm-20190417monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-s-leading-clinical-preclinical-production-and-ip-efforts-related-to-actinium-225--atnm-20190408monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-highlights-actimab-a-and-venetoclax-synergies-observed-in-new-studies-presented-a-atnm-20190403monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-successfully-completes-second-module-of-collaborative-research-program-with-astel-atnm-20190329monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-highlights-its-participation-at-the-upcoming-targeted-alpha-therapy-international-atnm-20190326monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-update-including-ip-and-new-data-from-novel-combination-of-actimab-a-an-atnm-20190320monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-appoints-accomplished-fda-and-industry-professional-mamata-gokhale-ph-d-rac-as-vi-atnm-20190319monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-reports-fourth-quarter-and-year-end-2018-financial-results-and-provides-corporate-atnm-20190319monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-provides-comprehensive-patent-portfolio-update-including-new-ip-filings-atnm-20190315monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-present-at-the-oppenheimer-co-29th-annual-healthcare-conferenc-atnm-20190315monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-s-late-breaking-oral-presentation-at-2019-tct-meetings-reports-new-data-on-donor--atnm-20190225monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-highlights-new-data-at-tct-meetings-demonstrating-effective-lymphodepletion-suppo-atnm-20190221monthly0.5https://www.biopharmawatch.com/news/ATNM/iomab-b-one-of-four-late-breaking-oral-presentations-to-be-presented-at-the-2019-transplan-atnm-20190212monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-provides-patent-portfolio-update-for-its-iomab-act-next-generation-car-t-lymphode-atnm-20190206monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-initiates-novel-phase-1-2-combination-trial-of-actimab-a-and-venetoclax-atnm-20190205monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-initiates-second-dosing-cohort-of-novel-combination-trial-with-actimab-a-and-clag-atnm-20190204monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-host-key-opinion-leader-breakfast-on-targeted-conditioning-for-atnm-20190129monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-to-present-at-noble-capital-markets-atnm-20190125monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-appoints-accomplished-industry-executive-cynthia-pussinen-as-exec-atnm-20190123monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-successfully-completes-first-module-of-collaborative-research-program-with-astell-atnm-20190117monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-appoints-qing-liang-phd-dabr-as-vice-president-head-of-radiation--atnm-20190116monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-to-present-at-the-2019-biotech-showcase-in-san-francisco-atnm-20190103monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-highlights-analysis-of-pivotal-iomab-b-phase-3-sierra-trial-prese-atnm-20181204monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-highlights-actimab-a-phase-2-trial-results-in-older-patients-with-unfit-aml-from--atnm-20181203monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-to-present-at-30th-annual-piper-jaffray-healthcare-conference-atnm-20181119monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-present-at-bio-europe-24th-annual-international-partnering-con-atnm-20181105monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-ash-annual-meeting-presence-to-include-oral-presentation-of-feasi-atnm-20181101monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-cd33-program-to-focus-on-actimab-mds-pivotal-trial-enabling-study-atnm-20181030monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-hold-webinar-showcasing-actimab-a-post-phase-2-trial-plans-and-atnm-20181026monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-participation-at-bio-europe-24th-annual-international-p-atnm-20181024monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-webinar-showcasing-actimab-a-post-phase-2-trial-plans-a-atnm-20181022monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-launches-iomab-act-program-offering-its-targeted-chemo-free-lymphodepletion-techn-atnm-20181001monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-host-webinar-today-introducing-next-generation-targeted-lympho-atnm-20180926monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-participate-in-the-oppenheimer-co-fall-summit-focused-on-speci-atnm-20180920monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-host-webinar-showcasing-new-pipeline-initiative-focused-on-the-atnm-20180918monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-appoints-robert-n-daly-ph-d-to-newly-created-role-of-vice-president-head-of-clini-atnm-20180906monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-present-at-upcoming-investor-conferences-and-participate-in-fe-atnm-20180904monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-to-provide-update-on-pivotal-phase-3-sierra-trial-following-positive-data-monitor-atnm-20180814monthly0.5https://www.biopharmawatch.com/news/ATNM/with-impressive-data-in-tow-actinium-pharma-an-overlooked-leader-in-new-aml-therapies-atnm-20160810monthly0.5https://www.biopharmawatch.com/news/ATNM/with-bone-marrow-transplants-rising-new-therapy-gives-hope-to-those-over-55-atnm-20140108monthly0.5https://www.biopharmawatch.com/news/ATNM/four-things-to-ask-your-doctor-about-bone-marrow-transplants-atnm-20131220monthly0.5https://www.biopharmawatch.com/news/ATNM/encouraging-clinical-data-from-multicenter-phase-1-2-trial-on-actinium-atnm-20131209monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-present-at-the-24th-annual-oppenheimer-healthcare-conference-atnm-20131209monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-presenting-at-the-ld-micro-conference-today-at-12-30-pm-pacific-atnm-20131205monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-2013-annual-shareholder-meeting-atnm-20131203monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceutical-atnm-20131203monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-additional-clinical-data-from-multicenter-phase-1-2-tri-atnm-20131202monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-present-at-the-ld-micro-conference-atnm-20131121monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-plans-for-iomab-b-phase-3-pivotal-trial-following-meeti-atnm-20131118monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-appoints-richard-steinhart-as-new-independent-director-atnm-20131112monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-host-corporate-update-and-virtual-roadshow-conference-call-on--atnm-20131108monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-host-corporate-update-and-virtual-roadshow-conference-call-on--atnm-20131031monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-webinar-to-discuss-iomab-b-at-11am-edt-today-atnm-20131015monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-upcoming-webinar-to-discuss-iomab-b-atnm-20131003monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-appoints-corey-sohmer-as-vice-president-of-finance-and-business-d-atnm-20130918monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-appoints-kaushik-j-dave-ph-d-mba-as-president-chief-executive-off-atnm-20130916monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-atnm-20130605monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-clinical-results-to-be-presented-at-8th-international-symposium-o-atnm-20130516monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-receives-notice-of-patent-allowance-for-a-key-application-atnm-20130513monthly0.5https://www.biopharmawatch.com/news/ATNM/cactus-ventures-inc-changes-name-to-actinium-pharmaceuticals-inc-atnm-20130417monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-to-present-at-the-15th-annual-bio-ceo-investor-conference-atnm-20130206monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-present-at-emit-targeted-radiotherapy-conference-atnm-20130128monthly0.5https://www.biopharmawatch.com/news/ATNM/university-of-pennsylvania-joins-actinium-pharmaceuticals-atnm-20130117monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-to-present-at-the-biotech-showcase-2013-atnm-20130104monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-goes-public-via-a-reverse-merger-into-cactus-ventures-inc-atnm-20130103monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-successfully-completes-the-first-closing-of-5-1-million-in-it-atnm-20121226monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-and-philogen-s-p-a-announce-start-of-pre-clinical-development-of--atnm-20121129monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-sponsors-webinar-on-clinical-use-of-alpha-immunotherapy-atnm-20121127monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-presentation-for-actimab-a-a-novel-targeted-immunothera-atnm-20121010monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-johns-hopkins-university-school-of-medicine-joins-multi-atnm-20121009monthly0.5https://www.biopharmawatch.com/news/ATNM/dr-hagop-kantarjian-joins-actinium-pharmaceuticals-clinical-advisory-board-atnm-20121001monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-new-round-of-financing-atnm-20120921monthly0.5https://www.biopharmawatch.com/news/ATNM/gerri-henwood-joins-actinium-pharmaceuticals-as-chief-development-officer-atnm-20120912monthly0.5https://www.biopharmawatch.com/news/ATNM/md-anderson-cancer-center-joins-actinium-pharmaceuticals-atnm-20120912monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-commences-screening-for-the-second-cohort-of-patients-in-the-comp-atnm-20120907monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-stockholders-vote-to-approve-fundraising-and-public-listing-atnm-20120906monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-strengthens-management-team-atnm-20120823monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-and-philogen-s-p-a-announce-collaboration-for-alpha-therapy-based-atnm-20120809monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-announces-the-addition-of-the-fred-hutchinson-cancer-research-cen-atnm-20120801monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-successfully-completes-first-cohort-in-multicenter-phase-i-ii-leu-atnm-20120719monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-presents-four-studies-at-american-diabetes-association-scientific-sessions-highlight-drio-20260608monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results-drio-20260319monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-report-fourth-quarter-and-full-year-2025-results-on-thursday-march-19-2026-drio-20260311monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-demonstrates-clinically-meaningful-blood-glucose-improvements-and-personalized-glyce-drio-20260310monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-issues-shareholder-update-multi-condition-leadership-in-momentum-driven-digita-drio-20250903monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-secures-five-new-employer-contracts-across-cardiometabolic-suite-including-its-large-drio-20250902monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-second-quarter-2025-financial-and-operating-results-drio-20250812monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-report-second-quarter-2025-results-on-tuesday-august-12-2025-drio-20250805monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-and-greenkey-health-announce-strategic-commercial-agreement-to-transform-chronic-con-drio-20250626monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-unveils-groundbreaking-glp-1-and-ai-personalization-digital-health-findings-drio-20250624monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-first-quarter-2025-financial-and-operating-results-drio-20250514monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-s-digital-health-solution-demonstrates-effectiveness-in-new-research-examining-flu-v-drio-20250508monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-report-first-quarter-2025-results-on-wednesday-may-14-2025-drio-20250507monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-closes-strategic-refinancing-of-existing-debt-facility-of-up-to-50-million-to--drio-20250501monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-cfo-transition-drio-20250421monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-collaborates-with-leading-national-benefit-plan-administrator-to-offer-cardiom-drio-20250417monthly0.5https://www.biopharmawatch.com/news/DRIO/top-u-s-healthcare-institution-deploys-dariohealth-drio-20250408monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-new-agreement-with-a-large-regional-health-plan-drio-20250317monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-fourth-quarter-and-full-year-2024-financial-and-operating-results-drio-20250310monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-expands-behavioral-health-offerings-to-include-a-provider-network-through-strategic--drio-20250307monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-signs-first-healthcare-system-as-employer-contract-expanding-market-presence-and-rec-drio-20250305monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-report-fourth-quarter-and-full-year-2024-results-on-monday-march-10-2025-drio-20250304monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-expands-glp-1-solution-with-prescribing-capabilities-through-collaboration-wit-drio-20250114monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-signs-four-new-employer-contracts-across-full-product-suite-drio-20241121monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-third-quarter-2024-financial-and-operating-results-drio-20241107monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-expands-pharma-collaborations-with-global-pharma-leader-to-enhance-user-engagement-drio-20241104monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-signs-new-regional-health-plan-expanding-reach-in-medicaid-population-drio-20241030monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-report-third-quarter-2024-results-on-thursday-november-7th-drio-20241023monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-announces-complete-integration-of-twill-capabilities-across-full-multi-condition-pla-drio-20241017monthly0.5https://www.biopharmawatch.com/news/DRIO/twill-by-dario-to-offer-a-benefit-for-aarp-members-drio-20241015monthly0.5https://www.biopharmawatch.com/news/DRIO/national-medicare-health-plan-partners-with-twill-by-dario-to-promote-healthy-aging-with-n-drio-20241008monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-introduces-integration-of-twill-behavioral-health-capabilities-into-cardiometabolic--drio-20240912monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-publishes-new-research-revealing-how-physical-activity-mediates-the-impact-of-depres-drio-20240910monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-second-quarter-2024-financial-and-operating-results-drio-20240808monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-report-second-quarter-2024-results-on-thursday-august-8th-drio-20240730monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-expands-glp-1-solution-client-base-with-new-employer-contract-drio-20240716monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-demonstrates-12-months-of-sustained-healthy-behavior-change-for-members-taking-a-glp-drio-20240625monthly0.5https://www.biopharmawatch.com/news/DRIO/empowering-commercial-expansion-dariohealth-announces-strategic-reorganization-and-appoint-drio-20240605monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-first-quarter-2024-financial-and-operating-results-drio-20240515monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-report-first-quarter-2024-results-on-wednesday-may-15th-drio-20240507monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-publishes-new-peer-reviewed-study-that-deepens-the-body-of-evidence-that-managing-ca-drio-20240425monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-signs-two-employers-for-cardiometabolic-suite-with-integrated-glp-1-solution-drio-20240418monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-publishes-two-new-peer-reviewed-studies-demonstrating-impact-of-digital-behavioral-h-drio-20240410monthly0.5https://www.biopharmawatch.com/news/DRIO/two-national-employers-select-dario-drio-20240402monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-fourth-quarter-and-full-year-2023-financial-and-operating-results-drio-20240328monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-report-fourth-quarter-2023-results-on-thursday-march-28th-drio-20240321monthly0.5https://www.biopharmawatch.com/news/DRIO/new-research-from-dario-demonstrates-ability-to-deliver-improved-health-outcomes-with-inte-drio-20240312monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-participate-in-the-cowen-43rd-annual-healthcare-conference-drio-20240228monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-acquires-twill-creating-one-of-the-most-comprehensive-digital-health-platform-across-drio-20240221monthly0.5https://www.biopharmawatch.com/news/DRIO/regional-union-selects-dario-drio-20240111monthly0.5https://www.biopharmawatch.com/news/DRIO/national-employer-selects-dario-cardiometabolic-and-glp-1-solutions-to-improve-employee-he-drio-20231205monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-contracts-with-new-employer-for-cardiometabolic-solution-drio-20231127monthly0.5https://www.biopharmawatch.com/news/DRIO/new-research-sheds-light-on-mediators-of-improved-outcomes-in-dario-users-drio-20231121monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-publishes-new-research-demonstrating-that-dario-users-that-increased-physical-activi-drio-20231113monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-third-quarter-2023-financial-and-operating-results-drio-20231102monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-launches-apple-iphone-15-accessible-smart-blood-glucose-meter-drio-20231101monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-report-third-quarter-2023-results-on-thursday-november-2nd-drio-20231030monthly0.5https://www.biopharmawatch.com/news/DRIO/new-research-shows-36-reduction-in-30-day-hospital-readmission-rate-for-dario-users-with-t-drio-20231017monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-signs-national-preferred-partner-agreement-with-a-top-five-national-employee-benefit-drio-20231005monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-host-investor-day-on-the-rise-of-digital-health-drio-20231003monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-publishes-new-research-demonstrating-clinically-significant-reductions-in-depression-drio-20230927monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-publishes-new-research-demonstrating-greater-engagemenet-and-improved-clinical-outco-drio-20230824monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-partners-with-plansource-to-offer-employers-easy-access-to-proven-digital-health-sol-drio-20230815monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-second-quarter-2023-financial-and-operating-results-drio-20230810monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-expands-partnership-with-large-regional-health-plan-drio-20230808monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-report-second-quarter-2023-results-on-thursday-august-10th-drio-20230803monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-introduces-glp-1-behavior-change-program-to-help-achieve-weight-loss-goals-and-bette-drio-20230802monthly0.5https://www.biopharmawatch.com/news/DRIO/new-research-shows-5-077-in-medical-costs-savings-for-dario-users-drio-20230726monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-announces-new-full-suite-employer-contract-drio-20230706monthly0.5https://www.biopharmawatch.com/news/DRIO/new-research-demonstrates-2-3-point-reduction-in-hba1c-for-dario-digital-health-users-with-drio-20230626monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-announces-two-new-full-suite-employer-contracts-drio-20230607monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-management-to-participate-in-the-stifel-2023-virtual-cross-sector-insight-conference-drio-20230601monthly0.5https://www.biopharmawatch.com/news/DRIO/medone-launches-dario-drio-20230518monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-first-quarter-financial-and-operating-results-drio-20230511monthly0.5https://www.biopharmawatch.com/news/DRIO/sanofi-research-demonstrates-9-3-reduction-in-all-cause-healthcare-resource-utilization-ra-drio-20230509monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-report-first-quarter-2023-results-on-thursday-may-11th-drio-20230504monthly0.5https://www.biopharmawatch.com/news/DRIO/digital-health-product-leader-eitan-shay-joins-dario-as-chief-product-officer-drio-20230404monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-selected-as-digital-therapeutics-partner-by-a-top-ten-digitally-enabled-pharmacy-ben-drio-20230327monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-announces-strategic-partnership-with-amwell-to-expand-access-to-its-cardiometabolic--drio-20230322monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-publishes-new-research-demonstrating-digital-personalization-of-pain-management-with-drio-20230314monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-fourth-quarter-and-record-revenue-in-full-year-2022-financial-and-oper-drio-20230309monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-report-fourth-quarter-2022-results-on-thursday-march-9th-drio-20230302monthly0.5https://www.biopharmawatch.com/news/DRIO/new-research-from-dario-demonstrates-improved-clinical-outcomes-in-two-new-studies-at-the--drio-20230227monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-participate-in-the-cowen-43rd-annual-healthcare-conference-drio-20230224monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-partners-to-integrate-dexcom-cgm-data-drio-20230208monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-adds-new-senior-vice-president-of-growth-to-expanding-sales-team-drio-20230124monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-publishes-new-research-in-peer-reviewed-journal-demonstrating-improved-outcomes-by-r-drio-20230109monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-achieves-goal-of-100-business-to-business-contracts-in-2022-drio-20230103monthly0.5https://www.biopharmawatch.com/news/DRIO/leading-international-wellness-company-selects-dario-as-partner-for-musculoskeletal-health-drio-20221222monthly0.5https://www.biopharmawatch.com/news/DRIO/new-research-published-in-peer-reviewed-journal-demonstrating-dario-drio-20221219monthly0.5https://www.biopharmawatch.com/news/DRIO/two-new-employers-join-dario-through-benefits-brokerage-partner-drio-20221201monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-to-participate-in-craig-hallum-and-btig-digital-health-drio-20221116monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-third-quarter-2022-financial-and-operating-results-drio-20221114monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-report-third-quarter-2022-results-on-monday-november-14th-drio-20221109monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-announces-two-employer-contracts-for-full-suite-of-digital-health-solutions-drio-20221020monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-s-full-suite-of-digital-solutions-selected-by-midwestern-city-to-improve-employee-he-drio-20221013monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-publishes-new-clinical-research-linking-the-use-of-its-biofeedback-device-to-r-drio-20220922monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-two-new-employer-contracts-drio-20220920monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-presents-new-research-demonstrating-the-ability-to-support-people-in-rural-are-drio-20220812monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-selected-by-national-health-plan-to-enhance-mental-health-and-well-being-for-m-drio-20220811monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-report-second-quarter-2022-results-on-monday-august-15-drio-20220810monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-presents-new-research-demonstrating-the-impact-of-a-digital-solution-on-depres-drio-20220804monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-demonstrates-continued-growth-in-multi-chronic-contracts-with-latest-addition--drio-20220721monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-new-contract-with-a-national-employer-drio-20220621monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-presents-three-new-studies-demonstrating-improved-health-in-users-with-multipl-drio-20220603monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-additional-commercial-contracts-for-its-digital-therapeutic-solution-drio-20220519monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-record-quarterly-revenues-in-its-2022-first-quarter-drio-20220512monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-report-first-quarter-2022-results-on-thursday-may-12-drio-20220504monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-presents-new-clinical-research-demonstrating-improved-outcomes-for-participant-drio-20220427monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-agreement-with-health-plan-colorado-access-drio-20220414monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-additional-new-employer-contracts-drio-20220323monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-fourth-quarter-and-full-year-2021-results-and-operational-highlights-drio-20220322monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-report-fourth-quarter-and-full-year-2021-results-on-monday-march-21-drio-20220314monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-two-new-contracts-within-the-employer-and-provider-market-drio-20220309monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-participate-in-the-cowen-42nd-annual-healthcare-conference-drio-20220307monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announced-pricing-of-its-registered-direct-offering-for-aggregate-proceeds-of--drio-20220301monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-publishes-clinical-outcomes-demonstrating-the-impact-of-using-a-single-digital-drio-20220209monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-four-new-employer-contracts-drio-20220208monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-enters-agreement-to-acquire-physimax-a-leading-provider-of-validated-computer--drio-20220120monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-enters-into-agreement-with-large-regional-health-plan-drio-20220119monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-host-investor-webinar-on-navigating-emerging-digital-health-trends-for-stra-drio-20220118monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-two-new-contracts-within-the-employer-market-drio-20220106monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-selected-as-exclusive-digital-therapeutics-provider-to-a-leading-benefits-brok-drio-20211221monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-two-new-contracts-within-the-employer-and-provider-markets-drio-20211202monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-two-new-employer-contracts-drio-20211118monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-third-quarter-2021-results-and-operational-highlights-drio-20211115monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-appoints-seasoned-health-care-executive-jerrod-helms-as-chief-commercial-offic-drio-20211115monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-three-new-contracts-as-growth-continues-to-accelerate-across-the-emp-drio-20211111monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-report-third-quarter-2021-results-on-monday-november-15-drio-20211108monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-participate-in-upcoming-investor-conferences-drio-20211105monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-partners-with-national-group-benefits-platform-drio-20211103monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-gathers-momentum-in-the-provider-market-with-two-new-contracts-for-remote-pati-drio-20211101monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-joins-virgin-pulse-partner-network-drio-20211027monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-contract-with-a-u-s-national-employer-to-provide-its-full-multi-cond-drio-20211025monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-unveils-its-digital-musculoskeletal-solution-dario-move-at-hlth-2021-drio-20211018monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-agreement-with-leading-national-health-plan-drio-20211014monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-agreement-with-global-employer-for-metabolic-and-musculoskeletal-hea-drio-20211007monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-participate-in-the-cantor-fitzgerald-virtual-global-healthcare-conference-drio-20210924monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-chief-medical-officer-dr-omar-manejwala-to-speak-at-american-health-insurance--drio-20210917monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-chosen-by-northeast-regional-employer-drio-20210909monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-selected-by-another-employer-for-behavioral-health-services-drio-20210908monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-chosen-by-regional-primary-care-provider-peopleone-health-as-its-digital-behav-drio-20210831monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-presents-new-study-demonstrating-significant-clinical-impact-of-personalized-d-drio-20210812monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-report-second-quarter-2021-results-on-monday-august-16-drio-20210809monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-behavioral-health-solution-selected-by-national-employer-drio-20210804monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-launches-behavioral-health-solutions-globally-in-new-partnership-with-workplac-drio-20210727monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-chosen-to-provide-remote-patient-monitoring-for-alabama-regional-medical-servi-drio-20210720monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-chief-medical-officer-omar-manejwala-m-d-to-present-on-the-role-of-digital-the-drio-20210713monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-expands-employer-footprint-with-three-new-contracts-drio-20210712monthly0.5https://www.biopharmawatch.com/news/DRIO/new-research-from-dariohealth-expands-evidence-that-personalized-interventions-impact-heal-drio-20210629monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-remote-patient-monitoring-selected-by-coastal-family-health-center-to-improve--drio-20210624monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-expands-footprint-in-musculoskeletal-sensor-technologies-with-the-upright-go-s-drio-20210616monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-be-added-to-russell-2000-and-3000-indexes-drio-20210615monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-releases-study-demonstrating-the-impact-of-personalized-digital-interventions--drio-20210604monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-participate-in-the-stifel-2021-virtual-cross-sector-insight-conference-drio-20210603monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-publishes-research-confirming-the-impact-of-a-digital-therapeutic-platform-and-drio-20210527monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-participate-in-the-virtual-18th-annual-craig-hallum-institutional-investor--drio-20210526monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-acquires-digital-behavioral-health-platform-wayforward-drio-20210518monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-first-quarter-2021-results-and-operational-highlights-drio-20210517monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-report-first-quarter-2021-results-on-monday-may-17-drio-20210510monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-present-at-the-fifth-international-vatican-conference-drio-20210506monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-partners-with-mediorbis-on-virtual-care-offering-for-diabetes-drio-20210420monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-fourth-quarter-and-full-year-2020-results-and-operational-highlights-drio-20210309monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-participation-in-stephens-virtual-best-ideas-conference-drio-20210305monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-study-examines-connection-between-personalization-and-sustained-behavior-chang-drio-20210302monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-report-fourth-quarter-and-full-year-2020-results-on-tuesday-march-9-drio-20210301monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-participation-in-the-cowen-41st-annual-healthcare-conference-drio-20210223monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-participate-in-10th-annual-svb-leerink-global-healthcare-conference-drio-20210219monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-hiring-of-leading-digital-health-innovator-as-senior-vice-president--drio-20210121monthly0.5https://www.biopharmawatch.com/news/DRIO/diabetes-and-behavioral-health-global-experts-join-dariohealth-scientific-advisory-board-e-drio-20210113monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-appoints-claudia-rimerman-kraut-as-vice-president-of-broker-and-consultant-par-drio-20210107monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-drio-20210105monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-agreement-with-presbyterian-medical-services-for-remote-patient-moni-drio-20201222monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-drio-20201124monthly0.5https://www.biopharmawatch.com/news/DRIO/new-dariohealth-study-shows-increased-digital-therapeutics-engagement-leads-to-marked-redu-drio-20201119monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-third-quarter-2020-results-drio-20201112monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-report-financial-results-for-the-third-quarter-2020-on-november-12-drio-20201104monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-inclusion-of-its-digital-therapeutics-platform-in-vitality-group-drio-20201013monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-and-hmc-healthworks-announce-partnership-agreement-drio-20200921monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-appoints-eric-milledge-as-chairman-of-its-newly-established-scientific-advisor-drio-20200916monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-poster-presentation-at-the-virtual-association-of-diabetes-care-and--drio-20200813monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-second-quarter-2020-results-drio-20200812monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-report-financial-results-for-the-second-quarter-2020-results-on-august-12-drio-20200807monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-28-6-million-private-placement-drio-20200731monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-enters-uk-remote-patient-monitoring-rpm-market-through-agreement-with-williams-drio-20200720monthly0.5https://www.biopharmawatch.com/news/DRIO/dennis-matheis-president-of-optima-health-a-multi-line-health-plan-with-more-than-850-000--drio-20200706monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-health-to-host-key-opinion-leader-call-on-digital-therapeutics-for-the-management-of-drio-20200618monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-participation-in-the-virtual-going-digital-behavioral-health-tech-su-drio-20200617monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-presents-new-studies-demonstrating-sustained-improvements-in-blood-glucose-and-drio-20200615monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-two-remote-patient-monitoring-rpm-agreements-and-commences-enrollmen-drio-20200611monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-first-quarter-2020-results-drio-20200512monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-self-test-blood-glucose-meters-can-now-be-utilized-within-hospitals-during-the-drio-20200506monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-report-financial-results-for-the-first-quarter-2020-results-on-may-12-drio-20200505monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-expands-offering-to-include-behavioral-health-drio-20200504monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-expands-remote-care-offering-with-integration-of-full-service-telemedicine-drio-20200429monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-key-new-hires-expanding-its-management-depth-in-the-employer-and-man-drio-20200326monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-diabetes-management-is-recognized-as-a-leading-application-for-children-young-people-drio-20200325monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-enters-into-a-partnership-with-vitality-to-accelerate-penetration-into-the-sel-drio-20200324monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-fourth-quarter-and-year-end-2019-results-drio-20200317monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-host-fourth-quarter-2019-conference-call-march-17-2020-drio-20200312monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-appoints-two-new-board-members-drio-20200305monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-digital-diabetes-management-system-is-now-available-at-albertsons-drio-20200224monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-presents-new-clinical-study-outcomes-showing-the-dario-digital-therapeutics-pl-drio-20200219monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-drio-20200131monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-strengthens-management-team-with-appointment-of-digital-health-veteran-rick-an-drio-20200109monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-closing-of-21-3-million-private-placement-drio-20191220monthly0.5https://www.biopharmawatch.com/news/DRIO/walmart-starts-distributing-the-dariohealth-digital-diabetes-management-system-drio-20191203monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-introduces-membership-in-a-box-to-brick-and-mortar-retailers-drio-20191125monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-clinical-study-data-highlights-the-material-benefit-digital-interventions-have-drio-20191115monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-corp-ceo-erez-raphael-invited-to-participate-in-btig-digital-health-2019-drio-20191114monthly0.5https://www.biopharmawatch.com/news/DRIO/action-urgent-care-selects-mydario-drio-20191112monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-results-for-third-quarter-2019-drio-20191028monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-appoints-digital-therapeutics-pioneer-dr-abigail-hirsch-to-its-advisory-board--drio-20191022monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-host-third-quarter-2019-conference-call-october-28-2019-drio-20191017monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-ceo-erez-raphael-presents-to-digital-therapeutics-leaders-at-dtx-east-2019-drio-20190923monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-awarded-u-s-patent-for-optical-transmission-of-data-between-a-sensor-and-smart-drio-20190918monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-present-at-rhk-capital-disruptive-growth-conference-on-thursday-september-5-drio-20190828monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-alliance-with-digitalhealth-london-as-part-of-the-uk-israel-dangoor--drio-20190815monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-results-for-second-quarter-2019-drio-20190813monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-clinical-study-data-shows-the-dario-membership-program-assists-diabetes-patien-drio-20190812monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-host-second-quarter-2019-conference-call-august-13-2019-drio-20190807monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-present-new-data-at-aade-conference-that-shows-improvement-of-type-2-diabet-drio-20190806monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-launches-new-blood-pressure-monitoring-system-drio-20190730monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-usb-type-c-connector-for-the-european-android-market-is-ce-marked-drio-20190725monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-bid-price-rule-drio-20190708monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-improvement-in-glycemic-outcomes-with-key-diabetes-findings-at-the-ame-drio-20190611monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-signs-new-functional-medicine-clinic-to-its-digital-diabetes-platform-drio-20190604monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-present-new-evidence-of-digital-therapeutics-benefits-at-2019-american-diab-drio-20190529monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-corp-announces-pricing-of-7-2-million-public-offering-of-common-stock-drio-20190522monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-corp-announces-commencement-of-public-offering-of-common-stock-drio-20190521monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-record-results-for-first-quarter-2019-drio-20190513monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-host-first-quarter-2019-conference-call-may-13-2019-drio-20190507monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-new-partnership-with-the-american-diabetes-association-drio-20190503monthly0.5https://www.biopharmawatch.com/news/DRIO/darior-becomes-a-member-of-the-digital-therapeutics-alliance-drio-20190430monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-elevates-digital-therapeutics-capabilities-by-further-enhancing-patient-experience-drio-20190410monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-signs-leading-functional-medicine-clinic-to-darioengage-remote-digital-diabete-drio-20190401monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-partners-with-glytec-on-outpatient-diabetes-management-drio-20190327monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-fourth-quarter-and-year-end-2018-record-results-drio-20190325monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-granted-license-by-health-canada-to-sell-dario-smart-glucose-meters-for-lightn-drio-20190320monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-host-fourth-quarter-and-year-end-2018-conference-call-march-25-2019-drio-20190318monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-signs-national-distribution-deal-in-the-u-s-with-better-living-now-for-its-dig-drio-20190102monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-offer-diabetes-content-and-coaching-to-patients-in-canada-in-collaboration--drio-20181212monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-drio-20181114monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-third-quarter-2018-results-drio-20181113monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-drio-20181112monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-host-third-quarter-2018-conference-call-on-november-13-2018-drio-20181106monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-launches-integrated-diabetes-digital-health-solution-including-version-4-1-of--drio-20181025monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-drio-20181023monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-appoints-glen-d-moller-healthcare-executive-investor-and-former-ceo-of-arrohea-drio-20181018monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-host-investor-conference-call-on-october-4-2018-drio-20180920monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-closes-on-10-345-000-through-private-placement-offering-drio-20180914monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-appoints-olivier-jarry-former-head-of-diabetes-care-at-bayer-and-executive-at--drio-20180905monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-chosen-by-attain-health-for-pilot-study-to-improve-cystic-fibrosis-related-dia-drio-20180822monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-exhibit-at-american-association-of-diabetes-educators-conference-on-august--drio-20180815monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-second-quarter-2018-results-drio-20180809monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-host-second-quarter-2018-conference-call-on-august-9-2018-drio-20180801monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-launches-new-annual-membership-product-enhancements-to-promote-long-term-use-h-drio-20180725monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-ceo-erez-raphael-drio-20180712monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-appoints-healthcare-technology-entrepreneur-and-venture-capital-partner-yoav-s-drio-20180709monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-presents-new-data-at-american-diabetes-association-drio-20180625monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-deliver-three-poster-presentations-with-new-data-at-american-diabetes-assoc-drio-20180621monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-set-to-join-russell-microcap-index-effective-june-25-2018-drio-20180619monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-provides-update-on-recently-launched-iphone-7-8-and-x-smart-glucose-meter-in-t-drio-20180607monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-present-at-chardan-drio-20180521monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-first-quarter-2018-results-drio-20180515monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-releases-next-generation-version-4-0-of-its-award-winning-app-drio-20180508monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-host-first-quarter-2018-conference-call-on-may-15-2018-drio-20180502monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-ramps-up-commercialization-capabilities-drio-20180430monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-launches-customer-hotline-to-pre-order-its-apple-iphone-lightning-compatible-g-drio-20180329monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-receives-u-s-fda-clearance-for-iphone-7-8-and-iphone-x-smart-glucose-meter-drio-20180326monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-fourth-quarter-and-year-end-2017-results-drio-20180319monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-revised-date-for-fourth-quarter-and-year-end-2017-conference-call-drio-20180314monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-host-fourth-quarter-and-year-end-2017-conference-call-on-march-20-2018-drio-20180308monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-presents-dario-engage-vision-at-the-himss-annual-conference-exhibition-drio-20180305monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-launches-sales-of-dario-blood-glucose-monitoring-system-on-amazon-prime-drio-20180220monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-partners-with-a-leading-diabetes-clinic-drio-20180212monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-wins-key-contract-ensuring-its-platform-to-be-utilized-in-clinical-study-drio-20180208monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-introduces-iphone-7-iphone-8-and-iphone-x-compatible-smart-glucose-meter-to-th-drio-20180117monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-begins-selling-iphone-7-iphone-8-and-iphone-x-smart-glucose-meter-in-the-u-k-drio-20180108monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-granted-another-u-s-patent-strengthening-its-core-technology-drio-20171227monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-gains-regulatory-approval-in-australia-for-iphone-7-iphone-8-and-iphone-x-smar-drio-20171218monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-launches-version-3-5-of-its-mydario-app-to-support-iphone-7-and-iphone-8-drio-20171120monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-third-quarter-2017-results-drio-20171114monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-host-third-quarter-conference-call-on-november-14-2017-drio-20171106monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-expanding-its-mobile-health-and-data-offerings-to-include-a-business-to-busine-drio-20171030monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-gains-ce-mark-for-iphone-7-and-iphone-8-smart-glucose-meter-drio-20171018monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-launches-into-the-german-diabetes-market-drio-20171003monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-drio-20170927monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-launches-its-dario-app-in-the-google-play-store-expanding-its-u-s-market-reach-drio-20170907monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-closes-on-5-million-through-private-placement-offerings-drio-20170823monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-second-quarter-2017-results-drio-20170814monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-host-second-quarter-conference-call-on-august-14-2017-drio-20170811monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-partners-with-byram-healthcare-to-further-expand-insurance-health-coverage-for-drio-20170725monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-looks-to-accelerate-market-penetration-with-expanded-health-insurance-coverage-drio-20170621monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-launching-new-social-initiative-at-ada-drio-20170605monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-present-at-the-7th-annual-ld-micro-invitational-drio-20170530monthly0.5https://www.biopharmawatch.com/news/DRIO/lazier-racing-partners-teams-up-with-dariohealth-for-the-indy-500-drio-20170524monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-adds-former-bayer-diabetes-executive-and-visionary-to-its-advisory-board-drio-20170517monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-first-quarter-2017-results-drio-20170515monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-host-first-quarter-conference-call-on-may-15-2017-drio-20170509monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-lowers-diabetes-healthcare-costs-in-canada-drio-20170504monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-expands-global-presence-with-direct-to-consumer-launch-in-the-u-k-drio-20170426monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-signs-nba-legend-dominique-wilkins-as-brand-ambassador-drio-20170419monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-corp-prices-offering-of-1-450-000-shares-of-common-stock-drio-20170331monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-corp-announces-proposed-public-offering-of-common-stock-drio-20170330monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-launches-insurance-coverage-option-for-u-s-consumers-drio-20170327monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-fourth-quarter-and-year-end-2016-results-drio-20170322monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-host-fourth-quarter-and-year-end-2016-conference-call-on-march-23-2017-drio-20170320monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-corp-strengthens-board-of-directors-with-two-additional-appointments-drio-20170302monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-present-at-the-ourcrowd-global-investor-summit-drio-20170208monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-corp-presentation-now-available-for-on-demand-viewing-drio-20170206monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-corp-to-webcast-live-at-virtualinvestorconferences-com-february-2-drio-20170130monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-accelerates-u-s-device-sales-and-consumable-strips-growth-in-fourth-quarter-drio-20170123monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-corp-announces-5-1-million-private-placement-led-by-ourcrowd-qure-israeli-digi-drio-20170112monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-third-quarter-2016-results-drio-20161110monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-to-host-third-quarter-2016-conference-call-on-november-11-2016-drio-20161107monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-successful-traction-for-dario-drio-20161025monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-launches-new-digital-platform-and-online-store-in-canada-drio-20160927monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-preps-for-new-iphone-drio-20160908monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-second-quarter-2016-results-drio-20160811monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-is-now-direct-to-consumer-in-australia-drio-20160728monthly0.5https://www.biopharmawatch.com/news/BON/bon-announces-breakthrough-development-of-apple-bio-electronic-mask-clinical-data-exceeds--bon-20260219monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-announces-record-first-half-year-revenue-and-net-income-bon-20220801monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-announces-2022-half-year-earnings-release-date-and-webcast-bon-20220728monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-introduces-new-powder-drink-for-anti-h-pylori-and-digestive-healt-bon-20220616monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-advances-towards-near-term-production-and-completes-building-cons-bon-20220505monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-adds-new-multi-functional-health-supplements-to-product-line-bon-20220421monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-announces-record-setting-full-fiscal-year-2021-results-bon-20220202monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-announces-fy2021-earnings-release-date-and-webcast-bon-20220128monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-received-initial-purchase-order-for-its-stachyose-and-apple-extra-bon-20220112monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-announces-corporate-reorganization-and-removal-of-vie-structure-bon-20211109monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-announces-strategic-cooperation-with-chongqing-jingfubao-to-penet-bon-20210909monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-announces-record-first-half-year-revenue-and-net-income-bon-20210817monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-announces-2021-half-year-earnings-release-date-and-webcast-bon-20210812monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-breaks-ground-on-its-third-production-facility-in-yumen-bon-20210729monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-presentations-at-upcoming-medical-meetings-calc-20250417monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-to-participate-in-the-jones-healthcare-and-technology-innovation-conference-calc-20250401monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-upcoming-plenary-presentation-at-the-30th-international-aki-crrt-con-calc-20250219monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-confere-calc-20250203monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-appointment-of-dr-alan-glicklich-to-board-of-directors-calc-20250114monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference-calc-20241121monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-presentations-at-upcoming-medical-meetings-calc-20241120monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-strengthens-leadership-team-with-appointment-of-stephen-bardin-as-chief-financ-calc-20241107monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-to-host-a-call-to-review-full-data-set-including-a-win-ratio-analysis-from-pha-calc-20241028monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-upcoming-late-breaker-plenary-presentation-at-the-american-college-o-calc-20241016monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-calc-20240903monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-first-patient-enrolled-in-phase-2-kourage-trial-of-auxora-in-severe--calc-20240709monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-presentations-at-two-upcoming-healthcare-investment-conferences-calc-20240708monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-set-to-join-russell-microcap-index-calc-20240701monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-to-host-conference-call-to-review-topline-data-from-phase-2b-carpo-trial-of-au-calc-20240626monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-upcoming-presentation-at-digestive-disease-week-2024-calc-20240507monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-last-patient-enrolled-in-phase-2b-carpo-trial-of-auxora-in-acute-pan-calc-20240424monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-presents-data-from-preclinical-studies-of-auxora-in-acute-kidney-injury-at-the-calc-20240313monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-presentation-of-data-from-a-preclinical-study-of-auxora-in-acute-kid-calc-20240228monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-fda-clearance-of-ind-application-for-phase-2-trial-of-auxora-for-the-calc-20240213monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-to-present-at-the-oppenheimer-34th-annual-healthcare-life-sciences-conference-calc-20240207monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-collaborator-st-jude-children-calc-20231211monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-to-present-results-of-pd-pk-study-in-acute-pancreatitis-patients-for-its-crac--calc-20191107monthly0.5https://www.biopharmawatch.com/news/CALC/henry-ford-hospital-physician-presents-results-from-the-initial-patient-study-of-calcimedi-calc-20191030monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-names-life-science-veteran-to-its-board-of-directors-calc-20190326monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-inc-to-present-study-population-profile-from-its-initial-patient-study-of-its--calc-20190319monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-doses-first-patients-in-acute-pancreatitis-clinical-study-calc-20180801monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-names-two-senior-executives-to-its-board-of-directors-calc-20180501monthly0.5https://www.biopharmawatch.com/news/CALC/research-collaboration-between-the-san-francisco-va-ucsf-and-calcimedica-inc-to-present-re-calc-20180124monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-receives-fast-track-designation-for-cm4620-a-novel-crac-channel-inhibitor-to-t-calc-20170524monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-initiates-phase-1-clinical-studies-for-crac-channel-inhibitor-calc-20170106monthly0.5https://www.biopharmawatch.com/news/CALC/san-francisco-va-ucsf-and-calcimedica-inc-present-results-on-crac-channel-inhibitors-in-tr-calc-20161115monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-senior-clinical-development-hire-calc-20161114monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-inc-and-the-university-of-liverpool-announce-publication-on-crac-channel-inhib-calc-20150724monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-publication-of-preclinical-data-supporting-therapeutic-po-rnaz-20260106monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-and-quantum-leap-healthcare-collaborative-launch-a-phase-2a-dose-ex-rnaz-20251211monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-1-for-28-reverse-stock-split-rnaz-20250502monthly0.5https://www.biopharmawatch.com/news/RNAZ/an-open-letter-to-shareholders-of-transcode-therapeutics-inc-asking-stockholders-to-vote-f-rnaz-20250416monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-initial-dosing-in-fourth-cohort-of-phase-1-clinical-trial-rnaz-20250327monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-inc-announces-closing-of-registered-direct-offering-rnaz-20250325monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-inc-announces-registered-direct-offering-priced-at-the-market-under-rnaz-20250323monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-safety-review-committee-approval-to-open-fourth-cohort-in-rnaz-20250313monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-inc-announces-results-of-special-meeting-rnaz-20250225monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-completion-of-cohort-3-initial-dosing-with-lead-candidate-rnaz-20250206monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-inc-announces-adjournment-of-special-meeting-and-information-for-ad-rnaz-20250204monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-first-patient-dosed-in-third-cohort-with-lead-candidate-i-rnaz-20250114monthly0.5https://www.biopharmawatch.com/news/RNAZ/nasdaq-determines-that-transcode-therapeutics-has-regained-compliance-with-continued-listi-rnaz-20250107monthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-safety-review-committee-approval-of-opening-third-cohort--rnaz-20241218monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-invited-to-present-at-stop-tb-partnership-summit-in-washington-d-c-codx-20260416monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-to-showcase-co-dx-pcr-platform-and-ce-ivd-solutions-at-escmid-2026-in-munic-codx-20260414monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-executives-to-participate-in-european-trade-mission-with-utah-governor-and--codx-20260409monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-to-present-at-medical-korea-2026-codx-20260316monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-regains-compliance-with-nasdaq-listing-requirements-codx-20260310monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-to-showcase-pcr-platform-at-world-health-expo-labs-dubai-codx-20260209monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-joint-venture-cosara-receives-cdsco-license-to-manufacture-and-sell-cosara--codx-20260205monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-jv-cosara-receives-iso-13485-certification-in-preparation-for-manufacturing-codx-20260204monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-joint-venture-cosara-invited-to-participate-in-2nd-advanced-tb-diagnostics--codx-20251218monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-closing-of-7-0-million-registered-direct-offering-of-common-s-codx-20251029monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-signs-definitive-agreement-with-arabian-eagle-in-the-kingdom-of-saudi-arabi-codx-20251027monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-executive-leadership-team-to-attend-global-health-exhibition-2025-in-riyadh-codx-20251022monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-announces-development-of-proprietary-sample-prep-instrument-for-poc-testing-codx-20251016monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-attend-2025-maxim-growth-summit-codx-20251013monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-closing-of-3-8-million-registered-direct-offering-of-common-s-codx-20250918monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-signs-strategic-mou-with-partner-in-kingdom-of-saudi-arabia-to-introduc-codx-20250916monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-performs-analysis-of-chikungunya-co-primers-to-confirm-reactivity-again-codx-20250911monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-honored-at-utah-business-2025-innovation-awards-summit-codx-20250909monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-17th-next-generation-dx-summit-in-washington-d-c-codx-20250818monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-second-quarter-2025-earnings-release-date-and-webcast-codx-20250731monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-whx-kuala-lumpur-on-july-16-18-2025-codx-20250715monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-fourth-quarter-and-full-year-2024-earnings-release-date-and-w-codx-20250313monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-wins-dismissal-of-class-action-lawsuit-codx-20250306monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-and-cosara-to-host-hpv-and-cancer-symposium-on-international-hpv-day-20-codx-20250303monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-exhibit-at-bioutah-codx-20250130monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-participate-at-the-nasdaq-live-from-marketsite-broadcast-at-silicon--codx-20250107monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-and-cosara-diagnostics-to-inaugurate-new-oligo-facility-codx-20241210monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-medica-trade-fair-in-du-sseldorf-germany-on-nov-11-14--codx-20241105monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-third-quarter-2024-earnings-release-date-and-webcast-codx-20241025monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-medlab-africa-in-cape-town-on-oct-22-24-2024-codx-20241021monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-the-2024-uhca-ucal-fall-convention-expo-on-oct-2-3-codx-20241002monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-accompany-utah-governor-and-wtc-utah-on-trade-mission-to-south-korea-codx-20240924monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-completes-updated-clade-ib-analysis-of-2-gene-mpox-ruo-test-codx-20240905monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-present-at-16th-next-generation-dx-summit-in-washington-d-c-codx-20240815monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-and-discuss-advancing-poc-otc-diagnostics-at-adlm-2024-in-codx-20240729monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-second-quarter-2024-earnings-release-date-and-webcast-codx-20240725monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-expands-vector-control-customer-base-to-25-customers-across-15-u-s-stat-codx-20240702monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-participate-at-fime-2024-in-miami-beach-june-19-21-codx-20240618monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-first-quarter-2024-earnings-release-date-and-webcast-codx-20240425monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-and-deliver-presentation-at-aprc-2024-in-taiwan-codx-20240424monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-inaugurates-new-manufacturing-facility-in-utah-with-ribbon-cutting-even-codx-20240412monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-appoints-new-president-and-other-c-level-positions-codx-20240404monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-ceo-delivers-manufacturing-and-commercialization-update-in-conference-k-codx-20240321monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-ceo-to-deliver-keynote-address-at-marketsandmarkets-2024-in-london-engl-codx-20240318monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-jv-cosara-receives-clearance-from-indian-regulators-for-influenza-multi-codx-20240307monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-fourth-quarter-and-full-year-2023-earnings-release-date-and-w-codx-20240229monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-shares-list-of-upcoming-industry-conferences-and-events-for-february-20-codx-20240201monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-ces-2024-january-9-12-codx-20240103monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-completes-submission-to-fda-for-co-dx-pcr-pro-codx-20231227monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-participate-in-the-piper-sandler-35th-annual-healthcare-conference-i-codx-20231129monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-additional-grant-award-for-tuberculosis-test-in-development-codx-20231102monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-shares-list-of-upcoming-industry-conferences-and-events-for-november-20-codx-20231031monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-third-quarter-2023-earnings-release-date-and-webcast-codx-20231026monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-casmet-symposium-october-23-25-codx-20231023monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-medlab-africa-2023-in-johannesburg-south-africa-codx-20231016monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-participate-in-the-2023-uhca-ucal-fall-convention-expo-on-sept-27-28-codx-20230927monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-participate-in-6th-actc-conference-in-skiathos-greece-codx-20230922monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-participate-in-gilmartin-group-annual-emerging-growth-showcase-on-se-codx-20230921monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conf-codx-20230907monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-appoints-chief-regulatory-affairs-officer-codx-20230829monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-present-at-15th-next-generation-dx-summit-in-washington-d-c-codx-20230818monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-medlab-asia-conference-in-bangkok-thailand-codx-20230816monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-second-quarter-2023-earnings-release-date-and-webcast-codx-20230727monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-and-discuss-recent-grant-awards-at-aacc-2023-in-anaheim-c-codx-20230720monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-recent-grant-awards-codx-20230718monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-awarded-funding-for-co-dx-pcr-home-platform-from-nih-radx-tech-program-codx-20230713monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-senior-living-executive-conference-in-new-orleans-la-codx-20230509monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-first-quarter-2023-earnings-release-date-and-webcast-codx-20230505monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-67th-annual-carpha-conference-april-27-29-codx-20230426monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-eccmid-2023-april-15-18-in-copenhagen-denmark-codx-20230413monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-ceo-to-deliver-keynote-address-at-2023-marketsandmarkets-conference--codx-20230321monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-10th-gene-quantification-event-in-munich-germany-march-codx-20230317monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-fourth-quarter-and-full-year-2022-earnings-release-date-and-w-codx-20230309monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-present-and-host-booth-at-tri-con-in-san-diego-ca-march-6-8-codx-20230302monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-89th-annual-amca-conference-in-reno-nv-on-feb-28-march-codx-20230228monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-initiates-clinical-evaluations-for-its-at-home-and-point-of-care-co-dx--codx-20230222monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-medlab-middle-east-2023-in-dubai-on-february-6-9-codx-20230202monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-commemorates-third-anniversary-of-the-completion-of-its-first-covid-19--codx-20230124monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-ces-2023-january-5-8-codx-20230105monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-present-at-the-piper-sandler-34th-annual-healthcare-conference-on-de-codx-20221130monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-medica-2022-trade-fair-in-du-sseldorf-germany-codx-20221114monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-amp-this-week-in-phoenix-az-codx-20221103monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-appoints-dr-mark-poritz-as-new-chief-scientific-officer-codx-20221101monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-third-quarter-2022-earnings-release-date-and-webcast-codx-20221027monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-medlab-africa-on-oct-26-28-in-south-africa-codx-20221026monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booths-at-conferences-in-washington-d-c-and-bangkok-thailand-codx-20221019monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-sponsor-present-and-host-booth-at-66th-annual-carpha-conference-on-s-codx-20220914monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conf-codx-20220912monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-medical-fair-asia-2022-in-singapore-on-aug-31-sep-2-codx-20220831monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-present-at-14th-next-generation-dx-summit-in-washington-d-c-codx-20220822monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-second-quarter-2022-earnings-release-date-and-webcast-codx-20220802monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-participate-in-yale-university-salivadirect-conference-held-july-28--codx-20220727monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-announce-expansion-of-oem-agreement-with-bio-molecular-systems-at-aa-codx-20220726monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-aacc-held-july-24-28-in-chicago-codx-20220720monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-shipment-of-monkeypox-virus-test-codx-20220711monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-present-at-29th-international-biodetection-technologies-virtual-conf-codx-20220628monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-present-at-sidoti-summer-small-cap-virtual-conference-codx-20220615monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-medexpo-africa-2022-in-nairobi-kenya-on-june-9-11-codx-20220609monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-completes-principal-design-of-test-for-monkeypox-virus-codx-20220526monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-participate-in-the-h-c-wainwright-2022-global-investment-conference--codx-20220519monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-medical-fair-brasil-2022-in-sa-o-paulo-on-may-3-6-codx-20220503monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-first-quarter-2022-earnings-release-date-and-webcast-codx-20220428monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-eccmid-2022-in-lisbon-portugal-on-april-23-26-codx-20220422monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-jv-cosara-receives-clearance-from-indian-regulators-for-hepatitis-c-vir-codx-20220419monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-present-at-marketsandmarkets-conference-on-march-23-24-in-london-eng-codx-20220322monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-makes-strategic-additions-to-scientific-advisory-board-codx-20220317monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-fourth-quarter-and-full-year-2021-earnings-release-date-and-w-codx-20220314monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-sponsor-and-present-at-molecular-med-tri-con-2022-codx-20220217monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-life-sciences-day-on-the-hill-on-february-16-at-the-ut-codx-20220210monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-jv-cosara-receives-clearance-from-indian-regulators-for-hepatitis-b-vir-codx-20220203monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-medlab-middle-east-2022-in-dubai-on-january-24-27-codx-20220121monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-jv-cosara-receives-clearance-from-indian-regulators-for-high-risk-hpv-m-codx-20220113monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-participate-in-the-h-c-wainwright-2022-bioconnect-virtual-conference-codx-20220110monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-completion-of-the-acquisition-of-all-assets-and-intellectual--codx-20211231monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-jv-cosara-receives-clearance-from-indian-regulators-for-abc-multiplex-test-codx-20211207monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-reports-that-suite-of-covid-19-diagnostics-not-affected-by-heavily-muta-codx-20211129monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-host-booth-at-medica-2021-trade-fair-in-du-sseldorf-germany-codx-20211115monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-logix-smart-covid-19-2-gene-test-approved-for-use-in-the-united-kingdom-codx-20211104monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-third-quarter-2021-earnings-release-date-and-webcast-codx-20211028monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-jv-cosara-receives-clearance-from-indian-regulators-for-dengue-chikungunya--codx-20211006monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-introduce-at-home-point-of-care-device-at-aacc-on-sept-28-codx-20210927monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-corporate-rebranding-following-period-of-transformative-growt-codx-20210923monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-present-at-actc-liquid-biopsy-conference-in-kalamata-greece-codx-20210921monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-logix-smart-abc-test-authorized-for-use-in-mexico-codx-20210921monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-present-at-sidoti-virtual-investor-conference-codx-20210920monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-jv-cosara-receives-clearance-from-indian-fda-for-chikungunya-and-dengue-tes-codx-20210916monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-ceo-to-participate-in-panel-discussion-with-scott-gottlieb-m-d-at-h-c-w-codx-20210913monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-sars-cov-2-test-used-in-new-community-surveillance-method-in-italy-codx-20210908monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-present-at-13th-next-generation-dx-summit-in-washington-d-c-codx-20210823monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-second-quarter-2021-earnings-release-date-and-webcast-codx-20210804monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-strengthens-intellectual-property-portfolio-with-new-international-copr-codx-20210722monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-receives-ce-marking-for-direct-saliva-sars-cov-2-test-codx-20210618monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-present-at-upcoming-technology-and-health-research-conferences-codx-20210615monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-first-quarter-2021-earnings-release-date-and-webcast-codx-20210504monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-and-partner-crl-to-discuss-saliva-testing-and-future-applications-of-pc-codx-20210429monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-jv-cosara-diagnostics-recognized-for-work-combating-covid-19-surge-in-i-codx-20210428monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-test-performance-demonstrated-by-australian-researchers-in-peer-reviewe-codx-20210420monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-ceo-discusses-company-strategy-for-the-future-with-yahoo-finance-codx-20210331monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-fourth-quarter-and-full-year-2020-earnings-release-date-and-w-codx-20210318monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-invited-to-present-at-maxim-group-llc-emerging-growth-virtual-conference-codx-20210316monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-to-present-point-of-care-and-at-home-testing-platform-at-infectious-disease-codx-20210310monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-to-discuss-recent-company-advances-at-h-c-wainwright-global-life-sciences-v-codx-20210308monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-new-rapid-pcr-point-of-care-and-at-home-testing-platform-to-detect-covid-19-codx-20210302monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-partner-to-offer-at-home-saliva-collection-kits-for-coprimer-based-covi-codx-20210225monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-new-chief-financial-officer-codx-20210223monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-present-on-direct-saliva-testing-technology-at-molecular-med-tri-con-codx-20210216monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-completes-fda-eua-submission-for-extraction-free-saliva-covid-19-test-codx-20210128monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-to-present-at-h-c-wainwright-bioconnect-2021-virtual-conference-codx-20210107monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-designs-test-to-detect-mutations-for-new-coronavirus-strain-using-coprimer--codx-20201222monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-announces-milestone-of-over-10-million-covid-19-tests-sold-codx-20201214monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-jv-cosara-receives-clearance-from-indian-fda-for-covid-19-2-gene-multiplex--codx-20201125monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-receives-ce-markings-for-abc-and-sars-cov-2-2-gene-multiplex-tests-codx-20201117monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-coprimers-shown-to-be-effective-in-covid-19-saliva-pcr-tests-without-sa-codx-20201111monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-q3-2020-earnings-release-date-and-earnings-webcast-codx-20201110monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-logix-smart-kit-to-be-used-with-newly-authorized-saline-oral-rinse-coll-codx-20201002monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-provides-update-on-abc-test-for-influenza-a-influenza-b-and-covid-19-codx-20200924monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-details-to-access-presentation-at-h-c-wainwright-global-inves-codx-20200911monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-enters-into-agreement-with-arches-research-to-expand-covid-19-testing-s-codx-20200908monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-issues-operational-update-codx-20200901monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-discuss-recent-company-growth-and-upcoming-expansion-plans-at-h-c-wa-codx-20200825monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-receives-enhanced-u-s-patent-protection-for-coprimer-technology-used-in-codx-20200820monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-q2-2020-results-on-form-10-q-codx-20200813monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-q2-2020-earnings-release-date-and-earnings-webcast-codx-20200811monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-logix-smart-covid-19-test-authorized-for-use-in-australia-codx-20200807monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-technology-to-be-used-in-fda-authorized-self-collected-covid-19-saliva--codx-20200803monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-join-russell-2000-and-russell-3000-indexes-codx-20200609monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-present-at-covid-19-virtual-conference-hosted-by-maxim-group-on-may--codx-20200527monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-covid-19-test-successfully-used-to-identify-coronavirus-in-cancer-tissu-codx-20200526monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-releases-prepared-remarks-for-first-quarter-2020-conference-call-codx-20200514monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-q1-2020-earnings-release-date-and-earnings-call-codx-20200512monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-government-approvals-and-increased-orders-for-covid-19-test-k-codx-20200504monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-releases-covid-19-test-performance-data-consistently-demonstrates-100-s-codx-20200501monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-expansion-of-covid-19-test-orders-in-the-united-states-codx-20200420monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-covid-19-test-technology-validated-for-use-on-saliva-samples-codx-20200416monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-contracts-with-promega-corp-for-covid-19-test-manufacturing-as-company--codx-20200414monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-receives-fda-emergency-use-authorization-for-covid-19-test-codx-20200406monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-presents-data-at-obesityweek-2025-highlighting-promise-of-melanocortin-based-thera-ptn-20251106monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-1-for-50-reverse-stock-split-ptn-20250808monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-positive-preclinical-efficacy-data-for-oral-mc4r-agonist-pl7737-in-anima-ptn-20250715monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-reports-fiscal-year-2025-third-quarter-results-and-business-update-ptn-20250514monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-presents-promising-preclinical-data-on-melanocortin-agonists-for-retinopathy-at-ar-ptn-20250509monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-closing-of-reduced-public-offering-ptn-20250508monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-presents-breakthrough-symptom-resolution-data-from-phase-3-pl9643-melody-1-clinica-ptn-20250508monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-expects-11-5-million-financing-to-cure-nyse-american-delisting-notice-ptn-20250507monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-pricing-of-up-to-23-million-public-offering-ptn-20250507monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-presents-promising-preclinical-data-for-melanocortin-agonist-pl9588-at-arvo-2025-h-ptn-20250505monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-breakthrough-symptom-resolution-in-updated-analyses-from-phase-3-pl9643--ptn-20250429monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-reports-positive-appetite-suppression-results-from-phase-2-obesity-study-of-mc4r-a-ptn-20250417monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-appeals-nyse-american-notice-of-delisting-ptn-20250414monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-present-positive-phase-2b-data-for-melanocortin-agonist-in-diabetic-kidney-dise-ptn-20250410monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-mc4r-agonist-bremelanotide-co-administered-with-glp-1-gip-tirzepatide-me-ptn-20250331monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-s-oral-mc4r-agonist-pl7737-receives-fda-orphan-drug-designation-for-obesity-due-to-ptn-20250325monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-reports-second-quarter-fiscal-year-2025-financial-results-and-provides-business-up-ptn-20250213monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-report-second-quarter-fiscal-year-2025-results-teleconference-and-webcast-to-be-ptn-20250210monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-completes-phase-2-obesity-study-with-mc4r-bremelanotide-plus-glp-1-gip-tirzepatide-ptn-20250206monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-provides-update-on-anticipated-2025-corporate-milestones-ptn-20250128monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-positive-phase-iib-breakout-study-results-in-patients-with-type-2-diabet-ptn-20241219monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-completion-of-patient-enrollment-in-phase-2-study-of-orally-administered-ptn-20241125monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-report-first-quarter-fiscal-year-2025-results-teleconference-and-webcast-to-be--ptn-20241108monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-presents-data-on-novel-melanocortin-4-receptor-selective-oral-small-molecule-pl773-ptn-20241104monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-completes-enrollment-in-phase-2-clinical-study-of-bremelanotide-mc4r-agonist-co-ad-ptn-20241031monthly0.5https://www.biopharmawatch.com/news/PTN/inflammatory-disease-healing-data-via-palatin-ptn-20241024monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-presents-foundational-data-on-novel-and-highly-selective-melanocortin-4-receptor-a-ptn-20241023monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-report-fourth-quarter-and-fiscal-year-end-2024-results-ptn-20240926monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-provides-update-on-clinical-programs-strategic-priorities-and-anticipated-mileston-ptn-20240909monthly0.5https://www.biopharmawatch.com/news/PTN/fda-confirms-acceptability-of-palatin-ptn-20240828monthly0.5https://www.biopharmawatch.com/news/PTN/first-patient-dosed-in-phase-2-clinical-study-of-palatin-ptn-20240822monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-the-initiation-of-a-phase-2-clinical-study-of-bremelanotide-co-administe-ptn-20240620monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-initiates-phase-2-clinical-study-of-bremelanotide-for-the-treatment-of-obesity-ptn-20240612monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-report-third-quarter-fiscal-year-2024-results-teleconference-and-webcast-to-be--ptn-20240509monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-fda-clearance-of-ind-application-for-the-co-administration-of-bremelanot-ptn-20240502monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-host-virtual-kol-event-beyond-glps-the-multiple-roles-for-novel-melanocortin-re-ptn-20240430monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-phase-3-pl9643-melody-1-dry-eye-disease-ded-clinical-data-results-presen-ptn-20240408monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-results-of-pl9643-melody-1-pivotal-phase-3-clinical-trial-in-patients-wi-ptn-20240228monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-report-second-quarter-fiscal-year-2024-results-teleconference-and-webcast-to-be-ptn-20240209monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-database-lock-for-pl9643-melody-1-pivotal-phase-3-clinical-trial-in-pati-ptn-20240205monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-closing-of-10-million-registered-direct-offering-ptn-20240201monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-provides-corporate-update-and-highlights-strategic-priorities-for-calendar-year-20-ptn-20240108monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-report-first-quarter-fiscal-year-2024-results-teleconference-and-webcast-to-be--ptn-20231109monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-closing-of-5-million-registered-direct-offering-ptn-20231024monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-5-million-registered-direct-offering-ptn-20231023monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-preliminary-quarter-ended-september-30-2023-vyleesi-product-revenue-resu-ptn-20231019monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-positive-preclinical-data-showing-synergistic-weight-loss-initiating-cli-ptn-20231018monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-presents-data-at-the-united-european-gastroenterology-week-2023-conference-on-pl81-ptn-20231016monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-report-fourth-quarter-and-fiscal-year-end-2023-results-teleconference-and-webca-ptn-20230922monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-ptn-20230907monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-s-vyleesi-licensee-fosun-pharma-reports-first-commercial-sale-in-china-and-south-k-ptn-20230808monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-participate-in-canaccord-genuity-ptn-20230804monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-presents-pl8177-ulcerative-colitis-data-at-digestive-disease-week-annual-conferenc-ptn-20230509monthly0.5https://www.biopharmawatch.com/news/PTN/pre-clinical-data-of-palatin-ptn-20230418monthly0.5https://www.biopharmawatch.com/news/PTN/frontiers-in-immunology-publishes-pre-clinical-study-of-palatin-ptn-20230302monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-issued-patent-on-vyleesi-bremelanotide-injection-for-hypoactive-sexual-desire-diso-ptn-20230228monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-report-second-quarter-fiscal-year-2023-results-teleconference-and-webcast-to-be-ptn-20230210monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-initiates-enrollment-in-the-phase-2-bremelanotide-breakout-study-in-patients-with--ptn-20230119monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-receives-4-7-million-of-non-dilutive-funding-ptn-20230118monthly0.5https://www.biopharmawatch.com/news/PTN/frontiers-in-immunology-publishes-pre-clinical-study-of-palatin-ptn-20230110monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-preliminary-second-quarter-fiscal-2023-vyleesi-product-sales-results-ptn-20230105monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-report-first-quarter-fiscal-year-2023-results-teleconference-and-webcast-to-be--ptn-20221109monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-presents-pl8177-data-at-american-college-of-gastroenterology-annual-meeting-ptn-20221024monthly0.5https://www.biopharmawatch.com/news/PTN/first-patient-enrolled-in-palatin-ptn-20221020monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-publication-of-vyleesi-bremelanotide-fmri-study-in-women-with-hypoactive-ptn-20221017monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-preliminary-first-quarter-fiscal-2023-vyleesi-product-sales-results-ptn-20221013monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-presentation-at-the-eyecelerator-aao-2022-conference-ptn-20220929monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-participate-in-ladenburg-thalmann-healthcare-conference-ptn-20220929monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-report-fourth-quarter-and-fiscal-year-end-2022-results-teleconference-and-webca-ptn-20220919monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-initiation-of-patient-recruitment-for-phase-2-clinical-study-evaluating--ptn-20220908monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-intent-to-effect-reverse-stock-split-ptn-20220819monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-reports-positive-interim-analysis-in-phase-3-pivotal-study-of-pl9643-in-patients-w-ptn-20220816monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-preliminary-fourth-quarter-vyleesi-net-product-revenue-increased-225-ove-ptn-20220726monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-15-million-private-placement-of-convertible-redeemable-preferred-stock-ptn-20220512monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-report-third-quarter-fiscal-year-2022-results-teleconference-and-webcast-to-be--ptn-20220511monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-present-at-the-association-for-research-in-vision-and-ophthalmology-arvo-2022-a-ptn-20220502monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-present-at-eyecelerator-american-society-of-cataract-and-refractive-surgery-asc-ptn-20220421monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-hosting-key-opinion-leader-webinar-on-dry-eye-disease-ptn-20220303monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-report-second-quarter-fiscal-year-2022-results-teleconference-and-webcast-to-be-ptn-20220210monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-presentation-at-the-2022-crohn-ptn-20220121monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-present-at-h-c-wainwright-bioconnect-conference-ptn-20220107monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-initiation-of-pivotal-phase-3-pl9643-melody-1-clinical-trial-in-patients-ptn-20211228monthly0.5https://www.biopharmawatch.com/news/PTN/notice-of-allowance-issued-for-method-of-treating-cytokine-storm-using-melanocortin-specif-ptn-20211130monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-report-first-quarter-fiscal-year-2022-results-teleconference-and-webcast-to-be--ptn-20211110monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-awarded-top-10-poster-designation-at-the-american-society-of-retina-specialists-as-ptn-20211022monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-presentation-of-positive-protective-effects-of-pl8331-and-pl9654-on-reti-ptn-20210927monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-report-fourth-quarter-and-fiscal-year-end-2021-results-teleconference-and-webca-ptn-20210924monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-present-peptides-platform-at-the-tides-usa-conference-ptn-20210915monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-participate-in-h-c-wainwright-23rd-annual-global-investment-virtual-conference-ptn-20210913monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-presentation-at-the-eyecelerator-ascrs-conference-ptn-20210722monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-positive-end-of-phase-2-meeting-with-fda-on-pl9643-for-the-treatment-of--ptn-20210629monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-new-additions-to-its-senior-leadership-team-ptn-20210628monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-adjournment-of-annual-meeting-of-stockholders-ptn-20210610monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-hosting-key-opinion-leader-webinar-in-role-of-melanocortin-agonists-in-inflammatio-ptn-20210514monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-report-third-quarter-fiscal-year-2021-results-teleconference-and-webcast-to-be--ptn-20210513monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-u-s-patent-term-extension-for-vyleesi-bremelanotide-injection-ptn-20210504monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-two-presentations-at-the-2021-association-for-research-in-vision-and-oph-ptn-20210420monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-to-participate-in-h-c-wainwright-global-life-sciences-virtual-confere-ptn-20210305monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-second-quarter-fiscal-year-2021-financial-results-and-rec-ptn-20210217monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-second-quarter-fiscal-year-2021-results-teleconference--ptn-20210212monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-filing-of-international-patent-application-claiming-pl9643-ptn-20210210monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-positive-results-from-its-phase-2-study-of-pl9643-in-patien-ptn-20201215monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-first-quarter-fiscal-year-2021-results-teleconference-a-ptn-20201112monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-fourth-quarter-and-fiscal-year-end-2020-results-telecon-ptn-20200924monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-to-present-at-the-h-c-wainwright-co-22nd-annual-global-investment-con-ptn-20200910monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-participates-in-canaccord-genuity-ptn-20200813monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-announces-completion-of-enrollment-of-phase-2-study-with-pl9643-f-ptn-20200805monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-announces-reinitiation-of-enrollment-of-phase-2-study-with-pl9643-ptn-20200708monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-to-develop-pl8177-as-a-potential-treatment-for-covid-19-and-associate-ptn-20200623monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-third-quarter-fiscal-year-2020-results-teleconference-a-ptn-20200507monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-provides-assessment-of-impact-of-covid-19-pandemic-on-business-operat-ptn-20200430monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-announces-first-patient-enrolled-in-dry-eye-disease-phase-2-clini-ptn-20200219monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-second-quarter-fiscal-year-2020-results-teleconference--ptn-20200206monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-provides-corporate-update-and-2020-calendar-outlook-ptn-20200121monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-first-quarter-fiscal-year-2020-results-teleconference-a-ptn-20191107monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-presents-on-pl8177-oral-colon-delivery-formulation-for-ulcerative-colitis-at-the-7-ptn-20191017monthly0.5https://www.biopharmawatch.com/news/PTN/vyleesi-phase-3-data-to-be-presented-at-the-13th-european-society-of-gynecology-congress-ptn-20191016monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-fourth-quarter-fiscal-year-end-2019-results-teleconfere-ptn-20190911monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-to-present-at-canaccord-genuity-ptn-20190806monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-provides-mid-calendar-year-corporate-update-ptn-20190701monthly0.5https://www.biopharmawatch.com/news/PTN/fda-approves-new-drug-application-for-vyleesi-bremelanotide-injection-ptn-20190621monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-granted-fda-orphan-drug-designation-pl-8177-for-the-treatment-of-non--ptn-20190606monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-third-quarter-fiscal-year-2019-results-teleconference-a-ptn-20190503monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-positive-top-line-results-of-oral-clinical-study-of-pl-8177-ptn-20190404monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-second-fiscal-quarter-2019-results-and-provides-corporate-ptn-20190212monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-second-quarter-fiscal-year-2019-results-teleconference--ptn-20190206monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-announces-first-in-human-study-results-of-subcutaneous-administra-ptn-20181108monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-first-quarter-fiscal-year-2019-results-teleconference-a-ptn-20181107monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-fourth-quarter-and-fiscal-year-end-2018-results-telecon-ptn-20180907monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-added-to-russell-3000-index-ptn-20180625monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-fda-acceptance-for-review-of-bremelanotide-nda-ptn-20180604monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-third-quarter-fiscal-year-2018-results-teleconference-a-ptn-20180510monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-presents-positive-preclinical-mc1-receptor-agonist-data-at-tides-olig-ptn-20180509monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-presents-preclinical-oral-formulation-data-on-pl-8177-an-investigatio-ptn-20180403monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-second-quarter-fiscal-year-2018-results-teleconference--ptn-20180207monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-initiates-subject-dosing-in-first-in-human-clinical-study-of-pl-8-ptn-20180205monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-announces-fda-clearance-of-investigational-new-drug-ind-applicati-ptn-20180103monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-signing-of-licensing-agreement-with-kwangdong-pharmaceutica-ptn-20171121monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-first-quarter-fiscal-year-2018-results-teleconference-a-ptn-20171108monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-fourth-quarter-and-fiscal-year-end-2017-results-telecon-ptn-20170920monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-third-quarter-fiscal-year-2017-results-teleconference-a-ptn-20170511monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-receives-notice-of-allowance-on-bremelanotide-methods-of-use-patent-f-ptn-20170320monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-to-present-at-the-29th-annual-roth-conference-ptn-20170309monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-to-hold-call-following-closing-of-licensing-agreement-for-north-ameri-ptn-20170110monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-closes-on-16-5-million-financing-ptn-20161207monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-pricing-of-public-offering-of-common-stock-and-warrants-ptn-20161201monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-proposed-public-offering-of-common-stock-and-warrants-ptn-20161130monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-first-quarter-fiscal-year-2017-results-teleconference-a-ptn-20161110monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-presents-bremelanotide-neurobiology-and-treatment-efficacy-review-at--ptn-20160923monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-receives-audit-opinion-with-going-concern-explanation-ptn-20160923monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-fourth-quarter-fiscal-year-end-2016-results-teleconfere-ptn-20160914monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-to-present-at-the-36th-annual-canaccord-genuity-growth-conference-ptn-20160808monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-completion-of-all-patient-visits-in-phase-3-clinical-trials-ptn-20160804monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-closing-of-9-2-million-financing-ptn-20160804monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-9-25-million-financing-ptn-20160801monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-receives-patent-strengthening-its-melanocortin-peptide-intellectual-p-ptn-20160606monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-receives-patent-strengthening-its-melanocortin-peptide-intellectual-p-ptn-20160526monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-third-quarter-fiscal-year-2016-results-teleconference-and-ptn-20160517monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-third-quarter-fiscal-year-2016-results-ptn-20160512monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-presents-bremelanotide-alcohol-interaction-study-at-international-soc-ptn-20160226monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-second-quarter-fiscal-year-2016-results-ptn-20160210monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-strengthens-intellectual-property-surrounding-use-of-bremelanotide-fo-ptn-20160208monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-to-present-at-the-bio-ceo-investor-conference-ptn-20160204monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-achieves-target-patient-enrollment-in-pivotal-phase-3-studies-for-bre-ptn-20151210monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-first-quarter-fiscal-year-2016-results-teleconference-a-ptn-20151110monthly0.5https://www.biopharmawatch.com/news/PTN/preclinical-data-on-pl-3994-for-heart-failure-and-resistant-hypertension-presented-at-2015-ptn-20150928monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-and-richter-terminate-license-agreement-for-bremelanotide-for-female--ptn-20150921monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-fourth-quarter-fiscal-year-end-2015-results-ptn-20150916monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-supports-fda-ptn-20150818monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-completes-30-million-financing-ptn-20150706monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-supports-fda-advisory-committee-ptn-20150604monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-third-quarter-fiscal-year-2015-results-teleconference-and-ptn-20150513monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-third-quarter-fiscal-year-2015-results-ptn-20150508monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-to-present-at-the-27th-annual-roth-conference-ptn-20150306monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-launches-reconnectstudy-com-in-support-of-bremelanotide-phase-3-program-for-female-ptn-20150220monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-second-quarter-fiscal-year-2015-results-teleconference-an-ptn-20150213monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-second-quarter-fiscal-year-2015-results-teleconference--ptn-20150209monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-to-present-at-the-bio-ceo-investor-conference-ptn-20150206monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-start-of-bremelanotide-phase-3-program-for-female-sexual-dysfunction-ptn-20141229monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-first-quarter-fiscal-year-2015-results-teleconference-and-ptn-20141118monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-first-quarter-fiscal-year-2015-results-ptn-20141113monthly0.5https://www.biopharmawatch.com/news/PTN/survey-reveals-low-sexual-desire-disrupts-relationships-ptn-20141104monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-to-present-at-the-13th-annual-bio-investor-forum-ptn-20141008monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-fourth-quarter-and-fiscal-year-end-2014-results-ptn-20140909monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-fourth-quarter-and-fiscal-year-2014-results-ptn-20140904monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-licenses-bremelanotide-in-europe-and-other-selected-countries-to-rich-ptn-20140903monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-notification-of-patent-allowance-on-melanocortin-receptor-1-ptn-20140709monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-to-join-russell-microcap-index-ptn-20140627monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-notification-of-patent-allowance-on-next-generation-melanoc-ptn-20140610monthly0.5https://www.biopharmawatch.com/news/PTN/new-survey-reveals-that-low-sexual-desire-disrupts-relationships-ptn-20140520monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-third-quarter-fiscal-year-2014-results-teleconference-and-ptn-20140513monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-third-quarter-fiscal-year-2014-results-ptn-20140509monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-presents-at-the-annual-clinical-meeting-of-the-american-college-of-ob-ptn-20140429monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-option-extension-for-license-to-bremelanotide-in-europe-ptn-20140331monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-to-present-at-the-26th-annual-roth-conference-ptn-20140306monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-second-quarter-fiscal-year-2014-results-teleconference-an-ptn-20140218monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-second-quarter-fiscal-year-2014-results-ptn-20140213monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-to-present-at-the-16th-congress-of-the-european-society-for-sexual-me-ptn-20140130monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-receives-1-85-million-from-sale-of-new-jersey-state-tax-credits-ptn-20140123monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-responds-to-unusual-market-activity-ptn-20140113monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-to-participate-in-the-25th-annual-piper-jaffray-healthcare-conference-ptn-20131202monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-first-quarter-fiscal-year-2014-results-teleconference-and-ptn-20131114monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-option-for-license-to-bremelanotide-in-europe-ptn-20131113monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-issuance-of-two-natriuretic-peptide-receptor-specific-mimet-ptn-20131112monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-first-quarter-fiscal-year-2014-results-teleconference-a-ptn-20131111monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-reports-successful-completion-of-device-bioequivalence-trial-ptn-20131028monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-to-present-at-the-12th-annual-bio-investor-forum-ptn-20131004monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-fiscal-year-2013-fourth-quarter-results-ptn-20130925monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-third-quarter-fiscal-year-2013-results-and-update-on-develo-ptn-20130514monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-fiscal-year-2013-third-quarter-results-teleconference-a-ptn-20130508monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-notification-of-patent-allowance-on-melanocortin-receptor-s-ptn-20130502monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-notification-of-patent-allowance-on-melanocortin-receptor-1-ptn-20130319monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-to-present-at-the-25th-annual-roth-conference-ptn-20130315monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-second-quarter-fiscal-year-2013-results-teleconference-an-ptn-20130214monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-fiscal-year-2013-second-quarter-results-teleconference--ptn-20130208monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-present-at-15th-annual-bio-ceo-investor-conference-ptn-20130207monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-receives-1-75-million-from-sale-of-new-jersey-state-tax-credits-ptn-20130103monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-present-at-the-24th-annual-piper-jaffray-healthcare-conference-ptn-20121120monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-present-at-the-lazard-capital-markets-9th-annual-healthcare-co-ptn-20121112monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-fiscal-year-2013-first-quarter-results-teleconference-a-ptn-20121109monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-reports-positive-results-for-phase-2b-bremelanotide-female-sexual-dys-ptn-20121108monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-last-patient-completed-treatment-in-phase-2b-bremelanotide--ptn-20120910monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-provides-update-regarding-its-obesity-research-development-collaborat-ptn-20120907monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-fiscal-year-2012-fourth-quarter-results-teleconference--ptn-20120906monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-announces-pricing-of-35-million-private-placement-of-common-stock-ptn-20120702monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-halting-of-phase-i-clinical-trial-of-obesity-compound-in-as-ptn-20120619monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-third-quarter-fiscal-year-2012-results-teleconference-and-ptn-20120514monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-fiscal-year-2012-third-quarter-results-teleconference-a-ptn-20120508monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-completes-enrollment-in-phase-2b-bremelanotide-female-sexual-dysfunct-ptn-20120308monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-present-at-the-24th-annual-roth-oc-growth-stock-conference-ptn-20120307monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-second-quarter-fiscal-year-2012-results-teleconference-an-ptn-20120215monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-to-present-at-14th-annual-bio-ceo-investor-conference-ptn-20120209monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-fiscal-year-2012-second-quarter-results-teleconference--ptn-20120208monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-receives-1-1-million-from-sale-of-new-jersey-state-tax-credits-ptn-20120117monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-to-present-at-bocemb-noble-financial-capital-markets-ptn-20120116monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-to-present-at-windhover-ptn-20111130monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-fiscal-year-2012-first-quarter-results-teleconference-a-ptn-20111110monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-fourth-quarter-and-fiscal-year-end-2011-results-ptn-20110922monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-fiscal-year-2011-fourth-quarter-results-teleconference--ptn-20110919monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-present-at-the-rodman-renshaw-annual-global-investment-confere-ptn-20110909monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-commencement-of-a-phase-1-trial-for-obesity-compound-in-collaboration-wi-ptn-20110804monthly0.5https://www.biopharmawatch.com/news/PTN/alan-dunton-m-d-joins-board-of-directors-of-palatin-technologies-inc-ptn-20110623monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-issued-u-s-patent-for-key-component-in-pl-3994-drug-candidate-ptn-20110621monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-announces-presentation-and-publication-on-validation-of-scale-for-ptn-20110615monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-third-quarter-fiscal-year-2011-results-ptn-20110516monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-march-31-2011-quarter-results-teleconference-and-webcast-to-be-he-ptn-20110512monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-announces-results-of-annual-stockholders-ptn-20110511monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-present-at-the-roth-23rd-annual-oc-growth-stock-conference-ptn-20110309monthly0.5https://www.biopharmawatch.com/news/PTN/fda-clears-palatin-technologies-ptn-20110303monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-closes-23-million-public-offering-ptn-20110301monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-announces-proposed-public-offering-of-common-stock-and-warrants-ptn-20110223monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-december-31-2010-quarter-results-teleconference-and-webcast-to-be-ptn-20110218monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-second-quarter-fiscal-year-2011-results-ptn-20110215monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-listing-compliance-plan-accepted-by-nyse-amex-ptn-20110204monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-receives-non-compliance-letter-from-nyse-amex-ptn-20101202monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-appoints-jeffrey-d-edelson-m-d-chief-medical-officer-ptn-20101116monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-first-quarter-fiscal-year-2011-results-teleconference-and-ptn-20101115monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-fiscal-year-2011-first-quarter-results-teleconference-a-ptn-20101112monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-receives-978-000-in-grants-under-the-patient-protection-and-affor-ptn-20101102monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-to-present-at-9th-annual-bio-investor-forum-ptn-20101001monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-fourth-quarter-and-fiscal-year-end-2010-results-teleconfe-ptn-20100927monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-strategic-realignment-of-operations-ptn-20100924monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-report-fiscal-year-2010-fourth-quarter-results-teleconference--ptn-20100922monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-to-present-at-rodman-renshaw-annual-global-investment-conference-ptn-20100910monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-announces-positive-safety-results-in-subcutaneous-bremelanotide-t-ptn-20100817monthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-announces-initiation-of-a-phase-1b-trial-of-the-once-weekly-topical-a-drma-20210330monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-to-report-2025-full-year-financial-and-operating-results-on-march-17-2026-iccm-20260310monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-announces-thomas-hospital-of-infirmary-health-installs-prosense-becomes-first-hosp-iccm-20260219monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-iccm-20251003monthly0.5https://www.biopharmawatch.com/news/ICCM/two-new-publications-from-the-independent-thermac-trial-featuring-icecure-iccm-20250908monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-reports-financial-operational-results-for-the-first-half-of-2025-iccm-20250813monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-to-report-first-half-2025-financial-and-operating-results-on-august-13-2025-iccm-20250806monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-reminds-shareholders-of-upcoming-expiration-of-rights-offering-subscription-period-iccm-20250724monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-reports-preliminary-financial-results-for-the-three-and-six-months-ended-june-30-2-iccm-20250703monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-to-report-first-quarter-2025-financial-operational-results-on-may-28-2025-iccm-20250521monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-receives-high-level-of-interest-from-breast-surgeons-at-asbrs-2025-annual-meeting--iccm-20250506monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-exhibits-prosense-sponsors-breast-cryoablation-courses-at-the-society-of-breast-im-iccm-20250428monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-prosense-featured-at-european-conference-on-interventional-oncology-with-an-emph-iccm-20250422monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-icesecret-kidney-cancer-cryoablation-study-interim-results-presented-at-european-iccm-20250324monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-to-report-2024-full-year-financial-operational-results-on-march-27-2025-iccm-20250321monthly0.5https://www.biopharmawatch.com/news/ICCM/data-on-icecure-iccm-20241216monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-to-report-third-quarter-2024-financial-operational-results-on-november-26--iccm-20241120monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-prosense-chosen-for-breast-cryoablation-study-led-by-the-prestigious-european-in-iccm-20241119monthly0.5https://www.biopharmawatch.com/news/ICCM/upcoming-fda-advisory-panel-for-icecure-iccm-20241029monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-to-meet-institutional-investors-at-the-h-c-wainwright-and-lake-street-capital-mark-iccm-20240904monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-reports-20-growth-in-prosense-system-and-probe-sales-for-the-first-half-of-iccm-20240820monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-to-report-second-quarter-2024-financial-operational-results-on-august-20-2-iccm-20240813monthly0.5https://www.biopharmawatch.com/news/ICCM/99-74-recurrence-free-rate-for-women-with-breast-cancer-treated-with-icecure-iccm-20240722monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-to-provide-overview-and-share-recent-progress-at-northland-capital-markets-iccm-20240618monthly0.5https://www.biopharmawatch.com/news/ICCM/positive-data-from-icecure-iccm-20240612monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-to-report-first-quarter-2024-financial-operational-results-on-may-28-2024-iccm-20240521monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-to-highlight-key-achievements-and-provide-business-overview-at-a-g-p-allia-iccm-20240520monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-to-report-2023-full-year-financial-operational-results-on-april-3-2024-iccm-20240327monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-to-present-at-34th-annual-oppenheimer-healthcare-medtech-services-conferen-iccm-20240307monthly0.5https://www.biopharmawatch.com/news/ICCM/fourth-briit-conference-in-india-features-icecure-iccm-20240227monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-prosense-to-be-featured-at-two-upcoming-medical-conferences-in-japan-icecure-med-iccm-20240215monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-iccm-20240129monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-iccm-20240116monthly0.5https://www.biopharmawatch.com/news/ICCM/new-study-reports-icecure-iccm-20240103monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-prosense-deepens-regulatory-approval-in-india-icecure-medical-ltd-nasdaq-iccm-ic-iccm-20231129monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-reports-financial-results-as-of-and-for-the-nine-months-ended-september-30-iccm-20231115monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-to-report-third-quarter-2023-financial-operational-results-on-november-15--iccm-20231108monthly0.5https://www.biopharmawatch.com/news/ICCM/substantial-evidence-based-data-currently-being-generated-by-19-ongoing-studies-using-icec-iccm-20231106monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-ice3-trial-results-demonstrating-96-91-recurrence-free-rate-featured-in-a-presen-iccm-20231030monthly0.5https://www.biopharmawatch.com/news/ICCM/independent-scientific-paper-by-doctors-using-icecure-iccm-20231025monthly0.5https://www.biopharmawatch.com/news/ICCM/renowned-spanish-radiologist-luci-a-gran-a-lo-pez-to-present-data-using-icecure-medical-iccm-20230922monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-to-join-hands-on-cryoablation-session-with-prosense-and-host-symposium-led-iccm-20230908monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-continues-to-experience-growing-global-interest-in-prosense-featured-at-th-iccm-20230821monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-reports-first-half-2023-financial-operational-results-global-adoption-of-c-iccm-20230814monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-to-report-second-quarter-2023-financial-operational-results-on-august-14-2-iccm-20230807monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-expands-distribution-of-prosense-into-portugal-through-agreement-with-medi-iccm-20230717monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-to-review-recent-progress-at-maxim-group-iccm-20230613monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-prosense-installation-in-india-is-the-first-to-offer-cryoablation-for-the-treatm-iccm-20230531monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-to-report-first-quarter-2023-financial-operational-results-on-may-22-2023-iccm-20230515monthly0.5https://www.biopharmawatch.com/news/ICCM/cryoablation-takes-center-stage-at-american-society-of-breast-surgeons-iccm-20230501monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-to-provide-educational-support-in-a-first-of-its-kind-cryotherapy-course-a-iccm-20230424monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-to-report-2022-full-year-financial-operational-results-on-march-29-2023-iccm-20230320monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-prosense-featured-in-breast-session-at-the-society-of-interventional-oncology-s--iccm-20230126monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-ltd-announces-proposed-public-offering-iccm-20221220monthly0.5https://www.biopharmawatch.com/news/ICCM/time-change-icecure-medical-to-report-financial-results-for-the-9-month-period-ended-septe-iccm-20221129monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-to-report-financial-results-for-the-9-month-period-ended-september-30-2022-iccm-20221128monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-launches-global-freezecancernotyourlife-movement-during-breast-cancer-awareness-mo-iccm-20221026monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-iccm-20221011monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-to-report-h1-2022-results-and-conduct-conference-call-on-august-15-2022-iccm-20220809monthly0.5https://www.biopharmawatch.com/news/ICCM/former-itamar-medical-ceo-president-gilad-glick-joins-icecure-medical-as-a-strategic-advis-iccm-20220705monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-prosense-featured-at-sir-2022-annual-meeting-in-breast-cancer-cryoablation-categ-iccm-20220615monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-to-report-q1-2022-results-and-conduct-conference-call-may-18-2022-iccm-20220511monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-presents-ice3-breast-cancer-trial-interim-data-hosts-cryoablation-symposiu-iccm-20220427monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-iccm-20211202monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-announces-new-independent-data-published-in-the-journal-of-cancer-therapy--iccm-20211101monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-enters-into-an-exclusive-agreement-in-poland-for-distribution-of-the-prose-iccm-20211020monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-announces-first-peer-reviewed-publication-for-the-3-year-interim-analysis--iccm-20210913monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-announces-8-for-1-reverse-stock-split-in-preparation-for-nasdaq-listing-iccm-20210809monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-announces-exclusive-6-6m-distribution-agreement-to-sell-prosense-cryoablat-iccm-20210607monthly0.5https://www.biopharmawatch.com/news/ICCM/positive-interim-results-from-icecure-medical-iccm-20210504monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-announces-upcoming-presentation-at-the-american-society-of-breast-surgeons-iccm-20210420monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-granted-fda-breakthrough-device-designation-for-prosense-cryoablation-syst-iccm-20210405monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-signs-exclusive-distribution-agreement-with-rise-general-trading-lcc-expanding-mar-iccm-20210217monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-inks-expanded-distribution-agreement-with-terumo-corporation-for-thailand-iccm-20210105monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-expands-strategic-collaboration-with-terumo-new-commercial-distribution-agreement--iccm-20201005monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-raises-nis-20-7-million-in-equity-share-offering-received-oversubscribed-demand-of-iccm-20200810monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-global-expansion-accelerates-tumor-freezing-product-now-approved-for-market-in-i-iccm-20200428monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-enters-german-cryoablation-oncology-market-inks-exclusive-distribution-agreement-w-iccm-20200422monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-continues-global-expansion-to-freeze-tumors-iccm-20200420monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-continues-expansion-in-asia-receives-largest-purchase-order-for-prosense-c-iccm-20200401monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-receives-fda-clearance-for-expanded-indications-of-cryoablation-technology-and-reg-iccm-20200107monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-appoints-medical-device-veteran-sharon-levita-to-its-board-of-directors-iccm-20191202monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-announces-landmark-strategic-deal-with-global-medical-company-terumo-corpo-iccm-20190903monthly0.5https://www.biopharmawatch.com/news/ICCM/another-success-icecure-receives-israeli-amar-approval-for-use-of-its-freezing-technology--iccm-20190805monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-announces-new-category-iii-cpt-code-for-breast-cryoablation-therapy-issued-iccm-20190702monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-presents-promising-results-from-first-ever-interventional-radiology-study--iccm-20190320monthly0.5https://www.biopharmawatch.com/news/ICCM/new-non-surgical-treatment-freezes-breast-cancer-in-its-tracks-iccm-20151026monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-and-eos-senolytix-announce-merger-agreement-to-advance-novel-mitochondrial-thera-pulm-20260326monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-and-cullgen-continue-to-pursue-merger-while-granting-each-other-waivers-to-explo-pulm-20251218monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-year-end-and-fourth-quarter-2024-financial-results-and-divestment-plan-pulm-20250321monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-and-cullgen-announce-proposed-merger-pulm-20241113monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-second-quarter-2024-financial-results-and-provides-corporate-update-pulm-20240813monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-first-quarter-2024-financial-results-and-provides-corporate-update-pulm-20240510monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-year-end-and-q4-2023-financial-results-and-provides-corporate-update-pulm-20240328monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-stopping-the-pur1900-phase-2b-study-patient-enrollment-and-closing-the-pulm-20240108monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-announces-third-quarter-2023-financial-results-and-provides-corporate-update-pulm-20231109monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-appoints-mark-iwicki-chairman-of-the-board-pulm-20151208monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-reports-second-quarter-results-and-provides-business-update-acxp-20250812monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-announces-exercise-of-warrants-for-2-67-million-gross-proceeds-acxp-20250618monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-publication-in-lancet-microbe-of-phase-2b-clinical-trial-data-for-ibezapol-acxp-20250617monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-announces-presentation-of-results-from-leiden-university-medical-cen-acxp-20250609monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-reports-first-quarter-results-and-provides-business-update-acxp-20250513monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-13-2025-confe-acxp-20250430monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-to-present-at-the-alliance-global-partners-a-g-p-healthcare-company--acxp-20250428monthly0.5https://www.biopharmawatch.com/news/ACXP/indian-patent-office-grants-acurx-patent-for-dna-polymerase-iiic-inhibitors-acxp-20250417monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-reports-fourth-quarter-and-full-year-2024-results-and-provides-b-acxp-20250318monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-announces-closing-of-1-1-million-registered-direct-offering-acxp-20250310monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-publication-of-nonclinical-in-vivo-data-differentiating-ibezapolstat-acxp-20250303monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-ma-acxp-20250228monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-publication-of-positive-results-from-an-in-silico-study-predicting-the-mic-acxp-20250224monthly0.5https://www.biopharmawatch.com/news/ACXP/jpo-grants-acurx-pharmaceuticals-patent-in-japan-for-dna-polymerase-iiic-inhibitors-acxp-20250219monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-announces-closing-of-2-5-million-registered-direct-offering-pric-acxp-20250107monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-receives-positive-regulatory-guidance-from-ema-for-ibezapolstat-phase-3-program-for--acxp-20250106monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-updates-phase-3-readiness-for-ibezapolstat-in-c-difficile-infection-based-on-recent--acxp-20241209monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-vorstand-genehmigt-die-verwendung-von-bitcoin-als-wa-hrungsreserve-acxp-20241121monthly0.5https://www.biopharmawatch.com/news/ACXP/le-conseil-d-acxp-20241120monthly0.5https://www.biopharmawatch.com/news/ACXP/la-junta-directiva-de-acurx-aprueba-bitcoin-como-activo-de-reserva-de-tesoreri-a-acxp-20241120monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-board-of-directors-approves-bitcoin-as-treasury-reserve-asset-acxp-20241120monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-sponsored-and-participated-in-the-peggy-lillis-foundation-inaugural-cdi-scientific-s-acxp-20241118monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-reports-third-quarter-2024-results-and-provides-business-update-acxp-20241113monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-new-bile-acid-and-microbiome-analyses-from-ph2b-trial-of-ibezapolstat-in-c-acxp-20241021monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-announces-participation-at-the-spartan-capital-investor-conference-t-acxp-20241017monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-to-discuss-third-quarter-2024-financial-results-on-november-13-2024-acxp-20241016monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-additional-ibezapolstat-ph2b-results-in-cdi-as-well-as-anthrax-b-anthracis-acxp-20240926monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-results-of-its-pioneering-research-with-ibezapolstat-in-collaboration-with-acxp-20240924monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-announces-participation-at-the-h-c-wainwright-26th-annual-global-inv-acxp-20240826monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-reports-second-quarter-2024-results-and-provides-business-update-acxp-20240809monthly0.5https://www.biopharmawatch.com/news/ACXP/uspto-grants-acurx-pharmaceuticals-new-patent-for-ibezapolstat-to-treat-cdi-while-reducing-acxp-20240717monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-to-discuss-second-quarter-2024-financial-results-on-august-9-202-acxp-20240716monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-announces-presentation-of-ibezapolstat-phase-2-clinical-trial-result-acxp-20240715monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-successful-fda-end-of-phase-2-meeting-and-phase-3-readiness-for-ibezapolst-acxp-20240515monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-reports-first-quarter-2024-results-and-provides-business-update-acxp-20240515monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-announces-presentation-of-ibezapolstat-phase-2-clinical-trial-result-acxp-20240502monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-announces-presentation-of-ibezapolostat-phase-2-clinical-trial-resul-acxp-20240425monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-to-discuss-first-quarter-2024-financial-results-on-may-15-2024-c-acxp-20240423monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-reports-fourth-quarter-and-full-year-2023-results-and-provides-b-acxp-20240318monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-to-discuss-fourth-quarter-and-full-year-2023-financial-results-o-acxp-20240304monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-fda-has-granted-an-end-of-phase-2-meeting-for-ibezapolstat-for-c-difficile-acxp-20240227monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-positive-extended-clinical-cure-data-for-ibezapolstat-from-phase-2b-clinic-acxp-20240129monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-to-present-at-the-microcap-conference-january-31-2024-february-1-202-acxp-20240123monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-positive-comparative-microbiology-and-microbiome-data-for-ibezapolstat-fro-acxp-20240117monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-acxp-20240103monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-positive-phase-2b-results-showing-100-of-patients-who-had-clinical-cure-wi-acxp-20231211monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-reports-third-quarter-2023-results-and-provides-business-update-acxp-20231114monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-positive-top-line-ibezapolstat-phase-2-efficacy-results-with-96-clinical-c-acxp-20231102monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-to-discuss-third-quarter-2023-financial-results-and-provide-business-acxp-20231025monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-ibezapolstat-scientific-posters-and-presentations-at-clostpath-2023-and-id-acxp-20231019monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-announces-successful-completion-and-early-discontinuation-of-the-ibe-acxp-20231002monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-presentation-and-update-of-its-pol-iiic-r-d-pipeline-at-the-world-antimicr-acxp-20230912monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-to-present-at-the-h-c-wainwright-25th-annual-global-investment-confe-acxp-20230822monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-reports-second-quarter-2023-results-and-provides-business-update-acxp-20230814monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-to-discuss-second-quarter-2023-financial-results-and-provide-busines-acxp-20230724monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-to-present-at-the-emerging-growth-conference-on-july-12-2023-acxp-20230620monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-to-participate-in-the-maxim-group-llc-virtual-healthcare-conference--acxp-20230615monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-reports-first-quarter-2023-results-and-provides-business-update-acxp-20230512monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-to-discuss-first-quarter-2023-financial-results-and-provide-business-acxp-20230505monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-ibezapolstat-scientific-poster-and-update-on-its-pol-iiic-pipeline-present-acxp-20230419monthly0.5https://www.biopharmawatch.com/news/ACXP/fda-accepts-interim-analysis-plan-for-ongoing-phase-2b-ibezapolstat-clinical-trial-and-acu-acxp-20230411monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2022-financial-results-and-p-acxp-20230306monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-to-present-at-the-emerging-growth-conference-on-january-25-2023-acxp-20230116monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-reports-third-quarter-2022-results-and-provides-business-update-acxp-20221114monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-to-discuss-2022-third-quarter-financial-results-on-november-14-2-acxp-20221101monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-scientific-oral-and-poster-presented-at-idweek-2022-acxp-20221026monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-scientific-oral-and-poster-presentations-at-idweek-acxp-20221017monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-reports-second-quarter-2022-results-and-provides-business-update-acxp-20220815monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-to-discuss-2022-second-quarter-financial-results-on-august-16-20-acxp-20220804monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-new-data-presentations-from-ongoing-ph2-clinical-trial-program-of-ibezapol-acxp-20220802monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-reports-first-quarter-2022-results-and-provides-business-update-acxp-20220511monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-to-discuss-2022-first-quarter-financial-results-on-may-11-2022-c-acxp-20220429monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-reports-fourth-quarter-and-full-year-2021-results-and-provides-b-acxp-20220317monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-to-participate-in-the-2022-virtual-growth-conference-presented-by-ma-acxp-20220316monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2021-financial-results-and-p-acxp-20220307monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-publication-of-positive-phase-2a-clinical-trial-results-of-ibezapolstat-fo-acxp-20220207monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-first-patient-enrolled-in-phase-2b-clinical-trial-of-its-lead-antibiotic-f-acxp-20211206monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-new-microbiome-data-from-its-phase-2a-clinical-trial-of-ibezapolstat-for-c-acxp-20211108monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-new-microbiome-data-from-its-phase-2a-clinical-trial-of-ibezapolstat-for-c-acxp-20211101monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-to-discuss-2021-third-quarter-financial-results-on-november-15-2021--acxp-20211027monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-presents-positive-ibezapolstat-microbiome-data-from-its-phase-2a-trial-at-idweek-acxp-20211004monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-to-participate-in-the-a-g-p-biotech-and-specialty-pharma-conference--acxp-20210929monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-new-microbiome-data-from-its-phase-2a-clinical-trial-of-ibezapolstat-for-c-acxp-20210927monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-to-join-the-russell-microcap-index-acxp-20210902monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-confe-acxp-20210831monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-to-present-at-the-emerging-growth-conference-on-august-18-2021-acxp-20210812monthly0.5https://www.biopharmawatch.com/news/ACXP/health-holland-awards-innovative-research-grant-for-dna-pol-iiic-inhibitors-to-leiden-univ-acxp-20210802monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-to-discuss-2021-second-quarter-financial-results-on-august-17-2021-c-acxp-20210728monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-announces-filing-of-provisional-patent-application-for-ibezapolstat-to-treat-cdi-whi-acxp-20210707monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-online-publication-of-preclinical-data-demonstrating-significant-activ-mbrx-20241211monthly0.5https://www.biopharmawatch.com/news/MBRX/new-findings-show-moleculin-mbrx-20241118monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-accelerates-planned-unblinded-data-readout-for-miracle-phase-3-r-r-acute-myeloid-mbrx-20241114monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-receives-institutional-review-board-approval-for-miracle-phase-3-pivotal-trial-o-mbrx-20241112monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-third-quarter-2024-financial-results-and-provides-corporate-update-mbrx-20241111monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-report-third-quarter-2024-financial-results-on-november-8-2024-and-host-confe-mbrx-20241105monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-appoints-leading-expert-in-pancreatic-cancer-to-its-scientific-advisory-board-to-mbrx-20241104monthly0.5https://www.biopharmawatch.com/news/MBRX/transcript-from-moleculin-mbrx-20241017monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-host-virtual-acute-myeloid-leukemia-kol-event-on-october-14-2024-mbrx-20241007monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-present-at-two-upcoming-investor-conferences-mbrx-20241004monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-positive-in-vivo-efficacy-data-of-annamycin-in-orthotopic-and-experime-mbrx-20240923monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-participates-in-virtual-investor-what-this-means-segment-mbrx-20240916monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-first-patients-treated-in-phase-2-clinical-trial-of-stat3-inhibitor-in-mbrx-20240909monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-mbrx-20240903monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-present-at-live-with-webull-corporate-connect-healthcare-investment-webinar-mbrx-20240826monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-closing-of-up-to-16-5-million-public-offering-mbrx-20240819monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-pricing-of-up-to-16-5-million-public-offering-mbrx-20240816monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-second-quarter-2024-financial-results-and-provides-corporate-update-mbrx-20240814monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-host-webcast-presentation-to-discuss-recently-announced-plans-for-miracle-pha-mbrx-20240805monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-plans-for-miracle-phase-3-pivotal-trial-mbrx-20240801monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-completes-end-of-phase-2-meeting-with-fda-for-annamycin-in-aml-mbrx-20240710monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-additional-positive-preliminary-interim-data-from-aml-clinical-trial-mbrx-20240614monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-present-at-the-virtual-investor-pitch-conference-mbrx-20240612monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-participate-in-the-virtual-investor-lunch-break-series-mbrx-20240605monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-abstract-accepted-for-poster-presentation-at-the-european-hematology-association-mbrx-20240516monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-commencement-of-nih-funded-phase-2-clinical-trial-of-stat3-inhibitor-f-mbrx-20240515monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-first-quarter-2024-financial-results-and-provides-corporate-update-mbrx-20240513monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-u-s-patent-issue-notification-for-lipid-based-delivery-technology-for--mbrx-20240509monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-report-first-quarter-2024-financial-results-on-may-10-2024-and-host-conferenc-mbrx-20240508monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-higher-aml-complete-remission-cr-rates-and-significant-durability-with-a-mbrx-20240507monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-host-virtual-aml-clinical-day-featuring-internationally-renowned-clinician-ma-mbrx-20240502monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-formation-of-scientific-advisory-board-to-support-development-of-annam-mbrx-20240501monthly0.5https://www.biopharmawatch.com/news/MBRX/european-medicines-agency-ema-grants-orphan-drug-designation-for-moleculin-mbrx-20240418monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-presentation-of-positive-data-demonstrating-high-anti-cancer-activity--mbrx-20240410monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-present-at-the-medinvest-biotech-pharma-investor-conference-mbrx-20240328monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-participate-in-the-virtual-investor-lunch-break-the-moleculin-opportunity-mbrx-20240327monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-u-s-patent-issue-notification-for-annamycin-targeting-unmet-need-in-am-mbrx-20240327monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-positive-interim-data-in-annamycin-mb-106-phase-1b-2-aml-trial-mbrx-20240325monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-full-year-2023-financial-results-mbrx-20240322monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-report-full-year-2023-financial-results-on-march-22-2024-and-host-conference--mbrx-20240320monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-reverse-stock-split-mbrx-20240319monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-present-at-the-36th-annual-roth-conference-mbrx-20240312monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-2023-year-end-annamycin-clinical-trials-preliminary-data-and-2024-expe-mbrx-20240124monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-pricing-of-4-5-million-registered-direct-offering-and-concurrent-priva-mbrx-20231220monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-presents-positive-interim-data-from-phase-1b-2-clinical-trial-in-aml-at-meeting--mbrx-20231211monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-positive-interim-data-in-annamycin-clinical-trials-mb-106-aml-trial-co-mbrx-20231113monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-third-quarter-2023-financial-results-mbrx-20231113monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-report-third-quarter-financial-results-on-november-13-2023-and-host-conferenc-mbrx-20231107monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-presents-positive-preliminary-efficacy-findings-from-phase-1b-2-clinical-trial-d-mbrx-20231106monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-participate-in-the-virtual-investor-ask-the-ceo-conference-mbrx-20231011monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-doses-first-subjects-in-phase-2-portion-of-clinical-trial-evaluating-annamycin-i-mbrx-20231002monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-completion-of-enrollment-in-u-s-phase-1b-2-clinical-trial-evaluating-a-mbrx-20230921monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-new-positive-independent-report-of-no-cardiotoxicity-in-annamycin-mbrx-20230918monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-abstract-accepted-for-poster-presentation-at-the-2023-connective-tissu-mbrx-20230914monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-mbrx-20230905monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-second-quarter-2023-financial-results-mbrx-20230811monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-provides-update-on-ongoing-clinical-trials-and-outlines-expected-upcoming-milest-mbrx-20230810monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-retains-shareholder-intelligence-services-llc-to-investigate-potential-naked-sho-mbrx-20230807monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-report-second-quarter-financial-results-on-august-11-2023-and-host-conference-mbrx-20230803monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-publication-of-data-from-successful-european-phase-1-trial-evaluating--mbrx-20230713monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-participate-in-the-virtual-investor-summer-spotlight-series-mbrx-20230706monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-participate-in-the-healthcare-virtual-conference-presented-by-maxim-group-llc-mbrx-20230613monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-adjournment-of-2023-annual-meeting-to-june-15-2023-mbrx-20230530monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-first-quarter-2023-financial-results-mbrx-20230511monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-provides-update-on-ongoing-clinical-trials-and-outlines-expected-upcoming-milest-mbrx-20230510monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-report-first-quarter-financial-results-on-may-11-2023-and-host-conference-cal-mbrx-20230504monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-successfully-completes-first-cohort-in-phase-1b-2-trial-evaluating-annamycin-in--mbrx-20230502monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-presentation-of-positive-pharmacokinetics-and-tissue-organ-distributio-mbrx-20230418monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-full-year-2022-financial-results-and-provides-pipeline-update-mbrx-20230323monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-interim-phase-2-data-in-sts-clinical-trial-and-update-on-recruiting-pr-mbrx-20230322monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-acceptance-of-abstract-to-be-presented-at-the-american-association-for-mbrx-20230321monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-report-full-year-2022-financial-results-on-march-22-2023-and-host-conference--mbrx-20230315monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-present-at-the-oppenheimer-33rd-annual-healthcare-conference-mbrx-20230313monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-it-has-no-exposure-to-silicon-valley-bank-situation-mbrx-20230313monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-publication-of-data-supporting-development-of-non-cardiotoxic-anthracy-mbrx-20230309monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-dosing-of-first-subject-in-italy-for-phase-1-2-trial-evaluating-annamy-mbrx-20230301monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-final-topline-data-from-successful-european-phase-1-trial-evaluating-a-mbrx-20230213monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-present-at-the-virtual-investor-2023-companies-to-watch-event-mbrx-20230105monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-receives-approval-in-italy-to-conduct-phase-1-2-trial-evaluating-annamycin-in-co-mbrx-20221221monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-80-overall-response-rate-in-final-cohort-of-phase-1-single-agent-trial-o-mbrx-20221215monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-granted-fda-fast-track-designation-of-wp1122-for-the-treatment-of-glioblastoma-m-mbrx-20221207monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-third-quarter-2022-financial-results-and-provides-pipeline-update-mbrx-20221110monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-report-third-quarter-2022-financial-results-on-november-10-2022-and-host-inau-mbrx-20221107monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-provides-update-on-second-multiple-ascending-dose-mad-cohort-in-phase-1a-clinica-mbrx-20221014monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-wp1122-portfolio-compound-wp1096-selected-for-niaid-funded-animal-studie-mbrx-20220927monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-to-present-at-the-virtual-investor-innovations-in-acute-myeloid-leukemia-mbrx-20220923monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-selected-to-present-at-the-2nd-annual-marie-sklodowska-curie-symposium-on-cancer-mbrx-20220908monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference-mbrx-20220907monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-receives-fda-orphan-drug-designation-of-wp1122-for-the-treatment-of-glioblastoma-mbrx-20220906monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-completion-of-third-single-ascending-dose-sad-cohort-in-phase-1a-clini-mbrx-20220819monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-second-quarter-2022-financial-results-and-provides-programs-update-mbrx-20220815monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-concludes-phase-1b-and-opens-recruitment-in-phase-2-clinical-trial-of-annamycin--mbrx-20220728monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-completion-of-second-single-ascending-dose-sad-cohort-in-phase-1a-clin-mbrx-20220708monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-completion-of-first-single-ascending-dose-sad-cohort-in-phase-1a-clini-mbrx-20220616monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-commences-dosing-in-healthy-volunteers-in-phase-1a-clinical-trial-of-wp1122-for--mbrx-20220526monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-present-at-the-h-c-wainwright-global-investment-conference-mbrx-20220519monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-first-quarter-2022-financial-results-and-provides-programs-update-mbrx-20220512monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-receives-approval-from-the-uk-mbrx-20220510monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-receives-allowance-to-proceed-with-phase-1-2-study-of-annamycin-in-combination-w-mbrx-20220505monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-engages-wolfram-c-m-dempke-md-phd-mba-as-its-european-chief-medical-officer-mbrx-20220504monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-receives-ind-clearance-to-conduct-phase-1-study-of-wp1066-for-the-treatment-of-r-mbrx-20220421monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-corporate-rebranding-and-launch-of-new-website-mbrx-20220414monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-presentation-of-positive-preclinical-annamycin-data-at-the-aacr-2022-a-mbrx-20220411monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-full-year-financial-results-and-provides-programs-update-mbrx-20220325monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-participate-in-the-2022-virtual-growth-conference-presented-by-maxim-group-ll-mbrx-20220323monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-present-at-the-oppenheimer-32nd-annual-healthcare-conference-mbrx-20220311monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-appointment-of-joy-yan-m-d-ph-d-to-board-of-directors-mbrx-20220301monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-provides-annamycin-aml-program-update-and-outlines-next-steps-to-advance-towards-mbrx-20220214monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-to-present-at-the-virtual-investor-2022-top-picks-conference-mbrx-20220120monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-updated-preliminary-safety-data-for-annamycin-in-its-three-phase-1-cli-mbrx-20220118monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-present-at-the-h-c-wainwright-bioconnect-conference-mbrx-20220107monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-preliminary-third-cohort-interim-data-in-phase-1b-2-clinical-trial-of--mbrx-20211227monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-receives-fda-allowance-to-begin-a-phase-1-study-of-wp1122-for-the-treatment-of-g-mbrx-20211201monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-to-present-at-the-virtual-investor-roundtable-event-mbrx-20211112monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-third-quarter-2021-financial-results-and-provides-programs-update-mbrx-20211111monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-receives-authorization-from-the-medicines-and-healthcare-products-regulatory-age-mbrx-20211019monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-interim-data-in-phase-1b-2-clinical-trial-of-annamycin-for-the-treatme-mbrx-20211018monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-present-at-the-2021-cantor-virtual-global-healthcare-conference-mbrx-20210927monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-present-at-the-oppenheimer-fall-healthcare-life-sciences-and-medtech-summit-mbrx-20210917monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference-mbrx-20210908monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-second-quarter-2021-financial-results-and-provides-programs-update-mbrx-20210812monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-receives-approval-to-extend-dose-escalation-in-phase-1-2-european-clinical-trial-mbrx-20210713monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-first-subject-enrolled-and-dosed-in-phase-1b-2-clinical-trial-of-annam-mbrx-20210621monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-inclusion-in-the-russell-2000-index-mbrx-20210615monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-commences-phase-1b-2-clinical-trial-of-annamycin-for-the-treatment-of-sarcoma-lu-mbrx-20210525monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-first-quarter-2021-financial-results-and-provides-programs-update-mbrx-20210512monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-to-present-at-the-q2-virtual-investor-summit-mbrx-20210511monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-awarded-new-rare-pediatric-disease-designation-from-u-s-fda-for-wp1066-for-the-t-mbrx-20210414monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-engages-iqvia-to-manage-potential-covid-19-clinical-trial-mbrx-20210406monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-receives-fda-approval-of-fast-track-designation-for-annamycin-in-the-treatment-o-mbrx-20210330monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-reports-financial-results-for-the-year-ended-december-31-2020-mbrx-20210324monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-participate-in-four-upcoming-healthcare-conferences-mbrx-20210309monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-full-exercise-of-over-allotment-option-mbrx-20210210monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-grant-awarded-to-polish-research-institute-for-independent-clinical-tr-mbrx-20210208monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-pricing-of-67-8-million-underwritten-public-offering-mbrx-20210203monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-proposed-underwritten-public-offering-mbrx-20210202monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-100-survival-achieved-in-osteosarcoma-lung-metastases-animal-model-mbrx-20210202monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-signs-agreement-with-catalyst-clinical-research-to-begin-sarcoma-trial-mbrx-20210201monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-reverse-stock-split-mbrx-20210129monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-present-at-the-h-c-wainwright-bioconnect-2021-conference-mbrx-20210107monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-annamycin-receives-fda-orphan-drug-designation-for-soft-tissue-sarcoma-mbrx-20201229monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-fda-permission-to-begin-clinical-study-of-annamycin-for-sarcoma-lung-m-mbrx-20201217monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-present-antitumor-activity-of-annamycin-in-combination-with-ara-c-in-aml-at-a-mbrx-20201203monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-fda-approves-3-rare-pediatric-disease-designations-for-wp1066-mbrx-20201201monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-new-data-demonstrating-synergistic-antitumor-activity-of-annamycin-com-mbrx-20201119monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-reports-financial-results-for-the-quarter-ended-september-30-2020-mbrx-20201113monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-additional-collaboration-on-drug-candidate-targeting-covid-19-mbrx-20201029monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-participate-in-panel-at-roth-capital-mbrx-20201027monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-independent-study-validates-annamycin-mbrx-20201021monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-additional-positive-interim-results-in-adult-glioblastoma-clinical-tri-mbrx-20201013monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-new-antiviral-drug-candidates-demonstrate-in-vitro-activity-against-hi-mbrx-20201006monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-appoints-elizabeth-cermak-to-board-of-directors-mbrx-20201005monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-positive-interim-results-in-pediatric-brain-tumor-phase-1-clinical-tri-mbrx-20201001monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-discovery-of-significant-in-vitro-activity-against-covid-19-virus-for--mbrx-20200929monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-covid-19-in-vivo-testing-contracted-for-wp1122-mbrx-20200914monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-present-at-upcoming-healthcare-investor-conferences-mbrx-20200910monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-successful-completion-of-pre-ind-meeting-with-the-fda-mbrx-20200909monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-present-at-ld-micro-500-virtual-investor-conference-mbrx-20200827monthly0.5https://www.biopharmawatch.com/news/MBRX/additional-independent-research-further-supports-glucose-metabolism-as-important-covid-19--mbrx-20200729monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-present-at-the-life-sciences-investor-forum-mbrx-20200623monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-submission-to-expand-clinical-sites-in-european-aml-trial-mbrx-20200604monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-emory-university-clinical-trial-of-wp1066-begins-enrollment-mbrx-20200602monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-intention-to-adjourn-2020-annual-meeting-of-stockholders-to-june-15-20-mbrx-20200508monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-trading-halt-mbrx-20200504monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-speak-on-covid-19-panel-at-maxim-group-mbrx-20200429monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-approved-to-accelerate-european-clinical-trial-mbrx-20200428monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-agreement-with-imquest-biosciences-to-expand-coronavirus-testing-mbrx-20200420monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-host-investor-conference-call-to-discuss-covid-19-potential-for-drug-candidat-mbrx-20200416monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-patent-filing-to-cover-new-coronavirus-drug-candidate-mbrx-20200320monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-issues-video-shareholder-letter-mbrx-20200304monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-6-0-million-registered-direct-offering-mbrx-20200206monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-beginning-of-preclinical-development-of-new-approach-to-pancreatic-can-mbrx-20191113monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-its-sponsored-research-at-md-anderson-cancer-center-has-resulted-in-th-mbrx-20190916monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-ctrc-approval-of-wp1066-pediatric-brain-tumor-trial-mbrx-20190820monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-files-for-new-patents-for-annamycin-after-receiving-fda-approval-of-fast-track-d-mbrx-20190710monthly0.5https://www.biopharmawatch.com/news/MBRX/us-biopharma-company-undertakes-anti-cancer-clinical-trials-in-poland-first-patient-showin-mbrx-20190429monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-conference-call-to-discuss-significant-discovery-for-lung-cancer-and-f-mbrx-20190422monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-receives-fda-approval-of-fast-track-designation-for-annamycin-mbrx-20190418monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-significant-discovery-in-lung-cancer-models-mbrx-20190417monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-successful-expansion-of-its-leukemia-drug-program-mbrx-20190409monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-preclinical-pancreatic-cancer-data-presented-at-american-association-f-mbrx-20190403monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-pricing-of-underwritten-public-offering-mbrx-20190327monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-first-patients-enrolled-in-lymphoma-clinical-trial-mbrx-20190319monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-memorial-sloan-kettering-chief-of-leukemia-joins-science-advisory-boar-mbrx-20190318monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-to-present-at-the-oppenheimer-29th-annual-healthcare-conference-and--mbrx-20190318monthly0.5https://www.biopharmawatch.com/news/GNPX/positive-clinical-data-on-biomarkers-in-patients-receiving-reqorsa-gene-therapy-published--gnpx-20260526monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-signs-sponsored-research-agreement-to-study-biomarkers-that-may-predict-patient-re-gnpx-20260421monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-ther-gnpx-20260318monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-participate-at-bio-europe-spring-2026-gnpx-20260310monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-positive-preliminary-preclinical-data-from-study-of-gpx-002-in-type-2-di-gnpx-20260106monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-european-patent-office-gnpx-20251104monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-registered-direct-offering-of-up-to-8-1-million-priced-at-the-market-und-gnpx-20251023monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-ther-gnpx-20251023monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-ther-gnpx-20251014monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-receives-notice-of-allowance-for-multiple-patents-for-reqorsa-gene-therapy-with-pd-gnpx-20250818monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-issues-stockholder-letter-and-provides-2025-corporate-update-gnpx-20250804monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-collaborators-present-positive-preclinical-research-on-diabetes-gene-therapy-at-th-gnpx-20250624monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-collaborators-present-research-on-non-viral-approach-to-diabetes-gene-therapy-usin-gnpx-20250623monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-participate-at-bio-2025-international-convention-gnpx-20250603monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-present-trial-design-of-acclaim-3-clinical-trial-evaluating-reqorsa-gene-therap-gnpx-20250529monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-collaborators-present-positive-preclinical-data-on-diabetes-gene-therapy-at-the-as-gnpx-20250528monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-signs-sponsored-research-agreement-with-the-university-of-pittsburgh-to-study-diab-gnpx-20250507monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-signs-exclusive-license-to-additional-gene-therapy-technology-with-uthealth-housto-gnpx-20250506monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-collaborators-report-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy--gnpx-20250430monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-collaborators-to-present-positive-preclinical-data-on-diabetes-gene-therapy-at-the-gnpx-20250429monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-signs-exclusive-technology-license-agreement-with-new-york-university-langone-heal-gnpx-20250428monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-selected-to-present-trial-design-of-acclaim-3-clinical-trial-evaluating-reqorsa-ge-gnpx-20250424monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-research-collaborators-gnpx-20250422monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-ther-gnpx-20250326monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-collaborators-selected-to-present-positive-preclinical-data-on-diabetes-gene-thera-gnpx-20250325monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-participate-at-bio-europe-spring-2025-gnpx-20250304monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-advances-diabetes-program-with-addition-of-research-focused-on-non-viral-delivery--gnpx-20250219monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-provides-update-on-diabetes-gene-therapy-program-gnpx-20250218monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-collaborators-find-nprl2-gene-therapy-using-oncoprex-delivery-system-is-a-potentia-gnpx-20250213monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-first-patient-dosed-in-phase-2-expansion-portion-of-acclaim-3-clinical-s-gnpx-20250123monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-participate-at-the-43rd-annual-j-p-morgan-healthcare-conference-gnpx-20250106monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-receives-safety-review-committee-approval-to-advance-to-phase-2-portion-of-acclaim-gnpx-20241216monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-signs-exclusive-license-to-additional-gene-therapy-technologies-with-the-universit-gnpx-20241120monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-collaborators-present-positive-preclinical-data-on-reqorsa-gene-therapy-at-the-soc-gnpx-20241105monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-participate-in-2024-bio-europe-conference-gnpx-20241031monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-collaborators-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-gnpx-20241028monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-sponsored-research-agreement-with-the-university-of-michigan-rogel-cance-gnpx-20241024monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-receives-safety-review-committee-approval-to-advance-to-highest-dose-group-in-phas-gnpx-20241015monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-ther-gnpx-20241010monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-collaborators-to-present-positive-preclinical-data-on-reqorsa-gene-therapy-at-the--gnpx-20241007monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-featured-in-ceo-cfo-magazine-discussing-novel-gene-therapies-for-cancer-and-diabet-gnpx-20240923monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-formation-of-mesothelioma-clinical-advisory-board-gnpx-20240919monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-ther-gnpx-20240909monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-plans-to-launch-separate-company-to-focus-on-the-development-of-gene-the-gnpx-20240904monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-present-and-participate-at-upcoming-september-investor-and-industry-conferences-gnpx-20240903monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-releases-new-video-featuring-chief-medical-officer-discussing-positive-patient-out-gnpx-20240815monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-positive-clinical-study-updates-from-acclaim-1-and-acclaim-3-phase-1-2-c-gnpx-20240814monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-granted-patent-in-singapore-for-reqorsa-gene-therapy-with-pd-1-antibodies-to-treat-gnpx-20240813monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-present-at-the-august-sidoti-microcap-conference-gnpx-20240808monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-issues-stockholder-letter-and-provides-2024-corporate-update-gnpx-20240627monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-present-at-the-2024-bio-international-convention-gnpx-20240530monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-doses-first-patient-in-acclaim-3-clinical-study-of-reqorsa-immunogene-therapy-in-c-gnpx-20240514monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-the-appointment-of-jose-a-moreno-toscano-as-chairman-of-the-board-of-dir-gnpx-20240513monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-the-passing-of-its-co-founder-and-chief-executive-officer-rodney-varner-gnpx-20240508monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-present-and-participate-at-upcoming-may-investor-and-industry-conferences-gnpx-20240501monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-collaborators-report-positive-preclinical-data-on-the-use-of-reqorsa-and-on-nprl2--gnpx-20240409monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-expands-clinical-trial-sites-for-acclaim-3-clinical-study-of-reqorsa-therapy-in-co-gnpx-20240403monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-collaborators-publish-positive-preclinical-data-with-nprl2-gene-therapy-utilizing--gnpx-20240402monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-closing-of-6-5-million-registered-direct-offering-priced-at-the-market-u-gnpx-20240322monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-6-5-million-registered-direct-offering-priced-at-the-market-under-nasdaq-gnpx-20240319monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-receives-notice-of-patent-grant-for-korean-patent-claiming-reqorsa-immunogene-ther-gnpx-20240312monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-and-on-np-gnpx-20240306monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-expands-nonclinical-programs-into-new-therapeutic-indications-with-research-collab-gnpx-20240207monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-present-at-upcoming-bio-ceo-investor-conference-gnpx-20240206monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-first-patient-dosed-in-phase-2a-expansion-of-acclaim-1-clinical-study-of-gnpx-20240205monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-1-for-40-reverse-stock-split-effective-february-2-2024-gnpx-20240131monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-provides-business-update-and-outlook-for-2024-gnpx-20240105monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-present-at-bio-europe-2023-conference-gnpx-20231101monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-host-a-virtual-key-opinion-leader-event-on-bringing-gene-therapy-to-the-fight-a-gnpx-20231020monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-present-data-on-the-use-of-reqorsa-for-the-treatment-of-lung-cancers-at-2023-20-gnpx-20231004monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-present-at-upcoming-september-investor-conference-gnpx-20230907monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-appoints-suzanne-thornton-jones-as-senior-vice-president-regulatory-affairs-gnpx-20230822monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-granted-fda-orphan-drug-designation-odd-for-reqorsa-immunogene-therapy-for-the-tre-gnpx-20230810monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-closing-of-7-5-million-registered-direct-offering-priced-at-the-market-u-gnpx-20230721monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-7-5-million-registered-direct-offering-priced-at-the-market-under-nasdaq-gnpx-20230719monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-signs-exclusive-license-to-additional-diabetes-technology-with-the-university-of-p-gnpx-20230718monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-granted-chinese-patent-for-reqorsa-immunogene-therapy-in-combination-with-pd-1-ant-gnpx-20230705monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-receives-u-s-fda-fast-track-designation-for-reqorsa-immunogene-therapy-in-combinat-gnpx-20230628monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-receives-safety-review-committee-approval-to-advance-to-phase-2-expansion-portion--gnpx-20230530monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-publishes-positive-clinical-data-from-phase-1-portion-of-acclaim-1-clinical-trial--gnpx-20230525monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-unveils-new-video-featuring-chief-medical-officer-discussing-positive-preclinical--gnpx-20230523monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-participate-and-present-at-upcoming-may-industry-and-investor-conferences-gnpx-20230508monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-collaborators-report-positive-preclinical-data-with-nprl2-gene-therapy-utilizing-n-gnpx-20230419monthly0.5https://www.biopharmawatch.com/news/GNPX/independent-researchers-find-that-tusc2-the-gene-delivered-by-genprex-gnpx-20230418monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-ceo-commends-fda-gnpx-20230323monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-present-at-bioprocessing-summit-conference-gnpx-20230313monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-participate-in-march-investor-and-industry-conferences-gnpx-20230308monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-inc-announces-4-million-registered-direct-offering-with-a-single-healthcare-focuse-gnpx-20230227monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-groundbreaking-data-from-non-human-primate-study-evaluating-novel-gene-t-gnpx-20230223monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-signs-exclusive-license-to-additional-diabetes-technology-with-the-university-of-p-gnpx-20230105monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-selection-of-preclinical-data-for-oral-presentation-at-16th-internationa-gnpx-20230104monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-strengthens-diabetes-gene-therapy-program-with-license-of-additional-technology-fr-gnpx-20221215monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-receives-safety-review-committee-approval-to-proceed-to-final-cohort-in-acclaim-1--gnpx-20221214monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-present-at-upcoming-december-investor-conference-gnpx-20221202monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-present-at-upcoming-october-investor-and-industry-conferences-gnpx-20221007monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-present-at-upcoming-september-investor-conference-gnpx-20220908monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-u-s-patent-for-reqorsa-immunogene-therapy-in-combination-with-immune-che-gnpx-20220816monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-safety-review-committee-approves-dose-escalation-in-acclaim-1-phase-1-2--gnpx-20220815monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-participate-in-next-generation-lipid-based-nanoparticles-delivery-summit-gnpx-20220713monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-present-at-upcoming-june-investor-conferences-gnpx-20220602monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-present-at-upcoming-investor-conference-in-may-2022-gnpx-20220519monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-s-chief-medical-officer-to-be-featured-as-an-expert-panelist-at-the-33rd-annual-ca-gnpx-20220509monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-issues-shareholder-letter-and-provides-2022-corporate-update-gnpx-20220505monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-participate-in-upcoming-investor-and-industry-conferences-in-april-2022-gnpx-20220418monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-present-at-the-singular-research-summer-solstice-2018-conference-gnpx-20180718monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-selects-4clinics-to-provide-clinical-and-regulatory-support-for-oncoprex-developme-gnpx-20180626monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-engages-wirb-copernicus-group-inc-to-provide-clinical-trial-services-to-support-on-gnpx-20180531monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-nasdaq-gnpx-to-ring-the-nasdaq-stock-market-closing-bell-gnpx-20180529monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-present-at-upcoming-investor-and-industry-conferences-gnpx-20180523monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-selects-accenture-to-support-acceleration-of-oncoprex-clinical-development-program-gnpx-20180508monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-present-at-2018-disruptive-growth-healthcare-conference-gnpx-20180507monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-10-million-private-placement-gnpx-20180507monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-joins-the-health-discovery-building-at-dell-medical-school-to-help-drive-innovatio-gnpx-20180418monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-provides-clinical-and-corporate-update-gnpx-20180416monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-appoints-julien-pham-md-mph-as-president-to-lead-commercialization-of-oncoprex-imm-gnpx-20180411monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-present-at-the-microcap-conference-gnpx-20180406monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-closing-of-initial-public-offering-gnpx-20180404monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-pricing-of-initial-public-offering-of-common-stock-gnpx-20180329monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-recognized-as-finalist-in-technology-innovation-category-for-fierce-innovation-awa-gnpx-20171129monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-inc-commences-initial-public-offering-and-sets-price-gnpx-20171013monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-files-registration-statement-for-proposed-initial-public-offering-gnpx-20170721monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-reports-new-pre-clinical-data-showing-strong-anti-tumor-effect-of-tusc2-in-combina-gnpx-20170402monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-positive-interim-data-from-phase-ii-clinical-trial-of-oncoprex-for-late--gnpx-20170106monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-to-present-at-biotech-showcase-2017-gnpx-20161219monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-retains-icr-healthcare-as-integrated-strategic-communications-counsel-gnpx-20161207monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-expands-executive-management-team-and-completes-funding-gnpx-20161104monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-signs-capital-markets-advisory-agreement-with-network-1-financial-as-part-of-an-ov-gnpx-20160824monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-moving-toward-public-share-listing-gnpx-20160323monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-begins-phase-ii-clinical-trial-for-lung-cancer-gnpx-20140520monthly0.5https://www.biopharmawatch.com/news/GNPX/clinical-trial-highlights-positive-oncoprex-results-in-lung-cancer-patients-gnpx-20120426monthly0.5https://www.biopharmawatch.com/news/GNPX/oncoprex-shows-synergistic-tumor-suppression-in-combination-with-akt-inhibitor-mk2206-gnpx-20120402monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-annonce-l-gnpx-20111018monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-gibt-neue-patenterteilung-in-japan-bekannt-gnpx-20111018monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-new-patent-issuance-in-japan-gnpx-20111018monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-new-branding-gnpx-20110906monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-ceo-issues-letter-to-shareholders-detailing-strategic-reorientation-initiatives-aztr-20260617monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-to-present-at-2026-bio-international-convention-aztr-20260616monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-announces-adjournment-of-2026-annual-meeting-and-information-for-reconvened-meeting-aztr-20260604monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-announces-intention-to-adjourn-annual-meeting-and-reconvene-annual-meeting-aztr-20260527monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-announces-pricing-of-private-placement-financing-of-up-to-approximately-10-5-millio-aztr-20260319monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-receives-notice-of-non-compliance-from-nyse-american-and-makes-nyse-american-sectio-aztr-20260313monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-to-present-at-bio-investment-growth-summit-aztr-20260219monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-announces-q2-2025-results-and-provides-business-updates-aztr-20250811monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-reports-promising-safety-data-from-phase-1b-trial-in-netherton-syndrome-aztr-20250617monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-announces-presentation-at-the-2025-bio-international-convention-aztr-20250610monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-announces-presentation-at-asco-2025-highlighting-clinical-trial-investigating-a-aztr-20250528monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-to-present-abstract-at-american-society-of-gene-and-cell-therapy-highlighting-p-aztr-20250514monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-announces-q1-2025-results-and-provides-business-updates-aztr-20250513monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-to-present-atr-04-program-update-at-asco-2025-aztr-20250425monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-announces-share-purchase-agreement-for-up-to-20-million-in-partnership-with-alumni--aztr-20250424monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-to-present-at-microbiome-times-partnering-forum-aztr-20250312monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-announces-full-year-2024-financial-results-and-provides-business-updates-aztr-20250224monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-announces-pricing-of-930-0-thousand-registered-direct-offering-of-common-stock-aztr-20250204monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-to-present-at-the-bio-ceo-investor-conference-aztr-20250203monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-to-present-at-the-microcap-conference-aztr-20250127monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-announces-pricing-of-1-5-million-public-offering-of-common-stock-aztr-20250115monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-announces-proposed-public-offering-of-common-stock-aztr-20250114monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-to-present-at-biotech-showcase-2025-alongside-the-j-p-morgan-annual-healthcare--aztr-20241220monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-announces-q3-2024-financial-results-and-provides-business-updates-aztr-20241112monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-aztr-20230829monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-announces-second-quarter-2023-financial-results-and-business-updates-aztr-20230814monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-adds-biotech-leaders-barbara-ryan-and-john-schroer-to-its-board-of-directors-aztr-20230719monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-appoints-travis-whitfill-as-chief-operating-officer-aztr-20230711monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-announces-closing-of-initial-public-offering-aztr-20230621monthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-inc-announces-pricing-of-initial-public-offering-aztr-20230615monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-highlights-expanded-cdmo-platform-and-immunology-pipeline-at-bio-scni-20260319monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-receives-nasdaq-notification-regarding-minimum-bid-price-scni-20260316monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-announces-completion-of-acquisition-of-recipharm-israel-ltd-and-strategic-commercia-scni-20260217monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-signs-an-option-agreement-to-acquire-rare-disease-company-pincell-and-its-novel-ant-scni-20250327monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-to-connect-with-investors-showcase-its-innovative-i-i-pipeline-and-its-boutique-cgm-scni-20250317monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-announces-10-million-standby-equity-purchase-agreement-scni-20250305monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-to-connect-with-investors-and-pharma-leaders-at-upcoming-key-us-conferences-scni-20250106monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-establishes-u-s-subsidiary-for-cdmo-business-unit-scinai-bioserv-scni-20241216monthly0.5https://www.biopharmawatch.com/news/SCNI/prof-michael-scho-n-director-of-dermatology-and-venereology-at-the-university-medical-cent-scni-20241205monthly0.5https://www.biopharmawatch.com/news/SCNI/dr-jonathan-sadeh-former-senior-vice-president-of-immunology-r-d-at-bristol-myers-squibb-j-scni-20241127monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-publishes-financial-results-and-provides-business-update-shareholders-scni-20241122monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-leadership-to-showcase-company-scni-20241031monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-to-host-online-expert-panel-on-plaque-psoriasis-treatment-and-intralesional-injecti-scni-20240916monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-regains-full-compliance-with-nasdaq-listing-requirements-scni-20240829monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-announces-closing-of-loan-restructuring-agreement-with-european-investment-bank-con-scni-20240821monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-announces-entering-into-2-million-private-equity-commitment-agreement-with-its-larg-scni-20240820monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-publishes-q2-2024-financial-results-and-provides-business-update-restructures-29-mi-scni-20240815monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-announces-signing-of-loan-restructuring-agreement-with-european-investment-bank-con-scni-20240813monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-announces-positive-regulatory-feedback-from-the-pei-on-the-path--scni-20240723monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-announces-promising-results-in-an-in-vivo-proof-of-concept-psori-scni-20240715monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-announces-receipt-of-an-updated-letter-of-intent-from-the-europe-scni-20240708monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-granted-extension-by-nasdaq-hearing-panel-to-regain-compliance-w-scni-20240703monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-publishes-q1-2024-financial-results-and-provides-business-update-scni-20240702monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-announces-receipt-of-a-letter-of-intent-from-the-european-invest-scni-20240613monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-con-scni-20240607monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-announces-receipt-of-a-nasdaq-staff-determination-letter-regardi-scni-20240524monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-publishes-fy-2023-financial-statements-files-annual-report-on-form-20-f-and-provide-scni-20240515monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-announces-receipt-of-nasdaq-delisting-notification-and-appeal-scni-20240506monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-to-showcase-its-novel-biological-local-therapeutic-for-plaque-psoriasis-at-dermatol-scni-20240410monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-scni-20240408monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-leadership-to-attend-bio-europe-spring-2024-scni-20240312monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-to-showcase-its-cgmp-biologics-cdmo-and-innovative-nanoab-pipeline-at-mixiii-2024-scni-20240229monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-welcomes-liat-halpert-as-head-of-business-development-and-sales-scni-20240213monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-congratulates-its-co-lead-scientific-research-collaborator-dirk--scni-20240125monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-announces-closing-of-exercise-of-outstanding-warrants-for-1-69-m-scni-20240104monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-ceo-issues-letter-to-shareholders-scni-20240104monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-announces-exercise-of-outstanding-warrants-for-1-69-million-in-g-scni-20231229monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-nasdaq-scni-to-host-analyst-and-investor-webinar-on-january-9-scni-20231227monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-announces-promising-results-in-a-psoriatic-human-skin-model-scni-20231212monthly0.5https://www.biopharmawatch.com/news/SCNI/study-published-in-antiviral-research-supports-promise-of-scinai-immunotherapeutics-scni-20231211monthly0.5https://www.biopharmawatch.com/news/SCNI/european-investment-bank-eib-extends-maturity-of-its-finance-facility-with-scinai-immunoth-scni-20231129monthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-regains-compliance-with-nasdaq-scni-20231120monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-launches-redesigned-corporate-website-clgn-20260318monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-announces-date-for-full-year-2025-financial-results-clgn-20260311monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-targets-new-aesthetic-market-driven-by-glp-1-weight-loss-treatments-clgn-20260217monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-announces-date-for-2025-third-quarter-financial-results-clgn-20251118monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-announces-date-for-second-quarter-financial-results-clgn-20250805monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-appoints-collagen-biomaterials-expert-as-new-head-of-north-america-commercial-op-clgn-20250714monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-broadens-its-collaboration-with-stemcell-technologies-clgn-20250609monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-announces-european-patent-allowance-secured-for-its-collagen-bas-clgn-20250604monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-announces-3-6-million-registered-direct-offering-priced-at-the-m-clgn-20250530monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-reports-2025-first-quarter-financial-results-and-provides-a-corp-clgn-20250528monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-announces-date-for-first-quarter-financial-results-clgn-20250514monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-s-collink-3d-bioinks-and-technologies-offer-a-relevant-and-timely-solution-to-fd-clgn-20250415monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-reports-2024-financial-results-and-provides-a-corporate-update-clgn-20250326monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-announces-date-for-2024-fourth-quarter-and-full-year-2024-financ-clgn-20250319monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-expands-distribution-for-its-vergenixstr-product-in-europe-and-asia-clgn-20250224monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-provides-a-corporate-update-clgn-20250212monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-reports-2024-third-quarter-financial-results-and-provides-corpor-clgn-20241127monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-announces-date-for-2024-third-quarter-financial-results-and-conf-clgn-20241112monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-reports-2024-second-quarter-financial-results-and-provides-corpo-clgn-20240820monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-and-stratasys-announce-pre-clinical-study-for-regenerative-commercial-sized-brea-clgn-20240819monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-announces-date-for-2024-second-quarter-financial-statements-and--clgn-20240806monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-unveils-inaugural-esg-and-sustainability-report-clgn-20240729monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-successfully-bio-prints-200cc-commercial-size-regenerative-breast-implants-and-r-clgn-20240606monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-announces-first-quarter-financial-results-for-2024-and-provides--clgn-20240529monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-announces-date-for-2024-first-quarter-financial-results-and-conf-clgn-20240516monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-reports-2023-full-year-financial-results-and-provides-corporate--clgn-20240404monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-announces-date-for-2023-full-year-financial-results-and-conferen-clgn-20240326monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-issues-letter-to-shareholders-clgn-20240215monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-s-ceo-to-present-at-the-octane-aesthetic-tech-forum-conference-in-newport-beach--clgn-20240108monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-begins-preclinical-trial-with-commercial-size-regenerative-breas-clgn-20240102monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-announces-third-quarter-financial-results-for-2023-clgn-20231129monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-announces-date-for-2023-third-quarter-financial-results-and-conf-clgn-20231109monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-announces-patent-granted-in-u-s-for-photocurable-dermal-filler-clgn-20231101monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-joins-the-united-nations-global-compact-the-world-clgn-20230921monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-to-present-at-the-h-c-wainwright-annual-growth-conference-clgn-20230905monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-announces-second-quarter-financial-results-for-2023-with-revenue-clgn-20230824monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-announces-date-for-2023-second-quarter-financial-results-and-con-clgn-20230809monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-achieves-milestone-and-to-receive-10-million-from-abbvie-in-accordance-with-its--clgn-20230626monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-announces-first-quarter-financial-results-for-2023-and-provides--clgn-20230524monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-announces-date-for-2023-first-quarter-financial-results-and-conf-clgn-20230502monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-announces-full-year-financial-results-for-2022-and-provides-corp-clgn-20230329monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-announces-date-for-2022-full-year-financial-results-and-conferen-clgn-20230314monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-issues-letter-to-shareholders-clgn-20230124monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-announces-successful-pre-clinical-results-in-3d-bioprinted-regenerative-breast-i-clgn-20230104monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-enriches-portfolio-of-rhcollagen-based-bioinks-with-launch-of-collink-3dtm-50l-i-clgn-20230103monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-provides-business-updates-and-third-quarter-2022-financial-resul-clgn-20221201monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-tel-aviv-university-and-sheba-medical-center-join-forces-to-co-develop-rhcollage-clgn-20221115monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-expands-rhcollagen-based-bioink-platform-with-launch-of-collink-3d-90-clgn-20221107monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-to-present-at-canaccord-genuity-medtech-diagnostics-and-digital-health-services--clgn-20221103monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-to-present-at-the-dawson-james-small-cap-growth-conference-on-october-12-clgn-20221003monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-to-present-at-the-international-conference-on-biofabrication-2022-in-tuscany-ita-clgn-20220919monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-to-participate-in-september-investor-conferences-clgn-20220906monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-provides-business-updates-and-second-quarter-2022-financial-resu-clgn-20220825monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-to-present-and-exhibit-at-termis-annual-conference-in-toronto-canada-clgn-20220705monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-advances-its-3d-bioprinted-regenerative-breast-implants-into-porcine-study-clgn-20220629monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-provides-business-updates-and-first-quarter-2022-financial-resul-clgn-20220526monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-ceo-yehiel-tal-to-moderate-isbf-clgn-20220425monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-to-present-at-the-aesthetics-innovation-summit-2022-clgn-20220413monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-provides-business-updates-and-fiscal-year-2021-financial-results-clgn-20220324monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-issues-letter-to-shareholders-clgn-20220105monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-announces-publication-highlighting-its-rhcollagen-based-photocurable-dermal-fill-clgn-20211202monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-provides-business-updates-and-third-quarter-2021-financial-resul-clgn-20211118monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-announces-commercial-launch-of-bioink-platform-with-collink-3d-for-use-in-3d-bio-clgn-20211115monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-to-present-at-dawson-james-small-cap-growth-conference-on-october-21st-clgn-20211014monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-s-rhcollagen-bioink-used-by-technion-researchers-to-develop-3d-bioprinted-vascul-clgn-20211011monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-to-present-at-fall-harvest-best-ideas-from-the-buy-side-on-october-5-2021-clgn-20210930monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-ceo-yehiel-tal-to-discuss-emerging-uses-of-rhcollagen-in-aesthetic-and-regenerat-clgn-20210927monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-ceo-yehiel-tal-elected-to-the-board-of-directors-of-the-international-society-fo-clgn-20210909monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-to-present-at-the-h-c-wainwright-annual-global-investment-conference-in-septembe-clgn-20210907monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-appoints-medical-aesthetics-veteran-alisa-lask-to-board-of-directors-clgn-20210819monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-provides-business-updates-and-second-quarter-2021-financial-resu-clgn-20210819monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-to-present-on-the-use-of-collagen-bioink-as-a-platform-for-3d-bi-clgn-20210816monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-announces-effectiveness-of-uplisting-to-the-nasdaq-global-market-ordinary-shares-clgn-20210604monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-reports-first-quarter-2021-financial-results-with-record-revenue-clgn-20210527monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-announces-uplisting-to-the-nasdaq-global-market-and-transition-to-trading-of-ord-clgn-20210525monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-appoints-additive-manufacturing-executive-hugh-evans-to-its-board-of-directors-clgn-20210329monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-reports-year-end-financial-results-for-fiscal-year-2020-clgn-20210326monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-to-present-at-the-h-c-wainwright-global-life-sciences-conference-clgn-20210304monthly0.5https://www.biopharmawatch.com/news/CLGN/termination-of-licensing-agreement-for-bioprinting-of-scaffolds-for-lung-transplants-clgn-20210225monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-issues-letter-to-shareholders-clgn-20210218monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-announces-development-and-global-commercialization-agreement-with-allergan-aesth-clgn-20210208monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-to-supply-rhcollagen-to-stemcell-technologies-for-use-in-a-broad-range-of-cell-c-clgn-20201210monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-reports-third-quarter-q3-2020-financial-results-and-provides-bus-clgn-20201201monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-announces-early-development-program-of-antiviral-agent-for-potential-treatment-o-clgn-20201110monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-receives-substantial-first-order-for-its-vergenix-flowable-gel-product-in-ukrain-clgn-20201026monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-presents-on-the-use-of-novel-plant-derived-recombinant-human-col-clgn-20200916monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-signs-distribution-agreement-for-its-vergenix-flowable-gel-produ-clgn-20200914monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-to-present-at-science-of-aging-virtual-symposium-2020-during-hea-clgn-20200831monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-reports-second-quarter-q2-2020-financial-results-clgn-20200828monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-reports-first-quarter-q1-2020-financial-results-clgn-20200527monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-to-host-webinar-highlighting-its-plant-based-human-recombinant-collagen-rhcollag-clgn-20200505monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-reports-year-end-financial-results-for-fiscal-year-2019-clgn-20200401monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-raising-4-45-million-in-u-s-private-placement-clgn-20200214monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-announces-appointment-of-roger-j-pomerantz-m-d-f-a-c-p-as-chairman-of-the-board--clgn-20200210monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-launches-new-corporate-website-to-showcase-recent-developments-in-core-business--clgn-20200204monthly0.5https://www.biopharmawatch.com/news/CLGN/3d-systems-and-collplant-biotechnologies-join-forces-to-accelerate-breakthroughs-in-regene-clgn-20200113monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-partners-in-the-advanced-regenerative-manufacturing-institute-clgn-20200106monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-publishes-letter-to-shareholders-clgn-20191219monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-reports-third-quarter-2019-financial-results-and-provides-business-update-clgn-20191129monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-ceo-yehiel-tal-appointed-to-serve-on-international-society-for-biofabrication-clgn-20191022monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-to-present-at-dawson-james-small-cap-growth-conference-on-october-29-2019-in-flo-clgn-20191016monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-reports-second-quarter-2019-financial-results-and-provides-business-update-clgn-20190926monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-closes-on-5-5-million-financing-clgn-20190909monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-to-present-at-the-21st-annual-rodman-renshaw-global-investment-c-clgn-20190905monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-raising-5-5-million-clgn-20190903monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-is-developing-3d-bioprinted-implants-for-regeneration-of-breast-tissue-clgn-20190805monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-announces-corporate-name-change-to-collplant-biotechnologies-to-better-reflect-i-clgn-20190620monthly0.5https://www.biopharmawatch.com/news/CLGN/clinical-results-from-collplant-clgn-20190604monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-reports-first-quarter-2019-financial-results-and-provides-business-update-clgn-20190530monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-presents-its-rhcollagen-based-bioinks-for-3d-bioprinting-of-tissues-and-organs-a-clgn-20190528monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-launches-new-hq-and-r-d-center-in-israel-clgn-20190522monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-announces-publication-of-study-in-science-translational-medicine-showing-composi-clgn-20190424monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-to-present-at-thinkequity-conference-on-may-2-2019-in-new-york-city-clgn-20190423monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-reports-fourth-quarter-and-year-end-2018-financial-results-and-provides-business-clgn-20190401monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-renews-distribution-agreement-for-its-soft-tissue-repair-product-vergenix-str-wi-clgn-20190318monthly0.5https://www.biopharmawatch.com/news/CLGN/study-published-in-wounds-journal-shows-remarkable-wound-closure-performance-with-collplan-clgn-20190311monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-announces-approval-of-its-rhcollagen-manufacturing-facility-by-european-union-no-clgn-20190219monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-announces-appointment-of-jonathan-m-n-rigby-as-chairman-of-the-board-clgn-20190204monthly0.5https://www.biopharmawatch.com/news/CLGN/clinical-trial-published-in-the-journal-of-shoulder-and-elbow-surgery-concludes-that-collp-clgn-20181210monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-reports-third-quarter-2018-financial-results-and-provides-business-update-clgn-20181129monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-announces-closing-of-global-licensing-and-commercialization-agreement-with-unite-clgn-20181112monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-to-ring-nasdaq-opening-bell-on-november-8-2018-clgn-20181107monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-shares-will-be-traded-from-tuesday-oct-30-exclusively-on-nasdaq-clgn-20181028monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-reports-second-quarter-2018-financial-results-and-provides-business-update-clgn-20180921monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-holdings-to-present-at-the-20th-annual-rodman-renshaw-global-investment-conferen-clgn-20180828monthly0.5https://www.biopharmawatch.com/news/CLGN/dual-listed-collplant-to-voluntarily-delist-from-tel-aviv-stock-exchange-clgn-20180808monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-appoints-dr-wolfgang-ruttenstorfer-to-its-board-of-directors-clgn-20180705monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-receives-research-and-development-project-approval-from-the-israel-innovation-au-clgn-20180626monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-appoints-professor-shay-soker-from-wake-forest-institute-for-regenerative-medici-clgn-20180619monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-reports-first-quarter-2018-financial-results-and-provides-business-update-clgn-20180524monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-files-u-s-patent-application-for-next-generation-dermal-filler-clgn-20180508monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-announces-completion-of-the-third-closing-of-alpha-investment-clgn-20180501monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-opens-a-new-rhcollagen-production-facility-clgn-20180423monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-petitions-court-to-voluntarily-delist-ordinary-shares-from-the-tel-aviv-stock-ex-clgn-20180416monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-appoints-revital-mandil-levin-as-chief-business-development-officer-clgn-20180412monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-reports-fourth-quarter-and-year-end-2017-financial-results-and-provides-business-clgn-20180321monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-joins-remdo-clgn-20180221monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-announces-ads-listing-on-nasdaq-clgn-20180131monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-appoints-david-tsur-as-chairman-of-the-board-clgn-20180116monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-receives-substantial-repeat-order-for-its-biological-ink-clgn-20171128monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-expands-european-sales-network-the-company-has-signed-a-distribution-agreement-i-clgn-20171128monthly0.5https://www.biopharmawatch.com/news/CLGN/vote-of-confidence-in-collplant-completion-of-agreement-for-immediate-investment-of-usd-1--clgn-20171113monthly0.5https://www.biopharmawatch.com/news/CLGN/innovation-authority-gives-vote-of-confidence-collplant-receives-innovation-authority-appr-clgn-20171030monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-signs-definitive-agreement-for-5-million-private-placement-with-us-investor-clgn-20170911monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-in-advanced-negotiations-for-us-private-placement-of-usd-5-0-million-agreement-i-clgn-20170905monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-files-patent-for-3d-bio-printing-of-organs-and-tissues-clgn-20170612monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-provides-operational-update-for-q1-2017-clgn-20170531monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-extends-its-european-distribution-network-with-signing-of-new-distribution-agree-clgn-20170522monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-establishes-a-separate-division-to-focus-on-3d-bio-printing-of-organs-and-tissue-clgn-20170511monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-reports-positive-results-from-post-marketing-surveillance-of-vergenix-fg-clgn-20170411monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-provides-commercial-and-operational-update-clgn-20170330monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-receives-ce-mark-for-vergenix-str-for-treatment-of-tendinopathy-clgn-20161019monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-receives-ce-mark-for-vergenix-fg-wound-filler-clgn-20160223monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-to-present-results-of-its-product-for-the-treatment-in-tendinopathy-at-the-4th-t-clgn-20150908monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-executes-non-binding-term-sheet-to-develop-and-commercialize-a-novel-product-for-clgn-20150713monthly0.5https://www.biopharmawatch.com/news/CLGN/another-clinical-trial-for-collplant-trials-for-vergenix-str-have-begun-a-human-collagen-b-clgn-20150112monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-launched-a-clinical-trial-with-vergenix-fg-a-gel-based-on-a-human-collagen-for-t-clgn-20141201monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-names-dr-nadav-orr-vice-president-research-and-development-clgn-20140908monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-holds-intellectual-property-rights-in-usa-one-of-the-largest-target-markets-for--clgn-20140623monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-takes-a-step-closer-to-commercializing-its-vergenix-flowable-gel-product-for-tre-clgn-20140616monthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-takes-significant-steps-towards-sales-in-europe-clgn-20121217monthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-to-hold-an-extraordinary-general-meeting-on-july-25-2024-pursuant-to-s-lsb-20240705monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-reports-inducement-award-under-nasdaq-listing-rules-aray-20260529monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-fourth-quarter-fiscal-2025-financial-results-on-august-13-2025-aray-20250730monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-in-the-jefferies-global-healthcare-conference-2025-aray-20250529monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-showcases-new-long-term-data1-on-benefits-of-5-session-radiotherapy-treatment-for--aray-20250507monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-first-srs-sbrt-patient-treatments-in-austria-with-the-cyberknife-system-aray-20250505monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-third-quarter-fiscal-2025-financial-results-on-april-30-2025-aray-20250416monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-cyberknife-platform-featured-in-new-studies-showcasing-its-benefits-in-central-ner-aray-20250403monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-at-37th-annual-roth-conference-aray-20250312monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-first-100-patient-treatment-regimens-completed-in-china-using-the-tomo-c-aray-20250123monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-second-quarter-fiscal-2025-financial-results-on-february-5-2025-aray-20250122monthly0.5https://www.biopharmawatch.com/news/ARAY/leonel-peralta-to-join-accuray-as-chief-operations-officer-aray-20250121monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-china-national-medical-products-administration-approval-of-the-radixact--aray-20250113monthly0.5https://www.biopharmawatch.com/news/ARAY/new-data-indicates-the-cyberknife-system-can-provide-a-safe-and-effective-treatment-option-aray-20241218monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-reports-inducement-award-under-nasdaq-listing-rules-aray-20241126monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-first-quarter-fiscal-2025-financial-results-on-november-6-2024-aray-20241023monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-appoints-michael-murphy-as-vp-corporate-controller-aray-20241021monthly0.5https://www.biopharmawatch.com/news/ARAY/new-england-journal-of-medicine-study-reaffirms-five-session-radiation-treatment-provides--aray-20241017monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-celebrates-opening-of-genolier-innovation-hub-in-switzerland-initiation-of-cyberkn-aray-20240930monthly0.5https://www.biopharmawatch.com/news/ARAY/gifu-prefectural-general-medical-center-achieves-milestone-with-treatment-of-the-first-can-aray-20240910monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-receives-ce-mark-for-a-new-helical-radiation-delivery-system-accuray-helix-aray-20240827monthly0.5https://www.biopharmawatch.com/news/ARAY/halifax-health-in-florida-is-first-in-the-u-s-to-treat-patients-with-cancer-using-the-accu-aray-20240813monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-fourth-quarter-fiscal-2024-financial-results-on-august-14-2024-aray-20240731monthly0.5https://www.biopharmawatch.com/news/ARAY/heidelberg-university-hospital-in-germany-invests-in-fourth-accuray-radiotherapy-device-th-aray-20240627monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-and-truenorth-medical-physics-sign-agreement-to-provide-radiation-oncology-support-aray-20240620monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-approval-of-the-accuray-precision-treatment-planning-system-by-china-aray-20240612monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-in-the-jefferies-global-healthcare-conference-2024-aray-20240522monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-showcases-advances-in-radiation-therapy-solutions-designed-to-improve-the-cancer-t-aray-20240425monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-expands-global-training-center-network-with-opening-of-new-facility-in-genolier-sw-aray-20240418monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-third-quarter-fiscal-2024-financial-results-on-may-1-2024-aray-20240417monthly0.5https://www.biopharmawatch.com/news/ARAY/new-data-from-two-clinical-studies-indicate-high-risk-and-recurrent-prostate-cancers-can-b-aray-20240326monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-speak-at-36th-annual-roth-conference-aray-20240304monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-speak-at-oppenheimer-34th-annual-healthcare-medtech-services-confe-aray-20240227monthly0.5https://www.biopharmawatch.com/news/ARAY/quebec-cancer-center-is-first-in-canada-to-treat-cancer-patients-using-the-accuray-radixac-aray-20240213monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-in-the-btig-medtech-digital-health-life-science-diagnostic-tools-co-aray-20240205monthly0.5https://www.biopharmawatch.com/news/ARAY/providence-swedish-radiosurgery-center-in-seattle-invests-in-second-accuray-cyberknife-sys-aray-20240125monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-second-quarter-fiscal-2024-financial-results-on-january-31-2024-aray-20240116monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-initiates-sales-of-the-vitalhold-solution-in-japan-supporting-surface-guided-radia-aray-20231205monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-in-the-14th-annual-jefferies-london-healthcare-conference-aray-20231031monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-first-quarter-fiscal-2024-financial-results-on-november-7-2023-aray-20231026monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-approval-of-the-tomo-c-radiation-treatment-delivery-system-by-china-aray-20231003monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-and-limbus-ai-unveil-online-adaptive-therapy-solution-for-the-radixact-system-at-a-aray-20231002monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-opens-new-global-training-center-at-madison-wi-headquarters-to-advance-radiotherap-aray-20230918monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-host-investor-day-at-astro-on-october-3-2023-aray-20230914monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-receives-fda-clearance-for-vitalhold-on-the-radixact-system-breast-cancer-treatmen-aray-20230809monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-fiscal-year-end-2023-financial-results-on-august-9-2023-aray-20230726monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-announces-its-addition-to-the-russell-2000-index-aray-20230626monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-suzanne-winter-selected-as-one-of-the-top-50-healthcare-technology-ceos--aray-20230615monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-cyberknife-and-tomotherapy-platforms-featured-in-more-than-55-abstracts-presented--aray-20230517monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-third-quarter-fiscal-2023-financial-results-on-april-26-2023-aray-20230413monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-speak-at-33rd-annual-oppenheimer-healthcare-conference-aray-20230308monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-in-the-cowen-43rd-annual-health-care-conference-aray-20230221monthly0.5https://www.biopharmawatch.com/news/ARAY/trial-data-indicates-targeted-short-course-radiation-therapy-preserves-urinary-continence--aray-20230216monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-in-the-btig-medtech-digital-health-life-science-diagnostic-tools-co-aray-20230207monthly0.5https://www.biopharmawatch.com/news/ARAY/robert-c-kill-joins-accuray-board-of-directors-aray-20230201monthly0.5https://www.biopharmawatch.com/news/ARAY/european-radiosurgery-center-munich-invests-in-second-accuray-cyberknife-system-to-support-aray-20230126monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-second-quarter-fiscal-2023-financial-results-on-february-1-2023-aray-20230118monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-first-patient-treatments-in-new-zealand-with-the-cyberknife-system-the-w-aray-20230117monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-in-the-b-riley-securities-aray-20230110monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-receives-imv-award-for-best-in-service-in-radiation-oncology-for-2022-aray-20221128monthly0.5https://www.biopharmawatch.com/news/ARAY/oscar-lambret-center-in-france-installs-second-accuray-radixact-system-the-hospital-aray-20221116monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-tomo-c-registration-submission-to-china-aray-20221101monthly0.5https://www.biopharmawatch.com/news/ARAY/new-reimbursement-approved-by-the-japanese-ministry-of-health-labor-and-welfare-for-the-ac-aray-20221026monthly0.5https://www.biopharmawatch.com/news/ARAY/ge-healthcare-and-accuray-collaborate-to-expand-access-advance-the-practice-of-precision-r-aray-20221021monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-first-quarter-fiscal-2023-financial-results-on-november-2-2022-aray-20221019monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-and-c-rad-unveil-automated-breast-cancer-treatment-package-for-the-radixact-system-aray-20221013monthly0.5https://www.biopharmawatch.com/news/ARAY/data-published-in-the-lancet-oncology-indicate-men-with-prostate-cancer-treated-with-the-a-aray-20221011monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-host-meeting-with-analysts-and-investors-at-astro-on-october-24-2022-aray-20221006monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-first-cyberknife-systems-in-africa-providing-a-new-option-and-hope-for-p-aray-20220930monthly0.5https://www.biopharmawatch.com/news/ARAY/dr-seth-blacksburg-joins-accuray-as-vp-chief-medical-officer-americas-region-aray-20220914monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-partners-with-swiss-based-genolier-innovation-hub-to-bring-medical-and-technologic-aray-20220907monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-fiscal-year-end-2022-financial-results-on-august-10-2022-aray-20220727monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-cyberknife-system-real-world-data-and-clinical-studies-show-benefits-in-treatment--aray-20220712monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-appoints-franco-n-palomba-as-vp-chief-accounting-officer-controller-aray-20220615monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-reports-inducement-awards-under-nasdaq-listing-rules-aray-20220606monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-and-limbus-ai-inc-partner-to-leverage-limbus-aray-20220602monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-appoints-sandeep-chalke-as-svp-chief-commercial-officer-aray-20220517monthly0.5https://www.biopharmawatch.com/news/ARAY/new-data-presented-at-estro-2022-reinforce-benefits-of-accuray-cyberknife-and-tomotherapy--aray-20220510monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-clearrt-helical-fan-beam-kvct-imaging-wins-best-new-technology-solution-for-oncolo-aray-20220505monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-suzanne-winter-president-promoted-to-president-and-ceo-joshua-levine-wil-aray-20220427monthly0.5https://www.biopharmawatch.com/news/ARAY/owner-of-arkansas-derby-winner-named-horse-after-the-life-changing-accuray-cyberknife-radi-aray-20220421monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-third-quarter-fiscal-2022-financial-results-on-april-27-2022-aray-20220413monthly0.5https://www.biopharmawatch.com/news/ARAY/10-year-data-shows-accuray-cyberknife-system-provides-long-lasting-relief-of-the-excruciat-aray-20220331monthly0.5https://www.biopharmawatch.com/news/ARAY/carti-selects-accuray-cyberknife-s7-system-to-increase-access-to-advanced-cancer-care-for--aray-20220308monthly0.5https://www.biopharmawatch.com/news/ARAY/nice-endorses-radiosurgery-treatments-for-trigeminal-neuralgia-supporting-accuray-cyberkni-aray-20220228monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-in-the-cowen-42nd-annual-health-care-conference-aray-20220224monthly0.5https://www.biopharmawatch.com/news/ARAY/largest-hospital-in-queensland-australia-acquires-multiple-accuray-radixact-systems-with-t-aray-20220214monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-tomotherapy-helical-radiotherapy-system-helps-preserve-breast-cancer-patients-aray-20220210monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-in-the-btig-medtech-digital-health-life-science-diagnostic-tools-co-aray-20220207monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-second-quarter-fiscal-2022-financial-results-on-january-26-2022-aray-20220112monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-cyberknife-robotic-radiosurgery-system-receives-shonin-approval-to-treat-trigemina-aray-20211215monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-cyberknife-robotic-radiotherapy-platform-expands-range-of-neurological-indications-aray-20211110monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-at-stifel-2021-virtual-healthcare-conference-aray-20211109monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fiscal-2022-first-quarter-financial-results-aray-20211103monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-cyberknife-robotic-radiotherapy-platform-could-significantly-improve-survival-in-e-aray-20211025monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-preliminary-first-quarter-fiscal-2022-financial-results-and-raises-fy22--aray-20211021monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-unveils-volo-ultra-the-latest-innovation-for-the-radixact-system-at-astro-2021-aray-20211019monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-first-quarter-fiscal-2022-financial-results-on-november-3-2021-aray-20211013monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-host-astro-analyst-investor-meeting-on-october-25-2021-aray-20211012monthly0.5https://www.biopharmawatch.com/news/ARAY/c-rad-and-accuray-sign-agreement-to-enhance-radixact-system-breast-cancer-treatment-capabi-aray-20211004monthly0.5https://www.biopharmawatch.com/news/ARAY/french-hospital-network-unicancer-acquires-multiple-accuray-radixact-systems-with-the-clea-aray-20210929monthly0.5https://www.biopharmawatch.com/news/ARAY/nagoya-city-university-hospital-is-first-in-japan-to-treat-cancer-patients-using-the-accur-aray-20210923monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-cyberknife-robotic-radiotherapy-platform-is-superior-to-conventional-linear-accele-aray-20210914monthly0.5https://www.biopharmawatch.com/news/ARAY/mika-nishimura-joins-accuray-board-of-directors-aray-20210823monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fourth-quarter-and-fiscal-2021-financial-results-aray-20210811monthly0.5https://www.biopharmawatch.com/news/ARAY/hong-kong-sanatorium-hospital-transforms-cancer-care-in-asia-with-treatment-of-first-patie-aray-20210722monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-fiscal-year-end-2021-financial-results-on-august-11-2021-aray-20210714monthly0.5https://www.biopharmawatch.com/news/ARAY/beloved-family-pet-aray-20210624monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-promotion-of-suzanne-winter-to-president-aray-20210622monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-expands-cyberknife-system-versatility-with-integration-of-raysearch-aray-20210616monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-expands-commercialization-of-clearrt-helical-fan-beam-kvct-imaging-for-the-radixac-aray-20210610monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-continua-a-expansa-o-global-do-sistema-radixact-para-mais-centros-de-tratamento-de-aray-20210511monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-continu-a-la-expansio-n-global-del-sistema-radixact-a-ma-s-centros-de-tratamiento--aray-20210511monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-new-120-million-credit-facility-aray-20210506monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-reports-inducement-awards-under-nasdaq-listing-rules-aray-20210506monthly0.5https://www.biopharmawatch.com/news/ARAY/geisinger-becomes-first-in-u-s-to-treat-cancer-patients-with-accuray-synchrony-technology--aray-20210503monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-customers-achieve-top-scores-in-aapm-markerless-lung-target-tracking-challenge-mat-aray-20210429monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-third-quarter-fiscal-2021-financial-results-aray-20210427monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-appoints-jean-philippe-pignol-m-d-ph-d-as-chief-medical-technology-officer-aray-20210426monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-receives-shonin-approval-for-clearrt-helical-kvct-imaging-ce-mark-expected-by-end--aray-20210422monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-third-quarter-fiscal-2021-financial-results-on-april-27-2021-aray-20210413monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-in-the-cowen-41st-annual-health-care-conference-aray-20210223monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-appoints-healthcare-executive-and-physician-byron-c-scott-to-board-of-directors-aray-20210219monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-in-btig-aray-20210205monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-second-quarter-fiscal-2021-financial-results-aray-20210127monthly0.5https://www.biopharmawatch.com/news/ARAY/seven-year-data-shows-accuray-tomotherapy-system-provides-excellent-long-term-control-of-l-aray-20210119monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-second-quarter-fiscal-2021-financial-results-on-january-27-2021-aray-20210108monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-at-j-p-morgan-aray-20210106monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-receives-510-k-fda-clearance-for-clearrt-helical-kvct-imaging-for-the-radixact-tre-aray-20210105monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-reports-inducement-awards-under-nasdaq-listing-rules-aray-20201203monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-and-dhl-supply-chain-establish-global-service-logistics-platform-to-support-delive-aray-20201118monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-appoints-renowned-medical-device-industry-executive-jim-dennison-as-senior-vice-pr-aray-20201112monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-showcases-radiation-therapy-innovations-designed-to-enable-better-outcomes-with-le-aray-20201110monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-first-quarter-fiscal-2021-financial-results-aray-20201029monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-agreement-with-brainlab-to-expand-cyberknife-platform-treatment-capabili-aray-20201028monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-appoints-mike-leischer-vice-president-and-general-manager-americas-region-aray-20201019monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-first-quarter-fiscal-2021-financial-results-on-october-29-2020-aray-20201015monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-host-astro-analyst-investor-meeting-on-october-26-2020-aray-20201013monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-radixact-system-with-synchrony-technology-delivers-advanced-cancer-treatments-at-m-aray-20200917monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-present-at-lake-street-capital-markets-aray-20200910monthly0.5https://www.biopharmawatch.com/news/ARAY/university-hospital-citta-della-salute-e-della-scienza-turin-italy-is-first-in-eimea-to-tr-aray-20200901monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fourth-quarter-and-fiscal-2020-financial-results-aray-20200813monthly0.5https://www.biopharmawatch.com/news/ARAY/anne-b-le-grand-joins-accuray-board-of-directors-aray-20200722monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-fiscal-year-end-2020-financial-results-on-august-13-2020-aray-20200716monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-launches-new-cyberknife-s7-system-aray-20200617monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-synchrony-real-time-adaptive-technology-for-the-radixact-system-wins-2020-medtech--aray-20200519monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fiscal-2020-third-quarter-financial-results-aray-20200428monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-fiscal-2020-third-quarter-financial-results-on-april-28-2020-aray-20200416monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-reports-inducement-awards-under-nasdaq-listing-rules-aray-20200305monthly0.5https://www.biopharmawatch.com/news/ARAY/first-accuray-cyberknife-m6-system-installed-in-missouri-at-mercy-hospital-st-louis-aray-20200225monthly0.5https://www.biopharmawatch.com/news/ARAY/studies-support-use-of-the-accuray-tomotherapy-system-for-advanced-rectal-cancer-to-improv-aray-20200205monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fiscal-2020-second-quarter-financial-results-aray-20200128monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-fiscal-2020-second-quarter-financial-results-on-january-28-2020-aray-20200116monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-discuss-revenue-growth-expectations-for-the-next-three-fiscal-years-at-the-jp-m-aray-20200113monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-cyberknife-system-provides-excellent-disease-control-for-men-with-recurrent-prosta-aray-20200108monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-on-january-15-2020-aray-20200106monthly0.5https://www.biopharmawatch.com/news/ARAY/timpanogos-cancer-services-first-in-utah-to-offer-precise-and-accurate-radiation-treatment-aray-20191212monthly0.5https://www.biopharmawatch.com/news/ARAY/stanford-university-medical-center-to-acquire-second-accuray-cyberknife-m6-system-aray-20191204monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-reports-inducement-awards-under-nasdaq-listing-rules-aray-20191106monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fiscal-2020-first-quarter-financial-results-aray-20191029monthly0.5https://www.biopharmawatch.com/news/ARAY/first-asia-pacific-hospital-treats-patients-with-raystation-and-radixact-aray-20191028monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-fiscal-2020-first-quarter-financial-results-on-october-29-2019-aray-20191010monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-educates-radiation-oncology-practices-on-the-potential-impact-of-the-proposed-alte-aray-20190919monthly0.5https://www.biopharmawatch.com/news/ARAY/data-published-in-the-lancet-oncology-suggest-cyberknife-prostate-patients-experienced-low-aray-20190917monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-appoints-healthcare-veteran-james-m-hindman-to-board-of-directors-aray-20190912monthly0.5https://www.biopharmawatch.com/news/ARAY/geisinger-medical-center-is-first-in-pennsylvania-to-treat-cancer-patients-with-accuray-ra-aray-20190910monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-set-astro-2019-in-motion-with-patient-first-cancer-treatment-innovations-aray-20190905monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-host-astro-investor-meeting-on-september-16-2019-aray-20190904monthly0.5https://www.biopharmawatch.com/news/ARAY/froedtert-the-medical-college-of-wisconsin-cancer-network-is-first-in-the-world-to-treat-c-aray-20190821monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fourth-quarter-and-fiscal-2019-financial-results-aray-20190815monthly0.5https://www.biopharmawatch.com/news/ARAY/new-data-demonstrating-benefits-of-accuray-software-solutions-presented-at-the-annual-meet-aray-20190724monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-provides-update-on-china-joint-venture-operational-progress-aray-20190723monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-fiscal-2019-fourth-quarter-and-full-year-financial-results-on-august-15--aray-20190719monthly0.5https://www.biopharmawatch.com/news/ARAY/swiss-medical-network-advances-cancer-care-in-switzerland-with-multi-system-agreement-for--aray-20190718monthly0.5https://www.biopharmawatch.com/news/ARAY/hong-kong-sanatorium-hospital-signs-agreement-at-estro-to-acquire-the-synchrony-motion-tra-aray-20190501monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-launches-synchrony-motion-tracking-and-correction-technology-for-the-radixact-syst-aray-20190424monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fiscal-2019-third-quarter-results-aray-20190423monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-fiscal-2019-third-quarter-financial-results-on-april-23-2019-aray-20190402monthly0.5https://www.biopharmawatch.com/news/ARAY/phase-3-randomized-trial-data-shows-sbrt-has-similar-acute-safety-profile-to-conventional--aray-20190222monthly0.5https://www.biopharmawatch.com/news/ARAY/primer-sistema-radixact-de-accuray-instalado-en-ame-rica-latina-en-la-cli-nica-el-rosario--aray-20190207monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fiscal-2019-second-quarter-results-aray-20190122monthly0.5https://www.biopharmawatch.com/news/ARAY/the-urology-group-surpasses-1-600-prostate-cancer-patients-treated-with-the-accuray-cyberk-aray-20190117monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-fiscal-2019-second-quarter-financial-results-on-january-22-2019-aray-20190108monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-on-january-9-2019-aray-20190102monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-cyberknife-system-treatment-delivery-times-up-to-50-percent-faster-with-software-u-aray-20181206monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fiscal-2019-first-quarter-financial-results-aray-20181030monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-showcases-radiation-therapy-innovations-designed-to-improve-what-aray-20181017monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-fiscal-2019-first-quarter-financial-results-on-october-30-2018-aray-20181011monthly0.5https://www.biopharmawatch.com/news/ARAY/technische-universita-t-mu-nchen-hospital-is-first-in-germany-to-treat-cancer-patients-wit-aray-20181009monthly0.5https://www.biopharmawatch.com/news/ARAY/hcg-is-first-in-india-to-treat-cancer-patients-using-the-accuray-radixact-system-aray-20181004monthly0.5https://www.biopharmawatch.com/news/ARAY/largest-prostate-sbrt-studies-to-date-show-accuray-cyberknife-system-provides-excellent-pr-aray-20180925monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fourth-quarter-and-fiscal-2018-financial-results-aray-20180816monthly0.5https://www.biopharmawatch.com/news/ARAY/addenbrooke-aray-20180725monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-fiscal-2018-fourth-quarter-and-full-year-financial-results-on-august-16--aray-20180719monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-receives-aerb-approval-for-sale-and-supply-of-its-radixact-x9-system-in-india-aray-20180621monthly0.5https://www.biopharmawatch.com/news/ARAY/new-studies-show-the-accuray-tomotherapy-system-provides-greater-precision-excellent-clini-aray-20180530monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-cyberknife-customer-achieves-top-score-in-multiple-brain-metastases-trog-2018-trea-aray-20180522monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-unveils-new-company-website-reflecting-industry-leading-patient-first-cancer-treat-aray-20180515monthly0.5https://www.biopharmawatch.com/news/ARAY/mercy-advances-cancer-care-in-missouri-with-multi-system-multi-hospital-agreement-for-accu-aray-20180509monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-reports-inducement-awards-under-nasdaq-listing-rules-aray-20180504monthly0.5https://www.biopharmawatch.com/news/ARAY/south-florida-radiation-oncology-treats-first-cancer-patients-using-its-new-cyberknife-m6--aray-20180424monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-bring-patient-first-cancer-treatment-innovations-to-estro-37-aray-20180417monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-fiscal-2018-third-quarter-financial-results-on-april-30-2018-aray-20180409monthly0.5https://www.biopharmawatch.com/news/ARAY/apollo-hospitals-in-india-to-acquire-two-accuray-radixact-systems-aray-20180328monthly0.5https://www.biopharmawatch.com/news/ARAY/erasmus-mc-completes-first-step-in-the-evolution-of-online-adaptive-radiation-therapy-with-aray-20180327monthly0.5https://www.biopharmawatch.com/news/ARAY/confe-rence-europe-enne-aero-academy-d-aray-20180220monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-s-european-aero-academy-meeting-innovation-and-safety-in-the-field-of-advanced-rad-aray-20180220monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-present-at-the-2018-rbc-capital-markets-global-healthcare-conference-on-februar-aray-20180215monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-retires-february-2018-convertible-notes-aray-20180205monthly0.5https://www.biopharmawatch.com/news/ARAY/study-shows-cyberknife-system-provides-long-lasting-pain-relief-for-trigeminal-neuralgia-p-aray-20180129monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-fiscal-second-quarter-revenue-exceeds-100-million-and-increases-15-percent-year-ov-aray-20180123monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-fiscal-2018-second-quarter-financial-results-on-january-23-2018-aray-20180110monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-on-january-10-2018-aray-20180103monthly0.5https://www.biopharmawatch.com/news/ARAY/first-hospitals-in-the-world-achieve-inter-system-connectivity-across-accuray-radiation-th-aray-20171214monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-military-veterans-support-u-s-veteran-community-aray-20171108monthly0.5https://www.biopharmawatch.com/news/ARAY/treatment-planning-for-the-cyberknife-system-now-up-to-40-faster-aray-20171026monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-generated-55-6-million-in-first-quarter-gross-orders-revenue-increased-5-percent-y-aray-20171024monthly0.5https://www.biopharmawatch.com/news/ARAY/european-court-of-appeal-rejects-varian-aray-20171019monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-fiscal-2018-first-quarter-financial-results-on-october-24-2017-aray-20171010monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-reports-inducement-grant-under-nasdaq-listing-rules-aray-20171004monthly0.5https://www.biopharmawatch.com/news/ARAY/10-year-data-shows-cyberknife-system-provides-excellent-long-term-control-of-low-risk-pros-aray-20170926monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-showcases-cyberknife-and-radixact-systems-at-astro-2017-aray-20170920monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fourth-quarter-and-fiscal-2017-financial-results-aray-20170822monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-fiscal-2017-fourth-quarter-and-full-year-results-on-august-22-2017-aray-20170814monthly0.5https://www.biopharmawatch.com/news/ARAY/first-radixact-system-research-results-presented-at-the-american-association-of-physicists-aray-20170804monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-receives-510-k-clearance-for-idms-data-management-system-upgrade-for-the-tomothera-aray-20170731monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-enhances-capital-structure-through-convertible-debt-transactions-aray-20170728monthly0.5https://www.biopharmawatch.com/news/ARAY/new-data-show-tomotherapy-system-superior-to-rapidarc-in-achieving-local-control-of-head-a-aray-20170720monthly0.5https://www.biopharmawatch.com/news/ARAY/neuro-spinal-hospital-in-dubai-to-acquire-accuray-cyberknife-and-radixact-systems-aray-20170711monthly0.5https://www.biopharmawatch.com/news/ARAY/montefiore-is-first-in-ny-metropolitan-area-to-treat-cancer-patients-with-accuray-radixact-aray-20170627monthly0.5https://www.biopharmawatch.com/news/ARAY/iuct-oncopole-advances-cancer-care-in-france-with-the-new-accuray-radixact-system-aray-20170620monthly0.5https://www.biopharmawatch.com/news/ARAY/anova-marks-1-500th-prostate-cancer-patient-treated-with-the-accuray-cyberknife-system-aray-20170616monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-enters-into-new-revolving-loan-agreement-aray-20170615monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-appoints-stan-gee-vp-of-revenue-management-aray-20170524monthly0.5https://www.biopharmawatch.com/news/ARAY/new-data-reinforce-benefits-of-tomotherapy-platform-for-mainstream-radiation-therapy-treat-aray-20170511monthly0.5https://www.biopharmawatch.com/news/ARAY/new-data-presented-at-estro-36-reinforce-unmatched-versatility-and-precision-of-the-cyberk-aray-20170511monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-showcase-cyberknife-and-radixact-systems-at-estro-2017-aray-20170503monthly0.5https://www.biopharmawatch.com/news/ARAY/cyberknife-system-provides-effective-treatment-option-with-minimal-side-effects-and-excell-aray-20170502monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-names-lionel-hadjadjeba-chief-commercial-officer-aray-20170427monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-third-quarter-gross-orders-increase-49-yoy-backlog-up-21-aray-20170427monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-fiscal-2017-third-quarter-financial-results-on-april-27-2017-aray-20170413monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-2017-regional-aero-summit-brings-together-leading-oncology-specialists-to-advance--aray-20170412monthly0.5https://www.biopharmawatch.com/news/ARAY/first-cancer-patients-in-africa-treated-with-the-tomotherapy-system-aray-20170411monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-launches-new-cancer-patient-websites-aray-20170302monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-present-at-cowen-and-company-37th-annual-healthcare-conference-on-march-6-2017-aray-20170221monthly0.5https://www.biopharmawatch.com/news/ARAY/cyberknife-system-provides-long-term-disease-control-for-prostate-cancer-patients-aray-20170216monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-in-the-2017-rbc-capital-markets-healthcare-conference-on-february-2-aray-20170213monthly0.5https://www.biopharmawatch.com/news/ARAY/the-accuray-radixact-system-receives-shonin-approval-aray-20170208monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-grows-second-quarter-gross-orders-17-backlog-up-16-yoy-aray-20170131monthly0.5https://www.biopharmawatch.com/news/ARAY/miami-cancer-institute-treats-first-cancer-patients-with-the-accuray-radixact-system-aray-20170126monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-continues-to-set-the-industry-standard-for-customer-satisfaction-aray-20170119monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-fiscal-2017-second-quarter-financial-results-on-january-31-2017-aray-20170117monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-present-at-jp-morgan-aray-20170110monthly0.5https://www.biopharmawatch.com/news/ARAY/hong-kong-sanatorium-hospital-to-acquire-three-radixacttm-systems-aray-20161221monthly0.5https://www.biopharmawatch.com/news/ARAY/first-cancer-patients-in-the-world-treated-with-the-smart-new-accuray-radixact-system-aray-20161208monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-in-the-citi-2016-global-healthcare-conference-aray-20161121monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-financial-results-for-first-quarter-and-affirms-full-year-fiscal-2017-guid-aray-20161027monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-fiscal-2017-first-quarter-financial-results-on-october-27-2016-aray-20161006monthly0.5https://www.biopharmawatch.com/news/ARAY/prospective-multi-institutional-study-shows-five-treatments-with-the-cyberknife-system-pro-aray-20160927monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-unveil-new-technology-at-the-astro-2016-annual-meeting-aray-20160922monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-in-the-morgan-stanley-global-healthcare-conference-2016-aray-20160906monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fourth-quarter-and-fiscal-2016-financial-results-aray-20160817monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-ce-marks-its-new-radixact-system-aray-20160809monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-retires-remaining-3-75-convertible-debt-aray-20160802monthly0.5https://www.biopharmawatch.com/news/ARAY/tomotherapy-system-provides-favorable-cosmetic-outcomes-without-compromising-efficacy-in-l-aray-20160721monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-products-continue-to-receive-highest-composite-user-satisfaction-ratings-in-latest-aray-20160714monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-fiscal-2016-fourth-quarter-and-full-year-results-on-august-17-2016-aray-20160707monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-receives-510-k-fda-clearance-for-the-radixact-image-guided-radiation-therapy-platf-aray-20160627monthly0.5https://www.biopharmawatch.com/news/ARAY/fucam-treats-1-000-breast-cancer-patients-with-the-tomotherapy-system-aray-20160621monthly0.5https://www.biopharmawatch.com/news/ARAY/fucam-trata-1-000-pacientes-de-ca-ncer-de-mama-com-o-sistema-tomotherapy-aray-20160621monthly0.5https://www.biopharmawatch.com/news/ARAY/fucam-trata-a-1000-pacientes-con-ca-ncer-de-mama-con-el-sistema-tomotherapy-aray-20160621monthly0.5https://www.biopharmawatch.com/news/ARAY/united-kingdom-aray-20160616monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-in-the-2016-jefferies-healthcare-conference-aray-20160525monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-host-analyst-and-investor-day-on-may-20-2016-aray-20160519monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-signs-long-term-strategic-development-and-supply-agreement-with-medphoton-for-volu-aray-20160501monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-submits-510-k-premarket-notification-to-fda-for-its-radixact-treatment-delivery-sy-aray-20160426monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-generates-105-3-million-in-third-quarter-revenues-aray-20160426monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-hosts-regional-aero-users-aray-20160422monthly0.5https://www.biopharmawatch.com/news/ARAY/primer-sistema-tomotherapy-en-colombia-instalado-en-cli-nica-foscal-aray-20160412monthly0.5https://www.biopharmawatch.com/news/ARAY/primeiro-sistema-tomotherapy-da-colo-mbia-e-instalado-na-clinica-foscal-aray-20160412monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-results-for-third-quarter-fiscal-2016-on-april-26-2016-aray-20160406monthly0.5https://www.biopharmawatch.com/news/ARAY/medstar-georgetown-university-hospital-treats-1-000-prostate-cancer-patients-with-the-cybe-aray-20160331monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-in-the-36th-annual-cowen-and-company-health-care-conference-aray-20160224monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-generates-108-9-million-in-second-quarter-revenues-aray-20160128monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-first-radiation-therapy-systems-installed-in-qatar-latvia-and-bulgaria-aray-20160114monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-closes-70-million-straight-debt-financing-aray-20160112monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-preliminary-second-quarter-financial-results-aray-20160111monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-results-for-second-quarter-fiscal-2016-on-january-28-2016-aray-20160107monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-hosts-first-regional-users-aray-20151217monthly0.5https://www.biopharmawatch.com/news/ARAY/primeiros-sistemas-cyberknife-m6-e-tomotherapy-no-chile-instalados-no-instituto-do-ca-ncer-aray-20151105monthly0.5https://www.biopharmawatch.com/news/ARAY/first-cyberknife-m6-and-tomotherapy-systems-in-chile-installed-at-fundacion-arturo-lopez-p-aray-20151105monthly0.5https://www.biopharmawatch.com/news/ARAY/primeros-sistemas-cyberknife-m6-y-tomotherapy-en-chile-instalados-en-centro-cli-nico-oncol-aray-20151105monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-cowealth-arbitration-ruling-delivered-aray-20151104monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-in-the-24th-annual-credit-suisse-healthcare-conference-aray-20151103monthly0.5https://www.biopharmawatch.com/news/ARAY/new-cyberknife-and-tomotherapy-system-data-presented-at-leading-scientific-industry-meetin-aray-20151102monthly0.5https://www.biopharmawatch.com/news/ARAY/kelly-londy-named-chief-operating-officer-of-accuray-aray-20151015monthly0.5https://www.biopharmawatch.com/news/ARAY/anova-cancer-care-treats-1-000th-prostate-cancer-patient-with-the-cyberknife-system-aray-20151013monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-fiscal-2016-first-quarter-financial-results-on-october-29-2015-aray-20151008monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-and-raysearch-announce-second-long-term-collaboration-agreement-aray-20151005monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-in-the-morgan-stanley-global-healthcare-conference-2015-aray-20150901monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-awarded-multi-system-order-by-21st-century-oncology-aray-20150821monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-generates-14-year-over-year-gross-order-growth-during-fourth-quarter-aray-20150820monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-products-received-highest-composite-user-satisfaction-ratings-in-latest-md-buyline-aray-20150727monthly0.5https://www.biopharmawatch.com/news/ARAY/new-cyberknife-system-data-presented-at-leading-scientific-industry-meeting-aray-20150714monthly0.5https://www.biopharmawatch.com/news/ARAY/new-tomotherapy-system-data-presented-at-leading-scientific-industry-meeting-aray-20150714monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-and-raysearch-announce-long-term-collaboration-agreement-regarding-the-raycare-onc-aray-20150713monthly0.5https://www.biopharmawatch.com/news/ARAY/total-marrow-irradiation-provides-greater-precision-fewer-side-effects-aray-20150609monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-in-the-goldman-sachs-36th-annual-global-healthcare-conference-aray-20150602monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-in-the-jefferies-2015-healthcare-conference-aray-20150526monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-in-the-bank-of-america-merrill-lynch-2015-healthcare-conference-aray-20150505monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-signs-agreement-with-mim-software-inc-to-develop-adaptive-therapy-software-aray-20150430monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-financial-results-for-third-quarter-of-fiscal-year-2015-aray-20150430monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-realiza-el-lanzamiento-comercial-internacional-del-incise-multileaf-collimator-par-aray-20150421monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-entame-la-commercialisation-a-l-aray-20150421monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-initiates-international-commercial-launch-of-the-incise-multileaf-collimator-for-t-aray-20150421monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-startet-die-internationale-markteinfu-hrung-des-incise-multileaf-kollimators-fu-r--aray-20150421monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-results-for-third-quarter-fiscal-2015-on-april-30-2015-aray-20150409monthly0.5https://www.biopharmawatch.com/news/ARAY/completan-primer-tratamiento-de-paciente-con-sistema-cyberknife-m6-y-el-colimador-multihoj-aray-20150302monthly0.5https://www.biopharmawatch.com/news/ARAY/foi-conclui-do-o-tratamento-do-primeiro-paciente-com-o-sistema-cyberknife-m6-e-o-colimador-aray-20150302monthly0.5https://www.biopharmawatch.com/news/ARAY/first-patient-treatment-with-the-cyberknife-m6-system-and-the-incise-multileaf-collimator--aray-20150302monthly0.5https://www.biopharmawatch.com/news/ARAY/erste-patientenbehandlung-mit-dem-cyberknife-m6-system-und-dem-incise-multileaf-kollimator-aray-20150302monthly0.5https://www.biopharmawatch.com/news/ARAY/le-premier-traitement-d-aray-20150302monthly0.5https://www.biopharmawatch.com/news/ARAY/lancaster-general-health-receives-first-commercial-incise-multileaf-collimator-for-the-cyb-aray-20150224monthly0.5https://www.biopharmawatch.com/news/ARAY/class-a-user-licenses-for-accuray-products-awarded-to-16-hospitals-in-china-aray-20150217monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-in-the-cowen-35th-annual-healthcare-conference-aray-20150209monthly0.5https://www.biopharmawatch.com/news/ARAY/primeiro-sistema-tomotherapy-da-ame-rica-latina-dedicado-exclusivamente-aos-cuidados-do-ca-aray-20150205monthly0.5https://www.biopharmawatch.com/news/ARAY/el-primer-sistema-tomotherapy-en-ame-rica-latina-dedicado-exclusivamente-a-la-atencio-n-de-aray-20150204monthly0.5https://www.biopharmawatch.com/news/ARAY/first-tomotherapy-system-in-latin-america-dedicated-solely-to-breast-cancer-care-now-treat-aray-20150204monthly0.5https://www.biopharmawatch.com/news/ARAY/selon-la-nouvelle-enque-te-accuray-ifop-60-1-de-la-population-franc-aise-s-aray-20150128monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-financial-results-for-second-quarter-of-fiscal-year-2015-aray-20150127monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-results-for-second-quarter-fiscal-2015-on-january-27-2015-aray-20150112monthly0.5https://www.biopharmawatch.com/news/ARAY/le-centre-hospitalier-universitaire-chru-de-tours-prend-en-charge-ses-premiers-patients-av-aray-20150109monthly0.5https://www.biopharmawatch.com/news/ARAY/first-cyberknife-full-body-radiosurgery-system-in-manhattan-now-treating-patients-aray-20141118monthly0.5https://www.biopharmawatch.com/news/ARAY/studie-unterstu-tzt-die-verwendung-des-cyberknife-systems-als-eine-sichere-und-effektive-o-aray-20141103monthly0.5https://www.biopharmawatch.com/news/ARAY/des-e-tudes-appuient-l-aray-20141103monthly0.5https://www.biopharmawatch.com/news/ARAY/los-estudios-apoyan-el-uso-del-sistema-cyberknife-para-tratar-las-enfermedades-neurolo-gic-aray-20141103monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-et-le-centre-hospitalier-universitaire-vaudois-de-lausanne-conjuguent-leurs-forces-aray-20141031monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-und-universita-tsklinik-in-lausanne-bu-ndeln-ihre-kra-fte-um-patienten-personalisi-aray-20141031monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-y-lausanne-university-hospital-ofrecera-n-tratamientos-de-radiacio-n-personalizado-aray-20141031monthly0.5https://www.biopharmawatch.com/news/ARAY/studien-stu-tzen-zunehmende-verwendung-des-tomotherapy-systems-von-accuray-bei-brustkrebs--aray-20140919monthly0.5https://www.biopharmawatch.com/news/ARAY/des-e-tudes-soutiennent-l-aray-20140919monthly0.5https://www.biopharmawatch.com/news/ARAY/studies-support-growing-use-of-the-accuray-tomotherapy-system-for-breast-cancer-to-improve-aray-20140918monthly0.5https://www.biopharmawatch.com/news/ARAY/latest-md-buyline-report-shows-highest-user-satisfaction-composite-ratings-for-accuray-inc-aray-20140717monthly0.5https://www.biopharmawatch.com/news/ARAY/the-european-cyberknife-center-munich-is-celebrating-its-5-000th-patient-treatment-using-t-aray-20140407monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-identifies-eimea-region-as-growth-territory-aray-20140403monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-aray-20140327monthly0.5https://www.biopharmawatch.com/news/ARAY/latest-md-buyline-ratings-show-significant-sustained-increase-in-user-satisfaction-for-acc-aray-20140211monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-financial-results-for-second-quarter-of-fiscal-year-2014-aray-20140130monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-present-at-jp-morgan-32nd-annual-healthcare-conference-aray-20140106monthly0.5https://www.biopharmawatch.com/news/ARAY/widespread-acceptance-and-use-of-accuray-aray-20131125monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-present-at-piper-jaffray-25th-annual-healthcare-conference-aray-20131118monthly0.5https://www.biopharmawatch.com/news/ARAY/two-papers-from-a-large-multi-site-study-further-demonstrate-efficacy-and-quality-of-life--aray-20131107monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-financial-results-for-first-quarter-of-fiscal-year-2014-aray-20131107monthly0.5https://www.biopharmawatch.com/news/ARAY/more-than-100-presentations-at-leading-radiation-oncology-meeting-demonstrate-high-value-a-aray-20131003monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-showcase-clinical-utilization-and-adoption-of-its-latest-advanced-product-platf-aray-20130922monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-cfo-resigns-aray-20130903monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-results-for-fourth-quarter-and-fiscal-year-2013-aray-20130827monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-host-investor-meeting-at-astro-2013-aray-20130826monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-present-at-upcoming-investor-conferences-aray-20130822monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-will-showcase-its-cyberknife-and-tomotherapy-systems-at-china-hospeq-2013-aray-20130816monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-financial-results-for-fourth-quarter-and-year-end-fiscal-2013-aray-20130807monthly0.5https://www.biopharmawatch.com/news/ARAY/first-u-s-center-treats-patient-with-the-new-tomohda-system-aray-20130625monthly0.5https://www.biopharmawatch.com/news/ARAY/premier-patient-au-monde-traite-avec-le-nouveau-syste-me-tomohda-d-aray-20130625monthly0.5https://www.biopharmawatch.com/news/ARAY/first-u-s-center-to-treat-a-patient-with-the-new-cyberknife-m6-system-aray-20130613monthly0.5https://www.biopharmawatch.com/news/ARAY/weltweit-erste-patientin-mit-dem-neuen-tomohda-system-von-accuray-behandelt-aray-20130606monthly0.5https://www.biopharmawatch.com/news/ARAY/first-patient-treated-worldwide-with-accuray-aray-20130605monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-is-honored-for-delivering-aray-20130529monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-present-at-2013-jefferies-global-healthcare-conference-aray-20130522monthly0.5https://www.biopharmawatch.com/news/ARAY/new-data-validates-cyberknife-sbrt-for-prostate-cancer-treatment-aray-20130521monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-results-for-third-quarter-fiscal-2013-aray-20130507monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-provides-clarification-on-recently-initiated-voluntary-recalls-aray-20130418monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-report-financial-results-for-third-quarter-fiscal-2013-aray-20130418monthly0.5https://www.biopharmawatch.com/news/ARAY/first-patient-treated-worldwide-with-the-new-tomoedge-dynamic-jaws-technology-aray-20130404monthly0.5https://www.biopharmawatch.com/news/ARAY/dr-emad-rizk-joins-accuray-board-of-directors-aray-20130328monthly0.5https://www.biopharmawatch.com/news/ARAY/first-center-in-hong-kong-treats-patients-with-cyberknife-and-tomotherapy-systems-aray-20130311monthly0.5https://www.biopharmawatch.com/news/ARAY/first-european-conference-on-srs-sbrt-and-ig-imrt-held-in-milan-aray-20130304monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-speak-at-cowen-and-company-33rd-annual-healthcare-conference-aray-20130226monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-aray-20130211monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-prices-offering-of-100-million-of-3-50-convertible-senior-notes-aray-20130208monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-proposed-offering-of-75-million-of-convertible-senior-notes-aray-20130206monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-results-for-second-quarter-fiscal-2013-aray-20130206monthly0.5https://www.biopharmawatch.com/news/ARAY/first-patient-treated-worldwide-with-the-new-cyberknife-m6-system-aray-20130204monthly0.5https://www.biopharmawatch.com/news/ARAY/premie-re-mondiale-du-traitement-d-aray-20130204monthly0.5https://www.biopharmawatch.com/news/ARAY/weltweit-erster-patient-mit-dem-neuen-cyberknife-m6-system-behandelt-aray-20130204monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-report-financial-results-for-second-quarter-fiscal-2013-aray-20130117monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-speak-at-needham-aray-20130108monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-preliminary-results-for-second-quarter-fiscal-2013-and-updated-guidance--aray-20130103monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-aray-20121220monthly0.5https://www.biopharmawatch.com/news/ARAY/primeros-pacientes-tratados-con-el-sistema-de-radiocirugi-a-robo-tica-cyberknife-en-venezu-aray-20121217monthly0.5https://www.biopharmawatch.com/news/ARAY/first-patients-treated-with-the-cyberknife-robotic-radiosurgery-system-in-venezuela-aray-20121217monthly0.5https://www.biopharmawatch.com/news/ARAY/primeiros-pacientes-tratados-com-o-sistema-robo-tico-de-radio-cirurgia-cyberknife-na-venez-aray-20121217monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-speak-at-23rd-annual-oppenheimer-healthcare-conference-aray-20121206monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-speak-at-24th-annual-piper-jaffray-healthcare-conference-aray-20121120monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-speak-at-lazard-capital-markets-healthcare-conference-aray-20121109monthly0.5https://www.biopharmawatch.com/news/ARAY/90-presentations-at-leading-radiation-oncology-meeting-demonstrate-the-breadth-and-depth-o-aray-20121108monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-results-for-first-quarter-fiscal-2013-aray-20121107monthly0.5https://www.biopharmawatch.com/news/ARAY/presentations-at-leading-radiation-oncology-meeting-highlight-cyberknife-prostate-outcomes-aray-20121105monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-receives-fda-510-k-clearance-for-new-cyberknife-m6-series-merging-multileaf-collim-aray-20121101monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-launches-new-tomotherapy-h-series-featuring-tomoedge-aray-20121028monthly0.5https://www.biopharmawatch.com/news/ARAY/substantial-clinical-evidence-and-adoption-presented-at-accuray-aray-20121026monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-report-financial-results-for-first-quarter-fiscal-2013-aray-20121019monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-announce-significant-product-news-at-astro-aray-20121018monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-ceo-resigns-board-appoints-successor-for-next-phase-of-growth-aray-20121012monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-host-investor-meeting-at-astro-2012-aray-20121001monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-first-cyberknife-system-in-south-america-aray-20120802monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-anuncia-el-primer-sistema-cyberknife-en-sudame-rica-aray-20120802monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-report-financial-results-for-fourth-quarter-and-fiscal-year-2012-aray-20120731monthly0.5https://www.biopharmawatch.com/news/ARAY/clinical-research-on-accuray-aray-20120729monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-acquire-morphormics-inc-aray-20120716monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-installation-of-tomotherapy-system-at-university-of-california-san-franc-aray-20120627monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-and-erasmus-medical-center-sign-master-research-and-collaboration-agreement-aray-20120626monthly0.5https://www.biopharmawatch.com/news/ARAY/one-year-after-tomotherapy-acquisition-accuray-on-track-to-meet-or-exceed-integration-succ-aray-20120621monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-rolls-out-comprehensive-customer-service-program-in-japan-aray-20120620monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-speak-at-wells-fargo-healthcare-conference-aray-20120613monthly0.5https://www.biopharmawatch.com/news/ARAY/cyberknife-prostate-sbrt-outcomes-and-quality-of-life-data-presented-at-american-urologica-aray-20120607monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-speak-at-jefferies-global-healthcare-conference-aray-20120530monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-und-das-deutsche-krebsforschungszentrum-unterschreiben-eine-forschungs-und-koopera-aray-20120523monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-et-le-centre-allemand-de-recherche-sur-le-cancer-ont-signe-un-accord-cadre-de-rech-aray-20120522monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-y-el-german-cancer-research-center-firman-un-acuerdo-maestro-de-investigacio-n-y-c-aray-20120522monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-and-the-german-cancer-research-center-sign-master-research-and-collaboration-agree-aray-20120522monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-appoints-richard-pettingill-lfache-to-board-of-directors-aray-20120517monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-de-voile-un-syste-me-de-planification-ame-liore-du-traitement-tomotherapy-a-l-aray-20120509monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-presenta-el-sistema-de-planificacio-n-de-tratamiento-tomotherapy-mejorado-en-estro-aray-20120509monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-stellt-erweitertes-tomotherapy-system-zur-behandlungsplanung-auf-der-estro-31-vor-aray-20120509monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-unveils-enhanced-tomotherapy-treatment-planning-system-at-estro-31-aray-20120509monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-results-for-third-quarter-fiscal-2012-aray-20120508monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-launches-first-study-to-compare-cyberknife-sbrt-to-surgery-and-imrt-for-treatment--aray-20120426monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-lisa-a-potilaiden-hoitovaihtoehtoja-suomessa-aray-20120402monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-signs-master-research-and-collaboration-agreement-with-university-of-heidelberg-aray-20120330monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-rolls-out-plantouch-for-the-cyberknife-system-aray-20120326monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-receives-microsoft-dynamics-customer-excellence-award-aray-20120319monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-recognized-for-delivering-aray-20120229monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-speak-at-citi-2012-global-health-care-conference-aray-20120215monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-results-for-second-quarter-fiscal-2012-aray-20120208monthly0.5https://www.biopharmawatch.com/news/ARAY/study-highlights-cyberknife-sbrt-benefits-for-treatment-of-central-lung-tumors-aray-20120126monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-report-financial-results-for-second-quarter-of-fiscal-2012-aray-20120118monthly0.5https://www.biopharmawatch.com/news/ARAY/first-cyberknife-robotic-radiosurgery-system-goes-live-in-mexico-aray-20120117monthly0.5https://www.biopharmawatch.com/news/ARAY/primer-sistema-de-radiocirugi-a-robo-tica-cyberknife-se-implementa-en-me-xico-aray-20120117monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-surpasses-600-installations-globally-aray-20120110monthly0.5https://www.biopharmawatch.com/news/ARAY/study-highlights-cyberknife-stereotactic-body-radiotherapy-sbrt-noninvasive-brachytherapy--aray-20120109monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-speak-at-14th-annual-needham-growth-conference-aray-20120105monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-aray-20111222monthly0.5https://www.biopharmawatch.com/news/ARAY/medical-centers-worldwide-adopt-both-accuray-aray-20111219monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-speak-at-22nd-annual-oppenheimer-healthcare-conference-aray-20111205monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-speak-at-23rd-annual-piper-jaffray-healthcare-conference-aray-20111122monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-aray-20111110monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-results-for-first-quarter-fiscal-2012-aray-20111108monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-rapid-clinical-adoption-of-tomodirect-treatment-delivery-mode-aray-20111026monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-receives-510-k-clearance-for-a-rotational-dose-control-for-the-tomotherapy-system-aray-20111025monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-report-financial-results-for-first-quarter-of-fiscal-2012-aray-20111024monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-ranked-274th-fastest-growing-company-in-north-america-on-deloitte-aray-20111019monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-unveils-cyberknife-and-tomotherapy-product-enhancements-and-service-offerings-at-a-aray-20111003monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-speak-at-jmp-securities-healthcare-conference-aray-20110926monthly0.5https://www.biopharmawatch.com/news/ARAY/2011-international-conference-on-tomotherapy-ict-highlights-widespread-acceptance-of-the-b-aray-20110923monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-hires-chief-commercial-officer-aray-20110921monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-results-for-fourth-quarter-and-fiscal-year-2011-aray-20110919monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-speak-at-ubs-global-life-sciences-conference-aray-20110916monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-report-financial-results-for-fourth-quarter-and-fiscal-year-2011-aray-20110913monthly0.5https://www.biopharmawatch.com/news/ARAY/growing-clinical-evidence-the-focus-of-accuray-aray-20110909monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-extends-industry-leading-customer-service-program-to-tomotherapy-systems-aray-20110906monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-launches-new-organization-for-cyberknife-and-tomotherapy-system-users-aray-20110831monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-drives-growth-in-radiosurgery-for-early-stage-prostate-cancer-aray-20110830monthly0.5https://www.biopharmawatch.com/news/ARAY/beth-israel-deaconess-medical-center-treats-2-000th-patient-with-the-cyberknife-system-aray-20110816monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-speak-at-2011-wedbush-life-sciences-management-access-conference-aray-20110809monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-prices-offering-of-100-million-3-75-convertible-senior-notes-aray-20110727monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-proposed-offering-of-75-million-convertible-senior-notes-aray-20110726monthly0.5https://www.biopharmawatch.com/news/ARAY/five-leading-academic-hospitals-install-the-cyberknife-system-for-dedicated-radiosurgery-aray-20110725monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-hosts-symposium-on-quality-assurance-in-radiation-oncology-at-joint-aapm-comp-meet-aray-20110720monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-s-cyberknife-and-tomotherapy-systems-highlighted-at-world-conference-on-lung-cance-aray-20110707monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-hosts-korean-embassy-aray-20110624monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-speak-at-wells-fargo-2011-healthcare-conference-aray-20110616monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-successfully-completes-acquisition-of-tomotherapy-aray-20110613monthly0.5https://www.biopharmawatch.com/news/ARAY/tomotherapy-shareholders-approve-accuray-acquisition-of-tomotherapy-aray-20110609monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-aray-20110519monthly0.5https://www.biopharmawatch.com/news/ARAY/el-85-de-los-centros-cyberknife-r-en-europa-realiza-tratamientos-de-radioterapia-estereota-aray-20110516monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-showcases-cyberknife-robotic-radiosurgery-system-at-american-urological-associatio-aray-20110516monthly0.5https://www.biopharmawatch.com/news/ARAY/85-prozent-der-cyberknife-r-zentren-in-europa-fu-hren-ko-rperstereotaxie-sbrt-der-prostata-aray-20110513monthly0.5https://www.biopharmawatch.com/news/ARAY/quatre-vingt-cinq-pourcent-des-sites-europe-ens-utilisant-le-cyberknife-r-traitent-des-can-aray-20110512monthly0.5https://www.biopharmawatch.com/news/ARAY/85-percent-of-cyberknife-sites-within-europe-performing-prostate-stereotactic-body-radiati-aray-20110511monthly0.5https://www.biopharmawatch.com/news/ARAY/sec-declares-accuray-form-s-4-registration-statement-effective-in-proposed-acquisition-of--aray-20110509monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-results-for-third-quarter-of-fiscal-2011-aray-20110505monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-announces-hsr-clearance-in-acquisition-of-tomotherapy-aray-20110426monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-report-financial-results-for-third-quarter-of-fiscal-2011-aray-20110414monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-speak-at-10th-annual-needham-healthcare-conference-aray-20110328monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-s-general-counsel-wins-best-bay-area-corporate-counsel-award-accuray-incorporated--aray-20110225monthly0.5https://www.biopharmawatch.com/news/ARAY/cyberknife-robotic-radiosurgery-summit-provides-forum-for-clinicians-to-share-knowledge-an-aray-20110214monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-speak-at-2011-citi-global-healthcare-conference-aray-20110209monthly0.5https://www.biopharmawatch.com/news/ARAY/cyberknife-radiosurgery-to-be-highlighted-by-leading-thoracic-surgeons-at-2011-sts-annual--aray-20110131monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-results-for-second-quarter-of-fiscal-2011-aray-20110127monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-hires-chief-marketing-officer-aray-20110118monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-report-financial-results-for-second-quarter-of-fiscal-2011-aray-20110114monthly0.5https://www.biopharmawatch.com/news/ARAY/first-five-year-outcomes-published-on-cyberknife-radiosurgery-for-prostate-cancer-aray-20110111monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-elevated-to-nasdaq-global-select-market-aray-20110103monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-aray-20101228monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-establishes-medical-affairs-function-aray-20101217monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-receives-fda-clearance-for-the-cyberknife-system-aray-20101215monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-s-cyberknife-vsi-system-named-best-new-radiology-device-accuray-incorporated-nasda-aray-20101129monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-aray-20101123monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-speak-at-seventh-annual-lazard-capital-markets-aray-20101110monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-results-for-first-quarter-of-fiscal-2011-aray-20101108monthly0.5https://www.biopharmawatch.com/news/ARAY/installation-of-a-second-cyberknife-robotic-radiosurgery-system-in-vicenza-hospital-aray-20101101monthly0.5https://www.biopharmawatch.com/news/ARAY/cyberknife-radiosurgery-for-early-stage-breast-cancer-aray-20101031monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-expanded-service-program-aray-20101029monthly0.5https://www.biopharmawatch.com/news/ARAY/cyberknife-vsi-system-expands-treatment-applications-and-significantly-reduces-treatment-t-aray-20101029monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-s-cyberknife-vsi-system-featured-at-2010-american-society-for-radiation-oncology-a-aray-20101029monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-hires-general-manager-for-the-asia-pacific-region-aray-20101028monthly0.5https://www.biopharmawatch.com/news/ARAY/eighth-cyberknife-system-in-south-korea-installed-and-treating-patients-aray-20101027monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-speak-at-oppenheimer-aray-20101026monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-report-financial-results-for-first-quarter-of-fiscal-2011-aray-20101025monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-ranked-number-113-fastest-growing-company-in-north-america-on-deloitte-aray-20101020monthly0.5https://www.biopharmawatch.com/news/ARAY/first-cyberknife-system-in-clinical-use-in-czech-republic-aray-20101014monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-host-analyst-meeting-at-astro-2010-aray-20101013monthly0.5https://www.biopharmawatch.com/news/ARAY/100-000th-patient-treated-with-accuray-aray-20101006monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-awarded-1-million-grant-by-u-s-government-aray-20101005monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-speak-at-jmp-securities-healthcare-conference-aray-20100920monthly0.5https://www.biopharmawatch.com/news/ARAY/benefits-of-cyberknife-lung-radiosurgery-treatments-emphasized-during-europe-aray-20100917monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-aray-20100916monthly0.5https://www.biopharmawatch.com/news/ARAY/le-syste-me-cyberknife-vsi-la-dernie-re-ge-ne-ration-du-syste-me-cyberknife-a-e-te-le-prem-aray-20100902monthly0.5https://www.biopharmawatch.com/news/ARAY/cancer-center-to-be-the-first-in-europe-to-install-a-cyberknife-vsi-system-the-latest-gene-aray-20100901monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-results-for-fourth-quarter-and-fiscal-year-2010-aray-20100831monthly0.5https://www.biopharmawatch.com/news/ARAY/presentaciones-de-la-tercera-terapia-europea-de-radiacio-n-estereota-ctica-y-de-los-taller-aray-20100706monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-announces-results-from-first-in-man-pharmacokinetics-study-of-oral-formulation-of-a-glmd-20260514monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-announces-a-collaboration-agreement-with-tel-aviv-university-to-evaluate-its-scd1-i-glmd-20260414monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-reports-first-quarter-2025-financial-results-and-provides-business--glmd-20250522monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-reports-significant-anti-fibrotic-effects-of-aramchol-in-psc-models-glmd-20250513monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-announces-first-time-results-in-oncology-studies-aramchol-significantly-enhances-ba-glmd-20250506monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-signed-term-sheet-for-the-development-of-novel-semaglutide-sublingual-formulation-glmd-20250428monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-launches-vcu-collaboration-to-tackle-drug-resistance-in-gi-cancers-glmd-20250417monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-unveils-novel-pharmacodynamic-blood-markers-for-aramchol-the-most-clinically-advanc-glmd-20250415monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-announces-positive-part-1-results-from-the-am-001-study-of-aramchol-meglumine-an-en-glmd-20250410monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-ltd-files-annual-report-on-form-20-f-for-the-fiscal-year-ended-dece-glmd-20250402monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-secures-new-patent-grant-extending-aramchol-glmd-20250320monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-publishes-results-from-aramchol-phase-3-open-label-part-in-hepatology-glmd-20240925monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-announces-an-expansion-of-its-activities-to-cancer-and-major-cardiometabolic-diseas-glmd-20240919monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-ltd-files-annual-report-on-form-20-f-for-the-fiscal-year-ended-dece-glmd-20240404monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-announces-grant-of-new-patent-for-the-combination-of-aramchol-with-resmetirom-mgl-3-glmd-20240315monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-announces-a-delay-in-the-initiation-of-its-primary-sclerosing-cholangitis-psc-phase-glmd-20231120monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-announces-allowance-of-new-patent-for-aramchol-for-the-treatment-of-pulmonary-and-d-glmd-20230926monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-receipt-of-nasdaq-minimum-bid-price-notification-glmd-20230922monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-pricing-of-7-million-public-offering-glmd-20230714monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-to-employ-onkai-glmd-20230710monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-reports-first-quarter-2023-financial-results-and-recent-development-glmd-20230601monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-announces-initiation-of-a-clinical-development-program-to-evaluate-aramchol-meglumi-glmd-20230509monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-forms-a-strategic-partnership-with-onkai-glmd-20230504monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-ltd-files-annual-report-on-form-20-f-for-the-fiscal-year-ended-dece-glmd-20230329monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-announces-issuance-of-new-composition-of-matter-patent-for-aramchol-meglumine-salt-glmd-20230208monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-reports-results-from-the-open-label-part-of-the-armor-study-showing-improvements-in-glmd-20230104monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-ltd-nasdaq-glmd-announces-receipt-of-extension-to-meet-the-nasdaq-glmd-20221214monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-provides-business-update-and-reports-second-quarter-2022-financial--glmd-20220804monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-reports-significant-anti-fibrotic-effects-of-aramchol-in-a-lung-fibrosis-model-glmd-20220707monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-receipt-of-nasdaq-minimum-bid-price-notification-glmd-20220617monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-reports-first-quarter-2022-financial-results-glmd-20220517monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-updates-business-and-clinical-development-strategy-to-better-leverage-aramchol-glmd-20220517monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-provides-business-update-and-reports-fourth-quarter-and-year-end-20-glmd-20220502monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-reports-interim-results-from-the-open-label-part-of-the-armor-study-with-aramchol-s-glmd-20220428monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-report-fourth-quarter-and-year-end-2021-financial-results-and-pr-glmd-20220426monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-continues-to-drive-innovation-with-three-new-us-patents-granted-for-aramchol-and-it-glmd-20220111monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-announces-positive-results-of-phase-1-study-of-amilo-5mer-glmd-20220110monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-provides-additional-positive-data-from-the-open-label-part-of-armor-glmd-20211108monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-announces-new-positive-data-from-ongoing-armor-study-open-label-part-showing-clinic-glmd-20211108monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-announces-positive-results-from-first-16-patients-in-open-label-part-of-armor-study-glmd-20211101monthly0.5https://www.biopharmawatch.com/news/GLMD/results-of-galmed-glmd-20211011monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-publication-in-the-journal-of-autoimmunity-for-its-ind-re-glmd-20210819monthly0.5https://www.biopharmawatch.com/news/GLMD/mhra-agrees-with-galmed-glmd-20210816monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-provides-business-update-and-reports-second-quarter-2021-financial--glmd-20210805monthly0.5https://www.biopharmawatch.com/news/GLMD/fda-agrees-with-galmed-glmd-20210802monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-report-second-quarter-2021-financial-results-and-provide-busines-glmd-20210729monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-provides-business-updates-and-reports-first-quarter-2021-financial--glmd-20210513monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-report-first-quarter-2021-financial-results-and-provide-business-glmd-20210506monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-announces-approval-of-ind-application-in-china-for-aramchol-for-the-treatment-of-na-glmd-20210503monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-provides-business-update-and-reports-fourth-quarter-and-year-end-20-glmd-20210318monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-dosing-of-first-subject-in-first-in-human-phase-1-trial-o-glmd-20210316monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-report-fourth-quarter-and-year-end-2020-financial-results-and-pr-glmd-20210311monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-pricing-of-10-million-public-offering-of-ordinary-shares-glmd-20210216monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-proposed-offering-of-ordinary-shares-glmd-20210216monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-upcoming-publication-in-jhep-reports-of-new-data-supporti-glmd-20210126monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-hosting-kol-symposium-and-pipeline-update-glmd-20210119monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-to-add-open-label-part-to-armor-study-first-read-out-expected-in-q4-2021-glmd-20201217monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-reports-third-quarter-2020-financial-results-glmd-20201112monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-report-third-quarter-2020-financial-results-and-provide-business-glmd-20201105monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-and-gannex-expand-development-programs-for-nash-through-research-collaboration-of-a-glmd-20200910monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-provides-business-update-and-reports-second-quarter-2020-financial--glmd-20200806monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-acceleration-of-its-new-clinical-amilo-5mer-program-glmd-20200806monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-report-second-quarter-2020-financial-results-and-provide-busines-glmd-20200730monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-provides-business-update-and-reports-first-quarter-2020-financial-r-glmd-20200514monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-report-first-quarter-2020-financial-results-and-provide-business-glmd-20200507monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-provides-business-update-and-reports-fourth-quarter-and-year-end-20-glmd-20200312monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-report-fourth-quarter-and-year-end-2019-financial-results-and-pr-glmd-20200305monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-provides-business-update-and-reports-third-quarter-2019-financial-r-glmd-20191106monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-present-new-data-on-aramchol-effect-on-glucose-metabolism-moa-an-glmd-20191031monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-report-third-quarter-2019-financial-results-and-provide-business-glmd-20191030monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-initiated-armor-a-phase-3-4-registrational-study-of-aramchol-in-sub-glmd-20190926monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-provides-business-update-and-reports-second-quarter-2019-financial--glmd-20190805monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-report-second-quarter-2019-financial-results-and-provide-busines-glmd-20190729monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-provides-business-update-and-reports-first-quarter-2019-financial-r-glmd-20190507monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-report-first-quarter-2019-financial-results-and-provide-business-glmd-20190430monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-successful-completion-of-end-of-phase-2-meeting-with-fda--glmd-20190409monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-reports-fourth-quarter-and-full-year-2018-financial-results-and-pro-glmd-20190313monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-reports-positive-results-from-pharmacokinetic-split-dose-study-of-aramchol-glmd-20190312monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-report-fourth-quarter-and-year-end-2018-financial-results-and-pr-glmd-20190306monthly0.5https://www.biopharmawatch.com/news/GLMD/phase-2-data-for-galmed-pharmaceutical-glmd-20181113monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-provides-business-update-and-reports-third-quarter-2018-financial-r-glmd-20181105monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-report-third-quarter-2018-financial-results-and-provide-business-glmd-20181029monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-a-late-breaking-abstract-on-aramchol-to-be-presented-at-t-glmd-20181002monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-present-at-the-cantor-global-healthcare-conference-roth-battle-o-glmd-20180927monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-provides-business-update-and-reports-second-quarter-2018-financial--glmd-20180802monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-report-second-quarter-2018-financial-results-and-provide-busines-glmd-20180726monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-ltd-announces-pricing-of-public-offering-of-ordinary-shares-glmd-20180619monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-ltd-announces-proposed-public-offering-of-ordinary-shares-glmd-20180618monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-s-600-mg-aramchol-achieved-a-regulatory-approvable-endpoint-showing-nash-resolution-glmd-20180612monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-host-conference-call-to-discuss-top-line-52-week-results-from-th-glmd-20180611monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-provides-business-update-and-reports-first-quarter-2018-financial-r-glmd-20180509monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-report-first-quarter-2018-financial-results-and-provide-business-glmd-20180501monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-host-post-easl-key-opinion-leader-call-on-the-scientific-rationa-glmd-20180416monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-pricing-of-6-0-million-registered-direct-offering-glmd-20180403monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-present-new-scientific-data-on-the-mechanism-by-which-aramchol-e-glmd-20180327monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-reports-fourth-quarter-and-full-year-2017-financial-results-and-pro-glmd-20180313monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-report-full-year-and-fourth-quarter-2017-financial-results-and-p-glmd-20180305monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-participate-in-investor-conferences-in-march-glmd-20180302monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-announces-arrive-study-data-glmd-20180214monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-provide-corporate-update-at-the-leerink-partners-7th-annual-glob-glmd-20180208monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-granted-preferred-technological-enterprise-status-which-may-provide-the-company-wit-glmd-20180207monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-raised-gross-proceeds-of-11-6-million-under-atm-programs-during-dec-glmd-20180102monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-present-at-hep-dart-2017-meeting-glmd-20171127monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-reports-third-quarter-2017-financial-results-and-provides-business--glmd-20171109monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-report-third-quarter-financial-results-on-thursday-november-9th-glmd-20171101monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-publication-of-data-on-aramchol-mechanism-of-action-in-he-glmd-20171005monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-pricing-of-offering-of-ordinary-shares-to-existing-invest-glmd-20170803monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-reports-second-quarter-2017-financial-results-and-provides-business-glmd-20170731monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-second-quarter-2017-conference-call-and-webcast-scheduled-for-monda-glmd-20170724monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-the-election-of-dr-carol-l-brosgart-as-a-new-member-of-th-glmd-20170608monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-reports-first-quarter-2017-financial-results-glmd-20170515monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-first-quarter-2017-conference-call-and-webcast-scheduled-for-monday-glmd-20170508monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-reports-fourth-quarter-and-full-year-2016-financial-results-glmd-20170323monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-fourth-quarter-2016-conference-call-and-webcast-scheduled-for-thurs-glmd-20170316monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-completes-patient-recruitment-for-arrest-phase-iib-nash-study-glmd-20170109monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-reports-third-quarter-2016-financial-results-and-provides-business--glmd-20161107monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-third-quarter-2016-conference-call-and-webcast-scheduled-for-monday-glmd-20161031monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-that-it-has-raised-approximately-5-0-million-to-date-unde-glmd-20160929monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-and-the-university-of-california-san-diego-enter-into-an-investigat-glmd-20160922monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-the-appointment-of-dr-liat-hayardeny-ph-d-mba-as-chief-sc-glmd-20160908monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-reports-second-quarter-2016-financial-results-and-provides-business-glmd-20160803monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-the-appointment-of-professor-ran-oren-m-d-as-chief-medica-glmd-20160801monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-and-samil-pharm-sign-a-license-agreement-for-the-commercialization--glmd-20160728monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-second-quarter-2016-conference-call-and-webcast-scheduled-for-wedne-glmd-20160727monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-and-weizmann-institute-of-science-to-enter-a-research-collaboration-glmd-20160630monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-expands-its-ongoing-phase-iib-arrest-study-to-china-glmd-20160607monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-randomizes-120th-patient-in-the-arrest-trial-glmd-20160601monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-reports-first-quarter-2016-financial-results-and-provides-business--glmd-20160516monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-first-quarter-2016-conference-call-and-webcast-scheduled-for-monday-glmd-20160509monthly0.5https://www.biopharmawatch.com/news/GLMD/mount-sinai-and-galmed-pharmaceuticals-to-collaborate-in-an-investigator-initiated-phase-i-glmd-20160503monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-hold-a-symposium-on-non-invasive-diagnostics-during-the-internat-glmd-20160407monthly0.5https://www.biopharmawatch.com/news/GLMD/aramchol-demonstrates-significant-anti-fibrotic-effect-in-a-pre-clinical-model-of-fatty-li-glmd-20160330monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-reports-full-year-2015-financial-results-and-provides-business-upda-glmd-20160322monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-fourth-quarter-2015-conference-call-and-webcast-scheduled-for-tuesd-glmd-20160315monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-present-at-the-roth-conference-glmd-20160307monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-the-enrollment-of-the-first-patient-in-the-arrive-study-glmd-20160301monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-retirement-of-chief-medical-officer-glmd-20160211monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-present-at-the-biotech-showcase-glmd-20160105monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-fda-clearance-of-ind-of-aramachol-for-the-treatment-of-pa-glmd-20151201monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-commencement-of-patient-screening-for-the-arrest-study-in-glmd-20151109monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-third-quarter-2015-conference-call-and-webcast-scheduled-for-novemb-glmd-20151102monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-unfolds-the-development-of-aramchol-non-invasive-companion-diagnost-glmd-20150708monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-reports-first-quarter-2015-financial-results-and-provides-business--glmd-20150513monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-first-quarter-2015-conference-call-and-webcast-scheduled-for-wednes-glmd-20150506monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-the-appointment-of-george-tonelli-as-vice-president-of-cl-glmd-20150401monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-reports-full-year-2014-financial-results-and-provides-business-upda-glmd-20150331monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-fourth-quarter-2014-conference-call-and-webcast-scheduled-for-tuesd-glmd-20150324monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-present-at-the-metabolic-leaders-glmd-20150317monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-the-beginning-of-enrollment-in-its-phase-iib-arrest-trial-glmd-20150309monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-present-at-the-27th-annual-roth-conference-glmd-20150302monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-present-at-the-european-fatty-liver-conference-glmd-20150225monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-and-perrigo-execute-manufacturing-agreement-for-large-scale-aramchol-api-production-glmd-20150128monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-present-at-the-biotech-showcase-glmd-20150106monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-the-appointment-of-josh-blacher-as-chief-financial-office-glmd-20150105monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-completes-analysis-of-a-pharmacokinetic-study-of-aramchol-in-health-glmd-20141201monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-first-administration-of-aramchol-in-its-phase-iia-trial-f-glmd-20141113monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-provides-business-update-and-reports-year-to-date-2014-financial-re-glmd-20141112monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-to-host-key-opinion-leader-meeting-and-webcast-on-november-7-2014-i-glmd-20141105monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-third-quarter-2014-conference-call-and-webcast-scheduled-for-wednes-glmd-20141105monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-and-itamar-medical-to-collaborate-on-assessing-aramchol-glmd-20140929monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-u-s-fda-approval-of-fast-track-designation-of-aramchol-fo-glmd-20140923monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-completes-two-chronic-toxicology-studies-and-reports-no-significant-glmd-20140902monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-reports-first-half-2014-financial-results-glmd-20140725monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-announces-fda-clearance-of-ind-of-armachol-for-the-treatment-of-fatty-liver-disorde-glmd-20140722monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-second-quarter-2014-conference-call-and-webcast-scheduled-for-frida-glmd-20140721monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-announces-publication-of-aramchol-phase-iia-trial-in-the-clinical-gastroenterology--glmd-20140708monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-reports-first-quarter-2014-financial-results-glmd-20140515monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-commences-patient-screening-for-aramchol-pharmacokinetic-and-food-e-glmd-20140428monthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-announces-closing-of-initial-public-offering-and-full-exercise-of-u-glmd-20140318monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-announces-form-f-3-resale-registration-statement-filing-imcc-20260609monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-raises-us-225-000-of-gross-proceeds-in-convertible-note-financing-imcc-20260603monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-appoints-asi-levi-as-chief-financial-officer-imcc-20251212monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-reports-second-quarter-2025-financial-results-imcc-20250812monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-to-report-second-quarter-2025-financial-results-on-tuesday-august-12th-at-9-00-imcc-20250804monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-closes-private-placement-for-gross-proceeds-of-approximately-us-4-1-million-imcc-20250731monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-announces-filing-of-shelf-registration-statement-on-form-f-3-imcc-20250711monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-announces-the-signing-of-a-loan-agreement-and-appointment-of-oz-adler-to-board-imcc-20250709monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-provides-corporate-updates-imcc-20250701monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-announces-plans-to-voluntarily-delist-from-the-canadian-securities-exchange-imcc-20250528monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-provides-corporate-updates-imcc-20250527monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-reports-first-quarter-financial-results-imcc-20250515monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-announces-filing-of-information-circular-for-upcoming-annual-general-and-speci-imcc-20250507monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-to-report-first-quarter-2025-financial-results-on-thursday-may-15th-at-9-00am--imcc-20250506monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-provides-corporate-updates-imcc-20250411monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-reports-fourth-quarter-and-full-year-2024-financial-results-imcc-20250331monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-monday-march--imcc-20250320monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-announces-change-of-auditors-imcc-20250117monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-reports-third-quarter-financial-results-imcc-20241114monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-closes-non-brokered-private-placement-led-by-management-and-concurrent-debt-se-imcc-20241112monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-to-report-third-quarter-2024-financial-results-on-thursday-november-14th-at-9--imcc-20241106monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-announces-up-to-us-1-613-000-private-placement-offering-led-by-management-imcc-20241004monthly0.5https://www.biopharmawatch.com/news/IMCC/imc-germany-announces-outstanding-preliminary-q3-2024-performance-with-50-growth-over-q2-imcc-20241002monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-announces-appointment-of-shmulik-arbel-to-board-of-directors-imcc-20240911monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-reports-second-quarter-financial-results-imcc-20240814monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-to-report-second-quarter-2024-financial-results-on-wednesday-august-14th-at-9--imcc-20240806monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-receives-nasdaq-notification-of-regaining-compliance-with-nasdaq-imcc-20240729monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-shares-commence-trading-on-6-1-consolidated-basis-imcc-20240712monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-announces-intention-to-complete-consolidation-imcc-20240705monthly0.5https://www.biopharmawatch.com/news/IMCC/imcc-addresses-accelerated-growth-in-germany-through-new-supply-agreement-with-eu-gmp-cert-imcc-20240605monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-closes-convertible-debenture-offering-to-support-accelerated-growth-in-germany-imcc-20240529monthly0.5https://www.biopharmawatch.com/news/IMCC/imc-announces-the-termination-of-a-preliminary-term-sheet-with-kadimastem-ltd-a-public-com-imcc-20240528monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-reports-first-quarter-financial-results-imcc-20240508monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-to-report-first-quarter-2024-financial-results-on-wednesday-may-8th-at-9-00am--imcc-20240501monthly0.5https://www.biopharmawatch.com/news/IMCC/imc-to-transfer-its-oranim-pharmacy-shares-back-to-the-seller-imcc-20240416monthly0.5https://www.biopharmawatch.com/news/IMCC/avant-and-imc-execute-blk-mkt-trademark-licensing-agreement-for-the-german-medical-cannabi-imcc-20240404monthly0.5https://www.biopharmawatch.com/news/IMCC/imc-applauds-the-april-1st-implementation-of-the-new-israeli-cannabis-regulation-facilitat-imcc-20240401monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-reports-2023-financial-results-imcc-20240328monthly0.5https://www.biopharmawatch.com/news/IMCC/imc-expects-accelerated-growth-in-germany-from-the-country-imcc-20240325monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-to-report-fourth-quarter-and-full-year-2023-financial-results-on-thursday-marc-imcc-20240320monthly0.5https://www.biopharmawatch.com/news/IMCC/imc-announces-potential-reverse-merger-with-kadimastem-a-leading-clinical-cell-therapy-com-imcc-20240228monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-receives-180-calendar-day-extension-from-the-nasdaq-stock-market-to-regain-com-imcc-20240131monthly0.5https://www.biopharmawatch.com/news/IMCC/imc-reschedules-the-final-payment-of-the-oranim-pharmacy-acquisition-imcc-20240112monthly0.5https://www.biopharmawatch.com/news/IMCC/imc-announces-the-conclusion-of-the-planning-and-construction-legal-proceedings-imcc-20240102monthly0.5https://www.biopharmawatch.com/news/IMCC/new-israeli-cannabis-regulation-facilitating-access-for-many-new-patients-scheduled-for-de-imcc-20231208monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-announces-receipt-of-court-action-imcc-20231127monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-reports-third-quarter-2023-financial-results-imcc-20231113monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-to-report-third-quarter-2023-financial-results-on-monday-november-13-at-9-00am-imcc-20231108monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-releases-a-message-from-the-ceo-about-the-israel-hamas-war-and-announces-secur-imcc-20231013monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-announces-the-appointment-of-uri-birenberg-as-chief-financial-officer-imcc-20231010monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-announces-cfo-departure-imcc-20230919monthly0.5https://www.biopharmawatch.com/news/IMCC/imc-welcomes-new-israeli-cannabis-regulations-which-are-about-to-change-significantly-faci-imcc-20230811monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-to-report-second-quarter-2023-financial-results-on-monday-august-14-at-9-00am--imcc-20230808monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-receives-nasdaq-notification-regarding-minimum-bid-price-deficiency-imcc-20230804monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-receives-nasdaq-notification-of-regaining-compliance-with-nasdaq-imcc-20230613monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-reports-first-quarter-2023-financial-results-gross-profit-increased-46-year-ov-imcc-20230515monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-completes-debt-settlement-with-l5-capital-imcc-20230508monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-to-report-first-quarter-2023-financial-results-on-monday-may-15-at-9-00am-et-imcc-20230508monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-announces-units-for-debt-settlement-imcc-20230428monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-receives-nasdaq-notification-regarding-minimum-bid-price-deficiency-imcc-20230414monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-to-report-fourth-quarter-full-year-2022-financial-results-on-wednesday-march-2-imcc-20230315monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-announces-additional-restructuring-initiatives-designed-to-drive-sustainable-p-imcc-20230308monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-closes-additional-tranche-of-life-offering-imcc-20230216monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-provides-an-update-on-panaxia-transaction-imcc-20230213monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-closes-additional-tranches-of-private-placement-offerings-imcc-20230207monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-closes-third-tranche-of-life-offering-imcc-20230131monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-closes-second-tranche-of-private-placement-offerings-imcc-20230120monthly0.5https://www.biopharmawatch.com/news/IMCC/rafael-gabay-acquires-securities-of-im-cannabis-corp-imcc-20230117monthly0.5https://www.biopharmawatch.com/news/IMCC/oren-shuster-acquires-securities-of-im-cannabis-corp-imcc-20230117monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-common-shares-commence-trading-on-consolidated-basis-after-1-for-10-reverse-st-imcc-20221117monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-reports-third-quarter-2022-financial-results-revenues-increased-78-yoy-and-12--imcc-20221114monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-closes-second-tranche-of-non-brokered-private-placement-of-common-shares-imcc-20221006monthly0.5https://www.biopharmawatch.com/news/IMCC/rafael-gabay-acquires-common-shares-of-im-cannabis-corp-imcc-20220908monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-reports-record-second-quarter-2022-financial-results-revenues-increase-114-yoy-imcc-20220815monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-to-report-second-quarter-2022-financial-results-on-monday-august-15-at-9-00am--imcc-20220804monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-receives-nasdaq-notification-regarding-minimum-bid-price-deficiency-imcc-20220719monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-reports-record-first-quarter-2022-financial-results-revenues-increase-169-yoy--imcc-20220512monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-to-report-first-quarter-2022-financial-results-on-thursday-may-12-at-5-00-p-m--imcc-20220505monthly0.5https://www.biopharmawatch.com/news/IMCC/oren-shuster-acquires-common-shares-of-im-cannabis-corp-imcc-20220412monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-strengthens-focus-on-importing-premium-and-ultra-premium-products-from-its-can-imcc-20220406monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-reports-record-fourth-quarter-and-fiscal-year-2021-financial-results-and-provi-imcc-20220331monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-closes-previously-announced-acquisition-of-oranim-pharm-jerusalem-imcc-20220330monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-reschedules-fourth-quarter-and-full-year-2021-conference-call-to-thursday-marc-imcc-20220329monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-to-report-fourth-quarter-and-full-year-2021-financial-results-on-wednesday-mar-imcc-20220323monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-closes-three-previously-announced-strategic-acquisitions-in-israel-imcc-20220315monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-reports-record-preliminary-fourth-quarter-and-full-year-2021-financial-results-imcc-20220310monthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-engages-mz-group-to-lead-strategic-investor-relations-and-shareholder-communic-imcc-20220208monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-second-quarter-2025-financial-results-and-host-conference-call-on-august-dvax-20250729monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-urges-stockholders-to-support-its-director-nominees-at-june-11-annual-meeting-dvax-20250609monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-comments-on-glass-lewis-recommendation-dvax-20250604monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-william-blair-dvax-20250528monthly0.5https://www.biopharmawatch.com/news/DVAX/leading-independent-proxy-advisory-firm-iss-recommends-stockholders-vote-for-all-four-of-d-dvax-20250523monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-files-investor-presentation-highlighting-superior-strategy-and-board-that-is-deliv-dvax-20250512monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-issues-statement-and-mails-letter-to-stockholders-emphasizing-record-financial-res-dvax-20250509monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-first-quarter-2025-financial-results-and-announces-new-pipeline-programs-dvax-20250506monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-nationwide-harris-poll-survey-results-finding-americans-underestimate-th-dvax-20250501monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-highlights-superior-board-leadership-overseeing-long-term-value-creation-strategy-dvax-20250429monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-first-quarter-2025-financial-results-and-host-conference-call-on-may-6-2-dvax-20250422monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-files-definitive-proxy-statement-and-sends-letter-to-stockholders-dvax-20250417monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-files-preliminary-proxy-statement-dvax-20250403monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-convertible-debt-refinancing-and-common-stock-share-repurchase-dvax-20250306monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-participate-in-upcoming-investor-conferences-dvax-20250225monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-full-year-dvax-20250220monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-responds-to-deep-track-and-highlights-long-term-value-creation-strategy-dvax-20250219monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-fourth-quarter-and-full-year-2024-financial-results-and-host-conference--dvax-20250206monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-advances-board-refreshment-program-dvax-20250127monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-preliminary-unaudited-fourth-quarter-and-full-year-2024-financial-highli-dvax-20250113monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-7th-annual-evercore-healthconx-conference-dvax-20241126monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-100-million-accelerated-share-repurchase-program-dvax-20241111monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-third-quarter-2024-financial-results-and-provides-business-updates-dvax-20241107monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-200-million-share-repurchase-program-dvax-20241107monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-adopts-limited-duration-stockholder-rights-plan-dvax-20241029monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-third-quarter-2024-financial-results-and-host-conference-call-on-novembe-dvax-20241024monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-second-quarter-2024-financial-results-and-provides-business-updates-dvax-20240806monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-second-quarter-2024-financial-results-and-host-conference-call-on-august-dvax-20240723monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-initiates-phase-1-2-study-of-novel-shingles-vaccine-program-dvax-20240627monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-upcoming-investor-conferences-dvax-20240528monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-provides-regulatory-update-on-sbla-for-four-dose-heplisav-b-regimen-for-adults-on--dvax-20240514monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-first-quarter-2024-financial-results-and-provides-business-updates-dvax-20240508monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-first-quarter-2024-financial-results-and-host-conference-call-on-may-8-2-dvax-20240424monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-td-cowen-dvax-20240227monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-full-year-dvax-20240222monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-fourth-quarter-and-full-year-2023-financial-results-and-host-conference--dvax-20240208monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-preliminary-unaudited-fourth-quarter-and-full-year-2023-financial-highli-dvax-20240108monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-dvax-20240103monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-6th-annual-evercore-isi-healthconx-conference-dvax-20231120monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-third-quarter-2023-financial-results-and-raises-full-year-revenue-guidance-dvax-20231102monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-third-quarter-2023-financial-results-and-host-conference-call-on-novembe-dvax-20231026monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-h-c-wainwright-4th-annual-hepatitis-b-virus-virtual-conference-dvax-20231019monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-dvax-20230906monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-second-quarter-2023-financial-results-and-raises-full-year-revenue-guidanc-dvax-20230803monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-second-quarter-2023-financial-results-and-host-conference-call-on-august-dvax-20230720monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-upcoming-investor-conferences-dvax-20230530monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-jmp-securities-life-sciences-conference-dvax-20230508monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-first-quarter-2023-financial-results-dvax-20230502monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-2-2-dvax-20230418monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-cowen-43rd-annual-health-care-conference-dvax-20230301monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-great-britain-marketing-authorization-for-heplisav-b-a-two-dose-adult-he-dvax-20230228monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-full-year-dvax-20230223monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference--dvax-20230209monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-uplisting-to-the-nasdaq-global-select-market-dvax-20230131monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-preliminary-unaudited-fourth-quarter-and-full-year-2022-financial-highli-dvax-20230109monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-two-upcoming-investor-conferences-dvax-20221109monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-third-quarter-2022-financial-results-dvax-20221103monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-third-quarter-financial-results-and-host-conference-call-on-november-3-2-dvax-20221020monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-h-c-wainwright-3rd-annual-hepatitis-b-virus-virtual-conference-dvax-20221014monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-first-participant-dosed-in-a-phase-2-clinical-trial-evaluating-an-adjuva-dvax-20220912monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference-dvax-20220908monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-second-quarter-2022-financial-results-dvax-20220804monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-second-quarter-financial-results-and-host-conference-call-on-august-4-20-dvax-20220721monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-william-blair-42nd-annual-growth-stock-conference-dvax-20220525monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-h-c-wainwright-global-investment-conference-dvax-20220516monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-first-quarter-2022-financial-results-dvax-20220505monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-first-quarter-2022-financial-results-and-host-conference-call-on-may-5-2-dvax-20220421monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dvax-20220405monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dvax-20220308monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dvax-20220303monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-full-year-dvax-20220228monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-cowen-42nd-annual-health-care-conference-dvax-20220223monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-fourth-quarter-and-full-year-2021-financial-results-and-host-conference--dvax-20220216monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dvax-20220202monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-highlights-2022-priorities-and-announces-initiation-of-phase-1-clinical-trial-for--dvax-20220110monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dvax-20220107monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-h-c-wainwright-virtual-bioconnect-2022-conference-dvax-20220105monthly0.5https://www.biopharmawatch.com/news/DVAX/covid-19-vaccine-developed-by-biological-e-using-dynavax-dvax-20211228monthly0.5https://www.biopharmawatch.com/news/DVAX/elaine-d-sun-appointed-to-dynavax-board-of-directors-dvax-20211214monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dvax-20211202monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-4th-annual-evercore-virtual-isi-healthconx-conference-dvax-20211118monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-third-quarter-2021-financial-results-dvax-20211104monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dvax-20211102monthly0.5https://www.biopharmawatch.com/news/DVAX/scott-myers-appointed-to-dynavax-board-of-directors-and-elected-board-chairman-dvax-20211021monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-third-quarter-2021-financial-results-and-host-conference-call-on-novembe-dvax-20211021monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dvax-20211018monthly0.5https://www.biopharmawatch.com/news/DVAX/covid-19-vaccine-developed-by-valneva-using-dynavax-dvax-20211018monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-and-u-s-department-of-defense-announce-collaboration-to-develop-an-adjuvanted-plag-dvax-20211004monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dvax-20211001monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-upcoming-investment-conferences-dvax-20210927monthly0.5https://www.biopharmawatch.com/news/DVAX/covid-19-vaccine-developed-by-clover-biopharmaceuticals-using-dynavax-dvax-20210922monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-provides-update-on-its-covid-19-collaboration-with-valneva-dvax-20210913monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference-dvax-20210909monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dvax-20210902monthly0.5https://www.biopharmawatch.com/news/DVAX/medigen-vaccine-biologics-announces-launch-of-its-covid-19-vaccine-mvc-cov1901-adjuvanted--dvax-20210823monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-second-quarter-2021-financial-results-dvax-20210804monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dvax-20210803monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-second-quarter-2021-financial-results-and-host-conference-call-on-august-dvax-20210721monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-and-biological-e-announce-commercial-supply-agreement-of-dynavax-dvax-20210706monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dvax-20210702monthly0.5https://www.biopharmawatch.com/news/DVAX/clover-and-dynavax-announce-commercial-supply-agreement-of-dynavax-dvax-20210630monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-dvax-20210629monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-goldman-sachs-42nd-annual-global-healthcare-conference-dvax-20210609monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-agreement-with-bavarian-nordic-for-commercialization-of-heplisav-b-a-two-dvax-20210527monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-william-blair-41st-annual-growth-stock-conference-dvax-20210519monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-pricing-of-200-million-convertible-senior-notes-offering-dvax-20210511monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-proposed-private-offering-of-200-million-of-convertible-senior-notes-dvax-20210510monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-first-quarter-2021-financial-results-dvax-20210506monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dvax-20210504monthly0.5https://www.biopharmawatch.com/news/DVAX/heplisav-b-post-marketing-observational-study-results-presented-at-2021-annual-conference--dvax-20210427monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-first-quarter-2021-financial-results-and-host-conference-call-on-may-6-2-dvax-20210422monthly0.5https://www.biopharmawatch.com/news/DVAX/valneva-initiates-pivotal-phase-3-clinical-trial-for-its-inactivated-covid-19-vaccine-cand-dvax-20210421monthly0.5https://www.biopharmawatch.com/news/DVAX/two-heplisav-b-abstracts-selected-for-oral-presentation-at-the-2021-annual-conference-on-v-dvax-20210419monthly0.5https://www.biopharmawatch.com/news/DVAX/positive-phase-1-2-results-for-valneva-dvax-20210406monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dvax-20210402monthly0.5https://www.biopharmawatch.com/news/DVAX/clover-biopharmaceuticals-and-dynavax-announce-first-participants-dosed-in-spectra-a-globa-dvax-20210324monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-h-c-wainwright-virtual-2021-global-life-sciences-conference-dvax-20210301monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dvax-20210301monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-fourth-quarter-and-full-year-2020-financial-results-dvax-20210225monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-european-commission-marketing-authorization-for-heplisav-b-a-2-dose-adul-dvax-20210219monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-cowen-41st-annual-health-care-conference-dvax-20210216monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-fourth-quarter-and-full-year-2020-financial-results-and-host-conference--dvax-20210211monthly0.5https://www.biopharmawatch.com/news/DVAX/dong-yu-ph-d-joins-dynavax-as-senior-vice-president-of-vaccine-research-dvax-20210208monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dvax-20210204monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-and-serum-institute-of-india-announce-first-participant-dosed-in-a-phase-1-clinica-dvax-20210204monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-exercise-of-option-to-reserve-additional-cpg-1018-to-produce-40-million--dvax-20210201monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-and-cepi-announce-99-million-in-funding-for-cpg-1018-adjuvant-manufacturing-to-sup-dvax-20210201monthly0.5https://www.biopharmawatch.com/news/DVAX/clover-and-dynavax-announce-planned-global-phase-2-3-efficacy-trial-of-adjuvanted-covid-19-dvax-20210201monthly0.5https://www.biopharmawatch.com/news/DVAX/medigen-vaccine-biologics-covid-19-vaccine-adjuvanted-with-dynavax-dvax-20210125monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-appoints-kelly-macdonald-as-chief-financial-officer-dvax-20210120monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-final-immunogenicity-and-interim-safety-results-from-clinical-trial-eval-dvax-20210107monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference-dvax-20210106monthly0.5https://www.biopharmawatch.com/news/DVAX/serum-institute-of-india-and-dynavax-announce-first-participants-dosed-in-the-phase-1-2-cl-dvax-20201223monthly0.5https://www.biopharmawatch.com/news/DVAX/european-chmp-adopts-positive-opinion-for-heplisav-b-dynavax-dvax-20201210monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference-dvax-20201117monthly0.5https://www.biopharmawatch.com/news/DVAX/biological-e-limited-starts-phase-i-ii-clinical-trial-of-its-covid-19-vaccine-candidate-dvax-20201116monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-third-quarter-2020-financial-results-dvax-20201105monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-present-at-the-stifel-2020-virtual-healthcare-conference-dvax-20201102monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-to-report-third-quarter-2020-financial-results-and-host-conference-call-on-novembe-dvax-20201022monthly0.5https://www.biopharmawatch.com/news/DVAX/medigen-s-covid-19-vaccine-combined-with-dynavax-s-cpg-1018-adjuvant-receives-taiwan-gover-dvax-20201013monthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-appointment-of-new-board-member-and-planned-retirement-of-chief-financia-dvax-20200924monthly0.5https://www.biopharmawatch.com/news/DVAX/valneva-and-dynavax-announce-commercial-supply-agreement-for-inactivated-adjuvanted-covid--dvax-20200914monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-announces-the-appointment-of-tal-parnes-as-the-new-chairman-of-the-board-bringing--iinn-20250121monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-collaborates-with-zriha-medical-to-launch-cutting-edge-production-lin-iinn-20250117monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-unveils-modular-configuration-for-revolutionary-vortx-blood-oxygenati-iinn-20250114monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-preparing-production-in-response-to-spread-of-respiratory-virus-in-china-iinn-20250110monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-flagship-technology-to-be-showcased-at-arab-health-expo-2025-in-dubai-iinn-20250107monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-announces-pricing-of-3-2m-private-placement-by-new-and-existing-investors-of-the-c-iinn-20241227monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-delivers-systems-to-leading-distributor-for-u-s-deployment-iinn-20241216monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-expands-hyla-blood-sensor-technology-into-personalized-blood-lab-testing-for-rapid-iinn-20241210monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-collaborates-with-new-york-iinn-20241204monthly0.5https://www.biopharmawatch.com/news/IINN/join-inspira-technologies-iinn-20241108monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-announces-establishment-of-distribution-facility-to-support-u-s-deployment-of-insp-iinn-20241025monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-announces-development-of-new-disposable-kit-with-built-in-performance-monitoring-m-iinn-20241009monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-launches-inspira-art100-at-the-world-iinn-20240924monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-secures-a-second-u-s-patent-approval-for-orbiting-blood-oxygenation-delivery-syste-iinn-20240913monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-to-publish-hyla-clinical-results-in-fourth-quarter-2024-iinn-20240828monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-announces-fda-listing-and-market-readiness-of-new-product-iinn-20240822monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-approached-by-large-medical-company-to-evaluate-operation-of-their-key-product-wit-iinn-20240813monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-introduces-the-inspira-cardi-art-aiming-to-provide-oxygen-to-the-brai-iinn-20240730monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-receives-israeli-regulatory-approval-for-the-inspira-art100-system-iinn-20240711monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-announces-business-plan-targets-iinn-20240620monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-introduces-advanced-life-support-solutions-to-key-international-leaders-at-the-ann-iinn-20240617monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-receives-first-ever-purchase-order-for-inspira-art100-systems-in-the-u-s-iinn-20240613monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-to-exhibit-the-fda-cleared-inspira-art100-system-at-a-world-renowned-event-in-the--iinn-20240605monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-announces-business-targets-presentation-following-fda-clearance-and-s-iinn-20240530monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-art100-receives-fda-510-k-clearance-iinn-20240528monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-announces-start-of-production-of-the-inspira-art100-iinn-20240502monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-receives-csa-certification-of-compliance-to-u-s-standards-for-the-inspira-art100-iinn-20240425monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-signs-term-sheet-for-use-of-inspira-art100-device-in-organ-transplant-procedures-iinn-20240416monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-and-ennocure-in-vitro-study-results-show-100-prevention-of-bacterial-growth-that-c-iinn-20240410monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-announces-program-to-pioneer-the-applicable-use-of-the-inspira-art100-device-for-a-iinn-20240403monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-announces-1-65-million-registered-direct-offering-of-ordinary-shares-by-inspira-ce-iinn-20240401monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-reports-full-year-2023-financial-results-iinn-20240325monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-announces-amar-regulatory-submission-of-the-inspira-art100-to-enter-the-southeast--iinn-20240318monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-releases-new-data-demonstrating-superiority-of-its-core-technology-across-key-endp-iinn-20240312monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-announces-plans-to-report-the-primary-results-for-a-core-blood-oxygenation-technol-iinn-20240304monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-to-host-conference-call-to-discuss-investor-presentation-and-announce-next-major-m-iinn-20240227monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-announces-breakthrough-update-nears-first-fda-510-k-approval-3-u-s-patents-approve-iinn-20240227monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-introduces-high-end-platform-for-bio-mimicking-blood-parameters-for-development-an-iinn-20240222monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-receives-first-ever-u-s-patent-approval-for-an-orbiting-blood-oxygenation-delivery-iinn-20240214monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-collaborates-with-a-leading-israeli-medical-center-for-clinical-evalu-iinn-20240208monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-signs-strategic-agreement-to-enter-gulf-states-with-glo-med-for-deplo-iinn-20240130monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-announces-plans-to-launch-and-target-single-use-disposable-blood-oxygenation-kit-f-iinn-20240109monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-signs-letter-of-intent-with-northwestern-memorial-hospital-in-chicago-iinn-20240102monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-closes-on-3-88-million-registered-direct-offering-iinn-20231228monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-announces-3-88-million-registered-direct-offering-iinn-20231226monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-announces-95-accuracy-results-for-hyla-blood-sensor-planning-fda-submission-for-cl-iinn-20231226monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-to-participate-in-j-p-morgan-healthcare-conference-iinn-20231218monthly0.5https://www.biopharmawatch.com/news/IINN/in-preparation-for-fda-clearance-and-device-deployment-inspira-has-appointed-dr-dan-gorfil-iinn-20231211monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-collaborates-with-ennocure-for-development-of-a-proprietary-bio-electronic-treatme-iinn-20231129monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-reports-third-quarter-2023-financial-results-iinn-20231116monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-announces-israeli-innovation-authority-grant-for-new-vortx-disposable-blood-oxygen-iinn-20231106monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-granted-u-s-patent-for-inspira-art500-medical-device-iinn-20231025monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-terminates-atm-program-and-provides-an-update-iinn-20231024monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-enters-into-a-distribution-agreement-in-central-america-with-cio-med-group-iinn-20231010monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-unveils-the-inspira-art-line-of-medical-devices-at-the-world-iinn-20230928monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-announces-510-k-fda-submission-of-inspira-art100-towards-commercialization-iinn-20230913monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-signs-agreement-expansion-with-innovimed-for-clinical-trials-of-inspira-art-respir-iinn-20230829monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-reports-second-quarter-2023-financial-results-iinn-20230810monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-art100-completes-usability-study-in-boston-massachusetts-u-s-iinn-20230809monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-receives-certification-of-medical-devices-quality-management-systems--iinn-20230724monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-enters-into-collaboration-agreement-with-u-s-based-perfusion-solution-iinn-20230719monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-unveils-investor-deck-showcasing-revolutionary-advancement-in-acute-r-iinn-20230615monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-appoints-dr-nir-as-chief-medical-officer-iinn-20230530monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-reports-first-quarter-2023-financial-results-iinn-20230518monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-will-reveal-the-new-alice-device-at-the-world-iinn-20230516monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-is-developing-the-vortx-blood-oxygenator-a-unique-technology-for-satu-iinn-20230511monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-reports-fourth-quarter-2022-and-full-year-financial-results-iinn-20230404monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-announces-first-in-human-of-hyla-blood-sensor-in-clinical-study-iinn-20230322monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-receives-approval-from-sheba-medical-center-to-conduct-clinical-study-iinn-20230213monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-granted-patent-by-u-s-patent-office-for-the-inspira-art-system-iinn-20230123monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-signs-strategic-oem-agreement-with-terumo-cardiovascular-iinn-20221228monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-interview-to-air-on-bloomberg-u-s-on-the-redchip-money-report-iinn-20221222monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-begins-manufacturing-of-the-alice-cpb-device-ahead-of-planned-2023-fd-iinn-20221220monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-signs-agreement-to-conduct-clinical-study-of-hyla-blood-sensor-iinn-20221214monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-reports-third-quarter-2022-financial-results-iinn-20221123monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-signs-a-strategic-agreement-in-europe-to-potentially-provide-26-1-mil-iinn-20221122monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-granted-patent-by-the-israeli-patent-office-for-key-safety-component--iinn-20221110monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-to-present-advanced-respiratory-solutions-to-key-international-leader-iinn-20221108monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-performed-hyla-blood-sensor-in-vivo-study-in-preparation-of-planned-h-iinn-20220907monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-to-present-at-the-h-c-wainwright-24th-annual-global-investor-conferen-iinn-20220901monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-reports-second-quarter-2022-financial-results-iinn-20220811monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-reveals-next-generation-liby-system-an-extracorporeal-membrane-oxygen-iinn-20220711monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-signs-strategic-agreement-in-u-s-to-potentially-provide-59-million-fo-iinn-20220707monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-develops-a-non-invasive-blood-sensor-designed-to-alert-real-time-chan-iinn-20220706monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-announces-first-quarter-2022-financial-results-iinn-20220519monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-to-participate-in-upcoming-events-in-may-iinn-20220503monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-announces-deployment-agreement-in-the-israeli-market-to-target-15m-iinn-20220406monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-releases-q4-fy2021-financial-results-iinn-20220331monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-is-awarded-the-2021-frost-sullivan-technology-innovation-leadership-a-iinn-20220228monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-to-present-at-the-aegis-capital-corp-virtual-conference-iinn-20220210monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-appointed-an-expert-in-the-field-of-artificial-lung-as-the-new-chief--iinn-20220203monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-signs-a-strategic-agreement-in-the-u-s-to-target-212-million-for-insp-iinn-20220131monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-has-listed-an-fda-class-i-510-k-exempt-component-of-the-art-system-iinn-20220128monthly0.5https://www.biopharmawatch.com/news/IINN/professor-daniel-brodie-the-president-of-the-international-extracorporeal-organization-els-iinn-20220119monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-signs-strategic-agreement-with-innovimed-for-the-potential-deployment-iinn-20211209monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-files-a-pct-patent-application-for-its-flagship-art-device-and-propri-iinn-20211208monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-professor-eddy-fan-expert-in-critical-care-medicine-and-extracorporea-iinn-20211130monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-announces-2021-third-quarter-financial-results-iinn-20211123monthly0.5https://www.biopharmawatch.com/news/IINN/dr-stephane-ledot-an-expert-in-critical-care-and-anesthesia-has-joined-inspira-technologie-iinn-20211122monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-to-present-at-the-h-c-wainwright-7th-annual-israel-virtual-conference-iinn-20211112monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-files-a-pct-patent-application-for-its-novel-dual-lumen-cannula-used--iinn-20211110monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-enters-europe-signs-a-strategic-agreement-with-waas-group-for-the-dep-iinn-20211026monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-to-present-in-person-at-the-hlth-conference-in-boston-sponsored-by-in-iinn-20211013monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-to-host-covid-19-virtual-conference-on-october-6-iinn-20210930monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-iinn-20210922monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-files-a-patent-application-for-a-supportive-device-to-be-utilized-wit-iinn-20210915monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-to-participate-in-upcoming-conferences-in-september-iinn-20210909monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-reached-important-milestone-as-it-completed-a-pump-bench-study-iinn-20210818monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-announces-first-half-2021-financial-results-and-provides-business-upd-iinn-20210813monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-expands-board-of-directors-to-accelerate-company-iinn-20210810monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-expands-medical-advisory-board-as-part-of-future-expansion-into-north-american-mar-iinn-20210726monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-and-ben-gurion-university-have-developed-a-platform-designed-to-preve-iinn-20210719monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-oxy-b-h-n-ltd-announces-closing-of-initial-public-offering-iinn-20210716monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-oxy-b-h-n-ltd-announces-pricing-of-initial-public-offering-iinn-20210713monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-announces-new-medical-advisory-board-member-dr-avraham-abutbul-specia-iinn-20210616monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-appoints-benad-goldwasser-as-chairman-of-the-board-iinn-20210224monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-and-sheba-medical-center-collaborate-on-breakthrough-respiration-trea-iinn-20210217monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-reveals-the-axt-an-intelligent-system-that-directly-oxygenates-blood--iinn-20201210monthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-files-u-s-patent-application-for-its-innovative-respiratory-support-t-iinn-20201203monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-present-new-data-on-anti-gpc3-in-vivo-car-m-therapy-for-hepatocell-carm-20241105monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-announces-changes-to-its-board-of-directors-carm-20241030monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-announces-upcoming-presentations-at-sitc-2024-carm-20241004monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-and-moderna-expand-collaboration-to-develop-two-in-vivo-car-m-therapies-for-autoim-carm-20240910monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-present-at-upcoming-conferences-carm-20240903monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-reports-second-quarter-2024-financial-results-and-recent-business-hig-carm-20240808monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-announces-upcoming-presentation-at-the-american-association-for-the-s-carm-20240806monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-announces-expansion-of-its-scientific-advisory-board-carm-20240806monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-announces-changes-to-its-board-of-directors-carm-20240701monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-announces-nomination-of-first-in-vivo-car-m-development-candidate-for-carm-20240627monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-granted-fda-fast-track-designation-for-ct-0525-for-the-treatment-of-h-carm-20240625monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-participate-in-the-stifel-2024-cell-therapy-forum-carm-20240625monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-announces-adjournment-of-annual-meeting-of-stockholders-carm-20240613monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-carm-20240530monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ct-0525-a--carm-20240516monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-reports-first-quarter-2024-financial-results-and-recent-business-high-carm-20240509monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-presents-preclinical-proof-of-concept-data-demonstrating-the-anti-fib-carm-20240508monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-participate-in-the-citizens-jmp-life-sciences-conference-carm-20240506monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-appoints-dr-eugene-p-kennedy-as-chief-medical-officer-carm-20240502monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-announces-upcoming-presentation-at-the-american-society-of-clinical-o-carm-20240424monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-present-new-data-at-the-american-society-of-gene-and-cell-therapy--carm-20240422monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-present-at-upcoming-conferences-carm-20240403monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-provides-business-update-and-reports-fourth-quarter-and-full-year-202-carm-20240401monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-announces-changes-to-its-board-of-directors-carm-20240401monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-announces-upcoming-presentations-at-the-american-association-for-cancer-research-a-carm-20240321monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-participate-in-td-cowen-carm-20240228monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-carm-20231221monthly0.5https://www.biopharmawatch.com/news/CARM/first-in-vivo-car-m-lead-candidate-nominated-under-carisma-moderna-collaboration-carm-20231214monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-announces-fda-clearance-of-ind-application-for-ct-0525-a-novel-her2-t-carm-20231128monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-participate-in-evercore-isi-healthconx-conference-carm-20231122monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-reports-third-quarter-2023-financial-results-and-recent-business-high-carm-20231109monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-presents-pre-clinical-proof-of-concept-for-in-vivo-car-m-using-mrna-platform-in-co-carm-20231031monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-to-present-first-results-from-in-vivo-car-m-collaboration-with-moderna-at-sitc-202-carm-20231025monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-present-at-upcoming-investor-conferences-carm-20230905monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-announces-latest-data-from-phase-1-clinical-trial-of-ct-0508-at-8th-annual-car-tcr-carm-20230901monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-present-at-upcoming-healthcare-industry-conferences-in-september-2-carm-20230824monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-reports-second-quarter-2023-financial-results-and-recent-business-hig-carm-20230810monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-announces-first-patient-dosed-in-phase-1-study-of-ct-0508-in-combinat-carm-20230628monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-be-added-to-russell-2000-russell-3000-and-russell-microcap-indexes-carm-20230626monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-appoints-eric-siegel-as-general-counsel-and-corporate-secretary-and-t-carm-20230614monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-present-at-upcoming-investor-conferences-in-june-2023-carm-20230605monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-present-at-upcoming-healthcare-industry-conferences-in-june-2023-carm-20230530monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-reports-first-quarter-2023-financial-results-and-provides-business-hi-carm-20230511monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference-carm-20230508monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-present-at-upcoming-healthcare-industry-conferences-in-may-2023-carm-20230505monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-present-at-the-american-association-for-cancer-research-annual-mee-carm-20230414monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-present-at-upcoming-healthcare-industry-and-investor-conferences-i-carm-20230406monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-reports-fiscal-2022-financial-results-and-recent-business-highlights-carm-20230404monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-closes-merger-with-sesen-bio-carm-20230307monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-appoints-moderna-cso-of-external-research-ventures-lin-guey-to-scient-carm-20230207monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-appoints-leading-solid-tumor-immunotherapy-expert-padmanee-sharma-md--carm-20230131monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-announces-clinical-pre-clinical-updates-carm-20221111monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-announces-multiple-abstracts-accepted-for-presentation-at-the-society-carm-20221101monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-present-at-upcoming-healthcare-industry-and-investor-conferences-carm-20221026monthly0.5https://www.biopharmawatch.com/news/CARM/steven-kelly-president-and-ceo-of-carisma-therapeutics-named-ernst-young-entrepreneur-of-t-carm-20220627monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-host-webcast-on-phase-1-clinical-trial-of-engineered-macrophage-th-carm-20220617monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-present-latest-data-from-phase-1-clinical-trial-of-engineered-macr-carm-20220526monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-announces-appointment-of-michael-klichinsky-pharmd-phd-as-chief-scien-carm-20220425monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-present-engineered-cell-therapy-data-at-the-american-association-f-carm-20220408monthly0.5https://www.biopharmawatch.com/news/CARM/moderna-and-carisma-establish-collaboration-to-develop-in-vivo-engineered-chimeric-antigen-carm-20220110monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-participate-in-40th-annual-j-p-morgan-healthcare-conference-carm-20220105monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-announces-collaboration-with-merck-to-evaluate-car-macrophages-in-com-carm-20211206monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-appoints-sanford-zweifach-as-chairman-to-board-of-directors-carm-20211129monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-presents-data-from-phase-i-clinical-trial-of-ct-0508-a-her2-targeted--carm-20211112monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-announces-multiple-abstracts-accepted-for-presentation-at-the-society-for-immunoth-carm-20211101monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-announces-u-s-food-and-drug-administration-grants-fast-track-designat-carm-20210922monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-appoints-richard-morris-as-chief-financial-officer-carm-20210608monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-present-data-at-the-american-society-of-gene-cell-therapy-24th-ann-carm-20210428monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-establishes-collaboration-with-leading-cell-therapy-expert-to-explore-carm-20210426monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-present-data-at-the-american-association-for-cancer-research-annua-carm-20210409monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-announces-first-patient-dosed-in-landmark-clinical-study-evaluating-e-carm-20210318monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-completes-series-b-financing-totaling-59-million-carm-20210301monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-completes-series-b-funding-for-47-million-to-advance-development-of-n-carm-20210107monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-to-present-new-data-at-the-society-for-immunotherapy-of-cancer-35th-anniversary-an-carm-20201109monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-present-at-upcoming-healthcare-industry-conferences-carm-20201008monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-participate-in-upcoming-investor-conferences-carm-20201005monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-participate-in-upcoming-investor-conferences-carm-20200730monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-announces-fda-clearance-of-ind-application-for-first-ever-engineered--carm-20200727monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-present-and-meet-with-potential-investors-at-upcoming-healthcare-i-carm-20200521monthly0.5https://www.biopharmawatch.com/news/CARM/new-data-uncover-potential-of-expedited-pathway-for-immunotherapy-development-through-car--carm-20200515monthly0.5https://www.biopharmawatch.com/news/CARM/first-of-its-kind-engineered-macrophage-cell-therapy-platform-shows-ability-to-reduce-tumo-carm-20200323monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-to-present-at-march-scientific-and-investor-conferences-carm-20200228monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-expands-leadership-with-appointments-of-debora-barton-as-chief-medica-carm-20200106monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-announces-investor-conference-participation-carm-20191116monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-names-dr-robert-petit-as-chief-scientific-officer-carm-20190603monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-announces-upcoming-conference-participation-carm-20190305monthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-announces-a-53-million-series-a-financing-to-develop-novel-car-macrop-carm-20180627monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-present-its-pharma-division-achievements-at-the-bio-international-convention-evgn-20260609monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-first-quarter-2026-financial-results-evgn-20260520monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-present-at-the-24th-schro-dinger-european-user-group-meeting-evgn-20260512monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-schedules-first-quarter-2026-financial-results-release-evgn-20260507monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-schedules-fourth-quarter-and-full-year-2025-financial-results-release-evgn-20260219monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-and-queensland-university-of-technology-qut-announce-a-collaboration-to-advance-ai-evgn-20260217monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-second-quarter-2025-financial-results-evgn-20250819monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-schedules-second-quarter-2025-financial-results-release-evgn-20250729monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-schedules-first-quarter-2025-financial-results-release-evgn-20250508monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-fourth-quarter-and-full-year-2024-financial-results-evgn-20250306monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-the-appointment-of-nir-nimrodi-as-the-new-chairperson-of-the-board-effec-evgn-20250306monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-schedules-fourth-quarter-2024-financial-results-release-evgn-20250220monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-third-quarter-2024-financial-results-evgn-20241121monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-schedules-third-quarter-2024-financial-results-release-evgn-20241107monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-collaboration-with-google-cloud-to-pioneer-generative-ai-foundation-mode-evgn-20241031monthly0.5https://www.biopharmawatch.com/news/EVGN/watershed-ac-evogene-and-ben-gurion-university-receive-approval-for-second-year-grant-to-c-evgn-20241008monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-pricing-of-us-5-5-million-registered-direct-offering-and-concurrent-priv-evgn-20240823monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-second-quarter-2024-financial-results-evgn-20240822monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-regains-compliance-with-nasdaq-minimum-closing-bid-price-rule-evgn-20240812monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-schedules-second-quarter-2024-financial-results-release-evgn-20240812monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-expected-implementation-of-1-for-10-reverse-share-split-evgn-20240723monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-first-quarter-2024-financial-results-evgn-20240523monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-schedules-first-quarter-2024-financial-results-release-evgn-20240509monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-and-the-kitchen-foodtech-hub-by-strauss-group-established-finally-foods-ltd-revolu-evgn-20240402monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-filing-of-annual-report-on-form-20-f-evgn-20240328monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-receipt-of-nasdaq-minimum-bid-price-notification-evgn-20240320monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-fourth-quarter-and-full-year-2023-financial-results-evgn-20240307monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-schedules-fourth-quarter-2023-financial-results-release-conference-call-for-march--evgn-20240226monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-third-quarter-2023-financial-results-evgn-20231115monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-schedules-third-quarter-2023-financial-results-release-conference-call-for-novembe-evgn-20231102monthly0.5https://www.biopharmawatch.com/news/EVGN/colors-farm-evogene-and-ben-gurion-university-collaborate-to-establish-crustacean-gene-edi-evgn-20231031monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-provides-operational-update-amidst-current-security-situation-in-israel-evgn-20231018monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-second-quarter-2023-financial-results-evgn-20230817monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-schedules-second-quarter-2023-financial-results-release-conference-call-for-august-evgn-20230801monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-s-chempass-ai-tech-engine-is-introduced-with-new-breakthrough-machine-learning-tec-evgn-20230725monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-pricing-of-us-8-500-000-registered-direct-offering-evgn-20230717monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-first-quarter-2023-financial-results-evgn-20230518monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-ag-seed-division-awarded-prestigious-1-2m-horizon-grant-to-develop-oil-seed-crops--evgn-20230509monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-schedules-first-quarter-2023-financial-results-release-conference-call-for-may-18--evgn-20230504monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-filing-of-annual-report-on-form-20-f-evgn-20230330monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-fourth-quarter-and-full-year-2022-financial-results-evgn-20230309monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-attend-the-annual-roth-investor-conference-in-california-on-march-13-2023-evgn-20230301monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-schedules-fourth-quarter-and-full-year-2022-financial-results-release-conference-c-evgn-20230227monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-receive-3-5-million-payment-related-to-patent-portfolio-under-its-existing-seed-evgn-20221208monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-schedules-third-quarter-of-2022-financial-results-release-conference-call-for-nove-evgn-20221107monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-present-at-the-ld-micro-main-event-xv-investor-conference-in-los-angeles-evgn-20221006monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference-evgn-20220907monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-second-quarter-2022-financial-results-evgn-20220831monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-regains-compliance-with-nasdaq-minimum-closing-bid-price-rule-evgn-20220825monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-financial-results-and-earnings-announcement-schedule-for-the-second-quarter-of-202-evgn-20220802monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-first-quarter-2022-financial-results-evgn-20220526monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-financial-results-and-earnings-announcement-schedule-for-the-first-quarter-of-2022-evgn-20220510monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-present-at-the-jefferies-virtual-synthetic-biology-week-on-march-23-2022-evgn-20220314monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-fourth-quarter-and-full-year-2021-financial-results-evgn-20220310monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-attend-to-world-agri-tech-innovation-summit-from-march-22-23-2022-evgn-20220307monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-attend-the-34th-annual-roth-investor-conference-in-dana-point-california-betwee-evgn-20220303monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-financial-results-and-earnings-announcement-schedule-for-the-full-year-and-fourth--evgn-20220215monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-participate-in-edison-group-evgn-20220119monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-third-quarter-2021-financial-results-evgn-20211117monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-participation-in-the-second-research-period-of-the-crispr-il-consortium-evgn-20211110monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-financial-results-and-earnings-announcement-schedule-for-the-third-quarter-of-2021-evgn-20211027monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-present-at-cantor-virtual-global-healthcare-conference-september-2021-evgn-20210914monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference-2021-evgn-20210901monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-second-quarter-2021-financial-results-evgn-20210811monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-present-at-jefferies-virtual-industrials-conference-2021-evgn-20210729monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-financial-results-and-earnings-announcement-schedule-for-the-second-quarter-of-202-evgn-20210728monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-ms-sarit-firon-to-become-evogene-evgn-20210623monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-first-quarter-2021-financial-results-evgn-20210526monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-financial-results-and-earnings-announcement-schedule-for-the-first-quarter-of-2021-evgn-20210512monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-hold-virtual-investor-analyst-days-evgn-20210407monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-fourth-quarter-and-full-year-2020-financial-results-evgn-20210303monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-financial-results-and-earnings-announcement-schedule-for-the-fourth-quarter-and-fu-evgn-20210217monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-provides-2020-year-end-update-for-crispr-il-consortium-evgn-20210105monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-third-quarter-2020-financial-results-evgn-20201118monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-closing-of-12-million-registered-direct-offering-evgn-20201104monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-financial-results-and-earnings-announcement-schedule-for-the-third-quarter-of-2020-evgn-20201102monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-prices-12-million-registered-direct-offering-evgn-20201030monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-participation-at-the-h-c-wainwright-22nd-annual-global-investment-confer-evgn-20200909monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-10-million-equity-led-investment-by-ark-investment-management-llc-evgn-20200901monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-second-quarter-2020-financial-results-evgn-20200805monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-present-at-jefferies-virtual-2020-industrials-conference-evgn-20200729monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-financial-results-and-earnings-announcement-schedule-for-the-second-quarter-of-202-evgn-20200715monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligen-evgn-20200603monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-first-quarter-2020-financial-results-evgn-20200526monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-launches-its-new-branding-to-reflect-the-company-evgn-20200520monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-financial-results-and-earnings-announcement-schedule-for-the-first-quarter-of-2020-evgn-20200507monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-publishes-letter-to-shareholders-evgn-20200505monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-files-annual-report-for-the-year-ended-december-31-2019-evgn-20200430monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-fourth-quarter-and-full-year-2019-financial-results-evgn-20200304monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-attend-in-bank-of-america-2020-global-agriculture-and-materials-conference-evgn-20200225monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-financial-results-for-the-fourth-quarter-and-full-year-of-2019-earnings-announceme-evgn-20200212monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-third-quarter-2019-financial-results-evgn-20191113monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-financial-results-for-the-third-quarter-of-2019-earnings-announcement-schedule-evgn-20191023monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-second-quarter-of-2019-financial-results-evgn-20190731monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-amends-its-collaboration-agreement-with-bayer-to-include-genome-editing-targets-evgn-20190716monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-present-at-jefferies-2019-industrials-conference-evgn-20190715monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-financial-results-for-the-second-quarter-of-2019-earnings-announcement-schedule-evgn-20190711monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-first-quarter-of-2019-financial-results-evgn-20190528monthly0.5https://www.biopharmawatch.com/news/EVGN/evofuel-to-participate-in-the-2019-international-castor-oil-association-icoa-conference-evgn-20190521monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-financial-results-for-the-first-quarter-of-2019-evgn-20190507monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-files-annual-report-for-the-year-ended-december-31-2018-evgn-20190430monthly0.5https://www.biopharmawatch.com/news/EVGN/biomica-initiates-pre-clinical-studies-in-its-immuno-oncology-program-evgn-20190416monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-develop-next-generation-medical-cannabis-products-through-new-subsidiary-canoni-evgn-20190403monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-to-participate-in-the-world-agritech-innovation-summit-in-san-francisco-in-march-1-evgn-20190314monthly0.5https://www.biopharmawatch.com/news/EVGN/agplenus-evogene-evgn-20190314monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-fourth-quarter-and-full-year-2018-financial-results-evgn-20190313monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-fourth-quarter-and-full-year-of-2018-earnings-announcement-schedule-evgn-20190228monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-announces-establishment-of-ag-biologicals-subsidiary-lavie-bio-ltd-evgn-20190226monthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-appoints-dr-adrian-percy-to-its-board-of-directors-evgn-20190204monthly0.5https://www.biopharmawatch.com/news/HLN/poligrip-polident-showcases-impact-of-receiving-dentures-in-new-video-and-launches-second--hln-20250320monthly0.5https://www.biopharmawatch.com/news/HLN/haleon-issues-voluntary-nationwide-recall-of-robitussin-honey-cf-max-day-adult-and-robitus-hln-20240124monthly0.5https://www.biopharmawatch.com/news/HLN/voltaren-partners-with-fitness-instructor-and-tv-personality-amanda-kloots-to-help-caregiv-hln-20230516monthly0.5https://www.biopharmawatch.com/news/HLN/haleon-launches-with-purpose-to-deliver-better-everyday-health-with-humanity-hln-20220718monthly0.5https://www.biopharmawatch.com/news/HLN/se-lanza-haleon-con-el-propo-sito-de-cuidar-la-salud-del-di-a-a-di-a-con-humanidad-hln-20220718monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-s-opaganib-receives-fda-rare-pediatric-disease-designation-for-neuroblastoma-in-ad-rdhl-20260609monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-advancing-opaganib-options-for-ebola-virus-disease-outbreak-rdhl-20260603monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-full-year-2025-financial-results-and-operational-highlights-rdhl-20260427monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-s-opaganib-enhances-efficacy-of-neuroblastoma-chemo-combination-and-augment-anti-t-rdhl-20260422monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-secures-kukbo-asset-freeze-following-redhill-rdhl-20250513monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-supported-medscape-h-pylori-educational-program-to-launch-at-major-gastroenterolog-rdhl-20250502monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-secures-allowance-of-key-chinese-patent-application-for-proprietary-covi-rdhl-20250428monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-receives-nasdaq-notification-regarding-minimum-stockholders-rdhl-20250417monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-rdhl-20250416monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-full-year-2024-financial-results-and-operational-highlights-rdhl-20250410monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-submit-fda-approved-talicia-for-uk-marketing-authorisation-rdhl-20250318monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-advances-its-groundbreaking-late-stage-crohn-rdhl-20250312monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-presents-business-update-at-the-sachs-rdhl-20250227monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-licenses-rhb-102-for-commercialization-worldwide-excluding-north-america-to-hylori-rdhl-20250225monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-announces-initiation-of-phase-2-study-of-opaganib-and-darolutamide-in-advanced-pro-rdhl-20250204monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-s-talicia-adds-8-million-lives-with-coverage-by-humana-s-part-d-plan-also-new-data-rdhl-20250121monthly0.5https://www.biopharmawatch.com/news/RDHL/radioprotective-activity-of-redhill-rdhl-20241210monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-awarded-judgment-of-approximately-8-million-plus-costs-by-new-york-supre-rdhl-20241202monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-selected-to-present-opaganib-at-conference-organized-by-u-s-government-rdhl-20241028monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-announces-collaboration-with-a-leading-u-s-academic-medical-center-to-develop-opag-rdhl-20241022monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-secures-u-s-government-funding-through-barda-to-advance-opaganib-for-ebo-rdhl-20241014monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-and-medi-cal-deal-maintains-talicia-reimbursement-without-prior-authorization-for--rdhl-20241001monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-announces-new-u-s-coronavirus-patent-for-opaganib-valid-through-2041-rdhl-20240930monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-s-talicia-listed-as-first-line-choice-for-h-pylori-in-new-american-college-of-gast-rdhl-20240909monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-regains-compliance-with-nasdaq-minimum-bid-price-requirement-rdhl-20240905monthly0.5https://www.biopharmawatch.com/news/RDHL/new-peer-reviewed-publication-of-opaganib-phase-2-3-data-shows-62-reduction-in-covid-19-mo-rdhl-20240903monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-first-half-2024-business-highlights-rdhl-20240829monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-s-opaganib-granted-orphan-drug-designation-by-the-fda-for-childhood-cancer-neurobl-rdhl-20240826monthly0.5https://www.biopharmawatch.com/news/RDHL/talicia-launched-in-the-united-arab-emirates-rdhl-20240821monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-announces-positive-obesity-and-diabetes-results-with-opaganib-rdhl-20240819monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-plan-to-implement-ads-ratio-change-rdhl-20240816monthly0.5https://www.biopharmawatch.com/news/RDHL/newly-published-positive-phase-3-data-demonstrates-64-increased-efficacy-with-redhill-rdhl-20240801monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-strengthens-cash-balance-settles-obligations-and-removes-talicia-lien-rdhl-20240722monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-terminates-license-agreement-for-aemcolo-rdhl-20240709monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-announces-a-new-patent-covering-opaganib-in-combination-with-immune-checkpoint-inh-rdhl-20240603monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-announces-new-opaganib-chinese-patent-against-ebola-virus-valid-through-2035-rdhl-20240506monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-announces-first-patient-enrolled-in-u-s-government-supported-covid-19-study-rdhl-20240424monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-full-year-2023-results-and-operational-highlights-rdhl-20240408monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-1-25-million-registered-direct-offering-at-a-premium-to-market-rdhl-20240402monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-announces-new-uspto-patent-covering-talicia-through-2034-rdhl-20240311monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-s-opaganib-selected-for-evaluation-by-barda-and-nih-countermeasures-programs-the-u-rdhl-20240305monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-s-opaganib-protects-against-radiation-induced-lung-inflammation-and-fibrosis-new-p-rdhl-20240220monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-closing-of-8-million-registered-direct-offering-rdhl-20240126monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-8-million-registered-direct-offering-rdhl-20240125monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-announces-new-uspto-patent-grant-for-talicia-for-h-pylori-treatment-through-2042-rdhl-20240125monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-and-u-s-army-announce-opaganib-and-rhb-107-combinations-with-remdesivir-show-disti-rdhl-20231220monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-regains-compliance-with-nasdaq-minimum-bid-price-requirement-rdhl-20231212monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-announces-new-non-dilutive-external-funding-of-entire-rhb-107-covid-19-300-patient-rdhl-20231204monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-fda-grant-of-5-year-u-s-market-exclusivity-for-talicia-with-ip-rdhl-20231127monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-the-transfer-of-its-listing-to-the-nasdaq-capital-market-rdhl-20231114monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-and-u-s-army-announce-opaganib-rdhl-20231003monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-receipt-of-nasdaq-notification-regarding-minimum-bid-price-def-rdhl-20230922monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-announces-fda-snda-approval-for-talicia-rdhl-20230918monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-announces-new-uspto-notice-of-patent-allowance-for-opaganib-and-eu-patent-grant-fo-rdhl-20230905monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-h1-23-financial-results-and-operational-highlights-rdhl-20230817monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-talicia-approved-in-the-united-arab-emirates-and-first-commerc-rdhl-20230801monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-s-rhb-107-included-in-u-s-government-supported-covid-19-platform-trial-and-cleared-rdhl-20230731monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-announces-additional-u-s-government-funding-for-opaganib-nuclear-countermeasure-de-rdhl-20230721monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-q1-2023-financial-results-and-operational-highlights-rdhl-20230612monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-publishes-new-talicia-data-on-generic-non-bioequivalence-in-ap-t-and-presents-new--rdhl-20230509monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-s-rhb-102-bekinda-and-opaganib-granted-new-patents-in-oncology-setting-redhill-bio-rdhl-20230501monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-q4-22-full-year-2022-results-and-operational-highlights-rdhl-20230428monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-regains-compliance-with-nasdaq-minimum-bid-price-requirement-rdhl-20230411monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-6-million-registered-direct-offering-rdhl-20230330monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-initiates-first-community-setting-warranty-program-to-refund-talicia-non-responder-rdhl-20230321monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-definitive-agreement-for-up-to-6-million-private-placement-wit-rdhl-20230308monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-s-opaganib-selected-by-the-nih-radiation-and-nuclear-countermeasures-program-the-n-rdhl-20230228monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-announces-positive-mhra-meeting-and-planned-uk-marketing-authorisation-application-rdhl-20230216monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-positive-fda-meeting-regarding-opaganib-for-acute-nuclear-radi-rdhl-20230215monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-and-healthcare-royalty-agree-to-extinguish-all-redhill-rdhl-20230206monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-receives-uspto-notice-of-allowance-for-a-patent-covering-phase-3-stage-rhb-204-for-rdhl-20230126monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-announces-publication-of-positive-phase-2-study-results-with-once-daily-oral-rhb-1-rdhl-20230103monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-prices-8-0-million-underwritten-public-offering-rdhl-20221202monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-proposed-public-offering-rdhl-20221201monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-q3-22-results-and-operational-highlights-rdhl-20221129monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-positive-new-data-with-opaganib-for-nuclear-radiation-injury-rdhl-20221117monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reaches-agreement-in-principle-with-hcr-to-extinguish-all-debt-obligatio-rdhl-20221114monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-h1-22-highlights-and-q3-22-estimates-rdhl-20221107monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-presents-new-talicia-and-movantik-data-analyses-at-acg-2022-rdhl-20221026monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-s-oral-broad-acting-antiviral-opaganib-granted-new-covid-19-treatment-patent-uspto-rdhl-20221019monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-receipt-of-nasdaq-notification-regarding-minimum-bid-price-def-rdhl-20221018monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-eu-orphan-drug-designation-for-rhb-204-for-ntm-infections-rdhl-20220817monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-announces-new-h-pylori-and-covid-19-data-publication-and-presentations-at-leading--rdhl-20220712monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-q1-22-highlights-on-track-for-positive-cash-from-operations-in-rdhl-20220623monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-first-quarter-2022-financial-results-and-operational-highlights--rdhl-20220617monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-presents-new-talicia-data-analyses-at-ddw-2022-rdhl-20220525monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-15-million-registered-direct-offering-with-a-leading-healthcar-rdhl-20220509monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-reports-potent-inhibition-of-omicron-with-oral-covid-19-drug-candidate-opaganib-in-rdhl-20220411monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-operational-highlights-and-fourth-quarter-full-year-2021-financi-rdhl-20220317monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-and-kukbo-enter-oral-opaganib-license-for-covid-19-in-south-korea-rdhl-20220315monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-fourth-quarter-and-full-year-2021-financial-results-and-operatio-rdhl-20220310monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-announces-positive-phase-2-study-results-with-oral-rhb-107-in-non-hospitalized-cov-rdhl-20220301monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-record-quarterly-revenues-and-first-commercial-operations-brea-rdhl-20220217monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-rdhl-20220207monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-rdhl-20220113monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-and-gaelan-medical-enter-into-license-agreement-for-talicia-for-the-unit-rdhl-20220106monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-additional-insider-buying-rdhl-20211215monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-concerning-rates-of-clarithromycin-prescribing-for-h-pylori-despite-incr-rdhl-20211209monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-opaganib-wirkmechanismus-wird-durch-mutationen-im-viralen-spike-protein--rdhl-20211208monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-informa-que-o-mecanismo-do-opaganibe-na-o-foi-impactado-por-mutac-o-es-n-rdhl-20211208monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-informa-que-el-mecanismo-de-accio-n-del-opaganib-no-se-ve-afectado-por-m-rdhl-20211208monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-informa-que-el-mecanismo-de-opaganib-no-se-ve-afectado-por-mutaciones-de-rdhl-20211208monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-re-ve-le-que-les-mutations-dans-la-prote-ine-spike-et-les-mutations-du-v-rdhl-20211208monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-informa-aspectos-operacionales-destacados-y-resultados-financieros-del-t-rdhl-20211206monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-that-opaganib-mechanism-not-impacted-by-viral-spike-protein-muta-rdhl-20211206monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-informa-destaques-operacionais-e-resultados-financeiros-do-terceiro-trim-rdhl-20211206monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-pre-sente-ses-faits-saillants-ope-rationnels-et-ses-re-sultats-financier-rdhl-20211206monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-meldet-operative-highlights-und-finanzergebnisse-fu-r-das-dritte-quartal-rdhl-20211206monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-data-published-in-gastrohep-shows-consistent-efficacy-of-talicia-irrespe-rdhl-20211202monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-resultados-operativos-y-financieros-del-tercer-trimestre-de-2021-rdhl-20211202monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-rdhl-20211201monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-operational-highlights-and-third-quarter-2021-financial-results-rdhl-20211130monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-third-quarter-2021-financial-results-and-operational-highlights--rdhl-20211124monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-closing-of-15-5-million-public-offering-of-american-depositary-rdhl-20211123monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-pricing-of-15-5-million-public-offering-of-american-depositary-rdhl-20211119monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-underwritten-public-offering-of-american-depositary-shares-rdhl-20211118monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-anuncia-el-u-ltimo-paciente-aleatorizado-en-la-parte-a-del-estudio-covid-rdhl-20211117monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-gibt-die-ambulante-behandlung-des-letzten-patienten-im-teil-a-der-laufen-rdhl-20211117monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-annonce-que-le-dernier-patient-a-e-te-ale-atoirement-se-lectionne-dans-l-rdhl-20211117monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-anuncia-u-ltimo-paciente-randomizado-na-parte-a-do-estudo-de-fase-2-3-da-rdhl-20211116monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-last-patient-randomized-in-part-a-of-ongoing-phase-2-3-covid-1-rdhl-20211115monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-und-das-su-dkoreanische-unternehmen-kukbo-co-ku-ndigen-eine-strategische-rdhl-20211111monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-et-la-socie-te-sud-core-enne-kukbo-co-annoncent-un-investissement-strate-rdhl-20211111monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-e-kukbo-co-da-coreia-do-sul-anunciam-investimento-estrate-gico-de-ate-de-rdhl-20211110monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-y-kukbo-co-de-corea-del-sur-anuncian-una-inversio-n-estrate-gica-de-hast-rdhl-20211110monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-h-c-wainwright-7th-annual-israel-conference-and-german-equ-rdhl-20211109monthly0.5https://www.biopharmawatch.com/news/RDHL/kukbo-co-invierte-hasta-10-millones-de-do-lares-en-redhill-rdhl-20211109monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-and-south-korea-rdhl-20211108monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-presents-new-talicia-and-movantik-data-analyses-at-acg-2021-rdhl-20211025monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-bio-europe-2021-conference-rdhl-20211020monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-insider-buying-rdhl-20211018monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-new-u-s-patent-covering-talicia-for-h-pylori-infection-through-rdhl-20211012monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-pre-sente-une-analyse-plus-approfondie-des-donne-es-de-la-phase-2-3-comp-rdhl-20211007monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-informa-nuevos-ana-lisis-de-datos-de-fase-2-3-que-incluye-una-reduccio-n-rdhl-20211006monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-rdhl-20211006monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-informa-ana-lise-adicional-de-dados-de-fase-2-3-incluindo-reduc-a-o-de-6-rdhl-20211006monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-gibt-zusa-tzliche-analyse-der-phase-2-3-ergebnisse-mit-oral-verabreichtem-opaganib-rdhl-20211006monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-informa-un-ana-lisis-adicional-de-los-datos-de-la-fase-2-3-rdhl-20211005monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-further-analysis-of-phase-2-3-data-including-a-62-reduction-in-m-rdhl-20211004monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-settlement-of-movantik-patent-litigation-with-aurobindo-rdhl-20210923monthly0.5https://www.biopharmawatch.com/news/RDHL/suite-a-l-approbation-des-autorite-s-sud-africaines-redhill-biopharma-acce-le-re-son-e-tud-rdhl-20210917monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-erweitert-seine-laufende-us-amerikanische-phase-2-3-covid-19-studie-mit--rdhl-20210915monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-acelera-estudo-de-fase-2-3-da-covid-19-em-andamento-nos-eua-do-rhb-107-a-rdhl-20210914monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-acelera-el-estudio-de-covid-19-de-fase-2-3-en-curso-en-los-estados-unido-rdhl-20210914monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-top-line-data-from-opaganib-phase-2-3-study-in-severe-covid-19-p-rdhl-20210914monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-acelera-el-estudio-actual-de-fase-2-3-covid-19-de-rhb-107-rdhl-20210914monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-accelerates-ongoing-u-s-phase-2-3-covid-19-study-of-once-daily-oral-rhb--rdhl-20210913monthly0.5https://www.biopharmawatch.com/news/RDHL/opaganibe-da-redhill-biopharma-demonstra-reduc-a-o-significativa-da-fibrose-renal-rdhl-20210909monthly0.5https://www.biopharmawatch.com/news/RDHL/el-opaganib-de-redhill-biopharma-demuestra-una-significativa-disminucio-n-de-la-fibrosis-r-rdhl-20210909monthly0.5https://www.biopharmawatch.com/news/RDHL/opaganib-von-redhill-biopharma-zeigt-signifikante-verringerung-der-nierenfibrose-rdhl-20210909monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-pre-sente-trois-nouvelles-analyses-de-donne-es-movantik-a-painweek-2021-rdhl-20210909monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-presenta-tres-nuevos-ana-lisis-de-los-datos-de-movantik-en-painweek-2021-rdhl-20210908monthly0.5https://www.biopharmawatch.com/news/RDHL/l-opaganib-de-redhill-biopharma-de-montre-une-diminution-significative-de-la-fibrose-re-na-rdhl-20210908monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-apresenta-tre-s-novas-ana-lises-de-dados-do-movantik-na-painweek-2021-rdhl-20210908monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-stellt-auf-der-painweek-2021-drei-neue-analysen-von-movantik-daten-vor-rdhl-20210908monthly0.5https://www.biopharmawatch.com/news/RDHL/opaganib-de-redhill-biopharma-demuestra-una-disminucio-n-significativa-de-la-fibrosis-rena-rdhl-20210908monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-rdhl-20210907monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-presents-three-new-analyses-of-movantik-data-at-painweek-2021-rdhl-20210907monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-h-c-wainwright-annual-global-investment-and-cantor-global--rdhl-20210902monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-informa-resultados-financeiros-e-destaques-operacionais-do-segundo-trime-rdhl-20210830monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-pre-sente-ses-re-sultats-financiers-et-faits-saillants-ope-rationnels-du-rdhl-20210830monthly0.5https://www.biopharmawatch.com/news/RDHL/opaganib-de-redhill-biopharma-demuestra-una-fuerte-inhibicio-n-de-la-variante-delta-de-la--rdhl-20210830monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-informa-los-resultados-financieros-y-aspectos-operacionales-destacados-d-rdhl-20210830monthly0.5https://www.biopharmawatch.com/news/RDHL/opaganibe-da-redhill-biopharma-demonstra-forte-inibic-a-o-da-variante-delta-da-covid-19-rdhl-20210830monthly0.5https://www.biopharmawatch.com/news/RDHL/opaganib-von-redhill-biopharma-zeigt-starke-hemmung-der-covid-19-delta-variante-rdhl-20210830monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-meldet-finanzergebnisse-und-operative-highlights-fu-r-das-zweite-quartal-rdhl-20210830monthly0.5https://www.biopharmawatch.com/news/RDHL/l-opaganib-de-redhill-biopharma-de-montre-une-forte-inhibition-du-variant-delta-de-covid-1-rdhl-20210830monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-informa-de-los-resultados-financieros-del-segundo-trimestre-de-2021-rdhl-20210830monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-second-quarter-2021-financial-results-and-operational-highlights-rdhl-20210826monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-rdhl-20210826monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-annonce-deux-nouveaux-brevets-ame-ricains-couvrant-l-rdhl-20210825monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-anuncia-dos-nuevas-patentes-de-los-estados-unidos-que-cubren-el-opaganib-rdhl-20210824monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-anuncia-duas-novas-patentes-dos-eua-que-cobrem-o-opaganibe-para-o-vi-rus-rdhl-20210824monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-gibt-zwei-neue-us-patente-fu-r-opaganib-fu-r-ebola-virus-und-rhb-104-fu--rdhl-20210824monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-anuncia-dos-nuevas-patentes-estadounidenses-que-cubren-opaganib-y-rhb-10-rdhl-20210824monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-two-new-u-s-patents-covering-opaganib-for-ebola-virus-and-rhb--rdhl-20210823monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-second-quarter-2021-financial-results-and-operational-highlights-rdhl-20210819monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-settlement-of-movantik-patent-litigation-with-apotex-rdhl-20210722monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-anuncia-el-egreso-del-u-ltimo-paciente-del-estudio-en-fase-2-3-del-opaga-rdhl-20210721monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-annonce-qu-rdhl-20210721monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-anuncia-o-u-ltimo-paciente-para-o-estudo-de-fase-2-3-de-opaganibe-por-vi-rdhl-20210721monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-umum-pesakit-terakhir-melengkapkan-kajian-oral-opaganib-fasa-2-3-covid-1-rdhl-20210720monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-opaganib-2-3-19-rdhl-20210720monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-gibt-bekannt-dass-der-letzte-patient-die-phase-2-3-covid-19-studie-mit-o-rdhl-20210720monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-significantly-extends-unrestricted-commercial-coverage-for-talicia-with--rdhl-20210720monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-completa-el-tratamiento-del-estudio-en-fase-2-3-de-la-covid-19-de-opaganib-oral-rdhl-20210720monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-last-patient-out-for-phase-2-3-covid-19-study-of-oral-opaganib-rdhl-20210719monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-rdhl-20210713monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-anuncia-la-presentacio-n-de-datos-positivos-del-estudio-en-fase-2-del-op-rdhl-20210623monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-pra-sentiert-positive-phase-2-studiendaten-mit-oral-verabreichtem-opagan-rdhl-20210623monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-anuncia-apresentac-a-o-de-dados-positivos-de-fase-2-do-opaganib-administ-rdhl-20210623monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-annonce-la-pre-sentation-de-donne-es-positives-de-phase-2-sur-l-rdhl-20210623monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-presentation-of-positive-oral-opaganib-phase-2-data-in-covid-1-rdhl-20210621monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-the-bio-digital-international-convention-rdhl-20210609monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-completes-enrollment-of-oral-opaganib-phase-2-3-covid-19-study-rdhl-20210607monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-reports-first-quarter-2021-financial-results-and-operational-highlights-rdhl-20210527monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-receives-allowances-for-u-s-patent-applications-covering-opaganib-and-rh-rdhl-20210526monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-presents-analyses-of-movantik-onset-of-action-and-symptom-improvement-at-rdhl-20210524monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-presents-a-new-travelers-rdhl-20210521monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-first-quarter-2021-financial-results-and-operational-highlights--rdhl-20210520monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-rdhl-20210409monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-settlement-of-movantik-patent-litigation-with-msn-pharmaceutic-rdhl-20210325monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-compassionate-use-treatment-with-opaganib-of-first-covid-19-pa-rdhl-20210322monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-provides-fourth-quarter-and-full-year-2020-financial-results-and-operati-rdhl-20210318monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-host-fourth-quarter-and-full-year-2020-financial-results-and-operatio-rdhl-20210311monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-to-present-at-upcoming-conferences-in-march-rdhl-20210305monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-closing-of-35-million-bought-deal-offering-of-american-deposit-rdhl-20210304monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-increases-previously-announced-bought-deal-to-35-million-of-american-dep-rdhl-20210302monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-10-million-bought-deal-offering-of-american-depositary-shares-rdhl-20210301monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-planned-expansion-of-opaganib-global-phase-2-3-covid-19-study--rdhl-20210223monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-strengthens-partnership-with-cosmo-pharmaceuticals-with-manufacturing-ag-rdhl-20210218monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-first-patient-dosed-in-u-s-phase-2-3-covid-19-outpatient-study-rdhl-20210217monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-svb-leerink-global-healthcare-and-bio-ceo-investor-confere-rdhl-20210209monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-anuncia-valoracio-n-positiva-de-la-futilidad-del-dsmb-para-el-estudio-de-rdhl-20210202monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-anuncia-avaliac-a-o-positiva-de-futilidade-pelo-dsmb-para-estudo-de-fase-rdhl-20210202monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-positive-dsmb-futility-review-for-phase-2-3-covid-19-study-of--rdhl-20210129monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-further-expands-opaganib-manufacturing-capacity-for-covid-19-with-cosmo--rdhl-20210128monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-closing-of-25-million-bought-deal-offering-rdhl-20210114monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-partner-cosmo-pharmaceuticals-schlie-t-erfolgreich-phase-2-studie-mit-rifamycin-sv-rdhl-20210113monthly0.5https://www.biopharmawatch.com/news/RDHL/cosmo-pharmaceuticals-partenaire-de-redhill-a-acheve-avec-succe-s-son-e-tude-de-phase-2-su-rdhl-20210113monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-increases-previously-announced-bought-deal-to-25-million-rdhl-20210112monthly0.5https://www.biopharmawatch.com/news/RDHL/el-socio-de-redhill-cosmo-pharmaceuticals-completa-con-e-xito-el-estudio-de-fase-2-rdhl-20210112monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-10-million-bought-deal-offering-rdhl-20210111monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-s-partner-cosmo-pharmaceuticals-successfully-completes-phase-2-study-of-rifamycin--rdhl-20210111monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-rdhl-20210106monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-anuncia-datos-positivos-de-primera-li-nea-acerca-de-la-seguridad-y-efica-rdhl-20210104monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-anuncia-dados-positivos-de-primeira-linha-de-seguranc-a-e-efica-cia-do-e-rdhl-20210104monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-gibt-positive-topline-sicherheits-und-wirksamkeitsdaten-der-phase-ii-cov-rdhl-20210104monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-anuncia-datos-positivos-de-seguridad-y-eficacia-del-estudio-de-covid-19--rdhl-20210104monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-annonce-les-re-sultats-positifs-de-la-phase-2-de-l-rdhl-20210104monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-announces-positive-top-line-safety-and-efficacy-data-from-phase-2-covid--rdhl-20201231monthly0.5https://www.biopharmawatch.com/news/RDHL/estudo-de-fase-2-3-para-covid-19-da-redhill-com-opaganibe-passa-pela-segunda-recomendac-a--rdhl-20201224monthly0.5https://www.biopharmawatch.com/news/RDHL/estudio-de-fase-2-3-con-opaganib-para-tratar-la-covid-19-de-redhill-recibe-recomendacio-n--rdhl-20201224monthly0.5https://www.biopharmawatch.com/news/RDHL/l-e-tude-covid-19-phase-2-3-de-redhill-sur-l-opaganib-passe-le-deuxie-me-dsmb-avec-une-rec-rdhl-20201223monthly0.5https://www.biopharmawatch.com/news/RDHL/zweites-dsmb-meeting-gibt-einstimmige-empfehlung-redhills-phase-2-3-studie-mit-opaganib-zu-rdhl-20201223monthly0.5https://www.biopharmawatch.com/news/RDHL/el-estudio-de-covid-19-de-fase-2-3-de-redhill-de-opaganib-aprueba-un-segundo-dsmb-rdhl-20201223monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-s-phase-2-3-covid-19-study-of-opaganib-passes-second-dsmb-with-unanimous-recommend-rdhl-20201222monthly0.5https://www.biopharmawatch.com/news/RDHL/opaganib-el-fa-rmaco-de-redhill-para-la-covid-19-que-se-encuentra-en-fase-2-3-de-estudio-r-rdhl-20201217monthly0.5https://www.biopharmawatch.com/news/RDHL/der-redhill-phase-ii-iii-kandidat-opaganib-reduziert-ards-bedingte-blutgerinnung-im-pra-kl-rdhl-20201217monthly0.5https://www.biopharmawatch.com/news/RDHL/l-opaganib-candidat-the-rapeutique-pour-le-traitement-du-covid-19-dans-l-e-tude-de-phase-2-rdhl-20201217monthly0.5https://www.biopharmawatch.com/news/RDHL/opaganibe-candidato-da-redhill-no-estudo-de-fase-2-3-da-covid-19-reduz-coagulac-a-o-sangui-rdhl-20201217monthly0.5https://www.biopharmawatch.com/news/RDHL/el-opaganib-candidato-de-redhill-para-covid-19-reduce-los-coa-gulos-sangui-neos-relativos--rdhl-20201217monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-s-phase-2-3-covid-19-candidate-opaganib-reduces-ards-related-blood-clotting-in-pre-rdhl-20201215monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-added-to-nasdaq-biotechnology-index-rdhl-20201214monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-extends-talicia-unrestricted-national-and-regional-commercial-coverage-t-rdhl-20201207monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-expands-u-s-based-manufacturing-capacity-of-opaganib-for-covid-19-rdhl-20201125monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-anuncia-recomendacio-n-una-nime-del-dsmb-para-continuar-el-estudio-de-fase-2-3-con-rdhl-20201123monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-evercore-isi-healthconx-and-piper-sandler-healthcare-confe-rdhl-20201123monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-anuncia-recomendac-a-o-una-nime-do-dsmb-para-continuar-o-estudo-de-fase-2-3-com-op-rdhl-20201123monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-initiates-phase-3-study-of-rhb-204-for-first-line-treatment-of-ntm-disea-rdhl-20201120monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-announces-unanimous-dsmb-recommendation-to-continue-phase-2-3-covid-19-study-with--rdhl-20201119monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-rdhl-20201117monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-completes-enrollment-for-covid-19-u-s-phase-2-study-with-opaganib-data-e-rdhl-20201116monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-estara-presente-en-el-evento-online-virtualinvestorconferences-com-el-5--rdhl-20150305monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-pre-sentera-a-l-rdhl-20150304monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-to-present-at-virtualinvestorconferences-com-online-event-on-march-5-201-rdhl-20150303monthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-ist-teilnehmer-der-online-veranstaltung-von-virtualinvestorconferences-c-rdhl-20150303monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-third-quarter-2024-financial-results-axdx-20241107monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-second-quarter-2024-financial-results-axdx-20240808monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-scheduled-call-to-review-2024-second-quarter-results-axdx-20240808monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-preliminary-first-quarter-2024-financial-results-axdx-20240508monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-scheduled-call-to-review-2024-first-quarter-results-axdx-20240502monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-fourth-quarter-and-full-year-2023-financial-results-axdx-20240328monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-scheduled-call-to-review-2023-fourth-quarter-and-full-year-results-axdx-20240307monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-pricing-of-approximately-15-million-public-offering-and-p-axdx-20240119monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-launch-of-proposed-public-offering-axdx-20240116monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-certain-preliminary-fourth-quarter-and-full-year-2023-res-axdx-20240107monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-collaboration-for-the-use-of-the-arc-system-in-combinatio-axdx-20231127monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-third-quarter-2023-results-axdx-20231109monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-scheduled-call-to-review-2023-third-quarter-results-axdx-20231030monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-second-quarter-2023-financial-results-axdx-20230810monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-scheduled-call-to-review-2023-second-quarter-results-axdx-20230727monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-1-for-10-reverse-stock-split-axdx-20230710monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-successful-completion-of-debt-restructuring-support-agree-axdx-20230613monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-first-quarter-2023-financial-results-axdx-20230511monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-scheduled-call-to-review-2023-first-quarter-results-axdx-20230427monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-fourth-quarter-and-full-year-2022-financial-results-axdx-20230329monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-scheduled-call-to-review-2022-fourth-quarter-and-full-year-results-axdx-20230315monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-departure-of-cfo-steve-reichling-and-appointment-of-david-axdx-20230314monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-appointment-of-hany-massarany-to-chairman-of-board-of-dir-axdx-20230308monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-submits-510-k-application-to-fda-for-gram-negative-menu-expansion-a-axdx-20221219monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-third-quarter-2022-financial-results-axdx-20221114monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-scheduled-call-to-review-2022-third-quarter-results-axdx-20221024monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-pricing-of-public-offering-of-common-stock-axdx-20220818monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-proposed-public-offering-of-common-stock-axdx-20220817monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-second-quarter-2022-financial-results-axdx-20220815monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-scheduled-call-to-review-2022-second-quarter-results-axdx-20220725monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-commercialization-in-europe-of-its-accelerate-arc-system--axdx-20220711monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-to-participate-in-42nd-annual-william-blair-growth-stock-conference-axdx-20220523monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-first-quarter-2022-financial-results-axdx-20220516monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-scheduled-call-to-review-2022-first-quarter-results-axdx-20220429monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-presents-new-data-at-eccmid-2022-demonstrating-rapid-and-accurate-r-axdx-20220425monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-launch-of-accelerate-arc-module-and-bc-kit-axdx-20220328monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-fourth-quarter-and-full-year-2021-financial-results-axdx-20220308monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-scheduled-call-to-review-2021-fourth-quarter-and-full-year-results-axdx-20220224monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-to-participate-in-btig-medtech-digital-health-life-science-diagnost-axdx-20220202monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-preliminary-fourth-quarter-full-year-2021-financial-resul-axdx-20220113monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-wins-suzhou-innovation-award-to-support-continued-china-commerciali-axdx-20220112monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-to-participate-virtually-in-40th-annual-j-p-morgan-healthcare-confe-axdx-20211229monthly0.5https://www.biopharmawatch.com/news/AXDX/new-accelerate-pheno-system-multi-center-study-published-in-clinical-infectious-diseases-axdx-20211122monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-third-quarter-2021-financial-results-axdx-20211109monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-schedules-call-to-review-3rd-quarter-2021-results-axdx-20211019monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-agreements-to-exchange-approximately-51-million-in-princi-axdx-20210923monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-second-quarter-2021-financial-results-axdx-20210805monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-ce-mark-and-availability-in-europe-of-fast-antimicrobial--axdx-20210803monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-schedules-call-to-review-2nd-quarter-2021-results-axdx-20210715monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-launches-a-fast-antimicrobial-susceptibility-test-for-use-with-exis-axdx-20210707monthly0.5https://www.biopharmawatch.com/news/AXDX/new-accelerate-pheno-landmark-study-validates-important-clinical-benefits-to-be-presented--axdx-20210630monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-to-participate-in-william-blair-41st-annual-growth-stock-conference-axdx-20210519monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-first-quarter-2021-financial-results-axdx-20210506monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-to-host-call-to-review-first-quarter-2021-results-axdx-20210505monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-fourth-quarter-and-full-year-2020-financial-results-axdx-20210223monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-to-participate-in-btig-medtech-digital-health-life-science-diagnost-axdx-20210201monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-schedules-call-to-review-2020-fourth-quarter-and-full-year-results-axdx-20210201monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-preliminary-fourth-quarter-and-full-year-2020-financial-r-axdx-20210112monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-third-quarter-2020-financial-results-axdx-20201105monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-virtual-product-demo-day-and-schedules-call-to-review-thi-axdx-20201012monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-new-fda-clearance-for-accelerate-phenotest-improvements-axdx-20200916monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-fda-emergency-use-authorization-for-covid-19-individual-i-axdx-20200910monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-names-nedal-safwat-chief-strategy-officer-axdx-20200824monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-fda-emergency-use-authorization-for-covid-19-antibody-tes-axdx-20200818monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-second-quarter-2020-financial-results-announces-new-product-axdx-20200806monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-schedules-call-to-review-second-quarter-2020-results-axdx-20200716monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-first-quarter-financial-results-and-provides-covid-19-bus-axdx-20200507monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-preliminary-first-quarter-financial-results-and-provides--axdx-20200415monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-and-biocheck-announce-commercial-supply-and-collaboration-agreement-axdx-20200415monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-fourth-quarter-2019-financial-results-axdx-20200227monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-schedules-call-to-review-2019-fourth-quarter-and-full-year-results-axdx-20200218monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-preliminary-fourth-quarter-and-full-year-2019-financial-r-axdx-20200113monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-to-participate-in-38th-annual-j-p-morgan-healthcare-conference-in-s-axdx-20200103monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-to-participate-in-31st-annual-piper-jaffray-healthcare-conference-i-axdx-20191204monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-executive-transition-lawrence-mehren-to-retire-as-chief-e-axdx-20191204monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-appoints-louise-francesconi-to-its-board-of-directors-axdx-20191202monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-third-quarter-2019-financial-results-axdx-20191107monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-appoints-roland-diggelmann-to-its-board-of-directors-axdx-20191104monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-schedules-call-to-review-third-quarter-2019-results-axdx-20191017monthly0.5https://www.biopharmawatch.com/news/AXDX/studies-confirm-rapid-phenotypic-susceptibility-results-enable-earlier-antimicrobial-inter-axdx-20191003monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-highlights-clinical-endpoints-achieved-across-mayo-clinic-ucla-univ-axdx-20190918monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-names-jack-phillips-chief-operating-officer-axdx-20190808monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-second-quarter-2019-financial-results-axdx-20190808monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-expands-antimicrobials-in-new-ce-marked-accelerate-phenotest-bc-kit-axdx-20190802monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-schedules-call-to-review-second-quarter-2019-results-axdx-20190708monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-to-present-at-the-william-blair-growth-stock-conference-on-june-6-2-axdx-20190524monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-first-quarter-2019-financial-results-axdx-20190509monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-schedules-call-to-review-first-quarter-2019-results-axdx-20190426monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-to-present-at-the-cowen-and-company-39th-annual-health-care-confere-axdx-20190308monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-2018-fourth-quarter-and-full-year-financial-results-axdx-20190219monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-schedules-call-to-review-2018-fourth-quarter-and-full-year-results-axdx-20190205monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-preliminary-2018-fourth-quarter-and-full-year-financial-r-axdx-20190106monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-in-s-axdx-20190102monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-pledges-matching-support-for-sepsis-alliance-givingtuesday-movement-axdx-20181127monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-reports-q3-2018-financial-results-axdx-20181106monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-to-review-third-quarter-2018-results-on-november-6th-axdx-20181017monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-resignation-of-joan-martin-as-head-of-europe-middle-east--axdx-20180927monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-commences-rights-offering-axdx-20140407monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-launches-investor-portal-to-website-axdx-20140131monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-inc-names-mark-c-miller-to-board-of-directors-axdx-20131106monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-final-results-of-rights-offering-axdx-20130813monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-final-terms-of-rights-offering-axdx-20130712monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-joins-the-russell-2000-index-axdx-20130701monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-appoints-chief-commercial-officer-axdx-20130701monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-announces-plans-for-rights-offering-to-stockholders-axdx-20130604monthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-inc-names-frank-j-m-ten-brink-to-board-of-directors-axdx-20130306monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-announces-grant-of-european-patent-for-targeting-of-microbial-oncological-and-viral-i-tcbp-20250409monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-to-present-at-sequire-investor-summit-2025-tcbp-20250113monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-issues-25-stock-dividend-tcbp-20250106monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-trading-continues-unabated-on-nasdaq-stock-exchange-tcbp-20250106monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-provides-update-on-acquisition-strategy-and-current-targets-tcbp-20241231monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-advances-achieve-phase-2b-clinical-trial-with-final-dosing-of-3-patients-tcbp-20241220monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-announces-general-meeting-of-shareholders-to-approve-one-time-shareholder-dividend-tcbp-20241218monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-partners-with-caredx-to-support-achieve-clinical-trial-using-allocell-for-pharmacokin-tcbp-20241211monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-provides-quarterly-update-on-the-achieve-uk-clinical-trial-tcbp-20241204monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-awarded-non-dilutive-funding-scaleready-tcbp-20241112monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-provides-shareholder-update-and-highlights-recent-milestone-achievements-tcbp-20241030monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-responds-to-false-social-media-claim-tcbp-20241025monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-enters-research-planning-collaboration-with-dr-carlos-maluquer-de-motes-for-mpox-ther-tcbp-20241022monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-announces-artificial-intelligence-initiative-with-partner-carnegie-mellon-university--tcbp-20241003monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-announces-site-opening-of-guys-and-st-thomas-hospital-tcbp-20240925monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-to-present-at-the-2024-thinkequity-conference-in-nyc-tcbp-20240924monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-announces-first-patient-completed-the-full-dose-regimen-in-achieve-clinical-trial-tcbp-20240920monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-intends-to-launch-preclinical-studies-for-treatment-of-monkey-pox-tcbp-20240909monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-intends-to-launch-preclinical-studies-for-treatment-of-monkey-pox-tcbp-20240906monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-announces-participation-at-the-h-c-wainwright-26th-annual-global-investment-conferenc-tcbp-20240905monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-announces-dosing-of-5-new-patients-in-achieve-tcbp-20240903monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-closing-of-upsized-6-0-million-public-offering-tcbp-20240828monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-grant-of-european-patent-covering-use-of-modified-gamma-delta-cells--tcbp-20240828monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-regains-compliance-with-nasdaq-listing-rule-5550-b-tcbp-20240815monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-closing-of-2-0-million-public-offering-tcbp-20240815monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-pricing-of-2-0-registered-direct-offering-tcbp-20240813monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-announces-plan-to-implement-ads-ratio-change-tcbp-20240731monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-announces-dosing-of-6th-patient-in-achieve-study-in-patients-with-acute-myeloid-leuke-tcbp-20240722monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-announces-launch-of-compassionate-use-program-for-tcb008-tcbp-20240515monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-exercise-of-warrants-for-3-1-million-gross-proceeds-tcbp-20240506monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-execution-of-second-non-binding-letter-of-intent-for-acquisition-tar-tcbp-20240506monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-announces-execution-of-non-binding-letter-of-intent-for-acquisition-of-nk-platform-te-tcbp-20240404monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-increasing-treatment-capacity-with-expanded-manufacturing-process-tcbp-20240402monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-adjourns-general-meeting-until-a-later-date-tcbp-20240319monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-announces-exercise-of-series-d-warrants-for-cash-tcbp-20240318monthly0.5https://www.biopharmawatch.com/news/TCBP/bryan-kobel-ceo-of-tcbp-appears-on-nationally-syndicated-the-big-biz-show-tcbp-20240301monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-announces-shareholder-update-call-on-march-5th-2024-tcbp-20240227monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-announces-mhra-acceptance-of-amendment-for-achieve-uk-trial-tcbp-20240222monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-management-to-participate-at-upcoming-7th-car-tcr-summit-europe-tcbp-20240215monthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-provides-shareholder-update-and-highlights-upcoming-milestones-tcbp-20240214monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-chief-executive-officer-bryan-kobel-featured-on-tcbp-20240129monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-to-present-at-the-sequire-investor-summit-tcbp-20240118monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-regains-compliance-with-nasdaq-minimum-bid-price-requirement-tcbp-20240104monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-additional-cost-reduction-steps-to-improve-financial-standing-and-st-tcbp-20240103monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-closing-of-3-5-million-public-offering-tcbp-20231222monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-pricing-of-3-5-million-public-offering-tcbp-20231219monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-formation-of-commercial-development-division-led-by-industry-veteran-tcbp-20231218monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-plan-to-implement-ads-ratio-change-tcbp-20231213monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-fda-clearance-of-phase-1b-ind-for-tcb-008-in-acute-myeloid-leukemia-tcbp-20231127monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-successful-completion-of-safety-cohort-and-positive-dsmb-results-tcbp-20231114monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-streamlined-efficiencies-and-reduces-overhead-with-selection-of-sing-tcbp-20231102monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-selects-excellos-as-cdmo-in-anticipation-of-expanded-us-clinical-trial-require-tcbp-20231025monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-submission-of-investigational-new-drug-ind-application-to-u-s-fda-fo-tcbp-20231023monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-to-present-at-the-ld-micro-main-event-xvi-tcbp-20230927monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-grant-funding-in-collaboration-with-queen-mary-university-of-london--tcbp-20230905monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-tcbp-20230829monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-maintains-nasdaq-listing-tcbp-20230731monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-to-present-at-ld-micro-invitational-xiii-conference-on-june-7-2023-tcbp-20230524monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-increases-allogeneic-car-and-partnering-focus-for-advancement-of-tcb-008-tcbp-20230426monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-closing-of-5-5-million-public-offering-tcbp-20230330monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-pricing-of-5-5-million-public-offering-tcbp-20230328monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-corporate-restructuring-reduction-in-overhead-tcbp-20230322monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-receives-extension-from-nasdaq-hearings-panel-to-regain-compliance-with-listin-tcbp-20230316monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-shifts-focus-to-fda-clinical-trials-tcbp-20230307monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-dr-mike-leek-as-chief-technology-officer-tcbp-20230223monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-publication-of-paper-in-aml-research-highlighting-the-company-tcbp-20230221monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-new-chair-of-the-board-arlene-morris-tcbp-20230214monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-to-reschedule-shareholder-update-call-and-webcast-tcbp-20230213monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-successful-dosing-of-final-patient-in-achieve-safety-cohort-tcbp-20230207monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-hiring-of-chief-clinical-officer-bree-harlin-to-lead-global-clinical-tcbp-20230130monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-to-host-shareholder-update-call-tcbp-20230120monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-receives-notice-of-non-compliance-with-nasdaq-tcbp-20230119monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-strategic-collaboration-to-advance-gamma-delta-t-cells-in-oncology-tcbp-20230117monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-reports-first-half-2022-financial-results-and-provides-shareholder-update-tcbp-20221212monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-closing-of-7-35-million-private-placement-tcbp-20221130monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-7-35-million-private-placement-tcbp-20221128monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-begins-dosing-phase-2b-clinical-study-evaluating-its-lead-compound-omnimmune-i-tcbp-20221122monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-key-additions-to-scientific-advisory-board-expanding-cell-therapy-ex-tcbp-20221026monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-to-present-at-upcoming-investor-conferences-tcbp-20221003monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-receives-mhra-approval-for-18-month-extrapolated-shelf-life-of-allogeneic-cell-tcbp-20220913monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference-tcbp-20220822monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-executives-to-speak-at-the-3rd-gamma-delta-t-therapies-summit-tcbp-20220725monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-ceo-bryan-kobel-to-speak-at-the-innovating-cell-and-gene-therapy-quality-contr-tcbp-20220708monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-closing-of-4-million-underwritten-public-offering-tcbp-20220607monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-pricing-of-4-million-underwritten-public-offering-tcbp-20220602monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-highlights-need-for-disruptive-treatment-as-acute-myeloid-leukemia-cases-rise--tcbp-20220531monthly0.5https://www.biopharmawatch.com/news/TCBP/kuick-research-recognizes-tc-biopharm-as-a-key-player-in-the-gamma-delta-t-cell-therapy-ma-tcbp-20220523monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-formation-of-scientific-advisory-board-with-renowned-cell-therapy-ex-tcbp-20220518monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-invited-to-present-at-ld-micro-conference-tcbp-20220503monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-to-participate-in-upcoming-conferences-tcbp-20220426monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-donates-to-leukemia-and-lymphoma-society-in-sponsorship-of-world-aml-day-tcbp-20220421monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-receives-cryotc-trademark-for-proprietary-cell-freezing-process-tcbp-20220406monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-initiation-of-equity-analyst-coverage-by-ef-hutton-with-a-buy-recomm-tcbp-20220329monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-receives-mhra-and-research-ethics-committee-approvals-to-initiate-phase-2b-3-c-tcbp-20220323monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-fda-orphan-drug-status-granted-for-omnimmune-tcbp-20220317monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-updates-intellectual-property-portfolio-tcbp-20220315monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-positive-phase-1b-2a-data-in-late-stage-acute-myeloid-leukemia-patie-tcbp-20220308monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-to-host-corporate-update-call-on-march-8th-tcbp-20220302monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-appointment-of-new-board-members-tcbp-20220222monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-closing-of-17-5-million-initial-public-offering-tcbp-20220215monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-begins-trading-on-nasdaq-today-under-symbol-tcbp-tcbp-20220211monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-pricing-of-upsized-17-5-million-initial-public-offering-and-nasdaq-l-tcbp-20220210monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-to-participate-in-advanced-therapies-week-january-25-28-tcbp-20220118monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-holdings-limited-names-chris-camarra-executive-vice-president-communications-tcbp-20220111monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-launch-of-covid-19-phase-i-ii-human-trial-tcbp-20211013monthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-announces-dr-sebastian-wanless-as-senior-clinical-director-tcbp-20210920monthly0.5https://www.biopharmawatch.com/news/TCBP/allogeneic-car-t-specialists-tc-biopharm-appoint-prof-john-anderson-as-scientific-and-medi-tcbp-20190329monthly0.5https://www.biopharmawatch.com/news/TCBP/immunotherapy-company-tc-biopharm-partners-with-trinity-college-dublin-to-develop-v-delta--tcbp-20190225monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-reports-financial-results-for-fiscal-first-quarter-ended-december-31-2024-epix-20250211monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-third-quart-epix-20240805monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-the-joneshealthcare-seaside-summit-epix-20240708monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-the-jefferies-global-healthcare-conference-epix-20240530monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-second-quar-epix-20240514monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-the-2024-bloom-burton-co-healthcare-investor-conference-epix-20240409monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-reports-results-of-annual-general-meeting-of-shareholders-epix-20240307monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-first-quart-epix-20240213monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-the-oppenheimer-34th-annual-healthcare-life-sciences-conference-epix-20240206monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-presents-updated-phase-1-masofaniten-epi-7386-clinical-data-at-the-2024-asco-g-epix-20240125monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-fourth-quar-epix-20231212monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-the-piper-sandler-35th-annual-healthcare-conference-epix-20231121monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-the-jefferies-london-healthcare-conference-epix-20231108monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-enters-into-at-the-market-equity-offering-sales-agreement-epix-20231106monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-presents-updated-phase-1-masofaniten-epi-7386-clinical-data-at-the-30th-annual-epix-20231026monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-presents-updated-phase-1-masofaniten-epi-7386-clinical-data-at-the-european-so-epix-20231021monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-initiation-of-phase-2-study-evaluating-masofaniten-epi-7386-in-combi-epix-20230918monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-insiders-establish-automatic-securities-disposition-plans-epix-20230831monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-third-quart-epix-20230808monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-appoints-lauren-merendino-to-its-board-of-directors-epix-20230606monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-2023-jefferies-healthcare-conference-epix-20230601monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-jmp-securities-life-sciences-conference-epix-20230511monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-second-quar-epix-20230509monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-the-2023-bloom-burton-co-healthcare-investor-conference-epix-20230418monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-clinical-trial-support-agreement-with-janssen-to-evaluate-epi-7386-c-epix-20230412monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-the-oppenheimer-33rd-annual-healthcare-conference-epix-20230308monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-presentations-at-the-american-society-of-clinical-oncology-genitouri-epix-20230213monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-first-quart-epix-20230207monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-participate-in-the-guggenheim-healthcare-talks-5th-annual-oncology-conferen-epix-20230202monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-fourth-quar-epix-20221213monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-participate-in-two-upcoming-investor-conferences-epix-20221110monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-provides-an-update-on-its-clinical-collaboration-with-janssen-epix-20221031monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-presents-preclinical-data-for-its-first-generation-androgen-receptor-n-termina-epix-20221026monthly0.5https://www.biopharmawatch.com/news/EPIX/updated-results-from-the-phase-1-2-study-of-essa-epix-20221026monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-appoints-philip-kantoff-to-its-board-of-directors-epix-20220913monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-third-quart-epix-20220804monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-presents-clinical-update-on-epi-7386-monotherapy-and-combination-therapy-clini-epix-20220627monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-2022-jefferies-healthcare-conference-epix-20220602monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-second-quar-epix-20220510monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-the-2022-bloom-burton-co-healthcare-investor-conference-epix-20220426monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-the-presentation-of-preclinical-data-for-its-first-generation-of-and-epix-20220408monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-oppenheimer-annual-healthcare-conference-epix-20220310monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-reports-results-of-annual-general-meeting-of-shareholders-epix-20220309monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-preclinical-data-for-its-first-generation-of-androgen-receptor-n-te-epix-20220308monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-first-quart-epix-20220203monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-first-patient-dosed-in-a-phase-1-2-clinical-trial-of-epi-7386-in-com-epix-20220119monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-fourth-quar-epix-20211118monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-participate-in-three-upcoming-investor-conferences-epix-20211108monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-presents-at-28th-annual-prostate-cancer-foundation-scientific-retreat-epix-20211028monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-the-presentation-of-preclinical-data-characterizing-the-mechanism-of-epix-20211007monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-upcoming-september-investor-conferences-epix-20210831monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-third-quart-epix-20210816monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-the-jefferies-virtual-healthcare-conference-epix-20210525monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-second-quar-epix-20210506monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-clinical-collaboration-agreement-with-bayer-to-evaluate-the-combinat-epix-20210428monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-the-bloom-burton-co-healthcare-investor-conference-epix-20210414monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-presents-preclinical-data-supporting-the-therapeutic-potential-of-epi-7386-at--epix-20210410monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-announces-change-to-its-board-of-directors-epix-20210326monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-exercise-of-option-in-connection-with-recently-completed-130-million-epix-20210304monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-reports-results-of-annual-general-and-special-meeting-of-shareholders-epix-20210225monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-upcoming-march-investor-conferences-epix-20210225monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-clinical-collaboration-with-astellas-to-evaluate-the-combination-of--epix-20210225monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-closing-of-130-million-public-offering-of-common-stock-epix-20210222monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-pricing-of-public-offering-of-common-shares-epix-20210217monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-proposed-public-offering-of-common-shares-epix-20210216monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-presents-favorable-initial-phase-1-clinical-pharmacology-data-of-epi-7386-for--epix-20210211monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-first-quart-epix-20210211monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-clinical-collaboration-with-janssen-to-evaluate-epi-7386-combination-epix-20210113monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-fourth-quar-epix-20201215monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-participate-at-evercore-isi-3rd-annual-healthconx-conference-epix-20201125monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-participate-in-upcoming-investor-conferences-epix-20201110monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-announces-delisting-from-the-tsx-v-epix-20201026monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-presents-therapeutic-potential-of-epi-7386-at-32nd-eortc-nci-aacr-symposium-epix-20201024monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-multiple-abstracts-accepted-for-presentation-at-upcoming-medical-and-epix-20201019monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-participate-in-oppenheimer-fall-healthcare-life-science-medtech-summit-epix-20200921monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-the-presentation-of-additional-preclinical-data-for-epi-7386-at-the--epix-20200917monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-fast-track-designation-granted-by-the-fda-to-epi-7386-for-the-treatm-epix-20200914monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-participate-in-multiple-upcoming-investor-conferences-epix-20200910monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-third-quart-epix-20200806monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-completes-public-offering-for-aggregate-gross-proceeds-of-us-48-990-000-epix-20200731monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-pricing-of-public-offering-of-common-shares-epix-20200728monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-proposed-public-offering-of-common-shares-epix-20200728monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-first-patient-dosed-in-a-phase-1-clinical-trial-of-epi-7386-for-meta-epix-20200715monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-presents-therapeutic-potential-of-epi-7386-at-the-2020-american-association-fo-epix-20200622monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-jefferies-virtual-healthcare-conference-epix-20200527monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-presents-therapeutic-potential-of-epi-7386-at-2020-virtual-american-urological-epix-20200515monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-second-quar-epix-20200507monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-fda-allowance-of-the-clinical-investigation-of-epi-7386-in-prostate--epix-20200430monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-enters-into-at-the-market-equity-offering-sales-agreement-epix-20200413monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-submits-ind-for-epi-7386-for-prostate-cancer-and-provides-business-update-epix-20200331monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-reports-results-of-annual-general-and-special-meeting-of-shareholders-epix-20200227monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-first-quart-epix-20200213monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-multiple-abstracts-accepted-for-presentation-at-upcoming-medical-and-epix-20200210monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-fourth-quar-epix-20191219monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-grants-stock-options-epix-20191030monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-presents-data-on-epi-7386-at-the-aacr-nci-eortc-international-conference-on-mo-epix-20191028monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-announces-changes-to-its-board-of-directors-epix-20191018monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-board-of-directors-approves-stock-option-plan-rsu-plan-and-option-grants-epix-20191007monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-presents-new-data-on-epi-7386-at-the-european-society-of-medical-oncology-esmo-epix-20190928monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-to-present-at-ladenburg-thalmann-healthcare-conference-epix-20190919monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-h-c-wainwright-21st-annual-global-investment-conference-epix-20190905monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-completes-public-offering-and-concurrent-private-placement-for-aggregate-gross-epix-20190827monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-36-million-public-offering-of-common-stock-and-concurrent-private-pl-epix-20190823monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-third-quart-epix-20190814monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-announces-that-the-scheme-of-arrangement-with-realm-therapeutics-has-become-effective-epix-20190731monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-announces-court-sanction-of-the-scheme-of-arrangement-with-realm-therapeutics-epix-20190730monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-expands-leadership-team-by-appointing-alessandra-cesano-as-chief-medical-officer-epix-20190715monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-provides-update-on-court-hearing-epix-20190708monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-provides-an-update-to-the-acquisition-of-realm-therapeutics-epix-20190626monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-reports-results-of-annual-general-meeting-of-shareholders-epix-20190625monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-hold-annual-shareholders-epix-20190621monthly0.5https://www.biopharmawatch.com/news/EPIX/agreement-reached-for-essa-pharma-to-acquire-realm-therapeutics-epix-20190516monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-second-quar-epix-20190510monthly0.5https://www.biopharmawatch.com/news/EPIX/preclinical-data-highlighting-therapeutic-potential-of-epi-7386-presented-at-2019-american-epix-20190504monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-attend-bloom-burton-co-healthcare-investor-conference-2019-epix-20190425monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-abstract-presentation-at-the-2019-american-urological-association-an-epix-20190417monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-grants-stock-options-epix-20190412monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-upcoming-presentations-at-the-american-association-for-cancer-resear-epix-20190328monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-nomination-of-epi-7386-as-lead-clinical-candidate-in-metastatic-cast-epix-20190328monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-the-oppenheimer-29th-annual-healthcare-conference-epix-20190318monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-attend-the-31st-annual-roth-conference-epix-20190314monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-two-abstracts-selected-to-be-presented-at-the-2019-genitourinary-can-epix-20190211monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-first-quart-epix-20190207monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-fourth-quar-epix-20181213monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-appoints-otello-stampacchia-ph-d-of-omega-funds-to-board-of-directors-epix-20181022monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-20th-annual-global-investment-conference-in-new-york-city-septem-epix-20180829monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-third-quart-epix-20180814monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-second-quar-epix-20180514monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-epix-20180510monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-to-present-at-bloom-burton-co-healthcare-investor-conference-2018-epix-20180426monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-announces-completion-of-share-consolidation-epix-20180425monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-enhances-r-d-capabilities-with-two-new-key-hires-epix-20180424monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-announces-share-consolidation-epix-20180419monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-reports-results-of-annual-general-and-special-meeting-of-shareholders-epix-20180328monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-approves-stock-option-plan-rsu-plan-and-option-grants-epix-20180223monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-first-quart-epix-20180213monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-to-present-at-noble-capital-markets-epix-20180126monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-announces-management-team-change-epix-20180125monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-expects-180-day-extension-to-regain-compliance-with-the-nasdaq-bid-price-rule-epix-20180116monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-completes-us-21-million-equity-offering-epix-20180109monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-announces-filing-of-second-amended-and-restated-prospectus-supplement-and-an-update-t-epix-20180105monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-announces-filing-of-amended-and-restated-prospectus-supplement-and-an-update-to-previ-epix-20180102monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-announces-filing-of-prospectus-supplement-and-an-update-to-previously-announced-equit-epix-20171215monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-pricing-of-previously-announced-equity-offering-epix-20171213monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-overnight-marketed-equity-offering-epix-20171212monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-financial-results-for-the-fiscal-fourth-quarter-and-year-ended-septe-epix-20171211monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-new-listing-on-the-tsx-venture-exchange-concurrent-with-voluntary-de-epix-20171122monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-results-from-the-phase-1-clinical-trial-of-epi-506-for-treatment-of--epix-20170911monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-abstract-presentation-on-epi-506-at-the-european-society-for-medical-epix-20170907monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-rodman-renshaw-19th-annual-global-investment-conference-epix-20170901monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-business-update-and-announces-financial-results-for-the-fiscal-third--epix-20170814monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-further-update-on-proposed-equity-offering-epix-20170724monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-update-to-proposed-equity-offering-epix-20170718monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-pricing-of-proposed-equity-offering-epix-20170713monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-overnight-marketed-equity-offering-epix-20170712monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-presents-data-from-phase-1-trial-of-epi-506-at-2017-asco-annual-meeting-epix-20170605monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-data-from-phase-1-trial-of-epi-506-to-be-presented-during-2017-asco--epix-20170517monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-business-update-and-announces-financial-results-for-the-second-quarte-epix-20170515monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-to-present-at-bloom-burton-co-healthcare-investor-conference-2017-epix-20170412monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-clinical-study-update-and-announces-presentations-at-the-american-ass-epix-20170403monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-reports-results-of-annual-general-and-special-meeting-of-shareholders-epix-20170308monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-business-update-and-announces-financial-results-for-the-first-quarter-epix-20170213monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-2017-bio-ceo-investor-conference-epix-20170210monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-receives-us-4-0-million-grant-payment-from-cancer-prevention-research-institute-of-te-epix-20170130monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-provides-business-update-and-announces-fourth-quarter-and-year-ended-september-epix-20161214monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-secures-us-10-million-term-loan-from-silicon-valley-bank-epix-20161121monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-to-present-at-rodman-renshaw-18th-annual-global-investment-conference-epix-20160912monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-reports-financial-results-for-the-third-quarter-june-30-2016-epix-20160812monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-names-peter-virsik-as-executive-vice-president-chief-operating-officer-epix-20160801monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-reports-financial-results-for-the-second-quarter-ended-march-31-2016-epix-20160513monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-closing-of-a-secondary-offering-epix-20160321monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-closing-of-us-5-million-private-placement-epix-20160321monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-reports-results-of-annual-general-and-special-meeting-of-shareholders-epix-20160310monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-reports-financial-results-for-the-first-quarter-ended-december-31-2015-epix-20160212monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-closing-of-us-15-million-private-placement-epix-20160114monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-senior-leadership-changes-epix-20160107monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-announces-proposed-us-15-million-private-placement-epix-20160106monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-reports-financial-results-for-the-fourth-quarter-and-year-ended-september--epix-20151214monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-announces-enrollment-of-first-patient-in-phase-1-2-trial-epix-20151124monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-receives-health-canada-approval-to-commence-clinical-development-for-epi-5-epix-20151105monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-receives-fda-approval-to-commence-clinical-development-epix-20150923monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-reports-third-quarter-2015-financial-results-epix-20150817monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-to-commence-trading-on-the-toronto-stock-exchange-epix-20150728monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-to-commence-trading-on-the-nasdaq-capital-market-epix-20150702monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-announces-appointment-of-new-director-epix-20150624monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-reports-second-quarter-2015-financial-results-epix-20150528monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-receives-fda-response-on-ind-application-epix-20150504monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-announces-filing-of-investigational-new-drug-application-for-epi-506-epix-20150331monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-announces-appointment-of-new-director-epix-20150305monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-reports-first-quarter-2015-financial-results-epix-20150302monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-and-bloom-burton-announce-additional-release-of-shares-from-voluntary-lock-up--epix-20150227monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-announces-confidential-submission-of-draft-registration-statement-on-form--epix-20150225monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-lists-on-the-tsx-venture-exchange-epix-20150127monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-reports-year-end-financial-and-operating-results-epix-20150126monthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-inc-becomes-reporting-issuer-and-receives-conditional-approval-to-commence-tra-epix-20141223monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-sgx945-receives-promising-innovative-medicine-designation-from-the-uk--sngx-20260310monthly0.5https://www.biopharmawatch.com/news/SNGX/positive-clinical-results-from-phase-2-trial-of-sgx945-for-the-treatment-of-behc-et-sngx-20251218monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-achieves-important-safety-milestone-in-its-confirmatory-phase-3-clinical-trial-o-sngx-20251007monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-second-quarter-2025-financial-results-sngx-20250814monthly0.5https://www.biopharmawatch.com/news/SNGX/biological-efficacy-demonstrated-in-a-phase-2-clinical-trial-of-sgx945-for-the-treatment-o-sngx-20250731monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-corporate-update-letter-key-highlights-and-upcoming-milestones-sngx-20250708monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-synthetic-hypericin-successfully-manufactured-at-sterling-pharma-solut-sngx-20250701monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-first-quarter-2025-financial-results-sngx-20250509monthly0.5https://www.biopharmawatch.com/news/SNGX/positive-outcome-in-75-of-ctcl-patients-treated-with-hybryte-for-18-weeks-sngx-20250414monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-publication-demonstrating-civax-booster-induces-rapid-broad-protection-sngx-20250325monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-year-end-2024-financial-results-sngx-20250321monthly0.5https://www.biopharmawatch.com/news/SNGX/hybryte-treatment-studies-presented-at-two-medical-conferences-in-march-sngx-20250306monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-bio-ceo-investor-conference-sngx-20250204monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-upcoming-investor-conferences-sngx-20250116monthly0.5https://www.biopharmawatch.com/news/SNGX/hybryte-expanded-treatment-continues-to-demonstrate-positive-outcomes-in-early-stage-cutan-sngx-20250114monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-initiates-confirmatory-phase-3-clinical-trial-of-hybryte-for-the-treatment-of-cu-sngx-20241216monthly0.5https://www.biopharmawatch.com/news/SNGX/hybryte-clinical-results-demonstrate-continued-improvement-post-treatment-sngx-20241202monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-formation-of-european-medical-advisory-board-for-cutaneous-t-cell-lymp-sngx-20241119monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-initiates-a-phase-2-clinical-trial-of-sgx945-dusquetide-for-the-treatment-of-beh-sngx-20241114monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-third-quarter-2024-financial-results-sngx-20241108monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-hong-kong-patent-for-improved-production-of-synthetic-hypericin-sngx-20241022monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-invited-to-present-at-upcoming-investor-conferences-sngx-20241016monthly0.5https://www.biopharmawatch.com/news/SNGX/hybryte-expanded-treatment-results-to-be-presented-at-the-european-organisation-for-resear-sngx-20241007monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-partnership-with-sterling-pharma-solutions-sngx-20241003monthly0.5https://www.biopharmawatch.com/news/SNGX/join-soligenix-sngx-20240916monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-european-patent-for-improved-production-of-synthetic-hypericin-sngx-20240903monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-second-quarter-2024-financial-results-sngx-20240809monthly0.5https://www.biopharmawatch.com/news/SNGX/expanded-hybryte-treatment-demonstrating-positive-outcomes-in-early-stage-cutaneous-t-cell-sngx-20240709monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-positive-clinical-results-from-a-comparative-study-evaluating-hybryte--sngx-20240625monthly0.5https://www.biopharmawatch.com/news/SNGX/a-comparison-of-vaccine-technologies-to-be-presented-at-the-asm-microbe-conference-sngx-20240614monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-reverse-stock-split-sngx-20240531monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-encourages-stockholders-to-vote-their-shares-at-the-annual-meeting-sngx-20240529monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-inc-announces-adjournment-of-annual-meeting-information-for-reconvened-annual-me-sngx-20240524monthly0.5https://www.biopharmawatch.com/news/SNGX/suvax-and-marvax-thermostable-vaccine-platform-to-be-presented-at-the-vaccine-technology-i-sngx-20240521monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-encourages-stockholders-to-vote-prior-to-annual-meeting-sngx-20240520monthly0.5https://www.biopharmawatch.com/news/SNGX/positive-clinical-results-from-hybryte-compatibility-study-in-the-treatment-of-cutaneous-t-sngx-20240516monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-first-quarter-2024-financial-results-sngx-20240510monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-upcoming-conferences-sngx-20240506monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-extends-patent-protection-for-its-filovirus-vaccine-platform-to-the-united-kingd-sngx-20240425monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-pricing-of-4-75-million-public-offering-sngx-20240418monthly0.5https://www.biopharmawatch.com/news/SNGX/fda-grants-soligenix-orphan-drug-designation-for-the-prevention-and-post-exposure-prophyla-sngx-20240415monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-agreement-on-the-design-of-a-second-confirmatory-placebo-controlled-tr-sngx-20240403monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-year-end-2023-financial-results-sngx-20240315monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-formation-of-behc-et-sngx-20240208monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-microcap-conference-sngx-20240125monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-top-line-results-of-the-phase-2a-study-of-sgx302-synthetic-hypericin-i-sngx-20240104monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-publication-demonstrating-complete-protection-against-filovirus-diseas-sngx-20240102monthly0.5https://www.biopharmawatch.com/news/SNGX/hybryte-use-in-early-stage-cutaneous-t-cell-lymphoma-published-in-frontiers-in-drug-discov-sngx-20231201monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-fda-ind-clearance-for-phase-2-clinical-trial-of-dusquetide-in-the-treat-sngx-20231130monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-inc-announces-adjournment-of-annual-meeting-information-for-reconvened-annual-me-sngx-20231117monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-third-quarter-2023-financial-results-sngx-20231113monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-inc-announces-adjournment-of-annual-meeting-information-for-reconvened-annual-me-sngx-20231020monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-thinkequity-conference-sngx-20231016monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-achievement-of-two-year-stability-with-bivalent-and-trivalent-thermost-sngx-20230925monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-inc-announces-adjournment-of-annual-meeting-information-for-reconvened-annual-me-sngx-20230922monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-second-quarter-2023-financial-results-sngx-20230821monthly0.5https://www.biopharmawatch.com/news/SNGX/hybryte-expanded-treatment-trial-in-cutaneous-t-cell-lymphoma-opens-enrollment-sngx-20230810monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-expansion-of-sgx302-synthetic-hypericin-phase-2a-study-in-mild-to-mode-sngx-20230711monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-european-patent-grant-for-use-of-dusquetide-in-oral-mucositis-sngx-20230516monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-first-quarter-2023-financial-results-sngx-20230515monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-scheduling-of-type-a-meeting-with-the-u-s-fda-to-review-proposed-study-sngx-20230511monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-closing-of-8-5-million-public-offering-sngx-20230509monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-pricing-of-8-5-million-public-offering-sngx-20230505monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-positive-clinical-results-from-compatibility-study-of-hybryte-in-the-t-sngx-20230504monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-appointment-of-timothy-r-cote-m-d-to-its-board-of-directors-sngx-20230503monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-enters-into-exclusive-option-agreement-with-silk-road-therapeutics-for-rights-to-sngx-20230501monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-submits-type-a-meeting-request-to-u-s-fda-to-review-proposed-study-design-for-a--sngx-20230424monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-provides-regulatory-update-on-hybryte-sngx-20230414monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-usan-approval-for-hypericin-sodium-as-nonproprietary-name-for-novel-act-sngx-20230405monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-scheduling-of-type-a-meeting-with-the-u-s-fda-for-hybryte-new-drug-app-sngx-20230403monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-year-end-2022-financial-results-sngx-20230331monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-submits-type-a-meeting-request-to-u-s-fda-for-hybryte-new-drug-application-in-th-sngx-20230309monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-refusal-to-file-letter-from-u-s-fda-for-hybryte-new-drug-application-in-sngx-20230214monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-reverse-stock-split-sngx-20230209monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-invited-to-present-at-the-virtual-investor-summit-event-sngx-20230119monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-distribution-of-series-d-preferred-stock-to-holders-of-its-common-stoc-sngx-20221223monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-publication-demonstrating-positive-correlates-of-protection-with-rivax-sngx-20221220monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-initiates-phase-2-clinical-trial-of-sgx302-synthetic-hypericin-for-the-treatment-sngx-20221219monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-submission-of-new-drug-application-to-the-fda-for-hybryte-in-the-treat-sngx-20221215monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-receive-1-2-m-in-non-dilutive-funding-through-new-jersey-technology-business--sngx-20221115monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-third-quarter-2022-financial-results-sngx-20221110monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-invited-to-submit-barda-contract-proposal-for-development-of-thermostabilized-su-sngx-20221027monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-formation-of-psoriasis-medical-advisory-board-sngx-20221025monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-adjournment-of-annual-meeting-and-information-for-reconvened-meeting-sngx-20221020monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-partial-adjournment-of-annual-meeting-and-information-for-reconvened-a-sngx-20220923monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference-sngx-20220908monthly0.5https://www.biopharmawatch.com/news/SNGX/u-s-food-and-drug-administration-awards-2-6-million-orphan-products-development-grant-for--sngx-20220906monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-second-quarter-2022-financial-results-sngx-20220812monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-agreement-from-fda-on-initial-pediatric-study-plan-for-hybryte-for-the--sngx-20220727monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-strategic-partnership-with-serb-pharmaceuticals-to-supply-its-novel-ri-sngx-20220725monthly0.5https://www.biopharmawatch.com/news/SNGX/hybryte-phase-3-flash-study-for-the-treatment-of-cutaneous-t-cell-lymphoma-published-in-ja-sngx-20220720monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-fda-ind-clearance-for-phase-2-clinical-trial-of-synthetic-hypericin-in--sngx-20220628monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-successful-protection-using-a-bivalent-thermostabilized-filovirus-vacc-sngx-20220623monthly0.5https://www.biopharmawatch.com/news/SNGX/key-binding-characteristics-of-dusquetide-to-important-intracellular-protein-identified-sngx-20220601monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-us-patent-allowance-for-its-thermostabilized-vaccine-platform-sngx-20220523monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-h-c-wainwright-global-investment-conference-sngx-20220518monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-first-quarter-2022-financial-results-sngx-20220513monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-1-4m-in-non-dilutive-government-funding-sngx-20220419monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-year-end-2021-financial-results-sngx-20220329monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-covid-19-vaccine-civax-boosts-neutralizing-activity-against-sars-cov-2-including-sngx-20220317monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-q1-virtual-investor-summit-sngx-20220302monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-2022-bio-ceo-investor-conference-sngx-20220208monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-corporate-update-letter-key-highlights-and-upcoming-catalysts-sngx-20220110monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-upcoming-investor-conferences-sngx-20220106monthly0.5https://www.biopharmawatch.com/news/SNGX/dusquetide-demonstrates-positive-anti-tumor-efficacy-in-multiple-nonclinical-animal-studie-sngx-20220104monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-successful-protection-using-a-bivalent-thermostabilized-filovirus-vacc-sngx-20211202monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-third-quarter-2021-financial-results-sngx-20211112monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-granted-pediatric-investigational-plan-waiver-for-hybryte-in-ctcl-in-the-united--sngx-20211108monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-publication-demonstrating-enduring-protection-of-its-thermostable-riva-sngx-20211104monthly0.5https://www.biopharmawatch.com/news/SNGX/thermostable-vaccine-technology-platform-to-be-presented-at-the-6th-international-conferen-sngx-20211101monthly0.5https://www.biopharmawatch.com/news/SNGX/hybryte-flash-study-selected-as-a-sngx-20211012monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-accelerated-publication-demonstrating-efficacy-and-broad-neutralizing--sngx-20210928monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-invited-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-sngx-20210927monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-advance-synthetic-hypericin-development-in-psoriasis-sngx-20210916monthly0.5https://www.biopharmawatch.com/news/SNGX/fda-grants-soligenix-orphan-drug-designation-for-the-treatment-of-t-cell-lymphoma-sngx-20210909monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-publication-demonstrating-successful-formulation-and-heat-stabilizatio-sngx-20210823monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-positive-preclinical-data-with-multiple-heat-stable-filovirus-vaccine--sngx-20210818monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-second-quarter-2021-financial-results-sngx-20210813monthly0.5https://www.biopharmawatch.com/news/SNGX/hybryte-positive-pivotal-phase-3-flash-study-selected-for-presentation-at-the-united-state-sngx-20210622monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-pediatric-investigational-plan-waiver-for-hybryte-in-ctcl-from-the-euro-sngx-20210610monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-865-000-in-non-dilutive-funding-through-new-jersey-technology-business--sngx-20210609monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-japanese-patent-for-improved-production-of-synthetic-hypericin-composit-sngx-20210520monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-first-quarter-2021-financial-results-sngx-20210517monthly0.5https://www.biopharmawatch.com/news/SNGX/hybryte-awarded-innovation-passport-in-the-united-kingdom-sngx-20210510monthly0.5https://www.biopharmawatch.com/news/SNGX/broad-efficacy-and-improved-safety-profile-of-hybryte-presented-at-society-for-investigati-sngx-20210504monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-presents-at-the-national-foundation-for-infectious-diseases-annual-conference-on-sngx-20210428monthly0.5https://www.biopharmawatch.com/news/SNGX/hybryte-expanded-efficacy-and-safety-data-presented-at-the-american-academy-of-dermatology-sngx-20210426monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-presentations-at-prominent-scientific-conferences-sngx-20210413monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-conditional-fda-acceptance-of-proposed-brand-name-hybryte-for-sgx301-in-sngx-20210407monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-year-end-2020-financial-results-sngx-20210330monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-receive-865-000-in-non-dilutive-funding-through-new-jersey-technology-busines-sngx-20210309monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-positive-progress-in-the-pre-clinical-development-of-its-covid-19-vacc-sngx-20210304monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-provides-important-highlights-and-upcoming-catalysts-in-corporate-update-letter-sngx-20210224monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-2021-bio-ceo-investor-digital-conference-sngx-20210211monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-investor-webcast-event-u-s-commercialization-of-sgx301-in-the-treatmen-sngx-20210119monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-strategic-partnership-with-daavlin-for-supply-and-distribution-of-the--sngx-20210107monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-1-5-million-nih-small-business-innovation-research-award-advancing-cov-sngx-20201228monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-topline-results-from-its-phase-3-clinical-trial-of-sgx942-for-the-trea-sngx-20201222monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-20-million-strategic-convertible-debt-financing-agreement-with-pontifa-sngx-20201216monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-demonstrates-extended-protection-with-its-rivax-ricin-toxin-vaccine-sngx-20201208monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-third-quarter-2020-financial-results-sngx-20201112monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-invited-to-present-at-upcoming-virtual-investor-conferences-sngx-20201110monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-phase-3-flash-study-continues-to-demonstrate-positive-benefits-in-pati-sngx-20201022monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-bio-investor-forum-sngx-20201008monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-publication-demonstrating-thermostabilization-of-filovirus-vaccine-ant-sngx-20200915monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-investor-webcast-event-and-presentation-today-advantages-of-the-civax--sngx-20200910monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-invited-to-present-at-upcoming-virtual-investor-conferences-sngx-20200909monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-investor-webcast-event-advantages-of-the-civax-program-for-development-sngx-20200903monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-ld-micro-conference-sngx-20200827monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-second-quarter-2020-financial-results-sngx-20200814monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-publication-of-positive-pre-clinical-results-for-a-novel-covid-19-vacc-sngx-20200728monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-issues-corporate-update-highlights-important-catalysts-for-second-half-of-2020-sngx-20200720monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-completes-enrollment-in-its-pivotal-phase-3-clinical-trial-of-sgx942-for-the-tre-sngx-20200624monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-join-russell-microcap-index-sngx-20200622monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-medinvest-infectious-disease-and-immunology-investor-conferenc-sngx-20200609monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-first-quarter-2020-financial-results-sngx-20200515monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-publication-of-correlates-of-immune-protection-for-the-rivax-ricin-tox-sngx-20200511monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-840-000-in-non-dilutive-funding-through-new-jersey-technology-business--sngx-20200507monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-positive-phase-3-flash-study-demonstrates-increased-efficacy-with-cont-sngx-20200430monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-exclusive-licensing-agreement-for-novel-vaccine-adjuvant-from-btg-spec-sngx-20200416monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-european-patent-for-therapeutic-use-of-synthetic-hypericin-to-treat-cut-sngx-20200406monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-year-end-2019-financial-results-sngx-20200330monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-and-university-of-hawai-i-at-ma-noa-initiate-work-on-novel-coronavirus-vaccine-f-sngx-20200323monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-positive-top-line-results-for-its-pivotal-phase-3-flash-trial-evaluati-sngx-20200319monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-successful-demonstration-of-heat-stabilization-for-filovirus-vaccine-p-sngx-20200227monthly0.5https://www.biopharmawatch.com/news/SNGX/fda-grants-soligenix-fast-track-designation-for-rivax-in-the-prevention-of-ricin-poisoning-sngx-20200213monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-sgx301-patient-case-study-presentation-at-the-4th-world-congress-of-cu-sngx-20200211monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-japanese-patent-allowance-for-use-of-dusquetide-in-oral-mucositis-sngx-20200203monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-22nd-annual-bio-ceo-investor-conference-sngx-20200130monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-advancing-to-important-inflection-points-with-two-pivotal-phase-3-clinical-trial-sngx-20200114monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-receive-850-000-in-non-dilutive-funding-through-new-jersey-technology-busines-sngx-20191218monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-initiates-clinical-trial-of-its-heat-stable-ricin-toxin-vaccine-sngx-20191212monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-completes-enrollment-in-its-pivotal-phase-3-clinical-trial-of-sgx301-in-the-trea-sngx-20191203monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-pcg-spotlight-series-conference-sngx-20191118monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-third-quarter-2019-financial-results-sngx-20191112monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-25th-annual-bio-europe-international-partnering-conference-sngx-20191106monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-us-patent-for-improved-production-of-synthetic-hypericin-composition-sngx-20191024monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-20th-annual-gcff-investor-conference-in-vancouver-british-colu-sngx-20191003monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-appoints-daniel-p-ring-as-vice-president-of-business-development-and-strategic-p-sngx-20190916monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-appoints-jonathan-guarino-as-chief-financial-officer-sngx-20190911monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-rhk-capital-2019-disruptive-growth-conference-sngx-20190829monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-positive-recommendation-by-independent-data-monitoring-committee-on-it-sngx-20190828monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-150-000-nih-small-business-innovation-research-award-supporting-evalua-sngx-20190815monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-second-quarter-2019-financial-results-sngx-20190813monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-conference-presentations-demonstrating-formulations-of-single-and-mult-sngx-20190731monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-european-patents-for-oral-bdp-in-the-treatment-of-acute-radiation-injur-sngx-20190729monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-appointment-of-diane-l-parks-to-its-board-of-directors-sngx-20190708monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-rivax-program-at-the-13th-annual-counteract-network-research-symposiu-sngx-20190613monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-600-000-subaward-supporting-evaluation-of-innate-defense-regulator-pla-sngx-20190528monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-first-quarter-2019-financial-results-sngx-20190514monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-advancing-to-important-inflection-points-with-two-pivotal-phase-3-clinical-trial-sngx-20190423monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-achieves-significant-enrollment-milestone-for-its-pivotal-phase-3-clinical-trial-sngx-20190418monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-611-000-in-non-dilutive-funding-through-new-jersey-technology-business--sngx-20190415monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-and-the-european-medicines-agency-pediatric-committee-reach-agreement-on-the-ped-sngx-20190409monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-us-patent-for-dusquetide-related-analogs-sngx-20190404monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-year-end-2018-financial-results-sngx-20190326monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-national-institutes-of-health-commercialization-accelerator-progra-sngx-20190318monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-boston-oncology-investor-conference-2019-sngx-20190311monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-us-patent-expanding-protection-for-its-ricin-toxin-vaccine-rivax-sngx-20190211monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-publication-demonstrating-thermostabilization-of-an-ebola-subunit-vacc-sngx-20190207monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-european-patent-for-dusquetide-and-related-innate-defense-regulator-ana-sngx-20190123monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-receive-611-000-in-non-dilutive-funding-through-new-jersey-technology-busines-sngx-20181211monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-publication-of-scientific-review-discussing-clinical-applications-of-i-sngx-20181205monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-selected-to-present-rivax-data-at-the-fourth-international-conference-on-vaccine-sngx-20181112monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-third-quarter-2018-financial-results-sngx-20181109monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-positive-recommendation-by-independent-data-monitoring-committee-on-it-sngx-20181015monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-poster-presentations-of-its-ricin-vaccine-and-dusquetide-oral-mucositi-sngx-20181004monthly0.5https://www.biopharmawatch.com/news/SNGX/nih-selects-soligenix-sngx-20180913monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-biocentury-sngx-20180905monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-publication-of-positive-long-term-data-supporting-thermostability-and--sngx-20180904monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-2018-escmid-asm-conference-on-drug-development-to-meet-the-cha-sngx-20180829monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-us-patent-for-improved-production-of-synthetic-hypericin-sngx-20180822monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-second-quarter-2018-financial-results-sngx-20180808monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-a-rivax-program-presentation-at-the-31st-annual-congress-on-vaccines-c-sngx-20180726monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-appointment-of-mark-pearson-to-its-board-of-directors-sngx-20180724monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-driving-towards-key-inflection-points-with-two-pivotal-phase-3-clinical-trials-sngx-20180719monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-european-and-canadian-patents-for-its-ricin-toxin-vaccine-rivax-formula-sngx-20180709monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-closing-of-8-000-000-at-the-market-public-offering-sngx-20180702monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-inc-prices-8-000-000-public-offering-at-the-market-sngx-20180628monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-poster-at-the-2018-american-society-of-microbiology-microbe-conference-sngx-20180604monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-first-quarter-2018-financial-results-sngx-20180511monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-nyc-oncology-investor-conference-2018-sngx-20180507monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-orphan-drug-designation-from-the-european-commission-for-rivax-for-prev-sngx-20180322monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-year-end-2017-financial-results-sngx-20180315monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-12th-annual-international-partnering-conference-bio-europe-spr-sngx-20180313monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-driving-towards-key-inflection-points-with-two-pivotal-phase-3-clinical-trials-sngx-20180125monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-us-patent-issuance-for-use-of-dusquetide-in-oral-mucositis-sngx-20180102monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-identifies-biomarkers-for-ricin-toxin-vaccine-testing-under-the-fda-animal-rule-sngx-20171221monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-receive-417-000-in-non-dilutive-funding-through-new-jersey-technology-busines-sngx-20171130monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-presentation-and-poster-at-the-2017-chemical-and-biological-defense-sc-sngx-20171127monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-2017-biotech-and-money-showcase-conference-sngx-20171113monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-data-on-dusquetide-in-combating-antibiotic-resistant-infections-at-th-sngx-20171109monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-third-quarter-2017-financial-results-sngx-20171106monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-closing-of-5-115-000-concurrent-registered-direct-offering-and-private-sngx-20171103monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-pricing-of-5-115-000-concurrent-registered-direct-offering-and-private-sngx-20171031monthly0.5https://www.biopharmawatch.com/news/SNGX/broad-spectrum-innate-defense-regulator-platform-technology-to-be-presented-at-the-peptide-sngx-20171024monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-3rd-annual-dawson-james-small-cap-conference-sngx-20171017monthly0.5https://www.biopharmawatch.com/news/SNGX/dusquetide-technology-platform-to-be-presented-at-the-2nd-world-congress-and-expo-on-immun-sngx-20171005monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-700-000-subaward-supporting-development-collaboration-on-thermostabili-sngx-20170925monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-1-5-million-nidcr-sbir-grant-award-supporting-the-pivotal-phase-3-clin-sngx-20170920monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-1-5-million-nci-sbir-grant-award-supporting-the-pivotal-phase-3-clinic-sngx-20170918monthly0.5https://www.biopharmawatch.com/news/SNGX/dusquetide-as-a-potential-solution-to-antimicrobial-resistant-bacteria-to-be-presented-at--sngx-20170911monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-rodman-renshaw-19th-annual-global-investment-conference-in-new-sngx-20170907monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-8th-annual-investing-for-cures-forum-in-new-york-city-sngx-20170905monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-2-5m-in-additional-niaid-funding-to-advance-development-of-heat-stable--sngx-20170814monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-second-quarter-2017-financial-results-sngx-20170811monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-initiates-pivotal-phase-3-clinical-trial-of-sgx942-dusquetide-for-the-treatment--sngx-20170727monthly0.5https://www.biopharmawatch.com/news/SNGX/dusquetide-technology-platform-to-be-presented-at-the-2017-drug-discovery-and-therapy-worl-sngx-20170706monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-additional-niaid-funding-to-advance-development-of-heat-stable-ricin-va-sngx-20170621monthly0.5https://www.biopharmawatch.com/news/SNGX/complete-efficacy-and-long-term-follow-up-safety-results-from-sgx942-phase-2-oral-mucositi-sngx-20170619monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-publication-of-its-phase-2-long-term-follow-up-results-of-sgx942-for-t-sngx-20170518monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-first-quarter-2017-financial-results-sngx-20170511monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-japanese-patent-for-thermovax-vaccine-heat-stabilization-platform-techn-sngx-20170509monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-fda-protocol-clearance-of-pivotal-phase-3-clinical-trial-of-sgx942-for--sngx-20170503monthly0.5https://www.biopharmawatch.com/news/SNGX/efficacy-results-from-soligenix-sngx-20170419monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-world-orphan-drug-congress-sngx-20170412monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-year-end-2016-financial-results-sngx-20170327monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-data-on-dusquetide-in-combating-antibiotic-resistant-infections-at-th-sngx-20170315monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-results-from-its-ricin-toxin-vaccine-program-at-the-society-of-toxico-sngx-20170310monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-european-patent-for-formulation-of-synthetic-hypericin-to-treat-psorias-sngx-20170222monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-sgx301-receives-promising-innovative-medicine-designation-from-the-uk--sngx-20170202monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-9th-annual-biotech-showcase-conference-sngx-20170106monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-positive-scientific-advice-from-the-european-medicines-agency-for-sgx94-sngx-20170105monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-extension-of-development-agreement-with-emergent-biosolutions-sngx-20170103monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-advances-collaboration-with-idt-biologika-sngx-20161220monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-closing-of-public-offering-sngx-20161216monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-inc-prices-5-277-000-public-offering-and-completes-listing-on-nasdaq-sngx-20161213monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-sgx942-receives-promising-innovative-medicine-designation-from-the-uk--sngx-20161212monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-positive-long-term-follow-up-results-from-its-phase-2-clinical-trial-o-sngx-20161208monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-investor-webcast-event-origins-of-innate-defense-regulators-and-review-sngx-20161208monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-third-quarter-2016-financial-results-highli-sngx-20161110monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-european-medicines-agency-designation-as-small-and-medium-enterprise-sngx-20161025monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-publication-of-its-phase-2-clinical-trial-results-of-sgx942-for-the-tr-sngx-20161018monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-receive-530-000-in-non-dilutive-funding-through-new-jersey-technology-busines-sngx-20161017monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-poster-presentations-from-its-gastrointestinal-acute-radiation-syndrom-sngx-20161013monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-poster-presentation-of-its-ricin-vaccine-and-dusquetide-orphan-program-sngx-20161011monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-reverse-split-in-preparation-for-proposed-up-listing-of-its-common-sto-sngx-20161007monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-2016-aegis-growth-conference-sngx-20160915monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-and-sciclone-establish-regional-licensing-agreement-for-sgx942-a-novel-product-c-sngx-20160912monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-issuance-of-new-composition-of-matter-patent-for-dusquetide-analogs-sngx-20160906monthly0.5https://www.biopharmawatch.com/news/SNGX/fda-grants-soligenix-orphan-drug-designation-for-dusquetide-for-treatment-of-macrophage-ac-sngx-20160818monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-second-quarter-2016-financial-results-highl-sngx-20160811monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-additional-barda-and-niaid-funding-to-advance-development-of-orbeshield-sngx-20160725monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-presentation-of-positive-preliminary-results-of-a-heat-stable-ebola-va-sngx-20160718monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-appoints-karen-krumeich-as-chief-financial-officer-sngx-20160620monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-presentation-of-phase-2-oral-mucositis-clinical-trial-results-at-the-2-sngx-20160606monthly0.5https://www.biopharmawatch.com/news/SNGX/fda-grants-soligenix-fast-track-designation-for-sgx943-for-the-treatment-of-melioidosis-sngx-20160531monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-2016-marcum-microcap-conference-sngx-20160526monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-additional-niaid-funding-to-advance-development-of-heat-stable-ricin-va-sngx-20160525monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-first-quarter-2016-financial-results-sngx-20160512monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-additional-niaid-funding-to-advance-development-of-heat-stable-ricin-va-sngx-20160505monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-issuance-of-new-patents-for-dusquetide-sngx-20160414monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-publication-of-preclinical-efficacy-results-with-dusquetide-in-infecti-sngx-20160329monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-year-end-2015-financial-results-sngx-20160324monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-additional-niaid-funding-to-advance-development-of-heat-stable-ricin-va-sngx-20160317monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-source-capital-group-sngx-20160202monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-provides-2016-business-outlook-sngx-20160126monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-will-host-a-conference-call-to-update-shareholders-on-recent-positive-clinical-r-sngx-20151216monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-positive-preliminary-results-from-its-phase-2-clinical-trial-of-sgx942-sngx-20151216monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-initiation-of-its-pivotal-phase-3-clinical-trial-of-sgx301-synthetic-h-sngx-20151214monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-490-000-in-non-dilutive-financing-from-new-jersey-sngx-20151209monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-provides-clinical-program-updates-for-december-2015-sngx-20151204monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-highlights-and-third-quarter-2015-financial-results-sngx-20151112monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-3rd-annual-bionj-ceo-summit-sngx-20151005monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-completion-of-patient-enrollment-into-its-phase-2-clinical-trial-of-sg-sngx-20150831monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-additional-niaid-funding-to-advance-development-of-orbeshield-in-gi-ars-sngx-20150827monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-additional-niaid-funding-to-advance-development-of-heat-stable-ricin-va-sngx-20150819monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-collaboration-with-the-national-organization-for-rare-disorders-and-th-sngx-20150623monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-publication-of-successful-application-of-its-heat-stabilization-techno-sngx-20150602monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-collaboration-with-the-university-of-hawai-sngx-20150528monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-first-quarter-2015-highlights-and-financial-results-sngx-20150514monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-development-agreement-with-emergent-biosolutions-sngx-20150513monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-presentation-and-poster-at-the-2015-chemical-and-biological-defense-sc-sngx-20150504monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-fda-protocol-clearance-of-pivotal-phase-3-clinical-trial-of-sgx203-in--sngx-20150414monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-recent-accomplishments-and-year-end-2014-financial-results-sngx-20150324monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-publication-of-successful-preclinical-efficacy-and-immunogenicity-resu-sngx-20150311monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-27th-annual-roth-conference-sngx-20150305monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-positive-recommendation-by-data-review-committee-on-its-phase-2-clinic-sngx-20150303monthly0.5https://www.biopharmawatch.com/news/SNGX/ricin-toxin-vaccine-poster-presented-at-the-2015-asm-biodefense-and-emerging-diseases-rese-sngx-20150213monthly0.5https://www.biopharmawatch.com/news/SNGX/preclinical-melioidosis-results-presented-at-the-2015-asm-biodefense-and-emerging-diseases-sngx-20150211monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-17th-annual-bio-ceo-investor-conference-in-new-york-city-sngx-20150205monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-presentation-and-poster-at-the-2015-asm-biodefense-and-emerging-diseas-sngx-20150202monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-publication-successfully-demonstrating-enhanced-immunogenicity-of-its--sngx-20150129monthly0.5https://www.biopharmawatch.com/news/SNGX/fda-grants-soligenix-fast-track-designation-for-sgx301-for-the-first-line-treatment-of-cut-sngx-20150107monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-positive-preliminary-nonclinical-results-in-macrophage-activation-synd-sngx-20150105monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-publication-of-combination-ricin-anthrax-vaccine-data-sngx-20141229monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-closing-of-public-offering-of-units-sngx-20141224monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-pricing-of-public-offering-of-units-sngx-20141219monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-617-000-in-non-dilutive-financing-from-new-jersey-sngx-20141211monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-appoints-oreola-donini-phd-as-chief-scientific-officer-sngx-20141210monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-formation-of-cutaneous-t-cell-lymphoma-medical-advisory-board-sngx-20141117monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-reports-third-quarter-2014-financial-results-highlighted-with-the-acquisition-of-sngx-20141110monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-appoints-rasappa-arumugham-phd-as-vice-president-of-biopharmaceutical-developmen-sngx-20140923monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-awarded-niaid-contract-valued-up-to-24-7-million-for-the-development-of-heat-sta-sngx-20140919monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-fda-clearance-of-phase-3-clinical-protocol-of-sgx301-in-cutaneous-t-ce-sngx-20140917monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-issuance-of-us-patent-for-thermovax-technology-sngx-20140909monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-16th-annual-rodman-renshaw-global-investment-conference-in-new-sngx-20140908monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-expands-pipeline-with-acquisition-of-phase-3-ready-oncology-clinical-program-sngx-20140905monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-positive-survival-results-with-heat-stable-ricin-toxin-vaccine-sngx-20140902monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-reports-second-quarter-2014-financial-results-and-highlights-recent-accomplishme-sngx-20140811monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-advances-development-of-a-heat-stable-rapidly-acting-anthrax-vaccine-velothrax-sngx-20140807monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-additional-niaid-funding-to-advance-development-of-orbeshield-in-gi-ars-sngx-20140801monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-combination-vaccine-for-ricin-and-anthrax-achieves-simultaneous-protec-sngx-20140709monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-reports-first-quarter-2014-financial-results-and-highlights-recent-accomplishmen-sngx-20140512monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-200-000-nidcr-sbir-grant-award-supporting-phase-2-clinical-trial-of-sg-sngx-20140407monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-reports-year-end-2013-financial-results-and-highlights-recent-accomplishments-sngx-20140326monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-2014-world-vaccine-congress-in-washington-dc-sngx-20140311monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-300-000-niaid-sbir-grant-award-supporting-further-evaluation-of-sgx943-sngx-20140214monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-16th-annual-bio-ceo-investor-conference-in-new-york-city-sngx-20140205monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-750-000-in-non-dilutive-financing-from-new-jersey-sngx-20140116monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-positive-one-year-high-temperature-stability-results-with-thermovax-va-sngx-20140115monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-2014-biotech-showcase-in-san-francisco-sngx-20140109monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-appoints-richard-straube-md-as-chief-medical-officer-sngx-20140106monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-initiation-of-a-phase-2-clinical-trial-of-sgx942-for-the-treatment-of--sngx-20131205monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-initiation-of-a-phase-2-clinical-trial-of-orbec-for-the-treatment-of-c-sngx-20131202monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-initial-600-000-investment-and-up-to-10-6-million-common-stock-purchas-sngx-20131121monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-reports-third-quarter-2013-financial-results-and-highlights-recent-accomplishmen-sngx-20131112monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-submits-niaid-contract-proposal-for-development-of-a-thermostable-ricin-vaccine-sngx-20131031monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-host-conference-call-and-webcast-discussion-on-oral-mucositis-sngx-20131028monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-appointment-of-marco-maria-brughera-to-its-board-of-directors-sngx-20131021monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-formation-of-international-melioidosis-scientific-advisory-board-sngx-20131017monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-appoints-oreola-donini-phd-as-vice-president-of-preclinical-research-and-develop-sngx-20131003monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-awarded-niaid-contract-valued-up-to-6-4-million-for-the-development-of-orbeshiel-sngx-20130925monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-awarded-barda-contract-valued-up-to-26-3-million-for-advanced-development-of-orb-sngx-20130919monthly0.5https://www.biopharmawatch.com/news/SNGX/fda-grants-soligenix-orphan-drug-designation-for-sgx94-for-treatment-of-acute-radiation-sy-sngx-20130916monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-15th-annual-rodman-renshaw-global-investment-conference-in-new-sngx-20130905monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-reports-second-quarter-2013-financial-results-and-highlights-recent-accomplishme-sngx-20130812monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-commercial-collaboration-with-sciclone-pharmaceuticals-in-china-for-sg-sngx-20130708monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-completes-phase-1-clinical-study-with-sgx203-for-the-treatment-of-pediatric-croh-sngx-20130628monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-closes-7-1-million-public-offering-sngx-20130626monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-pricing-of-public-offering-of-common-stock-and-warrants-sngx-20130621monthly0.5https://www.biopharmawatch.com/news/SNGX/fda-grants-soligenix-fast-track-designation-for-sgx942-for-the-treatment-of-oral-mucositis-sngx-20130603monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-issuance-of-us-patent-for-its-thermovax-technology-sngx-20130522monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-initiates-phase-1-clinical-study-with-sgx203-for-the-treatment-of-pediatric-croh-sngx-20130515monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-reports-first-quarter-2013-financial-results-and-highlights-recent-accomplishmen-sngx-20130503monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-and-intrexon-pursue-melioidosis-therapy-through-worldwide-exclusive-collaboratio-sngx-20130501monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-world-vaccine-congress-expo-sngx-20130416monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-ind-clearance-from-fda-to-initiate-clinical-program-to-evaluate-sgx942--sngx-20130327monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-significant-progress-with-thermovax-towards-the-development-of-heat-st-sngx-20130319monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-reports-year-end-2012-financial-results-and-highlights-recent-accomplishments-sngx-20130226monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-submits-barda-contract-proposal-for-development-of-orbeshield-in-gi-ars-sngx-20130220monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-15th-annual-bio-ceo-investor-conference-sngx-20130208monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-formation-of-oral-mucositis-medical-advisory-board-sngx-20130204monthly0.5https://www.biopharmawatch.com/news/SNGX/fda-grants-soligenix-fast-track-designation-for-orbeshield-tm-for-the-reduction-of-mortali-sngx-20130129monthly0.5https://www.biopharmawatch.com/news/SNGX/barda-invites-soligenix-to-submit-contract-proposal-for-development-of-orbeshield-in-gi-ar-sngx-20130107monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-ind-clearance-from-fda-to-initiate-program-evaluating-orbeshieldtm-as-a-sngx-20130104monthly0.5https://www.biopharmawatch.com/news/SNGX/fda-grants-soligenix-orphan-drug-designation-for-orbeshield-for-treatment-after-exposure-t-sngx-20130102monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-521-000-in-non-dilutive-financing-from-new-jersey-sngx-20121228monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-regains-north-american-and-european-commercial-rights-to-oral-bdp-sngx-20121227monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-expands-pipeline-with-acquisition-of-novel-innate-defense-regulator-clinical-pro-sngx-20121218monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-reports-third-quarter-2012-financial-results-and-highlights-recent-accomplishmen-sngx-20121114monthly0.5https://www.biopharmawatch.com/news/SNGX/fda-grants-soligenix-fast-track-designation-for-sgx203-for-the-treatment-of-pediatric-croh-sngx-20121108monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-formation-of-acute-radiation-syndrome-scientific-advisory-board-sngx-20121003monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-presentation-of-orbeshield-data-at-annual-radiation-research-society-m-sngx-20121001monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-issuance-of-us-patent-for-topically-active-steroids-to-treat-inflammat-sngx-20120913monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-ind-clearance-from-fda-to-initiate-clinical-program-to-evaluate-sgx203--sngx-20120906monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-300-000-nci-sbir-grant-award-supporting-a-phase-2-trial-of-orbec-as-a--sngx-20120904monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-positive-phase-1b-clinical-results-with-rivax-its-vaccine-against-rici-sngx-20120830monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-reports-second-quarter-2012-financial-results-and-highlights-recent-accomplishme-sngx-20120810monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-600-000-niaid-sbir-grant-award-supporting-further-evaluation-of-orbesh-sngx-20120717monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-collaboration-with-infectious-disease-research-institute-to-develop-th-sngx-20120627monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-reports-first-quarter-2012-financial-results-and-highlights-recent-accomplishmen-sngx-20120514monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-further-progress-with-thermovax-for-long-term-vaccine-thermostability-sngx-20120425monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-reports-year-end-2011-financial-results-and-highlights-recent-accomplishments-sngx-20120327monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-positive-survival-results-of-sgx202-in-radiation-injury-sngx-20120221monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-results-from-its-phase-1-2-clinical-trial-of-sgx201-for-the-prevention-sngx-20120210monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-demonstrates-positive-proof-of-concept-with-its-proprietary-vaccine-thermostabil-sngx-20120206monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-1-for-20-reverse-split-of-its-common-stock-sngx-20120201monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-574-000-in-non-dilutive-financing-from-new-jersey-sngx-20120126monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-demonstrates-robust-stability-results-with-its-sgx204-anthrax-vaccine-sngx-20120118monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-initiates-next-generation-anthrax-vaccine-development-program-under-agreement-wi-sngx-20111215monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-publication-of-results-of-its-phase-2-clinical-trial-of-orbec-in-the-p-sngx-20111212monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-reports-third-quarter-2011-financial-results-sngx-20111114monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-formation-of-pediatric-crohn-sngx-20111011monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-results-of-recent-data-safety-monitoring-board-review-for-phase-3-orbe-sngx-20110915monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-reports-second-quarter-2011-financial-results-and-reviews-accomplishments-sngx-20110812monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-expansion-of-partnership-with-sigma-tau-pharmaceuticals-for-orbec-in-e-sngx-20110728monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-appointment-of-jerome-zeldis-md-phd-and-keith-brownlie-cpa-to-its-boar-sngx-20110627monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-appoints-joseph-warusz-as-vice-president-of-administration-and-controller-sngx-20110602monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-reports-first-quarter-2011-financial-results-and-reviews-accomplishments-sngx-20110513monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-reports-year-end-2010-financial-results-and-highlights-recent-accomplishments-sngx-20110329monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-13th-annual-bio-ceo-investor-conference-sngx-20110209monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-appoints-kevin-horgan-md-as-chief-medical-officer-sngx-20110201monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-executes-exclusive-license-with-the-university-of-colorado-for-vaccine-thermosta-sngx-20110127monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-245-810-in-non-dilutive-financing-from-new-jersey-sngx-20110125monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-fda-orphan-drug-designation-for-rivax-for-the-prevention-of-ricin-intox-sngx-20110120monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-positive-preliminary-results-of-sgx202-in-radiation-injury-sngx-20110118monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-issuance-of-united-states-patent-for-rivax-its-vaccine-against-ricin-t-sngx-20101122monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-reports-third-quarter-2010-financial-results-and-reviews-accomplishments-sngx-20101112monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-receives-award-totaling-244-479-for-orbec-program-from-qualifying-therapeutic-di-sngx-20101103monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-completion-of-enrollment-and-preliminary-safety-results-of-a-phase-1b--sngx-20101102monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-preliminary-results-of-its-phase-2-clinical-trial-of-orbec-in-the-prev-sngx-20101025monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-provides-corporate-update-sngx-20100927monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-to-present-at-the-rodman-renshaw-healthcare-conference-on-september-15-2010-at-1-sngx-20100913monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-publication-of-article-identifying-domains-within-the-ricin-toxin-a-su-sngx-20100902monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-announces-award-of-1-2-million-fda-orphan-products-development-grant-sngx-20100823monthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-reports-second-quarter-2010-financial-results-and-reviews-accomplishments-sngx-20100813monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-to-present-preclinical-data-for-eo-1022-at-the-american-association-for-elev-20250325monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-reports-fourth-quarter-and-full-year-2024-financial-results-and-highlig-elev-20250306monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-to-present-at-the-piper-sandler-36th-annual-healthcare-conference-elev-20241126monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-reports-third-quarter-2024-financial-results-and-highlights-recent-busi-elev-20241106monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-receives-fast-track-designation-from-the-fda-for-eo-3021-for-the-treatm-elev-20240923monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conferen-elev-20240903monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-reports-second-quarter-2024-financial-results-and-highlights-recent-bus-elev-20240806monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-announces-promising-initial-data-from-phase-1-clinical-trial-evaluating-elev-20240806monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-announces-planned-combination-strategy-for-eo-3021-in-patients-with-gas-elev-20240627monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-to-present-at-the-citizens-jmp-life-sciences-conference-elev-20240507monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-reports-first-quarter-2024-financial-results-and-highlights-recent-busi-elev-20240502monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-presents-preclinical-proof-of-concept-data-for-her3-adc-program-at-aacr-elev-20240408monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-reports-fourth-quarter-and-full-year-2023-financial-results-and-highlig-elev-20240306monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-to-present-preclinical-proof-of-concept-data-for-her3-adc-program-at-th-elev-20240305monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-appoints-experienced-clinical-development-leaders-julie-cherrington-ph--elev-20240304monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-to-participate-in-upcoming-investor-conferences-elev-20240228monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-expands-ongoing-phase-1-clinical-trial-of-eo-3021-globally-dosing-first-elev-20240222monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-announces-appointment-of-darcy-mootz-ph-d-to-its-board-of-directors-elev-20240122monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-announces-program-updates-and-upcoming-2024-milestones-elev-20240105monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-to-present-at-the-piper-sandler-35th-annual-healthcare-conference-elev-20231122monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-reports-third-quarter-2023-financial-results-and-highlights-recent-busi-elev-20231102monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conferen-elev-20230905monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-announces-first-patient-dosed-in-the-phase-1-clinical-trial-evaluating--elev-20230816monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-reports-second-quarter-2023-financial-results-and-highlights-recent-bus-elev-20230803monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-appoints-joseph-ferra-as-chief-executive-officer-and-promotes-tammy-fur-elev-20230713monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-announces-pricing-of-50-million-public-offering-elev-20230608monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-announces-launch-of-proposed-public-offering-elev-20230608monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-highlights-first-in-human-phase-1-sysa1801-eo-3021-clinical-data-to-be--elev-20230603monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-reports-first-quarter-2023-financial-results-and-highlights-recent-busi-elev-20230515monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-highlights-clinical-data-for-sysa1801-eo-3021-to-be-presented-by-partne-elev-20230426monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-presents-eo-3021-preclinical-proof-of-concept-data-and-highlights-a-cli-elev-20230417monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-to-present-at-the-american-association-of-cancer-research-aacr-annual-m-elev-20230314monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-reports-fourth-quarter-and-full-year-2022-financial-results-elev-20230309monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-to-participate-at-upcoming-investor-conferences-elev-20230301monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-to-present-at-the-svb-securities-global-biopharma-conference-elev-20230208monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-elev-20230109monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-announces-pipeline-prioritization-realignment-of-resources-to-advance-e-elev-20230106monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-to-participate-at-the-jmp-securities-hematology-and-oncology-summit-elev-20221130monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-reports-third-quarter-2022-financial-results-and-highlights-recent-comp-elev-20221103monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-reports-second-quarter-2022-financial-results-and-highlights-recent-com-elev-20220804monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-to-participate-at-the-wedbush-pacgrow-healthcare-conference-elev-20220803monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-secures-50-million-loan-facility-with-k2-healthventures-elev-20220728monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-expands-pipeline-through-exclusive-licensing-of-eo-3021-sysa1801-a-clin-elev-20220728monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-to-participate-at-cowen-elev-20220601monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-to-present-initial-seribantumab-proof-of-concept-data-from-phase-2-cres-elev-20220526monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-announces-fda-fast-track-designation-granted-to-seribantumab-for-the-tu-elev-20220525monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-reports-first-quarter-2022-financial-results-and-highlights-recent-comp-elev-20220505monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-announces-initial-data-from-phase-2-crestone-study-of-seribantumab-sele-elev-20220427monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-appoints-david-dornan-ph-d-as-chief-scientific-officer-elev-20220314monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-reports-fourth-quarter-and-full-year-2021-financial-results-elev-20220303monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-to-participate-at-upcoming-virtual-investor-conferences-elev-20220301monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-highlights-2021-achievements-and-outlines-expected-2022-milestones-elev-20220110monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-to-present-at-the-h-c-wainwright-bioconnect-virtual-conference-elev-20220106monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-elev-20220105monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-to-present-at-the-piper-sandler-33rd-annual-virtual-healthcare-conferen-elev-20211118monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-reports-third-quarter-2021-financial-results-elev-20211112monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-announces-the-promotion-of-valerie-malyvanh-jansen-m-d-ph-d-to-chief-me-elev-20211020monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-elev-20211014monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conferen-elev-20210907monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-reports-second-quarter-2021-financial-results-elev-20210812monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-to-present-at-the-12th-annual-wedbush-pacgrow-healthcare-conference-elev-20210804monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-announces-pricing-of-initial-public-offering-elev-20210624monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-announces-appointment-of-joseph-ferra-as-chief-financial-officer-elev-20210617monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-appoints-michael-carruthers-to-board-of-directors-and-chair-of-the-audi-elev-20210518monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-announces-the-presentation-of-new-preclinical-data-in-pancreatic-and-ch-elev-20210410monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-announces-clinical-cancer-research-publication-highlighting-the-specifi-elev-20210406monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-elev-20210106monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-announces-65m-series-b-financing-and-promotion-of-founder-shawn-m-lelan-elev-20201118monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-announces-the-presentation-of-preclinical-data-on-the-specific-inhibiti-elev-20201026monthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-emerges-from-stealth-with-32-5m-series-a-to-develop-precision-medicines-elev-20200721monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-publication-calling-for-updated-fda-approaches-to-a-bcli-20260602monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-appoints-former-fda-associate-commissioner-peter-j-pitts-to-b-bcli-20260528monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-first-quarter-2026-financial-results-and-provides-c-bcli-20260515monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-full-year-2025-financial-results-and-provides-corpo-bcli-20260331monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-secures-second-1-million-strategic-placement-total-2-million--bcli-20260226monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-1-million-strategic-financing-at-premium-to-market-bcli-20260220monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-third-quarter-2025-financial-results-and-provides-c-bcli-20251114monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-second-quarter-2025-financial-results-and-provides--bcli-20250814monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-announce-second-quarter-financial-results-and-provide-a-corporate-update-bcli-20250808monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-announce-first-quarter-results-and-provide-a-corporate-upd-bcli-20250507monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-present-biomarker-insights-supporting-nurown-bcli-20250506monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-bcli-20250429monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-submits-ind-amendment-to-fda-paving-the-way-for-phase-3b-tria-bcli-20250410monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-full-year-2024-financial-results-and-provides-corpo-bcli-20250331monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-granted-compliance-extension-from-nasdaq-bcli-20250326monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-announce-fourth-quarter-and-fiscal-year-2024-financial-results-and-provide-a-bcli-20250324monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-issues-2024-letter-to-shareholders-bcli-20241230monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-host-investor-call-and-provide-a-corporate-update-bcli-20241209monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-strengthens-exosome-patent-portfolio-receives-notice-of-allowance-for-u-s-paten-bcli-20241203monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-host-kol-webinar-on-current-developments-in-the-treatment--bcli-20241202monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-third-quarter-2024-financial-results-and-provides-c-bcli-20241114monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-and-pluri-partner-to-support-nurown-phase-3b-trial-manufactur-bcli-20241111monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-bcli-20241030monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-presented-positive-survival-data-from-nurown-expanded-access--bcli-20241028monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-provide-corporate-update-on-phase-3b-nurown-trial-at-the-2-bcli-20241007monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-presentations-on-nurown-at-2024-annual-neals-meetin-bcli-20240924monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-second-quarter-2024-financial-results-and-provides--bcli-20240814monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-announce-second-quarter-results-and-provide-a-corporate-up-bcli-20240807monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-provide-corporate-mid-year-update-on-nurown-program-bcli-20240701monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-pricing-of-4-0-million-registered-direct-offering-bcli-20240627monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-reaches-alignment-with-fda-on-cmc-aspects-of-phase-3b-nurown--bcli-20240626monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-appointment-of-haro-hartounian-ph-d-as-chief-operat-bcli-20240620monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-new-biomarker-data-suggesting-als-patients-may-ben-bcli-20240520monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-first-quarter-2024-financial-results-and-provides-c-bcli-20240514monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-management-changes-as-company-plans-registrational--bcli-20240416monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-regains-compliance-with-nasdaq-minimum-market-value-rule-bcli-20240411monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-peer-reviewed-publication-of-biomarker-data-from-nu-bcli-20240410monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-agreement-with-fda-on-a-special-protocol-assessment-bcli-20240409monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-provide-update-on-nurown-program-bcli-20240408monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-full-year-2023-financial-results-and-provides-corpo-bcli-20240401monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-unveil-phase-3b-nurown-trial-design-at-mda-clinical-and-sc-bcli-20240227monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-submits-special-protocol-assessment-spa-request-to-fda-for-ph-bcli-20240223monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-at-european-life-sciences-ceo-forum-bcli-20240213monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-granted-patents-for-allogeneic-exosome-platform-product-in-neurological-disorde-bcli-20231226monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-issues-2023-letter-to-shareholders-bcli-20231220monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-outcome-of-fda-meeting-on-nurown-in-als-bcli-20231207monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-at-6th-annual-als-research-symposia-bcli-20231117monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-third-quarter-2023-financial-results-and-provides-c-bcli-20231114monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-announce-third-quarter-2023-financial-results-and-provide-a-corporate-update-bcli-20231107monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-strategic-realignment-prioritizing-nurown-for-the-t-bcli-20231024monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-meet-with-us-fda-to-discuss-development-plan-for-nurown-as-bcli-20231018monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-provides-update-on-fda-advisory-committee-meeting-to-review-n-bcli-20230927monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-stock-trading-halted-today-bcli-20230927monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-second-quarter-2023-financial-results-and-provides--bcli-20230814monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-announce-second-quarter-2023-financial-results-and-provide-a-corporate-updat-bcli-20230807monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-pricing-of-7-5-million-registered-direct-offering-bcli-20230717monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-appoints-bob-dagher-m-d-as-executive-vice-president-and-chief-bcli-20230712monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-data-show-treatment-with-nurown-significantly-reduces-nfl-a-k-bcli-20230707monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-appoints-nir-naor-as-board-member-and-audit-committee-chair-bcli-20230620monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-participate-in-the-maxim-group-healthcare-virtual-conferen-bcli-20230616monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-fda-advisory-committee-meeting-to-review-nurown-bio-bcli-20230606monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-summarizes-key-messages-from-its-participation-as-expert-spea-bcli-20230519monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-first-quarter-2023-financial-results-and-provides-c-bcli-20230515monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-announce-first-quarter-2023-financial-results-and-provide-a-corporate-update-bcli-20230509monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-strengthens-leadership-team-with-appointment-of-kirk-taylor-m-bcli-20230424monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-full-year-2022-financial-results-and-provides-a-cor-bcli-20230330monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-fda-advisory-committee-meeting-to-review-biologics--bcli-20230327monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-announce-fourth-quarter-and-fiscal-year-2022-financial-results-and-provide-a-bcli-20230321monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-partners-with-neals-the-als-association-and-i-am-als-to-provi-bcli-20230110monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-at-biotech-showcase-2023-bcli-20230105monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-promotion-of-dr-stacy-lindborg-to-co-chief-executiv-bcli-20230104monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-type-a-meeting-with-fda-granted-for-nurown-bcli-20221227monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-submits-type-a-meeting-request-to-u-s-food-and-drug-administr-bcli-20221212monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-third-quarter-2022-financial-results-and-provides-a-bcli-20221114monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-receives-refusal-to-file-letter-from-fda-for-its-new-biologic-bcli-20221110monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-announce-third-quarter-results-and-provide-a-corporate-upd-bcli-20221107monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-presents-new-analyses-from-nurown-bcli-20221107monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-presents-nurown-phase-2-progressive-ms-biomarker-data-at-the--bcli-20221020monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-peer-reviewed-publication-of-results-from-the-nurow-bcli-20220915monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-strengthens-executive-team-with-key-appointments-in-r-d-and-legal-bcli-20220512monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-upcoming-scientific-conference-presentations-bcli-20220503monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-announce-fourth-quarter-and-fiscal-year-2021-financial-results-and-provide-a-bcli-20220314monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-at-biotech-showcase-2022-bcli-20220104monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-peer-reviewed-publication-of-nurown-bcli-20211213monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-expands-leadership-team-to-support-clinical-development-and-m-bcli-20211108monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-second-quarter-2021-financial-results-and-provides-a-corporate-update-bcli-20210805monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-first-quarter-2021-financial-results-and-provides-a-corporate-update-bcli-20210426monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-present-at-svb-leerink-10th-global-healthcare-conference-bcli-20210223monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-feedback-from-fda-type-c-meeting-on-future-nurown-manufacturing-plan-bcli-20210209monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-nurown-expanded-access-program-bcli-20201214monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-present-nurown-phase-3-clinical-trial-results-at-31st-international-symposiu-bcli-20201123monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-topline-results-from-nurown-phase-3-als-study-bcli-20201117monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-publication-of-new-preclinical-data-supporting-proposed-nurown-mechan-bcli-20200819monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-grant-of-a-new-european-patent-for-nurown-bcli-20180725monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-financial-results-for-the-second-quarter-of-2018-and-provides-a-corpo-bcli-20180723monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-announce-second-quarter-financial-results-of-2018-and-provide-a-corporate-up-bcli-20180717monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-granted-japanese-patent-for-nurown-bcli-20180705monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-second-u-s-manufacturing-site-for-nurown-production-bcli-20180702monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-strengthens-executive-management-team-with-the-appointment-of-susan-ward-ph-d-a-bcli-20180628monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-fournit-de-nouvelles-informations-concernant-la-loi-right-to-try-droit-d-bcli-20180627monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-proporciona-una-actualizacio-n-de-la-poli-tica-right-to-try-bcli-20180627monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-provides-update-on-right-to-try-policy-bcli-20180626monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-gibt-neuigkeiten-hinsichtlich-der-right-to-try-gesetzgebung-bekannt-bcli-20180626monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-host-tomorrow-a-conference-call-to-announce-its-right-to-try-policy-bcli-20180625monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-exercise-of-warrants-resulting-in-cash-proceeds-of-12-3-million-at-5--bcli-20180607monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-host-call-following-president-trump-bcli-20180601monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-provide-corporate-update-at-the-bio-international-conventi-bcli-20180530monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-issues-statement-on-right-to-try-legislation-bcli-20180525monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-first-quarter-2018-financial-results-and-provides-corporate-and-clini-bcli-20180514monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-ceo-to-present-at-world-advanced-therapy-and-regenerative-medicine-congress-in--bcli-20180509monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-announce-first-quarter-financial-results-and-provide-corporate-update-on-mon-bcli-20180508monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-participate-in-movement-disorder-panel-at-the-neurotech-in-bcli-20180501monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-at-arm-bcli-20180411monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-bcli-20180328monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-appoints-two-leading-thought-leaders-in-the-fields-of-neuroscience-and-regenera-bcli-20180321monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-at-the-bio-asia-international-conference-and-the-w-bcli-20180315monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-formation-of-scientific-advisory-board-and-appoints-neuroscientist-je-bcli-20180312monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-operational-highlights-and-financial-results-for-the-year-ended-decem-bcli-20180308monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-host-an-annual-financial-results-call-and-provide-a-corporate-update-on-thur-bcli-20180305monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-bcli-20180207monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-at-the-bio-ceo-investor-conference-bcli-20180206monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-appoints-senior-kite-executive-anthony-polverino-ph-d-to-boar-bcli-20180205monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-present-at-precision-medicine-world-conference-2018-silicon-valley-on-januar-bcli-20180116monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-granted-gmp-certification-for-a-marketing-level-manufacturing-of-nurown-bcli-20180103monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-issues-2017-letter-to-shareholders-bcli-20171229monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-at-the-10th-annual-biotech-showcase-bcli-20171220monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-bcli-20171129monthly0.5https://www.biopharmawatch.com/news/BCLI/new-peer-reviewed-publication-shows-that-brainstorm-bcli-20171109monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-strengthens-executive-team-appoints-eyal-rubin-as-chief-financial-officer-bcli-20171102monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-expands-its-patent-portfolio-to-include-a-new-us-patent-for-its-nurown-technolo-bcli-20171023monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-third-quarter-2017-financial-results-bcli-20171017monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-enrolls-first-patients-in-phase-3-trial-of-nurown-in-als-bcli-20171016monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-announce-third-quarter-financial-results-and-provide-corporate-updates-on-tu-bcli-20171003monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-at-the-2017-disruptive-growth-company-showcase-nyc-bcli-20170927monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-second-quarter-2017-financial-results-bcli-20170814monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-host-second-quarter-2017-earnings-teleconference-and-provide-important-corpo-bcli-20170810monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-supports-commitment-to-als-patient-community-with-appointment-of-a-vice-preside-bcli-20170807monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-agreement-with-university-of-california-irvine-medical-center-to-part-bcli-20170725monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-awarded-16-million-non-dilutive-grant-from-cirm-in-support-of-phase-3-clinical--bcli-20170721monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-agreements-with-mass-general-hospital-and-california-pacific-medical--bcli-20170718monthly0.5https://www.biopharmawatch.com/news/BCLI/worldwide-clinical-trials-selected-by-brainstorm-as-cro-for-phase-3-nurown-trial-in-als-bcli-20170703monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-provide-corporate-update-at-the-bio-international-convention-bcli-20170614monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-awarded-2-1-million-non-dilutive-grant-for-2017-by-the-israel-innovation-author-bcli-20170613monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-present-at-cell-gene-exchange-conference-in-washington-dc-bcli-20170522monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-initiated-technology-transfer-to-city-of-hope-for-u-s-production-of-nurown-for--bcli-20170516monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-first-quarter-2017-financial-results-and-provides-corporate-update-bcli-20170515monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-present-at-two-scientific-conferences-in-may-bcli-20170501monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-at-arm-bcli-20170420monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-publication-of-nurown-autism-research-study-bcli-20170419monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-financial-results-for-2016-and-provides-business-update-bcli-20170330monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-ceo-to-present-at-the-sachs-associates-2nd-annual-neuroscience-biopartnering-an-bcli-20170322monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-fortalece-el-equipo-directivo-con-ralph-z-kern-como-director-de-operaciones-y-d-bcli-20170306monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-versta-rkt-sein-management-team-mit-der-ernennung-von-dr-ralph-z-kern-mhsc-zum--bcli-20170306monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-renforce-son-e-quipe-de-direction-avec-la-nomination-de-ralph-z-kern-md-mhsc-en-bcli-20170306monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-strengthens-management-team-with-appointment-of-ralph-z-kern-md-mhsc-as-chief-o-bcli-20170306monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-mou-with-tel-aviv-sourasky-medical-center-to-make-nurown-available-to-bcli-20170301monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-names-dr-june-s-almenoff-and-arturo-o-araya-to-its-board-of-directors-as-compan-bcli-20170227monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-seeking-approval-to-distribute-nurown-in-canada-bcli-20170221monthly0.5https://www.biopharmawatch.com/news/BCLI/city-of-hope-to-manufacture-nurown-for-brainstorm-bcli-20170216monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-ceo-to-present-at-the-bio-ceo-investor-conference-bcli-20170206monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-validation-of-nurown-cryopreservation-process-bcli-20170130monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-ceo-to-present-at-the-phacilitate-cell-gene-therapy-world-conference-2017-in-mi-bcli-20170117monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-ceo-to-present-at-the-9th-annual-biotech-showcase-bcli-20170105monthly0.5https://www.biopharmawatch.com/news/BCLI/21st-century-cures-act-passed-by-u-s-congress-provides-an-accelerated-approval-pathway-for-bcli-20161215monthly0.5https://www.biopharmawatch.com/news/BCLI/in-depth-analyses-presented-at-international-symposium-on-als-mnd-suggest-strong-biologica-bcli-20161214monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-host-year-end-call-with-investors-to-discuss-important-corporate-development-bcli-20161206monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-reports-third-quarter-2016-financial-results-bcli-20161115monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-granted-united-states-patent-for-its-stem-cell-technology-bcli-20161031monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-ceo-to-present-at-two-investor-conferences-in-september-bcli-20160906monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-reports-second-quarter-2016-financial-results-and-provides-co-bcli-20160811monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-positive-top-line-results-from-the-u-s-phase-2-study-of-nurown-in-pat-bcli-20160718monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-announce-top-line-results-from-the-u-s-phase-2-study-of-nurown-in-patients-w-bcli-20160714monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-present-at-world-stem-cells-regenerative-medicine-congress-in-london-bcli-20160517monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-awarded-1-5-million-non-dilutive-grant-for-2016-from-israel-bcli-20160512monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-reports-first-quarter-2016-financial-results-and-provides-cor-bcli-20160510monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-present-at-the-israstem-2016-and-the-6th-international-israel-stem-cell-soci-bcli-20160329monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-financial-results-for-2015-and-provides-business-update-bcli-20160310monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-to-present-at-bio-asia-international-and-arm-investor-day-conferences-bcli-20160308monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-bcli-20160111monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-conduct-phase-2-multi-dose-nurown-trial-in-als-at-hadassah-bcli-20160111monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-reschedules-corporate-update-conference-call-to-january-11-2016-bcli-20151210monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-appointment-of-dr-revital-geffen-aricha-as-vice-pre-bcli-20151207monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-hosting-conference-call-to-update-shareholders-on-important-developments-bcli-20151202monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-and-octane-biotech-announce-success-in-cocoon-application-development-based-on--bcli-20151201monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-awarded-additional-735-000-non-dilutive-grant-for-2015-from-israel-bcli-20151130monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-reports-third-quarter-2015-financial-results-and-provides-cor-bcli-20151117monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-positive-dsmb-review-in-phase-2-trial-of-nurown-in--bcli-20151109monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-strengthens-intellectual-property-position-granted-patent-for-company-bcli-20151016monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-bcli-20151008monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-treatment-of-final-patient-in-us-multicenter-double-blinded-phase-2-a-bcli-20151007monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-at-2015-stem-cell-meeting-on-the-mesa-bcli-20151001monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-appointment-of-chaim-lebovits-as-chief-executive-officer-bcli-20150922monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-at-rodman-renshaw-17th-annual-global-investment-co-bcli-20150902monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-at-cantor-fitzgerald-bcli-20150706monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-added-to-russell-microcap-index-bcli-20150629monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-at-the-bio-international-convention-bcli-20150616monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-announces-first-quarter-2015-financial-results-and-provides-c-bcli-20150514monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-at-upcoming-conferences-bcli-20150511monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-report-first-quarter-2015-financial-results-on-thursday-ma-bcli-20150507monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-bcli-20150421monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-positive-nurown-phase-2a-clinical-data-at-american-bcli-20150414monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-financial-results-for-2014-and-provides-business-update-bcli-20150326monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-report-fourth-quarter-and-full-year-2014-financial-results-bcli-20150319monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-present-at-3rd-annual-regen-med-investor-day-on-march-25-i-bcli-20150318monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-receives-notice-of-allowance-for-its-nurown-technology-platform-from-israel-bcli-20150209monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-ceo-to-present-at-the-17th-annual-bio-ceo-investor-conference-bcli-20150204monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-positive-dsmb-recommendation-in-ongoing-phase-2-trial-with-nurown-in--bcli-20150203monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-exceptional-preclinical-results-of-nurown-in-mouse-autism-model-bcli-20150126monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-enters-into-warrant-exercise-agreement-for-approximately-13-million-in-proceeds-bcli-20150108monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-receipt-of-approximately-3-1-million-from-warrant-exercises-bcli-20150107monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-ceo-to-present-at-two-upcoming-investor-conferences-bcli-20150106monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-final-analysis-of-phase-2a-als-study-showing-nearly-all-subjects-expe-bcli-20150105monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-host-conference-call-to-discuss-final-results-of-phase-2a--bcli-20141222monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-receives-1-100-000-for-its-8th-annual-non-dilutive-grant-from-israel-bcli-20141215monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-announces-financial-results-for-the-third-quarter-of-2014-and-provides-corporat-bcli-20141113monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-to-report-third-quarter-2014-financial-results-on-thursday-no-bcli-20141105monthly0.5https://www.biopharmawatch.com/news/BCLI/fda-grants-fast-track-designation-to-nurown-for-the-treatment-of-als-bcli-20141007monthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-reports-last-patient-visit-in-phase-2a-als-study-bcli-20141006monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-fiscal-first-quarter-financial-results-and-host-conference-call-aemd-20250805monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-financial-results-for-the-fiscal-fourth-quarter-ended-march-31-2-aemd-20250626monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-fiscal-fourth-quarter-financial-results-and-host-conference-cal-aemd-20250620monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-treats-second-patient-in-australian-hemopurifier-cancer-trial-aemd-20250618monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-new-pre-clinical-data-at-the-keystone-symposium-on-long-covid-a-aemd-20250609monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-publication-of-preclinical-data-showing-ability-of-the-hemopurif-aemd-20250514monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-publishes-preclinical-data-on-the-hemopurifier-in-transplant-immunology-jo-aemd-20250310monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-the-emerging-growth-conference-on-february-19-2025-aemd-20250213monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-financial-results-for-the-fiscal-third-quarter-ended-december-31-aemd-20250212monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-fiscal-third-quarter-financial-results-and-host-conference-call-aemd-20250205monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-treats-first-patient-in-australian-hemopurifier-cancer-trial-aemd-20250129monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-provides-update-on-the-ability-of-its-hemopurifier-to-capture-h5n1-bird-fl-aemd-20241220monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-financial-results-for-the-fiscal-second-quarter-ended-september--aemd-20241113monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-reaches-key-milestone-with-enrollment-of-the-first-patient-in-fpi-its-hemo-aemd-20241111monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-fiscal-second-quarter-financial-results-and-host-conference-cal-aemd-20241106monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-participate-in-the-2024-maxim-healthcare-virtual-summit-aemd-20241008monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-receives-ethics-committee-approval-for-hemopurifier-cancer-trial-in-india-aemd-20240919monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-virtual-investor-conferences-in-september-aemd-20240917monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-activation-of-royal-adelaide-hospital-to-begin-patient-screening-aemd-20240916monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-publication-of-preclinical-data-showing-ability-of-the-hemopurif-aemd-20240827monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-financial-results-for-the-fiscal-first-quarter-ended-june-30-202-aemd-20240814monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-receives-second-ethics-committee-approval-for-hemopurifier-cancer-trial-aemd-20240812monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-fiscal-first-quarter-financial-results-and-host-conference-call-aemd-20240806monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-financial-results-for-the-fiscal-year-ended-march-31-2024-and-pr-aemd-20240627monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-fiscal-year-end-financial-results-and-host-conference-call-on-j-aemd-20240621monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-receives-ethics-committee-approval-for-hemopurifier-cancer-trial-aemd-20240618monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-prepares-for-potentially-transformative-phase-1-cancer-treatment-studies-aemd-20240603monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-pricing-of-4-7-million-public-offering-aemd-20240515monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-reports-positive-results-from-an-in-vitro-binding-study-of-its-hemopurifie-aemd-20240510monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-enters-into-materials-transfer-agreement-for-santersus-ag-aemd-20240221monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-fiscal-third-quarter-financial-results-and-provides-corporate-up-aemd-20240214monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-fiscal-third-quarter-financial-results-and-host-conference-call-aemd-20240207monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-fiscal-second-quarter-financial-results-and-provides-corporate-u-aemd-20231114monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-appointment-of-james-b-frakes-m-b-a-as-interim-chief-executive-o-aemd-20231113monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-second-quarter-financial-results-and-host-conference-call-on-no-aemd-20231106monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-receives-clearance-from-drug-controller-general-of-india-for-potential-phase-1-tri-aemd-20231010monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-announces-reverse-stock-split-aemd-20231004monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-aemd-20230830monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-fiscal-first-quarter-financial-results-and-provides-corporate-up-aemd-20230810monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-first-quarter-financial-results-and-host-conference-call-on-aug-aemd-20230803monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-signs-collaboration-agreement-with-34-lives-to-evaluate-the-ability-of-the-aemd-20230724monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-appoints-medical-device-and-biomedical-executive-nicolas-gikakis-to-its-bo-aemd-20230706monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-fiscal-year-end-financial-results-and-provides-corporate-update-aemd-20230628monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-fourth-quarter-and-year-end-financial-results-and-host-conferen-aemd-20230622monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-investigation-of-the-hemopurifier-for-use-in-organ-transplantati-aemd-20230621monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-participate-in-the-healthcare-virtual-conference-presented-by-maxim-gro-aemd-20230614monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-the-13th-annual-ld-micro-invitational-aemd-20230601monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-receives-ethics-board-approval-to-add-second-site-to-its-ongoing-clinical--aemd-20230522monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-third-quarter-financial-results-and-provides-corporate-update-aemd-20230213monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-third-quarter-financial-results-and-host-conference-call-on-feb-aemd-20230206monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-sequire-biotechnology-conference-on-february-2nd-2023-aemd-20230131monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-contract-with-namsa-to-advance-hemopurifier-clinical-programs-in-aemd-20230130monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-second-quarter-financial-results-and-provides-corporate-update-aemd-20221114monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-second-quarter-financial-results-and-host-conference-call-on-no-aemd-20221102monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-two-investor-conferences-in-september-aemd-20220906monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-first-quarter-financial-results-and-provides-corporate-update-aemd-20220809monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-first-quarter-financial-results-and-host-conference-call-on-aug-aemd-20220803monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-publication-of-peer-reviewed-journal-article-describing-hemopuri-aemd-20220728monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-u-s-fda-approval-of-hemopurifier-covid-19-study-protocol-amendme-aemd-20220711monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-fiscal-year-end-financial-results-and-provides-corporate-update-aemd-20220628monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-fiscal-year-end-financial-results-and-host-conference-call-on-j-aemd-20220621monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-the-h-c-wainwright-global-investment-conference-aemd-20220524monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-publishes-in-vitro-studies-demonstrating-hemopurifier-resin-binding-of-sev-aemd-20220502monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-inc-appoints-angela-rossetti-to-board-of-directors-aemd-20220328monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-third-quarter-financial-results-and-provides-corporate-update-aemd-20220214monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-third-quarter-financial-results-and-host-conference-call-on-feb-aemd-20220131monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-second-quarter-financial-results-and-provides-corporate-update-aemd-20211109monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-second-quarter-financial-results-and-host-conference-call-on-no-aemd-20211102monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-peer-reviewed-publication-of-two-case-studies-of-critically-ill--aemd-20211012monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-contracting-with-ppd-to-advance-hemopurifier-clinical-programs-aemd-20210930monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference-aemd-20210907monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-first-quarter-financial-results-and-provides-corporate-update-aemd-20210809monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-first-quarter-financial-results-and-host-conference-call-on-aug-aemd-20210729monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-fiscal-year-end-financial-results-and-provides-corporate-update-aemd-20210624monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-fourth-quarter-financial-results-and-host-conference-call-on-ju-aemd-20210621monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-12-425-million-registered-direct-offering-priced-at-the-market-u-aemd-20210610monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-publishes-case-studies-of-two-critically-ill-covid-19-patients-treated-wit-aemd-20210603monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-participate-in-two-upcoming-healthcare-investor-conferences-aemd-20210301monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-third-quarter-financial-results-and-provides-corporate-update-aemd-20210210monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-third-quarter-financial-results-and-host-conference-call-on-feb-aemd-20210204monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-expands-leadership-team-with-appointment-of-chief-business-officer-and-chi-aemd-20210106monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-the-h-c-wainwright-bioconnect-2021-conference-aemd-20210104monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-first-patient-treated-in-first-in-human-clinical-trial-of-hemopu-aemd-20201216monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-announces-appointment-of-charles-j-fisher-jr-m-d-as-chief-executive-officer-aemd-20201103monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-second-quarter-financial-results-and-provides-corporate-update-aemd-20201028monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-second-quarter-financial-results-and-host-conference-call-on-oc-aemd-20201019monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-the-h-c-wainwright-22nd-annual-global-investment-conference-aemd-20200909monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-the-ld-micro-500-virtual-conference-aemd-20200827monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-first-quarter-financial-results-and-provides-corporate-update-aemd-20200811monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-collaboration-with-university-of-pittsburgh-on-nih-grant-for-hea-aemd-20200806monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-first-quarter-financial-results-and-host-conference-call-on-aug-aemd-20200804monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-fiscal-year-financial-results-and-provides-corporate-update-aemd-20200625monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-presents-hemopurifier-data-at-the-american-association-for-cancer-research-aemd-20200622monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-announces-fda-approval-of-ide-supplement-for-covid-19-patients-aemd-20200618monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-fourth-quarter-financial-results-and-host-conference-call-on-ju-aemd-20200616monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-announces-issuance-of-european-patent-for-the-hemopurifier-in-cancer-aemd-20200324monthly0.5https://www.biopharmawatch.com/news/AEMD/securities-and-exchange-commission-sec-order-for-halt-in-trading-of-aethlon-medical-stock--aemd-20200224monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-third-quarter-financial-results-and-provides-corporate-update-aemd-20200210monthly0.5https://www.biopharmawatch.com/news/AEMD/securities-and-exchange-commission-sec-order-for-halt-in-trading-of-aethlon-medical-nasdaq-aemd-20200210monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-third-quarter-financial-results-and-host-conference-call-on-feb-aemd-20200206monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-completion-of-3-77-million-registered-direct-offering-aemd-20200122monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-3-77-million-registered-direct-offering-priced-at-the-market-und-aemd-20200117monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-closing-of-5-million-public-offering-aemd-20191217monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-pricing-of-5-million-public-offering-aemd-20191213monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-second-quarter-financial-results-and-provides-corporate-update-aemd-20191101monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-second-quarter-financial-results-and-host-conference-call-on-no-aemd-20191029monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-announces-reverse-stock-split-aemd-20191014monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-fda-approval-of-ide-for-oncology-indications-aemd-20191007monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-receives-extension-from-nasdaq-to-regain-compliance-with-continued-listing-aemd-20191003monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-announces-collaboration-to-identify-exosomes-involved-in-cancer-progression-and-tr-aemd-20190924monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-receives-national-cancer-institute-contract-award-aemd-20190916monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-first-quarter-financial-results-and-provides-corporate-update-aemd-20190814monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-first-quarter-financial-results-and-host-conference-call-on-aug-aemd-20190807monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-fiscal-year-end-financial-results-and-provides-corporate-update-aemd-20190701monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-inc-and-seastar-medical-inc-announce-strategic-joint-cross-licensing-agree-aemd-20190701monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-fiscal-year-end-financial-results-and-host-conference-call-on-j-aemd-20190619monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-collaboration-with-prostate-on-site-project-pop-host-of-the-jerr-aemd-20190513monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-releases-shareholder-update-aemd-20190417monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-inc-announces-appointment-of-lisa-m-boswell-as-director-quality-systems-an-aemd-20190307monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-third-quarter-financial-results-and-provides-corporate-update-aemd-20190211monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-quarterly-financial-results-and-host-conference-call-on-februar-aemd-20190204monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-announces-appointment-of-timothy-rodell-as-interim-chief-executive-officer-aemd-20181213monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-aemd-20181127monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-second-quarter-fiscal-year-2019-results-aemd-20181106monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-quarterly-financial-results-and-host-conference-call-on-novembe-aemd-20181101monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-the-nyc-oncology-conference-aemd-20181029monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-the-2018-bio-investor-forum-aemd-20181016monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-receives-national-cancer-institute-award-aemd-20180918monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-first-quarter-fiscal-year-2019-results-aemd-20180808monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-financial-results-for-the-first-quarter-fiscal-year-2019-and-ho-aemd-20180802monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-issuance-of-hemopurifier-patent-to-treat-life-threatening-viruse-aemd-20180723monthly0.5https://www.biopharmawatch.com/news/AEMD/guy-cipriani-joins-aethlon-medical-aemd-20180625monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-fiscal-2018-results-aemd-20180608monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-2018-fiscal-year-end-financial-results-and-host-conference-call-aemd-20180531monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-third-quarter-fiscal-year-2018-financial-results-and-host-confe-aemd-20180129monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-allowance-of-u-s-patent-that-broadens-protection-for-the-aethlon-aemd-20180118monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-names-dr-charles-j-fisher-chairman-of-the-board-aemd-20171129monthly0.5https://www.biopharmawatch.com/news/AEMD/dr-charles-j-fisher-jr-joins-aethlon-medical-aemd-20171109monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-fiscal-2018-second-quarter-results-aemd-20171102monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-financial-results-for-the-second-quarter-fiscal-year-2018-and-h-aemd-20171030monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-large-scale-production-collaboration-aemd-20171016monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-the-2017-bio-investor-forum-aemd-20171011monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-compliance-with-nasdaq-listing-criteria-aemd-20171010monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-pricing-of-6-million-public-offering-aemd-20171002monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-receives-national-cancer-institute-contract-award-aemd-20170914monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-receives-expedited-access-pathway-designation-from-fda-to-accelerate-u-s-a-aemd-20170912monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-the-19th-annual-rodman-renshaw-global-investment-conference--aemd-20170906monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-fiscal-2018-first-quarter-results-aemd-20170810monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-financial-results-for-the-first-quarter-fiscal-year-2018-and-ho-aemd-20170803monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-the-grant-of-a-u-s-patent-protecting-methods-of-capturing-mhc-an-aemd-20170719monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-fiscal-2017-results-aemd-20170628monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-release-2017-fiscal-year-end-financial-results-and-host-conference-call-aemd-20170626monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-clinical-study-results-at-the-bio-international-convention-aemd-20170614monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-inc-announces-upcoming-presentation-and-webcast-at-the-ld-micro-invitation-aemd-20170606monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-to-present-at-the-ld-micro-invitational-conference-on-june-6-2017-aemd-20170524monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-releases-shareholder-update-aemd-20170424monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-discloses-tech-nation-interview-on-national-public-radio-aemd-20170404monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-the-conclusion-of-hemopurifier-clinical-study-aemd-20170313monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-roth-capital-partners-29th-annual-growth-stock-conference-on-aemd-20170308monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-the-grant-of-a-european-patent-protecting-methods-of-quantifying-aemd-20170301monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-ceo-note-bill-gates-on-the-threat-of-bioterrorism-aemd-20170224monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-reports-results-of-cytomegalovirus-epstein-barr-and-herpes-simplex-virus-s-aemd-20170222monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-fiscal-2017-third-quarter-results-aemd-20170210monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-host-third-quarter-fiscal-2017-investor-call-on-february-10-2017-aemd-20170206monthly0.5https://www.biopharmawatch.com/news/AEMD/researchers-announce-plans-for-study-of-candidate-blood-test-to-detect-chronic-traumatic-e-aemd-20170125monthly0.5https://www.biopharmawatch.com/news/AEMD/ceo-note-clinical-study-update-and-a-review-of-2016-accomplishments-aemd-20170111monthly0.5https://www.biopharmawatch.com/news/AEMD/passage-of-the-21st-century-cures-act-and-its-potential-implications-on-biodefense-aemd-20161221monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-announces-initiation-of-sepsis-related-virus-study-aemd-20161215monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-fiscal-2017-second-quarter-results-aemd-20161110monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-host-second-quarter-fiscal-2017-investor-call-on-november-10-2016-aemd-20161103monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-achieves-darpa-milestones-including-middle-east-respiratory-syndrome-coron-aemd-20161013monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-corporate-update-presentation-at-next-week-aemd-20161012monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-updates-corporate-presentation-schedule-aemd-20160920monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-the-rodman-renshaw-18th-annual-global-investment-conference--aemd-20160912monthly0.5https://www.biopharmawatch.com/news/AEMD/the-dilemma-in-funding-zika-and-other-pandemic-therapies-aemd-20160909monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-upcoming-september-investor-and-industry-conferences-aemd-20160906monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-zika-virus-data-aemd-20160811monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-fiscal-2017-first-quarter-results-aemd-20160811monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-host-first-quarter-fiscal-2017-investor-call-on-august-11-2016-aemd-20160809monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-fiscal-2016-results-aemd-20160629monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-12-5-million-at-the-market-program-aemd-20160628monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-joins-russell-microcap-index-aemd-20160627monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-host-fourth-quarter-and-full-year-fiscal-2016-investor-call-on-june-29--aemd-20160627monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-set-to-join-russell-microcap-index-aemd-20160622monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-issuance-of-exosome-capture-patent-aemd-20160614monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-cancer-and-infectious-disease-initiatives-as-well-as-chronic-tr-aemd-20160606monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-2nd-annual-sachs-associates-immuno-oncology-bd-l-and-investm-aemd-20160601monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-aemd-20160504monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-aemd-ceo-note-hemopurifier-clinical-progression-usa-today-on-the-next-zika-aemd-20160502monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-discloses-hemopurifier-clinical-trial-and-manufacturing-advancements-aemd-20160331monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-inc-reports-annual-meeting-results-aemd-20160330monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-roth-capital-partners-28th-annual-growth-stock-conference-on-aemd-20160309monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-4th-annual-sachs-cancer-bio-partnering-investment-forum-on-f-aemd-20160218monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-source-capital-group-aemd-20160205monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-fiscal-2016-third-quarter-results-aemd-20160204monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-dengue-virus-study-approval-chikungunya-virus-capture-data-and-c-aemd-20160203monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-the-18th-annual-bio-ceo-investor-conference-aemd-20160201monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-host-third-quarter-fiscal-2016-investor-call-on-february-4-2016-aemd-20160129monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-aemd-20160112monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-fiscal-2016-second-quarter-results-aemd-20151116monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-participate-in-the-in3-medical-device-360-summit-aemd-20151110monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-host-second-quarter-fiscal-2016-investor-call-on-november-16-2015-aemd-20151026monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-extends-contract-with-the-defense-advanced-research-projects-agency-aemd-20150928monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-the-rodman-renshaw-17th-annual-global-investment-conference-aemd-20150902monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-ring-the-nasdaq-stock-market-closing-bell-on-july-24th-aemd-20150721monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-begins-trading-on-the-nasdaq-capital-market-aemd-20150713monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-nasdaq-capital-market-listing-approval-aemd-20150708monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-6-million-equity-investment-aemd-20150624monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-discloses-upcoming-presentations-aemd-20150611monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-resignation-of-inside-director-to-comply-with-nasdaq-corporate-g-aemd-20150609monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-the-bio-international-convention-aemd-20150605monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-expands-clinical-research-studies-to-include-chikungunya-virus-aemd-20150604monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-seethruequity-microcap-investor-conference-aemd-20150526monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-health-canada-approval-of-ebola-treatment-protocol-aemd-20150513monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-institutional-review-board-approval-of-multi-indication-cancer-s-aemd-20150512monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-withdrawal-of-s-1-registration-statement-aemd-20150504monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-discloses-presentation-of-preliminary-cte-related-study-results-aemd-20150416monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-cancer-clinical-trial-agreement-aemd-20150415monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-effectiveness-of-reverse-stock-split-aemd-20150414monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-ebola-humanitarian-use-device-submission-to-the-fda-aemd-20150409monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-reverse-stock-split-and-nasdaq-listing-submission-aemd-20150408monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-discloses-head-and-neck-cancer-collaboration-aemd-20150402monthly0.5https://www.biopharmawatch.com/news/AEMD/update-changed-time-for-aethlon-medical-presentation-at-the-27th-annual-roth-conference-aemd-20150306monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-the-27th-annual-roth-conference-aemd-20150304monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-first-patient-completes-hemopurifier-clinical-study-protocol-aemd-20150226monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-inc-cte-data-presentation-at-the-upcoming-2015-tbi-conference-aemd-20150224monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-inc-a-publication-describing-the-first-treatment-of-ebola-with-the-aethlon-aemd-20150212monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-inc-the-launch-of-a-clinical-program-that-re-thinks-the-treatment-of-viral-aemd-20150205monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-biotech-showcase-2015-aemd-20150108monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-approval-of-ebola-treatment-protocol-aemd-20150102monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-initiates-patient-recruitment-for-fda-approved-clinical-study-aemd-20141211monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-reports-rapid-and-sustained-virologic-response-rates-in-hepatitis-c-hcv-tr-aemd-20141202monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-first-hemopurifier-shipment-to-support-the-treatment-of-ebola-in-aemd-20141126monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-3-3-million-equity-investment-aemd-20141126monthly0.5https://www.biopharmawatch.com/news/AEMD/ebola-patient-who-received-aethlon-hemopurifier-therapy-has-been-discharged-from-hospital-aemd-20141125monthly0.5https://www.biopharmawatch.com/news/AEMD/time-magazine-names-the-aethlon-hemopurifier-one-of-the-25-best-inventions-of-2014-aemd-20141121monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-discloses-expanded-access-emergency-use-pathway-to-treat-ebola-in-the-unit-aemd-20141119monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-aemd-20141114monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-tomorrow-aemd-20141111monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-presentation-of-ebola-treatment-data-this-friday-november-14th-a-aemd-20141110monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-undetectable-ebola-virus-in-patient-treated-with-hemopurifier-th-aemd-20141106monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-discloses-ebola-treatment-pathways-in-the-united-states-aemd-20141029monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-first-treatment-of-an-ebola-patient-aemd-20141014monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-and-exosome-sciences-announce-clinical-collaboration-with-boston-universit-aemd-20140926monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-dengue-virus-treatment-agreement-aemd-20140924monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-receives-notice-of-darpa-contract-renewal-aemd-20140922monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-and-exosome-sciences-to-present-at-the-exosomes-singlecell-analysis-summit-aemd-20140917monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-inc-launches-digital-corporate-communication-channels-aemd-20140910monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-and-exosome-sciences-announce-the-advancement-of-a-broad-spectrum-cancer-d-aemd-20140908monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-receipt-of-irb-approval-to-initiate-hemopurifier-clinical-studie-aemd-20140902monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-aemd-ceo-note-a-novel-strategy-to-address-ebola-aemd-20140806monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-online-access-to-infectious-disease-and-cancer-therapy-presentat-aemd-20140625monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-the-wall-street-analyst-forum-aemd-20140617monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-reports-rapid-and-sustained-virologic-response-rates-in-hepatitis-c-hcv-tr-aemd-20140521monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-definitive-agreement-with-davita-clinical-research-and-site-loca-aemd-20140520monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-aemd-ceo-note-cancer-treatment-discovery-exosomes-transport-pharmaceutical-aemd-20140514monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-aemd-ceo-note-cancer-therapy-publication-references-aethlon-medical-aemd-20140422monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-and-exosome-sciences-expand-brain-research-discoveries-to-include-isolatio-aemd-20140319monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-and-exosome-sciences-announce-brain-research-discoveries-aemd-20140305monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-agreement-with-davita-clinical-research-aemd-20140226monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-biotech-showcase-investor-conference-aemd-20140107monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-seethruequity-investor-conference-aemd-20131107monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-aemd-note-grand-opening-of-exosome-sciences-subsidiary-on-november-12th-at-aemd-20131104monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-aemd-note-cancer-immunotherapy-article-introduction-to-dr-douglas-taylor-aemd-20131024monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-aemd-note-clinical-partnering-programs-manufacturing-optimization-and-ramp-aemd-20131015monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-renewal-of-darpa-dialysis-like-therapeutics-contract-aemd-20130926monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-the-appointment-of-dr-cicek-gercel-taylor-as-clinical-research-d-aemd-20130924monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-dr-douglas-taylor-as-chief-scientific-officer-of-exosome-science-aemd-20130913monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-launch-of-exosome-sciences-subsidiary-aemd-20130912monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-exosomes-and-circulating-biomarkers-2013-summit-aemd-20130905monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-european-patent-to-remove-viruses-from-blood-aemd-20130725monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-the-appointment-of-chetan-s-shah-m-d-to-its-board-of-directors-aemd-20130712monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-fda-approval-of-ide-to-treat-hepatitis-c-hcv-patients-aemd-20130625monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-aemd-note-an-update-on-the-clinical-status-of-the-aethlon-hemopurifier-in--aemd-20130507monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-discloses-cancer-and-infectious-disease-therapy-presentation-at-isev-2013-aemd-20130418monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-aemd-note-new-government-contract-resubmission-of-ide-to-treat-hepatitis-c-aemd-20130416monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-aemd-note-multiple-shots-on-goal-a-therapeutic-strategy-to-address-infecti-aemd-20130228monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-inc-investor-presentation-now-available-for-on-demand-viewing-at-retailinv-aemd-20130211monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-inc-to-webcast-live-at-retail-investorconferences-com-on-february-7th-aemd-20130206monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-aemd-note-since-september-30th-2011-thank-you-shareholders-aemd-20130205monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-discloses-ceo-interview-aemd-20130129monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-aemd-note-extracorporeal-methods-to-reduce-inflammation-in-sepsis-aemd-20130124monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-today-at-the-15th-international-conference-on-dialysis-aemd-20130123monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-the-appointment-of-laszlo-radvanyi-ph-d-to-its-scientific-adviso-aemd-20130117monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-aemd-note-an-emerging-strategy-to-treat-metastatic-breast-cancer-aemd-20130115monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-today-at-biotech-showcase-2013-aemd-20130108monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-discloses-submission-of-hepatitis-c-virus-hcv-ide-to-fda-aemd-20130103monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-expansion-of-compassionate-use-program-to-treat-hepatitis-c-viru-aemd-20121212monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-aemd-note-a-medical-device-strategy-to-address-metastatic-melanoma-aemd-20121207monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-initiation-of-compassionate-use-program-to-treat-hepatitis-c-vir-aemd-20121203monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-receives-intent-to-issue-notice-on-european-patent-to-remove-hepatitis-c-v-aemd-20121106monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-issuance-of-cancer-therapy-patent-aemd-20121025monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-the-redchip-15th-annual-small-cap-conference-on-october-11th-aemd-20121009monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-releases-exosomes-microvesicles-2012-presentation-aemd-20121003monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-releases-hepatitis-c-virus-hcv-treatment-protocol-and-inclusion-exclusion--aemd-20121002monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-the-appointment-of-dr-stephen-z-fadem-to-its-extracorporeal-scie-aemd-20120926monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-the-exosomes-and-microvesicles-2012-conference-aemd-20120925monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-discloses-md-anderson-cancer-center-presentation-aemd-20120911monthly0.5https://www.biopharmawatch.com/news/AEMD/thisweekinmedit-tv-features-the-aethlon-medical-hemopurifier-aemd-20120910monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-discusses-therapeutic-device-strategies-to-address-cancer-hepatitis-c-and--aemd-20120823monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-renewal-of-darpa-dialysis-like-therapeutics-contract-aemd-20120821monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-expanded-access-to-hemopurifier-therapy-for-individuals-infected-aemd-20120809monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-reports-undetectable-hepatitis-c-virus-hcv-seven-days-after-initiation-of--aemd-20120731monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-the-appointment-of-thomas-v-wornham-and-philip-a-ward-to-its-boa-aemd-20120727monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-aemd-note-cancer-treatment-publication-authored-by-aethlon-medical-researc-aemd-20120627monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-notice-of-allowance-of-u-s-patent-application-covering-a-medical-aemd-20120619monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-aemd-note-cancer-research-discovery-melanoma-exosomes-fuel-organ-metastasi-aemd-20120612monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-today-aemd-20120515monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-reports-undetectable-hepatitis-c-virus-hcv-in-genotype-1-genotype-3-and-ge-aemd-20120508monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-note-fiscal-year-revenue-guidance-aemd-20120503monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-note-marc-robins-joins-the-aethlon-team-aemd-20120425monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-note-an-unprecedented-data-point-the-single-treatment-capture-of-hepatitis-aemd-20120424monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-hepatitis-c-hcv-treatment-technology-at-the-32nd-annual-dialysi-aemd-20120207monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-reports-immediate-and-rapid-virologic-responses-in-hepatitis-c-hcv-patient-aemd-20120201monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-establishes-extracorporeal-therapy-scientific-advisory-board-aemd-20120123monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-establishes-sepsis-inflammation-scientific-advisory-board-aemd-20120112monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-discloses-availability-of-the-biotech-showcase-2012-presentation-aemd-20120109monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-biotech-showcase-2012-presentation-aemd-20120104monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-hiv-aids-research-discovery-aemd-20111213monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-approval-and-initiation-of-cancer-research-study-to-target-tumor-aemd-20111206monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-releases-shareholder-letter-aemd-20111116monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-in3-medical-innovation-summit-on-october-27th-aemd-20111025monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-availability-of-its-exosome-detection-assay-to-the-research-comm-aemd-20111018monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-hemopurifier-and-her2osome-cancer-therapy-presentation-at-exosom-aemd-20111005monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-receives-government-contract-award-from-darpa-aemd-20111003monthly0.5https://www.biopharmawatch.com/news/AEMD/a-medical-device-strategy-to-inhibit-her2-breast-cancer-progression-released-by-aethlon-me-aemd-20110927monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-introduces-her2osome-a-novel-therapeutic-device-strategy-to-address-breast-aemd-20110921monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-sarcoma-lung-cancer-prostate-cancer-metastatic-melanoma-and-head-aemd-20110824monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-releases-shareholder-letter-aemd-20110714monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-tomorrow-aemd-20110621monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-discuss-recent-progress-at-the-lha-life-sciences-medical-technologies-v-aemd-20110607monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-president-rodney-s-kenley-to-present-at-the-20th-international-vicenza-cou-aemd-20110602monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-the-aethlon-adapt-system-at-c21-bioventures-life-sciences-partn-aemd-20110523monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-introduces-the-aethlon-adapt-system-aemd-20110519monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-discloses-fda-meeting-request-and-proposed-expansion-of-u-s-treatment-indi-aemd-20110509monthly0.5https://www.biopharmawatch.com/news/AEMD/abc-news-reports-on-aethlon-medical-aemd-20110420monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-clarifies-news-report-aemd-20110420monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-discloses-interview-on-therapeutic-strategies-to-address-hepatitis-c-hcv-a-aemd-20110415monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-multi-target-exosome-assay-validation-aemd-20110412monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-releases-shareholder-letter-aemd-20110406monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-discloses-part-ii-of-emerging-opportunities-in-biodefense-interview-aemd-20110401monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-discloses-emerging-opportunities-in-biodefense-interview-aemd-20110325monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-releases-shareholder-letter-aemd-20110315monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-receives-fda-approval-to-export-its-hemopurifier-to-india-aemd-20110308monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-the-wall-street-analyst-forum-22nd-annual-investor-conferenc-aemd-20110215monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-4th-congress-of-the-international-society-for-hemodialysis-i-aemd-20110210monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-releases-shareholder-letter-aemd-20110204monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-host-investor-event-on-january-20-2011-aemd-20110105monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-demonstrates-ability-to-capture-colorectal-and-lymphoma-cancer-exosomes-aemd-20101220monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-washington-dc-shareholder-presentation-aemd-20101220monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-presentation-at-u-s-department-of-health-and-human-services-bard-aemd-20101214monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-releases-shareholder-letter-aemd-20101201monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-3rd-annual-ld-micro-conference-on-december-9th-aemd-20101123monthly0.5https://www.biopharmawatch.com/news/AEMD/a-platform-technology-to-address-bioterrorism-released-by-aethlon-medical-inc-aemd-20101118monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-the-singular-research-fifth-annual-aemd-20101103monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-names-rod-kenley-president-aemd-20101028monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-the-appointment-of-miriam-provost-as-its-u-s-regulatory-advisor-aemd-20101026monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-initiates-patient-enrollment-of-hepatitis-c-virus-hcv-clinical-studies-aemd-20101021monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-appointment-of-rod-kenley-to-its-board-of-directors-aemd-20101019monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-engages-fabiani-company-to-advance-u-s-government-partnerships-aemd-20100930monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-appoints-jim-frakes-as-chief-financial-officer-aemd-20100928monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-reestablishes-biodefense-programs-aemd-20100921monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-data-against-metastatic-melanoma-aemd-20100909monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-to-present-at-rodman-renshaw-annual-global-investment-conference-aemd-20100830monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-approval-of-hepatitis-c-virus-hcv-treatment-program-aemd-20100826monthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-announces-expansion-of-hepatitis-c-virus-hcv-treatment-programs-aemd-20100818monthly0.5https://www.biopharmawatch.com/news/DRRX/bausch-health-to-acquire-durect-corporation-strengthening-commitment-to-developing-innovat-drrx-20250729monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-reports-fourth-quarter-and-full-year-2024-financial-results-and-provide-drrx-20250326monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-reports-third-quarter-2024-financial-results-and-provides-business-upda-drrx-20241113monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-announce-third-quarter-2024-financial-results-and-provide-a-business-drrx-20241106monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-present-data-on-larsucosterol-at-the-liver-meeting-2024-drrx-20241017monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-phase-3-registrational-trial-design-for-larsucosterol-in-alco-drrx-20240925monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-present-at-the-h-c-wainwright-global-investment-conference-drrx-20240904monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-reports-second-quarter-2024-financial-results-and-business-update-drrx-20240813monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-announce-second-quarter-2024-financial-results-and-provide-a-busines-drrx-20240807monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-receives-fda-breakthrough-therapy-designation-for-larsucosterol-in-alco-drrx-20240521monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-reports-first-quarter-2024-financial-results-and-business-update-drrx-20240513monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-announce-first-quarter-2024-financial-results-and-provide-a-business-drrx-20240507monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-late-breaking-oral-presentation-at-the-easl-congress-2024-to--drrx-20240430monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-reports-fourth-quarter-and-full-year-2023-financial-results-and-provide-drrx-20240327monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-announce-fourth-quarter-and-full-year-2023-financial-results-and-pro-drrx-20240320monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-and-charles-river-laboratories-enter-into-co-marketing-and-collaboration-agreement--drrx-20240304monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-present-at-the-oppenheimer-34th-annual-healthcare-life-sciences-conf-drrx-20240207monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-reports-third-quarter-2023-financial-results-and-business-update-drrx-20231113monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-announce-third-quarter-2023-financial-results-and-provide-a-business-drrx-20231109monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-topline-results-from-phase-2b-ahfirm-trial-of-larsucosterol-i-drrx-20231107monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-last-patient-last-visit-in-phase-2b-ahfirm-trial-of-larsucost-drrx-20230907monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-presentations-in-upcoming-investor-conferences-drrx-20230831monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-reports-second-quarter-2023-financial-results-and-business-update-drrx-20230809monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-announce-second-quarter-2023-financial-results-and-provide-a-busines-drrx-20230803monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-15-million-registered-direct-offering-priced-at-the-market-un-drrx-20230720monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-completes-enrollment-in-phase-2b-ahfirm-trial-of-larsucosterol-in-alcohol-associate-drrx-20230607monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-reports-first-quarter-2023-financial-results-and-business-update-drrx-20230508monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-announce-first-quarter-2023-financial-results-and-provide-business-u-drrx-20230501monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-host-kol-event-on-alcohol-associated-hepatitis-drrx-20230427monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-participate-in-fireside-chat-at-the-h-c-wainwright-bioconnect-invest-drrx-20230425monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-peer-reviewed-article-accepted-for-publication-with-additional-data-from--drrx-20230410monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-appointment-of-gail-maderis-as-chair-of-the-board-drrx-20230321monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-fireside-chat-at-the-oppenheimer-33rd-annual-healthcare-conference-drrx-20230309monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-reports-fourth-quarter-and-full-year-2022-financial-results-and-ahfirm--drrx-20230307monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-announce-fourth-quarter-and-full-year-2022-financial-results-and-pro-drrx-20230228monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-10-million-registered-direct-offering-of-common-stock-and-war-drrx-20230203monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-1-for-10-reverse-stock-split-drrx-20221128monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-reports-third-quarter-2022-financial-results-and-update-of-programs-drrx-20221102monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-announce-third-quarter-2022-financial-results-and-provide-business-u-drrx-20221026monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-reaches-enrollment-milestone-in-phase-2b-ahfirm-trial-drrx-20221006monthly0.5https://www.biopharmawatch.com/news/DRRX/innocoll-and-durect-announce-u-s-launch-of-posimir-drrx-20220926monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-present-at-the-h-c-wainwright-global-investment-conference-drrx-20220906monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-reports-second-quarter-2022-financial-results-and-update-of-programs-drrx-20220804monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-announce-second-quarter-2022-financial-results-and-provide-business--drrx-20220727monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-appoints-timothy-m-papp-as-chief-financial-officer-drrx-20220705monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-present-at-the-h-c-wainwright-global-investment-conference-drrx-20220518monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-reports-first-quarter-2022-financial-results-and-update-of-programs-drrx-20220504monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-announce-first-quarter-2022-financial-results-and-provide-business-u-drrx-20220427monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-present-at-the-2022-cantor-fitzgerald-virtual-rare-orphan-disease-su-drrx-20220323monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-fireside-chat-at-the-oppenheimer-32nd-annual-healthcare-conference-drrx-20220309monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-reports-fourth-quarter-and-full-year-2021-financial-results-and-update--drrx-20220307monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-doses-first-european-patient-in-phase-2b-ahfirm-study-of-larsucosterol--drrx-20220301monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-announce-fourth-quarter-and-full-year-2021-financial-results-and-pro-drrx-20220228monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-participate-in-h-c-wainwright-bioconnect-conference-drrx-20220106monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-and-innocoll-announce-a-136-million-u-s-licensing-agreement-for-posimir-bupivacaine-drrx-20211222monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-expands-board-of-directors-with-appointment-of-biopharmaceutical-indust-drrx-20211214monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-participate-in-alcoholic-liver-disease-workshop-today-at-the-5th-ann-drrx-20211129monthly0.5https://www.biopharmawatch.com/news/DRRX/data-presentation-today-at-the-liver-meeting-2021-shows-increasing-hospital-admissions-for-drrx-20211112monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-doses-first-ex-u-s-patient-in-phase-2b-ahfirm-study-of-larsucosterol-du-drrx-20211110monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-poster-presentation-on-the-prevalence-of-hospitalized-alcohol-drrx-20211108monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-reports-third-quarter-2021-financial-results-and-update-of-programs-drrx-20211102monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-announce-third-quarter-2021-financial-results-and-provide-business-u-drrx-20211026monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-fireside-chat-at-the-h-c-wainwright-5th-annual-nash-investor-conference-drrx-20211007monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-fireside-chat-at-the-cantor-fitzgerald-global-healthcare-conference-202-drrx-20210923monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-fireside-chat-at-oppenheimer-drrx-20210915monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-fireside-chat-at-the-h-c-wainwright-annual-global-investment-conference-drrx-20210907monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-second-quarter-2021-financial-results-and-update-of-programs-drrx-20210729monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-announce-second-quarter-2021-financial-results-and-provide-business--drrx-20210722monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-present-at-the-2021-epigenetic-therapeutic-targets-virtual-summit-drrx-20210714monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-presents-additional-clinical-data-from-dur-928-phase-1b-trial-in-nash-a-drrx-20210623monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-present-additional-clinical-data-from-dur-928-studies-in-nash-phase--drrx-20210609monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-first-quarter-2021-financial-results-and-update-of-programs-drrx-20210504monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-announce-first-quarter-2021-financial-results-and-provide-business-u-drrx-20210427monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-publication-of-dur-928-drrx-20210309monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-fourth-quarter-and-full-year-2020-financial-results-and-updat-drrx-20210304monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-participate-in-three-investor-conferences-in-march-2021-drrx-20210303monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-announce-2020-financial-results-and-provide-business-update-on-march-drrx-20210225monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-pricing-of-42-5-million-public-offering-of-common-stock-drrx-20210204monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-proposed-offering-of-common-stock-drrx-20210203monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-u-s-fda-approval-of-posimir-for-post-surgical-pain-reduction--drrx-20210202monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-first-patient-dosed-in-phase-2b-ahfirm-study-of-dur-928-in-se-drrx-20210125monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-appoints-two-new-board-members-drrx-20210105monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-closing-of-lactel-absorbable-polymer-product-line-sale-to-evo-drrx-20210104monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-participate-in-investor-conferences-in-january-2021-drrx-20201221monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-dur-928-granted-fda-fast-track-designation-for-treatment-of-a-drrx-20201216monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-sell-its-lactel-absorbable-polymer-product-line-to-evonik-for-15-mil-drrx-20201207monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-additional-safety-data-and-efficacy-signals-from-phase-1b-cli-drrx-20201113monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-host-webinar-on-the-treatment-of-alcoholic-hepatitis-featuring-chief-drrx-20201110monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-third-quarter-2020-financial-results-and-update-of-programs-drrx-20201102monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-appoints-dr-norman-sussman-as-chief-medical-officer-drrx-20201102monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-announce-third-quarter-2020-financial-results-and-provide-business-u-drrx-20201027monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-participate-in-the-roth-capital-partners-healthcare-event-covid-19-t-drrx-20201026monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-present-additional-safety-and-efficacy-signals-from-phase-1b-clinica-drrx-20201005monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-participate-in-fireside-chat-at-h-c-wainwright-4th-annual-nash-inves-drrx-20200930monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-first-patient-dosed-in-phase-2-safety-and-efficacy-study-of-d-drrx-20200923monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-design-of-phase-2b-ah-study-ahfirm-drrx-20200922monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-participate-in-september-virtual-investor-conferences-drrx-20200910monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-presentation-of-phase-2a-pharmacokinetic-data-of-dur-928-in-a-drrx-20200827monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-fireside-chat-hosted-by-ellie-merle-of-cantor-fitzgerald-drrx-20200826monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-btig-biotechnology-conference-2020-drrx-20200805monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-second-quarter-2020-financial-results-and-update-of-programs-drrx-20200803monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-announce-second-quarter-2020-financial-results-and-provide-business--drrx-20200728monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-initiation-of-patient-recruitment-in-phase-2-safety-and-effic-drrx-20200701monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-joins-the-russell-3000-index-drrx-20200629monthly0.5https://www.biopharmawatch.com/news/DRRX/gilead-terminates-license-agreement-for-long-acting-injectable-hiv-investigational-product-drrx-20200626monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-jefferies-2020-virtual-health-care-conference-drrx-20200528monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-positive-topline-data-from-phase-1b-study-of-dur-928-in-nash-drrx-20200526monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-first-quarter-2020-financial-results-and-update-of-programs-drrx-20200511monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-announce-first-quarter-2020-financial-results-and-provide-business-u-drrx-20200504monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-fourth-quarter-and-full-year-2019-financial-results-and-updat-drrx-20200303monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-announce-2019-financial-results-on-march-3-drrx-20200226monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-outcome-of-fda-advisory-committee-meeting-for-posimir-drrx-20200117monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-trading-halted-today-fda-advisory-committee-to-discuss-posimir-bupivaca-drrx-20200116monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-top-line-results-from-phase-2a-clinical-trial-in-patients-wit-drrx-20200102monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-stifel-2019-health-care-conference-drrx-20191115monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-positive-results-from-the-phase-2a-clinical-trial-of-dur-928--drrx-20191112monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-host-key-opinion-leader-call-on-dur-928-phase-2a-alcoholic-hepatitis-study-resul-drrx-20191106monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-third-quarter-2019-financial-results-and-update-of-programs-drrx-20191104monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-announce-third-quarter-2019-financial-results-and-provide-business-u-drrx-20191030monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-dur-928-phase-2a-alcoholic-hepatitis-study-results-selected-for-late-brea-drrx-20191021monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-two-upcoming-nash-investor-conferences-drrx-20191017monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-completion-of-enrollment-in-its-phase-2a-clinical-trial-of-dur-928-in-pso-drrx-20191007monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-fda-advisory-committee-meeting-to-review-posimir-for-the-treatment-of-pos-drrx-20191002monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-2019-cantor-fitzgerald-global-health-care-conference-drrx-20190926monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-positive-data-from-its-phase-2a-clinical-trial-of-dur-928-in-alcoholic-he-drrx-20190917monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-earns-10-million-milestone-payment-for-further-development-of-a-long-acting-injecta-drrx-20190909monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-21st-annual-rodman-and-renshaw-global-investment-conference-spons-drrx-20190904monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-second-quarter-2019-financial-results-and-update-of-programs-drrx-20190801monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-announce-second-quarter-2019-financial-results-on-august-1-drrx-20190725monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-and-gilead-enter-into-license-agreement-for-long-acting-injectable-hiv-investigatio-drrx-20190722monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-that-the-fda-agreed-to-file-the-full-response-to-the-posimir-complete-res-drrx-20190717monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-submission-to-fda-of-a-full-response-to-the-posimir-complete-response-let-drrx-20190627monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-receives-approval-from-nasdaq-for-transfer-of-listing-to-nasdaq-capital-market-drrx-20190625monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-15-million-registered-direct-offering-drrx-20190620monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-completion-of-the-90-mg-severe-cohort-and-dose-escalation-committee-appro-drrx-20190618monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-20th-annual-b-riley-fbr-institutional-investor-conference-on-may--drrx-20190516monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-preliminary-data-from-the-ongoing-dur-928-alcoholic-hepatitis-drrx-20190507monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-first-quarter-2019-financial-results-and-update-of-programs-drrx-20190507monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-present-preliminary-data-from-the-ongoing-dur-928-alcoholic-hepatiti-drrx-20190503monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-appoints-two-new-board-members-drrx-20190425monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-h-c-wainwright-global-life-sciences-conference-and-host-an-upcomi-drrx-20190401monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-patient-enrollment-in-phase-1b-clinical-trial-of-oral-dur-928-in-patients-drrx-20190327monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-patient-dosing-in-phase-2a-proof-of-concept-clinical-trial-of-topical-dur-drrx-20190321monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-fourth-quarter-and-full-year-2018-financial-results-and-updat-drrx-20190307monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-fourth-quarter-2018-earnings-conference-call-drrx-20190304monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-plans-to-submit-to-fda-a-full-response-to-the-posimir-complete-response-l-drrx-20190227monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-participate-in-the-berenberg-nash-day-drrx-20190221monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-provides-corporate-update-drrx-20190107monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-investor-call-to-provide-corporate-update-drrx-20190103monthly0.5https://www.biopharmawatch.com/news/DRRX/commercial-launch-plans-announced-for-perseris-risperidone-extended-release-injectable-sus-drrx-20181219monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-retirement-of-dr-felix-theeuwes-as-chairman-of-the-board-and--drrx-20181217monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-amendment-to-accelerate-ongoing-phase-2a-trial-of-dur-928-in-alcoholic-he-drrx-20181119monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-third-quarter-2018-financial-results-and-provides-corporate-u-drrx-20181107monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-third-quarter-2018-earnings-conference-call-drrx-20181101monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-abstracts-on-dur-928-to-be-presented-at-upcoming-scientific-meetings-drrx-20181025monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-appoints-michael-h-arenberg-j-d-m-b-a-as-chief-financial-officer-drrx-20181001monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-drrx-20180925monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-methydur-sustained-release-capsules-receive-marketing-authorization-for-a-drrx-20180918monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-receipt-of-5-million-milestone-payment-from-indivior-drrx-20180830monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-20th-annual-rodman-renshaw-global-investment-conference-drrx-20180827monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-s-licensee-pain-therapeutics-receives-complete-response-letter-from-fda-for-remoxy--drrx-20180806monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-second-quarter-2018-financial-results-and-provides-corporate--drrx-20180801monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-fda-approval-of-indivior-drrx-20180730monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-second-quarter-2018-earnings-conference-call-drrx-20180724monthly0.5https://www.biopharmawatch.com/news/DRRX/results-of-fda-advisory-committee-meeting-for-remoxy-er-drrx-20180626monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-amendment-to-licensing-agreement-with-sandoz-related-to-posimir-saber-bup-drrx-20180509monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-first-quarter-2018-financial-results-and-provides-corporate-u-drrx-20180502monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-patient-dosing-in-phase-2a-trial-of-dur-928-in-alcoholic-hepatitis-drrx-20180425monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-first-quarter-2018-earnings-conference-call-drrx-20180424monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-host-key-opinion-leader-call-on-alcoholic-hepatitis-drrx-20180329monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-fda-advisory-committee-meeting-for-remoxy-er-drrx-20180320monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-fourth-quarter-and-full-year-2017-financial-results-and-updat-drrx-20180301monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-patient-dosing-in-phase-2a-trial-of-dur-928-in-primary-sclerosing-cholang-drrx-20180226monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-fourth-quarter-2017-earnings-conference-call-drrx-20180222monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-host-key-opinion-leader-call-on-treatment-of-primary-sclerosing-chol-drrx-20180220monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-resubmission-of-remoxy-er-new-drug-application-by-its-licensee-pain-thera-drrx-20180214monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-nda-acceptance-of-indivior-drrx-20171213monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-third-quarter-2017-financial-results-and-provides-corporate-u-drrx-20171101monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-third-quarter-2017-earnings-conference-call-drrx-20171026monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-top-line-results-from-the-persist-phase-3-trial-of-posimir-saber-bupivaca-drrx-20171019monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-and-indivior-plc-sign-a-17-5-million-patent-purchase-agreement-drrx-20171002monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-appoints-dr-myriam-theeuwes-as-senior-vice-president-clinical-development-drrx-20170920monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-participate-in-upcoming-healthcare-conferences-drrx-20170905monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-second-quarter-2017-financial-results-and-provides-corporate--drrx-20170808monthly0.5https://www.biopharmawatch.com/news/DRRX/oradur-methylphenidate-er-capsule-achieves-primary-endpoint-in-phase-3-study-in-adhd-in-ta-drrx-20170808monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-second-quarter-2017-earnings-conference-call-drrx-20170801monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-completes-enrollment-in-persist-phase-3-trial-for-posimir-drrx-20170622monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-s-collaboration-with-sandoz-clears-hsr-review-and-is-effective-durect-corporation-n-drrx-20170619monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-first-quarter-2017-financial-results-and-provides-corporate-u-drrx-20170510monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-and-sandoz-have-signed-a-293-million-development-and-commercialization-agreement-fo-drrx-20170508monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-first-quarter-2017-earnings-conference-call-drrx-20170504monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-presentation-of-data-from-a-phase-1b-study-of-dur-928-in-nonalcoholic-ste-drrx-20170424monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-clinical-data-at-the-international-liver-congress-2017-drrx-20170417monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-h-c-wainwright-nash-investor-conference-drrx-20170403monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-fourth-quarter-and-full-year-2016-financial-results-and-updat-drrx-20170314monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-fourth-quarter-2016-earnings-conference-call-drrx-20170224monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-update-on-dur-928-development-program-drrx-20170130monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-third-quarter-2016-financial-results-and-update-of-programs-drrx-20161031monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-update-on-dur-928-development-program-drrx-20161031monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-third-quarter-2016-earnings-conference-call-drrx-20161021monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-s-licensee-pain-therapeutics-receives-complete-response-letter-from-fda-for-remoxy--drrx-20160926monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-rodman-renshaw-global-investment-conference-drrx-20160906monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-second-quarter-2016-financial-results-and-update-of-programs-drrx-20160801monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-second-quarter-2016-earnings-conference-call-drrx-20160725monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-provides-remoxy-update-drrx-20160701monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-cantor-fitzgerald-healthcare-conference-drrx-20160628monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-jefferies-healthcare-conference-drrx-20160531monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-fda-advisory-committee-meeting-for-remoxy-drrx-20160519monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-new-remoxy-data-being-presented-at-american-pain-society-meeting-drrx-20160511monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-first-quarter-2016-financial-results-and-update-of-programs-drrx-20160505monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-closing-of-public-offering-of-common-stock-drrx-20160429monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-first-quarter-2016-earnings-conference-call-drrx-20160428monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-pricing-of-public-offering-of-common-stock-drrx-20160426monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-proposed-public-offering-of-common-stock-drrx-20160425monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-fda-acceptance-of-remoxy-nda-pdufa-date-of-september-25-2016-drrx-20160412monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-posimir-program-update-drrx-20160407monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-resubmission-of-remoxy-new-drug-application-to-the-u-s-food-and-drug-admi-drrx-20160329monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-fourth-quarter-2015-financial-results-and-update-of-programs-drrx-20160229monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-fourth-quarter-2015-earnings-conference-call-drrx-20160218monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-bio-ceo-investor-conference-drrx-20160128monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-initiation-of-dur-928-dosing-in-patients-drrx-20160111monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-positive-phase-1-data-for-dur-928-drrx-20160106monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-oppenheimer-healthcare-conference-drrx-20151130monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-stifel-nicolaus-healthcare-conference-drrx-20151105monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-third-quarter-2015-financial-results-and-update-of-programs-drrx-20151102monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-third-quarter-2015-earnings-conference-call-drrx-20151026monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-bio-investor-forum-drrx-20151015monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-participate-in-upcoming-healthcare-conferences-drrx-20150827monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-second-quarter-2015-earnings-conference-call-drrx-20150724monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-cantor-fitzgerald-healthcare-conference-drrx-20150629monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-plans-for-a-new-posidur-saber-bupivacaine-clinical-trial-drrx-20150623monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-positive-results-from-dur-928-multi-dose-phase-1-study-drrx-20150518monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-first-quarter-2015-financial-results-and-update-of-programs-drrx-20150430monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-first-quarter-2015-earnings-conference-call-drrx-20150422monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-initiation-of-dur-928-multi-dose-phase-1-study-drrx-20150330monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-fourth-quarter-2014-financial-results-and-update-of-programs-drrx-20150302monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-epigenomic-regulator-program-including-a-new-nafld-nash-and-acute-organ-i-drrx-20150302monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-fourth-quarter-2014-earnings-conference-call-drrx-20150223monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-bio-ceo-investor-conference-drrx-20150129monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-enters-into-license-agreement-granting-santen-the-worldwide-rights-to-a-sustained-r-drrx-20141216monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-oppenheimer-healthcare-conference-drrx-20141201monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-provides-update-on-posidur-program-drrx-20141111monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-third-quarter-2014-financial-results-and-update-of-programs-drrx-20141103monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-provides-update-on-remoxy-and-posidur-programs-drrx-20141027monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-third-quarter-2014-earnings-conference-call-drrx-20141024monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-posidur-saber-bupivacaine-data-presentation-at-the-american-society-of-an-drrx-20141010monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-rodman-renshaw-investment-conference-drrx-20140825monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-second-quarter-2014-financial-results-and-update-of-programs-drrx-20140807monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-second-quarter-2014-earnings-conference-call-drrx-20140730monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-secures-20-million-debt-financing-drrx-20140626monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-wall-street-analyst-forum-institutional-investor-conference-drrx-20140609monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-posidur-saber-bupivacaine-data-presentation-at-the-international-anesthes-drrx-20140516monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-first-quarter-2014-earnings-conference-call-drrx-20140423monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-posidur-saber-bupivacaine-data-presentations-at-the-39th-annual-american--drrx-20140401monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-fourth-quarter-2013-financial-results-and-update-of-programs-drrx-20140227monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-fourth-quarter-2013-earnings-conference-call-an-drrx-20140218monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-receives-complete-response-letter-from-fda-for-posidur-saber-bupivacaine-drrx-20140212monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-closing-of-public-offering-of-common-stock-drrx-20131113monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-pricing-of-public-offering-of-common-stock-drrx-20131108monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-proposed-public-offering-of-common-stock-drrx-20131107monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-third-quarter-2013-financial-results-and-update-of-programs-drrx-20131104monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-third-quarter-2013-earnings-conference-call-drrx-20131028monthly0.5https://www.biopharmawatch.com/news/DRRX/pfizer-proceeding-with-remoxy-development-drrx-20131022monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-changes-to-its-board-of-directors-drrx-20130927monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-second-quarter-2013-financial-results-and-update-of-programs-drrx-20130805monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-selection-with-orient-pharma-of-lead-formulation-for-oradur-methylphenida-drrx-20130801monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-second-quarter-2013-earnings-conference-call-drrx-20130726monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-fda-acceptance-of-new-drug-application-nda-submission-for-posidur-saber-b-drrx-20130620monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-update-on-remoxy-drrx-20130510monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-first-quarter-2013-financial-results-and-update-of-programs-drrx-20130502monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-first-quarter-2013-earnings-conference-call-drrx-20130424monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-submission-of-new-drug-application-for-posidur-saber-bupivacaine-drrx-20130416monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-fourth-quarter-2012-financial-results-and-update-of-programs-drrx-20130228monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-fourth-quarter-2012-earnings-conference-call-drrx-20130222monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-participate-in-upcoming-healthcare-conferences-drrx-20130205monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-positive-results-from-relday-phase-1-clinical-trial-drrx-20130103monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-pricing-of-public-offering-of-common-stock-drrx-20121206monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-participate-in-upcoming-healthcare-conferences-drrx-20121113monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-third-quarter-2012-financial-results-and-update-of-programs-drrx-20121105monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-third-quarter-2012-earnings-conference-call-drrx-20121030monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-participate-in-upcoming-healthcare-conferences-drrx-20120821monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-second-quarter-2012-financial-results-and-update-of-programs-drrx-20120806monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-intent-to-submit-nda-for-posidur-for-post-operative-analgesia-drrx-20120806monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-second-quarter-2012-earnings-conference-call-drrx-20120726monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-issuance-of-u-s-patents-covering-oradur-technology-drrx-20120503monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-first-quarter-2012-financial-results-and-update-of-programs-drrx-20120503monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-first-quarter-2012-earnings-conference-call-drrx-20120425monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-receives-back-u-s-and-canadian-product-rights-to-posidur-drrx-20120329monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-fourth-quarter-and-year-end-2011-financial-results-drrx-20120301monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-fourth-quarter-2011-earnings-conference-call-drrx-20120224monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-participate-in-upcoming-healthcare-conferences-drrx-20120223monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-bio-ceo-investor-conference-drrx-20120207monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-receives-back-european-product-rights-to-posidur-drrx-20120130monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-top-line-data-from-besst-posidur-u-s-pivotal-phase-iii-trial-drrx-20120105monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-participate-in-upcoming-healthcare-conferences-drrx-20111107monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-third-quarter-2011-earnings-conference-call-drrx-20111026monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-completes-enrollment-in-pivotal-u-s-phase-iii-trial-for-posidur-besst-drrx-20110906monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-to-participate-in-upcoming-healthcare-conferences-drrx-20110831monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-second-quarter-2011-financial-results-and-update-of-programs-drrx-20110804monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-second-quarter-2011-earnings-conference-call-drrx-20110728monthly0.5https://www.biopharmawatch.com/news/DRRX/pfizer-receives-complete-response-letter-from-fda-for-remoxy-drrx-20110624monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-jefferies-healthcare-conference-drrx-20110603monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-resignation-of-chief-medical-officer-drrx-20110602monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-ubs-global-specialty-pharmaceuticals-conference-drrx-20110512monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-first-quarter-2011-financial-results-and-update-of-programs-drrx-20110505monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-first-quarter-2011-earnings-conference-call-drrx-20110428monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-eladur-transdur-bupivacaine-phase-ii-study-results-in-chronic-low-back-pa-drrx-20110411monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-fourth-quarter-and-year-end-2010-financial-results-drrx-20110302monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-cowen-and-company-health-care-conference-drrx-20110301monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-fourth-quarter-2010-earnings-conference-call-drrx-20110224monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-reports-data-from-european-phase-iib-shoulder-study-of-posidur-saber-bupivacaine-an-drrx-20110209monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-launch-of-first-fda-approved-saber-injectable-peptide-product-drrx-20110208monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-bio-ceo-investor-conference-drrx-20110207monthly0.5https://www.biopharmawatch.com/news/DRRX/remoxy-new-drug-application-accepted-by-the-fda-with-pdufa-goal-date-of-june-23-2011-drrx-20110127monthly0.5https://www.biopharmawatch.com/news/DRRX/remoxy-new-drug-application-resubmitted-drrx-20101227monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-piper-jaffray-2010-health-care-conference-drrx-20101122monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-to-present-at-the-credit-suisse-2010-healthcare-conference-drrx-20101108monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-announces-third-quarter-2010-financial-results-drrx-20101103monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-awarded-733-438-in-grants-under-the-patient-protection-and-affordable-care-program-drrx-20101102monthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-invites-you-to-join-its-third-quarter-2010-earnings-conference-call-drrx-20101027monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-becomes-rocket-one-inc-nasdaq-rkto-targeting-the-space-economy-with-next-hoth-20260527monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-awarded-u-s-patent-for-cancer-fighting-ht-kit-oncology-platform-hoth-20260526monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-reports-positive-female-preclinical-data-showing-ht-va-restores-choleste-hoth-20260310monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-taps-lantern-pharma-hoth-20250904monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-hoth-20250902monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-engagement-with-icon-and-expansion-of-phase-ii-clinical-trial--hoth-20250729monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-signs-va-research-deal-to-advance-gdnf-as-breakthrough-therapy-for-obesi-hoth-20250722monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-hoth-and-silo-pharma-nasdaq-silo-today-announced-the-formation-of-a-50-5-hoth-20250625monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-ht-001-interim-results-first-in-class-topical-therapy-preserves-cancer-t-hoth-20250624monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-to-host-kol-event-spotlighting-ht-001-novel-therapy-hoth-20250623monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-regains-nasdaq-compliance-clears-key-listing-hurdle-reaffirms-path-towar-hoth-20250618monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-reports-positive-preclinical-safety-data-for-cancer-fighting-ht-kit-dose-hoth-20250618monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-to-attend-2025-bio-international-convention-hoth-20250616monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-secures-japanese-patent-for-breakthrough-ht-kit-platform-targeting-mast--hoth-20250612monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-launches-expanded-access-initiative-for-ht-001-offering-critical-relief--hoth-20250611monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-to-spotlight-ht-001-in-investor-focused-kol-event-addressing-breakthroug-hoth-20250605monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-reports-positive-preclinical-results-for-ht-kit-a-precision-antisense-th-hoth-20250512monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-granted-japanese-patent-for-novel-rna-based-cancer-therapy-tar-hoth-20250417monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-positive-initial-data-in-phase-2a-clinical-trial-hoth-20250415monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-collaborates-with-washington-university-on-nih-grant-application-advanci-hoth-20250402monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-positive-pre-clinical-data-ht-alz-shows-promising-breakthrough-hoth-20250402monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-receives-uspto-filing-receipt-for-ht-001-formulation-patent-application--hoth-20250331monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-advances-cancer-fighting-ht-kit-program-with-new-patent-filing-and-precl-hoth-20250326monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-positive-preclinical-results-for-ht-kit-in-aggressive-cancer-g-hoth-20250318monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-plans-to-submit-expanded-access-application-for-ht-001-to-supp-hoth-20250310monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-positive-results-for-ht-001-in-treating-egfr-inhibitor-associa-hoth-20250305monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-positive-findings-on-gdnf-hoth-20250304monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-partners-with-ontargetx-r-d-to-advance-research-for-cancer-fighting-ht-k-hoth-20250210monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-regains-compliance-with-nasdaq-listing-requirements-hoth-20250124monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-expands-intellectual-property-portfolio-with-acquisition-of-new-patent-a-hoth-20250121monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-to-attend-sequire-investor-summit-january-21-23-2025-hoth-20250117monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-responds-to-market-rumors-and-shareholder-inquiries-hoth-20250108monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-achieves-breakthrough-in-phase-2a-trial-ht-001-delivers-100-success-in-c-hoth-20250107monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-enters-partnership-with-the-department-of-veterans-affairs-to-develop-ob-hoth-20241226monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-board-of-directors-approves-bitcoin-as-treasury-reserve-asset-hoth-20241120monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-update-on-cancer-therapeutic-ht-kit-results-suggesting-the-tre-hoth-20241029monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-awarded-key-us-patent-for-groundbreaking-alzheimer-hoth-20241015monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-promising-preclinical-results-for-alzheimer-hoth-20240917monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-expansion-of-clinical-sites-for-ht-001-phase-2a-trial-hoth-20240905monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-positive-data-from-first-of-its-kind-human-patient-treatment-o-hoth-20240905monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-and-aronnax-inc-enter-master-services-agreement-for-ht-kit-cancer-therap-hoth-20240815monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-partners-with-lts-therapy-systems-to-accelerate-novel-alzheimer-hoth-20240724monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-expands-clinical-trial-for-cancer-patients-hoth-20240716monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-joint-development-agreement-with-wise-systems-international-sr-hoth-20240610monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-to-attend-ef-hutton-annual-global-conference-may-15-2024-hoth-20240501monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-exercise-of-warrants-for-4-2-million-gross-proceeds-hoth-20240327monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-hoth-20240327monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-positive-data-in-completed-study-of-alzheimer-hoth-20240319monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-retains-venable-llp-to-expand-its-patent-portfolio-hoth-20240229monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-engages-altasciences-to-perform-key-study-for-ht-kit-cancer-fighting-the-hoth-20240226monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-to-attend-bio-ceo-and-investor-conference-february-26-27-2024-hoth-20240213monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-it-received-fda-approval-to-expand-ht-001-clinical-trial-to-tr-hoth-20240118monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-expansion-of-fda-cleared-first-in-human-clinical-trial-for-can-hoth-20231227monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-it-has-successfully-completed-manufacturing-of-its-cancer-figh-hoth-20231205monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-successful-completion-of-pre-ind-meeting-with-fda-regarding-de-hoth-20231114monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-to-present-at-noblecon-hoth-20231110monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-merveille-ai-artificial-intelligence-initiative-for-drug-disco-hoth-20231005monthly0.5https://www.biopharmawatch.com/news/HOTH/fda-grants-hoth-therapeutics-pre-ind-meeting-for-ht-kit-treatment-for-cancer-patients-hoth-20231002monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-closing-of-2-89-million-registered-direct-offering-priced-at-t-hoth-20230915monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-2-89-million-registered-direct-offering-priced-at-the-market-u-hoth-20230913monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-positive-results-killing-cancer-cells-in-both-gastrointestinal-hoth-20230913monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-fda-accepts-pre-investigational-new-drug-pre-ind-submission-fo-hoth-20230911monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-positive-final-results-from-14-day-phase-1b-clinical-trial-of--hoth-20230906monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-positive-preclinical-end-point-results-of-ht-alz-treatment-for-hoth-20230809monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-major-milestone-of-first-patient-dosed-in-phase-2a-clinical-tr-hoth-20230725monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-receives-protocol-approval-for-ht-001-cancer-therapeutic-hoth-20230719monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-irb-approval-for-fda-cleared-first-in-human-clinical-trial-of--hoth-20230614monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-positive-preclinical-results-of-ht-alz-treatment-for-alzheimer-hoth-20230606monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-and-algorithm-sciences-terminate-letter-of-intent-to-merge-hoth-20230512monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-and-algorithm-sciences-execute-letter-of-intent-to-merge-hoth-20230426monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-collaboration-with-first-active-clinical-site-for-its-phase-2--hoth-20230308monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-retains-shareintel-to-investigate-illegal-naked-shorting-activity-hoth-20230216monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-increased-positive-results-of-its-alzheimer-hoth-20230208monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-selection-of-first-3-clinical-sites-for-its-phase-2-clinical-t-hoth-20230125monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-closing-of-10-million-private-placement-priced-at-the-market-u-hoth-20230103monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-10-million-private-placement-priced-at-the-market-under-nasdaq-hoth-20221229monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-fda-acceptance-of-ind-application-for-ht-001-for-the-treatment-hoth-20221229monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-submission-of-investigational-new-drug-application-for-ht-001-hoth-20221201monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-regains-compliance-with-nasdaq-listing-requirements-hoth-20221109monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-reports-positive-biolexa-phase-1b-clinical-trial-results-in-mild-to-mode-hoth-20221031monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-a-1-25-reverse-stock-split-effective-pre-market-opening-on-oct-hoth-20221024monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-partnership-with-altasciences-for-manufacturing-ht-tbi-for-tra-hoth-20220920monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-mrna-frame-shifting-therapeutic-ht-004-shows-potential-to-reduce-lung-in-hoth-20220906monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-pipeline-presentation-at-the-2022-sidoti-investor-conference-hoth-20220812monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-ht-alz-therapeutic-shows-cognitive-improvements-in-alzheimer-hoth-20220712monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-bid-price--hoth-20220629monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-hrec-approval-in-australia-for-the-next-phase-of-its-trial-of--hoth-20220621monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-announces-adjournment-of-annual-meeting-of-shareholders-until-june-23-2022-hoth-20220615monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-extension-of-washington-university-alzheimer-hoth-20220609monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-preliminary-efficacy-findings-from-phase-1b-clinical-trial-wit-hoth-20220503monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-new-pipeline-asset-ht-tbi-for-stroke-and-traumatic-brain-injur-hoth-20220419monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-inc-announces-closing-of-7-0-million-underwritten-public-offering-priced-hoth-20220414monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-acceptance-to-present-ht-alz-proof-of-concept-alzheimer-hoth-20220412monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-inc-announces-pricing-of-7-0-million-underwritten-public-offering-priced-hoth-20220411monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-inc-announces-proposed-public-offering-of-common-stock-hoth-20220411monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-mrna-frame-shifting-therapeutic-ht-kit-proves-effective-against-aggressi-hoth-20220411monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-pipeline-presentation-at-the-2022-bio-international-convention-hoth-20220401monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-it-has-successfully-completed-manufacturing-feasibility-of-the-hoth-20220322monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-orphan-drug-designation-granted-to-cancer-therapeutic-ht-kit-t-hoth-20220311monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-the-selection-of-nuvisan-for-manufacturing-ht-001-drug-batches-hoth-20220209monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-presentation-of-the-ht-alz-proof-of-concept-alzheimer-hoth-20220207monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-the-appointment-of-john-cirrito-phd-and-carla-yuede-phd-to-ove-hoth-20220131monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-ht-alz-therapeutic-shows-positive-results-reduce-amyloid-in-al-hoth-20220104monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-submission-of-orphan-drug-designation-request-for-ht-kit-to-tr-hoth-20211221monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-licenses-lupus-therapeutic-back-to-zylo-therapeutics-hoth-20211208monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-hoth-20211130monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-a-sponsored-research-agreement-to-further-develop-novel-mrna-c-hoth-20211116monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-inks-api-and-drug-product-contracts-with-wuxi-sta-to-advance-manufacturi-hoth-20211108monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-extends-partnership-agreement-with-reprocell-hoth-20211019monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-receives-approval-to-commence-cohort-2-in-clinical-trial-of-biolexa-for--hoth-20211012monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-submits-to-ethics-committee-for-approval-to-initiate-patient-cohort-2-in-hoth-20210921monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-positive-phase-1b-results-for-completed-first-cohort-of-patien-hoth-20210908monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-hoth-20210811monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-initiates-preclinical-study-of-ht-alz-for-alzheimer-hoth-20210802monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-positive-confirmatory-results-from-in-vivo-model-of-ht-003-ass-hoth-20210713monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-positive-safety-results-from-ad001-cohort-1-of-phase-1b-clinic-hoth-20210628monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-sponsored-research-agreement-with-washington-university-for-no-hoth-20210607monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-shares-positive-preclinical-results-of-novel-ht-kit-therapeutic-hoth-20210603monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-plans-shareholder-presentation-on-ht-kit-therapeutic-hoth-20210601monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-participation-at-the-american-society-of-clinical-oncology-asc-hoth-20210524monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-provides-shareholder-update-on-novel-endocannabinoid-therapeutic-for-cut-hoth-20210513monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-and-virginia-commonwealth-university-expand-research-agreement-for-covid-hoth-20210505monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-development-of-ht-kit-to-treat-multiple-orphan-diseases-includ-hoth-20210503monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-hoth-20210422monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-its-mrna-frame-shifting-therapeutic-significantly-inhibits-tum-hoth-20210420monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-completes-ht-001-formulation-development-for-upcoming-cancer-patient-cli-hoth-20210412monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-engages-worldwide-clinical-trials-as-contract-research-organization-for--hoth-20210406monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-inc-announces-notice-of-allowance-for-a-new-patent-application-related-t-hoth-20210405monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-positive-preclinical-results-for-novel-covid-19-therapeutic-hoth-20210323monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-to-present-at-the-benzinga-biotech-small-cap-conference-on-march-24-2021-hoth-20210322monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-ceo-robb-knie-featured-on-the-redchip-money-report-on-bloomberg-tv-this--hoth-20210319monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-partners-with-university-of-cincinnati-to-perform-critical-studies-for-s-hoth-20210317monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-executes-agreement-to-assess-the-effect-of-ht-003-therapeutic-platform-o-hoth-20210311monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-completes-closing-of-previously-announced-15-0-million-private-placement-hoth-20210310monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-15-million-private-placement-priced-at-the-market-under-nasdaq-hoth-20210308monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-provides-update-on-novel-peptide-covid-19-therapeutic-ht-002-preclinical-hoth-20210303monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-completes-site-recruitment-for-cohort-1-of-first-in-human-clinical-trial-hoth-20210301monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-expands-license-agreement-to-include-innovative-cancer-and-anaphylactic--hoth-20210226monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-retains-redchip-to-increase-investor-awareness-hoth-20210225monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-expands-intellectual-property-portfolio-with-novel-alzheimer-hoth-20210224monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-successful-completion-of-pre-ind-meeting-with-fda-regarding-pr-hoth-20210223monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-hoth-20210218monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-to-present-at-the-diamond-equity-research-emerging-growth-invitational-2-hoth-20210217monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-scientific-advisory-board-member-michael-peters-ph-d-publishes-whitepape-hoth-20210210monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-partners-with-camargo-pharmaceutical-services-for-the-ht-001-ind-a-treat-hoth-20210208monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-provides-operational-update-on-novel-therapeutic-pipeline-hoth-20210202monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-expands-research-collaboration-agreement-with-weill-cornell-medicine-to--hoth-20210128monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-the-appointment-of-mario-e-lacouture-m-d-to-oversee-dermatolog-hoth-20210127monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-positive-initial-mechanism-of-action-data-for-ht-003-in-pursui-hoth-20210120monthly0.5https://www.biopharmawatch.com/news/HOTH/fda-grants-hoth-therapeutics-pre-ind-meeting-regarding-proposed-drug-development-plan-for--hoth-20210113monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-to-initiate-ind-enabling-studies-of-ht-001-treatment-for-cancer-patients-hoth-20210111monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-private-placement-of-equity-priced-at-the-market-under-nasdaq--hoth-20210105monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-licensing-agreement-and-collaboration-with-u-s-army-medical-re-hoth-20210104monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-production-of-ht-001-for-cancer-treatment-hoth-20201231monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-submits-request-for-a-pre-investigational-new-drug-pre-ind-meeting-for-h-hoth-20201223monthly0.5https://www.biopharmawatch.com/news/HOTH/endocannabinoid-pathway-targeted-drug-demonstrates-proof-of-concept-efficacy-in-a-cutaneou-hoth-20201221monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-receives-approval-to-commence-phase-1b-clinical-trial-of-biolexa-for-the-hoth-20201210monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-positive-statistically-significant-proof-of-concept-preclinica-hoth-20201103monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-provides-update-for-novel-covid-19-therapeutic-on-the-go-sars-cov-2-test-hoth-20201102monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-uspto-grant-of-patent-for-targeted-13-cis-ramba-retinamides-fo-hoth-20201020monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-its-ht-003-shows-positive-initial-data-inhibiting-toll-like-re-hoth-20200924monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-enters-into-sponsored-research-agreement-for-on-the-go-covid-19-testing--hoth-20200921monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-hoth-20200901monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-appoints-stefanie-johns-ph-d-as-chief-scientific-officer-hoth-20200831monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-participation-at-upcoming-investor-conferences-in-september-hoth-20200828monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-provides-shareholder-update-on-covid-19-initiatives-and-dermatological-t-hoth-20200819monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutic-announces-that-it-has-submitted-its-request-to-australia-ethics-board-to--hoth-20200813monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-licenses-intellectual-property-to-develop-real-time-breath-based-covid-1-hoth-20200810monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-executes-licensing-agreement-of-vnlg-152-for-treatment-of-dermatological-hoth-20200731monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-sponsored-research-agreement-with-vcu-for-potential-covid-19-t-hoth-20200630monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-enters-into-expanded-sponsored-research-agreement-with-the-george-washin-hoth-20200616monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-hoth-20200615monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-receives-notice-of-allowance-for-u-s-patent-regarding-methods-for-treati-hoth-20200608monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-provides-shareholder-update-on-therapeutics-pipeline-hoth-20200603monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-closing-of-public-offering-of-common-stock-hoth-20200527monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-the-appointment-of-michael-peters-ph-d-to-scientific-advisory--hoth-20200522monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-announces-pricing-of-public-offering-of-shares-of-common-stock-hoth-20200521monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-announces-proposed-public-offering-of-common-stock-hoth-20200521monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-licenses-novel-peptide-covid-19-therapeutic-hoth-20200520monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-procures-full-licensing-rights-for-biolexa-platform-atopic-dermatitis-tr-hoth-20200518monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-expands-partnership-with-zylo-therapeutics-inc-hoth-20200505monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-inc-voltron-therapeutics-inc-halovax-announce-selection-of-the-first-of--hoth-20200424monthly0.5https://www.biopharmawatch.com/news/HOTH/reminder-hoth-therapeutics-to-host-shareholder-update-conference-call-with-dr-mark-poznans-hoth-20200423monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-to-host-shareholder-update-conference-call-with-dr-mark-poznansky-to-dis-hoth-20200422monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-top-line-preclinical-data-from-cutaneous-lupus-erythematosus-c-hoth-20200421monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-additions-to-its-board-of-directors-hoth-20200417monthly0.5https://www.biopharmawatch.com/news/HOTH/dr-mark-poznansky-co-creator-of-vaxcelerate-appeared-on-msnbc-to-discuss-covid-19-vaccines-hoth-20200415monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-commences-next-phase-of-vnlg-152-study-hoth-20200409monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-update-on-halovax-partnership-vaccine-to-fight-covid-19-with-sponsored-research-agree-hoth-20200402monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-enters-into-letter-of-intent-with-isoprene-pharmaceuticals-inc-to-licens-hoth-20200330monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-announces-pricing-of-5-million-public-offering-of-common-stock-hoth-20200324monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-inc-announces-proposed-public-offering-of-common-stock-hoth-20200323monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-agreement-to-joint-development-for-a-self-assembling-vaccine-s-hoth-20200323monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-positive-preclinical-data-of-weg232-treatment-developed-for-ca-hoth-20200319monthly0.5https://www.biopharmawatch.com/news/HOTH/diamond-equity-research-publishes-report-valuing-hoth-common-stock-at-7-00-per-share-hoth-20200316monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-inc-states-covid-19-coronavirus-poses-no-negative-effect-on-company-hoth-20200309monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-receives-notice-of-allowance-from-european-patent-office-hoth-20200219monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-positive-preliminary-preclinical-data-on-its-therapeutic-for-c-hoth-20200212monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-inc-to-present-at-2020-noble-capital-market-hoth-20200211monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-initiates-preclinical-gene-therapy-program-with-nc-state-for-the-treatment-of-asthma--hoth-20200204monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-to-further-its-research-of-vnlg-152-and-plans-exercise-of-its-option-agr-hoth-20200129monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-completes-animal-safety-study-of-proprietary-biolexa-platform-for-the-treatment-of-at-hoth-20200121monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-exercises-patent-licensing-option-with-the-george-washington-university--hoth-20200115monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-inc-issues-2019-shareholder-letter-hoth-20191223monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-enters-into-research-collaboration-agreement-with-weill-cornell-medicine-hoth-20191219monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-the-appointment-of-dr-william-weglicki-m-d-to-scientific-advis-hoth-20191217monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-and-north-carolina-state-university-initiate-preclinical-gene-therapy-st-hoth-20191209monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-and-north-carolina-state-university-enter-license-agreement-for-gene-the-hoth-20191126monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-to-attend-benchmark-hoth-20191118monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-initiates-preclinical-study-including-topical-form-of-aprepitant-for-der-hoth-20191114monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-initiates-confirmatory-study-for-lupus-treatment-hoth-20191106monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-to-present-at-the-dawson-james-5th-annual-small-cap-growth-conference-hoth-20191015monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-makes-donation-to-national-eczema-association-in-sponsorship-of-national-hoth-20191014monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-successfully-completes-phase-i-of-in-life-dose-escalation-study-for-trea-hoth-20191008monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-inc-to-present-at-diamond-equity-research-emerging-growth-invitational-hoth-20190924monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-to-present-at-the-h-c-wainwright-21st-annual-global-investment-conferenc-hoth-20190906monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-inc-issues-letter-to-shareholders-hoth-20190904monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-and-zylo-therapeutics-finalize-agreement-hoth-20190821monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-inc-announces-positive-results-from-pilot-study-of-biolexa-on-diabetic-s-hoth-20190722monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-inc-expands-working-relationship-with-the-george-washington-university-a-hoth-20190715monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-inc-enters-into-sponsored-research-agreement-with-the-george-washington--hoth-20190627monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-to-present-to-to-the-philadelphia-securities-association-hoth-20190613monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-forms-wholly-owned-australian-subsidiary-in-preparation-of-upcoming-clin-hoth-20190606monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-to-present-at-the-9th-annual-ld-micro-invitational-investor-conference-o-hoth-20190529monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-signs-term-sheet-with-zylo-therapeutics-to-acquire-a-license-and-jointly-hoth-20190514monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-inc-to-present-at-the-thinkequity-conference-hoth-20190430monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-inc-to-ring-nasdaq-closing-bell-on-april-22-2019-hoth-20190418monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-inc-announces-the-addition-of-dr-lawrence-a-schachner-m-d-and-dr-vincent-hoth-20190408monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-inc-announces-the-addition-of-dr-stefanie-johns-ph-d-to-the-company-hoth-20190319monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-enters-into-commercial-licensing-agreement-with-university-of-maryland-b-hoth-20190313monthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-announces-dr-jonathan-zippin-as-senior-scientific-advisor-hoth-20190311monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-to-report-third-quarter-2024-results-and-corporate-update-aadi-20241030monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-announces-financial-results-for-the-second-quarter-2024-and-provides-corpo-aadi-20240807monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-to-report-second-quarter-2024-results-and-corporate-update-aadi-20240731monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-to-participate-in-the-jefferies-healthcare-conference-aadi-20240529monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-presents-new-nonclinical-data-demonstrating-preferential-tumor-uptake-of-n-aadi-20240523monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-announces-financial-results-for-the-first-quarter-2024-and-provides-corpor-aadi-20240508monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-to-report-first-quarter-2024-results-and-corporate-update-aadi-20240501monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-to-present-new-non-clinical-data-highlighting-combinability-of-nab-sirolim-aadi-20240409monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-presents-new-subgroup-analysis-of-patients-with-advanced-malignant-pecoma--aadi-20240317monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-announces-financial-results-for-the-fourth-quarter-and-full-year-2023-and--aadi-20240313monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-to-report-fourth-quarter-and-full-year-2023-results-and-corporate-update-aadi-20240306monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-to-present-multiple-posters-at-the-american-association-for-cancer-researc-aadi-20240305monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-announces-publication-of-long-term-efficacy-and-safety-data-further-suppor-aadi-20240301monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-to-present-at-the-td-cowen-44th-annual-healthcare-conference-aadi-20240226monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-announces-poster-presentations-at-the-2024-american-society-of-clinical-on-aadi-20240126monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-announces-poster-presentations-at-the-2024-american-society-of-clinical-on-aadi-20240119monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-reports-interim-results-from-precision1-trial-of-nab-sirolimus-demonstrati-aadi-20231214monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-reports-financial-results-for-the-third-quarter-2023-and-provides-corporat-aadi-20231108monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-to-participate-in-jefferies-london-healthcare-conference-aadi-20231106monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-to-report-third-quarter-2023-results-and-operational-update-aadi-20231101monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-announces-poster-presentations-on-nab-sirolimus-at-the-international-gynec-aadi-20231019monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-announces-poster-presentations-at-2023-aacr-nci-eortc-international-confer-aadi-20231012monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-announces-poster-presentations-at-the-north-american-neuroendocrine-tumor--aadi-20231005monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-grants-new-ceo-dave-lennon-ph-d-inducement-award-under-nasdaq-listing-rule-aadi-20231003monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-appoints-dave-lennon-ph-d-as-president-and-chief-executive-officer-aadi-20231002monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-announces-poster-presentations-at-2023-aacr-nci-eortc-international-confer-aadi-20230920monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-to-participate-at-upcoming-investor-conferences-aadi-20230905monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-announces-financial-results-for-the-second-quarter-2023-and-provides-corpo-aadi-20230809monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-to-report-second-quarter-2023-results-and-operational-update-aadi-20230802monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-announces-presentations-at-the-2023-american-society-of-clinical-oncology--aadi-20230525monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-to-participate-in-upcoming-investor-events-aadi-20230523monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-announces-financial-results-and-operational-update-for-the-first-quarter-2-aadi-20230510monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-to-report-first-quarter-2023-results-and-operational-update-aadi-20230503monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-announces-multiple-presentations-on-nab-sirolimus-at-the-2023-american-soc-aadi-20230426monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-to-present-multiple-posters-on-nab-sirolimus-at-the-2023-american-associat-aadi-20230414monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-to-present-multiple-posters-at-the-american-association-for-cancer-researc-aadi-20230406monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-announces-financial-results-for-the-fourth-quarter-and-full-year-2022-and--aadi-20230328monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-appoints-mohammad-hirmand-m-d-to-board-of-directors-aadi-20230327monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-presents-clinical-data-from-precision-1-and-ampect-trials-at-the-society-o-aadi-20230326monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-to-report-fourth-quarter-and-full-year-2022-results-and-corporate-update-aadi-20230315monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-announces-leadership-transition-aadi-20230303monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-to-present-at-the-43rd-annual-cowen-healthcare-conference-aadi-20230222monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-presents-precision-1-trial-in-progress-poster-and-ampect-trial-final-analy-aadi-20221117monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-announces-financial-results-for-the-third-quarter-of-2022-and-provides-cor-aadi-20221109monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-announces-planned-leadership-transition-aadi-20221108monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-to-present-at-upcoming-investor-conferences-aadi-20221103monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-to-report-third-quarter-2022-results-and-corporate-update-aadi-20221102monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-announces-improved-anti-tumor-activity-of-kras-inhibitors-in-combination-w-aadi-20221027monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-announces-improved-anti-tumor-activity-of-kras-inhibitors-in-combination-w-aadi-20221012monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-announces-72-5-million-private-placement-equity-financing-aadi-20220922monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-announces-participation-in-upcoming-september-investor-conferences-aadi-20220901monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-announces-financial-results-for-the-second-quarter-of-2022-and-provides-co-aadi-20220810monthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-to-report-second-quarter-2022-results-and-corporate-update-aadi-20220728monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-securities-raises-200-000-000-00-in-world-domh-20260615monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-congratulates-cerebras-systems-on-blockbuster-initial-public-offering-domh-20260515monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-releases-letter-to-shareholders-and-clients-domh-20260316monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-announces-change-of-record-date-and-payment-date-for-10-million-cash-div-domh-20251212monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-announces-record-date-for-cash-dividend-domh-20250822monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-featured-in-the-wall-street-journal-domh-20250819monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-marks-inflection-point-with-second-quarter-2025-financial-results-domh-20250812monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-securities-serves-as-exclusive-placement-agent-to-srm-entertainment-on-a-100-mill-domh-20250617monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-issues-letter-to-shareholders-domh-20250604monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-set-to-join-russell-microcap-index-domh-20250528monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holding-domh-20250513monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-investment-american-data-centers-becomes-american-bitcoin-in-transformat-domh-20250331monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-reports-preliminary-fy-2024-financial-results-domh-20250328monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-securities-receives-finra-approval-to-expand-operations-domh-20250304monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-securities-appoints-30-year-financial-industry-expert-to-manage-operations-and-co-domh-20240315monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-securities-llc-expands-investment-banking-practice-with-appointment-of-experience-domh-20240312monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-securities-llc-continues-to-add-depth-with-three-new-hires-domh-20240307monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-securities-llc-welcomes-wealth-management-team-gotham-equities-domh-20240306monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-securities-llc-welcomes-another-wealth-management-team-domh-20240305monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-securities-llc-welcomes-seasoned-wealth-management-advisor-raymond-guarini-domh-20240227monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-securities-llc-serves-as-lead-underwriter-for-5-million-initial-public-offering-f-domh-20240215monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-inc-releases-shareholder-update-domh-20230906monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-securities-ceo-kyle-wool-shares-positive-view-of-ipo-market-on-varnay-co-domh-20230630monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-securities-ceo-kyle-wool-discusses-the-ipo-market-on-the-claman-countdown-domh-20230621monthly0.5https://www.biopharmawatch.com/news/DOMH/kyle-wool-ceo-of-dominari-securities-to-appear-on-fox-business-domh-20230605monthly0.5https://www.biopharmawatch.com/news/DOMH/kyle-wool-ceo-of-dominari-securities-to-appear-on-fox-business-domh-20230530monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-inc-expands-kyle-wool-domh-20230524monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-financial-ceo-kyle-wool-scheduled-to-appear-on-fox-business-network-domh-20230427monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-securities-acquires-broker-team-with-700-million-in-assets-under-management-domh-20230418monthly0.5https://www.biopharmawatch.com/news/DOMH/kyle-wool-appears-on-fox-business-domh-20230410monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-appoints-george-way-chief-financial-officer-domh-20230403monthly0.5https://www.biopharmawatch.com/news/DOMH/kyle-wool-named-ceo-of-dominari-financial-domh-20230328monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-financial-inc-acquires-leading-broker-dealer-and-registered-investment-advisor-bu-domh-20230327monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-financial-granted-approval-to-acquire-broker-dealer-domh-20230321monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230321monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230317monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230315monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-business-update-domh-20230314monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230310monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230308monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230306monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230303monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230301monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230224monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230221monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230217monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230215monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230213monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230209monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230207monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230203monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230131monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230127monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230125monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230123monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230120monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230118monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230113monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230111monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230109monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230106monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20230104monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20221230monthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-provides-update-on-share-repurchase-program-domh-20221228monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-rebrands-as-cypherpunk-expands-leadership-team-to-drive-new-zcash-treasu-lptx-20251112monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-final-clinical-data-from-part-b-of-the-defiance-study-at-the--lptx-20250925monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-first-quarter-2025-financial-results-lptx-20250513monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-preclinical-data-of-fl-501-a-novel-gdf-15-neutralizing-antibo-lptx-20250425monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-host-virtual-kol-event-to-discuss-sirexatamab-dkn-01-in-second-line-p-lptx-20250415monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-lptx-20250326monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-positive-updated-data-from-sirexatamab-colorectal-cancer-study-lptx-20250326monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-initial-clinical-data-from-part-b-of-the-defiance-study-and-part-lptx-20250128monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-participate-at-the-43rd-annual-j-p-morgan-healthcare-conference-lptx-20250106monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-participate-at-piper-sandler-36th-annual-healthcare-conference-lptx-20241126monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-third-quarter-2024-financial-results-lptx-20241113monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-completion-of-enrollment-in-part-b-of-the-defiance-study-of-dk-lptx-20240930monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-second-quarter-2024-financial-results-lptx-20240812monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-first-quarter-2024-financial-results-lptx-20240513monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-40-million-private-placement-lptx-20240411monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-lptx-20240318monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-new-clinical-data-from-part-a-of-defiance-study-at-the-2024-a-lptx-20240116monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-participate-at-the-42nd-annual-j-p-morgan-healthcare-conference-lptx-20240103monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-completion-of-enrollment-in-randomized-controlled-part-c-of-th-lptx-20240102monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-new-data-from-part-a-of-the-defiance-study-of-dkn-01-plus-bev-lptx-20231211monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-participate-at-piper-sandler-35th-annual-healthcare-conference-lptx-20231121monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-third-quarter-2023-financial-results-lptx-20231113monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-participate-at-upcoming-investor-conferences-lptx-20230905monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-second-quarter-2023-financial-results-lptx-20230814monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-initiation-of-randomized-controlled-part-b-of-the-defiance-stu-lptx-20230712monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-reverse-stock-split-lptx-20230620monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-updated-data-from-part-a-of-the-distinguish-study-of-dkn-01-p-lptx-20230525monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-first-quarter-2023-financial-results-lptx-20230515monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-updated-data-from-part-a-of-the-distinguish-study-of-dkn-01-p-lptx-20230426monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-completion-of-enrollment-in-part-a-of-the-defiance-study-of-dk-lptx-20230412monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-lptx-20230324monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-provides-update-on-beigene-option-agreement-for-dkn-01-lptx-20230316monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-acquires-flame-biosciences-lptx-20230117monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-at-b-riley-securities-lptx-20230111monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-participate-at-the-piper-sandler-34th-annual-healthcare-conference-lptx-20221121monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-third-quarter-2022-financial-results-lptx-20221114monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-updated-data-from-the-distinguish-study-of-dkn-01-plus-tislel-lptx-20221107monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-first-patient-enrolled-in-defiance-study-of-dkn-01-for-the-tre-lptx-20221017monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-first-patient-enrolled-in-part-c-of-phase-2-distinguish-study--lptx-20221012monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-updated-data-from-the-distinguish-study-of-dkn-01-plus-tislel-lptx-20221005monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-participate-at-the-baird-2022-global-healthcare-conference-lptx-20220907monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-appointment-of-richard-l-schilsky-md-to-its-board-of-directors-lptx-20220906monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-new-data-from-distinguish-study-of-dkn-01-plus-tislelizumab-a-lptx-20220904monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-lptx-20220812monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-second-quarter-2022-financial-results-lptx-20220812monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-initiation-of-new-dkn-01-clinical-trials-in-gastric-cancer-col-lptx-20220712monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-host-virtual-r-d-day-on-july-12-2022-lptx-20220627monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-initial-data-from-the-investigator-sponsored-study-of-dkn-01--lptx-20220526monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-first-quarter-2022-financial-results-lptx-20220513monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-lptx-20220311monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-at-raymond-james-43rd-annual-institutional-investors-conferen-lptx-20220302monthly0.5https://www.biopharmawatch.com/news/LPTX/leica-biosystems-and-leap-therapeutics-partner-on-companion-diagnostic-to-advance-care-for-lptx-20220131monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-at-b-riley-securities-oncology-investor-conference-lptx-20220124monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-positive-new-data-from-the-distinguish-study-of-dkn-01-plus-t-lptx-20220118monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-at-h-c-wainwright-bioconnect-2022-conference-lptx-20220105monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-at-40th-annual-j-p-morgan-healthcare-conference-lptx-20220103monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-participate-at-the-piper-sandler-33rd-annual-virtual-healthcare-confe-lptx-20211115monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-third-quarter-2021-financial-results-lptx-20211112monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-closing-of-public-offering-of-common-stock-and-pre-funded-warr-lptx-20210924monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-pricing-of-90-million-of-common-stock-and-pre-funded-warrants-lptx-20210922monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded-warran-lptx-20210921monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-presents-updated-positive-data-from-the-distinguish-study-of-dkn-01-plus-lptx-20210916monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-new-data-from-the-distinguish-study-of-dkn-01-plus-tislelizum-lptx-20210913monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-participate-at-two-upcoming-virtual-investor-conferences-lptx-20210907monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-second-quarter-2021-financial-results-and-upcoming-data-presenta-lptx-20210813monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-at-the-esmo-2021-virtual-congress-lptx-20210726monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-at-ladenburg-thalmann-2021-virtual-healthcare-conference-lptx-20210707monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-at-raymond-james-2021-virtual-human-health-innovation-confere-lptx-20210614monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-first-quarter-2021-financial-results-lptx-20210514monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-and-flagship-biosciences-develop-image-analysis-rnascope-assay-for-prosp-lptx-20210512monthly0.5https://www.biopharmawatch.com/news/LPTX/flagship-biosciences-and-leap-therapeutics-announce-partnership-and-approach-using-rnascop-lptx-20210412monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-completion-of-enrollment-for-first-line-patient-cohort-in-stud-lptx-20210401monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-presents-dkn-01-clinical-data-at-the-society-of-gynecologic-oncology-202-lptx-20210322monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-lptx-20210312monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-at-upcoming-virtual-investor-conferences-lptx-20210222monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference-lptx-20210106monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference-lptx-20210104monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-publication-of-dkn-01-mechanism-of-action-data-in-molecular-ca-lptx-20201222monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-participate-at-piper-sandler-32nd-annual-virtual-healthcare-conferenc-lptx-20201123monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-third-quarter-2020-financial-results-lptx-20201112monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-at-stifel-2020-healthcare-conference-lptx-20201110monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-presents-dkn-01-monotherapy-data-at-aacr-virtual-special-endometrial-can-lptx-20201109monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-presents-updated-data-for-dkn-01-in-esophagogastric-cancer-patients-at-s-lptx-20201109monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-esophagogastric-cancer-data-at-sitc-2020-annual-meeting-lptx-20201015monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-fda-fast-track-designation-granted-to-dkn-01-for-the-treatment-lptx-20200924monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-and-beigene-announce-first-patient-dosed-in-study-of-dkn-01-in-combinati-lptx-20200921monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-at-h-c-wainwright-22nd-annual-global-investment-conference-lptx-20200909monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-expands-leadership-team-with-addition-of-two-industry-veterans-lptx-20200824monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-second-quarter-2020-financial-results-lptx-20200813monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-full-exercise-of-underwriters-lptx-20200625monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-closing-of-public-offering-of-common-stock-and-pre-funded-warr-lptx-20200622monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-pricing-of-45-million-of-common-stock-and-pre-funded-warrants-lptx-20200618monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded-warran-lptx-20200617monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-oprhan-drug-designation-of-dkn-01-for-the-treatment-of-gastric-lptx-20200611monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-changes-to-virtual-format-and-time-for-2020-annual-meeting-of--lptx-20200611monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-first-quarter-2020-financial-results-lptx-20200514monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-updated-data-for-dkn-01-monotherapy-and-paclitaxel-combinatio-lptx-20200423monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-executive-leadership-changes-lptx-20200318monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-lptx-20200316monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-at-cowen-40th-annual-health-care-conference-lptx-20200226monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-at-22nd-annual-bio-ceo-investor-conference-lptx-20200204monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-presents-updated-data-at-the-asco-2020-gastrointestinal-cancers-symposiu-lptx-20200123monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-closing-of-previously-announced-equity-financing-lptx-20200107monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-and-beigene-announce-exclusive-option-and-license-agreement-for-dkn-01-a-lptx-20200103monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-third-quarter-2019-financial-results-lptx-20191114monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-updated-data-for-dkn-01-monotherapy-and-paclitaxel-combinatio-lptx-20190917monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-second-quarter-2019-financial-results-lptx-20190809monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-presents-positive-clinical-results-for-the-combination-of-dkn-01-plus-keytruda-and-pr-lptx-20190806monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-host-conference-call-to-provide-dkn-01-program-update-lptx-20190725monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-common-stock-purchase-agreements-for-up-to-21-million-with-lin-lptx-20190711monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-at-the-2019-raymond-james-life-sciences-and-medtech-conferenc-lptx-20190611monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-first-quarter-2019-financial-results-lptx-20190515monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-at-the-2019-needham-company-18th-annual-healthcare-conference-lptx-20190403monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-clinical-update-and-2018-financial-results-lptx-20190401monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-presents-at-society-of-gynecologic-oncology-50th-annual-meeting-on-women-lptx-20190318monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-at-the-society-of-gynecologic-oncology-2019-annual-meeting-on-lptx-20190308monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-closing-of-public-offering-and-full-exercise-of-underwriters-lptx-20190205monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-pricing-of-11-5-million-public-offering-of-common-stock-and-wa-lptx-20190201monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-proposed-public-offering-of-common-stock-and-warrants-lptx-20190131monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-announces-an-investigator-initiated-study-of-dkn-01-in-patients-with-dkk-lptx-20190114monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-presents-trx518-data-at-esmo-immuno-oncology-congress-2018-and-updated-d-lptx-20181214monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-reports-third-quarter-2018-business-update-and-financial-results-lptx-20181109monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-presents-esophagogastric-cancer-data-at-sitc-2018-annual-meeting-lptx-20181109monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-presents-esophagogastric-cancer-data-at-esmo-2018-annual-congress-lptx-20181021monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-data-from-study-evaluating-dkn-01-in-combination-with-keytrud-lptx-20181008monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-present-at-two-october-conferences-lptx-20180925monthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-to-participate-in-the-h-c-wainwright-20th-annual-global-investment-confe-lptx-20180830monthly0.5https://www.biopharmawatch.com/news/CKPT/checkpoint-therapeutics-reports-full-year-2024-financial-results-and-recent-corporate-upda-ckpt-20250328monthly0.5https://www.biopharmawatch.com/news/CKPT/checkpoint-therapeutics-reports-third-quarter-2024-financial-results-and-recent-corporate--ckpt-20241112monthly0.5https://www.biopharmawatch.com/news/CKPT/checkpoint-therapeutics-reports-second-quarter-2024-financial-results-and-recent-corporate-ckpt-20240812monthly0.5https://www.biopharmawatch.com/news/CKPT/checkpoint-therapeutics-reports-first-quarter-2024-financial-results-and-recent-corporate--ckpt-20240510monthly0.5https://www.biopharmawatch.com/news/CKPT/checkpoint-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your--ckpt-20240410monthly0.5https://www.biopharmawatch.com/news/CKPT/checkpoint-therapeutics-reports-full-year-2023-financial-results-and-recent-corporate-high-ckpt-20240322monthly0.5https://www.biopharmawatch.com/news/CKPT/checkpoint-therapeutics-announces-14-million-registered-direct-offering-priced-at-the-mark-ckpt-20240129monthly0.5https://www.biopharmawatch.com/news/CKPT/checkpoint-therapeutics-announces-pricing-of-public-offering-of-common-stock-ckpt-20191120monthly0.5https://www.biopharmawatch.com/news/CKPT/checkpoint-therapeutics-announces-proposed-public-offering-of-common-stock-ckpt-20191119monthly0.5https://www.biopharmawatch.com/news/CKPT/checkpoint-therapeutics-inc-announces-pricing-of-public-offering-of-common-stock-ckpt-20180308monthly0.5https://www.biopharmawatch.com/news/CKPT/checkpoint-therapeutics-inc-announces-proposed-public-offering-of-common-stock-ckpt-20180307monthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-inc-nasdaq-pulm-to-ring-the-nasdaq-stock-market-opening-bell-pulm-20151222monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-two-october-conferences-insm-20181001monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-second-quarter-2018-financial-results-conference-call-on-thursday-august-2--insm-20180726monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-fda-advisory-committee-meeting-to-review-alis-as-a-treatment-for-ntm-lung-insm-20180615monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-three-june-conferences-insm-20180607monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-presentations-at-the-american-thoracic-society-2018-international-confere-insm-20180522monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-appoints-leo-lee-to-its-board-of-directors-insm-20180517monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-deutsche-bank-43rd-annual-health-care-conference-insm-20180501monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-first-quarter-2018-financial-results-conference-call-on-wednesday-may-2-201-insm-20180425monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-cowen-and-company-38th-annual-health-care-conference-insm-20180307monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insm-20180221monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-extends-alis-intellectual-property-protection-to-2035-with-issuance-of-ninth-u-s-pa-insm-20180220monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-fourth-quarter-and-full-year-2017-financial-results-conference-call-on-frid-insm-20180215monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-leerink-partners-7th-annual-global-healthcare-conference-insm-20180207monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-closing-of-public-offering-insm-20180126monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insm-20180124monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-pricing-of-public-offering-of-convertible-senior-notes-insm-20180124monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-nasdaq-37th-annual-investor-conference-insm-20171128monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insm-20171122monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-two-november-conferences-insm-20171108monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-third-quarter-2017-financial-results-conference-call-on-thursday-november-2-insm-20171025monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-two-september-investor-conferences-insm-20170919monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-closing-of-public-offering-insm-20170911monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-pricing-of-public-offering-of-common-stock-insm-20170907monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-second-quarter-2017-financial-results-conference-call-on-thursday-august-3--insm-20170727monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-analyst-and-investor-day-on-july-19-2017-insm-20170712monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-jmp-securities-life-sciences-conference-insm-20170613monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insm-20170608monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-deutsche-bank-42nd-annual-health-care-conference-insm-20170427monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-first-quarter-2017-financial-results-conference-call-on-wednesday-may-3-201-insm-20170426monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-cowen-and-company-37th-annual-health-care-conference-insm-20170228monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-fourth-quarter-and-year-end-2016-financial-results-conference-call-on-thurs-insm-20170216monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-inc-extends-arikayce-intellectual-property-protection-with-issuance-of-new-u-s-pate-insm-20170214monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-insm-20170104monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-participate-at-november-investor-conferences-insm-20161114monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-third-quarter-2016-financial-results-conference-call-on-thursday-november-3-insm-20161027monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-publication-of-phase-2-study-of-arikayce-in-treatment-refractory-nontuber-insm-20161018monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-worldwide-license-agreement-with-astrazeneca-for-oral-dpp1-inhibitor-insm-20161005monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-appoints-roger-adsett-as-chief-commercial-officer-insm-20160927monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-participate-at-september-investor-conferences-insm-20160908monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-upcoming-presentations-at-european-respiratory-society-2016-international-insm-20160831monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-second-quarter-2016-financial-results-insm-20160804monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-withdrawal-of-marketing-authorization-application-for-arikayce-in-europe-insm-20160608monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-bank-of-america-global-healthcare-conference-insm-20160509monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-first-quarter-2016-financial-results-insm-20160505monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-upcoming-presentations-at-the-american-thoracic-society-2016-internationa-insm-20160503monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-36th-annual-cowen-company-healthcare-conference-insm-20160302monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-fourth-quarter-2015-financial-results-insm-20160225monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-34th-annual-j-p-morgan-healthcare-conference-insm-20160105monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-piper-jaffray-27th-annual-healthcare-conference-insm-20151124monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-stifel-2015-healthcare-conference-insm-20151111monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-third-quarter-2015-financial-results-and-provides-business-update-insm-20151106monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-third-quarter-2015-financial-results-conference-call-on-friday-november-6-2-insm-20151029monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-upcoming-data-presentation-at-amcp-nexus-2015-insm-20151026monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-launches-comprehensive-educational-campaign-to-raise-awareness-of-ntm-lung-disease-insm-20151014monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-upcoming-data-presentations-at-infectious-disease-week-2015-insm-20151006monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-leerink-partners-rare-disease-roundtable-insm-20150923monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-upcoming-data-presentations-at-ers-2015-insm-20150922monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-upcoming-data-presentations-at-icaac-icc-2015-insm-20150914monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-second-quarter-2015-financial-results-and-provides-business-update-insm-20150806monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-second-quarter-2015-financial-results-conference-call-on-thursday-august-6--insm-20150728monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-td-cowen-45th-annual-healthcare-conference-argx-20250225monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-full-year-2024-financial-results-and-fourth-quarter-business-update-on-fe-argx-20250220monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-extraordinary-general-meeting-of-shareholders-on-september-8-2022-argx-20220728monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-positive-topline-results-from-phase-3-adapt-trial-of-efgartigimod-in-pati-argx-20200526monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-closing-of-u-s-public-offering-for-gross-proceeds-of-approximately-300-6--argx-20180921monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-raises-approximately-100-million-gross-proceeds-with-nasdaq-ipo-argx-20170518monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-that-staten-biotech-exercised-its-option-to-develop-therapeutic-simple-an-argx-20170306monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-cowen-co-37th-annual-health-care-conference-argx-20170228monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-extension-of-therapeutic-antibody-alliance-with-shire-argx-20170227monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-launches-phase-ii-proof-of-concept-study-of-argx-113-for-the-treatment-of-myastheni-argx-20170109monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-publication-of-seminal-data-supporting-the-therapeutic-potential-of-argx--argx-20161229monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-launches-phase-i-ii-study-of-argx-110-in-combination-with-azacitidine-in-newly-diag-argx-20161215monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-provide-updates-on-argx-113-and-argx-110-during-american-society-of-hematology-a-argx-20161202monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-upcoming-investor-conferences-argx-20161108monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-third-quarter-2016-financial-results-and-provides-business-update-argx-20161027monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-host-inaugural-r-d-day-and-webcast-on-september-22-2016-argx-20160915monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-second-quarter-business-update-and-half-year-2016-financial-results-argx-20160826monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-host-conference-call-webcast-to-report-second-quarter-2016-business-update-and-h-argx-20160819monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-wedbush-pacgrow-healthcare-conference-argx-20160810monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-initial-results-from-phase-1-multiple-ascending-dose-mad-study-of-argx-11-argx-20160630monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-presentation-of-updated-argx-110-phase-1-data-in-tcl-at-eha-2016-argx-20160610monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-successfully-closes-30-million-private-placement-argx-20160603monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-efficacy-and-expanded-safety-data-from-phase-1-trial-of-argx-111-argx-20160603monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-first-quarter-2016-financial-results-and-provides-business-update-argx-20160511monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-and-abbvie-to-collaborate-on-argx-115-against-novel-immuno-oncology-target-argx-20160421monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-s-partner-bird-rock-bio-demonstrates-potential-for-gerilimzumab-a-novel-simple-anti-argx-20160316monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-fourth-quarter-business-update-and-full-year-2015-financial-results-argx-20160311monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-host-conference-call-webcast-to-report-fourth-quarter-business-update-and-full-y-argx-20160303monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-home-member-state-selection-argx-20160226monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-opens-clinical-trial-sites-in-south-korea-for-argx-111-program-argx-20160218monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-the-leerink-partners-5th-annual-global-healthcare-conference-argx-20160205monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-receives-milestone-payment-in-leo-pharma-collaboration-argx-20160202monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-initial-results-from-a-phase-1-single-ascending-dose-study-of-argx-113-in-argx-20160106monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-host-workshop-and-webcast-announcing-topline-clinical-tcl-data-and-preclinical-a-argx-20151207monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-to-report-financial-results-for-the-third-quarter-ended-december-31-2025-and-provi-roiv-20260123monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-pro-roiv-20251027monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-to-report-financial-results-for-the-first-quarter-ended-june-30-2025-and-provide-b-roiv-20250728monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-to-report-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march-31--roiv-20250515monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-to-host-investor-webcast-at-8-00-am-et-on-wednesday-march-19-to-review-results-fro-roiv-20250318monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-to-report-financial-results-for-the-third-quarter-ended-december-31-2024-and-provi-roiv-20250129monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-to-report-financial-results-for-the-second-quarter-ended-september-30-2024-and-pro-roiv-20241029monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-to-report-financial-results-for-the-first-quarter-ended-june-30-2024-and-provide-b-roiv-20240725monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-to-report-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march-31--roiv-20240516monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-to-report-financial-results-for-the-third-quarter-ended-december-31-2023-and-provi-roiv-20240130monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-reports-financial-results-for-the-second-quarter-ended-september-30-2023-and-provi-roiv-20231113monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-announces-appointment-of-mayukh-sukhatme-to-its-board-of-directors-roiv-20231110monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-to-report-financial-results-for-the-second-quarter-ended-september-30-2023-and-pro-roiv-20231030monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-announces-positive-initial-imvt-1402-phase-1-sad-and-300-mg-subcutaneous-mad-resul-roiv-20230926monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-to-report-financial-results-for-the-quarter-ended-june-30-2023-and-provide-busines-roiv-20230803monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-ranks-no-25-on-fast-company-s-fifth-annual-list-of-the-100-best-workplaces-for-inn-roiv-20230711monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-to-report-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march-31--roiv-20230626monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-to-host-investor-call-at-8-00-am-et-on-thursday-june-22-to-review-results-from-the-roiv-20230621monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-to-host-investor-call-at-8-00-am-et-on-wednesday-march-15-to-review-results-from-a-roiv-202303142023-03-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-sciences-announces-change-to-its-board-of-directors-roiv-202302222023-02-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-sciences-announces-proposed-public-offering-of-common-shares-roiv-202302012023-02-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-to-report-financial-results-for-the-third-quarter-ended-december-31-2022-on-monday-roiv-202301302023-01-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-social-ventures-publishes-global-access-scorecard-to-guide-impact-investors-in-mak-roiv-20221128monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-sciences-to-report-financial-results-for-the-second-quarter-ended-september-30-202-roiv-20221018monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-to-participate-in-september-investor-events-roiv-20220830monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-sciences-to-report-financial-results-for-the-quarter-ended-june-30-2022-on-monday--roiv-20220803monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-and-pfizer-unveil-priovant-therapeutics-and-ongoing-registrational-studies-for-ora-roiv-20220628monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-sciences-to-report-financial-results-for-the-fourth-quarter-and-fiscal-year-ended--roiv-20220615monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-to-present-at-upcoming-investor-conferences-roiv-20220519monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-appoints-chief-development-officer-and-announces-multiple-collaborations-in-target-roiv-20220502monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-to-present-at-targeted-protein-degradation-conference-roiv-20220311monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-to-report-financial-results-for-the-quarter-ended-december-31-2021-on-monday-febru-roiv-20220207monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-to-present-at-upcoming-investor-conferences-roiv-20220125monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-licenses-splicing-modulator-and-announces-upcoming-presentation-at-40th-annual-j-p-roiv-20220105monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-to-report-financial-results-for-the-quarter-ended-september-30-2021-on-monday-nove-roiv-20211108monthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-acquires-sb742457-from-glaxosmithkline-roiv-20141223monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-dividend-of-0-63-per-share-ste-20260505monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-dividend-of-0-63-per-share-ste-20260128monthly0.5https://www.biopharmawatch.com/news/STE/steris-to-host-a-conference-call-for-fiscal-2026-first-quarter-results-on-august-7-2025-ste-20250722monthly0.5https://www.biopharmawatch.com/news/STE/steris-to-host-a-conference-call-for-fiscal-2025-fourth-quarter-and-full-year-financial-re-ste-20250422monthly0.5https://www.biopharmawatch.com/news/STE/steris-declares-dividend-of-0-57-per-share-ste-20250128monthly0.5https://www.biopharmawatch.com/news/STE/steris-to-host-a-conference-call-for-fiscal-2025-third-quarter-financial-results-on-februa-ste-20250122monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-outcome-of-ethylene-oxide-trial-ste-20250121monthly0.5https://www.biopharmawatch.com/news/STE/steris-declares-dividend-of-0-57-per-share-ste-20241030monthly0.5https://www.biopharmawatch.com/news/STE/steris-to-host-a-conference-call-for-fiscal-2025-second-quarter-financial-results-on-novem-ste-20241023monthly0.5https://www.biopharmawatch.com/news/STE/steris-to-present-at-the-morgan-stanley-healthcare-conference-ste-20240826monthly0.5https://www.biopharmawatch.com/news/STE/steris-raises-dividend-to-0-57-per-share-ste-20240731monthly0.5https://www.biopharmawatch.com/news/STE/steris-to-host-a-conference-call-for-fiscal-2025-first-quarter-financial-results-on-august-ste-20240723monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-dividend-of-0-52-per-share-ste-20240501monthly0.5https://www.biopharmawatch.com/news/STE/steris-to-host-a-conference-call-for-fiscal-2024-fourth-quarter-and-full-year-financial-re-ste-20240424monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-dividend-of-0-52-per-share-ste-20240130monthly0.5https://www.biopharmawatch.com/news/STE/steris-to-host-a-conference-call-for-fiscal-2024-third-quarter-financial-results-on-februa-ste-20240123monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-dividend-of-0-52-per-share-ste-20231031monthly0.5https://www.biopharmawatch.com/news/STE/steris-to-host-a-conference-call-for-fiscal-2024-second-quarter-financial-results-on-novem-ste-20231024monthly0.5https://www.biopharmawatch.com/news/STE/steris-to-present-at-the-morgan-stanley-healthcare-conference-ste-20230830monthly0.5https://www.biopharmawatch.com/news/STE/steris-completes-the-acquisition-of-surgical-instrumentation-assets-from-bd-ste-20230802monthly0.5https://www.biopharmawatch.com/news/STE/steris-raises-dividend-to-0-52-per-share-ste-20230726monthly0.5https://www.biopharmawatch.com/news/STE/steris-to-host-a-conference-call-for-fiscal-2024-first-quarter-financial-results-on-august-ste-20230719monthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-500-million-share-repurchase-authorization-and-declares-0-47-per-share-di-ste-202305032023-05-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STE/steris-to-host-a-conference-call-for-fiscal-2023-fourth-quarter-and-full-year-financial-re-ste-202304242023-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STE/steris-declares-0-47-per-share-dividend-ste-202302012023-02-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STE/steris-to-host-a-conference-call-for-fiscal-2023-third-quarter-financial-results-on-februa-ste-202301252023-01-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STE/steris-declares-0-47-per-share-dividend-ste-20221102monthly0.5https://www.biopharmawatch.com/news/STE/steris-to-host-a-conference-call-for-fiscal-2023-second-quarter-financial-results-on-novem-ste-20221025monthly0.5https://www.biopharmawatch.com/news/STE/steris-raises-dividend-to-0-47-per-share-ste-20220728monthly0.5https://www.biopharmawatch.com/news/STE/steris-to-host-a-conference-call-for-fiscal-2023-first-quarter-financial-results-on-august-ste-20220720monthly0.5https://www.biopharmawatch.com/news/STE/steris-declares-0-43-per-share-dividend-ste-20220504monthly0.5https://www.biopharmawatch.com/news/STE/steris-to-host-a-conference-call-for-fiscal-2022-fourth-quarter-and-full-year-financial-re-ste-20220425monthly0.5https://www.biopharmawatch.com/news/STE/steris-declares-0-43-per-share-dividend-ste-20220131monthly0.5https://www.biopharmawatch.com/news/STE/steris-to-host-a-conference-call-for-fiscal-2022-third-quarter-financial-results-on-februa-ste-20220125monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-44th-annual-j-p-morgan-healthcare-conference-rmd-20251218monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-inc-announces-results-for-the-fourth-quarter-of-fiscal-year-2025-rmd-20250731monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-to-report-fourth-quarter-fiscal-2025-earnings-on-july-31-2025-rmd-20250701monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-acquires-virtuox-rmd-20250501monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2025-rmd-20250423monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-names-salli-schwartz-as-chief-investor-relations-officer-rmd-20250421monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-small-easy-to-use-home-sleep-apnea-test-nightowl-now-available-across-the-rmd-20250403monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-to-report-third-quarter-fiscal-2025-earnings-on-april-23-2025-rmd-20250402monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-unveils-unified-brand-to-lead-the-global-sleep-and-health-technology-revolution-rmd-20250311monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-s-fifth-annual-global-sleep-survey-reveals-a-world-struggling-with-poor-sleep-rmd-20250226monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-inc-announces-results-for-the-second-quarter-of-fiscal-year-2025-rmd-20250130monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-to-report-second-quarter-fiscal-2025-earnings-on-january-30-2025-rmd-20250109monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-43rd-annual-j-p-morgan-healthcare-conference-rmd-20250106monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-ubs-global-healthcare-conference-rmd-20241105monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-inc-announces-results-for-the-first-quarter-of-fiscal-year-2025-rmd-20241024monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-to-report-first-quarter-fiscal-2025-earnings-on-october-24-2024-rmd-20241003monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-unveils-2030-strategy-to-drive-growth-profitability-and-shareholder-returns-rmd-20240930monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-enhances-cpap-therapy-with-its-first-fabric-mask-designed-to-make-it-easier-for-peo-rmd-20240930monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-unveils-new-collection-of-digital-and-personalized-solutions-designed-to-improve-sl-rmd-20240930monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-to-host-its-2024-investor-day-on-september-30-2024-at-the-new-york-stock-exchange-rmd-20240910monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-morgan-stanley-22nd-annual-global-healthcare-confere-rmd-20240828monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-expands-its-board-of-directors-and-appoints-healthcare-executive-and-seasoned-finan-rmd-20240815monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-inc-announces-results-for-the-fourth-quarter-of-fiscal-year-2024-rmd-20240801monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-to-report-fourth-quarter-fiscal-2024-earnings-on-august-1-2024-rmd-20240703monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-rbccm-global-healthcare-conference-rmd-20240507monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2024-rmd-20240425monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-to-report-third-quarter-fiscal-2024-earnings-on-april-25-2024-rmd-20240404monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-s-2024-global-sleep-survey-uncovers-a-world-in-sleep-crisis-rmd-20240315monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-s-new-aircurve-11-bilevel-devices-enable-healthcare-providers-to-make-informed-deci-rmd-20240212monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-inc-announces-results-for-the-second-quarter-of-fiscal-year-2024-rmd-20240124monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-to-report-second-quarter-fiscal-2024-earnings-on-january-24-2024-rmd-20240103monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-42nd-annual-j-p-morgan-healthcare-conference-rmd-20231227monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-notifies-customers-about-updated-instructions-and-labeling-for-masks-with-magnets-d-rmd-20231220monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-secures-significant-victory-in-patent-fight-against-new-york-university-rmd-20231211monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-adopts-new-operating-model-to-accelerate-long-term-growth-rmd-20231109monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-inc-announces-results-for-the-first-quarter-of-fiscal-year-2024-rmd-20231026monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-to-report-first-quarter-fiscal-2024-earnings-on-october-26-2023-rmd-20231005monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-upcoming-conferences-rmd-20230905monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-inc-announces-results-for-the-fourth-quarter-of-fiscal-year-2023-rmd-20230803monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-to-report-fourth-quarter-fiscal-2023-earnings-on-august-3-2023-rmd-20230706monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-acquires-somnoware-a-leader-in-digital-sleep-and-respiratory-care-diagnostics-softw-rmd-20230705monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-goldman-sachs-44th-annual-global-healthcare-conferen-rmd-20230605monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-appoints-michael-rider-its-next-global-general-counsel-dawn-haake-its-first-chief-q-rmd-202305022023-05-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2023-rmd-202304272023-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-to-report-third-quarter-fiscal-2023-earnings-on-april-27-2023-rmd-202304062023-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-chief-administrative-officer-and-global-general-counsel-to-retire-rmd-202303302023-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-2023-keybanc-life-sciences-medtech-investor-forum-rmd-202303152023-03-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-s-annual-global-sleep-survey-finds-8-in-10-adults-experience-signs-of-disruption-re-rmd-202303132023-03-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-oppenheimer-33rd-annual-healthcare-conference-rmd-202303072023-03-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-appoints-michael-farrell-as-chair-of-its-board-of-directors-peter-farrell-to-become-rmd-202301262023-01-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-inc-announces-results-for-the-second-quarter-of-fiscal-year-2023-rmd-202301262023-01-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-to-report-second-quarter-fiscal-2023-earnings-on-january-26-2023-rmd-202301122023-01-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-41st-annual-j-p-morgan-healthcare-conference-rmd-202301022023-01-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-completes-acquisition-of-medifox-dan-a-german-leader-in-out-of-hospital-care-manage-rmd-20221122monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-opens-manufacturing-centre-in-singapore-expanding-manufacturing-footprint-to-suppor-rmd-20221116monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-inc-announces-results-for-the-first-quarter-of-fiscal-year-2023-rmd-20221027monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-to-report-first-quarter-fiscal-2023-earnings-on-october-27-2022-rmd-20221013monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-bank-of-america-global-healthcare-conference-rmd-20220907monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-20th-annual-morgan-stanley-global-healthcare-confere-rmd-20220906monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-inc-announces-results-for-the-fourth-quarter-of-fiscal-year-2022-rmd-20220811monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-acquires-leipzig-based-mementor-with-insomnia-digital-health-solution-somnio-rmd-20220802monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-to-report-fourth-quarter-fiscal-2022-earnings-on-august-11-2022-rmd-20220714monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-promotes-lucile-blaise-to-president-sleep-respiratory-care-rmd-20220628monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-to-acquire-medifox-dan-a-german-leader-in-out-of-hospital-software-solutions-rmd-20220614monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-43rd-annual-goldman-sachs-global-healthcare-conferen-rmd-20220607monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-42nd-annual-william-blair-growth-stock-conference-rmd-20220601monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-38th-annual-bernstein-strategic-decisions-conference-rmd-20220525monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-leadership-change-rmd-20220505monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2022-rmd-20220428monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-24th-annual-macquarie-australia-conference-rmd-20220427monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-to-report-third-quarter-fiscal-2022-earnings-on-april-28-2022-rmd-20220407monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-keybanc-capital-markets-life-sciences-medtech-invest-rmd-20220317monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-s-global-sleep-surveys-reveal-what-s-keeping-us-up-at-night-aim-to-bring-awareness--rmd-20220314monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-oppenheimer-32nd-annual-healthcare-conference-rmd-20220310monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-citi-healthcare-conference-rmd-20220216monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-welcomes-urvashi-tyagi-as-new-chief-technology-officer-rmd-20220201monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-inc-announces-results-for-the-second-quarter-of-fiscal-year-2022-rmd-20220127monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-to-report-second-quarter-fiscal-2022-earnings-on-january-27-2022-rmd-20220106monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-40th-annual-j-p-morgan-healthcare-conference-rmd-20220103monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-goldman-sachs-14th-annual-healthcare-ceos-unscripted-rmd-20211230monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-elects-health-tech-leaders-desney-tan-and-john-hernandez-to-its-board-of-directors-rmd-20211119monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-credit-suisse-30th-annual-healthcare-conference-rmd-20211103monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-inc-announces-results-for-the-first-quarter-of-fiscal-year-2022-rmd-20211028monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-to-report-first-quarter-fiscal-2022-earnings-on-october-28-2021-rmd-20211007monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-bank-of-america-global-healthcare-conference-rmd-20210908monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-morgan-stanley-19th-annual-global-healthcare-confere-rmd-20210902monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-saas-leadership-change-rmd-20210825monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-launches-airsense-11-pap-series-advancing-digital-health-in-sleep-apnea-treatment-rmd-20210816monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-inc-announces-results-for-the-fourth-quarter-of-fiscal-year-2021-rmd-20210805monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-to-report-fourth-quarter-fiscal-2021-earnings-on-august-5-2021-rmd-20210715monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-goldman-sachs-42nd-annual-global-healthcare-conferen-rmd-20210602monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-william-blair-41st-annual-growth-stock-conference-rmd-20210525monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2021-rmd-20210429monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-announces-participation-in-the-23rd-annual-macquarie-australia-conference-rmd-20210427monthly0.5https://www.biopharmawatch.com/news/RMD/resmed-to-report-third-quarter-fiscal-2021-earnings-on-april-29-2021-rmd-20210408monthly0.5https://www.biopharmawatch.com/news/EW/edwards-ew-alert-bragar-eagel-squire-p-c-is-investigating-edwards-lifesciences-corporation-ew-20250916monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-investors-company-investigated-by-the-portnoy-law-firm-ew-20250814monthly0.5https://www.biopharmawatch.com/news/EW/edwards-ew-alert-bragar-eagel-squire-p-c-is-investigating-edwards-lifesciences-corporation-ew-20250813monthly0.5https://www.biopharmawatch.com/news/EW/edwards-alert-bragar-eagel-squire-p-c-is-investigating-edwards-lifesciences-corp-on-behalf-ew-20241218monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-ew-faces-investor-class-action-lawsuit-over-tavm-platform-disclosures-ew-20241212monthly0.5https://www.biopharmawatch.com/news/EW/edwards-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-be-ew-20241211monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-ew-faces-investor-class-action-lawsuit-over-tavm-platform-disclosures-ew-20241209monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-nyse-ew-investor-alert-bernstein-liebhard-llp-reminds-edw-ew-20241209monthly0.5https://www.biopharmawatch.com/news/EW/edwards-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-be-ew-20241206monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-investors-reminder-kessler-topaz-meltzer-check-llp-remind-ew-20241205monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-securities-fraud-class-action-lawsuit-pending-contact-the-ew-20241204monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-ew-faces-investor-class-action-lawsuit-over-tavm-platform-disclosures-ew-20241204monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-investors-please-contact-the-portnoy-law-firm-to-recover--ew-20241202monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-nyse-ew-investor-alert-bernstein-liebhard-llp-reminds-edw-ew-20241202monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-ew-investors-december-13-2024-filing-deadline-in-securiti-ew-20241129monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-ew-faces-investor-class-action-over-loss-of-16-billion-of-market-capi-ew-20241128monthly0.5https://www.biopharmawatch.com/news/EW/edwards-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-be-ew-20241126monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-ew-faces-investor-class-action-over-loss-of-16-billion-of-market-capi-ew-20241125monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-nyse-ew-investor-alert-bernstein-liebhard-llp-reminds-edw-ew-20241125monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-ew-faces-investor-class-action-over-loss-of-16-billion-of-market-capi-ew-20241121monthly0.5https://www.biopharmawatch.com/news/EW/edwards-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-be-ew-20241120monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-nyse-ew-investor-alert-bernstein-liebhard-llp-reminds-edw-ew-20241119monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-ew-faces-investor-class-action-over-loss-of-16-billion-of-market-capi-ew-20241115monthly0.5https://www.biopharmawatch.com/news/EW/edwards-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-be-ew-20241113monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-sued-for-securities-law-violations-contact-the-gross-law--ew-20241112monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-nyse-ew-investor-alert-bernstein-liebhard-llp-reminds-edw-ew-20241112monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-ew-faces-investor-class-action-over-loss-of-16-billion-of-market-capi-ew-20241111monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-ew-faces-investor-class-action-over-loss-of-16-billion-of-market-capi-ew-20241107monthly0.5https://www.biopharmawatch.com/news/EW/edwards-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-be-ew-20241107monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-nyse-ew-investor-alert-bernstein-liebhard-llp-reminds-edw-ew-20241104monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-has-been-sued-for-securities-fraud-after-stock-plummets-31-contact-th-ew-20241102monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-ew-investors-december-13-2024-filing-deadline-in-securiti-ew-20241030monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-ew-faces-investor-class-action-over-loss-of-16-billion-of-market-capi-ew-20241028monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-nyse-ew-investor-alert-bernstein-liebhard-llp-reminds-edw-ew-20241028monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-class-action-the-gross-law-firm-reminds-edwards-investors-ew-20241023monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-class-action-alert-shareholder-rights-law-firm-robbins-ll-ew-20241021monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-nyse-ew-investor-alert-bernstein-liebhard-llp-reminds-edw-ew-20241021monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-nyse-ew-investor-alert-investors-with-large-losses-in-edw-ew-20241016monthly0.5https://www.biopharmawatch.com/news/EW/edwards-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-ew-20241016monthly0.5https://www.biopharmawatch.com/news/EW/edwards-hemosphere-platform-receives-expanded-use-indication-from-health-canada-in-treatme-ew-20200427monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-choses-selectica-smartcontracts-r-solution-ew-20150629monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-lead-rise-in-european-tissue-heart-valve-market-ew-20150127monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-boston-scientific-and-medtronic-fuel-double-digit-growth-in-the-europ-ew-20140512monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corp-shareholder-alert-levi-korsinsky-llp-reminds-investors-of-class--ew-20131029monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-shareholder-alert-levi-korsinsky-llp-announces-class-acti-ew-20131015monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-corporation-shareholder-alert-levi-korsinsky-llp-announces-class-acti-ew-20131007monthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-fot-ew-20130920monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5-mdgl-20260604monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5-mdgl-20260507monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5-mdgl-20260421monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5-mdgl-20260305monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-mdgl-20260219monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5-mdgl-20251218monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5-mdgl-20251204monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5-mdgl-20251120monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-participation-at-three-upcoming-investor-conferences-mdgl-20251117monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-release-third-quarter-2025-financial-results-and-host-webcast--mdgl-20251022monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5-mdgl-20251021monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5-mdgl-20251007monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5-mdgl-20250918monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5-mdgl-20250904monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5-mdgl-20250821monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-receives-european-commission-approval-for-rezdiffra-resmetirom-for-the-treatment--mdgl-20250819monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-confer-mdgl-20250811monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5-mdgl-20250807monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-corpor-mdgl-20250805monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-release-second-quarter-2025-financial-results-and-host-webcast-mdgl-20250725monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5-mdgl-20250716monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-receives-notice-of-allowance-from-u-s-patent-and-trademark-office-mdgl-20250716monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-receives-positive-chmp-opinion-for-resmetirom-rezdiffra-for-the-treatment-of-mash-mdgl-20250620monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5-mdgl-20250617monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-participate-in-the-46th-annual-global-goldman-sachs-health-car-mdgl-20250602monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-announces-new-clinical-data-demonstrating-rezdiffra-resmetirom-significantly-impr-mdgl-20250510monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-to-present-late-breaking-resmetirom-data-in-patients-with-compensated-mash-cirrho-mdgl-20250429monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-release-first-quarter-2025-financial-results-and-host-webcast--mdgl-20250418monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-company-founder-rebecca-taub-m-d-to-become-senior-scien-mdgl-20250416monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-announces-new-two-year-data-from-the-compensated-mash-cirrhosis-arm-of-the-maestr-mdgl-20250226monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-participate-in-the-45th-annual-td-cowen-health-care-conference-mdgl-20250221monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-release-fourth-quarter-and-full-year-2024-financial-results-an-mdgl-20250212monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-preliminary-fourth-quarter-and-full-year-2024-net-sales-mdgl-20250113monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-mdgl-20250103monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-inc-announces-participation-at-three-upcoming-investor-conference-mdgl-20241106monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-present-multiple-rezdiffra-resmetirom-abstracts-in-nash-mash-a-mdgl-20241030monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-completes-enrollment-of-clinical-outcomes-study-of-resmetirom-in--mdgl-20241021monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-release-third-quarter-2024-financial-results-and-host-webcast--mdgl-20241018monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-participate-in-the-h-c-wainwright-co-8th-annual-mash-investor--mdgl-20241002monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-appoints-dr-michael-r-charlton-as-senior-vice-president-clinical--mdgl-20241001monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-publication-of-positive-health-related-quality-of-life--mdgl-20240930monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-inc-to-participate-in-the-morgan-stanley-22nd-annual-global-healt-mdgl-20240826monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-appoints-shannon-kelley-as-general-counsel-mdgl-20240802monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-release-second-quarter-2024-financial-results-and-host-webcast-mdgl-20240724monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-new-data-from-the-phase-3-maestro-nash-study-of-rezdiff-mdgl-20240606monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-participate-in-the-goldman-sachs-45th-annual-global-healthcare-mdgl-20240605monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-present-multiple-rezdiffra-resmetirom-and-health-economics-out-mdgl-20240529monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-statement-on-the-passing-of-dr-stephen-harrison-mdgl-20240424monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-release-first-quarter-2024-financial-results-and-host-webcast--mdgl-20240423monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mdgl-20240416monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-u-s-availability-of-rezdiffra-resmetirom-for-the-treatm-mdgl-20240409monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mdgl-20240403monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-pricing-of-upsized-600-million-public-offering-mdgl-20240319monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-proposed-public-offering-mdgl-20240318monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mdgl-20240306monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-ema-validation-of-its-marketing-authorization-applicati-mdgl-20240305monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-appoints-mardi-c-dier-as-chief-financial-officer-mdgl-20240228monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mdgl-20240221monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-publication-of-the-phase-3-maestro-nash-trial-of-resmet-mdgl-20240208monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mdgl-20240206monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-additions-to-its-leadership-team-mdgl-20240129monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mdgl-20240122monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-presents-five-health-economics-outcomes-research-abstracts-at-the-mdgl-20240104monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-mdgl-20240103monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mdgl-20231222monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mdgl-20231127monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-appoints-ronald-filippo-as-chief-information-officer-mdgl-20231121monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mdgl-20231115monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-presents-new-data-from-the-phase-3-maestro-nash-trial-demonstrati-mdgl-20231110monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-appoints-carole-huntsman-as-chief-commercial-officer-mdgl-20231110monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-participation-at-three-upcoming-investor-conferences-mdgl-20231102monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mdgl-20231012monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-pricing-of-500-million-public-offering-mdgl-20230929monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-proposed-public-offering-mdgl-20230928monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mdgl-20230914monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-appoints-bill-sibold-as-chief-executive-officer-mdgl-20230911monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-presents-phase-3-maestro-nash-data-during-the-opening-general-ses-mdgl-20230622monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-supports-international-nash-day-on-june-8-mdgl-20230606monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-participation-at-two-upcoming-investor-conferences-mdgl-20230601monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-participate-in-the-jmp-securities-life-sciences-conference-mdgl-202305112023-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-receives-breakthrough-therapy-designation-from-fda-for-resmetirom-and-completes-e-mdgl-202304182023-04-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-participation-at-three-upcoming-investor-conferences-mdgl-202302082023-02-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-announces-additional-positive-results-from-the-pivotal-phase-3-maestro-nash-clini-mdgl-202301062023-01-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-announces-positive-topline-results-from-the-pivotal-phase-3-maestro-nash-clinical-mdgl-20221219monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-announce-topline-results-from-the-phase-3-maestro-nash-study-o-mdgl-20221218monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-participate-in-the-h-c-wainwright-24th-annual-global-investmen-mdgl-20220907monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-initiates-the-maestro-nash-outcomes-study-evaluating-resmetirom-f-mdgl-20220831monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-presents-late-breaking-phase-3-nash-data-and-multiple-oral-abstra-mdgl-20220625monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-supports-international-nash-day-on-june-9-mdgl-20220606monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-participation-at-three-upcoming-investor-conferences-mdgl-20220602monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-participation-at-two-upcoming-investor-conferences-mdgl-20220517monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-announce-first-quarter-2022-financial-results-and-provide-clin-mdgl-20220428monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-present-at-the-oppenheimer-healthcare-conference-mdgl-20220309monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-announce-topline-results-from-the-phase-3-maestro-nafld-1-stud-mdgl-20220130monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-provides-update-on-timeline-for-topline-results-from-the-phase-3-maestro-nafld-1--mdgl-20211230monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-participation-at-two-upcoming-virtual-investor-conferen-mdgl-20211123monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-support-of-fatty-liver-foundation-s-screening-fund-to-i-mdgl-20211004monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-offers-patients-resmetirom-in-a-planned-open-label-active-treatme-mdgl-20210713monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-completes-enrollment-of-the-52-week-liver-biopsy-patient-populati-mdgl-20210630monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-presentation-of-positive-clinical-data-of-resmetirom-fr-mdgl-20210625monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-participation-at-two-upcoming-virtual-investor-conferen-mdgl-20210608monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-participate-in-ubs-global-healthcare-virtual-conference-mdgl-20210521monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-present-at-rbc-capital-markets-virtual-2021-global-healthcare--mdgl-20210518monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-highlights-presentations-at-the-liver-meeting-digital-experience--mdgl-20201113monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-three-abstracts-accepted-by-the-liver-meeting-digital-e-mdgl-20201001monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-exceeds-target-enrollment-in-phase-3-maestro-nafld-1-trial-mdgl-20200903monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-present-secondary-analyses-of-data-from-phase-2-nash-study-of--mdgl-20200826monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-maestro-phase-3-nash-trials-continue-without-protocol-modifications-new-data-demo-mdgl-20200414monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-first-patient-dosed-in-maestro-nafld-1-a-second-phase-3-mdgl-20191218monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-pricing-of-secondary-offering-mdgl-20191211monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-secondary-offering-of-1-200-000-shares-of-common-stock-mdgl-20191210monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-publication-in-the-lancet-of-positive-phase-2-results-f-mdgl-20191111monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-promotes-rebecca-taub-m-d-chief-medical-officer-and-executive-vic-mdgl-20190711monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-appointment-of-jim-daly-to-board-of-directors-mdgl-20190702monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-present-at-upcoming-investment-conferences-mdgl-20190604monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-to-present-additional-analyses-of-data-from-the-phase-2-nash-stud-mdgl-20190408monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-initiates-phase-3-multinational-double-blind-randomized-placebo-c-mdgl-20190328monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-prices-public-offering-of-common-stock-mdgl-20180607monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-proposed-public-offering-of-common-stock-mdgl-20180605monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-s-mgl-3196-achieves-primary-endpoint-in-patients-with-heterozygous-familial-hyper-mdgl-20180208monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-announces-acceptance-of-mgl-3196-abstract-for-a-main-plenary-presentation-at-the--mdgl-20180130monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-prices-public-offering-of-common-stock-mdgl-20171219monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-proposed-public-offering-of-common-stock-mdgl-20171218monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-s-mgl-3196-achieves-primary-endpoint-in-patients-with-biopsy-proven-non-alcoholic-mdgl-20171206monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-positive-outcome-from-pre-planned-dsmb-safety-review-an-mdgl-20170919monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-completes-enrollment-in-phase-2-proof-of-concept-study-with-mgl-3-mdgl-20170801monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-35-million-private-placement-offering-mdgl-20170621monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-the-initiation-of-a-phase-2-study-of-mgl-3196-in-patien-mdgl-20170223monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-reports-third-quarter-2016-financial-results-mdgl-20161114monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-the-initiation-of-a-phase-2-study-of-mgl-3196-in-patien-mdgl-20161020monthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-and-tarveda-therapeutics-announce-exclusive-license-agreement-for-mdgl-20160919monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20260508monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20260422monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20260320monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20260127monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-to-participate-in-december-investor-conferences-bbio-20251125monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20251119monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-to-report-phase-3-results-for-small-molecule-bbp-418-in-lgmd2i-r9-fortify-study--bbio-20251024monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-to-present-additional-cardiovascular-outcomes-data-from-attribute-cm-at-the-hfsa-bbio-20250922monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20250910monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesda-bbio-20250903monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-to-present-phase-2-proof-of-concept-data-for-encaleret-in-post-surgical-hypopara-bbio-20250902monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-to-participate-in-september-investor-conferences-bbio-20250827monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-to-present-additional-open-label-extension-data-from-attribute-cm-at-esc-congres-bbio-20250825monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-reports-second-quarter-2025-financial-results-and-business-updates-bbio-20250805monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-to-host-second-quarter-2025-financial-results-conference-call-on-tuesday-august--bbio-20250722monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-raises-300-million-through-partial-capped-monetization-of-beyonttra-european-roy-bbio-20250630monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-to-host-limb-girdle-muscular-dystrophy-type-2i-r9-investor-webinar-on-friday-jul-bbio-20250626monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-to-participate-in-the-goldman-sachs-46th-annual-global-healthcare-conference-202-bbio-20250602monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20250514monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-to-present-clinical-outcomes-quality-of-life-measures-and-incidence-of-atrial-fi-bbio-20250512monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-to-participate-in-the-bank-of-america-merrill-lynch-global-healthcare-conference-bbio-20250507monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-reports-first-quarter-2025-financial-results-and-business-updates-bbio-20250429monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-to-host-first-quarter-2025-financial-results-conference-call-on-tuesday-april-29-bbio-20250422monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20250411monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-to-present-cardiovascular-outcomes-data-in-patients-with-variant-and-wild-type-t-bbio-20250324monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20250321monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-prices-offering-of-500-million-convertible-senior-notes-due-2031-to-refinance-se-bbio-20250226monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-publication-in-the-new-england-journal-of-medicine-of-phase-2-p-bbio-20241118monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-announces-publication-of-case-study-exploring-portfolio-theory-s-impact-on-biome-bbio-20241105monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-shares-positive-data-from-high-dose-cohort-of-phase-1-2-canaspire-study-of-gene--bbio-20241024monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-to-present-outcomes-data-through-42-months-from-the-open-label-extension-of-attr-bbio-20241003monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-completes-enrollment-of-fortify-phase-3-registrational-study-of-bbp-418-in-limb--bbio-20240930monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-shares-recurrent-event-analysis-of-attribute-cm-demonstrating-a-42-reduction-by--bbio-20240927monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-announces-infigratinib-is-the-first-ever-investigational-therapeutic-option-for--bbio-20240917monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-receives-fda-s-regenerative-medicine-advanced-therapy-rmat-designation-for-bbp-8-bbio-20240910monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20240906monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-shares-data-on-serum-ttr-increase-when-switching-participants-from-placebo-and-t-bbio-20240830monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-to-present-additional-analyses-from-the-phase-3-attribute-cm-trial-of-acoramidis-bbio-20240829monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-participate-in-september-investor-events-bbio-20240828monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-partners-with-leading-cardiovascular-data-science-lab-cards-lab-to-improve-trans-bbio-20240826monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-launches-myachonjourney-a-new-resource-for-families-navigating-achondroplasia-bbio-20240819monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20240808monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20240705monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-surpasses-interim-analysis-enrollment-target-and-receives-u-s-fda-rare-pe-bbio-20240618monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20240610monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-participate-in-the-45th-annual-goldman-sachs-global-healthcare-confere-bbio-20240606monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-to-host-call-on-month-12-and-18-phase-2-cohort-5-results-of-oral-infigratinib-in-bbio-20240603monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-present-additional-analyses-from-the-phase-3-attribute-cm-study-of-aco-bbio-20240524monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20240515monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-participate-in-the-bank-of-america-merrill-lynch-global-healthcare-con-bbio-20240514monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-presents-additional-data-and-analyses-from-its-phase-3-attribute-cm-study-bbio-20240513monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-launches-bridgebio-oncology-therapeutics-bbot-with-200m-of-private-external-capi-bbio-20240502monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20240410monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-presents-cardiac-magnetic-resonance-cmr-imaging-evidence-consistent-with--bbio-20240407monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20240320monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-pricing-of-public-offering-of-common-stock-bbio-20240306monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-and-bayer-announce-european-licensing-agreement-for-acoramidis-in-attr-cm-bbio-20240304monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-and-kyowa-kirin-announce-partnership-with-an-upfront-payment-of-100-milli-bbio-20240207monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20240206monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-u-s-food-and-drug-administration-fda-acceptance-of-new-drug-app-bbio-20240205monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-announces-first-child-dosed-in-propel-3-its-phase-3-clinical-trial-for-infigrati-bbio-20231213monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20231208monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-submission-of-new-drug-application-nda-to-u-s-food-and-drug-adm-bbio-20231205monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-presents-additional-clinical-outcomes-data-from-the-phase-3-attribute-cm--bbio-20231112monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-present-additional-data-from-the-phase-3-attribute-cm-study-in-patient-bbio-20231109monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20231108monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20231011monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-new-england-journal-of-medicine-publication-of-positive-encaler-bbio-20231010monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-shares-positive-long-term-data-from-an-ongoing-phase-2-study-which-suppor-bbio-20231009monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-and-resilience-announce-strategic-multi-year-partnership-to-advance-bbp-631-bbp--bbio-20231003monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20230908monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-participate-in-the-morgan-stanley-21st-annual-global-healthcare-confer-bbio-20230907monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-positive-feedback-from-the-u-s-fda-and-eu-ema-on-the-regulatory-bbio-20230906monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-presents-detailed-positive-results-from-phase-3-attribute-cm-study-of-acoramidis-bbio-20230827monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-present-detailed-results-from-the-phase-3-attribute-study-in-patients--bbio-20230824monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20230804monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-opportunity-for-accelerated-approval-pathway-in-limb-girdle-mus-bbio-20230731monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20230718monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-to-host-investor-call-to-share-topline-30-month-results-from-the-phase-3-attribu-bbio-20230714monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-presents-updated-six-month-results-from-its-phase-2-cohort-5-trial-of-inf-bbio-20230620monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20230613monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-present-updated-six-month-results-from-its-phase-2-cohort-5-study-of-i-bbio-20230608monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-presents-updated-encouraging-clinical-and-biomarker-data-from-its-bbp-812-bbio-20230522monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-pro-bbio-202305152023-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-202305112023-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-participate-in-the-bank-of-america-merrill-lynch-global-healthcare-con-bbio-202304272023-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-202304112023-04-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-202304072023-04-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-first-lung-cancer-patient-dosed-in-phase-1-trial-for-shp2-inhib-bbio-202303232023-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-shares-preliminary-findings-on-novel-bioassay-measuring-glycosylated-alph-bbio-202303212023-03-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-present-preliminary-findings-on-its-novel-bioassay-measuring-glycosyla-bbio-202303172023-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-pricing-of-public-offering-of-common-stock-bbio-202303082023-03-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-initiates-calibrate-a-pivotal-phase-3-study-of-encaleret-in-autosomal-dom-bbio-20221222monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-participate-in-november-investor-events-bbio-20221109monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-presents-12-month-results-from-phase-2-study-of-bbp-418-in-limb-girdle-mu-bbio-20221014monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-presents-updated-positive-data-from-its-bbp-812-canavan-disease-gene-ther-bbio-20221013monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-first-lung-cancer-patient-dosed-in-phase-1-2-trial-and-us-fda-f-bbio-20221011monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-present-new-data-on-its-novel-approaches-to-ras-driven-cancers-at-the--bbio-20221007monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-and-sentynl-therapeutics-receive-marketing-authorization-in-the-eu-for-nu-bbio-20220920monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-participate-in-september-investor-events-bbio-20220906monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-dosing-of-first-patient-in-phase-1-trial-of-bbp-671-a-potential-bbio-20220818monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-sentynl-therapeutics-and-medison-pharma-announce-approval-in-israel-for-n-bbio-20220810monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-positive-interim-results-from-a-phase-2-trial-of-infigratinib-i-bbio-20220726monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-and-sentynl-therapeutics-receive-positive-chmp-opinion-for-nulibry-fosden-bbio-20220725monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-academic-collaboration-with-baylor-college-of-medicine-to-advan-bbio-20220721monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-founding-affiliation-with-bakar-labs-incubator-at-uc-berkeley-s-bbio-20220721monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-positive-phase-1-data-and-phase-2-3-trial-design-for-bbp-711-a--bbio-20220627monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-early-positive-data-for-bbp-812-its-investigational-aav9-gene-t-bbio-20220622monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-shares-positive-phase-2b-data-and-announces-pivotal-study-design-for-phas-bbio-20220613monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-affiliate-venthera-presents-preliminary-results-from-clinical-trial-of-vt-bbio-20220610monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-present-phase-2b-data-and-pivotal-phase-3-study-design-of-encaleret-in-bbio-20220609monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-participate-in-june-investor-events-bbio-20220606monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-presents-positive-phase-1-data-in-healthy-volunteers-advancing-developmen-bbio-20220526monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-affiliate-phoenix-tissue-repair-announces-positive-results-from-phase-2-t-bbio-20220520monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-participate-in-may-investor-events-bbio-20220517monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-participate-in-the-bank-of-america-securities-healthcare-conference-bbio-20220510monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-presents-updated-results-from-phase-2-open-label-extension-study-of-acora-bbio-20220403monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-present-updated-results-from-phase-2-open-label-extension-study-of-aco-bbio-20220328monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20211210monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-and-helsinn-group-announce-strategic-collaboration-to-co-develop-and-co-c-bbio-20211119monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20210614monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-receives-fda-fast-track-designation-for-encaleret-for-the-treatment-of-au-bbio-20210601monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-s-affiliate-qed-therapeutics-and-partner-helsinn-group-announce-fda-appro-bbio-20210528monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20210514monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-receives-fda-fast-track-designation-for-investigational-gene-therapy-for--bbio-20210514monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-reports-first-quarter-2021-financial-results-and-business-update-bbio-20210506monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-and-the-university-of-california-san-diego-announce-collaboration-to-adva-bbio-20210413monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-and-uc-davis-establish-collaboration-to-transform-research-into-poten-bbio-20210413monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-and-roswell-park-establish-collaboration-to-translate-pioneering-rese-bbio-20210413monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-and-oregon-health-science-university-establish-collaboration-to-trans-bbio-20210413monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-and-the-lundquist-institute-collaborate-to-advance-treatments-for-gen-bbio-20210413monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-and-glyconet-initiate-collaboration-to-discover-potential-treatments--bbio-20210413monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-and-brown-university-announce-partnership-to-drive-the-advancement-of-aca-bbio-20210413monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20210406monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-s-affiliate-qed-therapeutics-and-helsinn-group-announce-strategic-collabo-bbio-20210331monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-proof-of-concept-data-of-encaleret-in-adh1-at-the-endocrine-soc-bbio-20210320monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20210302monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-and-affiliate-origin-biosciences-announce-fda-approval-of-nulibry-fosdeno-bbio-20210228monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-announce-proof-of-concept-data-from-adh1-at-the-endocrine-society-s-20-bbio-20210224monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-and-affiliate-ml-bio-solutions-announce-dosing-of-first-patient-in-phase--bbio-20210219monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-announces-pricing-of-secondary-offering-of-common-stock-bbio-20210212monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20210205monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-and-affiliate-venthera-announce-dosing-of-first-patient-in-phase-1-2-clin-bbio-20210202monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-and-maze-therapeutics-establish-joint-venture-to-advance-precision-medici-bbio-20201207monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20201204monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-and-affiliate-qed-therapeutics-announce-fda-acceptance-of-new-drug-applic-bbio-20201201monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-and-affiliate-navire-pharma-announce-dosing-of-first-patient-in-phase-1-c-bbio-20201113monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20201104monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-and-affiliate-phoenix-tissue-repair-announce-first-patient-dosing-in-phas-bbio-20201027monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-and-the-university-of-colorado-anschutz-medical-campus-collaborate-to-bbio-20201021monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-and-affiliate-origin-biosciences-announces-fda-acceptance-of-its-new-drug-bbio-20200929monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-host-virtual-r-d-day-on-september-29-2020-bbio-20200922monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-s-calcilytix-therapeutics-initiates-phase-2-study-of-encaleret-for-autoso-bbio-20200921monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20200903monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20200812monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-expands-reach-into-china-and-other-major-asian-markets-through-strategic--bbio-20200811monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-s-qed-therapeutics-doses-first-child-in-phase-2-clinical-trial-of-the-inv-bbio-20200715monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-s-phoenix-tissue-repair-to-highlight-interim-phase-1-2-study-data-in-a-pr-bbio-20200710monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20200706monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-and-university-of-florida-establish-collaboration-to-advance-therapies-fo-bbio-20200618monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-enters-into-collaboration-agreement-with-johns-hopkins-university-to--bbio-20200618monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-s-ml-bio-solutions-announces-dosing-of-first-subject-in-phase-1-clinical--bbio-20200611monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20200605monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-s-qed-therapeutics-presents-data-on-infigratinib-in-cholangiocarcinoma-an-bbio-20200529monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-s-phoenix-tissue-repair-provides-updates-to-its-recessive-dystrophic-epid-bbio-20200513monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-se-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-more-informatio-bntx-20260310monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-se-nasdaq-bntx-deadline-alert-bernstein-liebhard-llp-reminds-investors-of-the-dea-bntx-20240311monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-deadline-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-laws-bntx-20240309monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-se-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-march-12--bntx-20240304monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-se-nasdaq-bntx-deadline-alert-bernstein-liebhard-llp-reminds-investors-of-the-dea-bntx-20240304monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-se-sued-for-securities-law-violations-contact-the-gross-law-firm-before-march-12--bntx-20240228monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-se-nasdaq-bntx-deadline-alert-bernstein-liebhard-llp-reminds-investors-of-the-dea-bntx-20240226monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-shareholder-notice-faruqi-faruqi-securities-litigation-partner-james-josh-wilson--bntx-20240223monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-se-nasdaq-bntx-deadline-alert-bernstein-liebhard-llp-reminds-investors-of-the-dea-bntx-20240220monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-investor-deadline-approaching-faruqi-faruqi-llp-securities-litigation-partner-jam-bntx-20240215monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-se-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-march-12--bntx-20240214monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-se-nasdaq-bntx-deadline-alert-bernstein-liebhard-llp-reminds-investors-of-the-dea-bntx-20240213monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-investor-deadline-approaching-faruqi-faruqi-securities-litigation-partner-james-j-bntx-20240208monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-se-nasdaq-bntx-deadline-alert-bernstein-liebhard-llp-reminds-investors-of-the-dea-bntx-20240206monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-investor-deadline-approaching-faruqi-faruqi-securities-litigation-partner-james-j-bntx-20240202monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-se-nasdaq-bntx-deadline-alert-bernstein-liebhard-llp-reminds-investors-of-the-dea-bntx-20240129monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-shareholder-notice-faruqi-faruqi-securities-litigation-partner-james-josh-wilson--bntx-20240124monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-se-bntx-investor-alert-robbins-llp-reminds-shareholders-of-class-action-against-b-bntx-20240122monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-se-nasdaq-bntx-deadline-alert-bernstein-liebhard-llp-reminds-investors-of-the-dea-bntx-20240122monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-bntx-20240118monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-shareholder-notice-faruqi-faruqi-securities-litigation-partner-james-josh-wilson--bntx-20240117monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-se-shareholder-alert-bernstein-liebhard-llp-announces-that-a-securities-class-act-bntx-20240116monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-inc-investigated-by-the-portnoy-law-firm-gmed-20260319monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-fourth-quarter-and-full-year-2025-earnings-release-and-conference-gmed-20260212monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-second-quarter-2025-results-gmed-20250807monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-second-quarter-earnings-release-and-conference-call-gmed-20250717monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-first-quarter-2025-results-gmed-20250508monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-first-quarter-earnings-release-and-conference-call-gmed-20250417monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-completes-acquisition-of-nevro-corp-gmed-20250403monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-extends-versatility-of-advanced-materials-science-anterior-interbody-portfo-gmed-20250311monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-to-feature-excelsiusflex-for-total-knee-arthroplasty-at-the-american-academ-gmed-20250306monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-to-participate-in-the-canaccord-genuity-2025-musculoskeletal-conference-gmed-20250306monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-fourth-quarter-and-full-year-2024-results-gmed-20250220monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-fourth-quarter-and-full-year-2024-earnings-release-and-conference-gmed-20250130monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-preliminary-record-fourth-quarter-and-full-year-sales-results-gmed-20250108monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-launches-excelsiushub-navigation-system-gmed-20241122monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-third-quarter-2024-results-gmed-20241105monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-to-participate-in-orthopedic-trauma-association-annual-meeting-gmed-20241018monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-third-quarter-earnings-release-and-conference-call-gmed-20241015monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-launches-the-next-wave-of-orthopedic-trauma-solutions-gmed-20241002monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-inc-gmed-investigation-bronstein-gewirtz-grossman-llc-encourages-investors--gmed-20240827monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-launches-adira-xlif-plate-system-gmed-20240821monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-inc-gmed-investigation-bronstein-gewirtz-grossman-llc-encourages-investors--gmed-20240821monthly0.5https://www.biopharmawatch.com/news/GMED/globus-alert-bragar-eagel-squire-p-c-is-investigating-globus-medical-inc-on-behalf-of-glob-gmed-20240820monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-inc-gmed-investigation-bronstein-gewirtz-grossman-llc-encourages-investors--gmed-20240815monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-second-quarter-2024-results-gmed-20240806monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-receives-fda-510-k-clearance-for-excelsiusflex-and-actify-3d-total-knee-sys-gmed-20240717monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-second-quarter-earnings-release-and-conference-call-gmed-20240716monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-first-quarter-2024-results-gmed-20240507monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-first-quarter-earnings-release-and-conference-call-gmed-20240416monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-fourth-quarter-and-full-year-2023-results-gmed-20240220monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-fourth-quarter-and-full-year-2023-earnings-release-and-conference-gmed-20240213monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-promotes-keith-pfeil-to-chief-operating-officer-and-chief-financial-officer-gmed-20240205monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-preliminary-record-fourth-quarter-and-full-year-sales-results-gmed-20240110monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-third-quarter-2023-results-gmed-20231107monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-third-quarter-earnings-release-and-conference-call-gmed-20231024monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-and-nuvasive-to-sponsor-and-participate-at-eurospine-2023-gmed-20230927monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-completes-merger-with-nuvasive-gmed-20230901monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-second-quarter-2023-results-gmed-20230803monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-launch-of-the-marvel-growing-rod-system-the-company-s-first-produ-gmed-20230731monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-second-quarter-earnings-release-and-conference-call-gmed-20230713monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-fda-approval-for-its-non-fusion-scoliosis-correction-system-the-l-gmed-202305152023-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-first-quarter-2023-results-gmed-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-first-quarter-earnings-release-and-conference-call-gmed-202304192023-04-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-fourth-quarter-and-full-year-2022-results-gmed-202302212023-02-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-fourth-quarter-and-full-year-2022-earnings-release-and-conference-gmed-202302022023-02-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-partners-with-the-uk-s-nhs-to-provide-hospitals-with-surgical-robotic-navig-gmed-20221117monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-third-quarter-2022-results-gmed-20221108monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-third-quarter-earnings-release-and-conference-call-gmed-20221019monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-second-quarter-2022-results-gmed-20220804monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-first-surgeries-using-excelsiusgps-in-sydney-gmed-20220727monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-second-quarter-earnings-release-and-conference-call-gmed-20220718monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-first-surgeries-using-excelsius3d-gmed-20220518monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-first-quarter-2022-results-gmed-20220510monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-first-quarter-earnings-release-and-conference-call-gmed-20220421monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-ceo-transition-and-preliminary-first-quarter-2022-sales-results-gmed-20220421monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-the-expansion-of-its-share-repurchase-program-gmed-20220304monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-fourth-quarter-and-full-year-2021-results-gmed-20220217monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-fourth-quarter-and-full-year-2021-earnings-release-and-conference-gmed-20220127monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-third-quarter-2021-results-gmed-20211104monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-premieres-anthem-mini-fragment-fracture-system-at-orthopaedic-trauma-associ-gmed-20211019monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-third-quarter-earnings-release-and-conference-call-gmed-20211014monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-files-suit-against-life-spine-for-ip-infringement-gmed-20211013monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-to-participate-in-north-american-spine-society-annual-meeting-gmed-20210928monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-first-excelsiusgps-cranial-surgery-gmed-20210927monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-fda-510-k-clearance-for-excelsius3d-gmed-20210816monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-second-quarter-2021-results-gmed-20210804monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-second-quarter-earnings-release-and-conference-call-gmed-20210716monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-completion-of-20-000-procedures-utilizing-excelsiusgps-gmed-20210715monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-first-quarter-2021-results-gmed-20210504monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-first-quarter-earnings-release-and-conference-call-gmed-20210421monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-first-surgeries-with-revolutionary-creo-one-robotic-screw-gmed-20210415monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-fourth-quarter-and-full-year-2020-results-gmed-20210217monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-fourth-quarter-and-full-year-2020-earnings-release-and-conference-gmed-20210128monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-trauma-division-awarded-purchasing-agreement-with-premier-inc-gmed-20201209monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-first-surgeries-with-excelsiusgps-interbody-solutions-gmed-20201112monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-third-quarter-2020-results-gmed-20201028monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-third-quarter-2020-earnings-release-and-conference-call-gmed-20201016monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-to-participate-as-platinum-sponsor-at-north-american-spine-society-annual-m-gmed-20201005monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-second-quarter-2020-results-gmed-20200805monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-second-quarter-2020-earnings-release-and-conference-call-gmed-20200721monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-first-quarter-2020-results-gmed-20200507monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-first-quarter-2020-earnings-release-and-conference-call-gmed-20200416monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-200-million-share-repurchase-program-gmed-20200311monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-fourth-quarter-and-full-year-2019-results-gmed-20200220monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-fourth-quarter-and-full-year-2019-earnings-release-and-conference-gmed-20200206monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-first-case-with-next-generation-3d-printed-spine-implant-gmed-20200204monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-preliminary-record-fourth-quarter-and-full-year-sales-results-gmed-20200108monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-board-of-director-addition-and-departure-gmed-20191213monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-third-quarter-2019-results-gmed-20191106monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-third-quarter-2019-earnings-release-and-conference-call-gmed-20191016monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-launches-autobahn-intramedullary-nailing-platform-at-2019-ota-annual-meetin-gmed-20190924monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-showcases-latest-innovations-at-nass-2019-gmed-20190919monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-second-quarter-2019-results-gmed-20190801monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-second-quarter-2019-earnings-release-and-conference-call-gmed-20190715monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-launches-first-expandable-interspinous-fixation-aerial-gmed-20190530monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-first-quarter-2019-results-gmed-20190502monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-first-quarter-2019-earnings-release-and-conference-call-gmed-20190417monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-launches-fortify-variable-angle-expandable-corpectomy-spacer-system-gmed-20190415monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-fourth-quarter-and-full-year-2018-earnings-release-and-conference-gmed-20190205monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-s-secure-c-cervical-artificial-disc-receives-expanded-insurance-coverage-gmed-20190124monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-enters-international-market-with-excelsiusgps-robotic-guidance-and-navigati-gmed-20181206monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-third-quarter-2018-results-gmed-20181108monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-third-quarter-2018-earnings-release-and-conference-call-gmed-20181019monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-supporting-resident-and-surgeon-education-workshops-at-ota-2018-gmed-20181017monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-sponsors-nass-2018-hosts-in-booth-presentations-on-excelsiusgps-gmed-20180925monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-acquires-surgimap-gmed-20180913monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-to-exhibit-latest-advancements-in-mis-spine-surgery-at-smiss-annual-forum-gmed-20180829monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-second-quarter-2018-earnings-release-and-conference-call-gmed-20180716monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-features-latest-innovative-technologies-at-scoliosis-research-society-s-int-gmed-20180711monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-adds-two-innovative-solutions-to-growing-trauma-portfolio-gmed-20180703monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-excelsiusgps-milestone-3-000-screws-implanted-gmed-20180626monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-launches-cement-augmented-pedicle-screw-system-gmed-20180613monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-appointment-of-orthopedic-trauma-division-s-vice-president-of-sal-gmed-20180521monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-positive-clinical-results-for-lateral-expandable-technology-gmed-20180515monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-corporate-alliance-partnership-with-the-society-of-lateral-access-gmed-20180510monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-first-quarter-2018-results-gmed-20180502monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-first-quarter-2018-earnings-release-and-conference-call-gmed-20180417monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-launch-of-elsa-expandable-lateral-spacer-system-gmed-20180405monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-enters-trauma-market-gmed-20180306monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-fourth-quarter-and-full-year-2017-earnings-release-and-conference-gmed-20180209monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-clinical-results-showing-superiority-of-its-secure-c-to-acdf-at-s-gmed-20171201monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-to-participate-in-the-piper-jaffray-29th-annual-healthcare-conference-gmed-20171120monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-third-quarter-2017-results-gmed-20171108monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-third-quarter-2017-earnings-release-and-conference-call-gmed-20171017monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-first-spine-surgeries-using-excelsiusgps-gmed-20171010monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-first-case-in-orthopedic-trauma-gmed-20170914monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-appoints-david-m-demski-as-ceo-gmed-20170829monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-acquisition-of-robotics-developer-kb-medical-gmed-20170802monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-second-quarter-2017-earnings-release-and-conference-call-gmed-20170710monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-first-quarter-2017-results-gmed-20170503monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-first-quarter-2017-earnings-release-and-conference-call-gmed-20170417monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-to-present-at-leerink-partners-6th-annual-global-healthcare-conference-2017-gmed-20170209monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-fourth-quarter-and-full-year-2016-earnings-release-and-conference-gmed-20170207monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-ce-mark-for-excelsius-gps-gmed-20170105monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-third-quarter-2016-results-gmed-20161108monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-launches-quartex-oct-stabilization-system-gmed-20161025monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-launches-independence-mis-a-minimally-invasive-alif-integrated-plate-spacer-gmed-20161025monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-third-quarter-2016-earnings-release-and-conference-call-gmed-20161019monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-second-quarter-2016-earnings-release-and-conference-call-gmed-20160715monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-appoints-eric-ian-schwartz-as-senior-vice-president-and-general-counsel-gmed-20160510monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-first-quarter-2016-results-gmed-20160503monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-first-quarter-2016-earnings-release-and-conference-call-gmed-20160414monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-fourth-quarter-and-full-year-2015-earnings-release-and-conference-gmed-20160204monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-to-participate-in-34th-annual-j-p-morgan-healthcare-conference-gmed-20160105monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-to-host-analyst-day-meeting-thursday-november-12th-gmed-20151109monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-third-quarter-2015-results-gmed-20151103monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-inc-shareholder-alert-kessler-topaz-meltzer-check-llp-announces-shareholder-gmed-20151026monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-announces-creo-mis-tm-a-low-profile-minimally-invasive-posterior-stabilizat-gmed-20151022monthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-schedules-third-quarter-2015-earnings-release-and-conference-call-gmed-20151012monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-innovations-to-advance-quintuple-aim-isrg-20260521monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-second-quarter-earnings-isrg-20250722monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-first-quarter-earnings-isrg-20250422monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-45-million-donation-to-the-intuitive-foundation-to-promote-health-and--isrg-20250127monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-fourth-quarter-earnings-isrg-20250123monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-plans-to-establish-direct-presence-in-italy-spain-portugal-isrg-20250121monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-preliminary-fourth-quarter-and-full-year-2024-results-isrg-20250115monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-executive-leadership-changes-to-support-continued-global-growth-isrg-20250103monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-third-quarter-earnings-isrg-20241017monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-president-david-j-rosa-appointed-to-intuitive-board-of-directors-isrg-20240725monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-second-quarter-earnings-isrg-20240718monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-isrg-company-profile-2024-product-pipeline-analysis-and-ongoing-clinica-isrg-20240610monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-fda-clearance-of-revised-da-vinci-xi-and-x-labeling-on-radical-prostat-isrg-20240605monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-board-of-directors-elections-and-retirements-isrg-20240425monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-first-quarter-earnings-isrg-20240418monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-fda-clearance-of-fifth-generation-robotic-system-da-vinci-5-isrg-20240314monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-fourth-quarter-earnings-isrg-20240123monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-preliminary-fourth-quarter-and-full-year-2023-results-isrg-20240109monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-appoints-sreelakshmi-kolli-to-its-board-of-directors-isrg-20231031monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-third-quarter-earnings-isrg-20231019monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-second-quarter-earnings-isrg-20230720monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-executive-leadership-changes-isrg-20230516monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-receives-fda-clearance-of-da-vinci-sp-for-simple-prostatectomy-isrg-202304282023-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-first-quarter-earnings-isrg-202304182023-04-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-fourth-quarter-earnings-isrg-202301242023-01-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-preliminary-fourth-quarter-and-full-year-2022-results-isrg-202301112023-01-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-becomes-largest-robotic-assisted-surgery-provider-to-be-accredited-by-the-royal--isrg-20221019monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-third-quarter-earnings-isrg-20221018monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-second-quarter-earnings-isrg-20220721monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-and-siemens-healthineers-enhance-scanning-integration-for-ion-endoluminal-proced-isrg-20220630monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-first-quarter-earnings-isrg-20220421monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-fourth-quarter-earnings-isrg-20220120monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-preliminary-fourth-quarter-and-full-year-2021-results-isrg-20220112monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-receives-fda-clearance-for-8-mm-sureform-30-curved-tip-stapler-isrg-20211215monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-reaches-10-million-procedures-performed-using-da-vinci-surgical-systems-isrg-20211214monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-third-quarter-earnings-isrg-20211019monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-executive-leadership-changes-isrg-20211019monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-appoints-new-general-manager-in-south-korea-isrg-20210831monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-second-quarter-earnings-isrg-20210720monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-first-quarter-earnings-isrg-20210420monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-fourth-quarter-earnings-isrg-20210121monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-preliminary-fourth-quarter-and-full-year-2020-results-isrg-20210113monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-launches-100-million-venture-capital-fund-isrg-20201027monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-third-quarter-earnings-isrg-20201015monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-second-quarter-earnings-isrg-20200721monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-provides-update-on-supporting-customers-communities-employees-during-covid-19-isrg-20200428monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-first-quarter-earnings-isrg-20200416monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-acquires-orpheus-medical-to-expand-informatics-platform-for-hospitals-isrg-20200210monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-fourth-quarter-earnings-isrg-20200123monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-preliminary-fourth-quarter-and-full-year-2019-results-isrg-20200109monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-third-quarter-earnings-isrg-20191017monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-second-quarter-earnings-isrg-20190718monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-first-quarter-earnings-isrg-20190418monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-fourth-quarter-earnings-isrg-20190124monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-preliminary-fourth-quarter-and-full-year-2018-results-isrg-20190109monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-new-general-manager-in-korea-isrg-20181109monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-third-quarter-earnings-isrg-20181018monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-submits-new-robotic-assisted-platform-to-fda-for-obtaining-lung-biopsies-isrg-20180906monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-appoints-don-kania-ph-d-to-its-board-of-directors-isrg-20180801monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-second-quarter-earnings-isrg-20180719monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-receives-fda-clearance-for-first-60mm-stapler-isrg-20180705monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-innovative-single-port-platform-the-da-vinci-sp-surgical-syst-isrg-20180531monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-to-begin-direct-operations-in-india-isrg-20180530monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-first-quarter-earnings-isrg-20180417monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-fourth-quarter-earnings-isrg-20180125monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-preliminary-fourth-quarter-and-full-year-2017-results-isrg-20180110monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-third-quarter-earnings-isrg-20171019monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-august-2017-isrg-20170811monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-board-of-directors-approves-a-three-for-one-stock-split-isrg-20170811monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-second-quarter-earnings-isrg-20170720monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-july-2017-isrg-20170718monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-june-2017-isrg-20170608monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-receives-fda-clearance-for-latest-da-vinci-robotic-assisted-surgical-sy-isrg-20170530monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-may-2017-isrg-20170512monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-receives-ce-mark-for-latest-da-vinci-robotic-assisted-surgical-system-isrg-20170426monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-first-quarter-earnings-isrg-20170418monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-april-2017-isrg-20170417monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-march-2017-isrg-20170313monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-february-2017-isrg-20170213monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-fourth-quarter-earnings-and-a-2-0-billion-accelerated-share-r-isrg-20170124monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-january-2017-isrg-20170117monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-preliminary-fourth-quarter-and-full-year-2016-results-isrg-20170111monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-december-2016-isrg-20161214monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-increases-share-repurchase-program-to-3-0-billion-isrg-20161213monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-november-2016-isrg-20161110monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-third-quarter-earnings-isrg-20161018monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-october-2016-isrg-20161014monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-and-fosun-pharma-establish-joint-venture-to-research-develop-manufactur-isrg-20160929monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-september-2016-isrg-20160909monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-august-2016-isrg-20160817monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-second-quarter-earnings-isrg-20160719monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-july-2016-isrg-20160712monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-selection-of-2016-thoracic-program-fellows-isrg-20160622monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-june-2016-isrg-20160613monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-support-for-2016-gynecology-fellowship-programs-isrg-20160525monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-may-2016-isrg-20160511monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-first-quarter-earnings-isrg-20160419monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-april-2016-isrg-20160414monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-march-2016-isrg-20160316monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-u-s-clearance-for-da-vinci-xi-single-site-instruments-and-acc-isrg-20160316monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-u-s-clearance-for-da-vinci-xi-endowrist-stapler-30-instrument-isrg-20160314monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-february-2016-isrg-20160209monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-and-hill-rom-announce-u-s-clearance-for-integrated-table-motion-isrg-20160121monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-fourth-quarter-earnings-isrg-20160121monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-january-2016-isrg-20160115monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-preliminary-fourth-quarter-and-full-year-2015-results-isrg-20160113monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-december-2015-isrg-20151215monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-inc-nasdaq-isrg-to-ring-the-nasdaq-stock-market-opening-bell-isrg-20151117monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-november-2015-isrg-20151113monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-third-quarter-earnings-isrg-20151020monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-october-2015-isrg-20151014monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-and-trumpf-medical-team-up-to-address-hospitals-need-for-operating-room-isrg-20151014monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-september-2015-isrg-20150911monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-august-2015-isrg-20150810monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-simulator-grants-to-top-medical-centers-for-research-in-robot-isrg-20150803monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-second-quarter-earnings-isrg-20150721monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-brings-stapler-instrumentation-to-da-vinci-robotic-assisted-surgical-sy-isrg-20150714monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-july-2015-isrg-20150713monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-june-2015-isrg-20150612monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-may-2015-isrg-20150518monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-first-quarter-earnings-isrg-20150421monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-april-2015-isrg-20150410monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-march-2015-isrg-20150319monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-joins-industry-partners-in-sponsorship-of-the-american-hernia-society-s-isrg-20150224monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-february-2015-isrg-20150217monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-1-0-billion-share-repurchase-program-isrg-20150202monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-fourth-quarter-earnings-isrg-20150122monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-january-2015-isrg-20150116monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-preliminary-fourth-quarter-and-full-year-2014-results-isrg-20150113monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-december-2014-isrg-20141211monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-november-2014-isrg-20141111monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-third-quarter-earnings-isrg-20141021monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-october-2014-isrg-20141013monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-receives-fda-clearance-for-first-single-site-r-wristed-needle-driver-fo-isrg-20140929monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-inc-third-quarter-2014-earnings-conference-call-isrg-20140915monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-september-2014-isrg-20140909monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-receives-firefly-tm-fda-clearance-for-da-vinci-r-xi-tm-surgical-system-isrg-20140821monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-august-2014-isrg-20140813monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-supports-inaugural-aats-graham-foundation-fellowship-course-isrg-20140724monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-second-quarter-earnings-isrg-20140722monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-july-2014-isrg-20140714monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-to-begin-direct-sales-of-da-vinci-r-surgical-systems-in-japan-isrg-20140702monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-receives-ce-mark-for-the-da-vinci-r-xi-tm-surgical-system-isrg-20140625monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-inc-second-quarter-2014-earnings-conference-call-isrg-20140616monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-june-2014-isrg-20140612monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-sponsors-new-women-s-cancer-research-database-in-collaboration-with-the-isrg-20140609monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-may-2014-isrg-20140508monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-accelerated-share-repurchase-isrg-20140502monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-first-quarter-earnings-isrg-20140422monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-fda-clearance-of-da-vinci-r-sp-tm-surgical-system-isrg-20140422monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-april-2014-isrg-20140410monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-issues-preliminary-first-quarter-results-isrg-20140408monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-new-da-vinci-r-xi-tm-surgical-system-isrg-20140401monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-inc-first-quarter-2014-earnings-conference-call-isrg-20140320monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-march-2014-isrg-20140312monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-february-2014-isrg-20140213monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-fourth-quarter-earnings-isrg-20140123monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-inc-recommends-stockholders-reject-mini-tender-offer-by-trc-capital-cor-isrg-20140121monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-preliminary-fourth-quarter-and-full-year-2013-results-isrg-20140114monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-january-2014-isrg-20140113monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-december-2013-isrg-20131210monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-november-2013-isrg-20131108monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-third-quarter-earnings-isrg-20131017monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-october-2013-isrg-20131008monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-inc-third-quarter-2013-earnings-conference-call-isrg-20130925monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-clearance-to-expand-use-of-fluorescence-imaging-in-gallbladde-isrg-20130923monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-september-2013-isrg-20130910monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-august-2013-isrg-20130808monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-increases-share-repurchase-program-to-1-5-billion-and-uses-500-million-to-execut-isrg-20130729monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-second-quarter-earnings-isrg-20130718monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-july-2013-isrg-20130710monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-preliminary-second-quarter-2013-results-isrg-20130708monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-june-2013-isrg-20130611monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-shareholder-alert-levi-korsinsky-notifies-investors-with-losses-on-thei-isrg-20130605monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-may-2013-isrg-20130509monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-first-quarter-earnings-isrg-20130418monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-april-2013-isrg-20130410monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-increase-in-share-repurchase-program-isrg-20130321monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-comments-on-medical-device-reporting-practices-isrg-20130314monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-march-2013-isrg-20130313monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-february-2013-isrg-20130213monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-fourth-quarter-earnings-isrg-20130122monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-january-2013-isrg-20130109monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-december-2012-isrg-20121211monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-november-2012-isrg-20121119monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-third-quarter-earnings-isrg-20121016monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-october-2012-isrg-20121009monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-september-2012-isrg-20120914monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-august-2012-isrg-20120810monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-second-quarter-earnings-isrg-20120719monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-july-2012-isrg-20120711monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-june-2012-isrg-20120611monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-may-2012-isrg-20120511monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-first-quarter-earnings-isrg-20120417monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-april-2012-isrg-20120406monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-february-2012-isrg-20120308monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-february-2012-isrg-20120208monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-annnounces-fourth-quarter-earnings-isrg-20120119monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-january-2012-isrg-20120110monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-new-endowrist-r-one-tm-vessel-sealer-for-the-da-vinci-r-si-tm-isrg-20120104monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-new-single-site-tm-instrumentation-for-the-da-vinci-r-si-tm-s-isrg-20111213monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-december-2011-isrg-20111209monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-november-2011-isrg-20111108monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-increase-in-share-repurchase-authorization-isrg-20111028monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-third-quarter-earnings-isrg-20111018monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-october-2011-isrg-20111011monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-september-2011-isrg-20110909monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-august-2011-isrg-20110808monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-second-quarter-earnings-isrg-20110719monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-july-2011-isrg-20110711monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-june-2011-isrg-20110610monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-april-2011-isrg-20110511monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-first-quarter-earnings-isrg-20110419monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-march-2011-isrg-20110408monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-february-2011-isrg-20110310monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-january-2011-isrg-20110211monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-share-repurchase-program-isrg-20110208monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-fourth-quarter-earnings-isrg-20110120monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-december-2010-isrg-20110108monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-november-2010-isrg-20101211monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-october-2010-isrg-20101105monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-third-quarter-earnings-isrg-20101019monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-september-2010-isrg-20101009monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-august-2010-isrg-20100910monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-july-2010-isrg-20100809monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-share-repurchase-program-isrg-20100723monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-second-quarter-earnings-isrg-20100721monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-june-2010-isrg-20100709monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-may-2010-isrg-20100610monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-april-2010-isrg-20100508monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-first-quarter-earnings-isrg-20100415monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-reports-new-employee-option-grants-for-march-2010-isrg-20100409monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-fourth-quarter-earnings-isrg-20100121monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-transition-of-gary-guthart-to-ceo-isrg-20091023monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-third-quarter-earnings-isrg-20091020monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-second-quarter-earnings-isrg-20090722monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-first-quarter-earnings-isrg-20090416monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-new-da-vinci-r-si-tm-surgical-system-isrg-20090402monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-share-repurchase-program-isrg-20090305monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-fourth-quarter-earnings-isrg-20090122monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-preliminary-fourth-quarter-2008-revenue-results-isrg-20090107monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-236-million-third-quarter-revenue-up-50-percent-isrg-20081016monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-219-2-million-second-quarter-revenue-up-56-percent-isrg-20080722monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-188-2-million-first-quarter-revenue-up-65-percent-isrg-20080417monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-189-4-million-fourth-quarter-revenue-up-68-percent-isrg-20080131monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-156-9-million-third-quarter-revenue-up-64-isrg-20071018monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-140-2-million-second-quarter-revenue-up-61-percent-net-income-isrg-20070719monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-promotions-isrg-20070712monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-114-2-million-first-quarter-revenue-up-48-percent-net-income--isrg-20070419monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-its-annual-meeting-and-record-date-isrg-20070226monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-announces-112-6-million-fourth-quarter-revenue-up-56-percent-isrg-20070201monthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-surgical-names-rick-epstein-as-senior-vice-president-of-marketing-isrg-20070131monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-publication-in-new-england-journal-of-medicine-of-phase-1-2-rvmd-20260506monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-present-preclinical-data-on-innovative-mutant-targeted-catalytic-r-rvmd-20260421monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-present-pivotal-phase-3-rasolute-302-clinical-trial-results-for-da-rvmd-20260421monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-closing-of-concurrent-upsized-public-offerings-with-aggrega-rvmd-20260417monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-dar-rvmd-20260402monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2025-aft-rvmd-20260218monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-doses-first-patient-in-clinical-trial-evaluating-rmc-5127-a-ras-on-g1-rvmd-20260129monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-fda-breakthrough-therapy-designation-for-zoldonrasib-rvmd-20260108monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-first-patient-randomized-in-the-rasolute-304-clinical-trial-rvmd-20251218monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-publication-of-a-peer-reviewed-research-paper-in-science-on-rvmd-20250724monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-fda-breakthrough-therapy-designation-for-elironrasib-rvmd-20250723monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-and-iambic-announce-technology-and-research-collaboration-using-iambi-rvmd-20250709monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-and-summit-therapeutics-enter-into-clinical-collaboration-to-evaluate-rvmd-20250630monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-fda-breakthrough-therapy-designation-for-daraxonrasib-in-pr-rvmd-20250623monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-first-patient-dosed-in-phase-3-clinical-trial-evaluating-da-rvmd-20250514monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-report-financial-results-for-first-quarter-2025-after-market-close-rvmd-20250430monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-presents-initial-data-from-zoldonrasib-rmc-9805-study-in-patients-wit-rvmd-20250427monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-fo-rvmd-20250401monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-april-2025-investor-conferences-rvmd-20250331monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-march-2025-investor-conferences-rvmd-20250224monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-aft-rvmd-20250219monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conferen-rvmd-20250129monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-present-at-43rd-annual-j-p-morgan-healthcare-conference-rvmd-20250106monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-closing-of-upsized-public-offering-of-common-stock-and-pre--rvmd-20241205monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-pricing-of-upsized-750-0-million-public-offering-of-common--rvmd-20241204monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-commencement-of-public-offering-of-common-stock-rvmd-20241202monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-provides-clinical-updates-from-its-ras-on-inhibitor-portfolio-rvmd-20241202monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-host-ras-on-inhibitor-clinical-update-webcast-on-december-2-2024-rvmd-20241127monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-upcoming-investor-conferences-rvmd-20241105monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-report-financial-results-for-third-quarter-2024-after-market-close-rvmd-20241030monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-presents-initial-data-from-rmc-9805-monotherapy-study-in-patients-wit-rvmd-20241025monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-presents-updated-data-from-rmc-6236-monotherapy-study-in-patients-wit-rvmd-20241023monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-first-patient-dosed-in-phase-3-study-evaluating-rmc-6236-in-rvmd-20241021monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-deliver-multiple-presentations-at-the-2024-aacr-nci-eortc-symposiu-rvmd-20241007monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-report-financial-results-for-second-quarter-2024-after-market-clos-rvmd-20240731monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-publication-demonstrating-robust-anti-tumor-activity-of-ras-rvmd-20240711monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-provide-update-on-rmc-6236-pancreatic-ductal-adenocarcinoma-clinic-rvmd-20240708monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-goldman-sachs-45th-annual-global-healthcare-confere-rvmd-20240605monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-report-financial-results-for-first-quarter-2024-after-market-close-rvmd-20240501monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-publication-on-the-discovery-of-and-translational-research--rvmd-20240409monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-publications-on-the-discovery-and-preclinical-profile-of-re-rvmd-20240408monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-upcoming-investor-conferences-rvmd-20240404monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-deliver-multiple-presentations-at-the-upcoming-american-associatio-rvmd-20240328monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2023-aft-rvmd-20240220monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-upcoming-investor-conferences-rvmd-20240201monthly0.5https://www.biopharmawatch.com/news/RVMD/revolutionising-facial-rejuvenation-mckeown-medical-release-comprehensive-guide-to-cutting-rvmd-20240131monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-present-at-42nd-annual-j-p-morgan-healthcare-conference-rvmd-20240104monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-completes-acquisition-of-eqrx-rvmd-20231109monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-and-eqrx-stockholders-approve-eqrx-acquisition-rvmd-20231108monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-report-financial-results-for-third-quarter-2023-after-market-close-rvmd-20231031monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-presents-promising-clinical-activity-and-safety-data-from-phase-1-1b--rvmd-20231022monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-presents-encouraging-clinical-data-for-rmc-6236-and-rmc-6291-at-2023--rvmd-20231013monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-present-new-clinical-data-at-major-oncology-conferences-and-host-i-rvmd-20231004monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-doses-first-patient-in-phase-1-1b-clinical-trial-of-rmc-9805-an-oral--rvmd-20230919monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-publication-describing-molecular-basis-of-tri-complex-inhib-rvmd-20230817monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-report-financial-results-for-second-quarter-2023-after-market-clos-rvmd-20230803monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-inc-to-acquire-eqrx-inc-in-all-stock-transaction-to-gain-more-than-1--rvmd-20230801monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-upcoming-investor-conferences-rvmd-20230608monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-td-cowen-4th-annual-oncology-innovation-summit-rvmd-20230524monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-rvmd-202305012023-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-22nd-annual-needham-healthcare-conference-rvmd-202304132023-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-present-preclinical-data-at-the-upcoming-american-association-for--rvmd-202304062023-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-closing-of-public-offering-of-common-stock-and-full-exercis-rvmd-202303072023-03-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-pricing-of-300-0-million-public-offering-of-common-stock-rvmd-202303032023-03-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-commencement-of-public-offering-of-common-stock-rvmd-202303012023-03-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2022-aft-rvmd-202302212023-02-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-micro-and-osram-score-in-top-ten-of-global-ssl-awards-rvmd-202302212023-02-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-upcoming-investor-conferences-rvmd-202302022023-02-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-present-at-41st-annual-j-p-morgan-healthcare-conference-rvmd-202301032023-01-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-publication-describing-design-and-synthesis-of-rmc-5552-a-f-rvmd-20221219monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-regain-global-rights-to-rmc-4630-following-sanofi-s-termination-of-rvmd-20221207monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-upcoming-investor-conferences-rvmd-20221109monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-report-financial-results-for-third-quarter-2022-after-market-close-rvmd-20221101monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-doses-first-patient-in-phase-1-1b-clinical-trial-of-rmc-6291-company--rvmd-20220922monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-strengthens-senior-management-team-with-promotions-and-a-new-hire-rvmd-20220901monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-upcoming-investor-conferences-rvmd-20220831monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-report-financial-results-for-second-quarter-2022-after-market-clos-rvmd-20220728monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-closing-of-upsized-public-offering-of-common-stock-and-full-rvmd-20220722monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-pricing-of-upsized-230-0-million-public-offering-of-common--rvmd-20220720monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-commencement-of-public-offering-of-common-stock-rvmd-20220719monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-appoints-lorence-kim-m-d-accomplished-health-care-industry-leader-to--rvmd-20220713monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-advances-first-ras-on-inhibitor-into-clinic-dosing-first-patient-in-p-rvmd-20220628monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-the-43rd-annual-goldman-sachs-global-healthcare-con-rvmd-20220609monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-report-financial-results-for-first-quarter-2022-after-market-close-rvmd-20220421monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-seven-oral-presentations-at-the-upcoming-american-associati-rvmd-20220309monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-cowen-42nd-annual-health-care-conference-rvmd-20220301monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2021-aft-rvmd-20220222monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-guggenheim-healthcare-talks-2022-oncology-conferenc-rvmd-20220203monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-progress-across-pipeline-of-targeted-therapeutics-for-ras-add-rvmd-20220111monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-provide-r-d-update-including-expansion-of-development-stage-ras-on-rvmd-20220104monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-4th-annual-evercore-isi-healthconx-conference-rvmd-20211124monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-stifel-2021-virtual-healthcare-conference-rvmd-20211108monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-report-financial-results-for-third-quarter-2021-after-market-close-rvmd-20211103monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-present-new-preclinical-data-from-ras-on-inhibitor-programs-at-aac-rvmd-20210930monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit-rvmd-20210915monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference-rvmd-20210907monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-report-financial-results-for-second-quarter-2021-after-market-clos-rvmd-20210804monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-publication-of-scientific-paper-describing-novel-class-of-a-rvmd-20210624monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-host-science-talk-webcast-highlighting-learnings-from-recent-precl-rvmd-20210610monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-confere-rvmd-20210602monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-cowen-2nd-annual-virtual-oncology-innovation-summit-rvmd-20210518monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-highlights-slate-of-diverse-board-of-directors-nominees-for-upcoming--rvmd-20210503monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-dosing-of-first-patient-in-phase-1-1b-clinical-study-of-rmc-rvmd-20210421monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-six-presentations-at-the-american-association-for-cancer-re-rvmd-20210311monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-upcoming-investor-conferences-rvmd-20210309monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-digital-ras-targeted-drug-discovery-summit-and-upco-rvmd-20210218monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-closing-of-upsized-public-offering-of-common-stock-and-full-rvmd-20210208monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-pricing-of-upsized-260-9-million-public-offering-of-common--rvmd-20210204monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-proposed-public-offering-of-common-stock-rvmd-20210201monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-provide-r-d-pipeline-update-including-progress-of-ras-on-inhibitor-rvmd-20210105monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-progress-and-expansion-of-combination-strategy-with-rmc-4630--rvmd-20201024monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-present-interim-data-at-ena-2020-from-phase-1b-2-clinical-trial-co-rvmd-20201012monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-preclinical-tumor-regressions-induced-by-first-in-class-kras--rvmd-20200916monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-present-at-the-h-c-wainwright-22nd-annual-global-investment-confer-rvmd-20200909monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-to-participate-in-2nd-annual-ras-targeted-drug-development-conference-rvmd-20200908monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-closing-of-upsized-public-offering-of-common-stock-and-full-rvmd-20200713monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-pricing-of-156-0-million-public-offering-of-common-stock-rvmd-20200709monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-proposed-public-offering-of-common-stock-rvmd-20200706monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-reports-new-application-of-tri-complex-modality-for-undruggable-prote-rvmd-20200630monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-provides-research-and-development-update-for-its-portfolio-of-novel-t-rvmd-20200622monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-dosing-of-first-patient-in-clinical-study-of-rmc-4630-sar44-rvmd-20200622monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-appoints-eric-t-schmidt-ph-d-and-peter-svennilson-to-its-board-of-dir-rvmd-20200618monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-dosing-of-first-patient-in-phase-1b-combination-study-of-rm-rvmd-20200609monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-four-presentations-at-the-2020-american-association-for-can-rvmd-20200519monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-publication-of-scientific-paper-describing-anti-tumor-immun-rvmd-20200429monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-issuance-of-u-s-patent-covering-compositions-of-matter-for--rvmd-20200318monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-closing-of-initial-public-offering-and-full-exercise-of-und-rvmd-20200218monthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-announces-pricing-of-initial-public-offering-rvmd-20200213monthly0.5https://www.biopharmawatch.com/news/RVMD/revolutionary-changes-ahead-with-innovative-5g-uses-rvmd-20191118monthly0.5https://www.biopharmawatch.com/news/RVMD/revolutions-medical-s-proprietary-mri-software-tools-being-utilized-in-additional-irb-appr-rvmd-20110119monthly0.5https://www.biopharmawatch.com/news/RVMD/revolutions-medical-discusses-presentation-of-mri-paper-at-ipcv-and-relevance-to-clinical--rvmd-20100820monthly0.5https://www.biopharmawatch.com/news/RVMD/revolutions-medical-corporation-begins-clinical-applications-and-validation-process-of-its-rvmd-20100816monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-to-present-data-on-obefazimod-at-digestive-disease-week-abvx-20260422monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-annual-ordinary-and-extraordinary-general-meeting-of-may-11-2026-availability-of-th-abvx-20260420monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-publishes-financial-reports-with-the-french-and-u-s-securities-regulatory-agencies-abvx-20260401monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-announces-full-year-2025-financial-results-and-provides-business-updates-abvx-20260323monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-provides-2026-corporate-outlook-abvx-20260107monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-to-be-added-to-nasdaq-biotechnology-index-abvx-20251218monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-presents-third-quarter-2025-financial-results-abvx-20251215monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-to-join-cac-mid-60-and-sbf-120-indices-following-euronext-paris-annual-review-abvx-20250912monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-announces-closing-of-747-5-million-public-offering-abvx-20250728monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-announces-full-exercise-of-underwriters-option-to-purchase-additional-adss-bringing-abvx-20250725monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-announces-trading-resumption-of-its-ordinary-shares-on-euronext-paris-abvx-20250724monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-announces-pricing-of-650m-554m-public-offering-of-american-depositary-shares-abvx-20250724monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-announces-temporary-trading-halt-of-its-ordinary-shares-on-euronext-paris-abvx-20250724monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-announces-launch-of-public-offering-abvx-20250723monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-announces-results-of-its-june-6-2025-annual-general-meeting-abvx-20250611monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-presents-first-quarter-2025-financial-results-abvx-20250602monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-announces-completion-of-enrollment-for-the-phase-3-abtect-trials-in-patients-with-m-abvx-20250429monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-publishes-financial-reports-with-the-french-and-u-s-securities-regulatory-agencies-abvx-20250326monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-announces-full-year-2024-financial-results-abvx-20250324monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025-abvx-20250221monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-publishes-2025-financial-calendar-abvx-20250128monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2-abvx-20250123monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-presents-third-quarter-2024-key-financial-information-abvx-20241114monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-announces-former-prometheus-coo-mark-stenhouse-appointed-as-board-observer-advisor--abvx-20241113monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-congratulates-victor-ambros-and-gary-ruvkun-on-their-nobel-prize-for-the-discovery--abvx-20241007monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-announces-first-patient-enrolled-in-enhance-cd-the-phase-2b-trial-of-obefazimod-in--abvx-20241003monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-reports-positive-interim-efficacy-and-safety-analysis-of-once-daily-25mg-obefazimod-abvx-20241003monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-to-present-three-abstracts-for-obefazimod-in-ulcerative-colitis-at-the-ueg-week-202-abvx-20240926monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-provides-update-on-ulcerative-colitis-uc-combination-therapy-program-strategy-and-a-abvx-20240925monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-presents-first-half-2024-financial-results-abvx-20240909monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-announces-abtect-phase-3-trial-achieves-key-enrollment-milestone-abvx-20240806monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-provides-operational-and-key-program-update-abvx-20240715monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-releases-the-results-of-its-may-30-2024-ordinary-and-extraordinary-general-meeting-abvx-20240604monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-announces-presentation-of-four-abstracts-for-obefazimod-in-ulcerative-colitis-and-p-abvx-20240508monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-annual-ordinary-and-extraordinary-general-meeting-of-may-30-2024-availability-of-th-abvx-20240507monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-publishes-financial-reports-with-the-french-and-u-s-securities-regulatory-agencies-abvx-20240405monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-reports-2023-financial-results-and-operational-update-abvx-20240402monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-appoints-ana-sharma-as-vice-president-global-head-of-quality-abvx-20240207monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-announces-update-to-obefazimod-phase-2b-clinical-development-program-in-moderately--abvx-20240202monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-to-host-kol-investor-event-to-review-phase-2b-clinical-data-and-phase-3-trial-desig-abvx-20240124monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-provides-2024-strategic-outlook-and-lays-out-key-milestones-over-next-12-months-abvx-20240122monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-2024-financial-communication-calendar-abvx-20240104monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-announces-the-resumption-of-its-liquidity-contract-abvx-20231121monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-to-participate-in-the-piper-sandler-35th-annual-healthcare-conference-abvx-20231114monthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-to-host-key-opinion-leader-luncheon-for-investors-focused-on-novel-approaches-to-hi-abvx-20161122monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-alert-bragar-eagel-squire-p-c-is-investigating-elanco-animal-health-incorporated-on-elan-20250430monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-bee-elan-20241205monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-incorporated-sued-for-securities-law-violations-investors-should-cont-elan-20241204monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-elan-faces-securities-class-action-lawsuit-over-alleged-safety-risks-of-zenrelia-ha-elan-20241204monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-incorporated-investors-please-contact-the-portnoy-law-firm-to-recover-elan-20241202monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-incorporated-nyse-elan-deadline-alert-bernstein-liebhard-llp-reminds--elan-20241202monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-elan-hit-with-investor-lawsuit-over-new-drug-december-6th-deadline-pending-hagens-b-elan-20241130monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-incorporated-investors-please-contact-the-portnoy-law-firm-to-recover-elan-20241127monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-elan-faces-federal-lawsuit-over-alleged-misrepresentation-of-zenrelia-s-safety-prof-elan-20241127monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-bee-elan-20241126monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-incorporated-nyse-elan-deadline-alert-bernstein-liebhard-llp-reminds--elan-20241125monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-elan-faces-federal-lawsuit-over-alleged-misrepresentation-of-zenrelia-s-safety-prof-elan-20241124monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-elan-hit-with-investor-lawsuit-over-new-drug-hagens-berman-elan-20241121monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-incorporated-class-action-the-gross-law-firm-reminds-elanco-investors-elan-20241120monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-bee-elan-20241120monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-incorporated-nyse-elan-deadline-alert-bernstein-liebhard-llp-reminds--elan-20241119monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-elan-faces-federal-lawsuit-over-alleged-misrepresentation-of-zenrelia-s-safety-prof-elan-20241118monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-incorporated-investors-please-contact-the-portnoy-law-firm-to-recover-elan-20241114monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-elan-faces-federal-lawsuit-over-alleged-misrepresentation-of-zenrelia-s-safety-prof-elan-20241114monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-bee-elan-20241113monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-incorporated-nyse-elan-deadline-alert-bernstein-liebhard-llp-reminds--elan-20241112monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-elan-hit-with-investor-lawsuit-over-new-drug-hagens-berman-elan-20241111monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-elan-hit-with-investor-lawsuit-over-new-drug-hagens-berman-elan-20241107monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-bee-elan-20241107monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-elan-faces-federal-lawsuit-over-alleged-misrepresentation-of-zenrelia-s-safety-prof-elan-20241104monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-incorporated-nyse-elan-deadline-alert-bernstein-liebhard-llp-reminds--elan-20241104monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-has-been-sued-for-securities-fraud-after-stock-plummets-21-contact-th-elan-20241102monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-elan-faces-federal-lawsuit-over-alleged-misrepresentation-of-zenrelia-s-safety-prof-elan-20241031monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-incorporated-class-action-the-gross-law-firm-reminds-elanco-investors-elan-20241029monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-elan-faces-federal-lawsuit-over-alleged-misrepresentation-of-zenrelia-s-safety-prof-elan-20241028monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-incorporated-nyse-elan-deadline-alert-bernstein-liebhard-llp-reminds--elan-20241028monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-elan-faces-investor-suit-over-zenrelia-safety-concerns-hagens-berman-elan-20241024monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-elan-hit-with-investor-lawsuit-over-new-drug-hagens-berman-elan-20241021monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-incorporated-nyse-elan-deadline-alert-bernstein-liebhard-llp-reminds--elan-20241021monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-elan-hit-with-investor-lawsuit-over-new-drug-hagens-berman-elan-20241017monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-incorporated-securities-fraud-class-action-lawsuit-pending-contact-le-elan-20241014monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-incorporated-nyse-elan-deadline-alert-bernstein-liebhard-llp-reminds--elan-20241014monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-elan-faces-investor-suit-over-zenrelia-safety-concerns-hagens-berman-elan-20241011monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-incorporated-investors-please-contact-the-portnoy-law-firm-to-recover-elan-20241009monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed--elan-20241009monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-elan-faces-investor-suit-over-zenrelia-safety-concerns-hagens-berman-elan-20241009monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-incorporated-nyse-elan-investor-alert-investors-with-large-losses-in--elan-20241008monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-elan-faces-scrutiny-over-delayed-product-launches-hagens-berman-elan-20240806monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-nyse-elan-investors-are-alerted-that-the-company-is-under-inquiry-for-securities-fr-elan-20240802monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-elan-faces-scrutiny-over-delayed-product-launches-hagens-berman-elan-20240801monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-elan-faces-scrutiny-over-delayed-product-launches-hagens-berman-elan-20240725monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-elan-faces-scrutiny-over-delayed-product-launches-hagens-berman-elan-20240722monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-shareholder-notification-elanco-nyse-elan-investors-that-suffered-an-investment-los-elan-20240716monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-elan-faces-scrutiny-over-delayed-product-launches-hagens-berman-elan-20240715monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-investor-notice-elanco-nyse-elan-shareholders-that-incurred-losses-are-urged-to-con-elan-20240713monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-elan-faces-scrutiny-over-delayed-product-launches-hagens-berman-elan-20240712monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-investor-alert-elanco-nyse-elan-shareholders-that-suffered-losses-are-notified-to-c-elan-20240711monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-elan-faces-scrutiny-and-shareholder-investigation-over-delayed-produc-elan-20240708monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-elan-faces-scrutiny-and-shareholder-investigation-over-delayed-produc-elan-20240706monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-alert-bragar-eagel-squire-p-c-is-investigating-elanco-animal-health-incorporated-on-elan-20240702monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-presents-new-symbravo-data-at-the-americal-headache-society-ahs-68th-a-axsm-20260604monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-participate-in-upcoming-investor-conferences-axsm-20260527monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-participate-in-upcoming-investor-conferences-axsm-20260505monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-third-quarter-2025-financial-results-on-november-3-axsm-20251007monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-participate-in-upcoming-investor-conferences-axsm-20250827monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-second-quarter-2025-financial-results-on-august-4-axsm-20250709monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-showcase-its-innovative-cns-pipeline-at-upcoming-frontiers-in-brain-axsm-20250707monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-champions-brain-health-during-alzheimer-s-brain-awareness-month-axsm-20250620monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-data-spanning-the-symbravo-meloxicam-and-rizatriptan-clinic-axsm-20250618monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-proudly-supports-migraine-and-headache-awareness-month-alongside-the-a-axsm-20250616monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-participate-in-upcoming-investor-conferences-axsm-20250529monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-presents-data-from-three-of-its-innovative-neuroscience-programs-at-th-axsm-20250528monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-and-mental-health-america-mha-join-voices-to-highlight-mental-health-m-axsm-20250501monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-participate-in-upcoming-investor-conferences-axsm-20250422monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-first-quarter-2025-financial-results-on-may-5-axsm-20250408monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-participate-in-upcoming-investor-conferences-axsm-20250226monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-symbravo-meloxicam-and-rizatriptan-achieves-primary-endpoint-axsm-20250224monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-hosts-symbravo-fda-approval-virtual-investor-event-with-expert-thought-axsm-20250131monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-febru-axsm-20250122monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-presents-data-from-multiple-programs-spanning-its-innovative-neuroscie-axsm-20241029monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-third-quarter-2024-financial-results-on-november-12-axsm-20241015monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-presents-data-from-multiple-programs-at-sleep-europe-2024-axsm-20240924monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-participate-in-investor-conferences-in-september-axsm-20240827monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-alert-bragar-eagel-squire-p-c-is-investigating-axsome-therapeutics-inc-on-behalf-of-axsm-20240811monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-second-quarter-2024-financial-results-on-august-5-axsm-20240711monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-joins-the-american-migraine-foundation-to-highlight-unmet-treatment-ne-axsm-20240604monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-supports-alzheimer-s-brain-awareness-month-axsm-20240603monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-participate-in-upcoming-investor-conferences-axsm-20240530monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-highlights-data-on-solriamfetol-demonstrating-improvement-in-cognitive-axsm-20240529monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-presents-data-from-multiple-programs-at-the-2024-american-society-of-c-axsm-20240528monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-upcoming-investor-conferences-axsm-20240508monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-recognizes-may-as-mental-health-awareness-month-axsm-20240501monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-alert-bragar-eagel-squire-p-c-is-investigating-axsome-therapeutics-inc-on-behalf-of-axsm-20240501monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-alert-bragar-eagel-squire-p-c-is-investigating-axsome-therapeutics-inc-on-behalf-of-axsm-20240418monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-highlights-innovative-neuroscience-portfolio-at-the-american-academy-o-axsm-20240415monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-alert-bragar-eagel-squire-p-c-is-investigating-axsome-therapeutics-inc-on-behalf-of-axsm-20240412monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-first-quarter-2024-financial-results-on-may-6-axsm-20240410monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-alert-bragar-eagel-squire-p-c-is-investigating-axsome-therapeutics-inc-on-behalf-of-axsm-20240404monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-alert-bragar-eagel-squire-p-c-is-investigating-axsome-therapeutics-inc-on-behalf-of-axsm-20240326monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-leerink-partners-global-biopharma-conference-axsm-20240305monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-td-cowen-44th-annual-healthcare-conference-axsm-20240227monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-fourth-quarter-and-full-year-2023-financial-results-on-febru-axsm-20240123monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-loss-axsm-20231128monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-host-solriamfetol-virtual-investor-event-on-december-7-axsm-20231122monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-piper-sandler-35th-annual-healthcare-conference-axsm-20231121monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-and-the-global-alzheimer-s-disease-community-come-together-in-raising--axsm-20231102monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-upcoming-investor-conferences-axsm-20231031monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-presents-results-of-the-accord-trial-of-axs-05-in-alzheimer-s-disease--axsm-20231024monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-third-quarter-2023-financial-results-on-november-6-axsm-20231010monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-joins-the-national-alliance-on-mental-illness-and-others-advocating-fo-axsm-20231002monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-joins-the-global-narcolepsy-community-in-raising-awareness-on-world-na-axsm-20230921monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-highlights-commitment-to-innovating-treatments-for-mental-health-condi-axsm-20230907monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-three-upcoming-investor-conferences-axsm-20230905monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-second-quarter-2023-financial-results-on-august-7-axsm-20230712monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-pricing-of-public-offering-of-225-million-of-shares-of-commo-axsm-20230628monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-new-sunosi-data-at-sleep-2023-axsm-20230601monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-bank-of-america-securities-2023-healthcare-conferenc-axsm-202305032023-05-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-joins-mental-health-america-and-the-state-of-new-york-to-raise-awarene-axsm-202305012023-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-five-abstracts-including-new-data-from-the-positive-sharp-s-axsm-202304212023-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference-axsm-202304142023-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-axsm-202304132023-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-cowen-s-43rd-annual-health-care-conference-axsm-202303012023-03-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference-axsm-202302072023-02-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-on-febru-axsm-202301312023-01-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-5th-annual-evercore-isi-healthconx-conference-axsm-20221123monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-guggenheim-4th-annual-immunology-and-neurology-confe-axsm-20221109monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-ring-the-nasdaq-stock-market-opening-bell-today-axsm-20221027monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-third-quarter-2022-financial-results-on-november-7-2022-axsm-20221021monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-voices-its-commitment-to-mental-health-on-world-mental-health-day-2022-axsm-20221010monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-ladenburg-thalmann-healthcare-conference-axsm-20220921monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-cowen-2nd-annual-novel-mechanisms-in-neuropsychiatry-axsm-20220914monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-publication-of-post-hoc-analysis-of-sunosi-effect-on-excessi-axsm-20220907monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-morgan-stanley-20th-annual-global-healthcare-confere-axsm-20220906monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-second-quarter-2022-financial-results-on-august-9-2022-axsm-20220728monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-inc-investors-filing-date-july-12-2022-contact-the-portnoy-law-firm-to-axsm-20220708monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-inc-nasdaq-axsm-shareholder-class-action-alert-bernstein-liebhard-llp--axsm-20220706monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-inc-investors-filing-date-july-12-2022-contact-the-portnoy-law-firm-to-axsm-20220629monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-inc-nasdaq-axsm-shareholder-class-action-alert-bernstein-liebhard-llp--axsm-20220628monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-hosts-sunosi-investor-update-virtual-event-today-with-key-opinion-lead-axsm-20220628monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-inc-nasdaq-axsm-shareholder-class-action-alert-bernstein-liebhard-llp--axsm-20220622monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-host-sunosi-investor-update-virtual-event-axsm-20220622monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-inc-nasdaq-axsm-shareholder-class-action-alert-bernstein-liebhard-llp--axsm-20220615monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-inc-investors-contact-the-portnoy-law-firm-to-recover-losses-axsm-20220613monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-inc-nasdaq-axsm-shareholder-class-action-alert-bernstein-liebhard-llp--axsm-20220608monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-results-of-the-support-survey-of-patients-with-major-depress-axsm-20220606monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-inc-investors-contact-the-portnoy-law-firm-to-recover-losses-axsm-20220602monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-inc-nasdaq-axsm-shareholder-class-action-alert-bernstein-liebhard-llp--axsm-20220601monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announc-axsm-20220518monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-inc-nasdaq-axsm-shareholder-class-action-alert-bernstein-liebhard-llp--axsm-20220517monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-inc-investors-contact-the-portnoy-law-firm-to-recover-losses-axsm-20220517monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-alert-bragar-eagel-squire-p-c-is-investigating-axsome-therapeutics-inc-on-behalf-of-axsm-20220428monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-inc-investors-company-investigated-by-the-portnoy-law-firm-axsm-20220425monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-participate-in-the-1st-annual-needham-virtual-neuroscience-forum-axsm-20220311monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-cowen-42nd-annual-health-care-conference-axsm-20220302monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-11th-annual-svb-leerink-global-healthcare-conference-axsm-20220211monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-third-quarter-2021-financial-results-on-november-8-2021-axsm-20211020monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-investigation-block-leviton-investigates-axsome-therapeutics-for-poten-axsm-20210809monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-axs-05-achieves-primary-and-key-secondary-endpoints-in-the-m-axsm-20210809monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-inc-investors-company-investigated-by-the-portnoy-law-firm-axsm-20210722monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-second-quarter-2021-financial-results-on-august-9-2021-axsm-20210715monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-joins-mental-health-america-and-other-advocacy-organizations-in-raisin-axsm-20210507monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-first-quarter-2021-financial-results-on-may-10-2021-axsm-20210427monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-upcoming-investor-conferences-axsm-20210219monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-march-axsm-20210216monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-initiates-accord-phase-3-trial-of-axs-05-in-alzheimer-s-disease-agitat-axsm-20201231monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-and-veeva-systems-partner-to-build-axsome-s-digital-centric-commercial-axsm-20201104monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-data-from-the-advance-1-trial-of-axs-05-in-alzheimer-s-dise-axsm-20201103monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-third-quarter-2020-financial-results-on-november-5-2020-axsm-20201028monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-axs-07-phase-3-migraine-trial-results-selected-by-the-americ-axsm-20200917monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-new-data-for-axs-05-in-major-depressive-disorder-at-the-33r-axsm-20200910monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-morgan-stanley-18th-annual-global-healthcare-confere-axsm-20200908monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-upcoming-investor-conferences-axsm-20200903monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-confirms-pivotal-status-and-advancement-of-axs-05-for-the-treatment-of-axsm-20200831monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-data-from-the-concert-phase-2-trial-of-axs-12-in-narcolepsy-axsm-20200828monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-further-progress-in-axs-05-depression-clinical-program-axsm-20200810monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-second-quarter-2020-financial-results-on-august-10-2020-axsm-20200730monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-upcoming-investor-conferences-axsm-20200604monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-presents-data-from-gemini-phase-3-trial-of-axs-05-in-major-depressive--axsm-20200529monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-host-2020-annual-meeting-of-stockholders-virtually-axsm-20200526monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-first-quarter-2020-financial-results-on-may-8-2020-axsm-20200430monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-the-promotion-of-mark-jacobson-to-chief-operating-officer-axsm-20200305monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-fourth-quarter-and-full-year-2019-financial-results-on-march-axsm-20200304monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-upcoming-investor-conferences-axsm-20200219monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-host-investor-r-d-call-with-key-opinion-leaders-focusing-on-axs-07--axsm-20191121monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-third-quarter-2019-financial-results-on-november-7-2019-axsm-20191029monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-morgan-stanley-17th-annual-global-healthcare-confere-axsm-20190903monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-second-quarter-2019-financial-results-on-august-8-2019-axsm-20190730monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-added-to-russell-3000-and-russell-2000-indexes-axsm-20190701monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-data-from-ascend-phase-2-trial-of-axs-05-in-major-depressiv-axsm-20190521monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-acceleration-of-momentum-phase-3-trial-of-axs-07-in-migraine-axsm-20190506monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-first-quarter-2019-financial-results-on-may-9-2019-axsm-20190429monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-fourth-quarter-and-full-year-2018-financial-results-on-march-axsm-20190305monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-biotech-showcase-2019-axsm-20181218monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-participate-in-2018-global-mizuho-investor-conference-axsm-20181119monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-third-quarter-2018-financial-results-on-november-9-2018-axsm-20181101monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-hosts-r-d-day-today-with-key-opinion-leaders-focusing-on-axs-05-and-un-axsm-20181018monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-host-call-today-with-key-opinion-leader-focusing-on-axs-12-and-unme-axsm-20181016monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-upcoming-investor-conferences-axsm-20181012monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-upcoming-investor-conferences-axsm-20180924monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-host-r-d-day-with-key-opinion-leaders-focused-on-axs-05-and-unmet-n-axsm-20180919monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-20th-annual-rodman-renshaw-global-investment-confere-axsm-20180828monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-second-quarter-2018-financial-results-on-august-8-2018-axsm-20180801monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-data-on-axs-05-at-the-2018-american-society-of-clinical-psy-axsm-20180529monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-2018-bio-international-convention-axsm-20180522monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-first-quarter-2018-financial-results-on-may-8-2018-axsm-20180501monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-hosts-r-d-day-today-with-key-opinion-leaders-focusing-on-axs-05-and-un-axsm-20180424monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-participate-in-the-leerink-partners-2018-cns-day-axsm-20180411monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-host-r-d-day-with-key-opinion-leaders-focused-on-axs-05-and-unmet-n-axsm-20180327monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-h-c-wainwright-annual-global-life-sciences-conference-axsm-20180326monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-17th-annual-needham-healthcare-conference-axsm-20180319monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-presents-scientific-rationale-for-the-development-of-axs-05-at-the-20t-axsm-20180312monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-fourth-quarter-and-full-year-2017-financial-results-on-march-axsm-20180228monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-2018-bio-ceo-investor-conference-axsm-20180205monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-biotech-showcase-2018-axsm-20171219monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-closing-of-9-5-million-registered-direct-offering-axsm-20171206monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-upcoming-investor-conferences-axsm-20170918monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-16th-annual-needham-healthcare-conference-axsm-20170323monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-pricing-of-its-public-offering-of-common-stock-axsm-20170321monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-29th-annual-roth-conference-axsm-20170227monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-2017-rbc-capital-markets-global-healthcare-conferenc-axsm-20170213monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-biotech-showcase-2017-axsm-20170104monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-publication-of-research-showing-axs-02-inhibits-pain-in-anim-axsm-20161004monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-ladenburg-thalmann-2016-healthcare-conference-axsm-20160919monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-upcoming-investor-conferences-axsm-20160906monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-cantor-fitzgerald-2nd-annual-healthcare-conference-axsm-20160705monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-added-to-russell-3000-and-russell-2000-indexes-axsm-20160627monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-15th-annual-needham-healthcare-conference-axsm-20160404monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-initiates-phase-3-study-of-axs-02-for-knee-osteoarthritis-associated-w-axsm-20160328monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-receives-new-u-s-patent-covering-axs-02-for-the-treatment-of-complex-r-axsm-20160315monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-inc-nasdaq-axsm-to-ring-the-nasdaq-stock-market-opening-bell-axsm-20160222monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-2016-bio-ceo-investor-conference-axsm-20160201monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-issuance-of-u-s-patent-covering-axs-02-for-the-treatment-of--axsm-20160127monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-biotech-showcase-2016-axsm-20160104monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-closing-of-initial-public-offering-axsm-20151124monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-appoints-world-leading-experts-to-depression-scientific-advisory-board-axsm-20150319monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-appointments-to-its-board-of-directors-axsm-20140917monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635--prax-20260109monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-proposed-public-offering-prax-20260106monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-announces-alignment-with-fda-on-simplified-and-accelerated-regi-prax-20251209monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-announces-positive-results-from-embold-study-for-relutrigine-in-prax-20251204monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-announces-positive-pre-nda-meeting-with-fda-for-ulixacaltamide--prax-20251204monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635--prax-20251203monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-to-present-latest-preclinical-and-clinical-advancements-across-leading-epilepsy-por-prax-20251124monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-participate-in-upcoming-fireside-chat-prax-20251120monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635--prax-20251002monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-alert-bragar-eagel-squire-p-c-is-investigating-praxis-precision-medicines-inc-on-be-prax-20250915monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-participate-in-september-investor-conferences-prax-20250904monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635--prax-20250903monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-participate-in-upcoming-fireside-chat-prax-20250829monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-medicines-to-present-at-36th-international-epilepsy-congress-2025-in-lisbon-showcas-prax-20250825monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-alert-bragar-eagel-squire-p-c-is-investigating-praxis-precision-medicines-inc-on-be-prax-20250823monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635--prax-20250806monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-participate-in-upcoming-fireside-chat-prax-20250805monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-investors-company-investigated-by-the-portnoy-law-firm-prax-20250805monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-announces-positive-best-in-disease-topline-results-in-patients--prax-20250804monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-host-conference-call-to-announce-topline-results-from-the-ra-prax-20250729monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-receives-fda-breakthrough-therapy-designation-for-relutrigine-f-prax-20250717monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635--prax-20250702monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635--prax-20250604monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-highlights-dee-clinical-program-updates-at-virtual-investor-eve-prax-20250505monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635--prax-20250502monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-hold-virtual-investor-event-to-discuss-clinical-programs-in--prax-20250408monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-participate-in-upcoming-april-conferences-prax-20250403monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635--prax-20250403monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-on-late-stage-programs-across-epilepsy-and-movement--prax-20250324monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635--prax-20250304monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-participate-in-five-upcoming-investor-conferences-prax-20250304monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635--prax-20250204monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-j-p-morgan-healthcare-conference-prax-20250106monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-participate-in-three-upcoming-november-investor-conferences-prax-20241106monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-presents-on-ulixacaltamide-essential3-program-at-the-movement-d-prax-20240926monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-participate-in-upcoming-investor-conferences-prax-20240905monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-highlight-their-epilepsy-portfolio-at-the-international-leag-prax-20240904monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-announce-second-quarter-2024-financial-results-and-host-conf-prax-20240805monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635--prax-20240604monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-participate-in-upcoming-investor-conferences-prax-20240517monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-first-quarter-2024-financ-prax-20240513monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-report-first-quarter-2024-financial-results-on-monday-may-13-prax-20240510monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635--prax-20240503monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635--prax-20240402monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-proposed-public-offering-prax-20240327monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-reports-positive-results-of-prax-628-study-evaluating-photo-par-prax-20240326monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-host-prax-628-program-update-prax-20240325monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-participate-in-td-cowen-s-44th-annual-health-care-conference-prax-20240301monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635--prax-20240202monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-pricing-of-150-0-million-public-offering-prax-20240111monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-proposed-public-offering-prax-20240110monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-update-on-advancing-clinical-stage-portfolio-prax-20240108monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-announces-licensing-and-collaboration-agreement-with-tenacia-bi-prax-20240105monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-the-piper-sandler-35th-annual-healthcare-conferen-prax-20231121monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-receives-prime-designation-from-the-ema-for-elsunersen-prax-222-prax-20231116monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-truist-securities-biopharma-symposium-prax-20231102monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-host-hybrid-r-d-day-on-monday-october-2-2023-prax-20230927monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-h-c-wainwright-25th-annual-global-investment-conf-prax-20230907monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-data-from-epilepsy-portfolio-at-the-35th-internation-prax-20230831monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-analyses-of-patient-focused-clinically-meaningful-en-prax-20230828monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-second-quarter-2023-finan-prax-20230809monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-announces-positive-data-from-randomized-withdrawal-sub-study-an-prax-20230808monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-announces-positive-results-of-eeg-analysis-of-prax-628-phase-1--prax-20230807monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-participate-at-the-2023-wedbush-pacgrow-healthcare-conferenc-prax-20230803monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-announces-closing-of-financing-and-reiterates-corporate-priorit-prax-20230622monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-pricing-of-59-1-million-public-offering-prax-20230616monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-proposed-public-offering-prax-20230615monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-announces-plans-to-begin-ulixacaltamide-phase-3-in-essential-tr-prax-20230609monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-the-2023-jefferies-healthcare-conference-prax-20230602monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-first-quarter-2023-financ-prax-202305112023-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-announces-positive-topline-results-from-prax-628-phase-1-study--prax-202305112023-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-the-american-academy-of-neurology-2023-annual-mee-prax-202304192023-04-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-announces-upcoming-ulixacaltamide-presentations-events-prax-202304172023-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-22nd-annual-needham-virtual-healthcare-conference-prax-202304062023-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-upcoming-investor-conferences-prax-202303032023-03-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-the-american-epilepsy-society-2022-annual-meeting-prax-20221128monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-upcoming-investor-conferences-prax-20221107monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference-prax-20220921monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-h-c-wainwright-24th-annual-global-investment-conf-prax-20220907monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-2022-wedbush-pacgrow-healthcare-conference-prax-20220803monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-upcoming-investor-conferences-prax-20220511monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-bofa-securities-2022-healthcare-conference-prax-20220504monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-provide-corporate-update-and-report-first-quarter-2022-finan-prax-20220502monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-host-epilepsy-day-on-april-27-2022-prax-20220413monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-stifel-s-4th-annual-cns-day-prax-20220321monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-cowen-s-42nd-annual-healthcare-conference-prax-20220301monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-provide-corporate-update-and-report-fourth-quarter-and-full--prax-20220222monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-piper-sandler-s-33rd-annual-virtual-healthcare-co-prax-20211124monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-provide-corporate-update-and-report-third-quarter-2021-finan-prax-20211022monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-reports-prax-114-perimenopausal-depression-pmd-phase-2a-proof-o-prax-20210816monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-2021-wedbush-pacgrow-healthcare-conference-prax-20210802monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-upcoming-investor-conferences-prax-20210706monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-appoints-tim-kelly-as-chief-financial-officer-prax-20210525monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-upcoming-investor-conferences-prax-20210514monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-prices-public-offering-of-common-stock-prax-20210514monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-receives-orphan-drug-designation-for-prax-562-for-the-treatment-prax-20210430monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-receives-orphan-drug-designation-for-prax-562-for-the-treatment-prax-20210414monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-stifel-s-3rd-annual-cns-day-prax-20210324monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-report-fourth-quarter-and-full-year-2020-financial-results-a-prax-20210315monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-partners-with-ciitizen-to-improve-patient-guided-drug-developme-prax-20210216monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-announces-closing-of-initial-public-offering-and-exercise-in-fu-prax-20201020monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-to-report-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march--imvt-20260511monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-to-report-financial-results-for-the-third-quarter-ended-december-31-2025-and-pr-imvt-20260123monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and--imvt-20251027monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-investigation-initiated-by-former-louisiana-attorney-general-kahn-swick-foti-ll-imvt-20250917monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-announces-oral-presentation-of-late-breaking-abstract-for-phase-2-graves-diseas-imvt-20241029monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-to-host-graves-disease-program-update-on-september-9-2024-imvt-20240905monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-awarded-u-s-patent-for-imvt-1402-imvt-20240312monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-imvt-20240103monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-to-present-at-upcoming-investor-conferences-imvt-20231113monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-announces-closing-of-upsized-common-stock-financing-and-full-exercise-of-underw-imvt-20231002monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-announces-pricing-of-450-million-common-stock-financing-imvt-20230928monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-announces-proposed-offering-of-300-million-of-common-stock-imvt-20230926monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-to-host-conference-call-and-webcast-to-report-initial-imvt-1402-phase-1-results-imvt-20230926monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-to-present-at-guggenheim-4th-annual-immunology-and-neurology-day-on-november-14-imvt-20221107monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-to-present-at-roivant-investor-day-on-september-28th-imvt-20220921monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference-on-se-imvt-20220909monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-announces-two-new-development-programs-for-batoclimab-imvt-20220907monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-to-host-investor-webcast-to-announce-two-new-indications-for-batoclimab-on-sept-imvt-20220824monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-to-report-fourth-quarter-and-full-year-2022-financial-results-on-june-8-2022-imvt-20220606monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-to-present-at-the-h-c-wainwright-global-investment-conference-on-may-25th-imvt-20220523monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-to-present-at-the-ubs-global-healthcare-conference-on-may-23rd-imvt-20220519monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-to-present-at-lifesci-partners-immunology-and-inflammation-symposium-on-may-10t-imvt-20220504monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-to-host-virtual-r-d-day-on-march-30-2022-imvt-20220328monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-to-present-at-the-11th-annual-svb-leerink-global-healthcare-conference-imvt-20220209monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-appoints-mark-levine-as-chief-legal-officer-imvt-20220125monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-to-report-financial-results-for-quarter-ended-june-30-2021-imvt-20210806monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-imvt-investigation-alert-andrews-springer-llc-is-investigating-immunovant-inc-f-imvt-20210628monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-provides-corporate-updates-and-reports-financial-results-for-the-quarter-and-fi-imvt-20210601monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-inc-technology-investors-last-days-to-participate-actively-in-the-class-action--imvt-20210414monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-inc-investors-company-investigated-by-the-portnoy-law-firm-imvt-20210210monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-appoints-rita-jain-chief-medical-officer-and-provides-corporate-update-imvt-20210112monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-announces-closing-of-200-0-million-public-offering-including-full-exercise-of-u-imvt-20200904monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-announces-pricing-of-public-offering-imvt-20200902monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-appoints-michael-elliott-chief-scientific-officer-imvt-20200824monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-announces-closing-of-139-4-million-public-offering-including-full-exercise-of-u-imvt-20200416monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-announces-pricing-of-121-2-million-public-offering-imvt-20200414monthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-to-present-at-the-9th-annual-svb-leerink-global-healthcare-conference-imvt-20200210monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-united-kingdom-mhra-approval-of-vyjuvek-for-the-treatment-of-dys-krys-20260518monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-provides-business-update-at-44th-annual-j-p-morgan-healthcare-conference-krys-20260111monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-announce-interim-clinical-update-from-highest-dose-cohort-of-phase-1-co-krys-20260107monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-report-third-quarter-2025-financial-results-on-november-3-2025-krys-20251021monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-second-quarter-2025-financial-and-operating-results-krys-20250804monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-report-second-quarter-2025-financial-results-on-august-4-2025-krys-20250729monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-first-patient-dosed-in-phase-3-clinical-trial-of-kb803-for-the-t-krys-20250624monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-goldman-sachs-46th-annual-global-healthcare-conference-krys-20250603monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-bofa-securities-2025-health-care-conference-krys-20250507monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-first-quarter-2025-financial-and-operating-results-krys-20250506monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-upcoming-scientific-conferences-krys-20250424monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-report-first-quarter-2025-financial-results-on-may-6-2025-krys-20250417monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-receives-positive-chmp-opinion-for-vyjuvek-for-the-treatment-of-dystrophic-krys-20250228monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-td-cowen-45th-annual-health-care-conference-krys-20250226monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-fourth-quarter-and-full-year-2024-financial-and-operating-result-krys-20250219monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-report-fourth-quarter-and-full-year-2024-financial-results-on-february--krys-20250206monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-early-evidence-of-monotherapy-activity-in-heavily-pre-treated-pa-krys-20241218monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-initial-clinical-update-for-rare-respiratory-disease-programs-kb-krys-20241212monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-provides-update-on-ema-s-ongoing-regulatory-review-of-b-vec-for-dystrophic-krys-20241209monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-upcoming-investor-conferences-krys-20241127monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-stifel-2024-healthcare-conference-krys-20241112monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-guggenheim-securities-healthcare-innovation-conference-krys-20241106monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-third-quarter-2024-financial-results-and-provides-business-updat-krys-20241104monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-report-third-quarter-2024-financial-results-on-november-4-2024-krys-20241028monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-2024-cantor-global-healthcare-conference-krys-20240913monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-h-c-wainwright-26th-annual-global-investment-conference-krys-20240906monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-second-quarter-2024-financial-results-and-provides-business-upda-krys-20240805monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-report-second-quarter-2024-financial-results-on-august-5-2024-krys-20240726monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-goldman-sachs-45th-annual-global-healthcare-conference-krys-20240605monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-the-american-thoracic-society-2024-international-conference-krys-20240515monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-bofa-securities-2024-health-care-conference-krys-20240508monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-the-association-for-research-in-vision-and-ophthalmology-202-krys-20240502monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-report-first-quarter-2024-financial-results-on-may-6-2024-krys-20240426monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-first-patient-dosed-in-phase-1-clinical-trial-of-inhaled-kb707-f-krys-20240422monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-the-american-association-for-cancer-research-2024-annual-mee-krys-20240404monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-td-cowen-44th-annual-health-care-conference-krys-20240228monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-fourth-quarter-and-full-year-2023-financial-results-and-provides-krys-20240226monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-report-fourth-quarter-and-full-year-2023-financial-results-on-february--krys-20240220monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-receives-fda-fast-track-designation-for-inhaled-oncology-candidate-kb707-t-krys-20240213monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-publication-in-the-new-england-journal-of-medicine-on-the-applic-krys-20240208monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-guggenheim-6th-annual-biotechnology-conference-krys-20240201monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-receives-permanent-j-code-j3401-for-vyjuvek-krys-20240104monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-receives-orphan-drug-designation-from-the-japanese-mhlw-for-beremagene-gep-krys-20231219monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-ema-validation-of-marketing-authorization-application-for-vyjuve-krys-20231127monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-the-stifel-2023-healthcare-conference-krys-20231109monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-third-quarter-2023-financial-results-and-provides-business-updat-krys-20231106monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-report-third-quarter-2023-financial-results-on-november-6-2023-krys-20231030monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-the-chardan-7th-annual-genetic-medicines-conference-krys-20230928monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-fda-clearance-of-investigational-new-drug-application-for-kb408--krys-20230921monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-the-morgan-stanley-21st-annual-global-healthcare-conference-krys-20230907monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-orphan-drug-designation-granted-to-kb408-for-the-treatment-of-al-krys-20230905monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-sale-of-priority-review-voucher-for-100-million-krys-20230821monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-second-quarter-2023-financial-results-and-operational-highlights-krys-20230807monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-first-patient-dosed-in-phase-1-clinical-trial-of-kb407-for-the-t-krys-20230703monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-upcoming-investor-conferences-krys-20230605monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-receives-fda-approval-for-the-first-ever-redosable-gene-therapy-vyjuvek-be-krys-20230519monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-first-quarter-2023-financial-results-and-operational-highlights-krys-202305082023-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-association-for-research-in-vision-and-ophthalmology-annual--krys-202304132023-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-the-43rd-annual-td-cowen-health-care-conference-krys-202303022023-03-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-receives-european-commission-orphan-designation-for-kb407-for-the-treatmen-krys-202301182023-01-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-fda-s-3-month-extension-of-bla-pdufa-date-and-regulatory-update--krys-202301092023-01-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-bofa-securities-2022-biotech-smid-cap-conference-krys-20221201monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-5th-annual-evercore-isi-healthconx-conference-krys-20221123monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-third-quarter-2022-financial-results-and-operational-highlights-krys-20221107monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-chardan-s-6th-annual-genetic-medicines-conference-krys-20220929monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-receives-positive-opinion-from-ema-pediatric-committee-on-the-pediatric-in-krys-20220921monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-h-c-wainwright-24th-annual-global-investment-conference-krys-20220908monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-second-quarter-2022-financial-results-and-reports-updates-on-ope-krys-20220808monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-fda-acceptance-of-kb407-ind-application-for-cystic-fibrosis-clin-krys-20220801monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-receives-fda-acceptance-of-kb407-ind-application-for-cystic-fibrosis-clini-krys-20220801monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-william-blair-biotech-focus-conference-2022-krys-20220706monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-submits-biologics-license-application-to-u-s-fda-seeking-approval-of-b-vec-krys-20220622monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-goldman-sachs-43rd-annual-global-healthcare-conference-krys-20220607monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-additional-data-on-b-vec-from-the-gem-3-phase-3-study-at-the-so-krys-20220519monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-participate-in-bank-of-america-merrill-lynch-global-healthcare-conferen-krys-20220503monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-home-dosing-in-b-vec-open-label-extension-study-krys-20220411monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-publication-of-phase-1-and-2-clinical-trial-gem-1-2-study-of-ber-krys-20220328monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-participate-in-h-c-wainwright-and-guggenheim-investor-conferences-krys-20220324monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-2022-american-academy-of-dermatology-annual-meeting-krys-20220318monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-u-krys-20220228monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-participate-in-cowen-s-42nd-annual-health-care-conference-krys-20220224monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-pricing-of-200-million-public-offering-of-common-stock-krys-20211201monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-proposed-200-million-public-offering-of-common-stock-krys-20211129monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-completion-of-the-gem-3-pivotal-phase-3-study-evaluating-b-vec-f-krys-20211026monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-virtual-presentation-of-pre-clinical-data-on-kb407-for-the-treat-krys-20211019monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-virtual-presentation-of-pre-clinical-data-on-kb408-for-the-treat-krys-20211014monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-the-chardan-5th-annual-genetic-medicines-conference-krys-20211001monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-receives-approval-from-the-human-research-ethics-committee-in-australia-fo-krys-20210929monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-appoints-laurent-goux-as-general-manager-of-europe-krys-20210915monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-202-krys-20210909monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-participate-in-h-c-wainwright-23rd-annual-global-investment-conference-krys-20210907monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-participate-in-upcoming-investor-conferences-krys-20210603monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-appoints-andy-orth-as-chief-commercial-officer-krys-20210503monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-virtual-presentation-of-data-from-its-vector-encoded-antibody-pl-krys-20210427monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-provides-update-on-pivotal-gem-3-study-of-b-vec-for-deb-krys-20210426monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-provides-updates-from-its-rare-genetic-lung-disease-pipeline-krys-20210419monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-completion-of-patient-enrollment-in-the-gem-3-pivotal-trial-of-b-krys-20210330monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-participate-in-upcoming-investor-conferences-krys-20210329monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-the-cowen-41st-annual-health-care-conference-krys-20210223monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-pricing-of-upsized-125-million-public-offering-of-common-stock-krys-20210203monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-hc-wainwright-and-morgan-stanley-healthcare-conferences-krys-20200909monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-initiation-of-phase-1-study-evaluating-kb301-in-aesthetic-indica-krys-20200825monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-s-kb407-granted-orphan-drug-designation-by-the-fda-to-treat-patients-with--krys-20200817monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-the-william-blair-biotech-conference-krys-20200730monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-initiation-of-pivotal-phase-3-study-of-beremagene-geperpavec-in--krys-20200728monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-appoints-whitney-ijem-as-senior-vice-president-strategy-and-business-devel-krys-20200720monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-the-goldman-sachs-41st-annual-global-healthcare-conference-w-krys-20200608monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-pricing-of-125-million-public-offering-of-common-stock-krys-20200519monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-proposed-public-offering-of-common-stock-krys-20200518monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-the-cowen-40th-annual-healthcare-conference-krys-20200221monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-breaks-ground-on-second-commercial-gene-therapy-manufacturing-facility-krys-20200124monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-appoints-jennifer-chien-as-chief-commercial-officer-krys-20200121monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-the-piper-jaffray-31st-annual-healthcare-conference-krys-20191126monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-receives-positive-ema-opinion-on-orphan-designation-for-kb105-to-treat-pat-krys-20191010monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-the-cantor-2019-global-healthcare-conference-and-chardan-s-3-krys-20190930monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-granting-of-its-first-foreign-patent-and-reinforces-its-ip-portf-krys-20190927monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-initiation-of-phase-1-2-study-of-kb105-in-transglutaminase-1-tgm-krys-20190904monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-attendance-at-citi-s-14th-annual-biotech-conference-krys-20190827monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-inc-added-to-the-russell-2000-index-krys-20190701monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-pricing-of-100-0-million-public-offering-of-common-stock-krys-20190624monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-proposed-100-million-public-offering-of-common-stock-krys-20190624monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-submits-investigational-new-drug-ind-application-for-kb105-topical-gene-therapy-ca-krys-20190614monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-the-rbc-capital-markets-2019-healthcare-conference-krys-20190515monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-five-presentations-of-clinical-and-preclinical-data-at-the-socie-krys-20190429monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-continues-vertical-integration-with-official-inauguration-of-ancoris-gene--krys-20190306monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-the-cowen-and-company-39th-annual-health-care-conference-krys-20190301monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-the-8th-annual-svb-leerink-global-healthcare-conference-krys-20190222monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-completes-construction-of-ancoris-a-new-gmp-facility-for-commercial-manufa-krys-20190115monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-completes-dosing-in-the-gem-phase-2-study-in-pediatric-patients-for-the-tr-krys-20181219monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-evercore-isi-healthconx-krys-20181120monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-pricing-of-60-0-million-public-offering-of-common-stock-krys-20181018monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-chardan-annual-genetic-medicines-conference-krys-20181004monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-2018-cell-gene-meeting-on-the-mesa-krys-20181001monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-upcoming-cantor-fitzgerald-and-ladenburg-thalmann-conference-krys-20180925monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-at-upcoming-b-riley-fbr-and-h-c-wainwright-healthcare-investor--krys-20180829monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotechs-kb105-receives-rare-pediatric-disease-designation-from-the-fda-to-treat-p-krys-20180823monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-10-million-private-placement-with-frazier-healthcare-partners-krys-20180816monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-s-kb105-granted-orphan-drug-designation-by-the-fda-to-treat-patients-with--krys-20180809monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-reports-second-quarter-2018-financial-results-and-provides-corporate-updat-krys-20180806monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-to-present-update-on-kb103-program-for-treatment-of-dystrophic-epidermolys-krys-20180716monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-dosing-of-first-patient-in-the-phase-1-2-trial-of-kb103-a-first--krys-20180510monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-presents-in-vivo-kb103-data-at-the-international-investigative-dermatology-krys-20180509monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-fda-clearance-of-ind-on-kb103-to-begin-enrolling-patients-for-th-krys-20180426monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-s-kb103-receives-orphan-medicinal-product-designation-in-europe-for-dystro-krys-20180419monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-presents-their-skin-targeted-delivery-platform-at-the-world-orphan-drug-co-krys-20180418monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-submits-investigational-new-drug-ind-application-for-kb103-topical-gene-therapy-ca-krys-20180327monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-reports-2017-financial-results-and-business-progress-krys-20180312monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-inc-to-present-at-the-30th-annual-roth-conference-krys-20180305monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-inc-announces-granting-of-u-s-composition-of-matter-patent-covering-herpes-krys-20180116monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-s-kb103-granted-orphan-drug-designation-by-the-fda-to-treat-patients-with--krys-20171107monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-receives-equity-based-award-from-eb-research-partnership-and-eb-medical-re-krys-20171103monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-closing-of-initial-public-offering-and-full-exercise-of-underwri-krys-20170922monthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-announces-presentation-of-kb103-data-at-eb2017-the-5th-world-conference-of-krys-20170921monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-s-phase-3-viktoria-2-trial-of-gedatolisib-as-a-first-line-treatment-for-hr-her2-a-celc-20260514monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-schedules-release-of-fourth-quarter-and-full-year-2025-financial-results-and-webc-celc-20260318monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-announces-publication-of-results-from-pik3ca-wild-type-cohort-of-phase-3-viktoria-celc-20260309monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-to-participate-in-upcoming-investor-conferences-celc-20260225monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-presents-updated-results-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-celc-20251211monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria--celc-20251126monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-schedules-release-of-second-quarter-2025-financial-results-and-webcast-confer-celc-20250807monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-to-announce-topline-results-for-the-pik3ca-wild-type-cohort-from-phase-3-viktoria-celc-20250725monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-announces-first-patient-dosed-in-phase-3-viktoria-2-clinical-trial-of-gedatolisib-celc-20250724monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-announces-issuance-of-new-patent-for-gedatolisib-that-extends-patent-exclusivity--celc-20250714monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-reports-clinical-data-from-two-early-phase-studies-of-gedatolisib-celc-20250630monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-to-present-at-upcoming-td-cowen-and-jefferies-investor-conferences-celc-20250521monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-schedules-release-of-first-quarter-2025-financial-results-and-webcast-confere-celc-20250507monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences-celc-20250401monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-schedules-release-of-fourth-quarter-and-full-year-2024-financial-results-and--celc-20250324monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences-celc-20250225monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-presents-overall-survival-data-from-phase-1b-study-evaluating-gedatolisib-in-comb-celc-20241211monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-to-present-at-upcoming-stifel-and-jefferies-investor-conferences-celc-20241112monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-schedules-release-of-third-quarter-2024-financial-results-and-webcast-confere-celc-20241107monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-schedules-release-of-second-quarter-2024-financial-results-and-webcast-confer-celc-20240807monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-to-participate-in-jefferies-global-healthcare-conference-celc-20240603monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-schedules-release-of-first-quarter-2024-financial-results-and-webcast-confere-celc-20240508monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences-celc-20240404monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-schedules-release-of-fourth-quarter-and-full-year-2023-financial-results-and--celc-20240320monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-to-participate-in-leerink-partners-global-biopharma-conference-2024-celc-20240306monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-to-participate-in-cowen-s-44th-annual-health-care-conference-celc-20240228monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-announces-first-patient-dosed-in-phase-1b-2-celc-g-201-clinical-trial-of-gedatoli-celc-20240222monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-appoints-eldon-mayer-as-chief-commercial-officer-celc-20240220monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-presents-preclinical-data-on-therapeutic-effects-of-gedatolisib-in-breast-cancer--celc-20231206monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-to-present-preclinical-data-for-gedatolisib-at-the-2023-san-antonio-breast-cancer-celc-20231201monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-to-participate-in-the-6th-annual-evercore-isi-healthconx-conference-celc-20231122monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-schedules-release-of-third-quarter-2023-financial-results-and-webcast-confere-celc-20231106monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-to-present-at-upcoming-stifel-and-jefferies-investor-conferences-celc-20231101monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-to-host-virtual-science-day-for-investors-celc-20230907monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-enters-into-a-clinical-trial-collaboration-and-supply-agreement-with-bayer-to-pro-celc-20230822monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-inc-schedules-release-of-second-quarter-2023-financial-results-and-webcast-confer-celc-20230803monthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-to-participate-in-the-btig-virtual-biotechnology-conference-2023-celc-20230731monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-commencement-of-proposed-public-offering-of-common-stock-and-pre-funded--pcvx-20260129monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-advances-to-second-stage-of-ongoing-phase-2-study-evaluating-vax-31-for-the-preven-pcvx-20250205monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-present-at-the-guggenheim-smid-cap-biotech-conference-pcvx-20250130monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-initiates-phase-2-study-evaluating-vax-31-for-the-prevention-of-invasive-pneumococ-pcvx-20241203monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-provides-positive-regulatory-updates-on-vax-31-pediatric-and-adult-programs-pcvx-20241112monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-present-at-the-2024-cantor-global-healthcare-conference-pcvx-20240911monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-closing-of-1-5-billion-public-offering-including-full-exercise-of-underw-pcvx-20240906monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-pricing-of-1-3-billion-public-offering-pcvx-20240905monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-commencement-of-proposed-public-offering-of-common-stock-and-pre-funded--pcvx-20240903monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-stud-pcvx-20240902monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-appoints-john-furey-to-board-of-directors-pcvx-20240702monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-present-at-the-23rd-annual-needham-virtual-healthcare-conference-pcvx-20240402monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-completes-enrollment-of-phase-2-study-evaluating-vax-24-for-the-prevention-of-inva-pcvx-20240304monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-report-fourth-quarter-and-full-year-2023-financial-results-on-february-27-2024-pcvx-20240215monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-closing-of-862-5-million-public-offering-including-full-exercise-of-unde-pcvx-20240202monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-present-at-the-guggenheim-healthcare-talks-6th-annual-biotechnology-conference-pcvx-20240201monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-pricing-of-750-million-public-offering-pcvx-20240131monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-commencement-of-proposed-public-offering-of-common-stock-and-pre-funded--pcvx-20240130monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-completes-enrollment-of-phase-1-2-study-evaluating-vax-31-for-the-prevention-of-in-pcvx-20240129monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-appoints-whitney-jones-as-chief-people-officer-pcvx-20240116monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-provides-clinical-and-regulatory-progress-update-on-potential-best-in-class-pneumo-pcvx-20240104monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-appoints-jacks-lee-to-board-of-directors-pcvx-20231128monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-exercises-option-and-enters-into-manufacturing-rights-agreement-with-sutro-biophar-pcvx-20231127monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-doses-first-participants-in-phase-1-2-clinical-study-evaluating-vax-31-for-the-pre-pcvx-20231109monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-present-at-upcoming-investor-conferences-pcvx-20231031monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-fda-clearance-of-investigational-new-drug-application-for-vax-31-for-the-pcvx-20231019monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-and-lonza-expand-collaboration-for-global-commercial-manufacturing-of-broad-spectr-pcvx-20231016monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-present-at-the-2023-cantor-fitzgerald-global-healthcare-conference-pcvx-20230919monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-advances-to-second-stage-of-ongoing-phase-2-study-evaluating-vax-24-for-the-preven-pcvx-20230711monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-present-at-the-jefferies-healthcare-conference-pcvx-20230601monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-present-at-the-bofa-securities-2023-health-care-conference-pcvx-202305032023-05-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-closing-of-575-million-public-offering-including-full-exercise-of-underw-pcvx-202304212023-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-pricing-of-500-million-public-offering-pcvx-202304192023-04-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-commencement-of-proposed-public-offering-of-common-stock-and-pre-funded--pcvx-202304172023-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-host-webcast-and-conference-call-to-discuss-results-from-phase-2-study-of-its-2-pcvx-202304162023-04-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-doses-first-participants-in-phase-2-study-evaluating-vax-24-for-the-prevention-of--pcvx-202303302023-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-fda-clearance-of-investigational-new-drug-application-for-vax-24-for-the-pcvx-202302212023-02-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023-pcvx-202302162023-02-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-present-at-the-svb-securities-global-biopharma-conference-pcvx-202302072023-02-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-s-vax-24-granted-fda-breakthrough-therapy-designation-for-the-prevention-of-invasi-pcvx-202301052023-01-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-present-at-upcoming-investor-conferences-pcvx-20221103monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-closing-of-690-million-public-offering-including-full-exercise-of-underw-pcvx-20221028monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-pricing-of-600-million-public-offering-pcvx-20221026monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-commencement-of-proposed-public-offering-of-common-stock-and-pre-funded--pcvx-20221024monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-host-webcast-and-conference-call-to-discuss-topline-results-from-the-phase-1-2--pcvx-20221023monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-expands-executive-leadership-team-with-key-appointments-pcvx-20221011monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-completes-enrollment-of-phase-2-study-evaluating-safety-tolerability-and-immunogen-pcvx-20220906monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-provides-positive-regulatory-updates-for-vax-24-adult-and-pediatric-programs-pcvx-20220804monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-completes-enrollment-of-phase-2-portion-of-phase-1-2-clinical-proof-of-concept-stu-pcvx-20220712monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-present-at-the-jefferies-healthcare-conference-pcvx-20220602monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-participate-in-upcoming-investor-conferences-in-may-pcvx-20220503monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-present-at-the-21st-annual-needham-virtual-healthcare-conference-pcvx-20220405monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-doses-first-participants-in-phase-2-portion-of-ongoing-vax-24-phase-1-2-clinical-p-pcvx-20220404monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-doses-first-participants-in-phase-1-2-clinical-study-evaluating-vax-24-for-the-pre-pcvx-20220223monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-report-fourth-quarter-and-full-year-2021-financial-results-on-february-28-2022-pcvx-20220217monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-present-at-the-11th-annual-svb-leerink-global-healthcare-conference-pcvx-20220210monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-pricing-of-100-million-public-offering-pcvx-20220113monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-pcvx-20220112monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-fda-clearance-of-investigational-new-drug-application-for-vax-24-for-the-pcvx-20220106monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-present-at-upcoming-investor-conferences-pcvx-20211111monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-appoints-carlos-paya-and-michael-kamarck-to-its-board-of-directors-pcvx-20211028monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-present-at-guggenheim-2nd-annual-vaccine-and-infectious-disease-conference-pcvx-20210928monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-present-at-2021-cantor-virtual-global-healthcare-conference-pcvx-20210921monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-appoints-annie-drapeau-and-teri-loxam-to-its-board-of-directors-pcvx-20210920monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-expanded-carb-x-award-to-advance-development-of-vax-a1-a-vaccine-to-prev-pcvx-20210805monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-present-at-the-jefferies-virtual-healthcare-conference-pcvx-20210527monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-publication-of-preclinical-data-supporting-the-potential-of-vax-24-for-t-pcvx-20210510monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-present-at-bofa-securities-2021-health-care-conference-pcvx-20210506monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-present-at-20th-annual-needham-virtual-healthcare-conference-pcvx-20210405monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-report-fourth-quarter-and-full-year-2020-financial-results-on-march-29-2021-pcvx-20210322monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-publication-of-preclinical-proof-of-concept-data-supporting-potential-of-pcvx-20210106monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-promotes-andrew-guggenhime-to-president-and-chief-financial-officer-pcvx-20201222monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference-pcvx-20201124monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-present-at-jefferies-virtual-london-healthcare-conference-pcvx-20201110monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-to-present-at-2020-cantor-virtual-global-healthcare-conference-pcvx-20200909monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-pricing-of-upsized-initial-public-offering-pcvx-20200612monthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-appoints-halley-e-gilbert-to-board-of-directors-pcvx-20200603monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-alert-bragar-eagel-squire-p-c-is-investigating-biomarin-pharmaceuticals-on-behalf-bmrn-20211230monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-bmrn-20211215monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-bmrn-20211210monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-bmrn-20211204monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-bmrn-20211129monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-bmrn-20211123monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-bmrn-20211117monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pharmaceutical-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-ann-bmrn-20211027monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pharmaceutical-inc-investors-last-days-to-participate-actively-in-the-class-actio-bmrn-20201120monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-bmrn-20200929monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pharmaceutical-inc-nasdaq-bmrn-to-ring-the-nasdaq-stock-market-closing-bell-bmrn-20171016monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-attend-three-upcoming-investor-conferences-bmrn-20161103monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-third-quarter-2016-financial-results-conference-call-and-webcast-on-thurs-bmrn-20161011monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-attend-upcoming-investor-conferences-bmrn-20160831monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-pricing-of-public-offering-of-common-stock-bmrn-20160809monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-public-offering-of-common-stock-bmrn-20160808monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-second-quarter-2016-financial-results-bmrn-20160804monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-provides-positive-proof-of-concept-data-for-bmn-270-gene-therapy-in-hemophilia-a--bmrn-20160727monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-provide-updated-data-for-bmn-270-in-hemophilia-a-in-late-breaking-oral-present-bmrn-20160721monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-appoints-two-biopharmaceutical-veterans-to-board-of-directors-willard-dere-m-d-an-bmrn-20160718monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-second-quarter-2016-financial-results-conference-call-and-webcast-on-thur-bmrn-20160714monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-acceptance-of-late-breaking-abstract-for-bmn-270-at-the-world-federatio-bmrn-20160620monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-withdrawal-of-market-authorization-application-for-kyndrisa-drisapersen-bmrn-20160531monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-attend-upcoming-investor-conferences-bmrn-20160504monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-ema-grants-accelerated-assessment-for-cerliponase-alfa-experimental-tre-bmrn-20160503monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-first-quarter-2016-financial-results-bmrn-20160428monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-enrolls-first-patient-in-phase-1-2-trial-of-naglu-fusion-protein-bmn-250-for-trea-bmrn-20160421monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-provides-program-update-on-vosoritide-in-achondroplasia-bmrn-20160420monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-provides-encouraging-preliminary-data-on-first-8-patients-in-hemophilia-a-gene-th-bmrn-20160420monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pharmaceutical-inc-nasdaq-bmrn-to-ring-the-nasdaq-stock-market-closing-bell-bmrn-20160418monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-highlight-breadth-of-innovative-development-pipeline-at-r-d-day-on-april-20th--bmrn-20160418monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-first-quarter-2016-financial-results-conference-call-and-webcast-on-thurs-bmrn-20160412monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-receives-european-orphan-drug-designation-for-bmn-270-first-investigational-aav-f-bmrn-20160324monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-phase-3-study-of-pegvaliase-for-phenylketonuria-pku-meets-primary-endpoint-of-blo-bmrn-20160321monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-attend-three-upcoming-investor-conferences-in-march-bmrn-20160303monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-positive-data-from-cerliponase-alfa-program-for-treatment-of-cln2-disea-bmrn-20160303monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-receives-orphan-drug-designation-from-fda-for-first-aav-factor-viii-gene-therapy--bmrn-20160301monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-biomarin-rareconnections-tm-rebranding-and-consolidating-biomarin-s-com-bmrn-20160229monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-21-presentations-at-12th-annual-worldsymposium-2016-february-29-march-4-bmrn-20160229monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-fourth-quarter-and-full-year-2015-financial-results-bmrn-20160225monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-fourth-quarter-and-full-year-2015-financial-results-conference-call-and-w-bmrn-20160128monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-interim-analysis-of-inspire-clinical-trial-in-pompe-disease-at-34th-ann-bmrn-20160111monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-34th-annual-j-p-morgan-healthcare-conference-in-san-francisco-bmrn-20160105monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-addition-of-david-pyott-former-allergan-chairman-and-ceo-to-company-s-b-bmrn-20160104monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-that-fda-has-advised-it-will-not-take-action-on-the-kyndrisa-drisaperse-bmrn-20151218monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-posts-presentation-from-fda-advisory-committee-meeting-for-kyndrisa-tm-drisaperse-bmrn-20151124monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pharmaceutical-inc-nasdaq-bmrn-announced-today-the-stock-is-halted-bmrn-20151124monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-data-analysis-demonstrating-consistent-efficacy-of-kyndrisa-drisapersen-bmrn-20151120monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-third-quarter-2015-financial-results-and-company-update-bmrn-20151029monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-attend-upcoming-investor-conference-in-november-bmrn-20151027monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-third-quarter-2015-financial-results-conference-call-and-webcast-on-thurs-bmrn-20151015monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-fda-advisory-committee-to-review-drisapersen-for-treatment-of-patients--bmrn-20151015monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-s-initial-6-month-data-from-phase-2-study-of-vosoritide-bmn-111-in-children-with--bmrn-20151012monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-acquire-rights-to-phenylketonuria-pku-franchise-from-merck-serono-bmrn-20151001monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-research-results-on-duchenne-muscular-dystrophy-and-pompe-disease-prog-bmrn-20150930monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-receives-favorable-ruling-in-the-use-of-exon-51-antisense-oligonucleotides-patent-bmrn-20150929monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-enrolls-first-patient-in-phase-1-2-trial-of-gene-therapy-drug-candidate-bmn-270-f-bmrn-20150928monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-kuvan-r-sapropterin-dihydrochloride-patent-challenge-settlement-bmrn-20150918monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-attend-upcoming-investor-conferences-in-september-bmrn-20150902monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-launches-knowyourduchenne-comprehensive-program-for-patients-with-duchenne-muscul-bmrn-20150901monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-two-oral-and-19-poster-presentations-at-the-society-for-the-study-of-in-bmrn-20150831monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-receives-rare-pediatric-disease-designation-from-fda-for-drisapersen-for-the-pote-bmrn-20150819monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-second-quarter-2015-financial-results-and-company-update-bmrn-20150803monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-joins-the-nasdaq-100-index-bmrn-20150727monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pharmaceutical-inc-to-join-the-nasdaq-100-index-beginning-july-27-2015-bmrn-20150723monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-provides-program-update-for-talazoparib-in-metastatic-breast-cancer-bmrn-20150720monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-second-quarter-2015-financial-results-conference-call-and-webcast-on-mond-bmrn-20150715monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-fda-accepts-drisapersen-nda-for-treatment-of-duchenne-muscular-dystroph-bmrn-20150629monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-ema-validates-maa-for-drisapersen-for-treatment-of-duchenne-muscular-dy-bmrn-20150625monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-ceo-jean-jacques-bienaime-awarded-ey-entrepreneur-of-the-year-r-2015-award-in-nor-bmrn-20150615monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-submits-drisapersen-maa-to-ema-for-the-treatment-of-duchenne-muscular-dystrophy-a-bmrn-20150608monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-management-to-present-at-the-deutsche-bank-40th-annual-health-care-conference-on--bmrn-20150501monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-first-quarter-2015-financial-results-and-company-update-bmrn-20150430monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-completes-rolling-nda-submission-to-fda-for-drisapersen-for-treatment-of-duchenne-bmrn-20150427monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-presents-data-on-duchenne-muscular-dystrophy-at-the-67th-american-academy-of-neur-bmrn-20150423monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bmrn-20150421monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-first-quarter-2015-financial-results-conference-call-and-webcast-on-thurs-bmrn-20150414monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-one-oral-and-7-poster-presentations-at-the-2015-american-college-of-med-bmrn-20150330monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bmrn-20150318monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-fourth-quarter-and-full-year-2014-financial-results-bmrn-20150225monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bmrn-20150220monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-2-oral-and-8-poster-presentations-at-lysosomal-disease-network-s-11th-a-bmrn-20150209monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-attend-upcoming-investor-conferences-bmrn-20150204monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-fourth-quarter-and-full-year-2014-financial-results-conference-call-and-w-bmrn-20150203monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-final-results-of-tender-offer-for-prosensa-s-shares-and-completion-of-s-bmrn-20150130monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-underwriters-full-exercise-of-option-to-purchase-additional-shares-bmrn-20150123monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-pricing-of-public-offering-of-common-stock-bmrn-20150122monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-public-offering-of-common-stock-bmrn-20150121monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-completion-of-tender-offer-for-prosensa-s-shares-and-commences-subseque-bmrn-20150115monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-provides-preliminary-data-from-ongoing-phase-1-2-pivotal-study-of-bmn-190-for-tre-bmrn-20150112monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-planned-changes-to-board-of-directors-leadership-structure-bmrn-20150107monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-j-p-morgan-healthcare-conference-bmrn-20150106monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-approval-of-vimizim-r-elosulfase-alfa-in-japan-for-treatment-of-morquio-bmrn-20141229monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-and-prosensa-announce-expiration-of-the-hart-scott-rodino-waiting-period-for-biom-bmrn-20141224monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-s-vimizim-r-elosulfase-alfa-approved-in-brazil-for-treatment-of-morquio-a-syndrom-bmrn-20141210monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-highlight-breadth-of-innovative-development-pipeline-at-analyst-and-investor-d-bmrn-20141209monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-s-vimizim-r-elosulfase-alfa-approved-in-australia-for-treatment-of-morquio-a-synd-bmrn-20141207monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-analyst-and-investor-day-on-december-10th-in-new-york-bmrn-20141203monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-and-prosensa-holding-n-v-reach-agreement-on-intended-public-offer-for-100-of-pros-bmrn-20141124monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-attend-upcoming-investor-conferences-bmrn-20141119monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-third-quarter-2014-financial-results-bmrn-20141023monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-third-quarter-2014-financial-results-conference-call-and-webcast-on-thurs-bmrn-20141008monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-attend-upcoming-investor-conferences-bmrn-20140923monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-named-by-centerwatch-as-one-of-the-fastest-developers-of-medicines-bmrn-20140915monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-attend-upcoming-investor-conferences-in-london-bmrn-20140910monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-upcoming-investor-conferences-bmrn-20140819monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-second-quarter-2014-financial-results-bmrn-20140730monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-sells-priority-review-voucher-for-67-5-million-bmrn-20140730monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-second-quarter-2014-financial-results-conference-call-and-webcast-on-wedn-bmrn-20140709monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-wells-fargo-healthcare-conference-on-june-17th-bmrn-20140610monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-doses-first-patient-in-phase-3-inspire-trial-with-bmn-701-for-the-treatment-of-po-bmrn-20140527monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-bank-of-america-merrill-lynch-2014-healthcare-conference-on-may-bmrn-20140506monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-first-quarter-2014-financial-results-and-vimizim-tm-launch-progress-bmrn-20140501monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-european-commission-approval-for-vimizim-r-elosulfase-alfa-for-the-trea-bmrn-20140428monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-first-quarter-2014-financial-results-conference-call-and-webcast-on-thurs-bmrn-20140416monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-appoints-pioneer-in-personalized-medicine-dennis-j-slamon-m-d-ph-d-to-board-of-di-bmrn-20140321monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-pricing-of-public-offering-of-common-stock-bmrn-20140305monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-public-offering-of-common-stock-bmrn-20140304monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-barclays-global-healthcare-conference-in-miami-bmrn-20140304monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-fourth-quarter-and-full-year-2013-financial-results-bmrn-20140226monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-cowen-healthcare-conference-in-boston-bmrn-20140225monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-receives-positive-opinion-from-the-chmp-in-the-european-union-for-vimizim-tm-elos-bmrn-20140220monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-two-upcoming-investor-conferences-in-new-york-bmrn-20140219monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-discuss-fda-approval-of-vimizim-tm-and-provide-preliminary-2013-results-bmrn-20140217monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-fda-approval-for-vimizim-tm-elosulfase-alfa-for-the-treatment-of-patien-bmrn-20140214monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-presents-15-abstracts-from-basic-research-to-clinical-trials-at-lysosomal-disease-bmrn-20140213monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-selection-of-naglu-fusion-protein-drug-development-candidate-bmn-250-fo-bmrn-20140211monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-fourth-quarter-and-full-year-2013-financial-results-conference-call-and-w-bmrn-20140205monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-agreement-with-repligen-for-pre-clinical-compounds-bmrn-20140121monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-doses-first-patient-in-phase-2-trial-with-bmn-111-for-the-treatment-of-children-w-bmrn-20140114monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-selection-of-factor-viii-gene-therapy-drug-development-candidate-bmn-27-bmrn-20140113monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-stock-trading-halted-today-bmrn-20131119monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-french-atu-granted-for-vimizim-tm-for-the-treatment-of-morquio-a-syndro-bmrn-20131115monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-initiates-phase-3-trial-for-bmn-673-for-the-treatment-of-metastatic-gbrca-breast--bmrn-20131031monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-third-quarter-2013-financial-results-bmrn-20131024monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-exercise-by-underwriters-of-full-over-allotment-option-bmrn-20131010monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-third-quarter-2013-financial-results-conference-call-and-webcast-on-thurs-bmrn-20131010monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-pricing-of-340-million-of-senior-subordinated-convertible-notes-due-201-bmrn-20131009monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-proposed-offering-of-300-million-of-senior-subordinated-convertible-not-bmrn-20131007monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-provides-updated-phase-1-2-data-on-bmn-673-in-breast-cancer-at-the-european-cance-bmrn-20130929monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-doses-first-patient-in-phase-1-2-trial-with-bmn-190-for-the-treatment-of-neuronal-bmrn-20130923monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-attend-newsmakers-in-the-biotech-industry-conference-bmrn-20130923monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-provides-highlights-ahead-of-research-and-development-day-bmrn-20130917monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-a-research-and-development-day-on-september-17th-bmrn-20130905monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-attend-upcoming-conferences-citi-biotech-day-morgan-stanley-global-healthcare--bmrn-20130903monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-appoints-richard-ranieri-as-senior-vice-president-human-resources-and-corporate-a-bmrn-20130903monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-oral-presentation-of-bmn-673-most-recent-data-on-breast-and-ovarian-can-bmrn-20130816monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-provides-bmn-673-program-update-bmrn-20130725monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-second-quarter-2013-financial-results-bmrn-20130725monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-second-quarter-2013-financial-results-conference-call-and-webcast-on-thur-bmrn-20130703monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-goldman-sachs-global-healthcare-conference-bmrn-20130606monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-initiates-phase-3-trial-for-peg-pal-for-the-treatment-of-pku-bmrn-20130605monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-provides-preliminary-data-on-ongoing-phase-1-2-trial-for-bmn-673-for-the-treatmen-bmrn-20130603monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-jefferies-global-healthcare-conference-bmrn-20130530monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bmrn-20130520monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-bmn-673-data-in-breast-and-ovarian-cancers-to-be-released-at-asco-bmrn-20130516monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-ubs-global-healthcare-conference-bmrn-20130514monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-baird-growth-stock-conference-bmrn-20130502monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-first-quarter-2013-financial-results-bmrn-20130425monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-submits-vimizim-maa-to-ema-for-the-treatment-of-mps-iva-bmrn-20130424monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bmrn-20130418monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-first-quarter-2013-financial-results-conference-call-and-webcast-on-thurs-bmrn-20130404monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-submits-cta-for-bmn-190-for-batten-disease-bmrn-20130401monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-submits-vimizim-bla-to-the-u-s-fda-for-the-treatment-of-mps-iva-bmrn-20130401monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-completes-additional-partial-exchange-of-convertible-notes-due-2017-for-common-st-bmrn-20130325monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-advance-bmn-701-for-pompe-disease-to-next-phase-of-development-bmrn-20130319monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bmrn-20130319monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-completes-partial-exchange-of-convertible-notes-due-2017-for-common-stock-bmrn-20130318monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-attend-upcoming-conferences-cowen-healthcare-conference-credit-suisse-global-h-bmrn-20130228monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-fourth-quarter-and-full-year-2012-financial-results-bmrn-20130221monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-licenses-factor-viii-gene-therapy-program-for-hemophilia-a-from-university-colleg-bmrn-20130221monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bmrn-20130220monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-attend-upcoming-conferences-canaccord-genuity-orphan-drug-day-citibank-global--bmrn-20130219monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-kuvan-significantly-improves-inattentiveness-in-kuvan-responding-pku-pa-bmrn-20130219monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-bio-ceo-investor-conference-bmrn-20130206monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-fourth-quarter-and-full-year-2012-financial-results-conference-call-and-w-bmrn-20130131monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bmrn-20130118monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-acquires-zacharon-pharmaceuticals-bmrn-20130107monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-j-p-morgan-healthcare-conference-bmrn-20130103monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bmrn-20121221monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-a-research-and-development-day-on-december-6th-bmrn-20121127monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-deutsche-bank-biofest-conference-bmrn-20121127monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-piper-jaffray-healthcare-conference-bmrn-20121120monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bmrn-20121119monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-credit-suisse-healthcare-conference-bmrn-20121109monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-lazard-capital-markets-healthcare-conference-bmrn-20121106monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-phase-3-study-of-galns-for-the-treatment-of-mps-iva-meets-primary-endpoint-bmrn-20121105monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-third-quarter-2012-financial-results-bmrn-20121025monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-third-quarter-2012-financial-results-conference-call-and-webcast-on-thurs-bmrn-20121004monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-phase-1-results-for-bmn-111-for-achondroplasia-bmrn-20120926monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-decision-to-start-phase-3-program-for-peg-pal-in-2q-2013-bmrn-20120926monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-names-jeff-ajer-senior-vice-president-chief-commercial-officer-bmrn-20120905monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-newsmakers-conference-bmrn-20120823monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-canaccord-genuity-growth-conference-bmrn-20120809monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-second-quarter-2012-financial-results-bmrn-20120801monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bmrn-20120725monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-second-quarter-2012-financial-results-conference-call-and-webcast-on-wedn-bmrn-20120711monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-nasdaq-omx-28th-investor-program-bmrn-20120619monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-william-blair-growth-stock-conference-bmrn-20120607monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-pricing-of-public-offering-of-common-stock-bmrn-20120531monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-public-offering-of-common-stock-bmrn-20120530monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bmrn-20120530monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-jefferies-global-healthcare-conference-bmrn-20120529monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-goldman-sachs-global-healthcare-conference-bmrn-20120529monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-appoints-dan-spiegelman-as-executive-vice-president-and-chief-financial-officer-bmrn-20120508monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-deutsche-bank-healthcare-conference-bmrn-20120508monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-baird-growth-stock-conference-bmrn-20120508monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-first-quarter-2012-financial-results-bmrn-20120426monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-first-quarter-2012-financial-results-conference-call-and-webcast-on-thurs-bmrn-20120405monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-completes-enrollment-for-phase-3-trial-for-galns-for-the-treatment-of-mps-iva-bmrn-20120308monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-barclays-global-healthcare-conference-bmrn-20120306monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-rbc-global-healthcare-conference-bmrn-20120222monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-citi-global-health-care-conference-bmrn-20120222monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-chief-financial-officer-jeffrey-cooper-to-leave-the-company-bmrn-20120221monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-initiates-phase-1-trial-for-bmn-111-for-the-treatment-of-achondroplasia-bmrn-20120216monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-fourth-quarter-and-full-year-2011-financial-results-bmrn-20120216monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-bio-ceo-investor-conference-bmrn-20120207monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-fourth-quarter-and-full-year-2011-financial-results-conference-call-and-w-bmrn-20120123monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-syre-20260605monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-completion-of-enrollment-in-skyway-basket-trial-evaluating-sp-syre-20260603monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-to-participate-in-upcoming-june-investor-conferences-syre-20260526monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-syre-20260501monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-syre-20260403monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-announces-acceleration-of-expected-topline-readout-of-skyway-rheumatoid-arthritis-su-syre-20260316monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-syre-20260306monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-syre-20260206monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-syre-20260123monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-syre-20251205monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-syre-20251003monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-doses-first-patient-in-pioneering-phase-2-skyway-basket-trial-of-spy072-syre-20250915monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-to-participate-in-stifel-2025-virtual-immunology-and-inflammation-forum-syre-20250908monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-syre-20250905monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-syre-20250801monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-syre-20250703monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-alert-bragar-eagel-squire-p-c-is-investigating-spyre-therapeutics-inc-on-behalf-of-s-syre-20241204monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference-lnth-20260603monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-present-at-the-william-blair-46th-annual-growth-stock-conference-lnth-20260527monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-highlights-new-radiodiagnostic-data-at-the-2026-snmmi-annual-meeting-lnth-20260521monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-host-first-quarter-2026-earnings-conference-call-and-webcast-on-may-7-2026-at--lnth-20260423monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-three-month-extension-of-pdufa-date-for-lnth-2501-ga-68-edotreotide-a-p-lnth-20260317monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-fda-approval-of-pylarify-truvu-piflufolastat-f-18-injection-lnth-20260306monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-deadline-rosen-a-leading-law-firm-encourages-lantheus-holdings-inc-investors-to-s-lnth-20251109monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-class-action-deadline-bragar-eagel-squire-p-c-urgently-reminds-lantheus-stockhold-lnth-20251108monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-disc-lnth-20251107monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-inc-class-action-levi-korsinsky-reminds-lantheus-investors-of-the-pendin-lnth-20251106monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-deadline-rosen-a-top-ranked-law-firm-encourages-lantheus-holdings-inc-investors-t-lnth-20251106monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-disc-lnth-20251104monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-class-action-bragar-eagel-squire-p-c-urges-lantheus-investors-to-contact-the-firm-lnth-20251103monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-inc-nasdaq-lnth-shareholder-alert-bernstein-liebhard-llp-reminds-lantheu-lnth-20251103monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-inc-nasdaq-lnth-shareholder-alert-bernstein-liebhard-llp-reminds-lantheu-lnth-20251030monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-class-action-alert-bragar-eagel-squire-p-c-urgently-reminds-lantheus-investors-of-lnth-20251029monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-disc-lnth-20251028monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-inc-nasdaq-lnth-deadline-alert-bernstein-liebhard-llp-reminds-lantheus-h-lnth-20251027monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-class-action-reminder-bragar-eagel-squire-p-c-urges-lantheus-holdings-investors-t-lnth-20251025monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-class-action-alert-bragar-eagel-squire-p-c-reminds-lantheus-holdings-investors-of-lnth-20251021monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-inc-sued-for-securities-law-violations-investors-should-contact-levi-kor-lnth-20251017monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-deadline-reminder-bragar-eagel-squire-p-c-reminds-lantheus-holdings-investors-to--lnth-20251015monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-alert-bragar-eagel-squire-p-c-urges-investors-to-contact-the-firm-before-the-nove-lnth-20251011monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-inc-lnth-investors-november-10-2025-filing-deadline-in-securities-class--lnth-20251007monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-deadline-reminder-bragar-eagel-squire-p-c-reminds-lantheus-holdings-investors-of--lnth-20251007monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-inc-nasdaq-lnth-shareholder-alert-bernstein-liebhard-llp-reminds-lantheu-lnth-20251006monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-class-action-alert-bragar-eagel-squire-p-c-reminds-investors-to-contact-the-firm--lnth-20251004monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-lnth-20250930monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-inc-nasdaq-lnth-deadline-alert-bernstein-liebhard-llp-reminds-lantheus-h-lnth-20250929monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-inc-sued-for-securities-law-violations-investors-should-contact-levi-kor-lnth-20250925monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-inc-nasdaq-lnth-shareholder-alert-bernstein-liebhard-llp-reminds-lantheu-lnth-20250925monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-inc-lnth-investors-november-10-2025-filing-deadline-in-securities-class--lnth-20250924monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-alert-bragar-eagel-squire-p-c-is-investigating-lantheus-holdings-inc-on-behalf-of-lnth-20250918monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-inc-nasdaq-lnth-shareholder-alert-bernstein-liebhard-llp-reminds-lantheu-lnth-20250918monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-inc-lnth-investors-november-10-2025-filing-deadline-in-securities-class--lnth-20250917monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-inc-class-action-the-gross-law-firm-reminds-lantheus-holdings-inc-invest-lnth-20250915monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-alert-bragar-eagel-squire-p-c-is-investigating-lantheus-holdings-inc-on-behalf-of-lnth-20250911monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-alert-bragar-eagel-squire-p-c-is-investigating-lantheus-holdings-inc-on-behalf-of-lnth-20250908monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-alert-bragar-eagel-squire-p-c-is-investigating-lantheus-holdings-inc-on-behalf-of-lnth-20250825monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-host-second-quarter-2025-earnings-conference-call-and-webcast-on-august-6-2025-lnth-20250723monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-presentations-to-be-featured-at-the-2025-society-of-nuclear-medicine-an-lnth-20250611monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-present-at-the-2025-truist-securities-medtech-conference-lnth-20250610monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-present-at-the-goldman-sachs-46th-annual-global-healthcare-conference-2025-lnth-20250603monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-sale-of-spect-business-to-shine-technologies-lnth-20250506monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-alzheimer-s-disease-radiodiagnostic-mk-6240-meets-co-primary-endpoints--lnth-20250430monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-host-first-quarter-2025-earnings-conference-call-and-webcast-on-may-7-2025-at--lnth-20250423monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-present-at-upcoming-investor-conferences-lnth-20250221monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-host-fourth-quarter-and-full-year-2024-earnings-conference-call-and-webcast-on-lnth-20250212monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-presentations-featuring-pylarify-piflufolastat-f-18-data-at-the-asco-gu-lnth-20250205monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-increases-to-12-16-shareholding-in-radiopharm-with-us-5m-a-8m-placement-lnth-20250110monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-present-at-the-jefferies-london-healthcare-conference-lnth-20241113monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-continues-to-commend-cms-cy25-rule-to-enhance-payment-for-specialized-diagnostic--lnth-20241111monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-applauds-cms-cy25-rule-to-enhance-payment-for-specialized-diagnostic-radiopharmac-lnth-20241104monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-host-third-quarter-2024-earnings-conference-call-and-webcast-on-november-6-202-lnth-20241023monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-presents-results-from-the-primary-analysis-of-phase-3-pivotal-splash-trial-in-psm-lnth-20240915monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-present-at-the-morgan-stanley-22nd-annual-global-healthcare-conference-lnth-20240828monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-present-additional-clinical-data-from-phase-3-pivotal-splash-trial-in-psma-pos-lnth-20240820monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-host-second-quarter-2024-earnings-conference-call-and-webcast-on-july-31-2024--lnth-20240717monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-welcomes-cms-proposed-cy25-rule-for-improved-payment-for-specialized-diagnostic-r-lnth-20240710monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-appoints-jamie-spaeth-as-chief-people-officer-lnth-20240708monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-ai-enabled-apromise-now-available-on-siemens-healthineers-syngo-via-platform-lnth-20240603monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-present-at-the-william-blair-44th-annual-growth-stock-conference-lnth-20240528monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-host-first-quarter-2024-earnings-conference-call-and-webcast-on-may-2-2024-at--lnth-20240418monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-present-at-the-leerink-partners-global-biopharma-conference-2024-lnth-20240305monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-the-fda-approval-of-definity-perflutren-lipid-microsphere-for-pediatric-lnth-20240304monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-promotion-of-amanda-morgan-to-chief-commercial-officer-lnth-20240228monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-present-at-the-td-cowen-44th-annual-health-care-conference-lnth-20240226monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-collaboration-to-provide-novel-tau-imaging-agent-for-large-consortium-c-lnth-20240213monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-host-fourth-quarter-and-full-year-2023-earnings-conference-call-and-webcast-on-lnth-20240208monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-ceo-succession-plan-lnth-20240123monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-acceptance-of-its-first-to-file-anda-for-generic-lutathera-lutetium-lu--lnth-20240111monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-expands-radiopharmaceutical-oncology-pipeline-via-strategic-agreements-with-persp-lnth-20240109monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-lnth-20240103monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-and-point-biopharma-announce-positive-topline-results-from-pivotal-splash-trial-i-lnth-20231218monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-present-at-the-jefferies-london-healthcare-conference-lnth-20231108monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-host-third-quarter-2023-earnings-conference-call-and-webcast-on-november-2-202-lnth-20231019monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-top-rated-oral-presentation-featuring-pylarify-ai-at-the-2023-european--lnth-20230901monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-present-at-the-wells-fargo-healthcare-conference-lnth-20230831monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-agreement-to-sell-relistor-royalties-to-healthcare-royalty-lnth-20230803monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-host-second-quarter-2023-earnings-conference-call-and-webcast-on-august-3-2023-lnth-20230720monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-presentations-featuring-pylarify-ai-at-the-2023-society-for-nuclear-med-lnth-20230612monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-present-at-the-jefferies-healthcare-conference-lnth-20230601monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-payment-to-contingent-value-rights-cvr-holders-of-99-7-million-or-1-15--lnth-20230523monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-and-point-biopharma-announce-fda-grants-fast-track-designation-for-77lu-pnt2002-f-lnth-202304242023-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-host-first-quarter-2023-earnings-conference-call-and-webcast-on-may-4-2023-at--lnth-202304202023-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-two-key-executive-promotions-lnth-202303172023-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-presents-data-reinforcing-real-world-clinical-utility-of-piflufolastat-f-18-pet-s-lnth-202302162023-02-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-host-fourth-quarter-and-full-year-2022-earnings-conference-call-and-webcast-on-lnth-202302092023-02-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-present-piflufolastat-f-18-data-at-the-2023-american-society-of-clinical-oncol-lnth-202302082023-02-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-acquisition-of-cerveau-technologies-inc-expanding-imaging-pipeline-into-lnth-202302062023-02-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-present-at-the-j-p-morgan-2023-healthcare-conference-lnth-202301042023-01-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-grants-rights-for-the-use-of-its-microbubbles-to-sonothera-for-its-ultrasound-gui-lnth-20221212monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-appointment-of-amanda-morgan-as-senior-vice-president-commercial-lnth-20221129monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-the-approval-of-definity-perflutren-lipid-microsphere-by-china-s-nmpa-lnth-20221128monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-and-point-biopharma-announce-strategic-collaboration-and-exclusive-license-agreem-lnth-20221114monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-present-at-the-jefferies-london-healthcare-conference-lnth-20221109monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-reports-third-quarter-2022-financial-results-lnth-20221103monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-host-third-quarter-2022-earnings-conference-call-and-webcast-on-november-3-202-lnth-20221020monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-presentations-at-the-european-association-of-nuclear-medicine-annual-meeting-show-lnth-20221017monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-present-at-the-wells-fargo-healthcare-conference-lnth-20220901monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-reports-second-quarter-2022-financial-results-lnth-20220804monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-to-host-second-quarter-2022-earnings-conference-call-and-webcast-on-augu-lnth-20220721monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-promotion-of-paul-blanchfield-to-chief-operating-officer-lnth-20220615monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-highlights-preliminary-study-results-demonstrating-potential-of-nm-01-a-novel-tec-lnth-20220613monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-pylarify-ai-platform-demonstrates-higher-efficiency-and-consistency-while-maintai-lnth-20220613monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-present-at-the-jefferies-healthcare-conference-lnth-20220602monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-presentations-featuring-pylarify-piflufolastat-f18-pylarify-ai-and-nm-0-lnth-20220526monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-hosts-inaugural-investor-day-lnth-20220516monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-presents-results-from-a-pylarify-ai-study-at-the-american-urological-association--lnth-20220516monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-first-patient-dosed-in-phase-2-clinical-trial-of-nm-01-to-monitor-pd-l1-lnth-20220513monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-updates-to-the-nccn-guidelines-for-psma-pet-imaging-for-prostate-cancer-lnth-20220511monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-present-at-the-ubs-global-healthcare-conference-lnth-20220510monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-inc-reports-first-quarter-2022-financial-results-lnth-20220429monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-to-host-first-quarter-2022-earnings-conference-call-and-webcast-on-april-lnth-20220415monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-appoints-jean-claude-provost-md-as-interim-chief-medical-officer-lnth-20220404monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-collaboration-to-support-prostate-cancer-clinical-development-lnth-20220329monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-to-present-at-the-barclays-global-healthcare-conference-lnth-20220308monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-to-host-inaugural-investor-day-lnth-20220303monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-appointment-of-minnie-baylor-henry-as-new-board-member-lnth-20220301monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-inc-reports-fourth-quarter-and-full-year-2021-financial-results-lnth-20220224monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-receives-u-s-fda-approval-of-new-manufacturing-facility-lnth-20220223monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-presentation-featuring-pylarify-piflufolastat-f18-at-the-2022-asco-gu-m-lnth-20220210monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-to-host-fourth-quarter-and-full-year-2021-earnings-conference-call-and-w-lnth-20220210monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-collaborates-with-the-prostate-cancer-clinical-trial-consortium-pcctc-to-advance--lnth-20220127monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-appoints-vivian-yao-as-chief-human-resources-officer-lnth-20211201monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-pylarify-ai-is-now-available-lnth-20211129monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-cms-grants-transitional-pass-through-payment-for-pylarify-piflufolastat-lnth-20211122monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-announces-presentations-featuring-pylarify-piflufolastat-f-18-its-psma-t-lnth-20211117monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-to-present-at-the-4th-annual-evercore-isi-healthconx-conference-lnth-20211116monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-inc-reports-third-quarter-2021-financial-results-lnth-20211104monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-to-present-at-upcoming-investor-conferences-lnth-20211028monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-to-host-third-quarter-2021-earnings-conference-call-and-webcast-on-novem-lnth-20211021monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-lnth-20210913monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-and-reflexion-announce-development-and-commercialization-collaboration-with-the-p-lnth-20210913monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-announces-presentation-at-the-2021-american-urological-association-aua-annual-mee-lnth-20210910monthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-holdings-to-present-at-upcoming-investor-conferences-lnth-20210902monthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-bio-rad-and-thermo-fisher-propel-safety-and-automation-in-blood-collectio-bdx-20251212monthly0.5https://www.biopharmawatch.com/news/BDX/becton-deadline-alert-faruqi-faruqi-llp-encourages-investors-who-suffered-losses-exceeding-bdx-20200425monthly0.5https://www.biopharmawatch.com/news/BDX/becton-deadline-alert-faruqi-faruqi-llp-encourages-investors-who-suffered-losses-exceeding-bdx-20200415monthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-and-company-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-an-bdx-20200305monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-new-preclinical-ibd-data-for-kt-579-a-first-in-class-oral-irf-kymr-20260505monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-kt-621-broaden-data-in-late-breaking-research-session-at-the--kymr-20260328monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-announce-kt-621-broaden-phase-1b-atopic-dermatitis-trial-results-on-kymr-20251205monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-report-third-quarter-2025-financial-results-on-november-4-2025-kymr-20251028monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-participate-in-upcoming-september-investor-conferences-kymr-20250827monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-announce-kt-621-phase-1-healthy-volunteer-trial-results-on-june-2-2-kymr-20250530monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-participate-in-upcoming-june-investor-conferences-kymr-20250529monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-new-preclinical-data-for-kt-621-a-first-in-class-oral-stat6-d-kymr-20250519monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-expands-industry-leading-immunology-pipeline-with-new-first-in-class-o-kymr-20250509monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-unveil-new-oral-immunology-program-and-report-first-quarter-2025-fi-kymr-20250424monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-first-patient-dosed-in-broaden-phase-1b-atopic-dermatitis-cl-kymr-20250422monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences-kymr-20250226monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-febru-kymr-20250220monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-participate-in-upcoming-february-investor-conferences-kymr-20250130monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-participate-in-upcoming-december-investor-conferences-kymr-20241126monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences-kymr-20241105monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-report-third-quarter-2024-financial-results-on-october-31-kymr-20241023monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-kt-kymr-20241009monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-preclinical-data-for-kt-621-a-potent-selective-first-in-class-kymr-20240925monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-participate-in-upcoming-september-investor-conferences-kymr-20240828monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-report-second-quarter-2024-financial-results-on-august-7-kymr-20240731monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-in-fireside-chat-at-the-ubs-virtual-targeted-protein-degrad-kymr-20240709monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-new-clinical-data-from-the-ongoing-phase-1-trial-of-stat3-deg-kymr-20240614monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-new-clinical-data-from-ongoing-phase-1-trial-of-mdm2-degrader-kymr-20240601monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-participate-in-upcoming-june-investor-conferences-kymr-20240529monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-new-clinical-data-from-ongoing-phase-1-trial-of-mdm2-degrad-kymr-20240523monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-new-preclinical-data-for-kt-621-a-first-in-class-oral-stat6-d-kymr-20240522monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-new-clinical-data-from-the-ongoing-phase-1-trial-of-stat3-d-kymr-20240514monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-participate-in-upcoming-may-investor-conferences-kymr-20240508monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-report-first-quarter-2024-financial-results-on-may-2-kymr-20240425monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-preclinical-data-for-stat6-and-tyk2-first-in-class-oral-degra-kymr-20240308monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences-kymr-20240228monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-report-fourth-quarter-and-full-year-2023-financial-results-on-febru-kymr-20240215monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-in-fireside-chat-at-the-guggenheim-healthcare-conference-kymr-20240131monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-closing-of-upsized-275-million-public-offering-and-full-exer-kymr-20240109monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-on-tues-kymr-20240102monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-host-virtual-immunology-r-d-day-on-january-4-kymr-20231213monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-interim-results-from-stat3-degrader-phase-1-clinical-trial-at-kymr-20231211monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-publication-of-phase-1-trial-results-for-kt-474-sar444656-a--kymr-20231113monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences-kymr-20231101monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-report-third-quarter-2023-financial-results-on-november-2-kymr-20231026monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-preclinical-data-demonstrating-activity-of-mdm2-degraders-in--kymr-20231016monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-receives-u-s-fda-fast-track-designation-for-kt-333-a-first-in-class-in-kymr-20230918monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-participate-in-upcoming-september-investor-conferences-kymr-20230828monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-report-second-quarter-2023-financial-results-on-august-3-kymr-20230727monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-receives-fda-orphan-drug-designation-for-kt-253-a-novel-highly-potent--kymr-20230622monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-stat3-degrader-kt-333-and-irakimid-degrader-kt-413-demonstrate-desired-kymr-20230614monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-updated-clinical-data-from-the-phase-1-trials-of-stat3-degra-kymr-20230609monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-data-demonstrating-superior-efficacy-of-kt-253-a-potent-and-s-kymr-20230609monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-participate-in-upcoming-june-investor-conference-kymr-20230601monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-doses-first-patient-in-phase-1-oncology-trial-of-mdm2-degrader-kt-253-kymr-20230519monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-clinical-data-from-the-phase-1-trial-of-irak4-degrader-kt-474-kymr-20230518monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-report-first-quarter-2023-financial-results-on-may-4-kymr-202304112023-04-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences-kymr-202303012023-03-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-on-febru-kymr-202302012023-02-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-appoints-ellen-chiniara-j-d-as-chief-legal-officer-and-corporate-secretary-kymr-202301042023-01-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-on-tues-kymr-202301032023-01-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-provides-webcast-information-for-december-14-investor-event-kymr-20221201monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-appoints-biopharmaceutical-leader-victor-sandor-m-d-c-m-to-board-of-di-kymr-20221103monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-report-third-quarter-2022-results-on-november-3-kymr-20221020monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-receives-fda-orphan-drug-designation-for-kt-333-a-first-in-class-inves-kymr-20220915monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-participate-in-upcoming-september-conferences-kymr-20220829monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-report-second-quarter-2022-results-on-august-9-kymr-20220727monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-strengthens-board-of-directors-with-appointment-of-people-and-business-kymr-20220708monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-receives-fda-orphan-drug-designation-for-kt-333-a-first-in-class-inves-kymr-20220601monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presented-preclinical-data-showcasing-impact-of-irak4-degrader-kt-474--kymr-20220520monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-share-novel-preclinical-findings-reinforcing-the-advantage-of-irak4-kymr-20220505monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-first-quarter-2022-financial-results-and-provides-a-business-kymr-20220503monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-report-first-quarter-2022-results-and-announces-participation-at-up-kymr-20220419monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences-kymr-20220302monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-participate-in-upcoming-january-and-february-investor-conferences-kymr-20220125monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-appoints-healthcare-industry-leader-john-maraganore-ph-d-to-board-of-d-kymr-20220118monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-positive-preclinical-data-on-selective-stat3-degraders-for-he-kymr-20211213monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-strengthens-leadership-team-with-the-appointment-of-vijay-sabesan-as-s-kymr-20211206monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-host-virtual-r-d-day-on-december-16-2021-kymr-20211117monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-new-preclinical-data-on-stat3-degraders-at-the-society-for-im-kymr-20211112monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-new-preclinical-data-on-stat3-degraders-at-the-society-for--kymr-20211104monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-participate-in-upcoming-fourth-quarter-investor-conferences-kymr-20211101monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-to-hold-webcast-and-conference-call-discussing-data-from-its-kt-474-phase-1-trial-t-kymr-20211020monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-pharmacokinetic-and-pharmacodynamic-data-including-cytokine-kymr-20211013monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences-kymr-20210902monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-kymr-20210729monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-new-preclinical-data-on-stat3-degraders-showing-antitumor-act-kymr-20210712monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-closing-of-upsized-public-offering-of-common-stock-and-full--kymr-20210706monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-proposed-public-offering-of-common-stock-kymr-20210628monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-appoints-elaine-caughey-mba-as-chief-business-officer-kymr-20210621monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-new-preclinical-data-for-its-irakimid-degrader-kt-413-demonst-kymr-20210621monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-new-data-demonstrating-both-single-agent-and-combination-re-kymr-20210609monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conferen-kymr-20210602monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-new-data-demonstrating-proof-of-degradation-using-novel-tissu-kymr-20210526monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-appoints-juliet-williams-phd-as-senior-vice-president-head-of-biology-kymr-20210505monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-at-upcoming-may-investor-conferences-kymr-20210504monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-new-in-vivo-data-demonstrating-the-broad-anti-inflammatory--kymr-20210503monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-positive-late-breaking-data-from-non-interventional-study-in--kymr-20210503monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-new-results-from-non-interventional-study-in-patients-with--kymr-20210409monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-appoints-elena-ridloff-cfa-to-board-of-directors-kymr-20210316monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-at-upcoming-march-investor-conferences-kymr-20210225monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-at-upcoming-february-investor-conferences-kymr-20210204monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-strengthens-leadership-with-key-appointments-and-promotions-kymr-20210203monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-on-thur-kymr-20210105monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-key-leadership-appointments-kymr-20201216monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-preclinical-data-on-irakimid-and-stat3-programs-at-virtual-62-kymr-20201207monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-at-the-piper-sandler-32nd-annual-healthcare-conference-kymr-20201123monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-at-the-stifel-2020-virtual-healthcare-conference-kymr-20201111monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-data-on-novel-irakimid-and-stat3-protein-degraders-at-virtu-kymr-20201104monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-deliver-two-podium-presentations-at-3rd-annual-targeted-protein-deg-kymr-20201012monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-interim-results-from-a-non-interventional-study-characteriz-kymr-20201009monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-at-morgan-stanley-18th-annual-global-healthcare-conference-kymr-20200914monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-appoints-biopharma-veterans-pamela-esposito-and-jeff-albers-to-its-boa-kymr-20200909monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-appoints-dr-richard-chesworth-as-chief-scientific-officer-kymr-20200827monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-first-quarter-2026-financial-results-rgen-20260422monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-executive-chair-tony-hunt-to-retire-dr-martin-d-madaus-elected-chair-rgen-20260106monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-j-p-morgan-2026-healthcare-conference-rgen-20251218monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-introduces-next-generation-chromatography-resins-to-advance-new-modality-workflow-rgen-20251216monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-upcoming-september-conferences-rgen-20250822monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-second-quarter-2025-financial-results-and-updates-full-year-2025-financia-rgen-20250729monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-second-quarter-2025-financial-results-rgen-20250717monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-first-quarter-2025-financial-results-rgen-20250429monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-first-quarter-2025-financial-results-rgen-20250415monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-appoints-jacob-johnson-as-vice-president-investor-relations-rgen-20250408monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-purchases-bioprocessing-analytics-portfolio-from-908-devices-rgen-20250304monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-fourth-quarter-and-full-year-2024-financial-results-rgen-20250220monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-fourth-quarter-and-full-year-2024-financial-results-rgen-20250211monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-43rd-annual-j-p-morgan-healthcare-conference-rgen-20250107monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-launches-the-ctech-solovpe-plus-system-rgen-20250106monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-announces-publication-of-the-company-s-2023-corporate-sustainability-report-rgen-20241212monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-launches-novel-avipure-dsrna-resin-in-opus-pre-packed-columns-rgen-20241209monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-third-quarter-2024-financial-results-rgen-20241112monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-upcoming-investor-conferences-rgen-20241105monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-third-quarter-2024-financial-results-rgen-20241031monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-opens-training-innovation-center-to-elevate-customer-experience-rgen-20240924monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-wells-fargo-healthcare-conference-rgen-20240823monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-second-quarter-2024-financial-results-rgen-20240730monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-announces-agreement-to-acquire-chromatography-innovator-tantti-rgen-20240729monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-second-quarter-2024-financial-results-rgen-20240716monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-announces-ceo-transition-plan-rgen-20240613monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-upcoming-june-investor-conferences-rgen-20240522monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-upcoming-may-investor-conferences-rgen-20240507monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-first-quarter-2024-financial-results-rgen-20240501monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-first-quarter-2024-financial-results-rgen-20240417monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-appoints-maggie-a-pax-to-board-of-directors-rgen-20240319monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-fourth-quarter-and-full-year-2023-financial-results-rgen-20240221monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-fourth-quarter-and-full-year-2023-financial-results-rgen-20240207monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-42nd-annual-j-p-morgan-healthcare-conference-rgen-20231219monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-announces-private-convertible-transaction-of-600-million-principal-amount-of-1-00-rgen-20231207monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-upcoming-investor-conferences-rgen-20231107monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-launches-tangenx-sc-as-first-to-market-holder-free-self-contained-tff-device-rgen-20231102monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-third-quarter-2023-financial-results-and-updates-full-year-2023-financial-rgen-20231031monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-third-quarter-2023-financial-results-rgen-20231017monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-appoints-olivier-loeillot-as-president-and-chief-commercial-officer-rgen-20231002monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-announces-agreement-to-acquire-fluid-management-innovator-metenova-rgen-20230926monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-appoints-jason-k-garland-as-chief-financial-officer-rgen-20230912monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-wells-fargo-healthcare-conference-rgen-20230901monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-second-quarter-2023-financial-results-and-updates-full-year-2023-financia-rgen-20230802monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-second-quarter-2023-financial-results-rgen-20230719monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-upcoming-investor-conferences-rgen-20230531monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-first-quarter-2023-financial-results-and-updates-full-year-2023-financial-rgen-202305022023-05-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-first-quarter-2023-financial-results-rgen-20230418monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-rgen-202303142023-03-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-fourth-quarter-and-full-year-2022-financial-results-rgen-202302222023-02-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-appoints-martin-d-madaus-to-board-of-directors-rgen-202302092023-02-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-fourth-quarter-and-full-year-2022-financial-results-rgen-202302082023-02-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-41st-annual-j-p-morgan-healthcare-conference-rgen-202301032023-01-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-upcoming-investor-conferences-rgen-20221108monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-third-quarter-2022-financial-results-and-updates-full-year-2022-financial-rgen-20221101monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-extends-and-expands-long-term-supply-agreement-with-purolite-for-affinity-ligands-rgen-20221101monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-third-quarter-2022-financial-results-rgen-20221012monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-expands-process-analytics-portfolio-with-drs-daylight-solutions-agreement-rgen-20220919monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-host-investor-day-2022-rgen-20220824monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-second-quarter-2022-financial-results-and-raises-full-year-2022-financial-rgen-20220802monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-second-quarter-2022-financial-results-rgen-20220719monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-appoints-dr-konstantin-konstantinov-to-board-of-directors-rgen-20220526monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-upcoming-investor-conferences-rgen-20220525monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-first-quarter-2022-financial-results-and-updates-full-year-2022-financial-rgen-20220427monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-first-quarter-2022-financial-results-rgen-20220413monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-rgen-20220318monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-fourth-quarter-and-full-year-2021-financial-results-rgen-20220217monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-launches-aav-affinity-resins-for-gene-therapy-purification-rgen-20220215monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-11th-annual-svb-leerink-healthcare-conference-rgen-20220211monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-fourth-quarter-and-full-year-2021-financial-results-rgen-20220203monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-40th-annual-j-p-morgan-healthcare-conference-rgen-20211230monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-upcoming-investor-conferences-rgen-20211112monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-releases-inaugural-sustainability-report-rgen-20211105monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-third-quarter-2021-financial-results-and-updates-full-year-2021-financial-rgen-20211028monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-third-quarter-2021-financial-results-rgen-20211014monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-announces-agreement-to-acquire-avitide-inc-rgen-20210916monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-and-navigo-gmbh-announce-launch-of-industry-first-protein-a-ligand-for-purificati-rgen-20210909monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-second-quarter-2021-financial-results-and-updates-full-year-2021-financia-rgen-20210727monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-second-quarter-2021-financial-results-rgen-20210713monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-announces-agreement-to-acquire-polymem-s-a-rgen-20210622monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-upcoming-investor-conferences-rgen-20210525monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-first-quarter-2021-financial-results-and-updates-full-year-2021-financial-rgen-20210504monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-first-quarter-2021-financial-results-rgen-20210420monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-keybanc-life-science-and-medtech-investor-forum-rgen-20210317monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-barclays-global-healthcare-conference-rgen-20210303monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-fourth-quarter-and-full-year-2020-financial-results-rgen-20210224monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-10th-annual-svb-leerink-healthcare-conference-rgen-20210222monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-fourth-quarter-and-full-year-2020-financial-results-rgen-20210211monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-and-navigo-proteins-announce-the-launch-of-an-affinity-resin-for-the-purification-rgen-20210208monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-to-present-at-39th-annual-j-p-morgan-healthcare-conference-rgen-20210104monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-announces-closing-of-public-offering-of-312-2-million-including-full--rgen-20201210monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-prices-public-offering-of-shares-of-common-stock-rgen-20201208monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-announces-proposed-public-offering-of-shares-of-common-stock-rgen-20201207monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-third-quarter-2020-financial-results-and-updates-full-year-2020-financial-rgen-20201105monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-announces-agreement-to-acquire-bioprocess-systems-innovator-artesyn-b-rgen-20201027monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-third-quarter-2020-financial-results-rgen-20201022monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-and-navigo-proteins-announce-achievement-of-key-milestone-in-developing-an-affini-rgen-20201001monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-second-quarter-2020-financial-results-and-updates-full-year-2020-financia-rgen-20200730monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-second-quarter-2020-financial-results-rgen-20200715monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-announces-agreement-to-acquire-engineered-molding-technology-rgen-20200629monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-appoints-carrie-eglinton-manner-to-board-of-directors-rgen-20200615monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-first-quarter-2020-financial-results-and-updates-full-year-2020-financial-rgen-20200506monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-first-quarter-2020-financial-results-rgen-20200422monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-appoints-rohin-mhatre-ph-d-to-board-of-directors-rgen-20200227monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-fourth-quarter-and-full-year-2019-financial-results-rgen-20200220monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-fourth-quarter-and-full-year-2019-financial-results-rgen-20200206monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-rgen-20200107monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-third-quarter-2019-financial-results-and-updates-full-year-2019-financial-rgen-20191031monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-third-quarter-2019-financial-results-rgen-20191023monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-second-quarter-2019-financial-results-and-updates-full-year-2019-financia-rgen-20190801monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-second-quarter-2019-financial-results-rgen-20190723monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-announces-closing-of-public-offerings-of-138-1-million-of-common-stoc-rgen-20190719monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-announces-pricing-of-public-offerings-of-120-million-of-common-stock--rgen-20190717monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-announces-proposed-public-offerings-of-100-million-of-common-stock-an-rgen-20190715monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-present-at-jefferies-2019-healthcare-conference-rgen-20190604monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-first-quarter-2019-financial-results-and-updates-full-year-2019-financial-rgen-20190509monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-first-quarter-2019-financial-results-rgen-20190502monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-prices-public-offering-of-shares-of-common-stock-rgen-20190430monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-announces-proposed-public-offering-of-shares-of-common-stock-rgen-20190429monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-announces-agreement-to-acquire-process-analytics-innovator-c-technolo-rgen-20190426monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-fourth-quarter-and-full-year-2018-financial-results-rgen-20190221monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-fourth-quarter-and-full-year-2018-financial-results-rgen-20190215monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-present-at-37th-annual-j-p-morgan-healthcare-conference-rgen-20190103monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-third-quarter-2018-financial-results-rgen-20181101monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-third-quarter-2018-financial-results-rgen-20181022monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-second-quarter-2018-financial-results-rgen-20180802monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-second-quarter-2018-financial-results-rgen-20180719monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-selects-purolite-life-sciences-as-commercial-partner-for-new-high-performance-lig-rgen-20180628monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-announces-agreement-with-navigo-proteins-for-the-exclusive-co-development-of-next-rgen-20180627monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-present-at-the-william-blair-2018-growth-stock-conference-rgen-20180530monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-present-at-jefferies-2018-global-healthcare-conference-rgen-20180523monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-participate-in-15th-annual-craig-hallum-institutional-investor-conference-rgen-20180517monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-first-quarter-2018-financial-results-rgen-20180508monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-first-quarter-2018-financial-results-rgen-20180430monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-announces-market-launch-of-opus-80r-reinforces-technology-leadership-in-pre-packe-rgen-20180320monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-fourth-quarter-2017-financial-results-provides-guidance-for-2018-rgen-20180222monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-fourth-quarter-and-full-year-2017-financial-results-rgen-20180216monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-present-at-36th-annual-j-p-morgan-healthcare-conference-rgen-20171229monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-third-quarter-2017-financial-results-rgen-20171109monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-extends-long-term-supply-agreement-with-purolite-for-protein-a-ligands-rgen-20171107monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-third-quarter-2017-financial-results-rgen-20171101monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-announces-analyst-day-and-webcast-rgen-20170915monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-present-at-baird-s-2017-global-healthcare-conference-rgen-20170830monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-second-quarter-2017-financial-results-rgen-20170803monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-second-quarter-2017-financial-results-rgen-20170727monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-prices-public-offering-of-shares-of-common-stock-rgen-20170627monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-announces-proposed-public-offering-of-shares-of-common-stock-rgen-20170626monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-and-spectrum-inc-to-join-forces-rgen-20170623monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-present-at-jefferies-2017-global-annual-healthcare-conference-rgen-20170531monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-participate-in-14th-annual-craig-hallum-institutional-investor-conference-rgen-20170524monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-present-at-bank-of-america-merrill-lynch-2017-healthcare-conference-rgen-20170509monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-first-quarter-2017-financial-results-rgen-20170504monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-first-quarter-2017-financial-results-rgen-20170421monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-fourth-quarter-2016-financial-results-provides-guidance-for-2017-rgen-20170222monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-fourth-quarter-and-full-year-2016-financial-results-provides-financial--rgen-20170216monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-present-at-35th-annual-j-p-morgan-healthcare-conference-rgen-20170104monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-acquires-tangenx-technology-corporation-rgen-20161215monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-participate-in-stephens-inc-fall-investment-conference-2016-rgen-20161107monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-third-quarter-2016-financial-results-rgen-20161103monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-third-quarter-2016-financial-results-rgen-20161020monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-hires-ralf-kuriyel-as-senior-vice-president-of-research-development-rgen-20161018monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-launches-single-use-xcell-atf-system-for-bioprocess-intensification-rgen-20161005monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-present-at-baird-global-healthcare-conference-2016-rgen-20160901monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-second-quarter-2016-financial-results-rgen-20160804monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-second-quarter-2016-financial-results-rgen-20160727monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-present-at-jefferies-2016-healthcare-conference-rgen-20160602monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-participate-in-13th-annual-craig-hallum-institutional-investor-conference-rgen-20160526monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-announces-pricing-of-100-million-of-2-125-convertible-senior-notes-due-2021-rgen-20160519monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-announces-proposed-public-offering-of-100-million-of-convertible-senior-notes-due-rgen-20160518monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-first-quarter-2016-financial-results-rgen-20160505monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-first-quarter-2016-financial-results-rgen-20160429monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-acquires-atoll-gmbh-rgen-20160404monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-forms-scientific-advisory-board-rgen-20160331monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-fourth-quarter-and-year-2015-financial-results-rgen-20160225monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-announces-extension-of-long-term-supply-agreement-for-protein-a-rgen-20160224monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-fourth-quarter-and-full-year-2015-financial-results-rgen-20160217monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-present-at-the-stifel-2015-healthcare-conference-rgen-20151111monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-third-quarter-2015-financial-results-rgen-20151105monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-third-quarter-2015-financial-results-rgen-20151022monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-appoints-glenn-p-muir-to-board-of-directors-rgen-20150915monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-second-quarter-2015-financial-results-rgen-20150806monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-second-quarter-2015-financial-results-rgen-20150729monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-present-at-jefferies-2015-healthcare-conference-rgen-20150526monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-first-quarter-2015-financial-results-rgen-20150507monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-first-quarter-2015-financial-results-rgen-20150429monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-financial-results-for-the-year-2014-and-issues-2015-financial-guidance-rgen-20150313monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-year-2014-financial-results-and-provide-2015-financial-guidance-rgen-20150309monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-completes-expansion-of-u-s-facility-rgen-20150210monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-present-at-2015-leerink-global-healthcare-conference-rgen-20150204monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-names-tony-hunt-as-next-chief-executive-officer-rgen-20150121monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-receives-milestone-payment-from-pfizer-rgen-20150108monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-present-at-stifel-healthcare-conference-2014-rgen-20141112monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-third-quarter-2014-financial-results-rgen-20141106monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-present-at-stephens-inc-fall-investment-conference-rgen-20141105monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-third-quarter-2014-financial-results-rgen-20141023monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-host-investor-analyst-event-on-october-16-rgen-20141010monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-second-quarter-2014-financial-results-rgen-20140811monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-second-quarter-2014-financial-results-rgen-20140728monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-hires-jon-k-snodgres-as-chief-financial-officer-rgen-20140715monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-appoints-nicolas-m-barthelemy-to-board-of-directors-rgen-20140612monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-acquires-bioprocessing-business-of-refine-technology-rgen-20140603monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-present-at-jefferies-2014-global-healthcare-conference-rgen-20140528monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-first-quarter-2014-financial-results-rgen-20140508monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-hires-former-life-technologies-executive-tony-j-hunt-as-chief-operating-officer-rgen-20140506monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-first-quarter-2014-financial-results-rgen-20140425monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-launches-opus-r-ready-to-use-chromatography-columns-with-largest-capacity-availab-rgen-20140326monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-full-year-and-fourth-quarter-2013-financial-results-rgen-20140306monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-fourth-quarter-and-fiscal-year-2013-financial-results-rgen-20140225monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-announces-asset-purchase-agreement-with-biomarin-for-hdaci-portfolio-rgen-20140121monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-present-at-the-25th-annual-piper-jaffray-healthcare-conference-rgen-20131126monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-appoints-biogen-idec-executive-john-g-cox-to-board-of-directors-rgen-20131119monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-third-quarter-2013-financial-results-rgen-20131107monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-present-at-the-2013-stephens-fall-investment-conference-rgen-20131106monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-completes-expansion-of-u-s-manufacturing-facility-rgen-20131101monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-third-quarter-2013-financial-results-rgen-20131024monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-present-at-the-stifel-healthcare-conference-2013-rgen-20130904monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-receives-first-milestone-payment-from-pfizer-under-licensing-agreement-for-spinal-rgen-20130904monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-second-quarter-2013-financial-results-rgen-20130801monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-second-quarter-2013-financial-results-rgen-20130718monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-ceo-to-present-at-jefferies-2013-global-healthcare-conference-rgen-20130523monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-first-quarter-2013-financial-results-rgen-20130502monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-first-quarter-2013-financial-results-rgen-20130423monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-fourth-quarter-and-full-year-2012-financial-results-and-provides-financia-rgen-20130307monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-to-report-fourth-quarter-and-full-year-2012-financial-results-rgen-20130301monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-initiates-phase-1b-trial-of-rg3039-for-spinal-muscular-atrophy-licensed-from-fami-rgen-20120926monthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-positive-results-from-phase-1-clinical-trial-for-spinal-muscular-atrophy--rgen-20120425monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-call-for-proposals-for-annual-corporate-giving-program-cytk-20260608monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-launches-myqorzo-aficamten-in-european-union-with-first-commercial-availabili-cytk-20260601monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-hold-annual-meeting-of-stockholders-cytk-20260520monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20260518monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-host-annual-symposium-on-contemporary-landscapes-in-muscle-biology-climb-cytk-20260514monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-positive-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinic-cytk-20260505monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-tria-cytk-20260504monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-first-quarter-results-on-may-5-2026-cytk-20260421monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20260318monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-four-presentations-at-the-american-college-of-cardiology-annual-sci-cytk-20260316monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-march-investor-conferences-cytk-20260302monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-fourth-quarter-results-on-february-24-2026-cytk-20260212monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20251216monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-positive-chmp-opinion-of-myqorzo-aficamten-for-the-treatment-of-obs-cytk-20251212monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20251118monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-liv-cytk-20251117monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-incorporated-sued-for-securities-law-violations-contact-the-djs-law-group-to--cytk-20251117monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-incorporated-sued-for-securities-law-violations-contact-the-djs-law-group-to--cytk-20251114monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100--cytk-20251113monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-re-cytk-20251112monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-incorporated-sued-for-securities-law-violations-contact-the-djs-law-group-to--cytk-20251111monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-incorporated-sued-for-securities-law-violations-contact-the-djs-law-group-to--cytk-20251107monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-incorporated-securities-fraud-class-action-lawsuit-pending-contact-levi-korsi-cytk-20251106monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100--cytk-20251106monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-incorporated-sued-for-securities-law-violations-contact-the-gross-law-firm-be-cytk-20251105monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-re-cytk-20251105monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-class-action-bragar-eagel-squire-p-c-urges-cytokinetics-stockholders-to-conta-cytk-20251103monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-incorporated-securities-fraud-class-action-lawsuit-pending-contact-levi-korsi-cytk-20251103monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-incorporated-securities-fraud-class-action-lawsuit-pending-contact-the-gross--cytk-20251030monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100--cytk-20251030monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-class-action-reminder-bragar-eagel-squire-p-c-urgently-reminds-cytk-investors-cytk-20251029monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-re-cytk-20251029monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-incorporated-sued-for-securities-law-violations-contact-the-djs-law-group-to--cytk-20251027monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-class-action-alert-bragar-eagel-squire-p-c-reminds-cytokinetics-investors-of--cytk-20251025monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100--cytk-20251023monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-incorporated-securities-fraud-class-action-lawsuit-pending-contact-the-gross--cytk-20251022monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-re-cytk-20251022monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-class-action-reminder-bragar-eagel-squire-p-c-announces-that-a-class-action-l-cytk-20251021monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100--cytk-20251016monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-re-cytk-20251015monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100--cytk-20251009monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-re-cytk-20251008monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100--cytk-20251002monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-re-cytk-20251001monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-incorporated-sued-for-securities-law-violations-investors-should-contact-the--cytk-20250929monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-incorporated-securities-fraud-class-action-lawsuit-pending-contact-levi-korsi-cytk-20250925monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100--cytk-20250925monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-re-cytk-20250923monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been--cytk-20250918monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20250918monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-three-upcoming-presentations-at-the-hfsa-annual-scientific-meeting--cytk-20250918monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-pricing-of-upsized-650-0-million-convertible-senior-notes-offering--cytk-20250917monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-presents-new-data-related-to-aficamten-at-the-european-society-of-cardiology--cytk-20250831monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-primary-results-from-maple-hcm-presented-at-the-european-society-of-cytk-20250830monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-september-investor-conferences-cytk-20250827monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-five-presentations-related-to-aficamten-at-the-european-society-of--cytk-20250825monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-names-jim-daly-to-board-of-directors-cytk-20250820monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20250819monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-second-quarter-results-on-august-7-2025-cytk-20250724monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20250718monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-five-presentations-related-to-aficamten-at-the-european-society-of--cytk-20250710monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20250617monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-call-for-proposals-for-annual-corporate-giving-program-cytk-20250610monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-the-jefferies-global-healthcare-conference-cytk-20250529monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-presents-additional-data-related-to-aficamten-at-the-european-society-of-card-cytk-20250518monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20250516monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-host-symposium-on-contemporary-landscapes-in-muscle-biology-cytk-20250515monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-positive-topline-results-from-maple-hcm-cytk-20250513monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-four-upcoming-presentations-at-the-european-society-of-cardiology-h-cytk-20250508monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-hold-annual-meeting-of-stockholders-cytk-20250507monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-new-pdufa-date-for-aficamten-in-obstructive-hypertrophic-cardiomyop-cytk-20250501monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-may-investor-conferences-cytk-20250430monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-first-quarter-results-on-may-6-2025-cytk-20250422monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20250417monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference-cytk-20250331monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-launch-of-earth-hcm-a-public-health-education-tool-for-the-hypertro-cytk-20250320monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20250318monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-five-presentations-at-the-american-college-of-cardiology-annual-sci-cytk-20250317monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-march-investor-conferences-cytk-20250303monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20250219monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-fourth-quarter-results-on-february-27-2025-cytk-20250213monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-names-robert-e-landry-to-board-of-directors-cytk-20250211monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-confer-cytk-20250205monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20250204monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-recipients-of-its-seventh-annual-communications-grant-program-cytk-20250130monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-start-of-amber-hfpef-a-phase-2-clinical-trial-of-ck-586-in-patients-cytk-20250121monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-2025-corporate-milestones-and-vision-2030-cytk-20250113monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-cytk-20250106monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20250103monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-european-medicines-agency-validation-of-marketing-authorization-app-cytk-20241223monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-sanofi-acquired-rights-to-develop-and-commercialize-aficamten-in-gr-cytk-20241220monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20241203monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-start-of-comet-hf-a-confirmatory-phase-3-clinical-trial-of-omecamti-cytk-20241203monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-december-investor-conferences-cytk-20241202monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-fda-acceptance-of-new-drug-application-for-aficamten-for-the-treatm-cytk-20241202monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-and-bayer-announce-exclusive-licensing-collaboration-for-aficamten-in-japan-cytk-20241119monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-presents-new-data-relating-to-aficamten-and-hypertrophic-cardiomyopathy-at-th-cytk-20241116monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-presents-additional-data-from-galactic-hf-at-the-american-heart-association-s-cytk-20241116monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-the-2024-jefferies-london-healthcare-conference-cytk-20241112monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-initiation-of-phase-1-clinical-study-of-ck-4015089-cytk-20241111monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-third-quarter-2024-financial-results-cytk-20241106monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-six-upcoming-presentations-at-the-american-heart-association-scient-cytk-20241105monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20241104monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-third-quarter-results-on-november-6-2024-cytk-20241023monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-highlights-progress-in-cardiac-myosin-modulation-programs-and-global-commerci-cytk-20241016monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20241003monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-host-investor-analyst-day-on-october-16-2024-cytk-20241002monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-presents-additional-data-from-sequoia-hcm-at-the-hfsa-annual-scientific-meeti-cytk-20240930monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-presents-additional-data-from-sequoia-hcm-at-the-hcms-scientific-sessions-cytk-20240927monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-call-for-proposals-for-its-seventh-annual-communications-grant-prog-cytk-20240924monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-upcoming-presentations-at-the-hcms-scientific-sessions-and-the-hfsa-cytk-20240919monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-data-from-phase-1-study-of-ck-4021586-cytk-20240909monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-two-presentations-at-the-2024-american-college-of-clinical-pharmaco-cytk-20240905monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20240904monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-presents-new-data-related-to-the-safety-and-long-term-use-of-aficamten-at-the-cytk-20240901monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-presents-additional-data-from-sequoia-hcm-at-the-european-society-of-cardiolo-cytk-20240901monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-september-investor-conferences-cytk-20240829monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20240801monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-call-for-proposals-for-corporate-giving-program-cytk-20240730monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-second-quarter-results-on-august-8-2024-cytk-20240725monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-seven-upcoming-presentations-at-the-european-society-of-cardiology--cytk-20240716monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20240703monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-initiation-of-phase-1-study-of-aficamten-in-healthy-japanese-partic-cytk-20240617monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20240604monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-june-investor-conferences-cytk-20240529monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-closing-of-public-offering-of-common-stock-cytk-20240528monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-pricing-of-public-offering-of-common-stock-cytk-20240523monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-proposed-public-offering-of-common-stock-cytk-20240522monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-and-royalty-pharma-announce-expanded-strategic-funding-collaboration-totaling-cytk-20240522monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-hosts-muscle-biology-focused-research-symposium-contemporary-landscapes-in-mu-cytk-20240517monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-five-presentations-related-to-aficamten-at-the-european-society-of--cytk-20240515monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-additional-results-from-sequoia-hcm-presented-in-late-breaking-clin-cytk-20240513monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-start-of-cedar-hcm-a-clinical-trial-of-aficamten-in-a-pediatric-pop-cytk-20240508monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-topline-data-from-phase-1-clinical-study-of-ck-4021586-cytk-20240508monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-hold-annual-meeting-of-stockholders-cytk-20240507monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20240502monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-host-investor-event-and-conference-call-to-discuss-the-primary-results-fro-cytk-20240429monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-first-quarter-results-on-may-8-2024-cytk-20240424monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-three-late-breaking-clinical-trial-presentations-relating-to-sequoi-cytk-20240410monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20240402monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-the-23rd-annual-needham-virtual-healthcare-conference-cytk-20240401monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-four-upcoming-presentations-at-the-american-college-of-cardiology-7-cytk-20240325monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-march-investor-conferences-cytk-20240304monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20240301monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-joins-global-initiative-to-recognize-international-rare-disease-day-cytk-20240229monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-the-mended-hearts-inc-and-womenheart-announce-launch-of-new-initiative-to-inc-cytk-20240228monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-fourth-quarter-results-on-february-27-2024-cytk-20240213monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-the-oppenheimer-34th-annual-healthcare-life-sciences-confer-cytk-20240206monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-recipients-of-its-sixth-annual-communications-grant-program-cytk-20240129monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-presents-new-data-at-cmr-2024-from-forest-hcm-the-open-label-extension-clinic-cytk-20240125monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-new-data-from-forest-hcm-to-be-presented-at-cmr-2024-cytk-20240118monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20240103monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-cytk-20240102monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-positive-results-from-sequoia-hcm-the-pivotal-phase-3-clinical-tria-cytk-20231227monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-host-investor-call-on-december-27-to-discuss-the-topline-results-from-sequ-cytk-20231226monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-presents-results-from-courage-als-at-the-34th-international-symposium-on-als--cytk-20231207monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20231201monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-five-presentations-at-the-34th-international-symposium-on-als-mnd-cytk-20231129monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20231103monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-upcoming-investor-conferences-cytk-20231101monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-third-quarter-results-on-november-2-2023-cytk-20231023monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-provides-update-on-cardiac-myosin-inhibitor-programs-and-plans-to-build-a-spe-cytk-20231019monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-presents-baseline-characteristics-from-sequoia-hcm-at-the-hcm-society-scienti-cytk-20231006monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-host-virtual-investor-analyst-day-on-october-19-2023-cytk-20231005monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20231003monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-upcoming-presentations-at-the-2023-hcms-scientific-sessions-and-the-cytk-20231002monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-call-for-proposals-for-its-sixth-annual-communications-grant-progra-cytk-20230928monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-upcoming-investor-conferences-cytk-20230907monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-start-of-acacia-hcm-a-pivotal-phase-3-clinical-trial-of-aficamten-i-cytk-20230906monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20230901monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20230801monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-second-quarter-results-on-august-3-2023-cytk-20230727monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20230705monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-start-of-maple-hcm-a-phase-3-clinical-trial-of-aficamten-compared-t-cytk-20230620monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20230602monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-upcoming-investor-conferences-cytk-20230601monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-three-upcoming-presentations-at-the-european-society-of-cardiology--cytk-202305152023-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-initiation-of-phase-1-clinical-study-of-ck-4021586-cytk-202305112023-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-the-jmp-securities-life-sciences-conference-cytk-202305082023-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-hold-annual-meeting-of-stockholders-cytk-202305032023-05-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-202305012023-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-first-quarter-results-on-may-4-2023-cytk-202304202023-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-the-22nd-annual-needham-virtual-healthcare-conference-cytk-202304102023-04-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-202304032023-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-courage-als-met-criteria-for-futility-at-second-interim-analysis-cytk-202303312023-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-releases-inaugural-corporate-responsibility-report-cytk-202303272023-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-upcoming-investor-conferences-cytk-202303062023-03-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-presents-positive-results-from-cohort-4-of-redwood-hcm-and-long-term-results--cytk-202303042023-03-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-202303022023-03-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-receives-complete-response-letter-from-fda-for-new-drug-application-for-omeca-cytk-202302282023-02-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-three-upcoming-presentations-at-the-american-college-of-cardiology--cytk-202302242023-02-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-joins-global-initiative-to-recognize-international-rare-disease-day-cytk-202302222023-02-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-fourth-quarter-results-on-march-1-2023-cytk-202302152023-02-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-202302012023-02-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-recipients-of-its-fifth-annual-communications-grant-program-cytk-202301302023-01-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-202301042023-01-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-the-41st-annual-j-p-morgan-healthcare-conference-cytk-202301032023-01-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-outcome-of-fda-advisory-committee-vote-on-omecamtiv-mecarbil-cytk-20221213monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-stock-trading-halted-today-cytk-20221213monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-availability-of-briefing-documents-for-fda-advisory-committee-meeti-cytk-20221209monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-presents-data-at-the-virtual-33rd-international-symposium-on-als-mnd-cytk-20221208monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-initiation-of-phase-1-clinical-study-of-ck-3828136-cytk-20221207monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20221202monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-presentation-at-the-virtual-33rd-international-symposium-on-als-mnd-cytk-20221201monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-presents-new-data-at-the-american-heart-association-scientific-sessions-2022-cytk-20221107monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20221101monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-three-upcoming-presentations-at-the-american-heart-association-scie-cytk-20221031monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-third-quarter-results-on-november-3-2022-cytk-20221020monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-continuation-of-courage-als-following-first-interim-analysis-cytk-20221010monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20221003monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-presents-new-data-from-redwood-hcm-ole-in-late-breaking-clinical-trial-sessio-cytk-20221002monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-presents-new-data-from-redwood-hcm-ole-in-late-breaking-clinical-trial-sessio-cytk-20220930monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-progra-cytk-20220928monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-upcoming-presentations-at-the-2022-inaugural-hcm-society-scientific-cytk-20220926monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-upcoming-investor-conferences-cytk-20220906monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20220901monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-and-the-als-association-announce-release-of-updated-pro-act-database-includin-cytk-20220804monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20220801monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-second-quarter-results-on-august-4-2022-cytk-20220721monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20220705monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-pricing-of-450-million-convertible-senior-notes-offering-cytk-20220701monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-proposed-convertible-senior-notes-offering-cytk-20220629monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-date-for-fda-advisory-committee-meeting-to-review-new-drug-applicat-cytk-20220624monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-provides-regulatory-update-for-omecamtiv-mecarbil-cytk-20220617monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-start-of-open-label-extension-study-for-patients-completing-courage-cytk-20220616monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-additional-data-from-redwood-hcm-presented-at-the-american-society--cytk-20220613monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-additional-results-from-redwood-hcm-to-be-presented-at-the-american-cytk-20220603monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-upcoming-investor-conferences-cytk-20220602monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20220601monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-data-from-redwood-hcm-ole-and-galactic-hf-presented-as-late-breakin-cytk-20220523monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-and-the-als-association-renew-partnership-to-advance-the-fight-against-als-cytk-20220518monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-the-2022-h-c-wainwright-global-life-sciences-conference-cytk-20220517monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-provides-regulatory-update-related-to-new-drug-application-for-omecamtiv-meca-cytk-20220517monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-three-upcoming-presentations-at-the-european-society-of-cardiology--cytk-20220516monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-first-quarter-2022-financial-results-cytk-20220504monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-hold-annual-meeting-of-stockholders-cytk-20220503monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-first-quarter-results-on-may-4-2022-cytk-20220420monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-changes-to-board-of-directors-cytk-20220408monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-the-21st-annual-needham-virtual-healthcare-conference-cytk-20220406monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-results-from-meteoric-hf-and-additional-data-from-galactic-hf-prese-cytk-20220403monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-results-from-cohort-3-of-redwood-hcm-presented-at-american-college--cytk-20220402monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20220401monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-four-upcoming-presentations-at-the-american-college-of-cardiology-7-cytk-20220324monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-upcoming-investor-conferences-cytk-20220308monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-cohort-4-of-redwood-hcm-is-open-to-enrollment-cytk-20220302monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20220301monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-joins-global-initiative-to-recognize-international-rare-disease-day-cytk-20220228monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-fourth-quarter-2021-financial-results-cytk-20220224monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-start-of-sequoia-hcm-a-phase-3-clinical-trial-of-aficamten-in-patie-cytk-20220223monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-and-the-american-heart-association-bay-area-announce-a-three-year-collaborati-cytk-20220216monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-topline-results-from-meteoric-hf-cytk-20220215monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-fourth-quarter-results-on-february-24-2022-cytk-20220210monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-fda-acceptance-of-new-drug-application-for-omecamtiv-mecarbil-for-t-cytk-20220204monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20220201monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-positive-topline-results-from-cohort-3-of-redwood-hcm-cytk-20220201monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-recipients-of-fourth-annual-communications-fellowship-grants-cytk-20220124monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20220110monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-and-royalty-pharma-announce-funding-agreements-totaling-up-to-450-million-cytk-20220107monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-the-40th-annual-j-p-morgan-healthcare-conference-cytk-20220103monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-and-ji-xing-announce-expansion-of-collaboration-to-include-licensing-of-omeca-cytk-20211220monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-data-from-its-als-program-presented-at-the-32nd-international-sympo-cytk-20211210monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-receipt-of-breakthrough-therapy-designation-from-fda-for-aficamten-cytk-20211209monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20211201monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-four-presentations-at-the-32nd-international-symposium-on-als-mnd-cytk-20211130monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-the-piper-sandler-33rd-annual-virtual-healthcare-conference-cytk-20211115monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-additional-results-from-galactic-hf-presented-at-american-heart-ass-cytk-20211115monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-two-presentations-at-the-aha-scientific-sessions-2021-cytk-20211108monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-third-quarter-2021-financial-results-cytk-20211103monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20211101monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-preclinical-data-relating-to-ck-3828136-presented-at-the-2021-medic-cytk-20211029monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-preclinical-data-for-ck-3828136-to-be-presented-at-the-2021-medicin-cytk-20211021monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-third-quarter-results-on-november-3-2021-cytk-20211020monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-outlines-go-to-market-strategy-for-omecamtiv-mecarbil-and-provides-updates-on-cytk-20211007monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20211001monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-fourth-annual-communications-fellowship-grant-program-call-for-prop-cytk-20210928monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-host-analyst-investor-day-on-october-7-2021-cytk-20210923monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-results-from-redwood-hcm-and-galactic-hf-presented-in-late-breaking-cytk-20210912monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-september-investor-conferences-cytk-20210908monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-host-investor-call-and-webcast-to-discuss-the-full-results-from-redwood-hc-cytk-20210907monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20210901monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-results-from-redwood-hcm-and-galactic-hf-to-be-presented-in-late-br-cytk-20210831monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-and-cure-sma-renew-partnership-to-advance-education-and-awareness-of-sma-cytk-20210819monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-second-quarter-2021-financial-results-cytk-20210805monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20210802monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-start-of-courage-als-a-phase-3-clinical-trial-of-reldesemtiv-in-pat-cytk-20210802monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-und-cytk-20210723monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-second-quarter-results-on-august-5-2021-cytk-20210722monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-pricing-of-public-offering-of-common-stock-cytk-20210721monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-proposed-public-offering-of-common-stock-cytk-20210719monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-positive-topline-results-of-redwood-hcm-cytk-20210719monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20210701monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-additional-results-from-galactic-hf-presented-at-the-european-socie-cytk-20210630monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-three-presentations-to-occur-at-the-european-society-of-cardiology--cytk-20210623monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-completion-of-enrollment-in-meteoric-hf-the-second-phase-3-clinical-cytk-20210615monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-upcoming-investor-conferences-cytk-20210602monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20210601monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-and-the-als-association-renew-partnership-to-advance-the-fight-against-als-cytk-20210519monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-secondary-analysis-of-galactic-hf-presented-in-late-breaking-clinic-cytk-20210517monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-presentations-related-to-health-economics-and-outcomes-research-in--cytk-20210516monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-three-upcoming-presentations-related-to-heart-failure-and-hypertrop-cytk-20210510monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-first-quarter-2021-financial-results-cytk-20210506monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-start-of-open-label-extension-study-for-patients-completing-redwood-cytk-20210506monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-hold-annual-meeting-of-stockholders-cytk-20210505monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-cohort-3-of-redwood-hcm-is-open-to-enrollment-cytk-20210504monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20210503monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-first-quarter-results-on-may-6-2021-cytk-20210422monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-preclinical-data-for-ck-3773274-presented-at-the-american-chemical--cytk-20210412monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-the-20th-annual-needham-virtual-healthcare-conference-cytk-20210405monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-preclinical-data-for-ck-3773274-to-be-presented-at-the-american-che-cytk-20210402monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20210401monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-secondary-analysis-from-galactic-hf-to-be-presented-in-late-breakin-cytk-20210318monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-upcoming-investor-conferences-cytk-20210302monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20210226monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-joins-global-initiative-to-recognize-international-rare-disease-day-cytk-20210226monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-fourth-quarter-2020-financial-results-cytk-20210225monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-names-muna-bhanji-to-board-of-directors-cytk-20210218monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-fourth-quarter-results-on-february-25-2021-cytk-20210211monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-recipients-of-third-annual-communications-fellowship-grants-cytk-20210202monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20210201monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-first-patient-dosed-in-cohort-2-of-redwood-hcm-cytk-20210113monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-granted-orphan-drug-designation-for-ck-3773274-for-the-treatment-of-hypertrop-cytk-20210111monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference-cytk-20210106monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-regains-european-rights-to-omecamtiv-mecarbil-cytk-20201223monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-data-and-trial-design-presented-at-the-international-symposium-on-a-cytk-20201214monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-progression-of-redwood-hcm-to-cohort-2-cytk-20201209monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-additional-results-from-galactic-hf-presented-at-the-17th-global-ca-cytk-20201207monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-three-presentations-at-the-international-symposium-on-als-mnd-cytk-20201203monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20201201monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-additional-results-from-galactic-hf-to-be-presented-at-the-17th-glo-cytk-20201201monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-upcoming-investor-conferences-cytk-20201124monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-regains-rights-to-develop-and-commercialize-omecamtiv-mecarbil-and-amg-594-fr-cytk-20201123monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-names-nancy-wysenski-to-board-of-directors-cytk-20201120monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-preclinical-data-for-ck-3773274-and-ck-3772271-presented-at-the-aha-cytk-20201116monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-presentations-related-to-health-economics-and-outcomes-research-in--cytk-20201116monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-results-from-galactic-hf-presented-at-late-breaking-clinical-trial--cytk-20201113monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20201110monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-six-presentations-related-to-heart-failure-and-hypertrophic-cardiom-cytk-20201106monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-third-quarter-2020-financial-results-cytk-20201104monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-third-quarter-results-on-november-4-2020-cytk-20201021monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cytk-20201005monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-data-from-two-presentations-at-the-hfsa-virtual-annual-scientific-m-cytk-20201005monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-publication-of-manuscript-detailing-baseline-characteristics-of-gal-cytk-20201002monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-data-to-be-presented-at-the-hfsa-virtual-annual-scientific-meeting--cytk-20200924monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-third-annual-communications-fellowship-program-call-for-proposals-cytk-20200924monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-initiation-of-phase-1-clinical-study-of-ck-3772271-cytk-20200923monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-galactic-hf-accepted-for-presentation-in-late-breaking-clinical-tri-cytk-20200917monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-upcoming-investor-conferences-cytk-20200902monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-and-cure-sma-renew-partnership-to-advance-education-and-awareness-of-sma-cytk-20200826monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-partnership-to-improve-prediction-of-risk-and-outcomes-in-hypertrop-cytk-20200818monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-second-quarter-2020-financial-results-cytk-20200806monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-second-quarter-results-on-august-6-2020-cytk-20200723monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-und-cytk-20200721monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-pricing-of-public-offering-of-common-stock-cytk-20200717monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-proposed-public-offering-of-common-stock-cytk-20200715monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-provides-updates-on-its-cardiovascular-pipeline-and-strategies-to-build-a-com-cytk-20200715monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-licensing-collaboration-and-royalty-monetization-deals-with-rtw-inv-cytk-20200714monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-participation-in-the-launch-of-kainomyx-inc-focused-to-the-treatmen-cytk-20200713monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-host-virtual-investor-analyst-day-on-july-15-2020-cytk-20200701monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-upcoming-investor-conferences-cytk-20200608monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-and-the-als-association-renew-partnership-to-advance-the-fight-against-als-cytk-20200527monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-hold-annual-meeting-of-stockholders-cytk-20200507monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-first-quarter-2020-financial-results-cytk-20200506monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-first-quarter-results-on-may-6-2020-cytk-20200422monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-provides-clinical-trials-and-business-update-in-response-to-covid-19-pandemic-cytk-20200414monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-the-19th-annual-needham-virtual-healthcare-conference-cytk-20200408monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-baseline-characteristics-from-galactic-hf-at-acc-20-wcc-virtual-cytk-20200330monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-baseline-characteristics-from-galactic-hf-during-acc-20-wcc-cytk-20200320monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-granted-european-orphan-designation-for-reldesemtiv-for-the-treatment-of-amyo-cytk-20200304monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-fourth-quarter-2019-financial-results-cytk-20200303monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-preclinical-data-for-amg-594-presented-at-the-keystone-symposium-on-cytk-20200303monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-joins-global-initiative-to-recognize-international-rare-disease-day-cytk-20200228monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-preclinical-data-for-ck-3773274-presented-at-the-biophysical-societ-cytk-20200220monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-fourth-quarter-results-on-march-3-2020-cytk-20200218monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-publication-relating-to-design-of-galactic-hf-a-phase-3-clinical-tr-cytk-20200206monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-recipients-of-second-annual-communications-fellowship-grants-cytk-20200122monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-vision-2025-and-outlines-2020-corporate-milestones-cytk-20200113monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-start-of-redwood-hcm-a-phase-2-clinical-trial-of-ck-3773274-cytk-20200106monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-granted-orphan-drug-designation-for-reldesemtiv-for-the-treatment-of-amyotrop-cytk-20191218monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-new-results-presented-at-the-international-symposium-on-als-mnd-cytk-20191205monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-the-piper-jaffray-healthcare-conference-cytk-20191127monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-five-presentations-at-the-international-symposium-on-als-mnd-cytk-20191126monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-additional-results-from-cosmic-hf-to-be-presented-at-the-american-h-cytk-20191111monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-pricing-of-public-offering-of-convertible-senior-notes-cytk-20191108monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-proposed-public-offering-of-convertible-senior-notes-cytk-20191106monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-the-credit-suisse-28th-annual-healthcare-conference-cytk-20191105monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-third-quarter-2019-financial-results-cytk-20191031monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-third-quarter-results-on-october-31-2019-cytk-20191024monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-presentation-of-additional-analyses-from-fortitude-als-at-the-18th--cytk-20191004monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-cytk-20190926monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-additional-results-from-fortitude-als-to-be-presented-at-the-18th-a-cytk-20190926monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-second-annual-communications-fellowship-program-call-for-proposals-cytk-20190925monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-presentations-at-the-23rd-annual-hfsa-scientific-meeting-cytk-20190906monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-present-at-september-investor-conferences-cytk-20190903monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-and-cure-sma-renew-partnership-to-advance-education-and-awareness-of-sma-cytk-20190827monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-second-quarter-2019-financial-results-cytk-20190808monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-preclinical-data-for-ck-3773274-presented-at-the-american-heart-ass-cytk-20190731monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-second-quarter-results-on-august-8-2019-cytk-20190725monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-publication-of-preclinical-data-demonstrating-fast-skeletal-muscle--cytk-20190724monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-granted-european-orphan-designation-for-reldesemtiv-for-the-treatment-of-spin-cytk-20190723monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-preclinical-data-relating-to-ck-3773274-to-be-presented-at-the-amer-cytk-20190722monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-completion-of-enrollment-in-galactic-hf-phase-3-clinical-trial-of-o-cytk-20190715monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-preclinical-data-for-reldesemtiv-presented-at-the-2019-annual-cure--cytk-20190628monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-preclinical-data-for-reldesemtiv-to-be-presented-at-the-2019-annual-cytk-20190624monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-present-at-the-jmp-securities-life-sciences-conference-cytk-20190612monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-and-the-als-association-renew-partnership-to-advance-the-fight-against-als-cytk-20190530monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-first-quarter-2019-financial-results-cytk-20190509monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-hold-annual-meeting-of-stockholders-cytk-20190508monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-results-of-fortitude-als-a-phase-2-clinical-trial-of-reldesemtiv-in-cytk-20190505monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-first-quarter-results-on-may-9-2019-cytk-20190425monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-present-at-april-investor-conferences-cytk-20190401monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-presentation-of-additional-results-from-cosmic-hf-at-acc-19-cytk-20190318monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-additional-results-from-cosmic-hf-to-be-presented-at-acc-19-cytk-20190311monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-presentation-of-results-from-fortitude-als-at-the-american-academy--cytk-20190307monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-joins-global-initiative-to-recognize-international-rare-disease-day-cytk-20190228monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-reports-fourth-quarter-2018-financial-results-cytk-20190221monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-initiation-of-phase-1-clinical-study-of-amg-594-a-cardiac-troponin--cytk-20190220monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-fourth-quarter-results-on-february-21-2019-cytk-20190207monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-receipt-of-fda-feedback-regarding-reldesemtiv-in-patients-with-sma-cytk-20190122monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-new-data-presented-at-the-international-symposium-on-als-mnd-cytk-20181210monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-initiation-of-phase-1-clinical-trial-of-ck-3773274-a-cardiac-myosin-cytk-20181205monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-completes-enrollment-in-fortitude-als-phase-2-clinical-trial-of-reldesemtiv-i-cytk-20181127monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-five-presentations-at-the-international-symposium-on-als-mnd-cytk-20181126monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-upcoming-investor-conferences-cytk-20181107monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-inc-reports-third-quarter-2018-financial-results-cytk-20181101monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-third-quarter-results-on-november-1-2018-cytk-20181018monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-unveils-expanded-development-pipeline-and-provides-key-updates-on-late-stage--cytk-20181016monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-and-astellas-provide-updates-regarding-collaborative-skeletal-muscle-program-cytk-20181005monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-host-r-d-day-on-october-16-2018-cytk-20181002monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-cytk-20180925monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-present-at-the-morgan-stanley-global-healthcare-conference-cytk-20180905monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-awards-inaugural-communications-fellowship-to-the-als-association-golden-west-cytk-20180828monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-inc-reports-second-quarter-2018-financial-results-cytk-20180726monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-second-quarter-results-on-july-26-2018-cytk-20180712monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-data-from-phase-2-clinical-study-of-reldesemtiv-in-patients-with-sp-cytk-20180616monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-present-at-the-jmp-securities-life-sciences-conference-cytk-20180613monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-data-from-phase-2-clinical-study-of-reldesemtiv-in-patients-with-sp-cytk-20180608monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-and-cure-sma-renew-and-expand-partnership-to-advance-education-and-awareness--cytk-20180517monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-hold-annual-meeting-of-stockholders-cytk-20180510monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-and-the-als-association-renew-partnership-to-advance-the-fight-against-als-cytk-20180501monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-inc-reports-first-quarter-2018-financial-results-cytk-20180426monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-presentation-of-data-from-phase-2-clinical-study-of-reldesemtiv-in--cytk-20180424monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-first-quarter-results-on-april-26-2018-cytk-20180412monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-present-at-march-investor-conferences-cytk-20180305monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-joins-global-initiative-to-recognize-international-rare-disease-day-cytk-20180228monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-inc-reports-fourth-quarter-2017-financial-results-cytk-20180215monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-present-at-the-rbc-capital-markets-global-healthcare-conference-cytk-20180214monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-names-robert-califf-m-d-to-board-of-directors-cytk-20180212monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-fourth-quarter-results-on-february-15-2018-cytk-20180202monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-progress-against-vision-2020-cytk-20180103monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-presentation-of-results-from-vitality-als-at-28th-international-sym-cytk-20171208monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-results-of-vitality-als-to-be-presented-at-the-international-sympos-cytk-20171201monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-negative-results-from-vitality-als-cytk-20171121monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-additional-results-from-cosmic-hf-at-the-american-heart-association-cytk-20171113monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-additional-results-from-cosmic-hf-to-be-presented-at-the-american-h-cytk-20171106monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-inc-reports-third-quarter-2017-financial-results-cytk-20171026monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-third-quarter-results-on-october-26-2017-cytk-20171012monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-dosing-of-first-patient-in-japan-in-galactic-hf-phase-3-clinical-tr-cytk-20170919monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-presentation-of-additional-results-from-cosmic-hf-at-the-hfsa-21st--cytk-20170918monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-additional-results-from-cosmic-hf-to-be-presented-at-the-hfsa-21st--cytk-20170911monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-present-at-september-investor-conferences-cytk-20170905monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-inc-reports-second-quarter-2017-financial-results-cytk-20170802monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-positive-results-from-phase-2-clinical-trial-of-omecamtiv-mecarbil--cytk-20170802monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-start-of-fortitude-als-a-phase-2-clinical-trial-of-ck-2127107-in-pa-cytk-20170727monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-second-quarter-results-on-august-2-2017-cytk-20170726monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-baseline-data-from-first-cohort-of-phase-2-clinical-trial-of-ck-212-cytk-20170705monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-start-of-phase-1b-clinical-trial-of-ck-2127107-in-elderly-subjects--cytk-20170629monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-presentations-at-the-cure-sma-2017-annual-sma-conference-cytk-20170623monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-panel-on-neuromuscular-disorders-at-the-jmp-securities-life-cytk-20170613monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-orphan-drug-designation-for-ck-2127107-for-the-treatment-of-spinal--cytk-20170515monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-hold-annual-meeting-of-stockholders-cytk-20170511monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-pricing-of-public-offering-of-common-stock-cytk-20170509monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-proposed-public-offering-of-common-stock-cytk-20170508monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-and-the-als-association-renew-partnership-to-advance-the-fight-against-als-cytk-20170503monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-results-from-dose-escalation-phase-of-cosmic-hf-presented-at-heart--cytk-20170501monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-inc-reports-first-quarter-2017-financial-results-cytk-20170427monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-added-to-s-p-smallcap-600-cytk-20170421monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-first-quarter-results-on-april-27-2017-cytk-20170413monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-present-at-the-16th-annual-needham-healthcare-conference-cytk-20170329monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-start-of-second-cohort-in-phase-2-clinical-trial-of-ck-2127107-in-p-cytk-20170329monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-preclinical-data-for-ck-2127107-presented-at-mda-scientific-confere-cytk-20170322monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-additional-results-from-cosmic-hf-presented-at-acc-17-cytk-20170320monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-presentation-of-additional-results-from-cosmic-hf-at-acc-17-cytk-20170306monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-joins-global-initiative-to-recognize-international-rare-disease-day-cytk-20170228monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-present-at-march-investor-conferences-cytk-20170227monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-inc-reports-fourth-quarter-2016-financial-results-cytk-20170216monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-fourth-quarter-results-on-february-16-2017-cytk-20170203monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-and-royalty-pharma-announce-100-million-transaction-for-omecamtiv-mecarbil-cytk-20170202monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-added-to-nasdaq-biotechnology-index-cytk-20161216monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-new-data-presented-at-the-international-symposium-on-als-mnd-cytk-20161209monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-presentations-at-the-international-symposium-on-als-mnd-cytk-20161202monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-start-of-galactic-hf-a-phase-3-clinical-trial-of-omecamtiv-mecarbil-cytk-20161201monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-upcoming-investor-conferences-cytk-20161122monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-presentation-of-additional-results-from-cosmic-hf-at-the-aha-annual-cytk-20161114monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-new-results-from-cosmic-hf-to-be-presented-at-the-american-heart-as-cytk-20161107monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-publication-relating-to-novel-smooth-muscle-myosin-inhibitor-cytk-20161107monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-inc-reports-third-quarter-2016-financial-results-cytk-20161027monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-first-patient-enrolled-in-vigor-als-an-open-label-extension-clinica-cytk-20161018monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-third-quarter-results-on-october-27-2016-cytk-20161013monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-early-termination-of-hart-scott-rodino-waiting-period-for-expanded--cytk-20160929monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-presentation-of-additional-results-from-cosmic-hf-at-the-hfsa-annua-cytk-20160919monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-additional-results-from-cosmic-hf-to-be-presented-at-the-hfsa-annua-cytk-20160909monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-next-generation-fast-skeletal-muscle-activator-entering-ind-enablin-cytk-20160908monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-and-amgen-to-advance-omecamtiv-mecarbil-to-phase-3-clinical-development-cytk-20160901monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-completes-enrollment-in-vitality-als-phase-3-clinical-trial-of-tirasemtiv-in--cytk-20160817monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-inc-reports-second-quarter-2016-financial-results-cytk-20160728monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-and-the-als-association-renew-partnership-to-advance-the-fight-against-als-cytk-20160727monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-and-astellas-announce-option-right-for-tirasemtiv-and-expansion-of-global-col-cytk-20160727monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-second-quarter-results-on-july-28-2016-cytk-20160714monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-present-at-cantor-fitzgerald-s-2nd-annual-healthcare-conference-cytk-20160705monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-start-of-phase-2-clinical-trial-of-ck-2127107-in-patients-with-chro-cytk-20160630monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-upcoming-investor-conferences-cytk-20160614monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-presentation-of-additional-results-from-cosmic-hf-at-heart-failure--cytk-20160523monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-appoints-edward-m-kaye-m-d-to-board-of-directors-cytk-20160520monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-additional-cosmic-hf-results-to-be-presented-at-heart-failure-2016-cytk-20160513monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-hold-annual-meeting-of-stockholders-cytk-20160511monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-ring-nasdaq-closing-bell-to-launch-als-awareness-month-cytk-20160502monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-inc-reports-first-quarter-2016-financial-results-cytk-20160428monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-first-quarter-results-on-april-28-2016-cytk-20160414monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-present-at-the-15th-annual-needham-healthcare-conference-cytk-20160405monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-start-of-phase-2-clinical-trial-of-omecamtiv-mecarbil-in-japanese-s-cytk-20160404monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-present-at-march-investor-conferences-cytk-20160301monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-joins-global-movement-to-recognize-international-rare-disease-day-cytk-20160229monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-inc-reports-fourth-quarter-2015-financial-results-cytk-20160216monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-participate-in-upcoming-investor-conferences-cytk-20160203monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-fourth-quarter-results-on-february-16-2016-cytk-20160202monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-outlines-vision-2020-strategic-initiative-to-advance-portfolio-of-muscle-biol-cytk-20160111monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-presents-analyses-demonstrating-predictive-value-of-slow-vital-capacity-for-c-cytk-20160110monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-start-of-phase-2-clinical-trial-of-ck-2127107-in-patients-with-spin-cytk-20160104monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-present-at-27th-annual-piper-jaffray-healthcare-conference-cytk-20151124monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-results-from-cosmic-hf-to-be-presented-in-late-breaking-clinical-tr-cytk-20151106monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-inc-reports-third-quarter-2015-financial-results-cytk-20151029monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-third-quarter-results-on-october-29-2015-cytk-20151015monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-inc-reports-second-quarter-2015-financial-results-cytk-20150729monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-announce-second-quarter-results-on-july-29-2015-cytk-20150715monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-and-the-als-association-announce-awarding-of-grant-for-phase-3-clinical-trial-cytk-20150714monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-start-of-phase-3-clinical-trial-of-tirasemtiv-in-patients-with-als-cytk-20150714monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-presents-results-from-phase-i-studies-of-ck-2127107-cytk-20150619monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-present-at-the-9th-annual-jmp-securities-life-sciences-conference-2015-cytk-20150616monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-announces-poster-presentation-on-ck-2127107-at-the-19th-international-sma-res-cytk-20150611monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-and-the-als-association-announce-partnership-to-advance-the-fight-against-als-cytk-20150604monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-to-hold-annual-meeting-of-stockholders-cytk-20150513monthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-incorporated-reports-first-quarter-2015-financial-results-cytk-20150430monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-upcoming-departure-of-chief-financial-officer-srrk-20190827monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-second-quarter-2019-financial-results-and-highlights-business-progres-srrk-20190814monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-to-present-at-the-2019-wedbush-pacgrow-healthcare-conference-srrk-20190807monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-exercise-in-full-of-underwriters-option-to-purchase-additional-shar-srrk-20190702monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-pricing-of-public-offering-of-common-stock-srrk-20190619monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-to-present-at-the-2019-bmo-prescriptions-for-success-healthcare-conference-srrk-20190619monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-proposed-public-offering-of-common-stock-srrk-20190618monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-positive-final-results-from-phase-1-clinical-trial-of-srk-015-in-he-srrk-20190603monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-to-present-at-the-jefferies-2019-global-healthcare-conference-srrk-20190528monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-first-quarter-2019-financial-results-and-highlights-business-progress-srrk-20190514monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-initiation-of-patient-dosing-in-phase-2-trial-of-srk-015-in-spinal--srrk-20190508monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-appoints-akshay-vaishnaw-m-d-ph-d-to-its-board-of-directors-srrk-20190430monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-appointment-of-lisa-amaya-price-as-senior-vice-president-human-reso-srrk-20190411monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-full-year-2018-financial-results-and-highlights-business-progress-srrk-20190318monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-to-participate-in-upcoming-investor-conferences-srrk-20190306monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-positive-interim-results-from-phase-1-trial-of-srk-015-in-healthy-v-srrk-20190226monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-srrk-20190103monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-positive-opinion-by-the-european-medicines-agency-on-orphan-drug-de-srrk-20181203monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-to-present-at-the-bmo-2018-prescriptions-for-success-healthcare-conference-srrk-20181129monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-publication-of-preclinical-data-on-the-therapeutic-benefit-of-inhib-srrk-20181127monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-announces-the-addition-of-edward-ted-myles-to-its-board-of-directors-srrk-20181119monthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-second-quarter-2018-financial-results-and-updates-on-business-progres-srrk-20180808monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-to-participate-in-upcoming-investor-conferences-cnta-20250519monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-reports-financial-results-and-business-highlights-for-the-first-q-cnta-20250514monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-reports-business-highlights-and-financial-results-for-the-fourth--cnta-20250324monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-poster-presentation-of-phase-1-clinical-data-for-orx750-cnta-20250306monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-to-participate-in-upcoming-investor-conferences-cnta-20250128monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-appointment-of-stephen-kanes-md-phd-as-chief-medical-of-cnta-20250108monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-reports-financial-results-for-the-third-quarter-of-2024-and-provi-cnta-20241112monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-to-participate-in-upcoming-investor-conferences-cnta-20241104monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-presents-preclinical-data-for-orx142-a-novel-orexin-receptor-2-ox-cnta-20240926monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-pricing-of-upsized-225-000-000-public-offering-of-ameri-cnta-20240913monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-late-breaking-poster-presentation-of-non-human-primate--cnta-20240827monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-to-participate-in-the-morgan-stanley-22nd-annual-global-healthcar-cnta-20240821monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-reports-financial-results-and-business-highlights-for-the-second--cnta-20240813monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-to-participate-in-upcoming-investor-conferences-cnta-20240521monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-reports-financial-results-and-business-highlights-for-the-first-q-cnta-20240513monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-pricing-of-100-million-public-offering-of-american-depo-cnta-20240424monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-open-ind-for-orx750-proof-of-concept-data-in-sleep-depr-cnta-20240422monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-reports-business-highlights-and-financial-results-for-the-fourth--cnta-20240328monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-to-participate-in-td-cowen-s-44th-annual-health-care-conference-cnta-20240222monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-to-present-additional-52-weeks-of-continuous-treatment-data-from--cnta-20240209monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-to-participate-in-upcoming-investor-conferences-cnta-20240122monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-new-data-from-an-additional-52-weeks-of-continuous-trea-cnta-20231210monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-reports-financial-results-and-business-highlights-for-the-third-q-cnta-20231113monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-to-present-additional-52-weeks-of-continuous-treatment-data-from--cnta-20231102monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-dosing-of-first-subject-in-registrational-present-3-stu-cnta-20231031monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-to-participate-in-upcoming-investor-conferences-cnta-20231030monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-additions-to-senior-leadership-team-cnta-20231003monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-to-participate-in-the-morgan-stanley-21st-annual-global-healthcar-cnta-20230831monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-to-present-preclinical-data-for-novel-orexin-receptor-2-ox2r-agon-cnta-20230823monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-reports-financial-results-and-business-highlights-for-the-second--cnta-20230814monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-dosing-of-first-subject-in-registrational-present-2-stu-cnta-20230710monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-to-participate-in-upcoming-investor-conferences-cnta-20230524monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-receives-fast-track-designation-from-the-u-s-fda-for-serpinpc-for-cnta-20230522monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-reports-financial-results-and-business-highlights-for-the-first-q-cnta-202305122023-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-reports-recent-business-progress-and-financial-results-for-the-fo-cnta-202303302023-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-to-participate-in-upcoming-investor-conferences-cnta-202303272023-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-addition-of-patrick-yue-md-as-senior-vice-president-of--cnta-202303012023-03-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-to-present-additional-data-from-open-label-extension-ole-of-phase-cnta-202302062023-02-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-presentation-at-the-svb-securities-global-biopharma-con-cnta-202302022023-02-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-fda-clearance-of-ind-application-for-phase-1-2a-clinica-cnta-202301262023-01-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-additional-18-months-of-continued-treatment-data-from-o-cnta-20221210monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-new-chief-people-officer-karen-anderson-cnta-20221130monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-ex-cnta-20221123monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-plc-nasdaq-cnta-shareholder-class-action-alert-bernstein-liebhard-cnta-20221122monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-cnta-20221116monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-plc-nasdaq-cnta-shareholder-class-action-alert-bernstein-liebhard-cnta-20221115monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-reports-financial-results-and-business-highlights-for-the-third-q-cnta-20221110monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-ex-cnta-20221109monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-plc-nasdaq-cnta-shareholder-class-action-alert-bernstein-liebhard-cnta-20221108monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-to-present-additional-18-months-of-continued-treatment-data-with--cnta-20221103monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-cnta-20221102monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-plc-nasdaq-cnta-shareholder-class-action-alert-bernstein-liebhard-cnta-20221101monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-to-participate-in-upcoming-investor-conferences-cnta-20221031monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-ex-cnta-20221026monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-plc-nasdaq-cnta-shareholder-class-action-alert-bernstein-liebhard-cnta-20221025monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-plc-investors-please-contact-the-portnoy-law-firm-to-recover-your-cnta-20221020monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-plc-cnta-class-action-notice-if-you-incurred-significant-losses-i-cnta-20221019monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-cnta-20221019monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-plc-nasdaq-cnta-shareholder-class-action-alert-bernstein-liebhard-cnta-20221018monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-plc-equity-notice-centessa-pharmaceuticals-plc-cnta-shareholders--cnta-20221014monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-ex-cnta-20221012monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-plc-nasdaq-cnta-shareholder-class-action-alert-bernstein-liebhard-cnta-20221011monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-cnta-20221005monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-plc-shareholder-alert-robbins-llp-reminds-investors-of-lead-plain-cnta-20221004monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-plc-nasdaq-cnta-shareholder-class-action-alert-bernstein-liebhard-cnta-20221004monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-plc-nasdaq-cnta-shareholder-class-action-alert-bernstein-liebhard-cnta-20220929monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-poster-presentation-featuring-novel-orexin-receptor-2-o-cnta-20220920monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-orphan-drug-designation-granted-to-serpinpc-for-the-tre-cnta-20220914monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-non-human-primate-pharmacokinetic-and-safety-data-for-l-cnta-20220912monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-to-participate-in-upcoming-investor-conferences-cnta-20220829monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceutical-plc-investors-company-investigated-by-the-portnoy-law-firm-cnta-20220812monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-reports-financial-results-and-business-highlights-for-the-second--cnta-20220810monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-addition-of-harris-l-rotman-phd-as-senior-vice-presiden-cnta-20220725monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-appointment-of-dr-mathias-hukkelhoven-to-its-board-of-d-cnta-20220701monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-to-participate-in-upcoming-investor-conferences-cnta-20220606monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-poster-presentation-of-first-preclinical-data-for-lockb-cnta-20220605monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-makes-strategic-decision-to-discontinue-clinical-development-of-l-cnta-20220602monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-reports-fourth-quarter-and-2021-financial-results-and-provides-bu-cnta-20220330monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-to-present-at-the-guggenheim-genomic-medicines-rare-disease-day-cnta-20220323monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-expands-management-team-and-adds-to-extensive-development-experti-cnta-20220307monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-doses-first-subject-in-global-phase-3-action-study-of-lixivaptan--cnta-20220224monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-initiates-global-phase-3-action-study-of-lixivaptan-in-autosomal--cnta-20211214monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-addition-to-nasdaq-biotechnology-index-cnta-20211213monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-third-quarter-2021-financial-results-and-business-updat-cnta-20211115monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-to-present-at-upcoming-conferences-in-2021-cnta-20211110monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-appoints-david-grainger-phd-a-leading-biotech-entrepreneur-as-chi-cnta-20211005monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-300-million-financing-agreement-with-oberland-capital-cnta-20211004monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-positive-topline-data-from-proof-of-concept-study-of-se-cnta-20210909monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-to-present-at-the-morgan-stanley-virtual-19th-annual-global-healt-cnta-20210901monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-announces-second-quarter-2021-financial-results-and-business-upda-cnta-20210816monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-to-present-at-the-goldman-sachs-42nd-annual-global-healthcare-con-cnta-20210607monthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-op-cnta-20210604monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-multiple-presentations-at-the-european-hematology-association-cogt-20260512monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-fda-acceptance-of-new-drug-application-for-bezuclastinib-in-p-cogt-20260316monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-anticipated-2026-commercial-and-clinical-milestones-for-bezuc-cogt-20260112monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-presentation-at-the-44th-annual-j-p-morgan-healthcare-confere-cogt-20260106monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-positive-top-line-results-of-apex-trial-of-bezuclastinib-in-p-cogt-20251208monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-presents-full-summit-results-of-bezuclastinib-in-patients-with-nonadvan-cogt-20251206monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-participation-in-the-jefferies-global-healthcare-conference-cogt-20251114monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-proposed-concurrent-public-offerings-of-convertible-senior-no-cogt-20251110monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-closing-of-upsized-public-offering-of-shares-of-common-stock--cogt-20250710monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-pricing-of-upsized-public-offering-of-shares-of-common-stock-cogt-20250709monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-proposed-150-million-public-offering-of-common-stock-cogt-20250708monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-participation-in-the-jefferies-global-healthcare-conference-cogt-20250529monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-first-quarter-2025-financial-results-cogt-20250506monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-presents-four-posters-at-the-american-association-for-cancer-research-a-cogt-20250425monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-multiple-poster-presentations-at-2025-american-association-fo-cogt-20250325monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-participation-in-the-leerink-healthcare-conference-cogt-20250307monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-summit-continues-to-showcase-powerful-symptomatic-improvement-cogt-20250227monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-bezuclastinib-poster-in-nonadvanced-systemic-mastocytosis-non-cogt-20250210monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-to-participate-in-the-guggenheim-biotech-conference-cogt-20250130monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-planned-2025-milestones-for-bezuclastinib-and-emerging-portfo-cogt-20250113monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-presentation-at-the-43rd-annual-j-p-morgan-healthcare-confere-cogt-20250108monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-updated-clinical-results-from-summit-showcasing-powerful-symp-cogt-20241209monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-positive-updated-data-from-ongoing-phase-2-apex-trial-evaluat-cogt-20241208monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-bezuclastinib-presentations-at-the-66th-annual-american-socie-cogt-20241105monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-pipeline-expansion-into-kras-and-poster-presentations-at-the--cogt-20241023monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-additional-clinical-data-from-part-1-of-its-ongoing-summit-tr-cogt-20240614monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-appoints-cole-pinnow-as-chief-commercial-officer-cogt-20240523monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-positive-updated-lead-in-data-from-ongoing-phase-3-peak-trial-cogt-20240523monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-presents-data-highlighting-potential-best-in-class-potency-and-selectiv-cogt-20240409monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-positive-part-1b-data-from-summit-trial-evaluating-bezuclasti-cogt-20240222monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-to-present-summit-part-1b-data-with-bezuclastinib-in-nonadvanced-system-cogt-20240205monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-planned-2024-milestones-for-bezuclastinib-and-emerging-portfo-cogt-20240109monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-presentation-at-the-42nd-annual-j-p-morgan-healthcare-confere-cogt-20240102monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-positive-data-from-ongoing-phase-2-apex-trial-evaluating-bezu-cogt-20231211monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-positive-initial-data-from-phase-2-summit-trial-evaluating-be-cogt-20231209monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-to-host-investor-webcast-on-december-11-2023-at-8-00-am-et-to-review-cl-cogt-20231204monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-poster-presentations-at-upcoming-san-antonio-breast-cancer-sy-cogt-20231129monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-presents-preclinical-data-highlighting-precision-oncology-pipeline-at-t-cogt-20231014monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-closing-of-upsized-public-offering-of-common-stock-cogt-20230609monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-participation-in-the-jefferies-healthcare-conference-cogt-20230607monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-pricing-of-upsized-public-offering-of-shares-of-common-stock-cogt-20230607monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-proposed-public-offering-of-common-stock-cogt-20230606monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-positive-lead-in-data-from-ongoing-phase-3-peak-trial-evaluat-cogt-20230603monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-to-host-investor-webcast-to-discuss-lead-in-data-being-presented-at-asc-cogt-20230523monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-presents-preclinical-data-at-aacr-annual-meeting-highlighting-precision-cogt-202304172023-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-participation-at-upcoming-investor-conferences-cogt-202304122023-04-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-participation-at-upcoming-investor-conferences-cogt-202302012023-02-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-planned-2023-milestones-for-bezuclastinib-and-emerging-portfo-cogt-202301092023-01-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-presentation-at-the-41st-annual-j-p-morgan-healthcare-confere-cogt-202301052023-01-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-to-host-investor-webcast-to-discuss-updated-clinical-data-at-ash-from-t-cogt-20221205monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-appoints-rachael-easton-md-ph-d-vp-head-of-clinical-development-cogt-20221128monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-participation-at-upcoming-investor-conferences-cogt-20221109monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-bezuclastinib-presentations-at-the-64th-annual-american-socie-cogt-20221103monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-to-showcase-precision-therapy-pipeline-at-the-eortc-nci-aacr-annual-mee-cogt-20221026monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-pricing-of-upsized-public-offering-of-shares-of-common-stock--cogt-20220614monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-proposed-public-offering-of-common-stock-cogt-20220613monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-to-host-investor-webcast-on-june-10-2022-at-8-00am-et-cogt-20220606monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-annual-meeting-of-stockholders-cogt-20220602monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-presentation-at-european-hematology-association-eha-annual-co-cogt-20220512monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-to-participate-in-the-lifesci-partners-immunology-and-inflammation-symp-cogt-20220506monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-presents-nonclinical-data-at-aacr-annual-meeting-and-provides-updates-o-cogt-20220411monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-to-host-virtual-r-d-investor-event-cogt-20220329monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-announces-upcoming-presentations-at-aacr-annual-meeting-2022-cogt-20220308monthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-to-present-at-11th-annual-svb-leerink-global-healthcare-conference-cogt-20220209monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-deadline-today-rosen-trusted-investor-counsel-encourages-corcept-therapeutics-inco-cort-20260421monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-deadline-tomorrow-bragar-eagel-squire-p-c-urges-corcept-therapeutics-incorporated--cort-20260420monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-cort-20260416monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-iss-cort-20260415monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-sued-for-securities-law-violations-investors-should-cont-cort-20260413monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-cort-20260409monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-iss-cort-20260408monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-sued-for-securities-law-violations-investors-should-cont-cort-20260406monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-cort-20260402monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-iss-cort-20260401monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-cort-20260326monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-iss-cort-20260325monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-cort-20260319monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-iss-cort-20260318monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-securities-fraud-class-action-lawsuit-pending-contact-le-cort-20260316monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-cort-shareholder-alert-bernstein-liebhard-llp-reminds-co-cort-20260312monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-cort-20260312monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-shareholders-are-encouraged-to-contact-johnson-fistel-for-more-inform-cort-20260311monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-iss-cort-20260311monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-cort-litigation-hagens-berman-alerts-corcept-cort-investors-to-securi-cort-20260306monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-cort-shareholder-alert-bernstein-liebhard-llp-reminds-co-cort-20260305monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-cort-20260305monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-cort-litigation-hagens-berman-alerts-corcept-cort-investors-to-securi-cort-20260304monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-iss-cort-20260304monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-cort-litigation-hagens-berman-alerts-corcept-cort-investors-to-securi-cort-20260302monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-cort-litigation-hagens-berman-alerts-cort-investors-to-securities-cla-cort-20260227monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-cort-shareholder-alert-bernstein-liebhard-llp-reminds-co-cort-20260226monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-cort-20260226monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-cort-litigation-hagens-berman-alerts-corcept-cort-investors-to-securi-cort-20260225monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-iss-cort-20260225monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-class-action-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-h-cort-20260223monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-cort-investor-alert-investors-with-large-losses-in-corce-cort-20260223monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-cort-litigation-hagens-berman-alerts-corcept-cort-investors-to-securi-cort-20260223monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-shareholders-are-encouraged-to-contact-johnson-fistel-for-more-inform-cort-20260223monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-nasdaq-cort-investigation-alert-bernstein-liebhard-is-in-cort-20260219monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-nasdaq-cort-investigation-alert-bernstein-liebhard-is-in-cort-20260217monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-nasdaq-cort-investigation-alert-bernstein-liebhard-is-in-cort-20260212monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-nasdaq-cort-investigation-alert-bernstein-liebhard-is-in-cort-20260210monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-nasdaq-cort-investigation-alert-bernstein-liebhard-is-in-cort-20260205monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-investigation-alert-bragar-eagel-squire-p-c-encourages-corcept-therapeutics-invest-cort-20260204monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-nasdaq-cort-investigation-alert-bernstein-liebhard-is-in-cort-20260202monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-nasdaq-cort-investigation-alert-bernstein-liebhard-is-in-cort-20260130monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-cort-faces-investor-scrutiny-amid-receipt-of-fda-complete-response-le-cort-20260116monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-cort-faces-investor-scrutiny-amid-receipt-of-fda-complete-response-le-cort-20260109monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-alert-bragar-eagel-squire-p-c-is-investigating-corcept-therapeutics-incorporated-o-cort-20260108monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-cort-faces-investor-scrutiny-amid-receipt-of-fda-complete-response-le-cort-20260107monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-second-quarter-financial-results-provide-corporate-update-cort-20240722monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-announces-presentation-of-results-from-prevalence-phase-of-catalyst-clinical-trial-cort-20240624monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-presentations-of-results-of-pivotal-phase-3-grace-trial-eva-cort-20240603monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-announces-primary-endpoint-met-in-pivotal-phase-3-grace-trial-of-relacorilant-in-p-cort-20240528monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-completes-enrollment-in-phase-4-catalyst-trial-cort-20240429monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-first-quarter-financial-results-provide-corporate-update--cort-20240424monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-announces-positive-results-from-open-label-portion-of-pivotal-phase-3-grace-trial--cort-20240422monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-completes-enrollment-in-phase-2-dazals-trial-in-patients-with-amyotrophic-lateral--cort-20240415monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-completes-enrollment-in-pivotal-phase-3-rosella-trial-of-relacorilant-in-patients--cort-20240408monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-completes-enrollment-in-phase-3-gradient-trial-of-relacorilant-in-patients-with-ad-cort-20240401monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-and-full-year-2023-audited-financial-results-cort-20240215monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-announces-preliminary-results-from-prevalence-phase-of-catalyst-clinical-trial-cort-20240215monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-fourth-quarter-and-full-year-2023-financial-results-provi-cort-20240208monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-appoints-roberto-vieira-as-president-oncology-cort-20240129monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-provides-financial-update-and-announces-stock-repurchase-program-cort-20240108monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-appoints-monica-tellado-as-president-emerging-markets-cort-20231101monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-initiates-monarch-a-phase-2b-trial-in-non-alcoholic-steatohepatitis-nash-cort-20231026monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-third-quarter-financial-results-provide-corporate-update--cort-20231025monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-second-quarter-financial-results-provide-corporate-update-cort-20230726monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-s-miricorilant-shows-great-promise-in-treatment-of-non-alcoholic-steatohepatitis-n-cort-20230717monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-first-quarter-financial-results-provide-corporate-update--cort-202304262023-04-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-final-results-of-tender-offer-cort-202304052023-04-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-preliminary-results-of-tender-offer-cort-202304032023-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-initiates-catalyst-clinical-trial-cort-202303282023-03-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-commencement-of-tender-offer-to-purchase-up-to-7-500-000-sh-cort-202303062023-03-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-fourth-quarter-and-full-year-2022-financial-results-provi-cort-202302142023-02-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-preliminary-settlement-of-purported-securities-class-action-cort-202302132023-02-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-provides-miricorilant-clinical-development-update-cort-20221208monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-settles-patent-litigation-with-hikma-pharmaceuticals-cort-20221208monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-third-quarter-financial-results-provide-corporate-update--cort-20221027monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-initiates-dazals-a-phase-2-trial-in-amyotrophic-lateral-sclerosis-als-cort-20221011monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-second-quarter-financial-results-provide-corporate-update-cort-20220727monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-initiates-rosella-a-pivotal-phase-3-trial-in-recurrent-platinum-resis-cort-20220629monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-start-phase-3-trial-of-relacorilant-plus-nab-paclitaxel-in-patient-cort-20220606monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-first-quarter-financial-results-provide-corporate-update--cort-20220428monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-appointment-of-three-senior-leaders-cort-20220407monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-completes-enrollment-in-phase-2-gratitude-study-of-miricorilant-in-pa-cort-20220404monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-host-ovarian-cancer-program-update-on-thursday-march-31-2022-cort-20220301monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-fourth-quarter-and-full-year-2021-financial-results-provi-cort-20220208monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-final-results-of-previously-announced-tender-offer-cort-20211220monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-preliminary-results-of-previously-announced-tender-offer-cort-20211216monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-waiver-of-condition-to-its-tender-offer-for-common-shares-cort-20211215monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-extension-of-previously-announced-tender-offer-cort-20211208monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-present-at-upcoming-investor-conferences-cort-20211110monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-commencement-of-tender-offer-to-purchase-up-to-10-million-s-cort-20211108monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-third-quarter-financial-results-provide-corporate-update--cort-20211027monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-announces-presentation-of-positive-results-from-randomized-controlled-phase-2-tria-cort-20210909monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-second-quarter-financial-results-provide-corporate-update-cort-20210722monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-observes-large-reductions-of-liver-fat-and-transient-liver-enzyme-ele-cort-20210506monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-first-quarter-financial-results-provide-corporate-update--cort-20210429monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-initiates-phase-1b-trial-of-relacorilant-plus-pembrolizumab-keytruda--cort-20210315monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-expands-executive-team-atabak-mokari-joins-as-chief-financial-officer-cort-20210301monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-preliminary-selected-financial-results-provide-corporate--cort-20210201monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-third-quarter-financial-results-provide-corporate-update--cort-20201027monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-initiates-second-phase-2-trial-of-miricorilant-to-treat-weight-gain-c-cort-20200910monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-second-quarter-financial-results-provide-corporate-update-cort-20200728monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-initiates-phase-3-trial-of-relacorilant-in-patients-with-cushing-s-sy-cort-20200728monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-completes-enrollment-in-controlled-phase-2-trial-of-relacorilant-plus-cort-20200723monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-initiates-phase-3-trial-of-relacorilant-plus-nab-paclitaxel-in-patien-cort-20200630monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-present-data-at-the-american-association-of-cancer-research-annual-cort-20200615monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-present-data-at-the-american-society-of-clinical-oncology-annual-m-cort-20200514monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-first-quarter-financial-results-provide-corporate-update--cort-20200427monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-publishes-abstract-in-the-journal-of-the-endocrine-society-cort-20200401monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-audited-financial-results-provide-corporate-update-and-ho-cort-20200213monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-third-quarter-financial-results-provide-corporate-update--cort-20191031monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-appoints-kimberly-park-to-board-of-directors-cort-20190918monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-allowance-of-additional-patent-covering-the-use-of-korlym-t-cort-20190828monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-second-quarter-2019-financial-results-and-provides-corporat-cort-20190801monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-second-quarter-financial-results-provide-corporate-update-cort-20190725monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-present-data-from-phase-1-2-trial-of-relacorilant-plus-nab-paclita-cort-20190528monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-first-quarter-2019-financial-results-and-provides-corporate-cort-20190509monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-first-quarter-financial-results-provide-corporate-update--cort-20190503monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-present-data-at-the-2019-american-association-of-clinical-endocrin-cort-20190418monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-a-cort-20190409monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-a-cort-20190328monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-a-cort-20190320monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-poster-presentations-at-the-2019-annual-meeting-of-the-endo-cort-20190320monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-cort-class-action-lawsuit-bernstein-liebhard-llp-announces-a-securities-class-acti-cort-20190319monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-cort-bronstein-gewirtz-grossman-llc-announces-class-acti-cort-20190318monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-appoints-former-amgen-development-executive-andreas-grauer-m-d-as-chi-cort-20190318monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-and-full-year-2018-audited-financial-results-cort-20190225monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-audited-financial-results-provide-corporate-update-and-ho-cort-20190219monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-and-full-year-2018-preliminary-selected-fina-cort-20190131monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-allowance-of-additional-patent-covering-the-use-of-korlym-t-cort-20181213monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-first-patient-dosed-in-phase-3-trial-of-relacorilant-to-tre-cort-20181119monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-third-quarter-2018-financial-results-and-provides-corporate-cort-20181101monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-third-quarter-financial-results-provide-corporate-update--cort-20181025monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-receives-orphan-designation-for-relacorilant-as-treatment-for-pancrea-cort-20181001monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-second-quarter-2018-financial-results-and-stock-repurchase--cort-20180809monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-second-quarter-financial-results-provide-corporate-update-cort-20180802monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-positive-relacorilant-data-at-the-2018-american-society-of--cort-20180604monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-presentations-at-the-american-association-of-clinical-endoc-cort-20180516monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-first-quarter-2018-financial-results-and-provides-corporate-cort-20180508monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-first-quarter-financial-results-provide-corporate-update--cort-20180501monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-files-lawsuit-against-teva-pharmaceuticals-for-infringement-of-korlym-cort-20180315monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-2017-financial-results-and-positive-interim-results-of-rela-cort-20180222monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-fourth-quarter-and-full-year-2017-financial-results-provi-cort-20180215monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-and-full-year-2017-preliminary-selected-fina-cort-20180201monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-third-quarter-2017-financial-results-raises-2017-revenue-gu-cort-20171102monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-third-quarter-financial-results-provide-corporate-update--cort-20171026monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-second-quarter-2017-financial-results-raises-2017-revenue-g-cort-20170801monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-second-quarter-financial-results-provide-corporate-update-cort-20170725monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-presentations-on-mifepristone-for-the-treatment-of-patients-cort-20170504monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-first-quarter-2017-financial-results-raises-2017-revenue-gu-cort-20170501monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-first-quarter-financial-results-and-corporate-update-and--cort-20170424monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-and-full-year-2016-financial-results-increas-cort-20170306monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-preliminary-fourth-quarter-and-full-year-2016-financial-res-cort-20170130monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-preliminary-2016-financial-results-provide-2017-revenue-g-cort-20170123monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-encouraging-results-of-phase-1-2-trial-of-mifepristone-plus-cort-20161210monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-third-quarter-2016-financial-results-and-provides-corporate-cort-20161101monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-third-quarter-2016-financial-results-and-corporate-update-cort-20161026monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-second-quarter-2016-financial-results-and-provides-corporat-cort-20160802monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-second-quarter-2016-financial-results-and-corporate-updat-cort-20160726monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-appoints-renee-d-gala-to-board-of-directors-cort-20160628monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-provides-update-of-progress-in-cortisol-modulation-oncology-program-cort-20160602monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-first-quarter-2016-financial-results-and-provides-corporate-cort-20160503monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-first-quarter-financial-results-and-corporate-update-and--cort-20160429monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-2015-financial-results-cort-20160301monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-preliminary-fourth-quarter-and-full-year-2015-summary-finan-cort-20160128monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-preliminary-2015-financial-results-provide-2016-revenue-g-cort-20160121monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-initial-efficacy-results-in-phase-1-2-trial-of-mifepristone-cort-20151214monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-third-quarter-2015-results-and-provides-corporate-update-cort-20151105monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-third-quarter-financial-results-and-corporate-update-and--cort-20151029monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-appoints-robert-s-fishman-m-d-as-chief-medical-officer-cort-20150928monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-second-quarter-2015-results-and-provides-corporate-update-cort-20150805monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-second-quarter-financial-results-and-corporate-update-and-cort-20150729monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-appoints-daniel-swisher-to-board-of-directors-cort-20150622monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-poster-presentations-on-mifepristone-for-the-treatment-of-p-cort-20150514monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-mifepristone-combined-with-eribulin-to-improve-antitumor-activity-in--cort-20150513monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-first-quarter-2015-results-and-provides-corporate-update-cort-20150507monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-first-quarter-financial-results-and-corporate-update-and--cort-20150430monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-nine-poster-presentations-on-mifepristone-for-the-treatment-cort-20150305monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-2014-financial-results-and-provides-clinical-update-cort-20150304monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-and-full-year-2014-revenue-provides-2015-rev-cort-20150129monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-fourth-quarter-and-full-year-2014-revenue-and-corporate-u-cort-20150122monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-third-quarter-2014-financial-results-and-provides-corporate-cort-20141104monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-third-quarter-financial-results-and-host-conference-call-cort-20141028monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-second-quarter-2014-financial-results-and-provides-corporat-cort-20140805monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-second-quarter-financial-results-and-host-conference-call-cort-20140729monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-first-quarter-2014-financial-results-cort-20140507monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-first-quarter-financial-results-and-corporate-update-and--cort-20140430monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-and-full-year-2013-financial-results-cort-20140305monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-full-year-2013-revenue-and-provides-2014-out-cort-20140130monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-fourth-quarter-and-full-year-revenue-and-corporate-update-cort-20140127monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-oncology-development-program-cort-20131212monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-third-quarter-2013-financial-results-and-corporate-update-cort-20131107monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-third-quarter-2013-financial-results-and-host-conference--cort-20131104monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-second-quarter-2013-financial-results-and-corporate-update-cort-20130808monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-second-quarter-2013-financial-results-and-host-conference-cort-20130801monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-partnership-with-idis-for-global-access-to-korlym-r-cort-20130724monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-first-quarter-2013-financial-results-cort-20130502monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-announce-first-quarter-2013-financial-results-and-host-conference--cort-20130426monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-and-full-year-2012-financial-results-cort-20130307monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-and-full-year-revenue-and-corporate-update-cort-20130212monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-third-quarter-results-and-corporate-update-cort-20121031monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-appoints-daniel-m-bradbury-to-board-of-directors-cort-20121015monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-30-million-synthetic-capped-royalty-transaction-terminates--cort-20120807monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-second-quarter-results-and-corporate-update-cort-20120807monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-underwritten-public-offering-of-common-stock-cort-20120702monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-commences-public-offering-of-common-stock-cort-20120702monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-first-quarter-results-and-corporate-and-development-update-cort-20120503monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-national-product-launch-of-korlym-tm-for-patients-with-endo-cort-20120410monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-exercise-of-warrants-and-private-placement-of-new-warrants-cort-20120326monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-results-and-corporate-and-development-update-cort-20120305monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-incorporated-announces-fda-approval-of-korlym-tm-mifepristone-first-a-cort-20120217monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-third-quarter-results-and-corporate-and-development-update-cort-20111107monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-second-quarter-results-and-corporate-and-development-update-cort-20110808monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-detailed-findings-from-phase-3-study-which-show-corlux-sign-cort-20110604monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-conference-call-to-discuss-detailed-findings-from-corlux-ph-cort-20110601monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-present-detailed-findings-from-corlux-phase-3-trial-in-cushing-s-s-cort-20110519monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-first-quarter-results-and-corporate-and-development-update-cort-20110504monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-nda-submitted-to-the-fda-for-the-use-of-corlux-in-cushing-s-cort-20110415monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-nda-submission-to-be-completed-the-week-of-april-11-2011-cort-20110331monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-results-and-corporate-and-development-update-cort-20110309monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-closing-of-44-9-million-underwritten-public-offering-of-com-cort-20110126monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-pricing-of-39-0-million-underwritten-public-offering-of-com-cort-20110121monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-proposed-public-offering-of-common-stock-cort-20110120monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-key-secondary-endpoint-was-met-in-phase-3-study-of-corlux-f-cort-20110111monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-positive-phase-3-study-results-for-corlux-for-the-treatment-cort-20101222monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-to-hold-conference-call-wednesday-december-22-at-8-30-am-eastern-time-cort-20101221monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-third-quarter-results-and-corporate-and-development-update-cort-20101110monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-second-quarter-results-and-corporate-and-development-update-cort-20100812monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-completes-enrollment-in-phase-3-cushing-s-syndrome-study-data-announc-cort-20100701monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-pricing-of-15-million-underwritten-public-offering-of-commo-cort-20100625monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-nears-completion-of-enrollment-in-phase-3-cushing-s-syndrome-study-da-cort-20100625monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-first-quarter-results-and-update-on-development-programs-cort-20100511monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-updates-cushing-s-syndrome-development-and-recent-financing-cort-20100503monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-exercise-of-existing-warrants-and-private-placement-of-warr-cort-20100422monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-and-full-year-2009-results-and-update-on-dev-cort-20100325monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-initiates-a-phase-1-study-of-its-lead-selective-cortisol-receptor-gr--cort-20100223monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-four-anticipated-milestones-for-2010-cort-20100105monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-recent-highlights-and-third-quarter-2009-financial-results-cort-20091110monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-pricing-of-private-placement-cash-sufficient-to-fund-compan-cort-20091013monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-second-quarter-2009-results-and-development-highlights-cort-20090811monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-first-quarter-2009-results-and-development-highlights-cort-20090511monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-and-full-year-2008-results-and-update-on-dev-cort-20090330monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-third-quarter-2008-results-cort-20081113monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-continues-collaboration-with-eli-lilly-and-company-cort-20080903monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-second-quarter-2008-results-cort-20080813monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-first-quarter-2008-results-cort-20080512monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-promising-results-of-human-microdosing-study-of-selective-g-cort-20080501monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-2007-results-cort-20080327monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-completes-25-million-private-equity-financing-and-secures-committed-e-cort-20080326monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-commencement-of-next-phase-3-study-with-corlux-r-for-the-tr-cort-20080324monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-25-3-million-private-equity-financing-cort-20080317monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-commencement-of-a-phase-3-trial-for-corlux-r-for-the-treatm-cort-20071219monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-third-quarter-2007-results-cort-20071108monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-completes-second-closing-under-august-private-equity-financing-agreem-cort-20070925monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-receives-fda-notification-opening-ind-for-corlux-r-for-the-treatment--cort-20070911monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-10-1-million-private-equity-financing-cort-20070820monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-second-quarter-2007-results-cort-20070813monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-and-xceleron-sign-agreement-for-microdosing-study-using-accelerator-m-cort-20070725monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-receives-orphan-drug-designation-for-corlux-r-treatment-of-cushing-s--cort-20070709monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-positive-results-from-its-proof-of-concept-study-evaluating-cort-20070621monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-first-quarter-2007-results-cort-20070509monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-9-million-private-equity-financing-cort-20070330monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-chief-financial-officer-resignation-cort-20070328monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-fourth-quarter-2006-results-cort-20070328monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-announces-phase-3-study-evaluating-corlux-r-for-psychotic-major-depre-cort-20070320monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-rule-cort-20070116monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-receives-nasdaq-notice-of-non-compliance-cort-20061227monthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-completes-3-million-private-equity-financing-cort-20061215monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-present-at-the-deutsche-bank-american-depositary-receipt-virtual-investor-co-blte-20260422monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-present-at-the-dbvic-deutsche-bank-adr-virtual-investor-conference-november--blte-20251029monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update-blte-20250811monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference-blte-20250806monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-host-webcast-on-august-11-2025-to-discuss-second-quarter-2025-financial-resu-blte-20250804monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-participate-in-the-btig-virtual-biotechnology-conference-blte-20250723monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-inc-to-present-at-the-dbvic-deutsche-bank-adr-virtual-investor-conference-may-1-blte-20250512monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-participate-in-four-upcoming-investor-conferences-blte-20250512monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-host-webcast-on-may-14-2025-to-discuss-first-quarter-2025-financial-results-blte-20250507monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-poster-presentations-at-the-association-for-research-in-vision-and-op-blte-20250429monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-host-webcast-on-march-17-2025-to-discuss-fourth-quarter-and-full-year-2024-f-blte-20250311monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-participate-in-the-leerink-partners-global-healthcare-conference-blte-20250304monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-host-webcast-on-november-12-2024-to-discuss-third-quarter-2024-financial-res-blte-20241105monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-exercise-of-warrants-for-us-28-75-million-gross-proceeds-blte-20241103monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-presentations-at-the-american-academy-of-ophthalmology-2024-annual-me-blte-20241014monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-participate-in-the-maxim-group-2024-healthcare-virtual-summit-blte-20241008monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-first-patient-dosed-in-phase-2-3-dragon-ii-trial-of-tinlarebant-for-t-blte-20240910monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-participate-in-three-upcoming-investor-conferences-blte-20240903monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-reports-second-quarter-2024-financial-results-and-provides-a-corporate-update-blte-20240809monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference-blte-20240808monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-host-webcast-on-august-12-2024-to-discuss-second-quarter-2024-financial-resu-blte-20240805monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-present-at-the-joneshealthcare-seaside-summit-blte-20240708monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-receives-sakigake-pioneer-drug-designation-of-tinlarebant-for-stargardt-disease-blte-20240612monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-participate-in-the-benchmark-s-4th-annual-healthcare-house-call-investor-con-blte-20240514monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-participate-in-the-h-c-wainwright-2nd-annual-bioconnect-investor-conference-blte-20240513monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-host-webcast-on-may-14-2024-to-discuss-first-quarter-2024-financial-results-blte-20240508monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-participate-in-key-opinion-leader-webinar-to-discuss-unmet-needs-in-stargard-blte-20240506monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-presents-additional-analysis-from-phase-2-study-of-tinlarebant-in-stargardt-dis-blte-20240506monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-presentation-at-the-association-for-research-in-vision-and-ophthalmol-blte-20240501monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-host-webcast-on-march-12-2024-to-discuss-fourth-quarter-and-full-year-2024-f-blte-20240306monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-participate-in-the-leerink-partners-global-biopharma-conference-blte-20240304monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-present-at-the-oppenheimer-34th-annual-healthcare-life-sciences-conference-blte-20240207monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-participate-in-the-benchmark-company-s-upcoming-discovery-one-on-one-investo-blte-20231130monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-participate-in-the-btig-ophthalmology-day-blte-20231120monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-host-webcast-on-november-14-2023-to-discuss-third-quarter-2023-financial-res-blte-20231107monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-inc-to-present-at-the-deutsche-bank-adr-virtual-investor-conference-on-8-novemb-blte-20231106monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-presentation-at-the-american-academy-of-ophthalmology-2023-annual-mee-blte-20231027monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-host-webcast-on-august-9-2023-to-discuss-second-quarter-2023-financial-resul-blte-20230804monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-doses-first-subject-in-pivotal-phase-3-phoenix-trial-evaluating-oral-tinlareban-blte-20230727monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-host-webcast-on-may-11-2023-to-discuss-first-quarter-2023-financial-results-blte-202305102023-05-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-host-key-opinion-leader-webinar-discussing-progression-of-childhood-onset-st-blte-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-host-key-opinion-leader-webinar-on-rbp4-antagonist-tinlarebant-in-late-stage-blte-202304112023-04-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-reports-full-year-2022-operational-highlights-and-financial-results-blte-202303312023-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-host-webcast-on-april-3-2023-to-discuss-2022-full-year-financial-results-blte-202303312023-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-host-key-opinion-leader-webinar-on-october-27-2022-to-discuss-lbs-008-interi-blte-20221020monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-late-breaking-presentation-at-the-american-academy-of-ophthalmology-2-blte-20220923monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-to-host-conference-call-on-august-11-2022-to-discuss-first-half-2022-financial--blte-20220801monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-submits-investigational-new-drug-ind-application-to-fda-for-approval-to-proceed-blte-20220719monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-presented-interim-results-of-lbs-008-phase-1b-2-study-in-adolescent-stgd1-at-ar-blte-20220505monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-closing-of-36-million-initial-public-offering-blte-20220503monthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-announces-pricing-of-36-million-initial-public-offering-blte-20220428monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-reports-fourth-quarter-and-full-year-2025-results-and-recent-highlights-legn-20260310monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-highlights-recent-business-updates-at-44th-annual-j-p-morgan-healthcare-con-legn-20260112monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-highlights-new-carvykti-data-in-multiple-myeloma-and-first-in-human-results-legn-20251206monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-celebrates-official-opening-of-new-state-of-the-art-cell-therapy-research-a-legn-20251113monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-reports-second-quarter-2025-results-and-recent-highlights-legn-20250811monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-to-host-investor-conference-call-on-second-quarter-2025-results-legn-20250728monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-reports-first-quarter-2025-results-and-recent-highlights-legn-20250513monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-to-host-investor-conference-call-on-first-quarter-2025-results-legn-20250429monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-reports-fourth-quarter-and-full-year-2024-results-and-recent-highlights-legn-20250311monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-to-host-investor-conference-call-on-fourth-quarter-and-full-year-2024-resul-legn-20250225monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-legn-20241219monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-reports-third-quarter-2024-results-and-recent-highlights-legn-20241112monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-to-host-investor-event-during-the-66th-american-society-of-hematology-ash-a-legn-20241107monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-to-unveil-minimal-residual-disease-data-from-landmark-cartitude-4-trial-in--legn-20241105monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-appoints-alan-bash-as-president-of-carvykti-legn-20241104monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-to-host-investor-conference-call-on-third-quarter-2024-results-legn-20241024monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-to-establish-new-state-of-the-art-cell-therapy-research-and-development-fac-legn-20241003monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-to-participate-in-the-morgan-stanley-22nd-annual-global-healthcare-conferen-legn-20240820monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-reports-second-quarter-2024-results-and-recent-highlights-legn-20240809monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-appoints-peter-salovey-ph-d-to-its-board-of-directors-legn-20240808monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-preliminary-results-for-the-six-months-ended-june-30-2024-legn-20240726monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-to-host-investor-conference-call-on-second-quarter-2024-results-legn-20240710monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-announces-positive-overall-survival-results-of-landmark-phase-3-cartitude-4-legn-20240702monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-alert-bragar-eagel-squire-p-c-is-investigating-legend-biotech-corporation-o-legn-20201007monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-alert-bragar-eagel-squire-p-c-is-investigating-legend-biotech-corporation-o-legn-20200930monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-corporation-investors-company-investigated-by-the-portnoy-law-firm-legn-20200925monthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-alert-bragar-eagel-squire-p-c-is-investigating-legend-biotech-corporation-o-legn-20200922monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-an-0-88-per-share-quarterly-dividend-syk-20260507monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-announce-financial-results-for-its-second-quarter-of-fiscal-year-2025-syk-20250701monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-an-0-84-per-share-quarterly-dividend-syk-20250508monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-announce-financial-results-for-its-first-quarter-of-fiscal-year-2025-syk-20250407monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-completes-sale-of-u-s-spinal-implants-business-syk-20250401monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-intention-to-nominate-manny-maceda-to-board-of-directors-syk-20250326monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-annual-meeting-of-shareholders-syk-20250325monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-completes-acquisition-of-inari-medical-inc-providing-entry-into-the-high-growth-pe-syk-20250219monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-citi-s-2025-unplugged-medtech-and-life-sciences-access-day-syk-20250213monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-allan-golston-will-retire-from-board-of-directors-syk-20250210monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-an-0-84-per-share-quarterly-dividend-syk-20250205monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-definitive-agreement-for-the-sale-of-its-u-s-spinal-implants-business-an-syk-20250128monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-commences-tender-offer-for-all-outstanding-shares-of-common-stock-of-inari-medical-syk-20250117monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-definitive-agreement-to-acquire-inari-medical-inc-providing-entry-into-h-syk-20250106monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-announce-financial-results-for-its-fourth-quarter-and-full-year-2024-syk-20250106monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-an-0-84-per-share-quarterly-dividend-syk-20241210monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-announce-its-third-quarter-2024-financial-results-syk-20241001monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-completes-acquisition-of-vertos-medical-inc-expanding-interventional-pain-manageme-syk-20241001monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-completes-acquisition-of-care-ai-syk-20240917monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-definitive-agreement-to-acquire-vertos-medical-inc-expanding-interventio-syk-20240822monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-the-2024-wells-fargo-healthcare-conference-syk-20240819monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-definitive-agreement-to-acquire-care-ai-a-leading-virtual-care-and-ambie-syk-20240812monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-an-0-80-per-share-quarterly-dividend-syk-20240807monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-announce-financial-results-for-its-second-quarter-of-fiscal-year-2024-syk-20240701monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-80-per-share-quarterly-dividend-syk-20240509monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-announce-financial-results-for-its-first-quarter-of-fiscal-year-2024-syk-20240401monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-annual-meeting-of-shareholders-syk-20240326monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-80-per-share-quarterly-dividend-syk-20240207monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-citi-s-2024-unplugged-medtech-and-life-sciences-access-day-syk-20240205monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-2023-sales-surpassed-20-billion-syk-20240108monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-announce-financial-results-for-its-fourth-quarter-and-full-year-2023-syk-20240105monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-intention-to-nominate-a-new-director-rachel-ruggeri-syk-20231207monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-dr-srikant-datar-will-retire-from-board-of-directors-syk-20231206monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-80-per-share-quarterly-dividend-syk-20231205monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-the-6th-annual-evercore-isi-healthconx-conference-syk-20231030monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-investor-day-syk-20231009monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-announce-financial-results-for-its-third-quarter-of-fiscal-year-2023-syk-20231002monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-the-2023-wells-fargo-securities-healthcare-conference-syk-20230807monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-75-per-share-quarterly-dividend-syk-20230802monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-announce-financial-results-for-its-second-quarter-of-fiscal-year-2023-syk-20230630monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-75-per-share-quarterly-dividend-syk-202305102023-05-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-announce-financial-results-for-its-first-quarter-of-fiscal-year-2023-syk-202303302023-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-annual-meeting-of-shareholders-syk-202303282023-03-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-75-per-share-quarterly-dividend-syk-202302092023-02-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-january-31-2023-syk-20221228monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-75-per-share-quarterly-dividend-syk-20221207monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-the-5th-annual-evercore-isi-healthconx-conference-syk-20221103monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-october-31-2022-syk-20220929monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-the-2022-wells-fargo-securities-healthcare-conference-syk-20220822monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-695-per-share-quarterly-dividend-syk-20220803monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-corp-and-zimmer-biomet-holdings-inc-among-leading-companies-in-the-bone-cement-mar-syk-20220707monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-july-26-2022-syk-20220630monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-new-investor-relations-leader-syk-20220505monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-board-changes-following-annual-meeting-of-shareholders-syk-20220505monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-695-per-share-quarterly-dividend-syk-20220504monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-the-bank-of-america-securities-2022-health-care-conference-syk-20220502monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-april-28-2022-syk-20220330monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-annual-meeting-of-shareholders-syk-20220324monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-completes-acquisition-of-vocera-communications-syk-20220223monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-cowen-42nd-annual-health-care-conference-syk-20220215monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-695-per-share-quarterly-dividend-syk-20220202monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-commences-tender-offer-for-all-outstanding-shares-of-common-stock-of-vocera-commun-syk-20220125monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-definitive-agreement-to-acquire-vocera-communications-syk-20220106monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-january-27-2022-syk-20220105monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-695-per-share-quarterly-dividend-syk-20211209monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-analyst-meeting-syk-20211011monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-october-28-2021-syk-20210923monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-morgan-stanley-s-19th-annual-global-healthcare-conference-syk-20210830monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-president-and-coo-timothy-j-scannell-to-retire-syk-20210818monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-63-per-share-quarterly-dividend-syk-20210804monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-july-27-2021-syk-20210624monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-munley-group-launches-new-diversity-equity-and-inclusion-practice-syk-20210511monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-63-per-share-quarterly-dividend-syk-20210504monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-the-bank-of-america-securities-2021-virtual-health-care-conferen-syk-20210426monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-april-27-2021-syk-20210329monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-annual-meeting-of-shareholders-syk-20210324monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-the-41st-annual-cowen-health-care-conference-syk-20210217monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-63-per-share-quarterly-dividend-syk-20210202monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-acquires-orthosensor-syk-20210105monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-january-27-2021-syk-20210104monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-munley-group-selects-mapragency-for-expansion-to-colorado-s-front-range-syk-20201208monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-63-per-share-quarterly-dividend-syk-20201202monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-pricing-of-600-million-senior-notes-offering-syk-20201118monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-the-3rd-annual-evercore-isi-healthconx-virtual-conference-syk-20201117monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-completes-acquisition-of-wright-medical-syk-20201111monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-intention-to-complete-acquisition-of-wright-medical-syk-20201111monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-elects-giovanni-caforio-to-board-of-directors-syk-20201109monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-receipt-of-all-required-regulatory-approvals-for-proposed-acquisition-of-syk-20201104monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-extends-cash-tender-offer-for-all-outstanding-shares-of-wright-medical-syk-20201026monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-extends-cash-tender-offer-for-all-outstanding-shares-of-wright-medical-syk-20201013monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-extends-cash-tender-offer-for-all-outstanding-shares-of-wright-medical-syk-20200929monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-october-29-2020-syk-20200928monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-the-morgan-stanley-18th-annual-virtual-global-healthcare-confere-syk-20200902monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-extends-cash-tender-offer-for-all-outstanding-shares-of-wright-medical-syk-20200828monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-575-per-share-quarterly-dividend-syk-20200730monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-extends-cash-tender-offer-for-all-outstanding-shares-of-wright-medical-syk-20200629monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-july-30-2020-syk-20200625monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-pricing-of-2-3-billion-senior-notes-offering-syk-20200526monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-575-per-share-quarterly-dividend-syk-20200505monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-extends-cash-tender-offer-for-all-outstanding-shares-of-wright-medical-syk-20200427monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-april-30-2020-syk-20200409monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-annual-meeting-of-shareholders-syk-20200324monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-new-investor-relations-leader-syk-20200302monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-extends-cash-tender-offer-for-all-outstanding-shares-of-wright-medical-syk-20200226monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-cowen-40th-annual-health-care-conference-syk-20200225monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-nomination-of-new-director-lisa-skeete-tatum-syk-20200225monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-named-to-the-100-best-companies-to-work-for-list-for-10th-consecutive-year-syk-20200218monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-575-per-share-quarterly-dividend-syk-20200205monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-2019-results-and-2020-outlook-syk-20200128monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-january-28-2020-syk-20200106monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-increases-dividend-11-declaring-a-0-575-per-share-quarterly-dividend-syk-20191204monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-pricing-of-2-4-billion-senior-notes-offering-syk-20191125monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-definitive-agreement-to-acquire-wright-medical-syk-20191104monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-completes-acquisition-of-mobius-imaging-and-cardan-robotics-syk-20191021monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-october-29-2019-syk-20190925monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-definitive-agreement-to-acquire-mobius-imaging-cardan-robotics-syk-20190904monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-morgan-stanley-17th-annual-global-healthcare-conference-syk-20190821monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-commercial-structure-realignment-syk-20190812monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-52-per-share-quarterly-dividend-syk-20190731monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-july-25-2019-syk-20190624monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-bank-of-america-merrill-lynch-2019-health-care-conference-syk-20190501monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-52-per-share-quarterly-dividend-syk-20190501monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-new-vice-president-chief-legal-officer-syk-20190327monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-april-23-2019-syk-20190321monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-annual-meeting-of-shareholders-syk-20190320monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-acquires-orthospace-ltd-syk-20190314monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-acquires-arrinex-syk-20190225monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-8th-annual-leerink-partners-global-healthcare-conference-syk-20190212monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-52-per-share-quarterly-dividend-syk-20190206monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-2018-results-and-2019-outlook-syk-20190129monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-january-29-2019-syk-20190104monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-increases-dividend-11-declaring-a-0-52-per-share-quarterly-dividend-syk-20181204monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-pricing-of-2-25-billion-senior-notes-offering-syk-20181127monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-evercore-isi-healthconx-conference-syk-20181120monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-completes-acquisition-of-k2m-syk-20181109monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-completes-acquisition-of-invuity-inc-syk-20181023monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-analyst-meeting-syk-20181004monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-acquires-hyperbranch-medical-technology-inc-syk-20181001monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-october-25-2018-syk-20180920monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-definitive-agreement-to-acquire-invuity-inc-syk-20180911monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-morgan-stanley-16th-annual-global-healthcare-conference-syk-20180904monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-2018-wells-fargo-securities-healthcare-conference-syk-20180822monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-47-per-share-quarterly-dividend-syk-20180801monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-organizational-changes-syk-20180710monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-definitive-agreement-to-acquire-safeair-ag-syk-20180625monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-july-24-2018-syk-20180619monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-bank-of-america-merrill-lynch-2018-health-care-conference-syk-20180504monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-47-per-share-quarterly-dividend-syk-20180502monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-deutsche-bank-s-43rd-annual-health-care-conference-syk-20180501monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-organizational-changes-lonny-j-carpenter-to-retire-syk-20180403monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-april-26-2018-syk-20180322monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-annual-meeting-of-shareholders-syk-20180321monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-completes-acquisition-of-entellus-medical-syk-20180228monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-corporation-announces-pricing-of-600-million-senior-notes-offering-syk-20180226monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-corporation-named-one-of-fortune-magazine-s-100-best-companies-to-work-for-for-eig-syk-20180215monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-crosses-the-95-thresholds-in-vexim-and-announces-its-intention-to-file-a-proposed--syk-20180214monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-47-per-share-quarterly-dividend-syk-20180207monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-2017-results-and-2018-outlook-syk-20180130monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-36th-annual-j-p-morgan-healthcare-conference-syk-20180102monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-the-success-of-the-simplified-tender-offer-for-outstanding-shares-of-vex-syk-20171211monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-definitive-agreement-to-acquire-entellus-syk-20171207monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-increases-dividend-11-declaring-a-0-47-per-share-quarterly-dividend-syk-20171206monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-third-quarter-2017-results-syk-20171026monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-acquire-vexim-syk-20171024monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-october-26-2017-syk-20170921monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-morgan-stanley-15th-annual-global-healthcare-conference-syk-20170906monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-completes-acquisition-of-novadaq-technologies-inc-syk-20170901monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-provides-an-update-regarding-sage-warning-letter-and-revised-financial-guidance-syk-20170823monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-election-of-new-director-mary-k-brainerd-syk-20170802monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-425-per-share-quarterly-dividend-syk-20170802monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-second-quarter-2017-results-syk-20170727monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-july-27-2017-syk-20170622monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-definitive-agreement-to-acquire-novadaq-technologies-inc-syk-20170619monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-goldman-sachs-38th-annual-global-healthcare-conference-syk-20170531monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-orthopaedics-2016-settlement-program-reaches-milestone-syk-20170508monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-bank-of-america-merrill-lynch-2017-health-care-conference-syk-20170504monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-425-per-share-quarterly-dividend-syk-20170503monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-first-quarter-2017-results-syk-20170425monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-april-25-2017-syk-20170327monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-annual-meeting-of-shareholders-syk-20170320monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-enabling-surgeons-to-have-a-more-predictable-surgical-experience-with-launch-of-ma-syk-20170314monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-corporation-named-one-of-fortune-magazine-s-100-best-companies-to-work-for-for-sev-syk-20170309monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-cowen-company-37th-annual-health-care-conference-syk-20170221monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-425-per-share-quarterly-dividend-syk-20170208monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-2016-results-and-2017-outlook-syk-20170124monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-provides-2016-preliminary-net-sales-results-syk-20170110monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-35th-annual-j-p-morgan-healthcare-conference-syk-20170103monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-orthopaedics-to-compensate-additional-eligible-u-s-patients-who-had-surgery-to-rep-syk-20161219monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-increases-2017-annual-dividend-by-12-and-declares-a-0-425-per-share-quarterly-divi-syk-20161207monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-multi-year-partnership-with-indo-uk-institute-of-health-to-deliver-affor-syk-20161114monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-stifel-2016-healthcare-conference-syk-20161108monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-third-quarter-2016-results-syk-20161027monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-analyst-meeting-syk-20161011monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-october-27-2016-syk-20160926monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-morgan-stanley-global-healthcare-conference-syk-20160907monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-11th-annual-wells-fargo-securities-healthcare-conference-syk-20160831monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-38-per-share-quarterly-dividend-syk-20160727monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-second-quarter-2016-results-syk-20160721monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-july-21-2016-syk-20160616monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-goldman-sachs-37th-annual-global-healthcare-conference-syk-20160531monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-ubs-2016-global-healthcare-conference-syk-20160517monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-bank-of-america-merrill-lynch-2016-health-care-conference-syk-20160502monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-acquires-stanmore-implants-worldwide-limited-syk-20160429monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-38-per-share-quarterly-dividend-syk-20160427monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-completion-of-the-acquisition-of-vertebral-compression-fracture-portfoli-syk-20160421monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-first-quarter-2016-results-syk-20160420monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-completes-acquisition-of-physio-control-international-inc-syk-20160405monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-completes-the-acquisition-of-synergetics-usa-inc-s-neuro-portfolio-syk-20160401monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-completes-acquisition-of-sage-products-llc-syk-20160401monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-annual-meeting-of-shareholders-syk-20160323monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-april-20-2016-syk-20160318monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-corporation-announces-pricing-of-3-5-billion-senior-notes-offering-syk-20160303monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-corporation-named-one-of-fortune-magazine-s-100-best-companies-to-work-for-for-six-syk-20160303monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-cowen-company-36th-annual-health-care-conference-syk-20160229monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-canaccord-genuity-2016-musculoskeletal-conference-syk-20160222monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-definitive-agreement-to-acquire-physio-control-international-inc-for-1-2-syk-20160216monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-38-per-share-quarterly-dividend-syk-20160210monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-definitive-agreement-to-acquire-synergetics-usa-inc-s-neuro-portfolio-syk-20160210monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-definitive-agreement-to-acquire-sage-products-llc-from-madison-dearborn--syk-20160201monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-the-retirement-of-william-r-jellison-and-the-promotion-of-glenn-s-boehnl-syk-20160126monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-2015-results-and-2016-outlook-syk-20160126monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-provides-2015-preliminary-sales-results-and-increases-adjusted-earnings-guidance-syk-20160112monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-34th-annual-j-p-morgan-healthcare-conference-syk-20160104monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-38-per-share-quarterly-dividend-syk-20151210monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-corporation-announces-pricing-of-750-million-senior-notes-offering-syk-20151026monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-third-quarter-2015-results-syk-20151022monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-october-22-2015-syk-20150918monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-2015-morgan-stanley-global-healthcare-conference-syk-20150908monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-completes-acquisition-of-muka-metal-a-s-syk-20150901monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-2015-wells-fargo-securities-healthcare-conference-syk-20150828monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-receives-fda-clearance-for-mako-total-knee-application-syk-20150806monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-canaccord-genuity-35th-annual-growth-conference-syk-20150806monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-345-per-share-quarterly-dividend-syk-20150729monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-second-quarter-2015-results-syk-20150723monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-definitive-agreement-to-acquire-muka-metal-a-s-syk-20150720monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-july-23-2015-syk-20150622monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-orthopaedics-settlement-program-reaches-milestone-95-of-registered-eligible-u-s-pa-syk-20150612monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-and-black-diamond-lead-transformation-in-u-s-integrated-operating-room-market-syk-20150611monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-jefferies-2015-healthcare-conference-syk-20150515monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-ubs-global-healthcare-conference-syk-20150506monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-participate-in-bank-of-america-merrill-lynch-2015-health-care-conference-syk-20150505monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-345-per-share-quarterly-dividend-syk-20150429monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-first-quarter-2015-results-syk-20150421monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-annual-meeting-of-shareholders-syk-20150319monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-april-21-2015-syk-20150318monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conference-syk-20150311monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-corporation-named-one-of-fortune-magazine-s-100-best-companies-to-work-for-for-5th-syk-20150305monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-new-2-billion-share-repurchase-authorization-syk-20150303monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conference-syk-20150223monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-13-increase-in-quarterly-dividend-syk-20150211monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conference-syk-20150203monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-2014-results-and-2015-outlook-syk-20150127monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-provides-2014-preliminary-results-and-updates-2015-foreign-exchange-outlook-syk-20150113monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conference-syk-20150105monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-acquires-the-assets-of-chg-hospital-beds-inc-syk-20150105monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-resolves-government-investigation-of-otismed-matter-syk-20141208monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-13-increase-in-quarterly-dividend-syk-20141203monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conference-syk-20141105monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-orthopaedics-announces-settlement-agreement-to-compensate-eligible-u-s-patients-wh-syk-20141103monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-third-quarter-2014-results-and-2014-outlook-syk-20141016monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-october-16-2014-syk-20140908monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conference-syk-20140903monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-completes-acquisition-of-north-american-assets-of-small-bone-innovations-inc-syk-20140801monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-appointment-of-kevin-a-lobo-as-chairman-of-the-board-of-directors-syk-20140722monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-305-quarterly-dividend-syk-20140721monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-analyst-meeting-syk-20140718monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-second-quarter-2014-results-and-2014-outlook-syk-20140717monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-definitive-agreement-to-acquire-assets-of-small-bone-innovations-inc-syk-20140630monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-july-17-2014-syk-20140612monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conferences-syk-20140522monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conference-syk-20140505monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-corporation-announces-pricing-of-1-0-billion-senior-notes-offering-syk-20140428monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-first-quarter-2014-results-and-2014-outlook-syk-20140423monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-305-quarterly-dividend-syk-20140422monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-completes-acquisition-of-berchtold-holding-ag-syk-20140415monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-legal-function-leadership-change-syk-20140331monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-april-23-2014-syk-20140324monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-completes-acquisition-of-patient-safety-technologies-inc-syk-20140324monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-annual-meeting-of-shareholders-syk-20140317monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-completes-acquisition-of-pivot-medical-inc-syk-20140307monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conference-syk-20140225monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-definitive-agreement-to-acquire-pivot-medical-inc-syk-20140219monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-15-increase-in-quarterly-dividend-syk-20140212monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conferences-syk-20140207monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-fourth-quarter-and-full-year-2013-results-and-2014-outlook-syk-20140122monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-corporation-named-one-of-fortune-magazine-s-100-best-companies-to-work-for-syk-20140116monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conference-syk-20140102monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-definitive-agreement-to-acquire-patient-safety-technologies-inc-for-120--syk-20131231monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-receives-fda-clearance-for-waste-management-system-syk-20131230monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-completes-acquisition-of-mako-surgical-corp-syk-20131217monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-provide-fourth-quarter-2013-results-and-2014-outlook-on-january-22-2014-syk-20131213monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-15-increase-in-quarterly-dividend-syk-20131204monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-r-d-executive-to-speak-at-clinical-research-conference-on-december-4-2013-syk-20131126monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-election-of-new-director-andrew-k-silvernail-syk-20131126monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-third-quarter-2013-results-syk-20131017monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-definitive-agreement-to-acquire-mako-surgical-corp-for-1-65-billion-syk-20130925monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-october-17-2013-syk-20130917monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conference-syk-20130830monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conference-syk-20130806monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-analyst-meeting-syk-20130729monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-265-per-share-quarterly-dividend-syk-20130725monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-second-quarter-2013-results-syk-20130718monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-july-18-2013-syk-20130618monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conferences-syk-20130604monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conference-syk-20130523monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-extends-co-marketing-agreement-with-orthosensor-tm-inc-syk-20130522monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conference-syk-20130520monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conference-syk-20130507monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-265-per-share-quarterly-dividend-syk-20130430monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-first-quarter-2013-results-syk-20130424monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-appointment-of-william-jellison-to-the-position-of-vice-president-chief--syk-20130408monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-april-24-2013-syk-20130327monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-annual-meeting-of-shareholders-syk-20130321monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-corporation-announces-pricing-of-1-0-billion-senior-notes-offering-syk-20130320monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-hip-replacement-recall-news-rottenstein-law-group-responds-to-reports-that-fda-iss-syk-20130312monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-receives-fda-warning-letter-syk-20130312monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-250-million-accelerated-share-repurchase-program-syk-20130301monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-completes-acquisition-of-trauson-holdings-company-limited-syk-20130301monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conferences-syk-20130215monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-correction-of-dividend-record-date-syk-20130214monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-265-per-share-quarterly-dividend-syk-20130213monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-fourth-quarter-and-full-year-2012-results-syk-20130123monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-definitive-offer-to-acquire-trauson-holdings-company-limited-syk-20130117monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-corporation-named-one-of-fortune-magazine-s-100-best-companies-to-work-for-syk-20130116monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-provides-preliminary-2012-results-and-updates-2013-outlook-syk-20130109monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-appointment-of-scott-bruder-md-phd-to-the-position-of-vice-president-chi-syk-20130107monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conference-syk-20130102monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-25-increase-in-quarterly-dividend-and-announces-increase-in-its-share-r-syk-20121205monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-changes-to-executive-leadership-syk-20121108monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-completes-acquisition-of-privately-held-surpass-medical-ltd-syk-20121101monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-third-quarter-2012-results-syk-20121017monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-definitive-agreement-to-acquire-privately-held-surpass-medical-ltd-for-1-syk-20121016monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-names-kevin-a-lobo-as-president-and-chief-executive-officer-syk-20121001monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-october-17-2012-syk-20120918monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-2125-per-share-quarterly-dividend-syk-20120910monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conferences-syk-20120905monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-analyst-meeting-syk-20120726monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-second-quarter-2012-results-syk-20120718monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-2125-per-share-quarterly-dividend-syk-20120619monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-july-18-2012-syk-20120607monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conferences-syk-20120524monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conferences-syk-20120501monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-first-quarter-2012-results-syk-20120417monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-annual-meeting-of-shareholders-syk-20120319monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-host-conference-call-on-april-17-2012-syk-20120312monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conference-syk-20120302monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-a-0-2125-per-share-quarterly-dividend-syk-20120209monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conference-syk-20120203monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-fourth-quarter-and-full-year-2011-results-syk-20120124monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-corporation-named-one-of-fortune-magazine-s-100-best-companies-to-work-for-syk-20120119monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reaches-settlement-with-the-u-s-attorney-s-office-syk-20120118monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-increases-expected-2011-results-and-provides-2012-outlook-syk-20120110monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-to-present-at-investor-conference-syk-20120103monthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-additional-500-million-share-repurchase-program-and-declares-18-increase-syk-20111207monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dnth-20260501monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-inc-announces-pricing-of-upsized-625-million-underwritten-public-off-dnth-20260311monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-inc-announces-proposed-400-million-underwritten-public-offering-dnth-20260309monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-dnth-20260308monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-highlights-claseprubart-data-presentations-planned-for-2025-aanem-an-dnth-20251002monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-inc-announces-proposed-150-million-underwritten-public-offering-dnth-20250908monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2--dnth-20250907monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-to-webcast-presentation-at-the-jefferies-global-healthcare-conferenc-dnth-20250529monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-appoints-simon-read-ph-d-to-board-of-directors-dnth-20250522monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-completes-enrollment-of-phase-2-magic-trial-of-dnth103-in-generalize-dnth-20250505monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-to-participate-in-two-upcoming-investor-events-dnth-20250429monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-strengthens-strategic-commercial-leadership-with-appointment-of-john-dnth-20250305monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-to-participate-in-two-upcoming-investor-conferences-dnth-20250226monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-to-webcast-presentations-at-two-investor-conferences-dnth-20250130monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-to-webcast-presentation-at-the-43rd-annual-j-p-morgan-healthcare-con-dnth-20250108monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-to-participate-in-three-upcoming-healthcare-investor-conferences-dnth-20241104monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-announces-two-poster-presentations-for-dnth103-at-the-2024-american--dnth-20241015monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september-dnth-20240904monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-announces-two-poster-presentations-for-dnth103-at-the-10th-congress--dnth-20240628monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-announces-fda-clearance-to-initiate-phase-2-trial-of-dnth103-in-mult-dnth-20240612monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-dnth-20240530monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-to-participate-in-the-bank-of-america-securities-2024-health-care-co-dnth-20240508monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dnth-20240503monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-announces-oral-presentation-for-dnth103-at-the-2024-american-academy-dnth-20240411monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dnth-20240405monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-dnth-20240307monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-announces-initiation-of-phase-2-magic-trial-of-dnth103-in-generalize-dnth-20240226monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-to-participate-in-the-td-cowen-44th-annual-health-care-conference-dnth-20240223monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-to-participate-at-the-guggenheim-6th-annual-biotechnology-conference-dnth-20240131monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-to-webcast-presentation-at-the-42nd-annual-j-p-morgan-healthcare-con-dnth-20240102monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-dnth-20231204monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-enhances-leadership-team-with-appointment-of-jeffrey-stavenhagen-ph--dnth-20231129monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-highlights-recent-business-achievements-and-third-quarter-2023-finan-dnth-20231109monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-to-participate-in-upcoming-investor-healthcare-conferences-in-novemb-dnth-20231101monthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-announces-positive-top-line-phase-1-data-and-debuts-trading-on-nasda-dnth-20230912monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nams-20260501monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nams-20260306monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nams-20260206monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nams-20251205monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-december-nams-20251125monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-to-participate-in-upcoming-medical-meeting-and-investor-conferences-in-nams-20250825monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-to-present-alzheimer-s-biomarker-data-from-broadway-trial-at-aaic-2025-nams-20250722monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-to-host-r-d-day-on-june-11-2025-nams-20250605monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june-nams-20250527monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference-nams-20250514monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nams-20250502monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-to-present-new-clinical-and-preclinical-data-at-93rd-eas-congress-nams-20250430monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nams-20250404monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-to-present-at-the-24th-annual-needham-virtual-healthcare-conference-nams-20250331monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-march-nams-20250225monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nams-20250207monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-to-present-at-guggenheim-s-smid-cap-biotech-conference-nams-20250129monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nams-20250109monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-announces-closing-of-upsized-479-0-million-public-offering-of-ordinary-nams-20241213monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-announces-pricing-of-upsized-416-5-million-public-offering-of-ordinary-nams-20241212monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nams-20241206monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nams-20241101monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-to-participate-in-upcoming-medical-and-investor-conferences-in-novembe-nams-20241028monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nams-20241004monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nams-20240906monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-to-participate-in-upcoming-investor-conferences-in-september-nams-20240830monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nams-20240802monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial--nams-20240726monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-completes-enrollment-in-pivotal-phase-3-tandem-clinical-trial-evaluati-nams-20240708monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nams-20240703monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nams-20240607monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-to-participate-in-upcoming-investor-conferences-in-june-nams-20240529monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-to-present-new-clinical-and-preclinical-data-highlighting-obicetrapib--nams-20240521monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nams-20240503monthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-to-host-r-d-day-with-key-opinion-leaders-on-may-16-2024-nams-20240502monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-xene-20260529monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-mri-advances-as-a-cardiopulmonary-biomarker-platform-at-ats-2026-xene-20260507monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-xene-20260501monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-to-report-q1-2026-financial-results-on-may-7-2026-xene-20260430monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-to-present-at-upcoming-investor-conferences-xene-20260415monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-pricing-of-upsized-650-0-million-public-offering-xene-20260311monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-proposed-public-offering-xene-20260309monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-xene-20260308monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-xene-20260116monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-xene-20250829monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-to-report-q2-2025-financial-results-on-august-11-2025-xene-20250804monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-xene-20250801monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-joins-the-russell-3000-and-russell-2000-indexes-xene-20250627monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-xene-20250626monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-announces-appointment-of-darren-cline-as-chief-commercial-officer-xene-20250624monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-to-present-at-the-goldman-sachs-46th-annual-global-healthcare-conference-xene-20250603monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-xene-20250530monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-mri-featured-prominently-at-ats-2025-across-broad-clinical-spectrum-xene-20250515monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-to-present-at-the-2025-rbc-capital-markets-global-healthcare-conference-xene-20250514monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-to-report-q1-2025-financial-results-on-may-12-2025-xene-20250505monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-xene-20250502monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-to-showcase-long-term-36-month-azetukalner-data-at-aan-2025-xene-20250404monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-to-present-at-stifel-2025-virtual-cns-forum-xene-20250312monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-to-present-at-the-45th-annual-td-cowen-healthcare-conference-xene-20250225monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-to-report-q4-and-full-year-2024-financial-results-on-february-27-2025-xene-20250220monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-outlines-key-corporate-milestone-opportunities-for-2025-xene-20250113monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-xene-20250107monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-showcases-new-long-term-azetukalner-data-from-x-tole-ole-study-in-fos-at-aes-2024-xene-20241206monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-to-showcase-new-long-term-azetukalner-data-at-aes-2024-xene-20241125monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-to-present-at-upcoming-investor-conferences-xene-20241113monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-to-report-q3-2024-financial-results-on-november-12-2024-xene-20241105monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-to-present-at-bofa-securities-2024-cns-therapeutics-virtual-conference-xene-20241002monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-showcases-azetukalner-data-at-15th-european-epilepsy-congress-xene-20240909monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-expands-leadership-team-with-matthew-d-ronsheim-ph-d-as-chief-operating-officer-xene-20240812monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-to-report-q2-2024-financial-results-on-august-8-2024-xene-20240801monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-goldman-sachs-45th-annual-global-healthcare-confer-xene-20240605monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-presents-data-from-phase-2-x-nova-clinical-trial-of-azetukalner-in-m-xene-20240528monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-bofa-securities-health-care-conference-2024-xene-20240508monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-2024-rbc-capital-markets-global-healthcare-confere-xene-20240507monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-conference-call-and-webcast-to-discuss-first-quarter-2024--xene-20240502monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-showcases-xen1101-at-the-american-academy-of-neurology-2024-annual-m-xene-20240416monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-2024-bloom-burton-co-healthcare-investor-conferenc-xene-20240410monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-23rd-annual-needham-virtual-healthcare-conference-xene-20240404monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-stifel-2024-virtual-cns-days-xene-20240312monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-leerink-partners-global-biopharma-conference-2024-xene-20240305monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-conference-call-and-webcast-to-discuss-fourth-quarter-and--xene-20240222monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-outlines-key-milestone-opportunities-for-2024-xene-20240108monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-xene-20240103monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-closing-of-345-0-million-upsized-public-offering-including-xene-20231204monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-provides-updates-on-neurology-pipeline-programs-at-the-annual-meetin-xene-20231202monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-pricing-of-upsized-300-0-million-public-offering-xene-20231130monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-proposed-public-offering-xene-20231129monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-provides-update-on-partnered-program-with-neurocrine-biosciences-xene-20231109monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-conference-call-and-webcast-to-discuss-third-quarter-2023--xene-20231101monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-publication-of-results-from-xen1101-phase-2b-x-tole-clinic-xene-20231009monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-jefferies-inaugural-biotech-cns-neuro-summit-xene-20231006monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-td-cowen-s-3rd-annual-novel-mechanisms-in-neuropsychia-xene-20230914monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-upcoming-investor-webinar-with-leading-key-opinion-leaders-xene-20230912monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-showcases-xen1101-epilepsy-program-at-35th-international-epilepsy-co-xene-20230904monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-wells-fargo-2023-healthcare-conference-xene-20230831monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-conference-call-and-webcast-to-discuss-second-quarter-2023-xene-20230802monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-goldman-sachs-44th-annual-global-healthcare-confer-xene-20230606monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-2023-jefferies-healthcare-conference-xene-20230531monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-2023-rbc-capital-markets-global-healthcare-confere-xene-202305112023-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-bofa-securities-health-care-conference-2023-xene-202305032023-05-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-conference-call-and-webcast-to-discuss-first-quarter-2023--xene-202305022023-05-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-showcases-its-xen1101-epilepsy-program-at-the-2023-american-academy--xene-202304242023-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-2023-bloom-burton-co-healthcare-investor-conferenc-xene-202304212023-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference-xene-202304182023-04-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-stifel-2023-cns-days-xene-202303222023-03-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-conference-call-and-webcast-to-discuss-fourth-quarter-and--xene-202302222023-02-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference-xene-202302082023-02-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-outlines-key-milestone-opportunities-for-2023-xene-202301092023-01-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-xene-202301042023-01-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-provides-updates-on-proprietary-neurology-pipeline-programs-at-the-a-xene-20221202monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-bank-of-america-securities-biotech-smid-cap-confer-xene-20221130monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-xene-20221109monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-launch-of-xen1101-phase-3-program-with-initiation-of-x-tol-xene-20221103monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-conference-call-and-webcast-to-discuss-third-quarter-2022--xene-20221101monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-wells-fargo-2022-healthcare-conference-xene-20220901monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-13th-annual-wedbush-pacgrow-healthcare-conference-xene-20220808monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-conference-call-and-webcast-to-discuss-second-quarter-2022-xene-20220802monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-william-blair-biotech-focus-conference-2022-xene-20220711monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-closing-of-287-5-million-public-offering-including-full-ex-xene-20220627monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-pricing-of-250-0-million-public-offering-xene-20220623monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-proposed-public-offering-xene-20220622monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-provides-update-on-additional-positive-data-from-the-xen1101-program-xene-20220622monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-positive-outcome-of-end-of-phase-2-meeting-with-the-fda-xene-20220621monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-2022-jefferies-healthcare-conference-xene-20220601monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-conference-call-and-webcast-to-discuss-first-quarter-2022--xene-20220503monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-initiation-of-phase-2-clinical-trial-to-evaluate-xen1101-a-xene-20220503monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-xene-20220425monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-21st-annual-needham-virtual-healthcare-conference-xene-20220404monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-stifel-2022-cns-days-xene-20220322monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-2021-financial-results-and-provides-corporate-update-xene-20220301monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-conference-call-and-webcast-to-discuss-year-end-2021-finan-xene-20220222monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-participate-in-the-11th-annual-svb-leerink-global-healthcare-conf-xene-20220214monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-outlines-key-milestone-opportunities-for-2022-xene-20220110monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-presents-additional-positive-data-from-phase-2b-x-tole-clinical-tria-xene-20211203monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-provides-updates-on-proprietary-neurology-pipeline-programs-at-the-a-xene-20211203monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-xene-20211112monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-conference-call-and-webcast-to-discuss-third-quarter-2021--xene-20211103monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-closing-of-345-million-public-offering-including-full-exer-xene-20211008monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-pricing-of-300-0-million-public-offering-xene-20211006monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-proposed-public-offering-xene-20211004monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-conference-call-and-webcast-to-discuss-topline-results-fro-xene-20211003monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-participate-in-the-12th-annual-wedbush-pacgrow-healthcare-confere-xene-20210810monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-conference-call-and-webcast-to-discuss-second-quarter-2021-xene-20210804monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-participate-at-the-william-blair-biotech-focus-conference-2021-xene-20210713monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-completion-of-patient-randomization-in-xen1101-phase-2b-x--xene-20210707monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-provides-corporate-update-following-its-annual-meeting-of-shareholde-xene-20210603monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-jefferies-2021-virtual-healthcare-conference-xene-20210531monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-conference-call-and-webcast-to-discuss-first-quarter-2021--xene-20210504monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-xene-20210408monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-participate-in-the-stifel-3rd-annual-cns-day-xene-20210329monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-closing-of-115-million-public-offering-and-full-exercise-o-xene-20210312monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-pricing-of-100-0-million-public-offering-xene-20210310monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-proposed-public-offering-of-common-shares-xene-20210309monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-collaboration-with-researchers-at-icahn-school-of-medicine-xene-20210308monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-2020-financial-results-and-provides-corporate-update-xene-20210301monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-conference-call-and-webcast-to-discuss-year-end-2020-finan-xene-20210223monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-promising-new-pre-clinical-data-and-provides-clinical-over-xene-20210222monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-provides-updates-on-neurology-pipeline-programs-at-aes2020-the-virtu-xene-20201207monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-xene-20201113monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-third-quarter-2020-fi-xene-20201102monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-receives-fda-feedback-and-is-on-track-to-initiate-xen496-phase-3-cli-xene-20201008monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-appoints-dr-chris-von-seggern-as-chief-commercial-officer-xene-20200817monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-xene-20200804monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-second-quarter-2020-f-xene-20200730monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-jefferies-2020-virtual-healthcare-conference-xene-20200601monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-first-quarter-2020-fi-xene-20200514monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-provides-corporate-update-in-the-context-of-covid-19-xene-20200331monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-xene-20200326monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-2019-financial-results-and-provides-corporate-update-xene-20200309monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-2019-financial-result-xene-20200302monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-full-exercise-and-closing-of-underwriters-option-to-purcha-xene-20200214monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-closing-of-its-60-0-million-public-offering-of-common-shar-xene-20200127monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-pricing-of-60-0-million-public-offering-of-common-shares-xene-20200123monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-proposed-public-offering-of-common-shares-xene-20200122monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-outlines-key-milestone-opportunities-for-2020-and-provides-corporate-xene-20200113monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-provides-updates-on-partnered-neurology-pipeline-programs-at-the-201-xene-20191207monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-provides-updates-on-proprietary-neurology-pipeline-programs-at-the-2-xene-20191206monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-31st-annual-piper-jaffray-healthcare-conference-xene-20191203monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-corporate-update-on-l-xene-20191202monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-xene-20191115monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-third-quarter-2019-fi-xene-20191029monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-2019-cantor-global-healthcare-conference-xene-20190925monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-announces-appointment-of-shelley-mccloskey-as-senior-vice-president-human-resources-xene-20190917monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-second-quarter-2019-f-xene-20190731monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-presents-corporate-update-on-neurology-focused-pipeline-at-the-jeffe-xene-20190605monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-jefferies-2019-healthcare-conference-xene-20190529monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-first-quarter-2019-fi-xene-20190430monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-2019-bloom-burton-co-healthcare-investor-conferenc-xene-20190424monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-2018-financial-results-and-provides-corporate-update-xene-20190306monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-2018-financial-result-xene-20190227monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-provides-key-regulatory-updates-on-xen007-and-xen1101-xene-20190128monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-outlines-2019-key-milestones-xene-20190107monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-announces-final-results-of-xen1101-phase-1-clinical-trial-and-update-on-xen901-phase-xene-20181203monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-corporate-update-and--xene-20181130monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-stifel-2018-healthcare-conference-xene-20181107monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-third-quarter-2018-fi-xene-20181030monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-closing-of-its-63-0-million-public-offering-of-common-shar-xene-20180917monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-pricing-of-63-0-million-public-offering-of-common-shares-xene-20180913monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-proposed-public-offering-of-common-shares-xene-20180912monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-enters-into-agreement-to-buy-out-milestones-and-royalties-related-to-its-xen1101-pro-xene-20180911monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-expands-ion-channel-neurology-pipeline-with-addition-of-xen496-a-phase-3-ready-potas-xene-20180906monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-announces-positive-xen1101-pharmacodynamic-data-from-phase-1b-tms-study-xene-20180829monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-second-quarter-2018-f-xene-20180803monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-at-the-market-equity-offering-xene-20180712monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-jefferies-2018-healthcare-conference-xene-20180601monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-presents-positive-xen1101-tms-pharmacodynamic-phase-1-data-at-14th-eilat-conference-xene-20180515monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-corporate-update-and--xene-20180514monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-first-quarter-2018-fi-xene-20180501monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-2018-bloom-burton-co-healthcare-investor-conferenc-xene-20180425monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-2017-financial-results-and-provides-corporate-update-xene-20180307monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-2017-financial-result-xene-20180228monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-advances-second-proprietary-epilepsy-product-into-the-clinic-with-in-xene-20180220monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-outlines-key-milestones-for-2018-xene-20180108monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-stifel-2017-healthcare-conference-xene-20171108monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-third-quarter-2017-fi-xene-20171101monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-initiation-of-xen1101-phase-1-clinical-trial-xene-20171017monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-second-quarter-2017-f-xene-20170727monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-today-at-9-00-a-m-eastern-time-t-xene-20170627monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-jefferies-2017-healthcare-conference-xene-20170602monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-first-quarter-2017-fi-xene-20170504monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-2017-bloom-burton-co-healthcare-investor-conferenc-xene-20170428monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-2016-financial-results-and-provides-corporate-update-xene-20170308monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-2016-financial-result-xene-20170301monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-outlines-key-milestones-for-2017-xene-20170109monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-stifel-2016-healthcare-conference-xene-20161108monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-third-quarter-2016-fi-xene-20161027monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-appoints-dawn-svoronos-to-its-board-of-directors-xene-20160927monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-exercise-in-full-of-option-to-purchase-additional-shares-a-xene-20160913monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-pricing-of-30-million-public-offering-of-common-shares-xene-20160908monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-proposed-public-offering-of-common-shares-xene-20160907monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-canaccord-genuity-36th-annual-growth-conference-xene-20160802monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-second-quarter-2016-f-xene-20160725monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-presents-corporate-update-and-highlights-its-proprietary-therapeutic-xene-20160608monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-jefferies-2016-healthcare-conference-xene-20160602monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-first-quarter-2016-fi-xene-20160502monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-names-dr-raymond-j-winquist-as-head-translational-research-xene-20160404monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-provide-business-and-milestone-update-at-needham-healthcare-confe-xene-20160331monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-and-genentech-extend-collaborations-focused-on-pain-xene-20160315monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-2015-financial-results-and-provides-corporate-update-xene-20160308monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-2015-financial-result-xene-20160302monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-initiates-phase-2-clinical-trial-of-xen801-to-treat-moderate-to-severe-acne-xene-20160210monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-names-dr-james-r-empfield-senior-vice-president-drug-discovery-xene-20160209monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-outlines-key-milestones-for-2016-xene-20160111monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-and-genentech-publish-in-science-the-3-d-crystal-structure-of-a-novel-nav1-7-compoun-xene-20151217monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-stifel-2015-healthcare-conference-xene-20151112monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-third-quarter-2015-financial-results-and-provides-corporate--xene-20151110monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-third-quarter-2015-fi-xene-20151105monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-announces-its-partner-genentech-has-advanced-gdc-0310-a-second-nav1-7-inhibitor-for--xene-20151022monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-initiation-of-xen801-phase-1-clinical-trial-xene-20150924monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-achieves-milestone-in-genentech-collaboration-to-discover-novel-pain-xene-20150921monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-10th-annual-wells-fargo-healthcare-conference-xene-20150903monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-second-quarter-2015-financial-results-and-provides-corporate-xene-20150810monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-present-at-the-canaccord-genuity-35th-annual-growth-conference-xene-20150806monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-second-quarter-2015-f-xene-20150805monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-today-at-9-00-a-m-eastern-time-t-xene-20150701monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-provide-business-and-milestone-update-at-jefferies-2015-global-he-xene-20150528monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-appoints-steven-gannon-to-its-board-of-directors-xene-20150522monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-first-quarter-2015-financial-results-and-provides-corporate--xene-20150512monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-first-quarter-2015-fi-xene-20150507monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-appoints-dr-richard-h-scheller-to-its-board-of-directors-xene-20150316monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-2014-financial-results-and-provides-corporate-update-xene-20150312monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-2014-financial-result-xene-20150309monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-partner-teva-to-initiate-phase-2b-clinical-trial-of-tv-45070-in-post-xene-20150219monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-outlines-key-anticipated-milestones-for-2015-xene-20150108monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-third-quarter-2014-financial-results-xene-20141215monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-closing-of-initial-public-offering-and-full-exercise-of-th-xene-20141110monthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-announces-pricing-of-initial-public-offering-xene-20141105monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-to-present-at-upcoming-investor-conferences-knsa-20260529monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-launches-targeted-direct-to-consumer-tv-campaign-for-arcalyst-rilo-knsa-20260408monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-on-f-knsa-20260219monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-provides-corporate-update-knsa-20260112monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-to-present-at-44th-annual-j-p-morgan-healthcare-conference-knsa-20260107monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-to-report-third-quarter-2025-financial-results-on-october-28-2025-knsa-20251023monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-to-present-at-upcoming-investor-conferences-knsa-20250529monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-to-report-first-quarter-2025-financial-results-on-april-29-2025-knsa-20250424monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-announces-development-of-kpl-387-in-recurrent-pericarditis-and-upd-knsa-20250225monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-to-report-fourth-quarter-and-full-year-2024-financial-results-on-f-knsa-20250220monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-to-present-at-43rd-annual-j-p-morgan-healthcare-conference-knsa-20250106monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-to-present-at-7th-annual-evercore-isi-healthconx-conference-knsa-20241126monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-to-present-at-jefferies-london-healthcare-conference-knsa-20241112monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-partners-with-grammy-award-winning-singer-songwriter-carly-pearce--knsa-20241028monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-to-report-third-quarter-2024-financial-results-on-october-29-2024-knsa-20241022monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-to-present-at-2024-wells-fargo-healthcare-conference-knsa-20240828monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-to-report-second-quarter-2024-financial-results-on-july-23-2024-knsa-20240716monthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-to-present-data-on-the-burden-of-disease-in-patients-with-recurrent-pericarditis-a-knsa-20190516monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-announces-2026-investor-day-in-new-york-city-lgnd-20260610monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-to-participate-in-june-investor-conferences-lgnd-20260527monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-to-participate-in-may-investor-conferences-lgnd-20260505monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-to-report-first-quarter-2026-financial-results-on-may-7-2026-lgnd-20260422monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-partner-travere-therapeutics-receives-full-fda-approval-for-filspari-sparsentan-in--lgnd-20260414monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-hosts-2025-investor-day-and-introduces-2026-guidance-lgnd-20251209monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-to-report-third-quarter-2025-financial-results-on-november-6-2025-lgnd-20251023monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-to-participate-in-september-investor-conferences-lgnd-20250819monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-reports-second-quarter-2025-financial-results-and-raises-guidance-lgnd-20250807monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-and-medtronic-commit-70-million-in-strategic-capital-to-orchestra-biomed-lgnd-20250731monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-to-report-second-quarter-2025-financial-results-on-august-7-2025-lgnd-20250724monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-partner-pelthos-therapeutics-launches-zelsuvmi-lgnd-20250710monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-announces-completion-of-pelthos-therapeutics-merger-with-channel-therapeutics-lgnd-20250702monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-announces-2025-investor-day-in-new-york-city-lgnd-20250611monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-to-ring-the-nasdaq-opening-bell-on-may-19-2025-lgnd-20250514monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-reports-first-quarter-2025-financial-results-lgnd-20250508monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-to-participate-in-may-investor-conferences-lgnd-20250501monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-to-report-first-quarter-2025-financial-results-on-may-8-2025-lgnd-20250424monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-subsidiary-pelthos-therapeutics-to-combine-with-channel-therapeutics-lgnd-20250417monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-to-participate-in-march-investor-conferences-lgnd-20250303monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-reports-fourth-quarter-and-full-year-2024-financial-results-lgnd-20250227monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-leads-75-million-royalty-financing-in-castle-creek-biosciences-lgnd-20250225monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-and-pharmacopeia-to-present-at-the-rodman-renshaw-10th-annual-healthcare-conference-lgnd-20081104monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-and-pharmacopeia-to-present-at-the-oppenheimer-19th-annual-healthcare-conference-lgnd-20081028monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-to-acquire-pharmacopeia-for-stock-and-contingent-value-rights-lgnd-20080924monthly0.5https://www.biopharmawatch.com/news/LGND/ligand-pharmaceuticals-incorporated-lgnd-president-and-chief-executive-officer-to-ring-the-lgnd-20070925monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-incorporated-investigated-by-the-portnoy-law-firm-tfx-20260417monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-leadership-transition-tfx-20260108monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20250731monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-second-quarter-financial-results-and-full-year-2025-outlook-tfx-20250731monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-highlights-prostate-health-and-quality-of-life-awareness-through-two-key-public-i-tfx-20250611monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-incorporated-announcement-if-you-have-suffered-losses-in-teleflex-incorporated-ny-tfx-20250522monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-incorporated-announcement-if-you-have-suffered-losses-in-teleflex-incorporated-ny-tfx-20250519monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-publishes-2024-global-impact-report-tfx-20250519monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-showcases-new-clinical-data-presented-at-the-2025-american-urological-association-tfx-20250515monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20250512monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-incorporated-announcement-if-you-have-suffered-losses-in-teleflex-incorporated-ny-tfx-20250505monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-incorporated-announcement-if-you-have-suffered-losses-in-teleflex-incorporated-ny-tfx-20250503monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-first-quarter-financial-results-and-full-year-2025-outlook-tfx-20250501monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-bofa-securities-2025-health-care-conference-tfx-20250430monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-receives-fda-510-k-clearance-for-expanded-indications-of-the-quikclot-control-hem-tfx-20250430monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-clinical-and-real-world-evidence-studies-and-physician-educational-oppo-tfx-20250424monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-first-quarter-2025-earnings-conference-call-information-tfx-20250417monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-receives-fda-510-k-clearance-of-the-ac3-range-intra-aortic-balloon-pump-iabp-tfx-20250401monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-updated-clinical-study-data-presented-at-the-european-association-of-ur-tfx-20250325monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20250227monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-fourth-quarter-and-full-year-2024-financial-results-tfx-20250227monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-planned-retirement-of-thomas-powell-as-chief-financial-officer-tfx-20250227monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-intent-to-separate-into-two-publicly-traded-companies-tfx-20250227monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-acquire-biotronik-s-vascular-intervention-business-tfx-20250227monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-raymond-james-associates-46th-annual-institutional-investors-co-tfx-20250218monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-fourth-quarter-2024-earnings-conference-call-information-tfx-20250213monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-awarded-short-term-central-venous-catheters-contract-from-vizient-tfx-20250109monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-tfx-20250107monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-36th-annual-piper-sandler-healthcare-conference-tfx-20241119monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-jefferies-london-healthcare-conference-tfx-20241107monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20241031monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-third-quarter-financial-results-and-full-year-2024-outlook-tfx-20241031monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-launches-next-generation-arrow-vps-rhythm-dlx-device-and-navicurve-stylet-in-cana-tfx-20241023monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-third-quarter-2024-earnings-conference-call-information-tfx-20241017monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-s-barrigel-rectal-spacer-to-be-featured-in-three-presentations-at-the-2024-americ-tfx-20240926monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-morgan-stanley-22nd-annual-global-healthcare-conference-tfx-20240822monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-publication-of-a-propensity-matching-review-of-retrospective-data-repor-tfx-20240821monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20240801monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-second-quarter-financial-results-and-full-year-2024-outlook-tfx-20240801monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-expands-interventional-cardiology-portfolio-with-fda-510-k-clearance-of-the-ringe-tfx-20240731monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-awarded-hemostasis-products-agreements-with-premier-inc-tfx-20240729monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-the-teleflex-center-for-antimicrobial-protection-tfx-20240724monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-second-quarter-2024-earnings-conference-call-information-tfx-20240718monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-publishes-2023-global-impact-report-tfx-20240513monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-expands-intraosseous-vascular-access-portfolio-with-new-arrow-ez-io-intraosseous--tfx-20240509monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20240506monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-first-quarter-financial-results-and-full-year-2024-outlook-tfx-20240502monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-multiple-clinical-and-real-world-evidence-studies-to-be-highlighted-at--tfx-20240501monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-the-limited-market-release-of-the-wattson-temporary-pacing-guidewire-tfx-20240430monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-bofa-securities-2024-health-care-conference-tfx-20240430monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-first-quarter-2024-earnings-conference-call-information-tfx-20240418monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-incorporated-introduces-the-urolift-2-system-with-advanced-tissue-control-a-revol-tfx-20240402monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-s-climate-targets-validated-by-the-science-based-targets-initiative-tfx-20240328monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20240222monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-fourth-quarter-and-full-year-2023-financial-results-tfx-20240222monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-45th-annual-raymond-james-institutional-investors-conference-tfx-20240220monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-fourth-quarter-2023-earnings-conference-call-information-tfx-20240208monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-now-offers-its-titan-sgs-stapler-with-staple-line-reinforcement-tfx-20240109monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-tfx-20231226monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-awarded-peripheral-access-agreement-with-premier-inc-tfx-20231205monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-first-patient-enrollment-in-access-manta-registry-tfx-20231116monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-35th-annual-piper-sandler-healthcare-conference-tfx-20231114monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20231102monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-third-quarter-financial-results-and-full-year-2023-outlook-tfx-20231102monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-jefferies-london-healthcare-conference-tfx-20231031monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-third-quarter-2023-earnings-conference-call-information-tfx-20231019monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-completes-acquisition-of-palette-life-sciences-tfx-20231010monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-selected-to-exhibit-arrow-vps-rhythm-dlx-device-and-arrow-piccs-preloaded-with-th-tfx-20230915monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-morgan-stanley-21st-annual-global-healthcare-conference-tfx-20230830monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-extension-of-arrow-ergopack-complete-system-to-hemodialysis-and-large-b-tfx-20230821monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20230803monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-second-quarter-financial-results-and-full-year-2023-outlook-tfx-20230803monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-receives-fda-clearance-for-expanded-indication-for-quikclot-control-hemostatic-de-tfx-20230801monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-acquire-palette-life-sciences-tfx-20230726monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-awarded-national-group-purchasing-agreements-with-premier-inc-tfx-20230725monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-second-quarter-2023-earnings-conference-call-information-tfx-20230720monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-completes-enrollment-in-percutaneous-coronary-intervention-study-tfx-20230719monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-partnership-with-insighters-medical-for-exclusive-distribution-of-the-i-tfx-20230621monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-receives-fda-clearance-for-the-wattson-temporary-pacing-guidewire-tfx-20230607monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-the-arrow-ez-io-needle-is-now-fda-cleared-for-use-in-an-mri-environment-tfx-20230606monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-awarded-agreements-with-premier-inc-tfx-20230601monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-publishes-2022-global-impact-report-tfx-202305152023-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-202305082023-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-first-quarter-financial-results-and-full-year-2023-outlook-tfx-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-launches-new-arrow-vps-rhythm-dlx-device-and-navicurve-stylet-in-the-united-state-tfx-202305022023-05-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-bank-of-america-securities-2023-health-care-conference-tfx-202304252023-04-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-first-quarter-2023-earnings-conference-call-information-tfx-202304202023-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-selects-gore-seamguard-bioabsorbable-staple-line-reinforcement-material-for-use-w-tfx-202303292023-03-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-keybanc-capital-markets-life-sciences-medtech-investor-forum-vi-tfx-202303072023-03-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-202302232023-02-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-fourth-quarter-and-full-year-2022-financial-results-tfx-202302232023-02-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-expands-interventional-cardiology-portfolio-with-two-new-fda-cleared-catheter-dev-tfx-202302222023-02-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-44th-annual-raymond-james-institutional-investors-conference-tfx-202302212023-02-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-fourth-quarter-2022-earnings-conference-call-information-tfx-202302092023-02-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-launches-national-ad-campaign-pit-stop-to-raise-awareness-of-the-urolift-system-a-tfx-202302062023-02-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-tfx-20221227monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-celebrates-400-000-patients-treated-with-the-minimally-invasive-urolift-system-tfx-20221215monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-earns-top-spot-in-medreps-best-places-to-work-2023-ranking-tfx-20221121monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-34th-annual-piper-sandler-healthcare-conference-tfx-20221116monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-worldwide-recall-of-gibeck-iso-gard-filter-tfx-20221103monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-jefferies-london-healthcare-conference-tfx-20221101monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20221027monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-third-quarter-financial-results-and-full-year-outlook-tfx-20221027monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-third-quarter-2022-earnings-conference-call-information-tfx-20221013monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-completes-acquisition-of-standard-bariatrics-tfx-20220928monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-launches-new-arrow-pressure-injectable-midline-catheter-portfolio-tfx-20220927monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-morgan-stanley-20th-annual-global-healthcare-conference-tfx-20220831monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-collaboration-with-fundamentalvr-to-improve-training-through-virtual-re-tfx-20220825monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-expand-its-surgical-portfolio-with-differentiated-stapling-technology-for-bari-tfx-20220822monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-awarded-central-venous-access-contract-from-vizient-tfx-20220801monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-publishes-2021-global-impact-report-tfx-20220729monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20220728monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-second-quarter-financial-results-and-full-year-outlook-tfx-20220728monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-pocono-raceway-nascar-event-to-raise-visibility-of-enlarged-prostate-an-tfx-20220721monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-second-quarter-2022-earnings-conference-call-information-tfx-20220714monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-first-patient-enrollment-in-manta-ultra-study-tfx-20220622monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-launches-new-arrow-pressure-injectable-midline-catheter-in-australia-and-new-zeal-tfx-20220613monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-launches-new-arrow-pressure-injectable-midline-catheter-in-europe-the-middle-east-tfx-20220607monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-celebrates-june-men-s-health-month-with-launch-of-urolift-patient-ambassador-prog-tfx-20220601monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-hosts-2022-analyst-investor-day-tfx-20220520monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-regulatory-clearance-for-its-urolift-system-in-china-for-the-treatment--tfx-20220519monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-health-canada-approval-of-manta-vascular-closure-device-tfx-20220518monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-full-u-s-commercial-launch-of-the-urolift-2-system-and-urolift-atc-adva-tfx-20220513monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-host-analyst-investor-day-on-may-20-2022-tfx-20220502monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20220502monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-first-quarter-financial-results-and-full-year-outlook-tfx-20220428monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-named-to-forbes-best-employers-for-diversity-2022-list-tfx-20220426monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-bank-of-america-securities-2022-healthcare-conference-tfx-20220426monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-first-quarter-2022-earnings-conference-call-information-tfx-20220414monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-the-launch-of-the-urolift-system-in-japan-for-the-treatment-of-benign-p-tfx-20220411monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-keybanc-life-sciences-medtech-investor-forum-tfx-20220309monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-43rd-annual-raymond-james-institutional-investors-conference-tfx-20220302monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20220224monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-fourth-quarter-and-full-year-2021-financial-results-tfx-20220224monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-receives-fda-clearance-for-expanded-indication-for-specialty-catheter-and-coronar-tfx-20220223monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-fourth-quarter-and-full-year-2021-earnings-conference-call-information-tfx-20220210monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-tfx-20220104monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-receives-reimbursement-approval-for-the-urolift-system-in-japan-tfx-20211213monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-incorporated-announces-worldwide-recall-of-arrow-trerotola-over-the-wire-ptd-kit--tfx-20211126monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-earns-top-spot-in-medreps-best-places-to-work-2022-ranking-tfx-20211118monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-participate-in-the-33rd-annual-virtual-piper-sandler-healthcare-conference-tfx-20211118monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-integrates-medical-education-and-training-with-explorer-surgical-to-expand-urolog-tfx-20211104monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-comments-on-the-centers-for-medicare-medicaid-services-2022-medicare-physician-fe-tfx-20211103monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20211028monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-third-quarter-2021-results-and-full-year-outlook-tfx-20211028monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-completes-enrollment-in-cardiac-ide-study-tfx-20211027monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-third-quarter-2021-earnings-conference-call-information-tfx-20211014monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-large-scale-analysis-of-real-world-healthcare-claims-data-for-enlarged--tfx-20210914monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-unveils-the-urolift-advanced-tissue-control-atc-system-and-the-urolift-2-system-a-tfx-20210909monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-morgan-stanley-19th-annual-global-healthcare-conference-tfx-20210901monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-wells-fargo-2021-virtual-healthcare-conference-tfx-20210826monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20210729monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-second-quarter-2021-results-and-full-year-outlook-tfx-20210729monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-second-quarter-2021-earnings-conference-call-information-tfx-20210715monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-real-world-clinical-data-presentations-of-the-urolift-system-at-the-36t-tfx-20210706monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-completes-divestiture-of-respiratory-assets-to-medline-industries-tfx-20210628monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-raymond-james-2021-human-health-innovation-conference-tfx-20210607monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-signs-definitive-agreement-to-sell-certain-respiratory-assets-and-reaffirms-adjus-tfx-20210518monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-ubs-global-healthcare-virtual-conference-tfx-20210511monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20210503monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-first-quarter-2021-results-tfx-20210429monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-bank-of-america-securities-2021-virtual-health-care-conference-tfx-20210427monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-first-quarter-2021-earnings-conference-call-information-tfx-20210415monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-keybanc-capital-markets-life-sciences-medtech-investor-forum-tfx-20210310monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-250-000-patients-treated-for-enlarged-prostate-with-the-minimally-invasiv-tfx-20210309monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20210225monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-fourth-quarter-and-full-year-2020-results-provides-2021-guidance-tfx-20210225monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-submission-of-biologics-license-application-for-its-investigational-fre-tfx-20210224monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-barclays-global-healthcare-conference-tfx-20210223monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-completes-enrollment-in-cto-pci-ide-study-tfx-20210217monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-named-one-of-america-s-best-employers-2021-by-forbes-tfx-20210216monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-raymond-james-42nd-annual-institutional-investors-conference-tfx-20210216monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-fourth-quarter-and-full-year-2020-earnings-conference-call-information-tfx-20210211monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-continues-to-deliver-complete-confidence-with-new-arrow-ergopack-complete-mac-psi-tfx-20210119monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-tfx-20210104monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-completes-acquisition-of-market-leader-in-hemostatic-products-tfx-20201228monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-ranked-a-best-place-to-work-2021-by-medreps-com-tfx-20201203monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-stephens-investment-conference-2020-tfx-20201102monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20201029monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-third-quarter-2020-results-tfx-20201029monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-acquire-market-leader-in-hemostatic-products-tfx-20201028monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-interventional-urology-expands-portfolio-with-introduction-of-the-urolift-advance-tfx-20201028monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-delivers-complete-confidence-with-the-new-arrow-ergopack-complete-cvc-system-tfx-20201027monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-third-quarter-2020-earnings-conference-call-information-tfx-20201019monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-named-one-of-america-s-best-in-state-employers-2020-by-forbes-tfx-20201008monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-expanded-indications-for-the-arrow-ez-io-intraosseous-vascular-access-s-tfx-20201001monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-morgan-stanley-18th-annual-global-healthcare-conference-tfx-20200902monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-wells-fargo-2020-virtual-healthcare-conference-tfx-20200826monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-publishes-2nd-annual-global-join-impact-report-tfx-20200818monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20200730monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-second-quarter-2020-results-tfx-20200730monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-200-000-patients-treated-with-urolift-system-for-enlarged-prostate-tfx-20200730monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-positive-data-emphasizing-the-effectiveness-of-the-urolift-system-treat-tfx-20200721monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-second-quarter-2020-earnings-conference-call-information-tfx-20200720monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-covid-19-humanitarian-product-donation-program-tfx-20200623monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-publication-of-early-patient-experience-data-highlighting-the-urolift-s-tfx-20200622monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-raymond-james-2020-human-health-innovation-conference-tfx-20200603monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-first-patient-enrollment-in-cto-pci-ide-study-tfx-20200602monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-incorporated-announces-pricing-of-500-million-senior-notes-offering-tfx-20200521monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-incorporated-announces-private-offering-of-500-million-of-senior-notes-due-2028-tfx-20200521monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-positive-data-showing-that-the-urolift-system-effectively-relieves-enla-tfx-20200518monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20200504monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-ubs-virtual-global-healthcare-conference-tfx-20200504monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-first-quarter-2020-results-tfx-20200430monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-awarded-central-venous-access-arterial-access-agreements-with-premier-tfx-20200429monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-bank-of-america-merrill-lynch-2020-health-care-conference-tfx-20200429monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-first-quarter-2020-earnings-conference-call-information-tfx-20200420monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-2020-annual-meeting-of-stockholders-to-be-held-in-virtual-only-format-tfx-20200417monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-celebrates-175-000-patients-treated-with-the-urolift-system-tfx-20200311monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-barclays-global-healthcare-conference-tfx-20200225monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20200220monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-fourth-quarter-and-full-year-2019-results-provides-2020-guidance-tfx-20200220monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-raymond-james-41st-annual-institutional-investors-conference-tfx-20200218monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-incorporated-announces-worldwide-voluntary-recall-of-comfort-flo-humidification-s-tfx-20200214monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-9th-annual-svb-leerink-global-healthcare-conference-tfx-20200213monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-fourth-quarter-and-full-year-2019-earnings-conference-call-information-tfx-20200206monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-receives-fda-clearance-for-wattson-temporary-pacing-guidewire-tfx-20200122monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-convenes-urologists-in-australia-for-summit-on-treating-benign-prostatic-hyperpla-tfx-20200114monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-fda-clearance-for-expanded-indication-of-the-urolift-system-for-treatme-tfx-20200107monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-tfx-20200102monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-goldman-sachs-12th-annual-healthcare-ceos-unscripted-a-view-fro-tfx-20191230monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-ranked-a-best-place-to-work-by-medreps-com-tfx-20191219monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-31st-annual-piper-jaffray-healthcare-conference-tfx-20191121monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-showcase-its-interventional-portfolio-highlighting-the-manta-vascular-closure--tfx-20191111monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-stephens-nashville-2019-investment-conference-tfx-20191104monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20191031monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-third-quarter-2019-results-tfx-20191031monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-third-quarter-2019-earnings-conference-call-information-tfx-20191017monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-incorporated-announces-worldwide-voluntary-recall-of-galemed-corporation-third-pa-tfx-20191007monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-tenth-anniversary-of-guideliner-catheter-product-line-tfx-20190925monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-urology-times-article-highlighting-the-urolift-system-as-providing-a-su-tfx-20190916monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-support-responding-to-cardiac-arrest-at-erc-congress-2019-in-ljubljana-sloveni-tfx-20190913monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-showcase-its-peripheral-intervention-product-portfolio-highlighting-the-arrow--tfx-20190830monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-morgan-stanley-17th-annual-global-healthcare-conference-tfx-20190828monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-wells-fargo-securities-2019-healthcare-conference-tfx-20190821monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-wins-new-zealand-innovation-award-for-urolift-system-for-patients-with-enlarged-p-tfx-20190807monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20190801monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-second-quarter-2019-results-tfx-20190801monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-publication-of-pivotal-clinical-study-to-evaluate-the-safety-and-effect-tfx-20190801monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-second-quarter-2019-earnings-conference-call-information-tfx-20190718monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-publication-of-a-large-real-world-study-confirming-results-from-control-tfx-20190709monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-expanded-nationwide-coverage-for-the-urolift-system-for-patients-with-e-tfx-20190626monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-incorporated-announces-worldwide-voluntary-recall-of-select-hudson-rci-sheridan-e-tfx-20190624monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-raymond-james-life-sciences-and-medtech-conference-tfx-20190605monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-40th-annual-goldman-sachs-global-healthcare-conference-tfx-20190529monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-participate-at-the-european-association-for-percutaneous-cardiovascular-interv-tfx-20190515monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-tfx-20190506monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-positive-results-from-five-studies-underscoring-the-effectiveness-and-v-tfx-20190506monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-first-quarter-2019-results-tfx-20190502monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-multiple-data-presentations-from-studies-of-the-urolift-system-treatmen-tfx-20190501monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-to-present-at-the-bank-of-america-merrill-lynch-2019-health-care-conference-tfx-20190430monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-first-quarter-2019-earnings-conference-call-information-tfx-20190418monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-publishes-inaugural-corporate-social-responsibility-csr-report-tfx-20190326monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-real-world-data-demonstrating-the-effectiveness-of-the-urolift-system-t-tfx-20190321monthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-incorporated-selects-widen-media-collective-to-manage-digital-media-distribution-tfx-20160517monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-announces-secondary-offering-of-common-stock-shc-20260511monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-announces-first-quarter-2026-earnings-release-date-shc-20260421monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-appoints-kenneth-d-krause-to-the-board-of-directors-shc-20260316monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-announces-secondary-offering-of-common-stock-shc-20260304monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-to-showcase-continued-revenue-growth-and-strategic-value-creation-at-44th-an-shc-20260112monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-announces-secondary-offering-of-common-stock-shc-20250903monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-announces-second-quarter-2025-earnings-release-date-shc-20250728monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-reports-first-quarter-2025-results-shc-20250501monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-announces-first-quarter-2025-earnings-release-date-shc-20250417monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-announces-fourth-quarter-and-full-year-2024-earnings-release-date-shc-20250218monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-shc-20250107monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-announces-dates-for-third-quarter-2024-earnings-release-and-november-2024-in-shc-20241022monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-announces-secondary-offering-of-common-stock-shc-20240904monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-appoints-christopher-simon-to-the-board-of-directors-shc-20240801monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-announces-second-quarter-2024-earnings-release-date-shc-20240722monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-announces-closing-of-1-5-billion-term-loan-b-and-750-million-senior-secured--shc-20240530monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-reports-first-quarter-2024-results-shc-20240502monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-announces-first-quarter-2024-earnings-release-date-shc-20240411monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-announces-pricing-of-secondary-offering-shc-20240228monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-announces-secondary-offering-of-common-stock-shc-20240227monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-announces-fourth-quarter-and-full-year-2023-earnings-release-date-shc-20240215monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-chairman-and-ceo-presents-at-42nd-annual-j-p-morgan-healthcare-conference-shc-20240109monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-shc-20240103monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-investigation-initiated-by-former-louisiana-attorney-general-kahn-swick-foti-shc-20230617monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-company-shc-stock-news-robbins-llp-is-investigating-the-officers-and-directo-shc-20230614monthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-r-shc-202303222023-03-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-company-nasdaq-shc-shareholder-class-action-alert-bernstein-liebhard-llp-rem-shc-202303202023-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-shc-202303152023-03-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-company-nasdaq-shc-shareholder-class-action-alert-bernstein-liebhard-llp-rem-shc-202303132023-03-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-r-shc-202303082023-03-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-company-nasdaq-shc-shareholder-class-action-alert-bernstein-liebhard-llp-rem-shc-202303062023-03-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-shc-202303012023-03-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-r-shc-202302222023-02-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-company-please-contact-the-portnoy-law-firm-to-recover-your-losses-march-27--shc-202302172023-02-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-company-shc-class-action-alert-robbins-llp-urges-shareholders-to-contact-the-shc-202302162023-02-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-shc-202302152023-02-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-company-nasdaq-shc-shareholder-class-action-alert-bernstein-liebhard-llp-rem-shc-202302142023-02-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-company-shc-class-action-alert-contact-robbins-llp-for-information-regarding-shc-202302102023-02-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-r-shc-202302082023-02-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-company-investor-alert-kaplan-fox-kilsheimer-llp-notifies-sotera-investors-o-shc-202302072023-02-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-company-nasdaq-shc-shareholder-class-action-alert-bernstein-liebhard-llp-rem-shc-202302072023-02-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-shc-202302012023-02-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-company-nasdaq-shc-shareholder-class-action-alert-bernstein-liebhard-llp-ann-shc-202301302023-01-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-company-please-contact-the-portnoy-law-firm-to-recover-your-losses-march-27--shc-202301262023-01-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-wireless-joins-npsf-patient-safety-coalition-shc-20150630monthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-upd-orka-20260513monthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-announces-positive-interim-phase-1-data-for-orka-002-and-initiation-of--orka-20260112monthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-orka-20260106monthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-announces-new-board-member-and-board-transition-orka-20251211monthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-up-orka-20250811monthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-reports-first-quarter-2025-financial-results-and-provides-corporate-upd-orka-20250514monthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-to-present-at-bank-of-america-securities-2025-health-care-conference-orka-20250429monthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-announces-preclinical-data-for-orka-002-at-the-2025-american-academy-of-orka-20250307monthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provide-orka-20250306monthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-to-present-at-multiple-march-investor-conferences-orka-20250219monthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-announces-first-participants-dosed-in-phase-1-trial-of-orka-001-its-nov-orka-20241219monthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-to-be-added-to-the-nasdaq-biotechnology-index-nbi-orka-20241218monthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-to-present-at-piper-sandler-s-36th-annual-healthcare-conference-orka-20241119monthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-upd-orka-20241113monthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-to-present-at-multiple-november-investor-conferences-orka-20241104monthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-announces-preclinical-data-for-orka-001-at-the-european-academy-of-derm-orka-20240925monthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-announces-accelerated-clinical-timelines-and-upcoming-presentation-at-e-orka-20240912monthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-announces-key-additions-to-leadership-team-and-board-of-directors-orka-20240626monthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-to-present-at-the-2024-jefferies-global-healthcare-conference-orka-20240529monthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-expands-leadership-team-with-appointment-of-industry-veterans-drs-josep-orka-20240522monthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-expands-leadership-team-naming-joana-goncalves-mbchb-as-chief-medical-o-orka-20240424monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-announces-full-study-population-interim-phase-4-elevate-pd-results-reinforcing-prev-amrx-20260605monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-announces-u-s-fda-approval-of-romidepsin-injection-solution-amrx-20260604monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-first-quarter-2026-financial-results-amrx-20260507monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-to-participate-in-upcoming-investor-conference-amrx-20260305monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-announces-fda-approval-of-denosumab-biosimilars-referencing-prolia-and-xgeva-amrx-20251222monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-receives-u-s-fda-approval-for-epinephrine-injection-in-single-and-multi-dose-vials--amrx-20251209monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-announces-positive-interim-phase-4-elevate-pd-results-with-crexont-for-parkinson-s--amrx-20251205monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-to-participate-in-upcoming-investor-conferences-amrx-20251202monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-receives-u-s-fda-approval-for-iohexol-injection-amrx-20251113monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-certain-preliminary-second-quarter-2025-financial-results-amrx-20250721monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-to-report-second-quarter-2025-results-on-august-5-2025-amrx-20250709monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-highlights-positive-topline-results-from-confirmatory-clinical-study-of-biosimilar--amrx-20250625monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-receives-u-s-fda-approval-for-prednisolone-acetate-ophthalmic-suspension-amrx-20250612monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-to-participate-at-upcoming-investor-conferences-in-june-amrx-20250529monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-receives-u-s-fda-approval-for-brekiya-dihydroergotamine-mesylate-injection-for-the--amrx-20250515monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-and-apiject-to-expand-sterile-and-blow-fill-seal-bfs-capabilities-for-advanced-phar-amrx-20250508monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-announces-complete-response-resubmission-for-ipx203-new-drug-application-amrx-20240208monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-investigation-notice-kaskela-law-llc-announces-shareholder-investigation-of-amneal--amrx-20231227monthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-pharmaceuticals-selects-stayinfront-mobile-cloud-crm-solution-amrx-20160216monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-systems-3dhd-receives-enthusiastic-response-at-the-12th-world-congress-of-endoscopi-vktx-20100420monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-systems-inc-gains-clearance-to-market-3-d-visualization-systems-in-australia-and-ne-vktx-20070104monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-presents-full-results-from-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyp-crnx-20260614monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-presents-long-term-data-at-endo-2026-confirming-palsonify-paltusotine-provides-d-crnx-20260614monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-and-leading-patient-groups-launch-everyday-advocacy-initiative-to-empower-people-crnx-20260602monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-busine-crnx-20260507monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-crnx-20260107monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-the-44th-annual-j-p-morgan-healthcare-conferen-crnx-20251218monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-announces-first-patient-dosed-in-pivotal-adult-trial-of-atumelnant-in-congenital-crnx-20251211monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-announces-first-patient-dosed-in-phase-1-2-trial-evaluating-crn09682-for-the-tre-crnx-20251203monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-announces-first-patient-randomized-in-pivotal-phase-3-carefndr-trial-evaluating--crnx-20251120monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-october-2025-inducement-grants-under-nasdaq-listing-ru-crnx-20251010monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-report-third-quarter-2025-financial-results-on-november-6-202-crnx-20251006monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-september-2025-inducement-grants-under-nasdaq-listing--crnx-20250910monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-august-2025-inducement-grants-under-nasdaq-listing-rul-crnx-20250811monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-to-present-new-long-term-data-demonstrating-durable-control-of-once-daily-oral-p-crnx-20250713monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-report-second-quarter-2025-financial-results-on-august-7-2025-crnx-20250711monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-july-2025-inducement-grants-under-nasdaq-listing-rule--crnx-20250710monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-host-r-d-day-on-june-26-2025-crnx-20250616monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-june-2025-inducement-grants-under-nasdaq-listing-rule--crnx-20250610monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference-202-crnx-20250523monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-to-present-new-research-on-paltusotine-atumelnant-and-unmet-needs-in-acromegaly--crnx-20250515monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-may-2025-inducement-grants-under-nasdaq-listing-rule-5-crnx-20250512monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-report-first-quarter-2025-financial-results-on-may-8-2025-crnx-20250411monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-april-2025-inducement-grants-under-nasdaq-listing-rule-crnx-20250410monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-european-medicines-agency-ema-validation-of-marketing--crnx-20250327monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-march-2025-inducement-grants-under-nasdaq-listing-rule-crnx-20250310monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-two-upcoming-march-investor-conferences-crnx-20250220monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-february-2025-inducement-grants-under-nasdaq-listing-r-crnx-20250210monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-report-fourth-quarter-and-full-year-2024-financial-results-on-crnx-20250206monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-january-2025-inducement-grants-under-nasdaq-listing-ru-crnx-20250110monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conferen-crnx-20250106monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-december-2024-inducement-grants-under-nasdaq-listing-r-crnx-20241211monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-three-upcoming-december-investor-conferences-crnx-20241115monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-showcase-pipeline-advancements-with-neuroendocrine-tumor-cand-crnx-20241112monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-november-2024-inducement-grants-under-nasdaq-listing-r-crnx-20241111monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-report-third-quarter-2024-financial-results-on-november-12-20-crnx-20241016monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-october-2024-inducement-grants-under-nasdaq-listing-ru-crnx-20241010monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-pricing-of-upsized-public-offering-of-common-stock-crnx-20241009monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-september-2024-inducement-grants-under-nasdaq-listing--crnx-20240910monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-crnx-20240829monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-august-2024-inducement-grants-under-nasdaq-listing-rul-crnx-20240812monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-launches-acro-truth-educational-initiative-to-raise-awareness-of-acromegaly-trea-crnx-20240808monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-report-second-quarter-2024-financial-results-on-august-8-2024-crnx-20240718monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-july-2024-inducement-grants-under-nasdaq-listing-rule--crnx-20240710monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-june-2024-inducement-grants-under-nasdaq-listing-rule--crnx-20240610monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-presents-new-data-at-endo-2024-that-increases-body-of-evidence-positioning-once--crnx-20240603monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-appoints-robert-m-cuddihy-m-d-as-senior-vice-president-of-medica-crnx-20240530monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-may-2024-inducement-grants-under-nasdaq-listing-rule-5-crnx-20240510monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-report-first-quarter-2024-financial-results-on-may-9-2024-crnx-20240502monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-april-2024-inducement-grants-under-nasdaq-listing-rule-crnx-20240411monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-march-2024-inducement-grants-under-nasdaq-listing-rule-crnx-20240311monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-report-fourth-quarter-and-full-year-2023-financial-results-on-crnx-20240214monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-february-2024-inducement-grants-under-nasdaq-listing-r-crnx-20240212monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-january-2024-inducement-grants-under-nasdaq-listing-ru-crnx-20240110monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-the-42nd-annual-j-p-morgan-healthcare-conferen-crnx-20240103monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-december-2023-inducement-grants-under-nasdaq-listing-r-crnx-20231211monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-upcoming-investor-conferences-crnx-20231120monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-november-2023-inducement-grants-under-nasdaq-listing-r-crnx-20231110monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-third-quarter-2023-financial-results-and-provides-corpor-crnx-20231107monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-crnx-20231010monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-the-cantor-global-healthcare-conference-2023-crnx-20230920monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-pricing-of-upsized-public-offering-of-common-stock-crnx-20230913monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-crnx-20230911monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-crnx-20230810monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-second-quarter-2023-financial-results-and-provides-corpo-crnx-20230808monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-hosting-key-opinion-leader-webinar-to-discuss-the-current-treatment-landscape-an-crnx-20230731monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-crnx-20230710monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-crnx-20230612monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-to-highlight-broad-pipeline-at-endo-2023-crnx-20230609monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-crnx-202305102023-05-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-first-quarter-2023-financial-results-and-provides-corpor-crnx-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-crnx-202304102023-04-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-crnx-202303102023-03-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-and--crnx-202302282023-02-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-crnx-202302102023-02-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-the-svb-securities-global-biopharma-conference-crnx-202302102023-02-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-crnx-202301102023-01-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-present-corporate-and-clinical-update-at-41st-annual-j-p-morg-crnx-202301092023-01-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-crnx-20221212monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-the-5th-annual-evercore-isi-healthconx-confere-crnx-20221122monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-third-quarter-2022-financial-results-and-provides-corpor-crnx-20221114monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-crnx-20221110monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-crnx-20221010monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-crnx-20220912monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-the-h-c-wainwright-24th-annual-global-investme-crnx-20220908monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-second-quarter-2022-financial-results-and-provides-corpo-crnx-20220812monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-crnx-20220810monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-crnx-20220712monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-crnx-20220610monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-presents-clinical-and-research-results-at-endo-2022-crnx-20220608monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-the-jmp-securities-life-sciences-conference-crnx-20220607monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-positive-top-line-results-including-strong-adrenal-suppr-crnx-20220525monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-crnx-20220510monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-closing-of-underwritten-common-stock-offering-crnx-20220418monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-pricing-of-underwritten-common-stock-offering-crnx-20220413monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-crnx-20220411monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-positive-top-line-results-from-crn04777-phase-1-study-mu-crnx-20220330monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-appoints-chris-robillard-as-chief-business-officer-crnx-20220321monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-crnx-20220310monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-and-sanwa-kagaku-kenkyusho-enter-into-exclusive-licensing-agreem-crnx-20220228monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-svb-leerink-global-healthcare-conference-crnx-20220209monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-crnx-20220201monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-present-corporate-and-clinical-update-at-40th-annual-j-p-morg-crnx-20220112monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-present-at-the-4th-annual-evercore-isi-healthconx-conference-crnx-20211118monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-presenting-new-data-from-open-label-extension-trial-of-paltusoti-crnx-20211108monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-closing-of-public-offering-of-common-stock-including-f-crnx-20211025monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-crnx-20211021monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-unveil-its-parathyroid-hormone-receptor-antagonist-program-at-crnx-20210927monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-oral-sst5-agonist-crn04777-demonstrated-pharmacologic-proof-of-c-crnx-20210915monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences-crnx-20210907monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-oral-acth-antagonist-crn04894-demonstrates-pharmacologic-proof-o-crnx-20210810monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-15-0-million-private-placement-with-frazier-healthcare-crnx-20210729monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-dosing-of-first-patient-in-phase-3-pathfndr-1-study-ev-crnx-20210628monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-appoints-garlan-adams-as-general-counsel-crnx-20210616monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-closing-of-common-stock-offering-crnx-20210412monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-host-webcast-and-conference-call-to-discuss-2021-clinical-pla-crnx-20210324monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-pipeline-progress-on-display-at-endo-2021-crnx-20210322monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-showcasing-breadth-of-pipeline-at-endo-2021-with-presentations-o-crnx-20210312monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-lead-acth-antagonist-for-congenital-adrenal-hyperplasia-and-cush-crnx-20210204monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-advances-crn04777-for-congenital-hyperinsulinism-into-phase-1-st-crnx-20210203monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-review-2020-accomplishments-and-provide-2021-plans-at-39th-an-crnx-20210106monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-december-investor-conferences-crnx-20201123monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-appoints-acromegaly-expert-peter-trainer-vice-president-of-clini-crnx-20201116monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-hosting-key-opinion-leader-meeting-focusing-on-oral-paltusotine-for-the-treatmen-crnx-20201113monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-phase-2-acrobat-edge-study-with-paltusotine-in-acromeg-crnx-20201026monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-receives-rare-pediatric-disease-designation-from-fda-for-crn0477-crnx-20200921monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-provides-new-data-from-paltusotine-and-acth-antagonist-developme-crnx-20200904monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences-crnx-20200903monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-receives-orphan-drug-designation-for-paltusotine-for-the-treatme-crnx-20200708monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-confirms-completion-for-half-of-the-enrolled-patients-in-the-ong-crnx-20200611monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-closing-of-public-offering-of-common-stock-including-f-crnx-20200417monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-crnx-20200415monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-reports-positive-interim-results-for-the-acrobat-edge-phase-2-tr-crnx-20200406monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-svb-leerink-global-healthcare-conference-crnx-20200219monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-present-at-j-p-morgan-healthcare-conference-crnx-20200108monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-the-piper-jaffray-healthcare-conference-crnx-20191126monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-cantor-global-healthcare-conference-crnx-20190925monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-present-at-h-c-wainwright-global-investment-conference-crnx-20190903monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-receive-final-award-of-sbir-grant-from-nih-for-congenital-hyp-crnx-20190729monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-initiates-phase-1-study-of-crn01941-for-the-treatment-of-neuroen-crnx-20190521monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-doses-first-patients-in-phase-2-clinical-trials-of-crn00808-for--crnx-20190319monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-appoints-gina-ford-rph-mba-as-vice-president-corporate-strategy--crnx-20190318monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-upcoming-presentations-at-endo2019-crnx-20190314monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-present-at-svb-leerink-global-healthcare-conference-crnx-20190221monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-present-at-j-p-morgan-healthcare-conference-crnx-20190102monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-participate-in-piper-jaffray-30th-annual-healthcare-conferenc-crnx-20181120monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-present-at-leerink-partners-roundtable-series-rare-disease-on-crnx-20180926monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-closing-of-initial-public-offering-and-exercise-in-ful-crnx-20180720monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-pricing-of-initial-public-offering-crnx-20180717monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-awarded-up-to-3-2-million-in-sbir-grants-for-congenital-hyperins-crnx-20180621monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-appoints-alan-krasner-m-d-as-chief-medical-officer-crnx-20180618monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-completes-63-5-million-series-b-financing-crnx-20180313monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-announces-upcoming-presentations-at-endo-2018-crnx-20180312monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-present-at-cowen-and-company-38th-annual-health-care-conferen-crnx-20180307monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-appoints-marc-wilson-as-chief-financial-officer-crnx-20180104monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-to-present-at-j-p-morgan-healthcare-conference-crnx-20180102monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-initiates-phase-1-study-of-lead-candidate-crn00808-for-acromegal-crnx-20171026monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-awarded-two-sbir-grants-to-develop-new-therapeutics-for-congenit-crnx-20170906monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-awarded-2-8-million-sbir-grant-to-support-development-of-acromeg-crnx-20170713monthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-appoints-anne-klibanski-m-d-to-scientific-advisory-board-crnx-20161110monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-inc-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-mor-smmt-20260504monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-inc-investigated-by-the-portnoy-law-firm-smmt-20250916monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-loss-smmt-20250909monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-inc-company-investigated-by-the-portnoy-law-firm-smmt-20250606monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-inc-investors-company-investigated-by-the-portnoy-law-firm-smmt-202302082023-02-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-investor-alert-kaskela-law-llc-announces-stockholder-investigation-of-summit-therap-smmt-202301232023-01-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-rehabilitation-opens-new-outpatient-physical-therapy-clinic-in-kirkland-smmt-20221108monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-ri-codify-trial-results-for-microbiome-sparing-ridinilazole-smmt-20221013monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-inc-reports-financial-results-and-operational-progress-for-the-second--smmt-20220811monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-commencement-of-100-million-rights-offering-smmt-20220718monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-provides-update-on-ridinilazole-smmt-20220714monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-100-million-rights-offering-smmt-20220622monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-upcoming-annual-shareholders-meeting-smmt-20220603monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-appoints-ankur-dhingra-as-chief-financial-officer-smmt-20220601monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-inc-reports-financial-results-and-operational-progress-for-the-first-q-smmt-20220511monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-inc-reports-financial-results-and-operational-progress-for-the-fourth--smmt-20220317monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-postponement-of-its-planned-rights-offering-smmt-20220209monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-rights-offering-smmt-20220125monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-today-presents-its-company-vision-at-40th-annual-j-p-morgan-healthcare-smmt-20220110monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-company-vision-at-40th-annual-j-p-morgan-healthcare-virtual-smmt-20220105monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-topline-results-for-phase-iii-ri-codify-study-for-c-difficil-smmt-20211220monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-inc-reports-financial-results-and-operational-progress-for-the-third-q-smmt-20211115monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-presents-further-breakthrough-insights-surrounding-the-novel-mechanism-smmt-20210930monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-presents-breakthrough-research-data-from-phase-ii-studies-including-ev-smmt-20210712monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-breakthrough-research-updates-at-the-31st-annual-eccmid-con-smmt-20210701monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-set-to-join-russell-3000-index-smmt-20210608monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-upcoming-annual-shareholders-meeting-smmt-20210603monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-preclinical-candidate-and-associated-carb-x-funding-support--smmt-20210518monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-financial-results-and-operational-progress-for-the-first-quart-smmt-20210517monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-closing-of-75-million-rights-offering-smmt-20210512monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-publishes-scientific-updates-to-corporate-website-smmt-20210506monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-rights-offering-nearing-expiration-date-robert-w-duggan-declares-inten-smmt-20210505monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-commencement-of-rights-offering-smmt-20210421monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-rights-offering-smmt-20210326monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-financial-results-and-operational-progress-for-the-fourth-quar-smmt-20210317monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-appoints-dr-mahkam-maky-zanganeh-as-chief-operating-officer-smmt-20201123monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-financial-results-and-operational-progress-for-the-third-quart-smmt-20201116monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-announces-closing-of-private-placement-of-50-million-smmt-20201106monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-announces-agreement-for-a-fundraising-of-approximately-50-million-smmt-20201002monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-financial-results-and-operational-progress-for-the-second-quar-smmt-20200929monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-announces-effectiveness-of-scheme-of-arrangement-and-completion-of-redomiciliation--smmt-20200918monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-u-k-court-approval-of-scheme-smmt-20200917monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-announces-results-of-court-meeting-and-general-meeting-smmt-20200819monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-announces-intention-to-redomicile-its-holding-company-to-the-united-states-smmt-20200716monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-announces-publication-of-phase-2-clinical-analyses-of-gut-microbiome-health-smmt-20200713monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-appoints-michael-donaldson-as-chief-financial-officer-smmt-20200608monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-financial-results-and-operational-progress-for-the-first-quart-smmt-20200602monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-financial-results-for-the-fourth-period-and-eleven-months-ende-smmt-20200430monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-appoints-robert-w-duggan-as-chief-executive-officer-smmt-20200414monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-appoints-robert-w-duggan-as-executive-chairman-smmt-20200226monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-receive-1-0-million-milestone-payment-from-eurofarma-smmt-20200206monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-at-the-2020-bio-ceo-investor-conference-smmt-20200204monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-announces-management-update-smmt-20200124monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-announces-barda-expands-ridinilazole-award-by-8-8-million-to-include-additional-nda-smmt-20200123monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-launches-online-resource-for-patients-with-c-difficile-infection-smmt-20200107monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-financial-results-and-operational-progress-for-the-third-quart-smmt-20191217monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-announces-a-proposed-subscription-and-placing-to-raise-approximately-50-0-million-a-smmt-20191206monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-participate-in-panel-sessions-at-the-world-antimicrobial-resistance-smmt-20191106monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-recognises-c-difficile-awareness-month-smmt-20191104monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-at-the-2019-bio-investor-forum-smmt-20191016monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-new-data-from-phase-2-clinical-trial-connecting-ridinilazole-s-smmt-20191007monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-ridinilazole-significantly-improved-short-and-longer-term-qual-smmt-20191003monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-host-r-d-day-7-october-2019-smmt-20190925monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-data-from-phase-2-clinical-trial-of-ridinilazole-at-id-week-smmt-20190924monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-announces-publication-of-editorial-in-future-microbiology-advocating-for-innovation-smmt-20190918monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-presented-in-vivo-proof-of-concept-data-for-targeted-enterobacteriaceae-antibiotics-smmt-20190905monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-participate-in-upcoming-investor-conferences-smmt-20190904monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-at-the-canaccord-genuity-growth-conference-smmt-20190801monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-highlighted-potential-of-smt-571-to-combat-the-rising-global-health-threat-of-gonor-smmt-20190717monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-s-dds-04-enterobacteriaceae-programme-demonstrates-in-vivo-efficacy-in-sepsis-and-p-smmt-20190709monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-to-present-on-pipeline-and-strategy-for-its-new-classes-of-antibiotics-at-asm-micro-smmt-20190620monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-financial-results-and-operational-progress-for-the-first-quart-smmt-20190612monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-presents-in-vivo-proof-of-concept-data-for-new-mechanism-antibiotics-targeting-ente-smmt-20190415monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-s-pipeline-expands-with-series-of-new-mechanism-antibiotics-targeting-enterobacteri-smmt-20190403monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-at-h-c-wainwright-co-global-life-sciences-conference-smmt-20190402monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-at-upcoming-conferences-smmt-20190318monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-highlights-use-of-discuva-platform-in-identifying-new-mechanism-antibiotics-against-smmt-20190314monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-s-smt-571-potent-against-over-200-clinical-isolates-of-neisseria-gonorrhoeae-includ-smmt-20190225monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-doses-first-patient-in-phase-3-clinical-trials-of-precision-antibiotic-ridinilazole-smmt-20190213monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-at-the-bio-ceo-investor-conference-smmt-20190208monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-departure-of-chief-financial-officer-smmt-20181217monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-report-financial-results-for-the-third-quarter-and-nine-months-ende-smmt-20181206monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-highlights-importance-of-innovation-in-fight-against-antibiotic-resistance-during-a-smmt-20181112monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-participate-in-jefferies-2018-london-healthcare-conference-smmt-20181107monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-recognises-c-difficile-awareness-month-smmt-20181101monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-participate-in-upcoming-investor-events-smmt-20181010monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-highlights-phase-3-ready-precision-antibiotic-ridinilazole-at-idweek-2018-smmt-20181003monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-to-highlight-potential-of-precision-antibiotic-ridinilazole-to-treat-c-difficile-in-smmt-20180926monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-reports-financial-results-for-the-second-quarter-ended-31-july-2018-and-operational-smmt-20180920monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-report-financial-results-for-the-second-quarter-and-half-year-ended-smmt-20180914monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-participate-in-upcoming-investor-conferences-smmt-20180914monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-discovers-multiple-new-mechanism-antibiotics-against-novel-eskape-pathogen-targets-smmt-20180906monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-nominates-new-mechanism-antibiotic-smt-571-as-its-lead-clinical-candidate-for-the-t-smmt-20180905monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-at-the-rodman-renshaw-20th-annual-global-investment-confere-smmt-20180829monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-awarded-additional-12-million-by-barda-for-ridinilazole-smmt-20180816monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-at-the-canaccord-genuity-growth-conference-smmt-20180806monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-director-pdmr-shareholding-smmt-20180719monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-director-pdmr-shareholding-smmt-20180717monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-awarded-up-to-4-5-million-grant-from-carb-x-for-development-of-new-mechanism-gonorr-smmt-20180710monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-holding-s-in-company-smmt-20180702monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-phaseout-dmd-did-not-meet-primary-endpoint-smmt-20180627monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-announces-phaseout-dmd-did-not-meet-primary-endpoint-smmt-20180627monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference-smmt-20180615monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-unveils-second-novel-target-for-gonorrhoea-at-asm-microbe-2018-smmt-20180611monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-unveils-second-novel-target-for-gonorrhoea-at-asm-microbe-2018-smmt-20180611monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-result-of-agm-smmt-20180607monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-1st-quarter-results-smmt-20180605monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-financial-results-for-the-first-quarter-ended-30-april-2018-an-smmt-20180605monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-notice-of-1st-quarter-results-smmt-20180601monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-provides-notice-of-financial-results-for-the-first-quarter-ended-30-ap-smmt-20180601monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-notice-of-agm-smmt-20180503monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-holding-s-in-company-smmt-20180502monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-total-voting-rights-smmt-20180501monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-director-pdmr-shareholding-smmt-20180423monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-highlights-discovery-of-new-mechanism-antibiotics-for-the-treatment-of-gonorrhoea-a-smmt-20180423monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-highlights-discovery-of-a-series-of-new-mechanism-antibiotics-for-the-treatment-of--smmt-20180423monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-grant-of-share-options-and-rsus-smmt-20180423monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-presents-new-24-week-analyses-from-phaseout-dmd-at-the-2018-aan-conference-smmt-20180420monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-completes-dosing-of-ezutromid-in-phaseout-dmd-clinical-trial-smmt-20180419monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-files-us-annual-report-on-form-20f-smmt-20180413monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-financial-results-for-the-fiscal-year-ended-31-january-2018-smmt-20180411monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-total-voting-rights-smmt-20180411monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-director-pdmr-shareholding-smmt-20180410monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-provides-notice-of-financial-results-for-the-fourth-quarter-and-fiscal-smmt-20180409monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-notice-of-results-smmt-20180409monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-block-listing-interim-review-smmt-20180406monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference-smmt-20180405monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-holding-s-in-company-smmt-20180405monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-selected-for-emerging-science-presentation-at-the-2018-aan-annual-meet-smmt-20180328monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-the-results-of-placing-and-issue-of-equity-smmt-20180327monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-a-proposed-placing-to-raise-up-to-15-million-smmt-20180327monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-highlights-scientific-rigour-of-its-phaseout-dmd-clinical-trial-at-mda-clinical-con-smmt-20180314monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-s-infectious-diseases-technology-platform-yields-novel-antibiotics-with-potential-i-smmt-20180313monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-expands-enrolment-in-phase-2-clinical-trial-to-include-planned-additional-group-smmt-20180307monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-expands-enrolment-in-phaseout-dmd-phase-2-clinical-trial-to-include-planned-additio-smmt-20180307monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-research-update-smmt-20180226monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-announces-new-analysis-showing-ezutromid-significantly-reduced-muscle-inflammation--smmt-20180226monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-participate-in-2018-btig-healthcare-conference-smmt-20180223monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-participate-in-upcoming-investor-conferences-smmt-20180209monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-interim-24-week-data-from-phaseout-dmd-smmt-20180125monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-at-the-biotech-showcase-smmt-20180109monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-obtains-innovative-antibiotic-discovery-and-development-platform-through-acquisitio-smmt-20171223monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-enters-licence-and-commercialisation-agreement-with-eurofarma-for-latin-american-ri-smmt-20171221monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-enters-into-licence-and-commercialisation-agreement-with-eurofarma-for-latin-americ-smmt-20171221monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-3rd-quarter-results-smmt-20171206monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-financial-results-for-the-third-quarter-and-nine-months-ended--smmt-20171206monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-santhera-catabasis-and-duchenne-uk-to-host-dmd-awareness-day-smmt-20171206monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-notice-of-third-quarter-results-smmt-20171204monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-report-financial-results-for-the-third-quarter-and-nine-months-ende-smmt-20171204monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-participate-in-upcoming-investor-conferences-smmt-20171122monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-completes-initial-24-weeks-of-dosing-of-ezutromid-in-patients-with-dmd-in-phaseout--smmt-20171120monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-miscellaneous-smmt-20171116monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-highlights-utrophin-modulation-as-a-potential-universal-treatment-option-in-dmd-at--smmt-20171109monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-announces-signing-of-revenue-sharing-agreement-with-the-wellcome-trust-for-cdi-anti-smmt-20171106monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-revenue-sharing-agreement-with-wellcome-trust-smmt-20171106monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-grant-of-share-options-smmt-20171025monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-block-listing-application-smmt-20171023monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-holding-s-in-company-smmt-20171013monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-highlights-microbiome-preservation-during-ridinilazole-treatment-at-id-week-2017-smmt-20171009monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-exercise-of-options-smmt-20171005monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-highlights-dmd-biomarker-validation-data-at-22nd-wms-congress-smmt-20171004monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-highlights-dmd-biomarker-validation-data-and-phase-2-clinical-trial-baseline-charac-smmt-20171004monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-exercise-of-options-smmt-20171003monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-host-r-d-day-11-october-2017-smmt-20171002monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-exercise-of-share-options-smmt-20170929monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-joins-ctap-in-effort-to-enhance-development-of-utrophin-modulators-and-other-treatm-smmt-20170925monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-joins-ctap-in-collaborative-effort-to-enhance-the-development-of-utrophin-modulator-smmt-20170925monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-holding-s-in-company-smmt-20170921monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-closing-of-its-ads-public-offering-raising-usd20-1m-before-e-smmt-20170918monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-exercise-of-underwriters-over-allotment-option-smmt-20170915monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-announces-underwritten-public-offering-of-1-459-000-adss-to-raise-usd17-5-million-b-smmt-20170914monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-pricing-of-public-offering-of-1-459-000-american-depositary--smmt-20170914monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-proposed-public-offering-of-15-0-million-of-american-deposit-smmt-20170913monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-awarded-barda-contract-worth-up-to-62m-to-support-development-of-ridin-smmt-20170911monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-awarded-barda-contract-worth-up-to-62-million-to-support-the-development-of-ridinil-smmt-20170911monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-positive-top-line-phase-2-results-smmt-20170905monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-announces-positive-top-line-data-from-an-exploratory-phase-2-clinical-trial-support-smmt-20170905monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-half-yearly-report-smmt-20170831monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-financial-results-for-the-second-quarter-and-half-year-ended-3-smmt-20170831monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-notice-of-results-smmt-20170825monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-report-financial-results-for-the-second-quarter-and-half-year-ended-smmt-20170825monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-at-the-canaccord-genuity-growth-conference-smmt-20170803monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-total-voting-rights-smmt-20170731monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-grant-of-share-options-and-restricted-stock-units-smmt-20170719monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-result-of-agm-smmt-20170718monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-exercise-of-share-options-smmt-20170628monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-grant-of-share-options-smmt-20170628monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-presents-data-from-phase-1-clinical-programme-of-ezutromid-at-the-epns-congress-smmt-20170622monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-participate-in-jmp-securities-life-sciences-conference-smmt-20170615monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-1st-quarter-results-smmt-20170614monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-financial-results-for-the-first-quarter-ended-30-april-2017-an-smmt-20170614monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-notice-of-results-smmt-20170613monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-report-financial-results-for-the-first-quarter-ended-30-april-2017--smmt-20170613monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-presents-positive-new-preclinical-data-on-novel-cdi-antibiotic-ridinilazole-at-asm--smmt-20170605monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-announces-key-appointments-to-strengthen-research-development-team-smmt-20170523monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-completes-enrolment-of-phaseout-dmd-a-phase-2-clinical-trial-of-ezutromid-in-patien-smmt-20170515monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-phase-2-codify-trial-results-published-in-lancet-infectious-diseas-smmt-20170502monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-notice-of-agm-smmt-20170425monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-grant-of-share-options-smmt-20170412monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-exercise-of-options-smmt-20170410monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-file-us-annual-report-on-form-20-f-smmt-20170331monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-change-of-registered-office-smmt-20170330monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-at-the-needham-healthcare-conference-smmt-20170330monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-4th-quarter-and-year-end-financial-results-and-operational-pro-smmt-20170329monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-smmt-20170329monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-to-extend-ongoing-phaseout-dmd-clinical-trial-of-ezutromid-in-patients-with-dmd-smmt-20170327monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-notice-of-results-smmt-20170327monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-provides-notice-of-financial-results-for-the-fourth-quarter-and-fiscal-smmt-20170327monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-at-the-oppenheimer-27th-annual-healthcare-conference-smmt-20170315monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-recognises-tenth-annual-rare-disease-day-smmt-20170228monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-recognises-10th-annual-rare-disease-day-smmt-20170228monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-exercise-of-warrants-smmt-20170223monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-participate-in-february-investor-conferences-smmt-20170202monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-outline-phase-3-programme-for-novel-cdi-antibiotic-ridinilazole-smmt-20170201monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-outlines-phase-3-programme-for-novel-cdi-antibiotic-ridinilazole-following-fda-and--smmt-20170201monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-holding-s-in-company-smmt-20170125monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-exercise-of-options-smmt-20170119monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-appoints-dr-david-roblin-as-chief-operating-officer-and-president-of-research-devel-smmt-20170118monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-chiropractic-offers-chiropractic-treatment-for-victims-of-car-accidents-smmt-20170115monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-3rd-quarter-results-smmt-20161215monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-financial-results-for-the-third-quarter-ended-31-october-2016--smmt-20161215monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-notice-of-results-smmt-20161213monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-report-financial-results-for-the-third-quarter-ended-31-october-201-smmt-20161213monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-enrolls-patients-in-the-us-into-phaseout-dmd-a-phase-2-clinical-trial-of-ezutromid-smmt-20161116monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-enrols-patients-in-the-united-states-into-phaseout-dmd-a-phase-2-clinical-trial-of--smmt-20161116monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-exercise-of-options-smmt-20161024monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-holding-s-in-company-smmt-20161019monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-exercise-of-options-smmt-20161014monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-exercise-of-options-smmt-20161011monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-exercise-of-options-smmt-20161007monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-presents-preclinical-dmd-data-at-21st-congress-of-world-muscle-society-smmt-20161006monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-presents-preclinical-dmd-data-at-the-21st-international-congress-of-th-smmt-20161006monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-files-form-6-k-on-licensing-and-collaboration-agreement-with-sarepta-and-updated-ca-smmt-20161004monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-to-host-conference-call-to-discuss-exclusive-license-and-collaboration-agreement-wi-smmt-20161004monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-holding-s-in-company-smmt-20160928monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-received-rare-pediatric-disease-designation-from-us-fda-for-ezutromid-in-treatment--smmt-20160927monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-receives-rare-pediatric-disease-designation-from-us-fda-for-ezutromid-in-treatment--smmt-20160927monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-receives-fast-track-designation-from-us-fda-for-ezutromid-in-the-treatment-of-dmd-smmt-20160926monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-launches-online-resource-on-utrophin-modulation-for-the-duchenne-muscular-dystrophy-smmt-20160912monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-half-yearly-report-smmt-20160908monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-financial-results-for-the-second-quarter-ended-31-july-2016-an-smmt-20160908monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-at-18th-annual-rodman-renshaw-global-investment-conference-smmt-20160907monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-notice-of-results-smmt-20160905monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-report-financial-results-for-the-second-quarter-ended-31-july-2016--smmt-20160905monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-reports-positive-phase-1-data-and-outlines-route-to-market-strategy-for-dmd-candida-smmt-20160809monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-reports-positive-phase-1-new-formulation-data-and-outlines-route-to-market-strategy-smmt-20160809monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-at-canaccord-genuity-growth-conference-smmt-20160805monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-result-of-agm-smmt-20160718monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-exercise-of-options-smmt-20160628monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-award-of-options-smmt-20160624monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-s-ridinilazole-preserves-microbiome-during-treatment-of-c-difficile-infection-smmt-20160621monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-notice-of-agm-smmt-20160617monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-at-jmp-securities-life-sciences-conference-smmt-20160616monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-host-utrophin-r-d-day-15-june-2016-smmt-20160608monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-1st-quarter-results-smmt-20160602monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-financial-results-for-the-first-quarter-ended-30-april-2016-an-smmt-20160602monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-notice-of-results-smmt-20160531monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-report-financial-results-for-the-first-quarter-ended-30-april-2016--smmt-20160531monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-to-present-phase-2-codify-trial-data-at-asm-microbe-2016-smmt-20160523monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-to-present-phase-2-codify-trial-data-highlighting-ridinilazole-s-preservation-of-th-smmt-20160523monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-file-us-annual-report-on-form-20-f-smmt-20160512monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-financial-results-for-q4-and-fiscal-year-ended-31-january-2016-smmt-20160510monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-notice-of-results-smmt-20160506monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-provides-notice-of-financial-results-for-the-fourth-quarter-and-fiscal-smmt-20160506monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-announces-further-us-patent-granted-for-cdi-antibiotic-ridinilazole-smmt-20160428monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-s-ind-cleared-by-fda-allowing-expansion-of-phaseout-dmd-a-phase-2-clinical-trial-of-smmt-20160426monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-exercise-of-warrants-smmt-20160414monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-holding-s-in-company-smmt-20160411monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-at-15th-annual-needham-healthcare-conference-smmt-20160406monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-reports-positive-interim-data-from-phase-1-testing-a-new-formulation-of-smt-c1100-i-smmt-20160330monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-reports-positive-interim-data-from-ongoing-phase-1-clinical-trial-testing-a-new-for-smmt-20160330monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-to-present-additional-data-from-phase-2-codify-trial-for-the-treatment-of-c-diffici-smmt-20160329monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-shareholder-notifications-smmt-20160322monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-announces-publication-on-biomarkers-to-quantify-utrophin-and-regeneration-of-muscle-smmt-20160315monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-announce-ridinilazole-preserves-the-gut-microbiome-of-patients-with-c-difficile-inf-smmt-20160307monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-announces-ridinilazole-preserves-the-gut-microbiome-of-patients-with-c-difficile-in-smmt-20160307monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-supports-ninth-annual-rare-disease-day-smmt-20160229monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-publication-of-preclinical-data-showing-ridinilazole-outperf-smmt-20160224monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-participate-in-suntrust-robinson-humphrey-s-2016-orphan-drug-day-smmt-20160217monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-at-bio-ceo-investor-conference-smmt-20160203monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-at-18th-annual-bio-ceo-investor-conference-smmt-20160203monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-receives-regulatory-approval-to-initiate-phaseout-dmd-a-phase-2-clinic-smmt-20160121monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-granted-key-european-patent-for-novel-c-difficile-antibiotic-ridinilaz-smmt-20160119monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-financial-results-for-the-third-quarter-ended-31-october-2015-smmt-20151217monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-report-third-quarter-2015-financial-results-smmt-20151214monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-report-financial-results-for-the-third-quarter-ended-31-october-201-smmt-20151214monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-participate-in-the-jmp-securities-dmd-forum-smmt-20151210monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-at-the-26th-annual-oppenheimer-healthcare-conference-smmt-20151203monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-achieve-first-milestone-in-strategic-alliance-with-oxford-university-smmt-20151202monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-first-milestone-achieved-in-strategic-alliance-with-universi-smmt-20151202monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-holding-s-in-company-smmt-20151130monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-at-the-piper-jaffray-healthcare-conference-smmt-20151125monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-positive-phase-2-results-of-ridinilazole-for-treatment-of-c--smmt-20151123monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-novel-antibiotic-ridinilazole-smt19969-achieves-statistical--smmt-20151123monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-director-declaration-smmt-20151120monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-and-the-university-of-oxford-announce-multi-year-extension-of-strategi-smmt-20151117monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-award-of-share-options-smmt-20151015monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-presents-additional-data-from-phase-1b-modfied-diet-clinical-trial-of--smmt-20150930monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-phase-1b-clinical-and-preclinical-dmd-data-at-wms-congress--smmt-20150924monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-presents-new-positive-preclinical-data-on-c-difficile-antibiotic-smt19-smmt-20150918monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-completes-targeted-enrolment-for-smt19969-phase-2-trial-for-c-difficil-smmt-20150910monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-award-of-options-smmt-20150904monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-appoints-ralf-rosskamp-md-as-chief-medical-officer-smmt-20150902monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-financial-results-for-second-quarter-and-half-year-ended-31-ju-smmt-20150827monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-notice-of-results-smmt-20150824monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-report-second-quarter-2015-financial-results-on-27-august-2015-smmt-20150824monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-phase-1b-modified-diet-clinical-trial-achieves-primary-objec-smmt-20150817monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-exercise-of-options-smmt-20150730monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-result-of-agm-smmt-20150729monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-result-of-agm-smmt-20150714monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-annual-general-meeting-statement-smmt-20150714monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-agm-statement-smmt-20150714monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-publishes-preclinical-data-on-disease-modifying-potential-of-utrophin--smmt-20150713monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-receives-fast-track-designation-for-novel-antibiotic-smt19969-for-cdi-smmt-20150708monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-receives-fda-fast-track-designation-for-novel-antibiotic-smt19969-in-t-smmt-20150708monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-granted-key-patent-by-european-patent-office-for-utrophin-modulator-sm-smmt-20150707monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-exercise-of-share-options-smmt-20150702monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-exercise-of-options-smmt-20150622monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-director-pdmr-shareholding-smmt-20150622monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-new-preclinical-data-on-utrophin-modulator-programme-at-ppm-smmt-20150619monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-director-pdmr-shareholding-smmt-20150618monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-exercise-of-options-smmt-20150617monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-award-of-share-options-smmt-20150617monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-holding-s-in-company-smmt-20150617monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-present-at-jmp-securities-life-sciences-conference-smmt-20150615monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-to-present-at-jmp-securities-life-sciences-conference-smmt-20150615monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-1st-quarter-results-smmt-20150611monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-first-quarter-results-for-the-three-months-ended-30-april-2015-smmt-20150611monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-notice-of-results-smmt-20150605monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-to-report-first-quarter-2015-financial-results-on-11-june-2015-smmt-20150605monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-notice-of-agm-smmt-20150601monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-holding-s-in-company-smmt-20150522monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-exercise-of-options-smmt-20150513monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-files-us-annual-report-form-20f-smmt-20150508monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-reports-financial-results-for-the-fiscal-year-ended-31-january-2015-smmt-20150506monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-notice-of-results-smmt-20150501monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-provides-notice-of-full-year-financial-results-smmt-20150501monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-granted-key-patent-for-novel-c-difficile-antibiotic-smt19969-smmt-20150430monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-granted-key-patent-for-novel-antibiotic-smt19969-for-the-treatment-of--smmt-20150430monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-to-present-at-needham-company-s-annual-healthcare-conference-smmt-20150407monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-to-present-at-needham-and-company-s-annual-healthcare-conference-smmt-20150407monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-holding-s-in-company-smmt-20150327monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-exercise-of-options-smmt-20150324monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-exercise-of-over-allotment-option-smmt-20150318monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-holding-s-in-company-smmt-20150317monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-holding-s-in-company-smmt-20150312monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-the-closing-of-its-us-initial-public-offering-smmt-20150310monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-nasdaq-smmt-to-ring-the-nasdaq-stock-market-closing-bell-smmt-20150305monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-announces-pricing-of-us-initial-public-offering-and-nasdaq-listing-smmt-20150305monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-files-amended-registration-statement-for-nasdaq-listing-and-us-offerin-smmt-20150223monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-appoints-mr-david-wurzer-as-a-non-executive-director-smmt-20150223monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-plc-holding-s-in-company-smmt-20150220monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-announces-first-patients-dosed-in-phase-1b-modified-diet-clinical-trial-of-smt-c110-smmt-20150220monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-result-of-general-meeting-smmt-20150219monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-notice-of-general-meeting-smmt-20150203monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-files-registration-statement-for-nasdaq-listing-and-us-offering-of-adss-smmt-20150202monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-third-quarter-results-for-nine-months-ended-31-october-2014-smmt-20150202monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-award-of-options-smmt-20150123monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-share-option-award-smmt-20141224monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-considering-potential-us-registered-public-offering-and-stock-exchange-listing-smmt-20141219monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-receives-regulatory-approval-to-initiate-a-modified-diet-clinical-trial-of-smt-c110-smmt-20141211monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-to-present-company-overview-at-the-oppenheimer-annual-healthcare-conference-smmt-20141205monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-directorate-change-smmt-20141203monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-exercise-of-options-smmt-20141029monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-reports-positive-data-on-it-utrophin-modulation-programme-for-the-treatment-of-dmd--smmt-20141008monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-appoints-valerie-andrews-as-a-non-executive-director-smmt-20140919monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-presents-new-positive-preclinical-data-on-smt19969-for-c-difficile-at-icaac-2014-smmt-20140908monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-half-yearly-report-smmt-20140904monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-holding-s-in-company-smmt-20140902monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-notice-of-results-smmt-20140901monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-to-present-at-the-canaccord-genuity-34th-annual-growth-conference-smmt-20140807monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-update-on-capital-reorganisation-timetable-smmt-20140718monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-award-of-share-options-smmt-20140716monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-presents-new-data-from-phase-1b-clinical-trial-of-smt-c1100-for-treatment-of-dmd-smmt-20140707monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-holding-s-in-company-smmt-20140704monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-total-voting-rights-smmt-20140704monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-result-of-agm-smmt-20140703monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-release-agm-statement-smmt-20140703monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-announces-first-patients-dosed-in-a-phase-2-clinical-trial-of-novel-c-difficile-ant-smmt-20140703monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-share-option-awards-smmt-20140624monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-appoints-erik-ostrowski-as-chief-financial-officer-smmt-20140623monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-to-present-company-overview-at-jmp-securities-healthcare-conference-smmt-20140619monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-establishes-us-office-and-strengthens-its-drug-development-team-smmt-20140617monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-holding-s-in-company-smmt-20140605monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-notice-of-agm-and-proposed-capital-reorganisation-smmt-20140603monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-appoints-leopoldo-zambeletti-as-a-non-executive-director-smmt-20140530monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-report-preliminary-results-from-phase-1b-clinical-trial-of-smt-c1100-for-dmd-smmt-20140521monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-presents-new-positive-non-clinical-efficacy-data-at-eccmid-smmt-20140512monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-preliminary-results-smmt-20140430monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-notice-of-preliminary-results-smmt-20140428monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-holding-s-in-company-smmt-20140416monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-holding-s-in-company-smmt-20140324monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-receive-fda-clearance-of-ind-application-for-phase-2-study-of-smt19969-to-treat-cdi-smmt-20140318monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-holding-s-in-company-smmt-20140310monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-holding-s-in-company-smmt-20140307monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-completion-of-the-second-placing-smmt-20140304monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-change-of-adviser-smmt-20140304monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-completion-of-first-placing-smmt-20140303monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-result-of-general-meeting-smmt-20140228monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-presentation-at-cowen-co-34th-annual-healthcare-conference-smmt-20140226monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-result-of-offer-for-subscription-to-qualifying-shareholders-smmt-20140226monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-circular-and-notice-of-general-meeting-smmt-20140213monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-issue-of-equity-smmt-20140211monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-director-disclosure-update-smmt-20140127monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-award-of-share-options-smmt-20131219monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-holding-s-in-company-smmt-20131212monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-announces-first-patient-dosed-in-a-phase-1b-clinical-trial-of-smt-c1100-for-treatme-smmt-20131209monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-holding-s-in-company-smmt-20131204monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-total-voting-rights-smmt-20131202monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-and-the-university-of-oxford-enter-strategic-alliance-to-develop-treatments-for-dmd-smmt-20131125monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-and-joining-jack-enter-funding-agreement-to-develop-novel-biomarkers-for-dmd-smmt-20131105monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-receives-regulatory-approval-to-start-phase-1b-of-smt-c1100-in-dmd-patients-smmt-20131101monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-holding-s-in-company-smmt-20131016monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-to-present-clinical-and-biomarker-programmes-for-dmd-at-wms-congress-smmt-20130930monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-change-of-nomad-smmt-20130926monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-present-new-data-on-c-difficile-antibiotic-smt19969-at-icaac-2013-smmt-20130911monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-to-present-new-data-on-c-difficile-antibiotic-at-icaac-2013-smmt-20130904monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-granted-key-composition-of-matter-patent-for-smt-c1100-in-the-treatment-of-dmd-smmt-20130828monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-exercise-of-warrants-smmt-20130823monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-interim-financial-results-smmt-20130822monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-notice-of-interim-results-smmt-20130821monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-granted-us-patent-for-utrophin-modulator-smt-c1100-in-treatment-of-dmd-smmt-20130807monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-to-present-at-wedbush-securities-life-science-conference-smmt-20130806monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-awarded-2-4m-from-the-uk-biomedical-catalyst-fund-smmt-20130731monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-director-shareholding-smmt-20130726monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-holding-s-in-company-smmt-20130725monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-total-voting-rights-smmt-20130723monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-enter-aud-1-25m-funding-agreement-with-save-our-sons-to-support-dmd-programme-smmt-20130718monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-to-present-at-jmp-securities-healthcare-conference-smmt-20130701monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-achieves-clinical-milestone-triggering-740-000-payment-from-wellcome-trust-smmt-20130617monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-appoints-dr-david-roblin-as-chief-medical-officer-smmt-20130612monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-notice-of-agm-smmt-20130507monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-research-update-smmt-20130417monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-preliminary-results-smmt-20130411monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-notice-of-preliminary-results-smmt-20130409monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-research-update-smmt-20130321monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-new-data-reported-from-oga-inhibitor-programme-smmt-20130311monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-directorate-change-smmt-20130301monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-research-update-smmt-20130213monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-utrophin-biomarker-collaboration-for-dmd-programme-entered-smmt-20130206monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-award-of-share-options-smmt-20130201monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-nomura-code-appointed-nomad-and-joint-broker-smmt-20130125monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-award-of-share-options-smmt-20121227monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-summit-appoints-mr-jim-mellon-and-dr-frank-armstrong-as-non-executi-smmt-20121122monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-adviser-change-of-name-smmt-20121120monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-summit-to-present-at-proactive-investors-one2one-investor-forum-smmt-20121114monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-repeat-dosing-of-smt-c1100-for-treatment-of-dmd-meets-endpoints-in--smmt-20121107monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-initiation-of-phase-1-clinical-trial-of-antibiotic-to-treat-c-diffi-smmt-20121031monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-4-0-million-award-from-wellcome-trust-to-support-c-difficile-antibi-smmt-20121022monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-launch-of-new-corporate-website-smmt-20121015monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-research-update-smmt-20120925monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-technology-license-agreement-signed-wth-bristol-myers-squibb-smmt-20120911monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-interim-results-smmt-20120906monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-corporate-strategy-update-smmt-20120906monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-notice-of-results-smmt-20120904monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-notification-of-grant-award-from-uk-technology-strategy-board-smmt-20120802monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-result-of-agm-smmt-20120718monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-agm-statement-smmt-20120718monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-new-data-presented-on-oga-inhibition-at-alzheimer-s-association-int-smmt-20120717monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-presentation-at-international-muscular-dystrophy-conference-smmt-20120629monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-director-pdmr-shareholding-smmt-20120614monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-summit-achieves-smt-c1100-phase-1-dosing-milestone-that-triggers-mi-smmt-20120612monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-notice-of-agm-smmt-20120601monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-summit-announces-initiation-of-phase-1-trial-for-the-treatment-of-d-smmt-20120525monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-holding-s-in-company-amendment-smmt-20120427monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-holding-s-in-company-smmt-20120426monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-smt-c1100-receives-regulatory-approval-to-enter-phase-i-clinical-tr-smmt-20120424monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-application-to-trading-smmt-20120423monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-result-of-general-meeting-smmt-20120420monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-director-pdmr-shareholding-smmt-20120405monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-posting-to-shareholders-the-circular-and-notice-of-general-meeting-smmt-20120405monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-preliminary-results-for-the-year-ended-31-january-2012-smmt-20120404monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-proposed-placing-of-new-ordinary-shares-to-raise-5-0m-smmt-20120404monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-directorate-change-appointment-of-glyn-edwards-as-ceo-smmt-20120404monthly0.5https://www.biopharmawatch.com/news/SMMT/summit-corporation-plc-research-update-on-alzheimer-s-disease-programme-smmt-20120306monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-data-presentations-at-the-2026-european-congress-of-e-rytm-20260512monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-report-third-quarter-2025-financial-results-on-tuesday-november--rytm-20251021monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-three-late-breaking-data-abstracts-accepted-for-presentat-rytm-20250625monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-rytm-20250506monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-report-first-quarter-2025-financial-results-on-wednesday-may-7-2-rytm-20250423monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-and-raymond-a-wood-foundation-announce-research-collaboration-rytm-20250318monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-report-fourth-quarter-and-full-year-2024-financial-results-on-we-rytm-20250213monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-oppenheimer-annual-healthcare-life-sciences-conferenc-rytm-20250205monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-imcivree-setmelanotide-receives-expanded-marketing-author-rytm-20241203monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-five-presentations-at-espe-2024-including-new-real-world--rytm-20241118monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20241113monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-rytm-20241106monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-and-axovia-therapeutics-announce-joint-research-collaboration-in-ba-rytm-20241024monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-report-third-quarter-2024-financial-results-on-tuesday-november--rytm-20241023monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20241008monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20240916monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-wells-fargo-healthcare-conference-in-september-rytm-20240826monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20240813monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-report-second-quarter-2024-financial-results-on-tuesday-august-6-rytm-20240723monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20240711monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-receives-positive-chmp-opinion-for-imcivree-setmelanotide-for-the-t-rytm-20240628monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20240611monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-participation-at-upcoming-investor-conference-rytm-20240603monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-receives-positive-recommendation-from-nice-for-imcivree-setmelanoti-rytm-20240522monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20240509monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-presents-data-from-phase-3-pediatrics-trial-at-pediatric-endocrine--rytm-20240506monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-report-first-quarter-2024-financial-results-on-tuesday-may-7-202-rytm-20240424monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20240416monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20240311monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-participation-at-upcoming-investor-conferences-rytm-20240306monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-clinical-development-plan-of-setmelanotide-for-hypothalam-rytm-20240222monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20240208monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-positive-reimbursement-decision-in-italy-for-imcivree-set-rytm-20240207monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-report-fourth-quarter-and-full-year-2023-financial-results-on-th-rytm-20240131monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20240112monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-and-lg-chem-life-sciences-enter-agreement-for-rhythm-to-acquire-glo-rytm-20240104monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-completion-of-screening-for-enrollment-in-setmelanotide-p-rytm-20240104monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20231215monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-sponsors-second-annual-international-meeting-on-pathway-related-obe-rytm-20231213monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-updates-on-mc4r-pathway-programs-at-r-d-event-rytm-20231206monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20231113monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-receives-positive-cadth-reimbursement-recommendation-for-imcivree-s-rytm-20231102monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-report-third-quarter-2023-financial-results-on-tuesday-november--rytm-20231025monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20231013monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-presents-new-data-at-espe-2023-rytm-20230922monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-receives-orphan-drug-designation-from-european-medicines-agency-for-rytm-20230919monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20230908monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-update-to-september-conference-participation-rytm-20230908monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-icd-10-diagnosis-code-established-for-bardet-biedl-sy-rytm-20230906monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-investor-conferences-in-september-rytm-20230828monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-pre-marketing-early-access-authorization-for-setmelanotid-rytm-20230807monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20230804monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-two-publications-detailing-burden-of-hyperphagia-and-obes-rytm-20230719monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-report-second-quarter-2023-financial-results-on-tuesday-august-1-rytm-20230717monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20230713monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-goldman-sachs-44th-annual-global-healthcare-conferenc-rytm-20230607monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20230606monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-202305052023-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-commercial-launch-of-imcivree-setmelanotide-in-germany-fo-rytm-202304242023-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-tuesday-may-2-202-rytm-202304182023-04-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-202304062023-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-publication-of-bardet-biedl-syndrome-patient-and-caregive-rytm-202303272023-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-202303062023-03-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-acquisition-of-xinvento-b-v-and-portfolio-of-investigatio-rytm-202302272023-02-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-report-fourth-quarter-and-full-year-2022-financial-results-on-we-rytm-202302212023-02-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-202302082023-02-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-publication-of-analysis-of-quality-of-life-improvements-f-rytm-202301232023-01-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-202301052023-01-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20221207monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-bofa-securities-2022-virtual-biotech-smid-cap-confere-rytm-20221201monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-publication-of-results-from-phase-3-clinical-trial-of-imc-rytm-20221108monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20221107monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-11-presentations-at-the-obesity-society-s-annual-meeting--rytm-20221103monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-setmelanotide-granted-breakthrough-therapy-designation-fo-rytm-20221101monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-full-data-from-phase-2-clinical-trial-evaluating-setmela-rytm-20221025monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-convenes-inaugural-international-meeting-on-pathway-related-obesity-rytm-20221012monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-appoints-dana-washburn-m-d-as-senior-vice-president-of-clinical-dev-rytm-20221006monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20221006monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-publication-of-children-s-book-for-patients-and-families--rytm-20220923monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-inc-announces-closing-of-124-8-million-public-offering-rytm-20220919monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-presents-new-disease-burden-findings-and-analyses-of-setmelanotide--rytm-20220919monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-inc-announces-pricing-of-public-offering-rytm-20220915monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20220907monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-imcivree-setmelanotide-granted-marketing-authorization-by-rytm-20220906monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-investor-conferences-in-september-rytm-20220901monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20220808monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-canaccord-genuity-42nd-annual-growth-conference-rytm-20220803monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-report-second-quarter-2022-financial-results-on-tuesday-august-2-rytm-20220728monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-receives-positive-chmp-opinion-for-imcivree-setmelanotide-for-the-t-rytm-20220722monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-early-access-authorization-for-setmelanotide-for-use-in-p-rytm-20220720monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20220708monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-that-european-commission-authorized-variation-for-imcivre-rytm-20220622monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-enters-into-a-non-dilutive-revenue-interest-financing-agreement-wit-rytm-20220616monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-presents-new-data-from-long-term-extension-trial-evaluating-setmela-rytm-20220613monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-presents-initial-data-from-long-term-extension-trial-evaluating-set-rytm-20220613monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20220602monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20220505monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-bofa-securities-2022-healthcare-conference-rytm-20220504monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-presents-new-data-from-phase-3-trial-evaluating-setmelanotide-in-pa-rytm-20220502monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-report-first-quarter-2022-financial-results-on-tuesday-may-3-202-rytm-20220426monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-employment-inducement-grants-rytm-20220408monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-optimizes-design-of-emanate-and-daybreak-clinical-trials-to-advance-rytm-20220406monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-promotions-within-its-executive-leadership-team-rytm-20220223monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-report-fourth-quarter-and-full-year-2021-financial-results-on-tu-rytm-20220222monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-positive-interim-data-from-long-term-extension-study-of-s-rytm-20220216monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-host-virtual-bardet-biedl-syndrome-bbs-event-on-february-16-rytm-20220208monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-and-rarestone-ltd-announce-exclusive-licensing-agreement-for-the-de-rytm-20211206monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-stifel-2021-virtual-healthcare-conference-rytm-20211109monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-report-third-quarter-2021-financial-results-on-tuesday-november--rytm-20211020monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-presents-new-data-on-experience-of-people-living-with-rare-genetic--rytm-20211014monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-presents-new-data-from-phase-2-and-3-trials-evaluating-setmelanotid-rytm-20210922monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-completes-submission-of-supplemental-new-drug-application-to-u-s-fo-rytm-20210920monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-expanded-access-program-for-setmelanotide-for-patients-wi-rytm-20210908monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-cmo-transition-rytm-20210902monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-morgan-stanley-19th-annual-global-healthcare-conferen-rytm-20210902monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-the-59th-annual-espe-meeting-rytm-20210812monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-2021-canaccord-genuity-41st-annual-growth-conference-rytm-20210805monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-senior-leadership-additions-rytm-20210729monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-collaborative-research-agreement-with-clinical-registry-i-rytm-20210728monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-report-second-quarter-2021-financial-results-on-tuesday-august-3-rytm-20210727monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-and-medison-pharma-partner-to-commercialize-imcivree-setmelanotide--rytm-20210722monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-jefferies-virtual-healthcare-conference-rytm-20210527monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-receives-positive-chmp-opinion-for-setmelanotide-for-treatment-of-o-rytm-20210521monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-bofa-securities-2021-virtual-health-care-conference-rytm-20210505monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-20th-annual-needham-virtual-healthcare-conference-rytm-20210407monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-presents-new-data-from-phase-2-basket-study-showing-continued-weigh-rytm-20210320monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-cowen-co-41st-annual-health-care-conference-rytm-20210224monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-inc-announces-closing-of-172-5-million-public-offering-including-fu-rytm-20210210monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-inc-announces-proposed-public-offering-rytm-20210203monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-provide-update-on-phase-2-basket-study-and-genetic-sequencing-ef-rytm-20210119monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-sale-of-priority-review-voucher-for-100m-rytm-20210105monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-publication-of-results-from-phase-3-clinical-trials-of-se-rytm-20201030monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-appoints-jennifer-chien-as-executive-vice-president-head-of-north-a-rytm-20201028monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-appoints-yann-mazabraud-as-executive-vice-president-head-of-interna-rytm-20200914monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-investor-conferences-in-september-rytm-20200909monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-virtually-at-canaccord-genuity-40th-annual-growth-confer-rytm-20200806monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-appointment-of-joseph-shulman-as-senior-vice-president-of-rytm-20200727monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-publication-of-results-from-phase-2-study-of-setmelanotid-rytm-20200716monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-submission-of-marketing-authorization-application-to-the--rytm-20200701monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-positive-results-from-phase-2-study-of-once-weekly-formul-rytm-20200624monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-virtually-at-upcoming-investor-conference-in-june-rytm-20200526monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-virtually-at-2020-bofa-securities-health-care-conference-rytm-20200505monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-first-quarter-2020-financial-results-rytm-20200504monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-virtually-at-needham-co-19th-annual-healthcare-conferenc-rytm-20200407monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-provides-updates-on-leadership-transition-and-business-operations-rytm-20200330monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-cowen-co-40th-annual-health-care-conference-rytm-20200225monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-stifel-2019-healthcare-conference-rytm-20191113monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-inc-announces-closing-of-public-offering-and-full-exercise-of-the-u-rytm-20191018monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-upcoming-investor-conferences-in-september-rytm-20190903monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-positive-topline-results-from-pivotal-phase-3-clinical-tr-rytm-20190807monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-launches-free-genetic-testing-program-for-rare-genetic-disorders-of-rytm-20190717monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-election-of-jennifer-good-to-its-board-of-directors-rytm-20190619monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-jefferies-2019-healthcare-conference-rytm-20190530monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-bank-of-america-merrill-lynch-2019-health-care-confer-rytm-20190507monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-18th-annual-needham-healthcare-conference-rytm-20190402monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-cowen-co-39th-annual-health-care-conference-rytm-20190304monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-host-key-opinion-leader-symposium-on-mc4r-pathway-and-patient-ex-rytm-20181206monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-stifel-2018-healthcare-conference-rytm-20181107monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-appoints-murray-w-stewart-m-d-as-chief-medical-officer-rytm-20181015monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-launch-of-tempo-registry-for-rare-genetic-disorders-of-ob-rytm-20180928monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-ladenburg-thalmann-2018-healthcare-conference-rytm-20180925monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-morgan-stanley-16th-annual-global-healthcare-conferen-rytm-20180907monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-receives-european-medicines-agency-prime-designation-for-setmelanot-rytm-20180723monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-inc-announces-closing-of-public-offering-and-full-exercise-of-the-u-rytm-20180625monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-inc-announces-pricing-of-public-offering-rytm-20180621monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-inc-announces-proposed-public-offering-rytm-20180618monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-topline-clinical-data-from-ongoing-phase-2-basket-stu-rytm-20180618monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-completes-pivotal-enrollment-in-two-ongoing-phase-3-clinical-trials-rytm-20180614monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-the-jefferies-2018-healthcare-conference-rytm-20180601monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-the-bank-of-america-merrill-lynch-2018-health-care-co-rytm-20180509monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-nature-medicine-publication-of-longer-term-data-from-phas-rytm-20180509monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-upcoming-investor-conferences-in-march-rytm-20180307monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-progress-in-clinical-development-of-setmelanotide-for-tre-rytm-20180104monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-third-quarter-2017-financial-results-rytm-20171114monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-inc-nasdaq-rytm-to-ring-the-nasdaq-stock-market-closing-bell-rytm-20171113monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-announces-preliminary-data-from-phase-2-study-of-setmelanotide-for-treatment-of-bar-rytm-20171031monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-tvtx-20250213monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20250212monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-submit-snda-for-filspari-sparsentan-in-fsgs-tvtx-20250211monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-upcoming-investor-conferences-tvtx-20241125monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20241113monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-completion-of-public-offering-of-common-stock-and-exercise--tvtx-20241112monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-pricing-of-public-offering-of-common-stock-tvtx-20241108monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-upcoming-investor-conferences-tvtx-20241104monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-third-quarter-2024-financial-results-tvtx-20241031monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-presents-data-reinforcing-clinical-benefit-of-filspari-sparsentan-in--tvtx-20241026monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-report-third-quarter-2024-financial-results-tvtx-20241021monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-and-csl-vifor-announce-swissmedic-approval-of-filspari-sparsentan-for-tvtx-20241017monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-abstracts-at-american-society-of-nephrology-asn-kidney-wee-tvtx-20241014monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-voluntary-pause-of-enrollment-in-the-phase-3-harmony-study--tvtx-20240926monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20240912monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-the-2024-cantor-global-healthcare-conference-tvtx-20240910monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-full-fda-approval-of-filspari-sparsentan-the-only-non-immun-tvtx-20240905monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-abstracts-at-the-society-for-the-study-of-inborn-errors-of-tvtx-20240822monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-upcoming-investor-conferences-tvtx-20240806monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-second-quarter-2024-financial-results-tvtx-20240801monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-report-second-quarter-2024-financial-results-tvtx-20240725monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-kidney-virtual-conference-tvtx-20240708monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20240611monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20240515monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-national-kidney-foundation-spring-clinical-meetings-and-tvtx-20240509monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-upcoming-investor-conferences-tvtx-20240508monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-first-quarter-2024-financial-results-tvtx-20240506monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-report-first-quarter-2024-financial-results-tvtx-20240429monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-and-csl-vifor-announce-european-commission-approves-filspari-sparsent-tvtx-20240424monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-abstracts-at-the-society-for-inherited-metabolic-disorders-tvtx-20240404monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-abstracts-on-filspari-sparsentan-in-iga-nephropathy-at-wor-tvtx-20240403monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20240313monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-submits-supplemental-new-drug-application-to-the-u-s-food-and-drug-ad-tvtx-20240311monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-upcoming-investor-conferences-tvtx-20240226monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-and-csl-vifor-announce-sparsentan-receives-positive-chmp-opinion-for--tvtx-20240223monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-tvtx-20240215monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-tvtx-20240208monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-the-guggenheim-6th-annual-biotechnology-conference-tvtx-20240201monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-licensing-agreement-with-renalys-pharma-to-develop-and-comm-tvtx-20240125monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-provides-corporate-update-and-2024-outlook-tvtx-20240108monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-tvtx-20240102monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-initiates-pivotal-phase-3-clinical-trial-of-pegtibatinase-for-the-tre-tvtx-20231214monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-completes-successful-pre-nda-meeting-for-filspari-in-igan-provides-regulatory-upda-tvtx-20231204monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-the-6th-annual-evercore-isi-healthconx-conference-tvtx-20231121monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-third-quarter-2023-financial-results-tvtx-20231107monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-late-breaking-data-from-phase-3-studies-of-sparsentan-in-ig-tvtx-20231103monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-report-third-quarter-2023-financial-results-tvtx-20231024monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-abstracts-at-the-american-society-of-nephrology-asn-kidney-tvtx-20231013monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20231011monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-abstracts-at-the-17th-international-symposium-on-iga-nephr-tvtx-20230926monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-confirmatory-data-from-the-phase-3-protect-study-of-filspar-tvtx-20230921monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20230911monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-joins-american-kidney-fund-s-2023-corporate-membership-program-at-cha-tvtx-20230908monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-completes-sale-of-bile-acid-product-portfolio-to-mirum-pharmaceutical-tvtx-20230905monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-the-2023-wells-fargo-healthcare-conference-tvtx-20230831monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-abstracts-at-the-society-for-the-study-of-inborn-errors-of-tvtx-20230824monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20230814monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-second-quarter-2023-financial-results-tvtx-20230803monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-report-second-quarter-2023-financial-results-tvtx-20230720monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-enters-agreement-to-sell-its-bile-acid-product-portfolio-for-the-trea-tvtx-20230717monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20230711monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20230614monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-presentations-of-abstracts-at-the-60th-european-renal-assoc-tvtx-20230608monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-upcoming-investor-conferences-tvtx-20230601monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-positive-topline-results-from-cohort-6-in-the-phase-1-2-com-tvtx-20230531monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-202305112023-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-first-quarter-2023-financial-results-tvtx-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-topline-results-from-two-year-primary-efficacy-endpoint-in--tvtx-202305012023-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-report-first-quarter-2023-financial-results-tvtx-202304262023-04-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-202304132023-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-interim-analysis-from-the-phase-3-protect-study-of-filspari-tvtx-202304012023-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-upcoming-investor-conferences-tvtx-202303282023-03-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-late-breaker-presentations-of-the-interim-analysis-from-the-tvtx-202303232023-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-202303142023-03-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-abstracts-at-the-society-for-inherited-metabolic-disorders-tvtx-202303142023-03-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-completion-of-public-offering-of-common-stock-and-pre-funde-tvtx-202303032023-03-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-pricing-of-public-offering-of-common-stock-and-pre-funded-w-tvtx-202303012023-03-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-tvtx-202302232023-02-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-fda-accelerated-approval-of-filspari-sparsentan-the-first-a-tvtx-202302172023-02-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-tvtx-202302162023-02-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-202302132023-02-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-upcoming-investor-conferences-tvtx-202302082023-02-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-202301132023-01-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-provides-corporate-update-and-2023-outlook-tvtx-202301092023-01-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-tvtx-202301032023-01-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20221214monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20221116monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-the-iga-nephropathy-foundation-and-nephcure-kidney-international-part-tvtx-20221115monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-upcoming-investor-conferences-tvtx-20221109monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-third-quarter-2022-financial-results-tvtx-20221027monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-presentations-and-posters-at-american-society-of-nephrology-tvtx-20221026monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-report-third-quarter-2022-financial-results-tvtx-20221020monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-provides-regulatory-update-on-its-sparsentan-program-for-iga-nephropa-tvtx-20221013monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20221011monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20220914monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-abstracts-at-the-society-for-the-study-of-inborn-errors-of-tvtx-20220825monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-and-csl-vifor-announce-ema-has-accepted-for-review-the-conditional-ma-tvtx-20220822monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20220811monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-second-quarter-2022-financial-results-tvtx-20220804monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-provides-regulatory-updates-on-its-development-programs-tvtx-20220803monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-report-second-quarter-2022-financial-results-tvtx-20220728monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20220712monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20220614monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-the-2022-jefferies-healthcare-conference-tvtx-20220602monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-presentations-of-abstracts-at-the-59th-era-congress-tvtx-20220517monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-fda-acceptance-and-priority-review-of-new-drug-application--tvtx-20220516monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20220511monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-first-quarter-2022-financial-results-tvtx-20220505monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-the-bofa-securities-2022-healthcare-conference-tvtx-20220503monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-report-first-quarter-2022-financial-results-tvtx-20220428monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-plan-for-chief-financial-officer-transition-tvtx-20220420monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20220412monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-abstracts-at-the-society-for-inherited-metabolic-disorders-tvtx-20220406monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-submits-new-drug-application-for-sparsentan-for-the-treatment-of-iga--tvtx-20220321monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20220314monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-prices-upsized-275-million-convertible-senior-notes-offering-tvtx-20220309monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-the-barclays-global-healthcare-conference-tvtx-20220303monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-recognizes-rare-disease-day-2022-and-raises-awareness-for-people-livi-tvtx-20220228monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-tvtx-20220224monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20220214monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-report-fourth-quarter-and-full-year-2021-financial-results-tvtx-20220210monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-the-11th-annual-svb-leerink-global-healthcare-conferenc-tvtx-20220209monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20220112monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-provides-corporate-update-and-2022-outlook-tvtx-20220110monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-appoints-jula-inrig-m-d-as-chief-medical-officer-tvtx-20220104monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-positive-topline-results-from-the-ongoing-phase-1-2-compose-tvtx-20211215monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20211214monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-upcoming-investor-conferences-tvtx-20211111monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-abstracts-at-american-society-of-nephrology-kidney-week-20-tvtx-20211102monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-third-quarter-2021-financial-results-and-organizational-progr-tvtx-20211028monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-report-third-quarter-2021-financial-results-tvtx-20211014monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20211013monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-transition-of-chief-medical-officer-tvtx-20211012monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-and-vifor-pharma-announce-licensing-agreement-for-the-commercializati-tvtx-20210915monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-appoints-ruth-williams-brinkley-to-its-board-of-directors-tvtx-20210914monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20210913monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-successful-outcome-from-type-a-meeting-with-u-s-fda-for-spa-tvtx-20210907monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-positive-topline-interim-results-from-the-ongoing-phase-3-p-tvtx-20210816monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-second-quarter-2021-financial-results-tvtx-20210729monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-report-second-quarter-2021-financial-results-tvtx-20210722monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tvtx-20210714monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-presentation-of-abstracts-at-era-edta-congress-2021-tvtx-20210604monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-completes-enrollment-in-pivotal-phase-3-protect-study-of-sparsentan-i-tvtx-20210602monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-upcoming-investor-conferences-tvtx-20210527monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-provides-regulatory-update-on-sparsentan-development-program-for-foca-tvtx-20210525monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-first-quarter-2021-financial-results-tvtx-20210506monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-the-bofa-securities-2021-virtual-health-care-conference-tvtx-20210427monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-report-first-quarter-2021-financial-results-tvtx-20210426monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-tvtx-20210301monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-recognizes-rare-disease-day-2021-and-the-importance-of-working-togeth-tvtx-20210225monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-present-at-upcoming-investor-conferences-tvtx-20210222monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-european-commission-has-granted-orphan-designation-to-spars-tvtx-20210218monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-completion-of-public-offering-of-common-stock-and-exercise--tvtx-20210217monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-tvtx-20210216monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-pricing-of-public-offering-of-common-stock-tvtx-20210212monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-proposed-public-offering-of-common-stock-tvtx-20210210monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-achievement-of-interim-proteinuria-endpoint-in-the-ongoing--tvtx-20210202monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-orphan-drug-designation-for-sparsentan-for-the-treatment-of-tvtx-20210112monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-provides-corporate-update-and-2021-outlook-tvtx-20210111monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-to-host-virtual-r-d-day-on-wednesday-december-9-2020-tvtx-20201201monthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-announces-completion-of-patient-enrollment-in-pivotal-phase-3-duplex--tvtx-20201130monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-s-salanersen-receives-fda-breakthrough-therapy-designation-for-spinal-muscular-atro-biib-20260604monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-inc-biib-investors-with-losses-are-urged-to-contact-the-gross-law-firm-to-discuss-t-biib-20260529monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-new-late-breaking-litifilimab-phase-2-amethyst-data-in-cutaneous-lupus-e-biib-20260319monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-presents-additional-salanersen-data-showing-new-motor-milestones-achieved-in-childr-biib-20260311monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-completes-acquisition-of-alcyone-therapeutics-biib-20251114monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-acquire-alcyone-therapeutics-expanding-drug-delivery-solution-portfolio-for-key--biib-20250918monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-receives-european-commission-approval-for-zurzuvae-zuranolone-the-first-and-only-tr-biib-20250917monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-stoke-therapeutics-present-data-at-the-36th-international-epilepsy-congress-tha-biib-20250902monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-alert-bragar-eagel-squire-p-c-is-investigating-biogen-inc-on-behalf-of-long-term-st-biib-20250813monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-stoke-therapeutics-announce-first-patient-dosed-in-phase-3-emperor-study-of-zor-biib-20250811monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-highlight-scientific-progress-across-alzheimer-s-disease-at-the-alzheimer-s-asso-biib-20250721monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-2-billion-manufacturing-investment-in-north-carolina-s-research-triangle--biib-20250721monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-stoke-therapeutics-announce-presentation-of-data-from-studies-of-zorevunersen-a-biib-20250710monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-city-therapeutics-announce-strategic-research-collaboration-to-develop-select-n-biib-20250527monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-stoke-therapeutics-enter-into-collaboration-to-develop-and-commercialize-zorevu-biib-20250218monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-alert-bragar-eagel-squire-p-c-is-investigating-biogen-inc-on-behalf-of-long-term-st-biib-20241030monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-new-data-at-the-clinical-trials-on-alzheimer-s-disease-ctad-2024-annual--biib-20241024monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-late-breaker-and-new-data-presentations-at-american-society-of-nephrology-biib-20241022monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-board-appoints-two-new-independent-directors-biib-20240912monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-positive-topline-results-from-study-of-higher-dose-regimen-of-nusinersen--biib-20240904monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-beckman-coulter-and-fujirebio-to-collaborate-on-blood-based-biomarkers-and-test-for-biib-20240730monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-alert-bragar-eagel-squire-p-c-is-investigating-biogen-inc-on-behalf-of-long-term-st-biib-20240726monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-inc-nasdaq-biib-shareholder-alert-only-7-days-remain-for-investors-to-move-for-lead-biib-20240715monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-inc-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-portnoy-law-fir-biib-20240709monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-inc-nasdaq-biib-deadline-alert-bernstein-liebhard-llp-reminds-biogen-inc-investors--biib-20240708monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-completes-acquisition-of-human-immunology-biosciences-biib-20240702monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-inc-nasdaq-biib-deadline-alert-bernstein-liebhard-llp-reminds-biogen-inc-investors--biib-20240701monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-inc-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-portnoy-law-fir-biib-20240629monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-inc-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-portnoy-law-fir-biib-20240624monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-inc-nasdaq-biib-deadline-alert-bernstein-liebhard-llp-reminds-biogen-inc-investors--biib-20240624monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm--biib-20240618monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-inc-nasdaq-biib-investor-alert-bernstein-liebhard-llp-announces-that-a-securities-c-biib-20240617monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-stock-notice-lose-money-on-your-biogen-inc-nasdaq-biib-investment-bfa-law-encourage-biib-20240615monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-legal-deadline-if-you-lost-money-on-your-biogen-inc-nasdaq-biib-investment-you-are--biib-20240613monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-notice-if-you-suffered-losses-on-your-biogen-inc-nasdaq-biib-investment-you-are-rem-biib-20240611monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-inc-nasdaq-biib-investor-alert-bernstein-liebhard-llp-announces-that-a-securities-c-biib-20240610monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-inc-investor-alert-kessler-topaz-meltzer-check-llp-urges-biib-investors-with-losses-biib-20240610monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-case-deadline-biogen-inc-nasdaq-biib-investors-are-reminded-of-upcoming-july-2024-l-biib-20240608monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-inc-nasdaq-biib-investor-alert-bernstein-liebhard-llp-announces-that-a-securities-c-biib-20240604monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-50-day-notice-investors-of-biogen-inc-nasdaq-biib-are-encouraged-to-contact-bfa-law-biib-20240603monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-inc-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-portnoy-law-fir-biib-20240603monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-delta-flight-products-to-collaborate-with-advocates-and-patients-to-inform-the--biib-20240603monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-bee-biib-20240602monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for--biib-20240531monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-inc-nasdaq-biib-investors-notice-class-action-lawsuit-filed-on-behalf-of-investors--biib-20240529monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-alert-bfa-law-announces-biogen-inc-nasdaq-biib-sued-for-securities-fraud-after-sign-biib-20240529monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-bee-biib-20240529monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-inc-nasdaq-biib-deadline-alert-bernstein-liebhard-llp-reminds-biogen-inc-investors--biib-20240528monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed--biib-20240525monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-inc-nasdaq-biib-investor-alert-bernstein-liebhard-llp-announces-that-a-securities-c-biib-20240524monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-bolsters-late-stage-pipeline-expands-immunology-portfolio-with-agreement-to-acquire-biib-20240522monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-ionis-announce-topline-phase-1-2-study-results-of-investigational-drug-in-amyot-biib-20240516monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-receives-positive-chmp-opinion-for-tofidence-tocilizumab-a-biosimilar-referencing-r-biib-20240425monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-highlights-new-data-at-the-international-conference-on-alzheimer-s-and-parkinson-s--biib-20240304monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-alert-bragar-eagel-squire-p-c-is-investigating-biogen-inc-on-behalf-of-biogen-stock-biib-20240224monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-realign-resources-for-alzheimer-s-disease-franchise-biib-20240131monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-appoints-monish-patolawala-to-its-board-of-directors-biib-20231106monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-new-data-at-the-clinical-trials-on-alzheimer-s-disease-ctad-2023-meeting-biib-20231019monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-appoints-jane-grogan-as-head-of-research-biib-20230906monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-appoints-adam-keeney-as-head-of-corporate-development-biib-202304042023-04-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-receives-favorable-decision-from-court-of-justice-of-the-european-union-relating-to-biib-202303162023-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-names-priya-singhal-as-executive-vice-president-head-of-development-biib-202301052023-01-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-alcyone-therapeutics-announce-license-and-collaboration-agreement-to-evaluate-a-biib-202301042023-01-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-data-at-ectrims-2022-highlight-innovation-in-digital-health-focused-on-advancing-tr-biib-20221026monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-fda-s-3-month-extension-of-review-period-for-the-new-drug-application-for-biib-20221017monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announced-ema-filing-acceptance-of-biib800-a-biosimilar-candidate-referencing-roact-biib-20220930monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-alectos-therapeutics-announce-license-and-collaboration-agreement-for-al01811-a-biib-20220606monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-bio-thera-solutions-present-positive-phase-3-data-for-tocilizumab-biosimilar-ca-biib-20220603monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-deadline-alert-faruqi-faruqi-securities-litigation-partner-james-josh-wilson-encour-biib-20220219monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-that-a-sec-biib-20220218monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-xbrane-announce-commercialization-and-license-agreement-for-proposed-biosimilar-biib-20220207monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-sets-industry-record-with-recognition-on-dow-jones-sustainability-world-index-for-9-biib-20211115monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-r-d-day-to-provide-overview-of-diversified-pipeline-and-capabilities-with-potential-biib-20210921monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-topline-results-from-phase-3-gene-therapy-study-in-choroideremia-biib-20210614monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-investor-day-on-september-21-2021-biib-20210610monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-bio-thera-announce-positive-results-from-phase-3-study-of-bat1806-a-proposed-bi-biib-20210601monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-ginkgo-bioworks-announce-collaboration-and-license-agreement-to-develop-novel-g-biib-20210521monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-exercise-of-option-to-acquire-the-investigational-drug-tms-007-for-acute--biib-20210512monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-grows-presence-in-china-with-the-approval-of-tecfidera-dimethyl-fumarate-for-the-tr-biib-20210415monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-bio-thera-solutions-announce-commercialization-and-license-agreement-for-propos-biib-20210408monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-labcentral-award-two-golden-tickets-to-local-and-innovative-science-startups-biib-20210211monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-the-pricing-terms-of-its-cash-tender-offer-biib-20210210monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-cash-tender-offer-for-5-200-senior-notes-due-2045-open-to-certain-holders-biib-20210204monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed--biib-20201114monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-alert-bragar-eagel-squire-p-c-is-investigating-biogen-inc-on-behalf-of-biogen-stock-biib-20201113monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-positive-phase-2-systemic-lupus-erythematosus-data-at-american-college-o-biib-20201103monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-plans-to-initiate-phase-4-study-evaluating-benefit-of-spinraza-nusinersen-in-patien-biib-20200721monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-prices-3-0-billion-of-senior-unsecured-notes-biib-20200427monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-releases-2019-corporate-responsibility-report-demonstrating-continuous-progress-acr-biib-20200420monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-positive-phase-2-study-results-for-cutaneous-lupus-erythematosus-cle-and--biib-20191203monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-enrollment-completion-of-global-phase-3-gene-therapy-study-for-an-inherit-biib-20191121monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-host-investor-webcasts-from-clinical-trials-on-alzheimer-s-disease-ctad-congress-biib-20191104monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-alkermes-announce-fda-approval-of-vumerity-diroximel-fumarate-for-multiple-scle-biib-20191030monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-ranked-1-biotechnology-company-on-dow-jones-sustainability-world-index-biib-20190917monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-invitae-announce-availability-of-rapid-results-in-genetic-testing-program-for-s-biib-20190820monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-european-label-update-for-spinraza-nusinersen-which-includes-longer-term--biib-20190629monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-continues-to-advance-innovation-in-sma-with-new-data-in-adults-and-infants-to-be-pr-biib-20190412monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-eisai-to-discontinue-phase-3-engage-and-emerge-trials-of-aducanumab-in-alzheime-biib-20190321monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-responds-to-cadth-s-updated-recommendation-regarding-coverage-for-spinraza-biib-20190302monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-c4-therapeutics-enter-into-strategic-collaboration-to-discover-and-develop-pote-biib-20190104monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-applauds-quebec-decision-to-cover-spinraza-nusinersen-for-a-broad-population-of-sma-biib-20181220monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-exercises-option-with-ionis-to-develop-and-commercialize-investigational-treatment--biib-20181206monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-eisai-report-data-from-long-term-extension-phase-1b-study-of-investigational-al-biib-20180828monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-host-investor-webcast-to-discuss-alzheimer-s-disease-portfolio-on-july-25-2018-biib-20180720monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-second-quarter-2018-financial-results-on-july-24-2018-biib-20180625monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-host-investor-webcast-on-its-efforts-targeting-stroke-on-june-28-2018-biib-20180619monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-foundation-selects-grantees-to-receive-10-million-investment-for-stem-education-biib-20180618monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-exercises-option-to-enter-into-exclusive-worldwide-license-agreement-for-factor-ix--biib-20170105monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-inc-shareholder-alert-kessler-topaz-meltzer-check-llp-announces-shareholder-class-a-biib-20151007monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-sobi-announce-european-medicines-agency-validates-alprolix-rfixfc-marketing-aut-biib-20150626monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-inc-nasdaq-biib-to-ring-the-nasdaq-stock-market-opening-bell-biib-20150507monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-sobi-announce-positive-top-line-efficacy-and-safety-results-from-phase-3-a-biib-20150227monthly0.5https://www.biopharmawatch.com/news/BIIB/biogenic-reagents-highlights-success-of-recently-patented-product-biib-20150129monthly0.5https://www.biopharmawatch.com/news/BIIB/biogenic-reagents-and-west-fraser-enter-agreement-to-develop-renewable-biocarbon-products-biib-20140618monthly0.5https://www.biopharmawatch.com/news/BIIB/biogenic-reagents-commences-production-from-its-new-biocarbon-reactor-biib-20140528monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-sobi-to-donate-1-billion-international-units-of-clotting-factor-to-support-biib-20140512monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-signs-license-agreement-with-amunix-for-xtenylated-factor-viii-biib-20140421monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-sobi-announce-positive-top-line-efficacy-and-safety-results-from-phase-3-p-biib-20140410monthly0.5https://www.biopharmawatch.com/news/BIIB/biogenic-reagents-begins-commercial-production-of-new-ultra-adsorptive-graphene-carbon-com-biib-20130805monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-sobi-present-new-data-from-the-phase-3-study-of-their-long-lasting-haemoph-biib-20130704monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-sobi-initiate-global-clinical-trials-of-long-lasting-hemophilia-a-and-b-pr-biib-20120705monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-inc-biib-n-100-to-ring-the-nasdaq-stock-market-opening-bell-biib-20110916monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-swedish-orphan-biovitrum-present-data-on-long-lasting-recombinant-factor-v-biib-20110726monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-swedish-orphan-biovitrum-receive-opinion-from-ema-on-pediatric-plan-for-lo-biib-20110509monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-swedish-orphan-biovitrum-present-data-on-long-lasting-hemophilia-b-therapy-biib-20100712monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-swedish-orphan-biovitrum-announce-first-patient-dosed-in-global-registrati-biib-20100125monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-biovitrum-announce-decision-to-advance-long-acting-hemophilia-b-therapy-in-biib-20091019monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-vernalis-plc-announce-the-start-of-phase-ii-program-of-biib014-in-parkinso-biib-20070508monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-que-eras-20260618monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-eras-20260618monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-que-eras-20260616monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-investor-alert-bragar-eagel-squire-p-c-is-investigating-erasca-inc-on-behalf-of-era-eras-20260519monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-inc-eras-shares-crater-48-wiping-out-2-8-billion-of-market-cap-hagens-berman-invest-eras-20260519monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-investor-alert-bragar-eagel-squire-p-c-is-investigating-erasca-inc-on-behalf-of-era-eras-20260514monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-the-bank-of-america-securities-health-care-conference-eras-20260506monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-inc-investors-should-contact-block-leviton-llp-to-learn-more-about-securities-fraud-eras-20260504monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-inc-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-more-information-eras-20260428monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-inc-investigated-for-securities-fraud-block-leviton-encourages-investors-to-contact-eras-20260428monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-exercises-option-to-secure-worldwide-rights-for-eras-0015-pan-ras-molecular-glue-to-eras-20260310monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-closing-of-upsized-public-offering-of-common-stock-including-full-exercis-eras-20260123monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-pricing-of-upsized-public-offering-of-common-stock-eras-20260122monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-promising-early-clinical-data-for-eras-0015-and-2026-2027-milestones-eras-20260112monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-eras-20260106monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-the-8th-annual-evercore-healthcare-conference-eras-20251125monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-reports-second-quarter-2025-business-updates-and-financial-results-eras-20250812monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-presents-new-preclinical-data-reinforcing-best-in-class-potential-of-ras-targeting--eras-20250429monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-three-poster-presentations-at-the-2025-aacr-annual-meeting-eras-20250325monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-the-guggenheim-securities-smid-cap-biotech-conference-eras-20250131monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-eras-20250107monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-upcoming-investor-conferences-eras-20241105monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-strong-momentum-for-naporafenib-and-ras-targeting-franchise-eras-20241024monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-preliminary-seacraft-1-phase-1-data-for-naporafenib-plus-trametinib-in-r-eras-20240925monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-upcoming-investor-conferences-in-september-eras-20240829monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-initiates-seacraft-2-pivotal-phase-3-trial-evaluating-naporafenib-plus-trametinib-i-eras-20240618monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-upcoming-investor-conferences-in-june-eras-20240529monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-closing-of-underwritten-offering-of-common-stock-and-full-exercise-of-the-eras-20240521monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-strategic-in-licensing-of-ras-targeting-franchise-eras-20240517monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-the-bank-of-america-health-care-conference-eras-20240507monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-three-presentations-at-the-2024-asco-annual-meeting-eras-20240424monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-reports-fourth-quarter-2023-and-full-year-2023-business-updates-and-financial-resul-eras-20240327monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-two-clinical-trial-collaboration-and-supply-agreements-for-trametinib-to--eras-20240214monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-the-guggenheim-healthcare-talks-6th-annual-biotechnology-conference-eras-20240201monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-eras-20240103monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-granted-fda-fast-track-designation-for-pan-raf-inhibitor-naporafenib-in-patients-wi-eras-20231211monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-achieves-key-milestones-for-naporafenib-and-eras-801-programs-and-extends-cash-runw-eras-20231128monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-reports-third-quarter-2023-financial-results-and-business-updates-eras-20231109monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-upcoming-investor-conferences-in-november-eras-20231108monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-the-cantor-global-healthcare-conference-eras-20230919monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-the-morgan-stanley-21st-annual-global-healthcare-conference-eras-20230905monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-doses-first-patient-in-seacraft-1-phase-1b-trial-evaluating-naporafenib-plus-tramet-eras-20230829monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-granted-fda-orphan-drug-designation-for-cns-penetrant-egfr-inhibitor-eras-801-for-t-eras-20230622monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-provides-update-on-clinical-program-for-erk-inhibitor-eras-007-and-refines-pipeline-eras-20230605monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-upcoming-investor-conferences-eras-20230601monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-host-virtual-investor-event-on-pipeline-updates-with-a-focus-on-eras-007-erk-inh-eras-20230531monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-promising-preliminary-herkules-3-phase-1b-data-at-the-2023-asco-annual-m-eras-20230525monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-further-strengthens-business-leadership-with-two-key-promotions-eras-20230516monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-the-bank-of-america-securities-2023-health-care-conference-eras-202305022023-05-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-granted-fda-fast-track-designation-for-cns-penetrant-egfr-inhibitor-eras-801-in-pat-eras-202305012023-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-two-poster-presentations-at-the-2023-asco-annual-meeting-eras-202304262023-04-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-publication-of-promising-clinical-data-supporting-the-therapeutic-potenti-eras-202304252023-04-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-presents-promising-initial-phase-1b-dose-escalation-data-from-flagshp-1-for-eras-60-eras-202304182023-04-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-strengthens-clinical-and-regulatory-leadership-with-two-key-appointments-as-company-eras-202304102023-04-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-poster-presentation-at-the-2023-aacr-annual-meeting-eras-202303142023-03-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-the-guggenheim-oncology-conference-2023-eras-202302012023-02-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-eras-202301042023-01-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-first-patient-dosed-in-herkules-1-phase-1b-trial-evaluating-eras-007-and--eras-20221220monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-fda-clearance-of-ind-application-for-cns-penetrant-kras-g12c-inhibitor-er-eras-20221213monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-exclusive-worldwide-license-for-pan-raf-inhibitor-naporafenib-eras-20221209monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-clinical-trial-collaboration-and-supply-agreement-with-pierre-fabre-to-ev-eras-20221130monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-upcoming-investor-conferences-eras-20221122monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-clinical-trial-collaboration-and-supply-agreement-with-pfizer-to-evaluate-eras-20221020monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-four-poster-presentations-at-the-upcoming-34th-eortc-nci-aacr-symposium-eras-20221012monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-the-bank-of-america-securities-precision-oncology-conference-2022-eras-20220926monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-the-morgan-stanley-global-healthcare-conference-eras-20220909monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-presents-promising-preliminary-phase-1-1b-monotherapy-data-for-eras-007-erk-and-era-eras-20220907monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-host-r-d-day-with-kol-dr-david-hong-on-lead-clinical-programs-eras-007-and-eras--eras-20220824monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-and-md-anderson-announce-strategic-research-and-development-collaboration-in-ras-ma-eras-20220823monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-clinical-trial-collaboration-and-supply-agreement-with-eli-lilly-and-comp-eras-20220718monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-the-2022-jefferies-healthcare-conference-eras-20220603monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-trial-to-evaluate-eras-007-in-combination-with-kras-g12c-inhibitor-in-kra-eras-20220602monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-strengthens-clinical-and-commercial-leadership-with-three-key-appointments-eras-20220525monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-the-bank-of-america-securities-2022-healthcare-conference-eras-20220503monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-appoints-jean-liu-to-its-board-of-directors-eras-20220427monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-presents-compelling-preclinical-data-supporting-clinical-development-of-potentially-eras-20220412monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-host-investor-event-with-leading-kol-dr-scott-kopetz-on-therapeutic-opportunitie-eras-20220406monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-clinical-trial-collaboration-and-supply-agreement-with-eli-lilly-and-comp-eras-20220310monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-six-poster-presentations-at-the-2022-aacr-annual-meeting-eras-20220308monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-the-guggenheim-healthcare-talks-2022-oncology-day-eras-20220203monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-strengthens-leadership-team-with-two-key-executive-appointments-eras-20220118monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-eras-20220104monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-fda-clearance-of-ind-application-for-eras-801-in-glioblastoma-multiforme--eras-20211217monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-added-to-the-nasdaq-biotechnology-index-eras-20211214monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-present-at-the-evercore-isi-4th-annual-healthconx-conference-eras-20211116monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-presentation-of-preclinical-data-on-eras-801-a-cns-penetrant-egfr-inhibit-eras-20211025monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-is-named-one-of-fierce-biotech-s-fierce-15-biotechnology-companies-of-2021-eras-20210927monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-first-patient-dosed-in-herkules-3-a-phase-1b-2-gastrointestinal-cancer-ma-eras-20210922monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-first-patient-dosed-in-herkules-2-phase-1b-2-lung-cancer-master-protocol--eras-20210909monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-clinical-trial-collaboration-and-supply-agreement-with-pfizer-to-evaluate-eras-20210908monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-to-participate-in-the-morgan-stanley-19th-annual-global-healthcare-virtual-conferen-eras-20210902monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-opti-eras-20210720monthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-pricing-of-upsized-initial-public-offering-eras-20210716monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-april-2026-sny-20260519monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-march-2026-sny-20260414monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-combined-general-meeting-of-april-29-2026-availability-of-preparatory-documents-sny-20260408monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-february-2026-sny-20260312monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-digital-transformation-strategy-analysis-report-2025-accelerators-innovation-progra-sny-20260225monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-january-2026-sny-20260211monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-december-2025-sny-20260114monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-november-2025-sny-20251222monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-october-2025-sny-20251113monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-deepens-partnership-with-medidata-to-expedite-the-development-of-new-therapies-with-sny-20251023monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-september-2025-sny-20251014monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-august-2025-sny-20250912monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-july-2025-sny-20250818monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-june-2025-sny-20250709monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-may-2025-sny-20250609monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-exercises-license-extension-option-to-nurix-s-stat6-program-sny-20250602monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-april-2025-sny-20250515monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-garners-highest-physician-interest-in-asthma-pipeline-despite-gsk-s-later-stage-ass-sny-20250513monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-investing-in-prevention-builds-europe-s-health-and-competitiveness-sny-20250506monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-march-2025-sny-20250502monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-february-2025-sny-20250403monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-december-2024-sny-20250129monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-november-2024-sny-20250115monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-october-2024-sny-20241120monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-september-2024-sny-20241015monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-august-2024-sny-20240916monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-july-2024-sny-20240809monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-june-2024-sny-20240722monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-may-2024-sny-20240612monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-april-2024-sny-20240520monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-march-2024-sny-20240412monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-agm-30-04-2024-availability-of-preparatory-documents-sny-20240408monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-february-2024-sny-20240315monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-january-2024-sny-20240220monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-december-2023-sny-20240117monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-november-2023-sny-20231218monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-october-2023-sny-20231123monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-september-2023-sny-20231017monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-august-2023-sny-20230911monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-july-2023-sny-20230815monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-june-2023-sny-20230718monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-may-2023-sny-20230620monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-april-2023-sny-20230517monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-combined-general-meeting-of-may-25-2023-availability-of-preparatory-documents-sny-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-march-2023-sny-202304192023-04-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-market-leader-in-dtap-pediatric-combination-vaccines-with-55-4-million-doses-used-i-sny-202302232023-02-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-january-2023-sny-202302152023-02-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-december-2022-sny-202301172023-01-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-november-2022-sny-20221219monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-october-2022-sny-20221114monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-september-2022-sny-20221013monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-august-2022-sny-20220913monthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-information-concerning-the-total-number-of-voting-rights-and-shares-july-2022-sny-20220808monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tngx-20260605monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tngx-20260306monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-participate-in-44th-annual-j-p-morgan-healthcare-conference-tngx-20251217monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-participate-in-the-2025-jefferies-global-healthcare-conference-tngx-20251112monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-20-tngx-20251029monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-225-million-financing-tngx-20251023monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-reports-positive-data-from-ongoing-phase-1-2-study-with-vopimetostat-tn-tngx-20251023monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-present-first-clinical-data-from-tng260-at-society-for-immunotherapy-tngx-20251006monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-participate-in-the-2025-cantor-global-healthcare-conference-tngx-20250826monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-report-second-quarter-2025-financial-results-on-tuesday-august-5-202-tngx-20250722monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-first-patient-dosed-in-phase-1-2-trial-of-tng462-plus-revolut-tngx-20250627monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-participate-in-the-46th-annual-goldman-sachs-global-healthcare-confe-tngx-20250527monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-first-patient-dosed-in-tng456-phase-1-2-trial-in-patients-wit-tngx-20250521monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025-tngx-20250501monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-highlight-preclinical-data-on-precision-oncology-pipeline-with-five--tngx-20250325monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-present-at-three-upcoming-investment-bank-conferences-tngx-20250220monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-present-at-the-guggenheim-smid-cap-biotechnology-conference-tngx-20250130monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-highlight-preclinical-data-on-precision-oncology-pipeline-at-the-ame-tngx-20240305monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-present-at-the-guggenheim-healthcare-talks-6th-annual-biotechnology--tngx-20240131monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tngx-20240105monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-first-patient-dosed-in-phase-1-2-trial-of-tng348-in-patients--tngx-20240103monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-highlight-preclinical-data-on-prmt5-inhibitors-at-the-society-for-ne-tngx-20231113monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-present-at-the-jefferies-london-healthcare-conference-tngx-20231107monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-highlight-preclinical-data-on-precision-oncology-pipeline-at-aacr-nc-tngx-20230918monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-tng-tngx-20230906monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conf-tngx-20230905monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-updates-to-its-board-of-directors-tngx-20230829monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-first-patient-dosed-in-tng260-phase-1-2-trial-in-patients-wit-tngx-20230724monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-first-patient-dosed-in-tng462-phase-1-2-trial-in-patients-wit-tngx-20230710monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-participate-in-upcoming-investor-conferences-tngx-20230601monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-presents-preclinical-data-on-precision-oncology-programs-at-the-america-tngx-202304182023-04-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-tng-tngx-202304032023-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-highlight-preclinical-data-on-precision-oncology-programs-at-the-ame-tngx-202303152023-03-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-limited-exposure-to-silicon-valley-bank-tngx-202303112023-03-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tngx-202303062023-03-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-participate-in-upcoming-investor-conferences-tngx-202303012023-03-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-participate-in-upcoming-investor-conferences-tngx-202302022023-02-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-tng-tngx-202301252023-01-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-participate-in-upcoming-investor-conferences-tngx-20221107monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-presentation-of-preclinical-data-on-prmt5-inhibitors-tng908-a-tngx-20221019monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-presentation-of-preclinical-data-on-tng260-and-discovery-plat-tngx-20221005monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conf-tngx-20220906monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-participate-in-the-13th-annual-wedbush-pacgrow-healthcare-conference-tngx-20220802monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-added-to-russell-2000-3000-and-microcap-indexes-tngx-20220627monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-participate-in-the-goldman-sachs-43rd-annual-global-healthcare-confe-tngx-20220608monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-participate-in-the-guggenheim-synthetic-lethality-day-2022-tngx-20220509monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-presentation-of-preclinical-data-on-tng908-usp1-inhibitor-pro-tngx-20220308monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-presentation-of-tng908-preclinical-combination-data-at-2022-e-tngx-20220303monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-participate-in-upcoming-investor-conferences-tngx-20220228monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-participate-in-upcoming-investor-conferences-tngx-20220202monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-clearance-of-tng908-ind-by-fda-and-recent-pipeline-progress-u-tngx-20220124monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-to-participate-in-the-jefferies-london-healthcare-conference-tngx-20211111monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-announces-appointment-of-dr-marc-rudoltz-as-chief-medical-officer-and-d-tngx-20211101monthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-debuts-as-publicly-traded-precision-oncology-company-focused-on-the-nex-tngx-20210810monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-envudeucitinib-delivers-early-and-robust-improvements-in-skin-clearance-quality-of--alms-20260328monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-announces-late-breaker-oral-presentation-of-phase-3-data-for-envudeucitinib-in-mode-alms-20260318monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-announces-closing-of-upsized-public-offering-and-full-exercise-of-underwriters-opti-alms-20260109monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-announces-pricing-of-upsized-public-offering-of-common-stock-alms-20260108monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-announces-proposed-public-offering-of-common-stock-alms-20260106monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-to-participate-in-upcoming-september-investor-conferences-alms-20250829monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-and-acelyrin-file-joint-definitive-proxy-statement-for-proposed-merger-alms-20250404monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-to-present-at-leerink-s-2025-global-healthcare-conference-alms-20250310monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-announces-late-breaker-psoriasis-presentation-of-52-week-phase-2-ole-data-for-esk-0-alms-20250228monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-presents-additional-phase-1-data-at-actrims-forum-2025-supporting-potential-of-a-00-alms-20250227monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference-alms-20250210monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-strengthens-leadership-team-with-key-appointments-alms-20250128monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-announces-positive-phase-1-data-for-cns-penetrant-tyk2-inhibitor-a-005-alms-20241219monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-presents-data-highlighting-esk-001-s-potential-as-a-high-efficacy-oral-treatment-fo-alms-20241114monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-to-participate-in-guggenheim-s-inaugural-healthcare-innovation-conference-alms-20241104monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-to-participate-in-upcoming-september-investor-conferences-alms-20240903monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-initiates-onward-phase-3-clinical-program-evaluating-esk-001-an-oral-tyk2-inhibitor-alms-20240729monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-announces-pricing-of-initial-public-offering-alms-20240628monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-announces-first-participant-dosed-in-phase-1-clinical-trial-of-cns-penetrant-allost-alms-20240430monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-to-participate-in-the-2024-leerink-partners-global-biopharma-conference-alms-20240311monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-presents-positive-data-from-phase-2-clinical-trial-of-esk-001-an-oral-allosteric-ty-alms-20240309monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-announces-upsized-259m-series-c-financing-to-advance-clinical-stage-pipeline-of-ora-alms-20240306monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-announces-late-breaker-psoriasis-phase-2-data-presentation-for-allosteric-tyk2-inhi-alms-20240304monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-presents-preclinical-data-for-allosteric-tyk2-inhibitor-a-005-at-actrims-alms-20240301monthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-announces-expansion-of-allosteric-tyk2-inhibitor-esk-001-phase-2-program-into-syste-alms-20230629monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-alert-bragar-eagel-squire-p-c-is-investigating-dyne-therapeutics-inc-on-behalf-of-dyn-dyn-20240911monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-presents-enzyme-transportvehicle-progress-across-three-clinical-progra-dnli-20260205monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-proposed-offering-of-common-stock-and-pre-funded-warrants-dnli-20251209monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-and-royalty-pharma-announce-275-million-royalty-funding-agreement-dnli-20251204monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-u-s-fda-breakthrough-therapy-designation-granted-to-tivideno-dnli-20250108monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-first-participant-dosed-in-phase-2a-study-of-lrrk2-inhibitor-dnli-20241205monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-successful-meeting-with-the-fda-and-plans-to-file-for-accele-dnli-20240903monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-publication-in-science-translational-medicine-demonstrating--dnli-20240814monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-fda-has-selected-dnl126-etv-sgsh-for-mps-iiia-sanfilippo-syn-dnli-20240603monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-completion-of-enrollment-for-regimen-g-evaluating-eif2b-agon-dnli-20240501monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-500-million-private-placement-equity-financing-dnli-20240227monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-new-data-and-expansion-of-its-blood-brain-barrier-bbb-crossi-dnli-20240207monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-presentations-on-its-investigational-blood-brain-barrier-bbb-dnli-20240201monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-new-interim-data-from-phase-1-2-study-of-dnl310-etv-ids-in-m-dnli-20230830monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-new-dnl343-eif2b-agonist-phase-1b-data-in-als-to-be-presente-dnli-202304102023-04-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-new-interim-data-from-dnl310-phase-1-2-study-for-mps-ii-and--dnli-202302222023-02-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-presentations-on-enzyme-transport-vehicle-etv-development-pr-dnli-202302152023-02-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-achievement-of-ripk1-milestone-for-phase-2-clinical-trial-in-dnli-202301252023-01-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-dnl343-interim-phase-1b-data-in-als-and-entry-into-the-heale-dnli-20221205monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-phase-1-2-study-single-dose-healthy-volunteer-data-with-tak--dnli-20221101monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-closing-of-a-316-million-public-offering-including-full-exer-dnli-20221024monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-new-interim-data-from-phase-1-2-study-of-dnl310-etv-ids-in-m-dnli-20220831monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-and-biogen-announce-initiation-of-phase-2b-study-of-lrrk2-inhibitor-in-dnli-20220531monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-achievement-of-ripk1-milestone-for-phase-2-clinical-trial-in-dnli-20220502monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-initiation-of-phase-1-2-clinical-trial-of-dnl593-ptv-pgrn-fo-dnli-20220309monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-presentations-on-dnl310-etv-ids-development-program-in-mps-i-dnli-20220201monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-fda-clinical-hold-on-dnl919-investigational-new-drug-ind-app-dnli-20220113monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-positive-clinical-results-and-regulatory-progress-for-develo-dnli-20211006monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-upcoming-presentations-on-eif2b-activator-dnl343-and-ripk1-i-dnli-20210929monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-appoints-katie-peng-as-chief-commercial-officer-dnli-20210927monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-initiation-of-phase-1b-study-of-eif2b-activator-dnl343-in-al-dnli-20210909monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-publication-in-cell-on-new-approach-to-treat-ftd-grn-dnli-20210826monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-to-present-interim-data-from-phase-1-2-study-of-etv-ids-dnl310-for-the-dnli-20210715monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-initiation-of-phase-2-study-by-partner-sanofi-of-ripk1-inhib-dnli-20210628monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-presents-positive-results-from-phase-1-and-phase-1b-studies-of-its-lrr-dnli-20210501monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-fast-track-designation-granted-by-the-u-s-fda-to-etv-ids-dnl-dnli-20210311monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-to-present-new-data-on-etv-ids-dnl310-for-the-potential-treatment-of-h-dnli-20210205monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-significant-program-progress-and-expected-key-milestones-in--dnli-20210108monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-to-highlight-progress-across-broad-biotherapeutics-portfolio-for-neuro-dnli-20201015monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-to-host-webinar-on-transporting-biotherapeutics-across-the-blood-brain-dnli-20200930monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-decision-to-advance-dnl151-into-late-stage-clinical-studies--dnli-20200806monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-phase-1b-study-by-partner-sanofi-of-ripk1-inhibitor-dnl758-s-dnli-20200729monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-provides-broad-update-on-its-ripk1-program-partnered-with-sanofi-dnli-20200609monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-publication-of-two-new-papers-describing-its-blood-brain-bar-dnli-20200527monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-closing-of-public-offering-including-full-exercise-of-underw-dnli-20200201monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-first-patient-dosed-in-phase-1b-study-of-dnl151-for-parkinso-dnli-20190904monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-that-its-partner-sanofi-has-commenced-dosing-of-dnl758-in-a--dnli-20190805monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-receives-orphan-drug-and-rare-pediatric-disease-designation-for-dnl310-dnli-20190611monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-first-patient-dosed-in-phase-1b-study-of-dnl747-for-alzheime-dnli-20190215monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-first-patient-dosed-in-phase-1b-study-of-dnl747-for-als-dnli-20190108monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-first-patient-dosed-in-phase-1b-study-of-dnl201-for-parkinso-dnli-20181210monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-appoints-dana-andersen-ph-d-as-chief-technical-and-manufacturing-offic-dnli-20180807monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-and-lonza-pharma-biotech-announce-exclusive-partnership-to-develop-and-dnli-20180208monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-advancement-and-expansion-of-its-lrrk2-inhibitor-clinical-pr-dnli-20171220monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-inc-nasdaq-dnli-to-ring-the-nasdaq-stock-market-opening-bell-in-celebr-dnli-20171208monthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-announces-pricing-of-initial-public-offering-dnli-20171208monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-participate-in-upcoming-investor-conferences-tars-20260528monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-participate-in-upcoming-investor-conferences-tars-20260226monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-participate-in-upcoming-investor-conferences-tars-20250827monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-reports-second-quarter-2025-financial-results-and-recent-business-achievements-tars-20250806monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-report-second-quarter-2025-financial-results-on-wednesday-august-6-2025-tars-20250730monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-participate-in-upcoming-investor-conferences-tars-20250529monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-participate-in-upcoming-investor-conferences-tars-20250508monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-reports-first-quarter-2025-financial-results-and-recent-business-achievements-tars-20250501monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-report-first-quarter-2025-financial-results-on-thursday-may-1-2025-tars-20250424monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-present-several-scientific-abstracts-highlighting-the-global-prevalence-of-demod-tars-20250422monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-announces-pricing-of-upsized-125-0-million-public-offering-tars-20250313monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-participate-in-upcoming-investor-conference-tars-20250306monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-reports-strong-fourth-quarter-and-full-year-2024-financial-results-and-recent-busin-tars-20250225monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-report-fourth-quarter-and-full-year-2024-financial-results-on-tuesday-february-2-tars-20250220monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-participate-in-upcoming-investor-conferences-tars-20250130monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-provides-2025-update-accelerating-the-launch-of-xdemvy-and-establishing-ocular-rosa-tars-20250113monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-reports-third-quarter-and-year-to-date-2024-financial-results-and-recent-business-a-tars-20241113monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-welcomes-kate-goodrich-m-d-mhs-to-its-board-of-directors-tars-20241113monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-report-third-quarter-2024-financial-results-on-wednesday-november-13-2024-tars-20241106monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-appoints-elizabeth-yeu-m-d-as-chief-medical-officer-tars-20241105monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-launches-your-mitey-problem-the-first-direct-to-consumer-tv-campaign-for-xdemvy-lot-tars-20241017monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-participate-in-fireside-chat-at-ubs-virtual-ophthalmology-day-2024-tars-20240925monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-participate-in-fireside-chat-at-the-2024-wells-fargo-securities-healthcare-confe-tars-20240828monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-reports-second-quarter-and-year-to-date-2024-financial-results-and-recent-business--tars-20240808monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-report-second-quarter-2024-financial-results-on-thursday-august-8-2024-tars-20240729monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-participate-in-upcoming-investor-conferences-tars-20240529monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-participate-in-fireside-chat-at-the-2024-bank-of-america-healthcare-conference-tars-20240509monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-reports-first-quarter-2024-financial-results-and-recent-business-achievements-tars-20240508monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-report-first-quarter-2024-financial-results-on-wednesday-may-8-2024-tars-20240501monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-strengthens-financial-position-and-refinances-existing-debt-with-200-million-non-di-tars-20240423monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-participate-at-upcoming-investor-conferences-tars-20240305monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-introduces-mite-party-campaign-for-xdemvy-lotilaner-ophthalmic-solution-0-25-to-edu-tars-20240305monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-announces-pricing-of-100-0-million-public-offering-tars-20240301monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-reports-strong-fourth-quarter-and-full-year-2023-financial-results-and-recent-busin-tars-20240227monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-announces-positive-topline-results-from-carpo-a-phase-2a-proof-of-concept-tick-kill-tars-20240222monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-report-fourth-quarter-and-full-year-2023-financial-results-on-tuesday-february-2-tars-20240220monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-participate-in-fireside-chat-at-the-sixth-annual-guggenheim-healthcare-talks-con-tars-20240131monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-announces-positive-topline-results-from-the-ersa-phase-2a-clinical-trial-evaluating-tars-20231211monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-reports-third-quarter-2023-financial-results-and-recent-business-achievements-tars-20231109monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-report-third-quarter-2023-financial-results-on-thursday-november-9-2023-tars-20231101monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-ring-nasdaq-stock-market-closing-bell-in-celebration-of-the-launch-of-xdemvy-the-tars-20230906monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-present-at-upcoming-investor-conferences-tars-20230830monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-reports-second-quarter-2023-financial-results-and-recent-business-achievements-tars-20230810monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-announces-pricing-of-100-0-million-underwritten-public-offering-of-common-stock-tars-20230802monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-host-virtual-investor-webcast-highlighting-the-commercialization-strategy-plans--tars-20230612monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-present-at-the-jefferies-global-healthcare-conference-tars-20230605monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-reports-first-quarter-2023-financial-results-and-recent-business-achievements-tars-202305092023-05-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-launches-don-t-freak-out-get-checked-out-campaign-during-healthy-vision-month-to-en-tars-202305082023-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-participate-at-the-bank-of-america-2023-healthcare-conference-tars-202305032023-05-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-appoints-jeff-farrow-as-chief-financial-officer-and-chief-strategy-officer-tars-202304242023-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-reports-full-year-2022-financial-results-and-recent-business-achievements-tars-202303132023-03-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-present-at-upcoming-investor-conferences-tars-202303022023-03-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-added-to-nasdaq-biotechnology-index-tars-20221216monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-announces-positive-topline-data-from-phase-1b-callisto-trial-and-initiates-phase-2a-tars-20221215monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-reports-third-quarter-2022-financial-results-and-recent-business-achievements-tars-20221109monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-present-additional-saturn-2-pivotal-phase-3-trial-data-at-the-american-academy-o-tars-20221025monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-announces-transition-plans-for-board-of-directors-tars-20221011monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-appoints-scott-morrison-as-board-member-and-audit-committee-chair-tars-20221006monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-launches-look-at-the-lids-campaign-to-encourage-eye-care-professionals-to-identify--tars-20220929monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-present-saturn-2-pivotal-phase-3-trial-data-and-saturn-1-extension-study-long-te-tars-20220927monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-submits-new-drug-application-to-the-fda-for-tp-03-for-the-treatment-of-demodex-blep-tars-20220907monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-reports-second-quarter-2022-financial-results-and-recent-business-achievements-tars-20220811monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-initiates-phase-2a-ersa-trial-evaluating-tp-03-for-the-treatment-of-meibomian-gland-tars-20220805monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-present-at-the-jefferies-2022-healthcare-conference-tars-20220527monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-reports-first-quarter-2022-financial-results-and-recent-business-achievements-tars-20220510monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-present-at-bank-of-america-2022-healthcare-conference-tars-20220506monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-presents-new-findings-from-two-studies-demonstrating-the-impact-of-demodex-blephari-tars-20220505monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-announces-pricing-of-upsized-75-6-million-underwritten-public-offering-of-common-st-tars-20220503monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-announces-positive-topline-data-from-saturn-2-phase-3-the-second-pivotal-trial-of-t-tars-20220502monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-host-webcast-to-review-topline-results-from-saturn-2-phase-3-the-second-pivotal--tars-20220430monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-presents-results-of-two-studies-highlighting-demodex-blepharitis-patient-impact-and-tars-20220426monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-reports-full-year-2021-financial-results-and-recent-business-ac-tars-20220314monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-present-at-upcoming-investor-conferences-tars-20220309monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-host-eye-care-leaders-webcast-on-unmet-needs-in-demodex-blepharitis-and-potentia-tars-20220202monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-completes-enrollment-for-the-pivotal-phase-3-saturn-2-trial-of-tp-03-to-treat-demod-tars-20220202monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-appoints-elizabeth-yeu-m-d-a-nationally-recognized-ophthalmologist-and-eye-care-lea-tars-20220104monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-participate-at-upcoming-virtual-investor-conferences-tars-20211123monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-participate-in-the-virtual-jefferies-london-healthcare-conference-2021-tars-20211110monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-reports-third-quarter-2021-financial-results-and-recent-busines-tars-20211109monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-presents-data-from-two-pioneering-studies-on-the-prevalence-and-tars-20211104monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-to-participate-in-the-virtual-credit-suisse-30th-annual-healthcare-conference-tars-20211102monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-medical-group-announces-the-acquisition-of-the-international-peptide-society-tars-20210810monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-reports-second-quarter-2021-financial-results-and-provides-busi-tars-20210804monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-presents-new-saturn-1-pivotal-trial-data-and-titan-real-world-p-tars-20210724monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-to-participate-in-the-ladenburg-thalmann-2021-virtual-healthcar-tars-20210707monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-to-participate-in-the-raymond-james-2021-human-health-innovatio-tars-20210622monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-schedules-conference-call-and-webcast-to-announce-saturn-1-phas-tars-20210618monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-initiates-phase-1-callisto-trial-of-tp-05-a-novel-oral-non-vacc-tars-20210616monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-to-present-at-the-jefferies-virtual-healthcare-conference-tars-20210524monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-reports-first-quarter-2021-financial-results-and-provides-busin-tars-20210511monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-initiates-saturn-2-second-pivotal-phase-3-trial-evaluating-the--tars-20210506monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-announces-fda-acceptance-of-investigational-new-drug-applicatio-tars-20210504monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-presents-results-of-pioneering-atlas-study-at-arvo-2021-annual--tars-20210503monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-to-present-at-the-bofa-securities-2021-virtual-health-care-conf-tars-20210427monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-reports-full-year-2020-financial-results-and-business-and-clini-tars-20210331monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-appoints-bryan-wahl-md-jd-as-general-counsel-tars-20210119monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-appoints-dianne-whitfield-as-chief-human-resources-officer-tars-20210107monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-to-present-at-the-2021-icr-virtual-conference-tars-20210105monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-announces-type-c-meeting-with-fda-regarding-nda-submission-requ-tars-20201223monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-announces-inclusion-in-the-russell-3000-index-and-russell-2000--tars-20201221monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-to-present-at-the-jefferies-virtual-london-healthcare-conferenc-tars-20201114monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-announces-closing-of-initial-public-offering-and-full-exercise--tars-20201020monthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-inc-announces-pricing-of-initial-public-offering-tars-20201016monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-to-present-at-td-cowen-s-44th-annual-health-care-conference-elvn-20240227monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-to-present-at-two-upcoming-investor-conferences-elvn-20230531monthly0.5https://www.biopharmawatch.com/news/TLX/telix-resubmits-nda-to-u-s-fda-for-tlx101-px-pixclara-brain-cancer-imaging-candidate-tlx-20260315monthly0.5https://www.biopharmawatch.com/news/TLX/telix-final-class-action-alert-bragar-eagel-squire-p-c-urgently-reminds-telix-pharmaceutic-tlx-20260109monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-ltd-sued-for-securities-law-violations-investors-should-contact-the--tlx-20260108monthly0.5https://www.biopharmawatch.com/news/TLX/telix-tlx-2-day-deadline-alert-hagens-berman-urges-telix-investors-to-act-by-jan-9-in-clas-tlx-20260107monthly0.5https://www.biopharmawatch.com/news/TLX/telix-urgent-class-action-deadline-alert-bragar-eagel-squire-p-c-reminds-telix-pharmaceuti-tlx-20260105monthly0.5https://www.biopharmawatch.com/news/TLX/telix-tlx-4-day-deadline-alert-hagens-berman-urges-telix-investors-to-act-by-jan-9-in-clas-tlx-20260105monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-ltd-securities-fraud-class-action-lawsuit-pending-contact-levi-korsi-tlx-20251226monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-ltd-class-action-levi-korsinsky-reminds-telix-pharmaceuticals-ltd-in-tlx-20251218monthly0.5https://www.biopharmawatch.com/news/TLX/telix-class-action-reminder-bragar-eagel-squire-p-c-reminds-telix-pharmaceuticals-limited--tlx-20251211monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-tlx-sued-after-alleged-misstatements-on-prostate-cancer-drug-progres-tlx-20251210monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-ltd-securities-fraud-class-action-lawsuit-pending-contact-the-gross--tlx-20251208monthly0.5https://www.biopharmawatch.com/news/TLX/telix-tlx-facing-securities-class-action-lawsuit-over-alleged-dual-regulatory-failures-sec-tlx-20251208monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-tlx-20251204monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-tlx-sued-after-alleged-misstatements-on-prostate-cancer-drug-progres-tlx-20251202monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-tlx-20251201monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-tlx-20251127monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-tlx-faces-securities-class-action-amid-sec-subpoena-complete-tlx-20251124monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-tlx-20251124monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-tlx-faces-securities-class-action-amid-sec-subpoena-complete-tlx-20251121monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-ltd-sued-for-securities-law-violations-investors-should-contact-levi-tlx-20251120monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-tlx-faces-securities-class-action-amid-sec-subpoena-complete-tlx-20251119monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-tlx-faces-securities-class-action-amid-sec-subpoena-complete-tlx-20251117monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-tlx-20251117monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-tlx-faces-securities-class-action-amid-sec-subpoena-complete-tlx-20251114monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-tlx-faces-securities-class-action-amid-sec-subpoena-complete-tlx-20251112monthly0.5https://www.biopharmawatch.com/news/TLX/telix-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-a-tlx-20251111monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-investigation-alert-bragar-eagel-squire-p-c-reminds-telix-stockholde-tlx-20251101monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-investigated-by-the-portnoy-law-firm-tlx-20251023monthly0.5https://www.biopharmawatch.com/news/TLX/telix-investigation-reminder-bragar-eagel-squire-p-c-reminds-telix-pharmaceuticals-investo-tlx-20251015monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-tlx-hits-another-roadblock-after-sec-subpoena-shares-fall-ag-tlx-20250919monthly0.5https://www.biopharmawatch.com/news/TLX/telix-alert-bragar-eagel-squire-p-c-is-investigating-telix-pharmaceuticals-limited-on-beha-tlx-20250915monthly0.5https://www.biopharmawatch.com/news/TLX/telix-alert-bragar-eagel-squire-p-c-is-investigating-telix-pharmaceuticals-limited-on-beha-tlx-20250911monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-tlx-hits-another-roadblock-after-sec-subpoena-shares-fall-ag-tlx-20250911monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-tlx-hits-another-roadblock-after-sec-subpoena-shares-fall-ag-tlx-20250829monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-tlx-shares-fall-amid-sec-subpoena-hagens-berman-tlx-20250826monthly0.5https://www.biopharmawatch.com/news/TLX/telix-alert-bragar-eagel-squire-p-c-is-investigating-telix-pharmaceuticals-limited-on-beha-tlx-20250823monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-tlx-shares-fall-amid-sec-subpoena-hagens-berman-tlx-20250820monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-tlx-shares-fall-amid-sec-subpoena-hagens-berman-tlx-20250812monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-tlx-shares-fall-amid-sec-subpoena-hagens-berman-tlx-20250808monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-tlx-shares-fall-amid-sec-subpoena-hagens-berman-tlx-20250805monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-tlx-shares-fall-amid-sec-subpoena-hagens-berman-tlx-20250729monthly0.5https://www.biopharmawatch.com/news/TLX/telix-reports-204m-revenue-up-63-yoy-tlx-20250722monthly0.5https://www.biopharmawatch.com/news/TLX/telix-precision-medicine-announces-alfluor-radiochemistry-platform-tlx-20250620monthly0.5https://www.biopharmawatch.com/news/TLX/telix-theranostic-programs-and-satellite-symposia-on-innovation-in-psma-and-caix-imaging-f-tlx-20250620monthly0.5https://www.biopharmawatch.com/news/TLX/telix-launches-new-prostate-cancer-imaging-agent-gozellix-in-u-s-tlx-20250611monthly0.5https://www.biopharmawatch.com/news/TLX/telix-investor-day-in-new-york-city-on-june-11-2025-presenting-kols-tlx-20250603monthly0.5https://www.biopharmawatch.com/news/TLX/telix-to-host-investor-day-in-new-york-city-on-june-11-2025-tlx-20250522monthly0.5https://www.biopharmawatch.com/news/TLX/telix-fap-targeting-therapeutic-published-in-thyroid-journal-demonstrates-encouraging-effi-tlx-20250507monthly0.5https://www.biopharmawatch.com/news/TLX/telix-reports-us-186m-q1-revenue-up-62-yoy-tlx-20250422monthly0.5https://www.biopharmawatch.com/news/TLX/telix-announces-cardinal-health-for-gozellix-commercial-distribution-tlx-20250408monthly0.5https://www.biopharmawatch.com/news/TLX/telix-appoints-paul-schaffer-as-chief-technology-officer-tlx-20250407monthly0.5https://www.biopharmawatch.com/news/TLX/telix-announces-first-patient-dosed-in-first-in-human-zolar-trial-of-tlx300-cdx-in-advance-tlx-20250401monthly0.5https://www.biopharmawatch.com/news/TLX/telix-adds-lead-212-isotope-production-capability-tlx-20250312monthly0.5https://www.biopharmawatch.com/news/TLX/telix-to-showcase-urology-pipeline-at-upcoming-asco-genitourinary-cancers-symposium-asco-g-tlx-20250213monthly0.5https://www.biopharmawatch.com/news/TLX/telix-completes-acquisition-of-next-generation-therapeutic-assets-and-innovative-biologics-tlx-20250130monthly0.5https://www.biopharmawatch.com/news/TLX/telix-completes-acquisition-of-rls-usa-inc-tlx-20250127monthly0.5https://www.biopharmawatch.com/news/TLX/telix-presentation-to-the-43rd-annual-j-p-morgan-healthcare-conference-tlx-20250113monthly0.5https://www.biopharmawatch.com/news/TLX/telix-exceeds-fy24-guidance-with-us-142m-q4-revenue-tlx-20250113monthly0.5https://www.biopharmawatch.com/news/TLX/telix-files-tlx250-cdx-zircaix-bla-for-kidney-cancer-imaging-tlx-20241229monthly0.5https://www.biopharmawatch.com/news/TLX/telix-adss-commence-trading-on-nasdaq-tlx-20241113monthly0.5https://www.biopharmawatch.com/news/TLX/telix-and-eckert-ziegler-to-partner-on-actinium-225-production-technology-tlx-20241113monthly0.5https://www.biopharmawatch.com/news/TLX/telix-welcomes-cms-decision-to-improve-payments-for-diagnostic-radiopharmaceuticals-tlx-20241103monthly0.5https://www.biopharmawatch.com/news/TLX/telix-files-form-20-f-registration-statement-for-nasdaq-ads-tlx-20241017monthly0.5https://www.biopharmawatch.com/news/TLX/telix-q3-2024-business-update-quarterly-revenue-exceeds-au-200m-tlx-20241017monthly0.5https://www.biopharmawatch.com/news/TLX/telix-to-acquire-rls-to-expand-north-american-manufacturing-and-distribution-platform-tlx-20240922monthly0.5https://www.biopharmawatch.com/news/TLX/telix-announces-cardinal-health-as-u-s-commercial-distributor-for-zircaix-tlx-20240917monthly0.5https://www.biopharmawatch.com/news/TLX/telix-2024-half-year-results-strong-commercial-revenue-and-profit-growth-to-support-strate-tlx-20240822monthly0.5https://www.biopharmawatch.com/news/TLX/telix-welcomes-cms-proposal-to-improve-payment-for-specialised-diagnostic-radiopharmaceuti-tlx-20240711monthly0.5https://www.biopharmawatch.com/news/TLX/telix-announces-launch-of-proposed-initial-public-offering-in-the-united-states-tlx-20240605monthly0.5https://www.biopharmawatch.com/news/TLX/telix-submits-nda-for-new-prostate-cancer-imaging-agent-tlx-20240528monthly0.5https://www.biopharmawatch.com/news/TLX/telix-files-registration-statement-for-proposed-initial-public-offering-in-the-united-stat-tlx-20240517monthly0.5https://www.biopharmawatch.com/news/TLX/telix-signs-agreement-to-acquire-qsam-biosciences-and-its-bone-cancer-targeting-platform-tlx-20240207monthly0.5https://www.biopharmawatch.com/news/TLX/telix-highlights-presentations-at-upcoming-asco-genitourinary-cancers-symposium-asco-gu-20-tlx-20240122monthly0.5https://www.biopharmawatch.com/news/TLX/telix-announces-planned-registered-public-offering-and-listing-in-the-united-states-tlx-20240104monthly0.5https://www.biopharmawatch.com/news/TLX/telix-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-tlx-20240103monthly0.5https://www.biopharmawatch.com/news/TLX/telix-radiopharmaceutical-production-facility-buildout-commences-tlx-20220321monthly0.5https://www.biopharmawatch.com/news/TLX/telix-enters-commercial-distribution-agreement-for-illuccix-in-australia-tlx-20220215monthly0.5https://www.biopharmawatch.com/news/TLX/telix-and-shine-partner-for-lutetium-177-supply-tlx-20220210monthly0.5https://www.biopharmawatch.com/news/TLX/telix-expands-lutetium-177-network-with-eckert-ziegler-clinical-supply-agreement-tlx-20220208monthly0.5https://www.biopharmawatch.com/news/TLX/telix-and-biokosmos-sign-distribution-agreement-for-prostate-cancer-imaging-in-greece-and--tlx-20220127monthly0.5https://www.biopharmawatch.com/news/TLX/telix-collaborates-with-olivia-newton-john-cancer-research-institute-on-brain-cancer-imagi-tlx-20211222monthly0.5https://www.biopharmawatch.com/news/TLX/telix-and-nucliber-sign-distribution-agreement-for-prostate-cancer-imaging-in-spain-tlx-20211207monthly0.5https://www.biopharmawatch.com/news/TLX/telix-establishes-commercial-hub-in-geneva-switzerland-tlx-20211004monthly0.5https://www.biopharmawatch.com/news/TLX/telix-and-radius-sign-italian-distribution-agreement-for-prostate-cancer-imaging-tlx-20210912monthly0.5https://www.biopharmawatch.com/news/TLX/telix-in-licences-novel-tumour-microenvironment-pet-tracer-tlx-20210909monthly0.5https://www.biopharmawatch.com/news/TLX/telix-expands-prostate-cancer-activity-with-genesiscare-collaboration-tlx-20210818monthly0.5https://www.biopharmawatch.com/news/TLX/telix-and-merck-to-commence-pan-cancer-clinical-combination-studies-tlx-20210818monthly0.5https://www.biopharmawatch.com/news/TLX/telix-and-merck-kgaa-darmstadt-germany-to-commence-pan-cancer-clinical-combination-studies-tlx-20210818monthly0.5https://www.biopharmawatch.com/news/TLX/telix-progresses-novel-lung-and-ovarian-cancer-theranostic-apomab-tlx-20210817monthly0.5https://www.biopharmawatch.com/news/TLX/telix-s-tlx66-in-phase-ii-academic-study-of-pediatric-leukemia-tlx-20210816monthly0.5https://www.biopharmawatch.com/news/TLX/telix-to-present-at-the-2021-jefferies-virtual-healthcare-conference-tlx-20210601monthly0.5https://www.biopharmawatch.com/news/TLX/telix-and-monrol-expand-alliance-to-include-lutetium-supply-tlx-20210510monthly0.5https://www.biopharmawatch.com/news/TLX/telix-commences-phase-iii-clinical-trial-of-prostate-cancer-therapy-tlx-20210509monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-appoints-mr-richard-valeix-as-emea-president-tlx-20210502monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-and-grand-river-aseptic-manufacturing-complete-agreement-for-commerc-tlx-20210330monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-acquires-therapharm-gmbh-broadening-reach-to-hematologic-can-tlx-20201130monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-and-china-grand-pharma-announce-strategic-licence-and-commercial-par-tlx-20201102monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-submits-new-drug-application-to-us-fda-for-prostate-cancer-imaging-p-tlx-20200924monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-enters-strategic-collaboration-with-varian-medical-systems-for-advan-tlx-20200903monthly0.5https://www.biopharmawatch.com/news/TLX/telix-japan-signs-mou-with-atox-to-use-ire-elit-68ge-68ga-generator-for-phase-i-study-of-p-tlx-20200727monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-submits-european-marketing-authorisation-application-for-prostate-ca-tlx-20200501monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-and-aushealth-to-partner-on-novel-therapeutics-for-lung-ovarian-canc-tlx-20191029monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-and-ge-healthcare-maximising-68ga-supply-for-prostate-cancer-imaging-tlx-20191013monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-to-launch-japanese-renal-cancer-imaging-study-tlx-20190830monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-and-genesiscare-commence-enhancing-prostate-cancer-clinical-study-tlx-20190808monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-and-german-cancer-research-center-dkfz-enter-into-collaboration-and--tlx-20190805monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-and-grupo-rph-sign-latam-manufacturing-and-distribution-agreement-tlx-20190703monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-and-pi-medical-sign-distribution-agreement-for-the-netherlands-tlx-20190702monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-to-present-at-jefferies-healthcare-conference-tlx-20190603monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-and-emory-winship-cancer-institute-to-collaborate-on-clinical-trial--tlx-20190530monthly0.5https://www.biopharmawatch.com/news/TLX/telix-group-expands-prostate-imaging-capability-through-inin-technology-partnership-tlx-20190124monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-launches-illumet-microsite-kit-for-the-preparation-of-68ga-psma-tlx-20190123monthly0.5https://www.biopharmawatch.com/news/TLX/telix-and-nihon-medi-physics-to-collaborate-on-actinium-renal-cancer-therapeutics-tlx-20181128monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-acquires-advanced-nuclear-medicine-ingredients-anmi-sa-tlx-20181126monthly0.5https://www.biopharmawatch.com/news/TLX/telix-and-anmi-expand-psma-imaging-partnership-tlx-20181014monthly0.5https://www.biopharmawatch.com/news/TLX/telix-and-cyclotek-enter-into-manufacturing-partnership-for-kidney-cancer-imaging-tlx-20181014monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-and-cardinal-health-enter-into-distribution-agreement-for-prostate-c-tlx-20181003monthly0.5https://www.biopharmawatch.com/news/TLX/telix-completes-acquisition-of-atlab-for-prostate-cancer-program-tlx-20180910monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-university-of-melbourne-and-peter-mac-to-collaborate-on-colorectal-c-tlx-20180823monthly0.5https://www.biopharmawatch.com/news/TLX/telix-and-nihon-medi-physics-to-collaborate-on-renal-cancer-imaging-for-the-japanese-marke-tlx-20180815monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-and-jfe-progress-japanese-manufacturing-partnership-tlx-20180725monthly0.5https://www.biopharmawatch.com/news/TLX/telix-and-isologic-conclude-manufacturing-agreement-for-north-america-tlx-20180625monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-and-osaka-university-receive-japan-science-and-technology-agency-fun-tlx-20180529monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-inserm-and-arronax-enter-into-translational-research-partnership-tlx-20180416monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-and-radboud-university-medical-centre-conclude-clinical-collaboratio-tlx-20180314monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-establishes-japanese-subsidiary-appoints-key-executives-tlx-20180115monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-and-memorial-sloan-kettering-cancer-center-announce-renal-cancer-col-tlx-20171213monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-and-jfe-announce-japanese-radiopharmaceutical-manufacturing-partners-tlx-20171212monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-appointed-dr-bernard-lambert-as-president-of-telix-pharmaceuticals-u-tlx-20171203monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-lists-on-the-australian-securities-exchange-tlx-20171115monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-successfully-completes-50-million-oversubscribed-initial-pub-tlx-20171108monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-and-anmi-partner-for-prostate-cancer-imaging-tlx-20171023monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-limited-launches-50-million-underwritten-initial-public-offering-asx-tlx-20171023monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-and-cellsight-technologies-conclude-collaboration-and-license-agreem-tlx-20170920monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-acquires-glioblastoma-program-from-therapeia-tlx-20170119monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-and-atlab-pharma-conclude-therapeutic-product-development-agreement--tlx-20170118monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-announce-fourth-quarter-and-full-year-2025-financial-results-and-cor-rlay-20260219monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-efficacy-subset-analysis-of-zovegalisib-rly-2608-fulvestrant--rlay-20251212monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-announce-third-quarter-2025-financial-results-and-corporate-highligh-rlay-20251030monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-in-september-rlay-20250828monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-in-june-rlay-20250529monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-rlay-20250508monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-announce-first-quarter-2025-financial-results-and-corporate-highligh-rlay-20250428monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-rlay-20250224monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-cor-rlay-20250219monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-present-at-43rd-annual-j-p-morgan-healthcare-conference-rlay-20250107monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-a-rlay-20241209monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-and-elevar-therapeutics-announce-exclusive-global-licensing-agreement-f-rlay-20241203monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-participate-in-upcoming-investor-conferences-rlay-20241107monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-announce-third-quarter-2024-financial-results-and-corporate-highligh-rlay-20241030monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-pricing-of-public-offering-of-common-stock-rlay-20240911monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-webcast-to-report-rly-2608-data-on-september-9-2024-rlay-20240906monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-announce-second-quarter-2024-financial-results-and-corporate-highlig-rlay-20240730monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-discloses-three-new-programs-at-new-program-platform-event-rlay-20240606monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-participate-in-upcoming-investor-conferences-rlay-20240521monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-host-new-program-and-platform-event-on-june-6-2024-rlay-20240513monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-announce-first-quarter-2024-financial-results-and-corporate-highligh-rlay-20240425monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-participate-in-upcoming-investor-conferences-rlay-20240411monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-participate-in-three-upcoming-investor-conferences-rlay-20240226monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-announce-fourth-quarter-and-full-year-2023-financial-results-and-cor-rlay-20240215monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-6th-annual-biotechnol-rlay-20240201monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-30-million-private-placement-financing-rlay-20240108monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-present-at-42nd-annual-j-p-morgan-healthcare-conference-rlay-20240102monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-participate-in-stifel-2023-healthcare-conference-rlay-20231107monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-announce-third-quarter-2023-financial-results-and-corporate-highligh-rlay-20231026monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-present-clinical-data-on-rly-4008-in-advanced-fgfr2-altered-solid-tu-rlay-20230918monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-announce-second-quarter-2023-financial-results-and-corporate-highlig-rlay-20230801monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-rlay-20230524monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-announce-first-quarter-2023-financial-results-and-corporate-highligh-rlay-202304272023-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-rlay-202304192023-04-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-present-initial-clinical-data-on-rly-2608-at-aacr-rlay-202303062023-03-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-rlay-202303012023-03-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-announce-fourth-quarter-and-full-year-2022-financial-results-and-cor-rlay-202302162023-02-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-participate-in-guggenheim-healthcare-talks-oncology-day-rlay-202302022023-02-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-present-at-41st-annual-j-p-morgan-healthcare-conference-rlay-202301032023-01-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-rlay-20221107monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-announce-third-quarter-2022-financial-results-and-corporate-highligh-rlay-20221027monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-participate-in-fireside-chat-at-bank-of-america-securities-2022-prec-rlay-20220926monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-pricing-of-public-offering-of-common-stock-rlay-20220913monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-present-clinical-data-on-rly-4008-at-esmo-congress-rlay-20220818monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-announce-second-quarter-2022-financial-results-and-corporate-highlig-rlay-20220728monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-timing-of-virtual-analyst-and-investor-event-rlay-20220616monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-rlay-20220526monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-participate-in-fireside-chat-at-bank-of-america-securities-2022-heal-rlay-20220503monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-announce-first-quarter-2022-financial-results-and-corporate-highligh-rlay-20220428monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-announce-fourth-quarter-and-full-year-2021-financial-results-and-cor-rlay-20220217monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-rlay-20220202monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-dosing-of-first-patient-in-first-in-human-trial-of-rly-2608-a-rlay-20220104monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-present-at-40th-annual-j-p-morgan-healthcare-conference-rlay-20220103monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-preclinical-data-that-support-clinical-development-of-rly-260-rlay-20211210monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-announce-third-quarter-2021-financial-results-and-recent-corporate-h-rlay-20211104monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-pricing-of-public-offering-of-common-stock-rlay-20211013monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-interim-clinical-data-that-support-rly-4008-as-a-highly-selec-rlay-20211008monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-present-clinical-data-on-rly-4008-and-preclinical-data-on-rly-2608-a-rlay-20210913monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-announce-second-quarter-2021-financial-results-and-recent-corporate--rlay-20210805monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-rlay-20210602monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-participate-in-fireside-chat-at-the-cowen-2nd-annual-oncology-innova-rlay-20210514monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-strengthens-computational-leadership-team-with-addition-of-patrick-rile-rlay-20210510monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-participate-in-fireside-chat-at-bank-of-america-2021-health-care-con-rlay-20210505monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-present-preclinical-data-on-rly-4008-at-aacr-annual-meeting-rlay-20210310monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-participate-in-fireside-chat-at-guggenheim-healthcare-talks-2021-onc-rlay-20210204monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference-rlay-20210106monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-dosing-of-first-patient-in-first-in-human-clinical-trial-of-r-rlay-20200903monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-closing-of-initial-public-offering-and-full-exercise-of-under-rlay-20200720monthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-announces-pricing-of-initial-public-offering-rlay-20200716monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-expands-partnership-with-merge-as-ai-powered-agency-of-record-supn-20260617monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-participate-in-march-investor-conferences-supn-20260223monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-participate-in-the-piper-sandler-37th-annual-healthcare-confer-supn-20251121monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-participate-in-the-2025-jefferies-global-healthcare-conference-supn-20250528monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-participate-in-two-upcoming-investor-conferences-supn-20250304monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-participate-in-the-td-cowen-45th-annual-health-care-conference-supn-20250227monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-participate-in-the-36th-annual-piper-sandler-healthcare-conference-supn-20241126monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-participate-in-the-2024-jefferies-london-healthcare-conference-supn-20241113monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-presents-promising-data-from-open-label-phase-2a-study-of-spn-820-data-in-major-d-supn-20241031monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-host-webcast-to-review-open-label-phase-2a-study-of-spn-820-fo-supn-20241010monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-participate-in-the-td-cowen-4th-annual-novel-mechanisms-in-neu-supn-20240919monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-participate-in-the-2024-wells-fargo-healthcare-conference-supn-20240828monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference-supn-20240530monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-provides-regulatory-update-for-spn-830-supn-20240408monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-participate-in-two-upcoming-investor-conferences-supn-20240306monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-participate-in-the-td-cowen-44th-annual-healthcare-conference-supn-20240228monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-participate-in-the-jefferies-london-healthcare-conference-supn-20231107monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-announces-webcast-of-r-d-day-to-be-held-on-october-18-2023-in-new-supn-20230927monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-new-qelbree-data-showing-improvement-in-adhd-symptoms-supn-20230910monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-participate-in-the-wells-fargo-healthcare-conference-supn-20230831monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-participate-in-the-jefferies-healthcare-conference-supn-20230531monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-the-bank-of-america-2023-health-care-conference-supn-202305022023-05-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-repayment-of-convertible-notes-supn-202304032023-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-participate-in-two-upcoming-investor-conferences-supn-202303082023-03-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-the-cowen-43rd-annual-health-care-conference-supn-202303012023-03-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-enters-into-150-million-credit-facility-supn-202302142023-02-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-the-piper-sandler-34th-annual-healthcare-conference-supn-20221122monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-two-november-healthcare-conferences-supn-20221108monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-provides-regulatory-update-on-spn-830-supn-20221010monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-the-2022-wells-fargo-healthcare-conference-supn-20220831monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-participate-in-the-jefferies-healthcare-conference-supn-20220602monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-to-announce-first-quarter-2022-financial-results-and-host-confere-supn-20220502monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-participate-in-annual-cowen-health-care-conference-supn-20220302monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-receives-notice-assigning-early-october-2022-pdufa-for-spn-830-apomorphine-infusi-supn-20220222monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-announces-expiration-of-hart-scott-rodino-waiting-period-for-adam-supn-20211123monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-participate-in-annual-piper-sandler-healthcare-conference-supn-20211118monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-participate-in-upcoming-november-investor-conferences-supn-20211110monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-participate-in-upcoming-september-investor-conferences-supn-20210902monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-jefferies-virtual-healthcare-conference-supn-20210525monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-paragraph-iv-anda-filing-for-xadago-supn-20210505monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-cowen-healthcare-conference-supn-20210226monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-j-p-morgan-39th-annual-healthcare-conference-supn-20210106monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-participate-in-annual-piper-sandler-healthcare-conference-supn-20201119monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-two-november-investor-conferences-supn-20201112monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-provides-regulatory-updates-for-spn-812-and-spn-830-supn-20201109monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-third-quarter-2020-financial-results-conference-call-supn-20201027monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-the-morgan-stanley-18th-annual-global-healthcare-conference-supn-20200909monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-first-quarter-2020-financial-results-supn-20200505monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-provides-business-update-supn-20200330monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-the-2020-cowen-health-care-conference-supn-20200226monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-fourth-quarter-and-full-year-2019-financial-results-supn-20200225monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-two-november-healthcare-conferences-supn-20191112monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-webcast-of-investor-day-on-april-16-2019-supn-20190401monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-p304-phase-iii-data-confirming-positive-results-from-previous-three-pha-supn-20190328monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-the-2019-j-p-morgan-healthcare-conference-supn-20181221monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-positive-results-from-two-phase-iii-studies-for-spn-812-in-children-wit-supn-20181206monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-acquire-biscayne-neurotherapeutics-supn-20180913monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-wins-appeal-on-oxtellar-xr-against-twi-supn-20180906monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-proposed-private-offering-of-350-million-of-convertible-senior-notes-supn-20180313monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-mourns-the-loss-of-board-member-william-nuerge-supn-20180112monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-the-2018-j-p-morgan-healthcare-conference-supn-20180102monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-cowen-health-care-conference-in-march-supn-20170227monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-wins-appeal-case-on-oxtellar-xr-supn-20161212monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-receives-nasdaq-non-compliance-notice-supn-20161117monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-provides-business-update-supn-20161114monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-host-a-business-update-call-supn-20161111monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-positive-results-from-phase-iib-clinical-trial-for-spn-812-in-children--supn-20161011monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-march-cowen-health-care-conference-supn-20160225monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-prevails-in-oxtellar-xr-anda-litigation-supn-20160208monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-distribution-of-common-stock-by-nea-supn-20151204monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-two-investor-conferences-supn-20151109monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-settlement-with-par-on-trokendi-xr-r-patent-litigation-supn-20151015monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-corrects-earlier-statement-regarding-distribution-of-common-stock-by-nea-supn-20150617monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-distribution-of-common-stock-by-nea-supn-20150617monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-webcast-of-investor-day-on-june-17-2015-supn-20150608monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-march-cowen-conference-supn-20150218monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-sues-twi-for-infringement-of-oxtellar-xr-r-patents-supn-20150121monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-sues-par-for-infringement-of-trokendi-xr-r-patents-supn-20150116monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-paragraph-iv-anda-filing-for-oxtellar-xr-r-supn-20141210monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-paragraph-iv-anda-filing-for-trokendi-xr-r-supn-20141209monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-issuance-of-fifth-u-s-patent-protecting-trokendi-xr-r-supn-20141124monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-sues-zydus-for-infringement-of-trokendi-xr-r-patents-supn-20141121monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-third-quarter-2014-results-supn-20141111monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-issuance-of-fourth-u-s-patent-protecting-trokendi-xr-r-supn-20141107monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-two-investor-conferences-supn-20141104monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-sues-actavis-for-infringement-of-trokendi-xr-r-patents-supn-20141002monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-provides-business-update-supn-20140922monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-attend-fbr-healthcare-conference-in-september-supn-20140819monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-second-quarter-2014-results-supn-20140811monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-receive-30-million-in-non-dilutive-royalty-deal-supn-20140708monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-jefferies-healthcare-conference-in-june-supn-20140521monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-receives-2-million-milestone-for-united-therapeutics-launch-of-orenitram-tm-supn-20140520monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-first-quarter-2014-results-supn-20140512monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-issuance-of-third-us-patent-protecting-oxtellar-xr-r-supn-20140107monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-resignation-of-board-member-supn-20131224monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-fda-approval-of-its-partner-s-product-orenitram-tm-supn-20131223monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-posts-exciting-clinical-data-regarding-trokendi-xr-tm-and-oxtellar-xr-tm-on-the-c-supn-20131212monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-piper-jaffray-healthcare-conference-in-december-supn-20131121monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-reports-third-quarter-2013-financial-results-supn-20131112monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-third-quarter-2013-earnings-conference-call-and-webcast-supn-20131107monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-release-of-exciting-new-clinical-data-on-trokendi-xr-tm-supn-20131106monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-launches-trokendi-xr-tm-in-the-united-states-supn-20130905monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-two-investor-conferences-in-september-supn-20130829monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-final-fda-approval-and-upcoming-launch-of-trokendi-xr-tm-supn-20130819monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-reports-second-quarter-2013-financial-results-supn-20130813monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-sues-watson-for-infringement-of-oxtellar-xr-tm-patents-supn-20130807monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-second-quarter-2013-earnings-conference-call-and-webcast-supn-20130806monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-paragraph-iv-anda-filing-for-oxtellar-xr-tm-supn-20130627monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-receives-tentative-approval-for-trokendi-xr-tm-supn-20130610monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-two-investor-conferences-supn-20130520monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-reports-first-quarter-2013-financial-results-supn-20130513monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-first-quarter-2013-earnings-conference-call-and-webcast-supn-20130506monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-closing-of-90-million-of-7-50-convertible-senior-secured-notes-due-2019-supn-20130506monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-prices-offering-of-75-million-of-7-50-convertible-senior-secured-notes-due-2019-supn-20130426monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-proposed-offering-of-75-million-of-convertible-senior-secured-notes-supn-20130424monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-reports-fourth-quarter-2012-and-full-year-2012-financial-results-supn-20130314monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-year-end-and-fourth-quarter-2012-earnings-conference-call-and-webcast-supn-20130308monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-launches-oxtellar-xr-tm-in-the-united-states-supn-20130201monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-appoints-victor-vaughn-as-senior-vice-president-of-sales-supn-20130115monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-pricing-of-public-offering-supn-20121130monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-positive-phase-iib-results-on-spn-810-and-decision-to-advance-to-late-s-supn-20121121monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-receives-three-years-of-market-exclusivity-for-oxtellar-xr-tm-supn-20121119monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-reports-third-quarter-2012-financial-results-supn-20121107monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-issuance-of-two-patents-covering-trokendi-xr-tm-supn-20121105monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-resignation-of-board-member-supn-20121031monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-receives-fda-approval-for-oxtellar-xr-tm-in-epilepsy-supn-20121022monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-to-present-at-two-investor-conferences-in-september-2012-supn-20120829monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-reports-second-quarter-2012-financial-results-supn-20120810monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-appoints-dr-stefan-schwabe-md-phd-as-exec-vp-r-d-and-chief-medical-officer-supn-20120720monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-provides-update-on-the-launch-of-its-two-epilepsy-products-trokendi-xr-tm-and-spn-supn-20120713monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-receives-tentative-approval-of-trokendi-xr-tm-from-fda-supn-20120626monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-reports-first-quarter-2012-financial-results-supn-20120607monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-inc-announces-closing-of-initial-public-offering-supn-20120504monthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-inc-announces-pricing-of-initial-public-offering-supn-20120501monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-investigation-alert-bragar-eagel-squire-p-c-is-investigating-qiagen-n-v-on-behalf-o-qgen-20260515monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-n-v-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-more-information-qgen-20260429monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-nv-qia-2025-product-pipeline-and-strategy-analysis-report-qgen-20251021monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-expands-automated-liquid-biopsy-portfolio-to-enhance-oncology-prenatal-care-and-org-qgen-20241010monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-n-v-to-release-results-for-q3-2024-and-hold-webcast-qgen-20241010monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-launches-qiacuitydx-digital-pcr-system-for-clinical-testing-in-oncology-qgen-20240930monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-receives-european-ivdr-certification-for-qiastat-dx-syndromic-testing-instruments-a-qgen-20240926monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-and-bode-technology-partner-to-advance-use-of-gedmatch-pro-forensic-genetic-genealo-qgen-20240923monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-expands-qiacuity-digital-pcr-offering-with-over-new-100-assays-via-geneglobe-platfo-qgen-20240918monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-and-bio-manguinhos-fiocruz-collaborate-to-enhance-malaria-and-dengue-detection-in-b-qgen-20240912monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-and-lilly-collaborate-to-support-development-of-a-qiastat-dx-ivd-panel-that-identif-qgen-20240904monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-n-v-announces-conversion-price-of-new-net-share-settled-convertible-bonds-qgen-20240903monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-n-v-announces-successful-placement-of-new-net-share-settled-convertible-bonds-qgen-20240903monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-n-v-launches-non-us-offering-of-net-share-settled-convertible-bonds-qgen-20240903monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-expands-qiastat-dx-into-precision-medicine-through-partnership-for-companion-diagno-qgen-20240828monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-delivers-solid-performance-and-exceeds-outlook-for-q2-2024-qgen-20240731monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-to-enhance-the-identification-of-human-remains-of-indigenous-people-and-african-ame-qgen-20240708monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-n-v-to-release-results-for-q2-2024-and-hold-webcast-qgen-20240702monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-welcomes-new-u-s-guidelines-for-use-of-quantiferon-tb-gold-plus-in-detecting-tuberc-qgen-20240627monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-s-software-qci-interpret-accelerates-clinical-reporting-turnaround-time-for-high-th-qgen-20240613monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-publishes-2023-sustainability-report-highlighting-progress-on-esg-goals-and-commitm-qgen-20240612monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-launches-new-qiacuity-digital-pcr-assays-for-microbial-applications-enhancing-infec-qgen-20240611monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-launches-digital-pcr-assay-design-tool-for-qiacuity-expands-customization-capabilit-qgen-20240605monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-expands-qiastat-dx-syndromic-testing-menu-in-the-u-s-with-launch-of-molecular-test--qgen-20240603monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-and-myriad-genetics-develop-distributable-homologous-recombination-deficiency-test--qgen-20240530monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-launches-new-library-preparation-kit-facilitating-multiomic-studies-and-advancing-p-qgen-20240529monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-receives-european-ivdr-certification-for-qiagen-clinical-insight-interpret-its-medi-qgen-20240514monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-receives-fda-clearance-for-qiastat-dx-respiratory-syndromic-testing-panel-for-fast--qgen-20240513monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-partners-with-fbi-to-develop-digital-pcr-assay-for-qiacuity-for-use-in-forensics-qgen-20240507monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-enhances-bioinformatics-workflows-with-new-secondary-analysis-solution-for-oncology-qgen-20240502monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-expands-tuberculosis-portfolio-with-new-ngs-panel-to-support-real-time-surveillance-qgen-20240424monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-n-v-to-release-results-for-q1-2024-and-hold-webcast-qgen-20240409monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-strengthens-its-portfolio-for-cancer-research-showcasing-latest-product-launches-at-qgen-20240403monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-introduces-qiastat-dx-analyzer-2-0-with-remote-test-results-access-enhancing-collab-qgen-20240325monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-partners-with-international-panel-physicians-association-to-increase-awareness-of-t-qgen-20240318monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-announces-form-20-f-annual-report-filing-for-2023-results-qgen-20240311monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-launches-ai-derived-biomedical-knowledge-base-to-accelerate-data-driven-drug-discov-qgen-20240227monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-earns-act-label-for-new-eco-friendlier-qiawave-products-and-achieves-first-my-green-qgen-20240215monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-exceeds-outlook-for-q4-2023-led-by-8-cer-sales-growth-in-non-covid-products-and-imp-qgen-20240206monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-announces-partnership-with-penn-state-university-to-advance-microbiome-sciences-qgen-20240125monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-n-v-to-release-results-for-q4-2023-and-hold-webcast-qgen-20240111monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-receives-fda-clearance-of-neumodx-ct-ng-assay-for-use-on-both-neumodx-96-and-288-mo-qgen-20240108monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-announces-plans-to-return-approximately-300-million-to-shareholders-qgen-20240107monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-to-accelerate-investments-into-qiagen-digital-insights-bioinformatics-business-qgen-20240104monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-expands-business-in-middle-east-with-new-regional-headquarters-and-major-projects-qgen-20240103monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-launches-tissuelyser-iii-and-rneasy-powermax-soil-pro-kit-for-improved-sample-proce-qgen-20231115monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-launches-new-qiacuity-digital-pcr-kits-and-updated-software-to-expand-use-by-biopha-qgen-20231109monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-launches-complete-sample-to-insight-workflow-for-microbiome-research-qgen-20231106monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-and-element-biosciences-partner-to-offer-complete-next-generation-sequencing-workfl-qgen-20231102monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-exceeds-outlook-for-q3-2023-with-5-cer-sales-growth-in-non-covid-products-and-adjus-qgen-20231030monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-and-myriad-genetics-partner-to-advance-companion-diagnostics-development-for-cancer-qgen-20231026monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-n-v-to-release-results-for-q3-2023-and-hold-webcast-qgen-20231009monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-launches-quantiferon-ebv-ruo-assay-facilitating-research-of-cell-mediated-immune-re-qgen-20231004monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-extends-ai-capabilities-of-its-ngs-interpretation-software-qci-interpret-to-enable--qgen-20230928monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-s-quantiferon-solutions-recommended-for-use-by-kidney-specialists-in-tunisia-qgen-20230928monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-reports-progress-toward-achieving-environmental-social-and-governance-goals-in-2022-qgen-20230927monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-enhances-qiawave-portfolio-with-new-eco-friendlier-nucleic-acid-extraction-kits-qgen-20230925monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-delivers-ahead-of-outlook-for-q2-2023-with-9-cer-sales-growth-in-non-covid-products-qgen-20230808monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-receives-fda-approval-for-companion-diagnostic-to-blueprint-medicines-ayvakit-avapr-qgen-20230807monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-n-v-to-release-results-for-q2-2023-and-hold-webcast-qgen-20230724monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-expands-range-of-digital-pcr-kits-and-services-for-the-biopharma-industry-qgen-20230718monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-provides-reminder-on-settlement-mechanics-of-2023-and-2024-convertible-notes-qgen-20230616monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-s-quantiferon-tb-gold-plus-shows-unique-clinical-value-with-cd8-technology-in-new-m-qgen-20230615monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-exceeds-outlook-for-q1-2023-with-12-cer-sales-growth-in-non-covid-product-portfolio-qgen-202305032023-05-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-welcomes-u-s-preventive-services-task-force-reaffirmation-for-latent-tb-screening-i-qgen-202305032023-05-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-launches-qiastat-dx-in-japan-with-respiratory-panel-for-syndromic-testing-qgen-202304242023-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-announces-expansion-of-supervisory-board-qgen-202304202023-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-showcases-latest-technologies-to-advance-cancer-research-at-aacr-annual-meeting-202-qgen-202304142023-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-s-qiaxcel-connect-wins-red-dot-design-award-qgen-202303292023-03-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-receives-approval-for-its-net-zero-carbon-emissions-target-by-science-based-targets-qgen-202303272023-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-merger-investigation-halper-sadeh-llp-announces-investigation-into-whether-the-sale-qgen-20200303monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-and-tecan-announce-collaboration-to-streamline-preanalytical-processing-of-quantife-qgen-20190308monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-and-neogenomics-collaborate-to-offer-cancer-patients-day-one-access-to-innovative-c-qgen-20181130monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-and-clinical-genomics-partner-on-liquid-biopsies-to-monitor-patients-for-recurrence-qgen-20170821monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-posts-2013-annual-report-on-its-website-qgen-20140424monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-n-v-to-report-first-quarter-2014-results-and-hold-webcast-qgen-20140409monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-n-v-to-report-fourth-quarter-and-full-year-2013-results-and-hold-webcast-qgen-20140113monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-announces-european-launch-of-therascreen-r-idh1-2-test-for-gliomas-qgen-20140106monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-n-v-to-announce-third-quarter-2013-financial-results-qgen-20131009monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-n-v-to-announce-second-quarter-2013-financial-results-qgen-20130716monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-posts-2012-annual-report-on-its-website-qgen-20130515monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-n-v-to-report-first-quarter-2013-results-and-hold-webcast-qgen-20130415monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-n-v-to-report-fourth-quarter-and-full-year-2012-results-and-hold-webcast-qgen-20130115monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-to-present-at-the-31st-annual-j-p-morgan-healthcare-conference-qgen-20130104monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-n-v-reschedules-publication-of-q3-2012-results-due-to-severe-u-s-weather-conditions-qgen-20121030monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-n-v-to-report-third-quarter-2012-results-and-hold-webcast-qgen-20121016monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-n-v-to-report-second-quarter-2012-results-and-hold-webcast-qgen-20120723monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-posts-2011-annual-report-on-its-website-qgen-20120508monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-n-v-to-report-first-quarter-2012-results-and-hold-webcast-qgen-20120418monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-posts-2010-annual-report-on-its-website-qgen-20110516monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-reports-first-quarter-2011-results-qgen-20110427monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-reports-full-year-and-fourth-quarter-2010-results-qgen-20110131monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-to-present-at-the-jpmorgan-29th-annual-healthcare-conference-qgen-20110104monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-reports-third-quarter-2010-results-qgen-20101108monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-reports-solid-second-quarter-2010-results-qgen-20100809monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-posts-2009-annual-report-on-its-website-qgen-20100601monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-reports-strong-first-quarter-2010-results-qgen-20100503monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-reports-strong-fourth-quarter-and-fiscal-2009-results-qgen-20100208monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-to-present-at-the-jpmorgan-28th-annual-healthcare-conference-qgen-20100106monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-added-to-nasdaq-100-index-qgen-20091214monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-reports-strong-third-quarter-2009-results-qgen-20091109monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-announces-exercise-in-full-of-over-allotment-option-by-underwriters-in-offering-of--qgen-20090929monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-announces-pricing-of-offering-of-new-common-shares-qgen-20090924monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-announces-an-offering-of-new-common-shares-qgen-20090922monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-acquires-dxs-ltd-creating-leadership-in-personalized-healthcare-qgen-20090922monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-reports-strong-second-quarter-2009-results-and-increases-full-year-2009-guidance-qgen-20090810monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-transfers-distribution-rights-for-transplantation-testing-product-portfolio-and-rel-qgen-20090616monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-to-present-at-the-goldman-sachs-30th-annual-global-healthcare-conference-qgen-20090603monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-posts-2008-annual-report-on-its-website-qgen-20090603monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-to-present-at-the-bank-of-america-and-merrill-lynch-2009-healthcare-conference-qgen-20090507monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-to-present-at-baird-s-2009-growth-stock-conference-qgen-20090506monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-reports-first-quarter-2009-results-qgen-20090504monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-reports-strong-fourth-quarter-and-fiscal-2008-results-qgen-20090209monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-and-applied-biosystems-settle-all-disputes-over-real-time-pcr-thermal-cycler-patent-qgen-20090122monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-to-present-at-the-jpmorgan-27th-annual-healthcare-conference-qgen-20090107monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-introduces-ce-marked-molecular-assay-for-the-cancer-biomarker-k-ras-qgen-20081110monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-reports-strong-third-quarter-2008-results-qgen-20081110monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-acquires-biosystems-business-from-biotage-qgen-20081001monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-to-present-at-the-2008-ubs-global-life-sciences-conference-qgen-20080918monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-launches-olerup-ssp-ab-s-new-test-for-detecting-adverse-reactions-to-hiv-medicine-i-qgen-20080822monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-and-idaho-technology-settle-patent-dispute-qgen-20080804monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-reports-second-quarter-2008-results-and-increases-full-year-2008-adjusted-eps-guida-qgen-20080804monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-acquires-corbett-life-science-qgen-20080701monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-files-appeal-in-patent-case-qgen-20080611monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-to-present-at-the-goldman-sachs-29th-annual-global-healthcare-conference-qgen-20080606monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-to-present-at-bank-of-america-2008-health-care-conference-qgen-20080508monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-to-present-at-baird-s-2008-growth-stock-conference-qgen-20080507monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-reports-strong-first-quarter-2008-results-qgen-20080505monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-and-biohelix-enter-into-licensing-agreement-qgen-20080430monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-to-present-at-deutsche-bank-33rd-annual-health-care-conference-qgen-20080429monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-reports-strong-fourth-quarter-and-fiscal-2007-results-qgen-20080211monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-wins-judgment-against-third-wave-qgen-20080112monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-to-supply-singapore-ministry-of-health-with-avian-flu-surveillance-solutions-qgen-20080108monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-and-ventana-announce-settlement-of-patent-dispute-qgen-20071219monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-to-present-at-the-jpmorgan-26th-annual-healthcare-conference-qgen-20071212monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-reports-third-quarter-2007-results-increases-full-year-2007-guidance-qgen-20071105monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-to-present-at-the-2007-ubs-global-life-sciences-conference-qgen-20070917monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-reports-strong-second-quarter-2007-results-qgen-20070806monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-completes-acquisition-of-egene-qgen-20070709monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-launches-first-qiaplex-products-for-highly-multiplexed-pcr-based-assays-qgen-20070601monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-and-biomatrica-announce-strategic-partnership-targeting-biological-sample-storage-a-qgen-20070531monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-and-epigenomics-expand-successful-partnership-qgen-20070529monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-launches-novel-assay-technology-for-mirna-targets-qgen-20070507monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-reports-strong-first-quarter-2007-results-qgen-20070507monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-s-molecular-assays-detect-recently-discovered-chlamydia-trachomatis-strain-qgen-20070228monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-introduces-novel-technology-and-product-line-that-significantly-accelerates-pcr-rea-qgen-20061024monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-n-v-qgen-ceo-to-ring-the-nasdaq-stock-market-opening-bell-qgen-20060628monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-to-present-at-the-ubs-global-life-sciences-conference-qgen-20050919monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-to-present-at-the-ubs-global-life-sciences-conference-qgen-20040921monthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-and-evotec-technologies-demonstrate-significant-benefits-of-combining-rnai-applicat-qgen-20040913monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20260605monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-management-to-present-at-goldman-sachs-47th-annual-global-healthcare-conference-arqt-20260526monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20260508monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-first-quarter-2026-financial-results-and-provides-business-update-arqt-20260506monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-zoryve-roflumilast-cream-receives-strong-recommendation-in-american-academy-of-der-arqt-20260422monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-presents-new-phase-2-results-in-infants-with-atopic-dermatitis-in-late-breaking-se-arqt-20260328monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-new-clinical-data-in-a-late-breaking-podium-presentation-and-scientific-arqt-20260318monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-publication-of-positive-long-term-safety-and-efficacy-data-with-zoryve-r-arqt-20260310monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-management-to-present-at-td-cowen-s-46th-annual-health-care-conference-arqt-20260227monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-highlights-2026-strategic-priorities-and-anticipated-milestones-arqt-20260112monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-strengthens-board-of-directors-with-new-appointment-of-amit-munshi-and-honors-reti-arqt-20251208monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-launches-zoryve-roflumilast-cream-0-05-for-the-treatment-of-mild-to-moderate-atopi-arqt-20251030monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20251003monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financi-arqt-20250929monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-multiple-new-zoryve-roflumilast-data-analyses-at-european-academy-of-de-arqt-20250917monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20250905monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-submits-supplemental-new-drug-application-for-zoryve-roflumilast-cream-0-3-to-expa-arqt-20250903monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-upcoming-investor-conferences-arqt-20250819monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20250808monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-second-quarter-2025-financial-results-and-provides-business-update-arqt-20250806monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-report-second-quarter-2025-financial-results-and-host-conference-call-on-august-arqt-20250723monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20250703monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-zoryve-roflumilast-cream-0-15-receives-strong-recommendation-in-american-academy-o-arqt-20250626monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-enrolls-first-child-in-integument-infant-evaluating-zoryve-roflumilast-cream-0-05--arqt-20250610monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20250606monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-new-long-term-results-of-zoryve-roflumilast-cream-at-the-2025-revolutio-arqt-20250606monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-the-goldman-sachs-46th-annual-global-healthcare-conference-arqt-20250529monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-zoryve-roflumilast-topical-foam-0-3-approved-by-u-s-fda-for-the-treatment-of-plaqu-arqt-20250522monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-publication-of-positive-data-from-arrector-trial-evaluating-zoryve-roflu-arqt-20250507monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-first-quarter-2025-financial-results-and-provides-business-update-arqt-20250506monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20250502monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-report-first-quarter-2025-financial-results-and-host-conference-call-on-may-6-2-arqt-20250417monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-chief-financial-officer-transition-arqt-20250410monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20250404monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-and-padagis-agree-to-stay-patent-lawsuit-arqt-20250402monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-the-24th-annual-needham-virtual-healthcare-conference-arqt-20250327monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-highlight-data-from-phase-3-trials-for-scalp-and-body-psoriasis-and-atopic-derm-arqt-20250307monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20250305monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-two-posters-at-the-83rd-american-academy-of-dermatology-annual-meeting-arqt-20250228monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-fourth-quarter-and-full-year-2024-financial-results-and-provides-busines-arqt-20250225monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-publication-of-positive-data-from-integument-ped-trial-evaluating-zoryve-arqt-20250224monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-the-td-cowen-45th-annual-health-care-conference-arqt-20250218monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20250205monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-the-guggenheim-smid-cap-biotech-conference-arqt-20250127monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-preliminary-unaudited-fourth-quarter-product-revenue-and-full-year-2024--arqt-20250112monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20250106monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-submits-zoryve-roflumilast-cream-0-05-supplemental-new-drug-application-to-the-fda-arqt-20241216monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20241206monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-promotions-on-executive-management-team-arqt-20241203monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-zoryve-roflumilast-awarded-best-eczema-treatment-by-glamour-arqt-20241113monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-third-quarter-2024-financial-results-and-provides-business-update-arqt-20241106monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20241104monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-presents-positive-patient-reported-outcome-data-for-zoryve-roflumilast-cream-0-15--arqt-20241024monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-report-third-quarter-2024-financial-results-and-participate-in-an-upcoming-inve-arqt-20241023monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-health-canada-approval-of-zoryve-roflumilast-foam-0-3-to-treat-seborrhei-arqt-20241018monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20241004monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-publication-of-zoryve-roflumilast-cream-0-15-pivotal-results-from-phase--arqt-20240919monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20240905monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-completes-enrollment-of-phase-1b-alopecia-areata-study-evaluating-arq-255-arqt-20240905monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-positive-long-term-results-of-roflumilast-cream-0-05-show-durable-and-im-arqt-20240828monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-the-morgan-stanley-22nd-annual-global-healthcare-conference-arqt-20240822monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-second-quarter-2024-financial-results-and-provides-business-update-arqt-20240814monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20240802monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-report-second-quarter-2024-financial-results-and-host-conference-call-on-august-arqt-20240801monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-zoryve-u-s-co-promote-agreement-with-kowa-pharmaceuticals-america-inc-arqt-20240729monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-launches-zoryve-roflumilast-cream-0-15-for-the-treatment-of-atopic-dermatitis-arqt-20240729monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-submits-supplemental-new-drug-application-for-zoryve-roflumilast-foam-to-the-fda-f-arqt-20240723monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-host-zoryve-roflumilast-cream-0-15-fda-approval-call-with-kol-arqt-20240722monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-provides-update-on-snda-for-roflumilast-cream-0-15-for-atopic-dermatitis-arqt-20240709monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20240703monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-new-long-term-data-of-roflumilast-cream-0-15-for-the-treatment-of-mild-t-arqt-20240610monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20240605monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-multiple-abstracts-including-oral-presentation-accepted-at-the-revolutio-arqt-20240605monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-the-goldman-sachs-45th-annual-global-healthcare-conference-arqt-20240603monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-first-quarter-2024-financial-results-and-provides-business-update-arqt-20240514monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20240503monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-report-first-quarter-2024-financial-results-and-host-conference-call-on-may-14--arqt-20240429monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-appoints-david-topper-as-chief-financial-officer-arqt-20240410monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20240405monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-the-23rd-annual-needham-virtual-healthcare-conference-arqt-20240328monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-promotes-todd-tucker-to-chief-human-resources-officer-arqt-20240311monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-presents-late-breaking-data-from-integument-ped-phase-3-trial-of-roflumilast-cream-arqt-20240310monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20240305monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-closing-of-public-offering-of-common-stock-and-full-exercise-by-underwri-arqt-20240304monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-acceptance-of-late-breaking-abstract-in-atopic-dermatitis-among-five-new-arqt-20240304monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-the-td-cowen-44th-annual-health-care-conference-arqt-20240229monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-pricing-of-150-million-public-offering-arqt-20240229monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-proposed-public-offering-arqt-20240228monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-and-sato-announce-strategic-collaboration-and-licensing-agreement-for-topical-rofl-arqt-20240228monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-fourth-quarter-and-full-year-2023-financial-results-and-provides-busines-arqt-20240227monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-report-fourth-quarter-and-full-year-2023-financial-results-arqt-20240216monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20240206monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-the-guggenheim-healthcare-talks-6th-annual-biotechnology-conference-arqt-20240131monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20231202monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-third-quarter-2023-financial-results-and-provides-business-update-arqt-20231103monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20231102monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-report-third-quarter-2023-financial-results-arqt-20231025monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-pricing-of-100-million-public-offering-arqt-20231020monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-proposed-public-offering-arqt-20231019monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-presents-positive-patient-reported-outcome-data-from-the-pivotal-arrector-phase-3--arqt-20231013monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20231005monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-appoints-l-todd-edwards-as-chief-commercial-officer-arqt-20230927monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-positive-results-from-integument-ped-pivotal-phase-3-trial-of-roflumilas-arqt-20230919monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20230915monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-submits-roflumilast-cream-0-15-supplemental-new-drug-application-to-the-fda-for-th-arqt-20230912monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-positive-long-term-results-of-roflumilast-cream-0-15-showing-durable-and-arqt-20230907monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-upcoming-investor-conference-arqt-20230905monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-publishes-annual-environmental-social-and-governance-esg-report-arqt-20230831monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-launches-first-television-ad-for-zoryve-roflumilast-cream-0-3-arqt-20230829monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-appoints-interim-chief-financial-officer-cfo-arqt-20230818monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-and-huadong-announce-strategic-collaboration-and-licensing-agreement-for-topical-r-arqt-20230810monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-second-quarter-2023-financial-results-and-provides-business-update-arqt-20230808monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20230804monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-report-second-quarter-financial-results-arqt-20230724monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-zoryve-roflumilast-cream-0-3-has-been-included-in-a-preferred-position-o-arqt-20230717monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20230705monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-upcoming-investor-conference-arqt-20230606monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20230605monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-leadership-transition-arqt-20230524monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-first-quarter-2023-financial-results-and-provides-business-update-arqt-20230509monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20230505monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-completes-enrollment-in-integument-ped-pivotal-phase-3-trial-of-roflumilast-cream--arqt-20230502monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-canadian-approval-of-zoryve-roflumilast-cream-0-3-for-treatment-of-plaqu-arqt-20230428monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-report-first-quarter-financial-results-arqt-20230425monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-fda-acceptance-of-new-drug-application-for-roflumilast-foam-0-3-for-the--arqt-20230418monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-upcoming-investor-conference-arqt-20230412monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20230407monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-new-coverage-for-zoryve-roflumilast-cream-0-3-with-national-and-regional-arqt-20230405monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-presents-late-breaking-data-from-the-integument-phase-3-trials-in-atopic-dermatiti-arqt-20230318monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-new-topical-roflumilast-data-including-late-breaking-atopic-dermatitis--arqt-20230309monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20230303monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-fourth-quarter-and-full-year-2022-financial-results-and-provides-busines-arqt-20230228monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-submits-topical-roflumilast-foam-0-3-new-drug-application-to-the-fda-for-the-treat-arqt-20230221monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-report-fourth-quarter-2022-financial-results-and-participate-in-upcoming-invest-arqt-20230208monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20230203monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-presents-new-phase-2-long-term-data-showing-sustained-efficacy-and-clearance-for-a-arqt-20230114monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20230105monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-submits-supplemental-new-drug-application-for-zoryve-roflumilast-cream-0-3-for-exp-arqt-20221219monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-positive-topline-results-from-second-atopic-dermatitis-pivotal-phase-3-t-arqt-20221212monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20221205monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-enrolls-first-patient-in-phase-1b-alopecia-areata-study-evaluating-arq-255-arqt-20221205monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-publishes-first-environmental-social-and-governance-esg-report-arqt-20221121monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-zoryve-roflumilast-cream-0-3-added-to-express-scripts-inc-national-formularies-in--arqt-20221117monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-positive-topline-results-from-integument-1-pivotal-phase-3-trial-of-rofl-arqt-20221115monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-upcoming-investor-conference-arqt-20221111monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-third-quarter-2022-financial-results-and-provides-business-update-arqt-20221108monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-report-third-quarter-financial-results-arqt-20221025monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20221005monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-positive-topline-results-from-arrector-pivotal-phase-3-trial-of-roflumil-arqt-20220926monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20220902monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-appointment-of-neha-krishnamohan-to-board-of-directors-arqt-20220902monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-upcoming-investor-conference-arqt-20220901monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-arcutis-cares-patient-assistance-program-pap-for-financially-qualified-u-arqt-20220822monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-launches-zoryve-roflumilast-cream-0-3-in-the-united-states-for-treatment-of-plaque-arqt-20220810monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-second-quarter-2022-financial-results-and-provides-business-update-arqt-20220804monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-completes-enrollment-in-integument-1-pivotal-phase-3-trial-of-roflumilast-cream-in-arqt-20220804monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20220803monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-announces-pricing-of-public-offering-of-common-stock-arqt-20220803monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-announces-proposed-public-offering-of-common-stock-arqt-20220802monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-host-investor-conference-call-today-to-discuss-the-fda-approval-of-zoryve-roflu-arqt-20220801monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-announces-health-canada-accepts-for-review-the-new-drug-submission-arqt-20220711monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20220705monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-positive-topline-results-from-stratum-pivotal-phase-3-trial-of-roflumila-arqt-20220606monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20220603monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-first-quarter-2022-financial-results-and-provides-business-update-arqt-20220505monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20220505monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-completes-enrollment-in-arrector-pivotal-phase-3-trial-of-topical-roflumilast-foam-arqt-20220406monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-highlights-growth-opportunities-at-investor-day-in-advance-of-2022-catalysts-arqt-20220328monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-roflumilast-foam-demonstrates-clinically-meaningful-results-and-patient-quality-of-arqt-20220325monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-presents-new-data-on-once-daily-roflumilast-cream-for-plaque-psoriasis-from-dermis-arqt-20220325monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-host-investor-day-on-march-28-arqt-20220321monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-arqt-20220314monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-upcoming-investor-conference-arqt-20220302monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-fourth-quarter-and-full-year-2021-financial-results-and-provides-busines-arqt-20220222monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-completes-enrollment-of-stratum-pivotal-phase-3-trial-of-topical-roflumilast-foam--arqt-20220201monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-secures-225-million-in-non-dilutive-debt-financing-from-slr-capita-arqt-20211223monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-appoints-mas-matsuda-as-general-counsel-and-corporate-secretary-arqt-20211216monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-data-comparing-the-vehicle-in-investigational-roflumilast-cream-against--arqt-20211213monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-upcoming-investor-conference-arqt-20211110monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-third-quarter-2021-financial-results-and-provides-business-update-arqt-20211104monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-submits-topical-roflumilast-cream-new-drug-application-to-fda-for-the-treatment-of-arqt-20211004monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-expands-patent-portfolio-with-roflumilast-pharmacokinetics-patent-arqt-20210928monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-upcoming-investor-conferences-arqt-20210909monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors-arqt-20210902monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-enrolls-first-patient-in-phase-3-clinical-trial-of-topical-roflumilast-foam-arq-15-arqt-20210825monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-second-quarter-2021-financial-results-and-provides-business-update-arqt-20210805monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-additions-to-its-investor-relations-and-communications-team-arqt-20210802monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-advances-science-of-psoriasis-drug-development-with-new-precision-method-for-measu-arqt-20210721monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-first-patient-enrolled-in-phase-3-clinical-trial-of-topical-roflumilast--arqt-20210712monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-provides-update-on-phase-2a-clinical-trial-evaluating-arq-252-cream-as-a-potential-arqt-20210701monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-appointment-of-sue-jean-lin-to-board-of-directors-arqt-20210609monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-showcases-pivotal-dermis-1-and-2-phase-3-trial-data-for-topical-ro-arqt-20210506monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-first-quarter-2021-financial-results-and-provides-business-update-arqt-20210504monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-new-roflumilast-cream-phase-3-data-at-the-european-academy-of-dermatolo-arqt-20210503monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-the-2021-truist-securities-life-sciences-summit-arqt-20210428monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-showcases-new-roflumilast-data-in-psoriasis-and-seborrheic-dermati-arqt-20210423monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-to-present-new-roflumilast-data-at-the-american-academy-of-dermato-arqt-20210419monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-initiates-phase-3-clinical-trial-of-topical-roflumilast-cream-arq-151-as-a-potenti-arqt-20210412monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-updates-to-its-executive-team-arqt-20210326monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-first-patient-enrolled-in-phase-2a-clinical-trial-evaluating-arq-252-as--arqt-20210318monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-to-showcase-long-term-safety-efficacy-and-patient-reported-outcome-arqt-20210317monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-the-cowen-41st-annual-health-care-conference-arqt-20210225monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-fourth-quarter-and-full-year-2020-financial-results-and-provides-busines-arqt-20210216monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-announces-closing-of-underwriters-over-allotment-option-in-connect-arqt-20210216monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-announces-pricing-of-upsized-public-offering-of-common-stock-arqt-20210203monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-announces-proposed-public-offering-of-common-stock-arqt-20210201monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-positive-topline-results-from-pivotal-dermis-1-and-2-phase-3-trials-of-t-arqt-20210201monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-advance-topical-roflumilast-foam-arq-154-into-phase-3-development-for-the-treat-arqt-20210120monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-initiates-pivotal-phase-3-clinical-trials-evaluating-topical-roflumilast-cream-arq-arqt-20210113monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-added-to-nasdaq-biotechnology-index-arqt-20201221monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-highlights-advanced-pipeline-unique-immuno-dermatology-drug-development-capabiliti-arqt-20201209monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-last-patient-completes-final-study-visit-in-dermis-1-and-dermis-2-pivota-arqt-20201207monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-host-virtual-investor-day-on-wednesday-december-9-2020-arqt-20201202monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-to-present-at-the-stifel-2020-virtual-healthcare-conference-arqt-20201111monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-third-quarter-2020-financial-results-and-provides-business-update-arqt-20201105monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-presents-new-positive-data-from-phase-2-studies-of-arq-151-topical-arqt-20201102monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-to-present-new-data-from-arq-151-topical-roflumilast-cream-clinica-arqt-20201030monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-completes-enrollment-in-phase-1-2b-study-evaluating-arq-252-in-chronic-hand-eczema-arqt-20201026monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-announces-closing-of-public-offering-and-concurrent-private-placem-arqt-20201006monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-announces-pricing-of-public-offering-and-concurrent-private-placem-arqt-20201002monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-announces-proposed-public-offering-and-concurrent-private-placemen-arqt-20200929monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-positive-topline-data-from-phase-2-clinical-trial-evaluating-arq-154-top-arqt-20200929monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-completes-enrollment-in-dermis-1-and-dermis-2-pivotal-phase-3-clinical-trials-eval-arqt-20200916monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-2020-arqt-20200915monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-to-accelerate-arq-151-topical-roflumilast-cream-into-phase-3-trial-arqt-20200908monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-second-quarter-2020-financial-results-and-provides-business-update-arqt-20200811monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-the-wedbush-pacgrow-healthcare-conference-arqt-20200810monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-appoints-patrick-burnett-m-d-ph-d-faad-as-chief-medical-officer-arqt-20200727monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-enrolls-last-patient-in-phase-2b-clinical-trial-evaluating-arq-154-topical-roflumi-arqt-20200720monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-initiates-patient-enrollment-in-the-phase-2b-portion-of-the-phase-1-2b-study-evalu-arqt-20200713monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-enrolls-last-patient-in-phase-2-proof-of-concept-clinical-trial-evaluating-arq-154-arqt-20200622monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-the-goldman-sachs-41st-annual-global-health-care-conference-arqt-20200610monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-enrollment-of-first-patient-in-phase-1-2b-study-of-arq-252-in-patients-w-arqt-20200421monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-inclusion-of-children-in-on-going-pivotal-phase-3-clinical-trials-evalua-arqt-20200316monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-data-from-the-phase-2b-study-of-topical-roflumilast-cream-in-patients-wi-arqt-20200303monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-to-present-at-the-cowen-40th-annual-health-care-conference-arqt-20200219monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-enrollment-of-first-patient-in-topical-roflumilast-cream-phase-3-open-la-arqt-20200213monthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-opt-arqt-20200204monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-present-late-breaking-data-on-lorundrostat-at-the-endocrine-soci-mlys-20260608monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-announces-presentation-of-new-data-from-the-phase-3-launch-htn-tria-mlys-20260518monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-reports-inducement-awards-under-nasdaq-listing-rule-5635-c-4-mlys-20260505monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-reports-inducement-awards-under-nasdaq-listing-rule-5635-c-4-mlys-20260226monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-phase-3-launch-htn-trial-of-lorundrostat-recognized-in-inaugural-jo-mlys-20251212monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-reports-inducement-award-under-nasdaq-listing-rule-5635-c-4-mlys-20251126monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-announce-third-quarter-2025-financial-results-and-host-conferenc-mlys-20251103monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-announce-second-quarter-2025-financial-results-and-host-conferen-mlys-20250804monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-announces-journal-of-the-american-medical-association-jama-publicat-mlys-20250630monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-announces-late-breaking-presentation-of-data-from-the-launch-htn-pi-mlys-20250524monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-announces-late-breaking-presentation-of-phase-3-launch-htn-trial-at-mlys-20250520monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-participate-in-the-bank-of-america-securities-health-care-confer-mlys-20250507monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-announce-first-quarter-2025-financial-results-and-host-conferenc-mlys-20250505monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-announces-publication-of-pivotal-phase-2-advance-htn-results-in-the-mlys-20250423monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advan-mlys-20250325monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-announces-closing-of-underwriters-option-to-purchase-additional-sha-mlys-20250318monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-fo-mlys-20250317monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-announces-pricing-of-175-0-million-underwritten-public-offering-of--mlys-20250312monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-announce-topline-data-from-launch-htn-and-advance-htn-pivotal-tr-mlys-20250307monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-mlys-20250205monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-participate-in-upcoming-investor-conferences-mlys-20241105monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-announce-third-quarter-2024-financial-results-and-host-conferenc-mlys-20241104monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-to-host-virtual-kol-event-on-the-unmet-medical-need-in-uncontrolled-and-resistan-mlys-20241022monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-participate-in-the-wells-fargo-healthcare-conference-mlys-20240828monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-announce-second-quarter-2024-financial-results-and-host-conferen-mlys-20240805monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-appoints-biopharmaceutical-executive-alexander-m-gold-m-d-to-its-bo-mlys-20240614monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-participate-in-the-goldman-sachs-45th-annual-global-healthcare-c-mlys-20240603monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-participate-in-the-bank-of-america-securities-health-care-confer-mlys-20240506monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-announce-first-quarter-2024-financial-results-and-host-conferenc-mlys-20240502monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-announce-fourth-quarter-and-full-year-2023-financial-results-and-mlys-20240313monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-participate-in-the-guggenheim-securities-6th-annual-biotechnolog-mlys-20240129monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-participate-in-three-upcoming-conferences-mlys-20231109monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-announce-third-quarter-2023-financial-results-and-host-conferenc-mlys-20231031monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-announces-upcoming-poster-presentations-at-two-scientific-conferenc-mlys-20231013monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-expands-its-board-of-directors-with-appointments-of-glenn-sblendori-mlys-20230914monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-participate-in-the-cantor-fitzgerald-global-healthcare-conferenc-mlys-20230911monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-announces-jama-publication-of-full-target-htn-phase-2-trial-results-mlys-20230910monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-presents-target-htn-phase-2-trial-results-in-late-breaking-science--mlys-20230910monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-selected-for-oral-poster-presentation-of-target-htn-phase-2-trial-r-mlys-20230905monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-participate-in-the-wells-fargo-securities-healthcare-conference--mlys-20230829monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-announce-second-quarter-2023-financial-results-and-host-conferen-mlys-20230731monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-participate-in-the-jefferies-healthcare-conference-mlys-20230531monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-announces-first-patient-dosed-in-the-advance-htn-pivotal-trial-of-l-mlys-20230502monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-announce-first-quarter-2023-financial-results-and-host-conferenc-mlys-20230501monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-participate-in-the-bank-of-america-securities-2023-health-care-c-mlys-20230427monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-presents-positive-lorundrostat-results-from-the-phase-2-target-htn--mlys-20230304monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-to-announce-fourth-quarter-2022-financial-results-and-host-conferen-mlys-20230301monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-abstracts-selected-to-be-presented-at-the-american-college-of-cardi-mlys-20230220monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-announces-closing-of-initial-public-offering-and-full-exercise-of-u-mlys-20230214monthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-announces-pricing-of-upsized-initial-public-offering-mlys-20230209monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-inc-investors-with-losses-have-until-august-4-2026-to-join-securities-class-action-b-gral-20260617monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-lawsuit-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-gral-20260610monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-inc-gral-investor-alert-investors-with-large-losses-in-grail-inc-should-contact-bern-gral-20260610monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-appoints-chairman-bill-rastetter-to-chief-executive-officer-gral-20170802monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-announces-data-from-early-research-analyzing-its-high-intensity-sequencing-approach-gral-20170603monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-and-cirina-combine-to-create-global-company-focused-on-early-detection-of-cancer-gral-20170531monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-announces-board-of-directors-appointments-gral-20170504monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-initiates-the-strive-study-to-advance-development-of-blood-tests-to-detect-cancer-ea-gral-20170420monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-closes-over-900-million-initial-investment-in-series-b-financing-to-develop-blood-te-gral-20170301monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-announces-circulating-cell-free-genome-atlas-ccga-study-as-foundation-for-developmen-gral-20161201monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-advisors-announces-record-date-for-special-meeting-of-etf-shareholders-gral-20110415monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-advisors-and-riverpark-capital-fine-tune-investment-lineup-gral-20100820monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-advisors-forms-strategic-relationship-with-doubleline-capital-gral-20100624monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-advisors-adds-western-asset-management-to-growing-list-of-strategic-partners-gral-20100517monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-advisors-issues-white-paper-on-exchange-traded-bond-funds-gral-20100420monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-advisors-building-out-fixed-income-presence-in-actively-managed-etf-space-gral-20091008monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-advisors-bringing-fixed-income-to-actively-managed-etf-marketplace-gral-20091005monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-advisors-first-to-market-again-with-launch-of-riverpark-etfs-gral-20091001monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-advisors-issues-white-paper-on-exchange-traded-funds-gral-20090819monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-advisors-to-launch-industry-s-first-single-manager-etfs-using-traditional-active-man-gral-20090609monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-american-beacon-large-cap-value-etf-gvt-begins-trading-on-nyse-gral-20090504monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-advisors-sets-executive-team-for-distribution-of-industry-s-first-actively-managed-e-gral-20090407monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-advisors-to-launch-first-actively-managed-exchange-traded-equity-funds-gral-20090115monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-financial-success-faces-legal-scrutiny-amid-allegations-hagens-berm-tmdx-20250414monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-financial-success-faces-legal-scrutiny-amid-allegations-hagens-berm-tmdx-20250410monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-financial-success-faces-legal-scrutiny-amid-allegations-hagens-berm-tmdx-20250408monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-financial-success-faces-legal-scrutiny-amid-allegations-hagens-berm-tmdx-20250406monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-financial-success-faces-legal-scrutiny-amid-allegations-hagens-berm-tmdx-20250404monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-nasdaq-tmdx-deadline-approaching-berger-montague-advises-investors-of-de-tmdx-20250402monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-shares-down-60-from-class-period-high-class-action-suit-pending-hag-tmdx-20250402monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-nasdaq-tmdx-deadline-alert-bernstein-liebhard-llp-reminds-transmedic-tmdx-20250401monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-shares-down-60-from-class-period-high-class-action-suit-pending-hag-tmdx-20250331monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-shares-down-60-from-class-period-high-class-action-suit-pending-hag-tmdx-20250328monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-shareholders-are-reminded-of-the-pending-lead-plaintiff-deadline-con-tmdx-20250326monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-shares-down-60-from-class-period-high-class-action-suit-pending-hag-tmdx-20250326monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-faces-class-action-suit-over-alleged-fraud-and-safety-lapses-hagens-tmdx-20250324monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-nasdaq-tmdx-deadline-alert-bernstein-liebhard-llp-reminds-transmedic-tmdx-20250324monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-plunges-amidst-allegations-of-fraud-organ-trafficking-hagens-berman-tmdx-20250321monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-sued-for-securities-law-violations-investors-should-contact-the-gros-tmdx-20250320monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-plunges-amidst-allegations-of-fraud-organ-trafficking-hagens-berman-tmdx-20250319monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-sued-for-securities-law-violations-investors-should-contact-the-gros-tmdx-20250317monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-plunges-amidst-allegations-of-fraud-organ-trafficking-hagens-berman-tmdx-20250317monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-plunges-amidst-allegations-of-fraud-organ-trafficking-hagens-berman-tmdx-20250313monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-faces-class-action-suit-over-alleged-fraud-and-safety-lapses-hagens-tmdx-20250310monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-nasdaq-tmdx-deadline-alert-bernstein-liebhard-llp-reminds-transmedic-tmdx-20250310monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-plunges-amidst-allegations-of-fraud-organ-trafficking-hagens-berman-tmdx-20250307monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-apr-tmdx-20250307monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-plunges-amidst-allegations-of-fraud-organ-trafficking-hagens-berman-tmdx-20250305monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-sued-for-securities-law-violations-investors-should-contact-levi-kor-tmdx-20250304monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-plunges-amidst-allegations-of-fraud-organ-trafficking-hagens-berman-tmdx-20250303monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-nasdaq-tmdx-deadline-alert-bernstein-liebhard-llp-reminds-transmedic-tmdx-20250303monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-faces-class-action-suit-over-alleged-fraud-and-safety-lapses-hagens-tmdx-20250228monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-tmdx-investors-april-15-2025-filing-deadline-in-securities-class-act-tmdx-20250228monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-investor-alert-robbins-geller-rudman-dowd-llp-announces-that-transmedics-group-tmdx-20250227monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-sued-for-securities-law-violations-contact-the-gross-law-firm-before-tmdx-20250226monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-nasdaq-tmdx-deadline-alert-bernstein-liebhard-llp-reminds-transmedic-tmdx-20250225monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-faces-class-action-suit-over-alleged-fraud-and-safety-lapses-hagens-tmdx-20250224monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-investor-notice-robbins-geller-rudman-dowd-llp-announces-that-transmedics-grou-tmdx-20250221monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-faces-class-action-suit-over-alleged-fraud-and-safety-lapses-hagens-tmdx-20250220monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-nasdaq-tmdx-investor-alert-investors-with-large-losses-in-transmedic-tmdx-20250219monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-stockholder-notice-shareholder-rights-law-firm-robbins-llp-reminds-i-tmdx-20250219monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-f-tmdx-20250219monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-faces-class-action-suit-over-alleged-fraud-and-safety-lapses-hagens-tmdx-20250218monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-plunges-amidst-allegations-of-fraud-organ-trafficking-hagens-berman-tmdx-20250213monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-plunges-amidst-allegations-of-fraud-organ-trafficking-hagens-berman-tmdx-20250210monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-announcement-if-you-have-suffered-losses-in-transmedics-group-inc-na-tmdx-20250207monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-announcement-if-you-have-suffered-losses-in-transmedics-group-inc-na-tmdx-20250204monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-announcement-if-you-have-suffered-losses-in-transmedics-group-inc-na-tmdx-20250201monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-plunges-amidst-allegations-of-fraud-organ-trafficking-hagens-berman-tmdx-20250131monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-announcement-if-you-have-suffered-losses-in-transmedics-group-inc-na-tmdx-20250128monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-plunges-amidst-allegations-of-fraud-organ-trafficking-hagens-berman-tmdx-20250128monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-announcement-if-you-have-suffered-losses-in-transmedics-group-inc-na-tmdx-20250125monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-plunges-amidst-allegations-of-fraud-organ-trafficking-hagens-berman-tmdx-20250124monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-plunges-amidst-allegations-of-fraud-organ-trafficking-hagens-berman-tmdx-20250122monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-announcement-if-you-have-suffered-losses-in-transmedics-group-inc-na-tmdx-20250121monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-plunges-amidst-allegations-of-fraud-organ-trafficking-hagens-berman-tmdx-20250120monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-announcement-if-you-have-suffered-losses-in-transmedics-group-inc-na-tmdx-20250118monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-plunges-amidst-allegations-of-fraud-organ-trafficking-hagens-berman-tmdx-20250117monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-alert-bragar-eagel-squire-p-c-is-investigating-transmedics-group-inc-on-behalf-tmdx-20250116monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-announcement-if-you-have-suffered-losses-in-transmedics-group-inc-na-tmdx-20250115monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-investors-company-investigated-by-the-portnoy-law-firm-tmdx-20250114monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-tmdx-plunges-amidst-allegations-of-fraud-organ-trafficking-hagens-berman-tmdx-20250114monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-investors-company-investigated-by-the-portnoy-law-firm-tmdx-20240227monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-alert-bragar-eagel-squire-p-c-is-investigating-transmedics-group-inc-on-behalf-tmdx-20240227monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20260605monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20260508monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20260410monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20260327monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20260306monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20260206monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20260109monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-participate-in-the-44th-annual-j-p-morgan-healthcare-conference-vera-20260108monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-pricing-of-public-offering-of-class-a-common-stock-vera-20251210monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-proposed-public-offering-of-class-a-common-stock-vera-20251208monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20251010monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20250905monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20250808monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20250710monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20250609monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-participate-in-the-goldman-sachs-46th-annual-global-healthcare-confer-vera-20250604monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-refinancing-of-existing-oxford-debt-facility-providing-up-to-5-vera-20250603monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20250509monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20250409monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-completes-full-enrollment-in-pivotal-origin-phase-3-trial-for-atacicept--vera-20250403monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20250311monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference-vera-20250227monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20250213monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20250114monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-acquires-global-rights-to-novel-next-generation-dual-baff-april-inhibito-vera-20250113monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference-vera-20250107monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20241209monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20241122monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-appoints-jason-s-carter-as-chief-legal-officer-vera-20241118monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20241111monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-partners-with-university-of-michigan-on-the-neptune-match-project-and-pi-vera-20241111monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-participate-at-upcoming-investor-conferences-vera-20241108monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-pricing-of-public-offering-of-class-a-common-stock-vera-20241030monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-proposed-public-offering-of-class-a-common-stock-vera-20241028monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20241004monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-late-breaking-oral-presentation-of-origin-phase-2b-long-term-r-vera-20241002monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-host-in-person-r-d-day-in-new-york-to-discuss-potential-indication-ex-vera-20240916monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-completes-enrollment-for-primary-endpoint-in-pivotal-phase-3-origin-3-tr-vera-20240912monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20240910monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-participate-at-september-investor-conferences-vera-20240829monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20240809monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20240705monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-appointment-of-industry-veteran-david-l-johnson-as-chief-opera-vera-20240701monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-appoints-christy-j-oliger-to-board-of-directors-vera-20240611monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20240607monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-participate-in-the-goldman-sachs-45th-annual-global-healthcare-confer-vera-20240607monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-receives-u-s-fda-breakthrough-therapy-designation-for-atacicept-in-immun-vera-20240528monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-presents-72-week-egfr-stabilization-and-rapid-hematuria-improvement-in-p-vera-20240525monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vera-20240507monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-two-oral-presentations-at-the-61st-european-renal-association--vera-20240402monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-participate-at-the-44th-annual-td-cowen-health-care-conference-vera-20240228monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-6th-annual-biotechnolo-vera-20240202monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-closing-of-upsized-public-offering-and-full-exercise-of-underw-vera-20240201monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-pricing-of-upsized-public-offering-of-class-a-common-stock-vera-20240130monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-proposed-public-offering-of-class-a-common-stock-vera-20240129monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-host-in-person-r-d-day-in-new-york-to-present-week-72-data-from-phase-vera-20240108monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-participate-in-the-42nd-annual-j-p-morgan-healthcare-conference-vera-20231227monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-presents-positive-data-from-phase-2b-origin-study-showing-resolution-of--vera-20231104monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-scheduled-to-present-at-november-investor-conferences-vera-20231030monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-present-three-posters-at-the-american-society-of-nephrology-kidney-we-vera-20231013monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-scheduled-to-present-at-september-investor-conferences-vera-20230831monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-positive-week-36-efficacy-and-safety-results-of-phase-2b-origi-vera-20230617monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-host-presentation-of-week-36-data-from-phase-2b-origin-clinical-trial-vera-20230615monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-participate-in-the-44th-annual-goldman-sachs-global-healthcare-confer-vera-20230608monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-initiates-pivotal-phase-3-origin-3-clinical-trial-of-atacicept-for-the-t-vera-20230607monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-appoints-kerry-cooper-m-d-as-senior-vice-president-of-medical-affairs-vera-20230504monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-participate-in-the-cowen-43rd-annual-health-care-conference-vera-20230227monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-closing-of-upsized-public-offering-and-full-exercise-of-underw-vera-20230206monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-pricing-of-public-offering-of-class-a-common-stock-vera-20230202monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-commencement-of-public-offering-of-class-a-common-stock-vera-20230201monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-releases-36-week-interim-analysis-of-phase-2b-clinical-trial-of-atacicep-vera-20230130monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-hosting-a-key-opinion-leader-webinar-on-atacicept-for-the-treatment-iga--vera-20230125monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-positive-topline-results-of-phase-2b-origin-clinical-trial-of--vera-20230103monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-participate-in-the-41st-annual-j-p-morgan-healthcare-conference-vera-20221220monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-present-at-upcoming-investor-conferences-vera-20221122monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-host-key-opinion-webinar-on-targeting-the-source-of-iga-nephropathy-i-vera-20221117monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-presents-new-analysis-of-phase-2a-janus-trial-of-atacicept-in-iga-nephro-vera-20221105monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-present-final-phase-2-results-of-mau868-in-kidney-transplant-recipien-vera-20221017monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-present-at-upcoming-conferences-in-september-2022-vera-20220907monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-participate-in-the-13th-annual-wedbush-pacgrow-healthcare-conference-vera-20220804monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-completes-patient-enrollment-in-phase-2b-origin-clinical-trial-of-atacic-vera-20220706monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-reports-positive-interim-phase-2-data-showing-mau868-has-significant-bk--vera-20220604monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-participate-in-the-2022-jefferies-healthcare-conference-vera-20220602monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-new-atacicept-phase-2-clinical-data-in-two-oral-presentations--vera-20220520monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-present-at-upcoming-conferences-in-may-2022-vera-20220505monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-two-oral-presentations-at-the-59th-european-renal-association--vera-20220503monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-selected-to-present-interim-phase-2-data-for-mau868-to-treat-bk-virus-in-vera-20220502monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-appointment-of-michael-m-morrissey-ph-d-as-chairman-of-its-boa-vera-20220412monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-vera-20220324monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-host-bk-virus-webinar-featuring-stanley-c-jordan-m-d-world-renowned-t-vera-20220321monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-host-business-update-call-vera-20220317monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-participate-in-the-42nd-annual-cowen-health-care-conference-vera-20220301monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-closing-of-upsized-public-offering-of-class-a-common-stock-and-vera-20220214monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-pricing-of-upsized-public-offering-of-class-a-common-stock-vera-20220210monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-commencement-of-public-offering-of-class-a-common-stock-vera-20220207monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-phase-3-clinical-trial-for-atacicept-in-lupus-nephritis-vera-20220118monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-vera-20220104monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-acquisition-of-monoclonal-antibody-from-pfizer-to-treat-bk-vir-vera-20211217monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-appointment-of-kimball-hall-to-board-of-directors-vera-20211214monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-present-at-upcoming-investment-conferences-in-november-2021-vera-20211110monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-presents-phase-2a-data-showing-atacicept-reduces-serum-gd-iga1-in-patien-vera-20211104monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-present-phase-2a-data-on-atacicept-in-iga-nephropathy-at-the-american-vera-20211013monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-hosting-key-opinion-leader-webinar-on-iga-nephropathy-vera-20210909monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-appoints-sean-grant-as-chief-financial-officer-vera-20210714monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-to-participate-in-the-jefferies-virtual-healthcare-conference-vera-20210527monthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-pricing-of-initial-public-offering-vera-20210514monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-first-quarter-financial-results-and-provides-corporate-update-cldx-20260507monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercis-cldx-20260406monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-additional-positive-data-from-phase-2-chronic-spontaneous-urticaria-csu-a-cldx-20260227monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-initiates-global-registrational-phase-3-program-of-barzolvolimab-in-cold-urticaria-cldx-20251209monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-second-quarter-2025-financial-results-and-provides-corporate-update-cldx-20250807monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-data-demonstrating-profound-long-term-improvement-in-angioedema-in-barzol-cldx-20250614monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-unprecedented-76-week-results-from-barzolvolimab-phase-2-study-in-chronic-cldx-20250612monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-upcoming-presentations-of-barzolvolimab-phase-2-data-in-chronic-spontane-cldx-20250610monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-first-quarter-2025-financial-results-and-provides-corporate-update-cldx-20250508monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-histology-data-from-phase-2-study-of-barzolvolimab-in-eoe-supporting-pote-cldx-20250505monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-upcoming-investor-conferences-cldx-20250304monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-presents-positive-preclinical-data-from-inflammatory-bispecific-antib-cldx-20250303monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-presents-positive-results-from-barzolvolimab-phase-2-studies-in-patie-cldx-20250301monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-fourth-quarter-and-year-end-2024-financial-results-and-provides-corporate--cldx-20250227monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-initiates-phase-2-study-of-barzolvolimab-in-atopic-dermatitis-cldx-20241219monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-first-patient-dosed-in-phase-1-healthy-volunteer-study-of-cdx-622-a-bisp-cldx-20241120monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-upcoming-investor-conferences-cldx-20241111monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-third-quarter-2024-financial-results-and-provides-corporate-update-cldx-20241106monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-barzolvolimab-met-all-primary-and-secondary-endpoints-with-high-statisti-cldx-20241026monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-upcoming-late-breaking-oral-presentation-of-12-week-results-from-barzolv-cldx-20241025monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-presents-landmark-52-week-results-from-barzolvolimab-phase-2-study-in-cldx-20240925monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-upcoming-late-breaking-oral-presentation-of-52-week-results-from-barzolv-cldx-20240916monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-upcoming-investor-conferences-cldx-20240912monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-second-quarter-2024-financial-results-and-provides-corporate-update-cldx-20240808monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-presents-positive-topline-results-from-barzolvolimab-phase-2-study-in-cldx-20240729monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-initiates-global-phase-3-program-for-barzolvolimab-in-patients-with-c-cldx-20240716monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-jefferies-healthcare-conference-cldx-20240604monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-presents-data-demonstrating-profound-improvements-in-angioedema-in-ba-cldx-20240602monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-first-patient-dosed-in-phase-2-study-of-barzolvolimab-in-prurigo-nodular-cldx-20240515monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-first-quarter-2024-financial-results-and-provides-corporate-update-cldx-20240506monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-completion-of-enrollment-in-phase-2-study-of-barzolvolimab-in-patients-w-cldx-20240417monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-participate-in-the-leerink-partners-global-biopharma-conference-cldx-20240308monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-td-cowen-s-44th-annual-health-care-conference-cldx-20240305monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercis-cldx-20240305monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-pricing-of-upsized-400-million-public-offering-of-common-st-cldx-20240301monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-fourth-quarter-and-year-end-2023-financial-results-and-provides-corporate--cldx-20240226monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-presents-positive-12-week-results-from-barzolvolimab-phase-2-study-in-cldx-20240224monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-to-participate-in-the-guggenheim-healthcare-talks-6th-annual-biotechnology-confere-cldx-20240206monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-upcoming-presentation-of-barzolvolimab-phase-2-results-in-chronic-sponta-cldx-20240205monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-6th-annual-evercore-isi-healthconx-conference-cldx-20231127monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-pricing-of-public-offering-of-common-stock-cldx-20231108monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-positive-topline-results-from-barzolvolimab-phase-2-study-i-cldx-20231106monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-presents-positive-data-from-prurigo-nodularis-phase-1b-study-demonstr-cldx-20231105monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-third-quarter-2023-financial-results-and-provides-corporate-update-cldx-20231102monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-acceptance-of-abstract-for-barzolvolimab-phase-1b-results-in-prurigo-nod-cldx-20230926monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-cantor-global-healthcare-conference-cldx-20230925monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-second-quarter-2023-financial-results-and-provides-corporate-update-cldx-20230808monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-completion-of-enrollment-in-phase-2-study-of-barzolvolimab-in-patients-w-cldx-20230711monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-first-patient-dosed-in-phase-2-study-of-barzolvolimab-in-eosinophilic-es-cldx-20230706monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-presents-positive-data-from-barzolvolimab-chronic-urticaria-program-a-cldx-20230610monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-upcoming-barzolvolimab-presentations-at-eaaci-2023-cldx-20230608monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-jefferies-healthcare-conference-cldx-20230602monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-first-patient-dosed-in-phase-1-study-of-cdx-585-in-patients-with-advance-cldx-20230531monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-presents-positive-preclinical-data-from-tslp-scf-bispecific-antibody--cldx-20230515monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-first-quarter-2023-financial-results-and-provides-corporate-update-cldx-20230504monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-h-c-wainwright-autoimmune-inflammatory-disease-virtual--cldx-20230329monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-fourth-quarter-and-year-end-2022-financial-results-and-provides-corporate--cldx-20230228monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-presents-positive-data-from-barzolvolimab-phase-1b-study-in-chronic-s-cldx-20230226monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-appointment-of-rita-jain-m-d-to-board-of-directors-cldx-20230216monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-svb-securities-global-biopharma-conference-cldx-20230215monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-upcoming-presentation-of-barzolvolimab-phase-1b-results-in--cldx-20230203monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-presents-positive-data-from-barzolvolimab-phase-1b-study-in-chronic-i-cldx-20221206monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-multiple-upcoming-presentations-of-barzolvolimab-data-at-ga-cldx-20221202monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-to-participate-in-upcoming-november-investor-conferences-cldx-20221110monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-third-quarter-2022-financial-results-and-provides-corporate-update-cldx-20221109monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-second-quarter-2022-financial-results-and-provides-corporate-update-cldx-20220808monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-first-patient-dosed-in-phase-2-study-of-barzolvolimab-in-patients-with-c-cldx-20220721monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-presents-positive-interim-data-from-barzolvolimab-phase-1b-study-in-c-cldx-20220630monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-first-patient-dosed-in-phase-2-study-of-barzolvolimab-in-patients-with-c-cldx-20220621monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-two-new-appointments-to-its-board-of-directors-cldx-20220616monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-to-present-at-the-2022-jefferies-global-healthcare-conference-cldx-20220606monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-acceptance-of-abstract-for-barzolvolimab-phase-1b-results-in-chronic-spo-cldx-20220519monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-first-quarter-2022-financial-results-and-provides-corporate-update-cldx-20220505monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-corporate-cldx-20220228monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-to-host-fourth-quarter-and-full-year-2021-financial-results-and-corporate-highligh-cldx-20220222monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-to-present-at-the-11th-annual-svb-leerink-global-healthcare-conference-cldx-20220210monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-first-patient-dosed-in-phase-1-study-of-cdx-0159-in-prurigo-nodularis-cldx-20211208monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-positive-preclinical-data-from-pd-1-ilt4-bispecific-antibody-program-cdx--cldx-20211112monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-to-participate-in-upcoming-investor-conferences-cldx-20211111monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-third-quarter-2021-financial-results-and-provides-corporate-update-cldx-20211109monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-positive-data-on-symptom-control-and-quality-of-life-measurements-that-fu-cldx-20210929monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-to-present-at-the-2021-cantor-virtual-global-healthcare-conference-cldx-20210924monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-upcoming-presentation-of-cdx-0159-phase-1b-results-in-inducible-urticari-cldx-20210923monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-initiation-of-cdx-0159-subcutaneous-formulation-study-cldx-20210913monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-second-quarter-2021-financial-results-and-provides-corporate-update-cldx-20210805monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercis-cldx-20210716monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-pricing-of-upsized-250-million-public-offering-of-common-st-cldx-20210714monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-presents-positive-data-from-cdx-0159-phase-1b-study-in-chronic-induci-cldx-20210709monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-preliminary-data-from-ongoing-cdx-527-phase-1-dose-escalation-trial-at-th-cldx-20210604monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-acceptance-of-abstract-for-cdx-0159-phase-1b-results-in-inducible-urtica-cldx-20210601monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-to-present-at-the-jefferies-2021-virtual-healthcare-conference-cldx-20210526monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-first-quarter-2021-financial-results-and-provides-corporate-update-cldx-20210506monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-promising-data-from-ilt4-pd-l-1-bispecific-antibody-program-at-aacr-2021-cldx-20210412monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-provides-corporate-update-and-reports-fourth-quarter-and-year-end-2020-results-cldx-20210329monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-80-complete-response-rate-in-interim-data-update-from-phase-1b-study-of-cd-cldx-20210329monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-fireside-chat-presentation-at-the-h-c-wainwright-global-lif-cldx-20210305monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-expand-development-of-cdx-0159-into-prurigo-nodularis-pn-cldx-20210222monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-10th-annual-svb-leerink-global-healthcare-conference-cldx-20210222monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-doses-first-patient-in-phase-1b-study-of-cdx-0159-in-chronic-inducible-urticaria-cldx-20201209monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-3rd-annual-evercore-isi-healthconx-conference-cldx-20201130monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-data-from-oncology-portfolio-at-sitc-2020-cldx-20201109monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-provides-corporate-update-and-reports-third-quarter-2020-results-cldx-20201105monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-initiates-phase-1b-study-of-cdx-0159-in-chronic-spontaneous-urticaria-cldx-20201013monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-upcoming-healthcare-conferences-cldx-20200910monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-initiates-phase-1-study-of-new-bispecific-product-candidate-cdx-527-i-cldx-20200824monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-provides-corporate-update-and-reports-second-quarter-2020-results-cldx-20200806monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-to-report-second-quarter-2020-financial-results-and-host-corporate-update-call-cldx-20200803monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-closing-of-150-0-million-public-offering-of-common-stock-in-cldx-20200618monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-pricing-of-130-4-million-public-offering-of-common-stock-cldx-20200616monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-s-kit-inhibitor-cdx-0159-demonstrates-profound-sustained-dose-dependent-reductions-cldx-20200606monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-provides-corporate-update-and-reports-first-quarter-2020-results-cldx-20200506monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-acceptance-of-cdx-0159-late-breaking-poster-presentation-with-voice-over-cldx-20200506monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-provides-corporate-update-and-reports-fourth-quarter-and-year-end-2019-results-cldx-20200326monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-1-7-million-milestone-payment-from-rockefeller-university-r-cldx-20200303monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-initiates-phase-1-study-of-kit-inhibitor-cdx-0159-cldx-20191118monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-provides-corporate-update-and-reports-third-quarter-2019-results-cldx-20191112monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-promising-data-from-cdx-0159-and-cdx-527-programs-cldx-20191111monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-upcoming-data-presentations-cldx-20191002monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-the-cantor-global-healthcare-conference-cldx-20190930monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-provides-corporate-update-and-reports-second-quarter-2019-results-cldx-20190807monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-to-report-second-quarter-2019-financial-results-and-host-corporate-update-call-cldx-20190731monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-data-from-cdx-3379-clinical-program-presented-at-asco-2019-promising-bio-cldx-20190601monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-provides-corporate-update-and-reports-first-quarter-2019-results-cldx-20190507monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-positive-interim-results-from-phase-1-study-of-cd40-agonist-cdx-1140-at-a-cldx-20190402monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-promising-data-from-cdx-527-bispecific-and-tam-receptor-programs-at-ameri-cldx-20190401monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-provides-corporate-update-and-reports-full-year-2018-results-cldx-20190307monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-to-report-full-year-2018-business-financial-results-and-host-corporate-update-call-cldx-20190301monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-reverse-stock-split-cldx-20190208monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-emerging-mertk-antibody-program-at-the-society-for-immunotherapy-of-cance-cldx-20181110monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-promising-interim-data-from-phase-1-study-of-differentiated-cd40-agonist--cldx-20181109monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-provides-corporate-update-and-reports-third-quarter-2018-results-cldx-20181107monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-provides-corporate-update-and-reports-second-quarter-2018-results-cldx-20180808monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-to-report-second-quarter-2018-financial-results-and-host-corporate-update-call-cldx-20180802monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-promising-data-from-phase-1-2-study-of-varlilumab-and-opdivo-at-2018-asco-cldx-20180602monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-the-jefferies-2018-global-healthcare-conference-cldx-20180601monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-presentations-at-the-2018-american-society-of-clinical-oncology-asco-ann-cldx-20180516monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-provides-corporate-update-and-reports-first-quarter-2018-results-cldx-20180510monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-s-metric-study-in-metastatic-triple-negative-breast-cancer-does-not-meet-primary-e-cldx-20180416monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-provides-corporate-update-and-reports-full-year-2017-results-cldx-20180307monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-to-report-fourth-quarter-and-year-end-2017-business-financial-results-and-present--cldx-20180302monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-initiates-phase-1-study-of-new-product-candidate-cdx-1140-in-solid-tu-cldx-20171130monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-initiates-phase-2-combination-study-of-cdx-3379-and-cetuximab-in-head-cldx-20171117monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-third-quarter-2017-results-cldx-20171107monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-cldx-20170922monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-completion-of-enrollment-in-phase-2b-study-of-glembatumumab-vedotin-in-t-cldx-20170823monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-second-quarter-2017-results-cldx-20170808monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-to-report-second-quarter-2017-financial-results-and-host-corporate-update-call-cldx-20170802monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-participate-in-the-jefferies-2017-global-healthcare-conference-cldx-20170606monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-presents-phase-1-study-of-varlilumab-and-opdivo-at-2017-asco-annual-m-cldx-20170605monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-promising-overall-survival-data-from-phase-2-study-of-single-agent-glemba-cldx-20170605monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-clinical-results-at-2017-asco-annual-meeting-cldx-20170517monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-first-quarter-2017-results-cldx-20170509monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-provides-corporate-update-and-reports-full-year-2016-results-cldx-20170314monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-upcoming-investor-presentations-and-2016-year-end-call-cldx-20170213monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-data-on-cdx-1140-a-novel-cd40-agonist-antibody-for-hematologic-and-solid--cldx-20161205monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-data-on-new-product-candidate-cdx-1140-a-novel-cd40-agonist-antibody-cldx-20161114monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-third-quarter-2016-results-cldx-20161107monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-the-leerink-partners-rare-disease-immuno-oncology-round-cldx-20160923monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-second-quarter-2016-results-cldx-20160808monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-to-report-second-quarter-2016-financial-results-and-host-corporate-2016-objectives-cldx-20160802monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-initiates-phase-1-2-clinical-trial-of-new-product-candidate-cdx-014-i-cldx-20160711monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-participate-in-the-cantor-fitzgerald-2nd-annual-healthcare-confere-cldx-20160707monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-cdx-1401-cdx-301-combination-generates-potent-ny-eso-1-immune-respons-cldx-20160604monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-first-quarter-2016-results-cldx-20160505monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-initiates-phase-1-2-study-of-glembatumumab-vedotin-in-squamous-cell-l-cldx-20160427monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-presents-data-supporting-the-clinical-development-of-glembatumumab-ve-cldx-20160420monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-presents-favorable-safety-profile-and-immune-response-data-from-phase-cldx-20160418monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-new-clinical-and-preclinical-data-at-the-aacr-annual-meeti-cldx-20160317monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-the-cowen-and-company-36th-annual-health-care-conferenc-cldx-20160303monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-fourth-quarter-and-year-end-2015-results-cldx-20160225monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-preliminary-cohort-data-from-pilot-study-of-cdx-301-in-allogeneic-hematop-cldx-20160220monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-to-report-fourth-quarter-and-year-end-2015-business-financial-results-and-host-201-cldx-20160218monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-the-leerink-partners-5th-annual-global-healthcare-confe-cldx-20160204monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-initiates-phase-1-2-study-of-varlilumab-in-combination-with-atezolizu-cldx-20151208monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-varlilumab-mechanism-data-at-sitc-annual-meeting-2015-cldx-20151106monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-third-quarter-2015-results-cldx-20151105monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-the-leerink-partners-immuno-oncology-roundtable-cldx-20150930monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-second-quarter-2015-results-cldx-20150810monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-to-report-second-quarter-2015-financial-results-and-host-corporate-2015-objectives-cldx-20150804monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-the-cantor-fitzgerald-inaugural-healthcare-conference-cldx-20150702monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-appoints-richard-wright-as-chief-commercial-officer-cldx-20150701monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-initiates-phase-1-2-study-of-varlilumab-in-combination-with-sunitinib-cldx-20150528monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-the-jefferies-2015-global-healthcare-conference-cldx-20150527monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-data-from-the-react-study-at-2015-asco-annual-meeting-cldx-20150513monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-first-quarter-2015-results-cldx-20150429monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-s-varlilumab-demonstrates-synergistic-anti-tumor-activity-with-pd-1-signaling-bloc-cldx-20150420monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-phase-2-emerge-study-of-glembatumumab-vedotin-in-metastatic-breast-ca-cldx-20150406monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-initiation-of-phase-1-2-study-of-varlilumab-in-combination--cldx-20150406monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-clinical-trial-collaboration-with-roche-to-evaluate-the-com-cldx-20150317monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-upcoming-presentation-at-the-cowen-and-company-35th-annual--cldx-20150303monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-exercise-of-underwriters-option-to-purchase-additional-shares-cldx-20150227monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-proposed-public-offering-of-common-stock-cldx-20150224monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-s-rindopepimut-rintega-r-receives-fda-breakthrough-therapy-designation-for-the-tre-cldx-20150223monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-to-report-fourth-quarter-and-fiscal-2014-business-financial-results-and-host-2015--cldx-20150219monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-upcoming-presentation-at-the-2015-leerink-global-healthcare-cldx-20150209monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-and-bristol-myers-squibb-announce-initiation-of-phase-1-2-combination-cldx-20150129monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-appointment-to-board-of-directors-cldx-20141218monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-completion-of-enrollment-in-phase-3-study-of-rindopepimut-in-frontline-g-cldx-20141215monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-initiates-a-phase-2-study-of-glembatumumab-vedotin-in-patients-with-a-cldx-20141204monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-varlilumab-proof-of-concept-data-at-sitc-annual-meeting-2014-cldx-20141107monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-third-quarter-2014-results-cldx-20141104monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-upcoming-presentations-of-rindopepimut-data-at-19th-annual--cldx-20141103monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-publication-of-glembatumumab-vedotin-phase-1-2-studies-in-the-journal-of-cldx-20140930monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-initiates-pilot-study-of-cdx-301-in-allogeneic-hematopoietic-stem-cel-cldx-20140925monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-upcoming-presentation-at-the-morgan-stanley-healthcare-conference-cldx-20140903monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-second-quarter-2014-results-cldx-20140806monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-senior-leadership-promotions-cldx-20140730monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-to-report-second-quarter-2014-financial-results-and-host-corporate-2014-objectives-cldx-20140718monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-varlilumab-continues-to-demonstrate-very-favorable-profile-cldx-20140602monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-the-jefferies-2014-global-healthcare-conference-cldx-20140528monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-varlilumab-cdx-1127-phase-1-clinical-data-to-be-presented-a-cldx-20140514monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-to-present-at-two-upcoming-investor-conferences-cldx-20140502monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-first-quarter-2014-results-cldx-20140501monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-s-phase-1-study-of-cdx-1401-published-in-science-translational-medicine-cldx-20140416monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-establishes-preclinical-proof-of-concept-for-new-antibody-drug-conjug-cldx-20140407monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-antibody-drug-conjugate-cdx-014-preclinical-proof-of-conce-cldx-20140403monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-fiscal-2013-business-financial-results-and-outlines-2014-strategy-cldx-20140303monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-to-report-fourth-quarter-and-fiscal-2013-business-financial-results-and-host-2014--cldx-20140225monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-upcoming-presentation-at-the-2014-leerink-global-healthcare-conference-cldx-20140206monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-s-cdx-301-in-combination-with-mozobil-r-increases-hematopoietic-stem-cell-mobiliza-cldx-20131210monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-exercise-of-underwriters-option-to-purchase-additional-shares-cldx-20131209monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-prices-public-offering-of-common-stock-cldx-20131205monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-proposed-public-offering-of-common-stock-cldx-20131203monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-initiates-metric-an-accelerated-approval-study-of-glembatumumab-vedot-cldx-20131202monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-upcoming-presentation-at-the-deutsche-bank-2013-biofest-cldx-20131127monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-rindopepimut-demonstrates-promising-clinical-activity-in-patients-wit-cldx-20131124monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-publication-of-preliminary-data-from-the-phase-2-react-stud-cldx-20131111monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-third-quarter-2013-financial-results-cldx-20131108monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-cdx-1127-well-tolerated-and-demonstrates-anti-tumor-activity-in-phase-cldx-20131107monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-upcoming-data-presentations-at-the-society-for-immunotherap-cldx-20131021monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-upcoming-presentation-at-the-leerink-swann-rare-disease-rou-cldx-20130926monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-expansion-of-phase-2-react-study-in-recurrent-glioblastoma-cldx-20130812monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-second-quarter-2013-financial-results-cldx-20130806monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-issuance-of-seminal-patent-for-cd27-agonists-cldx-20130710monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-initiates-pilot-study-in-dense-deposit-disease-cldx-20130701monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-present-at-two-upcoming-investor-conferences-cldx-20130522monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-upcoming-presentation-at-the-credit-suisse-2013-antibody-da-cldx-20130506monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-first-quarter-2013-financial-results-cldx-20130502monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-cdx-1127-in-vitro-human-data-consistent-with-strong-potency-and-safety-pr-cldx-20130408monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-reports-fourth-quarter-and-fiscal-2012-financial-results-cldx-20130307monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-to-report-fourth-quarter-and-fiscal-2012-financial-results-and-host-c-cldx-20130228monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-therapeutics-announces-upcoming-presentation-at-leerink-swann-global-healthcare-co-cldx-20130211monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-upcoming-oral-presentation-on-cdx-301-at-the-american-society-for-blood--cldx-20130211monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-full-exercise-of-underwriters-option-to-purchase-additional-shares-cldx-20130208monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-pricing-of-90-million-public-offering-of-common-stock-cldx-20130206monthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-announces-75-000-000-proposed-public-offering-of-common-stock-cldx-20130204monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-investor-news-if-you-have-suffered-losses-in-disc-medicine-inc-nasdaq-iron-y-iron-20260621monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-investor-news-if-you-have-suffered-losses-in-disc-medicine-inc-nasdaq-iron-y-iron-20260619monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-investor-news-if-you-have-suffered-losses-in-disc-medicine-inc-nasdaq-iron-y-iron-20260615monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-inc-investigated-by-the-portnoy-law-firm-iron-20260327monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-participate-at-upcoming-investor-conferences-in-march-lmat-20260227monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-participate-at-upcoming-investor-conferences-in-september-lmat-20250828monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q2-2025-financial-results-lmat-20250805monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-will-announce-second-quarter-2025-earnings-results-august-5-2025-lmat-20250708monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q1-2025-financial-results-lmat-20250501monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-will-announce-first-quarter-2025-earnings-results-may-1-2025-lmat-20250407monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-participate-at-upcoming-investor-conferences-in-march-lmat-20250303monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q4-2024-financial-results-lmat-20250227monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-will-announce-fourth-quarter-2024-earnings-results-february-27-2025-lmat-20250127monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-participate-at-upcoming-investor-conferences-in-december-lmat-20241125monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-participate-at-upcoming-investor-conferences-in-november-lmat-20241101monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q3-2024-financial-results-lmat-20241031monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-will-announce-third-quarter-2024-earnings-results-october-31-2024-lmat-20241015monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-participate-at-upcoming-investor-conferences-in-september-lmat-20240827monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q2-2024-financial-results-lmat-20240801monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-will-announce-second-quarter-2024-earnings-results-august-1-2024-lmat-20240716monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-present-at-the-jefferies-global-healthcare-conference-lmat-20240521monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q1-2024-financial-results-lmat-20240502monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-will-announce-first-quarter-2024-earnings-results-may-2-2024-lmat-20240419monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-present-at-the-23rd-annual-needham-virtual-healthcare-conference-lmat-20240326monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-participate-at-upcoming-investor-conferences-in-march-lmat-20240301monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q4-2023-financial-results-lmat-20240227monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-will-announce-fourth-quarter-2023-earnings-results-february-27-2024-lmat-20240213monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-present-at-the-26th-annual-needham-growth-conference-lmat-20240111monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-participate-at-upcoming-investor-conferences-in-november-lmat-20231103monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q3-2023-financial-results-lmat-20231101monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-will-announce-third-quarter-2023-earnings-results-november-1-2023-lmat-20231017monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-present-at-the-2023-cantor-global-healthcare-conference-lmat-20230921monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q2-2023-financial-results-lmat-20230801monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-present-at-upcoming-investor-conferences-in-august-lmat-20230731monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-will-announce-second-quarter-2023-earnings-results-august-1-2023-lmat-20230717monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-present-at-upcoming-investor-conferences-in-june-lmat-20230606monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q1-2023-financial-results-lmat-20230502monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-distribute-aziyo-biologics-cardiovascular-patches-lmat-20230420monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-will-announce-first-quarter-2023-earnings-results-may-2-2023-lmat-20230417monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-go-direct-in-thailand-lmat-20230314monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-participate-at-upcoming-investor-conferences-in-march-lmat-20230303monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q4-2022-financial-results-lmat-20230223monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-will-announce-fourth-quarter-2022-earnings-results-february-23-2023-lmat-20230208monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-present-at-upcoming-investor-conferences-lmat-20221122monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-present-at-upcoming-investor-conferences-lmat-20221102monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q3-2022-financial-results-lmat-20221027monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-will-announce-third-quarter-2022-earnings-results-october-27-2022-lmat-20221017monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-present-at-the-morgan-stanley-20th-annual-global-healthcare-conference-lmat-20220831monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-present-at-the-canaccord-genuity-42nd-annual-growth-conference-lmat-20220801monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q2-2022-financial-results-lmat-20220728monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-will-announce-second-quarter-2022-earnings-results-july-28-2022-lmat-20220718monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-present-at-the-sidoti-summer-small-cap-virtual-conference-lmat-20220603monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-present-at-upcoming-investor-conferences-lmat-20220516monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q1-2022-financial-results-lmat-20220428monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-will-announce-first-quarter-2022-earnings-results-april-28-2022-lmat-20220415monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-present-at-the-needham-virtual-healthcare-conference-lmat-20220401monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-joins-nasdaq-dividend-achievers-index-10-years-of-dividend-increases-lmat-20220321monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-participate-at-upcoming-investor-conferences-in-march-lmat-20220301monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q4-2021-financial-results-lmat-20220224monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-will-announce-fourth-quarter-2021-earnings-results-february-24-2022-lmat-20220211monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-present-at-the-btig-medtech-digital-health-life-science-diagnostic-tools-confe-lmat-20220209monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-present-at-the-needham-virtual-growth-conference-lmat-20211230monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-participate-at-upcoming-investor-conferences-lmat-20211102monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q3-2021-financial-results-lmat-20211028monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-will-announce-third-quarter-2021-earnings-results-on-october-28-2021-lmat-20211014monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-participate-at-upcoming-investor-conferences-in-september-lmat-20210901monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-present-at-upcoming-investor-conferences-lmat-20210806monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q2-2021-financial-results-lmat-20210729monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-will-announce-second-quarter-2021-earnings-results-on-july-29-2021-lmat-20210715monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-announces-pricing-of-public-offering-of-common-stock-lmat-20210714monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-announces-proposed-public-offering-of-common-stock-lmat-20210713monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-provides-q2-2021-update-lmat-20210713monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-present-at-the-goldman-sachs-virtual-global-healthcare-conference-lmat-20210609monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-regains-five-ce-marks-lmat-20210525monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-present-at-the-jefferies-virtual-healthcare-conference-lmat-20210520monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q1-2021-financial-results-lmat-20210429monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-present-at-upcoming-investor-conferences-lmat-20210427monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-will-announce-first-quarter-2021-earnings-results-on-april-29-2021-lmat-20210414monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-present-at-the-needham-virtual-healthcare-conference-lmat-20210405monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q4-2020-financial-results-lmat-20210225monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-upcoming-investor-conferences-lmat-20210216monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-fourth-quarter-2020-earnings-results-on-february-25-2021-lmat-20210127monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-upcoming-investor-conferences-lmat-20201229monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-jefferies-virtual-london-healthcare-conference-lmat-20201111monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-upcoming-investor-conferences-lmat-20201104monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-announces-q3-2020-financial-results-lmat-20201029monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-third-quarter-2020-earnings-results-on-october-29-2020-lmat-20201009monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-upcoming-investor-conferences-lmat-20200831monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-upcoming-investor-conferences-lmat-20200729monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-announces-q2-2020-financial-results-lmat-20200723monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-second-quarter-2020-earnings-results-on-july-23-2020-lmat-20200710monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-acquires-artegraft-lmat-20200622monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-jefferies-virtual-healthcare-conference-lmat-20200528monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-ubs-virtual-global-healthcare-conference-lmat-20200512monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-announces-q1-2020-financial-results-lmat-20200430monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-withdraws-prior-annual-guidance-for-2020-and-announces-preliminary-q1-20-lmat-20200413monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-upcoming-investor-conferences-lmat-20200304monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-svb-leerink-global-healthcare-conference-on-tuesday-fe-lmat-20200218monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-announces-q4-2019-financial-results-lmat-20200206monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-fourth-quarter-2019-earnings-results-on-february-6-2020-lmat-20200129monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-needham-growth-conference-on-wednesday-january-15-2020-lmat-20200103monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-upcoming-investor-conferences-lmat-20191115monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-announces-q3-2019-financial-results-lmat-20191023monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-acquires-biologic-patch-business-from-admedus-lmat-20191013monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-third-quarter-2019-earnings-results-on-october-23-2019-lmat-20191011monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-upcoming-investor-conferences-lmat-20190826monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-canaccord-genuity-annual-growth-conference-on-thursday-lmat-20190730monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-announces-q2-2019-financial-results-lmat-20190724monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-second-quarter-2019-earnings-results-on-july-24-2019-lmat-20190711monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-jefferies-healthcare-conference-on-thursday-june-6-201-lmat-20190529monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-upcoming-investor-conferences-lmat-20190506monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-announces-q1-2019-financial-results-lmat-20190501monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-first-quarter-2019-earnings-results-on-may-1-2019-lmat-20190424monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-upcoming-investor-conferences-lmat-20190308monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-upcoming-investor-conferences-lmat-20190222monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-announces-q4-2018-financial-results-lmat-20190219monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-fourth-quarter-2018-earnings-results-on-february-19-2019-lmat-20190206monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-needham-growth-conference-on-wednesday-january-16-2019-lmat-20190108monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-upcoming-investor-conferences-lmat-20181109monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-acquires-cardial-business-of-bd-lmat-20181024monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-upcoming-investor-conferences-lmat-20180907monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-upcoming-investor-conferences-lmat-20180831monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-upcoming-investor-conferences-lmat-20180801monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-second-quarter-2018-earnings-results-on-july-26-2018-lmat-20180718monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-jefferies-healthcare-conference-on-friday-june-8-2018-lmat-20180601monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-upcoming-investor-conferences-lmat-20180503monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q1-2018-sales-26-0mm-8-eps-0-19-17-lmat-20180425monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-first-quarter-2018-earnings-results-on-april-25-2018-lmat-20180418monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-upcoming-investor-conferences-lmat-20180228monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-fourth-quarter-2017-earnings-results-on-february-21-2018-lmat-20180209monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-needham-growth-conference-on-thursday-january-18-2018-lmat-20180111monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-upcoming-november-and-december-investor-conferences-lmat-20171101monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-third-quarter-2017-earnings-results-on-october-26-2017-lmat-20171016monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-upcoming-investor-conferences-lmat-20170905monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-upcoming-investor-conferences-lmat-20170801monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-second-quarter-2017-earnings-results-on-july-27-2017-lmat-20170713monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-first-quarter-2017-earnings-results-on-april-26-2017-lmat-20170412monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-16th-annual-needham-healthcare-conference-on-tuesday-a-lmat-20170331monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-sidoti-company-spring-2017-convention-on-wednesday-mar-lmat-20170323monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-barclays-global-healthcare-conference-on-tuesday-march-lmat-20170309monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-29th-annual-roth-conference-on-tuesday-march-14-2017-lmat-20170308monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-cowen-company-37th-annual-health-care-conference-on-ma-lmat-20170301monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-participate-in-2017-btig-medical-technology-life-science-and-diagnost-lmat-20170223monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-fourth-quarter-2016-earnings-results-on-february-21-2017-lmat-20170207monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-needham-growth-conference-on-thursday-january-12-2017-lmat-20170105monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-participate-in-the-guggenheim-securities-4th-annual-boston-healthcare-lmat-20161207monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-participate-in-the-benchmark-micro-cap-discovery-conference-on-thursd-lmat-20161129monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-three-investor-conferences-in-november-lmat-20161108monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-sidoti-company-fall-2016-emerging-growth-convention-on-lmat-20161025monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-third-quarter-2016-earnings-results-on-october-26-2016-lmat-20161018monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-participate-in-the-dougherty-co-institutional-investor-conference-on--lmat-20160920monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-attend-the-9th-annual-barrington-research-fall-investment-conference--lmat-20160825monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-participate-in-the-midwest-ideas-investor-conference-on-august-30-201-lmat-20160816monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-participate-in-the-canaccord-genuity-36th-annual-growth-conference-on-lmat-20160802monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-second-quarter-2016-earnings-results-on-july-27-2016-lmat-20160719monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-east-coast-ideas-investor-conference-on-june-28-2016-lmat-20160616monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-participate-in-the-benchmark-one-on-one-conference-on-june-2-2016-lmat-20160518monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q1-2016-sales-20-3mm-7-op-inc-3-3mm-43-lmat-20160502monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-first-quarter-2016-earnings-results-on-may-2-2016-lmat-20160419monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-participate-in-the-needham-company-15th-annual-health-care-conference-lmat-20160404monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-acquires-procol-vascular-bioprosthesis-lmat-20160318monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-participate-in-the-cowen-and-company-36th-annual-health-care-conferen-lmat-20160304monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-participate-in-two-investor-conferences-in-march-lmat-20160301monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q4-2015-record-sales-20-5mm-14-organic-record-net-income-2-5mm-32-lmat-20160224monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-participate-in-btig-medtech-conference-february-24-26-2016-lmat-20160219monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-fourth-quarter-2015-earnings-results-on-february-24-2016-lmat-20160211monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-announces-details-for-its-december-3rd-investor-and-analyst-day-lmat-20151130monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-four-investor-conferences-in-november-lmat-20151104monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q3-2015-sales-19-0mm-12-organic-record-op-inc-3-3mm-79-lmat-20151027monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-announces-registration-of-trivex-r-system-in-china-lmat-20151016monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-third-quarter-2015-earnings-results-on-october-27-2015-lmat-20151014monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-hires-michael-wijas-vice-president-of-sales-for-the-americas-lmat-20150909monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-participate-in-two-investor-conferences-in-september-lmat-20150825monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q2-2015-record-sales-19-9mm-12-organic-record-op-inc-2-8mm-41-lmat-20150728monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-three-investor-conferences-in-august-lmat-20150720monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-second-quarter-2015-earnings-results-on-july-28-2015-lmat-20150715monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-announces-analyst-day-thursday-december-3-2015-lmat-20150709monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-continues-to-expand-direct-to-hospital-sales-lmat-20150630monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-set-to-join-russell-2000-index-lmat-20150617monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-on-wednesday-june-3-2015-at-the-three-part-advisors-east-coas-lmat-20150528monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-on-thursday-may-28-2015-at-the-marcum-microcap-conference-lmat-20150514monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q1-2015-record-sales-18-9mm-13-op-inc-2-3mm-lmat-20150428monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-first-quarter-2015-earnings-results-on-april-28-2015-lmat-20150420monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-attend-the-morgan-stanley-healthcare-corporate-access-day-on-wednesda-lmat-20150320monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-27th-annual-roth-conference-on-tuesday-march-10-2015-lmat-20150305monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q4-2014-record-sales-18-7mm-4-record-op-inc-2-7mm-134-lmat-20150225monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-fourth-quarter-2014-earnings-results-on-february-25-2015-lmat-20150217monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-attend-the-btig-medical-technology-diagnostics-and-healthcare-it-conf-lmat-20150213monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-attend-the-sidoti-company-emerging-growth-institutional-investor-foru-lmat-20150107monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-attend-the-benchmark-micro-cap-discovery-conference-on-thursday-decem-lmat-20141204monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-participate-in-three-investor-conferences-in-november-2014-lmat-20141112monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q3-2014-sales-17-5mm-14-op-income-1-9mm-139-lmat-20141028monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-third-quarter-2014-earnings-results-on-october-28-2014-lmat-20141021monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-acquires-angioscope-lmat-20140919monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-opens-office-in-shanghai-china-lmat-20140910monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-attend-the-barrington-research-fall-investment-conference-on-septembe-lmat-20140828monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-acquires-omniflow-ii-biologic-graft-lmat-20140818monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-canaccord-genuity-34th-annual-growth-conference-on-thu-lmat-20140812monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q2-2014-record-sales-18-2mm-14-op-profit-2-0mm-37-lmat-20140729monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-second-quarter-2014-earnings-results-on-july-29-2014-lmat-20140721monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-wells-fargo-2014-healthcare-conference-on-tuesday-june-lmat-20140611monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-inc-closes-public-offering-of-common-shares-lmat-20140604monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-inc-priced-public-offering-of-common-shares-lmat-20140530monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-inc-announces-proposed-public-offering-of-common-stock-lmat-20140529monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q1-2014-sales-of-16-8mm-9-lmat-20140429monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-first-quarter-2014-earnings-results-on-april-29-2014-lmat-20140410monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-needham-healthcare-conference-on-wednesday-april-9-201-lmat-20140404monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q4-2013-record-sales-of-17-9mm-21-lmat-20140225monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-three-upcoming-investor-conferences-lmat-20140224monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-fourth-quarter-2013-earnings-results-on-february-25-2014-lmat-20140220monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-sell-direct-to-hospital-in-australia-and-norway-lmat-20140102monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-benchmark-company-micro-cap-discovery-conference-on-we-lmat-20131127monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-announces-appointment-of-michael-thomas-to-its-board-of-directors-lmat-20131111monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-participate-in-two-investor-conferences-in-november-2013-lmat-20131108monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-announces-details-for-its-november-12th-13th-investor-and-analyst-days-lmat-20131106monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q3-2013-sales-15-3mm-12-lmat-20131029monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-canaccord-genuity-medical-technology-diagnostics-forum-lmat-20131025monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-third-quarter-2013-earnings-results-on-october-29-2013-lmat-20131002monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-host-two-investor-and-analyst-days-november-12-13-2013-lmat-20130911monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-stifel-healthcare-conference-2013-on-thursday-septembe-lmat-20130903monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-acquires-inavein-lmat-20130828monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-6th-annual-barrington-research-growth-conference-on-we-lmat-20130823monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-three-part-advisors-midwest-ideas-investor-conference--lmat-20130814monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q2-2013-record-sales-16mm-12-organic-op-income-1-4mm-lmat-20130730monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-canaccord-genuity-33rd-annual-growth-conference-on-thu-lmat-20130726monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-will-announce-second-quarter-2013-earnings-results-on-july-30-2013-lmat-20130712monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-acquires-clinical-instruments-lmat-20130709monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-launches-3-products-1-5mm-valvulotome-multitasc-albosure-patch-lmat-20130619monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-wells-fargo-securities-2013-healthcare-conference-on-w-lmat-20130604monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-sidoti-company-llc-semi-annual-microcap-conference-on--lmat-20130523monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-ranked-in-boston-globe-top-100-businesses-in-massachusetts-lmat-20130520monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-bank-of-america-merrill-lynch-2013-health-care-confere-lmat-20130509monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-three-part-advisors-east-coast-ideas-conference-on-may-lmat-20130508monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q1-2013-record-sales-15-4mm-11-organic-op-profit-1-1mm-lmat-20130430monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-12th-annual-needham-healthcare-conference-on-april-30t-lmat-20130423monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-inc-schedules-first-quarter-results-and-conference-call-on-april-30th-lmat-20130418monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-lazard-capital-markets-5th-annual-medical-technology-s-lmat-20130228monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q4-2012-sales-14-8mm-12-organic-op-profit-0-9mm-lmat-20130226monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-inc-schedules-fourth-quarter-results-and-conference-call-lmat-20130214monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-announces-changes-to-its-board-of-directors-lmat-20121210monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-open-toronto-office-lmat-20121126monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-southwest-ideas-investor-conference-on-november-15th-lmat-20121112monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-lazard-capital-markets-9th-annual-healthcare-conferenc-lmat-20121109monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-brean-capital-2012-life-sciences-summit-lmat-20121101monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q3-2012-sales-13-65mm-5-organic-op-profit-1-0mm-lmat-20121030monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-inc-schedules-third-quarter-results-and-conference-call-lmat-20121017monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-sell-directly-to-swiss-hospitals-lmat-20121015monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-acquire-xenosure-rights-for-4-6mm-lmat-20121001monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-host-analyst-day-lmat-20120925monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-rodman-renshaw-14th-annual-healthcare-conference-lmat-20120906monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-stifel-nicolaus-2012-healthcare-conference-lmat-20120831monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-5th-annual-barrington-research-growth-conference-lmat-20120830monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-canaccord-genuity-annual-growth-conference-lmat-20120808monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q2-2012-sales-14-4mm-8-organic-op-profit-1-5mm-lmat-20120731monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-analyst-day-changed-to-september-25-2012-lmat-20120725monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-inc-schedules-second-quarter-results-and-conference-call-lmat-20120719monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-jmp-securities-healthcare-conference-lmat-20120711monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-host-analyst-day-on-september-26-2012-lmat-20120709monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-sidoti-company-micro-cap-conference-and-the-wells-farg-lmat-20120607monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-east-coast-ideas-2012-investor-conference-lmat-20120531monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-bank-of-america-merrill-lynch-2012-health-care-confere-lmat-20120510monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-q1-2012-sales-13-9mm-8-organic-op-profit-0-9mm-lmat-20120502monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-inc-schedules-first-quarter-results-and-conference-call-lmat-20120420monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-q4-2011-sales-13-4mm-5-organic-op-profit-0-8mm-lmat-20120227monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-inc-schedules-fourth-quarter-results-and-conference-call-lmat-20120216monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-sidoti-company-micro-cap-conference-lmat-20120109monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-canaccord-genuity-cardiovascular-conference-lmat-20111201monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-doubles-its-stock-repurchase-program-from-5mm-to-10mm-lmat-20111109monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-q3-2011-sales-14-6mm-7-op-income-2-0mm-lmat-20111027monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-inc-schedules-third-quarter-results-and-conference-call-lmat-20111014monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-stifel-nicolaus-healthcare-conference-2011-lmat-20110829monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-canaccord-genuity-annual-growth-conference-lmat-20110808monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-q2-2011-record-sales-of-15-1mm-up-7-lmat-20110728monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-inc-schedules-second-quarter-results-and-conference-call-lmat-20110715monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-lazard-capital-markets-medical-technology-conference-a-lmat-20110614monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-ranked-48-of-the-100-best-of-massachusetts-businesses-lmat-20110527monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-east-coast-ideas-conference-lmat-20110527monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-security-research-associates-7th-annual-spring-growth--lmat-20110523monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-to-consolidate-california-factory-also-exiting-taarget-unifit-business-lmat-20110520monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-q1-2011-record-sales-of-14-6mm-up-6-lmat-20110428monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-inc-schedules-first-quarter-results-and-conference-call-lmat-20110418monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-cowen-company-31st-annual-healthcare-conference-and-th-lmat-20110303monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q4-sales-14-4mm-9-organic-2010-sales-56-1mm-12-organic-lmat-20110228monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-inc-schedules-fourth-quarter-results-and-conference-call-lmat-20110217monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-investment-conferences-in-january-lmat-20110104monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-host-analyst-day-on-december-2-2010-lmat-20101129monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-december-investment-conferences-lmat-20101129monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-acquires-lifespan-vascular-graft-lmat-20101117monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-november-investment-conferences-in-nyc-lmat-20101105monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-q3-2010-sales-13-7mm-6-organic-and-record-op-income-2-0mm-lmat-20101028monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-rodman-renshaw-annual-global-investment-conference-lmat-20100831monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-canaccord-genuity-30th-annual-growth-conference-lmat-20100730monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-q2-2010-sales-14-2mm-15-organic-and-op-profit-2-0mm-lmat-20100728monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-inc-schedules-second-quarter-results-and-conference-call-lmat-20100716monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-sidoti-company-s-semi-annual-new-york-micro-cap-conference-lmat-20100614monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-wells-fargo-securities-2010-healthcare-conference-lmat-20100611monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-needham-company-s-9th-annual-healthcare-conference-lmat-20100524monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-q1-2010-record-sales-13-8mm-22-op-profit-1-3mm-lmat-20100429monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-inc-schedules-first-quarter-results-and-conference-call-lmat-20100419monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-q4-2009-record-sales-13-6mm-12-op-profit-1-2mm-lmat-20100304monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-cowen-s-30th-annual-health-care-conference-and-roth-s-22nd-lmat-20100301monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-inc-schedules-fourth-quarter-results-and-conference-call-lmat-20100223monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-equities-and-c-k-cooper-winter-discovery-day-conferenc-lmat-20091210monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-canaccord-adams-3rd-annual-cardiovascular-conference-lmat-20091030monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-q3-2009-record-sales-13-3mm-up-11-op-profit-1-3mm-lmat-20091028monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-inc-schedules-third-quarter-results-and-conference-call-lmat-20091019monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-announces-extension-of-endologix-powerlink-distribution-lmat-20090811monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-canaccord-adams-29th-annual-global-growth-conference-lmat-20090806monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-q2-2009-operating-profit-of-1mm-stock-buyback-of-1mm-lmat-20090729monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-inc-schedules-second-quarter-results-and-conference-call-lmat-20090721monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-reports-3rd-consecutive-profitable-quarter-excluding-albograft-charge-lmat-20090428monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-inc-schedules-first-quarter-results-and-conference-call-lmat-20090423monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-participate-in-cowen-s-29th-annual-health-care-conference-lmat-20090310monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-q4-2008-sales-up-9-to-12-1-million-op-profit-of-354-000-lmat-20090303monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-inc-schedules-fourth-quarter-results-and-conference-call-lmat-20090219monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-rodman-renshaw-10th-annual-healthcare-conference-lmat-20081105monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q3-2008-sales-up-19-percent-to-12-0-million-op-profit-of-170-000-lmat-20081029monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-inc-schedules-third-quarter-results-and-conference-call-lmat-20081016monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-the-third-annual-jmp-securities-healthcare-focus-conferenc-lmat-20080930monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-appoints-john-j-o-connor-to-its-board-of-directors-lmat-20080919monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-to-present-at-canaccord-adams-28th-annual-global-growth-conference-lmat-20080811monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-receives-notice-of-noncompliance-with-nasdaq-marketplace-rule-lmat-20080808monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-reports-q2-2008-revenue-of-12-7-million-a-23-increase-lmat-20080729monthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-vascular-inc-schedules-second-quarter-results-and-conference-call-lmat-20080717monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-americ-trvi-20260430monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-in-upcoming-events-trvi-20260401monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-report-fourth-quarter-and-year-end-2025-financial-results-and-provid-trvi-20260310monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-present-at-stifel-healthcare-conference-trvi-20201110monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-present-at-h-c-wainwright-global-investment-conference-trvi-20200909monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-report-q2-2020-financial-results-on-august-13-trvi-20200806monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-present-at-btig-virtual-biotechnology-conference-trvi-20200805monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-positive-outcome-of-the-sample-size-re-estimation-analysis-in-trvi-20200713monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-present-at-bmo-prescriptions-for-success-healthcare-virtual-conferen-trvi-20200617monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-hold-virtual-2020-annual-meeting-of-stockholders-trvi-20200529monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-present-at-needham-healthcare-conference-trvi-20200408monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-present-at-svb-leerink-healthcare-conference-trvi-20200220monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-present-at-stifel-healthcare-conference-trvi-20191113monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-in-panel-discussion-at-btig-pain-pruritus-management-for-trvi-20190905monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-present-at-bmo-prescriptions-for-success-healthcare-conference-trvi-20190618monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-pricing-of-initial-public-offering-trvi-20190507monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-first-quarter-2026-results-and-updates-full-year-guidance-mmsi-20260430monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-launches-the-resilience-through-the-scope-esophageal-stent-mmsi-20260316monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-second-quarter-2025-results-and-updates-full-year-guidance-mmsi-20250730monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-names-martha-aronson-as-new-president-and-chief-executive-officer-mmsi-20250707monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-second-quarter-2025-results-on-july-30-2025-mmsi-20250703monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-acquires-biolife-delaware-l-l-c-mmsi-20250520monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-health-canada-approval-of-the-wrapsody-cell-impermeable-endoprosth-mmsi-20250506monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-releases-12-month-efficacy-results-for-the-single-arm-arteriovenous-graft-av-mmsi-20250505monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-first-quarter-2025-results-and-updates-full-year-guidance-mmsi-20250424monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-launches-the-ventrax-delivery-system-mmsi-20250409monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-first-quarter-2025-results-on-april-24-2025-mmsi-20250407monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-releases-12-month-efficacy-results-of-the-wrapsody-cell-impermeable-endopros-mmsi-20250325monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-rings-nasdaq-opening-bell-to-celebrate-35-year-partnership-mmsi-20250318monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-fourth-quarter-and-full-year-2024-results-and-issues-fiscal-year-202-mmsi-20250225monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-preliminary-unaudited-revenue-for-the-year-ended-december-31-2024--mmsi-20250114monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-fda-approval-of-the-wrapsody-cell-impermeable-endoprosthesis-mmsi-20241220monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-resignation-of-president-joseph-wright-mmsi-20241216monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-s-wrapsody-wave-trial-exceeds-performance-goals-for-arteriovenous-graft-avg--mmsi-20241125monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-completes-acquisition-of-lead-management-portfolio-from-cook-medical-mmsi-20241101monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-third-quarter-2024-results-and-raises-full-year-guidance-mmsi-20241030monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-third-quarter-2024-results-on-october-30-2024-mmsi-20241008monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-signs-agreement-to-purchase-lead-management-portfolio-from-cook-medical-mmsi-20240917monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-s-wrapsody-wave-trial-demonstrates-superior-patency-versus-standard-of-care--mmsi-20240916monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-the-2024-cardiovascular-and-interventional-radiological-societ-mmsi-20240911monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-second-quarter-2024-results-and-raises-full-year-guidance-mmsi-20240801monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-6-month-outcomes-from-randomized-arm-of-wrapsody-arteriovenous-ac-mmsi-20240801monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-asset-purchase-agreement-with-endogastric-solutions-inc-mmsi-20240701monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-second-quarter-2024-results-on-august-1-2024-mmsi-20240618monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-launches-basixsky-inflation-device-mmsi-20240521monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-executive-leadership-team-update-mmsi-20240515monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-expands-embolics-portfolio-with-new-siege-vascular-plug-and-bearing-nspva-ex-mmsi-20240514monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-results-for-first-quarter-ended-march-31-2024-mmsi-20240430monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-launches-the-micro-ace-advanced-micro-access-system-mmsi-20240319monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-first-quarter-2024-results-on-april-30-2024-mmsi-20240318monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-host-evening-of-innovation-during-the-2024-society-of-interventional-radi-mmsi-20240305monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-introduces-continued-growth-initiatives-program-and-financial-targets-for-th-mmsi-20240228monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-results-for-fourth-quarter-and-year-ended-december-31-2023-issues-fi-mmsi-20240228monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-receives-fda-510-k-clearance-for-scout-md-surgical-guidance-system-mmsi-20240215monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-projected-preliminary-unaudited-revenue-for-the-year-ended-decembe-mmsi-20240108monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-the-j-p-morgan-42nd-annual-healthcare-conference-mmsi-20240103monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-process-for-chief-executive-officer-succession-planning-mmsi-20231218monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-results-for-third-quarter-ended-september-30-2023-mmsi-20231026monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-launches-expanded-maestro-microcatheter-line-mmsi-20231010monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-third-quarter-2023-results-on-october-26-2023-mmsi-20231005monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-launches-the-aspira-evacuated-drainage-bottle-mmsi-20230906monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-s-wrapsody-arteriovenous-access-efficacy-wave-pivotal-study-completes-enroll-mmsi-20230803monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-results-for-second-quarter-june-30-2023-mmsi-20230725monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-second-quarter-2023-results-on-july-25-2023-mmsi-20230706monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-acquisition-of-dialysis-catheter-portfolio-and-the-biosentry-biops-mmsi-20230608monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-results-for-first-quarter-march-31-2023-mmsi-20230426monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-first-quarter-2023-results-on-april-26-2023-mmsi-20230406monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-launches-expanded-swiftninja-steerable-microcatheter-offering-mmsi-20230320monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-results-for-fourth-quarter-and-year-ended-december-31-2022-issues-fi-mmsi-20230222monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-receives-fda-breakthrough-device-designation-for-the-new-scout-md-surgical-g-mmsi-20230216monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-fourth-quarter-and-year-end-2022-results-and-issue-fisca-mmsi-20230203monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-launches-the-basixalpha-inflation-device-mmsi-20221128monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-launches-the-preludesync-ez-radial-compression-device-mmsi-20221121monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-the-appointment-of-joe-wright-to-chief-commercial-officer-mmsi-20221101monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-results-for-quarter-ended-september-30-2022-mmsi-20221026monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-third-quarter-results-on-october-26-2022-mmsi-20221013monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-launches-the-temno-elite-soft-tissue-biopsy-system-mmsi-20220927monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-launches-the-prelude-roadster-guide-sheath-mmsi-20220912monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-launches-safeguard-focus-cool-compression-device-mmsi-20220808monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-results-for-quarter-ended-june-30-2022-mmsi-20220727monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-launches-smallest-and-shortest-configuration-of-elation-pulmonary-balloon-di-mmsi-20220720monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-second-quarter-results-on-july-27-2022-mmsi-20220714monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-celebrates-completion-of-xeriscape-landscaping-project-mmsi-20220629monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-results-for-quarter-ended-march-31-2022-mmsi-20220427monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-s-chief-legal-officer-and-corporate-secretary-brian-lloyd-receives-corporate-mmsi-20220421monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-launch-of-resolve-thoracostomy-tray-mmsi-20220418monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-first-quarter-results-on-april-27-2022-mmsi-20220413monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-receives-fda-clearance-for-scout-bx-delivery-system-mmsi-20220411monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-receives-fda-breakthrough-device-designation-for-embosphere-microspheres-for-mmsi-20220307monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-results-for-fourth-quarter-and-year-ended-december-31-2021-issues-fy-mmsi-20220224monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-fourth-quarter-and-year-end-2021-results-on-february-24--mmsi-20220117monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-agreement-in-principle-to-settle-class-action-litigation-mmsi-20211123monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-results-for-quarter-ended-september-30-2021-mmsi-20211028monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-third-quarter-results-on-october-28-2021-mmsi-20211005monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-positive-results-in-first-in-human-study-of-wrapsody-cell-impermea-mmsi-20210920monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-launches-one-vac-evacuated-drainage-bottle-for-percutaneous-fluid-collection-mmsi-20210816monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-results-for-quarter-ended-june-30-2021-mmsi-20210729monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-second-quarter-results-on-july-29-2021-mmsi-20210709monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-results-for-quarter-ended-march-31-2021-mmsi-20210429monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-first-quarter-results-on-april-29-2021-mmsi-20210409monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-20th-annual-needham-healthcare-conference-mmsi-20210408monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-results-for-fourth-quarter-and-year-ended-december-31-2020-issues-fy-mmsi-20210224monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-fourth-quarter-and-year-end-2020-results-on-february-24--mmsi-20210212monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-2021-svb-leerink-global-healthcare-conference-mmsi-20210210monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-in-two-upcoming-investor-conferences-mmsi-20210107monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-foundations-for-growth-program-and-financial-targets-for-2020-to--mmsi-20201110monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-results-for-third-quarter-issues-updated-2020-guidance-mmsi-20201028monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-finalizes-resolution-with-the-government-mmsi-20201013monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-third-quarter-results-on-october-28-2020-and-host-founda-mmsi-20201009monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-four-conferences-in-september-mmsi-20200902monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-canaccord-genuity-and-needham-conferences-mmsi-20200806monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-results-for-quarter-ended-june-30-2020-mmsi-20200729monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-second-quarter-results-on-july-29-2020-mmsi-20200717monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-agreement-in-principle-with-department-of-justice-mmsi-20200715monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-agreement-with-starboard-mmsi-20200526monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-receives-ce-mark-for-wrapsody-endovascular-stent-graft-system-mmsi-20200526monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-earnings-for-quarter-ended-march-31-2020-withdraws-fy-2020-guidance-mmsi-20200423monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-designs-and-produces-sample-collection-and-transport-kit-mmsi-20200420monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-first-quarter-results-on-april-23-2020-mmsi-20200414monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-receives-two-additional-fda-breakthrough-device-designations-mmsi-20200406monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-provides-historical-revenues-in-revised-presentation-format-mmsi-20200403monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-response-to-earthquake-in-salt-lake-city-mmsi-20200318monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-oppenheimer-and-btig-conferences-mmsi-20200302monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-earnings-for-fourth-quarter-and-year-ended-december-31-2019-gives-fy-mmsi-20200224monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-announces-four-regulatory-approvals-mmsi-20200220monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-svb-leerink-conference-mmsi-20200218monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-fourth-quarter-and-year-end-2019-results-on-february-24--mmsi-20200213monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-deadline-alert-faruqi-faruqi-llp-encourages-investors-who-suffered-losses-ex-mmsi-20200129monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-issues-statement-regarding-director-nominations-from-starboard-mmsi-20200127monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-inc-investor-reminder-wolf-haldenstein-adler-freeman-herz-llp-announ-mmsi-20200107monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-inc-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-mmsi-20191211monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-loss-alert-rosen-law-firm-announces-filing-of-securities-class-action-lawsuit-agains-mmsi-20191207monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-receives-fda-breakthrough-device-designation-for-wrapsody-endovascular-stent-mmsi-20191121monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-three-upcoming-conferences-mmsi-20191106monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-earnings-for-third-quarter-of-2019-mmsi-20191030monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-third-quarter-results-on-october-30-2019-mmsi-20191018monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-three-conferences-in-september-mmsi-20190903monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-appointment-of-lynne-n-ward-to-its-board-of-directors-mmsi-20190819monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-canaccord-genuity-and-needham-conferences-mmsi-20190729monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-earnings-for-second-quarter-of-2019-mmsi-20190725monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-second-quarter-results-on-july-25-2019-mmsi-20190709monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-acquires-brightwater-medical-inc-mmsi-20190617monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-awarded-interventional-fluid-management-agreement-with-premier-mmsi-20190611monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-raymond-james-conference-mmsi-20190610monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-three-conferences-in-may-mmsi-20190430monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-earnings-for-quarter-ended-march-31-2019-mmsi-20190423monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-first-quarter-results-on-april-23-2019-mmsi-20190410monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-needham-healthcare-conference-mmsi-20190328monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-earnings-for-fourth-quarter-and-year-ended-december-31-2018-gives-20-mmsi-20190226monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-six-upcoming-conferences-mmsi-20190222monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-fourth-quarter-and-year-end-results-and-2019-guidance-on-mmsi-20190212monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-needham-growth-conference-mmsi-20190107monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-appointment-of-two-new-directors-mmsi-20190103monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-acquires-assets-of-vascular-insights-llc-mmsi-20181217monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-ireland-wins-medtech-company-of-the-year-award-2018-mmsi-20181210monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-closes-cianna-medical-inc-deal-mmsi-20181113monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-four-conferences-in-november-mmsi-20181101monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-earnings-for-third-quarter-of-2018-mmsi-20181025monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-third-quarter-results-on-october-25-2018-mmsi-20181008monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-signs-agreement-to-acquire-cianna-medical-inc-mmsi-20181001monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-three-upcoming-conferences-mmsi-20180919monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-three-upcoming-conferences-mmsi-20180828monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-two-conferences-in-august-mmsi-20180731monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-closing-of-public-offering-of-common-stock-and-exercise-in-full-of-mmsi-20180730monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-pricing-of-public-offering-of-common-stock-mmsi-20180725monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-commencement-of-public-offering-of-common-stock-mmsi-20180724monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-record-revenues-for-second-quarter-of-2018-merit-adjusts-2018-guidan-mmsi-20180723monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-second-quarter-results-on-july-23-2018-mmsi-20180716monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-leadership-change-and-appointment-of-interim-cfo-mmsi-20180531monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-enters-strategic-alliance-and-worldwide-distribution-with-ninepoint-medical-mmsi-20180502monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-three-conferences-in-may-mmsi-20180430monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-record-revenues-for-first-quarter-of-2018-mmsi-20180425monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-first-quarter-results-on-april-25-2018-mmsi-20180411monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-results-for-fourth-quarter-and-year-ended-december-31-2017-merit-mee-mmsi-20180228monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-six-conferences-mmsi-20180222monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-closes-deal-with-bd-for-purchase-of-divestment-assets-mmsi-20180215monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-fourth-quarter-and-year-end-results-on-february-28-2018-mmsi-20180212monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-signs-purchase-agreement-with-bd-for-divestment-assets-mmsi-20171116monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-three-conferences-mmsi-20171030monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-results-for-third-quarter-2017-mmsi-20171025monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-third-quarter-results-on-october-25-2017-mmsi-20171012monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-five-conferences-mmsi-20170829monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-three-conferences-mmsi-20170731monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-record-revenue-and-non-gaap-net-income-for-second-quarter-2017-raise-mmsi-20170726monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-second-quarter-results-on-july-26-2017-mmsi-20170710monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-s-embosphere-microspheres-receive-fda-513-f-2-de-novo-classification-for-pro-mmsi-20170622monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-appointment-of-new-director-mmsi-20170526monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-three-conferences-mmsi-20170503monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-results-for-first-quarter-of-2017-mmsi-20170427monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-first-quarter-results-on-april-27-2017-mmsi-20170404monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-needham-healthcare-conference-mmsi-20170330monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-closing-of-public-offering-of-common-stock-mmsi-20170329monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-full-exercise-of-option-to-purchase-additional-common-stock-mmsi-20170327monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-pricing-of-public-offering-of-common-stock-mmsi-20170323monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-commencement-of-public-offering-of-common-stock-mmsi-20170320monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-results-for-fourth-quarter-and-year-ended-december-31-2016-mmsi-20170221monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-btig-and-barclays-conferences-mmsi-20170216monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-rbc-conference-mmsi-20170207monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-acquires-products-from-argon-medical-devices-and-catheter-connections-inc-mmsi-20170206monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-j-p-morgan-healthcare-conference-mmsi-20161219monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-receives-510-k-clearance-for-the-swiftninja-steerable-microcatheter-mmsi-20161107monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-four-conferences-in-november-mmsi-20161101monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-sales-up-15-3-for-the-quarter-ended-september-30-2016-mmsi-20161026monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-completes-enrollment-in-evolve-study-mmsi-20161019monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-launches-super-hero-and-hero-ally-products-mmsi-20161018monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-third-quarter-results-on-october-26-2016-mmsi-20161004monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-receives-510-k-clearance-for-the-elation-pulmonary-dilation-balloon-mmsi-20160907monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-five-conferences-mmsi-20160825monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-two-conferences-mmsi-20160801monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-sales-up-9-4-for-the-quarter-ended-june-30-2016-mmsi-20160727monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-appointment-of-new-director-mmsi-20160726monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-second-quarter-results-on-july-27-2016-mmsi-20160714monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-acquires-dfine-inc-mmsi-20160706monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-ubs-global-healthcare-conference-mmsi-20160512monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-appointed-global-distributor-for-micro-guide-wire-mmsi-20160510monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-sales-up-6-6-for-the-quarter-ended-march-31-2016-mmsi-20160428monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-first-quarter-results-on-april-28-2016-mmsi-20160404monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-510-k-clearance-for-corvocet-biopsy-system-mmsi-20160328monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-results-for-fourth-quarter-and-year-ended-december-31-2015-mmsi-20160222monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-four-conferences-mmsi-20160210monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-fourth-quarter-and-year-end-results-on-february-22-2016-mmsi-20160204monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-acquires-the-hero-graft-from-cryolife-inc-mmsi-20160204monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-three-conferences-mmsi-20151110monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-receives-four-new-regulatory-approvals-mmsi-20151109monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-names-new-chief-financial-officer-mmsi-20151106monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-results-for-the-quarter-ended-september-30-2015-mmsi-20151022monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-inc-and-sumitomo-bakelite-co-ltd-sign-distribution-deal-for-steerabl-mmsi-20151006monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-announces-earnings-release-date-time-and-conference-call-information-mmsi-20151002monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-four-conferences-in-september-mmsi-20150826monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-canaccord-genuity-growth-conference-mmsi-20150805monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-receives-fda-510-k-clearance-expanding-indication-for-quadrasphere-microsphe-mmsi-20150804monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-record-revenues-for-the-quarter-and-six-months-ended-june-30-2015-mmsi-20150723monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-appointment-of-new-independent-director-mmsi-20150720monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-announces-earnings-release-date-time-and-conference-call-information-mmsi-20150706monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-sales-up-9-for-the-quarter-ended-march-31-2015-mmsi-20150423monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-announces-earnings-release-date-time-and-conference-call-information-mmsi-20150416monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-sidoti-company-s-small-cap-equity-conference-mmsi-20150310monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-details-three-year-plan-to-accelerate-profitable-growth-mmsi-20150305monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-record-revenues-and-income-for-the-quarter-and-year-ended-december-3-mmsi-20150224monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-announces-dates-for-earnings-release-and-investor-day-mmsi-20150116monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-multiple-regulatory-approvals-mmsi-20141210monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-piper-jaffray-healthcare-conference-mmsi-20141124monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-stephens-and-canaccord-genuity-conferences-this-month-mmsi-20141107monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-and-bard-access-systems-inc-settle-dispute-mmsi-20141030monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-results-for-the-quarter-ended-september-30-2014-mmsi-20141023monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-unveils-new-thinkradial-tm-website-and-educational-initiative-mmsi-20141013monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-announces-earnings-release-date-time-and-conference-call-information-mmsi-20141002monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-cl-king-conference-mmsi-20140902monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-canaccord-genuity-growth-conference-mmsi-20140805monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-record-revenues-for-the-quarter-and-six-months-ended-june-30-2014-mmsi-20140729monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-announces-earnings-release-date-time-and-conference-call-information-mmsi-20140716monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-receives-regulatory-approval-for-tracheobronchial-stent-systems-in-china-mmsi-20140709monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-corporate-developments-prior-to-shareholder-meeting-mmsi-20140611monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-wells-fargo-healthcare-conference-mmsi-20140611monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-ubs-global-healthcare-conference-mmsi-20140508monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-sales-up-15-for-the-quarter-ended-march-31-2014-mmsi-20140424monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-announces-earnings-release-date-time-and-conference-call-information-mmsi-20140407monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-sidoti-and-btig-conferences-next-week-mmsi-20140312monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-sales-and-earnings-guidance-for-2014-mmsi-20140303monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-update-2014-guidance-on-march-3-2014-mmsi-20140228monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-raymond-james-institutional-investors-conference-mmsi-20140225monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-record-revenues-for-the-quarter-and-year-ended-december-31-2013-mmsi-20140224monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-rbc-capital-markets-healthcare-conference-mmsi-20140218monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-fourth-quarter-and-year-end-results-on-february-24-2014-mmsi-20140204monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-noble-financial-s-equity-conference-mmsi-20140109monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-piper-jaffray-healthcare-conference-mmsi-20131126monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-stephens-and-canaccord-genuity-conferences-this-week-mmsi-20131112monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-results-for-the-quarter-ended-september-30-2013-mmsi-20131023monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-announces-earnings-release-date-time-and-conference-call-information-mmsi-20131007monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-acquires-assets-of-radial-assist-mmsi-20131007monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-acquires-pressure-assisted-hemostatic-devices-from-datascope-corp-mmsi-20131007monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-cl-king-conference-mmsi-20130903monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-canaccord-genuity-growth-conference-mmsi-20130801monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-record-revenues-up-nine-percent-for-the-quarter-and-six-months-ended-mmsi-20130731monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-announces-earnings-release-date-time-and-conference-call-information-mmsi-20130708monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-multiple-regulatory-approvals-mmsi-20130701monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-wells-fargo-healthcare-conference-mmsi-20130610monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-opens-hypotube-center-of-excellence-mmsi-20130604monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-jefferies-global-healthcare-conference-mmsi-20130528monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-ubs-global-healthcare-conference-mmsi-20130507monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-record-sales-up-9-for-the-quarter-ended-march-31-2013-mmsi-20130425monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-sidoti-and-credit-suisse-conferences-mmsi-20130312monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-receives-ce-marking-for-prostatic-artery-embolization-for-embosphere-r-micro-mmsi-20130307monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-raymond-james-institutional-investors-conference-mmsi-20130228monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-record-revenues-for-the-quarter-and-year-ended-december-31-2012-and--mmsi-20130221monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-rbc-and-lazard-conferences-mmsi-20130220monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-completes-acquisition-of-thomas-medical-products-a-unit-of-ge-healthcare-mmsi-20121220monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-lazard-s-corporate-access-day-mmsi-20121212monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-510-k-clearance-for-the-one-snare-tm-system-mmsi-20121210monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-acquires-assets-of-medigroup-mmsi-20121129monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-signs-agreement-to-acquire-thomas-medical-products-a-unit-of-ge-healthcare-mmsi-20121126monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-piper-jaffray-healthcare-conference-mmsi-20121119monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-lazard-and-stephens-conferences-mmsi-20121108monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-results-for-the-quarter-ended-september-30-2012-mmsi-20121025monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-fda-completes-evaluation-mmsi-20121023monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-receives-510-k-clearance-to-market-the-merit-laureate-r-hydrophilic-guide-wi-mmsi-20120924monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-cl-king-lazard-and-ubs-conferences-in-september-mmsi-20120906monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-record-revenues-up-ten-percent-for-the-quarter-ended-june-30-2012-mmsi-20120726monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-wells-fargo-healthcare-conference-mmsi-20120611monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-jefferies-global-healthcare-conference-mmsi-20120529monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-record-sales-up-10-for-the-quarter-ended-march-31-2012-mmsi-20120424monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-510-k-clearance-for-30-60um-quadrasphere-r-microspheres-mmsi-20120326monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-sidoti-company-s-emerging-growth-institutional-investor-fo-mmsi-20120314monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-raymond-james-institutional-investors-conference-mmsi-20120227monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-record-sales-and-net-income-for-the-year-ended-december-31-2011-and--mmsi-20120223monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-rbc-and-lazard-conferences-mmsi-20120222monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-receives-fda-warning-letter-regarding-merit-laureate-r-hydrophilic-g-mmsi-20120207monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-the-purchase-of-the-assets-of-ostial-solutions-llc-mmsi-20120201monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-noble-financial-capital-markets-equity-conference-mmsi-20120109monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-piper-jaffray-health-care-conference-mmsi-20111122monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-appointment-of-two-directors-mmsi-20111110monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-lazard-and-stephens-conferences-mmsi-20111101monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-results-for-the-quarter-ended-september-30-2011-mmsi-20111025monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-stifel-nicolaus-healthcare-conference-mmsi-20110907monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-regulatory-approvals-for-multiple-products-mmsi-20110907monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-cl-king-ubs-and-jefferies-conferences-in-september-mmsi-20110901monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-record-revenues-and-earnings-for-the-second-quarter-and-six-months-e-mmsi-20110721monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-inc-announces-closing-of-public-offering-of-common-stock-mmsi-20110622monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-inc-prices-common-stock-offering-mmsi-20110617monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-inc-announces-commencement-of-public-offering-of-common-stock-mmsi-20110616monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-jefferies-2011-global-healthcare-conference-mmsi-20110526monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-5-for-4-forward-stock-split-mmsi-20110421monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-record-revenues-and-earnings-for-the-quarter-ended-march-31-2011-mmsi-20110414monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-announces-earnings-release-date-time-and-conference-call-information-mmsi-20110412monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-510-k-clearance-for-the-asap-tm-thrombus-aspiration-catheter-mmsi-20110315monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-sidoti-company-s-emerging-growth-institutional-investor-fo-mmsi-20110310monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-roth-capital-partners-growth-stock-conference-mmsi-20110228monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-raymond-james-institutional-investors-conference-mmsi-20110222monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-record-revenues-for-the-fourth-quarter-and-year-ended-december-31-20-mmsi-20110217monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-rbc-capital-markets-healthcare-conference-mmsi-20110216monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-announce-fourth-quarter-and-year-end-results-on-february-17-2011-mmsi-20110201monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-canaccord-genuity-cardiovascular-diabetes-obesity-conference-mmsi-20101129monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-lazard-capital-s-medical-technology-conference-mmsi-20101124monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-piper-jaffray-health-care-conference-mmsi-20101119monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-sidoti-stephens-and-lazard-conferences-next-week-mmsi-20101110monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-results-for-the-quarter-ended-september-30-2010-and-gives-update-o-mmsi-20101104monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-completes-acquisition-of-biosphere-medical-mmsi-20100913monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-cl-king-s-best-ideas-conference-and-stifel-nicolaus-healthcare-mmsi-20100908monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-cjs-securities-investor-conference-mmsi-20100804monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-record-sales-up-16-for-the-second-quarter-and-six-months-ended-jun-mmsi-20100728monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-noble-financial-s-sixth-annual-equity-conference-mmsi-20100527monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-jefferies-2010-global-life-sciences-conference-mmsi-20100527monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-signs-agreement-to-acquire-biosphere-medical-mmsi-20100513monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-16-increase-in-sales-for-the-quarter-ended-march-31-2010-mmsi-20100429monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-sidoti-company-s-emerging-growth-institutional-investor-forum-mmsi-20100316monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-roth-capital-partners-growth-stock-conference-mmsi-20100305monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-raymond-james-institutional-investors-conference-mmsi-20100304monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-in-lazard-capital-markets-conference-mmsi-20100219monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-record-sales-and-earnings-for-the-year-ended-december-31-2009-mmsi-20100218monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-s-chief-executive-invited-to-the-president-s-forum-on-jobs-and-economic-grow-mmsi-20091130monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-at-piper-jaffray-s-health-care-conference-mmsi-20091124monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-510-k-clearance-for-the-merit-laureate-tm-hydrophilic-guide-wire-mmsi-20091110monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-sidoti-s-emerging-growth-conference-mmsi-20091109monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-canaccord-adams-cardiovascular-conference-mmsi-20091102monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-record-sales-up-15-and-record-earnings-up-17-for-the-third-quarter-mmsi-20091027monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-announces-three-part-deal-with-vysera-biomedical-limited-mmsi-20091027monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-cl-king-s-best-ideas-conference-mmsi-20090909monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-thomas-weisel-s-healthcare-conference-mmsi-20090902monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-canaccord-adams-global-growth-conference-mmsi-20090804monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-record-sales-up-13-percent-for-the-second-quarter-ended-june-30-20-mmsi-20090728monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-jefferies-healthcare-conference-mmsi-20090611monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-acquires-en-snare-r-product-rights-from-hatch-medical-mmsi-20090603monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-bank-of-america-s-health-care-conference-mmsi-20090505monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-28-percent-increase-in-net-income-on-record-sales-and-improved-gro-mmsi-20090428monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-510-k-clearance-mmsi-20090415monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-lazard-capital-markets-medical-technology-conference-mmsi-20090317monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-sidoti-s-emerging-growth-conference-mmsi-20090316monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-closing-of-alveolus-and-biosearch-deals-mmsi-20090316monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-raymond-james-investors-conference-mmsi-20090303monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-2009-sales-and-earnings-guidance-including-anticipated-effects-of--mmsi-20090219monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-agreement-to-acquire-assets-of-alveolus-inc-mmsi-20090219monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-to-give-sales-and-earnings-guidance-for-2009-mmsi-20090219monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-record-sales-and-earnings-for-the-year-ended-december-31-2008-mmsi-20090205monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-announces-earnings-release-date-time-and-conference-call-information-mmsi-20090202monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-microcatheter-market-entry-mmsi-20090114monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-sidoti-s-emerging-growth-conference-mmsi-20090109monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-year-end-developments-mmsi-20081230monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-piper-jaffray-health-care-conference-mmsi-20081120monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-stephens-fall-investment-conference-mmsi-20081112monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-record-revenues-up-15-percent-and-improved-earnings-for-the-third-qu-mmsi-20081023monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-510-k-clearance-mmsi-20081022monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-announces-earnings-release-date-time-and-conference-call-information-mmsi-20081015monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-discusses-angleton-texas-facility-mmsi-20080915monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-the-ubs-global-life-sciences-conference-mmsi-20080915monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-cl-king-s-best-ideas-conference-mmsi-20080911monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-the-credit-suisse-under-followed-opportunities-conference-mmsi-20080903monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-lineup-of-new-product-introductions-mmsi-20080902monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-thomas-weisel-partners-healthcare-conference-mmsi-20080821monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-the-noble-financial-equity-conference-mmsi-20080806monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-updated-guidance-for-gross-margins-profits-and-sales-mmsi-20080723monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-62-percent-increase-in-net-earnings-on-500-basis-point-gross-margin--mmsi-20080723monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-capstone-investments-conference-mmsi-20080612monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-the-fbr-capital-markets-spring-investor-conference-mmsi-20080514monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-50-percent-increase-in-eps-on-improved-sales-and-gross-margins-mmsi-20080424monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-the-raymond-james-investors-conference-mmsi-20080226monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-record-4q-revenues-and-net-income-up-55-percent-mmsi-20080214monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-finalizes-two-deals-mmsi-20080213monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-roth-capital-s-oc-growth-stock-conference-mmsi-20080211monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-report-results-ahead-of-previously-announced-forecasts-mmsi-20080115monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-510-k-notification-for-new-sea-dragon-torque-device-mmsi-20071220monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-host-investor-meetings-in-san-francisco-mmsi-20071219monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-510-k-notification-for-two-additional-products-mmsi-20071128monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-510-k-notification-for-resolve-biliary-catheter-mmsi-20071126monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-the-stephens-fall-investment-conference-mmsi-20071106monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-acquire-cardiac-and-peripheral-assets-from-micrus-endovascular-mmsi-20071105monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-announces-improved-gross-margins-and-profits-for-3q-2007-mmsi-20071025monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-the-cibc-world-markets-healthcare-conference-mmsi-20071024monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-improvement-in-gross-margins-and-profits-and-conference-call-infor-mmsi-20071015monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-the-ubs-global-life-sciences-conference-mmsi-20070919monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-cl-king-s-best-ideas-conference-mmsi-20070911monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-thomas-weisel-partners-healthcare-conference-mmsi-20070828monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-exclusive-distribution-deal-for-microcatheter-mmsi-20070815monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-the-noble-financial-two-double-o-seven-conference-mmsi-20070813monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-2q-2007-results-mmsi-20070726monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-510-k-notification-for-transradial-catheterization-mmsi-20070724monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-acquires-radiopaque-laminate-technology-mmsi-20070724monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-launches-proguide-chronic-dialysis-kit-mmsi-20070524monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-bank-of-america-health-care-conference-mmsi-20070522monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-participate-in-brean-murray-s-healthcare-conference-mmsi-20070508monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-increased-sales-and-improved-earnings-mmsi-20070502monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-stock-repurchase-plan-mmsi-20070502monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-announces-earnings-release-date-time-and-conference-call-information-for-fir-mmsi-20070424monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-repurchases-344-084-shares-in-private-transaction-mmsi-20070403monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-suntrust-robinson-humphrey-s-institutional-conference-mmsi-20070402monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-gives-2007-sales-and-earnings-guidance-mmsi-20070329monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-19-percent-increase-in-revenue-for-the-fourth-quarter-ended-december-mmsi-20070228monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-acquires-proguide-chronic-dialysis-catheter-from-datascope-mmsi-20070227monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-acquires-exclusive-rights-to-abdominal-retraction-system-mmsi-20070221monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-to-present-at-roth-capital-s-oc-conference-mmsi-20070214monthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-introduces-new-safety-product-mmsi-20070205monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-remind-nvcr-20230809monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-limited-please-contact-the-portnoy-law-firm-to-recover-your-losses-august-18-2023-nvcr-20230808monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-limited-nasdaq-nvcr-deadline-alert-bernstein-liebhard-llp-reminds-investors-of-th-nvcr-20230808monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000--nvcr-20230802monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-remind-nvcr-20230726monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-limited-nasdaq-nvcr-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-nvcr-20230725monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-limited-please-contact-the-portnoy-law-firm-to-recover-your-losses-august-18-2023-nvcr-20230724monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000--nvcr-20230719monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-limited-nasdaq-nvcr-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-nvcr-20230718monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-remind-nvcr-20230712monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-limited-nasdaq-nvcr-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-nvcr-20230711monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-investor-alert-kaplan-fox-kilsheimer-llp-notifies-novocure-investors-of-a-class-a-nvcr-20230710monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-limited-nvcr-shareholders-contact-robbins-llp-for-information-about-the-class-act-nvcr-20230705monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000--nvcr-20230705monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-limited-nvcr-equity-alert-robbins-llp-urges-nvcr-investors-with-significant-losse-nvcr-20230630monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-limited-nasdaq-nvcr-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-nvcr-20230628monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-remind-nvcr-20230628monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-limited-please-contact-the-portnoy-law-firm-to-recover-your-losses-august-18-2023-nvcr-20230626monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-limited-nvcr-shareholder-notice-robbins-llp-reminds-investors-of-class-action-aga-nvcr-20230623monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-limited-nasdaq-nvcr-shareholder-class-action-alert-bernstein-liebhard-llp-announc-nvcr-20230620monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-limited-please-contact-the-portnoy-law-firm-to-recover-your-losses-august-18-2023-nvcr-20230619monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-limited-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-nvcr-20230619monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-enrolls-first-patient-in-phase-3-pivotal-brain-metastases-trial-nvcr-20161012monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-to-report-third-quarter-2016-financial-results-nvcr-20160930monthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-limited-nasdaq-nvcr-to-ring-the-nasdaq-stock-market-opening-bell-in-celebration-o-nvcr-20151002monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-po-auph-20220613monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-po-auph-20220602monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-po-auph-20220513monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-po-auph-20220504monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-shareholder-notice-robbins-llp-reminds-investors-of-lead-plaintiff-deadline-in-cla-auph-20220422monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-third-quarter-2014-financial-results-auph-20141112monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-begin-trading-on-the-nasdaq-global-market-auph-20140902monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-second-quarter-2014-financial-results-auph-20140814monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-to-present-at-the-canaccord-genuity-34th-annual-growth-conference-auph-20140812monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-adds-financial-expertise-to-its-board-of-directors-auph-20140729monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-to-present-at-the-bio-international-convention-auph-20140623monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-to-present-at-the-bloom-burton-co-healthcare-investor-conference-auph-20140618monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-to-commence-trading-on-toronto-stock-exchange-auph-20140611monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-to-present-at-the-jefferies-2014-global-healthcare-conference-auph-20140602monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-first-quarter-2014-financial-results-auph-20140515monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-fourth-quarter-and-full-year-2013-financial-results-auph-20140331monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-to-present-at-the-26th-annual-roth-conference-auph-20140304monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-to-present-at-the-34th-annual-cowen-health-care-conference-auph-20140225monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-management-change-and-grant-of-stock-options-auph-20140219monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-us-52-million-private-placement-auph-20140214monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-change-to-board-of-directors-auph-20131209monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-reports-third-quarter-2013-financial-results-auph-20131122monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-appoints-accomplished-biotech-and-pharma-industry-veteran-stephen-w-zaruby-as-pres-auph-20131106monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-announces-official-name-trading-symbol-change-and-implementation-of-share-consolid-auph-20131022monthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-announces-post-merger-leadership-changes-and-strategic-restructuri-auph-20131022monthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-announces-expanded-research-collaboration-with-teva-abcl-20170613monthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-announces-an-antibody-discovery-program-in-influenza-vaccine-research-abcl-20170606monthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-receives-grant-to-help-fight-tuberculosis-abcl-20170119monthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-announces-multi-target-research-collaboration-with-pfizer-abcl-20170105monthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-completes-antibody-discovery-project-with-kodiak-sciences-to-identify-lead-thera-abcl-20160824monthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-and-massbiologics-partner-to-discover-fully-human-antibodies-against-drug-resist-abcl-20160720monthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-and-merck-sign-novel-therapeutic-antibody-discovery-collaboration-abcl-20160127monthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-announces-successful-completion-of-collaboration-for-the-discovery-of-fully-huma-abcl-20160121monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-outlines-2026-strategic-priorities-phvs-20260112monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-presents-data-supporting-ongoing-clinical-development-of-deucrictibant-in-bradyk-phvs-20250602monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcomin-phvs-20250519monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-host-a-virtual-r-d-call-deucrictibant-beyond-hae-type-1-2-on-june-4-phvs-20250512monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-orphan-designation-granted-to-deucrictibant-by-the-european-commission-phvs-20250401monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-presents-long-term-clinical-data-of-deucrictibant-for-the-prevention-and-treatme-phvs-20250303monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025-phvs-20250303monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-outlines-2025-strategic-priorities-phvs-20250113monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-participate-in-the-guggenheim-healthcare-innovation-conference-phvs-20241112monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-presents-clinical-and-non-clinical-data-supporting-hae-development-program-at-th-phvs-20241024monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-present-phvs-20241016monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-host-virtual-investor-event-on-october-23-2024-phvs-20241015monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-data-highlighting-deucrictibant-for-the-treatment-of-hae-to-be-present-phvs-20241003monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-provides-business-update-and-expands-development-program-for-deucrictibant-phvs-20240905monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-presents-deucrictibant-long-term-extension-data-for-both-the-prophylactic-and-on-phvs-20240905monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-present-clinical-and-nonclinical-data-at-upcoming-congresses-phvs-20240513monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-appoints-david-nassif-j-d-as-chief-financial-officer-phvs-20240410monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-present-deucrictibant-clinical-data-at-the-ciic-spring-2024-conference-phvs-20240404monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-phase-3-clinical-study-design-for-recently-initiated-rapide-3-study-an-phvs-20240318monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-present-deucrictibant-clinical-data-at-upcoming-congresses-phvs-20240306monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-participate-in-the-leerink-global-biopharma-conference-2024-phvs-20240305monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-present-at-the-wsaai-annual-meeting-2024-phvs-20240126monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-provides-business-update-and-outlines-2024-strategic-priorities-phvs-20240105monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-presents-deucrictibant-clinical-data-and-analysis-of-endpoints-for-trials-of-on--phvs-20231208monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-pricing-of-300-million-underwritten-offering-of-ordinary-shares-and-pr-phvs-20231206monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-positive-top-line-phase-2-data-from-the-chapter-1-study-of-deucrictiba-phvs-20231206monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-present-at-the-ga-len-ucare-conference-2023-phvs-20231130monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-appoints-stefan-abele-ph-d-as-chief-technical-operations-officer-phvs-20231115monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-presents-deucrictibant-clinical-data-and-real-world-hae-treatment-satisfaction-d-phvs-20231109monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-present-at-the-acaai-2023-annual-scientific-meeting-phvs-20231030monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-present-at-the-apaaaci-2023-international-conference-phvs-20231013monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-present-at-the-ciic-fall-2023-conference-phvs-20231004monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference-phvs-20230919monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-present-at-the-18th-german-allergy-congress-phvs-20230906monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-participate-in-the-morgan-stanley-21st-annual-global-healthcare-conference-phvs-20230906monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-present-at-the-2023-haei-regional-conference-emea-phvs-20230823monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-presents-clinical-data-at-the-2023-u-s-haea-national-summit-phvs-20230721monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-70-million-private-placement-financing-phvs-20230620monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-present-in-upcoming-march-investor-conferences-phvs-20230302monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-highlight-positive-phase-2-data-from-rapide-1-study-of-phvs416-for-the-on-dem-phvs-20230224monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-present-at-svb-securities-global-biopharma-conference-phvs-20230208monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-third-quarter-2022-financial-results-and-provides-business-update-phvs-20221208monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-present-phvs416-and-phvs719-clinical-data-for-treatment-of-hae-at-the-acaai-a-phvs-20221110monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-presents-data-supporting-hae-drug-development-strategy-at-the-2022-haei-global-l-phvs-20221007monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-the-promotion-of-annick-deschoolmeester-to-chief-human-resources-offic-phvs-20220930monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-highlights-data-supporting-clinical-development-program-for-hereditary-angioedem-phvs-20220916monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-participate-in-h-c-wainwright-1st-annual-hereditary-angioedema-hae-conference-phvs-20220714monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-host-virtual-expert-perspectives-on-hae-unmet-needs-and-therapeutic-options-w-phvs-20220706monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-participates-in-the-kinin-2022-conference-phvs-20220607monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-supports-hae-community-by-participating-in-company-wide-activities-challenge-for-phvs-20220516monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-participate-in-bofa-securities-2022-healthcare-conference-phvs-20220505monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-participate-in-upcoming-april-investor-conferences-phvs-20220406monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-preclinical-pharmacological-data-for-small-molecule-pha121-published-i-phvs-20220322monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-participate-in-upcoming-march-investor-conferences-phvs-20220303monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-participate-in-11th-annual-svb-leerink-global-healthcare-conference-phvs-20220209monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-participate-in-upcoming-september-investor-conferences-phvs-20210903monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-presents-clinical-data-on-oral-pha121-supporting-the-prophylactic-treatment-of-h-phvs-20210709monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-presents-pharmacokinetic-and-pharmacodynamic-data-for-oral-pha121-under-developm-phvs-20210604monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-fda-acceptance-of-ind-application-for-prophylactic-treatment-of-hae-us-phvs-20210421monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-to-participate-in-biocapital-europe-phvs-20210304monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-doses-first-patient-in-rapide-1-a-phase-2-study-evaluating-phvs416-for-the-on-de-phvs-20210226monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-presents-pharmacodynamic-activity-of-oral-pha121-under-development-for-the-treat-phvs-20210219monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-closing-of-initial-public-offering-phvs-20210209monthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-announces-pricing-of-upsized-initial-public-offering-phvs-20210205monthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-reports-first-quarter-2026-financial-results-sion-20260512monthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-to-participate-in-upcoming-september-investor-conferences-sion-20250827monthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-reports-second-quarter-2025-financial-results-sion-20250811monthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-to-present-at-the-goldman-sachs-46th-annual-global-healthcare-conferen-sion-20250603monthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-to-present-preclinical-data-during-oral-session-at-the-48th-european-c-sion-20250522monthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-reports-first-quarter-2025-financial-results-sion-20250512monthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-to-present-at-the-citizens-life-sciences-conference-2025-sion-20250430monthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-to-present-at-the-45th-annual-td-cowen-health-care-conference-sion-20250224monthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-announces-closing-of-219-2-million-upsized-initial-public-offering-inc-sion-20250210monthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-prices-upsized-initial-public-offering-sion-20250207monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-2025-third-quarter-financial-results-on-october-29-2025-axgn-20251015monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-participate-in-multiple-upcoming-investor-conferences-axgn-20250827monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-2025-second-quarter-financial-results-on-august-5-2025-axgn-20250722monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2025-first-quarter-financial-results-axgn-20250508monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-announces-chief-financial-officer-transition-axgn-20250508monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-2025-first-quarter-financial-results-on-may-8-2025-axgn-20250424monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-announces-appointment-of-rick-ditto-as-vice-president-global-health-economics-reimb-axgn-20250324monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-host-analyst-investor-day-on-march-4th-axgn-20250225monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2024-fourth-quarter-and-full-year-financial-results-axgn-20250225monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-2024-fourth-quarter-and-full-year-financial-results-on-february-25-20-axgn-20250211monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-announces-appointment-of-jesse-bishop-as-vice-president-of-regulatory-affairs-and-i-axgn-20250203monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-announces-new-vp-of-operations-and-inducement-grant-under-nasdaq-listing-rule-5635--axgn-20250110monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-reports-preliminary-unaudited-revenue-for-fourth-quarter-and-full-year-2024-axgn-20250110monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-third-quarter-2024-financial-results-and-provides-bla-update-axgn-20241107monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-third-quarter-2024-financial-results-and-host-conference-call-on-nove-axgn-20241024monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-completes-submission-of-biologics-license-application-to-u-s-food-and-drug-administ-axgn-20240906monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4-axgn-20240903monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-new-leadership-appointments-axgn-20240808monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-second-quarter-2024-financial-results-axgn-20240808monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-second-quarter-2024-financial-results-and-host-conference-call-on-aug-axgn-20240723monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-full-launch-of-avive-soft-tissue-matrix-axgn-20240624monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-processing-center-apc-celebrates-its-opening-with-ohio-leaders-in-vandalia-axgn-20240528monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-initiates-rolling-submission-of-biologics-license-application-to-u-s-food-and-d-axgn-20240516monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-participate-at-leerink-partners-healthcare-crossroads-conference-axgn-20240514monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-first-quarter-2024-financial-results-axgn-20240502monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-announces-first-surgical-implants-of-avive-soft-tissue-matrix-axgn-20240429monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-first-quarter-2024-financial-results-and-host-conference-call-on-may--axgn-20240416monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2023-fourth-quarter-and-full-year-financial-results-axgn-20240305monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-2023-fourth-quarter-and-full-year-financial-results-on-march-5-2024-axgn-20240213monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-positive-topline-results-from-repose-a-prospective-randomized-clinica-axgn-20240118monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-reports-preliminary-unaudited-revenue-for-fourth-quarter-and-full-year-2023-axgn-20240104monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-announces-plan-for-leadership-transition-with-ceo-karen-zaderej-to-retire-from-comp-axgn-20240104monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-announces-promotions-on-research-and-development-team-axgn-20240104monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-appoints-kathy-weiler-to-its-board-of-directors-axgn-20231226monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-announces-transition-of-finance-team-leadership-axgn-20231206monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-participate-at-the-piper-sandler-35th-annual-healthcare-conference-axgn-20231120monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2023-third-quarter-financial-results-axgn-20231107monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-third-quarter-2023-financial-results-and-host-conference-call-on-nove-axgn-20231018monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-full-launch-of-axoguard-ha-nerve-protector-axgn-20230905monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-participate-at-upcoming-investor-conferences-axgn-20230831monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-begins-processing-avance-nerve-graft-at-new-state-of-the-art-facility-in-dayton-axgn-20230821monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2023-second-quarter-financial-results-axgn-20230807monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-participate-at-canaccord-genuity-s-43rd-annual-growth-conference-axgn-20230727monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-second-quarter-2023-financial-results-and-host-conference-call-on-aug-axgn-20230726monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-participate-at-jefferies-healthcare-conference-axgn-20230524monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-participate-at-jmp-securities-life-sciences-conference-axgn-20230512monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2023-first-quarter-financial-results-axgn-20230509monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may--axgn-20230418monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2022-fourth-quarter-and-full-year-financial-results-axgn-20230314monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-appoints-marc-began-as-executive-vice-president-and-general-counsel-axgn-20230306monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-fourth-quarter-2022-financial-results-and-host-conference-call-on-mar-axgn-20230302monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-appoints-jens-schroeder-kemp-as-chief-marketing-officer-axgn-20230213monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-reports-preliminary-unaudited-revenue-for-fourth-quarter-and-full-year-2022-axgn-20230109monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-announces-independent-publication-of-comparative-nerve-gap-repair-meta-analysis-of--axgn-20230105monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-participate-at-j-p-morgan-41st-annual-healthcare-conference-axgn-20230104monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-patient-to-ride-the-2023-donate-life-rose-parade-float-supporting-awareness-of-orga-axgn-20221219monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2022-third-quarter-financial-results-axgn-20221108monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-participate-at-upcoming-investor-conferences-axgn-20221103monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-the-appointment-of-adrian-tyndall-m-d-mph-facep-to-its-board-of-direc-axgn-20221031monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-third-quarter-2022-financial-results-and-host-conference-call-on-nove-axgn-20221020monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-participate-in-the-77th-annual-meeting-of-the-american-society-for-surgery-of-th-axgn-20220922monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2022-second-quarter-financial-results-axgn-20220803monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-canaccord-genuity-s-42nd-annual-growth-conference-axgn-20220729monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-jefferies-virtual-healthcare-conference-and-the-jmp-securitie-axgn-20220518monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2022-first-quarter-financial-results-axgn-20220504monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-positive-topline-results-from-phase-3-recon-sm-study-for-avance-nerve-axgn-20220504monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-first-quarter-2022-financial-results-and-host-conference-call-on-may--axgn-20220413monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-publishes-inaugural-esg-report-axgn-20220317monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2021-fourth-quarter-and-full-year-financial-results-axgn-20220222monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-participate-at-upcoming-investor-conferences-axgn-20220203monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-fourth-quarter-and-full-year-2021-financial-results-and-host-conferen-axgn-20220202monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-reports-preliminary-unaudited-revenue-for-fourth-quarter-and-full-year-2021-axgn-20220110monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-participate-at-aahs-aspn-asrm-2022-annual-meetings-axgn-20220104monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-sponsors-2022-donate-life-rose-parade-float-to-help-raise-awareness-of-organ-and-ti-axgn-20211215monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-participate-at-canaccord-genuity-virtual-medtech-diagnostics-and-digital-hea-axgn-20211110monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-participate-at-jefferies-london-healthcare-conference-axgn-20211104monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2021-third-quarter-financial-results-axgn-20211103monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-third-quarter-financial-results-and-host-conference-call-on-november--axgn-20211013monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-participate-in-the-76th-annual-meeting-of-the-american-society-for-surgery-of-th-axgn-20210922monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2021-second-quarter-financial-results-axgn-20210804monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-canaccord-genuity-41st-annual-growth-conference-axgn-20210722monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-appoints-john-h-johnson-to-board-of-directors-axgn-20210719monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-second-quarter-financial-results-and-host-conference-call-on-august-4-axgn-20210714monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-jefferies-virtual-healthcare-conference-and-the-jmp-securitie-axgn-20210518monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-canaccord-genuity-musculoskeletal-conference-axgn-20210506monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2021-first-quarter-financial-results-axgn-20210505monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-first-quarter-financial-results-and-host-conference-call-on-may-5-202-axgn-20210414monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-promotes-peter-j-mariani-to-executive-vice-president-and-chief-financial-office-axgn-20210301monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2020-fourth-quarter-and-full-year-financial-results-axgn-20210222monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-sponsored-repose-study-completes-pilot-phase-analysis-axgn-20210218monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-participate-at-upcoming-february-investor-conferences-axgn-20210204monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-fourth-quarter-and-full-year-2020-financial-results-and-host-conferen-axgn-20210201monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-participate-at-aahs-aspn-asrm-2021-virtual-annual-meetings-axgn-20210105monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-sponsors-donate-life-at-2021-virtual-rose-parade-celebration-axgn-20201223monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-participate-at-jefferies-virtual-london-healthcare-conference-and-canaccord--axgn-20201104monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-third-quarter-2020-financial-results-and-host-conference-call-on-octo-axgn-20201008monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-jmp-securities-medtech-bio-summit-axgn-20200925monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-participate-in-the-75th-annual-american-society-for-surgery-of-the-hand-meeting-axgn-20200924monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-cantor-virtual-global-healthcare-conference-axgn-20200831monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-canaccord-genuity-40th-annual-growth-conference-axgn-20200729monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-recon-clinical-study-completes-target-enrollment-of-220-subjects-axgn-20200722monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-second-quarter-2020-financial-results-and-host-conference-call-on-aug-axgn-20200715monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-jefferies-virtual-healthcare-conference-axgn-20200520monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-first-quarter-2020-financial-results-and-host-conference-call-on-may--axgn-20200415monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-participate-at-upcoming-investor-conferences-axgn-20200302monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-leerink-partners-9th-annual-global-healthcare-conference-axgn-20200205monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-fourth-quarter-and-full-year-2019-financial-results-and-host-conferen-axgn-20200203monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-reports-preliminary-unaudited-revenue-for-fourth-quarter-and-full-year-2019-and-pro-axgn-20200113monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-sponsored-ranger-registry-reaches-2-000-nerve-repair-enrollment-milestone-axgn-20200108monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-participate-at-aahs-aspn-asrm-2020-annual-meetings-axgn-20200102monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-participate-at-jp-morgan-38th-annual-healthcare-conference-axgn-20200102monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-awarded-research-grant-from-the-advanced-regenerative-manufacturing-institute-axgn-20191218monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-participate-at-piper-jaffray-31st-annual-healthcare-conference-axgn-20191121monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-participate-at-jefferies-london-healthcare-conference-axgn-20191111monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-third-quarter-2019-financial-results-and-host-conference-call-on-nove-axgn-20191023monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-axgn-20190919monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-participate-in-the-74th-annual-american-society-for-surgery-of-the-hand-meeting-axgn-20190827monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-participate-at-canaccord-genuity-39th-annual-growth-conference-axgn-20190729monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-announces-publication-of-the-100th-peer-reviewed-clinical-paper-featuring-its-produ-axgn-20190726monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-second-quarter-2019-financial-results-and-host-conference-call-on-aug-axgn-20190723monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-participate-at-upcoming-investor-conferences-axgn-20190523monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-completion-of-planned-interim-analysis-and-one-time-enrollment-expans-axgn-20190422monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-first-quarter-2019-financial-results-and-host-conference-call-on-may--axgn-20190422monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-participate-at-upcoming-march-investor-conferences-axgn-20190304monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-axgn-20190302monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-class-action-lawsuit-bernstein-liebhard-llp-announces-that-a-securities-class-actio-axgn-20190227monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds--axgn-20190223monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-participate-at-upcoming-february-investor-conferences-axgn-20190219monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-fourth-quarter-and-full-year-2018-financial-results-and-host-conferen-axgn-20190214monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-axgn-20190126monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-participate-at-aahs-aspn-asrm-2019-annual-meetings-axgn-20190124monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-appoints-eric-sandberg-as-chief-commercial-officer-axgn-20190122monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-investor-alert-kaskela-law-llc-announces-shareholder-class-action-lawsuit-against-a-axgn-20190115monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-announces-recon-study-update-axgn-20190115monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds--axgn-20190112monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-that-a-securit-axgn-20190111monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-class-action-lawsuit-bernstein-liebhard-llp-announces-that-a-securities-class-actio-axgn-20190111monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-appoints-christopher-crisman-as-vice-president-u-s-sales-axgn-20190107monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-losses-alert-bernstein-liebhard-llp-announces-first-investigation-of-axogen-inc-axg-axgn-20181220monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-announces-avance-nerve-graft-recipient-selected-to-ride-on-donate-life-rose-parade--axgn-20181206monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-advances-its-platform-for-nerve-repair-at-annual-analyst-and-investor-day-axgn-20181119monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-host-third-annual-analyst-and-investor-day-on-november-19-2018-axgn-20181106monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-third-quarter-2018-financial-results-and-host-conference-call-on-octo-axgn-20181016monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-axgn-20180924monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-participate-at-73rd-annual-american-society-for-surgery-of-the-hand-meeting-axgn-20180907monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-morgan-stanley-global-healthcare-conference-axgn-20180828monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-canaccord-genuity-growth-conference-axgn-20180725monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-second-quarter-2018-financial-results-and-host-conference-call-on-aug-axgn-20180724monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-chairman-and-ceo-karen-zaderej-named-entrepreneur-of-the-year-2018-award-winner-in--axgn-20180608monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-upcoming-investor-conferences-axgn-20180606monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-appoints-kaila-krum-vice-president-investor-relations-and-corporate-development-axgn-20180604monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-repayment-in-full-of-its-25-million-outstanding-debt-axgn-20180529monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-jefferies-global-healthcare-conference-axgn-20180523monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-appointment-of-karen-zaderej-as-chairman-of-the-board-axgn-20180521monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-closing-of-public-offering-of-common-stock-axgn-20180514monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-upsizing-and-pricing-of-public-offering-of-common-stock-axgn-20180509monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-first-quarter-2018-financial-results-and-host-conference-call-on-apri-axgn-20180418monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-2018-annual-shareholders-meeting-axgn-20180412monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-named-employee-engagement-best-practices-award-winner-by-decisionwise-international-axgn-20180227monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-30th-annual-roth-conference-axgn-20180227monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-canaccord-genuity-musculoskeletal-conference-axgn-20180220monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-fourth-quarter-and-full-year-2017-financial-results-and-host-conferen-axgn-20180214monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-leerink-partners-7th-annual-global-healthcare-conference-axgn-20180201monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-participate-at-aahs-aspn-asrm-2018-annual-meetings-axgn-20180105monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-corporation-announces-avance-nerve-graft-recipient-selected-to-ride-on-donate-life--axgn-20171218monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-announces-closing-of-public-offering-of-common-stock-axgn-20171120monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-nasdaq-axgn-to-ring-the-nasdaq-stock-market-opening-bell-axgn-20171120monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-advances-its-platform-for-nerve-repair-at-annual-analyst-and-investor-day-axgn-20171120monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-pricing-of-public-offering-of-common-stock-axgn-20171116monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-proposed-public-offering-of-common-stock-axgn-20171115monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-29th-annual-piper-jaffray-healthcare-conference-axgn-20171114monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-host-second-annual-analyst-and-investor-day-on-november-20-2017-axgn-20171107monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-receives-david-j-gury-company-of-the-year-award-from-bioflorida-axgn-20171018monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-third-quarter-2017-financial-results-and-host-conference-call-on-nove-axgn-20171017monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-participate-at-99th-annual-american-association-of-oral-and-maxillofacial-surgeo-axgn-20171002monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-axgn-20170911monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-participate-at-72nd-annual-american-society-for-surgery-of-the-hand-meeting-axgn-20170824monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-wedbush-pacgrow-healthcare-conference-axgn-20170731monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-discloses-terms-of-recent-equity-award-axgn-20170720monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-second-quarter-2017-financial-results-and-host-conference-call-on-wed-axgn-20170719monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-jmp-securities-life-sciences-conference-axgn-20170607monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-jefferies-global-healthcare-conference-axgn-20170523monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-first-quarter-2017-financial-results-and-host-conference-call-on-thur-axgn-20170414monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-2017-annual-shareholders-meeting-axgn-20170407monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-oppenheimer-27th-annual-healthcare-conference-axgn-20170307monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-upcoming-investor-conferences-axgn-20170302monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-2016-fourth-quarter-and-full-year-financial-results-axgn-20170222monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-fourth-quarter-and-2016-full-year-financial-results-and-host-conferen-axgn-20170208monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-preannounces-estimated-fourth-quarter-and-full-year-2016-revenue-axgn-20170109monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-appoints-ivica-ducic-medical-director-axgn-20170105monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-participate-at-aahs-aspn-asrm-joint-2017-annual-meeting-axgn-20170103monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-avance-nerve-graft-recipient-to-be-honored-on-the-donate-life-tournam-axgn-20161214monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-commercial-release-and-first-clinical-implant-of-avive-soft-tissue-me-axgn-20161121monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-28th-annual-piper-jaffray-healthcare-conference-axgn-20161117monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-host-analyst-and-investor-event-on-november-21-2016-axgn-20161115monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-financial-results-for-third-quarter-2016-axgn-20161102monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-the-refinancing-of-its-debt-facility-axgn-20161026monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-third-quarter-financial-results-and-host-conference-call-on-wednesday-axgn-20161019monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-announces-closing-of-public-offering-of-common-stock-and-underwriters-full-exercise-axgn-20161013monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-announces-pricing-of-public-offering-of-common-stock-axgn-20161007monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-participate-at-71st-annual-american-society-for-surgery-of-the-hand-meeting-axgn-20160915monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-participate-at-the-american-association-of-oral-and-maxillofacial-surgeons-9-axgn-20160912monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-wedbush-pacgrow-healthcare-conference-2016-axgn-20160811monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-second-quarter-financial-results-and-host-conference-call-on-wednesda-axgn-20160720monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-added-to-russell-2000-index-axgn-20160627monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-s-avance-nerve-graft-data-to-be-presented-at-2016-federation-of-european-societ-axgn-20160621monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-to-present-at-jmp-securities-healthcare-conference-2016-axgn-20160616monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-first-quarter-results-axgn-20160420monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-feature-nerve-repair-solutions-at-the-american-college-of-oral-and-maxillofa-axgn-20160408monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-launches-acroval-tm-neurosensory-motor-testing-system-axgn-20160330monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-participate-at-the-28th-annual-roth-growth-conference-axgn-20160309monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-appoints-peter-j-mariani-chief-financial-officer-axgn-20160301monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-record-revenue-results-axgn-20160229monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-fourth-quarter-and-full-year-results-on-february-29-2016-axgn-20160210monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-avance-r-nerve-graft-recipient-to-be-honored-on-donate-life-rose-parade-float-axgn-20151228monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-third-quarter-results-on-november-5-2015-axgn-20151016monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-dawson-james-securities-small-cap-growth-conference-axgn-20151008monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-attend-american-association-of-oral-and-maxillofacial-surgeons-aaoms-97th-an-axgn-20150929monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-s-avance-r-nerve-graft-data-presented-during-best-clinical-papers-session-at-th-axgn-20150910monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-expands-presence-at-the-american-society-for-surgery-of-the-hand-assh-2015-axgn-20150824monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-wedbush-healthcare-conference-axgn-20150803monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-second-quarter-results-on-august-6-2015-axgn-20150715monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-meet-with-dr-alejandro-toledo-former-president-of-peru-and-director-of-globa-axgn-20150713monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-be-featured-on-living-better-with-laura-smith-on-abc-radio-axgn-20150626monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-enrollment-of-first-subject-in-multicenter-comparative-study-for-avan-axgn-20150624monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-host-first-international-surgeon-training-course-and-announces-presentation--axgn-20150615monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-completion-of-a-pilot-clinical-study-assessing-cavernous-nerve-recons-axgn-20150609monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-reports-58-year-over-year-revenue-growth-for-the-2015-first-quarter-axgn-20150505monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-clearance-from-fda-to-proceed-with-new-multicenter-comparative-study--axgn-20150504monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-2015-annual-shareholders-meeting-axgn-20150427monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-first-quarter-financial-results-on-may-5-2015-axgn-20150421monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-participate-in-american-academy-of-orthopedic-surgeons-aaos-2015-annual-meet-axgn-20150323monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-ceo-karen-zaderej-to-discuss-axogen-s-growth-nerve-injuries-and-new-options-for-axgn-20150319monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-canaccord-genuity-s-musculoskeletal-conference-axgn-20150316monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-fourth-quarter-and-full-year-financial-results-on-march-5-2015-axgn-20150226monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-presentation-of-additional-clinical-data-for-avance-r-nerve-graft-axgn-20150225monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-closing-of-public-offering-of-common-stock-axgn-20150210monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-prices-public-offering-of-common-stock-axgn-20150205monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-proposed-public-offering-of-common-stock-axgn-20150204monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-host-surgeon-education-event-at-aahs-aspn-asrm-joint-2015-annual-meeting-axgn-20150122monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-cmo-jill-schiaparelli-and-oral-maxillofacial-surgeon-dr-shahrokh-bagheri-to-dis-axgn-20150109monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-promotes-jill-schiaparelli-to-chief-marketing-officer-axgn-20150106monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-avance-r-nerve-graft-recipient-to-be-honored-on-donate-life-rose-parade-float-o-axgn-20141223monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-ceo-karen-zaderej-to-be-interviewed-on-clear-channel-iheart-business-talk-radio-axgn-20141202monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-signs-agreement-with-oberland-capital-axgn-20141113monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-third-quarter-financial-results-on-november-13-2014-axgn-20141106monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-presentation-of-clinical-data-for-avance-r-nerve-graft-at-american-so-axgn-20140930monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-host-surgeon-education-event-at-american-society-for-surgery-of-the-hand-201-axgn-20140916monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-host-surgeon-panel-on-nerve-repair-at-american-association-of-oral-and-maxil-axgn-20140909monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-announces-changes-to-board-of-directors-axgn-20140825monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-the-wedbush-2014-life-sciences-management-access-conference-axgn-20140805monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-report-second-quarter-financial-results-on-august-4-2014-axgn-20140715monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-nerve-repair-data-at-2014-federation-of-european-societies-for-surge-axgn-20140618monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-on-preliminary-list-of-additions-to-russell-microcap-r-index-axgn-20140616monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-to-present-at-jmp-securities-healthcare-conference-axgn-20140609monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-receives-department-of-defense-funding-for-next-generation-peripheral-nerve-rep-axgn-20140604monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-inc-appoints-lee-robert-johnston-jr-chief-financial-officer-axgn-20140512monthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-ceo-karen-zaderej-interview-on-clear-channel-business-talk-radio-dfw1190am-by-micha-axgn-20131213monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-provides-third-quarter-2025-operational-and-financial-update-along-with-2026-cl-nbtx-20251124monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-curadigm-nanoprimer-platform-advancements-with-updated-plans-for-inte-nbtx-20251113monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-first-data-from-phase-1-study-evaluating-jnj-1900-nbtxr3-for-patients-nbtx-20251001monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-provides-business-update-and-reports-half-year-2025-financial-results-nbtx-20250930monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-new-results-from-a-phase-1-study-evaluating-jnj-1900-nbtxr3-in-combin-nbtx-20250917monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference-nbtx-20250902monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-regulatory-harmonization-and-new-composition-of-matter-patent-filed-f-nbtx-20250707monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-participate-in-the-jefferies-global-healthcare-investor-conference-nbtx-20250528monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-provides-first-quarter-2025-operational-and-financial-update-nbtx-20250521monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-participate-in-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference--nbtx-20250512monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-full-results-from-completed-phase-1-study-evaluating-jnj-1900-nbtxr3--nbtx-20250505monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-presentation-of-full-results-from-completed-phase-1-study-evaluating--nbtx-20250430monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-provides-business-update-and-reports-full-year-2024-financial-results-nbtx-20250402monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-announce-fourth-quarter-and-full-year-2024-operational-and-financial-update--nbtx-20250331monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-first-data-from-the-completed-dose-escalation-part-of-a-phase-1-study-nbtx-20250327monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-presentation-of-data-from-two-phase-1-studies-evaluating-jnj-1900-nbt-nbtx-20250320monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-strengthens-financial-position-through-amendment-of-global-licensing-agreement--nbtx-20250317monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-participate-in-multiple-investor-conferences-in-february-and-march-2025-nbtx-20250129monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj--nbtx-20250121monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-introduce-vision-for-transforming-drug-design-and-development-with-next-nano-nbtx-20241217monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-completion-of-phase-1-study-of-nbtxr3-jnj-1900-in-pancreatic-cancer-nbtx-20241209monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-provides-third-quarter-2024-update-and-progress-on-nanotherapeutics-platforms-nbtx-20241112monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-participate-in-multiple-investor-conferences-in-november-nbtx-20241031monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-provides-business-update-and-reports-half-year-2024-financial-results-nbtx-20240918monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-two-key-supervisory-board-additions-intended-to-further-equip-the-com-nbtx-20240904monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-present-at-h-c-wainwright-26th-annual-global-investment-conference-nbtx-20240903monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-host-virtual-kol-event-discussing-potential-of-nbtxr3-combined-with-immunoth-nbtx-20240612monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-presentation-of-new-data-from-phase-1-immunotherapy-program-at-the-20-nbtx-20240528monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-present-at-the-jefferies-global-healthcare-conference-nbtx-20240523monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-provides-first-quarter-2024-operational-and-financial-update-nbtx-20240522monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-progress-in-global-nbtxr3-development-collaboration-highlighting-robu-nbtx-20240521monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-announce-first-quarter-operational-and-financial-update-on-may-22-2024-nbtx-20240515monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-us-fda-protocol-acceptance-for-new-randomized-phase-2-study-evaluatin-nbtx-20240514monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-provides-business-update-and-reports-full-year-2023-financial-results-nbtx-20240424monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-announce-fourth-quarter-and-full-year-2023-operational-and-financial-update--nbtx-20240417monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-completion-of-phase-1-dose-escalation-and-nbtxr3-recommended-phase-2--nbtx-20240402monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-present-at-upcoming-investor-conferences-in-march-nbtx-20240306monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-present-at-the-guggenheim-6th-annual-biotechnology-conference-nbtx-20240131monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-achievement-of-20m-development-milestone-payment-related-to-ongoing-g-nbtx-20240129monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-partner-lianbio-assigns-its-development-and-commercialization-rights-for-nbtxr3-nbtx-20231226monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-closing-of-the-remaining-4-8-million-investment-from-johnson-johnson--nbtx-20231204monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-provides-third-quarter-2023-operational-and-financial-update-nbtx-20231113monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-announce-third-quarter-2023-operational-and-financial-update-on-november-13--nbtx-20231109monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-closing-of-global-offering-nbtx-20231107monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-the-availability-of-a-prospectus-in-connection-with-capital-increases-nbtx-20231106monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-pricing-of-a-capital-increase-raising-total-gross-proceeds-of-55m-nbtx-20231102monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-launch-of-global-follow-on-offering-and-a-concurrent-private-placemen-nbtx-20231101monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-updated-preliminary-results-from-phase-1-pancreatic-cancer-trial-and--nbtx-20231023monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-the-presentation-of-the-final-efficacy-analysis-from-phase-1-cohort-e-nbtx-20231004monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-oral-presentation-of-final-results-from-a-phase-1-dose-expansion-stud-nbtx-20230929monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-presentation-of-first-data-from-phase-1-study-evaluating-nbtxr3-for-p-nbtx-20230928monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-provides-business-update-and-financial-results-for-the-first-half-of-2023-nbtx-20230926monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-announce-half-year-2023-financial-results-on-september-26-2023-nbtx-20230919monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-strengthens-global-development-capabilities-with-the-appointment-of-veteran-ind-nbtx-20230905monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-nbtx-20230831monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-expiration-of-hsr-waiting-period-regarding-the-agreement-for-worldwid-nbtx-20230815monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-host-extraordinary-general-meeting-of-shareholders-on-september-1st-2023-nbtx-20230804monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-first-patient-injected-in-new-phase-1-2-study-evaluating-radiotherapy-nbtx-20230719monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-license-agreement-for-worldwide-co-development-and-commercialization--nbtx-20230710monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-provides-first-quarter-2023-operational-and-financial-update-nbtx-20230517monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-entering-final-contract-negotiations-following-agreement-to-non-binding-term-sh-nbtx-20230505monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-provides-business-update-and-reports-full-year-2022-financial-results-nbtx-20230424monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-provide-operational-update-and-report-full-year-2022-financial-results-on-ap-nbtx-20230417monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call-nbtx-20230327monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-provide-operational-update-and-report-full-year-2022-financial-results-on-ma-nbtx-20230314monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-first-patient-randomized-in-the-united-states-in-global-phase-3-pivot-nbtx-20221227monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-termination-of-liquidity-contract-and-publishes-end-of-contract-state-nbtx-20221221monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-present-at-the-5th-annual-evercore-isi-healthconx-conference-nbtx-20221115monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-recommended-phase-2-dose-for-nbtxr3-in-pancreatic-cancer-nbtx-20221114monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-reports-updated-phase-1-anti-pd-1-combination-data-that-may-support-the-immune--nbtx-20221110monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-provides-third-quarter-2022-operational-and-financial-update-nbtx-20221109monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-voting-rights-and-shares-capital-of-the-company-nbtx-20221108monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-appoints-renowned-global-experts-to-comprehensive-scientific-advisory-board-for-nbtx-20221102monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-present-at-the-jefferies-london-healthcare-conference-nbtx-20221031monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-announce-third-quarter-2022-financial-results-on-november-9-2022-nbtx-20221027monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-executes-definitive-agreement-to-restructure-existing-loan-with-the-european-in-nbtx-20221018monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-publication-of-phase-iii-soft-tissue-sarcoma-data-for-first-in-class--nbtx-20190709monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-new-organizational-structure-as-the-company-enters-its-next-stage-aft-nbtx-20190701monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-appoints-new-chief-medical-officer-as-the-company-evolves-after-achievement-of--nbtx-20190604monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-the-launch-of-curadigm-a-new-nanotechnology-platform-for-healthcare-nbtx-20190528monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-raises-approximately-eur-29-5-million-in-placement-of-ordinary-new-shares-nbtx-20190409monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-launches-a-capital-increase-by-means-of-an-accelerated-bookbuild-offering-nbtx-20190408monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-first-ever-radioenhancer-to-receive-european-market-approval-nbtx-20190404monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-its-clinical-registration-plan-in-head-and-neck-cancers-for-the-unite-nbtx-20190326monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-2018-annual-results-nbtx-20190315monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-receives-14-million-through-the-second-tranche-disbursement-of-financing-from-t-nbtx-20190304monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-plans-to-conduct-registered-public-offering-in-the-united-states-nbtx-20190116monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-and-md-anderson-cancer-center-announce-a-large-scale-comprehensive-clinical-col-nbtx-20190107monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-revenues-for-the-3rd-quarter-of-2018-nbtx-20181115monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-positive-phase-ii-iii-results-for-nbtxr3-in-soft-tissue-sarcoma-presented-at-es-nbtx-20181019monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-receives-first-tranche-disbursement-of-16-million-euros-financing-from-european-nbtx-20181016monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-to-present-positive-results-from-its-phase-ii-iii-clinical-trial-of-nbtxr3-in-p-nbtx-20180926monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-update-on-head-and-neck-phase-i-ii-trial-with-nbtxr3-and-other-program-data-pre-nbtx-20180920monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-half-year-results-for-the-six-months-ended-june-30-2018-nbtx-20180904monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-signs-a-40-m-non-dilutive-financing-agreement-with-the-european-investment-bank-nbtx-20180726monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-positive-phase-ii-iii-topline-data-in-soft-tissue-sarcoma-with-nbtxr3-nbtx-20180621monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-management-statement-on-recent-share-price-variation-nbtx-20180606monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-partners-with-weill-cornell-medicine-on-pre-clinical-studies-to-evaluate-the-im-nbtx-20180503monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-the-university-of-texas-md-anderson-cancer-center-and-nanobiotix-have-an-agreem-nbtx-20180410monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-nanobiotix-2017-annual-results-nbtx-20180330monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-presents-first-promising-data-from-phase-i-ii-liver-cancers-trial-of-nbtxr3-at--nbtx-20180122monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-partners-with-the-providence-cancer-institute-to-run-immunotherapeutic-preclini-nbtx-20180111monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-2017-review-and-2018-expected-milestones-nbtx-20171226monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-fda-approves-nanobiotix-s-first-immuno-oncology-trial-nbtx-20171226monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-presented-new-clinical-and-pre-clinical-data-confirming-nbtxr3-s-significant-po-nbtx-20171113monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-provides-update-on-the-global-development-of-its-lead-product-nbtxr3-nbtx-20171109monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-successfully-completes-approximately-eur-27-2-million-placement-of-new-shares-nbtx-20171031monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-launches-capital-increase-by-means-of-an-accelerated-bookbuild-offering-nbtx-20171030monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-completes-patient-inclusion-for-phase-ii-iii-trial-of-nbtxr3-in-soft-tissue-sar-nbtx-20171023monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-plans-to-conduct-its-first-clinical-trial-with-nbtxr3-in-combination-with-immun-nbtx-20170928monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-half-year-results-for-the-six-months-ended-30-june-2017-nbtx-20170831monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-new-translational-data-presented-at-astro-nci-and-sitc-s-immunotherapy-workshop-nbtx-20170615monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-promising-data-from-phase-i-ii-head-and-neck-cancer-trial-with-nbtxr3-presented-nbtx-20170605monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-first-positive-human-data-showing-that-nbtxr3-could-become-a-backbone-nbtx-20170518monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-2016-annual-results-nbtx-20170428monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-successfully-completes-approx-eur-25-1-million-private-placement-of-new-shares-nbtx-20170407monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-launches-capital-increase-by-means-of-an-accelerated-bookbuild-offering-nbtx-20170406monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-nanobiotix-expands-its-clinical-development-in-head-and-neck-cancer-and-immuno--nbtx-20170404monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-the-independent-data-monitoring-committee-recommends-the-continuation-of-the-on-nbtx-20170323monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-nanobiotix-to-present-preclinical-data-on-nanoparticle-radioenhancer-nbtxr3-at--nbtx-20170307monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-appoints-senior-executive-from-pharmaceutical-industry-as-chief-operating-offic-nbtx-20170207monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-2016-review-and-2017-anticipated-milestones-nbtx-20170131monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-reports-positive-phase-i-ii-preliminary-data-on-feasibility-and-safety-of-nbtxr-nbtx-20161214monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-provides-update-on-global-development-of-lead-product-nbtxr3-nbtx-20161128monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-presents-nbtxr3-preclinical-data-demonstrating-its-potential-usage-as-in-situ-v-nbtx-20161114monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-s-partner-pharmaengine-has-launched-a-new-nbtxr3-clinical-trial-in-head-and-nec-nbtx-20161020monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-strengthens-u-s-leadership-with-appointments-of-head-of-u-s-clinical-developmen-nbtx-20161003monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-submission-for-first-market-approval-of-lead-product-nbtxr3-in-europe-nbtx-20160913monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-reports-successful-results-from-phase-i-ii-trial-of-nbtxr3-in-head-neck-cancer-nbtx-20160706monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-establishes-promising-preclinical-proof-of-concept-in-immuno-oncology-nbtx-20160531monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-2015-annual-results-nbtx-20160429monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-nanobiotix-completes-a-eur-21-3-million-private-placement-of-new-ordinary-share-nbtx-20160311monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-starts-a-new-research-program-in-immuno-oncology-with-its-lead-product-nbtxr3-nbtx-20160105monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-fda-approved-investigational-new-drug-for-nbtxr3-in-a-new-clinical-study-in-pro-nbtx-20160104monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-s-soft-tissue-sarcoma-pivotal-trial-expands-dynamically-as-planned-already-7-co-nbtx-20151113monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-starts-phase-i-ii-clinical-trial-in-liver-metastasis-and-hepatocellular-cancer--nbtx-20150701monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-reports-positive-preliminary-results-in-head-and-neck-cancer-phase-i-ii-clinica-nbtx-20150610monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-2014-annual-results-nbtx-20150414monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-receives-first-approval-to-start-phase-ii-iii-registration-trial-in-soft-tissue-nbtx-20141016monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-presents-successful-phase-i-results-for-its-lead-nanomedicine-product-nbtxr3-at-nbtx-20140602monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-sees-clinical-advance-in-soft-tissue-sarcoma-pilot-trial-with-lead-product-nbtx-nbtx-20140210monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-strengthens-its-nanoxray-pipeline-with-the-launch-of-nbtx-topo-development-the--nbtx-20131206monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-strengthens-its-management-team-nbtx-20130923monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-half-year-results-for-the-period-ended-30-june-2013-nbtx-20130830monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-2-8-million-grant-from-bpifrance-to-accelerate-development-of-nbtxr3--nbtx-20130703monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-the-selection-of-its-second-nanoxray-product-nbtx-iv-and-a-collaborat-nbtx-20130626monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-receives-approval-from-ansm-to-start-new-clinical-trial-with-lead-product-nbtxr-nbtx-20130613monthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-s-nbtxr3-achieves-clinical-milestone-reaching-proof-of-concept-in-phase-i-trial-nbtx-20130603monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-presents-new-clinical-data-and-real-world-evidence-demonstrating-impact-of-hae-po-bcrx-20260612monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20260609monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-first-quarter-2026-financial-results-and-provides-business-update-bcrx-20260506monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20260505monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-appoints-sandeep-m-menon-chief-research-and-development-officer-bcrx-20260406monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-preliminary-full-year-2025-orladeyo-berotralstat-net-revenue-of-601-mil-bcrx-20260112monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20260106monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-44th-annual-j-p-morgan-healthcare-conference-bcrx-20260106monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-fda-approval-of-orladeyo-berotralstat-oral-pellets-first-and-only-oral--bcrx-20251212monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20251204monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-third-quarter-2025-financial-results-on-november-3-bcrx-20251020monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20251003monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20250903monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conference-bcrx-20250821monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-departure-of-dr-helen-thackray-bcrx-20250811monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20250806monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-second-quarter-2025-financial-results-and-provides-business-update-bcrx-20250804monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-charlie-gayer-to-succeed-jon-stonehouse-as-chief-executive-officer-upon-bcrx-20250731monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-second-quarter-2025-financial-results-on-august-4-bcrx-20250721monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-highlight-patient-focused-research-at-the-2025-us-haea-national-summit-bcrx-20250709monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-appoints-babar-ghias-chief-financial-officer-and-head-of-corporate-development-bcrx-20250707monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20250703monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-sale-of-european-orladeyo-berotralstat-business-to-neopharmed-gentili-f-bcrx-20250627monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-presents-new-data-on-the-long-term-efficacy-and-safety-of-orladeyo-berotralstat-a-bcrx-20250616monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-achieves-reimbursement-for-orladeyo-across-all-major-european-countries-bcrx-20250606monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20250603monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-new-data-at-2025-meeting-of-the-european-academy-of-allergy-and-clinic-bcrx-20250602monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-highlights-real-world-data-showing-orladeyo-berotralstat-consistently-reduces-hae-bcrx-20250530monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20250527monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-presents-new-real-world-evidence-showing-significant-and-sustained-reductions-in--bcrx-20250516monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-fda-acceptance-of-nda-for-orladeyo-berotralstat-oral-granules-in-patien-bcrx-20250514monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-first-quarter-2025-financial-results-and-provides-business-update-bcrx-20250505monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20250502monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-appoints-steve-frank-to-board-of-directors-bcrx-20250501monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20250430monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-first-quarter-2025-financial-results-on-may-5-bcrx-20250421monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20250404monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conference-bcrx-20250402monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20250306monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-fourth-quarter-and-full-year-2024-financial-results-and-upcoming-key-mile-bcrx-20250224monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-positive-results-from-apex-p-trial-for-orladeyo-berotralstat-in-pediatr-bcrx-20250224monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20250219monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-launches-orladeyo-berotralstat-in-portugal-bcrx-20250212monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-new-orladeyo-berotralstat-results-from-apex-p-pediatric-trial-at-2025--bcrx-20250210monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-fourth-quarter-2024-financial-results-on-february-24-bcrx-20250210monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20250204monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-preliminary-full-year-2024-orladeyo-berotralstat-net-revenue-of-437-mil-bcrx-20250110monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-43rd-annual-j-p-morgan-healthcare-conference-bcrx-20250107monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20250106monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20241204monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-launches-orladeyo-berotralstat-in-ireland-bcrx-20241118monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20241106monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20241105monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-third-quarter-2024-financial-results-and-provides-business-update-bcrx-20241104monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-presents-new-real-world-evidence-showing-high-adherence-and-persistence-rates-wit-bcrx-20241024monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-third-quarter-2024-financial-results-on-november-4-bcrx-20241021monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-new-real-world-evidence-showing-significant-reductions-in-medical-visi-bcrx-20241014monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-new-real-world-evidence-on-long-term-prophylaxis-in-hae-including-orla-bcrx-20241010monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20241003monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-begins-enrollment-in-phase-1-trial-evaluating-bcx17725-a-klk5-inhibitor-for-the-t-bcrx-20241002monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-and-the-pan-canadian-pharmaceutical-alliance-pcpa-successfully-complete-negotiati-bcrx-20240917monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-presents-new-orladeyo-berotralstat-data-at-7th-bradykinin-symposium-bcrx-20240906monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-appoints-dr-donald-fong-chief-medical-officer-bcrx-20240905monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20240904monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20240822monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-second-quarter-2024-financial-results-and-provides-business-update-bcrx-20240805monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20240802monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-second-quarter-2024-financial-results-on-august-5-bcrx-20240722monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20240702monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20240604monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-presents-new-real-world-evidence-showing-reductions-in-attack-rates-in-hae-patien-bcrx-20240602monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-new-data-at-2024-meeting-of-the-european-academy-of-allergy-and-clinic-bcrx-20240514monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-presents-new-real-world-evidence-showing-significant-reductions-in-healthcare-res-bcrx-20240509monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20240507monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-first-quarter-2024-financial-results-and-provides-business-update-bcrx-20240506monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20240503monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-first-quarter-2024-financial-results-on-may-6-bcrx-20240422monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-approval-of-orladeyo-berotralstat-by-the-brazilian-health-regulatory-ag-bcrx-20240417monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20240403monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20240325monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20240305monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-fourth-quarter-and-full-year-2023-financial-results-and-upcoming-key-mile-bcrx-20240226monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-presents-new-real-world-data-showing-rapid-substantial-and-sustained-hae-attack-r-bcrx-20240223monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20240221monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-launches-orladeyo-berotralstat-in-italy-bcrx-20240219monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-fourth-quarter-2023-financial-results-on-february-26-bcrx-20240212monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-new-orladeyo-berotralstat-real-world-data-at-2024-american-academy-of--bcrx-20240205monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20240202monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-preliminary-full-year-2023-orladeyo-berotralstat-net-revenue-of-325-mil-bcrx-20240105monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20240103monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-42nd-annual-j-p-morgan-healthcare-conference-bcrx-20240103monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-publication-of-data-from-open-label-extension-of-the-apex-2-pivotal-tri-bcrx-20231219monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20231205monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-approval-of-orladeyo-berotralstat-by-the-national-administration-of-dru-bcrx-20231129monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20231121monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-launches-orladeyo-berotralstat-in-spain-bcrx-20231121monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-presents-new-real-world-data-showing-reduced-attack-rates-in-patients-with-hae-wi-bcrx-20231110monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20231106monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-r-d-day-highlights-new-diversified-pipeline-of-first-in-class-best-in-class-thera-bcrx-20231103monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-and-clearside-biomedical-enter-partnership-to-develop-avoralstat-for-diabetic-mac-bcrx-20231103monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-third-quarter-2023-financial-results-and-provides-business-update-bcrx-20231102monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-new-orladeyo-berotralstat-data-at-annual-scientific-meeting-of-america-bcrx-20231027monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-begins-enrollment-in-proof-of-concept-trial-to-confirm-safe-effective-once-daily--bcrx-20231026monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-host-r-d-day-on-november-3-bcrx-20231020monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-third-quarter-2023-financial-results-on-november-2-bcrx-20231019monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20231004monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20230905monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20230823monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20230804monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-second-quarter-2023-financial-results-and-provides-business-update-bcrx-20230803monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-second-quarter-2023-financial-results-on-august-3-bcrx-20230720monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-selects-er-kim-pharmaceuticals-as-commercial-partner-for-orladeyo-berotralstat-in-bcrx-20230719monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-participate-in-the-2023-us-haea-national-summit-bcrx-20230717monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20230706monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20230606monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conference-bcrx-20230601monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-new-orladeyo-berotralstat-data-at-2023-european-academy-of-allergy-and-bcrx-20230531monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-approval-of-orladeyo-berotralstat-by-the-public-health-institute-of-chi-bcrx-20230522monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20230504monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-first-quarter-2023-financial-results-and-provides-business-update-bcrx-20230503monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-presents-new-long-term-data-demonstrating-consistently-high-attack-free-status-am-bcrx-20230427monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-first-quarter-2023-financial-results-on-may-3-bcrx-20230419monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-refinances-existing-debt-with-450-million-financing-commitment-from-pharmakon-bcrx-20230418monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20230412monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20230404monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-appoints-dr-nancy-hutson-as-chair-of-the-board-bcrx-20230331monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-celebrates-bob-ingram-s-contributions-to-the-company-s-success-bcrx-20230329monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20230302monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-presents-new-long-term-and-real-world-data-demonstrating-sustained-reductions-in--bcrx-20230224monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20230222monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-fourth-quarter-and-full-year-2022-financial-results-and-upcoming-key-mile-bcrx-20230221monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-fourth-quarter-2022-financial-results-on-february-21-bcrx-20230207monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20230206monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-new-orladeyo-berotralstat-data-at-2023-american-academy-of-allergy-ast-bcrx-20230203monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-begins-enrollment-in-pivotal-apex-p-trial-evaluating-orladeyo-berotralstat-in-ped-bcrx-20230126monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-selects-swixx-biopharma-as-commercial-partner-for-orladeyo-berotralstat-in-centra-bcrx-20230123monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-preliminary-full-year-2022-orladeyo-berotralstat-net-revenue-and-provid-bcrx-20230109monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-initial-clinical-data-with-oral-factor-d-inhibitor-bcx10013-supporting-de-bcrx-20230109monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20230105monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-41st-annual-j-p-morgan-healthcare-conference-bcrx-20230104monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-discontinues-development-of-bcx9930-and-shifts-focus-to-potential-once-daily-oral-bcrx-20221215monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20221205monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-jmp-securities-hematology-oncology-summit-bcrx-20221205monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-approval-of-orladeyo-berotralstat-by-the-israeli-ministry-of-health-bcrx-20221128monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-presents-real-world-data-showing-rapid-and-sustained-hae-attack-rate-reduction-af-bcrx-20221110monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20221109monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20221104monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-third-quarter-2022-financial-results-and-upcoming-key-milestones-bcrx-20221101monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-new-orladeyo-berotralstat-data-at-annual-scientific-meeting-of-america-bcrx-20221024monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-third-quarter-2022-financial-results-on-november-1-bcrx-20221018monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20221004monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-names-dr-bill-sheridan-chief-development-officer-and-appoints-dr-ryan-arnold-chie-bcrx-20220914monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20220906monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20220831monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-presents-data-demonstrating-99-percent-suppression-of-alternative-pathway-complem-bcrx-20220826monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-approval-of-orladeyo-berotralstat-in-saudi-arabia-bcrx-20220818monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-second-quarter-2022-financial-results-and-upcoming-key-milestones-bcrx-20220804monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-resumes-enrollment-in-bcx9930-clinical-program-bcrx-20220804monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-second-quarter-2022-financial-results-on-august-4-bcrx-20220721monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conference-bcrx-20220715monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-presents-new-data-demonstrating-consistently-low-attack-rates-among-hae-patients--bcrx-20220701monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-orladeyo-berotralstat-data-to-be-presented-at-european-academy-of-aller-bcrx-20220622monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-selects-pint-pharma-as-commercial-partner-for-orladeyo-berotralstat-in-latin-amer-bcrx-20220609monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-approval-of-orladeyo-berotralstat-by-swissmedic-bcrx-20220607monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-health-canada-has-authorized-orladeyo-berotralstat-the-only-oral-treatm-bcrx-20220606monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20220601monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20220506monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-first-quarter-2022-financial-results-and-upcoming-key-milestones-bcrx-20220505monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20220504monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-first-quarter-2022-financial-results-on-may-5-bcrx-20220421monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conference-bcrx-20220411monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pauses-enrollment-in-bcx9930-clinical-trials-bcrx-20220408monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20220405monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20220303monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20220302monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-presents-new-data-demonstrating-sustained-reductions-in-attack-rates-and-improvem-bcrx-20220224monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-fourth-quarter-and-full-year-2021-financial-results-and-upcoming-key-mile-bcrx-20220223monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-begins-patient-enrollment-in-renew-proof-of-concept-trial-evaluating-bcx9930-for--bcrx-20220222monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-fourth-quarter-2021-financial-results-on-february-23-bcrx-20220209monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-appoints-machelle-sanders-to-board-of-directors-bcrx-20220208monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20220203monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-new-orladeyo-berotralstat-data-at-2022-american-academy-of-allergy-ast-bcrx-20220201monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-preliminary-full-year-2021-orladeyo-berotralstat-net-revenue-and-provid-bcrx-20220110monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-begins-patient-enrollment-in-redeem-1-pivotal-trial-evaluating-bcx9930-as-oral-mo-bcrx-20220107monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20220104monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-40th-annual-j-p-morgan-healthcare-conference-bcrx-20220104monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20211203monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-begins-patient-enrollment-in-redeem-2-pivotal-trial-evaluating-bcx9930-as-oral-mo-bcrx-20211129monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-adds-350-million-in-new-financing-with-royalty-pharma-and-omers-capital-markets-bcrx-20211122monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20211112monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-presents-new-data-showing-sustained-reduction-of-hae-attack-rates-and-improved-pa-bcrx-20211105monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-third-quarter-2021-financial-results-and-upcoming-key-milestones-bcrx-20211103monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20211102monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-appoints-jinky-ang-rosselli-chief-data-and-insights-officer-bcrx-20211101monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-new-orladeyo-berotralstat-data-at-annual-scientific-meeting-of-america-bcrx-20211026monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-third-quarter-2021-financial-results-on-november-3-bcrx-20211020monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20211004monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-2021-cantor-virtual-healthcare-conference-bcrx-20210921monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-appoints-dr-amy-mckee-to-board-of-directors-bcrx-20210920monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-approval-of-orladeyo-berotralstat-in-united-arab-emirates-bcrx-20210909monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20210903monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20210902monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-appoints-dr-steven-galson-to-board-of-directors-bcrx-20210826monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-acceptance-of-regulatory-applications-for-orladeyo-berotralstat-by-heal-bcrx-20210825monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-withdraws-public-offering-bcrx-20210810monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-commences-public-offering-of-common-stock-and-pre-funded-warrants-bcrx-20210809monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-second-quarter-2021-financial-results-and-upcoming-key-milestones-bcrx-20210805monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20210803monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-appoints-vincent-milano-to-board-of-directors-bcrx-20210728monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-second-quarter-2021-financial-results-on-august-5-bcrx-20210722monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-designs-for-redeem-1-and-redeem-2-pivotal-trials-with-bcx9930-as-oral-m-bcrx-20210715monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-96-week-data-from-apex-2-showing-orladeyo-berotralstat-reduced-hae-attack-bcrx-20210710monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-acceptance-and-accelerated-review-of-the-orladeyo-berotralstat-marketin-bcrx-20210616monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-launches-orladeyo-berotralstat-in-germany-bcrx-20210603monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20210526monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-receives-uk-approval-of-orladeyo-berotralstat-first-oral-once-daily-therapy-to-pr-bcrx-20210512monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-first-quarter-2021-financial-results-and-upcoming-key-milestones-bcrx-20210506monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20210505monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-receives-european-commission-approval-of-orladeyo-berotralstat-first-oral-once-da-bcrx-20210430monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-first-quarter-2021-financial-results-on-may-6-bcrx-20210422monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-approval-of-japanese-nhi-price-listing-of-orladeyo-berotralstat-for-pro-bcrx-20210414monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-20th-annual-needham-virtual-healthcare-conference-bcrx-20210407monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-s-oral-factor-d-inhibitor-bcx9930-advancing-to-pivotal-trials-in-pnh-following-su-bcrx-20210322monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-appoints-helen-thackray-m-d-as-chief-research-and-development-officer-bcrx-20210319monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-host-virtual-r-d-day-on-march-22-2021-bcrx-20210315monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-submits-marketing-authorization-application-for-uk-approval-of-orladeyo-berotrals-bcrx-20210302monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-receives-positive-chmp-opinion-for-orladeyo-berotralstat-an-oral-once-daily-thera-bcrx-20210225monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-fourth-quarter-and-full-year-2020-financial-results-and-upcoming-key-mile-bcrx-20210225monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20210218monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-fourth-quarter-and-full-year-2020-financial-results-on-february-25-bcrx-20210211monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-data-at-2021-american-academy-of-allergy-asthma-immunology-annual-meet-bcrx-20210209monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-fda-approval-of-supplemental-new-drug-application-for-rapivab-expanding-bcrx-20210203monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20210202monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-approval-of-orladeyo-berotralstat-in-japan-for-the-prophylactic-treatme-bcrx-20210122monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20210107monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-39th-annual-j-p-morgan-healthcare-conference-bcrx-20210106monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-provides-update-on-galidesivir-program-bcrx-20201222monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-positive-phase-1-results-with-bcx9250-an-oral-alk-2-inhibitor-for-treat-bcrx-20201221monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-u-s-availability-of-orladeyo-berotralstat-for-the-treatment-of-heredita-bcrx-20201216monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-jmp-securities-hematology-summit-bcrx-20201211monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-325-million-of-funding-from-royalty-pharma-and-athyrium-capital-managem-bcrx-20201207monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-s-oral-factor-d-inhibitor-bcx9930-shows-high-potency-and-specificity-for-alternat-bcrx-20201206monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-fda-approval-of-orladeyo-berotralstat-first-oral-once-daily-therapy-to--bcrx-20201204monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20201201monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-virtual-investment-conferences-bcrx-20201120monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-presents-data-showing-sustained-attack-rate-reductions-improved-patient-satisfact-bcrx-20201113monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-presents-new-data-highlighting-burden-of-therapy-with-current-injectable-prophyla-bcrx-20201113monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-data-at-the-2020-ash-annual-meeting-bcrx-20201112monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-third-quarter-2020-financial-results-and-upcoming-key-milestones-bcrx-20201105monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20201102monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-abstracts-at-annual-scientific-meeting-of-american-college-of-allergy--bcrx-20201028monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-third-quarter-2020-financial-results-on-november-5-bcrx-20201022monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20201005monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-22nd-annual-h-c-wainwright-global-investment-conference-bcrx-20200908monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20200903monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-second-quarter-2020-financial-results-and-upcoming-key-milestones-bcrx-20200806monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20200804monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-second-quarter-2020-financial-results-on-august-6-bcrx-20200723monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20200702monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-berotralstat-expanded-access-program-for-patients-with-hereditary-angio-bcrx-20200609monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20200602monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-full-exercise-of-underwriters-option-to-purchase-additional-shares-and--bcrx-20200601monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-jefferies-virtual-healthcare-conference-bcrx-20200528monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-prices-public-offering-of-common-stock-and-pre-funded-warrants-bcrx-20200528monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-commences-public-offering-of-common-stock-and-pre-funded-warrants-bcrx-20200527monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-new-berotralstat-data-at-european-academy-of-allergy-and-clinical-immu-bcrx-20200526monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-celebrates-hae-patients-with-hae-global-walk-bcrx-20200515monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20200507monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-first-quarter-2020-financial-results-and-upcoming-key-milestones-bcrx-20200506monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20200504monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-first-quarter-2020-financial-results-on-may-6-bcrx-20200422monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-begins-clinical-trial-with-galidesivir-for-treatment-of-patients-with-covid-19-bcrx-20200409monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-19th-annual-needham-healthcare-conference-bcrx-20200408monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20200403monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-appoints-anthony-doyle-chief-financial-officer-bcrx-20200402monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-fourth-quarter-and-full-year-2019-financial-results-and-upcoming-key-mile-bcrx-20200305monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-begins-proof-of-concept-trial-in-pnh-patients-with-oral-factor-d-inhibitor-bcx993-bcrx-20200305monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-barclays-global-healthcare-conference-bcrx-20200303monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20200302monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-new-data-at-american-academy-of-allergy-asthma-immunology-annual-meeti-bcrx-20200227monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-appoints-alan-g-levin-to-board-of-directors-bcrx-20200225monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-fourth-quarter-and-full-year-2019-financial-results-on-march-5-bcrx-20200220monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20200206monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-submits-japanese-new-drug-application-for-oral-once-daily-berotralstat-bcrx-20200203monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-strengthens-commercial-rare-disease-leadership-bcrx-20200115monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-provide-berotralstat-and-bcx9930-program-updates-at-38th-annual-j-p-morgan-hea-bcrx-20200112monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20200106monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-38th-annual-j-p-morgan-healthcare-conference-bcrx-20200103monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-submits-new-drug-application-for-oral-once-daily-berotralstat-bcx7353-to-prevent--bcrx-20191211monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20191204monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-full-exercise-of-underwriters-option-to-purchase-additional-shares-and--bcrx-20191118monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20191114monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-prices-public-offering-of-common-stock-bcrx-20191114monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-commences-public-offering-of-common-stock-bcrx-20191112monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-abstracts-at-annual-scientific-meeting-of-american-college-of-allergy--bcrx-20191107monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-third-quarter-2019-financial-results-and-upcoming-key-milestones-bcrx-20191106monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-partnership-with-torii-pharmaceutical-to-commercialize-bcx7353-in-japan-bcrx-20191105monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20191104monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-begins-phase-1-trial-with-bcx9250-an-oral-alk-2-inhibitor-for-treatment-of-fibrod-bcrx-20191101monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-provide-commercial-update-and-report-third-quarter-2019-financial-results-on-n-bcrx-20191029monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-data-from-phase-1-trial-of-bcx9930-and-announces-plans-to-advance-program-bcrx-20191028monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20191003monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pharmaceuticals-to-present-at-cantor-global-healthcare-conference-bcrx-20190924monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-appoints-helen-thackray-m-d-to-board-of-directors-bcrx-20190923monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20190904monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-h-c-wainwright-global-investment-conference-bcrx-20190903monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-second-quarter-2019-financial-results-bcrx-20190806monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20190805monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-second-quarter-2019-financial-results-on-august-6-bcrx-20190723monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20190703monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-appoints-megan-sniecinski-chief-business-officer-bcrx-20190701monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-begins-enrollment-of-phase-1-trial-of-bcx9930-an-oral-factor-d-inhibitor-for-comp-bcrx-20190627monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20190604monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20190531monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-s-oral-bcx7353-meets-primary-endpoint-in-phase-3-apex-2-trial-bcrx-20190521monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-bank-of-america-merrill-lynch-health-care-conference-bcrx-20190510monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-completes-phase-1-clinical-trial-of-galidesivir-bcrx-20190509monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-first-quarter-2019-financial-results-bcrx-20190508monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bcrx-20190506monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-first-quarter-2019-financial-results-on-may-8-bcrx-20190424monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20190401monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-fourth-quarter-and-full-year-2018-financial-results-bcrx-20190304monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-advancing-bcx9930-an-oral-factor-d-inhibitor-for-complement-mediated-diseases-int-bcrx-20190304monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-barclays-global-healthcare-conference-bcrx-20190228monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-zenith-1-results-with-oral-bcx7353-which-confirm-rapid-onset-of-action-su-bcrx-20190223monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-fourth-quarter-and-full-year-2018-financial-results-on-march-4-bcrx-20190218monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-strengthens-cash-position-with-flexible-100-million-debt-facility-bcrx-20190206monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-zenith-1-results-at-american-academy-of-allergy-asthma-immunology-annu-bcrx-20190205monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-appoints-steve-aselage-to-board-of-directors-bcrx-20190104monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-37th-annual-j-p-morgan-healthcare-conference-bcrx-20190102monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-initiates-phase-1-clinical-trial-of-galidesivir-bcrx-20190102monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-appoints-rare-disease-expert-theresa-heggie-to-board-of-directors-bcrx-20181120monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-presents-data-highlighting-the-rapid-and-sustained-plasma-concentrations-of-bcx73-bcrx-20181116monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conferences-bcrx-20181108monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-third-quarter-2018-financial-results-bcrx-20181106monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-abstracts-at-annual-scientific-meeting-of-american-college-of-allergy--bcrx-20181105monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-report-third-quarter-2018-financial-results-on-november-6-bcrx-20181023monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pharmaceuticals-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-bcrx-20180925monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-receives-additional-3-5-million-to-fund-clinical-trials-of-galidesivir-in-yellow--bcrx-20180917monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-positive-results-across-multiple-endpoints-in-zenith-1-trial-of-oral-bcx7-bcrx-20180904monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pharmaceuticals-to-present-at-the-baird-global-healthcare-conference-bcrx-20180829monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-second-quarter-2018-financial-results-bcrx-20180807monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pharmaceuticals-announces-full-exercise-of-underwriters-option-to-purchase-additi-bcrx-20180806monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pharmaceuticals-prices-public-offering-of-common-stock-bcrx-20180802monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pharmaceuticals-commences-public-offering-of-common-stock-bcrx-20180801monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-announce-second-quarter-2018-financial-results-on-august-7-bcrx-20180727monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-publication-of-apex-1-clinical-trial-results-for-bcx7353-in-the-new-eng-bcrx-20180725monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-agreement-with-pmda-on-phase-3-clinical-trial-and-regulatory-requirements-bcrx-20180625monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pharmaceuticals-and-idera-pharmaceuticals-to-present-at-the-jmp-securities-life-s-bcrx-20180613monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-presentation-of-additional-analyses-of-the-apex-1-clinical-trial-of-bcx-bcrx-20180529monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-s-bcx7353-receives-european-regulatory-designations-for-the-treatment-of-heredita-bcrx-20180524monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pharmaceuticals-and-idera-pharmaceuticals-to-present-at-the-jefferies-2018-global-bcrx-20180524monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-first-quarter-2018-financial-results-bcrx-20180508monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-receives-european-medicines-agency-approval-for-alpivab-for-the-treatment-of-infl-bcrx-20180501monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-announce-first-quarter-2018-financial-results-on-may-8-bcrx-20180426monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pharmaceuticals-and-idera-pharmaceuticals-to-present-at-the-17th-annual-needham-h-bcrx-20180322monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-initiation-of-the-phase-3-apex-2-trial-of-bcx7353-in-patients-with-here-bcrx-20180315monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-initiation-of-the-apex-s-long-term-safety-trial-of-bcx7353-in-patients--bcrx-20180228monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pharmaceuticals-and-idera-pharmaceuticals-file-preliminary-proxy-statement-and-in-bcrx-20180227monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-announce-fourth-quarter-and-full-year-2017-financial-results-on-february-27-bcrx-20180220monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pharmaceuticals-and-idera-pharmaceuticals-to-present-at-two-upcoming-healthcare-i-bcrx-20180219monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pharmaceuticals-and-idera-pharmaceuticals-announce-merger-to-combine-capabilities-bcrx-20180122monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-advancing-potential-treatment-for-rare-and-severely-debilitating-fibrodysplasia-o-bcrx-20180105monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-bcrx-20180103monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-29th-annual-piper-jaffray-healthcare-conference-bcrx-20171116monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-third-quarter-2017-financial-results-bcrx-20171107monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-the-jefferies-2017-london-healthcare-conference-bcrx-20171101monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-late-breaker-presentation-of-bcx7353-phase-2-apex-1-trial-results-at-th-bcrx-20171027monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-announce-third-quarter-2017-financial-results-on-november-7-bcrx-20171024monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-rapivab-peramivir-injection-and-galidesivir-presentations-at-idweek-201-bcrx-20171004monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-s-rapivab-peramivir-injection-receives-fda-approval-for-a-pediatric-indication-bcrx-20170921monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pharmaceuticals-announces-full-exercise-of-underwriters-option-to-purchase-additi-bcrx-20170915monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pharmaceuticals-prices-public-offering-of-common-stock-bcrx-20170913monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pharmaceuticals-commences-public-offering-of-common-stock-bcrx-20170911monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-positive-results-from-its-apex-1-phase-2-trial-in-hae-bcrx-20170905monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-corporate-update-conference-call-and-webcast-bcrx-20170904monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-three-upcoming-investor-conferences-bcrx-20170823monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-second-quarter-2017-financial-results-bcrx-20170807monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-initiation-of-zenith-1-a-clinical-trial-to-evaluate-bcx7353-as-an-acute-bcrx-20170802monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-announce-second-quarter-2017-financial-results-on-august-7-bcrx-20170724monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-the-jmp-securities-2017-life-sciences-conference-bcrx-20170613monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-rapivab-pediatric-snda-acceptance-bcrx-20170605monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-the-jefferies-2017-global-healthcare-conference-bcrx-20170531monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-additional-positive-results-from-the-second-interim-analysis-of-its-apex--bcrx-20170525monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-the-bank-of-america-merrill-lynch-2017-health-care-conference-bcrx-20170509monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-first-quarter-2017-financial-results-bcrx-20170504monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-announce-first-quarter-2017-financial-results-may-4-bcrx-20170424monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-expands-development-of-bcx7353-to-explore-treatment-of-acute-hae-attacks-bcrx-20170412monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-mundipharma-receives-approval-for-mundesine-in-japan-bcrx-20170403monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-the-16th-annual-needham-healthcare-conference-bcrx-20170329monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pharmaceuticals-prices-public-offering-of-common-stock-bcrx-20170310monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pharmaceuticals-commences-public-offering-of-common-stock-bcrx-20170308monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-fourth-quarter-and-full-year-2016-financial-results-bcrx-20170227monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-positive-interim-results-from-its-apex-1-trial-bcrx-20170227monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-announce-fourth-quarter-and-year-end-2016-financial-results-february-27-bcrx-20170215monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-the-acceptance-of-peramivir-maa-filing-by-the-european-medicines-agency-bcrx-20170130monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-receives-health-canada-approval-for-rapivab-for-the-treatment-of-influenza-bcrx-20170108monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-the-j-p-morgan-healthcare-conference-bcrx-20170104monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-the-piper-jaffray-healthcare-conference-november-30-bcrx-20161117monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-third-quarter-2016-financial-results-bcrx-20161107monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-late-breaker-presentation-of-galidesivir-bcx4430-nonclinical-results-in-bcrx-20161026monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-announce-third-quarter-2016-financial-results-november-7-bcrx-20161024monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-closes-23-million-senior-credit-facility-bcrx-20160926monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-positive-study-results-for-bcx4430-delayed-treatment-of-ebola-virus-inf-bcrx-20160907monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-the-baird-2016-global-healthcare-conference-september-8-bcrx-20160831monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-initiation-of-the-apex-1-clinical-trial-of-bcx7353-for-hereditary-angio-bcrx-20160811monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-second-quarter-2016-financial-results-bcrx-20160804monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-announce-second-quarter-2016-financial-results-august-4-bcrx-20160721monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-receives-additional-niaid-funding-to-advance-development-of-bcx4430-to-treat-hemo-bcrx-20160705monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-two-upcoming-investor-conferences-bcrx-20160526monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-first-quarter-2016-financial-results-bcrx-20160505monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-announce-first-quarter-2016-financial-results-may-5-bcrx-20160421monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-two-upcoming-investor-conferences-bcrx-20160407monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-barclays-healthcare-conference-bcrx-20160309monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-fourth-quarter-full-year-2015-financial-results-bcrx-20160223monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-announce-fourth-quarter-2015-financial-results-february-23-bcrx-20160216monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-results-from-opus-2-bcrx-20160208monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-the-j-p-morgan-healthcare-conference-bcrx-20160104monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-two-upcoming-investor-conferences-bcrx-20151124monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-third-quarter-2015-financial-results-bcrx-20151105monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-the-jefferies-autumn-2015-global-healthcare-conference-bcrx-20151104monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-announce-third-quarter-2015-financial-results-november-5-bcrx-20151027monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-completion-of-patient-enrollment-in-opus-2-a-clinical-trial-of-avoralst-bcrx-20151008monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-successful-phase-1-clinical-trial-of-bcx7353-bcrx-20151008monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-second-quarter-2015-financial-results-bcrx-20150807monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-announce-second-quarter-2015-financial-results-august-7-bcrx-20150723monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-the-jmp-securities-life-sciences-conference-bcrx-20150618monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-licenses-worldwide-rights-to-commercialize-rapivab-r-influenza-treatment-to-csl-l-bcrx-20150617monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-the-jefferies-2015-healthcare-conference-bcrx-20150526monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-initiation-of-a-phase-1-clinical-trial-of-bcx7353-for-the-treatment-of--bcrx-20150513monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-first-quarter-2015-financial-results-bcrx-20150508monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-the-bank-of-america-merrill-lynch-2015-healthcare-conference-bcrx-20150505monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-announce-first-quarter-2015-financial-results-may-8-bcrx-20150423monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-the-needham-healthcare-conference-bcrx-20150407monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-awarded-bcx4430-advanced-development-contract-bcrx-20150331monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-two-upcoming-investor-conferences-bcrx-20150226monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-fourth-quarter-full-year-2014-financial-results-bcrx-20150218monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-announce-2014-financial-results-february-18-present-at-the-2015-leerink-global-bcrx-20150205monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-receives-positive-opinion-on-european-orphan-drug-designation-for-bcx4161-for-the-bcrx-20150114monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-j-p-morgan-healthcare-conference-bcrx-20150106monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pharmaceuticals-announces-the-appointment-of-lynne-powell-as-chief-commercial-off-bcrx-20150105monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-receives-orphan-drug-designation-for-bcx4161-for-the-treatment-of-hereditary-angi-bcrx-20141223monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-study-results-for-bcx4430-in-a-non-human-primate-model-of-ebola-virus-i-bcrx-20141223monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-s-rapivab-tm-peramivir-injection-receives-fda-approval-for-the-treatment-of-acute-bcrx-20141222monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-initiates-opus-2-a-clinical-trial-of-bcx4161-in-patients-with-hereditary-angioede-bcrx-20141218monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-initiation-of-a-phase-1-clinical-trial-of-bcx4430-for-the-treatment-of--bcrx-20141215monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-two-upcoming-investor-conferences-bcrx-20141120monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-third-quarter-2014-financial-results-bcrx-20141106monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-announce-third-quarter-2014-financial-results-november-6-bcrx-20141030monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-late-breaker-presentation-of-opus-1-phase-2-trial-results-at-the-23rd-e-bcrx-20141007monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-receives-additional-niaid-funding-for-manufacture-and-development-of-bcx4430-to-t-bcrx-20140918monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-rapivab-tm-trial-results-for-the-treatment-of-influenza-at-the-icaac-20-bcrx-20140906monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-participates-in-world-health-organization-consultation-on-potential-ebola-therapi-bcrx-20140904monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-rodman-renshaw-conference-bcrx-20140903monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-peramivir-trial-results-for-the-treatment-of-influenza-at-the-icaac-20-bcrx-20140902monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-receives-additional-niaid-funding-to-conduct-a-non-human-primate-study-of-bcx4430-bcrx-20140829monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-receives-additional-niaid-funding-to-advance-development-of-bcx4430-to-treat-hemo-bcrx-20140813monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-second-quarter-2014-financial-results-bcrx-20140805monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-announce-second-quarter-2014-financial-results-august-5-bcrx-20140722monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-exercise-of-over-allotment-option-and-completion-of-public-offering-bcrx-20140603monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-two-upcoming-investor-conferences-bcrx-20140602monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pharmaceuticals-prices-public-offering-of-common-stock-bcrx-20140528monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-commences-public-offering-of-common-stock-bcrx-20140527monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-positive-results-from-opus-1-a-phase-2-trial-of-bcx4161-for-the-prophyl-bcrx-20140527monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-announce-results-from-the-bcx4161-opus-1-phase-2-trial-for-hereditary-angioede-bcrx-20140524monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-bank-of-america-merrill-lynch-2014-healthcare-conference-bcrx-20140509monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-first-quarter-2014-financial-results-bcrx-20140508monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-announce-first-quarter-2014-financial-results-may-8-bcrx-20140428monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-nature-publication-demonstrating-efficacy-of-bcx4430-in-a-non-human-pri-bcrx-20140303monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-presents-bcx4161-phase-1-trial-and-kallikrein-inhibition-assay-results-bcrx-20140301monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-fourth-quarter-and-full-year-2013-financial-results-bcrx-20140226monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-announces-peramivir-nda-acceptance-by-the-fda-bcrx-20140225monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-three-upcoming-investor-conferences-bcrx-20140220monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-announce-fourth-quarter-and-2013-financial-results-february-26-bcrx-20140212monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-to-present-at-j-p-morgan-healthcare-conference-bcrx-20140102monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pharmaceuticals-inc-is-today-s-focus-stock-on-microstockprofit-com-bcrx-20100630monthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pharmaceuticals-inc-bcrx-chairman-and-ceo-to-ring-the-nasdaq-stock-market-opening-bcrx-20060821monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of--rare-20260406monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-urgent-deadline-bragar-eagel-squire-p-c-reminds-ultragenyx-nasdaq-rare-investor-rare-20260406monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-deadline-rosen-recognized-investor-counsel-encourages-ultragenyx-pharmaceutical-rare-20260402monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-00-rare-20260402monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-nasdaq-rare-class-action-deadline-approaching-berger-montagu-rare-20260401monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-notice-of-april-6-2026-application-deadline-for-class-action-rare-20260401monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-deadline-rosen-top-ranked-investor-counsel-encourages-ultragenyx-pharmaceutical-rare-20260327monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-00-rare-20260326monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-notice-of-april-6-2026-application-deadline-for-class-action-rare-20260325monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-00-rare-20260319monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-notice-of-april-6-2026-application-deadline-for-class-action-rare-20260318monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-00-rare-20260312monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-notice-of-april-6-2026-application-deadline-for-class-action-rare-20260311monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-rare-investors-april-6-2026-filing-deadline-in-securities-fr-rare-20260307monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-with-substantial-losses-have-opportunity-to-lead-i-rare-20260307monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-00-rare-20260305monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-notice-of-april-6-2026-application-deadline-for-class-action-rare-20260304monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investors-with-substantial-losses-have-opportunity-to-lead-c-rare-20260302monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-00-rare-20260226monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-notice-of-april-6-2026-application-deadline-for-class-action-rare-20260225monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-securities-class-action-filed-lead-plaintiff-deadline-april--rare-20260223monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20260220monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-00-rare-20260219monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-notice-of-april-6-2026-application-deadline-for-class-action-rare-20260217monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-sued-for-securities-law-violations-investors-should-contact--rare-20260212monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-fourth-quarter-and-full-year-2025-financial-results-and-corporate-updat-rare-20260212monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-00-rare-20260212monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-securities-class-action-lawsuit-filed-lead-plaintiff-deadlin-rare-20260211monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-notice-of-april-6-2026-application-deadline-for-class-action-rare-20260211monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-fi-rare-20260205monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-rare-20260107monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-inc-investigated-by-the-portnoy-law-firm-rare-20251230monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20250919monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-mereo-biopharma-announce-ux143-phase-3-orbit-study-for-osteogenesis-imperfe-rare-20250709monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20250620monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-participate-at-bank-of-america-s-2025-healthcare-conference-rare-20250507monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-first-quarter-2025-financial-results-and-corporate--rare-20250430monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20250422monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-fourth-quarter-and-full-year-2024-financial-results-and-corporate-updat-rare-20250213monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-fourth-quarter-and-full-year-2024-financial-results-rare-20250206monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-new-data-demonstrating-that-treatment-with-ux111-aav-gene-therapy-sig-rare-20250205monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-second-quarter-2024-financial-results-and-corporate-rare-20240725monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-pricing-of-public-offering-of-common-stock-and-pre-funded-warrants-rare-20240614monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20231221monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-receives-european-commission-decision-for-evkeeza-evinacumab-expanded-indicatio-rare-20231218monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-third-quarter-2023-financial-results-and-corporate-update-rare-20231102monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-third-quarter-2023-financial-results-and-corporate--rare-20231026monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-closing-of-public-offering-of-common-stock-and-pre-funded-warrants-an-rare-20231023monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20231020monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-pricing-of-public-offering-of-common-stock-and-pre-funded-warrants-rare-20231019monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20231012monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-setrusumab-ux143-update-at-asbmr-2023-including-new-data-from-phase--rare-20231009monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-pipeline-update-at-analyst-day-on-monday-october-16-2023-rare-20231005monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-launches-evkeeza-evinacumab-for-injection-in-canada-for-the-treatment-of-homozy-rare-20230925monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20230920monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-participate-at-investor-conferences-in-september-rare-20230831monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20230818monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-second-quarter-2023-financial-results-and-corporate-update-rare-20230803monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-second-quarter-2023-financial-results-and-corporate-rare-20230727monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20230718monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20230620monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference-rare-20230607monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-2023-barclays-gene-editing-gene-therapy-summit-rare-20230519monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20230518monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20221004monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20220817monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-upcoming-data-presentations-at-american-society-of-gene-cell-therapy--rare-20220509monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-first-quarter-2022-financial-results-and-corporate-update-rare-20220505monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20220503monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-participate-at-bofa-securities-2022-healthcare-conference-rare-20220503monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-first-quarter-2022-financial-results-and-corporate--rare-20220427monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-issues-inaugural-environmental-social-and-governance-esg-report-rare-20220425monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-participate-in-the-cowen-health-care-conference-rare-20220302monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-h-c-wainwright-bioconnect-healthcare-conference-rare-20220106monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-evercore-4th-annual-healthconx-conference-rare-20211129monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-third-quarter-2021-financial-results-and-corporate-update-rare-20211102monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-initiates-cyprus2-a-pivotal-clinical-trial-evaluating-ux701-gene-therapy-for-th-rare-20211018monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-morgan-stanley-healthcare-conference-rare-20210907monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-second-quarter-2021-financial-results-and-corporate-rare-20210727monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-first-quarter-2020-financial-results-and-corporate-update-rare-20200506monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-first-quarter-2020-financial-results-and-corporate--rare-20200430monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-upcoming-data-presentations-at-american-society-of-gene-cell-therapy--rare-20200428monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-kyowa-kirin-announce-fda-acceptance-and-priority-review-designation-of-supp-rare-20200227monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-third-quarter-2019-financial-results-and-corporate--rare-20191030monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-fourth-quarter-and-full-year-2018-financial-results-rare-20190212monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-upcoming-investor-conferences-rare-20181109monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-third-quarter-2018-financial-results-and-corporate--rare-20181030monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-exclusive-license-to-regenxbio-aav-vectors-to-develop-gene-therapy-fo-rare-20181022monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-upcoming-investor-conferences-rare-20180830monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-second-quarter-2018-financial-results-and-corporate-rare-20180727monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-chmp-opinion-for-mepsevii-vestronidase-alfa-for-the-treatmen-rare-20180629monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-upcoming-investor-conferences-rare-20180604monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-fourth-quarter-and-full-year-2017-financial-results-rare-20180214monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-leerink-partners-global-healthcare-conference-rare-20180208monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-credit-suisse-healthcare-conference-rare-20171106monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-third-quarter-2017-financial-results-and-corporate--rare-20171030monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-dimension-announce-expiration-of-hart-scott-rodino-waiting-period-for-ultra-rare-20171026monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-kyowa-hakko-kirin-announce-fda-acceptance-and-priority-review-designation-o-rare-20171010monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-baird-2017-global-healthcare-conference-rare-20170831monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-burosumab-data-presentations-at-asbmr-2017-annual-meeting-rare-20170824monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-second-quarter-2017-financial-results-and-corporate-rare-20170721monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-provides-regulatory-update-on-burosumab-krn23-rare-20170623monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-goldman-sachs-38th-annual-global-healthcare-conference-rare-20170607monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-jefferies-global-healthcare-conference-rare-20170601monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-bank-of-america-merrill-lynch-healthcare-conference-rare-20170510monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-first-quarter-2017-financial-results-and-corporate--rare-20170428monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-initiates-global-phase-3-study-of-ux007-in-glut1-ds-patients-with-disabling-mov-rare-20170427monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-upcoming-investor-conferences-rare-20170302monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-leerink-partners-global-healthcare-conference-rare-20170210monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-fourth-quarter-and-full-year-2016-financial-results-rare-20170209monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-kyowa-kirin-international-announce-marketing-authorization-application-for--rare-20170105monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-j-p-morgan-healthcare-conference-rare-20170104monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-upcoming-investor-conferences-rare-20161108monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-third-quarter-2016-financial-results-and-corporate-update-rare-20161107monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-third-quarter-2016-financial-results-and-corporate--rare-20161031monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-first-patient-enrolled-in-global-phase-3-study-of-krn23-in-pediatric--rare-20161026monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-leerink-partners-roundtable-series-rare-20160927monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-positive-interim-data-from-pediatric-and-adult-phase-2-studies-of-krn23-rare-20160919monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-to-discuss-krn23-data-presented-at-asbmr-2016-annual-me-rare-20160916monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-baird-2016-global-healthcare-conference-rare-20160901monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-upcoming-investor-conferences-rare-20160809monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-second-quarter-2016-financial-results-and-corporate-update-rare-20160808monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-upcoming-investor-conferences-rare-20160601monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-first-quarter-2016-financial-results-and-corporate-update-rare-20160509monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-bank-of-america-merrill-lynch-healthcare-conference-rare-20160506monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-first-quarter-2016-financial-results-and-corporate--rare-20160429monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-appoints-lars-ekman-m-d-ph-d-to-board-of-directors-rare-20160321monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-cowen-and-company-36th-annual-health-care-conference-rare-20160302monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-data-presentations-of-rhgus-and-rhppca-at-12th-annual-world-symposium-rare-20160301monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-fourth-quarter-2015-and-full-year-2015-financial-results-and-corporate--rare-20160225monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-fourth-quarter-and-full-year-2015-financial-results-rare-20160218monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-leerink-partners-annual-healthcare-conference-rare-20160209monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-j-p-morgan-healthcare-conference-rare-20160105monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-first-patient-enrolled-in-global-phase-3-study-of-krn23-in-adults-wit-rare-20151203monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-oppenheimer-annual-healthcare-conference-rare-20151202monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-third-quarter-2015-financial-results-and-corporate-update-rare-20151109monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-update-to-ux007-development-program-in-glucose-transporter-type-1-def-rare-20151106monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-credit-suisse-annual-healthcare-conference-rare-20151103monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-third-quarter-2015-financial-results-and-corporate--rare-20151103monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-baird-health-care-conference-rare-20150902monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-presentation-of-data-from-long-chain-fatty-acid-oxidation-disorder-pa-rare-20150901monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-second-quarter-2015-financial-results-and-corporate-update-rare-20150813monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-second-quarter-2015-financial-results-and-corporate-rare-20150806monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-closing-of-public-offering-of-common-stock-and-exercise-of-underwrite-rare-20150721monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-appoints-john-pinion-as-chief-quality-operations-officer-and-senior-vice-presid-rare-20150720monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-pricing-of-public-offering-of-common-stock-rare-20150716monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-proposed-public-offering-of-common-stock-rare-20150714monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-releases-positive-interim-40-week-bone-treatment-data-from-ongoing-pediatric-ph-rare-20150709monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-names-daniel-g-welch-as-chairman-of-the-board-rare-20150625monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-appoints-jayson-dallas-m-d-as-chief-commercial-officer-and-senior-vice-presiden-rare-20150622monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-releases-positive-16-week-interim-data-from-pediatric-phase-2-study-of-krn23-in-rare-20150602monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-first-patient-enrolled-in-global-phase-3-study-of-aceneuramic-acid-si-rare-20150528monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-jefferies-2015-global-healthcare-conference-rare-20150526monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-first-quarter-2015-financial-results-and-corporate-update-rare-20150511monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-first-quarter-2015-financial-results-and-corporate--rare-20150505monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-granted-additional-orphan-drug-designations-for-triheptanoin-rare-20150423monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-fourth-quarter-and-full-year-2014-financial-results-and-corporate-updat-rare-20150325monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-fourth-quarter-and-full-year-2014-financial-results-rare-20150320monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-presentation-of-disease-burden-data-in-adult-patients-with-x-linked-h-rare-20150309monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-barclays-global-healthcare-conference-rare-20150304monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-cowen-and-company-35th-annual-health-care-conference-in-bosto-rare-20150225monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-appoints-michael-narachi-to-board-of-directors-rare-20150224monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-proposed-public-offering-of-common-stock-rare-20150203monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-intent-to-file-for-conditional-approval-in-europe-for-sialic-acid-ext-rare-20150112monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-initiates-new-development-program-studying-krn23-for-the-treatment-of-tumor-ind-rare-20150106monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-initiation-of-phase-3-study-of-recombinant-human-beta-glucuronidase-i-rare-20141215monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-oppenheimer-healthcare-conference-rare-20141203monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-third-quarter-2014-financial-results-and-corporate-update-rare-20141110monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-credit-suisse-annual-healthcare-conference-rare-20141104monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-granted-orphan-drug-designation-for-triheptanoin-for-the-treatment-of-glucose-t-rare-20141027monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-interim-data-from-phase-2-extension-study-of-sialic-acid-extended-rel-rare-20141013monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-leerink-partners-rare-disease-roundtable-rare-20140924monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-results-from-a-long-term-phase-1-2-study-of-krn23-in-adult-p-rare-20140915monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-morgan-stanley-global-healthcare-conference-rare-20140904monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-interim-data-from-phase-1-2-study-of-recombinant-human-beta--rare-20140903monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-baird-health-care-conference-rare-20140827monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-second-quarter-2014-financial-results-and-corporate-update-rare-20140811monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-upcoming-investor-conferences-rare-20140806monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-license-of-intellectual-property-for-the-treatment-of-epilepsy-and-ot-rare-20140805monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-appoints-sunil-agarwal-m-d-as-chief-medical-officer-and-senior-vice-president-rare-20140723monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-closing-of-public-offering-of-common-stock-and-exercise-of-underwrite-rare-20140714monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-pricing-of-public-offering-of-common-stock-rare-20140709monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-proposed-public-offering-of-common-stock-rare-20140707monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-initiation-of-a-phase-2-study-of-krn23-for-pediatric-x-linked-hypopho-rare-20140701monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-results-from-phase-1-2-study-of-krn23-in-x-linked-hypophosphatemia-in-rare-20140624monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-jmp-securities-healthcare-conference-rare-20140618monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-goldman-sachs-global-healthcare-conference-rare-20140604monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-jefferies-2014-global-healthcare-conference-rare-20140527monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-krn23-phase-1-2-study-data-to-be-presented-at-ice-endo-meeting-on-jun-rare-20140519monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-first-quarter-2014-financial-results-and-corporate-update-rare-20140512monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-data-from-phase-2-study-of-sialic-acid-extended-release-at-e-rare-20140430monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-preliminary-data-from-phase-1-2-study-of-recombinant-human-beta-glucu-rare-20140327monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-fourth-quarter-and-full-year-2013-financial-results-rare-20140324monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-biocentury-future-leaders-in-the-biotech-industry-conference-rare-20140321monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-first-patient-enrolled-in-phase-2-study-of-triheptanoin-in-glucose-tr-rare-20140311monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-cowen-and-company-34th-annual-health-care-conference-in-boston-rare-20140226monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-presentation-of-data-from-a-single-patient-treated-with-recombinant-h-rare-20140212monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-initiation-of-phase-2-study-for-patients-with-long-chain-fatty-acid-o-rare-20140211monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-appoints-clay-siegall-ph-d-and-matthew-fust-to-board-of-directors-rare-20140206monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-closing-of-initial-public-offering-and-exercise-of-underwriters-optio-rare-20140205monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-pricing-of-initial-public-offering-rare-20140131monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-results-from-phase-2-study-of-sialic-acid-extended-release-treatment--rare-20131220monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-gains-worldwide-rights-for-triheptanoin-ux007-rare-20130711monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-jefferies-2013-global-healthcare-conference-rare-20130529monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-appoints-eric-yuen-md-as-chief-medical-officer-and-senior-vice-president-rare-20130501monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference-nrix-20251125monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-nrix-20250828monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nrix-20250613monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-host-a-webcast-conference-call-to-discuss-data-from-the-ongoing-phas-nrix-20250606monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-nrix-20250528monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nrix-20250516monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-the-rbc-capital-markets-global-healthcare-conference-nrix-20250515monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-presentations-of-clinical-data-at-the-30th-european-hematolog-nrix-20250514monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-announces-fda-clearance-of-ind-application-for-gs-6791-nx-0479-a-novel-irak4-degrade-nrix-20250417monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nrix-20250411monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nrix-20250314monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-appoints-drug-development-expert-roy-d-baynes-mb-bch-m-med-ph-d-to-its--nrix-20250313monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nrix-20250214monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-appointment-of-john-northcott-as-chief-commercial-officer-nrix-20250122monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-presents-new-positive-data-from-phase-1a-1b-clinical-trial-of-nx-5948-i-nrix-20241209monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference-nrix-20241125monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-receives-prime-designation-from-the-european-medicines-agency-for-nx-59-nrix-20241120monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-presentations-at-the-66th-american-society-of-hematology-ash--nrix-20241105monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-nrix-20241031monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-presentations-at-the-7th-annual-tpd-induced-proximity-summit-nrix-20241021monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-presents-positive-results-from-the-ongoing-clinical-trial-of-its-btk-de-nrix-20241019monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-expands-its-board-of-directors-with-the-addition-of-drug-commercializat-nrix-20241016monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-presentations-at-acr-convergence-2024-the-annual-meeting-of-t-nrix-20241009monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-upcoming-adc-radiopharmaceuticals-pharma-biotech-part-nrix-20240906monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-nrix-20240829monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-second-quarter-fiscal-2024-financial-results-and-provides-a-cor-nrix-20240711monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-the-ubs-virtual-targeted-protein-degradation-tpd-day-nrix-20240708monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-presents-positive-results-from-ongoing-clinical-trial-of-nx-5948-in-pat-nrix-20240616monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-nrix-20240529monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-appoints-paula-g-o-connor-m-d-as-chief-medical-officer-and-pasit-phiasi-nrix-20240528monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-board-chair-transition-nrix-20240520monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-upcoming-oral-presentation-of-new-data-from-ongoing-clinical--nrix-20240514monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-rbc-capital-markets-global-healthcare-conference-nrix-20240507monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-closing-of-public-offering-and-full-exercise-of-underwriters--nrix-20240416monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-proposed-public-offering-nrix-20240411monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-first-quarter-fiscal-2024-financial-results-and-provides-a-corp-nrix-20240410monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-first-clinical-evidence-of-cns-activity-of-nx-5948-a-brain-pene-nrix-20240409monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-nrix-20240403monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-is-part-of-a-team-of-international-oncology-experts-selected-as-cancer--nrix-20240325monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-presents-the-discovery-and-chemical-structure-of-first-in-class-cbl-b-inhibitor-nx-1-nrix-20240320monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-nrix-20240306monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-presentations-at-the-american-association-for-cancer-research-nrix-20240305monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-publication-in-the-journal-science-identifying-a-new-class-of-nrix-20240201monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-receives-u-s-fda-fast-track-designation-for-nx-5948-for-the-treatment-o-nrix-20240116monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-present-at-42nd-annual-j-p-morgan-healthcare-conference-nrix-20240102monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-nrix-20231107monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-announces-strategic-collaboration-with-seagen-combining-industry-leading-technologie-nrix-20230907monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-nrix-20230831monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-presents-data-from-studies-of-its-targeted-protein-degraders-in-b-cell--nrix-20230614monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-the-2023-rbc-capital-markets-global-healthcare-confer-nrix-20230509monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-the-22nd-annual-needham-virtual-healthcare-conference-nrix-20230411monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-present-at-the-oppenheimer-33rd-annual-healthcare-conference-nrix-20230306monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-nrix-20230208monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-clearance-of-investigational-new-drug-application-for-nx-5948-nrix-20221215monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-webcast-to-review-data-from-its-phase-1-clinical-trial-of-btk-nrix-20221207monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-announces-detil-0255-scientific-presentations-at-the-37th-annual-meeting-of-the-soci-nrix-20221110monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-announces-initial-nx-1607-phase-1-data-presented-at-the-37th-annual-meeting-of-the-s-nrix-20221110monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-nrix-20221102monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-presentations-at-the-5th-annual-targeted-protein-degradation--nrix-20221019monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-nrix-20220831monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-appointment-of-eric-schlezinger-j-d-as-chief-people-officer-nrix-20220803monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-clearance-of-investigational-new-drug-application-for-nx-1607-nrix-20220630monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-will-present-trial-in-progress-posters-for-two-clinical-programs-at-the-nrix-20220610monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-positive-dose-finding-data-in-chronic-lymphocytic-leukemia-an-nrix-20220526monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-dosing-of-first-patient-in-phase-1-clinical-trial-of-nx-5948-a--nrix-20220517monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-participation-in-the-2022-rbc-capital-markets-global-healthca-nrix-20220511monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-host-r-d-day-on-may-26-2022-nrix-20220509monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-participation-in-the-21st-annual-needham-virtual-healthcare-c-nrix-20220404monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-awarded-innovation-passport-for-entry-into-innovative-licensing-and-acc-nrix-20220329monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-nrix-20220309monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-participation-in-the-11th-annual-svb-leerink-global-healthcar-nrix-20220210monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-present-at-40th-annual-j-p-morgan-healthcare-conference-nrix-20220103monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-ind-clearance-for-detil-0255-a-drug-enhanced-autologous-t-cel-nrix-20211112monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-presents-beneficial-effects-of-cbl-b-inhibition-on-human-tumor-infiltra-nrix-20211112monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-nrix-20211109monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-initial-data-from-the-first-phase-1a-dose-escalation-trial-of-nrix-20211027monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-present-initial-target-degradation-data-from-first-phase-1-trial-of--nrix-20211026monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-the-4th-annual-targeted-protein-degradation-summit-nrix-20211021monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-appointment-of-stefani-a-wolff-as-chief-operating-officer-and-nrix-20210621monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-nrix-20210511monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-participation-in-the-20th-annual-needham-virtual-healthcare-c-nrix-20210407monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-collaboration-for-the-discovery-of-novel-drugs-to-treat-pedia-nrix-20210316monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercise--nrix-20210309monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-and-present-at-upcoming-investor-conferences-nrix-20210309monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-launch-of-proposed-public-offering-of-common-stock-nrix-20210302monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-presentation-at-39th-annual-j-p-morgan-healthcare-conference-nrix-20210105monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-presents-preclinical-data-at-62nd-american-society-of-hematology-ash-an-nrix-20201207monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-present-at-upcoming-investor-conferences-nrix-20201109monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-present-preclinical-data-at-upcoming-5th-medicinal-chemistry-protein-nrix-20201104monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-addition-of-dr-jason-kantor-to-its-management-team-nrix-20200713monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-formation-of-decart-therapeutics-to-advance-new-car-t-therapi-nrix-20200625monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-present-at-the-cowen-co-40th-annual-health-care-conference-nrix-20200227monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-and-sanofi-establish-strategic-collaboration-to-develop-novel-targeted--nrix-20200109monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-nrix-20200108monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-scientific-presentations-on-its-btk-program-at-the-61st-ameri-nrix-20191118monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-key-management-additions-nrix-20191114monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-upcoming-investor-conference-schedule-nrix-20191112monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-upcoming-scientific-presentation-for-its-cbl-b-program-at-the-nrix-20191022monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-present-at-the-targeted-protein-degradation-summit-2019-nrix-20191015monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-key-additions-to-its-board-of-directors-nrix-20191008monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-present-at-the-needham-company-18th-annual-healthcare-conference-nrix-20190404monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-present-at-2019-american-association-for-cancer-research-aacr-annual-nrix-20190319monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-present-at-the-30th-annual-piper-jaffray-healthcare-conference-nrix-20181121monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-present-at-the-stifel-healthcare-conference-nrix-20181107monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-present-at-the-targeted-protein-degradation-summit-2018-nrix-20181017monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-present-at-the-2018-bio-investor-forum-nrix-20181010monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-appoints-nancy-pryer-ph-d-chief-development-officer-nrix-20180508monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-plse-20220228monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-announces-closing-of-initial-public-offering-over-allotment-plse-20160621monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-announces-closing-of-initial-public-offering-plse-20160523monthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-announces-pricing-of-initial-public-offering-plse-20160517monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-ryoncil-net-revenues-of-us-30-3m-and-improved-net-operating-cash-spend-f-meso-20260430monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for--meso-20260410monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-r-d-day-features-significant-commercial-progress-platform-innovation-meso-20260408monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-announces-changes-to-board-of-directors-leadership-roles-meso-20260101monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-retires-senior-debt-with-non-dilutive-lower-cost-five-year-credit-line-meso-20251229monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-participation-at-piper-sandler-conference-meso-20251203monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-trading-update-at-annual-general-meeting-highlights-continued-strong-growth-in-r-meso-20251124monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-and-bmt-ctn-to-initiate-pivotal-trial-of-ryoncil-as-part-of-first-line-regimen-i-meso-20251120monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-and-fda-align-on-key-items-for-revascor-biologic-license-application-in-ischemic-meso-20250701monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-maintains-momentum-with-fda-on-accelerated-approval-pathway-for-revascor-in-isch-meso-20250612monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-appoints-corporate-finance-leader-lyn-cobley-to-board-meso-20250428monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-extends-payer-coverage-for-ryoncil-to-over-100-million-us-lives-meso-20250417monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-allogeneic-cell-therapy-products-are-designated-u-s-country-of-origin-and-not-su-meso-20250403monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-files-request-for-type-b-meeting-with-fda-to-discuss-accelerated-approval-pathwa-meso-20250402monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-ceo-to-deliver-featured-presentation-at-isct-north-america-virtual-town-hall-meso-20250312monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-added-to-s-p-asx-200-index-meso-20250306monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-sets-ryoncil-price-based-on-economic-value-of-treatment-with-planned-product-ava-meso-20250226monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-financial-results-and-corporate-update-webcast-meso-20250225monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-s-ryoncil-is-the-first-u-s-fda-approved-mesenchymal-stromal-cell-msc-therapy-meso-20241219monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-be-added-to-nasdaq-biotechnology-index-meso-20241218monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-option-to-issue-up-to-us-50-million-convertible-notes-for-product-launch-meso-20240930monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-financial-results-and-operational-update-for-fiscal-year-ended-june-30-2-meso-20240828monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-financial-results-and-corporate-update-webcast-meso-20240827monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-resubmits-biologics-license-application-bla-with-united-states-food-drug-adminis-meso-20240709monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-file-biologics-license-application-for-ryoncil-fda-approval-next-week-meso-20240701monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-corporate-presentation-at-investor-conference-meso-20240603monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-financial-results-and-operational-update-for-half-year-ended-december-31-meso-20240228monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-financial-results-and-corporate-update-webcast-meso-20240226monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-files-for-orphan-drug-and-pediatric-rare-disease-designations-for-rexlemestrocel-meso-20231126monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-partners-with-blood-and-marrow-transplant-clinical-trials-network-bmt-ctn-on-piv-meso-20231121monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-financial-results-and-operational-update-for-fiscal-year-ended-june-30-2-meso-20230830monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-financial-results-and-corporate-update-webcast-meso-20230829monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-receives-complete-response-from-u-s-food-and-drug-administration-for-biologics-l-meso-20230804monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-financial-results-and-corporate-update-webcast-meso-20230524monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-completes-private-placement-meso-20230426monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-financial-results-and-corporate-update-webcast-meso-20230227monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-resubmits-biologic-license-application-bla-to-fda-for-remestemcel-l-in-children--meso-20230131monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-financial-results-and-operational-highlights-for-the-period-ended-septem-meso-20221122monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-financial-results-and-corporate-update-webcast-meso-20221121monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-operational-and-financial-highlights-for-quarter-ended-september-30-2022-meso-20221030monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-corporate-update-and-financial-results-webcast-meso-20220830monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-key-opinion-leader-event-series-for-investors-analysts-meso-20220609monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-corporate-update-and-financial-results-webcast-meso-20220224monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-corporate-update-and-financial-results-webcast-meso-20211123monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-corporate-update-and-financial-results-webcast-meso-20210830monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-corporate-update-and-financial-results-webcast-meso-20210602monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-corporate-update-meso-20210429monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-corporate-update-meso-20210210monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-operational-and-financial-highlights-for-quarter-ended-december-31-2020-meso-20210129monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-presents-heart-failure-phase-3-trial-results-at-investor-healthcare-conference-meso-20210111monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-webcast-update-on-covid-19-ards-trial-meso-20201218monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-update-on-covid-19-ards-trial-meso-20201217monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-corporate-update-meso-20201214monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-limited-investors-last-days-to-participate-actively-in-the-class-action-lawsuit--meso-20201204monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-corporate-update-and-financial-results-webcast-meso-20201119monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-limited-investors-last-days-to-participate-actively-in-the-class-action-lawsuit--meso-20201119monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-fil-meso-20201009monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-2020-full-year-financial-results-webcast-meso-20200826monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-limited-investors-company-investigated-by-the-portnoy-law-firm-meso-20200819monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-host-analyst-call-on-financial-results-for-period-ended-march-31-2020-meso-20200526monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-financial-results-and-corporate-highlights-for-first-half-ended-december-meso-20200226monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-host-analyst-call-on-first-half-financial-results-for-period-ended-december-3-meso-20200225monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-host-analyst-call-on-financial-results-for-first-quarter-ended-september-30-2-meso-20191121monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-corporate-update-analyst-call-meso-20190909monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-2019-full-year-results-meso-20190829monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-host-analyst-call-on-2019-financial-results-for-year-and-fourth-quarter-ended-meso-20190827monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-quarterly-cash-flow-report-meso-20190731monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-heart-failure-cell-therapy-receives-orphan-drug-designation-from-fda-for-prevent-meso-20190624monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-host-virtual-symposium-with-key-opinion-leader-highlighting-acute-graft-versu-meso-20190614monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-financial-results-webcast-for-period-ended-march-31-2019-meso-20190530monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-present-at-2019-rbc-capital-markets-global-healthcare-conference-meso-20190517monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-licensee-files-for-marketing-approval-to-treat-epidermolysis-bullosa-meso-20190325monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-financial-results-webcast-for-half-year-q2-ended-december-31-2018-meso-20190213monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-highlights-2019-key-priorities-for-its-leading-cellular-medicines-pipeline-at-bi-meso-20190108monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-corporate-review-meso-20181228monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-makes-executive-appointment-to-drive-product-commercialization-meso-20181219monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-financial-results-webcast-for-quarter-ended-september-30-2018-meso-20181115monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-host-analyst-call-on-results-of-end-stage-heart-failure-trial-being-presented-meso-20181109monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-provides-update-on-transaction-with-tasly-pharmaceutical-group-meso-20180829monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-financial-results-webcast-for-2018-financial-year-meso-20180827monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-enters-into-us-50m-financing-with-novaquest-capital-for-commercial-readiness-of--meso-20180702monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-appoints-new-chief-financial-officer-meso-20180530monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-financial-results-webcast-for-quarter-ended-march-31-2018-meso-20180529monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-cell-therapies-featured-at-vatican-international-healthcare-conference-meso-20180501monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-present-at-36th-annual-j-p-morgan-healthcare-conference-meso-20180111monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-host-first-quarter-financial-results-webcast-and-conference-call-meso-20171113monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-phase-2-trial-results-show-early-and-durable-effects-of-single-mesenchymal-precu-meso-20171110monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-presents-corporate-update-at-26th-annual-credit-suisse-healthcare-conference-meso-20171109monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-operational-highlights-and-financial-results-for-the-fourth-quarter-and-for-the--meso-20170829monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-receives-a-3-7-million-from-the-australian-government-for-research-and-developme-meso-20170406monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-raises-us-40-million-meso-20170327monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-presents-corporate-update-and-financial-results-for-the-half-year-period-ended-d-meso-20170226monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-host-second-quarter-and-first-half-financial-results-conference-call-and-webc-meso-20170224monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-director-recognized-by-peers-for-cardiovascular-leadership-meso-20170131monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-present-at-35th-annual-j-p-morgan-healthcare-conference-meso-20170111monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-host-first-quarter-financial-results-conference-call-and-webcast-meso-20161109monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-financial-results-and-operational-highlights-for-the-three-months-and-fo-meso-20160824monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-host-fourth-quarter-and-full-year-financial-results-conference-call-and-webca-meso-20160819monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-s-full-24-month-trial-results-for-chronic-low-back-pain-presented-at-spine-inter-meso-20160801monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-financial-results-for-period-ended-31-march-2016-and-provides-corporate--meso-20160509monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-host-third-quarter-and-nine-months-financial-results-conference-call-and-webc-meso-20160506monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-cell-therapy-shows-disease-modifying-effects-on-knee-osteoarthritis-meso-20160401monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-s-cell-therapy-increases-survival-in-children-with-acute-graft-versus-host-disea-meso-20160222monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-on-first-half-and-second-quarter-financial-results-meso-20160216monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-host-second-quarter-and-first-half-financial-results-conference-call-and-webc-meso-20160211monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-present-at-the-34th-annual-j-p-morgan-healthcare-conference-meso-20160107monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-to-host-first-quarter-financial-results-conference-call-and-webcast-on-16-decemb-meso-20151216monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-s-japan-licensee-receives-pricing-for-temcell-hs-inj-for-treatment-of-acute-graf-meso-20151127monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-investor-update-meso-20151123monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-lists-on-nasdaq-meso-20151115monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-announces-pricing-of-public-offering-on-nasdaq-meso-20151113monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-chairman-s-address-to-2015-annual-general-meeting-meso-20151022monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-partner-jcr-pharmaceuticals-receives-recommendation-for-approval-of-mesenchymal--meso-20150904monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-2015-financial-year-results-and-provides-update-on-phase-3-chronic-heart-meso-20150817monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-cell-therapy-reduces-inflammation-and-reverses-coronary-artery-dysfunction-in-rh-meso-20150512monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-phase-3-program-for-degenerative-disc-disease-to-include-european-sites-after-po-meso-20150408monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-key-patent-allowed-in-japan-for-the-treatment-of-heart-diseases-stroke-and-other-meso-20150327monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-selected-for-fast-track-access-to-potential-investment-incentives-in-japan-meso-20150318monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-2015-half-year-results-meso-20150211monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-positive-24-month-results-in-phase-2-trial-for-chronic-low-back-pain-and-meso-20150114monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-s-phase-2-trial-results-in-chronic-low-back-pain-presented-at-north-american-spi-meso-20141112monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-partner-jcr-pharmaceuticals-files-for-marketing-approval-of-the-first-allogeneic-meso-20141001monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-unveils-path-to-bring-its-key-products-to-market-meso-20140826monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-accelerates-plans-for-commercialization-manufacturing-operations-in-singapore-meso-20140528monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-provides-update-on-clinical-programs-of-prochymal-for-crohn-s-disease-and-acute--meso-20140429monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-strong-half-year-financial-results-meso-20140225monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-positive-type-2-diabetes-trial-results-meso-20131204monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-s-cell-therapy-strengthens-native-heart-function-in-patients-with-end-stage-hear-meso-20131118monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-s-mesenchymal-precursor-cells-induce-functional-recovery-in-ischemic-stroke-mode-meso-20131111monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-updates-market-on-registration-plans-for-gvhd-cell-product-in-japan-meso-20131028monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-intrexon-and-ziopharm-to-target-cancers-meso-20131023monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-acquires-osiris-culture-expanded-stem-cell-therapeutic-business-meso-20131011monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-s-phase-2-trial-for-lumbar-spinal-fusion-selected-for-presentation-at-premier-sp-meso-20130919monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-s-strong-cash-position-enables-execution-of-late-stage-clinical-trials-meso-20130829monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-receives-4-3-million-from-australian-government-for-adult-stem-cell-pipeline-dev-meso-20130718monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-receives-clearance-to-begin-phase-2-clinical-trial-of-mesenchymal-precursor-cell-meso-20130626monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-s-preclinical-trial-results-of-intracoronary-cell-therapy-published-in-circulati-meso-20130515monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-positive-interim-results-in-phase-2-trial-of-proprietary-adult-stem-cell-meso-20130422monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-chief-executive-honoured-at-the-vatican-with-inaugural-pontifical-award-for-inno-meso-20130412monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-completes-a-170m-private-placement-meso-20130314monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-reports-half-year-2013-financial-results-meso-20130211monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-receives-fda-clearance-for-phase-2-clinical-trial-of-mesenchymal-precursor-cells-meso-20130130monthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-s-neofuse-stem-cell-product-shows-positive-results-in-phase-2-lumbar-spinal-fusi-meso-20130111monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ocul-20260605monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-2026-ocul-20260604monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ocul-20260515monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ocul-20260508monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-host-investor-day-on-june-17-2026-ocul-20260422monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ocul-20260309monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-more-inf-ocul-20260218monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-ocul-20260213monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ocul-20260206monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ocul-20260123monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ocul-20251205monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025-ocul-20251028monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-participate-in-september-investor-and-scientific-conferences-ocul-20250827monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-receives-fda-agreement-under-special-protocol-assessment-spa-for-regist-ocul-20250812monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-report-second-quarter-2025-financial-results-on-august-5-2025-ocul-20250729monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences-ocul-20250722monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-unveils-new-corporate-branding-reflecting-its-transformation-to-a-retin-ocul-20250626monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025-ocul-20250616monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-close-enrollment-this-week-for-sol-r-its-second-registrational-trial-ocul-20250528monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-participate-in-upcoming-investor-conferences-ocul-20250514monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-participate-in-upcoming-investor-and-scientific-conferences-ocul-20250429monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-report-first-quarter-2025-financial-results-on-may-5-2025-ocul-20250428monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ocul-20250411monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-participate-in-two-investor-conferences-in-april-ocul-20250331monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ocul-20250307monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-hypertension-pipeline-insight-2025-comprehensive-insights-for-50-companies-and-75-p-ocul-20250307monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-present-at-two-investor-conferences-in-march-ocul-20250225monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-report-fourth-quarter-and-full-year-2024-results-on-march-3-2025-ocul-20250224monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-upcoming-presentations-at-the-angiogenesis-exudation-and-dege-ocul-20250203monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ocul-20250117monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-shares-sol-r-enrollment-progress-and-next-steps-for-axpaxli-in-npdr-ocul-20250114monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-co-ocul-20250108monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ocul-20241213monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-ocul-20241210monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-more-than-300-subjects-randomized-in-sol-1-ocul-20241202monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-participate-in-december-investor-and-scientific-conferences-ocul-20241126monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-present-at-the-jefferies-london-healthcare-conference-and-ophthalmol-ocul-20241113monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-appoints-namrata-saroj-od-as-chief-business-officer-ocul-20241112monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-report-third-quarter-2024-results-on-november-14-2024-ocul-20241106monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-accelerated-timelines-for-sol-1-registrational-trial-of-axpax-ocul-20241015monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ocul-20241009monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-present-at-october-ophthalmology-meetings-ocul-20241009monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-present-at-the-ubs-virtual-ophthalmology-day-2024-ocul-20240925monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-drug-delivery-technology-market-size-to-reach-a-valuation-of-usd-30-2-billion-by-20-ocul-20240923monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ocul-20240912monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-present-at-september-retina-meetings-ocul-20240905monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-present-at-two-investor-conferences-in-september-ocul-20240904monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ocul-20240809monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-fda-feedback-that-sol-r-trial-is-appropriate-as-a-registratio-ocul-20240807monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-report-second-quarter-2024-financial-results-on-august-7-2024-ocul-20240731monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-first-patients-enrolled-in-phase-3-sol-r-wet-amd-study-ocul-20240730monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ocul-20240718monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-late-breaking-abstract-of-helios-study-to-be-presented-at-42n-ocul-20240710monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ocul-20240708monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-highlights-exceptional-axpaxli-sol-1-enrollment-and-plans-for-repeat-do-ocul-20240613monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-host-investor-day-on-june-13-2024-ocul-20240605monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ocul-20240604monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ocul-20240507monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-present-at-two-upcoming-investor-conferences-ocul-20240506monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-present-at-two-ophthalmology-meetings-may-4-9-2024-ocul-20240503monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-host-investor-day-in-new-york-city-on-thursday-june-13-2024-ocul-20240501monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-positive-topline-phase-1-data-for-axpaxli-in-diabetic-retinop-ocul-20240418monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-strengthens-clinical-team-with-appointment-of-key-retinal-leaders-ocul-20240416monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-executive-chairman-pravin-u-dugel-md-becomes-president-and-ceo-antony-m-ocul-20240415monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-to-senior--ocul-20240409monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-positive-phase-2-paxtrava-glaucoma-data-at-the-american-socie-ocul-20240406monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-present-data-at-the-2024-ascrs-annual-meeting-american-society-of-ca-ocul-20240326monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-inflammation-treatment-market-insightace-exclusive-report-2024-2031-ocul-20240325monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-release-fourth-quarter-and-full-year-2023-results-on-march-11-2024-ocul-20240305monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-to-newly-a-ocul-20240222monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-board-of-directors-and-leadership-updates-ocul-20240222monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-appoints-steve-meyers-to-chief-commercial-officer-ocul-20240215monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-first-subjects-screened-in-phase-3-pivotal-clinical-trial-of--ocul-20240213monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-fda-agreement-to-amend-special-protocol-assessment-spa-for-pi-ocul-20240125monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-closing-of-public-offering-of-common-stock-and-full-exercise--ocul-20231218monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-pricing-of-public-offering-of-common-stock-ocul-20231214monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-proposed-public-offering-of-common-stock-ocul-20231213monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-present-at-three-upcoming-investor-conferences-ocul-20231108monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-receives-fda-agreement-under-special-protocol-assessment-spa-for-its-fi-ocul-20231101monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-report-third-quarter-2023-financial-results-ocul-20231024monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-initiation-of-its-first-pivotal-clinical-trial-of-otx-tki-in--ocul-20231003monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-present-at-three-upcoming-investor-conferences-ocul-20230906monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-hypertension-treatment-global-market-report-2023-ocul-20230824monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-present-at-the-h-c-wainwright-3rd-annual-ophthalmology-virtual-confe-ocul-20230809monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-report-second-quarter-2023-financial-results-ocul-20230724monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-appointment-of-new-board-member-ocul-20230712monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-12-month-topline-data-from-ongoing-u-s-based-phase-1-clinical-ocul-20230610monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-completes-enrollment-of-the-helios-clinical-trial-of-otx-tki-for-the-tr-ocul-20230607monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-present-12-month-top-line-data-from-u-s-based-phase-1-clinical-trial-ocul-20230605monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-present-at-the-jefferies-global-healthcare-conference-ocul-20230601monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-present-at-the-jmp-securities-life-sciences-conference-ocul-20230508monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-present-data-at-the-2023-american-society-of-cataract-and-refractive-ocul-20230428monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-report-first-quarter-2023-financial-results-ocul-20230424monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-present-pre-clinical-and-clinical-data-at-the-2023-association-for-r-ocul-20230414monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-present-at-cowen-s-43rd-annual-healthcare-conference-ocul-20230228monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-to-report-fourth-quarter-and-year-end-2022-financial-results-ocul-20230221monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-announces-interim-10-month-data-from-the-ongoing-u-s-phase-1-clinical-t-ocul-20230211monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-drug-delivery-market-is-expected-to-reach-48-103-million-by-2025-progressive-market-ocul-20180731monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-alert-faruqi-faruqi-llp-encourages-investors-who-suffered-losses-exceed-ocul-20170712monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-inc-nasdaq-ocul-to-ring-the-nasdaq-stock-market-opening-bell-ocul-20151211monthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-nasdaq-ocul-to-ring-the-nasdaq-stock-market-closing-bell-ocul-20140731monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-inc-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-m-vrdn-20260331monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-presentations-at-the-2023-annual-meeting-of-the-associatio-vrdn-20230420monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vrdn-20230404monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-presentations-at-the-49th-annual-meeting-of-the-north-amer-vrdn-20230307monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vrdn-20230303monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-to-webcast-fourth-quarter-and-full-year-2022-financial-results-on-ma-vrdn-20230301monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-to-participate-in-cowen-s-43rd-annual-health-care-conference-vrdn-20230228monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-to-participate-in-the-svb-securities-virtual-global-biopharma-confer-vrdn-20230207monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-appoints-scott-myers-as-president-and-chief-executive-officer-vrdn-20230206monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vrdn-20230202monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vrdn-20230105monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-to-webcast-presentation-at-the-41st-annual-j-p-morgan-healthcare-con-vrdn-20230103monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-first-patient-enrolled-in-the-thrive-phase-3-trial-in-pati-vrdn-20221221monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vrdn-20221207monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-to-participate-in-the-evercore-isi-healthconx-conference-vrdn-20221128monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-reports-third-quarter-2022-financial-results-and-provides-corporate--vrdn-20221114monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-announces-positive-data-from-ongoing-phase-1-2-trial-evaluating-vrdn-001-in-patie-vrdn-20221114monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-to-participate-in-guggenheim-4th-annual-neuro-immunology-conference--vrdn-20221108monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-to-report-third-quarter-2022-financial-results-and-host-conference-c-vrdn-20221108monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-presents-positive-clinical-data-from-ongoing-vrdn-001-phase-1-2-trial-in-active-t-vrdn-20221022monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-presentations-at-the-american-thyroid-association-91st-ann-vrdn-20221012monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vrdn-20220902monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-exercise-in-full-and-closing-of-underwriters-option-to-pur-vrdn-20220825monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-pricing-of-upsized-public-offering-of-shares-of-common-sto-vrdn-20220817monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-proposed-underwritten-public-offering-of-common-stock-and--vrdn-20220815monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-announces-positive-initial-clinical-data-from-ongoing-phase-1-2-trial-evaluating--vrdn-20220815monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-to-report-second-quarter-2022-financial-results-and-host-conference--vrdn-20220808monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vrdn-20220805monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vrdn-20220708monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-appoints-carrie-melvin-as-chief-operating-officer-vrdn-20220623monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vrdn-20220603monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-to-participate-in-june-investor-conferences-vrdn-20220601monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-to-report-first-quarter-2022-financial-results-and-host-conference-c-vrdn-20220503monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-to-participate-in-the-21st-annual-needham-virtual-healthcare-confere-vrdn-20220406monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-secures-flexible-credit-facility-for-up-to-75-million-from-hercules--vrdn-20220404monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-doses-first-subject-in-first-in-human-clinical-trial-evaluating-vrdn-vrdn-20220321monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-to-participate-in-32nd-annual-oppenheimer-healthcare-conference-on-m-vrdn-20220314monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-to-report-fourth-quarter-and-full-year-2021-financial-results-and-ho-vrdn-20220303monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-to-participate-in-the-svb-leerink-2022-global-healthcare-conference--vrdn-20220214monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-to-i-vrdn-20220131monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-submits-investigational-new-drug-application-for-vrdn-002-to-the-u-s-vrdn-20220104monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-first-subject-dosed-in-phase-1-2-clinical-trial-of-vrdn-00-vrdn-20211220monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vrdn-20211130monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-fda-clearance-of-investigational-new-drug-ind-application--vrdn-20211115monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-to-present-at-upcoming-investor-conferences-vrdn-20211103monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-submits-investigational-new-drug-application-for-vrdn-001-an-igf-1r--vrdn-20211014monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-to-present-preclinical-data-on-vrdn-001-and-vrdn-002-at-the-90th-ann-vrdn-20210930monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-closing-of-public-offering-of-shares-of-common-stock-and-p-vrdn-20210923monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-pricing-of-public-offering-of-shares-of-common-stock-and-p-vrdn-20210921monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-proposed-underwritten-public-offering-of-common-stock-and--vrdn-20210920monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-to-participate-in-the-wedbush-pacgrow-healthcare-virtual-conference-vrdn-20210805monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-appoints-kristian-humer-as-chief-financial-officer-and-chief-busines-vrdn-20210726monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-appoints-jennifer-moses-cpa-to-the-board-of-directors-and-as-chair-o-vrdn-20210715monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-vrdn-20210714monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-to-present-at-the-ladenburg-thalmann-2021-healthcare-conference-vrdn-20210707monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-to-participate-in-the-jmp-securities-life-sciences-conference-vrdn-20210610monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-to-participate-in-upcoming-investor-conferences-vrdn-20210514monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-to-host-conference-call-discussing-fourth-quarter-and-full-year-2020-vrdn-20210309monthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-to-present-at-three-upcoming-investor-conferences-vrdn-20210222monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20260619monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-clearance-of-investigational-new-drug-ind-application-fo-iova-20260601monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20260522monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20260417monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20260320monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20260220monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20260116monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20251121monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-investigation-reminder-bragar-eagel-squire-p-c-continues-investigation-on-behalf-o-iova-20251029monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-iova-alert-bragar-eagel-squire-p-c-continues-investigation-into-iovance-biotherape-iova-20251008monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20250919monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20250822monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-second-quarter-and-first-half-2025-financial-results-and-c-iova-20250724monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20250718monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-investigation-alert-bragar-eagel-squire-p-c-is-investigating-iovance-biotherapeuti-iova-20250715monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-deadline-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-b-iova-20250712monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-appoints-marc-r-theoret-m-d-as-senior-vice-president-regulatory-st-iova-20250710monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your--iova-20250709monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-s-iova-cfo-resigns-amid-launch-setbacks-and-legal-pressure-hagens-berman-iova-20250702monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-s-iova-cfo-resigns-amid-launch-setbacks-and-legal-pressure-hagens-berman-iova-20250630monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-befo-iova-20250627monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-s-iova-promising-cell-therapy-falters-triggering-ubs-downgrades-and-investor-lawsu-iova-20250627monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-s-iova-cfo-resigns-amid-launch-setbacks-and-legal-pressure-hagens-berman-iova-20250626monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20250623monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-s-iova-cfo-resigns-amid-launch-setbacks-and-legal-pressure-hagens-berman-iova-20250623monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-s-iova-cfo-resigns-amid-launch-setbacks-and-legal-pressure-hagens-berman-iova-20250618monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick--iova-20250618monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-s-iova-promising-cell-therapy-falters-triggering-ubs-downgrades-and-investor-lawsu-iova-20250613monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gros-iova-20250612monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-exc-iova-20250612monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-s-iova-promising-cell-therapy-falters-triggering-ubs-downgrades-and-investor-lawsu-iova-20250611monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick--iova-20250611monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-sued-for-securities-law-violations-investors-should-contact-le-iova-20250610monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conference-iova-20250610monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-s-iova-promising-cell-therapy-falters-triggering-ubs-downgrades-and-investor-lawsu-iova-20250609monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-s-iova-promising-cell-therapy-falters-triggering-ubs-downgrades-and-investor-lawsu-iova-20250606monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-exc-iova-20250605monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-s-iova-promising-cell-therapy-falters-triggering-ubs-downgrades-and-investor-lawsu-iova-20250604monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick--iova-20250604monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-s-iova-promising-cell-therapy-falters-triggering-ubs-downgrades-and-investor-lawsu-iova-20250602monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-s-iova-promising-cell-therapy-falters-triggering-ubs-downgrades-and-investor-lawsu-iova-20250529monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-exc-iova-20250529monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick--iova-20250528monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-iova-faces-investor-lawsuit-over-growth-projections-following-stoc-iova-20250527monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-announces-five-year-results-of-amtagvi-lifileucel-in-patients-with-advanced-melano-iova-20250522monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-iova-faces-investor-lawsuit-over-growth-projections-following-stoc-iova-20250522monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-exc-iova-20250522monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-iova-faces-investor-lawsuit-over-growth-projections-following-stoc-iova-20250519monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-iova-20250517monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20250516monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-iova-annual-maintenance-assurances-collide-with-adverse-disclosure-iova-20250514monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-alert-bragar-eagel-squire-p-c-is-investigating-iovance-biotherapeutics-inc-on-beha-iova-20250514monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-iova-annual-maintenance-assurances-collide-with-adverse-disclosure-iova-20250512monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-first-quarter-2025-financial-results-and-corporate-updates-iova-20250502monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-participation-in-upcoming-scientific-congresses-iova-20250423monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20250418monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20250321monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20250221monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-and--iova-20250218monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20250212monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20250117monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20241220monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-the-promotion-of-raj-puri-m-d-ph-d-to-chief-regulatory-o-iova-20241126monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-third-quarter-and-year-to-date-2024-financial-results-conf-iova-20241031monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conferences-iova-20240903monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20240816monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-second-quarter-and-first-half-2024-financial-results-confe-iova-20240729monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20240719monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20240621monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conferences-and-events-iova-20240524monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20240517monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-first-quarter-2024-financial-results-conference-call-and-w-iova-20240501monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conferences-iova-20240430monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-clinical-and-translational-data-at-2024-asco-annual-mee-iova-20240424monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20240419monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20240322monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conferences-iova-20240301monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-fourth-quarter-and-full-year-2023-financial-results-confer-iova-20240222monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20240216monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-conference-call-and-webcast-on-friday-february-16-2024-iova-20240216monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-s-amtagvi-lifileucel-receives-u-s-fda-accelerated-approval-for-advanced-melanoma-iova-20240216monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20240119monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20231222monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20231117monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-third-quarter-and-year-to-date-2023-financial-results-conf-iova-20231031monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-clinical-and-pre-clinical-data-for-tumor-infiltrating-l-iova-20231031monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20231020monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-clinical-data-for-lifileucel-in-advanced-mucosal-melanom-iova-20231016monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-clinical-and-pre-clinical-data-for-tumor-infiltrating-l-iova-20230927monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20230922monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-2023-wells-fargo-healthcare-conference-iova-20230907monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20230818monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-clinical-data-for-tumor-infiltrating-lymphocyte-til-the-iova-20230725monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-second-quarter-2023-financial-results-conference-call-and--iova-20230724monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20230721monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-announces-pricing-of-its-public-offering-of-150-million-of-com-iova-20230711monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-virtual-roundtable-with-key-opinion-leaders-to-discuss-mel-iova-20230620monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-first-patient-randomized-in-phase-3-tilvance-301-trial-i-iova-20230615monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-jefferies-global-healthcare-conference-iova-20230609monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-u-s-food-and-drug-administration-acceptance-of-the-biolo-iova-20230526monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-first-quarter-2023-financial-results-conference-call-and-w-iova-20230502monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conferences-iova-20230424monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conferences-iova-20230301monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-fourth-quarter-and-full-year-2022-financial-results-confer-iova-20230221monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conferences-iova-20221130monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-provides-update-on-biologics-license-application-submission-for-li-iova-20221118monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-updated-clinical-data-for-lifileucel-in-advanced-melanom-iova-20221110monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-updated-clinical-data-for-lifileucel-in-advanced-melanom-iova-20221107monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-third-quarter-financial-results-conference-call-and-webcas-iova-20221024monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-first-patient-dosed-with-pd-1-inactivated-tumor-infiltra-iova-20221010monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphoc-iova-20221005monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conferences-iova-20220906monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-posters-at-esmo-2022-iova-20220906monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-second-quarter-financial-results-conference-call-and-webca-iova-20220727monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20220722monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20220617monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conferences-iova-20220608monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20220520monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-translational-data-for-lifileucel-in-advanced-melanoma--iova-20220427monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-first-quarter-financial-results-conference-call-and-webcas-iova-20220426monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-chardan-genetic-medicines-and-cell-therapy-manufactu-iova-20220425monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20220422monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conferences-iova-20220316monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20220315monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-investigational-new-drug-application-ind-allowed-to-proceed-for-ta-iova-20220315monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-american-association-for-cancer-research-aacr-2022-a-iova-20220308monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20220218monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-fourth-quarter-and-full-year-financial-results-conference--iova-20220211monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20220121monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-data-on-tumor-infiltrating-lymphocyte-til-cell-therapy--iova-20220107monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-on--iova-20220106monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20211217monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conferences-iova-20211207monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-iova-20211119monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-clinical-data-for-lifileucel-in-combination-with-pembrol-iova-20211113monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-clinical-data-for-tumor-infiltrating-lymphocyte-til-cell-iova-20211109monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conferences-iova-20211108monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-third-quarter-financial-results-conference-call-and-webcas-iova-20211025monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-highlight-data-at-society-f-iova-20211018monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-clinical-data-for-tumor-infiltrating-lymphocyte-til-cel-iova-20211001monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-celebrates-grand-opening-of-iovance-cell-therapy-center-ictc-in-th-iova-20210928monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-initiates-clinical-supply-of-tumor-infiltrating-lymphocyte-til-cel-iova-20210923monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-second-quarter-financial-results-conference-call-and-webca-iova-20210719monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-l-iova-20210629monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-33-month-follow-up-data-for-lifileucel-in-advanced-melan-iova-20210606monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-clinical-data-for-lifileucel-in-combination-with-pembrol-iova-20210604monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conferences-iova-20210601monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-clinical-data-updates-for-lifileucel-in-advanced-melanom-iova-20210519monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conferences-iova-20210504monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-in-advanced-melanoma-at-as-iova-20210428monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-first-quarter-financial-results-conference-call-and-webcas-iova-20210427monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-clinical-data-updates-for-lifileucel-in-advanced-melanom-iova-20210409monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-updated-clinical-data-for-tumor-infiltrating-lymphocyte-iova-20210310monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-healthcare-conferences-iova-20210301monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-fourth-quarter-and-full-year-2020-financial-results-confer-iova-20210218monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-healthcare-conferences-iova-20210119monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-on--iova-20201228monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conferences-in-december-iova-20201130monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-presents-clinical-data-in-head-and-neck-cancer-at-society-for-immu-iova-20201109monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-third-quarter-2020-financial-results-conference-call-and-w-iova-20201030monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conferences-in-november-iova-20201028monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-clinical-data-in-head-and-neck-cancer-at-society-for-im-iova-20201014monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-october-conferences-iova-20201006monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-provides-update-for-lifileucel-in-metastatic-melanoma-iova-20201005monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-btig-biotechnology-conference-2020-iova-20200807monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-second-quarter-2020-financial-results-conference-call-and--iova-20200723monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-june-conferences-iova-20200608monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-presents-updated-clinical-data-for-tumor-infiltrating-lymphocyte-til-therapy-lifil-iova-20200529monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-announces-pricing-of-its-public-offering-of-approximately-525--iova-20200529monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-clinical-data-updates-for-lifileucel-in-advanced-melanom-iova-20200513monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-updated-data-from-clinical-study-in-advanced-melanoma-a-iova-20200429monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-first-quarter-2020-financial-results-conference-call-and-w-iova-20200427monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-h-lee-moffitt-cancer-center-to-present-lung-cancer-clini-iova-20200413monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conferences-iova-20200302monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-fourth-quarter-and-full-year-2019-financial-results-confer-iova-20200219monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-healthcare-conferences-iova-20200212monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-completes-patient-dosing-in-registration-enabling-cohort-4-of-the--iova-20200115monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-obtains-license-to-develop-and-commercialize-a-novel-il-2-analog-iova-20200112monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-and-cellectis-enter-into-a-research-collaboration-and-exclusive-wo-iova-20200112monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-investor-conferences-in-december-iova-20191202monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-results-of-a-subgroup-analysis-of-patients-in-the-lifile-iova-20191121monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-updated-phase-2-clinical-data-from-the-lifileucel-metast-iova-20191108monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-investor-conferences-in-november-iova-20191107monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-third-quarter-2019-financial-results-conference-call-and-w-iova-20191031monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-four-abstracts-to-be-presented-at-the-upcoming-2019-sitc-iova-20191002monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conferences-iova-20190927monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-investor-conferences-in-september-iova-20190826monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-second-quarter-2019-financial-results-conference-call-and--iova-20190726monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-appoints-friedrich-graf-finckenstein-m-d-as-chief-medical-officer-iova-20190718monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-provides-cervical-cancer-program-updates-following-end-of-phase-2--iova-20190702monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-participate-in-upcoming-conferences-in-june-iova-20190531monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-new-facility-to-support-u-s-production-of-tumor-infiltra-iova-20190529monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-participate-in-upcoming-conferences-in-may-iova-20190502monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-first-quarter-2019-financial-results-conference-call-and-w-iova-20190501monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-new-data-from-ongoing-studies-of-tumor-infiltrating-lym-iova-20190403monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-clinical-programs-update-iova-20190403monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-first-patient-dosed-in-cohort-4-of-pivotal-innovatil-01--iova-20190402monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-presents-data-at-aacr-annual-meeting-on-t-cell-diversity-and-persi-iova-20190401monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-april-scientific-and-investor-presentations-iova-20190329monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march-iova-20190306monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-was-granted-fast-track-designation-for-ln-145-for-cervical-cancer-iova-20190226monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-fourth-quarter-and-year-end-2018-financial-results-confere-iova-20190222monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-investor-and-medical-conferences-iova-20190201monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-iova-20181221monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-participate-at-november-investor-conferences-iova-20181113monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-updated-phase-2-clinical-data-from-the-lifileucel-metast-iova-20181106monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-third-quarter-2018-financial-results-conference-call-and-w-iova-20181030monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-melanoma-program-update-event-for-analysts-and-investors-d-iova-20181029monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-and-masthercell-announce-new-manufacturing-services-agreement-in-e-iova-20181018monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-announces-pricing-of-its-public-offering-of-approximately-220--iova-20181012monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-the-2018-cantor-global-healthcare-conference-iova-20180926monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-two-investor-conferences-in-september-iova-20180829monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-clinical-trial-updates-with-collaborators-md-anderson-an-iova-20180816monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-second-quarter-2018-financial-results-conference-call-and--iova-20180730monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-first-patient-dosed-in-europe-for-ongoing-c-144-01-phase-iova-20180607monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-two-investor-conferences-in-june-iova-20180531monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-first-quarter-2018-financial-results-conference-call-and-w-iova-20180503monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-two-upcoming-investor-conferences-in-may-iova-20180502monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-conference-call-to-discuss-fourth-quarter-and-year-end-201-iova-20180308monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-two-upcoming-investor-conferences-in-march-iova-20180307monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-the-rbc-capital-markets-2018-global-healthcare-confe-iova-20180214monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-announces-pricing-of-its-public-offering-of-150-million-of-com-iova-20180125monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-manufacturing-decision-provides-clinical-updates-and-hig-iova-20171213monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-expands-pipeline-of-til-therapies-into-lung-cancer-iova-20171213monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-webcast-analyst-day-on-wednesday-december-13-2017-iova-20171207monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-the-evercore-isi-biopharma-catalyst-deep-dive-confer-iova-20171128monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-the-jefferies-2017-london-healthcare-conference-iova-20171113monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-new-ln-144-phase-2-clinical-data-from-metastatic-melanom-iova-20171109monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-conference-call-to-discuss-third-quarter-2017-financial-re-iova-20171025monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-six-abstracts-to-be-presented-at-the-upcoming-2017-sitc--iova-20171011monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-inc-announces-pricing-of-its-public-offering-of-50-million-of-comm-iova-20170920monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-approval-of-first-clinical-trial-application-by-competen-iova-20170913monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-partners-with-trakcel-for-personalized-patient-product-management-iova-20170911monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-enters-into-a-research-collaboration-focused-on-hematologic-malign-iova-20170907monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-at-two-upcoming-september-conferences-iova-20170905monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-present-data-at-upcoming-esmo-2017-congress-on-tumor-infiltrati-iova-20170831monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-announces-first-patient-dosed-in-c-145-04-phase-2-trial-in-cervica-iova-20170816monthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-to-host-conference-call-to-discuss-second-quarter-2017-financial-a-iova-20170725monthly0.5https://www.biopharmawatch.com/news/ATAI/ataibeckley-launches-patient-impact-grant-program-for-mental-health-non-profit-organizatio-atai-20260528monthly0.5https://www.biopharmawatch.com/news/ATAI/ataibeckley-to-participate-in-upcoming-needham-healthcare-conferences-atai-20260414monthly0.5https://www.biopharmawatch.com/news/ATAI/ataibeckley-completes-redomiciliation-to-the-united-states-atai-20251230monthly0.5https://www.biopharmawatch.com/news/ATAI/ataibeckley-added-to-the-nasdaq-biotechnology-index-nbi-atai-20251223monthly0.5https://www.biopharmawatch.com/news/ATAI/ataibeckley-to-participate-in-the-jefferies-global-healthcare-conference-in-london-atai-20251113monthly0.5https://www.biopharmawatch.com/news/ATAI/ataibeckley-reports-third-quarter-2025-financial-results-and-recent-corporate-highlights-atai-20251112monthly0.5https://www.biopharmawatch.com/news/ATAI/ataibeckley-announces-positive-topline-data-from-the-phase-2b-open-label-extension-study-o-atai-20251110monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-showcases-revuforj-revumenib-clinical-activity-in-multiple-acute-leukemia-subtypes--sndx-20260611monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-publication-of-save-data-on-revuforj-revumenib-in-combination-with-decita-sndx-20260611monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sndx-20260604monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-highlights-12-revuforj-revumenib-abstracts-accepted-for-eha-2026-advancing-leadersh-sndx-20260512monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sndx-20260506monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sndx-20260403monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-to-announce-fourth-quarter-and-full-year-2025-financial-results-and-host-conference-sndx-20260219monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sndx-20251003monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sndx-20250905monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-participation-in-september-investor-conferences-sndx-20250826monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sndx-20250806monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-to-announce-second-quarter-2025-financial-results-and-host-conference-call-and-webc-sndx-20250728monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sndx-20250702monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-fda-priority-review-of-snda-for-revuforj-revumenib-in-relapsed-or-refract-sndx-20250624monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-publication-of-revumenib-data-from-the-beat-aml-trial-in-the-journal-of-c-sndx-20250612monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-presents-new-revuforj-revumenib-data-in-relapsed-refractory-mnpm1-and-nup98r-acute--sndx-20250612monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sndx-20250605monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-participation-in-june-investor-conferences-sndx-20250529monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-data-presentations-at-eha-2025-showcasing-revuforj-revumenib-and-niktimvo-sndx-20250514monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-participation-in-may-investor-conferences-sndx-20250508monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-publication-of-pivotal-revumenib-data-in-relapsed-or-refractory-mnpm1-acu-sndx-20250507monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sndx-20250502monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-to-announce-first-quarter-2025-financial-results-and-host-conference-call-and-webca-sndx-20250428monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sndx-20250404monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum-sndx-20250402monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sndx-20250305monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-participation-in-march-investor-conferences-sndx-20250225monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-sndx-20250224monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-prices-public-offering-of-common-stock-sndx-20170524monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-proposed-public-offering-of-common-stock-sndx-20170523monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-results-from-phase-2-encore-601-trial-of-entinostat-in-combination-with-k-sndx-20170517monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-announces-advancement-of-encore-601-in-non-small-cell-lung-cancer-p-sndx-20170516monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-to-present-at-the-2017-ubs-global-healthcare-conference-sndx-20170515monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-to-announce-first-quarter-2017-financial-results-and-host-conference-call-and-webca-sndx-20170501monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-expansion-of-immuno-oncology-collaboration-evaluating-entinostat-in-combi-sndx-20170427monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-entinostat-data-to-be-presented-at-the-2017-american-society-of-clinical--sndx-20170420monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-presentations-at-the-2017-american-association-for-cancer-research-annual-sndx-20170329monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-announces-participation-at-three-upcoming-investor-conferences-sndx-20170227monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-to-announce-fourth-quarter-and-year-end-2016-financial-results-and-host-conference--sndx-20170216monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-appoints-lisa-m-coussens-ph-d-to-scientific-advisory-board-sndx-20170131monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-adds-global-pharmaceutical-business-veteran-to-board-of-directors-sndx-20170105monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-announces-collaboration-with-the-national-cancer-institute-to-devel-sndx-20161214monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-to-present-at-the-28th-annual-piper-jaffray-healthcare-conference-sndx-20161121monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-to-present-at-the-sitc-31st-annual-scientific-meeting-sndx-20161108monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-to-announce-third-quarter-2016-financial-results-and-host-conference-call-and-webca-sndx-20161028monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-announces-participation-at-four-upcoming-investor-conferences-sndx-20160906monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-appoints-leading-experts-to-scientific-advisory-board-sab-sndx-20160727monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-to-announce-second-quarter-2016-financial-results-and-host-conference-call-and-webc-sndx-20160720monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-to-present-at-the-cantor-fitzgerald-2nd-annual-healthcare-conferenc-sndx-20160707monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-to-present-at-the-jmp-securities-life-sciences-conference-sndx-20160614monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-to-announce-first-quarter-2016-financial-results-and-host-conference-call-and-live--sndx-20160426monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-entinostat-data-to-be-presented-at-the-american-association-for-cancer-re-sndx-20160411monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-inc-nasdaq-sndx-to-ring-the-nasdaq-stock-market-opening-bell-in-cel-sndx-20160303monthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-announces-pricing-of-initial-public-offering-sndx-20160302monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-holdings-company-investigated-by-the-portnoy-law-firm-hrmy-20230330monthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-holdings-shareholder-news-johnson-fistel-urges-investors-with-losses-t-hrmy-20230328monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-first-quarter-2026-financial-results-and-raises-full-year-financial-guidan-vcel-20260507monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-on-wednesday-januar-vcel-20260106monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-third-quarter-2025-financial-results-on-november-6-2025-vcel-20251023monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-second-quarter-2025-financial-results-vcel-20250731monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-first-quarter-2025-financial-results-on-may-8-2025-vcel-20250424monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-fourth-quarter-and-full-year-2024-financial-results-vcel-20250227monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-fourth-quarter-and-full-year-2024-financial-results-on-february-27-2025-vcel-20250213monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-preliminary-2024-financial-results-2025-financial-guidance-and-increased-vcel-20250114monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-on-wednesday-januar-vcel-20250108monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-third-quarter-2024-financial-results-vcel-20241107monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-third-quarter-2024-financial-results-on-november-7-2024-vcel-20241024monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-morgan-stanley-global-healthcare-conference-on-friday-september--vcel-20240829monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-fda-approval-and-commercial-availability-of-maci-arthro-vcel-20240826monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-fda-approval-of-nexobrid-for-the-treatment-of-pediatric-patients-with-se-vcel-20240815monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-canaccord-genuity-growth-conference-on-wednesday-august-14-2024-vcel-20240807monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-second-quarter-2024-financial-results-vcel-20240801monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-appointment-of-karen-mahoney-as-chief-human-resources-officer-vcel-20240722monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-second-quarter-2024-financial-results-on-august-1-2024-vcel-20240718monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-truist-securities-medtech-conference-on-tuesday-june-18-2024-vcel-20240611monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-leerink-partners-healthcare-crossroads-conference-on-wednesday-m-vcel-20240522monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-first-quarter-2024-financial-results-and-raises-full-year-2024-financial-g-vcel-20240508monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-first-quarter-2024-financial-results-on-may-8-2024-vcel-20240424monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-full-year-vcel-20240229monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-td-cowen-44th-annual-health-care-conference-on-tuesday-march-5-2-vcel-20240227monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-fourth-quarter-and-full-year-2023-financial-results-on-february-29-2024-vcel-20240215monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-canaccord-genuity-musculoskeletal-conference-on-monday-february--vcel-20240205monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-preliminary-full-year-and-fourth-quarter-2023-financial-results-vcel-20240109monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-on-wednesday-januar-vcel-20240103monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-third-quarter-2023-financial-results-and-raises-full-year-2023-financial-g-vcel-20231108monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-stephens-annual-investment-conference-vcel-20231107monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-third-quarter-2023-financial-results-on-november-8-2023-vcel-20231025monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-publication-of-positive-results-from-phase-3-debride-and-protect-detect--vcel-20230928monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-u-s-commercial-availability-of-nexobrid-anacaulase-bcdb-for-the-treatmen-vcel-20230920monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-morgan-stanley-global-healthcare-conference-vcel-20230906monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-second-quarter-2023-financial-results-and-raises-full-year-2023-financial--vcel-20230802monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-second-quarter-2023-financial-results-on-august-2-2023-vcel-20230720monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-first-quarter-2023-financial-results-and-raises-full-year-2023-financial-g-vcel-20230510monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-first-quarter-2023-financial-results-on-may-10-2023-vcel-20230426monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-canaccord-genuity-musculoskeletal-conference-on-tuesday-march-7--vcel-20230228monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-full-year-vcel-20230223monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-fourth-quarter-2022-financial-results-on-february-23-2023-vcel-20230209monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-on-wednesday-januar-vcel-20230104monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-fda-approval-of-nexobrid-for-the-treatment-of-severe-thermal-burns-in-ad-vcel-20221229monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-ser-vcel-20221110monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-third-quarter-2022-financial-results-vcel-20221109monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-third-quarter-2022-financial-results-on-november-9-2022-vcel-20221026monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-ladenburg-thalmann-healthcare-conference-vcel-20220922monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-morgan-stanley-global-healthcare-and-h-c-wainwright-global-inves-vcel-20220906monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-second-quarter-2022-financial-results-vcel-20220803monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-publication-of-positive-results-from-retrospective-study-by-the-burn-and-vcel-20220721monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-second-quarter-2022-financial-results-on-august-3-2022-vcel-20220720monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-first-quarter-2022-financial-results-vcel-20220504monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-first-quarter-2022-financial-results-on-may-4-2022-vcel-20220420monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-canaccord-genuity-musculoskeletal-conference-on-march-22-2022-vcel-20220315monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-cowen-42nd-annual-health-care-conference-on-march-9-2022-vcel-20220301monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-appointment-of-jonathan-siegal-as-principal-accounting-officer-vcel-20220224monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-full-year-vcel-20220224monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-fourth-quarter-2021-financial-results-on-february-24-2022-vcel-20220210monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-plans-for-a-new-state-of-the-art-cell-therapy-manufacturing-facility-to--vcel-20220202monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-on-wednesday-januar-vcel-20220104monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-canaccord-genuity-virtual-medtech-diagnostics-and-digital-health-vcel-20211111monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-third-quarter-2021-financial-results-vcel-20211109monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-third-quarter-2021-financial-results-on-november-9-2021-vcel-20211021monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-participate-in-the-morgan-stanley-19th-annual-global-healthcare-conference-on-s-vcel-20210908monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-expands-executive-leadership-team-and-announces-appointment-of-patrick-fowler-as-s-vcel-20210907monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-second-quarter-2021-financial-results-and-raises-full-year-2021-revenue-gu-vcel-20210804monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-investors-company-investigated-by-the-portnoy-law-firm-vcel-20210722monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-second-quarter-2021-financial-results-on-august-4-2021-vcel-20210721monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-ladenburg-thalmann-healthcare-conference-on-tuesday-july-13-2021-vcel-20210707monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-provides-regulatory-update-for-nexobrid-vcel-20210629monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-goldman-sachs-42nd-annual-global-healthcare-conference-on-thursd-vcel-20210609monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-appointment-of-lisa-wright-to-board-of-directors-vcel-20210602monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-canaccord-genuity-virtual-musculoskeletal-conference-on-thursday-vcel-20210513monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-first-quarter-2021-financial-results-and-raises-full-year-2021-revenue-gui-vcel-20210505monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-first-quarter-2021-financial-results-on-may-5-2021-vcel-20210421monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-20th-annual-needham-virtual-healthcare-conference-on-thursday-ap-vcel-20210409monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-oppenheimer-31st-annual-healthcare-conference-on-wednesday-march-vcel-20210310monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-webcast-of-presentation-at-upcoming-h-c-wainwright-virtual-global-life-s-vcel-20210302monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-full-year-vcel-20210224monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-svb-leerink-10th-annual-global-healthcare-conference-on-thursday-vcel-20210222monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-participate-in-the-btig-virtual-medtech-digital-health-life-science-diagnostic--vcel-20210216monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-termination-of-shareholder-rights-agreement-vcel-20210212monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-fourth-quarter-2020-financial-results-on-february-24-2021-vcel-20210210monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-appointment-of-joe-mara-as-chief-financial-officer-vcel-20210125monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-preliminary-fourth-quarter-and-full-year-2020-financial-results-and-prov-vcel-20210111monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-23rd-annual-needham-growth-conference-on-friday-january-15-2021-vcel-20210108monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-expansion-of-maci-coverage-by-unitedhealthcare-to-include-patella-and-mu-vcel-20210107monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-on-thursday-january-vcel-20201218monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-record-third-quarter-revenues-and-net-income-vcel-20201105monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-upcoming-investor-conferences-vcel-20201102monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-third-quarter-2020-financial-results-on-november-5-2020-vcel-20201022monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-preliminary-third-quarter-2020-total-net-revenues-of-32-million-vcel-20201014monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-host-virtual-analyst-and-investor-day-on-october-16-2020-vcel-20201009monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-fda-acceptance-of-biologics-license-application-for-nexobrid-for-the-tre-vcel-20200916monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-multiple-upcoming-investor-conferences-vcel-20200909monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-18th-annual-morgan-stanley-global-healthcare-conference-on-thurs-vcel-20200904monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-second-quarter-2020-financial-results-vcel-20200805monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-second-quarter-2020-financial-results-on-august-5-2020-vcel-20200722monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-preliminary-second-quarter-2020-financial-results-and-provides-business--vcel-20200709monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-ubs-virtual-global-healthcare-conference-on-wednesday-may-20-202-vcel-20200513monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-first-quarter-2020-financial-results-vcel-20200505monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-first-quarter-2020-financial-results-on-may-5-2020-vcel-20200422monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-change-to-a-virtual-meeting-format-for-2020-annual-meeting-of-shareholde-vcel-20200410monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-19th-annual-needham-healthcare-conference-on-tuesday-april-14-20-vcel-20200408monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-provides-business-and-financial-updates-vcel-20200402monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-full-year-vcel-20200225monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-40th-annual-cowen-healthcare-conference-on-monday-march-2-2020-vcel-20200224monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-9th-annual-svb-leerink-global-healthcare-conference-on-wednesday-vcel-20200219monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-fourth-quarter-2019-financial-results-on-february-25-2020-vcel-20200211monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-22nd-annual-needham-growth-conference-on-wednesday-january-15-20-vcel-20200109monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-appointment-of-sean-c-flynn-as-vice-president-and-general-counsel-vcel-20191106monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-record-third-quarter-revenues-net-income-and-operating-cash-flow-vcel-20191105monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-third-quarter-2019-financial-results-on-november-5-2019-vcel-20191022monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-and-mediwound-announce-initiation-of-u-s-nexobrid-expanded-access-treatment-protoc-vcel-20191002monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-2019-cantor-fitzgerald-global-healthcare-conference-on-friday-oc-vcel-20190927monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-ladenburg-thalmann-2019-healthcare-conference-on-tuesday-septemb-vcel-20190918monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-17th-annual-morgan-stanley-global-healthcare-conference-on-wedne-vcel-20190904monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-second-quarter-2019-financial-results-and-raises-full-year-2019-revenue-gu-vcel-20190806monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-39th-annual-canaccord-genuity-growth-conference-on-thursday-augu-vcel-20190801monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-second-quarter-2019-financial-results-on-august-6-2019-vcel-20190723monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-2019-ubs-global-healthcare-conference-on-wednesday-may-22-2019-vcel-20190515monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-first-quarter-2019-financial-results-and-raises-full-year-2019-revenue-gui-vcel-20190507monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-enters-into-exclusive-license-agreement-with-mediwound-for-north-american-rights-t-vcel-20190507monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-first-quarter-2019-financial-results-on-may-7-2019-vcel-20190425monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-needham-healthcare-conference-vcel-20190403monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-multiple-upcoming-investor-conferences-vcel-20190304monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-fourth-quarter-and-full-year-2018-financial-results-and-provides-full-year-vcel-20190226monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-participate-in-multiple-upcoming-investor-conferences-vcel-20190220monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-fourth-quarter-2018-financial-results-on-february-26-2019-vcel-20190212monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-21st-annual-needham-growth-conference-vcel-20190111monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-publication-of-outcomes-data-from-954-burn-patients-treated-with-epicel-in-vcel-20190104monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-record-third-quarter-revenues-of-22-5-million-and-raises-full-year-2018-re-vcel-20181106monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-canaccord-genuity-medical-technologies-diagnostic-forum-vcel-20181101monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-third-quarter-2018-financial-results-on-november-6-2018-vcel-20181023monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-multiple-upcoming-conferences-vcel-20180921monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-appointment-of-jonathan-hopper-as-chief-medical-officer-vcel-20180820monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-record-second-quarter-revenues-of-19-0-million-and-raises-full-year-2018-r-vcel-20180806monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-38th-annual-canaccord-genuity-growth-conference-vcel-20180726monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-second-quarter-2018-financial-results-on-august-6-2018-vcel-20180723monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-added-to-russell-3000-index-vcel-20180625monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-announces-closing-of-74-8-million-public-offering-and-full-exercise-of-vcel-20180605monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-prices-65-million-public-offering-of-common-stock-vcel-20180601monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-announces-proposed-public-offering-of-common-stock-vcel-20180530monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-jefferies-2018-global-healthcare-conference-vcel-20180525monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-first-quarter-2018-financial-results-vcel-20180508monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-first-quarter-2018-financial-results-on-may-8-2018-vcel-20180424monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-6th-annual-cell-gene-therapy-investor-day-vcel-20180410monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-publication-of-results-from-the-phase-3-summit-extension-study-demonstrati-vcel-20180323monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-17th-annual-needham-healthcare-conference-vcel-20180313monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-host-analyst-and-investor-day-on-april-11-2018-vcel-20180312monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-biocentury-s-25th-annual-future-leaders-in-the-biotech-industry-conf-vcel-20180309monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-fourth-quarter-and-year-end-2017-financial-results-and-provides-full-year--vcel-20180305monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-13th-annual-canaccord-genuity-musculoskeletal-conference-vcel-20180226monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-report-fourth-quarter-and-full-year-2017-financial-results-on-march-5-2018-vcel-20180222monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-bio-ceo-investor-conference-vcel-20180205monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-7th-annual-leerink-partners-global-healthcare-conference-vcel-20180201monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-20th-annual-needham-growth-conference-vcel-20180110monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-initiates-collaboration-with-innovative-cellular-therapeutics-vcel-20180102monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-enters-into-expanded-25-million-debt-facilities-with-silicon-valley-bank-and-midca-vcel-20171207monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-29th-annual-piper-jaffray-healthcare-conference-vcel-20171116monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-third-quarter-2017-financial-results-vcel-20171107monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-host-third-quarter-2017-earnings-webcast-and-conference-call-on-november-7-2017-vcel-20171025monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-provides-business-updates-at-2017-cell-gene-meeting-on-the-mesa-vcel-20171005monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-2017-cell-gene-meeting-on-the-mesa-vcel-20170927monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-ladenburg-thalmann-2017-healthcare-conference-vcel-20170920monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-second-quarter-2017-financial-results-vcel-20170809monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-host-second-quarter-2017-earnings-webcast-and-conference-call-on-august-9-2017-vcel-20170726monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-host-symposium-on-maci-implant-for-treating-articular-cartilage-defects-in-the--vcel-20170713monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-first-quarter-2017-financial-results-vcel-20170510monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-ixmyeloce-vcel-20170510monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-host-first-quarter-2017-earnings-webcast-and-conference-call-on-may-10-2017-vcel-20170504monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-5th-annual-cell-gene-therapy-investor-day-vcel-20170420monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-appointment-of-michael-halpin-as-senior-vice-president-quality-and-regul-vcel-20170410monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-the-16th-annual-needham-healthcare-conference-vcel-20170328monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-fourth-quarter-and-year-end-2016-financial-results-vcel-20170310monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-host-fourth-quarter-2016-earnings-webcast-and-conference-call-on-march-10-2017-vcel-20170303monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-multiple-upcoming-investor-conferences-vcel-20170227monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-receives-fda-fast-track-designation-for-ixmyelocel-t-an-investigational-product-fo-vcel-20170221monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-first-maci-implant-in-the-united-states-for-the-treatment-of-symptomatic-vcel-20170201monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-announces-exercise-of-underwriters-over-allotment-option-and-closing-o-vcel-20161221monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-prices-17-million-public-offering-of-common-stock-vcel-20161216monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-corporation-announces-proposed-public-offering-of-common-stock-vcel-20161215monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-28th-annual-piper-jaffray-healthcare-conference-vcel-20161122monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-third-quarter-2016-financial-results-vcel-20161107monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-host-third-quarter-2016-earnings-webcast-and-conference-call-on-november-7-2016-vcel-20161031monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-2016-cell-gene-meeting-on-the-mesa-vcel-20160926monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-ladenburg-thalmann-healthcare-conference-vcel-20160921monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-enters-into-expanded-20-million-credit-facility-and-term-loan-with-silicon-valley--vcel-20160912monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-data-at-the-american-heart-association-s-scientific-sessions-2016-on-th-vcel-20160907monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-second-quarter-2016-financial-results-vcel-20160808monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-host-second-quarter-2016-earnings-webcast-and-conference-call-on-august-8-2016-vcel-20160801monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-cantor-fitzgerald-s-2nd-annual-healthcare-conference-vcel-20160706monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-first-quarter-2016-financial-results-vcel-20160510monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-host-first-quarter-2016-earnings-webcast-and-conference-call-on-may-10-2016-vcel-20160427monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-15th-annual-needham-healthcare-conference-vcel-20160408monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-host-review-of-positive-phase-2b-ixcell-dcm-trial-results-following-american-co-vcel-20160329monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-publication-of-clinical-trial-rationale-and-study-design-for-the-phase-2-vcel-20160328monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-fourth-quarter-and-year-end-2015-financial-results-vcel-20160314monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-positive-top-line-results-from-phase-2b-ixcell-dcm-clinical-trial-of-ixm-vcel-20160310monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-enters-into-10-million-credit-facility-and-5-million-term-loan-agreement-with-sili-vcel-20160309monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-28th-annual-roth-conference-vcel-20160308monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-fda-acceptance-for-filing-of-bla-for-maci-for-the-treatment-of-symptomat-vcel-20160307monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-host-fourth-quarter-2015-earnings-webcast-and-conference-call-on-march-14-2016-vcel-20160226monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-canaccord-genuity-investor-conference-vcel-20160224monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-fda-approval-of-epicel-hde-supplement-vcel-20160222monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-submits-biologics-license-application-to-the-fda-for-maci-for-the-treatment-of-car-vcel-20160104monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-submits-hde-supplement-to-the-fda-to-revise-the-labeled-indications-for-use-and-ad-vcel-20151208monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-third-quarter-2015-financial-results-vcel-20151113monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-host-third-quarter-2015-earnings-webcast-and-conference-call-on-november-13-201-vcel-20151103monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-upcoming-investor-conferences-vcel-20150923monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-second-quarter-2015-financial-results-vcel-20150812monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-host-second-quarter-2015-earnings-webcast-and-conference-call-on-august-12-2015-vcel-20150729monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-plan-to-submit-hde-supplement-to-the-fda-to-revise-the-labeled-indicatio-vcel-20150714monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-announces-plan-to-submit-biologics-license-application-to-fda-by-year-end-2015-for-vcel-20150610monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-first-quarter-2015-financial-results-vcel-20150514monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-host-first-quarter-2015-earnings-webcast-and-conference-call-on-may-14-2015-vcel-20150430monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-needham-healthcare-conference-vcel-20150408monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-three-year-follow-up-results-from-phase-3-summit-extension-study-of-maci-t-vcel-20150325monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-fourth-quarter-and-year-end-2014-financial-results-vcel-20150323monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-canaccord-genuity-and-arm-investor-conferences-vcel-20150318monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-host-fourth-quarter-2014-earnings-call-on-march-23-2015-vcel-20150312monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-to-present-at-27th-annual-roth-conference-vcel-20150306monthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-completes-patient-enrollment-in-phase-2b-ixcell-dcm-clinical-study-of-ixmyelocel-t-vcel-20150129monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-appoints-accomplished-commercial-leader-kent-taylor-as-senior-vice-p-pvla-20260407monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-to-host-third-quarter-2025-financial-results-and-corporate-update-co-pvla-20251104monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-to-host-second-quarter-2025-financial-results-and-corporate-update-c-pvla-20250807monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-added-to-russell-3000-and-russell-2000-indexes-pvla-20250630monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-receives-initial-proceeds-from-fda-orphan-products-grant-to-support--pvla-20250609monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-to-ring-the-nasdaq-opening-bell-on-may-12-2025-pvla-20250505monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-announces-abstract-highlighting-the-estimated-diagnosed-prevalence-a-pvla-20250423monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-pvla-20250402monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-announces-first-patients-dosed-in-phase-2-toiva-clinical-trial-of-qt-pvla-20250108monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-and-ligand-pharmaceuticals-expand-strategic-partnership-to-accelerat-pvla-20231201monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-announces-planned-pivotal-phase-3-study-design-of-qtorin-3-9-rapamyc-pvla-20230720monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-announces-pipeline-update-on-qtorin-3-9-rapamycin-anhydrous-gel-qtor-pvla-20230221monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-to-attend-three-upcoming-investor-conferences-in-may-june-prct-20260430monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-reports-first-quarter-2026-financial-results-prct-20260429monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-to-host-4q25-earnings-conference-call-on-february-24-2026-and-investor-prct-20260126monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-to-present-at-upcoming-37th-annual-piper-sandler-healthcare-conference-prct-20251120monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-to-report-third-quarter-2025-financial-results-on-november-4-2025-prct-20251015monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-reports-second-quarter-2025-financial-results-and-increases-2025-reven-prct-20250806monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-reports-first-quarter-2025-financial-results-and-increases-2025-revenu-prct-20250424monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-announces-investor-event-at-2025-aua-annual-meeting-at-the-aria-resort-prct-20250410monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-announces-investor-event-at-2025-aua-annual-meeting-in-las-vegas-nevad-prct-20250314monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-reports-fourth-quarter-and-full-year-2024-results-prct-20250225monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-to-report-fourth-quarter-2024-financial-results-on-february-25-2025-an-prct-20250207monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-to-present-at-upcoming-36th-annual-piper-sandler-healthcare-conference-prct-20241126monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corporation-announces-pricing-of-offering-of-common-stock-prct-20241030monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corporation-announces-proposed-offering-of-common-stock-prct-20241028monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-reports-third-quarter-2024-financial-results-and-increases-2024-revenu-prct-20241028monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-to-report-third-quarter-2024-financial-results-on-october-28-2024-prct-20241009monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-received-u-s-fda-approval-to-initiate-pivotal-randomized-clinical-stud-prct-20241007monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-to-present-at-upcoming-2024-wells-fargo-healthcare-conference-on-septe-prct-20240828monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-announces-fda-clearance-of-the-hydros-robotic-system-the-next-generati-prct-20240821monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-reports-second-quarter-2024-financial-results-and-increases-2024-reven-prct-20240801monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-to-report-second-quarter-2024-financial-results-on-august-1-2024-prct-20240715monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-announces-new-cpt-category-i-code-from-the-american-medical-associatio-prct-20240617monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-to-present-at-upcoming-2024-truist-securities-medtech-conference-on-ju-prct-20240603monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-to-present-at-upcoming-2024-leerink-partners-healthcare-crossroads-con-prct-20240513monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-reports-first-quarter-2024-financial-results-and-increases-2024-revenu-prct-20240501monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-announces-12-scientific-research-presentations-on-aquablation-therapy--prct-20240423monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corp-announces-investor-event-at-2024-aua-annual-meeting-in-san-antoni-prct-20240404monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-to-report-first-quarter-2024-financial-results-on-may-1-2024-and-atten-prct-20240402monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-reports-fourth-quarter-and-full-year-2023-results-prct-20240227monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-to-present-at-the-44th-annual-td-cowen-health-care-conference-in-bosto-prct-20240212monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-announces-preliminary-fourth-quarter-revenue-of-43-3-million-to-43-6-m-prct-20240108monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-reports-third-quarter-2023-financial-results-and-increases-2023-revenu-prct-20231101monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-to-report-third-quarter-2023-financial-results-on-november-1-2023-prct-20231016monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-announces-new-corporate-headquarters-in-san-jose-prct-20230920monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-receives-u-s-fda-investigational-device-exemption-to-investigate-aquab-prct-20230912monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-announces-first-commercial-aquablation-therapy-procedures-in-japan-prct-20230822monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-to-present-at-the-2023-wells-fargo-healthcare-conference-in-boston-prct-20230817monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corporation-announces-pricing-of-upsized-offering-of-common-stock-prct-20230802monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corporation-announces-proposed-offering-of-common-stock-prct-20230801monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-reports-second-quarter-2023-financial-results-and-increases-2023-reven-prct-20230727monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-to-report-second-quarter-2023-financial-results-on-july-27-2023-prct-20230711monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corporation-company-investigated-by-the-portnoy-law-firm-prct-20230428monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-reports-first-quarter-2023-financial-results-and-increases-2023-revenu-prct-20230427monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-to-report-first-quarter-2023-financial-results-on-april-27-2023-and-pr-prct-20230405monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-m-prct-20230403monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corp-announces-investor-event-at-2023-aua-annual-meeting-in-chicago-prct-20230330monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corp-to-present-at-the-virtual-key-bank-life-sciences-medtech-investor-prct-20230302monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-reports-fourth-quarter-and-full-year-2022-results-prct-20230228monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corp-to-present-at-the-43rd-annual-cowen-health-care-conference-in-bos-prct-20230213monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-announces-preliminary-fourth-quarter-and-fiscal-year-2022-revenue-prct-20230109monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corp-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-prct-20221214monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-reports-third-quarter-2022-financial-results-and-increases-2022-revenu-prct-20221103monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-to-report-third-quarter-2022-financial-results-on-november-3-2022-prct-20221012monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-announces-52-million-debt-refinancing-prct-20221010monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corp-to-present-at-2022-wells-fargo-healthcare-conference-prct-20220822monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-reports-second-quarter-2022-financial-results-and-increases-2022-reven-prct-20220804monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-to-report-second-quarter-2022-financial-results-on-august-4-2022-prct-20220714monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corporation-announces-additional-positive-coverage-policies-regarding--prct-20220609monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-reports-first-quarter-2022-financial-results-and-increases-2022-revenu-prct-20220505monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corporation-announces-aetna-and-independence-blue-cross-blue-shield-po-prct-20220428monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corp-to-report-first-quarter-2022-financial-results-on-may-5-2022-and--prct-20220412monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corp-announces-investor-event-at-2022-aua-annual-meeting-in-new-orlean-prct-20220411monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-reports-fourth-quarter-and-full-year-2021-financial-results-prct-20220308monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corp-to-report-fourth-quarter-and-full-year-2021-financial-results-on--prct-20220222monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-announces-5-year-water-study-data-comparing-aquablation-to-turp-prct-20220214monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corp-to-present-at-11th-annual-svb-leerink-global-healthcare-conferenc-prct-20220201monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corp-announces-preliminary-fourth-quarter-and-fiscal-year-2021-revenue-prct-20220111monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-appoints-mary-garrett-to-board-of-directors-prct-20220104monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corp-reports-third-quarter-2021-financial-results-and-provides-2021-re-prct-20211104monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-appoints-elisabeth-sandoval-to-board-of-directors-prct-20211026monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corp-to-report-third-quarter-2021-financial-results-on-november-4-2021-prct-20211021monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corporation-announces-cigna-adds-aquablation-therapy-to-its-coverage-p-prct-20210928monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corporation-announces-closing-of-upsized-initial-public-offering-and-f-prct-20210921monthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-corporation-announces-pricing-of-upsized-initial-public-offering-prct-20210914monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investor-notice-robbins-geller-rudman-dowd-llp-announces-that-adma-biologics-inc-inve-adma-20260619monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-shareholder-alert-august-10-2026-lead-plaintiff-deadline-in-adma-biologics-inc-securi-adma-20260619monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investors-have-opportunity-to-lead-adma-biologics-inc-securities-fraud-lawsuit-with-t-adma-20260619monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-10-adma-20260618monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-lawsuit-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been--adma-20260617monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-fraud-notice-adma-biologics-accused-of-securities-fraud-over-channel-stuffing-allegat-adma-20260617monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-inc-notice-of-august-10-2026-application-deadline-for-class-action-lawsuit--adma-20260617monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investors-have-opportunity-to-lead-adma-biologics-inc-securities-fraud-lawsuit-with-t-adma-20260616monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-class-action-notice-robbins-llp-reminds-investors-of-the-lead-plaintiff-deadline-in-t-adma-20260615monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-shareholder-alert-adma-biologics-inc-securities-class-action-lawsuit-investors-with-l-adma-20260615monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-shareholder-news-adma-biologics-investors-with-losses-may-have-been-misled-by-the-com-adma-20260615monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investor-deadline-approaching-faruqi-faruqi-llp-reminds-adma-biologics-investors-of-s-adma-20260612monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-class-action-alert-adma-biologics-channel-stuffing-claims-and-16-stock-drop-leads-to--adma-20260612monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-lawsuit-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been--adma-20260611monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investor-alert-class-action-lawsuit-filed-on-behalf-of-adma-biologics-inc-investors-h-adma-20260611monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-lawsuit-adma-biologics-inc-sued-for-securities-fraud-investors-should-contact-block-l-adma-20260611monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-investigation-adma-biologics-adma-investigated-for-alleged-channel-stuffing-adma-20260610monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-legal-claims-adma-biologics-may-have-misrepresented-its-revenue-sources-to-investors--adma-20260603monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investor-news-if-you-have-suffered-losses-in-adma-biologics-inc-nasdaq-adma-you-are-e-adma-20260602monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-securities-news-adma-biologics-investigated-for-securities-fraud-over-channel-stuffin-adma-20260529monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investor-alert-did-adma-biologics-mislead-investors-about-alleged-channel-stuffing-bf-adma-20260527monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investor-news-if-you-have-suffered-losses-in-adma-biologics-inc-nasdaq-adma-you-are-e-adma-20260526monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-shareholder-announcement-adma-biologics-may-have-misled-investors-about-its-revenue-c-adma-20260525monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investor-news-if-you-have-suffered-losses-in-adma-biologics-inc-nasdaq-adma-you-are-e-adma-20260522monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-inquiry-news-adma-biologics-investors-are-notified-of-bfa-law-s-ongoing-investigation-adma-20260522monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-securities-investigation-adma-biologics-29-stock-drop-triggers-securities-fraud-inves-adma-20260520monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investor-news-if-you-have-suffered-losses-in-adma-biologics-inc-nasdaq-adma-you-are-e-adma-20260520monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-fraud-notice-adma-biologics-is-being-investigated-for-securities-fraud-after-29-stock-adma-20260518monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-shareholder-news-adma-biologics-investigated-for-securities-fraud-over-alleged-misrep-adma-20260515monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investor-news-if-you-have-suffered-losses-in-adma-biologics-inc-nasdaq-adma-you-are-e-adma-20260513monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-inquiry-alert-investors-with-losses-after-channel-stuffing-allegations-are--adma-20260513monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investigation-reminder-adma-biologics-investigation-on-behalf-of-investors-is-ongoing-adma-20260511monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investor-news-if-you-have-suffered-losses-in-adma-biologics-inc-nasdaq-adma-you-are-e-adma-20260510monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investor-news-adma-biologics-stock-drops-29-amid-channel-stuffing-claims-triggering-s-adma-20260508monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investor-news-if-you-have-suffered-losses-in-adma-biologics-inc-nasdaq-adma-you-are-e-adma-20260506monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-shareholder-news-adma-biologics-29-stock-drop-leads-to-securities-fraud-investigation-adma-20260506monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-stock-drop-alert-adma-biologics-stock-plummeted-29-on-news-of-channel-stuffing-invest-adma-20260504monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investor-news-if-you-have-suffered-losses-in-adma-biologics-inc-nasdaq-adma-you-are-e-adma-20260503monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-investor-news-if-you-have-suffered-losses-in-adma-biologics-inc-nasdaq-adma-adma-20260430monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-fraud-adma-biologics-channel-stuffing-claims-trigger-securities-investigation-investo-adma-20260429monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-investor-news-if-you-have-suffered-losses-in-adma-biologics-inc-nasdaq-adma-adma-20260427monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-stock-adma-biologics-securities-fraud-investigation-is-ongoing-investors-with-losses--adma-20260427monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-investor-news-if-you-have-suffered-losses-in-adma-biologics-inc-nasdaq-adma-adma-20260424monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-legal-notification-adma-biologics-securities-class-action-investigation-ongoing-inves-adma-20260424monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investigation-bfa-law-notifies-adma-biologics-investors-that-lost-money-after-29-stoc-adma-20260422monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-investor-news-if-you-have-suffered-losses-in-adma-biologics-inc-nasdaq-adma-adma-20260421monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-securities-news-adma-biologics-hit-with-securities-fraud-investigation-after-channel--adma-20260420monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-investor-news-if-you-have-suffered-losses-in-adma-biologics-inc-nasdaq-adma-adma-20260418monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-nasdaq-adma-investigated-for-potential-federal-securities-laws-violations-l-adma-20260417monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investor-alert-adma-biologics-securities-fraud-investigation-investors-with-losses-ma-adma-20260416monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-legal-news-adma-biologics-investors-may-have-been-affected-by-fraud-after-channel-stu-adma-20260415monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investigation-reminder-adma-biologics-investors-are-reminded-to-contact-bfa-law-after-adma-20260413monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-nasdaq-adma-investigated-for-potential-federal-securities-laws-violations-l-adma-20260410monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-securities-alert-adma-biologics-securities-fraud-investigation-focuses-on-channel-stu-adma-20260410monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investor-announcement-adma-biologics-investigated-after-channel-stuffing-claims-cause-adma-20260408monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-inc-adma-crashes-16-amid-scrutiny-over-skyrocketing-days-sales-outstanding--adma-20260406monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-stock-news-adma-biologics-investigated-for-securities-fraud-following-channel-stuffin-adma-20260403monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-inc-adma-crashes-16-amid-scrutiny-over-skyrocketing-days-sales-outstanding--adma-20260401monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-securities-alert-adma-biologics-investigated-for-securities-fraud-over-culper-researc-adma-20260401monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investor-news-adma-biologics-faces-securities-fraud-investigation-after-culper-resear-adma-20260330monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-inc-adma-crashes-16-amid-scrutiny-over-skyrocketing-days-sales-outstanding--adma-20260328monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investigation-alert-bragar-eagel-squire-p-c-is-investigating-adma-biologics-inc-on-be-adma-20260327monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-shareholders-adma-biologics-hit-with-securities-fraud-investigation-after-stock-slide-adma-20260327monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-third-quarter-2025-financial-results-on-november-5-2025-adma-20251029monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-second-quarter-2025-financial-results-on-august-6-2025-adma-20250730monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-first-quarter-2025-financial-results-on-may-7-2025-adma-20250430monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-3-20-adma-20250225monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-participate-in-the-j-p-morgan-healthcare-conference-on-january-13-2025-adma-20250107monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-alert-bragar-eagel-squire-p-c-is-investigating-adma-biologics-inc-on-behalf-adma-20241113monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investor-news-adma-biologics-investors-with-losses-may-have-been-affected-by-fraud-co-adma-20241108monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-stock-report-adma-biologics-investors-are-notified-to-contact-bfa-law-about-the-secur-adma-20241106monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-inquiry-alert-a-securities-fraud-investigation-has-been-initiated-against-adma-biolog-adma-20241104monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investigation-adma-biologics-investors-with-losses-are-notified-to-contact-bfa-law-ab-adma-20241031monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-third-quarter-2024-financial-results-on-november-7-2024-adma-20241029monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investigation-notice-adma-biologics-stock-plummets-20-after-auditor-resigns-investors-adma-20241029monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-an-investigation-into-adm-adma-20241027monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-fraud-alert-bfa-law-notifies-adma-biologics-investors-of-ongoing-securities-fraud-inv-adma-20241027monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-legal-news-adma-biologics-investigated-for-securities-fraud-after-stock-drops-20-inve-adma-20241025monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-stock-alert-why-is-adma-biologics-being-sued-for-securities-fraud-investors-that-lost-adma-20241023monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-an-investigation-into-adm-adma-20241021monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investigation-news-the-securities-fraud-investigation-into-adma-biologics-inc-after-s-adma-20241021monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investigation-update-adma-biologics-investors-are-notified-of-securities-fraud-invest-adma-20241019monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-alert-securities-fraud-investigation-by-block-leviton-could-allow-investors-adma-20241017monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-fraud-notice-lost-money-on-your-adma-biologics-inc-securities-contact-bfa-law-about-i-adma-20241017monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-alert-bragar-eagel-squire-p-c-is-investigating-adma-biologics-inc-on-behalf-adma-20241016monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-an-investigation-into-adm-adma-20241015monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-legal-notice-adma-biologics-inc-is-being-investigated-for-securities-fraud-after-audi-adma-20241015monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-shareholder-alert-adma-biologics-inc-is-under-investigation-for-securities-fraud-afte-adma-20241013monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-fraud-alert-bfa-law-is-investigating-adma-biologics-inc-for-securities-fraud-after-st-adma-20241011monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-inc-investors-company-investigated-by-the-portnoy-law-firm-adma-20241010monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-investors-who-have-lost-money-should-contact-block-leviton-to-find-out-how--adma-20241010monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-set-to-join-s-p-smallcap-600-index-adma-20240917monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-participate-in-the-2024-cantor-global-healthcare-conference-adma-20240910monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-second-quarter-2024-financial-results-on-august-8-2024-adma-20240801monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-first-quarter-2024-financial-results-on-may-9-2024-adma-20240502monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-participate-in-the-raymond-james-institutional-investor-conference-adma-20240305monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-cfo-transition-adma-20240228monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-fourth-quarter-and-full-year-2023-financial-results-on-february-2-adma-20240221monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-third-quarter-2023-financial-results-on-november-8-2023-adma-20231101monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-second-quarter-2023-financial-results-on-august-9-2023-adma-20230802monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-first-quarter-2023-financial-results-on-may-10-2023-adma-20230503monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-23-2-adma-20230316monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-fda-approval-for-room-temperature-storage-of-asceniv-bivigam-adma-20221213monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-pricing-of-public-offering-for-60-million-of-common-stock-adma-20221207monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-proposed-public-offering-of-common-stock-adma-20221206monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-third-quarter-2022-financial-results-on-november-9-2022-adma-20221102monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-second-quarter-2022-financial-results-on-august-10-2022-adma-20220803monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-addition-to-the-russell-2000-index-adma-20220621monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-first-quarter-2022-financial-results-on-may-11-2022-adma-20220504monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-fourth-quarter-and-full-year-2021-financial-results-on-march-24-2-adma-20220321monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-senior-vice-president-of-plasma-services-cyndi-tolman-elected-to-ppta-sourc-adma-20211117monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-third-quarter-2021-financial-results-on-november-10-2021-adma-20211103monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-data-presented-at-the-2021-isirv-who-conference-adma-20211022monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-proposed-public-offering-of-common-stock-adma-20211020monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-a-poster-presentation-at-the-2021-international-society-for-influ-adma-20211019monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-the-presentation-of-real-world-experience-in-the-management-of-re-adma-20211004monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-presentation-on-respiratory-viral-infections-at-idweek-2021-adma-20211001monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-virtually-participate-in-the-cantor-healthcare-conference-adma-20210923monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-receives-fda-approval-for-vanrx-aseptic-fill-finish-machine-and-related-ope-adma-20210908monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-virtually-participate-in-the-morgan-stanley-19th-annual-global-healthcar-adma-20210902monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-advances-expansion-plans-and-opens-new-plasma-collection-center-in-conyers--adma-20210810monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-second-quarter-2021-financial-results-on-august-11-2021-adma-20210804monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-participate-in-the-raymond-james-human-health-innovation-virtual-confere-adma-20210614monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-participate-in-the-jefferies-virtual-healthcare-conference-adma-20210526monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-first-quarter-2021-financial-results-on-may-12-2021-adma-20210505monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-opens-newest-adma-biocenters-plasma-collection-facility-in-goose-creek-s-c-adma-20210426monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-poster-presentation-highlighting-pharmacoeconomic-burden-of-hiv-a-adma-20210413monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-march-25-2-adma-20210318monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-participate-in-the-jefferies-virtual-plasma-summit-adma-20210304monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-expands-global-regulatory-approval-presence-and-announces-fda-approval-to-c-adma-20210303monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-presents-late-breaking-poster-presentation-highlighting-clinical-utility-of-adma-20210226monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-participate-in-raymond-james-institutional-investor-conference-adma-20210222monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-opens-newest-adma-biocenters-plasma-collection-facility-in-maryville-tn-adma-20201201monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-participate-in-jefferies-2020-virtual-london-healthcare-conference-adma-20201110monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-third-quarter-2020-financial-results-and-business-highlights-on-n-adma-20201029monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-presentation-on-respiratory-viral-infections-and-new-data-on-s-pn-adma-20201021monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-participate-in-morgan-stanley-virtual-healthcare-conference-adma-20200909monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-participate-in-upcoming-investor-conferences-adma-20200902monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-business-highlights-and-second-quarter-2020-financial-results-on--adma-20200729monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-martha-j-demski-elected-to-board-of-directors-adma-20200623monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-provides-corporate-update-on-supply-chain-robustness-and-recent-accomplishm-adma-20200507monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-first-quarter-2020-financial-results-on-may-6-2020-adma-20200429monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-report-fourth-quarter-and-full-year-2019-financial-results-on-march-12-2-adma-20200305monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-highlights-expanded-intellectual-property-portfolio-for-specialty-plasma-de-adma-20200303monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-pricing-of-upsized-82-3-million-public-offering-of-common-stock-adma-20200207monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-acceptance-to-the-plasma-protein-therapeutics-association-adma-20191104monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-pricing-of-public-offering-of-common-stock-adma-20190517monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-submits-response-and-provides-supplemental-information-to-fda-for-bivigam-c-adma-20190107monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-receives-pdufa-date-for-ri-002-adma-20181017monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-present-at-the-20th-annual-rodman-renshaw-global-investment-conference-adma-20180827monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-pricing-of-public-offering-of-common-stock-adma-20180608monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-first-quarter-2018-financial-results-adma-20180514monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-present-at-raymond-james-39th-annual-institutional-investors-conference-adma-20180227monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-present-at-upcoming-investor-conferences-adma-20170823monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-year-end-2016-financial-results-accomplishments-and-upcoming-milest-adma-20170224monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-acquire-certain-assets-from-biotest-pharmaceuticals-corporation-and-beco-adma-20170123monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-third-quarter-2016-results-adma-20161110monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-present-at-upcoming-investor-conferences-adma-20160901monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-present-at-the-2016-jmp-securities-life-sciences-conference-adma-20160616monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-first-quarter-2016-results-adma-20160513monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-further-enhances-cash-position-by-securing-4-0-million-in-additional-capita-adma-20160513monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-full-exercise-of-underwriters-option-to-purchase-additional-share-adma-20160503monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-pricing-of-public-offering-of-common-stock-adma-20160428monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-proposed-public-offering-of-common-stock-adma-20160427monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-data-on-ri-002-to-be-presented-at-the-clinical-immunology-society-adma-20160412monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-data-presented-at-2016-american-academy-of-allergy-asthma-immunol-adma-20160307monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-present-at-cowen-and-company-36th-annual-health-care-conference-adma-20160301monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-recognized-as-one-of-new-jersey-s-best-places-to-work-2016-adma-20160224monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-expands-commercial-operations-team-in-preparation-for-commercial-launch-of--adma-20151209monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-present-at-the-oppenheimer-26th-annual-healthcare-conference-adma-20151203monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-third-quarter-2015-results-adma-20151110monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-data-to-be-presented-at-the-international-primary-immunodeficienc-adma-20151103monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-receives-milestone-payment-from-biotest-ag-for-ri-002-bla-submission-to-fda-adma-20150930monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-recognized-as-one-of-the-50-fastest-growing-companies-in-new-jersey-adma-20150928monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-present-at-the-ladenburg-thalmann-2015-healthcare-conference-adma-20150922monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-receives-fda-approval-for-second-plasma-collection-center-adma-20150917monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-present-at-the-rodman-renshaw-17th-annual-global-investment-conference-adma-20150902monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-receives-patent-issuance-pertaining-to-the-treatment-of-immunodeficiency-adma-20150831monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-submission-of-ri-002-biologics-license-application-bla-to-fda-adma-20150731monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-recent-commercialization-focused-appointments-adma-20150706monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-receives-notice-of-allowance-for-u-s-patent-pertaining-to-its-lead-product--adma-20150630monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-joins-russell-microcap-r-index-adma-20150629monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-present-at-the-2015-jmp-securities-life-sciences-conference-adma-20150616monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-jeffrey-modell-foundation-initiate-strategic-patient-advocacy-alliance-adma-20150611monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-present-at-the-2015-marcum-microcap-conference-adma-20150522monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-first-quarter-2015-results-adma-20150512monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-data-to-be-presented-at-the-clinical-immunology-society-2015-annu-adma-20150407monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-closing-of-public-offering-of-common-stock-and-exercise-of-over-a-adma-20150318monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-proposed-public-offering-of-common-stock-adma-20150312monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-positive-data-on-primary-and-secondary-endpoints-from-its-pivotal-adma-20150223monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-present-at-cowen-and-company-35th-annual-health-care-conference-adma-20150220monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-data-to-be-presented-at-2015-american-academy-of-allergy-asthma-i-adma-20150217monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-receives-5m-tranche-from-hercules-technology-growth-capital-adma-20141215monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-announces-positive-top-line-phase-iii-data-for-primary-immune-deficiency-di-adma-20141203monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-present-at-the-oppenheimer-25th-annual-healthcare-conference-adma-20141202monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-inc-nasdaq-adma-to-ring-the-nasdaq-stock-market-opening-bell-adma-20141125monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-opens-plasma-collection-center-in-marietta-georgia-adma-20141118monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-to-present-at-the-9th-international-respiratory-syncytial-virus-rsv-symposi-adma-20141110monthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-approved-for-trading-on-nasdaq-adma-20141105monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-cancels-first-quarter-2026-conference-call-and-webcast-cprx-20260507monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-showcase-real-world-findings-in-duchenne-muscular-dystrophy-an-cprx-20260306monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-monitor-report-q1-2026-outlook-regulatory-approvals-and-late-stage-trials-signal--cprx-20260120monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-receives-prestigious-ranking-on-forbes-2026-list-of-america-s-mos-cprx-20260108monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-monitor-outlook-q4-2025-report-pipeline-advances-with-key-approvals-and-trials-fe-cprx-20251031monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-report-third-quarter-2025-financial-results-on-november-5-2025-cprx-20251022monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-report-second-quarter-2025-financial-results-on-august-6-2025-cprx-20250722monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-in-the-bofa-securities-health-care-conference-2025-cprx-20250430monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-report-first-quarter-2025-financial-results-on-may-7-2025-cprx-20250422monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-in-the-barclays-27th-annual-global-healthcare-conf-cprx-20250304monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-report-fourth-quarter-and-full-year-2024-financial-results-on--cprx-20250212monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-receives-prestigious-ranking-on-forbes-2025-list-of-america-s-mos-cprx-20250123monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-cprx-20241216monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-recognized-as-one-of-north-america-s-fastest-growing-companies-on-cprx-20241125monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-in-upcoming-investor-conferences-cprx-20241119monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-recognized-among-biospace-2025-best-places-to-work-cprx-20241113monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-report-third-quarter-2024-financial-results-on-november-6-2024-cprx-20241022monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-donates-100-000-to-the-american-red-cross-hurricane-helene-relief-cprx-20241008monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-in-the-bofa-securities-cns-therapeutics-virtual-co-cprx-20241001monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-in-upcoming-investor-conferences-cprx-20240820monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-report-second-quarter-2024-financial-results-on-august-7-2024-cprx-20240722monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-at-the-jefferies-global-healthcare-conference-2024-cprx-20240528monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-at-the-bofa-securities-health-care-conference-2024-cprx-20240501monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-report-first-quarter-2024-financial-results-on-may-8-2024-cprx-20240422monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-support-for-the-inaugural-lambert-eaton-myasthenic-synd-cprx-20240328monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-in-the-2024-cantor-virtual-muscular-dystrophy-symp-cprx-20240327monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-at-the-barclays-26th-annual-global-healthcare-conf-cprx-20240305monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-mda-clinical-scientific-conference-details-of-regis-cprx-20240227monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-report-fourth-quarter-and-full-year-2023-financial-results-on--cprx-20240214monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-inc-announces-closing-of-public-offering-cprx-20240109monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-inc-announces-pricing-of-public-offering-of-common-stock-cprx-20240105monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-receives-prestigious-ranking-on-forbes-2024-list-of-america-s-mos-cprx-20231205monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-in-piper-sandler-35th-annual-healthcare-conference-cprx-20231116monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-biosciences-announces-completion-of-business-combination-with-beijing-continent-p-cprx-20231030monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-partners-with-sofie-s-journey-to-bring-focus-on-epilepsy-at-the-1-cprx-20231030monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-report-third-quarter-2023-financial-results-on-november-8-2023-cprx-20231023monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-at-the-2023-cantor-global-healthcare-conference-cprx-20230918monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-abstract-on-lambert-eaton-myasthenic-syndrome-lems-to-b-cprx-20230816monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-multiple-abstracts-on-fycompa-perampanel-from-eisai-co--cprx-20230814monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-report-second-quarter-2023-financial-results-on-august-9-2023-cprx-20230724monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-acquires-exclusive-north-american-license-for-vamorolone-for-duch-cprx-20230719monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-release-of-inaugural-esg-report-cprx-20230501monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-10-2023-cprx-20230424monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-third-party-abstracts-on-fycompa-perampanel-to-be-prese-cprx-20230420monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-market-set-to-experience-a-promising-growth-to-sustain-a-cagr-of-4-2-during-2022--cprx-20230404monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-a-recent-third-party-publication-in-peer-reviewed-journ-cprx-20230308monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-report-fourth-quarter-and-full-year-2022-financial-results-on--cprx-20230301monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-ring-the-nasdaq-closing-bell-in-honor-of-international-rare-di-cprx-20230222monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-named-bioflorida-2022-company-of-the-year-cprx-20221107monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-report-third-quarter-2022-financial-results-on-november-9-2022-cprx-20221025monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-in-the-h-c-wainwright-24th-annual-global-investmen-cprx-20220909monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-in-citi-s-17th-annual-biopharma-conference-cprx-20220824monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-report-second-quarter-2022-financial-results-on-august-9-2022-cprx-20220726monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-cprx-20220517monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-report-first-quarter-2022-financial-results-on-may-10-2022-cprx-20220425monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-named-among-forbes-2022-america-s-best-small-companies-cprx-20220308monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-report-fourth-quarter-and-full-year-2021-financial-results-on--cprx-20220303monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-teams-up-with-patients-and-advocacy-groups-to-ring-nasdaq-opening-cprx-20220224monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-launch-lems-aware-podcast-on-rare-disease-day-2022-cprx-20220217monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-in-january-2022-virtual-investor-conferences-cprx-20220104monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-at-the-piper-sandler-33rd-annual-virtual-healthcar-cprx-20211115monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-report-third-quarter-2021-financial-results-on-november-9-2021-cprx-20211025monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-at-the-oppenheimer-fall-healthcare-life-sciences-m-cprx-20210917monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-cprx-20210910monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-biosciences-announces-appointment-of-jeanne-jew-to-its-board-of-directors-cprx-20210908monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-second-quarter-2021-financial-results-and-corporate-updat-cprx-20210726monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-cprx-20210519monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-first-quarter-2021-financial-results-and-corporate-update-cprx-20210503monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-fourth-quarter-and-year-end-2020-financial-results-and-co-cprx-20210304monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-support-of-rare-disease-day-2021-cprx-20210222monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-third-quarter-2020-financial-results-and-corporate-update-cprx-20201102monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-second-quarter-2020-financial-results-and-corporate-updat-cprx-20200803monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-comments-on-magistrate-judge-s-report-and-recommendation-in-its-l-cprx-20200731monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-the-jefferies-virtual-healthcare-conference-cprx-20200601monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-first-quarter-2020-financial-results-and-corporate-update-cprx-20200504monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-fourth-quarter-and-year-end-financial-results-and-corpora-cprx-20200310monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-support-of-rare-disease-day-2020-cprx-20200227monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-the-cowen-40th-annual-health-care-conference-cprx-20200226monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-the-22nd-annual-bio-ceo-investor-conference-cprx-20200206monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-in-the-piper-jaffray-31st-annual-healthcare-confer-cprx-20191126monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-third-quarter-2019-financial-results-conference-call-and--cprx-20191031monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-in-the-2019-cantor-global-healthcare-conference-cprx-20190925monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-inc-announces-proposed-public-offering-of-common-stock-cprx-20190911monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-in-the-14th-annual-citi-biotech-conference-on-sept-cprx-20190828monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-its-support-of-spinal-muscular-atrophy-awareness-month-cprx-20190801monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-second-quarter-2019-financial-results-conference-call-and-cprx-20190731monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-the-jefferies-2019-global-healthcare-conference-cprx-20190604monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-first-quarter-financial-results-conference-call-and-webca-cprx-20190506monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-fourth-quarter-financial-results-and-corporate-update-con-cprx-20190311monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-support-of-rare-disease-day-2019-cprx-20190228monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-publication-of-phase-3-clinical-trial-data-for-firdapse-cprx-20190226monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-responds-to-letter-from-senator-bernie-sanders-cprx-20190221monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-the-21st-annual-bio-ceo-investor-conference-cprx-20190205monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-publication-of-clinical-data-from-the-investigator-spon-cprx-20190104monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-conference-call-to-discuss-commercialization-plan-for-f-cprx-20181203monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-firdapse-amifampridine-new-drug-application-continues-u-cprx-20181127monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-third-quarter-financial-results-and-corporate-update-conf-cprx-20181031monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-cprx-20180920monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-rodman-renshaw-s-20th-annual-global-investment-conf-cprx-20180829monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-appoints-dr-stanley-iyadurai-as-vice-president-of-clinical-develo-cprx-20180820monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-second-quarter-2018-financial-results-and-provides-corp-cprx-20180807monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-second-quarter-financial-results-and-corporate-update-con-cprx-20180801monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-the-jefferies-2018-global-healthcare-conference-cprx-20180531monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-first-quarter-financial-results-and-corporate-update-conf-cprx-20180502monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-introduces-new-corporate-website-cprx-20180424monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-date-and-time-change-for-fourth-quarter-and-year-end-fi-cprx-20180312monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-fourth-quarter-and-year-end-financial-results-conference--cprx-20180308monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-its-continuing-support-for-rare-disease-day-2018-cprx-20180228monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-cprx-20180207monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-biosciences-announces-appointment-of-edward-williams-to-its-board-of-directors-cprx-20171214monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-third-quarter-financial-results-conference-call-and-webca-cprx-20171101monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-biosciences-announces-the-appointment-of-industry-veteran-andrea-hunt-to-its-boar-cprx-20171026monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-biosciences-and-mosaic-biosciences-enter-into-strategic-collaboration-to-develop--cprx-20171024monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-16th-annual-bio-investor-forum-cprx-20171016monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-second-quarter-financial-results-conference-call-and-webc-cprx-20170801monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-joins-russell-3000-index-cprx-20170626monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-the-jefferies-2017-healthcare-conference-cprx-20170601monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-the-antiepileptic-drug-and-device-trials-xiv-sympos-cprx-20170517monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-receives-2017-beacon-council-award-for-contributions-in-life-scie-cprx-20170512monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-poster-presentation-of-musk-mg-clinical-data-at-the-13t-cprx-20170510monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-first-quarter-financial-results-conference-call-and-webca-cprx-20170502monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-the-29th-annual-roth-conference-cprx-20170310monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-fourth-quarter-financial-results-conference-call-and-webc-cprx-20170309monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-biosciences-reports-fourth-quarter-and-full-year-2016-financial-results-and-provi-cprx-20170308monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-supports-rare-disease-day-and-joins-global-movement-to-raise-impo-cprx-20170227monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-participation-at-suntrust-robinson-humphrey-s-2017-orph-cprx-20170209monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-biosciences-completes-manufacturing-agreements-for-its-novel-factor-viia-product--cprx-20161219monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-participate-in-the-28th-annual-piper-jaffray-healthcare-confer-cprx-20161121monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-third-quarter-financial-results-conference-call-and-webca-cprx-20161101monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-15th-annual-bio-investor-forum-cprx-20161013monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-launch-of-expanded-access-program-website-and-participa-cprx-20160914monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-rodman-renshaw-s-18th-annual-global-investment-conf-cprx-20160908monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-biosciences-reports-second-quarter-2016-financial-results-and-provides-corporate--cprx-20160804monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-second-quarter-financial-results-and-corporate-update-con-cprx-20160801monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-the-jefferies-2016-healthcare-conference-cprx-20160601monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-s-firdapse-phase-3-study-published-in-muscle-nerve-cprx-20160518monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-first-quarter-financial-results-conference-call-and-webca-cprx-20160506monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-biosciences-announces-appointments-of-chief-medical-officer-and-vice-president-of-cprx-20160418monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-the-28th-annual-roth-conference-cprx-20160310monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-fourth-quarter-financial-results-conference-call-and-webc-cprx-20160309monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-observes-rare-disease-day-2016-cprx-20160229monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-appoints-brian-elsbernd-as-senior-vice-president-of-legal-and-com-cprx-20160226monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-participation-at-suntrust-robinson-humphrey-s-2016-orph-cprx-20160218monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-the-18th-annual-bio-ceo-investor-conference-cprx-20160204monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-the-27th-annual-piper-jaffray-healthcare-conference-cprx-20151123monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-third-quarter-financial-results-conference-call-and-webca-cprx-20151104monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-poster-presentation-at-62nd-annual-meeting-of-the-ameri-cprx-20151027monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-14th-annual-bio-investor-forum-cprx-20151019monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-biosciences-names-andrew-hetherington-as-vice-president-of-manufacturing-operatio-cprx-20150928monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-rodman-renshaw-s-17th-annual-global-investment-conf-cprx-20150903monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-biosciences-completes-merger-with-targacept-and-creates-a-protease-based-hemostas-cprx-20150820monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-nasdaq-cprx-to-ring-the-nasdaq-stock-market-closing-bell-cprx-20150818monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-second-quarter-financial-results-conference-call-and-webc-cprx-20150804monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-joins-russell-2000-3000-and-global-indexes-cprx-20150629monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-the-jefferies-2015-healthcare-conference-cprx-20150527monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-hold-first-quarter-financial-results-and-corporate-update-conf-cprx-20150504monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-the-27th-annual-roth-conference-cprx-20150309monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-inc-prices-public-offering-of-common-stock-cprx-20150204monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-announces-encouraging-pre-nda-meeting-with-the-fda-for-firdapse-t-cprx-20150202monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-provides-an-update-of-2015-goals-for-its-product-portfolio-cprx-20150112monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-the-piper-jaffray-26th-annual-healthcare-conference-cprx-20141201monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-appoints-david-j-caponera-as-vice-president-patient-advocacy-and--cprx-20141028monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-firdapse-phase-3-trial-results-at-the-61st-annual-meet-cprx-20141027monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-top-line-safety-and-efficacy-results-from-phase-3-fird-cprx-20141008monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-to-present-at-13th-annual-bio-investor-forum-cprx-20141002monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-to-present-at-rodman-renshaw-s-16th-annual-global-investm-cprx-20140903monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-to-present-at-the-jmp-securities-2014-healthcare-conferen-cprx-20140619monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-set-to-join-russell-microcap-r-index-cprx-20140618monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-to-present-at-the-jefferies-2014-global-healthcare-confer-cprx-20140529monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-inc-prices-public-offering-of-common-stock-cprx-20140403monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-to-present-at-the-26th-annual-roth-conference-cprx-20140306monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-observes-rare-disease-day-today-cprx-20140228monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-to-present-at-16th-annual-bio-ceo-investor-conference-cprx-20140206monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-reports-positive-cardiac-safety-results-of-its-phase-3-pr-cprx-20140108monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-reports-dismissal-of-stockholder-class-action-lawsuit-cprx-20140107monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-announces-social-media-presence-cprx-20131030monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-updates-on-its-development-activities-for-firdapse-tm-cprx-20131029monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-recommendation-of-data-monitoring-committee-to--cprx-20131015monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-to-present-at-12th-annual-bio-investor-forum-cprx-20131004monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-to-present-at-aegis-capital-2013-healthcare-conference-cprx-20130925monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-inc-closes-previously-announced-15-1-million-registered-d-cprx-20130910monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-prices-registered-direct-public-offering-cprx-20130905monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-to-present-at-rodman-renshaw-s-15th-annual-global-investm-cprx-20130903monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-receives-breakthrough-therapy-designation-from-fda-for-fi-cprx-20130827monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-second-quarter-2013-financial-results-cprx-20130815monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-regains-compliance-with-nasdaq-minimum-bid-price-rule-cprx-20130802monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-provides-update-on-firdapse-tm-progress-cprx-20130627monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-receives-extension-to-regain-compliance-with-nasdaq-listi-cprx-20130625monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-reports-first-quarter-2013-financial-results-cprx-20130516monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-reports-fourth-quarter-and-year-end-2012-financial-result-cprx-20130402monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-recommendation-of-data-monitoring-committee-for-cprx-20130327monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-to-present-at-25th-annual-roth-conference-cprx-20130307monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-appoints-dr-bernardino-mosquera-as-vice-president-of-clin-cprx-20130305monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-launches-new-website-cprx-20130221monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-provides-update-on-research-and-development-pipeline-cprx-20130211monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-to-present-at-15th-annual-bio-ceo-investor-conference-cprx-20130205monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-receives-guidance-from-nasdaq-regarding-minimum-bid-price-requirement-cprx-20121227monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-automatic-conversion-of-5-million-promissory-no-cprx-20121211monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-third-quarter-2012-financial-results-cprx-20121115monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-top-line-results-of-cpp-109-phase-ii-b-trial-fo-cprx-20121108monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-and-biomarin-pharmaceutical-enter-into-strategic-collabor-cprx-20121031monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-updates-guidance-on-timing-of-top-line-data-from-cpp-109--cprx-20120926monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-commencement-of-cpp-109-investigator-sponsored--cprx-20120924monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-to-present-at-rodman-renshaw-s-14th-annual-healthcare-con-cprx-20120906monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-inc-announces-closing-of-previously-announced-6-million-r-cprx-20120830monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-inc-raises-6-million-in-registered-direct-offering-cprx-20120828monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-second-quarter-2012-financial-results-cprx-20120815monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-regains-compliance-with-nasdaq-minimum-bid-price-rule-cprx-20120803monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-to-announce-top-line-data-from-cpp-109-phase-ii-b-clinica-cprx-20120712monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-receives-guidance-from-nasdaq-regarding-minimum-bid-price-requirement-cprx-20120621monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-to-present-cpp-115-progress-at-the-2012-college-on-proble-cprx-20120607monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-closes-underwritten-offering-cprx-20120530monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-prices-underwritten-offering-cprx-20120524monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-reports-positive-results-from-phase-i-a-clinical-study-of-cprx-20120522monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-completion-of-enrollment-in-cpp-109-phase-ii-b--cprx-20120521monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-first-quarter-2012-financial-results-cprx-20120516monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-reports-fourth-quarter-and-year-end-2011-financial-result-cprx-20120402monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-to-present-at-24th-annual-roth-conference-cprx-20120306monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-to-present-at-cowen-and-company-s-32nd-annual-health-care-cprx-20120228monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-granted-orphan-medicinal-product-designation-in-european--cprx-20120213monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-files-u-s-provisional-patent-application-for-gaba-aminotr-cprx-20120209monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-to-present-cpp-115-progress-at-the-2012-epilepsy-pipeline-cprx-20120131monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-inc-announces-fda-designation-of-cpp-115-as-a-fast-track--cprx-20111220monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-inc-announces-commencement-of-phase-i-a-safety-study-for--cprx-20111213monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-presentation-to-be-made-at-the-american-epileps-cprx-20111202monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-promotes-alicia-grande-to-vice-president-and-chief-financ-cprx-20111202monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-third-quarter-2011-financial-results-cprx-20111115monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-appoints-richard-p-rieger-as-vice-president-commercial-op-cprx-20111114monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-inc-announces-closing-of-public-offering-of-common-shares-cprx-20111102monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-inc-announces-public-offering-of-common-shares-and-warran-cprx-20111028monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-to-present-at-the-10th-annual-bio-investor-forum-cprx-20111021monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-adopts-stockholder-rights-plan-cprx-20110921monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-presentation-of-data-regarding-cpp-115-at-the-a-cprx-20110831monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-second-quarter-2011-financial-results-cprx-20110816monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-reports-positive-non-clinical-efficacy-results-evaluating-cprx-20110616monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-first-quarter-2011-financial-results-cprx-20110516monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-presentation-to-be-made-at-arvo-2011-conference-cprx-20110428monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-to-present-at-the-antiepileptic-drug-trials-xi-conference-cprx-20110421monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-reports-fourth-quarter-and-year-end-2010-financial-result-cprx-20110401monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-announces-commencement-of-cpp-109-investigator-sponsored-study-in-cocaine-and-alc-cprx-20110329monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-to-present-at-the-roth-23rd-annual-oc-growth-stock-confer-cprx-20110309monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-inc-announces-public-offering-of-common-shares-cprx-20110308monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-promotes-steven-r-miller-ph-d-to-chief-operating-officer-cprx-20110125monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-to-present-at-the-biotech-showcase-tm-2011-conference-cprx-20110104monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-initiates-a-registration-directed-u-s-phase-ii-b-clinical-cprx-20101118monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-third-quarter-2010-financial-and-operational-re-cprx-20101116monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-awarded-488-958-in-grants-for-its-cpp-109-and-cpp-115-pro-cprx-20101101monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-reports-positive-non-clinical-safety-and-efficacy-results-cprx-20101101monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-inc-granted-orphan-drug-designation-for-cpp-115-for-the-t-cprx-20100921monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-announces-second-quarter-2010-financial-results-cprx-20100813monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-inc-raises-1-5-million-in-registered-direct-offering-cprx-20100806monthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceutical-partners-inc-is-today-s-focus-stock-on-microstockprofit-com-cprx-20100712monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-expands-strategic-partnership-with-citeline-to-advance-its-ai-enabled-clintech-p-rxrx-20260331monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-presents-phase-2-data-for-rec-994-in-ccm-in-late-breaking-oral-presentation-at-t-rxrx-20250205monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-reports-interim-phase-1-clinical-data-for-rec-617-monotherapy-a-potential-best-i-rxrx-20241209monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-announces-first-patient-dosed-in-phase-1-2-clinical-study-of-rec-1245-a-potentia-rxrx-20241203monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-and-exscientia-two-leaders-in-the-ai-drug-discovery-space-have-officially-combin-rxrx-20241120monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-announces-the-release-of-openphenom-s-16-in-google-cloud-s-model-garden-rxrx-20241112monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-announces-first-patient-dosed-in-phase-2-clinical-study-of-rec-3964-a-potential--rxrx-20241022monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-announces-phase-2-data-of-rec-994-a-first-in-disease-investigational-treatment-f-rxrx-20240903monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-appoints-najat-khan-phd-as-chief-r-d-officer-and-chief-commercial-officer-rxrx-20240416monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-announces-plans-to-open-new-office-in-london-rxrx-20240311monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-adds-new-chemical-entity-targeting-fibrotic-diseases-to-late-discovery-pipeline-rxrx-20240104monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-announces-data-collaboration-deal-with-tempus-top-50-supercomputer-ambition-powe-rxrx-20231109monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20260605monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20260501monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20260306monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-progress-across-tsha-102-pivotal-gene-therapy-program-in-r-tsha-20260106monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-to-release-third-quarter-2025-financial-results-and-host-conference--tsha-20251028monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20250905monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-to-release-second-quarter-2025-financial-results-and-host-conference-tsha-20250805monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20250801monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20250703monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20250606monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-details-for-oral-presentations-at-the-2025-irsf-rett-syndr-tsha-20250603monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-pricing-of-public-offering-of-common-stock-and-pre-funded--tsha-20250529monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-to-release-first-quarter-2025-financial-results-and-host-conference--tsha-20250508monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20250502monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20250404monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20250307monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-tsha-20250219monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20250207monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20250103monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20241206monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-to-release-third-quarter-2024-financial-results-and-host-conference--tsha-20241106monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20241101monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-to-present-biodistribution-data-from-an-analysis-evaluating-aav9-gen-tsha-20241022monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20241004monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-oral-presentation-on-tsha-102-in-rett-syndrome-at-upcoming-tsha-20240926monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20240906monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-to-release-second-quarter-2024-financial-results-and-host-conference-tsha-20240805monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20240802monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20240705monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-to-present-clinical-data-from-both-reveal-phase-1-2-trials-during-co-tsha-20240612monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20240607monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-to-release-first-quarter-2024-financial-results-and-host-conference--tsha-20240507monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20240503monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-regenerative-medicine-advanced-therapy-rmat-designation-gr-tsha-20240502monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20240405monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-to-release-full-year-2023-financial-results-provide-corporate-and-cl-tsha-20240314monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20240301monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-updates-to-tsha-102-clinical-program-in-rett-syndrome-tsha-20240229monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-provides-update-on-deprioritized-pipeline-programs-tsha-20240215monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20240202monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-poster-presentation-on-tsha-102-in-rett-syndrome-at-upcomi-tsha-20240122monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tsha-20240105monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-expanded-eligibility-in-reveal-phase-1-2-adult-trial-to-in-tsha-20231129monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-to-release-third-quarter-2023-financial-results-and-host-conference--tsha-20231107monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-presents-new-preclinical-in-vitro-data-on-tsha-102-in-rett-syndrome--tsha-20231024monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-two-poster-presentations-on-tsha-102-in-rett-syndrome-at-u-tsha-20231010monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-150-million-private-placement-financing-tsha-20230814monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-to-host-virtual-r-d-day-on-lead-clinical-investigational-programs-ts-tsha-20230615monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-to-release-first-quarter-2023-financial-results-and-host-conference--tsha-20230504monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-presentation-on-new-preclinical-data-for-tsha-102-in-rett--tsha-20230427monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-to-release-fourth-quarter-and-full-year-2022-financial-results-and-h-tsha-20230315monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-to-participate-in-jmp-securities-hematology-and-oncology-summit-tsha-20221129monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-to-release-third-quarter-2022-financial-results-and-host-conference--tsha-20221102monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-to-host-conference-call-to-discuss-astellas-pharma-s-strategic-inves-tsha-20221024monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-e-tsha-20221006monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-to-release-second-quarter-2022-financial-results-and-host-conference-tsha-20220809monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-to-participate-in-upcoming-august-investor-conferences-tsha-20220801monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-to-participate-in-upcoming-william-blair-biotech-focus-conference-20-tsha-20220706monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-annual-stockholder-meeting-tsha-20220613monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-to-participate-in-upcoming-june-investor-conferences-and-convention-tsha-20220602monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-to-release-first-quarter-2022-financial-results-and-host-conference--tsha-20220511monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-presentations-at-the-upcoming-25th-annual-meeting-of-the-a-tsha-20220510monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-receives-orphan-drug-designation-from-the-european-commission-for-ts-tsha-20220503monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-oral-presentations-at-the-upcoming-2022-irsf-rett-syndrome-tsha-20220425monthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-to-participate-in-upcoming-chardan-genetic-medicines-and-cell-therap-tsha-20220418monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ntla-20260605monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-participate-in-upcoming-investor-conferences-ntla-20260505monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ntla-20260501monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ntla-20260403monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ntla-20260306monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-fourth-quarter-and-full-year-2025-ntla-20260219monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ntla-20260102monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-completes-enrollment-in-the-global-phase-3-haelo-study-of-lonvoguran-ntla-20250918monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ntla-20250801monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-investigation-alert-bragar-eagel-squire-p-c-is-investigating-intellia-therapeutic-ntla-20250731monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2025-earnings-and--ntla-20250731monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ntla-20250707monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ntla-20250605monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-alert-bragar-eagel-squire-p-c-is-investigating-intellia-therapeutics-inc-on-behal-ntla-20250523monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ntla-20250506monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2025-earnings-and-c-ntla-20250501monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the--ntla-20250415monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-lo-ntla-20250411monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-lo-ntla-20250407monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-levi-ntla-20250404monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-lo-ntla-20250403monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ntla-20250403monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-first-patient-dosed-in-the-magnitude-2-phase-3-study-of-ne-ntla-20250403monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inc-nasdaq-ntla-deadline-alert-bernstein-liebhard-llp-reminds-intell-ntla-20250401monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-lo-ntla-20250327monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inc-shareholders-are-reminded-of-the-lead-plaintiff-deadline-contact-ntla-20250326monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-fda-regenerative-medicine-advanced-therapy-rmat-designatio-ntla-20250326monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inc-nasdaq-ntla-deadline-alert-bernstein-liebhard-llp-reminds-intell-ntla-20250324monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inc-nasdaq-ntla-deadline-alert-bernstein-liebhard-llp-reminds-intell-ntla-20250310monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ntla-20250304monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inc-nasdaq-ntla-deadline-alert-bernstein-liebhard-llp-reminds-intell-ntla-20250303monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inc-nasdaq-ntla-deadline-alert-bernstein-liebhard-llp-reminds-intell-ntla-20250225monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-ntla-20250221monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-fourth-quarter-and-full-year-2024-ntla-20250220monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inc-nasdaq-ntla-deadline-alert-bernstein-liebhard-llp-reminds-intell-ntla-20250218monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-ntla-20250215monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inc-shareholder-notice-shareholder-rights-law-firm-robbins-llp-remin-ntla-20250214monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inc-nasdaq-ntla-investor-alert-investors-with-large-losses-in-intell-ntla-20250212monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ntla-20250204monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-first-patient-dosed-in-the-haelo-phase-3-study-of-ntla-200-ntla-20250122monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ntla-20250106monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ntla-20241203monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-fda-regenerative-medicine-advanced-therapy-rmat-designatio-ntla-20241125monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ntla-20241105monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-two-upcoming-investor-events-in-november-2024-ntla-20241031monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-new-date-for-upcoming-investor-webcast-ntla-20241010monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-initiation-of-haelo-phase-3-study-of-ntla-2002-an-investig-ntla-20241007monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ntla-20241003monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-new-clinical-data-from-the-phase-1-study-of-nexiguran-zic-ntla-20241001monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-data-from-the-phase-2-study-of-ntla-2002-for-the-treatmen-ntla-20240912monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ntla-20240903monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2024-earnings-and--ntla-20240801monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-receives-authorization-to-initiate-phase-1-2-clinical-trial-of-ntla--ntla-20240730monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ntla-20240724monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-announces-positive-clinical-proof-of-concept-data-for-redosing-a-crispr-based-the-ntla-20240625monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-the-first-ever-clinical-data-from-patients-redosed-with-a-ntla-20240617monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-positive-long-term-data-from-ongoing-phase-1-study-of-ntla-ntla-20240602monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2024-earnings-and-c-ntla-20240502monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-updated-data-from-phase-1-2-study-of-ntla-2002-for-the-tr-ntla-20240429monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-first-patient-dosed-in-the-phase-3-magnitude-study-of-ntla-ntla-20240318monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-and-recode-therapeutics-announce-strategic-collaboration-to-develop--ntla-20240215monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-fourth-quarter-and-full-year-2023-ntla-20240214monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-receives-european-union-orphan-drug-designation-for-ntla-2002-an-inv-ntla-20231114monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-updated-data-from-ongoing-phase-1-study-of-ntla-2001-for--ntla-20231026monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-receives-priority-medicines-prime-designation-from-the-european-medi-ntla-20231013monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2023-earnings-and--ntla-20230727monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-updated-interim-data-from-ongoing-phase-1-2-study-of-ntla-ntla-20230531monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-releases-2023-corporate-responsibility-report-highlighting-the-advan-ntla-20230501monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2023-earnings-and-c-ntla-20230427monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-fda-regenerative-medicine-advanced-therapy-rmat-designatio-ntla-20230321monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-fourth-quarter-and-full-year-2022-ntla-20230216monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-awarded-innovation-passport-in-the-united-kingdom-for-ntla-2002-an-i-ntla-20230111monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-pricing-of-public-offering-of-common-stock-ntla-20221201monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-proposed-public-offering-of-common-stock-ntla-20221130monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-updated-interim-clinical-data-from-ongoing-phase-1-2-stud-ntla-20221031monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-third-quarter-2022-earnings-and-c-ntla-20221027monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences-ntla-20220926monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-positive-interim-clinical-data-for-its-second-systemically-ntla-20220916monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-upcoming-investor-event-to-present-interim-clinical-data-f-ntla-20220908monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-receives-u-s-fda-orphan-drug-designation-for-ntla-2002-an-investigat-ntla-20220901monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-interim-clinical-data-from-ongoing-phase-1-2-study-of-ntl-ntla-20220823monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2022-earnings-and--ntla-20220727monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-updated-interim-clinical-data-from-ongoing-phase-1-study--ntla-20220608monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-names-muna-bhanji-r-ph-to-its-board-of-directors-ntla-20220502monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-presents-preclinical-data-demonstrating-advancements-in-its-crispr-e-ntla-20220502monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2022-earnings-and-c-ntla-20220428monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-receives-u-s-fda-orphan-drug-designation-for-ntla-5001-for-the-treat-ntla-20220309monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-first-patient-dosed-in-phase-1-2a-clinical-trial-of-ntla-5-ntla-20220301monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-enters-lease-agreement-to-build-manufacturing-facility-for-its-crisp-ntla-20220223monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-two-upcoming-investor-events-in-february-2022-ntla-20220217monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-and-onk-therapeutics-announce-collaboration-to-advance-allogeneic-crispr-edited-n-ntla-20220215monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-on-we-ntla-20220105monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-and-kyverna-therapeutics-announce-collaboration-to-develop-next-gene-ntla-20220105monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-appoints-derek-hicks-as-chief-business-officer-ntla-20211220monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-first-patient-dosed-in-phase-1-2-clinical-trial-of-ntla-20-ntla-20211213monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-expansion-of-ongoing-phase-1-study-of-ntla-2001-to-include-ntla-20211122monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-highlight-ex-vivo-genome-editing-and-crispr-cas9-manufacturing-ad-ntla-20211105monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-third-quarter-2021-earnings-and-c-ntla-20211028monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-receives-u-s-fda-orphan-drug-designation-for-ntla-2001-an-investigat-ntla-20211021monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-presents-preclinical-data-demonstrating-advancements-in-its-broad-ge-ntla-20211020monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-and-sparingvision-announce-strategic-collaboration-to-develop-novel--ntla-20211013monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-new-preclinical-data-highlighting-in-vivo-and-ex-vivo-gen-ntla-20211012monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-receives-authorization-to-initiate-phase-1-2-clinical-trial-of-ntla--ntla-20211006monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-chardan-s-5th-annual-genetic-medicines-conference-ntla-20210927monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-u-s-fda-acceptance-of-investigational-new-drug-application-ntla-20210916monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-september-healthcare-investor-conferences-ntla-20210831monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and--ntla-20210729monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-closing-of-690-million-public-offering-of-common-stock-ntla-20210702monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-pricing-of-public-offering-of-common-stock-ntla-20210630monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-proposed-public-offering-of-common-stock-ntla-20210628monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-names-james-basta-j-d-as-executive-vice-president-general-counsel-an-ntla-20210624monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-interim-clinical-data-from-ongoing-phase-1-study-of-ntla--ntla-20210604monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-c-ntla-20210429monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-presentations-at-the-24th-american-society-of-gene-and-cel-ntla-20210427monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-investigational-crispr-treatment-ntla-2001-receives-european-union-o-ntla-20210330monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-presents-new-data-on-expanded-cell-engineering-capabilities-utilizin-ntla-20210325monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-presents-preclinical-proof-of-concept-for-crispr-based-in-vivo-editi-ntla-20210310monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-fourth-quarter-and-full-year-2020-ntla-20210218monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-achieves-normal-human-alpha-1-antitrypsin-protein-levels-in-non-huma-ntla-20201212monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-presents-new-preclinical-data-supporting-its-crispr-cas9-engineered--ntla-20201205monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-closing-of-201-million-public-offering-of-common-stock-inc-ntla-20201204monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-pricing-of-public-offering-of-common-stock-ntla-20201202monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-receives-grant-to-develop-curative-crispr-cas9-in-vivo-sickle-cell-d-ntla-20201111monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-third-quarter-2020-financial-results-ntla-20201105monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-third-quarter-2020-earnings-and-c-ntla-20201029monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-congratulates-co-founder-jennifer-doudna-on-winning-the-2020-nobel-p-ntla-20201007monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-presents-new-preclinical-data-showing-persistent-in-vivo-editing-and-ntla-20200929monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-chardan-s-virtual-4th-annual-genetic-medicines-confere-ntla-20200928monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-baird-s-2020-virtual-global-healthcare-conference-ntla-20200902monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-second-quarter-2020-financial-results-ntla-20200806monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-the-2020-wedbush-pacgrow-healthcare-virtual-conference-ntla-20200803monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2020-earnings-and--ntla-20200730monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-closing-of-115-million-public-offering-of-common-stock-inc-ntla-20200605monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-pricing-of-public-offering-of-common-stock-ntla-20200603monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-reports-progress-on-crispr-cas9-aml-cancer-therapy-using-proprietary-ntla-20200512monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-first-quarter-2020-financial-results-ntla-20200507monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-names-david-lebwohl-m-d-chief-medical-officer-ntla-20200430monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2020-earnings-and-c-ntla-20200430monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-new-preclinical-data-from-its-crispr-cas9-programs-at-the-ntla-20200428monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-fourth-quarter-and-full-year-2019-financial-results-ntla-20200227monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-fourth-quarter-and-full-year-2019-ntla-20200220monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-presents-new-data-from-its-engineered-cell-therapy-and-in-vivo-progr-ntla-20200210monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-evercore-isi-2nd-annual-healthconx-conference-ntla-20191126monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-third-quarter-2019-earnings-and-c-ntla-20191024monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-presents-in-vivo-and-ex-vivo-data-at-the-2019-annual-congress-of-the-ntla-20191024monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-presentations-at-the-2019-annual-congress-of-the-european--ntla-20191016monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences-ntla-20190930monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-august-healthcare-investor-conference-ntla-20190730monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2019-earnings-and--ntla-20190725monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-participate-at-june-healthcare-investor-conferences-ntla-20190530monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-names-laura-sepp-lorenzino-ph-d-chief-scientific-officer-ntla-20190528monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-first-quarter-2019-financial-results-and-company-update-ntla-20190502monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-presents-new-in-vivo-and-engineered-cell-therapy-data-at-the-22nd-an-ntla-20190429monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2019-earnings-and-c-ntla-20190425monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-three-oral-presentations-on-in-vivo-and-engineered-cell-th-ntla-20190415monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-november-healthcare-investor-conferences-ntla-20181108monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-third-quarter-2018-earnings-and-c-ntla-20181030monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-names-glenn-goddard-as-new-chief-financial-officer-ntla-20181029monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-presents-new-data-in-in-vivo-and-ex-vivo-programs-at-the-26th-annual-ntla-20181018monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences-ntla-20180924monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-september-healthcare-investor-conferences-ntla-20180827monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-presents-progress-in-lead-in-vivo-program-at-cold-spring-harbor-labo-ntla-20180823monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-host-educational-briefing-webinar-on-interference-proceedings-rel-ntla-20180823monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-wt1-as-its-first-cell-therapy-target-following-presentatio-ntla-20180517monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-march-healthcare-investor-conferences-ntla-20180228monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-publication-in-cell-reports-of-preclinical-data-demonstrat-ntla-20180227monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-february-healthcare-investor-conferences-ntla-20180131monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-new-robust-genome-editing-data-for-sickle-cell-disease-at--ntla-20171211monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-november-healthcare-investor-conferences-ntla-20171102monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-proposed-public-offering-of-common-stock-ntla-20171101monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-third-quarter-2017-earnings-ntla-20171030monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences-ntla-20171003monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-demonstrates-sustained-and-durable-genome-editing-with-crispr-cas9-i-ntla-20170926monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-upcoming-september-investor-healthcare-conferences-ntla-20170907monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-patent-for-crispr-cas-genome-editing-in-china-ntla-20170619monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-and-san-raffaele-university-and-research-hospital-to-combine-crispr--ntla-20170606monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-progress-with-crispr-cas9-at-the-american-society-of-gene--ntla-20170513monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-and-crispr-therapeutics-announce-u-s-patent-covering-crispr-cas9-rib-ntla-20170426monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-european-patent-office-s-decision-to-grant-crispr-cas9-gen-ntla-20170411monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-fourth-quarter-and-full-year-2016-financial-results-ntla-20170314monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-demonstrates-pioneering-crispr-cas9-genome-editing-efficiency-data-u-ntla-20170308monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-march-investor-healthcare-conferences-ntla-20170301monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-address-patent-interference-proceedings-ntla-20170215monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-leerink-partners-6th-annual-global-healthcare-conferen-ntla-20170201monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-joins-genomics-england-s-industry-consortium-ntla-20170111monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-names-graeme-bell-chief-financial-officer-ntla-20161213monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-opens-new-headquarters-as-company-continues-to-advance-crispr-cas9-p-ntla-20161201monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-november-investor-healthcare-conferences-ntla-20161031monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-data-at-the-european-society-of-gene-cell-therapy-congres-ntla-20161014monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-jefferies-gene-editing-therapy-summit-ntla-20161005monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-september-investor-healthcare-conferences-ntla-20160901monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-preclinical-data-show-continued-progress-in-in-vivo-gene-editing-wit-ntla-20160819monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-2016-wedbush-pacgrow-healthcare-conference-ntla-20160810monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-to-present-at-the-jefferies-2016-healthcare-conference-and-the-inter-ntla-20160603monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inc-nasdaq-ntla-to-ring-the-nasdaq-stock-market-opening-bell-ntla-20160511monthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-announces-pricing-of-initial-public-offering-ntla-20160505monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-final-deadline-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-srpt-20250825monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-lawsuit-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsui-srpt-20250821monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-g-srpt-20250821monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-los-srpt-20250819monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-class-action-levi-korsinsky-reminds-sarepta-investors-of-the-pend-srpt-20250819monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-srpt-august-25-2025-lead-plaintiff-deadline-approaching-srpt-investor-srpt-20250818monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-lawsuit-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsui-srpt-20250816monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-srpt-declines-again-on-ema-recommendation-to-refuse-elevidys-marketin-srpt-20250815monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-los-srpt-20250814monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-srpt-declines-again-on-ema-recommendation-to-refuse-elevidys-marketin-srpt-20250813monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-stock-lose-money-on-your-sarepta-therapeutics-inc-nasdaq-srpt-investment-contact-b-srpt-20250813monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-srpt-lawsuit-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-l-srpt-20250811monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsin-srpt-20250811monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-srpt-declines-again-on-ema-recommendation-to-refuse-elevidys-marketin-srpt-20250811monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-srpt-declines-again-on-ema-recommendation-to-refuse-elevidys-marketin-srpt-20250808monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-los-srpt-20250807monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-srpt-declines-again-on-ema-recommendation-to-refuse-elevidys-marketin-srpt-20250806monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-lawsuit-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-be-srpt-20250805monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-los-srpt-20250805monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-srpt-announces-restructuring-and-elevidys-black-box-warning-ema-recom-srpt-20250804monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-nasdaq-srpt-shareholder-alert-bernstein-liebhard-llp-reminds-sare-srpt-20250804monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-srpt-announces-restructuring-and-elevidys-black-box-warning-ema-recom-srpt-20250801monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-levi--srpt-20250731monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-srpt-tanks-36-after-3rd-patient-death-srpt-securities-class-action-pe-srpt-20250730monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-srpt-tanks-36-after-3rd-patient-death-srpt-securities-class-action-pe-srpt-20250728monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-los-srpt-20250728monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-srpt-tanks-36-after-3rd-patient-death-srpt-securities-class-action-pe-srpt-20250723monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before--srpt-20250722monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-nasdaq-srpt-shareholder-alert-bernstein-liebhard-llp-reminds-sare-srpt-20250721monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-levi--srpt-20250717monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-class-action-the-gross-law-firm-reminds-sarepta-investors-of-the--srpt-20250716monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-nasdaq-srpt-shareholder-alert-bernstein-liebhard-llp-reminds-sare-srpt-20250714monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-l-srpt-20250710monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-levi--srpt-20250708monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-nasdaq-srpt-shareholder-alert-bernstein-liebhard-llp-reminds-sare-srpt-20250707monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-class-action-notice-robbins-llp-reminds-srpt-stockholders-of-the--srpt-20250703monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-levi--srpt-20250703monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-srpt-20250701monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-nasdaq-srpt-investor-alert-investors-with-large-losses-in-sarepta-srpt-20250630monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-los-srpt-20250626monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-investors-company-investigated-by-the-portnoy-law-firm-srpt-20250318monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-company-investigated-by-the-portnoy-law-firm-srpt-20230414monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20221230monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20221130monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20221031monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-third-quarter-2022-financial-results-srpt-20221026monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-presents-new-data-from-its-gene-therapy-and-rna-platforms-at-world-mu-srpt-20221007monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20220930monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-submits-biologics-license-application-for-srp-9001-for-the-treatment--srpt-20220929monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-prices-1-0-billion-of-convertible-senior-notes-due-2027-srpt-20220914monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-proposed-offering-of-1-0-billion-of-convertible-senior-note-srpt-20220912monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-recipients-of-route-79-the-duchenne-scholarship-program-for-srpt-20220907monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-the-morgan-stanley-20th-annual-global-healthcare-confer-srpt-20220906monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-that-fda-has-lifted-its-clinical-hold-on-srp-5051-for-the-t-srpt-20220906monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20220831monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-progress-on-the-myoaav-program-and-exclusive-licensing-agre-srpt-20220808monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-second-quarter-2022-financial-results-and-recent-corporate--srpt-20220802monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20220729monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-intent-to-submit-an-accelerated-approval-biologics-license--srpt-20220729monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-second-quarter-2022-financial-results-and-recent-corporat-srpt-20220726monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-investigational-gene-therapy-srp-9001-for-duchenne-muscular-dystrophy-srpt-20220706monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-share-new-clinical-data-and-integrated-analysis-for-srp-9001-its-i-srpt-20220705monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20220630monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-provides-update-on-srp-5051-for-the-treatment-of-duchenne-muscular-dy-srpt-20220623monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-appoints-michael-chambers-and-kathryn-boor-ph-d-to-its-board-of-direc-srpt-20220602monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-the-goldman-sachs-43rd-annual-global-healthcare-confere-srpt-20220602monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20220531monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-first-quarter-2022-financial-results-and-recent-corporate-d-srpt-20220504monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-the-bofa-securities-2022-healthcare-conference-srpt-20220504monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20220429monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-first-quarter-2022-financial-results-and-recent-corporate-srpt-20220427monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20220331monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-fifth-year-of-route-79-the-duchenne-scholarship-program-srpt-20220308monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-upcoming-investor-conferences-srpt-20220302monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2021-financial-results-and-rec-srpt-20220301monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20220228monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-fourth-quarter-and-full-year-2021-financial-results-and-r-srpt-20220222monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-and-genedit-share-progress-on-research-collaboration-and-announce-agr-srpt-20220201monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20220131monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-srpt-20220106monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20220101monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20211130monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-names-louise-rodino-klapac-ph-d-head-of-research-and-development-srpt-20211117monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-appoints-stephen-l-mayo-ph-d-to-its-board-of-directors-srpt-20211117monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-third-quarter-2021-financial-results-and-recent-corporate-d-srpt-20211103monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-upcoming-investor-conferences-srpt-20211102monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20211029monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-third-quarter-2021-financial-results-and-recent-corporate-srpt-20211027monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-pricing-of-500-million-public-offering-of-common-stock-srpt-20211014monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-preliminary-financial-results-for-the-third-quarter-ended-s-srpt-20211012monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-proposed-500-000-000-public-offering-of-common-stock-srpt-20211012monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-srp-9001-shows-sustained-functional-improvements-in-multiple-studies--srpt-20211011monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-opens-genetic-therapies-center-of-excellence-in-columbus-ohio-srpt-20211004monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-initiation-of-embark-a-global-pivotal-study-of-srp-9001-a-g-srpt-20211004monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20210930monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-showcase-data-from-its-gene-therapy-and-rna-platforms-at-world-mus-srpt-20210914monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-upcoming-investor-conferences-srpt-20210907monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-recipients-of-route-79-the-duchenne-scholarship-program-srpt-20210907monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20210831monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-second-quarter-2021-financial-results-and-recent-corporate--srpt-20210804monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-executes-licensing-agreement-for-gene-therapy-program-from-nationwide-srpt-20210804monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20210730monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-second-quarter-2021-financial-results-and-recent-corporat-srpt-20210728monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20210630monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-upcoming-investor-conferences-srpt-20210603monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20210528monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-share-expression-and-safety-results-from-study-103-endeavor-evalua-srpt-20210517monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-first-quarter-2021-financial-results-and-recent-corporate-d-srpt-20210505monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-upcoming-investor-conferences-srpt-20210504monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20210430monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-share-clinical-update-for-30-mg-kg-arm-of-momentum-study-for-srp-5-srpt-20210430monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-first-quarter-2021-financial-results-and-recent-corporate-srpt-20210428monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-recommends-stockholders-reject-the-below-market-mini-tender-offer-by-trc-capital-i-srpt-20210426monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-fourth-year-of-route-79-the-duchenne-scholarship-program-srpt-20210323monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-investigational-gene-therapy-srp-9003-for-the-treatment-of-limb-girdl-srpt-20210318monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-results-from-its-gene-therapy-and-rna-platforms-at-the-202-srpt-20210315monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2020-financial-results-and-rec-srpt-20210301monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20210227monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-fda-approval-of-amondys-45-casimersen-injection-for-the-tre-srpt-20210225monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-upcoming-investor-conferences-srpt-20210224monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-fourth-quarter-and-full-year-2020-financial-results-and-r-srpt-20210222monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-winners-of-the-rare-lessons-lesson-planning-competition-srpt-20210204monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20210130monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-and-genevant-sciences-announce-research-collaboration-for-lipid-nanop-srpt-20210113monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-investors-company-investigated-by-the-portnoy-law-firm-srpt-20210112monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-srpt-20210108monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20201231monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-executive-management-changes-srpt-20201214monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-positive-clinical-results-from-momentum-a-phase-2-clinical--srpt-20201207monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-share-clinical-update-for-srp-5051-its-investigational-ppmo-for-th-srpt-20201204monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20201130monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-the-evercore-isi-3rd-annual-healthconx-virtual-conferen-srpt-20201125monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-named-one-of-the-boston-globe-s-top-places-to-work-2020-srpt-20201120monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-third-quarter-2020-financial-results-and-recent-corporate-d-srpt-20201105monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-commence-dosing-of-the-next-study-with-commercial-process-material-srpt-20201105monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-the-29th-annual-credit-suisse-virtual-healthcare-confer-srpt-20201102monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20201030monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-third-quarter-2020-financial-results-and-recent-corporate-srpt-20201029monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20200930monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-investigational-gene-therapy-srp-9003-for-the-treatment-of-limb-girdl-srpt-20200928monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-reports-sustained-functional-improvement-two-years-after-treatment-wi-srpt-20200928monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-recipients-of-route-79-the-duchenne-scholarship-program-srpt-20200915monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-upcoming-investor-conferences-srpt-20200903monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20200831monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-fda-acceptance-of-casimersen-srp-4045-new-drug-application--srpt-20200825monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-and-university-of-florida-announce-collaboration-to-accelerate-the-di-srpt-20200811monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-second-quarter-2020-financial-results-and-recent-corporate--srpt-20200805monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20200731monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-second-quarter-2020-financial-results-and-recent-corporat-srpt-20200729monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-receives-fast-track-designation-for-srp-9001-micro-dystrophin-gene-th-srpt-20200724monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-launches-rare-lessons-program-to-promote-greater-diversity-and-inclus-srpt-20200715monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-signs-agreement-with-hansa-biopharma-for-imlifidase-srpt-20200702monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20200630monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-retirement-of-sandy-mahatme-chief-financial-officer-and-chi-srpt-20200630monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-completes-submission-of-new-drug-application-seeking-approval-of-casi-srpt-20200626monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-and-codiak-biosciences-collaborate-to-research-and-develop-exosome-ba-srpt-20200622monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-and-selecta-biosciences-enter-into-research-license-and-option-agreem-srpt-20200618monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-positive-safety-and-efficacy-data-from-the-srp-9001-micro-d-srpt-20200615monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-share-clinical-update-from-srp-9003-gene-therapy-trial-to-treat-li-srpt-20200605monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-upcoming-investor-conferences-srpt-20200602monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20200529monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-the-2020-rbc-capital-markets-virtual-global-healthcare--srpt-20200512monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-and-dyno-therapeutics-announce-agreement-to-develop-next-generation-g-srpt-20200511monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-first-quarter-2020-financial-results-and-recent-corporate-d-srpt-20200506monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20200430monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-first-quarter-2020-financial-results-and-recent-corporate-srpt-20200429monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-research-agreement-with-u-s-department-of-defense-to-evalua-srpt-20200428monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20200331monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20200228monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-third-year-of-route-79-the-duchenne-scholarship-program-srpt-20200227monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2019-financial-results-and-rec-srpt-20200226monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-fourth-quarter-and-full-year-2019-financial-results-and-r-srpt-20200219monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20200131monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-appoints-renowned-biotech-executive-john-c-martin-to-its-board-of-dir-srpt-20200113monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-srpt-20200106monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20191231monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-partnership-with-roche-in-territories-outside-the-united-st-srpt-20191223monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-250-million-of-non-dilutive-senior-secured-loan-financing-srpt-20191213monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-fda-approval-of-vyondys-53-golodirsen-injection-for-the-tre-srpt-20191212monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20191129monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-and-stridebio-announce-multi-target-strategic-collaboration-to-advance-novel-gene--srpt-20191114monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-third-quarter-2019-financial-results-and-recent-corporate-d-srpt-20191107monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-the-credit-suisse-28th-annual-healthcare-conference-srpt-20191105monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20191031monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-third-quarter-2019-financial-results-and-recent-corporate-srpt-20191024monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-positive-functional-results-from-the-srp-9003-myo-101-gene--srpt-20191004monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20190930monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-srpt-aclaris-therapeutics-inc-acrs-canada-goose-holdings-inc-goos-srpt-20190927monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-9-month-functional-results-from-the-srp-9003-gene-therapy-srpt-20190925monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-recipients-of-route-79-the-duchenne-scholarship-program-srpt-20190905monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-the-morgan-stanley-17th-annual-global-healthcare-confer-srpt-20190903monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20190830monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-receives-complete-response-letter-from-the-us-food-and-drug-administr-srpt-20190819monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-second-quarter-2019-financial-results-and-recent-corporate--srpt-20190807monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20190731monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-second-quarter-2019-financial-results-and-recent-corporat-srpt-20190731monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20190628monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-the-goldman-sachs-40th-annual-global-healthcare-confere-srpt-20190604monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20190531monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-first-quarter-2019-financial-results-and-recent-corporate-d-srpt-20190508monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-announces-agreement-with-nationwide-children-s-hospital-for-rights-to-its-gene-the-srpt-20190508monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-first-quarter-2019-financial-results-and-recent-corporate-srpt-20190501monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20190430monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-gene-therapy-limb-girdle-muscular-dystrophy-type-2e-clinical-data-has-srpt-20190408monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20190329monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-provide-update-on-duchenne-muscular-dystrophy-gene-therapy-program-srpt-20190325monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-pricing-of-375-0-million-public-offering-of-common-stock-srpt-20190306monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20190228monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-second-year-of-route-79-the-duchenne-scholarship-program-srpt-20190228monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-positive-and-robust-expression-and-biomarker-data-from-the--srpt-20190227monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-exercises-option-to-acquire-myonexus-therapeutics-srpt-20190227monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-limb-girdle-muscular-dystrophy-type-2e-data-results-and-f-srpt-20190220monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-announces-fda-acceptance-of-golodirsen-srp-4053-new-drug-application-for-patients--srpt-20190214monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20190131monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-enters-into-long-term-strategic-relationship-with-aldevron-for-gmp-gr-srpt-20190102monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-srpt-20190102monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20181231monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-completes-submission-of-new-drug-application-seeking-approval-of-golo-srpt-20181220monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-appoints-mary-ann-gray-ph-d-to-its-board-of-directors-srpt-20181211monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20181130monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-pricing-of-500-000-000-public-offering-of-common-stock-srpt-20181109monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-credit-suisse-27th-annual-healthcare-conference-srpt-20181102monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20181031monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-third-quarter-2018-financial-results-and-recent-corporate-d-srpt-20181024monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-third-quarter-2018-financial-results-and-recent-corporate-srpt-20181018monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-and-lysogene-announce-exclusive-license-agreement-for-lys-saf302-a-late-stage-gene-srpt-20181015monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-enters-into-long-term-strategic-manufacturing-partnership-with-parago-srpt-20181008monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-announces-agreement-with-nationwide-children-s-hospital-for-rights-to-its-gene-the-srpt-20181005monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-that-at-the-23rd-international-congress-of-the-world-muscle-srpt-20181003monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20180928monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-and-jerry-r-mendell-m-d-from-nationwide-children-s-hospital-to-provid-srpt-20180926monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-announces-clinical-hold-lifted-for-its-duchenne-muscular-dystrophy-micro-dystrophi-srpt-20180924monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-receives-negative-chmp-re-examination-opinion-for-eteplirsen-srpt-20180921monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-recognize-world-duchenne-awareness-day-at-nasdaq-opening-bell-cere-srpt-20180907monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-two-upcoming-investor-conferences-srpt-20180904monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20180831monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-recipients-of-route-79-the-duchenne-scholarship-program-srpt-20180820monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-second-quarter-2018-financial-results-and-recent-corporate--srpt-20180808monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-signs-long-term-strategic-investment-and-license-agreements-with-lace-srpt-20180808monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20180731monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-that-phase-1-2a-duchenne-muscular-dystrophy-dmd-micro-dystr-srpt-20180725monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-second-quarter-2018-financial-results-and-recent-corporat-srpt-20180720monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20180629monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-enters-into-long-term-strategic-manufacturing-partnership-with-bramme-srpt-20180613monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20180611monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-host-r-d-day-on-tuesday-june-19-2018-srpt-20180608monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-appoints-gilmore-o-neill-m-b-m-m-sc-as-chief-medical-officer-srpt-20180607monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-two-upcoming-investor-conferences-srpt-20180605monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-appoints-louise-rodino-klapac-ph-d-to-lead-newly-created-gene-therapy-srpt-20180604monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20180531monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-partnership-with-myonexus-therapeutics-for-the-advancement--srpt-20180503monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20180430monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-first-quarter-2018-financial-results-and-recent-corporate-srpt-20180423monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20180330monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-launch-of-route-79-the-duchenne-scholarship-program-srpt-20180320monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20180228monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-two-upcoming-investor-conferences-srpt-20180227monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-fourth-quarter-and-full-year-2017-financial-results-and-r-srpt-20180208monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-the-leerink-partners-7th-annual-global-healthcare-confe-srpt-20180205monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20180131monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-pre-announces-fourth-quarter-2017-revenue-and-provides-full-year-2018-srpt-20180108monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-srpt-20180102monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20171229monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-publication-of-long-term-pulmonary-function-of-eteplirsen-t-srpt-20171227monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-elects-biopharmaceutical-veteran-michael-w-bonney-to-its-board-of-dir-srpt-20171205monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20171130monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-exercise-of-initial-purchasers-option-to-purchase-additiona-srpt-20171110monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-prices-475-million-of-convertible-senior-notes-due-2024-srpt-20171108monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-fda-clearance-of-ind-for-the-company-s-ppmo-exon-51-candida-srpt-20171107monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-and-nationwide-children-s-hospital-announce-fda-clearance-of-ind-for--srpt-20171106monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-and-nationwide-children-s-hospital-announce-u-s-food-and-drug-adminis-srpt-20171103monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-the-26th-annual-credit-suisse-healthcare-conference-srpt-20171101monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20171031monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-signs-exclusive-global-collaboration-with-duke-university-for-gene-ed-srpt-20171031monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-third-quarter-2017-financial-results-and-recent-corporate-srpt-20171016monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20170929monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-the-22nd-international-annual-congress-of-the-world-mus-srpt-20170928monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-appoints-guriqbal-s-basi-ph-d-as-chief-scientific-officer-srpt-20170925monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-ring-nasdaq-stock-market-closing-bell-in-recognition-of-world-duch-srpt-20170906monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-positive-results-in-its-study-evaluating-gene-expression-dy-srpt-20170906monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-nasdaq-srpt-to-ring-the-nasdaq-stock-market-closing-bell-srpt-20170905monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20170831monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-at-three-upcoming-investor-conferences-srpt-20170824monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20170731monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-its-partner-genethon-published-new-micro-dystrophin-gene-th-srpt-20170727monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-pricing-of-325-million-public-offering-of-common-stock-srpt-20170725monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-and-clinigen-launch-a-managed-access-program-to-treat-patients-with-d-srpt-20170719monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20170630monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-second-quarter-2017-financial-results-and-recent-corporat-srpt-20170628monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-grand-opening-of-its-research-and-manufacturing-center-at-a-srpt-20170627monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-and-genethon-announce-a-gene-therapy-research-collaboration-for-the-t-srpt-20170621monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20170531monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-company-overview-at-the-goldman-sachs-38th-annual-global-h-srpt-20170530monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20170501monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-announce-first-quarter-2017-financial-results-and-recent-corporate-srpt-20170417monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-srpt-20170405monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-appointment-of-catherine-stehman-breen-m-d-m-s-as-chief-med-srpt-20170403monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srpt-20170331monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-addition-of-kenneth-fischbeck-m-d-and-matthew-wood-m-d-ph-d-srpt-20170330monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-announces-presentations-at-the-2017-mda-scientific-conference-srpt-20170317monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-to-present-company-overview-at-the-cowen-and-company-37th-annual-heal-srpt-20170302monthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inc-srpt-to-ring-the-nasdaq-stock-market-closing-bell-srpt-20120807monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-co-capr-20260504monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-and-parent-project-muscular-dystrophy-to-host-webinar-highlighting-p-capr-20251216monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-proposed-public-offering-of-common-stock-capr-20251204monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-presents-new-data-demonstrating-a-scalable-framework-for-loading-the-capr-20251124monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-inc-long-term-shareholder-announcement-johnson-fistel-encourages-inv-capr-20251104monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-third-quarter-2025-financial-results-and-recent-corporate-capr-20251031monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-investigation-alert-bragar-eagel-squire-p-c-continues-investigation-into-capricor-capr-20251008monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-inc-long-term-shareholder-announcement-johnson-fistel-encourages-inv-capr-20251003monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-inc-long-term-shareholder-announcement-johnson-fistel-encourages-inv-capr-20250923monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-alert-bragar-eagel-squire-p-c-is-investigating-capricor-therapeutics-inc-on-behal-capr-20250916monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-deadline-alert-bragar-eagel-squire-p-c-reminds-investors-in-capricor-therapeutics-capr-20250914monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-deadline-alert-bragar-eagel-squire-p-c-reminds-investors-in-capricor-therapeutics-capr-20250911monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-lo-capr-20250909monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-inc-nasdaq-capr-shareholder-alert-bernstein-liebhard-llp-reminds-cap-capr-20250908monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-capr-20250907monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-lo-capr-20250905monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-inc-class-action-levi-korsinsky-reminds-capricor-investors-of-the-pe-capr-20250905monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-capr-20250903monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-lo-capr-20250902monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-inc-nasdaq-capr-shareholder-alert-bernstein-liebhard-llp-reminds-cap-capr-20250902monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-lo-capr-20250829monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-capr-20250822monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-lo-capr-20250818monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross--capr-20250818monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross--capr-20250813monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-second-quarter-2025-financial-results-and-recent-corporat-capr-20250806monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-inc-nasdaq-capr-shareholder-alert-bernstein-liebhard-llp-reminds-cap-capr-20250804monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross--capr-20250721monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-capr-20250719monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-inc-nasdaq-capr-investor-alert-investors-with-large-losses-in-capric-capr-20250718monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-provides-regulatory-update-on-deramiocel-bla-for-duchenne-muscular-d-capr-20250624monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-positive-4-year-data-from-hope-2-open-label-extension-stud-capr-20250620monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-orphan-drug-designation-for-becker-muscular-dystrophy-and--capr-20250617monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-key-regulatory-updates-for-its-duchenne-muscular-dystrophy-capr-20250611monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-appoints-michael-binks-m-d-as-chief-medical-officer-capr-20250513monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-first-quarter-2025-financial-results-and-recent-corporate-capr-20250506monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-completion-of-mid-cycle-review-meeting-with-fda-on-deramio-capr-20250505monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-at-the-2025-piper-sandler-virtual-cardio-day-capr-20250401monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-positive-data-demonstrating-long-term-efficacy-of-deramioc-capr-20250317monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-fourth-quarter-and-full-year-2024-financial-results-and-r-capr-20250311monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-at-leerink-s-global-healthcare-conference-2025-capr-20250307monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-participate-in-upcoming-investor-conferences-capr-20250210monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-at-upcoming-investor-conferences-capr-20241202monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-granted-orphan-drug-and-atmp-status-for-deramiocel-by-european-medic-capr-20241120monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-exosome-platform-updates-at-2024-american-association-of--capr-20241112monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-third-quarter-2024-financial-results-and-recent-corporate-capr-20241105monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-closing-of-underwritten-public-offering-and-full-exercise--capr-20241018monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-proposed-public-offering-of-common-stock-capr-20241016monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-positive-long-term-data-from-hope-2-ole-study-in-duchenne--capr-20241011monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-long-term-data-from-hope-2-open-label-extension-study-at--capr-20241004monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-provide-duchenne-muscular-dystrophy-program-update-on-september-2-capr-20240923monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-at-upcoming-investor-and-scientific-conferences-capr-20240906monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-second-quarter-2024-financial-results-and-recent-corporat-capr-20240731monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-set-to-join-russell-2000-and-russell-3000-indexes-capr-20240701monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-long-term-benefit-of-deramiocel-cap-1002-in-both-skeletal--capr-20240628monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-for-the-treatment-of-duchenne-muscular-dystrophy-capr-20240625monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-positive-type-b-meeting-with-fda-for-cap-1002-program-for--capr-20240611monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-positive-3-year-efficacy-results-from-hope-2-open-label-ex-capr-20240604monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-exosome-platform-updates-at-the-american-society-of-gene--capr-20240509monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-at-upcoming-scientific-and-medical-conferences-capr-20240508monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-first-quarter-2024-financial-results-and-recent-corporate-capr-20240506monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-positive-type-b-meeting-with-fda-for-cap-1002-program-for--capr-20240424monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-at-upcoming-investor-conferences-capr-20240321monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-presents-at-2024-muscular-dystrophy-association-mda-clinical-scienti-capr-20240306monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-upcoming-type-b-meeting-with-the-fda-to-discuss-commercial-capr-20240227monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-fourth-quarter-and-full-year-2023-financial-results-and-r-capr-20240222monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-manufacturing-scale-up-of-cap-1002-production-at-new-san-d-capr-20240220monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-collaboration-with-the-national-institutes-of-health-for-c-capr-20240124monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-third-quarter-2023-financial-results-and-recent-corporate-capr-20231107monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-and-parent-project-muscular-dystrophy-to-host-webinar-to-review-late-capr-20231019monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-late-breaking-presentations-at-28th-annual-congress-of-the-capr-20231010monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-second-quarter-2023-financial-results-and-recent-corporat-capr-20230802monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-positive-24-month-results-from-ongoing-hope-2-open-label-e-capr-20230630monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-24-month-results-from-ongoing-hope-2-open-label-extension-capr-20230613monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-follow-up-type-b-clinical-meeting-with-the-fda-for-cap-100-capr-20230607monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-capr-20230504monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-announces-peer-reviewed-publication-demonstrating-the-therapeutic-potential-of-ex-capr-20230427monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-presents-at-2023-muscular-dystrophy-association-mda-clinical-scienti-capr-20230323monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-fourth-quarter-and-full-year-2022-financial-results-and-r-capr-20230308monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-receives-clinical-research-forum-s-2023-top-ten-clinical-research-ac-capr-20230302monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-positive-18-month-results-from-ongoing-hope-2-open-label-e-capr-20230125monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-and-parent-project-muscular-dystrophy-to-host-webinar-to-provide-rec-capr-20230119monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-announces-publication-highlighting-new-advances-for-its-engineered-exosome-platfo-capr-20230112monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-third-quarter-2022-financial-results-and-recent-corporate-capr-20221103monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-one-year-results-from-hope-2-open-label-extension-study-a-capr-20221006monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-at-upcoming-investor-conferences-capr-20220907monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-second-quarter-2022-financial-results-and-recent-corporat-capr-20220803monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-statistically-significant-clinical-benefits-in-skeletal-mu-capr-20220627monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-one-year-efficacy-results-from-its-ongoing-hope-2-open-la-capr-20220617monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-appoints-xavier-avat-as-chief-business-officer-capr-20220525monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-at-the-h-c-wainwright-global-investment-conference-capr-20220518monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-first-quarter-2022-financial-results-and-recent-corporate-capr-20220503monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-participate-in-the-cantor-fitzgerald-rare-orphan-disease-summit-capr-20220329monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-topline-results-from-phase-2-exploratory-inspire-trial-in-se-capr-20220328monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-fourth-quarter-and-full-year-2021-financial-results-and-r-capr-20220303monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-names-dr-daniel-paulson-as-vice-president-of-clinical-development-capr-20220302monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-key-updates-on-its-vaccine-and-therapeutic-programs-for-co-capr-20211213monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-third-quarter-2021-financial-results-and-recent-corporate-capr-20211102monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-at-the-upcoming-investor-and-industry-healthcare-conferen-capr-20210922monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-confe-capr-20210907monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-final-data-from-hope-2-trial-with-cap-1002-in-duchenne-mu-capr-20210902monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporat-capr-20210805monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-announces-joint-publication-with-the-us-army-institute-of-surgical-research-for-c-capr-20210804monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-findings-from-hope-2-open-label-extension-study-at-parent-capr-20210617monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-participate-in-bio-digital-2021-conference-capr-20210610monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-to-present-preclinical-data-for-exosome-mrna-vaccine-for-sars-cov-2-at-the-intern-capr-20210518monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-to-present-at-the-american-society-of-gene-and-cell-therapy-s-24th-annual-meeting-capr-20210512monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-first-quarter-2021-financial-results-and-recent-corporate-capr-20210506monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-new-advances-in-exosome-mediated-mrna-delivery-platform-capr-20210309monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-fourth-quarter-and-full-year-2020-financial-results-and-r-capr-20210304monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-development-of-serology-test-to-confirm-activity-of-sars-c-capr-20210201monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-publication-demonstrating-methods-for-enhanced-potency-of--capr-20210119monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-collaborates-with-lonza-for-the-development-of-cap-1002-its-cell-therapy-candidat-capr-20210112monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-dsmb-recommendation-to-continue-phase-ii-inspire-trial-for-capr-20201229monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-commences-dosing-patients-in-phase-2-trial-of-cap-1002-in-patients-w-capr-20201124monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-third-quarter-2020-financial-results-and-recent-corporate-capr-20201105monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-results-from-the-hope-2-trial-with-cap-1002-in-duchenne-m-capr-20200923monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-at-h-c-wainwright-22nd-annual-global-investment-conferenc-capr-20200910monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-u-s-fda-acceptance-of-its-ind-application-for-a-phase-2-cl-capr-20200825monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-second-quarter-2020-financial-results-and-recent-corporat-capr-20200730monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-to-participate-in-bio-digital-international-convention-capr-20200604monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-to-participate-in-maxim-group-s-covid-19-virtual-conference-series-on-may-27-2020-capr-20200526monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-first-quarter-2020-financial-results-and-recent-corporate-capr-20200513monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-host-key-opinion-leader-call-on-cardiac-complications-of-duchenne-capr-20200413monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-initiates-compassionate-use-program-for-severe-covid-19-patients-using-cap-1002-i-capr-20200403monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-host-a-key-opinion-leader-call-on-why-exosomes-are-uniquely-suite-capr-20200324monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-strategic-plan-for-exosome-platform-technology-products-ex-capr-20200317monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-fourth-quarter-and-full-year-2019-financial-results-and-r-capr-20200311monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-third-quarter-2019-financial-results-and-recent-corporate-capr-20191101monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-host-key-opinion-leader-call-on-the-role-of-cap-1002-for-the-trea-capr-20191021monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-presents-additional-positive-data-from-ongoing-hope-2-study-of-cap-1002-in-duchen-capr-20191007monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-to-present-interim-results-from-the-hope-2-trial-in-a-late-breaking-session-of-th-capr-20191002monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-meet-with-fda-to-discuss-cap-1002-to-treat-duchenne-muscular-dyst-capr-20190924monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-results-from-the-hope-2-trial-of-cap-1002-in-duchenne-mus-capr-20190917monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-at-upcoming-conferences-capr-20190906monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-second-quarter-2019-financial-results-and-recent-corporat-capr-20190730monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-positive-dsmb-safety-and-futility-review-and-continuation--capr-20190725monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-and-parents-project-muscular-dystrophy-to-host-webinar-to-discuss-in-capr-20190717monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-first-quarter-2019-financial-results-and-recent-corporate-capr-20190506monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-fourth-quarter-and-full-year-2018-financial-results-and-r-capr-20190321monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-to-meet-with-fda-under-its-rmat-designation-to-discuss-hope-2-clinical-trial-capr-20181112monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-corporate-overview-and-poster-at-action-duchenne-internat-capr-20181108monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-third-quarter-financial-results-and-corporate-update-on-n-capr-20181106monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-provide-corporate-update-at-bio-europe-conference-on-nov-6-capr-20181102monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-participate-in-upcoming-conferences-capr-20181022monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-at-2018-cell-gene-meeting-on-the-mesa-capr-20181003monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-presents-results-of-studies-of-cap-2003-at-gordon-research-conferenc-capr-20180821monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-second-quarter-financial-results-and-corporate-update-on--capr-20180802monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-and-usaisr-announce-collaboration-to-investigate-exosome-platform-to-treat-injure-capr-20180717monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-and-ppmd-to-host-webinar-for-duchenne-muscular-dystrophy-community-o-capr-20180713monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-at-ppmd-annual-conference-capr-20180628monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-at-the-2018-bio-international-convention-in-boston-capr-20180529monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-first-quarter-2018-financial-results-and-corporate-update-capr-20180504monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-to-present-on-exosomes-at-the-plenary-session-of-the-international-society-for-ce-capr-20180503monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-announces-initiation-of-hope-2-clinical-trial-of-cap-1002-for-duchenne-muscular-d-capr-20180430monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-announces-new-pre-clinical-study-finds-repeat-doses-of-cap-1002-lead-to-enhanced--capr-20180419monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-to-provide-presentation-at-the-alliance-for-regenerative-medicine-s-investor-day-capr-20180412monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-at-upcoming-oppenheimer-and-needham-healthcare-conference-capr-20180321monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-fourth-quarter-and-full-year-2017-financial-results-and-c-capr-20180308monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-to-host-key-opinion-leader-lunch-on-march-9-capr-20180228monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-to-give-update-on-hope-2-clinical-trial-for-cap-1002-at-international-conference--capr-20180212monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-announces-licensing-of-additional-patent-applications-from-cedars-sinai-medical-c-capr-20180116monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-and-cureduchenne-to-host-webinar-on-november-3-2015-at-3-00-p-m-et-capr-20151029monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-at-2015-stem-cell-meeting-on-the-mesa-capr-20150930monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-hold-second-quarter-2015-business-update-and-financial-results-co-capr-20150806monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-appoints-deborah-ascheim-m-d-as-chief-medical-officer-capr-20150804monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-inc-nasdaq-capr-to-ring-the-nasdaq-stock-market-closing-bell-capr-20150622monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-appoints-houman-hemmati-m-d-ph-d-to-vice-president-of-medical-and-cl-capr-20150617monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-and-cureduchenne-to-host-webinar-on-june-19-2015-at-3-00-p-m-et-capr-20150615monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-announces-receipt-of-fda-clearance-for-the-phase-i-ii-study-of-cap-1002-for-the-t-capr-20150608monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-participate-in-two-upcoming-investor-conferences-in-june-capr-20150526monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-hold-first-quarter-2015-business-update-and-financial-results-con-capr-20150505monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-granted-fda-orphan-drug-designation-for-allogeneic-cardiosphere-derived-cells-for-capr-20150422monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-completes-enrollment-of-initial-phase-of-dynamic-clinical-trial-of-cardiosphere-d-capr-20150408monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-completes-enrollment-of-phase-ii-clinical-trial-for-cenderitide-to-t-capr-20150331monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-at-3rd-annual-regen-med-investor-day-on-march-25-2015-in--capr-20150323monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-fourth-quarter-and-full-year-2014-financial-business-highlig-capr-20150318monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-hold-fourth-quarter-2014-business-update-conference-call-on-march-capr-20150312monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-at-the-27th-annual-roth-conference-capr-20150310monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-announces-enrollment-of-its-phase-ii-clinical-trial-for-cenderitide-to-treat-hear-capr-20150305monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-appoints-thomas-copmann-ph-d-as-vice-president-of-regulatory-affairs-capr-20150227monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-and-cureduchenne-to-host-webinar-on-january-21-2015-at-3-00-p-m-et-capr-20150121monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-initiates-the-dynamic-clinical-trial-for-the-treatment-of-advanced-h-capr-20150112monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-linda-marban-ph-d-will-present-a-company-overview-and-serv-capr-20141202monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-favorable-allstar-phase-i-safety-results-capr-20141118monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-hold-duchenne-muscular-dystrophy-data-presentation-call-on-novemb-capr-20141107monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-hold-third-quarter-2014-business-update-conference-call-on-novemb-capr-20141031monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-announces-plans-to-pursue-a-cenderitide-clinical-program-and-enters--capr-20141009monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-hold-second-quarter-2014-business-update-conference-call-on-augus-capr-20140804monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-at-the-first-regenerative-medicine-forum-at-bio-internati-capr-20140623monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-speaks-at-panel-on-regulation-of-stem-cell-derived-therapeutic-produ-capr-20140619monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-on-exosomes-as-a-basis-for-innovative-platform-technology-capr-20140528monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-reports-first-quarter-2014-business-highlights-capr-20140515monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-hold-first-quarter-2014-business-update-conference-call-on-may-15-capr-20140514monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-allstar-phase-i-trial-data-at-acc-annual-meeting-2014-capr-20140328monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-to-present-at-two-upcoming-investor-conferences-capr-20140310monthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-and-janssen-biotech-inc-enter-into-collaboration-agreement-and-exclu-capr-20140106monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-to-present-at-the-american-diabetes-association-85th-scientific-sessions-mbx-20250610monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-announces-additions-to-leadership-team-mbx-20250305monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-presents-mbx-2109-phase-2-avail-hypoparathyroidism-trial-rationale-and-des-mbx-20240930monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-to-participate-in-piper-sandler-35th-annual-healthcare-conference-mbx-20231115monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-to-participate-in-jefferies-healthcare-conference-mbx-20230524monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference-mbx-20230307monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-second-quarter-2023-financial-resu-vir-20230803monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-provide-business-update-and-report-second-quarter-2023-financial-resu-vir-20230726monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-presents-new-data-evaluating-the-potential-for-vir-2218-and-vir-3434-as--vir-20230624monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-multiple-abstracts-highlighting-new-hepatitis-b-and-d-data-acc-vir-20230607monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-participate-in-the-44th-annual-goldman-sachs-global-healthcare-confer-vir-20230605monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-host-a-virtual-only-2023-annual-meeting-of-stockholders-vir-20230517monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-appoints-jeff-calcagno-m-d-as-executive-vice-president-and-chief-busines-vir-20230515monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-first-quarter-2023-financial-resul-vir-20230504monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-participate-in-the-bofa-securities-2023-health-care-conference-vir-20230503monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-receives-expanded-support-to-develop-its-novel-t-cell-vaccine-platform-w-vir-20230502monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-participate-in-the-22nd-annual-needham-virtual-healthcare-conference-vir-20230411monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-participate-in-the-barclays-global-healthcare-conference-vir-20230308monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-participate-in-the-cowen-43rd-annual-health-care-conference-vir-20230228monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2022--vir-20230223monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-positive-final-draft-guidance-on-sotrovimab-from-the-uk-s-nati-vir-20230222monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-vir-20230216monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-appoints-sung-lee-as-chief-financial-officer-vir-20230216monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-amended-collaboration-agreement-with-gsk-vir-20230213monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-retirement-of-ceo-george-scangos-ph-d-appoints-marianne-de-bac-vir-20230125monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-highlight-anticipated-2023-catalysts-and-long-term-growth-strategy-at-vir-20230103monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-achieves-target-enrollment-for-groundbreaking-phase-2-peninsula-trial-ev-vir-20221221monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-ranked-the-fastest-growing-company-in-north-america-on-the-2022-deloitte-vir-20221116monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-presents-new-data-evaluating-the-potential-for-vir-2218-and-vir-3434-to--vir-20221106monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-third-quarter-2022-financial-resul-vir-20221103monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-multiple-abstracts-highlighting-new-hepatitis-b-data-accepted--vir-20221031monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-provide-corporate-update-and-report-third-quarter-2022-financial-resu-vir-20221028monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-first-patient-dosed-in-groundbreaking-phase-2-trial-of-vir-248-vir-20221018monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-participate-in-the-h-c-wainwright-3rd-annual-hepatitis-b-virus-hbv-co-vir-20221011monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-first-patient-dosed-in-the-phase-2-solstice-trial-evaluating-v-vir-20220922monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-participate-in-the-morgan-stanley-20th-annual-global-healthcare-confe-vir-20220906monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-second-quarter-2022-financial-resu-vir-20220809monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-provide-corporate-update-and-report-second-quarter-2022-financial-res-vir-20220721monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-transition-of-chief-scientific-officer-vir-20220714monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-new-clinical-data-from-its-broad-hepatitis-b-program-vir-20220625monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-multiple-abstracts-highlighting-new-hepatitis-b-data-accepted--vir-20220608monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-reminds-stockholders-of-2022-annual-general-meeting-details-vir-20220518monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-provides-corporate-update-and-reports-first-quarter-2022-financial-resul-vir-20220505monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-new-data-from-the-march-hepatitis-b-trial-unveils-new-hepatiti-vir-20220427monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-provide-corporate-update-and-report-first-quarter-2022-financial-resu-vir-20220421monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-host-a-virtual-hepatitis-portfolio-r-d-day-vir-20220413monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-scientists-named-winners-of-the-barda-and-hhs-sponsored-pediatric-covid--vir-20220406monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-participate-in-the-21st-annual-needham-healthcare-conference-vir-20220404monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-participate-in-the-42nd-annual-cowen-healthcare-conference-vir-20220302monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2021-vir-20220210monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-appoints-johanna-friedl-naderer-as-executive-vice-president-and-chief-bu-vir-20220208monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-launches-new-antibody-research-initiative-aimed-at-a-functional-cure-for-vir-20220113monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-present-at-40th-annual-j-p-morgan-healthcare-conference-vir-20220104monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-new-research-describing-the-structural-basis-of-sars-cov-2-omi-vir-20211231monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-initiation-of-phase-2-clinical-trial-evaluating-vir-2218-selga-vir-20211209monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-host-a-call-on-sotrovimab-s-retained-activity-against-the-omicron-sar-vir-20211207monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-presents-new-data-evaluating-the-potential-for-vir-2218-and-vir-3434-to--vir-20211112monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-provide-corporate-update-and-report-third-quarter-2021-financial-resu-vir-20211021monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-multiple-abstracts-highlighting-new-hepatitis-b-data-accepted--vir-20211015monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-participate-in-the-h-c-wainwright-2nd-annual-hepatitis-b-virus-hbv-co-vir-20211006monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-participate-in-the-guggenheim-2nd-annual-vaccine-infectious-disease-d-vir-20210930monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-participate-in-the-morgan-stanley-19th-annual-global-healthcare-confe-vir-20210908monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-confe-vir-20210907monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-first-marketing-authorization-for-its-first-commercial-product-vir-20210823monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-provide-corporate-update-and-report-second-quarter-2021-financial-res-vir-20210722monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-initiates-phase-2-clinical-trial-evaluating-the-combination-of-vir-2218--vir-20210715monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-presents-new-clinical-data-from-ongoing-trials-of-vir-2218-and-vir-3434--vir-20210625monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-multiple-abstracts-highlighting-new-hepatitis-b-data-accepted--vir-20210614monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-participate-in-the-goldman-sachs-42nd-annual-global-healthcare-confer-vir-20210602monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-reminds-stockholders-of-2021-annual-general-meeting-details-vir-20210510monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-provide-corporate-update-and-report-first-quarter-2021-financial-resu-vir-20210422monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-new-research-demonstrating-novel-mechanisms-by-which-sars-cov--vir-20210408monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-present-at-the-20th-annual-needham-virtual-healthcare-conference-vir-20210406monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-new-preclinical-research-demonstrating-vir-7831-maintains-neut-vir-20210405monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-and-gsk-announce-vir-7831-reduces-hospitalization-and-risk-of-death-in-e-vir-20210311monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-and-gsk-provide-update-on-nih-sponsored-activ-3-trial-evaluating-vir-783-vir-20210303monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2020-vir-20210211monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-new-data-highlighting-the-importance-of-targeting-conserved-re-vir-20210201monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-and-gsk-announce-nhs-supported-agile-study-to-evaluate-vir-7832-in-the-e-vir-20210112monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-initiation-of-phase-1-clinical-trial-to-evaluate-a-novel-vacci-vir-20210106monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-present-at-39th-annual-j-p-morgan-healthcare-conference-vir-20210105monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-and-gsk-announce-start-of-nih-sponsored-activ-3-trial-evaluating-vir-783-vir-20201217monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-appoints-jeffrey-hatfield-to-its-board-of-directors-vir-20201210monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-publishes-new-research-characterizing-variation-in-the-sars-cov-2-spike--vir-20201106monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-provide-corporate-update-and-report-third-quarter-2020-financial-resu-vir-20201027monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-presents-new-data-on-vir-2482-the-company-s-investigational-monoclonal-a-vir-20201021monthly0.5https://www.biopharmawatch.com/news/VIR/vir-and-alnylam-to-webcast-virtual-fireside-chat-at-h-c-wainwright-hepatitis-b-virus-mini--vir-20201013monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-and-gsk-announce-global-expansion-to-phase-3-of-comet-ice-study-evaluati-vir-20201006monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-publishes-new-research-characterizing-antibody-response-to-sars-cov-2-in-vir-20200924monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-present-at-cantor-global-virtual-healthcare-conference-vir-20200909monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-present-at-h-c-wainwright-22nd-annual-global-investment-conference-vir-20200908monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-appoints-janet-napolitano-to-its-board-of-directors-vir-20200901monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-and-gsk-start-phase-2-3-study-of-covid-19-antibody-treatment-vir-20200831monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-presents-data-on-vir-2218-from-clinical-studies-for-the-treatment-of-hep-vir-20200820monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-provide-corporate-update-and-report-second-quarter-2020-financial-res-vir-20200728monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-appoints-elliott-sigal-m-d-ph-d-to-board-of-directors-vir-20200710monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-closing-of-public-offering-of-common-stock-and-full-exercise-o-vir-20200710monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-pricing-of-public-offering-of-common-stock-vir-20200708monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-proposed-public-offering-of-common-stock-vir-20200706monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-initiates-phase-1-clinical-trial-of-vir-3434-for-chronic-hepatitis-b-vir-vir-20200527monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-change-to-virtual-format-for-2020-annual-meeting-of-stockholde-vir-20200508monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-present-at-bofa-securities-2020-health-care-conference-vir-20200507monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-provide-corporate-update-and-report-first-quarter-2020-financial-resu-vir-20200428monthly0.5https://www.biopharmawatch.com/news/VIR/vir-2218-demonstrates-dose-dependent-and-durable-reductions-of-hepatitis-b-surface-antigen-vir-20200415monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-host-key-opinion-leader-call-and-present-update-on-phase-1-2-hbv-clin-vir-20200408monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-proceeding-with-two-clinical-development-candidates-for-covid-19-vir-20200325monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-intent-to-collaborate-with-biogen-on-manufacturing-of-antibodi-vir-20200312monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-research-collaboration-with-the-national-institutes-of-health--vir-20200311monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-present-at-barclays-global-healthcare-conference-vir-20200311monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-and-wuxi-biologics-announce-collaboration-for-global-development-of-anti-vir-20200225monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-present-at-40th-annual-cowen-healthcare-conference-vir-20200225monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-provide-pipeline-update-at-38th-annual-j-p-morgan-healthcare-conferen-vir-20200113monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-to-present-at-38th-annual-j-p-morgan-healthcare-conference-vir-20200107monthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-pricing-of-initial-public-offering-vir-20191010monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20260610monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-holding-ag-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-more-info-ocs-20260602monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20260529monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20260515monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-invitation-to-the-annual-general-meeting-ocs-20260421monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20260408monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20260327monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-present-at-upcoming-north-american-neuro-ophthalmology-society-annual-meeting-ocs-20260316monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20260316monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20260313monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20260311monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20260306monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-2025-consolidated-financial-statements-ocs-20260305monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20260304monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20260227monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20260218monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-showcase-transformative-late-stage-pipeline-in-neuro-ophthalmology-and-ophthalmo-ocs-20260108monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20260105monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20251209monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20251203monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20251128monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20251118monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20251014monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20251008monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notification-of-transactions-by-person-discharging-managerial-responsibil-ocs-20250926monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-announces-presentation-of-phase-2-acuity-trial-results-with-privosegtor-in-acute-op-ocs-20250922monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20250909monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-and-euretina-announce-the-winner-of-the-ramin-tadayoni-award-2025-ocs-20250904monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20250903monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-present-clinical-trial-results-in-diabetic-macular-edema-and-acute-optic-neuriti-ocs-20250901monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-participate-in-upcoming-september-investor-conferences-ocs-20250828monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-appoints-mark-kupersmith-m-d-and-sebastian-wolf-m-d-ph-d-world-renowned-neuro-ophth-ocs-20250825monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-reports-q2-2025-financial-results-and-provides-company-update-ocs-20250821monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-participate-in-upcoming-h-c-wainwright-5th-annual-ophthalmology-virtual-conferen-ocs-20250812monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-upsized-loan-facility-to-access-up-to-chf-100-million-ocs-20250801monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20250709monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20250609monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-results-of-2025-annual-general-meeting-ocs-20250605monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20250603monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-participate-in-upcoming-june-investor-conferences-ocs-20250603monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-invitation-to-the-annual-general-meeting-ocs-20250509monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-reports-q1-financial-results-and-provides-company-update-ocs-20250508monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-reports-q1-2025-financial-results-and-provides-company-update-ocs-20250508monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-present-at-upcoming-may-investor-conferences-ocs-20250507monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-present-its-innovative-late-stage-pipeline-candidates-at-upcoming-ophthalmology--ocs-20250501monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-updates-share-capital-ocs-20250425monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-and-euretina-announce-the-2025-ramin-tadayoni-award-ocs-20250417monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-hosts-r-d-event-today-to-showcase-progress-on-all-three-pipeline-assets-ocs-20250415monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-completes-enrollment-in-both-diamond-phase-3-trials-of-ocs-01-in-diabetic-macular-e-ocs-20250410monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20250409monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-host-in-person-and-virtual-r-d-day-on-key-business-updates-and-the-development-p-ocs-20250401monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-person-discharging-managerial-responsibi-ocs-20250320monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20250314monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-reports-q4-and-full-year-2024-financial-results-and-provides-company-update-ocs-20250311monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-present-at-upcoming-march-investor-conference-ocs-20250305monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20250303monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-announces-pricing-of-100-million-oversubscribed-offering-of-ordinary-shares-ocs-20250214monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20250207monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-updates-share-capital-for-its-existing-at-the-market-offering-program-ocs-20250131monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notification-of-major-changes-in-voting-rights-ocs-20250121monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notification-of-major-changes-in-voting-rights-ocs-20250103monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20241206monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20241129monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notification-of-transaction-by-person-discharging-managerial-responsibili-ocs-20241127monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-present-at-the-stifel-2024-healthcare-conference-ocs-20241113monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-reports-q3-2024-financial-results-and-provides-company-updates-ocs-20241107monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-accelerates-enrollment-in-both-diamond-phase-3-trials-of-ocs-01-in-diabetic-macular-ocs-20241021monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-diamond-phase-3-program-in-diabetic-macular-edema-to-be-presented-at-innovate-retin-ocs-20241015monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-announces-appointment-of-daniel-s-char-as-chief-legal-officer-ocs-20241002monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-and-euretina-announce-the-winner-of-the-inaugural-ramin-tadayoni-award-ocs-20240919monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-present-at-upcoming-september-investor-conferences-ocs-20240829monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-consolidated-q2-financial-statements-and-md-a-ocs-20240827monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-reports-q2-2024-financial-results-and-provides-recent-company-update-ocs-20240827monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-reports-q2-financial-results-and-provides-recent-company-update-ocs-20240827monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-appoints-sharon-klier-m-d-m-s-m-p-h-as-chief-development-officer-ocs-20240815monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-participate-in-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference-ocs-20240730monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-and-euretina-announces-the-ramin-tadayoni-award-ocs-20240627monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsib-ocs-20240604monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-results-of-2024-annual-general-meeting-and-announces-appointments-to-its--ocs-20240530monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-updates-share-capital-for-its-existing-at-the-market-offering-program-ocs-20240517monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-reports-q1-2024-financial-results-and-provides-company-updates-ocs-20240508monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-announces-completion-of-enrollment-in-phase-2-randomized-controlled-acuity-trial-wi-ocs-20240508monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-publishes-invitation-to-the-annual-general-meeting-ocs-20240507monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-present-at-bank-of-america-global-healthcare-conference-ocs-20240506monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-announces-closing-of-registered-direct-offering-and-commencement-of-trading-on-nasd-ocs-20240422monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-strengthens-its-executive-leadership-team-with-the-appointment-of-snehal-shah-pharm-ocs-20240410monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-participate-at-upcoming-april-investor-conferences-ocs-20240404monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-reports-q4-and-full-year-2023-financial-results-and-update-on-company-progress-ocs-20240318monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-provides-updates-at-r-d-day-on-late-stage-clinical-trials-and-announces-key-leaders-ocs-20240228monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-present-at-upcoming-february-investor-conferences-ocs-20240129monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-host-in-person-virtual-r-d-day-in-new-york-on-february-28-2024-ocs-20240122monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-announces-first-patient-first-visit-in-phase-3-optimize-2-trial-of-ocs-01-for-the-t-ocs-20231220monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-announces-first-patient-first-visit-in-phase-3-diamond-1-trial-of-ocs-01-eye-drop-i-ocs-20231218monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-reports-q3-2023-financial-results-and-provides-company-update-ocs-20231115monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-present-at-upcoming-november-investor-conferences-ocs-20231108monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-present-a-late-breaking-abstract-at-the-american-academy-of-ophthalmology-2023-a-ocs-20231101monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-present-a-late-breaking-abstract-at-the-23rd-euretina-congress-on-positive-phase-ocs-20231005monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-expands-its-executive-leadership-team-and-appoints-rebecca-weil-ph-d-as-chief-comme-ocs-20230911monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-present-at-upcoming-september-investor-conferences-ocs-20230830monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-reports-q2-and-first-half-2023-financial-results-and-provides-company-update-ocs-20230829monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-announces-to-present-at-upcoming-august-investor-conferences-ocs-20230726monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-present-at-ois-retina-innovation-summit-ocs-20230719monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-host-an-r-d-retina-day-to-showcase-clinical-programs-targeting-diabetic-macular--ocs-20230626monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-wins-the-2023-icelandic-knowledge-award-from-the-icelandic-association-of-business--ocs-20230612monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-participate-in-jefferies-healthcare-conference-ocs-20230601monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-participate-and-present-at-upcoming-eudes-meeting-ocs-20230524monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-co-founders-selected-as-finalists-in-european-inventor-award-2023-ocs-20230511monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-opens-new-offices-in-the-us-and-expands-its-us-team-by-appointing-dr-fang-li-as-sen-ocs-20230426monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-participate-at-upcoming-investor-conferences-ocs-20230405monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-host-conference-call-on-april-13-2023-to-discuss-late-stage-pipeline-and-near-te-ocs-20230404monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-to-ring-nasdaq-stock-market-opening-bell-in-celebration-of-its-successful-listing-ocs-20230322monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-completes-enrollment-in-phase-3-ocs-01-optimize-trial-ocs-20230316monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-announces-us-public-listing-on-nasdaq-ocs-20230303monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-sa-and-european-biotech-acquisition-corp-announce-business-combination-agreement-to-ocs-20221017monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-establishes-presence-in-u-s-and-appoints-sylvia-cheung-as-chief-financial-officer-ocs-20200901monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-appoints-marcia-de-souza-lima-m-d-as-chief-medical-officer-ocs-20200303monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-announces-positive-ocs-01-phase-2-data-in-patients-with-diabetic-macular-edema-dme-ocs-20200210monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-announces-upcoming-presentation-of-phase-2-data-of-ocs-01-in-patients-with-diabetic-ocs-20200122monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-announces-dosing-of-first-patient-in-randomized-phase-2b-skyggn-clinical-trial-of-o-ocs-20191007monthly0.5https://www.biopharmawatch.com/news/OCS/oculis-announces-appointment-of-leading-ophthalmology-specialists-to-scientific-advisory-b-ocs-20190917monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-showcases-rise-up-phase-3-results-at-eha-2026-plenary-session-reinforcing-strong-ant-agio-20260613monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-submits-snda-to-fda-for-u-s-accelerated-approval-of-mitapivat-in-sickle-cell-disease-agio-20260512monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-new-data-at-eha-2026-reinforcing-the-significant-therapeutic-impact-of-mi-agio-20260512monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-host-first-quarter-2026-financial-results-conference-call-and-webcast-on-april-29-agio-20260406monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-advances-mitapivat-toward-potential-u-s-accelerated-approval-in-sickle-cell-disease--agio-20260331monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia-agio-20251208monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-topline-results-from-rise-up-phase-3-trial-of-mitapivat-in-sickle-cell-dis-agio-20251119monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-host-webcast-conference-call-of-second-quarter-financial-results-on-july-31-2025--agio-20250714monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-highlight-pyruvate-kinase-activation-portfolio-with-new-data-in-rare-blood-disord-agio-20250514monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-2025-rbc-capital-markets-global-healthcare-conference-on-may-21-20-agio-20250509monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-bofa-securities-2025-health-care-conference-on-may-14-2025-agio-20250502monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-first-quarter-financial-results-on-may-1-2025-agio-20250417monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-to-newly-appointed-chie-agio-20250305monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-upcoming-investor-conferences-agio-20250304monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-td-cowen-45th-annual-healthcare-conference-on-march-3-2025-agio-20250220monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-phase-3-activate-kids-study-of-mitapivat-in-children-with-pyruvate-kinase-pk-deficie-agio-20250213monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-fourth-quarter-and-full-year-2024-financial-results-on-agio-20250206monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-on-january-15-2025-agio-20250103monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-positive-results-from-phase-3-energize-t-study-of-mitapivat-at-ash-2024-and-agio-20241208monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-new-data-on-mitapivat-and-tebapivat-in-rare-blood-disorders-at-66th-ash-a-agio-20241105monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-completes-enrollment-of-phase-3-rise-up-study-of-mitapivat-in-sickle-cell-disease-agio-20241023monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-third-quarter-2024-financial-results-on-october-31-202-agio-20241017monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-fda-orphan-drug-designation-granted-to-tebapivat-ag-946-for-treatment-of-m-agio-20240911monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-2024-cantor-global-healthcare-conference-on-september-18-2024-agio-20240905monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-receive-1-1-billion-in-milestone-payments-following-fda-approval-of-vorasidenib-agio-20240806monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-results-from-phase-3-activate-kidst-study-of-mitapivat-in-children-with-pk-agio-20240801monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-second-quarter-2024-financial-results-on-august-1-2024-agio-20240718monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-positive-results-from-phase-3-energize-study-of-mitapivat-in-non-transfusio-agio-20240615monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-phase-3-energize-t-study-of-mitapivat-met-primary-endpoint-and-all-key-sec-agio-20240603monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-goldman-sachs-45th-annual-global-healthcare-conference-on-june-10--agio-20240530monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-to-present-clinical-and-translational-data-in-rare-blood-disorders-a-agio-20240514monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-bofa-securities-2024-health-care-conference-on-may-16-2024-agio-20240506monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-rbc-capital-markets-global-healthcare-conference-on-may-14-2024-agio-20240503monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-first-quarter-2024-financial-results-on-may-2-2024-agio-20240418monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-publishes-2024-environmental-social-and-governance-esg-report-agio-20240409monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-leerink-partners-global-biopharma-conference-on-march-12-2024-agio-20240305monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-td-cowen-44th-annual-health-care-conference-on-march-4-2024-agio-20240222monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-fourth-quarter-and-year-end-2023-financial-results-on--agio-20240202monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-phase-3-energize-study-of-mitapivat-met-primary-endpoint-and-both-key-seco-agio-20240103monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-on-january-10-2024-agio-20240102monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-positive-results-from-phase-2-portion-of-the-rise-up-pivotal-study-in-sickl-agio-20231210monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-clinical-proof-of-concept-in-phase-2a-trial-of-ag-946-for-the-treatment-of-agio-20231120monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-to-present-broad-set-of-clinical-and-translational-data-in-rare-bloo-agio-20231102monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-third-quarter-2023-financial-results-on-nov-2-2023-agio-20231019monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-morgan-stanley-global-healthcare-conference-on-september-12-2023-agio-20230829monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-exclusive-worldwide-license-agreement-for-novel-sirna-for-the-potential-tr-agio-20230803monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-second-quarter-2023-financial-results-on-aug-3-2023-agio-20230713monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-positive-results-from-phase-2-portion-of-rise-up-pivotal-study-in-sickle-c-agio-20230626monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-goldman-sachs-global-healthcare-conference-on-june-15-2023-agio-20230605monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-appoints-catherine-owen-to-board-of-directors-agio-20230525monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-clinical-and-translational-data-at-european-hematology-association-annual-agio-20230511monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-rbc-capital-markets-global-healthcare-conference-on-may-16-2023-agio-20230425monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-appoints-jeffrey-capello-to-board-of-directors-agio-20230419monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-first-quarter-2023-financial-results-on-may-4-2023-agio-20230413monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-publishes-2023-environmental-social-and-governance-esg-report-agio-20230403monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-participate-in-march-investor-conferences-agio-20230302monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-launches-red-cell-revolution-in-recognition-of-rare-disease-day-agio-20230228monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-fourth-quarter-and-year-end-2022-financial-results-on--agio-20230202monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-to-newly-appointed-chie-agio-20230103monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-41st-annual-j-p-morgan-healthcare-conference-on-wednesday-january-11-2-agio-20221221monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-updated-pyrukynd-mitapivat-long-term-extension-data-demonstrating-sustained-agio-20221212monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-updated-pyrukynd-mitapivat-data-highlighting-long-term-safety-profile-and-d-agio-20221210monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-participate-in-december-investor-conference-agio-20221130monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-to-present-broad-set-of-clinical-and-translational-data-in-chronic-h-agio-20221103monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-third-quarter-2022-financial-results-on-november-3-202-agio-20221020monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-to-newly-appointed-chie-agio-20220926monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-receives-positive-chmp-opinion-for-pyrukynd-mitapivat-for-the-treatment-of-pyruvate--agio-20220916monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-participate-in-september-investor-conferences-agio-20220824monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-publication-of-phase-3-activate-t-data-in-the-lancet-haematology-demonstra-agio-20220818monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-appoints-rahul-ballal-and-cynthia-smith-to-board-of-directors-agio-20220815monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-to-newly-appointed-chie-agio-20220808monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-second-quarter-2022-financial-results-on-august-4-2022-agio-20220714monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-new-clinical-data-supporting-the-benefits-of-pyrukynd-mitapivat-treatment-i-agio-20220610monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-evolution-of-research-organization-agio-20220516monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-clinical-and-translational-data-at-the-european-hematology-association-an-agio-20220512monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-rbc-capital-markets-global-healthcare-conference-on-may-17-2022-agio-20220510monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-first-quarter-2022-financial-results-on-may-5-2022-agio-20220421monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-publication-of-phase-3-activate-study-in-new-england-journal-of-medicine-d-agio-20220414monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-participate-in-march-investor-conferences-agio-20220228monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-fda-approval-of-pyrukynd-mitapivat-as-first-disease-modifying-therapy-for--agio-20220217monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-fourth-quarter-and-year-end-2021-financial-results-on--agio-20220210monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-highlights-2022-anticipated-milestones-and-priorities-to-drive-company-s-strategic-v-agio-20220110monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-40th-annual-j-p-morgan-healthcare-conference-on-wednesday-january-12-2-agio-20211222monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-mitapivat-long-term-extension-data-demonstrating-durability-of-hemoglobin-r-agio-20211213monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-data-from-investigator-led-studies-of-mitapivat-in-adults-with-sickle-cell-agio-20211213monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-appoints-richa-poddar-as-chief-commercial-officer-agio-20211115monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-broad-set-of-clinical-and-translational-data-in-chronic-hemolytic-anemias-agio-20211104monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-third-quarter-2021-financial-results-on-nov-3-2021-agio-20211021monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-september-investor-conferences-agio-20210830monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-mitapivat-f-agio-20210817monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-second-quarter-2021-financial-results-on-july-29-2021-agio-20210715monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-submits-marketing-authorisation-application-to-european-medicines-agency-for-mitapiv-agio-20210628monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-launches-myagios-patient-support-services-for-pyruvate-kinase-deficiency-agio-20210622monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-submits-new-drug-application-to-fda-for-mitapivat-for-treatment-of-adults-with-pyruv-agio-20210621monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-updated-data-from-activate-and-activate-t-phase-3-studies-of-mitapivat-in--agio-20210611monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-updated-data-from-clinical-trials-of-mitapivat-in-pyruvate-kinase-deficie-agio-20210512monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-first-quarter-2021-financial-results-on-april-29-2021-agio-20210415monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-sponsors-program-promoting-health-literacy-for-patients-with-sickle-cell-disease-agio-20210318monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-submits-supplemental-new-drug-application-to-fda-for-tibsovo-ivosidenib-tablets-for--agio-20210301monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-recognizes-14th-annual-rare-disease-day-and-raises-awareness-of-unmet-needs-in-rare--agio-20210226monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-march-investor-conferences-agio-20210223monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-fourth-quarter-and-year-end-2020-financial-results-on--agio-20210211monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-final-data-from-phase-3-claridhy-study-of-tibsovo-ivosidenib-tablets-in-pat-agio-20210117monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-on-monday-january-11--agio-20210105monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-launches-anemia-id-a-no-cost-genetic-testing-program-for-hereditary-anemias-agio-20201130monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference-on-wednesd-agio-20201125monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-fda-orphan-drug-designation-granted-to-mitapivat-for-treatment-of-sickle-c-agio-20201112monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-broad-set-of-clinical-and-translational-data-for-oncology-and-rare-geneti-agio-20201104monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-host-a-webinar-on-its-pyruvate-kinase-r-pkr-activation-clinical-programs-and-comm-agio-20201029monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-third-quarter-2020-financial-results-on-november-5-202-agio-20201022monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-withdrawal-of-european-marketing-authorization-application-for-tibsovo-as--agio-20201016monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-citi-15th-annual-biopharma-virtual-conference-on-wednesday-septemb-agio-20200827monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-virtual-canaccord-40th-annual-growth-conference-on-thursday-august-agio-20200806monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-second-quarter-2020-financial-results-on-july-30-2020-agio-20200716monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-bmo-2020-prescriptions-for-success-healthcare-virtual-conference-o-agio-20200617monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-clinical-proof-of-concept-has-been-established-in-phase-1-study-of-mitapiv-agio-20200612monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-fda-orphan-drug-designation-granted-to-mitapivat-for-treatment-of-thalasse-agio-20200608monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-publication-of-tibsovo-phase-3-data-in-the-lancet-oncology-demonstrating-s-agio-20200519monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-updated-clinical-proof-of-concept-data-from-the-phase-2-study-of-mitapiva-agio-20200514monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-updated-data-from-the-phase-1-study-of-vorasidenib-in-non-enhancing-gliom-agio-20200513monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-rbc-capital-markets-global-healthcare-virtual-conference-on-tuesda-agio-20200512monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-first-quarter-2020-financial-results-on-april-30-2020-agio-20200416monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-receives-positive-opinion-on-orphan-drug-designation-from-the-european-medicines-age-agio-20200330monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-provides-update-on-2016-collaboration-agreement-with-celgene-a-wholly-owned-subsidia-agio-20200325monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-fda-clearance-of-investigational-new-drug-application-for-ag-946-a-next-ge-agio-20200323monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-cowen-40th-annual-healthcare-conference-on-tuesday-march-3-2020-agio-20200218monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-leerink-9th-annual-global-healthcare-conference-on-tuesday-februar-agio-20200211monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-fourth-quarter-and-full-year-2019-financial-results-on-agio-20200130monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-on-monday-january-13--agio-20191223monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-receives-fda-breakthrough-therapy-designation-for-tibsovo-ivosidenib-for-the-treatme-agio-20191216monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-updated-data-for-mitapivat-from-extension-phase-of-the-drive-pk-study-in-pa-agio-20191209monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-translational-data-to-further-characterize-the-role-of-tibsovo-ivosidenib-t-agio-20191209monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-appoints-bruce-car-ph-d-as-chief-scientific-officer-agio-20191202monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-appoints-jonathan-biller-as-chief-legal-officer-agio-20191125monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additio-agio-20191113monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-proposed-offering-of-common-stock-agio-20191106monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-broad-set-of-clinical-and-translational-data-for-oncology-and-rare-geneti-agio-20191106monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-third-quarter-2019-financial-results-on-october-31-201-agio-20191017monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-data-from-ag-270-phase-1-dose-escalation-study-in-patients-with-mtap-dele-agio-20191009monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-data-from-the-phase-3-claridhy-study-of-tibsovo-in-previously-treated-idh-agio-20190910monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-citi-14th-annual-biotech-conference-on-thursday-september-5-2019-agio-20190829monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-second-quarter-2019-financial-results-on-august-1-2019-agio-20190718monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-orlando-oliveira-appointed-as-senior-vice-president-and-general-manager-in-agio-20190701monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-goldman-sachs-global-healthcare-conference-on-tuesday-june-11-2019-agio-20190610monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-the-planned-retirement-of-chief-scientific-officer-scott-biller-ph-d-effec-agio-20190605monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-clinical-data-from-its-idh-program-at-asco-agio-20190515monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-first-quarter-2019-financial-results-on-may-2-2019-agio-20190425monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-new-commercial-leadership-structure-agio-20190402monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-receives-fda-breakthrough-therapy-designation-for-tibsovo-ivosidenib-in-combination--agio-20190326monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-cowen-39th-annual-health-care-conference-on-monday-march-11-2019-agio-20190304monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-updated-data-from-phase-1-study-of-ivosidenib-in-combination-with-azacitidin-agio-20190225monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-leerink-global-healthcare-conference-on-thursday-february-28-2019-agio-20190221monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-fda-acceptance-of-supplemental-new-drug-application-for-tibsovo-ivosidenib-agio-20190220monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-fourth-quarter-and-full-year-2018-financial-results-agio-20190214monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-fourth-quarter-and-full-year-2018-financial-results-on-agio-20190131monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-on-monday-january-7-2-agio-20181228monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-updated-data-from-the-ivosidenib-phase-1-dose-escalation-and-expansion-tria-agio-20181203monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-updated-clinical-data-at-the-2018-ash-annual-meeting-agio-20181101monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-third-quarter-2018-financial-results-on-november-1-201-agio-20181018monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-citi-13th-annual-biotech-conference-wednesday-september-5-2018-agio-20180828monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-second-quarter-2018-financial-results-on-august-2-2018-agio-20180723monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-initiation-of-global-phase-3-trial-activate-of-ag-348-in-adults-with-pyruv-agio-20180618monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-new-clinical-data-from-its-idh-programs-at-asco-agio-20180516monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-revised-starting-time-of-8-00am-et-for-investor-day-and-first-quarter-2018-agio-20180427monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-investor-day-and-first-quarter-2018-financial-results-on-friday-may-4-201-agio-20180411monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-first-patient-dosed-with-mat2a-inhibitor-ag-270-in-phase-1-study-in-patien-agio-20180319monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-cowen-38th-annual-healthcare-conference-monday-march-12-2018-agio-20180305monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-fourth-quarter-and-full-year-2017-financial-results-on-agio-20180131monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additio-agio-20180123monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-proposed-offering-of-common-stock-agio-20180117monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-on-monday-january-8-2-agio-20180102monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-submits-new-drug-application-to-the-fda-for-ivosidenib-for-the-treatment-of-patients-agio-20171226monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-appoints-jacqualyn-fouse-ph-d-to-the-board-of-directors-agio-20171205monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-new-data-from-pkr-and-idh-programs-at-the-2017-ash-annual-meeting-agio-20171101monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-26th-annual-credit-suisse-healthcare-conference-tuesday-november-7-agio-20171031monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-third-quarter-2017-financial-results-on-november-1-201-agio-20171025monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-morgan-stanley-15th-annual-global-healthcare-conference-monday-sep-agio-20170905monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-canaccord-genuity-37th-annual-growth-conference-thursday-august-10-agio-20170803monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-second-quarter-2017-financial-results-on-august-8-2017-agio-20170728monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-appoints-david-scadden-m-d-to-the-board-of-directors-agio-20170531monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-updated-clinical-data-from-pkr-activator-ag-348-at-eha-agio-20170518monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-new-clinical-data-from-its-idh-programs-at-asco-agio-20170517monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-closing-of-over-allotment-option-in-public-offering-agio-20170428monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-and-aurigene-enter-into-exclusive-license-agreement-for-novel-small-molecules-for-ca-agio-20170427monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-first-quarter-2017-financial-results-on-may-4-2017-agio-20170427monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-exercise-of-over-allotment-option-in-public-offering-agio-20170426monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-closing-of-public-offering-agio-20170424monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-proposed-offering-of-common-stock-agio-20170417monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-16th-annual-needham-healthcare-conference-on-tuesday-april-4-2017-agio-20170330monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-cowen-and-company-37th-annual-health-care-conference-on-monday-mar-agio-20170228monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-fourth-quarter-and-full-year-2016-financial-results-on-agio-20170209monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-key-upcoming-milestones-to-support-evolution-to-a-commercial-stage-biophar-agio-20170109monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-appoints-ian-clark-to-board-of-directors-agio-20170103monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-on-monday-january-9-2-agio-20170103monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-provides-update-on-pkr-program-agio-20161215monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-new-clinical-data-from-dose-escalation-portion-of-phase-1-trial-of-single--agio-20161206monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-new-data-from-pkr-and-idh-programs-at-the-2016-ash-annual-meeting-agio-20161103monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-25th-annual-credit-suisse-healthcare-conference-tuesday-november-8-agio-20161101monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-third-quarter-2016-financial-results-on-november-3-201-agio-20161027monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additio-agio-20160920monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-proposed-offering-of-common-stock-agio-20160913monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-morgan-stanley-global-healthcare-conference-tuesday-september-13-2016-agio-20160906monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-canaccord-genuity-36th-annual-growth-conference-wednesday-august-10-20-agio-20160805monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-second-quarter-2016-financial-results-on-august-4-2016-agio-20160728monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-host-conference-call-from-the-21st-congress-of-the-european-hematology-associatio-agio-20160601monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-clinical-and-preclinical-data-from-pkr-activators-ag-348-and-ag-519-at-th-agio-20160519monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-updates-2016-financial-guidance-agio-20160517monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-first-quarter-2016-financial-results-on-may-5-2016-agio-20160502monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-initiation-of-phase-1-2-frontline-combination-study-of-ag-221-or-ag-120-wi-agio-20160330monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-cowen-and-company-36th-annual-health-care-conference-on-tuesday-ma-agio-20160301monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-fourth-quarter-and-full-year-2015-financial-results-on-agio-20160211monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-leerink-partners-5th-annual-global-healthcare-conference-on-wednes-agio-20160203monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-outlines-key-2016-goals-and-priorities-agio-20160111monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-the-34th-annual-j-p-morgan-healthcare-conference-on-monday-january-11-agio-20160104monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-initiation-of-phase-1b-frontline-trial-of-ag-221-or-ag-120-in-combination--agio-20151218monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-data-from-ongoing-phase-1-2-trial-of-ag-221-showing-durable-responses-in-p-agio-20151206monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-data-from-ongoing-phase-1-trial-of-ag-120-showing-durable-responses-in-pat-agio-20151205monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-new-data-from-lead-programs-at-the-2015-ash-annual-meeting-agio-20151105monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-credit-suisse-24th-annual-healthcare-conference-on-tuesday-november-10-agio-20151103monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-third-quarter-2015-financial-results-on-november-5-201-agio-20151029monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-clinical-data-from-ongoing-ag-120-phase-1-trial-in-advanced-solid-tumors--agio-20151026monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-outlines-key-clinical-development-research-strategies-agio-20151016monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-r-d-day-on-october-16-2015-agio-20151008monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-leerink-partners-rare-disease-roundtable-agio-20150923monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-present-at-canaccord-genuity-35th-annual-growth-conference-wednesday-august-12-20-agio-20150805monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-to-webcast-conference-call-of-second-quarter-2015-financial-results-on-august-6-2015-agio-20150730monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-first-patient-dosed-with-ag-881-in-phase-1-study-in-patients-with-advanced-agio-20150624monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-appoints-maykin-ho-ph-d-to-its-board-of-directors-agio-20150623monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-fda-fast-track-designation-granted-to-ag-120-for-treatment-of-patients-wit-agio-20150518monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-first-quarter-2015-financial-results-and-outlines-late-stage-clinical-develo-agio-20150507monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-selects-third-novel-idh-mutant-inhibitor-ag-881-for-clinical-develop-agio-20150429monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-to-webcast-conference-call-of-first-quarter-2015-financial-results-o-agio-20150428monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-announces-orphan-drug-designation-of-ag-348-for-treatment-of-pyruvat-agio-20150324monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-to-present-at-cowen-and-company-35th-annual-health-care-conference-o-agio-20150220monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-reports-fourth-quarter-and-full-year-2014-financial-results-agio-20150217monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-to-webcast-conference-call-of-fourth-quarter-and-full-year-2014-fina-agio-20150210monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-to-present-at-the-2015-leerink-global-healthcare-conference-on-wedne-agio-20150203monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-that-celgene-has-agreed-to-exercise-its-option-to-license-ag-120-under-glo-agio-20150112monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-to-present-at-the-33rd-annual-j-p-morgan-healthcare-conference-on-mo-agio-20150105monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-announces-closing-of-public-offering-and-full-exercise-of-over-allot-agio-20141216monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-announces-pricing-of-220-million-public-offering-of-common-stock-agio-20141211monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-announces-proposed-offering-of-common-stock-agio-20141209monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-appoints-kaye-foster-cheek-to-its-board-of-directors-agio-20141209monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-positive-phase-1-data-in-healthy-volunteers-for-ag-348-a-first-in-class-inve-agio-20141208monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-celgene-decision-to-extend-discovery-phase-of-global-strategic-collaborati-agio-20141208monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-announces-new-data-from-ongoing-phase-1-trial-of-ag-221-showing-robust-clinical-acti-agio-20141207monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-announces-early-phase-1-data-showing-clinical-activity-of-ag-120-as--agio-20141118monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-reports-third-quarter-2014-financial-results-agio-20141107monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-to-present-clinical-and-preclinical-data-at-the-2014-american-societ-agio-20141106monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-to-webcast-conference-call-of-third-quarter-2014-financial-results-o-agio-20141027monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-announces-initiation-of-a-phase-1-2-clinical-trial-of-ag-221-in-pati-agio-20141021monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-announces-initiation-of-four-expansion-cohorts-in-phase-1-study-of-a-agio-20141015monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-to-webcast-r-d-day-on-october-15-2014-agio-20141006monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-to-present-at-the-2014-leerink-partners-rare-disease-roundtable-agio-20140923monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-announces-the-u-s-fda-grants-fast-track-designation-to-ag-221-for-tr-agio-20140813monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-reports-second-quarter-2014-financial-results-agio-20140807monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-to-webcast-conference-call-of-second-quarter-2014-financial-results--agio-20140728monthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pharmaceuticals-inc-agio-to-ring-the-nasdaq-stock-market-opening-bell-agio-20131122monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-the-25th-annual-needham-virtual-healthcare-conference-imcr-20260406monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-upcoming-investor-conferences-imcr-20250904monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-upcoming-investor-conferences-imcr-20250402monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-upcoming-investor-conferences-imcr-20250303monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-report-fourth-quarter-and-full-year-2024-financial-results-and-host-call-on--imcr-20250219monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-strategic-priorities-at-43rd-annual-j-p-morgan-healthcare-conference-imcr-20250110monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-imcr-20250106monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-appoints-travis-coy-previously-a-non-executive-director-as-its-evp-chief-financ-imcr-20250102monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-first-patient-dosed-in-the-phase-1-trial-of-imc-p115c-a-half-life-ext-imcr-20241223monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-treatment-of-first-patient-in-the-phase-1-2-trial-of-imc-r117c-target-imcr-20241217monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-reimbursement-agreement-in-england-for-kimmtrak-for-the-treatment-of--imcr-20241203monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-upcoming-investor-conferences-imcr-20241108monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-presents-phase-1-data-of-brenetafusp-an-immtac-bispecific-targeting-prame-in-pa-imcr-20240914monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-the-2024-cantor-global-healthcare-conference-imcr-20240912monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-report-second-quarter-2024-financial-results-and-host-call-on-august-8-2024-imcr-20240801monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-randomization-of-first-patient-in-the-global-registrational-phase-3-c-imcr-20240618monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-presents-kimmtrak-clinical-data-demonstrating-that-patients-with-stable-disease-imcr-20240601monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-the-jefferies-global-healthcare-conference-imcr-20240530monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-upcoming-presentation-and-posters-at-asco-2024-imcr-20240424monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-upcoming-investor-conferences-imcr-20240404monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-presented-two-posters-at-croi-2024-imcr-20240305monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-upcoming-investor-conferences-imcr-20240301monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-clinical-trial-collaboration-and-supply-agreement-with-bristol-myers--imcr-20240222monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-report-fourth-quarter-and-full-year-2023-financial-results-and-host-call-on--imcr-20240221monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-strategic-priorities-and-pipeline-expansion-ahead-of-42nd-annual-j-p--imcr-20240105monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-imcr-20240103monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-reports-third-quarter-2023-financial-results-and-provides-business-update-imcr-20231107monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-upcoming-poster-presentations-at-sitc-annual-meeting-2023-and-smr-con-imcr-20231101monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-upcoming-investor-conferences-imcr-20231030monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-presents-three-year-overall-survival-data-from-the-kimmtrak-phase-3-trial-imcr-20231021monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-upcoming-presentation-and-posters-at-esmo-2023-imcr-20231006monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-upcoming-investor-conferences-imcr-20230911monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-upcoming-investor-conferences-imcr-20230901monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-reports-second-quarter-2023-financial-results-and-provides-business-update-imcr-20230810monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-report-second-quarter-2023-financial-results-and-host-call-on-august-10-2023-imcr-20230803monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-presents-additional-ctdna-data-from-the-kimmtrak-phase-3-trial-at-asco-imcr-20230603monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-upcoming-investor-conferences-imcr-20230601monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-reports-first-quarter-2023-financial-results-and-provides-business-update-imcr-20230510monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-the-bank-of-america-securities-2023-health-care-conference-imcr-20230503monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference-imcr-20230411monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-four-posters-at-aacr-annual-meeting-2023-imcr-20230314monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-upcoming-investor-conferences-imcr-20230228monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-report-fourth-quarter-and-full-year-2022-earnings-and-host-call-on-march-1-2-imcr-20230223monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-upcoming-investor-conferences-imcr-20230201monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-strategic-priorities-including-pipeline-expansion-for-2023-2024-imcr-20230109monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-imcr-20230104monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-is-awarded-the-prix-galien-france-award-for-kimmtrak-imcr-20221215monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-the-5th-annual-evercore-isi-healthconx-conference-imcr-20221123monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-presents-new-biomarker-analysis-for-kimmtrak-tebentafusp-tebn-in-metastatic-uve-imcr-20221111monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-the-jefferies-london-healthcare-conference-imcr-20221110monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-reports-third-quarter-2022-financial-results-and-provides-business-update-imcr-20221109monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-reports-second-quarter-2022-financial-results-and-provides-business-update-imcr-20220810monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-report-second-quarter-2022-earnings-and-host-call-on-august-10-2022-imcr-20220803monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-upcoming-oral-presentation-of-initial-phase-1-data-of-immtac-candidat-imcr-20220801monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-140-million-private-placement-financing-imcr-20220718monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-dosing-of-first-patient-with-immtav-bispecific-for-hiv-imcr-20220711monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-the-presentation-of-initial-data-from-the-phase-1-immtav-trial-for-ch-imcr-20220625monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-presents-new-data-on-kimmtrak-tebentafusp-tebn-in-metastatic-cutaneous-mcm-and--imcr-20220606monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-upcoming-investor-conferences-imcr-20220601monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-upcoming-presentations-at-the-2022-american-society-of-clinical-oncol-imcr-20220526monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-reports-first-quarter-2022-financial-results-and-provides-business-update-imcr-20220511monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-the-21st-annual-needham-healthcare-conference-imcr-20220407monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-oppenheimer-s-32nd-annual-healthcare-conference-imcr-20220309monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-reports-full-year-2021-financial-results-and-provides-business-update-imcr-20220303monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-receives-positive-chmp-opinion-for-kimmtrak-tebentafusp-for-the-treatment-of-un-imcr-20220225monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-the-svb-leerink-global-healthcare-conference-imcr-20220211monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-imcr-20220106monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-the-jefferies-london-healthcare-conference-imcr-20211111monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-reports-third-quarter-2021-financial-results-and-provides-business-update-imcr-20211110monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-presents-new-data-on-tebentafusp-in-metastatic-cutaneous-melanoma-mcm-and-uveal-imcr-20211109monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-and-medison-pharma-partner-for-future-commercialization-of-tebentafusp-in-canad-imcr-20211018monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-publication-of-phase-3-data-comparing-tebentafusp-with-investigator-s-imcr-20210922monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-presents-data-at-the-european-society-for-medical-oncology-esmo-congress-2021-d-imcr-20210920monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-upcoming-presentations-at-the-european-society-for-medical-oncology-e-imcr-20210913monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-upcoming-investor-conferences-imcr-20210910monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-uk-s-medicines-and-healthcare-products-regulatory-agency-mhra-accepts-imcr-20210908monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-reports-second-quarter-2021-financial-results-and-provides-business-update-imcr-20210811monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-presents-clinical-data-further-characterizing-the-overall-survival-benefit-of-t-imcr-20210604monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-present-at-upcoming-investor-conferences-imcr-20210527monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-dosing-of-first-patient-with-immtav-bispecific-molecule-for-chronic-h-imcr-20210518monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-reports-first-quarter-2021-financial-results-imcr-20210512monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-upcoming-presentations-at-the-2021-american-society-of-clinical-oncol-imcr-20210428monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-presents-phase-3-data-comparing-tebentafusp-with-investigator-s-choice-in-the-c-imcr-20210412monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-provides-business-update-and-reports-full-year-2020-financial-results-imcr-20210325monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-upcoming-presentations-at-the-american-association-for-cancer-researc-imcr-20210311monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-s-tebentafusp-granted-breakthrough-therapy-designation-for-unresectable-or-meta-imcr-20210219monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-key-appointments-to-management-and-board-imcr-20210216monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-closing-of-312-1-million-aggregate-financing-consisting-of-297-1-mill-imcr-20210209monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-pricing-of-upsized-initial-public-offering-imcr-20210205monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-closing-of-75-0-million-series-c-round-imcr-20210111monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-presents-phase-2-tebentafusp-clinical-results-at-esmo-immuno-oncology-virtual-c-imcr-20201203monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-s-tebentafusp-demonstrates-superior-overall-survival-compared-to-investigator-s-imcr-20201123monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-appoints-brian-di-donato-as-chief-financial-officer-and-head-of-strategy-imcr-20200506monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-to-co-develop-imc-c103c-a-t-cell-redirecting-bi-specific-biologic-with-genentec-imcr-20181119monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-strengthens-ip-position-in-the-field-of-tcr-based-therapeutics-imcr-20180905monthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-announces-start-of-phase-i-immtac-study-in-patients-with-solid-tumours-imcr-20180820monthly0.5https://www.biopharmawatch.com/news/MAZE/maze-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-more-information-about-maze-20260326monthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-to-participate-in-two-upcoming-investor-conferences-maze-20250710monthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-to-participate-in-the-3rd-annual-h-c-wainwright-bioconnect-investor-conf-maze-20250513monthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-doses-first-patient-in-phase-2-horizon-clinical-trial-evaluating-mze829--maze-20250207monthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-announces-pricing-of-upsized-initial-public-offering-maze-20250131monthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provid-bcax-20260330monthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-announces-closing-of-oversubscribed-public-offering-and-full-exercise--bcax-20260226monthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-announces-phase-3-optimal-dose-and-provides-2026-corporate-outlook-bcax-20260112monthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-preliminary-phase-1b-expansion-cohort-data-evaluating-750mg-of-ficeraf-bcax-20251206monthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business-up-bcax-20250812monthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-upd-bcax-20250513monthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-to-present-updated-data-from-ongoing-phase-1-1b-trial-of-ficerafusp-al-bcax-20250423monthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provid-bcax-20250327monthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2025-bcax-20250325monthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference-bcax-20250224monthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-announces-first-patients-enrolled-in-fortifi-hn01-a-pivotal-phase-2-3--bcax-20250211monthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-presents-phase-1-1b-dose-expansion-results-with-ficerafusp-alfa-in-adv-bcax-20250127monthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-to-present-at-the-stifel-2024-healthcare-conference-bcax-20241111monthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-announces-closing-of-362-million-initial-public-offering-including-ful-bcax-20240916monthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-announces-pricing-of-upsized-initial-public-offering-bcax-20240913monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-presents-new-analysis-of-ath434-phase-2-trial-data-in-late-breaking--athe-20260422monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-receives-positive-fda-feedback-following-type-c-meeting-on-ath434-ph-athe-20260330monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-multiple-oral-and-poster-presentations-to-be-featured-at-t-athe-20250507monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-announces-positive-ath434-phase-2-trial-results-in-multiple-system-a-athe-20250130monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-issues-shareholder-letter-highlighting-pipeline-advances-and-key-upc-athe-20250109monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-appoints-abby-macnish-niven-as-company-secretary-athe-20241119monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-to-host-webcast-today-on-new-data-from-the-biomuse-natural-history-s-athe-20240529monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-to-present-new-data-on-ath434-at-the-world-orphan-drug-congress-usa--athe-20240410monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-receives-a-a-3-9-million-research-development-tax-incentive-refund-athe-20240326monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-to-participate-in-the-sharecafe-hidden-gems-webinar-this-week-athe-20240129monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-to-host-webcast-to-discuss-ath434-efficacy-data-in-primates-and-rece-athe-20231204monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-ceo-david-stamler-to-present-at-the-share-series-monday-management-u-athe-20230519monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-enrolls-first-patient-in-the-united-kingdom-in-ath434-phase-2-clinic-athe-20230404monthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-to-present-at-the-virtualinvestorconferences-com-life-sciences-inves-athe-20220620monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-appointment-of-john-orwin-as-chairman-of-the-board-of-directors-anab-20230918monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-present-at-the-stifel-2023-immunology-and-inflammation-virtual-summit-anab-20230912monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-second-quarter-2023-financial-results-and-provides-business-update-anab-20230807monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-and-gsk-partnered-immuno-oncology-agent-jemperli-dostarlimab-gxly-plus-chemothe-anab-20230731monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-participation-in-upcoming-investor-conferences-anab-20230530monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-first-quarter-2023-financial-results-and-provides-pipeline-update-anab-20230511monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-british-journal-of-dermatology-publication-of-imsidolimab-il-36r-prev-anab-20230502monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-appointment-of-rita-jain-m-d-to-board-of-directors-anab-20230406monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-and-gsk-partnered-immuno-oncology-agent-jemperli-dostarlimab-gxly-plus-chemothe-anab-20230327monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-fourth-quarter-and-full-year-2022-financial-results-and-provides-busi-anab-20230301monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-participate-at-the-cowen-and-company-43rd-annual-health-care-conference-anab-20230227monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-stock-repurchase-plan-anab-20230113monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-portfolio-update-across-best-in-class-immune-cell-modulating-antibodi-anab-20230105monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-and-gsk-partnered-immuno-oncology-agent-jemperli-dostarlimab-gxly-meets-primary-anab-20221202monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-participate-at-the-piper-sandler-34th-annual-healthcare-conference-anab-20221121monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-participate-in-upcoming-november-investor-conferences-anab-20221109monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-third-quarter-2022-financial-results-and-provides-pipeline-update-anab-20221108monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-and-gsk-partnered-immuno-oncology-agents-jemperli-dostarlimab-gxly-and-cobolima-anab-20221005monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-sale-of-zejula-royalties-for-up-to-45-million-anab-20220912monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-reports-harp-phase-2-top-line-data-of-imsidolimab-in-moderate-to-severe-hidrade-anab-20220831monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-second-quarter-2022-financial-results-and-provides-pipeline-update-anab-20220808monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-participate-at-the-2022-wedbush-pacgrow-healthcare-virtual-conference-anab-20220805monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-participate-at-the-2022-jefferies-healthcare-conference-anab-20220602monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-first-quarter-2022-financial-results-and-provides-pipeline-update-anab-20220504monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-positive-anb032-anti-btla-agonist-top-line-phase-1-data-and-provides--anab-20220427monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-appoints-daniel-faga-as-interim-chief-executive-officer-anab-20220321monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-reports-imsidolimab-acorn-phase-2-clinical-trial-data-in-moderate-to-severe-acn-anab-20220314monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-fourth-quarter-and-full-year-2021-financial-results-and-provides-pipe-anab-20220307monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-anab-20220105monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-appointment-of-daniel-faga-to-board-of-directors-anab-20211129monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-present-at-the-2021-jefferies-london-healthcare-conference-anab-20211116monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-positive-rosnilimab-healthy-volunteer-phase-1-top-line-data-anab-20211115monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-third-quarter-2021-financial-results-and-provides-pipeline-updates-anab-20211104monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-agreement-to-monetize-portion-of-jemperli-royalties-for-250-million-w-anab-20211025monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-presents-updated-data-from-imsidolimab-phase-2-gallop-trial-in-generalized-pust-anab-20211002monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference-anab-20210909monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-second-quarter-2021-financial-results-and-provides-pipeline-updates-anab-20210809monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference-anab-20210527monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-first-quarter-2021-financial-results-and-provides-pipeline-updates-anab-20210504monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-appointment-of-oleg-nodelman-to-board-of-directors-anab-20210412monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-reports-imsidolimab-poplar-phase-2-clinical-trial-in-moderate-to-severe-palmopl-anab-20210308monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-fourth-quarter-and-full-year-2020-financial-results-and-provides-pipe-anab-20210225monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-anab-20210107monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference-anab-20201113monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-third-quarter-2020-financial-results-and-provides-pipeline-updates-anab-20201104monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-and-glaxosmithkline-amend-strategic-immuno-oncology-collaboration-anab-20201026monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-reports-positive-topline-data-from-gallop-phase-2-clinical-trial-of-imsidolimab-anab-20201013monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-present-at-the-2020-cantor-global-virtual-healthcare-conference-anab-20200911monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-alert-bragar-eagel-squire-p-c-is-investigating-anaptysbio-inc-on-behalf-of-long-anab-20200901monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-second-quarter-2020-financial-results-and-provides-pipeline-updates-anab-20200810monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-reports-top-line-data-from-interim-analysis-of-eclipse-phase-2-clinical-trial-o-anab-20200810monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-present-at-the-2020-wedbush-pacgrow-healthcare-conference-anab-20200805monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-appoints-dr-paul-f-lizzul-as-chief-medical-officer-anab-20200731monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-expands-executive-leadership-team-anab-20200715monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-orphan-drug-designation-of-imsidolimab-for-treatment-of-generalized-p-anab-20200708monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-deadline-alert-faruqi-faruqi-llp-encourages-investors-who-suffered-losses-excee-anab-20200514monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-loss-alert-rosen-a-top-ranked-firm-reminds-anaptysbio-inc-investors-to-contact--anab-20200508monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-first-quarter-2020-financial-results-and-provides-pipeline-updates-anab-20200506monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-investor-anab-20200401monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-anab-class-action-alert-johnson-fistel-encourages-investors-to-contact-firm-anab-20200327monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-fourth-quarter-and-full-year-2019-financial-results-and-provides-pipe-anab-20200302monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-present-at-the-cowen-and-company-40th-annual-health-care-conference-anab-20200225monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-present-at-j-p-morgan-annual-healthcare-conference-anab-20200108monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-third-quarter-2019-financial-results-and-provides-pipeline-updates-anab-20191108monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-reports-etokimab-atlas-phase-2b-clinical-trial-in-moderate-to-severe-atopic-der-anab-20191108monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-reports-positive-topline-data-from-interim-analysis-of-gallop-phase-2-clinical--anab-20190930monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-anab-20190927monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-second-quarter-2019-financial-results-and-provides-pipeline-updates-anab-20190808monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-present-at-the-wedbush-pacgrow-2019-healthcare-conference-anab-20190806monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-presents-updated-data-from-etokimab-phase-2a-proof-of-concept-clinical-trial-in-anab-20190605monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-present-at-the-jefferies-2019-healthcare-conference-anab-20190528monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-first-quarter-2019-financial-results-and-provides-pipeline-updates-anab-20190507monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-present-at-the-bank-of-america-merrill-lynch-healthcare-conference-anab-20190501monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-present-at-the-cowen-and-company-39th-annual-health-care-conference-anab-20190304monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-fourth-quarter-and-full-year-2018-financial-results-and-provides-pipe-anab-20190228monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-present-at-j-p-morgan-37th-annual-healthcare-conference-anab-20190102monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-third-quarter-2018-financial-results-and-provides-pipeline-updates-anab-20181108monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-participate-in-upcoming-investor-conferences-anab-20181105monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-closing-of-public-offering-and-full-exercise-of-the-underwriters-opti-anab-20180928monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-proposed-public-offering-of-common-stock-anab-20180924monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-second-quarter-2018-financial-results-and-provides-pipeline-updates-anab-20180807monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-present-at-the-2018-wedbush-pacgrow-healthcare-conference-anab-20180806monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-present-at-the-jefferies-2018-global-healthcare-conference-anab-20180530monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-presents-updated-anb020-and-anb019-clinical-data-at-the-2018-eaaci-congress-anab-20180529monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-first-quarter-2018-financial-results-and-provides-pipeline-updates-anab-20180508monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-anb020-and-anb019-clinical-data-presentations-at-the-2018-eaaci-congr-anab-20180501monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-participate-in-upcoming-investor-conferences-anab-20180427monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-fourth-quarter-and-full-year-2017-financial-results-and-2018-pipeline-anab-20180305monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-presents-updated-data-from-anb020-phase-2a-atopic-dermatitis-trial-at-aad-annua-anab-20180217monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-present-data-from-anb020-phase-2a-atopic-dermatitis-trial-at-aad-annual-meet-anab-20180207monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-presentation-at-the-j-p-morgan-36th-annual-healthcare-conference-anab-20180102monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-third-quarter-2017-financial-results-and-provides-pipeline-updates-anab-20171107monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-reports-positive-anb019-top-line-phase-1-clinical-trial-results-anab-20171106monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-participate-in-upcoming-investor-conferences-anab-20171031monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-pricing-of-public-offering-anab-20171012monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-files-registration-statement-for-proposed-public-offering-anab-20171010monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-reports-positive-topline-proof-of-concept-data-from-phase-2a-clinical-trial-of--anab-20171010monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-second-quarter-2017-financial-results-and-provides-pipeline-updates-anab-20170810monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-present-at-wedbush-pacgrow-healthcare-conference-anab-20170808monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-participate-in-upcoming-investor-conferences-anab-20170601monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-first-in-human-dosing-of-anb019-anab-20170406monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-data-from-scientific-collaboration-with-the-benaroya-research-institu-anab-20170304monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-to-present-data-from-anb020-program-at-two-upcoming-medical-meetings-anab-20170213monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters--anab-20170131monthly0.5https://www.biopharmawatch.com/news/ANAB/anaptysbio-announces-pricing-of-initial-public-offering-anab-20170126monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-present-preclinical-data-highlighting-potent-activity-of-sls009-in-sls-20260317monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-appoints-linghua-wang-md-phd-to-scientific-advisory-board-sls-20250707monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-be-added-to-russell-3000-and-russell-2000-indexes-sls-20250624monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-expands-scientific-advisory-board-with-addition-of-two-world-renowned-sls-20250605monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-presents-preclinical-efficacy-of-sls009-in-asxl1-mutated-colorectal-cancer-at-2025--sls-20250602monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-participate-in-fireside-chat-at-the-a-g-p-virtual-healthcare-compa-sls-20250520monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-first-pediatric-aml-patient-dosed-in-the-ongoing-phase-2-tr-sls-20250515monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-unveils-breakthrough-preclinical-data-highlighting-efficacy-of-sls009-in-tp53-mutat-sls-20250428monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-to-present-at-the-2025-american-society-of-clinical-oncology-asco-annual-meeting-sls-20250423monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-positive-overall-survival-in-cohort-3-from-the-ongoing-phase-2-trial-of-s-sls-20250408monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-positive-data-from-phase-2a-trial-of-sls009-in-combination-with-zanubruti-sls-20250220monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-key-business-objectives-for-2025-sls-20250108monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-to-host-corporate-update-call-on-january-8-2025-at-9-00-am-et-sls-20250102monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-positive-overall-survival-and-overall-response-rate-data-from-the-phase-2-sls-20241209monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-positive-data-from-preclinical-studies-indicating-asxl1-mutations-as-pred-sls-20241127monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-present-at-the-66th-american-society-of-hematology-ash-annual-meet-sls-20241105monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-u-s-fda-rare-pediatric-disease-designation-rpdd-granted-to-galinpepimut-s-sls-20241015monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-participate-in-fireside-chat-at-the-2024-maxim-healthcare-virtual--sls-20241010monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-receives-ema-orphan-drug-designation-for-sls009-for-treatment-of-peripheral-t-cell--sls-20240806monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-u-s-fda-rare-pediatric-disease-designation-rpdd-granted-to-sls009-for-the-sls-20240716monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-receives-european-medicines-agency-orphan-drug-designation-for-sls009-for-the-treat-sls-20240708monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-u-s-fda-rare-pediatric-disease-designation-granted-to-sls009-for-the-trea-sls-20240624monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-positive-recommendation-from-the-independent-data-monitorin-sls-20240617monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-completion-of-enrollment-and-initial-positive-data-in-phase-2a-trial-of-s-sls-20240610monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-positive-phase-2-preliminary-data-of-sls009-in-r-r-aml-achieving-a-100-re-sls-20240501monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-positive-recommendation-of-independent-data-monitoring-comm-sls-20240429monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-positive-topline-data-from-the-phase-2a-study-of-sls009-in-r-r-aml-and-pr-sls-20240326monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-group-announces-closing-of-20-million-registered-direct-offering-and--sls-20240319monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-host-corporate-update-call-on-march-26-2024-at-8-15-am-et-sls-20240319monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-delivers-oral-presentation-of-sls009-phase-1-data-for-acute-myeloid-l-sls-20240301monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-present-sls009-phase-1-data-from-acute-myeloid-leukemia-patients-a-sls-20240229monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-publication-of-preclinical-data-on-its-highly-selective-cdk9-inhibitor-sl-sls-20240206monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-present-sls009-phase-1-data-from-acute-myeloid-leukemia-patients-a-sls-20240125monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-receives-fda-fast-track-designation-for-sls009-for-treatment-of-relap-sls-20240109monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-pricing-of-9-0-million-public-offering-sls-20240104monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-proposed-public-offering-sls-20240104monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-provides-corporate-updates-and-highlights-key-upcoming-milestones-sls-20240103monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-reports-positive-follow-up-immune-response-and-survival-data-in-compl-sls-20231227monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-receives-fda-orphan-drug-designation-for-sls009-for-treatment-of-peripheral-t-cell--sls-20231221monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-first-patients-enrolled-in-60-mg-dose-cohort-in-phase-2a-cl-sls-20231214monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-to-host-corporate-update-webinar-on-january-3-2024-at-8-30-am-et-sls-20231213monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-positive-recommendation-from-regal-independent-data-monitor-sls-20231204monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-reaches-target-enrollment-ex-china-in-phase-3-regal-trial-of-galinpep-sls-20231129monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-receives-favorable-fda-type-c-meeting-feedback-on-chemistry-manufactu-sls-20231113monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-provides-business-update-and-reports-third-quarter-2023-financial-results-sls-20231109monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-presents-positive-key-immunobiological-and-clinical-data-from-phase-1-sls-20231106monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-receives-fast-track-designation-from-fda-for-sls009-for-treatment-of--sls-20231030monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-present-final-data-from-phase-1-2-study-of-galinpepimut-s-in-combi-sls-20231017monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-first-patient-dosed-in-phase-ib-ii-trial-of-sls009-gfh009-in-relapsed-ref-sls-20231011monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-receives-fda-orphan-drug-designation-for-sls009-for-treatment-of-acute-myeloid-leuk-sls-20231010monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-positive-topline-data-in-lymphoma-cohort-from-sls009-phase-1-dose-escalat-sls-20230921monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-participate-in-the-cantor-fitzgerald-global-healthcare-conference-sls-20230918monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-independent-data-monitoring-committee-recommends-galinpepimut-s-regal-sls-20230822monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-reports-positive-data-in-completed-phase-1-study-of-galinpepimut-s-co-sls-20230628monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-first-patient-dosed-in-phase-2a-clinical-trial-of-gfh009-in-acute-myeloid-sls-20230622monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-international-gynecol-sls-20230615monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-to-participate-in-maxim-group-healthcare-virtual-conference-sls-20230613monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-present-phase-3-regal-trial-in-progress-poster-at-2023-asco-annual-sls-20230525monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-host-virtual-expert-panel-discussion-on-gfh009-in-acute-myeloid-le-sls-20230516monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-positive-topline-data-from-gfh009-phase-1-dose-escalation-trial-in-acute--sls-20230504monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meet-sls-20230426monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-successfully-completes-phase-i-trial-dose-escalation-of-novel-highly--sls-20230420monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-independent-data-monitoring-committee-recommends-galinpepimut-s-regal-sls-20230418monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-publication-of-positive-gps-clinical-data-in-ovarian-cancer-in-peer-revie-sls-20230307monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-pricing-of-20-0-million-underwritten-public-offering-sls-20230224monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-proposed-underwritten-public-offering-sls-20230223monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-host-key-opinion-leader-webinar-on-galinpepimut-s-acute-myeloid-le-sls-20230119monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-strengthens-leadership-team-with-appointment-of-vice-president-head-o-sls-20230105monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-independent-data-monitoring-committee-recommends-galinpepimut-s-regal-sls-20221208monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-cdk9-inhibitor-gfh009-selected-for-pediatric-preclinical-in-vivo-test-sls-20221206monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-cdk9-inhibitor-gfh009-demonstrates-tumor-growth-inhibition-in-small-c-sls-20221201monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-participate-in-the-jmp-securities-hematology-and-oncology-summit-sls-20221130monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-update-on-phase-3-regal-clinical-trial-evaluating-lead-asse-sls-20221114monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-confirmatory-top-line-data-showing-survival-and-clinical-benefits-based-o-sls-20221110monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-present-data-on-its-highly-selective-cdk9-inhibitor-gfh009-at-the--sls-20221103monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-provides-webcast-information-for-phase-3-regal-study-update-on-novemb-sls-20221102monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-host-update-call-on-phase-3-regal-study-on-november-14-2022-sls-20221017monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-licensee-3d-medicines-doses-first-patient-in-phase-1-clinical-trial-i-sls-20221011monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-presents-poster-at-2022-soho-meeting-highlighting-bioequivalence-data-sls-20220929monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-poster-presentation-at-the-society-of-hematologic-oncology--sls-20220922monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-o-sls-20220914monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-host-virtual-investor-symposium-on-its-lead-asset-galinpepimut-s-o-sls-20220908monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-highly-selective-cdk9-inhibitor-gfh009-demonstrates-cancer-cell-growt-sls-20220824monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-gfh009-demonstrates-cancer-cell-growth-inhibition-in-preclinical-in-v-sls-20220809monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-adds-once-a-week-dose-cohort-in-ongoing-phase-1-clinical-trial-with-i-sls-20220707monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-provides-clinical-update-for-gfh009-ongoing-phase-1-clinical-trial-sls-20220627monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-reports-encouraging-updated-clinical-data-indicating-increased-surviv-sls-20220608monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-present-at-the-jmp-securities-life-sciences-conference-on-june-15t-sls-20220602monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-reports-preliminary-data-showing-clinical-benefit-from-phase-1-2-clinical-trial-of--sls-20220526monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-launches-expanded-access-program-for-galinpepimut-s-sls-20220426monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-newly-licensed-gfh009-asset-shows-significant-anti-leukemic-effect-in-sls-20220411monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-achievement-of-development-milestone-for-approval-of-ind-fo-sls-20220406monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-provides-business-update-and-first-quarter-2022-highlights-sls-20220405monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-pricing-of-25-0-million-underwritten-public-offering-sls-20220401monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-proposed-underwritten-public-offering-sls-20220331monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-signs-exclusive-license-agreement-with-genfleet-therapeutics-for-next-sls-20220331monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-expands-executive-team-with-appointment-of-robert-francomano-as-chief-sls-20220314monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-final-court-approval-of-settlement-of-securities-litigation-sls-20220228monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-completion-of-enrollment-of-phase-1-2-clinical-trial-of-gps-sls-20220201monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-ind-acceptance-for-first-clinical-trial-of-gps-in-china-sls-20220127monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-promotes-john-burns-to-senior-vice-president-finance-and-chief-accoun-sls-20220105monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-final-court-approval-of-settlement-of-derivative-litigation-sls-20211123monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-participate-in-upcoming-conferences-in-october-2021-sls-20211007monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-present-at-the-2021-cantor-virtual-global-healthcare-conference-on-sls-20210914monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-host-virtual-investor-symposium-on-its-lead-asset-galinpepimut-s-o-sls-20210728monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-reports-promising-updated-clinical-data-and-initial-immune-response-profiles-from-o-sls-20210630monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-reports-encouraging-updated-clinical-data-from-ongoing-mesothelioma-study-of-galinp-sls-20210624monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-inclusion-in-russell-microcap-index-sls-20210622monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-uspto-decision-to-grant-new-patent-for-galinpepimut-s-in-co-sls-20210527monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-host-shareholder-update-call-on-june-3rd-sls-20210511monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-participate-in-the-m-vest-and-maxim-group-inaugural-emerging-growt-sls-20210311monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-highlights-2020-business-and-clinical-progress-and-2021-milestones-sls-20210114monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-strengthens-year-end-balance-sheet-with-addition-of-approximately-30-5-million-sls-20201217monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-positive-follow-up-data-from-the-randomized-phase-2-vadis-trial-of-nelipe-sls-20201211monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-receives-impd-approval-from-the-french-regulatory-authority-for-its-pivotal-phase-3-sls-20200909monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-9-2-million-private-placement-priced-at-the-market-sls-20200731monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-to-host-virtual-annual-meeting-of-stockholders-sls-20200522monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-establishes-independent-data-monitoring-committee-of-leading-clinical-and-biostatis-sls-20200518monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-to-present-at-ubs-virtual-global-healthcare-conference-sls-20200507monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-releases-annual-letter-to-shareholders-sls-20200428monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-appoints-steering-committee-of-leading-acute-myeloid-leukemia-experts-for-its-ongoi-sls-20200416monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-positive-antigen-specific-immune-response-data-for-nelipepimut-s-nps-in-w-sls-20200318monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-positive-follow-up-phase-1-2-clinical-data-for-galinpepimut-s-gps-in-acut-sls-20200226monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-provides-regulatory-update-for-nelipepimut-s-nps-for-triple-negative--sls-20200214monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-enrollment-of-first-patient-in-phase-1-trial-of-galinpepimut-s-gps-in-com-sls-20200211monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-names-dragan-cicic-md-as-senior-vice-president-clinical-development-sls-20200210monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-highlights-clinical-development-progress-and-expected-2020-milestones-sls-20200113monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-commences-pivotal-phase-3-regal-study-of-galinpepimut-s-gps-in-patients-with-acute--sls-20200108monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-to-present-at-biotech-showcase-sls-20200106monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-to-present-at-the-12th-annual-ld-micro-main-event-sls-20191204monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-to-host-r-d-investor-event-on-galinpepimut-s-gps-and-the-next-generation-of-cancer--sls-20191108monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-reverse-stock-split-sls-20191106monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-completion-of-enrollment-in-randomized-phase-2-vadis-trial-of-nelipepimut-sls-20190805monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-advances-galinpepimut-s-gps-in-combination-with-keytruda-pembrolizumab-program-with-sls-20190731monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-closing-of-15-million-public-offering-sls-20190618monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-pricing-of-15-million-public-offering-sls-20190614monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-announces-immune-response-data-in-triple-negative-breast-cancer-patients-from-phase-sls-20190603monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-group-and-world-renowned-cancer-center-to-study-galinpepimut-s-gps-in-sls-20190404monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-presentation-of-final-data-analysis-from-phase-2b-study-of--sls-20190304monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-review-of-strategic-alternatives-sls-20190226monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-provides-galinpepimut-s-and-nelipepimut-s-program-update-sls-20190212monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-present-at-the-2019-bio-ceo-investor-conference-sls-20190131monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-provides-update-on-late-stage-immunotherapy-clinical-development-pipe-sls-20190108monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-additional-positive-triple-negative-breast-cancer-tnbc-subg-sls-20181206monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-to-present-further-correlative-data-from-phase-2b-trial-of-neuvax-herceptin-at-the--sls-20181130monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-expedited-development-path-for-galinpepimut-s-gps-in-acute--sls-20181128monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-completion-of-enrollment-in-phase-2-randomized-controlled-c-sls-20181126monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-provides-business-update-and-reports-third-quarter-2018-financial-res-sls-20181115monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-additional-data-showing-consistent-clinical-effect-across-h-sls-20181109monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-settlement-of-counterclaims-against-jgb-cayman-newton-ltd-f-sls-20181109monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-provide-third-quarter-2018-financial-results-and-corporate-update--sls-20181108monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-positive-final-data-in-triple-negative-breast-cancer-patien-sls-20181022monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-to-host-conference-call-following-oral-presentation-of-phase-2b-results-of-neuvax-h-sls-20181015monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-to-present-data-from-phase-2b-trial-of-neuvax-herceptin-at-the-2018-society-for-imm-sls-20181002monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-present-at-the-2018-cantor-global-healthcare-conference-sls-20180924monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-receives-orphan-medicinal-product-designation-approval-by-the-committee-for-orphan--sls-20180913monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-provides-business-update-and-reports-second-quarter-2018-financial-re-sls-20180815monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-to-present-data-from-phase-2b-trial-of-neuvax-herceptin-at-upcoming-european-societ-sls-20180723monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-receives-fast-track-designation-from-fda-for-galinpepimut-s-for-the-treatment-of-pa-sls-20180720monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-closing-of-24-2-million-public-offering-sls-20180716monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-pricing-of-upsized-24-2-million-public-offering-sls-20180712monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-proposed-public-offering-of-common-stock-sls-20180626monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-presents-interim-phase-1-clinical-data-of-galinpepimut-s-gps-in-combi-sls-20180604monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-provides-clinical-update-on-phase-2b-neuvax-nelipepimut-s-study-in-co-sls-20180601monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-present-phase-1-2-clinical-data-of-galinpepimut-s-gps-in-ovarian-c-sls-20180517monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-receives-fda-orphan-drug-designation-for-galinpepimut-s-gps-for-treat-sls-20180509monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-completes-second-tranche-of-10-700-000-private-placement-sls-20180502monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-appointment-of-gene-mack-as-chief-financial-officer-treasur-sls-20180420monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-positive-interim-data-from-phase-2b-neuvax-nelipepimut-s-cl-sls-20180402monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-appointment-of-barbara-a-wood-as-executive-vice-president-g-sls-20180321monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-phase-2-results-for-galinpepimut-s-in-high-risk-multiple-myeloma-pres-sls-20180319monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-group-announces-notice-of-allowance-from-u-s-patent-and-trademark-off-sls-20180315monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-present-at-the-oppenheimer-28th-annual-healthcare-conference-sls-20180313monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-present-at-the-30th-annual-roth-conference-sls-20180305monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-to-present-at-two-upcoming-february-investor-conferences-sls-20180206monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-group-to-present-complete-phase-2-correlative-results-for-its-lead-ca-sls-20180124monthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-group-successfully-completes-business-combination-with-galena-biophar-sls-20171229monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-urgn-20260605monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-reports-94-5-six-month-duration-of-response-in-phase-3-utopia-trial-advancing-ugn-1-urgn-20260515monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-to-present-at-upcoming-investor-conferences-urgn-20260507monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-to-report-first-quarter-2026-financial-results-on-wednesday-may-6th-2026-urgn-20260429monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-tre-urgn-20260408monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-applauds-bcan-s-new-faces-of-bladder-cancer-report-highlighting-recurrence-burden-a-urgn-20260313monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-urgn-20260306monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-to-report-second-quarter-2025-financial-results-on-thursday-august-7th-2025-urgn-20250729monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-final-deadline-alert-bragar-eagel-squire-p-c-reminds-urogen-pharma-urgn-investors-o-urgn-20250728monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-announces-publication-of-phase-3b-study-results-demonstrating-the-feasibility-of-ho-urgn-20250728monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-deadline-alert-bragar-eagel-squire-p-c-reminds-urogen-pharma-urgn-investors-of-the--urgn-20250721monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-announces-five-year-long-term-extension-study-of-the-optima-ii-trial-demonstrates-l-urgn-20250721monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-alert-bragar-eagel-squire-p-c-urges-investors-in-urogen-pharma-urgn-to-inquire-abou-urgn-20250719monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-alert-bragar-eagel-squire-p-c-reminds-investors-of-the-class-action-lawsuit-against-urgn-20250715monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-announces-completion-of-enrollment-in-the-phase-3-utopia-clinical-trial-of-ugn-103--urgn-20250707monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-ltd-nasdaq-urgn-shareholder-alert-bernstein-liebhard-llp-reminds-urogen-phar-urgn-20250616monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-ltd-urgn-faces-securities-class-action-amid-fda-s-briefing-document-and-subs-urgn-20250613monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-ltd-urgn-faces-securities-class-action-amid-fda-s-briefing-document-and-subs-urgn-20250611monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-ltd-urgn-faces-securities-class-action-amid-fda-s-briefing-document-and-subs-urgn-20250609monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-ltd-nasdaq-urgn-shareholder-alert-bernstein-liebhard-llp-reminds-urogen-phar-urgn-20250609monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-ltd-urgn-faces-securities-class-action-amid-fda-s-briefing-document-and-subs-urgn-20250606monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-ltd-urgn-faces-securities-class-action-amid-fda-s-briefing-document-and-subs-urgn-20250604monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-ltd-nasdaq-urgn-investor-alert-investors-with-large-losses-in-urogen-pharma--urgn-20250603monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed--urgn-20250603monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-ltd-urgn-faces-securities-class-action-amid-fda-s-briefing-document-and-subs-urgn-20250602monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-ltd-urgn-faces-securities-class-action-amid-fda-s-briefing-document-and-subs-urgn-20250530monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-ltd-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-jul-urgn-20250529monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-ltd-urgn-shares-crash-again-amid-fda-s-odac-vote-against-ugn-102-company-fac-urgn-20250527monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-ltd-urgn-shares-crash-again-amid-fda-s-odac-vote-against-ugn-102-company-fac-urgn-20250522monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-reports-second-quarter-2018-financial-results-and-recent-corporate-developme-urgn-20180814monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-to-report-second-quarter-2018-financial-results-on-tuesday-august-14-2018-urgn-20180807monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-submits-investigational-new-drug-ind-application-for-ugn-102-vesigel-for-the-urgn-20180711monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-s-chairman-arie-belldegrun-md-facs-to-receive-ey-2018-master-entrepreneur-aw-urgn-20180613monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-to-present-at-the-jefferies-2018-global-healthcare-conference-urgn-20180529monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-positive-interim-results-from-pivotal-phase-3-olympus-trial-of-ugn-urgn-20180521monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-reports-first-quarter-2018-financial-results-and-recent-corporate-developmen-urgn-20180515monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-to-report-first-quarter-2018-financial-results-on-tuesday-may-15-2018-urgn-20180508monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-to-ring-the-nasdaq-stock-market-opening-bell-urgn-20180424monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-to-report-fourth-quarter-and-full-year-2017-financial-results-on-thursday-ma-urgn-20180308monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-to-present-at-march-2018-investor-conferences-urgn-20180307monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-closing-of-upsized-public-offering-of-ordinary-shares-and-full-exe-urgn-20180123monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-pricing-of-public-offering-of-ordinary-shares-urgn-20180119monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-proposed-public-offering-of-ordinary-shares-urgn-20180116monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-appoints-former-kite-pharma-executive-christine-cassiano-as-corporate-affair-urgn-20180108monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-urgn-20180102monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-oral-presentation-at-society-of-urologic-oncology-suo-annual-meeti-urgn-20171127monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-reports-third-quarter-2017-financial-results-and-recent-corporate-developmen-urgn-20171114monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-to-present-at-the-jefferies-2017-london-healthcare-conference-urgn-20171109monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-to-host-third-quarter-2017-financial-results-conference-call-on-tuesday-nove-urgn-20171108monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-expands-leadership-team-appoints-industry-veterans-jeffrey-bova-as-vice-pres-urgn-20171026monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-strengthens-management-team-with-the-appointment-of-paul-chu-as-vice-preside-urgn-20170906monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-to-present-at-the-rodman-renshaw-19th-annual-global-investment-conference-urgn-20170905monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-reports-second-quarter-2017-financial-results-and-recent-corporate-developme-urgn-20170814monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-ltd-nasdaq-urgn-to-ring-the-nasdaq-stock-market-opening-bell-urgn-20170607monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-to-ring-the-nasdaq-stock-market-opening-bell-urgn-20170602monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-to-present-at-the-jefferies-2017-global-healthcare-conference-urgn-20170530monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-two-data-presentations-related-to-its-clinical-stage-uro-oncology--urgn-20170511monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-closing-of-initial-public-offering-and-exercise-of-underwriters-op-urgn-20170510monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-pricing-of-initial-public-offering-urgn-20170503monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-welcomes-new-board-member-kate-falberg-urgn-20170424monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-enrollment-of-first-patient-in-phase-3-clinical-trial-of-mitogel-f-urgn-20170403monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-fda-acceptance-of-investigational-new-drug-application-for-mitogel-urgn-20161212monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-agreement-to-license-rtgel-for-use-with-neurotoxins-to-allergan-urgn-20161014monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-announces-three-data-presentations-related-to-its-clinical-stage-uro-oncolog-urgn-20160505monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-strengthens-board-of-directors-and-senior-management-team-urgn-20160209monthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-strengthens-leadership-team-and-expands-uro-oncology-clinical-pipeline-with--urgn-20160113monthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-to-participate-in-upcoming-investor-conferences-sepn-20250827monthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-alert-bragar-eagel-squire-p-c-is-investigating-septerna-inc-on-behalf-of-septerna-sepn-20250222monthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-inc-investors-company-investigated-by-the-portnoy-law-firm-sepn-20250218monthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-sepn-20241218monthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-announces-closing-of-331-2-million-upsized-initial-public-offering-sepn-20241030monthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-prices-upsized-initial-public-offering-sepn-20241025monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-inc-nasdaq-atrc-to-ring-the-nasdaq-stock-market-closing-bell-atrc-20150323monthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-to-announce-third-quarter-2014-financial-results-atrc-20141003monthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-ltd-to-report-second-quarter-fiscal-2026-financial-results-kmts-20251203monthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-ltd-announces-pricing-of-upsized-primary-public-offering-of-co-kmts-20251203monthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-ltd-to-report-first-quarter-fiscal-2026-financial-results-kmts-20250828monthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-ltd-to-report-fourth-quarter-and-fiscal-year-2025-results-on-j-kmts-20250701monthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-announces-inclusion-in-the-russell-2000-and-russell-3000-index-kmts-20250623monthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-announces-appointment-of-conor-hanley-to-its-board-of-director-kmts-20250605monthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-to-participate-in-upcoming-investor-conferences-kmts-20250430monthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-showcases-real-world-outcomes-for-assure-wcd-at-heart-rhythm-2025-kmts-20250429monthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-to-showcase-innovation-in-sudden-cardiac-arrest-protection-and-kmts-20250423monthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-ltd-to-report-third-quarter-fiscal-2025-financial-results-on-a-kmts-20250402monthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-ltd-announces-full-exercise-and-closing-of-underwriters-over-a-kmts-20250314monthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-ltd-announces-closing-of-upsized-initial-public-offering-kmts-20250307monthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-ltd-announces-pricing-of-upsized-initial-public-offering-kmts-20250306monthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-ltd-announces-launch-of-initial-public-offering-kmts-20250226monthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-ltd-appoints-neil-bhalodkar-as-vice-president-of-investor-rela-kmts-20250225monthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-ltd-appoints-al-ford-as-chief-commercial-officer-kmts-20250218monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-inc-nasdaq-nvax-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-inve-nvax-20211227monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-nvax-20211225monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-nvax-20211220monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-nvax-20211215monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-nvax-20211210monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-nvax-20211204monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-inc-nasdaq-nvax-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-inve-nvax-20211202monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-nvax-20211129monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-nvax-20211123monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-inc-nasdaq-nvax-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-inve-nvax-20211119monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-that-a-se-nvax-20211117monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-nvax-20211117monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-investigation-block-leviton-is-investigating-novavax-inc-for-potential-securities--nvax-20211108monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-investor-alert-faruqi-faruqi-llp-securities-litigation-partner-james-josh-wilson-e-nvax-20211025monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-inc-investors-company-investigated-by-the-portnoy-law-firm-nvax-20211022monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-investor-alert-faruqi-faruqi-llp-securities-litigation-partner-james-josh-wilson-e-nvax-20211020monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-investigation-block-leviton-is-investigating-novavax-inc-for-potential-securities--nvax-20211020monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-government-of-switzerland-announce-agreement-in-principle-to-supply-covid-19-v-nvax-20210204monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-memorandum-of-understanding-to-produce-covid-19-vaccine-made-in-canada-nvax-20210202monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-covid-19-vaccine-candidate-data-at-new-york-academy-of-science-nvax-20210202monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial-nvax-20210128monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-government-of-canada-finalize-advance-purchase-agreement-for-covid-19-vaccine-nvax-20210122monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-names-madelyn-caltabiano-senior-vice-president-global-program-management-nvax-20210122monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-finalizes-agreement-with-commonwealth-of-australia-for-51-million-doses-of-covid-1-nvax-20210107monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-upcoming-conferences-nvax-20210106monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-initiation-of-prevent-19-pivotal-phase-3-efficacy-trial-of-covid-19-vacc-nvax-20201228monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-agreement-with-government-of-new-zealand-for-10-7-million-doses-of-covid-nvax-20201217monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-covid-19-vaccine-clinical-development-progress-nvax-20201130monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-upcoming-conferences-nvax-20201125monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-for-questions-related-to-third-quarter-financial-and-opera-nvax-20201110monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-gregory-f-covino-as-chief-financial-officer-and-announces-leadership-upda-nvax-20201109monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-covid-19-vaccine-granted-fast-track-designation-by-u-s-fda-nvax-20201109monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-commonwealth-of-australia-announce-agreement-in-principle-for-acquisition-of-n-nvax-20201104monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-third-quarter-financial-and-operating-results-o-nvax-20201103monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-facility-expansion-to-support-global-vaccine-development-nvax-20201102monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-provides-phase-3-covid-19-vaccine-clinical-development-update-nvax-20201027monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-covid-19-vaccine-data-at-world-vaccine-congress-europe-2020-nvax-20201020monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-leadership-team-to-advance-nanoflu-through-regulatory-licensure-nvax-20201013monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-upcoming-conferences-nvax-20201005monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-covid-19-influenza-and-rsv-candidate-vaccine-data-at-world-vaccine-cong-nvax-20200928monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiates-phase-3-efficacy-trial-of-covid-19-vaccine-in-the-united-kingdom-nvax-20200924monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-covid-19-vaccine-manufacturing-agreement-with-serum-institute-of-india-i-nvax-20200915monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-upcoming-investor-conferences-nvax-20200910monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-publication-of-phase-1-data-for-covid-19-vaccine-candidate-in-the-new-en-nvax-20200902monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-canada-reach-agreement-in-principle-to-acquire-novavax-covid-19-vaccine-nvax-20200831monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiates-phase-2-portion-of-phase-1-2-clinical-trial-of-covid-19-vaccine-nvax-20200824monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiates-efficacy-trial-of-covid-19-vaccine-in-south-africa-nvax-20200817monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-uk-government-announce-collaboration-and-purchase-agreement-for-novavax-covid--nvax-20200814monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-sk-bioscience-announce-collaboration-for-novavax-covid-19-vaccine-candidate-nvax-20200813monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-takeda-announce-collaboration-for-novavax-covid-19-vaccine-candidate-in-japan-nvax-20200807monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-serum-institute-of-india-announce-development-and-commercial-collaboration-nvax-20200806monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-second-quarter-financial-and-operating-results--nvax-20200806monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-positive-phase-1-data-for-its-covid-19-vaccine-candidate-nvax-20200804monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-fujifilm-diosynth-biotechnologies-initiate-large-scale-manufacturing-of-covid--nvax-20200723monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-covid-19-vaccine-candidate-progress-at-2nd-isv-covid-19-vaccines-virtua-nvax-20200720monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-1-6-billion-funding-from-operation-warp-speed-nvax-20200707monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-updates-to-leadership-team-nvax-20200702monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-expands-executive-leadership-and-announces-key-promotions-nvax-20200629monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-h-c-wainwright-fireside-chat-series-nvax-20200624monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-additions-to-executive-leadership-nvax-20200617monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-president-of-r-d-dr-gregory-glenn-to-discuss-the-development-of-covid-19-vaccines--nvax-20200608monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-awarded-department-of-defense-contract-for-covid-19-vaccine-nvax-20200605monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiates-phase-1-2-clinical-trial-of-covid-19-vaccine-nvax-20200525monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-covid-19-vaccine-candidate-progress-in-world-vaccine-congress-webinar-s-nvax-20200511monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-first-quarter-financial-results-on-may-11-2020-nvax-20200506monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-identifies-coronavirus-vaccine-candidate-accelerates-initiation-of-first-in-human--nvax-20200408monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-serum-institute-of-india-to-develop-and-commercialize-malaria-vaccine-candidat-nvax-20200311monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-awarded-funding-from-cepi-for-covid-19-vaccine-development-nvax-20200310monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-fourth-quarter-financial-results-on-march-11-20-nvax-20200305monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-advances-development-of-novel-covid-19-vaccine-nvax-20200226monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-preclinical-nanoflu-data-published-in-vaccines-details-structural-basis-for-broadl-nvax-20200225monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-granted-fast-track-designation-for-nanoflu-in-older-adults-nvax-20200115monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-nvax-20200109monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-third-quarter-financial-results-on-november-7-2-nvax-20191031monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiates-pivotal-phase-3-clinical-trial-of-nanoflu-influenza-vaccine-in-older-adu-nvax-20191015monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-ladenburg-thalmann-2019-healthcare-conference-nvax-20190919monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-h-c-wainwright-21st-annual-global-investment-conference-nvax-20190906monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-scientific-leadership-to-present-new-rsv-maternal-immunization-program-phase-3-dat-nvax-20190808monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reaches-agreement-with-the-fda-on-pivotal-phase-3-trial-design-for-nanoflu-nvax-20190805monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-second-quarter-financial-results-on-august-7-20-nvax-20190801monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-confirms-accelerated-approval-pathway-available-for-licensure-of-nanoflu-nvax-20190627monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-provides-updates-on-the-global-pathways-to-licensure-for-resvax-nvax-20190610monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-cfo-john-trizzino-to-discuss-future-of-influenza-vaccines-on-industry-panel-at-201-nvax-20190604monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-adjustment-of-conversion-rate-for-its-3-75-convertible-senior-notes-due--nvax-20190510monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-reverse-stock-split-of-common-stock-nvax-20190508monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-presentation-of-phase-3-data-from-rsv-maternal-immunization-program-at-3-nvax-20190501monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-first-quarter-financial-results-on-may-2-2019-nvax-20190425monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-scientific-leadership-to-present-rsv-maternal-immunization-program-phase-3-data-an-nvax-20190409monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-fourth-quarter-and-year-end-2018-financial-resu-nvax-20190311monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-topline-results-from-phase-3-preparetm-trial-of-resvax-for-prevention-of-nvax-20190228monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-positive-phase-2-nanoflu-results-in-older-adults-nvax-20190103monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-nvax-20190102monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-leadership-promotions-nvax-20181204monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-expands-leadership-with-several-key-management-promotions-nvax-20181112monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-third-quarter-financial-results-on-november-7-2-nvax-20181101monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-highlight-rsv-program-data-at-two-upcoming-meetings-nvax-20181002monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-two-upcoming-investor-conferences-nvax-20180926monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiates-phase-2-clinical-trial-of-nanoflu-in-older-adults-nvax-20180925monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-at-two-upcoming-investor-conferences-nvax-20180828monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-second-quarter-financial-results-on-august-8-20-nvax-20180801monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reaches-significant-enrollment-milestone-in-the-prepare-tm-phase-3-trial-of-its-rs-nvax-20180507monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-first-quarter-financial-results-on-may-9-2018-nvax-20180502monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-closing-of-public-offering-nvax-20180416monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-prices-public-offering-of-common-stock-nvax-20180412monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-clinical-data-on-rsv-f-and-nanoflu-vaccines-at-world-vaccine-congress-nvax-20180402monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-promotes-john-j-trizzino-to-expanded-role-as-chief-business-officer-and-chief-fina-nvax-20180314monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-and-webcast-to-provide-corporate-update-and-report-of-four-nvax-20180307monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nanoflu-vaccine-demonstrates-improved-immune-responses-compared-to-egg-based-high--nvax-20180228monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-continues-phase-3-trial-of-the-rsv-f-vaccine-for-infants-via-maternal-immunization-nvax-20171218monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-stifel-2017-healthcare-conference-nvax-20171108monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-third-quarter-2017-financial-results-on-novembe-nvax-20171031monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-leadership-change-nvax-20171013monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-ladenburg-thalmann-2017-healthcare-conference-nvax-20170919monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiates-phase-1-2-trial-of-nanoflu-vaccine-in-older-adults-nvax-20170919monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-the-citi-12th-annual-biotech-conference-nvax-20170905monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-preclinical-influenza-nanoparticle-study-published-in-vaccine-nvax-20170823monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-and-webcast-to-discuss-second-quarter-2017-financial-resul-nvax-20170801monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-the-promotion-of-dr-james-f-cummings-to-vice-president-clinical-developm-nvax-20170511monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-first-quarter-2017-financial-results-on-may-8-2-nvax-20170501monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-fourth-quarter-and-year-end-2016-financial-resu-nvax-20170220monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiates-phase-2-safety-and-immunogenicity-trial-of-the-rsv-f-vaccine-in-older-ad-nvax-20170119monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-nvax-20170105monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-the-4th-annual-guggenheim-boston-healthcare-conference-nvax-20161206monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-the-citi-2016-global-healthcare-conference-nvax-20161130monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-28th-annual-piper-jaffray-healthcare-conference-nvax-20161122monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-third-quarter-financial-results-on-november-9-2-nvax-20161102monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reschedules-4th-annual-investor-and-analyst-meeting-nvax-20161007monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-4th-annual-investor-and-analyst-meeting-nvax-20161004monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-4th-annual-investor-and-analyst-meeting-nvax-20160907monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-second-quarter-financial-results-on-august-9-20-nvax-20160802monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-recognized-by-washington-post-as-top-workplace-nvax-20160617monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-new-seasonal-combination-respiratory-vaccine-program-nvax-20160602monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-receives-the-tech-council-of-maryland-s-chairman-s-award-nvax-20160512monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-the-2016-citi-midwest-healthcare-access-day-nvax-20160511monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-first-quarter-financial-results-on-may-4-2016-nvax-20160427monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-the-fbr-new-prescriptions-conference-nvax-20160413monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-15th-annual-needham-healthcare-conference-nvax-20160406monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-management-promotion-nvax-20160404monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-management-promotions-nvax-20160317monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-bob-darius-senior-vice-president-quality-operations-nvax-20160317monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-2015-financial-res-nvax-20160222monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-exercise-of-over-allotment-option-to-purchase-additional-shares-nvax-20160205monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-closing-of-300-million-offering-of-convertible-senior-notes-due-2023-nvax-20160129monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-prices-300-million-of-convertible-senior-notes-due-2023-nvax-20160126monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-proposed-offering-of-200-million-of-convertible-senior-notes-due-2023-nvax-20160125monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-jeffrey-stoddard-m-d-vice-president-medical-affairs-nvax-20160108monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-34th-annual-j-p-morgan-healthcare-conference-nvax-20160106monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-mark-twyman-vice-president-marketing-nvax-20151221monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-completes-enrollment-of-pivotal-phase-3-trial-of-the-rsv-f-vaccine-in-older-adults-nvax-20151214monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-the-guggenheim-securities-3rd-annual-boston-healthcare-conferenc-nvax-20151208monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiates-global-pivotal-phase-3-trial-of-the-rsv-f-vaccine-to-protect-infants-via-nvax-20151203monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-27th-annual-piper-jaffray-healthcare-conference-nvax-20151124monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-make-multiple-presentations-at-rsv-vaccines-for-the-world-nvax-20151116monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-stifel-2015-healthcare-conference-nvax-20151110monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-third-quarter-2015-financial-results-nvax-20151109monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiates-pivotal-phase-3-trial-of-the-rsv-f-vaccine-in-older-adults-nvax-20151109monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-third-quarter-financial-results-on-november-9-2-nvax-20151102monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiates-phase-2-safety-and-immunogenicity-trial-to-evaluate-annual-re-dosing-of--nvax-20151022monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-management-promotion-nvax-20151001monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-positive-top-line-data-from-rsv-f-vaccine-phase-1-clinical-trial-in-pedi-nvax-20150929monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-3rd-annual-analyst-and-investor-meeting-nvax-20150929monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-3rd-annual-analyst-and-investor-meeting-nvax-20150922monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-ladenburg-thalmann-2015-healthcare-conference-nvax-20150921monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-rsv-f-vaccine-is-highly-immunogenic-with-robust-transplacental-antibody-transfer-i-nvax-20150915monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-rsv-f-vaccine-clinical-trial-data-in-women-of-child-bearing-age-published-in-the-j-nvax-20150910monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-multiple-investor-conferences-in-september-nvax-20150902monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-3rd-annual-analyst-and-investor-meeting-nvax-20150826monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-wedbush-pacgrow-healthcare-conference-nvax-20150805monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-second-quarter-financial-results-on-august-10-2-nvax-20150803monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-positive-data-from-phase-2-trial-of-quadrivalent-seasonal-influenza-vlp-nvax-20150730monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-positive-top-line-data-from-phase-1-ebola-vaccine-trial-on-who-teleconfe-nvax-20150721monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-recognized-by-washington-post-as-top-workplace-nvax-20150619monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-gail-boudreaux-to-board-nvax-20150618monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-management-promotion-nvax-20150615monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-first-quarter-financial-results-on-may-7-2015-nvax-20150430monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-14th-annual-needham-healthcare-conference-nvax-20150408monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-closing-of-public-offering-nvax-20150331monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-presents-new-data-from-non-human-primate-ebola-challenge-at-the-7th-international--nvax-20150328monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-prices-public-offering-of-common-stock-nvax-20150326monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-brian-rosen-as-vice-president-government-affairs-nvax-20150310monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-2014-financial-res-nvax-20150219monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-initiation-of-ebola-vaccine-phase-1-clinical-trial-supported-by-non-huma-nvax-20150212monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-management-promotion-nvax-20150108monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-33rd-annual-j-p-morgan-healthcare-conference-nvax-20150107monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-26th-annual-piper-jaffray-healthcare-conference-nvax-20141126monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiates-phase-2-clinical-trial-of-quadrivalent-seasonal-influenza-vlp-nvax-20141117monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-jefferies-global-healthcare-conference-nvax-20141113monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiates-phase-1-clinical-trial-of-rsv-f-vaccine-in-pediatric-subjects-nvax-20141110monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-collaborators-make-multiple-presentations-at-the-9th-international-respiratory-nvax-20141106monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-third-quarter-2014-financial-results-on-novembe-nvax-20141030monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-ebola-vaccine-development-program-at-the-8th-vaccine-and-isv-conference--nvax-20141027monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-presents-rsv-f-protein-nanoparticle-vaccine-clinical-data-at-the-8th-vaccine-isv-c-nvax-20141026monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-rsv-vaccine-clinical-data-at-the-8th-vaccine-isv-congress-in-philadelph-nvax-20141023monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-study-published-in-vaccine-rsv-f-protein-nanoparticle-vaccine-induces-antigenic-si-nvax-20141015monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiates-phase-2-clinical-trial-of-rsv-vaccine-in-elderly-subjects-nvax-20141014monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-barda-exercise-of-contract-option-nvax-20140923monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-h7n9-avian-influenza-vlp-vaccine-candidate-with-matrix-m-tm-delivers-positive-phas-nvax-20140923monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiates-phase-2-clinical-trial-of-rsv-f-protein-nanoparticle-vaccine-candidate-i-nvax-20140916monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-2nd-annual-analyst-and-investor-meeting-nvax-20140911monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-presents-data-on-rsv-f-nanoparticle-vaccine-induced-monoclonal-antibody-at-icaac-nvax-20140906monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-rsv-vaccine-clinical-and-preclinical-results-at-icaac-nvax-20140903monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-wedbush-securities-life-sciences-management-access-conference-nvax-20140807monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-second-quarter-2014-financial-results-on-august-nvax-20140730monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-recognized-as-one-of-the-washington-post-s-top-workplaces-nvax-20140623monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-management-promotions-nvax-20140619monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-prices-public-offering-of-common-stock-nvax-20140606monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-proposed-public-offering-of-common-stock-nvax-20140604monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-jefferies-2014-global-healthcare-conference-nvax-20140602monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-first-quarter-2014-financial-results-nvax-20140507monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-sven-andreasson-as-senior-vice-president-corporate-development-nvax-20140506monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-report-first-quarter-financial-results-on-may-7-2014-nvax-20140501monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-positive-top-line-data-from-dose-confirmatory-phase-2-clinical-trial-of--nvax-20140428monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-dr-cindy-oliver-as-senior-vice-president-process-development-operations-nvax-20140407monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-13th-annual-needham-healthcare-conference-nvax-20140402monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-fourth-quarter-and-year-end-2013-financial-results-and-initiation-of-phase-nvax-20140310monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-john-j-trizzino-as-senior-vice-president-commercial-operations-nvax-20140310monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-extension-of-contract-for-advanced-development-of-recombinant-influenza--nvax-20140227monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-report-fourth-quarter-and-year-end-2013-financial-results-on-march-10-2014-nvax-20140219monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-management-promotions-to-support-expanded-clinical-activity-in-2014-nvax-20140113monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-continuation-of-rsv-vaccine-partnership-with-path-nvax-20140113monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-25th-annual-piper-jaffray-healthcare-conference-nvax-20131126monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-third-quarter-2013-financial-results-nvax-20131107monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-report-third-quarter-2013-financial-results-on-november-7-2013-nvax-20131030monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiates-dose-confirmatory-phase-2-clinical-trial-of-its-rsv-vaccine-candidate-nvax-20131007monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-completes-100-million-public-offering-of-common-stock-nvax-20130927monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-prices-public-offering-of-common-stock-nvax-20130924monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-initiate-seasonal-and-pandemic-influenza-trials-in-collaboration-with-barda-nvax-20130924monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-an-analyst-and-investor-update-call-with-webcast-nvax-20130917monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-highlights-positive-results-from-partner-s-clinical-trial-of-vaccine-using-matrix--nvax-20130913monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-2013-stifel-nicolaus-healthcare-conference-nvax-20130905monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-rsv-vaccine-clinical-and-preclinical-results-at-icaac-nvax-20130903monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-second-quarter-2013-financial-results-nvax-20130808monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-2013-wedbush-life-sciences-conference-nvax-20130806monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-report-second-quarter-2013-financial-results-on-august-8-2013-nvax-20130801monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-publishes-positive-preclinical-efficacy-data-against-influenza-a-h7n9-nvax-20130729monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiates-first-phase-1-clinical-trial-of-its-a-h7n9-influenza-vaccine-candidate-nvax-20130708monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-positive-top-line-results-from-phase-1-clinical-trial-of-rsv-vaccine-can-nvax-20130702monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-barclay-buck-phillips-as-senior-vice-president-and-chief-financial-office-nvax-20130624monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-produces-mers-cov-vaccine-candidate-nvax-20130606monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-public-offer-for-all-outstanding-shares-of-isconova-nvax-20130604monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-h7n9-vlp-influenza-vaccine-enters-animal-testing-nvax-20130510monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-first-quarter-2013-financial-results-nvax-20130507monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-report-first-quarter-2013-financial-results-on-may-7-2013-nvax-20130426monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-12th-annual-needham-healthcare-conference-nvax-20130425monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-review-recent-findings-from-vaccine-programs-at-world-vaccine-congress-and-expo-nvax-20130415monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-amy-b-fix-vice-president-of-regulatory-affairs-nvax-20130410monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-positive-top-line-results-from-phase-ii-clinical-trial-of-rsv-vaccine-cand-nvax-20130402monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-progress-on-rsv-vaccine-at-the-xv-international-symposium-on-respiratory-v-nvax-20130318monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-25th-annual-roth-conference-nvax-20130313monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-cplb-and-icgeb-collaboration-honored-for-malaria-vaccine-progress-at-vaccine-world-nvax-20130308monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-fourth-quarter-and-year-end-2012-financial-results-nvax-20130301monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-report-2012-fourth-quarter-and-year-end-financial-results-on-march-1-2013-nvax-20130222monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-15th-annual-bio-ceo-investor-conference-nvax-20130207monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-phase-i-rsv-vaccine-data-published-in-vaccine-nvax-20121206monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-publishes-preclinical-efficacy-study-of-its-rsv-protein-nanoparticle-vaccine-candi-nvax-20121203monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-24th-annual-piper-jaffray-healthcare-conference-nvax-20121120monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-lazard-capital-markets-9th-annual-healthcare-conference-nvax-20121112monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-third-quarter-2012-financial-results-nvax-20121102monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-report-third-quarter-2012-financial-results-on-november-2-2012-nvax-20121026monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-27-million-equity-offering-nvax-20121023monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-positive-top-line-results-from-two-phase-1-trials-of-pandemic-influenza-va-nvax-20121017monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiates-phase-1-clinical-trial-of-rsv-vaccine-candidate-in-elderly-adults-nvax-20121015monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiates-phase-2-clinical-trial-of-rsv-vaccine-candidate-nvax-20121008monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-presents-rsv-vaccine-data-at-the-8th-annual-international-respiratory-virus-sympos-nvax-20120927monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-rodman-renshaw-14th-annual-healthcare-conference-nvax-20120906monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-2012-stifel-nicolaus-healthcare-conference-nvax-20120904monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-2012-wedbush-life-sciences-conference-nvax-20120813monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-second-quarter-2012-financial-results-nvax-20120803monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-report-second-quarter-2012-financial-results-on-august-3-2012-nvax-20120727monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-provides-update-on-influenza-programs-nvax-20120724monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-path-announce-partnership-on-rsv-vaccine-nvax-20120718monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-cpl-biologicals-and-the-international-centre-for-genetic-engineering-and-biotechno-nvax-20120716monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-on-progress-with-rsv-vaccine-at-new-international-conference-on-modern-vac-nvax-20120705monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-review-rsv-program-at-new-international-conference-on-modern-vaccines-nvax-20120627monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-jefferies-2012-global-healthcare-conference-nvax-20120604monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-inc-announces-12-million-equity-offering-nvax-20120521monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-launches-additional-phase-i-clinical-trial-of-a-h5n1-influenza-vaccine-candidate-nvax-20120509monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-first-quarter-2012-financial-results-nvax-20120504monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-launches-phase-i-clinical-trial-of-a-h5n1-influenza-vaccine-candidate-nvax-20120502monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-report-first-quarter-2012-financial-results-on-may-4-2012-nvax-20120426monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-11th-annual-needham-healthcare-conference-nvax-20120403monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-results-from-phase-i-rsv-study-at-xiv-international-symposium-on-respir-nvax-20120322monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-24th-annual-roth-conference-nvax-20120312monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-fourth-quarter-and-2011-year-end-financial-results-nvax-20120309monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-john-a-herrmann-iii-vice-president-and-general-counsel-nvax-20120308monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-launches-phase-ii-clinical-trial-of-seasonal-influenza-vaccine-nvax-20120301monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-report-2011-fourth-quarter-and-year-end-financial-results-on-march-9-2012-nvax-20120224monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-14th-annual-bio-ceo-investor-conference-nvax-20120210monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-mervyn-l-hamer-vice-president-of-manufacturing-nvax-20120201monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-progress-under-joint-venture-in-india-with-cadila-pharmaceuticals-nvax-20120103monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-23rd-annual-piper-jaffray-health-care-conference-nvax-20111128monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-acquires-new-manufacturing-and-office-facilities-in-gaithersburg-md-nvax-20111122monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-lazard-capital-markets-8th-annual-healthcare-conference-nvax-20111110monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-russell-rip-wilson-senior-vice-president-of-business-development-nvax-20111107monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-third-quarter-2011-financial-results-nvax-20111104monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-erica-s-shane-ph-d-vice-president-process-development-nvax-20111103monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-report-third-quarter-2011-financial-results-on-november-4-2011-nvax-20111028monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-ceo-addresses-u-s-patent-and-trademark-office-uspto-on-behalf-of-the-biotechnology-nvax-20111027monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-conference-call-to-discuss-results-from-phase-i-trial-of-respiratory-syn-nvax-20111010monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-contract-award-from-u-s-department-of-homeland-security-to-develop-foot--nvax-20111005monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-positive-results-from-phase-i-trial-of-respiratory-syncytial-virus-vaccine-nvax-20111003monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-report-top-line-results-from-phase-i-respiratory-syncytial-virus-vaccine-clinic-nvax-20110926monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-publication-of-results-from-h5n1-influenza-virus-like-particle-vaccine-p-nvax-20110908monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-stifel-nicolaus-healthcare-conference-nvax-20110906monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-present-at-the-2011-wedbush-life-sciences-conference-nvax-20110816monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-second-quarter-2011-financial-results-nvax-20110805monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-the-mexican-social-security-institute-publish-results-from-h1n1-influenza-vacc-nvax-20110804monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-report-second-quarter-2011-financial-results-on-august-5-2011-nvax-20110729monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-dr-timothy-hahn-senior-vice-president-of-manufacturing-nvax-20110628monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-inc-is-today-s-focus-stock-on-microstockprofit-com-nvax-20110302monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-announces-publication-in-nature-medicine-highlighting-phase-2b-acce-gpcr-20260605monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-announces-closing-of-upsized-747-5-million-public-offering-of-adss--gpcr-20251211monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-announces-pricing-of-upsized-650-million-public-offering-of-adss-an-gpcr-20251210monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-announces-proposed-500-million-public-offering-of-american-deposita-gpcr-20251208monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-reports-positive-topline-data-from-access-program-for-its-once-dail-gpcr-20251208monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-to-participate-in-multiple-upcoming-healthcare-investor-conferences-gpcr-20250529monthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-to-participate-in-multiple-upcoming-healthcare-investor-conferences-gpcr-20250130monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-announces-proposed-75-million-public-offering-of-common-stock-and-pre-funded-warr-avbp-20250701monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-to-present-proof-of-concept-phase-1b-data-for-firmonertinib-in-egfr-pacc-mutant-n-avbp-20240812monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-appoints-kristine-peterson-to-its-board-of-directors-avbp-20240422monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-announces-pricing-of-upsized-initial-public-offering-avbp-20240126monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-appoints-winston-kung-as-chief-financial-officer-and-treasurer-avbp-20240105monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-receives-fda-breakthrough-therapy-designation-for-furmonertinib-for-first-line-tr-avbp-20231030monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-appoints-chris-nolet-to-its-board-of-directors-avbp-20230920monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-biopharma-closes-155-million-oversubscribed-series-b-financing-avbp-20230327monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-biopharma-announces-first-patient-enrolled-in-global-phase-1b-trial-of-furmonerti-avbp-20220705monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-biopharma-appoints-bahija-jallal-to-its-board-of-directors-avbp-20220215monthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-biopharma-launches-with-up-to-150m-in-series-a-financing-and-strategic-licensing--avbp-20210630monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-launches-spinamic-hybrid-scoliosis-brace-combining-corrective-performance-with-impr-enov-20260608monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-participate-in-the-44th-annual-j-p-morgan-healthcare-conference-enov-20260108monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-announces-second-quarter-2025-results-enov-20250807monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-participate-in-upcoming-investor-conferences-enov-20250606monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-announces-first-quarter-2025-results-enov-20250508monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-host-first-quarter-2025-results-conference-call-on-may-8th-enov-20250417monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-exhibit-extensive-range-of-foot-ankle-solutions-at-acfas-2025-enov-20250325monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-participate-in-upcoming-investor-conferences-enov-20250305monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-announces-fourth-quarter-and-full-year-2024-results-enov-20250226monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-announces-planned-ceo-succession-process-enov-20250226monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-host-fourth-quarter-and-full-year-2024-results-conference-call-on-february-26th-enov-20250129monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-announces-leadership-change-to-international-surgical-business-enov-20250117monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference-enov-20250106monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-participate-in-upcoming-investor-conferences-enov-20241118monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-announces-third-quarter-2024-results-enov-20241106monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-host-third-quarter-2024-results-conference-call-on-november-6th-enov-20241010monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-appoints-tim-czartoski-as-president-u-s-surgical-and-global-product-and-enabling-te-enov-20240909monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-introduces-the-next-generation-of-foot-and-ankle-surgery-offerings-at-aofas-annual--enov-20240905monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-continues-to-redefine-revision-knee-surgery-with-the-addition-of-empowr-cones-to-em-enov-20240820monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-introduces-star-ankle-now-with-e-polyethylene-for-unmatched-durability-enov-20240819monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-participate-in-upcoming-investor-conferences-enov-20240812monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-announces-second-quarter-2024-results-enov-20240807monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-announces-time-change-for-second-quarter-2024-results-conference-call-enov-20240725monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-host-second-quarter-2024-results-conference-call-on-august-7th-enov-20240716monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-releases-altivate-reverse-glenoid-system-widening-range-of-patients-who-may-be-trea-enov-20240712monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-participate-in-upcoming-investor-conferences-enov-20240510monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-announces-first-quarter-2024-results-enov-20240502monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-host-first-quarter-2024-results-conference-call-on-may-2nd-enov-20240417monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-participate-in-the-23rd-annual-needham-virtual-healthcare-conference-enov-20240328monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-announces-fourth-quarter-and-full-year-2023-results-enov-20240222monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-highlight-latest-technologies-across-the-orthopedic-care-continuum-at-2024-aaos--enov-20240212monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-present-at-the-canaccord-genuity-musculoskeletal-conference-on-monday-february-1-enov-20240207monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-showcases-new-foot-ankle-offerings-at-the-acfas-annual-meeting-enov-20240129monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-host-fourth-quarter-and-full-year-2023-conference-call-on-february-22nd-enov-20240126monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-introduces-the-donjoy-roam-oa-knee-brace-enov-20240125monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-completes-acquisition-of-limacorporate-s-p-a-enov-20240103monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-participate-in-the-42nd-annual-j-p-morgan-healthcare-conference-enov-20231228monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-participate-in-the-6th-annual-evercore-isi-healthconx-conference-enov-20231116monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-announces-third-quarter-2023-results-and-raises-full-year-outlook-enov-20231107monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-showcase-new-surgical-innovations-at-aahks-annual-meeting-enov-20231030monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-corporation-releases-preliminary-information-about-its-performance-for-the-third-qu-enov-20231019monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-corporation-announces-proposed-private-offering-of-400-million-of-convertible-senio-enov-20231019monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-host-third-quarter-2023-results-conference-call-on-november-7th-enov-20231016monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-acquire-limacorporate-s-p-a-enov-20230925monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-debuts-new-foot-ankle-offerings-at-the-aofas-annual-meeting-enov-20230918monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-participate-in-upcoming-investor-conferences-enov-20230808monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-announces-second-quarter-2023-results-and-raises-full-year-outlook-enov-20230803monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-host-second-quarter-2023-results-conference-call-on-august-3rd-enov-20230711monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-recognized-as-one-of-america-s-greatest-workplaces-2023-by-newsweek-enov-20230706monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-completes-acquisition-of-novastep-enov-20230628monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-participate-in-investor-conferences-in-june-enov-20230602monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-announces-first-quarter-2023-results-enov-20230504monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-host-first-quarter-2023-results-conference-call-on-may-4th-enov-20230413monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-acquire-novastep-enov-20230403monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-announces-board-leadership-transition-enov-20230315monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-showcases-next-generation-of-medical-technology-at-the-american-academy-of-orthopae-enov-20230303monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-announces-fourth-quarter-and-full-year-2022-results-enov-20230223monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-host-fourth-quarter-and-full-year-2022-conference-call-on-february-23rd-enov-20230210monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-showcase-latest-innovations-and-growing-foot-ankle-portfolio-at-acfas-2023-enov-20230208monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-expands-foot-ankle-portfolio-s-dynaclip-family-by-introducing-procedure-specific-st-enov-20230117monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-participate-in-the-41st-annual-j-p-morgan-healthcare-conference-enov-20230105monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-receives-fda-approval-of-patient-specific-instrumentation-for-star-ankle-enov-20221201monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-introduces-dynanail-helix-a-new-twist-on-hindfoot-fusions-enov-20221117monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-arvis-awarded-the-aahks-industry-innovation-award-at-the-2022-american-academy-of-h-enov-20221110monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-announces-third-quarter-2022-results-enov-20221102monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-participate-in-investor-conferences-in-november-enov-20221028monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-host-third-quarter-2022-conference-call-on-november-2nd-enov-20221013monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-showcase-new-510-k-cleared-foot-ankle-products-at-the-aofas-annual-meeting-enov-20220908monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-participate-in-investor-conferences-in-september-enov-20220825monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-announces-second-quarter-2022-results-enov-20220804monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-host-second-quarter-2022-conference-call-on-august-4th-enov-20220712monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-completes-acquisition-of-insight-medical-systems-enov-20220706monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-to-participate-in-the-goldman-sachs-global-healthcare-conference-enov-20220606monthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-schedules-first-quarter-2022-earnings-release-and-conference-call-enov-20220414monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-final-class-action-deadline-reminder-bragar-eagel-squire-p-c-reminds-perrigo-compa-prgo-20260115monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-prgo-class-action-alert-bragar-eagel-squire-p-c-reminds-perrigo-company-plc-invest-prgo-20260112monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-sued-for-securities-law-violations-contact-the-gross-law-firm-before-j-prgo-20260108monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-nyse-prgo-shareholder-alert-bernstein-liebhard-llp-reminds-perrigo-com-prgo-20260108monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-sued-for-securities-law-violations-investors-should-contact-levi-korsi-prgo-20260106monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-class-action-reminder-bragar-eagel-squire-p-c-encourages-perrigo-company-plc-inves-prgo-20260106monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-nyse-prgo-deadline-alert-bernstein-liebhard-llp-reminds-perrigo-compan-prgo-20251215monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-fi-prgo-20251211monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-nyse-prgo-shareholder-alert-bernstein-liebhard-llp-reminds-perrigo-com-prgo-20251208monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discus-prgo-20251204monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discus-prgo-20251201monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discus-prgo-20251127monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-class-action-levi-korsinsky-reminds-perrigo-company-plc-investors-of-t-prgo-20251125monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-nyse-prgo-investor-alert-investors-with-large-losses-in-perrigo-compan-prgo-20251118monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-that--prgo-20190107monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-72-hour-deadline-alert-approximately-72-hours-remain-former-louisiana-attorney-gen-prgo-20160716monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds-prgo-20160604monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds-prgo-20160521monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-to-join-the-nasdaq-100-index-beginning-december-6-2011-prgo-20111202monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-prgo-chief-executive-officer-to-ring-the-nasdaq-stock-market-closing-bell-prgo-20090925monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-prgo-chairman-and-chief-executive-officer-to-ring-the-nasdaq-stock-market--prgo-20080724monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-prgo-president-and-chief-executive-officer-to-ring-the-nasdaq-stock-market-prgo-20061215monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-december-15th-deadline-bragar-eagel-squire-p-c-urgently-reminds-moonlake-immunoth-mltx-20251215monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-class-action-deadline-bragar-eagel-squire-p-c-urgently-reminds-moonlake-immunothe-mltx-20251213monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-sued-for-securities-law-violations-investors-should-contact-le-mltx-20251212monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-class-action-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action--mltx-20251210monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-nasdaq-mltx-shareholder-alert-bernstein-liebhard-llp-reminds-m-mltx-20251208monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-mltx-investors-are-encouraged-to-act-before-the-upcoming-decem-mltx-20251205monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-sued-for-securities-law-violations-contact-the-djs-law-group-t-mltx-20251205monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-sued-for-securities-law-violations-investors-should-contact-th-mltx-20251203monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-nasdaq-mltx-shareholder-alert-bernstein-liebhard-llp-reminds-m-mltx-20251203monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-sued-for-securities-law-violations-contact-the-djs-law-group-t-mltx-20251128monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-kor-mltx-20251125monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-sued-for-securities-law-violations-contact-the-djs-law-group-t-mltx-20251125monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-mltx-reported-phase-3-trial-data-for-sole-drug-candidate-90-st-mltx-20251124monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-mltx-reported-phase-3-trial-data-for-sole-drug-candidate-90-st-mltx-20251121monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-sued-for-securities-law-violations-contact-the-djs-law-group-t-mltx-20251121monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-sued-for-securities-law-violations-contact-the-djs-law-group-t-mltx-20251118monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-nasdaq-mltx-shareholder-alert-bernstein-liebhard-llp-reminds-m-mltx-20251117monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-mltx-faces-securities-class-action-after-company-reported-disa-mltx-20251114monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-sued-for-securities-law-violations-contact-the-djs-law-group-t-mltx-20251113monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-mltx-faces-securities-class-action-after-company-reported-disa-mltx-20251112monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-mltx-faces-securities-class-action-after-company-reported-disa-mltx-20251110monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-sued-for-securities-law-violations-contact-the-djs-law-group-t-mltx-20251110monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-nasdaq-mltx-deadline-alert-bernstein-liebhard-llp-reminds-moon-mltx-20251110monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-sued-for-securities-law-violations-investors-should-contact-le-mltx-20251106monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-the-gros-mltx-20251105monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-sued-for-securities-law-violations-contact-the-djs-law-group-t-mltx-20251103monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-nasdaq-mltx-shareholder-alert-bernstein-liebhard-llp-reminds-m-mltx-20251103monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-kor-mltx-20251031monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-mltx-faces-securities-class-action-after-company-reported-disa-mltx-20251031monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-nasdaq-mltx-shareholder-alert-bernstein-liebhard-llp-reminds-m-mltx-20251030monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-sued-for-securities-law-violations-contact-the-djs-law-group-t-mltx-20251030monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-mltx-faces-securities-class-action-after-company-reported-disa-mltx-20251029monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-sued-for-securities-law-violations-investors-should-contact-le-mltx-20251028monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-stockholders-with-large-losses-are-encouraged-to-contact-robbins-llp-for-informat-mltx-20251027monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-mltx-faces-securities-class-action-after-company-reported-disa-mltx-20251027monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-nasdaq-mltx-deadline-alert-bernstein-liebhard-llp-reminds-moon-mltx-20251027monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-mltx-faces-securities-class-action-after-company-reported-disa-mltx-20251022monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-mltx-faces-securities-class-action-after-company-reported-disa-mltx-20251020monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-nasdaq-mltx-investor-alert-investors-with-large-losses-in-moon-mltx-20251016monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-mltx-faces-securities-class-action-after-company-reported-disa-mltx-20251016monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-mltx-investors-with-substantial-losses-have-opportunity-to-lea-mltx-20251015monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-mltx-20251015monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-reminder-bragar-eagel-squire-p-c-urges-investors-in-moonlake-t-mltx-20251009monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-mltx-faces-investor-scrutiny-after-reporting-disappointing-pha-mltx-20251009monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-investigation-alert-bragar-eagel-squire-p-c-reminds-investors-of-the-investigatio-mltx-20251007monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-mltx-faces-investor-scrutiny-after-reporting-disappointing-pha-mltx-20251006monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-investors-should-contact-block-leviton-to-find-out-how-they-mi-mltx-20251006monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-mltx-faces-investor-scrutiny-after-reporting-disappointing-pha-mltx-20251003monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-alert-bragar-eagel-squire-p-c-announces-investigation-into-moonlake-immunotherape-mltx-20251002monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-mltx-faces-investor-scrutiny-after-reporting-disappointing-pha-mltx-20250930monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-inks-three-year-technology-partnership-with-komodo-health-to-a-mltx-20240410monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-to-present-mira-trial-data-of-nanobody-sonelokimab-in-hidraden-mltx-20240304monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-to-host-a-capital-markets-day-on-monday-september-11-mltx-20230906monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-completes-patient-randomization-ahead-of-schedule-for-its-phase-2-trial-in-active-mltx-20230725monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-announces-proposed-underwritten-public-offering-mltx-20230626monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-and-shl-medical-collaborate-to-jointly-develop-an-autoinjector-mltx-20230503monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-reports-fourth-quarter-and-year-end-2022-financial-results-and-mltx-20230320monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-completes-patient-enrollment-and-randomization-ahead-of-schedu-mltx-20230202monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-announces-recipients-of-the-2026-derek-forfang-patient-advocate-award-ardx-20260312monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-announces-publication-of-a-review-article-demonstrating-rapid-and-meaningful-sympt-ardx-20260309monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-report-second-quarter-2025-financial-results-on-august-4-2025-ardx-20250721monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-appoints-mike-kelliher-chief-business-officer-and-james-p-brady-chief-human-resour-ardx-20250602monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-participate-at-the-jefferies-global-healthcare-conference-2025-ardx-20250521monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-presents-data-supporting-ibsrela-tenapanor-at-digestive-disease-week-2025-conferen-ardx-20250506monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-appoints-merdad-parsey-m-d-ph-d-to-its-board-of-directors-ardx-20250429monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-announces-three-abstracts-accepted-for-poster-presentations-at-digestive-disease-w-ardx-20250424monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-report-first-quarter-2025-financial-results-on-may-1-2025-ardx-20250417monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-share-a-post-hoc-analysis-of-the-optimize-study-supporting-xphozah-tenapanor-at-ardx-20250331monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-announces-the-first-recipients-of-derek-forfang-patient-advocate-award-ardx-20250313monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-participate-in-upcoming-investor-conferences-ardx-20250225monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-present-at-the-td-cowen-45th-annual-health-care-conference-ardx-20250219monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-report-full-year-and-fourth-quarter-2024-financial-results-on-february-20-2025-ardx-20250130monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-provides-update-on-increasing-commercial-momentum-and-2025-strategic-priorities-ardx-20250113monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-ardx-20250106monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-participate-at-the-piper-sandler-36th-annual-healthcare-conference-ardx-20241120monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-responds-to-district-court-decision-granting-motion-to-dismiss-ardx-20241108monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-participate-at-the-2024-jefferies-london-healthcare-conference-ardx-20241105monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-presents-results-from-its-ibs-in-america-2024-supplemental-survey-at-the-american--ardx-20241028monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-shares-additional-data-supporting-first-in-class-xphozah-tenapanor-at-the-american-ardx-20241024monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-alert-bragar-eagel-squire-p-c-is-investigating-ardelyx-inc-on-behalf-of-long-term--ardx-20241023monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-announces-launch-of-gut-matters-discoveries-and-innovations-a-new-podcast-for-the--ardx-20241022monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-announces-the-derek-forfang-patient-advocate-award-to-recognize-advocates-for-the--ardx-20241021monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-report-third-quarter-2024-financial-results-on-october-31-2024-ardx-20241017monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-present-additional-data-supporting-first-in-class-xphozah-tenapanor-for-adults--ardx-20241015monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-inc-class-action-levi-korsinsky-reminds-ardelyx-investors-of-the-pending-class-act-ardx-20241014monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-announces-publication-of-a-review-article-exploring-the-patient-burden-and-therape-ardx-20241009monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-october-1-ardx-20241008monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-oc-ardx-20240919monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-befor-ardx-20240910monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-participate-at-the-2024-cantor-global-healthcare-conference-ardx-20240905monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-october-1-ardx-20240830monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-october-15-20-ardx-20240828monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-ardx-20240821monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-appoints-experienced-biopharma-executive-eric-foster-as-chief-commercial-officer-ardx-20240808monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-announces-publication-of-two-plain-language-summaries-from-xphozah-tenapanor-clini-ardx-20240731monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-report-second-quarter-2024-financial-results-on-august-1-2024-ardx-20240718monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-aakp-and-nmqf-file-lawsuit-to-protect-dialysis-patient-choice-and-timely-access-to-ardx-20240717monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-presents-additional-data-detailing-educational-needs-related-to-ibs-c-management-a-ardx-20240628monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-inc-reports-employment-inducement-grants-ardx-20240530monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-participate-at-the-2024-jefferies-global-healthcare-conference-ardx-20240522monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-presents-additional-data-at-the-2024-digestive-disease-week-conference-on-ibsrela--ardx-20240521monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-presents-additional-data-at-the-nkf-2024-spring-clinical-meetings-on-xphozah-tenap-ardx-20240516monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-inc-reports-employment-inducement-grants-ardx-20240514monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-present-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults--ardx-20240507monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-present-additional-data-supporting-first-in-class-xphozah-tenapanor-for-adults--ardx-20240501monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-report-first-quarter-2024-financial-results-on-may-2-2024-ardx-20240418monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-inc-reports-employment-inducement-grants-ardx-20240328monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-appoints-veteran-biopharma-executive-mike-kelliher-as-executive-vice-president-cor-ardx-20240325monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-inc-reports-employment-inducement-grants-ardx-20240312monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-participate-at-the-cowen-44th-annual-health-care-conference-ardx-20240227monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-report-fourth-quarter-and-full-year-2023-financial-results-on-february-22-2024-ardx-20240201monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-inc-reports-employment-inducement-grants-ardx-20240112monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-provides-update-on-growing-commercial-momentum-and-2024-strategic-priorities-ardx-20240108monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-provide-company-update-on-ibsrela-and-host-a-kol-discussion-on-the-ibs-c-landsc-ardx-20240103monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-inc-reports-employment-inducement-grants-ardx-20231220monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-inc-reports-employment-inducement-grants-ardx-20231121monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-participate-at-the-piper-sandler-35th-annual-healthcare-conference-ardx-20231121monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-announces-departure-of-board-member-ardx-20231113monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-participate-at-the-jefferies-london-healthcare-conference-ardx-20231110monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-announces-xphozah-tenapanor-now-available-in-the-united-states-ardx-20231106monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-shares-positive-data-from-studies-of-xphozah-tenapanor-a-first-in-class-phosphate--ardx-20231103monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-third-quarter-2023-financial-results-and-updates-2023-u-s-ibsrela-net-sale-ardx-20231031monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-inc-reports-employment-inducement-grants-ardx-20231030monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-shares-positive-data-on-symptom-response-during-treatment-with-ibsrela-tenapanor-f-ardx-20231023monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-report-third-quarter-2023-financial-results-on-october-31-2023-ardx-20231018monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-announces-amendment-of-debt-financing-agreement-with-slr-capital-partners-to-provi-ardx-20231017monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-present-data-updates-for-xphozah-tenapanor-for-hyperphosphatemia-at-kidney-week-ardx-20231013monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-shares-preliminary-data-on-use-of-ibsrela-tenapanor-in-pediatric-ibs-c-patients-at-ardx-20231004monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-announces-publication-of-positive-results-from-t3mpo-3-long-term-open-label-safety-ardx-20230928monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-showcased-encouraging-data-on-treatment-satisfaction-and-efficacy-of-ibsrela-tenap-ardx-20230911monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-ardx-20230908monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-inc-reports-employment-inducement-grants-ardx-20230907monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-inc-reports-employment-inducement-grants-ardx-20230727monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-report-second-quarter-2023-financial-results-on-august-2-2023-ardx-20230726monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-present-at-the-h-c-wainwright-2nd-annual-kidney-conference-ardx-20230720monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-announces-acceptance-of-new-drug-application-for-tenapanor-for-hyperphosphatemia-i-ardx-20230713monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-inc-reports-employment-inducement-grants-ardx-20230629monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-present-at-the-jefferies-2023-healthcare-conference-ardx-20230531monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-inc-reports-employment-inducement-grants-ardx-20230523monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-announces-fda-acceptance-and-six-month-review-for-resubmission-of-its-new-drug-app-ardx-20230517monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-inc-reports-employment-inducement-grants-ardx-20230515monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-presents-positive-data-at-ddw-2023-on-ibsrela-tenapanor-a-first-in-class-treatment-ardx-20230509monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-first-quarter-2023-financial-results-and-provides-business-update-ardx-20230503monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-w-ardx-20230501monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may--ardx-20230426monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-resubmits-new-drug-application-to-u-s-food-and-drug-administration-for-xphozah-ten-ardx-20230418monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-inc-reports-employment-inducement-grants-ardx-20230413monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-presents-positive-data-further-supporting-efficacy-and-safety-of-xphozah-tenapanor-ardx-20230412monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-publishes-first-environmental-social-and-governance-esg-report-ardx-20230228monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-participate-at-the-cowen-43rd-annual-health-care-conference-ardx-20230227monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-ardx-20230223monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-alert-bragar-eagel-squire-p-c-is-investigating-ardelyx-inc-on-behalf-of-long-term--ardx-20220402monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-investigation-block-leviton-investigates-ardelyx-for-potential-securities-law-viol-ardx-20210804monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portno-ardx-20210730monthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-inc-investors-company-investigated-by-the-portnoy-law-firm-ardx-20210722monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-deadline-monday-bragar-eagel-squire-p-c-encourages-uniqure-n-v-stockholders-with-l-qure-20260410monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-o-qure-20260409monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-declin-qure-20260408monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-nasdaq-qure-class-action-deadline-approaching-berger-montague-advises-investor-qure-20260406monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-deadline-rosen-a-leading-and-longstanding-firm-encourages-uniqure-n-v-investors-wi-qure-20260406monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-deadline-rosen-trusted-investor-counsel-encourages-uniqure-n-v-investors-to-secure-qure-20260402monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-deadline-approaching-bragar-eagel-squire-p-c-encourages-uniqure-n-v-stockholders-w-qure-20260402monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-qure-shareholder-alert-bernstein-liebhard-llp-reminds-uniqure-n-v-investors-of-qure-20260402monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-o-qure-20260402monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-declin-qure-20260401monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-qure-shareholder-alert-bernstein-liebhard-llp-reminds-uniqure-n-v-investors-of-qure-20260326monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-o-qure-20260326monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-qure-investors-have-opportunity-to-lead-securities-fraud-class-action-lawsuit--qure-20260325monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-declin-qure-20260325monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-qure-securities-fraud-class-action-lawsuit-filed-by-kessler-topaz-meltzer-chec-qure-20260320monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-class-action-alert-bragar-eagel-squire-p-c-encourages-uniqure-n-v-stockholders-wit-qure-20260319monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-qure-shareholder-alert-bernstein-liebhard-llp-reminds-uniqure-n-v-investors-of-qure-20260319monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-o-qure-20260319monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-declin-qure-20260318monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-qure-shareholder-alert-bernstein-liebhard-llp-reminds-uniqure-n-v-investors-of-qure-20260312monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-o-qure-20260312monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-declin-qure-20260311monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-qure-20260306monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-qure-class-action-lawsuit-filed-by-kessler-topaz-meltzer-check-llp-investors-f-qure-20260306monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-qure-shareholder-alert-bernstein-liebhard-llp-reminds-uniqure-n-v-investors-of-qure-20260305monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-o-qure-20260305monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-declin-qure-20260304monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-ap-qure-20260302monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-qure-shareholder-alert-bernstein-liebhard-llp-reminds-uniqure-n-v-investors-of-qure-20260226monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-o-qure-20260226monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-class-action-alert-bragar-eagel-squire-p-c-encourages-uniqure-n-v-stockholders-wit-qure-20260225monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-qure-class-action-lawsuit-filed-by-kessler-topaz-meltzer-check-llp-investors-f-qure-20260225monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-declin-qure-20260225monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-qure-class-action-lawsuit-filed-by-kessler-topaz-meltzer-check-llp-investors-f-qure-20260220monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-qure-shareholder-alert-bernstein-liebhard-llp-reminds-uniqure-n-v-investors-of-qure-20260219monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-o-qure-20260219monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-declin-qure-20260217monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-qure-investor-alert-investors-with-large-losses-in-uniqure-n-v-should-contact--qure-20260217monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-o-qure-20260212monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-qure-investor-alert-investors-with-large-losses-in-uniqure-n-v-should-contact--qure-20260212monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-qure-20260210monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-investigation-alert-bragar-eagel-squire-p-c-is-investigating-uniqure-n-v-on-behalf-qure-20260122monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-notice-of-investigation-kessler-topaz-meltzer-check-llp-encourages-uniqure-n-v-nas-qure-20251224monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-alert-bragar-eagel-squire-p-c-is-investigating-uniqure-n-v-on-behalf-of-uniqure-st-qure-20251105monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-n-v-investigation-kirby-mcinerney-llp-announces-investigation-into-potential-secur-qure-20251104monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-announce-second-quarter-2025-financial-results-qure-20250722monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-appointment-of-kylie-o-keefe-as-chief-customer-and-strategy-officer-qure-20250611monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-presents-clinical-case-study-of-first-patient-dosed-with-amt-260-in-refractory-mes-qure-20250529monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-announce-first-quarter-2025-financial-results-qure-20250505monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-fda-breakthrough-therapy-designation-granted-to-amt-130-for-the-treatmen-qure-20250417monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-completion-of-enrollment-in-the-first-cohort-and-favorable-recommendatio-qure-20250203monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-favorable-recommendation-from-independent-data-monitoring-committee-for--qure-20250130monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-pricing-of-its-public-offering-qure-20250108monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-proposed-public-offering-qure-20250107monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-qure-20231208monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-fda-clearance-of-investigational-new-drug-application-for-amt-191-gene-t-qure-20231129monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-major-presence-at-the-european-society-of-gene-and-cell-therapy-esgct-an-qure-20231024monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-qure-20231002monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-fda-clearance-of-investigational-new-drug-application-for-amt-260-gene-t-qure-20230905monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-leadership-addition-to-support-advancement-of-clinical-programs-qure-20230626monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-update-on-u-s-phase-i-ii-clinical-trial-of-amt-130-gene-therapy-for-the--qure-20230621monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-qure-20230616monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-major-presence-at-upcoming-american-society-of-gene-and-cell-therapy-asg-qure-20230502monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-qure-20230502monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-qure-20230313monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-in-march-qure-20230302monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-hope-b-clinical-trial-data-published-in-the-new-england-journal-of-medic-qure-20230223monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-qure-20221220monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-highlights-therapeutic-potential-of-amt-260-in-refractory-temporal-lobe-epilepsy-r-qure-20221129monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-host-virtual-research-development-event-on-tuesday-november-29-2022-qure-20221117monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-multiple-presentations-at-the-upcoming-annual-meeting-of-the-european-so-qure-20221011monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-upcoming-industry-conferences-in-october-qure-20221003monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-upcoming-industry-conferences-in-september-qure-20220906monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-update-on-low-dose-cohort-in-phase-i-ii-clinical-trial-of-amt-130-gene-t-qure-20220623monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-qure-20220622monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-qure-20220511monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-multiple-presentations-at-upcoming-american-society-of-gene-and-cell-the-qure-20220502monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-latest-positive-recommendation-from-data-safety-monitoring-board-in-phas-qure-20211102monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-upcoming-industry-conferences-in-november-qure-20211101monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-the-appointment-of-rachelle-jacques-to-its-board-of-directors-qure-20211021monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-presentations-at-the-annual-meeting-of-the-european-society-of-gene-and--qure-20211019monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-in-october-qure-20210930monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-in-september-qure-20210907monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-completion-of-additional-patient-procedures-following-positive-recommend-qure-20210830monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-presentations-at-upcoming-international-society-on-thrombosis-and-haemos-qure-20210702monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-positive-52-week-clinical-data-from-hope-b-pivotal-trial-of-etranacogene-qure-20210622monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-enrollment-of-first-two-patients-in-second-cohort-of-phase-i-ii-clinical-qure-20210616monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-in-june-qure-20210602monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-positive-recommendation-to-advance-phase-i-ii-clinical-trial-of-amt-130--qure-20210527monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-presents-hope-b-clinical-data-demonstrating-clinical-benefit-in-hemophilia-b-patie-qure-20210513monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-in-may-qure-20210503monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-presentations-at-upcoming-american-society-of-gene-and-cell-therapy-asgc-qure-20210428monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-publications-of-preclinical-data-for-amt-130-in-huntington-s-disease-sho-qure-20210408monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-completion-of-enrollment-in-first-cohort-of-phase-i-ii-clinical-trial-of-qure-20210405monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-in-april-qure-20210401monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-findings-from-reported-case-of-hepatocellular-carcinoma-hcc-in-hemophili-qure-20210329monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-in-march-qure-20210226monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-positive-recommendation-from-data-safety-monitoring-board-of-phase-i-ii--qure-20210208monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-in-february-qure-20210201monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-in-december-qure-20201202monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-qure-20201130monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-clinical-data-presentations-at-the-62nd-american-society-of-hematology-a-qure-20201104monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-in-november-qure-20201104monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-enrollment-of-next-two-patients-in-phase-i-ii-clinical-trial-of-amt-130--qure-20201013monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-in-october-qure-20200930monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-recommendations-from-data-safety-monitoring-board-of-phase-i-ii-clinical-qure-20200925monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-in-september-qure-20200903monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-the-appointment-of-leonard-e-post-ph-d-to-its-board-of-directors-qure-20200617monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-change-for-its-2020-annual-general-meeting-of-shareholders-qure-20200615monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-significant-presence-at-upcoming-american-society-of-gene-and-cell-thera-qure-20200428monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-the-nomination-of-leonard-e-post-ph-d-to-its-board-of-directors-qure-20200417monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-investor-conferences-in-april-qure-20200330monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-in-march-qure-20200303monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-and-gen-x-enter-into-research-collaboration-and-license-agreement-for-the-developm-qure-20200302monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-presents-multiple-new-preclinical-data-on-amt-130-at-the-chdi-s-15th-annual-huntin-qure-20200227monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-presentations-at-the-upcoming-13th-annual-congress-of-the-european-assoc-qure-20200204monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-in-february-qure-20200131monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-publication-of-preclinical-data-for-amt-130-in-huntington-s-disease-supp-qure-20191219monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-one-year-follow-up-data-from-the-phase-iib-study-of-etranacogene-dezapar-qure-20191208monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-in-december-qure-20191202monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-clinical-data-presentations-at-the-61st-american-society-of-hematology-a-qure-20191106monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-in-november-qure-20191101monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-publication-of-positive-interim-data-from-phase-iib-clinical-trial-of-et-qure-20191031monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-third-quarter-2019-results-and-highlights-recent-company-progress-qure-20191028monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-in-october-qure-20190927monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-pricing-of-its-public-offering-qure-20190906monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-proposed-public-offering-qure-20190904monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-in-september-qure-20190830monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-qure-20190726monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-presentations-at-the-upcoming-27th-congress-of-the-international-society-qure-20190621monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-qure-20190531monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-qure-20190501monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-presentations-at-the-upcoming-annual-meeting-of-the-american-society-of--qure-20190415monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-qure-20190329monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-qure-20190301monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-publications-on-aav-gene-therapy-approach-to-treating-amyotrophic-latera-qure-20190215monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-qure-20190130monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-host-research-development-day-on-monday-november-19-in-new-york-city-qure-20181105monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-qure-20181031monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-development-of-a-highly-potent-next-generation-promoter-for-liver-direct-qure-20181018monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-presents-new-data-demonstrating-its-large-scale-manufacturing-capabilities-at-the--qure-20181017monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-presentations-at-the-upcoming-annual-meeting-of-the-european-society-of--qure-20181016monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-upcoming-industry-conferences-qure-20180928monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-provides-update-on-dose-confirmation-study-of-amt-061-in-patients-with-hemophilia--qure-20180924monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-at-multiple-upcoming-conferences-qure-20180830monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-first-patient-treated-in-dose-confirmation-study-of-amt-061-in-patients--qure-20180823monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-enrolls-first-patient-in-phase-iii-hope-b-pivotal-study-of-amt-061-in-patients-wit-qure-20180628monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-the-issuance-of-new-patents-providing-broad-protection-of-the-padua-vari-qure-20180529monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-presents-new-data-demonstrating-clinical-benefit-in-hemophilia-b-patients-with-pre-qure-20180521monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-presents-preclinical-data-demonstrating-advances-in-the-distribution-of-gene-thera-qure-20180518monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-closing-of-public-offering-and-full-exercise-of-the-underwriters-option--qure-20180507monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-pricing-of-its-public-offering-qure-20180502monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-proposed-public-offering-qure-20180501monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-presentations-at-the-upcoming-annual-meeting-of-the-american-society-of--qure-20180430monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-first-quarter-2018-financial-results-and-highlights-company-progress-qure-20180430monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-to-present-at-multiple-conferences-in-may-qure-20180427monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-delivers-oral-presentation-on-broad-set-of-preclinical-data-on-amt-130-in-huntingt-qure-20180425monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-conferences-in-march-qure-20180227monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-participate-in-multiple-conferences-in-february-qure-20180201monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-receives-orphan-medicinal-product-designation-in-europe-for-amt-130-in-huntington--qure-20180122monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-provides-year-end-2017-corporate-update-and-outlines-near-term-objectives-to-furth-qure-20180108monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-publication-in-the-journal-blood-of-clinical-data-from-phase-i-ii-trial--qure-20171218monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-added-to-nasdaq-biotechnology-index-qure-20171211monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-updated-long-term-clinical-data-from-ongoing-phase-i-ii-trial-of-amt-060-qure-20171211monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-presentation-of-non-clinical-data-of-amt-061-at-the-59th-american-societ-qure-20171209monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-presentations-at-the-59th-american-society-of-hematology-ash-annual-meet-qure-20171101monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-third-quarter-2017-financial-results-and-recent-company-progress-qure-20171101monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-multiple-company-presentations-at-upcoming-november-conferences-qure-20171031monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-closing-of-its-public-offering-qure-20171027monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-pricing-of-its-public-offering-qure-20171025monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-proposed-public-offering-qure-20171023monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-strengthens-intellectual-property-portfolio-with-acquisition-of-patent-family-prov-qure-20171019monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-presents-new-preclinical-data-on-amt-130-in-huntington-s-disease-at-the-esgct-25th-qure-20171018monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-fda-orphan-drug-designation-for-amt-130-in-huntington-s-disease-qure-20171006monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-company-participation-at-citi-healthcare-conference-qure-20170824monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-reacquires-development-and-commercialization-rights-for-its-gene-therapy-candidate-qure-20170731monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-the-successful-development-and-scale-up-of-manufacturing-processes-for-i-qure-20170721monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-expands-intellectual-property-portfolio-with-newly-issued-patent-providing-broad-p-qure-20170718monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-presents-new-clinical-data-in-hemophilia-b-patients-demonstrating-therapeutic-effi-qure-20170711monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-clinical-data-presentations-at-the-upcoming-international-society-on-thr-qure-20170623monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-publishes-data-further-demonstrating-favorable-immunogenicity-profile-and-broad-ut-qure-20170615monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-company-presentation-at-jefferies-healthcare-conference-qure-20170601monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-successful-readministration-of-gene-therapy-in-non-human-primates-qure-20170511monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-presents-new-data-demonstrating-successful-and-effective-transduction-of-aav5-vect-qure-20170510monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-company-presentations-at-upcoming-may-conferences-qure-20170501monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-presents-new-preclinical-data-on-amt-130-in-huntington-s-disease-at-chdi-s-12th-an-qure-20170426monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-receives-european-medicines-agency-priority-medicines-prime-designation-for-amt-06-qure-20170425monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-presentations-at-the-upcoming-annual-meeting-of-the-american-society-of--qure-20170424monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-publishes-data-demonstrating-wide-distribution-of-aav5-in-the-central-nervous-syst-qure-20170404monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-presentations-at-upcoming-april-conferences-qure-20170403monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-receives-2017-frost-sullivan-manufacturing-leadership-award-qure-20170303monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-presentations-at-upcoming-march-conferences-qure-20170301monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-presentations-at-upcoming-february-conferences-qure-20170206monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-appoints-alexander-kuta-as-senior-vice-president-of-regulatory-affairs-qure-20170125monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-outlines-key-initiatives-for-2017-and-vision-for-2018-qure-20170109monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-first-clinical-data-from-second-dose-cohort-of-amt-060-in-ongoing-phase--qure-20161203monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-present-at-the-genetic-rx-boston-biotech-conference-at-harvard-medical-school-qure-20161202monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-upcoming-presentation-of-data-at-annual-american-society-of-hematology-m-qure-20161103monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-present-at-the-jefferies-gene-editing-and-gene-therapy-summit-in-new-york-city-qure-20160926monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-management-and-board-changes-qure-20160922monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-present-at-upcoming-investor-conferences-in-september-qure-20160817monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-oral-presentation-of-updated-results-for-amt-060-at-the-world-federation-qure-20160711monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-appoints-jonathan-garen-as-chief-business-officer-qure-20160707monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-appoints-maria-e-cantor-as-senior-vice-president-investor-relations-communications-qure-20160627monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-presents-clinical-data-from-ongoing-phase-i-ii-study-in-hemophilia-b-demonstrating-qure-20160611monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-results-for-first-quarter-2016-qure-20160531monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-oral-presentation-of-clinical-data-from-ongoing-phase-i-ii-study-of-amt--qure-20160519monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-present-at-upcoming-investor-conferences-in-new-york-city-qure-20160512monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-the-nomination-of-jack-kaye-to-its-board-of-directors-and-proposed-corpo-qure-20160509monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-appoints-paul-firuta-as-chief-commercial-officer-qure-20160503monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-present-data-on-gene-therapy-technology-advances-at-annual-meeting-of-the-ameri-qure-20160419monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-preclinical-proof-of-concept-for-gene-therapy-approach-in-huntington-s-d-qure-20160322monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-dosing-of-first-patient-in-high-dose-cohort-in-phase-i-ii-hemophilia-b-c-qure-20160314monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-present-at-the-36th-cowen-company-health-care-conference-qure-20160302monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-present-at-the-rbc-capital-markets-2016-global-healthcare-conference-qure-20160215monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-conference-call-and-webcast-to-discuss-topline-results-from-low-dose-coh-qure-20160106monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-appoints-dan-soland-as-chief-executive-officer-qure-20151218monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-added-to-nasdaq-biotechnology-index-qure-20151214monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-conference-call-and-webcast-to-discuss-third-quarter-financial-results-a-qure-20151123monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-present-at-the-jefferies-2015-global-healthcare-conference-london-qure-20151112monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-host-investor-day-in-new-york-city-on-october-15-2015-qure-20151007monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-present-at-newsmakers-in-the-biotech-industry-conference-nyc-qure-20150901monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-financial-results-for-first-quarter-2015-qure-20150611monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-present-at-the-jefferies-2015-healthcare-conference-qure-20150527monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-pricing-of-follow-on-public-offering-qure-20150410monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-webcast-to-discuss-bristol-myers-squibb-collaboration-qure-20150406monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-present-at-the-at-the-cowen-and-company-35th-annual-health-care-conference-qure-20150223monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-present-at-the-at-the-leerink-partners-global-healthcare-conference-qure-20150206monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-appoints-matthew-kapusta-as-chief-financial-officer-qure-20150109monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-present-at-the-oppenheimer-25th-healthcare-conference-nyc-qure-20141205monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-results-for-the-third-quarter-of-2014-qure-20141201monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-host-investor-day-in-new-york-city-qure-20141121monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-present-at-jefferies-global-healthcare-conference-london-qure-20141110monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-present-at-the-leerink-partners-rare-disease-roundtable-conference-qure-20140925monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-results-for-the-second-quarter-and-first-half-of-2014-and-provides-updat-qure-20140902monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-acquires-cardiology-gene-therapy-company-inocard-qure-20140811monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-secures-additional-10m-venture-loan-from-hercules-capital-qure-20140701monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-will-lewis-as-new-board-member-qure-20140612monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-results-for-the-first-quarter-2014-qure-20140606monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-analysis-of-six-year-follow-up-data-for-glybera-r-qure-20140603monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-and-medison-sign-glybera-r-distribution-agreement-for-israel-qure-20140529monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-successful-transfection-of-liver-cells-with-aav5-and-strong-safety-data--qure-20140527monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-present-at-the-bioequity-europe-and-jefferies-global-healthcare-conferences-qure-20140515monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-changes-in-management-team-qure-20140409monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-results-for-financial-year-2013-qure-20140326monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-to-present-at-future-leaders-in-biotech-conference-qure-20140321monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-and-chiesi-announce-six-year-follow-up-data-from-glybera-r-treated-patients-qure-20140317monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-closing-of-initial-public-offering-qure-20140210monthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-announces-pricing-of-initial-public-offering-qure-20140205monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-participate-in-upcoming-investor-conferences-adpt-20260521monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-adpt-20251230monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-participate-in-jefferies-fireside-chat-series-on-minimal-resid-adpt-20251209monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-showcases-leadership-in-hematology-oncology-mrd-with-new-clonoseq-adpt-20251206monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-announces-nearly-90-abstracts-featuring-clonoseq-mrd-testing-acro-adpt-20251124monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-third-quarter-2025-financial-results-on-november-5-2025-adpt-20251015monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-second-quarter-2025-financial-results-on-august-5-2025-adpt-20250715monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-participate-in-the-goldman-sachs-46th-annual-global-healthcare-adpt-20250528monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-first-quarter-2025-financial-results-on-may-1-2025-adpt-20250410monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-receives-expanded-medicare-coverage-of-clonoseq-for-surveillance--adpt-20250408monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-launches-assay-enhancements-to-increase-clonoseq-sensitivity-for--adpt-20250311monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-participate-in-upcoming-investor-conferences-adpt-20250205monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-fourth-quarter-and-full-year-2024-financial-results-on--adpt-20250122monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-and-neogenomics-partner-to-expand-access-to-personalized-disease--adpt-20250114monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-announces-clinical-lab-fee-schedule-rate-of-2-007-for-clonoseq-te-adpt-20250107monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-adpt-20250102monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-announces-new-data-at-the-66th-ash-annual-meeting-highlighting-ad-adpt-20241207monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-announces-over-65-abstracts-featuring-clonoseq-mrd-testing-across-adpt-20241203monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-receives-expanded-medicare-coverage-of-clonoseq-for-assessing-mea-adpt-20241107monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-third-quarter-2024-financial-results-on-november-7-2024-adpt-20241009monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-announces-ivdr-certification-for-clonoseq-in-european-union-adpt-20240829monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-participate-in-the-morgan-stanley-22nd-annual-global-healthcar-adpt-20240822monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-second-quarter-2024-financial-results-on-august-1-2024-adpt-20240711monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-announces-data-supporting-the-clinical-benefits-of-mrd-assessment-adpt-20240531monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-participate-in-the-goldman-sachs-45th-annual-global-healthcare-adpt-20240529monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-first-quarter-2024-financial-results-on-may-7-2024-adpt-20240417monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-hold-a-business-update-conference-call-and-webcast-on-april-2--adpt-20240327monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-present-at-the-td-cowen-44th-annual-healthcare-conference-adpt-20240222monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-fourth-quarter-and-full-year-2023-financial-results-on--adpt-20240129monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-adpt-20231227monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-announces-new-data-highlighting-the-clinical-relevance-of-mrd-tes-adpt-20231209monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-and-collaborators-to-present-more-than-30-abstracts-demonstrating-adpt-20231205monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-announces-new-translational-collaboration-to-measure-minimal-resi-adpt-20231107monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-third-quarter-financial-results-on-november-9-2023-adpt-20231102monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-announces-launch-of-epic-integration-for-clonoseq-adpt-20230913monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-participate-in-the-morgan-stanley-21st-annual-global-healthcar-adpt-20230830monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-second-quarter-financial-results-on-august-2-2023-adpt-20230710monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-highlights-new-data-at-asco-2023-and-eha-2023-underscoring-the-cl-adpt-20230602monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-participate-in-upcoming-june-investor-conferences-adpt-20230524monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-participate-in-the-2023-rbc-capital-markets-global-healthcare--adpt-20230512monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-participate-in-the-bofa-securities-2023-healthcare-conference-adpt-20230425monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-announces-translational-collaboration-with-takeda-to-measure-mini-adpt-20230412monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-first-quarter-financial-results-on-may-3-2023-adpt-20230406monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-participate-in-the-43rd-annual-cowen-healthcare-conference-adpt-20230227monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-fourth-quarter-and-full-year-2022-financial-results-on--adpt-20230123monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-adpt-20221227monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-highlights-new-data-showcasing-the-clinical-utility-of-clonoseq-m-adpt-20221210monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-and-collaborators-to-present-more-than-30-abstracts-demonstrating-adpt-20221205monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-announces-launch-of-clonoseq-to-assess-minimal-residual-disease-m-adpt-20221201monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-participate-in-the-piper-sandler-healthcare-conference-adpt-20221121monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-announces-partnership-with-epic-to-increase-access-to-minimal-residual-disease-mr-adpt-20221011monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-third-quarter-of-2022-financial-results-on-november-3-2-adpt-20221005monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-announces-non-dilutive-royalty-financing-with-orbimed-for-up-to-2-adpt-20220912monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-participate-in-the-morgan-stanley-global-healthcare-conference-adpt-20220902monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-receives-expanded-medicare-coverage-of-clonoseq-for-monitoring-mi-adpt-20220728monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-second-quarter-of-2022-financial-results-on-august-3-20-adpt-20220708monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-launches-t-detect-lyme-a-new-t-cell-clinical-test-for-the-detecti-adpt-20220615monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-included-in-key-abstracts-at-asco-2022-supporting-the-role-of-the-adpt-20220602monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-participate-in-upcoming-june-investor-conferences-adpt-20220526monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-present-at-the-bofa-securities-2022-healthcare-conference-adpt-20220502monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-first-quarter-financial-results-on-may-4-2022-adpt-20220405monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-appoints-tycho-peterson-as-chief-financial-officer-reorganizes-an-adpt-20220309monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-present-at-the-42nd-annual-cowen-healthcare-conference-adpt-20220302monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-announces-new-data-demonstrating-immunoseq-technology-can-identif-adpt-20220218monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-present-at-the-btig-medtech-digital-health-life-science-diagno-adpt-20220202monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-fourth-quarter-and-full-year-2021-financial-results-on--adpt-20220124monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-announces-preliminary-unaudited-2021-revenue-results-and-cfo-tran-adpt-20220110monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-present-virtually-at-the-40th-annual-j-p-morgan-healthcare-con-adpt-20211229monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-announces-new-data-demonstrating-the-benefit-of-serial-mrd-testin-adpt-20211213monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-and-collaborators-to-present-more-than-30-abstracts-on-utility-of-adpt-20211202monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-receives-updated-medicare-coverage-for-its-minimal-residual-disea-adpt-20211111monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-third-quarter-financial-results-on-november-3-2021-adpt-20211006monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-presents-new-data-during-idweek-demonstrating-the-capability-of-i-adpt-20211002monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-launches-enhanced-clonoseq-assay-reports-for-patients-with-chroni-adpt-20210930monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-announces-grand-opening-of-state-of-the-art-headquarters-and-expa-adpt-20210921monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-present-new-sars-cov-2-data-from-its-immune-medicine-platform--adpt-20210916monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-present-at-the-morgan-stanley-global-healthcare-conference-adpt-20210907monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-appoints-nitin-sood-as-chief-commercial-officer-adpt-20210804monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-second-quarter-financial-results-on-august-4-2021-adpt-20210712monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-included-in-more-than-20-abstracts-at-asco-and-eha-2021-highlight-adpt-20210603monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-participate-in-upcoming-june-2021-investor-conferences-adpt-20210520monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-present-at-the-bofa-securities-2021-virtual-healthcare-confere-adpt-20210427monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-first-quarter-financial-results-on-may-5-2021-adpt-20210412monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-announces-fda-emergency-use-authorization-for-t-detect-covid-to-c-adpt-20210305monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-present-at-the-cowen-41st-annual-healthcare-conference-adpt-20210225monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-expands-collaboration-with-labcorp-to-increase-access-to-growing--adpt-20210223monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-launches-t-detect-covid-first-clinical-t-cell-based-test-for-pati-adpt-20210223monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-fourth-quarter-and-full-year-2020-financial-results-on--adpt-20210202monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune-response-to-adpt-20210111monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-adpt-20201230monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-announces-new-clinical-data-demonstrating-impact-of-clonoseq-assa-adpt-20201206monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-and-collaborators-to-present-data-from-more-than-35-abstracts-at--adpt-20201123monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-announces-collaboration-with-gsk-to-measure-minimal-residual-dise-adpt-20201110monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-third-quarter-financial-results-on-november-10-2020-adpt-20201013monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-present-at-the-morgan-stanley-2020-healthcare-conference-adpt-20200901monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-present-at-the-ubs-genomics-2-0-and-medtech-innovations-summit-adpt-20200810monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-receives-expanded-fda-clearance-for-the-clonoseq-assay-to-assess--adpt-20200806monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-launches-immunoseq-t-map-covid-first-molecular-t-cell-monitoring--adpt-20200804monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-launches-national-clinical-trial-to-develop-novel-t-cell-based-di-adpt-20200728monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-announces-pricing-of-public-offering-of-common-stock-adpt-20200715monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-second-quarter-financial-results-on-august-10-2020-adpt-20200709monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-participate-in-upcoming-june-investor-conferences-adpt-20200527monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-present-at-the-bofa-securities-2020-healthcare-conference-adpt-20200506monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-first-quarter-financial-results-on-may-12-2020-adpt-20200427monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-expands-executive-leadership-team-to-support-development-and-comm-adpt-20200409monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-present-at-the-40th-annual-cowen-health-care-conference-adpt-20200219monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-fourth-quarter-and-full-year-2019-financial-results-on--adpt-20200212monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-announces-pricing-of-public-offering-of-common-stock-adpt-20200124monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-announces-preliminary-unaudited-revenue-for-full-year-2019-adpt-20200121monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-and-genentech-partner-to-use-clonoseq-assay-to-measure-minimal-residual-disease-a-adpt-20200113monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-adpt-20191230monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-and-abbvie-partner-across-multiple-myeloma-trials-to-measure-minimal-residual-dis-adpt-20191209monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-and-collaborators-to-present-data-from-more-than-25-clonoseq-abst-adpt-20191204monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-third-quarter-financial-results-on-november-12-2019-adpt-20191029monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-enters-partnership-for-use-of-clonoseq-as-preferred-mrd-test-for--adpt-20190917monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-to-report-second-quarter-financial-results-on-august-13-2019-adpt-20190801monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-announces-closing-of-initial-public-offering-and-full-exercise-of-adpt-20190701monthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-corporation-nasdaq-adpt-to-ring-the-nasdaq-stock-market-opening-b-adpt-20190627monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20260504monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-initial-clinical-data-for-op-3136-at-the-2026-asco-annual-meetin-olma-20260421monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-preclinical-data-for-palazestrant-and-op-3136-at-the-2026-aacr-an-olma-20260417monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20260402monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-preclinical-data-for-palazestrant-and-op-3136-at-the-2026-aacr-a-olma-20260317monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-at-the-td-cowen-46th-annual-health-care-conference-olma-20260219monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-participate-in-upcoming-investor-conferences-olma-20260204monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-departure-of-chief-operating-and-financial-officer-olma-20260130monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20251202monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-participate-in-8th-annual-evercore-healthcare-conference-olma-20251121monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-closing-of-218-5-million-public-offering-of-common-stock-and-full-olma-20251120monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-pricing-of-190-0-million-public-offering-of-common-stock-olma-20251119monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-olma-20251118monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20251002monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20250903monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-participate-in-upcoming-investor-conferences-olma-20250820monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20250804monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20250702monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20250603monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-palazestrant-dose-selection-and-trial-in-progress-poster-at-asco--olma-20250528monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-participate-in-upcoming-investor-conferences-olma-20250521monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-participate-in-upcoming-investor-conferences-olma-20250509monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20250502monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-new-preclinical-data-for-op-3136-demonstrating-anti-tumor-activit-olma-20250425monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20250402monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-preclinical-data-for-op-3136-a-potent-kat6-inhibitor-demonstrati-olma-20250325monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-fourth-quarter-and-full-year-2024-financial-and-operating-results-olma-20250318monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20250304monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-at-the-td-cowen-45th-annual-health-care-conference-olma-20250219monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-appoints-shawnte-m-mitchell-j-d-as-chief-legal-officer-and-corporate-secret-olma-20250218monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20250204monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-participate-in-upcoming-investor-conferences-olma-20250203monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20250103monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-at-43rd-annual-j-p-morgan-healthcare-conference-olma-20250102monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-presents-updated-clinical-results-for-palazestrant-in-combination-with-ribo-olma-20241210monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20241203monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-anton-olma-20241125monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-participate-in-upcoming-investor-conferences-olma-20241106monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20241104monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-presents-compelling-new-preclinical-data-demonstrating-anti-tumor-activity--olma-20241023monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-new-preclinical-combination-data-to-be-presented-at-the-2024-eort-olma-20241009monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20241002monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20240904monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-participate-in-morgan-stanley-22nd-annual-global-healthcare-conference-olma-20240821monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20240802monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20240702monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20240604monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-participate-in-upcoming-investor-conferences-in-june-olma-20240528monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-new-clinical-data-for-palazestrant-in-combination-with-ribociclib-olma-20240508monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20240502monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-participate-in-upcoming-investor-conferences-in-may-olma-20240501monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-participate-in-canaccord-genuity-2024-horizons-in-oncology-virtual-confe-olma-20240408monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20240402monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-publication-of-data-highlighting-palazestrant-s-ability-to-inhibi-olma-20240306monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20240304monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-participate-in-upcoming-investor-conferences-olma-20240206monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20240202monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-at-42nd-annual-j-p-morgan-healthcare-conference-olma-20240102monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20231204monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-new-palazestrant-clinical-data-in-combination-with-cdk4-6-inhibi-olma-20231128monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20231102monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-participate-in-upcoming-investor-conferences-in-november-olma-20231101monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-phase-2-monotherapy-clinical-results-to-be-presented-at-the-2023--olma-20231016monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-kat6-inhibitor-compounds-demonstrate-potent-anti-tumor-activity-olma-20231012monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20231003monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-new-preclinical-kat6-inhibitor-data-to-be-presented-at-the-2023-a-olma-20230920monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-participate-in-upcoming-investor-conferences-olma-20230906monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20230905monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20230802monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference-olma-20230801monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20230705monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20230602monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-at-the-2023-jefferies-healthcare-conference-olma-20230530monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-first-quarter-2023-financial-results-and-provides-corporate-update-olma-20230509monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-upcoming-poster-presentation-at-the-2023-esmo-breast-cancer-annua-olma-20230508monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20230502monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-confe-olma-20230413monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20230404monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20230302monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-at-oppenheimer-33rd-annual-healthcare-conference-olma-20230302monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-participate-at-upcoming-investor-conferences-olma-20230221monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20230202monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20230104monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-at-41st-annual-j-p-morgan-healthcare-conference-olma-20230103monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-op-1250-demonstrates-attractive-combinability-with-cdk-4-6-inhibi-olma-20221207monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20221202monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-poster-presentations-at-the-2022-san-antonio-breast-cancer-sympos-olma-20221121monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20221102monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-at-upcoming-investor-conferences-in-november-olma-20221101monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-complete-er-antagonist-op-1250-continues-to-demonstrate-robust-ac-olma-20221026monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-upcoming-clinical-data-poster-presentation-at-the-34th-eortc-nci--olma-20221012monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20221004monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-at-h-c-wainwright-24th-annual-global-investment-conference-olma-20220906monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20220901monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-advances-op-1250-into-phase-2-monotherapy-expansion-in-patients-with-er-her-olma-20220809monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-at-canaccord-genuity-42nd-annual-growth-conference-olma-20220804monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20220803monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-receives-fda-fast-track-designation-for-op-1250-for-the-treatment-of-er-her-olma-20220721monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20220705monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-provides-clinical-update-reflecting-strong-progress-across-op-1250-developm-olma-20220609monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-and-aurigene-announce-exclusive-collaboration-and-license-agreement-to-disc-olma-20220609monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20220602monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-at-jefferies-healthcare-conference-olma-20220524monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20220503monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-olma-20220418monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-confer-olma-20220404monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-poster-presentations-at-the-american-association-for-cancer-resea-olma-20220308monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-at-cowen-42nd-annual-health-care-conference-olma-20220222monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-olma-20220203monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-appoints-naseem-zojwalla-m-d-as-chief-medical-officer-olma-20220131monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-at-40th-annual-j-p-morgan-healthcare-conference-olma-20220104monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-first-clinical-data-on-op-1250-in-advanced-er-her2-breast-cancer-olma-20211130monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-issues-statement-regarding-falsified-information-circulating-on-social-medi-olma-20211129monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-new-data-on-op-1250-at-2021-san-antonio-breast-cancer-symposium-olma-20211122monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-at-two-upcoming-investor-conferences-olma-20211109monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-trials-in-progress-poster-on-op-1250-at-aacr-nci-eortc-internatio-olma-20210930monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-data-on-op-1250-at-the-2021-jca-aacr-precision-cancer-medicine-i-olma-20210909monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-at-morgan-stanley-19th-annual-global-healthcare-conference-olma-20210830monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-at-canaccord-genuity-41st-annual-growth-conference-olma-20210728monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-participate-at-the-jefferies-2021-virtual-healthcare-conference-olma-20210518monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-confer-olma-20210407monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-appoints-oncology-biotech-executive-yi-larson-mba-to-board-of-directors-olma-20210406monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-late-breaking-poster-presentation-at-the-american-association-for-olma-20210310monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-participate-at-upcoming-virtual-investor-conferences-olma-20210223monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-to-present-at-39th-annual-j-p-morgan-virtual-healthcare-conference-olma-20201217monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposi-olma-20201207monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-closing-of-initial-public-offering-and-full-exercise-of-underwrit-olma-20201123monthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-pricing-of-initial-public-offering-olma-20201119monthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-to-participate-in-upcoming-conferences-jbio-20250825monthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-presents-jade101-preclinical-data-at-the-62nd-european-renal-association--jbio-20250609monthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-to-present-new-preclinical-data-on-jade101-at-the-62nd-european-renal-ass-jbio-20250602monthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-reports-first-quarter-2025-financial-results-and-provides-corporate-updat-jbio-20250514monthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-to-participate-in-the-2025-jefferies-global-healthcare-conference-jbio-20250513monthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-to-participate-in-td-cowen-s-45th-annual-health-care-conference-and-jeffe-jbio-20250212monthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-to-participate-in-upcoming-investor-conferences-jbio-20241113monthly0.5https://www.biopharmawatch.com/news/XERS/xeris-pharmaceuticals-announces-new-board-members-and-new-executive-to-management-team-xers-20180730monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-announces-special-cash-dividend-of-0-50-per-share-irmd-20251208monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-second-quarter-of-2025-financial-results-conference-call-on-a-irmd-20250725monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-first-quarter-of-2025-financial-results-conference-call-on-ma-irmd-20250428monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-participate-at-the-37th-annual-roth-conference-irmd-20250310monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-fourth-quarter-of-2024-full-year-of-2024-financial-results-co-irmd-20250130monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-irmd-20241219monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-on-forbes-list-of-america-s-most-successful-small-cap-companies-for-2-irmd-20241210monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-named-to-fortune-s-100-fastest-growing-companies-list-for-2024-irmd-20241104monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2024-third-quarter-financial-results-conference-call-on-octob-irmd-20241024monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-participate-in-the-3rd-annual-roth-healthcare-opportunities-confer-irmd-20241003monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-participate-in-the-lake-st-annual-best-ideas-growth-big-8-investor-irmd-20240910monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2024-second-quarter-financial-results-conference-call-on-augu-irmd-20240725monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2024-first-quarter-financial-results-conference-call-on-may-2-irmd-20240425monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-participate-at-the-36th-annual-roth-conference-irmd-20240313monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2023-fourth-quarter-financial-results-conference-call-on-febr-irmd-20240201monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-reports-unaudited-fourth-quarter-and-2023-revenue-irmd-20240109monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-irmd-20240102monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-establishment-of-a-quarterly-dividend-of-0-15-per-share-and-irmd-20231212monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-named-a-2024-most-successful-small-cap-company-in-america-by-forbes-irmd-20231130monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2023-third-quarter-financial-results-conference-call-on-novem-irmd-20231026monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-participate-at-upcoming-investor-conferences-irmd-20230906monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2023-second-quarter-financial-results-conference-call-on-augu-irmd-20230727monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2023-first-quarter-financial-results-conference-call-on-may-4-irmd-20230427monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-present-at-the-35th-annual-roth-conference-irmd-20230306monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-issues-urgent-medical-device-correction-irmd-20230224monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2022-fourth-quarter-financial-results-conference-call-on-febr-irmd-20230126monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-third-quarter-2022-financial-results-irmd-20221103monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2022-third-quarter-financial-results-conference-call-on-novem-irmd-20221027monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2022-second-quarter-financial-results-conference-call-on-july-irmd-20220722monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-names-john-f-glenn-chief-financial-officer-irmd-20220526monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-first-quarter-2022-financial-results-irmd-20220429monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-executive-transition-irmd-20220428monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2022-first-quarter-financial-results-conference-call-on-april-irmd-20220405monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2021-fourth-quarter-financial-results-conference-call-on-febr-irmd-20220120monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2021-third-quarter-financial-results-conference-call-on-octob-irmd-20211008monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-second-quarter-2021-financial-results-irmd-20210730monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2021-second-quarter-financial-results-conference-call-on-july-irmd-20210707monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-first-quarter-2021-financial-results-irmd-20210430monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2021-first-quarter-financial-results-conference-call-on-april-irmd-20210409monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2020-fourth-quarter-financial-results-conference-call-on-febr-irmd-20210127monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-third-quarter-2020-financial-results-irmd-20201030monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2020-third-quarter-financial-results-conference-call-on-octob-irmd-20201008monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-second-quarter-2020-financial-results-irmd-20200730monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2020-second-quarter-financial-results-conference-call-on-july-irmd-20200716monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-names-roger-susi-as-president-and-chief-executive-officer-irmd-20200529monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-issuance-of-u-s-patent-irmd-20200511monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2020-first-quarter-financial-results-conference-call-on-april-irmd-20200416monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-the-appointment-of-lynn-neuhardt-as-vice-president-of-resea-irmd-20200312monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-present-at-the-32nd-annual-roth-conference-irmd-20200306monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2019-fourth-quarter-financial-results-conference-call-on-febr-irmd-20200122monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-third-quarter-2019-financial-results-irmd-20191030monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2019-third-quarter-financial-results-conference-call-on-octob-irmd-20191016monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-resolves-warning-letter-related-to-its-infusion-pump-system-irmd-20191008monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-participate-in-the-morgan-stanley-17th-annual-global-healthcare-co-irmd-20190827monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-second-quarter-2019-financial-results-irmd-20190730monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-names-leslie-mcdonnell-as-president-and-chief-executive-officer-irmd-20190729monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2019-second-quarter-financial-results-conference-call-on-july-irmd-20190716monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-first-quarter-2019-financial-results-irmd-20190430monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2019-first-quarter-financial-results-conference-call-on-april-irmd-20190416monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-fda-510-k-clearance-for-neonatal-pulse-oximetry-and-capnogr-irmd-20190402monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-fourth-quarter-2018-financial-results-irmd-20190206monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2018-fourth-quarter-financial-results-conference-call-on-febr-irmd-20190122monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-expects-minor-impact-to-2019-revenue-after-temporarily-suspending-shi-irmd-20190122monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-510-k-clearance-of-invasive-blood-pressure-module-for-use-w-irmd-20181219monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-third-quarter-2018-financial-results-irmd-20181030monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2018-third-quarter-financial-results-conference-call-on-octob-irmd-20181016monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-clearance-of-mri-compatible-patient-vital-signs-monitor-in--irmd-20180911monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-second-quarter-2018-financial-results-irmd-20180731monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2018-second-quarter-financial-results-conference-call-on-july-irmd-20180716monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-first-quarter-2018-financial-results-irmd-20180430monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2018-first-quarter-financial-results-conference-call-on-april-irmd-20180416monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-present-at-30th-annual-roth-conference-irmd-20180305monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2017-fourth-quarter-financial-results-conference-call-on-febr-irmd-20180126monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-third-quarter-2017-financial-results-irmd-20171030monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2017-third-quarter-financial-results-conference-call-on-octob-irmd-20171016monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-present-at-cantor-fitzgerald-global-healthcare-conference-irmd-20170918monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-second-quarter-2017-financial-results-irmd-20170728monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2017-second-quarter-financial-results-conference-call-on-july-irmd-20170717monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-first-quarter-2017-financial-result-irmd-20170428monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2017-first-quarter-financial-results-conference-call-on-april-irmd-20170420monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-names-john-mccreery-chief-operating-officer-irmd-20170330monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-present-at-29th-annual-roth-conference-irmd-20170301monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-fourth-quarter-2016-financial-results-irmd-20170206monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2016-fourth-quarter-financial-results-conference-call-on-febr-irmd-20170125monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-2017-annual-and-first-quarter-financial-guidance-irmd-20170118monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-first-shipments-of-its-mri-compatible-patient-vital-signs-m-irmd-20170103monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-receives-fda-clearance-for-mri-compatible-iv-infusion-pump-irmd-20161219monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-third-quarter-2016-financial-results-irmd-20161028monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2016-third-quarter-financial-results-conference-call-on-octob-irmd-20161018monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-revises-financial-guidance-for-the-third-quarter-and-full-year-2016-irmd-20161004monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-second-quarter-2016-financial-results-irmd-20160729monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2016-second-quarter-financial-results-conference-call-on-july-irmd-20160715monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-appointment-of-jonathan-kennedy-to-its-board-of-directors-irmd-20160628monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-election-of-roger-susi-as-chairman-of-the-board-irmd-20160614monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-provides-regulatory-update-irmd-20160609monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-first-quarter-2016-financial-results-irmd-20160429monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-mourns-the-death-of-board-member-serge-novovich-irmd-20160419monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-investigation-alert-andrews-springer-llc-is-investigating-iradimed-co-irmd-20160411monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-provides-regulatory-update-and-schedules-first-quarter-conference-cal-irmd-20160401monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-changes-to-its-board-of-directors-irmd-20160329monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-present-at-28th-annual-roth-conference-irmd-20160304monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-fourth-quarter-2015-financial-results-irmd-20160205monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-10-million-share-repurchase-program-irmd-20160128monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2015-fourth-quarter-financial-results-conference-call-on-febr-irmd-20160122monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-2016-annual-and-first-quarter-financial-guidance-irmd-20160111monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-closing-of-29-1-million-secondary-offering-of-common-stock--irmd-20151223monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-pricing-of-secondary-offering-of-common-stock-irmd-20151218monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-proposed-secondary-offering-of-common-stock-irmd-20151217monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-updates-status-of-510-k-submission-irmd-20151210monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-dismissal-of-appeal-irmd-20151030monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-third-quarter-2015-financial-results-irmd-20151030monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2015-third-quarter-financial-results-conference-call-on-octob-irmd-20151013monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-second-quarter-2015-financial-results-irmd-20150730monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2015-second-quarter-financial-results-conference-call-on-july-irmd-20150713monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-favorable-court-ruling-irmd-20150527monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-hosts-governor-rick-scott-irmd-20150522monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2015-first-quarter-financial-results-conference-call-on-april-irmd-20150413monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-present-at-27th-annual-roth-conference-irmd-20150227monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2014-fourth-quarter-financial-results-conference-call-on-febr-irmd-20150121monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-2015-annual-and-first-quarter-financial-guidance-irmd-20150112monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-resumes-domestic-distribution-of-infusion-pumps-irmd-20141222monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-files-510-k-submission-for-premarket-notification-irmd-20141125monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2014-third-quarter-financial-results-conference-call-on-octob-irmd-20141013monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-conference-call-to-discuss-the-status-of-the-recent-fda-war-irmd-20140915monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-announces-receipt-of-fda-warning-letter-irmd-20140903monthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-to-hold-2014-second-quarter-financial-results-conference-call-on-augu-irmd-20140801monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-investigation-reminder-bragar-eagel-squire-p-c-continues-investigation-on-behalf-o-mrvi-20251029monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-mrvi-investigation-alert-bragar-eagel-squire-p-c-reminds-investors-of-the-investig-mrvi-20251002monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-investigation-alert-bragar-eagel-squire-p-c-continues-investigation-into-maravai-l-mrvi-20250909monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-investigation-alert-bragar-eagel-squire-p-c-continues-investigation-into-maravai-l-mrvi-20250722monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-alert-bragar-eagel-squire-p-c-is-investigating-maravai-lifesciences-holdings-inc-o-mrvi-20250714monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-alert-bragar-eagel-squire-p-c-is-investigating-maravai-lifesciences-holdings-inc-o-mrvi-20250709monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-alert-bragar-eagel-squire-p-c-is-investigating-maravai-lifesciences-holdings-inc-o-mrvi-20250625monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-mrvi-reports-weak-q4-faces-investor-class-action-hagens-berman-mrvi-20250503monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-mrvi-reports-weak-q4-faces-investor-class-action-hagens-berman-mrvi-20250501monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-to-host-earnings-conference-call-on-monday-may-12-2025-mrvi-20250501monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-investors-please-contact-the-portnoy-law-firm-to-recover-mrvi-20250428monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-mrvi-reports-weak-q4-faces-investor-class-action-hagens-berman-mrvi-20250428monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-sued-for-securities-law-violations-contact-the-gross-law-mrvi-20250423monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-mrvi-reports-weak-q4-faces-investor-class-action-hagens-berman-mrvi-20250421monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-mrvi-reports-weak-q4-faces-investor-class-action-hagens-berman-mrvi-20250418monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-mrvi-earnings-call-raises-questions-amid-legal-allegations-hagens-ber-mrvi-20250416monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-mrvi-earnings-call-raises-questions-amid-legal-allegations-hagens-ber-mrvi-20250414monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-mrvi-earnings-call-raises-questions-amid-legal-allegations-hagens-ber-mrvi-20250411monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-mrvi-admits-to-incorrect-revenue-recognition-ineffective-mrvi-20250409monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-mrvi-admits-to-incorrect-revenue-recognition-ineffective-mrvi-20250407monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-mrvi-investors-may-5-2025-filing-deadline-in-securities--mrvi-20250406monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-mrvi-admits-to-incorrect-revenue-recognition-ineffective-mrvi-20250404monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-sued-for-securities-law-violations-investors-should-cont-mrvi-20250403monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-mrvi-admits-to-incorrect-revenue-recognition-ineffective-mrvi-20250402monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-mrvi-admits-to-incorrect-revenue-recognition-ineffective-mrvi-20250331monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-class-action-the-gross-law-firm-reminds-maravai-lifescie-mrvi-20250331monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-mrvi-admits-to-incorrect-revenue-recognition-ineffective-mrvi-20250328monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-mrvi-faces-securities-class-action-after-delaying-q4-and-mrvi-20250326monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-mrvi-faces-securities-class-action-after-delaying-q4-and-mrvi-20250324monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-sued-for-securities-law-violations-contact-levi-korsinsk-mrvi-20250324monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-mrvi-faces-securities-class-action-after-delaying-q4-and-mrvi-20250321monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-sued-for-securities-law-violations-investors-should-cont-mrvi-20250320monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-mrvi-faces-securities-class-action-after-delaying-q4-and-mrvi-20250319monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-reports-fourth-quarter-and-full-year-2024-financial-results-mrvi-20250318monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-class-action-levi-korsinsky-reminds-maravai-lifesciences-mrvi-20250318monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-mrvi-faces-securities-class-action-after-delaying-q4-and-mrvi-20250317monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-mrvi-faces-securities-class-action-after-delaying-q4-and-mrvi-20250313monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-mrvi-faces-securities-class-action-after-delaying-q4-and-mrvi-20250310monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-shareholder-notice-robbins-llp-reminds-investors-of-the--mrvi-20250308monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-sued-for-securities-law-violations-investors-should-cont-mrvi-20250307monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-mrvi-20250306monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-mrvi-faces-securities-class-action-after-delaying-q4-and-mrvi-20250305monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-mrvi-shares-fall-21-after-delaying-q4-and-fy-2024-earnin-mrvi-20250303monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-alert-bragar-eagel-squire-p-c-is-investigating-maravai-lifesciences-holdings-inc-o-mrvi-20250228monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-holdings-inc-mrvi-shares-fall-21-after-delaying-q4-and-fy-2024-earnin-mrvi-20250228monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-preliminary-unaudited-2024-revenue-mrvi-20250108monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-november-2024-investor-conference-schedule-mrvi-20241112monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-to-host-earnings-conference-call-on-thursday-november-7-2024-mrvi-20241015monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-august-and-september-2024-investor-conference-schedule-mrvi-20240812monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-to-host-earnings-conference-call-on-wednesday-august-7-2024-mrvi-20240710monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-releases-2023-environmental-social-and-governance-esg-report-mrvi-20240702monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-may-and-june-2024-investor-conference-schedule-mrvi-20240509monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-to-host-earnings-conference-call-on-wednesday-may-8-2024-mrvi-20240410monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-march-2024-investor-conference-schedule-mrvi-20240312monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-to-host-earnings-conference-call-on-thursday-february-22-2024-mrvi-20240129monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-november-2023-investor-conference-schedule-mrvi-20231109monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-to-host-earnings-conference-call-on-tuesday-november-7-2023-mrvi-20231017monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-hosts-2023-investor-r-d-day-mrvi-20230929monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-chief-innovation-officer-kate-broderick-named-to-2023-pharmavoice-100-mrvi-20230919monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-to-host-2023-investor-r-d-day-mrvi-20230905monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-august-2023-investor-conference-schedule-mrvi-20230809monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-to-host-earnings-conference-call-on-monday-august-7-2023-mrvi-20230724monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-to-host-earnings-conference-call-on-monday-may-8-2023-mrvi-20230417monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-releases-2022-environmental-social-and-governance-esg-report-mrvi-20230328monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-march-2023-investor-conference-schedule-mrvi-20230308monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-to-host-earnings-conference-call-on-wednesday-february-22-2023-mrvi-20230201monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-named-to-the-2022-deloitte-technology-fast-500-list-of-fastest-growin-mrvi-20221116monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-november-and-december-2022-investor-conference-schedule-mrvi-20221103monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-to-host-earnings-conference-call-on-wednesday-november-2-2022-mrvi-20221018monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-ceo-leadership-transition-mrvi-20221003monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-september-2022-investor-conference-schedule-mrvi-20220815monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-to-host-earnings-conference-call-on-thursday-august-4-2022-mrvi-20220719monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-strengthens-executive-leadership-team-to-support-long-term-growth-mrvi-20220627monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-may-and-june-2022-investor-conference-schedule-mrvi-20220511monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-to-host-earnings-conference-call-on-thursday-may-5-2022-mrvi-20220421monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-march-2022-investor-conference-schedule-mrvi-20220309monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-acquires-mychem-a-leader-in-proprietary-ultra-pure-nucleotides-mrvi-20220128monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-upcoming-investor-events-mrvi-20220125monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-debt-repricing-mrvi-20220120monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-registration-and-webcast-information-for-upcoming-r-d-day-t-mrvi-20220105monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-added-to-the-nasdaq-biotechnology-index-mrvi-20211214monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-establishment-of-new-charitable-foundation-mrvi-20211209monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-november-2021-investor-conference-schedule-mrvi-20211102monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-to-host-earnings-conference-call-on-wednesday-november-10-2021-mrvi-20211013monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-expands-its-intellectual-property-portfolio-with-european-patent-mrvi-20211007monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-pricing-of-secondary-offering-of-class-a-common-stock-by-se-mrvi-20210910monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-launch-of-proposed-secondary-offering-of-class-a-common-sto-mrvi-20210907monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-september-2021-investor-conference-schedule-mrvi-20210907monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-to-host-earnings-conference-call-on-tuesday-august-10-2021-mrvi-20210720monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-june-2021-investor-conference-schedule-mrvi-20210526monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-investor-conference-schedule-for-the-month-of-may-2021-mrvi-20210505monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-to-host-earnings-conference-call-on-monday-may-10-2021-mrvi-20210413monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-closing-of-secondary-offering-of-class-a-common-stock-by-se-mrvi-20210412monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-pricing-of-an-upsized-secondary-offering-of-class-a-common--mrvi-20210408monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-launch-of-proposed-secondary-offering-of-class-a-common-sto-mrvi-20210405monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-preliminary-unaudited-first-quarter-revenues-and-income-fro-mrvi-20210405monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-offers-end-to-end-mrna-production-with-the-launch-of-trilink-biotechn-mrvi-20210315monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-march-2021-investor-conference-schedule-mrvi-20210301monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-expands-its-intellectual-property-portfolio-mrvi-20210210monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-to-host-earnings-conference-call-on-tuesday-march-2-2021-mrvi-20210128monthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-announces-pricing-of-an-upsized-initial-public-offering-mrvi-20201120monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-upcoming-investor-conferences-coll-20260408monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-upcoming-investor-conferences-coll-20250828monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-report-second-quarter-2025-financial-results-on-august-7-2025-coll-20250724monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-150-million-share-repurchase-program-coll-20250707monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-upcoming-investor-conferences-coll-20250519monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-25-million-accelerated-share-repurchase-program-coll-20250512monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-report-first-quarter-2025-financial-results-on-may-8-2025-coll-20250424monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-24th-annual-needham-virtual-healthcare-conference-coll-20250401monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-present-real-world-data-at-painconnect-2025-the-american-academy-of-pain-medi-coll-20250327monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-updates-to-its-board-of-directors-and-executive-leadership-team-coll-20250317monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-poster-presentations-at-the-2025-national-association-of-pediatric-nur-coll-20250310monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-upcoming-investor-conferences-coll-20250304monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-report-fourth-quarter-and-full-year-2024-financial-results-on-february-27-202-coll-20250213monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-appoints-nancy-s-lurker-to-its-board-of-directors-coll-20250205monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-upcoming-investor-conferences-coll-20241112monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-appoints-vikram-karnani-as-chief-executive-officer-coll-20241107monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-report-third-quarter-2024-financial-results-on-november-7-2024-coll-20241024monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-h-c-wainwright-26th-annual-global-investment-conference-coll-20240830monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-eight-poster-presentations-at-painweek-conference-2024-coll-20240828monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-report-second-quarter-2024-financial-results-on-august-8-2024-coll-20240725monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-jefferies-global-healthcare-conference-coll-20240529monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-35-million-accelerated-share-repurchase-program-coll-20240513monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-ceo-transition-coll-20240509monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-authorized-generic-agreement-with-hikma-pharmaceuticals-usa-inc-for-nu-coll-20240429monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-report-first-quarter-2024-financial-results-on-may-9-2024-coll-20240425monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-23rd-annual-needham-virtual-healthcare-conference-coll-20240403monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-report-fourth-quarter-and-full-year-2023-financial-results-on-february-22-202-coll-20240208monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-provides-2024-financial-guidance-coll-20240103monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-25-million-accelerated-share-repurchase-program-coll-20231109monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-upcoming-investor-conferences-coll-20231108monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-report-third-quarter-2023-financial-results-on-november-7-2023-coll-20231024monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-10-poster-presentations-at-painweek-conference-2023-coll-20230828monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-50-million-accelerated-share-repurchase-program-coll-20230807monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-report-second-quarter-2023-financial-results-on-august-3-2023-coll-20230720monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-jefferies-healthcare-conference-coll-20230601monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-report-first-quarter-2023-financial-results-on-may-4-2023-coll-20230420monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-22nd-annual-needham-virtual-healthcare-conference-coll-20230411monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-publishes-inaugural-2022-environmental-social-and-governance-report-coll-20230222monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-pharmaceutical-inc-announces-proposed-convertible-senior-notes-offering-coll-20230206monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-provides-2023-financial-guidance-coll-20230104monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-piper-sandler-34th-annual-healthcare-conference-coll-20221122monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-report-third-quarter-2022-financial-results-on-november-3-2022-coll-20221020monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-11-poster-presentations-at-painweek-2022-national-conference-coll-20220830monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-report-second-quarter-2022-financial-results-on-august-4-2022-coll-20220721monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-h-c-wainwright-global-investment-conference-coll-20220517monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-first-quarter-2022-financial-results-coll-20220426monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-upcoming-needham-healthcare-conference-coll-20220407monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-appoints-neil-mcfarlane-to-its-board-of-directors-coll-20220406monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-provides-2022-financial-guidance-coll-20220405monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-master-settlement-agreement-resolving-pending-opioid-related-litigatio-coll-20220330monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-completes-the-acquisition-of-bdsi-coll-20220322monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-acquire-biodelivery-sciences-in-an-all-cash-deal-coll-20220214monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-2021-financial-r-coll-20220210monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-ranks-as-a-top-place-to-work-for-2021-by-the-boston-globe-coll-20211206monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-25-million-accelerated-share-repurchase-program-coll-20211115monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-upcoming-conferences-coll-20211111monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-third-quarter-2021-financial-results-and-prov-coll-20211021monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-four-posters-presented-at-painweek-2021-national-conference-coll-20210913monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-upcoming-investor-conferences-coll-20210901monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-100-million-share-repurchase-program-coll-20210816monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-second-quarter-2021-financial-results-and-pro-coll-20210721monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-publication-of-real-world-data-in-journal-of-pain-research-coll-20210616monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-upcoming-investor-conference-coll-20210520monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-first-quarter-2021-financial-results-and-prov-coll-20210415monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-fourth-quarter-2020-financial-results-and-pro-coll-20210211monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-provides-2021-financial-guidance-coll-20210106monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-publication-of-postmarketing-analysis-of-misuse-abuse-and-diversion-of-coll-20201026monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-third-quarter-2020-financial-results-and-prov-coll-20201022monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-five-posters-presented-at-painweek-2020-national-conference-coll-20200914monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-scientific-presentations-at-painweek-2020-national-conference-coll-20200909monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-second-quarter-2020-financial-results-and-pro-coll-20200721monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-pharmaceutical-named-one-of-boston-business-journal-s-2020-best-places-to-work-coll-20200617monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-first-quarter-2020-financial-results-and-prov-coll-20200423monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-upcoming-investor-conference-coll-20200407monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-2019-financial-r-coll-20200226monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-pharmaceutical-inc-prices-125-0-million-convertible-senior-notes-offering-coll-20200211monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-pharmaceutical-inc-announces-proposed-convertible-senior-notes-offering-coll-20200210monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-provides-2020-financial-guidance-coll-20200107monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-upcoming-investor-conferences-coll-20191126monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-upcoming-investor-conference-coll-20191108monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-third-quarter-2019-financial-results-and-prov-coll-20191023monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-upcoming-investor-conference-coll-20190925monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-upcoming-investor-conferences-coll-20190903monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-scientific-presentations-at-painweek-2019-national-conference-coll-20190829monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-second-quarter-2019-financial-results-and-pro-coll-20190724monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-present-at-upcoming-investor-conferences-coll-20190529monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-upcoming-investor-conferences-coll-20190430monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-first-quarter-2019-financial-results-and-prov-coll-20190424monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-appoints-richard-malamut-m-d-as-chief-medical-officer-coll-20190402monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-present-at-upcoming-investor-conferences-coll-20190401monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-fourth-quarter-2018-financial-results-and-pro-coll-20190213monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-present-at-upcoming-investor-conferences-coll-20181112monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-third-quarter-financial-results-coll-20181108monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-publication-of-data-on-oral-abuse-potential-of-xtampza-er-coll-20181029monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-third-quarter-2018-financial-results-and-prov-coll-20181017monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-present-at-upcoming-investor-conference-coll-20180928monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-scientific-presentations-at-painweek-2018-meeting-coll-20180904monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-second-quarter-2018-financial-results-and-pro-coll-20180720monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-promotion-of-scott-dreyer-to-cco-coll-20180710monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-ceo-succession-coll-20180604monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-present-at-upcoming-investor-conferences-coll-20180530monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-present-at-the-deutsche-bank-health-care-conference-coll-20180502monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-first-quarter-2018-financial-results-and-prov-coll-20180420monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-present-at-the-h-c-wainwright-global-life-sciences-conference-coll-20180404monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-the-appointment-of-shirley-kuhlmann-as-general-counsel-coll-20180319monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-present-at-upcoming-investor-conferences-coll-20180316monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-fourth-quarter-2017-financial-results-and-pro-coll-20180226monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-participate-in-the-guggenheim-securities-5th-annual-boston-healthcare-confere-coll-20171212monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-present-at-the-29th-annual-piper-jaffray-healthcare-conference-coll-20171122monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-receives-fda-approval-for-snda-for-xtampza-er-coll-20171107monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-notified-that-the-fda-will-not-meet-pdufa-goal-date-for-snda-for-xtampza-er-coll-20171106monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-third-quarter-2017-financial-results-and-prov-coll-20171030monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-present-at-upcoming-investor-conferences-coll-20170906monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-scientific-presentations-at-painweek-2017-meeting-coll-20170905monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-second-quarter-2017-financial-results-and-pro-coll-20170718monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-scientific-presentations-at-the-2017-international-conference-on-opioi-coll-20170608monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-additional-managed-care-coverage-for-xtampza-er-for-medicare-part-d-pa-coll-20170601monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-present-at-upcoming-investor-conferences-coll-20170523monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-first-quarter-2017-financial-results-and-prov-coll-20170503monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-present-at-the-42nd-annual-deutsche-bank-healthcare-conference-coll-20170420monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-appointment-of-steven-passik-phd-as-vice-president-scientific-affairs--coll-20170404monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-expanded-managed-care-coverage-for-xtampza-er-for-medicare-part-d-pati-coll-20170403monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-present-at-the-16th-annual-needham-healthcare-conference-coll-20170328monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-scientific-presentation-at-american-academy-of-pain-medicine-2017-meet-coll-20170316monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-2016-financial-results-and-provide-corporate--coll-20170228monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-positive-topline-results-of-human-abuse-potential-clinical-trial-evalu-coll-20170201monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-the-addition-of-xtampza-er-to-express-scripts-formulary-coll-20161215monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-underwriters-exercise-of-option-to-purchase-additional-shares-coll-20161129monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-present-at-upcoming-investor-conferences-coll-20161111monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-third-quarter-2016-financial-results-and-prov-coll-20161102monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-submits-supplemental-new-drug-submission-to-fda-for-xtampza-er-coll-20161005monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-submits-new-drug-submission-to-health-canada-for-xtampza-er-an-analgesic-with-ab-coll-20161003monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-publication-of-data-on-oral-abuse-potential-of-xtampza-er-coll-20160929monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-present-at-the-biocentury-newsmakers-conference-coll-20160907monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-the-launch-of-opioidiq-coll-20160906monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-scientific-presentations-at-painweek-2016-meeting-coll-20160901monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-publication-of-data-on-alternative-modes-of-administration-of-xtampza--coll-20160816monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-second-quarter-2016-financial-results-and-pro-coll-20160805monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-receives-european-patent-allowance-covering-xtampza-er-coll-20160801monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-present-at-cantor-fitzgerald-s-2nd-annual-healthcare-conference-coll-20160706monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-ceo-michael-heffernan-named-ey-entrepreneur-of-the-year-coll-20160627monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-positive-topline-results-for-hydrocodone-deterx-clinical-study-coll-20160622monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-commercial-launch-of-xtampza-er-coll-20160620monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-election-of-john-a-fallon-m-d-to-board-of-directors-coll-20160613monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-poster-presentations-for-xtampza-er-at-the-international-conference-on-coll-20160602monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-present-at-jefferies-and-william-blair-conferences-coll-20160602monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-hosting-investor-day-event-on-may-25-2016-coll-20160523monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-poster-presentations-for-xtampza-er-at-american-pain-society-meeting-coll-20160511monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-positive-topline-results-of-comparative-clinical-trial-evaluating-the--coll-20160504monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-first-quarter-2016-financial-results-and-prov-coll-20160427monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-receives-fda-approval-for-xtampza-er-an-analgesic-with-abuse-deterrent-propertie-coll-20160426monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-present-at-the-15th-annual-needham-healthcare-conference-coll-20160408monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-publication-of-data-on-the-durability-of-pain-relief-with-xtampza-er-coll-20160407monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-2015-financial-results-and-provide-corporate--coll-20160310monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-publication-of-data-on-the-in-vitro-assessment-of-iv-abuse-of-xtampza--coll-20160303monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-favorable-judgment-by-the-district-court-of-massachusetts-coll-20160211monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-issuance-of-u-s-patent-covering-deterx-an-abuse-deterrent-extended-rel-coll-20160204monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-provides-litigation-update-coll-20160202monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-fda-acceptance-of-ind-application-for-abuse-deterrent-hydrocodone-dete-coll-20160121monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-pharmaceutical-inc-prices-public-offering-of-55-0-million-of-common-stock-coll-20160108monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-publication-of-nasal-human-abuse-potential-study-in-american-academy-o-coll-20151216monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-added-to-the-nasdaq-biotechnology-index-coll-20151214monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-present-at-the-27th-annual-piper-jaffray-healthcare-conference-coll-20151130monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-q3-financial-results-and-provide-corporate-up-coll-20151109monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-fda-tentative-approval-for-xtampza-tm-er-a-novel-abuse-deterrent-analg-coll-20151109monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-provides-update-on-fda-review-of-xtampza-tm-er-an-abuse-deterrent-analgesic-for--coll-20151012monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-fda-advisory-committees-unanimously-recommend-approval-of-xtampza-er-t-coll-20150912monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-present-highlights-from-xtampza-tm-er-oxycodone-extended-release-capsules-cli-coll-20150904monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-publishes-data-from-xtampza-tm-er-phase-3-clinical-trial-in-the-journal-pain-coll-20150824monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-host-conference-call-to-discuss-financial-results-and-provide-corporate-updat-coll-20150807monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-fda-advisory-committee-meeting-for-xtampza-tm-er-an-abuse-deterrent-an-coll-20150807monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-added-to-russell-2000-r-3000-r-and-global-indexes-coll-20150706monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-expands-leadership-team-with-vice-president-of-regulatory-affairs-and-quality-as-coll-20150701monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-publication-of-comparing-the-effect-of-tampering-on-the-oral-pharmacok-coll-20150625monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-present-xtampza-er-tm-oral-human-abuse-potential-data-at-the-college-on-probl-coll-20150615monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-announces-issuance-of-u-s-patent-covering-deterx-r-an-abuse-deterrent-extended-r-coll-20150608monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-expands-commercial-organization-with-key-appointments-coll-20150601monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-to-present-at-the-jefferies-2015-global-healthcare-conference-coll-20150527monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-pharmaceutical-announces-closing-of-its-initial-public-offering-and-exercise-in--coll-20150512monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-pharmaceutical-announces-pricing-of-its-initial-public-offering-coll-20150507monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-pharmaceutical-to-present-xtampza-er-tm-pivotal-phase-iii-data-at-the-2015-ameri-coll-20150317monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-pharmaceutical-raises-50-million-financing-to-support-commercial-development-of--coll-20150310monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-pharmaceutical-announces-notice-of-allowance-for-u-s-patent-covering-deterx-r-an-coll-20150226monthly0.5https://www.biopharmawatch.com/news/COLL/collegium-pharmaceutical-secures-fda-acceptance-for-filing-of-nda-for-xtampza-er-tm-oxycod-coll-20150217monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-investigation-alert-bragar-eagel-squire-p-c-is-investigating-alphatec-holdings-in-atec-20260603monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-more--atec-20260506monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-to-participate-in-upcoming-investor-conferences-atec-20200908monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-to-participate-in-40th-annual-canaccord-growth-conference-atec-20200731monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-to-report-second-quarter-2020-financial-results-on-august-6-2020-atec-20200723monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-to-report-first-quarter-2020-financial-results-on-may-11-2020-atec-20200428monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-to-report-fourth-quarter-and-fiscal-year-2019-financial-results-on-march-5th-2020-atec-20200220monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-enhances-its-lateral-portfolio-with-the-commercial-launch-of-approach-specific-in-atec-20191022monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-to-report-third-quarter-2019-financial-results-on-october-30-2019-atec-20191010monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-announces-commercial-launch-of-identiti-tlif-posterior-oblique-porous-titanium-in-atec-20190925monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-announces-favorable-judgment-in-nuvasive-v-miles-lawsuit-atec-20190827monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-to-participate-in-the-h-c-wainwright-21st-annual-global-investment-conference-and-atec-20190826monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-accelerates-organic-innovation-machine-with-key-senior-leadership-appointment-and-atec-20190815monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-advances-invictus-mis-spinal-fixation-system-with-commercial-launch-of-singlestep-atec-20190807monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-closing-of-public-stock-offering-and-full-exercise-of-unde-atec-20190802monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-to-present-at-the-canaccord-genuity-39th-annual-growth-conference-atec-20190802monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-reports-second-quarter-2019-financial-results-and-corporate-highlights-atec-20190724monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-announces-commercial-launch-of-the-invictus-mis-and-open-spinal-fixation-systems-atec-20190723monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-announces-commercial-launch-of-alif-identiti-porous-titanium-interbody-system-imp-atec-20190718monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-to-report-second-quarter-2019-financial-results-on-july-24-2019-atec-20190711monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-announces-organizational-and-corporate-updates-atec-20190627monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-announces-updated-presentation-date-and-time-at-the-raymond-james-life-sciences-a-atec-20190612monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-announces-commercial-launch-of-tlif-identiti-posterior-curved-porous-titanium-int-atec-20190530monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-to-participate-in-the-jefferies-2019-global-healthcare-conference-and-the-raymond-atec-20190528monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-to-present-at-the-20th-annual-b-riley-fbr-investor-conference-atec-20190515monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-reports-first-quarter-2019-financial-results-and-corporate-highlights-atec-20190509monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-announces-commercial-launch-of-plif-identiti-posterior-straight-porous-titanium-i-atec-20190506monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-to-report-first-quarter-2019-financial-results-on-may-9-2019-atec-20190418monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-announces-sales-leadership-appointment-and-successful-closing-of-expanded-credit--atec-20190415monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-announces-commercial-launch-of-its-first-identiti-porous-titanium-interbody-syste-atec-20190328monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-announces-participation-at-canaccord-and-cowen-investor-conferences-in-march-atec-20190308monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-reports-fourth-quarter-and-full-year-2018-financial-results-atec-20190307monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-announces-fda-clearance-of-its-automated-safeop-neuromonitoring-system-to-address-atec-20190225monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-to-report-fourth-quarter-and-fiscal-year-2018-financial-results-on-march-7-2019-atec-20190221monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-announces-stay-of-court-proceedings-in-nuvasive-patent-lawsuit-atec-20190211monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-reports-third-quarter-2018-financial-and-corporate-highlights-atec-20181108monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-announces-participation-at-stifel-2018-healthcare-conference-atec-20181031monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-to-report-third-quarter-2018-financial-results-on-november-8-2018-atec-20181023monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-accelerates-organic-innovation-machine-with-addition-of-key-senior-leadership-and-atec-20180927monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-advances-clinical-distinction-with-osseoscrew-clearance-atec-20180926monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-to-present-at-the-rodman-renshaw-20th-annual-global-investment-conference-atec-20180827monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-to-report-second-quarter-2018-financial-results-on-august-2-2018-atec-20180709monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-to-report-first-quarter-2018-financial-results-on-may-10-2018-atec-20180426monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-participation-at-the-oppenheimer-co-inc-28th-annual-healthcare-co-atec-20180319monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-disrupts-market-with-acquisition-of-safeop-surgical-50m-equity-financing-an-atec-20180308monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-to-report-fourth-quarter-and-fiscal-year-2017-financial-results-on-march-atec-20180301monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-reports-third-quarter-2017-financial-results-atec-20171109monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-denounces-baseless-nuvasive-complaint-atec-20171011monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-participation-at-the-19th-annual-rodman-renshaw-global-inv-atec-20170830monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-reports-second-quarter-2017-financial-results-atec-20170810monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-to-report-second-quarter-2017-financial-results-on-august-10-2017-atec-20170801monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-to-report-first-quarter-2017-financial-results-on-may-11-2017-atec-20170508monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-launches-battalion-lateral-system-with-squadron-retractor-to-support-minima-atec-20170407monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-adds-experienced-spine-executives-to-sales-leadership-team-atec-20170405monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-completes-its-senior-leadership-team-with-appointment-of-brian-snider-executive-v-atec-20170324monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-18-9-million-private-placement-atec-20170323monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-appoints-jeffrey-g-black-as-chief-financial-officer-atec-20170306monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-s-arsenal-deformity-adolescent-scoliosis-ais-system-launched-in-limited-markets-i-atec-20170228monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-appointment-of-david-h-mowry-to-its-board-of-directors-atec-20170214monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-board-and-executive-leadership-changes-atec-20161212monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-third-quarter-2016-revenue-and-financial-results-atec-20161109monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-showcase-new-minimally-invasive-mis-and-complex-spine-products-at-the-up-atec-20161018monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-company-updates-atec-20161005monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-company-updates-atec-20160915monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-one-for-twelve-reverse-stock-split-atec-20160824monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-fourth-quarter-and-full-year-2015-revenue-and-financial-result-atec-20160315monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-27th-annual-piper-jaffray-healthcare-conference-atec-20151118monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-third-quarter-2015-revenue-and-financial-results-atec-20151103monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-retirement-of-james-r-glynn-from-its-board-of-directors-donald-a--atec-20151030monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-introduces-new-titanium-coated-peek-interbody-fusion-system-atec-20151012monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-launches-alphatec-neocore-tm-osteoconductive-matrix-in-the-u-s-atec-20151001monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-s-less-invasive-arsenal-tm-cortical-bone-fixation-system-successfully-used-in-ove-atec-20150924monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-s-arsenal-tm-spinal-fixation-system-further-expanded-to-address-broader-market-atec-20150917monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-second-quarter-2015-revenue-and-financial-results-atec-20150804monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-release-second-quarter-2015-financial-results-atec-20150721monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-jefferies-2015-global-healthcare-conference-atec-20150520monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-ubs-2015-global-healthcare-conference-atec-20150506monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-appointment-of-donald-a-williams-to-its-board-of-directors-atec-20150501monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-first-quarter-2015-revenue-and-financial-results-atec-20150430monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-release-first-quarter-2015-financial-results-atec-20150417monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-10th-annual-canaccord-genuity-musculoskeletal-conference-atec-20150310monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-fourth-quarter-and-full-year-2014-revenue-and-financial-result-atec-20150226monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-35th-annual-cowen-and-company-healthcare-conference-atec-20150218monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-release-fourth-quarter-and-fiscal-year-2014-financial-results-atec-20150206monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-upcoming-investor-events-in-december-2014-atec-20141125monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-appointment-of-tom-c-davis-to-its-board-of-directors-atec-20141125monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-participate-in-upcoming-investor-events-in-november-2014-atec-20141105monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-third-quarter-2014-revenue-and-financial-results-atec-20141030monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-showcase-new-arsenal-tm-spinal-fixation-system-at-the-upcoming-29th-annu-atec-20141029monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-release-third-quarter-2014-financial-results-atec-20141015monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-showcase-product-portfolio-at-eurospine-2014-in-lyon-france-atec-20140922monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-34th-annual-canaccord-genuity-growth-conference-atec-20140805monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-second-quarter-2014-revenue-and-financial-results-atec-20140731monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-release-second-quarter-2014-financial-results-atec-20140717monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-jefferies-2014-global-healthcare-conference-atec-20140519monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-first-quarter-2014-revenue-and-financial-results-atec-20140430monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-executive-leadership-changes-atec-20140430monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-release-first-quarter-2014-financial-results-atec-20140416monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-fourth-quarter-and-full-year-2013-revenue-and-financial-result-atec-20140317monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-and-orthotec-llc-mutually-agree-to-settle-ongoing-litigation-atec-20140317monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-postpones-fourth-quarter-and-fiscal-year-2013-release-and-conference-call-atec-20140220monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-jury-verdict-in-the-orthotec-litigation-atec-20140211monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-release-fourth-quarter-and-fiscal-year-2013-financial-results-atec-20140210monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-executive-leadership-changes-atec-20140102monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-24th-annual-oppenheimer-healthcare-conference-atec-20131125monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-25th-annual-piper-jaffray-healthcare-conference-atec-20131119monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-reports-third-quarter-2013-financial-results-atec-20131107monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-enters-into-collaboration-agreement-with-group-of-experienced-spine-surgeon-atec-20131024monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-release-third-quarter-2013-financial-results-atec-20131022monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-showcase-comprehensive-product-portfolio-at-the-upcoming-28th-annual-nor-atec-20131001monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-showcase-product-portfolio-at-eurospine-2013-in-liverpool-uk-atec-20130925monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-intent-to-restructure-scient-x-business-operations-atec-20130916monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-restructured-and-expanded-credit-facility-atec-20130916monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-stifel-healthcare-conference-2013-atec-20130828monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-second-quarter-2013-revenue-and-financial-results-atec-20130806monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-date-for-release-of-second-quarter-2013-financial-results-atec-20130725monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-postpones-2013-annual-meeting-of-stockholders-to-june-21-2013-and-supplemen-atec-20130611monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-host-technology-day-on-june-6-2013-in-new-york-city-atec-20130529monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-jefferies-global-healthcare-conference-atec-20130521monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-host-technology-day-on-june-6-2013-in-new-york-city-atec-20130509monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-bank-of-america-merrill-lynch-2013-health-care-conference-atec-20130507monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-first-quarter-2013-revenue-and-financial-results-atec-20130430monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-date-for-release-of-first-quarter-2013-financial-results-atec-20130415monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-2013-canaccord-genuity-musculoskeletal-conference-in-chic-atec-20130313monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-receives-fda-510-k-market-clearance-for-its-alphatec-solus-tm-internal-fixa-atec-20130312monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-fourth-quarter-and-full-year-2012-revenue-and-financial-results-atec-20130228monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-date-for-release-of-fourth-quarter-and-full-year-2012-financial-r-atec-20130212monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-receives-u-s-fda-510-k-market-clearance-for-two-new-products-and-receives-j-atec-20130103monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-24th-annual-piper-jaffray-healthcare-conference-atec-20121115monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-completes-asset-acquisition-of-irvine-ca-based-phygen-llc-atec-20121107monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-third-quarter-2012-financial-results-atec-20121105monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-date-change-for-third-quarter-2012-financial-results-and-conferen-atec-20121031monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-signs-new-exclusive-supply-agreement-for-an-anchored-zero-profile-anterior--atec-20121023monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-showcase-new-products-at-the-upcoming-27th-annual-north-american-spine-s-atec-20121023monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-conference-call-and-business-update-in-advance-of-attendance-at-t-atec-20121022monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-appoints-new-senior-vice-president-of-u-s-commercial-operations-atec-20121004monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-receives-board-approval-to-acquire-assets-of-spine-implant-business-atec-20120927monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-releases-alphatec-nexoss-tm-nanostructure-bio-active-matrix-and-announces-t-atec-20120918monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-2012-ubs-global-life-sciences-conference-atec-20120906monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-launches-new-mis-device-the-bridgepoint-tm-spinous-process-fixation-system-atec-20120823monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-2012-stifel-nicolaus-health-care-conference-atec-20120823monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-second-quarter-2012-financial-results-atec-20120807monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-appoints-luke-t-faulstick-to-board-of-directors-atec-20120807monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-date-for-second-quarter-2012-financial-results-atec-20120724monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-new-and-expanded-credit-facility-atec-20120612monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-wells-fargo-securities-2012-health-care-conference-atec-20120607monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-bank-of-america-merrill-lynch-2012-health-care-conference-atec-20120511monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-first-quarter-2012-revenue-and-financial-results-atec-20120508monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-date-for-first-quarter-2012-financial-results-atec-20120424monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-appoints-new-vice-president-of-operations-atec-20120321monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-cowen-32nd-annual-health-care-conference-atec-20120302monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-fourth-quarter-and-full-year-2011-revenue-and-financial-results-atec-20120228monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-management-realignment-to-prepare-company-for-next-phase-of-globa-atec-20120228monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-attend-lazard-capital-management-medical-device-conference-atec-20120224monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-date-for-fourth-quarter-and-full-year-2011-financial-results-atec-20120214monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-canaccord-genuity-musculoskeletal-conference-atec-20120131monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-appoints-new-senior-director-of-investor-relations-atec-20120119monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-and-cross-medical-products-settle-license-agreement-dispute-atec-20120105monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-23rd-annual-piper-jaffray-health-care-conference-atec-20111122monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-appoints-new-vice-president-of-regulatory-clinical-affairs-and-quality-atec-20111116monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-appoints-new-senior-vice-president-global-marketing-and-asia-pacific-atec-20111116monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-lazard-capital-markets-8th-annual-healthcare-conference-atec-20111110monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-third-quarter-2011-revenue-and-financial-results-atec-20111101monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-new-products-at-upcoming-north-american-spine-society-nass-meetin-atec-20111101monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-hold-3q-2011-financial-results-investor-call-atec-20111013monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-successful-resolution-of-fda-warning-letter-atec-20111005monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-stifel-nicolaus-healthcare-conference-2011-atec-20110829monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-second-quarter-2011-revenue-and-financial-results-atec-20110804monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-2011-canaccord-genuity-growth-conference-atec-20110801monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-names-leslie-h-cross-chairman-of-the-board-of-directors-atec-20110801monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-inc-comments-on-untitled-letter-related-to-puregen-osteoprogenitor-cell-all-atec-20110725monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-inc-receives-japanese-regulatory-shonin-approval-for-illico-se-tm-posterior-atec-20110718monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-hold-2q-2011-financial-results-investor-call-atec-20110705monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-jefferies-2011-global-healthcare-conference-atec-20110601monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-first-quarter-2011-revenue-and-financial-results-atec-20110504monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-appointment-of-patrick-ryan-as-chief-operating-officer-atec-20110425monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-hold-1q-2011-financial-results-investor-call-atec-20110421monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-host-technology-day-may-12-2011-in-new-york-ny-atec-20110413monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-receives-510-k-clearance-for-its-solus-tm-anterior-lumbar-interbody-fusion--atec-20110404monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-the-addition-of-leslie-h-cross-to-its-board-of-directors-atec-20110329monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-fourth-quarter-and-full-year-2010-revenue-and-financial-results-atec-20110224monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-2011-rbc-capital-markets-healthcare-conference-atec-20110223monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-hold-4q-2010-financial-results-investor-call-atec-20110216monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-canaccord-genuity-musculoskeletal-conference-atec-20110208monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-inc-announces-the-first-three-level-guided-lumbar-interbody-fusion-procedur-atec-20110104monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-piper-jaffray-22nd-annual-health-care-conference-atec-20101122monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-third-quarter-2010-revenue-and-financial-results-atec-20101108monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-appoints-new-senior-vice-president-global-human-resources-atec-20101102monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-debt-refinancing-atec-20101101monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-hold-3q-2010-financial-results-investor-call-atec-20101025monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-four-new-product-launches-in-the-mis-biologics-and-thoracolumbar--atec-20101005monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-inc-releases-puregen-tm-osteoprogenitor-cell-allograft-to-facilitate-bone-r-atec-20101005monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-second-quarter-2010-revenue-and-financial-results-atec-20100805monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-canaccord-genuity-30th-annual-growth-conference-2010-atec-20100803monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-hold-2q-2010-financial-results-investor-call-atec-20100720monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-two-investor-conferences-in-june-atec-20100607monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-first-quarter-2010-revenue-and-financial-results-atec-20100510monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-ninth-annual-jmp-securities-research-conference-atec-20100506monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-adds-new-vice-president-and-general-manager-latin-america-atec-20100505monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-appoints-new-vice-president-of-clinical-quality-and-regulatory-atec-20100504monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-hold-1q-2010-financial-results-investor-call-atec-20100429monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-completion-of-public-offering-of-common-stock-and-full-exercis-atec-20100421monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-anuncia-pre-os-da-oferta-p-blica-para-ac-es-ordin-rias-atec-20100418monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-pricing-of-public-offering-of-common-stock-atec-20100416monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-announces-proposed-public-offering-of-common-stock-atec-20100412monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-reports-preliminary-first-quarter-2010-revenues-atec-20100412monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-completes-acquisition-of-scient-x-groupe-sas-atec-20100329monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-stockholder-approval-of-share-issuance-related-to-the-acquisition-atec-20100317monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-host-technology-day-april-23-2010-8-30am-11-30am-new-york-ny-atec-20100316monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-expiration-of-hart-scott-rodino-review-period-for-acquisition-of--atec-20100225monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-four-investor-conferences-in-march-atec-20100224monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-fourth-quarter-and-full-year-2009-revenue-and-financial-results-atec-20100223monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-hold-4q-2009-and-full-year-2009-financial-results-investor-call-atec-20100204monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-receives-ce-mark-for-its-osseoscrew-tm-spinal-fixation-system-and-its-glif--atec-20100202monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-inc-enters-into-exclusive-distribution-agreement-with-parcell-spine-llc-atec-20100113monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-agrees-to-acquire-scient-x-groupe-sas-atec-20091217monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-piper-jaffray-21st-annual-health-care-conference-atec-20091119monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-lazard-capital-markets-6th-annual-healthcare-conference-atec-20091110monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-third-quarter-2009-revenue-and-financial-results-atec-20091109monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-inc-enters-supply-and-distribution-agreement-with-etex-corporation-for-nove-atec-20091105monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-host-investor-community-breakfast-during-the-north-american-spine-societ-atec-20091030monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-hold-3q-2009-financial-results-investor-call-atec-20091026monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-key-activities-at-2009-american-academy-of-orthopedic-surgeons-an-atec-20090224monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-licenses-new-technology-to-treat-lumbar-spinal-stenosis-atec-20090223monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-canaccord-adams-musculoskeletal-conference-atec-20090217monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-hold-4q-and-year-end-2008-financial-results-investor-call-atec-20090217monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-rodman-renshaw-and-lazard-capital-markets-healthcare-conferen-atec-20081105monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-third-quarter-2008-revenue-and-financial-results-atec-20081103monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-expands-european-presence-names-peter-kohlbecher-as-vice-president-general--atec-20081031monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-appoints-siri-s-marshall-esq-to-its-board-of-directors-atec-20081029monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-announce-third-quarter-2008-financial-results-atec-20081027monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-launches-www-agingspinecenter-com-web-based-portal-for-healthcare-providers-atec-20081014monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-reports-preliminary-record-third-quarter-2008-revenues-provides-increased-r-atec-20081013monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-scheduled-company-update-and-conference-call-atec-20081010monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-launches-new-orthobiologics-product-profuse-bone-scaffold-packaged-in-propr-atec-20081007monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-510-k-clearance-for-its-novel-cervical-interbody-implant-atec-20080925monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-the-ubs-global-life-sciences-investor-conference-atec-20080916monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-present-at-canaccord-adams-and-noble-financial-investor-conferences-atec-20080811monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-announces-second-quarter-2008-revenue-and-financial-results-atec-20080804monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-to-announce-second-quarter-2008-financial-results-atec-20080730monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-spine-s-osseofix-clinical-study-initiated-atec-20080724monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-sales-launch-in-europe-atec-20080606monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-planned-management-transition-atec-20080509monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-reaches-successful-settlement-and-release-agreement-to-license-pedic-atec-20080507monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-record-first-quarter-2008-revenue-and-financial-results-atec-20080424monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-terminates-license-for-dynamo-semi-rigid-rod-system-atec-20080424monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-webcast-and-conference-call-to-review-q1-2008-results-atec-20080410monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-names-veteran-executive-mitsuo-asai-president-of-alphatec-pacific-in-atec-20080403monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-names-veteran-sales-and-marketing-executive-gary-fredericks-vice-pre-atec-20080402monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-acquires-a-worldwide-license-for-innovative-expandable-interbody-ver-atec-20080313monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-record-fourth-quarter-and-fiscal-year-2007-revenue-and-fin-atec-20080213monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-names-veteran-spinal-orthopedics-executive-j-p-timm-as-vice-presiden-atec-20080211monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-acquires-an-exclusive-worldwide-license-for-innovative-dynamic-anter-atec-20080206monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-appoints-executives-rohit-m-desai-and-dirk-kuyper-to-its-board-of-di-atec-20080205monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-webcast-and-conference-call-to-review-q4-2007-results-atec-20080205monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-the-commercial-introduction-of-its-unique-dynamo-semi-rigi-atec-20080116monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-names-leading-biomechanics-executive-andrew-mahar-as-senior-director-atec-20080115monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-acquires-an-exclusive-worldwide-license-for-innovative-pedicle-screw-atec-20071221monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-revenue-guidance-for-fiscal-year-2008-atec-20071213monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-webcast-and-conference-call-to-review-fiscal-year-2008-out-atec-20071211monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-to-present-at-upcoming-conferences-atec-20071128monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-receives-fda-510-k-clearance-for-the-zodiac-luxe-4-0-millimeter-diam-atec-20071119monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-receives-fda-510-k-clearance-for-the-dynamo-rod-system-atec-20071025monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-record-revenue-and-third-quarter-2007-financial-results-atec-20071023monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-to-present-at-upcoming-conference-atec-20071022monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-webcast-and-conference-call-to-review-q3-2007-results-atec-20071022monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-exercise-of-option-to-purchase-additional-shares-atec-20070925monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-pricing-of-common-stock-offering-atec-20070921monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-acquires-an-exclusive-worldwide-license-for-technology-related-to-gu-atec-20070913monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-names-veteran-marketing-executive-kathryn-liljestrand-as-vice-presid-atec-20070913monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-proposed-public-offering-of-common-stock-atec-20070912monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-names-veteran-operations-executive-kermit-p-stott-as-vice-president--atec-20070910monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-to-participate-in-57th-annual-2007-congress-of-neurological-surgeons-atec-20070907monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-second-quarter-2007-financial-results-and-plans-to-improve-atec-20070806monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-to-present-at-upcoming-conference-atec-20070726monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-webcast-and-conference-call-to-review-q2-2007-results-mond-atec-20070725monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-appoints-mortimer-berkowitz-iii-chairman-of-the-board-of-directors-atec-20070720monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-webcast-and-conference-call-to-review-q2-2007-results-atec-20070718monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-appoints-prominent-spine-surgeon-frank-p-cammisa-jr-m-d-to-scientifi-atec-20070628monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-expands-its-spinal-disorder-solution-technology-with-the-launch-of-t-atec-20070620monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-names-veteran-spinal-orthopedic-industry-executive-dirk-kuyper-as-pr-atec-20070606monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-drives-spinal-disorder-solution-technology-and-announces-the-launch--atec-20070515monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-appoints-james-r-glynn-to-board-of-directors-atec-20070501monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-first-quarter-2007-financial-results-atec-20070426monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-webcast-and-conference-call-to-review-q1-2007-results-thur-atec-20070423monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-licenses-technology-focused-on-minimally-invasive-spinal-surgery-mar-atec-20070412monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-enhances-technology-and-product-portfolio-with-global-licensing-agre-atec-20070411monthly0.5https://www.biopharmawatch.com/news/ATEC/alphatec-holdings-inc-announces-japanese-ministry-s-approval-of-its-novel-titanium-product-atec-20070329monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-to-report-third-quarter-2025-financial-results-after-market-close-on-november-10-20-hrow-20251027monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-to-report-second-quarter-2025-financial-results-after-market-close-on-august-11-202-hrow-20250729monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-inc-company-investigated-by-the-portnoy-law-firm-hrow-20230228monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-shareholder-news-johnson-fistel-encourages-harrow-health-shareholders-with-l-hrow-20230222monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-to-announce-second-quarter-2021-financial-results-on-august-10-2021-hrow-20210726monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-granted-two-patents-for-novel-surgical-dilation-formulation-hrow-20210715monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-announces-closing-of-20-million-aggregate-principal-amount-offering-of-8-625-hrow-20210617monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-launches-new-corporate-and-investor-website-hrow-20210601monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-announces-full-exercise-and-closing-of-option-to-purchase-additional-senior--hrow-20210505monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-to-announce-first-quarter-2021-financial-results-on-may-11-2021-hrow-20210427monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-announces-closing-of-50-million-offering-of-senior-notes-due-2026-hrow-20210420monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-announces-offering-of-25-million-senior-notes-due-2026-and-bb-rating-from-eg-hrow-20210414monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-uk-lasting-powers-of-attorney-agents-consulting-services-launched-hrow-20210409monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-to-participate-in-h-c-wainwright-global-life-sciences-conference-hrow-20210302monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-to-announce-fourth-quarter-and-year-end-2020-financial-results-on-march-8-20-hrow-20210225monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-announces-participation-at-the-piper-sandler-32nd-annual-healthcare-conferen-hrow-20201120monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-to-announce-third-quarter-2020-financial-results-on-november-9-2020-hrow-20201027monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-appoints-larry-van-horn-to-its-board-of-directors-hrow-20200930monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-to-attend-lake-street-s-virtual-4th-annual-big4-conference-september-17-2020-hrow-20200911monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-to-announce-second-quarter-2020-financial-results-on-august-10-2020-hrow-20200727monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-set-to-join-russell-2000-index-and-russell-3000-index-hrow-20200629monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-to-announce-first-quarter-2020-financial-results-on-may-11-2020-hrow-20200427monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-appoints-teresa-sparks-to-its-board-of-directors-hrow-20200317monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-to-announce-fourth-quarter-2019-financial-results-on-march-13-2020-hrow-20200227monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-to-announce-third-quarter-2019-financial-results-on-november-13-2019-hrow-20191024monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-to-attend-lake-street-s-3rd-annual-best-ideas-growth-conference-september-12-hrow-20190827monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-forms-stowe-pharmaceuticals-subsidiary-to-develop-broad-spectrum-anti-microb-hrow-20190802monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-announces-launch-of-mayfield-pharmaceuticals-hrow-20190731monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-to-announce-second-quarter-2019-financial-results-on-august-14-2019-hrow-20190725monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-adds-two-senior-executives-to-its-nashville-team-hrow-20190625monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-inc-to-locate-headquarters-in-nashville-tennessee-hrow-20190618monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-to-present-at-the-20th-annual-b-riley-fbr-institutional-investor-conference--hrow-20190507monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-to-announce-first-quarter-2019-financial-results-on-may-9-2019-hrow-20190502monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-to-attend-31st-annual-roth-conference-on-march-18-2019-hrow-20190304monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-to-announce-fourth-quarter-2018-financial-results-on-march-12-2019-hrow-20190228monthly0.5https://www.biopharmawatch.com/news/HROW/harrow-health-subsidiary-mayfield-pharmaceuticals-inc-acquires-patented-dyspareunia-drug-c-hrow-20190207monthly0.5https://www.biopharmawatch.com/news/HROW/harrowing-honeymoon-gay-couple-s-romantic-destination-turns-deadly-in-second-book-of-myste-hrow-20050209monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-but-bfly-20220301monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-announces-the-world-s-first-augmented-reality-telemedicine-technology-bfly-20180325monthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-announces-over-100m-in-financing-to-bring-together-novel-devices-deep-le-bfly-20141103monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-reports-2025-second-quarter-results-cron-20250807monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-reports-2025-first-quarter-results-cron-20250508monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-inc-announces-results-of-2024-annual-meeting-of-shareholders-cron-20240621monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-reports-2023-fourth-quarter-and-full-year-results-cron-20240229monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-enters-australian-cannabis-market-cron-20240109monthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-grants-stock-options-cron-20161121monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-investigation-alert-bragar-eagel-squire-p-c-is-investigating-savara-inc-on-behalf-o-svra-20260124monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-ri-svra-20251107monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-deadline-alert-bragar-eagel-squire-p-c-urgently-reminds-savara-stockholders-to-cont-svra-20251106monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-deadline-alert-bragar-eagel-squire-p-c-urgently-reminds-savara-stockholders-to-cont-svra-20251104monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-ri-svra-20251104monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-class-action-deadline-alert-bragar-eagel-squire-p-c-reminds-savara-investors-to-con-svra-20251031monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm--svra-20251030monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-ri-svra-20251028monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-deadline-alert-bragar-eagel-squire-p-c-urgently-reminds-savara-stockholders-of-the--svra-20251027monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-class-action-alert-bragar-eagel-squire-p-c-urgently-reminds-investors-of-the-novemb-svra-20251023monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm--svra-20251022monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-class-action-reminder-bragar-eagel-squire-p-c-urges-savara-inc-investors-to-contact-svra-20251018monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-inc-sued-for-securities-law-violations-contact-the-gross-law-firm-before-november-7-svra-20251016monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-deadline-reminder-bragar-eagel-squire-p-c-reminds-savara-investors-to-contact-the-f-svra-20251014monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-alert-bragar-eagel-squire-p-c-urges-investors-in-savara-inc-to-contact-the-firm-bef-svra-20251010monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-inc-investor-alert-kirby-mcinerney-llp-reminds-savara-inc-investors-of-looming-lead-svra-20251008monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-inc-investor-alert-kirby-mcinerney-llp-reminds-savara-inc-investors-of-looming-lead-svra-20251006monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-class-action-reminder-bragar-eagel-squire-p-c-reminds-investors-of-the-november-7th-svra-20251006monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm--svra-20250929monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm--svra-20250918monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-nov-svra-20250916monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed--svra-20250909monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-completes-enrollment-in-molgradex-optima-clinical-study-for-the-treatment-of-ntm-svra-20181031monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-to-host-second-quarter-2018-financial-results-and-business-update-conference-call-o-svra-20180802monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-announces-pricing-of-public-offering-of-common-stock-svra-20180726monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-announces-proposed-public-offering-of-common-stock-svra-20180725monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-to-ring-nasdaq-stock-market-opening-bell-on-july-23rd-svra-20180723monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-joins-russell-3000-index-svra-20180625monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-to-present-at-jmp-securities-2018-life-sciences-conference-on-june-20th-svra-20180613monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-provides-update-on-case-reports-of-inhaled-granulocyte-macrophage-colony-stimulatin-svra-20180529monthly0.5https://www.biopharmawatch.com/news/SVRA/savara-to-present-at-bank-of-america-merrill-lynch-2018-healthcare-conference-on-may-17th-svra-20180511monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-2026-jefferies-global-healthcare-conference-and-g-crvs-20260520monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-presents-soquelitinib-phase-1-atopic-dermatitis-data-at-the-society-crvs-20260514monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-host-investor-and-analyst-meeting-on-may-14-2026-to-highlight-so-crvs-20260421monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-fi-crvs-20260305monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-closing-of-upsized-public-offering-of-common-stock-and-fu-crvs-20260123monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-announce-results-from-cohort-4-of-placebo-controlled-phase-1-cli-crvs-20260116monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-presents-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-tr-crvs-20251208monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-third-quarter-2025-financial-results-crvs-20251028monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-second-quarter-2025-financial--crvs-20250807monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-second-quarter-2025-financial-result-crvs-20250731monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-2025-jefferies-global-healthcare-conference-crvs-20250528monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-data-from-cohorts-1-3-of-placebo-controlled-phase-1-clini-crvs-20250508monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-new-interim-data-from-placebo-controlled-phase-1-clinica-crvs-20250423monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-appoints-richard-a-van-den-broek-to-board-of-directors-crvs-20250409monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-fourth-quarter-and-full-year-2-crvs-20250325monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-presentation-of-additional-data-from-the-phase-1-1b-clini-crvs-20250320monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-crvs-20250319monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-fi-crvs-20250317monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-initiation-of-phase-2-clinical-trial-of-soquelitinib-for--crvs-20250312monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences--crvs-20250204monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-crvs-20250107monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-t-crvs-20241217monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-publication-of-biochemistry-and-preclinical-data-demonstr-crvs-20241204monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-new-preclinical-data-highlighting-potential-of-soquelitin-crvs-20241114monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-third-quarter-2024-financial-r-crvs-20241112monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-new-data-highlighting-potential-of-ciforadenant-to-overco-crvs-20241109monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-third-quarter-2024-financial-results-crvs-20241105monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-initiates-registrational-phase-3-clinical-trial-of-soquelitinib-for-crvs-20240910monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conf-crvs-20240903monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-second-quarter-2024-financial--crvs-20240806monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-granted-fda-fast-track-designation-for-soquelitinib-for-treatment-o-crvs-20240801monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-second-quarter-2024-financial-result-crvs-20240731monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-jefferies-global-health-conference-crvs-20240530monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-first-quarter-2024-financial-r-crvs-20240506monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-first-quarter-2024-financial-results-crvs-20240502monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-pricing-of-30-6-million-registered-direct-offering-crvs-20240502monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-initiation-of-placebo-controlled-phase-1-clinical-trial-o-crvs-20240409monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-fourth-quarter-and-full-year-2-crvs-20240319monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2023-fi-crvs-20240313monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-presents-soquelitinib-preclinical-data-at-the-keystone-symposia-on--crvs-20240212monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-orphan-drug-designation-granted-to-soquelitinib-for-the-t-crvs-20240208monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-appoints-jeffrey-arcara-as-chief-business-officer-crvs-20240206monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-the-passing-of-board-member-edith-p-mitchell-crvs-20240123monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-presents-new-interim-soquelitinib-data-from-its-phase-1-1b-t-cell-l-crvs-20231209monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-third-quarter-2023-financial-r-crvs-20231107monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-new-interim-soquelitinib-data-from-its-phase-1-1b-t-cell-crvs-20231102monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-publication-of-preclinical-data-demonstrating-potential-o-crvs-20231101monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-report-third-quarter-financial-resul-crvs-20231031monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-confirms-planned-initiation-of-soquelitinib-cpi-818-phase-3-registr-crvs-20230906monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-second-quarter-2023-financial--crvs-20230808monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-report-second-quarter-financial-resu-crvs-20230801monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-publication-of-preclinical-data-demonstrating-potential-n-crvs-20230706monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-presents-new-ciforadenant-preclinical-data-at-the-2nd-jca-aacr-prec-crvs-20230629monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-presents-new-cpi-818-interim-data-at-the-international-conference-o-crvs-20230615monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-jefferies-healthcare-conference-crvs-20230531monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-new-cpi-818-data-at-the-international-conference-on-mali-crvs-20230517monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-first-quarter-2023-financial-r-crvs-20230508monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-report-first-quarter-2023-financial--crvs-20230420monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-presents-new-cpi-818-data-demonstrating-the-potential-of-itk-inhibi-crvs-20230417monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-fourth-quarter-and-full-year-2-crvs-20230328monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-report-fourth-quarter-and-full-year--crvs-20230321monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-new-cpi-818-data-demonstrating-the-potential-of-itk-inhi-crvs-20230314monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-new-data-demonstrating-cpi-818-s-itk-inhibitor-potential--crvs-20230221monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-presents-updated-data-from-cpi-818-itk-inhibitor-phase-1-1b-clinica-crvs-20221212monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-host-investor-conference-call-and-webcast-on-december-12-2022-crvs-20221205monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-third-quarter-2022-financial-r-crvs-20221103monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-updated-cpi-818-itk-inhibitor-data-at-the-64th-american--crvs-20221103monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-report-third-quarter-2022-financial--crvs-20221027monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-initiation-of-phase-1b-2-clinical-trial-of-ciforadenant-a-crvs-20221025monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-partner-angel-pharmaceuticals-received-ind-approval-for-p-crvs-20220926monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conf-crvs-20220906monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-second-quarter-2022-financial--crvs-20220808monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-report-second-quarter-2022-financial-crvs-20220728monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-appoints-dr-james-rosenbaum-senior-vice-president-of-research-crvs-20220721monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-program-updates-at-r-d-symposium-crvs-20220510monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-first-quarter-2022-financial-r-crvs-20220505monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-host-r-d-symposium-on-may-10-2022-in-new-york-crvs-20220426monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-fourth-quarter-and-full-year-2-crvs-20220310monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-report-fourth-quarter-and-full-year--crvs-20220303monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-partner-angel-pharmaceuticals-initiated-phase-1-1b-clinic-crvs-20220113monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-presents-updated-data-from-mupadolimab-anti-cd73-phase-1-1b-clinica-crvs-20211112monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-jefferies-london-healthcare-conference-crvs-20211110monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-updated-mupadolimab-anti-cd73-data-at-2021-society-for-i-crvs-20211102monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-third-quarter-2021-financial-r-crvs-20211101monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-partner-angel-pharmaceuticals-received-ind-approval-for-p-crvs-20211027monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-updates-on-mupadolimab-anti-cd73-programs-in-oncology-and--crvs-20210922monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-crvs-20210907monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-ind-acceptance-for-phase-1-1b-clinical-trial-of-cpi-818-i-crvs-20210816monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-second-quarter-2021-financial--crvs-20210802monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-discontinues-phase-3-study-of-mupadolimab-anti-cd73-for-covid-19-du-crvs-20210715monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-jefferies-virtual-healthcare-conference-crvs-20210525monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-completes-sale-of-10-million-through-its-atm-program-crvs-20210505monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-first-quarter-2021-financial-r-crvs-20210429monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-fourth-quarter-and-full-year-2-crvs-20210325monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-crvs-20210305monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-closing-of-public-offering-of-common-stock-crvs-20210217monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-crvs-20210212monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-proposed-public-offering-of-common-stock-crvs-20210211monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-initiates-phase-3-clinical-trial-of-cpi-006-for-patients-with-covid-crvs-20210204monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-presents-new-data-on-its-investigational-itk-inhibitor-cpi-818-at-the-american-soci-crvs-20201206monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-announces-upcoming-cpi-818-data-presentations-at-the-american-society-of-hematology-crvs-20201130monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-hosting-r-d-symposium-on-november-12-to-highlight-covid-19-program-and-updated-stud-crvs-20201111monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-completes-enrollment-in-phase-1-study-of-cpi-006-for-patients-with-covid-19-and-pre-crvs-20201109monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-covid-19-abstract-selected-for-hot-topic-oral-session-at-the-2020-s-crvs-20201102monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-third-quarter-2020-financial-r-crvs-20201029monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-updated-data-from-its-clinical-trial-of-cpi-006-for-pati-crvs-20201029monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-co-founding-of-angel-pharmaceuticals-in-china-crvs-20201005monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-appoints-edith-mitchell-m-d-to-board-of-directors-crvs-20200911monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-update-on-clinical-trial-of-cpi-006-for-patients-with-covi-crvs-20200910monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-announces-participation-in-upcoming-investor-conferences-crvs-20200908monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-2020-wedbush-pacgrow-healthcare-virtual-conferenc-crvs-20200804monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-second-quarter-2020-financial--crvs-20200730monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-report-second-quarter-2020-financial-crvs-20200723monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-initiates-clinical-trial-of-novel-immunotherapy-for-patients-with-c-crvs-20200707monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-presents-updated-clinical-data-supporting-and-refining-the-adenosin-crvs-20200529monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-jefferies-2020-virtual-healthcare-conference-crvs-20200527monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-data-on-refinement-of-the-adenosine-gene-signature-and-c-crvs-20200513monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-first-quarter-2020-financial-r-crvs-20200430monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-report-first-quarter-2020-financial--crvs-20200422monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-fourth-quarter-and-full-year-2-crvs-20200305monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-report-fourth-quarter-2019-financial-crvs-20200228monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-presents-updated-clinical-data-from-its-phase-1b-2-clinical-trial-o-crvs-20200213monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-presents-updated-clinical-data-from-its-phase-1-1b-clinical-trial-o-crvs-20200201monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-presents-preclinical-and-initial-clinical-data-from-the-phase-1-1b--crvs-20191207monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-presents-updated-data-from-cpi-006-phase-1-1b-clinical-trial-at-201-crvs-20191108monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-preclinical-and-early-clinical-data-from-the-phase-1-1b--crvs-20191107monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-28th-annual-credit-suisse-healthcare-conference-crvs-20191105monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-webcast-investor-analyst-event-on-november-8-2019-crvs-20191104monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-third-quarter-2019-financial-r-crvs-20191029monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-report-third-quarter-2019-financial--crvs-20191017monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-updated-data-from-cpi-006-clinical-trial-at-the-society--crvs-20191003monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-2019-wedbush-healthcare-conference-crvs-20190807monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-second-quarter-2019-financial--crvs-20190801monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-report-second-quarter-2019-financial-crvs-20190724monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-presents-initial-cpi-006-phase-1-1b-clinical-data-at-2019-asco-annu-crvs-20190602monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-jefferies-2019-global-healthcare-conference-crvs-20190528monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-initial-clinical-data-from-cpi-006-clinical-trial-at-the-crvs-20190516monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-first-quarter-2019-financial-r-crvs-20190509monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-provide-business-update-and-report-first-quarter-2019-financial--crvs-20190501monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-reports-fourth-quarter-and-full-year-2018-financial-results-and-pro-crvs-20190307monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-cowen-and-company-39th-annual-health-care-confere-crvs-20190305monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-presents-updated-biomarker-and-clinical-results-from-lead-pipeline-programs-cpi-444-crvs-20190206monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-updated-biomarker-and-clinical-data-on-lead-development--crvs-20190130monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-appointment-of-new-member-of-board-of-directors-and-hirin-crvs-20190128monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-announces-presentation-of-preclinical-data-on-cpi-818-a-first-in-class-covalent-inh-crvs-20190110monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-announces-enrollment-in-second-arm-of-phase-1-1b-dose-escalation-trial-of-anti-cd73-crvs-20190108monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-27th-annual-credit-suisse-healthcare-conference-crvs-20181112monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-updated-results-from-ongoing-clinical-studies-of-lead-pro-crvs-20181110monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-webcast-investor-analyst-event-on-november-10-2018-crvs-20181105monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-reports-third-quarter-2018-financial-results-and-provides-business--crvs-20181101monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-new-data-on-adenosine-gene-signature-biomarker-associated-crvs-20181022monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-data-on-lead-programs-at-the-european-society-for-medica-crvs-20181004monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-publication-of-preclinical-results-highlighting-antitumor-crvs-20181003monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-crvs-20180925monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-reports-second-quarter-2018-financial-results-and-provides-business-crvs-20180802monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-2018-wedbush-pacgrow-healthcare-conference-crvs-20180731monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-publication-of-preclinical-study-results-demonstrating-cp-crvs-20180628monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-jefferies-2018-global-healthcare-conference-crvs-20180530monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-reports-first-quarter-2018-financial-results-and-provides-business--crvs-20180503monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-initiation-of-phase-1-1b-clinical-trial-of-investigationa-crvs-20180426monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-closing-of-public-offering-of-common-stock-crvs-20180312monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-crvs-20180308monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-proposed-public-offering-of-common-stock-crvs-20180307monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-cowen-and-company-38th-annual-health-care-confere-crvs-20180306monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-reports-fourth-quarter-and-full-year-2017-financial-results-and-pro-crvs-20180301monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-presentation-of-new-data-from-preclinical-study-of-novel--crvs-20180201monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-updated-clinical-data-from-phase-1-1b-study-of-cpi-444-an-crvs-20171111monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-reports-third-quarter-2017-financial-results-and-clinical-program-u-crvs-20171102monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-data-on-lead-checkpoint-inhibitor-cpi-444-at-the-society-crvs-20171018monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-2017-cantor-fitzgerald-global-healthcare-conferen-crvs-20170920monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-2017-wedbush-pacgrow-healthcare-conference-crvs-20170811monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-reports-second-quarter-2017-financial-results-and-provides-business-crvs-20170803monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-host-r-d-day-highlighting-role-of-adenosine-pathway-in-immuno-on-crvs-20170706monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-data-on-lead-checkpoint-inhibitor-cpi-444-in-renal-and-l-crvs-20170515monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-and-monash-university-enter-into-exclusive-license-agreement-for-no-crvs-20170509monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-reports-first-quarter-2017-financial-results-and-provides-business--crvs-20170504monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-expands-cpi-444-clinical-collaboration-with-genentech-crvs-20170502monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-interim-results-from-ongoing-phase-1-1b-study-demonstrati-crvs-20170404monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-data-that-advances-the-understanding-of-the-adenosine-pa-crvs-20170320monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-reschedule-r-d-day-due-to-severe-winter-storm-in-the-new-york-tr-crvs-20170313monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-reports-fourth-quarter-and-full-year-2016-financial-results-and-pro-crvs-20170310monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-host-r-d-day-highlighting-the-role-of-the-adenosine-pathway-in-i-crvs-20170309monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-cowen-and-company-37th-annual-health-care-confere-crvs-20170227monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-expansion-of-renal-cell-carcinoma-cohort-in-ongoing-phase-crvs-20170110monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-2017-crvs-20170104monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-names-ian-t-clark-former-genentech-chief-executive-officer-to-board-crvs-20170103monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-sitc-s-31st-annual-meeting-crvs-20161102monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-credit-suisse-25th-annual-healthcare-conference-crvs-20161101monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-data-on-lead-oral-checkpoint-inhibitor-cpi-444-at-esmo-2-crvs-20161004monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-data-on-lead-oral-checkpoint-inhibitor-cpi-444-at-second-crvs-20160919monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-cantor-fitzgerald-s-second-annual-healthcare-conferen-crvs-20160706monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-names-jason-v-coloma-to-newly-created-post-of-chief-business-office-crvs-20160629monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-ian-mccaffery-phd-to-present-at-rational-combinations-360-june-23-2-crvs-20160617monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-announces-first-quarter-2016-financial-results-crvs-20160505monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-to-present-at-aacr-annual-meeting-april-16-20-in-new-orleans-crvs-20160405monthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-announces-pricing-of-initial-public-offering-crvs-20160322monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20260616monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-announces-participation-at-upcoming-investor-conferences-eypt-20260519monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20260518monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-announces-third-consecutive-positive-dsmc-recommendation-for-phase-3-wet-amd-tria-eypt-20260514monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20260316monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20251117monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20250916monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-announces-participation-at-upcoming-investor-conferences-eypt-20250826monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20250818monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-to-present-at-the-h-c-wainwright-5th-annual-ophthalmology-virtual-conference-eypt-20250806monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-to-report-second-quarter-2025-financial-results-on-august-6-2025-eypt-20250730monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20250716monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20250616monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-announces-participation-at-upcoming-investor-conferences-eypt-20250528monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-completes-enrollment-in-pivotal-phase-3-lugano-trial-of-duravyu-for-treatment-of--eypt-20250527monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20250516monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-announces-participation-at-upcoming-investor-conferences-eypt-20250513monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-to-report-first-quarter-2025-financial-results-on-may-7-2025-eypt-20250430monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20250416monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-to-present-at-2025-rbc-capital-markets-ophthalmology-virtual-conference-eypt-20250327monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20250317monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-announces-participation-at-upcoming-investor-conferences-eypt-20250304monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-5-2025-eypt-20250226monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-to-present-corporate-update-at-td-cowen-45th-annual-health-care-conference-eypt-20250225monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20250217monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-to-present-at-guggenheim-smid-cap-biotech-conference-eypt-20250130monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20250116monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-provides-company-update-and-anticipated-development-milestones-for-2025-eypt-20250113monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-eypt-20241217monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20241216monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20241118monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-participation-at-upcoming-investor-conferences-eypt-20241104monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-closing-of-upsized-public-offering-and-full-exercise-of-eypt-20241031monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-pricing-of-upsized-public-offering-eypt-20241030monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20241016monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20240916monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-participation-at-upcoming-investor-conferences-eypt-20240827monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20240816monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-eypt-20240808monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20240716monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-highlight-duravyu-vorolanib-intravitreal-insert-clinical-and-r-eypt-20240626monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-host-r-d-day-on-june-26-2024-eypt-20240618monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20240617monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-present-at-goldman-sachs-45th-annual-global-healthcare-confere-eypt-20240605monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20240516monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-topline-data-from-the-phase-2-pavia-trial-of-duravyu-in-eypt-20240506monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20240416monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-expands-scientific-advisory-board-with-world-renowned-retina-spec-eypt-20240402monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20240318monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-and-h-eypt-20240307monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-appointment-of-ramiro-ribeiro-m-d-ph-d-as-chief-medical-eypt-20240304monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-report-fourth-quarter-and-full-year-2023-financial-results-on--eypt-20240229monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-participation-at-upcoming-investor-conferences-eypt-20240227monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20240216monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-two-presentations-of-topline-data-with-additional-subgr-eypt-20240203monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-present-at-the-guggenheim-healthcare-talks-6th-annual-biotechn-eypt-20240131monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20240116monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-first-patient-dosed-in-phase-2-verona-clinical-trial-of-eypt-20240110monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-eypt-20231220monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20231218monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-closing-of-upsized-public-offering-and-full-exercise-of-eypt-20231208monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-pricing-of-upsized-public-offering-eypt-20231206monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20231116monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-host-virtual-key-opinion-leader-kol-event-on-november-9-2023-eypt-20231031monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-presentations-at-eyecelerator-2023-american-academy-of--eypt-20231030monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-report-third-quarter-2023-financial-results-on-november-1-2023-eypt-20231025monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20230918monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-positive-masked-safety-update-for-lead-product-candidate--eypt-20230911monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-participation-at-upcoming-investor-conferences-eypt-20230830monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20230816monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-3rd-annual-ophthalmology-virtual-eypt-20230809monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-report-second-quarter-2023-financial-results-on-august-2-2023-eypt-20230726monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20230717monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-present-at-the-jefferies-healthcare-conference-eypt-20230531monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20230516monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023-eypt-20230426monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20230417monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-upcoming-data-presentations-at-2023-association-for-res-eypt-20230320monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-participation-at-upcoming-investor-conferences-eypt-20230227monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-and-rallybio-announce-research-collaboration-to-evaluate-rallybio-s-inhibitor-of--eypt-20230227monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-report-fourth-quarter-and-full-year-2022-financial-results-on--eypt-20230223monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20230216monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20230117monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-provides-business-update-and-key-2023-clinical-timelines-eypt-20230105monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-promotes-jay-s-duker-m-d-to-president-and-chief-operating-officer-eypt-20230104monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-alert-bragar-eagel-squire-p-c-is-investigating-eyepoint-pharmaceuticals-inc-on-be-eypt-20221229monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-alert-bragar-eagel-squire-p-c-is-investigating-eyepoint-pharmaceuticals-inc-on-be-eypt-20221224monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-alert-bragar-eagel-squire-p-c-is-investigating-eyepoint-pharmaceuticals-inc-on-be-eypt-20221217monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20221216monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20221116monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-participation-at-upcoming-investor-conferences-eypt-20221107monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-report-third-quarter-2022-financial-results-on-november-2-2022-eypt-20221026monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20221017monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20220916monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-participation-at-upcoming-investor-conferences-eypt-20220906monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-inc-investors-company-investigated-by-the-portnoy-law-firm-eypt-20220901monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-shareholder-news-johnson-fistel-encourages-eypt-shareholders-with-eypt-20220831monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-participation-at-upcoming-investor-conferences-eypt-20220802monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-report-second-quarter-2022-financial-results-on-august-3-2022-eypt-20220727monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-investor-day-to-highlight-eyp-1901-and-durasert-technology-develo-eypt-20220718monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20220718monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-host-investor-day-on-july-18-2022-eypt-20220711monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-election-of-tony-adamis-m-d-to-board-of-directors-eypt-20220623monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-and-ocumension-therapeutics-announce-approval-of-new-drug-applica-eypt-20220621monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20220616monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-present-12-month-results-from-phase-1-davio-clinical-trial-eva-eypt-20220610monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-global-healthcare-investment-con-eypt-20220517monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20220516monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-expanded-license-agreement-with-betta-pharmaceuticals-f-eypt-20220504monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-report-first-quarter-2022-financial-results-on-may-4-2022-eypt-20220427monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-participate-in-fireside-chat-at-the-b-riley-2022-virtual-neuro-eypt-20220421monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20220418monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20220316monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-debt-refinancing-with-45m-credit-facilities-from-silico-eypt-20220309monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-appoints-isabelle-lefebvre-as-chief-regulatory-officer-eypt-20220307monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-financial-results-and-h-eypt-20220303monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-participate-in-fireside-chat-at-the-cowen-42nd-annual-health-c-eypt-20220301monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-report-fourth-quarter-and-full-year-2021-financial-results-on--eypt-20220224monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-2022-clinical-plans-and-highlights-recent-corporate-and-eypt-20220110monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-and-harrow-health-s-imprimisrx-announce-expanded-u-s-commercial-a-eypt-20211207monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-closing-of-115-4-million-public-offering-eypt-20211119monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-pricing-of-public-offering-eypt-20211117monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-participation-at-upcoming-investor-conferences-eypt-20211111monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-host-conference-call-highlighting-interim-phase-1-clinical-dat-eypt-20211105monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-report-third-quarter-2021-financial-results-on-november-3-2021-eypt-20211027monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-presents-preliminary-safety-data-from-phase-1-davio-trial-and-yut-eypt-20211012monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-present-data-at-the-american-academy-of-ophthalmology-aao-2021-eypt-20210917monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-participation-at-upcoming-investor-conferences-eypt-20210907monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-present-at-the-h-c-wainwright-ophthalmology-virtual-conference-eypt-20210810monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-renowned-scientists-to-join-new-executive-scientific-ad-eypt-20210802monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-report-second-quarter-2021-financial-results-on-august-4-2021-eypt-20210728monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-receives-preliminary-extension-to-pass-through-payment-status-for-eypt-20210720monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-positive-30-day-safety-results-for-all-cohorts-from-the-d-eypt-20210706monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspen-eypt-20210701monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-joins-russell-2000-and-russell-3000-index-eypt-20210628monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-participate-in-fireside-chat-at-the-jefferies-virtual-healthca-eypt-20210526monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-completion-of-enrollment-of-phase-1-davio-clinical-tria-eypt-20210525monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-report-first-quarter-2021-financial-results-and-discuss-recent-eypt-20210428monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-participation-at-upcoming-investor-conferences-eypt-20210225monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-report-fourth-quarter-and-full-year-2020-financial-results-on--eypt-20210225monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-closing-of-115-million-public-offering-of-common-stock-eypt-20210204monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-eypt-20210202monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-proposed-public-offering-of-common-stock-eypt-20210201monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-provides-business-update-and-preliminary-fourth-quarter-and-full--eypt-20210111monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-1-for-10-reverse-stock-split-eypt-20201208monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-positive-results-from-glp-toxicology-study-of-eyp-1901-a--eypt-20201203monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-host-key-opinion-leader-virtual-roundtable-on-the-future-of-dr-eypt-20201119monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-presents-positive-data-of-yutiq-and-dexycu-in-four-poster-session-eypt-20201116monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-presentations-at-the-upcoming-american-academy-of-ophth-eypt-20201110monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-third-quarter-2020-financial-results-and-highlights-recen-eypt-20201105monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-third-quarter-2020-financial-results-release-date-and-c-eypt-20201029monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-participation-at-upcoming-investor-conferences-eypt-20200910monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-secures-new-purchase-and-marketing-agreement-with-vantage-outsour-eypt-20200824monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-and-harrow-health-s-imprimisrx-announce-u-s-commercial-alliance-f-eypt-20200804monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-second-quarter-2020-financial-results-release-date-and--eypt-20200729monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-presents-data-supporting-yutiq-at-the-american-society-of-retina--eypt-20200727monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-present-at-the-jefferies-virtual-healthcare-conference-eypt-20200526monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-presents-data-showcasing-dexycu-at-the-american-society-of-catara-eypt-20200518monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-first-quarter-2020-financial-results-release-date-and-c-eypt-20200429monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-positive-topline-36-month-follow-up-data-for-second-pha-eypt-20200302monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-fourth-quarter-and-full-year-2019-financial-results-rel-eypt-20200227monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-eypt-20200221monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-proposed-public-offering-of-common-stock-eypt-20200220monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-and-vision-center-network-of-america-sign-purchase-agreement-for--eypt-20200218monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-and-ocumension-therapeutics-sign-exclusive-license-agreement-to-d-eypt-20200127monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-new-agreement-for-expanded-access-of-dexycu-within-one--eypt-20191204monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-appoints-george-o-elston-as-chief-financial-officer-and-head-of-c-eypt-20191114monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-addition-of-dexycu-and-yutiq-to-department-of-veteran-a-eypt-20191104monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-secures-new-patient-access-agreement-with-vizient-inc-for-dexycu-eypt-20191101monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-third-quarter-2019-financial-results-release-date-and-c-eypt-20191024monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-permanent-and-specific-j-code-for-yutiq-now-in-effect-eypt-20191002monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-yutiq-presentations-at-the-american-academy-of-ophthalm-eypt-20190927monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-present-at-the-2019-cantor-global-healthcare-conference-eypt-20190926monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-data-highlighting-yutiq-to-be-presented-at-the-52nd-ann-eypt-20190909monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-presents-positive-data-showcasing-yutiq-at-the-37th-annual-scient-eypt-20190730monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-early-assignment-of-permanent-and-specific-j-code-j7314-eypt-20190725monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-second-quarter-2019-financial-results-release-date-and--eypt-20190724monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-data-highlighting-yutiq-to-be-presented-at-the-37th-ann-eypt-20190723monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-added-to-russell-3000-and-2000-indexes-eypt-20190701monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20190613monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-strengthens-executive-leadership-team-with-key-hires-eypt-20190610monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-present-at-upcoming-investor-conferences-eypt-20190515monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-presents-positive-yutiq-36-month-follow-up-phase-3-data-at-the-20-eypt-20190501monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-first-quarter-2019-financial-results-release-date-and-c-eypt-20190423monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-present-at-upcoming-medical-conferences-eypt-20190416monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-present-at-upcoming-investor-conferences-eypt-20190402monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-eypt-20190328monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-proposed-public-offering-of-common-stock-eypt-20190327monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-u-s-commercial-launch-of-dexycu-dexamethasone-intraocul-eypt-20190312monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-fiscal-period-ended-december-31-2018-financial-results--eypt-20190214monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-u-s-commercial-launch-of-yutiq-fluocinolone-acetonide-i-eypt-20190204monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-added-to-nasdaq-biotechnology-index-eypt-20181217monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-appoints-ron-honig-esq-as-svp-general-counsel-company-secretary-eypt-20181127monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-assignment-of-permanent-j-code-for-dexycu-by-the-center-eypt-20181112monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-present-at-the-stifel-2018-healthcare-conference-eypt-20181106monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-and-ocumension-therapeutics-sign-exclusive-license-agreement-to-d-eypt-20181105monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-first-quarter-fiscal-year-2019-financial-results-releas-eypt-20181030monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-presents-positive-yutiq-24-month-follow-up-data-at-the-american-a-eypt-20181029monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-data-highlighting-yutiq-to-be-presented-at-the-american-eypt-20181018monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-proceeds-of-28-9-million-from-exercised-warrants-eypt-20181001monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-fiscal-2018-fourth-quarter-full-year-financial-results-an-eypt-20180912monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-secures-pass-through-payment-status-and-assignment-of-c-code-for--eypt-20180905monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-fiscal-2018-fourth-quarter-full-year-financial-results--eypt-20180905monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-present-at-upcoming-investor-conferences-eypt-20180828monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-appoints-john-weet-ph-d-as-svp-regulatory-affairs-quality-eypt-20180815monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eypt-20180803monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-to-present-at-the-38th-annual-canaccord-genuity-growth-conference-eypt-20180802monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-presentation-of-data-highlighting-yutiq-for-posterior-s-eypt-20180725monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-data-highlighting-yutiq-for-posterior-segment-uveitis-t-eypt-20180711monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-stockholder-approval-of-second-tranche-of-capital-finan-eypt-20180625monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-appointment-of-leonard-blum-as-executive-vice-president-eypt-20180516monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-announces-third-quarter-fiscal-year-2018-financial-results-releas-eypt-20180419monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-yutiq-for-posterior-segment-uveitis-to-be-presented-at-the-2018-a-eypt-20180418monthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-pharmaceuticals-strengthens-global-ip-with-notices-of-allowance-for-two-u-s-paten-eypt-20180412monthly0.5https://www.biopharmawatch.com/news/AVR/anteris-advances-global-paradigm-expansion-with-french-regulatory-clearance-avr-20260608monthly0.5https://www.biopharmawatch.com/news/AVR/anteris-technologies-announces-first-u-s-patients-treated-in-global-pivotal-paradigm-trial-avr-20260505monthly0.5https://www.biopharmawatch.com/news/AVR/anteris-announces-results-for-the-second-quarter-of-2025-avr-20250811monthly0.5https://www.biopharmawatch.com/news/AVR/anteris-appoints-david-roberts-and-gregory-moss-to-its-board-of-directors-avr-20250610monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-and-miromatrix-announce-exclusive-partnership-to-advance-research-using-bioengineer-cdna-20230405monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inc-investor-news-robbins-llp-is-investigating-caredx-inc-cdna-on-behalf-of-shareho-cdna-20220927monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-cdna-20220720monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inc-nasdaq-cdna-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-inves-cdna-20220719monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds--cdna-20220713monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inc-nasdaq-cdna-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-inves-cdna-20220712monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inc-nasdaq-cdna-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-inves-cdna-20220706monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-cdna-20220706monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds--cdna-20220629monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inc-nasdaq-cdna-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-inves-cdna-20220628monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inc-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-portnoy-law-fir-cdna-20220627monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inc-nasdaq-cdna-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-inves-cdna-20220622monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-cdna-20220622monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inc-nasdaq-cdna-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-inves-cdna-20220615monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds--cdna-20220615monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-caredx-cdna-20220609monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inc-nasdaq-cdna-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-inves-cdna-20220608monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-cdna-20220608monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inc-nasdaq-cdna-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-inves-cdna-20220601monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds--cdna-20220531monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-class-action-complaint-filed-johnson-fistel-globally-recognized-law-firm-encourages-cdna-20220525monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inc-nasdaq-cdna-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-inves-cdna-20220525monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-receives-ce-mark-for-alloseq-hct-for-use-in-hematopoietic-cell-transplantation-cdna-20220524monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-portnoy-law-firm-cdna-20220524monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-sponsored-ishlt-innovation-challenge-award-tackles-chronic-lung-allograft-dysfuncti-cdna-20220518monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-showcases-latest-innovation-in-transplantation-at-european-efi-2022-conference-cdna-20220511monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-first-quarter-2022-results-cdna-20220505monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-validates-clinical-performance-of-allomap-kidney-to-comprehensively-assess-transpla-cdna-20220505monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-congratulates-board-member-dr-hannah-valantine-on-ishlt-lifetime-achievement-award-cdna-20220428monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-extends-artificial-intelligence-leadership-to-heart-transplantation-cdna-20220428monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-report-first-quarter-2022-financial-results-cdna-20220427monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-demonstrates-potential-of-alloheme-and-allocell-for-allogeneic-cell-transplant-and--cdna-20220422monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-supports-uc-davis-health-pluralist-program-aimed-at-reducing-health-disparities-in--cdna-20220421monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-showcases-leadership-with-over-25-oral-presentations-and-posters-at-the-internation-cdna-20220420monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-over-200-000-heart-transplant-patient-results-served-cdna-20220414monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-the-leading-sponsor-of-unos-transplant-management-forum-demonstrates-the-value-of-d-cdna-20220411monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-host-symposium-at-ceot-featuring-the-latest-multimodality-innovations-in-kidney--cdna-20220406monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-partners-with-the-european-society-for-organ-transplantation-to-provide-clinical-ev-cdna-20220330monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-partners-with-heartbrothers-foundation-to-help-patients-living-with-heart-failure-a-cdna-20220329monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-s-allocare-app-now-integrated-with-txaccess-to-help-pre-transplant-patients-navigat-cdna-20220324monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-xenosure-and-xenomap-cdna-20220323monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-brings-together-leading-transplant-experts-to-share-latest-advancements-in-the-fiel-cdna-20220316monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-wins-44-9m-in-damages-in-false-advertising-trial-against-natera-natera-intentionall-cdna-20220315monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-cibiltech-initiates-cibil-study-using-ibox-artificial-intelligence-to-mon-cdna-20220303monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-partners-with-the-national-kidney-foundation-to-advocate-for-kidney-transplant-pati-cdna-20220302monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-fourth-quarter-and-full-year-2021-results-cdna-20220224monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-leads-the-way-in-xenotransplant-organ-surveillance-in-monitoring-world-s-first-succ-cdna-20220222monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-report-fourth-quarter-and-full-year-2021-financial-results-cdna-20220217monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-taps-into-its-patient-network-to-deliver-insights-on-transplant-needs-cdna-20220208monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-joins-forces-with-mottep-the-national-minority-organ-tissue-transplant-education-pr-cdna-20220207monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-upcoming-conferences-cdna-20220203monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-joins-forces-with-mottep-to-increase-organ-donations-for-minority-transplant-patien-cdna-20220120monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-partners-with-multiple-biotechnology-companies-to-use-allocell-in-car-t-cell-therap-cdna-20220111monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-preliminary-revenue-results-for-fourth-quarter-and-full-year-2021-cdna-20220110monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-successfully-completes-clia-validation-of-allomap-kidney-in-preparation-for-commerc-cdna-20220106monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-expands-its-medication-adherence-services-with-the-acquisition-of-the-transplant-ph-cdna-20220105monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-partners-with-ishlt-in-a-transplant-innovation-research-grant-to-improve-outcomes-f-cdna-20220104monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-alert-bragar-eagel-squire-p-c-is-investigating-caredx-inc-on-behalf-of-caredx-stock-cdna-20211227monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-alert-bragar-eagel-squire-p-c-is-investigating-caredx-inc-on-behalf-of-caredx-stock-cdna-20211223monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-enrolls-first-patient-in-lungcare-registry-study-to-measure-impact-of-multimodality-cdna-20211216monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-partners-with-the-north-american-pediatric-renal-trials-and-collaborative-studies-n-cdna-20211213monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-alert-bragar-eagel-squire-p-c-is-investigating-caredx-inc-on-behalf-of-caredx-stock-cdna-20211213monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-alert-bragar-eagel-squire-p-c-is-investigating-caredx-inc-on-behalf-of-caredx-stock-cdna-20211208monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-alert-bragar-eagel-squire-p-c-is-investigating-caredx-inc-on-behalf-of-caredx-stock-cdna-20211203monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-the-transplant-company-surpasses-80-000-patient-milestone-cdna-20211202monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-alert-bragar-eagel-squire-p-c-is-investigating-caredx-inc-on-behalf-of-caredx-stock-cdna-20211127monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-investigation-block-leviton-is-investigating-caredx-inc-for-potential-securities-la-cdna-20211122monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-named-one-of-the-fastest-growing-companies-in-north-america-on-the-deloitte-technol-cdna-20211119monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-enrolls-first-patients-in-the-largest-digital-study-in-transplant-using-allocare-to-cdna-20211118monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-upcoming-conferences-cdna-20211115monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-investigation-block-leviton-is-investigating-caredx-inc-for-potential-securities-la-cdna-20211115monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-acquires-medactionplan-to-directly-support-patients-with-better-adherence-cdna-20211110monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-investigation-block-leviton-is-investigating-caredx-inc-for-potential-securities-la-cdna-20211108monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-focuses-on-innovation-in-transplant-at-asn-kidney-week-cdna-20211103monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-investigation-block-leviton-is-investigating-caredx-inc-for-potential-securities-la-cdna-20211029monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-third-quarter-2021-results-increases-full-year-revenue-guidance-cdna-20211028monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-s-allosure-demonstrates-better-accuracy-than-current-standards-of-care-in-independe-cdna-20211021monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-and-eledon-pharmaceuticals-announce-collaborative-research-agreement-cdna-20211019monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-report-third-quarter-2021-financial-results-cdna-20211014monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-extends-leadership-in-multimodality-transplant-care-with-kidneycare-validation-publ-cdna-20210930monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-continues-to-fight-for-innovation-in-transplantation-cdna-20210928monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-presents-latest-data-on-alloseq-portfolio-at-ashi-2021-cdna-20210927monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-upcoming-conferences-cdna-20210902monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-showcases-leadership-in-global-transplantation-at-esot-2021-cdna-20210826monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-77-revenue-growth-for-second-quarter-of-2021-and-increases-full-year-revenu-cdna-20210729monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-launches-acrobat-study-to-potentially-change-care-paradigm-for-stem-cell-transplant-cdna-20210726monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-report-second-quarter-2021-financial-results-cdna-20210715monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-transplant-patient-app-allocare-expands-access-to-the-majority-of-transplant-patien-cdna-20210701monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-ceo-reg-seeto-to-present-at-aakp-4th-annual-policy-summit-cdna-20210617monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-raymond-james-2021-human-health-innovation-conference-cdna-20210616monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-hosts-fireside-chat-with-pro-golfer-and-heart-transplant-recipient-erik-compton-cdna-20210615monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-congratulates-hannah-valantine-for-her-state-of-the-art-lecture-at-atc-on-transplan-cdna-20210609monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-acquire-transplant-hero-medication-management-application-cdna-20210608monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-presents-landmark-koar-1000-data-demonstrating-higher-1-year-graft-survival-and-red-cdna-20210607monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-presents-groundbreaking-allosure-data-at-the-2021-american-transplant-congress-cdna-20210604monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-advances-artificial-intelligence-in-transplantation-cdna-20210603monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-42nd-annual-goldman-sachs-global-healthcare-conference-cdna-20210603monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-starts-enrollment-in-maple-a-multi-modal-multi-center-prospective-study-of-livercar-cdna-20210601monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-strategic-minority-investment-in-miromatrix-cdna-20210528monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-jefferies-healthcare-conference-cdna-20210527monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-aakp-and-george-washington-university-global-summit-on-kidney-dis-cdna-20210513monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-first-quarter-2021-results-cdna-20210505monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-present-new-heart-transplant-data-at-the-international-society-for-heart-and-lun-cdna-20210423monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-debut-multicenter-data-on-allosure-lung-an-analytically-and-clinically-validated-cdna-20210422monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-report-first-quarter-2021-financial-results-cdna-20210421monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-showcases-transplantation-innovation-and-leadership-in-europe-at-efi-2021-cdna-20210420monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-present-at-unos-transplant-management-forum-cdna-20210416monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-new-hla-typing-service-offering-for-research-purposes-cdna-20210408monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-national-kidney-foundation-2021-spring-clinical-meetings-cdna-20210405monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-enhances-leadership-team-with-key-appointments-cdna-20210331monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-supports-vir-biotechnology-s-clinical-trial-recruitment-efforts-for-comet-ice-cdna-20210323monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-strengthens-bioinformatics-capabilities-with-acquisition-of-bfs-molecular-cdna-20210317monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-expands-into-the-pre-transplant-kidney-space-through-tx-connect-cdna-20210225monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-fourth-quarter-and-full-year-2020-results-cdna-20210224monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-report-fourth-quarter-and-full-year-2020-financial-results-cdna-20210212monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-full-exercise-of-underwriters-option-to-purchase-additional-shares-cdna-20210211monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-to-participate-in-upcoming-btig-virtual-medtech-digital-health-life-science-diag-cdna-20210210monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-showcases-cellular-transplantation-and-therapy-portfolio-at-tct-cdna-20210205monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-closing-of-public-offering-of-common-stock-cdna-20210125monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-proposed-public-offering-of-common-stock-cdna-20210119monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-preliminary-fourth-quarter-and-full-year-2020-results-cdna-20210111monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-agrees-to-acquire-transchart-and-expands-emr-connectivity-to-over-90-centers-cdna-20210108monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-transplant-leadership-showcased-at-asts-2021-cdna-20210108monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-alloid-and-exclusive-partnership-with-idbydna-cdna-20210107monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-s-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance-cdna-20210104monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-celebrates-the-long-awaited-passage-of-the-immuno-bill-cdna-20201222monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-first-allosure-pediatrics-publication-cdna-20201201monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-upcoming-piper-sandler-32nd-annual-virtual-healthcare-conference-cdna-20201125monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-receives-medicare-reimbursement-pricing-for-allosure-heart-cdna-20201117monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-at-upcoming-conferences-cdna-20201110monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-joins-national-kidney-foundation-in-virtual-walk-for-kidney-patients-cdna-20201106monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-showcases-leading-transplant-data-at-asn-2020-cdna-20201021monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-leads-in-innovation-with-alloseq-portfolio-at-ashi-2020-cdna-20201019monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-report-third-quarter-2020-financial-results-cdna-20201015monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-preliminary-third-quarter-2020-revenue-cdna-20201007monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-publication-of-pivotal-allosure-lung-data-cdna-20201002monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-receives-final-medicare-coverage-decision-for-allosure-heart-cdna-20201001monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-launches-allocare-at-virtual-transplant-festival-cdna-20200924monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-shares-latest-clinical-data-at-the-tts-2020-virtual-conference-cdna-20200911monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-strengthens-leadership-team-to-accelerate-growth-cdna-20200910monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-at-upcoming-conferences-cdna-20200902monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-second-quarter-2020-results-cdna-20200804monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-at-the-canaccord-genuity-40th-annual-growth-conference-cdna-20200730monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-report-second-quarter-2020-financial-results-cdna-20200716monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-chairman-and-ceo-peter-maag-to-present-at-global-kidney-innovations-summit-cdna-20200715monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-full-exercise-of-underwriters-option-to-purchase-additional-shares-cdna-20200618monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-closing-of-public-offering-of-common-stock-cdna-20200615monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-proposed-public-offering-of-common-stock-cdna-20200609monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-2020-annual-meeting-of-stockholders-to-be-held-as-a-virtual-meeting-cdna-20200608monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-at-the-goldman-sachs-global-healthcare-conference-cdna-20200604monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-present-at-the-jefferies-virtual-healthcare-conference-cdna-20200528monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-presents-the-latest-allosure-data-in-virtual-meetings-cdna-20200527monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-s-alloseq-tx-17-awarded-ce-mark-approval-cdna-20200515monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-brings-the-transplant-patient-community-together-cdna-20200507monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-collaborates-with-weill-cornell-medicine-to-lead-the-development-and-commercializat-cdna-20200505monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-first-quarter-2020-results-cdna-20200430monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-engages-european-lab-community-in-virtual-meetings-cdna-20200427monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-and-johns-hopkins-partner-on-allosure-lung-surveillance-cdna-20200423monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-presents-new-heart-and-lung-transplant-data-in-virtual-meetings-cdna-20200422monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-report-first-quarter-2020-financial-results-cdna-20200421monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-introduces-allocell-cell-therapy-surveillance-cdna-20200414monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-mobilizes-10-000-phlebotomists-for-home-blood-draws-of-transplant-patients-with-rem-cdna-20200409monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-supports-launch-of-international-covid-19-transplant-registry-c19txr-cdna-20200406monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-launches-remotrac-home-based-monitoring-of-transplant-patients-cdna-20200317monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-joins-national-kidney-foundation-on-world-kidney-day-to-support-kidney-transplant-c-cdna-20200312monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-brings-personalized-care-to-transplant-with-the-launch-of-kira-immuno-optimization--cdna-20200305monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-upcoming-investor-conferences-cdna-20200228monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-fourth-quarter-and-full-year-2019-results-cdna-20200227monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-report-fourth-quarter-and-full-year-2019-financial-results-on-february-27-2020-cdna-20200213monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-s-patent-rights-upheld-by-delaware-court-cdna-20200211monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-launches-aitrac-conference-cdna-20200204monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-preliminary-fourth-quarter-and-full-year-2019-results-cdna-20200113monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-s-alloseq-cfdna-awarded-ce-mark-approval-cdna-20200110monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-leadership-at-asts-meeting-cdna-20200109monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-s-false-advertising-complaint-upheld-by-court-cdna-20200108monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cdna-20191224monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-supports-bipartisan-legislation-to-protect-kidney-transplant-patients-cdna-20191223monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-upcoming-investor-conferences-cdna-20191119monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-at-asn-kidney-week-cdna-20191106monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-advances-patient-care-with-allosure-3-0-cdna-20191104monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-third-quarter-2019-results-cdna-20191031monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-announce-third-quarter-2019-financial-results-on-october-31st-2019-cdna-20191017monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-participates-in-transplant-roundtable-with-senator-durbin-cdna-20191008monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-files-patent-infringement-lawsuit-against-eurofins-viracor-cdna-20190926monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-adds-histomap-to-testing-portfolio-cdna-20190924monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-s-kidneycare-ibox-technology-clinically-validated-in-bmj-publication-cdna-20190923monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-launches-alloseq-tx-17-at-ashi-banff-meeting-cdna-20190920monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-the-cantor-fitzgerald-global-healthcare-conference-cdna-20190917monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-launches-alloseq-cfdna-at-esot-2019-cdna-20190912monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cdna-20190911monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-acquires-xynmanagement-cdna-20190828monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-second-quarter-2019-results-cdna-20190801monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-investor-alert-faruqi-faruqi-llp-encourages-investors-who-suffered-losses-exceeding-cdna-20190730monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-announce-second-quarter-2019-financial-results-on-august-1-2019-cdna-20190716monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-applauds-white-house-efforts-to-reform-america-s-kidney-health-system-cdna-20190711monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-supports-momentum-in-medicare-immunosuppressive-medication-legislation-cdna-20190627monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-upcoming-conferences-cdna-20190610monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-kidneycare-and-showcases-leadership-in-transplantation-at-atc-cdna-20190529monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-upcoming-conferences-cdna-20190522monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-applauds-hhs-report-on-cost-savings-of-lifetime-immunosuppressive-drug-coverage-for-cdna-20190514monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-first-quarter-2019-results-cdna-20190508monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-s-alloseq-cfdna-and-qtype-solutions-featured-at-efi-2019-cdna-20190507monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-adds-ibox-technology-next-step-towards-artificial-intelligence-in-transplant-care-cdna-20190502monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-announce-first-quarter-2019-financial-results-on-may-8th-2019-cdna-20190423monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-fourth-quarter-and-fy-2018-results-cdna-20190306monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-welcomes-initiatives-from-us-government-to-support-transplant-care-cdna-20190305monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-the-cowen-and-company-39th-annual-health-care-conference-cdna-20190226monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-drives-personalized-medicine-in-transplantation-at-ceot-cdna-20190220monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-announce-fourth-quarter-2018-financial-results-on-march-6th-2019-cdna-20190214monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-btig-6th-annual-medical-technology-life-science-tools-and-diagnos-cdna-20190206monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-present-new-allosure-data-at-american-society-of-transplant-surgeons-winter-symp-cdna-20190109monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-proposed-public-offering-of-common-stock-cdna-20181113monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-third-quarter-results-cdna-20181108monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-upcoming-investor-conferences-cdna-20181107monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-announce-third-quarter-2018-financial-results-on-november-8-2018-cdna-20181017monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-profiles-alloseq-suite-of-ngs-products-at-ashi-cdna-20181002monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-upcoming-investor-conference-cdna-20180921monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-broadens-heartcare-availability-cdna-20180917monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-upcoming-investor-conference-cdna-20180815monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-second-quarter-results-cdna-20180809monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-announce-second-quarter-2018-financial-results-on-august-9-2018-cdna-20180716monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-set-to-join-russell-2000-russell-3000-and-russell-microcap-indexes-cdna-20180619monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-promotes-living-donor-transplantation-through-employee-policy-cdna-20180605monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-hold-press-conference-at-american-transplant-congress-cdna-20180524monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-first-quarter-results-cdna-20180510monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-expands-ngs-transplant-product-offerings-cdna-20180509monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-activities-at-american-transplant-congress-cdna-20180501monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-announce-first-quarter-2018-financial-results-on-may-10-2018-cdna-20180420monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-closes-debt-refinancing-cdna-20180418monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-launches-heartcare-for-heart-transplant-recipients-cdna-20180410monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-completion-of-debt-conversion-cdna-20180329monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-announce-fourth-quarter-and-fiscal-year-2017-financial-results-on-march-22-2018-cdna-20180306monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-refinance-debt-with-perceptive-advisors-cdna-20180301monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-upcoming-investor-conferences-cdna-20180207monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-leadership-in-cfdna-highlighted-at-ceot-cdna-20180205monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-upcoming-investor-conferences-cdna-20171102monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cdna-20171031monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-announce-third-quarter-2017-financial-results-on-november-9-2017-cdna-20171027monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-confirms-allosure-will-receive-medicare-coverage-effective-october-9th-2017-cdna-20170824monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-upcoming-investor-conferences-cdna-20170815monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-second-quarter-2017-financial-results-cdna-20170810monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-describes-extensive-analytical-validation-data-on-allosure-robustness-at-american-a-cdna-20170804monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-announce-second-quarter-2017-financial-results-on-august-10-2017-cdna-20170727monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-restructures-and-defers-certain-obligations-to-march-2019-cdna-20170703monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-first-quarter-2017-financial-results-cdna-20170609monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-activities-at-european-federation-of-immunogenetics-congress-cdna-20170530monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-receipt-of-expected-letter-from-nasdaq-cdna-20170522monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-preliminary-first-quarter-2017-financial-results-cdna-20170522monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-announce-first-quarter-2017-preliminary-financial-results-on-may-22-2017-cdna-20170519monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-achieves-significant-milestone-towards-cms-coverage-for-allosure-cdna-20170504monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-present-key-allosure-validation-data-at-atc-cdna-20170428monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-appoints-michael-bell-as-chief-financial-officer-cdna-20170421monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-fourth-quarter-and-full-year-2016-financial-results-cdna-20170421monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-receipt-of-expected-letter-from-nasdaq-cdna-20170421monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-present-new-data-on-allomap-and-allosure-at-ishlt-cdna-20170403monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-preliminary-fourth-quarter-and-fy-2016-financial-results-cdna-20170315monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-closes-new-25-million-debt-facility-cdna-20170315monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-acquire-sbt-resolver-hla-typing-products-from-illumina-cdna-20170124monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-and-leading-transplant-clinicians-to-present-allosure-dart-data-during-kidney-week--cdna-20161116monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-third-quarter-2016-financial-results-cdna-20161109monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-upcoming-investor-conferences-cdna-20161108monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-present-allosure-data-at-amp-in-charlotte-nc-cdna-20161103monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-new-employment-inducement-grants-cdna-20161103monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-announce-third-quarter-2016-financial-results-and-host-conference-call-on-novemb-cdna-20161027monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-first-commercial-sale-of-olerup-qtype-cdna-20161024monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-s-allosure-featured-in-the-journal-of-molecular-diagnostics-cdna-20161013monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-launches-olerup-qtype-at-ashi-cdna-20160928monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-closing-of-public-offering-of-common-stock-cdna-20160926monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-pricing-of-public-offering-of-common-stock-cdna-20160921monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-proposed-public-offering-of-common-stock-cdna-20160920monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-status-of-form-10-q-cdna-20160816monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-reports-preliminary-second-quarter-2016-financial-results-cdna-20160810monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-presents-validation-of-allosure-at-aacc-conference-session-on-emerging-topics-in-la-cdna-20160804monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-supports-fda-development-of-next-generation-sequencing-guidelines-offers-further-pe-cdna-20160801monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-announce-second-quarter-2016-financial-results-and-host-conference-call-on-augus-cdna-20160801monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-appoints-douglas-miller-to-its-board-of-directors-cdna-20160715monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-new-employment-inducement-grants-cdna-20160615monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-host-call-to-provide-first-analysis-of-data-from-dart-study-cdna-20160606monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-and-qiagen-enter-into-commercial-collaboration-to-enhance-hla-lab-experience-using--cdna-20160531monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-present-at-2016-jefferies-healthcare-conference-cdna-20160531monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-completion-of-enrollment-in-multicenter-kidney-transplant-study-to-valida-cdna-20160527monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-initiates-compulsory-acquisition-proceedings-and-allenex-files-for-de-listing-cdna-20160520monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inc-reports-first-quarter-2016-financial-results-cdna-20160506monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-present-clinical-abstracts-containing-new-data-at-the-2016-ishlt-on-allomap-allo-cdna-20160428monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-announce-first-quarter-2016-financial-results-and-host-conference-call-on-may-6--cdna-20160426monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-completes-allenex-acquisition-cdna-20160414monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-22-million-private-placement-cdna-20160414monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-the-success-of-its-tender-offer-for-allenex-cdna-20160408monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-new-chief-commercial-officer-todd-whitson-cdna-20160329monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-cfo-transition-cdna-20160324monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inc-reports-fourth-quarter-and-full-year-2015-financial-results-cdna-20160324monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-announce-fourth-quarter-and-2015-year-end-financial-results-on-march-24-and-will-cdna-20160310monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-receives-positive-coverage-decision-for-allomap-from-tricare-covering-over-9-millio-cdna-20160308monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-revised-timeline-to-its-offer-to-acquire-allenex-cdna-20160229monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-revised-agreement-to-purchase-78-percent-of-the-outstanding-shares-of-all-cdna-20160209monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-upcoming-healthcare-conferences-in-february-2016-leerink-bio-ceo--cdna-20160202monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-and-diaxonhit-announce-completion-of-technology-transfer-of-allomap-test-in-europe-cdna-20160112monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-completes-analytical-validation-of-allosure-a-next-generation-sequencing-test-measu-cdna-20151223monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-agreement-to-purchase-78-percent-of-the-outstanding-shares-of-allenex-ab--cdna-20151216monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-upcoming-investor-conferences-cdna-20151117monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inc-reports-third-quarter-2015-financial-results-cdna-20151111monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-presents-donor-derived-cell-free-dna-data-at-the-association-for-molecular-patholog-cdna-20151109monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-completes-expansion-of-clia-laboratory-with-next-generation-sequencing-platform-cap-cdna-20151102monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-release-third-quarter-2015-financial-results-and-host-conference-call-on-novembe-cdna-20151028monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-ceo-to-present-at-cms-panel-meeting-on-monday-october-19-at-8-45am-et-cdna-20151018monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-new-clinical-data-on-allomap-score-variability-and-service-to-support-ass-cdna-20151015monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-responds-to-proposed-cms-clinical-laboratory-fee-schedule-changes-cdna-20150928monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-donor-derived-cell-free-dna-assay-selected-to-support-nih-funded-ctot-19-clinical-t-cdna-20150914monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inc-reports-second-quarter-2015-financial-results-cdna-20150810monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-and-dnanexus-collaborate-on-cloud-based-genomics-platform-for-cell-free-dna-cdna-20150806monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-release-second-quarter-2015-financial-results-and-host-conference-call-on-august-cdna-20150727monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-and-horizon-discovery-group-enter-into-a-collaboration-for-development-of-cell-free-cdna-20150603monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-present-at-jefferies-and-jmp-investor-conferences-in-june-cdna-20150527monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inc-reports-first-quarter-2015-financial-results-cdna-20150512monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-first-patients-enrolled-in-largest-ever-multicenter-kidney-transplant-stu-cdna-20150504monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-release-first-quarter-2015-financial-results-and-host-conference-call-on-may-12--cdna-20150430monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-cell-free-dna-cfdna-biomarker-in-combination-with-allomap-r-increases-accuracy-of-i-cdna-20150416monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-present-new-data-on-allomap-r-and-cell-free-dna-cfdna-biomarker-in-heart-transpl-cdna-20150408monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inc-reports-fourth-quarter-and-full-year-2014-financial-results-cdna-20150317monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-release-fourth-quarter-2014-financial-results-and-host-conference-call-on-march--cdna-20150303monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-appoints-william-a-hagstrom-to-its-board-of-directors-cdna-20150303monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-present-at-upcoming-investor-conferences-cdna-20150205monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-secures-20-million-term-loan-with-east-west-bank-replacing-existing-credit-facility-cdna-20150203monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-announces-its-commercial-european-partner-diaxonhit-has-selected-strasbourg-univers-cdna-20150112monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-receives-positive-coverage-decision-for-allomap-r-from-two-additional-medicare-admi-cdna-20150107monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-appoints-john-j-sninsky-ph-d-as-chief-scientific-officer-cdna-20150105monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-presents-heartbrothers-foundation-with-a-grant-to-support-heart-transplant-educatio-cdna-20141212monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-participate-in-upcoming-investor-conferences-cdna-20141118monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inc-reports-third-quarter-2014-financial-results-cdna-20141110monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-release-third-quarter-2014-financial-results-and-host-conference-call-on-monday--cdna-20141027monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-present-at-the-bio-investor-forum-cdna-20141003monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inc-reports-second-quarter-2014-financial-results-cdna-20140827monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-to-release-second-quarter-2014-financial-results-and-host-conference-call-on-wednes-cdna-20140814monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-and-allegheny-general-hospital-launch-research-study-of-novel-test-to-screen-heart--cdna-20140731monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-presents-cell-free-dna-biomarker-results-in-heart-and-kidney-transplant-recipients--cdna-20140728monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-and-illumina-enter-into-supply-agreement-for-next-generation-sequencing-technologie-cdna-20140616monthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-enters-into-agreement-to-acquire-immumetrix-cdna-20140522monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-investigated-by-the-portnoy-law-firm-tndm-20260327monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-tndm-shareholders-who-lost-money-contact-law-offices-of-howard-g--tndm-20251001monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-tndm-product-pipeline-analysis-report-2025-tndm-20250811monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-alert-bragar-eagel-squire-p-c-is-investigating-tandem-diabetes-care-inc-on-behalf-o-tndm-20240810monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-alert-bragar-eagel-squire-p-c-is-investigating-tandem-diabetes-care-inc-on-behalf-o-tndm-20240424monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-los-tndm-20231107monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-los-tndm-20231102monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-bee-tndm-20231030monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-bee-tndm-20231024monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-investors-lead-plaintiff-deadline-is-approaching-in-the-class-act-tndm-20231005monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-nasdaq-tndm-deadline-alert-bernstein-liebhard-llp-announces-that--tndm-20230925monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-nasdaq-tndm-deadline-alert-bernstein-liebhard-llp-announces-that--tndm-20230920monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-tndm-investor-alert-robbins-llp-reminds-investors-of-class-action-tndm-20230915monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-inc-shareholder-alert-bernstein-liebhard-llp-announces-that-a-securit-tndm-20230912monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-schedules-second-quarter-2015-earnings-press-release-and-conference-c-tndm-20150715monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-announces-upcoming-conference-presentations-tndm-20150423monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-schedules-first-quarter-2015-earnings-press-release-and-conference-ca-tndm-20150415monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-schedules-fourth-quarter-and-full-year-2014-earnings-press-release-an-tndm-20150210monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-to-present-at-piper-jaffray-healthcare-conference-tndm-20141119monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-to-present-at-stifel-healthcare-conference-tndm-20141106monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-announces-schedule-change-for-third-quarter-2014-earnings-press-relea-tndm-20141024monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-schedules-third-quarter-2014-earnings-press-release-and-conference-ca-tndm-20141022monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-schedules-second-quarter-2014-earnings-press-release-and-conference-c-tndm-20140716monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-announces-schedule-change-for-deutsche-bank-39th-annual-health-care-c-tndm-20140502monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-announces-upcoming-conference-presentations-tndm-20140428monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-schedules-first-quarter-2014-earnings-press-release-and-conference-ca-tndm-20140423monthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-and-capital-royalty-amend-and-restate-term-loan-facility-tndm-20140409monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-showcase-new-data-at-ada-2026-advancing-understanding-of-inhaled-insulin-afrez-mnkd-20260527monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-report-first-quarter-2026-financial-results-on-may-6-2026-mnkd-20260429monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-settlement-of-convertible-senior-notes-mnkd-20260305monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-participate-in-the-oppenheimer-36th-annual-healthcare-life-sciences-conference-mnkd-20260219monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-provides-business-updates-and-2026-growth-drivers-mnkd-20260108monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-shares-furoscix-business-updates-mnkd-20251223monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-u-s-fda-accepts-for-review-its-supplemental-new-drug-application-snda-o-mnkd-20251201monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-completes-acquisition-of-scpharmaceuticals-accelerating-revenue-growth-in-cardiom-mnkd-20251007monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-acquire-scpharmaceuticals-accelerating-revenue-growth-and-emerging-as-a-patien-mnkd-20250825monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-and-blackstone-announce-up-to-500-million-strategic-financing-agreement-mnkd-20250806monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2025-second-quarter-financial-results-conference-call-on-augu-mnkd-20250730monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-highlight-data-from-recent-pediatric-and-adult-studies-of-inhaled-insulin-afre-mnkd-20250609monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-present-at-upcoming-investor-conferences-mnkd-20250513monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2025-first-quarter-financial-results-conference-call-on-may-8-mnkd-20250501monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-teams-up-with-juncos-hollinger-racing-jhr-driver-conor-daly-to-drive-awareness-of-mnkd-20250407monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-showcases-efficacy-safety-and-mealtime-control-data-from-recent-pediatric-and-adu-mnkd-20250310monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2024-fourth-quarter-and-full-year-financial-results-conferenc-mnkd-20250219monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-present-at-upcoming-investor-conferences-mnkd-20250206monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-expands-executive-leadership-team-mnkd-20250106monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-announces-exchange-of-convertible-notes-for-stock-and-cash-mnkd-20241218monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-six-month-results-from-phase-3-inhale-1-pediatric-diabetes-trial-utiliz-mnkd-20241216monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-present-at-2024-ubs-healthcare-conference-mnkd-20241105monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-successfully-completes-phase-1-trial-of-nintedanib-dpi-for-pulmonary-fibrotic-dis-mnkd-20241104monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2024-third-quarter-financial-results-conference-call-on-novem-mnkd-20241031monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-clearance-from-pmda-to-initiate-phase-3-clinical-trial-icon-1-in-japan--mnkd-20240918monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-present-at-2024-cantor-fitzgerald-global-healthcare-conference-mnkd-20240910monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-present-at-upcoming-conferences-mnkd-20240827monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-launches-educational-website-to-raise-awareness-of-ntm-lung-disease-mnkd-20240731monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2024-second-quarter-financial-results-conference-call-on-augu-mnkd-20240730monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-establish-boston-area-research-development-foothold-and-expand-portfolio-of-dr-mnkd-20240529monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-receives-u-s-fda-fast-track-designation-for-clofazimine-inhalation-suspension-for-mnkd-20240506monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2024-first-quarter-financial-results-conference-call-on-may-8-mnkd-20240501monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-proceed-with-phase-1-nintedanib-dpi-mnkd-201-study-for-pulmonary-fibrotic-dise-mnkd-20240430monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-ind-clearance-from-u-s-fda-to-start-phase-3-study-of-clofazimine-inhala-mnkd-20240429monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-repays-certain-debt-obligations-mnkd-20240403monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-cfo-transition-mnkd-20240326monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-new-clinical-data-from-inhale-3-study-to-be-presented-by-dr-irl-b-hirsc-mnkd-20240305monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-announces-participation-at-upcoming-conferences-mnkd-20240304monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2023-fourth-quarter-and-full-year-financial-results-conferenc-mnkd-20240220monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-enrollment-goal-completion-of-inhale-1-pediatric-diabetes-trial-utilizi-mnkd-20240215monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-and-sagard-healthcare-enter-into-royalty-purchase-agreement-for-up-to-200-million-mnkd-20240102monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-present-at-42nd-annual-j-p-morgan-healthcare-conference-mnkd-20231228monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-completion-of-enrollment-in-u-s-phase-4-inhale-3-clinical-trial-in-pati-mnkd-20231106monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2023-third-quarter-financial-results-conference-call-on-novem-mnkd-20231031monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-expands-patent-portfolio-with-new-clofazimine-formulation-patent-mnkd-20231030monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-announces-participation-at-upcoming-conferences-mnkd-20230905monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-announces-participation-in-the-2023-wedbush-pacgrow-healthcare-confer-mnkd-20230801monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2023-second-quarter-financial-results-conference-call-on-augu-mnkd-20230731monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-launches-inhale-3-study-to-address-the-most-important-unmet-need-today-in-adults--mnkd-20230622monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-participate-in-the-2023-rbc-capital-markets-global-healthcare-conf-mnkd-20230510monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2023-first-quarter-financial-results-conference-call-on-may-9-mnkd-20230502monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-participate-in-oppenheimer-33rd-annual-healthcare-conference-mnkd-20230307monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-give-oral-presentation-on-meal-challenge-results-from-the-afrezza-with-basal-c-mnkd-20230222monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2022-fourth-quarter-and-full-year-financial-results-conferenc-mnkd-20230216monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-participate-in-the-svb-securities-global-biopharma-conference-mnkd-20230210monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-participate-in-the-lytham-partners-investor-select-conference-mnkd-20230124monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-s-inhaled-clofazimine-will-advance-to-an-adaptive-phase-2-3-study-for-potential-t-mnkd-20230123monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-present-at-2023-annual-j-p-morgan-healthcare-conference-mnkd-20230105monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-present-two-posters-at-22nd-annual-diabetes-technology-meeting-mnkd-20221110monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2022-third-quarter-financial-results-conference-call-on-novem-mnkd-20221101monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-participate-in-the-lytham-partners-fall-2022-investor-conference-mnkd-20220921monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-successfully-completes-phase-1-study-of-inhaled-clofazimine-mnkd-20220906monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-co-mnkd-20220901monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2022-second-quarter-financial-results-conference-call-on-augu-mnkd-20220802monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-participate-in-the-btig-biotechnology-conference-mnkd-20220801monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-host-product-theater-and-booth-at-the-american-diabetes-association-s-82nd-sci-mnkd-20220603monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-s-technosphere-inhalation-platform-utilized-in-fda-approved-tyvaso-dpi-mnkd-20220524monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-ring-the-nasdaq-stock-market-opening-bell-mnkd-20220519monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-announces-agreement-to-acquire-v-go-insulin-delivery-device-from-zeal-mnkd-20220517monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-participating-at-upcoming-conferences-mnkd-20220509monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2022-first-quarter-financial-results-conference-call-on-may-5-mnkd-20220428monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-presents-poster-at-15th-international-conference-on-advanced-technologies-treatme-mnkd-20220427monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-participate-in-the-lytham-partners-spring-2022-investor-conference-mnkd-20220328monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-participate-in-the-cantor-virtual-rare-orphan-disease-summit-mnkd-20220322monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-participate-in-oppenheimer-32nd-annual-healthcare-conference-mnkd-20220308monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2021-fourth-quarter-and-full-year-financial-results-conferenc-mnkd-20220221monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-participate-in-svb-leerink-2022-global-healthcare-conference-mnkd-20220210monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-participate-in-h-c-wainwright-bioconnect-conference-mnkd-20220105monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-extends-collaboration-with-thirona-bio-on-fibrotic-lung-diseases-mnkd-20220105monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-participate-in-the-lytham-partners-winter-2021-investor-conference-mnkd-20211206monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-closes-sale-leaseback-transaction-generating-102-25-million-in-non-di-mnkd-20211109monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-presents-data-at-21st-annual-diabetes-technology-meeting-mnkd-20211105monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2021-third-quarter-financial-results-conference-call-on-novem-mnkd-20211102monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-first-patient-enrolled-in-inhale-1-study-of-afrezza-in-pediatric-popula-mnkd-20211004monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-announces-sale-leaseback-transaction-generating-102-25-million-in-non-mnkd-20210929monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-participate-at-lytham-partners-fall-2021-investor-conference-mnkd-20210928monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-participating-at-upcoming-conferences-mnkd-20210915monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-participate-in-h-c-wainwright-23rd-annual-global-investment-confer-mnkd-20210907monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2021-second-quarter-financial-results-conference-call-on-augu-mnkd-20210804monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-participate-in-the-btig-virtual-biotechnology-conference-2021-mnkd-20210803monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-and-united-therapeutics-achieve-a-major-milestone-in-the-development-of-tyvaso-dp-mnkd-20210616monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-and-thirona-bio-join-forces-to-evaluate-potential-inhaled-therapy-for-fibrotic-lu-mnkd-20210610monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-at-the-lytham-partners-summer-2021-investor-conference-mnkd-20210608monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-partnership-with-type-1-diabetes-indycar-driver-conor-daly-mnkd-20210513monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-participate-in-2021-rbc-capital-markets-global-healthcare-conferen-mnkd-20210511monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2021-first-quarter-financial-results-conference-call-on-may-1-mnkd-20210505monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-reduces-legacy-debt-by-approximately-49-5-million-and-restructures-remaining-obli-mnkd-20210426monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-and-united-therapeutics-reach-a-milestone-in-the-development-of-tyvaso-dpi-with-n-mnkd-20210419monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-closing-of-initial-purchasers-option-to-purchase-additional-convertible-mnkd-20210316monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more--mnkd-20210315monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-participate-in-oppenheimer-s-31st-annual-healthcare-conference-mnkd-20210310monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-participate-in-h-c-wainwright-global-life-sciences-conference-mnkd-20210302monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-prices-upsized-200-0-million-convertible-senior-notes-offering-mnkd-20210302monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-announces-proposed-private-placement-of-convertible-senior-notes-mnkd-20210301monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-participate-in-2021-svb-leerink-global-healthcare-conference-mnkd-20210218monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2020-fourth-quarter-and-full-year-financial-results-conferenc-mnkd-20210218monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-participate-in-h-c-wainwright-bioconnect-2021-conference-mnkd-20210104monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-and-vertice-to-co-promote-thyquidity-levothyroxine-sodium-oral-solution-mnkd-20201217monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-and-midcap-amend-credit-facility-mnkd-20201201monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-receives-fourth-12-5-million-milestone-payment-from-united-therapeutics-mnkd-20201119monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2020-third-quarter-financial-results-conference-call-on-novem-mnkd-20201029monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-participating-at-upcoming-conferences-mnkd-20200908monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-participate-in-btig-virtual-biotechnology-conference-2020-mnkd-20200807monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2020-second-quarter-financial-results-conference-call-on-augu-mnkd-20200729monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-present-at-the-june-2020-lytham-partners-virtual-investor-growth-c-mnkd-20200617monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-presents-positive-original-analyses-of-afrezza-clinical-data-at-american-diabetes-mnkd-20200615monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2020-first-quarter-financial-results-conference-call-on-may-6-mnkd-20200429monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-receives-forgivable-loan-under-the-paycheck-protection-program-mnkd-20200415monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-refocuses-pipeline-resources-in-response-to-covid-19-pandemic-mnkd-20200317monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-present-at-the-9th-annual-svb-leerink-global-healthcare-conference-mnkd-20200224monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-presents-novel-scientific-data-at-13th-international-conference-on-advanced-techn-mnkd-20200220monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2019-fourth-quarter-and-full-year-financial-results-conferenc-mnkd-20200218monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-present-at-the-piper-jaffray-31st-annual-healthcare-conference-mnkd-20191129monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-receives-second-12-5-million-milestone-payment-from-united-therapeutics-mnkd-20191104monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2019-third-quarter-financial-results-conference-call-on-novem-mnkd-20191030monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-present-at-the-2019-cantor-global-healthcare-conference-mnkd-20190926monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-presents-positive-afrezza-clinical-data-from-type-1-diabetes-study-at-55th-annual-mnkd-20190919monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-present-at-h-c-wainwright-21st-annual-global-investment-conference-mnkd-20190830monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-and-one-drop-sign-collaboration-agreement-to-integrate-bluetooth-connected-inhale-mnkd-20190805monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2019-second-quarter-financial-results-conference-call-on-augu-mnkd-20190801monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-repays-maturing-debt-obligation-buys-back-certain-warrants-mnkd-20190718monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-partners-with-goodrx-to-help-raise-awareness-on-reducing-out-of-pocket-insulin-co-mnkd-20190715monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-expands-commercial-scale-manufacturing-capabilities-for-high-potency-molecules-mnkd-20190711monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-present-at-the-jmp-securities-life-sciences-conference-mnkd-20190612monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-presents-positive-afrezza-clinical-data-from-three-studies-at-ada-79th-scientific-mnkd-20190609monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-afrezza-distribution-agreement-in-australia-mnkd-20190516monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2019-first-quarter-financial-results-conference-call-on-may-7-mnkd-20190430monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-presents-scientific-data-at-28th-annual-scientific-and-clinical-congress-of-the-a-mnkd-20190425monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-present-at-the-h-c-wainwright-global-life-sciences-conference-mnkd-20190402monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-receives-12-5-million-milestone-payment-from-united-therapeutics-mnkd-20190401monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-sponsor-andretti-autosport-type-1-diabetes-driver-conor-daly-mnkd-20190314monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-presents-new-scientific-data-at-12th-international-conference-on-advanced-technol-mnkd-20190220monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-participating-at-upcoming-conferences-mnkd-20190220monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2018-fourth-quarter-and-full-year-financial-results-conferenc-mnkd-20190219monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-direct-purchase-insulin-program-providing-afrezza-for-as-low-as-4-a-day-mnkd-20190116monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-investor-conference-call-mnkd-20181227monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-pricing-of-40-million-public-offering-mnkd-20181220monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2018-third-quarter-financial-results-conference-call-on-novem-mnkd-20181025monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-presents-positive-afrezza-stat-study-clinical-data-at-54th-annual-meeting-of-the--mnkd-20181004monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-presents-new-scientific-data-at-54th-annual-meeting-of-the-european-association-f-mnkd-20181003monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-completion-of-cohort-1-and-opens-enrollment-for-cohort-2-of-afrezza-saf-mnkd-20180924monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-present-at-upcoming-conferences-mnkd-20180829monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-and-tanner-pharma-group-enter-into-an-ex-u-s-distribution-agreement-for-afrezza-mnkd-20180727monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2018-second-quarter-financial-results-conference-call-on-augu-mnkd-20180727monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-set-to-join-russell-3000-index-mnkd-20180625monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-presents-positive-afrezza-clinical-data-from-stat-and-affinity-studies-at-ada-78t-mnkd-20180623monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-host-institutional-investor-and-analyst-meeting-mnkd-20180620monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-successfully-completes-phase-1-trial-of-treprostinil-technosphere-for-pulmonary-a-mnkd-20180607monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-establishes-market-price-stock-purchase-plan-mnkd-20180605monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-and-cipla-enter-an-exclusive-marketing-and-distribution-agreement-for-afrezza-in--mnkd-20180509monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2018-first-quarter-financial-results-conference-call-on-may-9-mnkd-20180502monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-completion-of-previously-announced-28-0-million-registered-direct-offer-mnkd-20180409monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-28-0-million-registered-direct-offering-mnkd-20180406monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-participation-at-the-h-c-wainwright-annual-global-life-sciences-confere-mnkd-20180319monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-present-at-oppenheimer-28th-annual-healthcare-conference-mnkd-20180314monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-stat-study-results-accepted-for-presentation-at-american-diabetes-assoc-mnkd-20180313monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-restructures-79-7-million-debt-obligation-to-the-mann-group-and-reduces-principal-mnkd-20180312monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-opens-enrollment-of-phase-1-trial-of-treprostinil-technosphere-for-pulmonary-arte-mnkd-20180301monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2017-fourth-quarter-and-full-year-financial-results-conferenc-mnkd-20180223monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-present-at-noblecon14-noble-capital-markets-fourteenth-annual-inve-mnkd-20180116monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2017-third-quarter-financial-results-conference-call-on-novem-mnkd-20171027monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-restructures-near-term-debt-obligations-mnkd-20171023monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-and-biomm-submit-registration-dossier-to-brazilian-health-regulatory-agency-anvis-mnkd-20171023monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-donates-afrezza-to-support-people-with-diabetes-impacted-by-hurricane-maria-in-pu-mnkd-20171012monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-investor-conference-call-mnkd-20171001monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-responds-to-hurricane-harvey-devastation-with-afrezza-donation-mnkd-20170907monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-relocates-headquarters-to-westlake-village-mnkd-20170905monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-present-at-upcoming-conferences-mnkd-20170901monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2017-second-quarter-financial-results-mnkd-20170807monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-and-one-drop-partner-to-launch-the-a-one-clinical-trial-mnkd-20170807monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2017-second-quarter-financial-results-conference-call-on-augu-mnkd-20170725monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-renegotiates-near-term-maturities-with-deerfield-mnkd-20170629monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-draws-remaining-funds-under-mann-group-loan-arrangement-mnkd-20170629monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-engages-locust-walk-to-explore-strategic-options-for-mannkind-s-non-insulin-techn-mnkd-20170605monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-and-biomm-enter-into-distribution-agreement-for-afrezza-in-brazil-mnkd-20170531monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-provides-update-on-senior-management-mnkd-20170530monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2017-first-quarter-financial-results-mnkd-20170510monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-and-one-drop-to-collaborate-on-delivering-better-health-outcomes-for-people-with--mnkd-20170504monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2017-first-quarter-financial-results-conference-call-on-may-1-mnkd-20170428monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2016-fourth-quarter-and-full-year-financial-results-mnkd-20170316monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-and-charles-mattocks-announce-reversed-america-s-first-docu-series-ta-mnkd-20170308monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-announces-upcoming-events-mnkd-20170307monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-receives-16-7-million-from-sale-of-valencia-property-mnkd-20170221monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-launch-of-new-titration-pack-and-field-force-expansion-to-accelerate-af-mnkd-20170201monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-investor-conference-call-on-february-1-2017-mnkd-20170127monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-receives-30-6-million-from-sanofi-mnkd-20170109monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-present-at-the-j-p-morgan-2017-healthcare-conference-mnkd-20170105monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-key-addition-to-its-executive-management-ranks-mnkd-20170104monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-receives-1-million-milestone-from-rls-mnkd-20170103monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-and-sanofi-reach-agreement-on-afrezza-mnkd-20161110monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2016-third-quarter-financial-results-conference-call-on-novem-mnkd-20161101monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-present-at-the-rodman-renshaw-18th-annual-global-investment-confer-mnkd-20160902monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2016-second-quarter-financial-results-conference-call-on-augu-mnkd-20160801monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-assumes-responsibility-for-distribution-of-afrezza-and-launches-patient-reimburse-mnkd-20160801monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-present-at-cantor-fitzgerald-s-2nd-annual-healthcare-conference-mnkd-20160708monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-late-breaking-data-reinforcing-faster-onset-and-shorter-duration-of-act-mnkd-20160612monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-collaboration-with-jdrf-mnkd-20160610monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-pricing-of-registered-direct-public-offering-of-common-stock-and-warran-mnkd-20160509monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2016-first-quarter-financial-results-mnkd-20160509monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-present-at-the-bank-of-america-merrill-lynch-2016-health-care-conf-mnkd-20160505monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2016-first-quarter-financial-results-conference-call-on-may-9-mnkd-20160502monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-expands-commercial-capabilities-with-two-new-hires-mnkd-20160419monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-discuss-u-s-commercialization-update-for-afrezza-mnkd-20160411monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-regains-afrezza-marketing-rights-mnkd-20160405monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2015-fourth-quarter-and-full-year-financial-results-mnkd-20160314monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-appointment-of-michael-castagna-as-chief-commercial-officer-mnkd-20160314monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2015-fourth-quarter-and-full-year-financial-results-conferenc-mnkd-20160307monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-potentially-file-2015-10-k-filing-extension-mnkd-20160226monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-mourns-the-passing-of-chairman-emeritus-alfred-e-mann-mnkd-20160226monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-present-at-the-rbc-capital-markets-2016-healthcare-conference-mnkd-20160216monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-investor-conference-call-on-february-3-2016-mnkd-20160127monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-enters-into-collaboration-and-license-agreement-mnkd-20160121monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-provides-update-on-senior-management-mnkd-20160111monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-announces-termination-of-license-and-collaboration-agreement-with-san-mnkd-20160105monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-present-at-the-j-p-morgan-2016-healthcare-conference-mnkd-20151229monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-appointment-of-duane-desisto-as-chief-executive-officer-mnkd-20151223monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-senior-management-changes-mnkd-20151120monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-pricing-of-registered-direct-offering-mnkd-20151112monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-confirms-planned-stock-sale-mnkd-20151111monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2015-third-quarter-financial-results-mnkd-20151109monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2015-third-quarter-financial-results-conference-call-on-novem-mnkd-20151102monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-termination-of-stock-lending-agreement-mnkd-20151026monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-dual-listing-on-the-tel-aviv-stock-exchange-mnkd-20151023monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-present-at-aegis-capital-corp-2015-growth-conference-mnkd-20151005monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-renewal-of-shelf-registration-and-atm-agreements-mnkd-20150904monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-addition-of-chief-medical-officer-mnkd-20150810monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2015-second-quarter-financial-results-mnkd-20150810monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2015-second-quarter-financial-results-conference-call-on-augu-mnkd-20150804monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-triples-production-capacity-for-afrezza-mnkd-20150731monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-present-at-upcoming-conferences-mnkd-20150527monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2015-first-quarter-financial-results-mnkd-20150507monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-present-at-bank-of-america-merrill-lynch-2015-healthcare-conference-mnkd-20150506monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2015-first-quarter-financial-results-conference-call-on-may-8-mnkd-20150430monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-manufacture-12-unit-cartridge-strength-of-afrezza-r-following-fda-approval-mnkd-20150427monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2014-fourth-quarter-and-full-year-financial-results-mnkd-20150224monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-present-at-the-rbc-capital-markets-global-healthcare-conference-mnkd-20150219monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2014-fourth-quarter-and-full-year-financial-results-conferenc-mnkd-20150217monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-ceo-alfred-mann-to-transition-to-executive-chairman-coo-and-president-hakan-edstr-mnkd-20150112monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-earns-50-million-in-milestone-payments-from-sanofi-mnkd-20150108monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-present-at-the-j-p-morgan-2015-healthcare-conference-mnkd-20150107monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-present-at-the-26th-annual-piper-jaffray-healthcare-conference-mnkd-20141125monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2014-third-quarter-financial-results-mnkd-20141103monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2014-third-quarter-financial-results-conference-call-on-novem-mnkd-20141027monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-receipt-of-150-million-licensing-upfront-payment-mnkd-20140929monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-closing-of-global-licensing-agreement-with-sanofi-mnkd-20140924monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-present-at-morgan-stanley-global-healthcare-conference-mnkd-20140902monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2014-second-quarter-financial-results-mnkd-20140811monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2014-second-quarter-financial-results-conference-call-on-augu-mnkd-20140805monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-present-at-upcoming-conferences-mnkd-20140527monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2014-first-quarter-financial-results-mnkd-20140512monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-to-present-at-bank-of-america-merrill-lynch-2014-health-care-conference-mnkd-20140507monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2014-first-quarter-financial-results-conference-call-on-may-1-mnkd-20140505monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-updates-status-of-new-drug-application-for-afrezza-r-mnkd-20140407monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-present-at-upcoming-conferences-mnkd-20140219monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-reports-2013-fourth-quarter-and-full-year-financial-results-mnkd-20140218monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-hold-2013-fourth-quarter-and-full-year-financial-results-conferenc-mnkd-20140204monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-announces-tentative-date-of-fda-advisory-committee-review-of-afrezza-mnkd-20140110monthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-corporation-to-present-at-the-j-p-morgan-2014-healthcare-conference-mnkd-20140108monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kura-20260605monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-and-kyowa-kirin-to-present-updated-frontline-ziftomenib-7-3-combination-data-kura-20260512monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kura-20260504monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kura-20260306monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-third-quarter-2025-financial-results-kura-20251028monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kura-20251003monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-and-kyowa-kirin-announce-first-patient-dosed-in-pivotal-phase-3-komet-017-tr-kura-20250929monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-and-kyowa-kirin-announce-publication-of-pivotal-ziftomenib-data-in-relapsed--kura-20250925monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-upcoming-investor-conference-kura-20250924monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-highlights-preclinical-data-demonstrating-potential-of-farnesyl-transferase--kura-20250916monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kura-20250905monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-host-virtual-investor-and-analyst-events-on-farnesyl-transferase-inhibito-kura-20250903monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-three-upcoming-investor-conferences-kura-20250828monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kura-20250804monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-second-quarter-2025-financial-results-kura-20250731monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kura-20250703monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-and-kyowa-kirin-report-positive-updated-combination-data-for-ziftomenib-in-n-kura-20250612monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kura-20250606monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-and-kyowa-kirin-report-positive-pivotal-ziftomenib-monotherapy-data-at-2025--kura-20250602monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-and-kyowa-kirin-announce-fda-acceptance-and-priority-review-of-new-drug-appl-kura-20250601monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-and-kyowa-kirin-announce-pivotal-monotherapy-data-for-ziftomenib-in-oral-pre-kura-20250522monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-three-upcoming-investor-conferences-kura-20250520monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-and-kyowa-kirin-announce-combination-data-for-ziftomenib-in-oral-presentatio-kura-20250514monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-bank-of-america-securities-healthcare-conference-kura-20250506monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kura-20250502monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-first-patients-dosed-in-phase-1-combination-trial-of-ziftomenib-fo-kura-20250428monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-first-quarter-2025-financial-results-kura-20250424monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-and-kyowa-kirin-announce-submission-of-new-drug-application-for-ziftomenib-t-kura-20250408monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kura-20250404monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-stifel-targeted-oncology-forum-kura-20250401monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-preclinical-data-for-ko-2806-selected-for-oral-presentation-at-the-kura-20250326monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kura-20250307monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-three-upcoming-investor-conferences-kura-20250225monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-kura-20250219monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kura-20250207monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-and-kyowa-kirin-announce-positive-ziftomenib-monotherapy-registrational-tria-kura-20250205monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-senior-executive-promotions-kura-20250106monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-and-kyowa-kirin-report-positive-combination-data-for-ziftomenib-at-american--kura-20241209monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-host-virtual-investor-event-on-december-9-2024-kura-20241202monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-jmp-securities-hematology-and-oncology-summit-kura-20241125monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-and-kyowa-kirin-announce-global-strategic-collaboration-to-develop-and-comme-kura-20241120monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-updated-data-from-komet-007-combination-trial-of-ziftomenib-at-as-kura-20241105monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-third-quarter-2024-financial-results-kura-20241031monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-preclinical-data-supporting-opportunity-for-ziftomenib-in-treatment--kura-20241024monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-new-data-supporting-combination-of-ko-2806-with-kras-g12c-and-pan-kura-20241023monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-publication-of-ziftomenib-phase-1-results-in-the-lancet-oncology-kura-20240930monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-appoints-michael-vasconcelles-m-d-to-board-of-directors-kura-20240917monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-cantor-global-healthcare-conference-kura-20240910monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-fda-clearance-of-ind-application-for-menin-inhibitor-ziftomenib-in-kura-20240808monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-second-quarter-2024-financial-results-kura-20240801monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kura-20240705monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-preclinical-data-supporting-potential-for-menin-inhibitor-in-diabete-kura-20240624monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kura-20240607monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-jefferies-global-healthcare-conference-kura-20240529monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-completes-enrollment-in-registration-directed-trial-of-ziftomenib-in-npm1-mu-kura-20240514monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-bank-of-america-securities-healthcare-conference-kura-20240508monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kura-20240503monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-first-quarter-2024-financial-results-kura-20240425monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-receives-breakthrough-therapy-designation-for-ziftomenib-in-npm1-mutant-aml-kura-20240422monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-stifel-targeted-oncology-forum-kura-20240410monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kura-20240405monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-first-patient-dosed-in-trial-of-ko-2806-plus-cabozantinib-in-renal-c-kura-20240306monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kura-20240301monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-doses-first-patient-in-komet-008-trial-of-ziftomenib-in-combination-with-sta-kura-20240226monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-three-upcoming-investor-conferences-kura-20240222monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-fourth-quarter-and-full-year-2023-financial-results-kura-20240220monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kura-20240202monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-positive-preliminary-ziftomenib-combination-data-in-acute-myeloid-le-kura-20240130monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-s-menin-inhibitor-ziftomenib-selected-for-the-leukemia-lymphoma-society-s-pe-kura-20231208monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-the-jmp-securities-hematology-and-oncology-summit-kura-20231128monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-three-upcoming-investor-conferences-kura-20231030monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-third-quarter-2023-financial-results-kura-20231026monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-first-patient-dosed-in-fit-001-trial-of-next-generation-farnesyl-t-kura-20231019monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-positive-results-from-registration-directed-study-of-tipifarnib-in-kura-20231017monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-three-presentations-at-aacr-nci-eortc-international-conference-on--kura-20231004monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-cantor-global-healthcare-conference-2023-kura-20230919monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-appoints-brian-powl-as-chief-commercial-officer-kura-20230814monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-second-quarter-2023-financial-results-kura-20230727monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-pricing-of-100-million-public-offering-of-common-stock-and-pre-fun-kura-20230614monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-presents-late-breaking-clinical-data-for-menin-inhibitor-ziftomenib-at-2023--kura-20230611monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-late-breaking-abstract-accepted-for-oral-presentation-at-the-2023--kura-20230530monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-two-upcoming-investor-conferences-kura-20230523monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-jmp-securities-life-sciences-conference-kura-20230509monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-first-quarter-2023-financial-results-kura-20230503monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-stifel-targeted-oncology-days-kura-20230418monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-preclinical-data-highlighting-synergistic-activity-of-farnesyl-trans-kura-20230417monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-acceptance-of-two-abstracts-for-presentation-at-aacr-annual-meetin-kura-20230314monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-upcoming-investor-conferences-kura-20230301monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-fourth-quarter-and-full-year-2022-financial-results-kura-20230216monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-first-patients-dosed-in-phase-2-registration-directed-trial-of-zif-kura-20230209monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-svb-securities-global-biopharma-conference-kura-20230207monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-fda-clearance-of-ind-application-for-ko-2806-a-next-generation-far-kura-20230124monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-presents-updated-clinical-data-from-komet-001-trial-of-menin-inhibitor-zifto-kura-20221210monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-host-investor-event-on-december-10-2022-kura-20221201monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-two-upcoming-investor-conferences-kura-20221122monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-four-abstracts-accepted-for-presentation-at-ash-annual-meeting-kura-20221103monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-two-upcoming-investor-conferences-kura-20221102monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-third-quarter-2022-financial-results-kura-20221027monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-preliminary-proof-of-mechanism-in-phase-1-2-clinical-trial-of-tipifa-kura-20221026monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-h-c-wainwright-global-investment-conference-kura-20220901monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-wedbush-pacgrow-healthcare-virtual-conference-kura-20220802monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-second-quarter-2022-financial-results-kura-20220727monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-three-upcoming-investor-conferences-kura-20220526monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-first-quarter-2022-financial-results-kura-20220427monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-preclinical-data-supporting-use-of-tipifarnib-to-prevent-emergence-o-kura-20220408monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-multiple-abstracts-accepted-for-presentation-at-aacr-annual-meetin-kura-20220308monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-two-upcoming-investor-conferences-kura-20220228monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-fourth-quarter-and-full-year-2021-financial-results-kura-20220217monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-svb-leerink-global-healthcare-conference-kura-20220210monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-expands-leadership-team-with-key-promotions-kura-20220201monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-receives-fda-authorization-to-proceed-with-phase-1b-study-of-ko-539-in-acute-kura-20220120monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-doses-first-patient-in-phase-1-2-clinical-trial-of-tipifarnib-in-combination-kura-20211216monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-final-results-from-phase-2-study-of-tipifarnib-in-t-cell-lymphoma-kura-20211213monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-preclinical-data-highlighting-synergistic-activity-of-menin-inhibito-kura-20211213monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-provides-update-on-phase-1b-study-of-ko-539-in-acute-myeloid-leukemia-kura-20211124monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-two-upcoming-investor-conferences-kura-20211123monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-credit-suisse-healthcare-conference-kura-20211102monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-third-quarter-2021-financial-results-kura-20211028monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-appoints-teresa-bair-as-chief-legal-officer-kura-20211018monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-two-upcoming-investor-conferences-kura-20210907monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-wedbush-pacgrow-healthcare-virtual-conference-kura-20210804monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-second-quarter-2021-financial-results-kura-20210729monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-clinical-collaboration-to-evaluate-tipifarnib-in-combination-with--kura-20210706monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-doses-first-patient-in-phase-1b-expansion-cohorts-with-menin-inhibitor-ko-53-kura-20210624monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-jmp-securities-life-sciences-conference-kura-20210610monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-cowen-virtual-oncology-innovation-summit-kura-20210513monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-first-quarter-2021-financial-results-kura-20210429monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-publication-of-tipifarnib-phase-2-data-in-journal-of-clinical-onco-kura-20210322monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-receives-fda-breakthrough-therapy-designation-for-tipifarnib-in-head-and-nec-kura-20210224monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-four-upcoming-investor-conferences-kura-20210218monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-fourth-quarter-and-full-year-2020-financial-results-kura-20210217monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-h-c-wainwright-bioconnect-2021-conference-kura-20210107monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-at-j-p-morgan-healthcare-conference-kura-20210106monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-kura-20201211monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-the-jmp-securities-hematology-summit-kura-20201210monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-pricing-of-300-million-public-offering-of-common-stock-kura-20201209monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-presents-first-clinical-data-for-menin-inhibitor-ko-539-at-american-society--kura-20201205monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-host-virtual-investor-event-on-december-5-2020-kura-20201124monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-three-upcoming-investor-conferences-kura-20201104monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-third-quarter-2020-financial-results-kura-20201029monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-preliminary-data-for-menin-inhibitor-ko-539-accepted-for-oral-pres-kura-20201007monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-two-upcoming-investor-conferences-kura-20200908monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-appoints-dr-stephen-dale-as-chief-medical-officer-kura-20200825monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-at-wedbush-pacgrow-healthcare-virtual-conference-kura-20200804monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-second-quarter-2020-financial-results-kura-20200730monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-jmp-securities-hematology-oncology-forum-kura-20200611monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-three-abstracts-accepted-for-presentation-at-asco20-virtual-scient-kura-20200513monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-kura-20200508monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-at-bofa-securities-virtual-health-care-conference-2020-kura-20200507monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-pricing-of-125-million-public-offering-of-common-stock-kura-20200506monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-first-quarter-2020-financial-results-kura-20200429monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-three-upcoming-investor-conferences-kura-20200219monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-fourth-quarter-and-full-year-2019-financial-results-kura-20200218monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-transition-of-chief-medical-officer-kura-20200123monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-at-j-p-morgan-healthcare-conference-kura-20200109monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-appoints-kirsten-flowers-as-chief-commercial-officer-kura-20200106monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-piper-jaffray-healthcare-conference-kura-20191126monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-at-stifel-healthcare-conference-kura-20191112monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-upcoming-presentation-at-ash-annual-meeting-kura-20191106monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-appoints-james-basta-as-chief-legal-officer-kura-20191104monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-third-quarter-2019-financial-results-kura-20191030monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-data-selected-for-oral-presentation-at-aacr-nci-eortc-international-conferen-kura-20191023monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-upcoming-presentation-at-aacr-nci-eortc-international-conference-o-kura-20191016monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-doses-first-patient-in-phase-1-clinical-trial-of-menin-mll-inhibitor-ko-539--kura-20190916monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-two-upcoming-investor-conferences-kura-20190829monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-at-wedbush-pacgrow-healthcare-conference-kura-20190807monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-second-quarter-2019-financial-results-kura-20190725monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-s-menin-mll-inhibitor-ko-539-receives-orphan-drug-designation-from-fda-for-t-kura-20190724monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-expands-protection-for-tipifarnib-with-new-u-s-and-european-patents-kura-20190711monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-kura-20190621monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-pricing-of-100-million-public-offering-of-common-stock-kura-20190619monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-at-bank-of-america-merrill-lynch-health-care-conference-kura-20190508monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-first-quarter-2019-financial-results-kura-20190430monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-identifies-farnesylated-proteins-associated-with-cxcl12-expression-potential-kura-20190402monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-two-upcoming-investor-conferences-kura-20190306monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-fda-clearance-of-investigational-new-drug-application-for-menin-ml-kura-20190305monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-fourth-quarter-and-full-year-2018-financial-results-kura-20190226monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-at-svb-leerink-global-healthcare-conference-kura-20190220monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-clinical-activity-of-tipifarnib-in-subsets-of-pancreatic-cancer-asso-kura-20190118monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-at-j-p-morgan-healthcare-conference-kura-20190103monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-new-patent-for-tipifarnib-in-angioimmunoblastic-t-cell-lymphoma-kura-20181128monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-two-upcoming-investor-conferences-kura-20181106monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-initiates-registration-directed-trial-of-tipifarnib-in-hras-mutant-head-and--kura-20181105monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-upcoming-presentations-at-ash-annual-meeting-kura-20181101monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-third-quarter-2018-financial-results-kura-20181029monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-at-leerink-partners-rare-disease-oncology-roundtable-kura-20180926monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-at-h-c-wainwright-global-investment-conference-kura-20180830monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-at-2018-wedbush-pacgrow-healthcare-conference-kura-20180807monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-second-quarter-2018-financial-results-kura-20180730monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-kura-20180702monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-pricing-of-67-million-public-offering-of-common-stock-kura-20180628monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-at-jmp-securities-life-sciences-conference-kura-20180614monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-at-deutsche-bank-43rd-annual-health-care-conference-kura-20180503monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-new-patent-for-tipifarnib-in-hematologic-malignancies-kura-20180502monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-first-quarter-2018-financial-results-kura-20180501monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-upcoming-presentations-at-aacr-annual-meeting-2018-kura-20180409monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-at-oppenheimer-28th-annual-healthcare-conference-kura-20180316monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-at-cowen-and-company-38th-annual-health-care-conference-kura-20180306monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-fourth-quarter-and-full-year-2017-financial-results-kura-20180305monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-provides-update-on-phase-2-trial-of-tipifarnib-in-hras-mutant-head-and-neck--kura-20180215monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-at-the-leerink-partners-7th-annual-global-healthcare-conference-kura-20180208monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-added-to-nasdaq-biotechnology-index-kura-20171218monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-identifies-potential-biomarkers-of-activity-for-lead-candidate-tipifarnib-in-kura-20171211monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-positive-phase-2-study-of-tipifarnib-in-chronic-myelomonocytic-leuke-kura-20171210monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-host-investor-day-on-november-16-2017-kura-20171109monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-upcoming-presentations-at-american-society-of-hematology-annual-me-kura-20171101monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-third-quarter-2017-financial-results-kura-20171031monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-development-candidate-ko-539-shows-robust-preclinical-anti-tumor-activity-in-kura-20171028monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-lead-candidate-tipifarnib-shows-durable-anti-tumor-activity-in-hras-mutant-h-kura-20171027monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-late-breaking-presentations-for-tipifarnib-in-hras-mutant-squamous-kura-20171016monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-positive-phase-2-study-for-tipifarnib-in-hras-mutant-head-and-neck-kura-20170907monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-citi-s-12th-annual-biotech-conference-kura-20170829monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-pricing-of-public-offering-of-common-stock-kura-20170811monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-second-quarter-2017-financial-results-kura-20170731monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-issuance-of-u-s-patent-for-lead-product-candidate-tipifarnib-in-he-kura-20170718monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-establishes-collaboration-with-foundation-medicine-to-support-tipifarnib-dev-kura-20170713monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-added-to-russell-3000-index-kura-20170626monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-presents-preliminary-clinical-and-preclinical-data-for-tipifarnib-in-the-tre-kura-20170614monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-data-presentations-for-tipifarnib-at-the-international-conference--kura-20170607monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-two-upcoming-investor-conferences-kura-20170530monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-first-quarter-2017-financial-results-kura-20170508monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-granted-u-s-patent-for-clinical-stage-erk-inhibitor-ko-947-kura-20170419monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-doses-first-patient-in-phase-1-trial-of-erk-inhibitor-ko-947-kura-20170407monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-presents-preclinical-data-demonstrating-significant-anti-tumor-activity-of-k-kura-20170405monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-fourth-quarter-and-full-year-2016-financial-results-kura-20170307monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-updated-clinical-activity-data-in-ongoing-phase-2-trial-for-tipifarn-kura-20170306monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-presentation-of-preliminary-clinical-data-for-tipifarnib-in-hras-m-kura-20170227monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-three-upcoming-investor-conferences-kura-20170209monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-doses-first-patient-in-phase-2-study-of-tipifarnib-in-chronic-myelomonocytic-kura-20170117monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-receives-fda-clearance-to-proceed-with-clinical-trial-for-erk-inhibitor-ko-9-kura-20170104monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-presents-preclinical-data-on-ko-947-and-menin-mll-inhibitor-program-at-the-e-kura-20161201monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-preclinical-data-on-pipeline-programs-at-eortc-nci-aacr-symposium-kura-20161115monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-presents-update-on-pipeline-programs-targeting-ras-erk-pathway-at-european-s-kura-20161104monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-two-upcoming-investor-conferences-kura-20161101monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-third-quarter-2016-financial-results-kura-20161031monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-the-9th-european-scientific-oncology-conference-kura-20161031monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-the-2016-aegis-growth-conference-kura-20160914monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-the-5th-annual-gateway-conference-kura-20160902monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-second-quarter-2016-financial-results-kura-20160803monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-doses-first-patient-in-phase-2-study-of-tipifarnib-in-lower-risk-myelodyspla-kura-20160616monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-the-2016-jmp-life-sciences-conference-kura-20160614monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-the-jefferies-2016-healthcare-conference-kura-20160603monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-report-fourth-quarter-and-full-year-2015-financial-results-kura-20160311monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-participate-in-the-leerink-global-healthcare-conference-kura-20160204monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-data-presentation-on-lead-product-candidate-tipifarnib-at-the-upco-kura-20151203monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-at-the-oppenheimer-2015-healthcare-conference-kura-20151201monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-at-upcoming-investor-conference-kura-20151130monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-first-patient-dosed-in-an-investigator-sponsored-phase-2-trial-of--kura-20151130monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-at-the-jefferies-2015-global-healthcare-conference-kura-20151111monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-pricing-of-public-offering-of-common-stock-kura-20151104monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-launch-of-public-offering-of-common-stock-kura-20151028monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-initiates-phase-2-study-of-tipifarnib-in-peripheral-t-cell-lymphoma-kura-20150930monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-cleared-for-quotation-on-the-otcqb-kura-20150916monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-at-the-2015-wedbush-pacgrow-healthcare-conference-kura-20150805monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-to-present-at-the-jefferies-2015-global-healthcare-conference-kura-20150527monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-s-menin-mll-inhibitor-program-shows-promise-in-study-published-in-cancer-cel-kura-20150330monthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-announces-license-agreement-with-janssen-pharmaceutica-for-development-and-c-kura-20150312monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-present-at-piper-sandler-37th-annual-healthcare-conference-on-dece-eton-20251124monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-third-quarter-2025-financial-results-on-thursday-november-6-eton-20251023monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-second-quarter-2025-financial-results-eton-20250807monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-second-quarter-2025-financial-results-on-thursday-august-7--eton-20250728monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-first-quarter-2025-financial-results-eton-20250513monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-first-quarter-2025-financial-results-on-tuesday-may-13-2025-eton-20250501monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-submission-of-nda-for-et-600-desmopressin-oral-solution-eton-20250428monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-out-licenses-international-rights-to-increlex-eton-20250401monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-fourth-quarter-2024-financial-results-eton-20250318monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-positive-pivotal-clinical-study-results-for-product-candida-eton-20250314monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-host-virtual-investor-day-and-release-fourth-quarter-earnings-resu-eton-20250304monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-commercial-launch-of-galzin-zinc-acetate-capsules-eton-20250303monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-expands-patent-portfolio-with-issuance-of-new-u-s-patent-for-et-600-eton-20250207monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-extension-of-pdufa-goal-date-for-et-400-eton-20250206monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-advances-its-commitment-to-rare-disease-with-the-acquisition-of-galzi-eton-20250103monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-closes-acquisition-of-increlex-mecasermin-injection-eton-20241220monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-final-readout-of-pku-golike-clinical-trial-eton-20241217monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-appoints-ipek-erdogan-trinkaus-as-chief-commercial-officer-eton-20241203monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-acquisition-of-u-s-rights-to-amglidia-glyburide-oral-suspen-eton-20241125monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-third-quarter-2024-financial-results-eton-20241112monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-awarded-second-patent-for-et-400-hydrocortisone-oral-solution-eton-20241107monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-third-quarter-2024-financial-results-on-tuesday-november-12-eton-20241106monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-inc-to-acquire-increlex-mecasermin-injection-from-ipsen-eton-20241003monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-participate-at-the-h-c-wainwright-26th-annual-global-investment-co-eton-20240822monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-second-quarter-2024-financial-results-eton-20240808monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-second-quarter-2024-financial-results-on-thursday-august-8--eton-20240730monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-et-400-hydrocort-eton-20240715monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-first-quarter-2024-financial-results-eton-20240509monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-present-at-the-citizens-jmp-life-sciences-conference-eton-20240501monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-submission-to-fda-of-new-drug-application-for-et-400-hydroc-eton-20240430monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-first-quarter-2024-financial-results-on-thursday-may-9-2024-eton-20240429monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-acquisition-of-pku-golike-for-phenylketonuria-eton-20240322monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-eton-20240314monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-fourth-quarter-and-full-year-2023-financial-results-on-thur-eton-20240229monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-awarded-u-s-patent-for-proprietary-hydrocortisone-oral-liquid-formula-eton-20240221monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-commercial-availability-of-ultra-rare-disease-product-nitis-eton-20240202monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-third-quarter-2023-financial-results-eton-20231109monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-third-quarter-2023-financial-results-on-thursday-november-9-eton-20231030monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-acquisition-of-fda-approved-ultra-rare-disease-product-niti-eton-20231004monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-present-at-the-h-c-wainwright-25th-annual-global-investment-confer-eton-20230823monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-second-quarter-2023-financial-results-on-thursday-august-10-eton-20230801monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-thursday-may-11-202-eton-20230503monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-fourth-quarter-2022-financial-results-on-thursday-march-16--eton-20230307monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-third-quarter-2022-financial-results-on-thursday-november-1-eton-20221102monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-present-at-the-ld-micro-main-event-xv-conference-eton-20221018monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-present-at-the-h-c-wainwright-24th-annual-global-investment-confer-eton-20220830monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-second-quarter-2022-financial-results-on-thursday-august-11-eton-20220802monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-fda-approval-of-zonisade-zonisamide-oral-suspension-eton-20220718monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-first-quarter-2022-financial-results-on-thursday-may-12-202-eton-20220503monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-fourth-quarter-2021-financial-results-on-wednesday-march-16-eton-20220308monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-and-azurity-pharmaceuticals-inc-announce-fda-approval-of-eprontia-top-eton-20211108monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-third-quarter-2021-financial-results-on-monday-november-15--eton-20211103monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-second-quarter-2021-financial-results-on-monday-august-16-2-eton-20210803monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-first-quarter-2021-financial-results-on-thursday-may-13-202-eton-20210504monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-fourth-quarter-and-full-year-2020-financial-results-on-tues-eton-20210304monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-participate-in-10th-annual-svb-leerink-global-healthcare-conferenc-eton-20210216monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-third-quarter-2020-financial-results-eton-20201112monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-third-quarter-financial-results-on-thursday-november-12-202-eton-20201104monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-prices-underwritten-public-offering-of-common-stock-eton-20201014monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-fda-approval-of-orphan-drug-alkindi-sprinkle-hydrocortisone-eton-20200929monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-second-quarter-financial-results-on-wednesday-august-12-202-eton-20200804monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-first-quarter-financial-results-on-thursday-may-14-2020-eton-20200506monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-acquisition-of-u-s-marketing-rights-to-pediatric-orphan-dru-eton-20200327monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-fourth-quarter-and-full-year-2019-financial-results-on-thur-eton-20200227monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-present-at-the-9th-annual-svb-leerink-healthcare-conference-eton-20200213monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-10-million-debt-facility-with-swk-holdings-eton-20191113monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-third-quarter-2019-financial-results-on-thursday-november-1-eton-20191106monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-participate-in-lake-street-3rd-annual-best-ideas-growth-conference-eton-20190903monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-second-quarter-2019-financial-results-on-tuesday-august-6-2-eton-20190730monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-present-at-20th-annual-b-riley-fbr-investor-conference-eton-20190515monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-report-first-quarter-2019-financial-results-on-tuesday-may-7-2019-eton-20190430monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-submits-new-drug-application-for-ds-200-eton-20190314monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-to-present-at-the-8th-annual-svb-leerink-healthcare-conference-eton-20190221monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-enters-into-license-agreement-for-two-branded-hospital-product-candid-eton-20190211monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-licensing-of-oral-liquid-product-candidate-et-104-eton-20190124monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-third-quarter-results-and-business-update-eton-20181220monthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-announces-pricing-of-initial-public-offering-eton-20181112monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-participate-in-upcoming-investor-conferences-phat-20260522monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-participate-in-upcoming-investor-conferences-phat-20260406monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-pricing-of-130-million-public-offering-of-common-stock-a-phat-20260108monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-proposed-public-offering-of-common-stock-and-pre-funded--phat-20260107monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-report-third-quarter-2025-financial-results-and-provide-busines-phat-20251020monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-participate-in-upcoming-investor-conferences-phat-20250825monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-report-second-quarter-2025-financial-results-and-provide-busine-phat-20250728monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-phat-20250623monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-appoints-anne-marie-cook-as-chief-legal-officer-and-corporate-secr-phat-20250623monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-fda-correction-to-orange-book-listing-confirming-10-year-phat-20250616monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-positive-fda-decision-to-recognize-10-years-of-regulator-phat-20250606monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-participate-in-upcoming-investor-conferences-phat-20250515monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-phat-20250501monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-present-voquezna-vonoprazan-data-at-ddw-2025-annual-meeting-phat-20250428monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-report-first-quarter-2025-financial-results-and-provide-busines-phat-20250423monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-appoints-ted-schroeder-to-its-board-of-directors-phat-20250416monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-present-at-the-24th-annual-needham-virtual-healthcare-conferenc-phat-20250403monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-phat-20250401monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-leadership-succession-phat-20250401monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-report-fourth-quarter-and-full-year-2024-financial-results-and--phat-20250224monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-present-at-the-guggenheim-securities-smid-cap-biotech-conferenc-phat-20250129monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-submits-citizen-petition-to-fda-seeking-correction-of-orange-book--phat-20241211monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-participate-in-upcoming-investor-conferences-phat-20241104monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-report-third-quarter-2024-financial-results-and-provide-busines-phat-20241028monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-present-voquezna-data-at-the-american-college-of-gastroenterolo-phat-20241027monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-participate-in-upcoming-investor-conferences-phat-20240829monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-voquezna-vonoprazan-added-to-cvs-caremark-formularies-fo-phat-20240730monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-report-second-quarter-2024-financial-results-and-provide-busine-phat-20240729monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-fda-approval-of-voquezna-vonoprazan-tablets-for-the-reli-phat-20240718monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-participate-in-upcoming-investor-conferences-phat-20240528monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-present-voquezna-vonoprazan-data-at-ddw-2024-annual-meeting-phat-20240515monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-report-first-quarter-2024-financial-results-and-provide-busines-phat-20240429monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-participate-in-the-23rd-annual-needham-virtual-healthcare-confe-phat-20240403monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-launches-direct-to-consumer-campaign-voquezna-can-kick-some-acid-phat-20240326monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-report-fourth-quarter-and-full-year-2023-financial-results-and--phat-20240229monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-voquezna-vonoprazan-tablets-for-erosive-gerd-and-associa-phat-20240213monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-present-at-the-guggenheim-healthcare-talks-6th-annual-biotechno-phat-20240131monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-expansion-of-existing-loan-and-security-agreement-with-h-phat-20231214monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-fda-acceptance-for-filing-of-voquezna-vonoprazan-tablets-phat-20231206monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-commercial-availability-of-voquezna-vonoprazan-tablets-a-phat-20231128monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-fda-approval-of-voquezna-vonoprazan-tablets-for-the-trea-phat-20231101monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-fda-approval-of-reformulated-vonoprazan-tablets-for-voqu-phat-20231030monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-participate-in-upcoming-investor-conferences-phat-20231025monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-vonoprazan-nda-submission-for-non-erosive-gerd-phat-20230926monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-participate-in-upcoming-investor-conferences-phat-20230905monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-submission-of-six-month-stability-data-in-support-of-ero-phat-20230821monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-fda-acceptance-of-nda-resubmission-for-erosive-gerd-phat-20230612monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-closing-of-underwriters-option-to-purchase-additional-sh-phat-20230609monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-participate-in-upcoming-investor-conferences-phat-20230601monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-alert-bragar-eagel-squire-p-c-is-investigating-phathom-pharmaceuticals-inc-on-beha-phat-20230527monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-phat-20230523monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-resubmits-erosive-gerd-new-drug-application-to-fda-phat-20230523monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-presents-new-data-at-digestive-disease-week-ddw-2023-phat-20230509monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-inc-company-investigated-by-the-portnoy-law-firm-phat-20230414monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-participate-in-upcoming-investor-conferences-phat-20230412monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-regulatory-update-and-plans-for-2023-erosive-esophagitis-phat-20230404monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-provides-regulatory-updates-phat-20230209monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-alert-bragar-eagel-squire-p-c-is-investigating-phathom-pharmaceuticals-inc-on-beha-phat-20230112monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-positive-topline-results-from-phase-3-phalcon-nerd-301-t-phat-20230108monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your--phat-20230105monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-provides-update-on-new-drug-application-review-of-vonoprazan-for-e-phat-20230103monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-participate-in-upcoming-investor-healthcare-conferences-phat-20221103monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-completes-patient-enrollment-in-phase-3-phalcon-nerd-301-daily-dos-phat-20221024monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-presents-new-data-evaluating-first-in-class-potassium-competitive--phat-20221023monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-present-latest-data-on-vonoprazan-at-american-college-of-gastro-phat-20221018monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-appoints-dr-james-topper-to-its-board-of-directors-phat-20220926monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-present-at-the-h-c-wainwright-24th-annual-global-investment-con-phat-20220907monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-inc-investors-company-investigated-by-the-portnoy-law-firm-phat-20220804monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-present-at-the-2022-jefferies-healthcare-conference-phat-20220601monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-fda-acceptance-for-filing-of-vonoprazan-nda-for-the-trea-phat-20220525monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-presents-data-on-novel-potassium-competitive-acid-blocker-pcab-von-phat-20220524monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-present-data-at-ddw-2022-annual-meeting-phat-20220517monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-fda-approval-of-voquezna-triple-pak-vonoprazan-amoxicill-phat-20220503monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-appoints-frank-karbe-to-its-board-of-directors-phat-20220426monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-present-at-the-21st-annual-needham-virtual-healthcare-conferenc-phat-20220401monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-appointment-of-molly-henderson-as-chief-financial-and-bu-phat-20220322monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-submits-vonoprazan-nda-to-fda-for-the-treatment-of-erosive-esophag-phat-20220314monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-positive-topline-results-from-phase-2-trial-evaluating-v-phat-20220209monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-participate-in-the-4th-annual-evercore-isi-healthconx-conferenc-phat-20211123monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-participate-in-two-upcoming-investor-healthcare-conferences-phat-20211112monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-withdraws-public-offering-phat-20211028monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-proposed-public-offering-of-5-000-000-shares-of-common-s-phat-20211026monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-new-data-at-acg-2021-annual-scientific-meeting-phat-20211024monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-present-new-data-at-acg-2021-annual-scientific-meeting-phat-20211021monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-positive-topline-results-from-phalcon-ee-pivotal-phase-3-phat-20211018monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-results-from-vono-103-a-phase-1-study-evaluating-gastric-phat-20210927monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-secures-200-million-term-loan-facility-from-hercules-capital-phat-20210920monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-submits-two-ndas-to-u-s-fda-for-vonoprazan-based-treatment-regimen-phat-20210908monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-participate-in-the-morgan-stanley-19th-annual-global-healthcare-phat-20210831monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-participate-in-the-bmo-biopharma-spotlight-series-innovation-in-phat-20210802monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-present-at-the-jefferies-virtual-healthcare-conference-phat-20210525monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-present-at-the-bank-of-america-securities-2021-virtual-healthca-phat-20210506monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-positive-topline-results-from-pivotal-phase-3-trial-of-v-phat-20210429monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-present-at-20th-annual-needham-virtual-healthcare-conference-phat-20210406monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-completion-of-patient-enrollment-in-pivotal-phase-3-heli-phat-20210119monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-phat-20201216monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-plans-to-initiate-vonoprazan-development-program-in-non--phat-20201214monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-completion-of-patient-enrollment-in-pivotal-phase-3-eros-phat-20201130monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-participate-at-upcoming-investor-healthcare-conferences-phat-20201127monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-host-virtual-investor-day-phat-20201119monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-present-at-the-jefferies-virtual-london-healthcare-conference-phat-20201113monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-present-at-morgan-stanley-18th-annual-global-healthcare-confere-phat-20200909monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-announces-appointment-of-todd-branning-as-chief-financial-officer-phat-20200713monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-provides-clinical-trial-status-update-phat-20200615monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-present-at-upcoming-investor-conferences-phat-20200528monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-to-participate-at-the-19th-annual-needham-virtual-healthcare-conference-phat-20200409monthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-to-present-at-40th-annual-cowen-and-company-health-care-conference-phat-20200225monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-exclusive-licensing-agreement-with-viatris-for-sotagliflozin-in-all-mark-lxrx-20241016monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-completes-the-sale-of-xermelo-to-tersera-therapeutics-lxrx-20200908monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-second-quarter-2020-financial-results-conference-call-and--lxrx-20200723monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-upcoming-investor-conference-lxrx-20200527monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-first-quarter-2020-financial-results-conference-call-and-w-lxrx-20200422monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-virtual-annual-meeting-of-stockholders-on-april-23-2020-lxrx-20200407monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-an-update-on-the-sotagliflozin-type-2-diabetes-program-lxrx-20200319monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-additional-data-on-telotristat-ethyl-s-antiproliferative-lxrx-20200313monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-real-world-data-on-telotristat-ethyl-s-antiproliferative-lxrx-20200124monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-poster-presentation-at-the-asco-2020-gastrointestinal-ca-lxrx-20200120monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-positive-topline-phase-1-data-for-lx9211-lxrx-20191205monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-completes-safety-review-of-initial-safety-run-in-cohort-of-tele-ab-lxrx-20191203monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-upcoming-investor-conference-lxrx-20191126monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-upcoming-investor-conference-lxrx-20191115monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-third-quarter-2019-financial-results-conference-call-and-w-lxrx-20191031monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-poster-presentations-at-the-nanets-annual-multidisciplin-lxrx-20191002monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-sotagliflozin-clinical-data-at-the-european-association-lxrx-20190910monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-upcoming-investor-conference-lxrx-20190830monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-upcoming-investor-conference-lxrx-20190809monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-date-change-for-second-quarter-2019-financial-results-co-lxrx-20190730monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-second-quarter-2019-financial-results-conference-call-and--lxrx-20190725monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-new-clinical-data-at-79th-american-diabetes-association-lxrx-20190604monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-upcoming-investor-conference-lxrx-20190523monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-upcoming-investor-conference-lxrx-20190508monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-first-quarter-2019-financial-results-conference-call-and-w-lxrx-20190425monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-upcoming-investor-conference-lxrx-20190402monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-dosing-of-first-patient-in-tele-abc-study-a-phase-2a-cli-lxrx-20190315monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-fourth-quarter-and-full-year-2018-financial-results-confer-lxrx-20190311monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-upcoming-investor-conference-lxrx-20190311monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-poster-presentations-at-the-16th-annual-enets-conference-lxrx-20190228monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-conference-call-and-webcast-on-january-17-2019-to-discuss--lxrx-20190117monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-upcoming-investor-conference-lxrx-20181221monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-topline-phase-1-clinical-results-for-lx2761-in-diabetes-lxrx-20181220monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-positive-topline-clinical-data-for-lx9211-lxrx-20181218monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-upcoming-investor-conference-lxrx-20181108monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-upcoming-investor-conference-lxrx-20181106monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-third-quarter-2018-financial-results-and-provides-a-busine-lxrx-20181101monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-third-quarter-2018-financial-results-conference-call-and-w-lxrx-20181025monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-and-ipsen-biopharmaceuticals-canada-inc-announce-health-canada-app-lxrx-20181016monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-sotagliflozin-clinical-data-at-the-european-association-lxrx-20180924monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-upcoming-investor-conference-lxrx-20180924monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-upcoming-investor-conference-lxrx-20180830monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-upcoming-investor-conference-lxrx-20180822monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-upcoming-investor-conference-lxrx-20180731monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-second-quarter-2018-financial-results-and-provides-a-busin-lxrx-20180730monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-first-quarter-2018-financial-results-conference-call-and-w-lxrx-20180723monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-new-clinical-data-at-78th-american-diabetes-association-lxrx-20180618monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-upcoming-investor-conference-lxrx-20180524monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-first-quarter-2018-financial-results-and-provides-a-busine-lxrx-20180503monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-upcoming-investor-conference-lxrx-20180501monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-first-quarter-2018-financial-results-conference-call-and-w-lxrx-20180426monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-highlight-pipeline-progress-at-r-d-day-on-april-10-2018-lxrx-20180403monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-ema-acceptance-of-marketing-authorization-application-ma-lxrx-20180329monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-regulatory-submissions-for-sotagliflozin-to-treat-adults-lxrx-20180326monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-upcoming-investor-conferences-lxrx-20180227monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-fourth-quarter-and-full-year-2017-financial-results-and-pr-lxrx-20180222monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-fourth-quarter-and-full-year-2017-financial-results-confer-lxrx-20180216monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-poster-presentation-at-asco-gi-lxrx-20180102monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-upcoming-investor-conference-lxrx-20180102monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-secures-up-to-200-million-non-dilutive-term-loan-financing-lxrx-20171205monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-inc-nasdaq-lxrx-to-ring-the-nasdaq-stock-market-closing-bell-lxrx-20150407monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-inc-is-today-s-focus-stock-on-microstockprofit-com-lxrx-20110107monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-2008-fourth-quarter-and-full-year-financial-results-lxrx-20090225monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-report-fourth-quarter-and-year-end-2008-financial-results-on-february-25-2009-lxrx-20090218monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-consolidates-operations-to-focus-resources-on-most-advanced-drug-discovery-and-dev-lxrx-20090122monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-initiates-phase-2-clinical-trial-of-lx1031-in-patients-with-irritable-bowel-syndro-lxrx-20090112monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-27th-annual-jpmorgan-healthcare-conference-lxrx-20090108monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-s-drug-candidate-lx6171-for-cognitive-disorders-completes-phase-2a-clinical-trial-lxrx-20081212monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-files-investigational-new-drug-application-for-lx4211-as-a-potential-treatment-for-lxrx-20081201monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-webcast-of-annual-r-d-day-lxrx-20081125monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-two-upcoming-healthcare-conferences-lxrx-20081124monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-s-drug-candidate-lx1032-for-carcinoid-syndrome-successfully-completes-phase-1-clin-lxrx-20081113monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-2008-third-quarter-financial-results-lxrx-20081030monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-presents-phase-1-clinical-trial-results-for-lx2931-at-american-college-of-rheumato-lxrx-20081026monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-report-third-quarter-2008-financial-results-on-october-30-2008-lxrx-20081016monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-clinical-data-for-lx2931-an-investigational-new-drug-for-rheumatoid-art-lxrx-20081014monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-identifies-new-drug-candidate-for-glaucoma-lxrx-20080813monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-2008-second-quarter-financial-results-lxrx-20080729monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-drug-candidate-for-irritable-bowel-syndrome-completes-phase-1-clin-lxrx-20080729monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-report-second-quarter-2008-financial-results-on-july-29-2008-lxrx-20080717monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-s-drug-candidate-for-carcinoid-syndrome-receives-fast-track-status-from-the-fda-lxrx-20080603monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-implements-reorganization-to-deploy-resources-toward-drug-developm-lxrx-20080528monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-bank-of-america-health-care-conference-lxrx-20080508monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-2008-first-quarter-financial-results-lxrx-20080429monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-morgan-stanley-global-healthcare-unplugged-confe-lxrx-20080424monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-report-first-quarter-2008-financial-results-on-april-29-2008-lxrx-20080421monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-s-drug-candidate-for-rheumatoid-arthritis-lx2931-shows-positive-results-in-phase-1-lxrx-20080417monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-presents-clinical-data-for-lx6171-a-drug-candidate-for-cognitive-disorders-lxrx-20080415monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-future-leaders-in-the-biotech-industry-conferenc-lxrx-20080320monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-2007-annual-report-to-stockholders-available-online-lxrx-20080314monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-2007-fourth-quarter-and-full-year-financial-results-lxrx-20080306monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-participate-in-may-investor-conferences-drts-20260518monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-fda-approval-of-ide-supplement-to-expand-alpha-dart-impact-trial-to-pa-drts-20260423monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-present-at-sidoti-march-virtual-small-cap-conference-drts-20260316monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-participate-in-december-investor-conferences-drts-20251201monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-full-year-2024-financial-results-and-provides-corporate-update-drts-20250312monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-fda-approval-of-ide-supplement-to-expand-pilot-trial-of-alpha-dart-to--drts-20250203monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-drts-20241211monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-participate-in-the-h-c-wainwright-26th-annual-global-investment-conference-th-drts-20240822monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-participate-in-barclays-26th-annual-global-healthcare-conference-drts-20240226monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-drts-20231220monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-expands-its-alpha-dart-treatment-to-vulvar-cancer-in-novel-clinical-trial-with-c-drts-20230517monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-the-publication-of-its-us-multicenter-pilot-skin-cancer-trial-results--drts-20230511monthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-medical-initiates-first-clinical-trial-in-italy-to-treat-cancer-with-alpha-radia-drts-20171030monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-mails-letter-to-stockholders-reiterating-confidence-in-the-company-s-st-pcrx-20260527monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-sets-the-record-straight-regarding-doma-s-misleading-statements-about-p-pcrx-20260526monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-files-investor-presentation-highlighting-successful-execution-of-its-lo-pcrx-20260520monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pcrx-20260508monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-mails-letter-to-stockholders-pcrx-20260505monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-first-quarter-2026-financial-results-pcrx-20260430monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-files-definitive-proxy-materials-and-mails-letter-to-shareholders-pcrx-20260428monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reaffirms-commitment-to-shareholder-value-creation-pcrx-20260311monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pcrx-20260306monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-pcrx-20260226monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-to-report-2025-financial-results-on-thursday-february-26-2026-pcrx-20260212monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-joins-probe-consortium-to-transform-osteoarthritis-research-and-care-pcrx-20251218monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pcrx-20251203monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-files-exparel-patent-infringement-lawsuits-against-the-whiteoak-group-a-pcrx-20251126monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-3-year-data-demonstrating-sustained-pain-and-function-improv-pcrx-20251020monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pcrx-20251003monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pcrx-20250905monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-second-quarter-2025-financial-results-pcrx-20250805monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-to-report-second-quarter-2025-financial-results-on-tuesday-august-5-2025-pcrx-20250724monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-strategic-collaboration-to-significantly-expand-zilretta-prom-pcrx-20250722monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pcrx-20250703monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-debuts-inspiring-new-film-highlighting-one-patient-s-journey-to-pain-re-pcrx-20250618monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-alert-bragar-eagel-squire-p-c-is-investigating-pacira-biosciences-inc-on-behalf-of--pcrx-20250618monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-unveils-three-year-clinical-data-following-a-single-local-administratio-pcrx-20250611monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pcrx-20250605monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-presents-new-data-on-the-effects-of-clinical-immunogenicity-on-locally--pcrx-20250515monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-participate-in-fireside-chat-at-two-upcoming-healthcare-conferences-pcrx-20250514monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-first-quarter-2025-financial-results-pcrx-20250508monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-3-year-safety-and-efficacy-data-of-pcrx-201-following-single-pcrx-20250506monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-new-data-on-clinical-immunogenicity-of-intra-articular-pcrx--pcrx-20250502monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-to-report-first-quarter-2025-financial-results-on-thursday-may-8-2025-pcrx-20250429monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-two-year-efficacy-data-following-a-single-local-administratio-pcrx-20250428monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-104-week-efficacy-data-following-a-single-local-administrati-pcrx-20250422monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reaffirms-commitment-to-enhancing-value-for-all-shareholders-pcrx-20250417monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pcrx-20250411monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-settlement-of-u-s-patent-litigation-for-exparel-pcrx-20250407monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-first-patient-dosed-in-phase-2-study-evaluating-safety-and-ef-pcrx-20250403monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-participate-in-fireside-chat-at-the-24th-annual-needham-virtual-heal-pcrx-20250401monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-confirms-receipt-of-director-nominations-from-doma-perpetual-pcrx-20250314monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losse-pcrx-20250313monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsk-pcrx-20250313monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pcrx-20250306monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-o-pcrx-20250306monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti--pcrx-20250305monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-fourth-quarter-and-full-year-2024-financial-results-pcrx-20250227monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-acquires-remaining-equity-stake-of-gq-bio-pcrx-20250227monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-o-pcrx-20250227monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-participate-in-fireside-chat-at-two-healthcare-conferences-in-march-pcrx-20250226monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti--pcrx-20250226monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-inc-sued-for-securities-law-violations-investors-should-contact-the-gro-pcrx-20250220monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-to-report-2024-financial-results-on-thursday-february-27-2025-pcrx-20250220monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-o-pcrx-20250220monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti--pcrx-20250218monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-o-pcrx-20250213monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti--pcrx-20250212monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pcrx-20250206monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-o-pcrx-20250206monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti--pcrx-20250205monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-announces-updates-to-board-of-directors-pcrx-20250130monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-o-pcrx-20250130monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti--pcrx-20250129monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsk-pcrx-20250127monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-o-pcrx-20250123monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti--pcrx-20250122monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-strengthens-executive-leadership-team-with-two-key-appointments-pcrx-20250121monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-o-pcrx-20250116monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-announces-new-five-year-objectives-to-accelerate-transition-into-an-innovative-biop-pcrx-20250110monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-receives-fda-510k-clearance-for-new-iovera-smarttip-to-manage-chronic-l-pcrx-20250107monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-pcrx-20250102monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pcrx-20241206monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-awarded-new-u-s-patent-covering-exparel-composition-pcrx-20241203monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-announces-104-week-safety-and-efficacy-data-following-local-administration-of-pcrx--pcrx-20241114monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-participate-in-fireside-chat-at-two-upcoming-healthcare-conferences-pcrx-20241112monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-third-quarter-2024-financial-results-pcrx-20241106monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-to-report-third-quarter-2024-financial-results-on-wednesday-november-6-2024-pcrx-20241030monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-appoints-shawn-cross-as-chief-financial-officer-pcrx-20241021monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pcrx-20241007monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-new-product-specific-j-code-for-exparel-effective-january-1-2-pcrx-20241003monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-announces-the-presentation-of-104-week-safety-and-efficacy-data-following-local-adm-pcrx-20240926monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pcrx-20240909monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-comments-on-ruling-on-exparel-patent-litigation-from-u-s-district-court-pcrx-20240809monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-second-quarter-2024-financial-results-pcrx-20240730monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-to-report-second-quarter-2024-financial-results-on-tuesday-july-30-2024-pcrx-20240723monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-participate-in-fireside-chat-at-the-2024-jefferies-global-healthcare-pcrx-20240530monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-first-quarter-2024-financial-results-and-announces-150-million--pcrx-20240507monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-participate-in-fireside-chat-at-the-2024-rbc-capital-markets-global--pcrx-20240507monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-to-report-first-quarter-2024-financial-results-on-tuesday-may-7-2024-pcrx-20240430monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-participate-in-fireside-chat-at-the-23rd-annual-needham-virtual-heal-pcrx-20240402monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-pcrx-201-granted-regenerative-medicine-advance-therapy-rmat-d-pcrx-20240313monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-participate-in-fireside-chat-at-the-barclays-26th-annual-global-heal-pcrx-20240306monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-fourth-quarter-and-full-year-2023-financial-results-pcrx-20240229monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-to-report-2023-financial-results-on-thursday-february-29-2024-pcrx-20240222monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-announces-publication-of-pivotal-study-of-exparel-as-a-sciatic-nerve-block-in-the-p-pcrx-20240215monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-awarded-brand-pharmaceuticals-agreement-with-premier-inc-pcrx-20240207monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-reports-preliminary-unaudited-fourth-quarter-and-full-year-2023-revenues-pcrx-20240104monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-pcrx-20240103monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-appoints-frank-d-lee-as-chief-executive-officer-pcrx-20231221monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-participate-in-fireside-chat-at-two-healthcare-conferences-in-novemb-pcrx-20231107monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-third-quarter-2023-financial-results-pcrx-20231102monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-appoints-four-new-independent-directors-to-its-board-of-directors-pcrx-20231010monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-leadership-succession-plan-pcrx-20230926monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-fireside-chat-at-the-h-c-wainwright-25th-annual-global-invest-pcrx-20230906monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-second-quarter-2023-financial-results-pcrx-20230802monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-participate-in-fireside-chat-at-the-2023-jefferies-healthcare-confer-pcrx-20230531monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-participate-in-fireside-chat-at-the-2023-rbc-capital-markets-global--pcrx-20230509monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-first-quarter-2023-financial-results-pcrx-20230503monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-partners-with-the-invited-celebrity-classic-a-pga-tour-champions-event--pcrx-20230420monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-inc-appoints-christopher-young-as-chief-manufacturing-officer-pcrx-20230419monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-participate-in-fireside-chat-at-the-22nd-annual-needham-virtual-heal-pcrx-20230412monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-yvonne-greenstreet-to-retire-from-board-of-directors-pcrx-20230322monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-participate-in-fireside-chat-at-the-2023-barclays-global-healthcare--pcrx-20230308monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-full-year-and-fourth-quarter-2022-financial-results-pcrx-20230228monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-unaudited-total-revenue-for-2022-of-666-8-million-pcrx-20230105monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-pcrx-20230104monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-net-product-sales-of-57-5-million-for-november-2022-pcrx-20221213monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-net-product-sales-of-54-9-million-for-october-2022-pcrx-20221114monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-two-healthcare-conferences-in-november-pcrx-20221108monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-third-quarter-2022-financial-results-pcrx-20221103monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-third-quarter-2022-revenue-of-167-5-million-pcrx-20221013monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-positive-topline-data-from-phase-3-study-of-exparel-as-a-sing-pcrx-20220921monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-net-product-sales-of-59-1-million-for-august-2022-pcrx-20220913monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-positive-topline-data-from-phase-3-study-of-exparel-as-a-sing-pcrx-20220907monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-net-product-sales-of-50-2-million-for-july-2022-pcrx-20220810monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-second-quarter-2022-financial-results-pcrx-20220803monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-participate-in-fireside-chat-at-the-2022-wedbush-pacgrow-healthcare--pcrx-20220802monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-second-quarter-2022-revenue-of-169-4-million-pcrx-20220714monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-net-product-sales-for-exparel-and-iovera-of-46-0-mi-pcrx-20220614monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-participate-in-fireside-chat-at-the-jefferies-healthcare-conference-pcrx-20220602monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-net-product-sales-for-exparel-and-iovera-of-45-8-mi-pcrx-20220512monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-two-healthcare-conferences-in-may-pcrx-20220510monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-first-quarter-2022-financial-results-pcrx-20220504monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-revenues-of-157-4-to-158-4-million-for-the-first-qu-pcrx-20220412monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-participate-in-fireside-chat-at-the-21st-annual-needham-virtual-heal-pcrx-20220405monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-net-product-sales-for-exparel-and-iovera-of-42-6-mi-pcrx-20220315monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-participate-in-fireside-chat-at-the-barclays-global-healthcare-confe-pcrx-20220309monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-full-year-and-fourth-quarter-2021-financial-results-pcrx-20220224monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-net-product-sales-for-exparel-and-iovera-of-37-3-mi-pcrx-20220215monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-pcrx-20220103monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-closing-of-375-million-five-year-term-loan-b-pcrx-20211209monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-net-product-sales-for-exparel-and-iovera-of-48-0-mi-pcrx-20211207monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-piper-sandler-33rd-annual-virtual-healthcare-conferen-pcrx-20211123monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-jefferies-london-healthcare-conference-pcrx-20211110monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-net-product-sales-of-44-3-million-for-october-2021-pcrx-20211109monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-third-quarter-2021-financial-results-pcrx-20211103monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-host-investor-day-on-october-15th-2021-in-tampa-fl-pcrx-20211008monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-notified-of-abbreviated-new-drug-application-filing-for-exparel-pcrx-20211004monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-net-product-sales-of-42-3-million-for-august-2021-pcrx-20210915monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conferen-pcrx-20210908monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-net-product-sales-of-42-1-million-for-july-2021-pcrx-20210810monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-2021-wedbush-pacgrow-healthcare-virtual-conference-pcrx-20210804monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-record-revenue-of-135-6-million-for-the-second-quarter-of-2021-pcrx-20210803monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-record-revenue-of-135-6-million-for-the-second-quarter-of-2021-pcrx-20210713monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-net-product-sales-of-42-2-million-for-may-2021-pcrx-20210608monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-top-line-results-from-phase-3-stride-study-evaluating-exparel-pcrx-20210526monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-2021-jefferies-virtual-healthcare-conference-pcrx-20210525monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-notice-of-allowance-of-new-patent-for-exparel-pcrx-20210518monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-2021-rbc-capital-markets-global-healthcare-conference-pcrx-20210512monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-net-product-sales-of-44-6-million-for-april-2021-pcrx-20210511monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-first-quarter-2021-financial-results-and-business-update-pcrx-20210504monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-investment-in-spine-biopharma-pcrx-20210420monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-seeks-court-injunction-to-protect-clinical-integrity-of-exparel-in-the--pcrx-20210414monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-net-product-sales-of-36-2-million-for-february-2021-pcrx-20210309monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-2021-barclays-global-healthcare-conference-pcrx-20210303monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-full-year-and-fourth-quarter-2020-financial-results-pcrx-20210225monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-net-product-sales-of-36-0-million-for-january-2021-pcrx-20210210monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-equity-investment-in-genequine-biotherapeutics-pcrx-20210126monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-pcrx-20210106monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-net-product-sales-of-38-9-million-for-november-2020-pcrx-20201209monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-2020-piper-sandler-32nd-annual-virtual-healthcare-con-pcrx-20201124monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-net-product-sales-of-41-7-million-for-october-2020-pcrx-20201111monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-2020-jefferies-virtual-london-healthcare-conference-pcrx-20201110monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-third-quarter-2020-financial-results-and-business-update-pcrx-20201029monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-net-product-sales-of-116-9-million-for-the-third-qu-pcrx-20201007monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-2020-h-c-wainwright-22nd-annual-global-investment-con-pcrx-20200911monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-preliminary-net-product-sales-of-36-9-million-for-august-2020-pcrx-20200909monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-second-quarter-2020-financial-results-and-business-update-pcrx-20200806monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-2020-wedbush-pacgrow-healthcare-virtual-conference-pcrx-20200805monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-fda-acceptance-of-snda-for-exparel-use-in-pediatric-patients-pcrx-20200804monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-settlement-of-government-investigation-pcrx-20200728monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-inc-announces-pricing-of-350-0-million-aggregate-principal-amount-of-0--pcrx-20200707monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-conclusion-of-exparel-agreement-with-depuy-synthes-pcrx-20200702monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-2020-bmo-prescriptions-for-success-healthcare-confere-pcrx-20200616monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-2020-jefferies-virtual-healthcare-conference-pcrx-20200527monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-2020-rbc-capital-markets-global-healthcare-virtual-co-pcrx-20200513monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-first-quarter-2020-financial-results-and-business-update-pcrx-20200507monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-appoints-donald-c-manning-m-d-ph-d-as-chief-medical-officer-pcrx-20200504monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-2020-barclays-global-healthcare-conference-pcrx-20200309monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-launches-national-regional-anesthesia-training-initiative-with-envision-pcrx-20200121monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-pcrx-20200108monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-positive-results-from-phase-3-play-study-of-exparel-in-pediat-pcrx-20191217monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-31st-annual-piper-jaffray-healthcare-conference-pcrx-20191126monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-jefferies-2019-london-healthcare-conference-pcrx-20191113monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-third-quarter-2019-financial-results-and-business-update-pcrx-20191107monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-appoints-chris-christie-to-board-of-directors-pcrx-20190919monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-completes-enrollment-in-multicenter-registration-study-of-exparel-in-pe-pcrx-20190917monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-second-quarter-2019-financial-results-and-business-update-pcrx-20190808monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-2019-wedbush-pacgrow-healthcare-conference-pcrx-20190807monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-announces-validation-of-exparel-marketing-authorization-application-fro-pcrx-20190625monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-appoints-former-johnson-johnson-executive-max-reinhardt-as-president-pcrx-20190619monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-the-jefferies-2019-healthcare-conference-pcrx-20190528monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-to-present-at-two-healthcare-conferences-in-may-pcrx-20190507monthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-reports-first-quarter-2019-revenues-of-91-3-million-pcrx-20190502monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4-annx-20260616monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4-annx-20260316monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4-annx-20260116monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-annx-20260107monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4-annx-20251217monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-announces-closing-of-public-offering-and-full-exercise-of-underwriters-option-to-p-annx-20251114monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-annx-20251112monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4-annx-20250516monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-to-present-on-the-neuroprotective-effects-of-anx007-at-the-2025-arvo-annual-meetin-annx-20250507monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4-annx-20250416monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4-annx-20250317monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-to-present-at-the-td-cowen-45th-annual-health-care-conference-annx-20250226monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4-annx-20250218monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-announces-presentations-highlighting-anx007-functional-and-structural-differentiat-annx-20250213monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-annx-20250107monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4-annx-20241216monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-to-present-phase-2-archer-data-on-protection-of-vision-and-photoreceptors-with-anx-annx-20241205monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4-annx-20241115monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-to-present-at-the-jefferies-london-healthcare-conference-annx-20241113monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4-annx-20241016monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-to-present-new-phase-2-archer-data-for-anx007-in-dry-amd-patients-with-less-advanc-annx-20241015monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4-annx-20240916monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-to-present-phase-2-archer-data-on-protection-of-vision-and-photoreceptors-with-anx-annx-20240909monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-expands-senior-leadership-in-commercial-medical-affairs-and-health-economics-to-ad-annx-20240903monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-to-participate-in-upcoming-september-investor-conferences-annx-20240829monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4-annx-20240816monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4-annx-20240716monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-to-present-additional-phase-2-data-showing-preservation-of-visual-function-and-str-annx-20240711monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4-annx-20240617monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-announces-proposed-public-offering-of-common-stock-annx-20240604monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-to-host-conference-call-and-webcast-to-discuss-gbs-phase-3-data-annx-20240603monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4-annx-20240516monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-to-present-at-the-bank-of-america-health-care-conference-annx-20240509monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-to-present-data-reinforcing-the-neuroprotective-effects-of-anx007-and-c1q-inhibiti-annx-20240501monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4-annx-20240416monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-to-present-at-the-23rd-annual-needham-virtual-healthcare-conference-annx-20240403monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4-annx-20240318monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-to-present-at-the-td-cowen-44th-annual-health-care-conference-annx-20240227monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4-annx-20240220monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-annx-20231227monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-phase-1-results-for-anx1502-its-oral-small-molecule-inhibitor-of-the-class-annx-20231220monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4-annx-20231218monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-to-participate-in-the-6th-annual-evercore-isi-healthconx-conference-annx-20231122monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-to-participate-in-2023-jefferies-london-healthcare-conference-annx-20231109monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4-annx-20231018monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-to-participate-in-the-2023-cantor-global-healthcare-conference-annx-20230919monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4-annx-20230918monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4-annx-20230802monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-presents-archer-trial-results-at-asrs-2023-highlighting-potential-of-anx007-as-a-d-annx-20230730monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-to-report-archer-phase-2-trial-results-in-geographic-atrophy-at-asrs-2023-annx-20230724monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4-annx-20230516monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-to-participate-in-the-22nd-annual-needham-virtual-healthcare-conferenc-annx-20230411monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-to-participate-in-the-43rd-annual-cowen-healthcare-conference-annx-20230227monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4-annx-20230216monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4-annx-20230117monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-highlights-strategic-focus-to-advance-four-flagship-complement-programs-through-la-annx-20230108monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-to-present-at-41st-annual-j-p-morgan-healthcare-conference-annx-20230104monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4-annx-20221117monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4-annx-20221018monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4-annx-20220916monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4-annx-20220817monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-closes-130-million-private-placement-extending-its-operating-runway-into-the-secon-annx-20220711monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-to-present-at-the-2022-jefferies-healthcare-conference-annx-20220602monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-to-present-data-highlighting-novel-approach-to-treating-complement-dri-annx-20220601monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-to-participate-in-upcoming-may-investor-conferences-annx-20220505monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-to-participate-in-the-21st-annual-needham-virtual-healthcare-conferenc-annx-20220404monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-to-participate-in-the-cowen-42nd-annual-healthcare-conference-annx-20220228monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-annx-20220104monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-announces-clinical-and-preclinical-data-highlighting-potential-of-comp-annx-20211213monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-to-participate-in-2021-cantor-virtual-global-healthcare-conference-annx-20210923monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-to-highlight-neurodegeneration-franchise-in-upcoming-virtual-c1q-serie-annx-20210920monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-to-present-at-the-raymond-james-human-health-innovation-conference-annx-20210616monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-to-present-at-the-bofa-securities-2021-virtual-healthcare-conference-annx-20210505monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-advances-classical-complement-platform-with-initiation-of-global-phase-2-archer-tr-annx-20210301monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-highlights-recent-achievements-and-outlines-expected-key-milestones-in-2021-for-it-annx-20210112monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-to-present-at-the-j-p-morgan-39th-annual-healthcare-conference-annx-20210105monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-expands-classical-complement-platform-into-neurodegenerative-diseases-of-the-brain-annx-20201112monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-expands-leadership-team-with-the-appointment-of-michael-overdorf-as-ch-annx-20200730monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-announces-closing-of-initial-public-offering-annx-20200728monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-announces-pricing-of-initial-public-offering-annx-20200724monthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-closes-100-million-financing-to-advance-broad-pipeline-of-classical-complement-the-annx-20200701monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-to-report-first-quarter-2026-financial-results-and-provide-business-update--phar-20260423monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-n-v-investigated-by-the-portnoy-law-firm-phar-20260413monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-reports-preliminary-2025-revenues-and-announces-investor-day-phar-20260108monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-reports-second-quarter-and-first-half-2025-financial-results-and-provides-b-phar-20250731monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-to-report-second-quarter-and-first-half-2025-financial-results-and-provide--phar-20250717monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-to-host-webcast-on-findings-of-a-new-study-published-in-cell-advancing-func-phar-20250624monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-reports-on-results-of-the-2025-annual-general-meeting-of-shareholders-phar-20250611monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-to-participate-in-june-investor-conferences-phar-20250528monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-reports-first-quarter-2025-financial-results-and-provides-business-update-phar-20250508monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-announces-the-2025-annual-general-meeting-of-shareholders-and-the-nominatio-phar-20250430monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-announces-upcoming-presentations-at-the-2025-annual-meeting-of-the-clinical-phar-20250425monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-to-report-first-quarter-2025-financial-results-on-may-8-phar-20250424monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-receives-positive-recommendation-from-nice-for-joenja-leniolisib-as-a-treatment-f-phar-20250423monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-announces-the-filing-of-its-2024-annual-report-and-form-20-f-phar-20250403monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-to-participate-in-april-investor-conferences-phar-20250328monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-announces-first-patient-dosed-in-phase-ii-clinical-trial-of-leniolisib-for--phar-20250320monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-bu-phar-20250313monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-reports-on-results-of-the-2025-extraordinary-general-meeting-of-shareholder-phar-20250304monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-to-participate-in-march-investor-conference-phar-20250228monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-phar-20250227monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-technologies-b-v-increases-its-ownership-in-abliva-ab-publ-to-92-70-percent-phar-20250220monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-to-participate-in-february-investor-conference-phar-20250210monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-technologies-b-v-declares-unconditional-and-completes-the-recommended-cash-offer--phar-20250207monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-to-convene-extraordinary-general-meeting-of-shareholders-phar-20250121monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-to-nominate-biopharmaceutical-leader-fabrice-chouraqui-as-new-executive-director--phar-20250121monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-announces-public-cash-offer-to-the-shareholders-of-abliva-ab-phar-20241215monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-announces-positive-topline-data-in-pediatric-clinical-trial-of-leniolisib-phar-20241211monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-to-participate-in-november-investor-conference-phar-20241105monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-reports-third-quarter-2024-financial-results-and-provides-business-update-phar-20241024monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-to-report-third-quarter-2024-financial-results-on-october-24-phar-20241010monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-announces-start-of-phase-ii-clinical-trial-of-leniolisib-for-primary-immuno-phar-20241010monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-announces-marketing-authorization-in-the-u-k-for-joenja-leniolisib-phar-20240926monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-to-participate-in-september-investor-conferences-phar-20240904monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-reports-second-quarter-and-first-half-2024-financial-results-and-provides-b-phar-20240801monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-to-report-second-quarter-and-first-half-2024-financial-results-on-august-1-phar-20240718monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-to-participate-in-june-investor-conferences-phar-20240603monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-provides-update-on-ongoing-regulatory-review-of-leniolisib-for-the-treatmen-phar-20240530monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-reports-on-results-of-the-2024-annual-general-meeting-of-shareholders-phar-20240521monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-to-participate-in-may-investor-conference-phar-20240520monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-announces-the-early-redemption-of-the-remaining-outstanding-125-million-con-phar-20240515monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-reports-first-quarter-2024-financial-results-and-provides-business-update-phar-20240508monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-to-report-first-quarter-2024-financial-results-on-may-8-phar-20240424monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-to-be-honored-as-industry-innovator-at-national-organization-for-rare-disorders-n-phar-20240424monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-announces-the-repurchase-of-outstanding-125-million-convertible-bonds-due-2-phar-20240419monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-announces-the-placement-of-100-million-convertible-bonds-due-2029-phar-20240418monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-announces-the-launch-of-an-offering-of-approximately-100-million-convertibl-phar-20240418monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-announces-completion-of-enrollment-in-pediatric-clinical-trial-of-leniolisib-phar-20240408monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-announces-the-2024-annual-general-meeting-of-shareholders-phar-20240404monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-announces-the-filing-of-its-2023-annual-report-and-form-20-f-phar-20240404monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-to-participate-in-april-investor-conferences-phar-20240403monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-reports-fourth-quarter-and-full-year-2023-financial-results-phar-20240314monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-to-report-fourth-quarter-and-full-year-2023-financial-results-on-march-14-phar-20240229monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-to-participate-in-february-investor-conferences-phar-20240208monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-announces-updated-full-year-2023-guidance-and-joenja-u-s-launch-update-phar-20240108monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-announces-development-plans-for-leniolisib-for-additional-primary-immunodef-phar-20231213monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-announces-first-patient-dosed-in-pediatric-clinical-trial-for-children-aged-1-to--phar-20231121monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-provides-updates-on-ema-regulatory-review-of-leniolisib-maa-and-plans-to-fi-phar-20231110monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-announces-presentations-at-international-primary-immunodeficiencies-congres-phar-20231107monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-to-participate-in-november-investor-conferences-phar-20231101monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-reports-third-quarter-2023-financial-results-phar-20231026monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-to-report-third-quarter-2023-financial-results-on-october-26-phar-20231012monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-reports-on-results-of-the-2023-extraordinary-general-meeting-of-shareholder-phar-20230925monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-reports-on-preliminary-financial-results-2013-phar-20140306monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-and-salix-announce-extension-of-pdufa-action-date-for-ruconest-r-phar-20140224monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-and-santarus-announce-new-data-from-open-label-repeat-treatment-study-with-rucone-phar-20131108monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-reports-on-financial-results-for-the-first-nine-months-of-2013-phar-20131107monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-announces-eu12-0-million-private-equity-placement-with-institutional-investors-phar-20131009monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-s-marketing-authorization-application-for-rhucin-rhc1inh-accepted-for-review-by-e-phar-20060817monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-presents-rhc1inh-update-at-international-meetings-phar-20051117monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-candidate-for-amsterdam-midkap-index-on-euronext-phar-20051109monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-announces-results-for-first-nine-months-2005-phar-20051103monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-appoints-new-head-of-finance-and-administration-phar-20051024monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-presents-human-lactoferrin-results-at-international-conference-phar-20051019monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-expands-clinical-development-of-recombinant-human-c1-inhibitor-for-new-indication-phar-20050929monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-to-present-at-ubs-global-life-sciences-conference-phar-20050920monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-s-recombinant-human-fibrinogen-selected-for-u-s-army-project-phar-20050831monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-announces-first-half-2005-results-phar-20050819monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-receives-japanese-patent-on-recombinant-human-lactoferrin-phar-20050810monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-announces-research-collaboration-with-novathera-phar-20050712monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-to-receive-milestone-payment-from-esteve-phar-20050704monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-announces-partnership-with-agresearch-for-human-lactoferrin-phar-20050630monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-announces-key-appointments-to-strengthen-organization-phar-20050624monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-announces-first-quarter-2005-results-phar-20050506monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-presents-phase-ii-iii-clinical-results-with-recombinant-human-c1-inhibitor-phar-20050502monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-receives-over-800-000-shares-from-trust-foundation-phar-20050429monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-announces-annual-shareholders-meeting-phar-20050422monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-to-present-at-ubs-northern-europe-conference-phar-20050411monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-included-in-next-150-index-on-euronext-phar-20050324monthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-initates-phase-iii-clinical-trial-for-c1-inhibitor-in-europe-phar-20040428monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-to-host-immunology-day-to-showcase-promising-initial-clinical-data-i-cgem-20260526monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-cgem-20250821monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-to-present-results-from-rezilient1-a-phase-1-2-trial-of-zipalertinib-cgem-20250423monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-cgem-20250224monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-to-participate-in-fireside-chat-at-the-guggenheim-securities-smid-ca-cgem-20250130monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-announces-preclinical-data-for-cln-978-a-cd19-directed-t-cell-engage-cgem-20241114monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-to-participate-in-fireside-chat-at-stifel-2024-healthcare-conference-cgem-20241105monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-to-present-preclinical-data-for-cln-978-a-cd19-directed-t-cell-engag-cgem-20241104monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-announces-submission-of-investigational-new-drug-application-to-u-s--cgem-20240916monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-presents-positive-updated-data-from-module-c-of-zipalertinib-pivotal-cgem-20240914monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-cgem-20240828monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-to-participate-in-fireside-chat-at-td-cowen-5th-annual-oncology-inno-cgem-20240524monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-announces-appointment-of-mary-kay-fenton-as-chief-financial-officer-cgem-20240429monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-to-present-clinical-data-from-phase-1-study-evaluating-novel-anti-mi-cgem-20240424monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-announces-strategic-expansion-into-autoimmune-diseases-cgem-20240416monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-announces-u-s-fda-clearance-of-investigational-new-drug-application-for--cgem-20240301monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-participate-in-upcoming-investor-conferences-cgem-20240227monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-cgem-20231218monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-announces-first-patient-dosed-in-phase-1-trial-evaluating-cln-617-a-nove-cgem-20231214monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-present-data-demonstrating-progress-across-its-broad-immunotherapy-pi-cgem-20231103monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-participate-in-upcoming-investor-conferences-cgem-20231030monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-participate-in-upcoming-investor-conferences-cgem-20230906monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-announces-first-patient-dosed-in-phase-1-trial-evaluating-cln-978-a-nove-cgem-20230809monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-participate-in-upcoming-investor-conferences-cgem-20230731monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-participate-in-stifel-s-2023-targeted-oncology-days-cgem-20230420monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-announces-u-s-fda-clearance-of-investigational-new-drug-application-for--cgem-20230327monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-participate-in-cowen-s-43rd-annual-health-care-conference-cgem-20230227monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-participate-in-the-guggenheim-5th-annual-oncology-conference-and-the--cgem-20230202monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cgem-20230201monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-announces-u-s-fda-clearance-of-investigational-new-drug-application-for--cgem-20230124monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cgem-20230103monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cgem-20221202monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cgem-20221101monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-participate-in-upcoming-investor-conferences-cgem-20221101monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cgem-20221003monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-participate-in-the-hc-wainwright-global-investment-conference-and-the-cgem-20220907monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cgem-20220901monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-announces-appointment-of-jacquelyn-sumer-as-chief-legal-officer-cgem-20220815monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cgem-20220801monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-participate-in-btig-biotechnology-conference-and-canaccord-growth-con-cgem-20220801monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-participate-in-william-blair-biotech-focus-conference-cgem-20220705monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cgem-20220701monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cgem-20220601monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-host-analyst-and-investor-briefing-at-2022-asco-annual-meeting-cgem-20220526monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-present-at-h-c-wainwright-global-investment-conference-cgem-20220519monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cgem-20220502monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-present-updated-data-highlighting-the-therapeutic-potential-of-cln-08-cgem-20220427monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-participate-in-upcoming-virtual-healthcare-conferences-cgem-20220405monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cgem-20220404monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-announces-clinical-and-regulatory-update-for-cln-081-in-nsclc-egfr-exon--cgem-20220328monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-host-cln-081-regulatory-update-webinar-on-march-28-2022-cgem-20220317monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-present-at-the-barclays-global-healthcare-conference-cgem-20220309monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-expands-leadership-team-and-board-of-directors-with-appointments-of-jeff-cgem-20220228monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-present-at-svb-leerink-s-11th-annual-global-healthcare-conference-cgem-20220207monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-forms-strategic-collaboration-agreement-with-mount-sinai-to-advance-oral-cgem-20220110monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-present-at-upcoming-virtual-investor-conferences-cgem-20220105monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-provide-clinical-update-for-cln-081-in-nsclc-egfr-exon-20-patients-cgem-20211213monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-participate-in-the-evercore-isi-4th-annual-healthconx-conference-cgem-20211122monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-participate-in-upcoming-investor-conferences-cgem-20210908monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-participate-in-the-41st-annual-canaccord-genuity-growth-conference-cgem-20210805monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-inc-to-participate-in-the-20th-annual-needham-virtual-healthcare-confere-cgem-20210407monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-inc-to-participate-in-the-h-c-wainwright-global-life-sciences-conference-cgem-20210302monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20260605monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-oric-20260527monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20260501monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-investors-have-opportunity-to-join-oric-pharmaceuticals-inc-fraud-investigation-with--oric-20260422monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-inc-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-mo-oric-20260406monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20260403monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20260306monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20260206monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-oric-20260106monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-presents-potential-best-in-class-profile-for-enozertinib-with-robust--oric-20251206monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20251205monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-presents-enozertinib-data-in-nsclc-patients-with-her2-exon-20-mutatio-oric-20251205monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-eg-oric-20251203monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-enozertinib-oric-114-poster-presentation-in-her2-exon-20-ns-oric-20251201monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-the-8th-annual-evercore-healthcare-conference-oric-20251124monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-completion-of-dose-exploration-portion-of-oric-944-phase-1b-oric-20251113monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20250905monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-oric-20250827monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20250801monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20250703monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20250606monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-potentially-best-in-class-preliminary-efficacy-and-safety-d-oric-20250528monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-oric-20250527monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-present-initial-data-from-phase-1b-trial-of-oric-944-in-combinatio-oric-20250527monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20250502monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-presents-preclinical-data-to-support-the-potential-of-oric-944-as-a-b-oric-20250428monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20250404monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-oric-20250331monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-oric-944-preclinical-presentation-at-the-2025-american-asso-oric-20250325monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20250307monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20250207monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-oric-20250127monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-provides-early-phase-1b-combination-data-for-oric-944-operational-hig-oric-20250113monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-clinical-supply-agreement-to-evaluate-oric-114-in-combinati-oric-20250113monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-oric-20250106monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20250103monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-oric-20241125monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-oric-20241104monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20241101monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-presents-data-further-supporting-potential-best-in-class-profile-of-o-oric-20241023monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-presentation-at-the-eortc-nci-aacr-symposium-on-molecular-t-oric-20241009monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20241004monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20240906monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-oric-20240826monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-expands-leadership-team-with-the-appointment-of-keith-lui-as-senior-v-oric-20240805monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20240802monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-multiple-clinical-collaborations-with-strategic-partners-to-oric-20240716monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20240705monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20240607monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-oric-20240529monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20240503monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-first-patients-dosed-across-three-expansion-cohorts-in-phas-oric-20240415monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-presents-preclinical-data-on-two-programs-at-the-2024-american-associ-oric-20240408monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20240405monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-oric-20240404monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-present-at-the-leerink-partners-global-biopharma-conference-oric-20240306monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-multiple-presentations-at-the-2024-american-association-for-oric-20240305monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20240301monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-the-citi-2024-virtual-oncology-leadership-summit-oric-20240214monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20240202monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-oric-20240131monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-provides-initial-phase-1b-data-for-oric-944-operational-highlights-fo-oric-20240108monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-oric-20240102monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20231201monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-oric-20231109monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20231103monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-present-initial-phase-1b-clinical-data-for-oric-533-in-multiple-my-oric-20231102monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-present-initial-phase-1b-clinical-data-for-oric-114-in-egfr-her2-e-oric-20231017monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20231006monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-the-2023-cantor-global-healthcare-conference-oric-20230920monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20230901monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-oric-20230830monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20230804monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20230602monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-the-jefferies-healthcare-conference-oric-20230531monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20230505monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference-oric-20230425monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-presents-promising-preclinical-data-on-two-programs-at-the-2023-ameri-oric-20230418monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-multiple-presentations-at-the-2023-american-association-for-oric-20230314monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference-oric-20230306monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20230203monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-oric-20230201monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-oric-20230103monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-presents-preclinical-data-demonstrating-oric-533-as-a-potential-best--oric-20221213monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-present-at-the-jefferies-london-healthcare-conference-oric-20221108monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-present-preclinical-data-on-cd73-inhibitor-program-in-multiple-mye-oric-20221103monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-oric-20221007monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-oric-20220901monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-present-at-the-jefferies-healthcare-conference-oric-20220602monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-present-at-the-h-c-wainwright-global-investment-conference-oric-20220517monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-presents-promising-preclinical-data-on-three-programs-at-the-2022-ame-oric-20220412monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-host-fourth-quarter-and-full-year-2021-financial-results-and-opera-oric-20220317monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-multiple-presentations-at-the-2022-american-association-for-oric-20220308monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-the-guggenheim-2022-oncology-conference-oric-20220202monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-regulatory-clearance-of-clinical-trial-application-for-oric-oric-20220125monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-oric-20220104monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-presents-data-supporting-the-therapeutic-potential-of-oric-533-in-mul-oric-20211213monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-host-ash-conference-call-with-key-opinion-leader-to-discuss-potent-oric-20211209monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-oric-20211111monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-present-update-on-cd73-inhibitor-program-in-multiple-myeloma-at-th-oric-20211104monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-multiple-data-presentations-at-aacr-nci-eortc-virtual-inter-oric-20210930monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-update-on-oric-533-a-highly-potent-orally-bioavailable-smal-oric-20210921monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-oric-20210901monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-present-at-jefferies-virtual-healthcare-conference-oric-20210526monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-host-conference-call-with-kol-to-review-initial-data-being-present-oric-20210525monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-present-initial-data-from-ongoing-phase-1b-study-of-oric-101-in-co-oric-20210428monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-presents-posters-on-four-programs-at-the-2021-american-association-fo-oric-20210412monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-present-posters-on-four-programs-at-the-2021-american-association--oric-20210310monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-oric-20210302monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-oric-20210203monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-oric-20210104monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-initiation-of-expansion-cohorts-in-phase-1b-study-of-oric-1-oric-20201221monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-closing-of-public-offering-and-full-exercise-of-underwriter-oric-20201117monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-pricing-of-upsized-public-offering-oric-20201113monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-proposed-public-offering-of-common-stock-oric-20201110monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-oric-20201109monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-presentation-of-preclinical-data-on-glucocorticoid-receptor-oric-20201009monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-oric-20200902monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-expands-precision-oncology-pipeline-with-exclusive-worldwide-license--oric-20200805monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-host-second-quarter-2020-financial-results-conference-call-oric-20200804monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-presents-preclinical-data-on-glucocorticoid-receptor-antagonist-and-c-oric-20200622monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-five-presentations-at-the-2020-american-association-for-can-oric-20200527monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-to-present-at-the-jefferies-2020-global-healthcare-conference-oric-20200526monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-presents-preclinical-data-on-cd73-inhibitor-at-the-american-associati-oric-20200427monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-announces-pricing-of-initial-public-offering-oric-20200424monthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-appoints-ashraf-hanna-phd-md-as-chief-executive-officer-and-darcy-moo-oric-20160810monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-announces-sale-of-approximately-69-million-of-shares-through-its-at-the-sana-20260515monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-sana-20260107monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-june-2025-investor-conferences-sana-20250528monthly0.5https://www.biopharmawatch.com/news/SANA/sana-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-sana-biotechnology-inc-i-sana-20250520monthly0.5https://www.biopharmawatch.com/news/SANA/sana-deadline-tomorrow-rosen-leading-investor-counsel-encourages-sana-biotechnology-inc-in-sana-20250519monthly0.5https://www.biopharmawatch.com/news/SANA/sana-investors-have-the-opportunity-to-lead-the-sana-biotechnology-securities-fraud-lawsui-sana-20250518monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-inc-class-action-levi-korsinsky-reminds-sana-biotechnology-inc-investor-sana-20250516monthly0.5https://www.biopharmawatch.com/news/SANA/sana-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-sana-biotechnology-inc-i-sana-20250515monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-the-bofa-securities-2025-healthcare-conference-sana-20250512monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-inc-class-action-the-gross-law-firm-reminds-sana-biotechnology-inc-inve-sana-20250512monthly0.5https://www.biopharmawatch.com/news/SANA/sana-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-sana-biotechnology-inc-i-sana-20250509monthly0.5https://www.biopharmawatch.com/news/SANA/sana-lawsuit-alert-levi-korsinsky-notifies-sana-biotechnology-inc-investors-of-a-class-act-sana-20250508monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-inc-sued-for-securities-law-violations-investors-should-contact-the-gro-sana-20250507monthly0.5https://www.biopharmawatch.com/news/SANA/sana-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-sana-biotechnology-inc-i-sana-20250504monthly0.5https://www.biopharmawatch.com/news/SANA/sana-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-sana-biotechnology-inc-i-sana-20250427monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-inc-sued-for-securities-law-violations-investors-should-contact-levi-ko-sana-20250421monthly0.5https://www.biopharmawatch.com/news/SANA/sana-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-sana-biotechnology-inc-i-sana-20250420monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losse-sana-20250416monthly0.5https://www.biopharmawatch.com/news/SANA/sana-investors-have-the-opportunity-to-lead-the-sana-biotechnology-securities-fraud-lawsui-sana-20250416monthly0.5https://www.biopharmawatch.com/news/SANA/sana-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-sana-biotechnology-inc-i-sana-20250413monthly0.5https://www.biopharmawatch.com/news/SANA/sana-investors-have-the-opportunity-to-lead-the-sana-biotechnology-securities-fraud-lawsui-sana-20250413monthly0.5https://www.biopharmawatch.com/news/SANA/sana-stockholders-should-contact-shareholder-rights-law-firm-robbins-llp-for-information-o-sana-20250407monthly0.5https://www.biopharmawatch.com/news/SANA/sana-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-sana-biotechnology-inc-i-sana-20250406monthly0.5https://www.biopharmawatch.com/news/SANA/sana-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-sana-biotechnology-inc-i-sana-20250330monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-inc-stockholder-news-robbins-llp-reminds-investors-of-the-class-action--sana-20250326monthly0.5https://www.biopharmawatch.com/news/SANA/sana-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-sana-biotechnology-inc-i-sana-20250324monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-the-cowen-45th-annual-health-care-conference-sana-20250224monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-sana-20250108monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-announces-positive-clinical-results-from-type-1-diabetes-study-of-islet-sana-20250107monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-announces-fast-track-designation-for-sc291-in-relapsed-refractory-syste-sana-20241202monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-december-2024-investor-conferences-sana-20241125monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-announces-increased-focus-on-type-1-diabetes-and-b-cell-mediated-autoim-sana-20241104monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-the-goldman-sachs-cell-therapy-day-conference-sana-20240930monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-september-2024-investor-conferences-sana-20240829monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-appoints-accomplished-drug-developer-dhaval-patel-m-d-ph-d-as-executive-sana-20240826monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-highlights-publication-in-nature-biotechnology-of-novel-in-vivo-preclin-sana-20240521monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-may-and-june-2024-investor-conferences-sana-20240506monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-the-cowen-44th-annual-health-care-conference-sana-20240228monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-announces-publication-of-preclinical-diabetes-data-in-cell-stem-cell-de-sana-20240213monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-announces-closing-of-upsized-public-offering-and-full-exercise-of-under-sana-20240212monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-announces-proposed-public-offering-of-common-stock-sana-20240207monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-announces-fda-clearance-of-investigational-new-drug-application-for-sc2-sana-20240105monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-sana-20240103monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-highlights-preclinical-data-supporting-tumor-control-and-immune-evasion-sana-20231211monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-publishes-early-clinical-data-showing-that-sc291-a-cd19-directed-alloge-sana-20231201monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-november-and-december-2023-investor-conferences-sana-20231121monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-announces-fda-clearance-of-investigational-new-drug-application-for-sc2-sana-20231109monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-announces-five-presentations-at-the-65th-american-society-of-hematology-sana-20231102monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-september-2023-investor-conferences-sana-20230830monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-highlights-preclinical-data-from-hypoimmune-and-fusogen-platforms-at-th-sana-20230616monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-june-2023-investor-conferences-sana-20230531monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-announces-preclinical-data-published-in-nature-biotechnology-demonstrat-sana-20230508monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-may-2023-investor-conferences-sana-20230503monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-announces-the-acceptance-of-six-abstracts-for-presentation-at-the-ameri-sana-20230502monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-host-research-development-day-sana-20230424monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-highlights-preclinical-hypoimmune-data-for-its-allogeneic-car-t-platfor-sana-20230419monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-announces-preclinical-data-published-in-nature-communications-demonstra-sana-20230413monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-announces-the-acceptance-of-four-abstracts-for-presentation-at-the-2023-sana-20230314monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-the-cowen-43rd-annual-health-care-conference-sana-20230301monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-the-guggenheim-healthcare-talks-5th-annual-oncology-confe-sana-20230202monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-sana-20230103monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-highlights-hypoimmune-allogeneic-car-t-cell-programs-and-in-vivo-techno-sana-20221211monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-confirms-key-program-timelines-and-announces-portfolio-prioritization-sana-20221129monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-tops-biospace-s-2023-best-places-to-work-ranking-in-small-employer-cate-sana-20221114monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-announces-several-preclinical-data-presentations-at-the-64th-american-s-sana-20221103monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-september-2022-investor-conferences-sana-20220909monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-presents-data-at-isscr-2022-annual-meeting-showing-survival-of-transpla-sana-20220617monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-announces-multiple-preclinical-data-presentations-to-showcase-its-hypoi-sana-20220613monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-the-goldman-sachs-43rd-annual-global-healthcare-conferenc-sana-20220607monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-congratulates-senior-vice-president-and-head-of-t-cell-therapeutics-ter-sana-20220512monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-the-bofa-securities-2022-healthcare-conference-sana-20220504monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-data-from-multiple-preclinical-studies-at-the-american-socie-sana-20220502monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-the-32nd-annual-oppenheimer-healthcare-conference-sana-20220309monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-preclinical-data-on-its-engineered-hypoimmune-allogeneic-car-sana-20220308monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-obtains-exclusive-license-from-national-institutes-of-health-for-cd22-c-sana-20220111monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-iaso-biotherapeutics-and-innovent-biologics-announce-non-exclusive-lice-sana-20220110monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-sana-20220104monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-presentations-at-2021-ash-annual-meeting-highlight-progress-with-platfo-sana-20211212monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-pre-clinical-data-at-2021-american-society-of-hematology-ann-sana-20211104monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-obtains-a-non-exclusive-license-to-crispr-cas12b-gene-editing-technolog-sana-20211019monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-the-morgan-stanley-19th-annual-global-healthcare-conferen-sana-20210907monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-enters-long-term-lease-to-establish-manufacturing-facility-to-enable-it-sana-20210714monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-presents-data-at-isscr-2021-virtual-annual-meeting-showing-survival-of--sana-20210626monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-during-plenary-sessions-at-isscr-2021-virtual-annual-meeting-sana-20210614monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-the-goldman-sachs-42nd-annual-global-healthcare-conferenc-sana-20210602monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-at-the-bofa-securities-2021-healthcare-conference-sana-20210504monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-to-present-pre-clinical-data-at-american-society-of-gene-cell-therapy-a-sana-20210427monthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-presents-preclinical-data-at-american-association-for-cancer-research-a-sana-20210409monthly0.5https://www.biopharmawatch.com/news/SANA/sana-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-option-sana-20210208monthly0.5https://www.biopharmawatch.com/news/SANA/sana-announces-upsized-pricing-of-initial-public-offering-sana-20210204monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-leadership-transition-iart-20260505monthly0.5https://www.biopharmawatch.com/news/IART/integra-shareholder-alert-kaskela-law-firm-announces-shareholder-investigation-of-integra--iart-20260421monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-unveils-new-real-world-evidence-highlighting-primatrix-utilization-iart-20260407monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-welcomes-policy-advancements-supporting-medicare-beneficiary-access-iart-20251125monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-second-quarter-2025-financial-results-iart-20250731monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-second-quarter-2025-financial-results-conference-call-on-july-iart-20250714monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-first-quarter-2025-financial-results-iart-20250505monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-first-quarter-2025-financial-results-conference-call-on-may-5-iart-20250418monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-oppenheimer-35th-annual-healthcare-medtech-services-iart-20250313monthly0.5https://www.biopharmawatch.com/news/IART/integra-alert-bragar-eagel-squire-p-c-is-investigating-integra-lifesciences-holdings-corp--iart-20250226monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-fourth-quarter-and-full-year-2024-financial-results-and-provi-iart-20250225monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-fourth-quarter-and-full-year-2024-financial-results-conferenc-iart-20250204monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-integra-institute-for-healthcare-professionals-hcps-iart-20250114monthly0.5https://www.biopharmawatch.com/news/IART/integra-s-duraseal-dural-sealant-saves-healthcare-costs-according-to-an-economic-evaluatio-iart-20241113monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-third-quarter-2024-financial-results-iart-20241104monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-appointment-of-mojdeh-poul-as-president-and-chief-executive-iart-20241104monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-third-quarter-2024-financial-results-conference-call-on-novem-iart-20241014monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-22nd-annual-morgan-stanley-healthcare-conference-iart-20240904monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-2024-wells-fargo-healthcare-conference-iart-20240904monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-continues-to-make-progress-on-its-esg-strategy-iart-20240821monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-second-quarter-2024-financial-results-iart-20240729monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-provides-updated-plans-for-its-manufacturing-facility-in-braintree-ma-iart-20240715monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-second-quarter-2024-financial-results-conference-call-on-july-iart-20240715monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-2024-bank-of-america-healthcare-conference-iart-20240513monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-first-quarter-2024-financial-results-iart-20240506monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-spotlight-cerelink-intracranial-pressure-icp-monitoring-system-at--iart-20240430monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-reschedule-the-first-quarter-2024-financial-results-conference-cal-iart-20240418monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-completes-the-acquisition-of-acclarent-inc-iart-20240401monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-micromatrix-flex-to-provide-convenient-access-to-hard-to-rea-iart-20240311monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-leadership-transition-plan-iart-20240228monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-fourth-quarter-and-full-year-2023-financial-results-and-provi-iart-20240228monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-fourth-quarter-and-full-year-2023-financial-results-conferenc-iart-20240207monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-iart-20240105monthly0.5https://www.biopharmawatch.com/news/IART/integra-alert-bragar-eagel-squire-p-c-is-investigating-integra-lifesciences-holdings-corp--iart-20231215monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-definitive-agreement-to-acquire-acclarent-iart-20231213monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-appoints-jeff-graves-ph-d-to-board-of-directors-iart-20231212monthly0.5https://www.biopharmawatch.com/news/IART/integra-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-be-iart-20231109monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-iart-20231108monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-nasdaq-iart-deadline-alert-bernstein-liebhard-ll-iart-20231107monthly0.5https://www.biopharmawatch.com/news/IART/integra-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-be-iart-20231104monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-fot-iart-20231101monthly0.5https://www.biopharmawatch.com/news/IART/integra-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-be-iart-20231030monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-third-quarter-2023-financial-results-iart-20231025monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-iart-20231025monthly0.5https://www.biopharmawatch.com/news/IART/integra-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-be-iart-20231025monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-fot-iart-20231018monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-investors-please-contact-the-portnoy-law-firm-to-iart-20231011monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-iart-20231011monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-iart-shareholders-should-contact-robbins-llp-for-iart-20231004monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-third-quarter-2023-financial-results-conference-call-on-octob-iart-20231004monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-fot-iart-20231004monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-iart-20230927monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holding-corporation-nasdaq-iart-deadline-alert-bernstein-liebhard-llp-iart-20230925monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holding-corporation-nasdaq-iart-deadline-alert-bernstein-liebhard-llp-iart-20230920monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-fot-iart-20230920monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-iart-investor-alert-robbins-llp-reminds-investor-iart-20230918monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holding-corporation-shareholder-alert-bernstein-liebhard-llp-announce-iart-20230915monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-2023-wells-fargo-healthcare-conference-iart-20230901monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-second-quarter-2023-financial-results-iart-20230726monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-second-quarter-2023-financial-results-conference-call-on-july-iart-20230703monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-complete-enrollment-in-durasorb-monofilament-mesh-u-s-ide-s-iart-20230628monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-appoints-lea-daniels-knight-executive-vice-president-and-chief-financ-iart-20230621monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-opens-new-center-of-innovation-and-learning-iart-20230511monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-investor-day-on-may-4-2023-iart-20230503monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-first-quarter-2023-financial-results-iart-20230426monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-first-quarter-2023-financial-results-conference-call-on-april-iart-20230403monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-fourth-quarter-2022-financial-results-conference-call-on-febr-iart-20230209monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-select-preliminary-fourth-quarter-and-full-year-2022-financia-iart-20230110monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-41st-annual-j-p-morgan-healthcare-conference-iart-20221221monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-completes-the-acquisition-of-surgical-innovation-associates-iart-20221206monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-definitive-agreement-to-acquire-surgical-innovation-associa-iart-20221201monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-third-quarter-2022-financial-results-iart-20221026monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-third-quarter-2022-financial-results-conference-call-on-octob-iart-20221007monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-key-executive-appointment-iart-20221006monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-publishes-its-inaugural-esg-report-iart-20220929monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-participation-in-upcoming-investor-conferences-iart-20220823monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-the-passing-of-dr-richard-caruso-founder-and-former-chairma-iart-20220816monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-second-quarter-2022-financial-results-iart-20220727monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-appoints-renee-lo-as-director-iart-20220719monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-second-quarter-2022-financial-results-conference-call-on-july-iart-20220701monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-first-quarter-2022-financial-results-iart-20220427monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-first-quarter-2022-financial-results-conference-call-on-april-iart-20220401monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-neuragen-3d-nerve-guide-matrix-iart-20220322monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-fourth-quarter-and-full-year-2021-financial-results-and-provi-iart-20220223monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-preliminary-fourth-quarter-and-full-year-2021-revenue-and-pla-iart-20220111monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-third-quarter-2021-financial-results-iart-20211102monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-jan-de-witte-as-president-and-chief-executive-officer-iart-20211028monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-third-quarter-2021-financial-results-conference-call-on-novem-iart-20211006monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-participation-in-upcoming-investor-conferences-iart-20210902monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-second-quarter-2021-financial-results-iart-20210728monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-positive-clinical-outcomes-for-primatrix-dermal-repair-scaf-iart-20210719monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-receives-innovative-technology-contract-from-vizient-for-surgimend-co-iart-20210714monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-second-quarter-2021-financial-results-conference-call-on-july-iart-20210708monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-ceo-succession-plan-iart-20210624monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-hosts-virtual-investor-day-iart-20210520monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-virtual-investor-day-on-may-20-2021-iart-20210507monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-first-quarter-2021-financial-results-iart-20210428monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-statement-on-the-u-s-fda-safety-communication-on-acellular-dermal-mat-iart-20210419monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-first-quarter-2021-financial-results-conference-call-on-april-iart-20210408monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-appoints-shaundra-clay-as-director-iart-20210401monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-participation-in-upcoming-investor-conferences-iart-20210219monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-fourth-quarter-and-full-year-2020-financial-results-and-provi-iart-20210218monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-completes-the-acquisition-of-acell-inc-iart-20210120monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-preliminary-fourth-quarter-and-full-year-2020-revenue-resul-iart-20210114monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-completes-the-sale-of-its-extremity-orthopedics-business-to-smith-nep-iart-20210104monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-39th-annual-j-p-morgan-healthcare-conference-iart-20201221monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-definitive-agreement-to-acquire-acell-inc-iart-20201216monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-preliminary-third-quarter-revenue-results-will-host-third-q-iart-20201006monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-definitive-agreement-to-divest-its-extremity-orthopedics-bu-iart-20200929monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-september-2020-investor-conference-schedule-iart-20200902monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-receives-fda-clearance-for-specific-neurosurgery-indication-for-cusa--iart-20200722monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-preliminary-second-quarter-revenue-results-will-host-second-iart-20200709monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-key-executive-leadership-changes-iart-20200521monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-positive-clinical-results-for-integra-bilayer-wound-matrix--iart-20200515monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-may-2020-investor-conference-schedule-iart-20200511monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-announces-virtual-only-format-for-its-2020-annua-iart-20200423monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-preliminary-first-quarter-revenue-results-and-provides-an-u-iart-20200407monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-amnioexcel-plus-placental-allograft-membrane-iart-20200224monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-fourth-quarter-and-full-year-2019-financial-results-and-provi-iart-20200219monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-fourth-quarter-and-full-year-2019-financial-results-conferenc-iart-20200205monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-preliminary-fourth-quarter-and-full-year-2019-revenue-resul-iart-20200114monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-iart-20191216monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-the-piper-jaffray-31st-annual-healthcare-conference-iart-20191125monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-the-28th-annual-credit-suisse-healthcare-conference-iart-20191106monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-third-quarter-2019-earnings-results-conference-call-on-octobe-iart-20191009monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-supports-the-european-burns-association-s-share-your-care-educational-iart-20190923monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-presents-cadence-total-ankle-system-retrospective-study-abstract-at-a-iart-20190918monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-acquires-rebound-therapeutics-corporation-iart-20190909monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-the-wells-fargo-2019-healthcare-conference-and-the--iart-20190821monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-acquires-arkis-biosciences-inc-iart-20190729monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-second-quarter-2019-earnings-results-conference-call-on-july--iart-20190710monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-promotion-of-glenn-coleman-to-newly-created-role-of-chief-o-iart-20190624monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-the-jefferies-healthcare-conference-and-the-raymond-iart-20190523monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-bank-of-america-merrill-lynch-2019-healthcare-confe-iart-20190430monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-introduces-new-codman-specialty-surgical-products-at-aans-2019-iart-20190411monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-first-quarter-2019-earnings-results-conference-call-on-april--iart-20190409monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-the-approval-of-duragen-in-japan-iart-20190314monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-healthcare-conference-in-march-2019-iart-20190307monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-fourth-quarter-and-full-year-2018-financial-results-and-provi-iart-20190221monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-the-integra-panta-2-ttc-arthrodesis-nail-system-iart-20190213monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-fourth-quarter-and-full-year-2018-earnings-results-conference-iart-20190131monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-integra-titan-reverse-shoulder-system-s-iart-20190110monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-appoints-rhonda-germany-ballintyn-as-director-iart-20190109monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-agreement-with-consortium-of-focused-orthopedists-to-develo-iart-20190108monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-preliminary-fourth-quarter-2018-financial-results-iart-20190108monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-iart-20181218monthly0.5https://www.biopharmawatch.com/news/IART/integra-xt-revision-total-ankle-replacement-system-offers-innovative-solution-to-ankle-art-iart-20181120monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-appoints-eric-schwartz-corporate-vice-president-general-counsel-and-s-iart-20181112monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-healthcare-conferences-in-november-2018-iart-20181108monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-third-quarter-2018-earnings-results-conference-call-on-octobe-iart-20181011monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-the-cantor-global-healthcare-conference-iart-20180919monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-selected-for-healogics-isupply-program-iart-20180910monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-healthcare-conferences-in-september-2018-iart-20180815monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-second-quarter-2018-earnings-results-conference-call-on-july--iart-20180711monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-healthcare-conferences-in-june-2018-iart-20180523monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-prices-public-offering-of-common-stock-iart-20180509monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-proposed-public-offering-of-common-stock-iart-20180509monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-amendment-and-extension-of-credit-facility-iart-20180507monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-healthcare-conference-in-may-2018-iart-20180426monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-first-quarter-2018-earnings-results-conference-call-on-april--iart-20180411monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-fourth-quarter-and-full-year-2017-financial-results-iart-20180227monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-appoints-sravan-emany-as-vice-president-treasurer-and-investor-relati-iart-20180226monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-healthcare-conferences-in-march-2018-iart-20180221monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-fourth-quarter-2017-earnings-results-conference-call-on-febru-iart-20180201monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-preliminary-fourth-quarter-2017-financial-results-iart-20180108monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-iart-20171221monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-hosts-investor-day-2017-new-york-city-iart-20171211monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-third-quarter-2017-earnings-results-conference-call-on-octobe-iart-20171011monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-revize-revize-x-collagen-matrix-for-plastic-and-reconstructi-iart-20171006monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-surgimend-prs-meshed-collagen-matrix-for-plastic-and-reconst-iart-20171003monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-integra-surgimend-prs-meshed-collagen-matrix-for-breast-reco-iart-20171003monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-completes-the-acquisition-of-codman-neurosurgery-business-from-johnso-iart-20171002monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-first-patient-enrolled-in-cadence-total-ankle-system-post-m-iart-20170921monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-healthcare-conferences-in-september-2017-iart-20170817monthly0.5https://www.biopharmawatch.com/news/IART/integra-s-duraseal-dural-sealant-saves-healthcare-costs-according-to-a-study-recently-publ-iart-20170811monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-second-quarter-2017-earnings-results-conference-call-on-j-iart-20170711monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-hold-second-international-tissue-technologies-symposium-on-june-15-iart-20170615monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-healthcare-conferences-in-june-2017-iart-20170524monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-agreement-with-aap-to-distribute-loqteq-distal-radius-syste-iart-20170523monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-the-european-launch-of-integra-dermal-regeneration-template-iart-20170517monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-surgimend-mp-collagen-matrix-for-hernia-repair-iart-20170512monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-healthcare-conferences-in-may-2017-iart-20170503monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-first-quarter-2017-earnings-results-conference-call-on-ap-iart-20170412monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-expansion-of-credit-facility-to-include-new-700-million-ter-iart-20170404monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-commercial-expansion-of-the-cadence-total-ankle-system-iart-20170328monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-introduces-next-generation-cusa-clarity-ultrasonic-tissue-ablation-sy-iart-20170316monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-press-fit-reverse-shoulder-for-fracture-for-the-titan-modula-iart-20170315monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-barclays-global-healthcare-conference-and-oppenheim-iart-20170228monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-acceptance-of-shares-tendered-into-offer-for-derma-sciences-iart-20170223monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-fourth-quarter-and-full-year-2016-financial-results-and-updat-iart-20170223monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-fourth-quarter-2016-earnings-results-conference-call-on-f-iart-20170126monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-commences-previously-announced-cash-tender-offer-to-acquire-derma-sci-iart-20170125monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-in-jan-iart-20161219monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-regenerative-technology-investor-day-and-webcast-wednesday-de-iart-20161207monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-expansion-and-extension-of-credit-facility-to-1-5-billion-iart-20161207monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-key-executive-appointments-iart-20161205monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-28th-annual-piper-jaffray-healthcare-conference-iart-20161121monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-plans-for-a-two-for-one-stock-split-and-increase-in-authori-iart-20161027monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-organizes-hands-on-wound-workshop-on-best-practices-for-omnigraft-der-iart-20161017monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-third-quarter-2016-earnings-results-conference-call-on-oc-iart-20161006monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-first-clinical-uses-of-cadence-total-ankle-system-in-europe-iart-20160920monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-wells-fargo-2016-healthcare-conference-and-the-morg-iart-20160822monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-that-omnigraft-dermal-regeneration-matrix-was-recognized-as-iart-20160801monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-second-quarter-2016-earnings-results-conference-call-on-j-iart-20160711monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-nasdaq-iart-to-ring-the-nasdaq-stock-market-clos-iart-20160705monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-hold-first-international-tissue-technologies-symposium-on-june-16--iart-20160616monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-jefferies-2016-healthcare-conference-in-june-2016-iart-20160525monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-integra-fin-lock-glenoid-for-the-titan-modular-shoulder-syst-iart-20160523monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-receives-fda-approval-for-integra-omnigraft-dermal-regeneration-matri-iart-20160511monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-bank-of-america-merrill-lynch-2016-health-care-conf-iart-20160503monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-provides-update-for-omnigraft-commercialization-plans-including-expec-iart-20160427monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-initial-clinical-use-of-the-cadence-total-ankle-system-in-t-iart-20160426monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-agreement-with-allosource-to-commercialize-humend-human-ace-iart-20160426monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-agreement-with-vomaris-wound-care-inc-to-commercialize-volt-iart-20160414monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-first-quarter-2016-earnings-results-conference-call-on-ap-iart-20160406monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-awarded-10-3-million-department-of-defense-contract-iart-20160310monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-canaccord-11th-annual-musculoskeletal-conference-ra-iart-20160226monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-service-alliance-agreement-with-prezio-health-iart-20160225monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-fourth-quarter-and-full-year-2015-financial-results-and-issue-iart-20160225monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-fourth-quarter-2015-earnings-results-conference-call-on-f-iart-20160201monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-receives-fda-approval-of-integra-dermal-regeneration-template-idrt-fo-iart-20160107monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-34th-annual-j-p-morgan-healthcare-conference-in-jan-iart-20160104monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-27th-annual-piper-jaffray-healthcare-conference-and-iart-20151118monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-hosts-investor-day-today-november-12-2015-in-new-york-city-iart-20151112monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-third-quarter-2015-financial-results-iart-20151103monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-third-quarter-2015-earnings-results-conference-call-on-no-iart-20151007monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-completes-acquisition-of-salto-talaris-r-total-ankle-replacement-and--iart-20151002monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-files-patent-infringement-lawsuit-against-hyperbranch-medical-technol-iart-20150915monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-acquire-total-ankle-replacement-salto-talaris-r-and-silastic-toe-r-iart-20150903monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-expansion-of-credit-facility-to-1-1-billion-iart-20150901monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-wells-fargo-2015-healthcare-conference-and-the-2015-iart-20150826monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-founder-study-results-which-show-increased-rate-of-complete-iart-20150825monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-prices-public-offering-of-common-stock-iart-20150804monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-proposed-public-offering-of-common-stock-iart-20150803monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-second-quarter-2015-financial-results-iart-20150730monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-completes-acquisition-of-tei-biosciences-and-tei-medical-iart-20150720monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-second-quarter-2015-earnings-results-conference-call-on-j-iart-20150715monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-completes-spin-off-of-seaspine-iart-20150701monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-acquire-tei-biosciences-and-tei-medical-iart-20150628monthly0.5https://www.biopharmawatch.com/news/IART/integra-to-complete-tax-free-spin-off-of-seaspine-on-july-1-2015-iart-20150609monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-and-seaspine-to-present-at-the-jefferies-2015-global-healthcare-confe-iart-20150526monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-provide-historical-financials-adjusted-for-discontinued-operations-iart-20150520monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-features-new-mayfield-r-2-system-at-the-american-association-of-neuro-iart-20150501monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-names-keith-valentine-as-chief-executive-officer-of-seaspine-john-bos-iart-20150430monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-first-quarter-2015-financial-results-iart-20150430monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-three-investor-conferences-in-may-iart-20150420monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-first-quarter-2015-earnings-results-conference-call-on-ap-iart-20150410monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-the-filing-of-the-form-10-registration-statement-for-the-pl-iart-20150401monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-fourth-quarter-2014-financial-results-iart-20150224monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-the-raymond-james-institutional-investors-conferenc-iart-20150220monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-the-rbc-capital-markets-global-healthcare-conferenc-iart-20150209monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-submission-of-a-premarket-approval-supplement-application-f-iart-20150203monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-integra-r-reinforcement-matrix-iart-20150121monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-resolution-of-warning-letter-related-to-its-manufacturing-f-iart-20150120monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-fourth-quarter-2014-earnings-results-conference-call-on-f-iart-20150114monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-acquires-metasurg-s-foot-and-ankle-product-portfolio-iart-20150112monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-the-33rd-annual-j-p-morgan-healthcare-conference-in-iart-20150105monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-integra-r-meshed-dermal-regeneration-template-iart-20141217monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-the-piper-jaffray-and-oppenheimer-healthcare-confer-iart-20141120monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-fda-clearance-and-controlled-market-release-of-expandable-i-iart-20141113monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-introduces-integra-r-pocket-strip-and-integra-r-shaped-strip-dbm-impl-iart-20141112monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-strategic-portfolio-alignment-and-plans-to-create-stand-alo-iart-20141103monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-third-quarter-2014-financial-results-iart-20141103monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-completes-the-acquisition-of-microfrance-and-xomed-manual-ent-and-lap-iart-20141027monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-third-quarter-2014-earnings-results-conference-call-on-no-iart-20141009monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-full-market-release-for-the-integra-r-freedom-wrist-arthrop-iart-20140918monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-acquire-medtronic-s-microfrance-and-xomed-manual-ent-and-laparosco-iart-20140917monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-changes-within-its-orthopedics-and-tissue-technologies-busi-iart-20140902monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-the-morgan-stanley-global-healthcare-conference-in--iart-20140821monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-second-quarter-2014-financial-results-iart-20140805monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-completion-of-its-multicenter-clinical-trial-for-the-treatm-iart-20140805monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-second-quarter-2014-earnings-results-conference-call-on-a-iart-20140710monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-renewal-and-extension-of-credit-facility-iart-20140709monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-celebrates-25th-anniversary-iart-20140619monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-contract-with-premier-inc-iart-20140612monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-the-jefferies-2014-global-healthcare-conference-in--iart-20140523monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-nasdaq-iart-to-ring-the-nasdaq-stock-market-clos-iart-20140505monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-first-quarter-2014-financial-results-iart-20140501monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-chief-financial-officer-transition-iart-20140429monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-the-2014-deutsche-bank-and-bank-of-america-merrill--iart-20140422monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-first-quarter-2014-earnings-results-conference-call-on-ma-iart-20140411monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-investor-meeting-on-may-6-2014-iart-20140409monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-appoints-mark-augusti-as-corporate-vice-president-president-orthopedi-iart-20140407monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-camino-r-flex-ventricular-catheter-receives-fda-clearance-f-iart-20140404monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-integra-r-wound-matrix-thin-iart-20140325monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-first-implantation-of-integra-r-laminoplasty-system-iart-20140313monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-the-barclays-global-healthcare-conference-in-march-iart-20140303monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-receives-fda-clearance-for-integra-r-titanium-bone-wedges-iart-20140227monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-appoints-kenneth-burhop-ph-d-as-corporate-vice-president-and-chief-sc-iart-20140225monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-fourth-quarter-2013-financial-results-iart-20140225monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-the-2014-citi-global-and-rbc-capital-markets-health-iart-20140210monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-completes-acquisition-of-duraseal-product-lines-from-covidien-iart-20140115monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-fourth-quarter-2013-earnings-results-conference-call-on-f-iart-20140113monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-the-32nd-annual-j-p-morgan-healthcare-conference-iart-20131230monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-completion-of-patient-enrollment-in-clinical-study-of-integ-iart-20131223monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-neuragen-r-clinical-study-published-in-journal-of-hand-surg-iart-20131212monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-the-piper-jaffray-healthcare-and-oppenheimer-health-iart-20131118monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-prices-public-offering-of-common-stock-iart-20131107monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-proposed-public-offering-of-common-stock-iart-20131104monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-acquire-duraseal-tm-product-lines-from-covidien-iart-20131028monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-third-quarter-2013-financial-results-iart-20131028monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-update-on-optimization-initiatives-iart-20131023monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-introduces-next-generation-licox-r-brain-tissue-oxygen-monitoring-sys-iart-20131021monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-launch-of-integra-r-proximal-humeral-fracture-plate-system--iart-20131017monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-third-quarter-2013-earnings-results-conference-call-on-oc-iart-20131011monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-receives-fda-clearance-for-integra-r-laminoplasty-system-iart-20131010monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-introduction-of-integra-r-hollywood-tm-nanometalene-tm-inte-iart-20131009monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-podium-presentation-of-neuragen-r-nerve-guide-multi-center--iart-20131002monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-resolution-of-warning-letter-related-to-its-plainsboro-nj-m-iart-20130926monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-first-implantation-of-titan-tm-reverse-shoulder-system-iart-20130923monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-investor-conferences-in-september-iart-20130829monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-appoints-donald-e-morel-jr-ph-d-as-a-director-an-iart-20130827monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-iart-to-ring-the-nasdaq-stock-market-closing-bel-iart-20130820monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-second-quarter-2013-financial-results-iart-20130801monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-receives-fda-clearance-for-titan-tm-reverse-shoulder-system-iart-20130731monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-offers-surgeons-more-foot-fixation-options-with-next-generation-total-iart-20130718monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-second-quarter-2013-earnings-results-conference-call-on-a-iart-20130703monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-ce-mark-and-european-launch-of-integra-r-smart-cervical-sol-iart-20130626monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-investor-conferences-in-june-iart-20130529monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-investor-conferences-in-may-iart-20130507monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-first-quarter-2013-financial-results-iart-20130502monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-introduces-hollywood-tm-vi-spinal-fusion-system-iart-20130430monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-debuts-next-generation-camino-r-platform-at-2013-american-association-iart-20130429monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-integra-r-compact-cranial-closure-system-iart-20130429monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-first-quarter-2013-earnings-results-conference-call-on-ma-iart-20130410monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-issues-voluntary-recall-of-certain-products-manufactured-in-its-anasc-iart-20130410monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-integra-r-ipp-on-r-pip-fusion-system-surpasses-4-000-hammertoe-correc-iart-20130321monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-expands-its-product-offering-for-spinal-deformity-iart-20130320monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-expands-shoulder-product-line-with-the-introduction-of-a-proximal-hum-iart-20130320monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-announces-changes-to-its-board-of-directors-iart-20130318monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-investor-conferences-in-march-iart-20130305monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-fourth-quarter-2012-financial-results-iart-20130221monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-investor-conferences-in-february-iart-20130220monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-receives-warning-letter-in-anasco-puerto-rico-manufacturing-facility-iart-20130219monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-three-year-contract-with-premier-healthcare-alliance-iart-20130131monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-launch-of-integra-r-flowable-wound-matrix-in-europe-for-dia-iart-20130118monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-fourth-quarter-2012-earnings-results-conference-call-on-f-iart-20130115monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-31st-annual-j-p-morgan-healthcare-conference-iart-20121220monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-the-oppenheimer-23rd-annual-healthcare-conference-iart-20121203monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-led-headlight-system-receives-top-recognition-in-surgical-products-ma-iart-20121129monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-is-honored-as-one-of-new-jersey-s-2012-fifty-fastest-growing-companie-iart-20121114monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-receives-warning-letter-in-andover-england-manufacturing-facility-iart-20121113monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-investor-conferences-in-november-iart-20121108monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-now-offers-zero-profile-stand-alone-interbody-devices-for-neck-and-lu-iart-20121024monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-third-quarter-2012-financial-results-iart-20121024monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-receives-fda-clearance-for-expanded-indication-for-spinal-device-iart-20121009monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-new-integra-r-cusa-r-nxt-bone-tip-at-2012-congress-of-neurol-iart-20121009monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-third-quarter-2012-earnings-results-conference-call-on-oc-iart-20121008monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-features-new-mayfield-r-composite-series-cranial-stabilization-produc-iart-20121008monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-investor-meeting-on-october-24-2012-iart-20120920monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-two-key-executive-appointments-iart-20120904monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-investor-conferences-in-september-iart-20120831monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-iart-and-children-s-brain-tumor-foundation-to-ri-iart-20120821monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-second-quarter-2012-financial-results-iart-20120726monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-second-quarter-2012-earnings-results-conference-call-on-j-iart-20120709monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-contract-with-aap-implantate-ag-to-provide-stainless-headed-iart-20120621monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-launch-of-the-integra-r-ipp-on-r-pip-fusion-system-for-extr-iart-20120620monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-jefferies-global-healthcare-and-wells-fargo-securit-iart-20120530monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-deutsche-bank-health-care-and-bank-of-america-merri-iart-20120502monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-first-quarter-2012-financial-results-iart-20120425monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-expands-its-spinal-product-portfolio-with-a-stand-alone-zero-profile--iart-20120417monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-integra-r-cusa-r-nxt-bone-tips-at-2012-american-association--iart-20120416monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-first-quarter-2012-earnings-results-conference-call-on-ap-iart-20120406monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-launch-of-new-jarit-r-take-apart-laparoscopic-instruments-iart-20120326monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-new-shoulder-arthroplasty-device-in-italy-and-sweden-iart-20120322monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-veterinary-orthopedic-implants-iart-20120315monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-participate-in-upcoming-investor-conferences-iart-20120224monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-fourth-quarter-and-full-year-2011-financial-results-iart-20120223monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-launch-of-the-integra-r-allograft-wedge-system-for-extremit-iart-20120208monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-three-conferences-in-february-iart-20120202monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-fourth-quarter-2011-earnings-results-conference-call-on-f-iart-20120123monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-preliminary-fourth-quarter-and-full-year-2011-financial-resul-iart-20120105monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-30th-annual-j-p-morgan-healthcare-conference-iart-20120104monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-appointment-of-peter-arduini-as-president-and-chief-executi-iart-20111221monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-oppenheimer-healthcare-conference-iart-20111208monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-establishes-first-office-in-shanghai-china-iart-20111205monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-lazard-capital-markets-healthcare-and-piper-jaffray-iart-20111107monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-highlights-new-led-headlight-system-at-north-american-spine-society-a-iart-20111103monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-grows-its-presence-in-the-spinal-deformity-market-iart-20111102monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-a-zero-profile-stand-alone-interbody-device-for-neck-surgery-iart-20111102monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-analyst-forum-on-november-14-2011-iart-20111031monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-third-quarter-2011-financial-results-iart-20111031monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-features-new-led-headlight-system-at-american-college-of-surgeons-con-iart-20111024monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-third-quarter-2011-earnings-results-conference-call-on-oc-iart-20111007monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-an-anterior-cervical-plating-system-iart-20111004monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-meets-surgeon-demand-for-user-friendly-minimally-invasive-spinal-solu-iart-20111003monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-integra-tm-cusa-nxt-tm-extended-length-tip-at-2011-congress--iart-20111003monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-completes-acquisition-of-ascension-orthopedics-iart-20110926monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-agreement-to-acquire-ascension-orthopedics-iart-20110912monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-multi-year-agreement-with-premier-purchasing-partners-to-pr-iart-20110901monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-three-conferences-in-september-iart-20110831monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-an-integrated-plate-and-cervical-interbody-fixation-system-iart-20110809monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-canaccord-genuity-global-growth-conference-in-augus-iart-20110802monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-second-quarter-2011-financial-results-iart-20110728monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-expands-uni-cp-tm-compression-system-product-range-for-mid-and-hindfo-iart-20110713monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-second-quarter-2011-earnings-results-conference-call-on-j-iart-20110706monthly0.5https://www.biopharmawatch.com/news/IART/integra-announces-pricing-of-convertible-senior-notes-iart-20110610monthly0.5https://www.biopharmawatch.com/news/IART/integra-announces-private-placement-of-convertible-senior-notes-iart-20110609monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-lowers-costs-and-extends-term-of-its-600-million-credit-facility-iart-20110608monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-three-conferences-in-june-iart-20110531monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-acquires-seaspine-iart-20110524monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-three-year-contract-with-novation-to-provide-luxtec-r-surgi-iart-20110504monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-deutsche-bank-health-care-and-the-bank-of-america-m-iart-20110428monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-first-quarter-2011-financial-results-iart-20110428monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-cfo-jack-henneman-selected-as-a-2011-smartcxo-winner-by-philadelphia--iart-20110418monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-instrument-repair-partnership-with-instrumedics-iart-20110414monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-fda-clearance-for-new-indication-for-accell-evo3-r-deminera-iart-20110412monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-receives-fda-approvals-for-three-spinal-fixation-devices-iart-20110411monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-opens-new-facility-in-medina-ohio-iart-20110408monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-first-quarter-2011-earnings-results-conference-call-on-ap-iart-20110405monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-three-year-contract-with-novation-to-provide-jarit-r-steril-iart-20110404monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-features-the-integra-tm-endoscopic-gastroc-release-system-egr-product-iart-20110309monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-following-four-conferences-in-march-iart-20110224monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-fourth-quarter-and-full-year-2010-financial-results-iart-20110224monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-acquires-an-exclusive-worldwide-license-for-novel-minimally-invasive--iart-20110217monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-introduces-advanced-orthobiologics-for-extremity-reconstruction-iart-20110216monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-canaccord-genuity-musculoskeletal-conference-iart-20110207monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-introduces-allograft-cancellous-sponge-iart-20110207monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-fourth-quarter-2010-earnings-results-conference-call-on-f-iart-20110110monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-29th-annual-j-p-morgan-healthcare-conference-iart-20110104monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-expands-integra-tm-endoscopic-gastroc-release-system-egr-product-line-iart-20101214monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-piper-jaffray-s-healthcare-and-the-j-p-morgan-small-and-iart-20101119monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-introduces-xknife-r-5-stereotactic-radiosurgery-and-radiotherapy-trea-iart-20101103monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-awarded-three-contracts-with-the-broadlane-group-to-provide-dural-sub-iart-20101101monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-four-investor-conferences-in-november-iart-20101028monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-third-quarter-2010-financial-results-iart-20101028monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-featured-in-forbes-2010-list-of-america-s-100-best-small-companies-iart-20101026monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-features-integra-tm-flow-regulating-valve-mini-at-congress-of-neurolo-iart-20101019monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-introduces-the-crw-precision-tm-arc-stereotactic-system-for-use-in-st-iart-20101018monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-analyst-forum-on-november-15-2010-iart-20101015monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-new-corporate-identity-iart-20101014monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-appoints-peter-j-arduini-as-president-and-chief-operating-officer-iart-20101012monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-features-the-inforce-r-reinforcement-matrix-at-the-65th-annual-assh-m-iart-20101008monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-features-the-integra-tm-total-wrist-fusion-system-at-the-65th-annual--iart-20101007monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-the-completion-of-the-randomized-blind-multi-center-human-c-iart-20101007monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-receives-fda-clearance-for-multiple-fixation-options-for-vu-apod-tm-p-iart-20101006monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-integra-tm-endoscopic-gastroc-release-system-egr-iart-20101004monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-third-quarter-2010-earnings-results-conference-call-on-oc-iart-20100927monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-launch-of-new-surgical-spine-instruments-iart-20100915monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-five-investor-conferences-in-september-iart-20100901monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-opens-state-of-the-art-center-for-research-education-and-training-in--iart-20100820monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-introduces-the-ipassage-tm-retractor-for-minimally-invasive-spine-sur-iart-20100813monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-three-year-contract-with-gpo-amerinet-to-provide-jarit-r-su-iart-20100812monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-establishes-new-600-million-senior-secured-credit-facility-iart-20100810monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-bmo-capital-markets-10th-annual-focus-on-healthcare-con-iart-20100730monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-second-quarter-2010-financial-results-iart-20100729monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-introduces-duragen-plus-r-dural-regeneration-matrix-spinal-matrix-for-iart-20100709monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-its-second-quarter-2010-earnings-results-conference-call-on-j-iart-20100706monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reaches-milestone-of-over-800-implanted-vu-a-pod-tm-devices-iart-20100608monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-morgan-joseph-2010-best-ideas-conference-and-the-go-iart-20100604monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-will-feature-the-newest-additions-to-its-portfolio-of-hydrocephalus-m-iart-20100504monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-features-cusa-sheartip-tm-for-fibrous-tissue-at-the-aans-2010-annual--iart-20100503monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-first-quarter-2010-financial-results-iart-20100503monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-deutsche-bank-35th-annual-health-care-bank-of-ameri-iart-20100427monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-first-quarter-2010-earnings-results-conference-call-on-may-3--iart-20100405monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-introduces-four-new-products-at-the-association-of-perioperative-regi-iart-20100315monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-commercial-launch-of-paramount-r-pedicle-screw-ps-system-fo-iart-20100312monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-the-release-of-the-integra-tm-total-wrist-fusion-system-iart-20100310monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-integra-mozaik-tm-moldable-morsels-for-bone-grafting-procedu-iart-20100310monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-portfolio-of-advanced-orthobiologics-for-spine-surgery-iart-20100309monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-three-conferences-in-march-iart-20100301monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-the-newest-additions-to-its-portfolio-of-hydrocephalus-mana-iart-20100301monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-fourth-quarter-and-full-year-2009-financial-results-iart-20100301monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-donates-over-300-000-worth-of-medical-instruments-to-haiti-earthquake-iart-20100202monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-deutsche-bank-2010-small-and-mid-cap-conference-iart-20100201monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-first-two-level-surgery-with-paramount-r-pedicle-screw-syst-iart-20100125monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-first-surgery-with-coral-spinal-system-for-minimally-invasi-iart-20100122monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-fourth-quarter-2009-earnings-results-conference-call-on-march-iart-20100119monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-awarded-contract-with-healthtrust-purchasing-group-to-provide-luxtec--iart-20100119monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-first-surgery-with-paramount-r-pedicle-screw-system-for-min-iart-20100111monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-28th-annual-j-p-morgan-healthcare-conference-iart-20100106monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-new-three-year-agreement-with-premier-iart-20091221monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-contract-with-premier-purchasing-partners-iart-20091207monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-names-ken-yamada-director-of-sales-for-asia-iart-20091203monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-piper-jaffray-health-care-and-jp-morgan-smid-cap-co-iart-20091120monthly0.5https://www.biopharmawatch.com/news/IART/integra-spine-launches-the-paramount-r-minimally-invasive-system-at-the-north-american-spi-iart-20091111monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-third-quarter-2009-financial-results-iart-20091104monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-oppenheimer-20th-annual-healthcare-conference-iart-20091028monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-featured-in-forbes-2009-list-of-200-best-small-companies-iart-20091027monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-features-auragen-tm-electrodes-at-congress-of-neurological-surgeons-iart-20091027monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-cusa-sheartip-tm-for-fibrous-tissue-at-2009-congress-of-neur-iart-20091026monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-analyst-forum-on-november-16-2009-iart-20091015monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-third-quarter-2009-earnings-results-conference-call-on-novemb-iart-20091005monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-jmp-4th-annual-healthcare-focus-conference-iart-20090930monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-expands-accell-evo3-product-line-iart-20090929monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-acquires-the-assets-of-innovative-spinal-technologies-inc-iart-20090914monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-first-clinical-implant-of-integra-r-dermal-regeneration-tem-iart-20090903monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-coral-cobalt-chrome-rods-iart-20090901monthly0.5https://www.biopharmawatch.com/news/IART/integra-neurosciences-features-new-mayfield-r-infinity-xr2-radiolucent-cranial-stabilizati-iart-20090831monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-thomas-weisel-partners-healthcare-and-morgan-stanle-iart-20090828monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-the-release-of-the-panta-xl-arthrodesis-nail-iart-20090807monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-second-quarter-2009-financial-results-iart-20090806monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-canaccord-adams-global-growth-conference-in-august-iart-20090803monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-launch-of-hallu-lock-mtp-arthrodesis-system-iart-20090717monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-expands-uni-cp-compression-system-product-range-for-mid-and-hindfoot--iart-20090716monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-signs-licensing-agreement-with-organogenesis-inc-iart-20090715monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-expands-orthobiologics-product-line-iart-20090713monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-second-quarter-2009-earnings-results-conference-call-on-augus-iart-20090706monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-celebrates-20th-anniversary-iart-20090619monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-following-conferences-in-june-goldman-sachs-global--iart-20090603monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-appoints-deborah-leonetti-as-president-of-integra-surgical-iart-20090512monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-launch-of-luxtec-ultralite-pro-headlight-iart-20090511monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-first-quarter-2009-financial-results-iart-20090506monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-coral-tm-extended-tab-spinal-screw-series-iart-20090505monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-atoll-occipital-cervical-thoracic-system-iart-20090504monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-features-cusa-nxt-system-at-american-association-of-neurological-surg-iart-20090503monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-will-feature-the-new-limitorr-volume-limiting-csf-drainage-system-at--iart-20090501monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-feature-the-osvii-low-pro-flow-regulating-shunt-at-the-american-as-iart-20090501monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-two-conferences-in-may-iart-20090430monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-will-feature-the-cusa-excel-ultrasonic-tissue-ablation-system-at-the--iart-20090430monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-will-feature-the-integra-meshed-bilayer-wound-matrix-at-the-22nd-annu-iart-20090427monthly0.5https://www.biopharmawatch.com/news/IART/integra-dermal-regeneration-template-launched-in-japan-iart-20090415monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-appoints-raymond-g-murphy-to-its-board-of-direct-iart-20090413monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-first-quarter-2009-earnings-results-conference-call-on-may-6-iart-20090407monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-names-christopher-thatcher-president-of-integra-neurosciences-iart-20090303monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-two-conferences-in-march-iart-20090302monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-2008-financial-results-iart-20090302monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-in-kind-donation-of-over-1-million-in-medical-instruments-t-iart-20090218monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-two-conferences-in-february-iart-20090129monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-a-series-of-peek-optima-r-interbody-spinal-implants-iart-20090109monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-acquisition-of-omni-tract-surgical-iart-20090109monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-expects-2008-revenues-to-be-1-percent-below-prior-guidance-iart-20090109monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-27th-annual-jpmorgan-healthcare-conference-iart-20081229monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-three-conferences-in-december-iart-20081126monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-third-quarter-2008-financial-results-iart-20081107monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-two-conferences-in-november-iart-20081031monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-featured-in-forbes-2008-list-of-200-best-small-companies-iart-20081024monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-accell-evo3-the-next-generation-accell-technology-iart-20081015monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-theken-products-will-be-marketed-as-integra-spine-iart-20081014monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-launch-of-luxtec-mlx-300w-xenon-light-source-iart-20081013monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-third-quarter-2008-earnings-results-conference-call-on-novemb-iart-20081008monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-analyst-forum-on-november-17-2008-iart-20081007monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-two-conferences-in-october-iart-20081002monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-contract-with-novation-iart-20080924monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-will-feature-the-new-limitorr-volume-limiting-csf-drainage-system-at--iart-20080923monthly0.5https://www.biopharmawatch.com/news/IART/integra-announces-the-addition-of-a-low-profile-shunt-to-the-osvii-flow-regulating-shunts-iart-20080922monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-700-000-in-kind-donation-of-medical-devices-to-boston-unive-iart-20080922monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-will-feature-its-new-endorelease-endoscopic-cubital-tunnel-release-sy-iart-20080917monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-two-conferences-in-september-iart-20080901monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-names-gabrielle-wolfson-chief-information-officer-iart-20080818monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-second-quarter-2008-financial-results-iart-20080811monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-acquires-theken-spine-iart-20080804monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-two-conferences-in-august-iart-20080803monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-agreement-to-acquire-theken-spine-iart-20080724monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-second-quarter-2008-earnings-results-conference-call-on-augus-iart-20080723monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-the-launch-of-the-tibiaxys-plating-system-iart-20080626monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-features-large-qwix-fixation-and-positioning-screw-system-at-american-iart-20080625monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-piper-jaffray-europe-conference-iart-20080624monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-receives-nasdaq-notice-of-compliance-iart-20080606monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-first-quarter-2008-financial-results-iart-20080604monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-smaller-size-of-accell-total-bone-matrix-iart-20080604monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-first-quarter-2008-financial-results-conference-call-on-june--iart-20080604monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-receives-nasdaq-notice-of-non-compliance-due-to-delayed-form-10-q-iart-20080523monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-citi-investment-research-health-care-conference-iart-20080520monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-2007-financial-results-and-appointment-of-chief-financial-off-iart-20080517monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-2007-financial-results-conference-call-on-may-19-iart-20080516monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-launch-of-the-limitorr-volume-limiting-csf-drainage-system-iart-20080425monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-the-addition-of-a-new-size-for-its-integra-mozaik-moldable--iart-20080424monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-2-8-million-in-kind-donation-of-medical-devices-to-cure-int-iart-20080421monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-receives-nasdaq-notice-of-non-compliance-due-to-delayed-form-10-k-iart-20080324monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-will-feature-its-new-osteobiologics-line-for-reconstructive-surgery-a-iart-20080307monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-introduces-the-large-qwix-fixation-and-positioning-screws-iart-20080306monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-introduces-new-mayfield-pediatric-radiolucent-horseshoe-headrest-iart-20080229monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-2007-revenues-iart-20080229monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-introduces-interfix-radiosurgery-kit-for-use-with-tomotherapy-radiati-iart-20080228monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-introduces-titanium-skull-pins-for-intra-operative-brain-surgery-iart-20080227monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-five-conferences-in-march-iart-20080220monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-determination-of-entitlement-to-contingent-interest-on-conv-iart-20080220monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-upcoming-wachovia-healthcare-conference-iart-20080117monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-names-james-oti-senior-vice-president-of-global-operations-iart-20080111monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-2007-financial-results-conference-call-on-february-29-iart-20080104monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-upcoming-jpmorgan-healthcare-conference-iart-20071220monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-flowable-wound-matrix-iart-20071213monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-radionics-crw-biopsyplus-kit-iart-20071207monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-4-million-in-kind-donation-of-medical-devices-to-fiens-iart-20071205monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-acquisition-of-dental-businesses-iart-20071204monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-bmo-capital-markets-focus-on-healthcare-conference--iart-20071129monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-analyst-forum-today-iart-20071120monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-honored-as-2007-medical-device-manufacturer-of-the-year-by-medical-de-iart-20071114monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-third-quarter-2007-financial-results-iart-20071109monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-acquires-isotis-creating-a-global-leader-in-orthobiologics-iart-20071030monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-cibc-world-markets-18th-annual-healthcare-conferenc-iart-20071029monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-analyst-forum-on-november-20-2007-iart-20071015monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-partners-with-tomotherapy-to-deliver-image-guided-stereotactic-radios-iart-20071011monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-schedules-conference-call-for-friday-november-9-2007-to-discuss-third-iart-20071002monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-launch-of-new-cortical-stimulator-for-mapping-brain-functio-iart-20070921monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-ubs-global-life-sciences-conference-and-natixis-ble-iart-20070917monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-poster-presentation-periradicular-lumbar-fibrosis-what-to-d-iart-20070917monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-bone-cutting-selector-sabertip-at-2007-congress-of-neurologi-iart-20070917monthly0.5https://www.biopharmawatch.com/news/IART/integra-neurosciences-launches-duragen-xs-dural-regeneration-matrix-iart-20070916monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-launch-of-the-camino-advanced-monitor-a-state-of-the-art-mo-iart-20070911monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-resignation-of-chief-financial-officer-iart-20070907monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-bear-stearns-20th-annual-healthcare-conference-and--iart-20070904monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-aeon-shape-memory-implant-at-2007-american-podiatric-medical-iart-20070816monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-and-isotis-to-combine-creating-a-global-leader-in-orthobiologics-iart-20070807monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-second-quarter-2007-financial-results-iart-20070807monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-canaccord-adams-27th-annual-global-growth-conference-iart-20070724monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-creation-of-medical-instrument-selling-organization-formati-iart-20070713monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-launch-of-the-uni-cp-compression-plate-iart-20070712monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-features-the-advansys-mid-and-hind-foot-plating-systems-at-upcoming-a-iart-20070711monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-schedules-conference-call-for-tuesday-august-7-2007-to-discuss-second-iart-20070703monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-supports-newest-edition-of-brain-trauma-foundation-s-guidelines-for-t-iart-20070628monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-launch-of-the-integra-brain-retractor-system-iart-20070615monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-nasdaq-19th-investor-program-and-the-second-annual--iart-20070612monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-announces-closing-of-private-sale-of-165-000-000-iart-20070611monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-the-goldman-sachs-28th-annual-healthcare-conference-and-iart-20070606monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-announces-pricing-of-private-offering-of-150-000-iart-20070606monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-announces-private-offering-of-125-000-000-senior-iart-20070604monthly0.5https://www.biopharmawatch.com/news/IART/integra-mozaik-osteoconductive-scaffold-now-available-in-5-cc-size-iart-20070601monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-cusa-ultrasonic-aspirator-distribution-agreement-with-amco--iart-20070524monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-contract-with-medassets-supply-chain-systems-llc-iart-20070523monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-citigroup-s-2007-healthcare-conference-and-the-bank-of--iart-20070515monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-acquisition-of-the-pain-management-business-from-physician--iart-20070511monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-first-quarter-2007-financial-results-iart-20070509monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-closes-its-acquisition-of-lxu-healthcare-inc-iart-20070508monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-deutsche-bank-s-32nd-annual-health-care-conference-and--iart-20070420monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-releases-new-brain-mapping-software-to-treat-parkinson-s-disease-iart-20070417monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-new-proposed-tracking-codes-for-intracranial-monitoring-iart-20070416monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-showcases-its-new-accuracy-catheter-at-the-2007-american-association--iart-20070413monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-schedules-conference-call-for-wednesday-may-9-to-discuss-first-quarte-iart-20070403monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-agreement-to-acquire-lxu-healthcare-inc-iart-20070323monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-analyst-forum-on-april-16-2007-at-american-association-of-neu-iart-20070312monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-showcases-integra-mozaik-osteoconductive-scaffold-at-the-american-ass-iart-20070308monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-2006-financial-results-iart-20070228monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-contract-with-premier-purchasing-partners-iart-20070227monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-expands-credit-facility-iart-20070226monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-three-conferences-in-march-iart-20070223monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-appoints-thomas-j-baltimore-jr-to-its-board-of-d-iart-20070222monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-tenoglide-tendon-protector-sheet-iart-20070214monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-the-launch-of-the-mid-and-hind-foot-plating-systems-iart-20070213monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-the-launch-of-integra-mozaik-osteoconductive-scaffold-iart-20070212monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-adds-pet-imaging-to-its-cancer-fighting-xknife-system-iart-20070209monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-upcoming-merrill-lynch-and-first-albany-healthcare-conf-iart-20070201monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-upcoming-healthcare-conferences-iart-20070124monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-schedules-conference-call-for-wednesday-february-28-to-discuss-fourth-iart-20070122monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-miltex-business-acquires-denlite-product-line-from-welch-allyn-iart-20070103monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-jpmorgan-healthcare-conference-iart-20070103monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-the-first-patient-surgery-in-the-duragen-plus-adhesion-barr-iart-20061204monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-upcoming-healthcare-conferences-iart-20061130monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-analyst-forum-on-november-21-2006-iart-20061117monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-upcoming-healthcare-conferences-iart-20061116monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-names-jerry-corbin-to-role-of-principal-accounting-officer-iart-20061109monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-partners-with-siemens-to-deliver-stereotactic-radiosurgery-solutions-iart-20061104monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-xknife-rt-4-radiosurgery-software-at-astro-iart-20061104monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-third-quarter-2006-financial-results-iart-20061102monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-analyst-forum-on-november-21-2006-iart-20061031monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-present-at-upcoming-healthcare-conferences-iart-20061030monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-launch-of-the-mayfield-ultra-360-patient-positioning-system-iart-20061010monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-launch-of-the-mobius-tm-multi-modality-monitoring-system-iart-20061009monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-termination-of-interest-rate-swap-and-financial-impact-of-c-iart-20061003monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-completion-of-exchange-offer-for-its-2-1-2-percent-continge-iart-20061002monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-the-lumbartrak-lumbar-retraction-system-iart-20060927monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-amendment-to-exchange-offer-for-its-2-1-2-percent-contingen-iart-20060828monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-amendment-to-exchange-offer-for-its-2-1-2-percent-contingen-iart-20060815monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-second-quarter-2006-financial-results-iart-20060802monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-closes-its-acquisition-of-kinetikos-medical-inc-iart-20060802monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-appoints-neal-moszkowski-to-its-board-of-directo-iart-20060801monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-amendment-to-exchange-offer-for-its-2-1-2-percent-contingen-iart-20060731monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-exchange-offer-for-its-2-1-2-percent-contingent-convertible-iart-20060717monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-releases-the-large-uni-clip-and-2-7mm-spin-snap-off-screw-iart-20060713monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-introduces-the-qwix-compression-screw-iart-20060713monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-direct-sales-strategy-in-canada-iart-20060711monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-agreement-to-acquire-kinetikos-medical-inc-iart-20060630monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-closes-its-acquisition-of-the-miltex-companies-iart-20060512monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-first-quarter-2006-financial-results-iart-20060508monthly0.5https://www.biopharmawatch.com/news/IART/integra-announces-increased-use-of-neuragen-nerve-guide-in-complex-peripheral-nerve-injuri-iart-20060426monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-and-university-of-pennsylvania-to-present-results-of-licox-brain-tiss-iart-20060425monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-welcomes-the-cusa-excel-iart-20060424monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-agreement-to-acquire-the-miltex-companies-iart-20060420monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-introduces-the-panta-arthrodesis-nail-iart-20060322monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-the-release-of-the-b-bop-basal-osteotomy-plating-system-iart-20060321monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-record-revenues-for-the-fourth-quarter-and-full-year-2005-iart-20060305monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-closes-its-acquisition-of-the-radionics-division-of-tyco-healthcare-g-iart-20060305monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-names-maureen-bellantoni-chief-financial-officer-iart-20060110monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-establishes-new-200-million-credit-facility-iart-20051222monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-proposed-acquisition-of-the-radionics-division-of-tyco-healthcare-gro-iart-20051212monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-analyst-forum-on-november-21-2005-iart-20051102monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-record-operating-earnings-for-the-third-quarter-2005-iart-20051030monthly0.5https://www.biopharmawatch.com/news/IART/integra-neurosciences-features-accudrain-external-csf-drainage-system-at-the-congress-of-n-iart-20051012monthly0.5https://www.biopharmawatch.com/news/IART/integra-neurosciences-launches-new-non-stick-bipolar-forceps-iart-20051011monthly0.5https://www.biopharmawatch.com/news/IART/integra-foundation-donates-130-000-for-hurricane-katrina-relief-effort-iart-20051011monthly0.5https://www.biopharmawatch.com/news/IART/integra-neurosciences-features-the-integra-nph-low-flow-hydrocephalus-valve-at-the-congres-iart-20051010monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-acquires-eunoe-inc-s-intellectual-property-estate-iart-20050929monthly0.5https://www.biopharmawatch.com/news/IART/integra-introduces-line-extension-for-nerve-injury-products-iart-20050923monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-agreement-to-acquire-radionics-division-of-tyco-healthcare--iart-20050907monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-record-revenues-for-the-second-quarter-2005-iart-20050807monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-planned-restructuring-of-its-european-operations-iart-20050601monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-results-of-stockholders-vote-at-annual-meeting-iart-20050517monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-record-revenues-for-the-first-quarter-2005-iart-20050508monthly0.5https://www.biopharmawatch.com/news/IART/integra-neurosciences-launches-new-state-of-the-art-external-csf-drainage-system-iart-20050418monthly0.5https://www.biopharmawatch.com/news/IART/integra-neurosciences-launches-suturable-duragen-dural-regeneration-matrix-iart-20050417monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-fourth-quarter-and-full-year-2004-financial-results-iart-20050313monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-launch-of-newdeal-foot-and-ankle-implants-and-united-states-iart-20050216monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-first-implantation-of-the-hintegra-r-total-ankle-prosthesis-iart-20050210monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-closes-acquisition-of-newdeal-technologies-iart-20050103monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-appoints-anne-m-vanlent-to-its-board-of-director-iart-20041220monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-agreement-to-acquire-newdeal-technologies-iart-20041115monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-third-quarter-2004-financial-results-iart-20041107monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-to-host-analyst-forum-on-november-15-2004-iart-20041102monthly0.5https://www.biopharmawatch.com/news/IART/integra-neurosciences-tm-launches-mayfield-r-infinity-support-system-iart-20041019monthly0.5https://www.biopharmawatch.com/news/IART/integra-epilepsy-tm-products-receive-ce-mark-for-distribution-in-the-european-union-iart-20041019monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-and-university-of-pennsylvania-to-present-results-of-brain-tissue-oxy-iart-20041018monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-ce-mark-for-duragen-plus-tm-adhesion-barrier-matrix-iart-20041018monthly0.5https://www.biopharmawatch.com/news/IART/integra-neurosciences-launches-nph-tm-low-flow-hydrocephalus-valve-iart-20041015monthly0.5https://www.biopharmawatch.com/news/IART/integra-neurosciences-launches-neurosensor-cerebral-blood-flow-and-intracranial-pressure-s-iart-20041015monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-integra-tm-matrix-wound-dressing-at-plastic-surgery-2004-in--iart-20041012monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-receives-fda-approval-and-ce-mark-for-integra-r-dermal-regeneration-t-iart-20041011monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-new-web-site-for-physician-information-and-training-iart-20041008monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-neuromonitoring-strategic-alliance-with-cns-technology-llc--iart-20041001monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-achievement-of-product-development-milestone-by-novus-monit-iart-20041001monthly0.5https://www.biopharmawatch.com/news/IART/integra-neurosciences-launches-neurawrap-tm-nerve-protector-iart-20040908monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-kranios-tm-cranial-closure-system-iart-20040727monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-second-quarter-2004-financial-results-iart-20040727monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-extends-employment-agreement-of-chief-executive-officer-iart-20040727monthly0.5https://www.biopharmawatch.com/news/IART/integra-epilepsy-tm-products-featured-at-the-2004-national-teaching-institute-critical-car-iart-20040518monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-results-of-stockholders-vote-at-annual-meeting-iart-20040517monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-acquisition-of-mayfield-r-and-budde-r-cranial-stabilization-iart-20040510monthly0.5https://www.biopharmawatch.com/news/IART/integra-neurosciences-tm-launches-5-by-7-inch-duragen-plus-tm-dural-graft-matrix-iart-20040504monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-acquisition-of-berchtold-medizin-elektronik-gmbh-iart-20040504monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-licox-r-pmo-catheter-iart-20040503monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-first-quarter-2004-financial-results-iart-20040427monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-supports-study-on-spinal-cord-injuries-iart-20040402monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-features-recently-launched-integra-tm-bilayer-matrix-wound-dressing-a-iart-20040325monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-jarit-surgical-instruments-launches-redmond-r-b-instruments-at-2004-a-iart-20040323monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-record-operating-earnings-and-revenues-for-the-fourth-quarter-iart-20040227monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-acquisition-of-fleetwood-medical-s-sparta-implants-disposab-iart-20040203monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-jarit-surgical-instruments-awarded-surgical-instrument-agreements-by--iart-20040116monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-acquisition-of-reconstructive-technologies-inc-iart-20040115monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-acquisition-of-r-b-surgical-solutions-line-of-neurosurgical-iart-20040114monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-jarit-r-surgical-instruments-awarded-surgical-instrument-agreement-by-iart-20031113monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-record-operating-earnings-and-revenues-for-the-third-quarter--iart-20031031monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-agrees-to-acquire-spinal-specialties-from-i-flow-corporation-iart-20031029monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-new-padgett-model-s-dermatome-iart-20031027monthly0.5https://www.biopharmawatch.com/news/IART/integra-neurosciences-launches-duragen-plus-tm-dural-graft-matrix-iart-20031020monthly0.5https://www.biopharmawatch.com/news/IART/integra-neurosciences-launches-endura-no-react-dural-substitute-iart-20031020monthly0.5https://www.biopharmawatch.com/news/IART/integra-neurosciences-donates-camino-monitoring-systems-and-licox-brain-tissue-oxygen-moni-iart-20031013monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-plans-to-market-integra-dermal-regeneration-template-throug-iart-20031006monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-appoints-gerard-s-carlozzi-as-executive-vice-president-and-chief-oper-iart-20030925monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-acquisition-of-neuron-therapeutics-patent-estate-iart-20030903monthly0.5https://www.biopharmawatch.com/news/IART/integra-neurosciences-reports-positive-clinical-results-from-a-five-year-study-of-the-osvi-iart-20030805monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-record-operating-earnings-and-revenues-for-the-second-quarter-iart-20030731monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-schedules-conference-call-for-thursday-july-31-to-discuss-second-quar-iart-20030722monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-launch-of-new-and-improved-external-ventricular-drainage-sy-iart-20030501monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-1-000th-implant-of-neuragen-nerve-guide-for-peripheral-nerv-iart-20030429monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-record-pre-tax-earnings-and-revenues-for-the-first-quarter-20-iart-20030425monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-to-sell-additional-20-million-of-contingent-conv-iart-20030411monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-schedules-conference-call-for-friday-april-25-to-discuss-first-quarte-iart-20030409monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-confirms-earnings-guidance-iart-20030326monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-to-sell-100-million-of-contingent-convertible-su-iart-20030326monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-announces-proposed-100-million-contingent-conver-iart-20030326monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-acquisition-of-jarit-surgical-instruments-raises-revenue-an-iart-20030318monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-record-earnings-and-revenues-for-the-fourth-quarter-and-full--iart-20030227monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-schedules-conference-call-for-thursday-february-27-to-discuss-fourth--iart-20030219monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-ce-mark-for-the-neuragen-nerve-guide-for-repair-of-severed--iart-20030206monthly0.5https://www.biopharmawatch.com/news/IART/integra-neurosciences-awarded-neurosurgery-agreement-by-premier-inc-iart-20030102monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-record-revenues-of-30-2-million-iart-20021104monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-schedules-conference-call-for-monday-november-4-to-discuss-third-quar-iart-20021028monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-acquisition-of-padgett-instruments-inc-iart-20021022monthly0.5https://www.biopharmawatch.com/news/IART/integra-neurosciences-direct-salesforce-begins-marketing-helitene-hemostatic-agent-in-a-pa-iart-20020924monthly0.5https://www.biopharmawatch.com/news/IART/integra-neurosciences-announces-launch-of-camino-single-parameter-monitor-in-europe-and-ot-iart-20020924monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-acquisition-of-the-neurosensor-monitor-and-related-technolo-iart-20020923monthly0.5https://www.biopharmawatch.com/news/IART/integra-neurosciences-announces-fda-clearance-to-market-the-selector-integra-ultrasonic-su-iart-20020920monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-holdings-corporation-appoints-david-c-auth-to-board-of-directors-iart-20020918monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-and-reva-medical-announce-agreement-for-reva-medical-to-evaluate-inte-iart-20020806monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-second-quarter-earnings-per-share-of-0-14-on-record-revenues--iart-20020801monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-acquisition-of-signature-technologies-a-specialty-manufactu-iart-20020801monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-acquires-neurosciences-division-of-nmt-medical-iart-20020801monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-schedules-conference-call-for-tuesday-august-6-to-discuss-second-quar-iart-20020729monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-first-quarter-earnings-per-share-of-0-13-on-record-revenues-o-iart-20020508monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-schedules-conference-call-for-wednesday-may-8-to-discuss-first-quarte-iart-20020425monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-fda-approval-to-market-integra-dermal-regeneration-template-iart-20020423monthly0.5https://www.biopharmawatch.com/news/IART/integra-neurosciences-announces-fda-clearance-to-market-a-tunneled-catheter-for-the-licox--iart-20020409monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-preliminary-first-quarter-2002-revenues-forward-looking-earni-iart-20020406monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-announces-investor-forum-at-the-american-association-of-neurological--iart-20020308monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-record-fourth-quarter-and-full-year-2001-earnings-on-a-fully--iart-20020227monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-schedules-conference-call-for-wednesday-february-27-to-discuss-fourth-iart-20020220monthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-reports-preliminary-fourth-quarter-2001-revenues-product-sales-increa-iart-20020129monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-pricing-of-upsized-us-175-million-public-offering-of-co-drug-20260108monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-launch-of-us-100-million-public-offering-drug-20260106monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-present-at-piper-sandler-37th-annual-healthcare-conference-and-drug-20251125monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-expands-scientific-advisory-board-to-include-renowned-experts-in--drug-20251117monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-present-at-upcoming-conferences-drug-20250825monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-present-data-at-the-american-epilepsy-society-2024-annual-meet-drug-20241121monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-closes-us-35-million-non-brokered-private-placement-drug-20241104monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-us-35-million-non-brokered-private-placement-drug-20241018monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-proprietary-compound-bmb-201-5-ht2c-2a-mixed-agonist-demonstrated-drug-20241016monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-participation-in-upcoming-scientific-conferences-and-pa-drug-20241003monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-host-investor-analyst-kol-event-on-september-25th-drug-20240919monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-announces-effective-date-of-share-consolidation-drug-20230711monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-announces-proposed-share-consolidation-drug-20230622monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-present-at-the-20th-international-meeting-of-the-international-drug-20230410monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-non-executive-director-appointment-drug-20230217monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-resignation-of-board-member-drug-20230109monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-closing-of-non-brokered-private-placement-drug-20221203monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-non-brokered-private-placement-drug-20221128monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-appointment-of-doug-williamson-to-board-of-directors-drug-20220907monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-closing-of-4-million-unit-offering-drug-20220830monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-announces-pricing-of-overnight-marketed-offering-of-units-drug-20220824monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-announces-overnight-marketed-offering-of-units-drug-20220822monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-comments-on-recent-trading-activity-drug-20220818monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-changes-to-its-executive-leadership-team-marking-the-tr-drug-20220627monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-host-key-opinion-leader-symposium-on-dravet-syndrome-drug-20220512monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-host-symposium-on-therapeutic-developments-within-dravet-syndr-drug-20220419monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-present-at-the-oppenheimer-32nd-annual-healthcare-conference-drug-20220308monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-present-at-the-h-c-wainwright-bioconnect-conference-drug-20220104monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-present-at-the-stifel-gmp-2nd-annual-future-of-healthcare-conf-drug-20211206monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-provides-scientific-update-on-its-novel-5-ht2a-psychedelic-progra-drug-20211130monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-commences-trading-on-the-nasdaq-under-the-ticker-symbol-drug-drug-20211103monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-present-at-the-ld-micro-main-event-small-cap-investment-confer-drug-20211006monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-provides-scientific-update-drug-20210922monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-present-at-the-virtual-h-c-wainwright-23rd-annual-global-inves-drug-20210908monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-bmb-proprietary-5-ht2c-agonist-shows-significant-reduction-in-sei-drug-20210818monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-application-to-list-on-nasdaq-drug-20210616monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-appoints-new-board-member-and-expands-leadership-team-drug-20210614monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-present-at-the-h-c-wainwright-virtual-conference-psychedelics--drug-20210611monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-present-at-the-2021-ld-micro-invitational-xi-drug-20210609monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-shares-to-commence-trading-on-the-otcqb-venture-market-on-may-17--drug-20210517monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-present-at-the-benzinga-global-small-cap-conference-drug-20210511monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-appoints-industry-experts-for-key-roles-and-expands-scientific-ad-drug-20210427monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-closing-of-25-9-million-unit-offering-drug-20210317monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-bmb-proprietary-5-ht2c-agonist-shows-an-over-50-decrease-in-opioi-drug-20210315monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-to-present-at-the-stifel-gmp-healthcare-conference-healthcare-psy-drug-20210310monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-bmb-proprietary-5-ht2c-agonists-show-significant-reduction-in-bin-drug-20210303monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-inc-announces-pricing-of-public-marketed-offering-of-units-drug-20210223monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-inc-announces-marketed-public-offering-drug-20210222monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-strengthens-scientific-advisory-team-to-prepare-for-future-growth-drug-20210210monthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-announces-listing-on-canadian-stock-exchange-drug-20210205monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-resubmission-of-u-s-biologics-license-applications-for-avt05-a-proposed-alvo-20260604monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-planned-ceo-succession-and-leadership-transition-alvo-20260106monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-s-financial-calendar-for-2026-alvo-20251222monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-successfully-places-usd-108-million-senior-unsecured-convertible-bonds-in-a-signi-alvo-20251217monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-launches-100-million-senior-unsecured-convertible-bond-offering-to-continue-stron-alvo-20251216monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-alvo-faces-investor-scrutiny-amid-manufacturing-deficiencies-severely-impacting-a-alvo-20251124monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-alvo-faces-investor-scrutiny-amid-manufacturing-deficiencies-severely-impacting-a-alvo-20251119monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-alvo-faces-investor-scrutiny-amid-manufacturing-deficiencies-severely-impacting-a-alvo-20251114monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-alvo-faces-investor-scrutiny-amid-manufacturing-deficiencies-severely-impacting-a-alvo-20251112monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-alert-bragar-eagel-squire-p-c-is-investigating-alvotech-on-behalf-of-alvotech-sto-alvo-20251107monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-alert-bragar-eagel-squire-p-c-is-investigating-alvotech-on-behalf-of-alvotech-sto-alvo-20251105monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-investigation-kirby-mcinerney-llp-announces-investigation-into-potential-securiti-alvo-20251105monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-webcast-on-november-13-2025-to-report-financial-results-for-the-first-n-alvo-20251104monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-provides-update-on-the-status-of-u-s-biologics-license-application-for-avt05-alvo-20251102monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-changes-in-global-business-development-and-commercial-operations-team-alvo-20251022monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-marketing-approval-in-japan-of-three-new-biosimilars-alvo-20250919monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-meets-investors-and-participates-in-a-fireside-chat-at-the-morgan-stanley-23rd-an-alvo-20250904monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-appoints-patrik-ling-as-vp-of-investor-relations-scandinavia-alvo-20250820monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-reports-results-for-the-first-six-months-of-2025-and-provides-a-business-update-alvo-20250813monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-webcast-to-report-financial-results-for-the-first-half-of-2025-on-augus-alvo-20250806monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-expands-its-capacity-in-assembly-and-packaging-with-the-acquisition-of-ivers-lee--alvo-20250709monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-and-advanz-pharma-enter-into-european-supply-and-commercialization-agreement-for--alvo-20250701monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-s-lenders-lower-interest-on-senior-secured-term-loan-facility-alvo-20250626monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-s-private-placement-completed-with-delivery-of-sdrs-and-shares-to-investors-alvo-20250611monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-participates-in-the-goldman-sachs-global-healthcare-conference-in-miami-alvo-20250606monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-meets-investors-and-presents-at-the-goldman-sachs-global-healthcare-conference-in-alvo-20250606monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-and-dr-reddy-s-enter-into-collaboration-to-co-develop-biosimilar-candidate-to-key-alvo-20250605monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-has-carried-out-a-private-placement-of-7-500-000-sdrs-and-ordinary-shares-at-a-pr-alvo-20250605monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-intends-to-carry-out-a-private-placement-of-approximately-7-5-million-sdrs-and-or-alvo-20250604monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-completes-acquisition-of-xbrane-r-d-organization-and-biosimilar-candidate-to-cimz-alvo-20250604monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-meets-investors-and-presents-at-the-jefferies-global-healthcare-conference-2025-i-alvo-20250602monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-and-advanz-pharma-extend-strategic-partnership-to-commercialize-three-additional--alvo-20250528monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-annual-general-meeting-to-be-held-june-25-2025-alvo-20250526monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-appoints-dnb-carnegie-as-liquidity-provider-on-nasdaq-stockholm-alvo-20250519monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-the-outcome-of-the-offering-in-connection-with-the-company-s-listing-on-alvo-20250516monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-meets-investors-and-participates-in-fireside-chat-at-the-bofa-securities-healthca-alvo-20250509monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-publishes-prospectus-in-connection-with-its-listing-on-nasdaq-stockholm-alvo-20250508monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-reports-results-for-the-first-quarter-of-2025-and-provides-business-update-alvo-20250507monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-webcast-of-first-quarter-2025-financial-results-on-may-8-2025-at-8-00-a-alvo-20250502monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-appoints-dr-balaji-v-prasad-as-chief-strategy-officer-alvo-20250327monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-reports-record-results-for-2024-and-provides-business-update-alvo-20250326monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-acquires-xbrane-s-r-d-operations-in-sweden-and-further-affirms-its-global-leaders-alvo-20250320monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-and-dr-reddy-s-announce-fda-acceptance-of-biologic-license-application-for-avt03--alvo-20250318monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-meeting-investors-and-participates-in-fireside-chat-at-barclays-27th-global-healt-alvo-20250307monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-to-report-full-year-financial-results-for-2024-on-march-26-2025-and-hosts-confere-alvo-20250224monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-and-teva-announce-filing-acceptance-of-u-s-biologics-license-application-for-avt0-alvo-20250218monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-and-teva-announce-filing-acceptance-of-u-s-biologics-license-applications-for-avt-alvo-20250127monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-added-to-nasdaq-biotech-index-effective-monday-december-23-2024-alvo-20241223monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-reports-financial-results-for-the-first-nine-months-of-2024-alvo-20241113monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-attending-citi-s-global-healthcare-conference-on-december-4-2024-and-evercore-s-h-alvo-20241107monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-to-report-financial-results-for-the-first-nine-months-of-2024-on-november-13-2024-alvo-20241030monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-meeting-investors-and-presenting-at-the-jefferies-2024-london-healthcare-conferen-alvo-20241025monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-and-teva-announce-u-s-fda-approval-of-additional-presentation-of-selarsdi-ustekin-alvo-20241022monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-initiates-confirmatory-patient-study-for-avt16-a-proposed-biosimilar-to-entyvio-alvo-20240925monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-to-participate-in-the-morgan-stanley-22nd-annual-global-healthcare-conference-alvo-20240826monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-reports-record-revenues-and-adjusted-ebitda-for-the-second-quarter-and-first-six--alvo-20240815monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-to-report-financial-results-for-the-first-half-of-2024-on-august-15-2024-and-host-alvo-20240801monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-closing-of-private-debt-financing-alvo-20240711monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-positive-topline-results-from-confirmatory-patient-study-for-avt03-a-pr-alvo-20240702monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-issues-new-shares-to-holders-of-convertible-bonds-alvo-20240701monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-receives-conversion-notices-for-majority-of-convertible-bonds-alvo-20240626monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-and-advanz-pharma-sign-commercialization-agreement-for-proposed-biosimilar-to-eyl-alvo-20240618monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-and-stada-add-to-strategic-alliance-through-denosumab-partnership-alvo-20240611monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-strategic-refinancing-agreement-alvo-20240607monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-to-participate-in-jefferies-healthcare-conference-in-new-york-june-5-6-2024-alvo-20240529monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-reports-financial-results-for-first-quarter-of-2024-and-provides-a-business-updat-alvo-20240521monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-and-dr-reddy-s-enter-into-collaboration-for-commercialization-of-avt03-denosumab--alvo-20240521monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-s-a-annual-general-meeting-to-be-held-june-7-2024-alvo-20240515monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-webcast-of-first-quarter-2024-financial-results-on-may-22-2024-at-8-00--alvo-20240513monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-participation-at-bofa-securities-healthcare-conference-2024-alvo-20240502monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-topline-results-from-a-confirmatory-clinical-study-for-avt05-a-proposed-alvo-20240424monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-signs-u-s-agreement-to-expand-access-for-newly-approved-high-concentration-interc-alvo-20240419monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-and-teva-announce-u-s-fda-approval-of-selarsdi-ustekinumab-aekn-biosimilar-to-ste-alvo-20240416monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-hosts-audio-call-for-investors-at-8-15-am-edt-on-april-3-2024-alvo-20240403monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-increase-in-number-of-own-shares-alvo-20240322monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-reports-financial-results-for-full-year-2023-and-provides-a-business-update-alvo-20240320monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-webcast-of-full-year-2023-financial-results-on-march-21-2024-at-8-00-am-alvo-20240305monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-appoints-interim-chief-quality-officer-alvo-20240229monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-accepts-offer-for-the-sale-of-shares-for-a-value-of-approximately-usd-166-million-alvo-20240226monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-and-teva-announce-u-s-approval-of-simlandi-adalimumab-ryvk-injection-the-first-in-alvo-20240224monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-expected-global-market-entry-dates-for-avt04-biosimilar-to-stelara-uste-alvo-20240215monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-positive-top-line-results-from-a-pharmacokinetic-study-for-avt03-a-prop-alvo-20240129monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-provides-update-on-status-of-biologics-license-applications-for-avt02-and-avt04-alvo-20240119monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-clinical-study-results-demonstrate-therapeutic-equivalence-between-biosimilar-can-alvo-20240103monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-positive-top-line-results-from-a-pharmacokinetic-study-for-avt05-a-prop-alvo-20231129monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-reports-financial-results-for-first-nine-months-of-2023-and-provides-business-upd-alvo-20231128monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-to-report-financial-results-for-the-first-nine-months-of-2023-on-november-28-2023-alvo-20231121monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-and-jamp-pharma-announce-receipt-of-marketing-authorization-for-jamteki-avt04-the-alvo-20231114monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-to-present-at-the-jefferies-2023-london-healthcare-conference-alvo-20231107monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-provides-update-on-status-of-u-s-biologics-license-application-for-avt04-alvo-20231012monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-and-islandsbanki-enter-into-market-making-agreement-for-shares-trading-on-nasdaq--alvo-20231005monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-enters-into-exclusive-licensing-agreement-with-kashiv-biosciences-for-development-alvo-20231003monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-approval-in-japan-of-avt04-ustekinumab-a-biosimilar-to-stelara-alvo-20230925monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-to-participate-in-the-morgan-stanley-21st-annual-global-healthcare-conference-alvo-20230911monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-changes-to-the-leadership-team-alvo-20230905monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-reports-financial-results-for-first-six-months-of-2023-and-provides-business-upda-alvo-20230830monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-and-bioventure-announce-approval-of-avt02-adalimumab-in-egypt-alvo-20230829monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-to-report-financial-results-for-the-first-half-of-2023-on-august-30-2023-and-host-alvo-20230822monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-completes-100-million-convertible-bond-private-placement-alvo-20230731monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-to-participate-in-jefferies-healthcare-conference-alvo-20230531monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-to-participate-in-morgan-stanley-annual-sustainable-finance-summit-alvo-20230517monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-issues-annual-equality-report-covering-2022-alvo-20230515monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-alvo-20230510monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-s-a-annual-general-meeting-to-be-held-june-6-2023-alvo-20230505monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-alert-bragar-eagel-squire-p-c-is-investigating-alvotech-on-behalf-of-alvotech-sto-alvo-20230504monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-investigated-for-potential-securities-law-violations-by-block-leviton-llp-investo-alvo-20230503monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on--alvo-20230503monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-company-investigated-by-the-portnoy-law-firm-alvo-20230420monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-investigated-for-potential-securities-law-violations-by-block-leviton-llp-investo-alvo-20230414monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-provides-update-on-corporate-sustainability-framework-alvo-20230328monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-to-present-clinical-study-data-for-avt04-a-proposed-biosimilar-to-stelara-at-2023-alvo-20230317monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-webcast-of-2022-full-year-financial-results-at-8-00-am-et-on-march-2-20-alvo-20230228monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-and-fuji-pharma-expand-partnership-adding-a-new-biosimilar-candidate-alvo-20230113monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-completes-59-7-million-private-placement-alvo-20221216monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-shares-start-trading-on-nasdaq-iceland-main-market-alvo-20221208monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-and-stada-broaden-access-to-hukyndra-adalimumab-biosimilar-in-europe-alvo-20221207monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-changes-to-its-leadership-team-alvo-20221201monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-announces-australian-marketing-authorization-for-avt02-a-biosimilar-to-humira-alvo-20221114monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-to-present-switching-study-data-for-avt02-a-proposed-biosimilar-to-humira-at-2022-alvo-20221110monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-to-report-first-nine-months-financial-results-on-november-15-2022-and-host-busine-alvo-20221027monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-reports-first-half-2022-financial-results-and-business-update-alvo-20220831monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-to-participate-in-two-upcoming-investor-conferences-in-september-2022-alvo-20220824monthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-expands-its-board-of-directors-as-part-of-transition-from-private-to-publicly-tra-alvo-20220714monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-inc-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-f-amph-20260608monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-fourth-quarter-earnings-and-hold-conference-call-on-m-amph-20210308monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-raymond-james-2021-institutional-healthcare-co-amph-20210226monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-announces-approval-for-glucagon-for-injection-kit-1mg-amph-20201229monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-third-quarter-earnings-and-hold-conference-call-on-no-amph-20201029monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-receives-fda-approval-for-atropine-sulfate-injection-amph-20201006monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-wells-fargo-2020-virtual-healthcare-conference-amph-20200903monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-second-quarter-earnings-and-hold-conference-call-on-a-amph-20200730monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-bmo-prescriptions-for-success-healthcare-confe-amph-20200619monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-raymond-james-virtual-2020-human-healthcare-in-amph-20200612monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-inc-receives-fda-approval-for-succinylcholine-chloride-injection-amph-20200609monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-jefferies-virtual-healthcare-conference-amph-20200602monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-first-quarter-earnings-and-hold-conference-call-on-ma-amph-20200504monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-inc-receives-fda-approval-for-epinephrine-injection-usp-30mg-30m-amph-20200427monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-19th-annual-needham-virtual-healthcare-confere-amph-20200409monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-fourth-quarter-earnings-and-hold-conference-call-on-m-amph-20200305monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-receives-fda-approval-for-supplement-to-its-abbreviated-new-drug-amph-20200227monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-announces-the-receipt-of-a-minor-crl-for-epinephrine-injection-usp-30mg-30ml-1mg-amph-20200128monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-31st-annual-piper-jaffray-healthcare-conferenc-amph-20191127monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-jefferies-london-healthcare-conference-amph-20191115monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-third-quarter-earnings-and-hold-conference-call-on-no-amph-20191101monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-wells-fargo-2019-healthcare-conference-amph-20190829monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-second-quarter-earnings-and-hold-conference-call-on-a-amph-20190805monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-bmo-prescriptions-for-success-healthcare-confe-amph-20190624monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-raymond-james-life-sciences-and-medtech-health-amph-20190614monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-jefferies-2019-healthcare-conference-amph-20190531monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-bank-of-america-merrill-lynch-healthcare-confe-amph-20190510monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-first-quarter-earnings-and-hold-conference-call-on-ma-amph-20190506monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-receives-fda-approval-for-enoxaparin-sodium-injection-300mg-3ml--amph-20190319monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-fourth-quarter-earnings-and-hold-conference-call-on-m-amph-20190307monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-inc-announces-launch-of-primatene-mist-to-nationwide-retail-phar-amph-20190103monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-30th-annual-piper-jaffray-healthcare-conferenc-amph-20181120monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-jefferies-london-healthcare-conference-2018-amph-20181109monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-third-quarter-earnings-and-hold-conference-call-on-no-amph-20181106monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-third-quarter-earnings-and-hold-conference-call-on-no-amph-20181102monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-wells-fargo-healthcare-conference-2018-amph-20180829monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-second-quarter-earnings-and-hold-conference-call-on-a-amph-20180803monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-announces-approval-for-isoproterenol-hydrochloride-injection-usp-amph-20180619monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-jefferies-healthcare-conference-2018-amph-20180604monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-receives-fda-approval-for-semi-purified-heparin-at-amphastar-nan-amph-20180604monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-receives-fda-approval-for-calcium-chloride-injection-amph-20180514monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-bank-of-america-merrill-lynch-health-care-conf-amph-20180510monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-first-quarter-earnings-and-hold-conference-call-on-ma-amph-20180503monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-needham-s-17th-annual-healthcare-conference-amph-20180326monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-fourth-quarter-earnings-and-hold-conference-call-on-m-amph-20180305monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-announces-approval-for-sodium-nitroprusside-injection-usp-amph-20171219monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-announces-approval-for-medroxyprogesterone-acetate-injectable-suspension-usp-amph-20171129monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-29th-annual-piper-jaffray-healthcare-conferenc-amph-20171120monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-third-quarter-earnings-and-hold-conference-call-on-no-amph-20171031monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-announces-approval-for-neostigmine-methylsulfate-injection-usp-amph-20170925monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-receives-fda-approval-for-sodium-bicarbonate-injection-amph-20170920monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-2017-wells-fargo-securities-healthcare-confere-amph-20170830monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-second-quarter-earnings-and-hold-conference-call-on-a-amph-20170802monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-jefferies-global-healthcare-conference-amph-20170601monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-20th-annual-bank-of-america-merrill-lynch-heal-amph-20170510monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-first-quarter-earnings-and-hold-conference-call-on-ma-amph-20170504monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-fourth-quarter-earnings-and-hold-conference-call-on-m-amph-20170504monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-16th-annual-needham-healthcare-conference-amph-20170331monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-fourth-quarter-earnings-and-hold-conference-call-on-m-amph-20170309monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-announces-the-receipt-of-a-crl-for-intranasal-naloxone-for-the-emergency-treatme-amph-20170221monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-2016-piper-jaffray-healthcare-conference-amph-20161128monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-third-quarter-earnings-and-hold-conference-call-on-no-amph-20161028monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-2016-wells-fargo-healthcare-conference-amph-20160901monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-second-quarter-earnings-and-hold-conference-call-on-a-amph-20160801monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-jefferies-2016-healthcare-conference-amph-20160603monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-2016-bank-of-america-merrill-lynch-19th-annual-amph-20160506monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-first-quarter-earnings-and-hold-conference-call-on-ma-amph-20160504monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-15th-annual-needham-healthcare-conference-amph-20160411monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-fourth-quarter-earnings-and-hold-conference-call-on-m-amph-20160311monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-27th-annual-piper-jaffray-healthcare-conferenc-amph-20151124monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-third-quarter-earnings-and-hold-conference-call-on-no-amph-20151105monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-launches-amphadase-r-amph-20151020monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-net-revenues-of-53-9-million-for-the-second-quarter-ende-amph-20150812monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-second-quarter-earnings-and-hold-conference-call-on-a-amph-20150804monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-receives-approval-for-amphadase-r-supplement-marking-the-first-p-amph-20150622monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-jefferies-healthcare-conference-2015-amph-20150529monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-net-revenues-of-56-9-million-for-the-first-quarter-ended-amph-20150513monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-bank-of-america-merrill-lynch-2015-health-care-amph-20150511monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-first-quarter-earnings-and-hold-conference-call-on-ma-amph-20150507monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-present-at-the-14th-annual-needham-healthcare-conference-amph-20150414monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-revenues-of-55-9-million-for-the-fourth-quarter-ended-de-amph-20150324monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-fourth-quarter-earnings-and-hold-conference-call-on-m-amph-20150317monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-revenues-of-59-7-million-for-the-third-quarter-ended-sep-amph-20141112monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-third-quarter-earnings-and-hold-conference-call-on-no-amph-20141104monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-reports-revenues-of-49-0-million-for-the-second-quarter-ended-ju-amph-20140812monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-to-release-second-quarter-earnings-and-hold-conference-call-on-a-amph-20140806monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-announces-exercise-of-over-allotment-option-amph-20140630monthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-announces-pricing-of-initial-public-offering-amph-20140625monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-ltd-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-more-wve-20260527monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-more-inf-wve-20260326monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-fourth-quarter-and-full-year-2025-financial-results-scheduled-for-febru-wve-20260219monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-highlights-strategic-priorities-for-2026-at-the-44th-annual-j-p-morgan--wve-20260112monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-third-quarter-2025-financial-results-scheduled-for-november-10-2025-wve-20251104monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-oral-presentation-of-preclinical-data-supporting-wve-007-s-me-wve-20250620monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-appointment-of-dr-christopher-wright-as-chief-medical-officer-wve-20250528monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-first-quarter-2025-financial-results-scheduled-for-may-8-2025-wve-20250501monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-fourth-quarter-and-full-year-2024-financial-results-scheduled-for-march-wve-20250225monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-initiation-of-phase-1-inlight-clinical-trial-of-wve-007-in-ob-wve-20250206monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-43rd-annual-j-p-morgan-healthcare-conference-wve-20241216monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-upcoming-investor-conferences-wve-20241126monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-jefferies-london-healthcare-conference-wve-20241115monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-third-quarter-2024-financial-results-scheduled-for-november-12-2024-wve-20241104monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-upcoming-virtual-research-day-on-wednesday-october-30-2024-wve-20241016monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-closing-of-upsized-public-offering-of-ordinary-shares-and-pre-wve-20241001monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-chardan-8th-annual-genetic-medicines-conference-wve-20240930monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-proposed-public-offering-of-ordinary-shares-and-pre-funded-wa-wve-20240924monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-receives-fda-rare-pediatric-disease-designation-for-wve-n531-for-the-tr-wve-20240812monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-second-quarter-2024-financial-results-scheduled-for-august-8-2024-wve-20240801monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-upcoming-presentations-highlighting-novel-sirna-program-in-ob-wve-20240612monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-2024-jefferies-global-healthcare-conference-wve-20240530monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-appointment-of-dr-erik-ingelsson-as-chief-scientific-officer-wve-20240509monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-2024-rbc-capital-markets-global-healthcare-conference-wve-20240507monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-first-quarter-2024-financial-results-scheduled-for-may-9-2024-wve-20240502monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-continued-momentum-in-gsk-collaboration-and-advancements-in-s-wve-20240423monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-upcoming-investor-conferences-wve-20240327monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-fourth-quarter-and-full-year-2023-financial-results-scheduled-for-march-wve-20240228monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-highlights-recent-achievements-and-upcoming-2024-milestones-wve-20240108monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-42nd-annual-j-p-morgan-healthcare-conference-wve-20240103monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-initiation-of-dosing-in-phase-2-forward-53-trial-of-wve-n531--wve-20231215monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-proposed-public-offering-of-ordinary-shares-and-pre-funded-wa-wve-20231206monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-initiation-of-dosing-in-restoraation-clinical-program-evaluat-wve-20231206monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-third-quarter-2023-financial-results-scheduled-for-november-9-2023-wve-20231103monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-the-chardan-7th-annual-genetic-medicines-conference-wve-20230925monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conferen-wve-20230906monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-submission-of-first-clinical-trial-application-for-wve-006-th-wve-20230905monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-second-quarter-2023-financial-results-scheduled-for-august-3-2023-wve-20230727monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-joins-the-russell-2000-and-russell-3000-indexes-wve-20230626monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-highlight-leading-rna-editing-capability-and-multimodal-discovery-an-wve-20230516monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-first-quarter-2023-financial-results-scheduled-for-may-3-2023-wve-20230426monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-nucleic-acids-research-publication-highlighting-potential-bes-wve-20230420monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-the-guggenheim-genomic-medicines-and-rare-disease-days-wve-20230329monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-webcast-conference-call-of-fourth-quarter-and-full-year-2022-financi-wve-20230302monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-the-2023-virtual-svb-securities-global-biopharma-conferen-wve-20230209monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-the-stifel-2022-healthcare-conference-wve-20221109monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-webcast-conference-call-of-third-quarter-2022-financial-results-on-n-wve-20221103monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-highlight-advancements-from-prism-platform-at-upcoming-scientific-co-wve-20221003monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-chardan-s-6th-annual-genetic-medicines-conference-wve-20220927monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-host-analyst-and-investor-virtual-event-towards-the-clinic-spotlight-wve-20220916monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-webcast-conference-call-of-second-quarter-2022-financial-results-on--wve-20220728monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-the-2022-jefferies-healthcare-conference-wve-20220525monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-upcoming-investor-conferences-wve-20220510monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-webcast-conference-call-of-first-quarter-2022-financial-results-on-m-wve-20220505monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-publication-of-foundational-preclinical-data-supporting-devel-wve-20220425monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-chardan-s-6th-annual-genetic-medicines-and-cell-therapy-m-wve-20220419monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-stifel-2022-cns-days-wve-20220321monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-highlight-rna-base-editing-modality-and-alpha-1-antitrypsin-deficien-wve-20220315monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-nature-biotechnology-publication-highlighting-first-rna-base--wve-20220307monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-webcast-conference-call-of-fourth-quarter-and-full-year-2021-financi-wve-20220224monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-the-virtual-11th-annual-svb-leerink-global-healthcare-con-wve-20220209monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-two-papers-in-the-journal-nucleic-acids-research-describing-h-wve-20220202monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-the-stifel-2021-virtual-healthcare-conference-wve-20211108monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-webcast-conference-call-of-third-quarter-2021-financial-results-on-n-wve-20211101monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-initiation-of-dosing-in-phase-1b-2a-clinical-trial-of-wve-n53-wve-20210929monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-new-data-for-leading-rna-editing-capability-across-multiple-t-wve-20210928monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-the-chardan-virtual-genetic-medicines-conference-wve-20210922monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-initiation-of-dosing-in-phase-1b-2a-select-hd-clinical-trial--wve-20210909monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-highlight-rna-editing-capability-and-aatd-and-neurology-programs-at--wve-20210908monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conferen-wve-20210907monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-highlight-rna-editing-modality-and-prism-platform-advancements-durin-wve-20210907monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-webcast-conference-call-of-second-quarter-2021-financial-results-on--wve-20210726monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-initiation-of-dosing-in-phase-1b-2a-focus-c9-clinical-trial-o-wve-20210720monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-jefferies-virtual-healthcare-conference-wve-20210528monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-rbc-capital-markets-global-healthcare-virtual-conference-wve-20210510monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-webcast-conference-call-of-first-quarter-2021-financial-results-on-m-wve-20210503monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-the-third-annual-stifel-cns-day-wve-20210319monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-webcast-conference-call-of-fourth-quarter-and-full-year-2020-financi-wve-20210223monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-the-10th-annual-svb-leerink-global-healthcare-conference-wve-20210216monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-appointment-of-jonathan-rosin-as-chief-human-resources-office-wve-20201202monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-the-29th-annual-credit-suisse-healthcare-conference-wve-20201110monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-webcast-conference-call-of-third-quarter-2020-financial-results-on-n-wve-20201026monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-the-chardan-virtual-4th-annual-genetic-medicines-conferen-wve-20200928monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-highlight-preclinical-adar-editing-data-and-neurology-programs-at-ti-wve-20200915monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-the-h-c-wainwright-22nd-annual-global-investment-conferen-wve-20200910monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-highlight-prism-platform-advancements-and-preclinical-neurology-pipe-wve-20200806monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-the-jefferies-2020-virtual-healthcare-conference-wve-20200526monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-appoints-dr-ken-rhodes-as-senior-vice-president-therapeutics-discovery-wve-20200518monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-webcast-conference-call-of-first-quarter-2020-financial-results-on-m-wve-20200429monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-the-cowen-and-company-40th-annual-healthcare-conference-wve-20200219monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-preclinical-in-vivo-and-in-vitro-data-for-snp3-targeting-hun-wve-20200218monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-webcast-conference-call-of-fourth-quarter-and-full-year-2019-financi-wve-20200213monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-fast-track-designation-from-u-s-fda-for-suvodirsen-wve-20190916monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-host-analyst-and-investor-research-day-on-october-7-2019-wve-20190906monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-the-morgan-stanley-global-healthcare-conference-wve-20190826monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-appoints-mark-baldry-as-chief-commercial-officer-wve-20190806monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-initiation-of-dystance-51-a-phase-2-3-clinical-trial-of-suvod-wve-20190627monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-parent-project-muscular-dystrophy-2019-annual-conference-wve-20190612monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-the-jefferies-2019-healthcare-conference-wve-20190522monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-host-investor-conference-call-to-discuss-suvodirsen-dmd-clinical-dat-wve-20190412monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-suvodirsen-phase-1-safety-and-tolerability-data-and-phase-2--wve-20190325monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-the-cowen-39th-annual-health-care-conference-wve-20190306monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-duchenne-muscular-dystrophy-clinical-trial-selected-for-fda-complex-inn-wve-20190103monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-the-jefferies-2018-london-healthcare-conference-wve-20181108monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-develop-programs-in-rare-genetic-eye-diseases-wve-20181009monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-receives-us-orphan-drug-and-rare-pediatric-disease-designations-for-wve-wve-20180816monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-receives-positive-opinion-for-orphan-drug-designation-in-the-european-u-wve-20180702monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-parent-project-muscular-dystrophy-annual-conference-wve-20180625monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-the-jefferies-2018-healthcare-conference-wve-20180531monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-highlights-progress-on-hepatic-collaboration-with-pfizer-wve-20180507monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-data-on-als-and-ftd-programs-and-on-huntington-s-disease-at--wve-20180417monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-and-deep-genomics-form-collaboration-to-discover-novel-therapies-for-ge-wve-20180410monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-upcoming-investor-conferences-wve-20180405monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-participate-in-leerink-partners-7th-annual-global-healthcare-confere-wve-20180208monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-nasdaq-wve-to-ring-the-nasdaq-stock-market-opening-bell-wve-20160216monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-announces-publication-of-interim-analysis-of-teligan-a-china-phase-3-trial-of-teli-vor-20260514monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-vor-20260504monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-participate-in-the-44th-annual-j-p-morgan-healthcare-conference-vor-20260106monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-announces-proposed-public-offering-of-100-million-of-common-stock-vor-20251110monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vor-20251003monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-appoints-navid-z-khan-ph-d-as-chief-medical-affairs-officer-vor-20250923monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-announces-oral-presentation-of-48-week-china-phase-3-generalized-myasthenia-gravis-vor-20250917monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-participate-in-the-stifel-2025-virtual-immunology-and-inflammation-forum-vor-20250912monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-appoints-adi-osovsky-s-j-d-as-general-counsel-vor-20250902monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-participate-in-upcoming-investor-conferences-vor-20250826monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vor-20250818monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-appoints-seasoned-biotech-executive-dallan-murray-as-chief-commercial-officer-vor-20250804monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-appoints-biotech-industry-leaders-alexander-bo-cumbo-and-michel-detheux-ph-d-to-bo-vor-20250721monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-vor-20250718monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-report-inducement-grant-under-nasdaq-listing-rule-5635-c-4-vor-20250701monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-announces-175-million-private-placement-vor-20250625monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-company-u-vor-20250320monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-presents-novel-research-highlighting-opportunities-and-challenges-facing-instituti-vor-20250213monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-participate-in-the-oppenheimer-s-35th-annual-healthcare-life-sciences-conferenc-vor-20250203monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-announces-55-6-million-private-placement-vor-20241227monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-participate-in-the-stifel-2024-healthcare-conference-vor-20241112monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-third-quarter-2024-financial-results-and-provides-company-update-vor-20241107monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-participate-in-upcoming-investor-conferences-vor-20240828monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-second-quarter-2024-financial-results-and-provides-company-update-vor-20240808monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-vor-20240802monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-vor-20240709monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-vor-20240604monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-first-quarter-2024-financial-results-and-provides-company-update-vor-20240509monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-participate-in-upcoming-investor-conferences-vor-20240506monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-vor-20240503monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-participate-in-upcoming-investor-conferences-vor-20240401monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-company-u-vor-20240320monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-vor-20240305monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-participate-in-upcoming-investor-conferences-vor-20240304monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-participate-in-the-oppenheimer-34th-annual-healthcare-life-sciences-conference-vor-20240207monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-vor-20240202monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-doses-first-aml-patient-with-vcar33-allo-and-provides-corporate-update-vor-20240117monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-vor-20231221monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-vor-20231201monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-participate-in-the-jmp-securities-hematology-and-oncology-summit-vor-20231127monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-presents-positive-data-update-on-trem-cel-at-hsct-conference-vor-20231109monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-third-quarter-2023-financial-results-and-provides-company-update-vor-20231107monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-vor-20231103monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-participate-in-upcoming-investor-conferences-vor-20231103monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-vor-20231003monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-participate-in-upcoming-investor-conferences-vor-20230925monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-participate-in-upcoming-investor-conferences-vor-20230830monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-second-quarter-2023-financial-results-and-provides-company-update-vor-20230810monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-participate-in-the-wedbush-pacgrow-healthcare-conference-vor-20230801monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-participate-in-the-goldman-sachs-healthcare-conference-vor-20230605monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-first-quarter-2023-financial-results-and-provides-company-update-vor-20230511monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-participate-in-upcoming-investor-conferences-vor-20230418monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-company-u-vor-20230323monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-participate-in-upcoming-investor-conferences-vor-20230221monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-present-clinical-data-from-first-patient-treated-with-trem-cel-at-2023-tandem-m-vor-20230119monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-present-at-b-riley-securities-3rd-annual-oncology-conference-vor-20230112monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-participate-in-upcoming-investor-conferences-vor-20221122monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-third-quarter-2022-financial-results-and-provides-company-update-vor-20221110monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-participate-in-upcoming-investor-conferences-vor-20221101monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-appoints-eyal-c-attar-m-d-as-chief-medical-officer-vor-20221012monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-demonstrates-potential-of-base-and-sequential-multiplex-editing-of-hematopoietic-s-vor-20221011monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-initiates-in-house-clinical-manufacturing-at-cambridge-ma-headquarters-vor-20220928monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-participate-in-upcoming-investor-conferences-vor-20220906monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-second-quarter-2022-financial-results-and-provides-company-update-vor-20220811monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-participate-in-upcoming-investor-conferences-vor-20220801monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-successfully-demonstrates-multiplex-editing-of-hematopoietic-stem-cells-for-next-g-vor-20220610monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-participate-in-upcoming-investor-conferences-vor-20220601monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-first-quarter-2022-financial-results-and-provides-company-update-vor-20220512monthly0.5https://www.biopharmawatch.com/news/VOR/vor-to-participate-in-two-upcoming-investor-conferences-vor-20220505monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-to-present-at-keystone-symposia-precision-genome-engineering-meeting-vor-20220425monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-announces-retirement-of-chief-medical-officer-vor-20220414monthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-company-u-vor-20220314monthly0.5https://www.biopharmawatch.com/news/VOR/vor-to-participate-in-three-upcoming-investor-conferences-vor-20220228monthly0.5https://www.biopharmawatch.com/news/VOR/vor-to-participate-in-the-11th-annual-svb-leerink-global-healthcare-conference-vor-20220211monthly0.5https://www.biopharmawatch.com/news/VOR/vor-to-participate-in-two-upcoming-investor-conferences-vor-20220104monthly0.5https://www.biopharmawatch.com/news/VOR/vor-to-participate-in-the-jmp-securities-hematology-and-oncology-summit-vor-20211129monthly0.5https://www.biopharmawatch.com/news/VOR/vor-to-participate-in-piper-sandler-33rd-virtual-annual-healthcare-conference-vor-20211119monthly0.5https://www.biopharmawatch.com/news/VOR/vor-reports-third-quarter-2021-financial-results-and-provides-company-update-vor-20211110monthly0.5https://www.biopharmawatch.com/news/VOR/vor-to-present-new-data-on-its-cell-and-genome-engineering-platform-at-sitc-annual-meeting-vor-20211109monthly0.5https://www.biopharmawatch.com/news/VOR/vor-to-participate-in-two-upcoming-investor-conferences-vor-20211108monthly0.5https://www.biopharmawatch.com/news/VOR/vor-to-present-new-platform-and-preclinical-data-at-ash-vor-20211104monthly0.5https://www.biopharmawatch.com/news/VOR/vor-to-present-data-from-its-novel-cell-and-genome-engineering-platform-at-esgct-vor-20211019monthly0.5https://www.biopharmawatch.com/news/VOR/vor-strengthens-leadership-team-with-addition-of-dr-veit-schmelmer-as-svp-of-program-and-a-vor-20211012monthly0.5https://www.biopharmawatch.com/news/VOR/vor33-granted-u-s-fda-fast-track-designation-for-aml-vor-20210909monthly0.5https://www.biopharmawatch.com/news/VOR/vor-to-participate-in-three-upcoming-investor-conferences-vor-20210902monthly0.5https://www.biopharmawatch.com/news/VOR/vor-reports-second-quarter-2021-financial-results-and-provides-company-update-vor-20210809monthly0.5https://www.biopharmawatch.com/news/VOR/vor-biopharma-announces-collaboration-with-janssen-to-develop-engineered-hematopoietic-ste-vor-20210708monthly0.5https://www.biopharmawatch.com/news/VOR/vor-biopharma-names-matthew-r-patterson-as-chairman-and-promotes-tania-philipp-vor-20210611monthly0.5https://www.biopharmawatch.com/news/VOR/vor-to-develop-multi-targeted-car-ts-with-abound-bio-vor-20210610monthly0.5https://www.biopharmawatch.com/news/VOR/vor-biopharma-to-present-at-jefferies-and-goldman-sachs-investor-conferences-vor-20210525monthly0.5https://www.biopharmawatch.com/news/VOR/vor-reports-first-quarter-2021-financial-results-and-provides-company-update-vor-20210506monthly0.5https://www.biopharmawatch.com/news/VOR/vor-to-present-on-vor33-manufacturing-scale-up-and-off-target-editing-at-asgct-vor-20210428monthly0.5https://www.biopharmawatch.com/news/VOR/vor-reports-fiscal-year-2020-financial-results-vor-20210325monthly0.5https://www.biopharmawatch.com/news/VOR/vor-biopharma-to-present-at-the-barclays-global-healthcare-conference-vor-20210305monthly0.5https://www.biopharmawatch.com/news/VOR/vor-biopharma-announces-participation-at-cowen-41st-annual-health-care-conference-vor-20210301monthly0.5https://www.biopharmawatch.com/news/VOR/vor-biopharma-announces-pricing-of-initial-public-offering-vor-20210205monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-announces-expansion-of-strategic-research-collaboration-with-regeneron-in-the-field-ctmx-20260603monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-s-varsetatug-masetecan-epcam-probody-adc-continues-to-demonstrate-positive-data-sup-ctmx-20260316monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-business-update-and-company-milestones-for-2026-ctmx-20260108monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-upcoming-december-investor-conferences-ctmx-20251125monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-report-third-quarter-2025-financial-results-on-november-6-2025-ctmx-20251030monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-report-second-quarter-2025-financial-results-on-august-7-2025-ctmx-20250731monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-ctmx-20250529monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-first-patient-dosed-in-combination-arm-of-phase-1-study-of-c-ctmx-20250519monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-pricing-of-100-million-underwritten-offering-of-common-stock-ctmx-20250512monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-announces-positive-interim-data-from-phase-1-dose-escalation-study-of-epcam-antibod-ctmx-20250512monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-report-first-quarter-2025-financial-results-on-may-12-2025-ctmx-20250505monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-presents-preclinical-data-for-mrna-encoded-masked-il-12-molecule-in-co-ctmx-20250428monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-the-barclays-27th-annual-global-healthcare-conference-ctmx-20250305monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-ctmx-20250227monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-ctmx-20250108monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-2025-strategic-pipeline-priorities-and-provides-corporate-up-ctmx-20250106monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-the-36th-annual-piper-sandler-healthcare-conference-ctmx-20241127monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-report-third-quarter-2024-financial-results-on-november-7-2024-ctmx-20241031monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-first-patient-dosed-with-cx-801-a-dually-masked-interferon-a-ctmx-20240909monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-ctmx-20240904monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-report-second-quarter-2024-financial-results-on-august-8-2024-ctmx-20240801monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-the-h-c-wainwright-2nd-annual-immune-cell-engager-virtua-ctmx-20240618monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-promotes-chris-ogden-to-chief-financial-officer-ctmx-20240617monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-ctmx-20240522monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-new-employment-inducement-grants-ctmx-20240516monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-clinical-collaboration-with-merck-to-evaluate-cx-801-in-comb-ctmx-20240507monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-report-first-quarter-2024-results-and-provide-an-initial-cx-904-pha-ctmx-20240501monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-first-patient-dosed-with-cx-2051-a-conditionally-activated-e-ctmx-20240408monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-nomination-of-second-clinical-candidate-in-broad-probody-t-c-ctmx-20240403monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-appoints-dr-zhen-su-to-board-of-directors-ctmx-20240321monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-milestone-achievement-in-probody-t-cell-engaging-bispecific--ctmx-20240318monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2023-financial-results-on-march-ctmx-20240304monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-upcoming-march-investor-conferences-ctmx-20240227monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-fda-clearance-of-ind-applications-for-cx-2051-a-probody-anti-ctmx-20240124monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-the-b-riley-securities-virtual-annual-oncology-conferenc-ctmx-20240112monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-outlines-2024-company-priorities-and-milestones-ctmx-20240104monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-ctmx-20231221monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-upcoming-november-investor-conferences-ctmx-20231101monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-report-third-quarter-2023-financial-results-on-november-7-2023-ctmx-20231031monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-preclinical-data-for-conditionally-activated-interferon-alp-ctmx-20231030monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-presents-preclinical-profile-of-epcam-directed-antibody-drug-conjugate-ctmx-20231018monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-ctmx-20230905monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-the-h-c-wainwright-immune-cell-engager-virtual-conferenc-ctmx-20230810monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-report-second-quarter-2023-financial-results-on-august-8-2023-ctmx-20230801monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-new-employment-inducement-grants-ctmx-20230720monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-appoints-yu-waye-wayne-chu-m-d-as-chief-medical-officer-ctmx-20230717monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-30-million-private-placement-from-bvf-partners-l-p-ctmx-20230630monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-the-jefferies-healthcare-conference-ctmx-20230601monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-report-first-quarter-2023-financial-results-on-may-9-2023-ctmx-20230501monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nas-ctmx-20230425monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-ctmx-20230322monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-upcoming-march-investor-conferences-ctmx-20230228monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-milestone-achievement-in-probody-t-cell-engaging-bispecific--ctmx-20230126monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-the-b-riley-securities-virtual-annual-oncology-investor--ctmx-20230117monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-and-moderna-announce-strategic-research-collaboration-for-mrna-based-conditionally--ctmx-20230105monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-provides-business-update-and-outlines-2023-company-priorities-ctmx-20230105monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-outline-2023-company-priorities-and-provide-pipeline-update-on-janu-ctmx-20221222monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-ctmx-20221220monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-phase-2-data-for-praluzatamab-ravtansine-cx-2009-in-patient-ctmx-20221207monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-and-regeneron-announce-strategic-research-collaboration-in-the-field-of-conditional-ctmx-20221117monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-preclinical-data-for-conditionally-activated-interferon-alp-ctmx-20221107monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-upcoming-november-investor-conferences-ctmx-20221102monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-report-third-quarter-2022-financial-results-on-november-8-2022-ctmx-20221101monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-phase-1-data-update-for-anti-ctla-4-probody-therapeutic-bms--ctmx-20220912monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-presents-overview-of-conditionally-activated-antibody-drug-conjugate-a-ctmx-20220907monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-upcoming-virtual-august-investor-conferences-ctmx-20220803monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-report-second-quarter-2022-financial-results-on-august-4-2022-ctmx-20220728monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-provides-strategic-update-ctmx-20220713monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-phase-2-results-for-praluzatamab-ravtansine-in-breast-cancer-ctmx-20220706monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-new-employment-inducement-grants-ctmx-20220616monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-jefferies-2022-global-healthcare-conference-ctmx-20220601monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-first-patient-dosed-with-cx-904-in-phase-1-study-in-patients-ctmx-20220526monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-report-first-quarter-2022-financial-results-on-may-5-2022-ctmx-20220428monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-retirement-of-john-a-scarlett-m-d-from-board-of-directors-ctmx-20220414monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-retirement-of-frederick-w-gluck-from-board-of-directors-ctmx-20220323monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-updated-preclinical-data-for-conditionally-activated-cytoki-ctmx-20220317monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-cowen-42nd-annual-healthcare-conference-ctmx-20220228monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2021-financial-results-on-march-ctmx-20220222monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-new-employment-inducement-grants-ctmx-20220216monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-promotion-of-amy-c-peterson-m-d-to-president-and-chief-opera-ctmx-20220207monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-new-employment-inducement-grants-ctmx-20220120monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-cx-ctmx-20220119monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-ctmx-20220105monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-preliminary-results-for-ongoing-phase-2-expansion-study-of-c-ctmx-20211220monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-upcoming-november-investor-conferences-ctmx-20211111monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-preclinical-data-for-conditionally-activated-cytokine-platf-ctmx-20211101monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-announce-third-quarter-2021-financial-results-on-november-4-2021-ctmx-20211028monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-new-employment-inducement-grants-ctmx-20211018monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-appoints-dr-alan-ashworth-to-board-of-directors-ctmx-20211004monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-new-employment-inducement-grants-ctmx-20210916monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference-ctmx-20210907monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-new-employment-inducement-grants-ctmx-20210817monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-multiple-publications-on-pacmilimab-cx-072-a-conditionally-a-ctmx-20210804monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-upcoming-august-investor-conferences-ctmx-20210802monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-announce-second-quarter-2021-financial-results-on-august-5-2021-ctmx-20210729monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-publication-of-first-in-human-data-for-cx-2029-in-clinical-c-ctmx-20210621monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-ctmx-20210527monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-announce-first-quarter-2021-financial-results-on-may-6-2021-ctmx-20210429monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-new-employment-inducement-grants-ctmx-20210414monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-host-virtual-investor-event-on-april-7-2021-ctmx-20210324monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-upcoming-march-virtual-investor-conferences-ctmx-20210222monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-new-employment-inducement-grant-ctmx-20210219monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-announce-fourth-quarter-and-full-year-2020-financial-results-on-feb-ctmx-20210217monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-guggenheim-healthcare-talks-2021-oncology-day-ctmx-20210204monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-closing-of-public-offering-of-common-stock-ctmx-20210126monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-pricing-of-100-million-public-offering-of-common-stock-ctmx-20210121monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-proposed-public-offering-of-common-stock-ctmx-20210119monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-new-employment-inducement-grants-ctmx-20210119monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-ctmx-20210107monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-appoints-dr-mani-mohindru-to-board-of-directors-ctmx-20201222monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-updates-on-cx-2009-at-2020-san-antonio-breast-cancer-sympos-ctmx-20201203monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-upcoming-investor-conferences-ctmx-20201111monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-treatment-of-first-patient-in-phase-2-expansion-study-of-cx--ctmx-20201105monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-announce-third-quarter-2020-financial-results-ctmx-20201029monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-the-planned-retirement-of-chief-scientific-officer-w-michael-ctmx-20201006monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-new-employment-inducement-grants-ctmx-20200918monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-participate-in-upcoming-healthcare-conferences-ctmx-20200902monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-participate-in-the-2020-wedbush-pacgrow-healthcare-conference-ctmx-20200804monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-announce-second-quarter-2020-financial-results-ctmx-20200728monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-investors-last-days-to-seek-participation-in-class-action-as-lead-plaintiff-ctmx-20200716monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-investors-last-days-to-seek-participation-in-class-action-as-lead-plaintiff-ctmx-20200712monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-preclinical-data-from-anti-ctla-4-probody-therapeutic-progra-ctmx-20200622monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-clinical-programs-highlighted-at-american-society-of-clinical-oncology-ctmx-20200529monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-participate-at-upcoming-healthcare-conferences-ctmx-20200528monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-host-conference-call-and-webcast-to-review-asco-asco20-virtual-scie-ctmx-20200526monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-details-of-presentations-at-the-american-society-of-clinical-ctmx-20200513monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-the-2020-bank-of-america-securities-health-care-conferen-ctmx-20200505monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-presentations-at-the-2020-american-society-of-clinical-oncol-ctmx-20200429monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-appoints-halley-e-gilbert-to-board-of-directors-ctmx-20200428monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-announce-first-quarter-2020-financial-results-ctmx-20200427monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-milestone-achievement-in-abbvie-cd71-partnership-and-provide-ctmx-20200330monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-new-employment-inducement-grant-ctmx-20200325monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-and-astellas-announce-strategic-collaboration-to-develop-probody-t-cel-ctmx-20200324monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-appointment-of-carlos-campoy-as-chief-financial-officer-ctmx-20200323monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-new-employment-inducement-grant-ctmx-20200316monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-cowen-and-company-40th-annual-health-care-conference-ctmx-20200225monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-announce-fourth-quarter-2019-financial-results-ctmx-20200220monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-new-employment-inducement-grant-ctmx-20200207monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-appoints-alison-l-hannah-m-d-as-chief-medical-officer-ctmx-20200203monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-new-employment-inducement-grants-ctmx-20200117monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-provides-updates-on-lead-clinical-programs-and-2020-portfolio-outlook-ctmx-20191219monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-new-employment-inducement-grants-ctmx-20191217monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-new-employment-inducement-grants-ctmx-20191206monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-upcoming-healthcare-conferences-ctmx-20191111monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-initiation-of-phase-2-clinical-trial-evaluating-the-anti-pd--ctmx-20191029monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-announce-third-quarter-2019-financial-results-ctmx-20191024monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-new-employment-inducement-grants-ctmx-20191018monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-appointment-of-amy-c-peterson-m-d-as-chief-development-offic-ctmx-20191014monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-upcoming-healthcare-conferences-ctmx-20190828monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-the-2019-wedbush-pacgrow-healthcare-conference-ctmx-20190806monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-announce-second-quarter-2019-financial-results-ctmx-20190730monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-second-target-selection-and-program-initiation-with-abbvie-u-ctmx-20190709monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-provides-update-on-anti-pd-l1-probody-cx-072-at-2019-asco-annual-meeti-ctmx-20190601monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-upcoming-healthcare-conferences-ctmx-20190528monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-presentations-at-2019-asco-annual-meeting-ctmx-20190515monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-the-bank-of-america-merrill-lynch-2019-health-care-confe-ctmx-20190507monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-announce-first-quarter-2019-financial-results-ctmx-20190502monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-transition-of-chief-financial-officer-ctmx-20190325monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-to-present-at-upcoming-healthcare-conferences-ctmx-20190305monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-presentations-at-the-american-association-for-cancer-researc-ctmx-20190227monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-announce-full-year-2018-financial-results-and-host-webcast-conferen-ctmx-20190214monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-senior-management-appointments-ctmx-20190205monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-host-research-and-development-day-on-february-26-2019-ctmx-20190130monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-technology-acquisition-from-agensys-inc-an-affiliate-of-aste-ctmx-20190107monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-presents-cx-072-clinical-translational-data-at-2018-sitc-annual-meetin-ctmx-20181109monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-to-present-at-the-jefferies-2018-london-healthcare-conference-ctmx-20181107monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-cx-072-clinical-presentations-at-2018-sitc-annual-meeting-ctmx-20181106monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-announce-third-quarter-2018-financial-results-ctmx-20181030monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-presents-clinical-data-from-probody-platform-and-cx-072-at-2018-esmo-a-ctmx-20181022monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-presentations-at-2018-esmo-annual-meeting-ctmx-20181008monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-to-present-at-upcoming-healthcare-conferences-ctmx-20180925monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-to-present-at-the-2018-wedbush-pacgrow-healthcare-conference-ctmx-20180807monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-announce-second-quarter-2018-financial-results-ctmx-20180730monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-closing-of-public-offering-of-common-stock-ctmx-20180717monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-pricing-of-public-offering-of-common-stock-ctmx-20180712monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-proposed-public-offering-of-common-stock-ctmx-20180710monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-announces-appointment-of-lloyd-a-rowland-jr-as-general-counsel-ctmx-20180614monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-presents-preliminary-clinical-proof-of-concept-data-from-probody-platf-ctmx-20180604monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-announces-conference-call-and-webcast-to-review-proclaim-072-clinical-data-presenta-ctmx-20180601monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-to-present-at-the-jefferies-2018-healthcare-conference-ctmx-20180531monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-cx-ctmx-20180522monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-presentations-at-2018-asco-annual-meeting-ctmx-20180516monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-to-present-at-the-bank-of-america-merrill-lynch-2018-health-care-conference-ctmx-20180507monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-announce-first-quarter-2018-financial-results-ctmx-20180501monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-to-present-at-upcoming-investor-conferences-ctmx-20180301monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-announce-full-year-2017-financial-results-and-host-operational-upda-ctmx-20180222monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-added-to-nasdaq-biotechnology-index-ctmx-20171218monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-to-present-at-the-jefferies-2017-london-healthcare-conference-ctmx-20171101monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-announce-third-quarter-2017-financial-results-ctmx-20171026monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-announces-upcoming-poster-presentations-at-aacr-nci-eortc-molecular-targets-and-can-ctmx-20171016monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-to-present-at-the-cantor-fitzgerald-healthcare-conference-ctmx-20170913monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-announces-upcoming-trials-in-progress-poster-presentations-at-european-society-for--ctmx-20170908monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-to-present-at-the-2017-wedbush-pacgrow-healthcare-conference-ctmx-20170810monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-announce-second-quarter-2017-financial-results-and-provide-mid-year-ctmx-20170727monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-to-present-at-the-jefferies-2017-global-healthcare-conference-ctmx-20170525monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-announces-upcoming-poster-presentation-at-american-society-for-clinical-oncology-an-ctmx-20170517monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-announces-management-team-changes-ctmx-20170515monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-announce-first-quarter-2017-financial-results-ctmx-20170427monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-announces-teleconference-and-webcast-to-provide-corporate-update-ctmx-20170319monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-announce-full-year-2016-financial-results-ctmx-20170301monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-present-at-upcoming-investor-conferences-ctmx-20170221monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-to-present-at-upcoming-investor-conferences-ctmx-20170202monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-announces-the-first-patient-treated-in-phase-1-2-proclaim-072-trial-ctmx-20170202monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-ctmx-20170109monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-to-present-at-the-jefferies-2016-london-healthcare-conference-ctmx-20161109monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-announce-third-quarter-2016-financial-results-ctmx-20161027monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-to-announce-second-quarter-2016-financial-results-and-provide-mid-year-ctmx-20160727monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-to-present-at-the-jefferies-2016-healthcare-conference-ctmx-20160524monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-to-present-at-the-2016-bank-of-america-merrill-lynch-healthcare-conference-ctmx-20160426monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-and-abbvie-announce-strategic-collaboration-for-probody-drug-conjugates-ctmx-20160421monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-announces-data-to-be-presented-at-the-american-association-for-cancer-research-annu-ctmx-20160316monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-to-present-at-cowen-and-company-s-36th-annual-health-care-conference-ctmx-20160303monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-inc-nasdaq-ctmx-to-ring-the-nasdaq-stock-market-closing-bell-ctmx-20160223monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-added-to-russell-2000-index-ctmx-20151218monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-selects-probody-drug-conjugate-clinical-candidate-cx-2009-targeting-highly-expresse-ctmx-20151211monthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-to-present-at-oppenheimer-s-26th-annual-healthcare-conference-ctmx-20151201monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-gern-20260618monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-gern-20260518monthly0.5https://www.biopharmawatch.com/news/GERN/geron-plans-to-present-at-upcoming-investor-conferences-gern-20260505monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-gern-20260318monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-gern-20260218monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-provides-2026-financial-guidance-gern-20260112monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-gern-20251218monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-presents-new-data-at-ash-2025-highlighting-the-relationship-between-trea-gern-20251208monthly0.5https://www.biopharmawatch.com/news/GERN/geron-gern-investigation-alert-bragar-eagel-squire-p-c-is-investigating-geron-corporation--gern-20251023monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-investors-company-investigated-by-the-portnoy-law-firm-gern-20250814monthly0.5https://www.biopharmawatch.com/news/GERN/geron-gern-alert-bragar-eagel-squire-p-c-is-investigating-geron-corporation-on-behalf-of-l-gern-20250813monthly0.5https://www.biopharmawatch.com/news/GERN/geron-alert-bragar-eagel-squire-p-c-is-investigating-geron-corporation-on-behalf-of-long-t-gern-20250516monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-may-gern-20250512monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-may-gern-20250428monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-sued-for-securities-law-violations-contact-levi-korsinsky-before-may-12--gern-20250424monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-sued-for-securities-law-violations-contact-levi-korsinsky-before-may-12--gern-20250321monthly0.5https://www.biopharmawatch.com/news/GERN/geron-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-a-gern-20250320monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-shareholder-notice-robbins-llp-reminds-investors-of-the-pending-gern-cla-gern-20250317monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-gern-20250317monthly0.5https://www.biopharmawatch.com/news/GERN/geron-alert-bragar-eagel-squire-p-c-is-investigating-geron-corporation-on-behalf-of-geron--gern-20250307monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-nasdaq-gern-investor-update-notice-of-new-deadline-to-file-claim-or-requ-gern-20230501monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-investor-alert-geron-investors-who-have-held-their-stock-continuously-si-gern-20210420monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-third-quarter-2020-financial-results-and-current-events-gern-20201105monthly0.5https://www.biopharmawatch.com/news/GERN/geron-receives-positive-opinion-from-the-ema-committee-for-orphan-medicinal-products-for-o-gern-20200701monthly0.5https://www.biopharmawatch.com/news/GERN/geron-reports-four-imetelstat-data-presentations-at-virtual-edition-of-the-european-hemato-gern-20200612monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-first-quarter-2020-financial-results-gern-20200528monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-announces-the-closing-of-its-public-offering-of-common-stock-and-warrant-gern-20200527monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-announces-the-pricing-of-its-public-offering-of-common-stock-and-warrant-gern-20200522monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-announces-proposed-public-offering-of-common-stock-and-warrants-gern-20200521monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-plans-for-imetelstat-phase-3-clinical-trial-in-myelofibrosis-and-other-upd-gern-20200521monthly0.5https://www.biopharmawatch.com/news/GERN/geron-to-present-at-needham-virtual-healthcare-conference-gern-20200408monthly0.5https://www.biopharmawatch.com/news/GERN/geron-provides-covid-19-related-business-update-gern-20200402monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-fourth-quarter-and-full-year-2019-financial-results-and-2020-mil-gern-20200312monthly0.5https://www.biopharmawatch.com/news/GERN/geron-deadline-alert-faruqi-faruqi-llp-encourages-investors-who-suffered-losses-exceeding--gern-20200203monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-that-a--gern-20200128monthly0.5https://www.biopharmawatch.com/news/GERN/geron-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-gern-20191121monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-third-quarter-2019-financial-results-and-recent-events-gern-20191106monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-two-poster-presentations-at-upcoming-american-society-of-hematology-annual-gern-20191106monthly0.5https://www.biopharmawatch.com/news/GERN/geron-to-announce-third-quarter-financial-results-on-november-6-2019-gern-20191031monthly0.5https://www.biopharmawatch.com/news/GERN/geron-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-gern-20191017monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-first-patient-dosed-in-imerge-phase-3-clinical-trial-in-lower-risk-myelody-gern-20191010monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-fast-track-designation-granted-to-imetelstat-for-relapsed-refractory-myelo-gern-20190930monthly0.5https://www.biopharmawatch.com/news/GERN/geron-to-present-at-2019-cantor-global-healthcare-conference-gern-20190926monthly0.5https://www.biopharmawatch.com/news/GERN/geron-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-gern-20190822monthly0.5https://www.biopharmawatch.com/news/GERN/geron-starts-phase-3-clinical-trial-in-lower-risk-myelodysplastic-syndromes-gern-20190808monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-second-quarter-2019-financial-results-and-recent-events-gern-20190801monthly0.5https://www.biopharmawatch.com/news/GERN/geron-to-announce-second-quarter-financial-results-on-august-1-2019-gern-20190725monthly0.5https://www.biopharmawatch.com/news/GERN/geron-enhances-oncology-expertise-to-advance-corporate-objectives-gern-20190718monthly0.5https://www.biopharmawatch.com/news/GERN/geron-appoints-vice-president-human-resources-gern-20190620monthly0.5https://www.biopharmawatch.com/news/GERN/geron-reports-two-imetelstat-data-presentations-at-european-hematology-association-annual--gern-20190617monthly0.5https://www.biopharmawatch.com/news/GERN/geron-to-webcast-kol-event-on-june-25-2019-gern-20190610monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-two-presentations-on-imetelstat-at-upcoming-european-hematology-associatio-gern-20190516monthly0.5https://www.biopharmawatch.com/news/GERN/geron-provides-imetelstat-program-update-gern-20190516monthly0.5https://www.biopharmawatch.com/news/GERN/geron-continues-to-build-senior-leadership-of-its-development-team-gern-20190516monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-first-quarter-2019-financial-results-gern-20190502monthly0.5https://www.biopharmawatch.com/news/GERN/geron-expands-senior-leadership-of-its-development-team-gern-20190418monthly0.5https://www.biopharmawatch.com/news/GERN/geron-to-present-at-needham-healthcare-conference-gern-20190402monthly0.5https://www.biopharmawatch.com/news/GERN/geron-appoints-two-new-independent-board-members-gern-20190328monthly0.5https://www.biopharmawatch.com/news/GERN/geron-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-gern-20190321monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-fourth-quarter-and-full-year-2018-financial-results-and-recent-e-gern-20190307monthly0.5https://www.biopharmawatch.com/news/GERN/geron-to-announce-fourth-quarter-and-full-year-2018-financial-results-on-march-7-2019-gern-20190228monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-expansion-of-leadership-team-with-appointment-of-chief-medical-officer-gern-20190131monthly0.5https://www.biopharmawatch.com/news/GERN/geron-appoints-vice-president-pharmacovigilance-and-drug-safety-gern-20190117monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-new-board-leadership-structure-gern-20181231monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-new-overall-survival-data-from-imbark-in-imetelstat-treated-patients-with--gern-20181203monthly0.5https://www.biopharmawatch.com/news/GERN/geron-reports-updated-results-from-phase-2-portion-of-imerge-at-the-60th-american-society--gern-20181203monthly0.5https://www.biopharmawatch.com/news/GERN/geron-to-host-analyst-and-investor-event-on-december-10-2018-gern-20181128monthly0.5https://www.biopharmawatch.com/news/GERN/geron-to-present-at-upcoming-investor-conferences-in-november-gern-20181107monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-third-quarter-2018-financial-results-and-recent-company-events-gern-20181101monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-two-oral-presentations-on-imetelstat-at-upcoming-american-society-of-hemat-gern-20181101monthly0.5https://www.biopharmawatch.com/news/GERN/geron-to-announce-third-quarter-2018-financial-results-on-november-1-2018-gern-20181025monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-discontinuation-of-imetelstat-collaboration-by-janssen-gern-20180927monthly0.5https://www.biopharmawatch.com/news/GERN/geron-to-provide-an-update-on-the-imetelstat-collaboration-with-janssen-on-september-27-20-gern-20180927monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-second-quarter-2018-financial-results-and-recent-company-events-gern-20180731monthly0.5https://www.biopharmawatch.com/news/GERN/geron-to-announce-second-quarter-2018-financial-results-on-july-31-2018-gern-20180724monthly0.5https://www.biopharmawatch.com/news/GERN/geron-reports-imetelstat-oral-presentation-at-european-hematology-association-congress-gern-20180618monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-oral-presentation-at-european-hematology-association-congress-gern-20180517monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-first-quarter-2018-financial-results-gern-20180510monthly0.5https://www.biopharmawatch.com/news/GERN/geron-2018-annual-meeting-of-stockholders-to-be-held-on-may-15-gern-20180417monthly0.5https://www.biopharmawatch.com/news/GERN/geron-to-present-at-the-needham-healthcare-conference-gern-20180321monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-fourth-quarter-and-annual-2017-financial-results-and-recent-even-gern-20180316monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-conference-call-to-discuss-fourth-quarter-and-annual-2017-financial-result-gern-20180222monthly0.5https://www.biopharmawatch.com/news/GERN/geron-reports-imetelstat-presentations-at-american-society-of-hematology-annual-meeting-gern-20171212monthly0.5https://www.biopharmawatch.com/news/GERN/geron-to-host-analyst-and-investor-meeting-and-webcast-on-december-19-2017-gern-20171206monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-first-patient-dosed-in-expanded-part-1-of-imerge-clinical-trial-in-myelody-gern-20171120monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-november-investor-conference-presentation-webcasts-gern-20171107monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-third-quarter-2017-financial-results-gern-20171101monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-presentations-at-american-society-of-hematology-annual-meeting-gern-20171101monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-fast-track-designation-granted-to-imetelstat-for-lower-risk-myelodysplasti-gern-20171031monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-conference-call-to-discuss-third-quarter-2017-financial-results-gern-20171025monthly0.5https://www.biopharmawatch.com/news/GERN/geron-to-present-at-the-cantor-fitzgerald-healthcare-conference-gern-20170919monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-second-quarter-2017-financial-results-gern-20170809monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-updates-to-imetelstat-clinical-development-gern-20170731monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-first-quarter-2017-financial-results-and-recent-events-gern-20170509monthly0.5https://www.biopharmawatch.com/news/GERN/geron-2017-annual-meeting-of-stockholders-to-be-held-on-may-9-gern-20170425monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-completion-of-second-internal-data-reviews-for-imetelstat-trials-being-con-gern-20170410monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-conference-call-on-april-10-at-8-00-a-m-eastern-time-gern-20170409monthly0.5https://www.biopharmawatch.com/news/GERN/geron-reports-imetelstat-presentation-at-american-association-for-cancer-research-annual-m-gern-20170405monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-presentation-at-american-association-for-cancer-research-annual-meeting-gern-20170302monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-fourth-quarter-and-annual-2016-financial-results-gern-20170301monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-conference-call-to-discuss-fourth-quarter-and-annual-2016-financial-result-gern-20170222monthly0.5https://www.biopharmawatch.com/news/GERN/geron-reports-imetelstat-presentations-at-american-society-of-hematology-annual-meeting-gern-20161206monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-november-investor-conference-presentation-webcasts-gern-20161107monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-third-quarter-2016-financial-results-and-recent-events-gern-20161103monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-presentations-at-american-society-of-hematology-annual-meeting-gern-20161103monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-conference-call-to-discuss-third-quarter-2016-financial-results-gern-20161026monthly0.5https://www.biopharmawatch.com/news/GERN/geron-provides-update-on-imetelstat-trials-being-conducted-by-janssen-gern-20160912monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-conference-call-on-september-12-at-8-00-a-m-eastern-time-gern-20160911monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-second-quarter-2016-financial-results-and-recent-events-gern-20160803monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-conference-call-to-discuss-second-quarter-2016-financial-results-gern-20160727monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-issuance-of-u-s-patents-related-to-imetelstat-gern-20160713monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-first-quarter-2016-financial-results-and-recent-events-gern-20160505monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-conference-call-to-discuss-first-quarter-2016-financial-results-gern-20160427monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-two-imetelstat-poster-presentations-at-the-american-association-for-cancer-gern-20160420monthly0.5https://www.biopharmawatch.com/news/GERN/geron-to-present-at-the-needham-healthcare-conference-gern-20160405monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-presentations-at-american-association-of-cancer-research-annual-meeting-gern-20160317monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-fourth-quarter-and-annual-2015-financial-results-gern-20160225monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-conference-call-to-discuss-fourth-quarter-and-annual-2015-financial-result-gern-20160217monthly0.5https://www.biopharmawatch.com/news/GERN/geron-to-present-at-the-rbc-capital-markets-healthcare-conference-gern-20160210monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-initiation-of-janssen-phase-2-3-clinical-trial-of-imetelstat-in-myelodyspl-gern-20160114monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-december-conference-presentation-webcasts-gern-20151130monthly0.5https://www.biopharmawatch.com/news/GERN/geron-to-present-at-the-stifel-healthcare-conference-gern-20151110monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-third-quarter-2015-financial-results-gern-20151105monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-presentations-at-american-society-of-hematology-annual-meeting-gern-20151105monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-conference-call-to-discuss-third-quarter-2015-financial-results-gern-20151029monthly0.5https://www.biopharmawatch.com/news/GERN/geron-to-present-at-the-bio-investor-forum-gern-20151013monthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-initiation-of-janssen-phase-2-clinical-trial-of-imetelstat-in-myelofibrosi-gern-20150916monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-second-quarter-2015-financial-results-gern-20150805monthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-first-quarter-2015-financial-results-and-recent-events-gern-20150430monthly0.5https://www.biopharmawatch.com/news/GERN/geron-to-present-at-the-bank-of-america-merrill-lynch-healthcare-conference-gern-20150427monthly0.5https://www.biopharmawatch.com/news/GERN/geron-to-present-at-the-14th-annual-needham-healthcare-conference-gern-20150407monthly0.5https://www.biopharmawatch.com/news/GERN/geron-96-hour-deadline-alert-approximately-96-hours-remain-former-louisiana-attorney-gener-gern-20140510monthly0.5https://www.biopharmawatch.com/news/GERN/geron-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds-i-gern-20140318monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-to-present-at-the-leerink-partners-global-healthcare-conference-rlmd-20260309monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-provides-regulatory-update-confirming-fda-alignment-on-registrational-rlmd-20260112monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-up-rlmd-20250512monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025-rlmd-20250508monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-to-host-kol-event-on-phase-2-ndv-01-data-rlmd-20250424monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-to-present-ndv-01-data-at-aua2025-rlmd-20250414monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-to-report-fourth-quarter-2024-financial-results-on-thursday-march-27--rlmd-20250326monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-to-present-at-jefferies-london-healthcare-conference-rlmd-20241119monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-initiates-phase-1-dosing-with-rel-p11-for-metabolic-disease-rlmd-20241114monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-up-rlmd-20241107monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-to-report-third-quarter-2024-financial-results-on-november-7-2024-rlmd-20241104monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-reports-second-quarter-2024-financial-results-and-provides-business-u-rlmd-20240807monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-to-report-second-quarter-2024-financial-results-on-august-7-2024-rlmd-20240805monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-announces-proposed-public-offering-of-common-stock-rlmd-20211208monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-michael-becker-interviewed-by-the-life-sciences-report-rlmd-20160421monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-set-for-busy-2015-in-clinical-trials-developing-drugs-for-the-lucrati-rlmd-20150402monthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-adds-15-million-in-capital-to-expedite-development-of-pain-treatment--rlmd-20141029monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-first-quarter-2026-financial-results-dbvt-20260430monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-filing-of-2025-annual-report-on-form-10-k-and-universal-registr-dbvt-20260326monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-join-cac-mid-60-and-sbf-120-indices-following-euronext-paris-annual-re-dbvt-20260324monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-upcoming-march-investor-conferences-dbvt-20260304monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-highlights-additional-data-from-successful-phase-3-vitesse-study-at-the-a-dbvt-20260228monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-additional-data-from-the-vitesse-phase-3-study-of-the-viaskin--dbvt-20260210monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-the-guggenheim-securities-emerging-outlook-biotech-summ-dbvt-20260209monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-166-7-million-in-gross-proceeds-following-the-full-exercise-of--dbvt-20260116monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-positive-topline-results-from-phase-3-vitesse-trial-of-viaskin--dbvt-20251216monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-upcoming-acaai-2025-annual-scientific-meeting-dbvt-20251030monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-sale-of-approximately-30-million-of-adss-through-its-at-the-mar-dbvt-20251029monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-sale-of-approximately-30-million-of-adss-through-its-at-the-mar-dbvt-20251006monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-establishes-an-at-the-market-atm-program-on-nasdaq-dbvt-20250905monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-confer-dbvt-20250903monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-filing-of-2025-half-year-report-conditions-for-accessing-or-con-dbvt-20250729monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-appointment-of-james-briggs-as-chief-human-resources-officer-dbvt-20250722monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-upcoming-eaaci-congress-2025-dbvt-20250612monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-the-voting-results-of-its-2025-combined-general-meeting-dbvt-20250611monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-the-filing-of-an-addendum-to-the-2024-universal-registration-do-dbvt-20250603monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-the-citizens-jmp-life-sciences-conference-dbvt-20250505monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-filing-of-2024-annual-report-on-form-10-k-and-universal-registr-dbvt-20250411monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-financing-of-up-to-306-9-million-284-5-million-to-advance-viask-dbvt-20250328monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-upcoming-aaaai-wao-joint-congress-dbvt-20250225monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-third-quarter-2024-financial-results-dbvt-20241106monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-upcoming-acaai-2024-congress-dbvt-20241018monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-the-h-c-wainwright-26th-annual-global-investment-confer-dbvt-20240904monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-filing-of-2024-half-year-report-conditions-for-accessing-or-con-dbvt-20240730monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-provides-updates-on-the-viaskin-peanut-program-in-children-and-toddlers-a-dbvt-20240730monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-report-second-quarter-2024-financial-results-and-business-update-on-ju-dbvt-20240729monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-the-goldman-sachs-45th-annual-global-healthcare-confere-dbvt-20240605monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-plan-to-implement-ads-ratio-change-dbvt-20240531monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-upcoming-eaaci-2024-congress-dbvt-20240530monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-results-of-its-2024-combined-general-meeting-dbvt-20240516monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-upcoming-investor-conferences-dbvt-20240509monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-first-quarter-2024-financial-results-and-business-update-dbvt-20240507monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-full-year-2023-financial-results-and-business-update-dbvt-20240307monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-report-full-year-2023-financial-results-and-business-update-on-march-7-dbvt-20240304monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-upcoming-aaaai-2024-congress-dbvt-20240220monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-2-year-results-from-ongoing-phase-3-open-label-extension-to-the-dbvt-20231109monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-new-data-at-acaai-2023-dbvt-20231102monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-report-third-quarter-2023-financial-results-and-business-update-dbvt-20231027monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-appointment-of-virginie-boucinha-as-chief-financial-officer-dbvt-20231016monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-upcoming-investor-conference-dbvt-20230905monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-receives-feedback-from-fda-on-design-elements-for-viaskin-peanut-safety-s-dbvt-20230731monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-report-first-half-2023-financial-results-and-provide-a-corporate-updat-dbvt-20230725monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-upcoming-eaaci-congress-2023-dbvt-20230608monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-upcoming-investor-conference-dbvt-20230606monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-upcoming-investor-conference-dbvt-20230509monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-outlines-regulatory-path-for-viaskin-peanut-in-children-1-3-years-after-r-dbvt-20230419monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-results-of-its-2023-ordinary-and-extraordinary-general-meeting-dbvt-20230412monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-update-dbvt-20230313monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-filing-of-2022-annual-report-on-form-10-k-and-2022-universal-re-dbvt-20230302monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-full-year-2022-financial-results-and-business-update-dbvt-20230302monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-report-full-year-2022-financial-results-and-business-updates-on-march--dbvt-20230227monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-upcoming-aaaai-2023-congress-dbvt-20230221monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-upcoming-investor-conference-dbvt-20230210monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-upcoming-investor-conference-dbvt-20221122monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-highlight-new-clinical-data-at-acaai-2022-dbvt-20221109monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-report-third-quarter-2022-financial-results-and-provide-a-business-upd-dbvt-20221031monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-appointment-of-new-chair-of-its-audit-committee-and-appointment-dbvt-20221003monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-at-upcoming-investor-conferences-dbvt-20220902monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-second-quarter-2022-financial-results-dbvt-20220801monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-upcoming-eaaci-2022-congress-dbvt-20220628monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-at-the-jmp-securities-life-sciences-conference-in-new-york-dbvt-20220616monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-private-placement-financing-of-194-million-dbvt-20220609monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-positive-topline-results-from-phase-3-epitope-trial-of-viaskin--dbvt-20220607monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-results-of-its-2022-ordinary-and-extraordinary-general-meeting-dbvt-20220512monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-completes-adss-sale-of-an-amount-of-15-3-million-on-nasdaq-through-its-at-dbvt-20220504monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-recent-business-developments-and-first-quarter-2022-financial-res-dbvt-20220502monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-report-first-quarter-2022-financial-results-and-recent-business-develo-dbvt-20220425monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-at-the-oppenheimer-s-32nd-annual-healthcare-conference-dbvt-20220314monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-filing-of-2021-annual-report-on-form-10-k-and-2021-universal-re-dbvt-20220309monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-report-full-year-2021-financial-results-and-business-updates-on-march--dbvt-20220224monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-upcoming-aaaai-2022-congress-dbvt-20220222monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-at-the-11th-annual-svb-leerink-global-healthcare-conference-dbvt-20220214monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-at-the-h-c-wainwright-bioconnect-2022-conference-dbvt-20220107monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-an-upcoming-investor-conference-dbvt-20211124monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-highlight-new-long-term-data-from-realise-trial-at-acaai-2021-dbvt-20211101monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-third-quarter-2021-financial-results-and-recent-regulatory-develo-dbvt-20211026monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-at-upcoming-investor-conferences-dbvt-20210831monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-second-quarter-2021-financial-results-and-recent-business-develop-dbvt-20210802monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-report-first-half-2021-financial-results-and-business-updates-on-augus-dbvt-20210726monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-at-upcoming-investor-conferences-dbvt-20210602monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-results-of-its-2021-ordinary-and-extraordinary-general-meeting--dbvt-20210519monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-filing-of-its-first-form-10-q-for-the-first-quarter-of-2021-dbvt-20210505monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-q1-2021-financial-results-dbvt-20210503monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-upcoming-investor-conferences-dbvt-20210429monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-appointment-of-timothy-e-morris-to-board-of-directors-dbvt-20210402monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-a-new-chair-of-its-audit-committee-and-date-of-its-annual-gener-dbvt-20210326monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-filing-of-2020-annual-report-on-form-10-k-and-2020-universal-re-dbvt-20210317monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-full-year-2020-financial-results-and-recent-business-developments-dbvt-20210311monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-the-h-c-wainwright-global-life-sciences-conference-dbvt-20210305monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-date-change-for-reporting-full-year-2020-financial-results-dbvt-20210303monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-report-full-year-2020-financial-results-on-march-4-2021-dbvt-20210301monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-upcoming-aaaai-2021-congress-dbvt-20210224monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-appointment-of-michele-f-robertson-as-chief-legal-officer-dbvt-20210222monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-svb-leerink-global-partners-healthcare-conference-dbvt-20210219monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-change-in-u-s-reporting-status-and-final-approval-of-global-res-dbvt-20210107monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-leadership-changes-dbvt-20201124monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-highlight-data-on-viaskin-peanut-treatment-delivery-and-patient-experi-dbvt-20201110monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-upcoming-investor-conferences-dbvt-20201109monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-filing-and-validation-of-marketing-authorization-application-fo-dbvt-20201102monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-september-30-2020-cash-position-dbvt-20201030monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-leadership-changes-dbvt-20200909monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-participate-in-multiple-september-investor-conferences-dbvt-20200902monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-receives-complete-response-letter-from-fda-for-viaskin-peanut-bla-in-chil-dbvt-20200804monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-first-half-2020-financial-results-dbvt-20200731monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-publication-of-people-phase-iii-open-label-extension-study-eval-dbvt-20200710monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-provides-operational-and-business-update-dbvt-20200626monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-data-on-epicutaneous-immunotherapy-and-food-allergy-quality-of-dbvt-20200604monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-at-the-goldman-sachs-41st-annual-global-healthcare-conference-dbvt-20200602monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-march-31-2020-cash-position-dbvt-20200430monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-results-of-its-2020-ordinary-and-extraordinary-general-meeting-dbvt-20200420monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-filing-of-2019-universal-registration-document-and-2019-annual--dbvt-20200320monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-provides-update-on-viaskin-peanut-bla-for-children-ages-4-11-years-dbvt-20200316monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-full-year-2019-financial-results-and-provides-business-update-dbvt-20200304monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-closing-of-underwriters-option-to-purchase-additional-ordinary--dbvt-20200304monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-partial-exercise-of-underwriters-option-to-purchase-additional--dbvt-20200302monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-detailed-safety-and-efficacy-data-of-viaskin-peanut-at-aaaai-2-dbvt-20200224monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-fda-advisory-committee-meeting-to-review-viaskin-peanut-for-the-dbvt-20200221monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-at-the-svb-leerink-9th-annual-global-healthcare-conference-dbvt-20200210monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-appointment-of-pascal-wotling-as-chief-technical-operations-off-dbvt-20200206monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-closing-of-global-offering-dbvt-20200204monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-pricing-of-153-7-million-139-8-million-global-offering-of-ordin-dbvt-20200130monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-appointment-of-ramzi-benamar-as-chief-financial-officer-dbvt-20200102monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-at-the-stifel-2019-healthcare-conference-dbvt-20191105monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-highlight-the-burden-of-peanut-allergy-and-patient-experiences-with-vi-dbvt-20191024monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-closing-of-global-offering-dbvt-20191015monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-full-exercise-of-underwriters-option-to-purchase-additional-sha-dbvt-20191010monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-pricing-of-125-million-114-million-global-offering-of-ordinary--dbvt-20191009monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-the-launch-of-a-proposed-global-offering-of-ordinary-shares-whi-dbvt-20191008monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-fda-acceptance-of-bla-filing-for-viaskin-peanut-for-the-treatme-dbvt-20191004monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-submits-biologics-license-application-to-u-s-food-and-drug-administration-dbvt-20190807monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-first-half-2019-financial-results-dbvt-20190801monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-appointment-of-pharis-mohideen-m-d-as-chief-medical-officer-dbvt-20190626monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-attend-upcoming-investor-conferences-dbvt-20190603monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-data-from-epicutaneous-immunotherapy-at-eaaci-2019-dbvt-20190601monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-results-of-its-2019-ordinary-and-extraordinary-general-meeting--dbvt-20190524monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-departure-of-deputy-ceo-david-schilansky-dbvt-20190514monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-attend-upcoming-investor-conferences-dbvt-20190502monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-march-31-2019-cash-position-dbvt-20190430monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-closing-of-global-offering-dbvt-20190408monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-full-exercise-of-underwriters-option-to-purchase-additional-sha-dbvt-20190405monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-pricing-of-70-4-million-62-7-million-global-offering-of-ordinar-dbvt-20190404monthly0.5https://www.biopharmawatch.com/news/DBVT/dbvt-dbv-technologies-s-a-bronstein-gewirtz-grossman-llc-class-action-update-and-deadline--dbvt-20190314monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-march-18-deadline-zhang-investor-law-reminds-investors-of-deadline-in-securities-class-dbvt-20190312monthly0.5https://www.biopharmawatch.com/news/DBVT/dbvt-dbv-technologies-s-a-bronstein-gewirtz-grossman-llc-class-action-update-and-deadline--dbvt-20190307monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-full-year-2018-financial-results-and-provides-operational-update-dbvt-20190305monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-appointment-of-michel-de-rosen-as-non-executive-chairman-of-the-dbvt-20190305monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-attend-upcoming-investor-conferences-dbvt-20190301monthly0.5https://www.biopharmawatch.com/news/DBVT/dbvt-march-18th-deadline-rosen-law-firm-files-securities-class-action-lawsuit-against-dbv--dbvt-20190220monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-provides-update-on-regulatory-status-of-viaskin-peanut-for-the-treatment--dbvt-20190213monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20190208monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-data-on-epicutaneous-immunotherapy-at-aaaai-2019-dbvt-20190204monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-s-a-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-that-dbvt-20190201monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-at-the-8th-annual-leerink-partners-global-healthcare-conferenc-dbvt-20190201monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-s-a-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-that-dbvt-20190124monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-half-year-report-on-the-dbv-technologies-liquidity-contract-with-oddo-bhf-dbvt-20190117monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20190111monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-expands-and-strengthens-leadership-team-dbvt-20190103monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-dbv-technologies-provides-update-on-viaskin-peanut-for-children-four-to-1-dbvt-20181219monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-highlights-data-supporting-induction-of-immunotolerance-through-the-skin--dbvt-20181212monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20181206monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-presents-data-at-acaai-2018-on-investigational-viaskin-peanut-for-the-tre-dbvt-20181120monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-data-further-supporting-the-use-of-epicutaneous-immunotherapy--dbvt-20181109monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20181107monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-september-30-2018-cash-position-dbvt-20181030monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-initiation-of-part-b-of-phase-iii-study-in-peanut-allergic-todd-dbvt-20181026monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-submission-of-biologics-license-application-for-viaskin-peanut--dbvt-20181022monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20181009monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-at-the-cantor-global-healthcare-conference-dbvt-20180925monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-positive-dsmb-review-of-part-a-of-phase-iii-study-in-peanut-all-dbvt-20180912monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20180907monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-first-half-2018-financial-results-dbvt-20180907monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-geneva-university-hospitals-and-bionet-asia-presented-additional-phase-i--dbvt-20180905monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-attend-upcoming-investor-conferences-dbvt-20180831monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20180827monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-june-30-2018-cash-position-dbvt-20180727monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-appoints-industry-leader-kevin-trapp-as-chief-commercial-officer-dbvt-20180726monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20180719monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-half-year-report-on-the-dbv-technologies-liquidity-contract-and-transfer--dbvt-20180713monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20180626monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-results-of-its-2018-ordinary-and-extraordinary-general-meeting--dbvt-20180622monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20180611monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-attend-upcoming-investor-conferences-dbvt-20180605monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-ordinary-and-extraordinary-general-meeting-of-june-22-2018-procedures-for-dbvt-20180601monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-information-regarding-the-total-number-of-voting-rights-and-total-number--dbvt-20180529monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-shows-commitment-to-the-development-of-treatments-for-food-allergies-at-e-dbvt-20180529monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-appointment-of-michel-de-rosen-to-its-board-of-directors-dbvt-20180516monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20180514monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-partners-with-fare-to-help-raise-awareness-of-food-allergies-in-support-o-dbvt-20180514monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-new-clinical-data-from-viaskin-platform-at-the-2018-eaaci-meet-dbvt-20180508monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-attend-upcoming-investor-conferences-dbvt-20180501monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-march-31-2018-cash-position-dbvt-20180427monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20180405monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-attend-the-11th-kempen-life-sciences-conference-dbvt-20180403monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-closing-of-underwriters-option-to-purchase-additional-shares-in-dbvt-20180326monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-pricing-of-150-0-million-122-5-million-global-offering-of-ordin-dbvt-20180321monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-the-launch-of-a-proposed-global-offering-of-ordinary-shares-whi-dbvt-20180320monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-full-year-2017-financial-results-dbvt-20180314monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20180309monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-at-the-barclays-global-healthcare-conference-dbvt-20180307monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-results-from-phase-ii-study-of-viaskin-milk-in-milk-allergic-pa-dbvt-20180226monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-december-31-2017-cash-position-dbvt-20180220monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-provides-update-on-regulatory-progress-for-viaskin-peanut-dbvt-20180214monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20180213monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-attend-upcoming-investor-conferences-dbvt-20180201monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20180112monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-dbvt-20180103monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20171222monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20171205monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-ceo-chairman-and-co-founder-dr-pierre-henri-benhamou-recognized-for-his-l-dbvt-20171204monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-attend-citi-s-2017-global-healthcare-conference-dbvt-20171128monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-positive-topline-safety-results-from-realise-phase-iii-trial-of-dbvt-20171120monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-publication-of-positive-data-from-phase-iib-trial-and-long-term-dbvt-20171114monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20171113monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-september-30-2017-cash-position-dbvt-20171031monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-topline-results-of-phase-iii-clinical-trial-in-peanut-allergic--dbvt-20171020monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20171017monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-completion-of-blinded-period-in-realise-study-of-viaskin-peanut-dbvt-20171012monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20170905monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-attend-upcoming-investor-conferences-dbvt-20170901monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-completion-of-enrollment-in-phase-iii-extension-study-of-viaski-dbvt-20170829monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20170825monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20170822monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-initiates-phase-iii-study-of-viaskin-peanut-in-peanut-allergic-patients-o-dbvt-20170802monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-first-half-2017-financial-results-dbvt-20170728monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20170707monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-highlights-poster-presentations-on-epit-at-the-2017-eaaci-congress-dbvt-20170617monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-results-of-its-2017-ordinary-and-extraordinary-general-meeting-dbvt-20170615monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-appointment-of-julie-o-neill-to-board-of-directors-dbvt-20170615monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20170612monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-attend-upcoming-investor-conferences-dbvt-20170601monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-ordinary-and-extraordinary-general-meeting-of-june-15-2017-procedures-for-dbvt-20170524monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20170512monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-highlights-research-presentation-of-epit-for-the-treatment-of-crohn-s-dis-dbvt-20170508monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-attend-upcoming-investor-conferences-dbvt-20170502monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-march-31-2017-cash-position-dbvt-20170428monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20170405monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-attend-the-10th-kempen-life-sciences-conference-dbvt-20170405monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-bionet-asia-and-geneva-university-hospitals-announce-phase-i-trial-result-dbvt-20170330monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-full-year-2016-financial-results-dbvt-20170315monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-completion-of-enrollment-of-the-realise-study-in-peanut-allergi-dbvt-20170310monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20170307monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-data-at-aaaai-2017-show-lasting-response-and-favorable-safety-profile-of--dbvt-20170305monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-attend-upcoming-investor-conferences-dbvt-20170301monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-december-31-2016-cash-position-dbvt-20170220monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20170209monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-completion-of-enrollment-of-phase-iia-study-of-viaskin-milk-for-dbvt-20170203monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-at-the-leerink-partners-6th-annual-global-healthcare-conferenc-dbvt-20170126monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-financial-calendar-2017-dbvt-20170109monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-presents-its-half-year-statement-of-the-liquidity-contract-dbvt-20170104monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20170104monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20161207monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-bionet-asia-and-geneva-university-hospitals-complete-dosing-in-first-coho-dbvt-20161117monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20161116monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-poster-presentations-at-the-2016-american-college-of-allergy-as-dbvt-20161112monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-attend-upcoming-investor-conferences-dbvt-20161110monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-completes-enrollment-of-phase-ii-study-of-viaskin-milk-for-the-treatment--dbvt-20161108monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-september-30-2016-cash-position-dbvt-20161103monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-publication-of-positive-viaskin-peanut-data-from-niaid-sponsore-dbvt-20161026monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-topline-results-from-two-year-follow-up-study-of-viaskin-peanut-show-long-dbvt-20161024monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-andtotal--dbvt-20161017monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-receives-fda-fast-track-designation-for-viaskin-milk-for-the-treatment-of-dbvt-20160921monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20160909monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-bionet-asia-and-the-geneva-university-hospitals-initiate-phase-i-study-of-dbvt-20160906monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-attend-upcoming-investor-conferences-dbvt-20160901monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20160803monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-expansion-of-clinical-program-of-viaskin-peanut-for-the-treatme-dbvt-20160801monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-interim-financial-results-for-the-first-half-of-2016-dbvt-20160728monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20160708monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-proudly-welcomes-dr-lucia-septien-as-chief-medical-officer-dbvt-20160705monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-completion-of-recruitment-in-global-phase-iii-study-of-viaskin--dbvt-20160627monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-expands-its-board-of-directors-with-the-appointments-of-claire-giraut-and-dbvt-20160621monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announced-results-of-its-2016-annual-meeting-of-shareholders-dbvt-20160621monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-at-the-jmp-securities-life-sciences-conference-dbvt-20160616monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-late-breaking-presentation-at-eaaci-highlights-viaskin-r-peanut-data-prov-dbvt-20160615monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-publication-of-preclinical-data-in-jaci-suggesting-epit-r-provi-dbvt-20160613monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-appointment-of-leading-japanese-allergist-dr-motohiro-ebisawa-t-dbvt-20160607monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20160606monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-data-at-eaaci-2016-highlight-its-expansive-product-development-in-food-al-dbvt-20160601monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-and-nestle-health-science-form-collaboration-to-develop-and-commercialize-dbvt-20160531monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-mixed-general-assembly-of-june-21-2016-procedures-for-obtaining-preparato-dbvt-20160530monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-attend-upcoming-investor-conferences-dbvt-20160520monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20160510monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-march-31-2016-cash-position-dbvt-20160429monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-filing-of-2015-document-de-reference-and-2015-annual-report-on--dbvt-20160428monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-attend-upcoming-investor-conferences-dbvt-20160427monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20160415monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-publication-of-experimental-data-on-targeted-regulatory-t-cell--dbvt-20160411monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-full-year-2015-financial-results-dbvt-20160407monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-additional-phase-iib-trial-results-with-viaskin-peanut-presented-at-the-2-dbvt-20160306monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-presentation-from-niaid-sponsored-cofar6-phase-ii-trial-reaffir-dbvt-20160304monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-attend-upcoming-investor-conferences-and-events-dbvt-20160301monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-publication-of-phase-ib-trial-results-in-the-journal-of-allergy-dbvt-20160225monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-december-31-2015-cash-position-dbvt-20160215monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-new-data-at-the-2016-aaaai-annual-meeting-dbvt-20160210monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-at-the-leerink-partners-5th-annual-global-healthcare-conferenc-dbvt-20160208monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-proudly-welcomes-edward-jordan-as-senior-vice-president-commercial-operat-dbvt-20160126monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-2016-financial-calendar-dbvt-20160108monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-presents-its-half-year-statement-of-the-liquidity-contract-dbvt-20160107monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-first-experimental-results-for-the-treatment-of-colitis-with-viaskin-r-wi-dbvt-20151210monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-initiation-of-phase-iii-study-of-viaskin-r-peanut-for-the-treat-dbvt-20151207monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-preclinical-data-on-its-viaskin-r-technology-for-rsv-vaccinati-dbvt-20151118monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-enrollment-of-first-patient-in-phase-iia-study-in-pediatric-eos-dbvt-20151112monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-interim-financial-results-for-the-third-quarter-of-2015-dbvt-20151103monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-the-appointment-of-michael-j-goller-to-its-board-of-directors-dbvt-20151021monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-first-patient-enrolled-in-phase-ii-study-of-viaskin-milk-dbvt-20151014monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-enter-sbf-120-index-dbvt-20150911monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-invited-to-present-at-the-royal-society-of-medicine-11th-medical-innovati-dbvt-20150908monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-attend-upcoming-investor-conferences-and-events-dbvt-20150903monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20150901monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-dbv-technologies-extraordinary-general-assembly-on-september-21-2015-dbvt-20150901monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20150806monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-interim-financial-results-for-the-first-half-of-2015-dbvt-20150727monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-closing-of-281-5-million-public-offering-and-full-exercise-of-u-dbvt-20150720monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-pricing-of-underwritten-public-offering-of-ordinary-shares-dbvt-20150715monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-launch-of-proposed-underwritten-public-offering-of-ordinary-sha-dbvt-20150714monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-ind-acceptance-from-fda-for-a-proof-of-concept-trial-using-viaskin-r-milk-dbvt-20150708monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-the-filing-of-a-registration-statement-on-form-f-1-in-view-of-a-dbvt-20150702monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20150702monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-completion-of-part-a-of-the-miles-study-evaluating-the-safety-o-dbvt-20150630monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-proudly-welcomes-dr-hugh-sampson-as-chief-scientific-officer-dbvt-20150626monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-june-23-2015-combined-shareholders-meeting-dbvt-20150623monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-confirms-planned-initiation-of-viaskin-r-peanut-global-phase-iii-clinical-dbvt-20150622monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-presents-clinical-and-scientific-data-at-the-eaaci-congress-dbvt-20150608monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-ema-paediatric-committee-pdco-positive-opinion-on-the-paediatri-dbvt-20150604monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-mixed-general-assembly-of-june-23-2015-dbvt-20150602monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-attend-upcoming-investor-conferences-dbvt-20150602monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-publication-of-the-resolutions-proposed-to-the-mixed-general-assembly-of--dbvt-20150520monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-at-upcoming-investor-conferences-dbvt-20150505monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20150504monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-topline-financial-results-for-first-three-months-of-2015-dbvt-20150429monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-selected-to-enter-euronext-s-tech-40-label-dbvt-20150428monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-viaskin-data-at-the-2015-eaaci-congress-dbvt-20150415monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-receives-fda-breakthrough-therapy-designation-for-viaskin-peanut-for-the--dbvt-20150409monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-full-year-2014-financial-results-dbvt-20150325monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20150316monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-appoints-daniel-soland-to-board-of-directors-dbvt-20150310monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-at-upcoming-investor-conferences-dbvt-20150306monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-welcomes-dr-j-p-moreau-to-its-scientific-advisory-board-dbvt-20150213monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20150211monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-largest-presence-ever-of-dbv-technologies-at-2015-allergy-meeting-dbvt-20150203monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-at-the-2015-leerink-partners-global-healthcare-conference-in-n-dbvt-20150203monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-dbv-technologies-announces-topline-financial-results-for-full-year-2014-dbvt-20150129monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-half-year-update-on-the-dbv-technologies-liquidity-agreement-dbvt-20150114monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20150114monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-publication-in-the-journal-of-allergy-and-clinical-immunology-o-dbvt-20150112monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-additional-contribution-to-the-liquidity-agreement-with-natixis-dbvt-20141218monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20141208monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20141104monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-nasdaq-dbvt-to-ring-the-nasdaq-stock-market-opening-bell-in-celebration-o-dbvt-20141022monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-s-a-announces-pricing-of-global-offering-dbvt-20141022monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-s-a-announces-proposed-global-offering-dbvt-20141020monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-topline-financial-results-for-first-nine-months-2014-dbvt-20141014monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-primary-endpoint-met-in-vipes-viaskin-peanut-s-phase-iib-clinic-dbvt-20140922monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-attend-the-goldman-sachs-european-biotech-symposium-dbvt-20140826monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20140812monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20140801monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-dbv-technologies-reports-financial-results-for-the-first-six-months-of-20-dbvt-20140728monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-completes-last-food-challenge-visit-of-last-peanut-allergic-patient-in-vi-dbvt-20140717monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-half-year-update-on-the-dbv-technologies-liquidity-agreement-dbvt-20140701monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20140701monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-at-upcoming-us-investors-conferences-dbvt-20140616monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20140606monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-dbv-technologies-june-3rd-2014-combined-shareholders-meeting-dbvt-20140603monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-clinical-trial-agreement-to-develop-a-treatment-for-milk-induce-dbvt-20140513monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-host-and-webcast-investor-day-in-new-york-city-on-may-21-2014-dbvt-20140512monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20140506monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-dbv-technologies-publishes-its-2013-registration-document-and-its-2013-an-dbvt-20140417monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-dbv-technologies-announces-topline-financial-results-for-first-three-mont-dbvt-20140415monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-and-cea-conclude-a-scientific-cooperation-to-investigate-epigenetic-modul-dbvt-20140409monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-creation-of-us-subsidiary-and-appoints-ms-susanna-mesa-as-vice--dbvt-20140407monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20140402monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-full-year-2013-financial-results-and-provides-vipes-update-dbvt-20140317monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20140304monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-to-present-at-the-barclays-global-healthcare-conference-in-miami-usa-dbvt-20140303monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-and-mount-sinai-hospital-enter-research-collaboration-for-crohn-s-disease-dbvt-20140218monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20140203monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-full-year-2013-topline-financial-results-dbvt-20140130monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20140108monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-half-year-update-on-the-dbv-technologies-liquidity-agreement-dbvt-20140108monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20131202monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-enters-into-collaboration-agreement-with-bionet-asia-and-university-of-ge-dbvt-20131126monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-dbv-technologies-announces-the-completion-of-a-29-9m-private-placement-wi-dbvt-20131114monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-capital-increase-launch-of-a-private-placement-of-new-and-existing-shares-dbvt-20131113monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20131104monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-forms-research-collaboration-with-inserm-to-develop-viaskin-r-for-refract-dbvt-20131022monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20131001monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20130905monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-initiates-a-long-term-follow-up-study-of-viaskin-peanut-dbvt-20130904monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20130805monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-reports-financial-results-for-the-first-six-months-of-2013-dbvt-20130726monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-monthly-information-regarding-the-total-number-of-voting-rights-and-total-dbvt-20130708monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-completes-enrollment-of-phase-iib-vipes-study-the-first-ever-global-trial-dbvt-20130708monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-half-year-update-on-the-dbv-technologies-liquidity-agreement-dbvt-20130705monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-announces-breakthrough-data-presentations-at-eaaci-wao-congress-dbvt-20130628monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-viaskin-peanut-demonstrates-strong-efficacy-trend-in-severely-peanut-alle-dbvt-20130620monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-proudly-welcomes-mrs-veronique-foutel-as-chief-strategic-marketing-office-dbvt-20130606monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-june-4th-2013-combined-shareholders-s-meeting-dbvt-20130604monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-and-stallergenes-enter-into-partnership-for-the-development-of-innovative-dbvt-20130516monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-and-mount-sinai-hospital-enter-into-a-research-collaboration-agreement-dbvt-20130507monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-publishes-its-2012-registration-document-and-its-2012-annual-financial-re-dbvt-20130425monthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-first-quarter-2013-topline-and-cash-position-dbvt-20130415monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-alert-bragar-eagel-squire-p-c-is-investigating-alto-neuroscience-inc-on-behalf-of-lon-anro-20251007monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-anro-20250918monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-inc-class-action-the-gross-law-firm-reminds-alto-neuroscience-inc-invest-anro-20250915monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-deadline-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-ac-anro-20250915monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-laws-anro-20250911monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-inc-sued-for-securities-law-violations-investors-should-contact-the-gros-anro-20250910monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-inc-nyse-anro-shareholder-alert-bernstein-liebhard-llp-reminds-alto-neur-anro-20250908monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-class-action-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has--anro-20250907monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-anro-20250905monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-sep-anro-20250905monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-anro-20250903monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-class-action-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has--anro-20250903monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-inc-nyse-anro-shareholder-alert-bernstein-liebhard-llp-reminds-alto-neur-anro-20250902monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-anro-20250829monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-anro-20250825monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-anro-20250818monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-inc-sued-for-securities-law-violations-investors-should-contact-the-gros-anro-20250807monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-inc-sued-for-securities-law-violations-investors-should-contact-the-gros-anro-20250804monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-inc-nyse-anro-shareholder-alert-bernstein-liebhard-llp-reminds-alto-neur-anro-20250804monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-class-action-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has--anro-20250722monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-inc-nyse-anro-investor-alert-investors-with-large-losses-in-alto-neurosc-anro-20250722monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-announced-its-emergence-from-stealth-with-40-million-in-funding-to-advan-anro-20221115monthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-emerges-with-largest-clinical-stage-precision-psychiatry-pipeline-and-40-anro-20211014monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-receives-u-s-fda-fast-track-designation-for-imdusiran-for-the-treatment-of-chronic-abus-20260415monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-corporate--abus-20260323monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-second-quarter-2025-financial-results-and-provides-corporate-update-abus-20250806monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-first-quarter-2025-financial-results-and-provides-corporate-update-abus-20250514monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-fourth-quarter-and-year-end-2024-financial-results-and-provides-corporate--abus-20250327monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-in-h-c-wainwright-home-virtual-fireside-chat-abus-20241126monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-and-barinthus-bio-announce-new-data-from-the-im-prove-ii-trial-showing-that-the-ad-abus-20241115monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-jefferies-london-healthcare-conference-abus-20241114monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-third-quarter-2024-financial-results-and-provide-corporate-update-abus-20241023monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-multiple-abstracts-highlighting-imdusiran-data-accepted-for-presentation-abus-20241015monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-h-c-wainwright-5th-annual-viral-hepatitis-virtual-conference-abus-20241001monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-in-two-upcoming-investor-conferences-abus-20240903monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-second-quarter-2024-financial-results-and-provide-corporate-update-abus-20240718monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-in-jefferies-global-healthcare-conference-abus-20240529monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-imdusiran-data-at-easl-congress-2024-abus-20240522monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-in-two-upcoming-investor-conferences-abus-20240507monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-retirement-of-chief-scientific-officer-michael-j-sofia-phd-effective-dec-abus-20240502monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-first-quarter-2024-financial-results-and-provide-corporate-update-abus-20240418monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-biopharma-announces-claim-construction-ruling-in-its-ongoing-patent-infringement-l-abus-20240404monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-in-two-upcoming-investor-conferences-abus-20240308monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-fourth-quarter-and-year-end-2023-financial-results-and-provide-corporate-abus-20240215monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-jefferies-london-healthcare-conference-abus-20231108monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-ceo-william-collier-to-retire-december-31-2023-abus-20231107monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-third-quarter-2023-financial-results-and-provide-corporate-update-abus-20231024monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-h-c-wainwright-4th-annual-hepatitis-b-virus-hbv-virtual-conference-abus-20231018monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-multiple-abstracts-accepted-for-presentation-at-aasld-the-liver-meeting--abus-20231011monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-in-two-upcoming-investor-conferences-abus-20230907monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-second-quarter-2023-financial-results-and-provide-corporate-update-abus-20230720monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-appoints-melissa-v-rewolinski-phd-to-its-board-of-directors-abus-20230712monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-appoints-two-new-executives-abus-20230710monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-doses-first-patient-in-additional-treatment-arm-of-phase-2a-triple-combination-cli-abus-20230621monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-presents-preliminary-ab-729-and-pegylated-interferon-alfa-2a-combination-data-at-t-abus-20230621monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-ab-729-and-ab-836-data-at-easl-congress-2023-abus-20230607monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-jefferies-healthcare-conference-abus-20230531monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-jmp-securities-life-sciences-conference-abus-20230509monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-provides-ab-729-clinical-data-and-ab-161-preclinical-data-as-oral-presentations-at-abus-20230427monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-fda-clinical-hold-on-ind-application-for-ab-101-an-oral-pd-l1-inhibitor-abus-20230425monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-first-quarter-2023-financial-results-and-provide-corporate-update-abus-20230420monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-ab-729-and-ab-161-data-at-the-global-hepatitis-summit-2023-abus-20230418monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-biopharma-and-genevant-sciences-file-patent-infringement-lawsuit-against-pfizer-bi-abus-20230404monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-doses-first-subject-in-phase-1-clinical-trial-with-its-oral-rna-destabilizer-ab-16-abus-20230316monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-presents-ab-343-data-at-the-36th-international-conference-on-antiviral-research-abus-20230314monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-fourth-quarter-and-year-end-2022-financial-results-and-provide-corporate-abus-20230216monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-in-three-upcoming-investor-conferences-abus-20230206monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-resignation-of-board-member-abus-20230127monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-completes-enrollment-in-its-phase-2a-clinical-trial-combining-ab-729-with-na-thera-abus-20221213monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-jefferies-london-healthcare-conference-abus-20221108monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-presents-ab-729-clinical-data-and-ab-101-preclinical-data-at-aasld-the-liver-meeti-abus-20221101monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-three-poster-presentations-with-clinical-data-from-ab-729-and-preclinica-abus-20221031monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-third-quarter-2022-financial-results-and-provide-corporate-update-abus-20221026monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-chardan-s-6th-annual-genetic-medicines-conference-abus-20220922monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-in-september-investor-conferences-abus-20220906monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-biopharma-announces-issuance-of-a-new-key-u-s-patent-related-to-ab-729-abus-20220830monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-second-quarter-2022-financial-results-and-provides-corporate-update-abus-20220804monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-abus-20220721monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-biopharma-provides-update-on-the-phase-2a-combination-trial-with-ab-729-and-a-caps-abus-20220720monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-presents-new-data-on-ab-729-ab-836-and-ab-101-at-the-easl-international-liver-cong-abus-20220625monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-seven-scientific-posters-at-easl-international-liver-congress-2022-abus-20220608monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-and-vaccitech-dose-first-patient-in-phase-2a-clinical-trial-combining-therapies-fo-abus-20220606monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-in-june-investor-conferences-abus-20220602monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-abstract-selected-for-publication-at-the-2022-american-society-of-clinic-abus-20220526monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-h-c-wainwright-global-investment-conference-abus-20220517monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-first-quarter-2022-financial-results-and-provide-corporate-update-abus-20220421monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-biopharma-and-genevant-sciences-file-patent-infringement-lawsuit-against-moderna-abus-20220228monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-fourth-quarter-and-year-end-2021-financial-results-and-provide-corporate-abus-20220217monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-at-h-c-wainwright-bioconnect-virtual-conference-abus-20220104monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-and-qilu-pharmaceutical-enter-into-an-exclusive-licensing-agreement-and-strategic--abus-20211213monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-biopharma-x-chem-and-proteros-biostructures-achieve-first-milestone-under-covid-19-abus-20211207monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-biopharma-appoints-tram-tran-m-d-to-its-board-of-directors-abus-20211111monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-new-data-on-ab-729-in-late-breaker-poster-presentation-at-aasld-the-live-abus-20211110monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-at-jefferies-london-healthcare-conference-abus-20211110monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-late-breaker-abstract-accepted-for-presentation-at-aasld-the-liver-meeti-abus-20211101monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-third-quarter-2021-financial-results-and-provide-corporate-update-abus-20211021monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-in-october-investor-conferences-abus-20210928monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-appoints-lisa-m-caperelli-as-vice-president-investor-relations-abus-20210921monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-in-upcoming-investor-conferences-abus-20210907monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-wedbush-pacgrow-healthcare-virtual-conference-abus-20210803monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-second-quarter-2021-financial-results-and-provide-corporate-update-abus-20210729monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-receives-authorization-to-proceed-with-an-investigational-new-drug-application-ind-abus-20210707monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-biopharma-and-vaccitech-announce-clinical-trial-collaboration-agreement-to-evaluat-abus-20210706monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-biopharma-and-antios-therapeutics-announce-clinical-collaboration-agreement-to-eva-abus-20210629monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-new-data-on-ab-729-and-ab-836-programs-with-presentation-of-five-abstrac-abus-20210626monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-multiple-abstracts-accepted-for-oral-and-poster-presentations-at-the-eas-abus-20210602monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-in-upcoming-investor-conferences-abus-20210526monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-first-quarter-2021-financial-results-and-provide-corporate-update-abus-20210428monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-biopharma-x-chem-and-proteros-biostructures-enter-into-a-pan-coronavirus-discovery-abus-20210401monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-fourth-quarter-and-year-end-2020-financial-results-and-provides-corporate--abus-20210304monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-at-h-c-wainwright-global-life-sciences-conference-abus-20210302monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-fourth-quarter-and-year-end-2020-financial-results-and-provide-corporate-abus-20210222monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-in-virtual-fireside-chat-at-h-c-wainwright-bioconnect-2021-conferen-abus-20210104monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-robust-hbsag-decline-data-with-ab-729-dosed-at-60-mg-every-8-weeks-in-ch-abus-20201210monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-additional-robust-hbsag-decline-data-with-ab-729-in-chronic-hepatitis-b--abus-20201116monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-presentation-of-phase-1a-1b-clinical-trial-results-for-ab-729-in-chronic-abus-20201115monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-jefferies-virtual-london-healthcare-conference-abus-20201110monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-third-quarter-2020-financial-results-and-provides-corporate-update-abus-20201105monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-third-quarter-2020-financial-results-and-provide-corporate-update-abus-20201029monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-in-virtual-fireside-chat-at-h-c-wainwright-hepatitis-b-virus-hbv-mi-abus-20201013monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-in-virtual-fireside-chat-at-chardan-s-4th-annual-genetic-medicines--abus-20200928monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-in-virtual-fireside-chat-at-h-c-wainwright-22nd-annual-global-inves-abus-20200909monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-second-quarter-2020-financial-results-and-provides-corporate-update-abus-20200807monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-wedbush-pacgrow-healthcare-virtual-conference-abus-20200805monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-second-quarter-2020-financial-results-abus-20200729monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-jefferies-virtual-healthcare-conference-abus-20200527monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-single-dose-week-12-data-in-chronic-hepatitis-b-subjects-with-60-mg-ab-7-abus-20200518monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-ubs-virtual-global-healthcare-conference-abus-20200512monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-first-quarter-2020-financial-results-provides-pipeline-update-and-announce-abus-20200511monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-first-quarter-2020-financial-results-abus-20200504monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-positive-preliminary-phase-1a-1b-clinical-trial-results-for-ab-729-a-pro-abus-20200326monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-fourth-quarter-and-year-end-2019-financial-results-abus-20200227monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-decision-to-discontinue-ab-452-and-to-pursue-development-of-a-next-gener-abus-20200210monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-third-quarter-2019-financial-results-abus-20191030monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-decision-to-discontinue-development-of-ab-506-an-oral-capsid-inhibitor-f-abus-20191003monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-in-upcoming-investor-conferences-abus-20190926monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-biopharma-appoints-andrew-cheng-m-d-ph-d-to-its-board-of-directors-abus-20190820monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-at-wedbush-pacgrow-healthcare-conference-abus-20190806monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-second-quarter-2019-financial-results-and-provides-corporate-update-abus-20190805monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-second-quarter-2019-financial-results-abus-20190729monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-preliminary-phase-1a-1b-clinical-trial-results-for-ab-506-an-oral-capsid-abus-20190715monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-sells-part-of-its-onpattro-patisiran-royalty-interest-to-omers-abus-20190702monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-receives-regulatory-clearance-to-initiate-phase-1a-1b-clinical-trial-of-ab-729-abus-20190620monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-appoints-william-collier-as-next-president-ceo-and-announces-retirement-of-current-abus-20190617monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-at-jmp-securities-life-sciences-conference-abus-20190613monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-upcoming-may-2019-conferences-abus-20190513monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-first-quarter-2019-financial-results-and-provides-corporate-update-abus-20190506monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-first-quarter-2019-financial-results-abus-20190429monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-fourth-quarter-and-year-end-2018-financial-results-and-describes-recent-cl-abus-20190307monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-cowen-health-care-conference-abus-20190304monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-fourth-quarter-and-year-end-2018-financial-results-and-provide-corporate-abus-20190228monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-appoints-dr-frank-torti-as-chairman-of-its-board-of-directors-abus-20181126monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-2018-third-quarter-financial-results-and-provides-corporate-update-abus-20181107monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-third-quarter-2018-financial-results-abus-20181031monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-names-new-members-to-its-board-of-directors-abus-20181022monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-provides-update-on-hbv-development-programs-and-announces-appointment-of-dr-gaston-abus-20181009monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-chardan-s-genetic-medicines-conference-abus-20181002monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-at-the-2018-b-riley-fbr-healthcare-conference-abus-20180828monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-lnp-licensee-alnylam-announces-fda-approval-of-onpattro-patisiran-for-the-treatmen-abus-20180813monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-the-2018-wedbush-pacgrow-healthcare-conference-abus-20180809monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-2018-second-quarter-financial-results-and-provides-corporate-update-abus-20180802monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-report-second-quarter-2018-financial-results-abus-20180719monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-presents-corporate-update-on-key-milestones-abus-20180710monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-biopharma-to-present-at-first-annual-roivant-pipeline-day-abus-20180618monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-strengthens-management-team-with-appointment-of-david-c-hastings-as-new-chief-fina-abus-20180607monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-corporate-update-and-first-quarter-2018-financial-results-abus-20180503monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-conference-call-to-provide-a-corporate-update-and-first-quarter-2018-fin-abus-20180430monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-presents-complementary-results-from-preclinical-combination-studies-of-hbv-therape-abus-20180412monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-and-roivant-launch-genevant-sciences-with-industry-leading-platform-to-develop-bro-abus-20180411monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-hbv-data-at-2018-easl-liver-meeting-abus-20180328monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-corporate-update-and-year-end-2017-financial-results-abus-20180314monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-conference-call-to-provide-a-corporate-update-and-fourth-quarter-2017-ye-abus-20180312monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-settles-litigation-terminating-acuitas-rights-to-lnp-technology-abus-20180222monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-enters-exclusivity-agreement-with-roivant-sciences-abus-20180215monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-departure-of-chief-financial-officer-appoints-interim-cfo-abus-20180214monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-consolidates-hbv-business-around-warminster-pa-site-abus-20180208monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-presentations-at-hepdart-2017-abus-20171127monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-lnp-licensee-alnylam-initiates-rolling-submission-of-new-drug-application-nda-to-u-abus-20171116monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-lnp-licensee-alnylam-receives-accelerated-assessment-of-patisiran-from-european-me-abus-20171113monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-corporate-update-and-third-quarter-2017-financial-results-abus-20171102monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-conference-call-to-provide-a-corporate-update-and-third-quarter-2017-fin-abus-20171031monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-presents-hbv-data-at-2017-aasld-liver-meeting-abus-20171024monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-closing-of-50-million-first-tranche-of-116-4-million-strategic-investmen-abus-20171016monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-in-upcoming-investor-conferences-abus-20171010monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-hbv-data-at-2017-aasld-liver-meeting-abus-20171003monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-the-2017-cantor-fitzgerald-global-healthcare-conference-abus-20170925monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-topline-results-for-arb-1467-phase-ii-cohort-4-abus-20170925monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-presents-hbv-data-at-upcoming-scientific-conferences-abus-20170922monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-lnp-licensee-alnylam-announces-positive-phase-3-results-for-lnp-enabled-patisiran--abus-20170920monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-host-live-webinar-on-developments-of-lnp-delivery-for-mrna-based-therapeutics-abus-20170907monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-2017-wedbush-pacgrow-healthcare-conference-abus-20170814monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-corporate-update-and-second-quarter-2017-financial-results-abus-20170803monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-conference-call-to-provide-a-corporate-update-and-second-quarter-2017-fi-abus-20170801monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-conclusion-of-lnp-license-agreement-with-alexion-abus-20170727monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-in-upcoming-investor-conferences-abus-20170602monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-presents-hbv-drug-combination-studies-at-icar-abus-20170522monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-corporate-update-and-first-quarter-2017-financial-results-abus-20170504monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-conference-call-to-provide-a-corporate-update-and-first-quarter-2017-fin-abus-20170502monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-arb-1467-data-presentation-at-easl-abus-20170422monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-injunction-survives-attempted-appeal-by-acuitas-abus-20170413monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-appointment-of-daniel-burgess-to-board-of-directors-abus-20170323monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-year-end-2016-financial-results-abus-20170321monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-licenses-lnp-delivery-technology-to-alexion-for-use-in-single-messenger-rna-produc-abus-20170316monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-in-upcoming-investor-conferences-abus-20170306monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-in-upcoming-investor-conferences-abus-20170209monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-is-granted-a-pre-trial-injunction-restraining-acuitas-from-entering-into-agreement-abus-20170208monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-provides-additional-data-from-the-arb-1467-phase-ii-clinical-trial-in-hbv-patients-abus-20161212monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-presents-hbv-drug-combination-studies-at-aasld-abus-20161114monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-provides-corporate-update-and-announces-third-quarter-2016-financial-results-abus-20161103monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-recognizes-liver-cancer-awareness-month-with-grant-to-support-the-hepatitis-b-foun-abus-20161003monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-hbv-data-at-the-2016-aasld-liver-meeting-abus-20161001monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-interim-multi-dose-results-from-phase-ii-clinical-trial-of-arb-1467-in-pat-abus-20160929monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-chief-scientific-officer-dr-michael-j-sofia-awarded-the-2016-lasker-debakey-clinic-abus-20160913monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-the-2016-wedbush-pacgrow-healthcare-conference-abus-20160810monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-issuance-of-broad-new-us-patent-for-lnp-delivery-technology-abus-20160808monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-provides-corporate-update-and-announces-second-quarter-2016-financial-results-abus-20160804monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-topline-results-from-tkm-plk1-hcc-clinical-trial-abus-20160719monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-data-on-new-lnp-formulations-for-delivery-of-mrna-at-the-2016-controlle-abus-20160718monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-mrna-delivery-data-at-the-32nd-annual-meeting-of-the-japan-society-of-d-abus-20160630monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-in-upcoming-investor-conferences-abus-20160603monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-the-5th-antiviral-drugs-research-and-development-conference-abus-20160601monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-provides-corporate-update-and-announces-first-quarter-2016-financial-results-abus-20160504monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-expands-hbv-pipeline-abus-20160503monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-provide-a-corporate-update-and-release-first-quarter-2016-financial-results-abus-20160429monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-participate-in-upcoming-investor-conferences-abus-20160427monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-presents-data-from-combination-activity-studies-of-hbv-drug-candidates-abus-20160422monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-planned-executive-departure-abus-20160421monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-presents-data-on-hbv-capsid-assembly-inhibitor-ab-423-at-easl-2016-abus-20160414monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-preclinical-hbv-data-at-easl-2016-abus-20160330monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-year-end-2015-financial-results-abus-20160309monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-appoints-dr-elizabeth-howard-executive-vice-president-and-general-counsel-abus-20160308monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-biopharma-to-participate-in-upcoming-investor-conferences-abus-20160303monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-biopharma-to-participate-in-upcoming-investor-conferences-abus-20160204monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-provides-a-corporate-update-and-outlines-2016-milestones-abus-20160110monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-biopharma-announces-third-quarter-2015-financial-results-abus-20151105monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-provides-an-hbv-pipeline-update-abus-20151028monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-biopharma-presents-preclinical-data-at-the-2015-international-meeting-on-molecular-abus-20151006monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-tkm-hbv-data-at-the-2015-aasld-liver-meeting-abus-20151001monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-the-baird-2015-healthcare-conference-abus-20150909monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-announces-initiation-of-patient-dosing-in-the-tkm-plk1-hcc-expansion-cohort-abus-20150825monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-2015-wedbush-pacgrow-healthcare-conference-abus-20150807monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-biopharma-announces-second-quarter-2015-financial-results-abus-20150805monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-to-present-at-jefferies-hepatitis-b-summit-abus-20150803monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-biopharma-corporation-nasdaq-abus-to-ring-the-nasdaq-stock-market-opening-bell-abus-20150803monthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-biopharma-nasdaq-abus-finalizes-corporate-name-change-from-tekmira-pharmaceuticals-abus-20150803monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-bvs-20260106monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-present-at-the-piper-sandler-37th-annual-healthcare-conference-bvs-20251125monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-report-second-quarter-of-fiscal-year-2025-financial-results-on-august-6-2025-bvs-20250729monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-first-quarter-financial-results-bvs-20250506monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-report-first-quarter-of-fiscal-year-2025-financial-results-on-may-6-2025-bvs-20250428monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-report-fourth-quarter-of-fiscal-year-2024-financial-results-on-march-11-2025-bvs-20250228monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-bvs-20250107monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-third-quarter-financial-results-bvs-20241105monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-report-third-quarter-of-fiscal-year-2024-financial-results-on-november-5-2024-bvs-20241029monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-present-at-the-canaccord-genuity-44th-annual-global-growth-conference-bvs-20240807monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-alert-bragar-eagel-squire-p-c-is-investigating-bioventus-inc-on-behalf-of-long-t-bvs-20240803monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-report-second-quarter-of-fiscal-year-2024-financial-results-on-august-6-2024-bvs-20240730monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-first-quarter-financial-results-bvs-20240507monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-report-first-quarter-of-fiscal-year-2024-financial-results-on-may-7-2024-bvs-20240429monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-report-fourth-quarter-of-fiscal-year-2023-financial-results-on-march-12-2024-bvs-20240304monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-alert-bragar-eagel-squire-p-c-is-investigating-bioventus-inc-on-behalf-of-long-t-bvs-20240213monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-enters-into-an-amendment-with-its-credit-agreement-lenders-to-enhance-financial--bvs-20240118monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-announces-inducement-equity-to-president-and-chief-executive-officer-robert-clay-bvs-20240112monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-agrees-to-nationwide-contract-with-aetna-medicare-advantage-plans-for-durolane-f-bvs-20231206monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-report-third-quarter-of-fiscal-year-2023-financial-results-on-november-7-2023-bvs-20231031monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-present-at-the-cantor-global-healthcare-conference-bvs-20230920monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-present-at-the-morgan-stanley-21st-annual-global-healthcare-conference-bvs-20230906monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-present-at-the-canaccord-genuity-43rd-annual-global-growth-conference-bvs-20230804monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-report-second-quarter-of-fiscal-year-2023-financial-results-on-august-8-2023-bvs-20230801monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-first-quarter-financial-results-bvs-20230516monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reschedules-reporting-of-first-quarter-fiscal-year-2023-financial-results-to-aft-bvs-20230515monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reschedules-earnings-call-to-may-16-2023-files-for-extension-to-file-form-10-q-f-bvs-20230511monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-report-first-quarter-of-fiscal-year-2023-financial-results-on-may-11-2023-bvs-20230503monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-announces-ceo-leadership-change-bvs-20230405monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-enters-into-an-amendment-with-its-credit-agreement-lenders-to-enhance-financial--bvs-20230331monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reschedules-reporting-of-fourth-quarter-fiscal-year-2022-financial-results-to-ma-bvs-20230329monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-report-fourth-quarter-of-fiscal-year-2022-financial-results-on-march-30-2023-bvs-20230316monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-bvs-20230310monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-inc-nasdaq-bvs-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-inv-bvs-20230306monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-enters-into-settlement-agreement-to-preserve-maximum-optionality-up-to-350mm-of--bvs-20230228monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-bvs-20230214monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-inc-nasdaq-bvs-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-inv-bvs-20230214monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-inc-nasdaq-bvs-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-inv-bvs-20230207monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-inc-nasdaq-bvs-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-inv-bvs-20230131monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-bvs-20230126monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-inc-nasdaq-bvs-shareholder-class-action-alert-bernstein-liebhard-llp-announces-t-bvs-20230124monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-inc-investor-alert-kaplan-fox-kilshiemer-llp-notifies-bioventus-investors-of-a-c-bvs-20230119monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-bvs-20230104monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-bvs-20221128monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-inc-shareholder-alert-kaplan-fox-investigates-potential-securities-fraud-bvs-bvs-20221123monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-inc-shareholder-news-johnson-fistel-encourages-bvs-shareholders-with-losses-to-c-bvs-20221121monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-bvs-20221118monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-inc-investor-alert-kaplan-fox-investigates-potential-securities-fraud-bvs-bvs-20221117monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-files-for-extension-to-file-form-10-q-for-the-period-ended-october-1-2022-bvs-20221116monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-inc-shareholder-news-johnson-fistel-encourages-bvs-shareholders-with-losses-to-c-bvs-20221108monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-report-third-quarter-of-fiscal-year-2022-financial-results-on-november-8-2022-bvs-20221031monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-showcase-full-orthobiologics-and-ultrasonic-portfolio-at-nass-in-chicago-bvs-20221012monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-present-at-the-morgan-stanley-global-healthcare-conference-bvs-20220830monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-receives-fda-510-k-clearance-for-sonastar-elite-bvs-20220803monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-report-second-quarter-of-fiscal-year-2022-financial-results-on-august-11-2022-bvs-20220726monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-completes-cartiheal-acquisition-bvs-20220712monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-amends-cartiheal-acquisition-structure-bvs-20220621monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-cancels-proposed-415-million-offering-of-senior-notes-reaffirms-full-year-2022-f-bvs-20220503monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-agrees-to-nationwide-contract-with-cigna-commercial-plans-for-durolane-and-gelsy-bvs-20220502monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-announces-preliminary-first-quarter-net-sales-and-adjusted-ebitda-bvs-20220426monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-announces-415-million-offering-of-senior-notes-bvs-20220426monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-report-first-quarter-of-fiscal-year-2022-financial-results-on-may-10-2022-bvs-20220425monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-theraskin-coverage-expands-to-provide-for-17-million-more-covered-lives-bvs-20220408monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-announces-inducement-equity-to-svp-chief-financial-officer-mark-singleton-bvs-20220405monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-exercises-call-option-to-acquire-cartiheal-bvs-20220404monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-present-at-the-canaccord-genuity-musculoskeletal-conference-bvs-20220316monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-receives-510-k-clearance-for-stimrouter-pain-management-device-bvs-20220301monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-appoints-mark-singleton-as-chief-financial-officer-bvs-20220228monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-report-fourth-quarter-and-fiscal-year-2021-financial-results-on-march-10-2022-bvs-20220222monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-bvs-20211228monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-appoints-michelle-mcmurry-heath-to-board-of-directors-bvs-20211221monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-receives-us-fda-clearance-for-bonescalpel-access-bvs-20211220monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-expand-operations-and-manufacturing-in-memphis-bvs-20211118monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-announces-chief-financial-officer-transition-plan-bvs-20211115monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-completes-the-acquisition-of-misonix-bvs-20211029monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-release-third-quarter-of-fiscal-year-2021-financial-results-on-november-9-202-bvs-20211027monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-inc-and-misonix-inc-announce-election-deadline-of-5-00-p-m-new-york-city-time-on-bvs-20211018monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-proceeds-with-option-structure-agreement-with-cartiheal-bvs-20210830monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-invests-in-trice-medical-minimally-invasive-technologies-bvs-20210825monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-and-misonix-announce-definitive-agreement-for-bioventus-to-acquire-misonix-bvs-20210729monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-inc-reports-preliminary-second-quarter-net-sales-updates-full-year-2021-net-sale-bvs-20210729monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-management-to-present-at-canaccord-genuity-growth-conference-and-morgan-stanley--bvs-20210727monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-appoints-mary-kay-ladone-to-board-of-directors-bvs-20210714monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-launches-osteoamp-select-flowable-nationwide-bvs-20210713monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-invests-in-vaporox-bvs-20210624monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-release-second-quarter-of-fiscal-year-2021-financial-results-on-august-10-202-bvs-20210616monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-study-shows-novel-placental-tissue-biologic-candidate-inhibited-inflammatory-and-bvs-20210525monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-senior-management-to-present-at-upcoming-investor-conferences-bvs-20210517monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-announces-first-commercial-shipment-of-the-bioness-integrated-therapy-system-bit-bvs-20210427monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-release-first-quarter-of-fiscal-year-2021-financial-results-on-may-12-2021-bvs-20210412monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-acquires-bioness-inc-bvs-20210330monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-first-patients-enrolled-in-phase-1-clinical-trial-of-motys-ptp-001-for-t-bvs-20210311monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-to-release-fourth-quarter-and-fiscal-year-2020-financial-results-on-march-25-202-bvs-20210301monthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-announces-pricing-of-initial-public-offering-bvs-20210211monthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-to-participate-in-upcoming-march-investor-conferences-cbll-20260218monthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-to-participate-in-the-44th-annual-j-p-morgan-healthcare-conference-cbll-20251230monthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference-cbll-20251119monthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-to-report-third-quarter-2025-financial-results-on-november-4-2025-cbll-20251021monthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-to-participate-in-the-bank-of-america-securities-2025-health-care-conference-cbll-20250430monthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-receives-fedramp-high-authorization-expanding-approval-for-its-ai-powered-point-o-cbll-20250430monthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-to-report-first-quarter-2025-financial-results-on-may-8-2025-cbll-20250424monthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-to-participate-in-the-45th-annual-td-cowen-healthcare-conference-cbll-20250218monthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-to-report-fourth-quarter-and-full-year-2024-financial-results-on-february-25-2025-cbll-20250211monthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference-cbll-20241223monthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-appoints-kristie-rodenbush-as-chief-people-officer-and-brian-price-as-senior-vice-cbll-20241119monthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-receives-authority-to-operate-from-the-u-s-department-of-veterans-affairs-cbll-20241111monthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-se-cbll-20241107monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-announces-enrollment-completion-in-phase-3-compass-trial-of-bel-sar-in-ea-aura-20260601monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-to-participate-in-upcoming-investor-conferences-aura-20260512monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-to-participate-in-the-8th-annual-evercore-healthcare-conference-aura-20251124monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-announces-proposed-public-offering-of-common-stock-and-warrants-aura-20250515monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-announces-additional-data-from-ongoing-phase-1-trial-in-non-muscle-invasi-aura-20250303monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-to-participate-in-upcoming-investor-conferences-aura-20250225monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-to-participate-in-the-7th-annual-evercore-isi-healthconx-conference-aura-20241126monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-to-host-a-urologic-oncology-investor-event-to-present-early-non-muscle-in-aura-20240903monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-to-participate-in-upcoming-investor-conferences-aura-20240828monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-announces-the-presentation-of-phase-2-end-of-study-data-evaluating-suprac-aura-20240826monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-to-participate-in-the-jefferies-global-healthcare-conference-aura-20240530monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-to-host-virtual-kol-event-pioneering-a-new-standard-of-care-in-ocular-onc-aura-20240523monthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-to-participate-in-upcoming-investor-conferences-aura-20240508monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-announces-inducement-grants-to-new-employees-under-nasdaq-listing-rule--avtx-20260218monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-avtx-20250827monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-avtx-20250623monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-avtx-20250527monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-to-participate-in-the-citizens-life-sciences-conference-avtx-20250430monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-avtx-20250224monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-to-present-at-oppenheimer-s-35th-annual-healthcare-life-sciences-confer-avtx-20250204monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-to-present-at-upcoming-investor-conferences-avtx-20241111monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-announces-participation-in-september-investor-conferences-avtx-20240904monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit-avtx-20240617monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-appoints-biotech-leaders-to-board-of-directors-avtx-20240402monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-announces-1-for-240-reverse-stock-split-avtx-20231227monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-completes-divestiture-of-avtx-800-series-avtx-20231031monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-avtx-20230906monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-to-participate-in-svb-securities-therapeutics-forum-avtx-20230706monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-to-present-at-the-jefferies-healthcare-conference-avtx-20230601monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-announces-appointment-of-michael-croft-ph-d-and-jeff-edelson-m-d-to-its-scientific-a-avtx-20230522monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-to-present-at-ats-2023-respiratory-innovation-summit-avtx-20230515monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-to-present-at-the-2023-rbc-capital-markets-global-healthcare-conference-avtx-20230510monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-to-present-at-oppenheimer-s-33rd-annual-healthcare-conference-avtx-20230307monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-inc-announces-pricing-of-15-million-public-offering-of-common-stock-and-avtx-20230203monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-sells-economic-rights-to-previously-out-licensed-assets-for-5-million-avtx-20221107monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-advances-btla-agonist-fusion-protein-avtx-008-to-ind-enabling-stage-avtx-20220906monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-to-present-at-the-h-c-wainwright-global-investment-conference-avtx-20220901monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-announces-board-changes-avtx-20220811monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-announces-first-patient-dosed-in-the-avtx-803-pivotal-trial-ladder-for--avtx-20220802monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-announces-one-for-twelve-reverse-stock-split-avtx-20220706monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-to-present-at-the-2022-jefferies-healthcare-conference-avtx-20220602monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-to-present-at-the-h-c-wainwright-global-life-sciences-conference-avtx-20220517monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-to-present-at-oppenheimer-s-32nd-annual-healthcare-conference-avtx-20220308monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-to-present-at-the-2022-bio-ceo-and-investor-conference-avtx-20220207monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-appoints-stephen-smolinski-as-chief-commercial-officer-avtx-20220111monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-to-host-virtual-investor-day-on-january-6-2022-avtx-20211216monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-to-present-at-two-upcoming-conferences-avtx-20211111monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-to-present-at-the-jefferies-virtual-next-generation-ibd-therapeutics-summit-avtx-20211013monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-to-present-at-the-2021-cantor-virtual-global-healthcare-conference-avtx-20210920monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-inc-announces-closing-of-a-31-5-million-public-offering-of-common-stock-avtx-20210917monthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-inc-announces-pricing-of-27-5-million-public-offering-of-common-stock-avtx-20210915monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-to-present-at-upcoming-investor-conferences-bioa-20260522monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-to-host-r-d-day-focused-on-nlrp3-inhibition-on-may-8-2026-bioa-20260504monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-reports-positive-phase-1-data-for-bge-102-a-novel-oral-nlrp3-inhibitor-demonstratin-bioa-20260421monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-to-present-at-oppenheimer-36th-annual-healthcare-life-sciences-conference-bioa-20260219monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-investigation-alert-bragar-eagel-squire-p-c-continues-investigation-into-bioage-lab-bioa-20251002monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-alert-bragar-eagel-squire-p-c-is-investigating-bioage-labs-inc-on-behalf-of-long-te-bioa-20250703monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-expands-apj-agonist-pipeline-with-oral-small-molecule-and-long-acting-biologic-cand-bioa-20250603monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-completes-ind-enabling-studies-for-bge-102-a-potent-orally-available-brain-pen-bioa-20250529monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-to-present-at-upcoming-investor-conferences-bioa-20250527monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-alert-bragar-eagel-squire-p-c-is-investigating-bioage-labs-inc-on-behalf-of-long-te-bioa-20250522monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-abandons-obesity-drug-amid-shareholder-lawsuit-hagens-berman-bioa-20250307monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-march-bioa-20250305monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-befor-bioa-20250304monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-shares-plummet-after-discontinuing-trial-just-2-months-after-ipo-hagens-b-bioa-20250303monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-inc-nasdaq-bioa-deadline-alert-bernstein-liebhard-llp-reminds-bioage-labs-inc--bioa-20250303monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-shares-plummet-after-discontinuing-trial-just-2-months-after-ipo-hagens-b-bioa-20250228monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-abandons-obesity-drug-amid-shareholder-lawsuit-hagens-berman-bioa-20250227monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-inc-class-action-the-gross-law-firm-reminds-bioage-investors-of-the-pending-cl-bioa-20250226monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-inc-nasdaq-bioa-deadline-alert-bernstein-liebhard-llp-reminds-bioage-labs-inc--bioa-20250225monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-abandons-obesity-drug-amid-shareholder-lawsuit-hagens-berman-bioa-20250224monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-bioa-20250221monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-abandons-obesity-drug-amid-shareholder-lawsuit-hagens-berman-bioa-20250221monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-to-participate-in-td-cowen-s-45th-annual-health-care-conference-bioa-20250220monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-abandons-obesity-drug-amid-shareholder-lawsuit-hagens-berman-bioa-20250219monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-shares-plummet-after-discontinuing-trial-just-2-months-after-ipo-hagens-b-bioa-20250217monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-faces-securities-class-action-on-behalf-of-ipo-investors-after-discontinu-bioa-20250214monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-faces-securities-class-action-on-behalf-of-ipo-investors-after-discontinu-bioa-20250212monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-faces-securities-class-action-on-behalf-of-ipo-investors-after-discontinu-bioa-20250210monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-shares-plummet-after-discontinuing-trial-just-2-months-after-ipo-hagens-b-bioa-20250207monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-shares-plummet-after-discontinuing-trial-just-2-months-after-ipo-hagens-b-bioa-20250205monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-shares-plummet-after-discontinuing-trial-just-2-months-after-ipo-hagens-b-bioa-20250203monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-faces-securities-class-action-on-behalf-of-ipo-investors-after-discontinu-bioa-20250131monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-faces-securities-class-action-on-behalf-of-ipo-investors-after-discontinu-bioa-20250129monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-b-bioa-20250129monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-announces-company-updates-on-apj-nlrp3-and-platform-programs-bioa-20250128monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-faces-securities-class-action-on-behalf-of-ipo-investors-after-discontinu-bioa-20250127monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-inc-bioa-investors-march-10-2025-filing-deadline-in-securities-class-action-co-bioa-20250126monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-shares-plummet-after-discontinuing-trial-just-2-months-after-ipo-hagens-b-bioa-20250124monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-march-bioa-20250123monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-shares-plummet-after-discontinuing-trial-just-2-months-after-ipo-hagens-b-bioa-20250122monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-inc-sued-for-securities-law-violations-contact-the-gross-law-firm-before-march-bioa-20250121monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-faces-securities-class-action-on-behalf-of-ipo-investors-after-discontinu-bioa-20250120monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-inc-class-action-notice-robbins-llp-reminds-stockholders-of-the-lead-plaintiff-bioa-20250117monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-faces-securities-class-action-on-behalf-of-ipo-investors-after-discontinu-bioa-20250117monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-faces-securities-class-action-on-behalf-of-ipo-investors-after-discontinu-bioa-20250115monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-faces-securities-class-action-on-behalf-of-ipo-investors-after-discontinu-bioa-20250113monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-faces-securities-class-action-on-behalf-of-ipo-investors-after-discontinu-bioa-20250110monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-inc-nasdaq-bioa-investor-alert-investors-with-large-losses-in-bioage-labs-inc--bioa-20250108monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed--bioa-20250108monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-faces-securities-class-action-on-behalf-of-ipo-investors-after-discontinu-bioa-20250108monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-investigation-investors-are-alerted-the-company-is-being-investigated-after-ph-bioa-20250103monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-azelaprag-trial-halt-raises-questions-about-pre-ipo-disclosures-hagens-be-bioa-20241227monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-alert-bragar-eagel-squire-p-c-is-investigating-bioage-labs-inc-on-behalf-of-bioage--bioa-20241224monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-azelaprag-trial-halt-raises-questions-about-pre-ipo-disclosures-hagens-be-bioa-20241223monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-investors-who-have-lost-money-should-contact-block-leviton-to-find-out-how-the-bioa-20241223monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-azelaprag-trial-halt-raises-questions-about-pre-ipo-disclosures-hagens-be-bioa-20241219monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-announces-multi-year-collaboration-with-novartis-to-discover-novel-targets-for-bioa-20241218monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-alert-bragar-eagel-squire-p-c-is-investigating-bioage-labs-inc-on-behalf-of-bioage--bioa-20241218monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-azelaprag-trial-halt-raises-questions-about-pre-ipo-disclosures-hagens-be-bioa-20241216monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-azelaprag-trial-halt-raises-questions-about-pre-ipo-disclosures-hagens-be-bioa-20241212monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-inc-alert-securities-fraud-investigation-by-block-leviton-could-allow-investor-bioa-20241210monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-bioa-azelaprag-trial-halt-raises-questions-about-pre-ipo-disclosures-hagens-be-bioa-20241210monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-announces-discontinuation-of-strides-phase-2-clinical-trial-evaluating-azelapr-bioa-20241206monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-to-present-at-goldman-sachs-year-ahead-catalyst-clinic-bioa-20241205monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-to-present-at-upcoming-investor-conferences-bioa-20241121monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-reports-third-quarter-2024-financial-results-and-provides-business-updates-bioa-20241107monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-to-present-preclinical-data-for-apj-agonist-azelaprag-at-obesityweek-2024-bioa-20241104monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-to-present-at-jefferies-london-healthcare-conference-bioa-20241024monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-announces-closing-of-initial-public-offering-full-exercise-of-underwriters-opt-bioa-20241001monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-announces-pricing-of-upsized-initial-public-offering-bioa-20240926monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-raises-90m-to-treat-aging-and-age-related-diseases-bioa-20201203monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-discovers-key-pathway-and-identifies-promising-phase-2-ready-drug-to-treat-and-reve-bioa-20200825monthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-signs-exclusive-license-agreement-with-taisho-to-develop-and-commercialize-taisho-s-bioa-20200430monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-presents-new-data-from-clear-outcomes-and-the-clear-path-phase-2-pediatric-study--espr-20260526monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20260514monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-first-quarter-2026-financial-results-on-may-7-espr-20260423monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-therapeutics-closes-acquisition-of-corstasis-therapeutics-expanding-its-cardiovas-espr-20260402monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-25th-annual-needham-virtual-healthcare-conference-espr-20260331monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-s-bempedoic-acid-receives-multiple-class-1-recommendations-in-2026-acc-aha-multis-espr-20260316monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-espr-20260310monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-the-2026-citizens-life-sciences-conference-espr-20260218monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version--espr-20260217monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20260211monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-provides-business-update-at-44th-annual-j-p-morgan-healthcare-conference-espr-20260111monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20251209monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-piper-sandler-37th-annual-healthcare-conference-espr-20251119monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-partner-hls-therapeutics-announces-approval-of-nilemdo-for-the-reduction-of-ldl-c-espr-20251118monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-third-quarter-2025-financial-results-on-november-6-espr-20251023monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reaches-settlement-agreement-with-anda-filer-dr-reddy-s-laboratories-not-to-marke-espr-20251003monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-partner-otsuka-receives-regulatory-approval-to-market-nexletol-in-japan-for-the-t-espr-20250919monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-s-bempedoic-acid-receives-level-1a-recommendation-in-updated-esc-eas-guidelines-f-espr-20250829monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-september-investor-conferences-espr-20250826monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20250807monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-second-quarter-2025-financial-results-and-provides-business-update-espr-20250805monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-second-quarter-2025-financial-results-on-august-5-espr-20250722monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reaches-settlement-agreement-with-third-anda-filer-not-to-market-generic-version--espr-20250708monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-appoints-craig-thompson-to-board-of-directors-espr-20250701monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reaches-settlement-agreement-with-second-anda-filer-not-to-market-generic-version-espr-20250602monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-june-investor-conferences-espr-20250520monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reaches-settlement-agreement-with-anda-filer-not-to-market-generic-version-of-nex-espr-20250512monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-h-c-wainwright-s-3rd-annual-bioconnect-investor-conference-espr-20250509monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20250508monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-partners-with-hls-therapeutics-to-commercialize-nexletol-bempedoic-acid-and-nexli-espr-20250508monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-first-quarter-2025-financial-results-espr-20250506monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-the-citizens-life-sciences-conference-espr-20250425monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-unveils-promising-research-supporting-lead-development-candidates-for-primary-scl-espr-20250424monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-first-quarter-2025-financial-results-on-may-6-espr-20250423monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-host-r-d-day-to-highlight-cardiometabolic-pipeline-innovation-and-next-generat-espr-20250410monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-appoints-robert-e-hoffman-to-board-of-directors-espr-20250401monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-24th-annual-needham-virtual-healthcare-conference-espr-20250324monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-aligns-with-u-s-food-and-drug-administration-to-initiate-phase-3-clinical-trials--espr-20250320monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-fourth-quarter-and-full-year-2024-financial-results-espr-20250304monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-partners-with-csl-seqirus-to-commercialize-nexletol-bempedoic-acid-and-nexlizet-b-espr-20250303monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-4-espr-20250218monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20250213monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-11-30-a--espr-20250109monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-43rd-annual-j-p-morgan-healthcare-conference-espr-20250102monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-strengthens-balance-sheet-with-closing-of-significant-refinancing-transactions-espr-20241218monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-210-million-convertible-debt-financing-espr-20241213monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-partners-with-neopharm-to-commercialize-nexletol-bempedoic-acid-and-nexlizet-bemp-espr-20241212monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-new-drug-submissions-in-canada-for-nexletol-bempedoic-acid-and-nexlizet-espr-20241202monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-piper-sandler-36th-annual-healthcare-conference-espr-20241121monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-highlights-new-exploratory-data-from-clear-outcomes-trial-highlighting-value-of-n-espr-20241118monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20241108monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-third-quarter-2024-financial-results-and-provides-a-business-update-espr-20241107monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-jefferies-london-healthcare-conference-espr-20241104monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-a-featured-presentation-in-the-late-breaker-featured-science-track-and--espr-20241031monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-third-quarter-2024-financial-results-on-november-7-espr-20241024monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-eu-partner-reports-final-real-world-results-from-milos-german-cohort-demonstratin-espr-20241002monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-espr-20240925monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-2024-cantor-global-healthcare-conference-espr-20240905monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-secures-additional-commercial-and-medicare-formulary-coverage-for-nexletol-bemped-espr-20240903monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-h-c-wainwright-26th-annual-global-investment-conferenc-espr-20240826monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-second-quarter-2024-financial-results-and-provides-a-business-update-espr-20240812monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20240807monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-second-quarter-2024-financial-results-on-august-12-espr-20240725monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-btig-biotech-conference-espr-20240724monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-june-investor-conferences-espr-20240523monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-receives-five-year-patent-extension-for-bempedoic-acid-contained-in-nexletol-and--espr-20240514monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20240510monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-first-quarter-2024-financial-results-espr-20240507monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-may-investor-conferences-espr-20240429monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-first-quarter-2024-financial-results-on-may-7-espr-20240423monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-presents-important-new-data-from-clear-outcomes-at-acc-24-highlighting-value-of-n-espr-20240407monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-ring-nasdaq-opening-bell-today-april-1-2024-espr-20240401monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-23rd-annual-needham-virtual-healthcare-conference-espr-20240326monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-data-from-clear-outcomes-sub-groups-as-poster-presentations-moderated-s-espr-20240325monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-fourth-quarter-and-full-year-2023-financial-results-espr-20240227monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20240216monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-fourth-quarter-and-full-year-2023-financial-results-on-february-27-espr-20240213monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-closing-of-public-offering-of-common-stock-and-exercise-in-full-of-unde-espr-20240123monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-pricing-of-85-1-million-public-offering-of-common-stock-espr-20240119monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-and-daiichi-sankyo-europe-announce-125-million-amendment-to-their-collaboration-i-espr-20240103monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-42nd-annual-j-p-morgan-healthcare-conference-espr-20231218monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-presents-clear-outcomes-analysis-of-inflammation-as-predictor-of-cardiovascular-r-espr-20231113monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20231109monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-third-quarter-2023-financial-results-espr-20231107monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-jefferies-london-healthcare-conference-espr-20231031monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-third-quarter-2023-financial-results-on-november-7-espr-20231024monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-h-c-wainwright-25th-annual-global-investment-conference-espr-20230828monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-presents-two-clear-outcomes-study-late-breakers-at-european-society-of-cardiology-espr-20230826monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20230808monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-second-quarter-2023-financial-results-espr-20230801monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-btig-virtual-biotechnology-conference-2023-espr-20230724monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-second-quarter-2023-financial-results-on-august-1-espr-20230717monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-present-additional-data-from-the-clear-outcomes-study-on-cvd-prevention-at-the-espr-20230707monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-submission-of-application-for-expanded-indication-with-the-european-med-espr-20230628monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-presents-results-from-new-analysis-on-cardiovascular-benefits-with-bempedoic-acid-espr-20230615monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-present-new-key-science-at-the-american-diabetes-association-s-83rd-scientific-espr-20230608monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-present-additional-analyses-from-the-landmark-clear-outcomes-study-at-endo-202-espr-20230605monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-submission-of-supplemental-new-drug-applications-to-u-s-fda-for-nexleto-espr-20230601monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-adjournment-of-2023-annual-meeting-of-stockholders-espr-20230525monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-jefferies-healthcare-conference-espr-20230524monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20230512monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-first-quarter-2023-financial-results-espr-20230509monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-retains-gibson-dunn-to-secure-300-million-payment-from-dse-will-announce-first-qu-espr-20230504monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-jmp-securities-life-sciences-conference-espr-20230501monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-bank-of-america-securities-2023-health-care-conference-espr-20230427monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-first-quarter-2023-financial-results-may-9-2023-espr-20230425monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-co-promotion-agreement-with-currax-pharmaceuticals-llc-espr-20230419monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-needham-22nd-annual-virtual-healthcare-conference-espr-20230403monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-closing-of-56-7-million-registered-direct-offering-priced-at-the-market-espr-20230322monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-launches-new-scientific-website-espr-20230224monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-the-cowen-43rd-annual-healthcare-conference-espr-20230223monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-positive-clear-outcomes-results-to-be-presented-as-late-breaking-clinic-espr-20230220monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20230213monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-fourth-quarter-and-full-year-2022-financial-results-february-21-2023-espr-20230207monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20221213monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-january-investor-meetings-espr-20221213monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-clear-cardiovascular-outcomes-trial-of-nexletol-bempedoic-acid-meets-pr-espr-20221207monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-virtual-research-development-day-to-highlight-pipeline-programs-and-scientific-fo-espr-20221109monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-jefferies-london-healthcare-conference-espr-20221102monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-hosting-virtual-research-development-day-espr-20221027monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20221019monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-third-quarter-2022-financial-results-november-1-2022-espr-20221017monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-september-investor-conferences-espr-20220830monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-bempedoic-acid-nexletol-recommended-as-oral-non-statin-therapy-for-ldl--espr-20220826monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20220804monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-establishment-of-scientific-advisory-board-to-support-pipeline-and-life-espr-20220725monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-second-quarter-2022-financial-results-august-2-2022-espr-20220712monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-the-2022-jefferies-global-healthcare-conference-espr-20220602monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-the-appointment-of-j-martin-carroll-to-its-board-of-directors-espr-20220601monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-five-abstracts-accepted-for-presentation-at-the-national-lipid-associat-espr-20220531monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-h-c-wainwright-global-investment-conference-espr-20220517monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-publication-of-clear-harmony-open-label-extension-study-data-for-bemped-espr-20220502monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20220429monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-bank-of-america-securities-2022-healthcare-conference-espr-20220429monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-supports-collaborative-study-with-an-integrated-and-learning-health-care-delivery-espr-20220425monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-first-quarter-2022-financial-results-may-3-2022-espr-20220419monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-publication-of-phase-3-data-for-bempedoic-acid-in-the-journal-of-clinic-espr-20220413monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-two-nexletol-bempedoic-acid-data-presentations-at-the-american-college--espr-20220403monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-21st-annual-needham-virtual-healthcare-conference-espr-20220329monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-virtual-cowen-42nd-annual-healthcare-conference-espr-20220224monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-fourth-quarter-and-full-year-2021-financial-results-february-22-2022-espr-20220208monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20220128monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-virtual-j-p-morgan-40th-annual-healthcare-conference-espr-20220106monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-closing-of-225-million-public-offering-espr-20211207monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-pricing-of-225-million-public-offering-espr-20211203monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-presents-important-new-science-highlighting-potential-benefits-of-nexletol-bemped-espr-20211112monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-third-quarter-2021-financial-results-and-provides-company-update-espr-20211102monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-present-key-science-at-the-american-heart-association-scientific-sessions-2021-espr-20211101monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-virtual-investor-conference-espr-20211027monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-third-quarter-2021-financial-results-november-2-2021-espr-20211012monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-host-investor-webinar-on-the-current-landscape-and-future-directions-in-the-tr-espr-20210907monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-virtual-investor-conference-espr-20210826monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-second-quarter-2021-financial-results-and-provides-company-update-espr-20210803monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-virtual-investor-conference-espr-20210727monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-second-quarter-2021-financial-results-august-3-2021-espr-20210713monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20210701monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-two-upcoming-virtual-investor-conferences-espr-20210524monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-two-upcoming-virtual-investor-conferences-espr-20210506monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-first-quarter-2021-financial-results-and-provides-company-update-espr-20210504monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20210428monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-publication-of-rationale-and-design-of-landmark-clear-cardiovascular-ou-espr-20210427monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-secures-50-million-funding-from-oberland-capital-espr-20210426monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-expands-partnership-with-daiichi-sankyo-group-to-additional-territories-espr-20210426monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-first-quarter-2021-financial-results-may-4-2021-espr-20210412monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-fireside-chat-at-the-20th-annual-needham-virtual-healthcare-con-espr-20210406monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-company--espr-20210223monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-fourth-quarter-and-full-year-2020-financial-results-february-23-2021-espr-20210209monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20210129monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-preliminary-fourth-quarter-2020-financial-results-and-further-commits-to--espr-20210113monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-espr-20201221monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-appoints-sheldon-koenig-as-chief-operating-officer-espr-20201215monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-pricing-of-offering-of-250-0-million-of-convertible-senior-subordinated-espr-20201112monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20201106monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-third-quarter-2020-financial-results-and-provides-company-update-espr-20201102monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-three-upcoming-virtual-investor-conferences-espr-20201027monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-third-quarter-2020-financial-results-november-2-2020-espr-20201019monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-launches-u-s-direct-to-consumer-campaign-to-accelerate-awareness-of-nexletol-bemp-espr-20200928monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-two-upcoming-virtual-investor-conferences-espr-20200902monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-two-data-presentations-of-nexletol-bempedoic-acid-tablet-at-the-esc-con-espr-20200826monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20200821monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-second-quarter-2020-financial-results-and-provides-company-update-espr-20200810monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-second-quarter-2020-financial-results-august-10-2020-espr-20200803monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-publication-in-the-journal-of-the-american-medical-association-cardiolo-espr-20200701monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-and-daiichi-sankyo-europe-announce-amendment-to-license-and-commercial-collaborat-espr-20200622monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-pooled-analysis-from-phase-3-ldl-c-lowering-clinical-development-progra-espr-20200614monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-confirms-nexletol-bempedoic-acid-tablets-to-be-included-in-assessment-of-non-stat-espr-20200612monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-fireside-chat-at-the-goldman-sachs-41st-annual-global-healthcar-espr-20200608monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-commercial-availability-of-nexlizet-bempedoic-acid-and-ezetimibe-tablet-espr-20200604monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-fireside-chat-at-the-jefferies-virtual-global-healthcare-confer-espr-20200527monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20200515monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-fireside-chat-at-the-bofa-securities-2020-healthcare-conference-espr-20200507monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-reports-first-quarter-2020-financial-results-and-provides-company-update-espr-20200506monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-first-quarter-2020-financial-results-may-6-2020-espr-20200430monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-agreement-with-otsuka-pharmaceutical-co-ltd-for-development-and-commerc-espr-20200420monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-fireside-chat-at-the-19th-annual-needham-virtual-healthcare-con-espr-20200409monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-european-commission-approval-of-the-nustendi-bempedoic-acid-and-ezetimi-espr-20200406monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-commercial-availability-of-the-nexletol-bempedoic-acid-tablet-and-pledg-espr-20200330monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-three-data-presentations-of-the-nexletol-bempedoic-acid-tablet-and-the--espr-20200328monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-pooled-analyses-from-phase-3-ldl-c-lowering-development-program-of-the--espr-20200323monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-the-appointment-of-alan-fuhrman-to-its-board-of-directors-espr-20200318monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20200228monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-investor-conferences-espr-20200228monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-provides-lipid-management-franchise-updates-reports-fourth-quarter-and-full-year--espr-20200227monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-fda-approval-of-nexletol-bempedoic-acid-tablet-an-oral-once-daily-non-s-espr-20200221monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-positive-chmp-opinion-for-the-marketing-authorisation-application-for-t-espr-20200131monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-espr-20200107monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20200103monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20191122monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-pooled-analyses-from-phase-3-ldl-c-lowering-clinical-development-progra-espr-20191117monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-publication-in-the-journal-of-the-american-medical-association-of-bempe-espr-20191112monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-investor-conferences-espr-20191107monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-provides-bempedoic-acid-franchise-development-program-updates-reports-third-quart-espr-20191106monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-pooled-analyses-from-phase-3-ldl-c-lowering-development-program-of-bemp-espr-20191104monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-third-quarter-2019-financial-results-november-6-2019-espr-20191029monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-completes-patient-enrollment-in-the-global-clear-cardiovascular-outcomes-trial-fo-espr-20190905monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20190830monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-positive-top-line-results-from-phase-2-study-of-bempedoic-acid-ezetimib-espr-20190829monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-provides-bempedoic-acid-franchise-development-program-updates-reports-second-quar-espr-20190808monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-present-at-the-btig-biotechnology-conference-espr-20190806monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-report-second-quarter-2019-financial-results-august-8-2019-espr-20190730monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-and-oberland-capital-announce-200-million-funding-agreement-espr-20190626monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-the-appointment-of-tracy-m-woody-to-board-of-directors-espr-20190530monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-investor-conferences-espr-20190528monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-investor-conferences-espr-20190510monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-provides-bempedoic-acid-franchise-development-program-updates-reports-first-quart-espr-20190508monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-host-analyst-and-investor-day-event-on-may-30-espr-20190507monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-u-s-fda-acceptance-of-new-drug-applications-ndas-for-both-bempedoic-aci-espr-20190505monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-present-at-the-needham-company-18th-annual-healthcare-conference-espr-20190402monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-publication-in-the-journal-of-the-american-heart-association-of-bempedo-espr-20190401monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-late-breaking-presentation-of-final-results-of-bempedoic-acid-pivotal-p-espr-20190318monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-publication-of-bempedoic-acid-study-1-results-in-the-new-england-journa-espr-20190313monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-investor-conferences-espr-20190304monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-presentation-of-bempedoic-acid-pivotal-phase-3-study-2-results-in-a-lat-espr-20190304monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-provides-bempedoic-acid-franchise-development-program-updates-reports-fourth-quar-espr-20190228monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-submissions-of-two-ndas-and-official-completion-of-two-maa-validations--espr-20190228monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20190222monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-agreement-with-daiichi-sankyo-europe-dse-to-commercialize-bempedoic-aci-espr-20190104monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-espr-20190102monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-late-breaking-oral-presentation-of-final-study-3-results-1002-046-of-be-espr-20181110monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-upcoming-investor-conferences-espr-20181108monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-provides-bempedoic-acid-franchise-development-program-updates-reports-third-quart-espr-20181101monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-completion-of-phase-3-ldl-c-lowering-development-program-of-bempedoic-a-espr-20181028monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20181018monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-late-breaking-oral-presentation-of-final-results-of-phase-3-long-term-s-espr-20180825monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20180810monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-provides-bempedoic-acid-franchise-development-program-updates-reports-second-quar-espr-20180802monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-host-analyst-and-investor-day-event-on-july-10-espr-20180703monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-late-breaking-oral-presentation-of-full-study-4-results-1002-048-at-the-espr-20180612monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-fireside-chat-at-the-jefferies-2018-global-healthcare-conferenc-espr-20180530monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-the-appointment-of-jay-p-shepard-to-board-of-directors-espr-20180529monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20180525monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-third-pivotal-phase-3-study-of-bempedoic-acid-meets-primary-endpoint-espr-20180523monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-fireside-chat-at-the-ubs-global-healthcare-conference-espr-20180522monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-fireside-chat-at-the-bank-of-america-merrill-lynch-2018-healthc-espr-20180510monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-investor-alert-faruqi-faruqi-llp-encourages-investors-who-suffered-losses-exceedi-espr-20180508monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-fireside-chat-at-the-deutsche-bank-43rd-annual-health-care-conf-espr-20180504monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-provides-bempedoic-acid-franchise-development-program-updates-reports-first-quart-espr-20180502monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-positive-top-line-results-from-pivotal-phase-3-long-term-safety-study-o-espr-20180502monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20180413monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-positive-top-line-results-from-phase-2-study-of-bempedoic-acid-added-on-espr-20180327monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-fireside-chat-at-march-2018-investor-conferences-espr-20180307monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-positive-top-line-results-from-first-pivotal-phase-3-study-of-bempedoic-espr-20180307monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20180223monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-provides-bempedoic-acid-franchise-development-program-updates-reports-fourth-quar-espr-20180220monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-fireside-chat-at-the-36th-annual-j-p-morgan-healthcare-conferen-espr-20180103monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-the-appointment-of-jeffrey-berkowitz-to-board-of-directors-espr-20171214monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20171201monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-fireside-chat-at-the-jefferies-2017-london-healthcare-conferenc-espr-20171113monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-fireside-chat-at-the-stifel-2017-healthcare-conference-espr-20171109monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-provides-bempedoic-acid-franchise-development-program-updates-reports-third-quart-espr-20171107monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-initiation-of-pivotal-phase-3-study-for-the-bempedoic-acid-ezetimibe-co-espr-20171106monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-host-analyst-and-investor-day-event-on-october-17-espr-20171010monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-completes-patient-enrollment-in-global-pivotal-phase-3-program-for-bempedoic-acid-espr-20171002monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20170811monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-prices-public-offering-of-common-stock-espr-20170810monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-proposed-public-offering-of-common-stock-espr-20170808monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-provides-bempedoic-acid-franchise-development-program-updates-reports-second-quar-espr-20170808monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-positive-top-line-results-from-phase-2-study-of-bempedoic-acid-ezetimib-espr-20170808monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-provide-bempedoic-acid-franchise-development-program-updates-and-second-quarte-espr-20170802monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-initiation-of-phase-2-study-of-bempedoic-acid-added-on-to-a-pcsk9-inhib-espr-20170726monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-fda-confirmation-of-regulatory-pathway-to-approval-for-the-combination--espr-20170626monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-present-at-the-jmp-securities-2017-life-sciences-conference-espr-20170614monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-present-at-the-jefferies-2017-global-healthcare-conference-espr-20170531monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-provides-update-on-common-stock-trading-activity-espr-20170522monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-fireside-chat-at-the-ubs-global-healthcare-conference-espr-20170519monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-espr-20170518monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-fireside-chat-at-the-bank-of-america-merrill-lynch-2017-healthc-espr-20170512monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-provides-bempedoic-acid-development-program-updates-reports-first-quarter-2017-fi-espr-20170504monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-fireside-chat-at-the-16th-annual-needham-healthcare-conference-espr-20170328monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-fda-confirmation-regarding-regulatory-pathway-to-approval-for-an-ldl-c--espr-20170320monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-initiation-of-phase-2-triplet-oral-therapy-study-of-bempedoic-acid-ezet-espr-20170307monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-oral-presentation-on-genetic-validation-of-atp-citrate-lyase-inhibition-espr-20170306monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-provides-bempedoic-acid-development-program-update-reports-fourth-quarter-and-ful-espr-20170222monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-participate-in-fireside-chat-at-rbc-capital-markets-global-healthcare-conferen-espr-20170215monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-completes-enrollment-of-pivotal-phase-3-long-term-safety-and-tolerability-study-o-espr-20170125monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-initiation-of-global-cardiovascular-outcomes-trial-for-bempedoic-acid-espr-20170109monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-announces-initiation-of-three-pivotal-phase-3-studies-for-bempedoic-acid-espr-20170108monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-espr-20170104monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-therapeutics-announces-publication-of-definitive-paper-on-bempedoic-acid-mechanis-espr-20161128monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-therapeutics-to-present-at-the-stifel-2016-healthcare-conference-espr-20161109monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-therapeutics-provides-bempedoic-acid-development-program-updates-reports-third-qu-espr-20161103monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-therapeutics-to-present-at-the-credit-suisse-25th-annual-healthcare-conference-espr-20161101monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-therapeutics-provides-bempedoic-acid-development-program-updates-reports-second-q-espr-20160804monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-therapeutics-provides-clinical-development-and-regulatory-update-for-bempedoic-ac-espr-20160628monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-therapeutics-provides-bempedoic-acid-development-program-updates-reports-first-qu-espr-20160504monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-72-hour-deadline-alert-approximately-72-hours-remain-former-louisiana-attorney-ge-espr-20160312monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-therapeutics-to-present-at-the-barclays-global-healthcare-conference-espr-20160308monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-therapeutics-provides-bempedoic-acid-development-program-update-reports-fourth-qu-espr-20160225monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-therapeutics-to-present-at-the-2016-rbc-capital-markets-global-healthcare-confere-espr-20160216monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-therapeutics-announces-initiation-of-phase-3-clinical-program-with-long-term-safe-espr-20160113monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-therapeutics-to-present-at-34th-annual-j-p-morgan-healthcare-conference-espr-20160106monthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-therapeutics-inc-espr-to-ring-the-nasdaq-stock-market-opening-bell-espr-20130716monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-en-gyre-20260420monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-announces-nmpa-approval-for-clinical-trial-evaluating-pirfenidone-capsul-gyre-20250331monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-announces-publication-of-protocol-for-phase-3-trial-evaluating-f351-for--gyre-20250327monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-announces-last-patient-completed-pivotal-phase-3-trial-evaluating-f351-f-gyre-20241022monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-to-present-at-8th-annual-h-c-wainwright-mash-investor-conference-gyre-20241001monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-to-present-at-h-c-wainwright-26th-annual-global-investment-conference-gyre-20240904monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-to-present-at-sidoti-virtual-investor-conference-gyre-20240809monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-announces-china-s-nmpa-approval-of-avatrombopag-maleate-tablets-for-the--gyre-20240702monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-announces-publication-in-journal-of-gastroenterology-and-hepatology-gyre-20240618monthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-announces-expected-addition-to-the-russell-2000-and-russell-3000-indexes-gyre-20240528monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-announces-preliminary-unaudited-fourth-quarter-and-full-year-2025-resul-cstl-20260111monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-earns-a-houston-chronicle-top-workplaces-award-for-the-fifth-consecutiv-cstl-20251117monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-to-participate-in-upcoming-investor-conferences-cstl-20250821monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-to-present-at-the-canaccord-genuity-45th-annual-growth-conference-cstl-20250729monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-founder-president-and-ceo-derek-maetzold-named-a-most-admired-ceo-by-th-cstl-20250725monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-honored-with-multiple-top-workplaces-awards-recognizing-the-company-s-s-cstl-20250717monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-to-release-second-quarter-2025-financial-results-and-host-conference-ca-cstl-20250714monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cstl-20250619monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-enters-collaboration-and-license-agreement-with-scibase-to-develop-diag-cstl-20250616monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-chief-executive-officer-derek-maetzold-to-participate-in-panel-discussi-cstl-20250611monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-founder-president-and-ceo-derek-maetzold-honored-with-prestigious-lifet-cstl-20250604monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-to-present-at-the-2025-jefferies-global-healthcare-conference-cstl-20250521monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-celebrates-skin-cancer-awareness-month-cstl-20250507monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-to-acquire-previse-cstl-20250505monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-to-release-first-quarter-2025-financial-results-and-host-conference-cal-cstl-20250414monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-strengthens-commitment-to-esophageal-cancer-awareness-through-collabora-cstl-20250408monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-honored-with-a-top-workplaces-usa-award-for-fourth-consecutive-year-cstl-20250407monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-to-present-new-data-at-eado-supporting-the-clinical-value-of-the-decisi-cstl-20250401monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-decisiondx-scc-data-earns-top-five-abstract-at-nccn-2025-shows-signific-cstl-20250328monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losse-cstl-20230606monthly0.5https://www.biopharmawatch.com/news/CSTL/castle-creek-biosciences-announces-75-million-investment-to-advance-development-of-multipl-cstl-20200325monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-second-quarter-2025-financial-results-on-august-4-2025-sibn-20250714monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-first-quarter-2025-financial-results-on-may-5-2025-sibn-20250414monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-fourth-quarter-and-full-year-2024-financial-results-on-february-24-2025-sibn-20250203monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-piper-sandler-36th-annual-healthcare-conference-on-december-4-2024-sibn-20241120monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-receives-transitional-pass-through-payment-status-for-ifuse-bedrock-granite-sibn-20241105monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-third-quarter-2024-financial-results-on-november-12-2024-sibn-20241022monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-first-in-patient-procedures-with-fda-breakthrough-device-for-pelvic--sibn-20241010monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-morgan-stanley-22nd-annual-global-healthcare-conference-on-september-sibn-20240822monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-receives-510-k-clearance-and-fda-breakthrough-device-designation-for-pelvic-fr-sibn-20240820monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-canaccord-genuity-44th-annual-growth-conference-on-august-14-2024-sibn-20240806monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-second-quarter-2024-financial-results-on-august-5-2024-sibn-20240715monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-truist-securities-2024-medtech-conference-on-june-18-2024-sibn-20240605monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-expands-portfolio-with-the-launch-of-new-offering-for-the-ifuse-bedrock-granite-im-sibn-20240507monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-bofa-securities-2024-healthcare-conference-on-may-14-2024-sibn-20240429monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-first-quarter-2024-financial-results-on-may-6-2024-sibn-20240415monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-barclays-26th-annual-global-healthcare-conference-on-march-12-2024-sibn-20240304monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-fourth-quarter-and-full-year-2023-financial-results-on-february-26-2024-sibn-20240205monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-receives-fda-510-k-clearance-for-a-smaller-diameter-ifuse-bedrock-granite-impl-sibn-20240130monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-piper-sandler-35th-annual-healthcare-conference-on-november-28-2023-sibn-20231114monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-jefferies-london-healthcare-conference-on-november-15-2023-sibn-20231101monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-third-quarter-2023-financial-results-on-november-6-2023-sibn-20231016monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-ifuse-bedrock-granite-implant-system-compatibility-with-certain-medt-sibn-20230905monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-morgan-stanley-21st-annual-global-healthcare-conference-on-september-sibn-20230829monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-canaccord-genuity-43rd-annual-growth-conference-on-august-9-2023-sibn-20230719monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-second-quarter-2023-financial-results-on-august-7-2023-sibn-20230717monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-jefferies-2023-healthcare-conference-on-june-7-2023-sibn-20230524monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-announces-pricing-of-public-offering-of-common-stock-sibn-20230505monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-announces-launch-of-public-offering-of-common-stock-sibn-20230504monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-bank-of-america-merrill-lynch-2023-global-healthcare-conference-sibn-20230424monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-first-quarter-2023-financial-results-on-may-1-2023-sibn-20230410monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-fourth-quarter-2022-financial-results-on-february-27-2023-sibn-20230206monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-host-a-virtual-fireside-chat-at-the-25th-annual-needham-growth-conference-sibn-20230103monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-fda-clearance-for-expanded-rod-compatibility-with-the-ifuse-bedrock--sibn-20221227monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-third-quarter-2022-financial-results-on-november-7-2022-sibn-20221017monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-the-morgan-stanley-20th-annual-global-healthcare-conference-sibn-20220823monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-the-canaccord-genuity-42nd-annual-growth-conference-2022-sibn-20220718monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-second-quarter-2022-financial-results-on-august-8-2022-sibn-20220718monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-fda-clearance-for-expanded-indication-of-the-ifuse-torq-implant-syst-sibn-20220613monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-receives-fda-510-k-clearance-for-ifuse-bedrock-granite-a-breakthrough-pelvic-f-sibn-20220531monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-new-technology-add-on-payment-for-breakthrough-adult-spinal-deformit-sibn-20220419monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-bofa-securities-2022-healthcare-conference-sibn-20220418monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-first-quarter-2022-financial-results-on-may-9-2022-sibn-20220418monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-fourth-quarter-and-full-year-2021-financial-results-on-february-28-2022-sibn-20220201monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-participate-in-24th-annual-needham-virtual-growth-conference-sibn-20211227monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-updated-exclusive-blue-cross-blue-shield-association-evidence-street-sibn-20211213monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-third-quarter-2021-financial-results-on-november-8-2021-sibn-20211018monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-unitedhealthcare-adopts-exclusive-ifuse-only-coverage-for-minimally--sibn-20211011monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-participate-in-upcoming-conferences-sibn-20210823monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-anthem-inc-adopts-coverage-guidelines-for-sacroiliac-joint-fusion-ex-sibn-20210802monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-the-canaccord-genuity-41st-annual-growth-conference-sibn-20210729monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-second-quarter-2021-financial-results-on-august-2-2021-sibn-20210720monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-centene-establishes-positive-coverage-for-mis-si-joint-fusion-includ-sibn-20210714monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-publication-of-ifuse-3d-implant-clinical-study-results-showing-accel-sibn-20210707monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-the-introduction-of-the-si-bone-simulator-powered-by-medability-for--sibn-20210702monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-the-2021-jmp-securities-life-sciences-conference-sibn-20210608monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-the-7th-annual-truist-2021-life-sciences-summit-and-the-2021-bank-of-sibn-20210422monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-appoints-anshul-maheshwari-as-chief-financial-officer-and-announces-the-addition-o-sibn-20210419monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-first-quarter-2021-financial-results-on-may-3-2021-sibn-20210415monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-fourth-quarter-and-full-year-2020-financial-results-on-march-8-2021-sibn-20210209monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-that-updated-isass-policy-and-guidelines-on-mis-si-joint-fusion-supp-sibn-20210104monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-that-priority-health-became-the-36th-payor-with-exclusive-ifuse-cove-sibn-20201221monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-the-23rd-annual-needham-growth-conference-and-the-39th-annual-j-p-mo-sibn-20201217monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-that-humana-establishes-exclusive-coverage-for-ifuse-in-mis-si-joint-sibn-20201216monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-third-quarter-2020-financial-results-on-november-2-2020-sibn-20201019monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-announces-pricing-of-public-offering-of-common-stock-sibn-20201015monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-announces-launch-of-public-offering-of-common-stock-sibn-20201014monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-to-host-virtual-kol-surgeon-panel-at-nass-sibn-20201001monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-the-2020-cantor-global-healthcare-conference-sibn-20200902monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-the-morgan-stanley-18th-annual-global-healthcare-conference-and-the--sibn-20200901monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-exclusive-positive-ifuse-coverage-decision-by-medica-sibn-20200825monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-the-40th-annual-canaccord-genuity-growth-conference-sibn-20200730monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-second-quarter-2020-financial-results-on-august-3-2020-sibn-20200721monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-40-million-debt-re-financing-sibn-20200601monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-aetna-establishes-positive-coverage-for-mis-si-joint-fusion-using-th-sibn-20200529monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-the-bank-of-america-securities-2020-health-care-conference-sibn-20200505monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-first-quarter-2020-financial-results-on-may-4-2020-sibn-20200422monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-fourth-quarter-2019-financial-results-on-march-9-2020-sibn-20200219monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-announces-pricing-of-public-offering-of-common-stock-sibn-20200123monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-announces-launch-of-public-offering-of-common-stock-sibn-20200121monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-reports-preliminary-unaudited-revenue-for-fourth-quarter-and-full-year-2019-and-pr-sibn-20200109monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-cigna-establishes-positive-coverage-for-mis-si-joint-fusion-using-th-sibn-20191213monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-names-jeryl-jeri-hilleman-to-board-of-directors-sibn-20191204monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-participate-at-the-31st-annual-piper-jaffray-healthcare-conference-on-december--sibn-20191203monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-announces-medicare-physician-payment-increase-of-27-for-minimally-invasive-si-join-sibn-20191104monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-third-quarter-2019-financial-results-on-november-11-2019-sibn-20191028monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-publication-of-five-year-prospective-study-results-on-103-patients-t-sibn-20190926monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-wellmark-blue-cross-blue-shield-establishes-positive-coverage-for-mi-sibn-20190903monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-the-17th-annual-morgan-stanley-global-healthcare-conference-on-septe-sibn-20190826monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-the-canaccord-growth-conference-on-august-8-2019-sibn-20190724monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-second-quarter-2019-financial-results-on-august-6-2019-sibn-20190723monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-s-ifuse-implant-system-surpasses-40-000-procedures-sibn-20190627monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-announces-the-addition-of-mark-foley-and-heyward-donigan-to-the-board-of-directors-sibn-20190617monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-the-2019-jmp-securities-life-sciences-conference-sibn-20190605monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-the-bank-of-america-merrill-lynch-2019-health-care-conference-sibn-20190429monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-first-quarter-2019-financial-results-on-may-8-2019-sibn-20190424monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-fda-clearance-of-ifuse-bedrock-novel-spinopelvic-fixation-technology-sibn-20190415monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-journal-of-bone-and-joint-surgery-jbjs-publishes-2-year-results-from-sibn-20190306monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-the-canaccord-genuity-musculoskeletal-conference-sibn-20190228monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-report-fourth-quarter-and-full-year-2018-financial-results-on-march-7-2019-sibn-20190221monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-additional-exclusive-coverage-policies-for-ifuse-sibn-20190204monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-reports-preliminary-unaudited-revenue-for-fourth-quarter-and-full-year-2018-sibn-20190107monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-sibn-20181220monthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-inc-announces-blue-cross-blue-shield-of-arizona-bcbs-az-establishes-positive-cover-sibn-20181206monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-2026-strategic-priorities-caba-20260112monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-participate-in-upcoming-investor-conferences-in-september-caba-20250827monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-second-quarter-2025-financial-results-and-provides-business-update-caba-20250807monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-proposed-public-offering-of-securities-caba-20250611monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-participate-in-the-jefferies-global-healthcare-conference-caba-20250529monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-2027-rese-cel-bla-submission-anticipated-in-myositis-following-rec-caba-20250515monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-bus-caba-20250331monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-participate-in-the-td-cowen-45th-annual-health-care-conference-caba-20250226monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-updated-clinical-data-demonstrating-deepening-clinical-responses-a-caba-20250218monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-presentations-featuring-updated-clinical-data-on-rese-cel-at-upcom-caba-20250211monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-participate-in-guggenheim-s-smid-cap-biotech-conference-caba-20250129monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-outlines-strategic-priorities-and-anticipated-key-milestones-for-2025-caba-20250113monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-participate-in-upcoming-investor-conferences-in-december-caba-20241126monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-presents-positive-clinical-safety-and-efficacy-data-on-caba-201-at-acr-conve-caba-20241118monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-participate-in-guggenheim-s-inaugural-healthcare-innovation-conference-caba-20241106monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-new-and-updated-clinical-data-on-caba-201-in-oral-and-poster-pres-caba-20240925monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-participate-in-upcoming-investor-conferences-in-september-caba-20240828monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-second-quarter-2024-financial-results-and-provides-business-update-caba-20240808monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-participate-in-the-stifel-2024-virtual-cell-therapy-forum-caba-20240702monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-positive-initial-clinical-data-from-phase-1-2-reset-myositis-and-res-caba-20240614monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-participate-in-the-jefferies-global-healthcare-conference-caba-20240529monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-participate-in-the-h-c-wainwright-2nd-annual-bioconnect-investor-conferen-caba-20240513monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-participate-in-upcoming-investor-conferences-in-march-caba-20240227monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-participate-in-the-guggenheim-healthcare-talks-6th-annual-biotechnology-c-caba-20240131monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-receives-additional-fda-fast-track-designations-for-caba-201-in-dermatomyosi-caba-20240108monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-caba-20240102monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-participate-in-the-6th-annual-evercore-isi-healthconx-conference-caba-20231128monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-participate-in-multiple-upcoming-investor-conferences-in-november-caba-20231030monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-receives-fda-clearance-of-ind-application-for-treatment-of-systemic-sclerosi-caba-20231002monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-participate-in-upcoming-investor-conferences-in-september-caba-20230919monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-participate-in-multiple-upcoming-investor-conferences-in-september-caba-20230830monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-the-jefferies-healthcare-conference-caba-20230531monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-proposed-public-offering-of-common-stock-caba-20230517monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-receives-fda-fast-track-designation-for-caba-201-caba-20230501monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-caba-20230425monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference-caba-20230413monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-receives-fda-clearance-of-ind-application-for-caba-201-for-treatment-of-syst-caba-20230331monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-the-cowen-43rd-annual-health-care-conference-caba-20230228monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-caba-20230105monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-35-million-offering-caba-20221208monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-the-5th-annual-evercore-isi-healthconx-conference-caba-20221122monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-caba-201-a-newly-designed-cd19-targeting-car-t-cell-therapy-engine-caba-20221011monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-the-29th-annual-congress-of-the-european-society-of-gene-cell--caba-20221006monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-the-chardan-6th-annual-genetic-medicines-conference-caba-20220926monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-presents-new-interim-data-from-the-descaartes-phase-1-trial-at-the-31st-eadv-caba-20220910monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-participate-in-upcoming-investor-conferences-in-september-caba-20220906monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-presents-updated-interim-descaartes-trial-phase-1-data-at-the-asgct-25th-ann-caba-20220518monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-the-h-c-wainwright-global-investment-conference-caba-20220517monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-the-21st-annual-needham-virtual-healthcare-conference-caba-20220406monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-tha-caba-20220302monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-participate-in-the-cowen-virtual-42nd-annual-health-care-conference-caba-20220228monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-strengthens-executive-leadership-team-with-promotions-of-gwendolyn-binder-ph-caba-20220111monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-caba-20220110monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-conference-caba-20220103monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-top-line-biologic-activity-data-from-two-lowest-dose-cohorts-in-desc-caba-20211214monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-participate-in-upcoming-investor-conferences-in-november-caba-20211109monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-expands-executive-leadership-team-with-appointments-of-samik-basu-m-d-to-chi-caba-20211109monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-clinical-data-from-the-third-dose-cohort-in-descaartes-trial-in-pati-caba-20211101monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-presentation-of-preclinical-data-supporting-pla2r-caart-as-a-poten-caba-20211015monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-the-chardan-5th-annual-genetic-medicines-conference-caba-20210928monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-appointment-of-michael-gerard-as-general-counsel-caba-20210907monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-participate-in-upcoming-investor-conferences-in-september-caba-20210902monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-clinical-data-from-the-second-dose-cohort-in-descaartes-trial-in-pat-caba-20210818monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-the-jefferies-healthcare-conference-caba-20210527monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-first-quarter-2021-financial-results-and-provides-new-pipeline-updat-caba-20210503monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-acute-safety-data-from-the-first-dose-cohort-in-descaartes-trial-caba-20210503monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-the-20th-annual-needham-healthcare-conference-caba-20210407monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-participate-in-upcoming-investor-conferences-in-march-caba-20210223monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-caba-20210107monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-participate-in-upcoming-january-investor-conferences-caba-20210104monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-caba-20201208monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-participate-in-upcoming-december-investor-conferences-caba-20201123monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-upcoming-investor-conferences-in-october-caba-20200925monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-multiple-upcoming-september-investor-conferences-caba-20200908monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-publication-of-comprehensive-preclinical-study-results-for-dsg3-ca-caba-20200825monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-multiple-august-investor-conferences-caba-20200803monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-and-artisan-bio-announce-gene-editing-research-and-collaboration-agreement-t-caba-20200707monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-jefferies-virtual-healthcare-conference-caba-20200527monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-presentation-of-data-supporting-musk-caart-development-for-the-tre-caba-20200518monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-the-cowen-and-company-40th-annual-health-care-conference-caba-20200220monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-the-evercore-isi-2nd-annual-healthconx-conference-caba-20191126monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-pricing-of-initial-public-offering-caba-20191025monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-announces-presentation-of-preclinical-data-showing-specific-caar-t-activity--caba-20191007monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-receives-ind-clearance-from-fda-to-initiate-first-clinical-trial-of-dsg3-caa-caba-20191001monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-expands-management-team-with-appointment-of-brian-stalter-as-general-counsel-caba-20190905monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-appoints-distinguished-immunotherapist-and-cell-therapy-expert-catherine-bol-caba-20190402monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-the-cowen-and-company-39th-annual-healthcare-conference-caba-20190306monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-appoints-experienced-financial-executive-richard-henriques-to-its-board-of-d-caba-20190219monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-appoints-anup-marda-as-chief-financial-officer-caba-20190123monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-caba-20190103monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-closes-50-million-series-b-financing-to-establish-translational-research-and-caba-20190103monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-expands-scientific-regulatory-and-cell-therapy-manufacturing-expertise-with--caba-20181115monthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-emerges-out-of-university-of-pennsylvania-to-develop-caar-t-cell-technology--caba-20181108monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cadl-20260501monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-commercialization-agreement-with-eversana-to-support-potenti-cadl-20260429monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-host-virtual-r-d-event-on-december-5-2025-cadl-20251117monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-present-phase-3-results-of-can-2409-in-localized-prostate-cancer-at-cadl-20250917monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-participate-in-upcoming-investor-conferences-in-september-cadl-20250828monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-present-at-the-canaccord-genuity-45th-annual-growth-conference-cadl-20250730monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-receives-ema-orphan-designation-for-can-2409-for-the-treatment-of-panc-cadl-20250724monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-expands-russell-index-presence-with-addition-to-multiple-value-oriente-cadl-20250709monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-host-investor-conference-call-featuring-expert-clinical-perspective-cadl-20250527monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-present-at-upcoming-investor-conferences-cadl-20250506monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-publication-of-phase-1b-clinical-trial-data-on-the-combinati-cadl-20250401monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-and-idea-pharma-announce-strategic-partnership-to-advance-path-to-mark-cadl-20250320monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-appoints-renowned-pancreatic-cancer-expert-elizabeth-m-jaffee-m-d-to-r-cadl-20250318monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-provides-corporate-update-and-highlights-strong-pipeline-momentum-and--cadl-20250113monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-closing-of-public-offering-and-full-exercise-of-the-underwri-cadl-20241216monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-pricing-of-public-offering-cadl-20241213monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-present-at-jefferies-london-healthcare-conference-2024-cadl-20241107monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-present-preclinical-data-at-sitc-annual-meeting-showing-promise-for-cadl-20241105monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-present-preclinical-data-on-therapeutic-potential-of-can-3110-in-me-cadl-20241004monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-present-at-h-c-wainwright-26th-annual-global-investment-conference-cadl-20240903monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-participate-in-the-h-c-wainwright-2nd-annual-immune-cell-engager-vi-cadl-20240618monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-join-russell-3000-index-cadl-20240611monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-cadl-20240522monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-host-non-small-cell-lung-cancer-nsclc-r-d-breakfast-panel-during-20-cadl-20240520monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-oral-presentation-during-the-5th-glioblastoma-drug-developme-cadl-20240328monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-sets-path-to-success-recent-achievements-pave-the-way-for-a-promising--cadl-20240205monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-restructuring-to-prioritize-resources-on-key-value-drivers-f-cadl-20231128monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-three-abstracts-accepted-for-poster-presentations-at-sitc-20-cadl-20230927monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-con-cadl-20230906monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-participate-in-the-canaccord-genuity-43rd-annual-growth-conference-cadl-20230802monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-participate-in-the-2023-jefferies-healthcare-conference-cadl-20230605monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-new-data-from-ongoing-phase-1-clinical-trial-of-can-3110-in--cadl-20230519monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-upcoming-presentations-at-asgct-and-asco-cadl-20230502monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-participate-in-guggenheim-healthcare-talks-2023-oncology-day-cadl-20230201monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-participate-in-upcoming-b-riley-oncology-conference-cadl-20230112monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-host-virtual-r-d-day-on-december-6-2022-cadl-20221129monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-upcoming-clinical-data-presentations-at-sitc-and-sno-cadl-20221107monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-upcoming-investor-conference-participation-for-november-cadl-20221101monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-partners-with-the-university-of-pennsylvania-s-center-for-cellular-imm-cadl-20221026monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-receives-orphan-drug-designation-from-the-european-medicines-agency-fo-cadl-20220915monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-upcoming-investor-conference-participation-cadl-20220906monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-present-at-the-h-c-wainwright-annual-global-investment-conference-cadl-20220518monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-present-at-the-2022-american-society-of-clinical-oncology-asco-annu-cadl-20220427monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-appoints-seshu-tyagarajan-ph-d-rac-as-chief-technical-and-development--cadl-20220302monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-present-at-two-upcoming-investor-conferences-cadl-20220105monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-and-partnership-for-accelerating-cancer-therapies-pact-to-collaborate--cadl-20211210monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-presents-novel-biomarker-data-demonstrating-immune-activation-after-ad-cadl-20211112monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-to-participate-in-three-upcoming-investor-conferences-cadl-20211102monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-upcoming-data-presentations-on-its-oncolytic-viral-immunothe-cadl-20211101monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-patient-reported-tolerability-data-of-intraprostatic-injecti-cadl-20211028monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-appoints-mace-l-rothenberg-md-as-senior-advisor-to-the-chief-executive-cadl-20211019monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-participation-in-upcoming-society-for-immunotherapy-of-cance-cadl-20211004monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-participation-in-upcoming-scientific-conferences-related-to--cadl-20211001monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-presentations-of-key-clinical-data-at-admetech-and-european--cadl-20210909monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-completes-enrollment-in-phase-3-clinical-trial-of-can-2409-in-combinat-cadl-20210907monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-pricing-of-initial-public-offering-cadl-20210727monthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-completes-28-7-million-series-b-financing-cadl-20190104monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-therapeutics-to-participate-in-two-upcoming-investor-conferences-crmd-20260515monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-u-crmd-20260514monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-therapeutics-announces-leadership-and-board-updates-crmd-20260108monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-therapeutics-announces-positive-data-from-ongoing-real-world-evidence-study-of-de-crmd-20251218monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-third-quarter-2025-financial-results-and-provide-a-corporate-update-crmd-20251031monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-pricing-of-public-offering-of-common-stock-crmd-20250627monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-customer-implementation-crmd-20250623monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-participate-in-the-jefferies-global-healthcare-conference-crmd-20250530monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-participate-in-the-rbc-global-healthcare-conference-crmd-20250515monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-first-quarter-2025-financial-results-and-provide-a-corporate-update-crmd-20250429monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference-crmd-20250402monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-alert-bragar-eagel-squire-p-c-is-investigating-cormedix-inc-on-behalf-of-cormedix-crmd-20250328monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-a-c-crmd-20250318monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-announces-collaboration-for-defencath-promotion-to-the-va-and-other-federal-facil-crmd-20250121monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-preliminary-fourth-quarter-2024-results-and-provides-business-updat-crmd-20250107monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-added-to-nasdaq-biotechnology-index-crmd-20241219monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-supports-cms-policy-updates-regarding-access-to-innovative-drug-products-crmd-20241126monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-participate-in-the-truist-securities-biopharma-symposium-crmd-20241104monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-new-data-at-asn-kidney-week-2024-crmd-20241024monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-third-quarter-2024-financial-results-and-provide-a-corporate-update-crmd-20241023monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-announces-new-commercial-agreement-with-mid-sized-dialysis-operator-crmd-20241008monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-new-commercial-agreement-crmd-20240919monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-present-at-the-cantor-global-healthcare-conference-crmd-20240913monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-new-commercial-agreement-crmd-20240909monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-second-quarter-2024-financial-results-and-provide-a-corporate-updat-crmd-20240807monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-outpatient-availability-of-defencath-crmd-20240703monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-receives-fda-feedback-on-potential-label-expansion-crmd-20240618monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-cms-grants-pass-through-status-to-defencath-crmd-20240606monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-commercial-agreement-with-top-tier-dialysis-provider-crmd-20240528monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-participate-in-two-upcoming-investor-conferences-crmd-20240510monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-first-quarter-2024-financial-results-and-provide-a-corporate-update-crmd-20240506monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-cms-grants-tdapa-to-defencath-crmd-20240419monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-u-s-inpatient-commercial-availability-of-defencath-taurolidine-and--crmd-20240415monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-abstracts-at-upcoming-society-for-healthcare-epidemiology-of-americ-crmd-20240411monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-commercial-agreement-with-arc-dialysis-llc-crmd-20240408monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-present-at-the-needham-annual-healthcare-conference-crmd-20240327monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-fourth-quarter-and-full-year-2023-financial-results-and-provide-a-c-crmd-20240306monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-commercial-and-operational-updates-crmd-20240108monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-appointment-of-chief-legal-officer-crmd-20231215monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-partnership-with-the-leapfrog-group-crmd-20231204monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-third-quarter-2023-financial-results-and-provide-a-corporate-update-crmd-20231102monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-abstract-presentation-at-upcoming-idweek-conference-crmd-20231011monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-crmd-20230926monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-publication-of-phase-3-lock-it-100-study-data-in-the-clinical-journ-crmd-20230908monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-present-at-the-h-c-wainwright-annual-global-investment-conference-crmd-20230906monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-issuance-of-u-s-patent-covering-lead-product-defencath-crmd-20230830monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-second-quarter-2023-financial-results-and-provide-a-corporate-updat-crmd-20230726monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-pricing-of-40-million-public-offering-of-common-stock-and-pre-funde-crmd-20230629monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-strategic-initiative-with-boston-medical-center-to-reduce-health-di-crmd-20230615monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-present-at-the-jefferies-healthcare-conference-crmd-20230530monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-first-quarter-2023-financial-results-and-provide-a-corporate-update-crmd-20230508monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-participate-in-two-upcoming-investor-conferences-crmd-20230503monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-notice-of-allowance-for-u-s-patent-application-covering-lead-produc-crmd-20230501monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-busi-crmd-20230330monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-fourth-quarter-and-fiscal-year-2022-financial-results-and-provide-a-crmd-20230321monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-promotions-in-commercial-and-tech-ops-crmd-20230117monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-presentation-at-conference-showing-mortality-risk-and-complications-crmd-20221206monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-cms-revision-to-ntap-reimbursement-of-defencath-crmd-20221107monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-third-quarter-2022-financial-results-and-provide-a-corporate-update-crmd-20221102monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-abstract-presentation-at-upcoming-american-society-of-nephrology-co-crmd-20221020monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-present-at-the-h-c-wainwright-annual-global-investment-conference-crmd-20220907monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-second-quarter-2022-financial-results-and-provide-a-corporate-updat-crmd-20220801monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-to-participate-at-the-jmp-securities-life-sciences-conference-crmd-20220608monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-leadership-updates-and-operational-changes-crmd-20220512monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-first-quarter-2022-financial-results-and-provide-a-corporate-update-crmd-20220503monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-scientific-advisory-board-to-support-commercialization-and-pipeline-crmd-20220407monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-present-at-the-21st-annual-needham-virtual-healthcare-conference-crmd-20220404monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-fourth-quarter-and-fiscal-year-2021-financial-results-and-provide-a-crmd-20220322monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-to-participate-in-upcoming-january-conferences-crmd-20220104monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-third-quarter-2021-financial-results-and-provide-a-corporate-update-crmd-20211102monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-abstracts-at-upcoming-conferences-showing-patient-outcomes-and-econ-crmd-20211020monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-executive-leadership-changes-crmd-20211004monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-regulatory-update-crmd-20210907monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-second-quarter-2021-financial-results-and-provide-a-corporate-updat-crmd-20210728monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portn-crmd-20210727monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-completes-sale-of-1-3-million-of-nol-tax-benefits-through-the-new-jersey-econ-crmd-20210610monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-participate-in-fireside-chat-at-the-jmp-securities-life-sciences-conferenc-crmd-20210609monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-present-at-the-jefferies-virtual-healthcare-conference-crmd-20210527monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-first-quarter-2021-financial-results-and-provide-a-corporate-update-crmd-20210505monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-participate-at-the-7th-annual-truist-securities-life-sciences-summit-crmd-20210428monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-present-at-the-20th-annual-needham-virtual-healthcare-conference-crmd-20210407monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-fourth-quarter-and-fiscal-year-2020-financial-results-and-provide-a-crmd-20210323monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-approved-to-sell-1-3-million-of-nol-tax-benefits-through-the-new-jersey-economic--crmd-20210315monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-contract-extension-of-liz-masson-hurlburt-as-executive-vice-preside-crmd-20210311monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-host-regulatory-update-conference-call-crmd-20210308monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-third-quarter-2020-financial-results-and-provide-a-corporate-update-crmd-20201029monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-to-participate-in-bio-investor-forum-digital-crmd-20201008monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-present-at-the-h-c-wainwright-22nd-annual-global-investment-conference-crmd-20200909monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-second-quarter-2020-financial-results-and-provide-a-corporate-updat-crmd-20200803monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-announces-proposed-public-offering-of-common-stock-crmd-20200727monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-hosting-kol-call-on-antimicrobial-resistance-catheter-related-bloodstream-infecti-crmd-20200506monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-first-quarter-2020-financial-results-and-provide-a-corporate-update-crmd-20200504monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-contract-extension-of-jack-armstrong-as-executive-vice-president-an-crmd-20200423monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-fourth-quarter-2019-financial-results-and-provide-a-corporate-updat-crmd-20200306monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-reports-third-quarter-2019-financial-results-and-provides-business-update-crmd-20191114monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-third-quarter-2019-financial-results-and-provide-a-corporate-update-crmd-20191107monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-a-change-to-its-senior-leadership-crmd-20191106monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-completes-successful-cmc-interaction-with-the-fda-crmd-20191016monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-present-at-the-cantor-2019-global-healthcare-conference-crmd-20190926monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-announces-exercises-of-outstanding-warrants-crmd-20190926monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-present-at-the-h-c-wainwright-21st-annual-global-investment-conference-crmd-20190903monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-second-quarter-2019-financial-results-and-provide-a-corporate-updat-crmd-20190801monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-presents-at-fda-public-meeting-on-the-limited-population-pathway-for-antibacteria-crmd-20190717monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-announces-publication-of-taurolidine-pre-clinical-oncology-data-in-investigationa-crmd-20190708monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-set-to-join-the-russell-2000-index-crmd-20190626monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-ring-nyse-closing-bell-on-monday-june-10-crmd-20190610monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-present-at-the-20th-annual-b-riley-fbr-institutional-investor-conference-crmd-20190516monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-announces-presentation-of-lock-it-100-study-results-at-national-kidney-foundation-crmd-20190510monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-inc-to-report-first-quarter-2019-financial-results-and-provide-a-corporate-update-crmd-20190506monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-announces-online-pre-clinical-abstract-at-the-upcoming-annual-meeting-of-american-crmd-20190422monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-s-ceo-randy-milby-interviewed-by-the-life-sciences-report-crmd-20160212monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-licenses-new-technology-to-prevent-infection-and-clots-in-central-venous-catheter-crmd-20080206monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-enlists-world-class-panel-to-advise-on-cardiorenal-medicine-crmd-20080108monthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-studies-show-that-removing-toxic-iron-could-slow-progression-of-chronic-kidney-di-crmd-20071102monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-clym-20251125monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-to-present-at-upcoming-september-2025-investor-conferences-clym-20250825monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-appoints-edgar-d-charles-m-d-msc-as-chief-medical-officer-clym-20250618monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-clym-20250519monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-appoints-perrin-wilson-ph-d-as-chief-business-officer-clym-20250224monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-to-present-at-william-blair-s-upcoming-conference-event-on-transforming-autoimmu-clym-20241004monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-to-host-virtual-investor-event-on-october-15-2024-clym-20241003monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-report-second-quarter-2025-financial-results-on-august-12-2025-npce-20250729monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-reports-first-quarter-2025-financial-results-npce-20250513monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-present-at-the-24th-annual-needham-virtual-healthcare-conference-npce-20250326monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-reports-fourth-quarter-and-full-year-2024-financial-results-npce-20250304monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-present-at-the-leerink-partners-global-healthcare-conference-npce-20250303monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-4-2025-npce-20250219monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-announces-completion-of-public-offering-of-common-stock-and-exercise-in-full-of--npce-20250218monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-announces-pricing-of-public-offering-of-65-million-of-common-stock-npce-20250214monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-announces-proposed-public-offering-of-65-million-of-common-stock-npce-20250213monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-announces-upcoming-oral-presentation-of-data-from-the-post-approval-study-of-the-npce-20250203monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-issues-2025-financial-guidance-targets-npce-20250128monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-npce-20241218monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-host-investor-day-on-january-28th-in-new-york-city-npce-20241212monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-showcase-the-rns-system-at-the-2024-american-epilepsy-society-aes-annual-meet-npce-20241204monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-completes-enrollment-in-feasibility-study-of-rns-system-for-lennox-gastaut-syndr-npce-20241203monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-reports-third-quarter-2024-financial-results-and-increases-2024-revenue-guidance-npce-20241112monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-announces-fda-submission-of-three-year-data-from-post-approval-study-of-the-rns--npce-20241104monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-report-third-quarter-2024-financial-results-on-november-12-2024-npce-20241022monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-continues-to-strengthen-management-team-npce-20241016monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-strengthens-management-team-with-two-key-appointments-npce-20240904monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-announces-participation-at-two-upcoming-healthcare-investor-conferences-npce-20240827monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-participate-in-upcoming-healthcare-conferences-in-september-npce-20240822monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-reports-second-quarter-2024-financial-results-and-increases-2024-revenue-guidanc-npce-20240813monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-report-second-quarter-2024-financial-results-on-august-13-2024-npce-20240723monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-participate-in-two-healthcare-conferences-in-may-npce-20240514monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-reports-first-quarter-2024-financial-results-and-provides-corporate-update-npce-20240508monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-report-first-quarter-2024-financial-results-on-may-8-2024-npce-20240417monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-present-at-the-needham-23rd-annual-healthcare-conference-npce-20240327monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-announces-record-full-year-2023-revenue-of-65-4-million-npce-20240305monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-report-fourth-quarter-and-full-year-2023-financial-results-on-march-5-2024-npce-20240215monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-announces-early-completion-of-patient-enrollment-in-nautilus-pivotal-study-npce-20231221monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-npce-20231219monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-leverage-the-power-of-its-rns-system-s-novel-data-collection-brain-monitoring-npce-20231204monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-and-the-rns-system-showcased-at-the-77th-american-epilepsy-society-aes-annual-me-npce-20231201monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-present-at-the-piper-sandler-35th-annual-healthcare-conference-npce-20231121monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-reports-third-quarter-2023-financial-results-and-increases-full-year-2023-revenu-npce-20231106monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-announces-rns-system-enhancements-designed-to-streamline-care-npce-20231017monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-report-third-quarter-2023-financial-results-on-november-6-2023-npce-20231016monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-participate-in-2023-cantor-fitzgerald-global-healthcare-conference-npce-20230920monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-participate-in-upcoming-investor-conferences-npce-20230824monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-reports-second-quarter-2023-financial-results-and-increases-full-year-2023-reven-npce-20230808monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-announces-inducement-grants-under-listing-rule-5635-c-4-of-the-nasdaq-stock-mark-npce-20230719monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-report-second-quarter-2023-financial-results-on-august-8-2023-npce-20230718monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-announces-ceo-transition-npce-20230628monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-announces-addition-of-kelley-nicholas-as-vice-president-sales-npce-20230524monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-reports-first-quarter-2023-financial-results-and-increases-full-year-2023-revenu-npce-20230504monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-report-first-quarter-2023-financial-results-on-may-4-2023-npce-20230417monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference-npce-20230403monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-reports-fourth-quarter-full-year-2022-financial-results-npce-20230302monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-2-2023-npce-20230210monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-npce-20221221monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-reports-third-quarter-2022-financial-results-and-provides-a-business-update-npce-20221108monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-present-at-the-4th-annual-wolfe-research-healthcare-conference-npce-20221104monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-report-third-quarter-2022-financial-results-on-november-8-2022-npce-20221025monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-present-at-the-morgan-stanley-20th-annual-global-healthcare-conference-npce-20220823monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-reports-second-quarter-2022-financial-results-and-provides-a-business-update-npce-20220811monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-announces-distribution-agreement-with-dixi-medical-usa-provider-of-intracranial--npce-20220811monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-report-second-quarter-2022-financial-results-on-august-11-2022-npce-20220721monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-present-at-the-2022-rbc-capital-markets-global-healthcare-conference-npce-20220513monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-reports-first-quarter-2022-financial-results-npce-20220512monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-report-first-quarter-2022-financial-results-on-may-12-2022-npce-20220421monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-reports-fourth-quarter-full-year-2021-financial-results-npce-20220310monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-report-fourth-quarter-and-full-year-2021-financial-results-and-present-at-the-npce-20220127monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-present-at-40th-annual-j-p-morgan-healthcare-conference-npce-20211216monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-reports-third-quarter-2021-financial-results-npce-20211110monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-receives-ide-approval-to-initiate-nautilus-pivotal-study-of-its-rns-system-for-i-npce-20211110monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-report-third-quarter-2021-financial-results-on-november-10-2021-npce-20211020monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-announces-addition-of-lisa-andrade-to-the-board-npce-20211019monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-participate-in-upcoming-conferences-npce-20210823monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-reports-second-quarter-2021-financial-results-npce-20210812monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-report-second-quarter-2021-financial-results-on-august-12-2021-npce-20210722monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-awarded-five-year-nih-grant-funding-of-more-than-9m-to-study-rns-system-in-patie-npce-20210630monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-reports-first-quarter-2021-financial-results-and-provides-2021-financial-guidanc-npce-20210603monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-to-report-first-quarter-2021-financial-results-on-june-3-2021-npce-20210520monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-inc-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underw-npce-20210426monthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-inc-announces-pricing-of-initial-public-offering-npce-20210422monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-2026-bank-of-america-healthcare-conference-acrs-20260508monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammatory-skin-dis-acrs-20260408monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-poster-on-results-from-phase-2a-trial-of-ati-2138-at-the-20-acrs-20260320monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-completes-enrollment-in-phase-2-trial-of-bosakitug-ati-045-in-atopic--acrs-20260318monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-initiates-phase-1b-proof-of-concept-trial-in-atopic-dermatitis-ad-wit-acrs-20260112monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-two-september-healthcare-conferences-acrs-20250827monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-initiates-phase-1a-1b-program-for-its-novel-bispecific-antibody-ati-0-acrs-20250623monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-initiates-phase-2-trial-of-bosakitug-ati-045-in-atopic-dermatitis-acrs-20250602monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-two-june-healthcare-conferences-acrs-20250528monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-hc-wainwright-hcw-home-series-acrs-20250509monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-appoints-jesse-hall-m-d-as-chief-medical-officer-acrs-20250429monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-secures-u-s-food-and-drug-administration-ind-clearance-for-ati-052-en-acrs-20250422monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-two-march-healthcare-conferences-acrs-20250304monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-formation-of-new-scientific-advisory-board-acrs-20250130monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-acrs-20250106monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-acrs-20241203monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference-acrs-20241126monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-80-million-private-placement-acrs-20241118monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-first-patient-dosed-in-phase-2a-clinical-trial-of-ati-2138--acrs-20240917monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-2024-cantor-global-healthcare-conference-acrs-20240910monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-goldman-sachs-45th-annual-global-healthcare-con-acrs-20240606monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-announce-first-quarter-2024-financial-results-on-may-7-2024-and-to-acrs-20240430monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-top-line-results-from-4-week-phase-2b-trial-of-ati-1777-for-acrs-20240110monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-provides-corporate-update-acrs-20231219monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-patent-license-agreement-with-sun-pharma-for-alopecia-acrs-20231205monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-top-line-results-from-12-week-phase-2b-trial-of-oral-zunsem-acrs-20231113monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-completes-enrollment-in-phase-2b-study-of-ati-1777-for-mild-to-severe-acrs-20231003monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-2023-cantor-global-healthcare-conference-acrs-20230920monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-completes-enrollment-in-phase-2b-study-of-oral-zunsemetinib-ati-450-f-acrs-20230613monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-two-june-healthcare-investor-conferences-acrs-20230602monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-announce-first-quarter-2023-financial-results-on-may-8-2023-acrs-20230502monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease--acrs-20230327monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-virtual-svb-securities-global-biopharma-confere-acrs-20230209monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-provides-2023-outlook-acrs-20230106monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-and-pediatrix-therapeutics-announce-license-agreement-for-ati-1777-in-acrs-20221129monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-key-leadership-transitions-acrs-20221122monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-two-november-healthcare-investor-conferences-acrs-20221110monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-appoints-robert-doody-as-vice-president-investor-relations-acrs-20220927monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-co-acrs-20220830monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-patent-license-agreement-with-lilly-for-alopecia-areata-acrs-20220825monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-expands-leadership-team-acrs-20220801monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-expands-leadership-team-acrs-20220627monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-jefferies-healthcare-conference-acrs-20220601monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-global-investment-conference-acrs-20220516monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-lifesci-partners-immunology-inflammation-sympos-acrs-20220503monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-svb-leerink-virtual-11th-annual-global-healthca-acrs-20220202monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-expands-leadership-team-acrs-20220201monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-provides-r-d-update-acrs-20220111monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-bioconnect-virtual-conference-acrs-20211227monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-publication-of-preclinical-research-of-zunsemetinib-in-panc-acrs-20211203monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-host-virtual-r-d-day-on-december-7-2021-acrs-20211118monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-upcoming-investor-conferences-acrs-20211103monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-proposed-settlement-and-settlement-hearing-of-stockholder-d-acrs-20210827monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-upcoming-investor-conferences-acrs-20210826monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-william-blair-biotech-focus-conference-2021-acrs-20210708monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-announces-pricing-of-public-offering-of-common-stock-acrs-20210609monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-positive-preliminary-topline-data-from-phase-2a-trial-of-at-acrs-20210608monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-jefferies-virtual-healthcare-conference-acrs-20210517monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-completes-enrollment-in-its-phase-2a-clinical-trial-of-ati-1777-for-m-acrs-20210315monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-upcoming-investor-conferences-acrs-20210222monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-10th-annual-svb-leerink-global-healthcare-confe-acrs-20210210monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-announces-pricing-of-public-offering-of-common-stock-acrs-20210120monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-positive-preliminary-topline-data-from-12-week-phase-2a-tri-acrs-20210119monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-formation-of-new-scientific-advisory-board-acrs-20201215monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-evercore-isi-3rd-annual-healthconx-conference-acrs-20201116monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-first-patient-dosed-in-phase-2a-clinical-trial-of-ati-1777--acrs-20201020monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-present-at-upcoming-investor-conferences-acrs-20200901monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-submits-investigational-new-drug-application-for-ati-1777-a-topical-s-acrs-20200707monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-supports-investigator-initiated-clinical-trial-of-ati-450-for-cytokin-acrs-20200617monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-publication-of-an-abstract-of-the-phase-1-clinical-trial-re-acrs-20200603monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-present-at-the-jefferies-virtual-healthcare-conference-acrs-20200526monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-announce-fourth-quarter-and-full-year-2019-financial-results-on-fe-acrs-20200219monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-present-at-the-svb-leerink-9th-annual-global-healthcare-conference-acrs-20200210monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-positive-results-from-phase-1-single-and-multiple-ascending-acrs-20200109monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-present-at-upcoming-investor-conferences-acrs-20191112monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-announce-third-quarter-2019-financial-results-on-november-7-2019-acrs-20191031monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-a-101-45-topical-solution-meets-primary-and-all-secondary-efficacy-en-acrs-20191024monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-files-patent-infringement-lawsuit-against-taro-pharmaceuticals-inc-fo-acrs-20191008monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-hold-r-d-day-acrs-20190917monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-a-101-45-topical-solution-meets-primary-and-all-secondary-efficacy-en-acrs-20190916monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-inc-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-announces--acrs-20190807monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-announce-second-quarter-2019-financial-results-on-august-8-2019-acrs-20190801monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-issuance-of-additional-orange-book-listable-patent-covering-acrs-20190709monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-phase-2-clinical-trial-of-ati-502-topical-in-patients-with--acrs-20190626monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-present-at-the-2019-jmp-securities-life-sciences-conference-acrs-20190614monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-present-at-jefferies-2019-global-healthcare-conference-acrs-20190524monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-announce-first-quarter-2019-financial-results-on-may-8-2019-acrs-20190501monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-submits-investigational-new-drug-application-for-ati-450-an-oral-mk2--acrs-20190425monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-issuance-of-a-patent-covering-the-use-of-ruxolitinib-and-it-acrs-20190424monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-attend-upcoming-investor-conference-acrs-20190327monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-announce-fourth-quarter-and-full-year-2018-financial-results-on-ma-acrs-20190308monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-receives-european-approvals-of-eskata-hydrogen-peroxide-cutaneous-sol-acrs-20190228monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-present-scientific-posters-at-the-77th-annual-meeting-of-the-ameri-acrs-20190219monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-attend-upcoming-investor-conferences-acrs-20190102monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-attend-upcoming-investor-conferences-acrs-20181128monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-attend-upcoming-investor-conferences-acrs-20181102monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-announce-third-quarter-2018-financial-results-on-november-6-2018-acrs-20181029monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-announces-closing-of-public-offering-of-common-stock-acrs-20181022monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-announces-pricing-of-public-offering-of-common-stock-acrs-20181018monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-announces-proposed-public-offering-of-common-stock-acrs-20181017monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-poster-presentations-at-2018-american-society-for-dermatolo-acrs-20181003monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-acrs-20181002monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-launches-direct-to-consumer-campaign-for-eskata-hydrogen-peroxide-top-acrs-20181001monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-partnership-with-harris-stowe-state-university-to-support-d-acrs-20181001monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-first-patient-dosed-in-phase-3-studies-evaluating-a-101-45--acrs-20180924monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-attend-upcoming-investor-conferences-acrs-20180921monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-highlight-drug-discovery-targeting-the-human-kinome-at-16th-annual-acrs-20180917monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-acrs-20180905monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-ati-450-mk2-pathway-inhibitor-publication-in-the-journal-ca-acrs-20180821monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-acrs-20180802monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-announce-second-quarter-2018-financial-results-on-august-3-2018-acrs-20180726monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-acrs-20180703monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-positive-interim-data-from-phase-2-study-of-ati-502-a-topic-acrs-20180628monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-first-patient-dosed-in-a-phase-2-clinical-trial-of-ati-501--acrs-20180626monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-expands-leadership-team-appointing-dr-david-gordon-as-chief-medical-o-acrs-20180615monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-acrs-20180604monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-issuance-of-additional-orange-book-listable-patent-covering-acrs-20180530monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-poster-presentations-at-international-investigative-dermato-acrs-20180516monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-support-symposium-on-jak-inhibitors-at-the-international-investiga-acrs-20180515monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-present-at-the-2018-american-hair-research-summit-acrs-20180511monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-attend-upcoming-investor-conferences-acrs-20180510monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-availability-of-eskata-hydrogen-peroxide-topical-solution-4-acrs-20180507monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-acrs-20180502monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-announce-first-quarter-2018-financial-results-on-may-8-2018-acrs-20180424monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-first-patient-dosed-in-a-pilot-study-with-ati-502-topical-i-acrs-20180423monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-partners-with-cipher-pharmaceuticals-to-seek-regulatory-approval-and--acrs-20180406monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-acrs-20180403monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-ati-450-mk2-pathway-inhibitor-publication-in-journal-of-exp-acrs-20180320monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-positive-update-on-phase-2-results-after-a-3-month-follow-u-acrs-20180319monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-issuance-of-u-s-patent-covering-a-jak-inhibitor-for-treatin-acrs-20180309monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-acrs-20180306monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-20-acrs-20180228monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-present-data-on-eskata-hydrogen-peroxide-topical-solution-40-w-w-a-acrs-20180208monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-acrs-20180205monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-attend-upcoming-investor-conferences-acrs-20180202monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-a-101-45-topical-solution-meets-primary-and-all-secondary-endpoints-i-acrs-20180108monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-acrs-20180104monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-initiates-a-pilot-clinical-trial-to-study-ati-50002-topical-in-patien-acrs-20171219monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-presents-new-data-at-american-college-of-rheumatology-annual-meeting--acrs-20171121monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-mourns-the-passing-of-board-member-richard-a-bierly-acrs-20171109monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-attend-upcoming-investor-conferences-acrs-20171103monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-acrs-20171102monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-announce-third-quarter-2017-financial-results-on-november-7-2017-acrs-20171031monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-the-allowance-of-a-u-s-patent-application-and-issuance-of-a-acrs-20171024monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-acrs-20171006monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-host-r-d-and-investor-event-on-october-4-2017-in-new-york-acrs-20170920monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-publication-of-data-from-phase-2-clinical-trial-of-a-101-to-acrs-20170919monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-acrs-20170907monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-issuance-of-two-u-s-patents-covering-jak-inhibitors-for-tre-acrs-20170905monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-attend-upcoming-investor-conferences-acrs-20170817monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-announces-pricing-of-public-offering-of-common-stock-acrs-20170810monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-announces-proposed-public-offering-of-common-stock-acrs-20170809monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-second-quarter-2017-financial-results-acrs-20170808monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-acquires-confluence-life-sciences-inc-acrs-20170808monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-submits-marketing-authorization-application-in-europe-for-a-101-40-to-acrs-20170803monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-submits-investigational-new-drug-application-for-ati-50002-to-treat-a-acrs-20170802monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-announce-second-quarter-2017-financial-results-on-august-8-2017-acrs-20170801monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-initiates-phase-2b-clinical-trials-of-a-101-for-topical-treatment-of--acrs-20170629monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-issuance-of-new-u-s-patent-for-a-101-topical-solutions-acrs-20170613monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-announce-first-quarter-2017-financial-results-on-may-9-2017-acrs-20170509monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-completes-phase-1-clinical-trial-of-ati-50001-for-the-treatment-of-al-acrs-20170505monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-announce-first-quarter-2017-financial-results-on-may-9-2017-acrs-20170501monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-attend-upcoming-investor-conferences-acrs-20170501monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-notice-of-allowance-for-a-u-s-patent-application-covering-l-acrs-20170426monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-hosts-symposium-on-jak-inhibitors-at-the-76th-annual-society-for-inve-acrs-20170424monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-notice-of-allowance-for-two-u-s-patent-applications-coverin-acrs-20170404monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-submits-new-drug-application-for-a-101-as-a-novel-treatment-for-sebor-acrs-20170227monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-announce-fourth-quarter-and-full-year-2016-financial-results-on-ma-acrs-20170223monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-attend-upcoming-investor-conferences-acrs-20170206monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-appointment-of-andrew-powell-to-board-of-directors-acrs-20170126monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-to-present-at-35th-annual-j-p-morgan-healthcare-conference-acrs-20170103monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-initiates-phase-1-clinical-trial-for-ati-50001-an-investigational-jak-acrs-20161207monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-attend-upcoming-investor-conferences-acrs-20161122monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-announces-pricing-of-public-offering-of-common-stock-acrs-20161118monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-announces-proposed-public-offering-of-common-stock-acrs-20161116monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-reports-third-quarter-2016-financial-results-acrs-20161103monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-submits-investigational-new-drug-application-for-ati-50001-to-treat-a-acrs-20161031monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-honored-as-one-of-the-best-places-to-work-in-pennsylvania-acrs-20161028monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-announce-third-quarter-2016-financial-results-on-november-3-2016-acrs-20161025monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-present-at-the-morgan-stanley-2016-healthcare-conference-acrs-20160906monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-positive-results-in-phase-2-clinical-trial-of-a-101-for-tre-acrs-20160818monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-announce-second-quarter-2016-financial-results-on-august-11-2016-acrs-20160802monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-inc-nasdaq-acrs-to-ring-the-nasdaq-stock-market-closing-bell-acrs-20160725monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-completes-enrollment-of-phase-3-pivotal-trials-of-a-101-for-the-treat-acrs-20160725monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-present-at-the-cantor-fitzgerald-2nd-annual-healthcare-conference-acrs-20160705monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-present-at-upcoming-investor-conferences-in-june-acrs-20160531monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-announces-20-0-million-private-placement-acrs-20160527monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-inc-appoints-kevin-scott-as-vice-president-of-sales-acrs-20160505monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-present-at-the-bank-of-america-merrill-lynch-2016-healthcare-confe-acrs-20160502monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-announce-first-quarter-2016-financial-results-on-may-11-2016-acrs-20160426monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-announce-fourth-quarter-and-full-year-2015-financial-results-on-ma-acrs-20160317monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-to-present-at-the-2016-leerink-partners-annual-global-healthcare-conf-acrs-20160205monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-initiates-phase-3-clinical-trials-of-a-101-for-the-treatment-of-sebor-acrs-20160119monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-inc-added-to-russell-2000-index-acrs-20151222monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-inc-appoints-brett-fair-as-senior-vice-president-of-commercial-operat-acrs-20151216monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-initiates-phase-2-clinical-trial-of-a-101-for-treatment-of-common-war-acrs-20151207monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-opt-acrs-20151013monthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-announces-pricing-of-initial-public-offering-acrs-20151007monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-prok-20260106monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-prok-20250107monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-to-participate-in-two-upcoming-conferences-evercore-healthconx-conference-and-th-prok-20241126monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-to-participate-in-the-guggenheim-inaugural-healthcare-innovation-conference-and--prok-20241105monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-announces-five-abstracts-selected-for-presentation-at-the-american-society-of-ne-prok-20241014monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-to-participate-in-the-ubs-virtual-organ-restoration-day-prok-20241009monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-announces-strategic-updates-to-its-phase-3-program-to-accelerate-rilparencel-s-r-prok-20240903monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-to-participate-in-the-morgan-stanley-22nd-annual-global-healthcare-conference-prok-20240827monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-announces-the-closing-of-140-million-public-offering-of-class-a-ordinary-shares--prok-20240617monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-announces-proposed-125-million-public-offering-of-class-a-ordinary-shares-and-co-prok-20240610monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-to-participate-in-the-jefferies-global-healthcare-conference-prok-20240529monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-to-host-virtual-kol-event-to-discuss-current-treatment-landscape-of-chronic-kidn-prok-20240521monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-to-participate-in-jefferies-biotech-on-the-bay-summit-prok-20240229monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-appoints-nikhil-pereira-kamath-mba-as-chief-business-officer-prok-20231130monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-to-participate-in-a-fireside-chat-at-the-upcoming-evercore-isi-6th-annual-health-prok-20231121monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-reports-third-quarter-financial-results-prok-20231114monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-announces-positive-interim-data-from-rmcl-002-phase-2-clinical-trial-of-renal-au-prok-20231113monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-announces-four-abstracts-selected-for-presentation-at-the-american-society-of-ne-prok-20231030monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-to-participate-in-fireside-chat-at-the-morgan-stanley-global-healthcare-conferen-prok-20230905monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-appoints-bruce-culleton-md-as-executive-vice-president-clinical-development-and--prok-20230717monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-to-participate-in-fireside-chat-at-the-jefferies-healthcare-conference-prok-20230601monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-to-present-at-the-bofa-securities-health-care-conference-2023-prok-20230504monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-to-participate-in-td-cowen-s-43rd-annual-health-care-conference-prok-20230303monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-to-present-at-the-j-p-morgan-41st-annual-healthcare-conference-prok-20221222monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-to-participate-in-upcoming-investor-conferences-prok-20221111monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-receives-allowance-from-the-uk-medicines-and-healthcare-products-regulatory-agen-prok-20221103monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-announces-multiple-abstracts-selected-for-presentation-at-the-american-society-o-prok-20221014monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-to-present-at-the-jefferies-cell-and-genetic-medicine-summit-prok-20220923monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-to-present-at-the-morgan-stanley-20th-annual-global-healthcare-conference-prok-20220908monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-appoints-glenn-schulman-pharmd-mph-as-senior-vice-president-of-investor-relation-prok-20220831monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-strengthens-board-of-directors-with-appointments-of-dr-john-m-maraganore-and-jen-prok-20220811monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-appoints-kerry-cooper-m-d-as-senior-vice-president-of-medical-affairs-prok-20220720monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-corroborates-the-mechanism-of-action-of-react-with-cell-marker-analysis-in-patie-prok-20220623monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-announces-manufacturing-efficiency-initiatives-and-supply-chain-streamlining-exp-prok-20220615monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-to-present-at-upcoming-investor-conferences-prok-20220520monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-highlights-key-registrational-program-elements-supporting-advancement-of-react-prok-20220503monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-appoints-libbie-parker-mckenzie-md-fasn-as-chief-medical-officer-prok-20220428monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-and-social-capital-suvretta-holdings-corp-iii-scs-to-host-analyst-and-investor-d-prok-20220418monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-confirms-phase-3-program-for-autologous-kidney-cell-therapy-react-prok-20220412monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-appoints-todd-c-girolamo-as-general-counsel-prok-20220328monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-to-present-react-at-4th-annual-ckd-summit-prok-20220301monthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-announces-online-publication-of-trial-design-for-phase-ii-multicenter-clinical-t-prok-20220127monthly0.5https://www.biopharmawatch.com/news/CTNM/contineum-therapeutics-announces-pricing-of-initial-public-offering-ctnm-20240405monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharma-to-present-real-world-data-on-intranasal-epinephrine-at-2025-american-college-o-spry-20251103monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-announces-conference-call-and-webcast-for-its-second-quarter-2025-fina-spry-20250804monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-to-participate-in-upcoming-investor-conferences-spry-20250527monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-neffy-epinephrine-nasal-spray-1-mg-is-now-available-in-the-united-stat-spry-20250507monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-announces-conference-call-and-webcast-for-its-first-quarter-2025-finan-spry-20250505monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-announces-fda-approval-of-neffy-1-mg-epinephrine-nasal-spray-for-type--spry-20250305monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-announces-conference-call-and-webcast-for-its-fourth-quarter-and-full--spry-20250303monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-announces-optumrx-cigna-healthcare-and-navitus-health-systems-add-neff-spry-20250221monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-to-showcase-innovation-and-present-data-on-neffy-epinephrine-nasal-spr-spry-20250218monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-to-participate-in-the-oppenheimer-35th-annual-healthcare-conference-spry-20250205monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-launches-neffyinschools-program-providing-free-life-saving-needle-free-spry-20250121monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-announces-preliminary-fourth-quarter-2024-financial-results-and-2025-o-spry-20250113monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-announces-neffy-epinephrine-nasal-spray-is-available-on-express-script-spry-20241219monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference-spry-20241218monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-announces-filings-for-approval-of-neffy-in-china-japan-and-australia-spry-20241212monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-announces-planned-launch-of-neffyinschools-program-to-provide-life-sav-spry-20241204monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-announces-exclusive-agreement-with-global-allergy-leader-alk-to-commer-spry-20241111monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-announces-conference-call-and-webcasts-for-its-third-quarter-2024-fina-spry-20241106monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-showcases-intranasal-epinephrine-data-at-2024-american-college-of-alle-spry-20241024monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-announces-u-s-availability-of-neffy-epinephrine-nasal-spray-the-first--spry-20240923monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-to-participate-in-the-2024-cantor-global-healthcare-conference-spry-20240910monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-submits-snda-to-fda-for-neffy-1-mg-dose-for-pediatric-patients-with-ty-spry-20240909monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-launches-pre-ordering-services-for-neffy-to-help-patients-access-the-f-spry-20240904monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-receives-fda-approval-of-neffy-epinephrine-nasal-spray-the-first-and-o-spry-20240809monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-to-participate-in-the-2024-wedbush-pacgrow-healthcare-conference-spry-20240807monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-announces-eurneffy-adrenaline-nasal-spray-recommended-for-approval-by--spry-20240628monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-submits-response-for-neffy-epinephrine-nasal-spray-marketing-authoriza-spry-20240430monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-submits-response-to-fda-complete-response-letter-for-neffy-epinephrine-spry-20240403monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-reviews-recent-clinical-updates-and-commercial-opportunity-at-neffy-in-spry-20240307monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-to-participate-in-the-leerink-partners-global-biopharma-conference-202-spry-20240306monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-announces-neffy-meets-primary-endpoints-and-shows-rapid-symptom-contro-spry-20240226monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-to-host-virtual-neffy-investor-day-on-march-7-2024-spry-20240222monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharma-announces-favorable-topline-results-from-repeat-dosing-study-of-neffy-epinephri-spry-20240220monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-to-present-positive-clinical-efficacy-data-for-neffy-epinephrine-nasal-spry-20240205monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-announces-presentation-of-clinical-data-supporting-neffy-epinephrine-n-spry-20231109monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-announces-scheduling-of-a-type-a-meeting-with-the-u-s-fda-for-neffy-ep-spry-20231006monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-announces-pdufa-date-extension-for-neffy-intranasal-in-epinephrine-for-spry-20230620monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-investigated-by-block-leviton-for-potential-securities-law-violations--spry-20230510monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-announces-availability-of-briefing-documents-for-fda-advisory-committe-spry-20230509monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-announces-fda-advisory-committee-for-neffy-for-the-treatment-of-allerg-spry-20230328monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-announces-presentation-of-data-supporting-neffy-epinephrine-nasal-spra-spry-20230223monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-reacquires-european-marketing-rights-to-neffy-ars-1-for-the-treatment--spry-20230222monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-to-participate-in-the-svb-securities-virtual-global-biopharma-conferen-spry-20230209monthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-announces-presentation-of-clinical-data-supporting-neffy-epinephrine-n-spry-20221110monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-investor-alert-johnson-fistel-reviews-potential-claims-for-shareholders-bbnx-20260617monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-bbnx-securities-investigation-johnson-fistel-reviews-investor-losses-followin-bbnx-20260611monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-bbnx-securities-investigation-johnson-fistel-reviews-investor-losses-followin-bbnx-20260605monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-inc-bbnx-investigation-johnson-fistel-investigates-investor-losses-following--bbnx-20260604monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-inc-securities-fraud-investigation-robbins-llp-is-investigating-investor-loss-bbnx-20260603monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-inc-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-more-infor-bbnx-20260601monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-to-present-at-the-bank-of-america-securities-health-care-conference-bbnx-20260427monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-announces-first-quarter-2026-financial-results-and-raises-full-year-2026-guid-bbnx-20260421monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-inc-investigated-by-the-portnoy-law-firm-bbnx-20260414monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-introduces-bionic-insights-in-bionic-reports-transforming-how-clinicians-unde-bbnx-20260331monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-inc-alert-securities-fraud-investigation-by-block-leviton-could-allow-investo-bbnx-20260225monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-to-present-at-the-td-cowen-46th-annual-health-care-conference-bbnx-20260219monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-to-pre-announce-topline-fourth-quarter-2025-financial-results-the-week-of-jan-bbnx-20251208monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-announces-participation-at-upcoming-investor-conferences-bbnx-20250821monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-reports-second-quarter-2025-financial-results-and-raises-full-year-2025-guida-bbnx-20250729monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-to-announce-second-quarter-2025-financial-results-on-july-29-2025-bbnx-20250702monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-announces-agreement-with-abbott-to-integrate-the-ilet-bionic-pancreas-with-ab-bbnx-20250619monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-reports-first-quarter-2025-financial-results-and-raises-annual-guidance-for-f-bbnx-20250506monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-to-announce-first-quarter-2025-financial-results-on-may-6-2025-bbnx-20250416monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-to-host-investor-event-on-june-22-2025-bbnx-20250409monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-announces-board-appointment-of-gerard-michel-bbnx-20250327monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-announces-fourth-quarter-and-full-year-2024-financial-results-and-introduces--bbnx-20250325monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-to-announce-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2-bbnx-20250227monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-announces-pricing-of-upsized-204-million-initial-public-offering-bbnx-20250130monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-files-registration-statement-for-proposed-initial-public-offering-bbnx-20250106monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-appoints-dr-steven-russell-as-chief-medical-officer-in-preparation-for-the-co-bbnx-20230104monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-appoints-sean-saint-as-ceo-and-board-member-bbnx-20220815monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-appoints-gilad-glick-to-the-board-of-directors-and-veena-rao-ph-d-as-chief-co-bbnx-20220510monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-announces-executive-leadership-and-board-transitions-in-preparation-for-comme-bbnx-20220302monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-announces-closing-of-57-million-series-c-financing-bbnx-20220217monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-announces-data-lock-of-the-insulin-only-bionic-pancreas-pivotal-trial-and-enr-bbnx-20211222monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-announces-appointment-of-christy-jones-to-board-of-directors-bbnx-20210506monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-appoints-martha-aronson-and-sean-carney-to-its-board-as-independent-directors-bbnx-20200220monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-receives-fda-breakthrough-device-designation-for-the-ilet-bionic-pancreas-sys-bbnx-20191210monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-and-convatec-announce-partnership-to-bring-unomedical-infusion-set-portfolio--bbnx-20190717monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-announces-closing-of-a-63-million-series-b2-financing-bringing-the-total-seri-bbnx-20190701monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-announces-final-closing-of-its-63-million-series-b-financing-bbnx-20190108monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-awarded-up-to-2-million-nih-small-business-innovation-research-sbir-grant-bbnx-20181009monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-secures-an-initial-50-million-series-b-round-bbnx-20180917monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-announces-start-of-home-use-clinical-trials-with-the-ilet-bionic-pancreas-sys-bbnx-20180712monthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-receives-ide-approval-from-the-fda-to-begin-a-home-use-clinical-trial-testing-bbnx-20180521monthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-announces-grants-of-inducement-awards-cbio-20260611monthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-announces-grants-of-inducement-awards-cbio-20260529monthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-reports-first-quarter-2026-financial-results-and-recent-business-highli-cbio-20260429monthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-announces-grants-of-inducement-awards-cbio-20260424monthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-announces-grants-of-inducement-awards-cbio-20260327monthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-announces-grants-of-inducement-awards-cbio-20260306monthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-announces-grants-of-inducement-awards-cbio-20260219monthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-announces-grants-of-inducement-awards-cbio-20260130monthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-announces-grants-of-inducement-awards-cbio-20251218monthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-announces-transformational-partnership-with-kelun-biotech-and-185-milli-cbio-20251204monthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-announces-grants-of-inducement-awards-cbio-20251117monthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-to-present-at-september-investor-conferences-cbio-20250828monthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-reports-second-quarter-2025-financial-results-and-recent-business-highl-cbio-20250731monthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-to-present-at-the-td-cowen-45th-annual-health-care-conference-cbio-20250226monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-celebrates-one-year-of-operations-at-singapore-facility-accelerating-gro-ctkb-20260309monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-participate-at-the-td-cowen-46th-annual-health-care-conference-ctkb-20260218monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-report-fourth-quarter-and-full-year-2025-financial-results-on-februar-ctkb-20260212monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-report-third-quarter-2025-financial-results-on-november-5-2025-ctkb-20251022monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-participate-in-upcoming-investor-conferences-ctkb-20250812monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-report-second-quarter-2025-financial-results-on-august-6-2025-ctkb-20250723monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-is-setting-the-new-standard-for-full-spectrum-flow-cytometry-with-the-ne-ctkb-20250529monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-participate-at-the-goldman-sachs-46th-annual-global-healthcare-confer-ctkb-20250528monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-brings-cutting-edge-cell-analysis-solutions-to-cyto-and-immunology2025-ctkb-20250429monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-report-first-quarter-2025-financial-results-on-may-8-2025-ctkb-20250424monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-expands-cell-analysis-offerings-with-the-affordable-user-friendly-cytek--ctkb-20250318monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-report-fourth-quarter-and-full-year-2024-financial-results-on-februar-ctkb-20250213monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-participate-in-upcoming-investor-conferences-ctkb-20250205monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-ctkb-20250102monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-announces-50-million-stock-repurchase-program-for-2025-ctkb-20241230monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference-ctkb-20241120monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-named-overall-biotech-company-of-the-year-in-2024-biotech-breakthrough-a-ctkb-20241119monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-becomes-first-company-to-add-ability-to-detect-subcellular-particles-to--ctkb-20241107monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-participate-in-upcoming-investor-conferences-ctkb-20241030monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-report-third-quarter-2024-financial-results-on-november-5-2024-ctkb-20241029monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-brings-full-spectrum-profiling-fsp-technology-to-the-forefront-at-major--ctkb-20240918monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-announces-resignation-of-chief-operating-officer-chris-williams-ctkb-20240912monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-achieves-iso-13485-certification-at-san-diego-reagent-manufacturing-faci-ctkb-20240821monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-participate-in-upcoming-investor-conferences-ctkb-20240808monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-automates-panel-design-with-new-intelligent-algorithm-ctkb-20240730monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-report-second-quarter-2024-financial-results-on-august-6-2024-ctkb-20240730monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-announces-50-million-stock-repurchase-program-ctkb-20240606monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-participate-at-the-goldman-sachs-45th-annual-global-healthcare-confer-ctkb-20240530monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-adds-ability-to-detect-subcellular-particles-to-its-industry-leading-cel-ctkb-20240520monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-spotlight-cell-analysis-solutions-at-upcoming-conferences-in-the-unit-ctkb-20240430monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-report-first-quarter-2024-financial-results-on-may-8-2024-ctkb-20240429monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-opens-new-facility-to-address-increasing-global-demand-for-cutting-edge--ctkb-20240307monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-participate-in-upcoming-investor-conferences-ctkb-20240207monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-report-fourth-quarter-and-full-year-2023-financial-results-on-februar-ctkb-20240207monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-signs-agreement-with-crg-and-upf-to-accelerate-scientific-discoveries-ctkb-20240117monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-ctkb-20231228monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-introduces-the-cytek-orion-reagent-cocktail-preparation-system-the-first-ctkb-20231221monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-participate-in-the-piper-sandler-35th-annual-healthcare-conference-ctkb-20231114monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-aurora-cs-system-wins-biotech-breakthrough-award-for-cell-sorting-product-of-the-yea-ctkb-20231108monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-report-third-quarter-2023-financial-results-on-november-7-2023-ctkb-20231019monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-achieves-iso-13485-certification-at-headquarters-ctkb-20230927monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-participate-in-the-2023-cantor-fitzgerald-global-healthcare-conferenc-ctkb-20230920monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-cell-analysis-solutions-take-center-stage-at-upcoming-clinical-conferenc-ctkb-20230920monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-launches-educational-roadshow-focused-on-spectral-flow-cytometry-ctkb-20230914monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-participate-in-the-morgan-stanley-21st-annual-global-healthcare-confe-ctkb-20230906monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-appoints-dr-philippe-busque-senior-vice-president-of-global-sales-servic-ctkb-20230828monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-participate-in-the-ubs-medtech-tools-and-genomics-summit-ctkb-20230810monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-report-second-quarter-2023-financial-results-on-august-8-2023-ctkb-20230720monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-participate-in-the-44th-annual-goldman-sachs-healthcare-conference-ctkb-20230531monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-announces-50-million-stock-repurchase-program-ctkb-20230519monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-marks-shipment-of-its-100th-cell-sorter-as-the-company-continues-to-lead-ctkb-20230516monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-report-first-quarter-2023-financial-results-on-may-9-2023-ctkb-20230420monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-introduces-new-20-color-aml-panel-ctkb-20230307monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-acquire-flow-cytometry-and-imaging-business-from-diasorin-ctkb-20230213monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-report-fourth-quarter-and-full-year-2022-financial-results-on-februar-ctkb-20230207monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-partners-with-bio-rad-to-expand-reagent-portfolios-ctkb-20230207monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-participate-in-upcoming-investor-conferences-ctkb-20230206monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-participate-in-the-piper-sandler-healthcare-conference-ctkb-20221121monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-introduces-cytek-cloud-ctkb-20221115monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-report-third-quarter-2022-financial-results-on-november-9-2022-ctkb-20221026monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-to-participate-in-the-31st-annual-credit-suisse-healthcare-conference-ctkb-20221026monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-to-participate-in-the-20th-annual-morgan-stanley-global-healthcare-conference-ctkb-20220830monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-to-participate-in-the-42nd-annual-canaccord-genuity-global-growth-conference-ctkb-20220721monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-report-second-quarter-2022-financial-results-on-august-10-2022-ctkb-20220720monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-host-inaugural-analyst-and-investor-day-ctkb-20220601monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-receives-ce-marking-for-series-of-cfluor-reagents-tbnk-kit-ctkb-20220524monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-report-first-quarter-financial-results-on-may-11-2022-ctkb-20220428monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-appoints-todd-garland-chief-commercial-officer-ctkb-20220428monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-to-participate-in-the-42nd-annual-cowen-health-care-conference-ctkb-20220216monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-report-fourth-quarter-and-full-year-2021-financial-results-on-februar-ctkb-20220211monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-expands-fremont-headquarters-tripling-its-manufacturing-capacity-ctkb-20220105monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-marks-milestone-achievement-with-shipment-of-1000th-cell-analysis-system-ctkb-20211117monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-acquires-tonbo-biosciences-cell-analysis-business-ctkb-20211103monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-report-third-quarter-financial-results-on-november-8-2021-ctkb-20211026monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-introduces-new-25-color-immunoprofiling-assay-ctkb-20211007monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-to-present-at-the-morgan-stanley-19th-annual-global-healthcare-conferenc-ctkb-20210902monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-announces-full-exercise-of-underwriters-option-to-purchase-additional-sh-ctkb-20210802monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-announces-closing-of-its-initial-public-offering-ctkb-20210727monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-announces-pricing-of-its-initial-public-offering-ctkb-20210723monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-introduces-a-new-high-dimensional-sorter-ctkb-20210607monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-appoints-allen-poirson-as-senior-vice-president-of-marketing-and-corpora-ctkb-20210428monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-debuts-optimized-immunoprofiling-kit-ctkb-20201215monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-completes-series-d-funding-round-ctkb-20201105monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-receives-ce-marking-on-its-northern-lights-nl-clc-platform-ctkb-20200916monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-debuts-custom-reagents-at-cyto-2020-ctkb-20200803monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-strengthening-support-for-scientists-in-fight-against-covid-19-ctkb-20200423monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-expands-global-reach-ctkb-20191030monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-hits-flow-cytometry-milestone-40-color-analysis-from-a-single-sample-ctkb-20190925monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-northern-lights-platform-approved-for-clinical-use-in-china-ctkb-20190904monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-debuts-advanced-five-laser-flow-cytometer-ctkb-20190619monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-achieves-iso-9001-2015-certification-ctkb-20190516monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-adds-de-novo-software-to-lineup-of-advanced-flow-cytometry-systems-ctkb-20190108monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-ships-100th-advanced-flow-cytometry-system-ctkb-20181220monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-continues-momentum-by-strengthening-executive-team-adding-board-members-ctkb-20181113monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-debuts-advanced-flow-cytometry-system-that-breaks-the-cost-barrier-ctkb-20181023monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-adds-investors-completes-series-c-financing-ctkb-20180925monthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-spotlights-the-cytek-aurora-flow-cytometry-system-at-cyto-2018-ctkb-20180424monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-to-report-full-year-2025-consolidated-financial-results-on-march-18-2026-valn-20260309monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-to-participate-in-upcoming-investor-conferences-valn-20260302monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-provides-update-on-recommendations-for-use-of-ixchiq-in-the-united-kingdom-valn-20260213monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-se-declaration-of-voting-rights-december-2025-valn-20260108monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-and-serum-institute-of-india-announce-discontinuation-of-chikungunya-vaccine-licen-valn-20251231monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-reports-95-seroresponse-four-years-after-single-shot-of-chikungunya-vaccine-ixchiq-valn-20250930monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-alert-bragar-eagel-squire-p-c-is-investigating-valneva-se-on-behalf-of-valneva-sto-valn-20250918monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-alert-bragar-eagel-squire-p-c-is-investigating-valneva-se-on-behalf-of-valneva-sto-valn-20250911monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-alert-bragar-eagel-squire-p-c-is-investigating-valneva-se-on-behalf-of-valneva-sto-valn-20250904monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-reports-further-positive-phase-2-safety-and-immunogenicity-results-for-lyme-diseas-valn-20250903monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-fda-s-decision-to-suspend-license-of-chikungunya-vaccine-ixchiq-in-the-u-valn-20250825monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-s-chikungunya-vaccine-ixchiq-now-authorized-in-canada-for-individuals-aged-12-and--valn-20250818monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-reports-half-year-2025-financial-results-and-provides-corporate-updates-valn-20250812monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-removal-of-fda-recommended-pause-on-use-of-chikungunya-vaccine-ixchiq-in-valn-20250807monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-lifting-of-european-medicines-agency-s-temporary-restriction-on-use-of-c-valn-20250711monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-exclusive-vaccine-marketing-and-distribution-agreement-for-germany-with--valn-20250626monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-successful-outcome-of-its-annual-general-meeting-confirms-fy-2025-guidan-valn-20250625monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-reports-positive-six-month-antibody-persistence-and-safety-phase-2-results-in-chil-valn-20250605monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-se-declaration-of-shares-and-voting-rights-may-2025-valn-20250605monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-availability-of-documentation-for-its-combined-shareholder-meeting-and-p-valn-20250604monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-to-participate-at-u-s-and-european-investor-conferences-in-june-valn-20250526monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-provides-update-on-recommended-use-of-ixchiq-by-elderly-individuals-in-the-united--valn-20250512monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-provides-update-following-european-medicines-agency-announcement-on-use-of-ixchiq--valn-20250507monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-reports-first-quarter-2025-financial-results-and-provides-corporate-updates-valn-20250507monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-provides-update-on-recommendation-for-use-of-its-chikungunya-vaccine-by-french-aut-valn-20250426monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-se-company-investigated-by-the-portnoy-law-firm-valn-20250422monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-provides-update-on-acip-recommendation-for-its-chikungunya-vaccine-ixchiq-among-u--valn-20250418monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-to-participate-in-multiple-events-at-the-25th-world-vaccine-congress-including-a-p-valn-20250416monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-receives-first-marketing-authorization-for-ixchiq-in-a-chikungunya-endemic-country-valn-20250414monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-and-limmatech-announce-first-vaccination-in-phase-2-infant-study-of-tetravalent-sh-valn-20250409monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-se-shareholding-declaration-march-2025-valn-20250403monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-s-chikungunya-vaccine-ixchiq-now-authorized-in-eu-for-adolescents-aged-12-and-abov-valn-20250401monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-submits-adolescent-label-extension-application-for-its-chikungunya-vaccine-ixchiq--valn-20250331monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-renews-its-sales-agreement-in-connection-with-its-existing-at-the-market-atm-progr-valn-20250326monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-filing-of-2024-universal-registration-document-and-us-form-20-f-valn-20250325monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-reports-full-year-2024-results-and-provides-business-updates-and-outlook-valn-20250320monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-to-present-at-upcoming-td-cowen-and-van-lanschot-kempen-healthcare-investor-confer-valn-20250303monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-receives-ema-s-positive-chmp-opinion-for-adolescent-label-extension-for-chikunguny-valn-20250228monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-reports-preliminary-unaudited-2024-revenue-and-cash-and-provides-2025-outlook-valn-20250218monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-receives-marketing-authorization-in-the-uk-for-the-world-s-first-chikungunya-vacci-valn-20250205monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-new-ixiaro-supply-contract-with-the-u-s-government-worth-a-minimum-of-32-valn-20250130monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-reports-positive-phase-2-results-in-children-for-its-chikungunya-vaccine-and-annou-valn-20250122monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-reports-high-sustained-immune-response-in-adolescents-one-year-after-single-vaccin-valn-20250120monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-to-meet-with-investors-during-the-j-p-morgan-healthcare-conference-valn-20250106monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-successfully-expands-access-to-asia-for-its-chikungunya-vaccine-with-serum-institu-valn-20241219monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-peer-reviewed-publication-on-the-global-health-and-economic-burden-of-ch-valn-20241204monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-reports-positive-three-year-antibody-persistence-data-for-its-single-shot-chikungu-valn-20241203monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-submits-label-extension-application-for-its-chikungunya-vaccine-ixchiq-to-the-u-s--valn-20241126monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-and-limmatech-announce-first-vaccination-in-phase-2b-human-challenge-study-of-tetr-valn-20241113monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-to-present-and-hold-investor-meetings-at-upcoming-u-s-and-european-healthcare-conf-valn-20241112monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-reports-nine-month-2024-financial-results-and-provides-corporate-updates-valn-20241107monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-to-present-on-chikungunya-at-several-leading-scientific-conferences-valn-20241021monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-and-limmatech-awarded-fda-fast-track-designation-for-tetravalent-shigella-vaccine--valn-20241016monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-hosts-investor-day-in-new-york-city-valn-20241010monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-se-declaration-of-shares-and-voting-rights-september-30-2024-valn-20241004monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-to-host-investor-day-in-new-york-on-thursday-october-10-2024-at-10-00-am-et-valn-20241003monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-submits-label-extension-applications-for-its-chikungunya-vaccine-ixchiq-to-ema-and-valn-20240918monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-the-success-of-its-private-placement-raising-approximately-60-million-valn-20240913monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-the-launch-of-a-private-placement-of-ordinary-shares-for-approximately-6-valn-20240912monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-and-pfizer-report-further-positive-phase-2-booster-results-for-lyme-disease-vaccin-valn-20240903monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-reports-half-year-2024-financial-results-and-provides-corporate-updates-valn-20240813monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-receives-marketing-authorization-in-europe-for-the-world-s-first-chikungunya-vacci-valn-20240701monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-successful-outcome-of-its-combined-general-meeting-and-appointment-of-a--valn-20240626monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-health-canada-approval-of-the-world-s-first-chikungunya-vaccine-ixchiq-valn-20240624monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-availability-of-documentation-for-its-combined-shareholder-meeting-and-p-valn-20240605monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-to-present-and-hold-investor-meetings-at-upcoming-conferences-in-june-valn-20240604monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-publication-of-lyme-disease-phase-2-trials-in-the-lancet-infectious-dise-valn-20240603monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-receives-ema-s-positive-chmp-opinion-for-its-chikungunya-vaccine-valn-20240531monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-appoints-dr-hanneke-schuitemaker-ph-d-as-chief-scientific-officer-valn-20240521monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-reports-further-positive-pivotal-phase-3-data-in-adolescents-for-its-single-shot-c-valn-20240513monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-reports-first-quarter-2024-financial-results-and-provides-corporate-updates-valn-20240507monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-initiates-phase-1-trial-of-second-generation-zika-vaccine-candidate-valn-20240326monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-filing-of-2023-universal-registration-document-and-us-form-20-f-valn-20240325monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-to-present-on-its-chikungunya-vaccine-ixchiq-participate-in-multiple-events-at-the-valn-20240321monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-reports-full-year-2023-results-and-provides-business-updates-and-outlook-valn-20240320monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-extension-of-the-interest-only-period-of-its-debt-facility-with-deerfiel-valn-20240318monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-to-present-at-upcoming-td-cowen-and-van-lanschot-kempen-healthcare-investor-confer-valn-20240304monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-reports-full-year-2023-revenue-and-cash-provides-first-2024-guidance-valn-20240215monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-sale-of-priority-review-voucher-for-103-million-valn-20240205monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-vaccinates-first-participant-in-pediatric-trial-of-single-shot-chikungunya-vaccine-valn-20240110monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-to-conduct-investor-meetings-during-the-j-p-morgan-healthcare-conference-and-oddo--valn-20240104monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-provides-updated-2023-financial-guidance-valn-20231229monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-shareholders-approve-egm-resolutions-including-the-transition-to-a-board-of-direct-valn-20231220monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-se-declaration-of-shares-and-voting-rights-interim-status-at-june-22-2022-valn-20220627monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-se-declaration-of-shares-and-voting-rights-january-2022-valn-20220204monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-se-declaration-of-shares-and-voting-rights-november-2021-valn-20211206monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-signing-of-marketing-distribution-agreement-for-seqirus-flu-vaccines-san-valn-20160825monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-european-investment-bank-grants-valneva-a-eu25-million-loan-to-fund-r-d-activities-valn-20160712monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-successful-outcome-of-its-agm-confirms-its-growth-strategy-and-financial-valn-20160701monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-appoints-two-leading-pharma-executives-to-its-supervisory-board-valn-20160701monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-first-sales-of-flu-vaccines-produced-on-valneva-s-eb66-r-cell-line-valn-20160613monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-42-million-ixiaro-r-supply-contract-with-us-government-valn-20160316monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-posts-96-revenue-growth-in-2015-forecasts-2016-revenues-of-eu90-to-eu100-million-valn-20160224monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-signs-new-r-d-collaboration-with-glaxosmithkline-for-the-eb66-r-cell-line-valn-20160208monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-provides-update-on-dukoral-r-vaccine-in-canada-valn-20151223monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-u-s-distribution-and-marketing-services-agreements-with-vaxserve-for-jap-valn-20151109monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-valneva-announces-two-new-eb66-r-agreements-valn-20150827monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-takes-direct-control-over-marketing-distribution-of-ixiaro-r-to-increase-margin-an-valn-20150622monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-announces-signing-of-an-exclusive-license-agreement-on-eb66-r-cell-line-for-human--valn-20150317monthly0.5https://www.biopharmawatch.com/news/VALN/valneva-se-announces-the-sale-of-its-clinical-manufacturing-operations-cmo-in-france-to-bi-valn-20130607monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-first-quarter-2026-operating-financial-results-mdxg-20260429monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel-mdxg-20251222monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-participate-in-upcoming-investor-conferences-mdxg-20250827monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-host-second-quarter-2025-operating-and-financial-results-conference-call-on-july-mdxg-20250716monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-comments-on-proposed-medicare-reimbursement-rule-changes-for-cy-2026-mdxg-20250715monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-participate-in-upcoming-investor-conferences-mdxg-20250527monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-present-at-the-bofa-securities-2025-healthcare-conference-mdxg-20250506monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-publication-of-health-economics-data-in-mohs-micrographic-surgery-mms-mdxg-20250505monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-first-quarter-2025-operating-and-financial-results-mdxg-20250430monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-host-first-quarter-2025-operating-and-financial-results-conference-call-on-april-mdxg-20250416monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-feature-growing-body-of-clinical-and-scientific-evidence-at-upcoming-wound-surgi-mdxg-20250410monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-present-at-td-cowen-45th-annual-health-care-conference-mdxg-20250227monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-fourth-quarter-and-full-year-2024-operating-and-financial-results-mdxg-20250226monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-host-fourth-quarter-and-full-year-2024-operating-and-financial-results-conferenc-mdxg-20250205monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-files-patent-infringement-lawsuit-against-surgenex-mdxg-20241217monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-participate-in-upcoming-investor-conferences-mdxg-20241204monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-s-advocacy-to-rein-in-runaway-medicare-spend-for-skin-substitutes-has-yielded-signi-mdxg-20241114monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-participate-in-upcoming-investor-conferences-mdxg-20241104monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-host-third-quarter-2024-operating-and-financial-results-conference-call-on-octob-mdxg-20241014monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-points-to-the-new-york-times-article-on-the-vast-benefits-of-placental-tissue-mdxg-20241008monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-showcases-leading-allograft-portfolio-and-its-latest-scientific-and-clinical-eviden-mdxg-20241001monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-participate-in-upcoming-investor-conferences-mdxg-20240827monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-launch-of-heliogen-fibrillar-collagen-matrix-mdxg-20240731monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-publication-focused-on-surgical-applications-using-mimedx-placental-based-mdxg-20240722monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-host-second-quarter-2024-operating-and-financial-results-conference-call-on-july-mdxg-20240717monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-the-appointment-of-kim-moller-to-chief-commercial-officer-mdxg-20240626monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-participate-in-upcoming-investor-conferences-mdxg-20240515monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-host-first-quarter-2024-operating-and-financial-results-conference-call-on-april-mdxg-20240416monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-provides-update-on-axiofill-request-for-designation-rfd-from-fda-mdxg-20240327monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-expands-portfolio-with-fibrillar-collagen-wound-dressing-mdxg-20240320monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-introduces-e-commerce-and-account-management-platform-mdxg-20240313monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-appointment-of-two-new-independent-directors-mdxg-20240304monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-present-at-td-cowen-44th-annual-health-care-conference-mdxg-20240220monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-host-fourth-quarter-and-full-year-2023-operating-and-financial-results-conferenc-mdxg-20240212monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-group-investigated-by-block-leviton-for-potential-securities-law-violations-investo-mdxg-20240117monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-alert-bragar-eagel-squire-p-c-is-investigating-mimedx-group-inc-on-behalf-of-mimedx-mdxg-20240116monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-provides-axiofill-update-reiterates-2023-full-year-net-sales-and-fourth-quarter-adj-mdxg-20231229monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-highlight-published-data-at-sawc-fall-mdxg-20231102monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-host-third-quarter-2023-operating-and-financial-results-conference-call-on-octob-mdxg-20231016monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-launch-of-epieffect-mdxg-20230926monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-host-second-quarter-2023-operating-and-financial-results-conference-call-on-augu-mdxg-20230718monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-favorable-ruling-in-putative-securities-class-action-case-mdxg-20230711monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-appoints-doug-rice-as-chief-financial-officer-mdxg-20230705monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-host-first-quarter-2023-operating-and-financial-results-conference-call-on-may-2-mdxg-20230418monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-comments-on-recent-data-brief-published-by-office-of-inspector-general-mdxg-20230316monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-host-fourth-quarter-and-full-year-2022-operating-and-financial-results-conferenc-mdxg-20230215monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-confirms-fourth-quarter-and-full-year-2022-net-sales-expectations-comments-on-evolv-mdxg-20230109monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-commercial-launch-of-epifix-in-japan-with-exclusive-distribution-agreemen-mdxg-20230104monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-wound-surgical-product-pipeline-expansion-via-in-licensing-and-distributi-mdxg-20221208monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-present-at-upcoming-investor-conferences-mdxg-20221110monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-host-third-quarter-2022-operating-and-financial-results-conference-call-on-novem-mdxg-20221019monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-appoints-matt-notarianni-as-head-of-investor-relations-mdxg-20221004monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-launch-of-axiofill-mdxg-20220920monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-launch-of-amnioeffect-mdxg-20220919monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-epifix-receives-reimbursement-approval-in-japan-mdxg-20220912monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-leadership-transition-mdxg-20220906monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-present-at-the-canaccord-genuity-42nd-annual-growth-conference-mdxg-20220804monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-formation-of-regenerative-medicine-scientific-advisory-board-comprised-of-mdxg-20220727monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-host-second-quarter-2022-operating-and-financial-results-conference-call-on-augu-mdxg-20220720monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-welcomes-kate-surdez-as-chief-human-resources-officer-mdxg-20220718monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-engages-nordic-bioscience-clinical-development-a-s-to-propel-registrational-trials--mdxg-20220615monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-shareholders-vote-to-approve-all-proposals-at-the-2022-annual-meeting-mdxg-20220607monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-reminds-shareholders-to-pre-register-for-the-upcoming-virtual-2022-annual-meeting-o-mdxg-20220603monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-addresses-presentation-by-prescience-point-mdxg-20220602monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-board-chair-dr-m-kathleen-behrens-writes-letter-to-fellow-shareholders-mdxg-20220531monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-receives-4-6-million-award-from-the-department-of-defense-to-advance-the-treatment--mdxg-20220531monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-investor-presentation-highlights-clear-strategy-for-value-creation-mdxg-20220518monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-mails-letter-to-shareholders-mdxg-20220516monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-comments-on-prescience-point-s-false-and-misleading-statements-mdxg-20220509monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-participate-at-upcoming-investor-conferences-mdxg-20220505monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-host-first-quarter-2022-operating-and-financial-results-conference-call-on-may-4-mdxg-20220420monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-present-health-economics-clinical-data-for-epifix-in-treatment-of-lower-extremit-mdxg-20220405monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-present-at-the-canaccord-genuity-musculoskeletal-conference-mdxg-20220315monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-host-fourth-quarter-2021-operating-and-financial-results-conference-call-on-febr-mdxg-20220214monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-dismissal-of-putative-securities-class-action-lawsuit-mdxg-20220128monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-outlines-key-strategic-milestones-for-2022-mdxg-20220110monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-participate-at-the-h-c-wainwright-bioconnect-virtual-conference-mdxg-20220104monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-mdxg-20211222monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-outlines-long-term-value-creation-strategy-at-virtual-investor-day-mdxg-20211207monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-speakers-for-december-7-investor-day-mdxg-20211130monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-present-at-the-piper-sandler-33rd-annual-healthcare-conference-mdxg-20211122monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-participate-at-upcoming-investor-conferences-mdxg-20211102monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-host-third-quarter-2021-operating-and-financial-results-conference-call-on-novem-mdxg-20211020monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-host-virtual-investor-day-on-december-7-2021-mdxg-20211014monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-reports-top-line-data-from-two-late-stage-musculoskeletal-trials-with-proprietary-a-mdxg-20210913monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-effectiveness-of-shelf-registration-statement-mdxg-20210908monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference-mdxg-20210907monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-filing-of-shelf-registration-statement-with-securities-and-exchange-commi-mdxg-20210827monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-promotes-marion-snyder-to-chief-of-staff-senior-vice-president-government-affairs-mdxg-20210812monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-second-quarter-2021-operating-and-financial-results-mdxg-20210803monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-host-second-quarter-2021-operating-and-financial-results-conference-call-on-augu-mdxg-20210720monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-joins-russell-3000-and-2000-indexes-mdxg-20210628monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-present-at-the-raymond-james-2021-human-health-innovation-conference-mdxg-20210616monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-receives-regulatory-approval-to-commercialize-epifix-in-japan-mdxg-20210608monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-participate-at-the-jefferies-virtual-healthcare-conference-mdxg-20210527monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-reminds-shareholders-to-vote-at-the-upcoming-annual-meeting-mdxg-20210512monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-participate-at-upcoming-investor-conferences-mdxg-20210510monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-collaborative-agreement-with-the-wake-forest-institute-for-regenerative-m-mdxg-20210506monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-urges-shareholders-to-consider-prescience-point-s-motivations-before-voting-their-s-mdxg-20210504monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-welcomes-dirk-stevens-ph-d-as-senior-vice-president-quality-assurance-and-regulator-mdxg-20210428monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-host-first-quarter-2021-operating-and-financial-results-conference-call-on-april-mdxg-20210422monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-confirms-receipt-of-director-nominations-from-prescience-point-capital-management-mdxg-20210416monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-awarded-amniotic-tissue-supplier-agreement-with-premier-inc-s-surpass-purchasing-pr-mdxg-20210330monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-appointment-of-phyllis-gardner-m-d-to-board-of-directors-mdxg-20210308monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-participate-at-upcoming-investor-conferences-mdxg-20210303monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-host-fourth-quarter-and-full-year-2020-operating-and-financial-results-conferenc-mdxg-20210302monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-participate-at-the-btig-virtual-medtech-digital-health-life-science-diagnostic-t-mdxg-20210210monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-participate-at-the-h-c-wainwright-bioconnect-2021-conference-mdxg-20210104monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-mdxg-20201207monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-appoints-jack-howarth-as-senior-vice-president-investor-relations-mdxg-20201201monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference-mdxg-20201124monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-host-virtual-2020-annual-meeting-of-shareholders-on-friday-november-20-mdxg-20201113monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-present-at-canaccord-genuity-virtual-medtech-diagnostics-forum-mdxg-20201112monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-advance-the-conversation-of-study-bias-in-the-clinical-evaluation-of-skin-substi-mdxg-20201104monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-shares-to-commence-trading-on-nasdaq-on-wednesday-november-4-2020-mdxg-20201103monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-largest-u-s-commercial-payor-will-provide-coverage-for-epifix-in-the-trea-mdxg-20201103monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-relisting-on-nasdaq-mdxg-20201030monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-host-third-quarter-2020-financial-results-call-on-november-5-mdxg-20201029monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-files-definitive-proxy-materials-mdxg-20201015monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-preliminary-third-quarter-2020-net-sales-mdxg-20200921monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-launches-epicord-expandable-placental-allograft-as-addition-to-market-leading-portf-mdxg-20200914monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-to-discuss-strategic-priorities-at-upcoming-virtual-2019-annual-meeting-of-sharehol-mdxg-20200824monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-files-second-quarter-2020-form-10-q-mdxg-20200804monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-files-definitive-proxy-materials-mdxg-20200803monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-filing-of-2020-first-quarter-form-10-q-mdxg-20200706monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-filing-of-2019-annual-report-mdxg-20200706monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-concurrent-150-million-private-equity-and-debt-financings-mdxg-20200702monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-mdxg-20180414monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds--mdxg-20180407monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-group-lead-plaintiff-alert-faruqi-faruqi-llp-encourages-investors-who-suffered-loss-mdxg-20180404monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-mdxg-20180310monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds--mdxg-20180227monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-group-alert-andrews-springer-llc-announces-update-in-the-securities-fraud-lawsuit-a-mdxg-20160125monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-group-alert-andrews-springer-llc-announces-update-in-the-securities-fraud-lawsuit-a-mdxg-20151207monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-group-inc-fraud-alert-andrews-springer-llc-announces-that-a-securities-fraud-class--mdxg-20150126monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-96-hour-deadline-alert-approximately-96-hours-remain-former-louisiana-attorney-gene-mdxg-20131106monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-group-inc-deadline-levi-korsinsky-llp-reminds-investors-of-class-action-against-mim-mdxg-20131028monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-group-inc-shareholder-alert-levi-korsinsky-llp-announces-class-action-against-mimed-mdxg-20131015monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-group-inc-shareholder-alert-levi-korsinsky-llp-announces-class-action-against-mimed-mdxg-20131002monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-environmental-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-fot-mdxg-20130910monthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-group-inc-mdxg-to-ring-the-nasdaq-stock-market-opening-bell-mdxg-20130711monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-closing-of-150-million-underwritten-offering-of-common-stock-immx-20260522monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-closing-of-upsized-100-million-underwritten-offering-of-common-s-immx-20251209monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-class-leading-safety-profile-allowing-potential-future-indicatio-immx-20250711monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-accelerated-nexicart-2-clinical-trial-progress-in-relapsed-refra-immx-20250707monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-attends-fda-ceo-forum-in-washington-dc-immx-20250606monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-primary-endpoint-met-in-positive-nxc-201-interim-results-present-immx-20250603monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-further-expands-u-s-clinical-sites-for-relapsed-refractory-al-amyloidosis--immx-20250523monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-positive-results-for-nxc-201-at-asco-oral-presentation-enabling--immx-20250522monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-to-host-kol-event-to-discuss-nxc-201-clinical-data-presented-at-asco-2025--immx-20250521monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-s-nxc-201-nexicart-2-clinical-trial-data-selected-for-oral-presentation-at-immx-20250423monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-n-immx-20250210monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-accelerates-enrollment-in-u-s-al-amyloidosis-trial-of-nxc-201-car-t-immx-20250107monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-positive-u-s-clinical-data-from-first-four-patients-in-nexicart--immx-20241219monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-75-complete-response-rate-n-16-31-5-months-best-response-duratio-immx-20241210monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-to-host-conference-call-for-investors-analysts-and-members-of-the-media-immx-20241209monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-presents-positive-nxc-201-clinical-data-at-66th-american-society-of-hemato-immx-20241125monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-advances-car-t-nxc-201-to-expansion-cohort-dose-level-in-u-s-al-amyloidosi-immx-20241002monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-dr-raymond-comenzo-internationally-recognized-al-amyloidosis-exp-immx-20240919monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-expands-u-s-clinical-sites-for-relapsed-refractory-al-amyloidosis-trial-ne-immx-20240828monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-doses-1st-patient-in-u-s-al-amyloidosis-trial-with-car-t-nxc-201-immx-20240708monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-to-present-at-the-stifel-2024-cell-therapy-forum-immx-20240617monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-positive-nxc-201-relapsed-refractory-al-amyloidosis-clinical-dat-immx-20240510monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-awarded-european-union-orphan-drug-designation-for-nxc-201-in-multiple-mye-immx-20240429monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-on-track-to-dose-nxc-201-patients-in-united-states-immx-20240418monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-late-breaking-nxc-201-clinical-data-abstract-accepted-for-oral-p-immx-20240415monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-major-comprehensive-cancer-center-as-lead-site-for-nxc-201-al-am-immx-20240320monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-be-proactive-in-al-al-amyloidosis-awareness-initiative-immx-20240305monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-12-month-review-progress-update-immx-20240221monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-closing-of-15-million-public-offering-of-common-stock-immx-20240208monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-awarded-european-union-orphan-drug-designation-for-nxc-201-in-al-amyloidos-immx-20240207monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-pricing-of-15-million-public-offering-of-common-stock-immx-20240206monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-proposed-public-offering-of-common-stock-immx-20240205monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-statement-on-january-2024-fda-labeling-change-notification-for-approved-ca-immx-20240124monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-dr-vaishali-sanchorawala-al-amyloidosis-thought-leader-director--immx-20240104monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-dr-marko-radic-autoimmune-car-t-pioneer-and-associate-professor--immx-20231218monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-100-overall-response-rate-n-10-23-7-months-best-response-duratio-immx-20231211monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-to-present-at-the-2023-jmp-securities-hematology-and-oncology-summit-immx-20231130monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-to-host-kol-event-to-discuss-its-bcma-targeted-car-t-cell-therapy-candidat-immx-20231122monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-fda-approval-of-ind-application-for-car-t-nxc-201-enabling-u-s-p-immx-20231121monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-presents-nxc-201-data-at-65th-american-society-of-hematology-ash-annual-me-immx-20231106monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-subsidiary-nexcella-announces-dr-michaela-liedtke-stanford-medicine-cancer-immx-20231026monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-completes-3rd-nxc-201-engineering-batch-at-its-u-s-car-t-manufacturing-sit-immx-20231016monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-complete-response-in-9th-relapsed-refractory-al-amyloidosis-pati-immx-20231003monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-72-patient-nxc-201-clinical-data-at-the-ims-20th-annual-meeting--immx-20231002monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-subsidiary-nexcella-completes-2nd-nxc-201-engineering-batch-at-its-u-s-car-immx-20230919monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-dr-suzanne-lentzsch-director-of-the-multiple-myeloma-and-amyloid-immx-20230901monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-dr-heather-landau-memorial-sloan-kettering-cancer-center-amyloid-immx-20230818monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-additional-nxc-201-al-amyloidosis-clinical-data-accepted-for-ora-immx-20230816monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-subsidiary-nexcella-announces-nxc-201-multiple-myeloma-clinical-data-abstr-immx-20230725monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-reports-2nd-positive-interim-clinical-trial-data-readout-in-relapsed-refra-immx-20230717monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-subsidiary-nexcella-completes-initial-nxc-201-engineering-batch-at-its-u-s-immx-20230710monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-subsidiary-nexcella-completes-pre-ind-meeting-with-fda-on-nxc-201-us-clini-immx-20230626monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-subsidiary-nexcella-appoints-edward-j-borkowski-former-chief-financial-off-immx-20230622monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-subsidiary-nexcella-appoints-jeffrey-h-cooper-former-chief-financial-offic-immx-20230620monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-subsidiary-nexcella-appoints-mary-sue-coleman-former-johnson-johnson-indep-immx-20230616monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-completes-5-million-at-the-market-equity-offering-program-immx-20230614monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-subsidiary-nexcella-appoints-henry-mckinnell-jr-former-chairman-ceo-of-pfi-immx-20230612monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-subsidiary-nexcella-announces-commencement-of-nxc-201-engineering-batches--immx-20230526monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-positive-nxc-201-clinical-results-at-asgct-100-overall-response--immx-20230521monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-late-breaking-nxc-201-clinical-data-abstract-accepted-for-oral-p-immx-20230504monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-early-positive-imx-110-interim-clinical-trial-data-demonstrating-immx-20230503monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank-immx-20230311monthly0.5https://www.biopharmawatch.com/news/IMMX/immixbio-to-discuss-recent-positive-nxc-201-clinical-data-in-al-amyloidosis-and-multiple-m-immx-20230306monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-subsidiary-nexcella-enters-into-u-s-gmp-manufacturing-agreement-to-expand--immx-20230215monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-subsidiary-nexcella-inc-presents-42-patient-interim-data-with-90-overall-r-immx-20230209monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-dosing-of-first-2-patients-in-its-imx-110-beigene-novartis-anti--immx-20230207monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-doses-additional-patients-in-ongoing-phase-1b-2a-imx-110-monotherapy-clini-immx-20230113monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-subsidiary-nexcella-inc-announces-additional-positive-nxc-201-clinical-dat-immx-20230106monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-16th-patient-dosing-in-ongoing-phase-1b-2a-imx-110-monotherapy-c-immx-20221220monthly0.5https://www.biopharmawatch.com/news/IMMX/immixbio-ships-tislelizumab-for-patient-dosing-in-its-combination-clinical-trial-with-imx--immx-20221219monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-patient-dosing-in-ongoing-phase-1b-2a-imx-110-monotherapy-clinic-immx-20221213monthly0.5https://www.biopharmawatch.com/news/IMMX/immixbio-releases-and-ships-scaled-up-gmp-batches-of-imx-110-for-clinical-trial-patient-do-immx-20221212monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-receives-institutional-review-board-approval-to-enroll-pediatric-patients--immx-20221111monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-to-present-milestones-achieved-to-enable-kick-off-of-2-imx-110-clinical-tr-immx-20221025monthly0.5https://www.biopharmawatch.com/news/IMMX/immixbio-approves-4-additional-clinical-trial-sites-for-imx-110-clinical-trials-complement-immx-20221018monthly0.5https://www.biopharmawatch.com/news/IMMX/immixbio-completes-gmp-manufacturing-of-scaled-up-batch-of-imx-110-for-clinical-trials-immx-20220907monthly0.5https://www.biopharmawatch.com/news/IMMX/immixbio-imx-110-demonstrated-improved-survival-over-u-s-food-and-drug-administration-appr-immx-20220520monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-share-repurchase-program-immx-20220509monthly0.5https://www.biopharmawatch.com/news/IMMX/immixbio-management-discusses-key-milestones-drug-development-timelines-and-the-immx-advan-immx-20220405monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-inc-announces-immx-milestone-day-to-be-held-on-april-5-2022-immx-20220307monthly0.5https://www.biopharmawatch.com/news/IMMX/immixbio-initiates-gmp-manufacturing-of-imx-120-a-biologic-for-inflammatory-bowel-disease-immx-20220222monthly0.5https://www.biopharmawatch.com/news/IMMX/immixbio-management-answers-top-voted-investor-questions-at-immx-investors-day-february-1--immx-20220201monthly0.5https://www.biopharmawatch.com/news/IMMX/immixbio-initiates-imx-110-gmp-manufacturing-scale-up-potentially-accelerating-clinical-tr-immx-20220131monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-announces-immx-investors-day-to-be-held-on-february-1-2022-q-a-platform-fo-immx-20220106monthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-inc-announces-closing-of-initial-public-offering-immx-20211220monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-joins-the-michael-j-fox-foundation-s-lite-and-ppmi-programs-to-advance-new-therapi-arvn-20260604monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-employees-give-back-during-company-wide-impact-day-arvn-20260518monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-first-quarter-2026-financial-results-and-provides-corporate-update-arvn-20260512monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-and-pfizer-enter-into-a-transaction-with-rigel-pharmaceuticals-for-the-exclusive-g-arvn-20260512monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-fda-approval-of-veppanu-vepdegestrant-for-the-treatment-of-esr1m-er-her2-arvn-20260501monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-positive-phase-1-data-for-arv-102-showing-greater-than-50-lrrk2-degradat-arvn-20260318monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-arvn-20260311monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-presents-preclinical-data-supporting-mechanistic-synergies-and-enhanced-antitumor--arvn-20251206monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-clinical-data-for-arv-102-a-protac-lrrk2-degrader-at-the-2025-internati-arvn-20251001monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-provides-update-on-collaboration-with-pfizer-and-announces-further-actions-to-supp-arvn-20250917monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-participate-in-upcoming-investor-conferences-arvn-20250829monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-fda-acceptance-of-the-new-drug-application-for-vepdegestrant-for-the-tre-arvn-20250808monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-report-second-quarter-2025-financial-results-on-august-6-2025-arvn-20250730monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-retirement-of-chief-executive-officer-and-succession-plan-arvn-20250709monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematol-arvn-20250613monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-submission-of-new-drug-application-to-u-s-fda-for-vepdegestrant-for-pati-arvn-20250606monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-2025-european--arvn-20250605monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-and-pfizer-s-vepdegestrant-significantly-improves-progression-free-survival-for-pa-arvn-20250531monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-jefferies-global-healthcare-conference-arvn-20250530monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-alert-bragar-eagel-squire-p-c-is-investigating-arvinas-inc-on-behalf-of-arvinas-st-arvn-20250508monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-report-first-quarter-2025-financial-results-on-thursday-may-1-2025-arvn-20250428monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-shares-new-preclinical-combination-data-for-the-protac-bcl6-degrader-arv-393-at-th-arvn-20250428monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-results-from-the-veritac-2-trial-selected-as-late-breaking-oral-presenta-arvn-20250423monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-preclinical-data-for-protac-bcl6-degrader-arv-393-at-2025-american-asso-arvn-20250421monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-presents-first-in-human-data-for-investigational-oral-protac-arv-102-demonstrating-arvn-20250404monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-oral-presentation-at-2025-international-conference-on-alzheimer-s-parkin-arvn-20250327monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-and-pfizer-announce-positive-topline-results-from-phase-3-veritac-2-clinical-trial-arvn-20250311monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-participate-in-upcoming-investor-conferences-arvn-20250304monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-report-fourth-quarter-and-full-year-2024-financial-results-on-tuesday-february--arvn-20250203monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-updates-guidance-for-first-and-second-line-phase-3-combination-trials-with-vepdege-arvn-20250110monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-piper-sandler-36th-annual-healthcare-conference-arvn-20241127monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-upcoming-vepdegestrant-poster-presentations-at-the-2024-san-antonio-brea-arvn-20241125monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-participate-in-upcoming-investor-conferences-arvn-20241104monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-gives-back-to-local-greater-new-haven-community-in-third-annual-impact-day-arvn-20241022monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-report-third-quarter-2024-financial-results-and-provide-corporate-update-and-ho-arvn-20241021monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-participate-in-upcoming-investor-conferences-arvn-20240829monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-appoints-andrew-saik-as-chief-financial-officer-and-treasurer-arvn-20240624monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-presentations-for-two-of-its-protac-investigational-programs-targeting-b-arvn-20240621monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-promotions-of-ian-taylor-ph-d-to-president-of-research-and-development-a-arvn-20240617monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-participate-in-upcoming-investor-conferences-arvn-20240603monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-upcoming-presentations-at-the-2024-american-society-of-clinical-oncology-arvn-20240523monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-and-pfizer-announce-updated-clinical-data-from-phase-1b-trial-of-vepdegestrant-in--arvn-20240516monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-upcoming-vepdegestrant-poster-presentations-at-the-2024-european-society-arvn-20240509monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-upcoming-investor-conferences-arvn-20240502monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-appoints-randy-teel-ph-d-as-chief-business-officer-arvn-20240424monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-enters-into-a-transaction-with-novartis-including-a-global-license-agreement-for-t-arvn-20240411monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer-arvn-20240318monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-participate-in-upcoming-investor-conferences-arvn-20240304monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-chief-financial-officer-transition-arvn-20240220monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-first-in-human-dosing-of-arv-102-an-investigational-protac-protein-degra-arvn-20240220monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-and-pfizer-s-vepdegestrant-arv-471-receives-fda-fast-track-designation-for-the-tre-arvn-20240206monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-6th-annual-guggenheim-biotechnology-conference-arvn-20240201monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-appoints-jared-freedberg-as-general-counsel-arvn-20240116monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-host-conference-call-and-webcast-to-discuss-vepdegestrant-arv-471-data-presente-arvn-20231206monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-and-pfizer-announce-interim-data-from-phase-1b-trial-of-vepdegestrant-in-combinati-arvn-20231205monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-and-pfizer-announce-updated-vepdegestrant-arv-471-data-to-be-presented-at-the-2023-arvn-20231128monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-participate-in-upcoming-investor-conferences-arvn-20231102monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-gives-back-to-local-greater-new-haven-community-in-second-annual-impact-day-arvn-20231018monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-upcoming-bavdegalutamide-poster-presentation-at-esmo-congress-2023-arvn-20231015monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-and-pfizer-announce-upcoming-vepdegestrant-arv-471-poster-presentation-at-esmo-con-arvn-20231015monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-participate-in-upcoming-investor-conferences-arvn-20230901monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-and-pfizer-awarded-innovation-passport-designation-by-the-u-k-innovative-licensing-arvn-20230731monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-changes-to-its-board-of-directors-arvn-20230615monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-interim-data-from-the-arv-766-phase-1-2-dose-escalation-and-expansion-tr-arvn-20230608monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-participate-in-upcoming-investor-conferences-arvn-20230605monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-and-pfizer-announce-upcoming-vepdegestrant-arv-471-poster-presentations-at-the-202-arvn-20230508monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-the-bank-of-america-securities-2023-healthcare-conference-arvn-20230503monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-stifel-targeted-oncology-day-arvn-20230421monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-appoints-kelly-page-as-senior-vice-president-global-head-of-oncology-strategy-and--arvn-20230403monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-participate-in-upcoming-investor-conferences-arvn-20230227monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-participate-in-upcoming-investor-conferences-arvn-20230206monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-41st-annual-j-p-morgan-healthcare-conference-arvn-20230104monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-changes-to-its-board-of-directors-arvn-20221216monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-arv-471-achieves-a-clinical-benefit-rate-of-38-in-evaluable-patients-and-arvn-20221122monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-upcoming-conferences-arvn-20221101monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-winner-of-the-2022-arvinas-early-career-researcher-award-arvn-20221027monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-appoints-paul-mcinulty-as-senior-vice-president-regulatory-affairs-arvn-20221003monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-gives-back-to-local-greater-new-haven-community-arvn-20220930monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-bank-of-america-securities-precision-oncology-conference-arvn-20220926monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-upcoming-investor-conferences-arvn-20220831monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-changes-to-its-board-of-directors-arvn-20220818monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-appoints-lisa-sinclair-as-senior-vice-president-corporate-operations-arvn-20220815monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-appoints-john-northcott-as-chief-commercial-officer-arvn-20220801monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-goldman-sachs-43rd-annual-global-healthcare-conference-arvn-20220602monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-launches-global-early-career-researcher-award-and-announces-call-for-nominations-arvn-20220601monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-bank-of-america-securities-2022-healthcare-conference-arvn-20220503monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-upcoming-investor-conferences-arvn-20220304monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-upcoming-investor-conferences-arvn-20220203monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-and-pfizer-announce-updated-phase-1-dose-escalation-data-for-arv-471-to-be-present-arvn-20211119monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-stifel-2021-virtual-healthcare-conference-arvn-20211110monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-participate-in-upcoming-virtual-investor-conferences-arvn-20210901monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-participates-in-groundbreaking-ceremony-for-new-space-within-downtown-crossing-dev-arvn-20210607monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-the-42nd-annual-goldman-sachs-global-healthcare-conference-arvn-20210603monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-the-ubs-global-healthcare-virtual-conference-arvn-20210520monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-signs-lease-for-new-space-within-downtown-crossing-development-in-new-haven-arvn-20210504monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-upcoming-presentations-at-the-american-association-for-cancer-research-a-arvn-20210405monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-participate-in-upcoming-virtual-investor-conferences-arvn-20210310monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-the-guggenheim-healthcare-talks-2021-oncology-day-arvn-20210208monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-inc-announces-exercise-of-underwriters-option-to-purchase-additional-shares-arvn-20201228monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-inc-announces-proposed-offering-of-common-stock-arvn-20201214monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110-protac--arvn-20201211monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-participate-in-upcoming-virtual-investor-conferences-arvn-20201125monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-pipeline-programs-targeting-validated-and-classically-undruggable-diseas-arvn-20201014monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-the-3rd-annual-targeted-protein-degradation-summit-arvn-20201006monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-the-citi-15th-annual-biopharma-virtual-conference-arvn-20200904monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-the-2020-wedbush-pacgrow-virtual-healthcare-conference-arvn-20200807monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-appoints-wendy-dixon-ph-d-to-its-board-of-directors-arvn-20200629monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-virtually-at-the-bmo-2020-prescriptions-for-success-healthcare-conferen-arvn-20200617monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-appoints-linda-bain-to-its-board-of-directors-arvn-20200611monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-virtually-at-the-goldman-sachs-41st-annual-global-healthcare-conference-arvn-20200605monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-hold-virtual-2020-annual-meeting-of-stockholders-arvn-20200520monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-updated-phase-1-data-demonstrating-clinical-activity-of-protac-protein-d-arvn-20200513monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-provides-update-on-business-continuity-related-to-the-impact-of-the-covid-19-pande-arvn-20200413monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-the-american-society-of-clinical-oncology-annual-meeting-arvn-20200331monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-the-31st-annual-piper-jaffray-healthcare-conference-arvn-20191127monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-appoints-laurie-smaldone-alsup-m-d-to-board-of-directors-arvn-20191121monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-inc-announces-proposed-offering-of-common-stock-arvn-20191106monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-initial-data-from-ongoing-clinical-trials-and-a-pipeline-update-at-the--arvn-20191017monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-strengthens-scientific-advisory-board-with-leaders-in-oncology-and-neurological-di-arvn-20191002monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-the-initiation-of-patient-dosing-in-a-first-in-human-phase-1-study-of-ar-arvn-20190827monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-the-wedbush-pacgrow-healthcare-conference-arvn-20190807monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-appoints-ronald-peck-m-d-as-chief-medical-officer-arvn-20190729monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-strengthens-board-of-directors-with-addition-of-leslie-norwalk-arvn-20190725monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-preclinical-tau-directed-protac-protein-degrader-data-at-alzheimer-s-as-arvn-20190718monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-receives-authorization-to-proceed-for-arv-471-a-protac-protein-degrader-to-treat-p-arvn-20190625monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-the-bmo-prescriptions-for-success-healthcare-conference-arvn-20190620monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-the-goldman-sachs-40th-annual-global-healthcare-conference-arvn-20190606monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-receives-fast-track-designation-for-its-targeted-protein-degrader-arv-110-as-a-tre-arvn-20190529monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-strengthens-management-team-with-internal-appointments-of-andy-crew-ph-d-as-chief--arvn-20190402monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-initiation-of-patient-dosing-in-the-first-phase-1-clinical-trial-of-prot-arvn-20190325monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-poster-presentation-at-asco-2019-genitourinary-cancers-symposium-arvn-20190207monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-receives-authorization-to-proceed-for-its-ind-application-for-protac-therapy-to-tr-arvn-20190104monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-presents-preclinical-data-on-protein-degrader-arv-471-at-the-2018-san-antonio-brea-arvn-20181208monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-the-30th-annual-piper-jaffray-healthcare-conference-arvn-20181120monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-to-present-at-two-protein-degradation-conferences-arvn-20181023monthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-announces-pricing-of-initial-public-offering-arvn-20180927monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-alert-bragar-eagel-squire-p-c-is-investigating-altimmune-inc-on-behalf-of-long-t-alt-20251008monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-final-deadline-reminder-bragar-eagel-squire-p-c-urges-investors-to-contact-the-f-alt-20251006monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-class-action-reminder-bragar-eagel-squire-p-c-reminds-investors-of-october-6th-d-alt-20251003monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-alt-deadline-alert-bragar-eagel-squire-p-c-urges-investors-to-contact-the-firm-b-alt-20250929monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before--alt-20250925monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-deadline-alert-bragar-eagel-squire-p-c-reminds-investors-of-the-october-6th-dead-alt-20250924monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-class-action-levi-korsinsky-reminds-altimmune-investors-of-the-pending-class-alt-20250922monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-sued-for-securities-law-violations-contact-the-gross-law-firm-before-october-alt-20250904monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-fi-alt-20250827monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-in-upcoming-investor-conferences-alt-20250826monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-sued-for-securities-law-violations-contact-the-gross-law-firm-before-october-alt-20250821monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-october-6-2-alt-20250819monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-f-alt-20250814monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-fil-alt-20250811monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-f-alt-20250811monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-sued-for-securities-law-violations-contact-the-gross-law-firm-before-october-alt-20250807monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-october-alt-20250806monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-report-second-quarter-2025-financial-results-and-provide-business-update-on-a-alt-20250805monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-announce-topline-24-week-results-from-its-impact-phase-2b-trial-of-pemvidutid-alt-20250625monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-at-two-upcoming-investor-conferences-alt-20250514monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-presents-new-analyses-predicting-high-rates-of-mash-resolution-on-biopsy-followi-alt-20250508monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-report-first-quarter-2025-financial-results-and-provide-business-update-on-ma-alt-20250506monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-busine-alt-20250220monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-at-two-upcoming-investor-conferences-alt-20241126monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-alt-20241111monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-at-two-upcoming-investor-conferences-alt-20241106monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-report-third-quarter-2024-financial-results-and-provide-business-update-on-no-alt-20241104monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-in-the-h-c-wainwright-8th-annual-mash-virtual-conference-alt-20241001monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-oral-presentation-of-pemvidutide-clinical-data-at-60th-annual-meeting--alt-20240903monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-alert-bragar-eagel-squire-p-c-is-investigating-altimmune-inc-on-behalf-of-long-t-alt-20240731monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-publication-of-clinical-study-of-pemvidutide-in-metabolic-dysfunction--alt-20240725monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-deadline-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-law-alt-20240704monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-portnoy-law--alt-20240702monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-nasdaq-alt-deadline-alert-bernstein-liebhard-llp-reminds-altimmune-inc-inves-alt-20240701monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-portnoy-law--alt-20240624monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-nasdaq-alt-deadline-alert-bernstein-liebhard-llp-reminds-altimmune-inc-inves-alt-20240624monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-investors-pending-lead-plaintiff-deadline-in-alt-securities-fraud-class-acti-alt-20240620monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-nasdaq-alt-investor-alert-bernstein-liebhard-llp-announces-that-a-securities-alt-20240617monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-nasdaq-alt-investor-alert-bernstein-liebhard-llp-announces-that-a-securities-alt-20240610monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-bef-alt-20240606monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-nasdaq-alt-investor-alert-bernstein-liebhard-llp-announces-that-a-securities-alt-20240604monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-at-two-upcoming-investor-conferences-alt-20240529monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-nasdaq-alt-deadline-alert-bernstein-liebhard-llp-reminds-altimmune-inc-inves-alt-20240528monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-f-alt-20240521monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-investor-notice-robbins-llp-reminds-stockholders-of-the-altimmune-inc-alt-cl-alt-20240515monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-investor-news-rosen-trusted-investor-counsel-encourages-altimmune-inc-investors--alt-20240512monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-fil-alt-20240509monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-investors-who-have-lost-money-should-contact-block-leviton-to-find-out-how-t-alt-20240508monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-nasdaq-alt-investor-alert-bernstein-liebhard-llp-announces-that-a-securities-alt-20240507monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-at-two-upcoming-investor-conferences-alt-20240507monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-at-two-upcoming-investor-conferences-alt-20231017monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-oral-presentation-of-pemvidutide-clinical-data-at-59th-annual-meeting--alt-20230926monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-at-two-upcoming-investor-conferences-alt-20230830monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-oral-presentation-of-pemvidutide-clinical-data-in-treatment-of-nafld-a-alt-20230615monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-at-two-upcoming-investor-conferences-alt-20230531monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-at-two-upcoming-investor-conferences-alt-20230508monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-oral-presentation-of-pemvidutide-clinical-data-at-upcoming-nash-tag-co-alt-20230104monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-at-two-upcoming-investor-conferences-alt-20220603monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-pemvidutide-clinical-data-at-upcoming-american-diabetes-association-s-alt-20220531monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-pemvidutide-clinical-data-at-upcoming-global-nash-congress-may-27-202-alt-20220520monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-at-upcoming-investor-conferences-alt-20220516monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-alt-20211213monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-at-upcoming-investor-and-scientific-conferences-alt-20211122monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-at-upcoming-investor-conferences-alt-20211110monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-and-the-university-of-alabama-at-birmingham-announce-potent-respiratory-mucosal--alt-20200825monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-launches-clinical-trial-of-t-covidtm-an-investigational-intranasal-immune-modula-alt-20200601monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-clinical-program-updates-and-plans-for-pipeline-expansion-alt-20181213monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-alt-20181130monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-at-dawson-james-securities-4th-annual-small-cap-growth-conference-alt-20181026monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-closes-on-16-9-million-in-funding-alt-20181003monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-pricing-of-12-million-underwritten-public-offering-alt-20180928monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-announce-second-quarter-2018-financial-results-on-august-15-alt-20180807monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-restructures-financing-agreement-with-majority-of-the-remaining-series-b-investo-alt-20180712monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-announce-first-quarter-2018-financial-results-on-may-16-alt-20180508monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-positive-data-from-its-phase-2a-study-of-nasovax-intranasal-influenza--alt-20180327monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-at-the-h-c-wainwright-global-life-sciences-conference-alt-20180322monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-announce-year-end-2017-financial-results-on-march-29-alt-20180320monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-pre-clinical-data-from-its-sparvax-l-anthrax-vaccine-program-alt-20180312monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-at-two-investor-conferences-in-march-alt-20180306monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-notice-of-allowance-on-patent-covering-use-of-nasoshield-in-the-u-s-alt-20180123monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-at-the-noble-capital-14th-annual-investor-conference-alt-20180122monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-elects-mitchel-sayare-ph-d-as-chairman-of-its-board-of-directors-alt-20180103monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-in-the-10th-annual-biotech-showcase-in-san-francisco-january-8-10-alt-20171221monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-positive-initial-data-from-its-heptcell-phase-1-study-alt-20171221monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-submits-investigational-new-drug-application-for-nasoshield-in-preparation-for-i-alt-20171211monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-at-the-29th-annual-piper-jaffray-conference-alt-20171121monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-announce-third-quarter-2017-financial-results-on-november-9-alt-20171102monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-its-phase-2-flu-vaccine-trial-with-nasovax-open-for-enrollment-alt-20170920monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-provide-corporate-update-at-the-ladenburg-thalmann-3rd-annual-healthcare-conf-alt-20170919monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-provide-corporate-update-at-the-rodman-renshaw-global-investment-conference-alt-20170906monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-submits-investigational-new-drug-application-for-nasovax-in-preparation-for-phas-alt-20170821monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-announce-second-quarter-2017-financial-results-on-august-10-alt-20170731monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-provide-corporate-update-at-the-bio-international-convention-alt-20170619monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-inc-nasdaq-alt-to-ring-the-nasdaq-stock-market-opening-bell-alt-20170510monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-completes-merger-with-pharmathene-creating-immunotherapeutics-company-targeting--alt-20170504monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-receives-7-3-million-contract-modification-from-barda-to-fund-manufacturing-of-i-alt-20170328monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-acceptance-of-heptcell-abstract-for-presentation-at-bsi-nvvi-congress--alt-20161206monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-at-the-28th-annual-piper-jaffray-healthcare-conference-alt-20161118monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-poster-presentation-of-heptcell-program-at-2017-keystone-symposia-conf-alt-20161026monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-addition-of-christine-brennan-to-board-of-directors-alt-20160913monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-at-18th-annual-rodman-renshaw-global-investment-conference-alt-20160830monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-receives-barda-contract-of-up-to-120-2-million-to-fund-clinical-development-of-f-alt-20160801monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-at-cantor-fitzgerald-s-2nd-annual-healthcare-conference-alt-20160712monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-in-two-upcoming-conferences-alt-20160503monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-participation-in-vaccine-development-panel-at-the-annual-regional-biot-alt-20160413monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-expands-clinical-development-team-alt-20160405monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-at-two-upcoming-conferences-alt-20160301monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-presentation-at-bio-ceo-investor-conference-alt-20160126monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-presentation-at-biotech-showcase-2016-alt-20151221monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-chief-scientific-officer-to-present-at-two-premier-vaccine-conferences-alt-20151012monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-ceo-to-present-at-the-2015-ladenburg-thalmann-healthcare-conference-in-new-york--alt-20150928monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-third-quarter-2022-financial-results-on-november-3rd-prta-20221027monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-participate-in-upcoming-healthcare-conferences-prta-20220901monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-appointment-of-biotechnology-industry-leader-helen-s-kim-to-its-board-o-prta-20220901monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-prta-20220802monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-second-quarter-2022-financial-results-on-august-8th-prta-20220801monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-prta-20220701monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-participate-in-jefferies-healthcare-conference-prta-20220602monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-first-quarter-2022-financial-results-on-may-5th-prta-20220428monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-participate-in-stifel-2022-virtual-cns-days-prta-20220321monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-presents-new-data-for-alzheimer-s-and-parkinson-s-disease-programs-at-ad-pd-2022-prta-20220316monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-fourth-quarter-and-full-year-2021-financial-results-and-host-webcast-co-prta-20220210monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-participate-in-jmp-securities-hematology-and-oncology-summit-prta-20211129monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-third-quarter-2021-financial-results-on-november-4th-prta-20211028monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-prta-20211001monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-executive-appointments-prta-20211001monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-prta-20210903monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-participate-in-upcoming-september-healthcare-conferences-prta-20210901monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-second-quarter-2021-financial-results-on-august-5th-prta-20210729monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-presents-new-data-from-robust-alzheimer-s-portfolio-at-the-alzheimer-s-associatio-prta-20210726monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-present-data-from-two-of-its-alzheimer-s-disease-programs-at-the-alzheimer-s-a-prta-20210720monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothena-s-attr-amyloidosis-p-prta-20210712monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-bristol-myers-squibb-opt-in-of-anti-tau-prx005-as-the-first-program-fro-prta-20210624monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-participate-in-jmp-securities-life-sciences-conference-on-june-16-prta-20210610monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-appointment-of-sanjiv-patel-mbbs-to-its-board-of-directors-prta-20210520monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-achievement-of-60-million-milestone-from-roche-for-first-patient-dosed--prta-20210510monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-prta-20210507monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-first-quarter-2021-financial-results-on-may-11th-prta-20210504monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-presents-phase-1-study-results-of-prx004-in-oral-presentation-at-aan-2021-prta-20210418monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-prx004-phase-1-study-results-selected-for-emerging-science-oral-present-prta-20210415monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-prta-20210407monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-appointment-of-hideki-garren-md-phd-as-chief-medical-officer-prta-20210405monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-pricing-of-public-offering-of-3-500-000-ordinary-shares-prta-20210324monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-proposed-offering-of-ordinary-shares-prta-20210323monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-hold-investor-webcast-to-review-three-oral-presentations-from-ad-pd-2021-prta-20210308monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-promising-new-preclinical-and-clinical-data-from-its-neurodegenerative--prta-20210224monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-prta-20210205monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-fourth-quarter-and-full-year-2020-financial-results-and-host-webcast-co-prta-20210204monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-confirmatory-phase-3-affirm-al-study-of-birtamimab-in-mayo-stage-iv-pat-prta-20210201monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-positive-9-month-results-from-phase-1-long-term-extension-study-of-prx004-prta-20201209monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-prta-20201204monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-presentations-on-two-programs-from-its-alzheimer-s-disease-portfolio-at-prta-20201104monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-third-quarter-2020-financial-results-on-november-4-prta-20201028monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-prta-20201002monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-hold-investor-webcast-to-discuss-results-from-phase-2-pasadena-study-presented-prta-20200915monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-present-at-the-2020-cantor-virtual-global-healthcare-conference-on-september-1-prta-20200908monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-updated-timing-of-presentation-for-phase-2-pasadena-study-results-at-in-prta-20200903monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-prta-20200902monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-phase-2-pasadena-study-results-to-be-presented-at-international-congres-prta-20200805monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-second-quarter-2020-financial-results-on-august-6-prta-20200730monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-present-at-the-jefferies-virtual-healthcare-conference-on-june-3-prta-20200527monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-first-quarter-2020-financial-results-on-may-6-prta-20200429monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-provides-additional-information-regarding-upcoming-annual-general-meeting-of-shar-prta-20200424monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-prta-20200403monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-appointment-of-brandon-smith-as-chief-business-officer-prta-20200303monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-fourth-quarter-and-full-year-2019-financial-results-and-host-webcast-co-prta-20200205monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-appointment-of-oleg-nodelman-to-its-board-of-directors-prta-20191205monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-third-quarter-2019-financial-results-on-november-5-prta-20191029monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-second-quarter-2019-financial-results-on-august-6-prta-20190730monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-appointment-of-paula-k-cobb-to-its-board-of-directors-prta-20190701monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-participate-in-the-jefferies-healthcare-conference-prta-20190530monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-first-quarter-2019-financial-results-on-may-7-prta-20190430monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-participate-in-upcoming-march-healthcare-conferences-prta-20190305monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-fourth-quarter-and-full-year-2018-financial-results-and-host-webcast-co-prta-20190204monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-third-quarter-2018-financial-results-on-november-6-prta-20181030monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-second-quarter-2018-financial-results-on-august-7-prta-20180731monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-appointment-of-tran-b-nguyen-as-chief-operating-officer-prta-20180625monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-phase-1b-clinical-trial-results-of-prx002-rg7935-for-parkinson-s-diseas-prta-20180619monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-reorganization-to-focus-resources-on-advancing-neuroscience-pipeline-prta-20180524monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-first-quarter-2018-financial-results-on-may-8-prta-20180501monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-present-a-broad-range-of-scientific-and-health-outcomes-data-at-the-16th-inter-prta-20180312monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-participate-in-the-barclays-global-healthcare-conference-prta-20180307monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-participate-in-the-leerink-partners-7th-annual-global-healthcare-conference-prta-20180207monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-departure-of-chief-medical-officer-prta-20180202monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-fourth-quarter-and-full-year-2017-financial-results-and-host-webcast-co-prta-20180201monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-participate-in-the-36th-annual-j-p-morgan-healthcare-conference-prta-20180103monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-participate-in-the-evercore-isi-biopharma-catalyst-deep-dive-conference-prta-20171122monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-highlights-breadth-of-novel-pipeline-at-r-d-day-prta-20171116monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-participate-in-the-credit-suisse-26th-annual-healthcare-conference-prta-20171101monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-third-quarter-2017-financial-results-on-november-7-prta-20171031monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-presents-new-research-supporting-clinical-relevance-of-cardiac-biomarker-nt-probn-prta-20170918monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-present-new-research-on-cardiac-biomarker-nt-probnp-in-al-amyloidosis-at-hfsa--prta-20170815monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-second-quarter-2017-financial-results-on-august-8-prta-20170801monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-initiation-of-phase-2-pasadena-study-of-prx002-rg7935-in-patients-with--prta-20170705monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-appointment-of-wagner-zago-phd-as-chief-scientific-officer-prta-20170612monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-appointment-of-sarah-noonberg-md-phd-as-chief-medical-officer-prta-20170516monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-first-quarter-2017-financial-results-on-may-9-prta-20170502monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-participate-in-the-deutsche-bank-42nd-annual-health-care-conference-prta-20170426monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-pricing-of-public-offering-of-2-700-000-ordinary-shares-prta-20170303monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-public-offering-of-ordinary-shares-prta-20170302monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-participate-in-the-leerink-partners-6th-annual-global-healthcare-conference-prta-20170208monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-fourth-quarter-and-full-year-2016-financial-results-and-host-webcast-co-prta-20170201monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-participate-in-the-j-p-morgan-healthcare-conference-prta-20170104monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-appointment-of-chief-regulatory-officer-prta-20161215monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-third-quarter-2016-financial-results-on-november-1-prta-20161025monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-appointment-of-dr-gene-g-kinney-as-president-chief-executive-officer-an-prta-20161003monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-outlines-phase-2-development-strategy-for-prx003-prta-20160929monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-president-and-ceo-dr-dale-b-schenk-to-take-medical-leave-prta-20160926monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-host-update-on-prx003-phase-2-development-strategy-prta-20160922monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-appointment-of-gene-g-kinney-as-chief-operating-officer-prta-20160906monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-participate-in-upcoming-september-investor-conferences-prta-20160830monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-participate-in-cantor-fitzgerald-s-2nd-annual-healthcare-conference-prta-20160706monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-present-at-15th-international-symposium-on-amyloidosis-showcasing-broad-commit-prta-20160621monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-results-of-phase-1-single-ascending-dose-study-of-prx003-demonstrating-ta-prta-20160609monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-present-wide-range-of-studies-on-amyloidosis-including-new-clinical-data-on-ne-prta-20160523monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-present-quality-of-life-data-on-al-amyloidosis-at-european-hematology-associat-prta-20160519monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-present-clinical-results-from-its-phase-1-single-ascending-dose-study-of-prx00-prta-20160509monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-present-preclinical-data-for-prx003-at-2016-aaaai-annual-meeting-prta-20160229monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-appointment-of-chief-commercial-officer-prta-20160224monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-fourth-quarter-and-full-year-2015-financial-results-and-host-webcast-co-prta-20160204monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-participate-in-bio-ceo-investor-and-leerink-partners-healthcare-conferences-prta-20160201monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-pricing-of-public-offering-of-2-250-000-ordinary-shares-prta-20160107monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-proposed-offering-of-ordinary-shares-prta-20160105monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-participate-in-oppenheimer-and-rbc-capital-markets-healthcare-investor-confere-prta-20151201monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-present-new-preclinical-data-for-neod001-at-57th-annual-american-society-of-he-prta-20151105monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-present-at-the-2015-credit-suisse-healthcare-conference-on-november-10-prta-20151104monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-present-at-ladenburg-thalmann-2015-healthcare-conference-on-september-29-prta-20150922monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-presents-clinical-results-demonstrating-robust-rapid-reduction-in-levels-of-free--prta-20150617monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-present-at-jmp-securities-life-science-conference-2015-on-june-23-prta-20150616monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-s-neod001-protein-immunotherapy-clinical-data-highlighted-in-oral-presentation-at-prta-20150612monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-first-human-dosed-in-phase-1-study-of-prx003-for-the-treatment-of-psori-prta-20150609monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-present-clinical-results-from-its-phase-1-single-ascending-dose-study-of-prx00-prta-20150608monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-presents-compelling-new-data-from-ongoing-phase-1-2-study-of-neod001-in-patients--prta-20150602monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-presentation-of-clinical-data-from-the-ongoing-phase-1-2-neod001-study--prta-20150521monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-present-updated-clinical-data-from-ongoing-phase-1-2-study-of-neod001-at-2015--prta-20150513monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-present-at-upcoming-investor-healthcare-conferences-prta-20150428monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-pricing-of-public-offering-of-3-300-000-ordinary-shares-prta-20150408monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-proposed-offering-of-ordinary-shares-prta-20150406monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-robust-reduction-of-free-serum-alpha-synuclein-of-up-to-96-after-single-d-prta-20150319monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-fourth-quarter-and-full-year-2014-financial-results-and-host-webcast-an-prta-20150219monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-present-at-the-2015-rbc-capital-markets-healthcare-conference-in-new-york-on-f-prta-20150218monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-present-at-the-oppenheimer-25th-annual-healthcare-conference-in-new-york-prta-20141208monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-presentation-at-federation-of-european-physiological-societies-2014-con-prta-20140826monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-pricing-of-public-offering-of-4-750-000-ordinary-shares-prta-20140625monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-proposed-offering-of-ordinary-shares-prta-20140623monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-present-at-the-jefferies-2014-global-healthcare-conference-in-new-york-prta-20140527monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-host-webcast-and-conference-call-to-discuss-interim-phase-1-data-of-ongoing-ne-prta-20140501monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-appointment-of-chief-legal-officer-prta-20140430monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-s-neod001-demonstrates-encouraging-cardiac-biomarker-responses-in-ongoing-phase-1-prta-20140423monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-appointment-of-chief-business-officer-prta-20140303monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-fourth-quarter-and-full-year-2013-financial-results-and-host-webcast-an-prta-20140218monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-closing-of-underwritten-public-offering-of-ordinary-shares-and-full-exe-prta-20140203monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-pricing-of-secondary-offering-of-ordinary-shares-by-perrigo-prta-20140129monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-proposed-secondary-offering-of-ordinary-shares-by-perrigo-prta-20140127monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-receive-30-million-upfront-payment-from-roche-triggered-by-the-expiration-of-h-prta-20140123monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-be-added-to-nasdaq-biotechnology-index-and-nasdaq-global-select-market-prta-20131230monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-research-and-development-day-and-webcast-prta-20131028monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-pricing-of-public-offering-of-5-910-000-ordinary-shares-prta-20131003monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-second-quarter-2013-financial-results-prta-20130812monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-present-at-the-wedbush-securities-life-sciences-management-access-conference-i-prta-20130807monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-welcomes-new-director-to-its-board-prta-20130722monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-present-at-the-eighth-annual-jmp-securities-healthcare-conference-in-new-york-prta-20130701monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-shares-to-be-added-to-russell-global-index-prta-20130617monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-present-at-the-jefferies-2013-global-healthcare-conference-in-new-york-prta-20130529monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-first-quarter-financial-results-prta-20130514monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-reports-fourth-quarter-and-full-year-2012-financial-results-and-provides-research-prta-20130328monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-appointments-of-chief-medical-officer-and-chief-financial-officer-prta-20130325monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-report-fourth-quarter-and-full-year-2012-financial-results-and-host-webcast-an-prta-20130321monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-appointment-of-biotech-pioneer-to-board-of-directors-prta-20130319monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-achieves-orphan-drug-status-in-eu-for-lead-program-neod001-prta-20130227monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-to-ring-nasdaq-stock-market-opening-bell-prta-20130213monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-corporation-plc-prta-to-ring-the-nasdaq-stock-market-opening-bell-prta-20130212monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-announces-addition-of-industry-veterans-to-board-of-directors-prta-20130107monthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-begins-trading-on-nasdaq-global-market-under-symbol-prta-prta-20121221monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-reports-second-quarter-2025-financial-results-and-recent-business-highlights-sttk-20250814monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-reports-first-quarter-2025-financial-results-and-recent-business-highlights-sttk-20250501monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-busin-sttk-20250327monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-positive-data-from-the-preclinical-glp-toxicology-study-of-sl-325--sttk-20250220monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-oral-presentation-at-upcoming-20th-congress-of-european-crohn-s-an-sttk-20250213monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-poster-presentation-at-upcoming-2025-crohn-s-and-colitis-congress-sttk-20250204monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-presentation-at-the-43rd-annual-j-p-morgan-healthcare-conference-sttk-20250106monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-provides-corporate-update-and-highlights-upcoming-key-milestones-in-2025-sttk-20250102monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-december-conferences-sttk-20241125monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-reports-third-quarter-2024-financial-results-and-recent-business-highlights-sttk-20241114monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-reports-second-quarter-2024-financial-results-and-recent-business-highlights-sttk-20240801monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-btig-virtual-biotechnology-conference-sttk-20240730monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-addition-to-russell-2000-and-russell-3000-indexes-sttk-20240701monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-orphan-drug-designation-granted-by-the-u-s-food-and-drug-administr-sttk-20240610monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-to-host-investor-call-and-webcast-on-additional-interim-data-presented-at-th-sttk-20240606monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-to-present-additional-data-from-the-phase-1b-dose-expansion-clinical-trial-o-sttk-20240514monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-reports-first-quarter-2024-financial-results-and-recent-business-highlights-sttk-20240502monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-oral-presentation-of-preclinical-data-at-the-american-association--sttk-20240409monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-23rd-annual-needham-virtual-healthcare-c-sttk-20240401monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-reports-fourth-quarter-and-full-year-2023-financial-results-and-recent-busin-sttk-20240229monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-march-conferences-sttk-20240226monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-enters-into-strategic-collaboration-and-license-agreement-with-ono-pharmaceu-sttk-20240213monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-provides-corporate-update-and-highlights-upcoming-key-milestones-in-2024-sttk-20240108monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-presentation-at-upcoming-42nd-annual-j-p-morgan-healthcare-confere-sttk-20240104monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-50-million-public-offering-of-common-stock-and-concurrent-private--sttk-20231221monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-to-host-investor-call-and-webcast-to-share-initial-clinical-trial-data-from--sttk-20231205monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-6th-annual-evercore-isi-healthconx-confe-sttk-20231114monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-reports-third-quarter-2023-financial-results-and-recent-business-highlights-sttk-20231109monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-to-report-third-quarter-2023-financial-results-on-november-9-2023-sttk-20231106monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-to-present-topline-data-from-phase-1-a-b-clinical-trial-of-sl-172154-in-rela-sttk-20231102monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-reports-second-quarter-2023-financial-results-and-recent-business-highlights-sttk-20230810monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-to-present-complete-dose-escalation-data-from-phase-1a-monotherapy-clinical--sttk-20230525monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-reports-first-quarter-2023-financial-results-and-recent-business-highlights-sttk-20230509monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-22nd-annual-needham-virtual-healthcare-c-sttk-20230403monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-resear-sttk-20230316monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-march-conferences-sttk-20230301monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-bus-sttk-20230223monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-sttk-20230216monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conferen-sttk-20230209monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-provides-corporate-update-and-highlights-upcoming-key-milestones-in-2023-sttk-20230109monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-reports-third-quarter-2022-financial-results-and-recent-business-highlights-sttk-20221108monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-presents-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-platf-sttk-20221107monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-november-conferences-sttk-20221103monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-to-report-third-quarter-2022-financial-results-on-november-8-2022-sttk-20221101monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-to-present-updated-preclinical-data-on-gamma-delta-t-cell-engager-gadlen-pla-sttk-20221005monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-september-conferences-sttk-20220901monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-reports-second-quarter-2022-financial-results-and-recent-business-highlights-sttk-20220811monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-reports-first-quarter-2022-financial-results-and-recent-business-highlights-sttk-20220512monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-presents-preclinical-data-at-the-2022-american-association-for-cancer-resear-sttk-20220408monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-21st-annual-needham-virtual-healthcare-c-sttk-20220405monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent-busin-sttk-20220315monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-to-present-two-posters-at-the-2022-american-association-for-cancer-research--sttk-20220309monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-march-conferences-sttk-20220302monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-tha-sttk-20220210monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-11th-annual-svb-leerink-global-healthcar-sttk-20220209monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-tha-sttk-20220202monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-january-investor-conferences-sttk-20220105monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-to-present-at-tigit-therapies-digital-summit-2021-sttk-20211202monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-preliminary-clinical-data-from-ongoing-phase-1-clinical-trials-of--sttk-20211109monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-reports-third-quarter-2021-financial-results-and-recent-business-highlights-sttk-20211109monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-to-host-conference-call-and-webcast-highlighting-data-presented-at-the-2021--sttk-20211104monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-november-investor-conferences-sttk-20211103monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-to-present-clinical-data-on-sl-172154-and-sl-279252-and-preclinical-data-on--sttk-20211001monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-september-conferences-sttk-20210901monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-reports-second-quarter-2021-financial-results-and-upcoming-phase-1-dose-esca-sttk-20210811monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-participation-in-the-btig-biotechnology-conference-sttk-20210806monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-to-report-second-quarter-2021-financial-results-and-provide-corporate-update-sttk-20210804monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-appoints-abhinav-a-shukla-as-chief-technical-officer-sttk-20210601monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-reports-first-quarter-2021-financial-results-and-recent-business-highlights-sttk-20210510monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-may-conferences-sttk-20210430monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-participation-in-the-7th-annual-truist-securities-life-sciences-su-sttk-20210428monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-highlights-preclinical-data-for-sl-9258-tigit-fc-light-in-an-acquired-resist-sttk-20210412monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-participation-in-needham-s-20th-annual-healthcare-conference-sttk-20210406monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-promotion-of-andrew-r-neill-to-chief-financial-officer-sttk-20210316monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-reports-fourth-quarter-and-full-year-2020-financial-results-and-recent-busin-sttk-20210315monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-to-present-two-posters-at-the-2021-american-association-for-cancer-research--sttk-20210311monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-participation-in-upcoming-march-investor-conferences-sttk-20210223monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-participation-in-citi-s-2021-virtual-immuno-oncology-day-sttk-20210212monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-to-present-at-h-c-wainwright-bioconnect-2021-conference-sttk-20210107monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-to-present-at-39th-annual-j-p-morgan-healthcare-conference-sttk-20210106monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-added-to-russell-2000-and-3000-indexes-sttk-20201218monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-to-present-virtually-at-evercore-isi-3rd-annual-healthconx-conference-sttk-20201125monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-reports-third-quarter-2020-financial-results-and-recent-business-highlights-sttk-20201113monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-announces-preclinical-proof-of-concept-study-on-gamma-delta-t-cell-engager-g-sttk-20201111monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-to-present-virtually-at-cowen-4th-annual-io-next-summit-sttk-20201106monthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-to-present-poster-on-gamma-delta-t-cell-engager-gadlen-platform-at-the-socie-sttk-20201105monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-participate-in-upcoming-investor-conferences-ovid-20260604monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-pricing-of-60-million-private-placement-ovid-20260318monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-appoints-pioneering-industry-leader-dr-stelios-papadopoulos-to-board-of--ovid-20250303monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference-ovid-20250227monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-confe-ovid-20250205monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-multiple-posters-supporting-its-pipeline-programs-targeting-n-ovid-20241202monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-business-updates-and-third-quarter-2024-financial-results-ovid-20241112monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-host-investor-event-ovid-20241031monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-presents-pre-clinical-study-results-demonstrating-ov329-does-not-accumul-ovid-20240926monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-upcoming-september-investor-conferences-ovid-20240904monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-business-updates-and-second-quarter-2024-financial-results-ovid-20240813monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-appoints-dr-amanda-banks-experienced-biotech-leader-physician-as-chief-d-ovid-20240808monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-upcoming-august-investor-conferences-ovid-20240730monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-expands-scientific-advisory-board-with-appointments-of-leading-neurologi-ovid-20240723monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-h-c-wainwright-2nd-annual-bioconnect-investor-conferen-ovid-20240513monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-23rd-annual-needham-virtual-healthcare-conference-ovid-20240404monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-td-cowen-44th-annual-health-care-conference-ovid-20240228monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-oppenheimer-34th-annual-healthcare-life-sciences-confe-ovid-20240206monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-five-abstracts-supporting-its-epilepsy-programs-at-the-77th-a-ovid-20231201monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-jefferies-biotech-cns-neuro-summit-ovid-20231010monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-host-investor-event-r-d-day-on-monday-october-2-2023-ovid-20230926monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-2023-cantor-fitzgerald-global-healthcare-conference-ovid-20230920monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences-ovid-20230830monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-btig-virtual-biotechnology-conference-2023-ovid-20230801monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-expands-its-scientific-leadership-team-appoints-chief-strategy-officer-ovid-20230628monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-added-to-russell-3000-index-ovid-20230626monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference-ovid-20230410monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-2nd-annual-needham-virtual-neuroscience-forum-ovid-20230309monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-43rd-annual-cowen-healthcare-conference-ovid-20230228monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-expands-epilepsy-development-expertise-with-new-appointments-ovid-20230208monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-dosed-healthy-volunteers-with-ov329-in-phase-1-trial-ovid-20230105monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-data-on-its-epilepsy-programs-at-american-epilepsy-society-an-ovid-20221202monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference-ovid-20220927monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conferenc-ovid-20220907monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-presents-preclinical-data-on-ov329-at-the-epilepsy-foundation-pipeline-c-ovid-20220606monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-21st-annual-needham-virtual-healthcare-conference-ovid-20220408monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-participate-at-the-cowen-42nd-annual-health-care-conference-ovid-20220304monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-appoints-dr-kevin-fitzgerald-to-board-of-directors-ovid-20211007monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conferenc-ovid-20210907monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-strengthens-board-leadership-team-to-focus-efforts-on-expanding-its-neur-ovid-20210708monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-ladenburg-thalmann-2021-healthcare-conference-ovid-20210707monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-appoints-jeff-rona-as-chief-business-and-financial-officer-ovid-20210604monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-appoints-dr-joy-a-cavagnaro-and-dr-bruce-a-sullenger-to-its-scientific-a-ovid-20210526monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-participate-in-the-2021-rbc-capital-markets-global-healthcare-confere-ovid-20210512monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-appointment-of-professor-robert-s-langer-sc-d-as-chair-of-its--ovid-20210420monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index-ovid-20201216monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-american-epilepsy-society-aes-2020-virtual-congress-ovid-20201123monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-host-educational-webinar-on-angelman-syndrome-and-ov101-development-p-ovid-20201014monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-child-neurology-society-international-child-neurology--ovid-20201012monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-2020-cantor-fitzgerald-virtual-global-healthcare-confe-ovid-20200911monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-participate-at-the-william-blair-biotech-focus-conference-2020-ovid-20200805monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-and-university-of-connecticut-enter-into-strategic-research-collaboratio-ovid-20200723monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-and-angelini-pharma-enter-into-exclusive-license-agreement-to-develop-ma-ovid-20200713monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-added-to-russell-2000-and-russell-3000-indexes-ovid-20200629monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-strategic-research-collaboration-focused-on-accelerating-the-d-ovid-20200611monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-multiple-presentations-on-the-2020-american-academy-of-neurolo-ovid-20200608monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-launches-pipeline-teach-in-webinar-series-ovid-20200604monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-participation-in-the-2020-rbc-capital-markets-virtual-global-h-ovid-20200512monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-positive-topline-results-from-the-phase-2-rocket-trial-of-ov10-ovid-20200507monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-multiple-presentations-at-the-american-academy-of-neurology-20-ovid-20200305monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-names-alexander-kolevzon-m-d-to-scientific-advisory-board-ovid-20200302monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-cowen-and-company-40th-annual-health-care-conference-ovid-20200225monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-participate-at-the-31st-annual-piper-jaffray-healthcare-conference-ovid-20191126monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-appoints-jason-tardio-as-chief-commercial-officer-ovid-20191118monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-proposed-concurrent-public-offerings-of-common-stock-and-prefe-ovid-20191003monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-positive-initial-data-from-ongoing-endymion-open-label-extensi-ovid-20190923monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-h-c-wainwright-21st-annual-global-investment-conferenc-ovid-20190909monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-participation-in-two-upcoming-investor-conferences-ovid-20190903monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-reports-second-quarter-2019-financial-results-and-highlights-recent-prog-ovid-20190807monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-host-r-d-day-on-june-27-2019-ovid-20190618monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-american-academy-of-neurology-71st-annual-meeting-ovid-20190418monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-cowen-and-company-39th-annual-healthcare-conference-on-ovid-20190304monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-proposed-concurrent-public-offerings-of-common-stock-and-prefe-ovid-20190219monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-phase-1b-2a-results-of-ov935-tak-935-in-adults-with-rare-epile-ovid-20181217monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-ov935-tak-935-presentations-at-the-american-epilepsy-society-7-ovid-20181120monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-30th-annual-piper-jaffray-healthcare-conference-on-tuesday-ovid-20181114monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-presents-additional-data-and-analyses-from-the-phase-2-stars-clinical-tr-ovid-20181025monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-receives-company-making-a-difference-award-from-cdkl5-deficiency-disorde-ovid-20181022monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-host-conference-call-and-webcast-on-thursday-october-25-at-10-30-a-m--ovid-20181022monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-initiation-of-two-phase-2-clinical-trials-of-ov935-tak-935-for-ovid-20180924monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-two-investor-healthcare-conferences-in-october-2018-ovid-20180919monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-two-investor-healthcare-conferences-in-september-2018-ovid-20180829monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-phase-2-stars-topline-data-accepted-for-presentation-at-americ-ovid-20180816monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-positive-topline-data-from-phase-2-stars-trial-of-ov101-for-th-ovid-20180806monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-presentations-related-to-ov101-fragile-x-syndrome-program-at-t-ovid-20180711monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-jefferies-2018-global-healthcare-conference-on-june-8--ovid-20180530monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-two-oral-presentations-at-the-14th-eilat-conference-on-new-ant-ovid-20180509monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-deutsche-bank-s-43rd-annual-health-care-conference-on-may--ovid-20180502monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-host-fourth-quarter-and-full-year-2017-financial-results-conference-c-ovid-20180315monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-ov101-granted-fast-track-designation-by-u-s-fda-for-treatment--ovid-20180315monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-two-upcoming-investor-conferences-ovid-20180305monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-multiple-poster-presentations-of-ov101-and-tak-935-ov935-at-th-ovid-20180301monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-at-the-rbc-capital-markets-2018-global-healthcare-conference-ovid-20180215monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-tak-935-ov935-granted-orphan-drug-designation-by-u-s-fda-for-t-ovid-20171220monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-ov101-granted-fast-track-designation-by-u-s-fda-for-treatment--ovid-20171219monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-presents-new-data-demonstrating-potential-of-tak-935-ov935-as-a-novel-tr-ovid-20171203monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-five-poster-presentations-on-tak-935-ov935-at-the-american-epi-ovid-20171121monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-participate-in-two-upcoming-investor-conferences-ovid-20171120monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-participate-at-the-stifel-2017-healthcare-conference-ovid-20171108monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-preclinical-data-demonstrating-ov101-normalizes-behavioral-ab-ovid-20171005monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-appoints-ana-c-ward-as-senior-vice-president-and-general-counsel-ovid-20170906monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-first-patient-randomized-in-phase-1b-2a-clinical-trial-of-tak--ovid-20170821monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-be-added-to-russell-2000-3000-and-microcap-indexes-ovid-20170623monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-participate-in-the-jmp-securities-2017-life-sciences-conference-ovid-20170612monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-present-preclinical-data-on-tak-935-ov935-at-the-antiepileptic-drug-a-ovid-20170512monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-inc-nasdaq-ovid-to-ring-the-nasdaq-stock-market-closing-bell-ovid-20170509monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-pricing-of-initial-public-offering-ovid-20170504monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-initiation-of-phase-1-clinical-trial-of-ov101-for-adolescents--ovid-20170410monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-and-neuropointdx-announce-collaboration-to-identify-biomarkers-for-angel-ovid-20170209monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-announces-first-patient-randomized-in-the-phase-2-stars-clinical-trial-i-ovid-20170209monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-names-jacqueline-a-french-m-d-to-scientific-advisory-board-ovid-20170119monthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-to-participate-in-two-upcoming-investor-conferences-ovid-20161129monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-deadline-monday-bragar-eagel-squire-p-c-reminds-aquestive-therapeutics-inc-inves-aqst-20260501monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-deadline-rosen-leading-investor-counsel-encourages-aquestive-therapeutics-inc-in-aqst-20260428monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-inc-aqst-deadline-alert-bernstein-liebhard-llp-reminds-aquestive-th-aqst-20260409monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-inc-aqst-shareholder-alert-bernstein-liebhard-llp-reminds-aquestive-aqst-20260402monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-inc-aqst-shareholder-alert-bernstein-liebhard-llp-reminds-aquestive-aqst-20260326monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-inc-aqst-shareholder-alert-bernstein-liebhard-llp-reminds-aquestive-aqst-20260319monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-inc-aqst-shareholder-alert-bernstein-liebhard-llp-reminds-aquestive-aqst-20260312monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-grant-of-inducement-award-pursuant-to-nasdaq-listing-rule-aqst-20260309monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-investor-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-aqst-20260306monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-inc-aqst-investor-alert-investors-with-large-losses-in-aquestive-th-aqst-20260306monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-alert-bragar-eagel-squire-p-c-is-investigating-aquestive-therapeutics-inc-on-beh-aqst-20260120monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-report-second-quarter-2025-financial-results-and-recent-business-aqst-20250804monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-names-sherry-korczynski-as-chief-commercial-officer-aqst-20250722monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-provides-international-expansion-update-for-anaphylm-epinephrine-su-aqst-20250715monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-leerink-partners-therapeutics-forum-i-i-and-metab-aqst-20250707monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-present-positive-data-from-pharmacokinetic-and-pharmacodynamic-s-aqst-20250625monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-fda-acceptance-of-new-drug-application-and-pdufa-date-for-aqst-20250616monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-citizens-life-sciences-conference-aqst-20250505monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-report-first-quarter-2025-financial-results-and-recent-business--aqst-20250501monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-piper-sandler-spring-biopharma-symposium-aqst-20250409monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-positive-topline-pk-results-from-its-pediatric-study-and--aqst-20250401monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-two-upcoming-conferences-in-march-aqst-20250226monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-report-fourth-quarter-2024-financial-results-and-recent-business-aqst-20250220monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-present-new-findings-on-anaphylm-epinephrine-sublingual-film-at--aqst-20250212monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-oppenheimer-35th-annual-healthcare-conference-aqst-20250204monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-provides-business-update-and-outlines-key-2025-objectives-aqst-20250113monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-receives-u-s-fda-orphan-drug-exclusivity-for-libervant-diazepam-buc-aqst-20241219monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-positive-fda-feedback-and-reaffirms-nda-submission-guidan-aqst-20241202monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-two-upcoming-investor-conferences-aqst-20241112monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-present-subsequent-analysis-of-pivotal-study-for-anaphylm-epinep-aqst-20241025monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-positive-topline-results-from-oral-allergy-syndrome-oas-c-aqst-20241024monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-report-third-quarter-2024-financial-results-and-recent-business--aqst-20241021monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-spotlights-its-innovative-epinephrine-delivery-pipeline-at-virtual--aqst-20240927monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-hold-virtual-investor-day-to-provide-pipeline-updates-on-septemb-aqst-20240909monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-two-upcoming-investor-conferences-aqst-20240822monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-comments-on-recent-fda-approval-of-non-injection-based-epinephrine--aqst-20240814monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-positive-topline-data-for-anaphylm-epinephrine-sublingual-f-aqst-20240725monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-report-second-quarter-2024-financial-results-and-recent-business-aqst-20240723monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-leerink-partners-therapeutics-forum-i-i-and-metab-aqst-20240627monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-positive-topline-data-from-temperature-ph-study-of-anaphylm-aqst-20240625monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-join-the-russell-3000-and-russell-2000-indexes-effective-june-28-aqst-20240618monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-executive-appointments-and-builds-commercial-capabilities-aqst-20240603monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-present-anaphylm-epinephrine-sublingual-film-pharmacokinetic-and-aqst-20240528monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-the-citizens-jmp-life-sciences-conference-aqst-20240509monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-receives-u-s-fda-approval-and-market-access-for-libervant-diazepam--aqst-20240429monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-report-first-quarter-2024-financial-results-and-recent-business--aqst-20240425monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-present-crossover-study-data-for-libervant-diazepam-buccal-film--aqst-20240412monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-strengthens-board-of-directors-with-experienced-biotech-executive-aqst-20240401monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-closing-of-underwritten-public-offering-of-common-stock-aqst-20240325monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-pricing-of-75-million-underwritten-public-offering-of-com-aqst-20240320monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-proposed-public-offering-of-common-stock-aqst-20240319monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-pivotal-study-for-anaphylm-epinephrine-sublingual-film-su-aqst-20240314monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-report-fourth-quarter-2023-financial-results-and-recent-business-aqst-20240221monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-present-anaphylm-epinephrine-sublingual-film-pharmacokinetic-and-aqst-20240215monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-oppenheimer-34th-annual-healthcare-conference-aqst-20240130monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-doses-first-patient-in-phase-3-pivotal-clinical-study-evaluating-ph-aqst-20231205monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-present-positive-data-from-pharmacokinetic-and-pharmacodynamic-s-aqst-20231110monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-report-third-quarter-2023-financial-results-and-recent-business--aqst-20231031monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-provides-business-update-aqst-20231009monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reaffirms-timeline-and-pathway-for-anaphylm-epinephrine-sublingual--aqst-20230920monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-receives-fda-acceptance-of-new-drug-application-nda-for-libervant-d-aqst-20230911monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-two-upcoming-investor-conferences-aqst-20230823monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-2023-wedbush-pacgrow-healthcare-conference-aqst-20230802monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-positive-topline-pharmacokinetic-data-for-anaphylm-epinep-aqst-20230727monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-report-second-quarter-2023-financial-results-and-recent-business-aqst-20230725monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-present-positive-topline-data-from-pharmacokinetic-and-pharmacod-aqst-20230725monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-present-positive-data-from-pharmacokinetic-and-pharmacodynamic-s-aqst-20230706monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-provides-business-update-and-announces-chief-medical-officer-appoin-aqst-20230629monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-positive-results-from-latest-clinical-studies-evaluating-ph-aqst-20230531monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-two-upcoming-investor-conferences-aqst-20230426monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-receives-conditional-fda-acceptance-of-proprietary-name-anaphylm-fo-aqst-20230420monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-report-first-quarter-2023-financial-results-and-recent-business--aqst-20230418monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-expands-license-and-supply-agreement-with-pharmanovia-for-libervant-aqst-20230329monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference-aqst-20230301monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-report-fourth-quarter-2022-financial-results-and-recent-business-aqst-20230222monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-present-positive-data-from-pharmacokinetic-and-pharmacodynamic-s-aqst-20230221monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-provides-business-update-and-outlines-key-2023-objectives-aqst-20230106monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-completion-of-fda-end-of-phase-2-meeting-for-aqst-109-epi-aqst-20221222monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-publication-of-crossover-food-effect-study-of-diazepam-na-aqst-20221129monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-two-upcoming-investor-conferences-aqst-20221115monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-present-positive-data-from-pharmacokinetic-studies-for-aqst-109--aqst-20221109monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-licenses-sympazan-clobazam-oral-film-to-assertio-holdings-inc-aqst-20221027monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-positive-decision-in-states-suboxone-antitrust-lawsuit-on-aqst-20221024monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-report-third-quarter-2022-financial-results-and-recent-business--aqst-20221019monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-receives-positive-fda-written-response-for-aqst-109-epinephrine-sub-aqst-20221011monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-enters-license-and-supply-agreement-with-pharmanovia-for-libervant--aqst-20220928monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-positive-epiphast-ii-trial-data-for-aqst-109-when-compare-aqst-20220927monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-expert-allergy-scientific-advisory-board-aqst-20220912monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-two-investor-conferences-in-september-aqst-20220831monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-receives-fda-tentative-approval-for-libervant-diazepam-buccal-film-aqst-20220831monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-strengthens-team-to-align-with-strategic-focus-on-allergy-space-aqst-20220810monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-wedbush-pacgrow-healthcare-conference-aqst-20220726monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-report-second-quarter-2022-financial-results-and-recent-business-aqst-20220720monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-positive-results-from-final-two-arms-of-epiphast-trial-supp-aqst-20220711monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-positive-initial-topline-data-from-part-3-of-epiphast-trial-aqst-20220615monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-inc-announces-closing-of-8-5-million-registered-direct-offering-aqst-20220608monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-jmp-securities-life-sciences-conference-aqst-20220607monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-inc-announces-8-5-million-registered-direct-offering-aqst-20220606monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-ceo-transition-aqst-20220517monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-h-c-wainwright-global-investment-conference-aqst-20220510monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-report-first-quarter-2022-financial-results-and-recent-business--aqst-20220418monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-common-stock-purchase-agreement-for-up-to-40-million-with-aqst-20220413monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-positive-topline-data-from-part-2-of-epiphast-trial-evaluat-aqst-20220412monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-receives-fda-fast-track-designation-for-aqst-109-for-emergency-trea-aqst-20220317monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-and-haisco-pharmaceutical-group-enter-licensing-and-supply-agreemen-aqst-20220303monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-positive-topline-data-from-part-1-of-epiphast-trial-evaluat-aqst-20220225monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-ind-aqst-20220225monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-report-fourth-quarter-and-year-end-2021-financial-results-and-re-aqst-20220222monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-present-at-h-c-wainwright-bioconnect-virtual-conference-aqst-20220107monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-receives-notification-from-fda-that-it-will-not-be-ready-to-take-ac-aqst-20211221monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-added-to-nasdaq-biotechnology-index-aqst-20211217monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-receives-written-response-to-pre-ind-submission-for-aqst-109-epinep-aqst-20211213monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-piper-sandler-33rd-annual-virtual-healthcare-conf-aqst-20211117monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reports-positive-topline-data-from-phase-1-pharmacokinetic-trial-of-aqst-20211025monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-report-third-quarter-2021-financial-results-and-recent-business--aqst-20211014monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-reaches-agreement-to-extend-principal-payments-due-under-credit-fac-aqst-20211006monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-three-investor-conferences-in-september-aqst-20210907monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-negotiates-six-month-extension-to-june-30-2022-for-additional-liber-aqst-20210809monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-12th-annual-wedbush-pacgrow-healthcare-virtual-co-aqst-20210806monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-report-second-quarter-2021-financial-results-and-recent-business-aqst-20210721monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-fda-acceptance-of-new-drug-application-nda-resubmission-f-aqst-20210719monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-resubmits-new-drug-application-for-libervant-diazepam-buccal-film-aqst-20210624monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-leadership-transition-of-chief-financial-officer-aqst-20210621monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-jmp-securities-and-bmo-capital-market-investor-co-aqst-20210609monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-participate-in-2021-rbc-capital-markets-global-healthcare-confer-aqst-20210511monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-inc-investors-last-days-to-participate-actively-in-the-class-action-aqst-20210429monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-report-first-quarter-2021-financial-results-and-recent-business--aqst-20210421monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-successfully-demonstrates-repeatable-and-predictable-oral-sublingua-aqst-20210325monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-host-investor-analyst-virtual-epinephrine-drug-delivery-r-d-even-aqst-20210305monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-noti-aqst-20210304monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-announce-fourth-quarter-and-year-end-2020-financial-results-and--aqst-20210217monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-appoints-mark-lepore-md-as-chief-medical-officer-for-allergy-aqst-20210128monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-provides-business-update-aqst-20210107monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-present-at-two-upcoming-investor-conferences-aqst-20210104monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-present-at-piper-sandler-32nd-annual-virtual-healthcare-conferen-aqst-20201125monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-signs-royalty-monetization-agreement-with-marathon-asset-management-aqst-20201103monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-announce-third-quarter-financial-results-and-recent-business-hig-aqst-20201014monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-initiates-phase-1-pharmacokinetic-trial-of-aqst-108-sublingual-film-aqst-20200820monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-present-at-2020-wedbush-pacgrow-healthcare-virtual-conference-aqst-20200728monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-announce-second-quarter-financial-results-and-recent-business-hi-aqst-20200715monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-present-at-bmo-capital-markets-2020-prescriptions-for-success-he-aqst-20200616monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-hold-virtual-only-annual-meeting-of-stockholders-aqst-20200604monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-present-at-2020-rbc-capital-markets-global-healthcare-conference-aqst-20200507monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-announce-first-quarter-financial-results-and-recent-business-hig-aqst-20200421monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-announce-fourth-quarter-and-full-year-2019-financial-results-and-aqst-20200220monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-exceeds-top-end-of-guidance-range-for-preliminary-unaudited-full-ye-aqst-20200110monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-pricing-of-public-offering-of-common-stock-aqst-20191213monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-host-investor-analyst-libervant-diazepam-buccal-film-update-foru-aqst-20191204monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-poster-presentations-of-data-on-libervant-diazepam-buccal-aqst-20191126monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-attend-two-upcoming-investor-conferences-aqst-20190826monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-announces-positive-topline-results-from-libervant-diazepam-buccal-f-aqst-20190806monthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-to-present-at-2019-wedbush-pacgrow-healthcare-conference-aqst-20190729monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-first-quarter-2026-financial-results-and-increases-2026-finan-kids-20260430monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-expands-specialty-bracing-portfolio-with-traxio-halo-gravity-traction-syst-kids-20260430monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-fourth-quarter-and-full-year-2025-financial-results-kids-20260226monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-fourth-quarter-and-full-year-2025-financial-results-on-febr-kids-20260212monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-achieves-record-preliminary-unaudited-revenue-for-full-year-2025-and--kids-20260112monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-third-quarter-financial-results-on-october-28-2025-kids-20251015monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-second-quarter-2025-financial-results-and-increases-full-year-kids-20250805monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-continued-expansion-of-specialty-bracing-division-into-new--kids-20250805monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-in-the-45th-canaccord-genuity-annual-growth-conference-kids-20250804monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-launches-3p-pediatric-plating-platform-hip-system-and-completes-first-kids-20250801monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-second-quarter-financial-results-on-august-5-2025-kids-20250722monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-continued-leading-sponsorship-at-2025-posna-annual-meeting-kids-20250514monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-first-quarter-2025-financial-results-and-increases-full-year--kids-20250507monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-expands-trauma-and-deformity-portfolio-with-3p-pediatric-plating-plat-kids-20250507monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-first-quarter-financial-results-on-may-7-2025-kids-20250423monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-expands-scoliosis-portfolio-with-launch-of-verteglide-system-kids-20250408monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-in-the-24th-annual-needham-virtual-healthcare-conferen-kids-20250325monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-named-one-the-2025-best-places-to-work-in-indiana-kids-20250324monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-joins-crossroads-pediatric-device-consortium-to-advance-pediatric-med-kids-20250317monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-fourth-quarter-and-full-year-2024-financial-results-kids-20250304monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-fourth-quarter-and-full-year-2024-financial-results-on-marc-kids-20250219monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-distribution-agreement-with-thrive-orthopedics-llc-kids-20250122monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-achieves-record-preliminary-unaudited-revenue-for-full-year-2024-and--kids-20250113monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-expansion-of-specialty-bracing-division-kids-20250110monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-expands-specialty-bracing-portfolio-with-two-new-products-kids-20241205monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-host-educational-and-networking-events-at-20th-annual-internationa-kids-20241202monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-expands-specialty-bracing-portfolio-with-df2-brace-kids-20241126monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-in-upcoming-conferences-kids-20241112monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-third-quarter-2024-financial-results-and-increases-full-year--kids-20241106monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-third-quarter-2024-financial-results-on-november-7-2024-kids-20241023monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-launch-of-enabling-technologies-division-kids-20240912monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-host-investor-day-on-september-12-2024-kids-20240820monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-second-quarter-2024-financial-results-and-reaffirms-full-year-kids-20240805monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-private-financing-kids-20240805monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-second-quarter-2024-financial-results-on-august-6-2024-kids-20240722monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-in-the-truist-securities-medtech-conference-kids-20240604monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-continued-leading-sponsorship-at-2024-eposna-annual-meeting-kids-20240515monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-first-quarter-2024-financial-results-and-increases-full-year--kids-20240506monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-receives-breakthrough-device-designation-from-fda-for-elli-growing-ro-kids-20240502monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-first-quarter-2024-financial-results-on-may-7-2024-kids-20240422monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-highlight-its-pediatric-scoliosis-solutions-at-8th-annual-internat-kids-20240404monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-in-the-23rd-annual-needham-virtual-healthcare-conferen-kids-20240326monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-fourth-quarter-and-full-year-2023-financial-results-kids-20240306monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-launches-new-response-rib-and-pelvic-fixation-system-for-eos-scoliosi-kids-20240304monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-named-one-of-the-2024-best-places-to-work-in-indiana-kids-20240228monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-fourth-quarter-and-full-year-2023-financial-results-on-marc-kids-20240222monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-preliminary-unaudited-financial-highlights-for-the-fourth-q-kids-20240108monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-launch-of-specialty-bracing-division-kids-20231206monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-host-educational-and-networking-events-at-19th-annual-internationa-kids-20231204monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-in-upcoming-november-conferences-kids-20231109monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-third-quarter-2023-financial-results-kids-20231106monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-enters-distribution-agreement-with-ora-medical-kids-20231106monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-launches-mp-bar-for-clubfoot-kids-20231101monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-launches-pediatric-nailing-platform-tibia-kids-20231019monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-third-quarter-2023-financial-results-on-november-7-2023-kids-20231017monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-joins-alliance-for-pediatric-device-innovation-kids-20231012monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-launches-df2-brace-kids-20231010monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-was-a-gold-level-sponsor-of-the-scoliosis-research-society-58th-annual-mee-kids-20230925monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-at-the-gilmartin-group-emerging-growth-company-showcas-kids-20230914monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-receives-fda-510-k-clearance-for-pediatric-nailing-platform-tibia-kids-20230911monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-second-quarter-2023-financial-results-kids-20230731monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-second-quarter-2023-financial-results-on-august-1-2023-kids-20230718monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-the-launch-and-first-case-using-the-giro-growth-modulation--kids-20230627monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-announces-election-of-george-dyer-md-to-its-board-of-directors-kids-20230615monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announce-launch-of-response-power-scoliosis-system-kids-20230504monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-first-quarter-2023-financial-results-and-increases-full-year--kids-20230501monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-continues-leading-sponsorship-at-2023-posna-annual-meeting-kids-20230501monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-launch-of-response-5-5-6-0-cannulated-screw-system-kids-20230420monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-first-quarter-2022-financial-results-on-may-2-2023-kids-20230417monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-at-the-22nd-annual-needham-virtual-healthcare-conferen-kids-20230403monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-leading-sponsorship-at-annual-epos-meeting-kids-20230331monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-named-one-of-the-2023-best-places-to-work-in-indiana-kids-20230306monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-fourth-quarter-and-full-year-2022-financial-results-kids-20230228monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-fourth-quarter-and-full-year-2022-financial-results-on-marc-kids-20230214monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-publishes-environmental-social-and-governance-esg-summary-report-kids-20230201monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-preliminary-unaudited-net-revenue-for-the-fourth-quarter-fu-kids-20230109monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-establishes-direct-sales-organization-in-germany-kids-20230106monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-host-educational-and-networking-events-at-18th-annual-internationa-kids-20221205monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-to-participate-in-upcoming-november-conferences-kids-20221104monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-third-quarter-2022-financial-results-and-updates-2022-revenue-kids-20221031monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-appointment-of-jimmy-d-mcdonald-to-board-of-directors-kids-20221020monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-third-quarter-2022-financial-results-on-november-1-2022-kids-20221018monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-to-present-at-the-inaugural-gilmartin-group-emerging-growth-company-showca-kids-20220818monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-closing-of-its-public-offering-of-common-stock-and-pre-fund-kids-20220815monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-pricing-of-125-million-public-offering-of-common-stock-and--kids-20220811monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-second-quarter-2022-financial-results-and-increases-2022-reve-kids-20220803monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-second-quarter-2022-financial-results-on-august-4-2022-kids-20220721monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-distribution-agreement-with-3d-side-kids-20220713monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-completes-acquisition-of-pega-medical-kids-20220705monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-to-participate-in-the-jmp-securities-life-sciences-conference-kids-20220524monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-continues-double-diamond-sponsorship-for-2022-posna-meeting-kids-20220510monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-first-quarter-2022-financial-results-and-increases-2022-reven-kids-20220504monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-first-quarter-2022-financial-results-on-may-5-2022-kids-20220418monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-spotlights-award-winning-apifix-technology-at-imast-kids-20220412monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-apifix-system-selected-as-2022-mdea-finalist-kids-20220406monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-to-participate-in-the-21st-annual-needham-virtual-healthcare-conference-kids-20220331monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-launches-pediflex-advanced-interlock-clamp-system-kids-20220324monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-fourth-quarter-and-record-full-year-2021-financial-results-kids-20220302monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-highlight-its-pediatric-scoliosis-solutions-at-7th-annual-internat-kids-20220301monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-named-one-of-the-2022-best-places-to-work-in-indiana-kids-20220225monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-celebrates-1-000th-case-with-firefly-pedicle-screw-navigation-guides-kids-20220223monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-fourth-quarter-and-full-year-2021-financial-results-on-marc-kids-20220201monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-announces-preliminary-unaudited-revenue-for-the-fourth-quarter-full-year-2-kids-20220110monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-continued-double-diamond-support-of-international-pediatric-orthopaed-kids-20211213monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-to-participate-in-the-33rd-annual-piper-sandler-virtual-healthcare-confere-kids-20211122monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-third-quarter-2021-financial-results-kids-20211103monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-to-participate-in-the-stifel-2021-virtual-healthcare-conference-kids-20211026monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-recognized-in-covid-stops-here-campaign-kids-20211018monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-preliminary-unaudited-revenue-for-the-third-quarter-2021-an-kids-20211013monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-continues-support-of-autumn-surgical-society-meetings-kids-20211004monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-announces-entry-into-a-distribution-agreement-with-seaspine-to-exclusively-kids-20210909monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-second-quarter-2021-financial-results-kids-20210804monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-and-mighty-oak-medical-extend-exclusive-partnership-for-firefly-techn-kids-20210804monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-maintains-its-diamond-sponsorship-for-31st-annual-baltimore-limb-defo-kids-20210729monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-second-quarter-2021-financial-results-on-august-5-2021-kids-20210722monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-launch-of-next-generation-cannulated-screw-system-kids-20210610monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-present-at-the-2021-jmp-securities-life-sciences-conference-kids-20210609monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-completes-senior-leadership-transition-with-appointment-of-david-bail-kids-20210603monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-launches-response-neuromuscular-scoliosis-system-kids-20210528monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-continues-double-diamond-sponsorship-for-2021-posna-meeting-kids-20210517monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-first-quarter-2021-financial-results-kids-20210505monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-in-the-7th-annual-truist-securities-2021-life-sciences-kids-20210422monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-first-quarter-2021-financial-results-on-may-5-2021-kids-20210421monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-in-the-20th-annual-needham-virtual-healthcare-conferen-kids-20210331monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-surpasses-milestones-of-500-scoliosis-correction-cases-worldwide-and-nine--kids-20210323monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-fourth-quarter-and-full-year-2020-financial-results-kids-20210310monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-crosses-milestone-treating-200-000-children-with-orthopedic-condition-kids-20210304monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-fourth-quarter-and-full-year-2020-financial-results-on-marc-kids-20210303monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-launches-dedicated-apifix-website-to-support-game-changing-spinal-def-kids-20210218monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-in-the-btig-virtual-medtech-digital-health-life-scienc-kids-20210211monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corporation-investor-alert-securities-litigation-partner-james-wilson-enco-kids-20210123monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-introduces-orthex-in-australia-kids-20210122monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-introduces-expanded-product-portfolio-in-canada-kids-20210119monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corporation-investor-alert-securities-litigation-partner-james-wilson-enco-kids-20210119monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-expands-its-agent-network-in-three-strategic-european-countries-kids-20210115monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-preliminary-unaudited-revenue-for-fourth-quarter-and-full-y-kids-20210111monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-launches-sterile-implants-for-pnp-femur-system-kids-20210105monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-investors-company-investigated-by-the-portnoy-law-firm-kids-20210104monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-in-the-23rd-annual-needham-virtual-growth-conference-kids-20210104monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-first-pnp-femur-case-performed-in-the-united-kingdom-kids-20201229monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-international-expansion-in-the-united-kingdom-kids-20201221monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-alert-bragar-eagel-squire-p-c-is-investigating-orthopediatrics-corp-on-beh-kids-20201205monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-named-2020-corporate-champion-of-the-year-by-world-pediatric-project-kids-20201203monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-third-quarter-2020-financial-results-kids-20201104monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-present-at-four-upcoming-investor-conferences-in-november-and-dece-kids-20201029monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-third-quarter-2020-financial-results-on-november-4-2020-kids-20201021monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-support-the-3rd-annual-pediortho-west-resident-education-course-in-kids-20201008monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-sponsor-two-medical-meetings-in-september-2020-kids-20200909monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-in-the-morgan-stanley-18th-annual-global-healthcare-co-kids-20200908monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-1-000th-procedure-utilizing-its-innovative-pediatric-nailin-kids-20200903monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-maintains-its-diamond-sponsorship-for-virtual-30th-annual-baltimore-l-kids-20200824monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-in-the-5th-annual-needham-virtual-med-tech-1x1-confere-kids-20200810monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-second-quarter-2020-financial-results-kids-20200805monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-achieves-500th-case-with-firefly-pedicle-screw-navigation-guides-kids-20200803monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-second-quarter-2020-financial-results-on-august-5-2020-kids-20200723monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-closing-of-offering-of-common-stock-kids-20200622monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-pricing-of-offering-of-common-stock-kids-20200618monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-commences-initial-u-s-launch-of-apifix-s-fda-approved-spinal-deformit-kids-20200610monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-continue-sponsorship-for-2020-posna-annual-meeting-kids-20200513monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-first-quarter-2020-financial-results-kids-20200505monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-in-the-6th-annual-suntrust-robinson-humphrey-life-scie-kids-20200429monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-first-quarter-2020-financial-results-on-may-5-2020-kids-20200421monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-acquisition-of-apifix-ltd-with-fda-approved-non-fusion-scol-kids-20200401monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-receives-fda-510-k-clearance-and-expanded-neuromuscular-indications-f-kids-20200331monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-provides-covid-19-business-update-kids-20200330monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-u-s-launch-of-large-fragment-cannulated-screw-system-kids-20200309monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-fourth-quarter-and-full-year-2019-financial-results-kids-20200304monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-direct-sales-agency-expansion-in-italy-kids-20200303monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-highlight-its-pediatric-scoliosis-solutions-at-6th-annual-internat-kids-20200302monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-continues-to-be-honored-as-one-of-the-best-place-to-work-in-indiana-kids-20200226monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-fourth-quarter-and-full-year-2019-financial-results-on-marc-kids-20200218monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-preliminary-unaudited-revenue-for-fourth-quarter-and-record-s-kids-20200113monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-u-s-launch-of-quickpack-kids-20191220monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-closing-of-common-stock-offering-and-full-exercise-of-under-kids-20191217monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-pricing-of-offering-of-common-stock-kids-20191211monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-sponsor-the-annual-international-pediatric-orthopaedic-symposium-i-kids-20191120monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-u-s-launch-of-pedifoot-deformity-correction-system-kids-20191115monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-present-at-two-upcoming-investor-conferences-kids-20191111monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-third-quarter-2019-financial-results-kids-20191107monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-third-quarter-2019-financial-results-on-november-7-2019-kids-20191023monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-at-the-cantor-fitzgerald-global-healthcare-conference-kids-20190925monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-sponsor-three-medical-meetings-in-september-2019-kids-20190916monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-u-s-launch-of-next-generation-cannulated-screw-systems-kids-20190909monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-receives-fda-510-k-clearance-for-first-pediatric-specific-foot-system-kids-20190819monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-second-quarter-2019-financial-results-kids-20190807monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-in-4th-annual-needham-med-tech-diagnostics-conference-kids-20190805monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-second-quarter-2019-financial-results-on-august-7-2019-kids-20190802monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-receives-fda-510-k-clearance-for-next-generation-cannulated-screw-sys-kids-20190723monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-sponsor-26th-annual-international-meeting-on-advanced-spine-techni-kids-20190703monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-present-at-the-jmp-life-sciences-conference-kids-20190610monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-continue-sponsorship-for-2019-posna-meeting-kids-20190515monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-first-quarter-2019-financial-results-kids-20190508monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-first-quarter-2019-financial-results-on-may-8-2019-kids-20190429monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-licensing-partnership-with-coorstek-medical-kids-20190422monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-sponsor-38th-annual-european-paediatric-orthopaedic-society-epos-m-kids-20190403monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-fourth-quarter-and-full-year-2018-financial-results-kids-20190306monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-at-the-canaccord-genuity-2019-musculoskeletal-conferen-kids-20190304monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-fourth-quarter-and-full-year-2018-financial-results-on-marc-kids-20190225monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-global-launch-of-new-bandloc-duo-kids-20190225monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-honored-as-one-of-the-best-place-to-work-in-indiana-for-a-third-year-kids-20190222monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-in-btig-healthcare-conference-kids-20190220monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-preliminary-unaudited-revenue-for-fourth-quarter-and-full-y-kids-20190107monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-direct-sales-agency-expansion-in-belgium-and-the-netherland-kids-20190104monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-files-sanctions-motion-against-a-former-employee-and-wishbone-medical-kids-20190102monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-full-scale-u-s-launch-of-small-stature-scoliosis-system-kids-20181213monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-closing-of-common-stock-offering-and-full-exercise-of-under-kids-20181211monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-proposed-offering-of-common-stock-kids-20181206monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-enhances-product-offering-with-upgraded-pediloc-femur-plate-system-kids-20181127monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-sponsor-the-annual-international-pediatric-orthopaedic-symposium-i-kids-20181119monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-in-two-upcoming-conferences-kids-20181105monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-third-quarter-2018-financial-results-kids-20181031monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-third-quarter-2018-financial-results-on-october-31-2018-kids-20181024monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-receives-fda-510-k-clearance-for-small-stature-scoliosis-system-with--kids-20181019monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-sponsor-two-medical-meetings-in-october-kids-20180927monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-first-pnp-femur-cases-performed-in-australia-kids-20180917monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-at-the-morgan-stanley-16th-annual-global-healthcare-co-kids-20180904monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-expansion-of-its-warsaw-headquarters-kids-20180814monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-present-at-fda-conference-on-pediatric-devices-kids-20180810monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-second-quarter-2018-financial-results-kids-20180808monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-announces-expanded-indication-for-firefly-pedicle-screw-navigation-guides-kids-20180731monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-second-quarter-2018-financial-results-on-august-8-2018-kids-20180725monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-full-launch-of-pediatric-nailing-platform-femur-kids-20180711monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-first-response-spine-surgery-performed-in-japan-kids-20180618monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-first-surgery-performed-with-pediatric-nailing-platform-fem-kids-20180604monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-present-at-jefferies-william-blair-healthcare-conferences-kids-20180524monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-first-quarter-2018-financial-results-kids-20180514monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-fda-510-k-clearance-for-its-25th-surgical-system-pediatric--kids-20180514monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-supports-third-medical-mission-with-world-pediatric-project-kids-20180510monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-is-a-double-diamond-sponsor-for-2018-posna-meeting-kids-20180507monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-first-quarter-2018-financial-results-on-may-14-2018-kids-20180423monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-honored-as-one-of-the-best-places-to-work-in-indiana-for-a-second-yea-kids-20180416monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-sponsorship-of-2018-epos-meeting-and-lunch-symposium-kids-20180409monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-introduces-pediflex-advanced-surgical-system-kids-20180322monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-fourth-quarter-and-full-year-2017-financial-results-kids-20180307monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-fourth-quarter-and-full-year-2017-financial-results-on-marc-kids-20180227monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-in-canaccord-genuity-s-musculoskeletal-conference-kids-20180220monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-in-btig-healthcare-conference-kids-20180213monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-preliminary-revenue-for-fourth-quarter-and-full-year-2017-kids-20180105monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-expands-pediplates-franchise-with-titanium-system-kids-20180103monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-appoints-samuel-d-riccitelli-to-its-board-of-directors-kids-20171215monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-launches-new-wrist-fusion-plate-system-kids-20171211monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-highlight-its-products-at-the-14th-annual-international-pediatric--kids-20171127monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-participate-in-the-29th-annual-piper-jaffray-healthcare-conference-kids-20171116monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-start-distributing-bioretec-devices-via-private-label-kids-20171113monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-present-at-stifel-2017-healthcare-conference-kids-20171110monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-reports-third-quarter-2017-financial-results-kids-20171108monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-to-report-third-quarter-2017-financial-results-on-november-8-2017-kids-20171030monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-nasdaq-kids-to-ring-the-nasdaq-stock-market-opening-bell-in-celebrati-kids-20171013monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-pricing-of-initial-public-offering-kids-20171012monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-announces-launch-of-initial-public-offering-kids-20171002monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-files-amendment-to-registration-statement-for-proposed-initial-public-kids-20170911monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-and-mighty-oak-medical-team-up-to-bring-pediatric-friendly-spinal-navigati-kids-20170828monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-files-registration-statement-for-proposed-initial-public-offering-kids-20170811monthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-corp-files-registration-statement-for-proposed-initial-public-offering-kids-20160617monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-investors-have-the-opportunity-to-join-investigation-of-xoma-royalty-corporation-with-xoma-20260428monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-corporation-investigated-by-the-portnoy-law-firm-xoma-20260422monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-declares-quarterly-preferred-stock-dividends-xoma-20260318monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-to-present-at-investor-conferences-in-march-xoma-20260218monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-enters-into-agreement-to-acquire-generation-bio-xoma-20251215monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-declares-quarterly-preferred-stock-dividends-xoma-20250618monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-purchases-mezagitamab-royalty-and-milestone-rights-held-by-bioinvent-internat-xoma-20250527monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-to-present-at-h-c-wainwright-1st-annual-royalty-company-virtual-conference-xoma-20250507monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-completes-sale-of-kinnate-pipeline-assets-xoma-20250414monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-to-present-at-jones-healthcare-and-technology-innovation-conference-xoma-20250402monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-declares-quarterly-preferred-stock-dividends-xoma-20250320monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-to-present-at-investor-conferences-in-march-xoma-20250224monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference-xoma-20250204monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-declares-quarterly-preferred-stock-dividends-xoma-20241219monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-declares-quarterly-preferred-stock-dividends-xoma-20240923monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-to-present-at-upcoming-investor-conferences-in-september-xoma-20240904monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-expands-its-commercial-royalty-and-milestone-portfolio-with-dsuvia-acquisition-xoma-20240118monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-acquires-royalty-and-milestone-economics-to-phase-3-first-in-class-orphan-disease-ass-xoma-20230622monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-acquires-cashflow-generating-asset-for-its-royalty-and-milestone-portfolio-xoma-20230330monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-acquires-royalty-and-milestone-license-to-ebopiprant-a-preterm-labor-asset-being-deve-xoma-20221122monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-acquires-royalty-and-milestone-interest-in-checkmate-s-vidutolimod-cmp-001-from-kuros-xoma-20210715monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-s-royalty-portfolio-grows-with-addition-of-three-royalty-assets-xoma-20210415monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-earns-first-milestone-payment-from-2018-royalty-purchase-agreement-xoma-20201111monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-acquires-royalty-interest-in-four-lysosomal-storage-disorder-enzymes-being-developed--xoma-20201103monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-third-quarter-2019-royalty-asset-portfolio-highlights-and-financial-results-xoma-20191105monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-acquires-royalty-interest-position-in-six-clinical-stage-assets-xoma-20190926monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-s-royalty-portfolio-expands-significantly-xoma-20190812monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-reports-second-quarter-2019-royalty-asset-portfolio-highlights-and-financial-results-xoma-20190806monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-acquires-royalty-rights-to-five-hematology-candidates-xoma-20190408monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-announces-20-million-credit-facility-with-silicon-valley-bank-to-advance-royalty-aggr-xoma-20180508monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-receives-4-million-for-sale-of-royalty-interest-in-cimzia-r-xoma-20100818monthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-refinances-royalty-based-loan-facility-for-55-million-xoma-20080512monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-announces-closing-of-us-63-2-million-public-offering-including-fu-eprx-20260220monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-announces-pricing-of-us-55-million-public-offering-of-common-shar-eprx-20260219monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-announces-proposed-public-offering-eprx-20260218monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-reports-positive-tissue-health-data-from-its-ongoing-resolve-tria-eprx-20260108monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-reports-additional-52-week-follow-up-data-from-the-resolve-trial--eprx-20251113monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-busine-eprx-20250812monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-to-host-virtual-kol-event-to-discuss-the-phase-1b-2a-resolve-stud-eprx-20250507monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-reports-first-quarter-2025-financial-results-eprx-20250506monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-announces-sustained-positive-treatment-outcomes-in-patients-with--eprx-20250505monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-to-present-at-investor-and-scientific-conferences-in-april-and-ma-eprx-20250424monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-announces-closing-of-overnight-marketed-offering-for-gross-procee-eprx-20240315monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-announces-pricing-of-overnight-marketed-offering-eprx-20220412monthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-announces-overnight-marketed-offering-eprx-20220411monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-to-participate-in-two-upcoming-investor-conferences-sgmt-20250826monthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-presents-new-data-from-phase-2-vibrant-trial-of-verekitug-demonstrating-impro-upb-20260518monthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-to-host-conference-call-and-webcast-to-report-top-line-data-from-the-phase-2--upb-20250901monthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-to-participate-in-the-goldman-sachs-46th-annual-global-healthcare-conference-upb-20250604monthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-appoints-stacy-price-as-chief-technology-officer-upb-20250520monthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-to-present-at-upcoming-march-investor-conferences-upb-20250225monthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-upb-20250106monthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-appoints-allison-ambrose-as-general-counsel-upb-20241217monthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-announces-addition-to-russell-2000-index-upb-20241216monthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bioprocessing-market-to-reach-usd-82-10-billion-by-2032-from-usd-22-79-billion-in-upb-20241126monthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference-upb-20241121monthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-announces-closing-of-293-million-upsized-initial-public-offering-including-fu-upb-20241015monthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-announces-pricing-of-upsized-initial-public-offering-upb-20241010monthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-announces-oral-presentation-of-new-data-from-a-phase-1b-multiple-ascending-do-upb-20240909monthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-presents-results-from-a-dose-ranging-study-of-verekitug-upb-101-in-adults-wit-upb-20240522monthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-to-present-results-from-a-dose-ranging-study-of-verekitug-upb-101-in-adults-w-upb-20240515monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-stro-20260107monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-stro-20251216monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-to-highlight-its-next-generation-exatecan-and-dual-payload-adc-programs-in-stro-20250428monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-full-year-2024-financial-results-and-business-highlights-stro-20250313monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-announces-strategic-portfolio-review-resulting-in-the-prioritization-of-it-stro-20250313monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-to-present-at-the-td-cowen-45th-annual-health-care-conference-stro-20250303monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-stro-20250107monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-and-boehringer-ingelheim-bioxcellence-collaboration-established-first-in-c-stro-20250107monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-demonstrates-meaningful-adc-innovation-with-five-presentations-at-the-15th-stro-20241104monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-highlights-next-generation-adc-innovation-and-near-term-pipeline-at-resear-stro-20241010monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stro-20240920monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-announces-updated-data-from-phase-1b-study-of-luvelta-in-combination-with--stro-20240914monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-to-host-research-forum-highlighting-next-generation-adc-innovation-and-nea-stro-20240911monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-appoints-dr-barbara-leyman-as-chief-business-development-officer-stro-20240709monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-announces-pricing-of-75-million-underwritten-offering-stro-20240402monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-full-year-2023-financial-results-business-highlights-and-select-an-stro-20240325monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-to-participate-in-upcoming-investor-conferences-stro-20240206monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-announces-new-positive-data-from-the-compassionate-use-of-luveltamab-tazev-stro-20231211monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-to-participate-in-the-jmp-securities-hematology-and-oncology-summit-stro-20231204monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-announces-presentation-of-data-for-luveltamab-tazevibulin-luvelta-from-the-stro-20231022monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-demonstrates-meaningful-adc-innovation-with-five-presentations-and-one-poster-at-the-stro-20231016monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-appoints-dr-hans-peter-gerber-as-chief-scientific-officer-stro-20230919monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-to-participate-in-upcoming-investor-conferences-stro-20230830monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-and-blackstone-announce-royalty-financing-collaboration-stro-20230626monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-announces-oral-presentation-at-asco-2023-featuring-data-for-luveltamab-taz-stro-20230603monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-to-participate-in-the-jefferies-healthcare-conference-stro-20230531monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-to-present-at-the-jmp-securities-life-sciences-conference-stro-20230508monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-announces-the-departure-of-president-of-research-chief-scientific-officer-stro-20230427monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-presents-preclinical-data-for-its-ror1-targeting-antibody-drug-conjugate-s-stro-20230418monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-stro-20230317monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-to-present-at-the-cowen-43rd-annual-health-care-conference-stro-20230301monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-appoints-dr-anne-borgman-as-chief-medical-officer-stro-20230228monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-stro-20230217monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-announces-update-from-stro-002-luveltamab-tazevibulin-luvelta-phase-1-dose-stro-20230109monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-stro-20230104monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-to-provide-data-update-on-stro-002-and-plans-for-registrational-path-forwa-stro-20221221monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-and-vaxcyte-enter-into-option-grant-agreement-for-the-development-and-manu-stro-20221220monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-announces-presentation-of-stro-002-data-from-the-compassionate-use-program-stro-20221210monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-to-participate-in-upcoming-investor-conferences-stro-20221123monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-announces-oral-presentation-at-the-64th-american-society-of-hematology-ann-stro-20221103monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-to-participate-in-upcoming-investor-conferences-stro-20221102monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-announces-departure-of-chief-medical-officer-stro-20221024monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-to-present-at-the-2022-wells-fargo-healthcare-conference-stro-20220901monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-stro-20220819monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-to-present-at-the-2022-wedbush-pacgrow-healthcare-conference-stro-20220803monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-achieves-first-in-human-milestone-in-cytokine-derivatives-collaboration-wi-stro-20220726monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-announces-virtual-deep-dive-research-forum-next-gen-innovations-in-adcs-stro-20220712monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-stro-20220603monthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-to-participate-in-upcoming-investor-conferences-stro-20220602monthly0.5https://www.biopharmawatch.com/news/STRO/sutrovax-announces-name-change-to-vaxcyte-stro-20200521monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-reports-second-quarter-2025-financial-results-and-recent-developments-mnpr-20250812monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-reports-first-quarter-2025-financial-results-and-recent-developments-mnpr-20250513monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-presents-alxn1840-late-breaker-data-at-easl-2025-mnpr-20250507monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-alxn1840-data-selected-for-late-breaker-presentation-at-easl-congress-20-mnpr-20250429monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-development-mnpr-20250331monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-inc-announces-pricing-of-40-million-public-offering-of-common-stock-a-mnpr-20241220monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-first-patient-dosed-with-its-novel-therapeutic-radiopharmaceutical-mnpr--mnpr-20241205monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-to-present-at-the-36th-annual-piper-sandler-healthcare-conference-mnpr-20241203monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-reports-third-quarter-2024-financial-results-and-recent-developments-mnpr-20241108monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-inc-announces-closing-of-19-2-million-public-offering-of-common-stock-mnpr-20241030monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-inc-announces-pricing-of-19-2-million-public-offering-of-common-stock-mnpr-20241029monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-inc-announces-proposed-public-offering-of-common-stock-mnpr-20241028monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-agreement-with-alexion-astrazeneca-rare-disease-for-late-stage-wilson-di-mnpr-20241024monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-presents-encouraging-human-clinical-dosimetry-data-on-its-upar-program-at-eanm-202-mnpr-20241022monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-expands-radiopharma-intellectual-property-portfolio-with-patent-filing-on-new-comp-mnpr-20241015monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-initiates-clinical-trial-of-novel-upar-targeted-radiopharmaceutical-therapy-in-adv-mnpr-20241007monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-positive-early-human-clinical-data-validating-the-tumor-targeting-abilit-mnpr-20240912monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-to-participate-in-the-h-c-wainwright-26th-annual-global-investment-conference-mnpr-20240904monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-regains-compliance-with-nasdaq-minimum-bid-price-rule-mnpr-20240827monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-receives-clearance-to-proceed-with-phase-1-therapeutic-trial-of-novel-radiopharmac-mnpr-20240821monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-initial-data-for-first-patient-dosed-in-radiopharma-phase-1-clinical-tri-mnpr-20240814monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-announces-1-for-5-reverse-stock-split-mnpr-20240809monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-reports-second-quarter-2024-financial-results-and-recent-developments-mnpr-20240809monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-first-patient-enrolled-in-first-in-human-phase-1-trial-for-its-novel-rad-mnpr-20240709monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-mnpr-101-rit-abstract-accepted-as-a-top-rated-oral-presentation-at-eanm--mnpr-20240625monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-and-northstar-amend-extend-collaboration-mnpr-20240611monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-presents-data-showcasing-the-appeal-of-upar-as-a-radiopharma-cancer-target-and-of--mnpr-20240610monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-cfo-succession-mnpr-20240524monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-reports-first-quarter-2024-financial-results-and-strategic-focus-on-i-mnpr-20240509monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-radiopharma-presentation-selected-for-society-of-nuclear-medicine-and-mo-mnpr-20240418monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-filing-of-patent-protecting-mnpr-101-radiopharma-optimization-findings-mnpr-20240416monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-initiates-radiopharma-phase-1-clinical-trial-for-mnpr-101-zr-in-advanced-cancer-pa-mnpr-20240410monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-reports-fourth-quarter-and-full-year-2023-financial-results-and-recent-development-mnpr-20240328monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-positive-preclinical-therapeutic-isotope-data-for-its-mnpr-101-radiophar-mnpr-20240305monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-provides-update-on-mnpr-101-zr-radiopharma-clinical-trial-mnpr-20240227monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-promising-preclinical-data-for-its-mnpr-101-radiopharma-program-targetin-mnpr-20240222monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-receives-clearance-to-proceed-with-first-in-human-phase-1-trial-of-novel-radiophar-mnpr-20240220monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-reports-third-quarter-2023-financial-results-and-recent-developments-mnpr-20231109monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-presents-data-showing-tumor-reduction-benefit-of-camsirubicin-from-ongoing-phase-1-mnpr-20231101monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference-mnpr-20231010monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference-mnpr-20230905monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-reports-second-quarter-2023-financial-results-and-recent-developments-mnpr-20230810monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-provides-encouraging-camsirubicin-clinical-data-update-mnpr-20230808monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-mnpr-101-radiopharma-collaboration-agreement-with-national-university-of-mnpr-20230711monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023-mnpr-20230621monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-to-participate-in-the-maxim-group-s-healthcare-virtual-conference-mnpr-20230614monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-to-present-at-the-jefferies-radiopharma-innovation-summit-mnpr-20230328monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-to-present-at-the-35th-annual-roth-conference-mnpr-20230307monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202-mnpr-20221027monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-presentation-selected-for-2022-american-society-of-hematology-ash-64th-a-mnpr-20221019monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-presentation-selected-for-2022-connective-tissue-oncology-society-ctos-a-mnpr-20221012monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-to-present-at-roth-inaugural-healthcare-opportunities-conference-mnpr-20220928monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-to-present-at-the-34th-annual-roth-conference-and-maxim-s-2022-virtual-growth-conf-mnpr-20220308monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-to-present-at-the-h-c-wainwright-bioconnect-conference-mnpr-20220107monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september-mnpr-20210909monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-new-drug-candidate-mnpr-202-and-enters-into-collaboration-agreement-with-mnpr-20210603monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-and-northstar-announce-filing-of-composition-of-matter-patent-protecting-mnpr-101--mnpr-20210526monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-and-northstar-announce-patent-filing-on-promising-radiopharmaceutical-discovery-mnpr-20210524monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-reports-first-quarter-2021-financial-results-and-recent-business-upda-mnpr-20210513monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-s-upa-antibody-fragment-radiotracer-shows-potential-for-pet-imaging-of-breast-canc-mnpr-20210330monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-recen-mnpr-20210325monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-partners-with-seasoned-medtech-executive-to-explore-the-potential-of-mnpr-101-as-a-mnpr-20210302monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-to-present-at-upcoming-investor-conferences-mnpr-20210224monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-expands-clinical-team-with-appointment-of-laura-kelly-as-director-of-clinical-oper-mnpr-20210218monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-first-patient-dosed-in-its-phase-2b-3-voice-trial-evaluating-validive-fo-mnpr-20210216monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-publication-demonstrating-potential-utility-of-mnpr-101-as-an-imaging-ag-mnpr-20210211monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-issuance-of-patent-covering-composition-of-matter-for-mnpr-101-in-canada-mnpr-20210209monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-issuance-of-u-s-patent-covering-compositions-of-matter-for-a-novel-famil-mnpr-20201222monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-and-northstar-announce-selection-of-uprit-candidate-for-potential-treatment-of-sev-mnpr-20201210monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-initiation-of-its-phase-2b-3-voice-trial-to-evaluate-validive-for-the-pr-mnpr-20201208monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-reports-third-quarter-2020-financial-results-and-business-update-mnpr-20201112monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-issuance-of-new-patents-broadening-protections-for-phase-2b-3-clinical-s-mnpr-20201109monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-to-present-at-the-h-c-wainwright-22nd-annual-global-investment-confer-mnpr-20200914monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-and-northstar-collaborating-with-texas-lung-injury-institute-for-testing-of-novel--mnpr-20200909monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-and-northstar-partner-with-aragen-for-testing-of-novel-potential-therapeutic-for-s-mnpr-20200819monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-announces-plan-to-advance-development-of-novel-triage-test-for-severe-covid-19-uti-mnpr-20200812monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-and-northstar-partner-with-isotherapeutics-for-the-manufacturing-of-potential-ther-mnpr-20200810monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-reports-second-quarter-2020-financial-results-and-business-updates-mnpr-20200806monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-and-northstar-announce-filing-of-provisional-patent-protecting-development-and-use-mnpr-20200630monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-and-northstar-join-forces-to-develop-radio-immuno-therapeutics-rits-targeting-seve-mnpr-20200616monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-reports-first-quarter-2020-financial-results-and-business-updates-mnpr-20200507monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and-busin-mnpr-20200327monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-receives-orphan-drug-designation-from-the-european-commission-for-cam-mnpr-20200218monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-inc-announces-closing-of-initial-public-offering-of-common-stock-mnpr-20191223monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-inc-announces-full-exercise-of-over-allotment-by-underwriters-mnpr-20191220monthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-inc-announces-pricing-of-initial-public-offering-mnpr-20191219monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-deadline-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsui-ocgn-20240608monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-portnoy-law-fir-ocgn-20240607monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-june-10-20-ocgn-20240513monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed--ocgn-20240412monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-alert-bragar-eagel-squire-p-c-is-investigating-ocugen-inc-on-behalf-of-ocugen-stock-ocgn-20240403monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-ocgn-20210817monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-ocgn-20210812monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-ocgn-20210727monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-ocgn-20210701monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-investors-company-investigated-by-the-portnoy-law-firm-ocgn-20210611monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-present-during-the-jefferies-2025-global-healthcare-conference-asmb-20250527monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-presents-new-data-highlighting-long-acting-herpes-simplex-virus-candi-asmb-20250409monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-year-end-2024-financial-results-and-recent-highlights-asmb-20250320monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-doses-first-participant-in-phase-1a-clinical-study-of-oral-entry-inhi-asmb-20250226monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-30-1-million-equity-investment-and-accelerated-funding-from-asmb-20241219monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-presents-new-preclinical-data-highlighting-investigational-helicase-p-asmb-20240715monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-doses-first-participant-in-phase-1b-clinical-trial-evaluating-next-ge-asmb-20240618monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-doses-first-participant-in-phase-1a-b-clinical-trial-of-herpes-simple-asmb-20240610monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-presents-new-data-highlighting-hepatitis-d-virus-entry-inhibitor-abi--asmb-20240605monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-present-data-at-upcoming-international-herpesvirus-workshop-and-ea-asmb-20240522monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-effective-date-of-reverse-stock-split-asmb-20240208monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-provides-anticipated-development-milestones-for-2024-asmb-20240104monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-asmb-20231110monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-presents-new-data-highlighting-viral-hepatitis-portfolio-at-aasld-the-asmb-20231110monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-names-anuj-gaggar-md-phd-as-chief-medical-officer-asmb-20231108monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-present-new-data-at-aasld-the-liver-meeting-asmb-20231011monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-nominates-development-candidate-abi-6250-an-orally-bioavailable-hdv-e-asmb-20231002monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-highlight-pipeline-progress-in-hbv-and-hdv-at-the-2023-internation-asmb-20230919monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-presents-new-data-highlighting-herpes-simplex-virus-development-candi-asmb-20230717monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-presents-new-data-highlighting-entry-inhibitor-and-core-inhibitor-pro-asmb-20230621monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-present-data-at-upcoming-international-herpesvirus-workshop-and-ea-asmb-20230607monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-present-during-the-2023-jefferies-healthcare-conference-asmb-20230523monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-doses-first-subject-in-phase-1a-clinical-trial-to-evaluate-safety-tol-asmb-20221114monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-presents-new-data-at-aasld-the-liver-meeting-highlighting-breadth-of--asmb-20221104monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-present-data-in-four-poster-presentations-at-upcoming-aasld-the-li-asmb-20221024monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-host-webcast-on-august-31-2022-introducing-two-new-research-progra-asmb-20220824monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-presents-new-data-highlighting-clinical-progress-of-core-inhibitor-pr-asmb-20220622monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-highlight-data-from-hbv-core-inhibitor-programs-at-easl-s-internat-asmb-20220608monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-initiates-phase-1b-clinical-trial-evaluating-next-generation-core-inh-asmb-20220606monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-asmb-20220603monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-asmb-20220401monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-highlight-new-research-program-for-hbv-hdv-entry-inhibition-in-web-asmb-20220321monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-present-during-the-svb-leerink-11th-annual-global-healthcare-confe-asmb-20220209monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asmb-20220107monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-presentation-during-the-2022-h-c-wainwright-bioconnect-virt-asmb-20220106monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asmb-20211203monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-presents-new-data-at-aasld-the-liver-meeting-highlighting-the-progres-asmb-20211112monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-abstracts-selected-for-presentation-at-the-upcoming-aasld-the-liver-m-asmb-20211101monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-bio-announces-october-conference-participation-asmb-20211006monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asmb-20211001monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-bio-selects-fourth-hbv-core-inhibitor-candidate-for-advancement-into-clinical-dev-asmb-20210818monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-bio-announces-key-promotions-to-leadership-team-asmb-20210803monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asmb-20210702monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-presents-data-from-hbv-core-inhibitor-programs-at-the-international-l-asmb-20210623monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-present-data-from-hbv-core-inhibitor-programs-at-the-international-asmb-20210609monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asmb-20210604monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asmb-20210507monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asmb-20210305monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-updates-pipeline-strategy-focusing-on-finite-and-curative-therapies-f-asmb-20210225monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-bio-announces-upcoming-investor-events-asmb-20210219monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asmb-20210205monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asmb-20201204monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-appoints-nicole-s-white-phd-as-senior-vice-president-of-pharmaceutica-asmb-20201117monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-presents-data-from-hbv-core-inhibitor-programs-in-poster-sessions-at--asmb-20201113monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-asmb-20201106monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-provides-update-on-the-ongoing-phase-2-extension-study-of-vebicorvir--asmb-20201105monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-ceo-dr-john-mchutchison-named-recipient-of-the-prestigious-advance-20-asmb-20201015monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-october-conference-participation-asmb-20201005monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asmb-20201002monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asmb-20200904monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-and-arbutus-biopharma-announce-clinical-collaboration-agreement-to-ev-asmb-20200827monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asmb-20200807monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-fda-fast-track-designation-granted-to-abi-h2158-for-the-tre-asmb-20200709monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asmb-20200702monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-initiates-phase-2-trial-evaluating-second-generation-core-inhibitor-a-asmb-20200625monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-regains-worldwide-rights-to-microbiome-gastrointestinal-development-p-asmb-20200618monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asmb-20200601monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-management-transition-asmb-20200527monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-present-during-the-jefferies-virtual-healthcare-conference-asmb-20200526monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-move-to-virtual-only-annual-meeting-of-stockholders-on-june-asmb-20200519monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-asmb-20200501monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-host-conference-call-and-webcast-to-review-hbv-portfolio-progress-asmb-20200430monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-asmb-20200331monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-appoints-jason-okazaki-as-chief-legal-and-business-officer-asmb-20200330monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-present-at-the-9th-annual-svb-leerink-global-healthcare-conference-asmb-20200219monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-the-closing-of-its-public-offering-of-common-stock-and-full-asmb-20191216monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-pricing-of-125-million-public-offering-asmb-20191212monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-plenary-lecture-at-hep-dart-2019-asmb-20191206monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-presentation-at-jefferies-london-healthcare-conference-asmb-20191118monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-asmb-20191107monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-appoints-luisa-stamm-md-phd-as-chief-medical-officer-asmb-20191107monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-asmb-20191028monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-appoints-thomas-j-russo-as-chief-financial-officer-asmb-20191028monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asmb-20190809monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-appointment-of-john-mchutchison-ao-md-as-president-and-chie-asmb-20190807monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-first-patient-dosed-with-abi-m201-in-phase-1b-clinical-tria-asmb-20190627monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-participation-in-the-microbiome-movement-drug-development-s-asmb-20190625monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-presentation-at-international-association-for-the-study-of--asmb-20190621monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-presents-interim-data-from-two-phase-2a-studies-of-abi-h0731-in-hbv-i-asmb-20190413monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-presents-data-highlighting-next-generation-hbv-core-protein-inhibitor-asmb-20190411monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-multiple-abstracts-highlighting-hbv-core-inhibitor-portfoli-asmb-20190327monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-participate-in-the-jefferies-2019-hbv-summit-asmb-20190313monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-completion-of-enrollment-in-two-phase-2a-studies-with-abi-h-asmb-20190107monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-presents-final-results-of-phase-1b-study-of-abi-h0731-at-2018-aasld-asmb-20181112monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-november-conference-participation-asmb-20181031monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-oral-presentation-at-2018-aasld-asmb-20181002monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-present-at-upcoming-investor-conferences-asmb-20180828monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-fda-fast-track-designation-granted-to-abi-h0731-for-the-tre-asmb-20180725monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-the-closing-of-its-offering-of-common-stock-and-full-exerci-asmb-20180716monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-pricing-of-144-million-offering-of-common-stock-asmb-20180711monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-host-research-and-development-day-on-wednesday-june-20-2018-asmb-20180613monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asmb-20180608monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-participate-in-jefferies-2018-global-healthcare-conference-asmb-20180604monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-presents-positive-interim-data-from-phase-1a-and-1b-studies-of-abi-h0-asmb-20180412monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-host-conference-call-on-april-12-to-review-abi-h0731-interim-phase-asmb-20180410monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-appoints-jackie-papkoff-phd-senior-vice-president-chief-scientific-of-asmb-20180402monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-abi-h0731-phase-1b-interim-data-accepted-as-a-late-breaker--asmb-20180328monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-present-at-cowen-s-38th-annual-healthcare-conference-asmb-20180305monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-participate-in-leerink-partners-7th-annual-global-healthcare-confe-asmb-20180205monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asmb-20180202monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-present-at-the-j-p-morgan-healthcare-conference-asmb-20180104monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asmb-20171208monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-present-at-the-jefferies-london-healthcare-conference-asmb-20171108monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-pricing-of-60-million-offering-of-common-stock-asmb-20171102monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asmb-20171005monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-2017-aasld-presentations-asmb-20171002monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-september-conference-participation-asmb-20170831monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-asmb-20170728monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-june-conference-presentations-asmb-20170526monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-the-closing-and-early-termination-of-hart-scott-rodino-wait-asmb-20170221monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-successful-completion-of-abi-h0731-phase-1a-trial-and-upcom-asmb-20170216monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-present-data-on-abi-h0731-at-aasld-2016-liver-meeting-asmb-20161111monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-initiates-phase-1-clinical-program-of-abi-h0731-for-treatment-of-chro-asmb-20161109monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-key-additions-to-microbiome-team-asmb-20160928monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-participation-in-hbv-scientific-meetings-in-china-and-south-asmb-20160921monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-present-at-the-jefferies-2016-global-healthcare-conference-asmb-20160601monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-present-data-at-the-international-liver-congress-tm-2016-that-supp-asmb-20160413monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-present-data-on-new-series-of-hbv-core-protein-allosteric-modifier-asmb-20160330monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-webcast-upcoming-investor-conferences-asmb-20160219monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-presents-clinical-data-at-drug-formulation-bioavailability-summit-sho-asmb-20160127monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-expands-senior-leadership-team-asmb-20160111monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-present-at-jefferies-microbiome-summit-asmb-20151216monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-describe-improved-methods-for-hbv-drug-development-at-major-intern-asmb-20151006monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-announces-pricing-of-75-million-public-offering-of-its-common-stock-asmb-20150319monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-present-at-2015-rbc-capital-markets-healthcare-conference-asmb-20150220monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-to-present-at-investor-conferences-asmb-20141203monthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-provides-update-on-status-of-ven-307-asmb-20140725monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-to-present-phase-1-2-safety-and-translational-data-for-ronde-cel-in-lar-lyel-20260604monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-announces-participation-in-goldman-sachs-47th-annual-global-healthcare--lyel-20260601monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-to-participate-in-the-goldman-sachs-global-healthcare-conference-lyel-20250604monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-announces-oral-presentation-of-new-clinical-data-from-the-phase-1-2-tri-lyel-20250501monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-receives-regenerative-medicine-advanced-therapy-rmat-designation-for-ly-lyel-20250415monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-announces-participation-in-upcoming-investor-conferences-lyel-20250218monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-to-highlight-vision-for-its-next-generation-car-t-cell-therapy-pipeline-at-43rd-annu-lyel-20250109monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-announces-presentation-of-initial-clinical-data-from-the-phase-1-2-clinical-trial-of-lyel-20241105monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-announces-the-acceptance-abstracts-for-presentation-at-2024-society-for-lyel-20241004monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-announces-participation-in-goldman-sachs-cell-therapy-day-lyel-20240924monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-announces-participation-in-september-investor-conferences-lyel-20240828monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-to-participate-in-the-goldman-sachs-global-healthcare-conference-lyel-20240603monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-to-participate-in-bofa-securities-health-care-conference-lyel-20240507monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-announces-the-acceptance-of-three-abstracts-for-presentation-at-2024-aa-lyel-20240305monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-announces-participation-in-march-investor-conferences-lyel-20240226monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-to-participate-in-42nd-annual-j-p-morgan-healthcare-conference-lyel-20240103monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-receives-fda-orphan-drug-designation-for-lyl845-for-the-treatment-of-me-lyel-20231109monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-presentations-at-sitc-highlight-new-nonclinical-data-on-product-candida-lyel-20231031monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-announces-the-acceptance-of-six-abstracts-for-presentation-at-2023-soci-lyel-20230927monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-to-participate-in-upcoming-investor-conferences-lyel-20230831monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-appoints-matthew-lang-as-chief-business-officer-lyel-20230705monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-to-participate-in-the-goldman-sachs-global-healthcare-conference-lyel-20230607monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-to-participate-in-bofa-securities-healthcare-conference-lyel-20230502monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-to-participate-in-41st-annual-j-p-morgan-healthcare-conference-lyel-20230103monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-to-participate-in-bofa-securities-biotech-conference-lyel-20221201monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-to-participate-in-barclays-virtual-fireside-chat-series-lyel-20221110monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-presents-new-data-at-sitc-highlighting-its-growing-pipeline-of-t-cell-r-lyel-20221107monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-to-participate-in-credit-suisse-healthcare-conference-lyel-20221102monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-to-present-preclinical-data-highlighting-new-t-cell-reprogramming-techn-lyel-20221005monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-announces-the-appointment-of-rahsaan-thompson-as-chief-legal-officer-lyel-20220928monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-presents-first-in-human-trial-design-of-lyl797-at-esmo-2022-lyel-20220912monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-to-participate-in-morgan-stanley-global-healthcare-conference-lyel-20220830monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-to-participate-in-goldman-sachs-global-healthcare-conference-lyel-20220607monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-to-participate-in-bofa-securities-healthcare-conference-lyel-20220504monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-to-present-preclinical-data-for-two-product-candidates-in-clinical-deve-lyel-20220502monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-announces-upcoming-presentation-on-lyl797-at-the-american-association-f-lyel-20220308monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-appoints-gary-lee-ph-d-as-chief-scientific-officer-lyel-20220131monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-announces-fda-clearance-of-ind-for-lyl132-a-t-cell-receptor-therapy-for-lyel-20220124monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-to-participate-in-40th-annual-j-p-morgan-healthcare-conference-lyel-20220104monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-announces-fda-clearance-of-its-ind-for-lyl797-a-car-t-cell-therapy-inco-lyel-20211216monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-announces-return-of-dr-rick-klausner-as-board-chair-lyel-20211202monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-to-participate-in-morgan-stanley-global-healthcare-conference-lyel-20210908monthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-announces-pricing-of-initial-public-offering-lyel-20210617monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-inc-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-mo-fulc-20260602monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20260508monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20260306monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20260206monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20260109monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-proposed-150-0-million-public-offering-of-common-stock-fulc-20251208monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-positive-initial-results-from-the-20-mg-dose-cohort-of-the--fulc-20251206monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20251205monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20251010monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20250912monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20250808monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-results-from-the-12-mg-dose-cohort-of-the-phase-1b-pioneer--fulc-20250729monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-present-results-from-the-12-mg-dose-cohort-of-the-phase-1b-pioneer-fulc-20250728monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20250711monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20250606monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-present-at-upcoming-medical-meetings-fulc-20250529monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-in-the-46th-annual-goldman-sachs-global-healthcare-con-fulc-20250529monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20250509monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-in-upcoming-may-conferences-fulc-20250508monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-first-quarter-2025-financial-results-conference-call-and-webc-fulc-20250424monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20250411monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-in-the-leerink-partners-global-healthcare-conference-fulc-20250304monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-fourth-quarter-and-full-year-2024-financial-results-conferenc-fulc-20250218monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20250207monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-science-fulc-20250206monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-in-upcoming-december-conferences-fulc-20241126monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-in-the-stifel-healthcare-conference-fulc-20241112monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-third-quarter-2024-financial-results-conference-call-and-webc-fulc-20241106monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20241011monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20240913monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-in-upcoming-september-conferences-fulc-20240827monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20240823monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-strengthens-leadership-team-with-the-appointments-of-isabel-kalofonos-fulc-20240819monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20240809monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-second-quarter-2024-financial-results-conference-call-and-web-fulc-20240724monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-present-at-the-31st-annual-fshd-society-international-research-con-fulc-20240612monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-in-the-goldman-sachs-45th-annual-global-healthcare-con-fulc-20240606monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-enters-into-a-collaboration-and-license-agreement-with-sanofi-for-the-fulc-20240513monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-in-upcoming-may-conferences-fulc-20240509monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-publication-of-results-from-phase-2b-clinical-trial-of-losm-fulc-20240508monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-first-quarter-2024-financial-results-conference-call-and-webc-fulc-20240506monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-at-the-cantor-virtual-muscular-dystrophy-symposium-fulc-20240328monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20240322monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-appoints-patrick-horn-m-d-ph-d-as-chief-medical-officer-fulc-20240318monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20240308monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-at-the-leerink-partners-global-biopharma-conference-fulc-20240305monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-fourth-quarter-and-full-year-2023-financial-results-conferenc-fulc-20240220monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-at-the-oppenheimer-34th-annual-healthcare-life-science-fulc-20240206monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20231207monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20231110monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-at-upcoming-november-investor-conferences-fulc-20231109monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-third-quarter-2023-financial-results-conference-call-and-webc-fulc-20231031monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-at-the-cantor-fitzgerald-global-healthcare-conference-fulc-20230922monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20230915monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-announces-completion-of-enrollment-in-the-phase-3-reach-clinical-trial-of-losmapim-fulc-20230907monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20230811monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-appoints-chief-financial-officer-fulc-20230803monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-second-quarter-2023-financial-results-conference-call-and-web-fulc-20230727monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-signs-exclusive-global-license-agreement-in-rare-hematology-fulc-20230710monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20230707monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-inc-please-contact-the-portnoy-law-firm-to-recover-your-losses-june-2-fulc-20230622monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-inc-nasdaq-fulc-shareholder-class-action-alert-bernstein-liebhard-llp-fulc-20230621monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-inc-nasdaq-fulc-shareholder-class-action-alert-bernstein-liebhard-llp-fulc-20230613monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-inc-fulc-class-action-robbins-llp-reminds-investors-of-lead-plaintiff-fulc-20230612monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20230609monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-inc-nasdaq-fulc-shareholder-class-action-alert-bernstein-liebhard-llp-fulc-20230605monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-inc-fulc-equity-alert-contact-robbins-llp-to-learn-about-the-fulcrum--fulc-20230523monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-inc-nasdaq-fulc-shareholder-class-action-alert-bernstein-liebhard-llp-fulc-20230522monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-inc-fulc-class-action-alert-robbins-llp-urges-investors-to-contact-th-fulc-20230515monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-appoints-alex-c-sapir-chief-executive-officer-fulc-20230515monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-first-quarter-2023-financial-results-conference-call-and-webc-fulc-20230508monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-inc-nasdaq-fulc-shareholder-class-action-alert-bernstein-liebhard-llp-fulc-20230508monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20230505monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-inc-nasdaq-fulc-shareholder-class-action-alert-bernstein-liebhard-llp-fulc-20230503monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-inc-fulc-shareholder-notice-robbins-llp-reminds-investors-of-class-ac-fulc-20230502monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-inc-fulc-class-action-lawsuit-filed-by-holzer-holzer-llc-on-behalf-of-fulc-20230501monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20230407monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-cfo-resignation-fulc-20230405monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20230310monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-fourth-quarter-and-full-year-2022-financial-results-conferenc-fulc-20230306monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-clinical-hold-on-ftx-6058-in-sickle-cell-disease-fulc-20230224monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20230210monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-at-the-upcoming-svb-securities-global-biopharma-confer-fulc-20230208monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20230113monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-ceo-transition-fulc-20230104monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20221205monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-at-upcoming-2022-bofa-securities-biotech-smid-cap-conf-fulc-20221201monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20221111monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-appoints-chief-medical-officer-and-chief-scientific-officer-fulc-20221107monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-third-quarter-2022-financial-results-conference-call-and-webc-fulc-20221102monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-at-upcoming-november-investor-conferences-fulc-20221101monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-present-new-data-from-the-open-label-extension-of-phase-2-redux4-s-fulc-20221012monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20221007monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20220909monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-at-upcoming-september-investor-conferences-fulc-20220906monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-at-the-upcoming-stifel-2022-biotech-summer-summit-fulc-20220816monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-pricing-of-public-offering-of-common-stock-fulc-20220816monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-second-quarter-2022-financial-results-conference-call-and-web-fulc-20220804monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20220802monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20220715monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-departure-of-chief-medical-officer-fulc-20220711monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-enrolls-first-patient-in-pivotal-global-phase-3-clinical-trial-of-los-fulc-20220705monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20220610monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-proof-of-concept-for-ftx-6058-in-sickle-cell-disease-based--fulc-20220610monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-present-initial-data-from-phase-1b-trial-of-ftx-6058-in-adults-liv-fulc-20220512monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20220506monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-at-the-upcoming-bofa-securities-2022-healthcare-confer-fulc-20220505monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-first-quarter-2022-financial-results-conference-call-and-webc-fulc-20220502monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20220408monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-multiple-presentations-on-fshd-at-the-american-academy-of-n-fulc-20220401monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-webcast-featuring-losmapimod-for-f-fulc-20220317monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-presents-data-highlighting-reachable-workspace-rws-as-relevant-functi-fulc-20220314monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20220311monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-reach-a-phase-3-clinical-trial-of-losmapimod-in-facioscapul-fulc-20220303monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-fourth-quarter-and-full-year-2021-financial-results-conferenc-fulc-20220224monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20220211monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-in-11th-annual-svb-leerink-global-healthcare-conferenc-fulc-20220210monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fulc-20220107monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-fulc-20220106monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-additional-hbg-mrna-induction-from-higher-dose-cohorts-in-p-fulc-20211206monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-in-upcoming-november-investor-conferences-fulc-20211103monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-third-quarter-2021-financial-results-conference-call-and-webc-fulc-20211028monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-fulc-20211001monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-multiple-presentations-during-the-virtual-congress-of-the-w-fulc-20210920monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-fulc-20210910monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-appoints-mel-hayes-as-chief-commercial-officer-fulc-20210908monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-fulc-20210902monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercis-fulc-20210816monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-proposed-public-offering-of-common-stock-fulc-20210810monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-positive-interim-results-from-phase-1-healthy-adult-volunte-fulc-20210810monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-second-quarter-2021-financial-results-conference-call-and-web-fulc-20210804monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-results-from-redux4-trial-with-losmapimod-in-facioscapulohu-fulc-20210624monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-multiple-presentations-at-the-28th-annual-fshd-society-inte-fulc-20210621monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-u-s-food-and-drug-administration-grants-fast-track-designat-fulc-20210512monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-present-at-the-bofa-securities-2021-virtual-health-care-conference-fulc-20210507monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-appoints-christopher-morabito-m-d-as-chief-medical-officer-fulc-20210506monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-first-quarter-2021-financial-results-conference-call-and-webc-fulc-20210429monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-presents-published-structure-of-investigational-small-molecule-ftx-60-fulc-20210409monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-presents-data-for-potential-fshd-biomarker-and-clinical-outcome-asses-fulc-20210318monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-ceo-transition-fulc-20210304monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-recognizes-rare-disease-day-2021-fulc-20210226monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-fourth-quarter-and-full-year-2020-financial-results-conferenc-fulc-20210226monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-fulc-20210219monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercis-fulc-20210122monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-proposed-public-offering-of-common-stock-fulc-20210119monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-promotion-of-christopher-moxham-ph-d-to-chief-scientific-of-fulc-20210119monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-in-the-h-c-wainwright-bioconnect-2021-conference-fulc-20210106monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-virtual-key-opinion-leader-event-featuring-ftx-6058-for-sickl-fulc-20201209monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-presents-updated-data-on-sickle-cell-disease-program-at-the-62nd-amer-fulc-20201205monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-fulc-20201113monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-multiple-presentations-during-the-62nd-american-society-of--fulc-20201104monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-third-quarter-2020-financial-results-conference-call-and-webc-fulc-20201103monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-initiate-phase-1-trial-with-ftx-6058-for-sickle-cell-disease-fulc-20201005monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-multiple-presentations-during-the-virtual-25th-internationa-fulc-20201001monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-preclinical-proof-of-concept-data-for-ftx-6058-at-the-virtu-fulc-20200925monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-fulc-20200908monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-interim-analysis-data-from-its-redux4-trial-in-facioscapulo-fulc-20200811monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-fulc-20200806monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-second-quarter-2020-financial-results-conference-call-and-web-fulc-20200805monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-initiation-of-multi-center-phase-3-losvid-trial-with-losmap-fulc-20200624monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-completes-68-5-million-private-placement-fulc-20200610monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-multiple-presentations-at-the-2020-american-academy-of-neur-fulc-20200521monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-present-at-the-bofa-securities-2020-health-care-conference-fulc-20200511monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-first-quarter-2020-financial-results-conference-call-and-webc-fulc-20200507monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-completion-of-ind-enabling-safety-studies-for-ftx-6058-in-s-fulc-20200413monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-provides-business-update-on-impact-of-covid-19-fulc-20200402monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-complete-data-from-phase-1-trial-with-losmapimod-in-faciosc-fulc-20200324monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-joins-in-effort-to-reframe-rare-to-commemorate-rare-disease-day-2020-fulc-20200228monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-completion-of-enrollment-in-phase-2b-trial-of-losmapimod-fo-fulc-20200226monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-fourth-quarter-and-full-year-2019-financial-results-conferenc-fulc-20200225monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-fulc-20200220monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-receives-orphan-drug-designation-for-losmapimod-in-facioscapulohumera-fulc-20200129monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-present-at-the-31st-annual-piper-jaffray-healthcare-conference-fulc-20191202monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-present-at-the-stifel-2019-healthcare-conference-fulc-20191113monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-report-third-quarter-2019-financial-results-on-thursday-november-1-fulc-20191106monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-host-key-opinion-leader-breakfast-symposium-on-facioscapulohumeral-fulc-20191031monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-multiple-presentations-of-losmapimod-data-at-world-muscle-s-fulc-20191001monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-appoints-pamela-strode-seasoned-industry-executive-to-lead-regulatory-fulc-20190904monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-present-at-the-morgan-stanley-17th-annual-global-healthcare-confer-fulc-20190903monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-initiation-of-redux4-a-phase-2b-clinical-trial-of-losmapimo-fulc-20190819monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-to-present-at-the-svb-leerink-spotlight-series-rare-genetic-diseases--fulc-20190801monthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-announces-pricing-of-initial-public-offering-fulc-20190718monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-record-top-and-bottom-line-2025-financial-results-and-affirms-2026-guidance-kmda-20260311monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-record-top-and-bottom-line-2024-financial-results-and-affirms-2025-guidance-kmda-20250305monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-issues-2024-ceo-letter-to-shareholders-kmda-20240306monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-kedrion-exercised-its-option-for-two-year-extension-of-kedrab-distributio-kmda-20230712monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-issues-2023-ceo-letter-to-shareholders-kmda-20230315monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-resolution-to-the-labor-strike-at-the-company-s-manufacturing-facility-in-kmda-20220715monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-first-quarter-ended-march-31-2022-financial-results-and-host-conference-kmda-20220511monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-first-quarter-ended-march-31-2021-financial-results-and-host-conference-kmda-20210505monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-files-annual-report-for-the-year-ended-december-31-2020-kmda-20210224monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-third-quarter-ended-september-30-2020-financial-results-and-host-confer-kmda-20201104monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-second-quarter-ended-june-30-2020-financial-results-and-host-conference-kmda-20200805monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-first-quarter-ended-march-31-2020-financial-results-and-host-conference-kmda-20200511monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-files-annual-report-for-the-year-ended-december-31-2019-kmda-20200226monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-enrollment-of-first-patient-into-its-pivotal-phase-3-innovaate-clinical-t-kmda-20191216monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-enters-into-a-binding-term-sheet-for-contract-manufacturing-of-an-fda-approved-comm-kmda-20191209monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-enters-into-partnership-with-alvotech-for-commercialization-of-six-biosimilar-produ-kmda-20191202monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-financial-results-for-third-quarter-and-first-nine-months-of-2019-kmda-20191113monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-report-third-quarter-2019-financial-results-and-host-conference-call-on-november-kmda-20191107monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-and-kedrion-biopharma-announce-publication-of-results-from-the-registration-study-o-kmda-20191029monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-present-corporate-overview-at-the-2019-cantor-global-healthcare-conference-kmda-20190924monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-extension-of-glassia-alpha1-proteinase-inhibitor-human-supply-and-distrib-kmda-20190903monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-discussions-with-takeda-regarding-a-potential-extension-of-the-period-for-t-kmda-20190808monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-financial-results-for-second-quarter-and-first-six-months-of-2019-kmda-20190806monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-report-second-quarter-2019-financial-results-and-host-conference-call-on-august--kmda-20190731monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-financial-results-for-first-quarter-of-2019-kmda-20190514monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-report-first-quarter-2019-financial-results-and-host-conference-call-on-may-14-kmda-20190507monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-fda-acceptance-of-inhaled-aat-program-path-forward-kmda-20190416monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-awarded-the-israeli-outstanding-exporter-award-for-2017-kmda-20190314monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-files-annual-report-for-the-year-ended-december-31-2018-kmda-20190227monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-financial-results-for-fourth-quarter-and-fiscal-year-2018-kmda-20190212monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-additional-interim-results-from-phase-2-proof-of-concept-clinical-trial-o-kmda-20190206monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-fourth-quarter-and-fiscal-year-ended-december-31-2018-financial-results-kmda-20190205monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-appoints-senior-biopharmaceutical-executive-michal-ayalon-ph-d-as-vice-president-of-kmda-20190130monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-preliminary-revenue-for-fourth-quarter-and-full-year-2018-kmda-20190102monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-financial-results-for-third-quarter-and-first-nine-months-of-2018-kmda-20181112monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2018-financial-results-kmda-20181105monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-appointment-of-life-sciences-industry-executive-eitan-kyiet-as-vice-presi-kmda-20181022monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-present-corporate-overview-at-the-cantor-fitzgerald-global-healthcare-conference-kmda-20180925monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-extension-of-collaboration-with-massachusetts-general-hospital-for-a-proo-kmda-20180905monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-provides-updated-full-year-2018-revenue-guidance-kmda-20180829monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-the-end-of-the-labor-strike-in-the-company-s-manufacturing-facility-all-e-kmda-20180816monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-financial-results-for-second-quarter-and-first-six-months-of-2018-kmda-20180807monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-second-quarter-and-six-months-ended-june-30-2018-financial-results-and--kmda-20180801monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-receives-positive-scientific-advice-from-european-medicines-agency-on-a-new-phase-3-kmda-20180710monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-financial-results-for-first-quarter-of-2018-kmda-20180515monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-first-quarter-2018-financial-results-and-host-conference-call-on-may-15-kmda-20180509monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-received-feedback-from-fda-on-proposed-phase-3-protocol-for-inhaled-alpha-1-antitry-kmda-20180423monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-financial-results-for-fourth-quarter-and-full-year-2017-kmda-20180207monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-fiscal-year-2017-financial-results-and-host-conference-call-on-february-kmda-20180202monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-interim-results-from-phase-2-clinical-trial-of-intravenous-alpha-1-antitr-kmda-20180108monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-collaboration-with-a-consortium-of-prominent-hospitals-led-by-the-mount-s-kmda-20180104monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-new-supply-agreement-with-international-organization-for-kamrab-for-post--kmda-20171121monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-and-chiesi-farmaceutici-s-p-a-mutually-agree-to-terminate-european-distribution-agr-kmda-20171120monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-financial-results-for-third-quarter-and-first-nine-months-of-2017-kmda-20171113monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-nomination-of-three-new-members-to-its-board-of-directors-kmda-20171110monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-announce-third-quarter-2017-financial-results-and-host-conference-call-on-novemb-kmda-20171108monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-top-line-results-of-phase-2-trial-of-alpha-1-antitrypsin-in-newly-diagnos-kmda-20171101monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-cfo-transition-kmda-20170918monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-present-corporate-overview-at-two-investor-conferences-in-september-kmda-20170907monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-collaboration-with-bgn-technologies-for-advanced-alpha-1-antitrypsin-rese-kmda-20170906monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-full-exercise-of-underwriters-option-to-purchase-additional-shares-kmda-20170830monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-financial-results-for-second-quarter-and-first-six-months-of-2017-kmda-20170801monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-pricing-of-public-offering-of-ordinary-shares-kmda-20170728monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-pre-announces-certain-preliminary-financial-results-for-second-quarter-and-first-si-kmda-20170727monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-proposed-public-offering-of-ordinary-shares-kmda-20170727monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-host-second-quarter-2017-financial-results-conference-call-on-august-1-kmda-20170727monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-submits-proposed-phase-3-protocol-to-fda-for-inhaled-alpha-1-antitrypsin-for-treatm-kmda-20170720monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-withdrawal-of-european-marketing-authorization-application-for-inhaled-al-kmda-20170622monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-receives-additional-milestone-payment-under-glassia-exclusive-supply-and-distributi-kmda-20170612monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-provides-update-on-clinical-program-for-alpha-1-antitrypsin-iv-for-treatment-of-gra-kmda-20170607monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-appointment-of-michal-stein-m-d-as-vice-president-and-medical-director-kmda-20170605monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-presents-updated-data-from-phase-2-clinical-trial-of-inhaled-alpha-1-antitrypsin-fo-kmda-20170524monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-2017-first-quarter-financial-results-kmda-20170516monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-host-first-quarter-2017-financial-results-conference-call-on-may-16-kmda-20170508monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-host-r-d-day-focused-on-graft-versus-host-disease-gvhd-kmda-20170302monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-collaboration-with-massachusetts-general-hospital-for-proof-of-concept-st-kmda-20170221monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-appointment-of-biopharmaceutical-industry-veteran-gwen-melincoff-to-its-b-kmda-20170208monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-financial-results-for-the-fourth-quarter-and-full-year-2016-kmda-20170206monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-host-fiscal-year-2016-financial-results-conference-call-on-february-6-kmda-20170201monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-positive-scientific-advice-response-from-the-european-medicines-agency-fo-kmda-20170123monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-collaboration-agreement-with-yissum-for-development-of-a-recombinant-huma-kmda-20161115monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-financial-results-for-the-third-quarter-and-nine-months-of-2016-kmda-20161110monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-host-third-quarter-financial-results-conference-call-on-november-10-2016-at-8-30-kmda-20161103monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-plan-for-phase-2-3-clinical-trial-with-alpha-1-antitrypsin-iv-for-treatme-kmda-20161102monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-extension-of-glassia-supply-and-distribution-agreement-with-shire-with-mi-kmda-20161006monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-present-a-corporate-overview-at-the-rodman-renshaw-18th-annual-investment-confer-kmda-20160909monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-and-kedrion-seek-fda-approval-of-human-rabies-immunoglobulin-as-a-post-exposure-tre-kmda-20160901monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-meets-primary-endpoint-of-u-s-phase-2-study-of-inhaled-alpha-1-antitrypsin-for-the--kmda-20160830monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-financial-results-for-the-second-quarter-and-first-six-months-of-2016-kmda-20160802monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-host-second-quarter-financial-results-conference-call-on-august-2-2016-at-8-30-a-kmda-20160726monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-appointment-of-naveh-tov-m-d-ph-d-to-vice-president-clinical-development--kmda-20160623monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-s-alpha-1-antitrypsin-now-available-to-treat-graft-versus-host-disease-on-mytomorro-kmda-20160525monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-ltd-kmda-to-ring-the-nasdaq-stock-market-opening-bell-kmda-20140224monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-to-present-at-the-piper-jaffray-20th-annual-unplugged-health-care-conference-kmda-20081125monthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-signs-an-additional-long-term-supply-agreement-for-raw-material-to-manufacture-alph-kmda-20081110monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-announces-research-collaboration-to-explore-targeted-cardiac-delivery-o-lxeo-20260108monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascu-lxeo-20251204monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-to-present-new-cmc-data-at-the-28th-american-society-of-gene-cell-thera-lxeo-20250501monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-announces-positive-interim-phase-1-2-data-for-lx2006-in-friedreich-atax-lxeo-20250407monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-lxeo-20250107monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-appoints-kyle-rasbach-as-chief-financial-officer-lxeo-20241219monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-to-present-new-interim-data-from-phase-1-2-trial-of-lx1001-at-the-clini-lxeo-20241022monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-to-participate-in-upcoming-investor-conferences-lxeo-20240905monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-announces-investor-webcast-to-report-interim-phase-1-2-clinical-data-of-lxeo-20240711monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-to-participate-in-upcoming-investor-conferences-lxeo-20240507monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-announces-closing-of-oversubscribed-95-0-million-equity-financing-lxeo-20240313monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-announces-oversubscribed-95-0-million-equity-financing-lxeo-20240311monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-lxeo-20240103monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-announces-pricing-of-initial-public-offering-lxeo-20231103monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-announces-strategic-investment-from-sarepta-therapeutics-to-support-dev-lxeo-20230828monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-announces-fda-clearance-of-ind-for-lx2020-an-aav-based-gene-therapy-can-lxeo-20230801monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-announces-completion-of-first-cohort-and-dosing-in-second-cohort-in-sun-lxeo-20230613monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-announces-data-presentations-at-the-26th-american-society-of-gene-cell--lxeo-20230502monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-appoints-micah-zajic-as-chief-financial-officer-and-paula-h-j-cholmonde-lxeo-20230105monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-lxeo-20230103monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-bolsters-cardiac-gene-therapy-leadership-with-new-executive-appointment-lxeo-20221102monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-to-present-clinical-and-preclinical-data-at-upcoming-scientific-confere-lxeo-20221027monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-receives-orphan-drug-designation-for-lx1004-from-european-commission-lxeo-20221018monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-to-present-new-clinical-data-from-its-investigational-gene-therapy-lx10-lxeo-20221005monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-announces-data-presentations-at-the-25th-american-society-of-gene-cell--lxeo-20220503monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-to-participate-in-upcoming-investor-conferences-lxeo-20220321monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-announces-positive-initial-data-from-ongoing-phase-1-2-clinical-trial-o-lxeo-20220302monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-lx2-lxeo-20220216monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-lxeo-20220105monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-and-fujifilm-diosynth-biotechnologies-announce-collaboration-to-support-lxeo-20211013monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-closes-100-million-series-b-financing-to-advance-clinical-stage-gene-th-lxeo-20210909monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-receives-rare-pediatric-disease-designation-and-orphan-drug-designation-lxeo-20210728monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-expands-cardiac-gene-therapy-pipeline-with-acquisition-of-stelios-thera-lxeo-20210721monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-receives-rare-pediatric-disease-designation-and-orphan-drug-designation-lxeo-20210630monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-announces-upcoming-data-presentations-at-the-american-society-of-gene-a-lxeo-20210428monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-announces-fda-fast-track-designation-granted-to-lx1001-for-the-treatmen-lxeo-20210420monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-strengthens-management-team-with-key-appointments-to-accelerate-develop-lxeo-20210406monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clin-lxeo-20210301monthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-launches-with-85-million-series-a-financing-to-develop-gene-therapies-f-lxeo-20210107monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-reports-third-quarter-2021-results-and-provides-business-update-eols-20211102monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-reports-second-quarter-2021-results-and-provides-business-update-eols-20210804monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-reports-first-quarter-2021-results-and-provides-business-update-eols-20210512monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-announces-pricing-of-public-offering-of-common-stock-eols-20210422monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-announces-proposed-public-offering-of-common-stock-eols-20210421monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-reports-fourth-quarter-and-full-year-2020-results-and-provides-business-update-eols-20210324monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-strengthens-balance-sheet-through-a-25-5-million-cash-infusion-and-elimination-of-1-eols-20210323monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-reports-third-quarter-2020-results-and-provides-business-update-eols-20201029monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-reports-second-quarter-2020-results-and-provides-business-update-eols-20200810monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-announces-pricing-of-public-offering-of-common-stock-eols-20191107monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-announces-proposed-public-offering-of-common-stock-eols-20191106monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-reports-third-quarter-2019-financial-results-and-provides-business-update-eols-20191104monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-reports-fourth-quarter-and-full-year-2018-results-eols-20190318monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-inc-announces-full-exercise-and-closing-of-underwriters-overallotment-option-eols-20180815monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-inc-announces-pricing-of-public-offering-of-common-stock-eols-20180719monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-inc-announces-proposed-public-offering-of-common-stock-eols-20180716monthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-reports-fourth-quarter-and-full-year-2017-financial-results-eols-20180329monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-releases-third-quarter-2026-financial-results-and-provides-operational-u-bntc-20260514monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-to-host-industry-forum-breakfast-event-at-the-2026-muscular-dystrophy-as-bntc-20260310monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-provides-positive-long-term-clinical-study-results-for-bb-301-phase-1b-2-bntc-20260111monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-to-participate-in-upcoming-conferences-in-march-bntc-20250226monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-announces-acceptance-of-late-breaking-oral-abstract-for-the-bb-301-phase-bntc-20250214monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-to-participate-in-upcoming-conferences-in-january-and-february-bntc-20250127monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-to-participate-in-upcoming-investor-conferences-in-december-bntc-20241126monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-ceo-to-participate-in-the-guggenheim-securities-healthcare-conference-bntc-20241104monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-announces-updated-investor-webcast-information-bntc-20241014monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-announces-late-breaking-oral-abstract-presentation-on-bb-301-phase-1b-2a-bntc-20240918monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-ceo-to-participate-in-opmd-awareness-day-webinar-bntc-20240917monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-to-participate-in-the-citizens-jmp-life-science-conference-bntc-20240501monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-to-host-virtual-r-d-day-to-discuss-bb-301-clinical-program-in-oculophary-bntc-20240409monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-to-participate-in-a-fireside-chat-at-the-35th-annual-piper-sandler-healt-bntc-20231117monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-inc-announces-closing-of-30-million-underwritten-public-offering-bntc-20230811monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-to-present-at-the-opmd-international-conference-bntc-20230508monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-to-present-at-the-jmp-securities-life-sciences-conference-bntc-20230508monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-inc-announces-closing-of-18-million-underwritten-public-offering-bntc-20220916monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-limited-nasdaq-bntc-to-ring-the-nasdaq-stock-market-opening-bell-bntc-20150924monthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-announces-acquisition-of-tacere-therapeutics-and-phase-i-ii-ready-hepatitis-c-hcv--bntc-20121011monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-provides-update-regarding-form-10-k-filing-glsi-20260601monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-announces-addition-of-city-of-hope-to-flamingo-01-glsi-20260319monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-provides-update-on-upcoming-aacr-meeting-glsi-20260318monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-announces-use-of-commercially-manufactured-gp2-in-flamingo-01-glsi-20260316monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-announces-preliminary-analysis-showing-80-recurrence-rate-reduction-glsi-20251215monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-provides-global-update-on-flamingo-01-screening-over-1-000-patients-glsi-20251203monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-announces-positive-immune-response-data-from-flamingo-01-phase-iii--glsi-20250402monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-extends-lock-up-of-directors-and-officers-to-march-31-2026-glsi-20250327monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-provides-update-on-open-label-safety-data-from-flamingo-01-glsi-20250317monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-provides-update-on-open-label-hla-data-from-flamingo-01-glsi-20250210monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-approved-to-add-additional-sites-to-flamingo-01-in-europe-glsi-20250129monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-announces-activation-of-flamingo-01-in-poland-glsi-20250127monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-announces-additions-of-harvard-and-johns-hopkins-to-flamingo-01-glsi-20250123monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-provides-update-on-commercial-manufacturing-glsi-20250122monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-announces-partnership-with-gbg-in-germany-for-flamingo-01-glsi-20250114monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-partners-with-unicancer-expanding-flamingo-01-into-france-glsi-20250113monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-partners-with-gim-in-italy-glsi-20241126monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-provides-update-on-corporate-events-glsi-20241118monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-provides-update-on-expansion-of-flamingo-01-into-spain-glsi-20240801monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-set-to-join-russell-2000-index-again-glsi-20240626monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-announces-2-5-million-private-placement-glsi-20240614monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-extends-lock-up-of-directors-and-officers-to-june-30-2025-glsi-20240313monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-partners-with-geicam-in-spain-conducts-first-site-initiation-visits-glsi-20240312monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-phase-iii-clinical-trial-approved-to-expand-into-five-l-glsi-20240227monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-manufacturing-protocol-accepted-by-european-regulators-glsi-20240222monthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-extends-lock-up-of-directors-and-officers-to-end-of-2024-glsi-20231121monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-group-inc-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-more-in-repl-20260413monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-repl-20251218monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-alert-bragar-eagel-squire-p-c-is-investigating-replimune-group-inc-on-behalf-of--repl-20251008monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-final-deadline-alert-bragar-eagel-squire-p-c-urges-replimune-group-inc-investors-repl-20250922monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has--repl-20250919monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-group-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-s-repl-20250918monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-group-inc-nasdaq-repl-shareholder-alert-bernstein-liebhard-llp-reminds-replimune-repl-20250918monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has--repl-20250917monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-group-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-s-repl-20250916monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has--repl-20250915monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has--repl-20250911monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-group-inc-class-action-the-gross-law-firm-reminds-replimune-group-inc-investors--repl-20250910monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-repl-faces-investor-lawsuit-after-fda-blocks-cancer-drug-approval-hagens-berman-repl-20250910monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-group-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-s-repl-20250909monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-group-inc-nasdaq-repl-shareholder-alert-bernstein-liebhard-llp-reminds-replimune-repl-20250908monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-fil-repl-20250907monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-group-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-s-repl-20250905monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-repl-faces-investor-lawsuit-after-fda-blocks-cancer-drug-approval-hagens-berman-repl-20250905monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-alert-bragar-eagel-squire-p-c-is-investigating-replimune-group-inc-on-behalf-of--repl-20250903monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-group-inc-nasdaq-repl-shareholder-alert-bernstein-liebhard-llp-reminds-replimune-repl-20250902monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-repl-faces-investor-lawsuit-following-77-stock-crash-after-fda-rejects-key-drug--repl-20250902monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-repl-faces-investor-lawsuit-following-77-stock-crash-after-fda-rejects-key-drug--repl-20250829monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-repl-faces-investor-lawsuit-following-77-stock-crash-after-fda-rejects-key-drug--repl-20250827monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-repl-faces-investor-lawsuit-following-77-stock-crash-after-fda-rejects-key-drug--repl-20250825monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-repl-faces-securities-class-action-following-stock-s-collapse-amid-fda-s-rejecti-repl-20250822monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-repl-faces-securities-class-action-following-stock-s-collapse-amid-fda-s-rejecti-repl-20250820monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-group-inc-class-action-the-gross-law-firm-reminds-replimune-group-inc-investors--repl-20250818monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-repl-faces-securities-class-action-following-stock-s-collapse-amid-fda-s-rejecti-repl-20250818monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-repl-faces-securities-class-action-following-stock-s-collapse-amid-fda-s-rejecti-repl-20250815monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-repl-faces-securities-class-action-following-stock-s-collapse-amid-fda-s-rejecti-repl-20250813monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-repl-faces-securities-class-action-following-stock-s-collapse-amid-fda-s-rejecti-repl-20250811monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-group-inc-sued-for-securities-law-violations-contact-the-gross-law-firm-before-s-repl-20250807monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-repl-faces-securities-class-action-following-stock-s-collapse-amid-fda-s-rejecti-repl-20250806monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-group-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-septe-repl-20250805monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-repl-faces-securities-class-action-following-stock-s-collapse-amid-fda-s-rejecti-repl-20250804monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-group-inc-nasdaq-repl-shareholder-alert-bernstein-liebhard-llp-reminds-replimune-repl-20250804monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-repl-faces-securities-class-action-following-stock-s-collapse-amid-fda-s-rejecti-repl-20250801monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-repl-faces-securities-class-action-following-stock-s-collapse-amid-fda-s-rejecti-repl-20250730monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-repl-faces-securities-class-action-following-stock-s-collapse-amid-fda-s-rejecti-repl-20250728monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-group-inc-investors-company-investigated-by-the-portnoy-law-firm-repl-20250725monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-alert-bragar-eagel-squire-p-c-is-investigating-replimune-group-inc-on-behalf-of--repl-20250723monthly0.5https://www.biopharmawatch.com/news/REPL/replimune-repl-shares-plummet-after-fda-rejects-melanoma-drug-sparking-investor-concerns-h-repl-20250723monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-poster-presentation-at-the-2022-asco-annual-meeting-dcth-20220509monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-host-first-quarter-2022-results-dcth-20220428monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-participate-in-the-canaccord-genuity-horizons-in-oncology-conference-dcth-20220408monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-participate-in-the-lytham-partners-spring-2022-investor-conference-dcth-20220329monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-reports-fourth-quarter-and-full-year-2021-results-and-provides-business-up-dcth-20220325monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-host-fourth-quarter-and-full-year-2021-results-dcth-20220315monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-present-at-the-34th-annual-roth-conference-dcth-20220310monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-achieves-medical-device-regulation-certification-for-chemosat-in-europe-dcth-20220302monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-move-to-a-direct-sales-marketing-model-for-chemosat-dcth-20220222monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-present-at-upcoming-virtual-investor-conferences-dcth-20220210monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-appoints-anthony-dias-as-its-new-vice-president-of-finance-inducement-grant-report-dcth-20220207monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-present-at-the-h-c-wainwright-bioconnect-virtual-investor-conference-on-dcth-20220107monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-announces-positive-phase-3-focus-trial-results-for-hepzato-in-liver-do-dcth-20211202monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-provides-speaker-list-for-dec-2-2021-investor-update-meeting-dcth-20211130monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-participate-in-the-canaccord-virtual-medtech-diagnostics-and-digital-he-dcth-20211108monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-hold-investor-update-on-focus-trial-data-and-future-development-plans-o-dcth-20211105monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-schedules-conference-call-to-report-2021-third-quarter-financial-results-dcth-20211025monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-present-at-upcoming-virtual-investor-conferences-dcth-20210902monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-secures-up-to-a-20-0-million-debt-facility-with-avenue-venture-opportuniti-dcth-20210809monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-present-at-upcoming-virtual-investor-conferences-dcth-20210805monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-schedules-conference-call-to-report-2021-second-quarter-financial-results-dcth-20210728monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-present-at-access-to-giving-virtual-conference-on-july-13-2021-at-3-p-m-dcth-20210707monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-set-to-join-russell-microcap-index-dcth-20210608monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-present-at-ld-micro-virtual-investor-conference-on-june-10-2021-at-2-30-dcth-20210603monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-present-at-jefferies-virtual-healthcare-conference-dcth-20210526monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-schedules-conference-call-to-report-2021-first-quarter-financial-results-dcth-20210430monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-oral-presentation-at-the-american-society-of-clinical-oncology-a-dcth-20210430monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-announces-revised-nice-guidance-for-chemosat-in-the-united-kingdom-dcth-20210421monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-shares-additional-information-regarding-focus-trial-power-calculation-dcth-20210331monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-announces-positive-preliminary-results-from-phase-3-focus-trial-of-hep-dcth-20210331monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-schedules-conference-call-to-report-2020-fourth-quarter-financial-results-dcth-20210324monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-participate-at-upcoming-virtual-investor-conferences-dcth-20210308monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-participate-at-upcoming-virtual-investor-conferences-dcth-20210211monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference-dcth-20210111monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-completion-of-underwritten-public-offering-dcth-20201211monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-announces-third-quarter-2020-results-dcth-20201111monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-to-participate-in-oppenheimer-fall-medtech-summit-on-thursday-november-dcth-20201102monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-schedules-conference-call-to-report-2020-third-quarter-financial-results-dcth-20201102monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-a-kol-call-on-november-5-2020-to-discuss-the-results-of-a-prospe-dcth-20201029monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-to-participate-in-upcoming-virtual-investor-conferences-dcth-20200910monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-to-present-at-the-ld-micro-500-virtual-investor-conference-on-tuesday-september-1--dcth-20200825monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-schedules-conference-call-to-report-2020-second-quarter-financial-results-dcth-20200806monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-to-present-at-canaccord-genuity-40th-annual-growth-conference-dcth-20200803monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-leadership-transition-dcth-20200526monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-first-quarter-2020-results-dcth-20200515monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-closes-22-0-million-public-offering-of-common-stock-dcth-20200505monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-pricing-of-22-million-public-offering-and-uplisting-to-the-nasda-dcth-20200501monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-elects-seasoned-finance-and-capital-markets-executive-elizabeth-czerepak-t-dcth-20200219monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-completes-enrollment-in-its-united-states-registration-pivotal-trial-focus-investi-dcth-20200113monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-1-for-700-reverse-stock-split-to-be-effective-on-december-24-201-dcth-20191219monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-present-at-the-12th-annual-ld-micro-main-event-on-december-10-2019-dcth-20191203monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-postponement-of-reverse-stock-split-dcth-20191022monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-present-at-the-microcap-rodeo-investor-conference-dcth-20191008monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-participate-in-upcoming-investor-conferences-dcth-20190923monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-presentation-at-the-rodman-renshaw-21st-annual-global-investment-dcth-20190828monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-joins-the-ocular-melanoma-community-in-recognizing-rare-disease-day-dcth-20190228monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-health-authority-approval-for-chemosat-in-brazil-dcth-20190211monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-acceptance-of-abstract-for-oral-presentation-at-ecio-2019-dcth-20190208monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-commercial-licensing-agreement-for-chemosat-dcth-20181226monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-4th-independent-safety-review-of-registration-trial-data-for-metastatic--dcth-20181218monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-third-quarter-fiscal-2018-financial-results-dcth-20181113monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-enrollment-of-first-patient-in-align-trial-dcth-20181018monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-expands-rollout-of-registration-trial-in-metastatic-ocular-melanoma-dcth-20181015monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-reminds-shareholders-that-the-rights-offering-subscription-period-expires-wednesda-dcth-20180913monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-extension-of-rights-offering-period-to-september-26-2018-dcth-20180828monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-acceptance-of-abstract-for-poster-presentation-at-cirse-2018-dcth-20180827monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-3rd-independent-safety-review-of-randomized-trial-data-for-metastatic-oc-dcth-20180823monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-pending-expiration-to-rights-offering-subscription-period-dcth-20180822monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-beginning-of-enrollment-of-amended-metastatic-ocular-melanoma-registrati-dcth-20180820monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-issues-letter-to-stockholders-dcth-20180817monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-second-quarter-fiscal-2018-financial-results-dcth-20180815monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-commencement-of-rights-offering-subscription-period-dcth-20180806monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-amends-phase-3-ocular-melanoma-trial-protocol-dcth-20180727monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-rights-offering-and-backstop-commitment-ownership-date-of-august-dcth-20180716monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-100th-commercial-chemosat-treatment-completed-at-leiden-university-medic-dcth-20180709monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-present-at-the-8th-annual-ld-micro-invitational-dcth-20180529monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-sponsors-looking-for-a-cure-ocular-melanoma-charity-event-dcth-20180522monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-s-chemosat-included-in-german-treatment-guidelines-for-melanoma-liver-metastases-dcth-20180516monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-s-php-therapy-featured-in-video-learning-session-at-the-european-conference-of-int-dcth-20180514monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-first-quarter-2018-financial-results-dcth-20180510monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-initiation-of-registrational-trial-of-melphalan-hds-in-intrahepatic-chol-dcth-20180507monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-to-present-at-the-rhk-capital-2018-disruptive-growth-and-healthcare-conference-dcth-20180504monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-another-dsmb-recommendation-for-phase-3-focus-trial-dcth-20180503monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-ratio-for-reverse-split-authorization-dcth-20180501monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-shareholder-approval-of-consent-solicitation-dcth-20180409monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-s-php-therapy-to-be-featured-in-video-training-session-at-european-conference-of-i-dcth-20180403monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-to-present-at-oppenheimer-28th-annual-healthcare-conference-dcth-20180319monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-2017-financial-results-dcth-20180316monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-to-present-at-30th-annual-roth-conference-dcth-20180312monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-commercial-supply-agreement-for-melphalan-hydrochloride-for-injection-wi-dcth-20180307monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-500th-commercial-chemosat-treatment-in-europe-dcth-20180202monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-satisfaction-of-2016-convertible-note-dcth-20180201monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-special-protocol-agreement-modification-with-fda-dcth-20180110monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-exit-from-convertible-note-dcth-20171229monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-preliminary-safety-analysis-for-phase-3-focus-trial-dcth-20171219monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-third-quarter-2017-financial-results-dcth-20171114monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-issues-letter-to-shareholders-dcth-20170922monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-accelerated-listing-on-otcqb-dcth-20170914monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-relisting-on-otcqb-dcth-20170913monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-issues-letter-to-stockholders-dcth-20170901monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-medical-university-of-hannover-in-germany-celebrates-100th-chemosat-trea-dcth-20170829monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-announces-extension-of-expiration-date-of-its-consent-solicitation-and-dcth-20170822monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-announces-adjournment-of-annual-meeting-meeting-scheduled-to-reconvene-dcth-20170605monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-first-quarter-2017-financial-results-dcth-20170509monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-issues-letter-to-stockholders-dcth-20170427monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-2016-financial-results-dcth-20170329monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-special-protocol-assessment-agreement-with-fda-for-pivotal-trial-with-me-dcth-20170327monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-present-at-roth-capital-partners-29th-annual-growth-stock-conference-on-dcth-20170310monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inc-dcth-to-ring-the-nasdaq-stock-market-opening-bell-dcth-20100513monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-present-at-the-rodman-renshaw-10th-annual-global-healthcare-conference-dcth-20081107monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-president-and-ceo-richard-taney-to-present-at-two-medical-technology-confe-dcth-20081021monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-appoints-eamonn-hobbs-to-board-of-directors-dcth-20081015monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-present-at-the-maxim-group-growth-conference-dcth-20081002monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-adds-providence-cancer-center-to-phase-iii-trial-dcth-20080924monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-targeted-drug-delivery-technology-to-be-presented-at-western-angiographic--dcth-20080919monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-cancer-trials-welcome-new-principal-investigator-from-nci-dcth-20080902monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-host-quarterly-update-conference-call-dcth-20080828monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-expands-phase-iii-trial-for-metastatic-melanoma-to-include-swedish-medical-center--dcth-20080821monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-expands-phase-iii-trial-for-metastatic-melanoma-to-include-john-wayne-cancer-insti-dcth-20080812monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-to-present-at-the-28th-annual-canaccord-adams-global-growth-conference-dcth-20080807monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-expands-phase-iii-trial-for-metastatic-melanoma-to-florida-dcth-20080724monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-announces-clinical-and-regulatory-appointments-dcth-20080717monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-targeted-drug-delivery-system-for-liver-cancer-treatment-to-be-featured-on-dcth-20080715monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-expands-multi-center-phase-iii-trial-for-metastatic-melanoma-dcth-20080624monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-announces-expanded-clinical-initiatives-at-annual-meeting-today-dcth-20080604monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-reports-on-2005-annual-meeting-dcth-20050615monthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-receives-fast-track-status-from-u-s-fda-for-high-dose-cancer-treatment-with-melpha-dcth-20050511monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-upcoming-investor-conferences-sldb-20260601monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-upcoming-investor-conferences-sldb-20260407monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-sldb-20260106monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-upcoming-investor-conferences-sldb-20251030monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-upcoming-investor-conferences-sldb-20250828monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sldb-20250603monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-the-jefferies-global-healthcare-conference-sldb-20250528monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-the-citizens-life-sciences-conference-sldb-20250430monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-the-american-society-of-gene-and-cell-therapy-s-28th-annua-sldb-20250429monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-upcoming-investor-conferences-sldb-20250407monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sldb-20250401monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-the-2025-muscular-dystrophy-association-mda-clinical-scien-sldb-20250312monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-upcoming-investor-conferences-sldb-20250305monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sldb-20250304monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sldb-20250204monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-sldb-20250108monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sldb-20250106monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sldb-20241203monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-upcoming-investor-conferences-sldb-20241126monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-the-jefferies-london-healthcare-conference-sldb-20241114monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sldb-20241104monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-the-truist-securities-biopharma-symposium-sldb-20241031monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-chardan-s-8th-annual-genetic-medicines-conference-sldb-20240923monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-the-2024-cantor-global-healthcare-conference-sldb-20240912monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sldb-20240904monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-upcoming-investor-conferences-sldb-20240904monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-sldb-20240805monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sldb-20240604monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-the-american-society-of-gene-and-cell-therapy-annual-meeti-sldb-20240507monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sldb-20240502monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-cantor-s-virtual-muscular-dystrophy-symposium-sldb-20240327monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-upcoming-investor-conferences-sldb-20240306monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-42nd-annual-j-p-morgan-healthcare-conference-sldb-20240104monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-receives-fda-fast-track-designation-for-duchenne-muscular-dystrophy-gene-sldb-20231207monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-35th-annual-piper-sandler-healthcare-conference-sldb-20231122monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-jefferies-london-healthcare-conference-sldb-20231109monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-upcoming-investor-conferences-sldb-20230920monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-upcoming-investor-conferences-sldb-20230905monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-in-citi-s-18th-annual-biopharma-conference-sldb-20230831monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-the-jefferies-healthcare-conference-sldb-20230601monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-the-barclays-gene-editing-therapy-summit-sldb-20230522monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-the-american-society-of-gene-and-cell-therapy-annual-meeti-sldb-20230516monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-jmp-securities-life-sciences-conference-sldb-20230508monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-in-chardan-s-7th-annual-genetic-medicines-and-cell-therap-sldb-20230421monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-the-22nd-annual-needham-healthcare-conference-sldb-20230413monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-bmo-biopharma-spotlight-series-genetic-medicine-delive-sldb-20230321monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-svb-securities-global-biopharma-conference-sldb-20230208monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-tumor-testing-market-worth-usd-59-45-bn-by-2029-recent-trends-mergers-and-acquisitio-sldb-20230117monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-outlines-strategy-for-leadership-in-precision-genetic-medicines-with-foc-sldb-20230110monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grant-to-chief-financial-officer-and-treasurer-sldb-20230109monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-appoints-kevin-tan-cfa-as-chief-financial-officer-sldb-20230109monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-sldb-20230109monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-stockholder-approval-of-acquisition-of-aavantibio-sldb-20221201monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-the-piper-sandler-34th-annual-healthcare-conference-sldb-20221122monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-additional-preclinical-data-demonstrating-that-its-novel-capsid--sldb-20221017monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-upcoming-investor-conferences-sldb-20220929monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-upcoming-scientific-and-patient-advocacy-conferences-sldb-20220623monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grant-to-new-senior-vice-president-quality-sldb-20220602monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-the-jefferies-healthcare-conference-sldb-20220602monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-asgct-25th-annual-meeting-and-cureduchenne-2022-futures-na-sldb-20220517monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-management-to-host-call-on-april-27-2022-to-discuss-updated-corporate-st-sldb-20220425monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-the-svb-leerink-11th-annual-global-healthcare-conferen-sldb-20220210monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-40th-annual-j-p-morgan-healthcare-conference-sldb-20220106monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-the-jefferies-gene-therapy-editing-summit-sldb-20211021monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-additional-pulmonary-function-results-from-the-ongoing-ignite-dm-sldb-20210929monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-1-5-year-data-from-patients-in-the-ongoing-ignite-dmd-phase-i-ii-sldb-20210923monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-provide-update-on-long-term-outcomes-data-from-patients-in-the-ongoin-sldb-20210920monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-upcoming-investor-conferences-sldb-20210920monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-the-11th-annual-world-orphan-drug-congress-usa-2021-sldb-20210824monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grant-to-new-senior-vice-president-finance-sldb-20210819monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-appointment-of-michael-inbar-cpa-mba-as-senior-vice-president--sldb-20210819monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grant-to-new-senior-vice-president-clinical-developme-sldb-20210702monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-appointment-of-iman-barilero-pharmd-ph-d-as-chief-regulatory-o-sldb-20210607monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-the-jefferies-virtual-healthcare-conference-sldb-20210526monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-upcoming-scientific-conferences-sldb-20210525monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-host-first-quarter-2021-financial-results-and-business-update-call-on-sldb-20210511monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-highlights-expertise-in-aav-gene-therapy-with-multiple-abstracts-to-be-p-sldb-20210504monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-in-virtual-fireside-chat-at-the-chardan-5th-annual-geneti-sldb-20210420monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-sldb-20210325monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grant-to-new-chief-legal-officer-sldb-20210304monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-upcoming-investor-conferences-sldb-20210217monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-39th-annual-j-p-morgan-healthcare-conference-sldb-20210106monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-host-third-quarter-2020-financial-results-and-business-update-call-on-sldb-20201103monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-in-virtual-fireside-chat-at-the-chardan-4th-annual-geneti-sldb-20201002monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-appointment-of-ian-f-smith-as-chairman-of-the-board-of-directo-sldb-20200618monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-presents-data-from-duchenne-muscular-dystrophy-gene-therapy-program-at-a-sldb-20200514monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-participate-in-the-chardan-3rd-annual-genetic-medicines-conference-sldb-20191002monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-the-j-p-morgan-healthcare-conference-sldb-20190102monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-the-credit-suisse-healthcare-conference-sldb-20181109monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-the-chardan-genetic-medicines-conference-sldb-20181005monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-the-cell-gene-meeting-on-the-mesa-sldb-20181001monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-welcomes-sukumar-nagendran-m-d-to-its-board-of-directors-sldb-20180913monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-welcomes-industry-expert-dr-martin-freed-to-its-board-of-directors-sldb-20180626monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-sldb-20180519monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-upcoming-preclinical-data-presentations-sldb-20180515monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-l-sldb-20180512monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-sldb-20180414monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-l-sldb-20180328monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-closing-of-initial-public-offering-and-full-exercise-of-underw-sldb-20180130monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-to-announce-third-quarter-financial-results-on-november-4-2025-lab-20251021monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-schedules-first-quarter-earnings-conference-call-on-may-6-2025-lab-20250422monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-to-participate-in-upcoming-investor-conferences-lab-20250227monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-schedules-fourth-quarter-and-full-year-2024-earnings-conference-call-on--lab-20250212monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-somascan-assay-powers-key-insights-into-semaglutide-treatment-published--lab-20250108monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-lab-20241219monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-to-participate-in-upcoming-investor-conferences-lab-20241031monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-conference-call-and-webcast-for-third-quarter-2024-financial-r-lab-20241016monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-achieves-new-record-of-the-most-protein-measurements-on-the-most-sample--lab-20240924monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-proteomics-profiling-reveals-unique-biomarkers-and-insights-into-nonalco-lab-20240918monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-to-present-at-the-morgan-stanley-22nd-annual-global-healthcare-conferenc-lab-20240826monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-to-participate-in-upcoming-investor-conferences-lab-20240806monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-conference-call-and-webcast-for-second-quarter-2024-financial--lab-20240717monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-purchases-the-carterra-lsa-xt-system-to-accelerate-data-delivery-and-pro-lab-20240528monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-to-participate-in-upcoming-investor-conferences-lab-20240522monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-inc-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-lab-20240520monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-conference-call-and-webcast-for-first-quarter-2024-financial-r-lab-20240425monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-introduces-new-high-throughput-multiplexed-whole-slide-imaging-modalitie-lab-20240408monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-multi-year-strategic-engagement-with-bristol-myers-squibb-for--lab-20240403monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-and-next-gen-diagnostics-announce-partnership-to-provide-complete-automa-lab-20240226monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-to-participate-in-upcoming-investor-conferences-lab-20240222monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-conference-call-and-webcast-for-fourth-quarter-and-full-year-2-lab-20240214monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-and-navignostics-announce-collaboration-agreement-to-advance-imaging-cap-lab-20240207monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-completes-merger-with-somalogic-creating-a-diversified-and-scaled-leader-lab-20240105monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-to-present-at-the-jefferies-london-healthcare-conference-lab-20231102monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-conference-call-and-webcast-of-third-quarter-2023-financial-re-lab-20231025monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-reports-second-quarter-2023-financial-results-lab-20230808monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-to-participate-in-upcoming-investor-conferences-lab-20230726monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-conference-call-and-webcast-for-second-quarter-2023-financial--lab-20230725monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-to-participate-in-upcoming-investor-conferences-lab-20230614monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-to-present-at-the-jefferies-healthcare-conference-lab-20230525monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-ngs-library-preparation-as-an-upgrade-on-the-x9-high-throughpu-lab-20230518monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-conference-call-and-webcast-for-first-quarter-2023-financial-r-lab-20230425monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-lab-20230420monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-introduces-the-hyperion-xti-imaging-system-breaks-barriers-to-power-sign-lab-20230417monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-inc-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-lab-20230322monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-to-participate-in-the-keybanc-capital-markets-life-sciences-medtech-inve-lab-20230314monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-to-present-at-43rd-annual-cowen-health-care-conference-lab-20230301monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-lab-20230221monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-conference-call-and-webcast-for-fourth-quarter-and-full-year-2-lab-20230131monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-appointment-of-betsy-jensen-as-chief-human-resources-officer-lab-20230103monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-lab-20221122monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-third-quarter-2022-financial-results-lab-20221108monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-and-visiopharm-announce-partnership-for-the-development-of-complete-imag-lab-20221107monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-conference-call-and-webcast-of-third-quarter-2022-financial-re-lab-20221025monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-releases-the-x9-real-time-pcr-system-its-most-productive-and-flexible-hi-lab-20221006monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-lab-20220825monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-second-quarter-2022-financial-results-and-provides-strategic-u-lab-20220808monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-conference-call-and-webcast-of-second-quarter-2022-financial-r-lab-20220725monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-first-quarter-2022-financial-results-lab-20220505monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-announces-conference-call-and-webcast-of-first-quarter-2022-financial-re-lab-20220422monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-launches-hyperion-imaging-system-the-new-standard-in-high-plex-spatial-i-lab-20220411monthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotools-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-lab-20220405monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-lrmr-20251218monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-t-lrmr-20250620monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-to-present-at-the-leerink-partners-global-healthcare-conference-lrmr-20250303monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-dosing-of-adolescents-in-nomlabofusp-pediatric-pharmacokine-lrmr-20250123monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-presents-additional-data-from-phase-1-studies-and-phase-2-dose-explor-lrmr-20241118monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-three-poster-presentations-at-the-upcoming-international-co-lrmr-20240919monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-to-participate-in-upcoming-investor-conferences-lrmr-20240827monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-to-present-at-the-leerink-partners-global-biopharma-conference-lrmr-20240306monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-closing-of-underwritten-public-offering-of-common-stock-and-lrmr-20240216monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-pricing-of-underwritten-public-offering-of-common-stock-lrmr-20240214monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-proposed-underwritten-public-offering-lrmr-20240213monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-to-present-at-the-guggenheim-5th-annual-inflammation-neurology-immuno-lrmr-20231101monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-appoints-dr-jeffery-w-sherman-to-its-board-of-directors-lrmr-20231003monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-to-present-at-the-citi-18th-annual-biopharma-conference-lrmr-20230831monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-set-to-join-russell-3000-index-lrmr-20230621monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-to-participate-in-the-guggenheim-genomic-medicines-and-rare-disease-d-lrmr-20230328monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-to-present-at-the-34th-annual-piper-sandler-healthcare-conference-lrmr-20221121monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-to-participate-in-the-guggenheim-4th-annual-immunology-neurology-day-lrmr-20221107monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-issuance-of-u-s-patent-providing-composition-of-matter-prot-lrmr-20221020monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-oral-and-poster-presentations-at-the-upcoming-international-lrmr-20221019monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-closing-of-underwritten-offering-and-full-exercise-of-optio-lrmr-20220916monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-70-million-underwritten-offering-lrmr-20220914monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-presentation-at-the-upcoming-gordon-research-conference-on--lrmr-20220728monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-oral-presentation-at-the-upcoming-gordon-research-conferenc-lrmr-20220628monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-upcoming-scientific-conference-presentations-lrmr-20220602monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-upcoming-poster-presentations-at-the-4th-pan-american-parki-lrmr-20220519monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-to-participate-in-the-piper-sandler-33rd-annual-healthcare-conference-lrmr-20211122monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-to-participate-in-the-guggenheim-virtual-neuro-immunology-conference-lrmr-20211115monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseas-lrmr-20210916monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-to-present-at-the-morgan-stanley-19th-annual-global-healthcare-confer-lrmr-20210902monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congres-lrmr-20210819monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-to-present-at-the-william-blair-biotech-focus-conference-2021-lrmr-20210708monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference-lrmr-20210611monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-95-million-private-placement-financing-lrmr-20210521monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-reports-positive-topline-phase-1-clinical-trial-data-showing-dose-dep-lrmr-20210511monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-to-present-at-the-svb-leerink-10th-annual-global-healthcare-conferenc-lrmr-20210218monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-added-to-nasdaq-biotechnology-index-lrmr-20201215monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-completion-of-dosing-of-the-single-ascending-dose-clinical--lrmr-20201208monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-to-participate-in-upcoming-investor-conferences-lrmr-20201113monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-formation-of-scientific-advisory-board-lrmr-20201013monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-to-present-at-the-oppenheimer-fall-healthcare-life-sciences-medtech-s-lrmr-20200921monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-to-present-at-the-morgan-stanley-virtual-18th-annual-global-healthcar-lrmr-20200910monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-to-present-at-the-2020-wedbush-pacgrow-healthcare-conference-lrmr-20200804monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-positive-opinion-on-orphan-drug-designation-received-from-t-lrmr-20200728monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-announces-dosing-of-patients-in-third-cohort-of-phase-1-sad-trial-of--lrmr-20200720monthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-lrmr-20200529monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-supports-victoria-s-voice-foundation-s-national-naloxone-awareness-d-ebs-20260604monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-first-quarter-2026-financial-results-ebs-20260430monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-launches-new-narcan-nasal-spray-carrying-case-and-multipacks-alongsi-ebs-20260407monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-fourth-quarter-and-full-year-2025-financial-results-ebs-20260226monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-approximately-140-million-in-contract-awards-with-the-gove-ebs-20260226monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-new-50-million-stock-repurchase-program-ebs-20260226monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-u-s-fda-approval-of-supplemental-new-drug-application-snda--ebs-20260212monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-u-s-fda-approval-on-supplemental-new-drug-application-for-n-ebs-20260114monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-100-million-paydown-of-term-loan-principal-a-significant-s-ebs-20260112monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-and-panther-announce-agreement-to-support-the-continuation-of-the-af-ebs-20260108monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-on-ja-ebs-20260107monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-u-s-fda-approval-for-drug-product-manufacturing-of-raxibacu-ebs-20251212monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-report-third-quarter-2025-financial-results-on-october-29-2025-ebs-20251008monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-upcoming-investor-conferences-ebs-20250827monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-supports-voices-for-awareness-and-facing-fentanyl-now-on-august-21-2-ebs-20250821monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-second-quarter-2025-financial-results-ebs-20250806monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-applauds-availability-of-over-the-counter-naloxone-in-u-s-house-of-representative-ebs-20250728monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-report-second-quarter-2025-financial-results-on-august-6-2025-ebs-20250715monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-secures-51-9-million-contract-modification-award-for-cnj-016-vaccini-ebs-20250708monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-expands-narcandirect-to-offer-kloxxado-naloxone-hcl-nasal-spray-8-mg-ebs-20250702monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-secures-62-4-million-contract-modification-for-bat-botulism-antitoxi-ebs-20250623monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-addition-to-russell-3000-index-ebs-20250620monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-supports-victoria-s-voice-foundation-s-national-naloxone-awareness-d-ebs-20250605monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-upcoming-investor-conferences-ebs-20250514monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-first-quarter-2025-financial-results-ebs-20250507monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reinforces-commitment-to-opioid-emergency-preparedness-efforts-in-ca-ebs-20250501monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-report-first-quarter-2025-financial-results-on-may-7-2025-ebs-20250422monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-stock-repurchase-program-ebs-20250331monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-new-hire-equity-grant-under-nyse-rule-303a-08-ebs-20250320monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-finalizes-sale-of-baltimore-bayview-manufacturing-site-to-syngene-in-ebs-20250319monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-approximately-27-million-in-incremental-sales-to-supply-in-ebs-20250318monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reinforces-its-commitment-to-expanding-access-to-narcan-nasal-spray--ebs-20250313monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-and-rocketvax-announce-investment-agreement-and-pursuit-of-a-strateg-ebs-20250312monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-sale-of-baltimore-bayview-manufacturing-site-to-syngene-in-ebs-20250310monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-fourth-quarter-and-full-year-2024-financial-results-ebs-20250303monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-report-fourth-quarter-and-full-year-2024-financial-results-on-mar-ebs-20250218monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-and-pro-football-legend-emmitt-smith-raise-awareness-of-ready-to-res-ebs-20250207monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-gains-exclusive-commercial-rights-to-kloxxado-naloxone-hci-nasal-spr-ebs-20250114monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-contract-option-valued-at-approximately-16-7-million-to-con-ebs-20250113monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-on-ja-ebs-20250108monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-exercise-of-20-million-option-to-supply-u-s-department-of--ebs-20250108monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-50-million-contract-option-from-barda-to-procure-doses-of-c-ebs-20241216monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-supports-new-clinical-trial-evaluating-the-safety-and-efficacy-of-br-ebs-20241106monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-third-quarter-2024-financial-results-ebs-20241106monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-appoints-dr-simon-lowry-as-chief-medical-officer-and-head-of-researc-ebs-20241104monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-third-quarter-2024-financial-results-and-conduct-conferen-ebs-20241023monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-demonstrates-commitment-to-increasing-access-awareness-of-narcan-nas-ebs-20241008monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-the-execution-of-contract-options-valued-at-67-4-million-t-ebs-20240926monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-confirms-approximately-400-million-in-orders-in-2024-2025-to-support-ebs-20240925monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-agreement-to-settle-securities-class-action-litigation-ebs-20240913monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-awarded-research-and-development-option-valued-at-41-9-million-for-c-ebs-20240912monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-expands-ready-to-rescue-initiative-to-support-widespread-opioid-emer-ebs-20240830monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-receives-u-s-fda-ap-ebs-20240829monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-finalizes-sale-of-baltimore-camden-manufacturing-site-to-bora-pharma-ebs-20240820monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-responds-to-mpox-public-health-emergency-as-cases-surge-in-africa-ebs-20240819monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-second-quarter-2024-financial-results-ebs-20240806monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-expands-narcan-nasal-spray-distribution-capabilities-to-enhance-cust-ebs-20240806monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-completes-sale-of-rsdl-reactive-skin-decontamination-lotion-kit-to-s-ebs-20240731monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-launches-opioid-emergency-preparedness-lay-spray-stay-public-educati-ebs-20240724monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-second-quarter-2024-financial-results-conduct-conference--ebs-20240723monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-shelf-life-extension-for-narcan-nasal-spray-in-canada-ebs-20240722monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-continues-to-drive-improved-financial-position-as-part-of-multi-year-ebs-20240709monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-awarded-250-million-in-contract-modifications-to-supply-u-s-governme-ebs-20240702monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-sale-of-baltimore-camden-manufacturing-site-to-bora-pharma-ebs-20240620monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-continues-driving-progress-against-the-opioid-epidemic-recognizes-na-ebs-20240606monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-hold-virtual-annual-meeting-of-stockholders-on-thursday-may-23-20-ebs-20240510monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-first-quarter-2024-financial-results-ebs-20240501monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-strategic-operational-changes-to-stabilize-financial-posit-ebs-20240501monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-releases-new-survey-findings-underscoring-the-need-to-continue-expan-ebs-20240501monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-amendment-to-its-existing-credit-facility-ebs-20240430monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-first-quarter-2024-financial-results-conduct-conference-c-ebs-20240422monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-continues-to-broaden-access-awareness-and-availability-of-narcan-nas-ebs-20240328monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-nai-status-for-baltimore-bayview-manufacturing-facility-ebs-20240325monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-fourth-quarter-2023-financial-results-ebs-20240306monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-fourth-quarter-full-year-2023-financial-results-and-condu-ebs-20240229monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-appoints-industry-leader-joseph-c-papa-as-new-president-and-ceo-ebs-20240221monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-awarded-procurement-contract-valued-up-to-235-8-million-to-supply-bi-ebs-20240111monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-on-ja-ebs-20240109monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-75-million-contract-option-from-barda-to-procure-doses-of-c-ebs-20231128monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-nyse-notice-regarding-delayed-form-10-q-filing-ebs-20231124monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-third-quarter-2023-financial-results-ebs-20231108monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-third-quarter-2023-financial-results-and-conduct-conferen-ebs-20231019monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-names-two-pharmaceutical-industry-veterans-to-board-of-directors-ebs-20231002monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-narcan-nasal-spray-launches-over-the-counter-making-it-possible-for--ebs-20230830monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-financial-results-for-second-quarter-2023-ebs-20230808monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-strategic-steps-to-strengthen-core-business-and-financial--ebs-20230808monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-awarded-10-year-barda-contract-valued-at-up-to-a-maximum-of-704-mill-ebs-20230731monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-second-quarter-2023-financial-results-and-conduct-confere-ebs-20230725monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-u-s-fda-approval-of-cyfendus-anthrax-vaccine-adsorbed-adjuv-ebs-20230720monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-ceo-transition-ebs-20230627monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-finalizes-sale-of-travel-health-business-to-bavarian-nordic-ebs-20230515monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-hold-virtual-annual-meeting-of-stockholders-on-thursday-may-25-20-ebs-20230511monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-financial-results-for-first-quarter-2023-ebs-20230509monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-first-quarter-2023-financial-results-and-conduct-conferen-ebs-20230419monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-financial-results-for-fourth-quarter-2022-ebs-20230227monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-fda-advisory-committees-unanimous-vote-in-favor-of-narcan-na-ebs-20230215monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-sale-of-travel-health-business-to-bavarian-nordic-for-up-t-ebs-20230215monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-fourth-quarter-2022-financial-results-and-conduct-confere-ebs-20230206monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-organizational-changes-as-part-of-sharpened-strategic-focu-ebs-20230109monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-awarded-379-6-million-procurement-contract-to-supply-rsdl-reactive-s-ebs-20230105monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-u-s-fda-acceptance-and-priority-review-of-supplemental-new-ebs-20221206monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-department-of-defense-award-to-evaluate-chikungunya-vaccine-ebs-20221114monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-financial-results-for-third-quarter-2022-ebs-20221108monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-presents-data-from-phase-2-study-evaluating-safety-and-immunogenicit-ebs-20221101monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-third-quarter-2022-financial-results-and-conduct-conferen-ebs-20221018monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-completes-acquisition-of-exclusive-worldwide-rights-to-tembexa-brinc-ebs-20220926monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-initiates-phase-1-study-evaluating-lassa-virus-vaccine-candidate-ebs-20220906monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-investor-conferences-ebs-20220810monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-financial-results-for-second-quarter-2022-ebs-20220801monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-second-quarter-2022-financial-results-and-conduct-confere-ebs-20220718monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-and-ridgeback-biotherapeutics-enter-into-agreement-for-ebanga-treatm-ebs-20220707monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-appointment-of-sujata-dayal-to-board-of-directors-ebs-20220706monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-fda-acceptance-of-biologics-license-application-for-av7909-ebs-20220624monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-publication-of-chikv-vlp-phase-2-safety-and-immunogenicity-ebs-20220621monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-investor-conferences-ebs-20220602monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-acquire-from-chimerix-its-exclusive-worldwide-rights-to-tembexa-b-ebs-20220516monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-hold-virtual-annual-meeting-of-stockholders-on-thursday-may-26-20-ebs-20220512monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-financial-results-for-first-quarter-2022-ebs-20220428monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-first-quarter-2022-financial-results-and-conduct-conferen-ebs-20220408monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-provides-corporate-governance-update-ebs-20220323monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-investor-conferences-ebs-20220314monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-initiates-phase-1-study-evaluating-potential-intranasal-treatment-fo-ebs-20220311monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-financial-results-for-fourth-quarter-2021-ebs-20220224monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-fourth-quarter-2021-financial-results-and-conduct-confere-ebs-20220207monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-2022-financial-guidance-provides-preliminary-2021-results-ebs-20220109monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-investor-conferences-ebs-20220103monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-initiation-of-phase-1-study-evaluating-its-universal-influ-ebs-20211216monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-stock-repurchase-program-ebs-20211111monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-financial-results-for-third-quarter-2021-ebs-20211104monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-third-quarter-2021-financial-results-and-conduct-a-confer-ebs-20211018monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-initiation-of-pivotal-phase-3-study-evaluating-the-safety--ebs-20211015monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-secures-multi-year-development-and-manufacturing-agreement-with-prov-ebs-20210914monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-covid-19-human-immune-globulin-product-candidate-to-be-evaluated-in--ebs-20210825monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-investor-conferences-ebs-20210823monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-financial-results-for-second-quarter-2021-ebs-20210729monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-resume-manufacturing-covid-19-vaccine-at-bayview-facility-ebs-20210729monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-second-quarter-2021-financial-results-and-conduct-a-confe-ebs-20210715monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-inc-investors-last-days-to-participate-actively-in-the-class-action--ebs-20210615monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-inc-investors-last-days-to-participate-actively-in-the-class-action--ebs-20210528monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-positive-two-year-persistence-data-from-phase-2-study-eval-ebs-20210526monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-hold-virtual-annual-meeting-of-stockholders-on-thursday-may-20-20-ebs-20210506monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-investor-conferences-ebs-20210505monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-financial-results-for-first-quarter-2021-ebs-20210429monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-inc-investors-company-investigated-by-the-portnoy-law-firm-ebs-20210421monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-investors-with-losses-greater-than-100-000-encouraged-to-contact-keh-ebs-20210419monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-first-quarter-2021-financial-results-and-conduct-a-confer-ebs-20210415monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-ebs-20210408monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-on-track-with-respect-to-covid-19-contractual-commitments-receives-m-ebs-20210405monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-topline-data-from-niaid-phase-3-itac-trial-insight-013-eva-ebs-20210402monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-investor-conferences-ebs-20210301monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-financial-results-for-fourth-quarter-and-full-year-2020-ebs-20210218monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-fourth-quarter-and-full-year-2020-financial-results-and-c-ebs-20210204monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-2021-financial-guidance-provides-preliminary-2020-results-ebs-20210110monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-investor-conferences-ebs-20210104monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-and-mount-sinai-health-system-announce-initiation-of-dod-funded-clin-ebs-20201229monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-financial-results-for-third-quarter-and-nine-months-ended-se-ebs-20201105monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-third-quarter-2020-financial-results-and-conduct-conferen-ebs-20201015monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-covid-19-human-immune-globulin-product-candidate-to-be-included-in-n-ebs-20201008monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-teams-up-with-boston-red-sox-cincinnati-reds-philadelphia-phillies-a-ebs-20200831monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-appointment-of-marvin-white-to-the-company-s-board-of-dire-ebs-20200826monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-virtual-investor-conferences-ebs-20200818monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-fda-approval-of-narcan-naloxone-hcl-nasal-spray-shelf-life-ebs-20200817monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-upsize-and-pricing-of-450-million-of-3-875-senior-unsecure-ebs-20200804monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-proposed-offering-of-400-million-of-senior-unsecured-notes-ebs-20200804monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-financial-results-for-second-quarter-and-six-months-ended-ju-ebs-20200730monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-signs-agreement-with-astrazeneca-to-expand-manufacturing-for-covid-1-ebs-20200727monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-inc-to-be-added-to-the-s-p-midcap-400-index-ebs-20200721monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-second-quarter-2020-financial-results-and-conduct-confere-ebs-20200716monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-signs-five-year-agreement-for-large-scale-drug-substance-manufacturi-ebs-20200706monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-invest-75-million-in-canton-site-and-expand-viral-vector-and-gene-ebs-20200618monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-virtual-investor-conferences-ebs-20200616monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-signs-agreement-to-be-u-s-manufacturing-partner-for-astrazeneca-s-co-ebs-20200611monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-statement-on-u-s-district-court-decision-ebs-20200605monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-joins-u-s-government-s-warp-speed-program-in-landmark-public-private-ebs-20200601monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-virtual-investor-conferences-ebs-20200512monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-hold-virtual-annual-meeting-of-stockholders-on-thursday-may-21-20-ebs-20200507monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-financial-results-for-first-quarter-2020-ebs-20200430monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-signs-agreement-to-be-u-s-manufacturing-partner-for-johnson-johnson--ebs-20200423monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-appoints-dr-karen-l-smith-as-chief-medical-officer-ebs-20200421monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-first-quarter-2020-financial-results-and-conduct-conferen-ebs-20200416monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-appoints-nina-delorenzo-as-senior-vice-president-of-global-public-af-ebs-20200406monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-partners-with-u-s-government-for-comprehensive-response-to-expedite--ebs-20200402monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-signs-agreement-with-novavax-to-manufacture-nanoflu-ebs-20200331monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-signs-development-and-manufacturing-agreement-with-vaxart-for-their--ebs-20200318monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-initiates-development-of-plasma-derived-product-candidates-for-the-t-ebs-20200311monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-signs-development-and-manufacturing-agreement-with-novavax-for-exper-ebs-20200310monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-selects-axiom-fusion-eclinical-suite-as-its-global-eclinical-suite-ebs-20200304monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-financial-results-for-fourth-quarter-and-full-year-2019-ebs-20200220monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-fourth-quarter-and-full-year-2019-financial-results-and-c-ebs-20200203monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-positive-chmp-opinion-for-vaxchora-anticipates-near-term-ap-ebs-20200131monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-ema-agreement-for-proposed-development-path-of-investigatio-ebs-20200113monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-preliminary-2019-financial-results-and-provides-2020-finan-ebs-20200113monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-investor-conferences-ebs-20200106monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-board-members-dr-sue-bailey-and-dr-kathryn-c-zoon-named-most-influen-ebs-20191220monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-presents-positive-immunogenicity-results-from-phase-2-study-of-its-i-ebs-20191122monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-growth-strategy-and-2024-goals-at-analyst-and-investor-day-ebs-20191121monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-host-2019-analyst-and-investor-day-ebs-20191118monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-financial-results-for-third-quarter-and-nine-months-ended-se-ebs-20191106monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-host-2019-analyst-investor-day-ebs-20191021monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-ema-prime-designation-for-its-chikungunya-virus-vlp-vaccine-ebs-20191010monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-third-quarter-2019-financial-results-and-conduct-a-confer-ebs-20191009monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-nih-research-grant-to-further-develop-ap007-its-development-ebs-20190927monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-cantor-fitzgerald-global-healthcare-conference-ebs-20190926monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-awarded-20-million-to-develop-diazepam-auto-injector-to-treat-nerve--ebs-20190925monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-awarded-10-year-hhs-contract-to-deliver-acam2000-smallpox-vaccinia-v-ebs-20190903monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-series-of-investor-conferences-ebs-20190814monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-financial-results-for-second-quarter-and-six-months-ended-ju-ebs-20190801monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-exercise-by-barda-of-the-first-contract-option-valued-at-2-ebs-20190730monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-second-quarter-2019-financial-results-and-conduct-a-confe-ebs-20190718monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-fda-approval-of-change-in-storage-conditions-and-transfer--ebs-20190604monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-awarded-10-year-hhs-contract-valued-at-approximately-535-million-to--ebs-20190603monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-granting-of-marketing-authorization-in-five-eu-countries-f-ebs-20190520monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-series-of-investor-conferences-ebs-20190520monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-prepares-for-initial-shipments-of-av7909-anthrax-vaccine-candidate-i-ebs-20190515monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-hold-annual-meeting-of-stockholders-on-thursday-may-23-2019-at-9--ebs-20190509monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-first-quarter-2019-financial-results-ebs-20190502monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-first-quarter-2019-financial-results-and-conduct-a-confer-ebs-20190418monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-interim-results-from-phase-2-study-evaluating-chikv-vlp-ch-ebs-20190416monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-initiates-phase-3-clinical-study-to-evaluate-av7909-for-post-exposur-ebs-20190319monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-awarded-u-s-department-of-state-contract-to-supply-medical-counterme-ebs-20190228monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-appointment-of-seamus-mulligan-to-its-board-of-directors-ebs-20190212monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-fourth-quarter-and-full-year-2018-financial-results-and-c-ebs-20190207monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-appointment-of-robert-g-kramer-sr-to-its-board-of-director-ebs-20190124monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-daniel-j-abdun-nabi-to-retire-as-ceo-robert-g-kramer-sr-to-ebs-20190104monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-submission-to-fda-of-application-covering-emergency-use-au-ebs-20181228monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-health-canada-approval-of-biothrax-anthrax-vaccine-adsorbed-ebs-20181217monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-and-valneva-report-positive-phase-1-results-for-their-vaccine-candid-ebs-20181119monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-series-of-near-term-investor-conferences-ebs-20181106monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-financial-results-for-third-quarter-and-nine-months-of-2018-ebs-20181101monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-offer-all-public-libraries-and-ymcas-in-the-u-s-free-opioid-aware-ebs-20181024monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-completes-acquisition-of-adapt-pharma-and-flagship-product-narcan-na-ebs-20181015monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-third-quarter-2018-financial-results-and-conduct-a-confer-ebs-20181011monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-completes-acquisition-of-specialty-vaccines-company-paxvax-ebs-20181004monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-series-of-near-term-investor-conferences-ebs-20180817monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-acquire-specialty-vaccines-company-paxvax-ebs-20180813monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-initiates-phase-1-clinical-study-of-zika-virus-immune-globulin-thera-ebs-20180731monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-second-quarter-2018-financial-results-and-conduct-a-confe-ebs-20180718monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-the-goldman-sachs-39th-annual-global-healthcare-co-ebs-20180608monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-50-million-expansion-of-baltimore-fill-finish-facility-ebs-20180607monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-hold-annual-meeting-of-stockholders-on-thursday-may-24-2018-at-9--ebs-20180510monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-first-quarter-2018-financial-results-and-conduct-a-confer-ebs-20180419monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-successful-completion-of-mutual-recognition-procedure-for--ebs-20180412monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-implement-stock-repurchase-program-for-up-to-50-million-of-its-co-ebs-20180322monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-awarded-one-year-cdc-contract-valued-at-26-million-for-vaccinia-immu-ebs-20180228monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-and-valneva-initiate-phase-1-clinical-study-to-evaluate-vaccine-cand-ebs-20180226monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-fourth-quarter-and-full-year-2017-financial-results-and-c-ebs-20180208monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-initiates-phase-2-clinical-study-to-evaluate-flu-igiv-to-treat-serio-ebs-20180104monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-first-quarter-2018-investor-conferences-ebs-20180103monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-awarded-department-of-national-defence-contract-to-supply-anthrasil--ebs-20171212monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-host-2017-analyst-investor-day-ebs-20171130monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-fda-approval-to-manufacture-acam2000-at-canton-massachusett-ebs-20171120monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-notice-of-termination-of-conversion-rights-of-2-875-conver-ebs-20171114monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-third-quarter-and-nine-months-2017-financial-results-and--ebs-20171019monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-completes-acquisition-of-acam2000-business-from-sanofi-ebs-20171006monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-awarded-u-s-department-of-state-contract-valued-at-up-to-25-million--ebs-20171004monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-completes-acquisition-of-raxibacumab-an-fda-approved-anthrax-monoclo-ebs-20171003monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-closing-of-new-200-million-senior-secured-credit-facility-ebs-20171002monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-supply-dod-with-chemical-threat-countermeasure-rsdl-under-five-ye-ebs-20170925monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-awarded-63-million-barda-contract-to-develop-treatment-for-cyanide-e-ebs-20170918monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-awarded-23-million-to-develop-novel-multi-drug-auto-injector-for-u-s-ebs-20170731monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-secures-exclusive-worldwide-rights-to-valneva-s-zika-vaccine-technol-ebs-20170726monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-second-quarter-2017-financial-results-and-conduct-a-confe-ebs-20170720monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-acquire-raxibacumab-an-fda-approved-anthrax-monoclonal-antibody-f-ebs-20170719monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-hold-annual-meeting-of-stockholders-thursday-may-25-2017-at-9-00--ebs-20170511monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-unveils-its-expanded-center-for-innovation-in-advanced-development-a-ebs-20170510monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-unveil-its-expanded-center-for-innovation-in-advanced-development-ebs-20170509monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-first-quarter-2017-financial-results-and-conduct-a-confer-ebs-20170420monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-signs-53-million-modification-to-barda-contract-for-the-manufacture--ebs-20170331monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-awarded-100-million-barda-contract-for-biothrax-deliveries-to-the-st-ebs-20170317monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-fourth-quarter-and-twelve-months-2016-financial-results-reaf-ebs-20170223monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-barda-task-order-valued-at-up-to-30-5-million-to-develop-vi-ebs-20170213monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-fourth-quarter-and-full-year-2016-financial-results-and-c-ebs-20170209monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-initiates-niaid-funded-phase-1b-clinical-study-to-evaluate-broad-spe-ebs-20170201monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-german-federal-ministry-of-health-approval-of-building-55-f-ebs-20170127monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-preliminary-2016-financial-results-and-provides-2017-finan-ebs-20170109monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-first-quarter-2017-investor-conferences-ebs-20161229monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-health-canada-approval-for-botulism-antitoxin-ebs-20161212monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-support-hhs-anthrax-preparedness-strategy-with-up-to-1-billion-in-ebs-20161208monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-third-quarter-2016-financial-results-and-conduct-a-confer-ebs-20161101monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-provides-update-on-status-of-biothrax-procurement-contract-and-discu-ebs-20160930monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-remind-ebs-20160903monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-fda-approval-for-large-scale-manufacturing-of-biothrax-in-b-ebs-20160815monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-conversion-rate-adjustment-to-2-875-convertible-senior-not-ebs-20160812monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-completes-spin-off-of-aptevo-therapeutics-ebs-20160801monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-remind-ebs-20160730monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-remind-ebs-20160723monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-second-quarter-2016-financial-results-and-conduct-a-confe-ebs-20160721monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-commencement-of-when-issued-trading-of-aptevo-common-stock-ebs-20160720monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-effectiveness-of-aptevo-therapeutics-form-10-registration--ebs-20160715monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-implement-stock-repurchase-program-for-up-to-50-million-of-its-co-ebs-20160715monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-board-of-directors-approves-spin-off-of-aptevo-therapeutics-and-sets-ebs-20160711monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-barda-task-order-valued-at-up-to-21-9-million-to-develop-an-ebs-20160627monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-fda-orphan-drug-status-for-biothrax-for-post-exposure-proph-ebs-20160615monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-hold-annual-meeting-of-stockholders-thursday-may-19-2016-at-9-00--ebs-20160504monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-the-bank-of-america-merrill-lynch-healthcare-confe-ebs-20160426monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-first-quarter-2016-financial-results-and-conduct-a-confer-ebs-20160421monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-presents-preclinical-data-on-es425-a-bispecific-immunotherapeutic-pr-ebs-20160420monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-submits-sbla-for-fda-approval-of-large-scale-manufacturing-of-biothr-ebs-20160418monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-filing-of-form-10-registration-statement-for-its-planned-s-ebs-20160415monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-needham-company-s-15th-annual-healthcare-conferenc-ebs-20160330monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-emergard-auto-injector-platform-for-nerve-agent-antidote-delivery-se-ebs-20160217monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-fourth-quarter-and-full-year-2015-financial-results-and-c-ebs-20160211monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-executive-management-team-of-new-spin-off-company-aptevo-t-ebs-20160121monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-favorable-irs-private-letter-ruling-in-connection-with-its--ebs-20160110monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-composition-of-board-of-directors-of-new-spin-off-company--ebs-20151222monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-first-quarter-2016-investor-conferences-ebs-20151221monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-third-quarter-2015-financial-results-and-conduct-a-confer-ebs-20151022monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-44-million-cdc-contract-to-further-advance-vaccinia-immune--ebs-20150813monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-plan-to-implement-tax-free-spin-off-of-biosciences-busines-ebs-20150806monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-expands-biodefense-business-through-launch-of-a-military-grade-auto--ebs-20150803monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-second-quarter-2015-financial-results-and-conduct-a-confe-ebs-20150723monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-awarded-19-7-million-barda-contract-to-develop-and-manufacture-ebola-ebs-20150720monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-signs-long-term-manufacturing-agreement-with-prometic-life-sciences-ebs-20150519monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-hold-annual-meeting-of-stockholders-thursday-may-21-2015-at-9-00--ebs-20150514monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-first-quarter-2015-financial-results-ebs-20150507monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-expands-commercial-product-portfolio-with-fda-approval-of-ixinity-a--ebs-20150430monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-may-and-june-2015-investor-conferences-ebs-20150429monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-completes-investigation-and-resumes-biothrax-manufacturing-activitie-ebs-20150422monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-receives-fda-approval-of-anthrasil-its-anthrax-immune-globulin-for-u-ebs-20150325monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-awarded-31-million-contract-for-advanced-development-of-nuthrax-a-ne-ebs-20150324monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-signs-agreements-with-oxford-university-glaxosmithkline-and-niaid-fo-ebs-20150316monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-and-morphosys-initiate-phase-1-clinical-study-to-evaluate-the-novel--ebs-20150309monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-march-2015-investor-conferences-ebs-20150220monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-announces-primary-endpoints-met-in-pivotal-study-supporting-licensur-ebs-20150213monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-release-fourth-quarter-and-full-year-2014-financial-results-and-c-ebs-20150212monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-participate-in-january-2015-investor-conferences-ebs-20150107monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-expands-biodefense-franchise-acquires-portfolio-of-broad-spectrum-an-ebs-20141217monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-webcast-presentation-at-25th-annual-oppenheimer-healthcare-confer-ebs-20141124monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-seeks-expanded-biothrax-label-submits-fda-application-for-post-expos-ebs-20141110monthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-to-webcast-presentation-at-credit-suisse-2014-healthcare-conference-ebs-20141020monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-results-of-annual-meeting-fenc-20260610monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-business--fenc-20260514monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-ma-fenc-20260318monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-completion-of-full-debt-redemption-fenc-20251119monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-closing-of-private-offering-of-common-shares-in-canada-fenc-20251118monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-closing-of-offering-of-common-shares-fenc-20251117monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-pricing-of-offering-of-common-shares-fenc-20251114monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides-business--fenc-20251113monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-to-report-second-quarter-2025-financial-results-on-august-14-2025-fenc-20250811monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-reports-first-quarter-2025-financial-results-and-provides-business--fenc-20250513monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-to-report-first-quarter-2025-financial-results-on-may-13-2025-fenc-20250508monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2024-financial-results-on-ma-fenc-20250306monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-pedmarqsi-positive-recommendation-by-nice-for-the-prevent-fenc-20241220monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference-fenc-20241212monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conference-fenc-20241113monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides-business--fenc-20241107monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-to-report-third-quarter-2024-financial-results-on-november-7-2024-fenc-20241031monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-fenc-20240905monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-reports-second-quarter-2024-financial-results-and-provides-business-fenc-20240813monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-to-report-second-quarter-2024-financial-results-on-august-13-2024-fenc-20240806monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-management-change-fenc-20240701monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-results-of-annual-meeting-fenc-20240625monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-business--fenc-20240514monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-to-report-first-quarter-2024-financial-results-on-may-14-2024-fenc-20240507monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2023-financial-results-on-ma-fenc-20240319monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-fenc-20231109monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-to-report-third-quarter-2023-financial-results-on-november-6-2023-fenc-20231030monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-fenc-20230907monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-to-report-second-quarter-2023-financial-results-on-august-3-2023-fenc-20230731monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-results-of-annual-meeting-fenc-20230612monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-first-quarter-2023-financial-results-and-provides-busines-fenc-20230511monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-11-2023-fenc-20230508monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-reports-full-year-and-fourth-quarter-2022-financial-results-fenc-20230330monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-third-quarter-2022-financial-results-and-provides-busines-fenc-20221111monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-second-quarter-2022-financial-results-and-provides-busine-fenc-20220812monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-results-of-annual-meeting-fenc-20220614monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-fenc-20220523monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-first-quarter-2022-financial-results-and-provides-busines-fenc-20220512monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-fda-acceptance-for-filing-of-new-drug-application-resubmi-fenc-20220427monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-inc-investors-reach-out-to-the-portnoy-law-firm-prior-to-the-april--fenc-20220408monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-to-participate-in-the-2022-maxim-virtual-growth-conference-fenc-20220325monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-fiscal-year-2021-financial-results-and-provides-business--fenc-20220228monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-anno-fenc-20220222monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-anno-fenc-20220216monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-third-quarter-2021-financial-results-and-provides-busines-fenc-20211110monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-fenc-20210909monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-second-quarter-2021-financial-results-and-provides-busine-fenc-20210810monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-results-of-annual-meeting-fenc-20210629monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-first-quarter-2021-financial-results-and-provides-busines-fenc-20210513monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-fiscal-year-2020-financial-results-and-provides-business-update-fenc-20210330monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-third-quarter-2020-financial-results-and-provides-busines-fenc-20201116monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-anno-fenc-20200908monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed--fenc-20200904monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-fenc-20200812monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-second-quarter-2020-financial-results-and-provides-busine-fenc-20200805monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-results-of-annual-meeting-fenc-20200622monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-first-quarter-2020-financial-results-and-provides-busines-fenc-20200514monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-exercise-and-closing-of-underwriters-option-to-purchase-additional-shares-fenc-20200508monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-closing-of-public-offering-fenc-20200505monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-pricing-of-public-offering-fenc-20200430monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-to-present-at-the-2019-cantor-global-healthcare-conference-on-october-4-2019-fenc-20191002monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-results-of-annual-meeting-fenc-20190619monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-initiates-rolling-new-drug-application-to-u-s-food-and-drug-adminis-fenc-20181220monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-scientific-symposium-on-ototoxicity-in-pediatric-cancer-p-fenc-20181116monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-provides-business-update-and-announces-third-quarter-2018-financial-results-fenc-20181113monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-to-present-at-cantor-fitzgerald-global-healthcare-conference-on-october-1-2018-in-n-fenc-20180926monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-provides-business-update-and-announces-second-quarter-2018-financial-results-fenc-20180813monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-receives-positive-opinion-on-the-pediatric-investigation-plan-from--fenc-20180807monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-publication-of-pedmark-tm-siopel-6-clinical-data-in-the-new-england-journ-fenc-20180621monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-results-of-annual-meeting-fenc-20180608monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-provides-business-update-and-announces-first-quarter-2018-financial-results-fenc-20180514monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-provides-business-update-and-announces-fiscal-year-ended-december-31-2017-financial-fenc-20180326monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-closing-of-public-offering-fenc-20171212monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-pricing-of-public-offering-fenc-20171208monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-provides-business-update-and-reports-third-quarter-2017-results-fenc-20171113monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-on-september-27-20-fenc-20170920monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-preliminary-results-of-siopel-6-study-on-pedmark-sodium-thiosulfate-to-be-fenc-20170913monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-listing-on-the-nasdaq-capital-market-fenc-20170911monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-provides-corporate-update-and-announces-second-quarter-2017-results-fenc-20170811monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-results-of-annual-meeting-fenc-20170628monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-launch-of-european-named-patient-programme-for-sodium-thiosulfate-for-ped-fenc-20170530monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-provides-corporate-update-and-announces-first-quarter-2017-results-fenc-20170512monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-to-present-at-pioneers-2017-joseph-gunnar-conference-on-may-2-2017-in-new-york-city-fenc-20170427monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-provides-corporate-update-and-announces-fiscal-year-ended-december-31-2016-financia-fenc-20170330monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-to-present-at-19th-annual-bio-ceo-investor-conference-fenc-20170209monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-the-lancet-oncology-publication-of-children-s-oncology-group-study-of-sod-fenc-20161201monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-repricing-of-warrants-fenc-20161115monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-provides-corporate-update-and-announces-third-quarter-2016-results-fenc-20161114monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-update-of-siopel-6-study-on-sodium-thiosulfate-sts-presented-at-the-inter-fenc-20161024monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-to-present-at-rodman-renshaw-18th-annual-global-investment-conference-in-new-york-o-fenc-20160908monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-provides-corporate-update-and-announces-second-quarter-2016-results-fenc-20160812monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-to-present-at-cantor-fitzgerald-s-2nd-annual-healthcare-conference-in-new-york-on-j-fenc-20160706monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-results-of-annual-meeting-fenc-20160608monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-upcoming-events-and-presentations-fenc-20160518monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-provides-corporate-update-and-announces-first-quarter-2016-results-fenc-20160512monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-sodium-thiosulfate-presentation-for-prevention-of-ototoxicity-in-children-fenc-20160421monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-5-0-million-private-placement-of-common-shares-by-sigma-tau-finanziaria-fenc-20160408monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-provides-corporate-update-and-announces-fiscal-year-ended-december-31-2015-financia-fenc-20160328monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-new-chairman-of-the-board-fenc-20151209monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-provides-corporate-update-and-announces-third-quarter-2015-financial-results-fenc-20151112monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-to-present-at-rodman-renshaw-17th-annual-global-investment-conference-in-new-york-o-fenc-20150903monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-provides-corporate-update-and-announces-second-quarter-2015-financial-results-fenc-20150811monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-presentation-of-positive-interim-sodium-thiosulfate-phase-iii-safety-data-fenc-20150601monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-to-present-at-the-jefferies-2015-global-healthcare-conference-fenc-20150529monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-results-of-annual-meeting-fenc-20150529monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-provides-corporate-update-and-first-quarter-ended-march-31-2015-financial-results-fenc-20150515monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-availability-of-siopel-6-study-abstract-for-asco-2015-meeting-fenc-20150514monthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-announces-the-exercise-of-warrants-by-the-company-s-largest-shareho-fenc-20150504monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-los-nmra-20250407monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-inc-class-action-levi-korsinsky-reminds-neumora-therapeutics-inc-inve-nmra-20250407monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-los-nmra-20250403monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-inc-nasdaq-nmra-deadline-alert-bernstein-liebhard-llp-reminds-neumora-nmra-20250401monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-los-nmra-20250331monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-inc-class-action-the-gross-law-firm-reminds-neumora-therapeutics-inc--nmra-20250326monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-los-nmra-20250325monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-inc-nasdaq-nmra-deadline-alert-bernstein-liebhard-llp-reminds-neumora-nmra-20250324monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-inc-investors-reminder-kessler-topaz-meltzer-check-llp-reminds-neumor-nmra-20250321monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-inc-class-action-the-gross-law-firm-reminds-neumora-therapeutics-inc--nmra-20250320monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-inc-class-action-the-gross-law-firm-reminds-neumora-therapeutics-inc--nmra-20250317monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-inc-nasdaq-nmra-deadline-alert-bernstein-liebhard-llp-reminds-neumora-nmra-20250310monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-inc-nasdaq-nmra-deadline-alert-bernstein-liebhard-llp-reminds-neumora-nmra-20250303monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-inc-nmra-investors-april-7-2025-filing-deadline-in-securities-class-a-nmra-20250302monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-inc-nasdaq-nmra-deadline-alert-bernstein-liebhard-llp-reminds-neumora-nmra-20250225monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-inc-class-action-levi-korsinsky-reminds-neumora-therapeutics-inc-inve-nmra-20250224monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-levi--nmra-20250221monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-inc-nmra-investors-april-7-2025-filing-deadline-in-securities-class-a-nmra-20250221monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-inc-nasdaq-nmra-deadline-alert-bernstein-liebhard-llp-reminds-neumora-nmra-20250218monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-inc-shareholder-notice-shareholder-rights-law-firm-robbins-llp-remind-nmra-20250214monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-remind-nmra-20250213monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-levi--nmra-20250213monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-inc-nasdaq-nmra-investor-alert-investors-with-large-losses-in-neumora-nmra-20250211monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-to-host-key-opinion-leader-roundtable-to-discuss-the-potential-of-nav-nmra-20240814monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-to-participate-in-upcoming-conferences-in-may-nmra-20240506monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-to-participate-at-stifel-2024-virtual-cns-days-nmra-20240313monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-appoints-kaya-pai-panandiker-as-chief-commercial-officer-nmra-20240122monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-to-present-at-42nd-annual-j-p-morgan-healthcare-conference-nmra-20240102monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-appoints-jason-duncan-as-chief-legal-officer-nmra-20231212monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-announces-nmra-266-ind-clearance-and-initiation-of-phase-1-clinical-s-nmra-20231127monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-to-participate-in-upcoming-conferences-in-november-nmra-20231030monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-announces-appointment-of-robert-lenz-m-d-ph-d-as-executive-vice-presi-nmra-20231010monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-inc-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-mo-cmpx-20260427monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3-companion--cmpx-20260424monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-health-invites-community-to-camp-out-for-youth-behavioral-health-cmpx-20260317monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-provides-corporate-update-cmpx-20260106monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-december-investor-events-cmpx-20251125monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-september-investor-events-cmpx-20250826monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-present-second-quarter-financial-results-and-provide-business-upda-cmpx-20250808monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-reports-2025-first-quarter-financial-results-and-provides-corporate-u-cmpx-20250508monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-may-investor-events-cmpx-20250506monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-presents-data-on-enhanced-efficacy-of-ctx-471-in-combination-with-tov-cmpx-20250428monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-announces-first-patient-dosed-in-an-investigator-sponsored-trial-of-t-cmpx-20250421monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum-cmpx-20250402monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-host-webcast-highlighting-top-line-clinical-data-from-the-ongoing--cmpx-20250331monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-reports-2024-financial-results-and-provides-corporate-update-cmpx-20250227monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conferen-cmpx-20250129monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-provides-corporate-update-and-announces-advancement-of-a-new-drug-can-cmpx-20250108monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-appoints-biopharmaceutical-industry-leader-barry-shin-as-chief-financ-cmpx-20241210monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference-cmpx-20241202monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-investor-events-cmpx-20241113monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-reports-2024-third-quarter-financial-results-and-provides-corporate-u-cmpx-20241112monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-presents-novel-biomarker-data-related-to-ctx-471-clinical-activity-at-cmpx-20241108monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-announces-upcoming-poster-presentation-at-the-39th-society-for-immuno-cmpx-20241004monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-investor-events-cmpx-20240903monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-reports-2024-second-quarter-financial-results-and-provides-corporate--cmpx-20240812monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-participate-in-the-wedbush-pacgrow-healthcare-conference-cmpx-20240807monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-completes-patient-enrollment-in-companion-002-a-randomized-study-of-c-cmpx-20240806monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-pathways-announces-second-quarter-2024-financial-results-and-business-highlights-cmpx-20240801monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-pathways-appoints-lori-englebert-as-chief-commercial-officer-cmpx-20240626monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-cmpx-20240530monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-announces-ceo-transition-cmpx-20240528monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-present-phase-1-data-for-ctx-471-a-novel-cd137-agonist-antibody-de-cmpx-20240523monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-participate-in-the-h-c-wainwright-2nd-annual-bioconnect-investor-c-cmpx-20240514monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-reports-2024-first-quarter-financial-results-and-provides-corporate-u-cmpx-20240513monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-pathways-announces-first-quarter-2024-financial-results-and-business-highlights-cmpx-20240508monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-receives-fda-fast-track-designation-for-the-investigation-of-ctx-009--cmpx-20240425monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-announces-first-patient-dosed-in-the-phase-1-study-of-ctx-8371-in-pat-cmpx-20240416monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-announces-poster-presentations-at-the-cholangiocarcinoma-foundation-2-cmpx-20240412monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-participate-in-the-stifel-targeted-oncology-days-cmpx-20240410monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-presents-data-demonstrating-elimination-of-mhc-class-i-negative-tumor-cmpx-20240409monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-reports-2023-financial-results-and-provides-corporate-update-cmpx-20240321monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-participate-in-the-leerink-partners-global-biopharma-conference-cmpx-20240229monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-announces-publication-of-ctx-8371-preclinical-data-in-oncoimmunology--cmpx-20240228monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-provides-corporate-update-cmpx-20240105monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-pathways-and-greenbrook-tms-enter-into-three-year-research-collaboration-agreement-cmpx-20240105monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-reports-third-quarter-2023-financial-results-and-provides-corporate-u-cmpx-20231109monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-investor-events-cmpx-20231107monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-investor-events-cmpx-20230830monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-reports-second-quarter-2023-financial-results-and-provides-corporate--cmpx-20230803monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes-cmpx-20230622monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-investor-events-cmpx-20230601monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-reports-first-quarter-financial-results-and-provides-corporate-update-cmpx-20230504monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference-a-cmpx-20230426monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-participate-in-the-stifel-2023-virtual-targeted-oncology-days-cmpx-20230419monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-participate-in-the-cantor-fitzgerald-future-of-oncology-symposium-cmpx-20230328monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-provi-cmpx-20230315monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference-cmpx-20230202monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-announces-that-the-phase-2-data-of-ctx-009-in-combination-with-paclit-cmpx-20230119monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-announces-first-patient-dosed-in-the-phase-2-u-s-study-of-ctx-009-in--cmpx-20230106monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-announces-presentation-of-updated-results-from-the-ongoing-phase-2-st-cmpx-20221215monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-announces-first-patient-dosed-in-the-phase-1b-ctx-471-combination-tri-cmpx-20221201monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-present-at-the-piper-sandler-34th-annual-healthcare-conference-cmpx-20221122monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-reports-third-quarter-2022-financial-results-and-provides-corporate-u-cmpx-20221109monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-present-at-upcoming-investment-conferences-cmpx-20221108monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-announces-80-million-private-placement-cmpx-20221102monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-announces-clinical-collaboration-with-merck-to-evaluate-ctx-471-in-co-cmpx-20221011monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-present-at-the-24th-annual-h-c-wainwright-global-investment-confer-cmpx-20220909monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-health-center-to-host-free-educator-and-clinician-webinar-ceu-understanding-and-tr-cmpx-20220816monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-present-at-the-13th-annual-wedbush-pacgrow-healthcare-conference-cmpx-20220802monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-reports-second-quarter-2022-financial-results-and-provides-corporate--cmpx-20220801monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-present-at-the-2022-jefferies-global-healthcare-conference-cmpx-20220531monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-present-at-the-2022-h-c-wainwright-annual-global-investment-confer-cmpx-20220523monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-reports-first-quarter-2022-financial-results-and-highlights-recent-co-cmpx-20220509monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-present-at-the-bank-of-america-securities-2022-healthcare-conferen-cmpx-20220505monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-to-host-conference-call-highlighting-clinical-data-from-ctx-009-cmpx-20220503monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-announces-appointment-of-two-new-directors-to-its-board-cmpx-20220426monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-presents-data-on-ctx-8371-a-bispecific-antibody-targeting-pd-1-and-pd-cmpx-20220408monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-announces-presentation-on-ctx-8371-a-bispecific-antibody-targeting-pd-cmpx-20220330monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-provi-cmpx-20220321monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-announces-us-fda-clearance-of-investigational-new-drug-application-fo-cmpx-20220120monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-pathways-nasdaq-cmps-ipo-proves-psychedelic-medicine-investment-thesis-cmpx-20201002monthly0.5https://www.biopharmawatch.com/news/CMPX/compass-cannabis-clinics-launches-international-venture-cmpx-20180611monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-u-prld-20260512monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-reports-full-year-2025-financial-results-and-provides-program-outlook-prld-20260310monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-presents-data-at-the-2025-ash-annual-meeting-from-its-myeloproliferat-prld-20251206monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate--prld-20250814monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-reports-first-quarter-2025-financial-results-and-provides-corporate-u-prld-20250506monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-reports-full-year-2024-financial-results-and-provides-program-outlook-prld-20250310monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-to-participate-in-barclays-27th-annual-global-healthcare-conference-prld-20250305monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-presents-preliminary-results-of-phase-1-dose-escalation-study-of-prt2-prld-20241211monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-to-participate-in-citizens-jmp-securities-hematology-and-oncology-sum-prld-20241127monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-u-prld-20241106monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-presents-new-data-from-smarca-degrader-portfolio-at-the-36th-eortc-nc-prld-20241024monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-publication-of-abstracts-for-presentation-at-the-36th-eortc-prld-20241009monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate--prld-20240812monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-clinical-collaboration-with-merck-to-evaluate-prt3789-in-co-prld-20240709monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-to-participate-in-upcoming-healthcare-conferences-prld-20240603monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-to-participate-in-citizens-jmp-life-sciences-conference-prld-20240509monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-reports-first-quarter-2024-financial-results-and-provides-corporate-u-prld-20240507monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-highlights-continued-strength-of-discovery-engine-at-2024-aacr-annual-meeting-prld-20240409monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-announces-acceptance-of-multiple-preclinical-abstracts-at-the-2024-aacr-annual-mee-prld-20240305monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-to-participate-in-barclays-global-healthcare-conference-prld-20240229monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-and-abcellera-enter-partnership-to-develop-first-in-class-precision-a-prld-20231101monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-announces-multiple-clinical-and-preclinical-poster-presentations-at-aacr-nci-eortc-prld-20231014monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-september-prld-20230829monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-to-participate-in-jefferies-healthcare-conference-prld-20230531monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-pricing-of-public-offering-prld-20230518monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-to-participate-in-three-healthcare-investor-conferences-in-may-prld-20230427monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-to-present-at-american-association-for-cancer-research-2023-conferenc-prld-20230411monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-clinical-trial-collaboration-with-beigene-to-evaluate-prt25-prld-20230315monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-to-participate-in-barclays-global-healthcare-conference-prld-20230301monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences-prld-20230209monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-receives-fda-clearance-of-ind-for-prt3789-a-potent-and-selective-firs-prld-20221018monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-to-participate-in-upcoming-hc-wainwright-and-morgan-stanley-healthcar-prld-20220906monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-to-participate-at-the-barclays-2022-global-healthcare-conference-prld-20220311monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-provides-clinical-update-and-announces-presentation-of-new-preclinica-prld-20220309monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-to-present-at-the-11th-annual-svb-leerink-global-healthcare-conferenc-prld-20220211monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-virtual-conference-prld-20220104monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-to-participate-at-the-4th-annual-evercore-isi-healthconx-conference-prld-20211123monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-ind-clearance-for-prt2527-a-highly-selective-cdk9-inhibitor-prld-20211108monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-presentation-of-encouraging-data-from-multiple-programs-at--prld-20211007monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences-prld-20210902monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-appointment-of-martin-babler-to-its-board-of-directors-prld-20210719monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-presentation-at-bofa-securities-2021-virtual-health-care-co-prld-20210505monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conference-prld-20210303monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-closing-of-upsized-public-offering-and-full-exercise-of-und-prld-20210111monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-pricing-of-upsized-public-offering-prld-20210107monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-launch-of-proposed-public-offering-prld-20210104monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-dosing-of-first-patient-in-phase-1-trial-of-mcl1-inhibitor--prld-20200930monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-closing-of-initial-public-offering-and-full-exercise-of-the-prld-20200929monthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-announces-pricing-of-initial-public-offering-prld-20200925monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-investigated-by-the-portnoy-law-firm-orgo-20260415monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-announces-successful-fda-meeting-and-plan-to-file-bla-for-renu-for-knee-oste-orgo-20260406monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-fourth-quarter-and-fiscal-year-2025-financial-results-orgo-20260219monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-third-quarter-of-fiscal-year-2025-financial-results-o-orgo-20251001monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-second-quarter-2025-financial-results-orgo-20250807monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-first-quarter-2025-financial-results-orgo-20250508monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-cov-orgo-20250411monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-first-quarter-of-fiscal-year-2025-financial-results-o-orgo-20250407monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-fourth-quarter-2024-financial-results-orgo-20250227monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-fourth-quarter-of-fiscal-year-2024-financial-results--orgo-20250127monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-commends-final-lcds-orgo-20241115monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-third-quarter-2024-financial-results-orgo-20241112monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-reports-positive-interim-analysis-of-second-phase-3-clinical-trial-of-renu-f-orgo-20241111monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-third-quarter-of-fiscal-year-2024-financial-results-o-orgo-20241016monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-announces-publication-of-randomized-clinical-trial-results-demonstrating-the-orgo-20241001monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-participate-in-upcoming-investor-conferences-in-september-orgo-20240904monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-second-quarter-2024-financial-results-orgo-20240808monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-shares-renu-program-update-orgo-20240808monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-second-quarter-of-fiscal-year-2024-financial-results--orgo-20240715monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-participate-in-the-truist-securities-medtech-conference-orgo-20240606monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-first-quarter-2024-financial-results-orgo-20240509monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-achieves-primary-endpoint-in-phase-3-clinical-trial-of-renu-for-knee-osteoar-orgo-20240502monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-first-quarter-of-fiscal-year-2024-financial-results-o-orgo-20240416monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-alert-bragar-eagel-squire-p-c-is-investigating-organogenesis-holdings-inc-on-orgo-20240216monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-participate-in-the-btig-snowbird-medtech-digital-health-life-orgo-20240212monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-alert-bragar-eagel-squire-p-c-is-investigating-organogenesis-holdings-inc-on-orgo-20240209monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-fourth-quarter-and-fiscal-year-2023-financial-results-orgo-20240208monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-alert-bragar-eagel-squire-p-c-is-investigating-organogenesis-holdings-inc-on-orgo-20240102monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-third-quarter-2023-financial-results-orgo-20231109monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-third-quarter-of-fiscal-year-2023-financial-results-o-orgo-20231005monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-applauds-withdrawal-of-local-coverage-determinations-by-novitas-first-coast--orgo-20230928monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-participate-in-the-morgan-stanley-21st-annual-global-healthc-orgo-20230906monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-second-quarter-of-fiscal-year-2023-financial-results--orgo-20230710monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-first-quarter-2023-financial-results-orgo-20230510monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-president-and-chief-executive-officer-gary-s-gillheeney-sr-elected-chair-of--orgo-20230427monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-first-quarter-of-fiscal-year-2023-financial-results-o-orgo-20230410monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-applauds-findings-from-the-office-of-inspector-general-orgo-20230327monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-fourth-quarter-2022-and-fiscal-year-2022-financial-resu-orgo-20230301monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-reports-positive-interim-analysis-of-phase-3-clinical-trial-of-renu-for-knee-orgo-20230301monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-fourth-quarter-and-fiscal-year-2022-financial-results-orgo-20230209monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-participate-in-the-cantor-fitzgerald-medical-and-aesthetic-d-orgo-20221205monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-third-quarter-2022-financial-results-orgo-20221109monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-third-quarter-of-fiscal-year-2022-financial-results-o-orgo-20220926monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-participate-in-the-morgan-stanley-20th-annual-global-healthc-orgo-20220907monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-second-quarter-2022-financial-results-orgo-20220809monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-second-quarter-of-fiscal-year-2022-financial-results--orgo-20220630monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-first-quarter-2022-financial-results-orgo-20220510monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-first-quarter-of-fiscal-year-2022-financial-results-o-orgo-20220405monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-present-at-the-oppenheimer-healthcare-conference-orgo-20220308monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-participate-in-upcoming-investor-conferences-in-february-orgo-20220211monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-fourth-quarter-and-fiscal-year-2021-financial-results-orgo-20220207monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-orgo-20211225monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-orgo-20211220monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-alert-bragar-eagel-squire-p-c-is-investigating-organogenesis-holdings-inc-on-orgo-20211213monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-orgo-20211211monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-alert-bragar-eagel-squire-p-c-is-investigating-organogenesis-holdings-inc-on-orgo-20211208monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-alert-bragar-eagel-squire-p-c-is-investigating-organogenesis-holdings-inc-on-orgo-20211203monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-alert-bragar-eagel-squire-p-c-is-investigating-organogenesis-holdings-inc-on-orgo-20211127monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-participate-in-the-credit-suisse-30th-annual-healthcare-conf-orgo-20211108monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-investigation-block-leviton-is-investigating-organogenesis-holdings-inc-for--orgo-20211020monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-investors-company-investigated-by-the-portnoy-law-firm-orgo-20211015monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-third-quarter-of-fiscal-year-2021-financial-results-o-orgo-20211007monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-participate-in-upcoming-investor-conferences-in-september-orgo-20210910monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-second-quarter-and-first-half-2021-financial-results-orgo-20210809monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-announces-new-200-million-credit-agreement-with-silicon-valley--orgo-20210809monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-second-quarter-of-fiscal-year-2021-financial-results--orgo-20210702monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-first-quarter-2021-financial-results-orgo-20210510monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-first-quarter-of-fiscal-year-2021-financial-results-o-orgo-20210412monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-participate-in-upcoming-investor-conferences-in-february-and-orgo-20210209monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-fourth-quarter-and-fiscal-year-2020-financial-results-orgo-20210208monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-participate-in-the-icr-conference-2021-orgo-20210105monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-announces-pricing-of-public-offering-of-class-a-common-stock-orgo-20201113monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-announces-proposed-public-offering-of-class-a-common-stock-orgo-20201110monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-third-quarter-and-nine-months-2020-financial-results-orgo-20201109monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-preliminary-financial-results-for-third-quarter-2020-orgo-20201014monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-updates-date-and-time-of-presentation-at-the-oppenheimer-fall-h-orgo-20200917monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-participate-in-upcoming-investor-conferences-in-september-orgo-20200903monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-announces-management-change-orgo-20200824monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-second-quarter-and-first-half-2020-financial-results-orgo-20200810monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-preliminary-revenue-results-for-second-quarter-2020-orgo-20200715monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-second-quarter-of-fiscal-year-2020-financial-results--orgo-20200629monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-first-quarter-2020-financial-results-orgo-20200511monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-preliminary-revenue-results-for-first-quarter-2020-orgo-20200408monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-present-at-the-9th-annual-svb-leerink-global-healthcare-conf-orgo-20200221monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-fourth-quarter-and-fiscal-year-2019-financial-results-orgo-20200123monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-announces-pricing-of-public-offering-of-class-a-common-stock-orgo-20191122monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-announces-proposed-public-offering-of-class-a-common-stock-orgo-20191119monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-third-quarter-of-fiscal-year-2019-financial-results-o-orgo-20190917monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-second-quarter-and-first-half-2019-financial-results-orgo-20190809monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-commences-offer-to-exchange-class-a-common-stock-for-any-and-all-ou-orgo-20190722monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-second-quarter-of-fiscal-year-2019-financial-results--orgo-20190606monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-first-quarter-2019-financial-results-orgo-20190510monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-first-quarter-of-fiscal-year-2019-financial-results-o-orgo-20190402monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-reports-fourth-quarter-and-fiscal-year-2018-financial-results-orgo-20190318monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-announces-renu-clinical-trial-results-at-aaos-2019-annual-meeti-orgo-20190312monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-present-at-oppenheimer-s-29th-annual-healthcare-conference-orgo-20190311monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-inc-to-report-fourth-quarter-and-fiscal-year-2018-financial-results-orgo-20190225monthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-neurobiological-technologies-and-insilco-holding-events-to-be-broadcast-by-v-orgo-20011109monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-avir-20260106monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-at-the-8th-annual-evercore-healthcare-conference-avir-20251119monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-host-third-quarter-2025-financial-results-and-business-update-conf-avir-20251105monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-new-data-supporting-combination-of-bemnifosbuvir-and-ruzas-avir-20251007monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-reports-first-quarter-2025-financial-results-and-provides-business-up-avir-20250512monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-announces-full-results-from-phase-2-study-of-regimen-of-bemnifosbuvir-avir-20250507monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-host-virtual-hcv-kol-panel-on-may-14-2025-avir-20250501monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-new-data-showcasing-potential-best-in-class-regimen-of-bem-avir-20250423monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-announces-dosing-of-first-patient-in-c-beyond-phase-3-study-evaluatin-avir-20250409monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-highlights-actions-underway-to-enhance-shareholder-value-avir-20250326monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-announces-presentation-of-bemnifosbuvir-preclinical-data-at-the-38th--avir-20250319monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-host-fourth-quarter-and-full-year-2024-financial-results-conferenc-avir-20250227monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-appoints-arthur-s-kirsch-to-board-of-directors-avir-20250224monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-avir-20250108monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-retains-financial-advisor-to-explore-strategic-partnerships-avir-20241216monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-announces-positive-results-from-phase-2-study-of-bemnifosbuvir-and-ru-avir-20241204monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-and-provide-a-business-update-at-the-7th-annual-evercore-h-avir-20241126monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-presents-multiple-new-datasets-supporting-the-combination-of-bemnifos-avir-20241115monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-host-third-quarter-2024-financial-results-conference-call-on-novem-avir-20241031monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-new-data-supporting-the-combination-of-bemnifosbuvir-and-r-avir-20241030monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-provides-update-on-global-phase-3-sunrise-3-trial-evaluating-bemnifos-avir-20240913monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-announces-publication-of-additional-data-further-highlighting-bemnifo-avir-20240828monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-host-second-quarter-2024-financial-results-conference-call-on-augu-avir-20240731monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-presents-positive-initial-phase-2-data-for-bemnifosbuvir-and-ruzasvir-avir-20240605monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-at-the-jefferies-healthcare-conference-avir-20240529monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-presents-new-data-showcasing-potential-best-in-class-combination-prof-avir-20240522monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-host-first-quarter-2024-financial-results-conference-call-on-may-1-avir-20240507monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-announces-presentation-of-data-highlighting-favorable-safety-profile-of-bemnifosbuvir-avir-20240429monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-completes-patient-enrollment-in-global-phase-3-sunrise-3-trial-evalua-avir-20240327monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-host-fourth-quarter-and-full-year-2023-financial-results-conferenc-avir-20240221monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-announces-positive-initial-data-from-phase-2-study-for-hepatitis-c-vi-avir-20240108monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-avir-20240103monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-presents-promising-bemnifosbuvir-and-ruzasvir-combination-data-for-th-avir-20231113monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-announces-participation-at-upcoming-investor-conferences-avir-20231108monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-bemnifosbuvir-and-ruzasvir-data-for-the-treatment-of-hepat-avir-20231102monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-host-third-quarter-2023-financial-results-conference-call-on-novem-avir-20231101monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-at-the-morgan-stanley-21st-annual-global-healthcare-confer-avir-20230906monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-host-second-quarter-2023-financial-results-conference-call-on-augu-avir-20230801monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-announces-first-patient-dosed-in-phase-2-study-for-treatment-of-hepat-avir-20230615monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-at-the-jefferies-healthcare-conference-avir-20230605monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-board-of-directors-unanimously-rejects-unsolicited-proposal-from-tang-avir-20230530monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-confirms-receipt-of-unsolicited-proposal-from-tang-capital-partners-a-avir-20230523monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-host-first-quarter-2023-financial-results-conference-call-on-may-8-avir-20230501monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-announces-u-s-fda-fast-track-designation-granted-to-bemnifosbuvir-an--avir-20230425monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-announces-presentation-of-bemnifosbuvir-data-demonstrating-reduced-hospitalizations-f-avir-20230412monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-presents-favorable-drug-interaction-profile-of-bemnifosbuvir-in-phase-avir-20230223monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-report-fourth-quarter-and-full-year-2022-financial-results-and-pro-avir-20230221monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conferen-avir-20230215monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference-avir-20230207monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-highlights-strategic-priorities-for-2023-avir-20230109monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-avir-20230104monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-announces-first-patient-dosed-in-sunrise-3-phase-3-registrational-tri-avir-20221129monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-at-the-5th-annual-evercore-isi-healthconx-conference-avir-20221122monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-at-the-jefferies-london-healthcare-conference-avir-20221108monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-presents-favorable-at-752-phase-1-data-for-treatment-of-dengue-fever--avir-20221103monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-host-third-quarter-2022-financial-results-conference-call-on-novem-avir-20221031monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-announces-u-s-fda-fast-track-designation-granted-to-at-752-for-treatm-avir-20220926monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-to-advance-global-phase-3-registrational-study-of-bemnifosbuvir-in-high-risk-non-hosp-avir-20220913monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-announces-upcoming-investor-events-avir-20220907monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-host-second-quarter-2022-financial-results-conference-call-on-augu-avir-20220801monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-participates-in-the-william-blair-biotech-focus-conference-avir-20220711monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-at-the-2022-jefferies-healthcare-conference-avir-20220601monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-host-first-quarter-2022-financial-results-conference-call-on-may-1-avir-20220503monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-reports-nonclinical-bemnifosbuvir-at-527-toxicology-data-at-society-o-avir-20220328monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-host-fourth-quarter-and-full-year-2021-financial-results-conferenc-avir-20220222monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-appoints-nancy-gail-berry-agrawal-ph-d-as-executive-vice-president-of-avir-20220210monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-at-11th-annual-svb-leerink-global-healthcare-conference-avir-20220209monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-announces-publication-of-data-supporting-bemnifosbuvir-s-at-527-novel-avir-20220202monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-highlights-strategic-priorities-for-2022-avir-20220107monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-at-40th-annual-j-p-morgan-healthcare-conference-avir-20220103monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-added-to-the-nasdaq-biotechnology-index-avir-20211217monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-introduces-new-strategic-clinical-development-program-for-at-527-in-c-avir-20211214monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-at-the-4th-annual-evercore-isi-healthconx-conference-avir-20211122monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-provides-update-on-strategic-collaboration-with-roche-avir-20211116monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-host-third-quarter-financial-results-conference-call-on-november-1-avir-20211104monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-provides-update-and-topline-results-for-phase-2-moonsong-trial-evalua-avir-20211019monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-virology-and-early-clinical-data-at-the-isirv-who-virtual--avir-20211007monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-at-guggenheim-2nd-annual-vaccines-infectious-day-conferenc-avir-20210929monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-at-the-morgan-stanley-19th-annual-global-healthcare-confer-avir-20210907monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-announces-publication-of-data-highlighting-at-752-s-potent-in-vitro-a-avir-20210824monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-host-second-quarter-financial-results-conference-call-on-august-12-avir-20210805monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-at-william-blair-biotech-focus-conference-avir-20210712monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-s-at-527-an-oral-antiviral-drug-candidate-reduces-viral-replication-in-hospitalized-p-avir-20210630monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-announces-achievement-of-at-527-development-milestone-under-license-a-avir-20210616monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-appoints-claudio-avila-mb-bs-ph-d-as-senior-vice-president-of-medical-avir-20210615monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-at-jefferies-virtual-healthcare-conference-avir-20210526monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-appoints-jerome-adams-m-d-m-p-h-to-board-of-directors-avir-20210520monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-host-first-quarter-financial-results-conference-call-on-may-13-202-avir-20210506monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-announces-first-patient-dosed-in-global-phase-3-morningsky-trial-of-a-avir-20210429monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-reports-full-year-2020-financial-results-and-provides-corporate-updat-avir-20210330monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-host-fourth-quarter-and-full-year-2020-financial-results-conferenc-avir-20210323monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-presents-favorable-phase-1-results-for-at-527-at-28th-annual-conferen-avir-20210306monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-announces-chugai-in-license-of-at-527-from-roche-for-the-treatment-of-avir-20210219monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-announces-publication-of-preclinical-data-highlighting-potent-activit-avir-20210208monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-announces-first-patient-dosed-in-phase-2-virology-trial-of-at-527-in--avir-20210204monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-expands-senior-management-team-with-key-additions-in-regulatory-affai-avir-20210119monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-at-39th-annual-j-p-morgan-healthcare-conference-avir-20201221monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-added-to-russell-2000-index-avir-20201218monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-at-evercore-isi-3rd-annual-healthconx-conference-avir-20201125monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-expands-board-of-directors-with-appointment-of-barbara-duncan-avir-20201106monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-announces-closing-of-initial-public-offering-avir-20201103monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-announces-pricing-of-initial-public-offering-avir-20201030monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-announces-strategic-collaboration-with-roche-to-develop-and-distribut-avir-20201022monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-appoints-polly-murphy-d-v-m-ph-d-to-the-board-of-directors-avir-20200914monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-strengthens-management-team-with-appointment-of-clinical-and-regulato-avir-20200824monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-appoints-janet-hammond-m-d-ph-d-as-chief-development-officer-avir-20200810monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-announces-ind-clearance-of-at-527-for-covid-19-and-215-million-financ-avir-20200520monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-to-present-positive-clinical-data-with-at-527-for-the-treatment-of-ch-avir-20181109monthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-reports-positive-proof-of-concept-clinical-data-with-at-527-for-the-t-avir-20180412monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-announce-third-quarter-2024-results-november-7-2024-clpt-20241017monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-early-repayment-of-10-million-note-clpt-20240826monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2024-results-august-7-2024-clpt-20240717monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-congratulates-partner-aspen-neuroscience-on-use-of-the-clearpoint-navigat-clpt-20240620monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-full-market-release-of-smartframe-or-and-clearpoint-prism-3t-la-clpt-20240601monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-present-novel-research-and-exhibit-at-the-27th-american-society-of-gen-clpt-20240502monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-fda-clearance-of-prism-bone-anchor-accessory-clpt-20240429monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-initiation-of-limited-market-release-for-the-smartframe-or-ster-clpt-20240424monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-announce-first-quarter-2024-results-may-7-2024-clpt-20240423monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-congratulates-its-partner-aviadobio-on-first-patient-treated-in-its-aspir-clpt-20240416monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-congratulates-its-partner-ptc-therapeutics-on-completion-of-biologics-lic-clpt-20240319monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-announce-fourth-quarter-and-full-year-2023-results-march-12-2024-clpt-20240301monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-pricing-of-public-offering-of-2-307-694-shares-of-common-stock-clpt-20240229monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-launches-proposed-public-offering-of-common-stock-clpt-20240228monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-fda-clearance-and-first-in-human-cases-performed-with-the-new-2-clpt-20240221monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-installation-and-first-procedure-using-the-clearpoint-prism-neu-clpt-20240124monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-first-eu-mdr-certification-success-and-approval-to-ship-product-clpt-20240122monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-fda-clearance-for-smartframe-or-stereotactic-system-clpt-20240116monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-inc-s-innovative-pipeline-products-under-analysis-in-new-2023-update-clpt-20231228monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-announce-third-quarter-2023-results-november-9-2023-clpt-20231026monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2023-results-august-8-2023-clpt-20230725monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-and-ucb-enter-license-agreement-for-gene-therapy-drug-delivery-clpt-20230524monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-present-at-the-b-riley-securities-2023-institutional-investor-conferen-clpt-20230518monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-present-investigational-research-and-showcase-novel-innovations-at-the-clpt-20230510monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-announce-first-quarter-2023-results-may-11-2023-clpt-20230428monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-showcase-two-novel-innovations-at-aans-2023-clearpoint-maestro-brain-m-clpt-20230420monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-agreement-with-ne-scientific-to-integrate-gene-therapy-infusion-clpt-20230418monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-anvisa-approval-of-neuro-navigation-portfolio-in-brazil-clpt-20230413monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-extends-software-license-and-research-agreement-with-philips-to-include-f-clpt-20230411monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-exclusive-multi-year-licensing-agreement-with-ucsf-for-innovati-clpt-20230328monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-announce-fourth-quarter-and-full-year-2022-revenue-results-march-1-202-clpt-20230215monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-present-at-upcoming-investor-conferences-clpt-20221109monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-announce-third-quarter-2022-results-november-8-2022-clpt-20221026monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-fda-clearance-for-clearpoint-prism-neuro-laser-therapy-system-clpt-20220923monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-fda-clearance-for-software-version-2-1-clpt-20220919monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-fda-clearance-for-clearpoint-maestro-brain-model-clpt-20220809monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-inc-announces-appointment-of-mary-mcnamara-cullinane-as-vice-president-of-clpt-20220808monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2022-results-august-9-2022-clpt-20220726monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-congratulates-partner-ptc-therapeutics-on-being-granted-marketing-authori-clpt-20220721monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-congratulates-neurona-therapeutics-on-dosing-of-initial-subject-in-first--clpt-20220629monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-receipt-of-mdsap-certification-clpt-20220602monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-congratulates-partner-ptc-therapeutics-on-receiving-positive-chmp-opinion-clpt-20220520monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-present-investigational-research-and-exhibit-at-the-american-society-o-clpt-20220513monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-and-higgs-boson-health-announce-collaboration-clpt-20220503monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-fda-clearance-of-the-smartframe-array-version-1-1-clpt-20220428monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-expands-software-license-and-research-agreement-with-philips-to-power-exp-clpt-20220427monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-announce-first-quarter-2022-results-may-11-2022-clpt-20220426monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-present-at-the-b-riley-securities-disruptive-biotech-enabling-technolo-clpt-20220329monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-participate-at-the-h-c-wainwright-bioconnect-virtual-conference-clpt-20220105monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-congratulates-blackrock-neurotech-on-receiving-breakthrough-device-design-clpt-20211117monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-congratulates-neurona-therapeutics-on-ind-clearance-for-neural-cell-thera-clpt-20211108monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-present-at-the-2021-stifel-virtual-healthcare-conference-clpt-20211104monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-announce-third-quarter-2021-results-november-9-2021-clpt-20211026monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-inc-announces-strategic-and-commercial-partnership-with-european-surgical-clpt-20210809monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2021-results-august-10-2021-clpt-20210802monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-set-to-join-russell-3000-index-clpt-20210614monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-inc-congratulates-bluerock-therapeutics-on-first-patient-dosed-with-da01--clpt-20210608monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-present-at-the-ubs-global-healthcare-virtual-conference-clpt-20210519monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-inc-announces-first-in-human-cases-of-the-smartframe-array-neuro-navigati-clpt-20210518monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-partnership-with-d-k-engineering-for-development-of-robotic-sys-clpt-20210510monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-announce-first-quarter-2021-results-may-11-2021-clpt-20210429monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-inc-congratulates-voyager-therapeutics-on-fda-clearance-of-ind-applicatio-clpt-20210428monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-clpt-20210423monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-inc-congratulates-uniqure-on-completion-of-enrollment-in-first-cohort-of--clpt-20210406monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel-clpt-20210324monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-closing-of-public-offering-of-2-127-660-shares-of-common-stock-clpt-20210223monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-announce-fourth-quarter-and-full-year-2020-results-on-march-4-2021-clpt-20210219monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-pricing-of-public-offering-of-1-850-140-shares-of-common-stock-clpt-20210219monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-launches-proposed-public-offering-of-common-stock-clpt-20210218monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-inc-announces-license-and-research-agreement-with-philips-clpt-20210218monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-inc-announces-multi-product-joint-development-option-agreement-with-black-clpt-20210211monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-inc-announces-expansion-of-pre-clinical-and-translational-development-tea-clpt-20210126monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-inc-announces-first-procedure-utilizing-clearpoint-2-0-software-in-europe-clpt-20210114monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-inc-reports-record-revenue-in-preliminary-fourth-quarter-2020-results-clpt-20210112monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-completes-4-000th-clearpoint-neuro-navigation-procedure-clpt-20201130monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-announce-third-quarter-2020-results-on-november-10-clpt-20201104monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2020-results-on-august-12-clpt-20200806monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-announce-first-quarter-2020-results-on-may-12-clpt-20200507monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-to-announce-fourth-quarter-and-full-year-2019-results-february-12-clpt-20200211monthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-navigation-system-s-real-time-mri-guided-platform-to-be-featured-at-aans--clpt-20170418monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program--naut-20260318monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-participate-in-the-td-cowen-46th-annual-health-care-conference-naut-20260219monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-launches-early-access-program-for-novel-single-molecule-proteomics--naut-20260108monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-announce-third-quarter-2025-financial-results-on-october-28-2025-naut-20251007monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-announce-second-quarter-2025-financial-results-on-july-31-2025-naut-20250715monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-announce-first-quarter-2025-financial-results-on-april-29-2025-naut-20250416monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-participate-in-the-td-cowen-45th-annual-healthcare-conference-naut-20250218monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-announce-fourth-quarter-and-full-year-2024-financial-results-on--naut-20250206monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-co-founder-and-chief-scientist-parag-mallick-ph-d-honored-with-the--naut-20241031monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-participate-in-the-inaugural-guggenheim-healthcare-conference-naut-20241030monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-announce-third-quarter-2024-financial-results-on-october-29-2024-naut-20241008monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-appoints-mass-spectrometry-leader-ken-suzuki-as-chief-marketing-off-naut-20240917monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-participate-in-the-morgan-stanley-22nd-annual-global-healthcare--naut-20240814monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-announce-second-quarter-2024-financial-results-on-july-30-2024-naut-20240709monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-participate-in-the-goldman-sachs-45th-annual-global-healthcare-c-naut-20240523monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-announce-first-quarter-2024-financial-results-on-april-30-2024-naut-20240411monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-announce-fourth-quarter-and-full-year-2023-financial-results-on--naut-20240207monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-co-founder-and-chief-scientist-parag-mallick-ph-d-honored-with-us-h-naut-20231130monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-appoints-martin-huber-ph-d-as-vice-president-of-biochemistry-and-fl-naut-20231101monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-announce-third-quarter-financial-results-on-october-31-2023-naut-20231011monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-participate-in-upcoming-september-investor-conferences-naut-20230906monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-participate-in-upcoming-august-investor-conferences-naut-20230804monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-announce-second-quarter-financial-results-on-august-2-2023-naut-20230711monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-participate-in-upcoming-june-investor-conferences-naut-20230524monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-announce-first-quarter-financial-results-on-may-2-2023-naut-20230418monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-participate-in-b-riley-securities-disruptive-biotech-enabling-te-naut-20230323monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-announces-first-access-challenge-winners-naut-20230307monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-participate-in-the-43rd-annual-cowen-health-care-conference-naut-20230221monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-announce-fourth-quarter-and-full-year-2022-financial-results-on--naut-20230126monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-expands-to-san-diego-naut-20230126monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-partners-with-the-translational-genomics-research-institute-tgen-to-naut-20230119monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-launches-first-access-challenge-naut-20221116monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-announce-third-quarter-2022-financial-results-on-november-1-2022-naut-20221005monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-participate-in-the-capital-one-spatial-biology-proteomics-summit-naut-20220923monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-joins-human-proteome-organization-hupo-industrial-advisory-board-naut-20220901monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-participate-in-the-morgan-stanley-global-healthcare-conference-naut-20220830monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-appoints-eric-spence-as-vice-president-of-instrument-engineering-an-naut-20220801monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-announce-second-quarter-2022-financial-results-on-august-2-2022-naut-20220713monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-appoints-gwen-weld-as-chief-people-officer-and-sheri-wilcox-ph-d-as-naut-20220412monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-announce-first-quarter-2022-financial-results-on-may-3-2022-naut-20220407monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-present-at-eupa-and-aacr-meetings-naut-20220404monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-to-participate-in-the-42nd-annual-cowen-health-care-conference-naut-20220216monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-announce-fourth-quarter-and-full-year-2021-financial-results-on--naut-20220127monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-and-abcam-announce-strategic-partnership-to-accelerate-exploration-of-the-proteom-naut-20211102monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-announce-third-quarter-of-fiscal-year-2021-financial-results-on--naut-20211011monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-to-participate-in-the-morgan-stanley-global-healthcare-conference-naut-20210903monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-reports-second-quarter-2021-financial-results-naut-20210810monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-appoints-karl-voss-ph-d-as-vice-president-of-life-sciences-research-naut-20210809monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-to-announce-second-quarter-of-fiscal-year-2021-financial-results-on-naut-20210713monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-appoints-emma-lundberg-ph-d-to-scientific-advisory-board-naut-20210617monthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-debuts-as-publicly-traded-company-seeks-to-deliver-on-the-untapped--naut-20210610monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-selected-for-oral-presentation-of-cnty-813-preclinical-data-at-the-am-ipsc-20260430monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-participate-in-piper-sandler-37th-annual-healthcare-conference-ipsc-20251125monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-announces-investigator-initiated-phase-1-2-trial-of-its-ipsc-derived--ipsc-20250121monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-the-piper-sandler-36th-annual-healthcare-conference-ipsc-20241126monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-announces-upcoming-poster-presentations-at-the-2024-american-society--ipsc-20241105monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-guggenheim-s-inaugural-healthcare-innovation-conference-ipsc-20241104monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-strengthens-leadership-team-with-appointments-of-chief-financial-offi-ipsc-20240926monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-presents-preclinical-data-highlighting-advances-in-ipsc-platform-tech-ipsc-20240510monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-chardan-s-8th-annual-genetic-medicines-and-cell-therapy-ipsc-20240423monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-the-h-c-wainwright-2nd-annual-cell-therapy-virtual-conf-ipsc-20240319monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-announces-six-upcoming-poster-presentations-at-the-2024-american-asso-ipsc-20240305monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-the-guggenheim-healthcare-talks-6th-annual-biotechnolog-ipsc-20240201monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-host-conference-call-to-discuss-preliminary-clinical-data-from-pha-ipsc-20231206monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-the-piper-sandler-35th-annual-healthcare-conference-ipsc-20231121monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-appoints-brent-pfeiffenberger-pharm-d-mba-as-chief-executive-officer-ipsc-20231109monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-and-fujifilm-cellular-dynamics-announce-licenses-for-the-development--ipsc-20231109monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-initial-clinical-data-supporting-the-potential-for-a-multi-ipsc-20231102monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-the-chardan-7th-annual-genetic-medicines-conference-ipsc-20230926monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-chardan-s-7th-annual-genetic-medicines-cell-therapy-man-ipsc-20230417monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-announces-leadership-changes-ipsc-20230412monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-the-aacr-annual-meeting-2023-ipsc-20230315monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-upcoming-investor-conferences-ipsc-20230221monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-announces-first-patient-dosed-in-first-in-human-phase-1-elipse-1-tria-ipsc-20230208monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-upcoming-investor-conferences-ipsc-20230201monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-announces-internal-portfolio-prioritization-to-extend-cash-runway-int-ipsc-20230105monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-ipsc-20230104monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-the-piper-sandler-34th-annual-healthcare-conference-ipsc-20221122monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-announces-presentation-of-preclinical-data-at-the-sitc-37th-annual-me-ipsc-20221111monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-host-virtual-research-and-development-day-on-november-11-2022-ipsc-20221102monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-the-sitc-37th-annual-meeting-ipsc-20221005monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-announces-appointment-of-daphne-quimi-and-timothy-walbert-to-its-boar-ipsc-20221003monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-chardan-s-6th-annual-genetic-medicines-conference-ipsc-20220926monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-the-h-c-wainwright-24th-annual-global-investment-confer-ipsc-20220906monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-announces-its-addition-to-the-russell-microcap-index-ipsc-20220624monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-the-lifesci-partners-2nd-annual-genetic-medicines-sympo-ipsc-20220621monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-host-virtual-research-and-development-day-on-june-13-2022-ipsc-20220606monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-upcoming-investor-conferences-ipsc-20220503monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-the-asgct-25th-annual-meeting-ipsc-20220502monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-the-chardan-genetic-medicines-and-cell-therapy-manufact-ipsc-20220418monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-the-21st-annual-needham-virtual-healthcare-conference-ipsc-20220406monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-the-h-c-wainwright-gene-therapy-and-gene-editing-confer-ipsc-20220323monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-the-11th-annual-svb-leerink-global-healthcare-conferenc-ipsc-20220209monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-and-bristol-myers-squibb-enter-into-a-strategic-collaboration-to-deve-ipsc-20220110monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-ipsc-20220104monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-added-to-the-nasdaq-biotechnology-index-ipsc-20211217monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-announces-presentation-of-data-at-the-63rd-american-society-of-hemato-ipsc-20211216monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-participate-in-the-piper-sandler-33rd-annual-virtual-healthcare-co-ipsc-20211122monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-to-present-at-the-63rd-american-society-of-hematology-annual-meeting--ipsc-20211104monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-and-outpace-bio-enter-research-collaboration-in-car-engineering-ipsc-20211007monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-announces-its-addition-to-the-russell-2000-index-ipsc-20210917monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-announces-closing-of-initial-public-offering-and-full-exercise-of-und-ipsc-20210622monthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-announces-pricing-of-initial-public-offering-ipsc-20210617monthly0.5https://www.biopharmawatch.com/news/IPSC/century-center-chiropractic-celebrates-over-25-years-of-chiropractic-service-to-the-atlant-ipsc-20170212monthly0.5https://www.biopharmawatch.com/news/IPSC/century-center-chiropractic-celebrates-23-years-of-service-to-atlanta-area-ipsc-20150927monthly0.5https://www.biopharmawatch.com/news/IPSC/century-center-chiropractic-announces-new-high-tech-equipment-for-enhanced-pain-relief-ipsc-20150426monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-to-report-second-quarter-2019-financials-and-provide-a-business-upd-dmac-20190808monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-announces-first-quarter-2019-financial-results-and-provides-busines-dmac-20190513monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-to-present-at-ckd3-kidney-summit-meeting-dmac-20190430monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-announces-2018-financial-results-and-provides-corporate-update-dmac-20190319monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-announces-date-for-the-release-of-full-year-2018-results-and-confer-dmac-20190318monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-to-attend-31st-annual-roth-investor-conference-on-march-18-19-2019-dmac-20190312monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-doses-first-patient-in-phase-1b-clinical-study-of-dm199-in-patients-dmac-20190214monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-announces-publication-of-a-paper-human-tissue-kallikrein-in-the-tre-dmac-20190122monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-announces-voluntary-delisting-from-tsx-venture-exchange-dmac-20190109monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-announces-fda-clearance-of-ind-application-to-study-dm199-in-patients-with-chron-dmac-20190103monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-closes-public-offering-in-the-united-states-dmac-20181211monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-announces-pricing-of-initial-public-offering-and-nasdaq-listing-dmac-20181207monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-has-applied-to-list-its-common-shares-on-nasdaq-announces-share-con-dmac-20181112monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-announces-results-from-annual-general-and-special-meeting-of-shareh-dmac-20181106monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-and-ahon-pharma-a-fosun-pharma-portfolio-company-announces-signing--dmac-20180927monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-announces-the-appointment-of-dr-harry-alcorn-jr-as-chief-medical-of-dmac-20180905monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-issues-stock-option-grant-dmac-20180823monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-announces-positive-results-from-fda-meeting-on-planned-clinical-trial-in-patient-dmac-20180503monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-issues-stock-option-grants-dmac-20180418monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-announces-appointment-of-scott-kellen-as-chief-financial-officer-dmac-20180405monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-announces-final-closing-of-private-placement-dmac-20180329monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-announces-closing-of-private-placement-dmac-20180320monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-announces-first-enrollment-in-its-phase-2-remedy-trial-for-acute-ischemic-stroke-dmac-20180222monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-to-present-at-the-14th-annual-noble-investor-conference-dmac-20180129monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-letter-to-shareholders-dmac-20180118monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-announces-results-of-annual-general-and-special-meeting-of-sharehol-dmac-20171221monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-completes-non-brokered-private-placement-dmac-20171219monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-announces-non-brokered-private-placement-dmac-20171213monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-announces-ethics-committee-clearance-at-first-site-to-initiate-reme-dmac-20171122monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-accelerates-warrant-expiry-date-dmac-20171120monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-announces-publication-of-positive-clinical-results-for-dm199-in-the-dmac-20171107monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-announces-dr-robert-stanton-as-scientific-advisor-for-upcoming-chronic-kidney-di-dmac-20171031monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-announces-the-early-exercise-of-warrants-from-strategic-investor-dmac-20171027monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-announces-the-initiation-of-phase-2-trial-evaluating-dm199-recombinant-human-klk-dmac-20170911monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-issues-stock-option-grant-dmac-20170619monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-completes-private-placement-with-u-s-based-family-office-dmac-20170418monthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-announces-name-change-to-diamedica-therapeutics-inc-dmac-20161223monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-to-participate-in-upcoming-investor-conferences-tenx-20251125monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-to-host-virtual-kol-call-to-discuss-tnx-103-oral-levosimendan-for-the-t-tenx-20251106monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-confe-tenx-20251103monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-to-participate-in-the-cantor-global-healthcare-conference-2025-tenx-20250828monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference-tenx-20250331monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-expands-phase-3-level-program-advancing-two-tnx-103-oral-levosimendan-r-tenx-20250305monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-to-participate-in-the-leerink-partners-2025-global-healthcare-conferenc-tenx-20250303monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-to-present-at-the-36th-annual-roth-conference-tenx-20240312monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-oral-presentation-of-levosimendan-for-the-treatment-of-ph-hfp-tenx-20240229monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-professor-javed-butler-m-d-m-p-h-m-b-a-joins-ph-hfpef-scienti-tenx-20231117monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-provides-2023-business-update-tenx-20230412monthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-announces-reverse-stock-split-tenx-20230104monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-deadline-rosen-a-leading-and-ranked-firm-encourages-regenxbio-inc-investors-with-rgnx-20260412monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-fi-rgnx-20260306monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-class-action-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-rgnx-20260218monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20180307monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-march-6-to-discuss-fourth-quarter-and-full-year-2017--rgnx-20180227monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20180207monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-upcoming-investor-conferences-rgnx-20171122monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-november-8-to-discuss-third-quarter-2017-financial-re-rgnx-20171101monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-upcoming-investor-conferences-rgnx-20171003monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-completion-of-dosing-of-first-cohort-in-phase-i-clinical-trial-of-rgx--rgnx-20170920monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-upcoming-investor-conferences-rgnx-20170831monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-acquire-dimension-therapeutics-rgnx-20170825monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-on-rgx-314-gene-therapy-program-for-wet-amd-at-35th-annual-scientific-rgnx-20170811monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-august-8-to-discuss-second-quarter-2017-financial-res-rgnx-20170801monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-the-piper-jaffray-genomerx-symposium-rgnx-20170706monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-and-avexis-announce-new-exclusive-worldwide-licenses-for-the-treatment-of-two-ra-rgnx-20170607monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-initiation-of-phase-i-clinical-trial-of-rgx-314-gene-therapy-for-wet-a-rgnx-20170531monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-the-bank-of-america-merrill-lynch-2017-health-care-conference-rgnx-20170510monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-may-9-to-discuss-first-quarter-2017-financial-results-rgnx-20170502monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-enhances-and-expands-scientific-leadership-rgnx-20170328monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-proposed-public-offering-of-common-stock-rgnx-20170321monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-initiation-of-phase-i-ii-clinical-trial-of-rgx-501-for-the-treatment-o-rgnx-20170307monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-the-cowen-and-company-37th-annual-health-care-conference-rgnx-20170306monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-honors-rare-disease-day-2017-rgnx-20170228monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-march-7-to-discuss-fourth-quarter-and-full-year-2016--rgnx-20170228monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-ind-active-for-phase-i-trial-of-rgx-314-to-treat-wet-age-related-macul-rgnx-20170214monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-the-6th-annual-leerink-partners-global-healthcare-conference-rgnx-20170209monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-the-suntrust-robinson-humphrey-2017-orphan-drug-day-rgnx-20170202monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-provides-year-end-2016-corporate-update-rgnx-20170106monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-and-voyager-therapeutics-announce-exercise-of-options-for-rights-to-nav-vectors-rgnx-20161129monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-the-28th-annual-piper-jaffray-healthcare-conference-rgnx-20161117monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-november-9-to-discuss-third-quarter-2016-financial-re-rgnx-20161102monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-the-jefferies-gene-editing-and-gene-therapy-summit-rgnx-20161004monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-publishes-data-from-ongoing-preclinical-studies-of-nav-gene-therapy-in-neurodege-rgnx-20160913monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-global-healthcare-conferences-rgnx-20160907monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-august-9-to-discuss-second-quarter-2016-financial-res-rgnx-20160801monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-and-biogen-enter-exclusive-license-agreement-for-the-development-of-gene-therapy-rgnx-20160516monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-may-investor-conferences-rgnx-20160503monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-appointment-of-faraz-ali-as-chief-business-officer-rgnx-20160301monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-provides-year-end-2015-corporate-update-rgnx-20160107monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-added-to-russell-2000-r-index-rgnx-20151218monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-and-scientific-conferences-rgnx-20151201monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-third-quarter-2015-results-rgnx-20151105monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-o-rgnx-20150922monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-inc-nasdaq-rgnx-to-ring-the-nasdaq-stock-market-opening-bell-rgnx-20150917monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-pricing-of-initial-public-offering-rgnx-20150917monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-enters-into-strategic-manufacturing-collaboration-with-wuxi-apptec-rgnx-20150611monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-secures-70-5-million-in-a-mezzanine-financing-rgnx-20150520monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-and-dimension-therapeutics-add-development-of-treatments-for-two-metabolic-disea-rgnx-20150423monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-licenses-key-technologies-from-university-of-pennsylvania-and-university-of-minn-rgnx-20150408monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-raises-30-million-in-series-c-financing-rgnx-20150121monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-26th-annual-piper-jaffray-healthcare-conference-rgnx-20141125monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-appoints-dr-stephen-yoo-as-chief-medical-officer-rgnx-20141028monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-s-nav-r-technology-demonstrates-correction-of-cardiovascular-symptoms-of-mps-i-i-rgnx-20140929monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-to-participate-in-the-jefferies-global-healthcare-conference-pali-20260527monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-to-present-at-the-needham-co-25th-annual-healthcare-conference-pali-20260408monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-to-present-at-the-piper-sandler-37th-annual-healthcare-conference-pali-20251125monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-adjournment-of-special-meeting-of-stockholders-due-to-lack-of-quoru-pali-20250918monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-releases-virtual-investor-kol-connect-segment-on-fscd-and-lead-candidate-pali-pali-20250825monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-reports-100-clinical-response-in-phase-1b-ulcerative-colitis-cohort-with-nove-pali-20250807monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-receives-notice-of-allowance-for-composition-of-matter-patent-covering-lead-p-pali-20250731monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-participates-in-the-virtual-investor-what-s-your-story-summer-spotlight-on-de-pali-20250722monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-reports-positive-phase-1a-results-for-pali-2108-a-first-in-class-terminal-ile-pali-20250527monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-presents-positive-preclinical-data-highlighting-potential-of-pali-2108-as-a-p-pali-20250506monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-s-ai-driven-approach-to-ibd-heterogeneity-and-efficacy-selected-for-presentat-pali-20250501monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-completes-dosing-in-phase-1a-portion-of-ongoing-phase-1a-b-study-of-pali-2108-pali-20250409monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-commences-dosing-in-first-ulcerative-colitis-patient-cohort-in-ongoing-phase--pali-20250314monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-two-abstracts-selected-to-be-showcased-as-poster-of-distinction-and-pali-20250312monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-participates-in-virtual-investor-what-this-means-segment-pali-20250304monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-inc-announces-receipt-of-cash-proceeds-from-canada-s-sr-ed-tax-incentive-prog-pali-20250220monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference-pali-20250219monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-presents-positive-preclinical-data-of-pali-2108-for-the-treatment-of-ulcerati-pali-20250210monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-selected-for-poster-presentation-at-the-2025-crohn-s-colitis-congress-pali-20250129monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-to-present-at-live-with-webull-corporate-connect-healthcare-investment-webina-pali-20250122monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-completes-all-five-sad-cohorts-and-advances-to-mad-cohorts-of-phase-1a-b-stud-pali-20250116monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-pali-20250103monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-appoints-brian-feagan-md-frcpc-to-its-clinical-advisory-board-pali-20241217monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-closing-of-5-million-underwritten-public-offering-priced-at-market--pali-20241213monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-pricing-of-5-million-underwritten-public-offering-priced-at-market--pali-20241212monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-preliminary-data-from-phase-1-clinical-study-of-pali-2108-for-the-t-pali-20241203monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-to-present-preclinical-results-for-pali-2108-demonstrating-engagement-of-key--pali-20241121monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-cmo-mitch-jones-md-phd-to-present-at-8th-annual-antifibrotic-drug-development-pali-20241114monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-reports-third-quarter-2024-financial-results-and-outlines-key-accomplishments-pali-20241112monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-first-subject-dosed-in-phase-1-clinical-study-of-pali-2108-for-the--pali-20241107monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-positive-data-from-two-ex-vivo-translational-studies-of-pali-2108-f-pali-20241031monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-abstract-accepted-for-presentation-at-the-american-college-of-gastr-pali-20241015monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-cleared-by-health-canada-to-commence-phase-1-clinical-study-for-lead-program--pali-20241010monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-to-participate-in-the-2024-maxim-healthcare-virtual-summit-presented-by-maxim-pali-20241008monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-provides-update-on-progress-toward-launch-of-phase-1-human-clinical-study-for-pali-20240925monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-launches-new-corporate-branding-and-reiterates-commitment-to-advancing-next-g-pali-20240916monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-reports-data-demonstrating-pde4b-expression-in-patient-cohorts-could-be-utili-pali-20240905monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-pali-20240819monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-reports-second-quarter-2024-financial-results-and-provides-business-update-pali-20240813monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-selects-dose-for-upcoming-phase-1-clinical-study-of-pali-2108-for-ulcerative--pali-20240808monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-participates-in-virtual-investor-what-this-means-segment-pali-20240731monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-successfully-completes-microbiome-study-confirming-bacterial-enzymes-for-loca-pali-20240729monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-european-patent-office-issued-a-decision-to-grant-notice-for-patent-pali-20240719monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-successful-completion-of-first-gmp-manufacturing-of-pali-2108-drug--pali-20240711monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-to-participate-in-the-virtual-investor-closing-bell-series-pali-20240624monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-provides-update-on-advancement-of-its-strategic-collaboration-with-strand-lif-pali-20240621monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-notice-of-allowance-for-canadian-patent-covering-lead-product-candi-pali-20240611monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-to-present-at-the-virtual-investor-pitch-conference-pali-20240610monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-s-lead-product-candidate-pali-2108-demonstrates-local-bioactivation-and-dose--pali-20240521monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-reports-first-quarter-2024-financial-results-and-provides-business-update-pali-20240514monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-closing-of-4-million-private-placement-priced-at-the-market-under-n-pali-20240507monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-s-lead-product-candidate-pali-2108-demonstrates-potent-anti-inflammatory-effe-pali-20240501monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-enters-into-strategic-collaboration-with-strand-life-sciences-to-advance-prec-pali-20240423monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-successfully-demonstrates-bioactivation-of-pali-2108-in-ex-vivo-study-of-norm-pali-20240416monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-to-participate-in-the-virtual-investor-lunch-break-event-pali-20240411monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-to-present-at-digestive-disease-week-ddw-2024-pali-20240215monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-formation-of-clinical-advisory-board-with-appointments-of-preeminen-pali-20240208monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-selected-for-poster-presentation-at-the-2024-crohn-s-colitis-congress-pali-20240109monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-receipt-of-second-milestone-payment-from-the-us-crohn-s-and-colitis-pali-20231228monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-reports-third-quarter-2023-financial-results-and-provides-business-outlook-pali-20231110monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-to-participate-at-the-virtual-investor-ask-the-ceo-conference-pali-20231011monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-closing-of-2-million-registered-direct-offering-priced-at-market-un-pali-20230911monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-reports-second-quarter-2023-financial-results-pali-20230811monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-topline-results-from-u-s-phase-2-profile-study-evaluating-lb1148-fo-pali-20230809monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-completion-of-enrollment-in-lb1148-dose-optimization-study-pali-20230705monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-participate-in-the-healthcare-virtual-conference-presented-by-maxim-group-llc-pali-20230614monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-promotes-j-d-finley-to-chief-executive-officer-pali-20230601monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-s-lb1148-two-ongoing-clinical-trials-expecting-topline-data-readouts-pali-20230524monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-reports-first-quarter-2023-financial-results-pali-20230512monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-enrollment-and-dosing-of-first-patient-in-lb1148-dose-optimization--pali-20230511monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-receives-canadian-patent-covering-composition-of-lead-program-in-development--pali-20230406monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-enrollment-of-first-patient-in-newsoara-phase-3-clinical-trial-eval-pali-20230405monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-6-million-registered-direct-offering-and-concurrent-private-placeme-pali-20230403monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-reports-year-end-2022-financial-results-and-provides-corporate-update-pali-20230323monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-receives-intention-to-grant-from-european-patent-office-for-lb1148-patent-pali-20230301monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-further-strengthens-balance-sheet-with-early-exercise-of-warrants-resulting-i-pali-20230110monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-to-present-at-the-virtual-investor-2023-companies-to-watch-event-pali-20230109monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-closing-of-2-5-million-registered-direct-offering-and-concurrent-pr-pali-20230104monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-early-exercise-of-warrants-resulting-in-cash-proceeds-of-1-25-milli-pali-20221207monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-regains-compliance-with-nasdaq-listing-requirements-pali-20221201monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-is-granted-fast-track-designation-from-the-u-s-food-and-drug-administration-f-pali-20221122monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-releases-in-depth-explanation-of-scientific-approach-of-lead-product-candidat-pali-20221117monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-reverse-stock-split-pali-20221115monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-reports-third-quarter-2022-financial-results-and-provides-business-update-pali-20221114monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeo-pali-20220929monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pali-20220923monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference-pali-20220921monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-to-present-at-the-virtual-investor-innovations-in-intestinal-health-launching-pali-20220913monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-first-patient-enrolled-and-dosed-in-pivotal-phase-3-study-evaluatin-pali-20220817monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-closing-of-13-8-million-upsized-underwritten-public-offering-and-fu-pali-20220816monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-reports-second-quarter-2022-financial-results-and-provides-corporate-update-pali-20220815monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-pricing-of-12-million-upsized-underwritten-public-offering-pali-20220812monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-launches-new-corporate-website-and-reiterates-commitment-to-develop-therapeut-pali-20220801monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-first-patient-screened-in-phase-3-study-evaluating-lb1148-for-posto-pali-20220727monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-initiates-phase-3-study-of-lb1148-in-lead-indication-for-postoperative-return-pali-20220629monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-to-present-at-the-2022-bio-international-convention-pali-20220607monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-reports-first-quarter-2022-financial-results-and-provides-corporate-update-pali-20220513monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-inducement-awards-under-inducement-plan-for-key-new-hires-pali-20220510monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-and-newsoara-receive-nmpa-clearance-to-commence-phase-3-clinical-trial-in-chi-pali-20220505monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-provides-business-outlook-and-highlights-expected-near-term-pipeline-advancem-pali-20220502monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-to-participate-in-the-virtual-investor-management-and-kol-roundtable-event-pali-20220429monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-nasdaq-pali-to-participate-in-the-2022-virtual-growth-conference-presented-by-pali-20220324monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-nasdaq-pali-receives-fda-study-may-proceed-letter-for-pivotal-phase-3-clinica-pali-20220322monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-nasdaq-pali-reports-year-end-2021-financial-results-and-corporate-update-pali-20220318monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-nasdaq-pali-announces-analysis-demonstrating-lb1148-reduced-the-extent-and-se-pali-20220316monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-nasdaq-pali-to-present-new-clinical-data-of-lb1148-for-preventing-adhesions-i-pali-20220309monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-nasdaq-pali-to-present-at-the-biocom-global-life-science-partnering-conferenc-pali-20220218monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-nasdaq-pali-adds-pharmaceutical-industry-executive-robert-mcrae-to-leadership-pali-20220215monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-nasdaq-pali-to-announce-adhesions-clinical-data-at-sages-2022-annual-meeting-pali-20220208monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-to-present-at-the-h-c-wainwright-bioconnect-virtual-conference-and-biotech-sh-pali-20211229monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-granted-new-u-s-patent-covering-protease-inhibitor-lb1148-for-treating-adhesi-pali-20211208monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-the-european-patent-office-to-grant-a-patent-for-its-lead-drug-cand-pali-20211130monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-inducement-awards-under-inducement-plan-for-key-new-hires-including-pali-20211123monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-reports-third-quarter-financial-results-pali-20211115monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-virtual-confer-pali-20210909monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-reports-second-quarter-financial-results-and-provides-business-update-pali-20210824monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-announces-5-2m-investment-by-the-yuma-regional-medical-center-pali-20210820monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-and-newsoara-announce-positive-topline-efficacy-results-from-phase-2-study-of-pali-20210729monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-enters-into-worldwide-in-licensing-agreement-with-university-of-california-fo-pali-20210713monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-launches-clinical-steering-committee-to-provide-clinical-oversight-and-guide--pali-20210615monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-receives-fda-fast-track-designation-for-lb1148-for-reduction-of-adhesions-fol-pali-20210513monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-and-newsoara-announce-completion-of-phase-2-study-in-gi-surgery-study-in-chin-pali-20210507monthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-hosting-key-opinion-leader-webinar-on-lb1148-an-oral-serine-protease-inhibito-pali-20210504monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ivvd-20260603monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ivvd-20260505monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-initiation-of-declaration-clinical-trial-a-phase-3-placebo-controlled-pi-ivvd-20251223monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-participate-at-the-8th-annual-evercore-healthcare-conference-ivvd-20251125monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-pricing-of-125-million-public-offering-of-common-stock-and-pre-funded-wa-ivvd-20251118monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-continued-neutralizing-activity-of-pemgarda-pemivibart-and-vyd2311-again-ivvd-20250818monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-aligns-with-u-s-fda-on-rapid-pathway-to-full-approval-bla-of-vaccine-alternative-m-ivvd-20250814monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-and-leading-researchers-form-spear-spike-protein-elimination-and-recovery-study-gr-ivvd-20250702monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-publication-of-landmark-canopy-phase-3-pemgarda-pemivibart-clinical-tria-ivvd-20250527monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-inclusion-of-pemgarda-pemivibart-in-national-comprehensive-cancer-networ-ivvd-20250523monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-commends-fda-focus-on-contemporary-evidence-in-evaluating-medical-interventions-to-ivvd-20250521monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-files-citizen-petition-urging-fda-to-focus-on-monoclonal-antibodies-for-endemic-vi-ivvd-20250514monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-participate-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference-ivvd-20250513monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-host-first-quarter-2025-financial-results-and-corporate-update-conference-call--ivvd-20250508monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference-on-f-ivvd-20250210monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-partnership-with-pro-football-coach-jim-harbaugh-to-elevate-awareness-an-ivvd-20250205monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-positive-phase-1-2-clinical-data-for-vyd2311-a-monoclonal-antibody-desig-ivvd-20250203monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-new-england-journal-of-medicine-publishes-letter-to-the-editor-highlight-ivvd-20241114monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-preprints-conveying-canopy-phase-3-clinical-trial-data-including-long-te-ivvd-20241112monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-participate-in-the-guggenheim-securities-healthcare-innovation-conference-ivvd-20241106monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-host-third-quarter-2024-financial-results-and-corporate-update-conference-call--ivvd-20241106monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-phase-3-long-term-exploratory-clinical-efficacy-data-shows-pemgarda-pemivibart-pro-ivvd-20241029monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-present-pemgarda-pemivibart-data-at-infectious-disease-week-idweek-2024-ivvd-20241016monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-u-s-fda-has-updated-the-pemgarda-eua-fact-sheet-with-accurate-sars-cov-2-ivvd-20241001monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-at-the-ready-for-upcoming-respiratory-virus-season-with-pemgarda-pemivibart-to-hel-ivvd-20240912monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-participate-in-upcoming-investor-conferences-ivvd-20240905monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-host-conference-call-discussing-second-quarter-2024-financial-results-and-busin-ivvd-20240812monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-its-addition-to-the-russell-2000-and-russell-3000-indexes-ivvd-20240701monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-participate-at-the-jefferies-global-healthcare-conference-ivvd-20240603monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-general-alignment-with-u-s-fda-on-a-repeatable-expedient-emergency-use-a-ivvd-20240531monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-present-data-at-2024-american-society-of-clinical-oncology-asco-annual-meeting--ivvd-20240529monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-participate-at-the-h-c-wainwright-2nd-annual-bioconnect-investor-conference-ivvd-20240513monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-pursue-rapid-immunobridging-pathway-to-potential-eua-for-treatment-of-covid-19--ivvd-20240507monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-host-conference-call-discussing-first-quarter-2024-financial-results-and-busine-ivvd-20240502monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-20-million-to-25-million-improvement-in-projected-2024-year-end-cash-pos-ivvd-20240430monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-receives-healthcare-common-procedure-coding-system-hcpcs-reimbursement-codes-from--ivvd-20240415monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-ceo-transition-ivvd-20240412monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-provides-pemgarda-launch-update-and-announces-2024-net-product-revenue-guidance-in-ivvd-20240404monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-interim-exploratory-data-on-vyd222-from-ongoing-canopy-clinical-trial-ivvd-20240322monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-fda-authorization-for-emergency-use-of-pemgarda-formerly-vyd222-for-pre--ivvd-20240322monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-participate-at-the-guggenheim-healthcare-talks-6th-annual-biotechnology-confere-ivvd-20240205monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-host-conference-call-discussing-third-quarter-2023-financial-results-and-busine-ivvd-20231102monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-participate-in-upcoming-investor-conferences-ivvd-20231031monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-dosing-of-first-participant-in-canopy-phase-3-pivotal-clinical-trial-inv-ivvd-20230911monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-participate-in-upcoming-investor-conferences-ivvd-20230906monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-appoints-william-duke-as-chief-financial-officer-ivvd-20230905monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-investigation-initiated-by-former-louisiana-attorney-general-kahn-swick-foti-llc-i-ivvd-20230810monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-host-conference-call-discussing-second-quarter-2023-financial-results-and-busin-ivvd-20230803monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-additional-positive-initial-data-from-ongoing-phase-1-clinical-trial-of--ivvd-20230717monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-general-alignment-with-fda-on-pathway-to-potential-eua-for-vyd222-and-an-ivvd-20230626monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-positive-initial-data-from-ongoing-phase-1-clinical-trial-of-vyd222-a-mo-ivvd-20230622monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-participate-at-the-jefferies-healthcare-conference-ivvd-20230601monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-host-conference-call-discussing-first-quarter-2023-financial-results-and-busine-ivvd-20230504monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-participate-at-h-c-wainwright-s-bioconnect-investor-conference-ivvd-20230425monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-the-fda-has-cleared-its-ind-application-for-vyd222-a-monoclonal-antibody-ivvd-20230425monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-appoints-robert-allen-as-chief-scientific-officer-and-stacy-price-as-chief-technol-ivvd-20230412monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-doses-first-participants-in-phase-1-trial-of-vyd222-a-novel-monoclonal-antibody-ca-ivvd-20230330monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-o-ivvd-20230329monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-inc-ivvd-investor-alert-robbins-llp-reminds-investors-of-pending-lead-plaintiff-de-ivvd-20230324monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-publishes-model-for-evaluating-biomarker-correlates-of-protection-for-monoclonal-a-ivvd-20230322monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds-ivvd-20230322monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-inc-nasdaq-ivvd-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-inve-ivvd-20230320monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-host-conference-call-discussing-full-year-2022-financial-results-and-business-h-ivvd-20230316monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-o-ivvd-20230315monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-inc-nasdaq-ivvd-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-inve-ivvd-20230313monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds-ivvd-20230308monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-inc-nasdaq-ivvd-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-inve-ivvd-20230306monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-o-ivvd-20230301monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-participate-at-cowen-s-43rd-annual-healthcare-conference-ivvd-20230228monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-inc-ivvd-class-action-notice-contact-robbins-llp-for-information-about-filing-a-le-ivvd-20230222monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds-ivvd-20230222monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-inc-ivvd-class-action-alert-robbins-llp-urges-shareholders-to-contact-the-firm-reg-ivvd-20230216monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-o-ivvd-20230215monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-inc-nasdaq-ivvd-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-inve-ivvd-20230214monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-inc-nasdaq-ivvd-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-inve-ivvd-20230208monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-inc-ivvd-f-k-a-adagio-therapeutics-inc-shareholder-notice-robbins-llp-informs-inve-ivvd-20230207monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-changes-to-executive-team-ivvd-20230203monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-inc-nasdaq-ivvd-shareholder-class-action-alert-bernstein-liebhard-llp-announces-th-ivvd-20230202monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-presented-joint-industry-rationale-on-potential-expedited-development-pathways-for-ivvd-20221219monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-participate-in-fireside-chat-at-the-jefferies-london-healthcare-conference-ivvd-20221109monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-host-conference-call-on-november-10-to-discuss-third-quarter-2022-financial-res-ivvd-20221102monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-to-present-multiple-posters-highlighting-clinical-data-from-adintrevimab-during-id-ivvd-20221012monthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-multiple-next-generation-covid-19-antibody-candidates-and-selects-combin-ivvd-20220912monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-siga-shares-tumble-after-mpox-therapy-fails-chief-medical-officer-termin-siga-20241108monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-siga-shares-tumble-after-mpox-therapy-fails-chief-medical-officer-termin-siga-20241023monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-alert-bragar-eagel-squire-p-c-is-investigating-siga-technologies-inc-on-behalf-of-sig-siga-20241008monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-siga-shares-tumble-after-mpox-therapy-fails-chief-medical-officer-termin-siga-20241007monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-siga-shares-tumble-after-mpox-therapy-fails-chief-medical-officer-termin-siga-20241003monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-host-business-update-call-on-may-7-following-release-of-first-quarter-siga-20240501monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-host-business-update-call-on-march-12th-2024-following-release-of-fou-siga-20240305monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-host-business-update-call-on-november-7th-2023-following-release-of-t-siga-20231026monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-host-business-update-call-on-tuesday-august-8th-2023-following-releas-siga-20230727monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-host-business-update-call-on-may-4th-2023-following-release-of-first--siga-20230427monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-host-business-update-call-on-march-2nd-2023-following-release-of-four-siga-20230223monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-host-business-update-call-on-november-3rd-2022-following-release-of-t-siga-20221027monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-announces-new-contract-awarded-by-u-s-department-of-defense-for-the-proc-siga-20220929monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-host-business-update-call-on-august-4th-2022-following-release-of-sec-siga-20220728monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-receives-approval-from-uk-for-tecovirimat-siga-20220708monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-host-business-update-call-on-may-5th-2022-following-release-of-first--siga-20220428monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-host-business-update-call-on-march-3rd-2022-following-release-of-four-siga-20220224monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-participate-in-edison-group-s-global-healthcare-open-house-virtual-co-siga-20220118monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-receives-approval-from-the-european-medicines-agency-for-tecovirimat-siga-20220110monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-host-business-update-call-on-november-4th-2021-following-release-of-t-siga-20211028monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-ceo-to-speak-at-nct-usa-conference-september-8-2021-siga-20210907monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-host-business-update-call-on-august-5th-2021-following-release-of-sec-siga-20210729monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-host-business-update-call-on-may-6th-2021-following-release-of-first--siga-20210429monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-host-business-update-call-on-march-4-2021-following-release-of-year-e-siga-20210226monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-chief-scientific-officer-to-participate-at-nct-asia-virtual-conference-o-siga-20201112monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-host-business-update-call-on-november-5-2020-following-release-of-thi-siga-20201029monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-host-business-update-call-on-august-6-2020-following-release-of-secon-siga-20200730monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-announces-department-of-defense-increases-funding-to-develop-post-exposu-siga-20200615monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-announces-first-international-delivery-of-oral-tpoxx-siga-20200601monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-host-business-update-call-on-may-6-2020-after-release-of-first-quarte-siga-20200429monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-ceo-to-speak-at-nct-asia-conference-on-october-23-2019-siga-20191021monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-cso-to-speak-at-the-13th-cbrne-protection-symposium-on-september-25-2019-siga-20190925monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-ceo-to-speak-at-nct-europe-on-june-27-2019-siga-20190618monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-host-business-update-webcast-on-june-18-2019-siga-20190611monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-host-business-update-webcast-on-september-27-2018-siga-20180917monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-ring-the-nasdaq-opening-bell-on-friday-september-14-2018-siga-20180913monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-announces-favorable-outcome-of-advisory-committee-in-support-of-tpoxx-siga-20180501monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-stock-trading-halted-today-fda-advisory-committee-is-scheduled-to-review-siga-20180501monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-announces-relisting-on-nasdaq-siga-20180320monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-announces-fda-accepts-nda-and-grants-priority-review-for-oral-tpoxx-to-t-siga-20180207monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-announces-fda-submission-of-its-new-drug-application-for-oral-tpoxx-teco-siga-20171211monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reports-financial-results-for-the-second-quarter-2014-siga-20140731monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reports-financial-results-for-the-first-quarter-2014-siga-20140501monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reports-financial-results-for-the-fourth-quarter-and-year-ended-2013-siga-20140310monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reports-financial-results-for-the-third-quarter-2013-siga-20131106monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reports-financial-results-for-the-second-quarter-2013-siga-20130805monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reports-financial-results-for-the-first-quarter-2013-siga-20130515monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reports-financial-results-for-the-fourth-quarter-and-year-ended-2012-siga-20130306monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reports-financial-results-for-the-third-quarter-of-2012-siga-20121105monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reports-financial-results-for-the-second-quarter-of-2012-siga-20120806monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reports-financial-results-for-the-first-quarter-2012-siga-20120507monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reports-financial-results-for-the-fourth-quarter-and-year-ended-2011-siga-20120301monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reports-financial-results-for-the-third-quarter-of-2011-siga-20111108monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reports-financial-results-for-the-second-quarter-and-first-half-of-2011-siga-20110801monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-awarded-u-s-government-contract-valued-at-up-to-2-8-billion-siga-20110513monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reports-financial-results-for-the-first-quarter-2011-siga-20110505monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reports-financial-results-for-the-fourth-quarter-and-year-ended-2010-siga-20110309monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reports-financial-results-for-the-third-quarter-of-2010-siga-20101102monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reports-financial-results-for-the-second-quarter-and-first-half-of-2010-siga-20100805monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reports-operating-results-for-the-first-quarter-of-2010-siga-20100504monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reports-financial-results-for-the-fourth-quarter-and-full-year-of-2009-siga-20100310monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-inc-announces-close-of-20-million-common-stock-offering-siga-20091214monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reports-operating-results-for-the-third-quarter-of-2009-siga-20091109monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-discuss-third-quarter-2009-results-of-operations-on-november-9-2009-siga-20091102monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-files-100-million-shelf-registration-siga-20091030monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-receives-a-3-million-research-grant-from-the-national-institutes-of-heal-siga-20090902monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reports-operating-results-for-the-second-quarter-of-2009-siga-20090806monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reschedules-quarterly-update-call-to-10-30-am-edt-on-august-6-2009-siga-20090803monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-announce-second-quarter-2009-results-of-operations-on-august-6-2009-siga-20090727monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-inc-to-be-added-to-the-russell-3000-r-and-russell-global-r-indices-siga-20090626monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-inc-to-present-at-the-2009-noble-financial-fifth-annual-equity-conferenc-siga-20090605monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-submits-response-to-barda-rfp-siga-20090514monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-announce-first-quarter-2009-results-of-operations-on-may-14-2009-siga-20090508monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-discuss-year-end-2008-results-of-operations-on-march-12-2009-siga-20090309monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-completes-human-pharmacokinetic-bridging-study-validating-commercial-for-siga-20081202monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reports-operating-results-for-the-third-quarter-of-2008-siga-20081110monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-present-at-the-rodman-and-renshaw-annual-global-investment-conference-siga-20081106monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-announce-third-quarter-2008-results-of-operations-on-november-10-2008-siga-20081031monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-named-to-deloitte-tri-state-area-technology-fast-50-siga-20081023monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-st-246-named-molecule-of-the-month-by-prous-science-siga-20081015monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-participate-in-committee-meeting-for-the-institute-of-medicine-siga-20080925monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-attend-the-hhs-public-health-emergency-medical-countermeasures-enterp-siga-20080918monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-reports-operating-results-for-the-second-quarter-of-2008-siga-20080812monthly0.5https://www.biopharmawatch.com/news/SIGA/siga-technologies-to-announce-second-quarter-2008-results-of-operations-on-august-12-2008-siga-20080805monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-four-presentations-at-the-upcoming-annual-meeting-of-the-endocrine-soci-rzlt-20260604monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-to-participate-in-upcoming-investor-conferences-rzlt-20260511monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-inc-investigated-by-the-portnoy-law-firm-rzlt-20260424monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-to-present-results-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-a-rzlt-20260421monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-inc-rzlt-shares-tank-90-amid-lead-asset-trial-failure-hagens-berman-investigating-rzlt-20260209monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-investigation-reminder-faruqi-faruqi-llp-investigates-claims-on-behalf-of-investo-rzlt-20251219monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-inc-rzlt-shares-tank-90-amid-lead-asset-trial-failure-hagens-berman-investigating-rzlt-20251216monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-to-participate-in-upcoming-investor-conferences-rzlt-20250827monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-presentation-of-participant-baseline-data-from-its-fully-enrolled-phase-rzlt-20250709monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-completion-of-enrollment-in-the-phase-3-sunrize-study-of-ersodetug-in-p-rzlt-20250528monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-receives-breakthrough-therapy-designation-from-fda-for-ersodetug-in-the-treatment-rzlt-20250505monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-to-participate-in-upcoming-investor-conferences-rzlt-20250501monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-appointment-of-rare-disease-commercial-leader-erik-harris-to-its-board--rzlt-20250326monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-to-participate-in-the-guggenheim-smid-cap-biotech-conference-rzlt-20250131monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-inducement-award-under-nasdaq-listing-rule-5635-c-4-rzlt-20241205monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-to-participate-in-upcoming-investor-conferences-rzlt-20241105monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-to-participate-in-upcoming-investor-conferences-rzlt-20240827monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-to-participate-in-the-btig-virtual-biotechnology-conference-rzlt-20240731monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-closing-of-public-offering-with-approximately-60m-in-gross-proceeds-rzlt-20240624monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-rzlt-20240613monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-to-participate-in-the-jefferies-global-healthcare-conference-rzlt-20240530monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-validation-of-the-potential-use-of-rz358-for-treatment-of-non-islet-cell--rzlt-20240306monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-expands-leadership-team-with-appointment-of-daron-evans-ms-mba-as-chief-financial-rzlt-20240124monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-initiates-phase-3-clinical-study-for-rz358-in-congenital-hyperinsulinism-rzlt-20231214monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-to-participate-in-btig-s-3rd-annual-ophthalmology-day-rzlt-20231117monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-to-participate-in-upcoming-investor-conferences-in-september-rzlt-20230906monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-kol-event-highlights-significant-unmet-medical-need-in-diabetic-macular-edema-rzlt-20230323monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-to-highlight-rz402-phase-2-clinical-program-with-leading-clinical-expert-rzlt-20230308monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-to-present-at-the-jefferies-london-healthcare-conference-rzlt-20221101monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-presentation-at-the-retina-society-55th-annual-scientific-meeting-rzlt-20221020monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-presentation-at-the-60th-annual-espe-meeting-rzlt-20220907monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-promotion-of-brian-roberts-m-d-to-chief-medical-officer-rzlt-20220601monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-to-host-corporate-update-call-on-may-4-2022-rzlt-20220504monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-positive-data-from-its-phase-2b-rize-study-of-rz358-in-patients-with-co-rzlt-20220501monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-joins-the-rare-disease-company-coalition-rzlt-20220329monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-pricing-of-public-offering-of-55-million-of-common-stock-and-pre-funded-rzlt-20211013monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-to-participate-in-upcoming-virtual-healthcare-conferences-rzlt-20210907monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-to-participate-in-upcoming-virtual-healthcare-conferences-rzlt-20210803monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-to-participate-in-upcoming-virtual-healthcare-conferences-rzlt-20210527monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-expands-leadership-team-with-the-appointment-of-davelyn-hood-md-as-director-scien-rzlt-20210520monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-appoints-leading-ophthalmology-expert-quan-dong-nguyen-md-msc-faao-farvo-to-scien-rzlt-20210518monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-to-present-at-the-oppenheimer-rare-and-orphan-disease-summit-rzlt-20210517monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-presents-data-on-rz358-in-post-gastric-bypass-hypoglycemia-at-endo-2021-rzlt-20210322monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-strengthens-board-of-directors-with-key-appointments-of-leading-rare-disease-expe-rzlt-20210308monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-to-participate-in-upcoming-investor-conferences-in-march-rzlt-20210302monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-initiation-of-phase-1-study-of-rz402-an-oral-plasma-kallikrein-inhibito-rzlt-20210112monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-change-of-transfer-agent-rzlt-20201228monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference-rzlt-20201119monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-uplisting-to-the-nasdaq-capital-market-rzlt-20201105monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-inc-provides-updates-in-the-context-of-the-covid-19-pandemic-announces-resumption-rzlt-20200727monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-publication-of-rz402-data-in-diabetic-macular-edema-dme-in-investigativ-rzlt-20200615monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-receives-rare-pediatric-disease-designation-for-rz358-phase-2b-candidate-for-the--rzlt-20200610monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-presents-rz358-clinical-data-validated-model-of-the-pharmacokinetics-and-glycemic-rzlt-20200601monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-to-present-clinical-data-for-rz358-lead-candidate-in-phase-2b-trial-in-congenital-rzlt-20200528monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-inc-announces-updates-to-clinical-and-business-operations-in-response-to-covid-19-rzlt-20200514monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-initiates-phase-2b-clinical-trial-of-lead-candidate-rz358-in-congenital-hyperinsu-rzlt-20200210monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-to-present-at-bio-ceo-investor-conference-2020-rzlt-20200127monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-inc-announces-top-line-results-from-phase-1-trial-evaluating-ab101-in-patients-wi-rzlt-20191218monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-management-to-present-at-2020-biotech-showcase-conference-rzlt-20191202monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-appoints-nektar-therapeutics-coo-cfo-to-its-board-of-directors-rzlt-20191125monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-management-to-present-at-2019-bio-investor-forum-conference-rzlt-20191011monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-management-to-present-at-2019-canaccord-genuity-growth-conference-rzlt-20190805monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-completes-45-million-investment-round-with-full-exercise-of-20-million-option-rzlt-20190724monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-25-million-private-placement-potential-total-investment-of-45-million-rzlt-20190107monthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-announces-appointment-of-hoyoung-huh-m-d-ph-d-as-vice-chairman-of-its-board-of-di-rzlt-20180404monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-to-present-at-upcoming-healthcare-investor-conference-srzn-20260225monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-to-present-at-upcoming-healthcare-investor-conference-srzn-20260205monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-srzn-20250904monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-to-present-at-upcoming-healthcare-investor-conference-srzn-20250903monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-to-present-at-upcoming-healthcare-investor-conference-srzn-20250828monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-to-present-at-upcoming-healthcare-investor-conference-srzn-20250806monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-to-present-at-upcoming-healthcare-investor-conferences-srzn-20241106monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-earns-10-million-milestone-payment-in-retinal-diseases-collaboration-srzn-20240924monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-publishes-study-in-elife-demonstrating-the-promise-of-the-proprietary-sweets-plat-srzn-20240612monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-presents-preliminary-results-from-phase-1a-study-of-szn-043-in-healthy-volunteers-srzn-20240610monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-initiates-dosing-of-first-patient-in-phase-1b-clinical-trial-of-szn-043-for-sever-srzn-20240604monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-presents-data-demonstrating-the-promise-of-antibody-based-wnt-mimetics-in-treatin-srzn-20240509monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-publishes-study-in-respiratory-research-demonstrating-the-promise-of-a-wnt-mimeti-srzn-20240403monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-announces-up-to-192-5-million-private-placement-of-securities-priced-at-the-marke-srzn-20240401monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-provides-corporate-update-on-clinical-programs-srzn-20240118monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-publishes-study-in-nature-communications-demonstrating-the-promise-of-a-fzd4-wnt--srzn-20230605monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-strengthens-board-of-directors-with-the-appointment-of-eric-bjerkholt-srzn-20230405monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-a-corpo-srzn-20230320monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-srzn-20230104monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-presents-data-on-two-lead-therapeutic-candidates-at-united-european-gastroenterol-srzn-20221010monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-announces-strategic-partnership-with-boehringer-ingelheim-to-develop-wnt-agonist--srzn-20221006monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-publishes-study-in-translational-vision-science-and-technology-demonstrating-the--srzn-20220926monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-initiates-dosing-in-phase-1-clinical-trial-of-szn-043-for-severe-alcoholic-hepati-srzn-20220613monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-presents-data-on-lead-therapeutic-candidates-at-digestive-disease-week-ddw-srzn-20220524monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-initiates-dosing-in-phase-1-clinical-trial-of-szn-1326-for-moderate-to-severe-ulc-srzn-20220518monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-publishes-article-in-cellular-and-molecular-gastroenterology-and-hepatology-demon-srzn-20220516monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-to-present-at-the-bofa-securities-2022-healthcare-conference-srzn-20220505monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-presents-data-supporting-potential-of-szn-413-for-the-treatment-of-diabetic-retin-srzn-20220502monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-announces-key-2022-milestones-for-lead-programs-and-acceleration-of-research-pipe-srzn-20220110monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-to-present-virtually-at-the-40th-annual-j-p-morgan-healthcare-conference-srzn-20220105monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-presents-data-supporting-potential-of-szn-043-at-the-liver-meeting-2021-the-annua-srzn-20211115monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-to-present-at-the-piper-sandler-33rd-annual-healthcare-conference-srzn-20211115monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-to-present-at-the-stifel-2021-virtual-healthcare-conference-srzn-20211105monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-presented-data-supporting-potential-of-szn-1326-at-the-2021-united-european-gastr-srzn-20211005monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-announces-appointment-of-liz-nguyen-as-vice-president-and-head-of-human-resources-srzn-20210923monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-to-present-at-canaccord-genuity-s-41st-annual-growth-conference-srzn-20210805monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-presents-new-data-demonstrating-superior-activity-of-szn-1326-in-preclinical-infl-srzn-20210709monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-presents-data-at-2021-international-liver-conference-for-wnt-modulating-antibody--srzn-20210625monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-presents-data-supporting-potential-of-szn-043-at-the-liver-biology-conference-fun-srzn-20210617monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-publishes-article-in-nature-communications-demonstrating-selective-wnt-mimetics-s-srzn-20210601monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-presents-data-from-lead-wnt-modulating-antibody-programs-szn-1326-and-szn-043-in--srzn-20210524monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-strengthens-board-of-directors-with-appointments-of-mace-rothenberg-m-d-and-chris-srzn-20210506monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-expands-board-of-directors-with-appointment-of-mary-haak-frendscho-ph-d-srzn-20210311monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-expands-board-of-directors-with-appointment-of-shao-lee-lin-m-d-ph-d-srzn-20210202monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-to-present-at-the-stifel-2020-virtual-healthcare-conference-srzn-20201112monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-appoints-charles-williams-as-chief-financial-officer-srzn-20201029monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-awarded-nih-grant-to-support-development-of-szn-043-a-liver-specific-regenerative-srzn-20201015monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-expands-board-of-directors-with-appointment-of-david-j-woodhouse-ph-d-srzn-20200925monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-to-present-at-morgan-stanley-18th-annual-global-healthcare-conference-srzn-20200916monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-announces-publication-of-second-antibody-platform-technology-in-scientific-report-srzn-20200819monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-raises-50-million-in-series-c-financing-to-advance-candidates-to-human-clinical-t-srzn-20200619monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-announces-publication-of-two-abstracts-providing-evidence-for-liver-targeted-tiss-srzn-20200504monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-scientific-founder-roel-nusse-phd-receives-prestigious-canada-gairdner-internatio-srzn-20200406monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-announces-publication-of-antibody-platform-technology-in-cell-chemical-biology-srzn-20200330monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-to-present-at-cowen-and-company-40th-annual-health-care-conference-srzn-20200302monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-appoints-dr-trudy-vanhove-as-chief-medical-officer-srzn-20190411monthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-raises-50-million-in-series-b-financing-to-advance-regenerative-antibody-platform-srzn-20190314monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-record-q1-2026-results-with-im8-revenue-reaching-a-record-16-7-million-pre-20260610monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-appoints-hudson-leogrande-founder-and-ceo-of-multi-billion-dollar-dtc-brand-comf-pre-20260604monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-jay-shetty-as-im8-global-ambassador-and-shareholder-in-multi-year-part-pre-20260520monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-welcomes-brian-j-rosin-as-chief-financial-officer-of-im8-pre-20260514monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-im8-named-exclusive-health-supplements-partner-of-inter-miami-cf-in-multi-year-p-pre-20260507monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-im8-health-partners-with-vitamin-angels-to-combat-global-malnutrition-commits-to-pre-20260414monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-to-participate-in-the-38th-annual-roth-conference-pre-20260318monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-authorizes-40-million-share-repurchase-program-pre-20260306monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-appoints-renowned-longevity-expert-and-health-tech-ceo-dr-darshan-shah-to-board--pre-20260217monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-reinforces-strategic-focus-on-im8-divests-europa-business-for-up-to-13-million-pre-20260106monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-enters-into-warrant-exchange-agreements-with-warrant-holders-strengthening-capit-pre-20251223monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-48-0-million-equity-offering-to-fuel-im8-s-global-expansion-and-bitcoi-pre-20251027monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-completes-72-million-act-exit-bolsters-cash-and-bitcoin-treasury-to-accelerate-i-pre-20251007monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-ceo-danny-yeung-keynote-at-token-2049-singapore-pre-20250930monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-im8-congratulates-global-ambassador-and-shareholder-world-no-1-aryna-sabalenka-o-pre-20250908monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-becomes-first-healthcare-company-to-execute-aggressive-bitcoin-treasury-strategy-pre-20250618monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-divests-act-genomics-to-delta-electronics-as-part-of-up-to-us-71-78-million-tran-pre-20250618monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-first-quarter-2025-financial-results-raises-fy2025-outlook-crypto-stra-pre-20250612monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-im8-health-expands-scientific-advisory-board-reinforcing-commitment-to-set-new-s-pre-20250318monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-to-participate-in-the-37th-annual-roth-conference-pre-20250311monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-unveils-im8-to-u-s-consumers-with-co-founding-partner-david-beckham-pre-20250121monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-im8-achieves-prestigious-nsf-certified-for-sport-for-daily-ultimate-essentials-pre-20250115monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-participation-in-december-investor-conferences-pre-20241204monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-third-quarter-2024-financial-results-pre-20241127monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-participation-in-the-sidoti-virtual-micro-cap-investor-conference-pre-20241030monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-tencent-s-us-30-million-investment-in-insighta-strengthening-strategic-pre-20241015monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-second-quarter-2024-financial-results-pre-20241007monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-acquisition-of-europa-sports-partners-in-strategic-expansion-to-consum-pre-20240819monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-welcomes-kathyrn-m-henry-and-david-vanderveen-to-board-of-directors-pre-20240701monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-first-quarter-2024-financial-results-pre-20240618monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-engages-mz-group-to-lead-strategic-investor-relations-and-shareholder-communicat-pre-20240617monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-fourth-quarter-and-full-year-2023-financial-results-pre-20240401monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-announces-mou-for-a-strategic-investment-and-5-year-research-collaboration-with--pre-20240209monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-to-participate-virtually-at-the-btig-medtech-digital-health-life-science-diagnos-pre-20230202monthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-rings-the-opening-bell-and-debuts-on-nasdaq-pre-20220518monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-upcoming-presentations-for-nxp900-at-the-2025-aacr-nci-eortc-int-nvct-20251016monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-nvct-20250516monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-provides-poster-presentation-highlights-for-nxp900-from-the-2025-aacr-meet-nvct-20250429monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-upcoming-presentations-for-nxp900-at-the-2025-american-associati-nvct-20250326monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-to-participate-in-the-37th-annual-roth-conference-nvct-20250314monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-a-new-publication-of-a-research-study-demonstrating-that-the-com-nvct-20250304monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-closing-of-15-5-million-public-offering-of-common-stock-and-full-nvct-20250207monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-pricing-of-13-5-million-public-offering-of-common-stock-nvct-20250205monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-to-present-at-the-2024-ladenburg-virtual-oncology-innovators-investors-sym-nvct-20241210monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-reports-encouraging-nxp800-interim-data-supporting-ongoing-enrollment-in-p-nvct-20241114monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-upcoming-presentations-for-nxp900-at-the-2024-aacr-nci-eortc-sym-nvct-20241023monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-to-participate-in-the-3rd-annual-roth-healthcare-opportunities-conference-nvct-20241007monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-nvct-20240905monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-nvct-20240516monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-s-nxp900-demonstrates-robust-activity-in-non-small-cell-lung-cancer-cell-l-nvct-20240408monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-upcoming-presentations-at-the-2024-american-association-for-canc-nvct-20240319monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-to-present-at-the-36th-annual-roth-conference-nvct-20240315monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-encouraging-preliminary-data-from-the-nxp800-phase-1b-clinical-t-nvct-20240314monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-participation-at-upcoming-investor-conferences-nvct-20240209monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-nvct-20240103monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-inc-announces-a-collaboration-with-mayo-clinic-to-evaluate-nxp800-in-an-in-nvct-20231218monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-upcoming-poster-presentation-for-nxp800-at-the-2023-aacr-special-nvct-20231024monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-updated-date-and-time-for-the-2023-cantor-global-healthcare-conf-nvct-20230925monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-upcoming-presentations-for-nxp800-and-nxp900-nvct-20230921monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-to-host-kol-event-to-discuss-its-two-precision-medicine-clinical-stage-dru-nvct-20230906monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-participation-at-upcoming-investor-conferences-nvct-20230901monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-set-to-join-the-russell-2000-and-russell-3000-indexes-nvct-20230620monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-nvct-20230427monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-recaps-poster-presentation-highlights-for-nxp800-s-activity-in-cholangioca-nvct-20230418monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-initiation-of-the-phase-1b-study-for-nxp800-in-platinum-resistan-nvct-20230410monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-upcoming-presentations-at-the-2023-american-association-for-canc-nvct-20230317monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-to-participate-in-a-fireside-chat-at-the-35th-annual-roth-conference-nvct-20230310monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-recaps-poster-presentation-highlights-for-nxp800-at-the-2023-esmo-gynecolo-nvct-20230223monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-a-publication-in-the-journal-of-experimental-medicine-for-nxp900-nvct-20230209monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-collaboration-with-engot-and-gog-foundation-to-conduct-the-nxp80-nvct-20230104monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-phrama-announces-two-upcoming-poster-presentations-at-the-34th-eortc-nci-aacr-sym-nvct-20221018monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-inc-to-present-at-the-roth-inaugural-healthcare-opportunities-conference-nvct-20221003monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-formation-of-a-scientific-advisory-board-nvct-20220928monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-positive-data-for-nxp800-in-a-preclinical-model-of-arid1a-mutate-nvct-20220913monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-inc-to-present-at-upcoming-investment-conferences-nvct-20220907monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-closing-of-approximately-15-9-million-private-placement-nvct-20220801monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-fda-clearance-of-ind-for-nxp800-nvct-20220621monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-positive-data-for-nxp900-in-a-preclinical-model-of-group-4-medul-nvct-20220613monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-to-present-in-the-h-c-wainwright-global-investment-conference-nvct-20220520monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-recaps-poster-presentation-highlights-for-nxp900-at-the-2022-american-asso-nvct-20220413monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-recaps-oral-presentation-highlights-for-nxp800-at-the-2022-american-associ-nvct-20220411monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-announces-upcoming-oral-and-poster-presentations-at-the-2022-american-association-nvct-20220310monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-to-participate-in-a-fireside-chat-at-the-34th-annual-roth-conference-nvct-20220309monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-announces-positive-data-for-nxp900-in-triple-negative-breast-cancer-preclinical-m-nvct-20220222monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-announces-closing-of-16-000-000-upsized-initial-public-offering-of-common--nvct-20220208monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-inc-announces-pricing-of-16-000-000-upsized-initial-public-offering-of-com-nvct-20220204monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-initiates-phase-1-clinical-trial-of-nxp800-nvct-20211231monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-in-licenses-exclusive-worldwide-rights-to-a-novel-src-yes1-inhibitor-nxp90-nvct-20210914monthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-raises-15-million-and-in-licenses-exclusive-worldwide-rights-to-novel-sele-nvct-20210826monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20260601monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-participation-in-upcoming-investor-conferences-abeo-20260526monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20260501monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20260406monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-first-patient-treatment-with-zevaskyn-gene-therapy-abeo-20251208monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-date-of-third-quarter-financial-results-and-upcoming-investo-abeo-20251107monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20251001monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20250902monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20250801monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-closes-sale-of-rare-pediatric-disease-priority-review-voucher-for-155--abeo-20250702monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-option-exercise-by-beacon-therapeutics-for-novel-aav204-caps-abeo-20250701monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20250701monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-added-to-membership-of-u-s-small-cap-russell-2000-index-and-broad-mark-abeo-20250630monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-publication-in-the-lancet-of-phase-3-viital-study-data-in-re-abeo-20250624monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20250602monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-abeo-20250530monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-and-lurie-children-s-open-first-center-for-zevaskyn-gene-therapy-to-tr-abeo-20250514monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20250507monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20250401monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-the-leerink-partners-global-healthcare-conference-abeo-20250304monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20250303monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20250203monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20241231monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20241202monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-participation-in-november-investor-conferences-abeo-20241104monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20241101monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20241001monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-participation-in-upcoming-investor-conferences-abeo-20240903monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20240902monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-favorable-medicare-reimbursement-decisions-for-pz-cel-abeo-20240813monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20240801monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-and-beacon-therapeutics-announce-non-exclusive-agreement-for-beacon-to-abeo-20240711monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-the-stifel-virtual-cell-therapy-forum-abeo-20240708monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20240603monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-abeo-20240528monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20240507monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20240401monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20240305monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20240201monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-progress-update-on-pz-cel-biologics-license-application-bla-abeo-20240201monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20231215monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-563-abeo-20231101monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-submits-biologics-license-application-to-u-s-fda-seeking-priority-revi-abeo-20230926monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-appoints-madhav-vasanthavada-ph-d-m-b-a-as-chief-commercial-officer-abeo-20230912monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-participation-in-upcoming-investor-conferences-abeo-20230907monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-positive-pre-bla-meeting-with-fda-for-eb-101-and-plans-for-b-abeo-20230830monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-submission-of-briefing-package-for-pre-biologics-license-app-abeo-20230728monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-joins-rare-disease-company-coalition-abeo-20230719monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-regulatory-update-on-biologics-license-application-bla-for-e-abeo-20230609monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-the-jefferies-healthcare-conference-abeo-20230601monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-date-change-for-first-quarter-2023-portfolio-update-conferen-abeo-20230522monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-preclinical-data-from-its-aav-ophthalmology-program-at-t-abeo-20230516monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-additional-phase-3-viital-study-results-for-eb-101-presented-abeo-20230511monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-multiple-abstracts-accepted-from-its-aav-ophthalmology-progr-abeo-20230410monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-abeo-20230324monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-acceptance-of-abstract-on-eb-101-phase-3-viital-study-result-abeo-20230316monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-update-on-aav-ophthalmology-program-abeo-20230314monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-positive-topline-results-with-both-co-primary-endpoints-met--abeo-20221103monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-database-lock-for-pivotal-phase-3-viital-study-of-eb-101-in--abeo-20221019monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-completion-of-patient-follow-up-in-pivotal-phase-3-viital-st-abeo-20221004monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit-abeo-20220922monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-participate-in-the-cantor-fitzgerald-cell-and-genetic-medicines-con-abeo-20220913monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-the-jefferies-healthcare-conference-abeo-20220606monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-aav204-a-novel-aav-capsid-demonstrated-robust-macular-transd-abeo-20220504monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-presentation-at-the-association-for-research-in-vision-and-o-abeo-20220429monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-participate-in-the-cantor-fitzgerald-virtual-rare-orphan-disease-su-abeo-20220328monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-achieves-target-enrollment-in-pivotal-phase-3-viital-study-of-eb-101-i-abeo-20220314monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-issues-letter-to-shareholders-abeo-20211222monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-support-of-eb-research-partnership-s-venture-into-cures-even-abeo-20211118monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-presentation-on-pivotal-transpher-a-study-of-abo-102-in-mps--abeo-20211117monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-participation-at-the-jefferies-london-healthcare-conference-abeo-20211116monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-third-quarter-financial-results-abeo-20211115monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-jefferies-gene-therapy-editing-summit-abeo-20211021monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-clinical-data-presentations-at-upcoming-scientific-congresse-abeo-20211013monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-appoints-gene-therapy-quality-leader-jon-voss-as-vice-president-head-o-abeo-20211012monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-upcoming-investor-conferences-abeo-20210907monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-appoints-edward-carr-as-chief-financial-officer-abeo-20210810monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-successful-type-b-meeting-with-u-s-fda-for-abo-102-aav-based-abeo-20210728monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-mri-data-showing-increased-brain-volume-in-young-patient-abeo-20210726monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital--abeo-20210723monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-updated-eb-101-phase-1-2a-clinical-results-in-recessive-dyst-abeo-20210707monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-abeo-20210602monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-issues-letter-to-stockholders-abeo-20210526monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-appoints-head-of-research-clinical-development-abeo-20210525monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-presentation-on-new-preclinical-data-supporting-the-potentia-abeo-20210420monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-appointment-of-michael-amoroso-as-chief-executive-officer-abeo-20210322monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-the-10th-annual-svb-leerink-global-healthcare-conference-abeo-20210222monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-clinical-investigator-webinar-to-review-abo-102-and-abo-101--abeo-20210202monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-acceptance-of-late-breaker-abstracts-highlighting-new-clinic-abeo-20201221monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-the-appointment-of-michael-amoroso-as-chief-operating-office-abeo-20201027monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-participate-in-upcoming-investor-conferences-abeo-20200908monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-and-taysha-gene-therapies-enter-into-licensing-and-inventory-purchase--abeo-20200817monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-two-presentations-related-to-its-rdeb-clinical-program-at-th-abeo-20200710monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-appointment-of-michael-amoroso-as-chief-commercial-officer-abeo-20200709monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reinitiates-enrollment-in-eb-101-pivotal-phase-3-viital-study-in-rdeb--abeo-20200708monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-upcoming-data-presentations-at-the-society-for-pediatric-der-abeo-20200618monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-the-jefferies-2020-virtual-healthcare-conference-abeo-20200528monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-abeo-20200421monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-stakeholder-letter-in-response-to-the-covid-19-pandemic-abeo-20200327monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-first-patient-treated-in-pivotal-phase-iii-clinical-trial-ev-abeo-20200317monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-the-9th-annual-svb-leerink-global-healthcare-conference-abeo-20200226monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-positive-interim-data-from-mps-iii-gene-therapy-programs-pre-abeo-20200212monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-participation-in-inaugural-world-congress-on-epidermolysis-b-abeo-20200121monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-issuance-of-u-s-patent-for-aim-capsids-abeo-20200115monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-initiates-pivotal-phase-3-clinical-trial-evaluating-eb-101-gene-therap-abeo-20200113monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-equity-loss-alert-rosen-a-leading-law-firm-reminds-abeona-therapeutics-inc-investor-abeo-20191231monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-announces-closing-of-103-5-million-underwritten-public-offering-and-full-exercise-o-abeo-20191224monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-presentations-at-the-27th-european-society-of-gene-and-cell--abeo-20191021monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-publication-of-positive-long-term-data-from-phase-1-2a-clini-abeo-20191015monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-strategic-review-abeo-20190903monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-appoints-dr-victor-paulus-senior-vice-president-of-regulatory-affairs-abeo-20190626monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-receives-fda-fast-track-designation-for-abo-202-aav9-gene-therapy-in-c-abeo-20190618monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-ab-abeo-20190521monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-treats-first-patient-in-second-cohort-of-phase-1-2-clinical-trial-for--abeo-20190514monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-first-quarter-2019-financial-results-and-business-highlights-abeo-20190510monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-presentation-of-eb-101-data-at-society-for-investigative-der-abeo-20190508monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-participation-in-upcoming-investor-conferences-abeo-20190507monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-preclinical-data-demonstrating-broad-therapeutic-potential-of--abeo-20190501monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-report-new-preclinical-data-demonstrating-therapeutic-potential-of--abeo-20190430monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-data-for-abo-401-in-cystic-fibrosis-and-retinal-disorders-a-abeo-20190415monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-receives-fda-fast-track-designation-for-abo-101-for-treatment-of-sanfi-abeo-20190404monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-fourth-quarter-and-full-year-2018-financial-results-abeo-20190318monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-participation-in-8th-annual-svb-leerink-global-healthcare-co-abeo-20190222monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-new-supportive-data-for-novel-gene-therapies-at-worldsympos-abeo-20190131monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-details-pathway-for-advancing-lead-clinical-programs-and-unveils-new-c-abeo-20181206monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-host-r-d-day-on-december-6-2018-abeo-20181129monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-ceo-transition-abeo-20181126monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-announces-participation-at-the-jefferies-2018-london-healthcare-conference-abeo-20181113monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-third-quarter-2018-financial-results-and-business-highlights-abeo-20181109monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-and-regenxbio-announce-worldwide-exclusive-licenses-for-the-treatment--abeo-20181105monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-announces-participation-at-upcoming-conferences-abeo-20180928monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-authorization-to-commence-phase-1-2-gene-therapy-clinical-st-abeo-20180912monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-announces-participation-at-upcoming-conferences-abeo-20180904monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-upcoming-presentation-at-jefferies-2018-global-healthcare-co-abeo-20180606monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-opening-of-commercial-gene-cell-therapy-manufacturing-facili-abeo-20180531monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-provides-clinical-update-on-mps-iiia-gene-therapy-trial-at-the-21st-an-abeo-20180518monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-reports-update-from-eb-101-gene-therapy-in-epidermolysis-bullosa-at-21st-annual-asg-abeo-20180517monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-appointment-of-stefano-buono-and-richard-van-duyne-to-its-bo-abeo-20180514monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-upcoming-presentations-abeo-20180508monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-announces-fda-grants-rmat-designation-to-abo-102-gene-therapy-in-mps-iiia-abeo-20180423monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-receives-orphan-drug-designation-in-the-european-union-for-abo-202-gen-abeo-20180420monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-fourth-quarter-2017-financial-results-and-business-highlights-abeo-20180316monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-receives-fda-rare-pediatric-disease-designation-for-abo-202-gene-thera-abeo-20180315monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-upcoming-conference-participation-abeo-20180221monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-receives-fda-orphan-drug-designation-for-abo-202-gene-therapy-program--abeo-20180212monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-top-line-data-from-phase-1-2-gene-therapy-trial-in-mps-iiia-abeo-20180208monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-on-initial-safety-and-biopotency-signals-in-mps-iiib-gene-ther-abeo-20180207monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-upcoming-presentations-at-the-14th-annual-worldsymposium-abeo-20180202monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-receives-fda-regenerative-medicine-advanced-therapy-designation-for-eb-101-gene-the-abeo-20180129monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-enrolls-first-patient-in-abo-101-phase-1-2-clinical-trial-for-mps-iiib-abeo-20171220monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-reports-third-quarter-2017-financial-results-and-recent-business-highlights-abeo-20171115monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-management-to-present-at-multiple-conferences-in-november-abeo-20171113monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-enrolls-first-subject-in-spain-in-ongoing-phase-1-2-clinical-trial-in-mps-iiia-abeo-20171109monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-enrolls-first-two-patients-in-pivotal-expansion-of-phase-1-2-clinical--abeo-20171011monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-announces-top-line-one-year-data-from-abo-102-mps-iiia-trial-at-arm-s-cell-gene-mee-abeo-20171006monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-dedication-of-commercial-gene-therapy-manufacturing-facility-abeo-20171004monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-and-brammer-bio-announce-collaboration-for-commercial-translation-of-a-abeo-20170928monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-upcoming-conference-participation-abeo-20170922monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-receives-fda-breakthrough-therapy-designation-for-eb-101-autologous-ce-abeo-20170829monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-host-gene-therapy-r-d-day-on-october-11-2017-abeo-20170817monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-pivotal-expansion-of-abo-102-gene-therapy-clinical-trials-in-abeo-20170816monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-second-quarter-2017-financial-results-and-recent-business-high-abeo-20170815monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-appointment-of-juan-ruiz-as-chief-medical-officer-abeo-20170725monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-receives-guidance-from-fda-to-commence-pivotal-phase-3-for-eb-101-gene-abeo-20170718monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-receives-fda-orphan-drug-designation-for-abo-201-juvenile-batten-disea-abeo-20170629monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-the-jefferies-2017-global-healthcare-conference-abeo-20170602monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-receives-rare-pediatric-disease-designation-for-eb-101-gene-therapy-pr-abeo-20170530monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-receives-fda-orphan-drug-designation-for-eb-101-gene-therapy-product-f-abeo-20170525monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-multiple-upcoming-conferences-abeo-20170519monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-first-quarter-2017-financial-results-and-recent-business-highl-abeo-20170516monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-top-line-data-for-abo-102-phase-1-2-mps-iiia-gene-therapy-tr-abeo-20170512monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-receives-regulatory-approval-to-initiate-clinical-trial-in-australia-w-abeo-20170509monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-gene-therapy-clinical-trial-and-preclinical-program-presenta-abeo-20170508monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-provides-update-on-eb-101-gene-therapy-for-severe-form-of-epidermolysi-abeo-20170502monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-eb-101-clinical-update-to-be-presented-at-the-society-for-in-abeo-20170425monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-to-present-at-multiple-upcoming-conferences-abeo-20170420monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-announces-rare-disease-gene-therapy-symposium-with-the-new-york-academy-of-sciences-abeo-20170405monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-multiple-upcoming-investor-conferences-abeo-20170313monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-receives-orphan-drug-designation-in-the-european-union-for-eb-101-gene-abeo-20170308monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-the-cowen-and-company-37th-annual-health-care-conference-abeo-20170307monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-maxim-group-llc-biotech-investor-partnering-conference-i-abeo-20170303monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-the-2017-rbc-capital-markets-global-healthcare-conferenc-abeo-20170221monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-provides-update-from-abo-102-phase-1-2-mps-iiia-clinical-trial-at-the--abeo-20170217monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-presentations-and-posters-at-the-13th-annual-worldsymposium--abeo-20170207monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-enrolls-first-high-dose-subject-in-ongoing-phase-1-2-gene-therapy-clin-abeo-20170201monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-receives-orphan-drug-designation-in-the-european-union-for-abo-101-gen-abeo-20170119monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-phacilitate-cell-gene-therapy-world-2017-abeo-20170117monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-receives-orphan-drug-designation-in-the-european-union-for-abo-201-gen-abeo-20170103monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-2016-genetic-rx-boston-biotech-conference-at-harvard-med-abeo-20161206monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-world-orphan-and-drug-congress-europe-2016-abeo-20161115monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-honored-with-partner-in-progress-award-from-debra-of-america-abeo-20161105monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-alliance-of-regenerative-medicine-4th-annual-advanced-th-abeo-20161103monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-jama-publication-of-positive-phase-1-study-results-for-eb-10-abeo-20161102monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-provides-update-from-abo-102-phase-1-2-mps-iiia-clinical-trial-at-orph-abeo-20161020monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-receives-orphan-drug-designation-in-the-european-union-for-abo-102-gen-abeo-20161018monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-top-line-data-of-low-dose-cohort-for-abo-102-in-phase-1-2-c-abeo-20161014monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-publication-of-preclinical-data-supporting-clinical-translat-abeo-20161007monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-data-safety-monitoring-board-approves-abo-102-dose-escalatio-abeo-20161005monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-jefferies-gene-editing-gene-therapy-summit-abeo-20161004monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-cell-gene-meeting-on-the-mesa-abeo-20160929monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-enrolls-first-patient-in-phase-2-for-eb-101-gene-therapy-clinical-tria-abeo-20160926monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-ladenburg-thalmann-2016-healthcare-conference-abeo-20160923monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-licensing-of-the-aim-tm-next-generation-aav-gene-therapy-vec-abeo-20160921monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-2016-aegis-growth-conference-abeo-20160916monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-publication-of-preclinical-data-supporting-clinical-translat-abeo-20160915monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-enrolls-5th-patient-in-phase-1-2-gene-therapy-clinical-trial-for-epide-abeo-20160908monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-rodman-renshaw-18th-annual-global-investment-conference-abeo-20160907monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-landmark-angels-6th-annual-investing-for-cures-2016-conf-abeo-20160901monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-completes-enrollment-of-low-dose-cohort-for-abo-102-in-phase-1-2-clini-abeo-20160829monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-european-regulatory-approval-for-phase-1-2-gene-therapy-clin-abeo-20160804monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-provides-update-on-initial-subjects-in-sanfilippo-type-a-gene-therapy--abeo-20160802monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-cantor-fitzgerald-s-2nd-annual-healthcare-conference-abeo-20160630monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-jefferies-2016-global-healthcare-conference-abeo-20160607monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-2016-bio-international-convention-abeo-20160602monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-fda-allowance-of-investigational-new-drug-ind-for-phase-1-2--abeo-20160524monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-ubs-2016-global-healthcare-conference-abeo-20160523monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-doses-first-patient-in-phase-1-2-trial-with-abo-102-gene-therapy-for-p-abeo-20160517monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-first-quarter-2016-summary-financial-results-and-recent-oper-abeo-20160516monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-appoints-christine-silverstein-as-vice-president-of-investor-relations-abeo-20160503monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-gene-cell-and-molecular-therapies-for-inherited-metaboli-abeo-20160415monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-alliance-of-regenerative-medicine-s-arm-4th-annual-cell--abeo-20160321monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-the-28th-annual-roth-conference-abeo-20160310monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-fourth-quarter-and-full-year-2015-summary-financial-results--abeo-20160308monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-highlights-new-preclinical-juvenile-neuronal-ceroid-lipofuscinosis-jnc-abeo-20160302monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-fda-allowance-of-investigational-new-drug-ind-for-systemic-a-abeo-20160229monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-inc-to-present-on-crispr-cas9-technology-platform-progress-at-crispr-p-abeo-20160224monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-source-capital-group-s-2016-disruptive-growth-healthcare-abeo-20160209monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-the-18th-annual-bio-ceo-investor-conference-abeo-20160204monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-initial-european-regulatory-approvals-for-phase-1-2-gene-the-abeo-20160111monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-piper-jaffray-27th-annual-healthcare-conference-abeo-20151201monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-jefferies-2015-global-healthcare-conference-abeo-20151118monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-financial-results-and-highlights-for-third-quarter-2015-abeo-20151117monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-license-for-next-generation-aav-delivery-vector-for-fanconi--abeo-20151006monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-2015-stem-cell-meeting-on-the-mesa-abeo-20151001monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-2015-rodman-renshaw-annual-global-investment-conference-abeo-20150903monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-to-present-at-the-2015-sidoti-emerging-growth-conference-abeo-20150824monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-recent-highlights-and-second-quarter-2015-conference-call-abeo-20150817monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-closing-of-upsized-15-5-million-equity-financing-with-instit-abeo-20150803monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-8-5-million-equity-financing-with-current-institutional-inve-abeo-20150728monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-provides-update-on-sdf-tm-salt-diafiltration-plasma-fractionation-prod-abeo-20150707monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-raises-additional-4-6-million-through-warrant-exercises-in-q2-15-abeo-20150701monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-set-to-join-russell-global-russell-3000-r-and-russell-microcap-r-index-abeo-20150622monthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-nasdaq-abeo-formerly-known-as-plasmatech-biopharmaceuticals-inc-to-rin-abeo-20150619monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-announces-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegopr-eldn-20260608monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-eldn-20260604monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprub-eldn-20260520monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-reports-first-quarter-2026-financial-results-and-recent-business-hi-eldn-20260513monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-announces-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegopr-eldn-20260316monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-orphan-drug-designation-granted-to-tegoprubart-for-the-pr-eldn-20260310monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-reports-preliminary-data-from-first-six-patients-with-type-1-diabetes-treated-with--eldn-20251118monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-recent-business-highlights-and-third-quarter-2025-financi-eldn-20251114monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-proposed-underwritten-public-offering-of-common-stock-and-eldn-20251111monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-present-results-from-phase-2-bestow-trial-of-tegoprubart-for-the-eldn-20251017monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-presents-updated-data-from-ongoing-phase-1b-trial-evaluating-tegoprubart-for-preven-eldn-20250806monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-host-r-d-day-on-july-9-2025-in-new-york-city-eldn-20250625monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-reports-first-quarter-2025-operating-and-financial-results-eldn-20250514monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-operating-and-financial-r-eldn-20250320monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference-eldn-20250304monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-use-of-tegoprubart-as-key-component-of-immunosuppression--eldn-20250207monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-participate-in-guggenheim-securities-smid-cap-biotech-conference-eldn-20250129monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-highlights-recent-business-milestones-and-provides-2025-outlook-eldn-20250113monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-recent-business-highlights-and-third-quarter-2024-financi-eldn-20241112monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-participate-in-guggenheim-securities-inaugural-healthcare-innova-eldn-20241106monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-pricing-of-85-million-underwritten-offering-of-common-sto-eldn-20241029monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-positive-initial-data-from-subjects-with-type-1-diabetes--eldn-20241029monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-present-at-the-cantor-global-healthcare-conference-eldn-20240911monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-announces-completion-of-enrollment-in-phase-2-bestow-clinical-trial-assessing-tegop-eldn-20240904monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-reports-preliminary-second-quarter-2024-operating-results-eldn-20240814monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-provides-enrollment-update-for-phase-2-bestow-trial-assessing-tegoprubart-for-the-p-eldn-20240729monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-to-participate-in-the-leerink-partners-therapeutics-forum-i-i-and-metabolism-eldn-20240702monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-presents-updated-data-from-ongoing-phase-1b-trial-evaluating-tegoprubart-for-preven-eldn-20240603monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-reports-first-quarter-2024-operating-and-financial-results-eldn-20240509monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-present-updated-data-from-ongoing-phase-1b-trial-of-tegoprubart--eldn-20240509monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-announces-clinical-progress-with-tegoprubart-in-the-prevention-of-transplant-reject-eldn-20240507monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-oversubscribed-50-million-private-placement-eldn-20240507monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-operating-and-financial-r-eldn-20240328monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-12th-participant-enrolled-in-phase-2-bestow-trial-evaluat-eldn-20240325monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-use-of-tegoprubart-in-first-ever-transplant-of-geneticall-eldn-20240321monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eldn-20240214monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-highlights-recent-business-milestones-and-provides-2024-outlook-eldn-20240104monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eldn-20231204monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-present-at-noble-capital-markets-emerging-growth-equity-conferen-eldn-20231129monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-reports-third-quarter-2023-operating-and-financial-results-eldn-20231109monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-present-at-jefferies-london-healthcare-conference-eldn-20231108monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-reports-updated-data-from-ongoing-phase-1b-trial-evaluating-tegoprubart-for-prevent-eldn-20231102monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-strengthens-leadership-team-with-appointment-of-eliezer-katz-m-d-fa-eldn-20231023monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-present-data-from-ongoing-phase-1b-trial-of-tegoprubart-in-patie-eldn-20231013monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-appoints-kidney-transplant-specialist-dr-allan-douglas-kirk-to-boar-eldn-20231002monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-use-of-tegoprubart-anti-cd40l-antibody-in-second-ever-tra-eldn-20230925monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-participate-at-the-2023-cantor-fitzgerald-global-healthcare-conf-eldn-20230920monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors-eldn-20230911monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-publication-of-data-showing-treatment-with-tegoprubart-pr-eldn-20230906monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-first-participant-dosed-in-phase-2-bestow-trial-evaluatin-eldn-20230905monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-dosing-of-10th-patient-in-ongoing-phase-1b-trial-evaluati-eldn-20230816monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-reports-second-quarter-2023-operating-and-financial-results-eldn-20230810monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-present-at-jefferies-healthcare-conference-eldn-20230602monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-reports-first-quarter-2023-operating-and-financial-results-eldn-20230511monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2-eldn-20230504monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-up-to-185-million-financing-to-advance-tegoprubart-kidney-eldn-20230501monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-reports-data-from-ongoing-phase-1b-trial-evaluating-tegoprubart-in-patients-undergo-eldn-20230331monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-operating-and-financial-r-eldn-20230330monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-report-fourth-quarter-and-full-year-2022-financial-results-on-th-eldn-20230323monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-to-present-data-from-ongoing-phase-1b-trial-evaluating-tegoprubart-in-kidney-transp-eldn-20230323monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-present-at-svb-securities-global-biopharma-conference-eldn-20230208monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-provides-business-and-pipeline-updates-eldn-20230109monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-report-third-quarter-2022-financial-results-on-monday-november-1-eldn-20221103monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-upcoming-presentations-at-asn-s-kidney-week-2022-and-neal-eldn-20221024monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences-eldn-20221003monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference-eldn-20220922monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-receives-fda-clearance-of-ind-application-to-evaluate-tegoprubart-i-eldn-20220906monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-eldn-20220829monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-reports-second-quarter-2022-operating-and-financial-results-eldn-20220811monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-report-second-quarter-2022-financial-results-on-thursday-august--eldn-20220804monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-receives-fda-clearance-of-ind-application-to-evaluate-tegoprubart-f-eldn-20220801monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-the-first-patient-dosed-in-phase-1b-trial-evaluating-tego-eldn-20220718monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eldn-20220610monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-orphan-drug-designation-granted-to-tegoprubart-for-the-pr-eldn-20220609monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-present-at-the-jefferies-healthcare-conference-eldn-20220602monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-first-patient-dosed-in-phase-2a-trial-evaluating-tegoprub-eldn-20220509monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-report-first-quarter-2022-financial-results-on-thursday-may-12-2-eldn-20220505monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-participate-in-lifesci-partners-immunology-inflammation-symposiu-eldn-20220503monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-participate-in-18th-annual-noble-capital-markets-investor-confer-eldn-20220418monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-to-host-virtual-r-d-day-on-thursday-april-28-2022-eldn-20220414monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-report-fourth-quarter-and-full-year-2021-financial-results-on-th-eldn-20220317monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-provides-corporate-update-and-2022-outlook-eldn-20220214monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-participate-in-11th-annual-svb-leerink-global-healthcare-confere-eldn-20220208monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-participate-in-january-2022-investor-conferences-eldn-20211227monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-ceo-david-alexandre-c-gros-m-d-to-present-at-caredx-virtual-transpl-eldn-20211104monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-participation-in-november-conferences-eldn-20211104monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-release-third-quarter-financial-results-on-thursday-november-11--eldn-20211101monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-presentation-on-at-1501-at-the-virtual-2021-northeast-amy-eldn-20211007monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-upcoming-presentation-on-at-1501-at-the-virtual-2021-inte-eldn-20211005monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-present-at-two-investor-conferences-in-september-eldn-20210901monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-release-second-quarter-financial-results-on-thursday-august-12-2-eldn-20210802monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-receives-health-canada-approval-to-commence-human-trials-to-evaluat-eldn-20210726monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-appoints-jan-hillson-m-d-to-its-board-of-directors-eldn-20210702monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference-eldn-20210629monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-present-at-the-2021-jefferies-virtual-healthcare-conference-eldn-20210518monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-announces-upcoming-presentations-on-at-1501-at-the-virtual-2021-ame-eldn-20210505monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-release-first-quarter-financial-results-on-thursday-may-13-2021-eldn-20210504monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-continues-to-bolster-leadership-team-with-addition-of-two-more-key--eldn-20210419monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-operating-and-financial-r-eldn-20210330monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-release-fourth-quarter-and-full-year-financial-results-on-tuesda-eldn-20210323monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-strengthens-leadership-team-with-chief-medical-officer-and-chief-fi-eldn-20210315monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-present-at-h-c-wainwright-global-life-sciences-conference-eldn-20210302monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-present-at-10th-annual-svb-leerink-global-healthcare-conference-eldn-20210217monthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-to-participate-in-the-virtual-noble-capital-markets-seventeenth-ann-eldn-20210119monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-host-virtual-investor-webinar-to-discuss-tara-002-for-lymphatic-ma-tara-20260518monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-participate-in-upcoming-investor-conferences-tara-20260219monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-highlights-recent-updates-and-anticipated-2026-milestones-tara-20260112monthly0.5https://www.biopharmawatch.com/news/TARA/protara-announces-closing-of-75-million-public-offering-tara-20251208monthly0.5https://www.biopharmawatch.com/news/TARA/protara-announces-proposed-public-offering-tara-20251204monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-host-conference-call-and-webcast-to-review-new-interim-data-from-p-tara-20251118monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tara-20250902monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tara-20250801monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tara-20250701monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-participate-in-upcoming-investor-conferences-tara-20250513monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tara-20250501monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-positive-interim-results-demonstrating-durable-responses-in-tara-20250426monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-host-conference-call-and-webcast-to-review-interim-data-from-phase-tara-20250423monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-appointment-of-leonardo-viana-nicacio-m-d-as-chief-medical--tara-20250415monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-present-interim-analysis-from-the-phase-2-advanced-2-trial-of-tara-tara-20250410monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-encore-presentation-of-results-from-thrive-1-prospective-ob-tara-20250319monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference-tara-20250226monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-co-tara-20250205monthly0.5https://www.biopharmawatch.com/news/TARA/protara-highlights-recent-updates-and-anticipated-2025-milestones-tara-20250113monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-tara-20250108monthly0.5https://www.biopharmawatch.com/news/TARA/protara-announces-closing-of-100-million-public-offering-tara-20241211monthly0.5https://www.biopharmawatch.com/news/TARA/protara-announces-pricing-of-100-million-public-offering-tara-20241210monthly0.5https://www.biopharmawatch.com/news/TARA/protara-announces-positive-results-from-the-ongoing-phase-2-advanced-2-trial-of-tara-002-i-tara-20241205monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-host-conference-call-and-webcast-to-review-new-interim-data-from-p-tara-20241203monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-tara-20241115monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-present-at-the-guggenheim-inaugural-healthcare-innovation-conferen-tara-20241106monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-granted-fda-fast-track-designation-for-intravenous-choline-chloride-f-tara-20241021monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-completion-of-first-cohort-in-phase-2-starborn-1-trial-of-t-tara-20240909monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-results-from-thrive-1-a-prospective-observational-study-eva-tara-20240909monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-present-at-the-h-c-wainwright-26th-annual-global-investment-confer-tara-20240903monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tara-20240624monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-present-at-the-td-cowen-5th-annual-oncology-innovation-summit-tara-20240521monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-oversubscribed-45-million-private-placement-financing-tara-20240405monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-positive-three-month-data-from-tara-002-clinical-program-in-tara-20240405monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-present-at-the-td-cowen-44th-annual-health-care-conference-tara-20240228monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-participate-in-upcoming-investor-conferences-tara-20240131monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-presentation-of-additional-encouraging-data-from-phase-1a-a-tara-20231130monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-dosing-of-first-patient-in-phase-2-starborn-1-trial-of-tara-tara-20231023monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-dosing-of-first-patient-in-phase-1b-2-advanced-2-trial-of-t-tara-20230920monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-present-at-the-h-c-wainwright-25th-annual-global-investment-confer-tara-20230905monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-dosing-of-first-patients-in-phase-1b-advanced-1exp-trial-of-tara-20230515monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-participate-in-upcoming-investor-conferences-tara-20230301monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-present-at-the-guggenheim-healthcare-talks-oncology-day-tara-20230202monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-trials-in-progress-poster-presentation-for-the-advanced-1-t-tara-20221201monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-present-at-h-c-wainwright-24th-annual-global-investment-conference-tara-20220906monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-trials-in-progress-poster-presentation-for-the-advanced-1-t-tara-20220526monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-present-at-the-h-c-wainwright-global-investment-conference-tara-20220517monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-presents-results-from-retrospective-analysis-of-randomized-and-open-l-tara-20220512monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-doses-first-patient-in-advanced-1-phase-1-study-of-tara-002-in-non-mu-tara-20220324monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-participate-in-upcoming-investor-conferences-tara-20220302monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-2022-oncology-confe-tara-20220201monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-virtual-conference-tara-20220104monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tara-20211025monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-present-at-the-oppenheimer-fall-healthcare-life-sciences-medtech-s-tara-20210917monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-results-from-a-retrospective-study-evaluating-the-prevalenc-tara-20210913monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-confer-tara-20210907monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-present-at-the-ladenburg-thalmann-healthcare-conference-tara-20210707monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-participate-in-upcoming-virtual-investor-conferences-tara-20210513monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-first-quarter-2021-financial-results-and-business-overview-tara-20210506monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tara-20210419monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-fourth-quarter-and-full-year-2020-financial-results-and-bus-tara-20210311monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-participate-in-the-oppenheimer-31st-annual-healthcare-conference-tara-20210310monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-present-at-upcoming-virtual-investor-conferences-tara-20210204monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tara-20210202monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-promotion-of-jacqueline-zummo-ph-d-to-chief-scientific-oper-tara-20201207monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tara-20201203monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-present-at-upcoming-virtual-investor-conferences-tara-20201124monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-third-quarter-2020-financial-results-and-business-overview-tara-20201112monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-to-present-at-the-jefferies-virtual-london-healthcare-conference-tara-20201111monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tara-20201104monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-pricing-of-147-6-million-of-securities-in-concurrent-public-tara-20200922monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tara-20200902monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-second-quarter-2020-financial-results-and-business-overview-tara-20200803monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-receives-rare-pediatric-disease-designation-for-tara-002-for-the-trea-tara-20200728monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tara-20200702monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tara-20200602monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-receives-fast-track-designation-from-u-s-fda-for-intravenous-choline--tara-20200526monthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-announces-first-quarter-2020-financial-results-and-business-overview-tara-20200513monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-rebrands-as-sab-bio-sabs-20240620monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-to-present-at-the-american-diabetes-association-84th-scientific-sessio-sabs-20240618monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-announces-q1-2024-financial-results-and-provides-company-updates-sabs-20240520monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-provides-sab-142-trial-update-sabs-20240416monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-to-present-at-innodia-annual-meeting-sabs-20240408monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-to-present-at-the-needham-virtual-healthcare-conference-sabs-20240404monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-announces-clinical-partnership-with-naval-medical-research-center-to-a-sabs-20240325monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-to-present-at-the-bio-ceo-investor-conference-sabs-20240223monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-to-present-at-the-oppenheimer-34th-annual-healthcare-life-sciences-con-sabs-20240208monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-announces-completion-of-67-1-million-financing-to-advance-potential-di-sabs-20231114monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-announces-q3-2023-financial-results-and-provides-company-updates-sabs-20231114monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-to-present-at-piper-sandler-healthcare-conference-sabs-20231109monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-appoints-michael-g-king-jr-as-chief-financial-officer-sabs-20231024monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-receives-australian-approval-to-commence-phase-1-clinical-trial-of-sab-sabs-20231019monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-approves-appointment-of-andrew-moin-to-board-of-directors-sabs-20231005monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-provides-company-update-for-q2-2023-financial-results-sabs-20230821monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-presents-positive-ind-enabling-glp-toxicology-study-for-sab-142-a-nove-sabs-20230621monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-to-present-novel-human-igg-platform-with-positive-data-and-breakthroug-sabs-20230530monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-presents-virtual-2023-r-d-day-portfolio-update-breakthrough-immunother-sabs-20230519monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-provides-company-update-for-q1-2023-financial-results-sabs-20230516monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-announces-first-publication-of-promising-nonclinical-data-for-sab-183--sabs-20230512monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-announces-progress-on-u-s-fda-s-phased-review-of-company-s-groundbreak-sabs-20230509monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-presents-positive-phase-1-and-2a-data-for-sab-176-influenza-immunother-sabs-20230504monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-to-present-at-sidoti-virtual-investor-conference-may-10-11-sabs-20230503monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-announces-positive-results-from-phase-3-trial-of-sab-185-in-patients-w-sabs-20230426monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-announces-u-s-fda-grants-breakthrough-therapy-designation-to-sab-176-i-sabs-20230418monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-granted-fast-track-designation-from-fda-for-sab-176-influenza-immunoth-sabs-20230413monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-announces-appointment-of-erick-lucera-cfa-to-board-of-directors-sabs-20230404monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-provides-company-update-for-full-year-2022-sabs-20230331monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-ceo-eddie-sullivan-phd-to-present-next-generation-biologics-in-immunol-sabs-20230119monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-receives-an-additional-8-2-million-in-closeout-of-dod-contract-sabs-20230118monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-cmo-selected-to-present-at-the-january-2023-biotech-showcase-in-san-fr-sabs-20221215monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-initiates-ind-enabling-glp-toxicology-study-for-sab-142-novel-immunoth-sabs-20221121monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-provides-company-update-for-q3-2022-financial-results-sabs-20221115monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-presents-novel-biologic-therapeutics-for-infectious-diseases-at-u-s-ph-sabs-20221108monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-presents-overview-of-diversitab-platform-and-data-showing-benefits-of--sabs-20221103monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-unveils-new-data-at-isirv-options-xi-conference-validating-sab-176-pro-sabs-20220928monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-sabs-20220923monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-provides-company-update-for-q2-2022-financial-results-sabs-20220810monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-advancing-pipeline-and-expands-into-treatment-for-c-diff-as-dod-contra-sabs-20220809monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-to-host-virtual-2022-annual-r-d-portfolio-update-sabs-20220804monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-announces-election-of-rear-admiral-retired-scott-giberson-rph-mph-d-sc-sabs-20220711monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-hosts-u-s-representatives-dusty-johnson-and-dean-phillips-for-south-da-sabs-20220705monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-chief-operating-officer-dr-christoph-bausch-to-present-at-the-large-an-sabs-20220531monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-provides-company-update-for-q1-2022-financial-results-sabs-20220512monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-to-present-at-2022-h-c-wainwright-global-investment-conference-sabs-20220512monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-appoints-mark-j-ratain-md-to-the-company-s-board-of-scientific-advisor-sabs-20220405monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-provides-company-update-and-reports-full-year-2021-financial-results-sabs-20220329monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-reports-nih-is-discontinuing-phase-3-activ-2-trial-assessing-sab-185-f-sabs-20220302monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-announces-publication-of-nonclinical-data-demonstrating-sab-185-has-hi-sabs-20220302monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-announces-update-to-the-phase-3-nih-activ-2-trial-design-evaluating-sa-sabs-20220225monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-reports-positive-phase-2-virology-data-demonstrating-sab-185-met-crite-sabs-20220124monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-to-present-at-2022-h-c-wainwright-bioconnect-virtual-conference-sabs-20220105monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-added-to-nasdaq-biotechnology-index-sabs-20211220monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-announces-sab-185-retains-neutralization-against-omicron-sars-cov-2-va-sabs-20211216monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-announces-sab-176-met-its-primary-endpoint-in-phase-2a-challenge-study-sabs-20211201monthly0.5https://www.biopharmawatch.com/news/SABS/sab-biotherapeutics-debuts-as-publicly-traded-next-generation-immunotherapy-company-sabs-20211025monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-inc-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-mo-trda-20260511monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-with-duchen-trda-20260506monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-highlights-progress-across-its-portfolio-of-rna-based-therapeutics-fo-trda-20260108monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-reports-second-quarter-2025-financial-results-trda-20250806monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-trda-20250602monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-reports-first-quarter-2025-financial-results-trda-20250508monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-receives-authorization-in-the-united-kingdom-to-initiate-elevate-45-2-trda-20250324monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-trda-20250227monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-announces-fda-removal-of-clinical-hold-on-entr-601-44-trda-20250224monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-receives-authorization-in-the-united-kingdom-to-initiate-elevate-44-2-trda-20250203monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-trda-20241218monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-reports-third-quarter-2024-financial-results-trda-20241105monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-presents-new-data-supporting-its-expanding-duchenne-franchise-at-the--trda-20241009monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-promotes-natarajan-sethuraman-phd-to-president-of-research-and-develo-trda-20240924monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-announces-recipients-of-second-annual-diversity-representation-equity-trda-20240906monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-reports-second-quarter-2024-financial-results-trda-20240813monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-to-present-at-goldman-sachs-45th-annual-global-healthcare-conference-trda-20240603monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-to-present-at-h-c-wainwright-2nd-annual-bioconnect-investor-conferenc-trda-20240516monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-reports-first-quarter-2024-financial-results-trda-20240507monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-trda-20240313monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-to-present-at-upcoming-investor-conferences-trda-20240207monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-reports-third-quarter-2023-financial-results-trda-20231107monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-to-present-at-upcoming-investor-conferences-trda-20231012monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-announces-first-participant-dosed-in-its-phase-1-clinical-trial-of-en-trda-20230921monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-awards-funding-to-non-profit-organizations-advancing-diversity-equity-trda-20230907monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-to-present-at-upcoming-investor-conferences-trda-20230829monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-reports-second-quarter-2023-financial-results-trda-20230808monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-to-present-at-goldman-sachs-44th-annual-global-healthcare-conference-trda-20230606monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-reports-first-quarter-2023-financial-results-trda-20230510monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-appoints-dr-bernhardt-zeiher-to-its-board-of-directors-trda-20230404monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-to-participate-in-guggenheim-genomic-medicines-and-rare-disease-confe-trda-20230329monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-trda-20230306monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-to-participate-in-cowen-43rd-annual-health-care-conference-trda-20230227monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-closes-agreement-with-vertex-to-discover-and-develop-endosomal-escape-trda-20230209monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-announces-clinical-candidate-entr-601-45-for-the-potential-treatment--trda-20230109monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-to-present-at-evercore-isi-5th-annual-healthconx-virtual-conference-trda-20221122monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-reports-third-quarter-2022-financial-results-trda-20221107monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-to-present-at-h-c-wainwright-24th-annual-global-investment-conference-trda-20220830monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-reports-second-quarter-2022-financial-results-trda-20220811monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-announces-collaboration-with-the-myotonic-dystrophy-clinical-research-trda-20220804monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-appoints-karla-macdonald-as-chief-corporate-affairs-officer-trda-20220719monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-to-present-at-william-blair-biotech-focus-conference-trda-20220706monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-to-present-at-goldman-sachs-global-healthcare-conference-trda-20220601monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-presents-new-data-supporting-its-growing-pipeline-of-endosomal-escape-trda-20220511monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-to-present-at-h-c-wainwright-global-investment-conference-trda-20220510monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-to-participate-in-cowen-42nd-annual-health-care-conference-trda-20220223monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-announces-the-appointment-of-jared-cohen-phd-jd-to-general-counsel-trda-20220105monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-to-be-added-to-russell-2000-and-russell-3000-indexes-trda-20211217monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-to-present-at-evercore-isi-4th-annual-healthconx-virtual-conference-trda-20211118monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-announces-closing-of-initial-public-offering-trda-20211102monthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-announces-pricing-of-upsized-initial-public-offering-trda-20211029monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-new-preclinical-data-demonstrating-progress-of-edit-401-as-potenti-edit-20260514monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-first-quarter-2026-results-and-business-updates-edit-20260505monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-second-quarter-2025-results-and-business-updates-edit-20250812monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-new-in-vivo-data-highlighting-the-potential-of-editas-gene-upregul-edit-20250514monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-new-in-vivo-proof-of-concept-data-in-an-undisclosed-liver-target-a-edit-20250513monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-first-quarter-2025-results-and-business-updates-edit-20250512monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-u-s-court-of-appeals-for-the-federal-circuit-remands-crispr-pate-edit-20250512monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-announce-first-quarter-2025-financial-results-and-to-participate-in-inv-edit-20250505monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-a-edit-20250428monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-chief-financial-officer-transition-edit-20250320monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-fourth-quarter-and-full-year-2024-results-and-business-updates-edit-20250305monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-announce-fourth-quarter-full-year-2024-financial-results-and-to-partici-edit-20250224monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-highlights-new-in-vivo-preclinical-proof-of-concept-data-anticipated-2025--edit-20250113monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-edit-20250106monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-strategic-transition-to-in-vivo-gene-editing-company-with-intent-edit-20241212monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-updated-clinical-data-from-the-ruby-trial-of-reni-cel-in-patients--edit-20241209monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-participate-in-upcoming-investor-conferences-edit-20241106monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-third-quarter-2024-results-and-business-updates-edit-20241104monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-progress-towards-2024-goals-including-achievement-of-in-vivo-pre-edit-20241022monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-and-genevant-sciences-to-collaborate-to-develop-novel-mrna-lnp-gene-editin-edit-20241021monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-strategic-update-webinar-to-detail-progress-towards-2024-goals-inc-edit-20241018monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-50-million-monetization-financing-with-dri-healthcare-trust-edit-20241003monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-participate-in-upcoming-investor-conferences-edit-20240828monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-second-quarter-2024-results-and-business-updates-edit-20240807monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-second-quarter-2024-results-conference-call-and-corporate-update-edit-20240731monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-new-safety-and-efficacy-data-from-the-ruby-trial-of-reni-cel-in-18-edit-20240614monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-new-safety-and-efficacy-data-from-the-edithal-trial-of-reni-cel--edit-20240614monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-clinical-data-from-the-ruby-and-edithal-trials-of-reni-cel-at-t-edit-20240514monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-preclinical-data-highlights-advancement-of-in-vivo-gene-editing-medicine-t-edit-20240510monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-first-quarter-2024-results-and-business-updates-edit-20240508monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-first-quarter-2024-results-conference-call-and-upcoming-investor-edit-20240502monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-and-bristol-myers-squibb-extend-alpha-beta-t-cell-collaboration-edit-20240501monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-pre-clinical-data-demonstrating-progression-of-in-vivo-medicine-edit-20240422monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-fourth-quarter-and-full-year-2023-results-conference-call-and-up-edit-20240221monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-participate-in-upcoming-investor-conferences-edit-20240131monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-highlights-2024-anticipated-milestones-and-strategic-priorities-at-the-j-p-edit-20240108monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-edit-20240103monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-and-vertex-pharmaceuticals-enter-into-non-exclusive-license-agreement-for--edit-20231213monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-new-edit-301-safety-and-efficacy-data-in-17-patients-presented-t-edit-20231211monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-clinical-data-from-the-ruby-and-edithal-trials-of-edit-301-at-t-edit-20231102monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-third-quarter-2023-results-conference-call-and-upcoming-investor-edit-20231027monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-granted-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-ed-edit-20231016monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-inducement-grants-to-new-chief-commercial-and-strategy-officer-edit-20230925monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-a-edit-20230925monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-upcoming-investor-events-edit-20230830monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-and-azzur-group-expand-partnership-to-accelerate-editas-manufacturing-capa-edit-20230727monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-second-quarter-2023-results-conference-call-and-corporate-update-edit-20230726monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-inducement-grant-to-new-chief-scientific-officer-edit-20230725monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-linda-c-burkly-p-edit-20230724monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-pricing-of-offering-of-common-stock-edit-20230615monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-virtual-event-to-discuss-edit-301-clinical-data-from-the-ruby-tria-edit-20230606monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-inducement-grant-to-new-chief-financial-officer-edit-20230518monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-appointment-of-erick-j-lucera-as-chief-financial-officer-edit-20230516monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-clinical-data-from-the-ruby-trial-of-edit-301-for-the-treatment-edit-20230511monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-publication-in-nature-biotechnology-of-comprehensive-sleek-gene--edit-20230501monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-first-quarter-2023-results-conference-call-and-upcoming-investor-edit-20230501monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-receives-fda-orphan-drug-designation-for-edit-301-for-the-treatment-of-sic-edit-20230427monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-strengthens-board-of-directors-with-appointment-of-new-chair-and-new-direc-edit-20230413monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-linea-aspesi-as--edit-20230308monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-fourth-quarter-and-full-year-2022-resul-edit-20230215monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-and-shoreline-biosciences-enter-into-definitive-agreement-for-shoreline-to-edit-20230119monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-strategic-updates-and-portfolio-reprioritization-edit-20230109monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-edit-20230104monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-virtual-event-to-highlight-initial-clinical-data-from-the-ruby-tri-edit-20221201monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-third-quarter-2022-results-and-corporat-edit-20221026monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-presents-preclinical-data-on-edit-103-for-rhodopsin-associated-autosomal-d-edit-20221013monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-participate-in-upcoming-investor-conferences-edit-20220901monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-clinical-achievements-in-the-development-of-edit-301-for-sickle--edit-20220727monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-second-quarter-2022-results-and-corpora-edit-20220726monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-inducement-grant-to-new-chief-medical-officer-edit-20220720monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-appoints-baisong-mei-m-d-ph-d-as-chief-medical-officer-edit-20220718monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-inducement-grants-to-new-chief-executive-officer-edit-20220606monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-presents-data-on-sleek-gene-editing-technology-at-the-american-society-of--edit-20220518monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-receives-fda-orphan-drug-designation-for-edit-301-for-the-treatment-of-bet-edit-20220512monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-presents-preclinical-data-on-edit-103-for-rhodopsin-associated-autosomal-d-edit-20220504monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-pipeline-and-platform-data-demonstrating-progress-towards-devel-edit-20220502monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-first-quarter-2022-results-and-corporat-edit-20220427monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-receives-fda-rare-pediatric-disease-designation-for-edit-301-for-the-treat-edit-20220426monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-appoints-gilmore-o-neill-as-chief-executive-officer-edit-20220414monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-dosing-of-first-pediatric-patient-in-the-brilliance-clinical-tri-edit-20220411monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-engineered-ink-cell-preclinical-data-at-american-association-for-c-edit-20220408monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-favorable-decision-from-u-s-patent-and-trademark-office-in-crisp-edit-20220228monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-fourth-quarter-and-full-year-2021-resul-edit-20220216monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-on-recent-progress-and-outlook-at-j-p-morgan-healthcare-conference-edit-20220110monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-edit-20220104monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-fda-clearance-of-investigational-new-drug-ind-application-for-ed-edit-20211220monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-preclinical-data-demonstrating-robust-tumor-reduction-and-clearanc-edit-20211212monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-presents-preclinical-data-on-novel-engineered-ipsc-derived-nk-cells-for-th-edit-20211112monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-data-demonstrating-progress-towards-transformative-gene-editing-edit-20211104monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-names-bernadette-connaughton-to-board-of-directors-edit-20211028monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-third-quarter-2021-results-and-corporat-edit-20211025monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-preclinical-data-on-novel-engineered-ipsc-derived-nk-cells-for--edit-20211007monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-at-chardan-s-5th-annual-genetic-medicines-conference-edit-20210930monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-names-emma-reeve-to-board-of-directors-edit-20210908monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-participate-in-upcoming-investor-conferences-edit-20210902monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-presents-data-on-new-sleek-gene-editing-technology-at-cold-spring-harbor-l-edit-20210820monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-and-idt-announce-publication-in-nature-communications-of-research-data-sup-edit-20210729monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-second-quarter-2021-results-and-corpora-edit-20210728monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-names-bruce-e-eaton-ph-d-as-executive-vice-president-and-chief-business-of-edit-20210726monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-enrollment-of-the-first-pediatric-cohort-in-the-brilliance-clini-edit-20210623monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-inducement-grants-to-new-chief-scientific-officer-and-chief-regula-edit-20210615monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-strengthens-executive-leadership-team-to-advance-pipeline-and-support-long-edit-20210614monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-presents-preclinical-data-supporting-the-initiation-of-the-edit-301-phase--edit-20210611monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-names-mark-s-shearman-ph-d-as-chief-scientific-officer-edit-20210505monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-development-of-gene--edit-20210504monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-preclinical-data-demonstrating-advancements-in-in-vivo-gene-edi-edit-20210501monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-first-quarter-2021-results-and-corporat-edit-20210428monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-fourth-quarter-and-full-year-2020-resul-edit-20210218monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-offering-of-common-stock-edit-20210119monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-on-recent-progress-and-outlook-at-j-p-morgan-healthcare-conference-edit-20210111monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-the-fda-has-cleared-initiation-of-the-edit-301-clinical-trial-edit-20210111monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-transition-of-chief-scientific-officer-edit-20210111monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-edit-20210104monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-names-meeta-chatterjee-ph-d-to-board-of-directors-edit-20201217monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-submission-of-ind-application-for-edit-301-with-the-fda-edit-20201209monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-preclinical-data-and-large-scale-manufacturing-process-for-edit--edit-20201205monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-inducement-grants-to-new-chief-medical-officer-edit-20201110monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-at-barclays-gene-editing-gene-therapy-summit-edit-20201109monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-appoints-lisa-a-michaels-m-d-as-chief-medical-officer-edit-20201109monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-third-quarter-2020-results-and-corporat-edit-20201029monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-participate-in-upcoming-investor-conference-edit-20201001monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-u-s-patent-and-trademark-office-grants-the-broad-institute-prior-edit-20200911monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-participate-in-upcoming-investor-conferences-edit-20200904monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-receives-rare-pediatric-disease-designation-for-edit-301-for-the-treatment-edit-20200824monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-regains-full-global-rights-to-ocular-medicines-edit-20200806monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-appoints-gad-berdugo-as-chief-business-officer-edit-20200727monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-second-quarter-2020-results-and-corpora-edit-20200723monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-and-azzur-group-announce-a-multi-year-agreement-for-edit-301-and-edit-201--edit-20200707monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-closing-of-offering-of-common-stock-and-full-exercise-by-underwr-edit-20200626monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-pricing-of-offering-of-common-stock-edit-20200624monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-presents-pre-clinical-data-from-a-study-of-edit-301-with-sickle-patient-ce-edit-20200612monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-presents-pre-clinical-data-supporting-the-use-of-crispr-cas12a-to-edit-ind-edit-20200515monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-first-quarter-2020-results-and-corporat-edit-20200430monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-initiates-ind-enabling-activities-for-edit-201-an-allogeneic-nk-cell-medic-edit-20200429monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-fourth-quarter-and-full-year-2019-resul-edit-20200219monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-on-recent-progress-at-j-p-morgan-healthcare-conference-edit-20200113monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-and-sandhill-therapeutics-inc-announce-collaboration-to-develop-engineered-edit-20200113monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-inducement-grants-to-new-chief-financial-officer-edit-20200110monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-strengthens-executive-leadership-team-to-support-long-term-growth-edit-20200109monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-edit-20200102monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-in-vivo-proof-of-concept-data-for-edit-301-in-development-for-th-edit-20191209monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-and-celgene-corporation-amend-existing-collaboration-to-develop-and-commer-edit-20191112monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-third-quarter-2019-results-and-corporat-edit-20191105monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-appoints-judith-r-abrams-m-d-as-chief-medical-officer-edit-20191028monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-and-askbio-enter-strategic-research-collaboration-to-explore-in-vivo-deliv-edit-20191015monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-and-maxcyte-announce-clinical-and-commercial-license-agreement-for-enginee-edit-20191007monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-participate-in-upcoming-investor-conferences-edit-20191001monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-participate-in-upcoming-investor-conferences-edit-20190829monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-appoints-cynthia-collins-as-president-and-chief-executive-officer-edit-20190806monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-second-quarter-2019-results-and-corpora-edit-20190730monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-presents-pre-clinical-data-for-treatment-of-sickle-cell-disease-and-beta-t-edit-20190615monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-first-quarter-2019-results-and-corporat-edit-20190430monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-and-bluerock-therapeutics-enter-strategic-research-collaboration-and-cross-edit-20190403monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-supports-global-movement-to-raise-awareness-on-rare-disease-day-edit-20190228monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-fourth-quarter-and-full-year-2018-corpo-edit-20190221monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-names-david-scadden-m-d-to-board-of-directors-edit-20190206monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-publication-in-nature-medicine-of-data-supporting-the-developmen-edit-20190121monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-on-recent-progress-at-j-p-morgan-healthcare-conference-edit-20190107monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-edit-20190102monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-transition-of-chief-financial-officer-edit-20181221monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-names-cynthia-collins-to-board-of-directors-edit-20181210monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-pre-clinical-data-supporting-novel-approach-for-treatment-of-sic-edit-20181203monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-fda-acceptance-of-ind-application-for-edit-101-edit-20181130monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-third-quarter-2018-corporate-update-and-edit-20181031monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-grows-scientific-leadership-with-two-new-appointments-edit-20181001monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-u-s-court-of-appeals-for-the-federal-circuit-affirms-favorable-u-edit-20180910monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-transition-of-chief-medical-officer-edit-20180827monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-the-completion-of-the-recombinant-dna-advisory-committee-rac-reg-edit-20180816monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-second-quarter-2018-corporate-update-an-edit-20180730monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-participate-in-the-jmp-securities-life-sciences-conference-edit-20180613monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-data-demonstrating-subretinal-injection-of-edit-101-well-tolerated-edit-20180518monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-at-the-bank-of-america-merrill-lynch-2018-health-care-conferenc-edit-20180508monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-new-data-demonstrating-progress-towards-creating-genome-editing-edit-20180430monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-first-quarter-2018-corporate-update-and-edit-20180426monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-names-james-c-mullen-as-chairman-of-the-board-of-directors-edit-20180328monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-supports-rare-disease-day-and-joins-global-movement-to-raise-important-awa-edit-20180228monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-fourth-quarter-and-full-year-2017-corpo-edit-20180227monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-names-jessica-hopfield-ph-d-to-board-of-directors-edit-20180216monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-participate-in-upcoming-investor-conferences-edit-20180208monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-on-recent-progress-and-announces-em22-five-year-goals-at-j-p-morga-edit-20180108monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-edit-20180103monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-data-supporting-multiple-approaches-to-create-treatments-for-sickl-edit-20171211monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-inc-announces-pricing-of-50-million-offering-of-common-stock-edit-20171206monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-third-quarter-2017-corporate-update-and-edit-20171103monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-demonstrates-dose-dependent-in-vivo-editing-with-edit-101-in-cep290-transg-edit-20171019monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-participate-in-investor-conferences-in-october-edit-20171003monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-receives-ema-s-orphan-medicinal-product-designation-for-edit-101-for-the-t-edit-20170926monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-initiates-clinical-natural-history-study-to-evaluate-patients-with-leber-c-edit-20170912monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-participate-in-morgan-stanley-15th-annual-global-healthcare-conference-edit-20170905monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-achieves-milestone-under-juno-therapeutics-collaboration-for-technical-pro-edit-20170809monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-second-quarter-2017-corporate-update-an-edit-20170807monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-participate-in-investor-conferences-in-june-edit-20170613monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-names-andrew-hirsch-to-board-of-directors-edit-20170531monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-demonstrates-first-achievement-of-in-vivo-editing-in-non-human-primate-ret-edit-20170513monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-pre-clinical-data-for-program-to-treat-sickle-cell-disease-and-b-edit-20170511monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-at-investor-conferences-in-may-edit-20170508monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-first-quarter-2017-corporate-update-and-edit-20170508monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-new-data-demonstrating-advancements-for-translating-crispr-tech-edit-20170424monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-inc-nasdaq-edit-to-ring-the-nasdaq-stock-market-opening-bell-edit-20170424monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-inc-announces-proposed-offering-of-common-stock-edit-20170315monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-departure-of-chief-operating-officer-edit-20170303monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-fourth-quarter-and-full-year-2016-corpo-edit-20170228monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-joins-global-movement-to-raise-awareness-on-rare-disease-day-2017-edit-20170228monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-at-investor-conferences-in-march-edit-20170227monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-u-s-patent-and-trademark-office-decision-favorable-to-broad-inst-edit-20170215monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-at-upcoming-february-investor-conferences-edit-20170210monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-on-recent-progress-and-2017-goals-at-j-p-morgan-healthcare-confere-edit-20170109monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-edit-20170104monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-extends-crispr-genome-editing-leadership-through-licensing-of-new-crispr-t-edit-20161219monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-at-the-stifel-healthcare-conference-2016-edit-20161109monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-third-quarter-2016-corporate-update-and-edit-20161031monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-data-on-crispr-cas9-mediated-gene-editing-in-hematopoietic-stem-edit-20161017monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-reports-inducement-grant-to-new-chief-medical-officer-edit-20161006monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-at-the-jefferies-gene-editing-therapy-summit-edit-20161003monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-expands-senior-management-team-edit-20161003monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-at-the-morgan-stanley-global-healthcare-conference-edit-20160906monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-names-charles-albright-as-chief-scientific-officer-edit-20160822monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-exclusive-license-to-advanced-crispr-genome-editing-technology-f-edit-20160803monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-second-quarter-2016-corporate-update-an-edit-20160802monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-appoints-akshay-vaishnaw-m-d-ph-d-to-its-board-of-directors-edit-20160729monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-scientific-multi-year-collaboration-with-fondazione-telethon-and-edit-20160728monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-at-upcoming-june-investor-conferences-edit-20160524monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-agreement-with-cystic-fibrosis-foundation-therapeutics-to-advanc-edit-20160516monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-host-conference-call-discussing-first-quarter-2016-corporate-update-and-edit-20160509monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-achieves-milestone-under-its-collaboration-with-juno-therapeutics-edit-20160504monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-presentations-at-upcoming-scientific-conferences-edit-20160427monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-at-deutsche-bank-41st-annual-health-care-conference-edit-20160427monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-at-15th-annual-needham-healthcare-conference-edit-20160406monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-to-present-at-cowen-and-company-36th-annual-health-care-conference-edit-20160301monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-closing-of-initial-public-offering-and-full-exercise-of-option-t-edit-20160208monthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-announces-pricing-of-initial-public-offering-edit-20160203monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-highlights-guideline-recommended-role-of-icosapent-ethyl-in-managing-cardiovascular-amrn-20260318monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-second-quarter-2025-financial-results-and-host-conference-call-on-july-30-amrn-20250723monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-first-quarter-2025-financial-results-and-host-conference-call-on-may-7-20-amrn-20250428monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-highlights-recent-data-presented-at-acc-25-evaluating-mechanistic-effects-of-eicosa-amrn-20250331monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-plan-to-initiate-a-ratio-change-under-its-american-depository-receipt-adr-amrn-20250312monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-marks-key-milestone-for-vascepa-vazkepa-icosapent-ethyl-publication-of-post-hoc-ana-amrn-20250227monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-receives-national-reimbursement-for-vazkepa-in-austria-amrn-20250225monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-c-amrn-20250219monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-receives-national-reimbursement-for-vazkepa-in-italy-amrn-20241216monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-two-upcoming-investor-events-amrn-20241001monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-receives-national-reimbursement-for-vazkepa-icosapent-ethyl-in-portugal-amrn-20240717monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-second-quarter-2024-financial-results-and-host-conference-call-on-july-31-amrn-20240717monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-partner-eddingpharm-receives-regulatory-approval-for-vascepa-icosapent-ethyl-in-mai-amrn-20240708monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-receives-national-reimbursement-for-vazkepa-icosapent-ethyl-in-greece-and-announces-amrn-20240528monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-h-c-wainwright-2nd-annual-bioconnect-investor-conference-amrn-20240506monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-applauds-healthywomen-s-citizen-s-petition-urging-fda-to-take-further-action-on-fen-amrn-20240424monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-results-of-annual-general-meeting-of-shareholders-amrn-20240422monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-first-quarter-2024-financial-results-and-host-conference-call-on-may-1-20-amrn-20240415monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-highlights-key-data-providing-mechanistic-insights-into-eicosapentaenoic-acid-epa-a-amrn-20240408monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-fourth-quarter-and-full-year-2023-financial-results-and-host-conference-o-amrn-20240215monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-chairman-ceo-issue-letter-to-shareholders-amrn-20240122monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-amrn-20231211monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-third-quarter-2023-financial-results-and-host-conference-call-on-november-amrn-20231019monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-2023-cantor-global-healthcare-conference-amrn-20230912monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-provides-pricing-reimbursement-updates-for-vazkepa-icosapent-ethyl-in-the-netherlan-amrn-20230809monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-and-neopharm-announce-exclusive-commercialization-agreement-for-vazkepa-icosapent-e-amrn-20230808monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-and-lotus-pharmaceuticals-announce-exclusive-partnership-agreement-to-commercialize-amrn-20230731monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-receives-positive-recommendation-from-spanish-drug-pricing-committee-for-national-r-amrn-20230725monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-board-of-directors-announces-executive-compensation-program-for-new-president-and-c-amrn-20230720monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-appoints-patrick-holt-as-president-and-chief-executive-officer-amrn-20230718monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-vascepa-icosapent-ethyl-approved-to-reduce-cardiovascular-risk-in-the-kin-amrn-20230621monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-two-upcoming-investor-conferences-amrn-20230601monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-partner-eddingpharm-receives-regulatory-approval-for-vascepa-icosapent-ethyl-in-mai-amrn-20230601monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-highlights-new-data-providing-potential-mechanistic-insight-into-vascepa-vazkepa-ic-amrn-20230512monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-20-amrn-20230419monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israel-s-ministry-of-health-amrn-20230404monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-board-departures-amrn-20230306monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-highlights-new-evidence-of-therapeutic-value-of-epa-in-reducing-cardiovascular-even-amrn-20230306monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-new-reduce-it-data-at-acc-23-wcc-showing-benefit-of-vascepa-vazkepa-icosa-amrn-20230305monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-preliminary-voting-results-following-2023-general-meeting-of-shareholders-amrn-20230228monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-and-csl-seqirus-announce-exclusive-license-and-distribution-agreement-to-commercial-amrn-20230228monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-sets-the-record-straight-on-sarissa-s-latest-misstatements-amrn-20230227monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-corporation-to-present-new-data-evaluating-vascepa-vazkepa-icosapent-ethyl-at-acc-2-amrn-20230227monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-cowen-s-43rd-annual-health-care-conference-amrn-20230222monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-fourth-quarter-and-full-year-2022-financial-results-and-host-conference-c-amrn-20230221monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-urges-shareholders-to-vote-against-sarissa-s-harmful-proposals-at-upcoming-general--amrn-20230217monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-clearly-and-definitively-instructed-registrar-to-accept-all-submitted-proxy-cards-amrn-20230216monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-shareholders-invited-to-webcast-with-board-and-management-team-amrn-20230213monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-mails-letter-highlighting-why-shareholders-should-vote-on-the-white-proxy-card-agai-amrn-20230209monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-mails-letter-to-shareholders-highlighting-sarissa-s-myths-vs-the-facts-amrn-20230206monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-mails-letter-to-shareholders-highlighting-new-board-and-superior-leadership-amrn-20230202monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-files-definitive-proxy-materials-and-mails-letter-to-shareholders-amrn-20230131monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-vazkepa-icosapent-ethyl-approved-by-medsafe-in-new-zealand-amrn-20230127monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-svb-securities-global-biopharma-conference-amrn-20230127monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-responds-to-inaccurate-and-misleading-statement-by-sarissa-amrn-20230119monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-comments-on-sarissa-s-notice-to-call-a-special-meeting-of-amarin-shareholders-amrn-20230111monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-amrn-20221214monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-vazkepa-icosapent-ethyl-receives-regulatory-approval-in-switzerland-amrn-20221207monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-vazkepa-icosapent-ethyl-approved-by-the-therapeutic-goods-administration--amrn-20221115monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-jefferies-london-healthcare-conference-amrn-20221109monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-highlights-key-data-presented-at-american-heart-association-2022-scientific-session-amrn-20221107monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-third-quarter-2022-financial-results-and-host-conference-call-on-october--amrn-20221020monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-board-of-directors-issues-statement-in-response-to-sarissa-amrn-20221011monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-h-c-wainwright-s-24th-annual-global-investment-conference-amrn-20220830monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-second-quarter-2022-financial-results-and-host-conference-call-on-august--amrn-20220720monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-receives-positive-recommendation-from-united-kingdom-s-uk-national-institute-for-he-amrn-20220610monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-appoints-tom-reilly-as-new-chief-financial-officer-amrn-20220606monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-appointment-of-new-directors-and-board-leadership-changes-amrn-20220519monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-two-upcoming-investor-conferences-amrn-20220512monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-partner-hls-therapeutics-completes-reimbursement-negotiations-with-pan-canadian-pha-amrn-20220426monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-first-quarter-2022-financial-results-and-host-conference-call-on-may-4-20-amrn-20220419monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-receives-reimbursement-for-vazkepa-in-sweden-amrn-20220328monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-participate-in-cowen-42nd-annual-health-care-conference-amrn-20220225monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-fourth-quarter-and-full-year-2021-financial-results-and-host-conference-c-amrn-20220215monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-amrn-20220104monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-bee-amrn-20211215monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-bee-amrn-20211210monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-bee-amrn-20211206monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-bee-amrn-20211129monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-bee-amrn-20211123monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-bee-amrn-20211117monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-overview-of-latest-clinical-research-evaluating-vascepa-vazkepa-icosapent-e-amrn-20211116monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-subgroup-data-from-reduce-it-highlighting-benefits-of-vascepa-vazkepa-icosa-amrn-20211115monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-two-upcoming-investor-conferences-amrn-20211111monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-third-quarter-2021-financial-results-and-host-conference-call-on-november-amrn-20211020monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-first-european-launch-of-vazkepa-icosapent-ethyl-in-germany-amrn-20210913monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-participate-in-september-investment-conferences-amrn-20210913monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-overview-of-latest-clinical-research-evaluating-vascepa-vazkepa-icosapent-e-amrn-20210831monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-data-from-reduce-it-showing-vascepa-vazkepa-icosapent-ethyl-significantly-r-amrn-20210823monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-second-quarter-and-six-month-2021-financial-results-and-host-conference-c-amrn-20210715monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-two-investor-conferences-in-june-2021-amrn-20210518monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-highlights-multiple-scientific-findings-for-vascepa-icosapent-ethyl-and-its-unique--amrn-20210517monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-planned-retirement-of-joseph-t-kennedy-evp-general-counsel-amrn-20210429monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-receives-great-britain-marketing-authorization-for-vazkepa-from-the-medicines-and-h-amrn-20210422monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-first-quarter-results-and-host-conference-call-on-april-29-2021-amrn-20210420monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-ceo-succession-plan-amrn-20210412monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-commences-commercial-initiatives-for-vazkepa-in-european-union-following-recent-reg-amrn-20210406monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-receives-european-commission-ec-approval-for-vazkepa-to-reduce-cardiovascular-risk-amrn-20210330monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-two-upcoming-investor-conferences-amrn-20210218monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-fourth-quarter-and-full-year-2020-results-and-host-conference-call-on-feb-amrn-20210217monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-provides-update-on-vascepa-icosapent-ethyl-regulatory-review-processes-in-mainland--amrn-20210209monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-receives-positive-chmp-opinion-for-icosapent-ethyl-for-cardiovascular-risk-reductio-amrn-20210129monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-expands-cardiovascular-risk-reduction-patent-infringement-lawsuit-to-include-health-amrn-20210126monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-39th-annual-j-p-morgan-healthcare-conference-amrn-20210104monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-highlights-multiple-vascepa-icosapent-ethyl-related-scientific-findings-presented-a-amrn-20201214monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-encouraging-efficacy-and-safety-results-from-pilot-study-treating-covid-19--amrn-20201213monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-files-patent-infringement-lawsuit-against-hikma-amrn-20201201monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-piper-sandler-s-32nd-annual-healthcare-conference-virtual-amrn-20201124monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-shares-topline-data-from-partner-s-pivotal-phase-3-study-of-vascepa-icosapent-ethyl-amrn-20201119monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-stifel-2020-virtual-healthcare-and-jefferies-virtual-london-healt-amrn-20201111monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-third-quarter-2020-results-and-host-conference-call-on-november-5-2020-amrn-20201019monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-2020-cantor-virtual-global-healthcare-conference-amrn-20200909monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-supports-latest-clinical-research-evaluating-vascepa-icosapent-ethyl-in-patients-wi-amrn-20200901monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-supports-investigator-initiated-trial-at-kaiser-permanente-in-the-u-s-to-study-the--amrn-20200807monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-plans-to-maximize-blockbuster-potential-of-vascepa-icosapent-ethyl-in-eur-amrn-20200804monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-second-quarter-2020-results-and-host-conference-call-on-august-4-2020-amrn-20200721monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-patent-litigation-settlement-agreement-with-apotex-inc-amrn-20200616monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-plans-to-increase-vascepa-icosapent-ethyl-promotion-and-education-amrn-20200601monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-supports-trial-to-investigate-the-effects-of-vascepa-icosapent-ethyl-in-the-treatme-amrn-20200521monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-first-quarter-2020-results-and-host-conference-call-on-april-30-2020-amrn-20200428monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-host-conference-call-on-april-13-2020-to-provide-preliminary-first-quarter-2020--amrn-20200408monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-highlights-vascepa-icosapent-ethyl-related-data-presented-at-american-college-of-ca-amrn-20200331monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-takes-proactive-steps-to-support-public-health-priorities-amrn-20200315monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-two-upcoming-investor-conferences-amrn-20200220monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-fourth-quarter-and-full-year-2019-results-and-host-conference-call-on-feb-amrn-20200219monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-honored-by-bionj-with-innovator-award-for-vascepa-development-and-regulatory-approv-amrn-20200207monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-launches-true-to-your-heart-a-campaign-to-educate-people-on-persistent-cardiovascul-amrn-20200113monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-38th-annual-j-p-morgan-healthcare-conference-amrn-20200106monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-receives-fda-approval-of-vascepa-icosapent-ethyl-to-reduce-cardiovascular-risk-amrn-20191213monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-highlights-key-reduce-it-related-data-presented-at-american-heart-association-2019--amrn-20191118monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-s-john-thero-awarded-ey-entrepreneur-of-the-year-2019-life-sciences-national-award-amrn-20191118monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announced-fda-advisory-committee-voted-unanimously-16-0-to-recommend-approval-of-va-amrn-20191114monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-corporation-plc-nasdaq-amrn-stock-trading-halted-today-for-scheduled-fda-advisory-c-amrn-20191114monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-jefferies-2019-london-healthcare-conference-amrn-20191111monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-third-quarter-2019-results-and-host-conference-call-on-november-5-2019-amrn-20191024monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-participate-in-the-cantor-global-healthcare-conference-amrn-20190923monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-participate-in-the-h-c-wainwright-21st-annual-global-investment-conference-amrn-20190828monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-provides-overview-on-growing-global-attention-on-reduce-it-results-and-cardiovascul-amrn-20190827monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-participate-in-a-fireside-chat-at-citi-s-14th-annual-biotech-conference-amrn-20190821monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-underwriters-full-exercise-of-option-to-purchase-additional-american-depo-amrn-20190729monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-second-quarter-2019-results-and-host-conference-call-on-july-31-2019-amrn-20190724monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-prices-public-offering-of-american-depositary-shares-amrn-20190719monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-s-john-thero-awarded-nj-ey-entrepreneur-of-the-year-2019-award-for-life-sciences-amrn-20190621monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-2019-bmo-prescription-for-success-healthcare-conference-amrn-20190618monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-goldman-sachs-40th-annual-global-healthcare-conference-amrn-20190604monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-jefferies-2019-healthcare-conference-amrn-20190530monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-first-quarter-2019-results-and-host-conference-call-on-may-1-2019-amrn-20190424monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-corporation-plc-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-inve-amrn-20190307monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-cowen-s-39th-annual-health-care-conference-amrn-20190305monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-corporation-plc-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-th-amrn-20190227monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-fourth-quarter-and-full-year-2018-results-and-host-conference-call-on-feb-amrn-20190219monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-8th-annual-svb-leerink-global-healthcare-conference-amrn-20190214monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-37th-annual-j-p-morgan-healthcare-conference-on-wednesday-january-9-2-amrn-20190102monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-participate-in-a-fireside-chat-at-citi-s-2018-global-healthcare-conference-amrn-20181128monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-prices-public-offering-of-american-depositary-shares-amrn-20181127monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-evercore-isi-healthconx-conference-amrn-20181120monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-jefferies-2018-london-healthcare-conference-amrn-20181108monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-schedules-webcast-discussion-of-primary-reduce-it-trial-results-following-presentat-amrn-20181026monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-third-quarter-2018-results-and-host-conference-call-on-november-1-2018-amrn-20181025monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-cantor-global-healthcare-conference-amrn-20180927monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-s-reduce-it-clinical-study-now-positioned-to-be-next-large-cardiovascular-outcomes--amrn-20180826monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-approval-for-vascepa-in-united-arab-emirates-amrn-20180726monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-second-quarter-2018-results-and-host-conference-call-on-august-1-2018-amrn-20180724monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-last-patient-study-visit-has-occurred-an-important-step-towards-completion--amrn-20180628monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-sponsors-three-scientific-presentations-scheduled-for-american-diabetes-association-amrn-20180607monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-patent-litigation-settlement-agreement-with-teva-amrn-20180524monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-jefferies-global-healthcare-conference-amrn-20180523monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-first-quarter-2018-results-and-host-conference-call-on-may-2-2018-amrn-20180426monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-sponsors-three-scientific-presentations-scheduled-for-national-lipid-association-sc-amrn-20180412monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-s-reduce-it-cardiovascular-outcomes-study-reaches-100-mark-for-estimated-onset-of-t-amrn-20180404monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-sponsors-two-scientific-presentations-scheduled-for-national-kidney-foundation-2018-amrn-20180329monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-h-c-wainwright-annual-global-life-sciences-conference-amrn-20180328monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-commemorates-national-triglycerides-day-on-march-28-amrn-20180327monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-first-middle-east-approval-for-vascepa-amrn-20180321monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-closing-of-underwriter-s-purchase-of-additional-shares-amrn-20180305monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-start-of-final-clinical-site-visits-in-the-reduce-it-cardiovascular-outco-amrn-20180301monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-sponsors-multiple-scientific-presentations-scheduled-for-2018-american-college-of-c-amrn-20180228monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-fourth-quarter-and-full-year-2017-results-and-host-conference-call-on-feb-amrn-20180220monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-prices-public-offering-of-american-depositary-shares-amrn-20180130monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-s-reduce-it-cardiovascular-outcomes-study-reaches-90-mark-for-reported-primary-even-amrn-20180123monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-commencement-of-vascepa-clinical-development-in-mainland-china-amrn-20180117monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-reduce-it-cardiovascular-outcomes-study-final-patient-visits-to-commence--amrn-20171219monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-36th-annual-j-p-morgan-healthcare-conference-in-san-francisco-amrn-20171218monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-jefferies-london-healthcare-conference-amrn-20171107monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-third-quarter-2017-results-and-host-conference-call-on-november-1-2017-amrn-20171025monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-and-hls-therapeutics-announce-agreement-to-commercialize-vascepa-in-canada-amrn-20170925monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-cantor-global-healthcare-conference-amrn-20170920monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-appoints-mark-w-salyer-to-new-position-of-chief-commercial-officer-amrn-20170913monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-rodman-renshaw-s-global-investment-conference-amrn-20170906monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-s-reduce-it-cardiovascular-outcomes-study-of-vascepa-to-continue-as-planned-at-reco-amrn-20170814monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-second-quarter-2017-results-and-host-conference-call-on-august-2-2017-amrn-20170726monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-corporation-plc-nasdaq-amrn-to-ring-the-nasdaq-stock-market-opening-bell-amrn-20170612monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-jefferies-2017-global-healthcare-conference-amrn-20170601monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-expanded-research-relationships-and-studies-to-help-improve-cardiovascula-amrn-20170518monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-first-quarter-2017-results-and-host-conference-call-on-may-3-2017-amrn-20170425monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-corporation-ceo-john-thero-to-chair-the-american-heart-association-s-heart-stroke-b-amrn-20170321monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reaches-the-onset-of-approximately-80-of-the-target-aggregate-number-of-primary-maj-amrn-20170316monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-publication-of-reduce-it-cardiovascular-outcomes-study-rationale-and-desi-amrn-20170315monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-fourth-quarter-and-full-year-2016-results-and-host-conference-call-on-feb-amrn-20170222monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-participate-in-the-leerink-partners-6th-annual-global-healthcare-conference-amrn-20170209monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-contractual-reminder-of-optional-put-to-holders-of-15-1-million-principal-amrn-20161216monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-jefferies-2016-london-healthcare-conference-amrn-20161111monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-third-quarter-2016-results-and-host-conference-call-on-november-3-2016-amrn-20161027monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-rodman-renshaw-18th-annual-global-investment-conference-amrn-20160907monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-randomizes-final-patient-into-reduce-it-cardiovascular-outcomes-study-of-vascepa-amrn-20160831monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-prices-public-offering-of-american-depositary-shares-amrn-20160811monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-first-quarter-2014-results-and-host-conference-call-on-may-9-2014-amrn-20140505monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-presentation-of-new-marine-and-anchor-post-hoc-analyses-at-national-lipid-amrn-20140502monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-fourth-quarter-and-year-end-2013-results-and-host-conference-call-on-febr-amrn-20140224monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-fda-award-of-three-year-exclusivity-for-vascepa-r-icosapent-ethyl-capsule-amrn-20140221monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-2014-leerink-global-healthcare-conference-amrn-20140206monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-promotion-of-aaron-berg-to-senior-vice-president-marketing-and-sales-amrn-20140204monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-fda-review-division-response-on-anchor-spa-agreement-reinstatement-reques-amrn-20140115monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-receives-fda-notification-that-action-on-anchor-snda-review-will-be-delayed-amrn-20131220monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-leadership-changes-amrn-20131216monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-notification-of-patent-allowances-for-u-s-applications-13-685-281-and-13--amrn-20131202monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-third-quarter-2013-results-and-host-conference-call-on-november-7-2013-amrn-20131031monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-plans-to-reduce-expenses-by-decreasing-staff-following-recent-fda-advisor-amrn-20131022monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-fda-advisory-committee-outcome-for-the-use-of-vascepa-in-the-treatment-of-amrn-20131016monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-corporation-nasdaq-amrn-stock-trading-halted-today-fda-advisory-committee-to-review-amrn-20131016monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-host-conference-call-on-october-16-2013-to-discuss-results-of-fda-advisory-commi-amrn-20131009monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-informed-by-fda-that-october-16th-advisory-committee-meeting-will-take-place-as-sch-amrn-20131003monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-enrollment-of-the-reduce-it-cardiovascular-outcomes-study-surpasses-6-000-amrn-20130925monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-2013-aegis-capital-healthcare-conference-amrn-20130918monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-30th-patent-for-vascepa-r-amrn-20130909monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-submission-of-supplemental-new-drug-application-for-novasep-as-fourth-vas-amrn-20130826monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-canaccord-genuity-33rd-annual-growth-conference-amrn-20130813monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-second-quarter-2013-results-and-host-conference-call-on-august-8-2013-amrn-20130802monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-completion-of-offering-of-american-depositary-shares-amrn-20130712monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-positive-results-of-phase-1-clinical-trial-measuring-the-bioavailability--amrn-20130621monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-informed-by-fda-of-october-16th-advisory-committee-date-in-connection-with-suppleme-amrn-20130619monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-jefferies-2013-global-healthcare-conference-amrn-20130530monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-additional-effects-of-vascepa-r-on-lipoprotein-particle-concentration-fro-amrn-20130530monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-notification-of-patent-allowance-for-u-s-application-13-417-899-related-t-amrn-20130522monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-first-quarter-2013-results-and-host-conference-call-on-may-9-2013-amrn-20130503monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-approval-of-supplemental-new-drug-application-for-basf-as-additional-vasc-amrn-20130430monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-fda-acceptance-of-supplemental-new-drug-application-snda-for-vascepa-r-fo-amrn-20130423monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-approval-of-supplemental-new-drug-application-for-chemport-as-additional--amrn-20130418monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-new-clinical-data-showing-significant-reductions-in-apolipoprotein-c-iii--amrn-20130408monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-notification-of-patent-allowance-for-u-s-application-13-614-111-related-t-amrn-20130307monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-submission-of-supplemental-new-drug-application-snda-for-vascepa-r-for-th-amrn-20130226monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-fourth-quarter-and-year-end-2012-results-and-host-conference-call-on-febr-amrn-20130222monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-citi-2013-global-healthcare-conference-amrn-20130221monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-notification-of-patent-allowance-for-u-s-application-13-614-129-related-t-amrn-20130212monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-leerink-swann-global-healthcare-conference-2013-amrn-20130207monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-notification-of-patent-allowance-for-u-s-application-13-614-146-related-t-amrn-20130207monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-notification-of-additional-u-s-patent-allowance-for-u-s-application-13-27-amrn-20130201monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-notification-of-two-additional-patent-allowances-for-u-s-applications-13--amrn-20130131monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-market-introduction-of-vascepa-r-icosapent-ethyl-capsules-for-the-treatme-amrn-20130124monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-first-notification-of-u-s-patent-allowance-based-on-anchor-clinical-trial-amrn-20130123monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-publication-of-additional-inflammatory-marker-data-from-marine-and-anchor-amrn-20130122monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-notification-of-patent-allowance-for-u-s-application-13-610-217-related-t-amrn-20130111monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-31st-annual-j-p-morgan-healthcare-conference-amrn-20130102monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-submission-of-a-supplemental-new-drug-application-for-basf-as-additional--amrn-20130102monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-submission-of-supplemental-new-drug-application-for-chemport-inc-as-an-ad-amrn-20121219monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-completion-of-dosing-in-a-fixed-dose-combination-study-with-vascepa-r-and-amrn-20121217monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-notification-of-patent-allowance-for-u-s-application-13-623-450-related-t-amrn-20121213monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-additional-vascepa-r-icosapent-ethyl-supplier-amrn-20121211monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-u-s-patent-8-324-195-issuance-for-vascepa-r-amrn-20121204monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-u-s-patent-8-318-715-issuance-for-vascepa-r-amrn-20121127monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-notification-of-patent-allowance-for-u-s-application-13-610-247-related-t-amrn-20121126monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-u-s-patent-8-314-086-issuance-for-vascepa-r-amrn-20121120monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-notification-of-patent-allowance-for-u-s-application-13-608-775-related-t-amrn-20121119monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-third-quarter-2012-financial-results-and-host-conference-call-on-november-amrn-20121101monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-u-s-patent-8-298-554-issuance-for-vascepa-tm-amrn-20121030monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-issuance-of-u-s-patents-8-793-727-and-8-293-728-for-vascepa-tm-amrn-20121023monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-notification-of-patent-allowance-for-u-s-application-13-349-150-related-t-amrn-20120910monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-notification-of-patent-allowance-for-u-s-application-13-284-408-related-t-amrn-20120906monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-notification-of-patent-allowances-for-u-s-applications-12-702-889-and-13--amrn-20120905monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-notification-of-patent-allowance-for-u-s-application-13-282-145-related-t-amrn-20120904monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-additional-publication-of-marine-phase-3-clinical-trial-results-in-the-jo-amrn-20120828monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-second-quarter-2012-financial-results-and-host-conference-call-on-august--amrn-20120731monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-fda-approval-of-vascepa-tm-icosapent-ethyl-capsules-for-the-reduction-of--amrn-20120726monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-receives-notice-of-intention-to-grant-on-european-patent-amrn-20120725monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-publication-of-anchor-phase-3-clinical-trial-results-in-the-american-jour-amrn-20120724monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-notice-of-allowance-for-additional-u-s-patent-covering-amr101-amrn-20120702monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-jefferies-2012-global-healthcare-conference-amrn-20120529monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-u-s-patent-issuance-for-amr101-amrn-20120529monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-first-quarter-2012-financial-results-and-host-conference-call-on-may-8-20-amrn-20120501monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-notification-of-patent-allowance-for-amr101-amrn-20120320monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-24th-annual-roth-oc-growth-stock-conference-amrn-20120306monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-report-fourth-quarter-and-year-end-2011-results-and-host-conference-call-on-febr-amrn-20120222monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-citi-2012-global-healthcare-conference-amrn-20120222monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-fda-advisory-committee-will-not-be-scheduled-in-connection-with-new-drug--amrn-20120213monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-leerink-swann-2012-global-healthcare-conference-amrn-20120207monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-corporation-plc-announces-pricing-of-150-million-of-exchangeable-senior-notes-due-2-amrn-20120104monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-commences-2012-with-letter-to-shareholders-amrn-20120103monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-appointment-of-joseph-t-kennedy-as-general-counsel-and-issuance-of-induce-amrn-20111219monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-the-addition-of-industry-veteran-patrick-o-sullivan-to-board-amrn-20111214monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-dosing-of-first-patient-in-cardiovascular-outcomes-study-reduce-it-amrn-20111207monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-fda-acceptance-for-filing-of-amr101-nda-amrn-20111125monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-resignation-of-david-feigal-from-board-of-directors-amrn-20111125monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-added-to-nasdaq-biotechnology-index-amrn-20111121monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-s-phase-3-anchor-study-results-presented-at-american-heart-association-s-scientific-amrn-20111116monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-s-phase-3-marine-study-results-presented-at-american-heart-association-s-scientific-amrn-20111115monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-s-phase-3-marine-and-anchor-study-data-to-be-presented-at-american-heart-associatio-amrn-20111114monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-two-upcoming-investor-conferences-amrn-20111110monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-third-quarter-2011-results-amrn-20111107monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-q3-2011-results-conference-call-amrn-20111103monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-corporation-plc-amrn-to-ring-the-nasdaq-stock-market-closing-bell-amrn-20111101monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-ring-nasdaq-closing-bell-amrn-20111031monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-nda-submission-for-amr101-for-the-treatment-of-patients-with-very-high-tr-amrn-20110926monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-ubs-global-life-sciences-conference-amrn-20110919monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-successful-marine-phase-3-clinical-trial-results-published-in-the-america-amrn-20110901monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-wedbush-securities-life-sciences-management-access-conference-amrn-20110812monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-agreement-from-fda-on-special-protocol-assessment-for-amr101-outcomes-stu-amrn-20110810monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-second-quarter-2011-results-amrn-20110809monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-2011-canaccord-genuity-growth-conference-amrn-20110808monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-q2-2011-results-conference-call-amrn-20110808monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-successfully-completes-all-remaining-clinical-studies-for-amr101-nda-amrn-20110801monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-completes-all-non-clinical-work-for-amr101-nda-submission-amrn-20110707monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-to-present-at-the-jefferies-2011-global-healthcare-conference-amrn-20110601monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-announces-global-supply-network-for-amr101-amrn-20110531monthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-sponsored-posters-to-be-presented-today-at-the-national-lipid-association-2011-annu-amrn-20110519monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-highlights-data-showing-broad-clinical-utility-of-precise-mrd-assay-at-202-mygn-20260527monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-launches-prolaris-ai-the-first-prostate-cancer-test-to-combine-genomics-an-mygn-20260526monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-participate-in-upcoming-investor-healthcare-conferences-mygn-20260507monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-national-survey-88-of-patients-with-depression-and-or-anxiety-would-feel-m-mygn-20260430monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-deliver-six-abstracts-including-two-podiums-at-aacr-2026-mygn-20260416monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-inc-investigated-by-the-portnoy-law-firm-mygn-20260406monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-receives-fda-approval-of-the-mychoice-cdx-test-as-the-companion-diagnostic-mygn-20260317monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-commercially-launches-precise-mrd-with-select-community-oncologists-mygn-20260302monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-mygn-20260216monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-8-abstracts-about-mrd-and-other-studies-at-2025-san-antonio-bre-mygn-20251209monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-release-third-quarter-2025-financial-results-on-november-3-2025-mygn-20251027monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-participate-in-upcoming-investor-healthcare-conferences-mygn-20250827monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-second-quarter-2025-financial-results-raises-2025-revenue-guidance-mygn-20250805monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-release-second-quarter-2025-financial-results-on-august-5-2025-mygn-20250729monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-earns-2025-great-place-to-work-certification-mygn-20250715monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-early-access-to-the-firstgene-multiple-prenatal-screen-mygn-20250603monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-shares-new-clinical-data-demonstrating-sensitivity-of-precise-mrd-across-m-mygn-20250602monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-highlights-new-research-advancements-and-oncology-innovations-at-2025-asco-mygn-20250527monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-riskscore-study-published-in-jco-precision-oncology-mygn-20250507monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-release-first-quarter-2025-financial-results-on-may-6-2025-mygn-20250429monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-highlights-mrd-clinical-validity-data-at-american-association-for-cancer-r-mygn-20250425monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-study-results-show-patients-with-depression-had-fewer-psychiatri-mygn-20250421monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-inducement-awards-mygn-20250408monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer-mygn-20250407monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-and-gabbi-to-work-together-to-increase-access-to-hereditary-cancer-risk-as-mygn-20250227monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fourth-quarter-and-full-year-2024-financial-results-full-year-2024-mygn-20250224monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-senior-leadership-transition-mygn-20250224monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-partners-with-pathomiq-to-add-artificial-intelligence-technology-platform--mygn-20250224monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-included-in-forbes-america-s-best-employers-2025-list-mygn-20250219monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-release-fourth-quarter-and-full-year-2024-financial-results-on-february-mygn-20250218monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-and-cancercare-for-life-announce-agreement-to-advance-access-to-myrisk-wit-mygn-20250206monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-two-new-patents-granted-for-its-molecular-residual-disease-mrd-a-mygn-20250205monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-and-lumea-collaborate-to-enhance-access-to-the-prolaris-biomarker-and-myri-mygn-20250205monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-unveils-groundbreaking-eight-weeks-gestation-nipt-study-results-at-society-mygn-20250129monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-introduces-online-prenatal-genetic-testing-resource-mygn-20250123monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-hereditary-cancer-risk-assessment-program-study-published-in-obs-mygn-20250121monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-select-preliminary-fourth-quarter-and-full-year-2024-financial-r-mygn-20250115monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-signs-agreement-with-nationally-renowned-sports-broadcaster-hannah-storm-t-mygn-20250109monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-43rd-annual-j-p-morgan-healthcare-conference-mygn-20250108monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-issues-quality-innovation-and-corporate-responsibility-report-mygn-20250106monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-riskscore-study-named-one-of-the-top-10-significant-advances-in-genomic-me-mygn-20241219monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-provides-update-on-discussions-with-unitedhealthcare-regarding-medical-pol-mygn-20241210monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-portfolio-elevated-by-updated-nccn-prostate-cancer-guidelines-mygn-20241210monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-new-data-at-san-antonio-breast-cancer-symposium-mygn-20241209monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-incorporation-of-its-proprietary-hrd-platform-in-illumina-s-upda-mygn-20241120monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-prequel-prenatal-screening-can-now-be-performed-eight-weeks-into-mygn-20241119monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-expands-access-to-at-home-early-fetal-sex-dna-test-with-retail-launch-mygn-20241113monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-third-quarter-2024-financial-results-updates-2024-financial-guidan-mygn-20241107monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-comments-on-unitedhealthcare-s-updated-medical-policy-for-pharmacogenetic--mygn-20241104monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-release-third-quarter-2024-financial-results-on-november-7-2024-mygn-20241030monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-and-jscreen-announce-strategic-partnership-to-advance-health-equity-and-ge-mygn-20241016monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-and-flatiron-health-partner-to-make-genetic-testing-more-accessible-with-e-mygn-20241015monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-five-research-collaborations-to-study-the-use-of-mrd-testing-in--mygn-20241008monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-and-ultima-genomics-to-explore-the-ug-100-sequencing-platform-to-advance-c-mygn-20241003monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-third-patent-granted-for-molecular-residual-disease-mrd-with-ear-mygn-20241001monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-share-new-data-highlighting-genetic-testing-advancements-at-2024-nation-mygn-20240918monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-host-investor-event-on-october-9-2024-mygn-20240905monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-participate-in-two-upcoming-investor-healthcare-conferences-mygn-20240821monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-strong-second-quarter-2024-financial-results-including-15-revenue--mygn-20240806monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-advances-international-reorganization-and-completes-sale-of-endopredict-bu-mygn-20240801monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-appoints-jennifer-fox-as-chief-legal-officer-mygn-20240731monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-release-second-quarter-2024-financial-results-on-august-6-2024-mygn-20240730monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-and-personalis-cross-license-foundational-mrd-intellectual-property-to-bro-mygn-20240711monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-second-foundational-patent-granted-for-molecular-residual-diseas-mygn-20240709monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-earns-2024-great-place-to-work-certification-mygn-20240702monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-collaborates-with-gsk-to-improve-access-to-hrd-testing-in-9-countries-mygn-20240611monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-launches-new-universal-plus-panel-for-foresight-carrier-screen-mygn-20240604monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-showcases-new-research-and-product-innovations-advancing-cancer-care-at-20-mygn-20240523monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-strong-first-quarter-2024-financial-results-achieves-12-revenue-gr-mygn-20240507monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-reorganization-of-european-operations-and-sale-of-endopredict-bu-mygn-20240507monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-release-first-quarter-2024-financial-results-on-may-7-2024-mygn-20240430monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-research-shows-reduction-in-hospitalizations-for-patients-with-depression--mygn-20240409monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-foundational-patent-granted-for-molecular-residual-disease-mrd-w-mygn-20240322monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-patent-granted-for-sneakpeek-snap-device-mygn-20240320monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-strong-fourth-quarter-and-full-year-2023-financial-results-fourth--mygn-20240227monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-and-national-cancer-center-hospital-east-in-japan-collaborate-on-pan-cance-mygn-20240227monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-release-fourth-quarter-and-full-year-2023-financial-results-on-february-mygn-20240221monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-appoints-dallas-reed-md-facog-facmg-as-principal-medical-advisor-of-women--mygn-20240215monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-completes-acquisition-of-precise-tumor-precise-liquid-and-laboratory-from--mygn-20240201monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-names-george-daneker-jr-md-as-president-and-chief-clinical-officer-of-onco-mygn-20240130monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-acquire-precise-tumor-precise-liquid-and-laboratory-from-intermountain--mygn-20240118monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-applauds-new-germline-testing-guideline-for-patients-with-breast-cancer-fr-mygn-20240109monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-42nd-annual-j-p-morgan-healthcare-conference-mygn-20240103monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-chief-financial-officer-bryan-riggsbee-retires-scott-leffler-appointed-as--mygn-20231221monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-establishes-comprehensive-pan-cancer-research-platform-to-advance-patient--mygn-20231220monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-celebrates-one-million-sneakpeek-results-shared-with-expectant-parents-mygn-20231120monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-and-personalis-partner-to-market-solutions-to-pharma-customers-mygn-20231116monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-participate-in-stephens-annual-investment-conference-mygn-20231109monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-pricing-of-upsized-offering-of-common-stock-mygn-20231109monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-proposed-offering-of-100-million-of-shares-of-common-stock-mygn-20231108monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-third-quarter-2023-financial-results-generates-double-digit-revenu-mygn-20231106monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-appoints-sam-raha-as-chief-operating-officer-mygn-20231101monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-release-third-quarter-financial-results-on-november-6-2023-mygn-20231031monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-and-illumina-achieve-milestones-in-strategic-partnership-to-support-biopha-mygn-20230919monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-issues-2022-environmental-social-and-governance-report-mygn-20230919monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-and-leading-cancer-center-collaborate-to-study-the-use-of-minimal-residual-mygn-20230918monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-named-to-2023-best-workplaces-in-health-care-list-by-fortune-and-great-pla-mygn-20230906monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-participate-in-morgan-stanley-global-healthcare-conference-mygn-20230905monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-and-onsite-women-s-health-partner-to-help-more-women-understand-breast-can-mygn-20230822monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-host-investor-day-on-september-19-2023-mygn-20230817monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-advances-prostate-cancer-care-with-addition-of-absolute-risk-reduction-to--mygn-20230815monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-and-intermountain-health-participate-in-combomatch-a-national-clinical-tri-mygn-20230808monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-enhancements-to-the-genesight-test-to-personalize-mental-health--mygn-20230807monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-second-quarter-2023-financial-results-and-reaffirms-2023-revenue-a-mygn-20230803monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-release-second-quarter-financial-results-on-aug-3-2023-mygn-20230727monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-inclusion-of-breast-density-to-myrisk-with-riskscore-breast-canc-mygn-20230724monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-new-90-million-asset-based-credit-facility-mygn-20230706monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-research-collaboration-to-use-minimal-residual-disease-testing-p-mygn-20230612monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-participate-in-goldman-sachs-healthcare-conference-mygn-20230607monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-highlights-latest-oncology-portfolio-advancements-and-new-data-at-asco-202-mygn-20230601monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-adds-folate-receptor-alpha-to-precise-oncology-solutions-portfolio-to-expa-mygn-20230524monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-earns-2023-great-place-to-work-certification-mygn-20230508monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-first-quarter-2023-financial-results-achieves-10-revenue-growth-ye-mygn-20230503monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-participate-in-bofa-securities-healthcare-conference-mygn-20230502monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-release-first-quarter-financial-results-on-may-3-2023-mygn-20230426monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-and-intermountain-precision-genomics-now-offer-solid-tumor-testing-in-all--mygn-20230418monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-and-simonmed-imaging-collaborate-to-advance-precision-medicine-with-new-ge-mygn-20230412monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-applauds-new-expanded-carrier-screening-practice-guidelines-from-nsgc-mygn-20230301monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fourth-quarter-financial-results-fourth-quarter-revenue-of-177-8-m-mygn-20230228monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-release-fourth-quarter-financial-results-on-feb-28-2023-mygn-20230222monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-participate-in-upcoming-healthcare-conferences-mygn-20230209monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-highlights-2022-research-findings-that-help-advance-more-accessible-and-eq-mygn-20230207monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-applauds-new-guidelines-recommending-screening-for-chromosomal-abnormaliti-mygn-20230105monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-41st-annual-j-p-morgan-healthcare-conference-mygn-20230104monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-hires-five-senior-leaders-to-advance-commercial-growth-plans-mygn-20221219monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-patient-outcomes-study-shows-riskscore-leads-to-more-accurate-breast-cance-mygn-20221209monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-new-data-at-san-antonio-breast-cancer-symposium-showcasing-adva-mygn-20221129monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-focuses-on-expanding-access-collaboration-and-equity-in-genetic-testing-at-mygn-20221114monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-urosuite-an-industry-first-suite-of-genetic-tests-for-prostate-c-mygn-20221110monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-expands-consumer-access-to-genetic-testing-with-acquisition-of-gateway-gen-mygn-20221101monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-third-quarter-financial-results-mygn-20221101monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-expands-board-of-directors-with-election-of-paul-m-bisaro-as-new-board-mem-mygn-20221031monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-release-third-quarter-financial-results-on-nov-1-2022-mygn-20221026monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-receives-expanded-coverage-in-japan-for-use-of-bracanalysis-diagnostic-sys-mygn-20220825monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-second-quarter-financial-results-mygn-20220804monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-release-2022-second-quarter-financial-results-on-aug-4-2022-mygn-20220728monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-share-update-on-business-transformation-research-and-development-pipeli-mygn-20220719monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-issues-inaugural-environmental-social-and-governance-report-mygn-20220628monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-teams-up-with-epic-to-make-genetic-testing-accessible-to-more-patients-wit-mygn-20220623monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-ceo-paul-diaz-to-speak-at-goldman-sachs-43rd-annual-global-healthcare-conf-mygn-20220609monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-showcases-advancements-in-precision-medicine-with-recent-oncology-portfoli-mygn-20220526monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-first-quarter-revenue-and-reiterates-guidance-for-2022-mygn-20220505monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-ceo-paul-diaz-to-speak-at-bank-of-america-securities-2022-healthcare-confe-mygn-20220504monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-expands-partnership-with-intermountain-precision-genomics-to-add-liquid-bi-mygn-20220503monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-release-first-quarter-2022-financial-results-on-may-5-2022-mygn-20220428monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-advances-precision-oncology-with-new-precise-solutions-combines-genetic-in-mygn-20220314monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-receives-fda-approval-of-bracanalysis-cdx-as-a-companion-diagnostic-for-ly-mygn-20220312monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-named-to-fast-company-s-annual-list-of-world-s-most-innovative-companies-mygn-20220308monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-ceo-paul-diaz-to-speak-at-42nd-annual-cowen-health-care-conference-mygn-20220302monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fourth-quarter-2021-results-provides-updates-on-product-performanc-mygn-20220224monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-release-fourth-quarter-2021-financial-results-on-february-24-2022-mygn-20220216monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-two-upcoming-healthcare-conferences-mygn-20220214monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-ceo-paul-diaz-to-speak-at-40th-annual-j-p-morgan-health-care-conference-mygn-20220105monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-chief-scientific-officer-jerry-lanchbury-retires-after-19-years-of-service-mygn-20220104monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-promotes-nicole-lambert-to-chief-operating-officer-mygn-20211214monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-new-data-at-san-antonio-breast-cancer-symposium-highlighting-va-mygn-20211122monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-third-quarter-2021-results-continues-strong-execution-of-strategic-mygn-20211102monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-release-third-quarter-financial-results-on-november-2-2021-mygn-20211027monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-names-pamela-wong-as-chief-legal-officer-mygn-20211018monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-completes-sale-of-myriad-autoimmune-s-vectra-testing-business-to-labcorp-mygn-20210913monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-delivers-strong-revenue-and-earnings-growth-in-june-2021-quarter-continues-mygn-20210803monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-expands-access-to-genetic-testing-with-launch-of-first-polygenic-breast-ca-mygn-20210802monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-release-second-quarter-financial-results-on-august-3-2021-mygn-20210728monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-supports-new-acmg-recommendation-statement-on-increasing-access-to-carrier-mygn-20210721monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-completes-sale-of-myriad-rbm-to-iqvia-s-q2-solutions-mygn-20210701monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-ceo-paul-j-diaz-to-present-at-goldman-sachs-2021-virtual-global-healthcare-mygn-20210604monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-bios-mygn-20210601monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-signs-definitive-agreement-to-sell-myriad-rbm-to-q2-solutions-mygn-20210524monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-appoints-melissa-gonzales-to-lead-women-s-health-business-mygn-20210520monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-share-new-data-at-2021-asco-validating-personalized-breast-cancer-risk--mygn-20210519monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-ceo-paul-j-diaz-to-present-at-bank-of-america-securities-2021-virtual-heal-mygn-20210505monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-delivers-12-sequential-revenue-growth-in-march-2021-quarter-company-execut-mygn-20210503monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-signs-definitive-agreement-to-sell-myriad-autoimmune-s-vectra-testing-busi-mygn-20210503monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-update-progress-on-transformation-plan-and-growth-initiatives-share-lon-mygn-20210503monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-release-march-2021-quarterly-financial-results-on-may-3-2021-host-inves-mygn-20210427monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-signs-definitive-agreement-to-sell-myriad-mypath-melanoma-llc-laboratory-t-mygn-20210427monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-eric-santa-as-chief-growth-officer-names-new-diversity-and-marke-mygn-20210329monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-receives-additional-reimbursement-for-mychoice-diagnostic-system-in-japan-mygn-20210324monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-joins-forces-with-intermountain-precision-genomics-for-a-comprehensive-off-mygn-20210302monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-delivers-6-sequential-revenue-growth-company-continues-to-execute-strategi-mygn-20210223monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-announce-december-2020-quarterly-financial-results-on-february-23-2021-mygn-20210216monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-participate-in-multiple-upcoming-health-and-technology-conferences-mygn-20210211monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-launches-new-vectra-cardiovascular-risk-assessment-for-patients-with-rheum-mygn-20210202monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-receives-reimbursement-for-bracanalysis-diagnostic-system-in-japan-mygn-20210119monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-forms-strategic-partnership-with-illumina-in-oncology-mygn-20210111monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-receives-first-reimbursement-decision-for-mychoice-diagnostic-system-in-ja-mygn-20210108monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-provides-transformation-update-pursues-strategic-alternatives-for-autoimmu-mygn-20210105monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-ceo-paul-j-diaz-to-present-at-39th-annual-j-p-morgan-healthcare-conference-mygn-20210104monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-global-expansion-of-myriad-mychoice-tumor-testing-in-europe-and--mygn-20201116monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-delivers-56-sequential-increase-in-quarterly-revenue-test-volumes-reach-90-mygn-20201109monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-announce-quarterly-financial-results-on-november-9-2020-mygn-20201104monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-files-fiscal-year-2020-proxy-statement-implements-corporate-governance-cha-mygn-20201015monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-expands-board-of-directors-with-new-member-mygn-20200910monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-inducement-awards-mygn-20200814monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-appoints-paul-j-diaz-as-president-and-chief-executive-officer-and-a-member-mygn-20200813monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-fourth-quarter-2020-financial-results-mygn-20200813monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-announce-fiscal-fourth-quarter-and-full-fiscal-year-2020-financial-results-on-au-mygn-20200806monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-launches-proprietary-amplify-technology-further-increasing-the-performance-of-its-p-mygn-20200729monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-the-launch-of-a-new-radiographic-progression-prognostic-tool-adding-to-cl-mygn-20200728monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-expands-board-of-directors-with-new-member-and-announces-upcoming-retireme-mygn-20200722monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-new-studies-validating-the-ability-of-myriad-s-riskscore-test-to-modify-b-mygn-20200707monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-partnership-with-optrahealth-to-deliver-gene-a-new-ai-based-information-t-mygn-20200706monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-launches-new-genesight-psychotropic-patient-collection-kit-mygn-20200701monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-new-favorable-coverage-policies-for-prolaris-from-three-new-commercial-he-mygn-20200615monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-publication-of-a-prospective-clinical-study-of-the-endopredict-t-mygn-20200604monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-presents-new-data-at-asco-validating-the-ability-of-riskscore-to-provide-personaliz-mygn-20200529monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-appoints-daniel-k-spiegelman-to-the-board-of-directors-and-announces-upcom-mygn-20200528monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-receives-fda-approval-of-bracanalysis-cdx-as-a-companion-diagnostic-for-lynparza-in-mygn-20200520monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-receives-fda-approval-of-mychoice-cdx-as-companion-diagnostic-for-lynparza-olaparib-mygn-20200511monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-third-quarter-2020-financial-results-mygn-20200505monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-announce-fiscal-third-quarter-2020-financial-results-on-may-5-2020-mygn-20200428monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-publication-of-a-meta-analysis-demonstrating-the-clinical-utilit-mygn-20200420monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-withdrawing-financial-guidance-for-fy2020-due-to-business-impact-from-coronavirus-p-mygn-20200408monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-receives-reimbursement-for-the-bracanalysis-diagnostic-system-in-japan-for-patients-mygn-20200406monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-seeks-japanese-regulatory-approval-for-its-bracanalysis-diagnostic-system-in-people-mygn-20200330monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-board-of-directors-leadership-transition-mygn-20200323monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-svb-leerink-global-healthcare-conference-mygn-20200212monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-submits-spma-for-mychoice-cdx-with-lynparza-in-first-line-maintenance-therapy-in-ad-mygn-20200211monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-second-quarter-2020-financial-results-mygn-20200206monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-leadership-transition-mygn-20200206monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-announce-fiscal-second-quarter-2020-financial-results-on-february-6-2020-mygn-20200130monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-submits-spma-for-mychoice-cdx-with-zejula-in-first-line-platinum-responsive-advance-mygn-20200122monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-submits-spma-for-bracanalysis-cdx-as-a-companion-diagnostic-for-lynparza-in-metasta-mygn-20200121monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-j-p-morgan-2020-healthcare-conference-mygn-20200106monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-receives-fda-approval-of-bracanalysis-cdx-as-companion-diagnostic-for-lynparza-olap-mygn-20191230monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-board-member-s-louise-phanstiel-recognized-by-womeninc-magazine-in-2019-li-mygn-20191219monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-polygenic-risk-score-personalizes-risk-of-breast-cancer-for-woman-with-a-genetic--mygn-20191214monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-prequel-prenatal-screen-has-superior-sensitivity-in-women-with-high-bmi-undergoin-mygn-20191204monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-multiple-studies-on-breast-cancer-at-the-2019-san-antonio-breas-mygn-20191203monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-regulatory-approval-of-the-bracanalysis-diagnostic-system-in-jap-mygn-20191121monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-inc-mygn-overstock-com-inc-ostk-waitr-holdings-inc-wtrh-bronstein-gewirtz--mygn-20191115monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-prequel-prenatal-screen-demonstrates-high-performance-across-all-fetal-fraction-l-mygn-20191111monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-inc-mygn-overstock-com-inc-ostk-waitr-holdings-inc-wtrh-bronstein-gewirtz--mygn-20191108monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-2019-stephens-nashville-investment-conference-mygn-20191107monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-first-quarter-2020-financial-results-mygn-20191104monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-inc-mygn-overstock-com-inc-ostk-waitr-holdings-inc-wtrh-bronstein-gewirtz--mygn-20191101monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-multiple-presentations-at-the-2019-american-college-of-rheumatol-mygn-20191101monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-announce-fiscal-first-quarter-2020-financial-results-on-november-4-2019-mygn-20191030monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-seven-studies-at-the-2019-national-society-of-genetic-counselor-mygn-20191028monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-five-studies-at-the-2019-american-society-of-human-genetics-ann-mygn-20191008monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-expands-board-of-directors-with-two-additional-members-mygn-20190925monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-research-collaboration-with-university-of-leeds-mygn-20190916monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-2019-morgan-stanley-global-healthcare-conference-mygn-20190830monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-applauds-the-u-s-preventive-services-task-force-recommendation-on-brca-related-canc-mygn-20190822monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-fourth-quarter-and-full-year-2019-financial-results-mygn-20190813monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-will-seek-fda-approval-of-bracanalysis-cdx-as-a-companion-diagnostic-for-lynparza-o-mygn-20190807monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-announce-fiscal-fourth-quarter-2019-financial-results-on-august-13-2019-mygn-20190806monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-publication-of-first-comprehensive-economic-study-demonstrating-cost-effe-mygn-20190625monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-receives-second-insurance-reimbursement-decision-for-its-bracanalysis-diag-mygn-20190619monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-2019-goldman-sachs-global-healthcare-conference-mygn-20190605monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-new-results-from-two-large-studies-of-its-myrisk-hereditary-canc-mygn-20190603monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-multiple-studies-at-the-2019-american-society-of-clinical-oncol-mygn-20190514monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-third-quarter-2019-financial-results-mygn-20190507monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-coverage-decision-by-kroger-prescription-plans-for-genesight-mygn-20190501monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-two-upcoming-healthcare-conferences-mygn-20190501monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-announce-fiscal-third-quarter-2019-financial-results-on-may-7-2019-mygn-20190423monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-present-multiple-women-s-health-studies-at-the-2019-american-college-of-obstetri-mygn-20190423monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-named-to-forbes-2019-list-of-america-s-best-midsize-employers-and-the-wome-mygn-20190417monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-submits-first-module-of-the-premarket-approval-application-to-fda-for-the--mygn-20190409monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-astrazeneca-and-merck-expand-companion-diagnostic-partnership-mygn-20190404monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-women-s-health-to-highlight-new-studies-demonstrating-the-superior-clinical-perform-mygn-20190402monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-present-18-studies-at-the-2019-annual-clinical-genetics-meeting-mygn-20190321monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-mypath-melanoma-test-receives-medicare-coverage-mygn-20190314monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-publication-of-expanded-carrier-screen-study-in-genetics-in-medicine-mygn-20190306monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-bracanalysis-cdx-test-successfully-identified-patients-with-metastatic-pancreatic-mygn-20190226monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-applauds-the-american-society-of-breast-surgeons-new-guidelines-recommending-geneti-mygn-20190215monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-multiple-upcoming-healthcare-conferences-mygn-20190213monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-prequel-prenatal-screen-with-expanded-aneuploidy-analysis-for-all-23-chro-mygn-20190211monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-present-new-data-for-its-expanded-carrier-and-noninvasive-prenatal-screens-at-th-mygn-20190208monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-second-quarter-2019-financial-results-mygn-20190205monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-announce-fiscal-second-quarter-2019-financial-results-on-february-5-2019-mygn-20190128monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-mygn-20181227monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-publication-of-vectra-study-in-journal-rheumatology-mygn-20181226monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-important-new-data-for-its-endopredict-breast-cancer-test-will-be-present-mygn-20181207monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-validates-polygenic-score-to-predict-breast-cancer-risk-in-women-of-hispanic-ancest-mygn-20181206monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-50-million-accelerated-share-repurchase-program-mygn-20181119monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-present-new-data-from-its-industry-leading-portfolio-of-genetic-tests-for-breast-mygn-20181112monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-first-quarter-2019-financial-results-mygn-20181106monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-receives-the-prestigious-2018-utah-top-workplaces-award-mygn-20181105monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-presents-two-new-studies-at-the-western-section-of-the-american-urological-associat-mygn-20181102monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-stephens-new-york-investment-conference-mygn-20181030monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-announce-fiscal-first-quarter-2019-financial-results-on-november-6-2018-mygn-20181024monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-publication-of-foresight-carrier-screen-clinical-utility-study-in-genetic-mygn-20181023monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-bracanalysis-cdx-test-identifies-patients-with-newly-diagnosed-advanced-ovarian-c-mygn-20181022monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-receives-fda-approval-of-bracanalysis-cdx-as-companion-diagnostic-for-pfizer-s-talz-mygn-20181016monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-new-laboratory-agreement-with-pfizer-mygn-20181010monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-and-pfizer-build-upon-a-previously-announced-companion-diagnostic-agreement-mygn-20181009monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-four-presentations-at-the-2018-american-college-of-rheumatology--mygn-20181003monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-new-genesight-study-published-in-personalized-medicine-mygn-20180926monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-publication-of-variant-reclassification-study-in-the-journal-of-the-ameri-mygn-20180925monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-2018-morgan-stanley-global-healthcare-conference-mygn-20180831monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-fourth-quarter-and-full-year-2018-financial-results-mygn-20180821monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-reschedules-release-of-fiscal-fourth-quarter-2018-financial-results-mygn-20180813monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-announce-fiscal-fourth-quarter-2018-financial-results-on-august-14-2018-mygn-20180801monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-closing-of-counsyl-acquisition-mygn-20180731monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-publication-of-impact-study-in-journal-of-psychiatric-research-mygn-20180725monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-coverage-decision-by-kroger-prescription-plans-for-vectra-da-mygn-20180718monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-bracanalysis-cdx-supplementary-pma-accepted-by-fda-for-review-as-a-companion-diag-mygn-20180618monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-1-mygn-20180609monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-mygn-20180602monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-presents-second-pivotal-validation-study-for-riskscore-test-at-the-2018-am-mygn-20180601monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-two-upcoming-investor-conferences-mygn-20180531monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-signs-definitive-agreement-to-acquire-counsyl-inc-mygn-20180528monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-seven-new-payer-coverage-decisions-for-prolaris-mygn-20180523monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-eight-studies-at-the-2018-american-society-of-clinical-oncology-mygn-20180515monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-inc-investor-update-wolf-haldenstein-adler-freeman-herz-llp-announces-that-mygn-20180510monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-third-quarter-2018-financial-results-mygn-20180508monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-1-mygn-20180505monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-five-studies-at-the-seventh-international-symposium-on-heredita-mygn-20180504monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-lawsuit-bernstein-liebhard-llp-reminds-investors-of-important-deadline-in-class-act-mygn-20180503monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-named-to-forbes-2018-list-of-america-s-best-midsize-employers-mygn-20180502monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-two-upcoming-healthcare-conferences-mygn-20180427monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-inc-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-that--mygn-20180425monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-mygn-20180423monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-launch-of-go-green-sustainability-initiative-in-support-of-earth-day-mygn-20180419monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-announce-fiscal-third-quarter-2018-financial-results-on-may-8-2018-mygn-20180417monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-receives-pre-market-approval-for-its-bracanalysis-diagnostic-system-in-japan-mygn-20180402monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-applauds-aacu-position-statement-on-molecular-testing-for-risk-stratification-in-pr-mygn-20180306monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-demonstrates-strong-commitment-to-preventing-hereditary-colon-cancer-as-pa-mygn-20180301monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-two-upcoming-healthcare-conferences-mygn-20180227monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-myrisk-hereditary-cancer-test-finds-more-than-12-percent-of-men-with-prostate-can-mygn-20180207monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-second-quarter-2018-financial-results-mygn-20180206monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-announce-fiscal-second-quarter-2018-financial-results-on-february-6-2018-mygn-20180125monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-applauds-new-consensus-statement-from-international-expert-panel-on-screening-recom-mygn-20180122monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-receives-fda-approval-of-bracanalysis-cdx-as-companion-diagnostic-for-lynparza-olap-mygn-20180112monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-expanded-research-collaboration-with-astrazeneca-mygn-20180103monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-mygn-20171219monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-bracanalysis-cdx-test-effectively-identified-metastatic-breast-cancer-patients-wi-mygn-20171212monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-presents-results-from-two-important-endopredict-studies-at-the-2017-san-an-mygn-20171208monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-presents-pivotal-validation-study-for-new-riskscore-test-at-the-2017-san-a-mygn-20171206monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-collaborates-with-department-of-veterans-affairs-in-large-trial-evaluating-the-gene-mygn-20171110monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-2017-jefferies-london-healthcare-conference-mygn-20171109monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-first-quarter-2018-financial-results-mygn-20171107monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-collaborates-with-carefirst-bluecross-blueshield-on-coverage-with-evidence-mygn-20171106monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-genesight-psychotropic-results-from-a-large-prospective-trial-in-patients-mygn-20171102monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-announce-fiscal-first-quarter-2018-financial-results-on-november-7-2017-mygn-20171024monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-submits-bracanalysis-cdx-application-for-regulatory-approval-in-japan-for-her2-meta-mygn-20171024monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-bracanalysis-cdx-supplementary-pma-accepted-by-fda-for-review-as-a-companion-diag-mygn-20171018monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-highlights-strong-commitment-to-preventing-and-fighting-breast-cancer-as-p-mygn-20171002monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-positive-data-supporting-new-riskscore-test-at-the-36th-annual-c-mygn-20170915monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-three-studies-at-the-2017-national-society-of-genetic-counselor-mygn-20170912monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-launches-riskscore-beginning-the-next-epoch-in-hereditary-cancer-testing-mygn-20170905monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-2017-morgan-stanley-global-healthcare-conference-mygn-20170830monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-2017-wells-fargo-healthcare-conference-mygn-20170829monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-fourth-quarter-2017-and-fiscal-full-year-2017-financial-res-mygn-20170808monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-announce-fiscal-fourth-quarter-2017-financial-results-on-august-8-2017-mygn-20170728monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-bracanalysis-cdx-test-identified-patients-with-metastatic-breast-cancer-who-benef-mygn-20170604monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-17-additional-health-insurance-plans-covering-endopredict-mygn-20170602monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-results-from-a-large-2-000-patient-clinical-utility-study-of-its-mygn-20170602monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-2017-william-blair-growth-stock-conference-mygn-20170531monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-2017-goldman-sachs-global-healthcare-conference-mygn-20170530monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-seven-studies-at-the-2017-american-society-of-clinical-oncology-mygn-20170518monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-prolaris-test-accurately-predicts-the-10-year-risk-of-metastases-in-men-tr-mygn-20170512monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-results-from-four-studies-at-the-american-urological-associatio-mygn-20170505monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-third-quarter-2017-financial-results-mygn-20170502monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-and-clovis-oncology-sign-agreement-for-use-of-fda-approved-bracanalysis-cd-mygn-20170427monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-announce-fiscal-third-quarter-2017-financial-results-on-may-2-2017-mygn-20170418monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-and-beigene-sign-agreement-to-develop-companion-diagnostics-for-use-with-b-mygn-20170406monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-five-scientific-presentations-at-the-2017-american-college-of-me-mygn-20170320monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-launches-the-endopredict-test-in-the-united-states-for-patients-with-breas-mygn-20170313monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-bracanalysis-cdx-test-successfully-identified-metastatic-breast-cancer-patients-w-mygn-20170217monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-prolaris-test-significantly-improves-the-risk-classification-for-one-third-of-men-mygn-20170217monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-second-quarter-2017-financial-results-mygn-20170207monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-announce-fiscal-second-quarter-2017-financial-results-on-february-7-2017-mygn-20170124monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-2017-jp-morgan-healthcare-conference-mygn-20161228monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-will-present-results-from-six-breast-cancer-studies-at-sabcs-mygn-20161128monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-will-seek-japanese-regulatory-approval-for-bracanalysis-cdx-mygn-20161107monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-first-quarter-2017-financial-results-mygn-20161101monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-bracanalysis-cdx-test-identifies-patients-with-ovarian-cancer-who-would-benefit-f-mygn-20161026monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-rbm-announces-an-agreement-with-sanofi-to-measure-predictive-cardiovascular-biomark-mygn-20161025monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-inc-forms-relationship-with-ion-solutions-to-deliver-quality-hereditary-ca-mygn-20161021monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-announce-fiscal-first-quarter-2017-financial-results-on-november-1-mygn-20161020monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-teams-up-with-project-bioeyes-to-advance-stem-education-in-utah-mygn-20161018monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-will-present-new-data-on-its-variant-classification-program-at-the-ashg-annual-meet-mygn-20161017monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-mychoice-hrd-test-identifies-patients-with-ovarian-cancer-who-may-benefit-from-tr-mygn-20161008monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-four-poster-presentations-at-the-2016-european-society-for-medical-oncolo-mygn-20161007monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-appoints-chip-parkinson-as-evp-for-reimbursement-strategy-mygn-20160929monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-present-new-myrisk-hereditary-cancer-data-further-demonstrating-the-benefits-of--mygn-20160926monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-rbm-s-truculture-and-gene-expression-profiling-characterizes-immune-responses-in-la-mygn-20160907monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-completes-acquisition-of-assurex-health-mygn-20160901monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-2016-morgan-stanley-global-healthcare-conference-mygn-20160830monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-fourth-quarter-2016-financial-results-mygn-20160809monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-signs-definitive-agreement-to-acquire-assurex-health-mygn-20160803monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-announce-fiscal-fourth-quarter-2016-financial-results-on-august-9-mygn-20160726monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-positive-results-for-an-endopredict-clinical-study-published-in-the-journ-mygn-20160711monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-mychoice-hrd-test-successfully-identifies-patients-that-meet-primary-endpoint-in--mygn-20160629monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-board-approves-200-million-increase-in-share-repurchase-program-mygn-20160607monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-myrisk-hereditary-cancer-test-demonstrates-the-magnitude-of-breast-and-ovarian-canc-mygn-20160606monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-2016-goldman-sachs-healthcare-conference-mygn-20160606monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-will-present-three-new-hereditary-cancer-studies-at-the-asco-annual-meeting-mygn-20160605monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-acquires-sividon-diagnostics-mygn-20160531monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-statement-on-hipaa-complaint-from-four-patients-mygn-20160519monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-plans-to-launch-a-web-portal-for-patients-that-will-provide-access-to-tes-mygn-20160518monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-present-new-research-at-the-2016-asco-annual-meeting-mygn-20160518monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-present-three-new-studies-at-the-aua-annual-meeting-mygn-20160506monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-third-quarter-2016-financial-results-mygn-20160503monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-bank-of-america-health-care-conference-mygn-20160502monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-announce-fiscal-third-quarter-2016-financial-results-on-may-3-mygn-20160422monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-presentations-at-the-2016-american-association-for-cancer-resear-mygn-20160414monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-myrisk-hereditary-cancer-article-in-journal-of-clinical-oncology-highlights-importa-mygn-20160330monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-teams-up-with-access-health-to-educate-the-public-about-hereditary-cancer--mygn-20160321monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-presents-second-pivotal-validation-study-for-its-mypath-melanoma-test-mygn-20160315monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-barclays-capital-2016-global-healthcare-conference-mygn-20160308monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-advances-proprietary-myvision-variant-classification-tools-to-a-broader-range-of-ca-mygn-20160308monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-expands-strategic-research-collaboration-with-abbvie-mygn-20160223monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-expands-diagnostic-research-collaboration-with-tesaro-and-merck-mygn-20160222monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-second-quarter-2016-financial-results-mygn-20160202monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-announce-fiscal-second-quarter-2016-financial-results-on-february-2-mygn-20160121monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-advances-prostate-and-renal-cancer-molecular-diagnostic-tests-at-the-2016-asco-geni-mygn-20160107monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-34th-annual-j-p-morgan-healthcare-conference-mygn-20160104monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-will-present-eight-studies-at-the-2015-san-antonio-breast-cancer-symposium-mygn-20151117monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-rbm-discoverymap-r-technology-identifies-novel-biomarkers-that-may-predict-increase-mygn-20151116monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-first-quarter-2016-financial-results-mygn-20151103monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-2015-credit-suisse-healthcare-conference-mygn-20151028monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-will-highlight-new-data-on-its-myrisk-tm-hereditary-cancer-test-at-the-national-soc-mygn-20151021monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-announce-fiscal-first-quarter-2016-financial-results-on-november-3-2015-mygn-20151020monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-present-new-data-on-its-myrisk-tm-hereditary-cancer-test-at-the-cga-icc-annual-m-mygn-20151009monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-highlight-new-clinical-outcomes-data-on-mypath-r-melanoma-at-the-americ-mygn-20151008monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-and-tufts-health-plan-sign-agreement-to-cover-prolaris-r-for-members-with--mygn-20151007monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-present-seven-studies-at-the-ashg-annual-meeting-mygn-20151005monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-appoints-jan-schluchter-as-chief-commercial-officer-for-europe-mygn-20151001monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-presents-new-data-on-its-companion-diagnostic-and-prostate-cancer-tests-at-mygn-20150924monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-2015-morgan-stanley-healthcare-conference-mygn-20150914monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-inc-nasdaq-mygn-to-ring-the-nasdaq-stock-market-opening-bell-mygn-20150911monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-adds-to-scientific-evidence-for-the-myplan-r-lung-cancer-prognostic-test-mygn-20150909monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-host-2015-investor-day-in-new-york-city-mygn-20150902monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-receives-favorable-medicare-final-coverage-decision-for-the-prolaris-r-test-mygn-20150813monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-fourth-quarter-and-full-year-2015-financial-results-mygn-20150811monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-announce-fiscal-fourth-quarter-2015-financial-results-on-august-11-2015-mygn-20150729monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-presents-new-myrisk-tm-hereditary-cancer-data-at-2015-asco-annual-meeting-mygn-20150529monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-significantly-advances-the-mychoice-r-hrd-tm-companion-diagnostic-test-mygn-20150529monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-2015-goldman-sachs-healthcare-conference-mygn-20150528monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-validates-active-surveillance-threshold-with-prolaris-r-for-men-with-prostate-cance-mygn-20150515monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-showcases-its-pioneering-research-at-the-2015-asco-annual-meeting-mygn-20150513monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-present-new-clinical-data-on-prolaris-r-at-the-aua-2015-annual-meeting-mygn-20150507monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-third-quarter-2015-financial-results-mygn-20150505monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-announce-fiscal-third-quarter-2015-financial-results-on-may-5-2015-mygn-20150422monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-and-astrazeneca-expand-research-collaboration-on-lynparza-mygn-20150401monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-prolaris-r-test-biopsy-results-from-empathy-p-study-at-european-associati-mygn-20150320monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-and-biomarin-expand-collaboration-to-evaluate-mychoice-hrd-tm-as-a-companion-diagno-mygn-20150317monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-rbm-launches-new-immunoassay-services-based-on-the-ultrasensitive-simoa-tm-platform-mygn-20150305monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-publishes-mypath-tm-melanoma-pivotal-validation-study-in-the-journal-of-cutaneous-p-mygn-20150304monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-barclays-global-healthcare-conference-mygn-20150302monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-board-approves-200-million-increase-in-share-repurchase-program-mygn-20150224monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-2015-leerink-global-healthcare-conference-mygn-20150206monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-retirement-of-peter-d-meldrum-president-and-ceo-mygn-20150203monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-second-quarter-2015-financial-results-mygn-20150203monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-names-johnathan-m-lancaster-as-vice-president-of-medical-affairs-mygn-20150122monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-announce-2q15-financial-results-on-february-3-2015-mygn-20150121monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-rbm-joins-institut-pasteur-in-the-global-fight-against-tuberculosis-mygn-20150120monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-obtains-ce-mark-for-tumor-bracanalysis-cdx-tm-and-launches-test-in-europe-as-compan-mygn-20150108monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-2015-j-p-morgan-annual-healthcare-conference-mygn-20150105monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-names-bernard-tobin-as-president-of-crescendo-bioscience-mygn-20141222monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-receives-fda-approval-of-bracanalysis-cdx-tm-as-companion-diagnostic-for-lynparza-t-mygn-20141219monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-present-eight-studies-at-2014-san-antonio-breast-cancer-symposium-mygn-20141203monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-mypath-tm-melanoma-improves-diagnosis-and-treatment-plans-mygn-20141107monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-first-quarter-2015-financial-results-mygn-20141104monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-and-abbvie-sign-expanded-agreement-for-tumor-bracanalysis-cdx-tm-mygn-20141103monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-2014-credit-suisse-annual-healthcare-conference-mygn-20141029monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-inclusion-of-prolaris-r-test-in-nccn-guidelines-mygn-20141027monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-establishes-tumor-bracanalysis-cdx-tm-laboratory-in-europe-mygn-20141024monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-announce-1q15-financial-results-on-november-4-2014-mygn-20141021monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-receives-draft-medicare-coverage-for-prolaris-r-mygn-20141017monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-appoints-r-bryan-riggsbee-as-chief-financial-officer-mygn-20141008monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-presents-tumor-bracanalysis-cdx-tm-study-at-esmo-mygn-20140929monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-mypath-tm-melanoma-test-reduced-indeterminate-cases-by-76-percent-and-changed-treat-mygn-20140909monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-publishes-myrisk-hereditary-cancer-study-in-cancer-mygn-20140903monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-morgan-stanley-healthcare-conference-mygn-20140828monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-fourth-quarter-and-full-year-2014-financial-results-mygn-20140812monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-announce-financial-results-for-the-fiscal-fourth-quarter-and-full-year--mygn-20140730monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-retirement-of-james-evans-chief-financial-officer-mygn-20140609monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-goldman-sachs-global-healthcare-conference-mygn-20140603monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-participation-in-innovative-collaboration-to-accelerate-heredita-mygn-20140602monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-presents-clinical-data-on-myriad-myrisk-tm-hereditary-cancer-test-at-asco-mygn-20140602monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-mypath-tm-melanoma-test-improves-the-reliability-of-melanoma-diagnosis-mygn-20140602monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-presents-data-on-bracanalysis-cdx-tm-and-hrd-tm-at-2014-asco-meeting-mygn-20140530monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-strengthens-commitment-to-cancer-research-at-the-asco-50th-annual-meeting-mygn-20140515monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-bank-of-america-2014-healthcare-conference-mygn-20140509monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-financial-results-for-third-quarter-of-fiscal-year-2014-mygn-20140506monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-and-unitedhealthcare-sign-three-year-agreement-making-myrisk-tm-hereditary-cancer-t-mygn-20140506monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-three-clinical-studies-on-prolaris-r-at-the-2014-american-urolo-mygn-20140501monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-announce-financial-results-for-the-third-quarter-of-fiscal-year-2014-on-mygn-20140422monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-submits-premarket-approval-to-fda-for-bracanalysis-r-mygn-20140407monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-present-seven-clinical-studies-at-the-annual-clinical-genetics-meeting-mygn-20140325monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-hrd-companion-diagnostic-collaboration-with-tesaro-mygn-20140324monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-publishes-clinical-utility-study-for-prolaris-r-mygn-20140303monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-publishes-prolaris-r-data-in-the-journal-of-urology-mygn-20140218monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-financial-results-for-second-quarter-of-fiscal-year-2014-mygn-20140204monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-acquire-crescendo-bioscience-r-mygn-20140204monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-prolaris-r-test-significantly-modifies-treatment-decisions-for-patients-with-pros-mygn-20140129monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-publishes-data-on-its-variant-classification-program-in-clinical-genetics-mygn-20140128monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-announce-financial-results-for-the-second-quarter-of-fiscal-year-2014-o-mygn-20140123monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-five-clinical-studies-at-2014-asco-gu-cancer-symposium-mygn-20140123monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-32nd-annual-j-p-morgan-healthcare-conference-mygn-20140107monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-hrd-tm-test-significantly-predicts-response-to-cisplatin-treatment-in-patients-wi-mygn-20131214monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-myrisk-hereditary-cancer-tm-test-significantly-improves-detection-of-women-at-risk--mygn-20131212monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-cancer-research-collaboration-with-janssen-mygn-20131209monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-upcoming-investor-event-mygn-20131205monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-prolaris-r-test-guides-treatment-decisions-for-men-with-prostate-cancer-mygn-20131204monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-second-hrd-collaboration-mygn-20131120monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-launches-mypath-tm-melanoma-diagnostic-test-mygn-20131112monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-2013-credit-suisse-annual-healthcare-conference-mygn-20131108monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-financial-results-for-first-quarter-of-fiscal-year-2014-mygn-20131105monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-myplan-tm-lung-cancer-test-launched-to-leading-oncologists-mygn-20131029monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-myplan-tm-lung-cancer-test-meets-primary-endpoint-in-validation-study-mygn-20131028monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-myrisk-tm-hereditary-cancer-test-is-highly-accurate-in-key-validation-study-mygn-20131024monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-announce-fiscal-first-quarter-2014-financial-results-on-tuesday-novembe-mygn-20131023monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-mypath-tm-melanoma-test-is-highly-effective-in-verification-study-mygn-20131014monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-study-highlights-importance-of-myrisk-tm-hereditary-cancer-testing-mygn-20131009monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-myrisk-hereditary-cancer-tm-test-improves-colon-cancer-testing-by-60-percent-mygn-20131007monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-and-biomarin-advance-parp-collaboration-into-phase-3-mygn-20131001monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-myplan-tm-lung-cancer-test-meets-primary-clinical-endpoint-mygn-20130925monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-morgan-stanley-global-healthcare-conference-mygn-20130905monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-launches-myrisk-tm-hereditary-cancer-panel-mygn-20130905monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-expands-collaboration-with-astrazeneca-on-olaparib-phase-3-clinical-trials-mygn-20130904monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-full-year-and-fiscal-fourth-quarter-2013-financial-results-mygn-20130813monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-date-of-full-year-and-fourth-quarter-fiscal-2013-financial-resul-mygn-20130730monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-expands-its-patient-financial-assistance-program-mygn-20130715monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-and-tesaro-enter-into-companion-diagnostic-agreement-mygn-20130624monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-goldman-sachs-global-healthcare-conference-mygn-20130603monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-prolaris-r-data-at-asco-2013-continuing-its-commitment-to-cance-mygn-20130530monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-bank-of-america-merrill-lynch-health-care-conference-mygn-20130514monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-third-quarter-fiscal-year-2013-results-mygn-20130507monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-2013-analyst-and-investor-day-mygn-20130502monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-to-present-new-molecular-data-for-patients-with-prostate-cancer-at-the-american-uro-mygn-20130502monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-announce-third-fiscal-quarter-2013-results-on-tuesday-may-7-2013-mygn-20130418monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-adopts-raindance-s-thunderstorm-platform-for-next-generation-sequencing-based-hered-mygn-20130417monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-and-pharmamar-announce-first-commercial-partnership-with-myriad-s-new-hrd-test-mygn-20130326monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-prolaris-r-test-predicts-risk-of-prostate-cancer-recurrence-in-fourth-peer-review-mygn-20130305monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-second-quarter-fiscal-year-2013-results-mygn-20130205monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-announce-second-fiscal-quarter-2013-results-on-tuesday-february-5-2013-mygn-20130115monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-2013-j-p-morgan-annual-healthcare-conference-mygn-20121217monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-diabetes-collaboration-with-sanofi-mygn-20121210monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-hrd-test-predicts-response-to-platinum-therapy-in-triple-negative-breast-c-mygn-20121207monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-prolaris-test-predicts-biochemical-recurrence-in-prostate-cancer-patients--mygn-20121128monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-piper-jaffray-healthcare-conference-mygn-20121115monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-first-quarter-fiscal-year-2013-results-mygn-20121105monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-2012-credit-suisse-annual-healthcare-conference-mygn-20121101monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-announce-first-fiscal-quarter-2013-results-on-monday-november-5-2012-mygn-20121015monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-hrd-score-detects-loss-of-dna-repair-function-in-ovarian-cancer-mygn-20121010monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-sponsors-cancer-awareness-initiatives-in-support-of-national-hereditary-br-mygn-20121003monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-morgan-stanley-global-healthcare-conference-mygn-20120830monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fourth-quarter-and-fiscal-year-2012-results-mygn-20120814monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-and-pharma-mar-enter-into-companion-diagnostic-agreement-mygn-20120726monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-announce-fiscal-fourth-quarter-and-fiscal-year-2012-results-on-tuesday--mygn-20120724monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-receives-the-charles-r-smart-visionary-award-from-the-american-cancer-soci-mygn-20120606monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-lung-cancer-prognosis-test-shown-to-significantly-predict-survival-in-early-stage-mygn-20120604monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-upcoming-investor-conferences-in-june-mygn-20120522monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-presentation-of-lung-cancer-study-at-american-society-for-clinic-mygn-20120516monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-bank-of-america-merrill-lynch-2012-health-care-conferenc-mygn-20120502monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-record-third-fiscal-quarter-2012-results-mygn-20120501monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-announce-fiscal-2012-third-quarter-results-on-tuesday-may-1-2012-mygn-20120410monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-study-finds-high-prevalence-of-mutations-in-the-pms2-gene-mygn-20120329monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-and-cephalon-enter-into-companion-diagnostic-agreement-mygn-20120328monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-prolaris-r-test-shown-to-significantly-predict-prostate-cancer-outcome-in-needle--mygn-20120224monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-cowen-and-company-32nd-annual-health-care-conference-mygn-20120222monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-leerink-swann-2012-global-healthcare-conference-mygn-20120206monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-prolaris-r-test-shown-to-significantly-predict-biochemical-recurrence-risk-after--mygn-20120202monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-second-quarter-fiscal-year-2012-results-mygn-20120131monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-acquires-exclusive-rights-to-rad51c-gene-mygn-20120118monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-announce-fiscal-2012-second-quarter-results-on-tuesday-january-31-2012-mygn-20120117monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-30th-annual-j-p-morgan-healthcare-conference-mygn-20111228monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-presents-bracanalysis-r-cost-effectiveness-study-at-the-2011-ctrc-aacr-san-mygn-20111209monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-22nd-annual-oppenheimer-healthcare-conference-mygn-20111201monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-attend-the-23rd-annual-piper-jaffray-health-care-conference-mygn-20111121monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-first-quarter-fiscal-year-2012-results-mygn-20111101monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-announce-fiscal-2012-first-quarter-results-on-tuesday-november-1-2011-mygn-20111011monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-makes-strategic-debt-investment-with-exclusive-option-to-acquire-crescendo-mygn-20110908monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-morgan-stanley-global-healthcare-conference-mygn-20110830monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-new-200-million-share-repurchase-program-mygn-20110815monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fourth-quarter-and-fiscal-year-2011-results-mygn-20110809monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-applauds-the-court-of-appeals-decision-to-uphold-gene-patenting-mygn-20110729monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-announce-fiscal-fourth-quarter-and-fiscal-year-2011-results-on-tuesday--mygn-20110719monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-prolaris-r-test-shown-to-significantly-predict-prostate-cancer-outcome-from-needl-mygn-20110606monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-completes-acquisition-of-rules-based-medicine-mygn-20110601monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-jefferies-global-healthcare-conference-mygn-20110524monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-presentation-of-prostate-cancer-study-at-american-society-for-cl-mygn-20110518monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-licenses-novel-technology-from-chronix-biomedical-mygn-20110510monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-2011-third-quarter-results-mygn-20110503monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-agreement-to-acquire-rules-based-medicine-mygn-20110427monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-and-biomarin-pharmaceutical-inc-enter-into-agreement-mygn-20110406monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-announce-fiscal-third-quarter-financial-results-on-tuesday-may-3-2011-mygn-20110405monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-new-100-million-share-repurchase-program-mygn-20110301monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-citi-global-healthcare-conference-mygn-20110216monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-s-prolaris-tm-test-shown-to-significantly-predict-prostate-cancer-outcome-mygn-20110209monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-2011-second-quarter-results-mygn-20110127monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-report-fiscal-2011-second-quarter-financial-results-on-january-27-mygn-20110110monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-29th-annual-j-p-morgan-healthcare-conference-mygn-20101222monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-launches-panexia-new-predictive-test-for-hereditary-pancreatic-and-related-mygn-20101220monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-acquires-novel-technology-from-melanoma-diagnostics-mygn-20101208monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-applauds-major-health-economic-study-that-supports-broad-application-of-ge-mygn-20101129monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-lazard-capital-markets-7th-annual-healthcare-conference--mygn-20101104monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-2011-first-quarter-financial-results-mygn-20101102monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-and-abbott-enter-into-cooperative-agreement-mygn-20101026monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-morningstar-s-5th-annual-stocks-forum-mygn-20101021monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-prostate-cancer-data-at-the-asco-nci-eortc-annual-meeting-on-mo-mygn-20101014monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-report-fiscal-2011-first-quarter-financial-results-on-november-2-mygn-20101012monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-prolaris-test-accurately-predicts-survival-with-prostate-cancer-mygn-20101011monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-ubs-global-life-sciences-conference-and-the-fifth-annual-mygn-20100831monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-additional-stock-repurchase-program-mygn-20100831monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-morgan-stanley-global-healthcare-conference-and-the-stif-mygn-20100824monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-2010-financial-results-mygn-20100810monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-establishes-charitable-program-to-give-back-to-salt-lake-community-mygn-20100803monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-report-fiscal-2010-fourth-quarter-and-year-end-financial-results-on-aug-mygn-20100720monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-new-executive-vice-president-of-international-operations-mygn-20100708monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-pharmaceuticals-formally-adopts-its-name-change-to-myrexis-inc-effective-july-1-201-mygn-20100630monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-elects-former-roche-molecular-systems-ceo-heiner-dreismann-to-its-board-of-mygn-20100610monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-goldman-sachs-31st-annual-global-healthcare-conference-mygn-20100601monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-william-blair-company-30th-annual-growth-stock-conferenc-mygn-20100601monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-garp-research-and-securities-company-investor-conference-mygn-20100526monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-pharmaceuticals-reports-third-quarter-fy-2010-financial-results-mygn-20100517monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-citi-2010-global-health-care-conference-mygn-20100513monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-announces-stock-repurchase-program-mygn-20100504monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-financial-results-for-fiscal-2010-third-quarter-mygn-20100504monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-ninth-annual-jmp-securities-research-conference-mygn-20100428monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-new-convenient-ondose-tm-sampling-kit-mygn-20100427monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-study-shows-pten-gene-is-useful-in-predicting-prostate-cancer-recurrence-mygn-20100419monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-report-fiscal-2010-third-quarter-financial-results-on-may-4-mygn-20100413monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-inc-mygn-president-and-ceo-to-ring-the-nasdaq-stock-market-opening-bell-mygn-20100302monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-launches-prolaris-tm-first-diagnostic-test-to-predict-prostate-cancer-recu-mygn-20100302monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-cowen-and-company-30th-annual-health-care-conference-mygn-20100223monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-host-investor-day-in-new-york-mygn-20100217monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-pharmaceuticals-reports-second-quarter-fy-2010-financial-results-mygn-20100216monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-rbc-capital-markets-healthcare-conference-mygn-20100216monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-financial-results-for-fiscal-2010-second-quarter-mygn-20100202monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-study-reveals-patients-receive-suboptimal-dosing-with-chemotherapy-regimens-of-folf-mygn-20100125monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-seventh-annual-gastrointestinal-cancers-symposium-of-the-mygn-20100114monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-report-fiscal-2010-second-quarter-financial-results-on-february-2-mygn-20100112monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-partners-with-mammography-reporting-systems-to-increase-identification-of--mygn-20100106monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-28th-annual-j-p-morgan-healthcare-conference-mygn-20091217monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-pharmaceuticals-initiates-phase-2b-study-of-mpc-4326-in-a-genetically-identified-re-mygn-20091201monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-21st-annual-piper-jaffray-health-care-conference-mygn-20091117monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-pharmaceuticals-reports-first-quarter-fy-2010-financial-results-mygn-20091112monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-lazard-capital-markets-sixth-annual-healthcare-conference-mygn-20091104monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-first-quarter-fiscal-2010-financial-results-mygn-20091103monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-acquires-exclusive-rights-to-pancreatic-cancer-gene-patents-from-johns-hop-mygn-20091015monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-report-fiscal-2010-first-quarter-financial-results-on-november-3-mygn-20091013monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-fourth-annual-jmp-securities-healthcare-focus-conference-mygn-20090922monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-elects-louise-phanstiel-and-lawrence-best-to-its-board-of-directors-mygn-20090921monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-pharmaceutical-s-tablet-formulation-of-mpc-4326-reduces-viral-load-in-hiv-1-patient-mygn-20090914monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-ubs-global-life-sciences-conference-mygn-20090908monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-present-at-the-morgan-stanley-global-healthcare-conference-mygn-20090831monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-reports-fiscal-2009-financial-results-mygn-20090825monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-to-report-fiscal-2009-fourth-quarter-and-year-end-financial-results-on-aug-mygn-20090803monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-announces-completion-of-spin-off-of-its-research-and-pharmaceutical-busine-mygn-20090701monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-pharmaceuticals-inc-established-as-an-independent-pharmaceutical-development-compan-mygn-20090701monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-pharmaceuticals-inc-to-host-initial-public-conference-call-on-july-1-2009-mygn-20090629monthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-files-ind-for-drug-candidate-from-compound-family-licensed-from-maxim-phar-mygn-20041209monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-first-quarter-2026-financial-results-and-commercial-and-pipeli-akba-20260507monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-akba-20260504monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-to-report-first-quarter-2026-financial-results-and-discuss-recent-busi-akba-20260430monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-disc-akba-20260219monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-announces-corporate-updates-and-2026-pipeline-outlook-akba-20260112monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-trial-of-praliciguat-akba-20260106monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-to-present-at-the-piper-sandler-37th-annual-healthcare-conference-akba-20251124monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-to-report-third-quarter-2025-financial-results-and-discuss-recent-busi-akba-20251030monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-akba-20251001monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-akba-20250902monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-to-present-at-upcoming-investor-conferences-akba-20250828monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-and-innovative-renal-care-announce-nationwide-availability-of-vafseo-v-akba-20250821monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business-high-akba-20250807monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-to-present-at-canaccord-genuity-s-45th-annual-growth-conference-akba-20250806monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-initiates-vafseo-vadadustat-post-marketing-study-in-conjunction-with-large-dialysis-akba-20250804monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-akba-20250801monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-to-report-second-quarter-2025-financial-results-and-discuss-recent-bus-akba-20250731monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference-akba-20250708monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-akba-20250701monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-akba-20250602monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-2025-akba-20250528monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-announces-three-poster-presentations-at-the-european-renal-association-akba-20250527monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-to-present-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-confer-akba-20250513monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-first-quarter-2025-financial-results-and-recent-business-highl-akba-20250508monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-akba-20250501monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-to-report-first-quarter-2025-financial-results-and-discuss-recent-busi-akba-20250501monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-announces-positive-opinion-of-european-medicines-agency-for-xoanacyl-a-akba-20250403monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-akba-20250402monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-announces-poster-presentations-at-nkf-spring-clinical-meetings-2025-akba-20250325monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-announces-proposed-public-offering-of-common-stock-akba-20250319monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-vafseo-akba-20250313monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-and-disc-akba-20250306monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-akba-20250304monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-akba-20250204monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-s-vafseo-vadadustat-poised-to-make-waves-for-gsk-s-jesduvroq-and-fibrogen-astellas--akba-20230720monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-inc-nasdaq-akba-shareholder-class-action-alert-bernstein-liebhard-llp--akba-20220510monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-inc-nasdaq-akba-shareholder-class-action-alert-bernstein-liebhard-llp--akba-20220428monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-inc-nasdaq-akba-shareholder-class-action-alert-bernstein-liebhard-llp--akba-20220407monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-inc-nasdaq-akba-shareholder-class-action-alert-bernstein-liebhard-llp--akba-20220331monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announc-akba-20220317monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-announces-third-quarter-2015-financial-results-akba-20151109monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-announces-presentation-of-vadadustat-phase-2-dialysis-data-at-american-society-of-n-akba-20151107monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-to-present-at-the-credit-suisse-24th-annual-healthcare-conference-akba-20151103monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-announces-presentations-at-the-upcoming-american-society-of-nephrology-kidney-week--akba-20151028monthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-inc-nasdaq-akba-to-ring-the-nasdaq-stock-market-opening-bell-akba-20140911monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-the-stifel-2026-virtual-targeted-oncology-forum-mgnx-20260514monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20260226monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-the-8th-annual-evercore-healthcare-conference-mgnx-20251125monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-fourth-quarter-and-full-year-2024-financial-results-conferen-mgnx-20250306monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20250227monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conference-mgnx-20241202monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20241106monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-leadership-transition-mgnx-20241030monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-third-quarter-2024-financial-results-conference-call-mgnx-20241029monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-septe-mgnx-20240923monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-mgnx-20240919monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-inc-nasdaq-mgnx-deadline-alert-bernstein-liebhard-llp-reminds-macrogenics-inc--mgnx-20240916monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-investors-alerted-to-september-24th-deadline-in-securities-class-action-e-mgnx-20240915monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-investors-alerted-to-september-24th-deadline-in-securities-class-action-e-mgnx-20240912monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-inc-nasdaq-mgnx-deadline-alert-bernstein-liebhard-llp-reminds-macrogenics-inc--mgnx-20240909monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-crashed-28-after-pausing-phase-2-tamarack-study-class-action-accuses-comp-mgnx-20240909monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-tamarack-phase-2-data-presentation-at-esmo-congress-2024-mgnx-20240908monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-crashed-28-after-pausing-phase-2-tamarack-study-class-action-accuses-comp-mgnx-20240906monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-inc-nasdaq-mgnx-deadline-alert-bernstein-liebhard-llp-reminds-macrogenics-inc--mgnx-20240903monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-accused-of-misleading-investors-over-cancer-drug-trial-hagens-berman-mgnx-20240902monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-inc-mgnx-investors-september-24-2024-filing-deadline-in-securities-class-actio-mgnx-20240902monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-septe-mgnx-20240830monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-accused-of-misleading-investors-over-cancer-drug-trial-hagens-berman-mgnx-20240829monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-b-mgnx-20240827monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-accused-of-misleading-investors-over-cancer-drug-trial-hagens-berman-mgnx-20240826monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-inc-nasdaq-mgnx-deadline-alert-bernstein-liebhard-llp-reminds-macrogenics-inc--mgnx-20240826monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-inc-mgnx-investors-september-24-2024-filing-deadline-in-securities-class-actio-mgnx-20240825monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-accused-of-misleading-investors-over-cancer-drug-trial-hagens-berman-mgnx-20240822monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-mgnx-20240822monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-under-fire-as-analyst-downgrade-deepens-crisis-hagens-berman-mgnx-20240819monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-inc-class-action-levi-korsinsky-reminds-macrogenics-investors-of-the-pending-c-mgnx-20240819monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-inc-nasdaq-mgnx-deadline-alert-bernstein-liebhard-llp-reminds-macrogenics-inc--mgnx-20240819monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-under-fire-as-analyst-downgrade-deepens-crisis-hagens-berman-mgnx-20240815monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-september-mgnx-20240814monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-inc-nasdaq-mgnx-deadline-alert-bernstein-liebhard-llp-reminds-macrogenics-inc--mgnx-20240812monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-halts-prostate-cancer-trial-after-fatal-adverse-events-investor-suit-hage-mgnx-20240812monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-halts-prostate-cancer-trial-after-fatal-adverse-events-investor-suit-hage-mgnx-20240808monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-inc-class-action-alert-robbins-llp-reminds-investors-of-the-lead-plaintiff-dea-mgnx-20240807monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-b-mgnx-20240807monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-faces-class-action-after-revealing-investigation-of-patient-deaths-in-tam-mgnx-20240805monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-inc-nasdaq-mgnx-deadline-alert-bernstein-liebhard-llp-reminds-macrogenics-inc--mgnx-20240805monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-class-action-lawsuit-alert-johnson-fistel-announces-shareholders-with-sub-mgnx-20240802monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-faces-class-action-after-revealing-investigation-of-patient-deaths-in-tam-mgnx-20240802monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-0-mgnx-20240801monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-f-mgnx-20240731monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-vobramitamab-duocarmazine-update-mgnx-20240730monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-achievement-of-100-million-in-milestones-related-to-retifanlimab-col-mgnx-20240730monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-faces-class-action-after-revealing-investigation-of-patient-deaths-in-tam-mgnx-20240730monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-inc-nasdaq-mgnx-investor-alert-investors-with-large-losses-in-macrogenics-inc--mgnx-20240729monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-alert-securities-fraud-lawsuit-could-allow-investors-to-recover-losses-block-l-mgnx-20240729monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-investigating-three-of-five-patient-deaths-in-tamarack-study-of-vobra-duo-mgnx-20240724monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-investigating-three-of-five-patient-deaths-in-tamarack-study-of-vobra-duo-mgnx-20240716monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-investigating-three-of-five-patient-deaths-in-tamarack-study-of-vobra-duo-mgnx-20240710monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-investigating-three-of-five-patient-deaths-in-tamarack-study-of-vobra-duo-mgnx-20240703monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-inc-investors-company-investigated-by-the-portnoy-law-firm-mgnx-20240624monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-stock-crashes-after-reporting-patient-deaths-in-tamarack-study-hagens-ber-mgnx-20240620monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-stock-crashes-after-reporting-patient-deaths-in-tamarack-study-hagens-ber-mgnx-20240613monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conference-mgnx-20240611monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-stock-crashes-after-reporting-patient-deaths-in-tamarack-study-hagens-ber-mgnx-20240529monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-stock-crashes-after-reporting-patient-deaths-in-tamarack-study-hagens-ber-mgnx-20240516monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-alert-bragar-eagel-squire-p-c-is-investigating-macrogenics-inc-on-behalf-of-ma-mgnx-20240515monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-stock-crashes-after-reporting-patient-deaths-in-tamarack-study-hagens-ber-mgnx-20240513monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20240513monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgnx-stock-crashes-after-reporting-patient-deaths-in-tamarack-study-hagens-ber-mgnx-20240510monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-first-quarter-2024-financial-results-conference-call-mgnx-20240503monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-phase-2-tamarack-study-early-interim-safety-data-and-plans-for-future-mgnx-20240403monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20240301monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-fourth-quarter-2023-financial-results-conference-call-mgnx-20240227monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conference-mgnx-20240202monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conference-mgnx-20240108monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20231102monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-third-quarter-2023-financial-results-conference-call-mgnx-20231031monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-achievement-of-15-million-milestone-related-to-gilead-s-nomination-o-mgnx-20230905monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20230831monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-second-quarter-2023-financial-results-conference-call-mgnx-20230731monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-first-quarter-2023-financial-results-conference-call-mgnx-20230504monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20230424monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-fourth-quarter-2022-financial-results-conference-call-mgnx-20230307monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20230302monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20230206monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-mgnx-20230104monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20221102monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-third-quarter-2022-financial-results-conference-call-mgnx-20221026monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20220902monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-second-quarter-2022-financial-results-conference-call-mgnx-20220725monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conference-mgnx-20220608monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conference-mgnx-20220517monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-first-quarter-2022-financial-results-conference-call-mgnx-20220425monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20220303monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-executive-promotion-mgnx-20220228monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-fourth-quarter-2021-financial-results-conference-call-mgnx-20220214monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20220203monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20211103monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-third-quarter-2021-financial-results-conference-call-mgnx-20211026monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-preliminary-clinical-results-from-phase-1-cohort-expansion-of-the-on-mgnx-20210916monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-clinical-results-from-cohort-a-part-1-of-phase-2-3-mahogany-study-of-mgnx-20210916monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-presentations-at-esmo-2021-virtual-annual-congress-mgnx-20210912monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-final-overall-survival-results-from-sophia-study-of-margenza-in-pati-mgnx-20210907monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20210902monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20210805monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-second-quarter-2021-financial-results-conference-call-mgnx-20210722monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-inc-investors-company-investigated-by-the-portnoy-law-firm-mgnx-20210617monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-and-zai-lab-enter-into-broad-strategic-collaboration-to-develop-and-commercial-mgnx-20210616monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-preliminary-clinical-results-from-phase-1-study-of-mgc018-to-be-pres-mgnx-20210519monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conference-mgnx-20210519monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-first-quarter-2021-financial-results-conference-call-mgnx-20210419monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-presentations-at-the-2021-aacr-annual-meeting-mgnx-20210410monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20210226monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-fourth-quarter-and-full-year-2020-financial-results-conferen-mgnx-20210218monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-names-federica-o-brien-to-its-board-of-directors-mgnx-20210211monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-achievement-of-10-million-milestone-related-to-retifanlimab-collabor-mgnx-20210211monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20210208monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-publication-of-sophia-trial-results-for-margenza-in-jama-oncology-mgnx-20210125monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20210111monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-mgd019-publication-in-cell-reports-medicine-mgnx-20201222monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-enters-research-collaboration-with-janssen-to-develop-novel-dart-molecule-mgnx-20201218monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-fda-approval-of-margenza-for-patients-with-pretreated-metastatic-her-mgnx-20201216monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-presents-tebotelimab-data-in-patients-with-relapsed-refractory-diffuse-large-b-mgnx-20201207monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-presents-flotetuzumab-data-in-patients-with-refractory-acute-myeloid-leukemia--mgnx-20201206monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-and-eversana-announce-agreement-to-support-the-potential-launch-and-commercial-mgnx-20201130monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-achievement-of-25-million-in-milestones-related-to-retifanlimab-coll-mgnx-20201130monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20201109monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-flotetuzumab-and-tebotelimab-presentations-at-the-ash-annual-meeting-mgnx-20201104monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-third-quarter-2020-financial-results-conference-call-mgnx-20201028monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-flotetuzumab-publication-in-blood-advances-mgnx-20201015monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-mgc018-publication-in-molecular-cancer-therapeutics-mgnx-20200923monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-publication-of-flotetuzumab-interim-phase-1-2-clinical-trial-results-mgnx-20200922monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-development-milestone-achieved-in-retifanlimab-mga012-collaboration--mgnx-20200921monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-presentation-of-mgd019-phase-1-data-at-the-esmo-virtual-congress-202-mgnx-20200920monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20200903monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20200805monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-second-quarter-2020-financial-results-conference-call-mgnx-20200723monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-lancet-oncology-publication-of-margetuximab-data-in-gastric-cancer-mgnx-20200709monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-presentation-of-preclinical-data-at-the-2020-aacr-annual-meeting-mgnx-20200622monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-margetuximab-granted-orphan-drug-designation-in-the-u-s-for-gastric--mgnx-20200605monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-publication-in-science-translational-medicine-supporting-flotetuzuma-mgnx-20200603monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-fda-review-of-margetuximab-for-her2-positive-metastatic-bre-mgnx-20200528monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-registration-study-of-flotetuzumab-in-patients-with-refractory-acute-mgnx-20200527monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-host-conference-call-and-webcast-to-review-preliminary-clinical-results-for-mgnx-20200521monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-preliminary-clinical-results-from-mgd013-and-mgc018-to-be-presented--mgnx-20200513monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-presentations-at-the-2020-asco-annual-meeting-mgnx-20200429monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-host-its-annual-meeting-of-stockholders-in-virtual-format-mgnx-20200428monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-first-quarter-2020-financial-results-conference-call-mgnx-20200428monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-presentation-of-flotetuzumab-translational-data-at-the-2020-aacr-ann-mgnx-20200427monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20200227monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-2019-financial-results-mgnx-20200225monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-fourth-quarter-and-full-year-2019-financial-results-conferen-mgnx-20200213monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20200210monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-j-p-morgan-healthcare-conference-mgnx-20200113monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-outlines-corporate-priorities-for-2020-mgnx-20200109monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-submission-of-margetuximab-biologics-license-application-to-u-s-fda-mgnx-20191219monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-presents-results-from-the-sophia-study-of-margetuximab-in-patients-with-her2-p-mgnx-20191211monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-presents-flotetuzumab-data-in-patients-with-primary-induction-failure-and-earl-mgnx-20191209monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-the-evercore-isi-healthconx-conference-mgnx-20191202monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20191107monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-third-quarter-2019-financial-results-mgnx-20191106monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-flotetuzumab-presentations-at-the-ash-annual-meeting-2019-mgnx-20191106monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-third-quarter-2019-financial-results-conference-call-mgnx-20191030monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-initiation-of-phase-2-3-mahogany-study-of-margetuximab-in-gastric-or-mgnx-20191025monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-second-interim-overall-survival-data-from-phase-3-sophia-study-of-ma-mgnx-20191022monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-presents-margetuximab-data-in-gastroesophageal-cancer-at-the-esmo-2019-congres-mgnx-20190930monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-cantor-global-healthcare-conference-mgnx-20190926monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-inc-shareholder-alert-kehoe-law-firm-p-c-investigating-claims-on-behalf-of-mac-mgnx-20190916monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20190829monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20190808monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-second-quarter-2019-financial-result-mgnx-20190731monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-second-quarter-2019-financial-results-conference-call-mgnx-20190724monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-flotetuzumab-program-in-acute-myeloid-leukemia-mgnx-20190717monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-and-i-mab-announce-exclusive-collaboration-and-license-agreement-to-develop-an-mgnx-20190710monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-jefferies-healthcare-conference-mgnx-20190530monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-host-conference-call-and-webcast-to-review-margetuximab-phase-3-sophia-stud-mgnx-20190528monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-positive-results-from-phase-3-sophia-study-of-margetuximab-in-patien-mgnx-20190515monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-first-quarter-2019-financial-results-mgnx-20190501monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-first-quarter-2019-financial-results-conference-call-mgnx-20190424monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-reports-presentation-of-data-at-the-aacr-annual-meeting-2019-mgnx-20190403monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20190402monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-upcoming-investor-conferences-mgnx-20190308monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-2018-financial-results-mgnx-20190226monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-participation-in-svb-leerink-global-healthcare-conference-mgnx-20190225monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-fourth-quarter-and-full-year-2018-financial-results-conferen-mgnx-20190219monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-guggenheim-healthcare-talks-idea-forum-mgnx-20190213monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-pricing-of-public-offering-of-common-stock-mgnx-20190213monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-proposed-public-offering-of-common-stock-mgnx-20190212monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-positive-results-from-pivotal-phase-3-sophia-study-of-margetuximab-mgnx-20190206monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-removal-of-partial-clinical-hold-on-mgd009-program-by-fda-mgnx-20190125monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-mgnx-20190107monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-partial-clinical-hold-on-mgd009-phase-1-studies-mgnx-20181207monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-and-zai-lab-announce-exclusive-collaboration-and-license-agreement-to-develop--mgnx-20181129monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-participation-in-three-investor-conferences-mgnx-20181127monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-poster-presentation-on-preclinical-pd-l1-x-cd137-dart-program-at-the-mgnx-20181114monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-reports-presentation-of-clinical-data-at-33rd-annual-sitc-meeting-mgnx-20181109monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-3rd-quarter-2018-financial-results-mgnx-20181107monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-third-quarter-2018-financial-results-conference-call-mgnx-20181031monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-and-nanostring-enter-translational-research-collaboration-to-identify-and-deve-mgnx-20181029monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-participation-in-three-investor-conferences-mgnx-20181022monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-participation-in-two-upcoming-investor-conferences-mgnx-20180926monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-participation-in-three-upcoming-investor-conferences-mgnx-20180830monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-wedbush-pacgrow-healthcare-conference-mgnx-20180809monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-2nd-quarter-2018-financial-results-mgnx-20180807monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-second-quarter-2018-financial-results-conference-call-mgnx-20180730monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-jefferies-global-healthcare-conference-mgnx-20180605monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-deutsche-bank-health-care-conference-mgnx-20180507monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-1st-quarter-2018-financial-results-mgnx-20180507monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-first-quarter-2018-financial-results-conference-call-mgnx-20180430monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-unde-mgnx-20180402monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-pricing-of-public-offering-of-common-stock-mgnx-20180328monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-proposed-public-offering-of-common-stock-mgnx-20180326monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-cowen-health-care-conference-mgnx-20180309monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-2017-financial-results-mgnx-20180227monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-fourth-quarter-and-full-year-2017-financial-results-conferen-mgnx-20180214monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-two-upcoming-investor-conferences-mgnx-20180206monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-continuation-of-sophia-study-of-margetuximab-based-on-completion-of--mgnx-20180123monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-mgnx-20180104monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-enters-research-collaboration-with-roche-to-develop-a-novel-bispecific-molecul-mgnx-20180104monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-closing-of-mga012-global-collaboration-and-license-agreement-with-in-mgnx-20171205monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-names-dr-jay-siegel-to-its-board-of-directors-mgnx-20171115monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-two-upcoming-investor-conferences-mgnx-20171113monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-poster-presentations-at-32nd-annual-sitc-meeting-2017-mgnx-20171110monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-third-quarter-2017-financial-results-conference-call-mgnx-20171101monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-phase-1-data-on-flotetuzumab-a-cd123-x-cd3-dart-molecule-at-59th-an-mgnx-20171101monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-advances-two-first-in-class-clinical-dart-molecules-mgnx-20170905monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-termination-of-duvortuxizumab-collaboration-and-license-agreement-wi-mgnx-20170831monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-three-investor-conferences-in-september-mgnx-20170830monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-wedbush-pacgrow-healthcare-conference-mgnx-20170809monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-second-quarter-2017-financial-result-mgnx-20170802monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-second-quarter-2017-financial-results-conference-call-mgnx-20170726monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-presents-updated-data-from-phase-1-study-of-mgd010-at-annual-european-congress-mgnx-20170617monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-registered-direct-offering-of-common-stock-mgnx-20170427monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-two-upcoming-investor-conferences-in-may-mgnx-20170426monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-first-quarter-2017-financial-results-conference-call-mgnx-20170425monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-needham-healthcare-conference-mgnx-20170329monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-2016-financial-results-mgnx-20170228monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-two-upcoming-investor-conferences-mgnx-20170227monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-fourth-quarter-and-full-year-2016-financial-results-conferen-mgnx-20170216monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-leerink-partners-6th-annual-global-healthcare-conference-mgnx-20170209monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-appointments-to-board-of-directors-mgnx-20170125monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-mgd006-granted-orphan-drug-status-for-aml-by-fda-mgnx-20170105monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-mgnx-20170105monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-highlights-progress-at-2016-r-d-day-mgnx-20161213monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-licenses-synthon-s-technology-to-develop-an-anti-b7-h3-adc-mgnx-20161212monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-host-2016-r-d-day-mgnx-20161208monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-two-upcoming-investor-conferences-mgnx-20161101monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-third-quarter-2016-financial-results-conference-call-mgnx-20161026monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-leerink-partners-rare-disease-immuno-oncology-roundtable-mgnx-20160923monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-the-promotion-of-three-executives-mgnx-20160920monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-two-upcoming-investor-conferences-mgnx-20160831monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-two-upcoming-investor-conferences-mgnx-20160804monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-second-quarter-2016-financial-results-conference-call-mgnx-20160727monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-closing-of-collaboration-and-license-agreement-with-janssen-to-devel-mgnx-20160628monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-presents-data-from-phase-1-study-of-mgd010-at-annual-european-congress-of-rheu-mgnx-20160610monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-enters-collaboration-and-license-agreement-with-janssen-to-develop-new-dart-mo-mgnx-20160518monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-mgd010-clinical-data-at-eular-2016-mgnx-20160511monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-bank-of-america-merrill-lynch-2016-health-care-conference-mgnx-20160504monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-first-quarter-2016-financial-results-conference-call-mgnx-20160427monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-presents-data-from-five-preclinical-programs-at-aacr-annual-meeting-2016-mgnx-20160419monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-15th-annual-needham-healthcare-conference-mgnx-20160406monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-five-posters-at-aacr-annual-meeting-2016-mgnx-20160316monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-fourth-quarter-and-full-year-2015-financial-results-conferen-mgnx-20160216monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-leerink-partners-5th-annual-global-healthcare-conference-mgnx-20160204monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-oppenheimer-26th-annual-healthcare-conference-mgnx-20151202monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-two-upcoming-investor-conferences-mgnx-20151104monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-third-quarter-2015-financial-results-conference-call-mgnx-20151028monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-and-merck-to-collaborate-on-immuno-oncology-study-evaluating-margetuximab-in-c-mgnx-20151022monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-highlights-progress-at-2015-r-d-day-mgnx-20151013monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-host-2015-r-d-day-mgnx-20151006monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-presentation-at-30th-annual-sitc-meeting-2015-mgnx-20151001monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-two-upcoming-investor-conferences-mgnx-20150922monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-participate-in-two-upcoming-investor-conferences-mgnx-20150903monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-second-quarter-2015-financial-result-mgnx-20150805monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-2015-wedbush-pacgrow-healthcare-conference-mgnx-20150804monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-second-quarter-2015-financial-results-conference-call-mgnx-20150729monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-pricing-of-public-offering-of-common-stock-mgnx-20150715monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-proposed-public-offering-of-common-stock-mgnx-20150713monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-presents-updated-data-from-phase-1-study-of-margetuximab-at-asco-annual-meetin-mgnx-20150530monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-preclinical-research-on-mgd006-dart-r-molecule-published-in-science-translatio-mgnx-20150527monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-presentation-at-asco-annual-meeting-2015-mgnx-20150513monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-first-quarter-2015-financial-results-mgnx-20150506monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-first-quarter-2015-financial-results-conference-call-mgnx-20150429monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-participation-in-two-investor-conferences-in-may-mgnx-20150428monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-presents-pre-clinical-data-on-its-multivalent-dr5-dart-at-the-aacr-annual-meet-mgnx-20150420monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-presentations-at-aacr-annual-meeting-2015-mgnx-20150416monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-14th-annual-needham-healthcare-conference-mgnx-20150407monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-initiates-phase-1-study-of-mgd010-for-the-treatment-of-autoimmune-disorders-mgnx-20150316monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-2014-financial-results-mgnx-20150303monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-roth-capital-partners-27th-annual-growth-stock-conference-mgnx-20150302monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-fourth-quarter-and-full-year-2014-financial-results-conferen-mgnx-20150224monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-leerink-global-healthcare-conference-mgnx-20150205monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-33rd-annual-j-p-morgan-healthcare-conference-mgnx-20150112monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-presentation-of-pre-clinical-data-on-new-dart-r-candidate-mgd011-at--mgnx-20141207monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-oppenheimer-25th-annual-healthcare-conference-mgnx-20141203monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-stifel-2014-healthcare-conference-mgnx-20141112monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-third-quarter-2014-financial-results-mgnx-20141111monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-pre-clinical-data-to-be-presented-at-ash-2014-annual-meeting-mgnx-20141106monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-pre-clinical-data-on-mgd006-at-26th-eortc-nci-aacr-symposium-mgnx-20141030monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-third-quarter-2014-financial-results-conference-call-mgnx-20141028monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-and-takeda-enter-second-strategic-alliance-to-develop-multiple-additional-dart-mgnx-20140929monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-wedbush-2014-life-sciences-management-access-conference-mgnx-20140806monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-second-quarter-2014-financial-result-mgnx-20140805monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-second-quarter-2014-financial-results-conference-call-mgnx-20140729monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-dart-candidate-ind-for-colorectal-cancer-mgd007-cleared-to-start-enrolling-pat-mgnx-20140724monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-initiates-phase-1-study-of-mgd006-for-the-treatment-of-acute-myeloid-leukemia-mgnx-20140619monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-bank-of-america-merrill-lynch-2014-health-care-conference-mgnx-20140507monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-provides-update-on-corporate-progress-and-first-quarter-2014-financial-results-mgnx-20140506monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-presents-pre-clinical-data-on-inhibition-of-autoimmune-diseases-with-dart-cand-mgnx-20140505monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-appoints-atul-saran-as-senior-vice-president-and-general-counsel-mgnx-20140430monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-first-quarter-2014-financial-results-conference-call-mgnx-20140429monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-pre-clinical-data-on-novel-dart-candidate-mgd010-for-autoimmune-dis-mgnx-20140428monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-presents-pre-clinical-data-demonstrating-potent-activity-with-colorectal-cance-mgnx-20140406monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-13th-annual-needham-healthcare-conference-mgnx-20140401monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-pre-clinical-data-on-mgd007-at-the-aacr-annual-meeting-mgnx-20140331monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-date-of-year-end-2013-financial-results-conference-call-mgnx-20140313monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-appoints-matthew-fust-to-its-board-of-directors-mgnx-20140306monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-at-the-26th-annual-roth-conference-mgnx-20140303monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-pricing-of-public-offering-of-common-stock-mgnx-20140213monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-proposed-public-offering-of-common-stock-mgnx-20140210monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-achieves-milestone-as-servier-exercises-option-to-develop-and-commercialize-da-mgnx-20140205monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-publication-of-cancer-stem-cell-research-in-lung-cancer-mgnx-20131211monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-presentation-of-pre-clinical-data-on-dart-r-molecule-targeting-cd123-mgnx-20131209monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-to-present-pre-clinical-data-on-targeting-cd123-positive-leukemic-stem-cells-a-mgnx-20131111monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-dart-therapeutic-selected-by-boehringer-ingelheim-as-a-bi-specific-pre-clinica-mgnx-20131111monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-announces-timing-for-third-quarter-2013-financial-results-and-conference-call-mgnx-20131105monthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-inc-mgnx-to-ring-the-nasdaq-stock-market-closing-bell-in-celebration-of-ipo-mgnx-20131010monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-present-at-jefferies-global-healthcare-conference-prme-20260528monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-present-at-8th-annual-evercore-healthcare-conference-prme-20251125monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-participate-in-upcoming-investor-conferences-prme-20250826monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-announces-proposed-public-offering-of-common-stock-prme-20250730monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-announces-additional-funding-of-up-to-24-million-from-the-cystic-fibrosis-f-prme-20250716monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-participate-in-upcoming-investor-conferences-prme-20250529monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-announces-strategic-restructuring-to-focus-on-opportunities-in-large-geneti-prme-20250519monthly0.5https://www.biopharmawatch.com/news/PRME/primemale-under-review-the-100-natural-testo-booster-for-best-libido-enhancement-prme-20250506monthly0.5https://www.biopharmawatch.com/news/PRME/primebiome-the-doctor-endorsed-skin-gut-gummies-backed-by-science-for-women-prme-20250503monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-i-ve-tested-it-for-90-days-here-s-my-honest-prime-biome-gummies-review-and-sho-prme-20250426monthly0.5https://www.biopharmawatch.com/news/PRME/primebiome-reviews-gut-skin-miracle-or-just-hype-expert-insights-prme-20250422monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-reviews-2025-updated-comprehensive-guide-to-the-revolutionary-gut-skin-health--prme-20250422monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-reviews-2025-investigative-consumer-complaints-report-examines-scientific-clai-prme-20250421monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-reviews-gut-skin-miracle-or-just-hype-a-renowned-dermatologist-weighs-in-prme-20250418monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-gummies-latest-study-2025-read-before-buying-prme-20250418monthly0.5https://www.biopharmawatch.com/news/PRME/primebiome-reviews-must-read-shocking-results-ingredients-it-s-benefits-prme-20250418monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-updated-2025-a-comprehensive-review-of-the-groundbreaking-skin-gut-axis-supple-prme-20250416monthly0.5https://www.biopharmawatch.com/news/PRME/primebiome-reviewed-top-5-reasons-why-prime-biome-is-the-best-option-available-prme-20250412monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-reviews-alert-i-tried-it-tracked-it-and-exposed-the-good-bad-unexpected-prme-20250409monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-we-tested-it-for-90-days-here-s-the-real-month-by-month-review-unexpected-bene-prme-20250409monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-reviews-shocking-research-exposed-does-this-gut-skin-link-actually-hold-up-in--prme-20250407monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-debuts-skin-gut-cell-turnover-breakthrough-with-essential-probiotics-prme-20250405monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-we-tested-it-here-s-my-honest-prime-biome-review-after-117-days-prme-20250403monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-reviews-don-t-skip-until-see-this-for-preventing-fraud-and-guaranteeing-reliab-prme-20250402monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-investigative-report-does-this-trending-gut-reset-supplement-actually-deliver--prme-20250401monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-reviews-consumer-warning-experts-reveal-what-most-people-miss-about-probiotic--prme-20250331monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-review-investigation-gut-skin-health-supplement-put-under-medical-microscope-prme-20250331monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-gummies-exposed-what-real-users-just-revealed-about-prime-biome-s-gut-skin-res-prme-20250327monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-reviews-shocking-truth-what-67-000-buyers-just-revealed-about-side-effects-gut-prme-20250327monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-reviews-is-it-legit-and-safe-ingredients-can-this-probiotic-really-transform-y-prme-20250325monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-reviews-exposed-doctor-breaks-down-whether-these-gummies-truly-support-aging-g-prme-20250323monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-reviews-a-comprehensive-review-of-the-revolutionary-skin-and-gut-health-supple-prme-20250321monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-gummies-exposed-clinical-analysis-is-this-probiotic-formula-really-a-game-chan-prme-20250320monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-reviews-2025-investigative-report-examines-whether-this-gut-skin-formula-is-sc-prme-20250320monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-unveils-program-for-the-treatment-of-alpha-1-antitrypsin-deficiency-aatd-prme-20250318monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-reviews-and-complaints-a-detailed-study-released-that-s-needs-to-be-adopted-fo-prme-20250312monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-reviews-consumer-report-analysis-safe-ingredients-for-skin-and-gut-health-or-s-prme-20250307monthly0.5https://www.biopharmawatch.com/news/PRME/prime-biome-under-review-the-truth-about-prime-biome-and-microbiome-synergy-for-gut-skin-h-prme-20250304monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-reports-full-year-2024-financial-results-and-provides-business-updates-prme-20250228monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-present-at-td-cowen-45th-annual-health-care-conference-prme-20250224monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-present-at-43rd-annual-j-p-morgan-healthcare-conference-prme-20250107monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-reports-third-quarter-2024-financial-results-and-provides-business-updates-prme-20241112monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-participate-in-upcoming-investor-conferences-prme-20241106monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-presents-in-vivo-proof-of-concept-data-highlighting-interim-preclinical-adv-prme-20241024monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-highlight-new-preclinical-data-including-in-vivo-data-in-wilson-s-diseas-prme-20241015monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-unveils-strategically-focused-pipeline-prme-20240930monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-announces-strategic-research-collaboration-and-license-agreement-with-brist-prme-20240930monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-participate-in-upcoming-investor-conferences-prme-20240828monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-reports-second-quarter-2024-financial-results-and-provides-business-updates-prme-20240808monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-present-at-upcoming-investor-conferences-prme-20240530monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-present-at-h-c-wainwright-2nd-annual-bioconnect-investor-conference-at-n-prme-20240513monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-reports-first-quarter-2024-financial-results-and-provides-business-updates-prme-20240510monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-presents-preclinical-data-demonstrating-ability-of-pm359-to-efficiently-rep-prme-20240508monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-participate-in-the-27th-annual-milken-institute-global-conference-prme-20240501monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-announces-fda-clearance-of-investigational-new-drug-ind-application-for-pm3-prme-20240429monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-present-preclinical-data-demonstrating-broad-potential-of-prime-editing--prme-20240423monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-reports-full-year-2023-financial-results-and-provides-business-updates-prme-20240301monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-participate-in-upcoming-investor-conferences-prme-20240228monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-announces-closing-of-upsized-public-offering-and-full-exercise-of-the-under-prme-20240220monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-announces-pricing-of-upsized-public-offering-prme-20240215monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-announces-proposed-public-offering-of-common-stock-prme-20240214monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-present-at-guggenheim-healthcare-talks-6th-annual-biotechnology-conferen-prme-20240201monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-receives-up-to-15-million-from-cystic-fibrosis-foundation-to-advance-hotspo-prme-20240125monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-appoints-allan-reine-m-d-as-chief-financial-officer-prme-20240105monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-present-at-42nd-annual-j-p-morgan-healthcare-conference-prme-20240102monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-present-at-upcoming-investor-conferences-prme-20231108monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-reports-third-quarter-2023-financial-results-and-provides-business-updates-prme-20231103monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-presents-first-ever-prime-editing-data-in-non-human-primates-demonstrating--prme-20231027monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-presents-first-in-vivo-proof-of-concept-prime-editing-data-demonstrating-ab-prme-20231024monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-highlight-positive-preclinical-developments-across-prime-editing-pipelin-prme-20231017monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-present-at-upcoming-investor-conferences-prme-20230919monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-present-at-upcoming-investor-conferences-prme-20230831monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-reports-second-quarter-2023-financial-results-and-provides-business-updates-prme-20230807monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-and-cimeio-therapeutics-announce-research-collaboration-to-develop-prime-ed-prme-20230622monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-present-at-investor-conferences-in-june-prme-20230531monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-present-at-virtual-investor-conferences-in-may-prme-20230517monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-present-new-preclinical-data-highlighting-broad-potential-of-prime-editi-prme-20230517monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-reports-first-quarter-2023-financial-results-and-provides-business-updates-prme-20230511monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-diseas-prme-20230327monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-present-at-cowen-43rd-annual-health-care-conference-prme-20230227monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-announces-recent-progress-and-highlights-2023-strategic-priorities-prme-20230109monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-to-present-at-41st-annual-j-p-morgan-healthcare-conference-prme-20230103monthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-announces-closing-of-upsized-initial-public-offering-prme-20221024monthly0.5https://www.biopharmawatch.com/news/PRME/prime-minister-roosevelt-skerrit-presents-1-2-billion-budget-for-fiscal-year-2022-2023-prme-20220801monthly0.5https://www.biopharmawatch.com/news/PRME/prime-blockchain-announces-proposed-reverse-takeover-by-ryah-prme-20190627monthly0.5https://www.biopharmawatch.com/news/PRME/prime-designation-granted-by-european-medicines-agency-for-roche-s-risdiplam-for-treatment-prme-20181217monthly0.5https://www.biopharmawatch.com/news/PRME/prime-designation-granted-by-european-medicines-agency-for-rg6042-for-treatment-of-hunting-prme-20180803monthly0.5https://www.biopharmawatch.com/news/PRME/prime-venture-partners-raises-inr-400-crore-in-fund-3-prme-20180307monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-showcases-data-from-ft819-and-ft839-programs-at-the-european-congress-of-fate-20260604monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-showcases-clinical-data-for-ft836-at-the-american-society-of-cancer-onco-fate-20260601monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-selected-for-u-s-fda-chemistry-manufacturing-and-controls-development-an-fate-20260505monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635-c-4-fate-20260501monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-presents-updated-phase-1-clinical-data-of-ft819-off-the-shelf-car-t-cell-fate-20251208monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-piper-sandler-37th-annual-healthcare-conference-fate-20251125monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-awards-under-nasdaq-listing-rule-5635-c--fate-20251002monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-awards-under-nasdaq-listing-rule-5635-c--fate-20250903monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-awards-under-nasdaq-listing-rule-5635-c--fate-20250805monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-awards-under-nasdaq-listing-rule-5635-c--fate-20250703monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-updated-clinical-data-for-ft819-off-the-shelf-car-t-cell-produ-fate-20250611monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-phase-1-data-presentation-of-ft819-off-the-shelf-car-t-cell-pr-fate-20250528monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-awards-under-nasdaq-listing-rule-5635-c--fate-20250502monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-five-presentations-on-off-the-shelf-car-t-cell-product-platfor-fate-20250429monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-receives-regenerative-medicine-advanced-therapy-rmat-designation-from-fd-fate-20250414monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-awards-under-nasdaq-listing-rule-5635-c--fate-20250402monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635-c-4-fate-20250304monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-upcoming-investor-conferences-fate-20250214monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-awards-under-nasdaq-listing-rule-5635-c--fate-20250204monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-awards-under-nasdaq-listing-rule-5635-c--fate-20250103monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-presents-new-phase-1-clinical-data-of-ft819-off-the-shelf-car-t-cell-pro-fate-20241209monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635-c-4-fate-20241203monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-leadership-transition-fate-20241129monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-upcoming-december-investor-conferences-fate-20241126monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-presents-6-month-follow-up-data-on-first-patient-treated-in-phase-1-auto-fate-20241118monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-highlights-ft522-off-the-shelf-adr-armed-car-nk-cell-product-candidate-a-fate-20241118monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-highlights-cancer-selective-her2-targeting-profile-of-ft825-ono-8250-car-fate-20241109monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-presents-pan-tumor-targeting-preclinical-data-for-ft836-mica-b-targeted--fate-20241108monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635-c-4-fate-20241104monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-awards-under-nasdaq-listing-rule-5635-c--fate-20241002monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-2024-cantor-global-healthcare-conference-fate-20240912monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-awards-under-nasdaq-listing-rule-5635-c--fate-20240802monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-awards-under-nasdaq-listing-rule-5635-c--fate-20240702monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-awards-under-nasdaq-listing-rule-5635-c--fate-20240604monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-2024-jefferies-global-healthcare-conference-fate-20240529monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-first-quarter-2024-financial-result-fate-20240506monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-presentation-of-ft522-preclinical-data-for-autoimmune-diseases-fate-20240503monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-presentation-of-ft819-proof-of-concept-data-for-b-cell-mediate-fate-20240422monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-23rd-annual-needham-virtual-healthcare-conference-fate-20240403monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635-c-4-fate-20240402monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635-c-4-fate-20240305monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-upcoming-march-investor-conferences-fate-20240301monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-fourth-quarter-and-full-year-2023-f-fate-20240215monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-awards-under-nasdaq-listing-rule-5635-c--fate-20240202monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-initiation-of-phase-1-clinical-trial-for-ft825-ono-8250-in-pat-fate-20240108monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-grants-under-nasdaq-listing-rule-5635-c--fate-20231213monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-alert-bragar-eagel-squire-p-c-is-investigating-fate-therapeutics-inc-on--fate-20231104monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-third-quarter-2023-financial-result-fate-20231025monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-upcoming-september-investor-conferences-fate-20230831monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-alert-bragar-eagel-squire-p-c-is-investigating-fate-therapeutics-inc-on--fate-20230828monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-second-quarter-2023-financial-resul-fate-20230728monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-investigation-initiated-by-former-louisiana-attorney-general-kahn-swick--fate-20230617monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-upcoming-june-investor-conferences-fate-20230531monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-first-quarter-2023-financial-result-fate-20230424monthly0.5https://www.biopharmawatch.com/news/FATE/fate-important-deadline-rosen-leading-investor-counsel-encourages-fate-therapeutics-inc-in-fate-20230321monthly0.5https://www.biopharmawatch.com/news/FATE/fate-final-deadline-alert-hagens-berman-national-trial-attorneys-encourages-fate-therapeut-fate-20230321monthly0.5https://www.biopharmawatch.com/news/FATE/fate-6-day-deadline-alert-hagens-berman-encourages-fate-therapeutics-fate-investors-with-1-fate-20230316monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-inc-please-contact-the-portnoy-law-firm-to-recover-your-losses-march-22--fate-20230310monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-inc-fate-lead-deadline-approaching-contact-robbins-llp-for-information-r-fate-20230307monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-upcoming-march-investor-conferences-fate-20230303monthly0.5https://www.biopharmawatch.com/news/FATE/fate-shareholder-notice-hagens-berman-national-trial-attorneys-encourages-fate-therapeutic-fate-20230227monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-inc-investors-company-investigated-by-the-portnoy-law-firm-fate-20230227monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-inc-fate-class-action-contact-robbins-llp-for-information-regarding-the--fate-20230215monthly0.5https://www.biopharmawatch.com/news/FATE/fate-investor-alert-hagens-berman-national-trial-attorneys-encourages-fate-therapeutics-fa-fate-20230213monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-fourth-quarter-and-full-year-2022-f-fate-20230213monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-inc-fate-class-action-alert-contact-robbins-llp-for-information-regardin-fate-20230209monthly0.5https://www.biopharmawatch.com/news/FATE/fate-investor-alert-robbins-geller-rudman-dowd-llp-announces-that-fate-therapeutics-inc-in-fate-20230201monthly0.5https://www.biopharmawatch.com/news/FATE/fate-class-action-hagens-berman-national-trial-attorneys-encourages-fate-therapeutics-inc--fate-20230130monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-inc-fate-shareholder-notice-robbins-llp-reminds-investors-of-class-actio-fate-20230127monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-inc-please-contact-the-portnoy-law-firm-to-recover-your-losses-march-22--fate-20230125monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-inc-investors-company-investigated-by-the-portnoy-law-firm-fate-20230122monthly0.5https://www.biopharmawatch.com/news/FATE/fate-investor-alert-hagens-berman-national-trial-attorneys-encourages-fate-therapeutics-in-fate-20230118monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-shareholder-investigation-submit-your-losses-to-johnson-fistel-fate-20230106monthly0.5https://www.biopharmawatch.com/news/FATE/fate-alert-monsey-law-firm-of-wohl-fruchter-llp-investigating-potential-securities-claims--fate-20230106monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-features-multiple-novel-approaches-to-eliminate-conditioning-chemotherap-fate-20221213monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-highlights-ipsc-derived-off-the-shelf-car-nk-cell-programs-for-multiple--fate-20221210monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-clinical-safety-and-activity-data-of-first-ever-ipsc-derived-c-fate-20221210monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-upcoming-investor-conferences-fate-20221104monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-clinical-and-preclinical-data-for-ipsc-product-platform-at-th-fate-20221103monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-third-quarter-2022-financial-result-fate-20221024monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-clinical-and-preclinical-data-for-ipsc-product-platform-at-th-fate-20221005monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-participate-at-upcoming-september-investor-conferences-fate-20220902monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-second-quarter-2022-financial-resul-fate-20220725monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-appoints-brian-t-powl-as-chief-commercial-officer-fate-20220630monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-the-2022-jefferies-global-healthcare-conference-fate-20220603monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-upcoming-may-investor-conferences-fate-20220506monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-first-quarter-2022-financial-result-fate-20220422monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-upcoming-march-investor-conferences-fate-20220302monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-fourth-quarter-and-full-year-2021-f-fate-20220216monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-upcoming-february-investor-conferences-fate-20220202monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-fda-clearance-for-ft536-a-first-in-class-mica-b-targeted-car-n-fate-20220110monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-showcases-positive-interim-phase-1-data-from-ft596-off-the-shelf-ipsc-de-fate-20211213monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-host-virtual-event-at-the-2021-ash-annual-meeting-fate-20211208monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-upcoming-investor-conferences-fate-20211111monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-abstract-highlighting-ft538-and-ft573-programs-selected-for-pr-fate-20211109monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-eight-presentations-at-the-2021-ash-annual-meeting-fate-20211104monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-third-quarter-2021-financial-result-fate-20211025monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-presentations-at-the-society-for-immunotherapy-of-cancer-2021--fate-20211001monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-publication-of-ft538-preclinical-data-demonstrating-enhanced-s-fate-20210915monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-upcoming-investor-conferences-fate-20210902monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-positive-interim-clinical-data-from-its-ft596-and-ft516-off-th-fate-20210819monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-treatment-of-first-patient-in-landmark-phase-1-clinical-trial--fate-20210802monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-host-virtual-event-highlighting-interim-phase-1-clinical-data-from-it-fate-20210716monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-second-quarter-2021-financial-resul-fate-20210715monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-appoints-mark-plavsic-dvm-phd-rac-as-chief-technical-officer-fate-20210615monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-highlights-positive-interim-data-from-its-phase-1-study-of-ft516-in-comb-fate-20210604monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-upcoming-investor-conferences-fate-20210525monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-encouraging-interim-phase-1-data-for-ipsc-derived-nk-cell-prog-fate-20210513monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-first-quarter-2021-financial-result-fate-20210429monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-four-presentations-at-the-2021-asgct-annual-meeting-fate-20210427monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-upcoming-investor-conferences-fate-20210308monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-the-10th-annual-svb-leerink-global-healthcare-conference-fate-20210222monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-fourth-quarter-and-full-year-2020-f-fate-20210219monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-completion-of-public-offering-of-common-stock-and-pre-funded-w-fate-20210108monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-pricing-of-public-offering-of-common-stock-and-pre-funded-warr-fate-20210106monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-presents-patient-case-study-demonstrating-clinical-activity-of-ft596-in--fate-20201206monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-positive-interim-data-from-its-phase-1-study-of-ft516-in-combina-fate-20201204monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-host-virtual-event-at-the-2020-ash-annual-meeting-fate-20201130monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-participation-in-upcoming-investor-conferences-fate-20201112monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-twelve-presentations-at-the-2020-ash-annual-meeting-fate-20201105monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-third-quarter-2020-financial-result-fate-20201102monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-presentations-at-the-2020-society-for-immunotherapy-of-cancer--fate-20201015monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-jefferies-cell-therapy-virtual-summit-fate-20200930monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-september-investor-events-fate-20200904monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-the-wedbush-pacgrow-healthcare-virtual-conference-fate-20200804monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-second-quarter-2020-financial-resul-fate-20200729monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-exclusive-license-agreement-with-baylor-college-of-medicine-fo-fate-20200714monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-fda-clearance-of-ind-application-for-first-ever-ipsc-derived-c-fate-20200709monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-completion-of-public-offering-of-common-stock-and-full-exercis-fate-20200611monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-pricing-of-public-offering-of-common-stock-fate-20200609monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-fda-clearance-of-ind-application-for-ft538-first-crispr-edited-fate-20200520monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-first-quarter-2020-financial-result-fate-20200504monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-preclinical-data-presentation-of-novel-car-mica-b-cell-based-c-fate-20200428monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-first-patient-treated-in-first-in-human-clinical-trial-of-ft59-fate-20200402monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-fourth-quarter-and-full-year-2019-f-fate-20200226monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-upcoming-investor-conferences-fate-20200207monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-expansion-of-ft516-clinical-investigation-and-publication-of-p-fate-20200113monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-presents-its-first-off-the-shelf-ipsc-derived-car-t-cell-cancer-immunoth-fate-20191210monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-new-preclinical-data-for-ft596-off-the-shelf-ipsc-derived-car--fate-20191208monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-clinical-data-from-landmark-phase-1-studies-of-first-ever-univ-fate-20191207monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-the-31st-annual-piper-jaffray-healthcare-conference-fate-20191127monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-the-jefferies-2019-london-healthcare-conference-fate-20191114monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-six-presentations-at-the-2019-ash-annual-meeting-fate-20191106monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-third-quarter-2019-financial-result-fate-20191029monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-the-opening-of-its-cgmp-manufacturing-facility-dedicated-to-ip-fate-20190930monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-completion-of-public-offering-of-common-stock-and-full-exercis-fate-20190918monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-pricing-of-public-offering-of-common-stock-fate-20190912monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-fda-clearance-of-ind-application-for-ft596-off-the-shelf-ipsc--fate-20190903monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-2019-wells-fargo-healthcare-conference-fate-20190829monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-issuance-of-foundational-u-s-patent-covering-ipsc-derived-car--fate-20190814monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-second-quarter-2019-financial-resul-fate-20190730monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-the-jefferies-2019-healthcare-conference-fate-20190530monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-first-quarter-2019-financial-result-fate-20190430monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-five-presentations-at-the-american-society-of-gene-cell-therap-fate-20190424monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-appoints-wayne-chu-m-d-as-vice-president-clinical-development-fate-20190418monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-first-patient-treated-with-ipsc-derived-nk-cell-cancer-immunot-fate-20190402monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-presents-late-breaking-preclinical-data-highlighting-unique-advantages-o-fate-20190401monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-fourth-quarter-and-full-year-2018-f-fate-20190228monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-the-8th-annual-svb-leerink-global-healthcare-conference-fate-20190222monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-appoints-sarah-cooley-m-d-m-s-as-senior-vice-president-clinical-translat-fate-20190220monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-guggenheim-healthcare-talks-idea-forum-oncology-day-fate-20190207monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-fda-clearance-of-ind-application-for-world-s-first-cell-therap-fate-20190206monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-presents-off-the-shelf-car-t-and-nk-cell-cancer-immunotherapy-pipeline-a-fate-20181204monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-secures-exclusive-option-to-novel-humanized-anti-bcma-car-constructs-for-fate-20181203monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-fda-clearance-of-landmark-ind-for-ft500-ipsc-derived-off-the-s-fate-20181130monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-encouraging-dose-escalation-clinical-data-of-fate-nk100-and-pr-fate-20181111monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-upcoming-investor-conferences-fate-20181108monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-seven-presentations-at-the-2018-ash-annual-meeting-fate-20181101monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-third-quarter-2018-financial-result-fate-20181029monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-appoints-wen-bo-wang-ph-d-as-senior-vice-president-technical-operations-fate-20181004monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-completion-of-public-offering-of-common-stock-and-full-exercis-fate-20180925monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-upcoming-investor-conferences-fate-20180925monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-pricing-of-public-offering-of-common-stock-fate-20180921monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-upcoming-investor-conferences-fate-20180829monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-the-2018-wedbush-pacgrow-healthcare-conference-fate-20180807monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-second-quarter-2018-financial-resul-fate-20180730monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-the-jefferies-2018-global-healthcare-conference-fate-20180601monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-first-quarter-2018-financial-result-fate-20180503monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-the-deutsche-bank-43rd-annual-health-care-conference-fate-20180502monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-off-the-shelf-car-t-cell-cancer-immunotherapy-to-be-featured-a-fate-20180416monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-initial-clinical-data-of-fate-nk100-for-recurrent-ovarian-canc-fate-20180329monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-additional-clinical-data-from-phase-1-stage-of-protect-clinica-fate-20180319monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-fourth-quarter-and-full-year-2017-f-fate-20180227monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-receipt-of-cirm-grant-for-clinical-translation-of-ft516-off-th-fate-20180223monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-first-subject-treated-with-fate-nk100-in-dimension-study-for-a-fate-20180220monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-the-leerink-partners-7th-annual-global-healthcare-conferen-fate-20180212monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-completion-of-public-offering-of-common-stock-and-full-exercis-fate-20171215monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-pricing-of-public-offering-of-common-stock-fate-20171213monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-day-100-clinical-results-from-phase-1-stage-of-protect-trial-o-fate-20171211monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-successful-completion-of-technology-transfer-and-initiation-of-fate-20171211monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-first-subject-treated-with-fate-nk100-in-apollo-study-for-recu-fate-20171208monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-and-university-of-california-san-diego-launch-research-collaboration-to--fate-20171206monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-the-2017-piper-jaffray-healthcare-conference-fate-20171121monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-initial-clinical-data-from-ongoing-first-in-human-voyage-study-fate-20171110monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-six-presentations-at-the-2017-ash-annual-meeting-fate-20171101monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-third-quarter-2017-financial-result-fate-20171025monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-initiates-phase-2-protect-study-of-protmune-for-prevention-of-acute-graf-fate-20170918monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-appoints-jim-beitel-as-senior-vice-president-corporate-development-fate-20170914monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-upcoming-investor-conferences-fate-20170901monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-issuance-of-u-s-patent-covering-use-of-viral-transduction-enha-fate-20170816monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-the-2017-wedbush-pacgrow-healthcare-conference-fate-20170809monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-publication-of-preclinical-data-in-cancer-research-and-fda-cle-fate-20170808monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-second-quarter-2017-financial-resul-fate-20170807monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-fate-fate-20170510monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-first-quarter-2017-financial-result-fate-20170508monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-kick-off-2017-annual-meeting-of-international-society-for-stem-cell-r-fate-20170427monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-the-5th-annual-cell-gene-therapy-investor-day-fate-20170420monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-fate-fate-20170313monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-fourth-quarter-and-full-year-2016-f-fate-20170309monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-highlight-natural-killer-cell-programs-and-engineered-pluripotent-cel-fate-20170302monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-two-upcoming-conferences-in-march-fate-20170301monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-and-regents-of-the-university-of-minnesota-expand-research-collaboration-fate-20170227monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-the-leerink-partners-6th-annual-global-healthcare-conferen-fate-20170208monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-first-patient-treated-in-protmune-protect-clinical-trial-for-t-fate-20170105monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-private-financing-fate-20161122monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-oral-presentation-on-natural-killer-cell-product-candidate-fat-fate-20161103monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-third-quarter-2016-financial-result-fate-20161031monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-issuance-of-u-s-patent-protecting-enhanced-hematopoietic-stem--fate-20161005monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-receives-fda-orphan-drug-designation-for-protmune-in-allogeneic-hematopo-fate-20160926monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-upcoming-investor-conferences-fate-20160831monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-the-2016-wedbush-pacgrow-healthcare-conference-fate-20160810monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-second-quarter-2016-financial-resul-fate-20160802monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-issuance-of-u-s-patent-on-compositions-of-human-induced-plurip-fate-20160726monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-fda-fast-track-designation-for-protmune-fate-20160620monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-host-off-the-shelf-cancer-immunotherapy-focus-session-at-2016-annual--fate-20160616monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-preclinical-data-from-immuno-regulatory-cd34-cell-therapy-for--fate-20160611monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-appoints-chris-m-storgard-m-d-as-chief-medical-officer-fate-20160517monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-preclinical-data-highlighting-persistent-effector-function-of--fate-20160516monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-first-quarter-2016-financial-result-fate-20160502monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-the-needham-company-15th-annual-healthcare-conference-fate-20160405monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-fourth-quarter-and-full-year-2015-f-fate-20160225monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-preclinical-data-for-protmune-at-2016-bmt-tandem-meetings-fate-20160221monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-leerink-partners-5th-annual-global-healthcare-conference-fate-20160203monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-prot-fate-20160126monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-biotech-showcase-2016-fate-20160106monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-provides-update-on-adoptive-immunotherapy-programs-for-hematopoietic-cel-fate-20151207monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-oppenheimer-co-26th-annual-healthcare-conference-fate-20151203monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-strategy-for-the-development-of-off-the-shelf-cancer-immunoth-fate-20151105monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-preclinical-data-for-protmune-tm-at-ash-2015-annual-meeting-fate-20151105monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-third-quarter-2015-financial-result-fate-20151029monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-strengthens-intellectual-property-position-with-new-u-s-patent-covering--fate-20151028monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-leadership-transition-fate-20151012monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-september-investor-conferences-fate-20150902monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-upcoming-investor-conferences-fate-20150806monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-second-quarter-2015-financial-resul-fate-20150729monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-appoints-dr-stewart-abbot-as-vice-president-translational-research-fate-20150715monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-and-regents-of-the-university-of-minnesota-enter-into-research-collabora-fate-20150714monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-enters-into-sponsored-research-agreement-with-boston-children-s-hospital-fate-20150605monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-completion-of-public-offering-of-common-stock-and-full-exercis-fate-20150527monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-pricing-of-public-offering-of-common-stock-fate-20150521monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-first-quarter-2015-financial-result-fate-20150504monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-deutsche-bank-40th-annual-health-care-conference-fate-20150429monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-14th-annual-needham-healthcare-conference-fate-20150408monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-the-regen-med-investor-day-fate-20150318monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-fourth-quarter-and-full-year-2014-f-fate-20150305monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-expands-and-strengthens-leadership-team-fate-20150303monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-cowen-company-35th-annual-health-care-conference-fate-20150225monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-the-2015-leerink-global-healthcare-conference-fate-20150205monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-key-2015-objectives-for-the-advancement-of-programmed-cellular-fate-20150112monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-biotech-showcase-2015-fate-20150106monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-highlights-effects-of-nutrient-rich-media-on-ex-vivo-programmed-cd34-cel-fate-20141208monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-unveils-preclinical-findings-of-newly-identified-small-molecule-modulato-fate-20141206monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-piper-jaffray-26th-annual-healthcare-conference-fate-20141125monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-third-quarter-2014-financial-result-fate-20141104monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-nomura-biotechnology-conference-fate-20141030monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-rodman-renshaw-16th-annual-global-investment-conference-fate-20140903monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-second-quarter-2014-financial-resul-fate-20140805monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-secures-up-to-20-million-in-debt-financing-fate-20140731monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-fda-clearance-of-ind-for-clinical-development-of-prohema-in-in-fate-20140729monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-submits-ind-application-for-the-clinical-development-of-prohema-r-in-inh-fate-20140630monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-highlight-potential-clinical-applications-of-ex-vivo-hematopoietic-ce-fate-20140605monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-jefferies-2014-global-healthcare-conference-fate-20140528monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-first-quarter-2014-financial-result-fate-20140506monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-deutsche-bank-39th-annual-health-care-conference-fate-20140430monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-fda-clearance-of-ind-amendment-for-clinical-development-of-pro-fate-20140423monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-secures-u-s-patent-for-class-of-small-molecule-modulators-key-to-the-dev-fate-20140410monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-commences-phase-2-clinical-trial-of-prohema-r-for-the-treatment-of-hemat-fate-20140312monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-fourth-quarter-and-full-year-2013-f-fate-20140311monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-publication-of-its-proprietary-stem-cell-modulation-platform-f-fate-20140306monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-observes-rare-disease-day-2014-fate-20140228monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-upcoming-march-conferences-fate-20140227monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-observed-effects-of-pharmacologic-modulation-on-t-cell-compart-fate-20140226monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-webcast-conference-call-reporting-third-quarter-2013-financial-result-fate-20131106monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-announces-closing-of-initial-public-offering-and-exercise-of-option-to-p-fate-20131004monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-world-muscle-society-congress-fate-20131002monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-inc-announces-pricing-of-initial-public-offering-fate-20131001monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-files-registration-statement-for-proposed-initial-public-offering-fate-20130814monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-presents-preclinical-efficacy-data-for-wnt7a-analog-program-at-muscular--fate-20130422monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-cowen-co-33rd-annual-health-care-conference-fate-20130225monthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-to-present-at-15th-annual-bio-ceo-investor-conference-fate-20130207monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-highlights-new-scientific-findings-on-shared-biology-between-autism-a-avxl-20260414monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-provides-comprehensive-regulatory-update-avxl-20260330monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-presents-new-data-from-its-ad-004-phase-iib-iii-trial-at-ad-pd-2026-c-avxl-20260323monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-presents-significant-treatment-effects-of-blarcamesine-in-new-advance-avxl-20260317monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-appoints-senior-vice-president-global-head-of-neurology-avxl-20260108monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-receives-fda-feedback-on-alzheimer-s-disease-program-avxl-20260106monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-submitted-request-for-ema-to-re-examine-its-opinion-avxl-20251218monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-provides-update-on-regulatory-review-in-the-eu-for-blarcamesine-to-tr-avxl-20251212monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-avxl-20251119monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2025-fourth-quarter-financial-results-on-tuesday-n-avxl-20251118monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2025-third-quarter-financial-results-on-tuesday-au-avxl-20250805monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-positive-precision-medicine-results-from-up-to-4-years-of-o-avxl-20250731monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-shareholder-alert-kaskela-law-llc-announces-investigation-of-anavex-life-sciences-c-avxl-20250616monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-participate-at-upcoming-healthcare-conferences-avxl-20250514monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-2025-second-quarter-financial-results-and-provides-bus-avxl-20250513monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2025-second-quarter-financial-results-on-tuesday-m-avxl-20250506monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-full-enrollment-of-phase-2-study-of-anavex-3-71-for-the-tre-avxl-20250501monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-participate-in-the-citizens-life-sciences-conference-avxl-20250430monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-appointment-of-dr-audrey-gabelle-md-phd-to-the-scientific-a-avxl-20250423monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimer-s-avxl-20250421monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-positive-up-to-4-years-oral-blarcamesine-results-from-phase-avxl-20250405monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-24th-annual-needham-virtual-healthcare-conference-avxl-20250331monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-45th-annual-td-cowen-health-care-conference-avxl-20250224monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-2025-first-quarter-financial-results-and-provides-busi-avxl-20250212monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2025-first-quarter-financial-results-on-wednesday--avxl-20250205monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-issuance-of-blarcamesine-anavex-2-73-composition-of-matter--avxl-20250127monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-peer-reviewed-publication-of-oral-blarcamesine-phase-iib-ii-avxl-20250115monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-avxl-20250106monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-2024-fourth-quarter-financial-results-and-provides-bus-avxl-20241223monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2024-fourth-quarter-financial-results-on-monday-de-avxl-20241216monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-report-new-long-term-oral-blarcamesine-phase-iib-iii-alzheimer-s-d-avxl-20241209monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-7th-annual-evercore-isi-healthconx-conference-2024-avxl-20241202monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-submission-of-blarcamesine-maa-for-treatment-of-alzheimer-s-avxl-20241126monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-acceptance-of-peer-reviewed-manuscript-of-oral-blarcamesine-avxl-20241125monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-s-blarcamesine-achieves-pre-specified-efficacy-in-phase-iib-iii-alzheimer-s-trial-d-avxl-20241031monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-encouraging-preliminary-biomarker-results-from-ongoing-phas-avxl-20241017monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-h-c-wainwright-26th-annual-global-investment-confer-avxl-20240903monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-2024-third-quarter-financial-results-and-provides-busi-avxl-20240806monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2024-third-quarter-financial-results-on-tuesday-au-avxl-20240801monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-translational-biomarker-data-for-anavex-2-73-blarcamesine-i-avxl-20240730monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-h-c-wainwright-5th-annual-neuro-perspectives-virtua-avxl-20240620monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-expansion-of-leadership-team-avxl-20240522monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-h-c-wainwright-2nd-bioconnect-investor-conference-a-avxl-20240514monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-corporation-securities-fraud-class-action-lawsuit-pending-contact-lev-avxl-20240510monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-bee-avxl-20240509monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-corporation-securities-fraud-class-action-lawsuit-pending-contact-lev-avxl-20240507monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2024-second-quarter-financial-results-on-thursday--avxl-20240502monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses--avxl-20240501monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-corporation-nasdaq-avxl-deadline-alert-bernstein-liebhard-llp-reminds-avxl-20240429monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-corporation-nasdaq-avxl-deadline-alert-bernstein-liebhard-llp-reminds-avxl-20240422monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-corporation-nasdaq-avxl-deadline-alert-bernstein-liebhard-llp-reminds-avxl-20240415monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-noble-capital-markets-virtual-healthcare-equity-con-avxl-20240411monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-corporation-nasdaq-avxl-deadline-alert-bernstein-liebhard-llp-reminds-avxl-20240401monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-corporation-sued-for-securities-law-violations-contact-the-gross-law--avxl-20240327monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-corporation-nasdaq-avxl-deadline-alert-bernstein-liebhard-llp-reminds-avxl-20240325monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-23rd-annual-needham-virtual-healthcare-conference-avxl-20240325monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses--avxl-20240318monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-corporation-nasdaq-avxl-deadline-alert-bernstein-liebhard-llp-reminds-avxl-20240318monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-initiates-placebo-controlled-u-s-phase-2-clinical-trial-of-anavex-3-7-avxl-20240318monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed--avxl-20240315monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-corporation-shareholder-alert-bernstein-liebhard-llp-announces-that-a-avxl-20240314monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-investigated-by-block-leviton-for-potential-securities-law-violations-avxl-20240304monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-44th-annual-td-cowen-health-care-conference-avxl-20240226monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-2024-first-quarter-financial-results-and-provides-busi-avxl-20240207monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2024-first-quarter-financial-results-on-wednesday--avxl-20240201monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-publication-of-anavex-3-71-in-clinical-journal-confirming-pha-avxl-20240124monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-u-s-phase-2-clinical-trial-of-anavex-3-71-in-schizophrenia-avxl-20240116monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-investigated-by-block-leviton-for-potential-securities-law-violations-avxl-20240112monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-grant-of-u-s-patent-covering-blarcamesine-anavex-2-73-for-t-avxl-20240108monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-investigated-by-block-leviton-for-potential-securities-law-violations-avxl-20240103monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-avxl-20240103monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-provides-an-update-on-rett-syndrome-program-avxl-20240102monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-first-entire-clinical-gene-pathway-data-of-anavex-2-73-from-avatar-study--avxl-20231220monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-received-agreement-from-the-committee-for-medicinal-products-for-human-use-chmp-for-avxl-20231219monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-2023-year-end-financial-results-and-provides-business--avxl-20231127monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2023-year-end-financial-results-on-monday-november-avxl-20231124monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-grant-of-u-s-patent-covering-blarcamesine-anavex-2-73-for-t-avxl-20231122monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-initiates-regulatory-submission-of-oral-blarcamesine-for-alzheimer-s-disease-to-eur-avxl-20231120monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-appoints-senior-vp-of-regulatory-affairs-avxl-20231106monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-new-publication-in-scientific-journal-demonstrating-the-poten-avxl-20231025monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-s-phase-2b-3-trial-of-blarcamesine-anavex-2-73-in-patients-with-alzheimer-s-disease-avxl-20230914monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-appointment-of-dr-marwan-n-sabbagh-md-as-chairman-of-the-scientific-advis-avxl-20230912monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-2023-third-quarter-financial-results-avxl-20230808monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-publication-of-anavex-3-71-in-clinical-journal-confirming-ana-avxl-20230807monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-btig-virtual-biotechnology-conference-2023-avxl-20230802monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2023-third-quarter-financial-results-on-tuesday-au-avxl-20230801monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-and-partex-group-announce-strategic-partnership-to-leverage-ai-for-dr-avxl-20230627monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-h-c-wainwright-4th-annual-neuropsychiatry-virtual-c-avxl-20230620monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-2-73-blarcamesine-receives-compassionate-use-authorization-for-pediatric-patients-w-avxl-20230615monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-publication-in-medical-journal-signifying-continued-commitmen-avxl-20230612monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-completion-of-anavex-2-73-blarcamesine-excellence-phase-2-3-avxl-20230606monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-issuance-of-new-u-s-intellectual-property-compositions-patent-for-anavex--avxl-20230601monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-2023-second-quarter-financial-results-avxl-20230509monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2023-second-quarter-financial-results-on-tuesday-m-avxl-20230502monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-issuance-of-new-u-s-patent-expanding-anavex-2-73-blarcamesi-avxl-20230501monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-na-avxl-20230425monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference-2-avxl-20230410monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-2-73-blarcamesine-shows-clinical-benefit-in-long-term-48-week-phase-2-extension-stu-avxl-20230330monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-appoints-former-fda-lead-neurology-statistician-as-vice-president-hea-avxl-20230309monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-2023-first-quarter-financial-results-avxl-20230207monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-exceeding-of-enrollment-target-for-the-anavex-2-73-blarcame-avxl-20230202monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2023-first-quarter-financial-results-on-tuesday-fe-avxl-20230131monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-strengthens-scientific-advisory-board-with-investigator-from-phase-2b-3-alzheimer-s-avxl-20221214monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-avxl-20221212monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-management-webcast-and-conference-call-on-monday-december-avxl-20221202monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-2022-year-end-financial-results-and-provides-business--avxl-20221128monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2022-year-end-financial-results-on-monday-november-avxl-20221123monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-guggenheim-4th-annual-immunology-and-neurology-conf-avxl-20221108monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-u-s-fda-orphan-drug-designation-to-anavex-2-73-blarcamesine-for-the-treat-avxl-20221107monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-late-breaking-presentation-of-phase-2b-3-data-of-oral-anave-avxl-20221017monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-issuance-of-u-s-patent-covering-anavex-2-73-blarcamesine-fo-avxl-20220921monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-new-publication-in-medical-journal-highlighting-the-relevance-avxl-20220823monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-provides-business-update-and-reports-fiscal-2022-third-quarter-financ-avxl-20220809monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2022-third-quarter-financial-results-on-tuesday-au-avxl-20220803monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-long-lasting-effect-of-anavex-3-71-preventing-cognitive-decline-in-a-tran-avxl-20220802monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-first-entire-clinical-alzheimer-s-gene-pathway-data-of-anavex-2-73-at-aai-avxl-20220731monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-its-very-first-scientific-educational-video-news-release-avxl-20220621monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-s-publication-supports-clinical-biomarker-for-anavex-2-73-in-fragile-x-syndrome-avxl-20220608monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-h-c-wainwright-global-investment-conference-2022-avxl-20220519monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-provides-business-update-and-reports-fiscal-2022-second-quarter-finan-avxl-20220510monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2022-second-quarter-financial-results-on-tuesday-m-avxl-20220503monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-presentations-at-the-irsf-rett-syndrome-scientific-meeting-avxl-20220427monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-invited-to-present-at-the-b-riley-securities-2022-virtual-neuro-ophth-avxl-20220426monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-needham-virtual-healthcare-conference-avxl-20220407monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-participate-in-the-cantor-virtual-rare-orphan-disease-summit-avxl-20220328monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-presentation-of-phase-2-clinical-biomarker-data-from-anavex-avxl-20220315monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-participate-in-the-annual-needham-virtual-neuroscience-forum-avxl-20220309monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-11th-annual-svb-leerink-global-healthcare-conferenc-avxl-20220210monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-provides-business-update-and-reports-fiscal-2022-first-quarter-financ-avxl-20220209monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2022-first-quarter-financial-results-on-wednesday--avxl-20220203monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-corp-investigated-by-block-leviton-for-potential-securities-law-viola-avxl-20220202monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-2-73-blarcamesine-avatar-phase-3-trial-met-primary-and-secondary-efficacy-endpoints-avxl-20220201monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-positive-results-from-phase-1-clinical-trial-of-anavex-3-71-avxl-20220110monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-promotes-walter-e-kaufmann-m-d-to-chief-scientific-officer-and-appoin-avxl-20220106monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-h-c-wainwright-virtual-bioconnect-2022-conference-avxl-20220105monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-40th-annual-j-p-morgan-healthcare-conference-avxl-20211214monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-4th-annual-evercore-isi-healthconx-conference-avxl-20211129monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-provides-business-update-and-reports-fiscal-2021-year-end-financial-r-avxl-20211124monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2021-year-end-financial-results-on-wednesday-novem-avxl-20211117monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-participation-at-upcoming-lausanne-viii-workshop-panel-buil-avxl-20211110monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-dawson-james-securities-6th-annual-conference-avxl-20211015monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-data-review-by-the-independent-data-safety-monitoring-board-f-avxl-20211013monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-participation-at-5th-pharma-pricing-reimbursement-market-ac-avxl-20210927monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-2021-cantor-virtual-global-healthcare-conference-avxl-20210920monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-confer-avxl-20210909monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-publication-of-foundational-data-for-anavex-2-73-blarcamesi-avxl-20210826monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-provides-business-update-and-reports-fiscal-2021-third-quarter-financ-avxl-20210812monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2021-third-quarter-financial-results-on-thursday-a-avxl-20210805monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-participate-in-the-btig-virtual-biotechnology-conference-2021-avxl-20210804monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-anavex-2-73-blarcamesine-improved-both-primary-cognitive-an-avxl-20210628monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-closing-of-50-million-registered-direct-offering-avxl-20210624monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-anavex-2-73-blarcamesine-biomarker-correlated-with-efficacy-avxl-20210621monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-new-publication-in-medical-journal-elucidating-the-mechanism--avxl-20210614monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-exceeding-of-enrollment-target-for-the-precision-medicine-a-avxl-20210608monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-notice-of-allowance-for-u-s-patent-application-anavex-2-73--avxl-20210603monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-appointment-of-ms-jiong-ma-phd-to-board-of-directors-avxl-20210526monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-2021-second-quarter-financial-results-and-business-out-avxl-20210513monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summi-avxl-20210507monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2021-second-quarter-financial-results-and-business-avxl-20210506monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-appoints-former-fda-officer-as-senior-vice-president-for-nonclinical--avxl-20210505monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-b-riley-securities-virtual-neuroscience-conference-avxl-20210426monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-the-results-of-review-by-the-independent-data-safety-monitori-avxl-20210412monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-20th-annual-needham-virtual-healthcare-conference-avxl-20210408monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-participation-at-upcoming-world-epa-evidence-pricing-and-ac-avxl-20210407monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-data-review-by-the-independent-data-safety-monitoring-board-f-avxl-20210331monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-anavex-2-73-blarcamesine-featured-as-a-disease-modifying-smal-avxl-20210316monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-h-c-wainwright-global-life-sciences-conference-avxl-20210304monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-participation-at-upcoming-worldwide-national-institutes-of--avxl-20210222monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-participation-at-precision-in-clinical-trials-virtual-summi-avxl-20210219monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-10th-annual-svb-leerink-global-healthcare-conferenc-avxl-20210218monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-2021-first-quarter-financial-results-and-business-outl-avxl-20210211monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2021-first-quarter-financial-results-and-business--avxl-20210208monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-receives-michael-j-fox-foundation-grant-for-clinical-study-of-anavex--avxl-20210111monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference-avxl-20210106monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2020-year-end-financial-results-december-28th-2020-avxl-20201222monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-webinar-on-rett-syndrome-and-anavex-2-73-blarcamesine-phase-avxl-20201221monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-anavex-2-73-blarcamesine-meets-primary-and-secondary-endpoi-avxl-20201215monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-notice-of-allowance-for-u-s-patent-application-with-expandi-avxl-20201130monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference-avxl-20201125monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-completion-of-anavex-2-73-blarcamesine-u-s-phase-2-rett-syn-avxl-20200910monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-upcoming-global-healthcare-conferences-avxl-20200908monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-commitment-for-financial-investment-by-shake-it-up-foundati-avxl-20200819monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-2020-third-quarter-financial-results-and-provides-busi-avxl-20200806monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-receives-tga-special-access-scheme-approval-for-anavex-2-73-blarcames-avxl-20200805monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2020-third-quarter-financial-results-on-thursday-a-avxl-20200804monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-first-participant-enrolled-in-phase-1-study-of-anavex-3-71--avxl-20200706monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-first-patient-dosed-in-excellence-phase-2-3-clinical-trial--avxl-20200701monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-exceeding-of-enrollment-target-for-the-anavex-2-73-blarcame-avxl-20200616monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-receives-regulatory-approval-from-health-canada-and-uk-mhra-expanding-avxl-20200604monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-initiation-of-first-in-human-phase-1-study-of-anavex-3-71-a-avxl-20200521monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-2020-second-quarter-financial-results-and-provides-bus-avxl-20200507monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2020-second-quarter-financial-results-on-thursday--avxl-20200505monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-publication-of-clinical-data-for-anavex-2-73-blarcamesine-i-avxl-20200423monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-provides-update-on-clinical-program-development-as-response-to-covid--avxl-20200331monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-webcast-2020-annual-meeting-of-shareholders-avxl-20200323monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-publication-of-foundational-data-for-anavex-2-73-blarcamesi-avxl-20200224monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-2020-first-quarter-financial-results-and-provides-clin-avxl-20200206monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-and-participate-in-a-panel-at-the-2020-bio-ceo-investor-co-avxl-20200204monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-fast-track-designation-granted-by-u-s-fda-for-anavex-2-73-b-avxl-20200203monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2020-first-quarter-financial-results-on-thursday-f-avxl-20200130monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-achievement-of-enrollment-target-for-the-anavex-2-73-blarca-avxl-20200127monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-issued-new-u-s-patent-for-anavex-2-73-treatment-of-neurodevelopmental-avxl-20200108monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-year-2019-financial-results-and-provides-clinical-stud-avxl-20191216monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2019-year-end-financial-results-on-monday-december-avxl-20191210monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-presents-anavex-2-73-blarcamesine-data-at-12th-clinical-trials-on-alz-avxl-20191204monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-receives-rare-pediatric-disease-designation-from-fda-for-anavex-2-73--avxl-20191114monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-publication-of-foundational-data-for-anavex-2-73-blarcamesi-avxl-20191106monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-attention-ad-anavex-2-73-extension-clinical-study-in-early--avxl-20191009monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-issued-new-u-s-patent-for-composition-of-matter-covering-anavex-2-73--avxl-20191002monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-presented-at-the-6th-annual-european-rett-syndrome-conference-prelimi-avxl-20190927monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-2019-cantor-fitzgerald-global-healthcare-conference-avxl-20190926monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-ladenburg-thalmann-2019-healthcare-conference-avxl-20190918monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-preliminary-clinical-efficacy-data-of-its-u-s-phase-2-clini-avxl-20190916monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-janney-healthcare-conference-2019-avxl-20190905monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-initiation-of-the-excellence-anavex-2-73-rs-003-clinical-st-avxl-20190904monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-2019-third-quarter-financial-results-and-provides-clin-avxl-20190807monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2019-third-quarter-financial-results-on-wednesday--avxl-20190802monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-recent-data-review-by-the-independent-data-safety-monitoring--avxl-20190731monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-receives-positive-opinion-for-orphan-designation-from-the-european-me-avxl-20190729monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-presents-new-clinical-data-identifying-gut-microbiota-biomarkers-asso-avxl-20190717monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-first-patient-dosed-in-extension-study-to-its-u-s-phase-2-c-avxl-20190625monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-first-patient-dosed-in-phase-2-clinical-trial-of-anavex-2-7-avxl-20190606monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-2019-second-quarter-financial-results-and-provides-cli-avxl-20190508monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2019-second-quarter-financial-results-on-wednesday-avxl-20190506monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-h-c-wainwright-annual-global-life-sciences-conferen-avxl-20190405monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-presents-data-on-anavex-2-73-in-alzheimer-s-disease-at-the-american-s-avxl-20190328monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-first-patient-dosed-in-phase-2-clinical-trial-of-anavex-2-7-avxl-20190318monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-31st-annual-roth-conference-2019-avxl-20190313monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reaches-50-enrollment-threshold-in-anavex-2-73-parkinson-s-disease-de-avxl-20190311monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-cowen-39th-annual-health-care-conference-2019-avxl-20190306monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-publication-of-new-data-that-show-anavex-2-73-induces-cellula-avxl-20190304monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-2019-first-quarter-financial-results-and-provides-clin-avxl-20190207monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-2019-bio-ceo-investor-conference-avxl-20190204monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-2019-first-quarter-financial-results-on-thursday-f-avxl-20190131monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-the-appointment-of-walter-e-kaufmann-md-as-chief-medical-of-avxl-20190102monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-year-2018-financial-results-and-provides-clinical-stud-avxl-20181212monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-2018-fiscal-year-end-financial-results-on-wednesday-decem-avxl-20181210monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-strengthens-its-scientific-advisory-board-with-distinguished-research-avxl-20181108monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-presents-new-three-year-longitudinal-clinical-efficacy-data-for-anave-avxl-20181026monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-fda-approval-of-ind-for-phase-2-trial-of-anavex-2-73-in-pat-avxl-20181019monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-2018-cantor-fitzgerald-global-healthcare-conference-avxl-20180926monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-third-quarter-2018-financial-results-avxl-20180809monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-third-quarter-2018-financial-results-on-thursday-a-avxl-20180807monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-presents-new-data-identifying-treatment-response-biomarkers-in-alzhei-avxl-20180725monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-receives-approval-to-initiate-phase-2-clinical-trial-of-anavex-2-73-f-avxl-20180709monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-receives-approval-to-initiate-phase-2b-3-clinical-trial-of-anavex-2-7-avxl-20180703monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-second-quarter-2018-financial-results-avxl-20180510monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-second-quarter-2018-financial-results-on-thursday--avxl-20180509monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-initiate-phase-2-study-of-anavex-2-73-in-parkinson-s-disease-demen-avxl-20180417monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-30th-annual-roth-conference-avxl-20180309monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-new-preclinical-data-at-the-20th-annual-meeting-of-the-ame-avxl-20180307monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-cowen-and-company-38th-annual-health-care-conference-avxl-20180306monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-2018-bio-ceo-investor-conference-avxl-20180208monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-provides-clinical-programs-update-and-reports-fiscal-first-quarter-20-avxl-20180207monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-announce-fiscal-first-quarter-2018-financial-results-and-provide-a-avxl-20180205monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-noble-capital-markets-14th-annual-institutional-inv-avxl-20180124monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-potential-normalization-of-hypertension-with-anavex-2-73-publ-avxl-20180116monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-2017-financial-results-and-provides-update-on-therapeu-avxl-20171211monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-newly-published-data-on-alzheimer-s-disease-research-demonstr-avxl-20171121monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-5th-annual-mental-health-parity-addiction-equity-ac-avxl-20171108monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-presents-new-clinical-data-of-investigational-alzheimer-s-disease-tre-avxl-20171104monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-additional-data-at-the-michael-j-fox-foundation-s-parkinson-avxl-20171030monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-new-data-related-to-multiple-sclerosis-presented-at-7th-ect-avxl-20171027monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-pk-and-pd-data-from-phase-2a-trial-of-anavex-2-73-in-mild-to--avxl-20171012monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-ladenburg-thalmann-2017-healthcare-conference-avxl-20170921monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-issued-new-u-s-patent-for-composition-of-matter-covering-anavex-2-73-avxl-20170905monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-reports-fiscal-third-quarter-2017-financial-results-avxl-20170807monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-appoints-distinguished-researcher-in-neurology-and-epilepsy-to-scient-avxl-20170720monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-jefferies-2017-global-healthcare-conference-avxl-20170605monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-new-data-for-anavex-2-73-in-neurodevelopmental-disorders-incl-avxl-20170522monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-reports-fiscal-second-quarter-2017-financial-results-avxl-20170510monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-appoints-former-fda-officer-as-senior-vice-president-of-regulatory-af-avxl-20170501monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-new-mechanism-of-action-data-related-to-anavex-compounds-targ-avxl-20170403monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-dismissal-of-appeal-in-the-cortina-lawsuit-avxl-20170330monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-the-13th-international-conference-on-alzheimer-s-and-pa-avxl-20170329monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-oppenheimer-27th-annual-healthcare-conference-avxl-20170315monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-14th-annual-bio-asia-international-conference-avxl-20170313monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-ceo-joins-bio-ceo-investor-conference-2017-panel-designing-clinical-t-avxl-20170209monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-reports-fiscal-first-quarter-2017-financial-results-avxl-20170207monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-noble-capital-markets-thirteenth-annual-investor-confer-avxl-20170123monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-receives-grant-from-rettsyndrome-org-to-commence-u-s-phase-2-trial-in-avxl-20170119monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-obtains-permanent-dismissal-of-all-claims-in-securities-lawsuit-avxl-20170103monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-reports-fiscal-2016-financial-results-conference-call-and-webcast-tod-avxl-20161212monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-12-month-data-of-anavex-2-73-in-a-phase-2a-study-in-mild-to-avxl-20161208monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-to-present-at-annual-mental-health-parity-addiction-equity-act-roundt-avxl-20161201monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-appoints-three-distinguished-researchers-to-scientific-advisory-board-avxl-20161128monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-announces-data-on-41-week-treatment-of-anavex-2-73-for-patients-with--avxl-20161122monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-novel-sigma-1-sigma-2-ligand-shows-encouraging-results-as-an-analgesi-avxl-20161114monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-and-ariana-pharma-collaborate-to-accelerate-timelines-and-improve-eff-avxl-20161005monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-compound-to-be-tested-in-biogen-neurological-protection-model-avxl-20160928monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-drug-shows-efficacy-to-support-potential-disease-modification-in-park-avxl-20160922monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-to-present-at-ladenburg-thalmann-2016-healthcare-conference-avxl-20160920monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-to-participate-in-mizuho-therapeutics-conference-avxl-20160914monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-reports-fiscal-third-quarter-2016-financial-results-avxl-20160811monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-confirms-data-from-phase-2a-study-of-anavex-2-73-in-alzheimer-s-patients-presented--avxl-20160729monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-presents-31-week-efficacy-data-from-phase-2a-study-of-anavex-2-73-in-alzheimer-s-pa-avxl-20160727monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-presents-31-week-safety-data-from-phase-2a-study-of-anavex-2-73-in-alzheimer-s-pati-avxl-20160724monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-to-present-at-the-alzheimer-s-association-international-conference-aaic-2016-avxl-20160712monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-to-present-at-the-2016-rett-syndrome-symposium-avxl-20160623monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-u-s-fda-orphan-drug-designation-for-anavex-2-73-for-treatment-of-infantil-avxl-20160622monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-positive-preclinical-results-with-anavex-2-73-in-fragile-x-autism-related-avxl-20160606monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-u-s-fda-orphan-drug-designation-to-anavex-2-73-for-the-treatment-of-rett--avxl-20160520monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-positive-preclinical-data-for-anavex-2-73-in-infantile-spasms-avxl-20160518monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-reports-fiscal-second-quarter-2016-financial-results-avxl-20160511monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-presents-new-data-on-preclinical-development-of-anavex-3-71-avxl-20160314monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-two-year-clinical-extension-study-of-anavex-2-73-and-presents-phase-2a-do-avxl-20160310monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-presents-preclinical-results-of-anavex-2-73-in-rett-syndrome-avxl-20160225monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-2-73-preclinical-data-in-new-indication-to-be-presented-at-actrims-2016-avxl-20160217monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-reports-fiscal-first-quarter-2016-financial-results-avxl-20160208monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-to-present-at-18th-annual-bio-ceo-investor-conference-on-february-9th-2016-avxl-20160202monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-positive-dose-response-data-for-anavex-2-73-in-alzheimer-s-disease-patien-avxl-20160111monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-issues-statement-addressing-recent-press-releases-by-law-firms-avxl-20160108monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-fiscal-2015-year-end-financial-results-avxl-20151229monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-to-present-at-third-annual-mhpaea-business-roundtable-in-washington-d-c-avxl-20151207monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-expands-management-team-avxl-20151202monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-executive-overseeing-regulatory-affairs-avxl-20151125monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-to-present-at-american-epilepsy-society-annual-meeting-anavex-2-73-demonstrates-ant-avxl-20151119monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-preparation-of-regulatory-filings-based-on-guidance-from-the-fda-avxl-20151118monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-confirms-data-for-phase-2a-alzheimer-s-trial-for-anavex-2-73-avxl-20151111monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-positive-primary-and-secondary-endpoints-were-achieved-in-a-phase-2a-clin-avxl-20151109monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-ctad-2015-abstract-avxl-20151105monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-corp-nasdaq-avxl-to-ring-the-nasdaq-stock-market-closing-bell-avxl-20151029monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-commences-trading-on-nasdaq-today-to-ring-friday-s-closing-bell-avxl-20151028monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-uplisting-to-nasdaq-avxl-20151026monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-to-present-at-4th-annual-oktoberinvestfest-conference-avxl-20151012monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-to-present-interim-phase-2a-clinical-trial-data-of-anavex-2-73-at-late-breaking-ora-avxl-20151007monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-prepares-for-uplisting-to-nasdaq-announces-reverse-stock-split-avxl-20151006monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-completes-patient-enrollment-for-phase-2a-alzheimer-s-trial-ahead-of-schedule-avxl-20150928monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-to-present-at-2015-ladenburg-thalmann-healthcare-conference-avxl-20150923monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-appoints-international-alzheimer-s-expert-to-scientific-advisory-board-avxl-20150921monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-reports-fiscal-third-quarter-2015-financial-results-avxl-20150817monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-receives-notice-of-allowance-for-u-s-patent-application-related-to-anavex-2-73-avxl-20150812monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-awarded-grant-from-the-michael-j-fox-foundation-for-parkinson-s-research-avxl-20150810monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-presents-positive-initial-phase-2a-study-data-with-anavex-2-73-showing-early-eviden-avxl-20150722monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-to-present-initial-clinical-data-from-the-phase-2a-clinical-trial-of-anavex-2-73-at-avxl-20150630monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-strengthens-board-of-directors-avxl-20150618monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-encouraged-by-data-showing-sigma-1-receptor-reduces-tau-dysfunction-a-hallmark-of-a-avxl-20150521monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-releases-promising-full-preclinical-epilepsy-data-at-antiepileptic-drug-trials-xiii-avxl-20150518monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-reports-fiscal-second-quarter-2015-financial-results-avxl-20150515monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-to-present-at-2015-marcum-conference-on-may-27th-avxl-20150513monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-to-present-on-sigma-1-receptors-at-the-world-orphan-drug-congress-and-to-reveal-new-avxl-20150423monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-encouraged-by-new-scientific-data-revealing-positive-role-of-sigma-1-receptors-in-b-avxl-20150407monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-presents-positive-results-for-both-anavex-2-73-and-anavex-3-71-in-alzheimer-s-model-avxl-20150323monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-to-participate-in-phase-3-clinical-trials-panel-at-ad-pd-2015-avxl-20150317monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-appoints-epilepsy-and-clinical-trial-methodology-expert-to-scientific-advisory-boar-avxl-20150312monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-to-present-at-sigma-1-receptors-symposium-avxl-20150310monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-appoints-scientific-advisory-board-member-with-expertise-in-protein-misfolding-neur-avxl-20150305monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-to-present-at-27th-annual-roth-conference-on-march-11th-avxl-20150303monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-2-73-could-prevent-alzheimer-s-disease-in-addition-to-modifying-and-treating-sympto-avxl-20150225monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-reports-fiscal-first-quarter-2015-financial-results-avxl-20150218monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-confirms-positive-preclinical-epilepsy-data-for-anavex-2-73-validation-as-potential-avxl-20150209monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-to-present-at-17th-annual-bio-ceo-investor-conference-on-february-10th-avxl-20150204monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-doses-first-alzheimer-s-patient-in-phase-2a-trial-of-anavex-2-73-and-anavex-plus-avxl-20150112monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-panel-discussion-and-presention-at-onemedforum-conference-avxl-20150108monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-encouraged-by-scientific-data-confirming-sigma-1-receptor-s-beneficial-direct-inter-avxl-20150106monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-fiscal-2014-fourth-quarter-and-year-end-financial-results-avxl-20141230monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-to-present-at-biotech-showcase-2015-in-san-francisco-avxl-20141218monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-begins-enrollment-of-alzheimer-s-patients-in-phase-2a-clinical-trial-of-anavex-2-73-avxl-20141216monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-upgrades-to-otcqx-marketplace-avxl-20141212monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-positive-phase-1-data-for-anavex-2-73-lead-candidate-for-the-treatment-of-avxl-20141117monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-to-present-full-phase-1-clinical-trial-data-for-anavex-2-73-at-cns-summit-2014-conf-avxl-20141110monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-to-present-at-seethruequity-investor-conference-in-new-york-city-avxl-20141106monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-receives-regulatory-approval-to-initiate-phase-2a-clinical-trial-of-anavex-2-73-and-avxl-20141103monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-supports-alzheimer-s-foundation-of-america-s-3rd-annual-concepts-in-care-educationa-avxl-20140908monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-to-present-at-rodman-renshaw-16th-annual-global-investment-conference-avxl-20140903monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-selects-the-alfred-hospital-in-melbourne-australia-as-lead-site-for-phase-2a-alzhei-avxl-20140826monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-reports-that-antidepressant-fluvoxamine-reduces-stress-through-sigma-1-receptor-avxl-20140819monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-reports-fiscal-third-quarter-2014-financial-results-avxl-20140813monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-appoints-experienced-pharma-executive-as-vice-president-of-clinical-operations-avxl-20140807monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-achieves-key-milestone-as-it-secures-cgmp-manufacturing-for-drug-candidate-trial-su-avxl-20140721monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-3-71-highly-effective-and-disease-modifying-against-all-major-alzheimer-s-hallmarks-avxl-20140714monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-report-expanding-opportunity-for-therapeutic-application-of-anavex-compou-avxl-20140630monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-awarded-new-u-s-patent-avxl-20140604monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-appoints-dr-abraham-fisher-to-scientific-advisory-board-avxl-20140528monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-reports-that-new-data-confirms-calcium-target-over-expression-may-be-involved-in-ca-avxl-20140522monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-provides-business-update-including-clinical-trial-plans-for-anavex-plus-in-alzheime-avxl-20140515monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-strengthens-scientific-advisory-board-with-clinical-trial-expert-avxl-20140512monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-appoints-senior-healthcare-and-pharmaceutical-executives-to-board-of-directors-avxl-20140508monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-encouraged-by-scientific-data-confirming-sigma-1-receptor-agonist-is-potentially-di-avxl-20140429monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-strengthens-alzheimer-s-pipeline-obtains-exclusive-worldwide-rights-to-intellectual-avxl-20140331monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-reports-predicted-clinical-effect-of-both-anavex-2-73-and-anavex-plus-in-a-humanize-avxl-20140327monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-successfully-closes-10-million-financing-to-initiate-phase-1b-2a-alzheimer-s-clinic-avxl-20140319monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-10-million-private-placement-of-convertible-debentures-avxl-20140313monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-encouraged-by-scientific-data-confirming-sigma-1-receptor-agonist-extends-survival--avxl-20140310monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-research-report-reveals-cardioprotective-action-of-sigma-1-receptor-agonists-avxl-20140304monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-to-present-at-16th-annual-bio-ceo-investor-conference-avxl-20140203monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-agreement-with-the-roskamp-institute-to-advance-the-clinical-development-of-anavex--avxl-20140113monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-ceo-invited-to-present-at-upcoming-investment-conferences-avxl-20140107monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-appoints-clinical-design-expert-to-scientific-advisory-board-avxl-20131210monthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-announces-appointment-of-oncology-specialist-to-board-of-directors-changes-to-execu-avxl-20080521monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-s-a-investigated-by-the-portnoy-law-firm-adct-20260423monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-contract-manufacturing-market-report-2026-7th-edition-commercial-scale-dominates-adc-m-adct-20260401monthly0.5https://www.biopharmawatch.com/news/ADCT/adcytherix-doses-first-patient-in-phase-1-trial-of-adcx-020-and-strengthens-leadership-to--adct-20260331monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-cytotoxic-payloads-and-warheads-industry-research-report-2026-2035-breakthrough-cancer-adct-20260303monthly0.5https://www.biopharmawatch.com/news/ADCT/adcytherix-powers-ahead-technology-and-team-in-place-to-deliver-strategy-and-build-an-adc--adct-20251117monthly0.5https://www.biopharmawatch.com/news/ADCT/adcytherix-raises-eur-105m-series-a-to-accelerate-breakthrough-antibody-drug-conjugate-pip-adct-20251016monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-innovator-myricx-bio-appoints-boston-based-mohit-rawat-as-ceo-and-expands-team-in-us-a-adct-20250922monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-contract-manufacturing-market-industry-trends-and-global-forecasts-to-2035-igg1-antibo-adct-20241202monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-adct-20240903monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-adct-20240801monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-host-second-quarter-2024-financial-results-conference-call-on-august-6-adct-20240730monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-adct-20240701monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-set-to-join-russell-2000-and-russell-3000-indexes-adct-20240627monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-contract-manufacturing-market-2035-surging-demand-for-antibody-drug-conjugates-driving-adct-20240620monthly0.5https://www.biopharmawatch.com/news/ADCT/adcytherix-launches-with-30m-in-seed-funding-to-develop-next-generation-antibody-drug-conj-adct-20240611monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-adct-20240603monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-adct-20240530monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-participate-in-the-h-c-wainwright-2nd-annual-bioconnect-investor-confe-adct-20240515monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-participate-in-2024-rbc-capital-markets-global-healthcare-conference-adct-20240509monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-105-million-underwritten-offering-of-common-shares-and-pre-fund-adct-20240506monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-reports-first-quarter-2024-financial-results-and-provides-business-update-adct-20240506monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-initial-data-from-investigator-initiated-phase-2-clinical-trial-adct-20240506monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-adct-20240501monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-host-first-quarter-2024-financial-results-and-pipeline-update-conferen-adct-20240501monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-updates-on-lotis-7-clinical-trial-evaluating-zynlonta-in-combin-adct-20240404monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-host-a-virtual-research-investor-event-on-tuesday-april-9-2024-adct-20240403monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-adct-20240401monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides--adct-20240313monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-participate-in-the-guggenheim-5th-annual-healthy-altitudes-summit-adct-20240306monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-host-fourth-quarter-and-year-end-2023-financial-results-conference-cal-adct-20240306monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-abstracts-accepted-for-presentation-at-the-american-association-adct-20240305monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-contract-manufacturing-market-projected-to-reach-usd-27-4-billion-by-2030-growing-at-a-adct-20240305monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-participate-in-the-td-cowen-44th-annual-health-care-conference-adct-20240227monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-regains-compliance-with-nyse-continued-listing-standards-adct-20240104monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-provides-business-updates-adct-20240104monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-initial-results-from-investigator-initiated-phase-2-clinical-tr-adct-20231212monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-participate-in-the-jefferies-london-healthcare-conference-adct-20231106monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-abstracts-accepted-for-presentation-at-the-65th-ash-annual-meet-adct-20231102monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-host-third-quarter-2023-financial-results-conference-call-on-november--adct-20231024monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-participate-in-september-investor-conferences-adct-20230905monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-updates-on-zynlonta-lotis-clinical-trial-programs-at-the-eleven-adct-20230830monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-host-second-quarter-2023-financial-results-conference-call-on-august-8-adct-20230801monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-plan-to-discontinue-the-phase-2-lotis-9-clinical-trial-of-zynlo-adct-20230720monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-sa-company-investigated-by-the-portnoy-law-firm-adct-20230714monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-voluntary-pause-of-enrollment-in-the-phase-2-lotis-9-clinical-t-adct-20230711monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-evolution-of-board-of-directors-adct-20230615monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-updated-lotis-2-results-demonstrating-durable-long-term-respons-adct-20230609monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-participate-in-the-jefferies-healthcare-conference-adct-20230601monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-sa-investors-company-investigated-by-the-portnoy-law-firm-adct-20220920monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-contract-manufacturing-market-by-phase-of-development-scale-of-operation-type-of-compo-adct-20220824monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-cytotoxic-payloads-warheads-products-and-services-market-2021-2035-adct-20220201monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-contract-manufacturing-market-2020-2030-adct-20201211monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-pricing-of-upsized-initial-public-offering-adct-20200515monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-launch-of-initial-public-offering-adct-20200511monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-a-115-million-convertible-credit-facility-with-deerfield-adct-20200501monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-appoints-victor-sandor-m-d-to-its-board-of-directors-adct-20200427monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-files-registration-statement-for-proposed-initial-public-offering-adct-20200424monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-appoints-jennifer-creel-as-chief-financial-officer-adct-20200421monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-appoint-ron-squarer-as-chairman-of-its-board-of-directors-and-an-advis-adct-20200319monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-appoints-joseph-camardo-md-as-head-of-medical-affairs-adct-20200110monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-positive-results-from-pivotal-phase-2-clinical-trial-of-single--adct-20200109monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-oral-presentation-of-interim-efficacy-data-from-pivotal-phase-2-adct-20191209monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-presentations-at-61st-american-society-of-hematology-ash-annual-adct-20191106monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-appoints-jennifer-herron-as-chief-commercial-officer-adct-20191105monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-publication-of-adct-402-data-in-clinical-cancer-research-adct-20191104monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-doses-first-patients-in-pivotal-phase-2-clinical-trial-of-adct-301-in-pat-adct-20191017monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-withdrawal-of-registration-statement-adct-20191002monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-launch-of-initial-public-offering-adct-20190923monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-files-registration-statement-for-proposed-initial-public-offering-adct-20190906monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-and-freenome-enter-biomarker-development-collaboration-adct-20190826monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-and-sophia-genetics-partner-for-biomarker-discovery-in-pivotal-phase-ii-c-adct-20190806monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-final-close-of-series-e-financing-expansion-adct-20190709monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-presents-clinical-data-on-adct-402-and-adct-301-in-subtypes-of-relapsed-o-adct-20190621monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-completion-of-a-series-e-financing-expansion-adct-20190612monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-presentations-at-the-15th-international-conference-on-malignant-adct-20190612monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-and-adagene-announce-license-agreement-adct-20190424monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-first-patient-dosed-in-phase-i-clinical-trial-of-adct-402-lonca-adct-20190220monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-first-patient-dosed-in-phase-i-clinical-trial-of-adct-402-lonca-adct-20190213monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-first-patient-dosed-in-phase-i-clinical-trial-of-adct-601-in-ad-adct-20190116monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-doses-first-patient-in-phase-ib-clinical-trial-of-adct-301-in-patients-wi-adct-20190104monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-appoint-peter-hug-ph-d-to-board-of-directors-adct-20190103monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-presents-updated-data-from-clinical-trials-of-novel-antibody-drug-conjuga-adct-20181205monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-first-patients-dosed-in-phase-i-ii-clinical-trial-of-adct-602-i-adct-20181127monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-presentations-at-60th-american-society-of-hematology-ash-annual-adct-20181114monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-presentations-at-the-society-for-immunotherapy-of-cancer-s-sitc-adct-20181108monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-doses-first-patient-in-pivotal-clinical-trial-of-adct-402-in-patients-wit-adct-20180807monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-licenses-proprietary-antibodies-from-five-prime-therapeutics-adds-an-addi-adct-20131105monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-files-annual-report-on-form-20-f-for-the-year-ended-december-31-2025-slgl-20260319monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-reports-third-quarter-2024-financial-results-and-provides-corporate-updates-slgl-20241115monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-reports-second-quarter-2024-financial-results-and-provides-corporate-updates-slgl-20240816monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-announces-the-signing-of-six-exclusive-license-agreements-to-commercialize-twyneo--slgl-20240725monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-announces-management-realignment-slgl-20240715monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-announces-receipt-of-nasdaq-minimum-price-notice-slgl-20240528monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-reports-first-quarter-2024-financial-results-and-provides-corporate-updates-slgl-20240520monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-and-beimei-pharma-announce-an-asset-purchase-agreement-to-commercialize-twyneo-in--slgl-20240516monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-s-collaboration-partner-first-to-file-anda-drug-product-generic-to-zoryve-cream-slgl-20240401monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-reports-full-year-2023-financial-results-and-corporate-developments-slgl-20240313monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-screens-first-patient-for-sgt-610-phase-3-study-slgl-20231130monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-ltd-to-host-virtual-kol-event-on-gorlin-syndrome-and-the-upcoming-pha-slgl-20231128monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-reports-third-quarter-2023-financial-results-and-provides-corporate-u-slgl-20231109monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-co-slgl-20230830monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-reports-second-quarter-2023-financial-results-and-provides-corporate--slgl-20230810monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-and-searchlight-pharma-announce-licensing-agreements-to-commercialize-twyneo-and-e-slgl-20230606monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-reports-first-quarter-2023-financial-results-and-provides-corporate-u-slgl-20230512monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-to-present-at-the-h-c-wainwright-autoimmune-inflammatory-disease-virt-slgl-20230320monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-reports-full-year-2022-financial-results-and-corporate-developments-slgl-20230310monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-announces-aggregate-22-8-million-concurrent-registered-direct-and-private-placemen-slgl-20230127monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-acquires-patidegib-a-phase-3-fda-breakthrough-designated-orphan-product-candidate--slgl-20230127monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-reports-third-quarter-2022-financial-results-and-provides-corporate-u-slgl-20221110monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-appoints-michael-glezin-vice-president-business-development-slgl-20221003monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-reports-second-quarter-2022-financial-results-and-provides-corporate--slgl-20220804monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-to-participate-in-the-2022-jefferies-global-healthcare-conference-slgl-20220601monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-to-present-in-upcoming-h-c-wainwright-global-investment-conference-slgl-20220517monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-reports-first-quarter-2022-financial-results-and-provides-corporate-u-slgl-20220513monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-and-galderma-announce-fda-approval-of-epsolay-slgl-20220425monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-announces-the-commercial-availability-of-twyneo-slgl-20220414monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-reports-full-year-2021-financial-results-and-corporate-developments-slgl-20220330monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-announces-u-s-commercial-partner-galderma-to-promote-twyneo-at-the-am-slgl-20220325monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-to-participate-in-upcoming-lifesci-partners-corporate-access-event-an-slgl-20211222monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-announces-positive-update-related-to-fda-review-status-of-epsolay-slgl-20211221monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-reports-third-quarter-2021-financial-results-and-highlights-recent-co-slgl-20211111monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-to-present-live-at-jefferies-london-healthcare-conference-slgl-20211109monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-announces-sale-of-generic-dermatology-portfolio-to-partner-padagis-fo-slgl-20211104monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-to-present-at-upcoming-cantor-virtual-global-healthcare-conference-slgl-20210922monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-to-present-at-upcoming-h-c-wainwright-global-investment-conference-slgl-20210909monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-reports-second-quarter-2021-financial-results-and-highlights-recent-c-slgl-20210804monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-announces-fda-approval-of-twyneo-slgl-20210727monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-to-report-second-quarter-2021-financial-results-on-august-4th-2021-slgl-20210720monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-announces-pipeline-update-and-future-development-plans-slgl-20210628monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-to-present-at-upcoming-jefferies-healthcare-conference-and-raymond-ja-slgl-20210527monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-reports-first-quarter-2021-financial-results-and-corporate-update-slgl-20210513monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-provides-update-on-fda-review-of-epsolay-slgl-20210427monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-reports-full-year-2020-financial-results-and-corporate-update-slgl-20210304monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-to-present-at-upcoming-2021-raymond-james-institutional-investors-con-slgl-20210224monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-to-present-at-upcoming-2021-solebury-trout-virtual-investor-conferenc-slgl-20210111monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-announces-fda-acceptance-for-filing-of-new-drug-application-for-twyne-slgl-20201207monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-reports-third-quarter-2020-financial-results-and-corporate-update-slgl-20201112monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-to-present-at-upcoming-healthcare-investor-conferences-in-november-2020-slgl-20201109monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-to-report-third-quarter-2020-financial-results-on-november-12-2020-slgl-20201104monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-announces-fda-acceptance-for-filing-of-new-drug-application-for-epsol-slgl-20200910monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-to-present-at-upcoming-healthcare-investor-conferences-in-september-slgl-20200908monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-collaboration-partner-filed-first-to-file-paragraph-iv-certification--slgl-20200903monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-reports-second-quarter-2020-financial-results-and-corporate-update-slgl-20200806monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-to-report-second-quarter-2020-financial-results-on-august-6-2020-slgl-20200729monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-partnered-generic-product-expected-to-launch-in-the-second-quarter-of-slgl-20200728monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-announces-agreements-with-perrigo-company-for-three-new-generic-produ-slgl-20200629monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-to-present-at-virtual-bmo-2020-prescriptions-for-success-healthcare-conference-slgl-20200616monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-to-present-at-upcoming-healthcare-investor-conferences-slgl-20200527monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-reports-first-quarter-2020-financial-results-and-corporate-update-slgl-20200514monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-to-report-first-quarter-2020-financial-results-and-company-updates-on-slgl-20200507monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-announces-closing-of-additional-5-0-million-investment-slgl-20200413monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-reports-full-year-2019-financial-results-and-corporate-update-slgl-20200324monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-to-report-full-year-2019-financial-results-and-corporate-update-slgl-20200319monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-to-present-at-the-cowen-40th-annual-health-care-conference-slgl-20200219monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-announces-pricing-of-public-offering-of-ordinary-shares-and-warrants-to-purchase-o-slgl-20200214monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-announces-positive-topline-results-from-open-label-long-term-safety-study-of-epsol-slgl-20200213monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-provides-product-pipeline-updates-and-anticipated-milestones-for-2020-slgl-20200205monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-announces-presentation-of-data-for-its-topical-product-candidates-for-acne-and-ros-slgl-20200121monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-hosts-investor-call-to-discuss-positive-results-from-twyneo-phase-3-program-in-acn-slgl-20200108monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-announces-initiation-of-sgt-210-phase-1-proof-of-concept-study-in-palmoplantar-ker-slgl-20200102monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-announces-positive-top-line-phase-3-trial-results-of-twyneo-for-the-treatment-of-a-slgl-20191230monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-reports-third-quarter-2019-financial-results-and-corporate-update-slgl-20191113monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-to-present-on-potential-of-sol-gel-microencapsulation-technology-in-rosacea-at-39t-slgl-20191016monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-reports-second-quarter-2019-financial-results-and-corporate-update-slgl-20190813monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-announces-pricing-of-public-offering-of-ordinary-shares-slgl-20190808monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-hosting-analyst-investor-day-slgl-20190725monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-announces-positive-top-line-results-from-epsolay-phase-3-program-in-papulopustular-slgl-20190708monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-to-host-analyst-investor-day-on-july-25-2019-slgl-20190617monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-announces-seventh-agreement-for-generic-product-candidates-with-perri-slgl-20190528monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-to-present-at-upcoming-healthcare-investor-conferences-in-june-slgl-20190523monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-reports-first-quarter-2019-financial-results-and-corporate-update-slgl-20190522monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-announces-participation-in-upcoming-investor-conference-slgl-20190418monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-announces-50-enrollment-in-pivotal-phase-iii-twin-program-for-the-tre-slgl-20190415monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-reports-full-year-2018-financial-results-and-provides-corporate-updat-slgl-20190321monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-announces-fda-approval-for-perrigo-s-generic-acyclovir-cream-5-slgl-20190206monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-appoints-john-vieira-as-u-s-head-of-commercialization-slgl-20190115monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-initiates-pivotal-phase-iii-clinical-program-of-twin-for-the-treatmen-slgl-20181217monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-announces-sixth-agreement-for-a-generic-product-candidate-with-perrig-slgl-20181204monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-announces-participation-in-upcoming-investor-conference-slgl-20181129monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-reports-third-quarter-2018-financial-results-slgl-20181113monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-announces-participation-in-upcoming-investor-conference-slgl-20181105monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-announces-an-additional-collaborative-agreement-for-a-generic-product-slgl-20181101monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-announces-50-enrollment-in-pivotal-phase-iii-epsolay-program-for-the--slgl-20180925monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-names-jonathan-b-siegel-to-the-board-of-directors-slgl-20180913monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-provides-program-update-for-twin-for-the-treatment-of-acne-vulgaris-slgl-20180904monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-announces-collaborative-agreement-for-generic-product-with-perrigo-slgl-20180815monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-reports-second-quarter-2018-financial-results-slgl-20180808monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-initiates-pivotal-phase-iii-clinical-program-for-papulopustular-rosac-slgl-20180618monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-announces-participation-in-upcoming-investor-conferences-slgl-20180529monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-reports-first-quarter-2018-financial-results-slgl-20180515monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-ltd-availability-of-its-annual-report-on-form-20-f-through-its-websit-slgl-20180326monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-reports-fourth-quarter-and-full-year-2017-financial-results-slgl-20180326monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-s-phase-2-data-on-twin-and-vered-to-be-presented-at-the-2018-american-academy-of-d-slgl-20180215monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-ltd-announces-closing-of-initial-public-offering-and-full-exercise-of-slgl-20180205monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-ltd-announces-pricing-of-initial-public-offering-slgl-20180131monthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-announces-positive-phase-2-clinical-trial-results-for-twin-in-patients-with-acne-v-slgl-20170720monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-con-fhtx-20260605monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-highlights-january-equity-financing-program-progress-and-strategic-ob-fhtx-20260110monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-fhtx-20250827monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-participate-in-four-upcoming-investor-conferences-fhtx-20250522monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-host-virtual-investor-event-to-review-pipeline-updates-in-conjunct-fhtx-20250415monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-announces-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-90-fhtx-20250325monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-participate-in-two-upcoming-investor-conferences-fhtx-20250225monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-fhtx-20241112monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-third-quarter-2024-financial-and-corporate-update-fhtx-20241104monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-announces-first-patient-dosed-with-first-in-class-oral-smarca2-select-fhtx-20241010monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-participate-in-the-bmo-oncology-summit-fhtx-20241001monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-strengthens-leadership-team-with-appointment-of-anna-rivkin-ph-d-as-c-fhtx-20240903monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-participate-in-two-upcoming-investor-conferences-in-september-fhtx-20240828monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-second-quarter-2024-financial-and-corporate-update-fhtx-20240808monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-participate-in-upcoming-investor-conferences-in-june-fhtx-20240528monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-raises-approximately-110-million-through-registered-direct-offering-t-fhtx-20240522monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-announces-pricing-of-registered-direct-offering-of-common-stock-and-pre-funded-war-fhtx-20240520monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-first-quarter-2024-financial-and-corporate-update-fhtx-20240506monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-presents-new-preclinical-data-on-potential-first-in-class-brm-selecti-fhtx-20240409monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-participate-in-needham-s-23rd-annual-virtual-healthcare-conference-fhtx-20240405monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-to-host-conference-call-and-webcast-on-pipeline-of-potential-first-in-class-medici-fhtx-20240326monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-present-new-preclinical-data-at-2024-aacr-annual-meeting-reflectin-fhtx-20240305monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-participate-in-cowen-s-44th-annual-health-care-conference-fhtx-20240228monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-provides-pipeline-update-on-fhd-909-brm-selective-inhibitor-fhtx-20240208monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-announces-cfo-departure-fhtx-20240103monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-announces-clinical-data-from-phase-1-study-of-fhd-286-a-novel-brg1-br-fhtx-20231201monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-present-at-upcoming-conferences-including-new-preclinical-data-fro-fhtx-20231024monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-announces-clinical-data-from-phase-1-study-of-fhd-286-in-metastatic-u-fhtx-20231013monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-present-clinical-and-pre-clinical-data-from-multiple-programs-acro-fhtx-20231004monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-announces-participation-in-upcoming-investor-conferences-fhtx-20230905monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-announces-first-patient-dosed-in-phase-1-combination-study-of-fhd-286-fhtx-20230831monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-announces-clinical-data-from-phase-1-study-of-fhd-286-in-metastatic-u-fhtx-20230628monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-announces-participation-in-upcoming-investor-conferences-fhtx-20230607monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-announces-fda-has-lifted-clinical-hold-on-phase-1-study-of-fhd-286-in-fhtx-20230605monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-investor-conference-fhtx-20230425monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-present-preclinical-data-from-its-selective-cbp-and-ep300-protein--fhtx-20230410monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-highlight-transcription-factor-and-protein-degradation-capabilitie-fhtx-20230406monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-2023-outlook-and-full-year-2022-corporate-update-fhtx-20230309monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-participate-at-cowen-s-43rd-annual-health-care-conference-fhtx-20230301monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-announces-new-preclinical-data-for-fhd-286-in-aml-to-be-presented-at--fhtx-20221205monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-participate-at-the-evercore-isi-healthconx-conference-fhtx-20221122monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-present-at-connective-tissue-oncology-society-annual-meeting-fhtx-20221114monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-present-new-preclinical-data-for-brg1-brm-inhibitor-fhd-286-in-com-fhtx-20221109monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors-fhtx-20221027monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-announces-new-data-demonstrating-brd9-degradation-in-patient-tumor-bi-fhtx-20221026monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-present-at-hanson-wade-s-5th-annual-targeted-protein-degradation-s-fhtx-20221020monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-participate-in-the-bank-of-america-2022-precision-oncology-confere-fhtx-20220927monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-announces-participation-in-upcoming-investor-conferences-fhtx-20220901monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-announces-change-to-board-of-directors-fhtx-20220831monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-appoints-lynne-parshall-to-its-board-of-directors-fhtx-20220817monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-announces-participation-in-upcoming-investor-conferences-fhtx-20220801monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-announces-upcoming-investor-conference-participation-fhtx-20220531monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-update-on-phase-1-study-of-fhd-286-in-relapsed-and-or-refrac-fhtx-20220519monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-presents-new-preclinical-data-on-novel-brg1-brm-inhibitor-fhd-286-at--fhtx-20220413monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-present-preclinical-data-for-fhd-286-at-the-2022-aacr-annual-meeti-fhtx-20220401monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-participate-at-the-2022-guggenheim-targeted-protein-degradation-da-fhtx-20220311monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-participate-at-the-cowen-s-42nd-annual-health-care-conference-fhtx-20220228monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-announces-chief-scientific-officer-succession-fhtx-20220110monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-participate-at-the-h-c-wainwright-bioconnect-conference-fhtx-20220107monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-participate-at-the-2021-jefferies-london-healthcare-conference-fhtx-20211111monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-third-quarter-2021-corporate-update-fhtx-20211109monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-announces-presentation-at-upcoming-4th-annual-targeted-protein-degrad-fhtx-20211019monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-participate-in-two-upcoming-virtual-investor-conferences-fhtx-20210901monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-announces-first-patient-dosed-in-first-in-human-clinical-trial-of-fhd-fhtx-20210823monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-second-quarter-2021-corporate-update-fhtx-20210810monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-participate-at-the-2021-wedbush-pacgrow-healthcare-virtual-confere-fhtx-20210803monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-participate-at-the-william-blair-biotech-focus-conference-2021-fhtx-20210709monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-host-research-development-day-webinar-on-june-15th-fhtx-20210608monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences-fhtx-20210526monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-announces-dosing-of-first-patient-in-first-in-human-clinical-program--fhtx-20210517monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-corporate-update-fhtx-20210511monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors-fhtx-20210428monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-provides-corporate-update-fhtx-20210318monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-present-poster-and-chair-a-panel-and-at-the-aacr-annual-meeting-20-fhtx-20210311monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-to-participate-in-the-41st-cowen-annual-healthcare-conference-fhtx-20210222monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-appoints-michael-lacascia-as-chief-legal-officer-fhtx-20201112monthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-announces-pricing-of-initial-public-offering-fhtx-20201023monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-to-present-avim-therapy-clinical-and-mechanistic-data-at-hrs-2026-obio-20260423monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-to-participate-in-upcoming-institutional-investor-conferences-obio-20260219monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-obio-20260213monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-obio-20251126monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-reports-second-quarter-2025-financial-results-and-highlights-recent-busin-obio-20250812monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-announces-rollout-of-fda-approved-backbeat-global-pivotal-study-protocol--obio-20250808monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-secures-over-111-million-in-proceeds-and-committed-capital-following-comp-obio-20250805monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-announces-pricing-of-40-million-public-offering-obio-20250801monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-showcases-avim-therapy-as-purpose-built-solution-for-hypertensive-heart-d-obio-20250618monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-reports-first-quarter-2025-financial-results-and-highlights-recent-regula-obio-20250512monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-s-avim-therapy-global-intellectual-property-estate-reaches-137-issued-pat-obio-20250507monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-receives-fda-approval-of-ide-to-initiate-u-s-coronary-pivotal-trial-rando-obio-20250429monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-to-participate-in-upcoming-institutional-investor-conferences-obio-20250428monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-mee-obio-20250423monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-reports-full-year-2024-financial-results-and-provides-a-fourth-quarter-bu-obio-20250331monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-to-present-at-upcoming-investor-conferences-obio-20250220monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-appoints-vivek-reddy-m-d-as-executive-chairman-of-the-backbeat-study-stee-obio-20250218monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-announces-data-demonstrating-favorable-impact-of-avim-therapy-on-diastoli-obio-20250212monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-announces-avim-therapy-program-presentations-at-ici-meeting-obio-20241209monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference-obio-20241126monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-reports-third-quarter-2024-financial-results-and-provides-a-business-upda-obio-20241112monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-to-participate-in-jefferies-london-healthcare-conference-obio-20241107monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-reports-second-quarter-2024-financial-results-and-provides-a-business-upd-obio-20240812monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-announces-further-details-on-in-person-r-d-day-in-new-york-featuring-key--obio-20240604monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-to-participate-in-jefferies-global-healthcare-conference-obio-20240522monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-reports-first-quarter-2024-financial-results-and-provides-a-business-upda-obio-20240513monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-announces-avim-therapy-global-intellectual-property-estate-reaches-110-is-obio-20240430monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-to-host-in-person-r-d-day-in-new-york-on-avim-therapy-program-in-hyperten-obio-20240430monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-reports-full-year-2023-financial-results-and-provides-fourth-quarter-busi-obio-20240327monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-announces-appointment-of-medical-device-industry-expert-david-pacitti-to--obio-20240326monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-demonstrates-strength-of-cardiovascular-pipeline-with-virtue-sab-and-avim-obio-20240313monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-to-participate-in-upcoming-investor-conferences-obio-20240307monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-announces-presentation-of-results-from-clinical-study-demonstrating-favor-obio-20240306monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-presents-new-data-showing-sustained-clinically-meaningful-reduction-in-24-obio-20240226monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-announces-initiation-of-backbeat-pivotal-study-of-avim-therapy-in-hyperte-obio-20240108monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-reports-third-quarter-2023-financial-results-and-provides-business-update-obio-20231113monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-to-present-at-upcoming-investor-conferences-obio-20231109monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-reports-second-quarter-2023-financial-results-and-provides-business-updat-obio-20230810monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-granted-fda-approval-of-ide-for-u-s-pivotal-study-of-virtue-sirolimus-ang-obio-20230808monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-set-to-join-russell-3000-and-other-ftse-russell-indexes-obio-20230626monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-to-present-at-the-jefferies-global-healthcare-conference-obio-20230601monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-reports-first-quarter-2023-financial-results-and-provides-business-update-obio-20230512monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-to-present-at-upcoming-investor-conferences-obio-20230307monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-announces-upcoming-presentations-on-backbeat-cnt-and-virtue-sab-at-crt-20-obio-20230224monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-strengthens-senior-leadership-team-obio-20230207monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-announces-presentation-of-positive-long-term-clinical-results-from-modera-obio-20220920monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-announces-strategic-collaboration-closing-of-110-million-private-equity-f-obio-20220705monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-appoints-drug-device-combination-expert-jagdish-parasrampuria-as-vice-pre-obio-20200713monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-enhances-management-team-with-appointment-of-regulatory-affairs-and-combi-obio-20200428monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-strengthens-management-team-with-appointments-of-expert-product-developme-obio-20191016monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-appoints-dennis-donohoe-m-d-leading-clinical-development-expert-as-chief--obio-20190827monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-appoints-c-evan-ballantyne-as-chief-financial-officer-obio-20181204monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-announces-completion-of-41-million-financing-obio-20181115monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-strengthens-operations-r-d-and-pharmaceutical-development-expertise-with--obio-20181010monthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-adds-three-industry-leaders-to-strategic-advisory-board-obio-20181009monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-publishes-nature-communications-article-on-a-non-viral-gene-editing-process-enab-clls-20251119monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-report-third-quarter-financial-results-on-november-7-2025-clls-20251031monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-hosts-r-d-day-today-showcasing-pipeline-progress-and-long-term-value-drivers-clls-20251016monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-present-data-on-non-viral-gene-therapy-and-tale-base-editors-at-the-esgct-ann-clls-20251007monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-second-quarter-2025-financial-results-business-updates-clls-20250804monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-report-second-quarter-2025-financial-results-on-august-4-2025-clls-20250728monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-results-from-shareholders-meeting-held-on-june-26-2025-clls-20250626monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-annual-shareholders-general-meeting-to-be-held-on-june-26-2025-clls-20250521monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-financial-results-for-the-first-quarter-2025-clls-20250512monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-report-first-quarter-financial-results-on-may-12-2025-clls-20250506monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-presents-non-viral-gene-editing-and-base-editing-innovation-at-the-asgct-annual--clls-20250428monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-financial-results-for-the-fourth-quarter-and-full-year-2024-and-provides-clls-20250313monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025-clls-20250307monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-presents-smart-car-t-strategy-to-enhance-efficacy-against-solid-tumors-at-aacr-i-clls-20250224monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-the-drawdown-of-the-third-tranche-of-5-million-under-the-credit-facili-clls-20241210monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-presents-multiple-strategies-to-enhance-car-t-cell-efficacy-in-solid-tumors-at-t-clls-20241105monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-provides-business-updates-and-financial-results-for-third-quarter-2024-clls-20241104monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-report-third-quarter-2024-financial-results-on-november-4-2024-clls-20241030monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-present-data-on-tale-base-editors-and-non-viral-gene-therapy-at-the-esgct-31s-clls-20241022monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-presents-pre-clinical-evidence-of-muc1-car-t-cells-reducing-triple-negative-brea-clls-20240903monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-publishes-a-molecular-therapy-article-on-a-smart-dual-car-t-cell-approach-for-tr-clls-20240826monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-appoints-dr-adrian-kilcoyne-as-chief-medical-officer-clls-20240807monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-provides-financial-results-for-the-second-quarter-2024-clls-20240806monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-results-from-shareholders-meeting-held-on-june-28-2024-clls-20240628monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-publishes-a-scientific-article-unveiling-three-key-factors-for-efficient-tale-ba-clls-20240620monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-unveils-a-non-viral-gene-therapy-approach-for-sickle-cell-disease-in-nature-comm-clls-20240612monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-receives-orphan-drug-designation-for-ucart22-its-allogeneic-car-t-product-for-pa-clls-20240604monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-annual-shareholders-general-meeting-to-be-held-on-june-28-2024-clls-20240529monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-financial-results-for-first-quarter-2024-clls-20240528monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-report-first-quarter-2024-financial-results-on-may-28-2024-clls-20240527monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-completion-of-the-additional-equity-investment-by-astrazeneca-clls-20240506monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-appoints-arthur-stril-as-interim-chief-financial-officer-clls-20240502monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-financial-results-for-the-fourth-quarter-and-full-year-2023-clls-20240429monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-presents-novel-talen-editing-processes-enabling-highly-efficient-gene-correction-clls-20240422monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-publishes-a-novel-intronic-gene-editing-approach-for-the-treatment-of-inborn-met-clls-20240410monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-two-poster-presentations-on-novel-talen-editing-process-for-gene-corre-clls-20240408monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-the-drawdown-of-the-second-tranche-of-15-million-under-the-credit-faci-clls-20240116monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-results-from-shareholders-meeting-held-on-december-22-2023-clls-20231222monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-shareholders-meeting-to-be-held-on-december-22-2023-clls-20231117monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-the-execution-of-the-subsequent-investment-agreement-with-astrazeneca-clls-20231115monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-financial-results-for-third-quarter-and-first-nine-months-2023-clls-20231106monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-report-third-quarter-2023-financial-results-on-november-6-2023-clls-20231101monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-presents-pre-clinical-data-on-multi-armored-allogeneic-muc1-car-t-cells-targetin-clls-20231031monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-present-pre-clinical-data-on-hspc-gene-therapy-program-and-comprehensive-anal-clls-20231024monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-present-pre-clinical-data-on-multi-armored-allogeneic-muc1-car-t-cells-target-clls-20230927monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-provides-full-report-for-second-quarter-2023-financial-results-clls-20230807monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-provides-business-updates-and-preliminary-financial-results-for-second-quarter-2-clls-20230803monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-report-second-quarter-2023-financial-results-on-august-3-2023-clls-20230727monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-s-a-reports-results-from-annual-shareholders-general-meeting-held-on-june-27-202-clls-20230628monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-presents-updated-clinical-and-translational-data-on-balli-01-at-the-european-hem-clls-20230609monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-showcased-preclinical-data-at-an-oral-presentation-and-two-poster-presentations--clls-20230605monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-publishes-an-article-in-cancer-immunology-research-demonstrating-preclinical-evi-clls-20230531monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-presents-clinical-data-on-ameli-01-and-preclinical-data-on-multiplex-engineering-clls-20230517monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-publishes-article-in-frontiers-in-immunology-unveiling-pre-clinical-data-on-a-no-clls-20230512monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-poster-presentation-on-balli-01-at-the-european-hematology-association-clls-20230511monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-provides-business-update-and-reports-financial-results-for-first-quarter-2023-clls-20230504monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-oral-presentation-on-ameli-01-and-poster-presentation-on-multiplex-eng-clls-20230502monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-report-first-quarter-2023-financial-results-on-may-4-2023-clls-20230427monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-implements-clls52-for-the-first-time-in-the-clinic-with-sanofi-s-alemtuzumab-clls-20230424monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-presents-preclinical-data-on-talen-edited-muc1-car-t-cells-to-enhance-efficacy-i-clls-20230417monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-dosing-of-the-first-patient-in-europe-with-its-in-house-manufactured-p-clls-20230411monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-poster-presentation-on-talen-edited-muc1-car-t-cells-targeting-triple--clls-20230314monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-provides-business-update-and-reports-fourth-quarter-and-full-year-2022-financial-clls-20230308monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-report-fourth-quarter-and-year-end-2022-financial-results-on-march-8-2023-clls-20230301monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-closing-of-global-offering-and-exercise-of-underwriters-option-to-purc-clls-20230208monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-supplements-the-announcement-of-the-pricing-of-follow-on-offering-with-allocatio-clls-20230203monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-pricing-of-follow-on-offering-clls-20230203monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-launch-of-follow-on-offering-clls-20230202monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-amends-20-million-convertible-note-under-collaboration-agreement-with-its-partne-clls-20230120monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-establishes-an-at-the-market-atm-program-on-nasdaq-clls-20230104monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-secures-a-40-million-credit-facility-from-the-european-investment-bank-to-suppor-clls-20221228monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-first-dosing-of-a-patient-with-its-in-house-manufactured-product-candi-clls-20221222monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-positive-preliminary-clinical-data-for-ucart22-in-all-and-ucart123-in--clls-20221213monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-host-a-live-webcast-and-provide-a-company-update-on-december-13-2022-clls-20221201monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-presents-pre-clinical-data-on-talen-edited-smart-car-t-cells-overcoming-key-chal-clls-20221110monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-publishes-manuscript-in-frontiers-bioengineering-and-biotechnology-unveiling-eff-clls-20221110monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-provides-business-update-and-reports-financial-results-for-third-quarter-and-fir-clls-20221103monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-showcase-clinical-data-from-ameli-01-and-preclinical-data-from-ucartcs1-at-as-clls-20221103monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-report-third-quarter-2022-financial-results-clls-20221027monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-presents-data-on-two-talen-based-gene-therapy-preclinical-programs-for-patients--clls-20221011monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-present-pre-clinical-data-on-talen-edited-smart-car-t-cells-supporting-improv-clls-20221005monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-appoints-mark-frattini-m-d-ph-d-as-chief-medical-officer-clls-20220928monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-participation-in-four-upcoming-investor-conferences-in-september-clls-20220901monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-provides-business-update-and-reports-financial-results-for-second-quarter-2022-clls-20220804monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-receives-ind-clearance-for-ucart20x22-its-first-in-house-manufactured-product-ca-clls-20220801monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-report-second-quarter-2022-financial-results-clls-20220728monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-publishes-article-in-nature-communications-unveiling-novel-immune-evasive-univer-clls-20220630monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-the-appointment-of-axel-sven-malkomes-dr-donald-a-bergstrom-m-d-ph-d-t-clls-20220628monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-s-a-reports-results-from-annual-shareholders-general-meeting-held-on-june-28-202-clls-20220628monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-annual-shareholders-general-meeting-to-be-held-on-june-28-2022-clls-20220523monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-presents-research-data-on-a-novel-immune-evasive-universal-car-t-cell-at-asgct-clls-20220516monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-provides-business-update-and-reports-financial-results-for-first-quarter-2022-clls-20220512monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-report-first-quarter-2022-financial-results-clls-20220505monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-publishes-two-articles-in-nature-communications-providing-strong-preclinical-val-clls-20220428monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-receives-20-million-convertible-note-under-collaboration-agreement-with-its-part-clls-20220427monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-presents-preclinical-data-from-its-first-allogeneic-dual-car-t-cell-product-cand-clls-20220408monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-participate-in-two-upcoming-investor-conferences-in-march-clls-20220311monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-provides-business-update-and-reports-4th-quarter-and-full-year-2021-financial-re-clls-20220303monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-hold-fourth-quarter-2021-earnings-call-on-friday-march-4-2022-at-8-00am-est-clls-20220224monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-encouraging-clinical-data-from-balli-01-study-in-relapsed-refractory-b-c-clls-20211211monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-presents-first-preclinical-data-on-ucartmeso-an-allogeneic-car-t-cell-product-ca-clls-20211112monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-provides-business-update-and-reports-financial-results-for-third-quarter-and-fir-clls-20211104monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-release-of-abstracts-at-ash-showcasing-updated-preliminary-clinical-da-clls-20211104monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-hold-third-quarter-earnings-call-on-friday-november-5-2021-at-8am-edt-clls-20211028monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-presents-initial-preclinical-data-on-two-novel-gene-therapies-for-patients-with--clls-20211019monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-present-preclinical-data-on-ucartmeso-supporting-anti-tumor-activity-at-the-s-clls-20211012monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-participation-in-five-investor-conferences-clls-20210826monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-provides-business-update-and-reports-financial-results-for-second-quarter-and-fi-clls-20210805monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-hold-second-quarter-2021-earnings-call-on-friday-august-6-2021-at-8am-edt-clls-20210729monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-innovation-days-event-highlighted-new-product-development-new-genome-surgery-pla-clls-20210614monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-s-a-reports-results-from-annual-shareholders-general-meeting-held-on-june-1-2021-clls-20210602monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-and-sanofi-partner-on-alemtuzumab-as-lymphodepletion-agent-for-allogeneic-car-t-clls-20210511monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-provides-business-update-and-reports-financial-results-for-first-quarter-2021-clls-20210506monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-annual-shareholders-general-meeting-to-be-held-on-june-1-2021-clls-20210426monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-completes-sale-of-47-million-through-its-atm-program-clls-20210409monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-establishes-an-at-the-market-atm-program-on-nasdaq-clls-20210329monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-provides-business-update-and-reports-4th-quarter-and-full-year-2020-financial-re-clls-20210304monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-hold-fourth-quarter-2020-earnings-call-on-friday-march-5-2021-at-8-00am-est-clls-20210225monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-monthly-information-on-share-capital-and-company-voting-rights-clls-20210210monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-withdrawal-of-follow-on-offering-clls-20201216monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-launch-of-follow-on-offering-clls-20201214monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-preliminary-results-from-its-phase-1-balli-01-study-of-ucart22-in-r-r-ad-clls-20201205monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-appoints-pharma-hr-leader-kyung-nam-wortman-as-executive-vice-president-chief-hu-clls-20201116monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-provides-business-update-and-reports-financial-results-for-third-quarter-and-fir-clls-20201105monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-hold-third-quarter-2020-earnings-call-on-friday-november-6-2020-at-8-00am-est-clls-20201021monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-participate-in-upcoming-investor-conferences-clls-20200902monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-provides-business-update-and-reports-financial-results-for-second-quarter-and-fi-clls-20200805monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-hold-second-quarter-2020-earnings-call-on-thursday-august-6-2020-at-7-30am-ed-clls-20200729monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-appoints-biopharma-veteran-steve-doares-ph-d-as-senior-vice-president-of-us-manu-clls-20200721monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-clinical-hold-placed-on-melani-01-study-clls-20200706monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-s-a-reports-results-from-annual-shareholders-general-meeting-held-on-june-29-202-clls-20200629monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-published-streamlined-manufacturing-method-to-generate-ultrapure-allogeneic-car--clls-20200625monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-appoints-biopharma-veteran-leopold-bertea-as-senior-vice-president-of-technical--clls-20200518monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-annual-shareholders-general-meeting-to-be-held-on-june-29-2020-clls-20200511monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-provides-business-update-and-reports-financial-results-for-first-quarter-2020-clls-20200506monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-hold-first-quarter-2020-earnings-call-on-thursday-may-7-2020-at-7-30-am-edt-clls-20200429monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-appoints-carrie-brownstein-m-d-as-chief-medical-officer-clls-20200413monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-sa-nasdaq-clls-to-ring-the-nasdaq-stock-market-opening-bell-in-celebration-of-ip-clls-20150325monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-acquires-exclusive-license-to-tal-effector-patents-from-university-of-minnesota-clls-20110120monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-grants-harvard-bioscience-a-license-to-cytopulse-electroporation-instruments-clls-20101202monthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-to-present-new-preclinical-data-demonstrating-cmp-002-improves-seizure--camp-20260514monthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-reports-first-quarter-2026-financial-results-and-corporate-highlights-camp-20260507monthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-camp-20260417monthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-to-participate-in-upcoming-investor-conferences-camp-20260306monthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-reports-full-year-2025-financial-results-and-corporate-highlights-camp-20260305monthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-camp-20260220monthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-camp-20260116monthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-camp-20260106monthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-announces-pricing-of-30-0-million-underwritten-offering-of-common-stock-camp-20251218monthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-camp-20251212monthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-camp-20251114monthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-reports-second-quarter-2025-financial-results-and-corporate-highlights-camp-20250814monthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-reports-first-quarter-2025-financial-results-and-corporate-highlights-camp-20250513monthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-camp-20250113monthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-provides-corporate-updates-and-highlights-key-upcoming-milestones-camp-20250107monthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-appoints-john-maraganore-and-rachel-meyers-as-strategic-advisors-camp-20241210monthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference-camp-20241202monthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-announces-pricing-of-initial-public-offering-camp-20241010monthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-enters-strategic-research-collaboration-to-advance-novel-regulatory-rna-targeting-me-camp-20241001monthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-secures-orphan-drug-designation-for-cmp-cps-001-for-the-treatment-of-ur-camp-20240917monthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-secures-rare-pediatric-disease-designation-for-cmp-cps-001-for-the-trea-camp-20240827monthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-announces-dosing-of-first-participant-in-phase-1-clinical-study-of-cmp--camp-20240321monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-announces-everest-medicines-acquired-rights-to-develop-and-commercialize-lenz-20260607monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-reports-first-quarter-2026-financial-results-and-recent-corporate-highli-lenz-20260511monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-inc-investigated-by-the-portnoy-law-firm-lenz-20260423monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-announces-submission-of-marketing-authorization-application-to-the-medic-lenz-20260420monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-announces-submission-of-marketing-authorization-application-to-european--lenz-20260310monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-announces-mfds-submission-of-new-drug-application-for-lnz100-vizz-in-sou-lenz-20251201monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-to-present-at-upcoming-investor-conferences-lenz-20251125monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-to-report-third-quarter-2025-financial-results-and-recent-corporate-high-lenz-20251029monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-reports-second-quarter-2025-financial-results-and-recent-corporate-highl-lenz-20250730monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-to-present-at-upcoming-investor-conferences-lenz-20250527monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-reports-first-quarter-2025-financial-results-and-recent-corporate-highli-lenz-20250507monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-to-participate-in-upcoming-bofa-securities-2025-health-care-conference-lenz-20250506monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-to-report-first-quarter-2025-financial-results-and-recent-corporate-high-lenz-20250430monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-c-lenz-20250319monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-and-recent-lenz-20250311monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-to-host-commercial-day-on-april-15-2025-lenz-20250303monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-lenz-20250224monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-lenz-20241112monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-reports-third-quarter-2024-financial-results-lenz-20241106monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-to-report-third-quarter-financial-results-and-business-update-on-novembe-lenz-20241030monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-announces-fda-acceptance-of-new-drug-application-for-lnz100-for-the-trea-lenz-20241021monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-announces-presentations-at-upcoming-ophthalmology-and-optometry-medical--lenz-20240930monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-lenz-20240827monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-reports-second-quarter-2024-financial-results-lenz-20240814monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-to-report-second-quarter-2024-financial-results-on-august-14-2024-lenz-20240807monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-to-host-key-opinion-leader-event-on-june-18-2024-lenz-20240610monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-lenz-20240530monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-reports-first-quarter-2024-financial-results-and-provides-business-updat-lenz-20240508monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-to-report-first-quarter-financial-results-and-business-update-on-may-8-2-lenz-20240501monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-present-at-two-upcoming-investor-conferences-sght-20260429monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-the-release-of-its-sustainability-report-sght-20260422monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-more-informa-sght-20260306monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-20-sght-20260218monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-the-results-of-a-cost-utility-analysis-demonstrating-cost-savings-sght-20250730monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-the-publication-of-the-24-month-results-of-the-sahara-rct-demonst-sght-20250729monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-report-second-quarter-2025-financial-results-on-august-7-2025-sght-20250724monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-present-at-the-stifel-2025-virtual-ophthalmology-forum-on-may-27th-sght-20250514monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-fresh-himalayan-fruit-jam-naturally-repair-blurry-eyesight-sght-20250507monthly0.5https://www.biopharmawatch.com/news/SGHT/sightfresh-under-review-secret-vision-berry-to-restore-eyesight-with-sight-fresh-ingredien-sght-20250425monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-report-first-quarter-2025-financial-results-on-may-8-2025-sght-20250424monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-the-release-of-its-sustainability-report-sght-20250423monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-debut-omni-edge-surgical-system-at-the-2025-ascrs-annual-meeting-expandi-sght-20250421monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-present-at-the-24th-annual-needham-healthcare-conference-on-april-8th-sght-20250325monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-present-comprehensive-clinical-data-on-the-omni-surgical-system-at-the-2-sght-20250224monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-5-20-sght-20250219monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-present-at-citi-s-2025-unplugged-medtech-and-life-sciences-access-day-sght-20250213monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-care-study-findings-reviews-ingredients-and-where-to-buy-it-sght-20250213monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-real-world-36-month-study-confirming-long-term-effectiveness-of-s-sght-20250107monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-the-results-of-a-budget-impact-analysis-for-its-tearcare-system-f-sght-20241219monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-present-at-the-piper-sandler-36th-annual-healthcare-conference-sght-20241119monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-appoints-mk-raheja-as-executive-vice-president-research-and-development-and-sght-20241107monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-report-third-quarter-financial-results-on-november-7-2024-sght-20241017monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-present-at-the-upcoming-morgan-stanley-global-healthcare-conference-sght-20240820monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-report-second-quarter-financial-results-on-august-1-2024-sght-20240718monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-the-release-of-its-first-sustainability-report-sght-20240610monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-the-publication-of-twelve-month-results-of-the-sahara-rct-demonst-sght-20240528monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-publication-of-a-new-analysis-from-the-romeo-study-showing-meanin-sght-20240528monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-present-at-the-upcoming-bank-of-america-healthcare-conference-sght-20240507monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-report-first-quarter-financial-results-on-may-2-2024-sght-20240418monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-the-publication-of-large-scale-real-world-migs-study-demonstratin-sght-20240410monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-the-results-of-the-three-year-prospective-gemini-trial-and-the-cr-sght-20240402monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-present-at-the-upcoming-23rd-annual-needham-healthcare-conference-sght-20240326monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-report-fourth-quarter-and-full-year-2023-financial-results-on-march-7-20-sght-20240222monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-european-launch-of-the-ergo-series-of-the-omni-surgical-system-at-sght-20240214monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-preliminary-unaudited-fourth-quarter-and-full-year-2023-financial-sght-20240108monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-withdrawal-of-final-lcds-on-micro-invasive-glaucoma-surgery-from--sght-20231228monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-the-publication-of-successful-results-of-the-sahara-randomized-co-sght-20231218monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-the-acceptance-for-publication-of-gemini-2-a-three-year-prospecti-sght-20231208monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-report-third-quarter-2023-financial-results-on-november-7-2023-sght-20231024monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-host-sahara-6-month-rct-results-reception-at-the-american-academy-of-oph-sght-20231019monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-presentation-of-successful-phase-i-results-of-the-sahara-randomiz-sght-20231012monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-new-large-scale-migs-data-from-41st-congress-of-escrs-demonstrati-sght-20231003monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-provides-revenue-guidance-for-the-third-quarter-of-2023-and-updates-revenue-sght-20230911monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-present-at-the-upcoming-morgan-stanley-21st-annual-global-healthcare-con-sght-20230830monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-report-second-quarter-2023-financial-results-on-august-3-2023-sght-20230720monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-positive-results-and-primary-endpoint-successfully-met-in-sahara--sght-20230720monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-addition-of-new-director-catherine-mazzacco-sght-20230609monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-two-year-multicenter-study-results-show-sustained-reductions-in-both-intrao-sght-20230523monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-12-month-results-from-the-first-minimally-invasive-glaucoma-surge-sght-20230506monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-glaucoma-and-dry-eye-technologies-to-be-featured-in-multiple-clinical-prese-sght-20230501monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-present-at-the-upcoming-bank-of-america-securities-2023-health-care-conf-sght-20230426monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-report-first-quarter-2023-financial-results-on-may-4-2023-sght-20230420monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-host-surgical-glaucoma-investor-symposium-on-friday-may-5-2023-sght-20230413monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-defeats-invalidity-challenges-filed-by-alcon-and-ivantis-in-the-u-s-patent--sght-20230330monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-launches-the-ergo-series-of-the-omni-surgical-system-sght-20230309monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-13-2-sght-20230223monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-present-at-the-upcoming-citi-2023-healthcare-services-medtech-tools-hcit-sght-20230222monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-1-000th-tearcare-customer-installation-sght-20230126monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-present-at-the-upcoming-piper-sandler-34th-annual-healthcare-conference-sght-20221122monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-publication-of-clinical-data-demonstrating-standalone-effectivene-sght-20221103monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-report-third-quarter-2022-financial-results-on-november-10-2022-sght-20221020monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-publication-of-data-showcasing-superior-symptoms-improvements-wit-sght-20220929monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-feature-interactive-panel-discussions-of-real-world-use-of-the-omni-surg-sght-20220928monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-omni-surgical-system-to-be-featured-in-multiple-presentations-at-the-2022-e-sght-20220916monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-completion-of-enrollment-in-sahara-a-randomized-clinical-trial-of-sght-20220913monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-present-at-the-upcoming-morgan-stanley-global-healthcare-conference-sght-20220902monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-present-at-the-inaugural-gilmartin-group-emerging-growth-company-showcas-sght-20220825monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-long-term-safety-and-effectiveness-data-of-standalone-use-of-the--sght-20220816monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-report-second-quarter-2022-financial-results-on-august-11-2022-sght-20220728monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-the-appointment-of-tamara-fountain-m-d-to-its-board-of-directors-sght-20220719monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-omni-surgical-system-reduces-iop-daily-fluctuations-in-iop-and-medication-u-sght-20220531monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-present-at-the-upcoming-piper-sandler-virtual-ophthalmology-diabetes-sym-sght-20220519monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-present-at-the-upcoming-bank-of-america-healthcare-conference-sght-20220429monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-multiple-presentations-and-event-at-the-2022-american-society-of--sght-20220420monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-report-first-quarter-2022-financial-results-on-may-10-2022-sght-20220414monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-first-patient-treated-in-trident-european-trial-to-evaluate-the-o-sght-20220324monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-appointment-of-brenda-becker-to-board-of-directors-sght-20220316monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-report-fourth-quarter-and-full-year-2021-financial-results-on-march-24-2-sght-20220303monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-multiple-presentations-at-the-2022-american-glaucoma-society-annu-sght-20220302monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-participate-in-the-upcoming-citi-virtual-healthcare-conference-sght-20220221monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-launches-don-t-wait-for-too-late-awareness-campaign-for-glaucoma-sght-20220217monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-receives-fda-510-k-clearance-of-the-tearcare-system-for-treatment-of-meibom-sght-20211222monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-participate-in-the-upcoming-piper-sandler-annual-healthcare-conference-sght-20211118monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-fda-authorization-for-the-precision-trial-a-groundbreaking-three--sght-20211110monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-report-third-quarter-2021-financial-results-on-november-10-2021-sght-20211027monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-tearcare-clinical-data-published-in-cornea-sght-20211020monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-files-lawsuit-against-ivantis-for-patent-infringement-sght-20210916monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-participate-in-the-morgan-stanley-global-healthcare-conference-sght-20210826monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-pioneering-the-development-of-the-standalone-migs-market-announces-publicat-sght-20210824monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-to-report-second-quarter-2021-financial-results-on-august-12-2021-sght-20210802monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-multiple-presentations-at-the-2021-american-society-of-cataract-a-sght-20210723monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-closing-of-initial-public-offering-and-full-exercise-of-the-under-sght-20210719monthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-announces-pricing-of-initial-public-offering-sght-20210714monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-provides-business-updates-and-second-quarter-financial-results-nerv-20250814monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-first-quarter-2025-financial-results-and-business-updates-nerv-20250513monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-fourth-quarter-and-fiscal-year-2024-financial-results-and-bu-nerv-20250225monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-third-quarter-2024-financial-results-and-business-updates-nerv-20241105monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-second-quarter-2024-financial-results-and-business-updates-nerv-20240806monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-first-quarter-2024-financial-results-and-business-updates-nerv-20240501monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-fourth-quarter-and-fiscal-year-2023-financial-results-and-bu-nerv-20240222monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-2023-third-quarter-financial-results-and-business-updates-nerv-20231107monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-2023-second-quarter-financial-results-and-business-updates-nerv-20230801monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-2023-first-quarter-financial-results-and-business-updates-nerv-20230515monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-update-on-its-new-drug-application-nda-for-roluperidone-fo-nerv-20230510monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-first-quarter-2023-financial-results-and-business-updates--nerv-20230508monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-fiscal-year-2022-fourth-quarter-and-year-end-financial-resul-nerv-20230308monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-fiscal-year-2022-financial-results-and-business-updates-on-nerv-20230301monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-third-quarter-2022-financial-results-and-business-updates-nerv-20221109monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-third-quarter-2022-financial-results-and-business-updates--nerv-20221102monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-second-quarter-2022-financial-results-and-business-updates-nerv-20220809monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-first-quarter-2022-financial-results-and-business-updates-nerv-20220504monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-fourth-quarter-2021-financial-results-and-business-updates-nerv-20220301monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-third-quarter-2021-financial-results-and-business-updates-nerv-20211108monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-third-quarter-2021-financial-results-and-business-updates--nerv-20211101monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-appointment-of-dr-ramana-kuchibhatla-as-senior-vice-presid-nerv-20210908monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-second-quarter-2021-financial-results-and-business-updates-nerv-20210802monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-second-quarter-2021-financial-results-and-business-updates-nerv-20210726monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-present-at-jmp-securities-life-sciences-conference-nerv-20210610monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-present-at-jefferies-virtual-healthcare-conference-nerv-20210528monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-first-quarter-2021-financial-results-and-business-updates-nerv-20210512monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-the-results-of-the-phase-3-trial-of-roluperidone-for-the-t-nerv-20210511monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-first-quarter-2021-financial-results-and-business-updates--nerv-20210505monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-fiscal-2020-fourth-quarter-and-year-end-financial-results-an-nerv-20210308monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-fiscal-2020-fourth-quarter-and-year-end-financial-results--nerv-20210301monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-final-deadline-notice-rosen-top-ranked-investor-counsel-encourages-minerva-neurosc-nerv-20210206monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-and-royalty-pharma-announce-sale-of-seltorexant-royalty-for-up-to-15-nerv-20210119monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-outcome-of-type-c-meeting-with-fda-and-next-steps-in-the-d-nerv-20201201monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-present-at-jefferies-virtual-london-healthcare-conference-nerv-20201109monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-third-quarter-2020-financial-results-and-business-updates-nerv-20201102monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-third-quarter-2020-financial-results-and-business-updates--nerv-20201026monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-present-at-h-c-wainwright-22nd-annual-global-investment-conferenc-nerv-20200909monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-present-at-citi-s-15th-annual-biopharma-virtual-conference-nerv-20200902monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-present-at-jmp-securities-cns-forum-nerv-20200813monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-second-quarter-2020-financial-results-and-business-updates-nerv-20200803monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-second-quarter-2020-financial-results-and-business-updates-nerv-20200727monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-exercises-right-to-opt-out-of-agreement-with-janssen-for-seltorexant-nerv-20200701monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-results-from-phase-3-trial-of-roluperidone-min-101-for-tre-nerv-20200529monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-first-quarter-2020-financial-results-and-business-updates-nerv-20200504monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-first-quarter-2020-financial-results-and-business-updates--nerv-20200427monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-host-key-opinion-leader-meeting-on-roluperidone-a-potentially-nov-nerv-20200324monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-updates-market-on-share-price-drop-and-trading-halt-nerv-20200312monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-fiscal-2019-fourth-quarter-and-year-end-financial-results-an-nerv-20200309monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-fiscal-2019-fourth-quarter-and-year-end-financial-results--nerv-20200302monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-host-key-opinion-leader-meeting-on-avolition-the-most-central-dom-nerv-20200228monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-completion-of-patient-enrollment-in-phase-3-trial-of-rolup-nerv-20200205monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-completion-of-patient-screening-in-phase-3-trial-of-rolupe-nerv-20200106monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-topline-results-from-phase-2b-trial-of-min-117-in-major-depr-nerv-20191218monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-present-at-jefferies-london-healthcare-conference-on-november-21--nerv-20191114monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-third-quarter-2019-financial-results-and-business-updates-nerv-20191104monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-third-quarter-2019-financial-results-and-business-updates--nerv-20191028monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-update-for-three-clinical-trials-nerv-20191001monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-host-conference-call-and-live-webcast-on-tuesday-october-1-at-8-3-nerv-20190926monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-second-quarter-2019-financial-results-and-business-updates-nerv-20190805monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-second-quarter-2019-financial-results-and-business-updates-nerv-20190729monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-host-live-conference-call-and-webcast-with-key-opinion-leaders-to-nerv-20190623monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-present-at-jmp-securities-life-sciences-conference-nerv-20190612monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-present-at-jefferies-2019-global-healthcare-conference-on-june-4--nerv-20190529monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-first-quarter-2019-financial-results-and-business-updates-nerv-20190506monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-first-quarter-2019-financial-results-and-business-updates--nerv-20190429monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-presents-pre-clinical-data-suggesting-a-mechanistic-role-of-roluperi-nerv-20190411monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-host-webcast-event-on-schizophrenia-nerv-20190318monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-fiscal-2018-fourth-quarter-and-year-end-financial-results-an-nerv-20190312monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-fiscal-2018-fourth-quarter-and-year-end-financial-results--nerv-20190305monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-new-patent-application-for-min-117-related-to-broad-effect-nerv-20181128monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-present-at-evercore-isi-healthconx-conference-on-november-28-2018-nerv-20181121monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-results-of-dose-escalation-study-evaluating-roluperidone-m-nerv-20181119monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-host-roluperidone-update-and-key-opinion-leader-discussion-of-neg-nerv-20181115monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-present-at-jefferies-london-healthcare-conference-on-november-14--nerv-20181107monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-third-quarter-2018-financial-results-and-business-updates-nerv-20181105monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-third-quarter-2018-financial-results-and-business-updates--nerv-20181029monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-findings-showing-effect-of-roluperidone-on-brain-derived-n-nerv-20180822monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-second-quarter-2018-financial-results-and-business-updates-nerv-20180802monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-second-quarter-2018-financial-results-and-business-updates-nerv-20180726monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-names-devin-smith-senior-vice-president-general-counsel-nerv-20180725monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-elects-jeryl-hilleman-to-board-of-directors-nerv-20180717monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-present-at-jefferies-2018-global-healthcare-conference-on-june-6--nerv-20180530monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-first-quarter-2018-financial-results-and-business-updates-nerv-20180503monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-first-quarter-2018-financial-results-and-business-updates--nerv-20180426monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-screens-first-patient-in-phase-2b-trial-of-min-117-to-treat-major-de-nerv-20180409monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-host-key-opinion-leader-meeting-on-the-negative-symptoms-of-schiz-nerv-20180315monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-fiscal-2017-fourth-quarter-and-year-end-financial-results-an-nerv-20180312monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-fiscal-2017-fourth-quarter-and-year-end-financial-results--nerv-20180305monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-names-remy-luthringer-as-executive-chairman-and-william-doyle-as-lea-nerv-20180205monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-enrollment-of-first-patient-in-phase-2b-trial-comparing-se-nerv-20171221monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-screens-first-patient-in-phase-3-trial-of-min-101-to-treat-negative--nerv-20171219monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-names-richard-russell-president-nerv-20171211monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-elects-william-doyle-and-hans-peter-hasler-to-board-of-directors-nerv-20171211monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-enrollment-of-first-patient-in-phase-2b-trial-of-seltorexa-nerv-20171206monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-present-at-jefferies-2017-london-healthcare-conference-on-novembe-nerv-20171108monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-third-quarter-2017-financial-results-and-business-updates-nerv-20171106monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-names-dr-justine-lalonde-as-senior-vice-president-product-strategy-nerv-20171031monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-third-quarter-2017-financial-results-and-business-updates--nerv-20171030monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-names-dr-jay-saoud-as-senior-vice-president-head-of-research-and-dev-nerv-20170911monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-enrollment-of-first-patient-in-phase-2b-trial-of-seltorexa-nerv-20170905monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-european-commission-approval-of-amendment-of-min-202-agree-nerv-20170825monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-second-quarter-2017-financial-results-and-business-updates-nerv-20170803monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-second-quarter-2017-financial-results-and-business-updates-nerv-20170727monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-departure-of-directors-nerv-20170724monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-closing-of-public-offering-of-common-stock-and-full-exerci-nerv-20170705monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-pricing-of-public-offering-of-common-stock-nerv-20170628monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-inc-to-offer-common-shares-nerv-20170627monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-announces-completion-of-bridging-study-to-select-improved-formulation-of-min-101-f-nerv-20170622monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-announces-amended-agreement-for-min-202-in-insomnia-nerv-20170531monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-present-at-jefferies-2017-healthcare-conference-on-june-6-2017-nerv-20170530monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-provides-update-on-phase-3-design-and-development-strategy-for-min-101-nerv-20170515monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-announces-outcome-of-end-of-phase-2-meeting-with-fda-nerv-20170515monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-first-quarter-2017-financial-results-and-business-updates-nerv-20170504monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-first-quarter-2017-financial-results-and-business-updates--nerv-20170427monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-recent-exercise-of-warrants-by-institutional-stockholders--nerv-20170321monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-fiscal-2016-fourth-quarter-and-year-end-financial-results-an-nerv-20170313monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-fiscal-2016-fourth-quarter-and-year-end-financial-results--nerv-20170306monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-present-at-cowen-and-company-37th-annual-health-care-conference-o-nerv-20170228monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-host-r-d-day-focused-on-unmet-needs-and-emerging-treatment-strate-nerv-20170221monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-names-michael-davidson-m-d-as-chief-medical-officer-nerv-20161220monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-clinical-data-featured-at-the-american-college-of-neuropsychopharmac-nerv-20161205monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-present-at-jefferies-2016-london-healthcare-conference-on-novembe-nerv-20161110monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-third-quarter-2016-financial-results-and-business-updates-nerv-20161103monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-third-quarter-2016-financial-results-and-business-updates--nerv-20161027monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-positive-data-from-six-month-extension-of-phase-iib-trial--nerv-20161026monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-acceptance-of-presentations-of-clinical-data-with-min-101--nerv-20161013monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-provides-update-on-min-101-and-min-117-clinical-programs-nerv-20160926monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-present-at-23rd-annual-newsmakers-in-the-biotech-industry-confere-nerv-20160902monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-second-quarter-2016-financial-results-and-business-updates-nerv-20160804monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-second-quarter-2016-financial-results-and-business-updates-nerv-20160728monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-set-to-join-russell-3000-and-russell-2000-indexes-nerv-20160627monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-present-at-jmp-securities-life-sciences-conference-june-21-2016-nerv-20160614monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-pricing-of-public-offering-of-common-stock-nerv-20160614monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-proposed-public-offering-of-common-stock-nerv-20160613monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-present-at-jefferies-2016-healthcare-conference-on-june-8-2016-nerv-20160601monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-positive-results-in-phase-iia-trial-of-min-117-in-major-de-nerv-20160526monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-positive-results-from-phase-iib-trial-of-min-101-monothera-nerv-20160526monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-first-quarter-2016-financial-results-and-business-updates-nerv-20160503monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-first-quarter-2016-financial-results-and-business-updates--nerv-20160426monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-fiscal-2015-fourth-quarter-and-year-end-financial-results-an-nerv-20160314monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-positive-top-line-results-from-phase-ib-clinical-trial-in--nerv-20160311monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-fiscal-2015-fourth-quarter-and-year-end-financial-results--nerv-20160307monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-completion-of-patient-enrollment-in-phase-iia-trial-of-min-nerv-20160222monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-top-line-data-from-min-202-phase-i-clinical-study-in-japan-nerv-20160201monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-favorable-top-line-results-from-min-202-phase-2a-clinical--nerv-20160111monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-update-on-min-101-clinical-development-program-nerv-20151229monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-achieves-enrollment-target-in-phase-iib-trial-with-min-101-nerv-20151218monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-provides-year-end-update-on-clinical-trials-with-three-central-nervous-system-prod-nerv-20151209monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-present-at-jefferies-2015-london-healthcare-conference-on-novembe-nerv-20151113monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-third-quarter-2015-financial-results-and-business-updates-nerv-20151105monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-third-quarter-2015-financial-results-and-host-conference-c-nerv-20151029monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-provides-update-on-clinical-development-program-with-min-202-selecti-nerv-20150924monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-present-at-baird-2015-healthcare-conference-on-september-9-2015-nerv-20150902monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-second-quarter-2015-financial-results-and-business-updates-nerv-20150805monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-report-second-quarter-2015-financial-results-and-host-conference--nerv-20150729monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-provides-update-on-min-202-selective-orexin-2-receptor-antagonist-nerv-20150616monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-present-at-upcoming-investor-conferences-in-june-nerv-20150528monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-appointment-of-dr-fouzia-laghrissi-thode-to-its-board-of-d-nerv-20150518monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-first-quarter-2015-financial-results-and-other-key-business--nerv-20150507monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-host-first-quarter-2015-financial-results-webcast-and-conference--nerv-20150430monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-host-fourth-quarter-and-full-year-2014-financial-results-webcast--nerv-20150319monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-appoints-dr-remy-luthringer-as-ceo-nerv-20141125monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-host-third-quarter-2014-financial-results-webcast-and-conference--nerv-20141030monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-completion-of-fda-review-of-investigational-new-drug-appli-nerv-20140922monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-present-at-baird-2014-health-care-conference-nerv-20140828monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-to-host-second-quarter-2014-financial-results-webcast-and-conference-nerv-20140731monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-inc-nasdaq-nerv-to-ring-the-nasdaq-stock-market-closing-bell-nerv-20140703monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-announces-pricing-of-100-million-public-offering-of-common-stock-a-ikt-20251121monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded--ikt-20251120monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-advancing-ikt-001-to-global-phase-3-study-in-pulmonary-arterial-hy-ikt-20251120monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-reports-third-quarter-financial-results-and-highlights-recent-acti-ikt-20241114monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-reports-second-quarter-financial-results-and-highlights-recent-per-ikt-20240814monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-to-report-second-quarter-2024-financial-results-on-august-14-2024-ikt-20240807monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-completes-enrollment-of-the-phase-2-201-trial-evaluating-risvodeti-ikt-20240617monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-announces-expansion-to-its-therapeutic-pipeline-and-updates-its-re-ikt-20240605monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-reports-first-quarter-financial-results-and-highlights-recent-peri-ikt-20240516monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-announces-request-for-withdrawal-of-s-1-registration-statement-ikt-20240515monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-announces-final-pre-ind-meeting-outcomes-for-ikt-001pro-as-a-treat-ikt-20240509monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-announces-pre-ind-meeting-with-the-fda-for-ikt-001pro-in-pulmonary-ikt-20240403monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-hi-ikt-20240327monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-to-provide-trial-update-for-risvodetinib-at-the-2024-international-ikt-20240307monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-announces-full-outcomes-of-its-pre-nda-meeting-with-the-fda-for-ik-ikt-20240228monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-announces-publication-highlighting-results-from-its-phase-1-studie-ikt-20240129monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-issues-letter-to-shareholders-and-provides-update-on-development-p-ikt-20231219monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-granted-pre-nda-meeting-with-the-fda-for-ikt-001pro-ikt-20231204monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-reports-third-quarter-financial-results-and-highlights-recent-peri-ikt-20231114monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-to-report-second-quarter-financial-results-on-november-14-2023-ikt-20231107monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-highlights-unblinded-functional-analysis-from-the-201-trial-of-ris-ikt-20231016monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-receives-fda-orphan-drug-designation-for-risvodetinib-for-the-trea-ikt-20231004monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-announces-appointment-of-elizabeth-o-farrell-to-its-board-of-direc-ikt-20190409monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-expands-its-scientific-advisory-board-with-the-appointment-of-lead-ikt-20190319monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-appoints-leading-experts-in-parkinson-s-disease-to-its-scientific--ikt-20190305monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-files-two-investigational-new-drug-applications-for-ikt-148009-a-d-ikt-20190226monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-to-report-second-quarter-2020-financial-results-and-provide-corporat-arct-20200804monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-agreement-with-israeli-ministry-of-health-to-supply-covid--arct-20200723monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-duke-nus-received-approval-to-proceed-with-phase-1-2-clinical-trial--arct-20200721monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-the-formation-of-its-vaccine-platform-scientific-advisory--arct-20200701monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-to-be-added-to-russell-2000-index-arct-20200629monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-to-present-at-the-raymond-james-human-health-innovation-virtual-conf-arct-20200611monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-first-healthy-volunteer-dosed-in-phase-1-study-of-arct-810-arct-20200605monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-reports-additional-supportive-preclinical-data-for-its-covid-19-vaccine-candidate-arct-20200508monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-to-report-first-quarter-2020-financial-results-and-provide-a-corpora-arct-20200504monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-and-catalent-announce-partnership-to-manufacture-mrna-based-covid-19-arct-20200504monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-reports-positive-preclinical-data-for-its-covid-19-vaccine-candidate-arct-20200427monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-closing-of-public-offering-and-full-exercise-of-underwrite-arct-20200421monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-pricing-of-70-0-million-public-offering-of-common-stock-arct-20200416monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-proposed-public-offering-of-common-stock-arct-20200415monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-allowance-of-ind-approval-of-clinical-trial-application-ct-arct-20200413monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-clinical-trial-timeline-for-its-covid-19-vaccine-arct-20200409monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-covid-19-vaccine-to-benefit-from-duke-nus-genetic-correlation-system-arct-20200327monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-to-report-fourth-quarter-and-year-end-2019-financial-results-and-pro-arct-20200224monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-to-present-at-two-investor-conferences-in-march-arct-20200219monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-appoints-steve-hughes-m-d-as-chief-development-officer-arct-20200108monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-expands-platform-with-starr-technology-arct-20191107monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-to-report-corporate-overview-and-financial-results-on-november-7th-arct-20191104monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-to-present-at-three-upcoming-investor-conferences-arct-20191002monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-to-present-at-two-investor-conferences-in-september-arct-20190826monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-to-report-corporate-overview-and-financial-results-on-august-15-arct-20190807monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-to-participate-in-two-panels-at-the-roth-rna-revolution-conference-arct-20190710monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-receives-orphan-drug-designation-from-the-u-s-fda-for-arct-810-for-t-arct-20190627monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-redomiciliation-to-the-united-states-as-a-delaware-corpora-arct-20190613monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-annual-and-extraordinary-general-meeting-of-shareholders-t-arct-20180720monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-announces-management-appointments-company-founder-joseph-e-payne-reinstated-as-pr-arct-20180531monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-extraordinary-general-meeting-of-shareholders-arct-20180531monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-appoints-four-new-directors-and-reaches-settlement-agreement-with-fo-arct-20180529monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-founder-joseph-payne-calls-for-an-end-to-company-s-frivolous-and-cos-arct-20180523monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-extraordinary-general-meeting-of-shareholders-arct-20180521monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-files-form-20-f-arct-20180514monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-founder-joseph-payne-welcomes-court-decision-to-set-date-and-agenda--arct-20180514monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-founder-joseph-payne-successfully-prevents-board-s-egregious-attempt-arct-20180502monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-founder-joseph-payne-dismisses-board-s-baseless-lawsuit-as-desperate-arct-20180423monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-files-lawsuit-against-joseph-e-payne-and-his-associates-for-violatio-arct-20180420monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-founder-joseph-payne-disappointed-by-board-s-desperate-attempt-to-de-arct-20180413monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-issues-statement-regarding-timing-of-extraordinary-general-meeting-o-arct-20180408monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-issues-open-letter-to-shareholders-arct-20180328monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-extraordinary-general-meeting-of-shareholders-arct-20180312monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-extraordinary-general-meeting-of-shareholders-arct-20180131monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-inc-announces-pricing-of-public-offering-of-common-stock-chrs-20260213monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-inc-announces-proposed-public-offering-of-common-stock-chrs-20260212monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-management-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-chrs-20260106monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-six-year-jupiter-02-follow-up-results-showing-loqtorzi-plus-chemotherapy-chrs-20251208monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-to-report-third-quarter-2025-financial-results-on-november-6-2025-chrs-20251030monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-to-participate-in-upcoming-investor-conferences-chrs-20250903monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-to-report-second-quarter-2025-financial-results-on-august-7-2025-chrs-20250731monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-clinical-collaboration-with-storm-therapeutics-to-evaluate-stc-15-in-com-chrs-20250527monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-to-report-first-quarter-2025-financial-results-on-may-12-2025-chrs-20250505monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-to-participate-in-upcoming-investor-conferences-chrs-20250501monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-presents-promising-early-clinical-data-from-phase-1-dose-expansion-study-of-chs-11-chrs-20250428monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-to-present-data-from-a-phase-1-dose-expansion-study-of-chs-114-a-cytolytic-antibod-chrs-20250325monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-10-2025-chrs-20250303monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-management-to-participate-at-the-45th-annual-td-cowen-health-care-conference-chrs-20250224monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-presents-final-phase-2-clinical-casdozokitug-combination-data-in-patients-with-met-chrs-20250122monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-management-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-chrs-20250108monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-to-present-final-phase-2-casdozokitug-combination-data-in-patients-with-metastatic-chrs-20241218monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-management-to-participate-in-the-2024-citi-global-healthcare-conference-chrs-20241127monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-to-report-third-quarter-2024-financial-results-on-november-6-2024-chrs-20241030monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-to-report-second-quarter-2024-financial-results-on-august-8-2024-chrs-20240801monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-appoints-rita-karachun-cpa-cgma-to-its-board-of-directors-chrs-20240605monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-management-to-present-at-the-2024-jefferies-global-healthcare-conference-chrs-20240530monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-presents-preliminary-results-from-phase-i-dose-escalation-study-of-its-anti-chemok-chrs-20240523monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-management-to-present-at-the-td-cowen-5th-annual-oncology-innovation-virtual-summi-chrs-20240523monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-full-repayment-of-pharmakon-advisors-75-million-term-loan-chrs-20240509monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-clinical-collaboration-with-the-cancer-research-institute-for-a-novel-co-chrs-20240508monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-to-report-first-quarter-2024-financial-results-on-may-9-2024-chrs-20240501monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-presentation-at-the-2024-american-society-of-clinical-oncology-asco-annu-chrs-20240424monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-presents-preclinical-data-for-chs-1000-a-novel-anti-ilt4-antibody-at-the-2024-aacr-chrs-20240408monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-fourth-quarter-full-year-2023-financial-results-and-provides-c-chrs-20240313monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-to-report-fourth-quarter-and-full-year-2023-financial-results-on-march-13-2024-chrs-20240305monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20240223monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-u-s-launch-of-udenyca-onbody-a-novel-and-proprietary-state-of-the-art-de-chrs-20240221monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-presents-positive-phase-2-clinical-data-on-casdozokitug-a-first-in-class-il-27-tar-chrs-20240118monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-the-42nd-annual-j-p-morgan-healthcare-confere-chrs-20240103monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-u-s-launch-of-loqtorzi-chrs-20240102monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-fda-approval-of-udenyca-onbody-a-novel-and-proprietary-state-of-the-art--chrs-20231226monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20231222monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-updated-nccn-clinical-practice-guidelines-positioning-loqtorzi-toripalim-chrs-20231211monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-cfo-transition-plans-chrs-20231207monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-presents-phase-1-2-clinical-data-on-casdozokitug-a-first-in-class-il-27-targeted-a-chrs-20231206monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-junshi-biosciences-announce-publication-of-positive-final-overall-survival-res-chrs-20231128monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-presents-data-from-next-generation-immuno-oncology-programs-at-38th-annual-meeting-chrs-20231103monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-participate-at-upcoming-november-investor-conferences-chrs-20231103monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-third-quarter-2023-financial-results-on-november-6-2023-chrs-20231030monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20231024monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-toripalimab-data-at-2023-aacr-nci-eortc-international-conference-on-mole-chrs-20231014monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-resubmission-of-biologics-license-application-bla-supplement-for-udenyca-chrs-20231005monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-applauds-congressional-designation-of-september-30th-as-rare-cancer-day-chrs-20231002monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-three-presentations-at-the-38th-annual-meeting-of-the-society-for-immuno-chrs-20230927monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20230923monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-completes-surface-oncology-acquisition-chrs-20230908monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-participate-at-upcoming-september-investor-conferences-chrs-20230901monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20230822monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-second-quarter-2023-financial-results-on-august-02-2023-chrs-20230726monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20230721monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-appoints-dr-michael-ryan-to-its-board-of-directors-chrs-20230720monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-superior-biologics-announce-national-distribution-agreement-for-yusimry-chrs-20230713monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-launches-yusimry-a-biosimilar-of-humira-at-995-per-carton-in-u-s-chrs-20230703monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20230627monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-to-acquire-surface-oncology-chrs-20230616monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-positive-final-overall-survival-results-of-jupiter-02-phase-3-trial-eval-chrs-20230605monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-industry-wide-lowest-list-price-for-adalimumab-biosimilar-yusimry-adalim-chrs-20230601monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-u-s-launch-of-udenyca-autoinjector-chrs-20230522monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-prices-public-offering-of-common-stock-chrs-20230516monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-proposed-public-offering-of-common-stock-chrs-20230515monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-present-at-upcoming-investor-conferences-in-may-chrs-20230504monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-first-quarter-2023-financial-results-on-may-8-2023-chrs-20230501monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-junshi-biosciences-announce-toripalimab-studies-to-be-presented-at-the-2023-am-chrs-20230427monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-present-at-upcoming-investor-conferences-in-march-chrs-20230301monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-chrs-20230228monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-junshi-biosciences-announce-positive-final-overall-survival-results-of-jupiter-chrs-20230215monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-granted-permanent-product-specific-q-code-for-cimerli-ranibizumab-eqrn-from-the-ce-chrs-20230213monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20230203monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-agrees-to-acquire-exclusive-u-s-commercial-rights-to-eylea-biosimilar-fyb203-from--chrs-20230109monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-the-41st-annual-j-p-morgan-healthcare-confere-chrs-20230104monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-junshi-biosciences-share-update-on-the-fda-review-of-the-biologics-license-app-chrs-20221224monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-third-quarter-2022-financial-results-on-november-8th-2022-chrs-20221101monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-junshi-biosciences-announce-publication-of-positive-results-from-choice-01-a-p-chrs-20221012monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-to-launch-cimerli-ranibizumab-eqrn-in-the-united-states-on-october-3-2022-chrs-20220919monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-h-c-wainwright-24th-annual-global-investment--chrs-20220912monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20220830monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20220802monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-second-quarter-2022-financial-results-on-august-4th-2022-chrs-20220728monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-junshi-biosciences-announce-fda-acceptance-of-resubmission-of-bla-for-toripali-chrs-20220706monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20220622monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-appoints-dr-jill-o-donnell-tormey-to-its-board-of-directors-chrs-20220511monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-upcoming-investor-conferences-chrs-20220510monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-appoints-charlie-newton-to-board-of-directors-chrs-20220505monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20220504monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-junshi-biosciences-receive-complete-response-letter-from-u-s-fda-for-toripalim-chrs-20220502monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-first-quarter-2022-financial-results-on-may-5th-2022-chrs-20220429monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-junshi-biosciences-announce-pd-1-inhibitor-toripalimab-granted-orphan-drug-des-chrs-20220414monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-junshi-biosciences-present-results-of-phase-3-study-of-toripalimab-in-first-li-chrs-20220408monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20220405monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-highlights-anticipated-new-product-launches-and-immuno-oncology-growth-strategy-at-chrs-20220329monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-highlight-new-product-pipeline-cancer-immunotherapy-development-pla-chrs-20220322monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-appoints-rosh-dias-md-mrcp-chief-medical-officer-chrs-20220315monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-management-to-present-at-upcoming-investor-conferences-chrs-20220304monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-junshi-biosciences-announce-positive-results-from-phase-3-esophageal-cancer-st-chrs-20220304monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-names-paul-reider-chief-commercial-officer-chrs-20220215monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20220214monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-fourth-quarter-and-full-year-2021-financial-results-on-febru-chrs-20220211monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-appoints-health-care-payer-expert-lee-n-newcomer-m-d-to-board-of-direc-chrs-20220207monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-the-40th-annual-j-p-morgan-healthcare-confere-chrs-20220104monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-u-s-fda-approval-of-yusimry-adalimumab-aqvh-chrs-20211220monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-appoints-theresa-lavallee-ph-d-chief-development-officer-chrs-20211217monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20211216monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-junshi-biosciences-announce-positive-interim-overall-survival-results-of-choic-chrs-20211213monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-junshi-biosciences-announce-toripalimab-granted-orphan-drug-designation-in-the-chrs-20211115monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20211110monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-cms-has-extended-enhanced-medicare-reimbursement-for-udenyca-chrs-20211105monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-junshi-biosciences-announce-fda-acceptance-of-bla-filing-for-toripalimab-for-t-chrs-20211101monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-third-quarter-2021-financial-results-on-november-8th-chrs-20211029monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-positive-results-of-udenyca-on-body-injector-clinical-trial-chrs-20211005monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-bla-filing-for-lucentis-ranibizumab-biosimilar-candidate-accepted-by-fda-chrs-20211001monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20210924monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-junshi-biosciences-to-present-positive-progression-free-survival-and-overall-s-chrs-20210916monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-junshi-biosciences-announce-results-from-phase-3-study-of-toripalimab-publishe-chrs-20210915monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-management-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conferen-chrs-20210910monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-upcoming-medical-conference-presentations-chrs-20210908monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-junshi-biosciences-announce-completion-of-rolling-bla-submission-to-u-s-fda-fo-chrs-20210901monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20210827monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-junshi-biosciences-announce-positive-interim-results-of-choice-01-a-phase-3-cl-chrs-20210818monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-second-quarter-2021-financial-results-on-august-5th-chrs-20210726monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-names-physician-scientist-ildiko-csiki-m-d-ph-d-chair-of-its-scientifi-chrs-20210721monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20210713monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-junshi-biosciences-to-host-virtual-investor-event-to-discuss-toripalimab-and-a-chrs-20210604monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-junshi-biosciences-announce-toripalimab-in-combination-with-chemotherapy-met-p-chrs-20210603monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-present-at-the-bank-of-america-health-care-conference-chrs-20210507monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20210430monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-first-quarter-2021-financial-results-on-may-6th-chrs-20210430monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-toripalimab-achieved-primary-endpoints-of-progression-free-survival-and--chrs-20210423monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-closing-of-sale-of-common-stock-to-immuno-oncology-partner-junshi-biosci-chrs-20210420monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-management-to-present-at-upcoming-investor-conferences-chrs-20210225monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-fourth-quarter-and-full-year-2020-financial-results-on-febru-chrs-20210218monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-bla-filing-for-adalimumab-biosimilar-candidate-accepted-by-fda-for-review-chrs-20210217monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-cfo-transition-plans-chrs-20210216monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-receive-50-million-strategic-investment-from-immuno-oncology-partne-chrs-20210202monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20210122monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-the-39th-annual-j-p-morgan-healthcare-confere-chrs-20210105monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20201221monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20201120monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-third-quarter-financial-results-on-november-5th-chrs-20201022monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20201016monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20200918monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20200821monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20200717monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-second-quarter-financial-results-on-august-6th-chrs-20200716monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20200619monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-bofa-securities-2020-health-care-conference-chrs-20200504monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-first-quarter-financial-results-on-may-7th-chrs-20200422monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-prices-200-0-million-convertible-senior-subordinated-notes-offering-chrs-20200415monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-provides-first-quarter-2020-financial-update-and-fiscal-year-2020-covi-chrs-20200413monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20200320monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-barclays-global-healthcare-conference-2020-chrs-20200305monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-the-40th-annual-cowen-healthcare-conference-chrs-20200226monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20200220monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-fourth-quarter-and-full-year-financial-results-on-february-2-chrs-20200206monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-acquires-commercial-rights-for-avastin-biosimilar-in-the-united-states-chrs-20200113monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-the-38th-annual-j-p-morgan-healthcare-confere-chrs-20200103monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-two-upcoming-investor-healthcare-conferences-chrs-20191112monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20191108monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-acquires-commercial-rights-for-leading-lucentis-biosimilar-in-the-united-states-chrs-20191106monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20191018monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-third-quarter-financial-results-on-november-6th-chrs-20191015monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20190920monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20190822monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-two-investor-healthcare-conferences-in-septem-chrs-20190821monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-victory-in-pegfilgrastim-patent-dispute-chrs-20190730monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20190719monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-second-quarter-financial-results-on-august-1st-chrs-20190708monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-production-exceeds-four-hundred-thousand-udenyca-pegfilgrastim-cbqv-pr-chrs-20190701monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20190621monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20190523monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-jefferies-2019-global-healthcare-conference-chrs-20190522monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-two-upcoming-investor-healthcare-conferences-chrs-20190502monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20190419monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-first-quarter-financial-results-on-may-9th-chrs-20190405monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-h-c-wainwright-co-global-life-sciences-confer-chrs-20190328monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20190322monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20190319monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-appoints-thomas-fitzpatrick-chief-legal-officer-chrs-20190318monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-two-investor-healthcare-conferences-in-march-chrs-20190226monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20190222monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-fourth-quarter-and-full-year-2018-financial-results-on-febru-chrs-20190214monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20190207monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-filing-of-patent-infringement-suit-against-amgen-directed-to-chrs-20190125monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-global-settlement-with-abbvie-securing-rights-to-commerciali-chrs-20190125monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20190118monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20190114monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-secures-75-million-credit-financing-with-healthcare-royalty-partners-chrs-20190107monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-appoints-darlene-horton-m-d-chief-medical-and-regulatory-affairs-offic-chrs-20190102monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-the-37th-annual-j-p-morgan-healthcare-confere-chrs-20190102monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20181219monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-apexus-contract-agreement-for-340b-hospitals-and-clinics-and-chrs-20181130monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20181127monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-the-27th-annual-credit-suisse-healthcare-conf-chrs-20181112monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-third-quarter-2018-financial-results-on-november-8th-chrs-20181022monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20181009monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20180921monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-the-2018-cantor-global-healthcare-conference--chrs-20180917monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-participate-in-two-investor-healthcare-conferences-in-se-chrs-20180820monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20180817monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20180725monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-second-quarter-2018-financial-results-on-august-8th-chrs-20180724monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20180622monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20180525monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-prices-public-offering-of-common-stock-chrs-20180522monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-the-bank-of-america-merrill-lynch-health-care-chrs-20180501monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-first-quarter-2018-financial-results-on-may-10th-chrs-20180424monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20180419monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-the-h-c-wainwright-annual-global-life-science-chrs-20180402monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20180313monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-two-investor-healthcare-conferences-in-march-chrs-20180301monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-fourth-quarter-and-full-year-2017-financial-results-on-march-chrs-20180227monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-the-36th-annual-j-p-morgan-healthcare-confere-chrs-20180102monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-bmo-s-prescriptions-for-success-healthcare-co-chrs-20171201monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-credit-suisse-scottsdale-healthcare-conferenc-chrs-20171101monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-third-quarter-2017-financial-results-on-november-6th-chrs-20171023monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-three-investor-healthcare-conferences-in-sept-chrs-20170901monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-secures-private-placement-from-temasek-chrs-20170821monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-files-petition-for-inter-partes-review-of-enbrel-patent-8-163-522-chrs-20170807monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-second-quarter-2017-financial-results-on-august-7th-chrs-20170724monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-36th-nasdaq-omx-investor-program-chrs-20170601monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-prevails-in-135-ipr-decision-chrs-20170516monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-two-investor-healthcare-conferences-in-may-chrs-20170501monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-first-quarter-2017-financial-results-on-may-8th-chrs-20170424monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-appoints-erik-wiberg-as-executive-vice-president-of-corporate-developm-chrs-20170327monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-addresses-trade-secret-action-filed-by-amgen-chrs-20170306monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-chs-1420-pharmacokinetic-clinical-bioequivalence-study-meets-primary-end-chrs-20170302monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-two-investor-healthcare-conferences-in-march-chrs-20170301monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-fourth-quarter-and-full-year-2016-financial-results-on-march-chrs-20170221monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20170217monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-prices-public-offering-of-common-stock-chrs-20170208monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-positive-topline-24-week-treatment-phase-three-results-for-c-chrs-20170110monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-the-35th-annual-j-p-morgan-healthcare-confere-chrs-20170104monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-present-at-bmo-prescriptions-for-success-healthcare-conference-on-d-chrs-20161207monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20161118monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20161104monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-third-quarter-2016-financial-results-on-november-9th-chrs-20161101monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-two-investor-healthcare-conferences-in-novemb-chrs-20161101monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20161021monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-regains-development-and-commercial-rights-to-chs-0214-from-shire-chrs-20160927monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20160916monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-management-to-present-at-two-investor-healthcare-conferences-in-septem-chrs-20160901monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-new-employment-inducement-grants-chrs-20160831monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-submits-351-k-biologics-license-application-to-u-s-food-and-drug-admin-chrs-20160809monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-positive-topline-phase-three-results-for-chs-1420-humira-bio-chrs-20160808monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-second-quarter-2016-financial-results-on-august-9th-chrs-20160725monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-provides-update-on-iprs-chrs-20160613monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-presents-study-results-demonstrating-equivalence-of-its-chs-0214-biosimilar-to-eta-chrs-20160610monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-present-at-jefferies-2016-healthcare-conference-on-june-8-chrs-20160603monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-advances-differentiated-ip-strategy-for-humira-market-access-chrs-20160526monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-prices-public-offering-of-common-stock-chrs-20160523monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-provides-update-on-135-ipr-chrs-20160517monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-appoints-patrick-o-brien-as-senior-vice-president-investor-relations-chrs-20160516monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-present-at-bank-of-america-merrill-lynch-health-care-conference-on--chrs-20160504monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-first-quarter-2016-financial-results-on-may-9-chrs-20160502monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-present-at-barclays-generic-pharmaceuticals-symposium-on-april-6-chrs-20160329monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-present-at-barclays-global-healthcare-conference-on-march-16-chrs-20160307monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-private-placement-of-100-million-senior-convertible-notes-chrs-20160229monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-present-at-cowen-and-company-healthcare-conference-on-march-8-chrs-20160226monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-fourth-quarter-and-year-end-2015-financial-results-on-februa-chrs-20160215monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-present-at-bloomberg-intelligence-healthcare-event-on-february-12th-chrs-20160205monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-the-appointment-of-jim-daly-executive-chairman-commercial-advisory-commi-chrs-20160201monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-present-at-j-p-morgan-healthcare-conference-on-january-11-chrs-20160104monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-present-at-jefferies-autumn-2015-global-healthcare-conference-on-no-chrs-20151110monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-baxalta-announce-chs-0214-investigational-etanercept-biosimilar-met-primary-ef-chrs-20151109monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-present-at-credit-suisse-healthcare-conference-on-november-10-chrs-20151028monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-present-at-bloomberg-biosimilars-conference-on-november-2-chrs-20151027monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-third-quarter-2015-financial-results-on-november-9-chrs-20151026monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-appoints-juliana-m-reed-vice-president-government-affairs-chrs-20150909monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-present-at-morgan-stanley-global-healthcare-conference-on-september-chrs-20150904monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-provides-updates-on-clinical-studies-chrs-20150903monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-second-quarter-2015-financial-results-on-august-10-chrs-20150728monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-present-at-jefferies-healthcare-conference-on-june-3-chrs-20150527monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-first-quarter-2015-financial-results-on-may-11-chrs-20150504monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-present-at-deutsche-bank-health-care-conference-on-may-7-chrs-20150430monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-prices-upsized-public-offering-of-120-0-million-of-common-stock-chrs-20150401monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-proposed-public-offering-of-common-stock-chrs-20150330monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-report-fourth-quarter-and-year-end-2014-financial-results-on-march--chrs-20150316monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-present-at-cowen-and-company-health-care-conference-on-march-2-chrs-20150223monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-present-at-leerink-healthcare-conference-on-february-11-chrs-20150204monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-present-at-the-j-p-morgan-healthcare-conference-on-january-12-chrs-20141208monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-host-earnings-conference-call-on-december-15-chrs-20141204monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-prices-initial-public-offering-of-85-million-of-common-stock-chrs-20141106monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-participate-in-a-september-investor-conference-nktx-20250902monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-participate-in-march-investor-conferences-nktx-20250225monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-announces-ind-clearance-of-investigator-sponsored-trial-in-myasthenia-gravis-and-op-nktx-20241205monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-participate-in-an-upcoming-investor-conference-nktx-20241126monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-participate-in-an-upcoming-investor-conference-nktx-20241112monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-participate-in-upcoming-investor-conference-nktx-20240903monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-announces-initiation-of-investigator-sponsored-clinical-trial-evaluating-nkx019-for-nktx-20240724monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-participate-in-upcoming-investor-conferences-nktx-20240403monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-announces-pricing-of-240-million-underwritten-offering-nktx-20240325monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-participate-in-upcoming-investor-conferences-nktx-20240228monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-presents-nkx101-clinical-data-at-the-2023-american-society-of-hematology-annual-mee-nktx-20231210monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-participate-at-upcoming-investor-conferences-nktx-20231107monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-receives-fda-clearance-of-ind-application-for-nkx019-in-lupus-nephritis-nktx-20231017monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-participate-at-upcoming-investor-conference-nktx-20230803monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-presents-nkx019-clinical-data-at-the-european-hematology-association-2023-congress--nktx-20230610monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-present-nkx019-phase-1-dose-escalation-data-at-european-hematology-association-2-nktx-20230511monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-presents-preclinical-data-exploring-gene-knockout-strategies-and-combination-agents-nktx-20230417monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-participate-at-upcoming-investor-conferences-nktx-20230413monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-participate-at-upcoming-investor-conferences-nktx-20230209monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-host-conference-call-to-discuss-updated-clinical-data-from-nkx019-nk-cell-therap-nktx-20221202monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-presents-data-supporting-engineered-nk-cell-based-combination-therapies-and-next-ge-nktx-20221107monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-participate-at-upcoming-investor-conferences-nktx-20221102monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-announces-key-senior-leadership-team-appointments-nktx-20220725monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-participate-at-upcoming-investor-conference-nktx-20220531monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-announces-closing-of-upsized-public-offering-of-common-stock-and-underwriters-full--nktx-20220428monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-announces-pricing-of-upsized-public-offering-of-common-stock-nktx-20220426monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-announces-proposed-public-offering-of-common-stock-nktx-20220425monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-host-conference-call-highlighting-preliminary-clinical-data-from-two-lead-nk-cel-nktx-20220422monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-presents-new-preclinical-data-from-engineered-nk-cell-platform-at-aacr-annual-meeti-nktx-20220408monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-participate-at-upcoming-investor-conference-nktx-20220408monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-present-preclinical-data-from-engineered-nk-cell-platform-at-the-american-associ-nktx-20220308monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-participate-at-upcoming-investor-conferences-nktx-20220210monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-receives-u-s-fda-orphan-drug-designation-for-nkx101-for-treatment-of-patients-with--nktx-20211216monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-presents-nkx019-trial-in-progress-poster-at-the-2021-ash-annual-meeting-and-exposit-nktx-20211213monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-presents-new-preclinical-data-from-engineered-nk-cell-platform-at-sitc-36th-annual--nktx-20211112monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-participate-at-upcoming-investor-conferences-nktx-20211104monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-present-preclinical-data-from-engineered-nk-cell-platform-at-sitc-36th-annual-me-nktx-20211001monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-participate-at-upcoming-investor-conference-nktx-20210914monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-present-at-upcoming-investor-conference-nktx-20210616monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-therapeutics-ceo-paul-hastings-named-bio-chair-for-2021-2022-term-nktx-20210614monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-announces-june-2021-investor-conference-schedule-nktx-20210525monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-announces-february-and-march-2021-investor-conference-schedule-nktx-20210217monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-announces-treatment-of-first-patient-in-first-in-human-clinical-trial-of-engineered-nktx-20201112monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-announces-presentation-of-preclinical-data-on-nkx019-engineered-nk-cell-therapy-can-nktx-20201109monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-announces-november-december-2020-investor-conference-schedule-nktx-20201105monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-announces-leadership-changes-nktx-20201005monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-announces-october-2020-investor-conference-schedule-nktx-20200929monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-announces-september-2020-virtual-investor-conference-schedule-nktx-20200908monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-announces-pricing-of-initial-public-offering-nktx-20200710monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-therapeutics-presents-preclinical-findings-supporting-gene-editing-of-natural-kille-nktx-20200622monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-therapeutics-appoints-two-new-independent-directors-nktx-20200427monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-therapeutics-to-present-at-the-j-p-morgan-healthcare-conference-nktx-20200109monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-therapeutics-expands-senior-management-team-with-key-hires-in-finance-and-clinical--nktx-20191209monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-therapeutics-presents-preclinical-data-for-cd19-car-nk-program-nktx-20191118monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-therapeutics-named-as-a-fierce-15-biotechnology-company-of-2019-nktx-20190923monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-therapeutics-promotes-nadir-mahmood-ph-d-to-chief-business-officer-nktx-20190918monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-therapeutics-appoints-vice-president-of-regulatory-affairs-nktx-20190910monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-therapeutics-raises-114-million-in-series-b-financing-to-advance-multiple-programs--nktx-20190904monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-therapeutics-presents-data-at-aacr-demonstrating-proprietary-nk-cell-engineering-an-nktx-20190401monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-therapeutics-announces-appointment-of-matthew-plunkett-ph-d-as-chief-financial-offi-nktx-20181210monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-therapeutics-appoints-kanya-rajangam-m-d-ph-d-as-chief-medical-officer-nktx-20181127monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-therapeutics-reports-potent-natural-killer-cell-anti-cancer-activity-in-preclinical-nktx-20181109monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-therapeutics-expands-management-team-and-establishes-new-corporate-headquarters-nktx-20180709monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-therapeutics-announces-exclusive-license-to-natural-killer-cell-technology-from-nat-nktx-20180611monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-therapeutics-appoints-veteran-executive-paul-hastings-as-ceo-to-lead-next-phase-of--nktx-20180301monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-presentation-at-vasa-meeting-of-research-highlighting-self-repair-of-at-huma-20260526monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-symvess-is-now-under-contract-with-the-strategic-acquisition-center-sac-huma-20260520monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-appoints-dr-todd-e-rasmussen-as-chief-surgical-officer-huma-20260512monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-appoints-jim-mercadante-as-chief-commercial-officer-huma-20260422monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-israeli-ministry-of-health-acceptance-of-marketing-authorization-applic-huma-20260421monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-receives-symvess-purchase-commitment-for-clinical-evaluation-and-outreach-program-huma-20260319monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-hospital-charge-data-showing-high-expense-of-preventable-extremity-arte-huma-20260108monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-credit-facility-of-up-to-77-5-million-with-avenue-capital-huma-20251216monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-second-quarter-financial-results-and-provide-corporate-update-on-augus-huma-20250807monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-first-symvess-sale-to-military-treatment-facility-huma-20250723monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-symvess-ecat-approval-from-u-s-defense-logistics-agency-huma-20250708monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-clinical-results-in-high-risk-dialysis-patients-from-v007-pivotal-phase-3-huma-20250602monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-at-the-h-c-wainwright-3rd-annual-bioconnect-investor-conference-at-nas-huma-20250519monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-first-quarter-financial-results-and-provide-corporate-update-on-may-13-huma-20250509monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-fourth-quarter-and-full-year-financial-results-and-provide-corporate-u-huma-20250326monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-inc-announces-pricing-of-public-offering-of-common-stock-huma-20250326monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-publication-of-the-budget-impact-model-bim-for-symvess-acellular-tissue-huma-20250310monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-host-in-person-and-virtual-investor-event-in-new-york-to-discuss-commercial-la-huma-20250303monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-at-the-td-cowen-45th-annual-health-care-conference-huma-20250227monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-issuance-of-u-s-patent-covering-manufacturing-of-symvess-and-other-bioe-huma-20250227monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-commercial-launch-of-symvess-acellular-tissue-engineered-vessel-tyod-fo-huma-20250226monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-and-pluristyx-announce-gene-editing-partnership-to-support-biovascular-pancreas-b-huma-20250128monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-alert-bragar-eagel-squire-p-c-is-investigating-humacyte-inc-on-behalf-of-long-ter-huma-20250124monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-planned-ind-filing-in-2025-to-support-first-in-human-clinical-study-of--huma-20250121monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-inc-nasdaq-huma-deadline-alert-bernstein-liebhard-llp-reminds-humacyte-inc-invest-huma-20250113monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-be-huma-20250113monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-provides-update-on-commercial-launch-and-pricing-of-symvess-acellular-tissue-engi-huma-20250113monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-january--huma-20250110monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-inc-nasdaq-huma-deadline-alert-bernstein-liebhard-llp-reminds-humacyte-inc-invest-huma-20250107monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-inc-nasdaq-huma-deadline-alert-bernstein-liebhard-llp-reminds-humacyte-inc-invest-huma-20241230monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-huma-20241227monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-huma-20241224monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-inc-nasdaq-huma-deadline-alert-bernstein-liebhard-llp-reminds-humacyte-inc-invest-huma-20241223monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-huma-20241220monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-s-huma-insiders-sell-millions-in-stock-amidst-lawsuit-and-regulatory-troubles-hag-huma-20241219monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-inc-class-action-lawsuit-alert-johnson-fistel-announces-shareholders-with-losses--huma-20241219monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-inc-nasdaq-huma-deadline-alert-bernstein-liebhard-llp-reminds-humacyte-inc-invest-huma-20241218monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-huma-20241218monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-s-huma-statements-to-investors-called-into-question-in-light-of-fda-violations-ha-huma-20241216monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-s-huma-statements-to-investors-called-into-question-in-light-of-fda-violations-ha-huma-20241212monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-huma-20241211monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-s-huma-statements-to-investors-called-into-question-in-light-of-fda-violations-ha-huma-20241209monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-inc-nasdaq-huma-deadline-alert-bernstein-liebhard-llp-reminds-humacyte-inc-invest-huma-20241209monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-huma-20241206monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-s-huma-statements-to-investors-called-into-question-in-light-of-fda-violations-ha-huma-20241205monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-inc-class-action-lawsuit-alert-johnson-fistel-announces-shareholders-with-losses--huma-20241203monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-s-huma-statements-to-investors-called-into-question-in-light-of-fda-violations-ha-huma-20241202monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-inc-nasdaq-huma-deadline-alert-bernstein-liebhard-llp-reminds-humacyte-inc-invest-huma-20241202monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-at-the-piper-sandler-36th-annual-healthcare-conference-huma-20241202monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-s-huma-statements-to-investors-called-into-question-in-light-of-fda-violations-ha-huma-20241128monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-huma-20241126monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-inc-class-action-lawsuit-alert-johnson-fistel-announces-shareholders-with-losses--huma-20241125monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-huma-faces-class-action-lawsuit-after-fda-inspection-reveals-manufacturing-issues-huma-20241125monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-inc-nasdaq-huma-deadline-alert-bernstein-liebhard-llp-reminds-humacyte-inc-invest-huma-20241125monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-inc-shareholder-alert-robbins-llp-reminds-investors-of-the-huma-securities-class--huma-20241124monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-efficacy-and-safety-results-from-v007-phase-3-av-access-clinical-trial-huma-20241122monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-inc-nasdaq-huma-investor-alert-investors-with-large-losses-in-humacyte-inc-should-huma-20241121monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-huma-faces-class-action-lawsuit-after-fda-inspection-reveals-manufacturing-issues-huma-20241121monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-clinical-results-highlighting-benefit-of-the-atev-in-the-repair-of-civilian-and-m-huma-20241121monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-huma-20241120monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-huma-faces-class-action-lawsuit-after-fda-inspection-reveals-manufacturing-issues-huma-20241119monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-presents-preclinical-results-of-small-diameter-atev-for-coronary-artery-bypass-gr-huma-20241118monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-s-huma-statements-to-investors-called-into-question-in-light-of-fda-violations-ha-huma-20241115monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-alert-bragar-eagel-squire-p-c-is-investigating-humacyte-inc-on-behalf-of-humacyte-huma-20241113monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-huma-faces-questions-after-fda-inspection-hagens-berman-huma-20241111monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-s-huma-statements-to-investors-called-into-question-in-light-of-fda-violations-ha-huma-20241108monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-third-quarter-financial-results-and-provide-corporate-update-on-novemb-huma-20241106monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-s-huma-statements-to-investors-called-into-question-in-light-of-fda-violations-ha-huma-20241104monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-huma-faces-questions-after-fda-inspection-hagens-berman-huma-20241031monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-s-huma-statements-to-investors-called-into-question-in-light-of-fda-violations-ha-huma-20241028monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-alert-bragar-eagel-squire-p-c-is-investigating-humacyte-inc-on-behalf-of-humacyte-huma-20241025monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-huma-faces-questions-after-fda-inspection-hagens-berman-huma-20241024monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-host-virtual-kol-event-on-the-use-of-acellular-tissue-engineered-vessel-atev-f-huma-20241023monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-late-breaking-abstract-accepted-for-oral-presentation-on-v007-phase-3-av-access-c-huma-20241008monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-host-virtual-kol-event-to-discuss-case-studies-on-the-use-of-acellular-tissue--huma-20240926monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-allowance-of-u-s-patent-covering-biovascular-pancreas-bvp-huma-20240919monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-participate-at-upcoming-investor-conferences-in-september-huma-20240903monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-presents-positive-long-term-results-of-atev-in-treatment-of-vascular-trauma-in-mi-huma-20240827monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-second-quarter-2024-financial-results-and-business-update-huma-20240813monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-second-quarter-financial-results-and-provide-corporate-update-on-augus-huma-20240812monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-board-of-directors-strengthened-with-addition-of-john-p-bamforth-and-keith-anthon-huma-20240716monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-acellular-tissue-engineered-vessel-atev-receives-fda-s-regenerative-medicine-adva-huma-20240701monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-presents-positive-preclinical-data-for-its-biovascular-pancreas-bvp-program-huma-20240625monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-at-the-jefferies-global-healthcare-conference-huma-20240530monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-participate-at-upcoming-investor-conferences-in-may-huma-20240513monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-first-quarter-financial-results-and-provide-corporate-update-on-may-10-huma-20240506monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-host-virtual-kol-event-hemodialysis-access-a-crossroads-of-care-on-march-28-20-huma-20240326monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-2023-fourth-quarter-and-year-end-financial-results-and-provide-corpora-huma-20240318monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-inc-to-present-at-the-td-cowen-44th-annual-health-care-conference-huma-20240301monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-inc-announces-pricing-of-40-2-million-public-offering-of-common-stock-huma-20240301monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-at-the-piper-sandler-35th-annual-healthcare-conference-huma-20231124monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-two-presentations-at-the-veithsymposium-of-positive-clinical-results-of-huma-20231117monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-third-quarter-financial-results-and-provide-corporate-update-on-novemb-huma-20231102monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-publishes-preclinical-results-showing-human-acellular-vessel-hav-patency-as-modif-huma-20231016monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-at-the-cantor-global-healthcare-conference-huma-20230921monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-host-in-person-kol-event-at-the-new-york-edition-on-september-20-2023-huma-20230918monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-announce-top-line-data-from-phase-2-3-v005-trial-in-vascular-trauma-evaluating-huma-20230911monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-presents-clinical-performance-of-human-acellular-vessel-hav-from-ukrainian-humani-huma-20230815monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-second-quarter-financial-results-and-provide-corporate-update-on-augus-huma-20230807monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-publication-of-biological-mechanism-explaining-low-rates-of-infection-o-huma-20230803monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-at-the-jefferies-healthcare-conference-huma-20230605monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-and-oberland-capital-announce-funding-arrangement-totaling-up-to-160-million-huma-20230512monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-publication-in-lancet-regional-health-europe-presenting-use-of-human-ac-huma-20230509monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-first-quarter-financial-results-and-provide-corporate-update-on-may-12-huma-20230505monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-s-human-acellular-vessel-hav-receives-fda-s-regenerative-medicine-advanced-therap-huma-20230504monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-huma-20230428monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-jdrf-collaborating-to-develop-insulin-producing-biovascular-pancreas-to-treat-typ-huma-20230427monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-publication-of-preclinical-study-comparing-human-acellular-vessel-hav-t-huma-20230418monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-completes-enrollment-in-phase-3-trial-of-human-acellular-vessel-hav-for-hemodialy-huma-20230411monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-fourth-quarter-and-full-year-financial-results-and-provide-corporate-u-huma-20230321monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-at-upcoming-investor-conferences-in-march-huma-20230227monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-publication-in-the-journal-of-vascular-surgery-vascular-science-reports-the-human-huma-20230124monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-hosting-key-opinion-leader-webinar-on-vascular-trauma-ukrainian-surgeons-discuss--huma-20221213monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-human-acellular-vessel-hav-ukraine-humanitarian-results-to-be-presented-at-multip-huma-20221201monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-at-the-34th-annual-piper-sandler-healthcare-conference-huma-20221123monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-presents-six-month-human-acellular-vessel-hav-coronary-artery-bypass-graft-cabg-d-huma-20221107monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-third-quarter-financial-results-and-provide-corporate-update-on-novemb-huma-20221103monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-presentations-by-ukrainian-surgeons-on-use-of-the-human-acellular-vesse-huma-20220923monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-presentation-on-investigational-human-acellular-vesseltm-for-treatment--huma-20220909monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-presents-at-multiple-conferences-in-september-2022-huma-20220908monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-second-quarter-2022-financial-results-and-provide-recent-corporate-upd-huma-20220805monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-preclinical-data-on-small-diameter-human-acellular-vessel-hav-in-coronary-artery--huma-20220726monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-presentation-of-preclinical-data-on-the-hav-in-coronary-artery-bypass-g-huma-20220719monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-hosting-key-opinion-leader-webinar-on-human-acellular-vessels-in-the-treatment-of-huma-20220707monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-jama-surgery-publication-highlighting-potential-of-human-acellular-vess-huma-20220629monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-expands-board-of-directors-with-appointment-of-diane-seimetz-ph-d-huma-20220627monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-provides-update-on-patients-treated-at-front-line-hospitals-in-ukraine-with-the-h-huma-20220621monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-presents-new-immunogenicity-data-on-human-acellular-vessels-havs-huma-20220608monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-at-the-h-c-wainwright-global-investment-conference-huma-20220516monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-provide-human-acellular-vessels-havs-to-front-line-hospitals-in-ukraine-for-tr-huma-20220509monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-first-quarter-2022-financial-results-and-provide-recent-corporate-upda-huma-20220506monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-expands-leadership-team-with-appointment-of-shamik-parikh-m-d-as-chief-medical-of-huma-20220405monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-date-of-annual-shareholder-meeting-huma-20220404monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-fourth-quarter-and-full-year-2021-financial-results-and-provide-corpor-huma-20220321monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-at-upcoming-investor-conferences-in-march-huma-20220301monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-publication-of-positive-long-term-follow-up-data-from-phase-2-trial-of--huma-20220228monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-participate-in-fireside-chat-at-btig-medtech-digital-health-life-science-diagn-huma-20220209monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-clinical-case-series-demonstrating-potential-of-human-acellular-vessel--huma-20220131monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-preclinical-results-of-small-diameter-human-acellular-vessel-hav-in-cor-huma-20220128monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-presentation-of-first-eight-expanded-access-cases-using-human-acellular-huma-20220106monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-presentation-of-first-preclinical-results-of-the-hav-in-coronary-artery-huma-20220104monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-the-appointments-of-three-surgical-and-cardiovascular-opinion-leaders-t-huma-20211231monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-publication-highlighting-the-first-use-of-the-human-acellular-vessel-ha-huma-20211215monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-presents-preclinical-results-of-small-diameter-hav-for-use-as-a-btt-shunt-in-pedi-huma-20211116monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-leadership-to-present-at-credit-suisse-30th-annual-healthcare-conference-huma-20211109monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-leadership-to-present-at-multiple-scientific-events-in-november-huma-20211108monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-leadership-to-present-at-seven-scientific-and-industry-events-in-october-huma-20211005monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-issuance-of-three-additional-u-s-patents-covering-its-proprietary-unive-huma-20210920monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-leadership-to-present-at-five-scientific-events-in-september-huma-20210917monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-successful-closing-of-business-combination-with-alpha-healthcare-acquis-huma-20210826monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-highlights-robust-expanded-access-program-and-patient-testimonial-for-human-acell-huma-20210819monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-publication-of-in-vivo-data-on-biovascular-pancreas-transplantation-for-huma-20210811monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-presents-potential-of-functional-lung-engineering-at-janelia-r3-replace-repair-re-huma-20210722monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-participate-in-fireside-chat-at-cowen-6th-annual-futurehealth-conference-huma-20210610monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-presents-in-vivo-data-on-biovascular-pancreas-transplantation-for-type-1-diabetes-huma-20210608monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-provide-investor-update-on-june-7-huma-20210604monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-receives-2021-life-sciences-award-from-triangle-business-journal-huma-20210526monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-presents-advances-in-whole-lung-engineering-huma-20210521monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-ceo-dr-laura-niklason-and-alpha-healthcare-ceo-rajiv-shukla-to-present-at-ced-ven-huma-20210323monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-at-oppenheimer-31st-annual-healthcare-conference-huma-20210311monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-preliminary-results-of-tender-offer-kros-20251119monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-highlights-commitment-to-maximizing-stockholder-value-kros-20250519monthly0.5https://www.biopharmawatch.com/news/KROS/keros-reinforces-commitment-to-maximizing-stockholder-value-kros-20250508monthly0.5https://www.biopharmawatch.com/news/KROS/keros-alert-bragar-eagel-squire-p-c-is-investigating-keros-therapeutics-inc-on-behalf-of-k-kros-20250125monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-66th-american-society-of-hematology-annual-meeting-an-kros-20241105monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-updated-time-of-presentation-at-2024-cantor-global-healthcare-kros-20240912monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-29th-annual-congress-of-the-european-hematology-assoc-kros-20240514monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-pulmonary-vascular-research-institute-2024-annual-congres-kros-20240129monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-pricing-of-upsized-public-offering-of-common-stock-kros-20240104monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-proposed-public-offering-of-common-stock-kros-20240103monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-develop-ker-065-for-the-treatment-of-obesity-kros-20240103monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-65th-american-society-of-hematology-annual-meeting-an-kros-20231102monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-glob-kros-20230612monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-28th-annual-congress-of-the-european-hematology-assoc-kros-20230511monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-cowen-s-43rd-annual-health-care-conference-kros-20230301monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-american-society-for-bone-and-mineral-research-2022-a-kros-20220906monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-27th-annual-congress-of-the-european-hematology-assoc-kros-20220512monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-results-from-a-preclinical-study-of-rker-012-at-the-american-kros-20211108monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-63rd-american-society-of-hematology-annual-meeting-an-kros-20211104monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-10th-annual-svb-leerink-global-healthcare-conference-kros-20210217monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-jefferies-virtual-london-healthcare-conference-kros-20201116monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-proposed-public-offering-of-common-stock-kros-20201110monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-virtual-62nd-american-society-of-hematology-annual-me-kros-20201104monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-h-c-wainwright-22nd-annual-global-investment-conferen-kros-20200914monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-be-featured-on-the-balancing-act-s-behind-the-mystery-rare-disease-s-kros-20200810monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-set-to-join-russell-2000-index-kros-20200626monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-jefferies-2020-virtual-healthcare-conference-kros-20200528monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-virtual-25th-annual-congress-of-the-european-hematolo-kros-20200514monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-closing-of-initial-public-offering-and-full-exercise-of-under-kros-20200413monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-receives-23-million-series-b-funding-for-development-of-therapies-to-tr-kros-20190107monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-investigated-by-the-portnoy-law-firm-smti-20260413monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-publication-of-peer-reviewed-study-evaluating-the-economic-an-smti-20260311monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-receives-innovative-technology-contract-from-vizient-for-biasurge-advan-smti-20260107monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-to-report-third-quarter-2025-financial-results-on-november-12-2025-smti-20251001monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-to-report-second-quarter-2025-financial-results-on-august-13-2025-smti-20250715monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-to-report-first-quarter-2025-financial-results-on-may-14-2025-smti-20250423monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-to-present-at-the-planet-microcap-showcase-vegas-2025-on-april-23-2025-smti-20250410monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2-smti-20250311monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-to-present-at-the-piper-sandler-36th-annual-healthcare-conference-on-decemb-smti-20241125monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-third-quarter-earnings-release-and-conference-call-dates-smti-20241031monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-second-quarter-earnings-release-and-conference-call-dates-smti-20240730monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-first-quarter-earnings-release-and-conference-call-dates-smti-20240429monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-fourth-quarter-and-full-year-2023-earnings-release-and-confer-smti-20240313monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-exclusive-license-agreement-for-patented-collagen-peptides-smti-20240103monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-the-publication-of-a-5-335-patient-study-demonstrating-a-sign-smti-20231130monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-third-quarter-earnings-release-and-conference-call-dates-smti-20231030monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-announces-first-sale-of-allocyte-plus-advanced-viable-bone-matrix-and-provi-smti-20231010monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-to-participate-in-two-upcoming-conferences-smti-20230912monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-second-quarter-earnings-release-and-conference-call-dates-smti-20230801monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-first-quarter-earnings-release-and-conference-call-dates-smti-20230503monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-510-k-clearance-for-biasurge-advanced-surgical-solution-smti-20230404monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-fourth-quarter-and-full-year-2022-earnings-release-and-confer-smti-20230306monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-to-participate-in-two-upcoming-healthcare-conferences-smti-20221121monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-and-infusystem-announce-wound-therapy-partnership-smti-20221103monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-third-quarter-2022-earnings-release-and-conference-call-dates-smti-20221101monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-to-present-at-the-virtual-microcap-leadership-summit-smti-20220906monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-second-quarter-2022-earnings-release-and-conference-call-date-smti-20220803monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-first-quarter-2022-earnings-release-and-conference-call-dates-smti-20220502monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-fourth-quarter-and-full-year-2021-earnings-release-and-confer-smti-20220314monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-confirms-receipt-of-director-nominations-from-altai-capital-osur-20260115monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-issues-statement-regarding-altai-capital-s-intent-to-nominate-directo-osur-20251217monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-to-participate-in-upcoming-investor-conference-osur-20251117monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-second-quarter-2025-financial-results-osur-20250805monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-to-announce-second-quarter-2025-financial-results-and-host-earnings-call-on-august-osur-20250721monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-first-quarter-2025-financial-results-osur-20250507monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-to-announce-first-quarter-2025-financial-results-and-host-earnings-call-on-may-7th-osur-20250423monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-reports-fourth-quarter-2024-financial-results-osur-20250225monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-to-announce-fourth-quarter-2024-financial-results-and-host-earnings-call-on-februa-osur-20250214monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-to-present-at-the-j-p-morgan-healthcare-conference-osur-20250107monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-acquires-sherlock-biosciences-osur-20241219monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-receives-federal-funding-for-development-of-marburg-virus-rapid-antigen-test-osur-20241202monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-to-participate-in-upcoming-investor-conference-osur-20241118monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-reports-q3-24-revenue-of-39-9-million-osur-20241106monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-to-announce-third-quarter-2024-financial-results-and-host-earnings-call-on-novembe-osur-20241022monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-elects-jack-kenny-to-the-board-of-directors-osur-20240909monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-reports-q2-24-revenue-of-54-3-million-osur-20240806monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-to-announce-second-quarter-2024-financial-results-and-host-earnings-call-on-august-osur-20240722monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-supports-national-hiv-testing-day-osur-20240627monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-reports-q1-24-revenue-of-54-1-million-osur-20240508monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-to-announce-first-quarter-2024-financial-results-and-host-earnings-call-on-may-8th-osur-20240422monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-reports-q4-23-revenue-of-75-9-million-osur-20240227monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-to-announce-fourth-quarter-2023-financial-results-and-host-earnings-call-on-februa-osur-20240213monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-secures-strategic-distribution-rights-and-invests-in-sapphiros-a--osur-20240104monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-to-participate-in-upcoming-investor-conferences-osur-20231113monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-reports-q3-23-revenue-of-89-2-million-core-revenue-grows-7-year-over-year-osur-20231107monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-to-announce-third-quarter-2023-financial-results-and-host-earnings-call-on-novembe-osur-20231023monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-reports-q2-23-revenue-of-85-4-million-core-revenue-grows-3-year-over-year-osur-20230803monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-to-announce-second-quarter-2023-financial-results-and-host-earnings-call-on-august-osur-20230720monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-elects-robert-mcmahon-to-the-board-of-directors-osur-20230720monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-reports-1q23-record-revenue-of-155-0-million-announces-new-collaborations-as-compa-osur-20230510monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-reports-4q22-record-revenue-of-123-1-million-growing-94-year-over-year-positions-f-osur-20230214monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-continues-its-dedication-to-ending-the-hiv-epidemic-osur-20221201monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-stephens-annual-investment-conference-osur-20221114monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-reports-3q22-record-revenue-of-116-5-million-growing-116-year-over-year-osur-20221108monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-receives-general-clearance-for-its-oracollect-dx-device-for-over-the--osur-20221103monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-receives-8-6-million-barda-contract-to-develop-2nd-generation-ebola-t-osur-20220928monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-wins-contract-to-supply-together-take-me-home-hiv-self-testing-initiative-sponsore-osur-20220920monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-partners-with-mars-petcare-in-one-of-the-largest-ever-microbiome-studies-to-evalua-osur-20220914monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-reports-2q22-record-revenue-of-80-2-million-growing-39-year-over-year-osur-20220809monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-hold-2022-second-quarter-earnings-conference-call-tuesday-august-9-osur-20220802monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-s-ongoing-commitment-to-end-the-hepatitis-c-epidemic-heats-up-at-the-racetrack-osur-20220728monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-launches-new-product-for-microbiome-researchers-to-study-dna-and-rna-osur-20220714monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-osur-20220608monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-reports-1q22-record-revenue-of-67-7-million-16-year-over-year-with-21-growth-in-no-osur-20220510monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-2022-first-quarter-earnings-conference-call-tuesday-may-10-2022-5-osur-20220503monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-subsidiary-dna-genotek-launches-the-first-device-with-de-novo-authori-osur-20220407monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-subsidiary-diversigen-launches-metatranscriptomic-sequencing-and-anal-osur-20220331monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-director-nancy-gagliano-selected-to-serve-as-interim-chief-executive-officer-bring-osur-20220322monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-reports-4q21-revenue-of-63-6-million-inteliswab-production-scales-up-osur-20220223monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-2021-fourth-quarter-earnings-conference-call-wednesday-february-2-osur-20220216monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-expands-hiv-oral-swab-in-home-test-into-europe-osur-20220125monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-actions-to-enhance-stockholder-value-osur-20220105monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-2022-annual-meeting-date-osur-20211214monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-remains-committed-to-the-global-fight-against-hiv-40-years-after-the--osur-20211130monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-upcoming-investor-conferences-osur-20211119monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-the-retirement-of-jack-e-jerrett-and-appointment-of-agniesz-osur-20211109monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-appoints-two-new-members-to-the-board-of-directors-osur-20211108monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-reports-3q21-revenue-of-53-9-million-signs-three-major-u-s-government-osur-20211103monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-2021-third-quarter-earnings-conference-call-wednesday-november-3-2021-osur-20211027monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-awarded-109-million-contract-from-u-s-department-of-defense-to-ramp-manufacturing--osur-20211004monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-to-receive-up-to-13-6-million-from-biomedical-advanced-research-development-author-osur-20210923monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-receives-205-million-procurement-contract-for-inteliswab-from-the-defense-logistic-osur-20210920monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-resignation-of-cfo-roberto-cuca-and-succession-plan-osur-20210902monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-reports-2q21-revenue-of-57-6-million-driven-by-strong-rebound-in-core-osur-20210803monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-to-hold-2021-second-quarter-earnings-conference-call-tuesday-augu-osur-20210727monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-raymond-james-2021-human-health-and-innovation-conf-osur-20210617monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-and-the-will-rodgers-liver-health-foundation-to-heighten-awareness-around-the-impo-osur-20210614monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-receives-three-emergency-use-authorizations-for-its-covid-19-rapid-an-osur-20210607monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-jefferies-virtual-healthcare-conference-osur-20210528monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-ubs-global-healthcare-virtual-conference-osur-20210518monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-appoints-scott-gleason-as-senior-vice-president-investor-relations-an-osur-20210517monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-hold-virtual-annual-meeting-of-stockholders-on-may-18-2021-osur-20210512monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-announces-first-quarter-2021-financial-results-and-provides-covid-osur-20210505monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-hold-2021-first-quarter-earnings-conference-call-wednesday-may-5-2-osur-20210430monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-submits-covid-19-rapid-antigen-prescription-home-self-test-and-profes-osur-20210330monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-announces-2020-full-year-and-fourth-quarter-financial-results-and-osur-20210301monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-raymond-james-42nd-annual-institutional-investors-c-osur-20210224monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-subsidiary-dna-genotek-s-omnigene-oral-included-in-eua-granted-to-ambry-genetics-f-osur-20210129monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-subsidiary-dna-genotek-s-omnigene-oral-saliva-collection-device-receives-health-ca-osur-20210128monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-s-omnigene-oral-saliva-collection-kit-selected-by-chronomics-for-use-in-uk-governm-osur-20210126monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-s-oragene-dx-saliva-collection-kit-included-in-industry-s-first-fda-authorization--osur-20210121monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-2021-annual-meeting-date-osur-20210108monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-osur-20210105monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-s-omnigene-oral-device-included-in-eua-amendment-granted-to-3b-blackbio-biotech-in-osur-20201223monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-provides-update-on-its-emergency-use-authorization-application-for-it-osur-20201221monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-2020-evercore-isi-healthconx-conference-osur-20201130monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-commemorate-world-aids-day-by-ringing-nasdaq-closing-bell-osur-20201130monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-stephens-annual-investment-conference-2020-osur-20201112monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-announces-third-quarter-2020-financial-results-and-provides-updat-osur-20201104monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-s-dna-genotek-subsidiary-receives-fda-emergency-use-authorization-for-its-oracolle-osur-20201103monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-hold-2020-third-quarter-earnings-conference-call-wednesday-novembe-osur-20201021monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-s-omnigene-oral-collection-device-receives-fda-emergency-use-authorization-for-sar-osur-20201019monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-s-oracollect-rna-device-included-in-eua-granted-to-quadrant-biosciences-inc-for-co-osur-20200924monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-s-oracollect-rna-device-included-in-eua-granted-to-miradx-inc-for-sars-cov-2-test-osur-20200903monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-upcoming-investor-conferences-osur-20200827monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-announces-2020-second-quarter-financial-results-and-update-on-cov-osur-20200805monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-s-omnigene-oral-device-included-in-eua-granted-to-clinical-reference-laboratory-fo-osur-20200731monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-hold-second-quarter-2020-earnings-conference-call-on-august-5th-20-osur-20200722monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-s-dna-genotek-subsidiary-unveils-first-in-home-self-collection-device-for-metabolo-osur-20200617monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-receives-barda-funding-for-coronavirus-antibody-elisa-using-oral-flui-osur-20200610monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-s-oragene-dx-included-in-eua-allowing-at-home-saliva-collection-for-use-with-phosp-osur-20200608monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-announces-exercise-of-option-to-purchase-additional-shares-of-com-osur-20200604monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-prices-underwritten-offering-of-common-stock-osur-20200603monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-announces-proposed-public-offering-of-common-stock-osur-20200601monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-announces-purchase-of-ursure-inc-osur-20200529monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-appoints-lelio-marmora-to-board-of-directors-osur-20200529monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-jefferies-2020-healthcare-conference-osur-20200526monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-s-omnigene-oral-kit-included-in-eua-granted-to-p23-labs-for-at-home-collection-of--osur-20200522monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-ubs-virtual-global-healthcare-conference-osur-20200515monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-hold-virtual-annual-meeting-of-stockholders-on-may-19-2020-osur-20200514monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-consolidates-microbiome-services-subsidiaries-osur-20200512monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2020-first-quarter-financial-results-and-provides-covid-19-update-osur-20200506monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-appoints-lisa-nibauer-as-infectious-disease-business-unit-lead-osur-20200505monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20200409monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-appoints-david-j-shulkin-m-d-to-board-of-directors-osur-20200408monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-receives-barda-contract-for-rapid-oral-fluid-pan-sars-coronavirus-in--osur-20200406monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-raymond-james-41st-annual-institutional-investors-c-osur-20200226monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2019-full-year-and-fourth-quarter-financial-results-osur-20200219monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20200129monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-osur-20200108monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-2020-annual-meeting-date-osur-20191217monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-commemorate-world-aids-day-by-ringing-nasdaq-opening-bell-osur-20191126monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-piper-jaffray-31st-annual-healthcare-conference-osur-20191126monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2019-third-quarter-financial-results-osur-20191106monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-announces-purchase-of-diversigen-osur-20191106monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-stephens-2019-nashville-investment-conference-osur-20191106monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-support-for-new-federal-oral-fluid-drug-testing-guidelines-osur-20191028monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20191022monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-sale-of-cryosurgical-systems-business-osur-20190819monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-appoints-james-a-datin-to-its-board-of-directors-osur-20190814monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2019-second-quarter-financial-results-osur-20190806monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-39th-annual-canaccord-genuity-growth-conference-osur-20190731monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20190725monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-and-others-join-forces-for-hiv-testing-day-osur-20190626monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-raymond-james-2019-life-sciences-and-medtech-conference-osur-20190613monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-jefferies-2019-healthcare-conference-osur-20190529monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-ubs-global-healthcare-conference-osur-20190515monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-hold-virtual-annual-meeting-of-stockholders-on-may-21-2019-osur-20190514monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2019-first-quarter-financial-results-osur-20190508monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20190417monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-raymond-james-40th-annual-institutional-investors-c-osur-20190227monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2018-full-year-and-fourth-quarter-financial-results-osur-20190206monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20190110monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-announces-two-acquisitions-and-reaffirms-fourth-quarter-2018-guid-osur-20190104monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-updated-release-to-clarify-timing-of-presentation-osur-20190102monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-osur-20190102monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-2019-annual-meeting-date-osur-20181210monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-ring-nasdaq-stock-market-opening-bell-in-honor-of-world-aids-day-osur-20181129monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-30th-annual-piper-jaffray-healthcare-conference-osur-20181121monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-canaccord-genuity-medical-technologies-diagnostics-foru-osur-20181108monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2018-third-quarter-financial-results-osur-20181107monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20181008monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-cantor-global-healthcare-conference-osur-20180926monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-cl-king-16th-annual-best-ideas-conference-osur-20180906monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2018-second-quarter-financial-results-osur-20180808monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-appoints-vice-president-corporate-communications-osur-20180723monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20180719monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-jefferies-global-healthcare-conference-osur-20180530monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-ubs-global-healthcare-conference-osur-20180514monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-appoints-new-chief-financial-officer-osur-20180504monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2018-first-quarter-financial-results-osur-20180502monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-hold-virtual-annual-meeting-of-stockholders-osur-20180501monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20180411monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-appoints-new-senior-vice-president-business-development-osur-20180410monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-raymond-james-39th-annual-institutional-investors-c-osur-20180226monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-leerink-7th-annual-global-healthcare-conference-osur-20180208monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-record-2017-fourth-quarter-and-full-year-financial-results-osur-20180207monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-appoints-aradhana-sarin-m-d-to-board-of-directors-osur-20180202monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20180117monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-osur-20180105monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-management-succession-plan-osur-20180104monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-2018-annual-meeting-date-osur-20171208monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-nasdaq-osur-to-ring-the-nasdaq-stock-market-opening-bell-in-honor-osur-20171130monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-supports-world-aids-day-with-innovative-programs-to-enable-hiv-testin-osur-20171130monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-2017-canaccord-genuity-medical-technologies-diagnos-osur-20171102monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2017-third-quarter-financial-results-osur-20171101monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-stephens-2017-fall-investment-conference-osur-20171101monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20171011monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-2017-cantor-fitzgerald-global-healthcare-conference-osur-20170920monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-cl-king-s-15th-annual-best-ideas-conference-osur-20170906monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2017-second-quarter-financial-results-osur-20170802monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-canaccord-genuity-37th-annual-growth-conference-osur-20170801monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-receives-world-health-organization-prequalification-of-oraquick-hiv-s-osur-20170721monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20170712monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-drive-accelerated-adoption-of-oraquick-hiv-self-test-osur-20170627monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-appoints-mara-g-aspinall-to-board-of-directors-osur-20170622monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-jefferies-2017-global-healthcare-conference-osur-20170531monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-ubs-global-healthcare-conference-osur-20170516monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-hold-virtual-annual-meeting-of-stockholders-osur-20170510monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2017-first-quarter-financial-results-osur-20170503monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20170412monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-receives-global-fund-classification-to-enable-hiv-self-test-procurement-osur-20170301monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-raymond-james-38th-annual-institutional-investors-c-osur-20170227monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-director-retirement-osur-20170224monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2016-fourth-quarter-and-full-year-financial-results-osur-20170208monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-settlement-of-litigation-with-ancestry-comdna-osur-20170206monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20170111monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-to-implement-18-million-product-supply-contract-from-foreign-government-for-hcv-el-osur-20161129monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-nasdaq-osur-to-ring-the-nasdaq-stock-market-opening-bell-osur-20161128monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-host-analyst-day-osur-20161121monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-appoints-stephen-s-tang-ph-d-as-chairman-of-the-board-of-directors-osur-20161115monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-10th-annual-canaccord-genuity-medical-technology-di-osur-20161109monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2016-third-quarter-financial-results-osur-20161102monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-2017-annual-meeting-date-osur-20161014monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20161012monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-cl-king-14th-annual-best-ideas-conference-osur-20160906monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-awarded-up-to-16-6-million-to-advance-rapid-zika-tests-osur-20160823monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2016-second-quarter-financial-results-osur-20160803monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-canaccord-genuity-36th-annual-growth-conference-osur-20160801monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20160713monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-investor-call-invitation-osur-20160630monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-jefferies-2016-healthcare-conference-osur-20160531monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-hold-virtual-annual-meeting-of-stockholders-osur-20160510monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2016-first-quarter-financial-results-osur-20160504monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-ubs-2016-global-healthcare-conference-osur-20160503monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-appoints-new-chief-science-officer-osur-20160415monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20160413monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-appoints-eamonn-p-hobbs-to-its-board-of-directors-osur-20160323monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-raymond-james-37th-annual-institutional-investors-c-osur-20160226monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-record-revenues-for-full-year-and-fourth-quarter-2015-osur-20160203monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20160113monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-canaccord-genuity-medical-technology-diagnostics-fo-osur-20151110monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2015-third-quarter-financial-results-osur-20151104monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20151014monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-provides-update-on-oraquick-ebola-rapid-antigen-test-business-osur-20150929monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-2016-annual-meeting-date-osur-20150828monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2015-second-quarter-financial-results-osur-20150805monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-canaccord-genuity-35th-annual-growth-conference-osur-20150804monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-receives-fda-emergency-use-authorization-for-ebola-rapid-diagnostic-t-osur-20150803monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20150715monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-supports-rapid-hiv-testing-initiatives-in-recognition-of-national-hiv-testing-day-osur-20150626monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-2015-jmp-securities-life-sciences-conference-osur-20150616monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-awarded-10-4-million-hhs-contract-to-advance-rapid-ebola-test-clinical-development-osur-20150612monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-jefferies-2015-global-healthcare-conference-osur-20150522monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-supports-rapid-hcv-testing-initiatives-across-the-u-s-in-recognition--osur-20150519monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-nasdaq-osur-to-ring-the-nasdaq-stock-market-opening-bell-osur-20150518monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-ubs-global-healthcare-conference-2015-osur-20150511monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2015-first-quarter-financial-results-osur-20150506monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-webcast-annual-meeting-of-stockholders-osur-20150504monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20150421monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-cowen-company-35th-annual-health-care-conference-osur-20150224monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-raymond-james-36th-annual-institutional-investor-co-osur-20150223monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-full-year-and-fourth-quarter-2014-financial-results-osur-20150204monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20150114monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-2015-annual-meeting-date-osur-20141202monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-canaccord-genuity-medical-technology-diagnostics-co-osur-20141112monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-stephens-2014-fall-investment-conference-osur-20141107monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2014-third-quarter-financial-results-osur-20141105monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20141015monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2014-second-quarter-financial-results-osur-20140806monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-canaccord-genuity-34th-annual-growth-conference-osur-20140806monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20140722monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-supports-rapid-hiv-testing-initiatives-in-recognition-of-national-hiv-testing-day-osur-20140626monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-provides-update-on-substance-abuse-testing-business-osur-20140625monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-jmp-securities-healthcare-conference-osur-20140617monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-new-co-promotion-agreement-for-oraquick-r-hcv-rapid-antibod-osur-20140611monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-investor-call-invitation-osur-20140610monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-jefferies-2014-global-healthcare-conference-osur-20140528monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-rapid-hcv-testing-initiatives-across-the-u-s-in-support-of--osur-20140519monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-nasdaq-osur-to-ring-the-nasdaq-stock-market-closing-bell-in-recog-osur-20140516monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-webcast-annual-meeting-of-stockholders-osur-20140516monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-ubs-global-healthcare-conference-osur-20140513monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2014-first-quarter-financial-results-osur-20140507monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20140422monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-debra-fraser-howze-receives-2014-top-blacks-in-healthcare-award-osur-20140404monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-cowen-company-34th-annual-health-care-conference-osur-20140226monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-raymond-james-35th-annual-institutional-investors-c-osur-20140224monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-2014-citi-global-healthcare-conference-osur-20140220monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-leerink-swan-global-healthcare-conference-osur-20140206monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-record-full-year-and-quarterly-revenues-osur-20140205monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-2014-annual-meeting-date-osur-20140128monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20140120monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-addresses-fda-warning-letter-received-by-its-subsidiary-dna-genotek-osur-20140107monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-reaffirms-4th-quarter-2013-financial-guidance-osur-20131125monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-terminates-oral-fluid-drugs-of-abuse-assay-collaboration-with-roche-d-osur-20131121monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-new-agreement-with-thermo-fisher-scientific-for-development-osur-20131121monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-canaccord-genuity-s-medical-technology-diagnostics-foru-osur-20131107monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2013-third-quarter-financial-results-osur-20131106monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-commends-new-york-state-hepatitis-c-testing-law-osur-20131023monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20131016monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2013-second-quarter-financial-results-osur-20130807monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-canaccord-genuity-s-33rd-annual-growth-conference-osur-20130806monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20130718monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-eighth-annual-jmp-securities-healthcare-conference-osur-20130708monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-teams-with-the-reed-for-hope-foundation-singer-songwriter-actress-ker-osur-20130626monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-praises-new-hepatitis-c-testing-recommendations-by-u-s-preventive-ser-osur-20130625monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-jefferies-2013-global-healthcare-conference-osur-20130528monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-walgreens-and-chronic-liver-disease-foundation-to-launch-rapid-hepati-osur-20130513monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-webcast-annual-meeting-of-stockholders-osur-20130510monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2013-first-quarter-financial-results-osur-20130508monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-participate-at-needham-s-twelfth-annual-healthcare-conference-osur-20130429monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20130418monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-cowen-company-33rd-annual-health-care-conference-osur-20130226monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-raymond-james-34th-annual-institutional-investors-c-osur-20130222monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-2013-citi-global-healthcare-conference-osur-20130219monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-full-year-and-fourth-quarter-2012-financial-results-osur-20130206monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20130116monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-appoints-senior-vice-president-and-general-manager-of-consumer-produc-osur-20121128monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-praises-new-routine-hiv-screening-recommendations-by-u-s-preventive-s-osur-20121121monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2012-third-quarter-financial-results-osur-20121107monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-stephens-inc-fall-investment-conference-osur-20121107monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20121025monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-joins-with-actress-model-dayana-mendoza-and-the-latino-commission-on--osur-20121015monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-participate-at-the-ubs-global-life-sciences-conference-osur-20120911monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-thinkequity-s-ninth-annual-growth-conference-osur-20120905monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-2013-annual-meeting-date-osur-20120822monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-applauds-new-cdc-recommendations-that-all-baby-boomers-be-tested-for--osur-20120816monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-canaccord-genuity-s-32nd-annual-growth-conference-osur-20120808monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2012-second-quarter-financial-results-osur-20120807monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-supports-rapid-hcv-testing-initiatives-for-world-hepatitis-day-osur-20120726monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-osur-to-ring-the-nasdaq-stock-market-closing-bell-osur-20120726monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20120725monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-announces-closing-of-underwritten-offering-of-common-stock-osur-20120716monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-prices-underwritten-offering-of-common-stock-osur-20120710monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-announces-proposed-public-offering-of-common-stock-osur-20120709monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-seventh-annual-jmp-securities-healthcare-conference-osur-20120709monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-conference-call-invitation-osur-20120703monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-receives-fda-approval-of-oraquick-r-in-home-hiv-test-osur-20120703monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-supports-rapid-hiv-testing-initiatives-in-recognition-of-18th-annual-national-hiv--osur-20120627monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-osur-president-ceo-to-ring-the-nasdaq-stock-market-opening-bell-osur-20120626monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-jefferies-2012-global-healthcare-conference-osur-20120529monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-applauds-cdc-proposed-draft-guidelines-for-testing-of-baby-boomers-fo-osur-20120518monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-rapid-hcv-testing-initiatives-for-first-national-hepatitis--osur-20120518monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-webcast-annual-meeting-of-stockholders-osur-20120508monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2012-first-quarter-financial-results-osur-20120502monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-deutsche-bank-s-37th-annual-health-care-conference-osur-20120430monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20120418monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-11th-annual-needham-healthcare-conference-osur-20120328monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-cowen-co-32nd-annual-health-care-conference-osur-20120227monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-2012-rbc-capital-markets-healthcare-conference-osur-20120222monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-2012-citi-global-healthcare-conference-osur-20120221monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-fourth-quarter-and-full-year-2011-financial-results-osur-20120208monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20120126monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-participate-at-the-fourteenth-annual-needham-growth-conference-osur-20120106monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-makes-final-fda-submission-for-approval-of-over-the-counter-rapid-hiv-test-osur-20120103monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-receives-clia-waiver-for-oraquick-r-hcv-rapid-test-osur-20111129monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-appoints-veteran-consumer-products-executive-to-its-board-of-director-osur-20111110monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-stephens-inc-fall-investment-conference-osur-20111109monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2011-third-quarter-consolidated-financial-results-osur-20111102monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-applauds-american-academy-of-pediatrics-updated-recommendations-for-routine-hiv-sc-osur-20111101monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20111019monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-participate-at-the-sixth-annual-jmp-securities-healthcare-conferen-osur-20110921monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-participate-at-the-ubs-global-life-sciences-conference-osur-20110913monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-2012-annual-meeting-date-osur-20110906monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-participate-at-the-william-blair-2011-life-sciences-conference-osur-20110901monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-closing-of-dna-genotek-acquisition-osur-20110818monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-closes-enrollment-in-final-clinical-study-for-rapid-hiv-over-the-counter-test-osur-20110809monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-canaccord-genuity-s-31st-annual-growth-conference-osur-20110803monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-acquire-dna-genotek-inc-acquisition-provides-entry-into-rapidly-gr-osur-20110725monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20110720monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-supports-17th-annual-national-hiv-testing-day-osur-20110627monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-osur-president-and-ceo-to-ring-the-nasdaq-stock-market-opening-be-osur-20110624monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-jefferies-2011-global-healthcare-conference-osur-20110602monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-thinkequity-s-2nd-annual-healthcare-conference-osur-20110519monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-webcast-annual-meeting-of-stockholders-osur-20110510monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2011-first-quarter-financial-results-osur-20110504monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-deutsche-bank-s-36th-annual-health-care-conference-osur-20110425monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20110420monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-appoints-stephen-s-tang-ph-d-to-its-board-of-directors-osur-20110407monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-10th-annual-needham-healthcare-conference-osur-20110328monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-submits-clia-waiver-application-for-oraquick-r-hcv-rapid-test-osur-20110323monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-roth-23rd-annual-oc-growth-stock-conference-osur-20110304monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-and-roche-announce-fda-510-k-clearance-for-four-fully-automated-oral--osur-20110303monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-cowen-co-health-care-conference-osur-20110301monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-2011-rbc-capital-markets-healthcare-conference-osur-20110228monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-2011-citi-global-healthcare-conference-osur-20110224monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-receives-fda-approval-for-its-oraquick-r-hcv-rapid-test-using-fingers-osur-20110222monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-fourth-quarter-and-full-year-2010-financial-results-osur-20110209monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20110131monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-launch-orasure-quickflu-tm-rapid-flu-a-b-test-osur-20110111monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-participate-at-the-thirteenth-annual-needham-growth-conference-osur-20110107monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-initiates-enrollment-in-final-clinical-study-for-oraquick-r-rapid-hiv-over-the-cou-osur-20101213monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-2011-annual-meeting-date-osur-20101202monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-supports-rapid-hiv-testing-initiatives-for-world-aids-day-osur-20101201monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-osur-president-and-chief-executive-officer-to-ring-the-nasdaq-sto-osur-20101130monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-receives-fda-approval-to-conduct-final-phase-of-clinical-studies-for--osur-20101122monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-participate-at-the-stephens-fall-investment-conference-osur-20101110monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2010-third-quarter-financial-results-osur-20101109monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20101027monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-participate-at-the-fifth-annual-jmp-securities-healthcare-conferen-osur-20100922monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-participate-at-the-ubs-global-life-sciences-conference-osur-20100914monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-participate-at-the-canaccord-adams-30th-annual-global-growth-confe-osur-20100805monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2010-second-quarter-financial-results-osur-20100804monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-participate-at-the-bmo-capital-markets-10th-annual-focus-on-health-osur-20100803monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20100721monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-receives-fda-approval-for-oraquick-r-hcv-rapid-test-the-first-rapid-h-osur-20100625monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-and-the-national-association-of-people-with-aids-launch-sixth-annual--osur-20100625monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-participate-at-thinkequity-s-mid-year-check-up-on-healthcare-osur-20100610monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-participate-at-thinkequity-s-mid-year-check-up-on-healthcare-osur-20100607monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-participate-at-jefferies-2010-global-life-sciences-conference-osur-20100604monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-participate-at-the-ninth-annual-needham-healthcare-conference-osur-20100602monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2010-first-quarter-financial-results-osur-20100505monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20100421monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-present-at-the-cowen-co-health-care-conference-osur-20100303monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-fourth-quarter-and-full-year-2009-financial-results-osur-20100210monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-ceo-appointed-to-presidential-advisory-council-on-hiv-aids-osur-20100203monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20100128monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-and-roche-diagnostics-sign-worldwide-commercialization-agreement-for--osur-20100119monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-files-additional-data-with-fda-in-support-of-pma-application-for-oraq-osur-20100107monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-participate-at-the-twelfth-annual-needham-growth-conference-osur-20100105monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-settlement-of-patent-infringement-lawsuit-with-inverness-an-osur-20091119monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-participates-in-bpac-meeting-on-hiv-over-the-counter-test-osur-20091118monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2009-third-quarter-financial-results-osur-20091104monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20091022monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-awarded-premier-contract-for-its-oraquick-advance-r-rapid-hiv-1-2-ant-osur-20090924monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-to-participate-at-the-ubs-global-life-sciences-conference-osur-20090917monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-appoints-robert-a-gregg-ph-d-as-vice-president-regulatory-affairs-and-osur-20090910monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-announces-2010-annual-meeting-date-osur-20090827monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2009-second-quarter-financial-results-and-resumption-of-full-scale-oraqu-osur-20090805monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-earnings-conference-call-invitation-osur-20090727monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-osur-chief-executive-officer-to-ring-the-nasdaq-stock-market-open-osur-20090625monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-osur-president-and-chief-executive-officer-to-ring-the-nasdaq-sto-osur-20080626monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-osur-president-and-chief-executive-officer-to-ring-the-nasdaq-sto-osur-20070626monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-osur-president-and-ceo-and-mayor-bloomberg-to-ring-the-nasdaq-sto-osur-20060626monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-receives-fda-ind-clearance-for-vy1706-first-gene-therapy-approach-to-reducing-tau--vygr-20260601monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-acquisition-corporation-announces-approval-of-its-business-combination-with-veraxa-vygr-20260313monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-acquisition-corporation-announces-redemption-results-in-connection-with-its-busine-vygr-20260311monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-fourth-quarter-2024-conference-call-and-webcast-vygr-20250304monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-reports-positive-topline-data-for-single-ascending-dose-sad-trial-of-anti-tau-anti-vygr-20250303monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-multiple-upcoming-investor-conferences-vygr-20250225monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-alert-bragar-eagel-squire-p-c-is-investigating-voyager-therapeutics-inc-on-behalf--vygr-20250225monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-provides-update-on-sod1-als-gene-therapy-program-vygr-20250211monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-to-present-at-oppenheimer-25th-annual-healthcare-life-sciences-conference-vygr-20250206monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-selects-tau-silencing-gene-therapy-development-candidate-for-alzheimer-s-disease-vygr-20241120monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-multiple-upcoming-investor-conferences-vygr-20241106monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-third-quarter-2024-conference-call-and-webcast-vygr-20241105monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-advances-collaboration-with-neurocrine-third-gene-therapy-development-candidate-se-vygr-20240916monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-enters-into-license-for-next-generation-capsid-bringing-partnered-portfolio-of-tra-vygr-20240905monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vygr-20240829monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-multiple-upcoming-investor-conferences-vygr-20240829monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-canaccord-genuity-44th-annual-growth-conference-private-vygr-20240807monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-second-quarter-2024-conference-call-and-webcast-vygr-20240730monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vygr-20240723monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vygr-20240709monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-multiple-virtual-investor-conferences-vygr-20240613monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-appointment-of-nathan-jorgensen-as-chief-financial-officer-vygr-20240613monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-first-participants-dosed-in-single-ascending-dose-trial-of--vygr-20240516monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-presents-data-for-second-generation-tracer-generated-capsids-and-cns--vygr-20240508monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-first-quarter-2024-conference-call-and-webcast-vygr-20240506monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-broad-set-of-translational-data-supporting-iv-delivered-cn-vygr-20240422monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-selection-of-development-candidate-for-gba1-program-in-coll-vygr-20240416monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vygr-20240326monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-appointment-of-toby-ferguson-as-chief-medical-officer-vygr-20240313monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-selection-of-gene-therapy-development-candidate-for-friedre-vygr-20240226monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-fourth-quarter-2023-conference-call-and-webcast-vygr-20240221monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-reports-robust-preclinical-activity-in-tau-silencing-gene-therapy-pro-vygr-20240220monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-the-oppenheimer-annual-life-sciences-conference-vygr-20240207monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-pricing-of-public-offering-vygr-20240105monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-proposed-public-offering-vygr-20240104monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-vygr-20240103monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-enters-capsid-license-agreement-and-strategic-collaboration-with-nova-vygr-20240102monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-third-quarter-2023-conference-call-and-webcast-vygr-20231030monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-the-chardan-genetic-medicines-conference-vygr-20230925monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vygr-20230907monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-vygr-20230830monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vygr-20230808monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-appointment-of-beth-shafer-as-chief-business-officer-vygr-20230807monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-the-canaccord-genuity-growth-conference-vygr-20230802monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-second-quarter-2023-conference-call-and-webcast-vygr-20230727monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vygr-20230711monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-appointment-of-jacquelyn-fahey-sandell-as-chief-legal-offic-vygr-20230710monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-the-jefferies-healthcare-conference-vygr-20230601monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-presents-robust-multi-species-results-from-preclinical-studies-of-iv--vygr-20230518monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-appointment-of-george-scangos-ph-d-to-board-of-directors-vygr-20230509monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-multiple-data-presentations-at-the-american-society-of-gene-vygr-20230502monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-first-quarter-2023-conference-call-and-webcast-vygr-20230502monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-presents-new-data-supporting-tau-antibody-program-for-alzheimer-s-dis-vygr-20230328monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-receive-25-million-payment-for-license-of-next-generation-aav-caps-vygr-20230306monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-fourth-quarter-and-full-year-2022-conference-call-and-webca-vygr-20230228monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-vygr-20230209monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vygr-20230124monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-vygr-20230104monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vygr-20221129monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-third-quarter-2022-conference-call-and-webcast-vygr-20221101monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vygr-20221018monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-presents-data-characterizing-a-novel-cns-receptor-and-demonstrating-t-vygr-20221011monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-pfizer-license-of-next-generation-aav-capsid-for-rare-neuro-vygr-20221004monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-europ-vygr-20221003monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-vygr-20220927monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vygr-20220922monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-appoints-peter-pfreundschuh-as-cfo-todd-carter-ph-d-as-chief-scientif-vygr-20220907monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-presents-new-data-demonstrating-novel-candidate-therapeutic-antibodie-vygr-20220803monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-second-quarter-2022-results-and-corporate-update-vygr-20220802monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-appoints-catherine-j-mackey-ph-d-to-its-board-of-directors-vygr-20220728monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-tracer-capsids-demonstrate-enhanced-cns-transduction-across-species-n-vygr-20220519monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-preclinical-data-from-its-vectorized-anti-her2-antibody-pr-vygr-20220516monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-multiple-data-presentations-at-the-american-society-of-gene-vygr-20220503monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-appoints-alfred-w-sandrock-jr-m-d-ph-d-as-chief-executive-officer-vygr-20220322monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-license-option-agreement-with-novartis-for-target-specific--vygr-20220308monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-vygr-20220210monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-positive-preclinical-data-from-new-vectorized-anti-her2-ant-vygr-20211119monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-preclinical-data-from-vectorized-antibody-program-at-the-2-vygr-20211116monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-presents-positive-preclinical-data-supporting-cns-directed-gba1-gene--vygr-20211020monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-vygr-20210902monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-vygr-20210810monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-strategic-shift-and-leadership-transitions-vygr-20210519monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-presents-new-preclinical-data-showing-reduction-of-pathological-tau-w-vygr-20210512monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-novel-capsids-demonstrate-robust-delivery-across-the-blood-brain-barr-vygr-20210511monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-upcoming-data-presentations-at-the-american-society-of-gene-vygr-20210428monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-receives-fda-clearance-of-ind-application-for-gene-therapy-candidate--vygr-20210426monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-inc-investors-last-days-to-participate-actively-in-the-class-action-l-vygr-20210316monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-remind-vygr-20210303monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announ-vygr-20210222monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-and-par-vygr-20210218monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-inc-investors-last-days-to-participate-actively-in-the-class-action-l-vygr-20210210monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-provides-update-on-nbib-1817-vy-aadc-gene-therapy-program-vygr-20210202monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announ-vygr-20210129monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vygr-20210111monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-provides-update-on-nbib-1817-vy-aadc-gene-therapy-program-vygr-20201222monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-provides-regulatory-update-on-vy-htt01-program-vygr-20201012monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vygr-20201001monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-appoints-nancy-vitale-to-its-board-of-directors-vygr-20200915monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-appoints-michelle-quinn-smith-as-chief-human-resources-officer-vygr-20200914monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-upcoming-presentations-at-the-international-parkinson-and-m-vygr-20200903monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-report-second-quarter-2020-financial-results-and-participate-in-up-vygr-20200803monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-provides-update-on-abbvie-vectorized-antibody-collaborations-vygr-20200803monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vygr-20200616monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-upcoming-data-presentations-at-the-american-society-of-gene-vygr-20200429monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-provides-update-on-the-restore-1-parkinson-s-disease-trial-vygr-20200403monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-cancellation-of-presentation-and-webcast-at-the-barclays-gl-vygr-20200309monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-vygr-20200226monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-report-fourth-quarter-and-full-year-2019-financial-results-and-cor-vygr-20200225monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-the-credit-suisse-healthcare-conference-vygr-20191031monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-host-third-quarter-2019-financial-results-and-corporate-highlights-vygr-20191030monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-upcoming-investor-conferences-in-october-2019-vygr-20190925monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-upcoming-investor-conferences-in-september-2019-vygr-20190828monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-host-second-quarter-2019-financial-results-and-corporate-highlight-vygr-20190805monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-upcoming-investor-conferences-in-august-2019-vygr-20190730monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-restructured-gene-therapy-relationship-with-sanofi-genzyme--vygr-20190617monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-the-raymond-james-life-sciences-medtech-conference-vygr-20190611monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-management-updates-vygr-20190520monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-new-data-in-multiple-presentations-at-the-american-society--vygr-20190429monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-upcoming-data-presentations-at-the-american-society-of-gene-vygr-20190415monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vygr-20190403monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference-vygr-20190402monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-and-abbvie-announce-collaboration-to-develop-vectorized-antibodies-to-vygr-20190222monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-upcoming-investor-conferences-vygr-20190219monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-host-fourth-quarter-and-full-year-2018-financial-results-and-corpo-vygr-20190218monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-appoints-robert-hesslein-as-general-counsel-vygr-20190122monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-appoint-omar-khwaja-m-d-ph-d-as-chief-medical-officer-vygr-20190115monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-provides-updates-for-vy-aadc-clinical-program-for-parkinson-s-disease-vygr-20190107monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-joins-michael-j-fox-foundation-initiatives-and-education-campaigns-to-vygr-20181217monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-first-patient-dosed-in-restore-1-a-phase-2-trial-of-vy-aadc-vygr-20181210monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-enters-into-strategic-manufacturing-collaborations-with-brammer-bio-a-vygr-20181129monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-the-evercore-isi-healthcare-conference-vygr-20181119monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-positive-longer-term-data-for-vy-aadc-for-parkinson-s-disea-vygr-20181107monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-host-third-quarter-2018-financial-results-and-corporate-highlights-vygr-20181031monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-preclinical-data-for-huntington-s-disease-and-amyotrophic-l-vygr-20181016monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-investor-conferences-in-september-vygr-20180828monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-investor-conferences-in-august-vygr-20180802monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-second-quarter-2018-financial-results-and-corporate-highlig-vygr-20180731monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-receives-fda-guidance-on-development-path-for-vy-aadc-for-parkinson-s-vygr-20180717monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-appoints-andre-turenne-as-president-and-chief-executive-officer-vygr-20180628monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-fda-regenerative-medicine-advanced-therapy-rmat-designation-vygr-20180621monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-management-change-vygr-20180529monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-additional-data-at-the-american-society-of-gene-and-cell-th-vygr-20180518monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-new-data-at-the-american-society-of-gene-and-cell-therapy-2-vygr-20180517monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-upcoming-data-presentations-at-the-american-society-of-gene-vygr-20180430monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-longer-term-data-from-ongoing-phase-1b-trial-of-vy-aadc-for-vygr-20180309monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-host-fourth-quarter-and-full-year-2017-financial-results-and-corpo-vygr-20180227monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-cowen-health-care-conference-vygr-20180226monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-and-abbvie-announce-global-strategic-collaboration-to-develop-potenti-vygr-20180220monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-leerink-partners-annual-global-healthcare-conference-vygr-20180207monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-v-vygr-20180123monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-highlights-lead-program-vy-aadc-for-advanced-parkinson-s-disease-aav--vygr-20171116monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-investor-conferences-in-november-vygr-20171113monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-host-r-d-day-on-november-16-2017-vygr-20171112monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-closing-of-public-offering-of-common-stock-vygr-20171110monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-proposed-offering-of-common-stock-vygr-20171106monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-update-to-parkinson-s-disease-program-vygr-20171030monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-host-third-quarter-2017-financial-results-and-corporate-highlights-vygr-20171030monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-new-data-presentations-at-the-congress-of-the-european-soci-vygr-20171017monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-multiple-data-presentations-at-the-congress-of-the-european-vygr-20171006monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-investor-conferences-in-october-vygr-20171003monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-appoints-matthew-p-ottmer-as-chief-operating-officer-vygr-20170918monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-positive-results-from-ongoing-phase-1b-trial-of-vy-aadc01-f-vygr-20170906monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-participate-in-september-investor-conferences-vygr-20170830monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-host-second-quarter-2017-financial-results-and-corporate-highlight-vygr-20170802monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-publication-from-the-california-institute-of-technology-of--vygr-20170717monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-clinical-trial-update-with-vy-aadc01-for-advanced-parkinson-vygr-20170626monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-attend-upcoming-investor-conferences-vygr-20170602monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-selects-lead-clinical-candidate-for-huntington-s-disease-vygr-20170601monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-host-first-quarter-2017-financial-results-and-corporate-highlights-vygr-20170504monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-additional-results-from-phase-1b-trial-of-vy-aadc01-for-adv-vygr-20170425monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-host-fourth-quarter-and-full-year-2016-financial-results-conferenc-vygr-20170308monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-supports-rare-disease-day-and-global-movement-to-raise-awareness-for--vygr-20170228monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-lead-clinical-candidate-selection-for-monogenic-form-of-amy-vygr-20170213monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-attend-upcoming-investor-conferences-vygr-20170202monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-publication-of-vectored-anti-tau-monoclonal-antibody-study--vygr-20170125monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-updates-from-phase-1b-trial-of-vy-aadc01-for-advanced-parki-vygr-20170120monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-elects-wendy-dixon-ph-d-and-glenn-pierce-m-d-ph-d-to-board-of-directo-vygr-20170105monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-appoints-jane-pritchett-henderson-as-chief-financial-officer-vygr-20170103monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-attend-upcoming-investor-conference-vygr-20161209monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-and-regenxbio-announce-exercise-of-options-for-rights-to-nav-vectors-vygr-20161129monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-host-third-quarter-2016-investor-update-call-vygr-20161101monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-planned-transition-process-for-chief-financial-officer-vygr-20161018monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-licenses-novel-gene-therapy-capsids-from-the-california-institute-of--vygr-20160915monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-and-chdi-foundation-collaborate-to-develop-novel-gene-therapy-for-hun-vygr-20160912monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-attend-upcoming-investor-conferences-vygr-20160812monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-initiates-third-cohort-in-ongoing-phase-1b-clinical-trial-of-vy-aadc0-vygr-20160809monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-host-second-quarter-2016-investor-update-call-vygr-20160804monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-interim-phase-1b-surgical-results-for-vy-aadc01-in-advanced-vygr-20160622monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-upcoming-investor-conferences-vygr-20160511monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-host-first-quarter-2016-investor-update-call-vygr-20160505monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-highlights-programs-in-parkinson-s-disease-and-als-announces-expansio-vygr-20160429monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-nasdaq-vygr-to-ring-the-nasdaq-stock-market-opening-bell-vygr-20160425monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-host-r-d-day-and-webcast-on-april-29-2016-vygr-20160414monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-alliance-for-regenerative-medicine-s-4th-annual-cell-ge-vygr-20160314monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-host-fourth-quarter-and-full-year-2015-investor-update-call-vygr-20160310monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-to-present-at-cowen-and-company-36th-annual-health-care-conference-vygr-20160229monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-promotes-jeff-goater-to-chief-financial-officer-vygr-20160202monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-added-to-russell-2000-3000-and-global-indexes-vygr-20151218monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-closing-of-initial-public-offering-including-full-exercise--vygr-20151116monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-pricing-of-initial-public-offering-vygr-20151111monthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-highlights-allonk-data-presented-at-eular-2026-fda-rmat-designation-artv-20260608monthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-to-participate-in-the-25th-annual-needham-virtual-healthcare-confer-artv-20260408monthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-announces-appointment-of-elaine-sorg-to-board-of-directors-artv-20260219monthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-to-present-longer-term-phase-1-2-data-for-allonk-in-combination-wit-artv-20250428monthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-appoints-subhashis-banerjee-m-d-as-chief-medical-officer-artv-20250408monthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-confer-artv-20250331monthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference-artv-20250220monthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-expands-board-of-directors-with-appointment-of-dan-baker-m-d-artv-20250129monthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-to-participate-in-the-jefferies-london-healthcare-conference-artv-20241111monthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-appoints-alison-moore-ph-d-to-its-board-of-directors-artv-20241022monthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-to-participate-in-the-2024-cantor-fitzgerald-global-healthcare-conf-artv-20240910monthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-announces-pricing-of-upsized-167-0-million-initial-public-offering-artv-20240718monthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-and-affimed-announce-platform-to-platform-r-d-collaboration-for-tar-artv-20201105monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-first-quarter-2026-financial-results-mdwd-20260507monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-new-escharex-data-at-leading-wound-care-conferences-mdwd-20260407monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-files-annual-report-on-form-20-f-mdwd-20260305monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-fourth-quarter-and-full-year-2025-financial-results-mdwd-20260219monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-provides-corporate-update-and-financial-outlook-ahead-of-the-j-p-morgan-healthca-mdwd-20260112monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-new-clinical-data-demonstrating-nexobrid-s-effectiveness-in-preventing-t-mdwd-20251210monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-second-quarter-2025-financial-results-mdwd-20250804monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-first-quarter-2025-financial-results-and-provides-corporate-update-mdwd-20250521monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-publication-of-phase-ii-escharex-data-demonstrating-superiority-over-c-mdwd-20250513monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-first-quarter-2025-financial-results-mdwd-20250505monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-new-escharex-data-at-leading-wound-care-conferences-mdwd-20250428monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-corpora-mdwd-20250319monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-fourth-quarter-and-full-year-2024-financial-results-mdwd-20250303monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-phase-iii-cids-publication-on-nexobrid-for-pediatric-burn-care-mdwd-20250225monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-at-the-45th-annual-td-cowen-health-care-conference-mdwd-20250224monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-initiates-the-value-global-phase-iii-pivotal-trial-of-escharex-for-treatment-of--mdwd-20250212monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conferenc-mdwd-20250204monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-host-virtual-key-opinion-leader-event-to-discuss-escharex-phase-iii-value-stu-mdwd-20241217monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-third-quarter-2024-financial-results-and-provides-company-update-mdwd-20241126monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-third-quarter-2024-financial-results-mdwd-20241112monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-phase-ii-head-to-head-study-evaluating-escharex-vs-collagenase-in-pati-mdwd-20241010monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-participate-in-the-2024-maxim-healthcare-virtual-summit-mdwd-20241008monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-mdwd-20240903monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-u-s-food-and-drug-administration-approval-of-nexobrid-for-the-treatmen-mdwd-20240815monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-second-quarter-2024-financial-results-and-provides-company-update-mdwd-20240814monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-positive-results-from-the-u-s-nexobrid-expanded-access-protocol-next-mdwd-20240805monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-second-quarter-2024-financial-results-mdwd-20240802monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-publication-of-the-escharex-phase-ii-chronex-study-results-for-venous--mdwd-20240729monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-16-25-million-funding-from-the-european-innovation-council-accelerator-mdwd-20240716monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-25-million-strategic-private-placement-financing-mdwd-20240715monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-first-quarter-2024-financial-results-and-provides-company-update-mdwd-20240529monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-first-quarter-2024-financial-results-mdwd-20240522monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-new-data-from-escharex-phase-ii-studies-at-three-leading-wound-care-c-mdwd-20240425monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-company-mdwd-20240321monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-fourth-quarter-and-full-year-2023-financial-results-mdwd-20240314monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-positive-results-in-head-to-head-comparison-of-escharex-vs-santyl-with-mdwd-20240212monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-participate-in-two-upcoming-investor-conferences-mdwd-20240205monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-that-fda-has-accepted-for-review-the-supplement-to-the-nexobrid-bla-to-mdwd-20240109monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-secures-additional-u-s-department-of-defense-funding-to-advance-nexobrid-develop-mdwd-20231228monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-peer-reviewed-publication-of-escharex-mechanism-of-action-study-assess-mdwd-20231221monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-third-quarter-2023-financial-results-and-provides-company-update-mdwd-20231121monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-appointment-of-shmulik-hess-ph-d-as-chief-operating-officer-and-chief--mdwd-20231121monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-third-quarter-2023-financial-results-mdwd-20231114monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-receives-positive-chmp-opinion-recommending-approval-for-nexobrid-to-treat-pedia-mdwd-20231113monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-a-collaboration-with-polymedics-innovations-pmi-for-nexobrid-distribut-mdwd-20231108monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-collaboration-with-3m-on-escharex-phase-iii-study-mdwd-20231011monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-deploys-nexobrid-for-emergency-supply-mdwd-20231009monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-secures-additional-u-s-department-of-defense-funding-to-advance-nexobrid-develop-mdwd-20230926monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-u-s-commercial-availability-of-nexobrid-for-the-treatment-of-severe-th-mdwd-20230921monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-s-nexobrid-highlighted-in-20-oral-and-poster-presentations-at-the-20th-european--mdwd-20230911monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-participate-in-fireside-chat-at-h-c-wainwright-25th-annual-global-investment--mdwd-20230905monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-second-quarter-2023-financial-results-and-provides-company-update-mdwd-20230815monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-collaboration-with-mimedx-on-escharex-phase-iii-study-mdwd-20230815monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-second-quarter-2023-financial-results-mdwd-20230807monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-commercial-launch-of-nexobrid-in-japan-mdwd-20230801monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-positive-results-in-its-u-s-phase-i-ii-study-of-mw005-for-the-treatmen-mdwd-20230710monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-receives-positive-scientific-advice-from-european-medicine-agency-ema-on-eschare-mdwd-20230703monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-participate-in-fireside-chat-at-maxim-group-healthcare-virtual-conference-202-mdwd-20230614monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-first-quarter-2023-financial-results-and-provides-a-company-update-mdwd-20230530monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-first-quarter-2023-financial-results-mdwd-20230512monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-an-additional-10-million-award-from-barda-mdwd-20230509monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-phase-2-escharex-data-at-the-symposium-on-advanced-wound-care-sawc-sp-mdwd-20230426monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-fourth-quarter-and-full-year-2022-financial-results-and-company-update-mdwd-20230316monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-the-appointment-of-hani-luxenburg-as-chief-financial-officer-mdwd-20230316monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-expands-its-global-leadership-team-to-help-drive-company-s-future-growth-mdwd-20230306monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-fourth-quarter-and-year-end-2022-financial-results-mdwd-20230302monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-corporate-highlights-at-upcoming-investor-conferences-mdwd-20230223monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-closing-of-27-5-million-registered-direct-offering-of-ordinary-shares-mdwd-20230207monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-27-5-million-registered-direct-offering-of-ordinary-shares-priced-at-t-mdwd-20230203monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-fda-approval-of-nexobrid-for-the-treatment-of-severe-thermal-burns-in--mdwd-20221229monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-expands-nexobrid-s-global-presence-with-marketing-approval-in-japan-mdwd-20221223monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-strengthens-european-presence-of-nexobrid-mdwd-20221220monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-positive-results-in-u-s-phase-i-ii-study-of-mw005-for-the-treatment-of-mdwd-20221219monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-expands-global-presence-as-nexobrid-gains-approval-in-india-mdwd-20221213monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-a-1-for-7-reverse-share-split-mdwd-20221205monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-third-quarter-2022-financial-results-and-provides-company-update-mdwd-20221115monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-s-escharex-featured-in-paper-as-a-potential-paradigm-shift-towards-non-surgical--mdwd-20221109monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-third-quarter-2022-financial-results-mdwd-20221103monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-formation-of-strategic-advisory-board-mdwd-20221025monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-s-escharex-featured-in-oral-and-poster-presentations-at-the-symposium-on-advance-mdwd-20221018monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-closing-of-the-concurrent-registered-direct-and-private-placement-offe-mdwd-20221007monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-concurrent-registered-direct-and-private-placement-offerings-priced-at-mdwd-20220922monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-s-nexobrid-highlighted-in-45-posters-and-presentations-at-the-19th-european-burn-mdwd-20220912monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-second-quarter-2022-financial-results-and-provides-company-updates-mdwd-20220809monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-enhances-its-board-and-executive-leadership-team-mdwd-20220808monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-u-s-fda-acceptance-of-biologics-license-application-for-nexobrid-for-t-mdwd-20220803monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-schedules-second-quarter-2022-financial-results-mdwd-20220801monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-positive-initial-data-from-its-u-s-phase-i-ii-study-of-mw005-for-the-t-mdwd-20220711monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-presentation-on-escharex-at-the-advanced-wound-care-summit-in-boston-o-mdwd-20220708monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-positive-results-from-its-u-s-phase-2-pharmacology-study-of-escharex-f-mdwd-20220707monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-host-a-key-opinion-leader-investor-day-on-escharex-mdwd-20220705monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-names-mr-tzvi-palash-as-chief-operating-officer-mdwd-20220630monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-ceo-transition-mdwd-20220517monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-first-quarter-2022-financial-results-mdwd-20220517monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-positive-results-from-its-u-s-phase-2-trial-of-escharex-for-debridemen-mdwd-20220512monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-first-quarter-financial-results-and-host-a-conference-call-and-webcast-mdwd-20220510monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-s-escharex-highlighted-in-poster-and-oral-presentation-at-the-symposium-on-advan-mdwd-20220412monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-escharex-clinical-data-at-the-symposium-on-advanced-wound-care-sawc-s-mdwd-20220329monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-exercise-of-over-allotment-option-mdwd-20220322monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-last-patient-out-in-escharex-u-s-phase-2-trial-for-the-debridement-of--mdwd-20220321monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-fourth-quarter-and-full-year-2021-financial-results-mdwd-20220317monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-closing-of-public-offering-of-ordinary-shares-mdwd-20220310monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-fourth-quarter-and-year-end-2021-financial-results-and-host-a-conferen-mdwd-20220310monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-pricing-of-public-offering-of-ordinary-shares-mdwd-20220303monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-ltd-announces-proposed-public-offering-of-ordinary-shares-mdwd-20220302monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-at-upcoming-investor-conferences-in-march-mdwd-20220301monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-awarded-a-u-s-department-of-defense-research-grant-for-the-development-of-nexobr-mdwd-20220217monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-at-upcoming-investor-conferences-in-february-mdwd-20220214monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-additional-9-million-in-funding-from-barda-to-support-nexobrid-bla-res-mdwd-20220210monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-positive-topline-results-from-its-u-s-phase-2-trial-of-escharex-for-de-mdwd-20220124monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-positive-initial-data-from-its-u-s-phase-2-pharmacology-study-of-escha-mdwd-20211220monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-completes-enrollment-of-its-escharex-u-s-phase-2-adaptive-design-study-mdwd-20211206monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-third-quarter-2021-financial-results-mdwd-20211116monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-third-quarter-2021-financial-results-and-host-a-conference-call-and-we-mdwd-20211104monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-peer-reviewed-publication-of-escharex-in-vivo-head-to-head-comparator--mdwd-20211004monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-at-upcoming-investor-conferences-mdwd-20210903monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-second-quarter-financial-results-mdwd-20210810monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-second-quarter-2021-financial-results-and-host-a-conference-call-and-w-mdwd-20210802monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-positive-outcome-of-interim-assessment-for-its-escharex-u-s-phase-2-ad-mdwd-20210728monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-initiation-of-u-s-phase-i-ii-study-of-mw005-for-the-treatment-of-basal-mdwd-20210726monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-positive-topline-results-from-phase-3-pediatric-study-cids-of-nexobrid-mdwd-20210720monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-peer-reviewed-paper-detailing-escharex-phase-2-randomized-control-tria-mdwd-20210709monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-receives-complete-response-letter-from-u-s-fda-for-nexobrid-biologics-license-ap-mdwd-20210629monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-completes-patient-enrollment-for-interim-assessment-of-its-u-s-escharex-phase-2--mdwd-20210609monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-peer-reviewed-paper-of-a-case-series-report-of-basal-cell-carcinoma-pu-mdwd-20210607monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-first-quarter-2021-financial-results-mdwd-20210505monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-first-quarter-2021-financial-results-and-host-a-conference-call-and-we-mdwd-20210426monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-enrolls-first-patient-in-phase-2-pharmacology-study-of-escharex-mdwd-20210422monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-hosting-analyst-day-webinar-on-escharex-enzymatic-debridement-agent-for-chronic--mdwd-20210324monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-participate-in-upcoming-march-investment-conferences-mdwd-20210225monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-fourth-quarter-and-full-year-2020-financial-results-mdwd-20210225monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-launches-clinical-development-program-for-treatment-of-non-melanoma-skin-cancer-mdwd-20210222monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-fourth-quarter-and-fiscal-2020-financial-results-and-host-a-conference-mdwd-20210216monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-participate-in-the-btig-virtual-medtech-digital-health-life-science-diagnosti-mdwd-20210210monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-provides-progress-update-on-its-escharex-clinical-development-program-mdwd-20210111monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-participate-in-upcoming-investor-conferences-in-january-mdwd-20210105monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-continues-global-expansion-with-distribution-agreement-for-nexobrid-in-united-ar-mdwd-20201214monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-third-quarter-2020-financial-results-mdwd-20201110monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-third-quarter-2020-financial-results-and-host-a-conference-call-and-we-mdwd-20201102monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-completes-enrollment-stage-of-its-nexobrid-phase-3-pediatric-study-mdwd-20201028monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-studying-the-effect-of-escharex-on-biofilm-burden-mdwd-20201014monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-fda-acceptance-of-biologics-license-application-for-nexobrid-for-the-t-mdwd-20200916monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-at-upcoming-investor-conferences-in-september-mdwd-20200903monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-and-vericel-announce-acceptance-of-the-first-delivery-of-nexobrid-to-barda-for-e-mdwd-20200825monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-second-quarter-2020-financial-results-and-provides-corporate-update-mdwd-20200806monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-second-quarter-2020-financial-results-and-host-a-conference-call-and-w-mdwd-20200728monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-submission-of-biologics-license-application-to-the-u-s-fda-for-nexobri-mdwd-20200630monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-first-quarter-2020-financial-results-and-provides-corporate-update-mdwd-20200520monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-first-quarter-2020-financial-results-and-host-a-conference-call-and-we-mdwd-20200513monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-strengthens-its-nexobrid-european-presence-with-additional-distribution-agreemen-mdwd-20200504monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-strengthens-board-of-directors-mdwd-20200427monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-provides-corporate-update-related-to-covid-19-pandemic-mdwd-20200330monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-at-cowen-and-company-40th-annual-healthcare-conference-mdwd-20200228monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-fourth-quarter-and-full-year-2019-financial-results-mdwd-20200225monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-fourth-quarter-fiscal-2019-financial-results-and-host-a-conference-cal-mdwd-20200218monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-expands-its-distribution-agreement-with-genfa-medica-sa-to-market-nexobrid-in-uk-mdwd-20200113monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-continues-nexobrid-s-global-expansion-through-a-new-distribution-agreement-in-au-mdwd-20200102monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-initiates-u-s-phase-2-adaptive-design-study-of-escharex-for-treatment-of-venous--mdwd-20191203monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-third-quarter-2019-financial-results-mdwd-20191114monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-third-quarter-2019-financial-results-and-host-a-conference-call-and-we-mdwd-20191106monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-second-quarter-2019-financial-results-mdwd-20190813monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-report-second-quarter-2019-financial-results-and-host-a-conference-call-and-w-mdwd-20190806monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-launches-escharex-u-s-clinical-development-program-mdwd-20190722monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-host-analyst-day-on-its-innovative-product-escharex-for-debridement-of-chroni-mdwd-20190716monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-appoints-mr-boaz-gur-lavie-as-chief-financial-officer-mdwd-20190611monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-first-quarter-2019-financial-results-mdwd-20190521monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-host-first-quarter-financial-results-conference-call-on-may-21at-8-30-a-m-eas-mdwd-20190514monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-enters-into-exclusive-license-agreement-with-vericel-for-commercial-rights-to-ne-mdwd-20190507monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-files-annual-report-on-form-20-f-for-the-year-ended-december-31-2018-mdwd-20190326monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-fourth-quarter-and-fiscal-year-2018-financial-results-mdwd-20190325monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-host-fourth-quarter-fiscal-2018-financial-results-conference-call-on-march-25-mdwd-20190318monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-executive-leadership-changes-mdwd-20190312monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-positive-top-line-results-from-its-pivotal-phase-3-study-detect-in-nex-mdwd-20190122monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-third-quarter-2018-financial-results-mdwd-20181113monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-host-third-quarter-2018-financial-results-conference-call-on-november-13-at-8-mdwd-20181107monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-awarded-additional-barda-contract-valued-up-to-43-million-for-development-of-nex-mdwd-20180924monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-at-13th-annual-wells-fargo-securities-healthcare-conference-mdwd-20180904monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-second-quarter-2018-financial-results-mdwd-20180807monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-host-second-quarter-2018-financial-results-conference-call-on-august-7-at-8-3-mdwd-20180731monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-expands-its-nexobrid-phase-3-children-innovation-debridement-study-cids-to-the-u-mdwd-20180619monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-completes-enrollment-in-nexobrid-u-s-phase-3-detect-study-mdwd-20180611monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-first-quarter-2018-financial-results-mdwd-20180510monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-host-first-quarter-2018-financial-results-conference-call-on-may-10-at-8-30-a-mdwd-20180504monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-s-nexobrid-to-be-highlighted-in-presentations-at-the-american-burn-association-5-mdwd-20180409monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-fourth-quarter-and-fiscal-year-2017-financial-results-mdwd-20180319monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-host-fourth-quarter-and-fiscal-year-2017-financial-results-conference-call-on-mdwd-20180313monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-at-two-investor-conferences-mdwd-20180308monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-third-quarter-2017-financial-results-mdwd-20171116monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-host-third-quarter-2017-financial-results-conference-call-on-november-16-2017-mdwd-20171110monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-exercise-of-underwriters-option-to-purchase-additional-shares-mdwd-20171027monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-appoints-mr-stephen-t-wills-as-chairman-to-its-board-of-directors-mdwd-20171025monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-further-expands-nexobrid-s-global-outreach-through-new-distribution-agreement-in-mdwd-20171016monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-ltd-announces-pricing-of-22-million-public-offering-of-ordinary-shares-mdwd-20170919monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-ltd-announces-public-offering-of-ordinary-shares-mdwd-20170918monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-s-nexobrid-wins-best-poster-presentation-award-at-the-17th-european-burns-associ-mdwd-20170911monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-s-nexobrid-highlighted-in-43-presentations-at-the-17th-european-burns-associatio-mdwd-20170906monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-successfully-completes-second-cohort-of-escharex-phase-2-study-mdwd-20170901monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-second-quarter-2017-financial-results-mdwd-20170803monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-host-second-quarter-2017-financial-results-conference-call-on-august-3-2017-a-mdwd-20170728monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-at-the-jefferies-global-healthcare-conference-mdwd-20170605monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-changes-to-its-board-of-directors-mdwd-20170518monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-first-quarter-2017-financial-results-mdwd-20170508monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-successful-gmp-manufacturing-audit-by-the-israeli-ministry-of-health-mdwd-20170503monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-host-first-quarter-2017-financial-results-conference-call-on-may-8-2017-at-8--mdwd-20170501monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-s-nexobrid-and-escharex-to-be-highlighted-in-multiple-presentations-at-the-sympo-mdwd-20170330monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-conference-call-and-webcast-of-meet-the-experts-panel-discussion-chair-mdwd-20170317monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-s-nexobrid-and-escharex-to-be-highlighted-in-presentations-at-the-american-burn--mdwd-20170314monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-at-the-oppenheimer-27th-annual-healthcare-conference-mdwd-20170313monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-2016-fourth-quarter-and-full-year-financial-results-mdwd-20170221monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-host-2016-fourth-quarter-and-full-year-financial-results-conference-call-on-f-mdwd-20170214monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-initiates-second-stage-of-european-pediatric-phase-3-study-of-nexobrid-expanding-mdwd-20170206monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-final-positive-results-of-phase-2-clinical-trial-of-escharex-for-the-deb-mdwd-20170131monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-granted-u-s-patent-for-mwpc003-for-the-treatment-of-connective-tissue-diseases-mdwd-20161220monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-third-quarter-2016-financial-results-mdwd-20161114monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-host-third-quarter-2016-financial-results-conference-call-on-november-14-2016-mdwd-20161104monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-at-the-credit-suisse-25th-annual-healthcare-conference-mdwd-20161101monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-at-11th-annual-wells-fargo-healthcare-conference-mdwd-20160826monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-s-nexobrid-and-escharex-to-be-featured-at-international-society-for-burn-injurie-mdwd-20160824monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-second-quarter-2016-financial-results-mdwd-20160728monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-host-second-quarter-2016-financial-results-conference-call-on-july-28-2016-at-mdwd-20160721monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-s-nexobrid-receives-reimbursement-in-italy-mdwd-20160607monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-at-jefferies-2016-healthcare-conference-mdwd-20160601monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-s-nexobrid-highlighted-in-best-oral-presentation-at-the-british-burn-association-mdwd-20160519monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-s-nexobrid-to-be-highlighted-in-presentations-at-the-american-burn-association-4-mdwd-20160502monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-s-nexobrid-to-be-available-in-japan-through-kaken-pharmaceuticals-co-ltd-mdwd-20160426monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-first-quarter-2016-financial-results-mdwd-20160421monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-host-first-quarter-2016-financial-results-conference-call-on-april-21-2016-at-mdwd-20160414monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-at-needham-company-s-15th-annual-healthcare-conference-mdwd-20160406monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-at-the-36th-annual-cowen-health-care-conference-mdwd-20160307monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-expands-nexobrid-to-india-bangladesh-and-sri-lanka-through-distribution-agreemen-mdwd-20160229monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-s-escharex-meets-primary-endpoint-in-second-phase-2-clinical-trial-for-the-debri-mdwd-20160202monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-2015-fourth-quarter-and-full-year-financial-results-mdwd-20160125monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-expands-latin-american-distribution-of-nexobrid-through-agreement-with-avalon-ph-mdwd-20160121monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-host-fourth-quarter-and-year-end-2015-financial-results-conference-call-on-ja-mdwd-20160119monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-s-nexobrid-highlighted-in-presentations-at-the-4th-international-conference-on-h-mdwd-20160111monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-appoints-aharon-yaari-as-chairman-of-its-board-of-directors-mdwd-20151223monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-at-the-oppenheimer-26th-annual-healthcare-conference-mdwd-20151201monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-appoints-aharon-yaari-to-its-board-of-directors-mdwd-20151201monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-at-the-canaccord-genuity-2015-medical-technology-diagnostics-forum-mdwd-20151112monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-at-the-credit-suisse-24th-annual-healthcare-conference-mdwd-20151106monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-appoints-dr-roland-frosing-as-european-medical-director-mdwd-20151105monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-provides-humanitarian-aid-for-a-mass-casualty-event-in-romania-mdwd-20151102monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-third-quarter-2015-financial-results-mdwd-20151027monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-host-third-quarter-2015-financial-results-conference-call-on-october-28-at-8--mdwd-20151016monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-awarded-barda-contract-valued-up-to-112-million-for-development-and-procurement--mdwd-20150930monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-highlights-from-the-european-burns-association-congress-mdwd-20150929monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-conference-call-and-webcast-of-meet-the-experts-panel-discussion-chair-mdwd-20150914monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-s-nexobrid-r-highlighted-at-the-16th-european-burns-association-congress-mdwd-20150910monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-completes-enrollment-in-second-phase-2-clinical-trial-of-escharex-r-to-treat-chr-mdwd-20150901monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-second-quarter-2015-financial-results-mdwd-20150803monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-host-second-quarter-2015-financial-results-conference-call-on-august-4-at-8-3-mdwd-20150728monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-approved-for-first-grant-to-support-escharex-tm-development-program-mdwd-20150611monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-at-jefferies-2015-global-healthcare-conference-mdwd-20150601monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-first-quarter-2015-financial-results-mdwd-20150504monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-host-first-quarter-2015-financial-results-conference-call-on-may-4-2015-at-8--mdwd-20150423monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-s-nexobrid-r-highlighted-in-presentations-at-the-2015-american-burn-association--mdwd-20150421monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-initiates-u-s-phase-3-trial-with-nexobrid-r-to-treat-severe-burns-mdwd-20150420monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-s-nexobrid-highlighted-in-a-presentation-at-the-international-conference-on-mini-mdwd-20150323monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-host-fourth-quarter-and-year-end-2014-financial-results-conference-call-on-fe-mdwd-20150206monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-ltd-nasdaq-mdwd-to-ring-the-nasdaq-stock-market-closing-bell-mdwd-20150204monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-ring-the-nasdaq-stock-market-closing-bell-on-february-5-2015-in-recognition-o-mdwd-20150204monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-s-nexobrid-to-be-featured-at-international-society-for-burn-injuries-2014-mdwd-20141007monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-second-quarter-2014-financial-results-mdwd-20140731monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-host-second-quarter-2014-financial-results-conference-call-on-july-31-2014-at-mdwd-20140722monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-nexobrid-marketing-approval-from-israeli-ministry-of-health-mdwd-20140716monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-to-present-at-jefferies-2014-global-healthcare-conference-mdwd-20140602monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-expands-distribution-of-nexobrid-to-south-korea-through-agreement-with-bexpharm--mdwd-20140530monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-initiates-second-phase-2-clinical-trial-of-escharex-tm-to-treat-chronic-and-othe-mdwd-20140521monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-successful-gmp-manufacturing-audit-by-the-israeli-ministry-of-health-mdwd-20140520monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-completes-recruitment-of-commercial-management-team-in-europe-mdwd-20140512monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-expands-distribution-of-nexobrid-to-russia-through-agreement-with-genfa-medica-mdwd-20140508monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-extraordinary-general-meeting-of-shareholders-mdwd-20140505monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-first-quarter-2014-financial-results-mdwd-20140502monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-announces-closing-of-initial-public-offering-mdwd-20140325monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-prices-initial-public-offering-mdwd-20140320monthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-positive-recommendation-for-marketing-authorization-from-the-european-medicines--mdwd-20120924monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-participate-in-upcoming-investor-conferences-crbp-20260513monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-host-in-person-and-virtual-kol-event-at-asco-2026-crbp-20260505monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-participate-in-the-bmo-2026-metabolic-health-summit-crbp-20260318monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-report-results-from-phase-1a-study-of-oral-cb1-inverse-agonist-c-crbp-20251210monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-upcoming-presentation-of-dose-expansion-phase-1-2-clinica-crbp-20250730monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-initiates-multiple-ascending-dose-portion-of-phase-1-study-of-highl-crbp-20250630monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-first-patient-dosed-with-its-nectin-4-targeting-adc-crb-7-crbp-20250625monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-participate-in-the-3rd-annual-piper-obesity-symposium-crbp-20250624monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-jefferies-global-healthcare-conference-crbp-20250522monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-names-industry-veteran-rachelle-jacques-as-board-chair-crbp-20250519monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-2025-rbc-capital-markets-global-healthcare-confer-crbp-20250508monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-first-patient-dosed-in-phase-1-clinical-study-of-next-gen-crbp-20250328monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-q4-and-2024-financial-results-and-provides-a-corporate-upda-crbp-20250311monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-participate-in-upcoming-investor-conferences-crbp-20250225monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-clinical-data-for-crb-701-from-western-dose-escalation-st-crbp-20250211monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-guggenheim-smid-cap-biotech-conference-crbp-20250128monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-that-clinical-data-for-crb-701-from-western-dose-escalati-crbp-20250108monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-crbp-20250106monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-dosing-of-first-patient-in-its-first-in-human-study-of-cr-crbp-20241209monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-7th-annual-evercore-healthconx-conference-crbp-20241121monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-jefferies-london-healthcare-conference-crbp-20241112monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-3rd-quarter-2024-financial-results-and-provides-a-corporate-crbp-20241107monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-guggenheim-securities-healthcare-innovation-confe-crbp-20241029monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial--crbp-20241016monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-participate-in-the-bmo-capital-markets-oncology-summit-crbp-20240926monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-2024-cantor-global-health-conference-crbp-20240905monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-participate-in-upcoming-investor-conferences-in-august-crbp-20240730monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-45th-annual-goldman-sachs-global-healthcare-confe-crbp-20240530monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-participate-in-the-2024-rbc-capital-markets-global-healthcare-co-crbp-20240509monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-participate-in-the-btig-obesity-health-forum-crbp-20240501monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-abstract-accepted-for-presentation-at-2024-asco-annual-me-crbp-20240424monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-announces-dosing-of-first-patient-in-u-s-phase-1-clinical-trial-of-its-next-generat-crbp-20240402monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-participate-in-the-bmo-capital-markets-inaugural-obesity-summit-crbp-20240306monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-appoints-dr-dominic-smethurst-as-chief-medical-officer-crbp-20240228monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-oppenheimer-34th-annual-healthcare-life-sciences--crbp-20240206monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-closing-of-94-5-million-public-offering-of-common-stock-i-crbp-20240202monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-pricing-of-public-offering-crbp-20240131monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-abstract-accepted-for-presentation-at-2024-asco-gu-crbp-20231218monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-publication-of-data-for-its-novel-cannabinoid-type-1-rece-crbp-20231017monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-presents-the-first-pre-clinical-characterization-of-its-next-genera-crbp-20231016monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-host-virtual-meet-the-expert-series-session-2-on-crb-701-on-octo-crbp-20231003monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-publication-of-two-abstracts-at-eular-2021-virtual-congre-crbp-20210525monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-adjournment-of-annual-meeting-crbp-20210519monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-three-upcoming-investor-conferences-crbp-20210511monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-completion-of-enrollment-in-nih-sponsored-phase-2-study-o-crbp-20210420monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-last-subject-visit-in-determine-phase-3-study-of-lenabasum--crbp-20210330monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-crbp-20210309monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-report-fourth-quarter-and-year-end-2020-results-on-march-15-2021-crbp-20210308monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-presentations-at-the-new-york-academy-of-sciences-webinar-crbp-20210120monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-jefferies-virtual-london-healthcare-conference-crbp-20201112monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-presents-additional-data-from-resolve-1-study-in-systemic-sclerosis-crbp-20201109monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-report-third-quarter-results-on-november-10-2020-crbp-20201103monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-presentation-of-data-from-its-phase-2b-study-in-cystic-fi-crbp-20201023monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-three-lenabasum-abstracts-to-be-presented-at-acr-converge-crbp-20201021monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-completes-enrollment-in-determine-phase-3-study-of-lenabasum-for-tr-crbp-20200805monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-crbp-20200803monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-report-second-quarter-results-on-august-6-2020-crbp-20200730monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-presents-data-demonstrating-acr-criss-score-reflects-patient-report-crbp-20200629monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-last-subject-visit-in-phase-2b-study-of-lenabasum-for-treat-crbp-20200622monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-publication-of-phase-2b-cystic-fibrosis-study-patient-dem-crbp-20200601monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-last-subject-visit-in-resolve-1-phase-3-study-of-lenabasum--crbp-20200527monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-publication-of-two-abstracts-at-eular-2020-e-congress-crbp-20200522monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-crbp-20200515monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-report-first-quarter-results-on-may-11-2020-crbp-20200504monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-announces-publication-of-lenabasum-systemic-sclerosis-double-blind-placebo-control--crbp-20200429monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-report-fourth-quarter-and-year-end-2019-results-on-march-12-2020-crbp-20200305monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-closing-of-46-million-public-offering-of-common-stock-inc-crbp-20200211monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-crbp-20200207monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-host-expert-symposium-on-the-therapeutic-potential-of-targeting--crbp-20191209monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-completes-enrollment-of-phase-2b-study-of-lenabasum-for-treatment-o-crbp-20191118monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-jefferies-2019-global-healthcare-conference-in-lo-crbp-20191112monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-updates-data-from-lenabasum-open-label-extension-studies-in-systemi-crbp-20191111monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-third-quarter-2019-o-crbp-20191104monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-presentation-of-three-abstracts-and-new-lenabasum-data-at-crbp-20191003monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-second-quarter-2019--crbp-20190801monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-host-2019-r-d-day-in-new-york-city-crbp-20190617monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-in-june-crbp-20190529monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-presentation-of-six-abstracts-at-eular-2019-annual-meetin-crbp-20190528monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-in-may-crbp-20190515monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-completes-enrollment-of-resolve-1-phase-3-study-of-lenabasum-for-tr-crbp-20190502monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-host-conference-call-and-webcast-to-discuss-first-quarter-2019-o-crbp-20190501monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-change-of-primary-endpoint-in-ongoing-resolve-1-phase-3-s-crbp-20190418monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-class-action-notice-rosen-law-firm-announces-filing-of-securities-class-action-laws-crbp-20190402monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-provides-management-team-updates-crbp-20190328monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-holdings-inc-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-crbp-20190321monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-oppenheimer-29th-annual-healthcare-conference-crbp-20190311monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-announce-full-year-2018-operational-and-financial-results-on-mar-crbp-20190307monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-appointment-of-craig-millian-as-chief-commercial-officer-crbp-20190304monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-closing-of-40-million-public-offering-of-common-stock-inc-crbp-20190130monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-crbp-20190125monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-issuance-of-composition-of-matter-patent-related-to-lenab-crbp-20181218monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-initiates-determine-phase-3-study-in-dermatomyositis-crbp-20181217monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-in-november-crbp-20181106monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-announce-third-quarter-2018-operational-and-financial-results-on-crbp-20181105monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-presents-lenabasum-long-term-open-label-clinical-data-showing-maint-crbp-20181022monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-presents-data-on-impact-of-lenabasum-on-inflammation-of-airway-macr-crbp-20181018monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-patent-issuance-covering-use-of-lenabasum-for-the-treatme-crbp-20181003monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-in-october-crbp-20180926monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-expands-target-indications-by-adding-more-than-600-compounds-focuse-crbp-20180920monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-receives-orphan-designation-for-lenabasum-for-the-treatment-of-derm-crbp-20180918monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-presentation-of-three-abstracts-and-new-lenabasum-data-at-crbp-20180914monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-annual-b-riley-fbr-healthcare-conference-crbp-20180823monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-commence-phase-3-study-of-lenabasum-for-the-treatment-of-rare-au-crbp-20180725monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-receives-fda-orphan-drug-designation-for-lenabasum-for-the-treatmen-crbp-20180720monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-resolution-of-inflammation-infection-and-tissue-regenerat-crbp-20180621monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-jmp-securities-life-science-conference-crbp-20180614monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-appoints-former-director-of-fda-office-of-new-drugs-john-k-jenkins--crbp-20180606monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-jefferies-2018-global-healthcare-conference-crbp-20180524monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-adds-two-key-executives-to-lead-its-regulatory-and-cmc-operations-crbp-20180522monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-acceptance-of-three-abstracts-for-presentation-at-eular-2-crbp-20180515monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-deutsche-bank-43rd-annual-health-care-conference-crbp-20180426monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-cowen-co-38th-annual-health-care-conference-crbp-20180302monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-publication-demonstrating-lenabasum-as-first-drug-to-stim-crbp-20180215monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-2018-rbc-capital-markets-global-healthcare-confer-crbp-20180214monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-7th-annual-leerink-partners-global-healthcare-con-crbp-20180206monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-receives-25-million-development-award-from-the-cystic-fibrosis-foun-crbp-20180130monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-agreement-with-fda-on-phase-2b-cystic-fibrosis-study-desi-crbp-20180129monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-initiation-of-phase-2-study-of-anabasum-for-treatment-of--crbp-20171222monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-initiates-resolve-1-phase-3-study-in-systemic-sclerosis-crbp-20171214monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-expands-intellectual-property-portfolio-with-patent-issuance-coveri-crbp-20171127monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-29th-annual-piper-jaffray-healthcare-conference-crbp-20171115monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-stifel-2017-healthcare-conference-crbp-20171109monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-significant-improvement-in-mrss-and-other-clinical-outcomes-crbp-20171106monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-new-patent-issuance-covering-the-use-of-anabasum-for-the--crbp-20171031monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-holdings-inc-prices-underwritten-public-offering-of-common-stock-crbp-20171024monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-presentation-of-three-abstracts-at-the-2017-north-america-crbp-20170925monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-presentation-of-six-abstracts-and-new-anabasum-data-at-20-crbp-20170920monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-crbp-20170914monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-host-fireside-chat-on-dermatomyositis-with-expert-physician-and--crbp-20170831monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-new-data-from-systemic-sclerosis-phase-2-study-of-anabas-crbp-20170807monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-inclusion-in-russell-3000-r-index-crbp-20170626monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-presented-data-from-phase-2-study-of-anabasum-for-the-treatment-of--crbp-20170615monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-data-from-phase-2-study-of-anabasum-at-the-european-cyst-crbp-20170608monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-2017-jefferies-global-healthcare-conference-crbp-20170601monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-last-subject-enrolled-in-phase-2-study-of-anabasum-for-th-crbp-20170511monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-commence-single-phase-3-study-of-anabasum-for-treatment-of-syste-crbp-20170405monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-gene-expression-data-from-recent-phase-2-systemic-sclero-crbp-20170308monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-completes-27-2-million-registered-direct-offering-crbp-20170303monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-cowen-and-company-37th-annual-health-care-confere-crbp-20170301monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-preclinical-data-demonstrating-jbt-101-reduces-inflammati-crbp-20170223monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-host-research-and-development-day-on-march-13-2017-crbp-20170221monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-receives-orphan-designation-for-jbt-101-for-the-treatment-of-system-crbp-20170117monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-completion-of-phase-2-study-of-jbt-101-resunab-for-the-tr-crbp-20161229monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-holdings-inc-nasdaq-crbp-to-ring-the-nasdaq-stock-market-closing-be-crbp-20161205monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-nasdaq-closing-bell-ceremony-crbp-20161205monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-commences-one-year-open-label-extension-to-its-ongoing-phase-2-stud-crbp-20161129monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-receives-orphan-designation-for-resunab-for-the-treatment-of-cystic-crbp-20161018monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-completion-of-phase-2-study-of-resunab-for-systemic-scler-crbp-20161013monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-announces-data-on-effects-of-resunab-jbt-101-in-a-clinical-research-model-of-resolu-crbp-20160928monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-jefferies-cystic-fibrosis-summit-crbp-20160919monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-last-subject-enrolled-in-phase-2-study-of-resunab-for-the-crbp-20160912monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-cantor-fitzgerald-2nd-annual-healthcare-conferenc-crbp-20160706monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-jmp-securities-life-sciences-conference-on-june-2-crbp-20160617monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-last-patient-enrolled-in-phase-2-study-of-resunab-for-sys-crbp-20160616monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-completes-15-million-registered-direct-offering-crbp-20160615monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-receives-fda-approval-for-open-label-extension-to-its-phase-2-trial-crbp-20160412monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-addition-of-phase-2-clinical-protocol-for-resunab-treatme-crbp-20160331monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-expands-clinical-development-of-resunab-tm-with-phase-2-trial-for-t-crbp-20160307monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-18th-annual-bio-ceo-investor-conference-on-februa-crbp-20160201monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-biotech-showcase-tm-on-january-12-2016-crbp-20160105monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-fda-orphan-drug-designation-and-fast-track-status-of-resu-crbp-20151020monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-first-patient-dosed-in-phase-2-study-of-resunab-tm-for-tr-crbp-20151015monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-14th-annual-bio-investor-forum-crbp-20151013monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-first-patient-dosed-in-phase-2-study-of-resunab-for-syste-crbp-20151007monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-additional-data-on-the-effects-of-resunab-tm-in-the-trea-crbp-20150922monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-commences-patient-enrollment-in-phase-2-clinical-study-of-resunab-t-crbp-20150921monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-commences-patient-enrollment-in-phase-2-clinical-study-of-resunab-t-crbp-20150831monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-investigational-drug-resunab-tm-granted-fast-track-status-by-the-u--crbp-20150819monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-canaccord-genuity-growth-conference-on-august-13--crbp-20150806monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-dosing-of-first-patient-in-phase-2-clinical-trial-of-resu-crbp-20150713monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-jmp-securities-life-sciences-conference-on-june-2-crbp-20150617monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-inclusion-in-russell-microcap-r-index-crbp-20150616monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-fda-orphan-drug-designation-for-resunab-tm-for-the-treatm-crbp-20150612monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-expands-clinical-development-of-resunab-tm-with-a-phase-2-trial-for-crbp-20150605monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-presentation-of-positive-data-on-resunab-tm-in-pre-clinic-crbp-20150601monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-receives-fda-clearance-to-initiate-phase-2-clinical-study-of-resuna-crbp-20150518monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-appoints-charles-n-serhan-ph-d-to-scientific-advisory-board-crbp-20150514monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-cystic-fibrosis-workshop-hosted-by-jmp-securities-crbp-20150504monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-holdings-inc-nasdaq-crbp-to-ring-the-nasdaq-stock-market-closing-be-crbp-20150416monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-initiation-of-trading-on-the-nasdaq-capital-market-crbp-20150416monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-uplisting-to-the-nasdaq-capital-market-crbp-20150413monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-presentation-of-positive-data-on-anti-fibrotic-effects-of-crbp-20150401monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-ind-receives-clearance-from-fda-to-initiate-phase-2-trials-in-scler-crbp-20150309monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-observes-annual-rare-disease-day-crbp-20150227monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-leerink-global-healthcare-conference-on-february--crbp-20150211monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-17th-annual-bio-ceo-investor-conference-on-februa-crbp-20150202monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-crbp-20150107monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-oppenheimer-25th-annual-healthcare-conference-on--crbp-20141203monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-commences-trading-on-otcqb-under-ticker-symbol-crbp-crbp-20141028monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-13th-annual-bio-investor-forum-in-san-francisco-o-crbp-20141001monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-leerink-partners-rare-disease-roundtable-in-new-y-crbp-20140930monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-two-investor-conferences-in-september-crbp-20140904monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-observes-world-scleroderma-day-crbp-20140626monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-to-present-at-the-2014-bio-international-convention-crbp-20140616monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-completes-10-3-million-private-placement-crbp-20140603monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-secures-up-to-150-million-of-non-dilutive-financing-from-k2-healthv-rnac-20260526monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grants-rnac-20260504monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grants-rnac-20260402monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grants-rnac-20260106monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-the-appointment-of-adrian-bot-to-board-of-directors-rnac-20251218monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grant-rnac-20251003monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grants-rnac-20250805monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grants-rnac-20250603monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grants-rnac-20250502monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grants-rnac-20250402monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-confer-rnac-20250401monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grant-rnac-20250306monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-to-participate-in-upcoming-investor-conferences-rnac-20250218monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grants-rnac-20250206monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-fda-special-protocol-assessment-agreement-for-phase-3-aur-rnac-20250127monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-highlights-progress-and-2025-strategic-priorities-across-pipeline-o-rnac-20250113monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grants-rnac-20250107monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grants-rnac-20241218monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-positive-updated-results-from-phase-2b-trial-of-descartes-rnac-20241203monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-to-present-updated-data-from-phase-2b-trial-of-descartes-08-in-pati-rnac-20241121monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grants-rnac-20241108monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-presentation-at-the-upcoming-66th-ash-annual-meeting-rnac-20241105monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-presentation-of-results-from-phase-2b-trial-of-descartes--rnac-20241015monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grants-rnac-20241004monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-receives-fda-rare-pediatric-disease-designation-for-descartes-08-fo-rnac-20240909monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grant-rnac-20240906monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-first-patient-dosed-in-first-in-human-phase-1-trial-of-ne-rnac-20240903monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-to-participate-in-upcoming-investor-conferences-rnac-20240826monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grants-rnac-20240807monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grants-rnac-20240708monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-strengthens-board-of-directors-with-appointment-of-kemal-malik-rnac-20240702monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-first-patient-dosed-in-phase-2-trial-of-descartes-08-in-s-rnac-20240702monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-positive-topline-results-from-phase-2b-trial-of-descartes-rnac-20240702monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grant-rnac-20240606monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-rmat-designatio-rnac-20240522monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-to-participate-in-the-h-c-wainwright-2nd-annual-bioconnect-investor-rnac-20240513monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-to-participate-in-upcoming-investor-conferences-rnac-20240306monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grant-rnac-20240305monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grants-rnac-20240205monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-highlights-progress-and-2024-strategic-priorities-across-innovative-rnac-20240108monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-positive-long-term-follow-up-data-from-phase-2a-study-of--rnac-20240108monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-publication-in-peer-reviewed-journal-science-advances-highli-eltx-20260601monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-reports-inducement-grants-eltx-20260317monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-reports-inducement-grants-eltx-20251216monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-appoints-veteran-cmc-and-technical-operations-executive-marc-j-wolfgan-eltx-20251119monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate-up-eltx-20251113monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-secures-10-million-in-financing-eltx-20250604monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-reports-first-quarter-2025-financial-results-and-provides-corporate-up-eltx-20250513monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-reports-inducement-grant-to-new-chief-strategy-and-financial-officer-a-eltx-20250416monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-reports-2024-financial-results-and-provides-corporate-updates-eltx-20250331monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-appoints-preetam-shah-ph-d-mba-as-chief-strategy-and-financial-officer-eltx-20250324monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-reaches-alignment-with-fda-on-eli-002-registrational-strategy-eltx-20250122monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-presents-updated-results-from-eli-002-phase-1-amplify-201-study-at-esm-eltx-20241212monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-up-eltx-20241113monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-presents-updated-translational-data-from-eli-002-phase-1-amplify-7p-st-eltx-20241107monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-to-present-clinical-data-at-the-society-for-immunotherapy-of-cancer-si-eltx-20241031monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-reports-inducement-grants-eltx-20241016monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-reports-inducement-grants-eltx-20240917monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-three-upcoming-presentations-focused-on-its-lymph-node-targe-eltx-20240913monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-to-present-at-the-h-c-wainwright-26th-annual-global-investment-confere-eltx-20240828monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-u-eltx-20240813monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-proposed-public-offering-eltx-20240627monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-reports-inducement-grants-eltx-20240618monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-preliminary-data-from-the-ongoing-amplify-7p-phase-1a-study--eltx-20240523monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-reports-first-quarter-2024-financial-results-and-provides-corporate-up-eltx-20240515monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-to-present-new-preliminary-data-from-the-ongoing-amplify-7p-phase-1-2--eltx-20240425monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-to-present-updated-clinical-t-cell-and-antigen-spreading-response-data-eltx-20240405monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-reports-2023-financial-results-and-provides-corporate-updates-eltx-20240329monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-6-0-million-private-placement-financing-eltx-20240318monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-upcoming-presentations-at-the-american-association-for-cance-eltx-20240306monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-to-present-at-the-oppenheimer-34th-annual-healthcare-life-sciences-con-eltx-20240205monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-publication-of-preclinical-data-demonstrating-tcr-t-cell-the-eltx-20240125monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-to-present-eli-002-7p-amplify-7p-trial-in-progress-poster-on-phase-1-2-eltx-20240117monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-to-present-at-the-b-riley-securities-4th-annual-oncology-conference-eltx-20240116monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-first-patient-dosed-in-randomized-phase-2-pancreatic-cancer--eltx-20240111monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-7-0-million-private-placement-financing-eltx-20231222monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-precision-oncology-virtual-eltx-20231204monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-reports-third-quarter-2023-financial-results-and-provides-corporate-up-eltx-20231109monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-presents-updated-preliminary-immunogenicity-data-from-the-ongoing-phas-eltx-20231103monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-c-eltx-20231011monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-presents-updated-preliminary-data-including-promising-relapse-free-sur-eltx-20230927monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-receives-2-6-million-grant-from-the-gastro-intestinal-gi-research-foun-eltx-20230907monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-to-present-at-the-h-c-wainwright-25th-annual-global-investment-confere-eltx-20230906monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-to-present-phase-1-data-on-cancer-vaccine-candidate-eli-002-in-patient-eltx-20230905monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-appointment-of-megan-filoon-as-general-counsel-and-dr-thian--eltx-20230828monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-reports-inducement-grants-eltx-20230822monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-reports-second-quarter-2023-financial-results-and-provides-corporate-u-eltx-20230811monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-publication-of-preclinical-data-demonstrating-amp-cpg-adjuva-eltx-20230809monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-completes-reverse-merger-and-provides-a-corporate-update-eltx-20230606monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-reports-inducement-grant-to-new-chief-financial-officer-eltx-20230602monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-completion-of-merger-with-angion-biomedica-eltx-20230601monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-publication-of-preclinical-data-in-science-translational-med-eltx-20221004monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-receives-2-8-million-grant-from-the-gastro-intestinal-research-foundat-eltx-20220920monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-publication-of-preclinical-data-on-eli-005-a-lymph-node-targ-eltx-20220907monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-presents-preclinical-data-on-amp-cpg-adjuvant-in-combination-with-ebv--eltx-20220706monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-presents-preclinical-data-on-its-lymph-node-targeted-sars-cov-2-amphip-eltx-20220706monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-presents-design-of-ongoing-amplify-201-study-in-mutant-kras-driven-can-eltx-20220527monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-publication-of-preclinical-data-showing-amp-peptide-vaccine--eltx-20220523monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-clinical-supply-agreement-with-regeneron-to-evaluate-eli-002-eltx-20220516monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-appointment-of-joy-seymour-as-vice-president-head-of-regulat-eltx-20220512monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-presents-preclinical-data-on-the-amp-peptide-vaccine-in-combination-wi-eltx-20220429monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-presents-updated-preclinical-data-at-vaccines-summit-boston-2022-on-el-eltx-20220329monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-presents-preclinical-data-on-its-amphiphile-cpg-adjuvant-at-the-sting--eltx-20220323monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-moves-into-boston-s-seaport-district-and-provides-update-on-programs-eltx-20220315monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-presents-preclinical-data-on-amp-tcr-t-and-car-t-combination-therapies-eltx-20211112monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-first-patient-dosed-in-the-eli-002-amplify-201-study-in-kras-eltx-20211006monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-presents-updated-preclinical-data-at-the-2021-vaccines-summit-demonstr-eltx-20210922monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-virtual-presentation-of-data-on-its-amphiphile-cpg-adjuvant--eltx-20210917monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-presents-preclinical-data-on-amp-tcr-t-combination-therapy-in-solid-tu-eltx-20210910monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-initiation-of-its-phase-1-2-dose-escalation-study-of-eli-002-eltx-20210629monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-late-breaker-oral-presentation-on-vilobelimab-phase-3-results-in-pyoderm-ifrx-20260318monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-announce-topline-data-from-phase-2a-clinical-trial-of-inf904-in-hidradenitis-su-ifrx-20251107monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-first-quarter-2025-financial-results-and-provides-business-update-ifrx-20250507monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-report-first-quarter-2025-results-on-may-7-2025-ifrx-20250430monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-showcases-vilobelimab-s-role-in-immuno-dermatology-at-the-2025-aad-annual-meeting-ifrx-20250307monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-showcase-vilobelimab-s-role-in-immuno-dermatology-at-the-2025-aad-annual-meetin-ifrx-20250228monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-report-full-year-2024-results-on-march-20-and-announces-participation-in-march--ifrx-20250225monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-closing-of-30-million-public-offering-of-ordinary-shares-and-pre-funded--ifrx-20250218monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-pricing-of-30-million-public-offering-of-ordinary-shares-and-pre-funded--ifrx-20250214monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-public-offering-of-ordinary-shares-and-pre-funded-warrants-ifrx-20250213monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-participation-in-guggenheim-smid-cap-biotech-conference-ifrx-20250123monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-participation-in-january-events-in-san-francisco-ifrx-20250107monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-third-quarter-2024-financial-results-and-provides-business-update-ifrx-20241108monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-report-third-quarter-2024-financial-results-on-november-8-and-to-participate-in-ifrx-20241031monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-presents-post-hoc-analysis-of-shine-trial-of-vilobelimab-in-hidradenitis-suppurati-ifrx-20240925monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-presents-new-preclinical-findings-for-inf904-at-the-19th-european-meeting-on-compl-ifrx-20240903monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-participation-in-september-investor-events-ifrx-20240827monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-second-quarter-2024-financial-results-and-provides-business-update-ifrx-20240808monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-report-second-quarter-2024-results-on-august-8-2024-ifrx-20240801monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-present-new-preclinical-data-on-inf904-at-the-19th-european-meeting-on-compleme-ifrx-20240730monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-first-quarter-2024-financial-results-and-provides-business-update-ifrx-20240508monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-host-virtual-r-d-event-on-june-5-2024-and-report-first-quarter-2024-results-on--ifrx-20240430monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-participate-in-capital-one-securities-1st-annual-biotech-biopharma-disrupters-e-ifrx-20240424monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-announce-development-plans-for-inf904-and-2023-financial-results-on-march-21-20-ifrx-20240319monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-appoints-jan-medina-as-head-of-investor-relations-ifrx-20240222monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-third-quarter-2023-financial-results-and-provides-business-update-ifrx-20231101monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-second-quarter-2023-financial-results-operating-update-ifrx-20230810monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-first-quarter-2023-financial-and-operating-results-and-provides-business-u-ifrx-20230511monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-closing-of-the-full-exercise-of-greenshoe-option-increasing-the-proceeds-ifrx-20230418monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-closing-of-40-million-public-offering-of-ordinary-shares-ifrx-20230414monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-pricing-of-40-million-public-offering-of-ordinary-shares-ifrx-20230412monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-public-offering-of-ordinary-shares-ifrx-20230411monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-third-quarter-2022-financial-operating-results-ifrx-20221109monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-present-at-upcoming-scientific-and-investor-conferences-ifrx-20220909monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-second-quarter-2022-financial-operating-results-ifrx-20220805monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-present-at-the-h-c-wainwright-global-investment-conference-ifrx-20220517monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-first-quarter-2022-financial-and-operating-results-and-provides-strategic--ifrx-20220512monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-present-at-annual-svb-leerink-global-health-conference-ifrx-20220208monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-presentation-at-j-p-morgan-healthcare-conference-and-other-investor-even-ifrx-20220105monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-present-at-h-c-wainwright-7th-annual-israel-conference-ifrx-20211111monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-third-quarter-2021-financial-operating-results-ifrx-20211105monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-present-at-the-credit-suisse-30th-annual-healthcare-conference-ifrx-20211103monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference-ifrx-20210909monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-present-at-the-btig-virtual-biotechnology-conference-ifrx-20210806monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-second-quarter-2021-financial-operating-results-ifrx-20210805monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-present-at-the-raymond-james-human-health-innovation-conference-ifrx-20210617monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-first-quarter-2021-financial-operating-results-ifrx-20210512monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-present-at-upcoming-investor-conferences-ifrx-20210303monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-closing-of-75-million-public-offering-of-common-shares-and-one-year-warr-ifrx-20210301monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-pricing-of-75-million-public-offering-of-common-shares-and-one-year-warr-ifrx-20210225monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-proposed-offering-of-common-shares-and-one-year-warrants-ifrx-20210224monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-presentation-of-new-c5a-and-vilobelimab-ifx-1-data-from-phase-iib-shine--ifrx-20210211monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-present-at-upcoming-annual-j-p-morgan-healthcare-conference-ifrx-20210107monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-q3-2020-financial-operating-results-ifrx-20201029monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-q2-2020-financial-operating-results-ifrx-20200730monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-decision-to-enter-phase-iii-development-of-ifx-1-in-severe-covid-19-indu-ifrx-20200721monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-q1-2020-financial-operating-results-ifrx-20200521monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-present-at-upcoming-svb-leerink-global-healthcare-conference-ifrx-20200219monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-present-at-upcoming-j-p-morgan-annual-healthcare-conference-ifrx-20200109monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-second-quarter-2019-financial-operating-results-ifrx-20190814monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-first-quarter-2019-financial-operating-results-ifrx-20190523monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-reports-third-quarter-2018-financial-operating-results-ifrx-20181121monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-to-host-r-d-day-on-hidradenitis-suppurativa-and-its-breakthrough-anti-c5a-mono-ifrx-20180828monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-reports-second-quarter-2018-financial-operating-results-ifrx-20180809monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-opens-new-research-facility-in-ann-arbor-ifrx-20180605monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-reports-first-quarter-2018-financial-operating-results-ifrx-20180517monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-announces-closing-of-primary-and-secondary-offering-of-common-shares-ifrx-20180508monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-announces-pricing-of-primary-and-secondary-offering-of-common-shares-ifrx-20180504monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-announces-proposed-primary-and-secondary-offerings-of-common-shares-ifrx-20180502monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-nv-nasdaq-ifrx-to-ring-the-nasdaq-stock-market-opening-bell-ifrx-20171108monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-anik-20260605monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-anik-20260403monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-present-at-the-canaccord-genuity-2026-musculoskeletal-conference-anik-20260218monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-issue-fourth-quarter-and-year-end-2025-financial-results-on-thursday-february-26--anik-20260212monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-investigation-reminder-bragar-eagel-squire-p-c-reminds-anika-therapeutics-investors--anik-20260126monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-inc-investigation-kirby-mcinerney-llp-announces-investigation-into-pote-anik-20251206monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-issue-third-quarter-2025-financial-results-on-wednesday-november-5-2025-anik-20251023monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-investigation-reminder-bragar-eagel-squire-p-c-reminds-anika-therapeutics-investors--anik-20251009monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-anik-alert-bragar-eagel-squire-p-c-is-investigating-anika-therapeutics-inc-on-behalf-anik-20250925monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-alert-bragar-eagel-squire-p-c-is-investigating-anika-therapeutics-inc-on-behalf-of-a-anik-20250826monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-anik-alert-bragar-eagel-squire-p-c-continues-investigating-anika-therapeutics-inc-on-anik-20250812monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-investigation-alert-bragar-eagel-squire-p-c-is-investigating-anika-therapeutics-inc--anik-20250804monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-second-quarter-2025-financial-results-anik-20250730monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-anik-20250703monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-anik-20250605monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-anik-20250512monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-first-quarter-2025-financial-results-anik-20250509monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-participate-in-the-sidoti-virtual-investor-conference-anik-20250507monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-issue-first-quarter-2025-financial-results-on-friday-may-9-2025-anik-20250425monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-anik-20250407monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-fourth-quarter-and-full-year-2024-financial-results-anik-20250312monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-completes-divestiture-of-parcus-medical-anik-20250307monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-issue-fourth-quarter-and-year-end-2024-financial-results-on-wednesday-march-12-20-anik-20250226monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-present-at-the-canaccord-genuity-2025-musculoskeletal-conference-anik-20250225monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-participate-in-43rd-annual-j-p-morgan-healthcare-conference-anik-20241223monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-participate-in-december-2024-investor-conferences-anik-20241122monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-third-quarter-2024-financial-results-anik-20241031monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-announces-strategic-update-of-business-with-sale-of-arthrosurface-and-plan-to-divest-anik-20241031monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-announces-third-quarter-2024-results-conference-call-date-anik-20241017monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-anik-20241004monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-anik-20240909monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-anik-20240815monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-second-quarter-2024-financial-results-anik-20240808monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-participate-in-the-sidoti-virtual-investor-conference-anik-20240805monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-issue-second-quarter-2024-financial-results-on-thursday-august-8-2024-anik-20240725monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-anik-20240716monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-announces-full-market-release-of-the-integrity-implant-system-a-regenerative-hyaluro-anik-20240711monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-anik-20240607monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-enters-into-cooperation-agreement-with-caligan-partners-anik-20240528monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-announces-cfo-transition-anik-20240508monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-first-quarter-2024-financial-results-anik-20240508monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-anik-20240503monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-issue-first-quarter-2024-financial-results-on-wednesday-may-8-2024-anik-20240418monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-participate-in-the-23rd-annual-needham-virtual-healthcare-conference-anik-20240402monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-fourth-quarter-and-year-end-2023-financial-results-anik-20240313monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-anik-20240308monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-issue-fourth-quarter-and-year-end-2023-financial-results-on-wednesday-march-13-20-anik-20240227monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-highlights-its-recently-launched-integrity-implant-system-and-revomotion-reverse-sho-anik-20240213monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-announces-first-surgeries-performed-using-the-integrity-implant-system-a-regenerativ-anik-20231128monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-participate-in-upcoming-investor-conferences-anik-20231107monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-third-quarter-2023-financial-results-and-raises-full-year-2023-financial-gui-anik-20231102monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-issue-third-quarter-2023-financial-results-on-thursday-november-2-2023-anik-20231010monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-announces-the-full-market-release-of-the-revomotion-reverse-shoulder-arthroplasty-sy-anik-20230919monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-anik-20230915monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-participate-in-the-sidoti-small-cap-virtual-investor-conference-anik-20230912monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-receives-510-k-clearance-for-integrity-implant-system-a-regenerative-hyaluronic-acid-anik-20230817monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-second-quarter-2023-financial-results-anik-20230808monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-issue-second-quarter-2023-financial-results-on-tuesday-august-8-2023-anik-20230720monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-showcases-highly-differentiated-joint-preservation-and-restoration-portfolio-at-the--anik-20230712monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-completes-enrollment-in-hyalofast-u-s-pivotal-phase-iii-study-achieving-key-mileston-anik-20230530monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-first-quarter-2023-financial-results-anik-20230509monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-issue-first-quarter-2023-financial-results-on-tuesday-may-9-2023-anik-20230419monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-participate-in-the-22nd-annual-needham-virtual-healthcare-conference-anik-20230412monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-continues-to-expand-addressable-market-for-tactoset-injectable-bone-substitute-with--anik-20230403monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-files-preliminary-proxy-statement-anik-20230327monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-participate-in-the-sidoti-small-cap-virtual-investor-conference-anik-20230315monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-highlights-products-in-high-growth-segments-of-joint-preservation-during-the-2023-aa-anik-20230308monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-fourth-quarter-and-year-end-fiscal-2022-financial-results-anik-20230306monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-participate-in-the-canaccord-genuity-musculoskeletal-conference-anik-20230228monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-issue-fourth-quarter-and-year-end-2022-financial-results-on-monday-march-6-2023-anik-20230221monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-issues-statement-anik-20230221monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-announces-first-surgeries-performed-using-the-new-revomotion-reverse-shoulder-arthro-anik-20230213monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-third-quarter-fiscal-2022-financial-results-anik-20221108monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-s-cingal-successfully-achieves-primary-endpoint-in-third-phase-iii-study-anik-20221101monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-issue-third-quarter-2022-financial-results-on-tuesday-november-8-2022-anik-20221025monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-announces-first-surgeries-performed-using-the-x-twist-fixation-system-and-commences--anik-20220912monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-second-quarter-fiscal-2022-financial-results-anik-20220803monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-receives-the-ace-award-for-cutting-edge-innovation-for-tactoset-injectable-bone-subs-anik-20220727monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-issue-second-quarter-2022-financial-results-on-wednesday-august-3-2022-anik-20220712monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-participate-in-the-sidoti-small-cap-virtual-investor-conference-anik-20220610monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-receives-fda-510-k-clearance-for-the-x-twist-knotless-fixation-system-expanding-its--anik-20220520monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-anik-20220513monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-participate-in-the-ubs-global-healthcare-conference-2022-anik-20220509monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-first-quarter-fiscal-2022-financial-results-anik-20220505monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-anik-20220415monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-issue-first-quarter-2022-financial-results-on-thursday-may-5-2022-anik-20220407monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-participate-in-the-21st-annual-needham-virtual-healthcare-conference-anik-20220404monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-showcase-its-transformation-into-a-global-leader-in-joint-preservation-during-the-anik-20220323monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-anik-20220315monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-participate-in-the-canaccord-genuity-musculoskeletal-conference-anik-20220310monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-fourth-quarter-and-year-end-2021-financial-results-anik-20220308monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-anik-20220211monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-issue-fourth-quarter-and-year-end-2021-financial-results-on-tuesday-march-8-2022-anik-20220208monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-anik-20211210monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-participate-in-upcoming-investor-conferences-anik-20211118monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-third-quarter-2021-financial-results-anik-20211104monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-appoints-sheryl-conley-to-board-of-directors-anik-20211101monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-issue-third-quarter-2021-financial-results-on-thursday-november-4-2021-anik-20211018monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-launches-the-wristmotion-total-wrist-arthroplasty-system-at-the-american-society-for-anik-20210930monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-participate-in-the-morgan-stanley-19th-annual-global-healthcare-conference-anik-20210907monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-debut-joint-preservation-portfolio-at-the-2021-aaos-annual-meeting-anik-20210901monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-second-quarter-2021-financial-results-anik-20210805monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-issue-second-quarter-2021-financial-results-on-thursday-august-5-2021-anik-20210719monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-hosts-2021-virtual-investor-day-anik-20210603monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-host-its-2021-virtual-investor-day-on-june-3-2021-anik-20210513monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-first-quarter-2021-financial-results-anik-20210506monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-participate-in-upcoming-virtual-investor-conferences-anik-20210504monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-issue-first-quarter-2021-financial-results-on-thursday-may-6-2021-anik-20210415monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-participate-in-the-20th-annual-needham-virtual-healthcare-conference-anik-20210405monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-participate-in-the-sidoti-spring-virtual-investor-conference-anik-20210311monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-fourth-quarter-and-year-end-2020-financial-results-anik-20210304monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-issue-fourth-quarter-and-year-end-2020-financial-results-on-thursday-march-4-2021-anik-20210209monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-third-quarter-2020-financial-results-anik-20201104monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-issue-third-quarter-2020-financial-results-and-business-highlights-on-wednesday-n-anik-20201022monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-announces-fda-510-k-clearance-for-its-wristmotion-total-arthroplasty-system-for-the--anik-20201021monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-announces-appointment-of-jack-henneman-and-stephen-richard-to-board-of-directors-anik-20200908monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-participate-in-upcoming-virtual-investor-conferences-anik-20200903monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-appoints-michael-levitz-as-chief-financial-officer-anik-20200805monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-second-quarter-2020-financial-results-anik-20200730monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-launch-six-fda-cleared-sports-medicine-and-extremities-products-in-third-quarter--anik-20200720monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-issue-second-quarter-2020-financial-results-and-business-highlights-on-thursday-j-anik-20200716monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-announces-planned-cfo-transition-anik-20200602monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-first-quarter-2020-financial-results-anik-20200507monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-takes-actions-to-strengthen-liquidity-in-light-of-covid-19-anik-20200408monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-fourth-quarter-and-full-year-2019-financial-results-anik-20200220monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-names-board-member-dr-cheryl-blanchard-as-interim-ceo-anik-20200212monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-closes-acquisition-of-arthrosurface-anik-20200203monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-mourns-the-sudden-passing-of-joseph-darling-president-and-chief-executi-anik-20200129monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-closes-acquisition-of-parcus-medical-anik-20200124monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-to-showcase-commercial-and-pipeline-portfolio-at-2018-aaos-annual-meeting-anik-20180306monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-first-quarter-2017-financial-results-anik-20170503monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-inc-nasdaq-anik-to-ring-the-nasdaq-stock-market-opening-bell-anik-20170227monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-first-magic-procedures-in-the-united-states-stxs-20260422monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-first-quarter-2026-financial-results-on-may-12-2026-stxs-20260421monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-definitive-agreement-to-acquire-robocath-stxs-20260415monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-fda-clearance-and-launch-of-synchrony-system-stxs-20260406monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-receives-fda-approval-for-magic-ablation-catheter-stxs-20260106monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-third-quarter-2025-financial-results-on-november-11-2025-stxs-20251021monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-receives-u-s-fda-clearance-for-magic-sweep-catheter-stxs-20250728monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-second-quarter-2025-financial-results-on-august-7-2025-stxs-20250723monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-first-quarter-2025-financial-results-on-may-12-2025-stxs-20250422monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-feature-first-ever-live-demo-of-genesisx-robotic-system-at-hrs-2025-stxs-20250421monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-highlighted-by-nvidia-at-gtc-artificial-intelligence-conference-and-accepted-i-stxs-20250319monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-present-at-37th-annual-roth-conference-stxs-20250310monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-submits-emagin-catheter-for-regulatory-clearance-as-it-pioneers-robotics-for-e-stxs-20250303monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-submits-first-ever-robotically-navigated-high-density-ep-mapping-catheter-for--stxs-20250303monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-present-at-45th-annual-td-cowen-healthcare-conference-stxs-20250225monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-3-2025-stxs-20250203monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-first-genesisx-robotic-system-order-stxs-20250130monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-receives-ce-mark-approval-for-the-magic-ablation-catheter-stxs-20250127monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-genesisx-robotic-system-to-be-showcased-for-the-first-time-at-rsna-2024-by-neu-stxs-20241202monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-participate-in-piper-sandler-36th-annual-healthcare-conference-stxs-20241126monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-genesis-robotic-system-achieves-regulatory-approval-in-china-stxs-20241125monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-third-quarter-2024-financial-results-on-november-11-2024-stxs-20241023monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-technology-to-be-featured-at-annual-meeting-of-the-society-for-cardiac-robotic-stxs-20241021monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-present-at-upcoming-investor-conferences-stxs-20240909monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-robotic-technology-to-be-featured-during-heart-rhythm-society-s-hrx-congress-stxs-20240903monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-achieves-ce-mark-in-europe-and-submits-510-k-in-the-us-for-next-generation-rob-stxs-20240812monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-second-quarter-2024-financial-results-on-august-12-2024-stxs-20240722monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-receives-ce-mark-recertification-under-eu-s-mdr-regulatory-framework-stxs-20240524monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-invited-by-africa-heart-rhythm-association-to-present-its-innovative-robotic-s-stxs-20240515monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-definitive-agreement-to-acquire-access-point-technologies-stxs-20240513monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-first-quarter-2024-financial-results-on-may-13-2024-stxs-20240422monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-regulatory-submissions-of-the-magic-ablation-catheter-in-europe-and--stxs-20240304monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-fourth-quarter-and-full-year-2023-financial-results-on-march-4-2024-stxs-20240220monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-first-patients-successfully-treated-using-magic-ablation-catheter-stxs-20240108monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-participate-in-piper-sandler-35th-annual-healthcare-conference-stxs-20231120monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-third-quarter-2023-financial-results-on-november-9-2023-stxs-20231017monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-robotic-technology-to-be-featured-during-7th-annual-meeting-of-the-society-for-stxs-20231004monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-and-abbott-combine-technologies-in-first-integrated-procedures-to-treat-arrhyt-stxs-20230718monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-second-quarter-2023-financial-results-on-august-10-2023-stxs-20230717monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-participate-in-20th-annual-craig-hallum-institutional-investor-conference-stxs-20230525monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-and-abbott-announce-global-collaboration-combining-leading-mapping-and-robotic-stxs-20230519monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-first-quarter-2023-financial-results-on-may-9-2023-stxs-20230418monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-present-at-cowen-43rd-annual-health-care-conference-stxs-20230221monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-3-2023-stxs-20230202monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-participate-in-piper-sandler-34th-annual-healthcare-conference-stxs-20221128monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-third-quarter-financial-results-on-november-10-2022-stxs-20221020monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-receives-st-louis-mayor-s-innovation-award-for-2022-stxs-20221003monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-second-quarter-financial-results-on-august-9-2022-stxs-20220719monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-ce-mark-submission-for-robotically-navigated-magic-ablation-catheter-stxs-20220711monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-first-quarter-financial-results-on-may-10-2022-stxs-20220414monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-grand-opening-of-new-global-headquarters-in-st-louis-stxs-20220309monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-present-at-upcoming-investor-conferences-stxs-20220214monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-fourth-quarter-and-full-year-2021-financial-results-on-march-3-2022-stxs-20220214monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-robotic-technology-reduces-incidence-of-silent-cerebral-embolism-during-atrial-stxs-20211208monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-host-inaugural-innovation-day-pioneering-endovascular-robotics-stxs-20211118monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-technology-clinical-value-and-innovations-to-be-highlighted-at-society-for-car-stxs-20211108monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-third-quarter-2021-financial-results-on-november-11-2021-stxs-20211028monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-present-at-upcoming-investor-conferences-stxs-20210909monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-and-microport-ep-collaborate-to-advance-innovation-and-adoption-of-robotic-ele-stxs-20210830monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-second-quarter-2021-financial-results-on-august-10-2021-stxs-20210720monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-first-quarter-2021-financial-results-on-may-10-2021-stxs-20210419monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-ceo-invited-as-keynote-speaker-at-robotic-surgery-enabling-technologies-summit-stxs-20210412monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-establish-global-headquarters-in-downtown-st-louis-globe-building-stxs-20210308monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-present-at-upcoming-investor-conferences-stxs-20210211monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-fourth-quarter-and-full-year-2020-financial-results-on-february-25-2-stxs-20210204monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-third-quarter-2020-financial-results-on-november-9-2020-stxs-20201026monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-ceo-invited-to-speak-on-plenary-panel-at-raps-convergence-2020-stxs-20200908monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-present-at-three-investor-conferences-in-september-stxs-20200828monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-and-acutus-medical-announce-first-integrated-cardiac-ablation-procedure-with-t-stxs-20200731monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-second-quarter-2020-financial-results-on-august-6-2020-stxs-20200723monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-be-added-to-the-russell-2000-and-russell-3000-indexes-stxs-20200622monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-present-at-cowen-5th-annual-futurehealth-conference-stxs-20200618monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-robotic-technology-now-referenced-in-over-400-scientific-publications-stxs-20200602monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-first-quarter-2020-financial-results-on-may-5-2020-stxs-20200430monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-earns-fda-clearance-and-announces-u-s-launch-of-genesis-robotic-magnetic-navig-stxs-20200306monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-present-at-three-investor-conferences-in-march-stxs-20200226monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-fourth-quarter-and-full-year-2019-financial-results-on-march-10-2020-stxs-20200226monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-ring-the-opening-bell-of-the-new-york-stock-exchange-stxs-20200116monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-ceo-to-present-at-the-12th-annual-ld-micro-main-event-investor-conference-stxs-20191204monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-ceo-to-present-at-the-12th-annual-biomedevice-san-jose-conference-stxs-20191122monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-and-catheter-precision-combine-robotic-navigation-and-preoperative-arrhythmia--stxs-20191108monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-third-quarter-2019-financial-results-on-november-14-2019-stxs-20191106monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-and-inheart-combine-robotic-precision-and-advanced-preoperative-3d-mapping-to--stxs-20191105monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-and-adas-3d-combine-robotic-precision-and-advanced-preoperative-substrate-mapp-stxs-20191101monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-uplisting-to-nyse-american-stxs-20190903monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-second-quarter-2019-financial-results-on-august-8-2019-stxs-20190807monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-the-first-graduating-class-of-the-robotic-electrophysiology-fellows--stxs-20190618monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-present-at-9th-annual-ld-micro-invitational-stxs-20190529monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-next-generation-robotic-magnetic-navigation-system-and-imaging-syste-stxs-20190509monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-and-osypka-enter-strategic-collaboration-to-advance-robotic-catheter-technolog-stxs-20190509monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-showcase-innovation-and-technology-at-heart-rhythm-2019-and-report-first-qu-stxs-20190429monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-highlight-latest-techniques-for-performing-robotic-ablations-at-european-he-stxs-20190315monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-and-acutus-medical-combine-robotic-precision-and-high-resolution-imaging-to-tr-stxs-20190315monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-fourth-quarter-and-full-year-2018-financial-results-on-march-12-2019-stxs-20190304monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-participate-in-btig-healthcare-investor-conference-stxs-20190219monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-partnership-with-kansas-city-heart-rhythm-institute-to-bring-new-tre-stxs-20190124monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-present-at-the-11th-annual-ld-micro-main-event-investor-conference-stxs-20181126monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-third-quarter-2018-financial-results-on-november-12-2018-stxs-20181102monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-present-at-otcqx-virtual-investor-conference-for-domestic-companies-stxs-20180925monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-second-quarter-2018-financial-results-on-august-7-2018-stxs-20180731monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-present-at-8th-annual-ld-micro-invitational-stxs-20180522monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-highlight-unique-advantages-of-robotic-cardiac-ablation-at-heart-rhythm-201-stxs-20180504monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-first-quarter-2018-financial-results-on-may-14-2018-stxs-20180504monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-and-acutus-medical-announce-strategic-collaboration-stxs-20180503monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-publication-of-clinical-research-supplement-highlighting-robotic-nav-stxs-20180501monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-expanded-european-labeling-for-navigation-in-the-pericardial-space-stxs-20180411monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-10-0-million-non-dilutive-financing-from-early-warrant-exercise-stxs-20180306monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-fourth-quarter-and-full-year-2017-financial-results-on-march-6-2018-stxs-20180302monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-receives-regulatory-approval-of-e-contact-module-in-canada-stxs-20171205monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-present-at-29th-annual-piper-jaffray-healthcare-conference-stxs-20171120monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-third-quarter-2017-financial-results-on-november-9-2017-stxs-20171102monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-attend-asia-pacific-heart-rhythm-society-conference-and-announces-japan-pro-stxs-20170911monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-second-quarter-2017-financial-results-on-august-10-2017-stxs-20170803monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-receives-second-odyssey-vision-system-orders-from-two-leading-heart-hospitals-stxs-20170711monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-launches-the-e-contact-module-in-europe-stxs-20170615monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-first-quarter-2017-financial-results-on-may-8-2017-stxs-20170427monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-leadership-in-robotic-cardiac-ablation-to-be-showcased-at-heart-rhythm-2017-an-stxs-20170425monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-present-at-29th-annual-roth-conference-stxs-20170307monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-launches-interface-between-niobe-es-system-and-philips-state-of-the-art-x-ray--stxs-20161214monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-third-quarter-2016-financial-results-on-november-7-2016-stxs-20161102monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-technologies-to-be-highlighted-at-society-for-cardiac-robotic-navigation-s-ina-stxs-20161018monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-awarded-patent-in-china-for-vdrive-system-with-v-loop-manipulator-stxs-20161013monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-completes-niobe-system-installation-at-kakogawa-hospital-stxs-20160809monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-second-quarter-2016-financial-results-on-august-9-2016-stxs-20160802monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-releases-second-generation-v-cas-deflect-system-in-europe-stxs-20160726monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-niobe-es-system-installed-at-texas-children-s-hospital-stxs-20160708monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-share-its-latest-technology-advancements-and-clinical-evidence-at-cardiosti-stxs-20160607monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-highlight-new-clinical-results-and-automation-enhancements-at-heart-rhythm--stxs-20160504monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-first-quarter-2016-financial-results-on-may-9-2016-stxs-20160502monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-awarded-u-s-patent-for-vmotion-spotlight-automation-feature-of-vdrive-robotic--stxs-20160429monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-completes-patient-enrollment-for-niobe-system-s-post-market-surveillance-in-ja-stxs-20160330monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-participate-at-btig-s-2016-medtech-conference-stxs-20160216monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-fourth-quarter-and-full-year-2015-financial-results-on-february-22-2-stxs-20160208monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-and-philips-extend-development-collaboration-to-interface-latest-systems-stxs-20160126monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-initiates-multi-center-randomized-superiority-study-on-ventricular-tachycardia-stxs-20160111monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-third-quarter-2015-financial-results-on-november-3-2015-stxs-20151027monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-introduces-respiratory-compensation-feature-for-remote-magnetic-navigation-pro-stxs-20151012monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-launches-vmotion-suite-of-automation-features-in-u-s-following-fda-clearance-stxs-20150923monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-ex-warrants-date-of-september-15-2015-for-warrants-offering-stxs-20150915monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-warrants-offering-stxs-20150904monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-awarded-u-s-patent-covering-transmission-of-data-for-odyssey-r-solutions-stxs-20150901monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-second-quarter-2015-financial-results-on-august-4-2015-stxs-20150728monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-present-at-cantor-fitzgerald-inaugural-healthcare-conference-in-new-york-on-stxs-20150702monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-present-new-clinical-evidence-and-product-innovations-at-heart-rhythm-2015--stxs-20150513monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-first-quarter-2015-financial-results-on-may-6-2015-stxs-20150429monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-fourth-quarter-and-full-year-2014-financial-results-on-february-25-2-stxs-20150218monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-and-princess-grace-hospital-share-significant-new-clinical-data-for-remote-mag-stxs-20150113monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-surpasses-75-000-procedures-with-remote-magnetic-navigation-system-stxs-20150106monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-receives-fda-clearance-of-vdrive-r-with-v-cas-tm-system-along-with-regulatory--stxs-20150105monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-third-quarter-2014-financial-results-on-november-5-2014-stxs-20141030monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-secures-first-niobe-r-system-order-in-japan-stxs-20140924monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-receives-fda-clearance-of-vdrive-tm-with-v-loop-tm-system-stxs-20140904monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-second-quarter-2014-financial-results-on-august-4-2014-stxs-20140728monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-present-niobe-r-system-technology-at-japan-heart-rhythm-society-stxs-20140721monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-highlight-efficiency-efficacy-and-safety-of-its-technology-at-cardiostim-20-stxs-20140616monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-submits-510-k-application-to-fda-for-vdrive-tm-with-v-cas-tm-catheter-advancem-stxs-20140610monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-present-new-clinical-evidence-features-of-automated-technologies-at-heart-r-stxs-20140506monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-first-quarter-2014-financial-results-on-may-6-2014-stxs-20140430monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-submits-510-k-application-to-fda-for-vdrive-tm-with-v-loop-tm-system-stxs-20140401monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-expands-credit-facility-with-silicon-valley-bank-to-10-million-stxs-20140331monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-signs-distribution-agreement-for-niobe-r-technology-in-japan-stxs-20140225monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2013-fourth-quarter-and-full-year-financial-results-stxs-20140225monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-fourth-quarter-and-full-year-2013-financial-results-on-february-25-2-stxs-20140219monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-appoints-william-c-mills-iii-to-chief-executive-officer-stxs-20140214monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-completes-clinical-trial-of-vdrive-tm-with-v-loop-tm-system-stxs-20140107monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-present-at-oppenheimer-24th-annual-healthcare-conference-in-new-york-on-dec-stxs-20131206monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-rights-offering-expires-november-21-2013-stxs-20131120monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-third-quarter-2013-financial-results-stxs-20131114monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-ex-rights-date-of-november-4-2013-for-rights-offering-stxs-20131104monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-niobe-r-system-receives-highest-reimbursement-classification-in-japan-stxs-20131023monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-preliminary-third-quarter-2013-financial-results-in-preparation-for--stxs-20131023monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-renewal-of-silicon-valley-bank-credit-facility-stxs-20130903monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-listing-transfer-to-nasdaq-capital-market-stxs-20130816monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-receives-fda-clearance-of-vdrive-tm-with-v-sono-tm-system-stxs-20130729monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-first-quarter-2013-financial-results-stxs-20130513monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-highlight-enhanced-technology-and-results-at-hrs-2013-in-denver-stxs-20130507monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-changes-date-of-first-quarter-2013-conference-call-to-may-13-2013-stxs-20130424monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-first-quarter-2013-financial-results-on-may-2-2013-stxs-20130422monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-receives-regulatory-approval-of-niobe-r-technology-in-japan-begins-commerciali-stxs-20130325monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-ceo-michael-kaminski-steps-down-board-chairman-william-mills-iii-to-serve-as-i-stxs-20130305monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2012-financial-results-provides-2013-outlook-stxs-20130305monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-fourth-quarter-and-full-year-2012-financial-results-on-march-5-2013-stxs-20130226monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-cfo-steps-down-to-pursue-new-career-opportunity-stxs-20130207monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-present-at-oppenheimer-healthcare-conference-in-new-york-on-december-13-201-stxs-20121206monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2012-third-quarter-financial-results-stxs-20121105monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-third-quarter-2012-financial-results-on-november-5-2012-stxs-20121023monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-elects-euan-s-thomson-ph-d-to-board-of-directors-stxs-20121022monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-experiencing-growth-of-second-system-orders-stxs-20121004monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2012-second-quarter-financial-results-stxs-20120806monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-appoints-dr-gery-tomassoni-m-d-fhrs-chief-medical-officer-stxs-20120806monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-report-second-quarter-financial-results-on-august-6-2012-stxs-20120726monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-inc-is-today-s-focus-stock-on-microstockprofit-com-stxs-20100714monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-ingn-shareholder-litigation-alert-should-inogen-management-be-held-accountable-for--ingn-20210902monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-ingn-20190503monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-ingn-20190427monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds--ingn-20190420monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds--ingn-20190406monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds--ingn-20190323monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-inc-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-that-a-securit-ingn-20190312monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds--ingn-20190309monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-participation-in-upcoming-investor-conferences-ingn-20151223monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-releases-enhanced-inogen-one-g3-oxygen-concentrator-ingn-20151208monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-provides-additional-full-year-2016-guidance-ingn-20151130monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-to-recognize-national-copd-awareness-month-at-the-nasdaq-stock-market-closing-bell--ingn-20151118monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-inc-nasdaq-ingn-to-ring-the-nasdaq-stock-market-closing-bell-ingn-20151118monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-participation-in-upcoming-investor-conferences-ingn-20151117monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-third-quarter-2015-financial-results-ingn-20151110monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-participation-in-stifel-2015-healthcare-conference-ingn-20151104monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-to-announce-third-quarter-2015-results-on-tuesday-november-10-2015-ingn-20151027monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-second-quarter-2015-financial-results-ingn-20150811monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-to-announce-second-quarter-2015-results-on-tuesday-august-11-2015-ingn-20150728monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-vice-president-of-strategic-alliances-bob-fary-selected-to-join-aa-homecare-board-o-ingn-20150701monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-named-company-of-the-year-at-the-2015-south-coast-business-technology-awards-ingn-20150612monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-participation-in-william-blair-35th-annual-growth-stock-conference-ingn-20150526monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-first-quarter-2015-financial-results-ingn-20150512monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-to-announce-first-quarter-2015-results-on-tuesday-may-12-2015-ingn-20150504monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-to-announce-fourth-quarter-and-full-year-2014-results-on-monday-april-27-2015-ingn-20150424monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-receives-expected-nasdaq-notice-related-to-delay-in-form-10-k-filing-ingn-20150420monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-delays-filing-of-form-10-k-ingn-20150414monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-to-file-form-12b-25-with-securities-and-exchange-commission-ingn-20150331monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-full-operation-of-new-primary-manufacturing-facility-ingn-20150325monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-to-announce-fourth-quarter-and-full-year-2014-results-on-thursday-march-12-2015-ingn-20150226monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-to-participate-in-upcoming-investor-conferences-ingn-20150128monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-donates-medical-device-to-holocaust-survivor-on-international-holocaust-remembrance-ingn-20150127monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-reimbursement-for-the-inogen-one-g3-in-germany-ingn-20141223monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-to-participate-in-upcoming-investor-conferences-ingn-20141222monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-discusses-oxygen-therapy-market-and-future-growth-drivers-at-investor-analyst-day-ingn-20141215monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-expands-manufacturing-capacity-to-accommodate-growth-ingn-20141205monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-investor-analyst-day-and-webcast-ingn-20141201monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-recognized-as-one-of-the-fastest-growing-companies-in-north-america-according-to-de-ingn-20141113monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-releases-third-quarter-2014-financial-results-ingn-20141111monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-selects-jpmorgan-chase-co-for-primary-banking-relationship-ingn-20141110monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-to-participate-in-stifel-2014-healthcare-conference-ingn-20141105monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-closing-of-secondary-public-offering-ingn-20141104monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-pricing-of-secondary-public-offering-ingn-20141030monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-preliminary-unaudited-third-quarter-2014-revenue-ingn-20141027monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-launch-of-proposed-secondary-public-offering-by-selling-stockholders-ingn-20141027monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-release-to-market-of-the-inogen-at-home-tm-an-innovative-home-oxygen-conc-ingn-20141021monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-to-announce-third-quarter-2014-results-on-tuesday-november-11-2014-ingn-20141014monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-reimbursement-for-the-inogen-one-g3-in-france-ingn-20140909monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-releases-second-quarter-2014-financial-results-ingn-20140812monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-strengthens-board-of-directors-with-addition-of-heather-d-rider-ingn-20140807monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-to-release-second-quarter-2014-financial-results-and-host-conference-call-on-tuesda-ingn-20140729monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-fda-clearance-of-innovative-home-oxygen-concentrator-ingn-20140624monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-to-present-at-the-william-blair-34th-annual-growth-stock-conference-ingn-20140527monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-founders-honored-with-prestigious-venky-award-from-the-university-of-california-san-ingn-20140514monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-releases-first-quarter-2014-financial-results-ingn-20140513monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-to-release-first-quarter-2014-financial-results-and-host-conference-call-on-tuesday-ingn-20140429monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-added-to-russell-2000-r-and-3000-r-indexes-ingn-20140331monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-to-release-fourth-quarter-2013-financial-results-and-host-conference-call-on-thursd-ingn-20140312monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-closing-of-initial-public-offering-ingn-20140220monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-pricing-of-initial-public-offering-ingn-20140214monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-releases-improved-inogen-one-g2-oxygen-concentrator-ingn-20131205monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-files-registration-statement-with-sec-for-an-initial-public-offering-ingn-20131127monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announcing-copd-awareness-giveaway-for-month-of-november-ingn-20131107monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-salutes-decorated-wwii-pow-veteran-and-vandenberg-staffer-ingn-20120717monthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-announces-new-date-for-upcoming-investor-call-okur-20241125monthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-to-present-at-the-stifel-2024-healthcare-conference-okur-20241105monthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-to-present-clinical-and-preclinical-data-for-oki-219-at-the-2024-san-antonio-breast-okur-20241101monthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-announces-closing-of-merger-with-reneo-pharmaceuticals-and-concurrent-private-place-okur-20241004monthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-announces-the-appointment-of-rogan-nunn-j-d-as-general-counsel-and-secretary-okur-20240619monthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-announces-the-appointment-of-samuel-agresta-m-d-as-chief-medical-officer-okur-20240215monthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-appoints-ann-howell-pharm-d-as-vice-president-of-regulatory-affairs-okur-20230920monthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-announces-54-million-series-c-financing-okur-20230523monthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-appoints-robbie-alton-pharm-as-vice-president-of-clinical-operations-okur-20221206monthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-appoints-kevin-s-litwiler-ph-d-as-senior-vice-president-of-dmpk-and-cl-okur-20220621monthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-announces-first-patient-dosed-in-the-phase-1b-2-nautilus-trial-of-oki--okur-20220602monthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-expands-boulder-footprint-with-the-opening-of-a-new-research-laborator-okur-20220425monthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-announces-promising-preclinical-data-on-oki-179-in-ras-mutated-tumor-m-okur-20220408monthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-to-present-late-breaking-preclinical-data-on-oki-179-at-the-aacr-annua-okur-20220308monthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-appoints-jason-leverone-cpa-as-chief-financial-officer-okur-20220208monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-present-at-the-37th-annual-roth-conference-tlsa-20250317monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-not-to-engage-in-capital-raising-activities-for-the-immediate-future-tlsa-20250123monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-positive-six-month-clinical-results-in-multiple-sclerosis--tlsa-20231016monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-reduction-in-microglial-activation-in-a-total-of-5-out-of--tlsa-20230605monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-date-of-annual-general-meeting-2022-tlsa-20221206monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-ltd-receives-nasdaq-deficiency-notice-tlsa-20220617monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-purchase-of-common-shares-by-executive-chairman-tlsa-20220610monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tlsa-nasdaq-releases-research-report-clinical-improvements-for-2-tlsa-20220609monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-an-interview-on-clinical-improvements-for-2nd-spms-patient-tlsa-20220609monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tlsa-nasdaq-clinical-improvements-for-2nd-spms-patient-tlsa-20220609monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-positive-clinical-results-in-the-second-patient-with-secon-tlsa-20220608monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-present-at-the-2022-biotechnology-innovation-organization-annual--tlsa-20220606monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-ltd-announces-annual-report-filed-to-regain-nasdaq-compliance-tlsa-20220524monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-death-of-director-tlsa-20220113monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-scheme-effective-date-tlsa-20211020monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-pdmr-dealing-tlsa-20211020monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-court-sanctions-the-scheme-of-arrangement-and-approves-reduction-tlsa-20211019monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-pdmr-dealing-tlsa-20210928monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-results-of-court-meeting-and-general-meeting-tlsa-20210927monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-interim-results-for-the-six-months-ended-30-june-2021-tlsa-20210924monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-posting-of-scheme-document-and-notice-of-meetings-tlsa-20210903monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-the-company-result-of-annual-general-meeting-tlsa-20210625monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-posting-of-notice-of-annual-general-meeti-tlsa-20210602monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-announces-plans-to-list-accustem-sciences-limited-in-the-u-s-tlsa-20210413monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-accustem-update-tlsa-20210330monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-interview-to-air-on-bloomberg-television-us-on-the-redchip-money-rep-tlsa-20210226monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-present-at-the-bio-ceo-investor-digital-conference-tlsa-20210216monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-appointment-of-director-tlsa-20210205monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-reports-positive-data-from-the-clinical-study-of-nasal-administration-with-foralum-tlsa-20210202monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-participate-in-a-fireside-chat-at-b-riley-virtual-oncology-invest-tlsa-20210120monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-announces-appointment-of-dr-neil-graham-mbbs-md-mph-as-chief-medical-officer-tlsa-20210113monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-participate-at-j-p-morgan-healthcare-conference-2021-tlsa-20210111monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-present-at-biotech-showcase-digital-2021-tlsa-20210111monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-publication-of-prospectus-tlsa-20201218monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-collaboration-with-parexel-biotech-to-conduct-phase-1b-2-c-tlsa-20201111monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-announces-initiation-of-clinical-trial-with-covid-19-patients-in-brazil-with-nasal-tlsa-20201102monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-the-company-result-of-general-meeting-tlsa-20201002monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-interview-to-air-on-bloomberg-international-on-the-redchip-money-rep-tlsa-20200925monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-publication-of-research-note-tlsa-20200921monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-to-conduct-a-clinical-study-with-nasally-administered-foralumab--tlsa-20200917monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-demerger-of-stemprinter-and-distribution--tlsa-20200916monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-clarifies-reason-for-filing-an-amended-ads-registration-statement-tlsa-20200828monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-ceo-updates-shareholders-on-its-patent-portfolio-clinical-pipeline-a-tlsa-20200827monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-granted-a-patent-on-the-use-of-milciclib-in-combination-with-tyrosine-kinase-inhib-tlsa-20200821monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-is-pleased-to-retain-dr-napoleone-ferrara-to-serve-on-its-scientific-advisory-boar-tlsa-20200820monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-granted-a-patent-on-methods-and-use-of-anti-cd3-monoclonal-antibodies-for-treatmen-tlsa-20200818monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-announces-closing-of-57-25-million-offering-tlsa-20200805monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-an-expedited-clinical-development-plan-for-its-anti-interl-tlsa-20200804monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-announces-pricing-of-u-s-follow-on-offering-of-adss-raising-57-25-million-tlsa-20200803monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-total-voting-rights-tlsa-20200731monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-announces-submission-of-a-patent-application-for-nasal-a-tlsa-20200731monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-early-notification-of-proposed-admission-to-the-official-list-an-tlsa-20200730monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-participate-in-investor-webinar-to-provide-corporate-updates-and--tlsa-20200730monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-announces-submission-of-patent-application-on-use-of-foralumab-the-only-fully-huma-tlsa-20200716monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-change-to-ads-ratio-updated-tlsa-20200715monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-change-to-ads-ratio-tlsa-20200715monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-interview-to-air-on-bloomberg-international-on-the-redchip-money-rep-tlsa-20200710monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-agreement-with-stc-biologics-for-gmp-manufacturing-of-an-a-tlsa-20200629monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-granted-first-ever-patent-on-a-transformational-technology-for-oral-delivery-of-al-tlsa-20200619monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-directorate-change-tlsa-20200618monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-that-its-scientific-advisory-board-chairman-dr-howard-wein-tlsa-20200604monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-presentation-of-stemprinter-a-superior-prognostic-test-as--tlsa-20200529monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-lifesciences-announces-intention-to-demerge-its-stemprinter-genomics-based-persona-tlsa-20200522monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-lifesciences-announces-online-publication-of-two-abstracts-at-the-american-society-tlsa-20200514monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-data-demonstrating-stemprinter-s-superiority-compared-to-o-tlsa-20200514monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-present-two-studies-featuring-stemprinter-a-stem-cell-biology-bas-tlsa-20200511monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-files-patent-on-combination-of-nanoparticle-actinomycin-d-with-anti--tlsa-20200427monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-acquires-a-nanoparticle-based-formulation-technology-for-controlled--tlsa-20200424monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-lifesciences-develops-novel-investigational-treatment-for-patients-infected-with-c-tlsa-20200409monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-submits-ind-application-for-oral-formulation-of-foralumab-for-treatment-of-nash-tlsa-20190320monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-exercise-of-warrants-issue-of-equity-tlsa-20170324monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-announces-interim-results-for-the-six-months-ended-30-june-2016-tlsa-20160929monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-confirmation-of-capital-reduction-tlsa-20160915monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-change-of-registered-office-tlsa-20160818monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-result-of-agm-tlsa-20160630monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-announces-exercise-of-warrants-conversion-of-convertible-loan-no-tlsa-20160629monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-final-results-for-the-year-ended-31-december-2015-tlsa-20160607monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-appointment-of-dr-robert-evans-tlsa-20160504monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-announces-exercise-of-warrants-issue-of-equity-tlsa-20160428monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziano-lazzaretti-appointed-as-chief-financial-officer-tlsa-20160404monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-fund-raising-tlsa-20160113monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-life-sciences-plc-announces-development-plans-for-foralu-tlsa-20160111monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-secures-second-commercial-payer-agreement-for-tonmya-expanding-total-tnxp-20260608monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-retrospective-u-s-real-world-claims-analysis-characterizin-tnxp-20260526monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-publication-of-steady-state-pharmacokinetics-of-tonmya-aft-tnxp-20260415monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-data-on-tonmya-in-treating-patients-with-fibromyalgia-at-t-tnxp-20260309monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-publication-of-clinical-pharmacokinetic-studies-of-tonmya--tnxp-20260305monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-two-investor-conferences-in-january-2026-tnxp-20260106monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-clinical-data-on-tonmya-for-the-treatment-of-fibromyalgia-a-tnxp-20250908monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-a-fireside-chat-at-the-cantor-global-healthcare-co-tnxp-20250828monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-fda-approval-of-tonmya-cyclobenzaprine-hcl-sublingual-tabl-tnxp-20250815monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-oral-presentation-on-mpox-and-smallpox-vaccine-candidate-t-tnxp-20250707monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-inclusion-in-the-russell-3000-and-russell-2000-indexes-tnxp-20250630monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentation-at-the-2025-bio-international-convention-tnxp-20250610monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-poster-presentation-at-the-annual-european-congress-of-rhe-tnxp-20250605monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentation-at-the-a-g-p-annual-healthcare-company-showca-tnxp-20250522monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-oral-presentation-and-panel-participation-at-the-world-vac-tnxp-20250416monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-data-and-analyses-of-tnx-102-sl-treatment-effects-on-fibro-tnxp-20250407monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-2025-jones-trading-healthcare-and-innovation-confe-tnxp-20250402monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-launches-tonix-one-a-fully-integrated-digital-platform-designed-to-h-tnxp-20250401monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentation-at-the-american-academy-of-pain-medicine-aapm-tnxp-20250327monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentation-at-bio-europe-spring-2025-tnxp-20250313monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-zacks-scr-life-sciences-virtual-investor-forum-on--tnxp-20250311monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-2025-virtual-investor-summit-tnxp-20250305monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-the-2025-bio-ceo-investor-conference-tnxp-20250205monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-two-upcoming-january-investor-conferences-tnxp-20250107monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-the-noblecon20-investor-conference-tnxp-20241126monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-winter-2024-investor-summit-virtual-tnxp-20241118monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-data-and-analyses-of-tnx-102-sl-treatment-effects-on-fibro-tnxp-20241118monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-poster-presentation-at-the-american-college-of-rheumatolog-tnxp-20241113monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-bio-europe-2024-tnxp-20241029monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-2024-thinkequity-conference-tnxp-20241025monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-oral-presentation-at-the-world-vaccine-congress-europe-202-tnxp-20241024monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-participation-in-endpoints-panel-at-the-long-covid-worksho-tnxp-20240930monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-launches-national-awareness-campaign-on-the-impact-of-gastroparesis--tnxp-20240906monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-data-and-analyses-of-tnx-102-sl-treatment-effects-on-fibro-tnxp-20240828monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-oral-presentation-and-three-poster-presentations-at-the-20-tnxp-20240821monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-provides-update-on-the-development-of-its-single-dose-live-attenuate-tnxp-20240816monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-summer-2024-virtual-investor-summit-tnxp-20240813monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-publication-in-microorganisms-of-technology-that-expands-c-tnxp-20240806monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-potential-positive-impact-of-the-u-s-national-academies-na-tnxp-20240731monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-poster-presentation-at-the-iasp-2024-world-congress-on-pai-tnxp-20240730monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-closing-of-4-0-million-public-offering-tnxp-20240710monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-pricing-of-approximately-4-0-million-public-offering-tnxp-20240709monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-awarded-up-to-34-million-u-s-department-of-defense-contract-for-acce-tnxp-20240701monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-closing-of-4-0-million-public-offering-tnxp-20240628monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-pricing-of-approximately-4-0-million-public-offering-tnxp-20240627monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-vaccine-platform-data-in-keynote-talk-at-the-vaccine-congre-tnxp-20240625monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-data-comparing-real-world-treatment-of-migraine-with-indus-tnxp-20240618monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-poster-of-tonmya-for-the-management-of-fibromyalgia-at-the-tnxp-20240617monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-closing-of-4-0-million-public-offering-tnxp-20240613monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-pricing-of-4-0-million-public-offering-tnxp-20240612monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-poster-presentation-at-the-annual-european-congress-of-rhe-tnxp-20240605monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-two-oral-presentations-and-one-poster-presentation-involvi-tnxp-20240529monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentation-at-the-2024-bio-international-convention-tnxp-20240528monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-alliance-global-partners-a-g-p-healthcare-company--tnxp-20240515monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentation-at-planet-microcap-showcase-tnxp-20240424monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentation-at-bio-europe-spring-tnxp-20240312monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentation-at-the-6th-international-congress-on-controve-tnxp-20240229monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-the-2024-bio-ceo-investor-conference-tnxp-20240220monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-hosted-kol-webinar-on-positive-phase-3-fibromyalgia-trial-for-tonmya-tnxp-20240214monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-kol-webinar-to-discuss-positive-phase-3-fibromyalgia-data--tnxp-20240125monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-additional-data-highlighting-the-favorable-tolerability-and-tnxp-20240109monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-in-january-focus-is--tnxp-20240103monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-national-academies-committee-on-the-current-state--tnxp-20231211monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-in-december-tnxp-20231128monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-2023-thinkequity-conference-tnxp-20231012monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-oral-presentation-at-the-world-vaccine-congress-europe-tnxp-20231011monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-provides-overview-of-tnx-2900-program-for-the-treatment-of-prader-wi-tnxp-20231009monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-pricing-of-4-5-million-public-offering-tnxp-20230929monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-new-preclinical-data-at-seventh-international-cancer-immuno-tnxp-20230921monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-august-virtual-investor-summit-tnxp-20230817monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-closing-of-7-million-public-offering-tnxp-20230801monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-pricing-of-7-million-public-offering-tnxp-20230728monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-comments-on-two-long-covid-conferences-sponsored-by-the-u-s-national-tnxp-20230706monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentation-at-the-2023-bio-international-convention-tnxp-20230530monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-poster-presentation-at-the-2023-american-society-of-clinic-tnxp-20230525monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-june-1st-virtual-investor-summit-tnxp-20230524monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-the-a-g-p-virtual-healthcare-conference-tnxp-20230518monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-pipeline-prioritization-update-for-2023-tnxp-20230404monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-oral-presentations-at-the-world-vaccine-congress-tnxp-20230327monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-oral-presentation-and-poster-at-the-5th-international-cong-tnxp-20230323monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-2023-virtual-march-investor-summit-tnxp-20230322monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentation-at-the-rare-disease-innovation-and-partnershi-tnxp-20230316monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-describes-emerging-research-on-the-incidence-of-multi-site-pain-symp-tnxp-20230222monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-event-titled-long-covid-what-will-it-take-to-accel-tnxp-20230216monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-conference-tnxp-20230203monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-biotech-showcase-2023-tnxp-20230103monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-the-a-g-p-biotech-conference-tnxp-20221123monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-oral-presentation-at-the-world-vaccine-and-immunotherapy-c-tnxp-20221122monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-poster-presentation-at-neuroscience-2022-by-the-society-fo-tnxp-20221109monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-2022-biofuture-conference-tnxp-20221031monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-2022-thinkequity-conference-tnxp-20221019monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-the-2022-bio-europe-conference-tnxp-20221017monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-data-presentations-involving-tnx-1500-fc-modified-anti-cd4-tnxp-20220915monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-oral-presentations-involving-tnx-1500-fc-modified-anti-cd4-tnxp-20220906monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-2022-virtual-q3-investor-summit-tnxp-20220809monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentation-at-the-world-orphan-drug-congress-usa-tnxp-20220706monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-ribbon-cutting-ceremony-for-its-advanced-development-cente-tnxp-20220616monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentation-of-licensed-antiviral-drug-technology-at-the--tnxp-20220608monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentation-at-the-2022-bio-international-convention-tnxp-20220606monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-2022-q2-investor-summit-tnxp-20220428monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-b-riley-securities-2022-virtual-neuro-ophthalmology-co-tnxp-20220425monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-the-noblecon18-investor-conference-tnxp-20220412monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-the-2022-virtual-growth-conference-presented-by-ma-tnxp-20220322monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-conference-tnxp-20220207monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-upcoming-january-conferences-tnxp-20220105monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-q4-investor-summit-tnxp-20211112monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-phase-1-formulation-development-data-for-tnx-601-cr-in-a-po-tnxp-20211109monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-positive-results-from-phase-3-relief-study-of-tnx-102-sl-fo-tnxp-20211108monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-bio-europe-digital-2021-tnxp-20211021monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-the-a-g-p-virtual-healthcare-conference-tnxp-20211007monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-oral-presentation-at-the-american-college-of-rheumatology--tnxp-20210927monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-cantor-virtual-global-healthcare-conference-tnxp-20210922monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-h-c-wainwright-global-investment-conference-tnxp-20210907monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-groundbreaking-ceremony-for-massachusetts-r-d-facility-to--tnxp-20210802monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-added-to-russell-2000-and-russell-3000-indexes-tnxp-20210628monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-raymond-james-human-health-innovation-conference-tnxp-20210616monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-bio-digital-conference-tnxp-20210610monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-positive-results-from-phase-3-relief-study-of-tnx-102-sl-fo-tnxp-20210603monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentation-of-two-posters-at-the-2021-american-society-o-tnxp-20210526monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-may-investor-summit-virtual-conference-tnxp-20210512monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-fourth-annual-neuroscience-innovation-forum-tnxp-20210421monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-needham-virtual-healthcare-conference-tnxp-20210407monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-achieves-50-percent-enrollment-in-rally-the-second-phase-3-study-of--tnxp-20210315monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences-tnxp-20210309monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-bio-ceo-investor-digital-conference-tnxp-20210210monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holdings-corp-closes-70m-common-stock-offering-priced-at-the-market--tnxp-20210209monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holdings-corp-closes-40m-common-stock-offering-priced-at-the-market--tnxp-20210113monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-upcoming-january-conferences-tnxp-20210105monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-topline-results-from-phase-3-recovery-study-of-tnx-102-sl-in-tnxp-20201221monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-positive-immune-response-results-from-covid-19-vaccine-candi-tnxp-20201116monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-outlines-new-statistical-method-to-analyze-future-ptsd-studies-at-th-tnxp-20201112monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-upcoming-november-conferences-tnxp-20201111monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-3rd-annual-neuropsychiatric-drug-development-summit-tnxp-20201109monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-bio-investor-forum-digital-tnxp-20201007monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-plan-to-complete-the-phase-3-relief-study-of-tnx-102-sl-fo-tnxp-20200929monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-host-live-webinar-antibody-vs-t-cell-immunity-is-a-single-vaccine-tnxp-20200917monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-initiates-enrollment-in-second-potentially-pivotal-phase-3-study-the-tnxp-20200903monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-upcoming-september-virtual-investor-conferences-tnxp-20200827monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-that-results-from-a-preclinical-study-of-tnx-1900-are-post-tnxp-20200804monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-snn-network-virtual-investor-conference-tnxp-20200730monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-that-results-from-a-preclinical-study-of-tnx-1900-will-be--tnxp-20200727monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-announces-rescheduling-of-special-meeting-of-stockholde-tnxp-20200721monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-closes-10-5-million-common-stock-registered-direct-offe-tnxp-20200715monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-results-from-preclinical-study-of-tnx-1700-presented-in-a--tnxp-20200622monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-that-results-from-preclinical-studies-of-tnx-1700-will-be--tnxp-20200617monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-two-june-virtual-investor-conferences-tnxp-20200603monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-posted-results-from-pharmacokinetic-analyses-of-tnx-102-sl-and-tnx-6-tnxp-20200521monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-achieves-50-percent-enrollment-in-phase-3-relief-study-of-tnx-102-sl-tnxp-20200424monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-deliver-virtual-presentation-and-participate-in-panel-discussion--tnxp-20200420monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-deliver-virtual-presentation-for-spring-investor-summit-tnxp-20200323monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-closes-16-005-000-common-stock-registered-direct-offeri-tnxp-20200303monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-outcome-of-interim-analysis-for-phase-3-recovery-study-of--tnxp-20200205monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-upcoming-february-investor-conferences-tnxp-20200204monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-results-from-a-preclinical-study-of-tnx-801-a-potential-va-tnxp-20200129monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-biotech-showcase-2020-tnxp-20200107monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-12th-annual-ld-micro-main-event-tnxp-20191204monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-receipt-of-fda-official-minutes-from-breakthrough-therapy--tnxp-20191126monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-benchmark-s-annual-discovery-1x1-conference-tnxp-20191125monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-initiation-of-the-phase-3-relief-study-of-tnx-102-sl-for-t-tnxp-20191121monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-joins-the-alliance-for-biosecurity-tnxp-20191015monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-speak-at-the-2019-annual-national-association-of-veterans-researc-tnxp-20190912monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-upcoming-september-investor-conferences-tnxp-20190910monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-closing-of-public-offering-of-common-stock-tnxp-20190718monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-results-from-pharmacokinetic-analyses-of-tnx-102-sl-in-a-p-tnxp-20190530monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-bio-2019-international-convention-tnxp-20190528monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-speak-at-the-second-chance-digital-impact-recipient-gala-tnxp-20190522monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-will-present-results-from-pharmacokinetic-analyses-of-tnx-102-sl-in--tnxp-20190521monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-upcoming-investor-conferences-tnxp-20190325monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-at-upcoming-investor-conferences-tnxp-20190312monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-new-european-use-patent-for-tnx-601-tnxp-20190307monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-bio-ceo-investor-conference-tnxp-20190204monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-upcoming-investor-conferences-and-participate-in-featu-tnxp-20190102monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-closing-of-15-000-000-public-offering-tnxp-20181211monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-results-and-retrospective-analyses-of-phase-3-p301-honor-s-tnxp-20181106monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-bio-europe-international-partnering-conference-tnxp-20181101monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-will-present-phase-3-honor-and-phase-2-atease-study-results-in-poste-tnxp-20181029monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-dawson-james-securities-small-cap-growth-conferenc-tnxp-20181023monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-microcap-conference-tnxp-20180926monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-sidoti-company-fall-2018-investor-conference-tnxp-20180920monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-upcoming-september-investor-conferences-tnxp-20180830monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-results-and-retrospective-analyses-of-two-double-blind-rand-tnxp-20180821monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-will-present-phase-3-honor-and-phase-2-atease-study-results-in-a-pos-tnxp-20180815monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-new-data-related-to-suicidal-ideation-and-behaviors-in-mil-tnxp-20180531monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-2018-bio-international-convention-tnxp-20180530monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-2018-american-society-of-clinical-psychopharmacolo-tnxp-20180523monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-bio-korea-2018-international-convention-tnxp-20180507monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-receives-ind-clearance-by-u-s-fda-for-tnx-102-sl-in-agitation-in-alz-tnxp-20180501monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-fda-breakthrough-therapy-designated-ptsd-program-at-the-m-tnxp-20180404monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-achieves-50-percent-enrollment-in-phase-3-trial-of-fda-designated-br-tnxp-20180403monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-expands-intellectual-property-portfolio-for-tnx-102-sl-tnxp-20180321monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-b-riley-fbr-inaugural-china-healthcare-investing-p-tnxp-20180313monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-30th-annual-roth-conference-tnxp-20180306monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-20th-annual-bio-ceo-investor-conference-in-new-yor-tnxp-20180207monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-noble-capital-markets-fourteenth-annual-investor-confe-tnxp-20180124monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-sachs-associates-neuroscience-innovation-forum-and-bio-tnxp-20180103monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-completes-positive-pre-ind-meeting-with-fda-for-tnx-102-sl-cyclobenz-tnxp-20171212monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-10th-annual-ld-micro-investor-conference-tnxp-20171130monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-23rd-annual-bio-europe-international-partnering-confer-tnxp-20171101monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-outcomes-from-u-s-fda-breakthrough-therapy-cmc-guidance-meet-tnxp-20171017monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-dawson-james-securities-3rd-annual-small-cap-growt-tnxp-20171012monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-at-the-2nd-annual-cohen-veterans-care-summit-in-washington-tnxp-20170929monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-rodman-renshaw-19th-annual-global-investment-confe-tnxp-20170906monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-additional-phase-2-clinical-results-in-military-related-pt-tnxp-20170829monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-additional-phase-2-clinical-results-and-design-of-ongoing-tnxp-20170821monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-second-quarter-2017-financial-results-and-provides-programs--tnxp-20170814monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-2017-bio-international-convention-tnxp-20170616monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-participated-in-the-pathophysiology-of-posttraumatic-stress-disorder-tnxp-20170615monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-an-update-of-fda-designated-breakthrough-therapy-tnx-102--tnxp-20170612monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-retrospective-analyses-of-treatment-response-and-remission-tnxp-20170530monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-additional-clinical-results-of-military-related-ptsd-stud-tnxp-20170524monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-analyses-of-potential-moderators-of-treatment-response-to--tnxp-20170522monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-first-quarter-2017-financial-results-and-provides-programs-u-tnxp-20170515monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-ptsd-clinical-data-at-the-society-of-biological-psychiatr-tnxp-20170511monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-issuance-of-u-s-patent-for-tnx-102-sl-composition-and-form-tnxp-20170502monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year-2016-financial-results-and-prov-tnxp-20170417monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-full-exercise-and-closing-of-underwriters-over-allotment-o-tnxp-20170413monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-results-from-u-s-fda-initial-cross-disciplinary-breakthrough-tnxp-20170411monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-completes-8-million-public-offering-of-common-stock-tnxp-20170404monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-prices-public-offering-of-1-800-000-shares-of-common-stock-tnxp-20170330monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-proposed-public-offering-of-common-stock-tnxp-20170329monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-fda-breakthrough-therapy-designated-ptsd-program-at-the-m-tnxp-20170329monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-enrolls-first-participant-in-military-related-ptsd-phase-3-trial-of--tnxp-20170328monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-1-for-10-reverse-stock-split-tnxp-20170316monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-breakthrough-therapy-designated-ptsd-program-at-oppenheim-tnxp-20170315monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-receives-notice-of-allowance-for-new-u-s-patent-covering-composition-tnxp-20170314monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-breakthrough-therapy-designated-ptsd-program-and-corporat-tnxp-20170307monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-demonstrated-vaccine-activity-in-first-ever-synthesized-ch-tnxp-20170302monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-breakthrough-therapy-designated-ptsd-program-and-corporat-tnxp-20170228monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-breakthrough-therapy-designated-ptsd-program-and-corporat-tnxp-20170209monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-breakthrough-therapy-designated-ptsd-program-and-corporat-tnxp-20170124monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-details-of-newly-expanded-product-development-pipeline-at--tnxp-20170110monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-breakthrough-therapy-designated-ptsd-program-and-corporat-tnxp-20170103monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-ptsd-phase-3-ready-drug-candidate-tnx-102-sl-granted-breakthrough-th-tnxp-20161219monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-new-clinical-results-from-sub-group-analysis-of-phase-2-at-tnxp-20161208monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-clinical-data-at-the-55th-annual-meeting-of-the-american--tnxp-20161202monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-9th-annual-ld-micro-main-event-investor-conference-tnxp-20161130monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-third-quarter-2016-financial-results-tnxp-20161110monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-new-clinical-results-from-retrospective-analysis-of-phase-tnxp-20161110monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-clinical-data-at-the-international-society-for-traumatic--tnxp-20161107monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-22nd-annual-bio-europe-international-partnering-confer-tnxp-20161102monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-clinical-data-at-the-2016-neuroscience-education-institut-tnxp-20161101monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-completes-5-2-million-underwritten-public-offering-tnxp-20161031monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-clinical-data-at-cns-summit-2016-tnxp-20161027monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-prices-5-2-million-underwritten-public-offering-tnxp-20161026monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-proposed-underwritten-public-offering-of-common-stock-and--tnxp-20161025monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-host-posttraumatic-stress-disorder-ptsd-awareness-day-tnxp-20161019monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-dawson-james-securities-2016-small-cap-growth-stock-co-tnxp-20161013monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-16th-annual-sachs-biotech-in-europe-forum-tnxp-20160926monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-rodman-renshaw-18th-annual-global-investment-conferenc-tnxp-20160907monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-topline-results-from-phase-3-affirm-study-of-tnx-102-sl-in-f-tnxp-20160906monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-successful-end-of-phase-2-meeting-with-fda-for-tnx-102-sl--tnxp-20160829monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-poster-on-the-development-of-tnx-102-sl-for-post-traumatic--tnxp-20160815monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-second-quarter-2016-financial-results-and-provides-programs--tnxp-20160808monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-initiates-second-pivotal-phase-3-clinical-study-of-tnx-102-sl-in-fib-tnxp-20160726monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-full-exercise-and-closing-of-underwriters-over-allotment-o-tnxp-20160712monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-cantor-fitzgerald-s-2nd-annual-healthcare-conference-tnxp-20160707monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-completes-10-million-public-offering-of-common-stock-tnxp-20160621monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-jmp-securities-life-sciences-conference-tnxp-20160617monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-prices-underwritten-public-offering-of-common-stock-tnxp-20160616monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-proposed-public-offering-of-common-stock-tnxp-20160615monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-at-eular-results-of-a-retrospective-analysis-from-the-phase-tnxp-20160609monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-2016-bio-international-convention-tnxp-20160603monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-positive-results-from-phase-2-atease-study-of-tnx-102-sl-in-tnxp-20160531monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-positive-results-from-phase-2-atease-study-of-tnx-102-sl--tnxp-20160526monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-positive-topline-results-from-phase-2-atease-study-of-tnx-10-tnxp-20160519monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-first-quarter-2016-financial-results-and-provides-programs-u-tnxp-20160509monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-completes-enrollment-in-phase-3-clinical-trial-of-tnx-102-sl-in-fibr-tnxp-20160502monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-10th-annual-bio-europe-spring-conference-tnxp-20160329monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-pharmacokinetic-data-on-tnx-102-sl-as-a-potential-treatment-tnxp-20160309monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-28th-annual-roth-conference-tnxp-20160308monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year-2015-financial-results-and-prov-tnxp-20160304monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-two-investor-conferences-in-march-2016-tnxp-20160303monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-appoints-chief-financial-officer-tnxp-20160225monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-top-line-results-from-phase-2-proof-of-concept-clinical-stud-tnxp-20160216monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-18th-annual-bio-ceo-investor-conference-tnxp-20160202monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-management-change-tnxp-20160108monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-biotech-showcase-2016-tnxp-20160105monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-completes-enrollment-in-phase-2-clinical-trial-of-tnx-102-sl-in-post-tnxp-20151223monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-completes-enrollment-in-phase-2-clinical-study-of-tnx-201-in-episodi-tnxp-20151208monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-and-u-s-department-of-defense-military-developer-in-partnership-to-e-tnxp-20151207monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-fireside-chat-at-the-oppenheimer-26th-annual-healt-tnxp-20151201monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-additional-data-on-tonmya-tm-demonstrating-improvements-in--tnxp-20151110monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-third-quarter-2015-financial-results-and-provides-programs-u-tnxp-20151109monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-acceptance-of-three-abstracts-to-be-presented-at-the-2015--tnxp-20151001monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-15th-annual-biotech-in-europe-forum-for-global-par-tnxp-20150924monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-rodman-renshaw-global-investment-conference-tnxp-20150908monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-on-the-development-of-tnx-102-sl-for-post-traumatic-stress--tnxp-20150818monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-second-quarter-2015-financial-results-and-provides-program-u-tnxp-20150810monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-appoints-mark-t-edgar-phd-as-senior-vice-president-of-product-develo-tnxp-20150721monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-closes-20-1-million-public-offering-of-common-stock-tnxp-20150717monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-prices-underwritten-public-offering-of-common-stock-tnxp-20150714monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-proposed-public-offering-of-common-stock-tnxp-20150713monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-non-clinical-data-on-tnx-201-at-the-57th-annual-scientific--tnxp-20150622monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-conditional-acceptance-of-tonmya-as-proposed-brand-name-fo-tnxp-20150617monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-initiates-phase-2-clinical-study-of-tnx-201-in-episodic-tension-type-tnxp-20150616monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-additional-data-from-phase-2b-bestfit-clinical-study-at-eul-tnxp-20150611monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-jefferies-2015-global-healthcare-conference-tnxp-20150528monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-acceptance-of-two-abstracts-for-presentation-at-eular-tnxp-20150526monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-data-at-the-annual-meeting-of-the-society-for-biological-ps-tnxp-20150515monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-launches-phase-3-clinical-study-of-tnx-102-sl-in-fibromyalgia-tnxp-20150513monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-first-quarter-2015-financial-results-and-clinical-update-tnxp-20150511monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-12th-annual-bio-asia-international-conference-tnxp-20150320monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-27th-annual-roth-conference-tnxp-20150304monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year-2014-financial-results-tnxp-20150303monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-8th-annual-european-life-sciences-ceo-forum-tnxp-20150302monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-closing-of-28-7-million-public-offering-of-common-stock-tnxp-20150209monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-bio-ceo-investor-conference-tnxp-20150205monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-prices-underwritten-public-offering-of-common-stock-tnxp-20150204monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-proposed-public-offering-of-common-stock-tnxp-20150203monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-commences-phase-2-trial-of-tnx-102-sl-in-post-traumatic-stress-disor-tnxp-20150115monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-noble-financial-annual-investor-conference-tnxp-20150114monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-clinical-progress-on-potential-treatment-for-headache-tnxp-20150109monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-provides-clinical-and-regulatory-update-on-its-continued-development-tnxp-20150106monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-ld-micro-investor-conference-tnxp-20141125monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-third-quarter-2014-financial-results-tnxp-20141110monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-receives-ind-clearance-for-tnx-201-in-episodic-tension-type-headache-tnxp-20141021monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-top-line-results-from-phase-2b-bestfit-trial-of-tnx-102-sl-i-tnxp-20140929monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-biocentury-newsmakers-conference-tnxp-20140919monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-rodman-renshaw-global-investment-conference-tnxp-20140903monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-transfer-to-the-nasdaq-global-market-tnxp-20140811monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-second-quarter-2014-financial-results-tnxp-20140808monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-two-investor-conferences-in-august-tnxp-20140806monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-registered-direct-offering-of-7-8-million-tnxp-20140711monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-joins-russell-microcap-index-tnxp-20140630monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-appoints-ronald-r-notvest-ph-d-as-senior-vice-president-of-commercia-tnxp-20140626monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-receives-ind-clearance-from-u-s-food-and-drug-administration-for-tnx-tnxp-20140610monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-appoints-gregory-m-sullivan-m-d-as-chief-medical-officer-tnxp-20140603monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-jefferies-2014-global-healthcare-conference-tnxp-20140529monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-ld-micro-invitational-conference-tnxp-20140529monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-be-added-to-the-msci-global-micro-cap-index-tnxp-20140528monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-mixiii-biomed-conference-in-israel-tnxp-20140520monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-first-quarter-2014-financial-results-tnxp-20140513monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-completes-enrollment-in-bestfit-trial-of-tnx-102-sl-for-fibromyalgia-tnxp-20140512monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-spotlighted-in-april-7-issue-of-biocentury-tnxp-20140409monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-appoints-donald-j-kellerman-senior-vice-president-clinical-developme-tnxp-20140401monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year-2013-financial-results-tnxp-20140331monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-roth-conference-tnxp-20140305monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-completes-pre-ind-meeting-with-fda-on-tnx-201-for-episodic-tension-t-tnxp-20140303monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-spotlighted-in-three-media-outlets-in-february-tnxp-20140221monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-bio-ceo-conference-tnxp-20140204monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-closing-of-43-5-million-public-offering-of-common-stock-tnxp-20140129monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-prices-underwritten-public-offering-raising-43-5-million-tnxp-20140124monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-proposed-public-offering-of-common-stock-tnxp-20140123monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-the-enrollment-of-completers-from-the-bestfit-trial-into-a-tnxp-20131210monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-oppenheimer-healthcare-conference-tnxp-20131126monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-the-ld-micro-conference-tnxp-20131121monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-third-quarter-2013-financial-results-tnxp-20131113monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-completes-private-placement-tnxp-20121205monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-at-fifth-annual-ld-micro-conference-tnxp-20121205monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-to-participate-in-william-blair-46th-annual-growth-stock-conference-lfcr-20260521monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-to-report-financial-results-for-the-first-quarter-ended-march-31-2026--lfcr-20260429monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-lfcr-20260422monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-to-participate-at-12th-annual-american-biomanufacturing-summit-lfcr-20260408monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-more-in-lfcr-20260316monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-to-participate-in-6th-annual-keybanc-capital-markets-healthcare-virtua-lfcr-20260310monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-to-report-financial-results-for-the-fourth-quarter-and-transition-peri-lfcr-20260309monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-lfcr-20260116monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-to-be-added-to-nasdaq-biotech-index-lfcr-20251218monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-to-report-financial-results-for-the-three-months-ended-september-30-20-lfcr-20251030monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-shareholder-alert-kaskela-law-llc-announces-investigation-of-lifecore-biomedical--lfcr-20251001monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-investigation-alert-bragar-eagel-squire-p-c-is-investigating-lifecore-biomedical--lfcr-20250927monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-to-participate-in-upcoming-investor-conferences-lfcr-20250902monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-alert-bragar-eagel-squire-p-c-is-investigating-lifecore-biomedical-inc-on-behalf--lfcr-20250815monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-to-report-fourth-quarter-and-fiscal-year-2025-financial-results-on-aug-lfcr-20250731monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-lfcr-20250717monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-signs-new-10-year-commercial-manufacturing-and-supply-agreement-with-k-lfcr-20250617monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-receives-accelerated-payment-of-remaining-10-million-in-proceeds-from--lfcr-20250612monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-names-mark-dafonseca-chief-commercial-officer-lfcr-20250527monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-to-participate-at-upcoming-cdmo-live-2025-conference-lfcr-20250422monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-lfcr-20250416monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-appoints-thomas-d-salus-as-chief-legal-and-administration-officer-lfcr-20250414monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-to-report-financial-results-for-third-quarter-of-fiscal-2025-on-april--lfcr-20250327monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-to-participate-in-upcoming-investor-and-industry-conferences-lfcr-20250226monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-to-participate-in-2025-bio-ceo-investor-conference-lfcr-20250203monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-capital--lfcr-20250107monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-to-participate-at-43rd-annual-j-p-morgan-healthcare-conference-lfcr-20250106monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-to-report-financial-results-for-second-quarter-of-fiscal-2025-on-janua-lfcr-20241219monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-selected-by-nirsum-labs-to-provide-cdmo-services-supporting-clinical-d-lfcr-20241219monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-amends-and-extends-revolving-credit-facility-with-bmo-lfcr-20241126monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-hosts-virtual-investor-day-lfcr-20241121monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-to-present-at-stephens-annual-investment-conference-lfcr-20241112monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-to-host-virtual-investor-day-prior-to-market-open-on-november-21-2024-lfcr-20241107monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-appoints-thomas-guldager-as-vice-president-operations-lfcr-20241104monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-reports-first-quarter-of-fiscal-2025-financial-results-and-provides-co-lfcr-20241004monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-raises-24-3-million-in-private-placement-of-common-stock-lfcr-20241004monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-to-report-financial-results-for-first-quarter-of-fiscal-2025-prior-to--lfcr-20241003monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-selected-by-lindy-biosciences-to-support-process-development-and-comme-lfcr-20241001monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-to-participate-at-upcoming-industry-conferences-and-events-lfcr-20240925monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-loss-lfcr-20240923monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-announces-high-speed-multi-purpose-5-head-isolator-filler-is-gmp-ready-lfcr-20240919monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-inc-nasdaq-lfcr-deadline-alert-bernstein-liebhard-llp-reminds-lifecore-lfcr-20240916monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-to-participate-in-craig-hallum-bioprocessing-conference-lfcr-20240912monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-regains-compliance-with-nasdaq-listing-requirements-lfcr-20240912monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-appoints-brikkelle-thompson-as-senior-vice-president-of-human-resource-lfcr-20240910monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-loss-lfcr-20240909monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-inc-nasdaq-lfcr-deadline-alert-bernstein-liebhard-llp-reminds-lifecore-lfcr-20240909monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-lfcr-20240906monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-to-participate-in-17th-annual-barrington-research-virtual-fall-investm-lfcr-20240905monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-inc-nasdaq-lfcr-deadline-alert-bernstein-liebhard-llp-reminds-lifecore-lfcr-20240903monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-announces-chief-financial-officer-transition-lfcr-20240829monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-reports-fourth-quarter-and-fiscal-year-end-2024-financial-results-and--lfcr-20240826monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-inc-nasdaq-lfcr-deadline-alert-bernstein-liebhard-llp-reminds-lifecore-lfcr-20240826monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-inc-nasdaq-lfcr-deadline-alert-bernstein-liebhard-llp-reminds-lifecore-lfcr-20240819monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-inc-nasdaq-lfcr-deadline-alert-bernstein-liebhard-llp-reminds-lifecore-lfcr-20240812monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-inc-nasdaq-lfcr-deadline-alert-bernstein-liebhard-llp-reminds-lifecore-lfcr-20240805monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-lfcr-20240801monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-inc-nasdaq-lfcr-investor-alert-investors-with-large-losses-in-lifecore-lfcr-20240731monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-lfcr-20240522monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-completes-incremental-liquidity-initiatives-lfcr-20240516monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-inc-receives-notice-from-nasdaq-regarding-delayed-quarterly-report-lfcr-20240419monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-provides-business-update-outlining-fiscal-2024-outlook-and-year-to-dat-lfcr-20240401monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-announces-pending-change-of-auditor-and-provides-expectation-for-busin-lfcr-20240326monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-alert-bragar-eagel-squire-p-c-is-investigating-lifecore-biomedical-inc-on-behalf--lfcr-20240323monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-concludes-strategic-evaluation-process-announces-management-succession-lfcr-20240320monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-completes-restatements-and-files-form-10-k-for-fiscal-year-2023-lfcr-20240320monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-inc-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-a-lfcr-20240216monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-inc-receives-notice-from-nasdaq-regarding-delayed-quarterly-report-lfcr-20240112monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-expands-relationship-with-existing-long-term-customer-through-a-series-lfcr-20240105monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-provides-business-update-lfcr-20231213monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-inc-receives-notice-from-nasdaq-regarding-delayed-annual-report-lfcr-20231018monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-provides-update-for-development-portfolio-and-timing-of-delayed-filing-lfcr-20231010monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-reports-fourth-quarter-and-full-fiscal-year-2023-results-lfcr-20230831monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-sets-fourth-quarter-2023-earnings-conference-call-for-august-31-2023-a-lfcr-20230822monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-inc-receives-notice-from-nasdaq-regarding-delayed-annual-report-lfcr-20230822monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-reports-third-quarter-fiscal-year-2023-results-lfcr-20230601monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-enters-into-150-0-million-in-new-financing-repays-its-outstanding-term-lfcr-20230522monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-sets-third-quarter-2023-earnings-conference-call-for-june-1-2023-at-7--lfcr-20230522monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-inc-receives-notice-from-nasdaq-regarding-delayed-quarterly-report-lfcr-20230414monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-announces-sale-of-curation-foods-o-olive-oil-and-vinegar-business-lfcr-20230406monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-signs-term-sheet-with-existing-long-term-customer-to-expand-cdmo-relat-lfcr-20230316monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-announces-intent-to-explore-strategic-alternatives-lfcr-20230316monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-reports-second-quarter-fiscal-year-2023-results-lfcr-20230316monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-announces-sale-of-curation-foods-avocado-products-business-lfcr-20230207monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-receives-notice-from-nasdaq-regarding-delayed-quarterly-report-lfcr-20230111monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-raises-capital-with-private-placement-of-convertible-preferred-stock-a-lfcr-20230109monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-raises-capital-for-growth-with-existing-stockholder-lfcr-20221125monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-announces-completion-of-corporate-name-change-lfcr-20221114monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-to-participate-in-the-stephens-annual-investment-conference-on-thursda-lfcr-20221110monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-to-manufacture-new-innovative-drug-for-treatment-of-postoperative-pain-following--lfcr-20210517monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-announces-first-patient-dosed-in-pivotal-phase-3-mapkeeper-301-trial-of-atebim-imrx-20260611monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-presents-compelling-17-3-month-median-overall-survival-and-favorable-tolerabil-imrx-20260601monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-to-present-new-survival-data-from-first-line-pancreatic-cancer-patients-treate-imrx-20260421monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-presents-genetic-data-at-aacr-annual-meeting-demonstrating-mechanism-to-improv-imrx-20260420monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference-imrx-20260218monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-announces-exceptional-64-overall-survival-at-12-months-in-first-line-pancreati-imrx-20260107monthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-to-be-added-to-the-nasdaq-biotechnology-index-nbi-imrx-20251216monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-treasury-portfolio-update-listing-of-the-rain-token-on-htx-a-leading-cryptocurrenc-enlv-20260430monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-treasury-update-total-rain-holdings-rise-to-78-819-756-062-tokens-as-of-april-27-2-enlv-20260428monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-212-000-000-private-placement-to-initiate-world-s-first-prediction-marke-enlv-20251124monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-adopts-bitcoin-treasury-reserve-strategy-enlv-20241120monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-to-host-webcast-on-april-12-2024-at-8-30-a-m-eastern-time-to-discuss-topline-resul-enlv-20240411monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-enlv-20230907monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-to-present-at-the-2023-jefferies-healthcare-conference-enlv-20230606monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-to-present-at-the-37th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-enlv-20221110monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit-enlv-20221003monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-to-present-at-upcoming-investor-and-media-conferences-enlv-20220913monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-second-quarter-2022-financial-results-and-provides-a-business-update-enlv-20220822monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-to-present-at-the-2022-jefferies-healthcare-conference-enlv-20220607monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-to-present-at-the-h-c-wainwright-global-investment-conference-enlv-20220519monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-upcoming-may-conference-presentations-enlv-20220510monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-upcoming-poster-presentation-at-the-american-society-of-clinical-oncolog-enlv-20220502monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-to-detail-the-application-of-its-innovative-macrophage-reprogramming-cell-therapy--enlv-20220103monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-cso-prof-dror-mevorach-publishes-foundational-paper-on-the-pfizer-biontech-covid-1-enlv-20211012monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-to-present-at-reuters-events-cell-gene-therapy-usa-2021-enlv-20210929monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference-enlv-20210909monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-to-present-at-the-improvate-life-saving-technologies-international-conference-2021-enlv-20210721monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-to-present-at-the-ards-drug-development-summit-2021-enlv-20210714monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-annouces-participation-in-a-g-p-s-upcoming-2021-virtual-summer-healthcare-symposiu-enlv-20210616monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-to-present-at-the-jefferies-2021-virtual-healthcare-conference-enlv-20210603monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-upcoming-virtual-investor-conference-participations-enlv-20210309monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-increases-previously-announced-bought-deal-offering-to-approximately-46-0-million--enlv-20210210monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-10-million-bought-deal-offering-of-ordinary-shares-enlv-20210209monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference-enlv-20210111monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-a-new-publication-apoptotic-cell-therapy-for-cytokine-storm-associated-w-enlv-20200720monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-to-present-at-the-jefferies-2020-virtual-healthcare-conference-enlv-20200601monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-closes-16-75-million-registered-direct-offering-enlv-20200305monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-announces-16-75-million-registered-direct-offering-enlv-20200302monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-announces-8-0-million-registered-direct-offering-enlv-20200224monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-announces-withdrawal-of-proposed-offering-of-ordinary-shares-enlv-20191121monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-announces-proposed-offering-of-ordinary-shares-enlv-20191120monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-completes-recruitment-in-phase-ib-trial-evaluating-safety-and-efficac-enlv-20191118monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-to-present-at-the-10th-annual-jefferies-2019-london-healthcare-confer-enlv-20191112monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-appointment-of-new-chief-executive-officer-enlv-20191024monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-to-present-at-the-21st-annual-global-investment-conference-sponsored--enlv-20190904monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-provides-clinical-update-on-positive-safety-profile-of-its-off-the-sh-enlv-20190606monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-to-present-at-the-2019-jefferies-global-healthcare-conference-enlv-20190530monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-to-present-at-the-2019-h-c-wainwright-global-life-sciences-conference-enlv-20190404monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-granted-eu-orphan-drug-designation-for-lead-product-apocell-for-graft-versus-host--enlv-20150126monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-krro-20260515monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-krro-20260108monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-to-participate-in-upcoming-investor-conferences-krro-20250514monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-krro-20250107monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-to-participate-in-upcoming-investor-conferences-krro-20241121monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-to-present-at-the-jefferies-london-healthcare-conference-krro-20241114monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-announces-oral-and-poster-presentations-at-the-20th-annual-meeting-of-the-oligonucle-krro-20240930monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-to-participate-in-upcoming-investor-conferences-krro-20240910monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-announces-addition-of-industry-veteran-katharine-knobil-to-and-resignation-of-david--krro-20240828monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-to-participate-in-upcoming-september-investor-and-scientific-conferences-krro-20240827monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-joins-the-russell-2000-russell-3000-and-russell-microcap-indexes-krro-20240701monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-to-participate-in-upcoming-june-investor-and-scientific-conferences-krro-20240530monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-presents-additional-preclinical-data-for-krro-110-at-the-american-thoracic-society-2-krro-20240520monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-announces-70-million-private-placement-krro-20240418monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-to-participate-in-upcoming-investor-conferences-krro-20240401monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-to-present-at-the-td-cowen-44th-annual-health-care-conference-krro-20240227monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-bio-highlights-data-for-its-lead-program-in-alpha-1-antitrypsin-deficiency-aatd-and--krro-20240118monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-krro-20240104monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-announces-selection-of-its-first-development-candidate-for-the-potential-treatment-o-krro-20231207monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-bio-appoints-dr-rachel-meyers-to-board-of-directors-krro-20231128monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-bio-and-frequency-therapeutics-announce-closing-of-merger-and-private-placement-of-1-krro-20231103monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-bio-announces-appointment-of-tim-pearson-to-board-of-directors-upon-closing-of-the-p-krro-20231025monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20200601monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-jefferies-virtual-healthcare-conference-kpti-20200526monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-investor-conference-call-to-discuss-phase-3-boston-data-to-be-present-kpti-20200526monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-submits-supplemental-new-drug-application-to-fda-for-xpovio-selinexor-as-a-trea-kpti-20200520monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-donates-60-000-medical-masks-across-massachusetts-and-the-united-states-in-part-kpti-20200513monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-2020-rbc-capital-markets-global-healthcare-virtual-conference-kpti-20200512monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-first-quarter-2020-financial-results-and-highlights-recent-company-prog-kpti-20200505monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20200501monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-data-from-phase-3-boston-study-selected-for-late-breaking-oral-presen-kpti-20200429monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-first-quarter-2020-financial-results-on-may-5-2020-kpti-20200428monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-dosing-of-first-patient-in-randomized-study-evaluating-low-dose-selin-kpti-20200420monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-evaluate-low-dose-selinexor-as-a-potential-treatment-for-hospitalized-patien-kpti-20200407monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20200401monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-kpti-20200317monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-expands-executive-leadership-team-with-the-appointment-of-john-demaree-as-chief-kpti-20200312monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20200309monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-closing-of-public-offering-of-common-stock-and-exercise--kpti-20200306monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-proposed-public-offering-of-common-stock-kpti-20200302monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-phase-3-boston-study-meets-primary-endpoint-with-significant-increase-kpti-20200302monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-appoints-richard-paulson-to-its-board-of-directors-kpti-20200228monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-at-9th-annual-svb-leerink-global-healthcare-conference-kpti-20200218monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-fourth-quarter-and-full-year-2019-financial-results-and-highlights-rece-kpti-20200213monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-and-promedico-a-member-of-the-neopharm-group-enter-into-an-exclusive-distributi-kpti-20200211monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-fourth-quarter-and-full-year-2019-financial-results-on-february-13-20-kpti-20200206monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20200203monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-preliminary-unaudited-fourth-quarter-and-full-year-2019-product-sales-kpti-20200113monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-kpti-20200107monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20200102monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-submits-new-drug-application-to-u-s-fda-for-xpovio-selinexor-as-a-treatment-for-kpti-20191223monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-presents-xpovio-selinexor-and-eltanexor-data-at-the-american-society-of-hematol-kpti-20191208monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-new-and-updated-xpovio-selinexor-data-in-relapsed-or-refractory-multipl-kpti-20191207monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20191202monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-xpovio-selinexor-clinical-data-to-be-presented-at-the-american-societ-kpti-20191106monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-third-quarter-2019-financial-results-and-highlights-recent-company-prog-kpti-20191104monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20191101monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-third-quarter-2019-financial-results-on-november-4-2019-kpti-20191028monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20191001monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-24-hour-deadline-alert-former-louisiana-attorney-general-and-kahn-swick-foti-ll-kpti-20190923monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-enters-into-royalty-agreement-with-healthcare-royalty-partners-for-up-to-150-mi-kpti-20190916monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-xpovio-selinexor-presentations-at-the-17th-international-myeloma-work-kpti-20190913monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20190903monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-inc-kpti-mallinckrodt-plc-mnk-national-general-holdings-corp-nghc--kpti-20190830monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-in-upcoming-investor-conferences-kpti-20190828monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-inc-kpti-mallinckrodt-plc-mnk-national-general-holdings-corp-nghc--kpti-20190823monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-publication-of-xpovio-selinexor-phase-2b-storm-study-results-in-the-n-kpti-20190821monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-second-quarter-2019-financial-results-and-highlights-recent-company-pro-kpti-20190806monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20190801monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-second-quarter-2019-financial-results-on-august-6-2019-kpti-20190730monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-shareholder-alert-kehoe-law-firm-p-c-investigating-claims-on-behal-kpti-20190725monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-fda-approval-of-xpovio-selinexor-for-the-treatment-of-patients-with-r-kpti-20190703monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20190628monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-updated-data-from-the-phase-2b-sadal-study-at-the-2019-international-co-kpti-20190619monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-new-and-updated-selinexor-combination-data-from-the-phase-1b-2-stomp-st-kpti-20190614monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20190603monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-in-upcoming-investor-conferences-kpti-20190528monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-results-of-clinical-studies-investigating-selinexor-to-be-presented-a-kpti-20190516monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-s-founder-sharon-shacham-phd-receives-nyipla-inventor-of-the-year-award-kpti-20190515monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-first-quarter-2019-financial-results-and-highlights-recent-company-prog-kpti-20190509monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-in-upcoming-investor-conferences-kpti-20190508monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-first-quarter-2019-financial-results-on-may-9-2019-kpti-20190502monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20190501monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20190401monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20190228monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-fourth-quarter-and-full-year-2018-financial-results-and-provides-corpor-kpti-20190228monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-outcome-of-fda-advisory-committee-meeting-reviewing-selinexor-for-the-kpti-20190226monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-stock-trading-halted-today-fda-advisory-committee-meeting-to-discuss-selinexor--kpti-20190226monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-strengthens-management-team-with-appointment-of-michael-p-mason-as-chief-financ-kpti-20190225monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-fourth-quarter-and-full-year-2018-financial-results-on-february-28-20-kpti-20190221monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-fda-advisory-committee-meeting-to-review-selinexor-for-the-treatment--kpti-20190207monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20190204monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-submission-of-marketing-authorization-application-to-the-european-med-kpti-20190108monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20190102monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-kpti-20190102monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20181204monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-updated-selinexor-data-from-the-phase-2b-storm-and-phase-1b-2-stomp-stu-kpti-20181203monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-positive-top-line-phase-2b-sadal-data-for-selinexor-in-patients-with-di-kpti-20181201monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-third-quarter-2018-financial-results-and-highlights-recent-company-prog-kpti-20181108monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-s-selinexor-receives-fast-track-designation-from-fda-for-the-treatment-of-patie-kpti-20181107monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-the-jefferies-2018-london-healthcare-conference-kpti-20181107monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-to-ring-nasdaq-closing-bell-on-november-6th-kpti-20181105monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20181102monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-results-of-clinical-studies-investigating-selinexor-in-multiple-myelo-kpti-20181101monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-third-quarter-2018-financial-results-on-november-8-2018-kpti-20181101monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-closing-of-additional-22-5-million-of-3-00-convertible-s-kpti-20181029monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-management-change-kpti-20181026monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-pricing-of-150-million-of-convertible-senior-notes-kpti-20181011monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-proposed-private-offering-of-150-million-of-convertible--kpti-20181009monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20181001monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-in-upcoming-investor-conferences-kpti-20180925monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20180904monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-appoints-carsten-thiel-ph-d-to-its-board-of-directors-kpti-20180904monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-in-upcoming-investor-conferences-kpti-20180829monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-phase-2b-storm-data-evaluating-selinexor-in-patients-with-penta-refr-kpti-20180828monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-second-quarter-2018-financial-results-and-highlights-recent-progress-kpti-20180807monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-completes-rolling-submission-of-new-drug-application-to-u-s-food-and-drug-admin-kpti-20180806monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20180803monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-in-upcoming-investor-conferences-kpti-20180802monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-second-quarter-2018-financial-results-on-august-7-2018-kpti-20180731monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-appoints-ian-karp-as-vice-president-investor-and-public-relations-kpti-20180725monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-initiates-rolling-submission-of-new-drug-application-to-u-s-food-and-drug-admin-kpti-20180718monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20180702monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-appoints-anand-varadan-as-chief-commercial-officer-and-reports-inducement-grant-kpti-20180625monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-presents-updated-selinexor-phase-1b-2-stomp-myeloma-data-from-multiple-combinat-kpti-20180615monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20180601monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-selinexor-phase-2-3-seal-data-at-the-american-society-of-clinical-on-kpti-20180601monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-in-upcoming-investor-conferences-kpti-20180531monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-selinexor-phase-1b-2-stomp-data-at-the-european-hematology-associati-kpti-20180517monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-selinexor-phase-2-seal-data-at-the-american-society-of-clinical-onco-kpti-20180516monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-first-quarter-2018-financial-results-and-highlights-recent-progress-kpti-20180510monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-closing-of-public-offering-of-common-stock-and-exercise--kpti-20180507monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20180504monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-first-quarter-2018-financial-results-on-may-10-2018-kpti-20180503monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-pricing-of-public-offering-of-common-stock-kpti-20180503monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-proposed-public-offering-of-common-stock-kpti-20180501monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-positive-top-line-data-from-phase-2b-storm-study-evaluating-selinexor-kpti-20180430monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-s-selinexor-receives-fast-track-designation-from-fda-for-the-treatment-of-patie-kpti-20180410monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20180402monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-preclinical-data-at-the-american-association-for-cancer-research-201-kpti-20180319monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-fourth-quarter-and-full-year-2017-financial-results-and-highlights-rece-kpti-20180315monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-fourth-quarter-and-year-end-2017-financial-results-on-march-15-2018-kpti-20180308monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20180301monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-in-upcoming-investor-conferences-kpti-20180207monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kpti-20180201monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-kpti-20180103monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-presents-positive-phase-1-2-eltanexor-data-at-the-american-society-of-hematolog-kpti-20171210monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-presents-positive-selinexor-data-from-the-phase-1b-2-stomp-study-at-the-america-kpti-20171210monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-to-present-at-the-jefferies-2017-london-healthcare-conference-kpti-20171113monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-to-participate-in-the-credit-suisse-26th-annual-healthcare-confere-kpti-20171103monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-third-quarter-2017-financial-results-and-highlights-recent-progress-kpti-20171102monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-phase-1b-2-stomp-clinical-data-at-the-american-society-of-hematology-kpti-20171101monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-third-quarter-2017-financial-results-on-november-2-2017-kpti-20171026monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-and-ono-pharmaceutical-co-ltd-sign-exclusive-license-agreement-to-develop-and-c-kpti-20171012monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-successful-outcome-from-phase-2-portion-of-phase-2-3-seal-study-evalu-kpti-20170920monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-appoints-michael-falvey-as-chief-financial-officer-adds-new-clinical-strategy-a-kpti-20170912monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-presentation-of-selinexor-and-kpt-9274-clinical-data-at-the-european--kpti-20170908monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-the-presentation-of-selinexor-and-kpt-9274-clinical-data-at-the-europ-kpti-20170830monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-to-participate-in-upcoming-investor-conferences-kpti-20170830monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-second-quarter-2017-financial-results-and-highlights-recent-progress-kpti-20170808monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-second-quarter-2017-financial-results-on-august-8-2017-kpti-20170801monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-updated-phase-2b-sadal-data-for-selinexor-in-diffuse-large-b-cell-lymph-kpti-20170623monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-doses-first-patient-in-pivotal-phase-3-boston-study-evaluating-selinexor-in-pat-kpti-20170607monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-to-participate-in-upcoming-investor-conferences-kpti-20170531monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-s-phase-2b-sadal-data-evaluating-selinexor-in-diffuse-large-b-cell-lymphoma-sel-kpti-20170518monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-first-quarter-2017-financial-results-and-highlights-recent-progress-kpti-20170504monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-and-anivive-lifesciences-sign-exclusive-global-license-agreement-for-verdinexor-kpti-20170503monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-first-quarter-2017-financial-results-on-may-4-2017-kpti-20170427monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-pricing-of-public-offering-of-common-stock-kpti-20170425monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-proposed-public-offering-of-common-stock-kpti-20170424monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-interim-phase-2b-sadal-data-at-the-2017-american-association-for-cancer-kpti-20170404monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-management-change-kpti-20170403monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-selinexor-phase-2b-sadal-data-at-the-american-association-for-cancer-kpti-20170331monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-the-16th-annual-needham-healthcare-conference-kpti-20170329monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-fourth-quarter-and-full-year-2016-financial-results-and-provides-seline-kpti-20170316monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-partial-clinical-hold-to-pause-enrollment-in-selinexor-trials-kpti-20170311monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-fourth-quarter-and-year-end-2016-financial-results-on-march-16-2017-kpti-20170309monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-results-from-interim-analysis-of-phase-2-sopra-study-evaluating-selin-kpti-20170302monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-the-presentation-of-new-data-at-the-2017-american-association-for-can-kpti-20170301monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-participate-in-upcoming-investor-conferences-kpti-20170131monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-kpti-20170103monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-and-collaborators-awarded-grant-for-als-research-kpti-20161215monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-presents-updated-phase-1b-stomp-data-at-the-american-society-of-hematology-2016-kpti-20161205monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-presents-updated-phase-2b-storm-data-at-the-american-society-of-hematology-2016-kpti-20161205monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-presents-updated-phase-2-sail-relapsed-refractory-aml-clinical-data-at-the-amer-kpti-20161204monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-and-the-multiple-myeloma-research-foundation-announce-panel-discussion-featurin-kpti-20161130monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-the-jefferies-2016-london-healthcare-conference-kpti-20161110monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-third-quarter-2016-financial-results-and-highlights-recent-progress-kpti-20161107monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-inc-nasdaq-kpti-to-ring-the-nasdaq-stock-market-closing-bell-kpti-20161103monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-updated-phase-2b-storm-and-phase-1b-stomp-clinical-data-at-the-ameri-kpti-20161103monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-ring-the-nasdaq-stock-market-closing-bell-kpti-20161102monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-third-quarter-2016-financial-results-on-november-7-2016-kpti-20161031monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-the-15th-annual-bio-investor-forum-kpti-20161011monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-updated-sign-phase-2-clinical-data-at-european-society-of-medical-on-kpti-20161005monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-publishes-preclinical-data-in-nature-demonstrating-selinexor-s-potential-in-kra-kpti-20160929monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-publishes-preclinical-and-phase-1-clinical-data-for-selinexor-in-ovarian-cancer-kpti-20160928monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-appoints-humphrey-a-r-gardner-md-fcap-as-senior-vice-president-clinical-develop-kpti-20160912monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-positive-top-line-phase-2b-storm-results-and-reviews-the-planned-develo-kpti-20160906monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-host-conference-call-with-update-on-multiple-myeloma-plans-kpti-20160830monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-second-quarter-2016-financial-results-and-highlights-recent-progress-kpti-20160804monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-upcoming-investor-conferences-kpti-20160803monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-second-quarter-2016-financial-results-on-august-4-2016-kpti-20160728monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-updated-phase-2-clinical-data-from-sign-study-at-european-society-of-kpti-20160727monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-phase-1b-selinexor-sarcoma-data-published-in-journal-of-clinical-onco-kpti-20160727monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-cantor-fitzgerald-s-2nd-annual-healthcare-conference-kpti-20160706monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-initiates-phase-1-clinical-trial-with-kpt-9274-kpti-20160622monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-outlines-key-selinexor-clinical-development-achievements-kpti-20160616monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-the-2016-jmp-securities-life-science-conference-kpti-20160615monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-presents-preliminary-stomp-phase-1b-clinical-data-at-2016-european-hematology-a-kpti-20160610monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-the-jefferies-2016-healthcare-conference-kpti-20160601monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-preliminary-stomp-phase-1b-clinical-data-at-2016-european-hematology-kpti-20160519monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-selinexor-clinical-data-at-the-american-society-of-clinical-oncology-kpti-20160518monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-first-quarter-2016-financial-results-and-highlights-recent-progress-kpti-20160509monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-first-quarter-2016-financial-results-on-may-9-2016-kpti-20160502monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-presents-data-demonstrating-the-potential-of-nuclear-export-protein-exportin-1--kpti-20160420monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-the-15th-annual-needham-healthcare-conference-kpti-20160405monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-receives-niaid-grant-to-advance-development-of-kpt-350-for-the-treatment-of-lup-kpti-20160331monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-data-on-oncology-pipeline-at-the-2016-american-association-for-cance-kpti-20160316monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-fourth-quarter-and-full-year-2015-financial-results-and-highlights-rece-kpti-20160314monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-fourth-quarter-and-full-year-2015-financial-results-on-march-14-2016-kpti-20160307monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-s-selinexor-first-in-human-phase-1-clinical-trial-data-published-in-journal-of--kpti-20160304monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-the-leerink-partners-5th-annual-global-healthcare-conference-kpti-20160203monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-initiates-second-generation-sine-compound-clinical-trial-in-multiple-myeloma-kpti-20160119monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-initiates-clinical-trial-of-oral-selinexor-in-advanced-liposarcoma-kpti-20160114monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-the-34th-annual-j-p-morgan-healthcare-conference-kpti-20160104monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-clinical-data-update-for-selinexor-kpt-330-in-hematologic-malignanci-kpti-20151130monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-third-quarter-2015-financial-results-and-highlights-recent-progress-kpti-20151109monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-data-on-oncology-pipeline-at-american-society-of-hematology-2015-ann-kpti-20151105monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-third-quarter-2015-financial-results-on-november-9-2015-kpti-20151102monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-initiates-stomp-clinical-trial-of-oral-selinexor-in-multiple-myeloma-kpti-20151019monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-advancing-neuroprotective-sine-tm-compounds-in-amyotrophic-lateral-sclerosis-al-kpti-20150903monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-second-quarter-2015-financial-results-and-highlights-recent-progress-kpti-20150810monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-second-quarter-2015-financial-results-on-august-10-2015-kpti-20150803monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-presents-hematologic-cancer-data-on-lead-drug-candidate-selinexor-at-internatio-kpti-20150622monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-presents-hematologic-cancer-data-on-lead-drug-candidate-selinexor-at-european-h-kpti-20150615monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-presents-clinical-data-for-selinexor-kpt-330-in-patients-with-recurrent-gliobla-kpti-20150601monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-presents-clinical-data-for-selinexor-kpt-330-in-patients-with-heavily-pretreate-kpti-20150530monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-initiates-storm-clinical-trial-of-oral-selinexor-kpt-330-in-multiple-myeloma-kpti-20150528monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-clinical-data-update-for-selinexor-kpt-330-in-solid-tumors-kpti-20150527monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-hematologic-cancer-data-on-lead-drug-candidate-selinexor-at-european-kpti-20150521monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-solid-tumor-data-on-lead-drug-candidate-selinexor-at-2015-american-s-kpti-20150513monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-first-quarter-2015-financial-results-and-highlights-recent-progress-kpti-20150511monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-bank-of-america-merrill-lynch-2015-healthcare-conference-kpti-20150507monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-first-quarter-2015-financial-results-on-may-11-2015-kpti-20150505monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-late-breaking-data-at-american-association-for-cancer-research-annua-kpti-20150417monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-granted-u-s-composition-of-matter-patent-for-selinexor-kpt-330-kpti-20150413monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-appoints-mikael-dolsten-md-phd-to-its-board-of-directors-kpti-20150401monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-data-on-its-novel-oral-pak4-allosteric-modulator-pam-at-the-american-kpti-20150318monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-data-on-oncology-pipeline-at-american-association-for-cancer-researc-kpti-20150318monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-fourth-quarter-and-full-year-2014-financial-results-and-highlights-rece-kpti-20150316monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-fourth-quarter-and-full-year-2014-financial-results-on-march-16-2015-kpti-20150309monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-leerink-partners-global-healthcare-conference-kpti-20150205monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-orphan-designation-granted-by-fda-for-selinexor-kpt-330-in-multiple-m-kpti-20150108monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-j-p-morgan-33rd-annual-healthcare-conference-kpti-20150107monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-proposed-public-offering-of-common-stock-kpti-20150105monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-addition-to-the-nasdaq-biotechnology-index-kpti-20141215monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-initiates-third-registration-directed-clinical-trial-of-oral-selinexor-kpt-330-kpti-20141211monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-presents-positive-clinical-data-for-selinexor-kpt-330-in-nhl-patients-at-ash-20-kpti-20141208monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-presents-positive-combination-data-for-selinexor-kpt-330-in-multiple-myeloma-pa-kpti-20141208monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-oppenheimer-25th-annual-healthcare-conference-kpti-20141204monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-clinical-data-update-for-selinexor-kpt-330-in-oncology-kpti-20141201monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-additional-orphan-designations-granted-for-selinexor-kpt-330-by-europ-kpti-20141201monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-presents-data-on-oncology-pipeline-at-eortc-nci-aacr-annual-meeting-kpti-20141124monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-third-quarter-2014-financial-results-and-highlights-recent-progress-kpti-20141110monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-initiates-registration-directed-clinical-study-of-selinexor-kpt-330-in-patients-kpti-20141110monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-data-presentations-at-american-society-of-hematology-annual-meeting-kpti-20141106monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-credit-suisse-2014-healthcare-conference-kpti-20141105monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-appoints-j-scott-garland-to-its-board-of-directors-kpti-20141104monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-report-third-quarter-2014-financial-results-on-november-10-2014-kpti-20141030monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-expands-global-presence-with-european-subsidiary-kpti-20141027monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-clinical-data-for-selinexor-kpt-330-in-advanced-solid-tumors-kpti-20140929monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-host-conference-call-to-discuss-selinexor-kpt-330-data-presented-at-esmo-201-kpti-20140925monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-three-clinical-data-presentations-at-esmo-2014-kpti-20140909monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-appoints-justin-renz-executive-vice-president-and-chief-financial-officer-kpti-20140808monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-the-wedbush-2014-life-sciences-management-access-conference-kpti-20140807monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-second-quarter-financial-results-for-2014-kpti-20140807monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-host-second-quarter-2014-earnings-call-on-august-7-2014-kpti-20140801monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-full-exercise-of-underwriters-option-to-purchase-additional-shares-in-kpti-20140630monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-pricing-of-public-offering-of-common-stock-kpti-20140627monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-proposed-public-offering-of-common-stock-kpti-20140625monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-initiates-registration-directed-randomized-study-of-selinexor-kpt-330-in-older--kpti-20140624monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-fda-considers-the-effectiveness-and-safety-technical-sections-complet-kpti-20140616monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-first-combination-data-of-selinexor-with-low-dose-dexamethasone-in-he-kpti-20140613monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-initiation-of-phase-2-study-of-selinexor-kpt-330-in-patients-with-hor-kpti-20140609monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-updates-data-for-selinexor-in-solid-tumors-at-2014-asco-annual-meeting-kpti-20140602monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-provides-data-update-for-selinexor-in-non-hodgkin-s-lymphoma-and-acute-myeloid--kpti-20140531monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-webcast-investor-analyst-briefing-on-monday-june-2-2014-kpti-20140530monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-six-data-presentations-at-the-19th-congress-of-the-european-hematolog-kpti-20140522monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-second-orphan-drug-designation-for-selinexor-in-diffuse-large-b-cell--kpti-20140520monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-receives-orphan-drug-designation-for-acute-myeloid-leukemia-aml-kpti-20140519monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-first-quarter-financial-results-for-2014-kpti-20140507monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-to-present-at-upcoming-healthcare-conferences-kpti-20140505monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-five-clinical-data-presentations-at-asco-2014-kpti-20140422monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-a-phase-1-trial-of-selinexor-kpt-330-in-pediatric-patients-with-relap-kpti-20140421monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-initiation-of-a-phase-1-study-of-decitabine-dacogen-r-and-selinexor-k-kpti-20140415monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-appoints-chris-primiano-as-general-counsel-kpti-20140410monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-to-present-at-13th-annual-needham-healthcare-conference-kpti-20140408monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-reports-2013-year-end-financial-results-and-provides-update-on-cli-kpti-20140305monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-initiation-of-an-investigator-sponsored-phase-1-dose-esc-kpti-20140227monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-nine-presentations-on-its-selective-inhibitors-of-nuclea-kpti-20140226monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-to-present-at-upcoming-healthcare-conferences-in-february-kpti-20140206monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-inc-kpti-to-ring-the-nasdaq-stock-market-closing-bell-kpti-20140205monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-presents-clinical-data-on-selinexor-kpt-330-in-colorectal-cancer-f-kpti-20140122monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-data-presentations-at-american-society-of-clinical-oncol-kpti-20140114monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-award-of-grant-from-national-multiple-sclerosis-society--kpti-20140108monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-submission-of-new-animal-drug-application-effectiveness--kpti-20140107monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-added-to-russell-3000-r-and-russell-2000-r-indexes-kpti-20131220monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-full-exercise-of-underwriters-option-to-purchase-additio-kpti-20131211monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-presents-promising-data-for-selinexor-an-oral-first-in-class-selec-kpti-20131209monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-highlights-from-poster-presentations-on-selective-inhibi-kpti-20131207monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-to-present-at-the-oppenheimer-24th-annual-healthcare-conference-kpti-20131205monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-to-host-investor-reception-and-webcast-at-the-2013-american-societ-kpti-20131202monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-data-presentations-at-american-society-of-hematology-ann-kpti-20131108monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-pricing-of-initial-public-offering-kpti-20131106monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-oral-presentations-at-the-american-college-of-rheumatolo-kpti-20131022monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-files-registration-statement-for-proposed-initial-public-offering-kpti-20131007monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-appointment-of-garen-bohlin-to-board-of-directors-kpti-20131003monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-preclinical-data-for-selinexor-kpt-330-in-acute-myelobla-kpti-20130807monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-secures-19-million-in-series-b-financing-extension-kpti-20130731monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-initiates-a-phase-1b-food-effect-clinical-trial-with-the-novel-ora-kpti-20130731monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-appointment-of-paul-brannelly-as-senior-vice-president-o-kpti-20130613monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-presents-clinical-data-for-selinexor-kpt-330-a-first-in-class-sele-kpti-20130602monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-to-present-new-data-on-selective-inhibitor-of-nuclear-export-sine--kpti-20130528monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-raises-48-2-million-in-series-b-financing-kpti-20130520monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-to-present-clinical-data-on-selective-inhibitor-of-nuclear-export--kpti-20130515monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-to-present-data-on-selective-inhibitors-of-nuclear-export-sine-to--kpti-20130509monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-15-presentations-on-selective-inhibitors-of-nuclear-expo-kpti-20130326monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-ken-weg-barry-greene-join-board-of-directors-dr-sharon-s-kpti-20130205monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-initiates-treatment-of-patients-with-acute-myeloid-leukemia-aml-in-kpti-20130117monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-initiates-a-phase-iib-efficacy-study-with-its-novel-oral-selective-kpti-20121204monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-eight-presentations-on-selective-inhibitors-of-nuclear-e-kpti-20121113monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-receives-positive-safety-reviews-from-independent-dsmbs-to-advance-both-tn-201-and--tnya-20250730monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tnya-20250516monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-to-highlight-capsid-engineering-gene-editing-and-manufacturing-researc-tnya-20250513monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-presents-interim-data-from-ridge-natural-history-and-seroprevalence-st-tnya-20250424monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-announces-late-breaker-presentation-of-new-data-from-mypeak-1-phase-1b-tnya-20250331monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-publishes-preclinical-data-demonstrating-tn-201-enhances-cardiac-funct-tnya-20250324monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-announces-late-breaker-and-new-data-presentations-at-the-american-coll-tnya-20250319monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-announces-proposed-public-offering-tnya-20250303monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-to-participate-in-upcoming-march-investor-conferences-tnya-20250303monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-receives-8-million-clinical-grant-from-california-institute-for-regene-tnya-20250203monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-announces-2025-strategic-priorities-and-anticipated-milestones-tnya-20250113monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-tnya-20241216monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-doses-first-patient-in-ridge-1-phase-1b-clinical-trial-of-tn-401-for-t-tnya-20241125monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tnya-20241119monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-announces-updates-on-tn-201-gene-therapy-program-for-mybpc3-associated-tnya-20241017monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-to-participate-in-upcoming-investment-conferences-tnya-20240903monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-announces-research-leadership-updates-tnya-20240627monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-to-participate-at-the-td-cowen-genetic-medicines-rna-summit-tnya-20240618monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-to-highlight-growing-capabilities-in-capsid-engineering-gene-editing-a-tnya-20240502monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-announces-publication-of-tn-401-gene-therapy-preclinical-data-in-natur-tnya-20240318monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-to-participate-in-upcoming-march-investor-conferences-tnya-20240227monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-announces-publication-of-preclinical-hdac6-inhibitor-data-for-heart-fa-tnya-20240226monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-to-participate-at-the-42nd-annual-j-p-morgan-healthcare-conference-tnya-20240103monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-to-participate-at-the-35th-annual-piper-sandler-healthcare-conference-tnya-20231121monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-announces-fda-clearance-to-begin-clinical-testing-of-tn-401-gene-thera-tnya-20231026monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-presents-encouraging-new-clinical-and-preclinical-data-from-hdac6-inhi-tnya-20231009monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-doses-first-patient-in-the-mypeak-1-phase-1b-clinical-trial-of-tn-201--tnya-20231005monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-publishes-preclinical-data-in-circulation-highlighting-the-clinical-po-tnya-20231002monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-to-present-data-for-tn-301-and-tn-201-at-upcoming-medical-conferences-tnya-20230921monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-to-participate-at-the-21st-annual-morgan-stanley-global-healthcare-con-tnya-20230831monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-to-participate-at-the-43rd-annual-canaccord-genuity-growth-conference-tnya-20230802monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-highlights-growing-capabilities-in-aav-manufacturing-capsid-engineering-and-expansi-tnya-20230503monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-receives-fda-fast-track-designation-for-tn-201-tnya-20230502monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-to-participate-at-chardan-s-7th-annual-genetic-medicines-and-cell-ther-tnya-20230421monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-to-participate-in-upcoming-investor-conferences-tnya-20230207monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-announces-tn-201-ind-clearance-and-anticipated-2023-milestones-tnya-20230109monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-receives-orphan-drug-designation-from-the-u-s-food-and-drug-administra-tnya-20221128monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-to-participate-in-upcoming-piper-sandler-34th-annual-healthcare-confer-tnya-20221123monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-announces-closing-of-public-offering-tnya-20221121monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-announces-proposed-public-offering-tnya-20221116monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-to-present-preclincial-study-data-from-tn-301-program-at-the-american--tnya-20221104monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-to-present-preclinical-data-on-its-novel-engineered-aav-capsids-for-ca-tnya-20221004monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-to-participate-in-inaugural-hypertrophic-cardiomyopathy-medical-societ-tnya-20220929monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-to-participate-in-upcoming-october-investor-and-industry-conferences-tnya-20220929monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-to-participate-in-upcoming-september-investor-conferences-tnya-20220906monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-and-in-tnya-20220906monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-publishes-preclinical-data-in-science-translational-medicine-detailing-tnya-20220706monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-inc-investigated-by-the-portnoy-law-firm-cvrx-20260409monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-alert-bragar-eagel-squire-p-c-is-investigating-cvrx-inc-on-behalf-of-cvrx-stockholder-cvrx-20260130monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-preliminary-fourth-quarter-and-fiscal-year-2025-financial-results-and-issues--cvrx-20260112monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-announces-implementation-of-new-category-i-cpt-codes-for-barostim-therapy-cvrx-20260106monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-participate-at-the-piper-sandler-37th-annual-healthcare-conference-cvrx-20251119monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-report-third-quarter-2025-financial-and-operating-results-and-host-conference-call-cvrx-20251022monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-report-first-quarter-2025-financial-and-operating-results-and-host-conference-call-cvrx-20250424monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-announces-new-real-world-evidence-demonstrating-significant-reductions-in-healthcare--cvrx-20250212monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-cal-cvrx-20250121monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-cvrx-20241223monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-present-at-the-piper-sandler-36th-annual-healthcare-conference-cvrx-20241120monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-announces-positive-outpatient-payment-for-barostim-procedure-in-2025-cvrx-20241104monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-announces-new-cpt-category-i-codes-for-barostim-cvrx-20241018monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-report-third-quarter-2024-financial-and-operating-results-and-host-conference-call-cvrx-20241015monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-announces-new-publication-reinforcing-the-long-term-quality-of-life-benefits-of-baros-cvrx-20240912monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-announces-appointment-of-two-new-board-members-cvrx-20240903monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-inc-cvrx-investigation-bronstein-gewirtz-grossman-llc-encourages-investors-to-seek-co-cvrx-20240819monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-inc-cvrx-investigation-bronstein-gewirtz-grossman-llc-encourages-investors-to-seek-co-cvrx-20240813monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-alert-bragar-eagel-squire-p-c-is-investigating-cvrx-inc-on-behalf-of-cvrx-stockholder-cvrx-20240809monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-inc-cvrx-investigation-bronstein-gewirtz-grossman-llc-encourages-investors-to-seek-co-cvrx-20240807monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-announces-increased-inpatient-payment-for-barostim-procedure-cvrx-20240802monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-present-at-the-canaccord-genuity-44th-annual-growth-conference-cvrx-20240731monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-report-second-quarter-2024-financial-and-operating-results-and-host-conference-cal-cvrx-20240715monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-announces-appointment-of-robert-allen-john-as-chief-revenue-officer-cvrx-20240625monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-present-at-the-william-blair-44th-annual-growth-stock-conference-cvrx-20240522monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-announces-key-senior-leadership-team-hires-cvrx-20240516monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-report-first-quarter-2024-financial-and-operating-results-and-host-conference-call-cvrx-20240416monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-announces-availability-of-additional-data-supporting-long-term-benefits-of-barostim-cvrx-20240415monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-report-fourth-quarter-2023-financial-and-operating-results-and-host-conference-cal-cvrx-20240111monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-cvrx-20231227monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-present-at-the-35th-annual-piper-sandler-healthcare-conference-cvrx-20231115monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-report-third-quarter-2023-financial-and-operating-results-and-host-conference-call-cvrx-20231012monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference-cvrx-20230727monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-report-second-quarter-2023-financial-and-operating-results-and-host-conference-cal-cvrx-20230711monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-set-to-join-russell-2000-3000-indexes-cvrx-20230622monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-present-at-the-william-blair-43rd-annual-growth-stock-conference-cvrx-20230525monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-report-first-quarter-2023-financial-and-operating-results-and-host-conference-call-cvrx-20230420monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-cvrx-20230316monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-report-fourth-quarter-and-fiscal-year-2022-financial-and-operating-results-and-hos-cvrx-20230112monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-cvrx-20221228monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-appoints-industry-veteran-kevin-hykes-to-board-of-directors-cvrx-20221220monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-present-at-the-piper-sandler-34th-annual-healthcare-conference-cvrx-20221116monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-launches-new-barostim-neo2-implantable-pulse-generator-cvrx-20221103monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-attend-upcoming-investor-conferences-cvrx-20221103monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-report-third-quarter-2022-financial-and-operating-results-and-host-conference-call-cvrx-20221018monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-present-at-the-canaccord-genuity-42nd-annual-growth-conference-cvrx-20220729monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-report-second-quarter-2022-financial-and-operating-results-and-host-conference-cal-cvrx-20220714monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-launches-a-new-barostim-programmer-cvrx-20220712monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-present-at-the-william-blair-42nd-annual-growth-stock-conference-cvrx-20220523monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-receives-mr-conditional-labeling-approval-for-its-barostim-heart-failure-system-cvrx-20220509monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-report-first-quarter-2022-financial-and-operating-results-and-host-conference-call-cvrx-20220412monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-report-fourth-quarter-and-fiscal-year-2021-financial-results-on-february-15-2022-cvrx-20220201monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-cvrx-20211221monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-participate-at-the-piper-sandler-33rd-annual-virtual-healthcare-conference-cvrx-20211116monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-report-third-quarter-2021-financial-and-operating-results-and-host-conference-call-cvrx-20211021monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-added-to-russell-2000-and-3000-indexes-cvrx-20210917monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-present-at-the-canaccord-genuity-41st-annual-growth-conference-cvrx-20210729monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-to-report-second-quarter-2021-financial-and-operating-results-and-host-conference-cal-cvrx-20210721monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-welcomes-veteran-life-science-industry-leader-martha-shadan-to-its-board-of-directors-cvrx-20210712monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-inc-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriter-cvrx-20210702monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-inc-announces-upsized-pricing-of-initial-public-offering-cvrx-20210630monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-announces-first-clinical-procedure-with-a-new-ultrasound-guided-implant-approach-the--cvrx-20210610monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-appoints-new-chief-marketing-officer-and-vice-president-of-european-sales-and-marketi-cvrx-20210105monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-barostim-therapy-receives-cms-approval-for-transitional-pass-through-payment-status-cvrx-20201203monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-announces-new-cfo-and-acceleration-of-barostim-therapy-commercialization-efforts-cvrx-20201118monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-fourth-quarter-and-full-year-2025-financial-results-apyx-20260310monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-preliminary-unaudited-fourth-quarter-and-full-year-2025-r-apyx-20260112monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-announces-approval-and-commercial-launch-of-apyx-one-console-and--apyx-20251203monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-announces-pricing-of-10-million-public-offering-of-common-stock-apyx-20251118monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-to-release-third-quarter-of-fiscal-year-2025-financial-results-on-apyx-20251023monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-expands-global-sales-leadership-with-strategic-hires-to-support-ayon-launch-a-apyx-20250807monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-second-quarter-2025-financial-results-apyx-20250807monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-to-release-second-quarter-of-fiscal-year-2025-financial-results-o-apyx-20250724monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-receives-fda-clearance-for-the-ayon-body-contouring-system-apyx-20250513monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-first-quarter-2025-financial-results-apyx-20250508monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-announces-two-peer-reviewed-publications-on-the-use-of-renuvion-i-apyx-20250429monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-to-release-first-quarter-of-fiscal-year-2025-financial-results-on-apyx-20250424monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-fourth-quarter-and-full-year-2024-financial-results-apyx-20250313monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-to-release-fourth-quarter-and-fiscal-year-2024-financial-results--apyx-20250227monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-preliminary-fourth-quarter-and-full-year-2024-revenue-res-apyx-20250113monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-submits-510-k-premarket-notification-to-the-u-s-food-and-drug-adm-apyx-20250106monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-to-participate-in-the-piper-sandler-36th-annual-healthcare-confer-apyx-20241127monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-to-attend-15th-annual-craig-hallum-alpha-select-conference-apyx-20241112monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-announces-7-000-000-million-registered-direct-offering-apyx-20241108monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-to-release-third-quarter-of-fiscal-year-2024-financial-results-on-apyx-20241025monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-final-deadline-friday-rosen-a-top-ranked-law-firm-encourages-apyx-medical-corporation-apyx-20220802monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-nasdaq-apyx-shareholder-class-action-alert-bernstein-liebhard-llp-apyx-20220802monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-investors-last-days-to-actively-participate-in-the-class-action-l-apyx-20220801monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-final-deadline-alert-rosen-a-longstanding-law-firm-encourages-apyx-medical-corporatio-apyx-20220728monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-nasdaq-apyx-shareholder-class-action-alert-bernstein-liebhard-llp-apyx-20220726monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-deadline-notice-nationally-ranked-rosen-law-firm-encourages-apyx-medical-corporation--apyx-20220723monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-nasdaq-apyx-shareholder-class-action-alert-bernstein-liebhard-llp-apyx-20220719monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-nasdaq-apyx-shareholder-class-action-alert-bernstein-liebhard-llp-apyx-20220712monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-nasdaq-apyx-shareholder-class-action-alert-bernstein-liebhard-llp-apyx-20220706monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-shareholder-alert-rosen-a-top-ranked-law-firm-encourages-apyx-medical-corporation-inv-apyx-20220705monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-nasdaq-apyx-shareholder-class-action-alert-bernstein-liebhard-llp-apyx-20220628monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corp-investors-company-investigated-by-the-portnoy-law-firm-apyx-20220627monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-nasdaq-apyx-shareholder-class-action-alert-bernstein-liebhard-llp-apyx-20220622monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-nasdaq-apyx-shareholder-class-action-alert-bernstein-liebhard-llp-apyx-20220615monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-shareholder-update-robbins-llp-reminds-investors-of-lead-plaintif-apyx-20220615monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announ-apyx-20220614monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-nasdaq-apyx-shareholder-class-action-alert-bernstein-liebhard-llp-apyx-20220608monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-alert-bragar-eagel-squire-p-c-is-investigating-apyx-medical-corp-on-behalf-of-apyx-st-apyx-20220423monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-alert-rosen-a-leading-law-firm-continues-to-investigate-securities-claims-against-apy-apyx-20200326monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-alert-rosen-an-internationally-recognized-law-firm-reminds-apyx-medical-corporation-i-apyx-20190613monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-june-17th-deadline-rosen-a-top-ranked-law-firm-reminds-apyx-medical-corporation-inves-apyx-20190530monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-reminder-hagens-berman-reminds-apyx-medical-corporation-apyx-investors-of-lead-plaint-apyx-20190530monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-deadline-pawar-law-group-reminds-investors-of-deadline-securities-class-action-lawsui-apyx-20190522monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-deadline-alert-rosen-law-firm-reminds-apyx-medical-corporation-investors-of-important-apyx-20190514monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-class-action-alert-hagens-berman-alerts-apyx-medical-corporation-apyx-investors-to-se-apyx-20190502monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-apyx-med-apyx-20190429monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-alert-zhang-investor-law-announces-the-filing-of-a-securities-class-action-lawsuit-ag-apyx-20190426monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-announces--apyx-20190425monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-shareholder-alert-kehoe-law-firm-p-c-investigating-potential-secu-apyx-20190418monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-to-participate-in-two-upcoming-investor-conferences-adag-20260512monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-fda-fast-track-designation-for-muzastotug-adg126-adag-20251216monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-to-present-at-jefferies-global-healthcare-conference-2025-adag-20250527monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-appoints-john-maraganore-ph-d-as-executive-advisor-adag-20250428monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-upcoming-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzas-adag-20250423monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-to-present-at-stifel-s-2025-virtual-targeted-oncology-forum-adag-20250407monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-to-present-at-11th-annual-immuno-oncology-3600-summit-adag-20250313monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-to-present-at-leerink-s-global-healthcare-conference-2025-adag-20250306monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-investigator-initiated-phase-2-trial-for-neoadjuvant-muzastotug-adg126-i-adag-20250227monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-k-adag-20250121monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-to-host-virtual-kol-event-to-discuss-anti-ctla-4-safebody-adg126-in-advanced-metas-adag-20250114monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-presents-two-posters-with-new-insights-on-increased-therapeutic-index-for-masked-a-adag-20241107monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-upcoming-poster-presentations-on-masked-anti-ctla-4-safebody-adg126-muza-adag-20241009monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-to-participate-in-investor-conferences-in-september-adag-20240829monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in--adag-20240712monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-to-present-at-investor-conferences-in-june-adag-20240522monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-appoints-heinz-josef-lenz-m-d-facp-to-scientific-and-strategic-advisory-board-adag-20240307monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-to-present-at-the-leerink-partners-global-biopharma-conference-2024-adag-20240227monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-to-present-interim-results-of-masked-anti-ctla-4-safebody-adg126-muzastotug-in-com-adag-20240104monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-saf-adag-20231012monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-to-present-at-investor-and-scientific-conferences-in-september-adag-20230907monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-reports-full-year-2022-financial-results-and-provides-corporate-update-adag-20230328monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-poster-presentations-on-anti-ctla-4-safebody-adg126-at-upcoming-american-adag-20230314monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-to-present-at-the-biotech-showcase-2023-in-san-francisco-on-january-9-adag-20230105monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-clinical-data-at-sitc-2022-on-anti-ctla-4-neobody-adg116-showing-differe-adag-20221110monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-poster-presentations-on-anti-ctla-4-neobody-adg116-at-upcoming-society-f-adag-20221011monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-to-participate-in-investor-conferences-in-may-and-june-adag-20220512monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-to-participate-in-the-svb-leerink-11th-annual-global-healthcare-conference-adag-20220208monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-to-participate-in-upcoming-investor-industry-conferences-in-november-adag-20211109monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-to-participate-in-the-jefferies-virtual-china-biotech-summit-adag-20211021monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-to-participate-at-the-morgan-stanley-19th-annual-global-healthcare-conference-adag-20210902monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-inclusion-in-ftse-russell-indexes-adag-20210616monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-to-present-at-upcoming-investor-conferences-adag-20210525monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-presents-clinical-data-from-neobody-program-adg106-anti-cd137-agonist-in-an-abstra-adag-20210519monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-clinical-advancement-for-adg116-adag-20210329monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-inc-announces-closing-of-initial-public-offering-and-exercise-of-underwriters-over-adag-20210211monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-inc-announces-pricing-of-initial-public-offering-adag-20210209monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood--adag-20210112monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-expansion-of-leadership-team-to-support-strategic-growth-adag-20201202monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-adag-20200109monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-completes-69-million-series-d-financing-led-by-growth-investor-general-atlantic-adag-20200108monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-highlights-pipeline-expansion-and-multiple-upcoming-clinical-catalysts-at-investor-a-prqr-20260408monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-second-quarter-2025-operating-and-financial-results-prqr-20250807monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-first-quarter-2025-operating-and-financial-results-prqr-20250508monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-third-quarter-2024-operating-and-financial-results-prqr-20241107monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-closing-of-underwritten-public-offering-and-concurrent-private-placement-prqr-20241025monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-prices-75-million-underwritten-public-offering-and-concurrent-private-placement-prqr-20241023monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-thera-prqr-20241007monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-webcast-presentation-at-the-2024-cantor-global-healthcare-conference-prqr-20240910monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-second-quarter-2024-operating-and-financial-results-prqr-20240808monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-presentation-on-its-axiomer-rna-editing-technology-at-rna-editing-summit-prqr-20240618monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-first-quarter-2024-operating-and-financial-results-prqr-20240509monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-preclinical-proof-of-concept-data-for-ax-0810-axiomer-rna-editing-program--prqr-20240508monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-highlights-upcoming-presentations-on-axiomer-rna-editing-at-asgct-27th-annual-meetin-prqr-20240422monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-third-quarter-2023-operating-and-financial-results-prqr-20231107monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-strengthens-leading-intellectual-property-estate-for-adar-mediated-rna-editing-prqr-20231106monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-participation-in-the-chardan-7th-annual-genetic-medicines-conference-prqr-20230928monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-webcast-of-presentation-at-the-upcoming-hc-wainwright-25th-annual-global-i-prqr-20230907monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-second-quarter-2023-operating-and-financial-results-prqr-20230803monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-data-on-its-axiomer-rna-editing-technology-at-rna-editing-summit-prqr-20230706monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-first-quarter-2023-operating-and-financial-results-prqr-20230516monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-its-axiomer-rna-editing-technology-at-tides-usa-2023-prqr-20230509monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-upcoming-investor-conferences-in-april-and-may-prqr-20230420monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-successful-defense-of-a-key-axiomer-patent-protecting-adar-mediated-rna-ed-prqr-20230314monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-upcoming-scientific-and-industry-conferences-prqr-20230307monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-to-host-virtual-r-d-event-on-march-29-2023-prqr-20230228monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-conference-call-to-discuss-axiomer-rna-editing-platform-prqr-20221222monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-its-axiomer-rna-editing-technology-at-the-oligonucleotide-and-peptide-the-prqr-20221114monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-third-quarter-2022-operating-and-financial-results-prqr-20221109monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-webcast-of-presentation-at-the-upcoming-stifel-2022-healthcare-conference-prqr-20221103monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-second-quarter-2022-operating-and-financial-results-prqr-20220804monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-participate-in-the-lifesci-2nd-annual-genetic-medicines-symposium-prqr-20220628monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-its-axiomer-rna-editing-technology-at-the-oligonucleotide-and-peptide-the-prqr-20220509monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-first-quarter-2022-operating-and-financial-results-prqr-20220505monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-the-retinal-cell-and-gene-therapy-innovation-summit-and-the-associatio-prqr-20220426monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-participate-in-the-kempen-life-sciences-conference-prqr-20220419monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-axiomer-rna-editing-platform-technology-at-rna-editing-summit-prqr-20220404monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-participate-in-the-cantor-virtual-rare-orphan-disease-summit-prqr-20220323monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-appoints-john-maraganore-phd-as-strategic-advisor-to-the-supervisory-board-prqr-20220307monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-fourth-quarter-and-full-year-2021-operating-and-financial-results-prqr-20220224monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-upcoming-svb-leerink-conference-prqr-20220207monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-last-patient-has-completed-12-month-visit-in-phase-2-3-illuminate-trial-of-prqr-20220104monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-highlights-from-analyst-event-prqr-20211118monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-webcast-virtual-analyst-event-on-november-18-prqr-20211111monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-upcoming-investor-conferences-in-november-and-december-prqr-20211108monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-third-quarter-2021-operating-and-financial-results-prqr-20211104monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-conference-call-to-discuss-the-axiomer-rna-editing-platform-prqr-20210908monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-virtual-presentation-at-euretina-2021-prqr-20210906monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-upcoming-investor-conferences-prqr-20210903monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-webcast-of-presentation-at-upcoming-hc-wainwright-ophthalmology-virtual-co-prqr-20210811monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-second-quarter-2021-operating-and-financial-results-prqr-20210805monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-upcoming-jmp-securities-life-sciences-conference-prqr-20210610monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-first-quarter-2021-operating-and-financial-results-prqr-20210506monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-virtual-presentation-of-phase-1-2-sepofarsen-extension-trial-data-at-the-a-prqr-20210423monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-participation-in-upcoming-kempen-life-sciences-conference-prqr-20210422monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-annual-meeting-of-shareholders-prqr-20210420monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-publication-in-nature-medicine-for-sepofarsen-in-leber-congenital-amaurosi-prqr-20210413monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-closing-of-underwritten-public-offering-of-ordinary-shares-with-full-exerc-prqr-20210405monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-virtual-presentation-at-american-association-for-pediatric-ophthalmology-a-prqr-20210402monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-proposed-underwritten-public-offering-of-ordinary-shares-prqr-20210330monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-results-from-phase-1-2-trial-of-qr-421a-for-usher-syndrome-prqr-20210317monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-webcast-of-presentation-at-upcoming-hc-wainwright-global-life-sciences-con-prqr-20210302monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-fourth-quarter-and-full-year-2020-operating-and-financial-results-prqr-20210225monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-expert-perspectives-call-on-disease-education-and-endpoints-in-usher-syndr-prqr-20210216monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-webcast-of-presentation-at-upcoming-hc-wainwright-bioconnect-conference-prqr-20201218monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-3rd-annual-evercore-isi-virtual-healthconx-conference-prqr-20201118monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-third-quarter-2020-operating-and-financial-results-prqr-20201116monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-virtual-presentations-at-american-academy-of-ophthalmology-aao-prqr-20201102monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-virtual-presentations-at-scientific-conferences-prqr-20200924monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-participate-in-upcoming-investor-conferences-prqr-20200903monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-second-quarter-2020-operating-and-financial-results-prqr-20200806monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-strengthens-scientific-advisory-board-with-leaders-in-inherited-retinal-disease-and--prqr-20200721monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-expert-perspectives-call-on-lca10-and-sepofarsen-prqr-20200713monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-expert-perspectives-conference-call-series-prqr-20200612monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-virtual-presentation-of-phase-1-2-sepofarsen-data-through-the-association--prqr-20200608monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-annual-meeting-of-shareholders-prqr-20200525monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-first-quarter-2020-operating-and-financial-results-prqr-20200507monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-findings-from-phase-1-2-interim-analysis-of-qr-421a-for-usher-syndrome-prqr-20200325monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-fourth-quarter-and-full-year-2019-results-and-provides-business-update-prqr-20200226monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-cowen-and-company-40th-annual-health-care-conference-prqr-20200224monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-teams-up-with-the-foundation-fighting-blindness-and-blueprint-genetics--prqr-20200206monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-receives-orphan-drug-designation-from-fda-for-qr-1123-for-autosomal-dominant-retinit-prqr-20191121monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-upcoming-scientific-conferences-prqr-20191118monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-upcoming-investor-conferences-prqr-20191113monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-recent-progress-and-financial-results-for-the-third-quarter-of-2019-prqr-20191106monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-closing-of-underwritten-public-offering-of-ordinary-shares-with-full-exerc-prqr-20191018monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-receives-rare-pediatric-disease-designation-from-fda-for-sepofarsen-for-the-treatmen-prqr-20191015monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-top-line-results-from-the-phase-1-2-study-of-sepofarsen-in-lca10-patients-prqr-20191007monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-two-investor-conferences-in-october-prqr-20190930monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-financial-results-for-the-second-quarter-of-2019-prqr-20190807monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-presentation-on-qr-421a-program-in-ophthalmology-at-usher-syndrome-coaliti-prqr-20190702monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-the-jmp-securities-life-sciences-conference-prqr-20190603monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-the-rbc-capital-markets-healthcare-conference-prqr-20190515monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-three-scientific-conferences-in-april-prqr-20190422monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-nominates-bart-filius-coo-and-cfo-at-galapagos-and-theresa-heggie-head-of-cemea-at-a-prqr-20190418monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-annual-meeting-of-shareholders-prqr-20190418monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-the-h-c-wainwright-global-life-sciences-conference-prqr-20190401monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-cowen-health-care-conference-prqr-20190305monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-reaches-agreement-with-the-fda-on-design-of-phase-2-3-pivotal-trial-for-sepofarsen-q-prqr-20190107monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-host-r-d-day-in-new-york-on-january-29-prqr-20190103monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-receives-fast-track-designation-from-fda-for-qr-421a-for-usher-syndrome-type-2-prqr-20190102monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-added-to-nasdaq-biotechnology-index-prqr-20181224monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-publication-in-nature-medicine-of-qr-110-data-for-leber-s-congenital-amaur-prqr-20181217monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-strategic-changes-to-the-management-team-and-key-new-hires-prqr-20181213monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-the-evercore-isi-healthconx-conference-prqr-20181120monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-financial-results-for-the-third-quarter-of-2018-prqr-20181107monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-presentations-at-the-european-oligonucleotide-and-peptide-therapeutics-con-prqr-20181031monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-in-licenses-worldwide-rights-to-ophthalmology-drug-candidate-from-ionis-pharmaceutic-prqr-20181029monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-the-chardan-genetic-medicines-conference-prqr-20181002monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-presentations-at-the-ots-annual-meeting-prqr-20180924monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-closing-of-underwritten-public-offering-of-ordinary-shares-with-full-exerc-prqr-20180911monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-interim-phase-1-2-results-for-qr-110-in-leber-s-congenital-amaurosis-10-a-prqr-20180815monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-financial-results-for-the-second-quarter-of-2018-prqr-20180808monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-publication-on-qr-110-for-leber-s-congenital-amaurosis-10-in-the-journal-m-prqr-20180801monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-presentations-on-programs-in-ophthalmology-at-conferences-in-july-prqr-20180712monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-initiates-phase-1-2-clinical-trial-of-qr-313-for-dystrophic-epidermolysis-bullosa-prqr-20180628monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-the-jmp-life-sciences-conference-prqr-20180614monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-receives-up-to-5-million-in-partnership-with-eb-research-partnership-and-eb-medical--prqr-20180612monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-presentations-at-ecfs-on-eluforsen-for-f508del-cystic-fibrosis-and-at-cff--prqr-20180604monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-appoints-yi-tao-yu-ph-d-to-its-scientific-advisory-board-prqr-20180523monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-results-for-the-first-quarter-of-2018-prqr-20180509monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-conference-presentations-for-axiomer-rna-editing-technology-and-qr-313-for-prqr-20180430monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-provides-enrollment-update-on-qr-110-clinical-trial-and-highlights-ophthalmology-pre-prqr-20180423monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-annual-meeting-of-shareholders-prqr-20180411monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-appoints-adar-expert-dr-peter-a-beal-to-scientific-advisory-board-to-focus-on-axiome-prqr-20180410monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-two-upcoming-conferences-prqr-20180403monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-upcoming-investor-conference-prqr-20180305monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-results-for-the-fourth-quarter-and-full-year-2017-and-provides-business-up-prqr-20180228monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-supports-rare-disease-day-2018-and-honors-henri-a-termeer-prqr-20180227monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-upcoming-scientific-meeting-and-investor-conference-prqr-20180206monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-and-galapagos-announce-research-collaboration-on-fibrosis-targets-using-proqr-s-axio-prqr-20180108monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-extraordinary-general-meeting-of-shareholders-prqr-20171227monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-receives-orphan-drug-designation-from-ema-for-drug-candidate-qr-313-for-dystrophic-e-prqr-20171129monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-the-annual-piper-jaffray-healthcare-conference-prqr-20171121monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-results-for-the-third-quarter-of-2017-prqr-20171120monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-prices-approximately-20-million-underwritten-public-offering-and-concurrent-register-prqr-20171114monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-proposed-public-offering-of-ordinary-shares-prqr-20171113monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-doses-first-lca-10-patient-in-clinical-trial-of-qr-110-proqr-s-lead-program-for-gene-prqr-20171113monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-appoints-thaddeus-dryja-m-d-to-scientific-advisory-board-prqr-20171109monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-eurotides-conference-prqr-20171031monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-management-change-and-key-promotions-prqr-20171026monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-presentations-and-investor-analyst-event-at-the-north-american-cystic-fibr-prqr-20171024monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-the-chardan-inaugural-gene-therapy-conference-prqr-20171006monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-positive-top-line-results-from-a-phase-1b-study-of-qr-010-in-subjects-with-prqr-20170925monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-presents-in-vivo-proof-of-concept-data-for-the-axiomer-rna-editing-platform-technolo-prqr-20170921monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-two-investor-conferences-in-september-prqr-20170921monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-receives-orphan-drug-designation-from-fda-for-drug-candidate-qr-313-for-dystrophic-e-prqr-20170919monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-spins-out-amylon-therapeutics-as-a-privately-held-company-focused-on-central-nervous-prqr-20170912monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-s-drug-candidate-qrx-421-for-usher-syndrome-receives-orphan-drug-designation-from-fd-prqr-20170905monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-completes-dosing-of-cystic-fibrosis-patients-in-qr-010-phase-1b-trial-prqr-20170829monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-strengthens-its-scientific-advisory-board-with-the-appointment-of-dr-phil-zamore-dr--prqr-20170828monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-results-for-the-second-quarter-of-2017-prqr-20170816monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-s-drug-candidate-qrx-411-for-usher-syndrome-receives-orphan-drug-designation-from-fd-prqr-20170705monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-r-d-day-highlights-progress-on-pipeline-and-introduces-axiomer-a-novel-proprietary-r-prqr-20170615monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-participate-in-a-cystic-fibrosis-panel-discussion-during-the-jmp-securities-life--prqr-20170613monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-qr-010-data-at-the-european-cystic-fibrosis-society-conference-and-provid-prqr-20170608monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-receives-fast-track-designation-from-the-fda-for-qr-110-for-leber-s-congenital-amaur-prqr-20170531monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-results-for-the-first-quarter-of-2017-prqr-20170517monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-remembers-co-founder-henri-termeer-after-his-unexpected-passing-prqr-20170515monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-r-d-day-in-new-york-on-june-15-prqr-20170509monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-its-ophthalmology-pipeline-at-arvo-highlighting-programs-in-leber-s-conge-prqr-20170501monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-clearance-of-ind-application-to-start-clinical-trial-for-qr-110-in-leber-s-prqr-20170427monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-the-deutsche-bank-health-care-conference-prqr-20170420monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-annual-meeting-of-shareholders-prqr-20170410monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-the-grant-of-two-key-patents-protecting-qr-010-for-cystic-fibrosis-in-the--prqr-20170403monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-appoints-david-m-rodman-md-as-chief-development-strategy-officer-prqr-20170327monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-two-upcoming-investor-conferences-in-march-prqr-20170301monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-results-for-the-fourth-quarter-and-full-year-2016-and-provides-a-business--prqr-20170228monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-the-leerink-partners-global-healthcare-conference-prqr-20170207monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-results-for-the-third-quarter-of-2016-prqr-20161114monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-that-qr-010-meets-the-primary-endpoint-in-a-proof-of-concept-study-of-homo-prqr-20161027monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-clinical-data-presentations-and-investor-analyst-event-at-nacfc-prqr-20160927monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-scientific-and-investor-conferences-in-september-prqr-20160906monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-results-for-the-second-quarter-of-2016-prqr-20160817monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-receives-fast-track-designation-from-fda-for-qr-010-for-cystic-fibrosis-prqr-20160719monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-release-topline-data-from-proof-of-concept-study-of-qr-010-in-cystic-fibrosis-pat-prqr-20160621monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-s-drug-candidate-qr-110-for-leber-s-congenital-amaurosis-type-10-receives-ema-and-fd-prqr-20160601monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-presentations-at-the-european-cf-conference-and-the-jmp-life-science-confe-prqr-20160601monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-results-for-the-first-quarter-of-2016-prqr-20160518monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-an-investor-and-analyst-event-and-pre-clinical-data-presentations-for-qr-1-prqr-20160425monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-annual-meeting-of-shareholders-prqr-20160407monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-highlight-a-growing-pipeline-during-a-research-development-day-and-present-at-the-prqr-20160301monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-results-for-the-fourth-quarter-and-full-year-2015-prqr-20160217monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-the-leerink-partners-global-healthcare-conference-prqr-20160203monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-r-d-day-and-provides-update-on-innovation-portfolio-prqr-20151130monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-results-for-the-third-quarter-of-2015-and-provides-update-on-clinical-tria-prqr-20151123monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-an-investor-and-analyst-event-and-pre-clinical-data-presentations-for-qr-0-prqr-20151001monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-the-leerink-partners-4th-annual-rare-disease-roundtable-prqr-20150923monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-results-for-the-second-quarter-of-2015-prqr-20150819monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-the-jmp-securities-life-science-conference-prqr-20150616monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-announces-results-for-the-first-quarter-of-2015-prqr-20150521monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-two-upcoming-investor-conferences-in-may-prqr-20150429monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-announces-results-for-the-fourth-quarter-and-full-year-2014-prqr-20150226monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-present-at-the-2015-leerink-global-healthcare-conference-prqr-20150204monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-announces-results-for-the-third-quarter-of-2014-prqr-20141124monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-optio-prqr-20140923monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-pricing-of-initial-public-offering-prqr-20140918monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-investigated-by-block-leviton-for-potential-securities-law-violations-inv-antx-20240212monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-to-present-at-upcoming-investor-conferences-antx-20221102monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-to-present-new-epetraborole-data-at-idweek-2022-antx-20221019monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-to-present-at-h-c-wainwright-24th-annual-global-investment-conference-antx-20220829monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-announces-pricing-of-upsized-initial-public-offering-antx-20220325monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-inc-investigated-by-the-portnoy-law-firm-galt-20260427monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-host-virtual-kol-event-to-discuss-belapectin-development-program--galt-20260226monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-the-american-association-for-the-study-of-liver-diseas-galt-20251007monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-the-h-c-wainwright-27th-annual-global-investment-confe-galt-20250902monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-financial-results-for-the-quarter-ended-march-31-2025-and-pr-galt-20250515monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-presented-navigate-trial-results-at-the-european-association-for-the-galt-20250512monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-the-european-association-for-the-study-of-the-liver-ea-galt-20250415monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-the-2025-mash-tag-conference-galt-20250110monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-presents-three-abstracts-at-the-american-association-for-the-study-o-galt-20241118monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-galt-20241015monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-participate-in-the-h-c-wainwright-mash-conference-galt-20240930monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-the-h-c-wainwright-26th-annual-global-investment-confe-galt-20240903monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-the-european-association-for-the-study-of-the-liver-ea-galt-20240604monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-participate-in-the-h-c-wainwright-bioconnect-conference-galt-20240513monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-the-positive-outcome-of-the-fifth-data-and-safety-monitoring-galt-20240409monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-expands-clinical-team-with-the-appointment-of-khurram-jamil-m-d-as-v-galt-20240312monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-share-five-scientific-presentations-at-the-liver-meeting-2023-hos-galt-20231103monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-participate-in-the-h-c-wainwright-7th-annual-nash-investor-confer-galt-20231023monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-nomination-of-dr-benjamin-s-carson-sr-to-board-of-director-galt-20231012monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-the-positive-outcome-of-the-fourth-data-and-safety-monitorin-galt-20231003monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-update-on-its-belapectin-liver-cirrhosis-program-at-the-2-galt-20230926monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-c-galt-20230913monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-c-galt-20230911monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-data-on-liver-cirrhosis-at-the-9th-edition-of-the-paris-n-galt-20230907monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-participate-in-the-h-c-wainwright-bioconnect-investment-conferenc-galt-20230427monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-statement-following-the-recent-2023-emerging-topic-conference-on-nas-galt-20230418monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-inhibitors-drugs-companies-clinical-trials-insight-2023-galt-20230414monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-the-positive-outcome-of-the-third-data-and-safety-monitoring-galt-20230316monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-contribution-to-improve-histology-interpretation-of-cirrhotic-liver--galt-20230124monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-webcast-corporate-update-on-december-1-2022-after-annual-meeting--galt-20221129monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-6th-obesity-nash-drug-development-summit-galt-20221128monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-share-five-scientific-presentations-at-the-liver-meeting-2022-hos-galt-20221101monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-in-upcoming-conferences-galt-20221014monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-c-galt-20220908monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-2-liver-cirrhosis-scientific-presentations-at-the-easl-int-galt-20220621monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-in-upcoming-h-c-wainwright-global-investment-conference-a-galt-20220523monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-conference-galt-20220106monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-discusses-corporate-transformation-progress-of-navigate-trial-and-ou-galt-20211213monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-pharmaceuticals-to-present-six-scientific-abstracts-at-the-liver-meeting-2021-hos-galt-20211027monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-inc-to-participate-in-the-h-c-wainwright-23rd-annual-global-investme-galt-20210909monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-strengthens-leadership-team-with-strategic-hires-to-advance-programs-galt-20210830monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-financial-results-for-the-quarter-ended-march-31-2021-and-pr-galt-20210517monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-4th-global-nash-congress-galt-20210427monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-3-has-a-key-role-in-gastric-cancer-galt-20210415monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-launches-navigatenash-com-a-resource-for-both-patients-and-physician-galt-20210406monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-h-c-wainwright-global-life-sciences-conference-galt-20210304monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-inc-to-present-at-the-4th-annual-digital-nash-summit-on-december-17--galt-20201211monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-inc-recaps-results-of-annual-meeting-of-stockholders-presentation-galt-20201204monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-webcast-corporate-update-on-december-3-2020-after-annual-meeting--galt-20201201monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-investor-conference-call-and-webinar-taking-place-today-galt-20200929monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-inc-to-present-at-the-h-c-wainwright-22nd-annual-global-investment-c-galt-20200910monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-update-on-the-impact-of-covid-19-galt-20200402monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-president-and-ceo-dr-harold-shlevin-to-present-at-the-3rd-global-nas-galt-20200204monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-phase-2-nash-cirrhosis-clinical-trial-results-on-belapectin-gr-md-02-galt-20191209monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-plans-adaptively-designed-phase-3-nash-rx-clinical-trial-in-nash-cir-galt-20191205monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-anti-fibrotic-drug-development-afdd-summit-galt-20191118monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reaches-agreement-with-siemens-healthineers-to-collaborate-on-nash-a-galt-20191111monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-alternate-price-of-common-stock-in-rights-offering-galt-20190523monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-q1-2019-financial-results-and-provides-business-update-galt-20190510monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-the-2019-h-c-wainwright-global-life-sciences-conferenc-galt-20190402monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-berenberg-nash-day-in-new-york-galt-20190225monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-the-2nd-annual-anti-fibrotic-drug-development-summit-galt-20181119monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-participate-in-the-roth-capital-battle-of-the-nash-thrones-invest-galt-20181015monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-the-roth-capital-battle-of-the-nash-thrones-investment-galt-20181015monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-h-c-wainwright-20th-annual-global-investment-conferenc-galt-20180828monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-receives-patent-for-gr-md-02-patent-for-method-and-treatment-of-pulm-galt-20180627monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-inc-announces-new-ceo-galt-20180612monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-inc-announces-richard-e-uihlein-elected-chairman-of-the-board-galt-20180604monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-2nd-annual-nash-summit-2018-galt-20180418monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-late-breaker-presentation-at-the-international-liver-congress-reinfo-galt-20180416monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-late-breaker-oral-presentation-at-the-international-liver-galt-20180404monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-h-c-wainwright-global-life-sciences-conference-galt-20180402monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-two-international-conferences-in-march-galt-20180309monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-2nd-annual-h-c-wainwright-nash-investor-conference-galt-20180308monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-record-date-and-annual-stockholders-meeting-date-for-2018-galt-20180305monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-30th-annual-roth-conference-galt-20180228monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-bio-ceo-investor-conference-galt-20180206monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-granted-patents-in-china-and-japan-that-support-nash-and-cancer-immu-galt-20180125monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-provides-corporate-update-at-annual-meeting-galt-20171214monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-webcast-corporate-update-at-annual-meeting-of-shareholders-galt-20171211monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-results-from-phase-2b-nash-cx-trial-galt-20171205monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-results-from-phase-2b-nash-cx-trial-on-december-5-2017-galt-20171204monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-ceo-peter-g-traber-m-d-named-chair-of-the-anti-fibrotic-drug-develop-galt-20171113monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-clinical-data-at-the-liver-meeting-2017-demonstrating-the-galt-20171020monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-ceo-peter-g-traber-m-d-named-chair-of-the-conference-for-nash-summit-galt-20170925monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-receives-notice-of-chinese-allowance-to-grant-a-key-patent-for-compo-galt-20170912monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-the-rodman-renshaw-19th-annual-global-investment-confe-galt-20170905monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-the-singular-research-summer-conference-galt-20170707monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-important-milestones-towards-completion-of-nash-cx-trial-galt-20170613monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-launches-the-liver-line-an-online-community-and-publication-on-liver-galt-20170503monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-receives-notice-of-japanese-decision-to-grant-a-composition-of-matte-galt-20170425monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-and-exalenz-to-present-late-breaking-abstract-at-the-international-l-galt-20170418monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-issues-statement-regarding-galtw-and-galtu-galt-20170323monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-fourth-quarter-and-full-year-2016-financial-results-and-prov-galt-20170321monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-29th-annual-roth-conference-galt-20170309monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-s-gr-md-02-demonstrates-efficacy-in-patients-with-moderate-to-severe-plaque-psori-galt-20170306monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-bio-ceo-investor-conference-galt-20170208monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-webcast-corporate-update-at-annual-meeting-of-stockholders-galt-20161208monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-webcast-corporate-presentation-at-the-microcap-conference-on-octo-galt-20161017monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-clinical-data-on-selective-non-invasive-tests-for-the-dev-galt-20161007monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-rodman-renshaw-18th-annual-global-investment-conferenc-galt-20160831monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-positive-preclinical-results-on-the-role-of-galectin-3-in--galt-20160602monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-needham-company-s-15th-annual-healthcare-conference-galt-20160407monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-hold-business-update-conference-call-on-march-15-galt-20160308monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-the-28th-annual-roth-conference-galt-20160307monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-receives-u-s-patent-allowance-for-gr-md-02-to-treat-pulmonary-fibros-galt-20160224monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-upcoming-conferences-galt-20160128monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-inc-to-present-at-noble-financial-capital-markets-12th-annual-invest-galt-20160114monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-selected-to-present-at-cavendish-global-health-impact-forum-galt-20151023monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-executive-chairman-to-discuss-silent-epidemic-and-company-s-role-in--galt-20151007monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-inc-executive-chairman-jim-czirr-to-be-interviewed-on-the-big-biz-sh-galt-20151006monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-begins-phase-2a-psoriasis-study-with-gr-md-02-galt-20150924monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-2015-ladenburg-thalmann-healthcare-conference-galt-20150922monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-participate-in-three-investment-conferences-in-september-galt-20150908monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-receives-u-s-patent-notice-of-allowance-for-use-of-pectin-compounds--galt-20150813monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-inc-appoints-adam-e-allgood-pharm-d-r-ph-as-executive-director-of-cl-galt-20150715monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-initiates-enrollment-for-gr-md-02-phase-2-clinical-trial-in-nash-wit-galt-20150629monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-names-dr-marc-rubin-lead-independent-director-galt-20150603monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-ld-micro-invitational-conference-galt-20150528monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-webcast-corporate-update-following-annual-meeting-of-stockholders-galt-20150515monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-presented-research-with-gr-md-02-at-the-american-association-for-the-galt-20150324monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-the-27th-annual-roth-conference-galt-20150302monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-details-of-the-design-of-its-phase-2-program-with-gr-md-02-galt-20150224monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-7th-annual-ld-micro-main-event-conference-galt-20141201monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-phase-1-data-presented-at-aasld-annual-meeting-advances-gr-md-02-int-galt-20141109monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-abstract-accepted-as-oral-presentation-at-the-liver-meeting-r-annual-galt-20141001monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-72-hour-deadline-alert-approximately-72-hours-remain-former-louisiana-attorney-ge-galt-20140927monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-elects-gilbert-s-omenn-m-d-ph-d-a-leading-cancer-researcher-to-its-b-galt-20140924monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-remind-galt-20140916monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-aegis-capital-corporation-2014-healthcare-and-technolo-galt-20140910monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-remind-galt-20140816monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-responds-to-class-action-lawsuit-galt-20140804monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-remind-galt-20140801monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-issues-statement-on-gr-md-02-development-program-galt-20140730monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-host-webcast-to-discuss-findings-from-cohort-2-of-phase-1-clinica-galt-20140725monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-added-to-russell-2000-index-galt-20140709monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-that-oral-treatment-with-galectin-3-inhibitor-gr-md-02-is--galt-20140623monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-jefferies-2014-global-healthcare-conference-galt-20140529monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-completes-enrollment-of-second-cohort-of-phase-1-trial-of-gr-md-02-f-galt-20140423monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-first-patient-dosed-in-second-cohort-of-phase-1-trial-of-g-galt-20140417monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-presents-at-jmp-securities-nonalcoholic-steatohepatitis-nash-worksho-galt-20140224monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-16th-annual-bio-ceo-investor-conference-galt-20140205monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-executive-chairman-james-czirr-to-present-at-redchip-emerging-growth-galt-20140123monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-chairman-discusses-details-of-fast-track-designation-today-at-11-a-m-galt-20130816monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-receives-fda-fast-track-designation-for-gr-md-02-for-fatty-liver-dis-galt-20130812monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-inc-galt-to-ring-the-nasdaq-stock-market-closing-bell-galt-20120905monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-inc-to-announce-first-quarter-financial-results-on-may-11-2023-hypr-20230420monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-inc-to-announce-fourth-quarter-and-full-year-2022-financial-results-on-march-21--hypr-20230306monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-inc-receives-fda-clearance-for-updated-software-to-further-improve-diffusion-wei-hypr-20230228monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-inc-announces-fda-clearance-for-improved-ai-powered-software-and-expanded-field--hypr-20230213monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-swoop-point-of-care-mri-system-takes-the-stage-at-ismrm-with-twelve-abstract-inc-hypr-20230206monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-to-present-at-the-5th-annual-evercore-isi-healthconx-conference-hypr-20221122monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-to-announce-third-quarter-2022-financial-results-on-november-10-2022-hypr-20221027monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-to-participate-in-upcoming-investor-conferences-hypr-20220824monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-to-announce-second-quarter-2022-financial-results-on-august-10-2022-hypr-20220720monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-announces-zero-radiation-dose-rapid-mr-imaging-test-for-pediatric-hydrocephalus--hypr-20220714monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-announces-ceo-transition-hypr-20220629monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-announces-expansion-into-australia-and-new-zealand-with-medical-device-registrat-hypr-20220614monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-to-present-at-the-2022-jefferies-global-healthcare-conference-hypr-20220525monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-to-announce-first-quarter-2022-financial-results-on-may-11-2022-hypr-20220420monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-to-announce-fourth-quarter-and-full-year-2021-financial-results-hypr-20220303monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-to-present-at-the-42nd-annual-cowen-healthcare-conference-hypr-20220301monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-appoints-chip-truwit-m-d-as-senior-medical-director-hypr-20220208monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-s-swoop-portable-mr-imaging-system-wins-gold-medical-design-excellence-award-hypr-20210518monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-research-brings-the-category-defining-swoop-portable-mr-imaging-system-on-the-ro-hypr-20210513monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-s-swoop-portable-mr-imaging-system-chosen-from-among-4-000-submissions-as-a-fast-hypr-20210504monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-dismantles-the-traditional-experience-for-acquiring-capital-medical-equipment-wi-hypr-20210330monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-raises-90-million-in-oversubscribed-series-d-financing-hypr-20210210monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-s-swoop-portable-mr-imaging-system-recognized-as-2021-innovation-awards-honoree--hypr-20201216monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-initiates-global-research-program-using-portable-mr-imaging-technology-to-identi-hypr-20201112monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-wins-incubated-medical-device-innovation-challenge-at-2020-american-college-of-e-hypr-20201030monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-receives-frost-sullivan-best-practices-product-innovation-award-for-world-s-firs-hypr-20201014monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-added-to-prism-emerging-biotech-index-crdl-20241113monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-announces-upsize-to-previously-announced-bought-deal-public-offering-crdl-20210506monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-announces-15-million-bought-deal-public-offering-crdl-20210505monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-appoints-mike-zumdahl-as-senior-vice-president-market-access-and-commercial-guts-20260601monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-to-report-first-quarter-2026-financial-results-and-provide-business-updates-guts-20260505monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-to-report-second-quarter-2025-financial-results-and-provide-business-update-guts-20250806monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-announces-proposed-public-offering-guts-20250805monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-reports-potent-and-durable-two-year-real-world-outcomes-with-revita-showing-guts-20250805monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-presents-new-data-at-the-american-diabetes-association-s-85th-scientific-se-guts-20250623monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-to-present-new-preclinical-data-from-its-rejuva-smart-glp-1-pancreatic-gene-guts-20250613monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-and-bariendo-sign-letter-of-intent-to-prepare-for-potential-offering-of-rev-guts-20250604monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-unveils-new-rejuva-smart-glp-1-pancreatic-gene-therapy-preclinical-data-hig-guts-20250517monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-to-report-first-quarter-2025-financial-results-and-provide-business-updates-guts-20250506monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-to-present-compelling-preclinical-data-from-its-rejuva-single-administratio-guts-20250428monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-b-guts-20250224monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-unveils-promising-preclinical-data-demonstrating-safety-and-feasibility-of--guts-20241212monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-to-present-new-preclinical-data-from-its-rejuva-single-administration-smart-guts-20241209monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-to-participate-in-the-upcoming-december-conferences-guts-20241126monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-to-present-new-preclinical-data-on-sustained-weight-maintenance-and-blood-s-guts-20241104monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-presented-new-analysis-from-pooled-data-of-revita-clinical-studies-demonstr-guts-20241104monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-to-report-third-quarter-2024-financial-results-and-provide-business-updates-guts-20241029monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-to-present-compelling-weight-maintenance-data-from-both-revita-and-rejuva-p-guts-20241028monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-to-present-at-chardan-s-8th-annual-genetic-medicines-conference-guts-20240924monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-to-participate-in-upcoming-september-investor-conferences-guts-20240903monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-announces-clinical-results-from-german-real-world-registry-showing-meaningf-guts-20240808monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-to-report-second-quarter-2024-financial-results-and-provide-business-update-guts-20240807monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-to-present-at-piper-sandler-2nd-annual-virtual-obesity-day-guts-20240625monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-presents-new-preclinical-data-on-sustained-weight-maintenance-and-improved--guts-20240623monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-to-present-new-preclinical-obesity-data-from-rejuva-platform-at-the-america-guts-20240529monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-presents-compelling-preclinical-data-from-single-administration-glp-1-pancr-guts-20240520monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-presents-clinical-update-on-revita-german-real-world-registry-for-patients--guts-20240513monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-to-present-at-bofa-securities-2024-health-care-conference-guts-20240508monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-to-report-first-quarter-2024-financial-results-and-provide-business-updates-guts-20240507monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-announces-multiple-presentations-at-the-upcoming-digestive-disease-week-ddw-guts-20240430monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-expands-leadership-with-appointment-of-adrian-kimber-as-chief-commercial-of-guts-20240402monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-announces-new-results-from-its-rejuva-platform-demonstrating-potent-and-dur-guts-20240312monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-appoints-samuel-conaway-to-its-board-of-directors-bolstering-new-product-co-guts-20240220monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-announces-pricing-of-initial-public-offering-guts-20240202monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-announces-nomination-of-rjva-001-as-first-clinical-candidate-in-its-rejuva--guts-20240105monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-announces-new-pooled-analysis-from-revita-clinical-studies-demonstrating-in-guts-20231214monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-demonstrated-that-a-single-dose-of-a-glp-1-based-pancreatic-gene-therapy-ca-guts-20231211monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-expands-landmark-academic-industry-collaboration-to-study-mechanisms-underl-guts-20231116monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provi-spro-20260318monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-report-second-quarter-2025-financial-results-and-provide-business-up-spro-20250805monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provi-spro-20250318monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-td-cowen-45th-annual-health-care-conference-spro-20250225monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-provides-business-update-and-announces-interim-leadership-changes-spro-20250110monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-report-third-quarter-2024-financial-results-and-provide-business-upd-spro-20241107monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-presentation-of-spr719-active-moiety-of-spr720-in-vitro-data--spro-20241016monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-publication-of-spr720-phase-1-lung-exposure-data-in-antimicro-spro-20241002monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-upcoming-september-investor-conferences-spro-20240904monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-report-second-quarter-2024-financial-results-and-provide-business-up-spro-20240729monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-spro-20240703monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-spro-20240603monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-participate-in-h-c-wainwright-annual-bioconnect-investor-conference-spro-20240516monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-report-first-quarter-2024-financial-results-and-provide-business-upd-spro-20240508monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20240501monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-provide-business-update-and-report-fourth-quarter-and-full-year-2023-spro-20240306monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-clearance-of-ind-for-spr206-to-treat-mdr-gram-negative-bacter-spro-20240228monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-cowen-s-44th-annual-healthcare-conference-spro-20240226monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20240131monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-provide-business-update-and-report-third-quarter-2023-financial-resu-spro-20231106monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-upcoming-november-investor-conferences-spro-20231101monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20231031monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20230929monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-cantor-s-global-healthcare-2023-investor-conference-spro-20230920monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-spro-20230906monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20230831monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-res-spro-20230803monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20230630monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20230531monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-resu-spro-20230504monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20230428monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-upcoming-investor-conference-spro-20230426monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology--spro-20230414monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20230331monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-fourth-quarter-and-full-year-2022-operating-results-and-provi-spro-20230330monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-reschedules-fourth-quarter-and-full-year-2022-earnings-release-and-conf-spro-20230313monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-provide-business-update-and-report-fourth-quarter-and-full-year-2022-spro-20230306monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20230228monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-upcoming-investor-conferences-spro-20230228monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20230131monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20221222monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-the-5th-annual-evercore-isi-healthconx-conference-spro-20221122monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-provide-business-update-and-report-third-quarter-2022-financial-resu-spro-20221107monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-data-at-idweek-2022-spro-20221019monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-host-virtual-r-d-event-on-non-tuberculous-mycobacterial-pulmonary-di-spro-20221003monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-appointment-of-kamal-hamed-md-mph-mba-as-chief-medical-office-spro-20220915monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-upcoming-investor-conference-spro-20220907monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-provide-business-update-and-report-second-quarter-2022-financial-res-spro-20220809monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-inc-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-por-spro-20220725monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-inc-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-por-spro-20220721monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-inc-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-por-spro-20220627monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-inc-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-por-spro-20220615monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-inc-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-por-spro-20220602monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announce-spro-20220531monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-upcoming-investor-conferences-spro-20220511monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2022-financial-resu-spro-20220509monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-data-at-the-32nd-european-congress-of-clinical-microbiology--spro-20220421monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-provide-business-update-and-report-fourth-quarter-and-full-year-2021-spro-20220317monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-lifting-of-fda-clinical-trial-hold-on-spr720-spro-20220104monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-upcoming-investor-conferences-spro-20211117monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-provide-business-update-and-report-third-quarter-2021-financial-resu-spro-20211103monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20211001monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-enters-into-a-non-dilutive-revenue-interest-financing-agreement-with-he-spro-20210930monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-data-at-idweek-2021-spro-20210916monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-three-upcoming-investor-conferences-spro-20210907monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20210831monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20210730monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-provide-business-update-and-report-second-quarter-2021-financial-res-spro-20210729monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-the-ladenburg-thalmann-healthcare-conference-spro-20210707monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20210702monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-the-initiation-of-bronchoalveolar-lavage-and-renal-impairment-spro-20210615monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20210528monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-awarded-up-to-23-million-by-the-national-institute-of-allergy-and-infec-spro-20210517monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-participate-at-the-berenberg-conference-usa-spro-20210513monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20210430monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-resu-spro-20210429monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20210331monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-provide-business-update-and-report-fourth-quarter-and-full-year-2020-spro-20210303monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-investor-conferences-in-march-spro-20210225monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20210129monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-issuance-of-allowance-for-a-u-s-patent-covering-lead-candidat-spro-20210121monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-added-to-the-nasdaq-biotechnology-index-spro-20201216monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-first-patient-dosed-with-spr720-in-phase-2a-clinical-trial-in-spro-20201210monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-appointment-of-tamara-joseph-as-chief-legal-officer-spro-20201202monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20201130monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-the-evercore-isi-healthconx-conference-on-december-3-2020-spro-20201130monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20201103monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-provide-business-update-and-report-third-quarter-2020-financial-resu-spro-20201029monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-data-for-all-pipeline-programs-at-idweek-2020-spro-20201016monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20200930monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-hosting-key-opinion-leader-call-on-oral-tebipenem-hbr-for-the-treatment-spro-20200924monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-investor-conferences-in-september-spro-20200915monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-pricing-of-securities-offering-spro-20200911monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-proposed-public-offering-spro-20200909monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-positive-topline-results-from-its-phase-3-adapt-po-clinical-t-spro-20200908monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-fda-acceptance-of-ind-application-for-spr720-spro-20200831monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20200731monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-provide-business-update-and-report-second-quarter-2020-financial-res-spro-20200729monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20200630monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-the-jefferies-2020-virtual-healthcare-conference-spro-20200601monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20200601monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-investor-alert-faruqi-faruqi-llp-encourages-investors-who-suffered-losses-exceeding--spro-20200528monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-completes-patient-enrollment-in-pivotal-phase-3-clinical-trial-adapt-po-spro-20200505monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2020-financial-resu-spro-20200504monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20200430monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20200331monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-receives-fda-orphan-drug-designation-for-spr720-for-the-treatment-of-no-spro-20200311monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-closing-of-rights-offering-spro-20200305monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20200228monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-march-investor-conferences-spro-20200226monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-commencement-of-rights-offering-spro-20200211monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-exercise-of-15-9-million-option-by-barda-for-tebipenem-hbr-de-spro-20200205monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20200131monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-reports-preliminary-findings-from-phase-1-clinical-trial-of-spr206-and-plans-to-adva-spro-20200113monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-reports-preliminary-findings-from-phase-1-clinical-trial-of-spr720-and-announces-pla-spro-20191204monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20191129monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-host-key-opinion-leader-symposium-in-december-spro-20191126monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20191031monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20190930monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-presentations-at-idweek-2019-spro-20190926monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-5-9-million-award-from-u-s-department-of-defense-to-further-c-spro-20190716monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20190628monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-collaboration-with-bill-melinda-gates-medical-research-instit-spro-20190620monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-data-for-all-pipeline-programs-at-the-asm-microbe-2019-confe-spro-20190617monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20190531monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-spro-20190501monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-highlights-spr994-data-at-the-29th-european-congress-of-clinical-microb-spro-20190408monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-receives-fda-fast-track-designation-for-spr994-for-the-treatment-of-com-spro-20190329monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-march-investor-conferences-spro-20190301monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-receives-qidp-designation-from-the-u-s-fda-for-the-development-of-spr72-spro-20190226monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-fda-acceptance-of-ind-application-for-spr994-spro-20190204monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-initiation-of-spr720-phase-1-clinical-trial-spro-20190129monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-positive-feedback-from-fda-pre-phase-3-meeting-for-oral-spr99-spro-20190107monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-positive-results-from-spr720-ind-enabling-studies-and-plans-t-spro-20181105monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-receives-qidp-designation-from-the-u-s-fda-for-the-development-of-spr20-spro-20181011monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-presentations-at-idweek-2018-spro-20180925monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-the-cantor-global-healthcare-conference-in-october-spro-20180919monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-new-data-for-spr994-and-spr206-at-escmid-asm-2018-conference-spro-20180828monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-pricing-of-securities-offering-spro-20180713monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-new-preclinical-data-for-spr994-at-asm-microbe-2018-spro-20180605monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-the-jefferies-2018-healthcare-conference-in-june-spro-20180601monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-positive-top-line-data-for-two-product-candidates-from-its-po-spro-20180523monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-bank-of-america-merrill-lynch-health-care-conference-in-m-spro-20180501monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-highlights-spr741-phase-1-and-preclinical-data-at-the-28th-european-con-spro-20180416monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-appoints-ian-a-critchley-ph-d-as-head-of-clinical-microbiology-spro-20180412monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-upcoming-investor-conferences-spro-20180322monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-to-present-at-march-investor-conferences-spro-20180301monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-appoints-david-melnick-m-d-as-chief-medical-officer-spro-20180104monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-inc-nasdaq-spro-to-ring-the-nasdaq-stock-market-closing-bell-spro-20171120monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-underwriters-option-exercise-spro-20171113monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-pricing-of-initial-public-offering-spro-20171101monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-launches-initial-public-offering-spro-20171023monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-initiates-clinical-program-for-oral-carbapenem-spr994-spro-20171020monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-licenses-exclusive-rights-to-spr994-a-novel-oral-carbapenem-being-studi-spro-20171010monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-files-registration-statement-for-proposed-initial-public-offering-spro-20171006monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-positive-phase-1-clinical-data-from-potentiator-platform-spro-20171003monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-announces-appointment-of-frank-thomas-to-its-board-of-directors-and-promotions-withi-spro-20170906monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and--abos-20260317monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-the-stifel-2026-virtual-cns-forum-abos-20260310monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-technology-for-oligomer-selectiv-abos-20251202monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-present-on-recruitment-strategies-for-phase-2-altitude-ad-trial--abos-20251118monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-announces-first-participant-dosed-in-phase-2-open-label-extension-s-abos-20251117monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-report-third-quarter-2025-financial-results-on-november-12-2025-abos-20251105monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-report-second-quarter-2025-financial-results-on-august-12-2025-abos-20250805monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-the-bank-of-america-healthcare-conference-abos-20250507monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-report-first-quarter-2025-financial-results-on-may-13-2025-abos-20250506monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-showcases-ptau217-trial-screening-progress-in-phase-2-altitude-ad-t-abos-20250402monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-completes-enrollment-of-altitude-ad-a-phase-2-clinical-trial-of-sab-abos-20250326monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2024-financial-results-on-mar-abos-20250320monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-announces-topline-results-from-phase-1-study-of-subcutaneous-formul-abos-20250319monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimer-s-abos-20250318monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimer-s-and-parki-abos-20250312monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-upcoming-investor-conferences-abos-20250310monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-announces-journal-of-prevention-of-alzheimer-s-disease-publication--abos-20250109monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-the-7th-annual-evercore-isi-healthconx-conference-abos-20241126monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-the-stifel-healthcare-conference-abos-20241111monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-the-ubs-global-healthcare-conference-abos-20241106monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-appoints-dr-amy-schacterle-as-chief-regulatory-officer-head-of-qual-abos-20241106monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-report-third-quarter-results-on-nov-12-2024-abos-20241105monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-presents-innovative-trial-screening-advancements-utilizing-ptau217--abos-20241031monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trial-abos-20241023monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-the-bank-of-america-cns-therapeutics-virtual-conf-abos-20240930monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-extends-collaboration-with-lonza-to-add-drug-product-manufacturing--abos-20240926monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-host-virtual-r-d-day-on-oct-2-2024-abos-20240925monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-the-h-c-wainwright-26th-annual-global-investor-co-abos-20240903monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-report-second-quarter-results-on-august-13-2024-abos-20240806monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-announces-first-subject-dosed-in-phase-1-study-of-subcutaneous-sabi-abos-20240729monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-presents-patient-experience-and-biomarker-data-from-phase-1-interce-abos-20240728monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-present-patient-experience-and-biomarker-insights-from-phase-1-i-abos-20240711monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-the-h-c-wainwright-2nd-annual-bioconnect-investor-abos-20240513monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-the-2024-bank-of-america-healthcare-conference-abos-20240508monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-announces-first-patient-dosed-in-altitude-ad-a-phase-2-clinical-tri-abos-20240508monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-report-first-quarter-results-on-may-14-2024-abos-20240507monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-presents-first-comprehensive-clinical-and-biomarker-data-for-sabirn-abos-20240416monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-collaborates-with-lonza-to-advance-sabirnetug-for-the-treatment-of--abos-20240404monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-reports-financial-results-for-the-year-ended-december-31-2023-and-b-abos-20240326monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-present-deeper-insights-including-fluid-biomarker-data-for-sabir-abos-20240321monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2023-financial-results-on-mar-abos-20240319monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-the-stifel-2024-cns-days-abos-20240312monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-presents-sabirnetug-acu193-fluid-biomarker-and-target-engagement-an-abos-20240308monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-present-sabirnetug-acu193-fluid-biomarker-and-target-engagement--abos-20240221monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-appoints-dr-james-doherty-as-president-and-chief-development-office-abos-20240201monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-abos-20240104monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-secures-50-0-million-credit-facility-with-k2-healthventures-abos-20231113monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-the-stifel-healthcare-conference-abos-20231107monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-report-third-quarter-financial-results-on-november-13-2023-abos-20231106monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-inc-and-halozyme-enter-global-collaboration-and-license-agreement-t-abos-20231106monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-the-ubs-biopharma-conference-abos-20231102monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-presents-late-breaker-phase-1-updates-exploring-novel-target-engage-abos-20231027monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-present-deeper-insights-from-first-in-human-phase-1-study-of-acu-abos-20231004monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-the-cantor-global-healthcare-conference-abos-20230919monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-the-h-c-wainwright-annual-global-investment-confe-abos-20230906monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-report-second-quarter-financial-results-on-august-8-2023-abos-20230801monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-announces-pricing-of-upsized-130-million-public-offering-abos-20230719monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-announces-proposed-public-offering-of-common-stock-abos-20230717monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-hold-conference-call-to-discuss-positive-topline-results-from-fi-abos-20230717monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-present-topline-results-from-first-in-human-phase-1-study-of-acu-abos-20230613monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-2023-bank-of-america-healthcare-conference-abos-20230504monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023-abos-20230502monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-presents-in-vitro-human-neuron-model-for-evaluating-binding-of-amyl-abos-20230328monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-stifel-2023-virtual-cns-days-abos-20230322monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2022-financial-results-on-mar-abos-20230320monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-the-needham-neuroscience-forum-abos-20230308monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-appoints-derrell-porter-m-d-to-its-board-of-directors-abos-20230104monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-the-stifel-healthcare-conference-abos-20221109monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-report-third-quarter-2022-financial-results-on-nov-14-2022-abos-20221107monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-publishes-phase-1-trial-design-and-clinical-development-plan-for-acu193-an-anti-amy-abos-20221101monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-report-second-quarter-2022-financial-results-on-august-15-2022-abos-20220808monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-upcoming-investor-and-scientific-conferences-abos-20220726monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-report-first-quarter-2022-financial-results-on-may-16-2022-abos-20220511monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-report-fourth-quarter-and-full-year-2021-financial-results-on-ma-abos-20220316monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-present-at-upcoming-investor-conferences-abos-20211108monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-to-present-clinical-trial-design-for-intercept-ad-the-phase-1-place-abos-20211102monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-announces-pricing-of-upsized-initial-public-offering-abos-20210701monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-host-virtual-investor-event-to-share-new-insights-into-the-aryl-hydrocarbon-r-eq-20260520monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eq-20260501monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-participate-in-upcoming-investor-conferences-eq-20251120monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-presents-data-on-target-engagement-and-modulation-of-cd6-on-t-cells-with-itolizu-eq-20210610monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-present-at-the-jmp-securities-life-sciences-conference-eq-20210609monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-host-conference-call-following-presentation-of-data-from-the-equate-study-in--eq-20210603monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-present-at-the-jefferies-virtual-healthcare-conference-eq-20210526monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-presents-multiple-posters-at-the-104th-annual-meeting-of-the-american-associatio-eq-20210517monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-oral-presentation-highlighting-positive-data-from-the-equate-study-in--eq-20210513monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-three-abstracts-accepted-for-presentation-at-the-104th-annual-meeting--eq-20210427monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-present-at-the-h-c-wainwright-global-life-sciences-conference-eq-20210302monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-present-at-the-svb-leerink-10th-annual-global-healthcare-conference-eq-20210218monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-presents-positive-interim-clinical-data-of-itolizumab-in-first-line-treatment-of-eq-20210212monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-the-appointment-of-katherine-xu-to-the-board-of-directors-eq-20210209monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-closing-of-30-million-registered-direct-offering-eq-20210205monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-acceptance-of-late-breaking-abstract-for-oral-presentation-of-interim--eq-20210122monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference-eq-20210105monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-present-at-investor-conferences-in-november-2020-eq-20201110monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-positive-interim-data-of-itolizumab-in-the-first-line-treatment-of-acu-eq-20201106monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-present-data-at-the-2020-american-college-of-rheumatology-meeting-demonstrati-eq-20201104monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-presented-new-data-and-insights-on-the-cd6-alcam-pathway-in-uncontrolled-asthma--eq-20200917monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-successful-completion-of-fda-pre-ind-meeting-enabling-advancement-of-i-eq-20200915monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-present-at-h-c-wainwright-22nd-annual-global-investment-conference-eq-20200903monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-closing-of-public-offering-of-common-stock-eq-20200818monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-pricing-of-public-offering-of-common-stock-eq-20200814monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-present-at-btig-virtual-biotechnology-conference-2020-eq-20200730monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-present-at-jefferies-virtual-healthcare-conference-eq-20200521monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-present-at-2020-rbc-capital-markets-virtual-global-healthcare-conference-eq-20200507monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-common-stock-purchase-agreement-for-up-to-15-million-with-lincoln-park-eq-20200330monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-strengthens-leadership-team-with-key-appointments-eq-20200227monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-present-at-9th-annual-svb-leerink-global-healthcare-conference-eq-20200213monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-present-translational-preclinical-data-demonstrating-increased-survival-and-d-eq-20200129monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-granted-u-s-fda-fast-track-designation-for-itolizumab-for-the-treatment-of-lupus-eq-20191209monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-present-translational-data-on-itolizumab-for-acute-graft-versus-host-disease--eq-20191126monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-featured-in-panel-discussion-at-capital-markets-day-for-kidney-health-eq-20191115monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-leadership-updates-eq-20191112monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-present-at-investor-conferences-in-november-2019-eq-20191107monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-present-new-data-and-insights-on-the-cd6-alcam-pathway-in-lupus-nephritis-at--eq-20191106monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-initiation-of-the-equalise-phase-1b-clinical-trial-of-itolizumab-for-p-eq-20191001monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-host-business-update-call-on-october-1-2019-eq-20190917monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-present-at-h-c-wainwright-21st-annual-global-investment-conference-eq-20190827monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-initiation-of-the-equip-phase-1b-clinical-trial-of-itolizumab-for-pati-eq-20190710monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-present-at-jefferies-2019-healthcare-conference-eq-20190523monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-expands-scientific-and-clinical-advisory-team-eq-20190506monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-present-at-solebury-trout-class-of-2018-biotech-ipo-investor-day-eq-20190416monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-present-at-h-c-wainwright-global-life-sciences-conference-eq-20190328monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-plan-to-develop-eq001-for-the-treatment-of-lupus-nephritis-eq-20190226monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-present-at-leerink-partners-global-healthcare-conference-eq-20190221monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-host-business-update-call-on-february-26-eq-20190219monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-granted-u-s-fda-orphan-drug-designations-for-eq001-itolizumab-for-both-the-preve-eq-20190207monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-granted-u-s-fda-fast-track-designation-for-eq001-for-the-treatment-of-acute-graf-eq-20181219monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-present-at-investor-conferences-in-november-2018-eq-20181101monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-pricing-of-initial-public-offering-eq-20181012monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-chief-scientific-officer-dr-michael-newman-to-present-at-the-donor-s-indp-20251117monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-chief-medical-officer-roger-waltzman-m-d-m-b-a-to-moderate-panel-at--indp-20250325monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-reports-new-data-demonstrating-successful-broad-immune-system-activa-indp-20250320monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-initiates-phase-1-combination-study-of-decoy20-with-pd-1-checkpoint--indp-20250318monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-expands-patent-portfolio-in-china-japan-and-israel-strengthening-its-indp-20250304monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-chief-scientific-officer-dr-michael-newman-to-present-at-the-10th-an-indp-20250225monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-receives-approval-from-health-canada-to-expand-clinical-trial-of-dec-indp-20250205monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-provides-year-end-review-and-outlook-for-2025-indp-20250108monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-pioneering-research-on-novel-immunotherapy-approach-published-in-pee-indp-20241111monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-presents-encouraging-interim-safety-data-from-phase-1-clinical-trial-indp-20241107monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-at-two-upcoming-investor-conferences-indp-20241023monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-announces-clinical-supply-agreement-with-beigene-to-evaluate-novel-c-indp-20241022monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-initiates-unrestricted-enrollment-of-patients-on-decoy20-weekly-dosi-indp-20241015monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-founder-and-chief-scientific-officer-to-speak-on-lumanity-webinar-ab-indp-20241010monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-participate-in-a-fireside-chat-at-the-2024-maxim-healthcare-virtu-indp-20241008monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-reports-encouraging-new-safety-data-for-decoy20-clinical-program-com-indp-20240905monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-at-the-h-c-wainwright-26th-annual-global-investment-confe-indp-20240903monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-positive-data-on-lead-product-candidate-decoy20-at-sting--indp-20240611monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-new-positive-data-on-decoy20-at-next-gen-immuno-oncology--indp-20240604monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-announces-new-positive-data-from-ongoing-phase-1-trial-of-decoy20-indp-20240603monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-indp-20240530monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-new-cohort-data-confirming-original-pulse-prime-hypothesi-indp-20240529monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-announces-completion-of-first-patient-to-receive-multiple-doses-of-d-indp-20240522monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-presents-positive-mechanism-of-action-data-at-the-american-associati-indp-20240411monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-at-the-medinvest-biotech-and-pharma-investor-conference-indp-20240328monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-previews-positive-mechanism-of-action-data-to-be-presented-at-the-am-indp-20240325monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-participate-in-tribe-public-webinar-on-wednesday-march-20-2024-indp-20240318monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-announces-positive-results-from-second-cohort-of-phase-1-trial-compa-indp-20240304monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-at-the-2024-bio-ceo-investor-conference-indp-20240215monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-expands-digital-presence-with-launch-of-social-media-channels-indp-20240208monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-decoy20-demonstrated-a-broad-immune-response-of-more-than-fifty-cyto-indp-20231106monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-positive-pharmacodynamic-pd-immune-and-pharmacokinetic-pk-indp-20231031monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-at-the-ld-micro-main-event-xvi-indp-20230927monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-doses-first-patient-in-second-cohort-of-single-dose-ranging-study-of-indp-20230919monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-at-the-h-c-wainwright-25th-annual-global-investment-confe-indp-20230906monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-announces-opening-of-next-cohort-in-single-dose-ranging-study-of-dec-indp-20230810monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-appoints-industry-veteran-roger-waltzman-m-d-chief-medical-officer-indp-20230807monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-participate-in-the-maxim-group-virtual-healthcare-conference-indp-20230615monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-at-the-jefferies-healthcare-conference-2023-indp-20230531monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-chief-scientific-officer-michael-newman-ph-d-named-a-chair-of-the-4t-indp-20230501monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023-indp-20230420monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-presents-data-demonstrating-preclinical-efficacy-of-decoy-its-bacter-indp-20230419monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-receives-brazilian-patent-allowance-for-decoy-platform-indp-20230417monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-at-the-investor-summit-conference-indp-20230322monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-poster-on-its-decoy-anti-tumor-platform-at-the-american-a-indp-20230315monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-activates-emory-winship-cancer-institute-as-trial-site-in-indp-d101--indp-20230313monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-doses-first-subject-in-its-ongoing-phase-1-open-label-clinical-trial-indp-20230307monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-names-robert-martell-m-d-ph-d-to-its-board-of-directors-indp-20230214monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-activates-morristown-medical-center-as-trial-site-in-indp-d101-its-o-indp-20230207monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-announces-initiation-of-first-in-human-open-label-dose-escalation-an-indp-20221213monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-at-the-ld-micro-main-event-xv-indp-20221018monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-at-the-24th-annual-h-c-wainwright-global-investment-confe-indp-20220906monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-at-jmp-securities-life-sciences-conference-indp-20220609monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-at-jefferies-healthcare-conference-indp-20220603monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-at-h-c-wainwright-global-investment-conference-indp-20220518monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-at-2nd-annual-chronic-hbv-drug-development-summit-indp-20220420monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-at-maxim-group-2022-virtual-growth-conference-indp-20220323monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-at-3rd-annual-sting-tlr-targeting-therapies-summit-indp-20220317monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-at-34th-annual-roth-conference-indp-20220307monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-to-present-at-h-c-wainwright-bioconnect-2022-virtual-conference-indp-20220105monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-appoints-mark-gilbert-m-d-to-board-of-directors-indp-20211201monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-receives-notice-of-allowance-for-strategic-patent-indp-20210915monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-vtvt-20260508monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-and-m42-s-iros-announce-submission-of-phase-2-clinical-study-protocol-for-vtvt-20251218monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-reinitiation-of-screening-in-catt1-phase-3-trial-evaluating-pot-vtvt-20250515monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-fda-has-lifted-clinical-hold-on-cadisegliatin-program-for-diabe-vtvt-20250317monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-to-participate-in-7th-annual-evercore-healthconx-conference-vtvt-20241202monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-cadisegliatin-program-for-type-1-diabetes-placed-on-clinical-ho-vtvt-20240726monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-screening-of-first-patient-in-catt1-pivotal-trial-evaluating-ca-vtvt-20240624monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-fda-submission-for-first-phase-3-study-of-cadisegliatin-in-pati-vtvt-20240304monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-to-participate-at-the-td-cowen-44th-annual-healthcare-conference-vtvt-20240301monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2023-third-quarter-financial-results-and-provides-corporate-upd-vtvt-20231109monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-to-participate-at-the-stifel-2023-healthcare-conference-vtvt-20231108monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-appoints-thomas-strack-m-d-as-chief-medical-officer-vtvt-20231102monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-partner-cantex-pharmaceuticals-licenses-exclusive-rights-to-intellectual--vtvt-20230616monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-issuance-of-u-s-patent-for-azeliragon-as-a-treatment-of-gliobla-vtvt-20230524monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-appoints-biotech-industry-veteran-steven-tuch-as-chief-financial-officer-vtvt-20221213monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-publication-in-diabetes-obesity-and-metabolism-of-complete-resu-vtvt-20220604monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-shares-updated-corporate-presentation-vtvt-20220113monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-restructuring-to-prioritize-its-lead-program-and-focus-operatio-vtvt-20211206monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-positive-results-from-mechanistic-study-indicating-no-increased-vtvt-20211012monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-results-of-multiple-ascending-dose-study-and-development-plan-f-vtvt-20210923monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-to-participate-at-the-6th-world-psoriasis-psoriatic-arthritis-conference--vtvt-20210629monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-and-cantex-pharmaceuticals-announce-strategic-licensing-agreement-for-dev-vtvt-20210622monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-receives-fda-breakthrough-therapy-designation-for-ttp399-for-the-treatmen-vtvt-20210413monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-issuance-of-u-s-patent-covering-methods-of-treatment-using-ttp3-vtvt-20210323monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-initiation-of-study-evaluating-ttp399-s-potential-to-reduce-ris-vtvt-20210318monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference-vtvt-20210308monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-publication-in-diabetes-care-of-results-from-simplicit-1-study--vtvt-20210223monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-initiation-of-multiple-ascending-dose-study-of-hpp737-an-oral-p-vtvt-20210217monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-to-participate-in-the-lifesci-partners-10th-annual-healthcare-corporate-a-vtvt-20210106monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-topline-results-of-phase-2-elevage-study-of-azeliragon-in-patie-vtvt-20201215monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-licensing-agreement-for-novel-nrf2-activator-to-anteris-bio-vtvt-20201215monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-common-stock-purchase-agreement-for-up-to-47-million-with-linco-vtvt-20201124monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-presents-baseline-characteristics-of-the-enrolled-subjects-in-the-elevage-vtvt-20201104monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-to-present-study-update-and-preliminary-data-on-baseline-characteristics--vtvt-20201029monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-presents-additional-positive-clinical-study-results-supporting-the-safety-vtvt-20200923monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-to-present-additional-positive-clinical-study-results-from-phase-2-simpli-vtvt-20200916monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-appointment-of-edward-p-taibi-to-its-board-of-directors-vtvt-20200915monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-to-present-additional-clinical-data-from-the-steadfast-study-of-azelirago-vtvt-20200727monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-presents-two-late-breaking-poster-sessions-on-simplici-t1-study-at-the-am-vtvt-20200613monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-to-present-full-clinical-study-results-from-the-positive-phase-2-simplici-vtvt-20200527monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-changes-its-2020-annual-meeting-of-stockholders-to-virtual-format-vtvt-20200522monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-positive-results-from-part-2-of-the-phase-2-simplici-t1-study-o-vtvt-20200210monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-to-host-investor-call-and-announce-results-from-part-2-of-the-phase-2-sim-vtvt-20200207monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-to-present-at-the-31st-annual-piper-jaffray-healthcare-conference-vtvt-20191202monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-to-host-key-opinion-leader-event-to-discuss-the-type-1-diabetes-treatment-landscape-an-vtvt-20191003monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-presents-additional-positive-data-from-the-phase-2-simplici-t1-study-in-p-vtvt-20190918monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-to-present-posters-at-two-scientific-conferences-in-september-vtvt-20190911monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-to-present-at-the-h-c-wainwright-21st-annual-global-investment-conference-vtvt-20190904monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-to-participate-in-upcoming-canaccord-genuity-and-solebury-trout-conferenc-vtvt-20190806monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-inc-nasdaq-vtvt-to-ring-the-nasdaq-stock-market-opening-bell-vtvt-20150730monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-reports-first-quarter-2026-financial-results-and-provides-business-updat-cntb-20260512monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-confe-cntb-20260219monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-highlights-new-mechanism-of-action-data-for-rademikibart-and-outlines-pr-cntb-20260112monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-to-present-at-the-8th-annual-evercore-healthcare-conference-cntb-20251124monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-reports-second-quarter-2025-financial-results-and-provides-business-upda-cntb-20250813monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-announces-plans-to-terminate-its-american-depositary-receipt-program-and-cntb-20250721monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-regains-compliance-with-nasdaq-minimum-bid-price-requirement-cntb-20250717monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-presents-data-supporting-rademikibart-at-the-european-academy-of-allergy-cntb-20250613monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-announces-two-oral-presentations-at-the-european-academy-of-allergy-and--cntb-20250603monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-to-present-at-two-upcoming-investor-conferences-in-june-cntb-20250528monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-presents-data-supporting-development-of-rademikibart-at-the-american-tho-cntb-20250520monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-reports-first-quarter-2025-financial-results-and-provides-business-updat-cntb-20250515monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-initiates-phase-2-seabreeze-stat-copd-study-evaluating-rademikibart-for--cntb-20250514monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-announces-multiple-presentations-at-the-american-thoracic-society-ats-20-cntb-20250424monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-announces-positive-type-c-meeting-with-the-fda-for-rademikibart-cntb-20250401monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-announces-publication-of-positive-data-from-global-phase-2-trial-of-rade-cntb-20250331monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-reports-2024-full-year-financial-results-and-provides-business-update-cntb-20250331monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-to-present-at-two-upcoming-investor-conferences-cntb-20250303monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-to-participate-in-the-cantor-fitzgerald-global-healthcare-conference-202-cntb-20240910monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-reports-first-half-2024-financial-results-and-provides-business-update-cntb-20240905monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-to-participate-in-the-leerink-partners-i-i-and-metabolism-therapeutics-f-cntb-20240701monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cntb-20240612monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-announces-new-leadership-and-chair-of-the-board-of-directors-cntb-20240612monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-presents-late-breaking-abstract-at-the-american-thoracic-society-2024-in-cntb-20240522monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-to-present-a-late-breaking-abstract-at-the-american-thoracic-society-ats-cntb-20240507monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-reports-full-year-2023-financial-results-and-provides-business-update-cntb-20240416monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-appoints-industry-veteran-james-huang-to-board-of-directors-cntb-20240212monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-to-announce-top-line-data-from-the-global-phase-2b-trial-of-rademikibart-cntb-20231211monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-and-simcere-announce-exclusive-licensing-and-collaboration-agreement-in--cntb-20231121monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-announces-positive-long-term-data-from-the-china-pivotal-trial-of-rademi-cntb-20231121monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-to-announce-long-term-data-from-the-china-pivotal-trial-of-rademikibart--cntb-20231120monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-pric-cntb-20230912monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-to-participate-in-upcoming-september-investor-conferences-cntb-20230824monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-presented-additional-data-from-its-atopic-dermatitis-pivotal-trial-in-ch-cntb-20230710monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-to-participate-in-the-svb-securities-therapeutics-forum-cntb-20230705monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-to-present-at-svb-securities-global-biopharma-conference-and-participate-cntb-20230206monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-to-present-at-the-san-francisco-biotech-showcase-in-january-cntb-20221219monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-pric-cntb-20221202monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-to-present-at-upcoming-investor-and-scientific-conferences-cntb-20221027monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-reports-cbp-201-achieved-all-primary-and-key-secondary-endpoints-in-pivo-cntb-20221004monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-to-host-a-conference-call-tuesday-october-4-to-discuss-topline-results-f-cntb-20221003monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-to-report-first-half-2022-financial-results-on-september-13-cntb-20220901monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-successfully-completes-cbp-174-phase-1-single-ascending-dose-study-cntb-20220830monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-moves-forward-cbp-201-top-line-results-timeline-for-pivotal-china-atopic-dermatiti-cntb-20220711monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-pric-cntb-20220617monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-to-participate-at-the-jefferies-healthcare-conference-cntb-20220602monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-presents-cbp-201-target-engagement-and-immune-modulation-data-at-the-soc-cntb-20220517monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-reports-full-year-2021-financial-results-and-provides-business-update-cntb-20220331monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-appoints-autoimmune-and-immunology-expert-chin-lee-md-mph-as-chief-medic-cntb-20220301monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-to-participate-at-the-svb-leerink-11th-annual-global-healthcare-conferen-cntb-20220209monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-presents-data-and-analyses-from-the-global-phase-2b-trial-of-cbp-201-at--cntb-20220124monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-to-host-conference-call-on-january-5-at-8-30-am-et-to-review-detailed-da-cntb-20220104monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-expands-executive-leadership-team-with-hire-of-chief-financial-officer-cntb-20211122monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-to-participate-at-upcoming-conferences-cntb-20211111monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-to-participate-at-the-jefferies-virtual-china-biotech-summit-cntb-20211019monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-provides-business-update-and-reports-first-half-2021-financial-results-cntb-20210831monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-to-host-first-half-2021-financial-results-conference-call-on-september-1-cntb-20210825monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-hires-general-counsel-chief-compliance-officer-and-appoints-a-new-board--cntb-20210823monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-to-participate-at-the-jefferies-virtual-healthcare-conference-cntb-20210526monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-completes-enrollment-of-cbp-201-global-phase-2-clinical-trial-in-moderat-cntb-20210408monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-holdings-limited-announces-closing-of-initial-public-offering-and-full-e-cntb-20210323monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-holdings-limited-announces-pricing-of-initial-public-offering-cntb-20210319monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-initiates-phase-1-study-of-rt-114-ranipill-for-the-treatment-of-obesity--rani-20260108monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-announces-oversubscribed-60-3-million-private-placement-priced-at-the-ma-rani-20251017monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-announces-preclinical-data-demonstrating-bioequivalence-of-rt-114-a-glp--rani-20250326monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-rani-20250325monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-sem-rani-20250205monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-to-participate-in-upcoming-investor-conferences-rani-20241107monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-announces-new-preclinical-pharmacokinetic-data-supporting-transenteric-d-rani-20241017monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-holdings-inc-announces-pricing-of-10-0-million-registered-direct-offerin-rani-20241015monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-to-participate-in-the-2024-maxim-healthcare-virtual-summit-rani-20241008monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-to-participate-in-september-investor-conferences-rani-20240903monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-reports-second-quarter-2024-financial-results-provides-corporate-update-rani-20240806monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-to-participate-in-august-investor-conferences-rani-20240729monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-holdings-inc-announces-pricing-of-10-0-million-registered-direct-offerin-rani-20240722monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-announces-partnership-with-progen-on-development-of-oral-obesity-treatme-rani-20240624monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-to-participate-in-may-investor-conferences-rani-20240514monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-to-present-clinical-and-preclinical-data-on-oral-delivery-of-an-ustekinu-rani-20240509monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-to-report-fourth-quarter-and-full-year-2023-financial-results-rani-20240315monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-host-investor-webinar-briefing-rcel-20260517monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-tga-certification-in-australia-and-medsafe-wand-listing-in-new-zea-rcel-20260429monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-announce-first-quarter-2026-financial-results-rcel-20260423monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-founder-fiona-wood-honored-with-lifetime-achievement-award-by-american-burn--rcel-20260415monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-positive-interim-results-from-cohealyx-study-demonstrating-acceler-rcel-20260414monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-inc-investigated-by-the-portnoy-law-firm-rcel-20260413monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-secures-10-year-barda-agreement-worth-up-to-25-5m-to-bolster-u-s-burn-emerge-rcel-20260408monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohe-rcel-20260407monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-participate-at-the-td-cowen-46th-annual-health-care-conference-rcel-20260223monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-rcel-20251218monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-announce-third-quarter-2025-financial-results-rcel-20251029monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-investigation-bragar-eagel-squire-p-c-reminds-avita-medical-investors-to-con-rcel-20251016monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-reminder-bragar-eagel-squire-p-c-reminds-avita-medical-investors-to-contact-the-firm-rcel-20251009monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-rcel-investigation-alert-bragar-eagel-squire-p-c-continues-investigation-into-avita--rcel-20251003monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-inc-rcel-shareholders-who-lost-money-contact-law-offices-of-howard-g-smith-a-rcel-20250930monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-investigation-alert-bragar-eagel-squire-p-c-is-investigating-avita-medical-inc-on-be-rcel-20250925monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-alert-bragar-eagel-squire-p-c-is-investigating-avita-medical-inc-on-behalf-of-avita--rcel-20250915monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-inc-investors-company-investigated-by-the-portnoy-law-firm-rcel-20250909monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-alert-bragar-eagel-squire-p-c-is-investigating-avita-medical-inc-on-behalf-of-avita--rcel-20250908monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-inc-rcel-investors-who-lost-money-contact-law-offices-of-howard-g-smith-abou-rcel-20250903monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-inc-investors-company-investigated-by-the-portnoy-law-firm-rcel-20250828monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-alert-bragar-eagel-squire-p-c-is-investigating-avita-medical-inc-on-behalf-of-avita--rcel-20250827monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-host-investor-webinar-briefing-rcel-20250810monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-announce-second-quarter-2025-financial-results-rcel-20250728monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-highlights-largest-real-world-analysis-demonstrating-reduced-hospital-stay-w-rcel-20250609monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-first-clinical-publication-demonstrating-accelerated-autograft-rea-rcel-20250605monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-s-recell-platform-recognized-for-surgical-innovation-in-2025-medtech-breakth-rcel-20250604monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-s-acute-wound-care-showcase-2025-streams-live-today-rcel-20250513monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-host-acute-wound-care-showcase-on-may-13-2025-rcel-20250424monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-announce-first-quarter-2025-financial-results-rcel-20250417monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-present-breakthrough-clinical-data-in-burn-and-wound-care-at-aba-2025-rcel-20250409monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-launches-cohealyx-supporting-healing-and-unlocking-new-market-opportunity-rcel-20250403monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-host-investor-webinar-briefing-rcel-20250214monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-fda-approval-of-recell-go-mini-optimizing-treatment-for-smaller-wo-rcel-20241223monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-fda-510-k-clearance-for-cohealyx-expanding-its-addressable-market-rcel-20241219monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-rcel-20241218monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-exclusive-distribution-agreement-to-expand-to-australia-and-new-ze-rcel-20241112monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-host-investor-webinar-briefing-rcel-20241108monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-announce-third-quarter-2024-financial-results-rcel-20241010monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-present-at-2024-cantor-global-healthcare-conference-rcel-20240912monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-participate-in-lake-street-s-8th-annual-best-ideas-growth-big8-conference-rcel-20240910monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-host-investor-webinar-briefing-rcel-20240808monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-names-robin-vandenburgh-as-svp-of-u-s-commercial-sales-rcel-20240801monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-announce-second-quarter-2024-financial-results-rcel-20240711monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-achieves-milestone-with-first-case-using-recell-go-rcel-20240605monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-fda-approval-of-recell-go-rcel-20240530monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-host-investor-webinar-briefing-rcel-20240516monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-announce-first-quarter-2024-financial-results-rcel-20240415monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-submits-response-to-fda-resuming-review-clock-for-recell-go-pma-supplement-rcel-20240229monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-present-at-td-cowen-44th-annual-health-care-conference-rcel-20240229monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-host-investor-webinar-briefing-rcel-20240223monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-announce-fourth-quarter-and-full-year-2023-financial-results-rcel-20240201monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-exclusive-distribution-agreement-with-stedical-scientific-rcel-20240110monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-rcel-20240104monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-host-investor-webinar-briefing-rcel-20231204monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-present-at-the-piper-sandler-35th-annual-healthcare-conference-rcel-20231121monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-updates-full-year-2023-guidance-rcel-20231120monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-distribution-partnership-with-polymedics-innovations-to-expand-to--rcel-20231109monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-announce-third-quarter-2023-financial-results-rcel-20231019monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-receives-best-product-award-at-the-american-association-for-the-surgery-of-t-rcel-20230925monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-present-at-the-cantor-global-healthcare-conference-rcel-20230921monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-participate-in-upcoming-investor-conferences-rcel-20230906monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-host-investor-webinar-briefing-rcel-20230814monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-announce-second-quarter-2023-financial-results-rcel-20230720monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-submits-fda-pma-supplement-for-recell-go-rcel-20230629monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-rejoins-the-russell-3000-index-rcel-20230626monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-fda-approval-of-recell-for-skin-repigmentation-in-vitiligo-patient-rcel-20230616monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-fda-approval-of-recell-for-treatment-of-full-thickness-skin-defect-rcel-20230608monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-host-investor-webinar-briefing-rcel-20230515monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-update-to-automation-device-rcel-20230413monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-present-at-the-td-cowen-43rd-annual-health-care-conference-rcel-20230302monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-host-investor-webinar-briefing-rcel-20230227monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-202-rcel-20230223monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-results-of-2022-annual-meeting-of-stockholders-rcel-20221213monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-submits-fda-pma-supplement-to-further-expand-indication-to-soft-tissue-repai-rcel-20221212monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-present-at-the-piper-sandler-34th-annual-healthcare-conference-rcel-20221121monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-host-investor-webinar-briefing-rcel-20221117monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-achievement-of-co-primary-endpoints-in-updated-analysis-of-pivotal-rcel-20221109monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-fda-breakthrough-device-designations-for-the-recell-system-rcel-20221104monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-announce-third-quarter-2022-financial-results-rcel-20221020monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-topline-results-from-pivotal-trial-in-patients-with-soft-tissue-in-rcel-20220811monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-announce-second-quarter-2022-financial-results-rcel-20220725monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-announce-first-quarter-2022-financial-results-rcel-20220428monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-inc-signs-agreement-with-premier-inc-to-supply-the-recell-system-to-hospital-rcel-20220302monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-quarter-ending-december-31-2021-and-transition-period-july-1-2021-to-rcel-20220228monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-present-at-the-cowen-42nd-annual-health-care-conference-rcel-20220223monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-announce-transition-period-july-1-2021-to-december-31-2021-financial-resu-rcel-20220215monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-preliminary-unaudited-results-for-the-quarter-ended-december-31-20-rcel-20220110monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-completes-enrollment-in-pivotal-trial-evaluating-the-recell-system-for-soft--rcel-20220106monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-establishes-proof-of-concept-for-novel-treatments-using-genetically-modified-rcel-20220106monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-completes-enrollment-in-pivotal-trial-evaluating-the-recell-system-for-repig-rcel-20211215monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-present-at-upcoming-investor-conferences-rcel-20211116monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-expanded-medicare-reimbursement-to-outpatient-hospital-and-ambulat-rcel-20211103monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-announce-fiscal-first-quarter-2022-financial-results-rcel-20211025monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-present-at-the-2021-cantor-virtual-global-healthcare-conference-rcel-20210913monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-participate-at-the-lake-street-2021-big5-conference-rcel-20210831monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-inc-appoints-two-new-non-executive-members-to-the-board-of-directors-rcel-20210601monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-announce-fiscal-third-quarter-2021-financial-results-rcel-20210429monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-inc-announces-pricing-of-its-public-offering-of-common-stock-rcel-20210225monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-inc-announces-proposed-public-offering-of-common-stock-rcel-20210224monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-present-at-upcoming-investor-conferences-rcel-20210218monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-full-second-quarter-2021-financial-results-rcel-20210211monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-present-at-the-btig-virtual-medtech-digital-health-life-science-and-diagn-rcel-20210203monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-announce-fiscal-second-quarter-2021-financial-results-rcel-20210128monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-preliminary-fiscal-second-quarter-2021-results-rcel-20210112monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-present-at-the-j-p-morgan-39th-annual-healthcare-conference-rcel-20201228monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-therapeutics-to-participate-at-the-piper-sandler-32nd-annual-virtual-healthcare-conf-rcel-20201118monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-therapeutics-reports-first-quarter-2021-financial-results-rcel-20201110monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-therapeutics-inc-results-of-2020-annual-meeting-of-shareholders-rcel-20201110monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-therapeutics-inc-announces-executive-change-rcel-20201106monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-therapeutics-announces-date-change-for-first-quarter-2021-earnings-release-and-confe-rcel-20201103monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-therapeutics-to-participate-in-upcoming-investor-conferences-rcel-20201028monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-therapeutics-to-announce-first-quarter-2021-financial-results-rcel-20201027monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-will-host-a-conference-call-on-may-13-2026-at-8-30-am-et-to-present-q1-2026-finan-snwv-20260506monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-preliminary-q1-2026-revenue-of-9-6-9-7-million-up-3-4-year-over-ye-snwv-20260416monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-will-host-a-conference-call-on-march-27-2026-at-8-30-am-et-to-present-q4-and-full-snwv-20260320monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-q2-fy2025-financial-results-snwv-20250808monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-will-host-a-conference-call-on-august-8-2025-at-8-30-am-et-to-present-q2-2025-fin-snwv-20250804monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-preliminary-revenue-results-for-the-second-quarter-2025-ended-ju-snwv-20250714monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-selected-for-inclusion-in-russell-2000-index-snwv-20250528monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-appoints-greg-bazar-to-board-of-directors-snwv-20250528monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-q1-fy2025-financial-results-snwv-20250509monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-will-host-a-conference-call-on-may-9-2025-at-8-30-am-et-to-present-q1-2025-financ-snwv-20250505monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-preliminary-revenue-results-for-the-first-quarter-2025-ended-mar-snwv-20250408monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-uplist-to-the-nasdaq-global-market-snwv-20250304monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-participate-in-37th-annual-roth-conference-snwv-20250219monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-will-host-a-conference-call-on-november-8-2024-at-8-30-am-et-to-present-q3-financ-snwv-20241104monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-reverse-stock-split-note-and-warrant-exchange-and-pipe-offering-snwv-20241018monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-1-for-375-reverse-stock-split-snwv-20241016monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-will-host-a-conference-call-on-august-13-2024-at-8-30-am-et-to-present-q2-financi-snwv-20240807monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-preliminary-revenue-results-for-the-first-quarter-2024-ended-mar-snwv-20240410monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-record-q4-and-fy2023-revenue-snwv-20240322monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-will-host-a-conference-call-on-march-22-2024-at-8-30-am-et-to-present-the-q4-and--snwv-20240320monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-stockholder-approval-of-sepa-merger-at-special-meeting-of-stockhol-snwv-20240222monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-special-meeting-of-stockholders-to-vote-on-business-combination-with-se-snwv-20240122monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-preliminary-revenue-results-for-the-fourth-quarter-and-fiscal-ye-snwv-20240110monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-q3-2023-financial-results-snwv-20231110monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-will-host-a-conference-call-on-november-10-2023-at-8-00-am-et-to-present-the-q3-2-snwv-20231108monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-preliminary-revenue-results-for-the-third-quarter-ended-septembe-snwv-20231010monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-q2-2023-financial-results-snwv-20230811monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-will-host-a-live-conference-call-on-august-11-2023-at-8-30-am-edt-to-present-its--snwv-20230809monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-signs-distribution-agreement-with-pacific-medical-inc-snwv-20230801monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-preliminary-revenue-results-for-the-second-quarter-ended-june-30-snwv-20230717monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-q1-2023-financial-results-snwv-20230512monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-will-host-a-live-conference-call-and-webcast-may-12-2023-at-9-00-am-to-provide-a--snwv-20230511monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-attend-the-2023-symposium-on-advanced-wound-care-sawc-spring-wound-heal-snwv-20230427monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-attends-3rd-annual-leaders-in-wound-healing-conference-snwv-20230426monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-will-host-a-live-conference-call-and-webcast-april-3-2023-at-9-00-am-to-provide-a-snwv-20230330monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-commences-trading-on-the-otcqb-under-ticker-symbol-snwv-snwv-20230130monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-q3-earnings-snwv-20221114monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-s-energy-first-technology-to-be-featured-in-3-clinical-posters-at-upcoming-2022-f-snwv-20221012monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-chief-financial-officer-snwv-20220816monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-second-quarter-2022-financial-results-will-host-live-conference-ca-snwv-20220815monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-appoints-new-board-chairman-snwv-20220808monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-closes-12-million-capital-raise-snwv-20220808monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-treats-football-legend-jim-mcmahon-with-energy-first-snwv-20220722monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-business-update-june-2022-snwv-20220721monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-business-update-snwv-20220607monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-business-update-snwv-20220518monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-patent-activity-from-march-2021-to-march-2022-snwv-20220420monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-new-board-leadership-snwv-20220412monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-business-update-snwv-20220408monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-present-at-the-emerging-growth-conference-on-march-2-2022-snwv-20220301monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-host-conference-call-and-provide-business-update-snwv-20220228monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-host-conference-call-and-provide-business-update-snwv-20220118monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-host-conference-call-and-provide-business-update-snwv-20211020monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-provides-business-update-snwv-20210928monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-collaboration-with-nasa-for-the-mitigation-of-bacterial-biofilms-formed-snwv-20210729monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-present-energy-first-solutions-at-upcoming-wound-care-industry-conferen-snwv-20210416monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-expansion-of-ametus-group-distribution-partnership-snwv-20210330monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-exclusive-distribution-agreement-for-southeast-asia-with-leading-snwv-20210329monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-secures-customer-medical-device-financing-snwv-20210324monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-distribution-agreement-with-labb-solutions-snwv-20210319monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-physician-office-channel-partnership-with-docshop-pro-snwv-20210317monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-increased-reimbursement-payments-for-ultramist-and-dermapace-in-20-snwv-20201223monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-participate-in-ld-micro-main-event-xiii-snwv-20201211monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-third-quarter-2020-financial-results-snwv-20201117monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-significantly-strengthens-intellectual-property-portfolio-with-multiple-im-snwv-20201106monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-regulatory-clearance-for-dermapace-in-mexico-by-the-federal-comm-snwv-20201014monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-participate-in-multiple-u-s-wound-care-medical-meetings-in-october-snwv-20200930monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-hosts-symposium-on-dermapace-at-wounds-canada-virtual-conference-snwv-20200922monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-reimbursement-coverage-for-biovance-from-largest-medicare-and-me-snwv-20200908monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-participate-in-upcoming-september-investor-conferences-snwv-20200827monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-receives-approval-from-the-national-health-surveillance-agency-anvisa-to-m-snwv-20200824monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-to-provide-update-on-recently-acquired-wound-care-assets-snwv-20200811monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-completes-acquisition-of-the-wound-care-assets-of-celularity-snwv-20200810monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-announces-successful-results-of-annual-meeting-of-stockholders-snwv-20200724monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-to-present-at-june-2020-lytham-partners-virtual-investor-growth-conference-snwv-20200618monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-investor-live-webcast-on-wednesday-june-10-2020-snwv-20200609monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-first-quarter-2020-financial-results-snwv-20200518monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-first-quarter-financial-results-and-business-update-call-on-monday-snwv-20200515monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-deliver-dermapace-to-patients-in-the-home-setting-snwv-20200514monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-successful-filing-of-patent-for-use-of-shockwaves-to-treat-respi-snwv-20200409monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-exclusive-licensing-of-nanovibronix-inc-surface-acoustic-wave-ul-snwv-20200402monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-full-year-2019-financial-results-snwv-20200331monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-2019-annual-financial-results-and-business-update-call-on-tuesday--snwv-20200327monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-participating-at-world-union-of-wound-healing-society-wuwhs-2020-in-abu-dhabi-uae-snwv-20200220monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-appoints-dr-tom-price-to-its-board-of-directors-snwv-20200207monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-completes-offering-funding-allows-path-to-profitability-in-2020-snwv-20200206monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-appoints-divicomed-srl-as-exclusive-distributor-for-dermapace-system-in-bolivia-snwv-20200129monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-third-quarter-2019-financial-results-snwv-20191115monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-signs-distribution-partnership-with-ametus-group-setting-stage-for-rapid-expansio-snwv-20191113monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-third-quarter-2019-financial-results-and-business-update-call-on-f-snwv-20191112monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-signs-agreement-for-dermapace-system-joint-venture-in-brazil-snwv-20191107monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-successfully-completes-extensive-round-of-quality-system-and-technical-file-audit-snwv-20191030monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-launches-partnership-in-oman-snwv-20191029monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-continues-to-increase-clinical-symposia-presence-with-sawc-fall-2019-snwv-20191016monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-increases-clinical-symposia-presence-with-three-posters-at-wounds-canada-snwv-20191010monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-to-attend-a-total-of-eight-medical-conferences-in-the-fourth-quarter-of-2019-supp-snwv-20190913monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-second-quarter-2019-financial-results-snwv-20190815monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-accelerates-claims-coverage-expansion-one-year-ahead-of-expectations-due-to-recen-snwv-20190814monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-to-hold-second-quarter-2019-financial-results-and-business-update-call-on-thursda-snwv-20190813monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-new-issue-of-the-pulse-newsletter-summer-2019-snwv-20190808monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-increases-clinical-symposia-presence-with-recent-abstracts-and-posters-clinical-r-snwv-20190801monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-exhibiting-at-the-apma-2019-annual-scientific-meeting-in-salt-lake-city-utah-july-snwv-20190709monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-president-shri-parikh-receives-top-100-healthcare-leaders-award-snwv-20190621monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-second-peer-review-article-published-on-treatment-of-diabetic-foot-ulce-snwv-20190613monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-raises-guidance-for-full-year-to-110-device-placements-snwv-20190521monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-first-quarter-2019-financial-results-snwv-20190521monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-engages-alira-health-to-explore-strategic-alternatives-and-partnerships-in-snwv-20190520monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-first-quarter-2019-financial-results-and-business-update-call-on-t-snwv-20190516monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-comments-on-recent-news-and-investor-relations-promotional-activity-snwv-20190425monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-enters-the-carolinas-hires-key-representative-and-will-participate-in-the--snwv-20190423monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-provides-an-update-on-international-registrations-received-attendance-at-trade-sh-snwv-20190410monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-launches-two-studies-perfusion-and-dosing-results-expected-in-2019-snwv-20190404monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-receives-u-s-and-european-patents-for-intracorporeal-shockwave-systems-for-treati-snwv-20190402monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-record-2018-financial-results-snwv-20190329monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-2018-financial-results-and-business-update-call-on-friday-march-29-snwv-20190327monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-announces-new-issue-of-the-pulse-spring-2019-snwv-20190326monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-plans-to-attend-a-total-of-seven-medical-and-investor-conferences-in-ma-snwv-20190313monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-proud-winner-of-the-jwc-2019-innovation-in-chronic-wound-healing-award-for-dermap-snwv-20190306monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-s-letter-to-stakeholders-snwv-20190219monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-announces-a-new-shock-this-blog-regarding-an-interview-with-michael-st-snwv-20181227monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-announces-a-new-shock-this-blog-interview-with-shri-parikh-president-o-snwv-20181220monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-celebrates-prolific-success-from-increased-patent-activity-this-year-snwv-20181212monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-attendance-at-the-5th-annual-innovations-in-wound-healing-symposium-key-snwv-20181207monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-peer-review-article-published-in-journal-of-wound-care-dec-2018-extraco-snwv-20181204monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-record-third-quarter-revenue-snwv-20181120monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-third-quarter-2018-financial-results-and-business-update-call-on-t-snwv-20181114monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-exhibition-at-fall-sawc-2018-including-a-poster-and-three-presentations-snwv-20181017monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-s-chairman-and-ceo-kevin-richardson-returns-to-uptick-newswire-s-stock-snwv-20180821monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-second-quarter-2018-financial-results-and-business-update-call-on--snwv-20180801monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-dfu-joint-investigational-partnership-with-hypermed-snwv-20180711monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-third-quarter-attendance-at-eight-medical-conferences-snwv-20180628monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-signs-mou-for-exclusive-joint-venture-with-fks-in-southeast-asia-snwv-20180626monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-signs-joint-venture-partnership-with-tarbaca-for-3-countries-in-central-america-snwv-20180626monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-hires-shri-parikh-as-president-for-global-healthcare-division-snwv-20180604monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-first-quarter-financial-results-and-provides-a-business-update-snwv-20180516monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-first-quarter-2018-financial-results-and-business-update-call-on-w-snwv-20180515monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-ambiensys-srl-as-distributor-for-dermapace-in-romania-snwv-20180509monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-joins-menacare-as-territory-sales-manager-for-sourcing-and-screening-of-potential-snwv-20180425monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-corporate-membership-with-wounds-canada-participation-in-the-2018-sprin-snwv-20180418monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-announces-the-eighth-shock-this-blog-snwv-20180412monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-selection-to-exhibit-in-the-new-product-showcase-at-sawc-in-charlotte-a-snwv-20180411monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-attendance-and-exhibition-at-sawc-visit-us-at-booth-number-108-snwv-20180410monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-2017-financial-results-and-provides-a-business-update-snwv-20180329monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-will-have-four-podium-presentations-as-new-clinical-research-at-ewma-in-poland-in-snwv-20180327monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-2017-financial-results-and-business-update-call-on-thursday-march--snwv-20180323monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-a-new-shock-this-blog-snwv-20180320monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-takes-next-step-in-wound-care-expansion-snwv-20180308monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-first-shipments-of-the-dermapace-system-in-the-u-s-market-snwv-20180302monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-ceo-kevin-richardson-returns-to-uptick-newswire-s-stock-day-with-evere-snwv-20180221monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-strategic-partnership-with-premier-shockwave-dermapace-enters-va-indian-snwv-20180213monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-signs-1-million-equipment-financing-line-with-nfs-leasing-snwv-20180212monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-exhibition-at-wounds-canada-2018-spring-conference-snwv-20180207monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-first-time-exhibition-at-ewma-in-poland-in-may-2018-snwv-20180202monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-receives-u-s-patent-for-the-use-of-shock-waves-in-cleaning-and-grooming-of-water--snwv-20180201monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-present-at-the-2018-bio-ceo-investor-conference-snwv-20180130monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-participate-at-2018-anti-biofilm-technologies-conference-in-washington--snwv-20180126monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-exhibition-at-sawc-commercialization-of-dermapace-has-begun-visit-us-at-snwv-20180119monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-receives-fda-de-novo-decision-to-immediately-market-the-dermapace-system-for-the--snwv-20180102monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-call-to-discuss-fda-approval-letter-on-tuesday-january-2-2018-snwv-20171229monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-third-quarter-financial-results-and-provides-a-business-update-snwv-20171120monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-host-upcoming-clinical-and-science-symposium-on-advanced-wound-care-snwv-20171116monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-third-quarter-2017-financial-results-and-business-update-call-on-t-snwv-20171113monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-host-conference-call-to-provide-update-on-international-activity-on-thu-snwv-20170925monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-attend-upcoming-symposium-on-advanced-wound-care-sawc-snwv-20170921monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-second-quarter-financial-results-and-provides-a-business-update-snwv-20170814monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-second-quarter-2017-financial-results-and-business-update-call-on--snwv-20170811monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-extension-of-healthtronics-promissory-notes-snwv-20170803monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-issues-a-new-shock-this-blog-snwv-20170802monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-announces-the-latest-shock-this-blog-snwv-20170627monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-appoints-maj-britt-kaltoft-to-its-board-of-directors-extensive-internation-snwv-20170616monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-appoints-colonel-dr-patrick-sesto-to-its-medical-and-science-advisory-boar-snwv-20170615monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-present-at-the-2017-marcum-microcap-conference-snwv-20170612monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-announces-the-third-installment-of-shock-this-blog-snwv-20170607monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-shock-wave-scientific-program-in-milan-italy-conducted-by-medica-snwv-20170523monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-first-quarter-financial-results-and-provides-a-business-update-snwv-20170516monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-first-quarter-2017-financial-results-and-business-update-call-on-t-snwv-20170512monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-record-revenue-in-2016-and-provides-a-business-update-snwv-20170404monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-2016-financial-results-and-business-update-call-on-tuesday-april-4-snwv-20170331monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-announces-latest-shock-this-blog-snwv-20170330monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-launches-shock-this-blog-snwv-20170223monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-achieves-high-end-of-revenue-guidance-for-q4-2016-snwv-20170126monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-issued-u-s-patent-for-a-shock-wave-applicator-construction-with-movable-electrode-snwv-20170124monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-receives-its-first-canadian-patent-for-the-energy-industry-regarding-the-use-of-s-snwv-20160915monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-record-year-to-date-order-book-for-orthopace-and-dermapace-up-280--snwv-20160830monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-second-quarter-financial-results-and-provides-a-business-update-snwv-20160815monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-submits-de-novo-petition-for-fda-review-and-classification-of-the-dermapac-snwv-20160811monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-second-amendment-and-extension-of-promissory-notes-snwv-20160805monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-second-quarter-2016-financial-results-and-business-update-call-on--snwv-20160801monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-showcase-its-shock-wave-technology-at-the-2016-biofilm-science-and-tech-snwv-20160718monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-first-quarter-financial-results-and-provides-a-business-update-snwv-20160517monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-first-quarter-2016-financial-results-and-business-update-call-on-m-snwv-20160506monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-2015-financial-results-and-provides-a-business-update-snwv-20160330monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-receives-u-s-patent-for-novel-electrode-design-to-increase-useful-life-of-electro-snwv-20160329monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-24-week-data-from-its-pivotal-trials-investigating-the-use-of-dermapace-snwv-20160324monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-receives-u-s-patent-for-special-reflectors-used-for-applying-pressure-shock-waves-snwv-20160317monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-attend-upcoming-trade-shows-and-medical-conferences-snwv-20160316monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-2015-financial-results-and-business-update-call-on-thursday-march--snwv-20160315monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-closes-1-5-million-equity-offering-snwv-20160314monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-provides-positive-fourth-quarter-business-update-snwv-20151215monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-appoints-lisa-sundstrom-as-chief-financial-officer-snwv-20151214monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-third-quarter-financial-results-and-provides-a-business-update-snwv-20151112monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-third-quarter-2015-financial-results-and-business-update-call-on-f-snwv-20151105monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-present-at-the-2015-seethruequity-microcap-investor-forum-snwv-20151103monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-releases-dermapace-clinical-trial-top-line-data-and-preliminary-data-analy-snwv-20151008monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-present-at-the-2015-aegis-growth-conference-snwv-20151001monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-receives-u-s-patent-for-cleaning-and-tenderizing-animal-meat-with-shock-waves-snwv-20150930monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-dermapace-clinical-trial-update-conference-call-on-thursday-octobe-snwv-20150929monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-receives-u-s-patent-for-cleaning-and-sterilization-of-harvested-tissue-for-implan-snwv-20150924monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-letter-to-shareholders-snwv-20150917monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-present-at-the-singular-research-10th-annual-uncovereds-investor-confer-snwv-20150915monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-present-at-the-rodman-renshaw-17th-annual-global-investment-conference-snwv-20150908monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-present-at-upcoming-financial-conferences-snwv-20150904monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-second-quarter-financial-results-and-provides-a-business-update-snwv-20150811monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-second-quarter-2015-financial-results-and-business-update-call-on--snwv-20150806monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-shareholders-approve-proposal-to-amend-articles-of-incorporation-snwv-20150730monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-encourages-stockholders-to-vote-on-proposal-to-amend-articles-of-incorpora-snwv-20150727monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-cfo-transition-snwv-20150720monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-presents-results-showing-effectiveness-of-its-shock-wave-technology-for-bi-snwv-20150716monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-showcase-its-shock-wave-technology-at-the-2015-biofilm-science-and-tech-snwv-20150708monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-provides-an-update-on-the-dermapace-clinical-trial-snwv-20150630monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-present-at-the-2015-landmark-venture-forum-snwv-20150629monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-dermapace-clinical-trial-update-conference-call-on-tuesday-june-30-snwv-20150625monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-receives-its-first-u-s-patent-for-the-energy-industry-regarding-the-use-of-shock--snwv-20150623monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-present-at-upcoming-financial-conferences-snwv-20150514monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-first-quarter-financial-results-and-provides-a-business-update-snwv-20150506monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-provides-an-update-on-the-dermapace-clinical-trial-snwv-20150506monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-first-quarter-2015-financial-results-conference-call-on-thursday-m-snwv-20150504monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-2014-financial-results-and-provides-a-business-update-snwv-20150303monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-2014-financial-results-and-business-update-call-on-wednesday-march-snwv-20150226monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-receives-u-s-patent-for-medical-treatment-systems-that-select-and-use-the-proper--snwv-20150225monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-signs-memoranda-of-understanding-with-dasman-diabetes-institute-and-kuwait-snwv-20141202monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-enrolls-130th-patient-in-its-dermapace-clinical-trial-treating-diabetic-foot-ulce-snwv-20141201monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-third-quarter-financial-results-and-provides-a-business-update-snwv-20141112monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-third-quarter-2014-financial-results-conference-call-on-thursday-n-snwv-20141106monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-receives-information-from-the-data-monitoring-committee-on-the-dermapace-c-snwv-20140910monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-present-at-upcoming-financial-conferences-snwv-20140827monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-second-quarter-financial-results-and-provides-a-business-update-snwv-20140806monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-second-quarter-2014-financial-results-conference-call-on-thursday--snwv-20140729monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-signs-strategic-agreement-with-premier-shockwave-to-manage-ossatron-device-snwv-20140722monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-present-at-the-newport-coast-securities-2014-national-sales-equity-conf-snwv-20140610monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-present-at-the-4th-annual-micro-cap-invitational-conference-hosted-by-l-snwv-20140530monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-present-at-the-accredited-members-spring-2014-small-cap-micro-cap-confe-snwv-20140529monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-present-at-the-third-annual-marcum-microcap-conference-snwv-20140523monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-receives-u-s-patent-for-stem-cell-treatments-using-shock-wave-technology-snwv-20140520monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-first-quarter-financial-results-and-provides-a-business-update-snwv-20140513monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-receives-u-s-patent-for-cleaning-and-sterilization-of-fluids-and-food-liquids-wit-snwv-20140512monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-present-at-upcoming-financial-conferences-snwv-20140507monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-first-quarter-2014-financial-results-and-business-update-conferenc-snwv-20140506monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-enrolls-90th-patient-in-its-dermapace-clinical-trial-treating-diabetic-foot-ulcer-snwv-20140430monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-executive-changes-snwv-20140421monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-2013-financial-results-and-business-update-conference-call-on-tues-snwv-20140326monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-closes-10-1m-private-placement-led-by-ra-capital-management-snwv-20140318monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-agreement-for-licensing-and-distribution-for-gulf-cooperation-council-g-snwv-20140211monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-provides-update-on-patient-enrollment-over-75-now-enrolled-in-pivotal-dermapace-c-snwv-20140129monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-reports-third-quarter-2013-financial-results-snwv-20131112monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-to-hold-third-quarter-financial-results-conference-call-on-tuesday-november-12-snwv-20131107monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-receives-u-s-patent-for-new-type-of-applicators-used-for-shock-wave-technology-snwv-20131017monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-provides-update-on-patient-enrollment-in-pivotal-dermapace-clinical-trial-snwv-20131008monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-s-orthopace-medical-device-receives-regulatory-approval-in-south-korea-snwv-20130910monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-appoints-life-sciences-industry-executive-alan-l-rubino-to-its-board-snwv-20130904monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-reports-second-quarter-2013-financial-results-snwv-20130814monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-to-hold-second-quarter-financial-results-conference-call-on-thursday-august-15-snwv-20130813monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-conversion-of-all-senior-secured-notes-snwv-20130805monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-closes-public-offering-snwv-20130725monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-s-pace-technology-protects-tissue-from-ischemia-reperfusion-injury-common-in-micr-snwv-20130715monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-s-pace-data-to-be-presented-at-the-2013-world-congress-of-microsurgery-snwv-20130710monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-enrolls-first-diabetic-foot-ulcer-patient-in-the-dermapace-clinical-trial-snwv-20130605monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-reports-first-quarter-2013-financial-results-snwv-20130514monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-completes-investigator-meeting-snwv-20130513monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-appoints-daniel-m-jorgensen-as-chief-medical-officer-snwv-20130501monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-receives-u-s-patent-to-sterilize-blood-using-its-shock-wave-technology-snwv-20130411monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-2012-financial-results-and-provides-business-update-snwv-20130326monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-dermapace-regulatory-approval-and-distribution-agreement-in-australia-a-snwv-20130326monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-to-hold-2012-financial-results-and-business-update-conference-call-on-wedn-snwv-20130321monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-the-appointment-of-ceo-and-closing-of-its-2-0-million-bridge-fin-snwv-20130226monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-reports-third-quarter-2012-financial-results-snwv-20121114monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-executive-changes-and-funding-update-snwv-20121107monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-reports-second-quarter-2012-financial-results-and-provides-a-business-update-snwv-20120808monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-to-hold-second-quarter-2012-financial-results-conference-call-on-thursday-august--snwv-20120806monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-reports-first-quarter-financial-results-and-provides-business-updates-gnlx-20260507monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-reports-fourth-quarter-and-full-year-2025-financial-results-and-provid-gnlx-20260319monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-reports-second-quarter-2025-financial-results-and-provides-general-bus-gnlx-20250807monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-reports-first-quarter-2025-financial-results-and-provides-general-busi-gnlx-20250506monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-reports-fourth-quarter-and-full-year-2024-financial-results-and-provid-gnlx-20250328monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-announces-new-chief-financial-officer-gnlx-20250203monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-to-participate-in-a-fireside-chat-with-h-c-wainwright-gnlx-20241213monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-reports-third-quarter-2024-financial-results-and-provides-general-busi-gnlx-20241114monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-to-participate-in-fireside-chat-at-the-guggenheim-inaugural-healthcare-gnlx-20241106monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-announces-first-patient-dosed-in-phase-2-trial-evaluating-systemic-the-gnlx-20241022monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-to-participate-in-the-2024-maxim-healthcare-virtual-summit-gnlx-20241009monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-to-present-at-the-h-c-wainwright-global-investment-conference-gnlx-20240903monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-reports-second-quarter-2024-financial-results-and-provides-general-bus-gnlx-20240814monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-to-participate-in-fireside-chat-at-btig-s-virtual-biotechnology-confer-gnlx-20240730monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-announces-pricing-of-approximately-27-5-million-underwritten-offering--gnlx-20240524monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-announces-proposed-public-offering-of-common-stock-and-warrants-gnlx-20240523monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-reports-first-quarter-2024-financial-results-and-provides-general-busi-gnlx-20240509monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-reports-fourth-quarter-and-full-year-2023-financial-results-and-provid-gnlx-20240401monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-receives-fda-fast-track-designation-for-olvi-vec-in-platinum-resistant-gnlx-20231127monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-reports-third-quarter-2023-financial-results-and-provides-general-busi-gnlx-20231114monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-gnlx-20230914monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-to-present-at-the-h-c-wainwright-global-investment-conference-gnlx-20230907monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-announces-new-chief-financial-officer-gnlx-20230828monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-reports-second-quarter-2023-financial-results-and-provides-general-bus-gnlx-20230814monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-to-participate-in-fireside-chat-at-btig-s-virtual-biotechnology-confer-gnlx-20230802monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-strengthens-senior-management-and-clinical-team-with-promotions-and-ne-gnlx-20230720monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-announces-publication-of-phase-i-trial-results-of-intrapleural-adminis-gnlx-20230710monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-and-tvax-biomedical-inc-announce-the-issuance-of-a-united-states-paten-gnlx-20230629monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-set-to-join-the-russell-3000-and-russell-2000-indexes-effective-june-2-gnlx-20230622monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-announces-18-million-private-placement-gnlx-20230612monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-announces-publication-of-positive-topline-data-from-phase-2-viro-15-tr-gnlx-20230525monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-announces-33-million-private-placement-gnlx-20230515monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-to-ring-nasdaq-opening-bell-on-march-29-2023-gnlx-20230323monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-announces-pricing-of-initial-public-offering-gnlx-20230126monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-initiates-a-pivotal-phase-3-trial-evaluating-olvi-vec-for-the-treatmen-gnlx-20220921monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-initiates-two-clinical-trials-of-gl-onc1-in-ovarian-cancer-and-solid-organ-cancers-gnlx-20160728monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-announces-promising-data-from-two-phase-i-trials-of-gl-onc1-in-head-neck-cancer-an-gnlx-20150527monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-to-present-posters-supporting-lead-oncolytic-viral-therapy-gl-onc1-at-asco-annual--gnlx-20150512monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-appoints-george-vandeman-and-thomas-zindrick-to-board-of-directors-gnlx-20140528monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-announces-former-amgen-and-abbott-executives-to-succeed-founder-aladar-gnlx-20140512monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-ceo-dr-aladar-a-szalay-to-give-a-keynote-lecture-at-the-8th-internatio-gnlx-20140408monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-appoints-john-d-prunty-chief-financial-officer-gnlx-20140211monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-appoints-stefan-m-manth-md-as-president-ceo-genelux-europe-gnlx-20130627monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-presents-abstracts-at-2013-asco-annual-meeting-for-clinical-trials-of--gnlx-20130530monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-announces-early-results-of-a-phase-i-ii-clinical-trial-of-virotherapeu-gnlx-20121101monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-announces-ground-breaking-clinical-study-evaluating-oncolytic-vaccinia-gnlx-20120628monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-announces-first-patient-dosed-in-phase-i-combination-clinical-trial-of-gnlx-20120614monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-announces-treatment-of-first-patient-in-phase-i-ii-clinical-trial-of-g-gnlx-20120531monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-announces-phase-i-data-presentation-at-2012-asco-annual-meeting-of-gl--gnlx-20120530monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-november-5-agen-20241030monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-agen-20241029monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-inc-nasdaq-agen-deadline-alert-bernstein-liebhard-llp-reminds-agenus-inc-investors--agen-20241028monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-inc-sued-for-securities-law-violations-contact-the-gross-law-firm-before-november-5-agen-20241023monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-inc-nasdaq-agen-deadline-alert-bernstein-liebhard-llp-reminds-agenus-inc-investors--agen-20241021monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-inc-nasdaq-agen-deadline-alert-bernstein-liebhard-llp-reminds-agenus-inc-investors--agen-20241014monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm--agen-20241008monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-inc-nasdaq-agen-deadline-alert-bernstein-liebhard-llp-reminds-agenus-inc-investors--agen-20241007monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-inc-class-action-reminder-agen-stockholders-with-large-losses-they-should-contact-s-agen-20240930monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-inc-nasdaq-agen-deadline-alert-bernstein-liebhard-llp-reminds-agenus-inc-investors--agen-20240930monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-inc-nasdaq-agen-deadline-alert-bernstein-liebhard-llp-reminds-agenus-inc-investors--agen-20240923monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-november-5-202-agen-20240919monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-inc-nasdaq-agen-deadline-alert-bernstein-liebhard-llp-reminds-agenus-inc-investors--agen-20240916monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-befo-agen-20240916monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed--agen-20240912monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-inc-nasdaq-agen-investor-alert-investors-with-large-losses-in-agenus-inc-should-con-agen-20240909monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-november-5-agen-20240909monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-participate-at-5th-annual-evercore-isi-healthconx-conference-agen-20221116monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-data-at-sitc-2022-highlight-durable-responses-of-botensilimab-balstilimab-combinati-agen-20221114monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-provides-corporate-update-and-third-quarter-2022-financial-report-agen-20221108monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-provide-corporate-update-and-third-quarter-2022-financial-report-agen-20221025monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-host-the-road-taken-r-d-event-on-november-12-2022-agen-20221005monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-present-botensilimab-data-at-a-plenary-session-of-the-society-for-immunotherapy--agen-20221005monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-initiates-botensilimab-phase-2-activate-trials-in-advanced-mss-colorectal-cancer-an-agen-20220912monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-makes-senior-regulatory-and-clinical-appointments-agen-20220912monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-provides-corporate-update-and-second-quarter-2022-financial-report-agen-20220809monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-participate-at-btig-biotechnology-conference-agen-20220802monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-first-patient-dosed-in-phase-1-study-of-agen1571-anti-ilt2-in-advanced-so-agen-20220801monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-provide-corporate-update-and-second-quarter-2022-financial-report-agen-20220727monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-participate-at-william-blair-s-biotech-focus-conference-agen-20220630monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-shows-unprecedented-activity-for-botensilimab-balstilimab-combination-in-microsatel-agen-20220629monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-host-investor-webcast-to-review-late-breaking-botensilimab-and-balstilimab-data--agen-20220621monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-advances-portfolio-with-6-clinical-collaborations-agen-20220531monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-virtual-annual-shareholders-meeting-agen-20220525monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-participate-at-jefferies-healthcare-conference-agen-20220525monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-late-breaking-oral-presentation-at-esmo-gi-and-strategies-to-advance-bote-agen-20220524monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-corporate-update-and-first-quarter-2022-financial-report-agen-20220510monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-provide-corporate-update-and-first-quarter-2022-financial-report-agen-20220426monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-presents-data-on-agen1571-anti-ilt2-at-aacr-and-announces-ind-clearance-agen-20220408monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-cd137-agonist-agen2373-advances-in-the-clinic-triggering-milestone-payment-from-gil-agen-20220405monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-provide-corporate-update-and-fourth-quarter-full-year-2021-financial-report-agen-20220215monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-participate-at-upcoming-investor-conferences-agen-20220105monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-participate-in-4th-annual-evercore-isi-healthconx-conference-agen-20211117monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-participate-in-fireside-chat-at-the-b-riley-fall-2021-growth-biotech-best-ideas--agen-20211109monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-corporate-update-and-third-quarter-2021-financial-report-agen-20211109monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-participate-in-webcast-hosted-by-william-blair-to-discuss-agen1181-clinical-data-agen-20211104monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-provide-corporate-update-and-third-quarter-2021-financial-report-agen-20211025monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-provides-update-on-balstilimab-development-agen-20211022monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-receive-20m-milestone-payment-from-bristol-myers-squibb-with-dosing-of-first-pat-agen-20211012monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-present-agen1181-clinical-data-at-sitc-agen-20211001monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-participate-in-september-investor-conferences-agen-20210909monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-corporate-update-and-second-quarter-2021-financial-report-agen-20210809monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021-agen-20210802monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-provide-corporate-update-and-second-quarter-2021-financial-report-agen-20210726monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-acquires-120-acres-in-the-heart-of-the-california-biomanufacturing-center-in-vacavi-agen-20210709monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-fo-agen-20210707monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-closes-200m-upfront-bms-collaboration-and-announces-fda-acceptance-of-ind-for-partn-agen-20210706monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-participate-in-the-raymond-james-2021-human-health-innovation-conference-agen-20210621monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-u-s-fda-acceptance-and-priority-review-of-balstilimab-biologics-license-a-agen-20210617monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-virtual-annual-shareholders-meeting-agen-20210615monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-presentations-at-asco-2021-demonstrate-differentiated-activity-of-balstilimab-and-p-agen-20210604monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-participate-in-fireside-chat-at-the-jefferies-2021-virtual-healthcare-conference-agen-20210601monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-presents-new-data-on-balstilimab-and-agen2373-in-asco-abstracts-agen-20210520monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-host-conference-call-to-discuss-global-licensing-agreement-with-bristol-myers-sq-agen-20210518monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-corporate-update-and-first-quarter-2021-financial-report-agen-20210506monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-present-at-the-2021-asco-annual-meeting-agen-20210428monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-provide-corporate-update-and-first-quarter-2021-financial-report-agen-20210422monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-submits-balstilimab-biologics-license-application-to-the-u-s-fda-for-patients-with--agen-20210419monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-doses-first-cancer-patient-with-inkt-cell-therapy-agen-20210414monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-participate-in-webcast-hosted-by-william-blair-on-agen1181-and-balstilimab-aacr--agen-20210406monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-corporate-update-and-fourth-quarter-full-year-2020-financial-report-agen-20210315monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-present-new-clinical-data-on-agen1181-at-aacr-2021-agen-20210310monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-provide-corporate-update-and-fourth-quarter-full-year-2020-financial-report-agen-20210302monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-agenus-insights-virtual-r-d-miniseries-agen-20210209monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-new-responses-for-agen1181-agen-20210209monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-positive-preliminary-results-of-inkt-cell-therapy-trial-in-covid-19-agen-20210204monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-enters-into-clinical-collaboration-with-nelum-for-zalifrelimab-combination-agen-20210126monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-participate-in-b-riley-securities-oncology-investor-conference-agen-20210119monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-launches-phase-2-trial-expansion-in-colon-cancer-for-agen1181-in-combination-with-b-agen-20201201monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference-agen-20201125monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-participate-in-fireside-chat-at-the-jefferies-2020-virtual-london-healthcare-con-agen-20201117monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-and-dr-steven-o-day-to-participate-in-webcast-hosted-by-william-blair-on-agen1181-a-agen-20201113monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-and-dr-steven-o-day-to-participate-in-panels-at-the-virtual-sitc-2020-immuno-oncolo-agen-20201112monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-presents-additional-clinical-responses-and-novel-biomarker-data-at-sitc2020-agen-20201109monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-doses-first-covid-19-patient-with-inkt-cell-therapy-agen-20201102monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-r-d-update-third-quarter-financial-report-agen-20201029monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-report-third-quarter-earnings-agen-20201020monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-present-on-seven-novel-programs-at-sitc-2020-agen-20201014monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-initiates-rolling-bla-submission-of-balstilimab-for-recurrent-metastatic-cervical-c-agen-20200918monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-presents-results-from-two-large-cervical-cancer-trials-at-esmo-agen-20200918monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-participate-in-webcast-hosted-by-william-blair-on-esmo2020-results-and-novel-pip-agen-20200917monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-second-quarter-2013-financial-results-agen-20130725monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-report-second-quarter-2013-financial-results-on-july-25-2013-conference-call-to--agen-20130718monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-present-at-the-jmp-securities-annual-healthcare-conference-agen-20130702monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-webcast-annual-shareholders-meeting-agen-20130610monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-initiation-of-enrollment-in-nci-sponsored-randomized-trial-of-prophage-g--agen-20130522monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-first-quarter-2013-financial-results-agen-20130424monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-report-first-quarter-2013-financial-results-on-april-24-2013-conference-call-to--agen-20130418monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-eliminates-its-39-million-senior-notes-and-completes-10-million-of-new-debt-financi-agen-20130416monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-brain-cancer-vaccine-results-to-be-presented-at-plenary-session-of-the-81st-america-agen-20130410monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-present-at-the-roth-annual-conference-agen-20130314monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-fourth-quarter-and-year-end-2012-financial-results-agen-20130228monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-herpv-phase-2-study-to-treat-genital-herpes-completes-enrollment-agen-20130227monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-present-at-cowen-and-company-annual-healthcare-conference-agen-20130226monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-report-fourth-quarter-and-year-end-2012-financial-results-on-february-28-2013-co-agen-20130221monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-present-at-bio-ceo-investor-conference-agen-20130206monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-present-at-onemedforum-san-francisco-2013-agen-20130102monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-present-at-windhover-s-therapeutic-area-partnerships-conference-agen-20121126monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-third-quarter-2012-financial-results-agen-20121025monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-commences-phase-2-study-of-herpv-vaccine-for-the-treatment-of-genital-herpes-agen-20121023monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-report-3rd-quarter-financial-results-on-october-25-2012-conference-call-to-follo-agen-20121018monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-present-at-3rd-annual-cancer-immunotherapy-conference-agen-20120928monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-present-at-the-newsmakers-in-the-biotech-industry-conference-and-the-rodman-rens-agen-20120904monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-publication-of-key-data-showing-antitumor-activity-of-prophage-vaccine-hs-agen-20120808monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-second-quarter-2012-financial-results-agen-20120802monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-report-2nd-quarter-financial-results-on-august-2-2012-conference-call-to-follow-agen-20120726monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-join-russell-3000-index-global-index-and-microcap-index-agen-20120618monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-webcast-2012-annual-shareholders-meeting-agen-20120601monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-first-quarter-2012-financial-results-and-corporate-updates-agen-20120425monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-brain-cancer-vaccine-phase-2-study-to-be-presented-at-plenary-session-of-the-80th-a-agen-20120402monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-fourth-quarter-and-year-end-2011-financial-results-and-corporate-updates-agen-20120305monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-expands-qs-21-license-and-grants-right-of-first-negotiation-to-glaxosmithkline-agen-20120305monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-present-at-the-2012-cowen-health-care-conference-agen-20120301monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-report-fourth-quarter-and-year-end-2011-financial-results-on-march-5-2012-confer-agen-20120229monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-present-at-bio-ceo-investor-conference-agen-20120206monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-present-at-onemedforum-san-francisco-2012-agen-20120104monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-and-chemrar-enter-into-agreement-in-the-area-of-personalized-cancer-vaccines-agen-20111219monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-vaccine-for-brain-cancer-highlighted-at-current-state-of-the-art-session-at-the-ann-agen-20111116monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-third-quarter-2011-financial-results-and-corporate-updates-agen-20111027monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-report-third-quarter-financial-results-on-october-27-2011-conference-call-to-fol-agen-20111020monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-present-at-newsmakers-in-the-biotech-industry-conference-agen-20111018monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-compliant-with-nasdaq-listing-requirements-agen-20111017monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-stock-symbol-to-revert-back-to-agen-agen-20111011monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-present-at-second-annual-cancer-immunotherapy-a-long-awaited-reality-conference-agen-20111003monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-reverse-stock-split-agen-20110930monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-present-at-jmp-securities-healthcare-conference-agen-20110922monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-present-at-rodman-renshaw-annual-global-investment-conference-agen-20110909monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-prices-at-market-underwritten-offering-of-common-stock-agen-20110811monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-second-quarter-2011-financial-results-and-corporate-updates-agen-20110728monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-report-second-quarter-financial-results-on-july-28-2011-conference-call-to-follo-agen-20110721monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-herpes-study-results-presented-at-bio-international-convention-show-robust-immune-r-agen-20110627monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-qs-21-stimulon-r-adjuvant-selected-for-biodefense-program-agen-20110614monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-webcast-2011-annual-shareholders-meeting-agen-20110601monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-investor-briefing-at-the-american-society-of-clinical-oncology-asco-2011--agen-20110524monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-first-quarter-2011-financial-results-agen-20110428monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-report-first-quarter-financial-results-on-april-28-2011-conference-call-to-follo-agen-20110421monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-receives-nasdaq-delisting-notification-agen-20110304monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-present-at-the-31st-annual-cowen-and-company-health-care-conference-agen-20110302monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-restructures-its-remaining-convertible-notes-agen-20110224monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-fourth-quarter-and-year-end-2010-financial-results-agen-20110217monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-report-fourth-quarter-and-year-end-2010-financial-results-on-february-17-2011-co-agen-20110210monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-research-collaboration-with-memorial-sloan-kettering-cancer-center-agen-20110124monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-regains-compliance-with-nasdaq-listing-requirements-agen-20110114monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-participate-in-jefferies-global-healthcare-conference-bdtx-20260522monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corp-bdtx-20250807monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-reports-first-quarter-2025-financial-results-and-provides-corpo-bdtx-20250512monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-bdtx-20250331monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-bdtx-20250306monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corpo-bdtx-20241105monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-bdtx-20241101monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-host-webcast-presentation-of-initial-phase-2-bdtx-1535-data--bdtx-20240922monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-presents-real-world-treatment-practices-and-patient-outcomes-in-bdtx-20240914monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corp-bdtx-20240806monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-presents-promising-bdtx-1535-clinical-data-in-patients-with-rec-bdtx-20240601monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-participate-in-jefferies-global-healthcare-conference-bdtx-20240529monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-reports-first-quarter-2024-financial-results-and-provides-corpo-bdtx-20240509monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-presentations-at-the-2024-american-society-of-clinica-bdtx-20240424monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-presents-novel-real-world-evidence-of-the-evolving-egfr-mutatio-bdtx-20240407monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-bdtx-20240403monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-bdtx-20240312monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-upcoming-presentation-at-aacr-annual-meeting-2024-bdtx-20240305monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-participate-in-the-td-cowen-44th-annual-health-care-conferen-bdtx-20240228monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-bdtx-20231107monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-reports-third-quarter-2023-financial-results-and-provides-corpo-bdtx-20231106monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-presents-dose-escalation-data-demonstrating-durable-responses-i-bdtx-20231014monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-preclinical-and-clinical-data-at-the-aacr-nci-eortc--bdtx-20231004monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-first-patients-dosed-in-phase-1-clinical-trial-expans-bdtx-20230911monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-bdtx-20230905monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-reports-second-quarter-2023-financial-results-and-provides-corp-bdtx-20230811monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-pricing-of-public-offering-of-common-stock-bdtx-20230630monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-proposed-public-offering-of-common-stock-bdtx-20230628monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-promotion-of-melanie-morrison-to-chief-development-of-bdtx-20230613monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-at-the-jefferies-healthcare-conference-bdtx-20230602monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corpo-bdtx-20230509monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-at-the-stifel-2023-targeted-oncology-days-bdtx-20230418monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-presents-trial-in-progress-poster-for-bdtx-1535-and-preclinical-bdtx-20230417monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-bdtx-20230309monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-at-the-cowen-43rd-annual-health-care-conference-bdtx-20230227monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-bdtx-20230105monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-bdtx-20221109monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-reports-third-quarter-2022-financial-results-and-provides-corpo-bdtx-20221108monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-presents-preclinical-data-on-bdtx-1535-and-bdtx-4933-at-the-34t-bdtx-20221026monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-bdtx-20220906monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-reports-second-quarter-2022-financial-results-and-provides-corp-bdtx-20220809monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-at-the-2022-wedbush-pacgrow-healthcare-virtual-confe-bdtx-20220803monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-bdtx-20220606monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-appoints-sergey-yurasov-m-d-ph-d-as-chief-medical-officer-bdtx-20220601monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-at-the-h-c-wainwright-global-investment-conference-bdtx-20220517monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-publication-of-new-computational-and-functional-analy-bdtx-20220512monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-reports-first-quarter-2022-financial-results-and-provides-corpo-bdtx-20220511monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-first-patient-dosed-in-phase-1-study-of-bdtx-1535-a-m-bdtx-20220418monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-at-the-canaccord-genuity-horizons-in-oncology-virtua-bdtx-20220407monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-bdtx-20220317monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-participate-at-the-cowen-42nd-annual-health-care-conference-bdtx-20220302monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-appoints-elizabeth-montgomery-as-chief-people-officer-bdtx-20220222monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-fda-allowance-of-ind-application-for-bdtx-1535-a-mast-bdtx-20220111monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-bdtx-20220105monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-at-upcoming-investor-conferences-bdtx-20211108monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-reports-third-quarter-2021-financial-results-and-provides-corpo-bdtx-20211108monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-presents-preclinical-data-on-bdtx-1535-braf-and-fgfr-programs-a-bdtx-20211008monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-pre-clinical-data-on-bdtx-1535-braf-and-fgfr-program-bdtx-20210930monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-at-the-2021-cantor-fitzgerald-virtual-global-healthc-bdtx-20210921monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-and-openeye-scientific-announce-collaboration-to-expand-map-dru-bdtx-20210921monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-reports-second-quarter-2021-financial-results-and-provides-corp-bdtx-20210812monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-at-upcoming-investor-conferences-bdtx-20210804monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-host-webcast-presentation-of-data-from-phase-1-dose-escalati-bdtx-20210517monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-reports-first-quarter-2021-financial-results-and-provides-corpo-bdtx-20210507monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-phase-1-bdtx-189-data-in-advanced-solid-tumors-at-am-bdtx-20210428monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-preclinical-data-presentations-on-bdtx-189-and-bdtx-1-bdtx-20210410monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-bdtx-20210325monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-pre-clinical-data-on-bdtx-189-and-bdtx-1535-at-ameri-bdtx-20210310monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-pre-clinical-data-presentations-on-new-programs-targe-bdtx-20210302monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-at-upcoming-investor-conferences-bdtx-20210223monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-bdtx-20210211monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-at-the-j-p-morgan-39th-annual-healthcare-conference-bdtx-20210105monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare--bdtx-20201124monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-provides-update-on-gbm-program-and-presents-pre-clinical-data-a-bdtx-20201120monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-at-the-jefferies-2020-virtual-london-healthcare-conf-bdtx-20201111monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-reports-third-quarter-2020-financial-results-and-provides-corpo-bdtx-20201110monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-presents-pre-clinical-data-on-lead-product-candidate-bdtx-189-a-bdtx-20201026monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-pre-clinical-data-on-lead-product-candidate-bdtx-189-bdtx-20201012monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-at-morgan-stanley-18th-annual-global-healthcare-conf-bdtx-20200910monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-the-appointment-of-rachel-humphrey-m-d-as-chief-medic-bdtx-20200908monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-reports-second-quarter-2020-financial-results-and-provides-corp-bdtx-20200811monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-at-upcoming-investor-conferences-bdtx-20200805monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-the-appointment-of-fang-ni-as-chief-business-officer-bdtx-20200804monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-granted-fast-track-designation-by-the-fda-for-bdtx-189-for-the--bdtx-20200728monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-at-the-bmo-2020-prescriptions-for-success-healthcare-bdtx-20200616monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-at-the-jefferies-virtual-healthcare-conference-bdtx-20200527monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-accepted-abstract-for-lead-product-candidate-bdtx-189-bdtx-20200513monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-reports-first-quarter-2020-financial-results-and-corporate-upda-bdtx-20200512monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-at-the-bank-of-america-global-research-health-care-c-bdtx-20200506monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and-bdtx-20200324monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-to-present-at-the-cowen-and-company-40th-annual-health-care-con-bdtx-20200224monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-closing-of-initial-public-offering-and-exercise-in-fu-bdtx-20200203monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-pricing-of-initial-public-offering-bdtx-20200130monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-to-participate-in-upcoming-investor-conferences-pyxs-20260513monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-appoints-nelson-azoulay-as-chief-business-officer-pyxs-20260507monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-to-present-new-preclinical-data-showing-synergistic-anti-tumor-activity-in--pyxs-20260417monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-to-participate-in-september-investor-and-industry-conferences-pyxs-20250821monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pyxs-20250630monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-to-participate-in-two-upcoming-investor-conferences-pyxs-20250514monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-presents-promising-preclinical-results-providing-proof-of-mechanism-of-micv-pyxs-20250425monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum-pyxs-20250402monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-to-present-new-preclinical-data-supporting-development-of-first-in-concept--pyxs-20250325monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-to-participate-at-the-leerink-partners-global-healthcare-conference-pyxs-20250303monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-announces-favorable-preliminary-pyx-201-clinical-phase-1-part-1-data-pyxs-20241120monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-to-host-in-person-nyc-and-virtual-investor-event-on-wednesday-november-20-2-pyxs-20241111monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-to-participate-in-two-upcoming-investor-conferences-pyxs-20240829monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-to-participate-in-the-btig-virtual-biotechnology-conference-pyxs-20240729monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pyxs-20240628monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-to-participate-in-a-fireside-chat-at-the-jefferies-global-healthcare-confer-pyxs-20240530monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-to-present-at-the-rbc-capital-markets-global-healthcare-conference-pyxs-20240509monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pyxs-20240328monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-to-present-at-leerink-global-biopharma-conference-2024-pyxs-20240307monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-to-present-new-pyx-201-pyx-106-and-pyx-102-preclinical-data-at-aacr-annual--pyxs-20240305monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pyxs-20231229monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-announces-four-abstracts-accepted-for-poster-presentation-at-society-for-im-pyxs-20230927monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-to-participate-in-two-upcoming-investment-conferences-pyxs-20230831monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-to-present-at-btig-virtual-biotechnology-conference-pyxs-20230801monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pyxs-20230630monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-advances-pyx-106-and-pyx-201-clinical-programs-pyxs-20230530monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-to-acquire-apexigen-pyxs-20230524monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pyxs-20230331monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-to-participate-in-the-virtual-2023-svb-securities-global-biopharma-conferen-pyxs-20230213monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pyxs-20221223monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pyxs-20220930monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-pyxs-20220712monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-to-present-at-h-c-wainwright-preclinical-cancer-drug-discovery-conference-pyxs-20220628monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-announces-presentations-at-upcoming-investor-conferences-pyxs-20220519monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-to-participate-in-fireside-chat-at-bofa-securities-2022-healthcare-conferen-pyxs-20220427monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-announces-preclinical-data-on-anti-siglec-15-bsi-060t-pyx-106-presented-by--pyxs-20220408monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-to-host-corporate-update-conference-call-and-webcast-on-march-29-2022-pyxs-20220322monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-to-be-added-to-russell-2000-index-pyxs-20211215monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-appoints-martina-molsbergen-as-interim-chief-business-officer-pyxs-20211209monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-to-present-at-the-jefferies-london-healthcare-conference-pyxs-20211110monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-announces-pricing-of-upsized-initial-public-offering-pyxs-20211008monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-appoints-jay-m-feingold-m-d-ph-d-as-chief-medical-officer-pyxs-20210914monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-strengthens-board-of-directors-pyxs-20210908monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-appoints-pamela-yanchik-connealy-as-chief-financial-officer-pyxs-20210831monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-strengthens-leadership-team-with-executive-and-scientific-advisory-board-ap-pyxs-20210608monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-presents-preclinical-data-and-details-on-antibody-drug-conjugate-candidates-pyxs-20210427monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-hosting-key-opinion-webinar-on-antibody-drug-conjugates-pyxs-20210419monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-closes-152-million-series-b-financing-to-further-advance-portfolio-of-biolo-pyxs-20210330monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-announces-worldwide-licensing-agreement-with-pfizer-to-develop-and-commerci-pyxs-20210318monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-presents-preclinical-data-on-its-plk1-inhibitor-onvansertib-in-combinatio-crdf-20260417monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-to-present-preclinical-data-with-highly-specific-plk1-inhibitor-onvansert-crdf-20260319monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-to-participate-in-three-upcoming-investor-conferences-crdf-20260226monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-confer-crdf-20260219monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-announces-clinical-data-from-investigator-sponsored-trial-with-onvanserti-crdf-20251208monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-to-present-at-sidoti-s-year-end-virtual-investor-conference-crdf-20251208monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-to-participate-in-two-upcoming-investor-conferences-crdf-20251002monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-to-participate-in-three-upcoming-investor-conferences-crdf-20250828monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-crdf-20250415monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-announces-completion-of-enrollment-in-phase-2-crdf-004-trial-evaluating-o-crdf-20250415monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-to-present-at-upcoming-investor-conferences-crdf-20250224monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update-crdf-20250220monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-announces-positive-initial-data-from-first-line-ras-mutated-mcrc-clinical-crdf-20241210monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-announces-new-patent-with-claims-for-the-use-of-onvansertib-in-treating-k-crdf-20241119monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-announces-journal-of-clinical-oncology-publication-of-data-from-phase-2-t-crdf-20241030monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-reports-second-quarter-2024-results-and-provides-business-update-crdf-20240808monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-to-report-second-quarter-2024-results-and-provide-business-update-crdf-20240801monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-to-present-at-the-jefferies-healthcare-conference-crdf-20240529monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-may-crdf-20240513monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-reports-first-quarter-2024-results-and-provides-business-update-crdf-20240502monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-to-report-first-quarter-2024-results-and-provide-business-update-crdf-20240425monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-presents-novel-preclinical-data-at-aacr-annual-meeting-2024-that-supports-crdf-20240408monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-announces-upcoming-presentations-at-the-aacr-annual-meeting-2024-crdf-20240306monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-reports-fourth-quarter-and-full-year-2023-results-and-provides-business-u-crdf-20240229monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-provides-clinical-update-on-phase-2-randomized-second-line-onsemble-trial-crdf-20240229monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-announces-first-patient-dosed-in-randomized-first-line-ras-mutated-metast-crdf-20240229monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-to-present-at-the-cowen-44th-annual-health-care-conference-crdf-20240226monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-to-report-fourth-quarter-and-full-year-2023-results-and-provide-business--crdf-20240222monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-inc-announces-peer-reviewed-publication-of-phase-2a-clinical-trial-data--coya-20220901monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-announces-peer-reviewed-publication-of-its-first-in-class-regulatory-t-c-coya-20220623monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-secures-option-agreement-for-exclusive-worldwide-rights-to-exosome-engin-coya-20220615monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-secures-10-million-financing-to-advance-clinical-and-pre-clinical-pipeli-coya-20220607monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-applauds-u-s-house-of-representatives-for-passing-act-for-als-coya-20211210monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-announces-successful-completion-of-pre-ind-meeting-with-fda-on-coya101-f-coya-20211116monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-appoints-dr-adrian-hepner-as-chief-medical-officer-and-dr-greg-macmichae-coya-20211101monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-appoints-gene-mack-as-chief-financial-officer-coya-20211012monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-to-participate-at-the-lifesci-partners-summer-symposium-coya-20210714monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-receives-orphan-drug-designation-from-the-fda-for-als001-an-autologous-t-coya-20210707monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-to-host-key-opinion-leader-webinar-on-als001-for-the-treatment-of-amyotr-coya-20210602monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-announces-the-appointment-of-anabella-villalobos-ph-d-to-its-board-of-di-coya-20210525monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-to-present-at-the-oppenheimer-rare-orphan-disease-summit-coya-20210514monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-to-present-at-the-b-riley-securities-virtual-neuroscience-conference-coya-20210427monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-announces-the-appointment-of-hideki-garren-m-d-ph-d-and-dov-goldstein-m--coya-20210414monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-announces-formation-of-scientific-advisory-board-coya-20210223monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-completes-merger-with-nicoya-health-inc-and-announces-10-million-series--coya-20210203monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-announces-closing-of-22-3-million-public-offering-of-common-stock--nrxp-20260604monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-report-full-year-2025-financial-results-and-provide-nrxp-20260319monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-confirms-path-to-new-drug-application-with-real-world-data-nrxp-20260316monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-announces-elimination-of-all-balance-sheet-debt-following--nrxp-20251218monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-to-discuss-new-nrx-101-pipeline-indication-for-augmentation-of-transcr-nrxp-20251203monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-reports-third-quarter-2025-financial-results-and-provi-nrxp-20251117monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-report-third-quarter-2025-financial-results-on-nove-nrxp-20251112monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-present-at-noble-capital-markets-october-2025-emerg-nrxp-20251006monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-re-files-abbreviated-new-drug-application-anda-for-ket-nrxp-20250929monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-receives-notification-of-us-food-and-drug-administrati-nrxp-20250924monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-to-participate-in-a-fireside-chat-at-h-c-wainwright-s-27th-nrxp-20250903monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-selected-to-present-at-the-2025-global-passion-project-nrxp-20250902monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-announces-expanded-access-policy-for-nrx-100-preservat-nrxp-20250827monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-reports-second-quarter-2025-financial-results-and-prov-nrxp-20250818monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-report-second-quarter-2025-financial-results-on-aug-nrxp-20250811monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-added-to-emerging-growth-conference-76-on-october-31-and-update-to-sch-nrxp-20241031monthly0.5https://www.biopharmawatch.com/news/NRXP/nrxp-alert-levi-korsinsky-llp-announces-an-investigation-into-the-fairness-of-nrx-pharmace-nrxp-20230718monthly0.5https://www.biopharmawatch.com/news/NRXP/nrxp-alert-levi-korsinsky-llp-announces-an-investigation-into-the-fairness-of-nrx-pharmace-nrxp-20230629monthly0.5https://www.biopharmawatch.com/news/NRXP/nrxp-deadline-today-rosen-respected-investor-counsel-encourages-nrx-pharmaceuticals-inc-in-nrxp-20220321monthly0.5https://www.biopharmawatch.com/news/NRXP/nrxp-nrxpw-deadline-did-you-suffer-a-substantial-loss-contact-johnson-fistel-about-leading-nrxp-20220228monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-reports-remarks-by-israel-institute-for-biological-research-on-the-future-of-the-brili-nrxp-20220211monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announc-nrxp-20220201monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announc-nrxp-20220125monthly0.5https://www.biopharmawatch.com/news/NRXP/nrxp-nrxpw-shareholder-alert-bronstein-gewirtz-grossman-llc-notifies-nrx-pharmaceuticals-i-nrxp-20220124monthly0.5https://www.biopharmawatch.com/news/NRXP/nrxp-alert-robbins-geller-rudman-dowd-llp-announces-that-nrx-pharmaceuticals-inc-investors-nrxp-20220123monthly0.5https://www.biopharmawatch.com/news/NRXP/nrxp-nrxpw-deadline-did-you-suffer-a-substantial-loss-contact-johnson-fistel-about-leading-nrxp-20220120monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-expansion-of-zyesami-aviptadil-us-expanded-access-and-right--nrxp-20220118monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-responds-to-relief-s-allegations-of-january-14-2022-nrxp-20220114monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-announces-planned-study-investigating-brilife-booster-vaccine-against-omicron-variant-nrxp-20220111monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-to-announce-new-details-for-planned-investigational-brilife-covid-19-v-nrxp-20220107monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceutical-s-chairman-and-chief-executive-officer-jonathan-javitt-to-present-compa-nrxp-20220107monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-added-to-the-nasdaq-biotech-index-nrxp-20211215monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-new-favorable-safety-report-for-zyesami-aviptadil-in-nih-spo-nrxp-20211214monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-and-hungarian-health-officials-agree-on-pathway-for-zyesami-and-brilif-nrxp-20211209monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-announces-completion-of-data-safety-meeting-for-phase-2-trial-of-brilife-vaccine-phase-nrxp-20211206monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-identifies-significantly-higher-likelihood-of-surviving-and-recovering-nrxp-20211129monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-notes-new-data-on-brilife-covid-19-vaccine-effectiveness-against-delta-nrxp-20211126monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-reports-third-quarter-2021-business-update-and-financial-results-nrxp-20211116monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceutical-s-chairman-and-chief-executive-officer-jonathan-javitt-to-present-compa-nrxp-20211112monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-receives-us-food-and-drug-administration-review-of-zyesami-aviptadil-m-nrxp-20211111monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-to-report-third-quarter-2021-financial-and-business-update-on-tuesday--nrxp-20211109monthly0.5https://www.biopharmawatch.com/news/NNOX/nano-x-investigation-alert-bragar-eagel-squire-p-c-is-investigating-nano-x-imaging-ltd-on--nnox-20260423monthly0.5https://www.biopharmawatch.com/news/NNOX/nano-x-deadline-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsui-nnox-20211204monthly0.5https://www.biopharmawatch.com/news/NNOX/nano-x-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-bee-nnox-20211129monthly0.5https://www.biopharmawatch.com/news/NNOX/nano-x-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-bee-nnox-20211123monthly0.5https://www.biopharmawatch.com/news/NNOX/nano-x-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-bee-nnox-20211117monthly0.5https://www.biopharmawatch.com/news/NNOX/nano-x-imaging-ltd-class-action-reminder-wolf-haldenstein-adler-freeman-herz-llp-reminds-i-nnox-20211109monthly0.5https://www.biopharmawatch.com/news/NNOX/nano-x-imaging-ltd-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-th-nnox-20211019monthly0.5https://www.biopharmawatch.com/news/NNOX/nano-x-imaging-ltd-files-2020-annual-report-on-form-20-f-nnox-20210406monthly0.5https://www.biopharmawatch.com/news/NNOX/nano-x-imaging-ltd-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-nnox-20201113monthly0.5https://www.biopharmawatch.com/news/NNOX/nano-x-imaging-ltd-portnoy-law-advises-last-days-to-participate-actively-in-the-class-acti-nnox-20201030monthly0.5https://www.biopharmawatch.com/news/NNOX/nano-x-imaging-ltd-investors-with-losses-greater-than-100-000-encouraged-to-contact-kehoe--nnox-20200923monthly0.5https://www.biopharmawatch.com/news/NNOX/nano-x-imaging-ltd-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-th-nnox-20200922monthly0.5https://www.biopharmawatch.com/news/NNOX/nano-x-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed--nnox-20200919monthly0.5https://www.biopharmawatch.com/news/NNOX/nano-x-imaging-alert-bragar-eagel-squire-p-c-is-investigating-nano-x-imaging-ltd-on-behalf-nnox-20200916monthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-blue-erection-formula-under-review-blue-salt-trick-recipe-for-nitric-boost-acog-20250515monthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-surge-under-review-what-the-ingredients-benefits-side-effects-risk-say-about-alphasu-acog-20250509monthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-drive-rx-under-review-the-alpha-drive-performance-enhancement-gummies-for-men-acog-20250506monthly0.5https://www.biopharmawatch.com/news/ACOG/alphacur-under-review-advanced-nutritional-support-for-neuropathy-nerve-health-acog-20250422monthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-tonic-under-review-himalayan-tonic-t-booster-powder-to-increase-testosterone-natural-acog-20250417monthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-bites-ingredients-under-review-best-male-enhancement-gummies-brand-on-the-market-acog-20250412monthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-bites-gummies-the-science-ingredients-and-real-user-experiences-behind-this-natural--acog-20250317monthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-bites-reviews-ingredients-studies-and-where-to-buy-acog-20250205monthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-to-present-at-the-life-science-investor-forum-march-7th-acog-20240301monthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-announces-withdrawal-of-marketed-public-offering-acog-20221128monthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-announces-marketed-offering-acog-20221117monthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-to-webcast-live-at-virtualinvestorconferences-com-june-23rd-acog-20220621monthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-announces-pricing-of-public-offering-acog-20210923monthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-announces-overnight-marketed-offering-acog-20210922monthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-to-webcast-live-at-life-sciences-investor-forum-september-16th-acog-20210909monthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-7-program-to-be-showcased-at-neuroscience-2012-acog-20121016monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-cntx-20260609monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202-cntx-20260518monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-reports-first-quarter-2026-operating-and-financial-results-cntx-20260506monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-announces-ctim-76-receives-fda-fast-track-designation-for-the-treatme-cntx-20260402monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-announces-poster-presentation-at-the-american-association-for-cancer--cntx-20260319monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cntx-20260116monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-to-participate-in-upcoming-investor-conferences-cntx-20250827monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-reports-second-quarter-2025-operating-and-financial-results-cntx-20250806monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cntx-20250512monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-reports-first-quarter-2025-operating-and-financial-results-cntx-20250507monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-announces-chief-medical-officer-transition-cntx-20250505monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-presents-preclinical-and-translational-data-for-ct-95-a-mesothelin-ta-cntx-20250430monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-ct-95-cntx-20250409monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-to-participate-in-upcoming-investor-conferences-cntx-20250401monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-announces-poster-presentation-at-the-american-association-for-cancer--cntx-20250326monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-reports-full-year-2024-operating-and-financial-results-cntx-20250320monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-cntx-20250224monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-to-participate-in-upcoming-investor-conferences-cntx-20250219monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-announces-first-patient-dosed-in-the-phase-1-clinical-trial-of-ctim-7-cntx-20250114monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-appoints-andy-pasternak-as-chairman-of-the-board-of-directors-cntx-20250113monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-reports-third-quarter-2024-operating-and-financial-results-cntx-20241106monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-to-participate-in-upcoming-investor-conferences-in-november-cntx-20241023monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-announces-poster-presentation-at-the-society-for-immunotherapy-of-can-cntx-20241016monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-appoints-dr-karen-smith-and-dr-luke-walker-to-board-of-directors-cntx-20240904monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-reports-second-quarter-2024-operating-and-financial-results-cntx-20240807monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-appoints-chief-medical-officer-and-vice-president-of-clinical-operati-cntx-20240801monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-acquires-phase-1-ready-t-cell-engager-ct-95-cntx-20240710monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-reports-first-quarter-2024-operating-and-financial-results-cntx-20240508monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-announces-fda-clearance-of-ind-application-for-a-phase-1-clinical-tri-cntx-20240502monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-announces-100-million-private-placement-cntx-20240502monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-submits-ind-application-to-evaluate-ctim-76-in-claudin-6-positive-can-cntx-20240401monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-reports-full-year-2023-operating-and-financial-results-cntx-20240321monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-reports-third-quarter-2023-operating-and-financial-results-cntx-20231109monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-announces-preclinical-data-demonstrating-differentiated-and-active-pr-cntx-20231031monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-announces-acceptance-of-abstract-to-be-presented-at-the-society-for-i-cntx-20230927monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-reports-second-quarter-2023-operating-and-financial-results-cntx-20230809monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-to-participate-in-two-august-2023-investor-conferences-cntx-20230801monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-reports-first-quarter-2023-operating-and-financial-results-cntx-20230510monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-to-participate-in-two-april-2023-investor-conferences-cntx-20230403monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-reports-full-year-2022-financial-results-and-recent-pipeline-updates-cntx-20230322monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-announces-acceptance-of-abstract-to-be-presented-at-the-american-asso-cntx-20230315monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-highlights-clinical-responses-from-the-phase-2-oath-clinical-trial-ev-cntx-20230206monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-clinical-partner-stemline-therapeutics-a-subsidiary-of-menarini-group-cntx-20230131monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-and-lonza-enter-manufacturing-agreement-for-bispecific-antibody-targe-cntx-20230109monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-highlights-2023-corporate-priorities-and-pipeline-milestones-cntx-20230104monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-reports-encouraging-preliminary-phase-2-data-for-ona-xr-in-metastatic-cntx-20221208monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-nominates-ctim-76-bispecific-antibody-candidate-to-develop-treatment--cntx-20221129monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-announces-clinical-updates-on-ona-xr-to-be-presented-at-2022-san-anto-cntx-20221121monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-reports-third-quarter-2022-operating-and-financial-results-cntx-20221109monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-amends-cash-guidance-extends-runway-into-q1-2024-cntx-20220927monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-co-cntx-20220906monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-reports-second-quarter-2022-operating-and-financial-results-cntx-20220811monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-and-the-menarini-group-announce-clinical-trial-collaboration-and-supp-cntx-20220802monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-reports-first-quarter-2022-operating-and-financial-results-cntx-20220511monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-announces-poster-presentation-at-the-upcoming-2022-asco-annual-meetin-cntx-20220505monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-announces-encouraging-preclinical-data-from-two-programs-to-be-presen-cntx-20220411monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-to-participate-in-two-april-2022-investor-conferences-cntx-20220406monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-reports-full-year-2021-operating-and-financial-results-cntx-20220323monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-announces-acceptance-of-five-abstracts-to-be-presented-at-the-america-cntx-20220308monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-to-participate-in-the-sachs-15th-annual-european-life-sciences-ceo-fo-cntx-20220222monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-strengthens-research-development-team-cntx-20220105monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-to-participate-in-two-january-2022-investor-conferences-cntx-20220104monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-announces-positive-data-from-ona-xr-in-early-breast-cancer-at-2021-sa-cntx-20211209monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-inc-announces-closing-of-31-25-million-private-placement-cntx-20211206monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-reports-third-quarter-2021-operating-and-financial-results-cntx-20211202monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-inc-announces-31-25-million-private-placement-cntx-20211201monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-to-present-clinical-data-on-ona-xr-in-breast-cancer-at-2021-san-anton-cntx-20211119monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-strengthens-leadership-team-with-appointments-of-chief-financial-offi-cntx-20211101monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-and-wisconsin-oncology-network-announce-first-patient-dosed-in-phase--cntx-20211027monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-announces-closing-of-initial-public-offering-including-full-exercise--cntx-20211022monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-announces-pricing-of-initial-public-offering-cntx-20211019monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-and-tyligand-bioscience-reach-ona-xr-manufacturing-optimization-miles-cntx-20210825monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-and-jefferson-health-announce-first-patient-dosed-in-phase-2-trial-of-cntx-20210512monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-and-integral-molecular-enter-collaboration-and-license-deal-for-novel-cntx-20210408monthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-expands-board-of-directors-cntx-20210322monthly0.5https://www.biopharmawatch.com/news/CNTX/context-matters-introduces-solid-tumor-cancer-module-into-its-proprietary-reimbursement-ri-cntx-20130530monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-participate-in-the-bank-of-america-2026-healthcare-conference-nyxh-20260430monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-participate-in-the-oppenheimer-36th-annual-healthcare-medtech-services-conferenc-nyxh-20260311monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-release-fourth-quarter-and-full-year-2025-financial-results-on-march-19-2026-nyxh-20260305monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-the-signature-of-a-memorandum-of-understanding-with-sheikh-shakhbout-medi-nyxh-20260218monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference-nyxh-20251127monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-secures-financing-commitments-of-up-to-u-s-77-million-to-drive-u-s-commercializatio-nyxh-20251114monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-reports-third-quarter-2025-financial-and-operating-results-nyxh-20251113monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-upcoming-investor-events-nyxh-20250902monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-reports-second-quarter-financial-and-operating-results-nyxh-20250818monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-preliminary-results-for-the-second-quarter-of-2025-nyxh-20250811monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-release-second-quarter-2025-financial-results-on-august-18-2025-nyxh-20250729monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-s-dream-pivotal-study-data-published-in-the-journal-of-clinical-sleep-medicine-nyxh-20250728monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-present-at-the-jefferies-global-healthcare-conference-nyxh-20250528monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-reports-first-quarter-financial-and-operating-results-nyxh-20250514monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-release-first-quarter-2025-financial-results-on-may-14-2025-nyxh-20250507monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-s-a-investors-company-investigated-by-the-portnoy-law-firm-nyxh-20250331monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-reports-fourth-quarter-and-financial-year-2024-financial-and-operating-results-nyxh-20250313monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-release-fourth-quarter-and-financial-year-2024-financial-results-on-march-13-202-nyxh-20250310monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-participate-in-the-oppenheimer-35th-annual-healthcare-medtech-services-conferenc-nyxh-20250303monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-commercial-launch-of-genio-breakthrough-therapy-in-the-middle-east-nyxh-20250219monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference-nyxh-20241120monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-reports-third-quarter-financial-and-operating-results-nyxh-20241106monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-release-third-quarter-2024-financial-results-on-november-6-2024-nyxh-20241022monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-raises-27-million-through-its-at-the-market-offering-nyxh-20241007monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-participate-in-upcoming-investor-conferences-nyxh-20240905monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-rings-the-closing-bell-at-nasdaq-while-preparing-for-u-s-market-launch-of-innovativ-nyxh-20240902monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-reports-second-quarter-and-first-half-2024-financial-and-operating-results-nyxh-20240806monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-release-second-quarter-and-first-half-2024-financial-results-on-august-6-2024-nyxh-20240729monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-has-signed-a-37-5-million-loan-facility-agreement-with-the-european-investment-bank-nyxh-20240703monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-participate-in-the-jefferies-global-healthcare-conference-nyxh-20240603monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-pricing-of-offering-nyxh-20240523monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-reduction-of-the-maximum-amount-available-under-its-at-the-market-equity--nyxh-20240522monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-proposed-offering-of-ordinary-shares-nyxh-20240522monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-reports-first-quarter-2024-financial-and-operating-results-nyxh-20240514monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-release-first-quarter-2024-financial-results-on-may-14-2024-nyxh-20240513monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-advances-patient-access-strategy-through-partnership-with-the-american-association--nyxh-20240325monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-dream-u-s-pivotal-study-meets-primary-endpoints-nyxh-20240319monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-reports-fourth-quarter-and-financial-year-2023-financial-and-operating-results-nyxh-20240305monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-participate-in-the-oppenheimer-34th-annual-healthcare-medtech-services-conferenc-nyxh-20240229monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-release-fourth-quarter-and-financial-year-2023-financial-results-on-march-5-2024-nyxh-20240215monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-2024-strategic-priorities-nyxh-20240117monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-real-world-case-series-demonstrating-positive-results-in-treating-ccc-pat-nyxh-20231211monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-strengthens-its-executive-leadership-team-nyxh-20231128monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-participate-in-the-piper-sandler-35th-annual-healthcare-conference-nyxh-20231121monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-reports-third-quarter-2023-financial-and-operating-results-nyxh-20231108monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-participate-in-the-jefferies-london-healthcare-conference-nyxh-20231107monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-release-third-quarter-2023-financial-results-on-november-8-2023-nyxh-20231026monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-participate-in-the-cantor-fitzgerald-global-healthcare-conference-nyxh-20230912monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-participate-in-upcoming-investor-conferences-nyxh-20230905monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-reports-second-quarter-and-first-half-2023-financial-and-operating-results-nyxh-20230808monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-participate-in-the-43rd-canaccord-genuity-growth-conference-nyxh-20230727monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-release-second-quarter-2023-financial-results-on-august-8-2023-nyxh-20230727monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-reports-first-quarter-2023-financial-and-operating-results-nyxh-20230516monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-release-first-quarter-2023-financial-results-on-may-16-2023-nyxh-20230501monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-raises-3-million-from-its-at-the-market-equity-offering-nyxh-20230413monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-a-15-million-private-placement-financing-nyxh-20230323monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-reports-fourth-quarter-and-full-year-2022-financial-and-operating-results-nyxh-20230322monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-release-fourth-quarter-and-full-year-2022-financial-results-on-march-22-2023-nyxh-20230308monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference-nyxh-20230307monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-inaugural-investor-analyst-meeting-nyxh-20230222monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-files-shelf-registration-statement-and-announces-at-the-market-equity-offering-prog-nyxh-20221222monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference-nyxh-20221117monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-reports-third-quarter-2022-financial-and-operating-results-nyxh-20221108monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-change-to-board-of-directors-nyxh-20221024monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-participate-in-the-jefferies-london-healthcare-conference-nyxh-20221020monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-participate-in-the-17th-annual-wells-fargo-securities-healthcare-conference-nyxh-20220818monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-reports-second-quarter-and-first-half-2022-financial-and-operating-results-nyxh-20220808monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-present-at-the-canaccord-genuity-42nd-annual-growth-conference-nyxh-20220727monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-joins-the-euronext-tech-leaders-initiative-included-in-the-euronext-tech-leaders-in-nyxh-20220607monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-reports-first-quarter-2022-financial-and-operating-results-nyxh-20220510monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-nominates-raymond-cohen-and-virginia-kirby-for-appointment-to-its-board-of-director-nyxh-20220506monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-release-first-quarter-2022-financial-results-on-may-9-and-host-conference-call-o-nyxh-20220428monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-reports-full-year-2021-operating-and-financial-results-nyxh-20220324monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-participate-in-the-oppenheimer-32nd-annual-healthcare-conference-nyxh-20220310monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-present-better-sleep-data-host-physician-events-at-world-sleep-congress-2022-nyxh-20220307monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-release-full-year-2021-financial-results-on-march-24-and-host-conference-call-on-nyxh-20220303monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-present-at-btig-medtech-digital-health-life-science-diagnostic-tools-conference-nyxh-20220204monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-participation-in-the-piper-sandler-33rd-annual-virtual-healthcare-confere-nyxh-20211112monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-participation-in-the-stifel-2021-virtual-healthcare-conference-nyxh-20211103monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-ce-mark-indication-approval-to-treat-complete-concentric-collapse-ccc-pat-nyxh-20211004monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-u-s-fda-breakthrough-device-designation-granted-for-the-genio-system-for--nyxh-20210914monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-participation-in-the-cantor-2021-virtual-global-healthcare-conference-nyxh-20210913monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-participation-in-the-baird-2021-global-healthcare-conference-nyxh-20210902monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-issues-first-half-2021-financial-results-nyxh-20210831monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-appoints-rita-johnson-mills-to-its-board-of-directors-nyxh-20210827monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-release-first-half-2021-financial-results-on-august-31-and-host-earnings-confere-nyxh-20210811monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-closing-of-nasdaq-initial-public-offering-and-underwriters-full-exercise--nyxh-20210708monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-pricing-of-nasdaq-public-offering-nyxh-20210702monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-launch-of-proposed-public-offering-in-the-united-states-nyxh-20210625monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-issues-first-quarter-2021-results-nyxh-20210610monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-files-registration-statement-for-proposed-initial-public-offering-in-the-united-sta-nyxh-20210610monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-better-sleep-trial-reaches-its-primary-endpoints-nyxh-20210607monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-submission-of-draft-registration-statement-for-proposed-public-listing-in-nyxh-20210419monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-reports-full-year-2020-results-nyxh-20210409monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-delay-full-year-2020-earnings-release-until-april-9-2021-nyxh-20210402monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-the-publication-of-first-positive-clinical-data-in-an-osa-patient-sufferi-nyxh-20210303monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-present-at-the-oppenheimer-31st-annual-healthcare-conference-nyxh-20210224monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-receives-fda-approval-for-full-body-1-5t-and-3t-mri-compatibility-for-the-genio-sys-nyxh-20210209monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-and-vanderbilt-university-enter-exclusive-licensing-agreement-regarding-next-genera-nyxh-20210202monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-full-body-1-5t-and-3t-mri-compatibility-for-the-genio-system-to-treat-obs-nyxh-20210126monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-participate-in-annual-piper-sandler-healthcare-conference-nyxh-20201120monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-the-end-of-the-stabilisation-period-and-the-full-exercise-of-the-over-all-nyxh-20200925monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-commencement-of-trading-of-shares-on-euronext-brussels-nyxh-20200918monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-raises-up-to-85-million-us-100m-in-successful-initial-public-offering-nyxh-20200917monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-initial-public-offering-multiple-times-over-subscribed-and-early-closing-announced-nyxh-20200914monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-launches-its-initial-public-offering-on-euronext-brussels-nyxh-20200909monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-intention-to-launch-an-initial-public-offering-on-euronext-brussels-nyxh-20200827monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-receives-ide-approval-from-the-u-s-food-and-drug-administration-fda-for-its-dream-s-nyxh-20200625monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-raises-25-million-in-private-funding-round-nyxh-20200213monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-data-demonstrating-the-benefits-and-safety-of-its-genio-system-implantati-nyxh-20191127monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-publishes-positive-obstructive-sleep-apnea-data-from-blast-osa-study-in-the-europea-nyxh-20191028monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-to-hold-analysts-and-investors-conference-call-to-review-recent-progress--mbot-20260515monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-first-closing-of-exercise-of-outstanding-preferred-investment-o-mbot-20250916monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-expands-commercial-leadership-with-appointment-of-christina-bailey-as-vp--mbot-20250722monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-strengthens-its-commercial-capabilities-with-the-addition-of-david-j-wils-mbot-20250113monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-closes-8-6-million-registered-direct-offering-mbot-20250110monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-raises-a-total-of-approximately-11-8-million-in-gross-proceeds-from-regis-mbot-20250107monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-ceo-harel-gadot-to-discuss-endovascular-robotics-on-benzinga-all-access-mbot-20241210monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-partners-with-brigham-and-women-s-hospital-for-its-pivotal-human-clinical-mbot-20240620monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-closing-of-2-35-million-registered-direct-offering-priced-at-th-mbot-20240604monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-submits-an-ide-application-to-gain-fda-approval-to-commence-its-pivotal-c-mbot-20240205monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announced-positive-results-of-its-glp-pivotal-pre-clinical-study-where-al-mbot-20231228monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-raises-a-total-of-7-6-million-in-gross-proceeds-from-four-recent-register-mbot-20230628monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-expand-ip-protection-in-japan-mbot-20230622monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-closing-of-1-5-million-registered-direct-offering-priced-at-the-mbot-20230606monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-closing-of-2-66-million-registered-direct-offering-of-common-st-mbot-20230524monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-closing-of-1-4-million-registered-direct-offering-of-common-sto-mbot-20230523monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-welcomes-distinguished-interventional-cardiologist-and-early-adopter-of-e-mbot-20230131monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-closing-of-5-million-registered-direct-offering-priced-at-the-m-mbot-20221025monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-enhances-strategic-focus-on-its-endovascular-solutions-mbot-20221011monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-to-review-recent-progress-during-h-c-wainwright-s-24th-annual-global-inve-mbot-20220913monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-announces-closing-of-10-0-million-registered-direct-offering-of-commo-mbot-20191231monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-announces-10-0-million-registered-direct-offering-priced-at-the-marke-mbot-20191230monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-announces-closing-of-9-59-million-registered-direct-offering-of-commo-mbot-20191227monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-increases-its-global-ip-portfolio-with-notice-of-allowance-from-the-europ-mbot-20190114monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-moves-to-state-of-the-art-facility-to-meet-next-phase-of-the-company-s-de-mbot-20180502monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-appointment-of-chief-technology-officer-mbot-20180405monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-s-ceo-to-speak-as-an-industry-expert-at-the-yjp-ceo-healthcare-symposium-mbot-20180213monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-to-report-second-quarter-results-on-august-14-2017-mbot-20170810monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-announces-investor-briefing-conference-call-and-webcast-mbot-20170329monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-to-present-at-the-29th-annual-roth-growth-conference-mbot-20170313monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-to-ring-closing-bell-at-nasdaq-on-february-23-2017-mbot-20170223monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-nasdaq-mbot-to-ring-the-nasdaq-stock-market-closing-bell-mbot-20170222monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-announces-significant-technology-patent-allowance-in-the-u-s-mbot-20170222monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-strengthens-board-of-directors-with-medical-device-veteran-martin-j-m-mbot-20170207monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-to-present-at-the-thirteenth-annual-noble-capital-markets-investor-co-mbot-20170123monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-announces-first-investor-briefing-conference-call-and-webcast-mbot-20161215monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-appoints-hezi-himelfarb-as-general-manager-and-chief-operating-officer-mbot-20161206monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-report-second-quarter-2025-financial-results-on-august-6-2025-mxct-20250709monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-and-ori-biotech-collaborate-to-improve-manufacturing-efficiencies-and-broaden-adop-mxct-20250611monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025-mxct-20250410monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-ce-mxct-20250212monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-11-2025-and-mxct-20250207monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-celebrates-25-years-of-innovation-driving-cell-engineering-based-therapeutics-mxct-20241113monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-participate-in-two-upcoming-investor-conferences-mxct-20241031monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-report-third-quarter-2024-financial-results-on-november-6-2024-mxct-20241011monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-appoints-ali-soleymannezhad-as-chief-commercial-officer-mxct-20241010monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-signs-strategic-platform-license-with-kamau-therapeutics-to-accelerate-the-develop-mxct-20240916monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-participate-in-virtual-craig-hallum-capital-group-bioprocessing-conference-mxct-20240905monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-report-second-quarter-2024-financial-results-on-august-6-2024-mxct-20240709monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-participate-in-william-blair-44th-annual-growth-stock-conference-mxct-20240529monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-signs-strategic-platform-license-agreement-with-legend-biotech-to-accelerate-cell--mxct-20240522monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-report-first-quarter-2024-financial-results-on-may-7-2024-mxct-20240410monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-signs-strategic-platform-license-with-be-biopharma-to-support-the-development-of-e-mxct-20240402monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-report-fourth-quarter-and-full-year-2023-financial-results-on-march-12-2024-and-mxct-20240209monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-and-wugen-sign-strategic-platform-license-to-expedite-scale-up-of-clinical-and-com-mxct-20240130monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-signs-strategic-platform-license-with-imugene-to-advance-their-cancer-immunotherap-mxct-20240123monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-and-lion-tcr-form-partnership-to-support-global-expansion-of-lion-tcr-s-tcr-t-cell-mxct-20240103monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-confirms-appointment-of-maher-masoud-as-president-chief-executive-officer-and-dire-mxct-20240102monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-joins-the-alliance-for-mrna-medicines-amm-as-a-founding-member-mxct-20231116monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-participate-in-two-upcoming-investor-conferences-mxct-20231106monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-appoints-ali-soleymannezhad-as-executive-vice-president-of-bioprocessing-mxct-20230906monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-participate-in-baird-global-healthcare-conference-mxct-20230905monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-signs-strategic-platform-license-with-prime-medicine-to-advance-next-generation-ge-mxct-20230801monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-report-second-quarter-2023-financial-results-on-august-9-2023-mxct-20230713monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-gener-mxct-20230710monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-signs-strategic-platform-license-with-lyell-immunopharma-mxct-20230706monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-participate-in-upcoming-investor-conferences-mxct-20230601monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-dev-mxct-20230504monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-report-first-quarter-2023-financial-results-on-may-10-2023-mxct-20230412monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-establishes-new-scientific-advisory-board-comprised-of-globally-recognized-experts-mxct-20230308monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-mxct-20230201monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-signs-strategic-platform-license-with-catamaran-bio-to-support-its-car-nk-cell-the-mxct-20230103monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-signs-strategic-platform-license-with-curamys-to-enable-cell-gene-therapies-for-th-mxct-20221205monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-participate-in-upcoming-investor-conferences-mxct-20221102monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-report-third-quarter-2022-financial-results-on-november-9-2022-mxct-20221012monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-signs-strategic-platform-license-with-vertex-pharmaceuticals-to-advance-crispr-cas-mxct-20220928monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-debuts-new-state-of-the-art-headquarters-in-maryland-s-i-270-biotech-corridor-mxct-20220921monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-participate-in-morgan-stanley-20th-annual-global-healthcare-conference-mxct-20220907monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-report-second-quarter-2022-financial-results-on-august-10-2022-mxct-20220715monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-signs-strategic-platform-license-with-lg-chem-to-advance-its-allogeneic-car-t-prog-mxct-20220712monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mxct-20220513monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-first-quarter-financial-results-mxct-20220509monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-participate-in-upcoming-investor-conferences-mxct-20220503monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-report-first-quarter-2022-financial-results-on-may-9-2022-mxct-20220420monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mxct-20220415monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-inc-names-cenk-sumen-chief-scientific-officer-mxct-20220309monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-report-fourth-quarter-and-full-year-2021-financial-results-on-march-22-2022-mxct-20220224monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-participate-in-upcoming-investor-conferences-mxct-20220214monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mxct-20220211monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-signs-strategic-platform-license-with-intima-bioscience-to-advance-tumor-infiltrat-mxct-20220201monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-participate-in-upcoming-investor-conferences-mxct-20211112monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-third-quarter-financial-results-mxct-20211110monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-board-member-richard-douglas-phd-appointed-chairman-of-the-board-mxct-20211103monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-signs-strategic-platform-license-with-nkarta-inc-to-advance-natural-killer-cell-th-mxct-20211028monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-report-third-quarter-2021-financial-results-on-november-10-2021-mxct-20211025monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-set-to-join-russell-2000-index-mxct-20210917monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-to-report-second-quarter-2021-financial-results-on-september-13-2021-mxct-20210902monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-appoints-anthony-baldor-as-chief-financial-officer-vani-20250611monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-to-present-at-the-2025-bio-international-convention-vani-20250610monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-announces-filing-of-form-10-registration-statement-for-planned-spin-off-of--vani-20250529monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-to-present-at-the-american-association-of-pharmaceutical-scientists-beyond--vani-20250507monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-to-participate-in-virtual-fireside-chat-hosted-by-h-c-wainwright-company-vani-20250416monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabo-vani-20250415monthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-aard-faces-investor-scrutiny-amid-56-drop-on-clinical-pause-for-lead-aard-20260602monthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-aard-faces-investor-scrutiny-amid-56-drop-on-clinical-pause-for-lead-aard-20260514monthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-aard-faces-investor-scrutiny-amid-56-drop-on-clinical-pause-for-lead-aard-20260428monthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-aard-faces-investor-scrutiny-amid-56-drop-on-clinical-pause-for-lead-aard-20260414monthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-aard-faces-investor-scrutiny-amid-56-drop-on-clinical-pause-for-lead-aard-20260409monthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-inc-investigated-by-the-portnoy-law-firm-aard-20260311monthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-to-present-at-upcoming-investor-conferences-in-december-aard-20251125monthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-aard-20251103monthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-aard-20250904monthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-to-present-at-upcoming-investor-conferences-in-september-aard-20250827monthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-aard-20250718monthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-to-join-prader-willi-syndrome-community-at-the-2025-united-in-hope-c-aard-20250624monthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-bolsters-leadership-team-with-strategic-hires-across-scientific-comm-aard-20250519monthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-to-present-at-upcoming-investor-conferences-in-may-aard-20250507monthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-announces-pricing-of-initial-public-offering-aard-20250213monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-more-information-pepg-20260331monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-more-information-pepg-20260306monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-pepg-final-deadline-alert-bragar-eagel-squire-p-c-reminds-pepgen-investors-of-the-a-pepg-20250807monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-august-8-2-pepg-20250807monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-pepg-urgent-deadline-alert-bragar-eagel-squire-p-c-reminds-pepgen-investors-of-the--pepg-20250805monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-august-8-2-pepg-20250805monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-sued-for-securities-law-violations-contact-the-gross-law-firm-before-august-8-2-pepg-20250804monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-nasdaq-pepg-shareholder-alert-bernstein-liebhard-llp-reminds-pepgen-inc-investo-pepg-20250804monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-pepg-alert-bragar-eagel-squire-p-c-reminds-investors-of-the-class-action-against-pe-pepg-20250802monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-august-8-2-pepg-20250801monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-pepg-20250730monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-august-8-2-pepg-20250728monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-pepg-alert-bragar-eagel-squire-p-c-reminds-investors-of-the-class-action-against-pe-pepg-20250724monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-nasdaq-pepg-shareholder-alert-bernstein-liebhard-llp-reminds-pepgen-inc-investo-pepg-20250721monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-alert-bragar-eagel-squire-p-c-urges-investors-in-pepgen-inc-pepg-to-inquire-about-t-pepg-20250720monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-alert-bragar-eagel-squire-p-c-urges-investors-in-pepgen-inc-pepg-to-inquire-about-t-pepg-20250716monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-sued-for-securities-law-violations-contact-the-gross-law-firm-before-august-8-2-pepg-20250716monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-nasdaq-pepg-shareholder-alert-bernstein-liebhard-llp-reminds-pepgen-inc-investo-pepg-20250714monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-class-action-levi-korsinsky-reminds-pepgen-inc-investors-of-the-pending-class-a-pepg-20250711monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-sued-for-securities-law-violations-contact-the-gross-law-firm-before-august-8-2-pepg-20250710monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-august-8-2-pepg-20250709monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-pepg-20250707monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-nasdaq-pepg-shareholder-alert-bernstein-liebhard-llp-reminds-pepgen-inc-investo-pepg-20250707monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-nasdaq-pepg-shareholder-alert-bernstein-liebhard-llp-reminds-pepgen-inc-investo-pepg-20250630monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-august-8-2-pepg-20250626monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-nasdaq-pepg-shareholder-alert-bernstein-liebhard-llp-reminds-pepgen-inc-investo-pepg-20250623monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm--pepg-20250618monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-nasdaq-pepg-shareholder-alert-bernstein-liebhard-llp-reminds-pepgen-inc-investo-pepg-20250616monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed--pepg-20250612monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-nasdaq-pepg-investor-alert-investors-with-large-losses-in-pepgen-inc-should-con-pepg-20250610monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-pepg-investigation-bronstein-gewirtz-grossman-llc-encourages-investors-to-seek--pepg-20240813monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-pepg-investigation-bronstein-gewirtz-grossman-llc-encourages-investors-to-seek--pepg-20240807monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-pepg-investigation-bronstein-gewirtz-grossman-llc-encourages-investors-to-seek--pepg-20240801monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-to-participate-in-upcoming-investor-conferences-pepg-20240313monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-receives-u-s-fda-orphan-drug-and-rare-pediatric-disease-designations-for-pgn-edo51--pepg-20240313monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-first-patient-dosed-in-phase-1-freedom-dm1-clinical-trial-of-pgn-edodm1-f-pepg-20231218monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-appointment-of-howard-mayer-m-d-to-board-of-directors-pepg-20231115monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-reports-third-quarter-2023-financial-results-and-recent-corporate-developments-pepg-20231108monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-upcoming-presentations-at-the-28th-annual-congress-of-the-world-muscle-so-pepg-20230927monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-presentations-at-the-2023-myotonic-dystrophy-foundation-annual-conference-pepg-20230901monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-clearance-by-health-canada-of-cta-for-pgn-edo51-to-begin-the-phase-2-clin-pepg-20230518monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-to-participate-in-the-bank-of-america-securities-2023-healthcare-conference-pepg-20230504monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-upcoming-data-presentations-at-the-2023-american-academy-of-neurology-ann-pepg-20230417monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-to-participate-in-the-22nd-annual-needham-virtual-healthcare-conference-pepg-20230413monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-to-participate-in-the-stifel-2023-cns-days-conference-pepg-20230321monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-to-host-fourth-quarter-and-full-year-2022-financial-results-call-pepg-20230316monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-upcoming-data-presentations-at-the-2023-annual-muscle-dystrophy-associati-pepg-20230313monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-to-participate-in-the-svb-securities-global-biopharma-conference-pepg-20230209monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-to-participate-in-the-stifel-2022-healthcare-conference-pepg-20221108monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-presents-data-from-its-duchenne-muscular-dystrophy-program-at-world-muscle-society--pepg-20221013monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-appoints-habib-dable-to-board-of-directors-pepg-20220922monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-appoints-caroline-godfrey-ph-d-to-the-company-s-scientific-advisory-board-pepg-20220722monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-pricing-of-initial-public-offering-pepg-20220506monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-first-participant-dosed-in-a-phase-1-clinical-trial-of-pgn-edo51-for-the--pepg-20220406monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-appoints-michelle-mellion-m-d-as-senior-vice-president-head-of-clinical-development-pepg-20220405monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-continues-to-build-leadership-team-with-additions-of-senior-vice-president-clinical-pepg-20220330monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-approval-by-health-canada-of-cta-to-begin-first-in-human-trials-of-pgn-ed-pepg-20220315monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-appoints-laurie-keating-as-chair-of-board-of-directors-pepg-20220119monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-appoints-vice-president-of-program-management-and-promotes-sonia-bracegirdle-ph-d-t-pepg-20211207monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-bolsters-r-d-team-with-appointment-of-jaya-goyal-ph-d-as-executive-vice-president-o-pepg-20211108monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-appoints-noel-donnelly-as-chief-financial-officer-pepg-20211028monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-welcomes-esteemed-neurologist-dr-john-day-to-scientific-advisory-board-pepg-20211013monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-to-present-research-on-enhanced-delivery-treatments-for-neuromuscular-disease-at-tw-pepg-20210920monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-new-additions-to-leadership-team-and-board-of-directors-pepg-20210831monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-closing-of-112-5-million-crossover-financing-to-advance-transformative-th-pepg-20210805monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-strengthens-leadership-team-with-svp-of-chemistry-manufacturing-controls-and-vp-of--pepg-20210607monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-presents-new-clinical-and-translational-data-for-icovamenib-at-the-american--bmea-20260605monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-first-patient-dosed-in-newly-initiated-phase-ii-programs-enrolling-bmea-20260331monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-participate-at-upcoming-investor-conferences-bmea-20260219monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-enters-2026-focused-on-executing-key-icovamenib-and-bmf-650-milestones-bmea-20260112monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-kol-presentation-and-interview-on-menin-and-icovamenib-at-wcirdc-2-bmea-20251209monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-presents-covalent-111-study-results-at-the-23rd-world-congress-on-insulin-re-bmea-20251205monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-oral-presentation-of-icovamenib-at-the-23rd-world-congress-on-insu-bmea-20251201monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-bmea-20251201monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-presents-data-demonstrating-enhanced-preclinical-activity-of-icovamenib-in-c-bmea-20250916monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-presents-new-preclinical-and-clinical-data-on-icovamenib-at-the-85th-scienti-bmea-20250623monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-reports-preclinical-data-for-bmf-650-a-next-generation-oral-glp-1-receptor-a-bmea-20250618monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-pricing-of-public-offering-of-securities-bmea-20250618monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-presents-updated-preliminary-clinical-data-for-covalent-flt3-inhibitor-bmf-5-bmea-20250613monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-s-bmf-500-selected-for-poster-presentation-at-eha-2025-highlighting-phase-i--bmea-20250514monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bmea-20250401monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-leadership-transition-bmea-20250325monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-bmea-20250303monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-unveil-new-icovamenib-data-at-the-18th-international-conference-on-advanc-bmea-20250227monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-reports-new-preclinical-data-on-icovamenib-semaglutide-combination-study-bmea-20250107monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-bmea-20250106monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-host-conference-call-to-announce-topline-results-from-phase-ii-covalent-1-bmea-20241216monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-oral-and-poster-presentations-of-icovamenib-at-the-22nd-world-cong-bmea-20241212monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-preliminary-data-from-ongoing-covalent-103-study-of-investigationa-bmea-20241209monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-host-conference-call-to-present-initial-clinical-data-from-phase-i-covale-bmea-20241206monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-bmea-20241202monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-bmea-20241101monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-presents-preclinical-data-showing-icovamenib-bmf-219-enhanced-effectiveness--bmea-20241030monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-approval-of-icovamenib-as-international-nonproprietary-name-for-bm-bmea-20241021monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-host-conference-call-and-webcast-on-wednesday-october-30th-at-4-30-pm-et--bmea-20241015monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-present-at-the-1st-annual-asian-conference-on-innovative-therapies-for-di-bmea-20241007monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-announces-formation-of-global-scientific-advisory-board-with-22-world-renowned-diab-bmea-20241001monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-bmea-20240801monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-bmea-20240603monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-completion-of-enrollment-of-first-3-arms-in-phase-2-expansion-coho-bmea-20240530monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bmea-20240501monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bmea-20240401monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bmea-20240301monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-highlights-recent-updates-and-anticipated-2024-corporate-milestones-at-42nd--bmea-20240109monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-dosing-of-first-type-1-diabetes-patient-in-phase-ii-study-covalent-bmea-20240108monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-bmea-20240102monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-presents-achievement-of-minimal-residual-disease-negativity-mrd-neg-in-first-bmea-20231211monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-near-doubling-the-percentage-of-patients-with-durable-hba1c-reduct-bmea-20231209monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-presents-long-term-follow-up-data-showing-improved-glycemic-control-after-22-bmea-20231208monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-present-long-term-follow-up-data-from-ongoing-phase-ii-study-covalent-111-bmea-20231207monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-health-canada-clearance-of-clinical-trial-application-cta-for-bmf--bmea-20231205monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-acceptance-of-three-abstracts-for-its-novel-menin-inhibitor-highli-bmea-20231127monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-abstract-bmf-219-a-novel-therapeutic-agent-to-reestablish-functional-beta-ce-bmea-20231116monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-present-new-data-from-ongoing-phase-ii-study-covalent-111-of-bmf-219-in-p-bmea-20231108monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-two-poster-presentations-at-upcoming-ash-annual-meeting-2023-bmea-20231102monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-first-patient-dosed-with-covalent-flt3-inhibitor-bmf-500-in-relaps-bmea-20231017monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-fda-clearance-of-investigational-new-drug-ind-application-for-bmf--bmea-20231005monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-fda-and-health-canada-clearance-of-the-expansion-cohorts-of-the-on-bmea-20230928monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-presents-positive-clinical-data-from-the-initial-cohorts-of-the-ongoing-phas-bmea-20230624monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-present-late-breaking-data-from-ongoing-phase-ii-trial-covalent-111-evalu-bmea-20230620monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-present-late-breaking-data-from-ongoing-phase-ii-trial-covalent-111-evalu-bmea-20230419monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-present-two-preclinical-posters-at-the-114th-aacr-annual-meeting-bmea-20230413monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-closing-of-upsized-public-offering-and-full-exercise-of-the-underw-bmea-20230413monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-pricing-of-upsized-public-offering-of-common-stock-bmea-20230330monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-host-conference-call-and-webcast-to-discuss-initial-phase-ii-clinical-dat-bmea-20230323monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-participate-in-upcoming-investor-events-bmea-20230302monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-doses-first-patient-in-phase-i-ib-clinical-trial-covalent-102-of-bmf-219-in--bmea-20230117monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-present-at-41st-annual-j-p-morgan-healthcare-conference-and-highlight-202-bmea-20230109monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-dosing-of-first-patient-with-type-2-diabetes-in-the-united-states--bmea-20230104monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-participate-in-piper-sandler-34th-annual-healthcare-conference-bmea-20221111monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-present-preclinical-data-for-bmf-500-an-investigational-oral-covalent-flt-bmea-20221103monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-first-patient-dosed-with-chronic-lymphocytic-leukemia-cll-in-coval-bmea-20221027monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-selected-for-two-oral-presentations-at-the-european-association-for-the-stud-bmea-20220701monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-first-patient-dosed-in-multiple-myeloma-cohort-of-covalent-101-tri-bmea-20220622monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-presents-novel-preclinical-data-at-ada-2022-suggesting-bmf-219-s-potential-a-bmea-20220604monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-participate-in-jefferies-healthcare-conference-bmea-20220602monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-present-new-preclinical-data-on-bmf-219-in-two-diabetic-animal-models-at--bmea-20220601monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-present-new-preclinical-data-showing-bmf-219-s-strong-activity-in-relapse-bmea-20220526monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-attend-h-c-wainwright-global-investment-conference-bmea-20220520monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-ind-candidate-selection-bmf-500-a-potential-best-in-class-oral-cov-bmea-20220519monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-participate-in-bank-of-america-securities-2022-healthcare-conference-bmea-20220509monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-acceptance-of-multiple-abstracts-at-the-2022-asco-annual-meeting-bmea-20220427monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-acceptance-of-late-breaking-presentation-of-lead-menin-inhibitor-b-bmea-20220406monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-present-at-oppenheimer-s-32nd-annual-virtual-healthcare-conference-bmea-20220315monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-presentation-of-lead-menin-inhibitor-bmf-219-in-diabetes-at-ada-82-bmea-20220314monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-upcoming-presentations-of-preclinical-data-in-diffuse-large-b-cell-bmea-20220308monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-appointment-of-steve-morris-m-d-as-chief-medical-officer-bmea-20220201monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-first-patient-dosed-bmea-20220125monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-participation-at-the-h-c-wainwright-2022-bioconnect-conference-bmea-20220111monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-2022-clinical-development-plan-to-initiate-studies-in-up-to-seven--bmea-20220110monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-releases-pre-clinical-data-with-bmf-219-in-diabetes-bmea-20220106monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-moves-into-new-headquarters-and-expands-r-d-facility-bmea-20220104monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-bmea-20211221monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-be-added-to-nasdaq-biotechnology-index-bmea-20211214monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-participate-in-two-upcoming-investor-conferences-bmea-20211110monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-publishes-abstract-on-bmf-219-at-ash-annual-meeting-bmea-20211104monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-strengthens-its-executive-team-with-appointment-of-franco-valle-as-chief-fin-bmea-20210628monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-announces-pricing-of-initial-public-offering-bmea-20210416monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-1st-quarter-2026-results-edsa-20260213monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-year-2025-results-edsa-20251212monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-2nd-quarter-2025-results-edsa-20250514monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-1st-quarter-2025-results-edsa-20250214monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-year-2024-results-edsa-20241213monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-s-founder-makes-strategic-investment-in-the-company-edsa-20241031monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-announces-upcoming-conference-schedule-edsa-20241021monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-3rd-quarter-2024-results-edsa-20240809monthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-to-report-first-quarter-2026-financial-results-on-may-14-2026-pths-20260501monthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-to-participate-in-piper-sandler-spring-biopharma-symposium-pths-20260414monthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-announces-cfo-transition-pths-20260410monthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-announces-first-patient-dosed-in-phase-1b-2a-clinical-trial-of-ct2000-pths-20260331monthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-pths-20260319monthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-signs-major-pharmacy-benefit-manager-agreement-expanding-patient-acce-pths-20251204monthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-to-present-at-the-piper-sandler-37th-annual-healthcare-conference-pths-20251202monthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-to-report-third-quarter-2025-financial-results-on-november-13-2025-pths-20251105monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-third-quarter-2025-financial-results-vrca-20251114monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-to-present-new-data-on-vp-315-from-its-phase-2-trial-in-basal-cell-vrca-20251007monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-to-report-second-quarter-2025-financial-results-and-provide-a-corp-vrca-20250806monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-to-report-first-quarter-2025-financial-results-and-provide-a-corpo-vrca-20250507monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-to-participate-in-the-citizens-life-sciences-conference-in-new-yor-vrca-20250430monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-strong-demand-led-growth-in-ycanth-dispensed-applicator-un-vrca-20250407monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-appoints-gavin-corcoran-m-d-to-its-board-of-directors-vrca-20250402monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-to-participate-in-the-24th-annual-needham-virtual-healthcare-confe-vrca-20250331monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-appoints-noah-l-rosenberg-m-d-as-chief-medical-officer-vrca-20250326monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2024-financial-results-and--vrca-20250303monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-to-participate-in-the-td-cowen-45th-annual-health-care-conference--vrca-20250225monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-presentation-of-three-posters-featuring-positive-prelimi-vrca-20250121monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-provides-business-and-operational-update-vrca-20241220monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-vrca-20241209monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-that-development-partner-torii-pharmaceutical-files-new--vrca-20241206monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-acceptance-of-two-abstracts-featuring-positive-prelimina-vrca-20241024monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-restructuring-of-commercial-organization-vrca-20241002monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-26th-annual-global-investment-vrca-20240904monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-positive-preliminary-topline-results-from-part-2-of-phas-vrca-20240814monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-to-report-second-quarter-financial-results-and-release-preliminary-vrca-20240806monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-litigation-settlement-with-dormer-laboratories-inc-vrca-20240701monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference-in-ne-vrca-20240530monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-alert-bragar-eagel-squire-p-c-is-investigating-verrica-pharmaceuticals-inc-on-beha-vrca-20240527monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-alert-bragar-eagel-squire-p-c-is-investigating-verrica-pharmaceuticals-inc-on-beha-vrca-20240518monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-to-present-at-upcoming-investor-conferences-vrca-20240509monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-to-provide-a-corporate-update-and-report-first-quarter-2024-financ-vrca-20240508monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-presentation-at-the-23rd-annual-needham-virtual-healthca-vrca-20240402monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-that-ycanth-receives-new-chemical-entity-status-and-oran-vrca-20240326monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-participation-in-the-td-cowen-44th-annual-healthcare-con-vrca-20240227monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-to-provide-a-corporate-update-and-report-fourth-quarter-and-full-y-vrca-20240222monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-files-lawsuit-against-canadian-drug-manufacturer-for-false-adverti-vrca-20240205monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-receives-permanent-j-code-j7354-for-ycanth-from-centers-for-medica-vrca-20240129monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-last-patient-dosed-in-part-2-of-phase-2-study-of-vp-315--vrca-20240105monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-receipt-of-minutes-from-type-c-meeting-with-fda-regardin-vrca-20240104monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-specialty-pharmacy-partnership-agreement-with-walgreens--vrca-20240103monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-development-and-commercialization-partner-torii-pharmaceutical-co--vrca-20231215monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-presentation-at-the-jefferies-global-healthcare-conferen-vrca-20231110monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-to-provide-a-corporate-update-and-report-third-quarter-financial-r-vrca-20231025monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-to-host-virtual-kol-event-discussing-the-approval-of-ycanth-cantha-vrca-20230927monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-participation-in-the-h-c-wainwright-25th-annual-global-i-vrca-20230831monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-first-sale-of-ycanth-to-fff-enterprises-vrca-20230824monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-issues-statement-in-support-of-fda-s-warning-letters-to-manufacturers-and-retailer-vrca-20230823monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-presentation-of-lesion-clearance-data-from-an-ongoing-ph-vrca-20230810monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-acceptance-of-abstract-featuring-clinical-data-of-vp-315-vrca-20230803monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-closing-of-125-million-debt-financing-with-orbimed-vrca-20230726monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-presentation-at-the-jefferies-healthcare-conference-in-n-vrca-20230531monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-presentation-at-the-rbc-capital-markets-global-healthcar-vrca-20230510monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-dosing-of-the-first-patient-in-part-2-of-phase-2-study-e-vrca-20230412monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthca-vrca-20230411monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-participation-at-the-cowen-43rd-annual-health-care-confe-vrca-20230228monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-fda-acceptance-of-filing-of-resubmitted-nda-for-vp-102-f-vrca-20230227monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-resubmission-of-new-drug-application-for-vp-102-for-the--vrca-20230124monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-the-successful-technology-transfer-of-bulk-solution-manu-vrca-20230104monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-participation-in-the-h-c-wainwright-24th-annual-global-i-vrca-20220831monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-start-of-phase-3-trial-of-vp-102-for-the-treatment-of-mo-vrca-20220801monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-inc-investors-class-action-lawsuit-filed-on-behalf-of-investors-de-vrca-20220801monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-announces-pricing-of-public-offering-of-common-stock-vrca-20220630monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-holds-type-a-meeting-with-fda-for-vp-102-for-molluscum-contagiosum-vrca-20220628monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-inc-investors-company-investigated-by-the-portnoy-law-firm-vrca-20220627monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-ann-vrca-20220614monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-receives-complete-response-letter-from-the-fda-for-its-nda-for-vp-102-as-a-direct--vrca-20220525monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-participation-in-the-21st-annual-needham-virtual-healthc-vrca-20220407monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-first-patient-dosed-in-phase-2-study-of-ltx-315-a-potent-vrca-20220405monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-participation-in-the-42nd-annual-cowen-virtual-healthcar-vrca-20220224monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-acceptance-by-fda-of-nda-resubmission-for-vp-102-for-the-vrca-20211215monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-resubmission-of-new-drug-application-for-vp-102-for-the--vrca-20211129monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-fda-acceptance-of-its-ind-application-for-ltx-315-a-pote-vrca-20211118monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-receives-complete-response-letter-from-the-fda-identifying-deficie-vrca-20210920monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-appointment-of-terry-kohler-as-chief-financial-officer-vrca-20210709monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-participation-in-the-jefferies-virtual-healthcare-confer-vrca-20210526monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-participation-in-the-2021-rbc-capital-markets-global-hea-vrca-20210512monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-participation-in-the-20th-annual-needham-virtual-healthc-vrca-20210406monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-announces-election-of-gary-goldenberg-md-verrica-s-chief-medical-officer-to-member-vrca-20210329monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-announces-pricing-of-public-offering-of-common-stock-vrca-20210323monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-exclusive-licensing-agreement-with-torii-pharmaceutical--vrca-20210317monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-participation-in-the-h-c-wainwright-annual-global-life-s-vrca-20210303monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-participation-in-the-cowen-41st-annual-health-care-confe-vrca-20210223monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-presents-positive-data-from-clinical-studies-evaluating-the-safety-vrca-20210119monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-resubmission-of-new-drug-application-for-vp-102-for-the--vrca-20201223monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-receipt-of-final-fda-minutes-following-type-a-meeting-re-vrca-20201117monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-participation-in-the-jefferies-virtual-london-healthcare-vrca-20201112monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-participation-in-the-h-c-wainwright-22nd-annual-global-i-vrca-20200909monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-licenses-ltx-315-a-first-in-class-oncolytic-peptide-based-immunoth-vrca-20200811monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-option-agreement-with-torii-pharmaceutical-to-develop-co-vrca-20200805monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-dr-lawrence-eichenfield-joins-board-of-directors-vrca-20200723monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-positive-results-from-two-new-pooled-analyses-of-the-pha-vrca-20200612monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-to-present-at-the-jefferies-2020-healthcare-conference-vrca-20200527monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare--vrca-20200506monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-to-participate-in-the-19th-annual-needham-virtual-healthcare-confe-vrca-20200409monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-secures-55-million-in-loan-facilities-led-by-silicon-valley-bank-vrca-20200311monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-to-attend-several-upcoming-investor-conferences-vrca-20200220monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-the-hiring-of-two-vice-presidents-to-further-grow-its-co-vrca-20200129monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-presentation-of-positive-data-from-new-pooled-analysis-o-vrca-20200118monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-fda-filing-acceptance-of-new-drug-application-for-vp-102-vrca-20191127monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-participation-in-the-piper-jaffray-31st-annual-healthcar-vrca-20191125monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-passing-of-board-of-directors-member-glenn-oclassen-vrca-20191119monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-appoints-eugene-scavola-to-the-position-of-executive-vice-presiden-vrca-20191009monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-leadership-team-update-vrca-20191007monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-submits-new-drug-application-to-u-s-food-and-drug-administration-f-vrca-20190916monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-participation-in-the-h-c-wainwright-21st-annual-global-i-vrca-20190828monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-enrolls-first-patient-in-phase-2-trial-of-vp-102-for-the-treatment-vrca-20190627monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-participation-in-the-jefferies-2019-healthcare-conferenc-vrca-20190521monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-vrca-20190501monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-presents-positive-results-from-two-phase-3-clinical-trials-of-vp-1-vrca-20190302monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-participation-in-the-cowen-and-company-39th-annual-healt-vrca-20190227monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-announces-late-breaking-oral-presentation-at-the-2019-american-academy-of-dermatol-vrca-20190212monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-appoints-neil-d-dehenes-as-vice-president-of-distribution-trade-and-channel-strate-vrca-20190107monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-participation-in-the-jefferies-2018-london-healthcare-co-vrca-20181101monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-inc-announces-inclusion-in-russell-2000-and-russell-3000-indexes-vrca-20180924monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-appoints-neetu-dhaliwal-as-vice-president-of-business-development-vrca-20180815monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-inc-announces-closing-of-initial-public-offering-vrca-20180619monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-inc-announces-pricing-of-initial-public-offering-vrca-20180614monthly0.5https://www.biopharmawatch.com/news/INO/inovio-deadline-rosen-trusted-investor-counsel-encourages-inovio-pharmaceuticals-inc-inves-ino-20260330monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-the-ino-20260306monthly0.5https://www.biopharmawatch.com/news/INO/inovio-class-action-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-la-ino-20260224monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-inc-sued-for-securities-law-violations-contact-levi-korsinsky-befor-ino-20260219monthly0.5https://www.biopharmawatch.com/news/INO/inovio-class-action-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-ha-ino-20260211monthly0.5https://www.biopharmawatch.com/news/INO/inovio-deadline-alert-faruqi-faruqi-llp-encourages-investors-who-suffered-losses-exceeding-ino-20200509monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-anno-ino-20200317monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-investors-who-have-lost-money-should-contact-block-leviton-ino-20200310monthly0.5https://www.biopharmawatch.com/news/INO/inovio-hiv-vaccine-pennvax-gp-delivered-intradermally-generated-robust-long-term-best-in-c-ino-20181025monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-report-third-quarter-2018-financial-results-on-november-8-2018-ino-20181024monthly0.5https://www.biopharmawatch.com/news/INO/inovio-presents-progression-free-survival-psa-doubling-time-improvements-in-prostate-cance-ino-20181022monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-dna-encoded-monoclonal-antibody-dmab-platform-moves-ahead-with-positive-data-pate-ino-20181017monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-ebola-vaccine-provides-100-protection-and-elicits-long-lasting-immune-responses-i-ino-20181015monthly0.5https://www.biopharmawatch.com/news/INO/inovio-successfully-develops-first-dna-encoded-monoclonal-antibody-dmab-checkpoint-inhibit-ino-20181008monthly0.5https://www.biopharmawatch.com/news/INO/inovio-develops-novel-h3n2-influenza-dna-vaccine-that-generates-cross-reactive-responses-a-ino-20180917monthly0.5https://www.biopharmawatch.com/news/INO/inovio-doses-1st-subject-in-phase-1-2-clinical-trial-for-vaccine-against-deadly-mers-infec-ino-20180905monthly0.5https://www.biopharmawatch.com/news/INO/inovio-and-korean-partner-dose-1st-subject-in-trial-to-develop-world-s-first-vaccine-to-pr-ino-20180904monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-participate-in-upcoming-investment-conferences-ino-20180821monthly0.5https://www.biopharmawatch.com/news/INO/inovio-treats-first-patient-in-immuno-oncology-study-for-advanced-or-metastatic-bladder-ca-ino-20180816monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-first-patient-dosed-in-trial-to-determine-pennvax-gp-s-ability-to-induce--ino-20180814monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2018-second-quarter-financial-results-ino-20180807monthly0.5https://www.biopharmawatch.com/news/INO/inovio-partners-with-aids-malignancy-consortium-to-advance-inovio-s-hpv-therapy-for-high-g-ino-20180806monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-report-second-quarter-2018-financial-results-on-august-7-2018-ino-20180724monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-mers-vaccine-generates-high-levels-of-antibodies-and-induces-broad-based-t-cell-r-ino-20180627monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-treatment-of-first-patient-in-immuno-oncology-study-for-glioblastoma-gbm--ino-20180621monthly0.5https://www.biopharmawatch.com/news/INO/inovio-ceo-to-speak-on-viral-epidemic-preparedness-panel-at-bio-international-convention-ino-20180531monthly0.5https://www.biopharmawatch.com/news/INO/inovio-boosts-leadership-focused-on-partnership-and-grant-funding-by-appointing-two-new-vp-ino-20180524monthly0.5https://www.biopharmawatch.com/news/INO/inovio-opens-phase-2-trial-for-vgx-3100-in-third-indication-to-treat-hpv-the-no-1-sexually-ino-20180521monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-demonstrates-psa-stabilizing-effect-of-ino-5150-immunotherapy-in-ph-ino-20180517monthly0.5https://www.biopharmawatch.com/news/INO/inovio-hiv-vaccine-which-generated-near-100-immune-responses-sustained-durable-memory-resp-ino-20180515monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2018-first-quarter-financial-results-ino-20180509monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-report-first-quarter-2018-financial-results-on-may-9-2018-ino-20180430monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-the-h-c-wainwright-annual-global-life-sciences-confer-ino-20180402monthly0.5https://www.biopharmawatch.com/news/INO/inovio-closes-license-and-collaboration-agreement-with-apollobio-to-develop-and-commercial-ino-20180320monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2017-fourth-quarter-and-year-end-financial-results-ino-20180314monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-dna-immunotherapy-demonstrates-immune-response-results-key-in-treating-chronic-he-ino-20180314monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-report-fourth-quarter-and-year-end-2017-financial-results-on-mar-ino-20180312monthly0.5https://www.biopharmawatch.com/news/INO/inovio-and-the-wistar-institute-receive-more-than-4-6-million-in-r-d-funding-to-advance-va-ino-20180212monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-participate-in-upcoming-investment-conferences-ino-20180205monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-published-universal-flu-vaccine-data-demonstrates-protective-respon-ino-20180122monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-co-founder-along-with-its-lead-antigen-designer-named-among-top-20-researchers-wi-ino-20180117monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-and-the-parker-institute-for-cancer-immunotherapy-establish-clinica-ino-20180109monthly0.5https://www.biopharmawatch.com/news/INO/inovio-receives-milestone-payment-from-medimmune-as-medi0457-and-checkpoint-inhibitor-comb-ino-20180108monthly0.5https://www.biopharmawatch.com/news/INO/inovio-enters-license-and-collaboration-agreement-with-apollobio-to-develop-and-commercial-ino-20180102monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-promotes-dr-laurent-humeau-to-senior-vice-president-research-develo-ino-20171211monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-appoints-wendy-yarno-to-its-board-of-directors-ino-20171206monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-further-analysis-of-vgx-3100-phase-2b-data-reveals-immune-correlates-and-biomarke-ino-20171129monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-syncon-tert-cancer-immunotherapy-combined-with-checkpoint-inhibitor-ino-20171127monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-presents-immuno-oncology-advancements-at-society-for-immunotherapy--ino-20171110monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-participate-in-upcoming-investment-conferences-ino-20171109monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2017-third-quarter-financial-results-ino-20171108monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-initiates-immuno-oncology-clinical-study-for-glioblastoma-in-combin-ino-20171101monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-report-third-quarter-2017-financial-results-on-november-8-2017-ino-20171026monthly0.5https://www.biopharmawatch.com/news/INO/inovio-and-u-s-army-co-developing-novel-vaccine-that-completely-prevents-lethal-lassa-feve-ino-20171024monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-begins-phase-1b-2-cancer-efficacy-trial-combining-its-t-cell-immuno-ino-20171016monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-positive-zika-vaccine-clinical-study-data-published-in-new-england-journal-of-med-ino-20171005monthly0.5https://www.biopharmawatch.com/news/INO/inovio-dmab-constructs-shrink-prostate-tumors-and-protect-against-lethal-antibiotic-resist-ino-20170921monthly0.5https://www.biopharmawatch.com/news/INO/inovio-and-partners-initiate-phase-1-2a-clinical-trial-to-further-advance-its-vaccine-agai-ino-20170918monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-cancer-immunotherapy-ino-5150-slowed-psa-rise-and-significantly-increased-psa-dou-ino-20170911monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-participate-in-upcoming-investment-conferences-ino-20170823monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2017-second-quarter-financial-results-ino-20170808monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-report-second-quarter-2017-financial-results-on-august-8-2017-ino-20170726monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-pricing-of-public-offering-of-common-stock-ino-20170720monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-dna-based-monoclonal-antibody-platform-achieves-further-proof-of-principle-valida-ino-20170706monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-leadership-appointments-ino-20170628monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-participate-on-panel-at-2017-bio-international-convention-ino-20170619monthly0.5https://www.biopharmawatch.com/news/INO/inovio-fully-enrolls-160-subjects-in-puerto-rico-for-second-zika-vaccine-phase-1-trial-con-ino-20170615monthly0.5https://www.biopharmawatch.com/news/INO/inovio-begins-phase-3-clinical-trial-of-vgx-3100-for-the-treatment-of-hpv-related-cervical-ino-20170608monthly0.5https://www.biopharmawatch.com/news/INO/inovio-zika-vaccine-prevents-persistence-of-virus-and-damage-in-male-reproductive-tract-in-ino-20170607monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-clinical-trial-collaboration-to-evaluate-a-novel-t-cell-immunotherapy-in--ino-20170601monthly0.5https://www.biopharmawatch.com/news/INO/inovio-hiv-vaccine-elicits-nearly-100-immune-response-rates-in-a-clinical-study-ino-20170524monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2017-first-quarter-financial-results-ino-20170510monthly0.5https://www.biopharmawatch.com/news/INO/inovio-provides-update-on-medimmune-launch-of-combination-trial-for-hpv-associated-head-ne-ino-20170510monthly0.5https://www.biopharmawatch.com/news/INO/inovio-regeneron-enter-immuno-oncology-clinical-study-agreement-for-glioblastoma-combinati-ino-20170508monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-participate-in-bank-of-america-merrill-lynch-2017-healthcare-con-ino-20170502monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-report-first-quarter-2017-financial-results-may-10-2017-ino-20170426monthly0.5https://www.biopharmawatch.com/news/INO/inovio-initiates-phase-2-efficacy-trial-with-vgx-3100-for-hpv-related-vulvar-pre-cancers-ino-20170424monthly0.5https://www.biopharmawatch.com/news/INO/inovio-ebola-vaccine-demonstrates-robust-immune-responses-with-favorable-safety-profile-in-ino-20170411monthly0.5https://www.biopharmawatch.com/news/INO/inovio-and-collaborators-receive-nih-grant-to-evaluate-hiv-immunotherapy-pennvax-gp-s-abil-ino-20170330monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2016-fourth-quarter-and-year-end-financial-results-ino-20170315monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-report-fourth-quarter-and-year-end-2016-financial-results-on-mar-ino-20170309monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-syncon-wt1-cancer-antigen-breaks-tolerance-highlights-potential-for-universal-can-ino-20170227monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-new-positive-clinical-data-on-vaccine-advances-in-the-fight-against-emergin-ino-20170223monthly0.5https://www.biopharmawatch.com/news/INO/inovio-and-apollobio-to-collaborate-on-development-and-commercialization-of-hpv-pre-cancer-ino-20170213monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-participate-in-upcoming-investment-conferences-ino-20170130monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-zika-vaccine-generates-robust-immune-responses-in-first-human-study-ino-20161221monthly0.5https://www.biopharmawatch.com/news/INO/inovio-mers-vaccine-development-to-be-expanded-with-funding-from-international-vaccine-ins-ino-20161206monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-awarded-6-1-million-sub-grant-through-wistar-institute-to-develop-d-ino-20161201monthly0.5https://www.biopharmawatch.com/news/INO/inovio-applies-to-cease-reporting-to-canadian-securities-regulatory-authorities-nasdaq-lis-ino-20161125monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-co-founder-and-chair-of-its-scientific-advisory-board-selected-as-a-top-20-transl-ino-20161121monthly0.5https://www.biopharmawatch.com/news/INO/inovio-wins-deloitte-s-fast-500-growth-award-ino-20161116monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-cancer-immunotherapy-ino-3112-generates-t-cell-immune-responses-in-tumor-tissue-a-ino-20161114monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-zika-vaccine-protects-animals-from-infection-brain-damage-and-death-ino-20161110monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2016-third-quarter-financial-results-ino-20161109monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-participate-in-upcoming-investment-conferences-ino-20161104monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-report-third-quarter-2016-financial-results-november-9-2016-ino-20161026monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-fda-request-for-additional-information-for-phase-iii-program-trial-initia-ino-20161024monthly0.5https://www.biopharmawatch.com/news/INO/inovio-ceo-selected-as-2016-healthcare-innovator-ino-20161021monthly0.5https://www.biopharmawatch.com/news/INO/inovio-expands-executive-team-to-advance-its-dna-immunotherapy-product-portfolio-ino-20161012monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-zika-vaccine-selected-as-2016-technology-breakthrough-ino-20160912monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-upcoming-investment-conferences-ino-20160901monthly0.5https://www.biopharmawatch.com/news/INO/inovio-launches-zika-vaccine-trial-in-midst-of-puerto-rico-epidemic-to-explore-early-signa-ino-20160829monthly0.5https://www.biopharmawatch.com/news/INO/inovio-licenses-veterinary-foot-and-mouth-disease-vaccine-to-plumbline-life-sciences-ino-20160816monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-expands-positive-phase-i-ebola-vaccine-trial-to-identify-most-optim-ino-20160811monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2016-second-quarter-financial-results-ino-20160808monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-appoints-dr-ami-shah-brown-as-vice-president-regulatory-affairs-ino-20160804monthly0.5https://www.biopharmawatch.com/news/INO/inovio-will-independently-develop-hepatitis-b-immunotherapy-ino-20160803monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-doses-first-subject-in-zika-vaccine-clinical-trial-ino-20160726monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-report-second-quarter-2016-financial-results-august-8-2016-ino-20160726monthly0.5https://www.biopharmawatch.com/news/INO/inovio-deploys-dna-based-monoclonal-antibody-technology-in-quest-to-cure-hiv-ino-20160714monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-and-geneone-life-science-receive-approval-for-first-in-man-zika-vac-ino-20160620monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-zika-vaccine-produces-robust-immune-responses-in-non-human-primates-ino-20160516monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-ubs-global-healthcare-conference-ino-20160511monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2016-first-quarter-financial-results-ino-20160509monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-showcases-its-broad-pipeline-of-dna-based-immunotherapies-vaccines--ino-20160504monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-completes-acquisition-of-needle-free-injection-technology-ino-20160502monthly0.5https://www.biopharmawatch.com/news/INO/inovio-partners-with-national-cancer-institute-and-mayo-clinic-to-initiate-hepatitis-c-imm-ino-20160427monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-report-first-quarter-2016-financial-results-may-9-2016-ino-20160426monthly0.5https://www.biopharmawatch.com/news/INO/inovio-ebola-vaccine-generates-robust-immune-responses-in-humans-ino-20160330monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-hpv-immunotherapy-selected-as-best-therapeutic-vaccine-by-world-vac-ino-20160330monthly0.5https://www.biopharmawatch.com/news/INO/inovio-updates-ino-3112-hpv-immunotherapy-development-plan-ino-20160329monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-dna-based-monoclonal-antibody-and-dna-vaccine-provide-100-protection-against-leth-ino-20160322monthly0.5https://www.biopharmawatch.com/news/INO/inovio-signs-collaborative-research-agreements-with-wistar-institute-for-dna-based-immunot-ino-20160316monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-acquires-needle-free-injection-technology-to-advance-strategy-for-n-ino-20160314monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2015-fourth-quarter-and-year-end-financial-results-ino-20160314monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-appoints-dna-immunotherapy-pioneer-david-b-weiner-ph-d-to-its-board-ino-20160311monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-report-fourth-quarter-and-year-end-2015-financial-results-on-mar-ino-20160303monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceutical-s-dna-vaccine-for-zika-virus-induces-robust-immune-responses-in-prec-ino-20160217monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-participate-in-upcoming-investor-conferences-ino-20160202monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-and-geneone-life-science-initiate-patient-recruitment-for-mers-vacc-ino-20160128monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-awarded-grant-to-advance-needle-free-vaccine-delivery-device-ino-20160119monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-biotech-showcase-ino-20160105monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-adds-dr-prakash-bhuyan-to-vgx-3100-leadership-team-for-hpv-related--ino-20160104monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-piper-jaffray-healthcare-conference-ino-20151123monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2015-third-quarter-results-ino-20151109monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-ino-3112-shows-robust-immune-responses-in-patients-with-head-neck-cancer-ino-20151105monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-host-third-quarter-2015-financial-results-conference-call-novemb-ino-20151026monthly0.5https://www.biopharmawatch.com/news/INO/inovio-and-partner-advance-mers-vaccine-ino-20151019monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-participate-in-upcoming-investor-conferences-ino-20150930monthly0.5https://www.biopharmawatch.com/news/INO/inovio-receives-24-million-option-grant-from-darpa-to-advance-ebola-program-development-ino-20150921monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-publishes-successful-phase-2b-trial-results-of-its-hpv-immunotherap-ino-20150917monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-chief-operating-officer-selected-by-pharmavoice-as-one-of-the-most-inspirational--ino-20150915monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-announces-first-patient-dosed-with-universal-hiv-vaccine-ino-20150908monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-participate-in-citi-and-rodman-renshaw-investor-conferences-ino-20150826monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-dna-vaccine-protects-100-against-deadly-mers-virus-in-non-human-pri-ino-20150819monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2015-second-quarter-results-conference-call-will-discuss-ne-ino-20150810monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-host-second-quarter-2015-financial-results-conference-call-augus-ino-20150730monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-dna-based-monoclonal-antibody-protects-animals-against-lethal-chall-ino-20150729monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-initiates-clinical-trial-of-ino-5150-dna-immunotherapy-for-prostate-ino-20150727monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-and-european-organization-for-research-and-treatment-of-cancer-to-c-ino-20150723monthly0.5https://www.biopharmawatch.com/news/INO/inovio-s-ceo-appointed-to-aspen-institute-s-health-innovators-fellowship-ino-20150713monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-ceo-named-entrepreneur-of-the-year-by-ernst-young-ino-20150612monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-partners-with-geneone-life-science-for-mers-immunotherapy-clinical--ino-20150527monthly0.5https://www.biopharmawatch.com/news/INO/inovio-to-present-at-jefferies-healthcare-conference-ino-20150526monthly0.5https://www.biopharmawatch.com/news/INO/inovio-initiates-clinical-trial-with-dna-immunotherapies-to-prevent-and-treat-ebola-ino-20150512monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2015-first-quarter-financial-results-ino-20150511monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-report-first-quarter-2015-financial-results-may-11-2015-ino-20150501monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-ino-20150430monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-and-roche-initiate-clinical-trial-for-inovio-s-dna-immunotherapy-to-ino-20150421monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-hpv-immunotherapy-recognized-as-best-therapeutic-vaccine-by-world-v-ino-20150409monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-hpv-immunotherapy-activates-robust-in-vivo-t-cell-responses-in-head-ino-20150409monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-selected-by-darpa-to-lead-a-45-million-program-to-expedite-developm-ino-20150408monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-alliance-regenerative-medicine-s-2015-regen-med-inves-ino-20150319monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-appoints-scott-m-white-m-d-vice-president-clinical-development-infe-ino-20150318monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-and-academic-collaborators-receive-16-million-hiv-grant-from-nation-ino-20150316monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-reports-2014-fourth-quarter-and-year-end-financial-results-ino-20150316monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-report-fourth-quarter-and-year-end-2014-financial-results-on-mar-ino-20150306monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-welcomes-nancy-wysenski-to-its-board-of-directors-ino-20150305monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-to-present-at-upcoming-investor-conferences-ino-20150202monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-inc-nasdaq-ino-to-ring-the-nasdaq-stock-market-opening-bell-ino-20141124monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-ceo-dr-j-joseph-kim-interviewed-by-the-life-sciences-report-ino-20141030monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-participate-in-roth-capital-partners-virtual-kol-event-on-december-10-2025-pypd-20251125monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-report-third-quarter-2025-financial-results-and-operational-highlights-on-novem-pypd-20251029monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-report-second-quarter-2025-financial-results-and-operational-highlights-on-augu-pypd-20250730monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-host-conference-call-and-webcast-to-discuss-d-plex100-shield-ii-phase-3-trial-t-pypd-20250606monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-participate-in-the-lytham-partners-spring-2025-investor-conference-on-may-29-20-pypd-20250520monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-report-first-quarter-2025-financial-results-and-operational-highlights-on-may-1-pypd-20250429monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-participate-in-the-citizens-life-sciences-conference-pypd-20250422monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-participate-in-the-37th-annual-roth-conference-pypd-20250303monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference-pypd-20250130monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-report-fourth-quarter-and-full-year-2024-financial-results-and-operational-high-pypd-20250129monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-participate-in-the-craig-hallum-15th-annual-alpha-select-conference-pypd-20241107monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-report-third-quarter-2024-financial-results-and-operational-highlights-on-novem-pypd-20241030monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-publication-in-international-journal-of-surgery-highlighting-results-of--pypd-20241021monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-participate-in-three-upcoming-fall-investor-conferences-pypd-20240903monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-report-second-quarter-2024-financial-results-and-operational-highlights-on-augu-pypd-20240731monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-host-virtual-kol-event-on-june-17-2024-and-provide-an-update-on-the-company-s-o-pypd-20240610monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-participate-in-citizens-jmp-life-sciences-conference-pypd-20240501monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-enrollment-of-200th-patient-in-ongoing-shield-ii-phase-3-trial-evaluatin-pypd-20240430monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-report-first-quarter-2024-financial-results-and-operational-highlights-on-may-8-pypd-20240424monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-participate-in-barclays-26th-annual-global-healthcare-conference-pypd-20240228monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-enrollment-of-the-100th-patient-in-the-ongoing-shield-ii-phase-3-trial-pypd-20240212monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-report-fourth-quarter-and-full-year-2023-financial-results-and-operational-high-pypd-20240131monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-report-third-quarter-2023-financial-results-and-operational-highlights-on-novem-pypd-20231101monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-presentation-at-the-american-college-of-surgeons-clinical-congress-2023-pypd-20231009monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-publication-of-preclinical-data-further-supporting-the-good-safety-profi-pypd-20231004monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-present-at-the-2023-cantor-fitzgerald-global-healthcare-conference-pypd-20230922monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-successful-commercial-good-manufacturing-practice-gmp-audit-by-israeli-m-pypd-20230921monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-successful-completion-of-manufacturing-process-validation-for-d-plex100-pypd-20230919monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-report-second-quarter-2023-financial-results-and-operational-highlights-on-augu-pypd-20230726monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-new-publication-highlighting-potent-antibacterial-activity-of-d-plex100--pypd-20230629monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-report-first-quarter-2023-financial-results-and-operational-highlights-on-may-1-pypd-20230426monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-participate-in-upcoming-investor-conferences-pypd-20230424monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-closing-of-underwritten-public-offering-including-full-exercise-of-overa-pypd-20230331monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-pricing-of-6-2-million-underwritten-public-offering-of-ordinary-shares-a-pypd-20230329monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-present-at-the-barclays-global-healthcare-conference-pypd-20230307monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-report-fourth-quarter-and-full-year-2022-financial-results-and-operational-high-pypd-20230131monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-presentation-of-phase-2-d-plex100-clinical-data-at-the-first-triennial-m-pypd-20221129monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-report-third-quarter-2022-financial-results-and-operational-highlights-on-novem-pypd-20221026monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-cost-reduction-plan-pypd-20221020monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-peer-reviewed-publication-of-phase-2-clinical-trial-results-for-d-plex10-pypd-20220919monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-presentation-of-phase-2-d-plex100-clinical-data-at-the-european-society--pypd-20220912monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-presentation-at-the-2022-military-health-system-research-symposium-pypd-20220830monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-report-second-quarter-2022-financial-results-and-operational-highlights-on-augu-pypd-20220727monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-presentation-of-phase-2-d-plex100-clinical-data-at-the-midwest-surgical--pypd-20220725monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-hosting-key-opinion-leader-webinar-on-managing-the-cost-of-surgical-site-infection-pypd-20220615monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-presentation-of-d-plex100-phase-2-clinical-data-at-asm-microbe-2022-pypd-20220606monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-present-at-the-jmp-securities-2022-life-sciences-conference-pypd-20220602monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-publication-of-animal-model-studies-in-2022-asco-annual-meeting-abstract-pypd-20220601monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-report-first-quarter-2022-financial-results-and-operational-highlights-on-may-1-pypd-20220427monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-presentation-at-the-13th-european-and-global-clinam-summit-for-nanomedic-pypd-20220425monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-presentation-of-clinical-data-at-surgical-infection-society-2022-annual--pypd-20220412monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-deliver-poster-presentation-at-sages-2022-pypd-20220308monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-750th-patient-enrolled-in-shield-i-phase-3-clinical-trial-of-d-plex100-i-pypd-20220302monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-present-at-the-barclays-global-healthcare-conference-pypd-20220301monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-report-fourth-quarter-and-full-year-2021-financial-results-and-operational-high-pypd-20220126monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-appoints-ucsf-brain-tumor-center-director-mitchel-s-berger-m-d-to-oncology-advisor-pypd-20220104monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-planned-ceo-transition-pypd-20220103monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-500th-patient-enrolled-in-shield-i-phase-3-clinical-trial-of-d-plex100-i-pypd-20211118monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-appoints-new-oncology-advisory-board-member-pypd-20211116monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-report-third-quarter-2021-financial-results-and-operational-highlights-on-novem-pypd-20211101monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-present-at-upcoming-cantor-fitzgerald-global-healthcare-conference-pypd-20210920monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-present-at-first-world-association-against-infection-in-orthopaedics-and-trauma-pypd-20210817monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-present-at-the-investor-summit-virtual-conference-on-august-18-2021-pypd-20210809monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-report-second-quarter-2021-financial-results-and-operational-highlights-on-augu-pypd-20210728monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-strengthens-executive-team-appointing-dr-anthony-senagore-as-senior-medical-direct-pypd-20210712monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-presents-today-at-the-raymond-james-human-health-innovation-conference-pypd-20210623monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-present-at-upcoming-healthcare-investor-conferences-pypd-20210602monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-report-first-quarter-2021-financial-results-and-operational-highlights-on-may-1-pypd-20210429monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-participate-in-upcoming-investor-conferences-pypd-20210223monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-100th-patient-enrolled-in-shield-i-phase-3-clinical-trial-of-d-plex100-f-pypd-20210216monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-report-fourth-quarter-and-full-year-2020-financial-results-and-operational-high-pypd-20210127monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-host-key-opinion-leader-call-discussing-d-plex100-and-the-prevention-of-surgica-pypd-20201203monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-participate-in-three-upcoming-investor-conferences-pypd-20201104monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-report-third-quarter-2020-financial-results-and-operational-highlights-on-novem-pypd-20201028monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-report-second-quarter-2020-financial-results-and-operational-highlights-on-augu-pypd-20200805monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-to-present-phase-2-results-of-d-plex100-for-the-prevention-of-surgical-site-infect-pypd-20200727monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-positive-top-line-results-from-phase-2-clinical-trial-of-d-plex100-for-t-pypd-20191016monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-positive-initial-preclinical-findings-supporting-further-eval-oncy-20260601monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-present-new-mechanistic-and-translational-data-supporting-pelareorep-oncy-20260319monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-attendance-of-upcoming-conferences-oncy-20181113monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-positive-clinical-trial-results-for-pelareorep-in-patients-wi-oncy-20181022monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-publication-of-positive-clinical-results-for-pelareorep-in-ab-oncy-20181011monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-a-publication-demonstrating-that-intravenously-delivered-onco-oncy-20181002monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-enters-into-common-stock-purchase-agreement-for-up-to-us-26-million-wit-oncy-20180928monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-present-at-the-ladenburg-thalmann-2018-healthcare-conference-oncy-20180926monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-provides-corporate-and-clinical-update-oncy-20180919monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-investigator-sponsored-multiple-myeloma-study-combining-reoly-oncy-20180917monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-collaborates-with-solti-to-conduct-a-window-of-opportunity-study-in-bre-oncy-20180910monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-a-master-clinical-supply-agreement-of-an-anti-pd-l1-checkpoin-oncy-20180906monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-2018-second-quarter-results-oncy-20180803monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-present-at-the-canaccord-genuity-38th-annual-growth-conference-oncy-20180731monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-closes-usd-8-9-million-public-offering-of-common-shares-oncy-20180605monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-prices-usd-8-000-000-million-public-offering-of-common-shares-oncy-20180601monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-new-otcqx-ticker-symbol-oncy-20180529monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-research-collaboration-with-the-keck-school-of-medicine-of-us-oncy-20180525monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-has-applied-to-list-its-common-shares-on-nasdaq-and-announces-share-con-oncy-20180522monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-collaboration-with-merck-and-northwestern-university-combinin-oncy-20180517monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-reports-2018-first-quarter-results-oncy-20180511monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-receives-special-protocol-assessment-agreement-from-fda-for-phase-3-cli-oncy-20180510monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-voting-results-from-its-annual-general-meeting-of-shareholder-oncy-20180504monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-expands-payer-coverage-with-four-new-medical-policies-nrxs-20260422monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-inc-announces-preferred-stock-dividend-nrxs-20260410monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-reports-strong-fourth-quarter-and-full-year-2025-financial-results-nrxs-20260319monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-achieves-major-milestone-with-ama-category-i-cpt-code-now-in-effect-establishing--nrxs-20260108monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-reports-strong-second-quarter-2025-financial-results-driven-by-a-46-growth-in-rev-nrxs-20250812monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-to-host-second-quarter-2025-results-and-business-update-call-on-tuesday-august-12-nrxs-20250805monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-to-participate-in-the-lytham-partners-spring-2025-investor-conference-on-may-29-2-nrxs-20250527monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-announces-closing-of-5-0-million-registered-direct-offering-nrxs-20250522monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-awarded-first-ever-fda-clearance-for-the-treatment-of-pediatric-fap-functional-dy-nrxs-20250520monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-reports-strong-first-quarter-2025-financial-results-driven-by-a-39-growth-in-reve-nrxs-20250512monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-to-host-first-quarter-2025-results-and-business-update-call-on-monday-may-12-2025-nrxs-20250505monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-to-present-at-the-planet-microcap-showcase-vegas-in-partnership-with-microcapclub-nrxs-20250415monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-reports-strong-fourth-quarter-2024-financial-results-driven-by-a-43-increase-in-r-nrxs-20250320monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-to-host-fourth-quarter-and-full-year-2024-results-and-business-update-call-on-thu-nrxs-20250312monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-inc-issues-letter-to-shareholders-nrxs-20250113monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-inc-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-janu-nrxs-20250106monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-inc-announces-fda-510-k-clearance-of-red-for-testing-and-evaluation-of-patients-w-nrxs-20241210monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-to-host-third-quarter-2024-results-and-business-update-call-on-tuesday-november-1-nrxs-20241105monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-receives-new-fda-510-k-clearance-for-ib-stim-expanding-its-addressable-market-nrxs-20241104monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-announces-new-cpt-category-i-code-for-percutaneous-electrical-nerve-field-stimula-nrxs-20241022monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-to-participate-in-the-lytham-partners-fall-2024-investor-conference-on-october-1--nrxs-20240919monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-announces-geisinger-health-plan-medical-policy-coverage-for-penfs-effective-septe-nrxs-20240827monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-announces-bcbs-of-vermont-medical-policy-coverage-for-penfs-effective-october-1st-nrxs-20240813monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-to-host-second-quarter-2024-results-and-business-update-call-on-friday-august-9-2-nrxs-20240805monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-announces-new-submission-to-the-fda-for-the-expansion-of-its-ib-stim-label-provid-nrxs-20240607monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-reports-first-quarter-2024-financial-results-nrxs-20240522monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-to-participate-in-the-lytham-partners-spring-2024-investor-conference-on-may-30-2-nrxs-20240521monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-announces-new-medical-policy-coverage-for-nearly-six-million-lives-in-florida-nrxs-20240516monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-to-host-first-quarter-2024-results-and-business-update-call-on-wednesday-may-22-2-nrxs-20240515monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-announces-new-medical-policy-coverage-in-north-dakota-nrxs-20240423monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-to-host-fourth-quarter-and-full-year-2023-results-and-business-update-call-on-tue-nrxs-20240401monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-announces-ib-stim-results-from-a-large-pediatric-multi-center-registry-nrxs-20240327monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-announces-highmark-bcbs-policy-coverage-nrxs-20240311monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-announces-blue-cross-and-blue-shield-of-kansas-city-policy-coverage-nrxs-20240304monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-to-present-at-oppenheimer-34th-annual-healthcare-medtech-services-conference-nrxs-20240227monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-inc-issues-letter-to-shareholders-from-brian-carrico-president-and-chief-executiv-nrxs-20231220monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-reports-third-quarter-2023-financial-results-nrxs-20231120monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-announces-carefirst-bcbs-policy-coverage-nrxs-20231115monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-secures-3-million-financing-nrxs-20231114monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-signs-exclusive-option-agreement-with-university-of-michigan-for-innovative-gastr-nrxs-20231108monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-announces-results-of-comparative-study-of-ib-stim-and-standard-medical-therapy-in-nrxs-20230926monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-to-present-at-the-gilmartin-group-emerging-growth-showcase-nrxs-20230913monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-announces-publication-of-prospective-study-showing-ib-stim-improves-quality-of-li-nrxs-20230912monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-highlights-pediatric-post-concussion-clinical-study-nrxs-20230829monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-highlights-strength-of-its-board-of-directors-nrxs-20230824monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-highlights-two-independent-studies-showing-benefits-of-ib-stim-in-adolescents-inv-nrxs-20230822monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-announces-over-8-million-in-ib-stim-revenue-nrxs-20230817monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-announces-positive-university-of-michigan-ib-stim-cost-effectiveness-study-at-anm-nrxs-20230815monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-highlights-current-commercial-insurance-coverage-with-bcbs-massachusetts-bcbs-sou-nrxs-20230810monthly0.5https://www.biopharmawatch.com/news/PROF/profound-to-showcase-tulsa-pro-the-tulsa-procedure-and-the-future-of-imri-at-aua2026-prof-20260514monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-reports-strong-first-quarter-2026-financial-results-prof-20260507monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-investigated-by-the-portnoy-law-firm-prof-20260409monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-reports-fourth-quarter-and-full-year-2025-financial-results-prof-20260305monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-fourth-quarter-and-full-year-2025-financial-results-on-march-5-prof-20260212monthly0.5https://www.biopharmawatch.com/news/PROF/profound-surpasses-2025-tulsa-pro-installed-base-goal-prof-20260112monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-upsize-of-private-placement-prof-20251224monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-closes-36-million-registered-direct-offering-expects-to-complete-sub-prof-20251223monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-celebrates-the-hong-center-s-200th-independent-tulsa-procedure-for-prosta-prof-20251118monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-reports-strong-third-quarter-2025-financial-results-prof-20251113monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-second-quarter-2025-financial-results-on-august-14-conference--prof-20250724monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-first-commercial-bph-patient-treatment-using-tulsa-pro-with-tul-prof-20250610monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-annual-general-and-special-meeting-of-shareholders-voting-results-prof-20250514monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-first-quarter-2025-financial-results-prof-20250508monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-the-2025-bloom-burton-co-healthcare-investor-conference-prof-20250430monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-first-quarter-2025-financial-results-on-may-8-conference-call--prof-20250417monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-aua-2025-investor-event-agenda-prof-20250415monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-fourth-quarter-and-full-year-2024-financial-results-prof-20250306monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-fourth-quarter-and-full-year-2024-financial-results-on-march-6-prof-20250213monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-preliminary-unaudited-fourth-quarter-and-full-year-2024-revenue-prof-20250108monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-prof-20250106monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-closing-of-us-40-25-million-underwritten-public-offering-of-com-prof-20241210monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-pricing-of-us-35-million-underwritten-public-offering-of-common-prof-20241206monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-proposed-public-offering-of-common-shares-prof-20241205monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-and-siemens-healthineers-to-offer-a-complete-solution-for-mri-guided-pros-prof-20241202monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-unveil-next-tulsa-ai-module-ua-alignment-assistant-prof-20241126monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-the-stifel-2024-healthcare-conference-prof-20241112monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-tulsa-reimbursement-raised-to-urology-apc-level-7-under-cms-out-prof-20241104monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-third-quarter-2024-financial-results-on-november-7-conference--prof-20241017monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-appoints-tom-tamberrino-as-chief-commercial-officer-prof-20241016monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-s-pro-talk-live-event-features-the-present-and-future-of-tulsa-prof-20240916monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-lake-street-s-best-ideas-growth-conference-prof-20240904monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-second-quarter-2024-financial-results-on-august-8-conference-c-prof-20240718monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-category-1-cpt-codes-proposed-cy2025-rule-for-tulsa-to-treat-pr-prof-20240711monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-annual-general-meeting-of-shareholders-voting-results-prof-20240515monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-receives-u-s-fda-510-k-clearance-for-contouring-assistant-ai-module-that--prof-20240514monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-first-quarter-2024-financial-results-and-issues-full-year-2024--prof-20240509monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-first-quarter-2024-financial-results-on-may-9-conference-call--prof-20240422monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-the-2024-bloom-burton-co-healthcare-investor-conference-prof-20240409monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-fourth-quarter-and-full-year-2023-financial-results-prof-20240307monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-barclays-26th-annual-global-healthcare-conference-prof-20240304monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-in-collaboration-with-siemens-healthineers-to-further-expand-physician-an-prof-20240227monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-fourth-quarter-and-full-year-2023-financial-results-on-march-7-prof-20240215monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-non-brokered-private-placement-prof-20240116monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-preliminary-unaudited-fourth-quarter-and-full-year-2023-revenue-prof-20240103monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-the-stifel-2023-healthcare-conference-prof-20231108monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-cms-extension-of-temporary-code-for-tulsa-to-asc-setting-prof-20231103monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-third-quarter-2023-financial-results-prof-20231102monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-third-quarter-2023-financial-results-on-november-2-conference--prof-20231019monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-2023-virtual-analyst-investor-day-agenda-prof-20231010monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-receives-u-s-fda-510-k-clearance-for-tulsa-pro-thermal-boost-prof-20230925monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-the-2023-cantor-global-healthcare-conference-prof-20230919monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-second-quarter-2023-financial-results-prof-20230809monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-second-quarter-2023-financial-results-on-august-9-conference-c-prof-20230802monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-new-cpt-category-1-codes-from-the-ama-for-tulsa-to-treat-prosta-prof-20230602monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-upcoming-investor-events-prof-20230530monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-a-g-p-s-virtual-healthcare-conference-prof-20230518monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-annual-and-special-meeting-of-shareholders-voting-results-prof-20230517monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-first-quarter-2023-financial-results-prof-20230510monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-first-quarter-2023-financial-results-on-may-10-conference-call-prof-20230419monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-to-participate-in-the-2023-bloom-burton-co-healthcare-investor-confere-prof-20230419monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-fourth-quarter-and-full-year-2022-financial-results-prof-20230307monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-present-at-the-43rd-annual-cowen-health-care-conference-prof-20230301monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-fourth-quarter-and-full-year-2022-financial-results-on-march-7-prof-20230214monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-present-at-the-2022-jefferies-london-healthcare-conference-prof-20221108monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-third-quarter-2022-financial-results-prof-20221103monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-third-quarter-2022-financial-results-on-november-3-conference--prof-20221013monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-changes-to-its-commercial-organization-to-support-continued-gro-prof-20220915monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-september-investor-conferences-prof-20220906monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-provides-tulsa-pro-reimbursement-update-prof-20220902monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-second-quarter-2022-financial-results-prof-20220804monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-second-quarter-2022-financial-results-on-august-4-conference-c-prof-20220714monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-the-cowen-7th-annual-futurehealth-conference-prof-20220616monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-the-2022-jefferies-global-healthcare-conference-prof-20220602monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-annual-and-special-meeting-of-shareholders-voting-results-prof-20220518monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-clarifies-recent-insider-buying-prof-20220518monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-first-quarter-2022-financial-results-prof-20220509monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-the-2022-bloom-burton-co-healthcare-investor-conference-prof-20220425monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-first-quarter-2022-financial-results-on-may-9-conference-call--prof-20220418monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-fourth-quarter-and-full-year-2021-financial-results-prof-20220303monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-march-investor-conferences-prof-20220302monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-s-tulsa-pro-now-compatible-with-ge-healthcare-s-3t-mri-scanners-prof-20220301monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-fourth-quarter-and-full-year-2021-financial-results-on-march-3-prof-20220210monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-the-btig-medtech-digital-health-life-science-diagnostic-prof-20220208monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-first-patients-treated-in-prospective-randomized-clinical-trial-prof-20220118monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-third-quarter-2021-financial-results-prof-20211104monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-november-virtual-investor-conferences-prof-20211101monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-third-quarter-2021-financial-results-on-november-4-conference--prof-20211018monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-september-virtual-investor-conferences-prof-20210908monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-second-quarter-2021-financial-results-prof-20210804monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-a-g-p-s-virtual-medtech-summer-conference-prof-20210722monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-second-quarter-2021-financial-results-on-august-4-conference-c-prof-20210715monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-june-investor-conferences-prof-20210525monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-voting-results-from-the-2021-annual-meeting-of-shareholders-and-prof-20210519monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-first-quarter-2021-financial-results-prof-20210512monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-and-akumin-enter-into-u-s-multi-center-commercial-agreement-for-tulsa-pro-prof-20210506monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-first-quarter-2021-financial-results-on-may-12-conference-call-prof-20210421monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-the-2021-bloom-burton-co-virtual-healthcare-investor-co-prof-20210414monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-the-appointment-of-cynthia-lavoie-to-its-board-of-directors-prof-20210303monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-fourth-quarter-and-full-year-2020-financial-results-prof-20210302monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-march-virtual-investor-conferences-prof-20210225monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-the-btig-virtual-medtech-digital-health-life-science-an-prof-20210211monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-fourth-quarter-and-full-year-2020-financial-results-on-march-2-prof-20210209monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-preliminary-unaudited-fourth-quarter-and-full-year-2020-revenue-prof-20210105monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-signs-agreement-with-ge-healthcare-to-expand-provider-access-to-tulsa-pro-prof-20201221monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-receives-fda-hde-approval-for-sonalleve-prof-20201130monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-changes-to-its-board-of-directors-prof-20201130monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-november-virtual-investor-healthcare-conferences-prof-20201110monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-third-quarter-2020-financial-results-prof-20201105monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-third-quarter-2020-financial-results-on-november-5-conference--prof-20201015monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-present-at-the-cantor-virtual-global-healthcare-conference-prof-20200909monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-present-at-the-canaccord-genuity-40th-annual-growth-conference-prof-20200810monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-second-quarter-2020-financial-results-prof-20200806monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-second-quarter-2020-financial-results-on-august-6-conference-c-prof-20200722monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-closing-of-offering-prof-20200721monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-pricing-of-offering-of-common-shares-prof-20200716monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-proposed-offering-of-common-shares-prof-20200715monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-annual-and-special-meeting-of-shareholders-voting-results-prof-20200520monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-first-quarter-2020-financial-results-on-may-7-conference-call--prof-20200416monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-fourth-quarter-and-full-year-2019-financial-results-prof-20200303monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-participate-in-march-investor-healthcare-conferences-prof-20200226monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-fourth-quarter-and-full-year-2019-financial-results-on-march-3-prof-20200212monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-retires-bank-debt-ahead-of-schedule-prof-20200204monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-closing-of-offering-prof-20200127monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-pricing-of-offering-of-common-shares-prof-20200122monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-proposed-offering-of-common-shares-prof-20200121monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-preliminary-unaudited-fourth-quarter-and-full-year-2019-revenue-prof-20200110monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-and-radnet-sign-the-first-ever-u-s-multi-center-commercial-agreement-for--prof-20200110monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-present-at-the-first-annual-biotuesdays-pre-jpm-virtual-conference-prof-20191203monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-health-canada-approval-of-tulsa-pro-prof-20191125monthly0.5https://www.biopharmawatch.com/news/PROF/profound-to-participate-in-november-investor-healthcare-conferences-prof-20191031monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-nasdaq-listing-prof-20191028monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-third-quarter-2019-financial-results-on-november-7-conference--prof-20191024monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-share-consolidation-in-connection-with-proposed-nasdaq-lis-prof-20191011monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-proposes-new-mjds-registration-for-its-proposed-u-s-listing-prof-20190923monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-closing-of-offerings-prof-20190920monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-pricing-of-offerings-prof-20190913monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-proposed-offerings-of-units-prof-20190912monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-receives-u-s-fda-510-k-clearance-for-tulsa-pro-prof-20190816monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-second-quarter-2019-financial-results-prof-20190814monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-present-at-the-canaccord-genuity-39th-annual-growth-conference-prof-20190731monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-second-quarter-2019-financial-results-on-august-14-conference--prof-20190730monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-sells-first-tulsa-pro-system-in-japan-prof-20190709monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-annual-and-special-meeting-of-shareholders-voting-results-prof-20190613monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-first-quarter-2019-financial-results-prof-20190506monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-present-at-the-2019-bloom-burton-co-healthcare-investor-conference-prof-20190423monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-first-quarter-2019-financial-results-on-may-6-conference-call--prof-20190417monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-first-of-its-kind-tulsa-pro-installation-prof-20190416monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-analyst-investor-day-agenda-prof-20190408monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-positive-topline-results-from-tact-pivotal-clinical-trial-of-tu-prof-20190404monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-fourth-quarter-and-full-year-2018-financial-results-prof-20190307monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-present-at-the-cowen-and-company-39th-annual-health-care-conference-prof-20190305monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-fourth-quarter-and-full-year-2018-financial-results-on-march-7-prof-20190221monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-the-2019-btig-medtech-life-science-diagnostic-tools-con-prof-20190220monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-preliminary-unaudited-fourth-quarter-2018-revenues-prof-20190103monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-changes-to-commercial-organization-prof-20181214monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-third-quarter-2018-financial-results-prof-20181108monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-present-at-the-stifel-2018-healthcare-conference-prof-20181107monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-third-quarter-2018-financial-results-on-november-8-conference--prof-20181030monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-files-preliminary-base-shelf-prospectus-prof-20180906monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-second-quarter-2018-financial-results-prof-20180814monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-second-quarter-2018-financial-results-on-august-14-conference--prof-20180802monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-present-at-the-canaccord-genuity-38th-annual-growth-conference-prof-20180731monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-term-loan-agreement-with-cibc-innovation-banking-prof-20180731monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-graduation-to-toronto-stock-exchange-prof-20180711monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-annual-meeting-of-shareholders-voting-results-welcomes-two-indu-prof-20180614monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-first-quarter-2018-financial-results-prof-20180510monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-chinese-food-and-drug-administration-approval-for-sonallev-prof-20180509monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-first-quarter-2018-financial-results-on-may-10-2018-conference-prof-20180502monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-further-strengthens-management-team-with-appointment-of-aaron-davidson-as-prof-20180501monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-present-at-the-2018-bloom-burton-co-healthcare-investor-conference-prof-20180425monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-fourth-quarter-and-full-year-2017-financial-results-prof-20180326monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-closing-of-bought-deal-financing-prof-20180320monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-release-fourth-quarter-and-full-year-2017-financial-results-on-march-2-prof-20180309monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-2018-btig-healthcare-conference-prof-20180226monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-completion-of-patient-enrollment-in-tact-pivotal-clinical--prof-20180131monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-preliminary-fourth-quarter-2017-revenue-and-provides-progr-prof-20180108monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-to-present-at-the-29th-annual-piper-jaffray-healthcare-conference-prof-20171114monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-third-quarter-2017-financial-results-prof-20171107monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-expanded-clinical-use-of-tulsa-pro-in-prostate-care-to-inc-prof-20171106monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-to-present-at-the-2017-canaccord-genuity-medical-technologies-diagno-prof-20171026monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-to-release-third-quarter-2017-financial-results-on-november-7-2017-c-prof-20171025monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-closing-of-10-million-bought-deal-financing-prof-20170920monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-10-million-bought-deal-financing-prof-20170824monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-second-quarter-2017-financial-results-prof-20170823monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-to-release-second-quarter-2017-financial-results-on-august-23-2017-c-prof-20170809monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-completes-acquisition-of-royal-philips-sonalleve-mr-hifu-business-prof-20170731monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-definitive-agreement-with-royal-philips-to-expand-collabor-prof-20170630monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-annual-meeting-of-shareholders-voting-results-prof-20170524monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-first-quarter-2017-financial-results-prof-20170509monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-present-at-the-cibc-technology-innovation-conference-5-0-prof-20170503monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-to-release-first-quarter-2017-financial-results-on-may-9-2017-confer-prof-20170425monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-obtains-dtc-eligibility-for-its-common-shares-in-the-u-s-prof-20170418monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-first-paid-procedure-using-tulsa-pro-system-prof-20170327monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-management-change-prof-20170324monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-and-philips-announce-first-tulsa-pro-sale-in-finland-to-turku-univer-prof-20170320monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-to-begin-trading-on-otcqx-on-march-13-2017-prof-20170309monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-fourth-quarter-and-full-year-2016-financial-results-prof-20170306monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-to-release-fourth-quarter-and-full-year-2016-financial-results-on-ma-prof-20170221monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-participate-in-2017-btig-medical-technology-life-science-and-diagnosti-prof-20170214monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-special-meeting-of-shareholders-voting-results-prof-20170126monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-appointment-of-kenneth-galbraith-to-its-board-of-directors-prof-20170117monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-third-quarter-2016-financial-results-prof-20161116monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-completes-previously-announced-17-4-million-bought-deal-offering-of--prof-20161114monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-to-present-at-the-2016-canaccord-genuity-medical-technologies-diagno-prof-20161103monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-to-present-at-the-stifel-2016-healthcare-conference-prof-20161101monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-to-release-third-quarter-2016-financial-results-on-november-16-2016--prof-20161026monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-17-4-million-bought-deal-financing-prof-20161017monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-receives-frost-sullivan-s-2016-new-product-innovation-award-prof-20161005monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-first-patient-treated-in-tact-pivotal-clinical-trial-at-va-prof-20160922monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-second-quarter-2016-financial-results-prof-20160818monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-senior-management-changes-to-support-global-growth-strateg-prof-20160815monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-to-release-second-quarter-2016-financial-results-on-august-18-2016-prof-20160810monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-annual-meeting-of-shareholders-voting-results-prof-20160622monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-and-philips-sell-tulsa-pro-system-to-university-hospital-of-cologne--prof-20160621monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-to-hold-annual-general-meeting-of-the-shareholders-prof-20160607monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-and-philips-sign-sales-and-marketing-agreement-in-mri-guided-therapy-prof-20160511monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-first-quarter-2016-financial-results-prof-20160506monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-to-present-at-upcoming-conference-prof-20160429monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-to-release-first-quarter-2016-financial-results-on-may-6-2016-prof-20160429monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-world-s-first-sale-of-tulsa-pro-for-prostate-ablation-prof-20160428monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-receives-ce-mark-approval-for-tulsa-pro-prof-20160411monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-full-year-2015-financial-results-prof-20160303monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-and-siemens-enter-into-strategic-agreement-to-further-the-developmen-prof-20160229monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-to-release-full-year-2015-financial-results-on-march-3-2016-prof-20160225monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-publication-in-european-urology-prof-20160108monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-named-2016-life-science-company-of-the-year-prof-20151127monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-departure-of-cfo-prof-20151117monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-announces-third-quarter-2015-financial-results-prof-20151104monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-corp-to-release-third-quarter-2015-financial-results-on-november-4-2015-prof-20151028monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-present-at-upcoming-investor-conferences-prof-20151021monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-presents-successful-12-month-phase-i-outcomes-at-the-european-symposium-o-prof-20151015monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-to-present-12-month-outcomes-of-phase-1-clinical-trial-at-european-sympos-prof-20151013monthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-announces-grant-of-share-options-prof-20150918monthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-inc-signs-media-deal-with-new-to-the-street-for-network-interview--telo-20240516monthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-announces-collaboration-with-argenta-to-study-osteoarthritis-in-ca-telo-20240326monthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-presents-promising-pre-clinical-data-for-its-lead-development-prod-telo-20240307monthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-announces-closing-of-initial-public-offering-telo-20240213monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-deadline-rosen-the-first-filing-firm-encourages-aldeyra-therapeutics-inc-investors-aldx-20260528monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-deadline-friday-may-29th-bragar-eagel-squire-p-c-urgently-reminds-aldeyra-therapeu-aldx-20260526monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-more-i-aldx-20260317monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-aldx-faces-scrutiny-after-stock-drops-70-on-fda-s-reproxalap-comp-aldx-20250506monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-aldx-faces-scrutiny-after-stock-drops-70-on-fda-s-reproxalap-comp-aldx-20250501monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-aldx-faces-scrutiny-after-stock-drops-70-on-fda-s-reproxalap-comp-aldx-20250429monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-aldx-faces-scrutiny-after-stock-drops-70-on-fda-s-reproxalap-comp-aldx-20250424monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-aldx-faces-scrutiny-after-stock-drops-70-on-fda-s-reproxalap-comp-aldx-20250421monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-aldx-faces-scrutiny-after-stock-drops-70-on-fda-s-reproxalap-comp-aldx-20250418monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-aldx-faces-scrutiny-after-stock-drops-70-on-fda-s-reproxalap-comp-aldx-20250416monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-aldx-faces-scrutiny-after-stock-drops-70-on-fda-s-reproxalap-comp-aldx-20250411monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-alert-bragar-eagel-squire-p-c-is-investigating-aldeyra-therapeutics-inc-on-behalf--aldx-20250411monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-aldx-faces-scrutiny-after-stock-drops-70-on-fda-s-reproxalap-comp-aldx-20250409monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-alert-bragar-eagel-squire-p-c-is-investigating-aldeyra-therapeutics-inc-on-behalf--aldx-20240210monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-los-aldx-20230908monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-los-aldx-20230828monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-los-aldx-20230809monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-aldx-shareholder-notice-robbins-llp-reminds-shareholders-of-class-aldx-20230804monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-presents-noninfectious-anterior-uveitis-phase-2-clinical-trial-data-a-aldx-20170517monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-schedules-webcast-and-conference-call-to-provide-corporate-update-and-aldx-20170508monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-first-patient-enrolled-in-noninfectious-anterior-uveitis-ph-aldx-20170427monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-announces-last-patient-dosed-in-allergic-conjunctivitis-phase-2b--aldx-20170418monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-schedules-webcast-and-conference-call-for-full-year-2016-financial-re-aldx-20170322monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-to-present-at-the-cowen-and-company-37th-annual-health-care-conferenc-aldx-20170228monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-first-patient-enrolled-in-allergic-conjunctivitis-phase-2b--aldx-20170207monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-to-participate-at-the-2017-rare-disease-biopharma-one-on-one-day-aldx-20170206monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-to-present-at-the-28th-annual-piper-jaffray-healthcare-conference-aldx-20161122monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-to-present-at-the-stifel-2016-healthcare-conference-aldx-20161109monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-schedules-webcast-and-conference-call-for-third-quarter-2016-financia-aldx-20161108monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-presentation-of-phase-2-allergic-conjunctivitis-results-at--aldx-20161107monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-provides-update-on-late-stage-clinical-trials-at-2016-research-and-de-aldx-20160926monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-2016-research-and-development-day-aldx-20160909monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-schedules-conference-call-to-present-results-of-a-randomized-double-b-aldx-20160808monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-to-present-at-the-canaccord-genuity-annual-growth-conference-aldx-20160804monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-schedules-webcast-and-conference-call-for-second-quarter-2016-financi-aldx-20160803monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-announces-closing-of-public-offering-of-common-stock-and-full-exe-aldx-20160601monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-proposes-public-offering-of-common-stock-aldx-20160525monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-schedules-webcast-and-conference-call-for-first-quarter-2016-financia-aldx-20160505monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-to-present-at-the-2016-ssadh-symposium-aldx-20160324monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-schedules-webcast-and-conference-call-for-fourth-quarter-and-full-yea-aldx-20160316monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-to-present-at-the-cowen-and-company-36th-annual-health-care-conferenc-aldx-20160303monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reports-positive-results-from-phase-iia-clinical-trial-in-subjects-wi-aldx-20160229monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-appoints-mary-taylor-mph-as-senior-vice-president-regulatory-affairs-aldx-20160209monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-appoints-david-j-clark-m-d-as-chief-medical-officer-aldx-20160111monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-last-patient-dosed-in-phase-ii-trial-of-ns2-in-patients-wit-aldx-20151216monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-to-present-at-the-27th-annual-piper-jaffray-healthcare-conference-aldx-20151124monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-to-present-at-the-stifel-2015-healthcare-conference-aldx-20151110monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-schedules-webcast-and-conference-call-for-third-quarter-2015-financia-aldx-20151105monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-first-patient-enrolled-in-allergic-conjunctivitis-phase-iia-aldx-20150929monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-to-present-novel-data-on-a-potential-treatment-for-succinic-semi-alde-aldx-20150909monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-to-present-at-the-canaccord-genuity-35th-annual-growth-conference-aldx-20150805monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-schedules-webcast-and-conference-call-for-second-quarter-2015-financi-aldx-20150728monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-to-ring-the-nasdaq-stock-market-closing-bell-aldx-20150629monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-nasdaq-aldx-to-ring-the-nasdaq-stock-market-closing-bell-aldx-20150626monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-closing-of-common-stock-offering-aldx-20150522monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-schedules-webcast-and-conference-call-for-first-quarter-2015-financia-aldx-20150511monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-pricing-of-follow-on-public-offering-of-common-stock-aldx-20150508monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-launches-proposed-follow-on-public-offering-of-common-stock-aldx-20150505monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-abstract-accepted-for-presentation-at-the-2015-multinational-associat-aldx-20150423monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-first-patient-enrolled-in-noninfectious-anterior-uveitis-ph-aldx-20150416monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-opens-enrollment-in-noninfectious-anterior-uveitis-phase-ii-clinical--aldx-20150326monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-first-patient-enrolled-in-sjogren-larsson-syndrome-phase-ii-aldx-20150324monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-opens-enrollment-in-sjogren-larsson-syndrome-clinical-trial-and-final-aldx-20150317monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-schedules-webcast-and-conference-call-for-fourth-quarter-2014-financi-aldx-20150310monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-provides-update-on-ns2-clinical-program-aldx-20150302monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-to-present-at-cowen-and-company-35th-annual-health-care-conference-aldx-20150223monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-abstracts-accepted-for-presentation-at-the-2015-annual-meeting-of-the-aldx-20150202monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-to-present-novel-data-on-a-potential-treatment-for-sjogren-larsson-sy-aldx-20150129monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-to-participate-in-canaccord-genuity-rare-disease-biopharma-one-on-one-aldx-20150126monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-submits-ind-filing-to-fda-for-clinical-testing-of-ns2-in-patients-wit-aldx-20150105monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-abstract-accepted-at-2015-american-academy-of-allergy-asthma-immunolo-aldx-20141216monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-collaboration-with-the-national-organization-for-rare-disor-aldx-20141204monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-to-present-at-the-therapeutic-area-partnerships-meeting-aldx-20141113monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-schedules-webcast-and-conference-call-for-third-quarter-2014-financia-aldx-20141103monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-to-present-at-upcoming-investor-conferences-aldx-20140905monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-schedules-webcast-and-conference-call-for-second-quarter-2014-financi-aldx-20140723monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-data-on-lead-candidate-ns2-to-be-presented-at-society-for-investigati-aldx-20140508monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-closing-of-initial-public-offering-of-1-500-000-shares-of-c-aldx-20140507monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-prices-initial-public-offering-of-1-500-000-shares-of-common-stock-aldx-20140502monthly0.5https://www.biopharmawatch.com/news/SEER/seer-adopts-limited-duration-tax-benefit-preservation-plan-to-protect-its-valuable-tax-ass-seer-20260226monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-participate-in-the-td-cowen-46th-annual-health-care-conference-seer-20260218monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-report-third-quarter-2025-financial-results-on-november-6-2025-seer-20251016monthly0.5https://www.biopharmawatch.com/news/SEER/seer-s-proteograph-platform-enables-unprecedented-20-000-sample-proteomics-study-with-kore-seer-20250601monthly0.5https://www.biopharmawatch.com/news/SEER/seer-redefining-deep-unbiased-proteomics-with-launch-of-new-proteograph-workflow-at-asms-2-seer-20250529monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-report-first-quarter-2025-financial-results-on-may-13-2025-seer-20250424monthly0.5https://www.biopharmawatch.com/news/SEER/seer-launches-carbon-focused-division-to-produce-licensed-biochar-monetize-and-tokenize-as-seer-20250331monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-participate-in-the-td-cowen-45th-annual-health-care-conference-seer-20250221monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-feature-proteomic-advancements-in-cancer-and-rna-therapy-research-among-other-find-seer-20250220monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-report-fourth-quarter-and-full-year-2024-financial-results-on-february-27-2025-seer-20250213monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-present-at-the-j-p-morgan-43rd-annual-healthcare-conference-seer-20250102monthly0.5https://www.biopharmawatch.com/news/SEER/seer-and-eco-tadweer-showcase-significant-achievements-in-the-kingdom-of-saudi-arabia-with-seer-20241216monthly0.5https://www.biopharmawatch.com/news/SEER/seer-partners-with-devvstream-to-monetize-insured-carbon-credits-arising-out-of-methane-re-seer-20241212monthly0.5https://www.biopharmawatch.com/news/SEER/seer-ranked-number-57-fastest-growing-company-in-north-america-on-the-2024-deloitte-techno-seer-20241121monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-participate-in-upcoming-november-investor-conferences-seer-20241108monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-third-quarter-2024-financial-results-seer-20241106monthly0.5https://www.biopharmawatch.com/news/SEER/seer-enters-into-a-co-marketing-and-sales-agreement-with-thermo-fisher-scientific-seer-20241106monthly0.5https://www.biopharmawatch.com/news/SEER/seer-highlights-capability-of-deep-proteomics-to-enhance-genomic-insights-into-alzheimer-s-seer-20241031monthly0.5https://www.biopharmawatch.com/news/SEER/seer-showcases-scalable-proteomic-advancements-impacting-alzheimer-s-population-health-and-seer-20241021monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-report-third-quarter-2024-financial-results-on-november-6-2024-seer-20241017monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-participate-in-the-morgan-stanley-22nd-annual-global-healthcare-conference-seer-20240822monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-participate-in-the-canaccord-genuity-44th-annual-growth-conference-seer-20240809monthly0.5https://www.biopharmawatch.com/news/SEER/seer-s-mv-technologies-receives-new-system-and-media-replacement-contracts-for-1-4mm-and-i-seer-20240724monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-report-second-quarter-2024-financial-results-on-august-8-2024-seer-20240718monthly0.5https://www.biopharmawatch.com/news/SEER/seer-receives-contract-from-biochar-now-for-the-manufacturing-of-kilns-and-intends-to-open-seer-20240614monthly0.5https://www.biopharmawatch.com/news/SEER/seer-proteograph-provides-differentiated-insights-into-spaceflight-proteomic-alterations-f-seer-20240611monthly0.5https://www.biopharmawatch.com/news/SEER/seer-technology-access-center-provides-unprecedented-scale-and-depth-of-coverage-for-progn-seer-20240602monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-first-quarter-2024-financial-results-seer-20240508monthly0.5https://www.biopharmawatch.com/news/SEER/seer-launches-new-technology-access-center-in-europe-to-expand-accessibility-to-unbiased-p-seer-20240508monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-report-first-quarter-2024-financial-results-on-may-8-2024-seer-20240423monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-participate-in-the-td-cowen-44th-annual-health-care-conference-seer-20240221monthly0.5https://www.biopharmawatch.com/news/SEER/seer-proteograph-enables-unprecedented-genetic-marker-mapping-for-proteogenomics-studies-t-seer-20240206monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-report-fourth-quarter-and-full-year-2023-financial-results-on-february-29-2024-seer-20240201monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-present-at-the-j-p-morgan-42nd-annual-health-care-conference-seer-20231221monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-present-at-the-canaccord-medtech-diagnostics-and-digital-health-services-forum-seer-20231110monthly0.5https://www.biopharmawatch.com/news/SEER/seer-wins-proteomics-solution-of-the-year-by-biotech-breakthrough-and-named-5-on-deloitte--seer-20231108monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-third-quarter-2023-financial-results-seer-20231107monthly0.5https://www.biopharmawatch.com/news/SEER/seer-s-mv-technologies-receives-new-contracts-for-1-5mm-and-increases-annual-media-supply--seer-20231102monthly0.5https://www.biopharmawatch.com/news/SEER/seer-announces-addition-of-panome-bio-to-centers-of-excellence-coe-program-seer-20231101monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-report-third-quarter-2023-financial-results-on-november-7-2023-seer-20231019monthly0.5https://www.biopharmawatch.com/news/SEER/seer-s-joint-venture-partner-in-the-kingdom-of-saudi-arabia-has-been-awarded-large-pilot-p-seer-20230912monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-participate-in-upcoming-september-investor-conferences-seer-20230908monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-second-quarter-2023-financial-results-seer-20230808monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference-seer-20230727monthly0.5https://www.biopharmawatch.com/news/SEER/seer-announces-the-sale-of-its-texas-based-paragon-southwest-medical-waste-affiliate-to-pa-seer-20230727monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-report-second-quarter-2023-financial-results-on-august-8-2023-seer-20230713monthly0.5https://www.biopharmawatch.com/news/SEER/seer-enters-into-mou-covering-multiple-long-term-green-projects-throughout-the-kingdom-of--seer-20230607monthly0.5https://www.biopharmawatch.com/news/SEER/seer-collaborates-to-make-scalable-unbiased-proteomics-accessible-to-more-researchers-via--seer-20230607monthly0.5https://www.biopharmawatch.com/news/SEER/seer-launches-the-proteograph-xt-assay-kit-allowing-labs-to-easily-expand-their-view-of-th-seer-20230601monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-first-quarter-2023-financial-results-seer-20230509monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-report-first-quarter-2023-financial-results-on-may-9-2023-seer-20230420monthly0.5https://www.biopharmawatch.com/news/SEER/seer-s-proteograph-product-suite-identifies-undiscovered-links-between-protein-variants-an-seer-20230329monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-full-year-20-seer-20230302monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-present-at-the-cowen-43rd-annual-health-care-conference-seer-20230221monthly0.5https://www.biopharmawatch.com/news/SEER/seer-s-mv-technologies-receives-contracts-for-more-than-2mm-seer-20230213monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-2-2023-seer-20230209monthly0.5https://www.biopharmawatch.com/news/SEER/seer-s-texas-operating-partner-completes-its-facility-relocation-and-improves-bottom-line--seer-20230103monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-present-at-the-j-p-morgan-41st-annual-health-care-conference-seer-20221227monthly0.5https://www.biopharmawatch.com/news/SEER/seer-s-proteomics-platform-named-as-top-10-innovation-in-2022-by-the-scientist-seer-20221212monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-third-quarter-2022-financial-results-seer-20221108monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-report-third-quarter-2022-financial-results-on-november-8-2022-seer-20221013monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-participate-in-the-morgan-stanley-global-healthcare-conference-seer-20220830monthly0.5https://www.biopharmawatch.com/news/SEER/seer-announces-publication-of-seminal-study-demonstrating-the-power-of-engineered-nano-bio-seer-20220823monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-second-quarter-2022-financial-results-seer-20220809monthly0.5https://www.biopharmawatch.com/news/SEER/seer-launches-first-of-its-kind-proteogenomics-workflow-to-link-genetic-changes-with-prote-seer-20220803monthly0.5https://www.biopharmawatch.com/news/SEER/seer-enters-into-an-agreement-with-its-texas-operating-partner-to-consolidate-the-north-am-seer-20220803monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-report-second-quarter-2022-financial-results-on-august-9-2022-seer-20220714monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-first-quarter-2022-financial-results-seer-20220504monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-present-at-the-bofa-securities-2022-healthcare-conference-seer-20220428monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-report-first-quarter-financial-results-on-may-4-2022-seer-20220407monthly0.5https://www.biopharmawatch.com/news/SEER/seer-announces-appointment-of-scott-d-thomas-as-chief-commercial-officer-seer-20220316monthly0.5https://www.biopharmawatch.com/news/SEER/seer-announces-publication-of-seminal-study-demonstrating-superior-performance-of-technolo-seer-20220314monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-full-year-20-seer-20220228monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-present-at-the-cowen-42nd-annual-health-care-conference-seer-20220222monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-report-fourth-quarter-and-full-year-2021-financial-results-on-february-28-2021-seer-20220201monthly0.5https://www.biopharmawatch.com/news/SEER/seer-s-mv-technologies-receives-approximately-1-75mm-of-biogas-system-contracts-for-four-u-seer-20220125monthly0.5https://www.biopharmawatch.com/news/SEER/seer-discovery-life-sciences-and-sciex-announce-first-of-its-kind-proteogenomics-consortiu-seer-20220110monthly0.5https://www.biopharmawatch.com/news/SEER/seer-announces-broad-commercial-release-of-the-proteograph-product-suite-and-launches-cent-seer-20220110monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-present-virtually-at-the-40th-annual-j-p-morgan-healthcare-conference-seer-20211229monthly0.5https://www.biopharmawatch.com/news/SEER/seer-alert-bragar-eagel-squire-p-c-is-investigating-seer-inc-on-behalf-of-seer-stockholder-seer-20211228monthly0.5https://www.biopharmawatch.com/news/SEER/seer-alert-bragar-eagel-squire-p-c-is-investigating-seer-inc-on-behalf-of-seer-stockholder-seer-20211213monthly0.5https://www.biopharmawatch.com/news/SEER/seer-alert-bragar-eagel-squire-p-c-is-investigating-seer-inc-on-behalf-of-seer-stockholder-seer-20211208monthly0.5https://www.biopharmawatch.com/news/SEER/seer-alert-bragar-eagel-squire-p-c-is-investigating-seer-inc-on-behalf-of-seer-stockholder-seer-20211203monthly0.5https://www.biopharmawatch.com/news/SEER/seer-appoints-meeta-gulyani-to-its-board-of-directors-seer-20211129monthly0.5https://www.biopharmawatch.com/news/SEER/seer-alert-bragar-eagel-squire-p-c-is-investigating-seer-inc-on-behalf-of-seer-stockholder-seer-20211127monthly0.5https://www.biopharmawatch.com/news/SEER/seer-investigation-block-leviton-is-investigating-seer-inc-for-potential-securities-law-vi-seer-20211122monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-participate-in-the-piper-sandler-virtual-healthcare-conference-seer-20211122monthly0.5https://www.biopharmawatch.com/news/SEER/seer-investigation-block-leviton-is-investigating-seer-inc-for-potential-securities-law-vi-seer-20211115monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-third-quarter-2021-financial-results-seer-20211109monthly0.5https://www.biopharmawatch.com/news/SEER/seer-appoints-rachel-haurwitz-ph-d-to-its-board-of-directors-seer-20211108monthly0.5https://www.biopharmawatch.com/news/SEER/seer-alert-did-you-lose-money-on-your-seer-investment-contact-johnson-fistel-regarding-inv-seer-20211104monthly0.5https://www.biopharmawatch.com/news/SEER/seer-investigation-block-leviton-is-investigating-seer-inc-for-potential-securities-law-vi-seer-20211104monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-report-third-quarter-financial-results-on-november-9-2021-seer-20211012monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-present-at-the-morgan-stanley-global-healthcare-conference-seer-20210902monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-second-quarter-2021-financial-results-seer-20210812monthly0.5https://www.biopharmawatch.com/news/SEER/seer-bio-partners-with-enlight-medical-to-commercialize-the-proteograph-product-suite-in-c-seer-20210812monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-report-second-quarter-financial-results-on-august-12-2021-seer-20210713monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-first-quarter-2021-financial-results-seer-20210510monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-present-at-the-bofa-securities-2021-healthcare-conference-seer-20210504monthly0.5https://www.biopharmawatch.com/news/SEER/seer-s-mv-technologies-receives-more-than-1-6mm-of-biogas-system-contracts-for-three-north-seer-20210421monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-report-first-quarter-financial-results-on-may-10-2021-seer-20210412monthly0.5https://www.biopharmawatch.com/news/SEER/seer-and-sciex-sign-commercial-agreement-to-offer-end-to-end-unbiased-proteomics-solutions-seer-20210329monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-fourth-quarter-and-full-year-2020-financial-results-and-fuels-commercial-prog-seer-20210329monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-report-fourth-quarter-and-full-year-2020-financial-results-on-march-29-2021-seer-20210301monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-present-at-the-cowen-41st-annual-healthcare-conference-seer-20210224monthly0.5https://www.biopharmawatch.com/news/SEER/seer-appoints-deep-nishar-and-mostafa-ronaghi-ph-d-to-its-board-of-directors-seer-20210217monthly0.5https://www.biopharmawatch.com/news/SEER/seer-announces-closing-of-public-offering-of-common-stock-seer-20210201monthly0.5https://www.biopharmawatch.com/news/SEER/seer-announces-pricing-of-upsized-public-offering-of-common-stock-seer-20210128monthly0.5https://www.biopharmawatch.com/news/SEER/seer-signs-commercial-agreement-to-provide-complete-end-to-end-solution-for-unbiased-deep--seer-20210111monthly0.5https://www.biopharmawatch.com/news/SEER/seer-and-bruker-sign-commercial-agreement-to-expand-market-for-unbiased-deep-proteomics-seer-20210111monthly0.5https://www.biopharmawatch.com/news/SEER/seer-signs-mou-with-us-based-bwab-inc-and-its-european-based-affiliates-for-international--seer-20210105monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-seer-20210104monthly0.5https://www.biopharmawatch.com/news/SEER/seer-announces-pricing-of-initial-public-offering-seer-20201204monthly0.5https://www.biopharmawatch.com/news/SEER/seer-appoints-catherine-friedman-to-its-board-of-directors-seer-20200915monthly0.5https://www.biopharmawatch.com/news/SEER/seer-announces-spin-out-of-prognomiq-with-55-million-initial-financing-seer-20200915monthly0.5https://www.biopharmawatch.com/news/SEER/seer-announces-publication-in-nature-communications-demonstrating-performance-scalability--seer-20200722monthly0.5https://www.biopharmawatch.com/news/SEER/seer-announces-55m-financing-led-by-fidelity-management-and-research-company-seer-20200722monthly0.5https://www.biopharmawatch.com/news/SEER/seer-announces-appointment-of-david-r-horn-as-chief-financial-officer-seer-20200520monthly0.5https://www.biopharmawatch.com/news/SEER/seer-announces-appointment-of-omead-ostadan-as-president-and-chief-operating-officer-seer-20200512monthly0.5https://www.biopharmawatch.com/news/SEER/seer-s-newly-formed-division-pellechar-receives-1-million-in-equity-capital-and-prepares-t-seer-20190225monthly0.5https://www.biopharmawatch.com/news/SEER/seer-awarded-1-3-million-contract-to-install-large-landfill-gas-system-seer-20190123monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-reschedule-third-quarter-financial-results-and-operational-update-conference-call--seer-20181127monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-third-quarter-2018-financial-results-seer-20181115monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-host-third-quarter-financial-results-and-operational-update-conference-call-on-thu-seer-20181108monthly0.5https://www.biopharmawatch.com/news/SEER/seer-appoints-dr-simon-tang-as-vice-chairman-of-the-board-and-chairman-of-newly-formed-see-seer-20180827monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-second-quarter-2018-financial-results-seer-20180814monthly0.5https://www.biopharmawatch.com/news/SEER/seer-s-service-division-receives-first-order-for-over-1-million-of-biochar-now-production--seer-20180814monthly0.5https://www.biopharmawatch.com/news/SEER/seer-appoints-scott-yenzer-to-its-board-of-directors-seer-20180813monthly0.5https://www.biopharmawatch.com/news/SEER/seer-to-host-second-quarter-financial-results-conference-call-on-wednesday-august-15-2018--seer-20180801monthly0.5https://www.biopharmawatch.com/news/SEER/seer-provides-operational-update-on-industrial-cleaning-and-environmental-technology-solut-seer-20180626monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-first-quarter-2018-financial-results-seer-20180515monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-march-31-2026-iccc-20260507monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-strategic-focus-on-first-defense-after-receiving-an-fda-incomplete-lett-iccc-20251224monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-quarter-ended-september-30-2025-iccc-20251113monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-quarter-ended-june-30-2025-iccc-20250814monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-june-30-2025-iccc-20250807monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-unaudited-sales-results-for-q2-of-2025-iccc-20250709monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-quarter-ended-march-31-2025-iccc-20250514monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-march-31-2025-iccc-20250512monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-unaudited-sales-results-for-q1-of-2025-iccc-20250408monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-hires-chief-financial-officer-iccc-20250407monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-initiation-of-investigational-product-use-of-re-tain-iccc-20250402monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-quarter-and-year-ended-december-31--iccc-20250225monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-and-year-ended-december-3-iccc-20250220monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-unaudited-sales-results-for-q4-and-full-year-2024-iccc-20250109monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-quarter-ended-september-30-2024-iccc-20241113monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-september-30-2024-iccc-20241107monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-unaudited-sales-results-for-q3-2024-iccc-20241008monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-quarter-ended-june-30-2024-iccc-20240813monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-june-30-2024-iccc-20240807monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-unaudited-sales-results-for-q2-2024-iccc-20240709monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-provides-update-on-regulatory-status-of-product-development-initiative-for-re-tai-iccc-20240605monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-hold-virtual-only-annual-meeting-of-stockholders-iccc-20240604monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-quarter-ended-march-31-2024-iccc-20240514monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-march-31-2024-iccc-20240508monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-unaudited-sales-results-for-q1-2024-iccc-20240409monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-and-year-ended-december-3-iccc-20240216monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-quarter-ended-september-30-2023-iccc-20231113monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-september-30-2023-iccc-20231107monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-unaudited-sales-results-for-q3-2023-iccc-20231005monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-submission-of-cmc-technical-section-to-the-fda-iccc-20230829monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-quarter-ended-june-30-2023-iccc-20230810monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-june-30-2023-iccc-20230807monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-unaudited-sales-results-for-q2-2023-iccc-20230711monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-appoints-bryan-k-gathagan-to-board-of-directors-iccc-20230621monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-approval-of-principal-terms-of-a-3-million-debt-facility-iccc-20230615monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-hold-virtual-only-annual-meeting-of-stockholders-iccc-20230516monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-quarter-ended-march-31-2023-iccc-20230511monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-march-31-2023-iccc-20230504monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-unaudited-sales-results-for-q1-2023-iccc-20230405monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-year-ended-december-31-2022-iccc-20230221monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-year-ended-december-31-2022-iccc-20230215monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-unaudited-sales-results-for-the-year-ended-december-31-2022-iccc-20230109monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-quarter-ended-september-30-2022-iccc-20221121monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-september-30-2022-iccc-20221110monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-unaudited-sales-results-for-third-quarter-of-2022-iccc-20221005monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-participate-in-the-lytham-partners-fall-2022-investor-conference-iccc-20220914monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-quarter-ended-june-30-2022-iccc-20220811monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-june-30-2022-iccc-20220804monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-receives-technical-section-incomplete-letter-from-fda-pertaining-to-re-tain-iccc-20220728monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-unaudited-sales-results-for-second-quarter-of-2022-iccc-20220707monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-hold-virtual-only-annual-meeting-of-stockholders-iccc-20220519monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-quarter-ended-march-31-2022-iccc-20220512monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-march-31-2022-iccc-20220510monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-record-preliminary-unaudited-sales-results-for-first-quarter-of-2022-iccc-20220411monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-and-year-ended-december-3-iccc-20220216monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-record-preliminary-unaudited-sales-results-for-the-year-ended-december--iccc-20220105monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-third-quarter-ended-september-30-20-iccc-20211115monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-third-quarter-ended-september-30--iccc-20211109monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-record-preliminary-unaudited-sales-results-for-third-quarter-of-2021-iccc-20211006monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-required-to-prepare-second-submission-of-final-major-technical-section-for-re-tai-iccc-20210824monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-second-quarter-ended-june-30-2021-iccc-20210812monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-second-quarter-ended-june-30-2021-iccc-20210805monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-strong-preliminary-unaudited-sales-results-for-second-quarter-of-2021-iccc-20210707monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-hold-virtual-only-annual-meeting-of-stockholders-iccc-20210519monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-first-quarter-ended-march-31-2021-iccc-20210513monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-first-quarter-ended-march-31-2021-iccc-20210506monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-closes-4-250-000-equity-financing-iccc-20210414monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-unaudited-sales-results-for-first-quarter-of-2021-iccc-20210407monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-makes-important-regulatory-submission-and-announces-unaudited-financial-results-f-iccc-20210222monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-year-ended-december-31-2020-iccc-20210216monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-unaudited-sales-results-for-the-year-ended-december-31-2020-iccc-20210107monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-restructuring-of-its-bank-debt-iccc-20201215monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-third-quarter-ended-september-30-20-iccc-20201112monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-third-quarter-of-2020-iccc-20201105monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-unaudited-sales-results-for-the-quarter-ended-september-30--iccc-20201006monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-second-quarter-ended-june-30-2020-iccc-20200812monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-second-quarter-of-2020-iccc-20200806monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-unaudited-sales-results-for-the-second-quarter-ended-june-3-iccc-20200707monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-hold-virtual-only-annual-meeting-of-stockholders-iccc-20200514monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-first-quarter-ended-march-31-2020-iccc-20200513monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-first-quarter-of-2020-iccc-20200507monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-receives-938-000-in-support-under-the-paycheck-protection-program-iccc-20200414monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-unaudited-product-sales-results-for-the-quarter-ended-march-iccc-20200402monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-refinancing-of-its-bank-debt-iccc-20200311monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-correction-to-its-reported-unaudited-loss-per-share-from-0-06-to-0-04-f-iccc-20200219monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-year-ended-december-31-2019-iccc-20200218monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-preliminary-financial-results-for-the-year-ended-december-31-2019-iccc-20200213monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-unaudited-product-sales-results-for-the-year-ended-december-iccc-20200121monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-third-quarter-of-2019-iccc-20191111monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-third-quarter-of-2019-iccc-20191105monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-enters-into-lease-agreement-for-a-facility-to-expand-first-defense-production-cap-iccc-20190917monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-an-agreement-covering-the-formulation-and-aseptic-filling-of-syringes-f-iccc-20190911monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-receives-fda-response-to-first-cmc-submission-for-re-tain-iccc-20190829monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-second-quarter-of-2019-iccc-20190812monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-second-quarter-of-2019-iccc-20190806monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-first-quarter-of-2019-iccc-20190513monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-first-quarter-of-2019-iccc-20190507monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-corporation-announces-closing-of-9-million-public-offering-of-common-stock-iccc-20190329monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-corporation-announces-pricing-of-9-0-million-public-offering-of-common-stock-iccc-20190327monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-corporation-announces-commencement-of-public-offering-of-common-stock-iccc-20190326monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-submission-of-manufacturing-technical-section-for-its-purified-nisin-pr-iccc-20190228monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-financial-results-for-fourth-quarter-and-full-year-2018-iccc-20190213monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-financial-results-for-fourth-quarter-and-full-year-2018-iccc-20190206monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-usda-approval-of-dual-force-first-defense-iccc-20181211monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-third-quarter-of-2018-iccc-20181113monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-participate-at-9th-annual-craig-hallum-alpha-select-conference-iccc-20181108monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-financial-results-for-third-quarter-of-2018-iccc-20181107monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-issuance-of-human-food-safety-technical-section-complete-letter-for-its-iccc-20180925monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-second-quarter-of-2018-iccc-20180813monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-financial-results-for-second-quarter-of-2018-iccc-20180807monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-hires-senior-director-of-quality-iccc-20180807monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-sale-of-certain-non-core-assets-iccc-20180725monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-sales-results-for-second-quarter-of-2018-iccc-20180710monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-join-russell-microcap-index-iccc-20180625monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-first-quarter-of-2018-iccc-20180514monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-financial-results-for-first-quarter-of-2018-iccc-20180507monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-financial-results-for-fourth-quarter-and-full-year-2017-iccc-20180208monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-financial-results-for-fourth-quarter-and-full-year-2017-iccc-20180205monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-appoints-two-new-members-to-its-board-of-directors-iccc-20180130monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-corporation-announces-closing-of-3-million-public-offering-of-common-stock-iccc-20171221monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-corporation-announces-pricing-of-3-million-public-offering-of-common-shares-iccc-20171219monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-third-quarter-of-2017-iccc-20171113monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-achieves-usda-approval-of-new-product-claim-to-prevent-rotavirus-infections-iccc-20171113monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-completion-of-construction-of-nisin-production-facility-iccc-20171107monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-financial-results-for-third-quarter-of-2017-iccc-20171102monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-expansion-of-sales-and-marketing-team-iccc-20170913monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-second-quarter-of-2017-iccc-20170814monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-financial-results-for-second-quarter-of-2017-iccc-20170807monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-closes-1-000-000-equity-investment-iccc-20170727monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-unveils-new-website-iccc-20170717monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-clarifies-number-of-authorized-common-shares-iccc-20170713monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-secures-2-million-in-debt-financing-iccc-20170302monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-preliminary-2016-financial-results-iccc-20170206monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-third-quarter-2016-financial-results-iccc-20161110monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-present-at-the-7th-annual-craig-hallum-alpha-select-conference-iccc-20161110monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-third-quarter-2016-financial-results-conference-call-scheduled-for-th-iccc-20161103monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-corporation-announces-closing-of-3-5-million-private-placement-of-common-stock-iccc-20161021monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-raise-3-5-million-in-private-placement-iccc-20161018monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-third-quarter-2016-financial-results-iccc-20161018monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-breaks-ground-for-mast-out-r-facility-iccc-20161011monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-second-quarter-2016-financial-results-iccc-20160811monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-second-quarter-2016-financial-results-iccc-20160803monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-first-quarter-2016-financial-results-iccc-20160511monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-first-quarter-2016-financial-results-iccc-20160504monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-appoints-elizabeth-williams-vice-president-of-manufacturing-operations-iccc-20160404monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-full-year-2015-financial-results-iccc-20160210monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-2015-financial-results-iccc-20160204monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-corporation-announces-closing-of-5-9-million-public-offering-of-common-stock-iccc-20160203monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-corporation-announces-pricing-of-5-9-million-public-offering-of-common-shares-iccc-20160129monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-acquires-certain-assets-from-minnesota-firm-iccc-20160106monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-enters-into-new-contract-with-norbrook-iccc-20151222monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-results-for-third-quarter-of-2015-iccc-20151112monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-third-quarter-2015-financial-results-iccc-20151105monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-results-for-second-quarter-of-2015-iccc-20150813monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-second-quarter-2015-financial-results-iccc-20150806monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-corp-increases-sales-guidance-for-second-quarter-of-2015-iccc-20150708monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-results-for-first-quarter-of-2015-iccc-20150512monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-first-quarter-2015-financial-results-iccc-20150506monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-board-of-directors-amends-its-common-stock-rights-plan-iccc-20150415monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-new-bacteriocin-collaboration-with-the-university-of-massachusetts-amhe-iccc-20150414monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-reports-results-from-rotavirus-pivotal-effectiveness-study-iccc-20150225monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-2014-iccc-20150211monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-2014-full-year-and-fourth-quarter-financial-results-iccc-20150204monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-present-at-ld-micro-conference-on-december-2-2014-iccc-20141125monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-third-quarter-of-2014-iccc-20141112monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-announce-third-quarter-fiscal-year-2014-financial-results-iccc-20141103monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-participating-at-multiple-dairy-and-beef-industry-events-throughout-september-201-iccc-20140917monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-the-second-quarter-of-2014-iccc-20140812monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-initiates-pivotal-effectiveness-study-to-prevent-calf-scours-caused-by-rotavirus-iccc-20140715monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-commences-manufacture-of-nisin-necessary-for-approval-of-mast-out-r-iccc-20140709monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-results-for-the-first-quarter-of-2014-iccc-20140513monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-retains-lytham-partners-to-conduct-national-investor-relations-program-iccc-20140410monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-increase-in-product-sales-and-other-annual-financial-results-iccc-20140213monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-increased-product-sales-and-continued-profitability-iccc-20131112monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-increase-in-product-sales-and-continued-profitability-iccc-20130812monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-suspends-mast-out-r-partnering-effort-pursuit-of-fda-product-approval-to-continue-iccc-20130718monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-increase-in-product-sales-and-continued-profitability-iccc-20130514monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-product-sales-increases-and-other-financial-results-iccc-20130214monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-product-sales-increases-and-other-financial-results-iccc-20121107monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-presents-strategic-business-overview-at-investment-forum-iccc-20120828monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-profitable-financial-results-iccc-20120813monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-receives-effectiveness-technical-section-complete-letter-from-fda-for-mast-out-r-iccc-20120719monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-presents-strategic-overview-at-annual-meeting-of-stockholders-iccc-20120619monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-product-sales-growth-and-profit-iccc-20120514monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-product-sales-growth-and-other-financial-results-for-2011-iccc-20120213monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-product-sales-growth-and-other-financial-results-for-third-quarter-of-2-iccc-20111114monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-product-sales-growth-and-other-financial-results-for-second-quarter-of--iccc-20110815monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-first-quarter-of-2011-iccc-20110516monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-sales-and-marketing-collaboration-with-agrilabs-iccc-20110317monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-receives-effectiveness-technical-section-incomplete-letter-from-fda-iccc-20110217monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-2010-iccc-20110209monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-third-quarter-of-2010-iccc-20101108monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-second-quarter-of-2010-iccc-20100805monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-first-quarter-of-2010-iccc-20100506monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-2009-iccc-20100210monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-hires-director-of-sales-and-marketing-iccc-20100104monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-third-quarter-of-2009-iccc-20091104monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-s-mastitis-drug-meets-pivotal-effectiveness-study-end-point-iccc-20090930monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-second-quarter-of-2009-iccc-20090804monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-first-quarter-of-2009-iccc-20090505monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-2008-iccc-20090211monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-third-quarter-iccc-20081104monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-the-first-half-of-2008-iccc-20080804monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-initiates-pivotal-trial-of-mast-out-r-iccc-20080605monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-first-quarter-of-2008-iccc-20080505monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-cross-license-with-anadis-iccc-20080312monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-2007-iccc-20080207monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-third-quarter-of-2007-iccc-20071102monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-second-quarter-of-2007-iccc-20070803monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-termination-of-mast-out-r-license-and-return-of-all-rights-and-data-fro-iccc-20070719monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-first-quarter-of-2007-iccc-20070419monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-fourth-quarter-and-full-year-2006-iccc-20070207monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-appoints-two-new-directors-to-board-iccc-20061221monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-for-third-quarter-and-first-nine-months-of-2006-iccc-20061019monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-first-quarter-2026-financial-results-and-recent-operating-highlights-clnn-20260514monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-present-at-the-emerging-growth-conference-clnn-20260219monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-present-at-the-emerging-growth-conference-clnn-20251209monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-announces-statistically-significant-als-biomarker-results-supporting-accelerated-app-clnn-20251203monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-provide-cnm-au8-als-program-update-clnn-20251202monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-second-quarter-2025-financial-results-and-recent-operating-highlights-clnn-20250814monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-present-at-the-emerging-growth-conference-clnn-20250813monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-first-quarter-2025-financial-results-and-recent-operating-highlights-clnn-20250507monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-present-at-the-emerging-growth-conference-clnn-20250414monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-presents-evidence-of-remyelination-and-neuronal-repair-with-cnm-au8-treatment-at-the-clnn-20250408monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-present-at-the-jones-healthcare-and-technology-innovation-conference-clnn-20250401monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-full-year-2024-financial-results-and-recent-operating-highlights-clnn-20250324monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-demonstrates-strengthened-als-survival-benefit-with-cnm-au8-treatment-clnn-20250312monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-present-at-the-37th-annual-roth-conference-clnn-20250306monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-and-apst-enter-into-an-agreement-to-support-fda-s-recommendation-for-long-term-nfl-b-clnn-20250225monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-improves-cash-position-and-runway-by-securing-new-debt-facility-to-pay-off-existing--clnn-20241219monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-third-quarter-2024-financial-results-and-recent-operating-highlights-clnn-20241113monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-present-at-upcoming-october-conferences-clnn-20241009monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-announces-closing-of-7-3-million-registered-direct-offering-and-concurrent-private-p-clnn-20241001monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-announces-7-3-million-registered-direct-offering-and-concurrent-private-placements-p-clnn-20240930monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-granted-in-person-meeting-with-fda-senior-leadership-to-discuss-cnm-au8-biomarker-an-clnn-20240916monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-clnn-20240903monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-second-quarter-2024-financial-results-and-recent-operating-highlights-clnn-20240807monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-announces-new-cnm-au8-biomarker-and-clinical-efficacy-data-submitted-to-fda-in-suppo-clnn-20240806monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-present-at-the-canaccord-genuity-44th-annual-growth-conference-private-company-sh-clnn-20240805monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-present-at-the-emerging-growth-conference-clnn-20240712monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-announces-plans-to-submit-briefing-book-to-the-u-s-food-and-drug-administration-in-c-clnn-20240711monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-announces-1-for-20-reverse-stock-split-clnn-20240709monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-present-at-h-c-wainwright-s-5th-annual-neuro-perspectives-virtual-conference-clnn-20240624monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-presents-preliminary-data-for-cnm-au8-as-a-potential-treatment-for-rett-syndrome-clnn-20240621monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-presents-extended-survival-data-through-3-5-years-and-new-nfl-responder-results-with-clnn-20240618monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-present-at-the-emerging-growth-conference-clnn-20240605monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-provides-update-on-its-nih-funded-expanded-access-program-for-cnm-au8-in-als-act-eap-clnn-20240528monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-present-at-upcoming-may-conferences-clnn-20240514monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-first-quarter-2024-financial-results-and-recent-operating-highlights-clnn-20240508monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-announces-peer-reviewed-publication-characterizing-the-protein-corona-of-the-investi-clnn-20240315monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-full-year-2023-financial-results-and-recent-operating-highlights-clnn-20240313monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-present-at-the-36th-annual-roth-conference-clnn-20240307monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-presents-clinical-results-of-cnm-au8-30mg-treatment-from-visionary-ms-trial-long-ter-clnn-20240229monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-significant-survival-benefit-with-cnm-au8-treatment-in-als-eap-compassionate-clnn-20240222monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-significant-improvement-in-vision-and-cognition-with-cnm-au8-treatment-in-vi-clnn-20240108monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-reduction-in-biomarker-plasma-neurofilament-light-nfl-levels-and-improved-su-clnn-20231221monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-provides-update-on-als-clinical-development-meeting-with-fda-clnn-20231221monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-announces-peer-reviewed-publication-describing-cnm-au8-brain-target-engagement-in-ne-clnn-20231214monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-third-quarter-2023-financial-results-and-operating-highlights-clnn-20231107monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-announces-peer-reviewed-publication-describing-cnm-au8-catalytic-neuroprotective-mec-clnn-20230928monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-present-at-cantor-fitzgerald-annual-global-healthcare-conference-clnn-20230925monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-significant-long-term-survival-improvement-from-cnm-au8-treatment-in-healey--clnn-20230925monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-present-at-upcoming-september-conferences-clnn-20230830monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-significantly-improved-survival-benefit-of-19-3-months-and-significantly-del-clnn-20230829monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-second-quarter-2023-financial-results-and-operating-highlights-clnn-20230814monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference-clnn-20230802monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-announces-publication-of-phase-2-cnm-au8-clinical-data-for-the-treatment-of-als-in-l-clnn-20230626monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-welcomes-new-shareholder-base-and-announces-closing-of-underwritten-public-offering--clnn-20230621monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-announces-pricing-of-40-million-public-offering-clnn-20230616monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-announces-launch-of-proposed-public-offering-clnn-20230615monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-s-cnm-au8-shows-statistically-significant-difference-in-plasma-neurofilament-light-n-clnn-20230615monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-participate-in-the-maxim-group-virtual-healthcare-conference-clnn-20230615monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-awarded-grant-from-national-multiple-sclerosis-society-to-advance-development-of-cnm-clnn-20230525monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-first-quarter-2023-financial-results-and-recent-operating-highlights-clnn-20230512monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-announces-the-plenary-presentations-of-ms-and-als-data-supporting-the-efficacy-and-s-clnn-20230411monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-appoints-neurology-expert-to-executive-team-clnn-20230316monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-full-year-2022-financial-results-and-recent-operating-highlights-clnn-20230313monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-announce-new-cnm-au8-data-from-the-healey-als-platform-trial-clnn-20230308monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-to-participate-in-roth-s-35th-annual-healthcare-conference-and-renmark--clnn-20230307monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-announces-updated-visionary-ms-phase-2-trial-data-presented-at-2023-actrims-forum-sh-clnn-20230227monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-new-data-from-the-visionary-ms-phase-2-study-in-multiple-sclerosis-demonstra-clnn-20230213monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-announces-participation-in-renmark-virtual-non-deal-roadshow-series-on--clnn-20230111monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-reports-topline-results-of-phase-2-covid-19-study-of-cnm-znag-clnn-20221227monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3-clnn-20220930monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-presents-updated-long-term-survival-data-from-rescue-als-participants-a-clnn-20220921monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-present-at-upcoming-september-investor-conferences-clnn-20220830monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-positive-topline-results-for-cnm-au8-in-the-phase-2-visionary-ms-trial-in-mu-clnn-20220815monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-host-visionary-ms-results-call-and-webcast-on-august-15-clnn-20220812monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-receives-positive-ema-opinion-on-orphan-drug-designation-for-cnm-au8-for-the-treatme-clnn-20220719monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-significantly-decreased-mortality-in-rescue-als-long-term-open-label-extensi-clnn-20220714monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-participate-in-panel-discussion-about-innovations-in-als-presented-by-maxim-group-clnn-20220627monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-salutes-collaboration-of-als-community-and-major-league-baseball-on-lou-gehrig-day-clnn-20220602monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-present-at-upcoming-investor-conferences-clnn-20220516monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-to-present-at-upcoming-investor-conferences-clnn-20220303monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-to-present-data-from-phase-2-multiple-sclerosis-programs-at-actrims-for-clnn-20220218monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-s-patent-portfolio-grows-to-more-than-150-issued-worldwide-including-tw-clnn-20211215monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-to-present-rescue-als-phase-2-data-in-late-breaking-session-at-32nd-int-clnn-20211210monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-s-rescue-als-phase-2-results-selected-for-late-breaking-presentation-at-clnn-20211207monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences-clnn-20210831monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-present-at-canaccord-genuity-s-annual-growth-conference-clnn-20210803monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-host-expert-perspectives-webinar-on-cellular-energetic-failure-and-the-unmet-medi-clnn-20210630monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-added-to-membership-of-russell-2000-index-clnn-20210628monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-to-present-at-the-raymond-james-human-health-innovation-conference-clnn-20210615monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-receives-catalyst-award-for-healthy-longevity-from-u-s-national-academy-clnn-20210517monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-presents-updated-blinded-efficacy-data-from-ongoing-phase-2-rescue-als--clnn-20210512monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-receives-two-patent-notice-of-allowances-in-the-u-s-for-its-platform-na-clnn-20210430monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-announces-upcoming-presentations-at-the-maxim-group-llc-inaugural-2021--clnn-20210310monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-announces-achievement-of-50-enrollment-in-the-phase-3-healey-als-platfo-clnn-20210309monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-to-present-at-upcoming-virtual-investor-conferences-clnn-20210303monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-awarded-michael-j-fox-foundation-grant-to-accelerate-the-development-of-clnn-20210301monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-presents-updated-interim-data-from-phase-2-multiple-sclerosis-programs--clnn-20210225monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-to-present-updated-interim-data-from-phase-2-multiple-sclerosis-program-clnn-20210219monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-initiates-phase-2-study-of-cnm-znag-for-patients-with-covid-19-clnn-20210216monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-receives-patent-notice-of-allowance-in-the-united-states-for-using-gold-clnn-20210119monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-presents-blinded-interim-results-from-rescue-als-phase-2-study-at-the-3-clnn-20201210monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-first-quarter-2026-financial-results-and-recent-strategic-developmen-cue-20260514monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-30-million-private-placement-cue-20260430monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-names-shao-lee-lin-m-d-ph-d-ceo-president-and-board-director-to-lead-continu-cue-20260430monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease--cue-20260415monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-ceo-transition-cue-20260327monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-proposed-public-offering-cue-20251218monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-first-quarter-2025-financial-results-and-recent-business-highlights-cue-20250512monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-host-virtual-investor-event-on-may-15-2025-cue-20250508monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-participate-in-fireside-chat-at-the-citizens-life-sciences-conference-cue-20250505monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-proposed-public-offering-cue-20250414monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-host-business-update-call-and-webcast-cue-20250414monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-cue-20241129monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-participate-in-fireside-discussion-at-the-piper-sandler-36th-annual-healt-cue-20241125monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-strategic-organizational-transition-cue-20241114monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-participate-in-fireside-chat-at-the-stifel-2024-healthcare-conference-cue-20241112monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-presents-positive-updated-data-from-its-phase-1-trials-of-cue-101-and-cue-10-cue-20241108monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-upcoming-scientific-presentations-at-the-society-for-immunotherapy-cue-20241004monthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-provides-clinical-trial-update-for-phase-2-renew-study-of-lti-03-in-idio-rntx-20260429monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-proposed-public-offering-cue-20240926monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-appoints-industry-veteran-lucinda-warren-as-chief-business-officer-cue-20240909monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-promise-of-interleukin-2-therapy-conference-cue-20240903monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-second-quarter-2024-financial-results-and-recent-business-highlights-cue-20240819monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-host-business-update-call-and-webcast-cue-20240813monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-presents-updated-data-from-phase-1-trial-of-cue-101-in-recurrent-metastatic--cue-20240604monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-two-upcoming-investor-healthcare-conferences-in-june-2024-cue-20240603monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-20th-annual-pegs-boston-summit-cue-20240508monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-participate-in-fireside-chat-at-the-citizens-jmp-life-sciences-conference-cue-20240507monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-2024-american-society-of-clinical-oncology-asco-annual-mee-cue-20240424monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-fourth-quarter-and-full-year-2023-financial-results-and-updated-busi-cue-20240408monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-host-business-update-call-and-webcast-cue-20240402monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-s-lead-clinical-asset-cue-101-to-be-featured-at-the-2024-multi-disciplinary--cue-20240229monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-corporate-update-at-the-oppenheimer-34th-annual-healthcare-life-s-cue-20240206monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-jmp-securities-hematology-and-oncology-summit-cue-20231122monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-third-quarter-2023-financial-results-and-recent-business-highlights-cue-20231109monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-three-upcoming-investor-healthcare-conferences-in-november-cue-20231107monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-presents-new-positive-data-from-phase-1-trials-of-cue-101-in-head-and-neck-c-cue-20231103monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-host-business-update-call-and-webcast-cue-20231102monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-upcoming-scientific-presentations-at-the-society-for-immunotherapy-cue-20230927monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-completion-of-patient-enrollment-in-phase-1b-study-of-cue-101-in-c-cue-20230926monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-second-quarter-2023-financial-results-and-recent-business-highlights-cue-20230809monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-host-business-update-call-and-webcast-cue-20230802monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-federation-of-clinical-immunology-societies-focis-2023-ann-cue-20230614monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-host-investor-call-cue-20230607monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-jefferies-2023-global-healthcare-conference-cue-20230605monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-presents-positive-data-update-from-ongoing-phase-1-trials-of-cue-101-for-rec-cue-20230525monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-2023-american-society-of-clinical-oncology-asco-annual-mee-cue-20230515monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-first-quarter-2023-financial-results-and-recent-business-highlights-cue-20230509monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-cue-20230508monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-welcomes-seasoned-pharmaceutical-executive-pamela-d-garzone-ph-d-to-its-boar-cue-20230425monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-welcomes-industry-veteran-mr-patrick-verheyen-to-its-board-of-directors-cue-20230412monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-fourth-quarter-and-full-year-2022-financial-results-and-recent-busin-cue-20230321monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-host-business-update-call-and-webcast-cue-20230315monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-two-march-2023-investor-healthcare-conferences-cue-20230301monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-enters-into-a-strategic-collaboration-and-option-agreement-with-ono-pharmace-cue-20230222monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-s-therapeutic-immuno-stat-biologics-to-be-featured-in-oxford-university-pres-cue-20230216monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-the-appointment-of-dr-rafi-ahmed-to-its-scientific-advisory-board-cue-20230216monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-two-february-2023-scientific-conferences-cue-20230201monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-chief-medical-officer-transition-cue-20230123monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-two-upcoming-investor-healthcare-conferences-cue-20221122monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-third-quarter-2022-financial-results-cue-20221114monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-presents-new-positive-data-from-ongoing-phase-1-trial-of-cue-101-in-combinat-cue-20221110monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-two-upcoming-investor-healthcare-conferences-in-november-cue-20221109monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-host-business-update-call-and-webcast-cue-20221107monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-upcoming-scientific-presentations-at-the-society-for-immunotherapy-cue-20221005monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-granted-fda-fast-track-designation-for-cue-101-for-the-treatment-of-recurren-cue-20221004monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-two-september-2022-scientific-conferences-cue-20220907monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-doses-first-patient-in-phase-1-study-of-cue-102-for-wilms-tumor-1-wt1-expres-cue-20220822monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-second-quarter-2022-financial-results-cue-20220804monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-guggenheim-i-i-spotlight-series-cue-20220711monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-jmp-securities-life-sciences-conference-cue-20220613monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-jefferies-healthcare-conference-cue-20220601monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-2022-american-society-of-clinical-oncology-asco-annual-mee-cue-20220526monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-receives-fda-acceptance-of-investigational-new-drug-ind-application-for-cue--cue-20220511monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-first-quarter-2022-financial-results-cue-20220510monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-upcoming-oppenheimer-32nd-annual-healthcare-conference-cue-20220310monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-an-updated-overview-of-immuno-stat-platform-at-the-2022-festival--cue-20220302monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-s-therapeutic-immuno-stat-biologics-to-be-featured-in-oxford-university-pres-cue-20220215monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-two-objective-responses-1-cpr-and-1upr-in-first-interim-update-from--cue-20220126monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-host-business-update-call-and-webcast-for-ongoing-cue-101-clinical-trials-cue-20220120monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-and-lg-chem-life-sciences-announce-development-milestone-in-immuno-stat-biol-cue-20220105monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-appointment-of-patricia-nasshorn-as-chief-business-officer-cue-20211215monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-jmp-securities-hematology-and-oncology-summit-cue-20211206monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-piper-sandler-33rd-annual-healthcare-conference-cue-20211122monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-presents-updated-data-from-lead-program-cue-101-for-the-treatment-of-recurre-cue-20211112monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-two-upcoming-investor-healthcare-conferences-in-november-cue-20211110monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-publication-in-the-journal-of-clinical-investigation-highlighting--cue-20211021monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-upcoming-scientific-presentations-at-the-society-for-immunotherapy-cue-20211004monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-publication-in-nature-journal-scientific-reports-of-immunotherapeu-cue-20210928monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-granted-u-s-patents-on-lead-clinical-program-novel-drug-product-candidate-cu-cue-20210921monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-two-upcoming-investor-healthcare-conferences-cue-20210909monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-second-quarter-2021-results-recent-data-updates-of-cue-101-phase-1-d-cue-20210817monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-host-business-update-call-and-webcast-cue-20210810monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-corporate-update-at-the-upcoming-btig-virtual-biotechnology-confe-cue-20210803monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-cue-20210614monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-first-patient-dosed-in-part-b-patient-expansion-of-cue-101-phase-1-cue-20210610monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-2021-federation-of-clinical-immunology-societies-focis-vir-cue-20210603monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-a-corporate-and-clinical-progress-update-at-the-upcoming-jefferie-cue-20210526monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-first-quarter-2021-results-recent-updates-of-cue-101-phase-1-dose-es-cue-20210517monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-host-business-update-call-and-webcast-cue-20210510monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-confirmed-partial-response-pr-in-ongoing-phase-1-monotherapy-study-o-cue-20210510monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-2021-frontiers-in-cancer-immunotherapy-conference-cue-20210506monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-fourth-quarter-and-full-year-2020-financial-results-and-recent-busin-cue-20210316monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenhei-cue-20210315monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-host-business-update-call-and-webcast-cue-20210309monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-cowen-41st-annual-health-care-conference-cue-20210301monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-enhances-scientific-advisory-board-with-appointments-of-immunology-and-immun-cue-20210225monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-7th-annual-immuno-oncology-360-conference-cue-20210222monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-appointment-of-matteo-levisetti-m-d-as-senior-vice-president-of-cl-cue-20210217monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-initiates-patient-dosing-in-phase-1-study-of-cue-101-in-combination-with-key-cue-20210208monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-piper-sandler-32nd-annual-healthcare-conference-cue-20201123monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics--cue-20201119monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-third-quarter-2020-results-and-cue-101-phase-1-dose-escalation-trial-cue-20201117monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-upcoming-investor-conferences-in-november-2020-cue-20201111monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-host-business-update-call-and-webcast-cue-20201110monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-presentations-highlighting-clinical-progress-of-cue-101-pipeline-p-cue-20201109monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-upcoming-scientific-presentations-at-the-society-for-immunotherapy-cue-20201019monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-welcomes-tamar-howson-to-its-board-of-directors-cue-20200917monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-nature-methods-publication-of-preclinical-data-showing-tumor-penet-cue-20200915monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-upcoming-investor-conferences-in-september-2020-cue-20200903monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-second-quarter-2020-results-and-cue-101-phase-1-dose-escalation-tria-cue-20200831monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-16th-annual-pegs-boston-essential-protein-engineering-cell-cue-20200824monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-host-business-update-call-and-webcast-cue-20200817monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-begins-dosing-cohort-5-in-an-ongoing-phase-1-monotherapy-trial-of-cue-101-in-cue-20200728monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-plos-one-publication-demonstrating-the-generation-and-evaluation-o-cue-20200708monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-provides-update-on-ongoing-phase-1-trial-evaluating-cue-101-in-recurrent-met-cue-20200615monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-corporate-overview-and-pipeline-progress-at-jefferies-virtual-hea-cue-20200528monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-aacr-virtual-annual-meeting-cue-20200518monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-strategic-research-collaboration-with-dr-michael-dustin-and-oxford-cue-20200514monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-host-business-update-call-and-webcast-cue-20200512monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-clinical-trial-collaboration-agreement-with-merck-to-evaluate-cue--cue-20200420monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-host-business-update-call-and-webcast-cue-20200310monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-upcoming-investor-conferences-in-march-2020-cue-20200226monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-s-therapeutic-immuno-stat-platform-to-be-featured-in-merck-presentation-at-a-cue-20200219monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-biomarkers-series-uk-cue-20200212monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-publication-in-clinical-cancer-research-of-preclinical-and-transla-cue-20200121monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-world-vaccine-immunotherapy-congress-cue-20191202monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-upcoming-investor-conferences-in-november-2019-cue-20191106monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-host-business-update-call-and-webcast-cue-20191105monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-upcoming-scientific-presentation-at-the-society-for-immunotherapy--cue-20191030monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-the-oppenheimer-houston-oncology-summit-at-the-university-of-t-cue-20191015monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-changes-to-its-board-of-directors-cue-20191009monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-upcoming-october-2019-scientific-conferences-cue-20191009monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-promotes-dr-anish-suri-to-president-and-cso-cue-20191007monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-corporate-overview-and-update-on-clinical-development-progress-fo-cue-20191002monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-initiates-patient-dosing-in-phase-1-study-of-cue-101-for-hpv16-driven-head-a-cue-20190930monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-corporate-overview-clinical-strategy-for-cue-101-at-jefferies-201-cue-20190603monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-host-business-update-call-and-webcast-cue-20190516monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-fda-acceptance-of-ind-for-lead-immuno-oncology-candidate-cue-101-i-cue-20190516monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-immuno-stat-platform-technology-at-pegs-boston-2019-cue-20190408monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-corporate-overview-and-update-at-the-oppenheimer-29th-annual-heal-cue-20190314monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-host-business-update-call-and-webcast-cue-20190307monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-corporate-update-at-2019-bio-ceo-investor-conference-cue-20190211monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-presentation-highlighting-immuno-stat-platform-and-cue-101-at-the--cue-20190116monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-host-business-update-call-and-webcast-cue-20181114monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-presents-foundational-data-on-immuno-stat-platform-and-cue-101-at-the-societ-cue-20181109monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-presentation-at-the-society-for-immunotherapy-of-cancer-s-sitc-33r-cue-20181030monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-strategic-research-collaboration-with-albert-einstein-college-of-m-cue-20181017monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-appoints-hon-randall-r-rader-to-chair-company-s-intellectual-property-commit-cue-20181003monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-host-investor-business-update-call-and-webcast-cue-20180814monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-adds-frank-morich-m-d-ph-d-to-board-of-directors-cue-20180803monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-appoints-bethany-mancilla-as-chief-business-officer-and-senior-vice-presiden-cue-20180724monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-produces-immuno-stat-biologic-candidate-for-treatment-of-autoimmune-disease--cue-20180712monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-strengthens-board-of-directors-with-addition-of-fred-driscoll-to-chair-audit-cue-20180628monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-host-investor-business-update-call-and-webcast-cue-20180510monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-appointment-of-anish-suri-ph-d-as-chief-scientific-officer-cue-20180425monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-to-present-at-bloomberg-biotech-innovations-conference-cue-20180405monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-director-acquires-shares-okyo-20260319monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-to-present-at-ois-xv-in-san-diego-okyo-20251118monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-to-participate-at-the-4th-annual-btig-ophthalmology-conference-okyo-20241126monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-chairman-acquires-shares-okyo-20240910monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-chairman-acquires-shares-okyo-20240905monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-ceo-interview-to-air-on-bloomberg-tv-okyo-20240823monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-chairman-acquires-shares-okyo-20240823monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-chairman-acquires-shares-okyo-20240821monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-participates-in-h-c-wainwright-4th-annual-ophthalmology-virtual-conference-okyo-20240815monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-to-release-new-and-comprehensive-data-from-phase-2-dry-eye-disease-trial-and-h-okyo-20240320monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-presentations-at-the-american-society-of-cataract-and-refractive-sur-okyo-20230503monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-activation-of-first-clinical-trial-site-in-the-u-s-for-the-phase-2-t-okyo-20230425monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-today-announces-director-acquires-shares-okyo-20230330monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-pdmr-dealing-okyo-20230324monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-announces-u-s-5-74-million-global-private-placement-and-investment-by--okyo-20230314monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-custom-clearance-of-gmp-packaged-ok-101-drug-to-be-used-in-phase-2-c-okyo-20230228monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-to-present-at-the-second-annual-gpcrs-targeted-drug-discovery-summit-in-boston-okyo-20230221monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-u-s-fda-clearance-of-ind-application-for-ok-101-for-the-treatment-of-okyo-20221222monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-change-of-auditor-okyo-20221201monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-pdmr-dealing-okyo-20221124monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-u-s-ind-filing-on-ok-101-for-the-treatment-of-dry-eye-disease-okyo-20221121monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-result-of-annual-general-meeting-okyo-20220907monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-pdmr-dealing-okyo-20220609monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-pdmr-dealing-okyo-20220520monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-announces-closing-of-public-offering-and-nasdaq-listing-okyo-20220519monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-pdmr-dealing-okyo-20220518monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-announces-pricing-of-initial-public-offering-of-adss-in-the-u-s-with-d-okyo-20220517monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-announces-pricing-of-public-offering-and-nasdaq-listing-okyo-20220516monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-okyo-or-the-company-announces-two-presentations-at-the-2022-association-for-re-okyo-20220427monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-or-the-company-okyo-publicly-files-a-registration-statement-with--okyo-20220307monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-okyo-or-the-company-announces-issuance-of-u-s-patent-no-11-254-720-covering-ok-okyo-20220223monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-or-the-company-conversion-of-clns-cashless-exercise-of-warrants-a-okyo-20220221monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-or-the-company-okyo-pharma-announces-successful-completion-of-a-p-okyo-20220215monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-or-the-company-grant-of-options-director-and-pdmr-dealings-okyo-20220201monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-pdmr-dealing-okyo-20220127monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-interim-results-for-the-six-months-to-30-september-2021-okyo-20220126monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-issuance-of-u-s-patent-no-11-197-906-covering-okyo-pharma-s-drug-can-okyo-20211214monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-or-the-company-announces-first-in-class-drug-candidate-ok-101-dis-okyo-20211213monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-or-the-company-to-file-ind-in-q3-2022-for-ok-101-to-treat-dry-eye-okyo-20211206monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-directorate-change-okyo-20211201monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-or-the-company-result-of-annual-general-meeting-okyo-20210927monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-or-the-company-notice-of-annual-general-meeting-okyo-20210909monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-announces-final-audited-results-for-the-year-ended-31-march-2021-okyo-20210802monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-or-the-company-okyo-pharma-retains-ora-inc-to-perform-regulatory-development-of-ok-10-okyo-20210629monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-or-the-company-okyo-pharma-announces-positive-data-and-results-in-an-animal-model-usi-okyo-20210428monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-or-the-company-okyo-announces-appointment-of-dr-rajkumar-patil-as-okyo-20210329monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-or-the-company-issue-of-equity-okyo-20210301monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-has-u-s-patent-issued-covering-its-lipid-conjugated-peptide-analogues-for-trea-okyo-20210223monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-or-the-company-okyo-announces-filing-of-a-patent-application-cove-okyo-20210119monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-or-the-company-result-of-the-annual-general-meeting-okyo-20200925monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-or-the-company-appointment-of-dr-napoleone-ferrara-to-serve-on-it-okyo-20200819monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-or-the-company-issue-of-additional-convertible-loan-notes-to-rais-okyo-20200818monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-or-the-company-company-presentation-okyo-20200803monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-upcoming-presentation-okyo-20200731monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-or-the-company-issue-of-convertible-loan-notes-to-raise-3-500-000-okyo-20200728monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-deadline-rosen-skilled-investor-counsel-encourages-atara-biotherapeutics-inc-investo-atra-20260519monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-deadline-rosen-a-ranked-and-leading-law-firm-encourages-atara-biotherapeutics-inc-in-atra-20260514monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-atra-20260511monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsi-atra-20260420monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-to-present-tab-cel-long-term-clinical-outcomes-from-a-multicenter-ex-atra-20191106monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-to-announce-third-quarter-2019-operational-progress-and-financial-re-atra-20191030monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-executive-departures-atra-20191025monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-reports-early-findings-of-potential-efficacy-from-phase-1-study-of-a-atra-20190913monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-to-present-initial-efficacy-and-additional-safety-results-from-phase-atra-20190909monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-to-participate-in-citi-14th-annual-biotech-conference-atra-20190828monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-to-announce-second-quarter-2019-financial-results-and-host-conferenc-atra-20190801monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-pricing-of-150-0-million-public-offering-atra-20190719monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-proposed-offering-of-common-stock-atra-20190718monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-plan-to-initiate-tab-cel-fda-biologics-license-application-atra-20190716monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-presents-initial-ata188-phase-1-safety-results-for-patients-with-pro-atra-20190629monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-atra-20190625monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-atra-20190605monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-collaborator-presentation-updating-positive-phase-1-clinic-atra-20190604monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-presents-tab-cel-clinical-biomarker-results-and-nasopharyngeal-carci-atra-20190601monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences-atra-20190530monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-appoints-pascal-touchon-president-chief-executive-officer-and-member-atra-20190528monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-presentations-highlighting-tab-cel-and-mesothelin-targeted-atra-20190515monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-presentation-of-initial-ata188-phase-1-safety-results-for--atra-20190515monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-to-announce-first-quarter-2019-financial-results-and-host-conference-atra-20190507monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-presents-off-the-shelf-allogeneic-car-t-preclinical-results-at-the-a-atra-20190401monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-collaborator-presentation-of-positive-phase-1-clinical-res-atra-20190331monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-to-participate-in-upcoming-conferences-atra-20190307monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-presentations-highlighting-next-generation-car-t-platform--atra-20190227monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-to-participate-in-the-37th-annual-j-p-morgan-healthcare-conference-atra-20190104monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-planned-chief-executive-officer-transition-atra-20190103monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-exclusively-licenses-mesothelin-targeted-car-t-immunotherapy-for-sol-atra-20190103monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-presents-positive-efficacy-and-safety-results-for-patients-with-epst-atra-20181215monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-next-generation-car-t-discoveries-and-positive-t-cell-immu-atra-20181204monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-highlights-next-generation-and-off-the-shelf-allogeneic-car-t-techno-atra-20181129monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-to-host-car-t-breakfast-teach-in-on-november-29-2018-atra-20181127monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-publication-of-phase-1-study-demonstrating-clinical-improv-atra-20181119monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-presentations-highlighting-robust-off-the-shelf-allogeneic-atra-20181101monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-atra-20180924monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-appoints-cancer-research-and-clinical-development-veteran-roy-baynes-atra-20180911monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-and-moffitt-cancer-center-announce-strategic-collaboration-to-develo-atra-20180906monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-to-participate-at-two-upcoming-conferences-atra-20180831monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-atra-20180806monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-to-participate-in-the-canaccord-genuity-38th-annual-growth-conferenc-atra-20180731monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-opens-state-of-the-art-operations-and-manufacturing-facility-to-supp-atra-20180625monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-tab-cel-achieves-positive-long-term-outcomes-in-phase-2-studies-of-p-atra-20180615monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-publication-of-new-research-linking-epstein-barr-virus-ebv-atra-20180613monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-atra-20180607monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-appointment-of-utpal-koppikar-as-chief-financial-officer-atra-20180607monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences-atra-20180529monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-to-present-long-term-tab-cel-phase-2-clinical-outcomes-for-patients--atra-20180517monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-expands-t-cell-immunotherapy-collaboration-to-advance-next-generatio-atra-20180508monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-atra-20180507monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-expands-commercial-leadership-team-with-the-appointment-of-manuela-m-atra-20180501monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-atra-20180409monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-to-participate-in-three-upcoming-immuno-oncology-conferences-atra-20180322monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-to-present-at-the-44th-annual-meeting-of-the-european-society-for-bl-atra-20180316monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-to-present-at-the-cowen-and-company-38th-annual-health-care-conferen-atra-20180306monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-pricing-of-public-offering-of-common-stock-atra-20180301monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-proposed-offering-of-common-stock-atra-20180227monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-chief-financial-officer-intention-to-retire-in-april-2018-atra-20180221monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-fda-clearance-to-proceed-with-enrollment-at-u-s-sites-for--atra-20180110monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-atra-20180104monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-pricing-of-public-offering-of-common-stock-atra-20180104monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-proposed-offering-of-common-stock-atra-20180102monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-initiation-of-two-phase-3-clinical-studies-to-evaluate-tab-atra-20180102monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-to-host-corporate-update-conference-call-on-friday-december-29-2017--atra-20171228monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-updated-positive-interim-results-from-multicenter-expanded-atra-20171211monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-to-participate-in-four-upcoming-investor-conferences-atra-20171107monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-two-presentations-at-59th-american-society-of-hematology-a-atra-20171101monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-receives-rare-pediatric-disease-designation-from-fda-for-ata230-for--atra-20171026monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-six-of-ten-progressive-multiple-sclerosis-ms-patients-expe-atra-20171025monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-initiates-60-patient-global-phase-1-clinical-study-to-evaluate-allog-atra-20171019monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-abstract-publication-for-two-msparis2017-congress-presenta-atra-20171016monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-receives-positive-health-canada-regulatory-feedback-for-ata129-atra-20170911monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-receives-fda-orphan-drug-designation-for-ata230-atra-20170905monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-to-participate-in-three-upcoming-investor-conferences-atra-20170831monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-atra-20170822monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-expands-leadership-team-with-the-appointment-of-dr-kanya-rajangam-as-atra-20170822monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-to-present-at-the-canaccord-genuity-37th-annual-growth-conference-atra-20170802monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-two-presentations-at-msparis2017-including-updated-interim-atra-20170731monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-to-present-at-three-upcoming-investor-conferences-atra-20170524monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-atra-20170510monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-enhances-commercial-expertise-with-the-appointment-of-dr-derrell-por-atra-20170510monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-announces-collaboration-with-merck-to-evaluate-keytruda-pembrolizumab-in-combina-atra-20170421monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-expands-management-team-appoints-joe-newell-as-executive-vice-president-chief-te-atra-20170403monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-s-collaborating-investigators-to-present-interim-results-from-phase-1-trial-of-t-atra-20170317monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-atra-20170104monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-concludes-ema-scientific-advice-and-plans-to-submit-conditional-marketing-author-atra-20170103monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-reaches-agreement-with-fda-on-design-of-phase-3-trials-for-its-lead-anti-cancer--atra-20161212monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-announces-results-from-ongoing-phase-2-trial-of-allogeneic-cytomegalovirus-cmv-s-atra-20161203monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-s-collaborating-investigators-to-present-results-from-phase-2-trial-of-allogenei-atra-20161103monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-granted-access-to-priority-medicines-prime-regulatory-support-for-allogeneic-eps-atra-20161018monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-receives-positive-opinion-from-ema-on-orphan-drug-designation-for-allogeneic-cyt-atra-20161011monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-to-participate-in-the-morgan-stanley-global-healthcare-conference-atra-20160908monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-to-present-at-the-canaccord-genuity-36th-annual-growth-conference-atra-20160804monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-doses-first-patient-in-multi-center-expanded-access-protocol-for-study-of-alloge-atra-20160712monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-receives-advanced-therapy-medicinal-product-classification-for-allogeneic-epstei-atra-20160623monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-to-present-at-the-jmp-securities-life-sciences-conference-atra-20160615monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-announces-clinical-trial-results-for-the-treatment-of-ebv-nasopharyngeal-carcino-atra-20160606monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-to-present-at-three-upcoming-investor-conferences-atra-20160531monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-announces-presentations-of-clinical-data-from-ebv-ctl-and-stm-434-product-candid-atra-20160518monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-s-collaborating-investigators-to-present-clinical-data-on-ebv-ctl-at-2016-americ-atra-20160509monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-s-collaborator-qimr-berghofer-medical-research-institute-reports-positive-clinic-atra-20160419monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-to-present-at-the-15th-annual-needham-healthcare-conference-atra-20160406monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-announces-participation-in-two-upcoming-immuno-oncology-conferences-atra-20160328monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-receives-ema-orphan-drug-designation-for-allogeneic-epstein-barr-virus-specific--atra-20160323monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-announces-collaborating-investigators-to-present-data-from-a-late-breaking-abstr-atra-20160316monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-to-present-at-the-cowen-and-company-36th-annual-health-care-conference-atra-20160229monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-receives-fda-orphan-drug-designation-for-ebv-ctl-to-treat-epstein-barr-virus-ass-atra-20160208monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-announces-participation-in-two-upcoming-investor-conferences-atra-20160127monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-to-present-at-the-34th-annual-j-p-morgan-healthcare-conference-atra-20160104monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-added-to-the-nasdaq-biotechnology-index-atra-20151218monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-announces-positive-results-from-a-phase-2-clinical-trial-of-cytomegalovirus-targ-atra-20151206monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-announces-positive-results-from-phase-1-clinical-trial-of-wilms-tumor-1-targeted-atra-20151205monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-s-collaborating-investigators-to-present-data-from-two-cellular-therapy-product--atra-20151105monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-participation-in-three-investor-conferences-atra-20151029monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-and-qimr-berghofer-medical-research-institute-announce-exclusive-lic-atra-20151021monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-receives-fda-orphan-drug-designation-for-stm-434-atara-bio-s-activin-inhibitor-f-atra-20151020monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-to-host-investor-day-on-october-21-2015-atra-20151014monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-s-pinta-745-improves-insulin-sensitivity-and-alters-fat-metabolism-in-mice-fed-w-atra-20151005monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-s-collaborating-investigators-to-present-data-at-the-american-society-of-nephrol-atra-20151005monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-s-t-cell-product-candidate-activated-against-wilms-tumor-1-protein-demonstrates--atra-20150924monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-inc-to-present-at-upcoming-investor-conferences-in-september-2015-atra-20150902monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-completion-of-enrollment-in-pinta-745-phase-2-clinical-tri-atra-20150831monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-announces-closing-of-underwritten-offering-of-common-stock-and-full-exercise-of--atra-20150715monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-announces-pricing-of-its-180-0-million-offering-of-common-stock-atra-20150710monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-announces-proposed-offering-of-common-stock-atra-20150707monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-exercises-exclusive-license-to-t-cell-technology-from-memorial-sloan-atra-20150615monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-inc-to-present-at-upcoming-investor-conferences-in-june-2015-atra-20150527monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-collaborating-investigators-to-present-data-at-the-2015-american-soc-atra-20150514monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-inc-to-present-at-the-ubs-global-healthcare-conference-atra-20150512monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-first-quarter-2015-results-atra-20150507monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-collaborating-investigators-abstract-on-t-cell-therapy-for-ebv-lymph-atra-20150419monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-inc-to-present-at-the-2015-jefferies-immuno-oncology-summit-atra-20150413monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-inc-to-present-at-the-needham-healthcare-conference-atra-20150409monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-inc-appoints-eric-dobmeier-chief-operating-officer-of-seattle-geneti-atra-20150327monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-collaborating-investigators-to-present-clinical-data-on-t-cell-thera-atra-20150319monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-names-david-a-carmel-as-head-of-immunotherapy-atra-20150303monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-fourth-quarter-and-full-year-2014-operating-results-atra-20150226monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-closing-of-underwritten-offering-of-common-stock-and-exerc-atra-20150218monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-announces-pricing-of-its-65-5-million-offering-of-common-stock-atra-20150212monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-announces-proposed-offering-of-common-stock-atra-20150209monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-to-present-at-the-j-p-morgan-healthcare-conference-atra-20150109monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-third-quarter-2014-operating-results-atra-20141112monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-collaborating-investigators-to-present-data-at-the-american-society--atra-20141106monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-doses-first-patient-in-phase-1-clinical-study-of-stm-434-an-activin--atra-20141022monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-nasdaq-atra-to-ring-the-nasdaq-stock-market-opening-bell-in-celebrat-atra-20141016monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-pricing-of-its-initial-public-offering-atra-20141016monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-immunotherapy-alliance-with-memorial-sloan-kettering-cance-atra-20140923monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-board-members-continue-to-participate-in-private-placement-financings-maia-20251224monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-s-ateganosine-surges-ahead-with-breakthrough-momentum-as-pivotal-phase-3-trial-initia-maia-20251211monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-open-market-purchases-by-ceo-and-directors-maia-20251201monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-investigated-by-the-portnoy-law-firm-fbio-20251001monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-first-patient-dosed-in-phase-2-clinical-trial-of-triplex-vaccin-fbio-20250127monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-and-cyprium-therapeutics-announce-u-s-fda-acceptance-and-priority-review--fbio-20250106monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-participate-in-october-2024-investor-conferences-fbio-20240926monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-pricing-of-8-million-registered-direct-offering-and-concurrent--fbio-20240920monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-fbio-20240904monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-participate-in-the-alliance-global-partners-a-g-p-virtual-healthcare-c-fbio-20240516monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-first-patient-dosed-in-multi-center-phase-2-study-of-triplex-fo-fbio-20240514monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-participate-in-36th-annual-roth-conference-fbio-20240312monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-and-cyprium-therapeutics-announce-4-1-million-grant-from-ninds-to-further-fbio-20240304monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-closing-of-11-million-registered-direct-offering-priced-at-the--fbio-20240103monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-closing-of-10-0-million-public-offering-fbio-20231114monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-pricing-of-10-0-million-public-offering-fbio-20231110monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-subsidiary-helocyte-announces-option-agreement-with-city-of-hope-for-excl-fbio-20231016monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-reverse-stock-split-fbio-20231009monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-present-at-roth-mkm-2023-healthcare-opportunities-conference-fbio-20231005monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-fbio-20230907monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-present-at-the-btig-virtual-biotechnology-conference-2023-fbio-20230803monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-participate-in-two-march-2023-investor-conferences-fbio-20230307monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-closing-of-13-9-million-registered-direct-offering-priced-at-th-fbio-20230210monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-participate-in-cantor-medical-aesthetic-dermatology-ophthalmology-medt-fbio-20221206monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-timing-of-regular-monthly-dividend-for-october-november-and-dec-fbio-20221005monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-confer-fbio-20220908monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-subsidiary-helocyte-announces-grant-that-could-provide-over-20-million-fr-fbio-20220811monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-dotinu-fbio-20220531monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-participate-in-two-upcoming-may-2022-investor-conferences-fbio-20220518monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-present-at-the-21st-annual-needham-virtual-healthcare-conference-fbio-20220407monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-virtual-two-day-r-d-summit-hosted-by-b-riley-securities-on-tues-fbio-20220401monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-cyprium-therapeutics-and-sentynl-therapeutics-announce-cutx-101-copper-hi-fbio-20220321monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-participate-in-three-march-2022-investor-conferences-fbio-20220309monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-virtual-two-day-corporate-access-summit-hosted-by-b-riley-secur-fbio-20220303monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-participate-in-the-2nd-annual-winter-wonderland-best-ideas-virtual-inv-fbio-20220207monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-participate-in-the-h-c-wainwright-bioconnect-virtual-conference-fbio-20220106monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-ring-nasdaq-stock-market-closing-bell-on-december-21-fbio-20211221monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-initiation-of-phase-2-clinical-trial-of-triplex-for-adults-co-i-fbio-20211216monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-cyprium-therapeutics-and-sentynl-therapeutics-announce-the-initiation-of--fbio-20211207monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-participate-in-dawson-james-securities-6th-annual-small-cap-growth-con-fbio-20211018monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-and-cyprium-therapeutics-announce-positive-clinical-data-for-cutx-101-cop-fbio-20211008monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-receipt-of-notice-of-option-exercise-from-astrazeneca-to-fully--fbio-20210929monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-participate-in-the-benzinga-healthcare-small-cap-conference-fbio-20210928monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-participate-in-three-september-2021-investor-conferences-fbio-20210909monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-participate-in-three-june-2021-virtual-investor-conferences-fbio-20210601monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-webinar-hosted-by-roth-capital-partners-featuring-partner-compa-fbio-20210519monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsu-fbio-20210514monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-exclusive-license-agreement-with-fuji-yakuhin-to-develop-dotinu-fbio-20210510monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-participate-in-the-20th-annual-needham-virtual-healthcare-conference-fbio-20210407monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-s-partner-company-journey-medical-corporation-in-licenses-and-launches-ac-fbio-20210322monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences-fbio-20210304monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-joins-global-movement-to-raise-awareness-for-rare-diseases-and-supports-r-fbio-20210226monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsu-fbio-20210121monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-participate-in-three-january-2021-virtual-investor-conferences-fbio-20210105monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-breakthrough-therapy-designation-for-cutx-101-copper-histidinat-fbio-20201215monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-investors-who-have-suffered-losses-greater-than-50-000-encouraged-to-cont-fbio-20201130monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-ranked-in-deloitte-s-technology-fast-500-for-the-second-year-in-a-row-fbio-20201118monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-oral-and-poster-data-presentations-at-the-62nd-american-society-fbio-20201104monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-s-partner-company-journey-medical-corporation-to-be-featured-in-webinar-h-fbio-20201019monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-initiation-of-phase-3-studies-of-cael-101-in-al-amyloidosis-fbio-20200914monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-participate-in-three-september-2020-virtual-investor-conferences-fbio-20200910monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-positive-topline-clinical-efficacy-results-for-cutx-101-copper--fbio-20200828monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-60-million-loan-agreement-with-oaktree-capital-management-fbio-20200828monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-virtual-two-day-corporate-access-summit-hosted-by-b-riley-fbr-o-fbio-20200812monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-positive-opinion-on-orphan-drug-designation-received-from-the-e-fbio-20200731monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-publication-of-study-on-targeted-next-generation-sequencing-for-fbio-20200729monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-added-to-russell-3000-index-fbio-20200629monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-present-at-the-raymond-james-human-health-innovation-conference-fbio-20200615monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-publication-of-study-on-estimated-birth-prevalence-of-menkes-di-fbio-20200611monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-host-virtual-annual-meeting-of-stockholders-fbio-20200602monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-exclusive-worldwide-license-agreement-with-columbia-university--fbio-20200508monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-closing-of-series-a-preferred-stock-offering-and-full-exercise--fbio-20200224monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-rare-pediatric-disease-designation-for-cutx-101-for-the-treatme-fbio-20200116monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-exclusive-worldwide-license-agreement-with-astrazeneca-and-cinc-fbio-20191223monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-participate-in-december-2019-investor-conferences-fbio-20191202monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-ranked-in-top-10-of-deloitte-s-2019-technology-fast-500-fbio-20191114monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-participate-in-the-5th-annual-dawson-james-small-cap-growth-conference-fbio-20191024monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-present-at-october-2019-investor-conferences-fbio-20190926monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-present-at-september-2019-investor-conferences-fbio-20190905monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-present-at-the-31st-annual-roth-conference-fbio-20190314monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-cael-101-strategic-partnership-with-alexion-pharmaceuticals-fbio-20190131monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-recaps-corporate-highlights-and-achievements-in-2018-fbio-20181221monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-publication-of-preclinical-data-on-aav-atp7a-gene-therapy-combi-fbio-20180912monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-aevitas-therapeutics-enters-sponsored-research-agreement-with-t-fbio-20180806monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-cyprium-therapeutics-cutx-101-copper-histidinate-granted-fda-fa-fbio-20180702monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-publication-of-phase-1-data-on-cndo-109-activated-allogeneic-na-fbio-20180619monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-appoints-michael-g-king-jr-as-entrepreneur-in-residence-fbio-20180515monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-present-at-oppenheimer-s-28th-annual-healthcare-conference-fbio-20180313monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-aevitas-therapeutics-enters-sponsored-research-agreement-with-t-fbio-20180226monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-participate-in-lifesci-advisors-corporate-access-event-in-san-francisc-fbio-20171214monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-positive-clinical-data-from-fortress-companies-presented-at-the-fbio-20171211monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-forms-subsidiary-tamid-bio-to-develop-novel-aav-gene-therapies-in-orphan--fbio-20171205monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-cellvation-s-ceva101-granted-fda-regenerative-medicine-advanced-fbio-20171108monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-pricing-of-series-a-preferred-stock-offering-fbio-20171107monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-proposed-public-offering-of-series-a-preferred-stock-fbio-20171101monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-subsidiary-data-to-be-presented-at-59th-american-society-of-hem-fbio-20171101monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-present-at-the-19th-annual-rodman-renshaw-global-investment-conference-fbio-20170905monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-forms-new-subsidiary-aevitas-therapeutics-inc-to-develop-novel-aav-gene-t-fbio-20170814monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-filing-of-provisional-patent-application-for-caelum-biosciences-fbio-20170717monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-appointment-of-lucy-lu-md-as-president-and-chief-executive-offi-fbio-20170703monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-present-at-the-2017-bio-international-convention-fbio-20170615monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-that-its-subsidiary-mustang-bio-enters-into-license-agreements--fbio-20170605monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-subsidiary-caelum-biosciences-enters-biopharmaceutical-manufacturing-agre-fbio-20170601monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-final-patient-dosed-in-phase-1b-trial-of-cael-101-for-the-treat-fbio-20170504monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-present-at-pioneers-2017-presented-by-joseph-gunnar-co-fbio-20170427monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-orphan-drug-designations-for-cael-101-in-amyloidosis-fbio-20170405monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-present-at-biocentury-s-24th-annual-future-leaders-in-the-biotech-indu-fbio-20170330monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-forms-new-subsidiary-cyprium-therapeutics-inc-to-develop-novel-therapies--fbio-20170314monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-to-present-at-the-29th-annual-roth-conference-fbio-20170309monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-forms-new-subsidiary-caelum-biosciences-inc-to-develop-novel-treatment-fo-fbio-20170104monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-forms-new-subsidiary-cellvation-inc-to-develop-novel-therapies-for-the-tr-fbio-20161107monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-completes-tender-offer-for-shares-of-national-holdings-corporation-fbio-20160912monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-presents-positive-data-from-the-phase-1-2-study-of-cndo-109-activated-all-fbio-20160518monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-subsidiary-altamira-bio-acquires-nih-license-and-cradas-relating-to-the-d-fbio-20150717monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-and-ant-neuro-announce-strategic-collaboration-to-integrate-neuronavigation-wi-stim-20260514monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stim-20260429monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stim-20250806monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-second-quarter-2025-financial-and-operating-results-stim-20250805monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-second-quarter-2025-financial-and-operating-results-and-host-confere-stim-20250722monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-appoints-new-chief-financial-officer-stim-20250715monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stim-20250619monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-clinical-presence-at-the-2025-clinical-tms-society-annual-meeting-an-stim-20250610monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-set-to-join-russell-2000-and-russell-3000-indexes-stim-20250602monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-launches-first-inaugural-national-tms-therapy-awareness-day-during-mental-heal-stim-20250514monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stim-20250505monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-first-quarter-2025-financial-and-operating-results-and-host-conferen-stim-20250422monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stim-20250303monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-confere-stim-20250221monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stim-20250207monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock-stim-20250207monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stim-20241218monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stim-20241216monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-present-at-the-piper-sandler-36th-annual-healthcare-conference-stim-20241120monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stim-20241112monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-third-quarter-2024-financial-and-operating-results-and-host-conferen-stim-20241029monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-and-greenbrook-tms-announce-definitive-agreement-to-merge-stim-20240812monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stim-20240805monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-present-at-the-canaccord-genuity-44th-annual-growth-conference-stim-20240731monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-second-quarter-2024-financial-and-operating-results-and-host-confere-stim-20240729monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-present-at-the-william-blair-44th-annual-growth-stock-conference-stim-20240523monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stim-20240503monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-first-quarter-2024-financial-and-operating-results-and-host-conferen-stim-20240423monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stim-20240327monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-5-year-exclusive-partnership-with-transformations-care-network-stim-20240307monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-fourth-quarter-2023-financial-and-operating-results-and-host-confere-stim-20240220monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-launches-latest-evolution-in-its-trakstar-patient-data-management-system-stim-20240212monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-receives-510-k-clearance-for-neurosite-coil-placement-accessory-stim-20231218monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-present-at-the-35th-annual-piper-sandler-healthcare-conference-stim-20231115monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-continued-momentum-from-health-plans-for-tms-therapy-coverage-stim-20231109monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stim-20231106monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-third-quarter-2023-financial-and-operating-results-and-host-conferen-stim-20231024monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-revolutionizes-patient-communication-and-provider-support-through-its-exclusiv-stim-20230814monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stim-20230804monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-second-quarter-2023-financial-and-operating-results-and-host-confere-stim-20230725monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-expanded-tms-therapy-access-through-aetna-health-plans-stim-20230719monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-receives-510-k-clearance-for-ocd-mt-cap-for-neurostar-advanced-therapy-stim-20230612monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-increased-tms-access-through-bluecross-blueshield-of-michigan-stim-20230526monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-present-at-the-william-blair-43rd-annual-growth-stock-conference-stim-20230524monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-wins-2023-bell-seal-for-workplace-mental-health-stim-20230515monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-present-at-the-jmp-securities-life-sciences-conference-stim-20230509monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-receives-mdsap-certification-and-ce-mark-certification-under-new-mdr-stim-20230508monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stim-20230505monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting-stim-20230503monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-lisa-metzner-rosas-as-svp-chief-marketing-officer-stim-20230501monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-expanded-tms-access-through-united-healthcare-stim-20230428monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-first-quarter-2023-financial-and-operating-results-and-host-conferen-stim-20230425monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-continued-momentum-for-expanded-health-insurance-coverage-for-tms-th-stim-20230413monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-tms-coverage-criteria-changes-for-over-23-million-covered-lives-stim-20230302monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stim-20230227monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-expands-neurostar-advanced-therapy-s-proprietary-trakstar-platform-stim-20230223monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-fourth-quarter-2022-financial-and-operating-results-and-host-confere-stim-20230222monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-sponsors-the-5th-international-brain-stimulation-conference-stim-20230221monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-elevation-of-sara-grubbs-to-svp-chief-revenue-officer-stim-20230216monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-updated-medicare-policy-expanding-access-to-neurostar-tms-therapy-th-stim-20230210monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-and-greenbrook-tms-announce-six-year-exclusive-partnership-stim-20230119monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stim-20230118monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-data-confirming-efficacy-in-treating-anxious-depression-with-neurost-stim-20230117monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-settles-litigation-against-brainsway-stim-20230110monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-appointment-of-joseph-h-capper-to-its-board-of-directors-stim-20221229monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stim-20221207monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announced-as-a-winner-by-2022-merit-awards-for-healthcare-in-the-patient-care--stim-20221205monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-present-at-the-piper-sandler-34th-annual-healthcare-conference-stim-20221121monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-neurostar-advanced-therapy-for-mental-health-system-innovations-stim-20221114monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stim-20221110monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announced-as-winner-by-2022-merit-awards-for-technology-stim-20221031monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-updated-tms-coverage-policies-that-will-expand-patient-access-to-neu-stim-20221025monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-third-quarter-2022-financial-and-operating-results-and-host-conferen-stim-20221025monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-launches-innovations-to-neurostar-advanced-therapy-s-proprietary-trakstar-plat-stim-20220926monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-inc-announces-grand-opening-of-neurostar-university-with-ribbon-cutting-ceremo-stim-20220913monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-510-k-clearance-of-d-tect-mt-accessory-for-neurostar-advanced-therap-stim-20220829monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stim-20220805monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-present-at-the-canaccord-genuity-42nd-annual-growth-conference-stim-20220728monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-and-alleviant-health-centers-announce-exclusive-partnership-stim-20220725monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-second-quarter-2022-financial-and-operating-results-and-host-confere-stim-20220719monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-recognized-as-top-non-invasive-devices-provider-in-2022-stim-20220713monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-positive-tms-coverage-policies-to-expand-patient-access-to-neurostar-stim-20220711monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-present-at-the-william-blair-42nd-annual-growth-stock-conference-stim-20220525monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-and-transformations-care-network-announce-extended-commercial-partnership-stim-20220511monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-tms-leadership-on-display-at-clinical-tms-society-annual-meeting-stim-20220511monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-files-federal-lawsuit-against-brainsway-for-misleading-psychiatrists-and-patie-stim-20220511monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stim-20220506monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-first-quarter-2022-financial-and-operating-results-and-host-conferen-stim-20220428monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stim-20220308monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-fourth-quarter-and-fiscal-year-2021-financial-and-operating-results--stim-20220222monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-510-k-clearance-of-mt-cap-technology-for-neurostar-advanced-therapy--stim-20211220monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-key-role-for-neurostar-advanced-therapy-at-4th-international-brain-s-stim-20211206monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-participate-at-the-piper-sandler-33rd-annual-virtual-healthcare-conference-stim-20211122monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-and-river-region-psychiatry-announce-exclusive-partnership-stim-20211108monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-third-quarter-2021-financial-and-operating-results-and-host-conferen-stim-20211026monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-celebrates-235-000-treatment-milestone-for-success-tms-stim-20211026monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-launches-upgrades-of-neurostar-advanced-therapy-for-mental-health-stim-20211019monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-commercial-agreement-with-success-tms-stim-20211005monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-and-zion-healing-announce-first-franchise-model-for-tms-clinics-stim-20210907monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-launches-new-website-to-meet-patient-demand-for-depression-resources-stim-20210817monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference-stim-20210729monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-second-quarter-2021-financial-and-operating-results-and-host-confere-stim-20210720monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-launches-enhanced-digital-resource-center-for-neurostar-providers-stim-20210714monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-set-to-join-russell-2000-index-stim-20210623monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-unveils-new-clinical-data-at-clinical-tms-society-2021-annual-meeting-stim-20210609monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-present-at-the-jmp-securities-life-sciences-conference-stim-20210603monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-names-todd-cushman-as-vice-president-business-development-stim-20210601monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-present-at-the-william-blair-41st-annual-growth-stock-conference-stim-20210520monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-celebrates-100-000-treatment-milestone-for-southern-california-tms-center-stim-20210517monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-employee-patient-advocates-honor-mental-health-awareness-month-by-sharing-pers-stim-20210503monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-present-clinical-data-at-the-american-psychiatric-association-2021-annual-m-stim-20210429monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-first-quarter-2021-financial-and-operating-results-and-host-conferen-stim-20210420monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-retirement-of-gregory-harper-vice-president-r-d-and-clinical-stim-20210311monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-enhances-trakstar-cloud-patient-data-management-system-to-maximize-physician-e-stim-20210309monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-names-cory-anderson-vice-president-clinical-affairs-and-medical-operations-stim-20210303monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-fourth-quarter-and-fiscal-year-2020-financial-and-operating-results--stim-20210216monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-strategic-leadership-promotions-to-support-future-growth-stim-20210211monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-participate-at-the-btig-virtual-medtech-digital-health-life-science-diagnos-stim-20210210monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-closing-of-public-offering-and-exercise-in-full-of-the-underwriters--stim-20210202monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-pricing-of-75-million-public-offering-of-common-stock-stim-20210129monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-proposed-public-offering-of-common-stock-stim-20210128monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-participate-at-the-23rd-annual-icr-westwicke-conference-stim-20210107monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-expansion-of-sales-organization-stim-20210107monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference-stim-20201130monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-receives-fda-clearance-for-three-minute-touchstar-treatment-protocol-stim-20201123monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-present-at-the-canaccord-genuity-virtual-medtech-diagnostics-forum-stim-20201112monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-third-quarter-2020-financial-and-operating-results-and-host-conferen-stim-20201019monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-appoints-sara-grubbs-as-vice-president-sales-stim-20201005monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-celebrates-500-000-treatment-milestone-for-greenbrook-tms-stim-20200929monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-unveils-new-depression-data-at-clinical-tms-society-s-virtual-events-stim-20200922monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-second-quarter-2020-financial-and-operating-results-and-host-confere-stim-20200721monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-stim-20200717monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-present-at-the-william-blair-40th-annual-growth-stock-conference-stim-20200604monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-inc-announces-virtual-2020-annual-meeting-of-stockholders-stim-20200512monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-recognizes-critical-health-professionals-during-mental-health-awareness-month-stim-20200507monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-first-quarter-2020-financial-and-operating-results-and-host-conferen-stim-20200421monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-recognized-as-2020-top-neurology-device-provider-stim-20200330monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-hits-major-milestones-with-more-than-2-5-million-treatments-and-1-000-installa-stim-20200316monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-fourth-quarter-and-fiscal-year-2019-financial-and-operating-results--stim-20200218monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-appoints-andrew-macan-as-senior-vice-president-general-counsel-chief-complianc-stim-20200121monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-present-at-the-31st-annual-piper-jaffray-healthcare-conference-stim-20191125monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-third-quarter-2019-financial-and-operating-results-and-host-conferen-stim-20191022monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-present-at-the-39th-annual-canaccord-genuity-growth-conference-stim-20190725monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-second-quarter-2019-financial-and-operating-results-and-host-confere-stim-20190723monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-present-at-the-jmp-life-sciences-conference-stim-20190605monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-present-at-the-william-blair-39th-annual-growth-stock-conference-stim-20190523monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-first-quarter-2019-financial-and-operating-results-and-host-conferen-stim-20190423monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-present-at-the-18th-annual-needham-company-healthcare-conference-stim-20190326monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-fourth-quarter-and-fiscal-year-2018-financial-and-operating-results--stim-20190219monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-present-at-the-30th-annual-piper-jaffray-healthcare-conference-stim-20181115monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-report-third-quarter-2018-financial-results-and-host-conference-call-stim-20181023monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-to-be-added-to-the-russell-2000-3000-and-microcap-indexes-stim-20181001monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-inc-to-report-second-quarter-2018-financial-results-and-host-conference-call-stim-20180731monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-inc-maker-of-neurostar-advanced-therapy-announces-closing-of-initial-public-of-stim-20180702monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-inc-maker-of-neurostar-advanced-therapy-announces-pricing-of-initial-public-of-stim-20180628monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-inc-raises-30-million-in-series-e-financing-stim-20110516monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-receives-tie50-award-for-technology-entrepreneurship-stim-20110509monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-appoints-vice-president-of-health-policy-and-government-relations-stim-20110302monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-announces-publications-in-nature-medicine-and-journal-of-infectious-dis-mcrb-20260106monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-to-announce-third-quarter-2025-financial-results-and-business-updates-o-mcrb-20251030monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-to-announce-second-quarter-2025-financial-results-and-business-updates--mcrb-20250722monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-presents-data-at-the-2025-digestive-disease-week-conference-highlightin-mcrb-20250429monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-to-announce-first-quarter-2025-financial-results-and-business-updates-o-mcrb-20250423monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-pro-mcrb-20250304monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-receives-feedback-from-fda-on-ser-155-allogeneic-hematopoietic-stem-cel-mcrb-20250303monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-announces-receipt-of-expected-50-million-installment-payment-related-to-mcrb-20250116monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-to-participate-in-2025-j-p-morgan-healthcare-conference-mcrb-20241216monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-to-participate-in-piper-sandler-healthcare-conference-mcrb-20241122monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-to-announce-third-quarter-2024-financial-results-and-business-updates-o-mcrb-20241106monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-to-participate-in-cantor-2024-global-healthcare-conference-mcrb-20240913monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled-cohort-2-study-safety-and-c-mcrb-20240912monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-to-announce-second-quarter-2024-financial-results-and-business-update-o-mcrb-20240806monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-mcrb-20240607monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-inc-nasdaq-mcrb-to-ring-the-nasdaq-stock-market-closing-bell-mcrb-20150819monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-inc-announces-closing-of-100-million-public-follow-on-offering-and-exercise-in--acet-20211210monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-inc-announces-pricing-of-public-offering-of-common-stock-acet-20211208monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-announces-positive-interim-clinical-data-from-first-ever-allogeneic-off-the-she-acet-20211206monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-to-host-webcast-presentation-of-adi-001-interim-clinical-data-in-b-cell-non-hod-acet-20211129monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-presents-preclinical-data-for-adi-002-a-gpc3-targeted-development-candidate-for-sol-acet-20211112monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-to-participate-in-stifel-2021-virtual-healthcare-conference-acet-20211108monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-announces-trials-in-progress-poster-presentation-for-adi-001-at-2021-ash-annual-mee-acet-20211104monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-announces-promotion-of-blake-aftab-ph-d-to-chief-scientific-officer-acet-20211012monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-platform-at-sitc-36t-acet-20211004monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-to-participate-in-upcoming-investor-conferences-acet-20210902monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-to-participate-in-upcoming-investor-conferences-acet-20210802monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-announces-formation-of-scientific-advisory-board-acet-20210715monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-added-to-the-russell-2000-index-acet-20210628monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-to-participate-in-upcoming-investor-conferences-acet-20210518monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-reports-first-quarter-2021-financial-results-and-provides-business-updates-acet-20210517monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-to-participate-in-fireside-chat-at-the-7th-annual-truist-securities-life-scienc-acet-20210429monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-to-participate-in-the-canaccord-genuity-2021-horizons-in-oncology-virtual-confe-acet-20210415monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-appoints-dr-blake-aftab-as-vice-president-of-research-acet-20210413monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-inc-announces-closing-of-152-million-public-offering-and-concurrent-private-pla-acet-20210216monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-to-participate-in-upcoming-investor-conferences-acet-20210211monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-inc-announces-pricing-of-135-million-public-offering-of-common-stock-and-concur-acet-20210210monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-to-participate-in-upcoming-investor-conferences-acet-20210107monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-to-participate-in-fireside-chat-at-jmp-securities-hematology-summit-acet-20201208monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-to-participate-in-upcoming-investor-conferences-acet-20201106monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-appoints-don-healey-ph-d-as-chief-technology-officer-acet-20201026monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-to-present-at-the-jefferies-cell-therapy-summit-acet-20201001monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-inc-determines-not-to-proceed-with-public-offering-of-common-stock-acet-20200923monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-inc-announces-proposed-public-offering-of-common-stock-acet-20200921monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-acet-20200918monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-appoints-nick-harvey-as-chief-financial-officer-acet-20200916monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-to-present-at-the-cantor-virtual-global-healthcare-conference-acet-20200915monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-lnsr-20250701monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-lnsr-20250602monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-lnsr-20250304monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-lnsr-20250204monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-lnsr-20250102monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-lnsr-20241209monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-to-participate-in-the-btig-4th-annual-ophthalmology-day-lnsr-20241126monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-lnsr-20241101monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-to-report-third-quarter-2024-financial-results-on-thursday-november-7-2024-lnsr-20241031monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-lnsr-20241001monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-s-ally-laser-cataract-system-cleared-by-fda-parkhurst-nuvision-will-be-among-the-fi-lnsr-20220614monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-closes-deal-with-optegra-to-install-its-refractive-cataract-laser-system-across-all-lnsr-20140320monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-initiates-clinical-study-to-evaluate-lens-softening-effects-of-the-lensar-tm-laser--lnsr-20131112monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-secures-87-million-in-financing-to-support-market-expansion-of-its-laser-cataract-s-lnsr-20131002monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-schedules-2025-fourth-quarter-and-full-year-financial-results-and-conference-c-mdai-20260310monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-schedules-2025-second-quarter-financial-results-and-conference-call-mdai-20250730monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-research-partner-using-deepview-system-wins-best-research-project-at-the-2025--mdai-20250520monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-schedules-2025-first-quarter-financial-results-and-conference-call-mdai-20250502monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-public-filing-of-registration-statement-for-proposed-initial-public--mdai-20250320monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-completes-three-device-installations-in-australia-mdai-20250306monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-schedules-2024-fourth-quarter-and-full-year-financial-results-and-conference-c-mdai-20250228monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-strengthens-financial-position-ahead-of-fda-submission-mdai-20250218monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-completes-data-analysis-for-u-s-burn-pivotal-study-mdai-20250207monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-completes-pediatric-enrollment-in-emergency-departments-for-u-s-burn-pivotal-s-mdai-20250128monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-provides-update-to-investors-mdai-20250122monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-provides-instructions-for-retail-investors-on-exercising-publicly-traded-warra-mdai-20241231monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-comments-on-compliance-with-nasdaq-listing-rule-5550-b-2-mdai-20241213monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-highlights-unprecedented-collaboration-with-national-leaders-in-burn-care-for--mdai-20241212monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-incorporates-frontline-feedback-into-improved-software-release-for-enhanced-di-mdai-20241209monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-completes-truthing-of-burn-center-images-initiates-emergency-department-image--mdai-20241202monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-repricing-of-its-public-warrants-mdai-20241126monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-deepview-snapshot-m-moves-forward-with-feedback-from-brooke-army-med-mdai-20241121monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-raises-up-to-5-million-financing-strengthening-financial-position-for-fda-path-mdai-20241119monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-2024-third-quarter-financial-results-mdai-20241106monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-plan-to-spin-off-spectral-ip-subsidiary-focused-on-intellectual-prop-mdai-20241106monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-last-patient-out-in-u-s-burn-pivotal-study-at-burn-centers-mdai-20241030monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-schedules-2024-third-quarter-financial-results-and-conference-call-mdai-20241023monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-completes-proof-of-concept-for-wound-measurement-technology-mdai-20241003monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-achieves-25-patient-enrollment-at-emergency-departments-for-u-s-burn-pivotal-s-mdai-20240924monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-outlines-u-s-regulatory-pathway-for-deepview-system-for-burn-indication-mdai-20240917monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-awarded-additional-funding-from-medical-technology-enterprise-consortium-to-su-mdai-20240905monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-to-participate-in-upcoming-investor-conferences-mdai-20240828monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-completes-burn-center-enrollment-for-u-s-burn-pivotal-study-mdai-20240827monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-podium-presentation-at-bba-isbi-joint-conference-assessing-burn-woun-mdai-20240819monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-2024-second-quarter-financial-results-mdai-20240812monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-continuing-progress-in-development-of-handheld-deepview-snapshot-m-f-mdai-20240731monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-schedules-2024-second-quarter-financial-results-and-conference-call-mdai-20240729monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-total-u-s-and-international-patent-portfolio-now-stands-at-26-grante-mdai-20240724monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-adds-three-new-clinical-trial-sites-to-expedite-emergency-department-patient-e-mdai-20240723monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-collaboration-with-global-wound-care-company-polynovo-to-introduce-d-mdai-20240708monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-expands-clinical-trial-sites-for-pivotal-u-s-burn-study-mdai-20240703monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-achieves-100-pediatric-enrollment-in-burn-centers-for-pivotal-u-s-burn-study-mdai-20240702monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-joins-russell-microcap-index-mdai-20240701monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-surpasses-90-of-pediatric-enrollment-target-in-burn-centers-for-pivotal-u-s-bu-mdai-20240627monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-supports-naked-short-selling-inquiry-mdai-20240624monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-to-participate-in-the-northland-capital-markets-virtual-growth-conference-mdai-20240617monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-reaches-50-enrollment-at-burn-centers-for-u-s-pivotal-burn-study-mdai-20240606monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-set-to-join-russell-microcap-index-mdai-20240529monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-to-participate-in-benzinga-s-ai-unleashed-exploring-the-possibilities-virtual--mdai-20240528monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-purchases-of-over-100-000-shares-by-insiders-mdai-20240517monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-voting-results-from-2024-annual-meeting-of-stockholders-and-the-appo-mdai-20240515monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-2024-first-quarter-financial-results-mdai-20240507monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-to-participate-at-the-sidoti-micro-cap-virtual-investor-conference-mdai-20240502monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-awarded-quality-achievement-award-from-the-texas-manufacturer-assistance-cente-mdai-20240430monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-schedules-2024-first-quarter-financial-results-and-conference-call-mdai-20240424monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-names-erich-spangenberg-ceo-of-its-ip-focused-subsidiary-and-explores-potentia-mdai-20240424monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-secures-access-to-12-5-million-of-new-equity-capital-mdai-20240320monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-receipt-of-1-million-of-financing-for-spectral-ip-inc-its-intellectu-mdai-20240319monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-schedules-2023-fourth-quarter-and-full-year-financial-results-and-conference-c-mdai-20240313monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-new-us-government-contract-to-further-accelerate-the-development-of--mdai-20240312monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-intellectual-property-subsidiary-to-focus-on-the-broader-ai-healthca-mdai-20240307monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-appoints-peter-m-carlson-as-ceo-mdai-20240229monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-to-participate-in-upcoming-investor-conferences-mdai-20240228monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-to-participate-in-the-2024-btig-medtech-digital-health-life-science-diagnostic-mdai-20240206monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-publication-of-letter-to-shareholders-mdai-20240205monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-submits-application-for-ukca-mark-classification-mdai-20240129monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-begins-enrollment-in-pivotal-study-to-validate-deepview-ai-for-burn-injuries-mdai-20240111monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-to-participate-in-benchmark-s-12th-annual-discovery-one-on-one-conference-mdai-20231130monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-schedules-2023-third-quarter-financial-results-and-conference-call-mdai-20231101monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-names-prof-paul-chadwick-former-ceo-of-the-royal-college-of-podiatry-uk-as-sen-mdai-20231024monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-provides-2023-2024-annual-revenue-guidance-mdai-20231023monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-s-deepview-snapshot-wound-imaging-system-achieves-ukca-mark-and-fda-class-1-me-mdai-20231019monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-adds-additional-clinical-sites-to-multi-center-diabetic-foot-ulcer-dfu-study-mdai-20231016monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-ceo-wensheng-fan-to-participate-in-ai-healthcare-panel-at-accelerate-health-co-mdai-20231005monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-adds-healthcare-services-leader-and-population-health-expert-deepak-sadagopan--mdai-20231002monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-to-present-at-2023-cantor-fitzgerald-global-healthcare-conference-mdai-20230920monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-md-holdings-ltd-spectral-md-or-the-company-iso-13485-certification-received-for-a-mdai-20230814monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-design-and-test-inc-announces-a-new-family-of-memoryip-targeted-at-the-5g-market-mdai-20190923monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-financial-launches-solutions-for-comprehensive-cryptocurrency-transactional-safet-mdai-20190829monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-introduces-neuralram-memory-architectures-in-14nm-finfet-tech-node-targeted-for-a-mdai-20180925monthly0.5https://www.biopharmawatch.com/news/IMDX/insights-into-the-2026-fallopian-tube-cancer-therapeutics-market-targeted-treatments-and-e-imdx-20260501monthly0.5https://www.biopharmawatch.com/news/IMDX/insights-into-the-50-billion-urology-care-devices-platforms-market-2025-2030-featuring-bos-imdx-20250904monthly0.5https://www.biopharmawatch.com/news/IMDX/insights-on-the-molecular-diagnostics-for-infectious-disease-global-market-to-2026-aging-p-imdx-20230116monthly0.5https://www.biopharmawatch.com/news/IMDX/insights-on-the-molecular-diagnostics-global-market-to-2031-focus-on-product-testing-locat-imdx-20211202monthly0.5https://www.biopharmawatch.com/news/IMDX/insights-on-the-worldwide-molecular-point-of-care-diagnostics-industry-to-2028-innovations-imdx-20200528monthly0.5https://www.biopharmawatch.com/news/IMDX/insight-genetics-launches-first-of-its-kind-test-for-triple-negative-breast-cancer-imdx-20181203monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-presentation-of-updated-data-from-the-phase-1-trial-of-pln-1-plrx-20260418monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-10109-plrx-20260318monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-interim-data-from-pln-101095-in-patients-with-immune-checkpo-plrx-20251204monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-second-quarter-2025-financial-re-plrx-20250807monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-update-on-beacon-ipf-a-phase-2b-3-trial-in-patients-with-idio-plrx-20250303monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-inc-company-investigated-by-the-portnoy-law-firm-plrx-20250212monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-plrx-20250122monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-appoints-delphine-imbert-ph-d-as-chief-technical-officer-plrx-20250122monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference-plrx-20250102monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-upcoming-investor-events-plrx-20241121monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-presents-data-from-its-bexotegrast-program-at-the-liver-meeting-2024-plrx-20241118monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-the-stifel-healthcare-conference-plrx-20241106monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-integris-psc-phase-2a-data-evaluating-bexotegrast-in-primary-sclerosin-plrx-20241017monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-appoints-gary-palmer-m-d-as-senior-vice-president-of-medical-affairs-plrx-20241001monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-plrx-20240930monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-presents-data-from-its-bexotegrast-program-at-the-european-respiratory-plrx-20240910monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-upcoming-investor-events-plrx-20240828monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-four-upcoming-presentations-at-the-european-respiratory-soci-plrx-20240826monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-the-canaccord-genuity-44th-annual-growth-conference-plrx-20240806monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-appointment-of-steve-krognes-to-board-of-directors-plrx-20240613monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-plrx-20240612monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-presents-data-from-its-bexotegrast-program-at-the-european-association-plrx-20240606monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-presents-data-from-its-bexotegrast-program-at-the-american-thoracic-so-plrx-20240521monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-upcoming-presentations-at-the-european-association-for-the-s-plrx-20240507monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-upcoming-investor-events-plrx-20240501monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-upcoming-investor-events-plrx-20240402monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-upcoming-presentations-at-the-2024-american-thoracic-society-plrx-20240327monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-upcoming-investor-conferences-plrx-20240226monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-upcoming-investor-events-plrx-20240207monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-the-42nd-annual-j-p-morgan-healthcare-conference-plrx-20240103monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-upcoming-investor-conferences-plrx-20231108monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-three-presentations-at-the-annual-meeting-of-the-society-for-plrx-20231031monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-integris-psc-phase-2a-interim-data-evaluating-bexotegrast-in-primary-s-plrx-20231019monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-appoints-s-mishima-gerhart-as-chief-regulatory-officer-plrx-20231016monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-host-investor-call-and-webcast-to-discuss-interim-results-from-inte-plrx-20230925monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-appoints-minnie-kuo-as-chief-development-officer-plrx-20230915monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-presentations-at-the-european-respiratory-society-internatio-plrx-20230911monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-upcoming-investor-conferences-plrx-20230830monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-three-upcoming-presentations-at-the-european-respiratory-soc-plrx-20230828monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-initiation-of-beacon-ipf-a-phase-2b-clinical-trial-of-bexote-plrx-20230809monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-upcoming-investor-conferences-plrx-20230725monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-presents-data-from-its-bexotegrast-program-at-the-european-association-plrx-20230623monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-presents-data-from-its-bexotegrast-program-at-the-american-thoracic-so-plrx-20230524monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-upcoming-investor-events-plrx-20230510monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-the-22nd-annual-needham-healthcare-conference-plrx-20230412monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-poster-presentations-at-the-2023-american-thoracic-society-i-plrx-20230327monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-positive-dsmb-safety-review-and-initiation-of-enrollment-of--plrx-20230313monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-appointments-of-darren-cline-and-thomas-mccourt-to-board-of--plrx-20230308monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-upcoming-investor-events-plrx-20230301monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-upcoming-investor-events-plrx-20230207monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-pl-plrx-20230202monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-closing-of-upsized-public-offering-and-full-exercise-of-the--plrx-20230127monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-appointment-of-lily-cheung-as-chief-human-resources-officer-plrx-20230125monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-pricing-of-upsized-250-0-million-public-offering-plrx-20230125monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-proposed-public-offering-of-common-stock-plrx-20230123monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-the-41st-annual-j-p-morgan-healthcare-conference-plrx-20230103monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-receives-orphan-designation-from-the-european-medicines-agency-for-bex-plrx-20221215monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-upcoming-investor-conferences-plrx-20221115monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lun-plrx-20221005monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-appointment-of-katharine-knobil-m-d-to-board-of-directors-plrx-20220915monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-positive-dsmb-safety-review-of-integris-ipf-phase-2a-trial-o-plrx-20220901monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-upcoming-investor-conferences-plrx-20220830monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-btig-biotechnology-conference-plrx-20220802monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-receives-fda-fast-track-designation-for-pln-74809-for-the-treatment-of-plrx-20220721monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-closing-of-upsized-public-offering-and-full-exercise-of-the--plrx-20220715monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-pricing-of-upsized-200-0-million-public-offering-plrx-20220712monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-proposed-public-offering-of-common-stock-plrx-20220711monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-presentations-at-the-international-liver-congress-2022-highl-plrx-20220624monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-presents-preclinical-data-highlighting-a-novel-approach-for-the-treatm-plrx-20220622monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-advancement-of-integrin-target-in-fibrosis-under-strategic-c-plrx-20220616monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-presentations-at-the-international-liver-congress-2022-plrx-20220615monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-presentations-at-2022-american-thoracic-society-internationa-plrx-20220518monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-upcoming-investor-conferences-plrx-20220511monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-enters-into-100-million-loan-facility-agreement-with-oxford-finance-to-plrx-20220505monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-receives-fda-fast-track-designation-for-pln-74809-for-the-treatment-of-plrx-20220503monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-multiple-presentations-at-the-2022-american-thoracic-society-plrx-20220502monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-needham-healthcare-conference-plrx-20220405monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-positive-dsmb-safety-review-and-commencement-of-enrollment-o-plrx-20220224monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-upcoming-investor-conferences-plrx-20220224monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-highlights-recent-developments-for-lead-program-pln-74809-and-expected-plrx-20220111monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-the-40th-annual-j-p-morgan-healthcare-conference-plrx-20211221monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-upcoming-investor-conferences-plrx-20211118monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-piper-sandler-lung-day-plrx-20211007monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase--plrx-20210903monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-upcoming-investor-conferences-plrx-20210902monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference-plrx-20210803monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-the-rbc-capital-markets-global-healthcare-conference-plrx-20210505monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-annual-needham-virtual-healthcare-conference-plrx-20210405monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-successful-completion-of-pln-1474-phase-1-study-and-developm-plrx-20210316monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-to-participate-in-upcoming-virtual-investor-events-plrx-20210218monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-appointment-of-david-pyott-to-board-of-directors-plrx-20210112monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-appointment-of-gregory-p-cosgrove-m-d-fccp-as-vice-president-plrx-20210104monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-announces-16-566-027-registered-direct-offering-priced-at-the-market-u-lixt-20260603monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-inc-announces-4-3-million-registered-direct-offering-priced-a-lixt-20251218monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-announces-closing-of-1-05-million-registered-direct-offering-priced-at-lixt-20250213monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement-lixt-20250210monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-provides-update-on-recent-activities-and-developments-lixt-20240819monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-announces-the-passing-of-its-founder-john-s-kovach-lixt-20231009monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-and-the-spanish-sarcoma-group-enroll-first-patient-in-a-phase-1b-2-ran-lixt-20230607monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-inc-announces-1-for-10-reverse-stock-split-of-its-common-stoc-lixt-20230602monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-announces-the-closing-of-5-8-million-registered-direct-offering-priced-lixt-20220414monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-announces-preclinical-results-of-its-collaboration-with-the-netherland-lixt-20220412monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-inc-to-present-at-medinvest-pharmaceutical-and-biotechnology--lixt-20220316monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-announces-filing-of-first-patent-application-resulting-from-collaborat-lixt-20220112monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-s-lb-100-reported-to-convert-immunologically-unresponsive-cold-tumors--lixt-20220105monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-inc-announces-that-enrollment-has-resumed-in-national-cancer--lixt-20211122monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-to-discuss-its-collaboration-with-leading-european-cancer-centers-at-t-lixt-20211020monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-s-lb-100-shown-in-animal-models-to-significantly-reduce-behavioral-sen-lixt-20210817monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-s-lb-100-elicits-anti-tumor-activity-in-small-lung-cancer-models-by-un-lixt-20210803monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-comments-on-report-that-its-pp2a-inhibitor-lb-100-combined-with-anothe-lixt-20210722monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-comments-on-outside-research-citing-lb-100-s-pp2a-inhibition-as-a-pote-lixt-20210713monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-to-present-its-drug-development-pipeline-for-cancer-treatment-at-the-m-lixt-20210707monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-to-present-key-advantages-of-novel-cancer-drug-candidate-lb-100-at-the-lixt-20210504monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-to-discuss-pipeline-of-clinical-investigations-for-four-cancer-targets-lixt-20210428monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-to-present-its-novel-product-candidate-for-targeted-cancer-therapy-at--lixt-20210317monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-to-showcase-its-anti-cancer-therapy-enhancer-lb-100-at-the-virtual-33r-lixt-20210303monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-announces-the-closing-of-4-19-million-registered-direct-offering-lixt-20210302monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-announces-4-19-million-registered-direct-offering-lixt-20210301monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-to-present-its-anti-cancer-therapy-enhancer-lb-100-at-the-virtual-h-c--lixt-20210224monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-inc-announces-pricing-of-5-700-000-public-offering-uplisting--lixt-20201125monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-inc-announces-the-appointment-of-internationally-recognized-c-lixt-20200721monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-s-pp2a-inhibitor-lb-100-enhances-the-effectiveness-of-pd1-immune-block-lixt-20200430monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-s-pp2a-inhibitor-lb-100-improves-brain-function-and-motor-impairment-i-lixt-20190625monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-s-lb-100-to-be-evaluated-by-the-national-cancer-institute-in-a-clinica-lixt-20190515monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-files-an-ind-with-the-fda-to-conduct-a-phase-1b-2-trial-of-lb-100-in-p-lixt-20181009monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-inc-s-lead-compound-lb-100-reported-to-rapidly-improve-sympto-lixt-20160203monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-to-obtain-high-quality-tissue-and-blood-samples-from-german-university-lixt-20070111monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-appoints-commercial-leader-stephen-camiolo-as-senior-vice-president-mar-tcrx-20250327monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-upcoming-presentation-at-the-td-cowen-45th-annual-health-care-tcrx-20250227monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-cell-therapy-virtual-co-tcrx-20250218monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-30-million-registered-direct-offering-at-a-37-premium-tcrx-20241226monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-named-a-top-place-to-work-by-the-boston-globe-for-three-consecutive-yea-tcrx-20241205monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-clinical-updates-from-the-alloha-p-tcrx-20241202monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-upcoming-oral-presentation-of-data-from-the-alloha-phase-1-he-tcrx-20241105monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-ca-tcrx-20241004monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-participate-in-upcoming-investor-conferences-tcrx-20240829monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-upcoming-presentation-at-the-jefferies-global-healthcare-conf-tcrx-20240530monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-receives-fda-s-regenerative-medicine-advanced-therapy-rmat-designation--tcrx-20240529monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-tcr--tcrx-20240509monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-upcoming-presentations-at-the-2024-american-society-of-clinic-tcrx-20240424monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-exercise-of-underwriters-option-to-purchase-additional-shares-tcrx-20240424monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-upcoming-presentations-at-the-american-society-of-gene-and-ce-tcrx-20240422monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-closing-of-upsized-public-offering-tcrx-20240419monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-pricing-of-upsized-150-million-public-offering-tcrx-20240417monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-upcoming-presentation-at-the-23rd-annual-needham-virtual-heal-tcrx-20240402monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-participate-in-the-td-cowen-44th-annual-health-care-conference-tcrx-20240228monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-presents-promising-updated-phase-1-clinical-results-on-tsc-100-and-tsc--tcrx-20240226monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-updated-results-from-phase-1-heme--tcrx-20240214monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-expands-clinical-team-with-the-appointment-of-dawn-pinchasik-m-d-m-s-as-tcrx-20240206monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-best-abstracts-award-and-upcoming-oral-presentation-at-the-20-tcrx-20240118monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-2024-clinical-plans-and-highlights-recent-progress-tcrx-20240104monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-results-from-ongoing-phase-1-trial-tcrx-20231204monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-expands-manufacturing-leadership-with-the-appointment-of-justin-mccue-p-tcrx-20231204monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-named-top-place-to-work-by-the-boston-globe-for-two-consecutive-years-tcrx-20231130monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-presents-phase-1-trial-design-for-solid-tumor-program-at-the-society-fo-tcrx-20231106monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-upcoming-presentation-at-the-65th-american-society-of-hematol-tcrx-20231102monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-upcoming-presentations-at-the-38th-society-for-immunotherapy--tcrx-20230927monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-participate-in-upcoming-investor-conferences-tcrx-20230905monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-tsc-tcrx-20230829monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-tsc-tcrx-20230606monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-upcoming-trial-in-progress-poster-presentation-at-the-2023-am-tcrx-20230601monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-closing-of-public-offering-tcrx-20230601monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-participate-in-the-jefferies-healthcare-conference-tcrx-20230601monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-pricing-of-140-million-public-offering-tcrx-20230526monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-upcoming-trial-in-progress-poster-presentation-at-the-america-tcrx-20230502monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-ceo-transition-tcrx-20230331monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-first-patient-dosed-in-phase-1-umbrella-clinical-trial-evalua-tcrx-20230314monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-participate-in-the-barclays-global-healthcare-conference-tcrx-20230313monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-participate-in-the-cowen-43rd-annual-health-care-conference-tcrx-20230301monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-presentation-at-the-h-c-wainwright-cell-therapy-virtual-confe-tcrx-20230221monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-2023-clinical-plans-and-highlights-recent-progress-tcrx-20230105monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-presents-phase-1-umbrella-trial-in-progress-on-ha-1-tsc-100-and-ha-2-ts-tcrx-20221212monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-named-the-highest-placed-midsize-biotechnology-company-in-the-top-place-tcrx-20221201monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-participate-in-the-5th-annual-evercore-isi-healthconx-conference-tcrx-20221122monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-presents-preclinical-data-for-solid-tumor-program-at-the-37th-society-f-tcrx-20221111monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-upcoming-virtual-investor-event-tcrx-20221107monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-upcoming-poster-presentation-at-the-64th-american-society-of--tcrx-20221103monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-upcoming-poster-presentations-at-the-37th-society-for-immunot-tcrx-20221005monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-participate-in-upcoming-investor-conferences-tcrx-20220922monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-participate-in-the-morgan-stanley-20th-annual-global-healthcare-conf-tcrx-20220907monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-participate-in-the-13th-annual-wedbush-pacgrow-healthcare-conference-tcrx-20220803monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-publication-in-cell-highlighting-the-discovery-of-tumor-antig-tcrx-20220711monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-appoints-debora-barton-m-d-as-chief-medical-officer-tcrx-20220707monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-participate-in-the-lifesci-2nd-annual-genetic-medicines-symposium-tcrx-20220622monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-participate-in-the-2022-jefferies-healthcare-conference-tcrx-20220602monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-presents-preclinical-data-at-the-american-society-of-gene-and-cell-ther-tcrx-20220519monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-participate-in-the-h-c-wainwright-global-investment-conference-tcrx-20220517monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-host-virtual-kol-event-to-discuss-its-solid-tumor-program-strategy-a-tcrx-20220512monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-upcoming-presentations-at-the-25th-american-society-of-gene-a-tcrx-20220502monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-appoints-leiden-dworak-cpa-mba-as-vice-president-finance-tcrx-20220411monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-participate-in-upcoming-investor-conferences-tcrx-20220302monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-presentation-at-the-11th-annual-svb-leerink-global-healthcare-tcrx-20220210monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-outlines-2022-priorities-as-programs-enter-clinic-tcrx-20220110monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-poster-presentations-at-the-63rd-american-society-of-hematolo-tcrx-20211213monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-host-a-virtual-event-to-discuss-highlights-from-the-63rd-ash-annual--tcrx-20211203monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-establishes-facility-to-manufacture-t-cell-receptor-engineered-t-cell-t-tcrx-20211202monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-participate-in-upcoming-investor-conferences-tcrx-20211111monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-upcoming-presentations-at-the-63rd-american-society-of-hemato-tcrx-20211104monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-appoints-heather-savelle-as-vice-president-investor-relations-tcrx-20211005monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-participate-in-the-chardan-5th-annual-genetic-medicines-conference-tcrx-20210928monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-appoints-zoran-zdraveski-j-d-ph-d-as-chief-legal-officer-tcrx-20210909monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-participate-in-the-morgan-stanley-19th-annual-global-healthcare-conf-tcrx-20210902monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-present-discovery-of-t-cell-targets-for-covid-19-at-the-cell-mediate-tcrx-20210721monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-inc-announces-pricing-of-initial-public-offering-tcrx-20210715monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-announces-board-chair-transition-pmvp-20260422monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-reports-full-year-2025-financial-results-and-corporate-highlights-pmvp-20260306monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-announces-promising-rezatapopt-monotherapy-interim-data-from-pynnacle--pmvp-20250910monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-to-participate-at-upcoming-investor-conferences-pmvp-20250211monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-provides-a-progress-update-on-pynnacle-clinical-trial-pmvp-20241023monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-to-participate-at-upcoming-investor-conferences-in-june-pmvp-20240530monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-announces-first-patient-dosed-in-global-tumor-agnostic-phase-2-pynnacl-pmvp-20240327monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-pynnacle-phase-i-data-of-rezatapopt-in-advanced-ovarian-cancer-feature-pmvp-20240318monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-to-participate-in-the-td-cowen-44th-annual-health-care-conference-pmvp-20240226monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-announces-prioritization-of-pc14586-clinical-development-and-extended--pmvp-20240118monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-reports-third-quarter-2023-financial-results-and-corporate-highlights-pmvp-20231109monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-to-present-updated-phase-1-data-on-pc14586-at-the-2023-aacr-nci-eortc--pmvp-20230920monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-to-participate-in-the-goldman-sachs-global-healthcare-conference-pmvp-20230606monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-to-participate-at-upcoming-investor-conferences-in-march-pmvp-20230228monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-to-participate-in-the-5th-annual-evercore-isi-healthconx-conference-pmvp-20221122monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-announces-a-clinical-trial-collaboration-with-merck-to-evaluate-pc1458-pmvp-20220718monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-to-participate-in-the-goldman-sachs-global-healthcare-conference-pmvp-20220608monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-to-present-pc14586-phase-1-clinical-data-at-the-2022-american-society--pmvp-20220427monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-to-participate-in-the-42nd-annual-cowen-health-care-conference-pmvp-20220228monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-to-participate-in-the-guggenheim-healthcare-talks-2022-oncology-day-pmvp-20220203monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharma-to-present-at-the-evercore-isi-4th-annual-healthconx-conference-pmvp-20211122monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-reports-third-quarter-2021-financial-results-and-corporate-highlights-pmvp-20211112monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-appoints-tim-smith-as-senior-vice-president-head-of-corporate-developm-pmvp-20210909monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-to-present-at-the-morgan-stanley-19th-annual-global-healthcare-confere-pmvp-20210902monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-reports-second-quarter-2021-financial-results-and-corporate-highlights-pmvp-20210813monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-announces-participation-at-the-bank-of-america-securities-2021-napa-bi-pmvp-20210609monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-announces-participation-at-the-goldman-sachs-annual-healthcare-confere-pmvp-20210603monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-announces-participation-at-the-bank-of-america-healthcare-conference-pmvp-20210505monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharma-presents-late-breaking-preclinical-data-on-lead-product-candidate-pc14586-at-th-pmvp-20210410monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-announces-presentation-of-pc14586-preclinical-data-at-the-american-ass-pmvp-20210310monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-announces-participation-at-the-cowen-41st-annual-health-care-conferenc-pmvp-20210223monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharma-appoints-p53-pioneer-dr-guillermina-lozano-to-scientific-advisory-board-pmvp-20210216monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-to-present-at-evercore-isi-3rd-annual-healthconx-conference-pmvp-20201124monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharma-doses-first-patient-in-phase-1-2-study-of-pc14586-a-first-in-class-precision-on-pmvp-20201123monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharma-granted-fda-fast-track-designation-of-pc14586-for-the-treatment-of-advanced-can-pmvp-20201013monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharma-announces-pricing-of-initial-public-offering-pmvp-20200925monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharma-appoints-laurie-stelzer-to-the-board-of-directors-and-robert-ticktin-as-general-pmvp-20200908monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharma-closes-70-million-in-series-d-financing-pmvp-20200803monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharma-appoints-leila-alland-m-d-as-chief-medical-officer-pmvp-20191211monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-appointment-of-new-senior-sales-leaders-xtnt-20190212monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-appointment-of-chief-operations-officer-xtnt-20190111monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-to-issue-third-quarter-2018-results-on-november-14-2018-xtnt-20181112monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-to-issue-second-quarter-2018-results-on-august-7-2018-xtnt-20180806monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-compliance-with-nyse-american-xtnt-20180215monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-joins-the-2018-donate-life-rose-parade-float-to-highlight-the-power-of-organ-xtnt-20170803monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-receives-going-concern-opinion-xtnt-20170405monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-ceo-dan-goldberger-announces-resignation-xtnt-20170123monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-expiration-of-rights-offering-and-estimated-gross-proceeds-of-3-8--xtnt-20161115monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-first-surgical-cases-of-xspan-laminoplasty-fixation-system-xtnt-20161114monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-commencement-of-subscription-period-for-previously-announced-right-xtnt-20161031monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-holdings-inc-to-report-third-quarter-2016-financial-results-on-november-7-20-xtnt-20161018monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-key-dates-related-to-previously-announced-rights-offering-xtnt-20161006monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-receives-non-compliance-notice-from-nyse-mkt-xtnt-20160819monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-reports-second-quarter-2016-results-xtnt-20160801monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-holdings-inc-to-report-second-quarter-2016-financial-results-on-august-1-201-xtnt-20160719monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-and-pinnacle-spine-group-announce-distribution-agreement-expanding-the-avail-xtnt-20160608monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-completes-new-accounts-receivable-revolver-credit-facility-with-silicon-vall-xtnt-20160526monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-to-present-at-investor-conferences-xtnt-20160517monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-the-fda-clearance-for-the-posterior-cervical-screw-indication-on-c-xtnt-20160512monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-reports-first-quarter-2016-results-xtnt-20160504monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-holdings-inc-to-report-first-quarter-2016-financial-results-on-may-4-2016-xtnt-20160427monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-montana-department-of-commerce-grant-awards-xtnt-20160426monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-holdings-inc-to-report-fourth-quarter-2015-financial-results-on-march-15-201-xtnt-20160308monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-to-present-at-icv-manhattan-conference-xtnt-20151203monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-holdings-inc-to-report-third-quarter-2015-financial-results-on-november-11-2-xtnt-20151102monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-holdings-announces-uplisting-to-nyse-mkt-xtnt-20151015monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-announces-preliminary-third-quarter-2015-revenue-xtnt-20151013monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-tm-medical-exhibits-at-north-american-spine-society-nass-meeting-xtnt-20151012monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-tm-medical-awarded-grant-from-the-montana-board-of-research-and-commercialization-te-xtnt-20151006monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-tm-medical-exhibits-at-the-congress-of-neurological-surgeons-annual-meeting-xtnt-20150928monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-r-medical-announces-expanded-patent-coverage-of-core-technologies-xtnt-20150922monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-to-exhibit-at-eurospine-2015-xtnt-20150901monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-reports-first-half-2015-financial-results-xtnt-20150812monthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-announces-commencement-of-halneuron-chemotherapy-induced-neuropathic--dwtx-20260518monthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-announces-worldwide-development-and-commercialization-partnership-for-dwtx-20260423monthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-announces-fda-acceptance-of-sp16-investigational-new-drug-application-dwtx-20260415monthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-announces-positive-interim-phase-2b-clinical-trial-results-in-chemoth-dwtx-20251222monthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-to-report-second-quarter-2025-financial-results-on-wednesday-august-1-dwtx-20250806monthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-announces-dosing-of-first-patient-in-phase-2b-trial-evaluating-halneu-dwtx-20250318monthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-announces-patient-dosing-in-phase-2b-trial-evaluating-halneuron-in-pa-dwtx-20250121monthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-inc-announces-low-dose-imc-2-treatment-reduces-long-covid-related-fat-dwtx-20241118monthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-to-report-third-quarter-2024-financial-results-and-provide-corporate--dwtx-20241031monthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-dwtx-20241030monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-first-quarter-results-om-20260507monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-alert-bragar-eagel-squire-p-c-is-investigating-outset-medical-inc-on-behalf-om-20250904monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-to-report-second-quarter-2025-financial-results-on-wednesday-august-6-2025-om-20250716monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-to-present-at-rbc-global-healthcare-conference-om-20250509monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-alert-bragar-eagel-squire-p-c-is-investigating-outset-medical-inc-on-behalf-om-20250430monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-to-report-first-quarter-2025-financial-results-on-wednesday-may-7-2025-om-20250416monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-to-present-at-the-45th-annual-td-cowen-health-care-conference-om-20250224monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-announces-resolution-of-warning-letter-om-20250213monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-to-report-fourth-quarter-and-full-year-2024-financial-results-on-wednesday--om-20250203monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-om-20250108monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-alert-bragar-eagel-squire-p-c-is-investigating-outset-medical-inc-on-behalf-om-20241204monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-to-present-at-the-2024-stifel-healthcare-conference-om-20241115monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-oc-om-20241023monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-to-report-third-quarter-2024-financial-results-on-wednesday-november-6-2024-om-20241023monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-om-shares-down-94-since-disclosing-fda-warning-letter-morgan-stanley-and-jp-om-20241016monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-om-receives-nasdaq-notice-shares-no-longer-meet-minimum-bid-requirement-cla-om-20241011monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-sued-for-securities-law-violations-contact-the-gross-law-firm-before-oc-om-20241008monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-om-receives-nasdaq-notice-shares-no-longer-meet-minimum-bid-requirement-cla-om-20241007monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-om-receives-nasdaq-notice-shares-no-longer-meet-minimum-bid-requirement-cla-om-20241004monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-om-receives-nasdaq-notice-shares-no-longer-meet-minimum-bid-requirement-cla-om-20241001monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-om-shares-down-94-since-disclosing-fda-warning-letter-morgan-stanley-and-jp-om-20240927monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-om-shares-down-94-since-disclosing-fda-warning-letter-morgan-stanley-and-jp-om-20240923monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-om-shares-down-94-since-disclosing-fda-warning-letter-morgan-stanley-and-jp-om-20240920monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-om-shares-down-94-since-disclosing-fda-warning-letter-class-action-pending--om-20240916monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-om-shares-down-94-since-disclosing-fda-warning-letter-class-action-pending--om-20240912monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-om-faces-investor-scrutiny-after-fda-warning-letter-leads-to-poor-financial-om-20240909monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-om-faces-investor-scrutiny-after-fda-warning-letter-leads-to-poor-financial-om-20240906monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-oc-om-20240903monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-om-faces-investor-scrutiny-after-fda-warning-letter-leads-to-poor-financial-om-20240903monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-om-faces-investor-scrutiny-after-fda-warning-letter-leads-to-poor-financial-om-20240831monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-bee-om-20240831monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-om-investigation-bronstein-gewirtz-grossman-llc-encourages-investors-to-om-20240822monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-om-investigation-bronstein-gewirtz-grossman-llc-encourages-investors-to-om-20240816monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-om-investigation-bronstein-gewirtz-grossman-llc-encourages-investors-to-om-20240811monthly0.5https://www.biopharmawatch.com/news/OM/outset-alert-bragar-eagel-squire-p-c-is-investigating-outset-medical-inc-on-behalf-of-outs-om-20240811monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-om-investigated-for-possible-securities-law-violations-hagens-berman-nation-om-20231116monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-om-investigated-for-possible-securities-law-violations-hagens-berman-nation-om-20231031monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-pm-investigated-for-possible-securities-law-violations-hagens-berman-encour-om-20231019monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-company-investigated-by-the-portnoy-law-firm-om-20231017monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-stock-nosedives-due-to-fda-warning-letter-headwinds-hagens-berman-om-20231013monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-company-investigated-by-the-portnoy-law-firm-om-20230724monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-portnoy-om-20220907monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-nasdaq-om-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-om-20220906monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-10-om-20220831monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-nasdaq-om-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-om-20220830monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-portnoy-om-20220824monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc--om-20220824monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-nasdaq-om-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-om-20220822monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-10-om-20220817monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-lawsuit-alert-kaplan-fox-kilshiemer-llp-notifies-outset-medical-investors-o-om-20220816monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-nasdaq-om-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-om-20220815monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc--om-20220810monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-nasdaq-om-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-om-20220808monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-lawsuit-alert-kaplan-fox-kilshiemer-llp-notifies-outset-medical-investors-o-om-20220803monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-10-om-20220803monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-nasdaq-om-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-om-20220802monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc--om-20220727monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-nasdaq-om-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-om-20220726monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-shareholder-update-robbins-llp-reminds-investors-of-lead-plaintiff-dead-om-20220722monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-portnoy-om-20220721monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-10-om-20220720monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-nasdaq-om-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-om-20220719monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc--om-20220713monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-nasdaq-om-shareholder-class-action-alert-bernstein-liebhard-llp-announc-om-20220712monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-investigated-by-block-leviton-for-potential-securities-law-violations-i-om-20220629monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-investors-company-investigated-by-the-portnoy-law-firm-om-20220620monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-investigated-by-block-leviton-for-potential-securities-law-violations-i-om-20220615monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-outset-om-20220614monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-appoints-nilay-patel-as-chief-legal-officer-to-support-growth-ahead-of-new-drug--cing-20250709monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-announces-positive-top-line-results-from-high-dose-50mg-fed-fast-study-of-lead-a-cing-20250429monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-completes-pre-nda-meeting-with-fda-to-discuss-new-drug-application-for-lead-adhd-cing-20250403monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-s-shane-schaffer-joins-cast-of-nationally-syndicated-big-biz-show-cing-20241008monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-to-participate-in-benzinga-all-live-access-event-cing-20240827monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-announces-adjournment-of-special-meeting-cing-20240823monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-issued-european-patent-for-lead-asset-ctx-1301-for-the-treatment-of-adhd-cing-20240815monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-and-adhd-expert-dr-ann-childress-md-to-participate-in-benzinga-all-live-access-e-cing-20240625monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-achieves-key-manufacturing-milestone-in-the-development-of-its-adhd-drug-ctx-130-cing-20240625monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-to-participate-in-planet-microcap-showcase-vegas-2024-cing-20240416monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-to-participate-in-benzinga-all-live-access-event-cing-20240319monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-to-attend-dcat-week-2024-in-new-york-city-cing-20240306monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-announces-closing-of-7-5-million-public-offering-cing-20240206monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-receives-guidance-from-fda-on-path-forward-for-anxiety-asset-ctx-2103-buspirone-cing-20231201monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-inc-to-present-at-the-ld-micro-main-event-xvi-cing-20230921monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-announces-closing-of-4-0-million-public-offering-cing-20230913monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-announces-pricing-of-4-0-million-public-offering-cing-20230911monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-announces-detailed-trial-results-from-phase-3-adult-efficacy-and-safety-trial-of-cing-20230911monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-announces-presentation-of-full-trial-results-from-phase-3-adult-efficacy-and-saf-cing-20230905monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-to-participate-in-the-healthcare-virtual-conference-part-ii-presented-by-maxim-g-cing-20230614monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-to-present-at-13th-annual-ld-micro-invitational-cing-20230525monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-indegene-to-participate-in-benzinga-all-live-access-event-cing-20230512monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-to-participate-in-benzinga-all-live-access-event-cing-20230414monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-completes-first-cohort-of-phase-3-adult-onset-and-duration-trial-of-ctx-1301-dex-cing-20230404monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-and-indegene-announce-joint-commercialization-agreement-for-lead-adhd-candidate--cing-20230313monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-announces-positive-top-line-results-from-fed-fast-study-of-lead-asset-ctx-1301-f-cing-20230223monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-initiates-phase-3-study-of-lead-asset-ctx-1301-designed-as-a-true-entire-active--cing-20230104monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-benzinga-all-live-access-appearance-rescheduled-for-december-16-cing-20221201monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-to-participate-in-benzinga-all-live-access-event-cing-20221130monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-completes-fed-fast-study-assessing-food-effect-with-ctx-1301-lead-candidate-for--cing-20221101monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-to-present-at-ld-micro-investor-conference-cing-20221020monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-presents-data-for-its-triple-release-buspirone-product-candidate-ctx-2103-cing-20220919monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-to-participate-in-benzinga-all-live-access-event-cing-20220815monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-announces-completion-of-ctx-2103-human-formulation-study-for-the-treatment-of-an-cing-20220623monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-to-present-at-diamond-equity-research-2022-virtual-emerging-growth-invitational-cing-20220617monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-and-adhd-expert-dr-ann-childress-md-to-participate-in-benzinga-all-live-access-e-cing-20220602monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-announces-complete-enrollment-in-human-formulation-study-of-ctx-2103-for-the-tre-cing-20220524monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-to-present-at-h-c-wainwright-global-investment-conference-cing-20220518monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-presents-at-noblecon18-cing-20220426monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-to-present-at-aegis-virtual-conference-cing-20220215monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-appoints-curt-medeiros-and-gregg-givens-to-board-of-directors-cing-20220125monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-inc-announces-closing-of-initial-public-offering-cing-20211210monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-inc-announces-pricing-of-25-0-million-initial-public-offering-cing-20211208monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-reports-robust-preclinical-data-for-eb612-oral-la-pth-1-34-for-hypoparathyroidism-a-entx-20260616monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-announces-first-quarter-2026-financial-results-and-updates-across-its-oral-peptide--entx-20260508monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-full-year-2025-financial-results-and-provides-business-updates-entx-20260327monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-entx-20251118monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-third-quarter-2025-financial-results-and-business-updates-entx-20251114monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-data-for-eb613-effects-on-trabecular-and-cortical-bone-in-post-menopausal-women-entx-20250626monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-first-quarter-2025-financial-results-and-business-updates-entx-20250509monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-s-eb613-demonstrates-early-impact-on-both-trabecular-and-cortical-bone-compartm-entx-20250415monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-full-year-2024-financial-results-and-provides-business-updates-entx-20250328monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-participate-in-upcoming-events-entx-20250224monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference-entx-20250127monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-reports-q3-2024-financial-results-and-provides-business-updates-entx-20241108monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-and-opko-health-provide-update-on-pk-pd-results-of-oral-oxyntomodulin-glp-1-glu-entx-20240925monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-participate-in-upcoming-investor-and-scientific-conferences-entx-20240820monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-reports-q2-2024-financial-results-and-provides-business-updates-entx-20240809monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-s-eb613-the-first-once-daily-pth-1-34-tablet-treatment-dedicated-to-post-menopausal-entx-20240801monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-reports-phase-1-clinical-data-of-first-in-class-oral-pth-1-34-peptide-candidate-entx-20240603monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-appoints-dr-rachel-b-wagman-as-key-clinical-advisor-and-scientific-advisory-boa-entx-20240515monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-present-phase-1-data-from-first-in-class-pth-1-34-peptide-tablets-eb612-for--entx-20240513monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-reports-q1-2024-financial-results-and-provides-business-updates-entx-20240510monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-publication-of-oral-pth-1-34-peptide-tablets-eb613-phase-2-trial-data-entx-20240408monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-key-regulatory-milestone-for-oral-pth-1-34-peptide-eb613-phase-3-prog-entx-20240326monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-robust-pharmacokinetic-data-for-first-in-class-oral-glp-2-peptide-tab-entx-20240320monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-full-year-2023-financial-results-and-provides-business-updates-entx-20240308monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-regains-compliance-with-nasdaq-minimum-bid-price-requirement-entx-20240304monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-present-at-the-oppenheimer-34th-annual-healthcare-life-sciences-conference-entx-20240130monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-receives-extension-from-nasdaq-to-regain-compliance-with-minimum-bid-price-rule-entx-20240103monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-closing-of-private-placement-extends-cash-runway-into-2025-entx-20231226monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-reports-q3-2023-financial-results-highlights-transformational-steps-and-unveils-entx-20231114monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-reports-key-milestone-relating-to-oral-pth-1-34-peptide-eb613-phase-3-program-a-entx-20231109monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-reports-rapid-pharmacodynamic-pd-response-and-consistent-pharmacokinetic-pk-dat-entx-20231016monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-collaboration-with-opko-biologics-to-develop-oral-peptide-tablet-form-entx-20230912monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-participate-in-upcoming-investor-conferences-entx-20230905monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-present-two-abstracts-on-its-first-in-class-once-daily-oral-hpth-1-34-peptid-entx-20230816monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-q2-2023-financial-results-and-corporate-updates-entx-20230811monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-adds-sanofi-commercial-leader-haya-taitel-to-its-board-of-directors-entx-20230607monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-q1-2023-financial-results-and-corporate-updates-entx-20230505monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-s-oral-delivery-of-glp-2-pre-clinical-data-to-be-published-in-peer-reviewed-interna-entx-20230503monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-provides-guidance-from-fda-type-d-meeting-related-to-eb613-pivotal-program-entx-20230403monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-provides-2022-corporate-milestones-and-financial-results-for-the-year-ended-dec-entx-20230331monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-regains-compliance-with-nasdaq-listing-requirements-entx-20230323monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-fda-s-acceptance-of-a-type-d-meeting-review-to-affirm-design-of-the-p-entx-20230215monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-participate-in-the-svb-securities-global-biopharma-conference-entx-20230213monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-provides-corporate-updates-and-financial-results-for-the-third-quarter-of-2022-entx-20221110monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-fda-agreement-for-a-single-phase-3-clinical-trial-to-support-an-nda-f-entx-20221006monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-hosting-key-opinion-leader-webinar-on-the-treatment-landscape-for-osteoporosis--entx-20220921monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-present-at-h-c-wainwright-24th-annual-global-investment-conference-entx-20220912monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-presents-dose-proportional-absorption-and-correlation-to-bmd-clinical-response--entx-20220912monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-provides-business-highlights-and-financial-results-for-the-second-quarter-2022-entx-20220811monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-formation-of-clinical-and-scientific-advisory-board-and-poster-presen-entx-20220726monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-execution-of-key-regulatory-milestones-for-eb613-the-first-oral-anabo-entx-20220718monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-departure-of-dr-phillip-schwartz-the-company-s-president-of-research--entx-20220617monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-board-member-miranda-toledano-to-assume-role-of-chief-business-officer-chief-fi-entx-20220516monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-reports-first-quarter-2022-financial-results-and-business-highlights-entx-20220512monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-files-patent-applications-for-inventions-that-optimize-its-platform-technology--entx-20220505monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-report-first-quarter-2022-financial-results-on-may-12-entx-20220428monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-present-at-2022-maxim-virtual-growth-conference-entx-20220322monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-reports-financial-results-for-the-year-ended-december-31-2021-entx-20220308monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-report-business-and-financial-results-for-the-year-ended-december-31-2021-on-entx-20220303monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-present-at-aegis-virtual-conference-on-february-23rd-entx-20220217monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-successful-eb613-end-of-phase-2-meeting-with-fda-fda-agrees-to-phase--entx-20220104monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-reports-third-quarter-2021-financial-results-entx-20211110monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-publishes-key-study-describing-its-oral-delivery-technology-platform-for-biolog-entx-20211028monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-presents-positive-phase-2-6-month-bone-mineral-density-data-for-oral-pth-formul-entx-20211006monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-selected-for-late-breaking-oral-presentation-of-phase-2-6-month-osteoporosis-da-entx-20210901monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-conduct-annual-shareholders-meeting-on-october-4-2021-entx-20210823monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference-entx-20210823monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-reports-second-quarter-2021-financial-results-and-provides-clinical-updates-entx-20210816monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-report-business-and-financial-results-for-the-quarter-ended-june-30-2021-on--entx-20210813monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-present-phase-2-eb613-oral-pth-osteoporosis-treatment-3-month-findings-at-th-entx-20210802monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-conduct-conference-call-on-june-30-to-discuss-phase-2-results-for-eb613-posi-entx-20210628monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-excellent-topline-phase-2-bmd-data-for-eb613-the-study-met-its-primar-entx-20210623monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-receives-foundational-patent-for-its-oral-pth-using-its-platform-oral-protein-d-entx-20210617monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-reports-first-quarter-2021-financial-results-and-provides-clinical-updates-entx-20210520monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-announces-ron-mayron-a-global-pharma-leader-joins-its-board-of-directors-entx-20210420monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-appoints-ramesh-ratan-as-chief-financial-officer-entx-20210415monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-ltd-announces-operating-and-financial-results-for-the-fourth-quarter-and-year-e-entx-20210318monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-report-financial-results-for-the-year-ended-december-31-2020-on-march-18-202-entx-20210311monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-ltd-announces-positive-topline-eb613-phase-2-biomarker-data-entx-20210311monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-present-at-the-h-c-wainwright-global-life-sciences-conference-entx-20210304monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-publication-of-phase-2-hypoparathyroidism-study-in-the-journal-of-bon-entx-20210225monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-initiates-new-research-program-for-oral-glp-2-entx-20210208monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-issues-letter-to-shareholders-entx-20210111monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-fda-approval-of-ind-application-for-eb613-an-oral-human-parathyroid-h-entx-20201210monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-appoints-spiros-jamas-as-chief-executive-officer-entx-20201130monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-ltd-announces-third-quarter-2020-financial-results-and-provides-clinical-update-entx-20201119monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-report-third-quarter-2020-business-and-financial-results-on-november-19-2020-entx-20201113monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-ltd-announces-completion-of-enrollment-in-phase-2-clinical-trial-of-eb613-in-os-entx-20201109monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-present-at-the-h-c-wainwright-6th-annual-israel-conference-entx-20201102monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-present-at-the-h-c-wainwright-22nd-annual-global-investment-conference-entx-20200910monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-ltd-announces-interim-data-from-phase-2-clinical-trial-of-eb613-in-osteoporosis-entx-20200820monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-report-second-quarter-2020-business-and-financial-results-on-august-20-2020-entx-20200817monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-management-changes-entx-20200810monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-present-at-btig-s-virtual-biotechnology-conference-entx-20200805monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-ltd-announces-highly-encouraging-oral-pth-market-survey-results-entx-20200722monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-ltd-provides-update-on-phase-2-clinical-trial-of-eb613-in-postmenopausal-women--entx-20200707monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-ltd-announces-interim-biomarker-data-from-phase-2-clinical-trial-of-eb613-and-f-entx-20200521monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-report-interim-data-from-eb613-phase-2-trial-and-first-quarter-2020-business-entx-20200507monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-ltd-announces-financial-and-operating-results-for-the-fourth-quarter-and-year-e-entx-20200326monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-report-2019-business-and-financial-results-on-march-26-2020-entx-20200316monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-the-completion-of-14-3-million-private-placement-entx-20191218monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-announces-closing-of-private-placement-entx-20191211monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-establishes-u-s-headquarters-and-announces-jonathan-lieber-as-chief-financial-o-entx-20191121monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-reports-third-quarter-2019-financial-results-and-provides-operating-update-entx-20191121monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-announce-third-quarter-2019-financial-results-on-thursday-november-21-2019-entx-20191107monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-reports-positive-results-from-a-phase-2-pk-pd-study-of-oral-pth-1-34-in-patient-entx-20190923monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-present-at-the-ladenburg-thalmann-2019-healthcare-conference-entx-20190919monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-reports-second-quarter-2019-financial-results-and-provides-operating-update-entx-20190820monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-announce-second-quarter-and-six-months-ended-june-30-2019-financial-results--entx-20190815monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-appoints-adam-gridley-as-chief-executive-officer-entx-20190805monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-announces-initiation-of-phase-2-dose-ranging-study-for-oral-pth-entx-20190702monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-reports-first-quarter-2019-financial-results-and-operating-update-entx-20190627monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-reports-2018-annual-financial-results-and-operating-update-entx-20190328monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-20-f-filing-entx-20190328monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-to-announce-fourth-quarter-and-year-ended-december-31-2018-financial-results-on-entx-20190327monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-a-transition-in-the-chief-financial-officer-position-entx-20190307monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-positive-feedback-and-guidance-from-the-us-fda-regarding-its-developm-entx-20190131monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-reports-third-quarter-2018-financial-results-and-operating-update-entx-20190122monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-appoints-gerald-m-ostrov-to-board-of-directors-entx-20190110monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-and-amgen-enter-strategic-research-collaboration-in-inflammatory-disease-and-ot-entx-20181211monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-reports-positive-results-from-part-1-of-a-phase-2-pk-pd-study-of-oral-pth-1-34--entx-20181108monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-appoints-two-new-external-independent-members-to-the-board-of-directors-entx-20181002monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-appoints-dr-arthur-santora-as-chief-medical-officer-entx-20180921monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-reports-second-quarter-2018-financial-results-and-operating-update-entx-20180820monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-ltd-announces-appointment-of-mr-gerald-lieberman-as-chairman-of-the-board-of-di-entx-20180809monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-completes-part-1-of-a-phase-2-pk-pd-study-in-hypoparathyroidism-patients-entx-20180801monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-ltd-announces-closing-of-initial-public-offering-entx-20180702monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-ltd-announces-pricing-of-initial-public-offering-entx-20180628monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-partners-with-neurorpm-to-deploy-ai-powered-digital-biomarker-technology-in-parkin-anvs-20260319monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-announces-open-label-extension-study-for-parkinson-s-disease-patients-anvs-20251218monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-to-host-corporate-update-webinar-on-january-28-2026-anvs-20251216monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group-anvs-20251203monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-announces-two-presentations-at-the-ctad-2025-conference-anvs-20251124monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-announces-fda-meeting-to-discuss-parkinson-s-disease-dementia-program-reaffirms-fd-anvs-20251118monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-reports-new-biomarker-data-linking-amyloid-co-pathology-to-accelerated-cognitive-d-anvs-20251117monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-completes-full-patent-transfer-to-crystal-buntanetap-anvs-20250807monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-to-attend-the-aaic-2025-with-four-poster-presentations-anvs-20250626monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-to-host-webinar-and-live-q-a-on-june-24-2025-anvs-20250605monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-appoints-hui-liu-as-director-of-biostatistics-anvs-20250429monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse-anvs-20250327monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program-anvs-20250325monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-joins-experts-at-drug-development-summit-to-redefine-parkinson-s-treatment-anvs-20250311monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-to-host-patients-live-forum-on-february-27-2025-anvs-20250219monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-to-present-at-oppenheimer-s-35th-annual-healthcare-life-sciences-conference-anvs-20250207monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-inc-announces-closing-of-21-million-public-offering-anvs-20250204monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-inc-announces-pricing-of-21-million-public-offering-anvs-20250203monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-granted-u-s-patent-for-treatment-and-prevention-of-acute-brain-or-nerve-injuries-s-anvs-20250114monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-to-host-year-end-investor-webcast-on-december-11-2024-anvs-20241125monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-invited-to-present-at-national-institute-on-aging-workshop-on-dementia-with-lewy-b-anvs-20241112monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-appoints-matthew-peterson-ph-d-as-senior-clinical-scientist-anvs-20241107monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-to-highlight-buntanetap-s-alzheimer-s-research-progress-with-presentations-at-ctad-anvs-20241022monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-inc-nyse-anvs-leading-way-in-development-of-safe-effective-drugs-for-neurodege-anvs-20241003monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-inc-nyse-anvs-research-points-to-potential-future-breakthroughs-in-ad-space-th-anvs-20241002monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-nyse-anvs-to-present-at-h-c-wainwright-26th-annual-global-investment-conferenc-anvs-20240905monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-secures-u-s-patent-for-treatment-of-acute-traumatic-brain-injury-with-buntanet-anvs-20240724monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-welcomes-four-new-executives-to-strengthen-leadership-team-anvs-20240709monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-files-provisional-patent-for-new-manufacturing-process-of-crystalline-form-of--anvs-20240627monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-files-patent-for-new-composition-of-matter-for-buntanetap-anvs-20240626monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-inc-nyse-anvs-schedules-investor-webcast-to-discuss-parkinson-s-disease-data-anvs-20240625monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-highlights-new-alzheimer-s-data-at-the-alzheimer-s-association-international-c-anvs-20240618monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-announces-statistically-significant-phase-ii-iii-data-in-patients-with-early-a-anvs-20240429monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-announces-publication-that-supports-understanding-of-buntanetap-s-mechanism-of-act-anvs-20240401monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-announces-participation-in-forum-discussion-at-ad-pd-2024-anvs-20240227monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-announces-last-patient-last-visit-in-the-phase-ii-iii-study-of-buntanetap-in-a-anvs-20240214monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-announces-the-filing-of-new-patent-application-for-treatment-of-mental-illness-anvs-20240130monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-refines-timeline-for-parkinson-s-phase-iii-study-data-announcement-anvs-20240124monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-to-participate-in-the-139th-yale-ceo-summit-anvs-20231211monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-announces-last-patient-last-visit-in-the-phase-iii-study-of-buntanetap-in-park-anvs-20231205monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-appoints-andrew-walsh-as-vice-president-finance-anvs-20231201monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-announces-full-enrollment-of-its-phase-ii-iii-alzheimer-s-disease-trial-exceed-anvs-20231127monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-announces-third-quarter-2023-financial-results-and-provides-corporate-update-anvs-20231108monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-announces-first-quarter-2023-financial-results-and-provides-corporate-update-anvs-20230511monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-announces-issuance-of-u-s-patent-covering-the-use-of-lead-drug-candidate-bunta-anvs-20230427monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-po-anvs-20211008monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-inc-investors-company-investigated-by-the-portnoy-law-firm-anvs-20210804monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-investigation-block-leviton-investigates-annovis-for-potential-securities-law--anvs-20210803monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-inc-to-present-at-the-q1-virtual-investor-summit-anvs-20210311monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-to-present-at-the-bio-ceo-investor-digital-conference-anvs-20210216monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-anvs-20201217monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-showcases-its-unique-approach-to-alzheimer-s-at-the-new-york-academy-of-scienc-anvs-20201215monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-to-present-at-benzinga-global-small-cap-conference-on-december-8-2020-anvs-20201207monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-to-present-at-the-new-york-academy-of-sciences-alzheimer-s-disease-therapeutic-anvs-20201203monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-to-participate-in-a-g-p-s-virtual-healthcare-symposium-anvs-20201116monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicolog-anvs-20201112monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-ceo-to-present-at-meridian-clinical-trials-summit-anvs-20201102monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-resumes-treatment-of-patients-in-ongoing-phase-2a-study-in-alzheimer-s-disease-anvs-20201029monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-ceo-receives-2020-smart-business-dealmaker-award-anvs-20201022monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-ceo-participates-in-roundtable-discussion-at-the-financial-times-outstanding-d-anvs-20201020monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-provides-third-quarter-2020-and-year-to-date-business-highlights-anvs-20201015monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-to-present-at-the-2020-bio-investor-forum-anvs-20201012monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-demonstrates-improved-axonal-transport-in-nerve-cells-and-brain-of-down-syndro-anvs-20200929monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-anvs-20200903monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-begins-treatment-of-first-patients-in-its-phase-2a-alzheimer-s-and-parkinson-s-anvs-20200901monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-actively-recruiting-patients-for-its-phase-2a-trials-in-alzheimer-s-and-parkin-anvs-20200820monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-ceo-appears-on-executive-leaders-radio-program-anvs-20200723monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-ceo-to-present-the-company-s-novel-approach-to-treating-parkinson-s-disease-at-anvs-20200720monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-receives-institutional-review-board-approval-to-initiate-15-site-phase-2-study-anvs-20200707monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-announces-positive-results-from-nih-funded-chronic-toxicology-study-anvs-20200616monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-issued-european-patent-for-method-of-treating-alzheimer-s-disease-with-anvs401-anvs-20200602monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-2020-annual-meeting-of-stockholders-to-be-held-on-june-3-2020-anvs-20200601monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-files-patent-application-for-method-of-inhibiting-preventing-or-treating-neuro-anvs-20200527monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-anvs-20200501monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-announces-plans-for-a-new-phase-ii-clinical-trial-to-treat-68-parkinson-s-and--anvs-20200430monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-publishes-results-of-alzheimer-s-and-parkinson-s-animal-studies-anvs-20200423monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-to-hold-investor-webinar-and-q-a-session-with-ceo-on-april-14-anvs-20200413monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-awarded-1-7-million-nih-grant-for-anvs401-chronic-toxicology-studies-anvs-20200227monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-issued-patent-for-method-of-treating-parkinson-s-disease-and-other-lewy-body-disea-anvs-20200220monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-announces-update-on-phase-ii-clinical-trial-for-alzheimer-s-disease-anvs-20200213monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-anvs-20200131monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-announces-pricing-of-initial-public-offering-anvs-20200129monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-appoints-jeffrey-mcgroarty-chief-financial-officer-anvs-20190709monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-leadership-transition-to-deliver-focused-execution-on-its-confirmat-bysi-20260604monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-reports-compelling-new-data-plinabulin-advances-both-the-anticancer-efficacy--bysi-20260422monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-esmo-asia-presentation-on-plinabulin-docetaxel-improving-survival-i-bysi-20251212monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-reports-first-quarter-2025-financial-results-and-provides-corporate-update-bysi-20250512monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-presents-updated-efficacy-results-from-a-phase-2-iit-study-of-triple-io-combo-bysi-20241111monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-presents-final-data-analysis-of-dublin-3-phase-3-study-in-2l-3l-egfr-wild-typ-bysi-20240916monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-presents-efficacy-safety-results-from-a-phase-2-study-of-pembrolizumab-plus-p-bysi-20240916monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-delivers-oral-presentation-at-islac-2024-world-conference-on-lung-cancer-of-i-bysi-20240910monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-oral-presentation-at-the-2024-world-conference-on-lung-cancer-and-t-bysi-20240903monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-r-d-day-highlights-new-plinabulin-development-strategy-for-cancer-and-updates-bysi-20240516monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-host-virtual-r-d-day-to-discuss-new-plinabulin-development-strategy-for-ca-bysi-20240503monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-files-2023-annual-report-on-form-20-f-bysi-20240429monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-provides-business-update-and-reports-year-end-2023-financial-results-bysi-20240429monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-first-patient-dosed-with-pembrolizumab-plinabulin-plus-etoposide-pl-bysi-20240325monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-presents-poster-highlighting-preclinical-and-clinical-poc-immunomodulating-ac-bysi-20231107monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-and-professor-k-eisenmann-of-the-university-of-toledo-college-of-medicine-pre-bysi-20231031monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-and-leading-cancer-center-to-present-poster-at-sitc-s-38th-annual-meeting-bysi-20230927monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-participate-in-the-r-w-baird-s-2023-global-healthcare-conference-bysi-20230907monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-and-leading-cancer-center-present-poster-highlighting-plinabulin-s-ability-to-bysi-20230607monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-and-leading-cancer-center-to-present-poster-at-2023-asco-annual-meeting-bysi-20230518monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-provides-business-update-and-reports-year-end-2022-financial-results-bysi-20230418monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-files-2022-annual-report-on-form-20-f-bysi-20230418monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-enrolls-first-patient-in-phase-2-study-with-plinabulin-keytruda-and-docetaxel-bysi-20230301monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-presents-positive-data-with-plinabulin-for-the-prevention-of-docetaxel-induce-bysi-20221213monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-presents-new-clinical-evidence-of-plinabulin-protection-of-granulocyte-monocy-bysi-20220913monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-presents-new-data-for-the-use-of-plinabulin-and-pegfilgrastim-to-decrease-neu-bysi-20220829monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-presents-new-clinical-data-in-the-chemotherapy-induced-neutropenia-and-nsclc--bysi-20220527monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-three-poster-presentations-at-the-american-society-of-clinical-onco-bysi-20220428monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-files-2021-annual-report-on-form-20-f-bysi-20220414monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-fourth-quarter-and-year-end-2021-financial-results-and-provides-a-c-bysi-20220414monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-announce-fourth-quarter-and-year-end-2021-financial-results-and-host-a-con-bysi-20220408monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-third-quarter-2021-financial-results-and-provides-a-corporate-updat-bysi-20211230monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-pharmaceuticals-announces-new-clinical-data-confirming-plinabulin-s-fast-onse-bysi-20211215monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-pharmaceuticals-announces-analysis-of-new-data-on-the-plinabulin-pegfilgrasti-bysi-20211210monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-inc-investigated-by-block-leviton-for-potential-securities-law-violations-inv-bysi-20211202monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-pharmaceuticals-receives-complete-response-letter-from-the-fda-for-plinabulin-bysi-20211201monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-pharmaceuticals-to-present-at-the-4th-annual-evercore-isi-healthconx-conferen-bysi-20211124monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-pharmaceuticals-to-present-at-the-2021-jefferies-london-healthcare-conference-bysi-20211112monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-first-patient-treated-in-phase-2-study-with-plinabulin-combined-wit-bysi-20211021monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-pharmaceuticals-announces-new-patient-derived-cancer-model-data-for-plinabuli-bysi-20211020monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-pharmaceuticals-announces-new-positive-data-on-plinabulin-from-its-chemothera-bysi-20210916monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-second-quarter-2021-financial-results-and-provides-a-corporate-upda-bysi-20210910monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-three-poster-presentations-about-its-chemotherapy-induced-neutropen-bysi-20210909monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-participate-in-the-upcoming-september-conferences-bysi-20210908monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-host-second-quarter-financial-results-and-corporate-update-conference-call-bysi-20210907monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-late-breaking-oral-presentation-of-final-phase-3-dublin-3-data-with-bysi-20210831monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-ceo-dr-lan-huang-named-to-pharmavoice-100-most-inspiring-people-in-life-scien-bysi-20210810monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-participate-in-the-william-blair-biotech-focus-conference-bysi-20210708monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-host-r-d-day-to-discuss-novel-immune-agent-plinabulin-s-development-progra-bysi-20210617monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-host-first-quarter-financial-results-and-corporate-update-conference-call--bysi-20210611monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-final-positive-data-from-the-protective-1-phase-3-cin-program-of-pl-bysi-20210610monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-a-late-breaking-poster-presentation-of-protective-2-phase-3-data-sh-bysi-20210608monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-three-presentations-highlighting-positive-clinical-outcome-data-fro-bysi-20210607monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-first-patient-dosed-in-a-triple-combination-study-with-plinabulin-p-bysi-20210604monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-u-s-fda-acceptance-and-priority-review-of-new-drug-application-for--bysi-20210601monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-at-the-jefferies-virtual-healthcare-conference-on-june-3-2021-bysi-20210526monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-presents-phase-1-data-on-the-anti-cancer-effect-of-plinabulin-in-combination--bysi-20210524monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-at-the-bank-of-america-securities-2021-health-care-conference-on-m-bysi-20210510monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-files-2020-annual-report-on-form-20-f-bysi-20210430monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-fourth-quarter-and-year-end-2020-financial-results-and-provides-a-c-bysi-20210430monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-five-presentations-at-the-american-society-of-clinical-oncology-asc-bysi-20210428monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-announce-fourth-quarter-and-year-end-2020-financial-results-and-host-a-con-bysi-20210427monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-hosting-key-opinion-leader-webinar-on-plinabulin-for-the-prevention-of-chemot-bysi-20210311monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-at-the-j-p-morgan-healthcare-conference-on-january-14-2021-bysi-20201229monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-new-positive-protective-2-phase-3-registrational-trial-results-at-t-bysi-20201210monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-at-two-upcoming-scientific-conferences-in-december-bysi-20201125monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-participate-in-upcoming-evercore-isi-2020-conference-bysi-20201123monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-pricing-of-ordinary-shares-bysi-20201119monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-proposed-public-offering-of-ordinary-shares-bysi-20201117monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-corporate-overview-at-jefferies-london-healthcare-conference-bysi-20201113monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-forms-partnership-advisory-committee-comprised-of-industry-veterans-bysi-20201012monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-at-the-h-c-wainwright-22nd-annual-global-investment-conference-on--bysi-20200911monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-receives-breakthrough-therapy-designations-from-both-u-s-fda-and-china-nmpa-f-bysi-20200908monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-host-second-quarter-2020-financial-results-and-operational-update-conferen-bysi-20200827monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-initiates-expanded-access-program-with-plinabulin-for-patients-suffering-from-bysi-20200811monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-pricing-of-ordinary-shares-bysi-20200619monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-proposed-public-offering-of-ordinary-shares-bysi-20200618monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-s-protective-2-study-106-phase-2-trial-for-chemotherapy-induced-neutropenia-s-bysi-20200609monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-data-safety-monitoring-board-recommendation-for-plinabulin-to-conti-bysi-20200603monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-e-poster-presented-at-2020-asco-virtual-scientific-program-bysi-20200602monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-granted-new-u-s-patent-for-plinabulin-to-treat-severe-chemotherapy-induced-ne-bysi-20200513monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-files-2019-annual-report-on-form-20-f-bysi-20200430monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-reports-fourth-quarter-and-full-year-2019-financial-results-and-operational-u-bysi-20200430monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-host-fourth-quarter-and-full-year-2019-financial-results-and-operational-u-bysi-20200423monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-initiates-new-drug-application-rolling-submission-for-plinabulin-in-china-for-bysi-20200330monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-s-plinabulin-may-prevent-tissue-iron-overload-in-anemic-cancer-patients-recei-bysi-20200323monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-s-plinabulin-stimulates-both-the-adaptive-and-innate-immune-system-in-cancer--bysi-20200210monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-appoints-pharma-veterans-drs-daniel-zabrowski-and-ramon-mohanlal-to-company-s-bysi-20200123monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-strengthens-executive-rank-for-pipeline-expansion-and-commercialization-readi-bysi-20200106monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-publishes-report-on-benefits-and-mechanism-of-plinabulin-in-reducing-neutrope-bysi-20191219monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-host-third-quarter-2019-financial-results-and-operational-update-conferenc-bysi-20191211monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-s-study-106-phase-3-superior-trial-design-combining-plinabulin-with-pegfilgra-bysi-20191210monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-s-abstracts-on-clinical-evidence-for-bone-marrow-stem-cell-protection-as-plin-bysi-20191209monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-s-single-blinded-design-for-patients-only-of-phase-3-study-103-dublin-3-preve-bysi-20191111monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-appoints-gregg-russo-as-senior-vice-president-human-resources-bysi-20191106monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-pricing-of-ordinary-shares-bysi-20191025monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-proposed-public-offering-of-ordinary-shares-bysi-20191024monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-enrolls-first-patient-in-global-phase-3-clinical-trial-with-plinabulin-in-com-bysi-20191023monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-s-lead-asset-plinabulin-granted-u-s-patent-covering-methods-of-treating-brain-bysi-20191017monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-presents-novel-trial-design-for-dublin-3-study-bpi-2358-103-at-esmo-congress--bysi-20191001monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-s-plinabulin-continues-to-build-on-superior-product-profile-in-breast-cancer--bysi-20190923monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-host-second-quarter-2019-financial-results-and-operational-update-conferen-bysi-20190911monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-s-novel-study-103-phase-3-design-in-nsclc-presented-at-2019-iaslc-world-confe-bysi-20190910monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-at-the-h-c-wainwright-21st-annual-global-investment-conference-bysi-20190906monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-s-plinabulin-demonstrates-superior-quality-of-life-over-pegfilgrastim-in-a-he-bysi-20190823monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-pricing-of-public-offering-of-ordinary-shares-bysi-20190717monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-proposed-public-offering-of-ordinary-shares-bysi-20190716monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-set-to-join-ftse-russell-3000-index-bysi-20190620monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-at-the-jefferies-2019-healthcare-conference-bysi-20190604monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-abstract-demonstrating-bone-pain-benefit-with-lead-asset-plinabulin-versus-ne-bysi-20190520monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-s-rationale-for-the-plinabulin-neulasta-combination-for-neutropenia-preventio-bysi-20190516monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-files-2018-annual-report-on-form-20-f-bysi-20190430monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-provides-business-update-and-fourth-quarter-and-full-year-2018-financial-resu-bysi-20190430monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-host-fourth-quarter-and-full-year-2018-financial-results-and-operational-u-bysi-20190424monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-at-the-18th-annual-needham-healthcare-conference-bysi-20190404monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-s-lead-asset-plinabulin-shifts-the-balance-of-macrophages-towards-anti-cancer-bysi-20190326monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-advancing-patient-targeting-strategies-for-lead-asset-plinabulin-bysi-20190325monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-clinical-trial-data-on-lead-asset-plinabulin-at-2019-st-gallen-int-bysi-20190320monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-presents-new-promising-data-in-chemotherapy-induced-neutropenia-at-2019-asco--bysi-20190305monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-positive-pre-nda-meeting-with-the-u-s-fda-for-its-lead-asset-plinab-bysi-20181227monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-phase-3-study-105-of-its-lead-asset-plinabulin-for-chemotherapy-ind-bysi-20181206monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-s-lead-asset-plinabulin-for-the-prevention-of-chemotherapy-induced-neutropeni-bysi-20181023monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-host-second-quarter-2018-financial-results-and-operational-update-conferen-bysi-20181019monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-s-lead-asset-plinabulin-prevents-docetaxel-chemo-induced-neutropenia-cin-due--bysi-20181016monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-clinical-trial-data-at-three-upcoming-scientific-conferences-bysi-20181003monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-s-lead-asset-plinabulin-continues-to-demonstrate-clinical-superiority-versus--bysi-20180925monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-strengthens-intellectual-property-portfolio-with-newly-granted-u-s-patent-for-bysi-20180919monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-s-lead-asset-plinabulin-shows-superior-efficacy-compared-to-neulasta-for-prev-bysi-20180906monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-at-the-h-c-wainwright-20th-annual-global-investment-conference-bysi-20180904monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-clinical-trial-data-on-lead-asset-plinabulin-at-iaslc-world-confer-bysi-20180815monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-s-principal-investigator-in-china-for-chemotherapy-induced-neutropenia-delive-bysi-20180625monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-provides-operational-updates-and-first-quarter-2018-financial-results-bysi-20180621monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-host-first-quarter-2018-financial-results-conference-call-on-june-21-2018-bysi-20180618monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-at-upcoming-conferences-bysi-20180531monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-20-million-registered-direct-offering-bysi-20180530monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-positive-data-from-prospective-phase-2-trial-comparing-plinabulin--bysi-20180517monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-at-the-deutsche-bank-43rd-annual-health-care-conference-bysi-20180507monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-neutropenia-clinical-trial-data-on-lead-asset-plinabulin-at-2018-a-bysi-20180425monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-presents-lead-asset-s-mechanism-data-for-prevention-of-chemotherapy-induced-n-bysi-20180417monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-files-its-2017-annual-report-on-form-20-f-bysi-20180403monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-provides-operational-update-and-fourth-quarter-and-full-year-2017-financial-r-bysi-20180403monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-host-fourth-quarter-and-full-year-2017-financial-results-conference-call-o-bysi-20180327monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-appoints-edward-dongheng-liu-as-chief-financial-officer-bysi-20180327monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-initiation-of-phase-3-clinical-development-for-plinabulin-for-preve-bysi-20180319monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-chief-medical-officer-presents-at-three-prominent-industry-conferences-in-mar-bysi-20180315monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-at-upcoming-investor-conferences-bysi-20180207monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-summarizes-key-messages-from-kol-call-regarding-lead-asset-plinabulin-for-the-bysi-20180205monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-presents-promising-data-for-lead-asset-plinabulin-at-2018-asco-sitc-clinical--bysi-20180126monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-data-from-phase-2-portion-of-study-105-phase-2-3-trial-with-plinab-bysi-20180117monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-at-the-10th-annual-biotech-showcase-bysi-20180105monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-appoints-life-sciences-veteran-patrick-fabbio-to-board-of-directors-as-an-ind-bysi-20180103monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-meets-primary-objective-in-phase-2-portion-of-phase-2-3-trial-study-105-with--bysi-20171214monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-webcast-key-opinion-leader-event-in-nyc-on-dec-14-2017-bysi-20171207monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-s-lead-asset-plinabulin-recognized-as-2017-national-science-and-technology-ma-bysi-20171204monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-initiates-global-phase-2-3-trial-with-plinabulin-in-china-for-the-prevention--bysi-20171130monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-host-quarterly-operational-update-conference-call-on-november-9-2017-bysi-20171102monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-the-first-patient-enrolled-in-china-in-its-global-phase-2-3-trial-w-bysi-20171026monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-receives-two-grants-in-china-to-further-develop-innovative-drug-pipeline-bysi-20171023monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-chief-medical-officer-to-present-at-the-2017-bio-investor-forum-on-oct-18-in--bysi-20171018monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-at-the-19th-annual-rodman-renshaw-global-investment-conference-bysi-20170905monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-at-the-2017-southern-california-investor-conference-bysi-20170817monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-host-quarterly-operational-update-conference-call-on-august-21-2017-bysi-20170814monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-chief-medical-officer-to-present-clinical-data-for-lead-asset-plinabulin-at-2-bysi-20170615monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-at-the-jefferies-2017-healthcare-conference-bysi-20170602monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-attend-jefferies-2017-healthcare-conference-bysi-20170601monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-chief-medical-officer-to-present-at-three-prominent-industry-conferences-in-m-bysi-20170508monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-files-its-2016-annual-report-on-form-20-f-bysi-20170501monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-provides-quarterly-operational-update-and-full-year-2016-results-bysi-20170428monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-participate-in-joseph-gunnar-s-pioneers-2017-conference-on-may-2-in-new-yo-bysi-20170426monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-enrolls-first-u-s-patient-in-phase-2-3-clinical-trial-of-plinabulin-for-neutr-bysi-20170425monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-host-quarterly-operational-update-conference-call-on-april-28-2017-bysi-20170413monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-chief-medical-officer-to-present-on-lead-asset-plinabulin-for-chemotherapy-in-bysi-20170322monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-lead-asset-plinabulin-s-anti-cancer-mechanism-accepted-for-poster-presentatio-bysi-20170320monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-chief-medical-officer-to-present-clinical-data-for-lead-asset-plinabulin-for--bysi-20170314monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-inc-prices-initial-public-offering-and-concurrent-private-placement-of-54-31--bysi-20170309monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-inc-nasdaq-bysi-to-ring-the-nasdaq-stock-market-opening-bell-bysi-20170309monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-pharmaceuticals-to-present-today-at-4th-annual-cancer-biopartnering-investmen-bysi-20160224monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-pharmaceuticals-data-indicating-plinabulin-enhances-immune-response-provides--bysi-20160208monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-pharmaceuticals-to-present-at-18th-annual-bio-ceo-investor-conference-bysi-20160203monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-pharmaceuticals-to-present-at-8th-annual-biotech-showcase-bysi-20160107monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-pharmaceuticals-and-fred-hutchinson-cancer-research-center-enter-collaboratio-bysi-20160106monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-pharmaceuticals-to-present-plinabulin-immune-system-interactions-at-aacr-s-20-bysi-20160105monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-pharmaceuticals-granted-cta-by-cfda-to-initiate-china-arm-of-global-phase-iii-bysi-20151221monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-data-demonstrating-activity-of-plinabulin-in-kras-mutant-tumors-presented-at--bysi-20151117monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-appointments-of-dr-ramon-mohanlal-as-chief-medical-officer-and-robe-bysi-20151030monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-positive-follow-up-results-for-phase-2-trial-of-plinabulin-in-advan-bysi-20150915monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-planned-start-of-phase-i-investigator-initiated-trial-of-plinabulin-bysi-20150915monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-to-present-two-posters-supporting-plinabulin-at-wclc-2015-bysi-20150831monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-extends-plinabulin-ip-portfolio-with-two-new-method-of-treatment-patent-appli-bysi-20150323monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-files-composition-of-matter-patent-application-for-plinabulin-combination-the-bysi-20150224monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-pharmaceuticals-names-dr-yan-sun-as-principal-investigator-for-global-phase-3-bysi-20141209monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-pharmaceuticals-to-conduct-phase-3-trial-of-lead-candidate-plinabulin-in-nscl-bysi-20141203monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-announces-asco-poster-presentations-demonstrating-compelling-clinical-actu-20260601monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-announces-positive-patient-outcomes-from-phase-1-trial-in-difficult-t-actu-20260106monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-phase-2-metastatic-pancreatic-cancer-data-selected-for-oral-and-poste-actu-20251218monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-presents-topline-elraglusib-phase-2-data-at-asco-2025-annual-meeting--actu-20250531monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-announces-details-for-2025-asco-annual-meeting-presentation-on-toplin-actu-20250522monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-to-host-kol-event-on-topline-phase-2-data-of-elraglusib-in-metastatic-actu-20250507monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-to-participate-in-citizens-life-sciences-conference-2025-actu-20250430monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-to-present-elraglusib-phase-2-topline-data-at-the-2025-american-society-of-clinica-actu-20250423monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-to-present-promising-data-on-elraglusib-in-advanced-salivary-gland-carcinoma-at-th-actu-20250417monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-announces-completion-of-enrollment-in-a-phase-2-trial-of-elraglusib-in-combination-actu-20250225monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-to-participate-in-upcoming-investor-conferences-in-february-actu-20250206monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-receives-ema-orphan-medicinal-product-designation-for-elraglusib-for--actu-20250107monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-to-be-added-to-russell-2000-index-actu-20241126monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-to-participate-in-lantern-s-pharma-webinar-on-ai-driven-drug-development-actu-20241029monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-announces-upcoming-presentation-on-initial-data-on-elraglusib-in-combination-with--actu-20240916monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-receives-fda-orphan-drug-designation-for-elraglusib-for-treatment-of-soft-tissue-s-actu-20240911monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-obtains-complete-responses-and-provides-update-on-clinical-trial-of-e-actu-20240909monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-actu-20240905monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-to-ring-the-nasdaq-opening-bell-on-friday-august-23-2024-actu-20240820monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-announces-closing-of-initial-public-offering-actu-20240814monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-announces-pricing-of-initial-public-offering-actu-20240813monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-files-registration-statement-for-initial-public-offering-actu-20240528monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-announces-poster-presentations-at-the-2024-aacr-annual-meeting-actu-20240408monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-receives-fda-orphan-drug-designation-for-elraglusib-for-treatment-of--actu-20230801monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-announces-poster-presentations-at-the-2023-asco-annual-meeting-actu-20230530monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-announces-poster-presentations-at-the-2023-aacr-annual-meeting-actu-20230410monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-congratulates-dr-patricia-lorusso-on-being-named-aacr-president-elect-actu-20230323monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-announces-poster-presentations-at-the-2022-aacr-annual-meeting-actu-20220328monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-announces-first-patient-enrolled-in-phase-2-clinical-trial-of-elraglu-actu-20220301monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-announces-initiation-of-a-multicenter-randomized-trial-of-elraglusib--actu-20220207monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-inc-investigated-by-the-portnoy-law-firm-til-20260420monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-s-subsidiary-discontinues-clinical-development-of-axn-2510-and-terminates-licen-til-20260106monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-reports-second-quarter-2025-financial-results-and-provides-corporate-update-til-20250813monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-reports-first-quarter-2025-financial-results-and-provides-corporate-update-til-20250513monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-corpor-til-20250304monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-announces-clinical-progress-in-china-for-imm2510-syn-2510-a-clinical-stage-pd-l-til-20250114monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-reports-third-quarter-2024-financial-results-and-provides-corporate-update-til-20241113monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-and-immuneonco-announce-global-registrational-strategy-for-pd-l1xvegf-bispecifi-til-20240916monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-reports-second-quarter-2024-financial-results-and-provides-corporate-update-til-20240813monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-and-immuneonco-announce-license-and-collaboration-agreement-for-development-of--til-20240801monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-reports-first-quarter-2024-financial-results-and-provides-corporate-update-til-20240510monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-corpor-til-20240321monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-announces-strategic-update-til-20240116monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-announces-effective-date-of-1-for-20-reverse-stock-split-til-20231205monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-reports-third-quarter-2023-financial-results-and-provides-corporate-update-til-20231113monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-announces-poster-presentations-of-itil-306-preclinical-data-at-sitc-2023-annual-til-20231106monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-reports-second-quarter-2023-financial-results-and-provides-corporate-update-til-20230814monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-announces-oral-presentation-of-itil-306-preclinical-data-at-british-society-for-til-20230626monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-reports-first-quarter-2023-financial-results-and-provides-corporate-update-til-20230511monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-corpor-til-20230331monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-announces-extension-of-cash-runway-beyond-2026-with-the-consolidation-of-r-d-op-til-20230131monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-announces-resumption-of-clinical-trial-of-costar-til-candidate-itil-306-in-lung-til-20230109monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-alert-bragar-eagel-squire-p-c-is-investigating-instil-bio-inc-on-behalf-of-inst-til-20221230monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-announces-prioritization-of-genetically-engineered-costar-til-program-with-itil-til-20221208monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-reports-third-quarter-2022-financial-results-and-provides-corporate-update-til-20221114monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-announces-poster-presentations-of-costar-platform-at-the-2022-society-for-immun-til-20221108monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-til-20221103monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-investigated-by-block-leviton-for-potential-securities-law-violations-investors-til-20221031monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-announces-voluntary-pause-of-enrollment-in-ongoing-clinical-trials-related-to-m-til-20221031monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-to-present-at-jefferies-cell-and-genetic-medicine-summit-til-20220919monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-to-present-at-morgan-stanley-global-healthcare-conference-til-20220909monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-announces-appointment-of-tim-moore-as-chief-operating-officer-til-20220906monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-reports-second-quarter-2022-financial-results-and-provides-corporate-update-til-20220812monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-announces-ind-clearance-of-first-costar-til-program-itil-306-designed-to-enhanc-til-20220527monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-to-present-novel-til-analytics-at-american-society-of-gene-and-cell-therapy-asg-til-20220518monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-reports-first-quarter-2022-financial-results-and-provides-corporate-update-til-20220516monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-corpor-til-20220307monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-to-present-at-the-cowen-42nd-annual-health-care-conference-til-20220302monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-announces-poster-presentations-at-the-2021-society-for-immunotherapy-of-cancer--til-20211115monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-reports-third-quarter-2021-financial-results-and-provides-corporate-update-til-20211115monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-to-present-at-upcoming-investor-conferences-in-november-til-20211108monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-presents-subset-analysis-of-patients-with-checkpoint-refractory-advanced-melano-til-20210916monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-receives-ind-clearance-to-initiate-a-phase-2-clinical-trial-for-patients-with-a-til-20210913monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-to-present-at-upcoming-investor-conferences-in-september-til-20210902monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-reports-second-quarter-2021-financial-results-and-provides-corporate-update-til-20210812monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-to-present-at-the-jefferies-virtual-healthcare-conference-til-20210601monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-reports-first-quarter-2021-financial-results-and-provides-corporate-update-til-20210513monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-receives-orphan-drug-designation-for-itil-168-in-melanoma-til-20210427monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-presents-clinical-data-in-metastatic-melanoma-in-a-late-breaking-e-poster-at-th-til-20210412monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters--til-20210323monthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-announces-pricing-of-upsized-initial-public-offering-til-20210319monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-to-present-at-the-small-cap-growth-virtual-investor-conference-february-5-coch-20260129monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-to-present-at-the-virtual-technology-investor-conference-on-october-28th-coch-20251023monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-to-present-at-the-life-sciences-virtual-investor-forum-june-12th-coch-20250611monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-technologies-a-blink-charging-subsidiary-files-registration-statement-for-proposed-i-coch-20250212monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-receives-additional-patent-protection-for-its-innovative-approach-to-hearing-coch-20241216monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-s-fully-implanted-acclaim-cochlear-implant-highlighted-in-peer-reviewed-publ-coch-20241112monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-receives-another-european-patent-for-its-modular-cochlear-implant-system-coch-20241108monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-receives-fda-approval-to-initiate-pivotal-clinical-study-for-breakthrough-he-coch-20241101monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-to-present-at-the-ld-micro-main-event-xvii-coch-20241023monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-technologies-inc-launches-turnkey-on-demand-luxury-lucid-ev-sharing-as-an-amenity-coch-20241003monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-celebrates-first-anniversary-trading-as-a-public-company-under-coch-on-nasda-coch-20241001monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-awarded-patent-for-recharge-system-used-with-implantable-battery-coch-20240916monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-secures-lending-facility-of-10m-coch-20240828monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-technologies-inc-to-provide-turnkey-on-demand-rivian-evs-and-blink-charging-stations-coch-20240717monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-announces-inclusion-in-the-russell-microcap-index-coch-20240701monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-announces-inclusion-in-the-msci-usa-micro-cap-index-coch-20240606monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-reports-first-quarter-2024-results-coch-20240515monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-to-present-at-the-planet-microcap-showcase-vegas-2024-coch-20240424monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-to-participate-in-the-ld-micro-invitational-xiv-conference-april-8-9-2024-coch-20240403monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-reports-fourth-quarter-and-full-year-2023-financial-results-coch-20240402monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-to-participate-in-the-36th-annual-roth-conference-coch-20240312monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-ceo-brent-lucas-interviewed-by-leading-healthcare-podcast-medical-alley-coch-20240205monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-announces-three-additional-patents-for-implantable-cochlear-systems-coch-20240122monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-to-host-fireside-chat-event-december-7-coch-20231204monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-provides-third-quarter-2023-financial-results-and-business-update-coch-20231120monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-announces-publication-of-additional-patent-for-implantable-cochlear-systems-coch-20231110monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-to-present-at-the-emerging-growth-virtual-conference-november-1-coch-20231024monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-announces-settlement-contract-coch-20231010monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-group-corp-black-cactus-global-adds-dr-ravindranath-kancheria-to-board-coch-20171211monthly0.5https://www.biopharmawatch.com/news/COCH/envoyai-launches-with-35-algorithms-contributed-by-14-newly-contracted-artificial-intellig-coch-20171126monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-group-corp-announces-key-services-agreement-coch-20160216monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-agricultural-incorporated-announces-initiation-of-ipo-process-with-wall-street-broke-coch-20140513monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023-tcrt-20230503monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-on-marc-tcrt-20230228monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-highlights-strategic-priorities-and-anticipated-portfolio-milestones--tcrt-20230109monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-announces-pricing-of-public-offering-of-common-stock-tcrt-20221129monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-to-report-third-quarter-2022-financial-results-on-november-14-2022-tcrt-20221108monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-to-participate-in-upcoming-investor-conferences-in-september-tcrt-20220907monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-to-report-second-quarter-2022-financial-results-on-august-15-2022-tcrt-20220808monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-to-present-at-the-jefferies-healthcare-conference-tcrt-20220601monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-to-present-trials-in-progress-poster-for-its-tcr-t-library-phase-1-2--tcrt-20220526monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-to-present-at-the-h-c-wainwright-global-investment-conference-tcrt-20220510monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-to-report-first-quarter-2022-financial-results-on-may-16-2022-tcrt-20220509monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-to-report-fourth-quarter-and-full-year-2021-financial-results-on-marc-tcrt-20220316monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-to-participate-in-the-oppenheimer-32nd-annual-healthcare-conference-tcrt-20220308monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-completion-of-patient-enrollment-evaluating-mn-166-ibudilast-in-the-p-mnov-20251218monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-appoints-dr-christopher-breder-md-phd-as-clinical-and-regulatory-advisor-mnov-20251118monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-provides-enrollment-update-for-ongoing-als-and-hypertriglyceridemia-clinical-tr-mnov-20250724monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-participate-in-d-boral-s-capital-global-conference-on-may-14-2025-mnov-20250414monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-presents-study-update-and-interim-analysis-of-phase-2-3-clinical-trial-of-mn-16-mnov-20241205monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-ceo-yuichi-iwaki-provides-corporate-update-in-letter-to-stockholders-mnov-20241119monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-from-united-states-patent-and-trademark-office-for-mnov-20241114monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-given-notice-of-monetary-damages-due-under-patent-settlement-of-sanofi-novartis-mnov-20241111monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-update-of-phase-2-3-clinical-trial-of-mn-166-ibudilast-in-als-patient-mnov-20241023monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-support-nih-funded-expanded-access-clinical-trial-to-evaluate-mn166-ibudilas-mnov-20240930monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-abstract-regarding-mn-166-ibudilast-in-combat-als-clinical-trial-acce-mnov-20240909monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-acceptance-of-abstract-regarding-mn-166-ibudilast-in-combat-als-clini-mnov-20240903monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-from-united-states-patent-and-trademark-office-for-mnov-20240829monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-chief-business-officer-david-h-crean-ph-d-assumes-communications-role-overseein-mnov-20240620monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-166-ibudilast-for-the-p-mnov-20240605monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-data-from-phase-1b-2a-clinical-trial-of-mn-166-ibudilast-in-glioblast-mnov-20240603monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-two-poster-presentations-at-the-92nd-eas-congress-2024-the-annual-mee-mnov-20240528monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-166-ibudilast-for-the-p-mnov-20240520monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-166-ibudilast-for-the-t-mnov-20240514monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-issue-notification-for-new-patent-covering-extended-release-formulatio-mnov-20240507monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-abstract-regarding-results-of-a-clinical-trial-of-mn-166-ibudilast-in-mnov-20240402monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-a-notice-of-allowance-for-a-new-patent-covering-mn-166-ibudilast-for-t-mnov-20240326monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-two-abstracts-regarding-mn-001-tipelukast-and-mn-002-accepted-for-pre-mnov-20240320monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-new-data-and-results-of-mn-166-ibudilast-in-chlorine-gas-induced-acut-mnov-20240312monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-a-notice-of-grant-for-a-new-patent-covering-mn-166-ibudilast-for-the-t-mnov-20240117monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-abstract-regarding-mn-166-ibudilast-in-chlorine-gas-induced-lung-inju-mnov-20231221monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-a-notice-of-decision-to-grant-for-a-new-patent-covering-mn-166-ibudila-mnov-20231206monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-new-data-and-results-of-a-phase-2-clinical-trial-of-mn-166-ibudilast--mnov-20231119monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-s-collaborator-initiates-clinical-development-of-a-gene-therapy-product-for-the-mnov-20231027monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-a-notice-of-allowance-for-a-new-patent-covering-the-combination-of-mn--mnov-20231010monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-gene-therapy-milestone-payment-mnov-20231004monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-results-of-studies-under-barda-contract-to-develop-mn-166-ibudilast-a-mnov-20230927monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-abstract-regarding-mn-166-ibudilast-in-glioblastoma-accepted-for-pres-mnov-20230817monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-a-notice-of-intention-to-grant-for-a-new-patent-covering-mn-166-ibudil-mnov-20230816monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-a-new-patent-covering-mn-001-for-the-treatment-of-scleroderma-and-syst-mnov-20230815monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-a-notice-of-intention-to-grant-for-a-new-patent-covering-mn-001-and-mn-mnov-20230814monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-presentation-of-results-from-the-phase-2b-trial-of-mn-166-ibudilast-i-mnov-20230629monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-a-notice-of-intention-to-grant-for-a-new-patent-covering-mn-166-ibudil-mnov-20230514monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-a-notice-of-allowance-for-a-new-patent-covering-mn-001-for-the-treatme-mnov-20230430monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-additional-extension-of-barda-contract-to-develop-mn-166-ibudilast-as-mnov-20230309monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-new-data-regarding-mn-166-ibudilast-in-glioblastoma-tumor-tissue-anal-mnov-20230220monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-health-canada-grants-authorization-to-commence-multi-arm-phase-2-3-cl-mnov-20230208monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-completion-of-enrollment-in-the-phase-2b-clinical-trial-of-mn-166-ibu-mnov-20230130monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-completion-of-enrollment-in-the-phase-2-clinical-trial-evaluating-mn--mnov-20230112monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-a-notice-of-allowance-for-a-new-patent-covering-mn-001-and-mn-002-for--mnov-20230111monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-meet-with-u-s-fda-to-discuss-clinical-development-of-a-parenteral-formulatio-mnov-20230105monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-additional-positive-results-regarding-the-effects-of-mn-001-tipelukas-mnov-20221206monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-positive-results-from-secondary-analysis-of-phase-2-trial-of-mn-166-i-mnov-20221205monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-participate-in-the-lytham-partners-fall-2022-investor-conference-mnov-20220915monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-issue-notification-for-a-new-patent-covering-mn-166-ibudilast-for-the--mnov-20220914monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-a-notice-of-allowance-for-a-new-patent-covering-mn-001-and-mn-002-for--mnov-20220913monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reaches-agreement-to-participate-in-grant-funded-clinical-trial-to-evaluate-mn--mnov-20220816monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-mn-001-tipelukast-abstract-regarding-improvement-of-serum-lipid-panel-mnov-20220809monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-001-and-mn-002-for-the--mnov-20220727monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-initiation-of-a-phase-2-trial-of-mn-001-tipelukast-in-nafld-with-type-mnov-20220726monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-initiates-clinical-evaluation-of-a-new-parenteral-formulation-of-mn-166-ibudila-mnov-20220721monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-extension-of-barda-contract-to-develop-mn-166-ibudilast-as-a-medical--mnov-20220629monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-mn-001-tipelukast-research-collaboration-with-the-juntendo-university-mnov-20220622monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-positive-top-line-results-from-phase-2-clinical-trial-of-mn-166-ibudi-mnov-20220608monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-participate-in-the-b-riley-neuro-ophthalmology-conference-mnov-20220421monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-publication-of-mn-166-ibudilast-data-regarding-prevention-of-metastas-mnov-20220420monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-completion-of-enrollment-in-the-phase-2-clinical-trial-of-mn-166-ibud-mnov-20220413monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-plans-for-a-phase-2-trial-of-mn-001-tipelukast-in-nafld-with-type-2-d-mnov-20220411monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-secondary-analysis-of-phase-2-trial-of-mn-166-ibudilast-in-alcohol-us-mnov-20220407monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-001-and-mn-002-for-the--mnov-20220317monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-participate-in-the-2022-virtual-growth-conference-presented-by-maxim-group-l-mnov-20220315monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-mn-166-ibudilast-identified-as-potential-beneficial-pharmacotherapy-f-mnov-20220228monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-mn-166-ibudilast-identified-as-promising-pharmacotherapy-for-alcohol--mnov-20220222monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-a-new-patent-covering-mn-001-for-the-treatment-of-hypertriglyceridemia-mnov-20220201monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-a-notice-of-allowance-for-a-new-patent-covering-mn-001-and-mn-002-for--mnov-20220131monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-a-notice-of-intention-to-grant-for-a-new-patent-covering-mn-166-ibudil-mnov-20220127monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-166-ibudilast-for-the-t-mnov-20211213monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-mn-166-ibudilast-poster-presentation-at-the-32nd-international-sympos-mnov-20211210monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-new-data-regarding-mn-166-ibudilast-in-glioblastoma-presented-at-the--mnov-20211122monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-mn-001-tipelukast-data-regarding-lipid-metabolism-in-nash-nafld-to-be-mnov-20211111monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-new-data-regarding-mn-166-ibudilast-in-uveal-melanoma-presented-at-th-mnov-20211110monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-new-data-regarding-mn-166-ibudilast-in-glioblastoma-to-be-presented-a-mnov-20211103monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-abstract-regarding-the-mechanism-by-which-mn-001-tipelukast-alters-tr-mnov-20211021monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-participate-in-the-morgan-stanley-19th-annual-global-healthcare-conference-mnov-20210903monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-mn-001-tipelukast-abstract-regarding-lipid-metabolism-in-nash-nafld-a-mnov-20210901monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-mn-166-ibudilast-als-abstract-accepted-for-presentation-at-the-32nd-i-mnov-20210830monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-second-quarter-2021-financial-results-and-business-update-mnov-20210812monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-166-ibudilast-for-the-t-mnov-20210706monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference-mnov-20210629monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-conduct-mouse-study-under-partnership-with-barda-to-develop-mn-166-ibudilast-mnov-20210628monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-positive-results-from-phase-2-trial-of-mn-166-ibudilast-in-alcohol-us-mnov-20210621monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-participate-in-maxim-group-llc-fireside-chat-mnov-20210614monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-initiates-sheep-study-under-partnership-with-barda-to-develop-mn-166-ibudilast--mnov-20210607monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-first-quarter-2021-financial-results-and-business-update-mnov-20210513monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-a-notice-of-intention-to-grant-for-a-new-patent-covering-the-combinati-mnov-20210506monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-gene-therapy-milestone-payments-mnov-20210422monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-participate-in-the-b-riley-neuroscience-conference-mnov-20210419monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-participate-in-the-ubs-global-healthcare-virtual-conference-mnov-20210415monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-partnership-with-barda-to-develop-mn-166-ibudilast-as-a-medical-count-mnov-20210309monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-participate-in-m-vest-llc-and-maxim-group-llc-inaugural-emerging-growth-virt-mnov-20210308monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-update-on-sars-cov-2-vaccine-for-covid-19-mnov-20210303monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-the-combination-of-mn-166--mnov-20210118monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-166-ibudilast-for-the-t-mnov-20201229monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-added-to-the-nasdaq-biotechnology-index-mnov-20201215monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-positive-optical-coherence-tomography-results-from-the-sprint-ms-phas-mnov-20201125monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-initiation-of-master-virus-seed-stock-production-for-its-intranasal-c-mnov-20201124monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-presentation-of-positive-findings-on-mn-001-tipelukast-in-acute-liver-mnov-20201113monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-in-collaboration-with-the-university-of-sydney-and-the-australasian-gastro-inte-mnov-20201022monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-positive-findings-on-mn-001-tipelukast-in-acute-liver-injury-model-to-mnov-20201013monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-positive-clinical-results-regarding-mn-166-ibudilast-for-prevention-o-mnov-20200924monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-that-its-intranasal-covid-19-vaccine-successfully-induced-systemic-ig-mnov-20200923monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-that-biocomo-s-intranasal-rs-virus-vaccine-successfully-induced-neutr-mnov-20200911monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-development-progress-on-intranasal-formulation-of-sars-cov-2-vaccine--mnov-20200901monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-the-presentation-of-positive-results-from-phase-2-trial-of-mn-166-ibu-mnov-20200806monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-participate-in-the-morgan-stanley-virtual-18th-annual-global-healthcare-conf-mnov-20200804monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-sars-cov-2-vaccine-joint-development-with-biocomo-and-mie-university--mnov-20200727monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-participate-in-panel-discussion-at-the-b-riley-fbr-virtual-infectious-diseas-mnov-20200720monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-opening-of-investigational-new-drug-application-for-mn-166-ibudilast--mnov-20200701monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-positive-preclinical-results-regarding-mn-166-ibudilast-in-glioblasto-mnov-20200625monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-a-notice-of-intention-to-grant-for-a-new-patent-covering-mn-001-and-mn-mnov-20200623monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-second-patent-covering-mn-166-ibudilast-for-th-mnov-20200420monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-plans-to-initiate-a-clinical-trial-of-mn-166-ibudilast-for-covid-19-a-mnov-20200408monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-plans-to-develop-mn-166-ibudilast-for-severe-pneumonia-and-acute-resp-mnov-20200309monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-001-and-mn-002-for-the--mnov-20200217monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-intention-to-grant-for-new-patent-covering-mn-001-for-the-tr-mnov-20200127monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-additional-analyses-from-completed-clinical-trial-of-mn-166-ibudilast-mnov-20191204monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-166-ibudilast-for-the-t-mnov-20191028monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-001-for-the-treatment-o-mnov-20191023monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-001-and-mn-002-for-the--mnov-20191007monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-001-for-the-treatment-o-mnov-20190930monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-ladenburg-thalmann-2019-healthcare-conference-in-new-york-mnov-20190911monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-attend-the-morgan-stanley-global-healthcare-conference-in-new-york-mnov-20190829monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-mn-001-research-collaboration-with-the-national-cerebral-and-cardiova-mnov-20190730monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-mn-166-ibudilast-als-abstract-accepted-for-presentation-at-the-30th-i-mnov-20190729monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-phase-3-clinical-trial-plan-for-mn-166-ibudilast-in-progressive-ms-mnov-20190711monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-jmp-securities-life-sciences-conference-mnov-20190612monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-kick-off-meeting-to-officially-launch-phase-3-trial-of-mn-166-ibudila-mnov-20190605monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-20th-annual-b-riley-fbr-institutional-investor-conference-mnov-20190515monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-participated-in-the-recede-phase-3-degenerative-cervical-myelopathy-trial-kick--mnov-20190507monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-166-ibudilast-for-the-t-mnov-20190423monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-plans-to-move-forward-with-a-phase-3-trial-of-mn-166-ibudilast-in-als-mnov-20190415monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-001-for-the-treatment-o-mnov-20190403monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-results-of-subgroup-analysis-from-the-sprint-ms-phase-2b-trial-of-mn--mnov-20190401monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-upcoming-presentations-regarding-the-sprint-ms-phase-2b-trial-of-mn-1-mnov-20190324monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-mn-001-research-collaboration-with-the-jikei-university-school-of-med-mnov-20190305monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-the-publication-of-results-of-the-animal-model-study-of-mn-166-ibudil-mnov-20190228monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-the-combination-of-mn-166--mnov-20190121monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-initiation-of-enrollment-in-a-clinical-trial-of-mn-166-ibudilast-in-g-mnov-20190108monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-001-and-mn-002-for-the--mnov-20190107monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-j-p-morgan-healthcare-conference-in-san-francisco-mnov-20181212monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-fda-grants-orphan-drug-designation-to-mn-166-ibudilast-for-glioblasto-mnov-20181004monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-positive-fda-feedback-regarding-phase-3-plan-for-mn-166-ibudilast-in--mnov-20180925monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-ladenburg-thalmann-2018-healthcare-conference-in-new-york-mnov-20180918monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-attend-the-morgan-stanley-global-healthcare-conference-in-new-york-mnov-20180904monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-the-publication-of-results-of-the-sprint-ms-phase-2b-trial-of-mn-166--mnov-20180829monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-initiation-of-nihr-grant-funded-phase-2-3-trial-of-mn-166-ibudilast-f-mnov-20180806monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-mn-166-ibudilast-als-abstract-accepted-for-presentation-at-the-29th-i-mnov-20180731monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-full-enrollment-in-als-biomarker-clinical-trial-mnov-20180729monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-clinical-data-from-subgroup-analyses-of-completed-clinical-trial-of-m-mnov-20180709monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-001-for-the-treatment-o-mnov-20180619monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-opening-of-investigational-new-drug-application-for-mn-166-ibudilast--mnov-20180509monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-ubs-global-healthcare-conference-in-new-york-mnov-20180508monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-plans-to-collaborate-with-ucla-researchers-in-grant-funded-clinical-t-mnov-20180507monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-additional-data-from-completed-clinical-trial-of-mn-166-ibudilast-in--mnov-20180426monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-the-presentation-of-the-sprint-ms-phase-2b-trial-of-mn-166-ibudilast--mnov-20180424monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-presentation-of-significant-positive-results-from-interim-analysis-of-mnov-20180413monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-phase-2-trial-of-mn-001-tipelukast-in-nash-nafld-will-be-terminated-e-mnov-20180401monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-results-of-phase-2-clinical-trial-of-mn-166-ibudilast-in-methamphetam-mnov-20180329monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-collaboration-with-the-university-of-sydney-concord-cancer-centre-to--mnov-20180328monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-participate-in-business-development-panel-session-at-the-bio-asia-internatio-mnov-20180312monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-cowen-health-care-conference-in-boston-mnov-20180225monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-upcoming-presentation-of-the-sprint-ms-phase-2b-trial-of-mn-166-ibudi-mnov-20180218monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-closing-of-underwritten-public-offering-of-common-stock-mnov-20180212monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-pricing-of-underwritten-public-offering-of-common-stock-mnov-20180208monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-mn-166-ibudilast-demonstrated-a-26-reduction-in-confirmed-disability--mnov-20180201monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-presentation-of-the-sprint-ms-phase-2b-study-of-mn-166-ibudilast-in-p-mnov-20180131monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-mn-166-ibudilast-als-abstract-accepted-for-presentation-at-the-americ-mnov-20180130monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-mn-001-tipelukast-nash-nafld-phase-2-trial-interim-results-selected-f-mnov-20180128monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-98th-annual-meeting-of-the-chemical-society-of-japan-mnov-20180116monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-positive-top-line-results-from-the-clinical-trial-of-mn-166-ibudilast-mnov-20171207monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-collaboration-with-the-u-s-department-of-veterans-affairs-and-oregon--mnov-20171109monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-mn-166-ibudilast-als-abstract-accepted-for-presentation-at-the-28th-i-mnov-20171101monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-positive-top-line-results-from-the-sprint-ms-phase-2b-trial-of-mn-166-mnov-20171026monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-the-completion-of-enrollment-in-the-phase-2-clinical-trial-of-mn-166--mnov-20170919monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-ladenburg-thalmann-2017-healthcare-conference-in-new-york-mnov-20170918monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-the-abstract-from-the-mn-166-ibudilast-sprint-ms-phase-2b-study-in-pr-mnov-20170830monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-positive-results-from-a-glioblastoma-animal-model-study-presented-at--mnov-20170605monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-exploratory-interim-clinical-outcomes-data-from-clinical-trial-of-mn--mnov-20170425monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-mn-166-ibudilast-glioblastoma-abstract-selected-for-presentation-at-t-mnov-20170409monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-mn-166-ibudilast-glioblastoma-abstract-selected-for-presentation-at-t-mnov-20170227monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-mn-166-ibudilast-als-abstract-accepted-for-presentation-at-the-americ-mnov-20170207monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-positive-findings-from-completed-trial-of-mn-166-ibudilast-in-methamp-mnov-20170206monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-attend-mizuho-healthcare-conference-in-new-york-mnov-20170201monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-publication-of-positive-findings-on-mn-166-ibudilast-in-alcohol-depen-mnov-20170123monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-european-commission-grants-orphan-medicinal-product-designation-for-m-mnov-20161220monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-phase-2b-trial-of-mn-166-ibudilast-in-progressive-ms-will-continue-as-mnov-20161219monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-added-to-nasdaq-biotechnology-index-mnov-20161214monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-exploratory-interim-clinical-outcomes-data-from-clinical-trial-of-mn--mnov-20161209monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-piper-jaffray-healthcare-conference-in-new-york-mnov-20161114monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-european-medicines-agency-recommends-orphan-medicinal-product-designa-mnov-20161110monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-attend-global-mizuho-investor-conference-in-new-york-mnov-20161107monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-mn-166-ibudilast-als-abstract-accepted-for-presentation-at-the-27th-i-mnov-20161030monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-fda-granted-orphan-drug-designation-to-mn-166-ibudilast-for-amyotroph-mnov-20161011monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-001-and-mn-002-for-the--mnov-20160724monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-initiation-of-interim-efficacy-analysis-in-phase-2b-trial-of-mn-166-i-mnov-20160713monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-results-from-clinical-trial-of-mn-166-ibudilast-in-alcohol-dependence-mnov-20160629monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-added-to-russell-3000-index-and-russell-global-index-mnov-20160626monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-additional-results-from-the-completed-trial-of-mn-166-ibudilast-in-al-mnov-20160525monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-interim-data-from-clinical-trial-of-mn-166-ibudilast-in-als-presented-mnov-20160420monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-publication-of-positive-findings-from-completed-phase-1b-clinical-tri-mnov-20160330monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-001-in-china-mnov-20160327monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-001-and-mn-002-for-the--mnov-20160323monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-166-ibudilast-for-the-t-mnov-20160307monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-positive-findings-from-a-completed-phase-2-trial-of-mn-166-ibudilast--mnov-20160306monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-mn-166-ibudilast-als-abstract-accepted-for-dual-presentation-at-the-a-mnov-20160222monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-presentation-regarding-mn-166-ibudilast-and-methamphetamine-dependenc-mnov-20160211monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-presentation-of-data-from-the-completed-phase-2-trial-of-mn-166-ibudi-mnov-20160207monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-001-and-mn-002-for-the--mnov-20160127monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-029-denibulin-di-hydroc-mnov-20160113monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-029-denibulin-di-hydroc-mnov-20151214monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-positive-interim-safety-and-clinical-outcomes-data-from-clinical-tria-mnov-20151213monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-positive-findings-from-a-clinical-trial-of-mn-166-ibudilast-in-alcoho-mnov-20151209monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-presentation-regarding-clinical-trial-of-mn-166-ibudilast-in-als-at-t-mnov-20151206monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-initiate-clinical-trial-evaluating-mn-001-in-nash-patients-with-hypertriglyc-mnov-20151119monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-221-bedoradrine-for-the-mnov-20151110monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-interim-data-from-clinical-trial-of-mn-166-ibudilast-in-als-to-be-pre-mnov-20151104monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-preclinical-data-on-mn-166-ibudilast-at-the-26th-international-sympo-mnov-20151013monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-initiate-clinical-trial-of-mn-001-tipelukast-in-ipf-mnov-20151009monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-ladenburg-thalmann-2015-healthcare-conference-mnov-20150924monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-first-advanced-als-patient-using-non-invasive-ventilation-support-enr-mnov-20150902monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-pricing-of-underwritten-public-offering-of-common-stock-mnov-20150818monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-fda-approval-of-the-second-phase-2-protocol-for-mn-001-in-nash-which--mnov-20150727monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-update-on-development-plans-for-mn-001-in-ipf-mnov-20150721monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-the-completion-of-enrollment-in-clinical-trial-of-mn-166-ibudilast-in-mnov-20150630monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-presentation-of-interim-data-from-clinical-trial-of-mn-166-ibudilast--mnov-20150624monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-new-article-published-on-mn-166-ibudilast-in-addiction-biology-mnov-20150616monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-randomization-of-255-subjects-completed-in-phase-2b-trial-of-mn-166-i-mnov-20150612monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-fda-granted-orphan-drug-designation-to-mn-166-ibudilast-for-krabbe-di-mnov-20150603monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-full-enrollment-in-phase-2b-trial-of-mn-166-ibudilast-in-progressive--mnov-20150507monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-positive-interim-safety-data-from-clinical-trial-of-mn-166-ibudilast--mnov-20150421monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-s-mn-001-tipelukast-nash-with-advanced-fibrosis-abstract-accepted-for-presentat-mnov-20150225monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-provides-update-on-clinical-trial-of-mn-166-ibudilast-in-als-mnov-20150216monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-fda-approval-of-protocol-for-phase-2-trial-of-mn-001-in-ipf-mnov-20150210monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-001-and-mn-002-for-the--mnov-20150203monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-new-patent-covering-mn-029-denibulin-di-hydrochloride-in-japan-mnov-20150129monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-an-open-investigational-new-drug-ind-application-for-mn-001-in-nash-mnov-20150128monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-001-and-mn-002-for-the--mnov-20141209monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-fda-granted-orphan-drug-designation-to-mn-001-tipelukast-for-idiopath-mnov-20141022monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-feedback-from-fda-regarding-study-protocol-for-phase-2-trial-of-mn-001-mnov-20141008monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-s-mn-001-tipelukast-nash-abstract-selected-for-late-breaking-session-at-the-65t-mnov-20141006monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-provides-update-on-phase-2b-trial-of-mn-166-ibudilast-in-progressive-ms-mnov-20140923monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-new-nida-grant-for-mn-166-ibudilast-in-opioid-dependence-mnov-20140907monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-data-on-mn-001-tipelukast-for-the-treatment-of-idiopathic-pulmonary--mnov-20140901monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-initiate-clinical-trial-of-mn-166-ibudilast-in-als-mnov-20140825monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-001-and-mn-002-for-the--mnov-20140811monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-positive-results-of-mn-001-in-advanced-nash-mouse-model-medicinova-re-mnov-20140805monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-data-on-mn-001-for-the-treatment-of-nash-nonalcoholic-steatohepatiti-mnov-20140707monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-positive-results-in-study-of-mn-001-in-mouse-model-of-pulmonary-fibro-mnov-20140611monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-management-appointment-mnov-20140408monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-positive-results-in-nash-mouse-model-with-mn-001-and-prepares-to-init-mnov-20140114monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-new-patent-covering-mn-221-in-irritable-bowel-syndrome-mnov-20131111monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-third-quarter-2013-results-mnov-20131107monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-appoints-geoffrey-o-brien-as-vice-president-mnov-20131016monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-029-denibulin-di-hydroc-mnov-20131006monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-second-quarter-2013-results-mnov-20130808monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-initiation-of-a-cooperative-phase-2b-trial-of-mn-166-in-progressive-m-mnov-20130718monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-first-quarter-2013-results-mnov-20130508monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-mn-166-ibudilast-opioid-withdrawal-and-analgesia-data-presentation-at-mnov-20130320monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-provides-development-update-mnov-20130103monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-patent-allowance-for-method-of-treating-acute-exacerbations--mnov-20121209monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-initiation-of-a-clinical-trial-of-mn-166-in-opioid-abusers-with-colum-mnov-20121120monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-extends-mn-166-patent-position-in-europe-mnov-20121118monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-fourth-world-congress-of-emergency-medicine-mnov-20121114monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-publication-of-mn-221-clinical-results-in-journal-of-asthma-mnov-20121112monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-third-quarter-2012-results-and-update-on-mn-221-development-mnov-20121108monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-lazard-capital-markets-healthcare-conference-mnov-20121107monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-a-notice-of-european-patent-allowance-for-treating-progressive-multipl-mnov-20121025monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-meets-with-fda-for-end-of-phase-2-meeting-for-mn-221-for-the-treatment-of-acute-mnov-20121022monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-rodman-renshaw-annual-global-investment-conference-on-septemb-mnov-20120828monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-positive-preliminary-results-from-a-multi-day-repeat-dose-clinical-tr-mnov-20120823monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-second-quarter-2012-results-mnov-20120809monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-scheduling-of-end-of-phase-2-meeting-with-fda-for-mn-221-for-the-trea-mnov-20120702monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-jmp-securities-seventh-annual-healthcare-conference-mnov-20120702monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-results-of-a-phase-2b-clinical-trial-of-mn-221-in-asthma-exacerbations-mnov-20120523monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-first-quarter-2012-results-mnov-20120510monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-an-australian-patent-allowance-for-a-method-of-treating-neur-mnov-20120423monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-management-to-host-a-conference-call-to-discuss-2011-earnings-thursday-march-29-mnov-20120322monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-completes-enrollment-in-phase-2-mn-221-trial-treating-patients-suffering-from-a-mnov-20120321monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-notice-of-a-japanese-patent-allowance-for-a-method-of-treating-neuropa-mnov-20120313monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-american-academy-of-emergency-medicine-annual-meeting-mnov-20120208monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-a-notice-of-patent-allowance-for-a-method-of-treating-progressive-mult-mnov-20120201monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-and-university-of-colorado-boulder-collaborate-on-potential-novel-therapy-for-t-mnov-20120116monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-appoints-kousuke-nakata-to-its-board-of-directors-mnov-20111130monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-third-quarter-2011-results-mnov-20111115monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-lazard-capital-markets-healthcare-conference-mnov-20111109monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-repeat-dose-clinical-trial-with-mn-221-in-chronic-obstructive-pulmona-mnov-20111027monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-receive-2-5-million-payment-from-kissei-pharmaceutical-co-ltd-to-expand-clin-mnov-20111013monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-closes-7-5-million-private-stock-sale-to-kissei-pharmaceutical-co-ltd-mnov-20111012monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-announces-private-sale-of-stock-to-kissei-pharmaceutical-co-ltd-mnov-20110927monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-appoints-mr-tatsuo-izumi-to-its-board-of-directors-mnov-20110926monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-management-appointments-mnov-20110902monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-second-quarter-2011-results-mnov-20110816monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-second-quarter-2011-earnings-conference-call-and-webcast-mnov-20110811monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-collaborate-on-a-phase-2-trial-of-ibudilast-mn-166-av411-in-medication-overu-mnov-20110810monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-first-quarter-2011-results-mnov-20110517monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-first-quarter-2011-earnings-conference-call-and-webcast-mnov-20110511monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-host-business-update-conference-call-by-management-on-april-7-2011-mnov-20110406monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-prices-8-25-million-public-offering-of-common-stock-and-warrants-mnov-20110324monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-receives-a-notice-of-allowance-for-a-method-of-treating-drug-addiction-or-depen-mnov-20110309monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-s-mn-166-program-recognized-as-one-of-windhover-s-top-10-neuroscience-projects--mnov-20101019monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-rodman-and-renshaw-annual-global-investment-conference-mnov-20100902monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-estimated-timing-of-payments-to-former-avigen-stockholders-mnov-20100712monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-appoints-michael-coffee-as-chief-business-officer-mnov-20100614monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-appoints-dr-kirk-johnson-chief-scientific-officer-mnov-20100201monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-extends-conversion-deadline-to-january-11-2010-mnov-20100105monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-completes-acquisition-of-avigen-mnov-20091219monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-and-avigen-stockholders-approve-merger-mnov-20091218monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-third-quarter-2009-results-mnov-20091112monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-initiation-of-a-phase-ib-clinical-trial-for-mn-221-in-patients-with-s-mnov-20091103monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-appoints-mr-hiroaki-shigeta-to-its-board-of-directors-mnov-20090916monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-rodman-and-renshaw-annual-global-investment-conference-mnov-20090904monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-second-quarter-2009-results-mnov-20090814monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-evaluate-mn-221-for-the-treatment-of-chronic-obstructive-pulmonary-disease-e-mnov-20090720monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-proposed-final-protocol-for-its-phase-ii-placebo-controlled-clinical--mnov-20090713monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-plan-to-modify-its-phase-ii-placebo-controlled-clinical-trial-evaluat-mnov-20090528monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-first-quarter-2009-results-mnov-20090515monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-final-data-from-phase-ii-mn-221-emergency-department-clinical-trial-mn--mnov-20090422monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-fourth-quarter-and-full-year-2008-results-mnov-20090331monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-sends-letter-to-avigen-board-of-directors-mnov-20090324monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-sends-letter-to-avigen-board-of-directors-mnov-20090319monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-sends-letter-to-avigen-board-of-directors-mnov-20090312monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reaffirms-proposal-to-acquire-avigen-inc-mnov-20090209monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-interim-phase-ii-data-from-mn-221-emergency-department-study-mnov-20090112monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-proposes-to-acquire-avigen-inc-mnov-20081223monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-third-quarter-2008-results-mnov-20081110monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-rodman-and-renshaw-10th-annual-healthcare-conference-mnov-20081103monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-7th-annual-bio-investor-forum-mnov-20081022monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-positive-preliminary-results-from-phase-ii-clinical-trial-of-mn-221-in--mnov-20080909monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-merriman-curhan-ford-s-5th-annual-investor-summit-2008-mnov-20080908monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-second-quarter-2008-results-mnov-20080811monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-4th-annual-collins-stewart-growth-conference-mnov-20080707monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-host-analyst-investor-meeting-in-new-york-city-mnov-20080702monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-initiates-phase-ii-clinical-trial-of-mn-221-in-moderate-to-severe-asthma-patien-mnov-20080623monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-rodman-and-renshaw-5th-annual-global-healthcare-conference-mnov-20080513monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-first-quarter-2008-results-mnov-20080512monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-clinical-results-from-two-year-phase-ii-clinical-trial-of-mn-166-in-mul-mnov-20080407monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-additional-clinical-data-demonstrating-potential-neuroprotection-ben-mnov-20080402monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-initiates-phase-ii-clinical-trial-of-mn-221-in-status-asthmaticus-patients-mnov-20080331monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-record-date-for-annual-meeting-mnov-20080327monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-fourth-quarter-and-full-year-2007-results-mnov-20080317monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-cash-cash-equivalents-and-short-term-marketable-securities-as-of-decemb-mnov-20080208monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-s-mn-166-reduces-persistent-black-hole-formation-in-multiple-sclerosis-patients-mnov-20080201monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-third-quarter-2007-results-mnov-20071109monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-withdrawal-of-common-stock-offering-mnov-20071108monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-public-offering-of-common-stock-mnov-20071025monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-phase-iia-clinical-study-results-for-mn-305-a-treatment-for-insomnia-mnov-20071018monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-positive-phase-iia-clinical-study-results-for-mn-221-a-novel-treatment--mnov-20071009monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-will-announce-clinical-results-from-a-phase-iia-clinical-study-for-mn-221-a-nov-mnov-20071008monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-2007-bio-investorforum-mnov-20071004monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-rule-10b5-1-stock-purchase-plan-mnov-20070911monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-2007-ubs-global-life-sciences-conference-mnov-20070911monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-phase-ib-clinical-study-results-for-mn-221-a-novel-treatment-for-preter-mnov-20070817monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-second-quarter-2007-results-mnov-20070809monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-clinical-data-on-mn-029-at-the-14th-european-cancer-conference-ecco--mnov-20070808monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-new-strategic-initiative-mnov-20070626monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-j-m-dutton-health-science-small-cap-conference-and-the-friedm-mnov-20070525monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-first-quarter-2007-financial-results-mnov-20070510monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-positive-clinical-results-from-mn-166-phase-ii-multiple-sclerosis-tri-mnov-20070327monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-at-the-lehman-brothers-tenth-annual-global-healthcare-conference-mnov-20070315monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-present-phase-ii-clinical-trial-results-for-mn-001-a-novel-oral-treatment-fo-mnov-20070221monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-2006-financial-results-mnov-20070215monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-to-host-year-end-call-on-february-15-2007-mnov-20070207monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-record-date-for-annual-meeting-mnov-20070202monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-pricing-of-common-stock-offering-mnov-20070129monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-initiates-phase-ii-clinical-trial-for-mn-305-a-novel-treatment-for-insomnia-mnov-20070122monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-results-from-a-phase-ii-iii-interstitial-cystitis-trial-with-mn-001-mnov-20070116monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-establishes-japanese-subsidiary-in-tokyo-mnov-20070105monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-initiation-of-phase-ii-clinical-program-for-mn-221-a-novel-treatment--mnov-20061218monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-establishes-a-european-subsidiary-in-the-u-k-mnov-20061213monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-mnov-chairman-and-chief-executive-officer-to-ring-the-nasdaq-stock-market-c-mnov-20061206monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-reports-new-data-on-agent-797-an-allo-inkt-cell-therapy-at-ats-2026-simu-inkt-20260520monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-and-first-lviv-territorial-medical-union-initiate-randomized-phase-2-tri-inkt-20260514monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-reports-phase-ii-data-on-immune-reprogramming-and-durable-survival-in-pd-inkt-20260417monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-announces-collaboration-with-c-further-to-advance-prame-targeted-inkt-ce-inkt-20260310monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-reports-q3-2025-results-and-accelerates-inkt-platform-toward-pivotal-dev-inkt-20251114monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-announces-virtual-annual-shareholders-meeting-inkt-20250610monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-awarded-prestigious-niaid-grant-to-advance-allo-inkt-cell-therapy-for-pr-inkt-20250602monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-reports-q1-2025-results-and-highlights-clinical-strategic-progress-inkt-20250515monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-provide-corporate-update-and-first-quarter-2025-financial-report-inkt-20250505monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-reports-fourth-quarter-full-year-2024-results-and-highlights-business-pr-inkt-20250318monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-provide-corporate-update-and-fourth-quarter-full-year-2024-financial--inkt-20250304monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-presents-first-in-kind-allo-inkts-combination-data-in-2l-gastric-cancer--inkt-20250224monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-regains-full-compliance-with-nasdaq-listing-requirements-inkt-20250220monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-present-updated-data-from-phase-2-study-testing-agent-797-in-gastric--inkt-20250212monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-targets-immune-reconstitution-to-combat-advanced-gastroesophageal-cancer-inkt-20250123monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-present-inkt-cell-therapy-in-gastric-cancer-at-asco-gi-annual-meeting-inkt-20241218monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-reports-third-quarter-2024-results-and-business-update-inkt-20241114monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-provide-corporate-update-and-third-quarter-2024-financial-report-inkt-20241111monthly0.5https://www.biopharmawatch.com/news/INKT/mink-s-inkt-cell-therapy-shows-potential-for-optimal-multi-combination-for-resistant-solid-inkt-20241107monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-and-autonomous-therapeutics-announce-collaboration-to-develop-novel-ther-inkt-20241008monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-present-data-from-inkt-cell-programs-at-sitc-2024-inkt-20241004monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-participate-in-h-c-wainwright-global-investment-conference-inkt-20240903monthly0.5https://www.biopharmawatch.com/news/INKT/mink-reports-second-quarter-2024-results-and-business-update-inkt-20240813monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-provide-corporate-update-and-second-quarter-2024-financial-report-inkt-20240801monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-regains-compliance-with-nasdaq-capital-market-requirement-inkt-20240731monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-announces-virtual-annual-shareholders-meeting-inkt-20240605monthly0.5https://www.biopharmawatch.com/news/INKT/mink-presents-agent-797-clinical-activity-in-immune-compromised-transplant-patient-with-se-inkt-20240522monthly0.5https://www.biopharmawatch.com/news/INKT/mink-reports-first-quarter-2024-results-inkt-20240514monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-announces-5-8-million-private-placement-and-appointment-of-board-observe-inkt-20240513monthly0.5https://www.biopharmawatch.com/news/INKT/mink-to-provide-corporate-update-and-first-quarter-2024-financial-report-inkt-20240430monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-announces-promising-preclinical-activity-of-mink-215-against-colorectal--inkt-20240408monthly0.5https://www.biopharmawatch.com/news/INKT/mink-reports-fourth-quarter-and-year-end-2023-results-inkt-20240321monthly0.5https://www.biopharmawatch.com/news/INKT/mink-to-provide-corporate-update-and-fourth-quarter-full-year-2023-financial-report-inkt-20240307monthly0.5https://www.biopharmawatch.com/news/INKT/mink-announces-preclinical-data-showcasing-activity-of-mink-215-against-colorectal-cancer--inkt-20240306monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-agent-797-shows-promising-results-in-the-treatment-of-severe-acute-respi-inkt-20240206monthly0.5https://www.biopharmawatch.com/news/INKT/mink-s-agent-797-offers-new-hope-in-overcoming-ici-resistance-in-pd-1-refractory-gastric-c-inkt-20240130monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-reports-third-quarter-2023-results-inkt-20231109monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-presents-clinical-activity-and-long-term-persistence-of-allogeneic-inkt--inkt-20231103monthly0.5https://www.biopharmawatch.com/news/INKT/mink-to-provide-third-quarter-2023-financial-report-and-corporate-update-inkt-20231030monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-present-data-update-from-allogeneic-inkt-cells-in-solid-tumors-at-sit-inkt-20230927monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-participate-in-september-investor-conferences-inkt-20230824monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-reports-second-quarter-2023-results-inkt-20230810monthly0.5https://www.biopharmawatch.com/news/INKT/mink-to-provide-second-quarter-2023-financial-report-and-corporate-update-inkt-20230728monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-announces-virtual-annual-shareholders-meeting-inkt-20230605monthly0.5https://www.biopharmawatch.com/news/INKT/mink-presents-clinical-data-on-allogeneic-inkt-cells-agent-797-in-severe-respiratory-distr-inkt-20230522monthly0.5https://www.biopharmawatch.com/news/INKT/mink-s-novel-fap-car-inkt-presented-at-asgct-inkt-20230518monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-reports-corporate-update-and-first-quarter-2023-financial-results-inkt-20230511monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results-inkt-20230427monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-announces-clinical-data-of-allogeneic-inkt-cells-agent-797-in-solid-tumo-inkt-20230418monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-inkt-20230321monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumo-inkt-20230315monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-inkt-20230307monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-participate-in-hc-wainwright-cell-therapy-virtual-conference-inkt-20230216monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-participate-in-b-riley-securities-oncology-conference-inkt-20230111monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-participate-in-evercore-isi-healthconx-conference-inkt-20221117monthly0.5https://www.biopharmawatch.com/news/INKT/mink-presents-clinical-data-at-sitc-2022-showcasing-inkt-cell-therapy-pipeline-inkt-20221110monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-reports-corporate-update-and-third-quarter-2022-financial-results-inkt-20221103monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-report-third-quarter-2022-financial-results-and-business-update-inkt-20221020monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-host-r-d-event-november-10-2022-inkt-20221005monthly0.5https://www.biopharmawatch.com/news/INKT/mink-selected-for-five-presentations-at-society-for-immunotherapy-of-cancer-s-sitc-37th-an-inkt-20221005monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-participate-at-upcoming-investor-conferences-inkt-20220831monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-reports-corporate-update-and-second-quarter-2022-financial-results-inkt-20220809monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-participate-at-btig-biotechnology-conference-inkt-20220802monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-report-second-quarter-2022-financial-results-and-business-update-inkt-20220727monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-announces-virtual-annual-shareholders-meeting-inkt-20220525monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-corporate-update-and-first-quarter-2022-financial-report-inkt-20220510monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-report-first-quarter-2022-financial-results-and-business-update-inkt-20220427monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2021--inkt-20220318monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-report-fourth-quarter-full-year-2021-financial-results-and-business-u-inkt-20220303monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-announces-patients-dosed-with-agent-797-inkt-cell-therapy-in-solid-tumor-inkt-20220303monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-participate-at-upcoming-b-riley-securities-virtual-oncology-conferenc-inkt-20220112monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-participate-in-4th-annual-evercore-isi-healthconx-conference-inkt-20211117monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-announces-77-survival-rate-in-intubated-patients-with-covid-19-respirato-inkt-20211112monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-presents-new-preclinical-and-clinical-data-on-inkt-cell-therapy-programs-inkt-20211109monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-announces-closing-of-initial-public-offering-inkt-20211019monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-inc-announces-pricing-of-initial-public-offering-inkt-20211015monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-to-present-three-abstracts-on-novel-allogeneic-inkt-programs-at-sitc-inkt-20211001monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-announces-confidential-submission-of-draft-registration-statement-for-pr-inkt-20210728monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-investors-with-losses-have-until-july-6-2026-to-join-securities-class-acti-immp-20260617monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-investors-with-losses-have-until-july-6-2026-to-join-securities-class-acti-immp-20260610monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-investors-with-losses-have-until-july-6-2026-to-join-securities-class-acti-immp-20260602monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-investors-with-losses-have-until-july-6-2026-to-join-securities-class-acti-immp-20260528monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-class-action-lawsuit-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-l-immp-20260520monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-investors-with-losses-have-until-july-6-2026-to-join-securities-class-acti-immp-20260520monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-investors-with-losses-have-until-july-6-2026-to-join-securities-class-acti-immp-20260514monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-immp-20260508monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-immp-investor-alert-investors-with-large-losses-in-immutep-limited-should--immp-20260507monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-investor-news-if-you-have-suffered-losses-in-immutep-ltd-nasdaq-immp-you-are-encou-immp-20260405monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-more-inform-immp-20260316monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-participate-in-upcoming-investor-conferences-immp-20250402monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-present-at-investor-conferences-immp-20220520monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-appoints-leading-oncologists-to-its-clinical-advisory-board-immp-20220518monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-appendix-4c-immp-20211028monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study-immp-20210107monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-improving-results-from-stage-i-of-phase-ii-tacti-002-study-immp-20200918monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-us-2-4-million-r-d-tax-incentive-from-french-government-immp-20200529monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-global-webcast-to-present-new-data-from-2020-asco-annual-meeting-immp-20200527monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-advances-cell-line-development-for-imp761-immp-20200416monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-s-partner-eoc-pharma-reports-completion-of-recruitment-of-phase-i-study-of-efti-immp-20200320monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-completes-a-6-31-million-share-purchase-plan-raises-total-of-a-13-16-million-immp-20180413monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-provides-corporate-update-qntm-20260601monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-provides-corporate-update-qntm-20260427monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-licensee-unbuzzd-wellness-inc-appoints-richard-buzbuzian-as-ceo-to-lead--qntm-20260422monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-wins-significant-court-challenge-in-usd-700-000-000-claim-as-defendants--qntm-20260402monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-provides-corporate-update-qntm-20260327monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-announces-closing-of-initial-tranche-of-private-placement-offering-qntm-20260320monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-provides-corporate-update-qntm-20260311monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-announces-completion-of-dosing-in-180-day-repeated-dose-oral-toxicity-an-qntm-20251223monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-licensee-unbuzzd-wellness-to-host-live-webinar-and-q-a-session-on-wednes-qntm-20250924monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-licensee-unbuzzd-wellness-to-host-investor-webinar-on-september-16-2025--qntm-20250912monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-announces-corporate-updates-qntm-20250821monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-signs-agreement-to-manufacture-oral-drug-formulation-of-its-potential-br-qntm-20250811monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-announces-very-promising-results-from-the-massachusetts-general-hospital-qntm-20250808monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-reports-strong-second-quarter-with-increased-current-and-total-assets-co-qntm-20250807monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-announces-positive-results-of-the-clinical-study-report-csr-for-the-phas-qntm-20250805monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-files-reply-and-provides-update-on-court-case-seeking-damages-against-ci-qntm-20250804monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-licensee-unbuzzd-wellness-inc-commences-reg-d-capital-raise-campaign-to--qntm-20250731monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-makes-strategic-investment-in-gamestop-corp-qntm-20250722monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-submits-its-candidate-breakthrough-patented-drug-for-multiple-sclerosis--qntm-20250708monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-announces-private-placement-of-12-class-a-multiple-voting-shares-at-a-pr-qntm-20250627monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-licensee-unbuzzd-wellness-inc-launches-5-million-reg-d-capital-raise-to--qntm-20250626monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-announces-first-person-with-multiple-sclerosis-ms-scanned-in-joint-study-qntm-20250617monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-announces-intention-to-declare-special-dividend-of-contingent-value-righ-qntm-20250613monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-purchases-more-bitcoin-btc-bringing-the-total-investment-in-digital-asse-qntm-20250610monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-clarifies-it-has-not-changed-its-name-qntm-20250603monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-receives-2-35-million-usd-from-a-mutually-agreed-global-legal-settlement-qntm-20250530monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-licensee-celly-nutrition-retains-leading-audit-firm-mnp-llp-to-advance-c-qntm-20250529monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-receives-ethics-committee-approval-for-phase-2-clinical-trial-of-fsd202--qntm-20250528monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-partners-with-bitgo-to-securely-store-its-crypto-currency-assets-qntm-20250521monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-announces-signing-of-an-agreement-with-a-global-pharmaceutical-contract--qntm-20250520monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-purchases-an-additional-usd-1-million-of-bitcoin-and-other-cryptocurrenc-qntm-20250519monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-to-attend-sidoti-micro-cap-investor-conference-and-the-agp-virtual-healt-qntm-20250516monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-announces-completion-of-dosing-in-90-day-repeated-dose-oral-toxicity-and-qntm-20250512monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-files-amended-complaint-against-cibc-world-markets-rbc-dominion-securiti-qntm-20250505monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-to-host-business-update-conference-call-on-tuesday-may-6-2025-at-4-30-p--qntm-20250424monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-announces-advocate-against-naked-short-selling-and-stock-manipulation-ke-qntm-20250422monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-wins-reconsideration-motion-by-dr-raza-bokhari-at-the-court-of-appeal-fo-qntm-20250414monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-licensee-celly-nutrition-announces-landmark-partnership-with-the-asian-a-qntm-20250410monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-licensee-celly-nutrition-launches-unbuzzd-in-puerto-rico-qntm-20250403monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-announces-joint-clinical-study-with-massachusetts-general-hospital-scien-qntm-20250401monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-announces-closing-of-final-2-42-million-tranche-of-5-million-total-finan-qntm-20250331monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-s-2024-financial-statements-show-strong-improvements-in-cash-working-cap-qntm-20250328monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-announces-leading-crusader-against-naked-short-selling-and-stock-manipul-qntm-20250327monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-licensee-celly-nutrition-expands-unbuzzd-alcohol-detox-product-lineup-fo-qntm-20250326monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-continues-to-grow-its-crypto-assets-and-diversify-its-treasury-with-the--qntm-20250320monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-announces-completion-of-the-phase-1-multiple-ascending-dose-clinical-tri-qntm-20250226monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-continues-to-diversify-its-treasury-with-the-purchase-of-another-usd-1-0-qntm-20250218monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-engages-mz-group-to-lead-strategic-investor-relations-and-shareholder-co-qntm-20250211monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-engages-enterprise-canada-and-empire-market-ventures-to-lead-public-comm-qntm-20250210monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-licensee-celly-nutrition-retains-leading-new-york-investment-bank-to-adv-qntm-20250206monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-announces-the-success-of-unbuzzd-clinical-trial-qntm-20250204monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-one-for-eight-reverse-stock-split-scyx-20260522monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-first-quarter-2026-financial-results-and-provides-corporate-update-scyx-20260511monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-second-quarter-2025-financial-results-and-provides-corporate-update-scyx-20250813monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-first-quarter-2025-financial-results-and-provides-corporate-update-scyx-20250515monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-full-year-2024-financial-results-and-provides-corporate-update-scyx-20250312monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-initiates-dosing-in-phase-1-trial-of-scy-247-a-second-generation-fungerp-candidat-scyx-20241218monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-third-quarter-2024-financial-results-and-provides-corporate-update-scyx-20241106monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-participate-in-the-2024-maxim-healthcare-virtual-summit-scyx-20241010monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-preclinical-data-on-second-generation-fungerp-scy-247-at-idweek-2024-scyx-20241003monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-participate-in-h-c-wainwright-26th-annual-global-investment-conference-scyx-20240827monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-second-quarter-2024-financial-results-and-provides-corporate-update-scyx-20240808monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-receive-10-million-milestone-payment-from-gsk-triggered-by-delivery-of-complet-scyx-20240723monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-first-quarter-2024-financial-results-and-provides-corporate-update-scyx-20240508monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-presented-preclinical-data-on-second-generation-fungerp-scy-247-at-the-congress-o-scyx-20240430monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-preclinical-data-on-second-generation-fungerp-scy-247-at-the-34th-euro-scyx-20240409monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-participate-in-guggenheim-s-6th-annual-biotechnology-conference-scyx-20240130monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-presented-preclinical-data-on-second-generation-fungerp-scy-247-against-mucormyco-scyx-20240129monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-deadline-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-laws-scyx-20240106monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-shareholder-action-reminder-faruqi-faruqi-securities-litigation-partner-james-jos-scyx-20240105monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-preclinical-data-on-second-generation-fungerp-scy-247-at-the-11th-adva-scyx-20240105monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-shareholder-notice-faruqi-faruqi-securities-litigation-partner-james-josh-wilson--scyx-20231227monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-scyx-20231225monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-scyx-20231221monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-ongoing-deadline-alert-faruqi-faruqi-securities-litigation-partner-james-josh-wil-scyx-20231219monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-scyx-20231216monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-scyx-20231211monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-investor-deadline-approaching-faruqi-faruqi-securities-litigation-partner-james-j-scyx-20231207monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-scyx-20231205monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-scyx-20231130monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-scyx-20231125monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-scyx-20231120monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-b-scyx-20231114monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-third-quarter-2023-financial-results-and-provides-corporate-update-scyx-20231113monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-presents-new-preclinical-data-on-second-generation-fungerp-scy-247-at-the-11th-co-scyx-20231024monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-preclinical-data-on-second-generation-fungerp-scy-247-at-the-11th-cong-scyx-20231016monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-participate-in-september-investor-conferences-scyx-20230828monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-second-quarter-2023-financial-results-and-provides-corporate-update-scyx-20230814monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-and-hansoh-pharma-announce-nmpa-acceptance-of-the-new-drug-application-for-ibrexa-scyx-20230720monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-achievement-of-first-development-milestone-of-25-million-under-exclusiv-scyx-20230621monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-participate-in-the-maxim-group-virtual-healthcare-conference-scyx-20230615monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-closing-of-exclusive-license-agreement-with-gsk-for-brexafemme-ibrexafung-scyx-20230512monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-first-quarter-2023-financial-results-and-provides-corporate-update-scyx-20230511monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-ibrexafungerp-data-at-the-33rd-annual-european-congress-of-clinical-mi-scyx-20230413monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-corporat-scyx-20230331monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-fda-approval-of-second-indication-for-brexafemme-ibrexafungerp-tablets--scyx-20221201monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-3-million-national-institutes-of-health-grant-has-been-awarded-to-case--scyx-20221130monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-applauds-the-biomedical-advanced-research-and-development-authority-barda-for-its-scyx-20221117monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-publication-of-review-article-highlighting-ibrexafungerp-as-a-potential-scyx-20221107monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-report-third-quarter-2022-financial-results-and-provide-a-corporate-update-on--scyx-20221101monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-presents-positive-interim-data-of-oral-ibrexafungerp-for-severe-fungal-infections-scyx-20221024monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-provides-corporate-commercial-and-r-d-strategy-updates-to-expand-market-potential-scyx-20221020monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-positive-interim-data-from-the-phase-3-furi-study-of-oral-ibrexafunger-scyx-20221011monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-participate-in-upcoming-september-investor-conferences-scyx-20220909monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-presents-positive-interim-data-of-ibrexafungerp-for-refractory-candida-infections-scyx-20220908monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-posters-highlighting-ibrexafungerp-data-at-four-upcoming-scientific-me-scyx-20220901monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-report-second-quarter-2022-financial-results-and-provide-a-corporate-update-on-scyx-20220809monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-presents-positive-data-from-its-pivotal-phase-3-candle-study-of-oral-ibrexafunger-scyx-20220804monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-u-s-food-and-drug-administration-acceptance-and-priority-review-of-the--scyx-20220801monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-presents-positive-data-from-phase-3-candle-nested-sub-study-investigating-ibrexaf-scyx-20220719monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-data-from-the-candle-nested-sub-study-of-ibrexafungerp-during-the-inte-scyx-20220714monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-initiation-of-new-phase-3b-study-vanquish-to-evaluate-oral-ibrexafunger-scyx-20220623monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-submission-of-supplemental-new-drug-application-of-brexafemme-ibrexafun-scyx-20220608monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-scyx-20220603monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-at-upcoming-h-c-wainwright-global-investment-conference-scyx-20220520monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-presents-new-interim-positive-data-of-ibrexafungerp-for-refractory-vulvovaginal-c-scyx-20220510monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-report-first-quarter-2022-financial-results-and-provide-a-corporate-update-on--scyx-20220505monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-new-data-of-ibrexafungerp-for-refractory-vulvovaginal-candidiasis-from-scyx-20220504monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-presents-data-analyses-showing-ibrexafungerp-s-potential-to-fight-invasive-candid-scyx-20220427monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-closing-of-45-million-public-offering-of-common-stock-pre-funded-warran-scyx-20220426monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-pricing-of-45-million-public-offering-of-common-stock-pre-funded-warran-scyx-20220422monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-positive-interim-data-from-phase-3-furi-and-cares-studies-highlighting--scyx-20220422monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-launch-of-public-offering-of-common-stock-and-warrants-scyx-20220421monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-positive-interim-data-from-ongoing-furi-and-cares-studies-at-the-32nd--scyx-20220420monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-secures-additional-commercial-insurance-formulary-coverage-for-brexafemme-ibrexaf-scyx-20220419monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-participate-in-upcoming-april-women-s-health-medical-conferences-scyx-20220404monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-report-fourth-quarter-and-full-year-2021-financial-results-and-provide-a-busin-scyx-20220324monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-named-to-fast-company-s-2022-top-50-list-of-the-world-s-most-innovative-companies-scyx-20220308monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-scyx-20220304monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-participate-in-upcoming-scientific-conferences-and-events-scyx-20220302monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-positive-results-from-its-pivotal-phase-3-candle-study-of-oral-ibrexafu-scyx-20220210monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-scyx-20220203monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-participate-in-upcoming-january-investor-conferences-scyx-20220106monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-the-exercise-of-warrants-totalling-21-1-million-scyx-20211222monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-agreement-with-fda-on-innovative-strategy-for-approval-of-oral-ibrexafu-scyx-20211206monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-scyx-20211203monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-the-exercise-of-warrants-totalling-7-9-million-scyx-20211203monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-host-ibrexafungerp-hospital-pipeline-update-call-and-kol-webcast-for-investors-scyx-20211129monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-pivotal-phase-3-vanish-306-trial-results-published-in-the-international-journal-o-scyx-20211123monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-successful-completion-of-phase-1-trial-evaluating-intravenous-iv-formul-scyx-20211109monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-provide-a-corporate-update-and-report-third-quarter-2021-financial-results-on--scyx-20211103monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-pivotal-phase-3-vanish-303-trial-results-published-in-clinical-infectious-disease-scyx-20211021monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-pooled-data-analysis-results-demonstrating-consistent-efficacy-and-saf-scyx-20211013monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-preclinical-data-at-the-10th-trends-in-medical-mycology-meeting-support-scyx-20211011monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-clinical-data-from-ongoing-furi-and-cares-studies-at-the-10th-trends-i-scyx-20211007monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-presents-interim-analysis-from-furi-at-virtual-idweek-2021-showing-favorable-ther-scyx-20210929monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-data-on-oral-ibrexafungerp-at-idweek-2021-from-interim-analyses-of-pha-scyx-20210923monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-u-s-availability-of-brexafemme-ibrexafungerp-tablets-the-first-new-anti-scyx-20210922monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-hansoh-pharma-s-application-to-national-medical-products-administration-scyx-20210913monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-participate-in-upcoming-investor-conferences-scyx-20210908monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-second-quarter-2021-financial-results-and-provides-corporate-update-scyx-20210816monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-scyx-20210802monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-two-oral-presentations-on-pooled-data-from-the-brexafemme-ibrexafungerp-scyx-20210729monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-three-oral-presentations-of-ibrexafungerp-demonstrating-clinical-and-in-scyx-20210712monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-at-ladenburg-thalmann-s-virtual-2021-healthcare-conference-scyx-20210707monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-scyx-20210702monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-commercial-launch-update-for-brexafemme-ibrexafungerp-tablets-scyx-20210623monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-at-the-bio-digital-international-convention-2021-scyx-20210611monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-confirms-that-brexafemme-ibrexafungerp-tablets-qualifies-for-10-years-of-regulato-scyx-20210609monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-fda-approval-of-brexafemme-ibrexafungerp-tablets-as-the-first-and-only--scyx-20210602monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-first-quarter-2021-financial-results-and-provides-corporate-update-scyx-20210517monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-secures-term-loan-facility-for-up-to-60-million-with-hercules-capital-and-silicon-scyx-20210514monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-appoints-accomplished-commercial-executive-christine-coyne-as-chief-commercial-of-scyx-20210511monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-presents-data-at-2021-acog-demonstrating-the-positive-outcome-and-sustained-respo-scyx-20210430monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-corporat-scyx-20210329monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-positive-results-from-interim-analyses-of-ongoing-phase-3-studies-furi--scyx-20210302monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-participate-in-maxim-group-s-late-stage-innovations-in-women-s-health-virtual--scyx-20210225monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-and-amplity-health-announce-agreement-to-support-the-anticipated-u-s-commercializ-scyx-20210223monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-licensing-agreement-and-strategic-partnership-with-hansoh-pharma-for-ri-scyx-20210217monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-closing-of-85-million-public-offering-of-common-stock-pre-funded-warran-scyx-20201222monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-pricing-of-85-million-public-offering-of-common-stock-pre-funded-warran-scyx-20201217monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-launch-of-50-million-public-offering-of-common-stock-and-warrants-scyx-20201216monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-advancement-of-ibrexafungerp-s-intravenous-formulation-to-clinical-stag-scyx-20201210monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-oral-ibr-scyx-20201207monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-participate-in-piper-sandler-and-evercore-isi-conferences-scyx-20201124monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-third-quarter-2020-financial-results-and-provides-company-update-scyx-20201106monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-data-supporting-the-efficacy-of-ibrexafungerp-against-invasive-fungal--scyx-20201021monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-submission-of-new-drug-application-to-the-u-s-food-and-drug-administrat-scyx-20201014monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-two-posters-highlighting-ibrexafungerp-for-the-treatment-of-vaginal-ye-scyx-20201012monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-participate-in-h-c-wainwright-conference-and-maxim-s-antifungal-webinar-scyx-20200910monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-presentations-at-2020-idsog-virtual-annual-meeting-highlighting-ibrexaf-scyx-20200813monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-second-quarter-2020-financial-results-and-provides-company-update-scyx-20200810monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-successful-completion-of-pre-nda-meetings-with-the-fda-regarding-ibrexafu-scyx-20200729monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-four-posters-presented-at-asm-microbe-2020-highlighting-the-potential-c-scyx-20200722monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-one-for-ten-reverse-stock-split-scyx-20200716monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-host-a-key-opinion-leader-discussion-on-the-immediate-need-in-treating-women-w-scyx-20200709monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-at-the-bio-digital-international-convention-2020-scyx-20200608monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-strengthens-leadership-team-with-appointment-of-jim-maffezzoli-as-vice-president--scyx-20200602monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-first-quarter-2020-financial-results-and-provides-company-update-scyx-20200511monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-six-abstracts-published-by-30th-eccmid-highlighting-the-potential-clini-scyx-20200506monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-participate-in-antifungals-panel-at-maxim-group-s-infectious-disease-virtual-c-scyx-20200428monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-and-aspire-capital-enter-into-20-million-common-stock-purchase-agreement-scyx-20200413monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-secures-10-million-in-financing-through-senior-convertible-note-purchase-agreemen-scyx-20200409monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-virtually-present-on-the-candida-auris-treatment-landscape-at-the-22nd-annual--scyx-20200326monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-full-year-2019-financial-results-and-provides-company-update-scyx-20200311monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-preclinical-data-on-ibrexafungerp-and-azoles-against-aspergillus-presen-scyx-20200305monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-presents-new-data-further-supporting-scy-078-as-a-potential-treatment-for-aspergi-scyx-20171005monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-data-on-lead-antifungal-candidate-scy-078-at-idweek-2017-scyx-20170927monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-at-upcoming-investor-conferences-scyx-20170831monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-presents-new-data-supporting-oral-scy-078-for-the-clinical-treatment-of-vulvovagi-scyx-20170814monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-second-quarter-2017-financial-results-and-provides-company-update-scyx-20170808monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-at-the-canaccord-genuity-growth-conference-scyx-20170807monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-initiation-of-dosing-in-phase-2-study-evaluating-oral-scy-078-in-vulvov-scyx-20170803monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-to-participate-in-the-2017-bio-international-convention-scyx-20170613monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-first-quarter-2017-financial-results-and-provides-update-on-iv-formulatio-scyx-20170508monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-host-a-conference-call-to-discuss-lead-anti-infective-candidate-scy-078-data-p-scyx-20170421monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-scy-078-data-on-novel-lead-anti-infective-candidate-at-27th-european-c-scyx-20170412monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-to-present-at-the-16th-annual-needham-healthcare-conference-scyx-20170329monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-full-year-2016-financial-results-and-provides-company-update-scyx-20170313monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-to-present-at-the-29th-annual-roth-conference-scyx-20170307monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-delays-initiation-of-new-clinical-studies-using-the-iv-formulation-of-scy-078-at--scyx-20170302monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-to-participate-in-upcoming-investor-conferences-scyx-20170131monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-appointment-of-industry-veteran-marion-mccourt-to-its-board-of-director-scyx-20170126monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-achieves-new-development-milestones-reinforcing-the-versatility-of-scy-078-in-tre-scyx-20161213monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-to-participate-in-the-guggenheim-securities-4th-annual-boston-healthcare-conf-scyx-20161212monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-reports-third-quarter-2016-financial-results-and-provides-company-update-scyx-20161107monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-completes-two-additional-clinical-studies-further-supporting-the-favorable-safety-scyx-20161025monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-complete-results-from-two-phase-2-studies-of-oral-scy-078-in-patients-w-scyx-20161005monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-to-present-at-the-ladenburg-thalmann-healthcare-conference-scyx-20160920monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-to-present-at-upcoming-investor-conferences-scyx-20160831monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-receives-orphan-drug-designation-for-scy-078-for-the-treatment-of-invasive-as-scyx-20160824monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-reports-second-quarter-2016-financial-results-and-provides-company-update-scyx-20160808monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-to-present-at-the-canaccord-genuity-growth-conference-scyx-20160804monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-interim-results-from-phase-2-study-of-oral-scy-078-in-patients-with-inv-scyx-20160801monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-announces-sale-of-cyclophilin-inhibitor-assets-to-cypralis-limited-scyx-20160713monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-to-present-at-cantor-fitzgerald-s-2nd-annual-healthcare-conference-scyx-20160706monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-pricing-of-22-5-million-public-offering-of-common-stock-and-warrants-scyx-20160621monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-launch-of-public-offering-of-common-stock-and-warrants-scyx-20160620monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-presents-new-clinical-and-non-clinical-data-confirming-the-potential-of-scy-0-scyx-20160620monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-data-from-lead-antifungal-drug-candidate-scy-078-at-asm-microbe-2016-scyx-20160610monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-announces-positive-results-in-its-proof-of-concept-phase-2-study-of-scy-078-t-scyx-20160608monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-receives-orphan-drug-designation-for-scy-078-for-the-treatment-of-invasive-ca-scyx-20160513monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-reports-first-quarter-2016-financial-results-and-provides-company-update-scyx-20160509monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-receives-designation-as-a-small-and-medium-enterprise-by-the-european-medicines-a-scyx-20160419monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-presents-data-supporting-the-activity-of-its-lead-antifungal-drug-candidate-scy-0-scyx-20160415monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-to-present-at-the-15th-annual-needham-healthcare-conference-scyx-20160406monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-data-from-lead-antifungal-drug-candidate-scy-078-at-13th-asm-conferenc-scyx-20160406monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-reports-full-year-2015-financial-results-and-provides-company-update-scyx-20160307monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-to-present-at-the-cowen-and-company-36th-annual-health-care-conference-scyx-20160229monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-to-present-at-upcoming-investor-conferences-scyx-20160203monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-receives-fda-fast-track-and-qidp-designations-for-intravenous-formulation-of--scyx-20160128monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-initiates-enrollment-of-the-phase-2-study-of-scy-078-in-vulvovaginal-candidia-scyx-20151201monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-reports-third-quarter-2015-financial-results-and-provides-company-update-scyx-20151113monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-announces-initiation-of-phase-1-clinical-trial-evaluating-intravenous-formula-scyx-20151112monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-appoints-eric-francois-as-chief-financial-officer-scyx-20151102monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-appoints-rajeshwar-motheram-as-vice-president-pharmaceutical-development-scyx-20151007monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-announces-board-of-directors-transitions-scyx-20150928monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-presents-data-supporting-the-potential-clinical-utility-of-antifungal-drug-candid-scyx-20150921monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-data-at-icaac-icc-2015-for-novel-antifungal-drug-candidate-scyx-20150910monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-reports-second-quarter-2015-financial-results-scyx-20150819monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-to-present-at-35th-canaccord-genuity-annual-growth-conference-scyx-20150810monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-to-focus-on-scy-078-development-scyx-20150723monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-to-present-at-10th-annual-jmp-securities-life-sciences-conference-scyx-20150618monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-announces-changes-to-board-of-directors-scyx-20150610monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-announces-new-employment-inducement-grant-scyx-20150605monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-to-present-at-jefferies-2015-healthcare-conference-scyx-20150526monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-reports-first-quarter-2015-financial-results-scyx-20150515monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-appoints-david-angulo-m-d-as-chief-medical-officer-scyx-20150514monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-pricing-of-public-offering-of-common-stock-scyx-20150423monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-launch-of-public-offering-of-common-stock-scyx-20150420monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-reports-full-year-2014-financial-results-scyx-20150330monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-to-present-at-jefferies-2015-antibiotic-summit-scyx-20150312monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-appoints-steven-c-gilman-ph-d-to-board-of-directors-scyx-20150227monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-to-present-at-rbc-capital-markets-2015-healthcare-conference-scyx-20150219monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-names-marco-taglietti-m-d-chief-executive-officer-scyx-20150206monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-receives-fda-fast-track-designation-for-oral-formulation-of-scy-078-for-the-t-scyx-20150109monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-announces-appointment-of-two-seasoned-industry-professionals-to-its-board-of--scyx-20141203monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-reports-third-quarter-2014-financial-results-scyx-20141113monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-enters-into-worldwide-agreement-with-waterstone-pharmaceutical-for-the-develo-scyx-20141103monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-reports-second-quarter-2014-financial-results-scyx-20140813monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-to-present-at-canaccord-genuity-growth-conference-2014-scyx-20140806monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-nasdaq-scyx-to-ring-the-nasdaq-stock-market-closing-bell-scyx-20140627monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-to-present-at-jmp-securities-healthcare-conference-scyx-20140618monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-provides-update-on-corporate-progress-and-first-quarter-2014-financial-results-scyx-20140616monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-appoints-vivian-doelling-as-vice-president-of-animal-health-scyx-20131120monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-signs-deal-with-r-pharm-to-develop-and-market-novel-antifungal-compound-in-russia-scyx-20130910monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-gains-worldwide-rights-to-novel-antifungal-compound-scyx-20130529monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-and-immune-design-collaborate-on-innovative-process-for-vaccine-production-techno-scyx-20130410monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-on-screening-technology-used-in-anti-malarial-research-at-acs-national-scyx-20120820monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-and-tb-alliance-sign-heos-software-agreement-scyx-20110616monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-introduces-application-for-mobile-access-to-heos-information-system-scyx-20101110monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-receives-merial-research-collaboration-milestone-payment-scyx-20101109monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-presentations-of-data-from-anti-fungal-drug-candidate-at-the-50th-icaac-scyx-20100914monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-and-trevena-announce-strategic-collaboration-to-enhance-discovery-of-biased-gpcr--scyx-20100519monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-receives-milestone-payment-from-collaboration-with-merck-co-inc-scyx-20091217monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-cgmp-facilities-audited-by-fda-no-form-483-observations-issued-scyx-20091216monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-and-dndi-extend-collaboration-to-identify-drug-candidates-to-treat-sleeping-sickn-scyx-20081211monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-und-dndi-setzen-kooperation-zur-identifizierung-von-wirkstoffkandidaten-zur-behan-scyx-20081211monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-completes-13-5-million-financing-scyx-20080327monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-to-present-at-the-jpmorgan-healthcare-conference-on-january-8-2008-scyx-20080107monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-receives-merial-research-collaboration-milestone-payment-scyx-20071213monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-and-dndi-enter-landmark-multi-year-agreement-to-identify-drug-candidates-to-treat-scyx-20071105monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-receives-preclinical-milestone-payment-in-collaboration-with-merck-scyx-20070109monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-research-agreement-with-merck-for-discovery-of-novel-oncology-agents-scyx-20061206monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-to-present-at-jefferies-global-healthcare-conference-in-london-mgx-20251117monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-highlights-progress-across-therapeutic-portfolio-and-outlines-anticipated-miles-mgx-20250116monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-announces-new-appointment-to-its-board-of-directors-mgx-20250115monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-mgx-20250108monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-presents-highly-specific-and-efficient-genome-editing-tools-at-nature-conferenc-mgx-20241211monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-to-present-new-preclinical-hemophilia-a-data-at-american-society-of-hematology--mgx-20241105monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-presents-novel-highly-specific-and-efficient-adenine-base-editors-for-broad-gen-mgx-20241024monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-presents-compact-smart-editing-platform-at-aiche-7th-international-conference-o-mgx-20241015monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-to-present-at-chardan-s-8th-annual-genetic-medicines-conference-mgx-20240919monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-presents-ai-enabled-advancements-of-smart-editing-platform-at-the-cold-spring-h-mgx-20240829monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-to-participate-in-upcoming-investor-conferences-mgx-20240828monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-to-present-at-the-2024-jefferies-global-healthcare-conference-mgx-20240529monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-to-regain-full-development-rights-to-its-wholly-owned-base-editing-and-rigs-sys-mgx-20240501monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-to-present-at-upcoming-scientific-meetings-mgx-20240408monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-to-participate-in-the-44th-annual-cowen-healthcare-conference-mgx-20240229monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-announces-closing-of-initial-public-offering-mgx-20240213monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-announces-pricing-of-initial-public-offering-mgx-20240209monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4-elut-20260518monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026-elut-20260430monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-to-present-at-sidoti-s-small-cap-virtual-investor-conference-march-18-19-elut-20260317monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-to-report-second-quarter-2025-financial-results-on-thursday-august-14-2025-elut-20250731monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-wins-dual-honors-for-innovation-and-product-launches-at-2025-medical-device-network-elut-20250626monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-strengthens-drug-eluting-biomatrix-platform-with-peer-reviewed-publication-of-novel-elut-20250528monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-to-report-first-quarter-2025-financial-results-on-thursday-may-8-2025-elut-20250501monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-to-participate-in-chardan-s-trending-issues-in-drug-development-conference-series-o-elut-20250422monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-initiates-elupro-registry-study-designed-to-generate-evidence-supporting-the-use-of-elut-20250421monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-confirms-no-material-impact-from-global-tariffs-elut-20250414monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-to-participate-in-upcoming-investor-conferences-elut-20250403monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-to-debut-elupro-at-hrs-2025-experience-the-difference-biology-makes-elut-20250402monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-announces-gpo-agreement-with-advantus-health-partners-to-expand-access-to-elupro-elut-20250327monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-advances-scientific-leadership-with-publication-of-new-study-on-antibiotic-eluting--elut-20250325monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-to-report-fourth-quarter-and-full-year-2024-financial-results-on-thursday-march-6-2-elut-20250220monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-announces-full-launch-of-elupro-following-strong-initial-demand-elut-20250114monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-announces-elupro-gpo-agreement-with-southern-strategic-sourcing-partners-elut-20250106monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-awarded-cardiac-rhythm-management-devices-agreement-with-premier-inc-elut-20241202monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-to-participate-at-the-canaccord-genuity-medtech-diagnostics-and-digital-health-serv-elut-20241113monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-to-report-third-quarter-2024-financial-results-on-thursday-november-14-2024-elut-20241029monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-to-present-at-the-ld-micro-main-event-xvii-conference-on-wednesday-october-30-elut-20241023monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-announces-new-peer-reviewed-publication-highlighting-the-robustness-of-elupro-compa-elut-20240918monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-celebrates-first-year-elut-20240906monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-announces-first-patient-implant-of-elupro-the-world-s-first-drug-eluting-bioenvelop-elut-20240905monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-to-participate-in-upcoming-investor-conferences-elut-20240903monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-announces-second-quarter-2024-results-elut-20240807monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-announces-full-exercise-of-warrants-generating-15-7-million-in-gross-proceeds-elut-20240801monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-appoints-ryan-marques-ph-d-mba-as-vice-president-of-operations-elut-20240731monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-to-report-second-quarter-2024-financial-results-on-wednesday-august-7-2024-elut-20240730monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-to-present-at-the-emerging-growth-conference-on-thursday-july-18-elut-20240711monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-to-showcase-bioenvelope-product-line-at-heart-rhythm-2024-elut-20240513monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-to-report-first-quarter-2024-financial-results-on-thursday-may-9-2024-elut-20240502monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-to-present-at-the-planet-microcap-showcase-vegas-2024-on-wednesday-may-1-elut-20240424monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-to-report-fourth-quarter-and-full-year-2023-financial-results-on-thursday-march-7-2-elut-20240222monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-regains-compliance-with-nasdaq-listing-requirements-elut-20240110monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-submits-cangaroorm-antibiotic-eluting-biomatrix-for-fda-clearance-elut-20231218monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-to-report-third-quarter-2023-financial-results-on-monday-november-13-2023-elut-20231106monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-to-participate-in-a-panel-discussion-at-the-cantor-global-healthcare-conference-elut-20230920monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-elut-20230908monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-investigation-reminder-bragar-eagel-squire-reminds-sensus-healthcare-investors-to-c-srts-20251009monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-alert-bragar-eagel-squire-p-c-is-investigating-sensus-healthcare-inc-on-behalf-of-s-srts-20250908monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-alert-bragar-eagel-squire-p-c-is-investigating-sensus-healthcare-inc-on-behalf-of-s-srts-20250831monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-inc-investors-company-investigated-by-the-portnoy-law-firm-srts-20250828monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-inc-investors-company-investigated-by-the-portnoy-law-firm-srts-20250821monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-host-second-quarter-2024-financial-results-and-business-update-confer-srts-20240725monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-issues-reminder-that-its-first-quarter-2024-financial-results-and-busine-srts-20240425monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-host-first-quarter-2024-financial-results-and-business-update-confere-srts-20240418monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-participate-in-the-36th-annual-roth-conference-srts-20240314monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-launches-fair-deal-agreement-for-its-srt-100-vision-at-the-american-acad-srts-20240313monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-issued-u-s-patent-for-srt-100-vision-system-ig-srt-capabilities-srts-20240208monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-collaborates-with-curerays-to-provide-oversight-to-help-customers-assure-srts-20240206monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-announces-retirement-of-director-samuel-o-rear-srts-20240201monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-host-fourth-quarter-and-full-year-2023-financial-results-and-business-srts-20240130monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-announces-preliminary-2023-revenue-exceeds-23-million-srts-20240123monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-host-third-quarter-2023-financial-results-and-business-update-confere-srts-20231102monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference--srts-20231009monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-sells-superficial-radiotherapy-system-to-cape-cod-hospital-srts-20230928monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-showcase-its-full-line-of-cutting-edge-superficial-radiotherapy-devic-srts-20230926monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-announces-new-3-million-share-repurchase-program-srts-20230808monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-host-second-quarter-2023-financial-results-and-business-update-confer-srts-20230726monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-completes-installation-of-its-first-srt-system-in-ireland-srts-20230725monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-partners-with-mis-healthcare-to-distribute-srt-systems-in-the-united-kin-srts-20230706monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-participate-in-the-maxim-group-virtual-healthcare-conference-hosted-b-srts-20230615monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-s-srt-treatment-shows-promise-in-treating-cutaneous-mast-cell-tumors-amo-srts-20230517monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-host-first-quarter-2023-financial-results-and-business-update-confere-srts-20230425monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-announces-the-sensus-cloud-unveils-new-features-at-american-academy-of-d-srts-20230316monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-host-fourth-quarter-2022-financial-results-and-business-update-confer-srts-20230201monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-announces-senior-management-appointments-and-promotions-srts-20230109monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-host-third-quarter-2022-financial-results-and-business-update-confere-srts-20221027monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-introduces-silk-laser-hair-removal-system-srts-20221020monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conferenc-srts-20220909monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-adds-dr-mohammad-k-khan-to-medical-advisory-board-srts-20220907monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-launches-upgrade-to-its-srt-100-vision-system-with-new-state-of-the-art--srts-20220809monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-takes-order-for-10-transdermal-infusion-systems-supporting-hair-enhancem-srts-20220727monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-host-second-quarter-2022-financial-results-and-business-update-confer-srts-20220726monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-participate-in-the-h-c-wainwright-global-investment-conference-srts-20220518monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-host-first-quarter-2022-financial-results-and-business-update-confere-srts-20220421monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-present-at-two-investment-conferences-in-march-srts-20220309monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-sells-its-sculptura-assets-to-empyrean-medical-systems-for-15-million-in-srts-20220302monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-prepares-organization-for-long-term-growth-with-three-promotions-srts-20220131monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-host-fourth-quarter-2021-financial-results-and-business-update-confer-srts-20220126monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-present-at-the-h-c-wainwright-bioconnect-virtual-conference-srts-20220106monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-signs-exclusive-u-s-distribution-agreement-with-mattioli-eng-italia-for--srts-20211201monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-host-third-quarter-2021-financial-results-and-business-update-confere-srts-20211020monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-participate-in-fireside-chat-hosted-by-maxim-group-and-m-vest-srts-20211015monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-announces-presentations-demonstrations-and-exhibit-booth-at-the-2021-fal-srts-20211007monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-participate-at-h-c-wainwright-23rd-annual-global-investment-conferenc-srts-20210908monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-host-second-quarter-2021-financial-results-and-business-update-confer-srts-20210729monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-announces-participation-in-a-g-p-s-virtual-medtech-summer-conference-on--srts-20210722monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-host-first-quarter-2021-financial-results-and-business-update-confere-srts-20210429monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-announces-the-sale-install-of-its-500th-unit-srts-20210413monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-participate-in-three-investment-conferences-during-the-month-of-march-srts-20210308monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-granted-u-s-patent-for-three-dimensional-beam-forming-x-ray-source-srts-20210223monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-host-fourth-quarter-2020-financial-results-and-business-update-confer-srts-20210218monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-engages-ekpac-healthcare-ltd-as-new-exclusive-distributor-in-china-for-s-srts-20201215monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-announces-cms-sets-rates-higher-for-srt-reimbursement-srts-20201208monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-announces-study-showing-single-low-dose-of-superficial-radiation-therapy-srts-20201201monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-appoints-megan-cornish-to-its-board-of-directors-srts-20201105monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-host-third-quarter-2020-financial-results-and-business-update-confere-srts-20201029monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-announces-publication-of-study-showing-use-of-superficial-radiation-ther-srts-20201022monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-host-second-quarter-2020-financial-results-and-business-update-confer-srts-20200730monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-names-hoi-bun-benson-suen-vice-president-of-international-sales-ships-sr-srts-20200728monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-present-at-covid-19-webinar-hosted-by-maxim-group-on-july-16th-srts-20200713monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-s-ceo-to-participate-in-dermatology-practice-panel-discussion-as-part-of-srts-20200630monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-announces-cme-presentation-by-dr-jeffrey-s-fromowitz-today-at-the-fall-c-srts-20200624monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-and-david-goldberg-m-d-j-d-to-host-a-virtual-program-on-dermatology-medi-srts-20200603monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-host-first-quarter-2020-financial-results-and-business-update-confere-srts-20200430monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-announces-publication-of-research-on-long-term-efficacy-and-safety-of-su-srts-20200303monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-host-fourth-quarter-2019-financial-results-and-business-update-confer-srts-20200206monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-announces-sculptura-shipment-to-california-based-medical-center-third-sc-srts-20200122monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-announces-management-promotions-srts-20200106monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-present-at-the-piper-jaffray-31st-annual-healthcare-conference-srts-20191121monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-third-quarter-2019-financial-results-srts-20191106monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-host-third-quarter-2019-financial-results-and-business-update-confere-srts-20191101monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-second-quarter-2019-financial-results-srts-20190808monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-host-second-quarter-2019-financial-results-and-business-update-confer-srts-20190730monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-present-at-the-raymond-james-inaugural-life-sciences-and-medtech-conf-srts-20190610monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-present-at-upcoming-investor-conferences-srts-20170905monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-to-present-at-the-6th-annual-liolios-gateway-conference-on-september-6-2-srts-20170823monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-to-present-at-the-2017-marcum-microcap-conference-srts-20170605monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-nasdaq-srtsu-to-ring-the-nasdaq-stock-market-opening-bell-srts-20160608monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-receives-fda-510k-clearance-for-next-generation-image-guided-superficial-srts-20151019monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-teams-up-with-jeffrey-klein-md-and-dermatology-associates-of-orange-coun-srts-20150519monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-reports-first-quarter-2026-financial-results-and-provides-pipeline-and--xlo-20260512monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-new-preclinical-data-at-aacr-annual-meeting-for-xtx601-a-mask-xlo-20260417monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-xlo-20260403monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-to-present-phase-2-data-for-vilastobart-highlighting-response-rate-in-p-xlo-20251030monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-xlo-20251002monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-xlo-20250801monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-xlo-20250702monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors-xlo-20250610monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-closing-of-50-0-million-public-offering-xlo-20250605monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-xlo-20250603monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-proposed-public-offering-xlo-20250602monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-updated-phase-2-data-for-vilastobart-a-tumor-activated-anti-c-xlo-20250531monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-xlo-20250502monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-to-present-updated-phase-2-data-for-vilastobart-a-tumor-activated-fc-en-xlo-20250423monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-xlo-20250404monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-to-present-at-td-cowen-45th-annual-health-care-conference-xlo-20250224monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-multiple-masked-t-cell-engager-programs-xlo-20250212monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-xlo-20250203monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-initial-phase-2-data-for-vilastobart-xtx101-a-tumor-activated-xlo-20250121monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-xlo-20250117monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-xlo-20250110monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-to-present-initial-phase-2-data-for-vilastobart-xtx101-a-tumor-activate-xlo-20241219monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-appoints-caroline-hensley-as-chief-legal-officer-xlo-20241216monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-xlo-20241203monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-initial-clinical-trial-data-from-phase-1c-dose-escalation-for-xlo-20241107monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-to-present-initial-phase-1c-dose-escalation-data-for-xtx101-vilastobart-xlo-20241030monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-upcoming-poster-presentation-at-the-society-for-immunotherapy-xlo-20241004monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-xlo-20241002monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-to-present-at-morgan-stanley-22nd-annual-global-healthcare-conference-xlo-20240828monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-appoints-aoife-brennan-m-d-and-james-shannon-m-d-to-its-board-of-direct-xlo-20240613monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-11-3-million-private-placement-equity-financing-xlo-20240328monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-to-participate-in-novel-immuno-oncology-panel-at-td-cowen-44th-annual-h-xlo-20240228monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-to-present-at-guggenheim-6th-annual-biotechnology-conference-xlo-20240131monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-highlights-recent-advances-across-clinical-pipeline-and-encouraging-pre-xlo-20240108monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-announces-initial-monotherapy-safety-and-anti-tumor-activity-data-for-xtx202-a-tumor-xlo-20231103monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-to-host-virtual-investor-conference-call-and-webcast-on-monday-november-6-2023-to-re-xlo-20231031monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-ca-xlo-20230927monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-to-present-at-morgan-stanley-21st-annual-global-healthcare-conference-xlo-20230905monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-pipeline-and-business-updates-and-second-quarter-2023-financi-xlo-20230814monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-promotion-of-chris-frankenfield-to-chief-operating-officer-xlo-20230803monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-preliminary-clinical-data-from-phase-1-trial-of-xtx101-a-tumo-xlo-20230525monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-xlo-20230403monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-to-present-at-upcoming-investor-conferences-xlo-20230227monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-to-present-at-the-citi-2023-virtual-oncology-leadership-summit-xlo-20230216monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-to-present-at-the-guggenheim-healthcare-talks-oncology-day-xlo-20230202monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-to-host-live-virtual-program-spotlighting-xtx301-a-tumor-activated-il-1-xlo-20221123monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-to-present-at-cowen-6th-annual-io-next-summit-xlo-20221104monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-to-present-at-guggenheim-nantucket-therapeutics-conference-xlo-20220922monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-appoints-tomas-j-heyman-to-board-of-directors-xlo-20220915monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-to-present-at-morgan-stanley-20th-annual-global-healthcare-conference-xlo-20220906monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-promotion-of-martin-huber-m-d-to-president-xlo-20220616monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-to-present-at-the-h-c-wainwright-global-investment-conference-xlo-20220518monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-appoints-stacey-davis-as-chief-business-officer-xlo-20220517monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-to-present-at-the-21st-annual-needham-virtual-healthcare-conference-xlo-20220407monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-to-participate-in-the-cowen-42nd-annual-healthcare-conference-xlo-20220228monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-to-participate-in-the-guggenheim-4th-annual-oncology-day-xlo-20220203monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-initiation-of-patient-dosing-in-phase-1-2-clinical-trial-of-x-xlo-20220120monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-preclinical-data-demonstrating-anti-tumor-activity-and-tolera-xlo-20211112monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-closing-of-initial-public-offering-xlo-20211026monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-at-the-38th-annual-roth-conference-ecor-20260310monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ecor-20250910monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-at-h-c-wainwright-global-investment-conference-ecor-20250902monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-names-kelly-benning-accomplished-healthcare-executive-as-svp-of-truvaga-ecor-20250812monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-appoints-james-c-theofilos-to-the-board-of-directors-ecor-20250805monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-second-quarter-june-30-2025-financial-results-on-wednesday-august--ecor-20250723monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-in-upcoming-investor-conferences-ecor-20250722monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-s-truvaga-now-works-with-the-apple-health-app-ecor-20250501monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-first-quarter-march-31-2025-financial-results-on-wednesday-may-7-2-ecor-20250430monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-at-the-planet-microcap-showcase-ecor-20250416monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-named-one-of-the-americas-fastest-growing-companies-by-the-financial-times-ecor-20250403monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-at-the-needham-virtual-healthcare-conference-ecor-20250401monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-extends-va-contract-for-five-years-ecor-20250331monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-fourth-quarter-and-full-year-ended-december-31-2024-financial-resu-ecor-20250306monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-at-upcoming-investor-conferences-ecor-20250305monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-ecor-20250227monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-s-truvaga-now-available-on-amazon-ecor-20250219monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-expands-intellectual-property-portfolio-ecor-20250206monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-at-the-btig-medtech-digital-health-life-science-diagnostic-tool-ecor-20250204monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-expands-intellectual-property-portfolio-ecor-20250107monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-s-truvaga-plus-wins-woman-s-world-magazine-50-over-50-award-ecor-20241120monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-donates-gammacore-sapphire-for-real-world-evaluation-of-nvns-in-trauma-among-i-ecor-20241119monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-at-the-canaccord-genuity-medtech-diagnostics-and-digital-health-ecor-20241114monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-s-truvaga-plus-wins-men-s-health-magazine-tech-award-ecor-20241112monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ecor-20241108monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-third-quarter-september-30-2024-financial-results-on-wednesday-nov-ecor-20241023monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-in-upcoming-investor-conferences-ecor-20240926monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-engages-fnk-ir-to-execute-expanded-investor-relations-program-ecor-20240924monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-in-the-h-c-wainwright-26th-annual-global-investment-conference-ecor-20240904monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-in-upcoming-investor-conferences-ecor-20240808monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ecor-20240802monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-second-quarter-june-30-2024-financial-results-on-wednesday-august--ecor-20240731monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-the-commercial-launch-of-tac-stim-ecor-20240625monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-join-russell-microcap-index-ecor-20240611monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-closing-of-9-3-million-registered-direct-offering-and-concurrent-ecor-20240606monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ecor-20240503monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-first-quarter-march-31-2024-financial-results-on-wednesday-may-8-2-ecor-20240501monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-the-launch-of-truvaga-plus-for-general-wellness-ecor-20240408monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-expands-intellectual-property-portfolio-ecor-20240402monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-in-upcoming-investor-conferences-ecor-20240312monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-fourth-quarter-and-full-year-ended-december-31-2023-financial-resu-ecor-20240305monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-expands-intellectual-property-portfolio-ecor-20240206monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-expands-intellectual-property-portfolio-ecor-20240109monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-expands-intellectual-property-portfolio-ecor-20231226monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-expands-intellectual-property-portfolio-for-nerve-stimulation-technology-ecor-20231212monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-in-canaccord-genuity-s-medtech-diagnostics-and-digital-health-s-ecor-20231107monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-two-year-extension-of-gammacore-device-listing-in-the-nhs-supply-cha-ecor-20231017monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-expands-intellectual-property-portfolio-for-non-invasive-vagus-nerve-stimulati-ecor-20231011monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-third-quarter-financial-results-on-wednesday-november-8-ecor-20231009monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-in-the-lytham-partners-fall-2023-virtual-investor-conference-ecor-20231005monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-expands-intellectual-property-portfolio-for-non-invasive-vagus-nerve-stimulati-ecor-20230926monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-in-the-ld-micro-main-event-xvi-conference-ecor-20230925monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-present-at-iaccess-alpha-s-top-10-best-ideas-from-the-buyside-virtual-confe-ecor-20230921monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference-ecor-20230907monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-dismissal-of-all-litigation-related-to-its-2018-initial-public-offer-ecor-20230823monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-second-quarter-financial-results-on-wednesday-august-9-ecor-20230801monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-expands-intellectual-patent-portfolio-for-nvns-technology-ecor-20230718monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-distribution-agreement-with-reliefband-technologies-llc-ecor-20230713monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-provides-select-second-quarter-2023-financial-guidance-ecor-20230711monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-in-the-healthcare-virtual-conference-presented-by-maxim-group-l-ecor-20230614monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-poster-to-be-presented-at-the-american-headache-society-s-65th-annua-ecor-20230613monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-departure-of-jp-errico-from-the-board-of-directors-ecor-20230526monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-at-13th-annual-ld-micro-invitational-xiii-ecor-20230523monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-at-annual-aegis-virtual-conference-ecor-20230501monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-first-quarter-financial-results-on-wednesday-may-3-ecor-20230419monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-provides-select-first-quarter-2023-financial-guidance-ecor-20230417monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-expands-intellectual-patent-portfolio-for-nvns-technology-ecor-20230412monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-remittance-of-annual-license-fee-from-teijin-for-certain-exclusive-r-ecor-20230411monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-product-registration-in-indonesia-malaysia-and-south-africa-ecor-20230406monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-gammacore-non-invasive-vagus-nerve-stimulator-available-through--ecor-20230404monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-reports-results-of-pre-clinical-trial-in-a-model-of-traumatic-brain-injury-ecor-20230323monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-s-truvaga-users-reported-improved-stress-anxiety-sleep-energy-and-mood-in-rece-ecor-20230321monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-affirms-no-direct-exposure-to-silicon-valley-bank-silvergate-bank-or-signature-ecor-20230314monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-poster-to-be-presented-at-the-2023-american-academy-of-neurology-ann-ecor-20230313monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-at-35th-annual-roth-conference-ecor-20230309monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-regains-compliance-with-nasdaq-listing-requirements-ecor-20230307monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-fourth-quarter-and-year-ended-december-31-2022-financial-results-o-ecor-20230301monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-exclusive-distribution-agreement-with-byond-healthcare-pty-ltd-s-ecor-20230221monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-expands-intellectual-patent-portfolio-for-nvns-technology-ecor-20230216monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-completes-sale-of-new-jersey-tax-benefits-ecor-20230215monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-reverse-stock-split-ecor-20230214monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-expected-record-4q-2022-revenue-of-2-5m-provides-business-update-ecor-20230117monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-launches-new-wellness-product-offering-for-stress-anxiety-and-sleep-truvag-ecor-20221220monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-issuance-of-two-new-u-s-patents-ecor-20221207monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-at-canaccord-genuity-medtech-and-diagnostics-and-digital-health-ecor-20221114monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-distribution-agreement-with-joerns-healthcare-llc-ecor-20221101monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-third-quarter-2022-financial-results-on-november-3-ecor-20221027monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-provides-select-third-quarter-2022-financial-guidance-ecor-20221014monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-strengthens-patent-portfolio-with-issuance-of-four-new-u-s-patents-ecor-20220921monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-date-for-fiscal-year-2022-annual-meeting-and-deadlines-for-stockhold-ecor-20220920monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-at-upcoming-investor-conferences-ecor-20220906monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-at-canaccord-genuity-42nd-annual-growth-conference-ecor-20220805monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-second-quarter-2022-financial-results-on-august-4-ecor-20220728monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-provides-select-second-quarter-2022-financial-guidance-ecor-20220712monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-study-of-gammacore-sapphire-for-the-treatment-of-post-covid-synd-ecor-20220707monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-gammacore-non-invasive-vagus-nerve-stimulator-available-through--ecor-20220524monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-at-upcoming-investor-conferences-ecor-20220518monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-first-quarter-2022-financial-results-on-may-5-ecor-20220428monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-completes-sale-of-new-jersey-tax-benefits-ecor-20220426monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-publication-of-investigator-initiated-trial-data-for-savior-1-in-cov-ecor-20220421monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-provides-business-update-and-select-first-quarter-2022-financial-guidance-ecor-20220412monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-exclusive-license-agreement-with-teijin-for-japan-territory-ecor-20220405monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-dr-peter-staats-to-keynote-the-fifth-annual-bioelectronic-medicine-f-ecor-20220323monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-present-at-2022-maxim-virtual-growth-conference-ecor-20220322monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-present-at-34th-annual-roth-conference-ecor-20220307monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-fourth-quarter-and-year-ended-december-31-2021-financial-results-o-ecor-20220303monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-completion-of-enrollment-in-the-transit-study-of-non-invasive-va-ecor-20220201monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-three-abstracts-to-be-presented-at-international-stroke-conferen-ecor-20220125monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-broadens-patient-access-to-gammacore-with-launch-of-u-s-telehealth-portal--ecor-20220111monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-publication-of-premium-ii-trial-of-gammacore-non-invasive-vagus-nerv-ecor-20220110monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-present-at-h-c-wainwright-bioconnect-virtual-conference-ecor-20220104monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-provides-update-on-global-distribution-partners-ecor-20211216monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-the-launch-of-a-new-online-shop-in-the-united-kingdom-ecor-20211215monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-provides-update-on-nvns-to-treat-post-traumatic-stress-disorder-ecor-20211214monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-new-patent-for-stroke-and-tia-treatment-ecor-20211213monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-at-canaccord-genuity-medtech-diagnostics-forum-ecor-20211111monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-third-quarter-2021-financial-results-on-thursday-november-4th-ecor-20211021monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-publication-reviewing-the-prescribing-of-gammacore-for-the-treatment-ecor-20211020monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-regulatory-approval-in-canada-to-treat-adolescent-migraine-ecor-20211014monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-acceptance-of-motion-to-dismiss-in-the-federal-court-securities-clas-ecor-20211007monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-presentation-at-the-cantor-fitzgerald-virtual-global-healthcare-conference-ecor-20210930monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-open-access-and-submission-of-manuscript-from-savior-1-study-of-non--ecor-20210929monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-at-upcoming-investor-conferences-ecor-20210923monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-new-patent-expanding-claims-related-to-delivery-of-non-invasive-vagu-ecor-20210915monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-510-k-clearance-of-gammacore-non-invasive-vagus-nerve-stimulation-nv-ecor-20210914monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-ecor-20210831monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-new-reseller-agreement-with-red-one-medical-devices-llc-ecor-20210824monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-publication-in-pharmacoeconomics-reiterating-economic-benefits-of-ga-ecor-20210804monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-present-at-the-canaccord-genuity-growth-conference-ecor-20210802monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-issuance-of-new-patent-for-migraine-treatment-using-smartphones-ecor-20210727monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-second-quarter-2021-financial-results-on-thursday-august-5th-ecor-20210722monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-dr-peter-staats-to-receive-lifetime-achievement-award-from-the-ameri-ecor-20210719monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-provides-business-update-and-select-second-quarter-2021-financial-guidance-ecor-20210713monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-in-the-ladenburg-thalmann-2021-virtual-healthcare-conference-ecor-20210709monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-proposed-public-offering-of-common-stock-ecor-20210629monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-publication-of-study-on-the-effect-of-non-invasive-vagus-nerve-stimu-ecor-20210624monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-exclusive-distribution-agreement-with-kromax-for-taiwan-and-chin-ecor-20210623monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-join-russell-microcap-index-ecor-20210616monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-completes-sale-of-1-4-million-of-nj-nol-tax-benefits-ecor-20210609monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-publication-of-study-on-non-invasive-vagus-nerve-stimulation-nvns-to-ecor-20210602monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-present-at-investor-conferences-in-june-ecor-20210526monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-u-s-department-of-veterans-affairs-study-of-gammacore-sapphire-n-ecor-20210504monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-first-quarter-2021-financial-results-on-thursday-may-6-ecor-20210429monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-johns-hopkins-university-school-of-medicine-study-of-non-invasiv-ecor-20210426monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-exclusive-distribution-agreement-with-east-agency-for-qatar-ecor-20210420monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-publication-in-nature-reviews-neurology-highlighting-the-role-of-non-ecor-20210415monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-top-line-results-from-savior-1-study-of-non-invasive-vagus-nerve-sti-ecor-20210408monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-regulatory-approval-in-canada-ecor-20210405monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-exclusive-distribution-agreement-with-silvert-medical-nv-sa-for--ecor-20210323monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-fourth-quarter-and-year-ended-december-31-2020-financial-results-o-ecor-20210304monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-at-two-upcoming-investor-conferences-ecor-20210303monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-exclusive-distribution-agreement-with-medistar-following-regulat-ecor-20210228monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-two-year-extension-of-gammacore-listing-in-the-nhs-supply-chain-cata-ecor-20210223monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-completion-of-enrollment-in-savior-1-study-of-non-invasive-vagus-ner-ecor-20210211monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-publication-of-study-on-non-invasive-vagus-nerve-stimulation-nvns-to-ecor-20210209monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-in-the-btig-virtual-medtech-digital-health-life-science-diagnos-ecor-20210203monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-full-enrollment-of-tr-venus-study-of-non-invasive-vagal-nerve-stimul-ecor-20210202monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-inclusion-of-gammacore-sapphire-in-new-nhs-england-and-nhs-impro-ecor-20210127monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-exclusive-distribution-agreement-with-rsk-medical-inc-in-canada-ecor-20210126monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-scottish-health-technology-group-recommendation-for-use-of-gamma-ecor-20210121monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-provides-business-update-and-select-financial-guidance-ecor-20210111monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-agreement-with-pro-medical-baltic-to-be-exclusive-distributor-fo-ecor-20201221monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-positive-top-line-results-from-premium-ii-migraine-prevention-study-ecor-20201208monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-present-at-the-13th-annual-ld-micro-main-event-conference-ecor-20201207monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-selection-of-gammacore-for-national-institute-on-drug-abuse-nida-spo-ecor-20201201monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-in-upcoming-virtual-investor-conferences-ecor-20201112monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-third-quarter-ended-september-30-2020-financial-results-on-thursda-ecor-20201105monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-appoints-business-development-leader-and-us-navy-veteran-sylvester-steele--ecor-20201021monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-extension-of-nhs-england-s-innovation-and-technology-payment-itp-ecor-20201001monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-department-of-veterans-affairs-sponsored-study-of-non-invasive-vagal-ecor-20200930monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-agreement-with-upscript-llc-to-be-exclusive-online-telehealth-provid-ecor-20200924monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-in-the-jmp-securities-medtech-bio-summit-ecor-20200923monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-present-at-the-hc-wainwright-virtual-22nd-annual-global-investment-conferen-ecor-20200911monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-publication-in-brain-stimulation-highlighting-non-invasive-vagal-ner-ecor-20200827monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-publication-of-a-voluntary-ex-ante-transparency-tender-notice-aw-ecor-20200824monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-second-quarter-ended-june-30-2020-financial-results-on-thursday-au-ecor-20200806monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-non-invasive-vagus-nerve-stimulation-clinical-update-publication-in--ecor-20200728monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-participate-in-three-upcoming-virtual-investor-conferences-ecor-20200709monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-to-present-at-little-grapevine-s-g1-microcap-virtual-conference-ecor-20200529monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-first-quarter-ended-march-31-2020-financial-results-on-thursday-ma-ecor-20200507monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-extension-of-nhs-england-s-innovation-and-technology-payment-itp-ecor-20200408monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-510-k-clearance-of-gammacore-label-expansion-into-migraine-preventio-ecor-20200330monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-common-stock-purchase-agreement-for-up-to-25-million-with-lincoln-pa-ecor-20200327monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-fourth-quarter-and-full-year-2019-financial-results-ecor-20200323monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-fourth-quarter-and-year-ended-december-31-2019-financial-results-o-ecor-20200319monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-rebate-agreement-with-ascent-health-services-for-gammacore-prefe-ecor-20200127monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-present-at-the-two-december-investor-conferences-ecor-20191126monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-third-quarter-2019-financial-results-on-wednesday-november-13th-ecor-20191107monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-that-a-se-ecor-20191010monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-appoints-medical-technology-veteran-daniel-s-goldberger-as-chief-executive-off-ecor-20190930monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-that-a-se-ecor-20190927monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-distribution-agreement-with-doctor-s-medical-llc-to-expand-patient-a-ecor-20190812monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-second-quarter-2019-financial-results-on-tuesday-august-13-ecor-20190806monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-investor-alert-faruqi-faruqi-llp-encourages-investors-who-suffered-losses-exce-ecor-20190711monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-gammacore-tm-listing-on-the-nhs-supply-chain-catalogue-ecor-20190624monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-frank-r-amato-to-step-down-as-chief-executive-officer-ecor-20190610monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-first-quarter-2019-financial-results-on-tuesday-may-14-ecor-20190508monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-selected-for-innovation-and-technology-payment-program-through-nhs-england-ecor-20190506monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-announce-fourth-quarter-and-year-ended-december-31-2018-financial-results-o-ecor-20190318monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-encouraging-research-supporting-key-areas-of-clinical-development-fo-ecor-20190314monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-appointments-multiple-industry-veterans-to-key-management-positions-ecor-20190308monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-positive-coverage-policies-of-gammacore-issued-by-highmark-ecor-20190226monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-and-healthywomen-announce-partnership-on-patient-program-to-increase-awareness-ecor-20190219monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-present-at-noble-capital-markets-fifteenth-annual-investor-conference-ecor-20190128monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-two-new-studies-and-a-publication-supporting-the-practical-utility-o-ecor-20190108monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-receives-fda-clearance-for-gammacore-nvns-for-adjunctive-use-for-the-preventiv-ecor-20181128monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-expands-manufacturing-capabilities-for-gammacore-ecor-20181127monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-to-present-at-the-evercore-isi-healthconx-conference-ecor-20181120monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-to-report-third-quarter-financial-results-on-november-13-2018-ecor-20181030monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-appointment-of-ardelle-ferris-as-vice-president-of-managed-care-ecor-20181030monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-to-present-at-the-cantor-global-healthcare-conference-ecor-20180918monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-present-additional-research-for-non-invasive-vagus-nerve-stimulation-in-hea-ecor-20180905monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-research-collaboration-with-massachusetts-general-hospital-to-ex-ecor-20180809monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-to-report-second-quarter-financial-results-on-august-13-2018-ecor-20180726monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-and-upscript-launch-program-to-offer-direct-to-patient-telemedicine-option-for-ecor-20180717monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-additions-to-board-of-directors-in-connection-with-recently-comp-ecor-20180710monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-present-additional-research-for-non-invasive-vagus-nerve-stimulation-nvns-i-ecor-20180628monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-exercise-of-underwriters-option-to-purchase-additional-shares-in-ecor-20180628monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-closing-of-initial-public-offering-ecor-20180626monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-pricing-of-initial-public-offering-ecor-20180622monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-scilex-announces-a-payment-date-of-june-15-2026-for-the-previously--sclx-20260604monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-files-federal-securities-fraud-lawsuit-seeking-recovery-of-approxim-sclx-20260313monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-confirms-dream-bowl-2026-meme-coin-claim-process-on-december-24-202-sclx-20251223monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-closing-of-previously-announced-second-tranche-investment-sclx-20251126monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-nasdaq-sclx-announces-its-majority-owned-subsidiary-semnur-pharmace-sclx-20250821monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-nasdaq-sclx-announces-effectiveness-of-registration-statement-on-fo-sclx-20250813monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-deferral-of-record-date-for-its-previously-announced-divi-sclx-20250623monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-publication-on-gloperba-dosing-adjustments-in-peer-review-sclx-20250605monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-presented-post-hoc-analysis-of-the-c-l-e-a-r-trial-on-clinical-mean-sclx-20250516monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-to-present-post-hoc-analysis-of-the-c-l-e-a-r-trial-on-clinical-mea-sclx-20250501monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-regains-compliance-with-nasdaq-minimum-bid-price-rule-sclx-20250430monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-change-in-record-date-for-its-previously-announced-divide-sclx-20250422monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-fda-has-approved-our-request-for-the-orphan-drug-designat-sclx-20250416monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-can-sclx-20250415monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-1-for-35-reverse-stock-split-sclx-20250411monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-has-appealed-lower-court-decision-to-the-u-s-court-of-appeals-for-t-sclx-20250327monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-change-in-record-date-for-its-previously-announced-divide-sclx-20250310monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-that-the-u-s-bankruptcy-court-has-extended-the-lockup-per-sclx-20250131monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-that-the-u-s-fda-has-acknowledged-the-submission-of-our-s-sclx-20250122monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-that-it-regains-nasdaq-compliance-under-listing-rule-5250-sclx-20250121monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-extension-of-the-maturity-date-of-its-secured-promissory--sclx-20250121monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-that-its-note-holders-intend-to-participate-in-the-fundin-sclx-20250121monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-that-it-will-be-filing-today-of-a-supplemental-new-drug-a-sclx-20250121monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-filing-of-its-quarterly-report-on-form-10-q-for-the-quart-sclx-20250121monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-amends-its-license-agreement-with-romeg-therapeutics-llc-for-the-wo-sclx-20250116monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-pain-medicine-news-published-retrospective-claims-data-on-sclx-20250113monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-change-in-record-date-for-its-previously-announced-divide-sclx-20241230monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-early-installment-payment-on-its-senior-secured-promissor-sclx-20241216monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-closing-of-17-million-registered-direct-offering-sclx-20241213monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-bio-a-controlling-interest-of-joint-venture-by-scilex-holding-company-reports-kds20-sclx-20241211monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-enters-into-a-binding-term-sheet-for-a-joint-venture-with-ipmc-and--sclx-20241210monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-receipt-of-notice-from-nasdaq-sclx-20241122monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-presentation-of-data-at-the-2024-american-college-of-rheu-sclx-20241115monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-pharmaceuticals-inc-a-wholly-owned-subsidiary-of-scilex-holding-company-announces-s-sclx-20241030monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-following-its-prior-announcement-of-the-record-date-for-a-dividend--sclx-20241029monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-sets-november-7-2024-as-the-record-date-for-a-dividend-of-preferred-sclx-20241028monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-that-its-board-of-directors-has-authorized-management-to--sclx-20241016monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-provides-certain-preliminary-unaudited-financial-results-for-the-qu-sclx-20241008monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-closing-of-a-50-million-registered-convertible-financing-sclx-20241008monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-signing-of-a-50-million-registered-convertible-financing--sclx-20241007monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-that-the-u-s-bankruptcy-court-has-extended-the-lockup-per-sclx-20240926monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-the-continuing-support-from-endeavor-distribution-llc-in--sclx-20240918monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-it-has-received-the-drug-distributor-accreditation-from-t-sclx-20240912monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-to-present-at-the-26th-annual-h-c-wainwright-global-investment-conf-sclx-20240909monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-acceptance-of-presentation-at-the-2024-american-college-o-sclx-20240905monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-to-present-oral-poster-presentations-and-symposia-on-ztlido-lidocai-sclx-20240830monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-fda-final-approval-to-precision-dosing-for-gloperba-label-sclx-20240829monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-the-u-s-patent-and-trademark-office-will-be-issuing-new-e-sclx-20240821monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-enters-into-master-distributor-agreement-among-ch-trading-group-and-sclx-20240809monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-provides-certain-preliminary-unaudited-financial-results-for-the-mo-sclx-20240801monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-publication-of-its-inaugural-sustainability-report-sclx-20240724monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-strengthens-board-of-directors-with-appointment-of-highly-accomplis-sclx-20240723monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-collaboration-to-leverage-acea-therapeutics-r-d-expertise-sclx-20240717monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-to-ring-nasdaq-closing-bell-on-friday-july-5th-at-4-00pm-et-at-the--sclx-20240702monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-provides-certain-preliminary-unaudited-financial-results-for-the-mo-sclx-20240701monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-partners-with-new-national-distributor-endeavor-distribution-llc-sclx-20240620monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-publication-in-pain-journal-regarding-phase-3-results-of--sclx-20240614monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-to-present-poster-on-elyxyb-celecoxib-oral-solution-at-the-66th-ann-sclx-20240613monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-5-year-term-of-100-million-financing-with-royalty-based-p-sclx-20240611monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-that-many-national-pharmacy-chains-and-independent-pharma-sclx-20240611monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-stocking-of-gloperba-is-underway-in-all-of-the-wholesaler-sclx-20240610monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-the-u-s-fda-has-approved-the-snda-for-commercial-manufact-sclx-20240606monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-sends-letters-to-the-u-s-securities-and-exchange-commission-and-fin-sclx-20240530monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-it-has-been-added-to-the-msci-global-microcap-index-sclx-20240524monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-sends-letter-to-u-s-house-of-representatives-on-illegal-market-mani-sclx-20240524monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-final-court-approval-of-a-settlement-agreement-with-taked-sclx-20240514monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-provides-information-to-scilex-stockholders-regarding-manipulative--sclx-20240513monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-closing-of-15-million-registered-direct-offering-sclx-20240425monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-provides-certain-preliminary-unaudited-financial-results-for-gross--sclx-20240416monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-launching-of-co-pay-programs-for-both-ztlido-and-elyxyb-f-sclx-20240409monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-that-the-u-s-bankruptcy-court-has-extended-the-lockup-per-sclx-20240327monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-new-out-of-pocket-costs-for-commercially-insured-patients-sclx-20240321monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-seeking-approval-from-the-fda-for-modification-of-the-glo-sclx-20240320monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-a-settlement-agreement-with-takeda-pharmaceuticals-to-res-sclx-20240320monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-repayment-in-full-of-the-remaining-balance-of-convertible-sclx-20240319monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-provides-responses-to-product-composition-questions-related-to-its--sclx-20240318monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-announces-issuance-of-halal-certification-for-its-ztlido-product-by-circle--sclx-20240315monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-s-wholly-owned-subsidiary-scilex-pharmaceuticals-inc-entered-into-a-sclx-20240315monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-closing-of-10-million-bought-deal-offering-sclx-20240305monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-sets-launch-price-of-595-per-150ml-bottle-of-gloperba-its-first-and-sclx-20240305monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-launches-new-website-to-showcase-growing-portfolio-of-non-opioid-pr-sclx-20240304monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-that-the-official-committee-of-unsecured-creditors-of-sor-sclx-20240302monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-major-initiative-with-a-leading-national-pharmacy-chain-t-sclx-20240228monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-acceptance-of-abstract-for-poster-and-oral-presentation-a-sclx-20240227monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-s-wholly-owned-subsidiary-scilex-pharmaceuticals-inc-enters-into-a--sclx-20240226monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-that-ztlido-achieves-a-major-milestone-over-one-million-p-sclx-20240226monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-publication-in-anesthesiology-journal-of-results-from-an--sclx-20240220monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-chief-executive-officer-and-president-issues-letter-to-stockholders-sclx-20240108monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-provides-certain-preliminary-unaudited-financial-results-for-gross--sclx-20240102monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-filing-of-a-new-drug-submission-nds-to-health-canada-s-ph-sclx-20231226monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-that-according-to-prescription-data-from-symphony-health--sclx-20231220monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-results-from-market-research-with-rheumatologists-reveal--sclx-20231219monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-major-pharmacy-initiative-with-the-national-leading-pharm-sclx-20231215monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-expanded-access-to-elyxyb-by-the-execution-of-first-elyxy-sclx-20231212monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-that-ztlido-lidocaine-topical-system-will-be-added-as-a-p-sclx-20231206monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-the-addition-of-ztlido-lidocaine-topical-system-as-a-pref-sclx-20231204monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-generates-monthly-revenue-in-november-2023-and-provides-certain-pre-sclx-20231201monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-successful-fda-audit-of-enhanced-ztlido-manufacturing-fac-sclx-20231130monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-pharmacy-initiative-to-stock-elyxyb-in-over-500-stores-fo-sclx-20231128monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-completion-of-commercial-manufacturing-of-gloperba-with-t-sclx-20231127monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-market-research-results-with-neurologists-headache-specia-sclx-20231122monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-production-increase-product-availability-and-the-brand-ma-sclx-20231121monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-issuance-of-a-second-new-patent-in-the-u-s-for-its-lead-c-sclx-20231117monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-issuance-of-new-patent-in-the-u-s-for-its-lead-commercial-sclx-20231115monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-new-data-from-deeper-skin-penetration-studies-to-support--sclx-20231102monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-positive-type-c-meeting-with-the-fda-and-reaches-agreemen-sclx-20231102monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-generates-record-monthly-revenue-in-october-2023-and-provides-certa-sclx-20231101monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-files-emergency-motion-in-the-united-states-bankruptcy-court-for-th-sclx-20231027monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-retains-warshaw-burstein-llp-and-christian-attar-law-to-investigate-sclx-20231007monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-provides-notice-to-all-lenders-of-short-positions-in-the-restricted-sclx-20231004monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-provides-notice-to-all-record-holders-and-beneficial-owners-of-rest-sclx-20231003monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-submits-a-request-to-the-securities-and-exchange-commission-to-with-sclx-20230927monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-the-state-of-indiana-medicaid-will-add-elyxyb-as-a-prefer-sclx-20230925monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-the-consummation-of-the-previously-announced-purchase-of--sclx-20230921monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-the-completion-of-its-sp-103-lidocaine-topical-system-5-4-sclx-20230914monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-enters-into-non-binding-term-sheets-for-the-purchase-of-all-of-the--sclx-20230913monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-presented-oral-and-poster-presentations-on-ztlido-lidocaine-topical-sclx-20230912monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-generates-record-monthly-revenue-in-august-2023-and-provides-certai-sclx-20230911monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-results-from-independent-market-research-study-conducted--sclx-20230713monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-generates-record-monthly-revenue-in-june-2023-and-provides-certain--sclx-20230705monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-to-present-data-on-elyxyb-celecoxib-oral-solution-at-the-65th-annua-sclx-20230616monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-that-sorrento-therapeutics-inc-s-bankruptcy-court-issues--sclx-20230615monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-provides-certain-preliminary-unaudited-financial-results-for-gross--sclx-20230601monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-enters-master-distributor-agreement-among-ch-trading-group-llc-cht--sclx-20230531monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-added-to-the-preliminary-list-of-the-russell-3000-index-and-the-sma-sclx-20230522monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-complete-enrollment-of-a-phase-2-study-to-evaluate-the-sa-sclx-20230504monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference-sclx-20230428monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-that-its-majority-stockholder-sorrento-therapeutics-inc-h-sclx-20230425monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-enters-into-master-distributor-agreement-with-ch-trading-group-llc--sclx-20230417monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-final-postponement-of-annual-meeting-of-stockholders-sclx-20230414monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-postponement-of-annual-meeting-of-stockholders-sclx-20230405monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-reports-substantial-underreporting-of-more-than-44-million-shares-o-sclx-20230327monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-financing-of-up-to-25-million-to-enhance-commercializatio-sclx-20230321monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-and-ch-trading-group-announce-territory-distribution-agreement-to-e-sclx-20230308monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-the-commercial-launch-of-elyxybtm-celecoxib-oral-solution-sclx-20230227monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-a-majority-owned-subsidiary-of-sorrento-therapeutics-inc-acquires-r-sclx-20230212monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-a-majority-owned-subsidiary-of-sorrento-therapeutics-inc-announces--sclx-20230205monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-that-its-majority-stockholder-sorrento-therapeutics-inc-h-sclx-20230202monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-that-its-majority-stockholder-sorrento-therapeutics-inc-h-sclx-20230130monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-scilex-a-sorrento-company-nearly-100-or-over-99-9-majority-owned-su-sclx-20221031monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-a-sorrento-company-announces-pre-emptive-pay-off-of-remaining-balan-sclx-20220929monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-a-sorrento-company-announces-that-the-fda-has-granted-fast-track-de-sclx-20220831monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-a-sorrento-company-announces-exclusive-product-distribution-agreeme-sclx-20220817monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-a-sorrento-company-has-entered-a-term-sheet-to-acquire-ancora-medic-sclx-20220707monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-a-sorrento-company-announces-that-the-honorable-tommy-g-thompson-ha-sclx-20220705monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-a-sorrento-company-enters-into-an-agreement-for-an-exclusive-licens-sclx-20220614monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-a-sorrento-company-announces-pre-emptive-repurchase-of-41-4-million-sclx-20220603monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-a-sorrento-company-and-vickers-vantage-corp-i-announced-today-the-f-sclx-20220516monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-a-majority-owned-subsidiary-of-sorrento-therapeutics-inc-appoints-h-sclx-20220428monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-a-majority-owned-subsidiary-of-sorrento-therapeutics-inc-announces--sclx-20220425monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-a-majority-owned-subsidiary-of-sorrento-therapeutics-inc-strengthen-sclx-20220413monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-a-majority-owned-subsidiary-of-sorrento-therapeutics-inc-announces--sclx-20220404monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-a-majority-owned-subsidiary-of-sorrento-therapeutics-inc-enters-int-sclx-20220325monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-a-majority-owned-subsidiary-of-sorrento-therapeutics-inc-announces--sclx-20220318monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-a-sorrento-therapeutics-inc-subsidiary-announces-highly-significant-sclx-20211209monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-a-sorrento-therapeutics-inc-subsidiary-and-vickers-vantage-corp-i-n-sclx-20211206monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-a-sorrento-therapeutics-inc-subsidiary-announces-expansion-of-ztlid-sclx-20210819monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-a-sorrento-company-announces-complete-enrollment-on-non-opioid-inje-sclx-20210720monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-a-subsidiary-of-sorrento-therapeutics-announces-continuous-sales-gr-sclx-20201007monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-announces-new-medicaid-agreements-with-ca-fl-sclx-20191001monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-strengthens-board-of-directors-with-appointment-of-two-highly-accom-sclx-20190930monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-procedural-update-on-its-settlement-of-a-previously-disclosed-class-actio-pavm-20220428monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-acquires-esophacap-manufacturer-capnostics-llc-pavm-20211007monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-receives-european-ce-mark-certification-for-its-carpx-minimally-invasive-carpal-tun-pavm-20210525monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-to-hold-business-update-conference-call-on-may-17-2021-pavm-20210503monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-chairman-ceo-lishan-aklog-m-d-named-top-50-healthcare-technology-ceo-by-healthcare--pavm-20210415monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-to-present-at-the-20th-annual-needham-healthcare-conference-pavm-20210408monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-to-participate-in-m-vest-llc-and-maxim-group-llc-inaugural-emerging-growth-virtual--pavm-20210310monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-retires-convertible-debt-pavm-20210303monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-chairman-and-chief-executive-officer-lishan-aklog-m-d-elected-to-advamed-board-of-d-pavm-20210301monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-pricing-of-45-million-public-offering-of-common-stock-pavm-20210223monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-reschedules-business-update-conference-call-on-february-22-2021-to-8-30-am-est-pavm-20210218monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-to-hold-business-update-conference-call-on-february-22-2021-pavm-20210209monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-to-hold-business-update-conference-call-on-november-17-2020-pavm-20201102monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-to-present-at-the-cantor-fitzgerald-virtual-global-healthcare-conference-on-septemb-pavm-20200908monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-secures-7-million-convertible-note-financing-pavm-20200806monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-to-hold-business-update-conference-call-on-august-18-2020-pavm-20200728monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-to-present-at-maxim-group-s-covid-19-webinar-on-july-16-2020-pavm-20200713monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-to-hold-business-update-conference-call-on-may-21-2020-pavm-20200511monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-to-hold-business-update-conference-call-on-april-9-2020-pavm-20200324monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-subsidiary-lucid-diagnostics-announces-commercial-launch-of-esoguard-esophageal-dna-pavm-20191219monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-provides-update-on-carpx-clinical-safety-study-pavm-20191213monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-reports-third-quarter-2019-financial-results-and-provides-business-update-pavm-20191121monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-partners-with-laser-technology-pioneer-dr-jacob-wong-to-develop-and-commercialize-n-pavm-20191114monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-s-portio-intraosseous-infusion-system-achieves-multiple-milestones-pavm-20191107monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-to-hold-business-update-conference-call-on-november-21-2019-pavm-20191106monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-secures-financing-up-to-14-million-for-advancement-of-its-lead-products-to-commerci-pavm-20191105monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-reports-second-quarter-2019-financial-results-and-provides-business-update-pavm-20190905monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-successfully-completes-clinical-safety-study-procedures-for-carpx-510-k-re-submissi-pavm-20190815monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-to-hold-business-update-conference-call-on-september-5-2019-pavm-20190807monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-to-join-russell-microcap-index-pavm-20190626monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-subsidiary-lucid-diagnostics-receives-fda-510-k-clearance-for-esocheck-pavm-20190624monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-reports-first-quarter-2019-financial-results-and-provides-business-update-pavm-20190521monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-first-human-carpx-procedures-pavm-20190520monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-to-hold-business-update-conference-call-on-may-21-2019-pavm-20190506monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-reports-fourth-quarter-2018-financial-results-and-provides-business-update-pavm-20190404monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-to-hold-business-update-conference-call-on-april-4-2019-pavm-20190321monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-nextflo-breakthrough-pavm-20190320monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-portio-breakthrough-pavm-20190313monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-subsidiary-lucid-diagnostics-launches-world-class-medical-advisory-board-and-appoin-pavm-20190228monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-provides-business-update-pavm-20190226monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-subsidiary-lucid-diagnostics-files-510-k-submission-with-fda-for-esocheck-cell-coll-pavm-20181129monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-reports-third-quarter-2018-financial-results-and-provides-business-update-pavm-20181115monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-to-hold-business-update-conference-call-on-november-15-2018-pavm-20181101monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-to-present-at-dawson-james-securities-4th-annual-small-cap-growth-conference-pavm-20181023monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-provides-business-update-pavm-20181017monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-reports-second-quarter-2018-financial-results-and-provides-business-update-pavm-20180814monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-inc-to-hold-second-quarter-financial-results-and-business-update-conference-call-on-pavm-20180809monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-provides-business-update-pavm-20180725monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-inc-nasdaq-pavmu-to-ring-the-nasdaq-stock-market-opening-bell-pavm-20160428monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-to-present-at-2014-jefferies-global-healthcare-conference-aray-20140519monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-signs-three-year-contract-with-novation-aray-20140430monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-financial-results-for-third-quarter-of-fiscal-year-2014-aray-20140430monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-report-financial-results-for-third-quarter-fiscal-2014-aray-20140410monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-participate-in-upcoming-investor-conferences-aray-20140212monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-ceo-gareth-sheridan-discusses-the-us-fentanyl-crisis-and-company-update-on-lates-ntrb-20260422monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-ai-kinesiology-tapes-approved-for-distribution-and-sale-in-costa-rica-ntrb-20260318monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-signs-exclusive-distribution-agreement-with-innomedica-for-aversa-fentanyl-and-a-ntrb-20260217monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-signs-letter-of-intent-with-qvanta-group-of-companies-to-explore-advanced-te-ntrb-20251218monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-differentiates-prescription-fentanyl-from-illicit-fentanyl-in-response-to-united-ntrb-20251218monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-ceo-gareth-sheridan-seeks-nomination-in-upcoming-irish-presidential-election-ntrb-20250811monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-confirms-record-and-pay-date-for-25-preferred-stock-dividend-as-it-targets-filin-ntrb-20250718monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-announces-25-preferred-stock-dividend-as-it-targets-filing-for-fda-approval-ntrb-20250702monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-added-to-the-russell-microcap-index-russell-microcap-growth-index-russell-30-ntrb-20250701monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-and-kindeva-complete-commercial-manufacturing-process-scale-up-for-aversa-fentan-ntrb-20250618monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-announces-u-s-patent-issued-for-its-transdermal-abuse-deterrent-technology-ntrb-20250609monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-to-present-at-the-2025-noble-capital-markets-virtual-equity-conference-ntrb-20250603monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-quarterly-report-highlights-record-revenue-for-q1-2025-up-63-yoy-and-strateg-ntrb-20250602monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-ceo-publishes-letter-to-shareholders-ntrb-20250430monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-granted-patent-in-macao-for-its-aversa-abuse-deterrent-transdermal-technology-ntrb-20250411monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-receives-certificate-of-registration-for-trademark-covering-pharmaceutical-and-p-ntrb-20250221monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-and-kindeva-drug-delivery-formalize-exclusive-development-partnership-for-aversa-ntrb-20250213monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-announces-olympian-anastasia-nichita-to-advisory-board-ntrb-20250211monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-issues-letter-to-shareholders-ntrb-20241231monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-quarterly-report-highlights-record-revenue-for-q3-up-50-94-yoy-and-strategic-ntrb-20241204monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-to-present-at-the-2024-noble-conference-in-boca-raton-on-december-4th-ntrb-20241204monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-receives-hong-kong-patent-notice-of-publication-for-its-aversa-abuse-deterrent-t-ntrb-20241127monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-announces-reverse-stock-split-kala-20260507monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-celebrates-trump-executive-order-as-game-changer-for-psychedelic-medicine-kala-20260421monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-engages-dr-saeid-babaei-as-senior-scientific-advisor-to-evaluate-clinical-assets--kala-20260401monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-launches-a-revolution-for-biotech-first-ai-agent-deploying-in-14-days-as-180-bill-kala-20260311monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-announces-closing-of-10-million-registered-direct-offering-of-common-stock-priced-kala-20251205monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-announces-completion-of-enrollment-in-chase-clinical-trial-evaluating-kpi-012-for-kala-20250709monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-to-present-at-td-cowen-45th-annual-health-care-conference-kala-20250226monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-announces-chief-executive-officer-transition-kala-20250212monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-to-present-at-piper-sandler-36th-annual-healthcare-conference-kala-20241127monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-to-present-at-h-c-wainwright-4th-annual-ophthalmology-virtual-conference-kala-20240808monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-to-present-at-jefferies-global-healthcare-conference-kala-20240529monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-to-present-at-td-cowen-44th-annual-healthcare-conference-kala-20240226monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-to-present-at-oppenheimer-34th-annual-healthcare-life-sciences-conference-kala-20240206monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kala-20240119monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-kala-20230920monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-kala-20230905monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-to-participate-in-upcoming-investor-conferences-in-august-kala-20230802monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-announces-name-change-to-kala-bio-kala-20230802monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-acquires-combangio-expanding-its-pipeline-with-a-clinical-stage-novel-kala-20211115monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-to-present-at-td-cowen-s-7th-annual-oncology-innovation-summit-moln-20260526monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-reports-financial-results-and-highlights-for-q1-2026-with-clinical-stud-moln-20260512monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-presents-three-posters-at-aacr-2026-with-new-preclinical-data-for-first-moln-20260419monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-announces-all-board-proposals-approved-clare-fisher-elected-as-new-boar-moln-20260414monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-presents-new-preclinical-data-highlighting-radio-darpins-amenability-to-moln-20260319monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-to-hold-three-poster-presentations-at-aacr-2026-moln-20260317monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-reports-highlights-and-financial-results-for-full-year-2025-moln-20260312monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-diagnostics-market-outlook-set-to-grow-at-10-cagr-through-2031-as-precision-medi-moln-20260310monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-highlights-clinical-development-progress-and-anticipated-milestones-at--moln-20260111monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-presents-updated-data-from-ongoing-phase-1-2a-trial-of-mp0533-in-aml-at-moln-20251207monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-biosensors-market-analysis-report-2025-rising-demand-for-rapid-accurate-diagnost-moln-20251202monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-diagnostics-collaboration-and-licensing-agreements-trends-analysis-report-2025-w-moln-20251126monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-cloning-market-to-attain-usd-8-89-billion-by-2034-driven-by-expanding-healthcare-moln-20251112monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-diagnostics-for-cancer-markets-forecasts-2025-2030-accelerated-growth-driven-by--moln-20251103monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-spectroscopy-market-to-reach-usd-9-04-billion-by-2034-driven-by-expanding-health-moln-20251028monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-diagnostics-for-cancer-market-research-2025-advances-in-personalized-medicine-an-moln-20250612monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-diagnostics-collaboration-and-licensing-agreements-analysis-report-2025-with-dir-moln-20250523monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-reports-financial-results-and-highlights-from-q1-2025-moln-20250515monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-oncology-diagnostics-market-report-2025-with-regional-growth-forecasts-to-2033-i-moln-20250505monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-presents-new-preclinical-data-on-radio-darpin-and-switch-darpin-program-moln-20250425monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-announces-all-board-proposals-approved-at-annual-general-meeting-moln-20250416monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-diagnostic-for-infectious-diseases-market-size-to-reach-17-61-billion-by-2030-dr-moln-20250404monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025-moln-20250325monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-publishes-invitation-to-annual-general-meeting-2025-moln-20250325monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-reports-highlights-from-q4-2024-and-key-financials-for-full-year-2024-moln-20250306monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-announces-participation-at-upcoming-investor-conferences-and-2024-finan-moln-20250228monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-cytogenetics-market-size-to-expand-usd-6-9-bn-by-2034-moln-20250213monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-cytogenetics-market-outlook-2025-2030-rising-adoption-of-advanced-genomic-techno-moln-20250210monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-and-orano-med-expand-partnership-to-develop-targeted-alpha-radio-therap-moln-20250112monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-outlines-clinical-expansion-plans-and-strengthens-radiopharma-strategic-moln-20250112monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-diagnostics-for-cancer-market-report-2025-cancer-companion-diagnostics-is-reshap-moln-20250106monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-to-present-at-jp-morgan-healthcare-conference-and-baader-helvea-swiss-e-moln-20241217monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-presents-clinical-data-supporting-its-ongoing-mp0533-study-and-preclini-moln-20241208monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-presents-preclinical-proof-of-concept-for-cd3-switch-darpin-t-cell-enga-moln-20241107monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-announces-upcoming-poster-presentations-at-the-65th-ash-annual-meeting--moln-20241105monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-health-technologies-named-supplement-manufacturing-company-of-the-year-by-food-b-moln-20241105monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-q3-2024-interim-management-statement-multiple-updates-across-portfolio--moln-20241031monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-and-orano-med-present-additional-positive-preclinical-data-supporting-d-moln-20241022monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-and-orano-med-strengthen-agreement-to-co-develop-212pb-based-radio-darp-moln-20241022monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-announces-upcoming-poster-presentations-at-the-2024-sitc-annual-meeting-moln-20241004monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-announces-upcoming-top-rated-oral-presentation-on-mp0712-a-pb-labeled-r-moln-20240927monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-reports-h1-2024-corporate-highlights-and-financials-moln-20240826monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-cytogenetics-market-size-envisaged-to-reach-usd-8-8-billion-by-2034-projected-11-moln-20240626monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-to-present-at-the-td-cowen-radiopharmaceutical-innovation-summit-moln-20240617monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-presents-positive-preclinical-data-for-first-switch-darpin-candidate-mp-moln-20240614monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-and-orano-med-share-positive-preclinical-data-of-their-dll3-targeting-r-moln-20240611monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-presents-positive-data-from-completed-phase-1-trial-of-mp0317-fap-x-cd4-moln-20240601monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-diagnostics-collaboration-and-licensing-deals-analysis-report-2024-with-director-moln-20240507monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-announces-publication-in-cancer-immunology-research-of-preclinical-data-moln-20240429monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-announces-all-board-proposals-approved-at-the-annual-general-meeting-moln-20240417monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-templates-announces-9-5-million-private-placement-offering-and-agreement-to-amen-moln-20240328monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-publishes-invitation-to-annual-general-meeting-2024-moln-20240326monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-reports-corporate-highlights-from-q4-2023-and-key-financials-for-full-y-moln-20240314monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-announces-dismissal-of-class-action-lawsuit-moln-20240301monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-to-hold-conference-call-to-discuss-fourth-quarter-and-full-year-2023-re-moln-20240301monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-cloning-kits-market-projected-to-reach-usd-1-250-25-million-by-2030-growing-at-a-moln-20240116monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-provides-updates-at-42nd-annual-j-p-morgan-healthcare-conference-moln-20240107monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-and-orano-med-announce-co-development-agreement-for-radio-darpin-therap-moln-20240105monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-cytogenetics-market-analysis-report-2023-2030-featuring-profiles-of-bioview-dana-moln-20231229monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-to-present-at-42nd-annual-j-p-morgan-healthcare-conference-and-swiss-in-moln-20231214monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-presents-positive-initial-data-from-first-four-dosing-cohorts-of-ongoin-moln-20231210monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-to-present-on-darpin-oncology-innovations-at-protein-antibody-engineeri-moln-20231114monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-presents-updated-positive-data-from-ongoing-phase-1-trial-of-mp0317-fap-moln-20231103monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-to-present-initial-data-from-ongoing-phase-1-2a-trial-of-mp0533-for-pat-moln-20231102monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-to-participate-in-the-td-cowen-7th-annual-fall-oncology-innovation-summ-moln-20231101monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-interim-management-statement-q3-2023-continued-validation-seen-across-t-moln-20231026monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-diagnostic-for-infectious-diseases-market-size-worth-17-61-billion-globally-by-2-moln-20231003monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-presents-new-data-on-its-radio-darpin-therapy-rdt-platform-at-the-eanm--moln-20230913monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-reports-h1-2023-corporate-highlights-and-financials-moln-20230824monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-to-present-on-its-radio-darpin-therapy-rdt-platform-at-snmmi-2023-moln-20230627monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-to-present-at-the-td-cowen-radiopharmaceutical-innovation-summit-moln-20230619monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-diagnostics-market-disease-area-technology-reach-36-17-billion-by-2028-at-12-1-c-moln-20230607monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-to-present-positive-data-from-ongoing-phase-1-trial-of-mp0317-fap-x-cd4-moln-20230525monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-to-participate-in-rbc-capital-2023-global-healthcare-conference-moln-20230516monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-to-present-additional-preclinical-data-supporting-the-company-s-radio-d-moln-20230414monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-announces-shareholders-approve-all-board-proposals-at-the-annual-genera-moln-20230404monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-publishes-invitation-to-annual-general-meeting-2023-moln-20230313monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-reports-corporate-highlights-from-q4-2022-and-key-financials-for-full-y-moln-20230309monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-to-hold-conference-call-to-discuss-fourth-quarter-and-full-year-2022-re-moln-20230302monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-presents-new-preclinical-data-supporting-its-radio-darpin-therapy-platf-moln-20230228monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-to-present-at-svb-leerink-global-healthcare-conference-moln-20230210monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-initiates-clinical-study-of-trispecific-candidate-mp0533-for-the-treatm-moln-20230116monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-you-launches-a-new-preventive-solution-shown-to-improve-health-outcomes-over-100-moln-20230110monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-provides-updates-at-41st-annual-jpm-healthcare-conference-moln-20230108monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-to-present-at-41st-annual-jp-morgan-healthcare-conference-and-swiss-inv-moln-20221230monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-presents-new-preclinical-data-supporting-its-mp0533-darpin-t-cell-engag-moln-20221213monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-presents-positive-interim-safety-and-mechanistic-data-from-ongoing-phas-moln-20221110monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-announces-acceptance-of-oral-presentation-at-the-annual-american-societ-moln-20221103monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-announces-upcoming-participation-in-investor-and-scientific-conferences-moln-20221102monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-announces-planned-departure-of-chief-financial-officer-moln-20221027monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-ag-investors-last-days-to-actively-participate-in-the-class-action-laws-moln-20220907monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-ag-nasdaq-moln-shareholder-class-action-alert-bernstein-liebhard-llp-re-moln-20220906monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-ag-investors-last-days-to-actively-participate-in-the-class-action-laws-moln-20220831monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-ag-nasdaq-moln-shareholder-class-action-alert-bernstein-liebhard-llp-re-moln-20220830monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-ag-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-port-moln-20220823monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-ag-nasdaq-moln-shareholder-class-action-alert-bernstein-liebhard-llp-re-moln-20220822monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-half-year-2022-news-release-and-investor-call-details-moln-20220818monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-ag-nasdaq-moln-shareholder-class-action-alert-bernstein-liebhard-llp-re-moln-20220815monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-ag-nasdaq-moln-shareholder-class-action-alert-bernstein-liebhard-llp-re-moln-20220808monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-ag-nasdaq-moln-shareholder-class-action-alert-bernstein-liebhard-llp-re-moln-20220802monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-th-moln-20220728monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-ag-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-port-moln-20220727monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-ag-nasdaq-moln-shareholder-class-action-alert-bernstein-liebhard-llp-re-moln-20220726monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-transport-medium-market-is-expected-to-progress-at-a-cagr-of-1-2-over-the-foreca-moln-20220725monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-ag-shareholder-update-robbins-llp-reminds-investors-of-lead-plaintiff-d-moln-20220722monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-announces-publication-in-nature-biotechnology-detailing-design-and-mech-moln-20220721monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-th-moln-20220720monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-ag-nasdaq-moln-shareholder-class-action-alert-bernstein-liebhard-llp-re-moln-20220719monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-ag-investors-class-action-lawsuit-filed-on-behalf-of-investors-the-port-moln-20220719monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-ag-nasdaq-moln-shareholder-class-action-alert-bernstein-liebhard-llp-an-moln-20220714monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-announces-participation-in-scientific-conferences-moln-20220610monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-diagnostics-market-to-reach-usd-33-5-billion-by-2030-exclusive-mdc-research-repo-moln-20220526monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-biology-enzymes-kits-and-reagents-market-worth-41-10bn-globally-by-2028-at-17-8--moln-20220526monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-to-participate-in-upcoming-healthcare-investor-conferences-moln-20220511monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-ceo-patrick-amstutz-elected-president-of-the-swiss-biotech-association-moln-20220503monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-adrs-investor-alert-kaplan-fox-investigates-potential-securities-fraud--moln-20220429monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-to-regain-global-rights-for-mp0310-from-amgen-moln-20220426monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-provides-update-on-ensovibep-following-novartis-quarterly-earnings-call-moln-20220426monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-announces-presentation-of-the-empathy-study-of-ensovibep-for-the-treatm-moln-20220423monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-to-present-at-kempen-life-sciences-investor-conference-moln-20220413monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-announces-shareholders-approve-all-board-proposals-at-the-annual-genera-moln-20220413monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-announces-publication-of-preclinical-data-from-cd40-therapeutic-candida-moln-20220324monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-reports-corporate-highlights-from-q4-2021-and-key-financials-for-full-y-moln-20220315monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-to-participate-at-the-rhk-capital-disruptive-growth-conference-on-december--ltrn-20221202monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-s-proprietary-a-i-platform-for-precision-oncology-drug-development-radr-sur-ltrn-20200629monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-announces-two-presentations-at-american-association-for-cancer-research-aac-ltrn-20200617monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-announces-closing-of-initial-public-offering-ltrn-20200615monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-announces-pricing-of-initial-public-offering-ltrn-20200610monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-appoints-david-margrave-as-chief-financial-officer-and-kishor-bhatia-ph-d-a-ltrn-20191217monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-expands-and-strengthens-board-of-directors-with-healthcare-and-pharma-indus-ltrn-20191211monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-ceo-panna-sharma-to-present-participate-in-panel-discussion-at-ai-applicati-ltrn-20191107monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-selects-reprocell-inc-to-provide-preclinical-screening-and-biomarker-discov-ltrn-20191029monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-ceo-panna-sharma-to-speak-at-bio-data-world-west-2019-ltrn-20191007monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-and-national-cancer-institute-partner-to-aid-precision-oncology-research-an-ltrn-20191001monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-ceo-panna-sharma-to-showcase-ai-platform-at-drug-repositioning-repurposing--ltrn-20190918monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nspr-20260612monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-fda-approval-of-investigational-device-exemption-application-for-cguar-nspr-20260501monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-publication-of-the-c-guardians-pivotal-trial-manuscript-in-the-journal-nspr-20260112monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-announce-third-quarter-2025-financial-results-nspr-20251021monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nspr-20250925monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-announce-second-quarter-2025-financial-results-nspr-20250722monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-present-at-upcoming-bank-of-america-2025-healthcare-conference-nspr-20250430monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-announce-first-quarter-2025-financial-results-nspr-20250425monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nspr-20250408monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-present-at-upcoming-24th-annual-needham-virtual-healthcare-conference-nspr-20250326monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-announce-fourth-quarter-and-full-year-2024-financial-results-nspr-20250226monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nspr-20250225monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-and-namsa-to-partner-on-cguardians-ii-pivotal-clinical-trial-of-the-cguard-prime-nspr-20250213monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nspr-20250204monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nspr-20250121monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nspr-20241108monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-third-quarter-2024-financial-results-and-provide-corporate-business-up-nspr-20241104monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-congratulates-crest-2-investigators-on-completion-of-trial-enrollment-nspr-20240805monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-second-quarter-2024-financial-results-and-provide-corporate-business-u-nspr-20240730monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-first-quarter-2024-financial-results-and-provide-corporate-business-up-nspr-20240507monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-present-at-the-23rd-annual-needham-virtual-healthcare-conference-nspr-20240403monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-fourth-quarter-and-full-year-2023-financial-results-and-provide-corpor-nspr-20240228monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-appoints-principal-investigators-for-c-guardians-ii-clinical-trial-of-the-switch-nspr-20240212monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-appointment-of-medical-technology-executive-pete-ligotti-as-executive--nspr-20240103monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-participate-in-upcoming-november-investor-conferences-nspr-20231102monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-third-quarter-2023-financial-results-and-provide-corporate-business-up-nspr-20231030monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-senior-leadership-changes-to-support-commercial-growth-initiatives-nspr-20231003monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-second-quarter-2023-financial-results-and-provide-corporate-business-u-nspr-20230725monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-nspr-20230518monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-may-16-2023-as-new-date-for-first-quarter-2023-results-conference-call-nspr-20230512monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-may-15th-as-new-date-for-first-quarter-2023-financial-results-and-corp-nspr-20230505monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-successful-first-in-human-procedure-utilizing-cguard-prime-its-next-ge-nspr-20230501monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-first-quarter-2023-financial-results-on-may-9-2023-and-provide-corpora-nspr-20230427monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-30-2023-a-nspr-20230302monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-hiring-of-medical-device-commercial-veteran-shane-gleason-as-general-m-nspr-20230214monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-12-days-of-carotid-stenting-video-series-featuring-fireside-chats-with-nspr-20221128monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-multiple-presentations-featuring-cguard-eps-and-its-novel-micronet-mes-nspr-20221115monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-third-quarter-2022-financial-results-on-november-8-2022-and-provide-co-nspr-20221025monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-presentation-at-the-2022-transcatheter-cardiovascular-therapeutics-tct-nspr-20220913monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-second-quarter-2022-financial-results-on-august-9-2022-and-provide-cor-nspr-20220802monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-appointment-of-endovascular-pioneer-dr-juan-parodi-as-strategic-adviso-nspr-20220714monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-provides-highlights-from-recent-presentations-and-live-case-transmission-at-linc-nspr-20220609monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-s-cguard-embolic-prevention-stent-system-to-be-featured-in-clinical-presentation-nspr-20220602monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-first-quarter-2022-financial-results-on-may-10-2022-and-provide-corpor-nspr-20220428monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-host-key-opinion-leader-event-on-carotid-artery-disease-management-and-stroke-nspr-20220316monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-fourth-quarter-and-full-year-2021-financial-results-on-march-8-2022-an-nspr-20220222monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-adnan-siddiqui-md-phd-as-a-member-of-its-scientific-advisory-board-and-nspr-20220215monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-present-at-the-16th-biennial-scientific-meeting-of-the-international-andreas--nspr-20220127monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-live-case-broadcast-at-iset-2022-conference-following-the-supplement-a-nspr-20220118monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-third-quarter-2021-financial-results-on-november-9-2021-and-provide-co-nspr-20211026monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-second-quarter-2021-financial-results-on-tuesday-august-10-2021-and-pr-nspr-20210804monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-present-at-the-ld-micro-virtual-invitational-conference-on-june-9-2021-nspr-20210602monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-commences-trading-on-nasdaq-cm-nspr-20210521monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-participate-at-the-investor-summit-conference-and-present-to-investors-on-may-nspr-20210514monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-participate-at-the-benzinga-global-small-cap-conference-and-present-to-invest-nspr-20210506monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-first-quarter-2021-financial-results-on-tuesday-may-11-2021-and-provid-nspr-20210504monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-appoints-acclaimed-interventional-cardiologist-kenneth-rosenfield-md-as-chair-of-nspr-20210429monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-1-for-15-reverse-stock-split-nspr-20210414monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-ceo-marvin-slosman-issues-letter-to-fellow-stockholders-urging-support-of-the-co-nspr-20210322monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-fourth-quarter-and-year-end-2020-financial-results-nspr-20210309monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-fourth-quarter-and-year-end-2020-financial-results-on-tuesday-march-9--nspr-20210302monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-engages-hart-clinical-consultants-to-conduct-clinical-trial-for-cguard-carotid-s-nspr-20210224monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-appoints-leading-interventional-cardiologist-chris-metzger-m-d-as-principal-inve-nspr-20210209monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-closing-of-an-upsized-20-7-million-underwritten-public-offering-and-fu-nspr-20210208monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-secures-partner-for-intended-registration-and-distribution-of-cguard-eps-in-main-nspr-20210203monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-s-cguard-featured-in-multiple-presentations-including-a-live-case-demonstration--nspr-20210126monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-third-quarter-2020-financial-results-on-monday-november-9-2020-and-pro-nspr-20201102monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-christina-brennan-m-d-mba-to-serve-in-advisory-role-for-pivotal-study--nspr-20200910monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-present-at-the-ld-micro-500-virtual-conference-on-september-3-2020-nspr-20200825monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-second-quarter-2020-financial-results-on-wednesday-august-5-2020-and-p-nspr-20200728monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-inc-announces-underwriter-exercise-of-over-allotment-option-in-full-and-closing--nspr-20200608monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-first-quarter-2020-financial-results-and-provide-business-update-on-tu-nspr-20200505monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-fourth-quarter-2019-financial-results-and-provide-business-update-on-t-nspr-20200303monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-planned-leadership-transition-nspr-20191210monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-third-quarter-2019-financial-results-and-provide-business-update-on-tu-nspr-20191105monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-provides-business-update-nspr-20190909monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-present-at-the-hc-wainwright-21st-annual-global-investment-conference-nspr-20190909monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-second-quarter-2019-financial-results-and-provide-business-update-on-t-nspr-20190730monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-first-quarter-2019-financial-results-and-provide-business-update-on-tu-nspr-20190507monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-inc-announces-pricing-of-2-4-million-public-offering-of-common-stock-nspr-20190404monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-1-for-50-reverse-stock-split-nspr-20190326monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-provides-amended-disclosure-nspr-20190322monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-presentation-of-interim-data-from-investigator-initiated-study-compari-nspr-20190124monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-results-from-initial-clinical-study-of-the-cguard-embolic-prevention-s-nspr-20190122monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-third-quarter-2018-financial-results-and-provide-business-update-on-tu-nspr-20181030monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-presentation-of-preliminary-cumulative-three-year-cguard-eps-safety-an-nspr-20180927monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-present-at-the-h-c-wainwright-20th-annual-global-investment-conference-in-new-nspr-20180904monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-schedules-second-quarter-2018-earnings-conference-call-nspr-20180731monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-s-cguard-eps-featured-at-the-sbhci-congress-in-brazil-nspr-20180620monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-on-expanded-2-year-follow-up-results-from-the-paradigm-clinical-study-us-nspr-20180530monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-schedules-first-quarter-2018-earnings-conference-call-nspr-20180501monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremds-cguard-embolic-prevention-system-to-be-featured-at-icca-stroke-2018-in-warsaw-p-nspr-20180419monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-inc-announces-pricing-of-5-0-million-public-offering-of-common-stock-nspr-20180328monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-exclusive-distribution-sales-and-marketing-agreement-for-cguard-eps-in-nspr-20180222monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-1-for-35-reverse-stock-split-nspr-20180207monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-projects-211-increase-in-cguard-tm-eps-sales-for-the-fourth-quarter-of-2017-nspr-20180110monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-s-cguard-eps-demonstrates-improved-outcomes-over-carotid-endarterectomy-in-50-pa-nspr-20171207monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-planned-recapitalization-nspr-20171129monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-schedules-third-quarter-2017-earnings-conference-call-nspr-20171101monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-s-cguard-tm-carotid-embolic-prevention-system-featured-in-live-case-at-cracow-va-nspr-20171025monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-distribution-agreement-for-mguard-prime-tm-in-chile-nspr-20171012monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-present-at-the-19th-annual-rodman-renshaw-global-investment-conference-in-new-nspr-20170906monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-notification-of-nyse-american-listing-deficiency-and-expectation-to-re-nspr-20170822monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-schedules-second-quarter-2017-earnings-conference-call-nspr-20170802monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-present-at-the-2017-marcum-microcap-conference-nspr-20170609monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-change-in-presentation-time-at-ld-micro-main-event-conference-to-tuesd-nspr-20161205monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-present-at-ld-micro-main-event-on-december-6-nspr-20161128monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-cguard-tm-embolic-prevention-system-commercialization-approval-in-russ-nspr-20161114monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-third-quarter-financial-results-on-monday-november-14-2016-nspr-20161107monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-cguard-tm-embolic-prevention-system-12-month-clinical-trial-data-further-validat-nspr-20161101monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-present-at-the-dawson-james-securities-2nd-annual-growth-stock-conference-on--nspr-20161013monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-1-for-25-reverse-stock-split-nspr-20160928monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-second-quarter-financial-results-on-tuesday-august-9-2016-nspr-20160802monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-listing-of-warrants-on-the-nyse-mkt-nspr-20160801monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-late-breaking-trial-presentation-on-cguard-tm-embolic-prevention-syste-nspr-20160505monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-receives-audit-opinion-with-going-concern-explanation-nspr-20160331monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-financial-results-for-the-fourth-quarter-and-year-ended-december-31-2015-nspr-20160328monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-closing-of-private-placement-to-certain-officers-and-directors-nspr-20160321monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-closing-of-public-offering-nspr-20160321monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-private-placement-to-certain-officers-and-directors-nspr-20160316monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-pricing-of-public-offering-nspr-20160316monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-proposed-public-offering-of-common-stock-and-warrants-nspr-20160315monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-financial-results-for-the-third-quarter-ended-september-30-2015-on-tue-nspr-20151102monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-cguardtm-approval-in-argentina-nspr-20151019monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-present-at-dawson-james-securities-growth-stock-conference-nspr-20151008monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-cguard-tm-approval-in-columbia-nspr-20151005monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-full-market-launch-of-cguard-tm-distributed-by-penumbra-at-cirse-annua-nspr-20150928monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-the-issuance-of-two-united-states-patents-nspr-20150917monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-allowance-of-us-patent-claims-nspr-20150909monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-ceo-shaun-bagai-to-present-at-the-iaccess-alpha-virtual-best-ideas-summer-investm-rnxt-20260604monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-announces-promising-pharmacokinetic-data-using-the-tamp-platform-presented-at-the-rnxt-20260526monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-t-rnxt-20260423monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-secures-first-notice-of-allowance-for-japanese-patent-covering-its-renovocath-dev-rnxt-20260408monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-named-to-fast-company-s-annual-list-of-the-world-s-most-innovative-companies-of-2-rnxt-20260401monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-initiates-patient-enrollment-at-scri-oncology-partners-for-ongoing-pivotal-phase--rnxt-20241211monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-ceo-to-host-investor-fireside-chat-on-tuesday-december-17th-at-4-30-p-m-et-rnxt-20241210monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-receives-first-purchase-orders-for-its-fda-cleared-renovocath-delivery-system-rnxt-20241205monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-announces-presentation-at-symposium-on-clinical-interventional-oncology-highlight-rnxt-20240919monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-ceo-shaun-bagai-to-present-at-h-c-wainwright-s-26th-annual-global-investment-conf-rnxt-20240827monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-announces-first-patient-enrolled-at-university-of-nebraska-medical-center-for-the-rnxt-20240814monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-announces-publication-of-positive-early-stage-clinical-data-in-international-peer-rnxt-20240731monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-announces-acceptance-for-publication-in-the-international-peer-reviewed-journal-t-rnxt-20240708monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-appoints-ryan-witt-as-senior-vice-president-head-of-corporate-strategy-and-partne-rnxt-20240610monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-and-parexel-biotech-reach-key-milestone-in-clinical-trial-for-locally-advanced-pa-rnxt-20200113monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-announces-formation-of-a-healthcare-services-initiative-tvgn-20260609monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-advances-strategic-acquisition-initiatives-with-potential-to-support-approximately-tvgn-20260528monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-signs-letter-of-intent-to-evaluate-potential-acquisition-of-a-management-services--tvgn-20260521monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-announces-3-million-private-investment-at-8-per-share-a-14-premium-from-latest-mar-tvgn-20260512monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-regains-compliance-with-nasdaq-minimum-bid-price-requirement-tvgn-20260325monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-cio-and-head-of-tevogen-ai-mittul-mehta-to-speak-at-microsoft-fabric-community-con-tvgn-20260318monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-reaffirms-capital-discipline-as-lead-investor-maintains-holdings-and-company-limit-tvgn-20260313monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ai-reports-advancements-in-predictcell-beta-demonstrates-improved-precision-metric-tvgn-20260313monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ceo-dr-ryan-saadi-reaffirms-clinical-commitment-during-international-long-covid-aw-tvgn-20260311monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-advances-generics-strategy-signs-letter-of-intent-to-evaluate-potential-acquisitio-tvgn-20260305monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-to-align-long-term-stock-based-incentive-program-with-company-milestones-including-tvgn-20260129monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ceo-donates-shares-to-support-education-for-underprivileged-children-tvgn-20251222monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-shares-valuation-of-key-assets-and-potential-forecast-for-pipeline-product-focused-tvgn-20250904monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-underscores-the-importance-of-precision-immunotherapies-including-tvgn-489-for-vul-tvgn-20250903monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-highlights-proprietary-assets-and-upcoming-valuation-disclosure-tvgn-20250827monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-expresses-gratitude-to-yale-for-recognition-of-dr-ryan-saadi-and-company-s-mission-tvgn-20250826monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-sees-continued-growth-in-institutional-ownership-in-q2-2025-72-of-holders-increase-tvgn-20250825monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-recognized-in-binje-s-best-health-care-2025-for-advancing-health-equity-and-sustai-tvgn-20250822monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-delivers-stronger-second-quarter-and-first-half-2025-financial-results-with-reduce-tvgn-20250819monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ceo-donates-personal-shares-to-support-local-law-enforcement-tvgn-20250818monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ceo-donates-personal-shares-to-support-brain-injury-recovery-tvgn-20250818monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-to-release-internal-asset-valuation-ceo-affirms-assets-are-fully-protected-tvgn-20250814monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-reaffirms-investor-confidence-with-estimated-asset-value-exceeding-10-billion-tvgn-20250811monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-oncology-reports-top-line-revenue-forecast-of-1-billion-in-launch-year-and-cum-tvgn-20250811monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-tvgn-20250807monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-sees-significant-institutional-ownership-growth-73-of-holders-increase-positions-tvgn-20250806monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ai-expands-collaboration-with-databricks-and-microsoft-to-build-the-beta-version-o-tvgn-20250805monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ceo-affirms-strong-growth-capital-position-and-ai-expansion-in-letter-to-stockhold-tvgn-20250801monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-to-accept-1-million-additional-grant-funding-for-ai-expansion-tvgn-20250801monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-highlights-74-insider-ownership-reinforcing-long-term-vision-tvgn-20250730monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ai-applauds-u-s-government-s-ai-action-plan-reaffirms-commitment-to-accelerating-a-tvgn-20250728monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ai-receives-international-patent-publication-for-ai-technology-predicting-immunolo-tvgn-20250718monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-signs-letter-of-intent-for-new-in-house-cell-therapy-manufacturing-facility-tvgn-20250717monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ai-targets-faster-time-to-market-with-ai-powered-patient-matching-following-predic-tvgn-20250716monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ai-builds-alpha-version-of-predictcell-model-with-microsoft-and-databricks-observe-tvgn-20250714monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-s-new-headquarters-fully-funded-by-ceo-centralizes-r-d-and-ai-teams-to-accelerate--tvgn-20250710monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ceo-contributes-to-build-out-and-first-year-operations-of-new-headquarters-tvgn-20250630monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-updates-on-development-of-ebv-specific-t-cell-therapy-with-support-from-ai-powered-tvgn-20250618monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-expands-headquarters-amid-growth-of-ai-and-generics-biosimilars-initiatives-tvgn-20250609monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-details-its-artificial-intelligence-initiative-tevogen-ai-proprietary-ai-powered-i-tvgn-20250530monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-plans-to-expand-specialty-care-pipeline-to-include-patients-65-building-on-pre-tvgn-20250523monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-to-update-on-robust-portfolio-assets-business-expansion-partnerships-limited-trada-tvgn-20250522monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-s-business-model-addresses-biopharma-industry-challenges-with-cost-efficient-i-tvgn-20250512monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-to-share-direct-registration-system-drs-process-details-following-increased-shareh-tvgn-20250502monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-informs-public-shareholders-about-drs-accounts-and-differences-to-brokerage-accoun-tvgn-20250429monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ceo-to-join-dialogue-on-paths-to-liquidity-strategies-for-adapting-to-a-volatile-m-tvgn-20250429monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-reaffirms-oncology-top-line-revenue-forecast-of-1-billion-in-launch-year-and-cumul-tvgn-20250428monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-announces-2025-annual-meeting-tvgn-20250425monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-commissions-databricks-to-accelerate-development-of-predictcell-a-precision-ai-tvgn-20250415monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ceo-to-join-dialogue-on-paths-to-liquidity-strategies-for-adapting-to-a-volatile-m-tvgn-20250414monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-announces-tevogen-generics-a-new-effort-in-support-of-president-trump-s-initiative-tvgn-20250409monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-cio-and-head-of-tevogen-ai-presented-at-ai-x-bio-philly-event-showcasing-phill-tvgn-20250408monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-highlights-most-recent-insider-ownership-of-74-management-maintains-conviction-tvgn-20250407monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-ceo-named-to-njbiz-2025-health-care-power-list-as-company-advances-commerciali-tvgn-20250326monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-tvgn-20250325monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-announces-unique-t-cell-vaccine-under-development-and-files-patent-with-the-us-tvgn-20250310monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-s-cio-head-of-tevogen-ai-mittul-mehta-featured-speaker-at-proskauer-s-ai-discu-tvgn-20250307monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-to-receive-8-million-of-non-dilutive-grant-funding-reiterates-efficient-operat-tvgn-20250303monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-founder-and-ceo-dr-ryan-saadi-named-to-2025-njbiz-power-100-celebrating-innova-tvgn-20250228monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-s-first-trading-year-efficiency-600-higher-market-cap-per-team-member-79-insid-tvgn-20250221monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-ceo-reinforces-commitment-to-retention-of-equity-capital-and-long-term-vision-tvgn-20250214monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-shares-2024-financing-activity-on-one-year-anniversary-of-becoming-a-publicly--tvgn-20250214monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-ceo-addresses-short-selling-and-its-potential-impact-on-the-nation-s-health-an-tvgn-20250214monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-ceo-congratulates-rfk-jr-on-his-confirmation-as-secretary-of-the-hhs-echoes-co-tvgn-20250213monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-s-business-model-addresses-biopharma-industry-challenges-with-cost-efficient-i-tvgn-20250210monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technology-s-potential-as-a--tvgn-20250207monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-ceo-congratulates-lynne-patton-on-being-appointed-deputy-assistant-to-the-pres-tvgn-20250127monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-broadens-relationship-with-microsoft-to-deepen-artificial-intelligence-collabo-tvgn-20250124monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-highlights-the-future-of-ai-driven-drug-development-in-fireside-chat-with-micr-tvgn-20250124monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-to-host-panel-discussions-ai-in-biopharma-next-frontier-of-medical-innovation--tvgn-20241226monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-to-host-panel-ai-in-biopharma-next-frontier-of-medical-innovation-during-the-4-tvgn-20241223monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-strengthens-robust-ip-portfolio-with-filing-of-predictive-ai-patent-with-the-g-tvgn-20241219monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-to-host-panel-pioneering-the-economics-of-health-balancing-access-and-outcomes-tvgn-20241217monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-to-attend-the-43rd-annual-j-p-morgan-healthcare-conference-tvgn-20241210monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-prepares-organizational-readiness-to-support-company-s-growth-strategy-tvgn-20241126monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-ceo-reflects-on-public-support-reaffirms-preserving-shareholder-value-remains--tvgn-20241121monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-reports-third-quarter-2024-financial-results-highlights-significantly-improved-tvgn-20241119monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-founder-reflects-on-importance-of-preserving-shareholder-value-while-navigating-gr-tvgn-20241114monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-nears-finalization-of-agreement-to-enhance-r-d-and-manufacturing-capabilities--tvgn-20241108monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-ceo-dr-ryan-saadi-expresses-gratitude-for-prestigious-roi-nj-recognition-highl-tvgn-20241105monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-leverages-microsoft-partnership-to-deliver-machine-learning-based-target-ident-tvgn-20241105monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-announces-appointment-of-anthony-tarantino-as-patient-advocate-to-enhance-comm-tvgn-20241104monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-expands-on-microsoft-partnership-to-integrate-machine-learning-and-ai-into-pre-tvgn-20241031monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-reports-nasdaq-listing-compliance-as-ceo-reaffirms-his-commitment-in-bridging--tvgn-20241029monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-signs-letter-of-intent-with-cd8-technology-to-build-up-to-a-50-million-r-d-and-tvgn-20241029monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-provides-additional-guidance-on-introduction-of-t-cell-therapy-for-oncology-an-tvgn-20241025monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-s-effort-in-artificial-intelligence-tevogen-ai-joins-microsoft-for-startups-be-tvgn-20241023monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-to-provide-timelines-associated-with-recently-announced-revenue-forecast-and-u-tvgn-20241022monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-specialty-care-reports-top-line-revenue-forecast-of-nearly-1-billion-in-launch-tvgn-20241021monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-provides-clarity-on-cso-share-sales-to-satisfy-tax-obligations-expects-additio-tvgn-20241021monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ceo-expresses-gratitude-for-unprecedented-public-support-of-company-s-business-mod-tvgn-20241019monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-oncology-reports-top-line-revenue-forecast-of-1-billion-in-launch-year-and-cum-tvgn-20241017monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-investors-congratulate-on-prestigious-recognition-of-pioneering-biopharma-business-tvgn-20241017monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-thanks-warren-township-for-proclamation-honoring-ceo-dr-ryan-saadi-nobel-peace-tvgn-20241016monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-takes-lead-in-developing-cell-therapies-designed-to-eradicate-post-procedure-h-tvgn-20241015monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-highlights-the-publication-of-promising-trial-data-as-the-ceo-expresses-optimi-tvgn-20241015monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ceo-reaffirms-the-company-s-commitment-to-closing-the-information-gap-on-its-multi-tvgn-20241014monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-plans-to-share-1b-revenue-potential-of-its-pipeline-portfolio-beginning-week-o-tvgn-20241011monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-extends-pipeline-prioritizing-oncology-and-long-covid-tvgn-20241011monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-highlights-promising-trial-data-as-ceo-leads-patient-advocacy-at-capitol-hill--tvgn-20241008monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-leadership-meets-members-of-u-s-congress-to-advocate-for-long-covid-patients-a-tvgn-20240924monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-secures-6-million-series-c-preferred-stock-investment-tvgn-20240822monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-reports-second-quarter-2024-financial-results-eliminates-doubt-about-company-s-tvgn-20240815monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-s-innovation-and-public-health-advisory-board-chairperson-professor-sten-vermu-tvgn-20240814monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-s-founding-ceo-ryan-saadi-expresses-conviction-in-company-s-growth-strategy-an-tvgn-20240809monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-issues-letter-to-stockholders-highlighting-recent-achievements-growth-plans-an-tvgn-20240711monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-s-r-d-leadership-discusses-the-promise-of-its-genetically-unmodified-off-the-s-tvgn-20240710monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-files-registration-statement-for-previously-disclosed-securities-does-not-rela-tvgn-20240626monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-announces-publication-of-positive-phase-i-clinical-trial-results-for-tvgn-489--tvgn-20240625monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ai-head-discusses-company-s-bold-strategy-to-shape-the-future-of-t-cell-therapies--tvgn-20240618monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-set-to-join-russell-3000-index-tvgn-20240612monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-enters-into-agreement-for-up-to-50-million-in-financing-to-advance-r-d-and-cli-tvgn-20240611monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-expresses-gratitude-to-patients-first-responders-elected-officials-and-members-tvgn-20240606monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-confirms-ongoing-efficacy-of-tvgn-489-its-investigational-allogeneic-off-the-s-tvgn-20240606monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-reports-first-quarter-2024-financial-results-tvgn-20240529monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-appoints-former-police-chief-fbi-national-academy-graduate-william-keane-as-vi-tvgn-20240516monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-announces-up-to-50-million-in-financing-to-further-advance-operational-objecti-tvgn-20240510monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-announces-full-year-2023-financial-results-and-upcoming-operational-objectives-tvgn-20240501monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-s-chief-scientific-officer-speaks-on-the-harnessing-of-cytotoxic-t-lymphocytes-tvgn-20240411monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-appoints-tapan-v-shah-as-head-of-investor-relations-and-corporate-development-tvgn-20240403monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-reports-series-a-1-preferred-stock-investment-at-10-conversion-price-tvgn-20240328monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-announces-series-a-1-preferred-stock-investment-tvgn-20240327monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-holdings-inc-a-cell-therapy-company-announces-completion-of-business-combinati-tvgn-20240214monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-lawsuit-deadline-today-bragar-eagel-squire-p-c-urges-mereo-biopharma-stockholders-wi-mreo-20260406monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-lawsuit-deadline-alert-bragar-eagel-squire-p-c-urges-mereo-biopharma-stockholders-wi-mreo-20260325monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-group-plc-class-action-the-gross-law-firm-reminds-mereo-investors-of-the-p-mreo-20260306monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-group-plc-class-action-the-gross-law-firm-reminds-mereo-investors-of-the-p-mreo-20260226monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-group-plc-sued-for-securities-law-violations-investors-should-contact-the--mreo-20260218monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-lawsuit-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-mreo-20260205monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-provides-corporate-update-mreo-20260112monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-participate-in-fireside-chat-at-the-jefferies-london-healthcare-confere-mreo-20241114monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-participate-in-fireside-chat-at-the-2024-cantor-global-healthcare-confe-mreo-20240912monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-participate-in-fireside-chat-at-the-jefferies-global-healthcare-confere-mreo-20240530monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-participate-in-fireside-chat-at-the-23rd-annual-needham-virtual-healthc-mreo-20240403monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-participate-in-fireside-chat-at-the-leerink-partners-global-biopharma-c-mreo-20240305monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-participate-in-fireside-chat-at-the-2023-cantor-global-healthcare-confe-mreo-20230921monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-reports-interim-financial-results-for-the-six-months-ended-june-30-2023-an-mreo-20230907monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-present-at-the-jefferies-healthcare-conference-mreo-20230531monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-participate-in-fireside-chat-at-the-22nd-annual-needham-healthcare-conf-mreo-20230413monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-participate-in-fireside-chat-at-the-svb-securities-global-biopharma-con-mreo-20230208monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-participate-in-fireside-chat-at-the-jefferies-london-healthcare-confere-mreo-20221108monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-host-alvelestat-r-d-update-call-on-october-31-2022-mreo-20221024monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-received-notification-of-nasdaq-minimum-bid-price-deficiency-mreo-20220526monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-host-conference-call-highlighting-top-line-clinical-data-from-astraeus--mreo-20220506monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-participate-in-fireside-chat-at-the-21st-annual-needham-virtual-healthc-mreo-20220406monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-hold-virtual-r-d-day-on-monday-march-14-2022-mreo-20220303monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-participate-in-fireside-chat-at-the-11th-annual-svb-leerink-global-heal-mreo-20220210monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-present-at-two-upcoming-investor-conferences-mreo-20211109monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-the-osteogenesis-imperfecta-federation-europe-oife-and-the-osteogenesis-im-mreo-20211013monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences-mreo-20210909monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-participate-in-a-fireside-chat-at-the-btig-virtual-biotechnology-confer-mreo-20210802monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-participate-in-a-fireside-chat-at-the-jefferies-2021-virtual-healthcare-mreo-20210527monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-hold-virtual-r-d-day-on-thursday-may-13-2021-mreo-20210504monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-present-at-the-20th-annual-needham-virtual-healthcare-conference-mreo-20210408monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-participate-in-a-fireside-chat-at-the-10th-annual-svb-leerink-global-he-mreo-20210218monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-group-plc-announces-pricing-of-public-offering-of-american-depositary-shar-mreo-20210210monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-and-ultragenyx-announce-collaboration-and-license-agreement-for-setrusumab-mreo-20201217monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-appoints-suba-krishnan-m-d-as-senior-vice-president-of-clinical-developmen-mreo-20201123monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-present-at-the-stifel-2020-virtual-healthcare-conference-mreo-20201110monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-announces-fda-clearance-to-proceed-into-a-phase-1b-2-study-for-etigilimab--mreo-20201019monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-receives-fda-rare-pediatric-disease-designation-for-setrusumab-for-the-tre-mreo-20200924monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-announce-interim-financial-results-for-the-six-months-ended-june-30-202-mreo-20200916monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-announces-initiation-of-placebo-controlled-phase-1b-2-clinical-trial-with--mreo-20200825monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-strengthens-management-team-appoints-john-lewicki-phd-as-chief-scientific--mreo-20200630monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-announces-financial-results-for-the-year-ended-december-31-2019-mreo-20200616monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-announces-completion-of-70-million-private-placement-mreo-20200604monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-announces-positive-feedback-from-type-b-end-of-phase-2-meeting-with-the-fd-mreo-20200228monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-announces-equity-investment-of-3-million-from-new-u-s-institutional-invest-mreo-20200219monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-enters-into-a-5-million-convertible-equity-financing-with-novartis-and-ann-mreo-20200210monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-announces-additional-positive-data-from-phase-2b-asteroid-study-of-setrusu-mreo-20200114monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-and-oncologie-enter-into-global-licensing-agreement-for-navicixizumab-mreo-20200113monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-s-setrusumab-demonstrates-dose-dependent-bone-building-and-trend-in-fractu-mreo-20191111monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-announce-interim-financial-results-for-the-six-months-ended-june-30-201-mreo-20190910monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-announces-setrusumab-6-month-phase-2b-data-in-osteogenesis-imperfecta-sele-mreo-20190904monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-appoints-richard-francis-as-head-of-pharmaceutical-development-mreo-20190716monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-announces-successful-type-b-meeting-with-u-s-fda-and-outlines-accelerated--mreo-20190715monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-group-plc-mereo-or-the-company-or-the-group-update-on-etigilimab-tigit-par-mreo-20190613monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-group-plc-announces-positive-early-6-month-data-from-the-open-label-arm-of-mreo-20190530monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-group-plc-mereo-or-the-company-or-the-group-intention-to-purchase-shares-b-mreo-20190503monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-group-plc-mereo-or-the-company-or-the-group-preliminary-results-for-the-ye-mreo-20190429monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-announce-preliminary-results-for-the-full-year-2018-and-host-conference-mreo-20190426monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-group-plc-mereo-or-the-company-or-the-group-admission-to-trading-on-aim-of-mreo-20190424monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-group-plc-mereo-or-the-company-or-the-group-merger-update-acquisition-of-o-mreo-20190418monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-present-at-the-cowen-and-company-39th-annual-healthcare-conference-on-t-mreo-20190305monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-publicly-files-registration-statement-on-form-f-4-with-u-s-securities-and-exchange-c-mreo-20190125monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-present-at-the-bmo-prescriptions-for-success-healthcare-conference-on-1-mreo-20181210monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20260507monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-strategic-board-refreshment-with-four-highly-experienced-commerical-lea-tela-20260430monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-announce-fourth-quarter-and-full-year-2025-financial-results-tela-20260310monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20260220monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20260123monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20251212monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-pricing-of-13-0-million-underwritten-registered-direct-offering-of-comm-tela-20251113monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-announce-second-quarter-2025-financial-results-tela-20250721monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tela-20250606monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-the-2025-jefferies-global-healthcare-conference-tela-20250522monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20250509monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-announce-first-quarter-2025-financial-results-tela-20250417monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-reports-fourth-quarter-and-full-year-2024-financial-results-tela-20250320monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-announce-fourth-quarter-and-full-year-2024-financial-results-tela-20250227monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20250221monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20250124monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20241213monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-piper-sandler-s-36th-annual-healthcare-conference-tela-20241119monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20241101monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-closing-of-public-offering-of-common-stock-and-pre-funded-warrants-and--tela-20241024monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-pricing-of-public-offering-of-common-stock-and-pre-funded-warrants-tela-20241023monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-tela-20241022monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-announce-third-quarter-2024-financial-results-tela-20241017monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20240809monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-the-canaccord-genuity-44th-annual-growth-conference-tela-20240725monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-announce-second-quarter-2024-financial-results-tela-20240722monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20240510monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-announce-first-quarter-2024-financial-results-tela-20240425monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-welcomes-acclaimed-surgeon-as-vice-president-of-medical-affairs-and-surgeon-strat-tela-20240408monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-u-s-commercial-launch-of-liquifix-the-only-fda-approved-liquid-adhesive-tela-20240321monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-announce-fourth-quarter-and-full-year-2023-financial-results-tela-20240229monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20240223monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20240119monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20231215monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-take-part-in-connecting-the-dots-tela-20231205monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-piper-sandler-s-35th-annual-healthcare-conference-tela-20231116monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20231110monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-announce-third-quarter-2023-financial-results-tela-20231026monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-the-gilmartin-group-emerging-growth-company-showcase-tela-20230918monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20230804monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-announce-second-quarter-2023-financial-results-and-confirms-participation-in-t-tela-20230726monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-the-jefferies-global-healthcare-conference-tela-20230525monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-invests-in-surgeon-training-and-education-with-upcoming-cadaver-lab-tela-20230519monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-supports-diversity-and-inclusion-at-international-hernia-collaboration-conference-tela-20230509monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20230508monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-the-jmp-securities-life-sciences-conference-tela-20230502monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-announce-first-quarter-2023-financial-results-tela-20230427monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-pricing-of-public-offering-of-common-stock-tela-20230419monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-proposed-public-offering-of-common-stock-tela-20230418monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-s-ovitex-reinforced-tissue-matrix-to-be-featured-in-three-case-reports-at-sages-2-tela-20230329monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-highlights-published-clinical-research-from-2022-showcasing-safety-and-performanc-tela-20230316monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-announce-fourth-quarter-and-full-year-2022-financial-results-tela-20230228monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20230224monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-awarded-biosynthetic-mesh-products-agreement-with-a-national-group-purchasing-org-tela-20230214monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20230120monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-the-41st-annual-j-p-morgan-healthcare-conference-tela-20221221monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20221209monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-piper-sandler-34th-annual-healthcare-conference-tela-20221121monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-canaccord-medtech-diagnostics-and-digital-health-services-forum-tela-20221103monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20221028monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-announce-third-quarter-2022-financial-results-tela-20221027monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-upcoming-investor-conferences-tela-20220901monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-inaugural-gilmartin-group-emerging-growth-company-showcase-tela-20220823monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwr-tela-20220818monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-pricing-of-public-offering-of-common-stock-tela-20220816monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-proposed-public-offering-of-common-stock-tela-20220815monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-upcoming-investor-conferences-tela-20220805monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-highlights-results-from-bravo-and-rebar-studies-on-the-benefits-of-ovitex-reinfor-tela-20220804monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20220729monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-announce-second-quarter-2022-financial-results-tela-20220727monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-awarded-synthetic-bioabsorbable-mesh-products-agreement-with-premier-inc-tela-20220720monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-upcoming-jmp-securities-life-sciences-conference-tela-20220602monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-secures-up-to-50-million-in-debt-financing-from-midcap-financial-tela-20220531monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-upcoming-jefferies-healthcare-conference-tela-20220526monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-upcoming-2022-h-c-wainwright-annual-global-investment-conferenc-tela-20220509monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20220429monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-announce-first-quarter-2022-financial-results-tela-20220426monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-appoints-d-taylor-ocasio-as-general-counsel-tela-20220418monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-upcoming-needham-co-21st-annual-healthcare-virtual-conference-tela-20220330monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-upcoming-canaccord-genuity-musculoskeletal-conference-in-chicag-tela-20220316monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-announce-fourth-quarter-and-full-year-2021-financial-results-tela-20220307monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tela-20220225monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-three-upcoming-conferences-tela-20211108monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-announce-third-quarter-2021-financial-results-tela-20211027monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-appoints-roberto-cuca-as-chief-operating-officer-and-chief-financial-officer-tela-20210927monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-new-data-on-use-of-ovitex-in-a-range-of-hernia-repair-applications-incl-tela-20210913monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-s-ovitex-reinforced-tissue-matrix-to-be-featured-in-three-presentations-at-sages--tela-20210816monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-canaccord-genuity-s-41st-annual-growth-conference-tela-20210803monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-announce-second-quarter-2021-financial-results-tela-20210728monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-upcoming-jmp-securities-life-sciences-conference-tela-20210614monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-changes-to-its-board-of-directors-tela-20210602monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-names-marissa-conrad-as-vice-president-of-clinical-and-regulatory-affairs-tela-20210525monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-upcoming-investor-conferences-tela-20210521monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-announce-first-quarter-2021-financial-results-tela-20210429monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-12-month-analysis-from-bravo-study-of-ovitex-for-ventral-hernia-repair-tela-20210318monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-report-fourth-quarter-and-full-year-2020-financial-results-on-march-24-2021-tela-20210302monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-upcoming-btig-virtual-medtech-digital-health-life-science-diagn-tela-20210204monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-upcoming-needham-virtual-growth-conference-tela-20210106monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-appoints-renowned-surgeon-as-vice-president-of-clinical-development-tela-20210105monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-in-upcoming-piper-sandler-32nd-annual-virtual-healthcare-conferenc-tela-20201124monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-at-upcoming-investor-conferences-tela-20201110monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-announce-third-quarter-2020-financial-results-and-host-conference-call-on-nove-tela-20201021monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-at-upcoming-conferences-tela-20200902monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-participate-at-the-canaccord-genuity-40th-annual-growth-conference-tela-20200730monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-announce-second-quarter-2020-financial-results-and-host-conference-call-on-aug-tela-20200723monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-closing-of-public-offering-of-common-stock-tela-20200630monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-proposed-public-offering-of-common-stock-tela-20200623monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-inc-to-join-the-russell-2000-index-tela-20200622monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-present-at-the-jefferies-virtual-healthcare-conference-tela-20200529monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-announce-first-quarter-2020-financial-results-and-host-conference-call-on-may--tela-20200428monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-to-announce-fourth-quarter-and-full-year-2019-financial-results-and-host-conferen-tela-20200311monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-publication-of-results-from-in-vivo-study-demonstrating-favorable-respo-tela-20200204monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-appoints-federica-o-brien-to-board-of-directors-tela-20191113monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-closing-of-initial-public-offering-of-common-stock-tela-20191113monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-pricing-of-initial-public-offering-of-common-stock-tela-20191108monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-issuance-of-u-s-patent-no-12-275-684-further-strengthening-z-atos-20250422monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-applauds-u-s-surgeon-general-s-advisory-highlighting-alcohol-as-a-lead-atos-20250106monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-to-present-poster-describing-the-discovery-of-molecules-synergistic-wi-atos-20241212monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-full-results-from-phase-2-karisma-endoxifen-study-demonstrat-atos-20241211monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-presents-data-from-study-investigating-anti-cancer-activity-of-z-endox-atos-20241209monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-to-present-poster-on-z-endoxifen-at-aacr-special-conference-in-cancer--atos-20241121monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-five-abstracts-highlighting-z-endoxifen-research-accepted-fo-atos-20241120monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-appoints-claudia-lopez-dvm-msc-as-vice-president-clinical-product-deve-atos-20241105monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-releases-promising-preliminary-analysis-demonstrating-z-endoxifen-s-po-atos-20241031monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-to-participate-in-fireside-chat-with-karolinska-institute-at-bio-europ-atos-20241021monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-to-present-at-the-2024-maxim-healthcare-virtual-summit-atos-20241014monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-commemorates-breast-cancer-awareness-month-highlighting-the-need-for-i-atos-20241001monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-support-of-final-rule-from-fda-requiring-patient-notificatio-atos-20240910monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-to-present-at-h-c-wainwright-26th-annual-global-investment-conference-atos-20240903monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-granted-additional-patent-protection-for-endoxifen-atos-20240828monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-and-quantum-leap-healthcare-collaborative-dose-first-patient-in-i-spy--atos-20240821monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-the-appointment-of-michael-parks-as-vice-president-investor--atos-20240820monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-completes-enrollment-of-80mg-pharmacokinetic-run-in-cohort-in-phase-2--atos-20240722monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-appoints-heather-rees-as-chief-financial-officer-atos-20240702monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-updated-protocol-for-clinical-trial-evaluating-z-endoxifen-i-atos-20240628monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-set-to-join-russell-3000-index-effective-june-28-2024-atos-20240617monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-to-present-at-the-sidoti-small-cap-investor-conference-atos-20240605monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-support-of-clinical-study-testing-new-artificial-intelligenc-atos-20240528monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-last-patient-last-dose-in-its-phase-2-karisma-endoxifen-clin-atos-20240515monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-support-of-new-breast-cancer-screening-guidelines-atos-20240507monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-expanded-research-agreement-with-weill-cornell-medicine-to-f-atos-20240429monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-and-quantum-leap-healthcare-announce-i-spy-2-clinical-trial-to-evaluat-atos-20240415monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-to-participate-in-noble-capital-markets-emerging-growth-healthcare-conference-atos-20240411monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-presents-data-from-40mg-cohort-of-phase-2-evangeline-clinical-trial-sh-atos-20240409monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-provides-five-year-z-endoxifen-treatment-update-on-fda-approved-expand-atos-20240319monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirements-atos-20240318monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-first-patient-dosing-of-z-endoxifen-in-the-ongoing-recast-dc-atos-20240222monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-full-enrollment-of-z-endoxifen-arm-of-i-spy-2-clinical-trial-atos-20240207monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-issues-letter-to-shareholders-atos-20240109monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-the-appointment-of-arezoo-mirad-m-d-as-senior-medical-direct-atos-20231204monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-full-enrollment-of-phase-2-karisma-endoxifen-clinical-trial-atos-20231120monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-third-quarter-2023-financial-results-and-provides-corporate--atos-20231113monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-appoints-financial-executive-jonathan-finn-to-its-board-of-directors-atos-20231109monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-to-present-at-cantor-fitzgerald-global-healthcare-conference-2023-atos-20230918monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-second-quarter-2023-financial-results-and-provides-corporate-atos-20230814monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-to-provide-business-update-and-report-second-quarter-2023-financial-re-atos-20230808monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-receives-approval-from-health-canada-to-conduct-phase-2-evangeline-cli-atos-20230720monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirements-atos-20230713monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-provides-enrollment-update-for-ongoing-phase-2-karisma-endoxifen-clini-atos-20230710monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-sponsored-research-agreement-with-weill-cornell-medicine-to--atos-20230706monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-and-quantum-leap-healthcare-provide-enrollment-update-for-z-endoxifen--atos-20230628monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-10m-stock-repurchase-program-atos-20230627monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-sponsorship-of-are-you-dense-musicfest-2023-atos-20230622monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-granted-additional-patent-protection-for-endoxifen-atos-20230621monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-to-participate-in-fireside-chat-at-healthcare-virtual-conference-presented-by-maxim-atos-20230614monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-completes-enrollment-of-pharmacokinetic-run-in-cohort-in-phase-2-evangeline-clinica-atos-20230612monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-appoints-life-sciences-financial-and-operations-industry-veteran-greg-weaver-as-chi-atos-20230601monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-first-quarter-2023-financial-results-and-provides-corporate--atos-20230515monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-to-present-a-trial-in-progress-poster-on-its-neoadjuvant-breast-cancer-phase-2-clin-atos-20230509monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-to-participate-in-tribe-public-s-webinar-event-redefining-breast-cance-atos-20230427monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-year-end-2022-financial-results-and-provides-corporate-updat-atos-20230322monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-and-quantum-leap-healthcare-announce-new-study-arm-to-evaluate-z-endox-atos-20230321monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-to-present-at-the-sidoti-small-cap-virtual-conference-atos-20230315monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-doses-first-patient-in-phase-2-neoadjuvant-clinical-study-of-z-endoxifen-in-premeno-atos-20230223monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-further-strengthens-intellectual-property-portfolio-with-additional-br-atos-20230213monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-issues-letter-to-shareholders-atos-20230125monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-the-appointment-of-eric-van-zanten-as-vice-president-investo-atos-20221207monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-third-quarter-2022-financial-results-and-provides-corporate--atos-20221107monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-inc-to-acquire-stake-in-privately-held-dynamic-cell-therapies-as-part--atos-20221101monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-inc-announces-appointment-of-pharma-industry-veteran-richard-graydon-m-atos-20221025monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-inc-receives-authorization-from-fda-to-initiate-its-phase-2-study-of-n-atos-20221024monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-inc-to-attend-the-24th-annual-h-c-wainwright-global-investment-confere-atos-20220907monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-appoints-dr-paul-wabnitz-to-its-scientific-advisory-board-atos-20220818monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-second-quarter-2022-financial-results-and-provides-corporate-atos-20220808monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-appoints-biotech-industry-communications-veteran-charles-butler-as-vic-atos-20220602monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-to-present-at-the-h-c-wainwright-global-hybrid-investment-conference-atos-20220518monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-first-quarter-2022-financial-results-and-provides-corporate--atos-20220509monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-to-present-at-the-q2-investor-summit-conference-atos-20220427monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-completion-of-part-b-of-clinical-study-of-at-h201-atos-20220420monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-to-present-at-the-maxim-group-2022-virtual-growth-conference-atos-20220323monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-issuance-of-key-u-s-patent-covering-endoxifen-atos-20220308monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-year-end-2021-financial-results-and-provides-corporate-updat-atos-20220228monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-president-and-ceo-dr-steven-c-quay-issues-annual-letter-to-stockholder-atos-20220127monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-advancement-to-part-b-of-clinical-study-of-at-h201-atos-20220118monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-begins-enrollment-of-phase-2-clinical-study-of-oral-endoxifen-in-swede-atos-20211222monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-completes-pre-ind-meeting-with-u-s-food-drug-administration-atos-20211206monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-third-quarter-2021-financial-results-and-provides-corporate--atos-20211115monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-ceo-dr-steven-quay-emphasizes-importance-of-breast-cancer-screening-du-atos-20211021monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-begins-enrollment-in-clinical-study-of-at-h201-in-australia-atos-20210930monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-adjourns-special-stockholder-meeting-to-october-7-2021-to-allow-additi-atos-20210907monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-receives-approval-from-the-swedish-ethics-review-authority-to-initiate-atos-20210902monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-second-quarter-2021-financial-results-provides-corporate-upd-atos-20210813monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-to-present-at-the-btig-virtual-biotechnology-conference-on-august-9-10-atos-20210805monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-receives-regulatory-approval-to-open-clinical-study-of-at-h201-in-aust-atos-20210707monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-set-to-be-included-in-the-russell-2000-and-russell-3000-indexes-atos-20210616monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-receives-approval-from-swedish-regulators-to-initiate-phase-2-clinical-atos-20210611monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-final-data-from-phase-2-endoxifen-breast-cancer-study-primar-atos-20210609monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-to-release-final-data-from-phase-2-study-of-endoxifen-administered-to--atos-20210607monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-first-quarter-2021-financial-results-and-provides-corporate--atos-20210514monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-to-participate-at-the-investor-summit-conference-and-present-to-invest-atos-20210514monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-urges-shareholders-to-vote-on-proposals-ahead-of-its-annual-stockholde-atos-20210511monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-ceo-dr-steven-quay-to-participate-in-panel-discussion-at-cello-health--atos-20210430monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-ovarian-cancer-patient-has-begun-treatment-with-oral-endoxif-atos-20210408monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-year-end-2020-financial-results-and-provides-corporate-updat-atos-20210331monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-pricing-of-50-0-million-registered-direct-offering-priced-at-atos-20210322monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-receipt-of-fda-safe-to-proceed-letter-for-treatment-of-an-ov-atos-20210311monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-final-results-from-phase-1-clinical-study-showing-safety-and-atos-20210225monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-president-and-ceo-dr-steven-c-quay-issues-annual-letter-to-stockholder-atos-20210210monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-two-year-update-of-fda-approved-expanded-access-treatment-wi-atos-20210203monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-phase-2-endoxifen-breast-cancer-study-produces-substantially-positive--atos-20210202monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-receives-21-million-from-recent-exercises-of-outstanding-warrants-atos-20210129monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-president-and-ceo-dr-steven-c-quay-to-speak-at-precision-medicine-worl-atos-20210125monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-pricing-of-25-2-million-registered-direct-offering-priced-at-atos-20210106monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-pricing-of-14-0-million-registered-direct-offering-priced-at-atos-20201217monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering-atos-20201209monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-third-quarter-2020-financial-results-and-provides-corporate--atos-20201113monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-preliminary-results-from-phase-1-clinical-study-showing-safe-atos-20201110monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-completes-enrollment-of-phase-1-clinical-study-of-at-301-nasal-spray-b-atos-20201019monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-to-present-at-the-oppenheimer-co-fall-healthcare-life-sciences-and-med-atos-20200921monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-receives-second-positive-interim-safety-assessment-in-clinical-study-o-atos-20200917monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-positive-interim-safety-assessment-of-first-group-of-partici-atos-20200901monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-to-present-at-the-ld-micro-500-virtual-conference-on-september-4-2020-atos-20200826monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-enrollment-and-dosing-completed-in-first-group-of-healthy-pa-atos-20200817monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-second-quarter-2020-financial-results-and-provides-corporate-atos-20200813monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-receives-approval-to-open-clinical-study-of-at-301-nasal-spray-being-d-atos-20200803monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-findings-from-fda-approved-expanded-access-treatment-with-en-atos-20200730monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-contracts-for-clinical-study-of-at-301-nasal-spray-atossa-s-second-cov-atos-20200716monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-successful-in-vitro-testing-of-nasal-spray-formulation-at-30-atos-20200715monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-advances-product-development-programs-with-multiple-key-hires-in-clini-atos-20200708monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-availability-of-manuscript-on-results-from-in-vitro-testing--atos-20200611monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-second-covid-19-therapeutic-development-program-at-301-nasal-atos-20200528monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-successful-in-vitro-testing-results-of-covid-19-drug-at-h201-atos-20200520monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-first-quarter-2020-financial-results-and-provides-company-up-atos-20200513monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-positive-interim-phase-2-data-from-endoxifen-breast-cancer-t-atos-20200507monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-receives-fda-feedback-on-two-ongoing-programs-atos-20200507monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-contracts-with-nyc-health-hospitals-metropolitan-for-covid-19-hope-cli-atos-20200427monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-seeks-clinical-investigation-approval-from-fda-to-launch-the-covid-19--atos-20200420monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-launches-covid-19-hope-drug-development-program-atos-20200416monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-clinical-progress-atos-20200402monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-fourth-quarter-and-year-end-2019-financial-results-and-provi-atos-20200326monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-upcoming-meeting-with-fda-atos-20200313monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-inc-files-for-swedish-regulatory-approval-to-initiate-a-phase-2-study--atos-20200302monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-inc-to-present-at-the-22nd-annual-bio-ceo-investor-conference-atos-20200205monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-president-and-ceo-dr-steven-c-quay-issues-annual-letter-to-shareholder-atos-20200122monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-corporate-name-change-to-atossa-therapeutics-inc-atos-20200106monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-phase-2-study-contract-for-oral-endoxifen-to-reduce-mammographic-atos-20191219monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-to-present-at-the-ld-micro-12th-annual-main-event-on-december-10-2019-atos-20191205monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-third-quarter-2019-financial-results-and-provides-company-update-atos-20191113monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-to-present-on-october-29th-at-the-5th-annual-dawson-james-small-cap-growth-atos-20191023monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-receives-irb-approval-for-phase-2-breast-cancer-study-using-intraductal-te-atos-20191016monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-preliminary-results-from-phase-1-study-of-modified-release-table-atos-20190930monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-to-present-september-10-at-the-21st-annual-rodman-and-renshaw-global-inves-atos-20190906monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-completion-of-enrollment-and-dosing-in-phase-1-clinical-trial-of-atos-20190903monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-second-quarter-2019-financial-results-and-provides-company-updat-atos-20190813monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-ceo-steven-quay-gives-tedx-talk-at-university-of-washington-regarding-the--atos-20190730monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-provides-information-on-fda-expanded-access-policy-and-requests-atos-20190717monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-new-proprietary-modified-release-oral-endoxifen-tablet-phase-1-c-atos-20190711monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-preliminary-phase-2-study-achieves-primary-endpoint-topical-endoxifen-rapi-atos-20190627monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-to-present-at-the-9th-annual-ld-micro-invitational-on-june-4-2019-atos-20190530monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-first-quarter-2019-financial-results-and-provides-company-update-atos-20190513monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-provides-clinical-update-at-the-4th-annual-precision-breast-cancer-world-r-atos-20190425monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-to-present-at-the-4th-annual-precision-breast-cancer-world-r-d-summit-apri-atos-20190422monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-year-end-2018-financial-results-and-provides-company-update-atos-20190328monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-institutional-review-board-approval-of-oral-endoxifen-as-post-ma-atos-20190326monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-receipt-of-10-million-atos-20190318monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-fda-approval-of-oral-endoxifen-for-expanded-access-as-post-maste-atos-20190314monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-reports-results-from-expanded-access-program-for-a-u-s-breast-cancer-patie-atos-20190207monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-provides-breast-cancer-prevention-recommendations-to-the-united-states-pre-atos-20190204monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-president-and-ceo-dr-steven-c-quay-issues-annual-letter-to-shareholders-hi-atos-20190128monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-successful-completion-and-final-results-from-male-phase-1-study--atos-20190109monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-fda-approval-of-endoxifen-for-expanded-access-as-preoperative-sy-atos-20181203monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-third-quarter-2018-financial-results-and-provides-company-update-atos-20181113monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-completes-enrollment-in-phase-2-study-of-topical-endoxifen-in-women-with-m-atos-20181011monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-to-host-conference-call-to-announce-preliminary-results-from-male-phase-1--atos-20180912monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-contracts-with-additional-manufacturer-of-endoxifen-atos-20180801monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-intraductal-microcatheter-immunooncology-pre-clinical-program-atos-20180718monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-opens-enrollment-in-phase-2-study-of-oral-endoxifen-to-treat-breast-cancer-atos-20180713monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-opens-its-phase-2-study-of-topical-endoxifen-to-treat-mammographic-breast--atos-20180626monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-completes-all-dosing-and-clinical-visits-in-its-phase-1-study-of-topical-e-atos-20180620monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-appoints-two-additional-prominent-industry-executives-to-strategic-advisor-atos-20180614monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-announces-13-4-million-in-expected-gross-proceeds-from-recently-expired-rights-offe-atos-20180525monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-receives-positive-interim-safety-review-from-independent-safety-committee--atos-20180515monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-to-host-corporate-conference-call-wednesday-may-16-2018-at-4-30pm-edt-atos-20180514monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-supports-national-women-s-health-week-lead-by-u-s-department-of-health-and-atos-20180511monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-regains-nasdaq-compliance-atos-20180508monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-reminds-investors-of-today-s-deadline-to-be-a-shareholder-of-record-atos-20180507monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-forms-strategic-advisory-board-to-accelerate-growth-atos-20180503monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-receives-approval-from-the-swedish-medical-products-agency-for-phase-2-top-atos-20180430monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-receives-positive-interim-review-from-independent-safety-committee-in-phas-atos-20180424monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-informs-stockholders-of-key-dates-and-terms-related-to-announced-rights-of-atos-20180423monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-1-for-12-reverse-stock-split-atos-20180420monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-requests-shareholders-to-vote-atos-20180416monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-enrolls-first-cohort-of-eight-subjects-in-endoxifen-study-of-male-subjects-atos-20180412monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-appoints-per-hall-md-ph-d-as-scientific-advisor-atos-20180327monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-launches-mens-breast-health-program-atos-20180322monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-to-present-at-adoptive-t-cell-therapy-symposium-molecular-medicine-tri-con-atos-20180213monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-to-host-conference-call-to-present-additional-findings-from-its-phase-1-st-atos-20180131monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-president-and-ceo-issues-letter-to-stockholders-highlighting-key-accomplis-atos-20171228monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-appoints-carl-novina-md-phd-as-scientific-advisor-atos-20171221monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-pricing-of-1-4-million-registered-direct-offering-atos-20171220monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-applauds-newly-introduced-federal-legislation-requiring-that-breast-densit-atos-20171106monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-closing-of-5-5-million-common-stock-public-offering-and-over-all-atos-20171030monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-proposed-public-offering-of-common-stock-atos-20171025monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-to-host-conference-call-to-announce-preliminary-results-from-phase-1-study-atos-20171023monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-that-rutgers-the-state-university-at-new-jersey-plans-study-util-atos-20171016monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-chimeric-antigen-receptor-therapy-car-t-program-in-breast-cancer-atos-20171002monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-to-present-at-the-microcap-conference-in-new-york-city-on-october-5-2017-atos-20170929monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-upcoming-phase-2-study-of-topical-endoxifen-atos-20170925monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-to-host-conference-call-to-announce-preliminary-results-from-phase-1-study-atos-20170911monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-completes-enrollment-in-endoxifen-phase-1-study-and-provides-update-on-ful-atos-20170725monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-first-quarter-2026-results-and-provides-corporate-update-atyr-20260515monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-participate-in-upcoming-investor-conferences-atyr-20260513monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-provides-regulatory-and-clinical-update-for-efzofitimod-in-pulmonary-sarcoidos-atyr-20260511monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-fourth-quarter-and-full-year-2025-results-and-provides-corporate-upd-atyr-20260305monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-atyr-20260220monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-deadline-alert-hagens-berman-alerts-atyr-pharma-atyr-investors-of-today-s-lead-plaint-atyr-20251208monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investors-have-opportunity-to-lead-atyr-pharma-inc-securities-fraud-lawsuit-with-the--atyr-20251208monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-lawsuit-hagens-berman-urges-atyr-pharma-investors-to-act-by-dec-8-deadline-in-suit-ov-atyr-20251206monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-deadline-monday-rosen-a-globally-respected-law-firm-encourages-atyr-pharma-inc-invest-atyr-20251205monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-atyr-pharma-inc-investor-atyr-20251205monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-yo-atyr-20251205monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-lawsuit-hagens-berman-urges-atyr-pharma-investors-to-act-by-dec-8-deadline-in-suit-ov-atyr-20251204monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investors-have-opportunity-to-lead-atyr-pharma-inc-securities-fraud-lawsuit-with-the--atyr-20251204monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investor-notice-faruqi-faruqi-llp-investigates-claims-on-behalf-of-investors-of-atyr--atyr-20251203monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-lawsuit-hagens-berman-urges-atyr-pharma-investors-to-act-by-dec-8-deadline-in-suit-ov-atyr-20251202monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-yo-atyr-20251202monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-atyr-pharma-inc-investor-atyr-20251201monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investors-have-opportunity-to-lead-atyr-pharma-inc-securities-fraud-lawsuit-with-the--atyr-20251201monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-deadline-rosen-leading-investor-counsel-encourages-atyr-pharma-inc-investors-to-secur-atyr-20251129monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-yo-atyr-20251128monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-lawsuit-hagens-berman-urges-atyr-pharma-investors-to-act-by-dec-8-deadline-in-suit-ov-atyr-20251127monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-atyr-pharma-inc-investor-atyr-20251127monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investors-have-opportunity-to-lead-atyr-pharma-inc-securities-fraud-lawsuit-with-the--atyr-20251127monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-december--atyr-20251125monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-atyr-posts-wider-than-expected-loss-as-investor-litigation-over-key-drug-s-eff-atyr-20251124monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investors-have-opportunity-to-lead-atyr-pharma-inc-securities-fraud-lawsuit-with-the--atyr-20251124monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-atyr-posts-wider-than-expected-loss-as-investor-litigation-over-key-drug-s-eff-atyr-20251121monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-atyr-pharma-inc-investor-atyr-20251121monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-yo-atyr-20251121monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investor-notice-faruqi-faruqi-llp-investigates-claims-on-behalf-of-investors-of-atyr--atyr-20251120monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investors-have-opportunity-to-lead-atyr-pharma-inc-securities-fraud-lawsuit-with-the--atyr-20251120monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-atyr-posts-wider-than-expected-loss-as-investor-litigation-over-key-drug-s-eff-atyr-20251119monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-yo-atyr-20251118monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-atyr-failed-drug-trial-spurs-securities-lawsuit-class-period-significantly-atyr-20251117monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investors-have-opportunity-to-lead-atyr-pharma-inc-securities-fraud-lawsuit-with-the--atyr-20251117monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-class-action-levi-korsinsky-reminds-atyr-investors-of-the-pending-class-ac-atyr-20251114monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-shareholder-alert-new-atyr-pharma-inc-atyr-securities-class-filed-class-period-signif-atyr-20251114monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-atyr-pharma-inc-investor-atyr-20251114monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investors-have-opportunity-to-lead-atyr-pharma-inc-securities-fraud-lawsuit-with-the--atyr-20251114monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-yo-atyr-20251113monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investors-securities-law-firm-robbins-llp-reminds-investors-of-the-pending-lead-plain-atyr-20251112monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investor-alert-new-atyr-pharma-inc-atyr-securities-class-filed-class-period-significa-atyr-20251112monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-atyr-20251111monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investors-have-opportunity-to-lead-atyr-pharma-inc-securities-fraud-lawsuit-with-the--atyr-20251111monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-lawsuit-alert-the-gross-law-firm-notifies-atyr-pharma-inc-investors-of-a-class-action-atyr-20251110monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investor-alert-new-atyr-pharma-inc-atyr-securities-class-filed-class-period-significa-atyr-20251110monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-shareholder-action-reminder-faruqi-faruqi-llp-announces-that-atyr-pharma-investors-ha-atyr-20251109monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-atyr-failed-drug-trial-spurs-securities-lawsuit-class-period-significantly-atyr-20251107monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-atyr-pharma-inc-investor-atyr-20251107monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investors-have-opportunity-to-lead-atyr-pharma-inc-securities-fraud-lawsuit-with-the--atyr-20251107monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-yo-atyr-20251106monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-atyr-failed-drug-trial-spurs-securities-lawsuit-class-period-significantly-atyr-20251105monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investor-notice-faruqi-faruqi-llp-investigates-claims-on-behalf-of-investors-of-atyr--atyr-20251104monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investors-have-opportunity-to-lead-atyr-pharma-inc-securities-fraud-lawsuit-with-the--atyr-20251104monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-atyr-failed-drug-trial-spurs-securities-lawsuit-class-period-significantly-atyr-20251103monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-yo-atyr-20251103monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-shareholder-alert-new-atyr-pharma-inc-atyr-securities-class-filed-class-period-signif-atyr-20251031monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investors-have-opportunity-to-lead-atyr-pharma-inc-securities-fraud-lawsuit-with-the--atyr-20251031monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-atyr-pharma-inc-investor-atyr-20251031monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-yo-atyr-20251030monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-atyr-securities-class-action-filed-class-period-significantly-enlarged-hag-atyr-20251029monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investors-have-opportunity-to-lead-atyr-pharma-inc-securities-fraud-lawsuit-with-the--atyr-20251028monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investor-alert-new-atyr-pharma-inc-atyr-securities-class-filed-class-period-significa-atyr-20251027monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-yo-atyr-20251027monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-shareholder-action-reminder-faruqi-faruqi-llp-investigates-claims-on-behalf-of-invest-atyr-20251026monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-atyr-pharma-inc-investor-atyr-20251024monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investors-have-opportunity-to-lead-atyr-pharma-inc-securities-fraud-lawsuit-with-the--atyr-20251024monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-s-atyr-failed-drug-trial-spurs-securities-lawsuit-hagens-berman-atyr-20251022monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-s-atyr-failed-drug-trial-spurs-securities-lawsuit-hagens-berman-atyr-20251020monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-atyr-20251017monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-atyr-pharma-inc-investor-atyr-20251017monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-s-atyr-failed-drug-trial-spurs-securities-lawsuit-hagens-berman-atyr-20251016monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-ag-atyr-20251014monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-s-atyr-failed-drug-trial-spurs-securities-lawsuit-hagens-berman-atyr-20251013monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-atyr-pharma-inc-investor-atyr-20251012monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-investor-notice-robbins-llp-reminds-investors-of-the-securities-fraud-class-action-ag-atyr-20251010monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-atyr-securities-class-action-deadline-alert-shamis-gentile-p-a-alerts-inve-atyr-20251010monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-atyr-faces-investor-scrutiny-after-efzo-fit-study-failure-drives-shares-80-atyr-20251009monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-atyr-faces-investor-scrutiny-after-efzo-fit-study-failure-drives-shares-80-atyr-20251003monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-atyr-faces-investor-scrutiny-after-efzo-fit-study-failure-drives-shares-80-atyr-20250930monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-atyr-faces-investor-scrutiny-after-efzo-fit-study-failure-drives-shares-80-atyr-20250925monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-atyr-faces-investor-scrutiny-after-efzo-fit-study-failure-drives-shares-80-atyr-20250922monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-atyr-faces-investor-scrutiny-after-efzo-fit-study-failure-drives-shares-80-atyr-20250918monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-atyr-faces-investor-scrutiny-after-efzo-fit-study-failure-drives-shares-80-atyr-20250916monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-second-quarter-2025-results-and-provides-corporate-update-atyr-20250807monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-last-patient-visit-in-phase-3-efzo-fit-study-of-efzofitimod-in-patie-atyr-20250722monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-presents-three-posters-on-efzofitimod-at-the-american-thoracic-society-ats-202-atyr-20250519monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-atyr-20250516monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-advances-atyr0101-to-ind-candidate-stage-for-pulmonary-fibrosis-atyr-20250514monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-first-quarter-2025-results-and-provides-corporate-update-atyr-20250507monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-presents-preclinical-data-for-nrp2-targeting-antibody-atyr2810-at-the-american-atyr-20250429monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-participate-in-april-investor-conferences-atyr-20250403monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-atyr-20250327monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-the-appointment-of-dalia-r-rayes-as-head-of-commercial-global-efzofi-atyr-20250326monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-fourth-quarter-and-full-year-2024-results-and-provides-corporate-upd-atyr-20250313monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-publication-demonstrating-efzofitimod-s-immunomodulatory-activity-in-atyr-20250312monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-fourth-positive-dsmb-review-for-efzofitimod-in-phase-3-efzo-fit-stud-atyr-20250306monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-webcast-conference-call-reporting-fourth-quarter-and-full-year-end-2024-fin-atyr-20250304monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-the-leerink-partners-global-healthcare-conference-atyr-20250224monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-three-posters-for-efzofitimod-at-the-american-thoracic-society-ats--atyr-20250129monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-atyr-20241217monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-the-appointment-of-eric-benevich-to-its-board-of-directors-atyr-20241212monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-third-positive-dsmb-review-for-efzofitimod-in-phase-3-efzo-fit-study-atyr-20241210monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-preclinical-research-demonstrating-anti-fibrotic-effects-of-atyr010-atyr-20241209monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-posters-on-trna-synthetase-candidate-atyr0101-at-keystone-symposia--atyr-20241115monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-third-quarter-2024-results-and-provides-corporate-update-atyr-20241107monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-upcoming-investor-conferences-atyr-20241031monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-s-lead-therapeutic-candidate-efzofitimod-for-pulmonary-sarcoidosis-to-be-featu-atyr-20241008monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-publication-demonstrating-efficacy-of-efzofitimod-in-pulmonary-sarco-atyr-20241002monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-participate-in-september-investor-conferences-atyr-20240821monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-second-quarter-2024-results-and-provides-corporate-update-atyr-20240813monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-appointment-of-jayant-aphale-phd-as-vice-president-of-technical-oper-atyr-20240806monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-research-study-with-stanford-medicine-atyr-20240730monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-completes-enrollment-in-global-pivotal-phase-3-efzo-fit-study-of-efzofitimod-i-atyr-20240722monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-nasdaq-stock-ticker-symbol-change-from-life-to-atyr-atyr-20240603monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-atyr-20240524monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-poster-describing-efzofitimod-s-mechanism-of-action-at-the-american-atyr-20240515monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-second-positive-dsmb-review-for-efzofitimod-in-phase-3-efzo-fit-stud-atyr-20240514monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-upcoming-investor-conferences-atyr-20240506monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-first-quarter-2024-results-and-provides-corporate-update-atyr-20240502monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-participate-in-april-investor-conferences-atyr-20240401monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-fourth-quarter-and-full-year-2023-results-and-provides-corporate-upd-atyr-20240314monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-webcast-conference-call-reporting-fourth-quarter-and-full-year-end-2023-fin-atyr-20240228monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-expanded-access-program-eap-for-efzo-fit-clinical-trial-participants-atyr-20240221monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-posters-highlighting-importance-of-neuropilin-2-in-immune-regulatio-atyr-20240129monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-howard-university-president-emeritus-dr-wayne-a-i-frederick-as-advis-atyr-20240118monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-presents-poster-demonstrating-preclinical-effects-of-efzofitimod-in-rheumatoid-atyr-20231113monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-third-quarter-2023-results-and-provides-corporate-update-atyr-20231109monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-november-investor-conferences-atyr-20231101monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-dosing-of-first-patient-in-phase-2-efzo-connect-study-of-efzofitimod-atyr-20231031monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-presents-efzofitimod-data-demonstrating-statistically-significant-improvements-atyr-20230911monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-atyr-20230824monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-second-quarter-2023-results-and-provides-corporate-update-atyr-20230809monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-on-lead-therapeutic-candidate-efzofitimod-at-the-world-association--atyr-20230620monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-atyr-20230609monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-highlight-advancements-in-trna-synthetase-biology-research-at-the-13th-inte-atyr-20230606monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-the-2023-jefferies-healthcare-conference-atyr-20230525monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-presents-new-data-on-efzofitimod-mechanism-of-action-and-positive-exposure-res-atyr-20230522monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-the-2023-rbc-capital-markets-global-healthcare-conference-atyr-20230511monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-first-quarter-2023-results-and-provides-corporate-update-atyr-20230509monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-presents-preclinical-research-demonstrating-treatment-with-atyr2810-inhibits-t-atyr-20230417monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-first-major-review-article-for-efzofitimod-published-in-the-journal--atyr-20230330monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-data-identifying-fibrosis-target-for-trna-synthetase-candidate-atyr-atyr-20230321monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-and-foundation-for-sarcoidosis-research-announce-town-hall-virtual-meeting-on--atyr-20230320monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-fourth-quarter-and-full-year-2022-results-and-provides-corporate-upd-atyr-20230309monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-march-investor-conferences-atyr-20230308monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-webcast-conference-call-reporting-fourth-quarter-and-full-year-end-2022-fin-atyr-20230302monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-phase-2-study-of-efzofitimod-in-patients-with-systemic-sclerosis-ass-atyr-20230301monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-pricing-of-public-offering-of-common-stock-atyr-20230209monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-commencement-of-public-offering-of-common-stock-atyr-20230208monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-achievement-of-development-milestone-by-partner-kyorin-pharmaceutica-atyr-20230206monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-new-data-on-the-mechanism-of-action-of-efzofitimod-at-the-american--atyr-20230131monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-gains-e-u-patent-covering-use-of-efzofitimod-with-pirfenidone-for-lung-inflamm-atyr-20230119monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-ltbp1-as-target-of-dars-trna-synthetase-fragment-atyr-20221215monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-atyr-20221118monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-third-quarter-2022-results-and-provides-corporate-update-atyr-20221110monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-upcoming-investor-conferences-atyr-20221110monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-publication-of-positive-data-from-phase-1b-2a-clinical-study-of-efzo-atyr-20221109monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-webcast-conference-call-reporting-third-quarter-2022-financial-results-atyr-20221103monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-the-jefferies-london-healthcare-conference-atyr-20221025monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-research-collaboration-with-dualsystems-biotech-ag-to-identify-10-ne-atyr-20221011monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-participate-in-rbc-biotech-expert-insights-pulmonary-lung-disease-mini-symp-atyr-20221004monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-notice-of-allowance-for-u-s-patent-for-anti-neuropilin-2-nrp2-monocl-atyr-20220929monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-dosing-of-first-patient-in-pivotal-phase-3-efzo-fit-study-of-efzofit-atyr-20220927monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-receives-fda-fast-track-designation-for-efzofitimod-for-treatment-of-systemic--atyr-20220913monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-the-life-sciences-investor-forum-on-september-15th-atyr-20220909monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference-2022-atyr-20220906monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-poster-at-the-european-respiratory-society-ers-international-congre-atyr-20220901monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-second-quarter-2022-results-and-provides-corporate-update-atyr-20220815monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-atyr-20220812monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-receives-fda-fast-track-designation-for-efzofitimod-atyr1923-for-treatment-of--atyr-20220811monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-webcast-conference-call-reporting-second-quarter-2022-financial-results-atyr-20220804monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-fgfr4-as-receptor-target-for-aars-trna-synthetase-fragment-atyr-20220614monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-findings-from-its-trna-synthetase-platform-at-the-international-28t-atyr-20220613monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-the-2022-jefferies-healthcare-conference-atyr-20220601monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-presents-clinical-data-for-efzofitimod-atyr1923-at-the-american-thoracic-socie-atyr-20220517monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-phase-3-study-of-efzofitimod-atyr1923-in-pulmonary-sarcoidosis-atyr-20220516monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-atyr-20220513monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-upcoming-investor-conferences-in-may-atyr-20220510monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-first-quarter-2022-results-and-provides-corporate-update-atyr-20220509monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-webcast-conference-call-reporting-first-quarter-2022-financial-results-atyr-20220502monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-fda-orphan-drug-designation-for-efzofitimod-atyr1923-for-treatment-o-atyr-20220413monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-presents-preclinical-research-characterizing-effects-of-atyr2810-in-highly-agg-atyr-20220411monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-clinical-data-for-efzofitimod-atyr1923-at-the-american-thoracic-soc-atyr-20220401monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-atyr-20220325monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-fourth-quarter-and-full-year-2021-results-and-provides-corporate-upd-atyr-20220314monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-positive-end-of-phase-2-meeting-with-fda-on-efzofitimod-for-the-trea-atyr-20220310monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-poster-presentation-at-the-american-association-for-cancer-research--atyr-20220308monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-webcast-conference-call-reporting-fourth-quarter-and-full-year-end-2021-fin-atyr-20220307monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-upcoming-investor-conferences-in-march-atyr-20220303monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-participate-in-panel-at-national-institutes-of-health-rare-disease-day-atyr-20220223monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-bio-ceo-investor-conference-atyr-20220207monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-advances-development-of-lead-therapeutic-candidate-atyr1923-with-announcement--atyr-20220113monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-fda-orphan-drug-designation-for-atyr1923-for-treatment-of-sarcoidosi-atyr-20220106monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-h-c-wainwright-virtual-bioconnect-conference-atyr-20220104monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-appoints-danielle-campbell-as-vice-president-of-human-resources-atyr-20211224monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-antibody-engineering-therapeutics-conference-atyr-20211210monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-and-fujifilm-diosynth-biotechnologies-announce-manufacturing-agreement-for-aty-atyr-20211130monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-upcoming-investor-conferences-in-november-atyr-20211112monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-third-quarter-2021-results-and-provides-corporate-update-atyr-20211110monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-presents-research-demonstrating-effects-of-novel-nrp2-targeting-antibody-atyr2-atyr-20211109monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-webcast-conference-call-reporting-third-quarter-2021-financial-results-atyr-20211103monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-participate-in-piper-sandler-investor-lung-day-atyr-20211011monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-appointment-of-robert-w-ashworth-phd-as-vice-president-of-regulatory-atyr-20211006monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-poster-presentation-at-the-society-for-immunotherapy-of-cancer-annua-atyr-20211001monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-closing-of-86-3-million-public-offering-including-full-exercise-of-u-atyr-20210920monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-the-oppenheimer-fall-healthcare-life-sciences-and-medtech-summit-atyr-20210916monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-pricing-of-75-million-public-offering-of-common-stock-atyr-20210916monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-proposed-public-offering-of-common-stock-atyr-20210915monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-and-its-hong-kong-subsidiary-pangu-biopharma-announce-positive-data-from-a-pha-atyr-20210913monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-positive-data-from-phase-1b-2a-clinical-trial-demonstrating-consiste-atyr-20210913monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-second-quarter-2021-results-and-provides-corporate-update-atyr-20210810monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-expansion-of-research-collaboration-with-the-ohio-state-university-atyr-20210810monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-two-abstracts-for-atyr1923-accepted-for-presentation-at-the-european-atyr-20210809monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-webcast-conference-call-reporting-second-quarter-2021-financial-results-atyr-20210803monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-grant-of-u-s-patent-for-use-of-histidyl-trna-synthetase-fc-fusion-pr-atyr-20210729monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-last-patient-visit-in-phase-1b-2a-clinical-trial-of-atyr1923-in-pati-atyr-20210708monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-host-virtual-key-opinion-leader-event-on-current-treatment-options-for-pulm-atyr-20210623monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-presents-poster-demonstrating-functional-selectivity-of-second-anti-nrp2-antib-atyr-20210610monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-strengthens-board-of-directors-with-appointment-of-dr-sara-zaknoen-atyr-20210525monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-presents-preclinical-research-highlighting-mechanistic-insights-into-tumor-inh-atyr-20210519monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-first-quarter-2021-results-and-provides-corporate-update-atyr-20210513monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-and-its-hong-kong-subsidiary-pangu-biopharma-achieve-milestones-for-first-year-atyr-20210512monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-promotion-of-leslie-nangle-ph-d-to-vice-president-of-research-atyr-20210511monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-webcast-conference-call-reporting-first-quarter-2021-financial-results-atyr-20210506monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-and-foundation-for-sarcoidosis-research-announce-town-hall-virtual-meeting-on--atyr-20210420monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-and-lonza-announce-manufacturing-agreement-for-atyr-s-anti-nrp2-antibody-atyr2-atyr-20210414monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-presents-preclinical-research-showing-effects-of-atyr2810-in-lung-and-breast-c-atyr-20210409monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-co-founder-of-the-foundation-for-sarcoidosis-research-and-leading-sa-atyr-20210408monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-fourth-quarter-and-full-year-2020-results-and-provides-corporate-upd-atyr-20210323monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-webcast-conference-call-reporting-fourth-quarter-and-full-year-end-2020-fin-atyr-20210316monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-positive-biomarker-data-from-phase-2-clinical-trial-of-atyr1923-demo-atyr-20210315monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-poster-presentations-at-the-american-association-for-cancer-research-atyr-20210311monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-march-investor-conferences-atyr-20210225monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-new-trna-synthetase-discovery-programs-atyr-20210211monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-bio-ceo-investor-digital-conference-atyr-20210209monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-presents-findings-further-validating-nrp2-as-a-potential-regulator-of-solid-tu-atyr-20210125monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-poster-highlighting-research-approach-for-identifying-receptor-targ-atyr-20210122monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-partner-kyorin-pharmaceutical-co-ltd-completes-subject-visits-for-ph-atyr-20210114monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-h-c-wainwright-virtual-bioconnect-conference-atyr-20210107monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-positive-topline-results-from-phase-2-clinical-trial-of-atyr1923-in--atyr-20210104monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-completion-of-enrollment-in-phase-1b-2a-clinical-trial-of-atyr1923-i-atyr-20201221monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-third-quarter-2020-results-and-provides-corporate-update-atyr-20201112monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-publication-in-the-journal-mabs-atyr-20201111monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-discovery-of-new-receptor-targets-for-two-trna-synthetases-from-its--atyr-20201110monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-webcast-conference-call-reporting-third-quarter-2020-financial-results-mana-atyr-20201105monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-research-collaboration-with-medical-university-of-south-carolina-atyr-20201029monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-participate-in-roth-capital-partners-webinar-on-covid-19-therapeutics-in-de-atyr-20201027monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-completion-of-enrollment-in-phase-2-clinical-trial-of-atyr1923-in-co-atyr-20201026monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-participate-in-october-virtual-investor-events-atyr-20201007monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-partner-kyorin-pharmaceutical-co-ltd-doses-first-subjects-in-phase-1-atyr-20200915monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-20-million-common-stock-purchase-agreement-with-aspire-capital-fund--atyr-20200914monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-september-investor-conferences-atyr-20200909monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-life-sciences-investor-forum-on-september-17th-atyr-20200902monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-second-quarter-2020-results-and-provides-corporate-update-on-atyr192-atyr-20200813monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-partner-kyorin-pharmaceutical-co-ltd-proceeds-to-phase-1-trial-of-at-atyr-20200811monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-webcast-conference-call-reporting-second-quarter-2020-financial-results-atyr-20200806monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-presents-preclinical-research-showing-nrp2-antibody-effects-in-triple-negative-atyr-20200622monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-highlights-new-literature-implicating-neuropilin-pathway-in-sars-cov-2-infecti-atyr-20200617monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-dosing-of-first-patient-in-phase-2-trial-of-atyr1923-in-covid-19-pat-atyr-20200615monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-poster-at-the-2020-american-association-for-cancer-research-aacr-vi-atyr-20200520monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-first-quarter-2020-results-and-provides-corporate-update-on-atyr1923-atyr-20200512monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-webcast-conference-call-reporting-first-quarter-2020-financial-results-atyr-20200506monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-publication-of-two-abstracts-in-american-journal-of-respiratory-and--atyr-20200505monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-phase-2-study-of-atyr1923-in-covid-19-patients-with-severe-respirato-atyr-20200421monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-fourth-quarter-and-full-year-2019-results-and-provides-corporate-upd-atyr-20200326monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-and-its-hong-kong-subsidiary-pangu-biopharma-announce-government-grant-to-fund-atyr-20200324monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-announce-fourth-quarter-and-full-year-end-2019-financial-results-on-march-2-atyr-20200319monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-exercise-and-closing-of-over-allotment-option-in-public-offering-atyr-20200310monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-poster-presentation-at-the-american-association-for-cancer-research--atyr-20200303monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-publication-in-the-journal-cellular-and-molecular-immunology-atyr-20200227monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-pricing-of-18-million-underwritten-public-offering-atyr-20200206monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-collaboration-with-kyorin-pharmaceutical-co-ltd-for-the-development--atyr-20200106monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-positive-interim-safety-results-from-ongoing-phase-1b-2a-clinical-tr-atyr-20191212monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-third-quarter-2019-results-and-provides-corporate-update-atyr-20191114monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-the-stifel-healthcare-conference-2019-atyr-20191113monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-announce-third-quarter-results-on-november-14th-atyr-20191107monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-research-collaboration-with-boston-children-s-hospital-atyr-20191022monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-participate-in-september-conferences-atyr-20190918monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-the-h-c-wainwright-21st-annual-global-investment-conference-atyr-20190904monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-second-quarter-2019-results-and-provides-corporate-update-atyr-20190814monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-announce-second-quarter-2019-results-on-august-14th-atyr-20190807monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-host-key-opinion-leader-call-and-webcast-on-sarcoidosis-and-the-current-tre-atyr-20190710monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-strengthens-board-of-directors-with-the-appointment-of-two-new-members-atyr-20190701monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-reverse-stock-split-to-regain-nasdaq-compliance-atyr-20190628monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-first-quarter-2019-results-and-provides-corporate-update-atyr-20190513monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-announce-first-quarter-2019-results-on-may-13th-atyr-20190506monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-host-inaugural-summit-meeting-on-neuropilin-2-nrp-2-biology-atyr-20190416monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-5-million-registered-direct-offering-led-by-the-federated-kaufmann-s-atyr-20190411monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-poster-at-the-american-thoracic-society-2019-international-conferen-atyr-20190408monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-fourth-quarter-and-full-year-2018-results-and-provides-corporate-upd-atyr-20190325monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-poster-presentation-at-the-2019-american-association-for-cancer-rese-atyr-20190321monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-announce-fourth-quarter-and-full-year-2018-financial-results-on-march-25th-atyr-20190318monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-research-collaboration-with-global-biotherapeutics-leader-csl-behrin-atyr-20190311monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-participation-at-march-investor-conferences-atyr-20190304monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-presents-compelling-preclinical-data-highlighting-potential-of-atyr1923-to-reg-atyr-20190227monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-the-bio-ceo-investor-conference-atyr-20190205monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-research-collaboration-with-the-university-of-nebraska-medical-cente-atyr-20190130monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-participation-at-upcoming-san-francisco-investor-events-atyr-20190103monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-initiation-of-phase-1b-2a-study-of-atyr1923-in-patients-with-pulmona-atyr-20181204monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-the-bmo-2018-prescriptions-for-success-healthcare-conference-atyr-20181129monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-third-quarter-2018-operating-results-and-provides-corporate-update-atyr-20181113monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-host-conference-call-and-webcast-of-third-quarter-2018-financial-results-on-atyr-20181108monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-presents-at-american-society-of-human-genetics-2018-meeting-atyr-20181017monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-leadership-transition-atyr-20181015monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-pulmonary-sarcoidosis-as-disease-indication-for-phase-1b-2a-clinical-atyr-20180927monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-the-cantor-fitzgerald-2018-global-healthcare-conference-atyr-20180920monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-the-baird-2018-global-healthcare-conference-atyr-20180830monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-second-quarter-2018-operating-results-and-provides-corporate-update-atyr-20180814monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-host-conference-call-and-webcast-of-second-quarter-2018-financial-results-o-atyr-20180808monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-appoints-jill-broadfoot-as-chief-financial-officer-atyr-20180731monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-presents-positive-lung-and-skin-findings-with-atyr1923-in-a-translational-anim-atyr-20180726monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-positive-phase-1-data-for-atyr1923-therapeutic-candidate-atyr-20180626monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-jefferies-2018-global-healthcare-conference-atyr-20180531monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-presents-poster-on-preclinical-data-from-atyr1923-program-at-american-thoracic-atyr-20180517monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-first-quarter-2018-operating-results-program-prioritization-and-corp-atyr-20180514monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-host-conference-call-and-webcast-of-first-quarter-2018-financial-results-on-atyr-20180508monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-provides-mechanistic-update-on-resokine-pathway-at-american-academy-of-immunol-atyr-20180502monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-fourth-quarter-and-year-end-2017-operating-results-and-provides-corp-atyr-20180319monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-host-conference-call-and-webcast-of-full-year-2017-financial-results-on-mar-atyr-20180307monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-two-upcoming-investor-conferences-in-march-atyr-20180301monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-atyr-20180104monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-poster-presentation-at-asco-sitc-clinical-immuno-oncology-symposium-atyr-20171221monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-participate-at-the-bmo-prescriptions-for-success-healthcare-conference-atyr-20171207monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-doses-first-subjects-in-phase-1-trial-of-imod-fc-atyr1923-atyr-20171127monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-participate-at-the-piper-jaffray-29th-annual-healthcare-conference-atyr-20171121monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-third-quarter-2017-operating-results-and-provides-corporate-update-atyr-20171114monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-leadership-transition-atyr-20171101monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-final-data-for-resolaris-phase-1b-2-trial-in-patients-with-early-on-atyr-20170927monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-two-upcoming-investor-conferences-in-september-atyr-20170906monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-45-million-equity-financing-atyr-20170828monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-second-quarter-2017-operating-results-and-provides-an-update-on-inno-atyr-20170814monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-date-of-earnings-release-for-second-quarter-2017-financial-results-atyr-20170810monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-jefferies-2017-global-healthcare-conference-atyr-20170531monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-presentations-on-interstitial-lung-disease-and-the-imod-fc-program-a-atyr-20170515monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-first-quarter-2017-operating-results-atyr-20170511monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-presents-analyses-of-resolaris-phase-1b-2-trial-in-patients-with-limb-girdle-m-atyr-20170424monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-promising-top-line-results-from-resolaris-phase-1b-2-clinical-trial--atyr-20170424monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-appointment-of-timothy-p-coughlin-to-its-board-of-directors-atyr-20170410monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-to-present-at-needham-and-company-16th-annual-healthcare-conference-atyr-20170329monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-inc-to-present-at-the-inaugural-ef-hutton-global-conference-on-may-10-2023-i-nnvc-20230504monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-inc-investors-who-purchased-nnvc-securities-after-january-2020-and-suffered--nnvc-20200716monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-ceo-dr-eugene-seymour-to-be-interviewed-on-clear-channel-dfw-1190am-nnvc-20131218monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-presents-at-the-premiere-event-of-the-year-for-connecticut-s-technology-lead-nnvc-20050928monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-announces-progress-in-development-of-flucide-i-influenza-drug-nnvc-20050920monthly0.5https://www.biopharmawatch.com/news/DARE/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-b-dare-20251210monthly0.5https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-announces-further-phase-2-revert-ipf-data-expanding-clinical-insights-tvrd-20260108monthly0.5https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-announces-publication-of-results-from-first-in-human-study-of-tti-101--tvrd-20250319monthly0.5https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference-tvrd-20250219monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-2025-results-and-provides-business-update-inmb-20260330monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-s-mindful-trial-featured-at-ad-pd-2026-plenary-as-successful-example-of-how-to--inmb-20260319monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-third-quarter-2025-financial-results-and-provide-a-corporate-upda-inmb-20251023monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-second-quarter-2025-financial-results-and-provide-corporate-updat-inmb-20250731monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-closing-of-approximately-19-million-registered-direct-offering-pr-inmb-20250630monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-fourth-quarter-2024-financial-results-and-provide-corporate-updat-inmb-20250324monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-completes-repayment-of-silicon-valley-bank-debt-inmb-20241210monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-completes-enrollment-for-phase-2-trial-in-early-alzheimer-s-disease-inmb-20240930monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-new-phase-1-study-data-demonstrating-dose-dependent-effect-of-xpr-inmb-20240729monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-second-quarter-2024-financial-results-and-provide-a-corporate-upd-inmb-20240725monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-publishes-novel-biology-on-natural-killer-cancer-immunotherapy-inkmune-in-t-inmb-20240723monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-join-russell-3000-index-inmb-20240530monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-first-quarter-2024-results-and-provides-business-update-inmb-20240509monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-provides-update-on-two-patients-from-the-phase-1b-alzheimer-s-disease-trial-inmb-20240430monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-cso-and-co-founder-mark-lowdell-ph-d-receives-the-isct-career-achievement-award-inmb-20240313monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-reports-significant-eeg-improvement-in-alzheimer-s-patients-treated-with-xpro-inmb-20240305monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-to-participate-in-the-oppenheimer-34th-annual-healthcare-life-sciences-conferen-inmb-20240212monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-to-participate-in-baird-s-biotech-discovery-series-webcast-on-february-13-2024-inmb-20240206monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-presents-new-biomarker-and-feasibility-data-from-phase-1b-study-supporting--inmb-20231017monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-deliver-keynote-talk-at-5th-world-aging-and-rejuvenation-conference-inmb-20230712monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-novel-mri-biomarker-data-demonstrating-improvement-in-gray-matter-inmb-20230711monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-s-chief-scientific-officer-mark-lowdell-ph-d-to-present-plenary-talk-at-int-inmb-20230524monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-receives-health-canada-no-objection-letter-to-commence-clinical-trial-of-xp-inmb-20221114monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-presents-data-on-combination-therapy-with-inb03-on-overcoming-resistance-to-inmb-20220616monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-nine-data-presentations-at-ad-pd-2022-international-conference-on-inmb-20220315monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-fourth-quarter-and-full-year-2021-results-and-provides-business-u-inmb-20220303monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-research-collaboration-with-chinese-university-of-hong-kong-to-ev-inmb-20220125monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-participate-in-january-investor-conferences-and-a-medical-meeting-inmb-20220104monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-key-breast-cancer-treatment-resistance-data-to-be-presented-at-th-inmb-20211209monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-present-at-the-btig-virtual-biotechnology-conference-inmb-20210805monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-second-quarter-2021-financial-results-and-provide-a-corporate-upd-inmb-20210728monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-participate-in-alzheimer-disease-panel-presented-by-maxim-group-llc-and--inmb-20210524monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-participation-in-fireside-chat-at-the-b-riley-neurosciences-confe-inmb-20210426monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-fourth-quarter-and-full-year-2020-results-and-provides-business-u-inmb-20210304monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-first-patient-dosed-in-phase-2-trial-of-quellor-for-pulmonary-com-inmb-20201109monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-third-quarter-2020-financial-results-and-provide-a-corporate-upda-inmb-20201029monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-present-at-the-btig-virtual-biotechnology-conference-2020-inmb-20200803monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-proposed-public-offering-of-common-stock-inmb-20200715monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-interim-phase-ib-data-demonstrating-that-xpro1595-decreases-neuro-inmb-20200713monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-s-inb03-inhibits-cell-migration-tumor-growth-and-induces-innate-immune-resp-inmb-20200511monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-announces-final-phase-i-clinical-data-for-its-soluble-tnf-inhibitor-inb03-demon-inmb-20191217monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-potentially-strong-link-between-obesity-and-alzheimer-s-disease-a-inmb-20191021monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-to-present-at-the-h-c-wainwright-21st-annual-healthcare-conference-on-tuesday-s-inmb-20190905monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-appoints-biotechnology-executive-edgardo-baracchini-as-new-board-member-inmb-20190808monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-announces-common-stock-purchase-agreement-for-up-to-20-0-million-with-lincoln-p-inmb-20190516monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-co-founder-and-ceo-to-speak-at-cambridge-healthtech-institute-s-10th-annual-inf-inmb-20190409monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-to-ring-the-nasdaq-closing-bell-on-tuesday-april-9-2019-inmb-20190402monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-co-founder-and-ceo-presented-at-cambridge-healthtech-institute-s-4th-annual-imm-inmb-20190319monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-to-present-at-bio-ceo-investor-conference-inmb-20190206monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-granted-phase-i-clinical-trial-authorization-of-lead-product-inkmune-in-refract-inmb-20181219monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-announces-publication-of-myeloid-derived-suppressor-cells-mdsc-report-in-the-ce-inmb-20181207monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-nominated-for-buzz-of-bio-award-at-2019-ceo-investor-conference-inmb-20181204monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-co-founder-and-cso-named-regional-vp-to-the-board-of-international-society-of-c-inmb-20181017monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-named-finalist-for-lifestars-u-s-private-company-of-the-year-award-inmb-20180927monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-co-founder-and-chief-scientific-officer-mark-lowdell-ph-d-chairing-sessions-at--inmb-20180912monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-to-present-at-two-prestigious-cambridge-healthtech-institute-events-inmb-20180828monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-ceo-dr-raymond-j-tesi-to-present-at-14th-annual-biomarkers-immuno-oncology-worl-inmb-20180607monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-initiates-phase-i-clinical-trial-of-inb03-inmb-20180523monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-co-founder-and-chief-scientific-officer-mark-lowdell-phd-delivers-keynote-at-ct-inmb-20180412monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-s-professor-mark-lowdell-to-participate-as-expert-speaker-at-the-third-annual-i-inmb-20180326monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-appoints-scott-juda-to-board-of-directors-inmb-20180313monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-to-present-at-upcoming-conferences-inmb-20180227monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-presenting-at-noblecon14-on-january-29th-inmb-20180123monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-appoints-edgardo-baracchini-to-its-board-of-directors-gains-additional-licensin-inmb-20171016monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-to-present-at-the-bio-investor-2017-healthcare-conference-inmb-20171011monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-licenses-inb03-a-first-in-class-innate-immune-system-check-point-inhibitor-that-inmb-20171010monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-licenses-technology-to-deplete-myeloid-derived-suppressor-cells-of-the-innate-i-inmb-20171009monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-adds-clinical-development-and-product-development-expertise-with-the-appointmen-inmb-20170926monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-crvo-20250805monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-announces-oral-presentation-at-19th-international-conference-on-alzheimer-s-and-p-crvo-20250325monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-to-present-at-the-8th-international-lewy-body-dementia-conference-crvo-20250129monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-announces-key-senior-leadership-appointments-crvo-20241113monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-awarded-the-prix-galien-usa-2024-prize-for-best-startup-crvo-20241108monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-to-participate-in-upcoming-investor-conferences-crvo-20241107monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-to-participate-in-3rd-annual-roth-healthcare-opportunities-conference-crvo-20241002monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-to-participate-in-upcoming-investor-conferences-crvo-20240827monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-to-participate-in-the-canaccord-genuity-44th-annual-growth-conference-crvo-20240730monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-to-participate-in-the-emerging-growth-conference-crvo-20240717monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-announces-addition-to-russell-2000-and-russell-3000-indexes-crvo-20240624monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-announces-completion-of-enrollment-in-phase-2b-rewind-lb-clinical-trial-of-neflam-crvo-20240611monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-corporat-crvo-20240401monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-to-participate-in-upcoming-investor-conferences-crvo-20240328monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-to-participate-in-the-bio-ceo-and-investor-conference-crvo-20240221monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-announces-appointment-of-industry-leader-joshua-boger-ph-d-as-chair-of-the-board-crvo-20240207monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-to-participate-in-the-emerging-growth-conference-67-crvo-20240205monthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-presents-preclinical-breast-cancer-data-from-its-oral-kinesin-degrader-progr-bold-20260417monthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-to-participate-in-the-piper-sandler-healthcare-conference-bold-20241125monthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-to-participate-in-the-2024-guggenheim-global-healthcare-conference-bold-20241105monthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-announces-departure-of-chief-financial-officer-bold-20241014monthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-to-participate-in-the-2024-cantor-global-healthcare-conference-bold-20240911monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-appoints-renowned-neurosurgeon-dr-parag-patil-as-chief-medical-advisor-nmtc-20250512monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-to-report-second-quarter-fiscal-year-2025-financial-results-on-tuesday-may-13-at--nmtc-20250501monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-completes-fda-submission-for-the-onerf-trigeminal-nerve-ablation-system-to-treat--nmtc-20250423monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-issues-letter-to-shareholders-nmtc-20250416monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-onerf-technology-success-story-featured-on-fox-news-nmtc-20250414monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-corporation-announces-pricing-of-8-0-million-public-offering-nmtc-20250404monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-today-s-marketplace-upd-nmtc-20250318monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-ceo-joins-today-s-marketplace-to-discuss-the-latest-treatments-for-epilepsy-nmtc-20250318monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-accelerates-timeline-of-510-k-submission-to-fda-for-the-onerf-trigeminal-nerve-ab-nmtc-20250311monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-to-present-at-the-oppenheimer-35th-annual-healthcare-medtech-services-conference-nmtc-20250305monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-to-report-first-quarter-fiscal-year-2025-financial-results-on-wednesday-february--nmtc-20250205monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-announces-change-of-virtual-investor-webinar-to-friday-january-10-2024-nmtc-20250106monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-announces-virtual-investor-webinar-on-january-9-2025-at-11-00-a-m-est-nmtc-20250103monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-to-report-fourth-quarter-and-fiscal-year-2024-financial-results-on-december-17-at-nmtc-20241204monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-to-present-at-the-2024-thinkequity-conference-nmtc-20241024monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-spinal-cord-stimulation-electrode-technology-to-be-featured-at-the-business-of-pa-nmtc-20240924monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-announces-breakthrough-case-completed-with-onerf-ablation-system-at-the-universit-nmtc-20240910monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-nmtc-20240905monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-to-report-third-quarter-fiscal-year-2024-financial-results-and-provide-corporate--nmtc-20240812monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-announces-2-65-million-equity-financing-and-3-0-million-credit-facility-nmtc-20240805monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-announces-first-in-human-ablations-completed-with-onerf-ablation-system-nmtc-20240625monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-granted-approval-of-icd-10-procedure-code-for-seeg-rf-ablation-nmtc-20240620monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-to-report-second-quarter-fiscal-year-2024-financial-results-and-provide-corporate-nmtc-20240510monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-ceo-dave-rosa-featured-on-bloomberg-technology-nmtc-20240410monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-announces-first-implant-of-onerf-ablation-electrodes-nmtc-20240409monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-ceo-dave-rosa-featured-on-fox-business-network-s-varney-co-nmtc-20240404monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-to-participate-in-the-36th-annual-roth-conference-nmtc-20240308monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-nmtc-20240223monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-to-report-first-quarter-fiscal-year-2024-financial-results-and-provide-corporate--nmtc-20240208monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-to-report-fourth-quarter-and-fiscal-year-2023-financial-results-and-provide-corpo-nmtc-20231207monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-to-present-at-the-thinkequity-conference-on-october-19-2023-nmtc-20231013monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-nmtc-20230906monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-to-report-third-quarter-fiscal-year-2023-financial-results-and-provide-a-corporat-nmtc-20230808monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-submits-510-k-application-to-fda-for-onerf-ablation-system-nmtc-20230612monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-announces-first-clinical-case-using-evo-seeg-electrode-in-robotic-neurosurgery-nmtc-20230517monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-to-report-second-quarter-fiscal-year-2023-financial-results-and-provide-a-corpora-nmtc-20230511monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-announces-first-clinical-case-using-evo-seeg-electrode-performed-at-mayo-clinic-nmtc-20230510monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-nmtc-20230505monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-to-present-at-the-sidoti-micro-cap-virtual-conference-on-may-10-nmtc-20230505monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-announces-u-s-commercial-launch-of-evo-seeg-electrodes-nmtc-20230502monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-nmtc-20230427monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-announces-hiring-of-senior-staff-nmtc-20190130monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-corporation-announces-appointments-to-artificial-intelligenc-nmtc-20181113monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-announces-2017-achievements-and-provides-corporate-update-nmtc-20180523monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-corporation-announces-appointment-to-scientific-advisory-boa-nmtc-20180517monthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-to-participate-in-16th-annual-craig-hallum-alpha-select-conference-grce-20251117monthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-to-participate-in-the-2025-bio-international-conference-grce-20250613monthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference-grce-20250225monthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-announces-private-placement-financing-of-up-to-30-million-grce-20250210monthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-to-participate-in-upcoming-investor-events-january-2025-grce-20250107monthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-to-exhibit-at-the-american-society-of-health-system-pharmacists-confere-grce-20241204monthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-to-host-virtual-kol-event-on-gtx-104-in-aneurysmal-subarachnoid-hemorrh-grce-20241030monthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-holdings-announces-positive-fda-rmat-meeting-on-registrational-clinical--snti-20260514monthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-bolsters-scientific-advisory-board-with-appointment-of-james-b-trager-ph-d-snti-20250410monthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-appoints-feng-hsiung-to-board-of-directors-snti-20250313monthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-strengthens-leadership-team-with-strategic-hires-snti-20250225monthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-announces-second-quarter-2024-results-and-reviews-recent-corporate-and-pipeline--snti-20240813monthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-announces-reverse-stock-split-snti-20240716monthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-announces-first-quarter-2024-results-and-reviews-recent-corporate-highlights-snti-20240509monthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-and-dynamics-special-purpose-corp-announce-business-combination-agreement-to-cre-snti-20211220monthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-highlights-preclinical-advances-on-pipeline-candidate-senti-202-at-ash-2021-annu-snti-20211213monthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-adds-prominent-scientific-and-industry-leaders-to-its-scientific-advisory-board-snti-20210817monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-reports-first-half-2025-financial-results-aplm-20251222monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-announces-settlement-of-cayman-litigation-aplm-20251119monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-announces-changes-to-its-board-of-directors-and-composition-of-committees-aplm-20251118monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-announces-shareholder-approval-and-effective-date-for-1-for-100-reverse-share-s-aplm-20241121monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-presents-vebreltinib-data-in-patients-with-non-small-cell-lung-cancer-with-mete-aplm-20240916monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-aplm-20240904monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-reports-first-half-2024-financial-results-and-highlights-vebreltinib-clinical-p-aplm-20240814monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-announces-positive-preliminary-data-of-vebreltinib-in-patients-with-non-cns-met-aplm-20240813monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-to-present-at-the-canaccord-genuity-44th-annual-growth-conference-aplm-20240808monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-announces-vebreltinib-data-at-the-2024-american-society-of-clinical-oncology-as-aplm-20240604monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-announces-presentation-at-the-2024-bio-international-convention-aplm-20240529monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-presents-vebreltinib-data-at-the-2024-american-association-for-cancer-research--aplm-20240410monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-announces-poster-presentations-of-vebreltinib-data-at-the-2024-american-associa-aplm-20240402monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-to-announce-full-year-2023-financial-results-and-host-conference-call-on-march--aplm-20240326monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-to-present-at-the-oppenheimer-34th-annual-healthcare-life-sciences-conference-aplm-20240207monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-to-participate-in-a-fireside-chat-at-the-b-riley-securities-2024-virtual-oncolo-aplm-20240117monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-completes-enrollment-in-phase-3-bridging-study-of-uproleselan-in-chinese-patien-aplm-20240103monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-to-present-at-the-2024-biotech-showcase-aplm-20240102monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-presents-interim-data-from-two-ongoing-phase-2-clinical-trials-with-vebreltinib-aplm-20231204monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-to-participate-in-a-fireside-chat-at-the-h-c-wainwright-4th-annual-precision-on-aplm-20231129monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-announces-presentation-of-vebreltinib-data-at-the-2023-iaslc-north-america-conf-aplm-20231128monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-announces-the-first-approval-of-vebreltinib-for-met-exon-14-skip-non-small-cell-aplm-20231116monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-announces-two-new-cohorts-in-global-phase-2-sparta-study-of-vebreltinib-in-non--aplm-20231031monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-announces-report-of-activity-of-vebreltinib-in-glioblastoma-multiforme-gbm-with-aplm-20231026monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-announces-efficacy-of-vebreltinib-in-nsclc-patients-with-metex14-skipping-mutat-aplm-20231023monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-announces-presentations-of-vebreltinib-data-at-esmo-2023-aplm-20231016monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-reports-first-half-2023-financial-results-and-provides-corporate-update-aplm-20230928monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-aplm-20230906monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-co-founder-and-president-sanjeev-redkar-ph-d-to-speak-at-23rd-annual-r-bryan-mi-aplm-20230411monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-receives-fda-orphan-drug-designation-for-vebreltinib-apl-101-for-treatment--aplm-20221115monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-a-late-stage-clinical-biopharmaceutical-company-to-be-listed-on-nasdaq-thro-aplm-20220914monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-expands-leadership-team-with-appointment-of-jane-wang-phd-as-chief-scientif-aplm-20220726monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-to-host-virtual-investor-events-on-wednesday-january-26-2022-and-thursday-j-aplm-20220112monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-announces-ceo-guo-liang-yu-phd-appointed-as-chairman-of-the-board-for-the-b-aplm-20220104monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-doses-first-patient-in-phase-3-clinical-trial-with-apl-106-uproleselan-inje-aplm-20211122monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-doses-first-patient-in-a-phase-i-clinical-trial-of-apl-102-aplm-20210810monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-announces-official-opening-of-shanghai-branch-aplm-20210520monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-appoints-seasoned-healthcare-executive-k-peony-yu-m-d-as-chief-medical-offi-aplm-20210309monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-announces-successful-enrollment-of-first-patient-into-phase-1-clinical-tria-aplm-20210304monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-licenses-a-targeted-active-checkpoint-control-immunotherapy-for-greater-chi-aplm-20210212monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-and-iterion-therapeutics-announce-exclusive-collaboration-and-license-agree-aplm-20210210monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-and-edison-oncology-announce-licensing-agreement-for-novel-protein-tyrosine-aplm-20210209monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-receives-china-investigational-new-drug-approval-for-apl-102-to-initiate-a--aplm-20201112monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-closes-124-million-series-c-financing-aplm-20201106monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-receives-china-investigational-new-drug-approval-for-apl-106-to-initiate-a--aplm-20200928monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-announces-initiation-of-sparta-phase-2-clinical-trial-for-c-met-inhibitor-a-aplm-20200521monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-appoints-fabio-m-benedetti-m-d-as-chief-medical-officer-aplm-20190501monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-presents-positive-preclinical-data-on-apl-102-an-oral-multi-kinase-inhibito-aplm-20190401monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-strengthens-leadership-with-key-hires-aplm-20190122monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-previously-cbt-pharmaceuticals-inc-raises-100-million-in-series-b-financing-aplm-20190107monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-first-quarter-2026-financial-resu-algs-20260507monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-announce-1st-quarter-2026-financial-results-on-may-7-2026-algs-20260430monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-algs-20260424monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-algs-20251212monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-algs-20251114monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-algs-20250815monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-first-subject-dosed-in-the-phase-2-b-supreme-study-of-alg-00-algs-20250813monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-second-quarter-2025-financial-res-algs-20250806monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-announce-2nd-quarter-2025-financial-results-on-august-6-2025-algs-20250730monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-algs-20250711monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-appoints-kieron-wesson-as-vice-president-head-of-chemistry-manufacturi-algs-20250618monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-algs-20250613monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-algs-20250529monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-appoints-laura-kavanaugh-as-vice-president-head-of-legal-algs-20250520monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-algs-20250516monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-positive-data-at-the-easl-congress-2025-algs-20250508monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-first-quarter-2025-financial-resu-algs-20250506monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-announce-1st-quarter-2025-financial-results-on-may-6-2025-algs-20250429monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-eight-abstracts-accepted-for-presentation-at-the-easl-congre-algs-20250423monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-positive-data-at-apasl-2025-algs-20250326monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-algs-20250314monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-fourth-quarter-and-full-year-2024-algs-20250310monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-announce-4th-quarter-2024-financial-results-on-march-10-2025-algs-20250303monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-algs-20241213monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-at-investor-conferences-in-december-algs-20241126monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-positive-data-at-the-liver-meeting-tlm-2024-algs-20241119monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-third-quarter-2024-financial-resu-algs-20241106monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-announce-3rd-quarter-2024-financial-results-on-november-6-2024-algs-20241030monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-u-s-fda-clearance-of-ind-application-for-alg-000184-algs-20241022monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-acceptance-of-abstracts-on-incremental-data-from-alg-000184--algs-20241015monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-algs-20241011monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-appoints-david-perry-as-vice-president-of-business-development-algs-20241001monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-at-investor-conferences-in-october-algs-20240930monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-strengthens-senior-leadership-team-with-the-appointment-of-hardean-ach-algs-20240924monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-positive-topline-results-from-the-phase-2a-herald-study-of-a-algs-20240919monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-announce-topline-results-from-the-phase-2a-herald-study-of-alg-0550-algs-20240918monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-algs-20240913monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-reverse-stock-split-algs-20240815monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-strengthens-board-with-two-new-independent-directors-algs-20240808monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-second-quarter-2024-financial-res-algs-20240806monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-announce-2nd-quarter-2024-financial-results-on-august-6-2024-algs-20240730monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-clinical-collaboration-with-xiamen-amoytop-biotech-co-ltd-algs-20240722monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-host-kol-event-to-discuss-the-positive-phase-1b-data-from-alg-00018-algs-20240710monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-positive-data-at-the-easl-congress-2024-algs-20240605monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-six-abstracts-accepted-for-presentation-at-easl-2024-algs-20240522monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-the-completion-of-enrollment-in-the-alg-055009-phase-2a-hera-algs-20240521monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-first-quarter-2024-financial-resu-algs-20240507monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-announce-1st-quarter-2024-financial-results-on-may-7-2024-algs-20240430monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-positive-clinical-data-at-escmid-2024-from-the-alg-097558-pha-algs-20240425monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-mourns-the-passing-of-mash-industry-leader-stephen-a-harrison-md-algs-20240425monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-participate-in-the-piper-sandler-spring-biopharma-symposium-2024-algs-20240409monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-first-subjects-dosed-in-the-phase-2a-herald-study-of-alg-055-algs-20240403monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-positive-clinical-data-at-apasl-2024-from-alg-055009-and-alg--algs-20240327monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-the-initiation-of-the-phase-2a-herald-study-of-alg-055009-in-algs-20240318monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-fourth-quarter-and-full-year-2023-algs-20240312monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-announce-4th-quarter-2023-financial-results-on-march-12-2024-algs-20240305monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-participate-in-the-leerink-partners-global-biopharma-conference-202-algs-20240226monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-host-kol-event-to-discuss-phase-2a-herald-study-of-alg-055009-in-ma-algs-20240220monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-strengthens-finance-leadership-team-with-two-new-appointments-algs-20240213monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-positive-clinical-data-at-hep-dart-2023-from-phase-1-studies--algs-20231207monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-at-the-piper-sandler-healthcare-conference-algs-20231120monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-clinical-and-nonclinical-data-at-the-aasld-liver-meeting-2023-algs-20231113monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-positive-data-at-the-aasld-liver-meeting-2023-demonstrating-t-algs-20231110monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-host-kol-event-to-discuss-alg-000184-phase-1-aasld-late-breaker-dat-algs-20231103monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-third-quarter-2023-financial-resu-algs-20231102monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-announce-3rd-quarter-results-on-november-2-2023-algs-20231026monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-late-breaking-poster-on-alg-000184-its-cam-e-drug-candidate-algs-20231025monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-92-million-private-placement-financing-algs-20231023monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-award-of-an-8-5-million-niaid-contract-to-advance-developmen-algs-20231003monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-ind-clearance-for-nash-lead-alg-055009-algs-20230921monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-second-quarter-2023-financial-res-algs-20230803monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-announce-second-quarter-results-on-august-03-2023-algs-20230727monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-the-selection-of-stephen-harrison-md-as-principal-investigat-algs-20230719monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-data-from-its-liver-disease-programs-at-the-european-associat-algs-20230621monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-data-on-its-liver-disease-programs-at-the-european-associat-algs-20230607monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-at-the-jefferies-2023-healthcare-conference-algs-20230524monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-research-collaboration-and-development-agreement-with-xiamen-algs-20230512monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-first-quarter-2023-financial-resu-algs-20230504monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023-algs-20230427monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-data-from-chronic-hepatitis-b-and-hepatocellular-carcinoma--algs-20230411monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-clinical-data-from-nash-program-at-the-2023-paris-hepatology--algs-20230329monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-fourth-quarter-and-full-year-2022-algs-20230309monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-announce-fourth-quarter-results-march-9-2023-algs-20230228monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-program-updates-at-the-32nd-conference-of-the-asian-pacific-a-algs-20230216monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-program-updates-at-the-32nd-conference-of-the-asian-pacific-algs-20230214monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference-algs-20230210monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-strategic-reprioritization-of-nash-and-covid-19-programs-and-algs-20230208monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-initiates-dosing-with-its-small-interfering-rna-sirna-drug-candidate-a-algs-20221214monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-nonclinical-data-for-its-coronavirus-therapeutic-program-at-t-algs-20221208monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-clinical-data-for-its-nash-program-and-nonclinical-data-for-i-algs-20221104monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-third-quarter-2022-financial-resu-algs-20221102monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-nonclinical-and-clinical-data-for-its-chronic-hepatitis-b-a-algs-20221021monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-announce-third-quarter-results-november-2-2022-algs-20221019monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-data-on-pan-coronavirus-protease-inhibitors-for-the-treatme-algs-20221018monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-initiates-dosing-in-healthy-volunteers-with-sirna-drug-candidate-alg-1-algs-20221014monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-files-response-to-janssen-biopharma-lawsuit-and-lodges-counterclaims-a-algs-20220928monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-second-quarter-2022-financial-res-algs-20220804monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-announce-second-quarter-2022-results-august-4-2022-algs-20220727monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-initiates-12-week-dosing-cohort-in-phase-1b-study-evaluating-its-class-algs-20220725monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-28-day-safety-efficacy-and-pharmacokinetic-clinical-data-for--algs-20220622monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-participate-in-metropolitan-antiviral-drug-accelerator-recipient-of-algs-20220606monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-at-the-jefferies-2022-healthcare-conference-algs-20220523monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-first-quarter-2022-financial-resu-algs-20220504monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-28-day-safety-efficacy-and-pharmacokinetic-data-for-cam-dru-algs-20220503monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-announce-first-quarter-2022-results-may-4-2022-algs-20220427monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-selects-drug-candidate-alg-097558-a-potent-ritonavir-free-oral-proteas-algs-20220404monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-discontinues-development-of-its-antisense-oligonucleotide-drug-candidate-alg-020572-algs-20220322monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent-algs-20220310monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-announce-fourth-quarter-and-full-year-2021-results-march-10-2022-algs-20220302monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-at-the-11th-annual-svb-leerink-global-healthcare-conference-algs-20220203monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-begins-dosing-in-chronic-hepatitis-b-patients-in-its-phase-1-antisense-algs-20220126monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-expands-collaboration-with-merck-to-develop-oligonucleotide-therapies--algs-20220111monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-halting-further-development-of-stops-drug-candidate-alg-010133-algs-20220106monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-algs-20211221monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-begins-dosing-with-nash-drug-candidate-alg-055009-in-healthy-volunteer-algs-20211209monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-presents-update-of-chronic-hepatitis-b-pipeline-portfolio-at-hep-dart-2021-algs-20211207monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-at-the-piper-sandler-33rd-annual-virtual-healthcare-confere-algs-20211122monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-appoints-bridget-martell-ma-m-d-to-its-board-of-directors-algs-20211118monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-virtually-at-the-jefferies-london-healthcare-conference-202-algs-20211115monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-data-for-its-chronic-hepatitis-b-chb-and-nonalcoholic-steatoh-algs-20211112monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-third-quarter-2021-financial-resu-algs-20211104monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-announce-third-quarter-2021-results-november-4-2021-algs-20211028monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-data-for-its-clinical-portfolio-targeting-chronic-hepatitis-algs-20211014monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-begins-dosing-with-antisense-oligonucleotide-drug-candidate-alg-020572-algs-20211011monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference-algs-20210920monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-second-quarter-2021-financial-res-algs-20210805monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-announce-second-quarter-2021-results-august-5-2021-algs-20210729monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-pricing-of-83-6-million-public-offering-of-common-stock-algs-20210701monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-proposed-public-offering-of-common-stock-algs-20210628monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-phase-1-safety-and-pharmacokinetic-data-for-stops-molecule--algs-20210621monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-pipeline-update-and-upcoming-presentations-at-the-european-a-algs-20210614monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-preliminary-antiviral-activity-of-alg-000184-in-chronic-hep-algs-20210610monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-at-the-jefferies-virtual-healthcare-conference-algs-20210520monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-first-quarter-2021-financial-resu-algs-20210510monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-announce-first-quarter-2021-results-may-10-2021-algs-20210505monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-appoints-james-scopa-j-d-mba-to-its-board-of-directors-algs-20210427monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-begins-dosing-with-capsid-assembly-modulator-drug-candidate-alg-000184-algs-20210414monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-recent-algs-20210323monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-begins-dosing-with-stops-molecule-drug-candidate-alg-010133-in-first-c-algs-20210310monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-nonclinical-data-for-its-covid-19-therapeutic-in-development--algs-20210308monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-data-for-its-chronic-hepatitis-b-drug-candidates-at-the-30th--algs-20210203monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-algs-20210107monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-update-on-development-of-sars-cov-2-therapeutic-candidate-and-algs-20201217monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-enters-into-an-exclusive-license-and-research-collaboration-agreement-with-merck-to-algs-20201207monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-data-on-chronic-hepatitis-b-nash-and-hepatocellular-carcinoma-algs-20201116monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-presentations-at-the-jefferies-virtual-london-healthcare-con-algs-20201113monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-is-awarded-1-8m-vlaio-grant-to-advance-chronic-hepatitis-b-research-algs-20201112monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-doses-first-subject-in-phase-1-proof-of-concept-study-of-small-molecul-algs-20201030monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-pricing-of-initial-public-offering-algs-20201016monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-coronavirus-therapeutic-screening-assay-development-at-isirv--algs-20201008monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-receives-clinical-trial-application-approval-for-chronic-hepatitis-b-c-algs-20200928monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-nonclinical-data-for-all-components-of-chronic-hepatitis-b--algs-20200827monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-nonclinical-nash-update-at-easl-digital-international-liver-algs-20200826monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-submits-clinical-trial-application-for-chronic-hepatitis-b-capsid-asse-algs-20200824monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-doses-first-subject-in-phase-1-proof-of-concept-study-of-oligonucleoti-algs-20200818monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-and-ku-leuven-announce-collaboration-for-the-development-of-a-therapeu-algs-20200701monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-and-emory-university-announce-expanded-license-agreement-and-ink-agree-algs-20200623monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-submits-clinical-trial-application-for-chronic-hepatitis-b-oligonucleo-algs-20200618monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-appoints-lesley-ann-calhoun-as-chief-financial-officer-algs-20200603monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-at-the-jefferies-virtual-healthcare-conference-algs-20200602monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-expands-licensing-agreement-with-luxna-biotech-in-oligonucleotide-tech-algs-20200415monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-closes-125m-series-b-financing-algs-20200110monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-algs-20200107monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-combination-based-approach-for-treating-chronic-hepatitis-b-c-algs-20191210monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-welcomes-kathleen-sereda-glaub-to-its-board-of-directors-algs-20191125monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-nash-asset-development-update-at-the-liver-meeting-2019-algs-20191111monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-presents-strong-chronic-hepatitis-b-drug-candidate-portfolio-at-the-li-algs-20191108monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-to-present-multiple-posters-during-the-liver-meeting-2019-algs-20191029monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-appoints-industry-veteran-matthew-w-mcclure-m-d-as-executive-vice-pres-algs-20191014monthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-responds-to-lynx1-s-revised-indication-of-interest-at-a-reduced-price-and-premiu-neup-20251204monthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-provides-facts-exposes-false-narratives-in-response-to-lynx1-fictions-neup-20251201monthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-therapeutics-inc-sends-letter-to-stockholders-neup-20251124monthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-therapeutics-completes-target-enrollment-in-phase-3-affirm-1-trial-of-bnc-210-in-neup-20250904monthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-therapeutics-inc-to-receive-15m-milestone-payment-from-merck-neup-20250212monthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-completes-re-domiciliation-and-successor-listing-on-nasdaq-neup-20241223monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-enrollment-of-first-patients-in-u-s-department-of-war-funde-btai-20260408monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-food-drug-administration-acceptance-of-supplemental-new-dru-btai-20260401monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-closing-of-8-0-million-registered-direct-offering-btai-20260311monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-approximately-8-0-million-registered-direct-offering-btai-20260310monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-host-virtual-roundtable-featuring-leading-medical-experts-addressi-btai-20260219monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-expands-leadership-team-to-prepare-for-launch-of-igalmi-in-the-at-hom-btai-20260112monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-planning-to-submit-snda-this-month-seeking-fda-approval-for-at-home-u-btai-20260107monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-serenity-at-home-pivotal-phase-3-safety-trial-met-its-prima-btai-20250827monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-announce-topline-results-from-serenity-at-home-pivotal-phase-3-saf-btai-20250826monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-positive-fda-pre-snda-meeting-comments-for-snda-submission--btai-20250818monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-participate-in-the-h-c-wainwright-co-hcw-home-series-btai-20250813monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-publication-in-frontiers-in-pharmacology-on-the-effects-of--btai-20250806monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-last-patient-last-visit-in-serenity-at-home-pivotal-phase-3-btai-20250801monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-submits-pre-supplemental-new-drug-application-meeting-package-in-supp-btai-20250721monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-receives-second-positive-recommendation-from-data-safety-monitoring-b-btai-20250701monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-receives-positive-recommendation-from-data-safety-monitoring-board-ds-btai-20250527monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-granted-extension-to-regain-compliance-with-nasdaq-continued-listing--btai-20250527monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-strengthens-cash-position-to-advance-serenity-at-home-pivotal-phase-3-btai-20250311monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-33-enrollment-in-serenity-at-home-pivotal-phase-3-safety-tr-btai-20250307monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-closing-of-14-million-registered-direct-offering-btai-20250304monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-14-million-registered-direct-offering-btai-20250303monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-fda-closed-its-inspection-of-site-for-phase-3-tranquility-i-btai-20250303monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-rule-btai-20250228monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-reverse-stock-split-btai-20250206monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-provides-clinical-and-business-update-btai-20250205monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-pricing-of-7-0-million-public-offering-btai-20241122monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-proposed-public-offering-btai-20241121monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-advances-pivotal-phase-3-trials-of-bxcl501-for-acute-treatment-of-agi-btai-20241112monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-report-third-quarter-2024-financial-results-on-november-14-2024-btai-20241108monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-thinkequity-conference-btai-20241029monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-u-s-department-of-defense-grant-to-university-of-north-caro-btai-20241015monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-clinical-prioritization-and-update-on-bxcl501-late-stage-pr-btai-20240919monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-initiation-of-serenity-at-home-pivotal-phase-3-safety-trial-btai-20240905monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-participate-in-canaccord-genuity-44th-annual-growth-conference-btai-20240807monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-report-second-quarter-2024-financial-results-on-august-6-2024-btai-20240730monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-positive-topline-results-from-post-marketing-requirement-st-btai-20240625monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-jefferies-global-healthcare-conference-btai-20240528monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-oral-and-poster-presentations-at-the-2024-american-society--btai-20240521monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-report-first-quarter-2024-financial-results-on-may-9-2024-btai-20240425monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-late-breaking-abstract-on-preliminary-findings-from-phase-2-btai-20240424monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-plan-for-evaluating-bxcl501-in-the-at-home-setting-to-expan-btai-20240422monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-tranquility-in-care-pivotal-phase-3-trial-plan-with-bxcl501-btai-20240410monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-25-million-registered-direct-offering-btai-20240325monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-european-patent-office-s-grant-of-patent-for-method-of-trea-btai-20240315monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-report-fourth-quarter-and-full-year-2023-financial-results-on-marc-btai-20240301monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-termination-of-proposed-public-offering-btai-20240213monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-receives-fda-fast-track-designation-for-bxcl701-for-treatment-of-smal-btai-20240212monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-alert-bragar-eagel-squire-p-c-is-investigating-bioxcel-therapeutics-inc-on-behalf--btai-20240210monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-proposed-public-offering-btai-20240208monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-completion-of-patient-enrollment-in-safety-portion-of-inves-btai-20240206monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-uspto-s-allowance-of-patent-application-for-method-of-treat-btai-20240205monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-hosting-virtual-neuroscience-r-d-day-today-btai-20231212monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-strengthens-clinical-development-leadership-to-advance-late-stage-pro-btai-20231211monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-host-virtual-neuroscience-r-d-day-on-dec-12-2023-btai-20231130monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-positive-overall-survival-results-from-single-arm-open-label--btai-20231108monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-update-on-nida-funded-trial-of-bxcl501-sublingual-dexmedeto-btai-20231106monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-report-third-quarter-2023-financial-results-on-november-14-2023-btai-20231031monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-receives-permanent-j-code-for-igalmi-dexmedetomidine-sublingual-film--btai-20231030monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-positive-findings-from-independent-third-party-audit-of-dat-btai-20231025monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-provides-update-on-recent-developments-for-late-stage-clinical-progra-btai-20231004monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-o-btai-20230830monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-inc-nasdaq-btai-shareholder-alert-bernstein-liebhard-llp-reminds-inve-btai-20230829monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds-btai-20230823monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-inc-nasdaq-btai-deadline-alert-bernstein-liebhard-llp-reminds-investo-btai-20230822monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-inc-please-contact-the-portnoy-law-firm-to-recover-your-losses-septem-btai-20230821monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-o-btai-20230816monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-los-btai-20230814monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds-btai-20230809monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-inc-nasdaq-btai-deadline-alert-bernstein-liebhard-llp-reminds-investo-btai-20230808monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-inc-class-action-notice-kessler-topaz-meltzer-check-llp-reminds-bioxc-btai-20230803monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-inc-investor-alert-kaplan-fox-kilsheimer-llp-notifies-btai-investors--btai-20230803monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-o-btai-20230802monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-report-second-quarter-2023-financial-results-on-august-14-2023-btai-20230731monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-inc-investors-contact-robbins-llp-if-you-incurred-significant-losses--btai-20230726monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds-btai-20230726monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-inc-nasdaq-btai-shareholder-alert-bernstein-liebhard-llp-reminds-inve-btai-20230725monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-inc-please-contact-the-portnoy-law-firm-to-recover-your-losses-septem-btai-20230724monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-inc-btai-sued-by-shareholders-btai-investors-should-contact-robbins-l-btai-20230720monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-o-btai-20230719monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-inc-investor-alert-kaplan-fox-kilsheimer-llp-notifies-bioxcel-therape-btai-20230718monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-inc-nasdaq-btai-shareholder-alert-bernstein-liebhard-llp-reminds-inve-btai-20230718monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-inc-btai-investor-alert-robbins-llp-reminds-investors-of-class-action-btai-20230713monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-inc-please-contact-the-portnoy-law-firm-to-recover-your-losses-septem-btai-20230712monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds-btai-20230712monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-inc-shareholder-alert-bernstein-liebhard-llp-announces-that-a-securit-btai-20230711monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-btai-20230706monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-positive-topline-results-from-tranquility-ii-phase-3-trial--btai-20230629monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-participate-at-two-upcoming-investor-conferences-btai-20230601monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-promising-topline-results-from-part-1-of-pivotal-serenity-i-btai-20230525monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-positive-top-line-data-from-repeat-dosing-of-bxcl501-in-pha-btai-20230516monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference-btai-20230502monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-report-first-quarter-2023-financial-results-on-may-8-2023-btai-20230424monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-on-marc-btai-20230223monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-ring-nasdaq-stock-market-closing-bell-today-btai-20230221monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-positive-full-data-from-phase-2-trial-of-bxcl701-in-rare-ag-btai-20230213monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-host-bxcl701-key-opinion-leader-day-to-highlight-company-s-investi-btai-20230208monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-promising-top-line-results-from-phase-2-trial-of-bxcl701-in-btai-20230111monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-41st-annual-j-p-morgan-healthcare-conference-btai-20221222monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-first-patient-dosed-in-tranquility-iii-phase-3-trial-for-ac-btai-20221219monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-bank-of-america-2022-biotech-smid-cap-conference-btai-20221201monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-first-patients-dosed-in-serenity-iii-phase-3-trial-for-acut-btai-20221130monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-two-upcoming-investor-conferences-btai-20221114monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-report-third-quarter-2022-financial-results-on-november-10-2022-btai-20221027monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-host-igalmi-commercial-day-on-october-18-2022-btai-20221005monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-participate-at-the-h-c-wainwright-24th-annual-global-investment-co-btai-20220907monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-participate-at-the-canaccord-genuity-42nd-annual-growth-conference-btai-20220803monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-nih-nida-grant-to-columbia-university-to-support-further-st-btai-20220801monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-report-second-quarter-2022-financial-results-on-august-9-2022-btai-20220726monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-appoints-michael-p-miller-to-board-of-directors-btai-20220705monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-participate-at-two-upcoming-investor-conferences-btai-20220607monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-updated-presentation-time-at-h-c-wainwright-global-investme-btai-20220520monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-three-upcoming-investor-conferences-btai-20220505monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-first-patient-dosed-in-tranquility-ii-phase-3-trial-for-acu-btai-20220503monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-report-first-quarter-2022-financial-results-on-may-9-2022-btai-20220426monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-formation-of-onkosxcel-therapeutics-to-develop-medicines-fo-btai-20220419monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-260-million-strategic-financing-with-oaktree-and-qatar-inve-btai-20220419monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-fda-approval-of-igalmi-dexmedetomidine-sublingual-film-for--btai-20220406monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-the-barclays-global-healthcare-conference-btai-20220309monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-report-fourth-quarter-and-full-year-2021-financial-results-on-marc-btai-20220224monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-journal-of-the-american-medical-association-publication-of--btai-20220222monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-presents-positive-data-from-phase-2-trial-of-bxcl701-in-aggressive-fo-btai-20220214monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-the-svb-leerink-11th-annual-global-healthcare-conferenc-btai-20220209monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-appoints-matt-wiley-chief-commercial-officer-btai-20220119monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-btai-20220104monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-initiates-pivotal-phase-3-program-of-bxcl501-for-acute-treatment-of-a-btai-20211215monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-extension-of-fda-review-period-of-its-nda-for-bxcl501-for-t-btai-20211201monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-the-2021-jefferies-london-healthcare-conference-btai-20211111monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-report-third-quarter-2021-financial-results-on-november-10-2021-btai-20211027monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-expansion-of-phase-2-trial-of-bxcl701-in-de-novo-and-treatm-btai-20211018monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-highlight-novel-approaches-in-ai-based-drug-candidate-discovery-an-btai-20210923monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-presents-results-from-ongoing-phase-2-trial-of-bxcl701-in-combination-btai-20210915monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-updates-from-ongoing-trial-of-bxcl701-in-aggressive-forms--btai-20210912monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-host-virtual-r-d-day-on-september-23-2021-btai-20210909monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-second-quarter-2021-financial-results-and-recent-operational--btai-20210810monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-report-second-quarter-2021-financial-results-on-august-10-2021-btai-20210728monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference-btai-20210719monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-pricing-of-public-offering-of-common-stock-btai-20210623monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-proposed-public-offering-of-common-stock-btai-20210622monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-host-virtual-commercial-day-on-june-25-2021-btai-20210618monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-participate-in-three-upcoming-healthcare-investor-conferences-btai-20210526monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-fda-acceptance-for-filing-of-nda-for-bxcl501-for-the-acute--btai-20210519monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-presentations-at-the-isbd-2021-global-annual-conference-btai-20210511monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences-btai-20210504monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-host-first-quarter-2021-operating-and-financial-results-conference-btai-20210503monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-launches-boiling-point-educational-campaign-to-shed-light-on-the-impo-btai-20210429monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-presentations-on-serenity-i-ii-at-the-2021-american-psychia-btai-20210426monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-results-of-phase-1b-2-study-of-bxcl501-for-the-treatment-of-btai-20210331monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-receives-fda-breakthrough-therapy-designation-for-bxcl501-for-the-acu-btai-20210315monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for--btai-20210311monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-host-fourth-quarter-and-full-year-2020-operating-and-financial-res-btai-20210304monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-provides-update-on-its-bxcl501-program-for-the-acute-treatment-of-dem-btai-20210303monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-initiation-of-phase-2-placidity-trial-of-bxcl501-for-the-tr-btai-20210225monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-appoints-javier-rodriguez-as-chief-legal-officer-and-corporate-secret-btai-20210223monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-host-virtual-key-opinion-leader-event-to-highlight-bxcl501-as-a-po-btai-20210212monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-an-update-from-its-ongoing-trial-of-bxcl701-in-aggressive--btai-20210204monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-bxcl501-met-the-primary-and-all-secondary-endpoints-in-the--btai-20210105monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-btai-20201217monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-grant-by-u-s-department-of-defense-to-evaluate-bxcl501-in-p-btai-20201207monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference-btai-20201113monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-completion-of-pre-nda-meeting-with-fda-for-bxcl501-for-the--btai-20201111monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-bxcl701-clinical-data-at-the-society-for-immunotherapy-of--btai-20201109monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-host-third-quarter-2020-operating-and-financial-results-conference-btai-20201105monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-receives-fda-clearance-of-ind-for-phase-2-trial-with-bxcl501-for-the--btai-20201026monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-the-h-c-wainwright-22nd-annual-global-investment-confer-btai-20200909monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-host-second-quarter-2020-operating-and-financial-results-conferenc-btai-20200807monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-participate-in-the-canaccord-genuity-40th-annual-growth-conference-btai-20200806monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-pricing-of-public-offering-of-common-stock-btai-20200729monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-proposed-public-offering-of-common-stock-btai-20200727monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-primary-and-secondary-endpoints-met-in-two-pivotal-phase-3--btai-20200720monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-compassionate-use-program-at-massachusetts-general-hospital-btai-20200709monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-notice-of-allowance-for-u-s-patent-application-covering-for-btai-20200707monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-appointment-of-reina-benabou-m-d-ph-d-as-chief-development--btai-20200623monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-appointment-of-william-p-kane-as-chief-commercial-officer-btai-20200616monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-participate-in-two-upcoming-investor-conferences-btai-20200615monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-first-patient-enrolled-in-phase-1b-2-release-trial-of-bxcl5-btai-20200611monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-the-jefferies-virtual-healthcare-conference-btai-20200528monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-completion-of-patient-enrollment-in-phase-3-serenity-trials-btai-20200514monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-the-ubs-virtual-global-healthcare-conference-btai-20200511monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-the-bofa-securities-virtual-health-care-conference-btai-20200507monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-host-first-quarter-2020-operating-and-financial-results-conference-btai-20200505monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-initiation-of-a-phase-2-study-of-bxcl701-in-combination-wit-btai-20200428monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-provides-an-update-on-its-ongoing-phase-3-serenity-trials-btai-20200319monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-host-fourth-quarter-and-full-year-2019-operating-and-financial-res-btai-20200302monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-two-upcoming-healthcare-investor-conferences-btai-20200226monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-pricing-of-public-offering-of-common-stock-btai-20200220monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-proposed-public-offering-of-common-stock-btai-20200219monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-initiation-of-a-phase-2-study-designed-to-assess-agitation--btai-20200218monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-the-2020-bio-ceo-investor-conference-btai-20200207monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-fda-clearance-of-ind-application-for-bxcl501-for-the-treatm-btai-20200205monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-first-patient-enrolled-in-phase-1b-2-study-of-bxcl501-for-a-btai-20200107monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-initiation-of-pivotal-phase-3-studies-of-bxcl501-for-acute--btai-20191230monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-expand-study-of-bxcl701-into-multiple-advanced-solid-tumor-types-btai-20191211monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-prepares-to-initiate-pivotal-phase-3-studies-with-bxcl501-following-p-btai-20191203monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-highlights-upcoming-major-milestones-btai-20191010monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-pricing-of-public-offering-of-common-stock-btai-20190926monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-proposed-public-offering-of-common-stock-btai-20190925monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-bxcl501-program-initiative-for-prevention-and-treatment-of--btai-20190918monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-receives-fda-orphan-drug-designation-for-bxcl701-for-the-treatment-of-btai-20190904monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-award-of-grant-by-u-s-department-of-defense-s-dod-congressi-btai-20190820monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-the-canaccord-genuity-2019-annual-growth-conference-btai-20190731monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-report-second-quarter-and-half-year-2019-financial-results-and-bus-btai-20190730monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-added-to-russell-3000-index-btai-20190701monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-participate-in-the-bmo-2019-prescriptions-for-success-healthcare-c-btai-20190618monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-completes-dosing-two-cohorts-of-agitated-schizophrenia-patients-with--btai-20190610monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-ceo-dr-vimal-mehta-to-participate-in-bio-international-convention-pan-btai-20190606monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-fda-clearance-of-ind-application-for-triple-combination-in--btai-20190603monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-the-jefferies-2019-global-healthcare-conference-btai-20190531monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-highlight-advances-in-the-bxcl501-program-at-2019-investor-event-i-btai-20190513monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-the-2019-ubs-global-healthcare-conference-btai-20190509monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-advances-process-development-for-bxcl501-thin-film-formulation-btai-20190502monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-host-first-quarter-2019-financial-results-and-business-update-btai-20190429monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-upcoming-investor-conferences-in-april-btai-20190403monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-29th-annual-oppenheimer-healthcare-conference-btai-20190313monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-participate-in-upcoming-investor-conferences-in-march-btai-20190305monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-host-fourth-quarter-full-year-2018-financial-results-and-business--btai-20190301monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-2019-bio-ceo-investor-conference-btai-20190206monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-expands-indication-for-lead-neuroscience-asset-bxcl501-to-treat-sympt-btai-20190204monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-positive-human-proof-of-concept-data-for-acute-treatment-of-a-btai-20190103monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-receives-fda-fast-track-designation-for-bxcl501-for-acute-treatment-o-btai-20181227monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-bmo-capital-markets-2018-prescriptions-for-success-heal-btai-20181203monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-host-third-quarter-2018-financial-results-and-business-update-conf-btai-20181102monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-presentation-on-functional-immunological-memory-formation-a-btai-20181031monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-the-2018-bio-investor-forum-btai-20181011monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-submission-of-ind-for-lead-immuno-oncology-candidate-bxcl70-btai-20181008monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-enhances-leadership-with-appointment-of-chetan-d-lathia-ph-d-as-senio-btai-20180918monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-appoints-dr-david-c-hanley-as-vice-president-and-head-of-global-pharm-btai-20180904monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-the-20th-annual-hc-wainwright-global-investment-confere-btai-20180828monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-establishes-immuno-oncology-clinical-advisory-board-to-advance-bxcl70-btai-20180822monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-strengthens-leadership-team-with-industry-veteran-michael-de-vivo-ph--btai-20180807monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-host-second-quarter-2018-financial-results-and-business-update-btai-20180802monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-the-38th-annual-canaccord-genuity-growth-conference-btai-20180802monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-enhances-leadership-with-appointment-of-vikas-sharma-ph-d-as-vice-pre-btai-20180731monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-forms-neuroscience-clinical-advisory-board-to-support-global-developm-btai-20180710monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-added-to-russell-microcap-index-btai-20180626monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-appoints-dr-cedric-burg-as-vice-president-and-head-of-global-clinical-btai-20180613monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-the-jefferies-2018-global-healthcare-conference-btai-20180605monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-at-2018-ubs-global-healthcare-conference-btai-20180518monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-ring-the-nasdaq-stock-market-opening-bell-on-april-20-2018-btai-20180419monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-closing-of-initial-public-offering-btai-20180312monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-files-registration-statement-for-proposed-initial-public-offering-btai-20180213monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-present-data-on-bxcl701-at-the-24th-annual-prostate-cancer-foundat-btai-20171005monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-inc-bti-is-launched-with-phase-2-ready-programs-addressing-unmet-need-btai-20170510monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-presents-promising-data-demonstrating-bxcl701-anti-pd1-combination-increases-anti--btai-20170403monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-appoints-eric-k-rowinsky-m-d-to-its-board-of-directors-btai-20170105monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-and-centrexion-therapeutics-further-advance-big-data-innovation-lab-collaboration--btai-20161019monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-appoints-dr-peter-mueller-as-chairman-of-scientific-advisory-board-btai-20161012monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-s-bxcl101-receives-orphan-drug-designation-from-the-u-s-fda-for-the-treatment-of-p-btai-20160913monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-begins-strategic-collaboration-with-alnylam-to-discover-novel-rnai-therapeutic-pro-btai-20160524monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-to-present-at-the-3rd-international-conference-on-the-progress-of-regenerative-med-btai-20160427monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-celebrates-10th-anniversary-as-leader-of-big-data-revolution-in-healthcare-btai-20160219monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-expands-into-cns-orphan-disease-therapeutics-btai-20160208monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-strengthens-position-in-immuno-oncology-with-dedicated-big-data-analytics-platform-btai-20160121monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-and-centrexion-partner-to-develop-novel-chronic-pain-therapies-btai-20160111monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-initiates-strategic-big-data-partnership-with-pronutria-btai-20151020monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-unveils-next-generation-big-data-analytics-platform-pharmgps-tm-2-0-btai-20151007monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-strengthens-leadership-team-with-two-key-appointments-btai-20150616monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-announces-poster-presentation-at-aacr-annual-meeting-2015-btai-20150417monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-and-takeda-partner-to-repurpose-assets-for-orphan-diseases-btai-20150409monthly0.5https://www.biopharmawatch.com/news/IGC/igc-announces-rebranding-changes-name-to-igc-pharma-inc-igc-20230320monthly0.5https://www.biopharmawatch.com/news/IGC/igc-announces-phytocannabinoid-focused-pharmaceutical-unit-igc-20150610monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference-veru-20260219monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-participate-in-the-virtual-btig-obesity-health-forum-veru-20250611monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-positive-safety-results-from-phase-2b-quality-study-enobosarm-added-to-semagl-veru-20250528monthly0.5https://www.biopharmawatch.com/news/VERU/veru-participates-in-a-virtual-investor-kol-connect-segment-veru-20250508monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-fiscal-2025-second-quarter-financial-results-and-clinical-program-progress-veru-20250508monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2025-second-quarter-financial-results-on-may-8-veru-20250501monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-the-2nd-annual-glp-1-based-therapeutics-summit-veru-20250416monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-participate-in-fireside-chat-at-the-jones-healthcare-and-technology-innovation-con-veru-20250331monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-fiscal-2025-first-quarter-financial-results-and-clinical-program-progress-veru-20250213monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2025-first-quarter-financial-results-on-february-13-2025-veru-20250206monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference-veru-20250204monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-positive-topline-data-from-phase-2b-quality-clinical-study-enobosarm-preser-veru-20250127monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-the-sale-of-the-fc2-female-condom-internal-condom-business-veru-20241231monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-the-17th-international-conference-of-the-society-on-sarcopenia-cachexia-veru-20241126monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-meta-analysis-of-body-composition-data-from-older-patients-with-obesity-whi-veru-20241105monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-obesityweek-meta-analysis-of-4-previous-randomized-clinical-trials-that-veru-20241021monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-deliver-keynote-presentation-on-the-scientific-support-for-enobosarm-in-combinatio-veru-20241016monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-the-2024-cantor-global-healthcare-conference-veru-20240911monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reaches-full-enrollment-for-phase-2b-quality-clinical-study-of-enobosarm-for-obesity--veru-20240808monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2024-third-quarter-financial-results-on-august-8-2024-veru-20240801monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-participate-in-the-btig-virtual-biotechnology-conference-veru-20240729monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-participate-in-the-leerink-therapeutics-forum-i-i-and-metabolism-veru-20240702monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-safety-and-body-composition-data-from-two-late-breaker-presentations-at-the-veru-20240624monthly0.5https://www.biopharmawatch.com/news/VERU/veru-adjourns-2024-annual-meeting-of-shareholders-to-june-27-2024-veru-20240618monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reminds-shareholders-to-vote-in-advance-of-tomorrow-s-deadline-for-2024-annual-meetin-veru-20240617monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-the-american-diabetes-association-s-84th-scientific-sessions-veru-20240610monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-the-jefferies-global-healthcare-conference-veru-20240522monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-steven-b-heymsfield-m-d-as-the-principal-investigator-for-its-enobosarm-pha-veru-20240515monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-mitchell-steiner-as-keynote-speaker-at-biomed-israel-2024-the-22nd-national-veru-20240514monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-fiscal-2024-second-quarter-financial-results-and-progress-of-its-enobosarm-hi-veru-20240508monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-the-glp-1-based-therapeutics-summit-veru-20240502monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2024-second-quarter-financial-results-on-may-8-2024-veru-20240501monthly0.5https://www.biopharmawatch.com/news/VERU/veru-enrolls-first-patients-in-phase-2b-clinical-trial-of-enobosarm-and-semaglutide-combin-veru-20240430monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-the-american-association-of-clinical-endocrinology-aace-2024-annual-mee-veru-20240425monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-date-of-2024-annual-meeting-of-shareholders-veru-20240401monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reschedules-annual-meeting-of-shareholders-veru-20240322monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-the-appointment-of-louis-aronne-md-as-chief-medical-advisor-for-its-enobosa-veru-20240312monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-notification-from-nasdaq-related-to-delayed-quarterly-report-on-form-10-q-veru-20240228monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-new-scientific-advisory-board-for-its-enobosarm-program-for-high-quality-we-veru-20240220monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-fiscal-2024-first-quarter-financial-highlights-veru-20240208monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-fda-clearance-of-ind-application-to-initiate-phase-2b-clinical-trial-with-e-veru-20240206monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-the-oppenheimer-34th-annual-healthcare-life-sciences-conference-veru-20240131monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2024-first-quarter-financial-results-on-february-8-2024-veru-20240125monthly0.5https://www.biopharmawatch.com/news/VERU/veru-submits-ind-application-to-fda-for-the-development-of-enobosarm-to-prevent-muscle-los-veru-20240108monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-host-investor-call-on-january-4th-2024-to-discuss-recent-financing-and-strategy-to-veru-20231219monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-pricing-of-public-offering-of-common-stock-veru-20231214monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-muscle-data-from-5-clinical-studies-of-enobosarm-that-support-the-advancement-veru-20231004monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reaches-agreement-with-fda-on-new-phase-3-clinical-trial-for-sabizabulin-for-broader--veru-20230926monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-participate-in-fireside-chat-at-the-2023-cantor-fitzgerald-global-healthcare-confe-veru-20230920monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-clinical-data-from-the-discontinued-artest-study-of-enobosarm-novel-selective-veru-20230911monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-on-septembe-veru-20230830monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-fiscal-2023-third-quarter-financial-results-veru-20230810monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2023-third-quarter-financial-results-on-august-10-2023-veru-20230803monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-s-oncology-drug-research-program-partner-the-university-of-tennessee-health-scien-veru-20230621monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-appointment-of-dr-erik-swenson-and-dr-robert-schooley-to-its-infectious-dis-veru-20230601monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-the-jefferies-healthcare-conference-veru-20230524monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-fiscal-2023-second-quarter-financial-results-veru-20230511monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reaches-agreement-with-fda-on-confirmatory-phase-3-clinical-trial-for-sabizabulin-tre-veru-20230504monthly0.5https://www.biopharmawatch.com/news/VERU/veru-enters-into-common-stock-purchase-agreement-for-up-to-100-million-with-lincoln-park-c-veru-20230503monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2023-second-quarter-financial-results-on-may-11-2023-veru-20230427monthly0.5https://www.biopharmawatch.com/news/VERU/veru-sells-entadfi-business-for-20-million-plus-up-to-an-additional-80-million-from-sales--veru-20230420monthly0.5https://www.biopharmawatch.com/news/VERU/veru-enters-into-supply-agreement-with-afaxys-to-expand-access-to-fc2-female-condom-in-u-s-veru-20230419monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-preclinical-study-results-that-demonstrate-sabizabulin-inhibits-poxviruses-veru-20230411monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-preclinical-results-from-expanded-sabizabulin-program-into-influenza-induce-veru-20230404monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-the-oppenheimer-33rd-annual-healthcare-conference-veru-20230307monthly0.5https://www.biopharmawatch.com/news/VERU/veru-provides-fda-update-on-request-for-emergency-use-authorization-for-sabizabulin-for-ho-veru-20230302monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-fiscal-2023-first-quarter-financial-results-veru-20230209monthly0.5https://www.biopharmawatch.com/news/VERU/veru-3-day-deadline-alert-hagens-berman-encourages-veru-inc-veru-investors-with-significan-veru-20230203monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-nasdaq-veru-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-investo-veru-20230131monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2023-first-quarter-financial-results-on-february-9-2023-veru-20230126monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-nasdaq-veru-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-investo-veru-20230123monthly0.5https://www.biopharmawatch.com/news/VERU/veru-2-week-deadline-alert-hagens-berman-encourages-veru-inc-veru-investors-with-significa-veru-20230123monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-nasdaq-veru-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-investo-veru-20230117monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-sued-by-block-leviton-llp-for-securities-law-violations-veru-20230110monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-appointment-of-dr-david-d-ho-as-chairman-of-its-infectious-disease-scientif-veru-20230110monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-nasdaq-veru-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-investo-veru-20230110monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-nasdaq-veru-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-investo-veru-20230103monthly0.5https://www.biopharmawatch.com/news/VERU/veru-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-been--veru-20221229monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-investors-that-veru-20221227monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-nasdaq-veru-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-investo-veru-20221227monthly0.5https://www.biopharmawatch.com/news/VERU/veru-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-been--veru-20221224monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-nasdaq-veru-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-investo-veru-20221220monthly0.5https://www.biopharmawatch.com/news/VERU/veru-alert-hagens-berman-national-trial-attorneys-encourages-veru-inc-veru-investors-with--veru-20221219monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-investors-that-veru-20221219monthly0.5https://www.biopharmawatch.com/news/VERU/veru-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-been--veru-20221217monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-veru-equity-alert-contact-robbins-llp-for-information-about-the-class-action-agai-veru-20221214monthly0.5https://www.biopharmawatch.com/news/VERU/veru-investor-fraud-hagens-berman-national-trial-attorneys-encourages-veru-inc-veru-invest-veru-20221212monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-investors-that-veru-20221212monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-veru-shareholder-alert-robbins-llp-reminds-investors-of-class-action-against-veru-veru-20221208monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-that-a-secur-veru-20221206monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-nasdaq-veru-shareholder-class-action-alert-bernstein-liebhard-llp-announces-that--veru-20221206monthly0.5https://www.biopharmawatch.com/news/VERU/veru-news-johnson-fistel-encourages-shareholders-with-losses-to-contact-the-firm-regarding-veru-20221206monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-fiscal-2022-fourth-quarter-and-full-year-financial-results-veru-20221205monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2022-fourth-quarter-and-full-year-financial-results-on-december-5-20-veru-20221128monthly0.5https://www.biopharmawatch.com/news/VERU/veru-provides-update-on-fda-advisory-committee-meeting-regarding-emergency-use-authorizati-veru-20221110monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-late-breaker-oral-presentation-of-sabizabulin-treatment-for-hospitalized-ad-veru-20221024monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-late-breaker-oral-presentation-of-sabizabulin-treatment-for-hospitalized-a-veru-20221013monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-veru-20221004monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th-veru-20220921monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-fda-has-updated-the-meeting-date-for-the-advisory-committee-meeting-to-revi-veru-20220919monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-date-for-fda-advisory-committee-meeting-to-review-emergency-use-authorizati-veru-20220907monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference-on-septembe-veru-20220906monthly0.5https://www.biopharmawatch.com/news/VERU/veru-granted-expedited-provisional-registration-regulatory-pathway-for-sabizabulin-treatme-veru-20220822monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-appointment-of-jason-davies-to-lead-emea-latam-and-apac-infectious-disease--veru-20220819monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-veru-20220812monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-third-quarter-fiscal-2022-financial-results-progresses-sabizabulin-treatment--veru-20220811monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-presentation-of-phase-3-study-of-sabizabulin-for-the-treatment-of-hospitali-veru-20220809monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2022-third-quarter-financial-results-host-conference-call-on-august--veru-20220728monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-veru-20220712monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-new-england-journal-of-medicine-evidence-publication-of-phase-3-clinical-tr-veru-20220706monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-veru-20220624monthly0.5https://www.biopharmawatch.com/news/VERU/verus-signs-distribution-agreement-in-florida-veru-20220621monthly0.5https://www.biopharmawatch.com/news/VERU/veru-submits-emergency-use-authorization-eua-application-to-u-s-fda-for-sabizabulin-its-no-veru-20220607monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-presentation-of-final-positive-phase-1b-2-clinical-trial-results-for-sabiza-veru-20220606monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-three-presentations-at-the-2022-american-society-for-clinical-oncology-ann-veru-20220531monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-participate-in-fireside-chat-at-the-jefferies-healthcare-conference-on-june-8-2022-veru-20220525monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-appointment-of-joel-batten-to-lead-u-s-infectious-disease-franchise-to-focu-veru-20220518monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-the-h-c-wainwright-global-investment-conference-on-may-24th-2022-veru-20220517monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-second-quarter-fiscal-2022-results-and-progress-of-sabizabulin-for-covid-19-t-veru-20220512monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2022-second-quarter-financial-results-host-conference-call-on-may-12-veru-20220428monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-oral-late-breaking-presentation-of-phase-2-data-of-sabizabulin-for-the-trea-veru-20220425monthly0.5https://www.biopharmawatch.com/news/VERU/veru-s-novel-covid-19-drug-candidate-reduces-deaths-by-55-in-hospitalized-patients-in-inte-veru-20220411monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-acceptance-of-two-abstracts-for-presentation-at-the-39th-miami-breast-cance-veru-20220304monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-the-oppenheimer-32nd-annual-healthcare-conference-on-march-15-17-2022-veru-20220301monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-the-presentation-of-updated-data-from-the-phase-1b-2-sabizabulin-study-in-m-veru-20220217monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-that-independent-data-monitoring-committee-for-the-phase-3-sabizabulin-covid--veru-20220214monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-first-quarter-fiscal-2022-results-as-us-fc2-prescription-net-revenues-climb-2-veru-20220209monthly0.5https://www.biopharmawatch.com/news/VERU/veru-enters-into-clinical-trial-collaboration-and-supply-agreement-with-eli-lilly-and-comp-veru-20220201monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-fda-grant-of-fast-track-designation-for-sabizabulin-for-the-treatment-of-ho-veru-20220131monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2022-first-quarter-financial-results-host-conference-call-on-februar-veru-20220126monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-fda-grant-of-fast-track-designation-for-enobosarm-for-the-treatment-of-ar-e-veru-20220110monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-corporate-update-at-the-h-c-wainwright-bioconnect-conference-on-january-10-veru-20220103monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-fda-approval-of-entadfi-a-new-treatment-for-benign-prostatic-hyperplasia-veru-20211213monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-presentation-of-preclinical-evidence-supporting-the-therapeutic-benefit-of--veru-20211208monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-record-fiscal-2021-full-year-financial-results-veru-20211202monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2021-fourth-quarter-full-year-financial-results-host-conference-call-veru-20211118monthly0.5https://www.biopharmawatch.com/news/VERU/veru-ranked-as-one-of-the-fastest-growing-companies-in-north-america-on-the-2021-deloitte--veru-20211118monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-participate-in-fireside-chat-at-the-jefferies-london-healthcare-conference-on-nove-veru-20211108monthly0.5https://www.biopharmawatch.com/news/VERU/veru-enrolls-first-patient-in-international-phase-3-artest-clinical-trial-of-enobosarm-in--veru-20211013monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-positive-updated-data-from-phase-1b-2-sabizabulin-study-in-men-with-metasta-veru-20210920monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-oral-presentation-of-updated-data-from-the-phase-1b-2-sabizabulin-study-in--veru-20210909monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-three-upcoming-healthcare-investment-conferences-veru-20210908monthly0.5https://www.biopharmawatch.com/news/VERU/veru-sets-another-quarterly-record-in-both-net-revenues-and-in-gross-profit-for-fiscal-202-veru-20210812monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2021-third-quarter-financial-results-host-conference-call-on-august--veru-20210729monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-signs-3rd-u-s-distributor-provides-ceo-update-veru-20210712monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-the-presentation-of-a-phase-1b-2-clinical-study-update-for-sabizabulin-veru-veru-20210628monthly0.5https://www.biopharmawatch.com/news/VERU/veru-enrolls-first-patient-in-phase-3-veracity-clinical-trial-of-sabizabulin-veru-111-in-m-veru-20210625monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-reports-fiscal-2021-q2-financial-results-posts-significant-improvement-veru-20210622monthly0.5https://www.biopharmawatch.com/news/VERU/veru-enrolls-first-patient-in-phase-2-clinical-trial-of-veru-100-novel-long-acting-gnrh-an-veru-20210610monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-positive-phase-2-clinical-data-efficacy-of-enobosarm-therapy-correlates-wit-veru-20210607monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-positive-phase-1b-2-clinical-study-update-for-sabizabulin-veru-111-in-men-w-veru-20210607monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-the-jefferies-virtual-healthcare-conference-veru-20210525monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-acceptance-of-two-abstracts-for-presentation-at-the-american-society-of-cli-veru-20210524monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-provides-corporate-update-veru-20210521monthly0.5https://www.biopharmawatch.com/news/VERU/veru-enrolls-first-patient-in-phase-3-clinical-trial-of-sabizabulin-veru-111-in-high-risk--veru-20210519monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-strong-second-quarter-financial-results-based-on-record-high-fc2-prescription-veru-20210512monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-inc-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-inv-veru-20210506monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-the-presentation-of-positive-phase-2-clinical-data-of-enobosarm-in-ar-er-he-veru-20210505monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-releases-ceo-corporate-update-letter-veru-20210429monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2021-second-quarter-financial-results-host-conference-call-on-may-12-veru-20210428monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-inc-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-t-veru-20210423monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-adds-second-distributor-for-new-hemp-based-waffles-line-veru-20210422monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-presentation-of-phase-2-study-of-enobosarm-a-selective-androgen-receptor-ta-veru-20210421monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-reports-fiscal-q1-2021-financial-results-realizes-73-improvement-in-op-veru-20210329monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-reports-60-increase-in-annual-revenue-veru-20210322monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-the-oppenheimer-31st-annual-healthcare-conference-veru-20210309monthly0.5https://www.biopharmawatch.com/news/VERU/veru-exploring-strategic-alternatives-for-its-legacy-female-health-business-veru-20210308monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-participate-in-fireside-chat-at-the-h-c-wainwright-global-life-sciences-conference-veru-20210302monthly0.5https://www.biopharmawatch.com/news/VERU/veru-receives-fda-agreement-to-advance-veru-111-into-phase-3-study-in-hospitalized-covid-1-veru-20210301monthly0.5https://www.biopharmawatch.com/news/VERU/veru-submits-new-drug-application-for-proprietary-tadfin-for-bph-veru-20210223monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-pricing-of-public-offering-of-common-stock-veru-20210218monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-names-new-ceo-and-provides-operational-update-veru-20210217monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-proposed-public-offering-of-common-stock-veru-20210217monthly0.5https://www.biopharmawatch.com/news/VERU/veru-sets-another-quarterly-record-in-both-net-revenues-and-in-gross-profit-for-fiscal-202-veru-20210210monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-positive-phase-2-clinical-results-of-veru-111-in-hospitalized-covid-19-patien-veru-20210208monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2021-first-quarter-financial-results-host-conference-call-on-februar-veru-20210127monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-nature-medicine-publication-demonstrating-that-enobosarm-an-androgen-recept-veru-20210119monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-finalizes-distribution-and-product-development-agreement-with-texas-ba-veru-20210115monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-completes-requirements-for-reverse-stock-split-veru-20210112monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-the-h-c-wainwright-bioconnect-2021-conference-on-january-11th-2021-veru-20210104monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-enters-into-agreements-with-game-on-foods-veru-20201228monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-positive-phase-2-clinical-trial-results-for-enobosarm-selective-androgen-rece-veru-20201214monthly0.5https://www.biopharmawatch.com/news/VERU/veru-111-cytoskeleton-disruptor-demonstrates-efficacy-in-preclinical-models-of-human-tripl-veru-20201214monthly0.5https://www.biopharmawatch.com/news/VERU/veru-expands-oncology-drug-pipeline-exclusively-licenses-phase-3-clinical-stage-targeted-t-veru-20201209monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-record-fiscal-2020-fourth-quarter-and-record-full-year-financial-results-veru-20201209monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2020-fourth-quarter-full-year-financial-results-host-conference-call-veru-20201123monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-reports-strong-pachyderm-sales-and-growing-backlog-veru-20201109monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-reports-record-growth-at-eliot-s-nut-butters-division-veru-20201021monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-issues-strategic-update-veru-20201013monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-issues-update-on-zc-top-apparel-manufacturing-veru-20201008monthly0.5https://www.biopharmawatch.com/news/VERU/veru-completes-enrollment-of-phase-2-clinical-trial-of-veru-111-novel-oral-drug-for-metast-veru-20200929monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-reports-record-third-quarter-results-veru-20200921monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-esmo-congress-2020-oral-presentation-of-positive-clinical-results-from-its--veru-20200918monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-participate-and-present-at-four-upcoming-healthcare-investor-conferences-veru-20200909monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-expands-product-line-acquires-eliot-s-nut-butters-veru-20200903monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-inc-ceo-discusses-recent-news-and-international-expansion-in-a-new-aud-veru-20200901monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-announces-new-head-of-verus-foods-america-veru-20200828monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-secures-retail-license-agreement-with-national-hockey-league-and-provi-veru-20200825monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-to-supply-meijer-supercenters-with-mlb-candy-announces-first-shipments-veru-20200824monthly0.5https://www.biopharmawatch.com/news/VERU/veru-extends-agreement-with-roman-for-veru-s-premature-ejaculation-treatment-product-veru-20200818monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-higher-net-revenues-for-fiscal-2020-third-quarter-veru-20200813monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-sets-initial-cbd-product-shipment-schedule-veru-20200804monthly0.5https://www.biopharmawatch.com/news/VERU/veru-111-suppresses-key-cytokines-responsible-for-severe-acute-respiratory-distress-syndro-veru-20200804monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2020-third-quarter-financial-results-host-conference-call-on-august--veru-20200730monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-esmo-congress-2020-acceptance-of-veru-111-a-novel-oral-tubulin-targeting-ag-veru-20200727monthly0.5https://www.biopharmawatch.com/news/VERU/veru-receives-positive-input-from-fda-on-phase-3-pivotal-trial-to-evaluate-veru-111-in-met-veru-20200723monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-announces-national-implementation-agreement-for-pachyderm-labs-product-veru-20200717monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-announces-new-equity-investment-and-notes-payable-update-veru-20200702monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-added-to-the-russell-2000-and-3000-indices-veru-20200629monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-announces-new-pachyderm-labs-division-veru-20200625monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-reports-record-second-quarter-results-veru-20200622monthly0.5https://www.biopharmawatch.com/news/VERU/veru-enrolls-first-patient-in-phase-2-clinical-trial-of-novel-drug-veru-111-to-combat-covi-veru-20200619monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-jefferies-virtual-healthcare-conference-on-june-2nd-veru-20200526monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-announces-expansion-plans-for-u-s-sales-network-veru-20200519monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-strong-fiscal-2020-second-quarter-results-as-net-revenues-increase-43-gross-p-veru-20200513monthly0.5https://www.biopharmawatch.com/news/VERU/veru-secures-fda-agreement-to-initiate-phase-2-study-of-veru-111-novel-microtubule-depolym-veru-20200512monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2020-second-quarter-financial-results-host-conference-call-on-may-13-veru-20200506monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-positive-clinical-results-from-veru-111-phase-1b-2-trial-in-men-with-metastat-veru-20200505monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-achieves-record-quarterly-revenue-and-provides-update-to-business-prog-veru-20200429monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-schedules-first-quarter-fiscal-2020-financial-results-conference-call-veru-20200427monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-announces-protective-supply-order-and-names-new-president-of-medical-s-veru-20200424monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-inc-reports-116-increase-in-quarterly-revenue-and-135-increase-in-annu-veru-20200413monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-acquires-controlling-interest-in-n95-mask-and-biohazard-suit-manufactu-veru-20200403monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-schedules-fiscal-2019-financial-results-conference-call-veru-20200402monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-announces-orders-with-homegoods-weis-markets-and-major-league-stadium--veru-20200312monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-announces-first-orders-with-major-retailers-tjx-companies-and-big-five-veru-20200311monthly0.5https://www.biopharmawatch.com/news/VERU/veru-initiates-phase-2-clinical-trial-of-veru-111-first-in-class-oral-advanced-prostate-ca-veru-20200226monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-provides-operational-update-veru-20200225monthly0.5https://www.biopharmawatch.com/news/VERU/veru-continues-strong-positive-sales-momentum-in-fiscal-2020-first-quarter-net-revenues-in-veru-20200212monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2020-first-quarter-financial-results-host-conference-call-on-februar-veru-20200205monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-acceptance-of-two-abstracts-for-presentation-at-the-genitourinary-cancer-sy-veru-20200121monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-positive-top-line-interim-data-from-phase-2-clinical-trial-of-zuclomiphene--veru-20200113monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-engages-top-ten-national-public-accounting-firm-veru-20191230monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-fiscal-2019-full-year-net-revenues-doubled-gross-profit-up-147-veru-20191212monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-to-open-first-manufacturing-faciltiy-veru-20191206monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2019-fourth-quarter-full-year-financial-results-host-conference-call-veru-20191205monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-inc-to-present-at-the-12th-annual-ld-micro-main-event-investor-confere-veru-20191205monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-inc-to-present-at-national-investment-banking-association-conference-i-veru-20191113monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-acquires-a-controlling-interest-in-nutribrands-enters-south-american-m-veru-20191104monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-full-enrollment-of-phase-2-trial-in-men-with-prostate-cancer-treatment-indu-veru-20191002monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-inc-names-general-counsel-veru-20190930monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-inc-reports-154-increase-in-quarterly-revenue-forecasts-continued-trip-veru-20190910monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-schedules-third-quarter-fiscal-2019-financial-results-conference-call-veru-20190905monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-acquires-uae-based-french-fry-operation-veru-20190903monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-participate-at-three-upcoming-healthcare-investor-conferences-in-new-york-veru-20190828monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-ring-nasdaq-closing-bell-on-september-4th-to-kick-off-national-prostate-cancer-awa-veru-20190827monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-signs-13-5-million-credit-insurance-policy-sells-out-first-run-of-mlb--veru-20190826monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-higher-net-revenues-and-gross-profit-for-its-fiscal-2019-third-quarter-veru-20190808monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2019-third-quarter-financial-results-host-conference-call-on-august--veru-20190801monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-announces-500-000-line-of-credit-with-the-columbia-bank-n-a-veru-20190801monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-dismissal-of-lawsuit-prevails-on-all-counts-in-motion-for-summary-judgment-veru-20190718monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-signs-605-000-note-increases-funded-backlog-veru-20190708monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-successful-completion-of-pre-nda-meeting-with-fda-for-tadfin-tadalafil-5mg--veru-20190626monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-inc-reports-153-increase-in-quarterly-revenue-forecasts-record-growth--veru-20190617monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-names-chief-financial-officer-veru-20190607monthly0.5https://www.biopharmawatch.com/news/VERU/veru-adds-breakthrough-novel-androgen-deprivation-therapy-formulation-to-its-advancing-pro-veru-20190604monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-announces-500-000-strategic-investment-from-arj-consulting-llc-veru-20190531monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-signs-new-2-500-store-distribution-agreement-veru-20190528monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-the-jefferies-2019-global-healthcare-conference-on-june-4th-veru-20190528monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-strong-fiscal-2019-second-quarter-financial-results-veru-20190515monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2019-second-quarter-financial-results-host-conference-call-on-may-15-veru-20190508monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-signs-600-000-note-provides-operational-update-veru-20190501monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-announces-acquisition-of-big-league-foods-inc-gains-license-with-major-veru-20190426monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-inc-reports-145-increase-in-quarterly-revenue-announces-largest-funded-veru-20190325monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-inc-reports-101-increase-in-annual-revenue-veru-20190319monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-participate-in-two-investor-conferences-in-march-veru-20190312monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-announces-4-million-rice-supply-agreement-veru-20190305monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-signs-10-million-honey-supply-agreement-veru-20190228monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-strong-fiscal-2019-first-quarter-financial-results-veru-20190213monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-scientific-presentations-for-novel-prostate-cancer-drug-candidates-at-the-2-veru-20190212monthly0.5https://www.biopharmawatch.com/news/VERU/verus-international-announces-1-45-million-financing-and-retirement-of-notes-veru-20190211monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2019-first-quarter-financial-results-host-conference-call-on-februar-veru-20190206monthly0.5https://www.biopharmawatch.com/news/VERU/veru-initiates-clinical-trial-for-proprietary-novel-first-in-class-drug-for-advanced-prost-veru-20190122monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-acceptance-of-four-abstracts-for-presentation-at-the-genitourinary-cancer-s-veru-20190115monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-successful-bioavailability-and-bioequivalence-clinical-trial-for-tadalafil--veru-20190114monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-strong-net-revenues-and-gross-profit-for-fiscal-2018-fourth-quarter-veru-20181213monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-year-2018-financial-results-host-conference-call-on-december-13th-veru-20181206monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-first-patient-dosed-in-bioequivalence-clinical-trial-for-combination-tadala-veru-20181203monthly0.5https://www.biopharmawatch.com/news/VERU/veru-advances-novel-first-in-class-oral-tubulin-inhibitor-for-refractory-metastatic-prosta-veru-20181113monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-upcoming-healthcare-investor-conferences-in-new-york-veru-20180927monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-pricing-of-public-offering-of-common-stock-veru-20180927monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-proposed-public-offering-of-common-stock-veru-20180926monthly0.5https://www.biopharmawatch.com/news/VERU/veru-has-successful-pre-ind-meeting-with-fda-for-veru-111-next-generation-novel-oral-anti--veru-20180912monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-ring-nasdaq-closing-bell-on-august-31-to-kick-off-national-prostate-cancer-awarene-veru-20180830monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-additional-information-regarding-its-south-africa-female-condom-tender-awar-veru-20180829monthly0.5https://www.biopharmawatch.com/news/VERU/veru-awarded-75-percent-of-south-africa-female-condom-tender-veru-20180827monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-fiscal-2018-third-quarter-financial-results-veru-20180814monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2018-third-quarter-financial-results-host-conference-call-on-august--veru-20180807monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-start-phase-2-trial-to-evaluate-cis-clomiphene-citrate-to-treat-hot-flashes-caused-veru-20180612monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-jefferies-2018-global-healthcare-conference-on-wednesday-june-6th-veru-20180530monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-publication-of-data-from-three-cancer-studies-as-part-of-the-upcoming-ameri-veru-20180517monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-publication-of-data-on-oral-veru-111-in-prostate-cancer-in-connection-with--veru-20180517monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-fiscal-2018-second-quarter-financial-results-veru-20180509monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-presentation-of-data-demonstrating-efficacy-of-veru-111-in-a-taxane-resista-veru-20180503monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2018-second-quarter-financial-results-host-conference-call-on-may-9t-veru-20180503monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-presentation-of-data-demonstrating-efficacy-of-veru-111-in-a-taxane-resista-veru-20180316monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-present-at-the-oppenheimer-28th-annual-healthcare-conference-on-march-21-2018-veru-20180314monthly0.5https://www.biopharmawatch.com/news/VERU/veru-completes-10-million-synthetic-royalty-financing-on-fc2-business-veru-20180305monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-fiscal-2018-first-quarter-financial-results-veru-20180214monthly0.5https://www.biopharmawatch.com/news/VERU/veru-to-report-fiscal-2018-first-quarter-financial-results-host-conference-call-on-februar-veru-20180207monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-presentation-of-data-demonstrating-efficacy-of-veru-111-in-a-taxane-resista-veru-20180206monthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-fiscal-2017-fourth-quarter-full-year-financial-results-veru-20180102monthly0.5https://www.biopharmawatch.com/news/VERU/veru-acquires-novel-proprietary-formulation-for-overactive-bladder-veru-20171211monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-tamsulosin-drs-bioequivalence-clinical-trial-results-veru-20171113monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-announces-agreement-with-timm-medical-technologies-llc-to-distribute-and-to-promo-veru-20171003monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-announces-initiation-of-telemedicine-capability-to-expand-access-to-prescriptions-veru-20170926monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-to-present-at-two-financial-conferences-in-september-veru-20170920monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-nasdaq-veru-to-ring-the-nasdaq-stock-market-closing-bell-veru-20170913monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-to-participate-in-upcoming-financial-conferences-veru-20170905monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-announces-change-in-nasdaq-ticker-symbol-to-veru-veru-20170810monthly0.5https://www.biopharmawatch.com/news/VERU/veru-inc-reports-fiscal-third-quarter-financial-results-veru-20170808monthly0.5https://www.biopharmawatch.com/news/VERU/veru-healthcare-to-report-fiscal-third-quarter-2017-financial-results-and-corporate-perfor-veru-20170731monthly0.5https://www.biopharmawatch.com/news/VERU/veru-healthcare-announces-key-advancements-in-the-development-of-tamsulosin-drs-for-benign-veru-20170720monthly0.5https://www.biopharmawatch.com/news/VERU/veru-healthcare-to-present-at-the-7th-annual-ld-micro-invitational-veru-20170602monthly0.5https://www.biopharmawatch.com/news/VERU/veru-healthcare-to-advance-proprietary-drug-for-the-treatment-of-hot-flashes-in-men-receiv-veru-20170524monthly0.5https://www.biopharmawatch.com/news/VERU/veru-healthcare-presents-results-from-phase-4-clinical-study-of-preboost-for-management-of-veru-20170513monthly0.5https://www.biopharmawatch.com/news/VERU/veru-healthcare-reports-fiscal-2017-second-quarter-financial-results-veru-20170509monthly0.5https://www.biopharmawatch.com/news/VERU/verus-claims-services-names-matthew-urbanovich-as-director-of-business-development-veru-20150518monthly0.5https://www.biopharmawatch.com/news/VERU/verus-launches-online-patient-accounts-center-for-freeman-health-system-veru-20050623monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-to-present-at-the-life-sciences-forum-on-june-24-2026-and-meet-virtually-with-ctso-20260618monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-rights-offering-ctso-20241209monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-and-converge-biotech-announce-strategic-partnership-to-expand-sepsis-and-crit-ctso-20241111monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-submits-health-canada-medical-device-license-application-for-drugsorb-atr-fol-ctso-20241104monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-to-report-third-quarter-2024-operating-and-financial-results-ctso-20241017monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ctso-20240816monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-to-report-second-quarter-2024-operating-and-financial-results-ctso-20240807monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-unveils-newly-redesigned-unified-company-and-product-website-ctso-20240730monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-to-present-at-the-inaugural-american-association-of-physicians-of-indian-orig-ctso-20240717monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-secures-20-million-credit-facility-ctso-20240702monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-regulatory-approval-of-cytosorb-in-taiwan-ctso-20240624monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-the-launch-and-immediate-availability-of-the-purifi-blood-pump-in-t-ctso-20240613monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-to-host-its-2024-virtual-annual-stockholders-meeting-ctso-20240605monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-star-registry-data-on-patients-on-ticagrelor-undergoing-cabg-surgery-with-cyt-ctso-20240604monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-first-quarter-2024-results-ctso-20240509monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-may-6-2024-virtual-kol-and-analyst-investor-day-star-t-pivotal-trial-topline--ctso-20240502monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-to-report-first-quarter-2024-operating-and-financial-results-ctso-20240426monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-to-report-fiscal-2023-operating-and-financial-results-ctso-20240306monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-to-present-at-the-td-cowen-44th-annual-health-care-conference-ctso-20240208monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-alert-bragar-eagel-squire-p-c-is-investigating-cytosorbents-corporation-on-be-ctso-20240109monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-to-report-third-quarter-2023-operating-and-financial-results-ctso-20231027monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-to-present-at-the-8th-annual-dawson-james-conference-ctso-20231005monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-granted-expanded-anvisa-registration-to-treat-shock-with-cytosorb-in-brazil-ctso-20230831monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-to-report-second-quarter-2023-operating-and-financial-results-ctso-20230726monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-appoints-alexander-d-amico-as-chief-financial-officer-ctso-20230719monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-and-humedics-announce-theranostic-collaboration-in-the-field-of-liver-disease-ctso-20230711monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-independent-data-safety-and-monitoring-board-recommends-completion--ctso-20230615monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-this-week-to-host-its-virtual-annual-stockholders-meeting-and-to-present-at-t-ctso-20230605monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-first-quarter-2023-results-ctso-20230502monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results-ctso-20230426monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-highlights-new-clinical-data-from-current-studies-at-the-live-42nd-internatio-ctso-20230322monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-comments-on-bank-exposure-and-diversified-cash-position-ctso-20230314monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-corporation-nasdaq-ctso-to-ring-the-nasdaq-stock-market-opening-bell-ctso-20151222monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-appoints-dr-rainer-kosanke-as-european-director-of-scientific-affairs-ctso-20130708monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-fda-approved-us-air-force-funded-human-trauma-pilot-study-for-rhabd-ctso-20130617monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-enters-into-exclusive-distribution-agreement-for-cytosorb-r-with-hitit-medica-ctso-20130613monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-2013-first-quarter-financial-results-ctso-20130516monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-enters-into-exclusive-distribution-agreement-for-cytosorb-r-with-l-in-c-medic-ctso-20130506monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-ceo-provides-exclusive-interview-with-medgadget-ctso-20130501monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-appoints-christopher-cramer-as-vice-president-of-business-development-ctso-20130415monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-awarded-additional-phase-i-option-on-us-army-sbir-trauma-contract-ctso-20130411monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-trauma-advisory-board-ctso-20130408monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-provides-corporate-update-and-reports-2012-year-end-financial-results-ctso-20130403monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-highlights-data-from-oxford-s-prompt-study-demonstrating-the-genomic-prostate-sc-mdxh-20260316monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-present-fourth-quarter-and-full-year-2025-financial-results-and-corporate-upd-mdxh-20260212monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-and-university-of-oxford-to-validate-gps-test-in-largest-randomized-trial-of-tre-mdxh-20260106monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-release-first-quarter-2025-financial-results-on-may-14-mdxh-20250430monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-participate-in-piper-sandler-healthcare-conference-mdxh-20241125monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-results-for-the-third-quarter-and-nine-month-period-ended-september-30-2-mdxh-20241106monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-present-third-quarter-2024-financial-results-and-corporate-update-on-november-mdxh-20241014monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-pricing-of-offering-of-ordinary-shares-mdxh-20240926monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-launch-of-offering-of-ordinary-shares-mdxh-20240925monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-q2-and-half-year-2024-results-mdxh-20240821monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-present-second-quarter-and-first-half-2024-financial-results-and-corporate-up-mdxh-20240812monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-preliminary-q2-and-half-year-2024-revenues-and-raises-2024-revenue-guida-mdxh-20240708monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-present-at-upcoming-investor-conferences-mdxh-20240515monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-present-fourth-quarter-and-full-year-2023-financial-results-and-corporate-upd-mdxh-20240221monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-resignation-of-board-member-mdxh-20240216monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-completion-of-transition-to-single-listing-on-nasdaq-mdxh-20231218monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-completion-of-mandatory-ads-exchange-and-commencement-of-transition-pe-mdxh-20231127monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-participate-in-the-35th-annual-piper-sandler-healthcare-conference-mdxh-20231114monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-completion-of-share-consolidation-and-update-of-outstanding-shares-and-mdxh-20231113monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-results-for-the-third-quarter-and-nine-month-period-ended-september-30-2-mdxh-20231108monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-the-approval-by-its-shareholders-of-the-proposed-transition-to-a-sole--mdxh-20231106monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-present-third-quarter-2023-financial-results-and-corporate-update-on-november-mdxh-20231025monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-new-share-capital-amount-and-new-number-of-shares-mdxh-20231020monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-preliminary-q3-2023-revenues-mdxh-20231009monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-proposed-transition-to-a-sole-listing-of-shares-on-nasdaq-and-convenes-mdxh-20231002monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-signs-research-collaboration-with-university-of-oxford-to-assess-the-correlation-mdxh-20230926monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-q2-and-half-year-2023-results-mdxh-20230823monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-present-q2-and-half-year-2023-financial-results-and-corporate-update-on-augus-mdxh-20230810monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-results-of-its-extraordinary-general-shareholders-meeting-mdxh-20230630monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-its-extraordinary-general-shareholders-meeting-mdxh-20230605monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-results-of-its-annual-and-extraordinary-general-shareholders-meetings-mdxh-20230525monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-present-at-the-43rd-annual-william-blair-growth-stock-conference-mdxh-20230523monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-q1-2023-results-mdxh-20230515monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-present-first-quarter-2023-financial-results-on-may-15-mdxh-20230501monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-its-ordinary-and-extraordinary-general-shareholders-meetings-mdxh-20230425monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-shareholder-transparency-declaration-mdxh-20230407monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank-mdxh-20230313monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-update-of-outstanding-shares-and-voting-rights-mdxh-20230308monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-financial-year-2022-results-and-provides-business-update-and-outlook-for-mdxh-20230308monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-exercise-of-option-mdxh-20230306monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-shareholder-transparency-declarations-mdxh-20230303monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-participate-in-43rd-annual-cowen-healthcare-conference-mdxh-20230228monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-present-fourth-quarter-and-full-year-2022-financial-results-on-march-8-2023-mdxh-20230222monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-shareholder-transparency-declaration-mdxh-20230221monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-update-of-outstanding-shares-and-voting-rights-and-update-of-financial-mdxh-20230215monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-unitedhealthcare-to-provide-commercial-coverage-for-the-genomic-prosta-mdxh-20230213monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-pricing-of-offering-of-adss-in-the-united-states-mdxh-20230203monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-launch-of-offering-of-adss-in-the-united-states-mdxh-20230201monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-provides-updated-and-supplemental-financial-information-related-to-acquisition-o-mdxh-20230120monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-preliminary-2022-revenues-and-reaffirms-2023-revenue-guidance-mdxh-20230109monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-files-u-s-shelf-registration-on-form-f-3-mdxh-20221219monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-provides-business-update-mdxh-20221129monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-q3-2022-results-mdxh-20221027monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-half-year-2022-results-mdxh-20220825monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-new-share-capital-amount-and-new-number-of-shares-mdxh-20220819monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-acquires-oncotype-dx-gps-prostate-cancer-business-from-exact-sciences-and-report-mdxh-20220802monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-results-of-its-annual-and-extraordinary-general-shareholders-meetings--mdxh-20220525monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-q1-2022-results-mdxh-20220427monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-its-ordinary-and-extraordinary-general-shareholders-meetings-mdxh-20220425monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-participate-in-the-14th-annual-kempen-life-sciences-conference-mdxh-20220330monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-financial-year-2021-results-and-provides-outlook-and-guidance-for-2022-mdxh-20220302monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-present-fourth-quarter-and-full-year-2021-financial-results-and-corporate-upd-mdxh-20220217monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-present-at-btig-medtech-digital-health-life-science-diagnostic-tools-conferen-mdxh-20220209monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-shareholder-transparency-declaration-mdxh-20211210monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-shareholder-transparency-declarations-mdxh-20211122monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-completion-of-initial-public-offering-of-adss-in-the-united-states-mdxh-20211115monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-completion-of-initial-public-offering-of-adss-in-the-united-states-mdxh-20211108monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-pricing-of-initial-public-offering-of-adss-in-the-united-states-mdxh-20211104monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-launch-of-proposed-initial-public-offering-of-adss-in-the-united-state-mdxh-20211028monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-provides-q3-2021-business-update-mdxh-20211021monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-files-registration-statement-for-proposed-initial-public-offering-in-the-united--mdxh-20211013monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-submission-of-draft-registration-statement-for-proposed-public-listing-mdxh-20210901monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-half-year-2021-results-mdxh-20210826monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-present-first-half-2021-financial-results-and-corporate-update-on-august-26-mdxh-20210811monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-results-of-its-annual-and-extraordinary-general-shareholders-meetings-mdxh-20210527monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-favorable-draft-medicare-coverage-for-the-selectmdx-for-prostate-cance-mdxh-20210521monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-its-ordinary-and-extraordinary-general-shareholders-meetings-mdxh-20210427monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-listing-of-9-639-489-existing-shares-on-euronext-brussels-following-th-mdxh-20210421monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-provides-q1-2021-business-update-mdxh-20210421monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-financial-year-2020-results-and-provides-outlook-for-2021-mdxh-20210303monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-shareholder-transparency-declarations-mdxh-20210203monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-new-share-capital-amount-and-new-number-of-shares-mdxh-20210126monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-successfully-completes-a-eur-25-0-million-usd-30-4-million-1-capital-increase-mdxh-20210121monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-launches-capital-increase-and-provides-preliminary-2020-financial-results-mdxh-20210121monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-provides-q3-2020-business-update-mdxh-20201021monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-listing-of-20-162-924-existing-shares-on-euronext-brussels-following-e-mdxh-20201016monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-half-year-2020-results-mdxh-20200826monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-report-half-year-2020-results-on-wednesday-august-26-2020-mdxh-20200820monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-provides-update-on-medicare-coverage-for-selectmdx-mdxh-20200807monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-results-of-special-and-extraordinary-general-shareholders-meetings-mdxh-20200730monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-mdxh-20200727monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-its-special-and-extraordinary-general-shareholders-meetings-mdxh-20200630monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-shareholder-transparency-declarations-mdxh-20200604monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-results-of-annual-and-extraordinary-general-shareholders-meetings-mdxh-20200528monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-shareholder-transparency-declarations-mdxh-20200525monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-new-share-capital-amount-and-new-number-of-shares-mdxh-20200525monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-completes-the-equity-investment-by-mvm-partners-mdxh-20200515monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-its-annual-and-extraordinary-general-shareholders-meetings-mdxh-20200428monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-growth-investment-from-mvm-partners-mdxh-20200427monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-receive-2-3-million-paycheck-protection-program-loan-under-the-u-s-cares-act-mdxh-20200420monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-provides-q1-2020-business-update-mdxh-20200409monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-updates-2020-reporting-calendar-and-provides-initial-view-on-coronavirus-situati-mdxh-20200401monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-financial-year-2019-results-and-provides-outlook-for-2020-mdxh-20200226monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-provides-q3-2019-business-update-mdxh-20191111monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-shareholder-transparency-declaration-mdxh-20191010monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-new-share-capital-amount-and-new-number-of-shares-mdxh-20191003monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-shareholder-transparency-declaration-mdxh-20191003monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-successfully-completes-a-eur-9-0-million-usd-9-8-million-1-capital-increase-mdxh-20190927monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-launches-capital-increase-and-secures-debt-financing-from-kreos-capital-mdxh-20190926monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-half-year-2019-financial-results-and-strategic-update-mdxh-20190829monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-mdxhealth-announces-favorable-draft-medicare-coverage-for-the-selectmdx-test-mdxh-20190826monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-mdxhealth-notice-of-interim-results-2019-mdxh-20190823monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-extraordinary-general-shareholders-meeting-mdxh-20190621monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-multi-center-study-validates-selectmdx-s-high-negative-predictive-value-and-se-mdxh-20190610monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-annual-general-shareholders-meeting-mdxh-20190529monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-presentation-of-new-data-for-mdxhealth-s-prostate-cancer-diagnostic-tests-at-aua-mdxh-20190503monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-mdxhealth-provides-q1-2019-business-update-mdxh-20190424monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-mdxhealth-announces-positive-data-from-pan-european-clinical-validation-study--mdxh-20190318monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-selectmdx-liquid-biopsy-test-for-prostate-cancer-included-in-the-2019-italian-so-mdxh-20190305monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-mdxhealth-reports-financial-year-2018-results-and-provides-outlook-for-2019-mdxh-20190228monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-mdxhealth-appoints-michael-k-mcgarrity-as-ceo-mdxh-20190219monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-mdxhealth-announces-presentation-of-positive-data-for-selectmdx-and-confirmmdx-mdxh-20190215monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-mdxhealth-signs-partnership-with-lifelabs-to-make-selectmdx-available-in-canad-mdxh-20190214monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-mdxhealth-shareholder-transparency-declaration-mdxh-20190209monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-selectmdx-outperforms-prostate-health-index-phi-blood-test-for-detecting-high--mdxh-20190124monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-mdxhealth-provides-business-update-mdxh-20190114monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-mdxhealth-announces-approval-for-selectmdx-for-prostate-cancer-by-new-york-sta-mdxh-20181126monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-selectmdx-improves-prostate-biopsy-decision-making-in-urology-practices-mdxh-20181107monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-provides-business-update-for-the-first-nine-months-of-2018-mdxh-20181023monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-shareholder-transparency-declaration-mdxhealth-r-mdxh-20181017monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-mdxhealth-reports-half-year-2018-results-mdxh-20180830monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-selectmdx-cost-effective-in-four-european-countries-mdxh-20180828monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-mdxhealth-notice-of-interim-results-2018-mdxh-20180810monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-mdxhealth-shareholder-transparency-declaration-mdxh-20180810monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-mdxhealth-shareholder-transparency-declaration-mdxh-20180807monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-selectmdx-study-demonstrates-cost-effectiveness-in-us-healthcare-system-mdxh-20180731monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-medicare-establishes-final-positive-local-coverage-determination-for-use-of-co-mdxh-20180723monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-selectmdx-test-successfully-stratifies-men-mdxh-20180627monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-launch-agreement-with-philips-for-prognostic-prostate-cancer-biomarker-mdxh-20180606monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-presentation-of-new-data-on-mdxhealth-s-prostate-and-bladder-cancer-products-a-mdxh-20180522monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-releases-2017-annual-report-mdxh-20180427monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-positive-clinical-updates-for-confirmmdx-mdxh-20180426monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-provides-first-quarter-2018-mdxh-20180424monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-selectmdx-included-in-dutch-drg-reimbursement-system-mdxh-20180420monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-shareholder-transparency-declaration-mdxh-20180406monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-mdxhealth-shareholder-transparency-declaration-mdxh-20180329monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-denominator-pr-mdxh-20180329monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-mdxhealth-successfully-completes-a-eur-36-million-usd-44-million-1-capital-inc-mdxh-20180322monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-mdxhealth-launches-capital-increase-mdxh-20180321monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-selectmdx-liquid-biopsy-test-for-prostate-cancer-included-in-the-2018-european-mdxh-20180319monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-contract-selectmdx-with-roman-hospital-mdxh-20180228monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-notice-of-financial-year-2017-results-mdxh-20180215monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-develops-blood-test-to-guide-precision-treatment-of-castration-resistant-prost-mdxh-20180118monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-shareholder-transparency-declaration-mdxh-20180117monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-mdxhealth-announces-lowering-of-2017-guidance-mdxh-20171228monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-teams-up-with-pharmaceutical-company-ferrer-for-distribution-of-its-prostate-can-mdxh-20171120monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-nine-month-trading-update-mdxh-20171102monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-enters-into-distribution-agreement-with-unilabs-for-selectmdx-for-prostate-cance-mdxh-20171030monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-opens-new-service-and-research-laboratory-in-the-netherlands-mdxh-20171005monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-prepares-for-growth-with-executive-team-expansion-mdxh-20170906monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-first-half-2017-financial-results-mdxh-20170831monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-notice-of-january-june-2017-financial-results-mdxh-20170816monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-service-agreement-with-kaiser-southern-california-permanente-medical-g-mdxh-20170808monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-appoints-seasoned-evp-to-lead-sales-force-expansion-mdxh-20170807monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-participate-in-canaccord-genuity-growth-conference-mdxh-20170802monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-launches-assuremdx-for-bladder-cancer-liquid-biopsy-test-mdxh-20170706monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-presents-three-selectmdx-studies-at-5th-global-congress-on-prostate-cancer-mdxh-20170628monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-and-queensland-university-of-technology-collaborate-on-oral-cancer-liquid-biopsy-mdxh-20170619monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-launches-ce-marked-selectmdx-ivd-pcr-kit-and-urncollect-device-mdxh-20170608monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-shareholder-transparency-notification-mdxh-20170516monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-trading-update-january-to-april-2017-mdxh-20170508monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-new-share-capital-amount-and-new-number-of-shares-mdxh-20170505monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-and-maastricht-university-collaborate-on-next-generation-epi-genetic-cancer-diag-mdxh-20170505monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-new-contract-with-medincrease-health-plans-regarding-confirmmdx-and-se-mdxh-20170502monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-and-exact-sciences-sign-collaboration-agreement-mdxh-20170427monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-and-ghent-university-ink-licensing-and-collaboration-agreements-to-develop-cance-mdxh-20170404monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-epigenetic-biomarkers-identify-men-at-increased-risk-of-prostate-cancer-recurren-mdxh-20170327monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-signs-agreement-with-lab21-to-make-selectmdx-liquid-biopsy-test-available-in-the-mdxh-20170321monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-agreement-with-istituto-diagnostico-varelli-for-distribution-of-select-mdxh-20170223monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-financial-year-2016-results-mdxh-20170223monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-notice-of-financial-year-2016-results-mdxh-20170209monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-awarded-us-department-of-veterans-affairs-contract-for-confirmmdx-testing-mdxh-20170208monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-horizon-blue-cross-blue-shield-of-new-jersey-issues-positive-coverage--mdxh-20170118monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-preliminary-update-on-2016-results-and-appointment-of-cfo-mdxh-20170109monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-acecgt-life-science-limited-as-the-exclusive-distributor-for-selectmdx-mdxh-20161219monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-receives-iso-13485-2016-certification-for-dutch-laboratory-mdxh-20161216monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-new-share-capital-amount-and-new-number-of-shares-mdxh-20161115monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-present-at-november-2016-investor-conferences-mdxh-20161114monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-assuremdx-multi-center-validation-study-published-in-the-journal-of-urology-mdxh-20161110monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-successfully-raises-eur-20-4-million-usd-22-6-million-in-equity-placement-mdxh-20161103monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-launches-equity-placement-mdxh-20161102monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-provides-third-quarter-2016-business-update-mdxh-20161102monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-unique-cpt-code-awarded-for-confirmmdx-from-the-american-medical-assoc-mdxh-20161031monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-positive-coverage-policy-with-fourth-largest-health-insurer-in-the-uni-mdxh-20161027monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-agreement-with-hifu-clinic-prostate-cancer-center-for-distribution-of--mdxh-20161019monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-highmark-blue-cross-blue-shield-issues-positive-medical-policy-on-confir-mdxh-20161006monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-agreement-with-southgenetics-for-distribution-of-selectmdx-in-central--mdxh-20161004monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-and-the-european-health-centre-innovation-sign-distribution-agreement-for-select-mdxh-20160928monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-independence-blue-cross-rendered-positive-medical-coverage-policy-for--mdxh-20160927monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-upgraded-revenue-forecast-mdxh-20160922monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-gains-medi-cal-approval-for-confirmmdx-mdxh-20160906monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-and-teva-pharmaceuticals-sign-distribution-agreement-for-selectmdx-in-israel-mdxh-20160831monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-second-quarter-and-first-half-2016-results-mdxh-20160818monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-positive-medical-policy-for-confirmmdx-issued-by-one-of-the-top-five-h-mdxh-20160810monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-and-cerba-healthcare-announce-collaboration-agreement-for-selectmdx-commercializ-mdxh-20160725monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-investor-newsletter-june-2016-mdxh-20160630monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-secures-new-reimbursement-coverage-for-selectmdx-mdxh-20160628monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-contracts-with-priority-health-for-coverage-of-confirmmdx-mdxh-20160623monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-agreement-with-major-academic-medical-center-for-confirmmdx-testing-mdxh-20160621monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-extraordinary-general-shareholders-meeting-mdxh-20160620monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-european-urology-editorial-supporting-selectmdx-use-in-detecting-prost-mdxh-20160616monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-grants-qiagen-rights-to-msp-technology-for-qiasure-methylation-test-for-cervic-mdxh-20160615monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-holds-capital-markets-day-in-new-york-city-mdxh-20160614monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-secures-first-reimbursement-coverage-for-selectmdx-mdxh-20160614monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-disclosure-of-the-number-of-outstanding-voting-securities-mdxh-20160520monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-confirmmdx-stratifies-risk-for-aggressive-prostate-cancer-mdxh-20160509monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-positive-data-supporting-prognostic-value-of-confirmmdx-and-selectmdx--mdxh-20160506monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-provides-first-quarter-2016-business-update-mdxh-20160503monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-selectmdx-study-published-in-european-urology-mdxh-20160425monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-partners-with-andros-men-s-clinic-to-offer-selectmdx-for-prostate-cancer-mdxh-20160329monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-launches-selectmdx-liquid-biopsy-test-in-the-united-states-mdxh-20160317monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-presents-selectmdx-tm-results-from-multicenter-validation-study-at-the-2016-annu-mdxh-20160314monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-appoints-global-commercial-team-for-selectmdx-mdxh-20160309monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-inclusion-of-confirmmdx-in-2016-nccn-guidelines-for-prostate-cancer-ea-mdxh-20160302monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-fourth-quarter-and-fiscal-year-2015-results-mdxh-20160218monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-conference-participation-for-first-half-2016-mdxh-20160128monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-receives-2016-frost-sullivan-global-prostate-cancer-diagnostics-technology-innov-mdxh-20160121monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-analytical-validation-study-on-assuremdx-for-bladder-cancer-published-in-the-jou-mdxh-20160119monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-provides-preliminary-update-on-2015-results-reporting-strong-sales-trajectory-fo-mdxh-20160112monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-positive-data-supporting-expanded-diagnostic-application-for-confirmmd-mdxh-20160111monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-confirmmdx-marketing-partnership-in-central-south-america-mdxh-20151208monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-disclosure-of-the-number-of-outstanding-voting-securities-mdxh-20151130monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-participate-in-prospective-clinical-validation-study-with-assuremdx-for-bladd-mdxh-20151109monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-present-at-november-2015-investor-conferences-mdxh-20151104monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-provides-third-quarter-2015-business-update-mdxh-20151103monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-participate-in-prospective-4m-clinical-study-evaluating-synergy-of-mri-and-se-mdxh-20151019monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-launches-selectmdx-liquid-biopsy-test-in-europe-mdxh-20151013monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-appoints-walter-narajowski-as-independent-director-mdxh-20151005monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-completion-of-the-acquisition-of-noviogendix-new-share-capital-amount-and-new--mdxh-20150918monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-confirmmdx-covered-by-tufts-health-plan-mdxh-20150917monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-acquires-noviogendix-to-expand-uro-oncology-product-offering-mdxh-20150915monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-new-confirmmdx-risk-score-data-at-11th-world-congress-on-urological-rese-mdxh-20150910monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-shareholder-transparency-notification-mdxh-20150903monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-first-half-2015-results-mdxh-20150820monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-positive-top-line-data-for-its-liquid-biopsy-test-for-bladder-cancer-mdxh-20150818monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-appoints-philip-j-ginsburg-m-d-as-chief-medical-officer-mdxh-20150714monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-transparency-declaration-update-mdxh-20150709monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-new-share-capital-amount-and-new-number-of-shares-mdxh-20150626monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-successfully-raises-27-7-million-usd-31-0-million-in-equity-placement-mdxh-20150624monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-launches-equity-placement-mdxh-20150623monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-shareholder-transparency-notification-mdxh-20150623monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-disclosure-of-the-number-of-outstanding-voting-securities-mdxh-20150608monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-annual-general-shareholders-meeting-mdxh-20150529monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-confirmmdx-r-predicts-prostate-cancer-aggressiveness-mdxh-20150518monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-confirmmdx-predicts-prostate-cancer-aggressiveness-mdxh-20150518monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-provides-first-quarter-2015-business-update-mdxh-20150505monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-named-winner-of-corporate-livewire-innovation-excellence-2015-award-mdxh-20150424monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-completes-enrollment-of-second-confirmmdx-clinical-utility-study-mdxh-20150420monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-confirmmdx-genes-detect-clinically-significant-prostate-cancer-mdxh-20150302monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-fourth-quarter-and-fiscal-year-2014-results-mdxh-20150226monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-named-euronext-best-bel-small-company-performer-for-2014-mdxh-20150121monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-licenses-epigenetic-technology-to-oncgnostics-gmbh-for-cervical-cancer-test-mdxh-20150114monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-ceo-dr-jan-groen-to-deliver-keynote-presentation-at-biomarkers-from-research-to--mdxh-20150105monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-shareholder-transparency-notification-mdxh-20141126monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-present-at-the-canaccord-genuity-medical-technology-diagnostics-forum-mdxh-20141112monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-new-share-capital-amount-and-new-number-of-shares-mdxh-20141107monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-successfully-raises-12-33-million-us-15-43-million-in-equity-offering-mdxh-20141105monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-launches-equity-placement-mdxh-20141104monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-provides-third-quarter-2014-business-update-mdxh-20141104monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-confirmmdx-genes-identify-prostate-cancer-aggressiveness-in-diagnostic-biopsie-mdxh-20141010monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-presents-results-from-epigenetic-test-to-identify-prostate-cancer-aggressiveness-mdxh-20141007monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-confirmmdx-for-prostate-cancer-test-qualifies-for-medicare-coverage-effective--mdxh-20140923monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-participate-in-the-rodman-renshaw-16th-annual-global-investment-conference-mdxh-20140908monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-first-half-year-2014-results-mdxh-20140821monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-confirmmdx-biomarker-associated-with-the-risk-of-recurrence-for-early-stage-pros-mdxh-20140818monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-signs-two-new-insurance-agreements-providing-increased-access-to-confirmmdx-for--mdxh-20140814monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-r-mdxhealth-licensee-exact-sciences-receives-fda-approval-for-its-cologuard-colo-mdxh-20140812monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-and-miraca-life-sciences-announce-agreement-to-promote-confirmmdx-for-prostate-c-mdxh-20140702monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-extraordinary-general-shareholders-meeting-mdxh-20140623monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-shareholder-transparency-notification-mdxh-20140617monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-annual-and-extraordinary-general-shareholders-meeting-mdxh-20140530monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-10-fold-reduction-of-repeat-prostate-biopsies-in-confirmmdx-clinical-uti-mdxh-20140520monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-presentations-on-confirmmdx-for-prostate-cancer-at-american-urological-mdxh-20140515monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-and-american-pathology-partners-announce-marketing-agreement-for-confirmmdx-for--mdxh-20140513monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-confirmmdx-document-validation-study-published-in-the-journal-of-urology-mdxh-20140508monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-provides-first-quarter-2014-business-update-mdxh-20140506monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-signs-agreement-with-galaxy-health-network-ppo-providing-increased-access-to-con-mdxh-20140422monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-and-li-path-announce-marketing-agreement-for-confirmmdx-for-prostate-cancer-mdxh-20140402monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-licensee-exact-sciences-receives-fda-panel-recommendation-for-approval-of-colore-mdxh-20140328monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-predictmdx-for-glioblastoma-identifies-newly-diagnosed-patients-with-improved--mdxh-20140304monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-fourth-quarter-and-fiscal-year-2013-results-mdxh-20140227monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-secures-agreement-with-prime-health-services-ppo-network-providing-increased-acc-mdxh-20140220monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-confirmmdx-r-for-prostate-cancer-epigenetic-test-correctly-identifies-prostate-mdxh-20140212monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-confirmmdx-for-prostate-cancer-epigenetic-test-correctly-identifies-prostate-c-mdxh-20140212monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-confirmmdx-genes-identify-aggressive-prostate-cancer-mdxh-20140203monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-present-results-from-epigenetic-prostate-test-to-identify-aggressive-prostate-mdxh-20140129monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-agreement-with-teva-pharmaceuticals-for-commercialization-of-two-cance-mdxh-20140123monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-secures-coverage-for-prostate-cancer-test-with-two-additional-insurance-companie-mdxh-20131202monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-present-at-the-canaccord-genuity-medical-technology-diagnostics-forum-mdxh-20131107monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-provides-third-quarter-2013-business-update-mdxh-20131106monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-mgmt-test-included-in-nccn-guidelines-and-awarded-tier-1-reimbursement-code-by-mdxh-20131016monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-confirmmdx-r-meets-all-primary-endpoints-in-blinded-u-s-clinical-validation-st-mdxh-20131007monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-confirmmdx-meets-all-primary-endpoints-in-blinded-u-s-clinical-validation-stud-mdxh-20131007monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-insurance-agreements-expand-access-to-confirmmdx-r-for-prostate-cancer-test-mdxh-20131001monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-signs-agreement-with-stratose-to-expand-insurance-coverage-for-confirmmdxtm-for--mdxh-20130903monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-2013-first-half-results-mdxh-20130822monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-establishes-agreements-with-multiplan-and-three-rivers-provider-network-for-conf-mdxh-20130730monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-and-bostwick-laboratories-announce-marketing-agreement-for-confirmmdx-tm-for-pro-mdxh-20130729monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-collaborates-with-histogenex-to-offer-pharmaco-molecular-diagnostic-services-mdxh-20130716monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-prostate-cancer-test-approved-by-new-york-state-department-of-health-mdxh-20130710monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-shareholder-transparency-notifications-mdxh-20130709monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-new-share-capital-amount-and-number-of-shares-mdxh-20130702monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-and-sumitomo-sign-pharmaco-molecular-diagnostic-partnership-for-japan-mdxh-20130701monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-extraordinary-general-shareholders-meeting-mdxh-20130627monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-completes-18-million-24m-equity-raise-mdxh-20130625monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-changes-to-its-board-of-directors-mdxh-20130618monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-epigenetic-marker-as-companion-diagnostic-for-irinotecan-based-therapy-in-colore-mdxh-20130603monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-tm-annual-and-extraordinary-general-shareholders-meeting-mdxh-20130531monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-confirmmdx-tm-combined-with-psa-and-other-risk-factors-improves-diagnosis-of-p-mdxh-20130508monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-provides-first-quarter-2013-business-update-mdxh-20130507monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-confirmmdx-tm-test-outperforms-psa-in-prostate-cancer-detection-algorithm-and--mdxh-20130422monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-publication-of-the-clinical-utility-of-combining-genetics-and-epigenet-mdxh-20130403monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-receives-iso-9001-2008-certification-for-its-commercial-u-s-based-clia-laborator-mdxh-20130402monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-and-ghent-university-aim-to-establish-sensitive-and-cost-effective-industry-stan-mdxh-20130319monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-fourth-quarter-and-fiscal-year-2012-results-mdxh-20130228monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-results-from-the-confirmmdx-tm-for-prostate-cancer-test-studies-presen-mdxh-20130218monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-publication-of-health-economic-analysis-demonstrating-cost-savings-of--mdxh-20130214monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-presentations-on-the-confirmmdx-tm-for-prostate-cancer-test-at-the-asc-mdxh-20130213monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-publication-of-positive-data-from-a-blinded-multicenter-clinical-study-mdxh-20130211monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-to-present-at-the-2013-bio-ceo-investor-conference-mdxh-20130204monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-its-delisting-from-euronext-amsterdam-mdxh-20121129monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-provides-third-quarter-2012-business-update-mdxh-20121115monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-is-continually-improving-their-subscribers-experience-mdxh-20121029monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-2011-half-year-results-mdxh-20110825monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-establishes-us-clia-laboratory-in-irvine-ca-and-makes-key-hires-to-expand-us-tea-mdxh-20110818monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-biomarker-part-of-large-pivotal-colon-cancer-trial-initiated-by-exact-sciences-mdxh-20110803monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-mgmt-test-shown-to-be-only-prognostic-factor-in-journal-of-clinical-oncology-r-mdxh-20110711monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-and-merck-kgaa-extend-agreement-for-use-of-mgmt-assay-in-brain-cancer-clinical-t-mdxh-20110609monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-mgmt-test-identifies-brain-cancer-patients-likely-to-live-longer-on-temozolomi-mdxh-20110606monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-methylation-based-companion-diagnostics-enables-better-personalized-treatment--mdxh-20110531monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-provides-first-quarter-2011-business-update-mdxh-20110518monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-s-methylation-tests-detect-prostate-cancer-in-patients-deemed-low-risk-by-pathol-mdxh-20110516monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-receives-usd-1-1-million-european-grant-to-progress-bladder-cancer-program-mdxh-20110503monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-successfully-raises-8-2-million-in-equity-issue-mdxh-20110405monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-launches-equity-offering-mdxh-20110404monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-appoints-new-scientific-advisory-board-mdxh-20110324monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-full-year-2010-results-new-strategy-positively-impacts-financial-and-ope-mdxh-20110221monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-closes-agreement-with-pfizer-newcastle-university-and-crt-to-identify-a-predicti-mdxh-20110131monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-biomarkers-used-in-successful-testing-of-predictive-biosciences-bladder-cancer-a-mdxh-20110126monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-licensee-exact-sciences-confirms-use-of-biomarker-and-methylation-technology-in--mdxh-20110110monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-expands-its-companion-diagnostics-capabilities-mdxh-20101221monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-amends-existing-methylation-biomarker-agreement-with-veridex-llc-mdxh-20101215monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-licenses-methylation-technology-to-takara-bio-inc-for-scientific-research-market-mdxh-20101129monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-licenses-biomarkers-for-bladder-cancer-to-predictive-biosciences-mdxh-20101122monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-provides-third-quarter-2010-business-update-mdxh-20101104monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-outlines-new-strategy-mdxh-20101019monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-congratulates-scientific-advisor-dr-christopher-wilson-recipient-of-p-aiff-20250207monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-announces-publications-demonstrating-the-utility-of-advanced-eeg-anal-aiff-20250124monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-discovers-breakthrough-cognitive-brain-age-biomarker-using-its-fda-cl-aiff-20250114monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-closes-on-financing-of-up-to-12-4-million-aiff-20241231monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-appoints-current-board-member-greg-lipschitz-as-executive-chairman-aiff-20241204monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-reports-third-quarter-2024-results-and-provides-stockholder-update-aiff-20241114monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-to-participate-in-the-8th-annual-florida-capital-event-aiff-20241106monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-aiff-20241025monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-collaborates-with-bright-minds-biosciences-to-analyze-the-data-from-i-aiff-20241016monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-announces-use-of-its-brain-network-analytics-platform-in-phase-1-stud-aiff-20241015monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-to-participate-in-upcoming-october-investor-conferences-aiff-20241011monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-advances-ai-driven-bna-technology-in-neuroscience-drug-development-af-aiff-20240920monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-announces-partnership-with-zeto-to-integrate-and-distribute-its-bna-t-aiff-20240910monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-appoints-dr-stella-vnook-to-its-board-of-directors-aiff-20240905monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-ceo-jon-olsen-to-present-at-h-c-wainwright-s-26th-annual-global-inves-aiff-20240826monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-an-ai-driven-brain-health-company-to-host-shareholder-update-call-on--aiff-20240822monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-forms-strategic-partnership-with-neurology-consultants-of-dallas-ncd--aiff-20240821monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-announces-closing-of-merger-agreement-and-is-scheduled-to-begin-tradi-aiff-20240812monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-an-ai-driven-brain-health-company-appoints-samer-kaba-md-as-chief-med-aiff-20240620monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-an-ai-driven-brain-health-company-names-brian-s-posner-to-its-board-o-aiff-20240529monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-an-ai-driven-brain-health-company-appoints-healthcare-industry-execut-aiff-20240514monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-announces-healthcare-science-and-ai-industry-leader-david-decaprio-to-aiff-20240417monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-s-white-paper-unveils-bna-platform-s-significant-impact-on-disease-ma-aiff-20240305monthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-inc-issues-letter-to-stockholders-on-proposed-merger-with-wavedancer-aiff-20240222monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-announces-cohort-review-committee-approved-opening-of-cohort-2-based-on-favorable-saf-skye-20260520monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-treats-first-patient-in-nimacimab-higher-dose-expansion-study-evaluating-e-skye-20260402monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-b-skye-20260310monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-deadline-rosen-a-leading-law-firm-encourages-skye-bioscience-inc-investors-to-secure--skye-20260115monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-final-deadline-alert-bragar-eagel-squire-p-c-urgently-reminds-skye-bioscie-skye-20260115monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investors-have-opportunity-to-lead-skye-bioscience-inc-securities-fraud-lawsuit-with--skye-20260115monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-deadline-rosen-recognized-investor-counsel-encourages-skye-bioscience-inc-investors-t-skye-20260113monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-inc-nasdaq-skye-securities-class-action-johnson-fistel-reminds-investors-o-skye-20260112monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-class-action-reminder-bragar-eagel-squire-p-c-urgently-reminds-skye-biosci-skye-20260112monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investors-have-opportunity-to-lead-skye-bioscience-inc-securities-fraud-lawsuit-with--skye-20260112monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-provides-2026-corporate-outlook-skye-20260112monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-final-deadline-rosen-recognized-investor-counsel-encourages-skye-bioscience-inc-inves-skye-20260109monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-inc-class-action-levi-korsinsky-reminds-skye-bioscience-inc-investors-of-t-skye-20260109monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investor-notice-faruqi-faruqi-llp-investigates-claims-on-behalf-of-investors-of-skye--skye-20260109monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investors-have-opportunity-to-lead-skye-bioscience-inc-securities-fraud-lawsuit-with--skye-20260108monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-class-action-alert-bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-laws-skye-20260106monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investors-have-opportunity-to-lead-skye-bioscience-inc-securities-fraud-lawsuit-with--skye-20260105monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investors-have-opportunity-to-lead-skye-bioscience-inc-securities-fraud-lawsuit-with--skye-20260101monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-fi-skye-20251231monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investors-have-opportunity-to-lead-skye-bioscience-inc-securities-fraud-lawsuit-with--skye-20251229monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investors-have-opportunity-to-lead-skye-bioscience-inc-securities-fraud-lawsuit-with--skye-20251226monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investors-have-opportunity-to-lead-skye-bioscience-inc-securities-fraud-lawsuit-with--skye-20251223monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-lawsuit-alert-the-gross-law-firm-notifies-skye-bioscience-inc-investors-of-a-class-ac-skye-20251222monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-skye-bioscience-inc-inve-skye-20251222monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-shareholder-action-reminder-faruqi-faruqi-llp-investigates-claims-on-behalf-of-invest-skye-20251220monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investors-have-opportunity-to-lead-skye-bioscience-inc-securities-fraud-lawsuit-with--skye-20251219monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsi-skye-20251218monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-skye-bioscience-inc-inve-skye-20251218monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-lawsuit-alert-the-gross-law-firm-notifies-skye-bioscience-inc-investors-of-a-class-ac-skye-20251217monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investors-have-opportunity-to-lead-skye-bioscience-inc-securities-fraud-lawsuit-with--skye-20251216monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-skye-bioscience-inc-inve-skye-20251215monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsi-skye-20251212monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investors-have-opportunity-to-lead-skye-bioscience-inc-securities-fraud-lawsuit-with--skye-20251212monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-skye-bioscience-inc-inve-skye-20251211monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsi-skye-20251209monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investors-have-opportunity-to-lead-skye-bioscience-inc-securities-fraud-lawsuit-with--skye-20251209monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-skye-bioscience-inc-inve-skye-20251208monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investors-have-opportunity-to-lead-skye-bioscience-inc-securities-fraud-lawsuit-with--skye-20251205monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-inc-class-action-levi-korsinsky-reminds-skye-bioscience-inc-investors-of-t-skye-20251204monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-skye-bioscience-inc-inve-skye-20251204monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discus-skye-20251204monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investor-notice-faruqi-faruqi-llp-investigates-claims-on-behalf-of-investors-of-skye--skye-20251203monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investors-have-opportunity-to-lead-skye-bioscience-inc-securities-fraud-lawsuit-with--skye-20251202monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-inc-nasdaq-skye-securities-class-action-johnson-fistel-reminds-investors-o-skye-20251201monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-skye-bioscience-inc-inve-skye-20251201monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discus-skye-20251201monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investors-have-opportunity-to-lead-skye-bioscience-inc-securities-fraud-lawsuit-with--skye-20251128monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-skye-bioscience-inc-inve-skye-20251127monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discus-skye-20251127monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-stockholders-with-large-losses-should-contact-robbins-llp-for-information-about-leadi-skye-20251125monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investors-have-opportunity-to-lead-skye-bioscience-inc-securities-fraud-lawsuit-with--skye-20251125monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-skye-bioscience-inc-inve-skye-20251124monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investors-have-opportunity-to-lead-skye-bioscience-inc-securities-fraud-lawsuit-with--skye-20251121monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investor-notice-faruqi-faruqi-llp-investigates-claims-on-behalf-of-investors-of-skye--skye-20251120monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-skye-bioscience-inc-inve-skye-20251120monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-stockholder-notice-shareholder-rights-law-firm-robbins-llp-reminds-investors-of-the-c-skye-20251118monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-skye-bioscience-inc-inve-skye-20251118monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-announce-third-quarter-2025-financial-results-and-business-update-on-no-skye-20251105monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-reports-second-quarter-2025-financial-results-and-business-update-skye-20250807monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-announce-second-quarter-2025-financial-results-and-business-update-on-a-skye-20250730monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-shares-nimacimab-anatomy-of-progress-video-series-and-highlights-preclinic-skye-20250623monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-present-expanded-preclinical-cb1-antibody-data-at-the-american-diabetes-skye-20250617monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-participate-in-upcoming-investment-conferences-skye-20250522monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-establishes-partnership-with-arecor-therapeutics-to-develop-enhanced-formu-skye-20250519monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-skye-20250513monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-clinical-model-demonstrating-necessity-of-peripheral-cb1-inhibition-for-we-skye-20250513monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-reports-first-quarter-2025-results-and-highlights-nimacimab-differentiatio-skye-20250508monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-announce-2025-first-quarter-financial-results-on-may-8th-2025-skye-20250507monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-participate-in-may-investment-and-medical-conferences-skye-20250429monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-skye-20250426monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-demonstrates-over-30-weight-loss-with-nimacimab-and-tirzepatide-combinatio-skye-20250415monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-conduct-meetings-at-piper-sandler-conference-skye-20250414monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-b-skye-20250320monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-announce-2024-financial-results-on-march-20th-2025-skye-20250314monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-skye-20250227monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-participate-in-sxsw-session-on-obesity-skye-20250224monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-present-at-td-cowen-health-care-conference-skye-20250220monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-announces-participation-in-february-conferences-skye-20250204monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-provides-2025-look-ahead-and-year-in-review-skye-20250113monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-present-at-j-p-morgan-healthcare-conference-skye-20241219monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-participate-in-upcoming-december-healthcare-investment-conferences-skye-20241118monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-surpasses-50-patient-enrollment-in-phase-2-obesity-study-of-differentiated-skye-20241114monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-reports-third-quarter-2024-financial-results-and-recent-highlights-skye-20241107monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-demonstrates-prominent-role-of-peripheral-cb1-inhibition-and-achieves-sign-skye-20241104monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-announce-third-quarter-2024-results-skye-20241101monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-names-independent-director-paul-grayson-as-chairman-of-the-board-skye-20241029monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-participate-in-upcoming-november-healthcare-investment-conferences-skye-20241021monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-comments-on-monlunabant-phase-2-top-line-data-and-reiterates-confidence-in-skye-20240923monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-appoints-puneet-s-arora-md-as-chief-medical-officer-skye-20240903monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-participate-in-upcoming-healthcare-investment-conferences-skye-20240826monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-skye-20240823monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-launches-phase-2-cbeyond-clinical-trial-of-its-differentiated-cb1-inhibito-skye-20240822monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-inc-skye-investigation-bronstein-gewirtz-grossman-llc-encourages-investors-skye-20240819monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-inc-skye-investigation-bronstein-gewirtz-grossman-llc-encourages-investors-skye-20240813monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-reports-second-quarter-2024-financial-results-and-recent-highlights-skye-20240809monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-inc-skye-investigation-bronstein-gewirtz-grossman-llc-encourages-investors-skye-20240807monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-hosts-virtual-kol-event-metabolic-rewiring-with-cb1-inhibition-and-details-skye-20240724monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-host-virtual-kol-event-metabolic-rewiring-with-cb1-inhibition-on-july-2-skye-20240711monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-establishes-metabolic-clinical-and-scientific-advisory-board-to-support-de-skye-20240711monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-appoints-dr-karen-smith-to-board-of-directors-skye-20240703monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-added-to-russell-2000-and-russell-3000-indexes-skye-20240701monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-participating-in-piper-sandler-virtual-obesity-day-skye-20240625monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-concentrates-strategy-and-clinical-development-focus-on-nimacimab-metabolic-program-skye-20240610monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-present-at-jefferies-global-healthcare-conference-skye-20240603monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-highlights-novel-synthetic-cannabinoid-based-library-capable-of-modulating-skye-20240510monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-present-two-posters-at-association-for-research-in-vision-and-ophthalmo-skye-20240430monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-present-at-upcoming-investment-conferences-skye-20240423monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-uplists-to-the-nasdaq-global-market-skye-20240410monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-appoints-dr-annalisa-jenkins-to-board-of-directors-skye-20240304monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-completes-enrollment-of-phase-2a-clinical-trial-of-sbi-100-ophthalmic-emul-skye-20240226monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-announces-clinical-development-plan-in-obesity-for-differentiated-peripheral-cb1-inhi-skye-20231211monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-treats-first-patient-in-glaucoma-phase-2-study-of-sbi-100-ophthalmic-emuls-skye-20231128monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-completes-drug-production-for-phase-1-clinical-study-skye-20220920monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-files-definitive-proxy-statement-and-announces-stockholder-meeting-date-skye-20220901monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-reports-that-emerald-health-therapeutics-shareholders-voted-in-favor-of-pl-skye-20220819monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-selects-nextpharma-as-phase-2-contract-drug-manufacturer-skye-20220721monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-updates-phase-1-timeline-skye-20220720monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-expands-cannabinoid-pharmaceutical-innovation-program-with-leading-cannabi-skye-20220607monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-signs-arrangement-agreement-with-emerald-health-therapeutics-skye-20220512monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-reports-enhanced-intraocular-pressure-lowering-of-sbi-100-formulation-publ-skye-20220505monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-engages-clinical-trial-site-for-phase-1-study-in-agreement-with-cmax-clini-skye-20220428monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-retains-novotech-as-cro-for-phase-1-trial-of-glaucoma-drug-candidate-skye-20220303monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-reports-positive-results-for-sbi-100-in-glp-toxicology-study-skye-20220216monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-reports-potential-neuroprotective-benefit-of-sbi-100-in-preclinical-glauco-skye-20220201monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-issues-shareholder-letter-providing-progress-update-and-business-outlook-f-skye-20220110monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-present-at-h-c-wainwright-bioconnect-virtual-conference-skye-20220104monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-expands-board-of-directors-with-the-appointment-of-life-sciences-executive-skye-20211215monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-sponsored-research-presented-at-american-association-of-pharmaceutical-sci-skye-20211021monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-establishes-new-cannabinoid-pharmaceutical-innovation-program-skye-20211012monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-appoints-head-of-regulatory-affairs-quality-assurance-and-senior-director--skye-20211007monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-appoints-kaitlyn-arsenault-as-chief-financial-officer-skye-20211005monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-announces-closing-of-7-0-million-registered-direct-offering-skye-20210929monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-announces-thcvhs-late-breaking-preclinical-abstracts-selected-by-american--skye-20210921monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-announces-special-virtual-investor-presentation-skye-20210914monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference-skye-20210907monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-present-at-the-h-c-wainwright-ophthalmology-conference-skye-20210811monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-completes-thcvhs-ind-enabling-in-vitro-genotoxicity-studies-skye-20210810monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-s-thcvhs-demonstrates-superior-therapeutic-benefit-compared-to-glaucoma-st-skye-20210517monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-completes-cmc-and-glp-production-for-thcvhs-lead-program-skye-20210422monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-present-at-upcoming-investment-conferences-in-april-skye-20210415monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-present-at-benzinga-biotech-small-cap-conference-skye-20210318monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-s-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-skye-20210316monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-present-at-h-c-wainwright-global-life-sciences-conference-skye-20210303monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-to-participate-in-investment-conferences-in-february-skye-20210203monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-reports-third-quarter-fiscal-year-2026-financial-results-poci-20260513monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-reports-second-quarter-fiscal-year-2026-financial-results-poci-20260217monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-reports-first-quarter-fiscal-year-2026-financial-results-poci-20251113monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-schedules-fourth-quarter-and-fiscal-year-2025-conference-call-for-septemb-poci-20250924monthly0.5https://www.biopharmawatch.com/news/POCI/precision-cleaning-solutions-industry-company-evaluation-report-2025-emerson-dow-and-crest-poci-20250908monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-to-participate-in-the-lytham-partners-2025-consumer-technology-investor-s-poci-20250818monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-to-participate-in-the-lytham-partners-spring-2025-investor-conference-on--poci-20250527monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-reports-third-quarter-fiscal-year-2025-financial-results-poci-20250515monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-market-global-forecast-report-to-2030-cumulative-impact-of-united-states--poci-20250514monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-schedules-third-quarter-of-fiscal-year-2025-conference-call-for-may-15-20-poci-20250508monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-to-present-at-the-planet-microcap-showcase-vegas-2025-on-april-23-2025-poci-20250421monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-enters-into-main-purchase-agreement-with-top-tier-aerospace-customer-and--poci-20250403monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-to-participate-in-the-lytham-partners-2025-industrials-basic-materials-in-poci-20250327monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-appoints-joseph-p-pellegrino-jr-to-board-of-directors-poci-20250320monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-appoints-buell-duncan-to-board-of-directors-dr-richard-miles-retires-from-poci-20250304monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-announces-closing-of-5-1-million-offering-of-common-stock-to-fund-busines-poci-20250224monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-announces-pricing-of-5-1-million-offering-of-common-stock-to-fund-busines-poci-20250220monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-reports-second-quarter-fiscal-year-2025-financial-results-poci-20250213monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-schedules-second-quarter-of-fiscal-year-2025-conference-call-for-february-poci-20250211monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-launches-revolutionary-unity-imaging-platform-poci-20250128monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-receives-initial-production-order-for-single-use-ophthalmic-program-poci-20241114monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-reports-first-quarter-fiscal-year-2025-financial-results-poci-20241114monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-schedules-first-quarter-of-fiscal-year-2025-conference-call-f-poci-20241111monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-customer-receives-fda-510-k-clearance-accelerates-production-order-for-po-poci-20241029monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-to-participate-in-lytham-partners-fall-2024-investor-conferen-poci-20241001monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-reports-fourth-quarter-and-fiscal-year-2024-financial-results-poci-20240930monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-schedules-fourth-quarter-and-fiscal-year-2024-conference-call-poci-20240924monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-appoints-clay-schwabe-as-vp-of-sales-and-marketing-poci-20240708monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-to-participate-in-the-lytham-partners-spring-2024-investor-conference-on--poci-20240523monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-reports-third-quarter-fiscal-year-2024-financial-results-poci-20240515monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-announces-record-9-million-production-order-for-high-volume-single-use-cy-poci-20240509monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-schedules-third-quarter-of-fiscal-year-2024-conference-call-f-poci-20240508monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-announces-receipt-of-1-26-million-follow-on-production-order-from-large-d-poci-20240425monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-to-present-at-the-planet-microcap-showcase-vegas-2024-on-wednesday-may-1--poci-20240423monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-announces-receipt-of-720-000-follow-on-production-order-from-top-tier-def-poci-20240418monthly0.5https://www.biopharmawatch.com/news/POCI/precision-neuroscience-names-verily-co-founder-brian-otis-as-chief-technology-officer-poci-20240408monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-acquires-ross-optical-industries-poci-20190708monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-announces-the-passing-of-dr-kenneth-schwartz-poci-20190619monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-announces-operating-results-for-the-third-quarter-and-nin-poci-20190515monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-schedules-third-quarter-conference-call-poci-20190508monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-announces-receipt-of-2-2-million-order-for-custom-designe-poci-20190429monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-announces-operating-results-for-the-second-quarter-and-si-poci-20190212monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-schedules-second-quarter-conference-call-poci-20190207monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-announces-operating-results-for-the-first-quarter-of-fisc-poci-20181114monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-reschedules-first-quarter-conference-call-poci-20181112monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-schedules-first-quarter-conference-call-poci-20181107monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-raises-2-million-in-private-placement-poci-20181018monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-announces-operating-results-for-the-fourth-quarter-and-fi-poci-20180927monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-schedules-fiscal-year-end-conference-call-poci-20180919monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-announces-fourth-quarter-2018-preliminary-revenue-of-1-4--poci-20180731monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-announces-operating-results-for-the-third-quarter-and-nin-poci-20180515monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-schedules-third-quarter-conference-call-poci-20180508monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-announces-operating-results-for-the-second-quarter-and-si-poci-20180214monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-schedules-second-quarter-conference-call-poci-20180207monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-announces-operating-results-for-the-first-quarter-of-fisc-poci-20171114monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-schedules-first-quarter-conference-call-poci-20171108monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-announces-operating-results-for-the-fourth-quarter-and-fi-poci-20170928monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-schedules-fiscal-year-end-conference-call-poci-20170921monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-announces-operating-results-for-the-third-quarter-and-nin-poci-20170515monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-schedules-third-quarter-conference-call-poci-20170508monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-announces-operating-results-for-the-second-quarter-and-si-poci-20170214monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-schedules-second-quarter-conference-call-poci-20170207monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-raises-800-000-in-private-placement-poci-20161129monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-announces-operating-results-for-the-first-quarter-of-fisc-poci-20161114monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-schedules-first-quarter-conference-call-poci-20161107monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-announces-operating-results-for-the-fourth-quarter-and-fi-poci-20160928monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-schedules-fiscal-year-end-conference-call-poci-20160927monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-announces-retirement-of-jack-p-dreimiller-and-appointment-poci-20160615monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-announces-operating-results-for-the-third-quarter-and-nin-poci-20160516monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-schedules-third-quarter-conference-call-poci-20160512monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-announces-changes-to-its-board-of-directors-poci-20160307monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-announces-operating-results-for-the-second-quarter-and-si-poci-20160216monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-schedules-second-quarter-conference-call-poci-20160211monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-announces-operating-results-for-the-first-quarter-of-fisc-poci-20151112monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-schedules-first-quarter-conference-call-poci-20151110monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-raises-700-000-in-private-placement-poci-20151026monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-schedules-fiscal-year-end-conference-call-poci-20151019monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-announces-operating-results-for-the-fourth-quarter-and-fi-poci-20151013monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-announces-partnership-with-omnivision-and-fujikura-creating-1-poci-20150617monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-announces-operating-results-for-the-third-quarter-and-nin-poci-20150514monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-schedules-third-quarter-conference-call-poci-20150511monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-announces-operating-results-for-the-second-quarter-and-si-poci-20150217monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-schedules-second-quarter-conference-call-poci-20150212monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-to-demonstrate-latest-cmos-micro-camera-modules-at-md-m-w-poci-20150210monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-announces-partnership-for-tpst-2003-in-preparation-for-planned-u-s-registrational--tpst-20260311monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-announces-amezalpat-poster-presentation-at-the-2025-american-association-for-cance-tpst-20250325monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-granted-fast-track-designation-from-the-u-s-food-and-drug-administration-for-ameza-tpst-20250210monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tpst-20250207monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-receives-orphan-drug-designation-from-the-u-s-food-and-drug-administration-for-ame-tpst-20250106monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tpst-20241206monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference-tpst-20241125monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-receives-fda-study-may-proceed-for-pivotal-phase-3-trial-of-amezalpat-combination--tpst-20241112monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-announces-agreement-with-roche-to-support-advancement-of-amezalpat-combination-the-tpst-20241010monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tpst-20240920monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-further-strengthens-leadership-team-with-appointment-of-sheldon-mullins-as-vice-pr-tpst-20240918monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-tpst-20240905monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tpst-20240823monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-announces-the-appointment-of-troy-m-wagner-as-vice-president-of-quality-assurance-tpst-20240821monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-announces-successful-end-of-phase-2-meeting-with-fda-for-amezalpat-tpst-1120-to-tr-tpst-20240815monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-report-new-data-from-global-randomized-combination-study-of-amezalpat-tpst-1120-tpst-20240618monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tpst-20240607monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-participate-in-upcoming-investor-conferences-tpst-20240521monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tpst-20240426monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-new-preclinical-data-for-tpst-1120-in-rcc-at-the-aacr-annual-meeting-tpst-20240409monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-announces-publication-of-positive-data-from-phase-1-trial-of-tpst-1120-in-patients-tpst-20240404monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-presents-new-data-at-the-sitc-2024-spring-scientific-meeting-supporting-potent-ant-tpst-20240312monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-announces-upcoming-presentation-of-preclinical-data-for-tpst-1120-in-renal-cell-ca-tpst-20240305monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-present-at-the-44th-annual-td-cowen-healthcare-conference-tpst-20240226monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tpst-20240202monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tpst-20240105monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-tpst-20231201monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-present-at-the-35th-annual-piper-sandler-healthcare-conference-tpst-20231120monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-adopts-limited-duration-stockholder-rights-plan-tpst-20231011monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-report-new-and-updated-data-from-global-randomized-combination-study-of-tpst-11-tpst-20231010monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-announces-expanded-role-for-sam-whiting-m-d-ph-d-as-chief-medical-officer-and-head-tpst-20230919monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-tpst-20230905monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-announces-publication-in-cancer-research-communications-highlighting-tpst-1495-sig-tpst-20230719monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-present-at-the-jefferies-global-healthcare-conference-tpst-20230531monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-present-phase-1-monotherapy-and-combination-data-at-asco-for-tpst-1495-in-patie-tpst-20230525monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-tpst-20230519monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-report-early-results-from-global-randomized-phase-1b-2-combination-study-of-tps-tpst-20230427monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting-tpst-20230426monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-announces-new-translational-and-preclinical-data-presented-at-the-2023-aacr-annual-tpst-20230417monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-year-end-2022-financial-results-and-provides-business-update-tpst-20230322monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-present-biomarker-data-for-tpst-1120-at-the-society-for-immunotherapy-of-cancer-tpst-20230315monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-present-new-translational-and-preclinical-data-at-the-2023-aacr-annual-meeting-tpst-20230314monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-present-at-the-piper-sandler-34th-annual-healthcare-conference-tpst-20221122monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-presents-data-showing-tpst-1120-induced-pharmacodynamic-changes-consistent-with-cl-tpst-20221110monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-third-quarter-2022-financial-results-and-provides-business-update-tpst-20221108monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-announces-data-presentations-including-a-late-breaking-presentation-on-tpst-1120-a-tpst-20221102monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit-tpst-20221006monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference-tpst-20220907monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-second-quarter-2022-financial-results-and-provides-business-update-tpst-20220815monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-participate-in-panel-discussion-at-2022-william-blair-biotech-focus-conference-tpst-20220707monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-present-at-the-jefferies-healthcare-conference-tpst-20220606monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-announces-oral-and-poster-presentations-at-the-upcoming-2022-asco-annual-meeting-tpst-20220427monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-presents-promising-preclinical-data-on-two-oncology-programs-at-the-2022-aacr-annu-tpst-20220408monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-present-at-the-32nd-annual-oppenheimer-healthcare-conference-tpst-20220310monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-present-two-posters-at-the-2022-american-association-for-cancer-research-aacr-a-tpst-20220308monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-present-at-the-11th-annual-svb-leerink-healthcare-conference-tpst-20220209monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-announces-first-patient-dosed-with-tpst-1495-in-combination-with-pembrolizumab-tpst-20211118monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-presents-data-supporting-the-dual-mechanism-of-tpst-1495-as-an-optimal-approach-fo-tpst-20211112monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-third-quarter-2021-financial-results-and-provides-corporate-highlights-tpst-20211110monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-present-at-two-upcoming-investor-conferences-in-november-tpst-20211109monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-further-bolsters-patent-portfolio-with-issuance-of-multiple-patents-for-tpst-1495-tpst-20211108monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-announces-presentation-at-the-society-for-immunotherapy-of-cancer-sitc-36th-annual-tpst-20211001monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-announces-first-patient-dosed-in-randomized-study-evaluating-tpst-1120-in-first-li-tpst-20210920monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-enters-into-exclusive-license-agreement-with-the-university-of-california-for-nove-tpst-20210913monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-present-at-upcoming-investor-conferences-tpst-20210909monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-announces-appointment-of-ronit-simantov-m-d-to-its-board-of-directors-tpst-20210809monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-to-participate-in-william-blair-2021-biotech-focus-conference-tpst-20210709monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-announces-appointment-of-christine-pellizzari-to-its-board-of-directors-tpst-20210701monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-to-present-at-the-jefferies-healthcare-conference-tpst-20210527monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-to-present-at-the-solebury-trout-credit-suisse-cooley-private-company-tpst-20210308monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-announces-clinical-collaboration-with-roche-to-advance-tpst-1120-into-tpst-20210303monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference-tpst-20210108monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-tpst-20210107monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-to-present-at-two-investor-conferences-in-august-tpst-20200731monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-announces-first-patient-dosed-with-the-combination-of-tpst-1120-plus--tpst-20200622monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-announces-first-patient-dosed-in-tpst-1495-clinical-study-dual-ep2-4--tpst-20200507monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-to-present-at-9th-annual-svb-leerink-global-healthcare-conference-tpst-20200224monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-t-tpst-20200130monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-oncology-programs-presented-at-society-of-immunotherapy-for-cancer-an-tpst-20191108monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-names-biopharmaceutical-executive-stephen-brady-as-president-and-chie-tpst-20191007monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-announces-multiple-presentations-at-upcoming-sitc-34th-annual-meeting-tpst-20191002monthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-announces-update-on-phase-1-avalon-clinical-trial-of-vtp-1000-for-the-treatm-brns-20251210monthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-reports-first-quarter-2025-financial-results-and-updates-on-corporate-develo-brns-20250507monthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-reports-full-year-2024-financial-results-and-updates-on-corporate-developmen-brns-20250320monthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-promotes-snap-ti-co-inventor-geoffrey-lynn-m-d-ph-d-to-chief-scientific-offi-brns-20241125monthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-announces-results-from-ongoing-phase-2b-chronic-hepatitis-b-trial-including--brns-20241115monthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-reports-third-quarter-2024-update-on-corporate-developments-and-financial-re-brns-20241106monthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-announces-late-breaking-presentation-at-aasld-2024-the-liver-meeting-and-att-brns-20241031monthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-completes-enrollment-for-phase-2b-hbv003-clinical-trial-in-chronic-hepatitis-brns-20241001monthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-initiates-phase-1-clinical-trial-of-vtp-1000-for-the-treatment-of-celiac-dis-brns-20240924monthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-reports-second-quarter-2024-update-on-corporate-developments-and-financial-r-brns-20240808monthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-announces-strategic-pipeline-prioritization-following-positive-interim-data--brns-20240612monthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-s-vtp-300-trials-demonstrate-ability-to-achieve-undetectable-hbsag-levels-an-brns-20240606monthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-to-present-vtp-300-clinical-data-updates-at-easl-congress-2024-brns-20240522monthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-reports-first-quarter-2024-financial-results-and-update-on-corporate-develop-brns-20240513monthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-names-experienced-physician-leon-hooftman-m-d-as-chief-medical-officer-brns-20240501monthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-announces-topline-data-from-phase-1b-2-apollo-trial-of-vtp-200-in-persistent-brns-20240418monthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-reports-full-year-2023-financial-results-and-update-on-corporate-development-brns-20240320monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-and-simcere-s-sim0505-cdh6-adc-phase-1-data-to-be-presented-at-asco-2026-nxtc-20260421monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-participate-in-the-36th-annual-piper-sandler-healthcare-conference-nxtc-20241126monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-reports-preclinical-data-for-lncb74-and-additional-clinical-biomarker-data-for-nc-nxtc-20241105monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting-nxtc-20241004monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-presented-results-of-the-phase-1b-study-of-nc410-in-combination-with-pembrolizuma-nxtc-20240916monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-the-h-c-wainwright-5th-annual-neuro-perspectives-virtual-conference-nxtc-20240620monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-presents-phase-1b-data-on-nc410-and-pembrolizumab-combination-at-asco-2024-nxtc-20240530monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-phase-1b-data-of-nc410-in-combination-with-pembrolizumab-at-asco-2024-nxtc-20240424monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-and-lcb-present-preclinical-data-on-b7-h4-antibody-drug-conjugate-at-aacr-2024-nxtc-20240408monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-appoints-dr-rakesh-dixit-to-scientific-advisory-board-nxtc-20240404monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-23rd-annual-needham-virtual-healthcare-conference-nxtc-20240402monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-publishes-preclinical-data-demonstrating-function-of-flrt3-as-a-t-cell-inhibitor--nxtc-20240305monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-presents-preclinical-data-on-a-novel-therapeutic-candidate-targeting-vstm-1-for-t-nxtc-20240118monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-publishes-non-clinical-data-demonstrating-anti-siglec-15-treatment-prevented-bone-nxtc-20231221monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-the-35th-annual-piper-sandler-healthcare-conference-nxtc-20231120monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-publishes-non-clinical-data-defining-the-mechanism-of-action-for-nc525-a-novel-la-nxtc-20231115monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-presents-preclinical-data-on-nc181-a-novel-therapeutic-candidate-targeting-apoe4--nxtc-20230926monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-and-nordic-bioscience-publish-review-article-on-the-regulation-of-tumor-immunity--nxtc-20230907monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-nxtc-20230831monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-presents-non-clinical-data-defining-the-mechanism-of-nc525-at-the-2023-federation-nxtc-20230621monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-the-jmp-securities-life-sciences-conference-nxtc-20230509monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-22nd-annual-needham-virtual-healthcare-conference-nxtc-20230411monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-svb-securities-global-biopharma-conference-nxtc-20230207monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-upcoming-investor-conferences-nxtc-20221122monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-and-legochem-biosciences-enter-into-collaboration-and-co-development-agreement-to-nxtc-20221115monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-presents-initial-data-from-clinical-trial-of-nc762-and-a-trial-in-progress-poster-nxtc-20221107monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-trial-in-progress-poster-for-nc525-at-the-2022-american-society-of-hem-nxtc-20221103monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-appoints-dr-lisa-m-coussens-to-scientific-advisory-board-nxtc-20221027monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting-nxtc-20221005monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-the-ladenburg-thalmann-healthcare-conference-nxtc-20220922monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-announces-development-of-a-highly-specific-immunohistochemical-diagnostic-for-sig-nxtc-20220706monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-presented-nc410-data-at-the-extracellular-matrix-ecm-pharmacology-congress-in-eur-nxtc-20220627monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-the-jmp-securities-life-sciences-conference-nxtc-20220608monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-the-bofa-securities-2022-healthcare-conference-nxtc-20220503monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-and-the-national-cancer-institute-announce-preclinical-data-in-journal-of-clinica-nxtc-20220419monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-21st-annual-needham-virtual-healthcare-conference-nxtc-20220405monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-11th-annual-svb-leerink-global-healthcare-conference-nxtc-20220208monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-and-collaborators-provide-data-on-targets-in-development-at-american-society-of-h-nxtc-20211213monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-the-jmp-securities-hematology-and-oncology-summit-nxtc-20211130monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-piper-sandler-33rd-annual-virtual-healthcare-conference-nxtc-20211122monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-announces-presentations-on-targets-in-development-by-collaborators-at-american-so-nxtc-20211104monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-host-virtual-oncology-pipeline-update-event-on-november-15-2021-nxtc-20211101monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-announces-three-new-members-of-its-scientific-advisory-board-nxtc-20211019monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-announces-publication-of-preclinical-data-for-nc410-nxtc-20211007monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-give-three-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting-nxtc-20211001monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference-nxtc-20210907monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-the-19th-annual-morgan-stanley-global-healthcare-conference-nxtc-20210902monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors-nxtc-20210706monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-and-collaborators-publish-preclinical-data-on-novel-immunomedicine-nc410-nxtc-20210621monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-the-jmp-securities-life-sciences-conference-nxtc-20210610monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-trials-in-progress-poster-for-nc410-at-the-2021-american-society-of-cl-nxtc-20210519monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-reports-first-quarter-2021-financial-results-nxtc-20210506monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-the-bofa-securities-2021-virtual-health-care-conference-nxtc-20210505monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-the-7th-annual-truist-securities-life-sciences-summit-nxtc-20210428monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-presents-preclinical-data-for-nc762-at-american-association-for-cancer-research-a-nxtc-20210410monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-the-20th-annual-needham-virtual-healthcare-conference-nxtc-20210407monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-host-virtual-r-d-update-event-on-march-4-2021-nxtc-20210226monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-provides-updates-on-nc318-clinical-program-nxtc-20201217monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference-nxtc-20201123monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portn-nxtc-20201119monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-reports-third-quarter-2020-financial-results-nxtc-20201105monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-that-a-s-nxtc-20200923monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-investors-with-losses-greater-than-100-000-encouraged-to-contact-kehoe-law-firm-p-nxtc-20200922monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-morgan-stanley-virtual-18th-annual-global-healthcare-conference-nxtc-20200908monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-reports-second-quarter-2020-financial-results-nxtc-20200806monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-btig-virtual-biotechnology-conference-nxtc-20200805monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-initiates-phase-1-2-clinical-study-of-nc410-a-novel-immunomedicine-for-solid-tumo-nxtc-20200707monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-presents-biomarker-data-and-updated-clinical-results-from-phase-1-portion-of-its--nxtc-20200529monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-reports-first-quarter-2020-financial-results-nxtc-20200507monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-bofa-securities-virtual-health-care-conference-nxtc-20200506monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-provides-update-on-clinical-trial-activities-due-to-impact-of-covid-19-pandemic-nxtc-20200413monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-the-19th-annual-needham-virtual-healthcare-conference-nxtc-20200408monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-reports-fourth-quarter-and-full-year-2019-financial-results-nxtc-20200312monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-the-40th-annual-cowen-health-care-conference-nxtc-20200225monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-9th-annual-svb-leerink-global-healthcare-conference-nxtc-20200218monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-nxtc-20200106monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-piper-jaffray-31st-annual-healthcare-conference-nxtc-20191126monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-announces-closing-of-public-offering-nxtc-20191119monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-announces-pricing-of-public-offering-of-common-stock-nxtc-20191115monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-announces-proposed-public-offering-of-common-stock-nxtc-20191112monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-reports-third-quarter-2019-financial-results-nxtc-20191112monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-presents-updated-clinical-data-from-nc318-phase-1-2-clinical-trial-at-the-34th-an-nxtc-20191109monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-host-and-webcast-event-at-the-2019-society-for-immunotherapy-of-cancer-sitc-an-nxtc-20191104monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-clinical-data-from-nc318-phase-1-2-clinical-trial-at-34th-annual-meeti-nxtc-20191001monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-to-present-at-morgan-stanley-17th-annual-global-healthcare-conference-nxtc-20190903monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-reports-second-quarter-2019-financial-results-nxtc-20190812monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-reports-first-quarter-2019-financial-results-nxtc-20190610monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-announces-closing-of-public-offering-and-full-exercise-of-underwriters-option-to--nxtc-20190513monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-announces-pricing-of-initial-public-offering-of-common-stock-nxtc-20190509monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-targets-3-15b-epilepsy-market-with-preclinical-studies-for-innovative-rescue-tre-plrz-20250513monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-ltd-announces-closing-of-17-0-million-private-placement-plrz-20250401monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-launches-preclinical-studies-for-intranasal-naloxone-to-combat-opioid-overdose-u-plrz-20250313monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-ltd-files-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2024-plrz-20250311monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-s-moving-forward-with-expected-2025-clinical-trial-entered-manufacturing-agreeme-plrz-20241218monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-announces-closing-of-4-2-million-initial-public-offering-plrz-20241030monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-filed-a-us-patent-application-for-formulations-and-methods-for-preventing-viral--plrz-20200506monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-present-at-aegis-virtual-conference-rmti-20220215monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rmti-20211112monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-submits-investigational-new-drug-application-with-fda-for-its-proposed-cl-rmti-20211111monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-report-third-quarter-2021-financial-and-operating-results-on-novem-rmti-20211108monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-presents-triferic-real-world-evidence-update-at-asn-kidney-week-2021-rmti-20211104monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-confer-rmti-20210909monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rmti-20210819monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-provides-second-quarter-2021-financial-and-operational-update-rmti-20210816monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-report-second-quarter-2021-financial-and-operating-results-on-augu-rmti-20210729monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-files-pre-ind-meeting-request-with-fda-for-its-proposed-clinical-tria-rmti-20210628monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-extension-of-multi-year-distribution-agreement-with-nipro-medic-rmti-20210611monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-and-drogsan-pharmaceuticals-enter-into-exclusive-license-agreement-for-th-rmti-20210608monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-present-at-the-2021-ld-micro-invitational-xi-rmti-20210603monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-provides-first-quarter-2021-financial-and-operational-update-rmti-20210517monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-report-first-quarter-2021-financial-and-operating-results-on-may-1-rmti-20210503monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-marketing-approval-of-triferic-avnu-in-canada-rmti-20210427monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-presents-data-on-diagnosis-and-management-of-iron-deficiency-anemia-in-ho-rmti-20210422monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-provides-fourth-quarter-and-full-year-2020-financial-and-operational--rmti-20210331monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-report-fourth-quarter-and-full-year-2020-financial-and-operating-r-rmti-20210318monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-present-at-the-h-c-wainwright-global-life-sciences-conference-rmti-20210304monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-u-s-availability-of-triferic-avnu-for-replacement-of-iron-and-m-rmti-20210209monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-submission-of-triferic-new-drug-application-in-south-korea-by-p-rmti-20210201monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-dosing-of-first-patient-in-pivotal-triferic-phase-3-trial-by-pa-rmti-20210113monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-present-at-h-c-wainwright-bioconnect-2021-conference-rmti-20210105monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-provides-third-quarter-2020-financial-and-operational-update-rmti-20201109monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-to-report-third-quarter-2020-financial-and-operating-results-on-november--rmti-20201027monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-announces-presentations-at-the-american-society-of-nephrology-virtual-rmti-20201013monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-growth-plan-and-new-therapeutic-opportunities-for-its-ferric-py-rmti-20200924monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-35-0-million-registered-direct-offering-priced-at-the-market-un-rmti-20200923monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-appointment-of-russell-l-skibsted-as-executive-vice-president-c-rmti-20200915monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-to-host-conference-call-and-webcast-with-management-and-key-opinion-leade-rmti-20200909monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-present-at-upcoming-september-investor-conferences-rmti-20200908monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-provides-second-quarter-2020-financial-and-operational-update-rmti-20200810monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-to-host-conference-call-and-webcast-to-discuss-second-quarter-2020-financ-rmti-20200803monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-appoints-dr-allen-r-nissenson-to-board-of-directors-rmti-20200610monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-files-new-drug-submission-with-health-canada-for-marketing-approval-o-rmti-20200526monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-provides-first-quarter-2020-financial-and-operational-update-and-top--rmti-20200511monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-appoints-pharmaceutical-industry-leader-robert-s-radie-to-board-of-di-rmti-20200331monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-confirms-medical-resource-acquisition-group-s-director-nominations-ar-rmti-20200320monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-reports-fourth-quarter-and-full-year-2019-financial-results-rmti-20200312monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-determines-medical-resource-acquisition-group-s-director-nominations-are--rmti-20200311monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-acknowledges-receipt-of-communications-from-medical-resource-acquisition--rmti-20200310monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-offered-15-million-by-medical-resource-acquisition-group-llc-rmti-20200309monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-discuss-fourth-quarter-and-full-year-2019-financial-results-on-mar-rmti-20200304monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-provides-business-update-rmti-20200227monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-present-at-2020-bio-ceo-investor-conference-rmti-20200206monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-pricing-of-7-5-million-public-offering-of-common-stock-rmti-20200204monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-proposed-public-offering-of-common-stock-rmti-20200203monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-enters-into-exclusive-license-and-supply-agreements-with-sun-pharma-f-rmti-20200115monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-appoints-russell-h-ellison-md-msc-to-board-of-directors-rmti-20200109monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-present-at-biotech-showcase-2020-rmti-20200108monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-present-at-31st-annual-piper-jaffray-healthcare-conference-rmti-20191121monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-expands-medical-capabilities-rmti-20191120monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-reports-third-quarter-2019-financial-results-rmti-20191111monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-sponsor-triferic-exhibitor-spotlight-presentation-at-american-soci-rmti-20191107monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-discuss-third-quarter-2019-financial-results-on-november-11-2019-rmti-20191104monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-appoints-john-p-mclaughlin-chairman-of-the-board-of-directors-rmti-20191031monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-provides-business-update-rmti-20191024monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-present-at-2019-cantor-global-healthcare-conference-rmti-20190924monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-appoints-industry-veteran-john-p-mclaughlin-to-board-of-directors-rmti-20190905monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-present-at-upcoming-september-conferences-rmti-20190828monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-reports-second-quarter-2019-financial-results-rmti-20190808monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-announces-completion-of-two-clinical-pharmacology-studies-of-triferic-rmti-20190808monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-announces-acceptance-by-fda-of-new-drug-application-for-i-v-triferic-rmti-20190806monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-discuss-second-quarter-2019-financial-results-on-august-8-2019-rmti-20190729monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-pricing-of-17-5-million-public-offering-of-common-stock-rmti-20190618monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-proposed-public-offering-of-common-stock-rmti-20190617monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-adjournment-of-annual-meeting-of-shareholders-rmti-20190607monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-announces-submission-of-new-drug-application-for-i-v-triferic-rmti-20190529monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-reports-first-quarter-2019-financial-results-rmti-20190509monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-commences-commercial-sales-of-dialysate-triferic-in-the-u-s-rmti-20190506monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-discuss-first-quarter-2019-financial-results-on-may-9-2019-rmti-20190502monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-present-at-h-c-wainwright-global-life-sciences-conference-rmti-20190403monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-present-at-sidoti-company-llc-spring-2019-investor-conference-rmti-20190320monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-i-v-triferic-and-peritoneal-dialysis-study-abstracts-selected-a-rmti-20190318monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-reports-fourth-quarter-and-full-year-2018-financial-results-rmti-20190314monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-discuss-fourth-quarter-and-full-year-2018-financial-results-on-mar-rmti-20190306monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-present-at-2019-bio-ceo-investor-conference-rmti-20190205monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-to-present-at-biotech-showcase-2019-rmti-20181221monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-investor-alert-wolf-haldenstein-adler-freeman-herz-llp-announces-that-rmti-20180809monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-class-action-bernstein-liebhard-llp-files-securities-class-action-lawsuit-against-rmti-20180805monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-notice-bernstein-liebhard-llp-files-securities-class-action-lawsuit-against-rockw-rmti-20180731monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-notice-bernstein-liebhard-llp-files-securities-class-action-lawsuit-against-rockw-rmti-20180727monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-shareholder-alert-bernstein-liebhard-llp-announces-investigation-of-rockwell-medi-rmti-20180718monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-ceo-issues-press-release-rmti-20180523monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-first-quarter-2018-results-rmti-20180510monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-update-on-calcitriol-new-manufacturing-submission-to-fda-rmti-20180508monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-first-quarter-2018-earnings-call-rmti-20180502monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-triferic-presentations-at-the-2018-international-congress-on-pe-rmti-20180502monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-triferic-presentations-at-the-2018-national-kidney-foundation-s-rmti-20180405monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-triferic-presentations-at-the-2018-asia-pacific-congress-of-nep-rmti-20180320monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-fourth-quarter-and-year-end-2017-results-rmti-20180315monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-year-end-2017-earnings-call-rmti-20180312monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-triferic-presentations-at-the-2018-annual-dialysis-conference-rmti-20180228monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-signs-exclusive-license-agreement-with-comercializadora-biorenal-spa-to-c-rmti-20171214monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-signs-exclusive-license-agreement-with-quimica-europea-to-commercialize-t-rmti-20171212monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-third-quarter-results-rmti-20171108monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-third-quarter-2017-earnings-call-rmti-20171101monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-two-triferic-poster-presentations-at-american-society-of-nephro-rmti-20171030monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-update-on-calcitriol-post-approval-manufacturing-submission-to-fda-rmti-20171025monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-files-calcitriol-post-approval-manufacturing-submission-with-fda-rmti-20170928monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-updates-progress-on-calcitriol-commercial-launch-rmti-20170913monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-appoints-john-g-cooper-to-board-of-directors-rmti-20170907monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-responds-to-richmond-group-rmti-20170829monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-second-quarter-results-rmti-20170809monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-second-quarter-2017-earnings-call-rmti-20170804monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-triferic-presentation-at-annual-conference-on-nephrology-urolog-rmti-20170628monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-sends-important-message-to-richmond-brothers-clients-you-have-the-sole-au-rmti-20170525monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-issues-letter-to-shareholders-explaining-why-electing-mark-ravich-could-d-rmti-20170522monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-encourages-shareholders-not-to-be-misled-by-richmond-brothers-rmti-20170516monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-files-investor-presentation-rmti-20170510monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-first-quarter-results-rmti-20170509monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-shareholders-express-support-for-the-election-of-david-domzalski-rmti-20170509monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-first-quarter-2017-earnings-call-rmti-20170505monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-mails-letter-to-shareholders-profiling-independent-director-nominee-david-rmti-20170504monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-poster-presentation-and-oral-presentation-on-triferic-at-the-7t-rmti-20170427monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-files-definitive-proxy-materials-rmti-20170421monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-triferic-poster-presentations-at-the-national-kidney-foundation-rmti-20170410monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-files-preliminary-proxy-statement-for-annual-meeting-rmti-20170404monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-esa-sparing-compositions-and-use-patent-allowed-in-china-rmti-20170328monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-fourth-quarter-results-rmti-20170315monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-fourth-quarter-year-end-2016-earnings-call-rmti-20170313monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-one-poster-and-two-oral-presentations-on-triferic-at-annual-dia-rmti-20170306monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-nomination-of-david-domzalski-to-board-of-directors-rmti-20170302monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-updates-progress-on-calcitriol-commercial-launch-rmti-20170221monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-will-present-data-on-triferic-intravenous-iv-administration-at-the-19th-i-rmti-20170126monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-third-quarter-results-rmti-20161107monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-third-quarter-2016-earnings-call-rmti-20161103monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-to-present-data-on-peritoneal-dialysis-pd-administration-of-triferic-at-a-rmti-20161019monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-triferic-human-intravenous-iv-pharmacokinetic-study-published-i-rmti-20161004monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-preparing-for-calcitriol-commercial-launch-rmti-20160922monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-enters-into-exclusive-license-agreement-with-aram-medical-to-commercializ-rmti-20160816monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-second-quarter-results-rmti-20160808monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-second-quarter-2016-earnings-call-rmti-20160803monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-appointment-of-dr-robin-smith-to-board-of-directors-rmti-20160623monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-multiple-international-trademark-approvals-for-triferic-rmti-20160512monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-first-quarter-results-rmti-20160510monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-first-quarter-2016-earnings-call-rmti-20160505monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-provides-update-on-preparations-for-calcitriol-commercial-launch-rmti-20160504monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-triferic-presentation-overcoming-functional-iron-deficiency-in--rmti-20160428monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-fourth-quarter-and-fiscal-2015-results-rmti-20160229monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-fourth-quarter-fiscal-2015-earnings-call-rmti-20160225monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-files-ind-to-investigate-triferic-for-rare-orphan-disease-iron-refractory-rmti-20160222monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-enters-into-exclusive-license-agreement-with-wanbang-biopharmaceutical-co-rmti-20160216monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-two-triferic-poster-presentations-accepted-for-presentation-at--rmti-20160119monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-to-present-at-oppenheimer-26th-annual-healthcare-conference-rmti-20151201monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-s-triferic-receives-permanent-j-code-for-renal-drug-reimbursement-rmti-20151130monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-to-present-at-stifel-2015-healthcare-conference-rmti-20151112monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-third-quarter-2015-results-rmti-20151109monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-third-quarter-earnings-call-rmti-20151102monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-presentation-schedule-for-triferic-clinical-posters-at-american-rmti-20151028monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-introduces-new-video-demonstrating-triferic-r-mode-of-action-at-www-trife-rmti-20151015monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-four-triferic-posters-accepted-for-presentation-at-american-soc-rmti-20151006monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-launches-new-triferic-tm-website-rmti-20151001monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-the-u-s-commercial-launch-of-triferic-tm-rmti-20150909monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-second-quarter-2015-results-rmti-20150804monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-second-quarter-earnings-call-rmti-20150727monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-triferic-tm-phase-3-cruise-studies-published-in-nephrology-dial-rmti-20150715monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-triferic-tm-esa-sparing-prime-study-published-in-kidney-interna-rmti-20150713monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-triferic-receives-q-code-assignment-for-product-reimbursement-rmti-20150601monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-triferic-clinical-data-selected-for-four-presentations-at-the-5-rmti-20150512monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-first-quarter-2015-results-rmti-20150507monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-to-present-at-bank-of-america-merrill-lynch-2015-health-care-conference-rmti-20150505monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-first-quarter-earnings-call-rmti-20150430monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-triferic-tm-clinical-data-selected-for-four-poster-presentation-rmti-20150326monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-fourth-quarter-2014-results-rmti-20150226monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-fourth-quarter-earnings-call-rmti-20150223monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-two-triferic-abstracts-to-be-presented-at-annual-dialysis-confe-rmti-20150107monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-closes-58-5-million-public-offering-of-common-stock-rmti-20141125monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-presentation-schedule-for-triferic-clinical-posters-at-the-amer-rmti-20141111monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-reports-third-quarter-2014-results-rmti-20141110monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-third-quarter-2014-investor-conference-call-rmti-20141030monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-fda-advisory-committee-review-of-triferic-for-the-treatment-of--rmti-20141009monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-receives-8-million-in-cash-via-exercise-of-warrants-rmti-20141007monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-reports-second-quarter-2014-results-rmti-20140731monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-2nd-quarter-2014-investor-conference-call-rmti-20140725monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-fda-approves-2-2-million-application-fee-refund-for-triferic-tm-rmti-20140630monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-receives-fda-approval-for-calcitriol-rmti-20140623monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-wins-appeal-for-determination-as-small-business-for-new-drug-application--rmti-20140609monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-fda-acceptance-for-filing-of-triferic-tm-new-drug-application-rmti-20140528monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-to-participate-at-craig-hallum-institutional-investor-conference-wednesda-rmti-20140522monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-to-present-triferic-tm-iron-replacement-clinical-data-at-51st-era-edta-co-rmti-20140514monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-reports-first-quarter-2014-results-rmti-20140512monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-1st-quarter-2014-investor-conference-call-rmti-20140506monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-triferic-tm-iron-replacement-clinical-data-to-be-presented-at-1-rmti-20140429monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-triferic-tm-iron-replacement-clinical-data-selected-for-three-a-rmti-20140414monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-submits-new-drug-application-for-triferic-tm-for-the-treatment-of-iron-re-rmti-20140324monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-to-host-investor-meeting-with-nephrology-key-opinion-leader-on-march-6-20-rmti-20140305monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-reports-fourth-quarter-2013-results-rmti-20140226monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-third-quarter-2013-results-rmti-20131105monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-second-quarter-2013-results-rmti-20130801monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-long-term-national-supply-agreement-with-davita-rmti-20130508monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-2013-first-quarter-results-signs-long-term-national-supply-agreem-rmti-20130508monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-to-raise-12-9-million-in-registered-direct-common-stock-offering-rmti-20130320monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-2012-fourth-quarter-and-full-year-results-rmti-20130318monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-conference-call-reporting-fourth-quarter-and-2012-year-end-resu-rmti-20130307monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-third-quarter-2012-results-rmti-20121108monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-conference-call-reporting-third-quarter-results-rmti-20121022monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-conference-call-reporting-second-quarter-results-rmti-20120726monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-first-quarter-2012-results-rmti-20120503monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-earnings-conference-call-rmti-20120501monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-appoints-raymond-pratt-m-d-facp-as-chief-medical-officer-rmti-20120419monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-data-safety-monitoring-board-recommends-sfp-phase-iii-efficacy-studies-to-rmti-20120319monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-2011-and-fourth-quarter-results-rmti-20120301monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-closes-17-5-million-registered-common-stock-offering-rmti-20120215monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-prices-registered-common-stock-offering-rmti-20120209monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-conference-call-reporting-fourth-quarter-and-year-end-results-rmti-20120127monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-data-safety-monitoring-board-recommends-phase-iii-cruise-studies-continue-rmti-20111212monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-third-quarter-2011-results-rmti-20111103monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-conference-call-rmti-20111028monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-to-present-at-jmp-securities-healthcare-conference-rmti-20110921monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-appoints-annamaria-t-kausz-m-d-m-s-to-vp-of-drug-development-and-medical--rmti-20110919monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-to-present-at-wedbush-life-sciences-management-access-conference-rmti-20110811monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-second-quarter-2011-results-rmti-20110804monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-investor-conference-call-rmti-20110728monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-acquisition-of-generic-drug-vitamin-d-to-treat-secondary-hyperp-rmti-20110726monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-gains-membership-into-the-russell-2000-index-rmti-20110629monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-u-s-patent-issued-for-sfp-packaging-and-method-of-use-rmti-20110511monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-first-quarter-2011-results-rmti-20110505monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-investor-conference-call-rmti-20110428monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-begins-second-phase-iii-clinical-trial-for-treatment-of-iron-deficiency-i-rmti-20110426monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-appoints-dr-alvin-l-crumbliss-to-scientific-advisory-board-rmti-20110415monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-new-supply-agreement-with-davita-inc-rmti-20110328monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-starts-pivotal-phase-iii-clinical-study-for-treatment-of-iron-deficiency--rmti-20110324monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-fourth-quarter-and-full-year-2010-results-rmti-20110303monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-investor-conference-call-rmti-20110224monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-to-present-at-citi-2011-global-health-care-conference-rmti-20110223monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-commences-prime-clinical-study-esa-sparing-examined-in-hemodialysis-patie-rmti-20110216monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-largest-dialysis-organizations-in-u-s-to-participate-in-phase-i-rmti-20110125monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-presents-new-data-on-proprietary-iron-delivery-drug-sfp-at-american-socie-rmti-20101119monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-to-present-at-the-annual-piper-jaffray-health-care-conference-rmti-20101117monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-third-quarter-results-rmti-20101104monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-to-present-data-at-american-society-of-nephrology-asn-annual-meeting-rmti-20101103monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-investor-conference-call-rmti-20101028monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-sfp-patent-issuance-for-its-proprietary-gmp-formulation-in-the--rmti-20101026monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-design-of-phase-iii-iron-therapy-program-for-sfp-rmti-20101020monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-appoints-carl-belczynski-as-vp-of-investor-relations-rmti-20101005monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-to-present-at-the-fifth-annual-jmp-securities-healthcare-conference-rmti-20100913monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-appoints-dr-iain-macdougall-to-scientific-advisory-board-rmti-20100816monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-record-second-quarter-results-rmti-20100805monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-investor-conference-call-rmti-20100729monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-successfully-completes-fda-meeting-regarding-sfp-rmti-20100708monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-to-present-phase-iib-data-at-xlvii-era-edta-congress-in-munich-germany-ju-rmti-20100525monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-first-quarter-results-rmti-20100505monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-to-present-at-the-ninth-annual-jmp-securities-research-conference-rmti-20100504monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-investor-conference-call-rmti-20100428monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-collins-selects-spark-pro-for-security-and-information-assurance-rmti-20100427monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-appoints-dr-ajay-singh-to-scientific-advisory-board-rmti-20100415monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-excellent-fourth-quarter-and-full-year-2009-business-results-rmti-20100310monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-investor-conference-call-rmti-20100309monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-reports-third-quarter-results-expanded-gross-profit-margins-rmti-20091104monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-completes-sfp-phase-iib-clinical-study-rmti-20091029monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-investor-conference-call-rmti-20091026monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-to-present-abstract-at-american-society-of-nephrology-as-rmti-20091013monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-appoints-jur-strobos-m-d-to-scientific-advisory-board-rmti-20091006monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-announces-closing-of-22-million-registered-direct-offeri-rmti-20091005monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-to-present-at-the-2009-jmp-securities-healthcare-focus-confe-rmti-20091001monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-announces-22-million-registered-direct-offering-rmti-20090930monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-reports-results-for-second-quarter-2009-rmti-20090810monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-schedules-investor-conference-call-rmti-20090804monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-appoints-ajay-gupta-m-d-as-chief-scientific-officer-rmti-20090630monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-named-to-russell-indexes-rmti-20090629monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-reports-results-for-first-quarter-2009-rmti-20090511monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-schedules-investor-conference-call-rmti-20090430monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-announces-patient-enrollment-complete-for-phase-2b-dose--rmti-20090429monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-announces-updated-dsmb-interim-results-no-safety-issues--rmti-20090416monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-reports-fourth-quarter-2008-results-sales-increase-20-ye-rmti-20090316monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-schedules-investor-conference-call-rmti-20090310monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-appoints-richard-yocum-m-d-as-vp-of-drug-development-and-rmti-20090302monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-reports-third-quarter-results-sales-gain-of-22-2-percent-rmti-20081113monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-to-present-at-the-2008-rodman-renshaw-annual-global-investme-rmti-20081106monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-schedules-investor-conference-call-rmti-20081104monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-announces-updated-dsmb-results-identifies-no-safety-conc-rmti-20081029monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-to-present-at-the-2008-oppenheimer-19th-annual-healthcare-co-rmti-20081027monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-reports-second-quarter-sales-increase-of-15-5-percent-ma-rmti-20080812monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-schedules-investor-conference-call-rmti-20080805monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-appoints-dr-richard-hurrell-international-iron-expert-to-rmti-20080709monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-appoints-dr-james-d-cook-to-scientific-advisory-board-rmti-20080617monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-appoints-dr-richard-zager-to-scientific-advisory-board-rmti-20080610monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-to-present-at-2008-barrington-research-healthcare-confer-rmti-20080520monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-reports-first-quarter-sales-increase-31-percent-sfp-deve-rmti-20080507monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-schedules-investor-conference-call-rmti-20080422monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-reports-fourth-quarter-2007-results-year-end-sales-incre-rmti-20080306monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-schedules-investor-conference-call-rmti-20080226monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-reports-patients-begin-dosing-in-nih-funded-sfp-clinical-rmti-20080131monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-announces-patient-enrollment-begins-for-nih-funded-sfp-c-rmti-20080123monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-reports-fda-approves-start-of-nih-sponsored-study-of-iro-rmti-20071204monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-closes-12-95-million-financing-rmti-20071129monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-reports-third-quarter-results-sales-increase-50-percent-rmti-20071108monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-receives-patent-grant-for-proprietary-sfp-iron-delivery--rmti-20071023monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-schedules-investor-conference-call-rmti-20071018monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-technologies-inc-schedules-investor-conference-call-rmti-20070719monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-inc-nasdaq-vtgn-shareholder-alert-bernstein-liebhard-llp-reminds-vis-vtgn-20260312monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-levi-vtgn-20260309monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-inc-nasdaq-vtgn-shareholder-alert-bernstein-liebhard-llp-reminds-vis-vtgn-20260305monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-inc-nasdaq-vtgn-shareholder-alert-bernstein-liebhard-llp-reminds-vis-vtgn-20260226monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-inc-nasdaq-vtgn-shareholder-alert-bernstein-liebhard-llp-reminds-vis-vtgn-20260219monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-vtgn-20260212monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-inc-nasdaq-vtgn-shareholder-alert-bernstein-liebhard-llp-reminds-vis-vtgn-20260212monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-inc-nasdaq-vtgn-shareholder-alert-bernstein-liebhard-llp-reminds-vis-vtgn-20260202monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-inc-nasdaq-vtgn-shareholder-alert-bernstein-liebhard-llp-reminds-vis-vtgn-20260127monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-class-action-alert-bragar-eagel-squire-p-c-reminds-vistagen-therapeutics-inc-stoc-vtgn-20260124monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-inc-nasdaq-vtgn-deadline-alert-bernstein-liebhard-llp-reminds-vistag-vtgn-20260122monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the--vtgn-20260122monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-file-vtgn-20260120monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-inc-nasdaq-vtgn-investor-alert-investors-with-large-losses-in-vistag-vtgn-20260116monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-reports-fiscal-year-2022-second-quarter-financial-results-and-provid-vtgn-20211110monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-to-report-fiscal-year-2022-second-quarter-financial-results-and-rece-vtgn-20211104monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-to-report-fiscal-year-2022-first-quarter-financial-results-and-host--vtgn-20210809monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference-vtgn-20210802monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021-vtgn-20210709monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-to-report-2021-fiscal-year-end-financial-results-provide-a-business--vtgn-20210625monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-to-present-at-two-investor-conferences-in-june-vtgn-20210520monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-s-poster-presentation-at-the-anxiety-and-depression-association-of-america-s-2021-vtgn-20210322monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-to-participate-in-upcoming-investor-conferences-in-march-vtgn-20210316monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-s-ph10-nasal-spray-demonstrates-different-mechanism-of-action-from-benzodiazepine-vtgn-20210311monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-announces-publication-in-cns-spectrums-detailing-proposed-mechanism-of-action-of--vtgn-20201230monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-announces-closing-of-100-million-underwritten-public-offering-vtgn-20201222monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-announces-pricing-of-underwritten-public-offering-vtgn-20201218monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-announces-proposed-underwritten-public-offering-vtgn-20201217monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-announces-pricing-of-underwritten-public-offering-of-common-stock-vtgn-20190226monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-announces-proposed-public-offering-of-common-stock-vtgn-20190225monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-receives-av-101-japanese-patent-for-treatment-of-depression-and-hype-vtgn-20190219monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-reports-fiscal-2019-third-quarter-financial-results-vtgn-20190212monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-to-present-at-the-21st-annual-bio-ceo-investor-conference-on-februar-vtgn-20190205monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-to-present-at-11th-annual-biotech-showcase-vtgn-20181227monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-receives-hong-kong-patent-for-methods-of-production-for-av-101-vtgn-20181129monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-to-present-at-credit-suisse-27th-annual-healthcare-conference-on-wed-vtgn-20181022monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-appoints-dr-michael-liebowitz-to-cns-clinical-and-regulatory-advisor-vtgn-20181015monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-reports-fiscal-2019-first-quarter-financial-results-vtgn-20180814monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-issued-two-key-u-s-patents-for-treatment-of-depression-with-av-101-vtgn-20180613monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-receives-notice-of-allowance-for-japanese-patent-for-use-of-stem-cel-vtgn-20180611monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-inc-nasdaq-vtgn-to-ring-the-nasdaq-stock-market-closing-bell-vtgn-20170310monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-presents-cardiosafe-3d-tm-and-liversafe-3d-tm-developments-at-intern-vtgn-20130617monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-and-duke-university-publish-results-on-production-of-functional-3d-h-vtgn-20130507monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-to-present-enhancements-and-expanded-validation-of-liversafe-3d-tm-a-vtgn-20130312monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-to-present-cardiosafe-3d-tm-developments-at-society-of-toxicology-s--vtgn-20130311monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-enters-strategic-collaboration-with-celsis-to-further-advance-livers-vtgn-20130304monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-successfully-completes-final-phase-1-safety-study-of-av-101-vtgn-20130123monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-to-present-at-noble-financial-capital-markets-ninth-annual-equity-co-vtgn-20130122monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-becomes-member-of-centre-for-commercialization-of-regenerative-medic-vtgn-20121203monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-enhances-predictive-liver-toxicology-and-drug-metabolism-bioassay-sy-vtgn-20121113monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-and-duke-university-announce-heart-tissue-engineering-progress-at-am-vtgn-20121107monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-completes-3-25-million-financing-and-3-0-million-debt-restructuring-vtgn-20121016monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-announces-strategic-financing-with-platinum-long-term-growth-fund-vtgn-20120906monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-enters-strategic-drug-screening-collaboration-with-vala-sciences-vtgn-20120321monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-and-duke-university-enter-into-strategic-research-collaboration-vtgn-20120305monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-engages-missionir-as-its-investor-relations-advisor-vtgn-20120221monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-increases-its-drug-rescue-opportunities-with-right-of-first-offer-ag-vtgn-20120208monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-and-synterys-sign-strategic-medicinal-chemistry-collaboration-agreem-vtgn-20111207monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-and-university-health-network-toronto-extend-broad-stem-cell-allianc-vtgn-20111117monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-reports-identification-of-cell-surface-marker-that-permits-high-yiel-vtgn-20111025monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-presents-highlights-of-its-human-stem-cell-derived-micro-heart-cardi-vtgn-20111005monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-expands-key-stem-cell-technology-patent-estate-supporting-its-drug-r-vtgn-20110928monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-reports-advances-in-its-pancreatic-cell-and-regenerative-medicine-pr-vtgn-20110926monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-provides-investor-update-on-corporate-activities-and-upcoming-initia-vtgn-20110914monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-report-third-quarter-2025-financial-results-and-provide-a-business--lsta-20251030monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-report-second-quarter-2025-financial-results-and-provide-a-business-lsta-20250731monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-and-gatc-health-expand-relationship-to-advance-ai-driven-drug-discover-lsta-20250617monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-present-at-the-2025-bio-international-convention-lsta-20250611monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-a-business--lsta-20250501monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-research-license-with-catalent-lsta-20250415monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-present-at-the-investival-showcase-usa-lsta-20250306monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-and-gatc-health-consummate-first-step-in-strategic-collaboration-to-us-lsta-20250305monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-report-full-year-2024-financial-results-and-provide-a-business-upda-lsta-20250220monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-present-at-the-2025-bio-ceo-investor-conference-lsta-20250205monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-and-warpnine-announce-encouraging-preliminary-results-from-the-phase-1-lsta-20250123monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-present-at-the-2025-sequire-investor-summit-lsta-20250115monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-completion-of-enrollment-in-the-cendifox-trial-lsta-20241210monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-and-kuva-labs-announce-global-license-agreement-for-solid-tumor-imagin-lsta-20241203monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-wins-2024-biotech-breakthrough-award-for-specialized-biotherapeutics-c-lsta-20241119monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-and-valo-therapeutics-announce-preclinical-research-collaboration-lsta-20241106monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-report-third-quarter-2024-financial-results-and-provide-a-business--lsta-20241106monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-participate-in-upcoming-november-2024-industry-and-investor-events-lsta-20241031monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-sponsored-preclinical-research-agreement-with-the-university-lsta-20241028monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-participate-in-upcoming-october-2024-industry-and-investor-events-lsta-20241003monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-first-patient-treated-in-the-second-line-cholangiocarcinoma--lsta-20240917monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-participate-in-upcoming-september-2024-industry-and-investor-events-lsta-20240909monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-certepetide-granted-fda-orphan-drug-designation-for-the-treatment-of-c-lsta-20240905monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-report-second-quarter-2024-financial-results-and-provide-a-business-lsta-20240805monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-completion-of-enrollment-in-its-phase-2a-bolster-trial-of-ce-lsta-20240716monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-certepetide-shows-promise-in-improving-standard-treatment-for-intrahep-lsta-20240710monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-full-enrollment-of-pancreatic-cancer-cohort-of-cendifox-tria-lsta-20240613monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-participate-in-upcoming-june-2024-industry-and-investor-events-lsta-20240528monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-receives-paediatric-investigation-plan-waiver-from-the-european-medici-lsta-20240520monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-participate-in-upcoming-may-2024-industry-and-investor-events-lsta-20240508monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-report-first-quarter-2024-financial-results-and-provide-a-business--lsta-20240502monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-and-qilu-pharmaceutical-announce-first-patient-treated-in-qilu-s-phase-lsta-20240423monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-u-s-fda-orphan-drug-designation-granted-to-lsta1-for-the-tre-lsta-20240409monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-participate-in-upcoming-april-2024-industry-and-investor-events-lsta-20240403monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-u-s-fda-rare-pediatric-disease-designation-granted-to-lsta1--lsta-20240321monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-host-year-end-2023-conference-call-on-thursday-february-29-2024-at--lsta-20240222monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-present-at-bio-ceo-investor-conference-lsta-20240220monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-present-at-the-sequire-investor-summit-in-puerto-rico-lsta-20240118monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-first-patient-treated-in-the-phase-2a-trial-of-lsta1-in-pati-lsta-20240117monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-publication-of-case-report-on-a-complete-response-in-a-metas-lsta-20240104monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-completion-of-enrollment-in-phase-2b-ascend-trial-of-lsta1-i-lsta-20231212monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-present-at-noblecon19-investor-conference-lsta-20231128monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-participation-in-upcoming-conferences-in-november-lsta-20231109monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-host-third-quarter-2023-financial-results-conference-call-on-thursd-lsta-20231026monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-first-patient-treated-in-the-cholangiocarcinoma-cohort-of-th-lsta-20231024monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-european-medicines-agency-has-granted-lsta1-orphan-drug-desi-lsta-20231017monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-participation-in-upcoming-conferences-in-october-lsta-20230928monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-participation-in-infosec-world-2023-lsta-20230920monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-first-patient-treated-in-the-bolster-trial-of-lsta1-a-novel--lsta-20230912monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-outcome-of-interim-futility-analysis-for-its-phase-2b-ascend-lsta-20230906monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-participation-in-upcoming-conferences-in-september-lsta-20230905monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-u-s-fda-orphan-drug-designation-granted-to-lsta1-for-the-tre-lsta-20230808monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-report-second-quarter-2023-financial-results-on-monday-august-14-af-lsta-20230807monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-present-at-the-gcff-innovation-and-healthcare-virtual-conference-lsta-20230612monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-enhancements-to-ongoing-phase-2b-ascend-trial-of-lsta1-lsta-20230524monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-host-first-quarter-2023-financial-results-conference-call-on-tuesda-lsta-20230502monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-participation-in-upcoming-conferences-in-may-lsta-20230427monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-receives-2-2-million-of-non-dilutive-capital-through-new-jersey-techno-lsta-20230420monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-present-at-the-sequire-investor-summit-in-puerto-rico-lsta-20230419monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-and-warpnine-announce-first-patient-treated-in-the-ilsta-trial-of-lsta-lsta-20230418monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-host-fourth-quarter-and-full-year-2022-financial-results-conference-lsta-20230323monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-webcast-live-at-the-life-sciences-investor-forum-on-march-9th-lsta-20230306monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-participation-in-upcoming-conferences-in-february-lsta-20230201monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-reports-third-quarter-2022-financial-results-and-provides-business-upd-lsta-20221110monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-participation-in-upcoming-conferences-in-november-2022-lsta-20221107monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-to-host-third-quarter-2022-financial-results-conference-call-on-thursd-lsta-20221103monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-participation-in-upcoming-conferences-in-october-2022-lsta-20221006monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-director-and-scientific-founder-of-the-cendr-platform-technology-erkki-lsta-20220929monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-granted-chinese-patent-for-potency-assay-methods-for-assessing-human-mesenchyma-lgvn-20260408monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-2025-full-year-financial-results-and-provides-business-update-lgvn-20260317monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-closing-of-private-placement-of-up-to-30-million-lgvn-20260311monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-private-placement-of-up-to-30-million-lgvn-20260310monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-chief-science-officer-and-chief-medical-officer-selected-as-speakers-at-the-glo-lgvn-20251203monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-new-mri-biomarker-data-linking-neuroinflammation-to-clinical-outcomes-in-patien-lgvn-20251201monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-laromestrocel-data-in-alzheimer-s-disease-selected-for-poster-presentation-at-t-lgvn-20251119monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-closing-of-up-to-17-5-million-public-offering-lgvn-20250811monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-report-second-quarter-2025-financial-results-and-host-conference-call-on-aug-lgvn-20250805monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-licensing-of-new-cardiac-selective-induced-pluripotent-stem-cell-tech-lgvn-20250721monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-appoints-than-powell-as-chief-business-officer-lgvn-20250626monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-completion-of-enrollment-of-pivotal-phase-2b-clinical-trial-evaluatin-lgvn-20250624monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-participate-in-the-h-c-wainwright-6th-annual-neuro-perspectives-hybrid-confe-lgvn-20250609monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-attend-bio-international-convention-2025-lgvn-20250520monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-named-xprize-healthspan-semifinalist-and-top-40-milestone-1-award-recipient-lgvn-20250512monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-report-first-quarter-2025-financial-results-and-host-conference-call-on-may--lgvn-20250502monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-issues-letter-to-shareholders-highlighting-corporate-strategy-recent-progress-a-lgvn-20250422monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-positive-type-b-meeting-with-u-s-fda-regarding-pathway-to-bla-for-lar-lgvn-20250320monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-nature-medicine-publication-of-results-of-phase-2a-clinical-trial-eva-lgvn-20250311monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-present-at-the-37th-annual-roth-conference-lgvn-20250305monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-report-full-year-2024-financial-results-and-host-conference-call-on-february-lgvn-20250221monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-world-health-organization-approval-of-laromestrocel-as-international--lgvn-20250218monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-present-at-the-emerging-growth-virtual-conference-on-february-19-2025-lgvn-20250214monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-present-at-biotech-showcase-2025-lgvn-20241218monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-present-at-the-emerging-growth-virtual-conference-on-december-5-2024-lgvn-20241202monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-appoints-devin-blass-as-chief-technology-officer-and-svp-of-chemistry-manufactu-lgvn-20241111monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-report-third-quarter-2024-financial-results-and-host-conference-call-on-nove-lgvn-20241104monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-presents-lomecel-b-data-for-alzheimer-s-disease-indication-in-late-breaking-pos-lgvn-20241029monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-presents-lomecel-b-long-term-transplant-free-survival-data-in-hypoplastic-left--lgvn-20241027monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-lomecel-b-data-in-alzheimer-s-disease-selected-for-late-breaking-poster-present-lgvn-20241014monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-lomecel-b-5-year-long-term-transplant-free-survival-data-in-hlhs-selected-for-o-lgvn-20241009monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-present-at-the-ubs-virtual-organ-restoration-and-cell-therapy-day-lgvn-20241007monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-participate-in-the-3rd-annual-roth-healthcare-opportunities-conference-lgvn-20241002monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-attend-alliance-for-regenerative-medicine-s-cell-gene-meeting-on-the-mesa-lgvn-20240926monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-positive-type-c-meeting-with-u-s-fda-regarding-pathway-to-bla-for-lom-lgvn-20240903monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-lgvn-20240826monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-report-second-quarter-2024-financial-results-and-host-conference-call-on-aug-lgvn-20240805monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-presents-study-results-from-clear-mind-phase-2a-clinical-trial-of-lomecel-b-in--lgvn-20240728monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-closing-of-9-0-million-registered-direct-offering-priced-at-the-marke-lgvn-20240719monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-u-s-fda-grants-fast-track-designation-for-lomecel-b-for-the-treatment-lgvn-20240717monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-u-s-fda-grants-lomecel-b-regenerative-medicine-advanced-therapy-rmat--lgvn-20240710monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-raises-4-4-million-in-gross-proceeds-from-warrant-exercise-transaction-lgvn-20240618monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-present-at-the-virtual-life-sciences-investor-forum-on-june-20-2024-lgvn-20240617monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-completion-of-successful-investigator-meeting-for-on-going-phase-2b-c-lgvn-20240611monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-present-at-the-emerging-growth-virtual-conference-on-june-12-2024-lgvn-20240610monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-contract-development-and-manufacturing-business-and-first-contract-lgvn-20240603monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-attend-bio-international-convention-2024-lgvn-20240528monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-first-quarter-2024-financial-results-and-provides-business-update-lgvn-20240514monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-report-first-quarter-2024-financial-results-and-host-conference-call-on-may--lgvn-20240502monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-present-at-the-planet-microcap-showcase-lgvn-20240425monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-raises-a-total-of-11-4-million-in-gross-proceeds-from-warrant-exercise-offering-lgvn-20240418monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-s-clear-mind-randomized-phase-2a-clinical-trial-evaluating-lomecel-b-in-mild-al-lgvn-20240415monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-closing-of-5-2-million-public-offering-lgvn-20240411monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-issues-letter-to-shareholders-highlighting-corporate-strategy-clinical-pipeline-lgvn-20240408monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-1-for-10-reverse-stock-split-lgvn-20240319monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-reports-year-end-2023-results-and-provides-corporate-update-lgvn-20240227monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-report-year-end-2023-results-and-provide-corporate-update-february-27-2024-lgvn-20240221monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-receives-notice-of-united-states-patent-allowance-for-the-technology-behind-its-lgvn-20240129monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-closing-of-2-36-million-registered-direct-offering-priced-at-the-mark-lgvn-20231222monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-2-36-million-registered-direct-offering-priced-at-the-market-under-na-lgvn-20231221monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-additional-positive-clinical-data-and-imaging-biomarker-results-from--lgvn-20231220monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-reports-third-quarter-2023-results-and-provides-corporate-update-lgvn-20231110monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-report-third-quarter-2023-results-and-provide-corporate-update-on-november-1-lgvn-20231103monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-inc-featured-in-syndicated-broadcast-highlighting-top-line-results-from-clear-m-lgvn-20231024monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-closing-of-4-million-registered-direct-offering-priced-at-the-market--lgvn-20231013monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-issues-letter-to-stockholders-lgvn-20230911monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-present-at-the-25th-annual-h-c-wainwright-global-investment-conference-lgvn-20230905monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-participate-in-the-149th-annual-national-investment-banking-association-conf-lgvn-20230829monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-rights-offering-subscription-period-begins-lgvn-20230822monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-host-key-opinion-leader-event-on-medicinal-signaling-cells-mscs-for-hypoplas-lgvn-20230814monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-reports-second-quarter-2023-results-and-provides-corporate-update-lgvn-20230811monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-achievement-of-surpassing-50-enrollment-threshold-in-phase-2-elpis-ii-lgvn-20230811monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-report-second-quarter-2023-results-and-provide-corporate-update-on-august-11-lgvn-20230807monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer-lgvn-20230711monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-congratulates-co-founder-and-chairman-dr-joshua-hare-on-induction-as-fellow-of--lgvn-20230710monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-files-registration-statement-for-rights-offering-lgvn-20230627monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-welcomes-three-new-prominent-board-members-lgvn-20230613monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-new-long-term-survival-data-from-elpis-i-trial-of-lomecel-b-for-hypop-lgvn-20230509monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-announce-first-quarter-2023-financial-results-on-may-12-2023-lgvn-20230508monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-first-patient-dosed-in-phase-2-clinical-trial-of-lomecel-b-for-aging--lgvn-20230419monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-announce-fourth-quarter-and-full-year-financial-results-on-march-10-2023-lgvn-20230306monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-publication-of-final-data-from-elpis-i-trial-of-lomecel-btm-for-hypop-lgvn-20230119monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-participate-in-upcoming-2022-investor-conferences-lgvn-20221129monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-completion-of-enrollment-in-phase-2a-trial-of-lomecel-b-for-the-treat-lgvn-20221110monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-announce-third-quarter-2022-financial-results-on-november-14-2022-lgvn-20221107monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-present-at-the-annual-dawson-james-small-cap-growth-conference-lgvn-20221005monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-names-jerome-bailey-vice-president-of-business-operations-lgvn-20220915monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-present-at-h-c-wainwright-24th-annual-global-investment-conference-lgvn-20220906monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-receives-intent-to-grant-notice-from-the-european-patent-office-for-methods-to--lgvn-20220825monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-inc-provides-corporate-update-and-reports-second-quarter-2022-financial-results-lgvn-20220812monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-announce-second-quarter-2022-financial-results-on-august-12-2022-lgvn-20220808monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-abstract-accepted-for-presentation-at-the-alzheimer-s-association-int-lgvn-20220707monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-ceo-transition-lgvn-20220509monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-announce-first-quarter-2022-financial-results-on-may-13-2022-lgvn-20220509monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-present-at-longevity-leaders-world-congress-latinos-and-alzheimer-s-symposiu-lgvn-20220414monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-enters-into-cooperative-research-and-development-agreement-with-the-us-departme-lgvn-20220413monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-publishes-peer-reviewed-study-of-phase-1-trial-results-of-lomecel-b-for-alzheim-lgvn-20220331monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-presents-at-second-euro-geroscience-conference-lgvn-20220324monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-present-at-oppenheimer-32nd-annual-healthcare-conference-lgvn-20220315monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-announce-fourth-quarter-and-full-year-2021-financial-results-on-march-11-202-lgvn-20220307monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-present-at-q1-virtual-investor-summit-conference-lgvn-20220302monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-participate-in-phacilitate-advanced-therapies-week-lgvn-20220125monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-publication-of-lomecel-b-phase-2b-trial-design-in-journal-of-frailty--lgvn-20220112monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-initiation-of-phase-2a-clinical-trial-of-lomecel-b-for-the-treatment--lgvn-20220105monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-participate-in-the-h-c-wainwright-bioconnect-2022-virtual-conference-lgvn-20220104monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-inc-announces-closing-of-a-20-5-million-private-placement-lgvn-20211203monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-phase-2-clinical-trial-in-japan-to-test-safety-and-efficacy-of-lomece-lgvn-20211130monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-release-third-quarter-2021-financial-results-and-hold-conference-call-on-nov-lgvn-20211108monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-selects-clinical-research-organization-for-phase-2-alzheimer-s-disease-trial-lgvn-20211105monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-activation-of-two-new-clinical-sites-in-elpis-ii-trial-of-lomecel-b-f-lgvn-20211020monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-inc-nasdaq-lgvn-class-action-lawsuit-filing-deadline-reminder-bernstein-liebhar-lgvn-20211019monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-present-at-the-2021-dawson-james-securities-6th-annual-small-cap-growth-conf-lgvn-20211014monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-inc-nasdaq-lgvn-investor-class-action-filing-deadline-bernstein-liebhard-llp-re-lgvn-20211006monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-potential-biomarker-correlating-with-lomecel-b-bioactivity-lgvn-20210929monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-multiple-presentations-at-the-11th-annual-international-conference-on-lgvn-20210928monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-dr-jorge-ruiz-as-speaker-for-roundtable-discussion-presentation-at-20-lgvn-20210921monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-inc-nasdaq-lgvn-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-lgvn-20210920monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-partners-with-kinesiometrics-to-create-and-implement-cutting-edge-smart-phone-a-lgvn-20210913monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-present-at-h-c-wainwright-23rd-annual-global-investor-conference-lgvn-20210901monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-release-second-quarter-2021-financial-results-and-hold-conference-call-on-au-lgvn-20210810monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-first-patient-treated-in-phase-2b-hypoplastic-left-heart-syndrome-hlh-lgvn-20210706monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-two-abstracts-accepted-for-presentation-at-the-gerontological-society-lgvn-20210630monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-abstract-highlighting-data-from-phase-1-alzheimer-s-disease-trial-acc-lgvn-20210624monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-present-at-noble-capital-markets-virtual-investor-forum-during-the-16th-annu-lgvn-20210615monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-s-chairman-and-chief-science-officer-invited-by-national-academy-of-medicine-to-lgvn-20210610monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-the-hiring-of-dan-gincel-ph-d-as-senior-vice-president-strategic-coll-lgvn-20210518monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-to-release-first-quarter-2021-financial-results-and-hold-conference-call-on-may-lgvn-20210511monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-invited-to-present-at-the-benzinga-global-small-cap-conference-lgvn-20210505monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-selected-to-present-at-the-2021-world-stem-cell-summit-lgvn-20210427monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-positive-results-of-phase-i-clinical-study-of-lomecel-b-cell-therapy--lgvn-20210413monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-schedules-2020-fiscal-year-end-business-update-conference-call-lgvn-20210326monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-inc-to-present-at-the-q1-virtual-investor-summit-on-march-24-lgvn-20210319monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-s-lomecel-b-approved-by-fda-for-compassionate-use-for-the-treatment-of-child-wi-lgvn-20210311monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-expands-enrollment-criteria-for-its-phase-1-recover-trial-evaluating-lomecel-b--lgvn-20210305monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-successful-completion-of-phase-2b-clinical-study-of-lomecel-b-infusio-lgvn-20210303monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-successful-completion-of-phase-1-clinical-study-of-lomecel-b-intramyo-lgvn-20210224monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-inc-announces-the-appointment-of-prominent-biotech-capital-markets-and-corporat-lgvn-20210218monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-inc-announces-pricing-of-an-upsized-26-6-million-initial-public-offering-and-na-lgvn-20210212monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-di-jspr-20251118monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-di-jspr-20251114monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-di-jspr-20251111monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-di-jspr-20251107monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-di-jspr-20251104monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-class-action-alert-bragar-eagel-squire-p-c-reminds-jasper-stockholders-of-the-novem-jspr-20251103monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-di-jspr-20251030monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-class-action-bragar-eagel-squire-p-c-reminds-jasper-stockholders-of-the-november-18-jspr-20251029monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-di-jspr-20251027monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-class-action-alert-bragar-eagel-squire-p-c-urges-jasper-therapeutics-stockholders-t-jspr-20251025monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-class-action-reminder-bragar-eagel-squire-p-c-reminds-jasper-therapeutics-investors-jspr-20251021monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-lawsuit-alert-bragar-eagel-squire-p-c-reminds-investors-a-jasper-investors-to-conta-jspr-20251004monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-class-action-alert-bragar-eagel-squire-p-c-reminds-investors-a-class-action-lawsuit-jspr-20250930monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed--jspr-20250923monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-present-at-upcoming-investor-conferences-jspr-20250827monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-present-at-upcoming-investor-conferences-jspr-20250514monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-presents-clinical-and-preclinical-briquilimab-data-at-the-american-aca-jspr-20250301monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-late-breaking-briquilimab-presentation-at-the-american-acade-jspr-20250228monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-present-at-upcoming-march-investor-conferences-jspr-20250225monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-briquilimab-presentations-at-the-american-academy-of-allergy-jspr-20250210monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-present-at-the-oppenheimer-healthcare-life-sciences-conference-jspr-20250204monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-host-webinar-to-present-preliminary-data-from-the-beacon-study-of-b-jspr-20250106monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-first-patient-dosed-in-phase-1b-2a-etesian-clinical-study-of-jspr-20241202monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-participate-at-upcoming-investor-conferences-jspr-20241113monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-present-preclinical-briquilimab-data-at-the-american-college-of-all-jspr-20241024monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-further-expansion-of-clinical-program-in-chronic-spontaneous-jspr-20241023monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-health-canada-clearance-of-clinical-trial-application-for-ph-jspr-20240910monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-present-at-present-at-upcoming-september-investor-conferences-jspr-20240904monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-reports-second-quarter-2024-financial-results-and-recent-corporate-dev-jspr-20240813monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit-jspr-20240617monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-presents-data-from-preclinical-briquilimab-study-at-the-2024-eha-hybri-jspr-20240614monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-present-data-on-briquilimab-in-mast-cell-driven-diseases-at-the-eaa-jspr-20240530monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-jspr-20240529monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-reports-first-quarter-2024-financial-results-and-recent-corporate-deve-jspr-20240514monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-briquilimab-development-program-in-asthma-jspr-20240513monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-present-at-upcoming-investor-conferences-in-may-jspr-20240507monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-present-at-the-23rd-annual-needham-virtual-healthcare-conference-jspr-20240402monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-participate-in-the-h-c-wainwright-2nd-annual-autoimmune-inflammator-jspr-20240321monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-first-patient-dosed-in-phase-1b-2a-spotlight-clinical-study--jspr-20240319monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-present-at-the-43rd-annual-td-cowen-healthcare-conference-jspr-20240226monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-presents-data-from-preclinical-briquilimab-studies-at-the-american-aca-jspr-20240223monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-present-at-the-oppenheimer-34th-annual-healthcare-conference-jspr-20240207monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-preclinical-data-presentations-at-the-american-academy-of-al-jspr-20240205monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-jspr-20240202monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-highlights-recent-accomplishments-and-key-upcoming-milestones-jspr-20240105monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-jspr-20231218monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-presents-positive-final-results-from-phase-1-study-of-briquilimab-in-p-jspr-20231210monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-announces-first-patient-dosed-in-phase-1b-2a-clinical-study-of-briquilimab-in-chron-jspr-20231130monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-participate-at-upcoming-medical-and-investor-conferences-jspr-20231108monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-oral-presentation-of-positive-final-results-from-phase-1-stu-jspr-20231102monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-host-key-opinion-leader-webinar-on-the-potential-of-briquilimab-for-jspr-20231009monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-present-at-the-cantor-fitzgerald-2023-global-healthcare-conference-jspr-20230915monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-jspr-20230804monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-strengthens-management-team-with-key-appointments-jspr-20230802monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-first-patient-dosed-in-a-phase-1-trial-of-briquilimab-in-low-jspr-20230622monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-appointment-of-edwin-j-tucker-m-d-as-chief-medical-officer-jspr-20230613monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-appointment-of-stephen-j-galli-m-d-to-scientific-advisory-bo-jspr-20230510monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-appointment-of-matthew-ford-as-vice-president-human-resource-jspr-20230413monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-appoints-david-hinds-as-senior-vice-president-development-operations-jspr-20230410monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-present-at-cantor-fitzgerald-s-the-future-of-oncology-virtual-sympo-jspr-20230331monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-appoints-daniel-adelman-m-d-as-acting-chief-medical-officer-jspr-20230323monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-present-at-upcoming-conferences-jspr-20230309monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-appoints-industry-veteran-vishal-kapoor-to-its-board-of-directors-jspr-20230217monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-jspr-20230203monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-host-investor-conference-call-and-webcast-on-january-31-2023-jspr-20230130monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-proposed-public-offering-of-common-stock-jspr-20230124monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-european-union-orphan-drug-designation-for-briquilimab-as-a--jspr-20230104monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-positive-clinical-data-from-a-phase-i-ii-trial-of-briquilima-jspr-20230103monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-positive-clinical-data-from-investigator-sponsored-study-of--jspr-20220926monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-present-at-upcoming-conferences-jspr-20220923monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-fda-fast-track-designation-for-jsp191-a-novel-monoclonal-ant-jspr-20220915monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-present-at-the-lifesci-partners-2nd-annual-genetic-medicines-sympos-jspr-20220623monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-participate-in-the-william-blair-42nd-annual-growth-stock-conferenc-jspr-20220607monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-annual-virtual-stockholders-meeting-to-be-held-on-thursday-j-jspr-20220606monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-treatment-of-first-patient-in-study-of-jsp191-conditioning-i-jspr-20220517monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-plans-for-registrational-study-of-jsp191-in-older-patients-w-jspr-20220428monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-updated-data-from-phase-1-clinical-trial-of-jsp191-as-target-jspr-20220426monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-host-in-person-key-opinion-leader-webinar-on-transforming-hematopoi-jspr-20220422monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-present-updated-data-on-jsp191-conditioning-in-scid-patients-at-the-jspr-20220331monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-jspr-20220325monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-participate-in-the-oppenheimer-32nd-annual-healthcare-conference-jspr-20220310monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-present-data-on-jsp191-conditioning-in-scid-patients-at-the-2021-am-jspr-20211208monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-research-collaboration-with-avrobio-to-evaluate-jsp191-as-co-jspr-20211109monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-present-at-the-credit-suisse-30th-annual-virtual-healthcare-confere-jspr-20211108monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-present-data-on-als-parkinsons-disease-programs-at-alzheimer-s-dis-pmn-20260318monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-exceeds-target-enrollment-in-precise-ad-phase-1b-clinical-trial-of-pm-pmn-20251218monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-new-peer-reviewed-publication-highlighting-selective-target-pmn-20251210monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-private-placement-financing-pmn-20250722monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-presents-at-h-c-wainwright-6th-annual-neuro-perspectives-hybrid-confe-pmn-20250617monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-showcases-preclinical-data-on-platform-derived-antibody-and-vaccines--pmn-20250324monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-showcases-preclinical-data-on-platform-derived-vaccines-for-neurodege-pmn-20250313monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference-pmn-20250311monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-participate-in-guggenheim-securities-smid-cap-biotech-conference-pmn-20250129monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-issues-letter-to-shareholders-pmn-20250113monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-participate-in-7th-annual-evercore-healthconx-conference-pmn-20241126monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-participate-in-guggenheim-s-inaugural-healthcare-innovation-confer-pmn-20241112monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-presents-positive-data-from-pmn310-phase1a-clinical-trial-at-the-17th-pmn-20241030monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-showcase-pmn310-s-ability-to-target-toxic-oligomers-and-distinguis-pmn-20240912monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-present-at-the-h-c-wainwright-26th-annual-global-investment-confer-pmn-20240905monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-data-on-the-pathogenic-role-of-toxic-misfolded-sod1-aggrega-pmn-20240806monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-participate-in-btig-virtual-biotechnology-conference-2024-pmn-20240801monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-showcases-novel-vaccine-approach-for-maximal-targeting-of-toxic-amylo-pmn-20240730monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-reports-positive-top-line-data-from-its-phase-1a-alzheimer-s-trial-pmn-20240726monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-publishes-in-the-journal-of-biological-chemistry-on-the-interaction-b-pmn-20240409monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-present-in-upcoming-investor-conferences-in-april-pmn-20240404monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-strengthens-global-intellectual-property-portfolio-pmn-20240311monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-present-at-the-2024-bio-ceo-investor-conference-pmn-20240222monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-achieves-milestone-in-development-of-therapeutic-alpha-synuclein-vacc-pmn-20240122monthly0.5